<SEC-DOCUMENT>0001140361-20-020242.txt : 20200921
<SEC-HEADER>0001140361-20-020242.hdr.sgml : 20200921
<ACCEPTANCE-DATETIME>20200911154544
<PRIVATE-TO-PUBLIC>
ACCESSION NUMBER:		0001140361-20-020242
CONFORMED SUBMISSION TYPE:	DRS
PUBLIC DOCUMENT COUNT:		44
FILED AS OF DATE:		20200911
<PUBLIC-REL-DATE>20200921
DATE AS OF CHANGE:		20200911

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ADC Therapeutics SA
		CENTRAL INDEX KEY:			0001771910
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			V8
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		DRS
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	377-03530
		FILM NUMBER:		201170873

	BUSINESS ADDRESS:	
		STREET 1:		BIOPOLE
		STREET 2:		ROUTE DE LA CORNICHE 3B
		CITY:			EPALINGES
		STATE:			V8
		ZIP:			1066
		BUSINESS PHONE:		41 21 653 02 00

	MAIL ADDRESS:	
		STREET 1:		BIOPOLE
		STREET 2:		ROUTE DE LA CORNICHE 3B
		CITY:			EPALINGES
		STATE:			V8
		ZIP:			1066
</SEC-HEADER>
<DOCUMENT>
<TYPE>DRS
<SEQUENCE>1
<FILENAME>filename1.htm
<TEXT>
<html><head>
    <title></title>
    <!-- Licensed to: Broadridge Financial Soultions, Inc.
         Document created using EDGARfilings PROfile 7.1.0.0
         Copyright 1995 - 2020 Broadridge -->
  </head><body style="color: #000000;" bgcolor="#ffffff">
<!--Begin Page 1-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 540pt;"><a name="nt10014672x1_drs_100-regcov_pg1"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 540pt; margin-left: 0pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 20pt; text-align: center;">As submitted confidentially with the Securities and Exchange Commission on September 11, 2020. This draft registration statement has not been <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">publicly filed with the Securities and Exchange Commission and all information herein remains strictly confidential.<font style="font-weight: normal;"> </font></div><div class="regno" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: right;">Registration No. 333-&#8199;&#8199;&#8199;&#8199;&#8199;&#8199; </div></div></div><div class="block-frill" style="width: 540pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: Arial, Helvetica, sans-serif; font-size: 9pt; font-weight: bold; margin-top: 6pt; text-align: center;">Confidential Treatment Requested by ADC Therapeutics SA Pursuant to 17 C.F.R. &#167; 200.83<br></div></div><div class="block-frill" style="width: 540pt; margin-left: 0pt;"><div><div class="rule-full" style="height: 0pt; width: 100%; border-bottom: 2pt solid #000000; margin-top: 1pt; margin-bottom: 1pt; margin-left: auto; margin-right: auto;"> </div><div class="rule-full" style="height: 0pt; width: 100%; border-bottom: 1pt solid #000000; margin-bottom: 1pt; margin-left: auto; margin-right: auto; margin-top: 4pt;"> </div></div></div><div class="block-main" style="width: 540pt; margin-left: 0pt;"><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: center;">UNITED STATES<br></div><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">SECURITIES AND EXCHANGE COMMISSION<br></div><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;"><font style="font-size: 8pt;">Washington, D.C. 20549</font></div><div><div class="rule-partial" style="height: 0pt; width: 96pt; border-bottom: 1pt solid #000000; margin-bottom: 2pt; margin-left: auto; margin-right: auto; margin-top: 3.25pt;"> </div></div><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.5pt; text-align: center;">FORM F-1<br></div><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">REGISTRATION STATEMENT<br></div><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">UNDER<br></div><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">THE SECURITIES ACT OF 1933</div><div><div class="rule-partial" style="height: 0pt; width: 96pt; border-bottom: 1pt solid #000000; margin-bottom: 2pt; margin-left: auto; margin-right: auto; margin-top: 3.25pt;"> </div></div><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 12pt; font-weight: bold; margin-top: 6.5pt; text-align: center;">ADC THERAPEUTICS SA<br></div><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 12pt; font-weight: bold; margin-top: 0pt; text-align: center;"><font style="font-size: 8pt; font-weight: normal;">(Exact name of Registrant as specified in its charter)</font></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 2.5pt; text-align: center;">Not Applicable<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;"><font style="font-size: 8pt; font-weight: normal;">(Translation of Registrant&#8217;s name into English)</font></div><table cellspacing="0" cellpadding="0" class="txttab" style="margin-top: 0.75pt; border-collapse: collapse; width: 540pt; margin-left: auto; margin-right: auto;"><tr><td style="width: 31.85%; text-align: center; vertical-align: top; padding-top: 6pt; padding-bottom: 2pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Switzerland</div></td><td class="gutter" style="width: 1.11%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 2pt;">&#8203;</td><td class="gutter" style="width: 1.11%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 2pt;">&#8203;</td><td style="width: 31.85%; text-align: center; vertical-align: bottom; padding-top: 6pt; padding-bottom: 2pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2834</div></td><td class="gutter" style="width: 1.11%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 2pt;">&#8203;</td><td class="gutter" style="width: 1.11%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 2pt;">&#8203;</td><td style="width: 31.85%; text-align: center; vertical-align: bottom; padding-top: 6pt; padding-bottom: 2pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Not Applicable</div></td></tr><tr><td style="width: 31.85%; text-align: center; vertical-align: top; padding-top: 2pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; text-align: center;">(State or other jurisdiction of <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; text-align: center;">incorporation or organization)</div></td><td class="gutter" style="width: 1.11%; border-bottom: none; font-size: 2pt; padding-top: 2pt;">&#8203;</td><td class="gutter" style="width: 1.11%; border-bottom: none; font-size: 2pt; padding-top: 2pt;">&#8203;</td><td style="width: 31.85%; text-align: center; vertical-align: bottom; padding-top: 2pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; text-align: center;">(Primary Standard Industrial <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; text-align: center;">Classification Code Number)</div></td><td class="gutter" style="width: 1.11%; border-bottom: none; font-size: 2pt; padding-top: 2pt;">&#8203;</td><td class="gutter" style="width: 1.11%; border-bottom: none; font-size: 2pt; padding-top: 2pt;">&#8203;</td><td style="width: 31.85%; text-align: center; vertical-align: bottom; padding-top: 2pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; text-align: center;">(I.R.S. Employer <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; text-align: center;">Identification No.)</div></td></tr></table><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 2.5pt; text-align: center;">Biop&#244;le <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Route de la Corniche 3B <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">1066 Epalinges <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Switzerland <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">+41 21 653 02 00<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;"><font style="font-weight: normal;">(Address, including zip code, and telephone number, including area code, of Registrant&#8217;s principal executive offices)</font></div><div><div class="rule-partial" style="height: 0pt; width: 96pt; border-bottom: 1pt solid #000000; margin-bottom: 2pt; margin-left: auto; margin-right: auto; margin-top: 4.25pt;"> </div></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 4.5pt; text-align: center;">ADC Therapeutics America, Inc. <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">430 Mountain Avenue, 4th Floor <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Murray Hill, NJ 07974 <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">(908) 546-5556<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;"><font style="font-weight: normal;">(Name, address, including zip code, and telephone number, including area code, of agent for service)</font></div><div><div class="rule-partial" style="height: 0pt; width: 96pt; border-bottom: 1pt solid #000000; margin-bottom: 2pt; margin-left: auto; margin-right: auto; margin-top: 4.25pt;"> </div></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-style: italic; font-weight: bold; margin-top: 2.5pt; text-align: center;">Copies to:</div><table cellspacing="0" cellpadding="0" class="txttab" style="border-collapse: collapse; width: 540pt; margin-left: auto; margin-right: auto;"><tr><td style="width: 23.33%; text-align: center; vertical-align: top; padding-top: 6pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Deanna L. Kirkpatrick <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Yasin Keshvargar <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Davis Polk &amp; Wardwell LLP <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">450 Lexington Avenue <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">New York, NY 10017 <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">(212) 450-4000</div></td><td class="gutter" style="width: 1.11%; border-bottom: none; font-size: 2pt; padding-top: 6pt;">&#8203;</td><td class="gutter" style="width: 1.11%; border-bottom: none; font-size: 2pt; padding-top: 6pt;">&#8203;</td><td style="width: 23.33%; text-align: center; vertical-align: top; padding-top: 6pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Dieter Gericke <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Benjamin Leisinger <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Homburger AG <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Hardstrasse 201 <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">CH-8005 Zurich, <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Switzerland <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">+41 43 222 10 00</div></td><td class="gutter" style="width: 1.11%; border-bottom: none; font-size: 2pt; padding-top: 6pt;">&#8203;</td><td class="gutter" style="width: 1.11%; border-bottom: none; font-size: 2pt; padding-top: 6pt;">&#8203;</td><td style="width: 23.33%; text-align: center; vertical-align: top; padding-top: 6pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Jacques Iffland <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Lenz &amp; Staehelin <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Route de Ch&#234;ne 30 <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">CH-1211 Geneva 6, <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Switzerland <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">+41 58 450 70 00</div></td><td class="gutter" style="width: 1.11%; border-bottom: none; font-size: 2pt; padding-top: 6pt;">&#8203;</td><td class="gutter" style="width: 1.11%; border-bottom: none; font-size: 2pt; padding-top: 6pt;">&#8203;</td><td style="width: 23.33%; text-align: center; vertical-align: top; padding-top: 6pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Divakar Gupta<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Richard C. Segal <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Alison A. Haggerty <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Cooley LLP <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">55 Hudson Yards <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">New York, NY 10001 <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">(212) 479-6000</div></td></tr></table><div><div class="rule-partial" style="height: 0pt; width: 96pt; border-bottom: 1pt solid #000000; margin-bottom: 2pt; margin-left: auto; margin-right: auto; margin-top: 2.25pt;"> </div></div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 3.5pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Approximate date of commencement of proposed sale to the public: <font style="font-weight: normal;">As soon as practicable after the effective date of this registration statement.</font></div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 2pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">If any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the Securities Act of 1933, check the following box. <font style="font-size: 1pt;">&#8201;</font>&#x2610; </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 2pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">If this Form is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. <font style="font-size: 1pt;">&#8201;</font>&#x2610; </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 2pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">If this Form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. <font style="font-size: 1pt;">&#8201;</font>&#x2610; </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 2pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">If this Form is a post-effective amendment filed pursuant to Rule 462(d) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. <font style="font-size: 1pt;">&#8201;</font>&#x2610; </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 2.5pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933. Emerging growth company&#160;&#x2612; </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 2pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">If an emerging growth company that prepares its financial statements in accordance with U.S. GAAP, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards&#8224; provided pursuant to Section 7(a)(2)(B) of the Securities Act.&#160;<font style="font-size: 1pt;">&#8201;</font>&#x2610; </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 2pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">&#8224; The term &#8220;new or revised financial accounting standard&#8221; refers to any update issued by the Financial Accounting Standards Board to its Accounting Standards Codification after April&#160;5, 2012.</div><div><div class="rule-partial" style="height: 0pt; width: 96pt; border-bottom: 1pt solid #000000; margin-top: 1pt; margin-bottom: 2pt; margin-left: auto; margin-right: auto;"> </div></div><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 6.5pt; text-align: center;">CALCULATION OF REGISTRATION FEE</div><div><div class="rule-full" style="height: 0pt; width: 100%; border-bottom: 1pt solid #000000; margin-bottom: 2pt; margin-left: auto; margin-right: auto; margin-top: 4.5pt;"> </div></div><table cellspacing="0" cellpadding="0" class="regtab" style="margin-top: 1.5pt; border-collapse: collapse; width: 540pt; margin-left: auto; margin-right: auto; border-top: 1pt solid #000000; border-bottom: 1pt solid #000000;"><tr class="header"><td style="width: 55.56%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6.5pt; padding-bottom: 3.25pt;"><div class="calc" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Title of each class of securities to be registered</div></td><td class="gutter" style="width: 0.56%; font-size: 2pt; border-right: 1pt solid #000000; border-bottom: 1pt solid #000000; padding-top: 6.5pt; padding-bottom: 3.25pt;">&#8203;</td><td class="gutter" style="width: 0.56%; font-size: 2pt; border-bottom: 1pt solid #000000; padding-top: 6.5pt; padding-bottom: 3.25pt;">&#8203;</td><td style="width: 10%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6.5pt; padding-bottom: 3.25pt;"><div class="calc" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Amount to be <br></div><div class="calc" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">registered<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(1)</sup> </div></td><td class="gutter" style="width: 0.56%; font-size: 2pt; border-right: 1pt solid #000000; border-bottom: 1pt solid #000000; padding-top: 6.5pt; padding-bottom: 3.25pt;">&#8203;</td><td class="gutter" style="width: 0.56%; font-size: 2pt; border-bottom: 1pt solid #000000; padding-top: 6.5pt; padding-bottom: 3.25pt;">&#8203;</td><td style="width: 10%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6.5pt; padding-bottom: 3.25pt;"><div class="calc" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Proposed maximum <br></div><div class="calc" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">aggregate offering price per unit<font style="font-size: 6pt;">(2)</font></div></td><td class="gutter" style="width: 0.56%; font-size: 2pt; border-right: 1pt solid #000000; border-bottom: 1pt solid #000000; padding-top: 6.5pt; padding-bottom: 3.25pt;">&#8203;</td><td class="gutter" style="width: 0.56%; font-size: 2pt; border-bottom: 1pt solid #000000; padding-top: 6.5pt; padding-bottom: 3.25pt;">&#8203;</td><td style="width: 10%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6.5pt; padding-bottom: 3.25pt;"><div class="calc" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Proposed maximum<br></div><div class="calc" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">aggregate offering<br></div><div class="calc" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">price<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(2)</sup> </div></td><td class="gutter" style="width: 0.56%; font-size: 2pt; border-right: 1pt solid #000000; border-bottom: 1pt solid #000000; padding-top: 6.5pt; padding-bottom: 3.25pt;">&#8203;</td><td class="gutter" style="width: 0.56%; font-size: 2pt; border-bottom: 1pt solid #000000; padding-top: 6.5pt; padding-bottom: 3.25pt;">&#8203;</td><td style="width: 10%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6.5pt; padding-bottom: 3.25pt;"><div class="calc" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Amount of registration fee</div></td></tr><tr><td style="width: 55.56%; text-align: left; vertical-align: bottom; padding-top: 3.25pt;"><div class="calc" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Common shares, par value CHF 0.08 per share<font style="padding-left: 3.41pt;"></font></div></td><td class="gutter" style="width: 0.56%; border-bottom: none; font-size: 2pt; border-right: 1pt solid #000000; padding-top: 3.25pt;">&#8203;</td><td class="gutter" style="width: 0.56%; border-bottom: none; font-size: 2pt; padding-top: 3.25pt;">&#8203;</td><td style="width: 10%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3.25pt;"><div class="calc" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">&#160;</div></td><td class="gutter" style="width: 0.56%; border-bottom: none; font-size: 2pt; border-right: 1pt solid #000000; padding-top: 3.25pt;">&#8203;</td><td class="gutter" style="width: 0.56%; border-bottom: none; font-size: 2pt; padding-top: 3.25pt;">&#8203;</td><td style="width: 10%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3.25pt;"><div class="calc" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; margin-left: 25pt; text-align: left;">$</div></td><td class="gutter" style="width: 0.56%; border-bottom: none; font-size: 2pt; border-right: 1pt solid #000000; padding-top: 3.25pt;">&#8203;</td><td class="gutter" style="width: 0.56%; border-bottom: none; font-size: 2pt; padding-top: 3.25pt;">&#8203;</td><td style="width: 10%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3.25pt;"><div class="calc" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; margin-left: 25pt; text-align: left;">$</div></td><td class="gutter" style="width: 0.56%; border-bottom: none; font-size: 2pt; border-right: 1pt solid #000000; padding-top: 3.25pt;">&#8203;</td><td class="gutter" style="width: 0.56%; border-bottom: none; font-size: 2pt; padding-top: 3.25pt;">&#8203;</td><td style="width: 10%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3.25pt;"><div class="calc" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; margin-left: 25pt; text-align: left;">$</div></td></tr></table><div><div class="rule-full" style="height: 0pt; width: 100%; border-bottom: 1pt solid #000000; margin-bottom: 1pt; margin-left: auto; margin-right: auto; margin-top: 3.5pt;"> </div></div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 3pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">(1)<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; text-align: left;">Includes &#8195;&#8195;&#8195;&#8195; common shares granted pursuant to the underwriters&#8217; option to purchase additional common shares.</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 3pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">(2)<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; text-align: left;">Estimated solely for the purpose of computing the amount of the registration fee pursuant to Rule 457(c) under the Securities Act of 1933, as amended. The maximum price per share and maximum aggregate offering price are based on the average of the high and low sale prices of the common shares as reported on the New York Stock Exchange on &#8195;&#8195;&#8195;&#8195;, 2020, which date is within five business days prior to filing this registration statement. </div></td></tr></table><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 6pt; margin-left: 0pt; text-align: left;">The Registrant hereby amends this registration statement on such date or dates as may be necessary to delay its effective date until the Registrant shall file a further amendment which specifically states that this registration statement shall thereafter become effective in accordance with Section 8(a) of the Securities Act of 1933, as amended, or until the registration statement shall become effective on such date as the Commission, acting pursuant to such Section 8(a), may determine.</div></div><div class="block-frill" style="width: 540pt; margin-top: 12pt; margin-left: 0pt;"><div><div class="rule-full" style="height: 0pt; width: 100%; border-bottom: 1pt solid #000000; margin-top: 1pt; margin-bottom: 1pt; margin-left: auto; margin-right: auto;"> </div><div class="rule-full" style="height: 0pt; width: 100%; border-bottom: 2pt solid #000000; margin-bottom: 1pt; margin-left: auto; margin-right: auto; margin-top: 4pt;"> </div></div></div></div>
<!--End Page 1-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 2-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 540pt;"><a name="nt10014672x1_drs_101-cov_pg1"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="block-frill" style="width: 540pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; font-weight: bold; margin-top: 6pt; text-align: center;">Confidential Treatment Requested by ADC Therapeutics SA Pursuant to 17 C.F.R. &#167; 200.83<br></div></div><div class="page-content"><div class="block-main" style="width: 456pt; margin-left: 42pt;"><div class="h1" style="color: #FC0014; font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: italic; margin-top: 6.75pt; margin-left: 0pt; text-align: left;"><div style="font-style: normal; text-align: left; margin-bottom: 12pt;">The information in this prospectus is not complete and may be changed. We may not sell these securities until the registration statement filed with the Securities and Exchange Commission is effective. This prospectus is not an offer to sell these securities and it is not soliciting an offer to buy these securities in any state where the offer or sale is not permitted.</div>SUBJECT TO COMPLETION DATED &#8195;&#8195;&#8195;&#8195;&#8195;&#8195;, 2020<br></div><div class="h1" style="color: #FC0014; font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: italic; margin-top: 0pt; margin-left: 0pt; text-align: left;">PRELIMINARY PROSPECTUS</div><div class="h1" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 16pt; font-style: italic; margin-top: 19.5pt; text-align: center;">&#8195;&#8195;&#8195;&#8195;&#8195;&#8195; Shares</div><div class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10pt; margin-top: 13.25pt; text-align: center;"><img style="height: 80px; width: 140px;" src="logo_adc2.jpg"><br></div><div class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">&#8201;</div><div class="h1" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 16pt; font-style: italic; font-weight: bold; margin-top: 20.5pt; text-align: center;">ADC THERAPEUTICS SA<br></div><div class="h1" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 16pt; font-style: italic; font-weight: bold; margin-top: 0pt; text-align: center;">&#8194;<br></div><div class="h1" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 16pt; font-style: italic; font-weight: bold; margin-top: 0pt; text-align: center;"><font style="font-weight: normal;">Common Shares</font></div><div><div class="rule-partial" style="height: 0pt; width: 96pt; border-bottom: 1pt solid #000000; margin-bottom: 2pt; margin-left: auto; margin-right: auto; margin-top: 5.25pt;"> </div></div><div class="fpara" style="color: #FFFFFF; font-family: Times New Roman, Times, Serif; font-size: 1pt; margin-top: -4pt; margin-left: 0pt; text-align: left;">startfonthere</div><div class="fpara" style="color: #000000; font-family: Bodoni MT; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 6pt; margin-left: 0pt; text-align: left;">We are offering &#8195;&#8195;&#8195;&#8195; common shares. The Selling Shareholder identified in this prospectus is offering &#8195;&#8195;&#8195;&#8195; common shares if and to the extent that the underwriters exercise their option to purchase additional common shares described below. We will not receive any of the proceeds from the potential sale of common shares by the Selling Shareholder. </div><div class="fpara" style="color: #000000; font-family: Bodoni MT; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 6pt; margin-left: 0pt; text-align: left;">The public offering price will be determined between us, the Selling Shareholder and the underwriters at the time of pricing and may be at a discount to the current market price. Accordingly, the recent market price used throughout this prospectus may not be indicative of the public offering price. </div><div class="fpara" style="color: #000000; font-family: Bodoni MT; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 6pt; margin-left: 0pt; text-align: left;">Our common shares are listed on the New York Stock Exchange (&#8220;NYSE&#8221;) under the symbol &#8220;ADCT.&#8221; On &#8195;&#8195;&#8195;, 2020, the last reported sale price of our common shares on the NYSE was $&#8195;&#8195;&#8195; per common share.</div><div><div class="rule-partial" style="height: 0pt; width: 96pt; border-bottom: 1pt solid #000000; margin-bottom: 2pt; margin-left: auto; margin-right: auto; margin-top: 7.25pt;"> </div></div><div class="fpara" style="color: #000000; font-family: Bodoni MT; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 6pt; margin-left: 0pt; text-align: left;">We are an &#8220;emerging growth company&#8221; as defined under U.S. federal securities laws and, as such, may elect to comply with reduced public company reporting requirements for this and future filings. See &#8220;Prospectus Summary&#8212;Implications of Being an Emerging Growth Company.&#8221;</div><div><div class="rule-partial" style="height: 0pt; width: 96pt; border-bottom: 1pt solid #000000; margin-bottom: 2pt; margin-left: auto; margin-right: auto; margin-top: 11.25pt;"> </div></div><div class="fpara" style="color: #000000; font-family: Bodoni MT; font-size: 12pt; font-style: italic; font-weight: bold; margin-top: 6pt; margin-left: 0pt; text-align: left;">Investing in our common shares involves a high degree of risk. See &#8220;Risk Factors&#8221; beginning on page <a href="#tRF">14</a> of this prospectus.</div><div><div class="rule-partial" style="height: 0pt; width: 96pt; border-bottom: 1pt solid #000000; margin-bottom: 2pt; margin-left: auto; margin-right: auto; margin-top: 9.25pt;"> </div></div><div class="fpara" style="color: #000000; font-family: Bodoni MT; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 6pt; margin-left: 0pt; text-align: left;">Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or determined if this prospectus is truthful or complete. Any representation to the contrary is a criminal offense. </div><div class="fpara" style="color: #FFFFFF; font-family: Bodoni MT; font-size: 1pt; margin-top: 8.5pt; margin-left: 0pt; text-align: left;">endfonthere</div><div class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10pt; margin-top: -2.5pt; text-align: center;"><div class="rule-partial" style="height: 0pt; width: 96pt; border-bottom: 1pt solid #000000; margin-top: 1pt; display: inline-block; margin-left: auto; margin-right: auto;"> </div> <br></div><table cellspacing="0" cellpadding="0" class="fintab" style="margin-top: 1.25pt; border-collapse: collapse; width: 456pt; margin-left: auto; margin-right: auto;"><tr class="header"><td style="width: 65.79%; text-align: left; vertical-align: bottom; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 4.32%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 4.32%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 10.75%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: italic; margin-top: 0pt; text-align: center;">PER SHARE</div></td><td class="gutter" style="width: 4.32%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 4.32%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 6.17%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: italic; margin-top: 0pt; text-align: center;">TOTAL</div></td></tr><tr><td style="width: 65.79%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: italic; margin-top: 0pt; margin-left: 0pt; text-align: left;">Public offering price<font style="padding-left: 3.35pt;"></font></div></td><td class="gutter" style="width: 4.32%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 4.32%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.75%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: italic; margin-top: 0pt; margin-left: 1.82pt; text-align: left;">$&#8194;&#8194;&#8195;&#8195;&#8195;</div></td><td class="gutter" style="width: 4.32%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 4.32%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.17%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: italic; margin-top: 0pt; margin-left: 6.38pt; text-align: left;">$&#8194;&#8194;</div></td></tr><tr><td style="width: 65.79%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: italic; margin-top: 0pt; margin-left: 0pt; text-align: left;">Underwriting discounts and commissions<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(1)</sup><font style="padding-left: 1.98pt;"></font></div></td><td class="gutter" style="width: 4.32%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 4.32%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 10.75%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: italic; margin-top: 0pt; margin-left: 1.82pt; text-align: left;">$</div></td><td class="gutter" style="width: 4.32%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 4.32%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 6.17%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: italic; margin-top: 0pt; margin-left: 6.38pt; text-align: left;">$</div></td></tr><tr><td style="width: 65.79%; text-align: left; vertical-align: bottom; padding-top: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: italic; margin-top: 0pt; margin-left: 0pt; text-align: left;">Proceeds, before expenses, to us<font style="padding-left: 3.93pt;"></font></div></td><td class="gutter" style="width: 4.32%; border-bottom: none; font-size: 2pt; padding-top: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 4.32%; border-bottom: none; font-size: 2pt; padding-top: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.75%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: italic; margin-top: 0pt; margin-left: 1.82pt; text-align: left;">$</div></td><td class="gutter" style="width: 4.32%; border-bottom: none; font-size: 2pt; padding-top: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 4.32%; border-bottom: none; font-size: 2pt; padding-top: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.17%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: italic; margin-top: 0pt; margin-left: 6.38pt; text-align: left;">$</div></td></tr></table><div><div class="rule-partial" style="height: 0pt; width: 72pt; border-bottom: 1pt solid #000000; margin-bottom: 1pt; margin-right: auto; margin-left: 0pt; margin-top: 13.25pt;"> </div></div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 3pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: italic;">(1)<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: italic; text-align: left;">See &#8220;Underwriters&#8221; for a description of all compensation payable to the underwriters.</div></td></tr></table><div class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: italic; margin-top: 6pt; margin-left: 0pt; text-align: left;">The Selling Shareholder has granted the underwriters an option for a period of 30 days to purchase up to an additional &#8195;&#8195;&#8195; common shares. </div><div class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: italic; margin-top: 6pt; margin-left: 0pt; text-align: left;">The underwriters expect to deliver the common shares against payment in New York, New York on or about &#8195;&#8195;, 2020.</div><div><div class="rule-partial" style="height: 0pt; width: 96pt; border-bottom: 1pt solid #000000; margin-bottom: 2pt; margin-left: auto; margin-right: auto; margin-top: 15.25pt;"> </div></div><table cellspacing="0" cellpadding="0" class="txttab" style="margin-top: 3.25pt; border-collapse: collapse; width: 456pt; margin-left: auto; margin-right: auto;"><tr><td style="width: 36.84%; text-align: left; vertical-align: top; padding-top: 6pt;"><div class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 16pt; font-style: italic; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">MORGAN STANLEY</div></td><td class="gutter" style="width: 1.32%; border-bottom: none; font-size: 2pt; padding-top: 6pt;">&#8203;</td><td class="gutter" style="width: 1.32%; border-bottom: none; font-size: 2pt; padding-top: 6pt;">&#8203;</td><td style="width: 42.11%; text-align: center; vertical-align: bottom; padding-top: 6pt;"><div class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 16pt; font-style: italic; font-weight: bold; margin-top: 0pt; text-align: center;">BofA SECURITIES</div></td><td class="gutter" style="width: 1.32%; border-bottom: none; font-size: 2pt; padding-top: 6pt;">&#8203;</td><td class="gutter" style="width: 1.32%; border-bottom: none; font-size: 2pt; padding-top: 6pt;">&#8203;</td><td style="width: 15.79%; text-align: right; vertical-align: bottom; padding-top: 6pt;"><div class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 16pt; font-style: italic; font-weight: bold; margin-top: 0pt; text-align: right;">COWEN</div></td></tr></table><div class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: italic; margin-top: 6.5pt; margin-left: 0pt; text-align: left;">Prospectus dated &#8195;&#8195;, 2020.</div></div></div></div>
<!--End Page 2-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 3-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 540pt;"><a name="nt10014672x1_drs_102-toc_pg1"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="block-frill" style="width: 540pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: Arial, Helvetica, sans-serif; font-size: 9pt; font-weight: bold; margin-top: 6pt; text-align: center;">Confidential Treatment Requested by ADC Therapeutics SA Pursuant to 17 C.F.R. &#167; 200.83<br></div></div><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 36pt;"><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: center;">TABLE OF CONTENTS</div><div><div class="rule-partial" style="height: 0pt; width: 96pt; border-bottom: 1pt solid #000000; margin-bottom: 2pt; margin-left: auto; margin-right: auto; margin-top: 13.75pt;"> </div></div></div><div class="columns" style="width: 468pt; margin-left: 36pt;"><div class="block-main-columns" style="width: 228pt; float: left;"><a name="TOC"><!--Anchor--></a><table cellspacing="0" cellpadding="0" class="fintab" style="margin-top: 4pt; border-collapse: collapse; width: 229pt; margin-left: auto; margin-right: auto;"><tr><td style="width: 90.83%; text-align: left; vertical-align: bottom; padding-top: 6pt; padding-bottom: 2.5pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tPS">Prospectus Summary<font style="padding-left: 4.97pt;"></font></a></div></td><td class="gutter" style="width: 1.31%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 2.5pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.31%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 2.5pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.55%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 6pt; padding-bottom: 2.5pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tPS"><font style="padding-left: 10pt;">1</font></a></div></td></tr><tr><td style="width: 90.83%; text-align: left; vertical-align: bottom; padding-top: 2.5pt; padding-bottom: 2.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tRF">Risk Factors<font style="padding-left: 4.41pt;"></font></a></div></td><td class="gutter" style="width: 1.31%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td class="gutter" style="width: 1.31%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td style="width: 6.55%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.5pt; padding-bottom: 2.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tRF"><font style="padding-left: 5pt;">14</font></a></div></td></tr><tr><td style="width: 90.83%; text-align: left; vertical-align: bottom; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-indent: -10pt; text-align: left;"><a href="#tCSR">Cautionary Statement Regarding Forward-Looking Statements<font style="padding-left: 1.62pt;"></font></a></div></td><td class="gutter" style="width: 1.31%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.31%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.55%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tCSR"><font style="padding-left: 5pt;">80</font></a></div></td></tr><tr><td style="width: 90.83%; text-align: left; vertical-align: bottom; padding-top: 2.5pt; padding-bottom: 2.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tMID">Market and Industry Data<font style="padding-left: 4.99pt;"></font></a></div></td><td class="gutter" style="width: 1.31%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td class="gutter" style="width: 1.31%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td style="width: 6.55%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.5pt; padding-bottom: 2.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tMID"><font style="padding-left: 5pt;">82</font></a></div></td></tr><tr><td style="width: 90.83%; text-align: left; vertical-align: bottom; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tUP">Use of Proceeds<font style="padding-left: 3.87pt;"></font></a></div></td><td class="gutter" style="width: 1.31%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.31%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.55%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tUP"><font style="padding-left: 5pt;">83</font></a></div></td></tr><tr><td style="width: 90.83%; text-align: left; vertical-align: bottom; padding-top: 2.5pt; padding-bottom: 2.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tDP">Dividend Policy<font style="padding-left: 4.4pt;"></font></a></div></td><td class="gutter" style="width: 1.31%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td class="gutter" style="width: 1.31%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td style="width: 6.55%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.5pt; padding-bottom: 2.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tDP"><font style="padding-left: 5pt;">84</font></a></div></td></tr><tr><td style="width: 90.83%; text-align: left; vertical-align: bottom; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tC">Capitalization<font style="padding-left: 4.4pt;"></font></a></div></td><td class="gutter" style="width: 1.31%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.31%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.55%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tC"><font style="padding-left: 5pt;">85</font></a></div></td></tr><tr><td style="width: 90.83%; text-align: left; vertical-align: bottom; padding-top: 2.5pt; padding-bottom: 2.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tD">Dilution<font style="padding-left: 2.17pt;"></font></a></div></td><td class="gutter" style="width: 1.31%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td class="gutter" style="width: 1.31%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td style="width: 6.55%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.5pt; padding-bottom: 2.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tD"><font style="padding-left: 5pt;">86</font></a></div></td></tr><tr><td style="width: 90.83%; text-align: left; vertical-align: bottom; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tSCF">Selected Consolidated Financial Data<font style="padding-left: 2.78pt;"></font></a></div></td><td class="gutter" style="width: 1.31%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.31%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.55%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tSCF"><font style="padding-left: 5pt;">87</font></a></div></td></tr><tr><td style="width: 90.83%; text-align: left; vertical-align: bottom; padding-top: 2.5pt; padding-bottom: 2.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-indent: -10pt; text-align: left;"><a href="#tMDA">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations<font style="padding-left: 0.56pt;"></font></a></div></td><td class="gutter" style="width: 1.31%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td class="gutter" style="width: 1.31%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td style="width: 6.55%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.5pt; padding-bottom: 2.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tMDA"><font style="padding-left: 5pt;">89</font></a></div></td></tr><tr><td style="width: 90.83%; text-align: left; vertical-align: bottom; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tB">Business<font style="padding-left: 4.95pt;"></font></a></div></td><td class="gutter" style="width: 1.31%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.31%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.55%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tB"><font style="padding-left: 0.37pt;">112</font></a></div></td></tr><tr><td style="width: 90.83%; text-align: left; vertical-align: bottom; padding-top: 2.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tM">Management<font style="padding-left: 3.3pt;"></font></a></div></td><td class="gutter" style="width: 1.31%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt;">&#8203;</td><td class="gutter" style="width: 1.31%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt;">&#8203;</td><td style="width: 6.55%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tM">190</a></div></td></tr></table></div><div class="block-main-columns" style="margin-left: 12pt; width: 228pt; float: left;"><table cellspacing="0" cellpadding="0" class="fintab" style="margin-top: 4pt; border-collapse: collapse; width: 229pt; margin-left: auto; margin-right: auto;"><tr><td style="width: 90.83%; text-align: left; vertical-align: bottom; padding-top: 6pt; padding-bottom: 2.5pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tS">Principal and Selling Shareholders<font style="padding-left: 4.43pt;"></font></a></div></td><td class="gutter" style="width: 1.31%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 2.5pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.31%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 2.5pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.55%; vertical-align: bottom; white-space: nowrap; padding-top: 6pt; padding-bottom: 2.5pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: justify;"><a href="#tS">201</a></div></td></tr><tr><td style="width: 90.83%; text-align: left; vertical-align: bottom; padding-top: 2.5pt; padding-bottom: 2.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tRPT">Related Party Transactions<font style="padding-left: 1.63pt;"></font></a></div></td><td class="gutter" style="width: 1.31%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td class="gutter" style="width: 1.31%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td style="width: 6.55%; vertical-align: bottom; white-space: nowrap; padding-top: 2.5pt; padding-bottom: 2.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: justify;"><a href="#tRPT">204</a></div></td></tr><tr><td style="width: 90.83%; text-align: left; vertical-align: bottom; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-indent: -10pt; text-align: left;"><a href="#tDSC">Description of Share Capital and Articles of Association<font style="padding-left: 3.29pt;"></font></a></div></td><td class="gutter" style="width: 1.31%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.31%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.55%; vertical-align: bottom; white-space: nowrap; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: justify;"><a href="#tDSC">208</a></div></td></tr><tr><td style="width: 90.83%; text-align: left; vertical-align: bottom; padding-top: 2.5pt; padding-bottom: 2.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tCOSL">Comparison of Swiss Law and Delaware Law<font style="padding-left: 1.7pt;"></font></a></div></td><td class="gutter" style="width: 1.31%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td class="gutter" style="width: 1.31%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td style="width: 6.55%; vertical-align: bottom; white-space: nowrap; padding-top: 2.5pt; padding-bottom: 2.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: justify;"><a href="#tCOSL">220</a></div></td></tr><tr><td style="width: 90.83%; text-align: left; vertical-align: bottom; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tCSE">Common Shares Eligible for Future Sale<font style="padding-left: 3.33pt;"></font></a></div></td><td class="gutter" style="width: 1.31%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.31%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.55%; vertical-align: bottom; white-space: nowrap; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: justify;"><a href="#tCSE">228</a></div></td></tr><tr><td style="width: 90.83%; text-align: left; vertical-align: bottom; padding-top: 2.5pt; padding-bottom: 2.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tT">Taxation<font style="padding-left: 0.65pt;"></font></a></div></td><td class="gutter" style="width: 1.31%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td class="gutter" style="width: 1.31%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td style="width: 6.55%; vertical-align: bottom; white-space: nowrap; padding-top: 2.5pt; padding-bottom: 2.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: justify;"><a href="#tT">230</a></div></td></tr><tr><td style="width: 90.83%; text-align: left; vertical-align: bottom; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tU">Underwriters<font style="padding-left: 2.75pt;"></font></a></div></td><td class="gutter" style="width: 1.31%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.31%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.55%; vertical-align: bottom; white-space: nowrap; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: justify;"><a href="#tU">238</a></div></td></tr><tr><td style="width: 90.83%; text-align: left; vertical-align: bottom; padding-top: 2.5pt; padding-bottom: 2.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tEO">Expenses of the Offering<font style="padding-left: 2.95pt;"></font></a></div></td><td class="gutter" style="width: 1.31%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td class="gutter" style="width: 1.31%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td style="width: 6.55%; vertical-align: bottom; white-space: nowrap; padding-top: 2.5pt; padding-bottom: 2.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: justify;"><a href="#tEO">247</a></div></td></tr><tr><td style="width: 90.83%; text-align: left; vertical-align: bottom; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tLM">Legal Matters<font style="padding-left: 3.86pt;"></font></a></div></td><td class="gutter" style="width: 1.31%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.31%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.55%; vertical-align: bottom; white-space: nowrap; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: justify;"><a href="#tLM">248</a></div></td></tr><tr><td style="width: 90.83%; text-align: left; vertical-align: bottom; padding-top: 2.5pt; padding-bottom: 2.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tE">Experts<font style="padding-left: 4.95pt;"></font></a></div></td><td class="gutter" style="width: 1.31%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td class="gutter" style="width: 1.31%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td style="width: 6.55%; vertical-align: bottom; white-space: nowrap; padding-top: 2.5pt; padding-bottom: 2.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: justify;"><a href="#tE">248</a></div></td></tr><tr><td style="width: 90.83%; text-align: left; vertical-align: bottom; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tEJ">Enforcement of Judgments<font style="padding-left: 1.09pt;"></font></a></div></td><td class="gutter" style="width: 1.31%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.31%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.55%; vertical-align: bottom; white-space: nowrap; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: justify;"><a href="#tEJ">249</a></div></td></tr><tr><td style="width: 90.83%; text-align: left; vertical-align: bottom; padding-top: 2.5pt; padding-bottom: 2.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tWYC">Where You Can Find More Information<font style="padding-left: 2.49pt;"></font></a></div></td><td class="gutter" style="width: 1.31%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td class="gutter" style="width: 1.31%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td style="width: 6.55%; vertical-align: bottom; white-space: nowrap; padding-top: 2.5pt; padding-bottom: 2.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: justify;"><a href="#tWYC">250</a></div></td></tr><tr><td style="width: 90.83%; text-align: left; vertical-align: bottom; padding-top: 2.5pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#fFINTOC">Index to Financial Statements<font style="padding-left: 3.87pt;"></font></a></div></td><td class="gutter" style="width: 1.31%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.31%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.55%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.5pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#fFINTOC"><font style="padding-left: 1.11pt;">F-</font>1</a></div></td></tr></table></div><div style="clear: both;"> </div></div><div class="block-main" style="width: 468pt; margin-left: 36pt;"><div><div class="rule-partial" style="height: 0pt; width: 96pt; border-bottom: 1pt solid #000000; margin-top: 6pt; margin-bottom: 2pt; margin-left: auto; margin-right: auto;"> </div></div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 12pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">We are organized under the laws of Switzerland and our registered office and domicile is located in Epalinges, Canton of Vaud, Switzerland. Moreover, a number of our directors and executive officers are not residents of the United States, and all or a substantial portion of the assets of such persons are located outside the United States. As a result, it may not be possible for investors to effect service of process within the United States upon us or upon such persons or to enforce against them judgments obtained in U.S. courts, including judgments in actions predicated upon the civil liability provisions of the federal securities laws of the United States. We have been advised by our Swiss counsel that there is doubt as to the enforceability in Switzerland of original actions, or in actions for enforcement of judgments of U.S. courts, of civil liabilities to the extent solely predicated upon the federal and state securities laws of the United States. See &#8220;Enforcement of Judgments&#8221; for additional information.</div><div><div class="rule-partial" style="height: 0pt; width: 96pt; border-bottom: 1pt solid #000000; margin-bottom: 2pt; margin-left: auto; margin-right: auto; margin-top: 14.75pt;"> </div></div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 12pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Unless otherwise indicated or the context otherwise requires, all references in this prospectus to &#8220;ADC Therapeutics,&#8221; &#8220;ADCT,&#8221; the &#8220;Company,&#8221; &#8220;we,&#8221; &#8220;our,&#8221; &#8220;ours,&#8221; &#8220;us&#8221; or similar terms refer to ADC Therapeutics SA and its consolidated subsidiaries.</div><div><div class="rule-partial" style="height: 0pt; width: 96pt; border-bottom: 1pt solid #000000; margin-bottom: 2pt; margin-left: auto; margin-right: auto; margin-top: 14.75pt;"> </div></div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 12pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">We own various trademark registrations and applications, and unregistered trademarks, including ADC Therapeutics, ADCT and our corporate logo. All other trade names, trademarks and service marks of other companies appearing in this prospectus are the property of their respective owners. Solely for convenience, the trademarks and trade names in this prospectus may be referred to without the <sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">&#174;</sup> and &#8482; symbols, but such references should not be construed as any indicator that their respective owners will not assert, to the fullest extent under applicable law, their rights thereto. We do not intend to use or display other companies&#8217; trademarks and trade names to imply a relationship with, or endorsement or sponsorship of us by, any other companies.</div><div><div class="rule-partial" style="height: 0pt; width: 96pt; border-bottom: 1pt solid #000000; margin-bottom: 2pt; margin-left: auto; margin-right: auto; margin-top: 14.75pt;"> </div></div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Our consolidated financial statements are presented in U.S. dollars and have been prepared in accordance with International Financial Reporting Standards as issued by the International Accounting Standards Board (&#8220;IFRS&#8221;). None of the consolidated financial statements were prepared in accordance with generally accepted accounting principles in the United States (&#8220;U.S. GAAP&#8221;). The terms &#8220;dollar,&#8221; &#8220;USD&#8221; or &#8220;$&#8221; refer to U.S. dollars and the term &#8220;Swiss franc&#8221; and &#8220;CHF&#8221; refer to the legal currency of Switzerland, unless otherwise indicated. We have made rounding adjustments to some of the figures included in this prospectus. Accordingly, any numerical discrepancies in any table between totals and sums of the amounts listed are due to rounding.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The financial information should be read in conjunction with &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; and our consolidated financial statements.</div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 36pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">i<br></div></div></div>
<!--End Page 3-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 4-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 540pt;"><a name="nt10014672x1_drs_102-toc_pg2"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="block-frill" style="width: 540pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: Arial, Helvetica, sans-serif; font-size: 9pt; font-weight: bold; margin-top: 6pt; text-align: center;">Confidential Treatment Requested by ADC Therapeutics SA Pursuant to 17 C.F.R. &#167; 200.83<br></div></div><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 36pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Our fiscal year ends on December 31. References in this prospectus to a fiscal year relate to our fiscal year ended on December 31 of that calendar year.</div><div><div class="rule-partial" style="height: 0pt; width: 96pt; border-bottom: 1pt solid #000000; margin-bottom: 2pt; margin-left: auto; margin-right: auto; margin-top: 15.25pt;"> </div></div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 12pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">We, the Selling Shareholder and the underwriters have not authorized anyone to provide any information or to make any representations other than as contained in this prospectus or in any free writing prospectus prepared by or on behalf of us or to which we may have referred you. We, the Selling Shareholder and the underwriters take no responsibility for, and can provide no assurance as to the reliability of, any other information that others may give you.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Neither we, the Selling Shareholder nor the underwriters are making an offer to sell the common shares in any jurisdiction where the offer or sale is not permitted. This offering is being made in the United States and elsewhere solely on the basis of the information contained in this prospectus. You should assume that the information appearing in this prospectus is accurate only as of the date on the front cover of this prospectus, regardless of the time of delivery of this prospectus or any sale of the common shares. Our business, financial condition, results of operations and prospects may have changed since the date on the front cover of this prospectus. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">For investors outside the United States: Neither we, the Selling Shareholder nor the underwriters have done anything that would permit this offering or the possession or distribution of this prospectus in any jurisdiction where action for those purposes is required, other than in the United States. Persons outside the United States who come into possession of this prospectus must inform themselves about, and observe any restrictions relating to, this offering of common shares and the distribution of this prospectus outside the United States.</div><div><div class="rule-partial" style="height: 0pt; width: 96pt; border-bottom: 1pt solid #000000; margin-bottom: 2pt; margin-left: auto; margin-right: auto; margin-top: 15.25pt;"> </div></div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 12pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">We are incorporated as a Swiss stock corporation (<font style="font-style: italic;">soci&#233;t&#233; anonyme</font>) under the laws of Switzerland. Under the rules of the U.S. Securities and Exchange Commission (the &#8220;SEC&#8221;), we are currently eligible for treatment as a &#8220;foreign private issuer.&#8221; As a foreign private issuer, we are not required to file periodic reports and financial statements with the SEC as frequently or as promptly as domestic registrants whose securities are registered under the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;).</div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 36pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">ii<br></div></div></div>
<!--End Page 4-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 5-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 540pt;"><a name="nt10014672x1_drs_103-summary_pg1"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="block-frill" style="width: 540pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: Arial, Helvetica, sans-serif; font-size: 9pt; font-weight: bold; margin-top: 6pt; text-align: center;">Confidential Treatment Requested by ADC Therapeutics SA Pursuant to 17 C.F.R. &#167; 200.83<br></div></div><div class="border-box" style="border-top: 1pt solid #000000; border-left: 1pt solid #000000; border-right: 1pt solid #000000; border-bottom: 1pt solid #000000; margin-bottom: 12pt; padding-top: 12pt; padding-bottom: 12pt; width: 492pt; margin-left: 24pt;"><div class="page-content" style="margin-left: 12pt;"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: center;"><a name="tPS"><!--Anchor--></a>PROSPECTUS SUMMARY </div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 6pt; margin-left: 0pt; text-align: left;">This summary highlights information contained elsewhere in this prospectus. This summary may not contain all the information that may be important to you, and we urge you to read this entire prospectus carefully, including the &#8220;Risk Factors,&#8221; &#8220;Business&#8221; and &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; sections and our consolidated financial statements, including the notes thereto, included elsewhere in this prospectus, before deciding to invest in our common shares.</div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 20.5pt; margin-left: 0pt; text-align: left;">Overview</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left; line-height: 12.4pt;">We are a late clinical-stage oncology-focused biotechnology company evolving into a commercial-stage company as we prepare for the launch of our lead product candidate, if approved. We are a pioneer in the development of highly potent and targeted antibody drug conjugates (&#8220;ADCs&#8221;) for patients suffering from hematological malignancies and solid tumors. We develop our ADCs by applying our decades of experience in this field and using next-generation pyrrolobenzodiazepine (&#8220;PBD&#8221;) technology to which we have proprietary rights for our targets. We are leveraging our R&amp;D strengths, our disciplined approach to target selection and our preclinical and clinical development strategy to generate a diverse and balanced portfolio and research pipeline. Our hematology franchise comprises three clinical-stage product candidates, loncastuximab tesirine (&#8220;Lonca&#8221;), camidanlumab tesirine (&#8220;Cami&#8221;) and ADCT-602. Our solid tumor franchise comprises two clinical-stage product candidates, Cami and ADCT-601, and two preclinical product candidates, ADCT-901 and ADCT-701. We retain exclusive worldwide development and commercialization rights to all of our product candidates other than Cami, for which we have a collaboration and license agreement with Genmab A/S (&#8220;Genmab&#8221;). Our commercial organization has initiated pre-launch market activities and is leveraging our team&#8217;s deep industry experience to maximize the commercial potential of any approved products. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left; line-height: 12.4pt;">Our two lead product candidates, Lonca and Cami, have demonstrated significant clinical activity across a broad population of heavily pre-treated patients, while maintaining tolerability profiles that we believe are manageable. We have evaluated Lonca in a 145-patient pivotal Phase 2 clinical trial for the treatment of relapsed or refractory diffuse large B-cell lymphoma (&#8220;DLBCL&#8221;) that showed a 48.3% overall response rate (&#8220;ORR&#8221;) and a 24.1% complete response rate (&#8220;CRR&#8221;) as of April 2020. We intend to submit a biologics license application (&#8220;BLA&#8221;) to the U.S. Food and Drug Administration (&#8220;FDA&#8221;) in the second half of 2020 for Lonca for the treatment of relapsed or refractory DLBCL. Concurrently, we intend to commence a confirmatory Phase 3 clinical trial of Lonca in combination with rituximab that, if successful, may serve as the basis for a supplemental biologics license application (&#8220;sBLA&#8221;) for Lonca for the treatment of relapsed or refractory DLBCL in transplant-ineligible patients. We are also conducting a Phase 1/2 clinical trial of Lonca in combination with ibrutinib for the treatment of relapsed or refractory DLBCL and mantle cell lymphoma (&#8220;MCL&#8221;) that showed a 75.0%&#160;ORR and a 58.3% CRR as of April 6, 2020 at the dose being used in the pivotal Phase 2 portion of the clinical trial. In July&#160;2020, we dosed the first patient in the pivotal Phase 2 portion of this clinical trial. We also had an end-of-Phase 1 meeting with the FDA in the second quarter of 2020 to discuss a potential pivotal Phase 2 clinical trial of Lonca for the treatment of relapsed or refractory follicular lymphoma (&#8220;FL&#8221;) that we expect to commence in the first half of 2021. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left; line-height: 12.39pt;">In addition, we are evaluating Cami in a 100-patient pivotal Phase 2 clinical trial for the treatment of relapsed or refractory Hodgkin lymphoma (&#8220;HL&#8221;) and have enrolled&#160;47 patients as of June&#160;30, 2020. We have completed enrollment of a 133-patient Phase 1 clinical trial of Cami for the treatment of relapsed or refractory HL and non-Hodgkin lymphoma (&#8220;NHL&#8221;) that has shown an 86.5% ORR and a 48.6% CRR in patients with HL at the initial dose for our pivotal Phase 2 clinical trial and a 44.0% ORR and an 8.0% CRR in a subset of patients with T-cell lymphoma as of April 2019. We anticipate reporting top-line response rate data from our pivotal Phase 2 clinical trial of Cami for the treatment of HL in the first half of 2021, and we believe that this clinical trial, if successful, will support a BLA submission. We are also evaluating Cami in a Phase 1b clinical trial as a novel immuno-oncology approach for the treatment of various advanced solid tumors. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left; line-height: 12.39pt;">Antibody drug conjugates are an established therapeutic approach in oncology. Currently, there are ten approved ADCs, six of which were approved by the FDA in the past two years. ADCs selectively deliver potent chemotherapeutic cytotoxins directly to tumor cells, with the goal of maximizing activity in tumor cells while minimizing toxicity to healthy cells. The antibody component is designed to selectively bind to a distinct antigen preferentially expressed on tumor cells or other cells in the tumor microenvironment. Upon binding to the antigen, most ADCs are internalized by the cell where the cytotoxic warhead is released, causing cell death. </div></div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 36pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">1<br></div></div></div>
<!--End Page 5-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 6-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 540pt;"><a name="nt10014672x1_drs_103-summary_pg2"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="block-frill" style="width: 540pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: Arial, Helvetica, sans-serif; font-size: 9pt; font-weight: bold; margin-top: 6pt; text-align: center;">Confidential Treatment Requested by ADC Therapeutics SA Pursuant to 17 C.F.R. &#167; 200.83<br></div></div><div class="border-box" style="border-top: 1pt solid #000000; border-left: 1pt solid #000000; border-right: 1pt solid #000000; border-bottom: 1pt solid #000000; margin-bottom: 12pt; padding-top: 12pt; padding-bottom: 12pt; width: 492pt; margin-left: 24pt;"><div class="page-content" style="margin-left: 12pt;"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-indent: 20pt; text-align: left; line-height: 12.4pt;">PBD warheads have a different mechanism of action from other warheads because they create cross-links in the cancer cells&#8217; DNA that do not distort the DNA helix, potentially evading the cells&#8217; natural DNA repair mechanisms. They have been shown preclinically to be approximately 100&#160;times more potent than warheads used in currently marketed ADCs. Our ADCs use next-generation PBD technology, which is designed to produce warheads that are less hydrophobic, causing them to be easier to conjugate and, based on preclinical data, have less off-target toxicity than first-generation PBD warheads. Preclinical studies have further shown that our next-generation PBD warheads have improved therapeutic indices compared to first-generation PBDs. We believe that this mechanism of action has the potential to allow our ADCs to achieve significant clinical activity and durable responses in difficult-to-treat patients. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left; line-height: 12.4pt;">We were founded in 2011 as a spinoff from Spirogen Ltd. (&#8220;Spirogen&#8221;), which was founded in 2000 and was an early innovator in PBD-based ADC research. Our co-founder and CEO, Dr. Christopher Martin, was a founder and the CEO of Spirogen until its sale to AstraZeneca plc in 2013. We leverage Dr. Martin&#8217;s decades-long experience in the development and evolution of PBD-based ADC research. Our senior management team also brings extensive experience in oncology research and development, clinical development, chemistry, manufacturing and controls (&#8220;CMC&#8221;), medical affairs, commercialization and regulatory and compliance, having held senior positions in such companies as Ariad Pharmaceuticals, Inc., AstraZeneca plc, Bristol-Myers Squibb Company, Celgene Corporation, Daiichi Sankyo Company, Genentech, Inc., Genmab, ImmunoGen, Inc., MorphoSys AG and Wyeth Pharmaceuticals, Inc. Our board of directors includes former senior executives of Array BioPharma Inc., AstraZeneca plc, GlaxoSmithKline plc, Pfizer Inc., F. Hoffmann-La Roche AG and Serono S.A.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Since inception, we have raised $891.2 million in gross cash proceeds from equity and convertible debt financings. Our headquarters are located in Lausanne, Switzerland, our research and development team is based in London, our clinical development team is based in New Jersey and in Lausanne, our commercialization team is based in New Jersey and our CMC team is based in the San Francisco Bay Area.</div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 20.5pt; margin-left: 0pt; text-align: left;">The Potential of Our Next-Generation PBD-Based Antibody Drug Conjugates </div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;"><font style="font-style: italic;">Cytotoxic Potency</font>. The PBD dimer warheads used in our ADCs have been shown preclinically to be approximately 100 times more potent than other warheads used in currently marketed ADCs, such as auristatin, maytansine and calicheamicin. </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 4pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;"><font style="font-style: italic;">Activity</font><font style="font-style: italic;"> in Tumors with Low-Expressing Targets</font>. The high potency of our PBD-based warheads means that, compared to other warheads, fewer molecules of warhead should be needed to be internalized into the cancer cell to kill it. We believe that the potency of our PBD-based warheads may allow us to develop ADCs that target antigens with low expression levels in the tumor microenvironment, potentially increasing the range of cancers amenable to treatment with ADCs. </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 4pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;"><font style="font-style: italic;">Durable Responses</font>. Our PBD-based ADCs create <font style="font-style: italic;">inter</font>strand cross-links in the target cells&#8217; DNA. As PBD cross-links are non-distortive, they are designed to be able to evade the cells&#8217; DNA repair mechanisms that result in limited clinical responses and relapses. We believe that this may contribute to the frequency and durability of responses in heavily pre-treated and primary refractory patients that we have observed in our clinical trials. </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 4pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;"><font style="font-style: italic;">Bystander Effect</font>. Since our PBD-based warheads are cell-permeable, they may be able to diffuse into adjacent cells and kill them in an antigen-independent manner. We believe that this may allow us to develop ADCs that target antigens with heterogeneous expression levels in the tumor microenvironment, potentially increasing the range of cancers amenable to treatment with ADCs. </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 4pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;"><font style="font-style: italic;">Immunogenic Cell Death</font>. PBD warheads have been observed to induce immunogenic cell death, whereby a cancer cell&#8217;s death expresses certain stress signals that induce the body&#8217;s anti-tumor immune response through the activation of T cells and antigen-presenting cells. This opens up the potential for combining our ADCs with other therapies, particularly with immuno-oncology therapies such as checkpoint inhibitors, that are specifically designed to activate the patient&#8217;s own immune system to combat cancer. </div></td></tr></table></div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 36pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">2<br></div></div></div>
<!--End Page 6-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 7-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 540pt;"><a name="nt10014672x1_drs_103-summary_pg3"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="block-frill" style="width: 540pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: Arial, Helvetica, sans-serif; font-size: 9pt; font-weight: bold; margin-top: 6pt; text-align: center;">Confidential Treatment Requested by ADC Therapeutics SA Pursuant to 17 C.F.R. &#167; 200.83<br></div></div><div class="border-box" style="border-top: 1pt solid #000000; border-left: 1pt solid #000000; border-right: 1pt solid #000000; border-bottom: 1pt solid #000000; margin-bottom: 12pt; padding-top: 12pt; padding-bottom: 12pt; width: 492pt; margin-left: 24pt;"><div class="page-content" style="margin-left: 12pt;"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">Our Pipeline</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 13.75pt; text-align: center;"><img style="height: 253px; width: 583px;" src="nt10014672x1_barchart1.jpg"><br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">&#8201;</div><div><div class="rule-partial" style="height: 0pt; width: 72pt; border-bottom: 1pt solid #000000; margin-bottom: 1pt; margin-right: auto; margin-left: 0pt; margin-top: 14.75pt;"> </div></div><div class="ftnote" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 3pt; margin-left: 0pt; text-align: left;">Anticipated milestones set forth in this chart and in this prospectus are subject to further future adjustment based on, among other factors, the impact of the COVID-19 pandemic. *We believe that our Phase 1/2 clinical trial of Lonca in combination with ibrutinib for the treatment of relapsed or refractory DLBCL and MCL, our Phase 2 clinical trial of Lonca for the treatment of relapsed or refractory FL and our Phase 2 clinical trial of Cami for the treatment of relapsed or refractory HL are pivotal clinical trials (i.e., a clinical trial intended to serve as the basis for BLA submission). Therefore, we believe that subsequent Phase 3 clinical trials will be confirmatory clinical trials. **We retain worldwide development and commercialization rights to Cami, subject to our collaboration and license agreement with Genmab. See &#8220;Recent Developments&#8221; and &#8220;Business&#8212;License and Collaboration Agreements&#8212;Genmab Collaboration and License Agreement.&#8221; </div><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 18pt; margin-left: 0pt; text-align: left;">Lonca </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Our lead product candidate, loncastuximab tesirine, or Lonca, is an ADC targeting CD19-expressing cancers. We are developing Lonca for the treatment of relapsed or refractory NHL, both when used as a monotherapy and when used in combination with other therapies. The following summary provides key information about Lonca: </div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">We retain exclusive worldwide development and commercialization rights to Lonca. We intend to commercialize Lonca in the United States through our own infrastructure and may selectively pursue strategic collaborations and licensing opportunities in other geographies. </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">We intend to submit a BLA to the FDA for Lonca for the treatment of relapsed or refractory DLBCL in the second half of 2020. Concurrently, we intend to commence a confirmatory clinical trial of Lonca in combination with rituximab, which, if successful, we believe will support an sBLA for Lonca to be used as a second-line therapy for the treatment of relapsed or refractory DLBCL in transplant-ineligible patients. </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">We completed enrollment of a 145-patient pivotal Phase 2 clinical trial for the treatment of relapsed or refractory DLBCL. </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 40pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 6pt;">&#9675;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 6pt; text-align: left;"><font style="font-size: 10pt;">As of </font><font style="font-size: 10pt;">April 2020</font><font style="font-size: 10pt;">, we observed a </font><font style="font-size: 10pt;">48.3</font><font style="font-size: 10pt;">% </font><font style="font-size: 10pt;">ORR </font><font style="font-size: 10pt;">and a 24.1% CRR </font><font style="font-size: 10pt;">in 145 heavily pre-treated </font><font style="font-size: 10pt;">patients who </font><font style="font-size: 10pt;">had</font><font style="font-size: 10pt;"> received a median of three prior lines of therapy. </font><font style="font-size: 10pt;">The median duration of </font><font style="font-size: 10pt;">response was 10.25 months</font><font style="font-size: 10pt;">.</font></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 40pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 6pt;">&#9675;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 6pt; text-align: left;"><font style="font-size: 10pt;">Lonca&#8217;s significant clinical activity was observed across a broad patient population in this clinical </font><font style="font-size: 10pt;">trial, including patients with primary refractory disease, bulky disease, double-hit or triple-hit </font><font style="font-size: 10pt;">disease and transformed disease, </font><font style="font-size: 10pt;">as well as </font><font style="font-size: 10pt;">elderly patients and patients who did not respond to </font><font style="font-size: 10pt;">any </font><font style="font-size: 10pt;">prior therapy.</font><font style="font-size: 10pt;"> </font></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">Lonca is also being evaluated in a Phase 1/2 clinical trial in combination with ibrutinib for the treatment of relapsed or refractory DLBCL and MCL. </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 40pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 6pt;">&#9675;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 6pt; text-align: left;"><font style="font-size: 10pt;">As of </font><font style="font-size: 10pt;">April&#160;</font><font style="font-size: 10pt;">6</font><font style="font-size: 10pt;">, 2020,</font><font style="font-size: 10pt;"> at the dose </font><font style="font-size: 10pt;">being</font><font style="font-size: 10pt;"> used in the pivotal Phase 2 part of the clinical trial,</font><font style="font-size: 10pt;"> we </font><font style="font-size: 10pt;">observed a </font><font style="font-size: 10pt;">75.0</font><font style="font-size: 10pt;">% ORR </font><font style="font-size: 10pt;">and a </font><font style="font-size: 10pt;">58.3% CRR</font><font style="font-size: 10pt;"> </font><font style="font-size: 10pt;">in heavily pre-treated evaluable DLBCL patients who </font><font style="font-size: 10pt;">had</font><font style="font-size: 10pt;"> received a median of </font><font style="font-size: 10pt;">two</font><font style="font-size: 10pt;"> prior lines of therapy.</font></div></td></tr></table></div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 36pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">3<br></div></div></div>
<!--End Page 7-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 8-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 540pt;"><a name="nt10014672x1_drs_103-summary_pg4"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="block-frill" style="width: 540pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: Arial, Helvetica, sans-serif; font-size: 9pt; font-weight: bold; margin-top: 6pt; text-align: center;">Confidential Treatment Requested by ADC Therapeutics SA Pursuant to 17 C.F.R. &#167; 200.83<br></div></div><div class="border-box" style="border-top: 1pt solid #000000; border-left: 1pt solid #000000; border-right: 1pt solid #000000; border-bottom: 1pt solid #000000; margin-bottom: 12pt; padding-top: 12pt; padding-bottom: 12pt; width: 492pt; margin-left: 24pt;"><div class="page-content" style="margin-left: 12pt;"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6.75pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">We also intend to commence an additional pivotal Phase 2 clinical trial of Lonca for the treatment of FL in the first half of 2021.</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 40pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 6pt;">&#9675;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 6pt; text-align: left;"><font style="font-size: 10pt;">In the Phase 1 clinical trial of Lonca for the treatment of relapsed or refractory </font><font style="font-size: 10pt;">B-cell lineage </font><font style="font-size: 10pt;">NHL</font><font style="font-size: 10pt;"> </font><font style="font-size: 10pt;">(&#8220;B-NHL&#8221;)</font><font style="font-size: 10pt;">, we observed a 78.6% ORR </font><font style="font-size: 10pt;">and a 64.3% CRR</font><font style="font-size: 10pt;"> </font><font style="font-size: 10pt;">in heavily pre-treated patients </font><font style="font-size: 10pt;">with relapsed or refractory FL who </font><font style="font-size: 10pt;">had</font><font style="font-size: 10pt;"> received a median of four prior lines of therapy. </font></div></td></tr></table><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">We believe that the commercial potential of Lonca, if approved, is supported by the following key attributes observed to date:</div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">Favorable clinical activity across a broad patient population, including transplant eligible and ineligible patients, patients who have not responded to first-line therapy or any prior therapy and patients with bulky disease, double-hit and triple-hit disease and transformed disease;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">Significant single-agent clinical activity while maintaining a manageable tolerability profile with a low incidence of febrile neutropenia;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">Activity in heavily pretreated patients, including those who had received prior CD19 therapies, including CAR T-cell therapy (&#8220;CAR-T&#8221;), and stem cell transplant (&#8220;SCT&#8221;);</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">Promising clinical activity observed in our combination clinical trial with ibrutinib, which we believe demonstrates the opportunity to advance Lonca into earlier lines of therapy in combination with other therapies such as ibrutinib and rituximab; and</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">Convenient 30-minute intravenous infusions once every three weeks in the out-patient setting. </div></td></tr></table><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">If approved, we intend to commercialize Lonca in the United States through our own infrastructure and may selectively pursue strategic collaborations and licensing opportunities in other geographies. Our U.S. commercial organization buildout and launch-readiness activities are ongoing to enable commercialization of Lonca promptly following the receipt of accelerated approval, and include:</div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">Our successful recruitment of an experienced Chief Commercial Officer and senior commercial leadership team, including a Vice President of Sales, a Vice President of Marketing and a Vice President of Market Access, with broader organizational recruitment underway;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">Our successful recruitment of a Vice President of Medical Affairs, with broader organizational recruitment underway, including field-based medical science liaisons;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">Investing resources to assess the competitive landscape, supporting our differentiated profile and accelerating our launch readiness efforts;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">Increased scientific interactions with Key Opinion Leaders; and</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">Our plans to build a highly talented and efficient U.S. customer-facing organization of more than 65 cross-functional employees, which we believe has the potential to capture more than 80% of the DLBCL commercial opportunity. </div></td></tr></table><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 20.5pt; margin-left: 0pt; text-align: left;">Cami </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Our second lead product candidate, camidanlumab tesirine, or Cami, is an ADC targeting CD25-expressing cancers. We are developing Cami for the treatment of relapsed or refractory HL, NHL and solid tumors. The following summary provides key information about Cami: </div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">We retain worldwide development and commercialization rights to Cami, subject to our collaboration and license agreement with Genmab. </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">We are advancing Cami through clinical development to support a BLA submission for the treatment of relapsed or refractory HL.</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">Cami is being evaluated in a 100-patient pivotal Phase 2 clinical trial for the treatment of relapsed or refractory HL, for which we anticipate reporting top-line response rate data in the first half of 2021.</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 40pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 6pt;">&#9675;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 6pt; text-align: left;"><font style="font-size: 10pt;">As of </font><font style="font-size: 10pt;">June&#160;30</font><font style="font-size: 10pt;">, 2020, </font><font style="font-size: 10pt;">47</font><font style="font-size: 10pt;"> patients have been </font><font style="font-size: 10pt;">enrolled</font><font style="font-size: 10pt;"> in this pivotal Phase 2 clinical trial</font><font style="font-size: 10pt;">.</font></div></td></tr></table></div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 36pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">4<br></div></div></div>
<!--End Page 8-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 9-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 540pt;"><a name="nt10014672x1_drs_103-summary_pg5"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="block-frill" style="width: 540pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: Arial, Helvetica, sans-serif; font-size: 9pt; font-weight: bold; margin-top: 6pt; text-align: center;">Confidential Treatment Requested by ADC Therapeutics SA Pursuant to 17 C.F.R. &#167; 200.83<br></div></div><div class="border-box" style="border-top: 1pt solid #000000; border-left: 1pt solid #000000; border-right: 1pt solid #000000; border-bottom: 1pt solid #000000; margin-bottom: 12pt; padding-top: 12pt; padding-bottom: 12pt; width: 492pt; margin-left: 24pt;"><div class="page-content" style="margin-left: 12pt;"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6.75pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">Enrollment has been completed in a 133-patient Phase 1 clinical trial of Cami for the treatment of relapsed or refractory HL and NHL, including 77 patients with relapsed or refractory HL. In this clinical trial, Cami demonstrated significant clinical activity across a broad patient population and maintained a tolerability profile that we believe was manageable. More specifically, as of April 2019, we observed: </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 40pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 6pt;">&#9675;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 6pt; text-align: left;"><font style="font-size: 10pt;">A</font><font style="font-size: 10pt;">t the initial dose for our pivotal Phase 2 clinical trial, </font><font style="font-size: 10pt;">an 86.5% ORR </font><font style="font-size: 10pt;">and a 48.6% CRR</font><font style="font-size: 10pt;"> </font><font style="font-size: 10pt;">in </font><font style="font-size: 10pt;">heavily pre-treated patients with relapsed or refractory HL who </font><font style="font-size: 10pt;">had</font><font style="font-size: 10pt;"> received a median of five </font><font style="font-size: 10pt;">prior lines of therapy</font><font style="font-size: 10pt;">, including patients who were relapsed or refractory to any or all of </font><font style="font-size: 10pt;">brentuximab vedotin, checkpoint inhibitors and stem cell transplant;</font><font style="font-size: 10pt;"> and</font><font style="font-size: 10pt;"> </font></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 40pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 6pt;">&#9675;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 6pt; text-align: left;"><font style="font-size: 10pt;">A</font><font style="font-size: 10pt;"> 44.0% ORR </font><font style="font-size: 10pt;">and an 8.0% CRR</font><font style="font-size: 10pt;"> </font><font style="font-size: 10pt;">in heavily pre-treated patients with relapsed or refractory T-cell </font><font style="font-size: 10pt;">lymphoma who </font><font style="font-size: 10pt;">had</font><font style="font-size: 10pt;"> received a median of four prior lines of therapy.</font><font style="font-size: 10pt;"> </font></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">Cami is also being evaluated in a Phase 1b clinical trial for the treatment of selected advanced solid tumors by targeting CD25-expressing regulatory T cells (&#8220;Tregs&#8221;), for which we anticipate reporting pharmacokinetics/pharmacodynamics (&#8220;PK/PD&#8221;) data at a medical conference in the second half of 2020. </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 40pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 6pt;">&#9675;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 6pt; text-align: left;"><font style="font-size: 10pt;">In paired biopsies from three </font><font style="font-size: 10pt;">of six </font><font style="font-size: 10pt;">patients in the Phase 1b clinical trial, we have observed a </font><font style="font-size: 10pt;">significant increase in the ratio of T effector cells (&#8220;Teffs&#8221;) to Tregs.</font><font style="font-size: 10pt;"> </font></div></td></tr></table><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">We believe that the commercial potential of Cami, if approved, is supported by the following key attributes observed to date:</div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">At the initial dose for our pivotal Phase&#160;2 clinical trial, an 86.5% ORR and a 48.6% CRR in heavily pre-treated patients with relapsed or refractory HL who were relapsed or refractory to any or all of brentuximab vedotin, checkpoint inhibitors and stem cell transplant;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">Tolerability profile that we believe is manageable;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">The potential opportunity to advance Cami into earlier lines of therapy as a monotherapy or in combination with other therapies;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">Novel immuno-oncology approach targeting Tregs for the treatment of various advanced solid tumors; and</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">Convenient 30-minute intravenous infusions once every three weeks in the out-patient setting. </div></td></tr></table><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 20.5pt; margin-left: 0pt; text-align: left;">Our Strategy</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 7.5pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Key elements of our strategy are outlined below: </div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">Continue to prepare for the near-term commercial launch of Lonca, if approved. </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">Expand the potential market opportunity by advancing Lonca into earlier lines of therapy and for multiple indications. </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">Advance our second lead product candidate, Cami, to support BLA submission. </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">Advance our two clinical-stage solid tumor product candidates to address multiple indications in areas of high unmet medical need. </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">Continue to build a diverse and balanced portfolio of product candidates to address high unmet medical needs in oncology by leveraging our R&amp;D strengths, our disciplined approach to target selection and our preclinical and clinical development strategy. </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">Maximize the commercial potential of our product candidates through both our own commercial organization and strategic collaborations and licensing opportunities in select markets.</div></td></tr></table></div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 36pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">5<br></div></div></div>
<!--End Page 9-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 10-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 540pt;"><a name="nt10014672x1_drs_103-summary_pg6"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="block-frill" style="width: 540pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: Arial, Helvetica, sans-serif; font-size: 9pt; font-weight: bold; margin-top: 6pt; text-align: center;">Confidential Treatment Requested by ADC Therapeutics SA Pursuant to 17 C.F.R. &#167; 200.83<br></div></div><div class="border-box" style="border-top: 1pt solid #000000; border-left: 1pt solid #000000; border-right: 1pt solid #000000; border-bottom: 1pt solid #000000; margin-bottom: 12pt; padding-top: 12pt; padding-bottom: 12pt; width: 492pt; margin-left: 24pt;"><div class="page-content" style="margin-left: 12pt;"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">Recent Developments</div><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 7.5pt; margin-left: 0pt; text-align: left;">Impact of the COVID-19 Pandemic</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">On March 11, 2020, the World Health Organization declared the outbreak of the coronavirus disease (&#8220;COVID-19&#8221;) caused by a novel strain of coronavirus as a pandemic. Since then, COVID-19 has continued to spread, impacting the economies of most countries around the world. Our operations, similar to those of other life sciences companies, have been impacted by the COVID-19 pandemic. As the COVID-19 pandemic continues to evolve, we believe that the extent of its impact to our operations, operating results, cash flows, liquidity and financial condition will be primarily driven by the severity and duration of the pandemic, the pandemic&#8217;s impact on the U.S. and global economies and the timing, scope and effectiveness of national and local governmental responses to the pandemic, especially in areas where the conditions have recently worsened. Those primary drivers are beyond our knowledge and control, and as a result, at this time, the COVID-19 pandemic&#8217;s ultimate impact on our results of operations, cash flows and financial position cannot be reasonably predicted. We are continuously assessing and adapting our working practices and business operations to ensure compliance with official guidance and containment measures related to the pandemic, and we are working proactively with our partners and other stakeholders to take steps to mitigate and minimize any negative impact of the COVID-19 pandemic on our research and development programs, clinical trials, regulatory submissions, commercialization preparations and other business operations. With respect to our clinical-stage product candidates:</div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">The pivotal Phase 2 clinical trial of Lonca in relapsed or refractory DLBCL has completed enrollment. Patients continue in follow-up, and data are being collected. We anticipate submitting a BLA in the second half of 2020. </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">We have not experienced any material impact of the COVID-19 pandemic on our clinical trial enrollment, timelines or expenses for our other clinical-stage product candidates. However, the ultimate impact of the COVID-19 pandemic is highly uncertain and subject to change.</div></td></tr></table><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">All anticipated milestones set forth in this prospectus are subject to further future adjustment as a result of the COVID-19 pandemic. See &#8220;Risk Factors&#8212;Risks Related to Our Business and Industry&#8212;Our business could be adversely affected by the effects of health epidemics, including the COVID-19 pandemic, in regions where we or third parties on which we rely have significant manufacturing facilities, concentrations of clinical trial sites or other business operations.&#8221;</div><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 20pt; margin-left: 0pt; text-align: left;">Genmab Collaboration and License Agreement </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Our collaboration and license agreement with Genmab may require a divestment of Cami, in which Genmab has a 25% interest. On June 24, 2020, we and Genmab agreed to enter into a period of good faith negotiations regarding the key financial terms on which we would acquire Genmab&#8217;s share of Cami. If we and Genmab reach agreement, we and Genmab will have a further period of time to negotiate a license agreement for Genmab&#8217;s rights in Cami, which period may be extended by our and Genmab&#8217;s mutual written agreement. If we fail to agree on the key financial terms or if no license agreement has been entered into during the respective time periods to do so, a defined process to facilitate the divestment of Cami by licensing the rights thereto to a third party will be initiated. See &#8220;Business&#8212;License and Collaboration Agreements&#8212;Genmab Collaboration and License Agreement.&#8221; </div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 20pt; margin-left: 0pt; text-align: left;">Risks Associated with Our Business</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Our ability to implement our business strategy is subject to numerous risks, as more fully described in the section entitled &#8220;Risk Factors&#8221; immediately following this prospectus summary. These risks include, among others:</div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">We have incurred net losses during all fiscal periods since our inception, have no products approved for commercial sale and anticipate that we will continue to incur substantial net losses for the foreseeable future.</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">Our $115.0&#160;million Facility Agreement with Deerfield Partners, L.P. and certain of its affiliates (the &#8216;&#8216;Facility Agreement&#8221;) and the associated restrictive covenants thereunder could adversely affect our financial condition and will restrict our ability to raise capital. </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">We have concentrated our research and development efforts on PBD-based ADCs, and our future success depends heavily on the successful development of this therapeutic approach.</div></td></tr></table></div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 36pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">6<br></div></div></div>
<!--End Page 10-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 11-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 540pt;"><a name="nt10014672x1_drs_103-summary_pg7"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="block-frill" style="width: 540pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: Arial, Helvetica, sans-serif; font-size: 9pt; font-weight: bold; margin-top: 6pt; text-align: center;">Confidential Treatment Requested by ADC Therapeutics SA Pursuant to 17 C.F.R. &#167; 200.83<br></div></div><div class="border-box" style="border-top: 1pt solid #000000; border-left: 1pt solid #000000; border-right: 1pt solid #000000; border-bottom: 1pt solid #000000; margin-bottom: 12pt; padding-top: 12pt; padding-bottom: 12pt; width: 492pt; margin-left: 24pt;"><div class="page-content" style="margin-left: 12pt;"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6.75pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">Our current product candidates are in various stages of development, and it is possible that none of our product candidates will ever become commercial products.</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">In the past, certain of our clinical trials, including our pivotal Phase 2 clinical trial of Cami for the treatment of relapsed or refractory HL, have been subject to clinical holds prior to the dosing of the first patient and partial clinical holds after the dosing of the first patient. A clinical hold on any of our clinical trials will result in delays of our clinical development timeline.</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">Our product candidates may cause undesirable side effects or have other properties that may delay or prevent their development or regulatory approval or limit their commercial potential.</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">The regulatory review and approval processes of the FDA, the European Medicines Agency (&#8220;EMA&#8221;) and comparable regulatory authorities in other jurisdictions are lengthy, time-consuming and inherently unpredictable. If we are unable to obtain, or if there are delays in obtaining, regulatory approval for our product candidates, we will not be able to commercialize our product candidates and our ability to generate revenue will be materially impaired.</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">As a company, we have never commercialized a product. We currently have no active sales force and we are in the process of building our commercial infrastructure. We may lack the necessary expertise, personnel and resources to successfully commercialize our product candidates.</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">We face substantial competition, which may result in others discovering, developing or commercializing products, treatment methods and/or technologies before or more successfully than we do.</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">Our rights to Cami are subject to our collaboration and license agreement with Genmab, and there can be no assurance that we will maintain the rights to develop or commercialize Cami.</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">We rely on third parties for the manufacture, production, storage and distribution of our product candidates. Our dependence on these third parties may impair the clinical advancement and commercialization of our product candidates.</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">Issued patents covering one or more of our product candidates or technologies, including Lonca, Cami or the technology we use in our product candidates, could be found invalid or unenforceable if challenged in court.</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">If we fail to attract and retain senior management and key scientific personnel or fail to adequately plan for succession, we may be unable to successfully develop our product candidates, conduct our clinical trials and commercialize our product candidates.</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">Our business could be adversely affected by the effects of health epidemics, including the COVID-19 pandemic, in regions where we or third parties on which we rely have significant manufacturing facilities, concentrations of clinical trial sites or other business operations.</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">We have identified material weaknesses in our internal control over financial reporting. If we are unable to remediate these material weaknesses or otherwise fail to maintain an effective system of internal controls, we may not be able to accurately or timely report our financial condition or results of operations, which may adversely affect our business and the price of our common shares.</div></td></tr></table><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 20.5pt; margin-left: 0pt; text-align: left;">Company and Corporate Information</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">We were incorporated as a Swiss limited liability company (<font style="font-style: italic;">soci&#233;t&#233; &#224; responsabilit&#233; limit&#233;e</font>) on June&#160;6, 2011 and converted into a Swiss stock corporation (<font style="font-style: italic;">soci&#233;t&#233; anonyme</font>) under the laws of Switzerland on October&#160;13, 2015. We have two subsidiaries: ADC Therapeutics (UK) Limited and ADC Therapeutics America, Inc. Our principal executive office is located at Biop&#244;le, Route de la Corniche 3B, 1066 Epalinges, Switzerland and our telephone number is +41&#160;21 653 02 00. Our website is www.adctherapeutics.com. The reference to our website is an inactive textual reference only, and information contained therein or connected thereto is not incorporated into this prospectus or the registration statement of which it forms a part. </div></div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 36pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">7<br></div></div></div>
<!--End Page 11-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 12-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 540pt;"><a name="nt10014672x1_drs_103-summary_pg8"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="block-frill" style="width: 540pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: Arial, Helvetica, sans-serif; font-size: 9pt; font-weight: bold; margin-top: 6pt; text-align: center;">Confidential Treatment Requested by ADC Therapeutics SA Pursuant to 17 C.F.R. &#167; 200.83<br></div></div><div class="border-box" style="border-top: 1pt solid #000000; border-left: 1pt solid #000000; border-right: 1pt solid #000000; border-bottom: 1pt solid #000000; margin-bottom: 12pt; padding-top: 12pt; padding-bottom: 12pt; width: 492pt; margin-left: 24pt;"><div class="page-content" style="margin-left: 12pt;"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">Implications of Being an Emerging Growth Company</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">We qualify as an &#8220;emerging growth company&#8221; as defined in the Jumpstart our Business Startups Act of 2012 (the &#8220;JOBS Act&#8221;). As an emerging growth company, we may take advantage of specified reduced reporting and other burdens that are otherwise applicable generally to public companies. These provisions include:</div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">a requirement to have only two years of audited financial statements in addition to any required interim financial statements and correspondingly reduced disclosure in the Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations disclosure in the registration statement of which this prospectus forms a part;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">an exemption from the auditor attestation requirement in the assessment of our internal control over financial reporting pursuant to Section 404 of the Sarbanes-Oxley Act of 2002 (the &#8220;Sarbanes-Oxley Act&#8221;); and</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">to the extent that we no longer qualify as a foreign private issuer, (i)&#160;reduced disclosure obligations regarding executive compensation in our periodic reports and proxy statements and (ii)&#160;exemptions from the requirements of holding a non-binding advisory vote on executive compensation, including golden parachute compensation.</div></td></tr></table><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">We may take advantage of these provisions for up to five years or such earlier time that we are no longer an emerging growth company. We will remain an emerging growth company until the earliest of (i)&#160;the last day of the fiscal year in which we have total annual gross revenues of $1.07&#160;billion or more; (ii)&#160;the last day of the fiscal year following the fifth anniversary of the date of the completion of our initial public offering; (iii)&#160;the date on which we have issued more than $1.0&#160;billion in non-convertible debt during the previous three years; and (iv)&#160;the date on which we are deemed to be a large accelerated filer under the rules of the SEC, which means the market value of our common shares that are held by non-affiliates exceeds $700.0&#160;million as of the prior June 30<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">th</sup>. We may choose to take advantage of some but not all of these reduced burdens. For example, Section 107 of the JOBS Act also provides that an emerging growth company can take advantage of an extended transition period for complying with new or revised accounting standards applicable to public companies. This provision allows an emerging growth company to delay the adoption of certain accounting standards until those standards would otherwise apply to private companies. This transition period is only applicable under U.S. GAAP. As a result, we will adopt new or revised accounting standards on the relevant dates on which adoption of such standards is required or permitted by the International Accounting Standards Board.</div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 20.5pt; margin-left: 0pt; text-align: left;">Implications of Being a Foreign Private Issuer</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">We are also considered a &#8220;foreign private issuer.&#8221; Accordingly, we report under the Exchange Act as a non-U.S. company with foreign private issuer status. This means that, even after we no longer qualify as an emerging growth company, as long as we qualify as a foreign private issuer under the Exchange Act, we will be exempt from certain provisions of the Exchange Act that are applicable to U.S. domestic public companies, including:</div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the sections of the Exchange Act regulating the solicitation of proxies, consents or authorizations in respect of a security registered under the Exchange Act; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the sections of the Exchange Act requiring insiders to file public reports of their stock ownership and trading activities and liability for insiders who profit from trades made in a short period of time; and </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the rules under the Exchange Act requiring the filing with the SEC of quarterly reports on Form 10-Q containing unaudited financial and other specified information, or current reports on Form 8-K, upon the occurrence of specified significant events.</div></td></tr></table></div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 36pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">8<br></div></div></div>
<!--End Page 12-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 13-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 540pt;"><a name="nt10014672x1_drs_103-summary_pg9"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="block-frill" style="width: 540pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: Arial, Helvetica, sans-serif; font-size: 9pt; font-weight: bold; margin-top: 6pt; text-align: center;">Confidential Treatment Requested by ADC Therapeutics SA Pursuant to 17 C.F.R. &#167; 200.83<br></div></div><div class="border-box" style="border-top: 1pt solid #000000; border-left: 1pt solid #000000; border-right: 1pt solid #000000; border-bottom: 1pt solid #000000; margin-bottom: 12pt; padding-top: 12pt; padding-bottom: 12pt; width: 492pt; margin-left: 24pt;"><div class="page-content" style="margin-left: 12pt;"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">We may take advantage of these exemptions until such time as we are no longer a foreign private issuer. We would cease to be a foreign private issuer at such time as more than 50% of our outstanding voting securities are held by U.S. residents and any of the following three circumstances applies: (i)&#160;the majority of our executive officers or directors are U.S. citizens or residents, (ii)&#160;more than 50% of our assets are located in the United States or (iii)&#160;our business is administered principally in the United States. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">In this prospectus, we have taken advantage of certain of the reduced reporting requirements as a result of being an emerging growth company and a foreign private issuer. Accordingly, the information contained herein may be different than the information you receive from other public companies in which you hold equity securities.</div></div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 36pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">9<br></div></div></div>
<!--End Page 13-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 14-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 540pt;"><a name="nt10014672x1_drs_103-summary_pg10"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="block-frill" style="width: 540pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: Arial, Helvetica, sans-serif; font-size: 9pt; font-weight: bold; margin-top: 6pt; text-align: center;">Confidential Treatment Requested by ADC Therapeutics SA Pursuant to 17 C.F.R. &#167; 200.83<br></div></div><div class="border-box" style="border-top: 1pt solid #000000; border-left: 1pt solid #000000; border-right: 1pt solid #000000; border-bottom: 1pt solid #000000; margin-bottom: 12pt; padding-top: 12pt; padding-bottom: 12pt; width: 492pt; margin-left: 24pt;"><div class="page-content" style="margin-left: 12pt;"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: center;">THE OFFERING</div><div class="sum1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 216pt; margin-top: 7pt; margin-left: 0pt; text-align: left;">Common shares offered by us<font style="padding-left: 0.4pt;"></font></div><div class="sum2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: -10pt; margin-left: 240pt; text-align: left;">&#8195;&#8195;&#8195;&#8195;&#8195; shares.</div><div class="sum1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 216pt; margin-top: 8pt; margin-left: 0pt; text-align: left;">The Selling Shareholder<font style="padding-left: 0.64pt;"></font></div><div class="sum1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 216pt; margin-top: 6pt; margin-left: 10pt; text-indent: -10pt; text-align: left;">Option to purchase additional common shares offered by the Selling Shareholder<font style="padding-left: 2.63pt;"></font></div><div class="sum2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: -12pt; margin-left: 240pt; text-align: left;">The Selling Shareholder has granted the underwriters an option for a period of 30 days to purchase up to &#8195;&#8195;&#8195;&#8195;&#8195; additional common shares.</div><div class="sum1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 216pt; margin-top: 6pt; margin-left: 10pt; text-indent: -10pt; text-align: left;">Common shares to be outstanding immediately after this offering<font style="padding-left: 3.7pt;"></font></div><div class="sum2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: -10pt; margin-left: 240pt; text-align: left;">&#8195;&#8195;&#8195;&#8195;&#8195; shares.</div><div class="sum1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 216pt; margin-top: 8pt; margin-left: 0pt; text-align: left;">Use of proceeds<font style="padding-left: 3.43pt;"></font></div><div class="sum2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: -12pt; margin-left: 240pt; text-align: left;">We estimate that the net proceeds to us from this offering will be approximately $ &#8195;&#8195;&#160;million, assuming a public offering price of $&#8199;&#8199;&#8201;&#8199;&#8199; per common share, which was the last reported sale price of our common shares on the NYSE on &#8195;&#8195;&#8195;&#8195;, 2020, after deducting estimated underwriting discounts and commissions and estimated offering expenses payable by us. </div><div class="sum2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 240pt; text-align: left;">We will not receive any of the proceeds from the potential sale of common shares by the Selling Shareholder pursuant to the underwriters&#8217; option to purchase additional common shares.</div><div class="sum2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 240pt; text-align: left;">We intend to use the net proceeds from this offering, together with our existing cash and cash equivalents, estimated revenue from Lonca, including revenue from potential commercial partnerships, and the second disbursement under the Facility Agreement, as follows: (i)&#160;to advance the clinical development of Lonca for the treatment of multiple hematological malignancies; (ii)&#160;to advance the clinical development of Cami for the treatment of both hematological malignancies and solid tumors; (iii)&#160;to advance the clinical development of ADCT-602 for the treatment of relapsed or refractory ALL as well as ADCT-601 and ADCT-901 for the treatment of select advanced solid tumors, and to fund the research and development of our preclinical product candidates and preclinical pipeline; (iv)&#160;to commercialize Lonca in the United States, if approved; and (v)&#160;for working capital and other general corporate purposes. See &#8220;Use of Proceeds&#8221; for a more complete description of the intended use of proceeds from this offering. </div><div class="sum1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 216pt; margin-top: 8pt; margin-left: 0pt; text-align: left;">Risk factors<font style="padding-left: 2.63pt;"></font></div><div class="sum2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: -12pt; margin-left: 240pt; text-align: left;">See &#8220;Risk Factors&#8221; and the other information included in this prospectus for a discussion of factors you should consider before deciding to invest in our common shares.</div><div class="sum1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 216pt; margin-top: 8pt; margin-left: 0pt; text-align: left;">NYSE symbol<font style="padding-left: 0.78pt;"></font></div><div class="sum2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: -10pt; margin-left: 240pt; text-align: left;">&#8220;ADCT&#8221;</div></div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 36pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">10<br></div></div></div>
<!--End Page 14-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 15-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 540pt;"><a name="nt10014672x1_drs_103-summary_pg11"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="block-frill" style="width: 540pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: Arial, Helvetica, sans-serif; font-size: 9pt; font-weight: bold; margin-top: 6pt; text-align: center;">Confidential Treatment Requested by ADC Therapeutics SA Pursuant to 17 C.F.R. &#167; 200.83<br></div></div><div class="border-box" style="border-top: 1pt solid #000000; border-left: 1pt solid #000000; border-right: 1pt solid #000000; border-bottom: 1pt solid #000000; margin-bottom: 12pt; padding-top: 12pt; padding-bottom: 12pt; width: 492pt; margin-left: 24pt;"><div class="page-content" style="margin-left: 12pt;"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The number of common shares that will be outstanding after this offering is based on 70,715,852 common shares outstanding as of June&#160;30, 2020 and excludes: </div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">3,247,523 common shares issuable upon the exercise of options outstanding under our 2019 Equity Incentive Plan as of June&#160;30, 2020, at a weighted-average exercise price of $20.55 per share;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">&#8195;&#8195;&#8195;&#8195; common shares issuable upon the exercise of options outstanding under our 2019 Equity Incentive Plan granted after June&#160;30, 2020, at a weighted-average exercise price of $&#8199;&#8199;&#8201;&#8199;&#8199; per share; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">149,984 common shares issued pursuant to restricted share units granted to certain of our executive officers under our 2019 Equity Incentive Plan after June&#160;30, 2020; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">7,820,000 common shares reserved for future issuance under our 2019 Equity Incentive Plan, which include the common shares described in the three preceding items; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">54,148 common shares we hold in treasury; and </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">common shares issuable upon the conversion of the senior secured convertible notes issued or to be issued under the Facility Agreement. </div></td></tr></table><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8.5pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Unless otherwise indicated, all information contained in this prospectus assumes:</div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">no exercise of the option granted to the underwriters to purchase up to &#8195;&#8195;&#8195;&#8195; additional common shares in connection with this offering; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">a public offering price of $&#8199;&#8199;&#8201;&#8199;&#8199; per common share, which was the last reported sale price of our common shares on the NYSE on &#8195;&#8195;&#8195;&#8195;, 2020;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">no purchase of common shares in this offering by directors, officers or existing shareholders;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">no exercise of outstanding options described above; and </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">no conversion of the senior secured convertible notes issued under the Facility Agreement. </div></td></tr></table></div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 36pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">11<br></div></div></div>
<!--End Page 15-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 16-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 540pt;"><a name="nt10014672x1_drs_103-summary_pg12"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="block-frill" style="width: 540pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: Arial, Helvetica, sans-serif; font-size: 9pt; font-weight: bold; margin-top: 6pt; text-align: center;">Confidential Treatment Requested by ADC Therapeutics SA Pursuant to 17 C.F.R. &#167; 200.83<br></div></div><div class="border-box" style="border-top: 1pt solid #000000; border-left: 1pt solid #000000; border-right: 1pt solid #000000; border-bottom: 1pt solid #000000; margin-bottom: 12pt; padding-top: 12pt; padding-bottom: 12pt; width: 492pt; margin-left: 24pt;"><div class="page-content" style="margin-left: 12pt;"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: center;">SUMMARY CONSOLIDATED FINANCIAL DATA</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The following summary consolidated financial data should be read in conjunction with &#8220;Selected Consolidated Financial Data,&#8221; &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; and our consolidated financial statements, including the notes thereto, included elsewhere in this prospectus. The summary consolidated income statement data for the years ended December 31, 2019 and 2018 are derived from our audited consolidated financial statements included elsewhere in this prospectus. The summary consolidated income statement data for the six months ended June 30, 2020 and 2019 and the summary consolidated balance sheet data as of June 30, 2020 are derived from our unaudited condensed consolidated interim financial statements included elsewhere in this prospectus. The unaudited condensed consolidated interim financial statements have been prepared on the same basis as our audited consolidated financial statements and include all normal recurring adjustments that we consider necessary for a fair statement of our financial position and operating results as of the dates and for the periods presented. Our historical results are not necessarily indicative of the results that may be expected in the future, and our results for the six months ended June 30, 2020 are not necessarily indicative of the results that may be expected for the year ending December 31, 2020. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Our audited consolidated financial statements are prepared in accordance with IFRS and presented in USD. Our unaudited condensed consolidated interim financial statements are prepared in accordance with IAS 34 and presented in USD. </div><table cellspacing="0" cellpadding="0" class="fintab" style="margin-top: 11.25pt; border-collapse: collapse; width: 468pt; margin-left: auto; margin-right: auto;"><tr class="header"><td style="width: 48.72%; text-align: left; vertical-align: bottom; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 1.6%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.6%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td colspan="4" style="width: 22.47%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Six Months Ended June&#160;30,</div></td><td class="gutter" style="width: 1.6%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.6%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td colspan="4" style="width: 22.42%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Year Ended December 31, </div></td></tr><tr class="header"><td style="width: 48.72%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 1.6%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.6%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 9.64%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2020</div></td><td class="gutter" style="width: 1.6%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.6%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 9.64%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2019</div></td><td class="gutter" style="width: 1.6%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.6%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 9.62%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2019<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(2)</sup></div></td><td class="gutter" style="width: 1.6%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.6%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 9.61%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2018 </div></td></tr><tr class="header"><td style="width: 48.72%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Consolidated Income Statement Data:</div></td><td class="gutter" style="width: 1.6%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.6%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td colspan="10" style="width: 48.09%; text-align: center; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">(in USD thousands except for share and per share data) </div></td></tr><tr><td style="width: 48.72%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Contract revenue<font style="padding-left: 1.09pt;"></font></div></td><td class="gutter" style="width: 1.6%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.6%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.64%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.05pt; text-align: left;"><font style="padding-left: 35pt;">&#8212;</font></div></td><td class="gutter" style="width: 1.6%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.6%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.64%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.05pt; text-align: left;"><font style="padding-left: 22.5pt;">2,340</font></div></td><td class="gutter" style="width: 1.6%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.6%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.62%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 22.5pt;">2,340</font></div></td><td class="gutter" style="width: 1.6%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.6%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.61%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 22.5pt;">1,140</font></div></td></tr><tr><td style="width: 48.72%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Research and development expense<font style="padding-left: 0.56pt;"></font></div></td><td class="gutter" style="width: 1.6%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.6%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 9.64%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.05pt; text-align: left;"><font style="padding-left: 14.17pt;">(61,325)</font></div></td><td class="gutter" style="width: 1.6%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.6%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 9.64%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.05pt; text-align: left;"><font style="padding-left: 14.17pt;">(46,572)</font></div></td><td class="gutter" style="width: 1.6%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.6%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 9.62%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 9.17pt;">(107,537)</font></div></td><td class="gutter" style="width: 1.6%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.6%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 9.61%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 9.54pt;">(118,313)</font></div></td></tr><tr><td style="width: 48.72%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">General and administrative expense<font style="padding-left: 0.01pt;"></font></div></td><td class="gutter" style="width: 1.6%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.6%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.64%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.05pt; text-align: left;"><font style="padding-left: 14.17pt; border-bottom: 1pt solid #000000; min-width: 45pt;">(27,509</font><font style="min-width: 45pt;">)</font></div></td><td class="gutter" style="width: 1.6%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.6%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.64%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.05pt; text-align: left;"><font style="padding-left: 19.17pt; border-bottom: 1pt solid #000000; min-width: 45pt;">(6,592</font><font style="min-width: 45pt;">)</font></div></td><td class="gutter" style="width: 1.6%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.6%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.62%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 14.17pt; border-bottom: 1pt solid #000000; min-width: 45pt;">(14,202</font><font style="min-width: 45pt;">)</font></div></td><td class="gutter" style="width: 1.6%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.6%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.61%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 19.17pt; border-bottom: 1pt solid #000000; min-width: 45pt;">(8,768</font><font style="min-width: 45pt;">)</font></div></td></tr><tr><td style="width: 48.72%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Operating loss<font style="padding-left: 1.63pt;"></font></div></td><td class="gutter" style="width: 1.6%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.6%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 9.64%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.05pt; text-align: left;"><font style="padding-left: 14.17pt;">(88,834)</font></div></td><td class="gutter" style="width: 1.6%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.6%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 9.64%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.05pt; text-align: left;"><font style="padding-left: 14.17pt;">(50,824)</font></div></td><td class="gutter" style="width: 1.6%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.6%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 9.62%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 9.54pt;">(119,399)</font></div></td><td class="gutter" style="width: 1.6%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.6%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 9.61%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 9.17pt;">(125,941)</font></div></td></tr><tr><td style="width: 48.72%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Other income<font style="padding-left: 4.97pt;"></font></div></td><td class="gutter" style="width: 1.6%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.6%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.64%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.05pt; text-align: left;"><font style="padding-left: 30pt;">278</font></div></td><td class="gutter" style="width: 1.6%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.6%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.64%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.05pt; text-align: left;"><font style="padding-left: 35pt;">&#8212;</font></div></td><td class="gutter" style="width: 1.6%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.6%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.62%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 22.5pt;">1,655</font></div></td><td class="gutter" style="width: 1.6%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.6%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.61%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 35pt;">&#8212;</font></div></td></tr><tr><td style="width: 48.72%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Convertible loans, derivatives, increase in fair value<font style="padding-left: 2.26pt;"></font></div></td><td class="gutter" style="width: 1.6%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.6%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 9.64%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.05pt; text-align: left;"><font style="padding-left: 14.17pt;">(79,261)</font></div></td><td class="gutter" style="width: 1.6%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.6%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 9.64%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.05pt; text-align: left;"><font style="padding-left: 35pt;">&#8212;</font></div></td><td class="gutter" style="width: 1.6%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.6%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 9.62%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 35pt;">&#8212;</font></div></td><td class="gutter" style="width: 1.6%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.6%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 9.61%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 35pt;">&#8212;</font></div></td></tr><tr><td style="width: 48.72%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-indent: -10pt; text-align: left;">Convertible loans, first tranche, derivative, transaction costs<font style="padding-left: 0.51pt;"></font></div></td><td class="gutter" style="width: 1.6%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.6%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.64%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.05pt; text-align: left;"><font style="padding-left: 19.17pt;">(1,571)</font></div></td><td class="gutter" style="width: 1.6%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.6%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.64%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.05pt; text-align: left;"><font style="padding-left: 35pt;">&#8212;</font></div></td><td class="gutter" style="width: 1.6%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.6%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.62%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 35pt;">&#8212;</font></div></td><td class="gutter" style="width: 1.6%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.6%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.61%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 35pt;">&#8212;</font></div></td></tr><tr><td style="width: 48.72%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Financial income<font style="padding-left: 0.52pt;"></font></div></td><td class="gutter" style="width: 1.6%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.6%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 9.64%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.05pt; text-align: left;"><font style="padding-left: 30pt;">569</font></div></td><td class="gutter" style="width: 1.6%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.6%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 9.64%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.05pt; text-align: left;"><font style="padding-left: 22.5pt;">1,306</font></div></td><td class="gutter" style="width: 1.6%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.6%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 9.62%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 22.5pt;">2,253</font></div></td><td class="gutter" style="width: 1.6%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.6%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 9.61%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 22.5pt;">2,856</font></div></td></tr><tr><td style="width: 48.72%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Financial expense<font style="padding-left: 2.75pt;"></font></div></td><td class="gutter" style="width: 1.6%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.6%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.64%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.05pt; text-align: left;"><font style="padding-left: 26.67pt;">(939)</font></div></td><td class="gutter" style="width: 1.6%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.6%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.64%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.05pt; text-align: left;"><font style="padding-left: 31.67pt;">(73)</font></div></td><td class="gutter" style="width: 1.6%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.6%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.62%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 26.67pt;">(156)</font></div></td><td class="gutter" style="width: 1.6%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.6%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.61%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 35pt;">&#8212;</font></div></td></tr><tr><td style="width: 48.72%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Exchange differences<font style="padding-left: 3.5pt;"></font></div></td><td class="gutter" style="width: 1.6%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.6%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 9.64%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.05pt; text-align: left;"><font style="padding-left: 31.67pt; border-bottom: 1pt solid #000000; min-width: 45pt;">(71</font><font style="min-width: 45pt;">)</font></div></td><td class="gutter" style="width: 1.6%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.6%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 9.64%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.05pt; text-align: left;"><font style="padding-left: 31.67pt; border-bottom: 1pt solid #000000; min-width: 45pt;">(68</font><font style="min-width: 45pt;">)</font></div></td><td class="gutter" style="width: 1.6%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.6%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 9.62%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 26.67pt; border-bottom: 1pt solid #000000; min-width: 45pt;">(255</font><font style="min-width: 45pt;">)</font></div></td><td class="gutter" style="width: 1.6%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.6%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 9.61%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 30pt; border-bottom: 1pt solid #000000; min-width: 45pt;">213</font></div></td></tr><tr><td style="width: 48.72%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Loss before taxes<font style="padding-left: 3.87pt;"></font></div></td><td class="gutter" style="width: 1.6%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.6%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.64%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.05pt; text-align: left;"><font style="padding-left: 9.17pt;">(169,829)</font></div></td><td class="gutter" style="width: 1.6%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.6%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.64%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.05pt; text-align: left;"><font style="padding-left: 14.17pt;">(49,659)</font></div></td><td class="gutter" style="width: 1.6%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.6%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.62%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 9.54pt;">(115,902)</font></div></td><td class="gutter" style="width: 1.6%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.6%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.61%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 9.17pt;">(122,872)</font></div></td></tr><tr><td style="width: 48.72%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Income tax expense<font style="padding-left: 4.43pt;"></font></div></td><td class="gutter" style="width: 1.6%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.6%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 9.64%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.05pt; text-align: left;"><font style="padding-left: 26.67pt; border-bottom: 1pt solid #000000; min-width: 45pt;">(204</font><font style="min-width: 45pt;">)</font></div></td><td class="gutter" style="width: 1.6%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.6%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 9.64%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.05pt; text-align: left;"><font style="padding-left: 26.67pt; border-bottom: 1pt solid #000000; min-width: 45pt;">(199</font><font style="min-width: 45pt;">)</font></div></td><td class="gutter" style="width: 1.6%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.6%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 9.62%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 26.67pt; border-bottom: 1pt solid #000000; min-width: 45pt;">(582</font><font style="min-width: 45pt;">)</font></div></td><td class="gutter" style="width: 1.6%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.6%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 9.61%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 26.67pt; border-bottom: 1pt solid #000000; min-width: 45pt;">(224</font><font style="min-width: 45pt;">)</font></div></td></tr><tr><td style="width: 48.72%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Loss for the period<font style="padding-left: 2.2pt;"></font></div></td><td class="gutter" style="width: 1.6%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.6%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.64%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.05pt; text-align: left;"><font style="padding-left: 9.17pt; border-bottom: 3pt double #000000; min-width: 45pt;">(170,033</font><font style="min-width: 45pt;">)</font></div></td><td class="gutter" style="width: 1.6%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.6%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.64%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.05pt; text-align: left;"><font style="padding-left: 14.17pt; border-bottom: 3pt double #000000; min-width: 45pt;">(49,858</font><font style="border-bottom: 3pt double #000000; min-width: 45pt;"></font><font style="min-width: 45pt;">)</font></div></td><td class="gutter" style="width: 1.6%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.6%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.62%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 9.54pt; border-bottom: 3pt double #000000; min-width: 45pt;">(116,484</font><font style="min-width: 45pt;">)</font></div></td><td class="gutter" style="width: 1.6%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.6%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.61%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 9.17pt; border-bottom: 3pt double #000000; min-width: 45pt;">(123,096</font><font style="min-width: 45pt;">)</font></div></td></tr><tr><td style="width: 48.72%; text-align: left; vertical-align: bottom; padding-top: 5.25pt; padding-bottom: 5.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Basic and diluted loss per share<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(1)</sup><font style="padding-left: 1.26pt;"></font></div></td><td class="gutter" style="width: 1.6%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 5.25pt;">&#8203;</td><td class="gutter" style="width: 1.6%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 5.25pt;">&#8203;</td><td style="width: 9.64%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 5.25pt; padding-bottom: 5.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.05pt; text-align: left;"><font style="padding-left: 24.17pt; border-bottom: 3pt double #000000; min-width: 45pt;">(2.97</font><font style="min-width: 45pt;">)</font></div></td><td class="gutter" style="width: 1.6%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 5.25pt;">&#8203;</td><td class="gutter" style="width: 1.6%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 5.25pt;">&#8203;</td><td style="width: 9.64%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 5.25pt; padding-bottom: 5.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.05pt; text-align: left;"><font style="padding-left: 24.17pt; border-bottom: 3pt double #000000; min-width: 45pt;">(1.05</font><font style="min-width: 45pt;">)</font></div></td><td class="gutter" style="width: 1.6%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 5.25pt;">&#8203;</td><td class="gutter" style="width: 1.6%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 5.25pt;">&#8203;</td><td style="width: 9.62%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 5.25pt; padding-bottom: 5.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 24.17pt; border-bottom: 3pt double #000000; min-width: 45pt;">(2.36</font><font style="min-width: 45pt;">)</font></div></td><td class="gutter" style="width: 1.6%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 5.25pt;">&#8203;</td><td class="gutter" style="width: 1.6%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 5.25pt;">&#8203;</td><td style="width: 9.61%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 5.25pt; padding-bottom: 5.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 24.17pt; border-bottom: 3pt double #000000; min-width: 45pt;">(2.64</font><font style="min-width: 45pt;">)</font></div></td></tr><tr><td style="width: 48.72%; text-align: left; vertical-align: bottom; padding-top: 5.25pt; padding-bottom: 6pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-indent: -10pt; text-align: left;">Weighted-average number of shares used to compute basic and diluted loss per share<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(1)</sup><font style="padding-left: 2.93pt;"></font></div></td><td class="gutter" style="width: 1.6%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.6%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.64%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 5.25pt; padding-bottom: 6pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.05pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 45pt;">57,225,939</font></div></td><td class="gutter" style="width: 1.6%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.6%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.64%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 5.25pt; padding-bottom: 6pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.05pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 45pt;">47,297,859</font></div></td><td class="gutter" style="width: 1.6%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.6%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.62%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 5.25pt; padding-bottom: 6pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 45pt;">49,279,961</font></div></td><td class="gutter" style="width: 1.6%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.6%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.61%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 5.25pt; padding-bottom: 6pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 45pt;">46,600,000</font></div></td></tr></table><div><div class="rule-partial" style="height: 0pt; width: 72pt; border-bottom: 1pt solid #000000; margin-bottom: 1pt; margin-right: auto; margin-left: 0pt; margin-top: 13.25pt;"> </div></div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 3pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">(1)<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; text-align: left;">See Note 28 to our audited consolidated financial statements and Note&#160;15 to our unaudited condensed consolidated interim financial statements, each included elsewhere in this prospectus for a description of the method used to compute basic and diluted net loss per share. </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 3pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">(2)<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; text-align: left;">On January&#160;1, 2019, we adopted IFRS 16 &#8220;Leases,&#8221; the impact of which is described in Note&#160;17 to our audited consolidated financial statements.</div></td></tr></table></div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 36pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">12<br></div></div></div>
<!--End Page 16-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 17-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 540pt;"><a name="nt10014672x1_drs_103-summary_pg13"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="block-frill" style="width: 540pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: Arial, Helvetica, sans-serif; font-size: 9pt; font-weight: bold; margin-top: 6pt; text-align: center;">Confidential Treatment Requested by ADC Therapeutics SA Pursuant to 17 C.F.R. &#167; 200.83<br></div></div><div class="border-box" style="border-top: 1pt solid #000000; border-left: 1pt solid #000000; border-right: 1pt solid #000000; border-bottom: 1pt solid #000000; margin-bottom: 12pt; padding-top: 12pt; padding-bottom: 12pt; width: 492pt; margin-left: 24pt;"><div class="page-content" style="margin-left: 12pt;"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><table cellspacing="0" cellpadding="0" class="fintab" style="margin-top: 4pt; border-collapse: collapse; width: 468pt; margin-left: auto; margin-right: auto;"><tr class="header"><td style="width: 71.79%; text-align: left; vertical-align: bottom; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 2.31%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 2.31%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td colspan="4" style="width: 23.59%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">As of June&#160;30, 2020</div></td></tr><tr class="header"><td style="width: 71.79%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 2.31%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 2.31%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 7.65%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Actual</div></td><td class="gutter" style="width: 2.31%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 2.31%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 11.32%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">As Adjusted<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(1)</sup></div></td></tr><tr class="header"><td style="width: 71.79%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Consolidated Balance Sheet Data:</div></td><td class="gutter" style="width: 2.31%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 2.31%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td colspan="4" style="width: 23.59%; text-align: center; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">(in USD thousands) </div></td></tr><tr><td style="width: 71.79%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Cash and cash equivalents<font style="padding-left: 0.77pt;"></font></div></td><td class="gutter" style="width: 2.31%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.31%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.65%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;"><font style="padding-left: 3.33pt; border-bottom: 3pt double #000000; min-width: 35.83pt;">348,593</font></div></td><td class="gutter" style="width: 2.31%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.31%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 11.32%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10.25pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 32.5pt;">&#8199;&#8199;&#8199;&#8201;&#8199;&#8199;&#8199;</font></div></td></tr><tr><td style="width: 71.79%; text-align: left; vertical-align: bottom; padding-top: 5.25pt; padding-bottom: 5.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Total assets<font style="padding-left: 1.44pt;"></font></div></td><td class="gutter" style="width: 2.31%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 5.25pt;">&#8203;</td><td class="gutter" style="width: 2.31%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 5.25pt;">&#8203;</td><td style="width: 7.65%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 5.25pt; padding-bottom: 5.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;"><font style="padding-left: 3.33pt; border-bottom: 3pt double #000000; min-width: 35.83pt;">373,842</font></div></td><td class="gutter" style="width: 2.31%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 5.25pt;">&#8203;</td><td class="gutter" style="width: 2.31%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 5.25pt;">&#8203;</td><td style="width: 11.32%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 5.25pt; padding-bottom: 5.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><font style="border-bottom: 3pt double #000000; padding-left: 32.5pt; margin-left: 10.25pt;"></font></div></td></tr><tr><td style="width: 71.79%; text-align: left; vertical-align: bottom; padding-top: 5.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Total liabilities<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(2)</sup><font style="padding-left: 3.8pt;"></font></div></td><td class="gutter" style="width: 2.31%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.31%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.65%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 5.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;"><font style="padding-left: 3.33pt; border-bottom: 3pt double #000000; min-width: 35.83pt;">177,540</font><font style="border-bottom: 3pt double #000000; min-width: 35.83pt;"> </font></div></td><td class="gutter" style="width: 2.31%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.31%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 11.32%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 5.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><font style="border-bottom: 3pt double #000000; padding-left: 32.5pt; margin-left: 10.25pt;"></font></div></td></tr><tr><td style="width: 71.79%; text-align: left; vertical-align: bottom; padding-top: 5.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Share capital<font style="padding-left: 0.75pt;"></font></div></td><td class="gutter" style="width: 2.31%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.31%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 7.65%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 5.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;"><font style="padding-left: 13.33pt;">5,795</font> </div></td><td class="gutter" style="width: 2.31%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.31%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 11.32%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 5.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 71.79%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Share premium<font style="padding-left: 1.3pt;"></font></div></td><td class="gutter" style="width: 2.31%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.31%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.65%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;"><font style="padding-left: 3.33pt;">792,605</font></div></td><td class="gutter" style="width: 2.31%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.31%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 11.32%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 71.79%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Accumulated losses<font style="padding-left: 2.98pt;"></font></div></td><td class="gutter" style="width: 2.31%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.31%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 7.65%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;">(618,602)</div></td><td class="gutter" style="width: 2.31%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.31%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 11.32%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 71.79%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 6pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Total equity<font style="padding-left: 4.76pt;"></font></div></td><td class="gutter" style="width: 2.31%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.31%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.65%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 6pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;"><font style="padding-left: 3.33pt; border-bottom: 3pt double #000000; min-width: 35.83pt;">196,302</font></div></td><td class="gutter" style="width: 2.31%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.31%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 11.32%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 6pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><font style="border-bottom: 3pt double #000000; padding-left: 32.5pt; margin-left: 10.25pt;"></font></div></td></tr></table><div><div class="rule-partial" style="height: 0pt; width: 72pt; border-bottom: 1pt solid #000000; margin-bottom: 1pt; margin-right: auto; margin-left: 0pt; margin-top: 13.25pt;"> </div></div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 3pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">(1)<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; text-align: left;">The as-adjusted information gives effect to our issuance and sale of &#8195;&#8195;&#8195;&#8195; common shares in this offering based on the assumed public offering price of $&#8199;&#8199;&#8201;&#8199;&#8199; per common share, which was the last reported sale price of our common shares on the NYSE on &#8195;&#8195;&#8195;, 2020, after deducting estimated underwriting discounts and commissions and estimated offering expenses payable by us. The as-adjusted information is illustrative only and will change based on the actual public offering price and other terms of this offering determined at pricing. Each $1.00 increase or decrease in the assumed public offering price would increase or decrease the as-adjusted amount of each of cash and cash equivalents, total assets and total equity by $&#8195;&#8195;&#8195; million, assuming that the number of common shares offered by us, as set forth on the cover page of this prospectus, remains the same and after deducting estimated underwriting discounts and commissions and estimated offering expenses payable by us. Each 1,000,000 share increase or decrease in the number of common shares offered by us would increase or decrease the as-adjusted amount of each of cash and cash equivalents, total assets and total equity by $&#8195;&#8195; million, assuming the assumed public offering price remains the same and after deducting estimated underwriting discounts and commissions and estimated offering expenses payable by us.</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 3pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">(2)<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; text-align: left;">See Notes 3 and 11 to our unaudited condensed consolidated interim financial statements included elsewhere in this prospectus for further information related to the Facility Agreement and accounting for the convertible loans and associated derivative instruments.</div></td></tr></table></div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 36pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">13<br></div></div></div>
<!--End Page 17-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 18-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 540pt;"><a name="nt10014672x1_drs_104-risk_pg1"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="block-frill" style="width: 540pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: Arial, Helvetica, sans-serif; font-size: 9pt; font-weight: bold; margin-top: 6pt; text-align: center;">Confidential Treatment Requested by ADC Therapeutics SA Pursuant to 17 C.F.R. &#167; 200.83<br></div></div><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 36pt;"><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: center;"><a name="tRF"><!--Anchor--></a>RISK FACTORS</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 6pt; margin-left: 0pt; text-align: left;">Investing in our common shares involves a high degree of risk. You should carefully consider the risks and uncertainties described below together with all of the other information contained in this prospectus, including our consolidated financial statements including the notes thereto, included elsewhere in this prospectus, before deciding to invest in our common shares. If any of the events or developments described below were to occur, our business, results of operations, financial condition and prospects could suffer materially, the trading price of our common shares could decline and you could lose all or part of your investment. The risks and uncertainties described below are not the only ones we face. Additional risks and uncertainties not presently known to us or that we currently believe to be immaterial may also adversely affect our business. If any of the following risks occur, our business, results of operations, financial condition and prospects could be materially and adversely affected.</div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 17pt; margin-left: 0pt; text-align: left;">Risks Related to Our Financial Position and Capital Requirements</div><div class="frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 6pt; margin-left: 0pt; text-align: left;">We have incurred net losses during all fiscal periods since our inception, have no products approved for commercial sale and anticipate that we will continue to incur substantial net losses for the foreseeable future. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">We are a late clinical-stage oncology-focused biotechnology company and have a history of net losses. For the years ended December 31, 2019 and 2018, our net losses were $116.5 million and $123.1 million, respectively. For the six months ended June 30, 2020 and 2019, our net losses were $170.0 million and $49.9 million, respectively. As of June 30, 2020, we had accumulated net losses of $618.6 million. Our net losses have resulted principally from costs incurred in our research and development activities, personnel expenses and fair value adjustments of the derivatives associated with the Facility Agreement.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">We expect to continue to incur significant expenses and increasing net losses for the foreseeable future as we continue our research and development efforts and seek to obtain regulatory approval for and commercialize our product candidates. We anticipate that our expenses will increase substantially as we:</div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">seek regulatory approval for Lonca and our other product candidates from applicable regulatory authorities;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">conduct a confirmatory clinical trial of Lonca in combination with rituximab for the treatment of relapsed or refractory DLBCL;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">conduct pivotal Phase 2 clinical trials of our product candidates, including the pivotal Phase 2 clinical trial of Lonca for the treatment of relapsed or refractory FL; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the Phase 1/2 clinical trial of Lonca in combination with ibrutinib for the treatment of relapsed or refractory DLBCL and MCL and the pivotal Phase 2 clinical trial of Cami for the treatment of relapsed or refractory HL;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">conduct Phase 1 clinical trials of our current and future product candidates; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">conduct any required confirmatory clinical trials of any of our product candidates in anticipation of potential accelerated approval from the FDA or similar conditional approval from the EMA or comparable regulatory agencies in other jurisdictions;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">expand our research and development efforts for our preclinical product candidates and research pipeline;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">invest in our late-stage clinical development, manufacturing and commercialization activities, including launching commercial sales, marketing and distribution operations;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">continue to prepare, file, prosecute, maintain, protect and enforce our intellectual property rights and claims;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">add clinical, scientific, operational, financial and management information systems and personnel; and</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">continue to operate as a public company.</div></td></tr></table><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Even if we obtain regulatory approval of and are successful in commercializing one or more of our product candidates, we may incur substantial research and development and other expenditures to develop and market additional product candidates. We may encounter unforeseen expenses, difficulties, complications, delays and </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 36pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">14<br></div></div></div>
<!--End Page 18-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 19-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 540pt;"><a name="nt10014672x1_drs_104-risk_pg2"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="block-frill" style="width: 540pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: Arial, Helvetica, sans-serif; font-size: 9pt; font-weight: bold; margin-top: 6pt; text-align: center;">Confidential Treatment Requested by ADC Therapeutics SA Pursuant to 17 C.F.R. &#167; 200.83<br></div></div><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 36pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">unknown factors that may adversely affect our business. The size of our future net losses will depend, in part, on the rate of future growth of our expenses and our ability to generate revenue. Our net losses may fluctuate significantly from quarter to quarter and from year to year.</div><div class="frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 16pt; margin-left: 0pt; text-align: left;">We may never achieve or sustain profitability.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">We do not know when or whether we will become profitable. To date, we have not commercialized any products or generated any revenues from the sale of products. To become and remain profitable, we must succeed in developing, obtaining regulatory approval for and commercializing one or more of our product candidates. This will require us to be successful in a range of challenging activities, including completing preclinical studies and clinical trials of our product candidates, discovering and developing additional product candidates, obtaining regulatory approval for any product candidates that successfully complete clinical trials, establishing commercialization capabilities for any approved products and achieving market acceptance for any approved products. We may never succeed in these activities. Even if we succeed in these activities, we may never generate revenue in an amount sufficient to achieve profitability.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Because of the numerous risks and uncertainties associated with biotechnology product development and commercialization, we are unable to accurately predict whether and when we will achieve profitability. If we are required by the FDA, the EMA or any comparable regulatory authority in other jurisdictions to perform preclinical studies or clinical trials in addition to those we currently expect to conduct, or if there are any delays or complications in completing preclinical studies of our product candidates or, if preclinical studies are successful, in submitting an investigational new drug application (&#8220;IND&#8221;) to the FDA, manufacturing clinical trial supplies and completing clinical trials, our expenses could increase substantially and our ability to achieve profitability could be further delayed.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Even if we achieve profitability, we may not be able to sustain profitability in subsequent periods. After we achieve profitability, if ever, we expect to continue to engage in substantial research and development activities and to incur substantial expenses to develop and commercialize additional product candidates. In addition, we may encounter unforeseen expenses, difficulties, complications, delays and other unknown factors that may adversely affect our revenues, expenses and profitability.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Our failure to achieve or sustain profitability would depress our market value and could impair our ability to execute our business plan, raise capital, develop additional product candidates or continue our operations. A decline in the value of our company could cause our shareholders to lose all or part of their investment.</div><div class="frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">We have a limited operating history and have never generated any revenue from product sales, which may make it difficult to evaluate the success of our business to date and to assess our future viability. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">We were incorporated in 2011, and our operations to date have been largely focused on developing our product candidates, including conducting preclinical studies and clinical trials, raising capital and building our management team and infrastructure. We have not yet demonstrated an ability to obtain regulatory approvals, manufacture products on a commercial scale, or partner with contract manufacturing organizations (&#8220;CMOs&#8221;) to do so on our behalf, or conduct sales and marketing activities necessary for successful commercialization. Additionally, the markets for our product candidates are competitive. Consequently, any predictions about our future success or viability may not be as accurate as they could be if we had a longer operating history or a history of successfully developing and commercializing products. Moreover, we will need to transition from a company with a research and development focus to a company capable of undertaking commercial activities. We may encounter unforeseen expenses, difficulties, complications and delays, and may not be successful in such a transition.</div><div class="frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">Even after the completion of this offering, we will require substantial additional capital to execute our business plan. Our inability to obtain this capital when needed could force us to delay, limit, reduce or terminate our product development efforts or our establishment of late-stage development and commercialization capabilities. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Since our inception, we have used substantial amounts of cash. The development of biotechnology product candidates is capital intensive and we expect that we will continue to expend substantial resources for the foreseeable future to develop and commercialize our current and future product candidates. Our expenditures in the foreseeable future may include costs associated with conducting research and development activities, </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 36pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">15<br></div></div></div>
<!--End Page 19-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 20-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 540pt;"><a name="nt10014672x1_drs_104-risk_pg3"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="block-frill" style="width: 540pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: Arial, Helvetica, sans-serif; font-size: 9pt; font-weight: bold; margin-top: 6pt; text-align: center;">Confidential Treatment Requested by ADC Therapeutics SA Pursuant to 17 C.F.R. &#167; 200.83<br></div></div><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 36pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">conducting preclinical studies and clinical trials, obtaining regulatory approvals, undertaking late-stage commercialization activities, establishing our sales and marketing capabilities, manufacturing and selling approved products and potentially acquiring new technologies.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">To date, we have financed our operations primarily through equity and convertible debt financings. Since inception, we have raised $891.2 million in gross cash proceeds from equity and convertible debt financings. As of June 30, 2020, we had $348.6 million in cash and cash equivalents. We believe that we have sufficient financial resources available to fund our projected operating requirements for at least the next twelve months. Because the outcome of our current and planned clinical trials is highly uncertain, we cannot reasonably estimate the actual amounts necessary to successfully complete the development and commercialization of our product candidates. For example, our costs will increase if we experience any delays in our current and planned clinical trials.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8.5pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Our future capital requirements, both in the near- and long-term, depend on many factors, including:</div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 5pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the outcome, timing and costs of obtaining regulatory approvals for Lonca and for our other product candidates if the requisite clinical trials are successful;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 5pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the progress, results and costs of our confirmatory clinical trial of Lonca in combination with rituximab for the treatment of relapsed or refractory DLBCL;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 5pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the progress, results and costs of our Phase 1 and potentially pivotal Phase 2 clinical trials of our product candidates;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 5pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the progress, results and costs of any required confirmatory clinical trials of any product candidates that receive accelerated approval from the FDA or similar conditional approval from the EMA or comparable regulatory agencies in other jurisdictions;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 5pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the scope, progress, results and costs of researching and developing product candidates in our research pipeline, including conducting preclinical studies and clinical trials of such product candidates;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 5pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the costs of outsourced manufacturing of our product candidates, which are complex biological molecules, for clinical trials and in preparation for regulatory approval and commercialization;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 5pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the size of the markets for approved indications in territories in which we receive regulatory approval, if any;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 5pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the timing and costs of commercialization activities for our product candidates, if any are approved for sale, including establishing our sales and marketing capabilities and engaging in the marketing, sales and distribution of our product candidates;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the revenue, if any, received from the commercialization of our product candidates, if any are approved for sale;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">our ability to maintain and establish collaboration, licensing or other arrangements and the financial terms of such agreements;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the costs involved in preparing, filing, prosecuting, maintaining, protecting and enforcing our intellectual property rights and claims, including any litigation costs and the outcome of such litigation;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the costs associated with potential product liability claims, including the costs associated with obtaining insurance against such claims and with defending against such claims;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the timing and amount of milestone payments we receive under our collaboration agreements;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the costs involved in maintaining and improving the technology we use in our product candidates;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">our efforts to enhance operational systems and hire additional personnel, including personnel to support the development and commercialization of our product candidates and to satisfy our obligations as a public company;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the effect of competing technological and market developments; and</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the types of available sources of private and/or public market financing.</div></td></tr></table></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 36pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">16<br></div></div></div>
<!--End Page 20-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 21-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 540pt;"><a name="nt10014672x1_drs_104-risk_pg4"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="block-frill" style="width: 540pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: Arial, Helvetica, sans-serif; font-size: 9pt; font-weight: bold; margin-top: 6pt; text-align: center;">Confidential Treatment Requested by ADC Therapeutics SA Pursuant to 17 C.F.R. &#167; 200.83<br></div></div><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 36pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Additional funds may not be available when we need them or on terms that are acceptable to us. In addition, market volatility resulting from the COVID-19 pandemic and other factors could also adversely impact our ability to access capital as and when needed. Further, as a Swiss company, we have less flexibility to raise capital, particularly in a quick and efficient manner, as compared to U.S. companies. See &#8220;&#8212;Risks Related to Our Common Shares and This Offering&#8212;Our shareholders enjoy certain rights that may limit our flexibility to raise capital, issue dividends and otherwise manage ongoing capital needs.&#8221; In addition, the terms of the Facility Agreement, and the senior secured convertible notes issued and issuable thereunder, will further impede our ability to raise capital. See &#8220;&#8212;Risks Related to Our Financial Position and Capital Requirements&#8212;The Facility Agreement and the associated restrictive covenants thereunder could adversely affect our financial condition and will restrict our ability to raise capital.&#8221; If adequate funds are not available to us on a timely basis or on terms acceptable to us, we may be required to delay, limit, reduce or terminate our product development efforts or our establishment of late-stage development and commercialization capabilities.</div><div class="frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">Raising additional capital may cause dilution to our existing shareholders, restrict our operations or require us to relinquish rights to our intellectual property or product candidates on unfavorable terms.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Unless and until we can generate sufficient revenue to finance our cash requirements, which may never happen, we may seek additional capital through a variety of means, including through public and private equity offerings and debt financings, credit and loan facilities and additional collaborations. If we raise additional capital through the sale of equity or convertible debt securities, your ownership interest will be diluted, and the terms of such equity or convertible debt securities may include liquidation or other preferences that are senior to or otherwise adversely affect your rights as a shareholder. If we raise additional capital through the sale of debt securities or through entering into credit or loan facilities, we may be restricted in our ability to take certain actions, such as incurring additional debt, making capital expenditures, acquiring or licensing intellectual property rights, declaring dividends or encumbering our assets to secure future indebtedness. Such restrictions could adversely impact our ability to conduct our operations and execute our business plan. If we raise additional capital through collaborations with third parties, we may be required to relinquish valuable rights to our intellectual property or product candidates or we may be required to grant licenses for our intellectual property or product candidates on unfavorable terms. If we are unable to raise additional capital when needed, we may be required to delay, limit, reduce or terminate our product development efforts or our establishment of late-stage development and commercialization capabilities or we may be required to grant rights to third parties to develop and market our product candidates that we would otherwise prefer to develop and market ourselves.</div><div class="frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">The Facility Agreement and the associated restrictive covenants thereunder could adversely affect our financial condition and will restrict our ability to raise capital.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">On April 24, 2020, we entered into the Facility Agreement with Deerfield Partners, L.P. and certain of its affiliates (collectively, &#8220;Deerfield&#8221;). See &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8212;Liquidity and Capital Resources&#8212;$115.0 Million Facility Agreement.&#8221; The Facility Agreement contains various covenants, including a requirement to retain $50.0 million in deposit and securities accounts as of the end of each fiscal quarter. In addition, the Facility Agreement restricts our and the guarantors&#8217; ability to, among other things, (i) declare or make any dividend payment, (ii) create or incur any lien on our assets beyond those outstanding on the date of the Facility Agreement and certain permitted licensing agreements, (iii) dispose of any assets or property, other than issuance and sale of common shares, certain financing transactions with respect to royalties on product sales, certain permitted licensing agreements and joint ventures or dispositions pursuant to the Genmab Collaboration and License Agreement, (iv) incur any indebtedness, (v) make any investments (other than investments in permitted joint ventures and other permitted transactions), (vi) amend our organizational documents or any material agreements in a manner that would reasonably be expected to be materially adverse to the rights of the lenders or (vii) change our reporting practices or fiscal year, in each case, subject to exceptions set forth in the Facility Agreement. Furthermore, under the Facility Agreement, we are required to, among other things, (i) remain a reporting company and maintain the listing of our common shares on an eligible market, (ii) provide the lenders with information regarding any event of default or the occurrence of any material adverse event and (iii) publicly disclose material, nonpublic information that is provided to the lenders without their prior written consent. Subject to customary exceptions and exclusions, our obligations under the Facility Agreement are guaranteed by a perfected, first-priority security interest in substantially all of our personal property, including our intellectual property and the equity ownership interests directly and indirectly held by us in our wholly-owned subsidiaries. Compliance </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 36pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">17<br></div></div></div>
<!--End Page 21-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 22-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 540pt;"><a name="nt10014672x1_drs_104-risk_pg5"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="block-frill" style="width: 540pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: Arial, Helvetica, sans-serif; font-size: 9pt; font-weight: bold; margin-top: 6pt; text-align: center;">Confidential Treatment Requested by ADC Therapeutics SA Pursuant to 17 C.F.R. &#167; 200.83<br></div></div><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 36pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">with such covenants and our indebtedness will result in the following, which could materially and adversely affect our business, financial condition and results of operations:</div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">require us to dedicate a substantial portion of cash and cash equivalents to the payment of interest on, and principal of, the indebtedness, which will reduce the amounts available to fund working capital, capital expenditures, product development efforts and other general corporate purposes;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">oblige us to comply with negative covenants restricting our activities, including limitations on dispositions, mergers or acquisitions, encumbering our intellectual property, incurring indebtedness or liens, paying dividends, making investments and engaging in certain other business transactions;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">limit our flexibility in planning for, or reacting to, changes in our business and our industry;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">place us at a competitive disadvantage compared to our competitors who have less debt or competitors with comparable debt at more favorable interest rates; and</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">limit our ability to borrow additional amounts for working capital, capital expenditures, research and development efforts, acquisitions, debt service requirements, execution of our business strategy and other purposes and otherwise restrict our financing options.</div></td></tr></table><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Furthermore, because the interests of the lenders may potentially differ from ours and from those of our shareholders, we may be unable to engage in transactions or other activities that may be beneficial to our shareholders. The covenants under the Facility Agreement could materially and adversely affect our business, financial condition and results of operations.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Upon the occurrence of a major transaction, as defined under the convertible notes, the holders of the convertible notes may elect to require us to redeem all or any portion of the notes for an amount equal to the principal amount thereof (in addition to accrued and unpaid interest, a make-whole amount and an exit charge). There can be no assurance that we will have sufficient capital to redeem such notes upon the occurrence of a major transaction.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Servicing our indebtedness requires a significant amount of cash. Our ability to repay the principal of, to pay interest on or to refinance our indebtedness depends on our future performance, which is subject to economic, financial, competitive and other factors beyond our control. Our business may not generate cash flow from operations in the future sufficient to service our indebtedness. If we are unable to generate cash flow, we may be required to adopt one or more alternatives, such as restructuring debt or obtaining additional financing on terms that may be unfavorable to us or highly dilutive. Our ability to refinance our indebtedness will depend on the capital markets and our financial condition at the time we seek to refinance such indebtedness. Our inability to satisfy our debt obligations could materially and adversely affect our financial position and results of operations.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">A failure to comply with the conditions of the Facility Agreement or the convertible notes could result in an event of default. An event of default under the Facility Agreement includes, among other things, a failure to pay any amount due under the Facility Agreement or to issue common shares when required upon conversion of the convertible notes as well as the occurrence of a criminal proceeding, investigation or other similar government inquiry that could reasonably be expected to result in a material adverse effect. If we fail to comply with any of the covenants under our indebtedness and are unable to obtain a waiver or amendment, the lenders may, among other things, accelerate our outstanding indebtedness and exercise rights with respect to collateral securing our outstanding indebtedness, each of which could have an adverse effect on our business, financial condition and results of operations.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Any of these events could materially and adversely affect our business, financial condition and results of operations.</div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 36pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">18<br></div></div></div>
<!--End Page 22-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 23-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 540pt;"><a name="nt10014672x1_drs_104-risk_pg6"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="block-frill" style="width: 540pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: Arial, Helvetica, sans-serif; font-size: 9pt; font-weight: bold; margin-top: 6pt; text-align: center;">Confidential Treatment Requested by ADC Therapeutics SA Pursuant to 17 C.F.R. &#167; 200.83<br></div></div><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 36pt;"><div class="frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">The senior secured convertible notes expose us to volatility in our income statement and to considerable non-cash charges. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The Facility Agreement provides for two separate disbursements of convertible loans, each subject to satisfaction of certain conditions precedent set forth in the Facility Agreement. On May&#160;19, 2020, Deerfield extended the initial disbursement to us in the amount of $65.0&#160;million in connection with our initial public offering. The Facility Agreement provides for a subsequent disbursement in the amount of $50.0&#160;million, which we will be required to draw down, upon receipt of regulatory approval for Lonca and satisfaction of certain other conditions. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The first disbursement of convertible loans in the amount of $65.0 million has been accounted for as two separate components: a convertible loan and an embedded derivative conversion feature. The embedded derivative conversion feature is re-measured to fair value at each reporting date. Decreases in the life of the convertible loans pursuant to which the senior secured convertible notes are issued and decreases in our share price and its expected volatility will tend to reduce the fair value of the derivative and lead to gains in our consolidated income statement. However, increases in our share price and its expected volatility will tend to increase the fair value of the derivative and lead to losses in our consolidated income statement. As a result, our consolidated income statement will be subject to volatility arising from factors beyond our direct control. We recorded a non-cash charge of $57.5&#160;million associated with the increase in the fair value of the embedded derivative during the six months ended June&#160;30, 2020.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The convertible loan&#8217;s fair value was determined as the residual amount of the consideration received, net of attributable costs, after separating out the fair value of the embedded conversion feature. This residual amount represents the net present value of the future cash outflows associated with the convertible loan: (i) periodic interest at a rate of 5.95% per annum; (ii) repayment of the principal amount at redemption or at maturity; and (iii) payment of an exit charge equal to 2.0% on the principal amount of the convertible loans repaid or converted upon redemption or at maturity. We inferred an effective interest rate of approximately 23% from the net present value of the expected cash outflows, which will be applied over the life of the convertible loans and that will cause the initial carrying value of the convertible loans to increase through accretion of interest to the actual amounts of those expected cash outflows. We will incur significantly greater, non-cash interest charges in our consolidated income statement as the effective interest rate was considerably higher than the nominal rate of 5.95%. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Prior to satisfying the conditions set forth in the Facility Agreement with respect to the subsequent disbursement, we will account for the obligation to draw down on the subsequent disbursement as a derivative instrument. The derivative instrument is re-measured to fair value at each reporting date until the earlier of (i) regulatory approval for Lonca and satisfaction of other conditions set forth in the Facility Agreement and (ii) December 31, 2021, the date on which Deerfield&#8217;s obligation to make the second disbursement will expire if these conditions are not satisfied. Decreases in our share price and its expected volatility as well as a decrease in the probability of success factor for achieving regulatory approval for Lonca will tend to reduce the fair value of the derivative and lead to gains in our consolidated income statement. However, increases in our share price and its expected volatility as well as an increase in the probability of success factor for achieving regulatory approval for Lonca will tend to increase the fair value of the derivative and lead to losses in our consolidated income statement. As a result, our consolidated income statement will be subject to volatility arising from factors beyond our direct control. We recorded a non-cash charge of $21.8&#160;million associated with the increase in the fair value of the derivative during the six months ended June&#160;30, 2020.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Upon receipt of regulatory approval for Lonca and satisifation of certain other conditions set forth in the Facility Agreement, we would receive the subsequent disbursement of convertible loans in the amount of $50.0 million. At such time, the second disbursement of convertible loans would be accounted for in a similar manner as the first disbursement (i.e., a convertible loan and an embedded derivative conversion feature). </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 36pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">19<br></div></div></div>
<!--End Page 23-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 24-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 540pt;"><a name="nt10014672x1_drs_104-risk_pg7"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="block-frill" style="width: 540pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: Arial, Helvetica, sans-serif; font-size: 9pt; font-weight: bold; margin-top: 6pt; text-align: center;">Confidential Treatment Requested by ADC Therapeutics SA Pursuant to 17 C.F.R. &#167; 200.83<br></div></div><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 36pt;"><div class="frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">Our ability to use tax loss carryforwards in Switzerland may be limited.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">As of December&#160;31, 2019, we reported $437.0 million in tax loss carryforwards from previous financial years for Swiss corporate income tax purposes. Such tax loss carryforwards could, with certain limitations, be used to offset future taxable income. However, if not used, tax loss carryforwards expire seven years after the tax year in which they were incurred. Due to our limited income, there is a high risk that our tax loss carryforwards will expire in part or in their entirety and cannot be used to offset future taxable income for Swiss corporate income tax purposes.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Furthermore, any tax loss carryforwards that we report on our tax returns are subject to review and confirmation by the competent Swiss tax authorities in their tax assessment of the tax year for which the tax loss carryforwards are used to offset taxable income. Consequently, we are exposed to the risk that the competent Swiss tax authorities may not accept the reported tax loss carryforwards in part or in their entirety. Any limitations in our ability to use tax loss carryforwards to offset taxable income could adversely affect our financial condition.</div><div class="frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 15pt; margin-left: 0pt; text-align: left;">Changes in tax laws or the interpretation of tax laws could have a material impact on our financial condition. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Due to the Swiss corporate tax law reform that took effect on January 1, 2020, all Swiss cantons, including the Canton of Vaud, have abolished the cantonal tax privileges. Therefore, since January 1, 2020, we are subject to standard cantonal taxation. The standard effective corporate tax rate in Epalinges, Canton of Vaud, can change from time to time. However, we expect that the standard combined (federal, cantonal, communal) effective corporate income tax rate, except for dividend income for which we could claim a participation exemption, for 2020 in Epalinges will be approximately 13.7%.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">In addition, in view of the ongoing implementation of the OECD G20 Base Erosion and Profit Shifting Project and the European Union anti-avoidance tax package, the existing transfer pricing system and our intercompany relationships could be challenged by the competent tax authorities, resulting in additional taxes, interest and penalties in case of profit add-backs, non-deductible expenses or objections to the transfer pricing documentation. A focus area is the taxation and allocation of profits generated from intangibles where the DEMPE (Development, Enhancement, Maintenance, Protection and Exploitation) functions will become more relevant compared to the pure bearing of costs. This may impact the taxation of our group profits and may impact our effective tax rate. These and other changes in tax laws or the interpretation of tax laws could have a material adverse effect on our financial condition.</div><div class="frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 15.5pt; margin-left: 0pt; text-align: left;">Exchange rate fluctuations may materially affect our results of operations and financial condition.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">We operate internationally and are exposed to fluctuations in foreign exchange rates between the U.S. dollar and other currencies, particularly the British pound, the Euro and the Swiss franc. Our reporting currency is the U.S. dollar and, as a result, financial line items are converted into U.S. dollars at the applicable foreign exchange rates. As our business grows, we expect that at least some of our revenues and expenses will be denominated in currencies other than the U.S. dollar. Therefore, unfavorable developments in the value of the U.S. dollar relative to other relevant currencies could adversely affect our business and financial condition.</div><div class="frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">We are subject to risks related to the accounting treatment of our pension and other post-employment benefit plans.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">We provide retirement benefits to our employees as required by Swiss law by means of a pension fund that is maintained by a life insurance company. The life insurance company operates a pension plan for all of our employees as a defined benefit plan under International Accounting Standard (&#8220;IAS&#8221;) 19. As of June&#160;30, 2020 and December&#160;31, 2019, we reported an employee benefit obligation, before deduction of plan assets, of $8.1 million and $7.9 million, respectively, in accordance with IAS 19. The obligation represents our projected obligations towards current and future pensioners discounted at an annual rate of 0.2%. Under Swiss statutory rules and pursuant to our contract with the group life assurance provider, all risks including investment risk are fully covered. That said, no underfunding exists under Swiss law. The variance between Swiss statutory rules and the IFRS is apparent in many Swiss companies, and the IFRS obligation of our pension plan does not necessarily reflect a true payment obligation under Swiss law because Swiss law allows us to maintain flexibility to adjust benefit levels under the plans and we could use this flexibility to mitigate any liability. For more information, see Note 3.7 (Significant accounting policies&#8212;Employee benefits) and Note 22 (Pension obligations) to the audited </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 36pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">20<br></div></div></div>
<!--End Page 24-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 25-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 540pt;"><a name="nt10014672x1_drs_104-risk_pg8"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="block-frill" style="width: 540pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: Arial, Helvetica, sans-serif; font-size: 9pt; font-weight: bold; margin-top: 6pt; text-align: center;">Confidential Treatment Requested by ADC Therapeutics SA Pursuant to 17 C.F.R. &#167; 200.83<br></div></div><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 36pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">consolidated financial statements included elsewhere in this prospectus. However, should the Swiss statutory rules at any time require a determination that our pension plan is significantly underfunded, we could be obliged to make additional contributions into the pension plan in addition to our obligation to make regular contributions as defined in the pension plan regulation. If such risk materializes, this could have a material adverse effect on our financial position or results of operations.</div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">Risks Related to the Development of Our Product Candidates</div><div class="frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 6pt; margin-left: 0pt; text-align: left;">We have concentrated our research and development efforts on PBD-based ADCs, and our future success depends heavily on the successful development of this therapeutic approach.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Our ADCs use next-generation PBD warheads, which have a different mechanism of action than warheads used in currently approved ADCs. Although multiple PBD-based ADCs are being developed, none have been approved for sale in the United States or in the European Union. Any failures or setbacks involving PBD technology or PBD-based ADCs, whether developed by us or third parties, including adverse events, could have a detrimental impact on our product candidates and our research pipeline. For example, we or another party may uncover a previously unknown risk associated with PBD or other issues that may be more problematic than we currently believe, which may prolong the period of observation required for obtaining, or result in the failure to obtain, regulatory approval or may necessitate additional clinical testing. If the PBD warhead technology that we use is not safe in certain product candidates, we would be required to abandon or redesign all of our current product candidates, which could have a material adverse effect on our business, results of operations, financial condition and prospects.</div><div class="frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">Our current product candidates are in various stages of development, and it is possible that none of our product candidates will ever become commercial products.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Our success depends heavily on the successful further development of our current and future product candidates and our research pipeline and regulatory approval of our current and future product candidates, all of which are subject to risks and uncertainties beyond our control. We are preparing a BLA submission for Lonca for the treatment of relapsed or refractory DLBCL, and we are currently conducting pivotal Phase 2 clinical trials for our two lead product candidates. However, the FDA may ultimately disagree that data generated from our clinical trials or our regulatory submissions are sufficient for regulatory approval. We are also conducting Phase&#160;1 clinical trials of Cami and our other product candidates. There can be no assurance that any of our product candidates will prove to be safe, effective or commercially viable treatments for cancer.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">If we discontinue development of a product candidate, we will not receive the anticipated revenues from that product candidate, and we may not receive any return on our investment in that product candidate. We may discontinue a product candidate for clinical reasons if it does not prove to be safe and effective for its targeted indications. In the past, we and other companies in our field have discontinued the development of product candidates that did not achieve the necessary efficacy at tolerated doses required for patient benefit. For example, in January 2020, we discontinued our Phase 1b clinical trial of Lonca in combination with durvalumab for the treatment of relapsed or refractory DLBCL, MCL or FL because we determined that the combination did not demonstrate the necessary efficacy for further development. In the future, we may discontinue development programs for similar or other reasons. In addition, there may be important facts about the safety, efficacy and risk versus benefit of our product candidates that are not known to us at this time. Any unexpected safety events or our failure to generate sufficient data in our clinical trials to demonstrate efficacy may cause a product candidate to fail clinical development. Furthermore, even if that product candidate meets its safety and efficacy endpoints, we may discontinue its development for various reasons, such as changes in the competitive environment or the standard of care and the prioritization of our resources.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Due to the uncertain and time-consuming clinical development and regulatory approval process, we may not successfully develop any of our product candidates and may choose to discontinue the development of any of our product candidates. Therefore, it is possible that none of our current product candidates will ever become commercial products. Our failure to develop and commercialize our current and future product candidates could have a material adverse effect on our business, results of operations, financial condition and prospects.</div><div class="frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">Results from early-stage clinical trials may not be predictive of results from late-stage or other clinical trials.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Positive and promising results from preclinical studies and early-stage clinical trials may not be predictive of results from late-stage clinical trials or from clinical trials of the same product candidates for the treatment of </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 36pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">21<br></div></div></div>
<!--End Page 25-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 26-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 540pt;"><a name="nt10014672x1_drs_104-risk_pg9"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="block-frill" style="width: 540pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: Arial, Helvetica, sans-serif; font-size: 9pt; font-weight: bold; margin-top: 6pt; text-align: center;">Confidential Treatment Requested by ADC Therapeutics SA Pursuant to 17 C.F.R. &#167; 200.83<br></div></div><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 36pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">other indications. Product candidates in later stages of clinical trials may fail to show the desired safety and efficacy traits despite having progressed through preclinical studies and initial clinical trials. Late-stage clinical trials could differ in significant ways from early-stage clinical trials, including changes to inclusion and exclusion criteria, efficacy endpoints, dosing regimen and statistical design. Moreover, success in clinical trials in a particular indication does not guarantee that a product candidate will be successful for the treatment of other indications. Many companies in the biotechnology industry have suffered significant setbacks in late-stage clinical trials after achieving encouraging or positive results in early-stage development. There can be no assurance that we will not face similar setbacks in our ongoing or planned late-stage clinical trials and any subsequent or post-marketing confirmatory clinical trials. Therefore, despite positive results observed in early-stage clinical trials, our product candidates may fail to demonstrate sufficient efficacy in our pivotal or confirmatory clinical trials.</div><div class="frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">Preliminary interim or &#8220;top-line&#8221; data that we announce or publish from time to time may change as more data become available and are subject to audit and verification procedures that could result in material changes in the final data. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">From time to time, we may announce or publish preliminary interim or &#8220;top-line&#8221; data from clinical trials. Positive preliminary data may not be predictive of such trial&#8217;s subsequent or overall results. Preliminary data are subject to the risk that one or more of the outcomes may materially change as more data become available. Additionally, preliminary data are subject to the risk that one or more of the clinical outcomes may materially change as patient enrollment continues and more patient data become available. Therefore, positive preliminary results in any ongoing clinical trial may not be predictive of such results in the completed trial. We also make assumptions, estimations, calculations and conclusions as part of our analyses of data, and we may not have received or had the opportunity to fully evaluate all data. As a result, preliminary data that we report may differ from future results from the same clinical trials, or different conclusions or considerations may qualify such results, once additional data have been received and fully evaluated. Preliminary data also remain subject to audit and verification procedures that may result in the final data being materially different from the preliminary data we previously published. As a result, preliminary data should be viewed with caution until the final data are available. Material adverse changes in the final data compared to preliminary data could significantly harm our business prospects.</div><div class="frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">Delays in the commencement and completion of clinical trials could increase costs and delay or prevent regulatory approval and commercialization of our product candidates.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">We cannot guarantee that clinical trials of our product candidates will be conducted as planned or completed on schedule, if at all. A failure of one or more clinical trials can occur at any stage of the clinical trial process, and other events may cause us to temporarily or permanently stop a clinical trial. Events that may prevent successful or timely commencement and completion of clinical development include:</div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">negative preclinical data;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">delays in receiving the required regulatory clearance from the appropriate regulatory authorities to commence clinical trials or amend clinical trial protocols, including any objections to our INDs or protocol amendments from the FDA;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">delays in reaching, or a failure to reach, a consensus with regulatory authorities on study design;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">delays in reaching, or a failure to reach, an agreement on acceptable terms with prospective clinical research organizations (&#8220;CROs&#8221;) and clinical trial sites, the terms of which can be subject to extensive negotiation and may vary significantly among different CROs and clinical trial sites;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">difficulties in obtaining required Institutional Review Board (&#8220;IRB&#8221;) or ethics committee approval at each clinical trial site;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">challenges in recruiting and enrolling suitable patients that meet the study criteria to participate in clinical trials;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the inability to enroll a sufficient number of patients in clinical trials to ensure adequate statistical power to detect statistically significant treatment effects;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">imposition of a clinical hold by regulatory authorities or IRBs for any reason, including safety concerns and non-compliance with regulatory requirements;</div></td></tr></table></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 36pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">22<br></div></div></div>
<!--End Page 26-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 27-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 540pt;"><a name="nt10014672x1_drs_104-risk_pg10"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="block-frill" style="width: 540pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: Arial, Helvetica, sans-serif; font-size: 9pt; font-weight: bold; margin-top: 6pt; text-align: center;">Confidential Treatment Requested by ADC Therapeutics SA Pursuant to 17 C.F.R. &#167; 200.83<br></div></div><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 36pt;"><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6.75pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">failure by CROs, other third parties or us to adhere to clinical trial requirements;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">failure to perform in accordance with the FDA&#8217;s good clinical practices (&#8220;GCP&#8221;) or applicable regulatory guidelines in other jurisdictions;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the inability to manufacture adequate quantities of a product candidate or other materials necessary in accordance with current Good Manufacturing Practices (&#8220;cGMPs&#8221;) to conduct clinical trials, including, for example, quality issues and delays in the testing, validation, manufacturing delays or failures at our CROs and delivery of the product candidates to the clinical trial sites;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">lower than anticipated patient retention rates;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">difficulties in maintaining contact with patients after treatment, resulting in incomplete data;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">ambiguous or negative interim results;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">our CROs or clinical trial sites failing to comply with regulatory requirements or meet their contractual obligations to us in a timely manner, or at all, deviating from the protocol or dropping out of a clinical trial;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">unforeseen safety issues, including occurrence of treatment emergent adverse events (&#8220;TEAEs&#8221;) associated with the product candidate that are viewed to outweigh the product candidate&#8217;s potential benefits;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">changes in regulatory requirements and guidance that require amending or submitting new clinical protocols; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">lack of adequate funding to continue the clinical trial; or</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">delays and disruptions as a result of the COVID-19 pandemic.</div></td></tr></table><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Delays, including delays caused by the above factors, can be costly and could negatively affect our ability to complete a clinical trial. If we are not able to successfully complete clinical trials, we will not be able to obtain regulatory approval and will not be able to commercialize our product candidates.</div><div class="frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 20.5pt; margin-left: 0pt; text-align: left;">In the past, certain of our clinical trials, including our pivotal Phase 2 clinical trial of Cami for the treatment of relapsed or refractory HL, have been subject to clinical holds prior to the dosing of the first patient and partial clinical holds after the dosing of the first patient. A clinical hold on any of our clinical trials will result in delays of our clinical development timeline.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">In October 2017, the FDA placed a partial clinical hold on our Phase 1 clinical trial of Cami for the treatment of relapsed or refractory HL and NHL after we informed the FDA that two patients with HL were diagnosed with Guillain&#8211;Barr&#233; syndrome and one patient with HL was diagnosed with polyradiculopathy. In consultation with the FDA, we amended the clinical trial protocol and in January 2018, the FDA lifted the partial clinical hold without condition. In April 2020, the FDA placed a partial clinical hold on our pivotal Phase 2 clinical trial of Cami for the treatment of relapsed or refractory HL after we informed the FDA that two patients were diagnosed with Guillain&#8211;Barr&#233; syndrome. At the FDA&#8217;s request, we submitted certain information, including an updated investigator&#8217;s brochure, an updated clinical trial protocol, the data safety monitoring board (&#8220;DSMB&#8221;) meeting minutes, an updated informed consent form, dose and exposure analysis for safety and response and an updated safety monitoring plan. In July&#160;2020, the FDA lifted the partial clinical hold. There can be no assurance that the FDA will not reinstate the clinical hold in the future. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">In connection with seeking clearance of our INDs for ADCT-601 and ADCT-602, we were subject to clinical holds prior to the dosing of the first patient in these clinical trials. For ADCT-602, the FDA required additional data to support the stability of the product candidate at low doses. For ADCT-601, the FDA had questions regarding the novel linker technology, the stability of the product candidate and the clinical trial protocol. The FDA subsequently lifted these clinical holds, and for ADCT-601, we must submit a protocol amendment before we commence Phase 1b of the clinical trial.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">There can be no assurance that our current or future clinical trials will not be subject to additional partial or full clinical holds, which could delay or impair the commencement and completion of our clinical trials and the regulatory approval of our product candidates.</div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 36pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">23<br></div></div></div>
<!--End Page 27-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 28-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 540pt;"><a name="nt10014672x1_drs_104-risk_pg11"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="block-frill" style="width: 540pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: Arial, Helvetica, sans-serif; font-size: 9pt; font-weight: bold; margin-top: 6pt; text-align: center;">Confidential Treatment Requested by ADC Therapeutics SA Pursuant to 17 C.F.R. &#167; 200.83<br></div></div><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 36pt;"><div class="frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">If we experience delays or difficulties in patient enrollment for clinical trials, our research and development efforts and the receipt of necessary regulatory approvals could be significantly delayed or prevented.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Commencement and successful and timely completion of clinical trials require us to enroll a sufficient number of eligible patients to participate in these trials as required by the FDA, EMA or comparable regulatory authorities in other jurisdictions. Any delay or difficulty in patient enrollment could significantly delay or otherwise hinder our research and development efforts and delay or prevent receipt of necessary regulatory approvals.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8.5pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Patient enrollment is affected by many factors, including:</div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the size and nature of the patient population;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the severity of the disease under investigation;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the eligibility criteria for the study in question, including any misjudgment of, and resultant adjustment to, the appropriate ranges applicable to the exclusion and inclusion criteria;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the number of clinical trial sites and the proximity of prospective patients to those sites;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the nature, severity and frequency of adverse side effects associated with our product candidates;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the standard of care in the diseases under investigation;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the commitment of our clinical investigators to identify eligible patients;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">competing studies or trials with similar eligibility criteria;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the patient referral practices of physicians;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">clinicians&#8217; and patients&#8217; perceptions as to the potential advantages and risks of the product candidate being studied in relation to other available therapies, including perception of ADCs generally and of PBD-based ADCs specifically; and</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">disruptions as a result of the COVID-19 pandemic.</div></td></tr></table><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">In particular, some of our clinical trials will seek to enroll patients with characteristics that are found in a small population. For example, our confirmatory clinical trial of Lonca in combination with rituximab seeks to enroll patients with DLBCL who are ineligible for SCT and who had failed at least one multi-agent systemic treatment regimen, our pivotal Phase 2 clinical trial of Cami seeks to enroll patients with HL who have failed three prior lines of therapy, including brentuximab vedotin and a checkpoint inhibitor approved for HL, and our pivotal Phase 2 clinical trial of Lonca for the treatment of FL will seek to enroll patients with FL or other indolent lymphoma who failed two or more prior lines of therapy, including rituximab. Our clinical trials will compete with those for other product candidates in the same therapeutic areas as our product candidates. This competition will reduce the number and types of patients available to us, as some patients who might have opted to enroll in our clinical trials may instead opt to enroll in one being conducted by one of our competitors. Because the number of qualified clinical investigators is limited, we expect to conduct some of our clinical trials at the same clinical trial sites used by some of our competitors, which will reduce the number of patients who are available for our clinical trials in these clinical trial sites. Moreover, because our product candidates represent a departure from more commonly used methods for cancer treatment, potential patients and their doctors may be inclined to use conventional therapies, such as chemotherapy and antibody therapy, rather than to participate in our clinical trials. In addition, patients may also be unwilling to participate in our clinical trials because of negative publicity from adverse events in the biotechnology industry. Challenges in recruiting and enrolling suitable patients to participate in clinical trials could increase costs, affect the timing and outcome of our planned clinical trials and result in delays to our current development plan for our product candidates.</div><div class="frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 20.5pt; margin-left: 0pt; text-align: left;">Our product candidates may cause undesirable side effects or have other properties that may delay or prevent their development or regulatory approval or limit their commercial potential.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Undesirable side effects caused by our product candidates or by ADCs developed by others could cause us or regulatory authorities to interrupt, delay or halt clinical trials and could result in more restrictive labeling or the denial of regulatory approval by the FDA, EMA or other regulatory authorities and potential product liability </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 36pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">24<br></div></div></div>
<!--End Page 28-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 29-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 540pt;"><a name="nt10014672x1_drs_104-risk_pg12"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="block-frill" style="width: 540pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: Arial, Helvetica, sans-serif; font-size: 9pt; font-weight: bold; margin-top: 6pt; text-align: center;">Confidential Treatment Requested by ADC Therapeutics SA Pursuant to 17 C.F.R. &#167; 200.83<br></div></div><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 36pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">claims. Such side effects could also affect patient recruitment or the ability of enrolled patients to complete the trial. Many compounds developed in the biotechnology industry that initially showed promise in early-stage testing for treating cancer have later been found to cause side effects that prevented their further development.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">In our clinical trials, we have observed certain class toxicities associated with our warheads, including elevated liver enzymes, skin rash, and effusions and edema. In addition, in our pivotal Phase&#160;2 clinical trial of Lonca for the treatment of relapsed or refractory DLBCL, reported Grade &#8805;3 TEAEs included neutropenia, thrombocytopenia, gamma-glutamyltransferase increased and anemia, while in our Phase 1 clinical trial of Cami for the treatment of relapsed or refractory HL and NHL, reported Grade &#8805;3 TEAEs include gamma-glutamyltransferase increased, maculopapular rash, alanine aminotransferase increased and anemia.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">In addition, certain patients with HL treated with Cami have reported Guillain&#8211;Barr&#233; syndrome. In August and September 2017, in our Phase 1 clinical trial of Cami for the treatment of relapsed or refractory HL and NHL, we informed the FDA that two patients with HL were diagnosed with Guillain&#8211;Barr&#233; syndrome and one patient with HL was diagnosed with polyradiculopathy. The FDA issued a partial clinical hold on our clinical trial, pursuant to which we suspended the enrollment of new patients but continued the treatment of enrolled patients who would derive clinical benefit from continued treatment with Cami. We amended the clinical trial protocol and informed consent to include, among other things, additional risk factors to patient screening, additional exclusion criteria and routine neurologic evaluation prior to and during the clinical trial to monitor the occurrence of Guillain&#8211;Barr&#233; syndrome. In January 2018, the FDA lifted the partial clinical hold without condition. In September 2018, we informed the FDA that two additional patients with HL were diagnosed with Guillain&#8211;Barr&#233; syndrome. We&#160;voluntarily suspended patient enrollment and undertook a detailed safety review of our clinical trial in accordance with our clinical trial protocol and submitted it to the FDA. Upon review, in October 2018, the FDA agreed that we can resume patient enrollment and made certain recommendations, including the expansion of the HL 30 &#956;g/kg dose cohort to ten additional patients, the continued assessment of pharmacokinetics and regulatory T-cell profiles in the clinical trial and that we consult with the FDA regarding the decision of final dose selection before closing the 30 &#956;g/kg dose cohort. We subsequently implemented the FDA&#8217;s recommendations. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">In March 2020, in our pivotal Phase 2 clinical trial of Cami for the treatment of relapsed or refractory HL, two patients were diagnosed with Guillain&#8211;Barr&#233; syndrome. Pursuant to the clinical trial protocol, which included specific stopping rules for Guillain&#8211;Barr&#233; syndrome, we suspended enrollment of new patients in this clinical trial but continued to treat enrolled patients who could derive clinical benefit from continued treatment with Cami. Before we resumed enrollment pursuant to the recommendations of an independent DSMB, on April 17, 2020, the FDA issued a partial clinical hold on this clinical trial. The FDA agreed that, pending its review, we could continue to treat enrolled patients, including patients with stable disease, who could derive clinical benefit from continued treatment with Cami. In May 2020, an additional patient was diagnosed with Guillain&#8211;Barr&#233; syndrome. At the FDA&#8217;s request, we submitted certain information, including an updated investigator&#8217;s brochure, an updated clinical trial protocol, the DSMB meeting minutes, an updated informed consent form, dose and exposure analysis for safety and response and an updated safety monitoring plan. In July&#160;2020, the FDA lifted the partial clinical hold. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">There can be no assurance that other patients treated with Cami will not experience Guillain&#8211;Barr&#233; syndrome or other serious adverse side effects and there can be no assurance that the FDA, EMA or comparable regulatory authorities in other jurisdictions will not place clinical holds on our current or future clinical trials, the result of which could delay or prevent us from obtaining regulatory approval for Cami. Even if approved, Cami may carry boxed warnings or precautions regarding the risk of Guillain&#8211;Barr&#233; syndrome.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">For our current and future clinical trials, we have contracted with and expect to continue to contract with CROs experienced in the assessment and management of toxicities arising during clinical trials. Nonetheless, they may have difficulty observing patients and treating toxicities, which may be more challenging due to personnel changes, shift changes, house staff coverage or related issues. This could lead to more severe or prolonged toxicities or even patient deaths, which could result in us or the FDA delaying, suspending or terminating one or more of our clinical trials and which could jeopardize regulatory approval.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Furthermore, clinical trials by their nature utilize a sample of the potential patient population. With a limited number of subjects and limited duration of exposure, rare and severe side effects of our product candidates or </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 36pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">25<br></div></div></div>
<!--End Page 29-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 30-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 540pt;"><a name="nt10014672x1_drs_104-risk_pg13"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="block-frill" style="width: 540pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: Arial, Helvetica, sans-serif; font-size: 9pt; font-weight: bold; margin-top: 6pt; text-align: center;">Confidential Treatment Requested by ADC Therapeutics SA Pursuant to 17 C.F.R. &#167; 200.83<br></div></div><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 36pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">those of our competitors may only be uncovered with a significantly larger number of patients exposed to the drug. For example, while we believe that Lonca and Cami have demonstrated manageable tolerability profiles thus far, there can be no assurance that these and our other product candidates will not cause more severe side effects in a greater proportion of patients.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">In addition, some of our product candidates are developed or intended to be used in combination with other therapies. We are investigating the use of Lonca in combination with rituximab and with ibrutinib. Rituximab may cause undesirable side effects, including infections, fatigue and nausea. Ibrutinib may cause undesirable side effects, including pneumonia, upper respiratory tract infection, low neutrophil count, low platelet count, rash and edema. Combining Lonca with these and other agents may cause additional, different or more severe side effects than when Lonca or these agents are used as monotherapies. In addition, Lonca and these agents may have common toxicities. For example, edema is a common toxicity of Lonca and ibrutinib. When used in combination, the severity and frequency of such undesirable side effects may be greater than the cumulative severity and frequency of such side effects when the therapies are used as monotherapies. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">In our Phase 1/2 clinical trial of Lonca in combination with ibrutinib, we observed two dose-limiting toxicities (&#8220;DLTs&#8221;). One DLT of Death Not Otherwise Specified was observed in a patient treated with Lonca at the 90 &#181;g/kg dose level in combination with ibrutinib, which the investigator assessed as unlikely to be related to Lonca and as possibly being related to ibrutinib, the disease and/or comorbidities. In addition, one DLT of anemia and thrombocytopenia was observed in a patient treated with Lonca at the 90 &#181;g/kg dose level in combination with ibrutinib, which the investigator assessed as possibly being related to Lonca, ibrutinib, the disease and/or comorbidities. In our Phase 1/2 clinical trial of ADCT-601 for the treatment of selected advanced solid tumors, we observed two DLTs. One DLT of Grade 3 hematuria was observed in a colorectal cancer patient treated at the 100 &#181;g/kg dose level who had a history of radiotherapy involving the bladder. In addition, one DLT of hyponatremia was observed in an ovarian cancer patient treated at the 150 &#181;g/kg dose level, which the investigator assessed as probably being related to ADCT-601. There can be no assurance that patients in our combination clinical trials will not experience serious adverse side effects, including death, in the future. The uncertainty resulting from the use of our product candidates in combination with other therapies may make it difficult to accurately predict side effects in clinical trials.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">If we or others identify undesirable side effects caused by our product candidates or those of our competitors, a number of potentially significant negative consequences could result, including:</div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">we may encounter delays or difficulties in enrolling patients for our clinical trials due to a negative perception of our product candidates&#8217; safety and tolerability profile;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">we and/or regulatory authorities may temporarily or permanently put our clinical trials on hold;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">we may be unable to obtain regulatory approval for our product candidates;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">regulatory authorities may withdraw or limit their approvals of our product candidates;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">regulatory authorities may require the addition of labeling statements, such as a contraindication, boxed warnings or additional warnings;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the FDA may require development of a Risk Evaluation and Mitigation Strategy with Elements to Assure Safe Use as a condition of approval;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">we may decide to remove our product candidates from the marketplace;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">we may be subject to regulatory investigations and government enforcement actions;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">we could be sued and held liable for harm caused to patients, including as a result of hospital errors; and</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">our reputation may suffer.</div></td></tr></table><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Any of these events could prevent us from achieving or maintaining market acceptance of our product candidates and could substantially increase commercialization costs.</div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 36pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">26<br></div></div></div>
<!--End Page 30-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 31-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 540pt;"><a name="nt10014672x1_drs_104-risk_pg14"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="block-frill" style="width: 540pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: Arial, Helvetica, sans-serif; font-size: 9pt; font-weight: bold; margin-top: 6pt; text-align: center;">Confidential Treatment Requested by ADC Therapeutics SA Pursuant to 17 C.F.R. &#167; 200.83<br></div></div><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 36pt;"><div class="frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">We may expend our resources to pursue particular product candidates and fail to capitalize on product candidates that may be more profitable or for which there is a greater likelihood of success.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Because we have limited financial resources and personnel, we focus on the development of specific product candidates based on our product development strategy. As a result, we may forgo or delay the pursuit of other product candidates that later prove to have greater commercial potential. Decision making about which product candidates to prioritize involves inherent subjectivity and/or uncertainty. Our resource allocation decisions may cause us to fail to capitalize on viable commercial products or profitable market opportunities. Failure to properly assess potential product candidates could result in our focus on product candidates with low market potential, which would harm our business and financial condition. Our spending on current and future research programs and product candidates for specific indications may not yield any commercially viable product candidates. If we do not accurately evaluate the commercial potential or target market for a particular product candidate, we may relinquish valuable rights to that product candidate through partnering, licensing or other arrangements in cases in which it would have been more advantageous for us to retain sole development and commercialization rights to such product candidate.</div><div class="frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">We may not be successful in our efforts to develop additional product candidates and build up our research pipeline.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">A key element of our development strategy is to build a robust pipeline of PBD-based ADCs targeting both novel and clinically validated cancer targets for the treatment of hematological malignancies and solid tumors. Our license and collaboration agreement with MedImmune Limited (&#8220;MedImmune&#8221;) allows us to develop PBD-based ADCs against 11 targets. See &#8220;Business&#8212;License and Collaboration Agreements&#8212;MedImmune License and Collaboration Agreement.&#8221; We have selected all 11 targets under this agreement. There can be no assurance that these targets will yield safe, effective and commercially viable product candidates. If we wish to develop ADCs for additional targets, we must secure additional licenses from MedImmune, which we may not be able to obtain at a reasonable cost or on reasonable terms, if at all.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">We also pursue research programs involving non-ADC product candidates. However, we may be unable to identify suitable additional product candidates for clinical development, which would limit our ability to develop product candidates and our ability to obtain revenues from commercializing any such product candidates. Even if we are successful in continuing to build our research pipeline, the potential product candidates that we identify may fail in clinical development or commercialization. For example, they may not demonstrate sufficient efficacy or may demonstrate harmful side effects or other characteristics that make them unlikely to receive regulatory approval and achieve market acceptance.</div><div class="frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">Our research and development activities could be affected or delayed as a result of possible restrictions on animal testing.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Certain laws and regulations require us to test our product candidates on animals before initiating clinical trials in humans. We conduct preclinical studies of our product candidates in rats, mice, dogs and non-human primates. Animal testing activities have been the subject of controversy and adverse publicity. Animal rights groups and other organizations and individuals have attempted to stop animal testing activities by pressing for legislation and regulation in these areas and by disrupting these activities through protests and other means. To the extent the activities of these groups are successful, our research and development activities may be interrupted or delayed or become more expensive.</div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 17.5pt; margin-left: 0pt; text-align: left;">Risks Related to the Regulatory Approval of Our Product Candidates</div><div class="frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 6pt; margin-left: 0pt; text-align: left;">The regulatory review and approval processes of the FDA, EMA and comparable regulatory authorities in other jurisdictions are lengthy, time-consuming and inherently unpredictable. If we are unable to obtain, or if there are delays in obtaining, regulatory approval for our product candidates, we will not be able to commercialize our product candidates and our ability to generate revenue will be materially impaired.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Our product candidates must be approved by the FDA in the United States, by the EMA in the European Union and by comparable regulatory authorities in other jurisdictions prior to commercialization. In order to obtain regulatory approval for the commercial sale of any product candidates, we must demonstrate through extensive preclinical studies and clinical trials that the product candidate is safe and effective for use in each target indication and that manufacturing of the product candidate is robust and reproducible. The time required to </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 36pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">27<br></div></div></div>
<!--End Page 31-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 32-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 540pt;"><a name="nt10014672x1_drs_104-risk_pg15"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="block-frill" style="width: 540pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: Arial, Helvetica, sans-serif; font-size: 9pt; font-weight: bold; margin-top: 6pt; text-align: center;">Confidential Treatment Requested by ADC Therapeutics SA Pursuant to 17 C.F.R. &#167; 200.83<br></div></div><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 36pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">obtain approval by the FDA, EMA and comparable regulatory authorities in other jurisdictions is unpredictable, typically takes many years following the commencement of clinical trials and depends upon numerous factors. Of the large number of drugs in development in the United States, only a small percentage will successfully complete the FDA regulatory approval process and will be commercialized. Accordingly, there can be no assurance that any of our product candidates will receive regulatory approval in the United States, the European Union or other jurisdictions.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Regulatory authorities have substantial discretion in the approval process. They may refuse to accept any application and may decide that our data are insufficient for approval and require additional clinical trials or other studies. Therefore, even if we believe the data collected from clinical trials of our product candidates are promising, such data may not be sufficient to support approval by the FDA, EMA or any comparable regulatory authority in other jurisdictions. For example, while we may designate certain of our clinical trials as &#8220;pivotal,&#8221; the FDA, EMA and other comparable regulatory authorities in other jurisdictions may not agree with such designation. In this prospectus, we designate our Phase 2 clinical trial of Lonca for the treatment of relapsed or refractory DLBCL, our Phase 1/2 clinical trial of Lonca in combination with ibrutinib for the treatment of DLBCL and MCL, our Phase 2 clinical trial of Lonca for the treatment of FL and our Phase 2 clinical trial of Cami for the treatment of relapsed or refractory HL as &#8220;pivotal,&#8221; as we believe that these clinical trials, if successful, will support BLA submissions for these product candidates in the respective indications. However, the FDA has not opined on whether these clinical trials will in fact be sufficient to support regulatory approval. Therefore, there can be no assurance that these clinical trials will be viewed as sufficient by the FDA, EMA and other comparable regulatory authorities in other jurisdictions to support regulatory approval. Accordingly, our assumptions about Phase 3 clinical trials being confirmatory clinical trials may be inaccurate, and we may need to conduct Phase 3 clinical trials of these and any other product candidates prior to receiving regulatory approval from the FDA and comparable regulatory authorities in other jurisdictions. We also intend to use the confirmatory clinical trial of Lonca in combination with rituximab to support an sBLA for Lonca to be used as a second-line therapy for the treatment of relapsed or refractory DLBCL in transplant-ineligible patients. However, there can be no assurance that the clinical trial will be viewed as sufficient by the FDA, EMA and other comparable regulatory authorities in other jurisdictions to support any expanded indication.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">If we are required to conduct additional clinical trials or other testing of any of our product candidates beyond those that are contemplated, we may incur significant additional costs and the regulatory approval of our product candidates may be delayed or prevented. For example, the FDA, EMA or comparable regulatory authorities in other jurisdictions may express safety concerns due to the partial clinical holds that were issued but subsequently lifted for Cami and may require additional preclinical studies or clinical trials. In such instance, our progress in the development of Cami may be significantly delayed or stopped and the associated costs may be significantly increased. Furthermore, additional clinical trials or other testing could shorten any periods during which we may have the exclusive right to commercialize our product candidates and could allow our competitors to bring products to market before we do, which may prevent the successful commercialization of our product candidates. Therefore, positive or promising results from clinical trials of our product candidates do not guarantee regulatory approval by the FDA, EMA or any comparable regulatory authority in other jurisdictions.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Furthermore, the process and time required to obtain regulatory approval differ by jurisdiction. In many countries outside the United States, a drug must be approved for reimbursement before it can be approved for sale in that country. Approval by one regulatory authority does not ensure approval by regulatory authorities in other jurisdictions.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Moreover, principal investigators for our clinical trials may serve as scientific advisors or consultants to us from time to time and receive compensation in connection with such services at market rates. Under certain circumstances, we may be required to report some of these relationships to the FDA, EMA or comparable regulatory authorities in other jurisdictions, which could conclude that a financial relationship between us and a principal investigator has created a conflict of interest or otherwise affected the integrity of the study. The FDA, EMA or comparable regulatory authorities in other jurisdictions may, therefore, question the integrity of the data generated at the applicable clinical trial site, and the utility of the clinical trial itself may be jeopardized. This could delay, or result in the rejection of, our marketing applications.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">To date, regulatory approval has not been obtained for any product candidate based on the PBD technology used in our product candidates in any jurisdiction, and it is possible that none of our existing product candidates or any product candidates we may seek to develop in the future will ever obtain regulatory approval in any </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 36pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">28<br></div></div></div>
<!--End Page 32-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 33-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 540pt;"><a name="nt10014672x1_drs_104-risk_pg16"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="block-frill" style="width: 540pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: Arial, Helvetica, sans-serif; font-size: 9pt; font-weight: bold; margin-top: 6pt; text-align: center;">Confidential Treatment Requested by ADC Therapeutics SA Pursuant to 17 C.F.R. &#167; 200.83<br></div></div><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 36pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">jurisdiction. Because our product candidates are based on next-generation PBD technology, the regulatory approval process for our product candidates can be more expensive and take longer than that for our competitors&#8217; better known or more extensively studied product candidates. It is difficult to determine the time and resources required to obtain regulatory approvals for our product candidates in the United States, the European Union or other major markets. In addition, we may gain regulatory approval for our product candidates in some but not all of the jurisdictions for which we seek approval or for some but not all of the target indications for which we seek approval, resulting in limited commercial opportunity for the approved product candidates.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Applications for regulatory approval and regulatory approval of our product candidates could be delayed or be denied for many reasons, including but not limited to the following:</div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the FDA, EMA or comparable regulatory authorities in other jurisdictions may disagree with the number, design or implementation of our clinical trials;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the population studied in the clinical trial may not be considered sufficiently broad or representative to assure safety in the full population for which we seek approval;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the FDA, EMA or comparable regulatory authorities in other jurisdictions may disagree with our interpretation of data from preclinical studies or clinical trials;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the data collected from clinical trials of our product candidates may not meet the level of statistical or clinical significance required by the FDA, EMA or comparable regulatory authorities in other jurisdictions or may otherwise not be sufficient to support the submission of a BLA, Marketing Authorization Application (&#8220;MAA&#8221;) or other submission or to obtain regulatory approval in the United States, the European Union or elsewhere;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the FDA, EMA or comparable regulatory authorities in other jurisdictions may not accept data generated by our preclinical service providers and clinical trial sites;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the FDA, EMA or comparable regulatory authorities in other jurisdictions may require us to conduct additional preclinical studies and clinical trials;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">we may be unable to demonstrate to the FDA, EMA or comparable regulatory authorities in other jurisdictions that a product candidate&#8217;s response rate, duration of response (&#8220;DoR&#8221;) or risk-benefit ratio for its proposed indication is acceptable;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the FDA, EMA or comparable regulatory authorities in other jurisdictions may fail to approve the manufacturing processes, test procedures and specifications applicable to the manufacture of our product candidates, the facilities of third-party manufacturers with which we contract for clinical or commercial supplies may fail to maintain a compliance status acceptable to the FDA, EMA or comparable regulatory authorities or the EMA or comparable regulatory authorities may fail to approve facilities of third-party manufacturers with which we contract for clinical and commercial supplies;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">we or any third-party service providers may be unable to demonstrate compliance with cGMPs to the satisfaction of the FDA, EMA or comparable regulatory authorities in other jurisdictions, which could result in delays in regulatory approval or require us to withdraw or recall products and interrupt commercial supply of our products;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the approval policies or regulations of the FDA, EMA or comparable regulatory authorities in other jurisdictions may change in a manner rendering our clinical data insufficient for approval; or</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">political factors surrounding the approval process, such as government shutdowns and political instability.</div></td></tr></table><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Any of these factors, many of which are beyond our control, may result in our failing to obtain regulatory approval for any of our product candidates, which would significantly harm our business, financial condition and prospects.</div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 36pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">29<br></div></div></div>
<!--End Page 33-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 34-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 540pt;"><a name="nt10014672x1_drs_104-risk_pg17"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="block-frill" style="width: 540pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: Arial, Helvetica, sans-serif; font-size: 9pt; font-weight: bold; margin-top: 6pt; text-align: center;">Confidential Treatment Requested by ADC Therapeutics SA Pursuant to 17 C.F.R. &#167; 200.83<br></div></div><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 36pt;"><div class="frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">We intend to seek accelerated approval for some of our product candidates, which may not lead to a faster development or regulatory review or approval process, and does not increase the likelihood that the product candidates will receive marketing approval.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Under the FDA&#8217;s accelerated approval program, the FDA may approve a drug for a serious or life-threatening illness that provides meaningful therapeutic benefit to patients over existing treatments based upon a surrogate endpoint that is reasonably likely to predict clinical benefit, or on a clinical endpoint that can be measured earlier than irreversible morbidity or mortality, that is reasonably likely to predict an effect on irreversible morbidity or mortality or other clinical benefit, taking into account the severity, rarity, or prevalence of the condition and the availability or lack of alternative treatments. We intend to seek accelerated approval for some of our product candidates on the basis of ORR with an acceptable DoR, a surrogate endpoint that we believe is reasonably likely to predict clinical benefit. However, full approval of another product for the same indication as any of our product candidates for which we are seeking accelerated approval may make accelerated approval of our product candidates more difficult.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">For drugs granted accelerated approval, post-marketing confirmatory clinical trials are required to describe the anticipated effect on irreversible morbidity or mortality or other clinical benefit. These confirmatory clinical trials must be completed with due diligence and, in some cases, the FDA may require that the trial be designed, initiated and/or fully enrolled prior to approval. If any of our competitors were to receive full approval on the basis of a confirmatory clinical trial for an indication for which we are seeking accelerated approval before we receive accelerated approval, the indication we are seeking may no longer qualify as a condition for which there is an unmet medical end and accelerated approval of our product candidate would be more difficult. Moreover, the FDA may withdraw approval of our product candidate approved under the accelerated approval pathway if, for example:</div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the clinical trial(s) required to verify the predicted clinical benefit of a product candidate fails to verify such benefit or does not demonstrate sufficient clinical benefit to justify the risks associated with the product candidate;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">other evidence demonstrates that a product candidate is not shown to be safe or effective under the conditions of use;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">we fail to conduct any required post-marketing confirmatory clinical trial with due diligence; or</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">we disseminate false or misleading promotional materials relating to the relevant product candidate.</div></td></tr></table><div class="frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 20pt; margin-left: 0pt; text-align: left;">Breakthrough Therapy Designation, Fast Track Designation and Priority Review Designation by the FDA, or comparable designations by foreign regulatory authorities, for our product candidates may not lead to a faster development or regulatory review or approval process and do not increase the likelihood that a product candidate would receive regulatory approval.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">We do not currently have Breakthrough Therapy Designation, Fast Track Designation or Priority Review Designation for any of our product candidates. We may seek such designations, and comparable designations by foreign regulatory authorities, for one or more of our product candidates for the treatment of certain indications. A breakthrough therapy is defined as a product candidate that is intended, alone or in combination with one or more other drugs, to treat a serious or life-threatening disease or condition, and preliminary clinical evidence indicates that the drug may demonstrate substantial improvement over currently approved therapies on one or more clinically significant endpoints, such as substantial treatment effects observed early in clinical development. For product candidates that have been designated as breakthrough therapies, interaction and communication between the FDA and the sponsor can help to identify the most efficient path for development. A Fast Track Designation may be available if a product candidate is intended for the treatment of a serious or life-threatening condition and preclinical or clinical data demonstrate the potential to address an unmet medical need for this condition. Priority review may be granted for products that are intended to treat a serious or life-threatening condition and, if approved, would provide a significant improvement in safety and effectiveness compared to available therapies. The FDA will attempt to direct additional resources to the evaluation of an application designated for priority review in an effort to facilitate the review.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The FDA has broad discretion whether or not to grant Breakthrough Therapy Designation, Fast Track Designation and Priority Review Designation. Accordingly, even if we believe, after completing early clinical trials, that one of our product candidates meets the criteria for such designations, the FDA may disagree and </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 36pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">30<br></div></div></div>
<!--End Page 34-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 35-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 540pt;"><a name="nt10014672x1_drs_104-risk_pg18"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="block-frill" style="width: 540pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: Arial, Helvetica, sans-serif; font-size: 9pt; font-weight: bold; margin-top: 6pt; text-align: center;">Confidential Treatment Requested by ADC Therapeutics SA Pursuant to 17 C.F.R. &#167; 200.83<br></div></div><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 36pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">instead determine not to make such designations. Even if we receive such designation for a product candidate, it may not result in a faster development process, review or approval compared to conventional FDA procedures and does not guarantee ultimate approval by the FDA. Many drugs that have received such designations have failed to obtain ultimate approval by the FD<font style="text-transform: uppercase;">A</font>. In addition, the FDA may decide to rescind such designations if it determines that our product candidates no longer meet the conditions for qualification, including as a result of the product candidates&#8217; failure to meet endpoints in any clinical trial.</div><div class="frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">We received orphan drug designation from the FDA for Lonca for the treatment of DLBCL and MCL, and we may seek it for our other product candidates. However, we may be unable to maintain the benefits associated with the designation and may not receive the designation for our other product candidates.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Regulatory authorities in some jurisdictions, including the United States and the European Union, may designate drugs for relatively small patient populations as orphan drugs. Under the Orphan Drug Act, the FDA may designate a product as an orphan drug if it is intended to treat a rare disease or condition, defined as a patient population of fewer than 200,000 in the United States, or a patient population greater than 200,000 in the United States where there is no reasonable expectation that the cost of developing the drug will be recovered from sales in the United States. In the European Union, the EMA&#8217;s Committee for Orphan Medicinal Products grants orphan drug designation to promote the development of products that meet the following criteria: (i)&#160;they are intended for the diagnosis, prevention, or treatment of a life-threatening or chronically debilitating condition affecting not more than five in 10,000 persons in the European Union or they are intended for the diagnosis, prevention, or treatment of a life-threatening, seriously debilitating or serious and chronic condition when, without incentives, it is unlikely that sales of the drug in the European Union would be sufficient to justify the necessary investment in developing the drug or biological product and (ii)&#160;where there is no satisfactory method of diagnosis, prevention or treatment, or, if such a method exists, the medicine must be of significant benefit to those affected by the condition.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">In the United States, orphan drug designation entitles a party to financial incentives such as opportunities for grant funding towards clinical trial costs, tax advantages and user fee waivers. In addition, if a product receives the first FDA approval for the indication for which it has orphan designation, the product is entitled to orphan drug exclusivity, which means the FDA may not approve any other application to market the same drug for the same indication for a period of seven years, except in limited circumstances, such as a showing of clinical superiority over the product with orphan exclusivity or where the manufacturer is unable to assure sufficient product quantity. The FDA&#8217;s determination of whether two ADCs are the same product for purposes of orphan drug exclusivity is based on a determination of sameness of the monoclonal antibody element and the functional element of the conjugated molecule. Two ADCs are deemed to be the same product if the complementarity determining region sequences of the antibody and the functional element of the conjugated molecule are the same. A difference in either of those two elements can result in a determination that the molecules are different.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">In the European Union, orphan drug designation entitles a party to financial incentives such as reduction of fees or fee waivers and ten years of market exclusivity for the orphan indication following drug or biological product approval, provided that the criteria for orphan designation are still applicable at the time of the granting of the marketing authorization. This period may be reduced to six years if, at the end of the fifth year, the orphan drug designation criteria are no longer met, including where it is shown that the product is sufficiently profitable not to justify maintenance of market exclusivity. However, orphan drug designation neither shortens the development time or regulatory review time of a drug or therapeutic biologic nor gives the drug or therapeutic biologic any advantage in the regulatory review or approval process.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">We received orphan drug designation in the United States for Lonca for the treatment of DLBCL and MCL in 2017. We may pursue orphan drug designation for one or more of our other product candidates. However, obtaining an orphan drug designation can be difficult, and we may not be successful in doing so. Even if we obtain orphan drug designation for our product candidates in specific indications, we may not be the first to obtain regulatory approval of these product candidates for the orphan-designated indication. In addition, exclusive marketing rights in the United States may be limited if we seek approval for an indication broader than the orphan-designated indication or may be lost if the FDA later determines that the request for designation was materially defective or if the manufacturer is unable to assure sufficient quantities of the product to meet the needs of patients with the rare disease or condition. Furthermore, even if we obtain orphan drug exclusivity for a product, that exclusivity may not effectively protect the product from competition because different ADCs with different monoclonal antibody elements or functional elements of the conjugated molecule can be approved for </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 36pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">31<br></div></div></div>
<!--End Page 35-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 36-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 540pt;"><a name="nt10014672x1_drs_104-risk_pg19"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="block-frill" style="width: 540pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: Arial, Helvetica, sans-serif; font-size: 9pt; font-weight: bold; margin-top: 6pt; text-align: center;">Confidential Treatment Requested by ADC Therapeutics SA Pursuant to 17 C.F.R. &#167; 200.83<br></div></div><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 36pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">the same condition. Even after an orphan product is approved, the FDA can subsequently approve the same ADC with the same monoclonal antibody element and functional element of the conjugated molecule for the same condition if the FDA concludes that the later ADC is safer, more effective or makes a major contribution to patient care. Our inability to obtain orphan drug designation for any product candidates for the treatment of rare cancers and/or our inability to maintain that designation for the duration of the applicable exclusivity period, could reduce our ability to make sufficient sales of the applicable product candidate to balance our expenses incurred to develop it.</div><div class="frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">We are required to comply with comprehensive and ongoing regulatory requirements for any product candidates that receive regulatory approval, including conducting confirmatory clinical trials of any product candidates that receive accelerated approval.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Any product candidates for which we receive accelerated approval from the FDA or similar conditional approval from the EMA or comparable regulatory authorities in other jurisdictions based on data from clinical trials that use single-arm designs are required to undergo one or more confirmatory clinical trials. If such a product candidate fails to meet its safety and efficacy endpoints in such confirmatory clinical trials, the regulatory authority may withdraw its conditional approval. There is no assurance that any such product will successfully advance through its confirmatory clinical trial(s). Therefore, even if a product candidate receives accelerated approval from the FDA or similar conditional approval from the EMA or comparable regulatory authorities, such approval may be withdrawn at a later date.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">In addition, any product candidates for which we receive regulatory approval in a particular jurisdiction and the activities associated with their commercialization, including testing, manufacture, recordkeeping, labeling, storage, approval, advertising, promotion, sale and distribution, will be subject to comprehensive regulation by the FDA, EMA or comparable regulatory authorities in other jurisdictions. These requirements include, without limitation, submissions of safety and other post-marketing information and reports, registration and listing requirements, the FDA&#8217;s cGMP requirements or comparable requirements in foreign jurisdictions, requirements relating to manufacturing, quality control, quality assurance and corresponding maintenance of records and documents, including periodic inspections by the FDA, EMA or comparable regulatory authorities in other jurisdictions, requirements regarding the distribution of samples to physicians, tracking and reporting of payments to physicians and other healthcare providers and recordkeeping.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The FDA, EMA or comparable regulatory authorities in other jurisdictions may also impose requirements for costly post-marketing studies or clinical trials and surveillance to monitor the safety or efficacy of any approved product. In the United States, the FDA closely regulates the post-approval marketing and promotion of drugs to ensure drugs are marketed only for the approved indications and in a manner consistent with the provisions of the approved labeling. The FDA also imposes stringent restrictions on manufacturers&#8217; communications regarding use of their products and, if we promote our products beyond their approved indications or in a manner inconsistent with the approved labeling, we may be subject to enforcement action for off-label promotion. Violations of the U.S. Federal Food, Drug, and Cosmetic Act (the &#8220;FDCA&#8221;) relating to the promotion of prescription drugs may lead to investigations alleging violations of federal and state healthcare fraud and abuse laws, as well as state consumer protection laws.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">In addition, the later discovery of previously unknown problems with an approved product, including adverse events of unanticipated severity or frequency, or with manufacturing operations or processes, or failure to comply with regulatory requirements, may result in, among other things:</div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">restrictions on the marketing or manufacturing of the product;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">withdrawal of the product from the market or voluntary or mandatory product recalls;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">fines, restitution or disgorgement of profits or revenues;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">warning or untitled letters;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">requirements to conduct post-marketing studies or clinical trials;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">holds on clinical trials;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">refusal by the FDA, EMA or comparable regulatory authorities in other jurisdictions to approve pending applications or supplements to approved applications filed by us, or suspension or revocation of product license approvals;</div></td></tr></table></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 36pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">32<br></div></div></div>
<!--End Page 36-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 37-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 540pt;"><a name="nt10014672x1_drs_104-risk_pg20"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="block-frill" style="width: 540pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: Arial, Helvetica, sans-serif; font-size: 9pt; font-weight: bold; margin-top: 6pt; text-align: center;">Confidential Treatment Requested by ADC Therapeutics SA Pursuant to 17 C.F.R. &#167; 200.83<br></div></div><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 36pt;"><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6.75pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">product seizure or detention;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">refusal to permit the import or export of products; and</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">injunctions or the imposition of civil or criminal penalties.</div></td></tr></table><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The policies of the FDA, EMA and comparable regulatory authorities in other jurisdictions may change and additional regulations may be enacted. If we are slow or unable to adapt to changes in existing requirements or to the adoption of new requirements, or not able to maintain regulatory compliance, we may lose any regulatory approval that may have been obtained. We cannot predict the likelihood, nature or extent of government regulation that may arise from future legislation or administrative action, either in the United States or abroad, as the regulatory environment changes rapidly. For example, certain policies of the current U.S. Presidential Administration may impact our business and industry. Namely, the current U.S. Presidential Administration has taken several executive actions that could impose significant burdens on, or otherwise materially delay, the FDA&#8217;s ability to engage in routine regulatory and oversight activities, such as implementing statutes through rulemaking, issuance of guidance and review and approval of marketing applications. It is difficult to predict how these requirements will be implemented, and the extent to which they will impact the FDA&#8217;s ability to exercise its regulatory authority. If these executive actions impose constraints on the FDA&#8217;s ability to engage in oversight and implementation activities in the normal course, our business may be negatively impacted.</div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 14pt; margin-left: 0pt; text-align: left;">Risks Related to the Commercialization of Our Product Candidates</div><div class="frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 6pt; margin-left: 0pt; text-align: left;">As a company, we have never commercialized a product. We currently have no active sales force and we are in the process of building our commercial infrastructure. We may lack the necessary expertise, personnel and resources to successfully commercialize our product candidates. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">We currently have no active sales force and we are in the process of building our commercial infrastructure. As a company, we have never commercialized a product for any indication. Even if we receive regulatory approval for one or more of our product candidates from the FDA, EMA or comparable regulatory authorities in other jurisdictions, we will need to develop robust internal sales, marketing and distribution capabilities to commercialize such products, which will be expensive and time-consuming, or enter into collaborations with third parties to perform these services. Given our initial focus on relapsed and refractory cancer patient populations, we intend to commercialize Lonca, if approved, in the United States using a focused and highly specialized sales and marketing team with a focus on hematologists and oncologists.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">There are costs and risks involved with establishing our own sales, marketing and distribution capabilities. For example, recruiting and training a sales force is expensive and time-consuming and could delay any product launch. If the commercial launch of a product candidate for which we recruit a sales force and establish marketing capabilities is delayed or does not occur for any reason, we would have prematurely or unnecessarily incurred these commercialization expenses. This may be costly, and our investment would be lost if we cannot retain or reposition our sales and marketing personnel. We must also compete with other biotechnology companies to recruit, hire, train and retain marketing and sales personnel.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Alternatively, we may wish to establish collaborations with third parties to maximize the potential of our product candidates in some or all non-U.S. jurisdictions in which a product candidate has been approved. The biotechnology industries are characterized by intense competition. Therefore, we may not be successful in entering into such commercialization arrangements with third parties on favorable terms, or at all. In addition, we may have limited control over such third parties, and any of them may fail to devote the necessary resources and attention to sell, market and distribute our products effectively.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">There can be no assurance that we will be able to develop the necessary commercial infrastructure and capabilities to successfully commercialize our product candidates or be able to establish or maintain relationships with third parties necessary to perform these services. As a result, we may not successfully commercialize any product in any jurisdiction.</div><div class="frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">Our product candidates are complex and difficult to manufacture. We could experience manufacturing problems that result in delays in our development or commercialization programs.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">There are four manufacturing streams for the manufacture of each of our product candidates: the antibody, the PBD-based payload, the ADC drug substance and the drug product. Because our PBD-based payload is completely synthetic, considerable synthetic chemistry efforts must be undertaken to develop manufacturing </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 36pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">33<br></div></div></div>
<!--End Page 37-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 38-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 540pt;"><a name="nt10014672x1_drs_104-risk_pg21"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="block-frill" style="width: 540pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: Arial, Helvetica, sans-serif; font-size: 9pt; font-weight: bold; margin-top: 6pt; text-align: center;">Confidential Treatment Requested by ADC Therapeutics SA Pursuant to 17 C.F.R. &#167; 200.83<br></div></div><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 36pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">processes for our PBD-based payloads. Although we believe we have access to scalable cGMP-compliant manufacturing processes for the PBD-based payloads used for our product candidates, our preparation of the process for commercial scale manufacturing is ongoing. In addition, because the antibodies used in our product candidates are biologics, there are risks inherent in their manufacture and their conjugation to the PBD-based warhead. There can be no assurance that we will not experience production problems in our manufacturing process. Moreover, scaling up manufacturing techniques used for the manufacture of an ADC product candidate at a clinical scale to commercial quantities may be difficult and may delay our ability to commercialize our product candidates, if approved.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Problems with the manufacturing process, including even minor deviations from the normal process, could result in product defects or manufacturing failures that result in lot failures, product recalls, product liability claims and insufficient inventory. If we successfully develop product candidates, we may encounter problems achieving adequate quantities and quality of clinical-grade materials that meet FDA, EMA or other applicable standards or specifications with consistent and acceptable production yields and costs. In the past, we have received batches of certain of our product candidates that did not meet our specifications. For example, in 2019, clinical sites reported higher pressure than specified in vials of ADCT-601 used in our Phase 1/2 clinical trial, as a result of which we suspended the dosing in that clinical trial. In the future, there can be no assurance that CMOs will be able to manufacture product candidates and/or components of product candidates that meet our specifications, which could delay our clinical trials and the regulatory approval and commercialization of our product candidates.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">We currently rely, and expect to continue to rely, on third parties for the manufacturing and supply of our product candidates. As a result, components of our product candidates are manufactured at different locations, and disruptions, delays and other difficulties may arise in the shipping and transportation of these components, resulting in delayed or failed components.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">In addition, the FDA, EMA and comparable regulatory authorities in other jurisdictions may require us to submit samples of any lot of any approved product together with the protocols showing the results of applicable tests at any time. Under some circumstances, the FDA, EMA or comparable regulatory authorities in other jurisdictions may prohibit the distribution of a lot until the agency authorizes its release. Slight deviations in the manufacturing process, including those affecting quality attributes and stability, may result in unacceptable changes in the product that could result in lot failures and product recalls.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Growth in the costs and expenses of components or raw materials may also adversely influence our business, results of operations and financial condition. Supply sources could be interrupted from time to time and, if interrupted, it is not certain that supplies could be resumed, whether in part or in whole, within a reasonable timeframe and at an acceptable cost, or at all. We also may encounter problems hiring and retaining the experienced scientific, quality control and manufacturing personnel needed to manage our manufacturing process, which could result in delays in our production or difficulties in maintaining compliance with applicable regulatory requirements.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Furthermore, given the nature of biologics manufacturing, there is a risk of contamination during manufacturing. Any contamination could materially harm our ability to produce product candidates on schedule and could cause reputational damage. Some of the raw materials required in our manufacturing process are derived from biologic sources. Such raw materials are difficult to procure and may be subject to contamination or recall. A material shortage, contamination, recall or restriction on the use of biologically derived substances in the manufacture of any product candidates we may develop could adversely impact or disrupt the commercial manufacturing or the production of clinical material, which could materially harm our development timelines and our business, financial condition, results of operations and prospects.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Any problems in our manufacturing process or the facilities with which we contract could make us a less attractive collaborator for potential partners, including larger pharmaceutical companies and academic research institutions, which could limit our access to additional attractive development programs. Problems in third-party manufacturing processes or facilities also could restrict our ability to meet market demand for any products we develop and commercialize.</div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 36pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">34<br></div></div></div>
<!--End Page 38-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 39-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 540pt;"><a name="nt10014672x1_drs_104-risk_pg22"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="block-frill" style="width: 540pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: Arial, Helvetica, sans-serif; font-size: 9pt; font-weight: bold; margin-top: 6pt; text-align: center;">Confidential Treatment Requested by ADC Therapeutics SA Pursuant to 17 C.F.R. &#167; 200.83<br></div></div><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 36pt;"><div class="frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">Our commercial success depends upon attaining significant market acceptance of our product candidates, if approved, among physicians, patients, patient advocacy groups, third-party payors and the medical community.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">If we obtain regulatory approval for any of our current or future product candidates, that product candidate may nevertheless not gain sufficient market acceptance among physicians, patients, patient advocacy groups, third-party payors and the medical community. For example, they may prefer current, well-established cancer treatments, such as chemotherapy and radiation therapy, to the exclusion of our product candidates or may prefer other novel product candidates rather than our product candidates. Efforts to educate physicians, patients, patient advocacy groups and third-party payors on the benefits of our product candidates may require significant resources and may not be successful. If our product candidates do not achieve an adequate level of acceptance, we may not generate significant product revenues and may not receive a satisfactory return on our investment into the research and development of those product candidates.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The degree of market acceptance of any approved products depends on a number of factors, including:</div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 5pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the safety and efficacy of the product, as demonstrated in clinical trials;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 5pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the indications for which the product is approved and the labeling approved by regulatory authorities for use with the product, including any warnings that may be required in the labeling;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 5pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">our ability to offer our products for sale at competitive prices;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 5pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the perceptions of physicians, patients and patient advocacy groups of ADCs generally and PBD-based ADCs specifically;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 5pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the treatment&#8217;s cost, safety, efficacy, convenience and ease of administration compared to that of alternative treatments;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 5pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">acceptance by physicians, patients and patient advocacy groups of the product as a safe and effective treatment;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 5pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the availability of coverage and adequate reimbursement by third-party payors, including cost-sharing programs such as copays and deductibles;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 5pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">patients&#8217; willingness to pay out-of-pocket in the absence of coverage and/or adequate reimbursement from third-party payors;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 5pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the effectiveness of our and our competitors&#8217; sales and marketing efforts;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 5pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">our ability to establish sales, marketing and commercial product distribution capabilities or to partner with third parties with such capabilities;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 5pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the effectiveness of pre-launch activities to raise awareness of our company and our product candidates;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 5pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the nature, severity and frequency of adverse side effects;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 5pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">any restrictions on the use of our products together with other medications;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 5pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">publication of any post-approval data on the safety and effectiveness of the product; and</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 5pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the success of randomized post-marketing commitment studies to confirm the benefit-risk ratio of the product.</div></td></tr></table><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Market acceptance of our product candidates is heavily dependent on patients&#8217; and physicians&#8217; perceptions that our product candidates are safe and effective treatments for their targeted indications. The perceptions of any product are influenced by perceptions of competitors&#8217; products that are in the same class or that have a similar mechanism of action. As a result, adverse public perception of our competitors&#8217; ADC products may negatively impact the market acceptance of our product candidates. If any approved products are not accepted by the market to the extent that we expect, we may not be able to generate significant product revenues and may not become or remain profitable.</div><div class="frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">The market opportunities for our product candidates may be smaller than we estimate and any approval that we obtain may be based on a narrower definition of the patient population.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Cancer therapies are sometimes characterized as first line, second line or third line. When cancer is detected early enough, first-line therapy is sometimes adequate to cure the cancer or prolong life without a cure. When first-line therapy proves unsuccessful, second-line therapy may be administered. When second-line therapy proves </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 36pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">35<br></div></div></div>
<!--End Page 39-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 40-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 540pt;"><a name="nt10014672x1_drs_104-risk_pg23"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="block-frill" style="width: 540pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: Arial, Helvetica, sans-serif; font-size: 9pt; font-weight: bold; margin-top: 6pt; text-align: center;">Confidential Treatment Requested by ADC Therapeutics SA Pursuant to 17 C.F.R. &#167; 200.83<br></div></div><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 36pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">unsuccessful, third-line therapy may be administered. We expect that regulatory approval as third-line therapies will be sought for Lonca and Cami for the treatment of relapsed or refractory DLBCL and HL, respectively. Subsequently, for those products that prove to be sufficiently beneficial, if any, regulatory approval as second-line therapies may be sought, as monotherapy or in combination with other therapies. However, there can be no assurance that our product candidates, even if approved as third-line therapies, would be approved as second-line therapies. In addition, we may have to conduct additional clinical trials prior to gaining approval as second-line therapies.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Our projections of both the number of people who have the cancers we are targeting, as well as the subset of people with these cancers in a position to receive third-line therapy and who have the potential to benefit from treatment with our product candidates, are based on estimates derived from a variety of sources, including scientific literature, surveys of clinicians and healthcare professionals and other forms of market research. These estimates may be inaccurate or based on imprecise data. For example, the total addressable market opportunity for our product candidates will depend on, among other things, the final labeling for such product candidates as agreed with the FDA, EMA or comparable regulatory authorities in other jurisdictions, acceptance by the medical community and patient access and drug pricing and reimbursement. The number of patients in the addressable markets may turn out to be lower than expected, patients may not be otherwise amenable to treatment with our product candidates or new patients may become increasingly difficult to identify or gain access to, all of which could materially adversely affect our business, financial condition, results of operations and prospects.</div><div class="frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 19.5pt; margin-left: 0pt; text-align: left;">Regulatory agencies actively enforce the laws and regulations prohibiting the promotion of drugs for off-label uses. If we are found to have improperly promoted off-label use, we may become subject to significant liability.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The FDA, EMA and comparable regulatory authorities in other jurisdictions strictly regulate the promotional claims that may be made about prescription drug products, such as our product candidates, if approved. While physicians, in the practice of medicine, may prescribe approved drugs for unapproved indications, a product may not be promoted for uses that are not approved by the applicable regulatory authority as reflected in the product&#8217;s approved labeling or for uses inconsistent with the product&#8217;s approved labeling. For example, if we receive regulatory approval for Lonca for the treatment of relapsed or refractory DLBCL in patients who have failed two or more treatment regimens, at least one of which must have contained rituximab, physicians, in their professional medical judgment, may nevertheless prescribe either drug product to their patients in a manner that is inconsistent with the approved labeling. In addition, although we believe our warhead may provide for superior efficacy as compared to marketed ADCs, without head-to-head data, we will be unable to make comparative claims for our product candidates, if approved. If we are found to have promoted such off-label use or made such unsubstantiated comparative claims, we may become subject to significant liability under the FDCA and other statutory authorities, such as laws prohibiting false claims for reimbursement. The U.S. government has levied large civil and criminal fines against companies for alleged improper promotion and has enjoined several companies from engaging in off-label promotion. The FDA has also requested that companies enter into consent decrees or permanent injunctions under which specified promotional conduct is changed or curtailed. If we cannot successfully manage the promotion of our products, if approved, we could become subject to significant liability, which would harm our reputation and negatively impact our financial condition.</div><div class="frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 19.5pt; margin-left: 0pt; text-align: left;">We are developing certain of our product candidates in combination with other therapies, and regulatory approval, safety or supply issues with these other therapies may delay or prevent the development and approval of our product candidates.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">We are evaluating the use of Lonca in combination with rituximab and ibrutinib, the use of Cami in combination with checkpoint inhibitors and the use of ADCT-601 in combination with other therapies. In the future, we may explore the use of these or our other product candidates in combination with other therapies. If we choose to develop a product candidate for use in combination with an approved therapy, we are subject to the risk that the FDA, EMA or comparable regulatory authorities in other jurisdictions could revoke approval of, or that safety, efficacy, manufacturing or supply issues could arise with, the therapy used in combination with our product candidate. If the therapies we use in combination with our product candidates are replaced as the standard of care, the FDA, EMA or comparable regulatory authorities in other jurisdictions may require us to conduct additional clinical trials. The occurrence of any of these risks could result in our product candidates, if approved, being removed from the market or being less successful commercially.</div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 36pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">36<br></div></div></div>
<!--End Page 40-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 41-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 540pt;"><a name="nt10014672x1_drs_104-risk_pg24"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="block-frill" style="width: 540pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: Arial, Helvetica, sans-serif; font-size: 9pt; font-weight: bold; margin-top: 6pt; text-align: center;">Confidential Treatment Requested by ADC Therapeutics SA Pursuant to 17 C.F.R. &#167; 200.83<br></div></div><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 36pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Where we develop a product candidate for use in combination with a therapy that has not been approved by the FDA, EMA or comparable regulatory authorities in other jurisdictions, we may not be able to market our product candidate for use in combination with such an unapproved therapy, unless and until the unapproved therapy receives regulatory approval. Currently, we are evaluating the use of Lonca in combination with ibrutinib for the treatment of relapsed or refractory DLBCL and MCL. However, ibrutinib has not been approved by the FDA for the treatment of DLBCL. Therefore, even if Lonca receives regulatory approval, we may not be able to market it for use in combination with ibrutinib unless and until it is approved for the indications that we are targeting. These unapproved therapies face the same risks described with respect to our product candidates currently in development, including serious adverse effects and delays in their clinical trials. In addition, other companies may also develop their products or product candidates in combination with the unapproved therapies with which we are developing our product candidates for use in combination. Any setbacks in these companies&#8217; clinical trials, including the emergence of serious adverse effects, may delay or prevent the development and approval of our product candidates.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">If the FDA, EMA or comparable regulatory authorities in other jurisdictions do not approve or revoke their approval of, or if safety, efficacy, manufacturing, or supply issues arise with, therapies we choose to evaluate in combination with any of our product candidates, we may be unable to obtain regulatory approval of or to commercialize such product candidates in combination with these therapies.</div><div class="frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">Coverage and reimbursement may be limited or unavailable for our product candidates, which could make it difficult to sell our products profitably.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The availability and extent of coverage and adequate reimbursement by governmental and private third-party payors are essential for most patients to be able to afford expensive medical treatments. In both domestic and foreign markets, sales of our product candidates will depend substantially on the extent to which the costs of our product candidates will be covered by third-party payors, such as government health programs, commercial insurance and managed healthcare organizations. These third-party payors decide which products will be covered and establish reimbursement levels for those products. We cannot be certain that coverage and adequate reimbursement will be available for any of our product candidates, if approved, or that reimbursement policies will not reduce the demand for any of our product candidates, if approved. If coverage and adequate reimbursement are not available, or is available only to limited levels, we may not be able to successfully commercialize our product candidates.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Coverage and reimbursement by a third-party payor may depend upon a number of factors, including the third-party payor&#8217;s determination that use of a product is:</div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">a covered benefit under its health plan;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">safe, effective and medically necessary;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">appropriate for the specific patient;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">cost-effective; and</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">neither experimental nor investigational.</div></td></tr></table><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Obtaining coverage approval and reimbursement for a product from a government or other third-party payor is a time-consuming and costly process that could require us to provide supporting scientific, clinical and cost-effectiveness data for the use of our products to the payor. We may not be able to provide data sufficient to gain acceptance with respect to coverage and reimbursement at a satisfactory level. If coverage and adequate reimbursement of our future products, if any, are unavailable or limited in scope or amount, such as may result where alternative or generic treatments are available, we may be unable to achieve or sustain profitability. Adverse coverage and reimbursement limitations may hinder our ability to recoup our investment in our product candidates, even if such product candidates obtain regulatory approval.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">There is significant uncertainty related to the insurance coverage and reimbursement of newly approved products. There is no uniform policy for coverage and reimbursement in the United States and, as a result, coverage and reimbursement can differ significantly from payor to payor. In the United States, the principal decisions about reimbursement for new medicines are typically made by the Centers for Medicare &amp; Medicaid Services (&#8220;CMS&#8221;), which decides whether and to what extent a new medicine will be covered and reimbursed under Medicare. Private payors often, but not always, follow the CMS&#8217;s decisions regarding coverage and </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 36pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">37<br></div></div></div>
<!--End Page 41-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 42-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 540pt;"><a name="nt10014672x1_drs_104-risk_pg25"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="block-frill" style="width: 540pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: Arial, Helvetica, sans-serif; font-size: 9pt; font-weight: bold; margin-top: 6pt; text-align: center;">Confidential Treatment Requested by ADC Therapeutics SA Pursuant to 17 C.F.R. &#167; 200.83<br></div></div><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 36pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">reimbursement. It is difficult to predict what third-party payors will decide with respect to coverage and reimbursement for fundamentally novel products such as ours, as there is no body of established practices and precedents for these new products. Further, one payor&#8217;s determination to provide coverage and adequate reimbursement for a product does not assure that other payors will also provide coverage and adequate reimbursement for that product. We may need to conduct expensive pharmaco-economic studies in order to demonstrate the medical necessity and cost-effectiveness of our product candidates. There can be no assurance that our product candidates will be considered medically necessary or cost-effective. In addition to third-party payors, professional organizations and patient advocacy groups such as the National Comprehensive Cancer Network and the American Society of Clinical Oncology can influence decisions about reimbursement for new medicines by determining standards for care. Therefore, it is possible that any of our product candidates, even if approved, may not be covered by third-party payors or the reimbursement limit may be so restrictive that we cannot commercialize the product candidates profitably.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Reimbursement agencies in Europe may be more restrictive than payors in the United States. For example, a number of cancer products have been approved for reimbursement in the United States but not in certain European countries. In Europe, pricing and reimbursement schemes vary widely from country to country and may require additional clinical trials. For example, some countries provide that products may be marketed only after an agreement on reimbursement price has been reached. Such pricing negotiations with governmental authorities can take considerable time after receipt of marketing approval for a product. Political, economic and regulatory developments may further complicate pricing negotiations, and pricing negotiations may continue after reimbursement has been obtained. Other countries require the completion of additional health technology assessments that compare the cost-effectiveness of a particular product candidate to currently available therapies. In addition, the European Union provides options for its member states to restrict the range of products for which their national health insurance systems provide reimbursement and to control the prices of medicinal products for human use. European Union member states may approve a specific price for a product, may adopt a system of direct or indirect controls on the profitability of the company placing the product on the market or monitor and control prescription volumes and issue guidance to physicians to limit prescriptions. Reference pricing used by various European Union member states and parallel distribution, or arbitrage between low-priced and high-priced member states, can further reduce prices. Furthermore, many countries in the European Union have increased the amount of discounts required on pharmaceutical products, and these efforts could continue as countries attempt to manage healthcare expenditures, especially in light of the severe fiscal and debt crises experienced by many countries in the European Union. The downward pressure on healthcare costs in general, and prescription products in particular, has become increasingly intense. As a result, there are increasingly higher barriers to entry for new products. There can be no assurance that any country that has reimbursement limitations for pharmaceutical products will allow favorable reimbursement and pricing arrangements for any of our products, if approved in those countries. Accordingly, the reimbursement for any products in Europe may be reduced compared with the United States and may be insufficient to generate commercially reasonable revenues and profits.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Furthermore, the containment of healthcare costs has become a priority of foreign and domestic governments as well as private third-party payors. The prices of drugs have been a focus in this effort. Governments and private third-party payors have attempted to control costs by limiting coverage and the amount of reimbursement for particular medications, which could affect our ability to sell our product candidates profitably. We also expect to experience pricing pressures due to the trend towards managed healthcare, the increasing influence of health maintenance organizations and additional legislative changes. These and other cost-control initiatives could cause us to decrease the price we might establish for products, which could result in lower-than-anticipated product revenues. In addition, the publication of discounts by third-party payors or authorities may lead to further pressure on the prices or reimbursement levels within the country of publication and other countries. If pricing is set at unsatisfactory levels or if coverage and adequate reimbursement of our products is unavailable or limited in scope or amount, our revenues and the potential profitability of our product candidates in those countries would be negatively affected.</div><div class="frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">Healthcare reform legislation and other changes in the healthcare industry and in healthcare spending may adversely affect our business model.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Our revenue prospects could be affected by changes in healthcare spending and policies in the United States, the European Union and any other potential jurisdictions we may seek to commercialize our product candidates, if approved. We operate in a highly regulated industry, and new laws, regulations and judicial </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 36pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">38<br></div></div></div>
<!--End Page 42-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 43-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 540pt;"><a name="nt10014672x1_drs_104-risk_pg26"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="block-frill" style="width: 540pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: Arial, Helvetica, sans-serif; font-size: 9pt; font-weight: bold; margin-top: 6pt; text-align: center;">Confidential Treatment Requested by ADC Therapeutics SA Pursuant to 17 C.F.R. &#167; 200.83<br></div></div><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 36pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">decisions, or new interpretations of existing laws, regulations and decisions, related to healthcare availability, the method of delivery and payment for healthcare products and services could negatively affect our business, financial condition and prospects. There is significant interest in promoting healthcare reforms, and it is likely that federal and state legislatures within the United States and the governments of other countries will continue to consider changes to existing healthcare legislation.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">For example, the United States and state governments continue to propose and pass legislation designed to reduce the cost of healthcare. In 2010, the U.S. Congress enacted the Patient Protection and Affordable Care Act and the Health Care and Education Reconciliation Act (collectively, the &#8220;Health Care Reform Act&#8221;), which included changes to the coverage and reimbursement of drug products under government healthcare programs such as:</div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">increased the minimum Medicaid rebates owed by manufacturers under the Medicaid Drug Rebate Program;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">established a branded prescription drug fee that pharmaceutical manufacturers of certain branded prescription drugs must pay to the federal government;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">expanded the list of covered entities eligible to participate in the 340B drug pricing program by adding new entities to the program;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">established a new Medicare Part D coverage gap discount program, in which manufacturers must agree to offer 70% point-of-sale discounts off negotiated prices of applicable brand drugs to eligible beneficiaries during their coverage gap period, as a condition for the manufacturer&#8217;s outpatient drugs to be covered under Medicare Part D;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">extended manufacturers&#8217; Medicaid rebate liability to covered drugs dispensed to individuals who are enrolled in Medicaid managed care organizations;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">expanded eligibility criteria for Medicaid programs by, among other things, allowing states to offer Medicaid coverage to additional individuals and by adding new mandatory eligibility categories for individuals with income at or below 133% of the federal poverty level, thereby potentially increasing manufacturers&#8217; Medicaid rebate liability;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">created a new methodology by which rebates owed by manufacturers under the Medicaid Drug Rebate Program are calculated for certain drugs and biologics, including our product candidates, that are inhaled, infused, instilled, implanted or injected;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">established a new Patient-Centered Outcomes Research Institute to oversee, identify priorities in, and conduct comparative clinical effectiveness research, along with funding for such research;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">established a Center for Medicare and Medicaid Innovation at the CMS to test innovative payment and service delivery models to lower Medicare and Medicaid spending, potentially including prescription drug spending; and</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">created a licensure framework for follow-on biologic products.</div></td></tr></table><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">There remain judicial and congressional challenges to certain aspects of the Health Care Reform Act as well as efforts by the current U.S. Presidential Administration to repeal or replace certain aspects of the Health Care Reform Act. For example, in 2017, the U.S. Congress enacted the Tax Cuts and Jobs Act (the &#8220;TCJA&#8221;), which eliminated the tax-based shared responsibility payment imposed by the Health Care Reform Act on certain individuals who fail to maintain qualifying health coverage for all or part of a year that is commonly referred to as the &#8220;individual mandate.&#8221; On December 14, 2018, the U.S. District Court for the Northern District of Texas held that the individual mandate is a critical and inseverable feature of the Health Care Reform Act, and therefore, because it was repealed by the TCJA, the remaining provisions of the Health Care Reform Act are invalid as well. On December 18, 2019, the U.S. Court of Appeals for the Fifth Circuit upheld the District Court ruling that the individual mandate was unconstitutional and remanded the case back to the District Court to determine whether the remaining provisions of the Health Care Reform Act are invalid as well. On March 2, 2020, the Supreme Court of the United States granted the petitions for writ of certiorari to review this case. Oral </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 36pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">39<br></div></div></div>
<!--End Page 43-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 44-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 540pt;"><a name="nt10014672x1_drs_104-risk_pg27"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="block-frill" style="width: 540pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: Arial, Helvetica, sans-serif; font-size: 9pt; font-weight: bold; margin-top: 6pt; text-align: center;">Confidential Treatment Requested by ADC Therapeutics SA Pursuant to 17 C.F.R. &#167; 200.83<br></div></div><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 36pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">arguments are expected to occur in the fall. It is unclear how this litigation and other efforts to repeal and replace the Health Care Reform Act will impact the Health Care Reform Act. It is difficult to predict the future legislative landscape in healthcare and the effect on our business, results of operations, financial condition and prospects.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">In addition, there have been and continue to be a number of initiatives at the United States federal and state levels that seek to reduce healthcare costs. In 2011, the U.S. Congress enacted the Budget Control Act of 2011 (the &#8220;Budget Control Act&#8221;), which included provisions intended to reduce the federal deficit. The Budget Control Act resulted in the imposition of 2% reductions in Medicare payments to providers beginning in 2013 and, due to subsequent legislative amendments to the statute, will remain in effect through 2030 absent additional congressional action. The Coronavirus Aid, Relief, and Economic Security Act (&#8220;CARES Act&#8221;), which was signed into law on March&#160;27, 2020, suspended the 2% Medicare sequester reductions under the Budget Control Act from May&#160;1, 2020 through December&#160;31, 2020 and extended the sequester by one year, through 2030. In 2012, the U.S. Congress enacted the American Taxpayer Relief Act, which, among other things, further reduced Medicare payments to several types of providers, including hospitals, imaging centers and cancer treatment centers, and increased the statute of limitations period for the government to recover overpayments to providers from three to five years. If government spending is further reduced, anticipated budgetary shortfalls may also impact the ability of relevant agencies, such as the FDA, to continue to function at current levels, which may impact the ability of relevant agencies to timely review and approve research and development, manufacturing and marketing activities, which may delay our ability to develop, market and sell any product candidates we may develop. In addition, any significant spending reductions affecting Medicare, Medicaid or other publicly funded or subsidized health programs that may be implemented, or any significant taxes or fees that may be imposed on us, as part of any broader deficit reduction effort or legislative replacement to the Budget Control Act, could have an adverse impact on our anticipated product revenues. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Furthermore, there has been heightened governmental scrutiny over the manner in which manufacturers set prices for their marketed products, which has resulted in several congressional inquiries and proposed legislation designed to, among other things, bring more transparency to product pricing, review the relationship between pricing and manufacturer patient programs and reform government program reimbursement methodologies for drug products. At the federal level, the U.S. Presidential Administration&#8217;s budget proposal for fiscal year 2021 includes a $135 billion allowance to support legislative proposals seeking to reduce drug prices, increase competition, lower out-of-pocket drug costs for patients and increase patient access to lower-cost generic and biosimilar drugs. On March 10, 2020, the current U.S. Presidential Administration sent &#8220;principles&#8221; for drug pricing to Congress, calling for legislation that would, among other things, cap Medicare Part D beneficiary out-of-pocket pharmacy expenses, provide an option to cap Medicare Part D beneficiary monthly out-of-pocket expenses and place limits on pharmaceutical price increases. Further, the current U.S. Presidential Administration previously released a &#8220;Blueprint&#8221; to lower drug prices and reduce out-of-pocket costs of drugs that contained proposals to increase drug manufacturer competition, increase the negotiating power of certain federal healthcare programs, incentivize manufacturers to lower the list price of their products, and reduce the out-of-pocket costs of drug products paid by consumers. The Department of Health and Human Services (the &#8220;HHS&#8221;) has solicited feedback on some of these measures and has implemented others under its existing authority. For example, CMS issued a final rule in May 2019 to allow Medicare Advantage plans the option to use step therapy for Part B drugs beginning January 1, 2020. This final rule codified CMS&#8217;s policy change that was effective January 1, 2019. On July&#160;24, 2020, the current U.S. Presidential Administration announced four executive orders related to prescription drug pricing that attempt to implement several of the administration&#8217;s proposals, including a policy that would tie Medicare Part&#160;B drug prices to international drug prices; one that directs HHS to finalize the Canadian drug importation proposed rule previously issued by HHS and makes other changes allowing for personal importation of drugs from Canada; one that directs HHS to finalize the rulemaking process for modifying the anti-kickback law safe harbors for discounts for plans, pharmacies, and pharmaceutical benefit managers; and one that reduces costs of insulin and some types of injectable epinephrine to patients of federally qualified health centers. While some of these and other measures may require additional authorization to become effective, Congress and the current U.S. Presidential Administration have each indicated that it will continue to seek new measures to control drug costs. Individual states in the United States have also become increasingly active in passing legislation and implementing regulations designed to control pharmaceutical product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 36pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">40<br></div></div></div>
<!--End Page 44-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 45-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 540pt;"><a name="nt10014672x1_drs_104-risk_pg28"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="block-frill" style="width: 540pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: Arial, Helvetica, sans-serif; font-size: 9pt; font-weight: bold; margin-top: 6pt; text-align: center;">Confidential Treatment Requested by ADC Therapeutics SA Pursuant to 17 C.F.R. &#167; 200.83<br></div></div><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 36pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">from other countries and bulk purchasing. In addition, regional healthcare authorities and individual hospitals are increasingly using bidding procedures to determine what pharmaceutical products and which suppliers will be included in their prescription drug and other healthcare programs. We expect that additional state and federal healthcare reform measures will be adopted in the future. Any adopted health reform measure could reduce the ultimate demand for our products, if approved, or put pressure on our product pricing.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">It is likely that federal and state legislatures within the United States and foreign governments will continue to consider changes to existing healthcare legislation, including those taken in response to the COVID-19 pandemic. For example, the current U.S. Presidential Administration issued an executive order on August 3, 2020 directing CMS to propose a regulation extending Medicare coverage for certain telemedicine services provided to certain Medicare beneficiaries beyond the duration of the COVID-19 public health emergency. CMS is required to propose the regulation within 60 days of the issuance of the executive order. Additionally, on August&#160;6, 2020, the current U.S. Presidential Administration issued another executive order that instructs the federal government to develop a list of &#8220;essential&#8221; medicines and then buy them and other medical supplies from U.S. manufacturers instead of from companies around the world, including China. The order is meant to reduce regulatory barriers to domestic pharmaceutical manufacturing and catalyze manufacturing technologies needed to keep drug prices low and the production of drug products in the United States. We cannot predict the reform initiatives that may be adopted in the future or whether initiatives that have been adopted will be repealed or modified. The continuing efforts of the government, insurance companies, managed care organizations and other payors of healthcare services to contain or reduce costs of healthcare may adversely affect:</div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the demand for any products for which we may obtain regulatory approval;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">our ability to set a price that we believe is fair for our products;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">our ability to obtain coverage and reimbursement approval for a product;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">our ability to generate revenues and achieve or maintain profitability; and</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the level of taxes that we are required to pay.</div></td></tr></table><div class="frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">We face substantial competition, which may result in others discovering, developing or commercializing products, treatment methods and/or technologies before or more successfully than we do.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The biotechnology industry is characterized by rapidly advancing technologies, intense competition and a strong emphasis on proprietary products. We face competition with respect to our current product candidates and will face competition with respect to any product candidates that we may seek to develop or commercialize in the future. Our competitors include large pharmaceutical and biotechnology companies, academic institutions, government agencies and other public and private research organizations that conduct research, seek patent protection and establish collaborative arrangements for research, development, manufacturing and commercialization. Many of our competitors have significantly greater financial resources and capabilities in research and development, manufacturing, preclinical testing, conducting clinical trials, obtaining regulatory approval and marketing than we do. In addition, many of these competitors are active in seeking patent protection and licensing arrangements in anticipation of collecting royalties for use of technology that they have developed. Smaller or early-stage companies may also prove to be significant competitors, particularly through strategic collaborations with large and established companies. Furthermore, mergers and acquisitions in the biotechnology industry may result in even more resources being concentrated among a smaller number of our competitors.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">With respect to our current and potential future product candidates, we believe that our ability to compete effectively and develop products that can be manufactured cost-effectively and marketed successfully will depend on our ability to:</div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">advance the technology we use in our product candidates;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">obtain, maintain, protect and enforce intellectual property protection for our technologies and product candidates;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">obtain required government and other public and private approvals on a timely basis;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">attract and retain key personnel;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">execute our research and development plans;</div></td></tr></table></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 36pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">41<br></div></div></div>
<!--End Page 45-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 46-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 540pt;"><a name="nt10014672x1_drs_104-risk_pg29"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="block-frill" style="width: 540pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: Arial, Helvetica, sans-serif; font-size: 9pt; font-weight: bold; margin-top: 6pt; text-align: center;">Confidential Treatment Requested by ADC Therapeutics SA Pursuant to 17 C.F.R. &#167; 200.83<br></div></div><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 36pt;"><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6.75pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">commercialize effectively;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">obtain and maintain coverage and reimbursement for our products in approved indications;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">obtain adequate funding for our activities;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">comply with applicable laws, regulations and regulatory requirements and restrictions with respect to the commercialization of our products, including with respect to any changed or increased regulatory restrictions; and</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">enter into additional strategic collaborations and licensing opportunities to advance the development and commercialization of our product candidates.</div></td></tr></table><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Many companies are active in the oncology market and are developing or marketing products for the specific therapeutic markets that we target, including both antibody and non-antibody-based therapies. Similarly, we also face competition from other companies and institutions that continue to invest in innovation in the ADC field including new payload classes, new conjugation approaches and new targeting moieties. Specifically, we are aware of multiple companies with ADC technologies that may be competitive to our product candidates, including, but not limited to, AbbVie, Inc., Astellas Pharma Inc., AstraZeneca plc, BioAtla, LLC, Bristol-Myers Squibb Company, CytomX Therapeutics, Daiichi Sankyo Company, Eli Lilly and Company, Genentech, Inc., Genmab, GlaxoSmithKline plc, ImmunoGen, Inc., Immunomedics, Inc., Mersana Therapeutics Inc., Millennium Pharmaceuticals, Inc., MorphoSys AG, Novartis International AG, Pfizer Inc., F. Hoffmann-La Roche AG, Sanofi S.A., Seattle Genetics, Inc., Sutro Biopharma, Inc., Takeda Pharmaceutical Company Ltd and Wyeth Pharmaceuticals, Inc. Currently, there are ten approved ADCs: (i)&#160;brentuximab vedotin (Adcetris&#174;), marketed by Seattle Genetics, Inc. and Takeda Pharmaceutical Company Ltd, (ii)&#160;ado-trastuzumab emtansine (Kadcyla&#174;), marketed by Genentech, Inc., (iii)&#160;inotuzumab ozogamicin (Besponsa&#174;), marketed by Pfizer Inc., (iv)&#160;gemtuzumab ozogamicin (Mylotarg&#174;), marketed by Pfizer Inc., (v)&#160;moxetumomab pasudotox (Lumoxiti&#174;), marketed by AstraZeneca plc, (vi)&#160;polatuzumab vedotin (Polivy&#174;), marketed by Genentech, Inc., (vii)&#160;enfortumab vedotin (Padcev&#174;), marketed by Astellas Pharma Inc., (viii) trastuzumab deruxtecan (Enhuertu&#174;), marketed by Daiichi Sankyo Company, (ix)&#160;sacituzumab govitecan (Trodelvy&#174;), marketed by Immunomedics, Inc., and (x) belantamab mafodotin (Blenrep&#174;), marketed by GlaxoSmithKline plc. In addition, there are hundreds of ADCs in development, the vast majority of which were being developed for the treatment of cancer.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">In the relapsed or refractory DLBCL setting, for which we are developing Lonca, current third-line treatment options include CAR-T, allogeneic stem cell transplant, Polivy&#174; in combination with bendamustine and a rituximab product, XPOVIO&#174;, Monjuvi&#174; in combination with lenalidomide and chemotherapy using small molecules. In addition, we expect potential new competitors, including bispecific antibodies, to enter the market as potential treatment options for such patients in the future. In the relapsed or refractory HL setting, for which we are developing Cami, current third-line treatment options include chemotherapy, immunotherapy and Adcetris&#174;. In addition, we expect changes to the treatment paradigm, such as the movement of Adcetris&#174; to earlier lines of therapy and the potential expanded use of checkpoint inhibitors, and potential new entrants such as bispecific antibodies. We expect our product candidates to compete on efficacy, tolerability and convenience compared to other treatment options. However, there can be no assurance that our product candidates would be able to compete effectively.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Our commercial opportunities could be reduced or eliminated if our competitors develop and commercialize products that are safer, more effective, have fewer or less severe side effects or are more convenient than any products that we may develop, which would render our products obsolete or noncompetitive. Our competitors also may obtain FDA, EMA or regulatory approval in other jurisdictions for their products more rapidly than we may obtain approval for ours, which could result in our competitors establishing a strong market position before we are able to enter the market. We anticipate that we will face increased competition in the future as additional companies enter our market and scientific developments surrounding other cancer therapies continue to accelerate.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">In addition, our ability to compete may be affected in many cases by insurers or other third-party payers seeking to encourage the use of generic products or biosimilars. Generic products are currently on the market for the indications that we are pursuing, and biosimilars and additional generic products are expected to become available over the coming years. In the United States, the Biologics Price Competition and Innovation Act of 2009 (the&#160;&#8220;BPCIA&#8221;), included as a subtitle in the Health Care Reform Act, established a pathway for the FDA </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 36pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">42<br></div></div></div>
<!--End Page 46-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 47-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 540pt;"><a name="nt10014672x1_drs_104-risk_pg30"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="block-frill" style="width: 540pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: Arial, Helvetica, sans-serif; font-size: 9pt; font-weight: bold; margin-top: 6pt; text-align: center;">Confidential Treatment Requested by ADC Therapeutics SA Pursuant to 17 C.F.R. &#167; 200.83<br></div></div><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 36pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">approval of follow-on biologics and provides a twelve-year data exclusivity period for reference products and an additional six-month exclusivity period if pediatric studies are conducted. It is unclear how the Health Care Reform Act repeal efforts discussed above, including the 2018 federal district court case, and subsequent appeals, if any, will impact the biosimilar framework created by the Health Care Reform Act and thus, our business. In Europe, the EMA has issued guidelines for approving products through an abbreviated pathway, and biosimilars have been approved in Europe. If a biosimilar version of one of our potential products is approved in the United States or Europe, it could have a negative effect on sales and gross profits of the potential product and our financial condition.</div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 19.5pt; margin-left: 0pt; text-align: left;">Risks Related to Our Relationship with Third Parties</div><div class="frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 6pt; margin-left: 0pt; text-align: left;">Our rights to Cami are subject to our collaboration and license agreement with Genmab, and there can be no assurance that we will maintain the rights to develop or commercialize Cami.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Our collaboration and license agreement with Genmab may require a divestment of Cami, in which Genmab has a 25% interest. On June&#160;24, 2020, we and Genmab agreed to enter into a period of good faith negotiations regarding the key financial terms on which we would acquire Genmab&#8217;s share of Cami. If we and Genmab reach agreement, we and Genmab will have a further period of time to negotiate a license agreement for Genmab&#8217;s rights in Cami, which period may be extended by our and Genmab&#8217;s mutual written agreement. If we fail to agree on the key financial terms or if no license agreement has been entered into during the respective time periods to do so, a defined process to facilitate the divestment of Cami by licensing the rights thereto to a third party will be initiated. See &#8220;Business&#8212;License and Collaboration Agreements&#8212;Genmab Collaboration and License Agreement.&#8221; Therefore, our rights to Cami are subject to our collaboration and license agreement with Genmab, and there can be no assurance that we will apply for regulatory approval of or commercialize Cami. In addition, there is no assurance that any of our negotiations with Genmab will be successful, or that we will be able to acquire any additional rights to Cami.</div><div class="frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 19.5pt; margin-left: 0pt; text-align: left;">We rely on third parties to conduct preclinical studies and/or clinical trials of our product candidates. If they do not properly and successfully perform their obligations to us, we may not be able to obtain regulatory approvals for our product candidates.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">We rely, and we expect that we will continue to rely, on CROs and other third parties to assist in managing, monitoring and otherwise carrying out preclinical studies and clinical trials of our product candidates. We currently rely on third parties to manage and conduct our clinical trials of Lonca and Cami. As a result of our reliance on CROs and other third parties, we have less direct control over the conduct, timing and completion of these clinical trials and the management of data developed through clinical trials than we would otherwise have if we relied entirely upon our own staff. These CROs and other third parties are not our employees and we have limited control over the amount of time and resources that they dedicate to our product candidates. In addition, communications with outside parties can also be challenging, potentially leading to mistakes as well as difficulties in coordinating activities. Outside parties may:</div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">have staffing difficulties;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">fail to comply with contractual obligations;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">experience regulatory compliance issues;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">undergo changes in priorities or become financially distressed; or</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">form relationships with other entities, some of which may be our competitors.</div></td></tr></table><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">If these third parties do not successfully carry out their duties under their agreements, or if the quality or accuracy of the data they obtain is compromised due to their failure to adhere to clinical trial protocols or to regulatory requirements, or if they otherwise fail to comply with clinical trial protocols or meet expected deadlines, the clinical trials of our product candidates may not meet regulatory requirements. Specifically, the FDA, EMA and comparable regulatory authorities in other jurisdictions require compliance with regulations and standards, including GCP, for designing, conducting, monitoring, recording, analyzing and reporting the results of clinical trials to assure that the data and results are credible and accurate and that the rights, integrity and confidentiality of study participants are protected. Although we rely, and intend to continue to rely, on third parties to conduct our clinical trials, they are not our employees, and we are responsible for ensuring that each of </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 36pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">43<br></div></div></div>
<!--End Page 47-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 48-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 540pt;"><a name="nt10014672x1_drs_104-risk_pg31"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="block-frill" style="width: 540pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: Arial, Helvetica, sans-serif; font-size: 9pt; font-weight: bold; margin-top: 6pt; text-align: center;">Confidential Treatment Requested by ADC Therapeutics SA Pursuant to 17 C.F.R. &#167; 200.83<br></div></div><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 36pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">these clinical trials is conducted in accordance with its general investigational plan, protocol, legal and regulatory requirements and scientific standards. Our reliance on these third parties for research and development activities will reduce our control over these activities, but will not relieve us of our responsibilities. If our CROs and other third-party research and development partners fail to comply with applicable GCPs or other regulatory requirements, the clinical data generated in our clinical trials may be deemed unreliable and preclinical development activities or clinical trials may be extended, delayed, suspended or terminated.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">We compete with many other companies for the resources of these third parties. These third parties may have contractual relationships with other entities, some of which may be our competitors, which may draw time and resources from our product candidates. The third parties with whom we contract might not be diligent, careful or timely in conducting our preclinical studies or clinical trials, resulting in the preclinical studies or clinical trials being delayed or unsuccessful.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Some of our CROs have an ability to terminate their respective agreements with us if it can be reasonably demonstrated that the safety of the subjects participating in our clinical trials warrants such termination, if we make a general assignment for the benefit of our creditors or if we are liquidated. If any of our relationships with these CROs terminate, we may not be able to enter into arrangements with alternative CROs or to do so on commercially reasonable terms. Switching or adding additional CROs involves additional cost and requires management time and focus. In addition, there is a natural transition period when a new CRO commences work. As a result, delays may occur in our clinical trials, which can materially impact our ability to meet our desired clinical development timelines. There can be no assurance that we will not encounter challenges or delays in the future or that these delays or challenges will not have a material adverse impact on our business, results of operations, financial condition and prospects.</div><div class="frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">We rely on third parties for the manufacture, production, storage and distribution of our product candidates. Our dependence on these third parties may impair the clinical advancement and commercialization of our product candidates.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">We rely, and expect that we will continue to rely, on third parties for the manufacturing and supply of our product candidates, and such reliance on third-party manufacturers may expose us to different risks than if we were to manufacture product candidates ourselves. There are four manufacturing streams for the manufacture of one of our product candidates: the antibody, the PBD-based payload, the ADC drug substance and the drug product. In addition, we contract with specialized analytical laboratories for lot release and stability testing of our product candidates. For the foreseeable future, we expect to continue to rely on such third parties for the manufacture, production, storage and distribution of our product candidates on a clinical or, if any of our product candidates receives regulatory approval, on a commercial scale. If our agreements with these third parties expire or are terminated, there is no guarantee that we would be able to negotiate new agreements with them or other third parties on equally favorable terms as the current agreements, or at all.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Reliance on third-party providers may expose us to different risks than if we were to manufacture and supply product candidates ourselves. The facilities used by our CMOs or other third-party manufacturers to manufacture our product candidates must be approved by the EMA and comparable regulatory authorities in other jurisdictions, and the FDA requires our CMOs or other third-party manufacturers to maintain a compliance status acceptable to the FDA, pursuant to inspections that will be conducted after we submit the marketing application to the applicable regulatory authorities. Although we have auditing rights with all our manufacturing counterparties, we do not have control over a supplier&#8217;s or manufacturer&#8217;s compliance with these laws, regulations, applicable cGMP standards and other laws and regulations, such as those related to environmental health and safety matters. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">If our CMOs or other third-party manufacturers cannot successfully manufacture material that conforms to our specifications and the strict regulatory requirements of the FDA, EMA and comparable regulatory authorities in other jurisdictions, or if the quality or accuracy of the manufacturing and quality control data they obtain is compromised due to their failure to adhere to protocols or to regulatory requirements, we will not be able to secure and/or maintain regulatory approval for our product candidates. In addition, we have no control over the ability of our CMOs or other third-party manufacturers to maintain adequate quality control, quality assurance and qualified personnel. If a CMO or other third-party manufacturer cannot maintain a compliance status acceptable to the FDA, or if the EMA or a comparable regulatory authority in another jurisdiction does not approve these facilities for the manufacture of our product candidates or if it withdraws any such approval in the future, we may need to find alternative manufacturing facilities, which would significantly impact our ability to </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 36pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">44<br></div></div></div>
<!--End Page 48-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 49-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 540pt;"><a name="nt10014672x1_drs_104-risk_pg32"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="block-frill" style="width: 540pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: Arial, Helvetica, sans-serif; font-size: 9pt; font-weight: bold; margin-top: 6pt; text-align: center;">Confidential Treatment Requested by ADC Therapeutics SA Pursuant to 17 C.F.R. &#167; 200.83<br></div></div><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 36pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">develop, obtain regulatory approval for or market our product candidates, if approved. Any failure to achieve and maintain compliance with these laws, regulations and standards could subject us to the risk that we may have to suspend the manufacturing of our product candidates and that obtained approvals could be revoked, which would adversely affect our business and reputation.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Due to the complexity to manufacture our product candidates and the small quantities of product candidates needed for clinical trials and regulatory submission purposes, we contract with one CMO for each component of our product candidates and/or the same CMO for multiple components of our product candidates or services involved in manufacturing our product candidates. We cannot ensure that these CMOs will remain in business or that they will not be purchased by one of our competitors or another company that is not interested in continuing to work with us. Our use of exclusive CMOs exposes us to several risks, including:</div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 5pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">delays or stoppages in product shipments for our product candidates, including loss shipments and cross-border logistical complications, resulting in delayed and lost shipments;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 5pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">delays to the development timelines for our product candidates;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 5pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">an inability to commence or continue clinical trials of product candidates under development;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 5pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">interruption of supply resulting from modifications to a CMO&#8217;s operations;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 5pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">delays or stoppage in manufacturing or shipment due to a CMO&#8217;s bankruptcy, winding up, reorganization or similar corporate failures or financial distress;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 5pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">delays in product manufacturing or shipments resulting from uncorrected defects, reliability or stability issues, or a CMO&#8217;s variation in a component;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 5pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">a lack of long-term arrangements for key components;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 5pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">inability to obtain adequate supply in a timely manner, or to obtain adequate supply on commercially reasonable terms;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 5pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">difficulty and cost associated with locating and qualifying alternative CMOs for our components or raw materials in a timely manner;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 5pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">production delays related to the evaluation and testing of components from alternative CMOs, and corresponding regulatory qualifications;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 5pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">delay in delivery due to our CMOs&#8217; prioritizing other customer orders over ours;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 5pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">damage to our reputation caused by defective product candidates produced by our CMOs; and</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 5pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">potential price increases.</div></td></tr></table><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The failure of one or more CMOs to supply product candidates and/or components of product candidates that meet our specifications could delay our clinical trials and the regulatory approval and commercialization of our product candidates. A CMO may not be able to correct batch failures in a reasonable timeframe, if at all, which may require us to seek replacement CMOs. In the past, we have received batches of certain of our product candidates that did not meet our specifications. There can be no assurance that CMOs will be able to manufacture product candidates and/or components of product candidates that meet our specifications, which could delay our clinical trials and the regulatory approval and commercialization of our product candidates.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Establishing additional or replacement CMOs could take a substantial amount of time and it may be difficult to establish replacement CMOs who meet regulatory requirements. In general, there are relatively few alternative CMOs that are able to manufacture our product candidates under cGMP. If we have to switch to a replacement CMO, the manufacture and delivery of our product candidates could be interrupted for an extended period, which could adversely affect our business. If we are able to find a replacement CMO, the replacement CMO would need to be qualified and may require additional regulatory authority approval, which could result in further delay regulatory approval and commercialization of our product candidates.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Furthermore, third-party providers may breach, terminate or decline to renew agreements they have with us because of factors beyond our control, such as their own financial difficulties or business priorities, international trade restrictions and financial costs, potentially at a time that is costly or otherwise inconvenient for us or our partners. In such cases, we would face the challenge of transferring complicated manufacturing techniques to other CMOs. We&#160;may incur significant costs and be required to devote significant time to verify that the new </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 36pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">45<br></div></div></div>
<!--End Page 49-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 50-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 540pt;"><a name="nt10014672x1_drs_104-risk_pg33"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="block-frill" style="width: 540pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: Arial, Helvetica, sans-serif; font-size: 9pt; font-weight: bold; margin-top: 6pt; text-align: center;">Confidential Treatment Requested by ADC Therapeutics SA Pursuant to 17 C.F.R. &#167; 200.83<br></div></div><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 36pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">manufacturer maintains facilities and procedures that comply with quality standards and with all applicable regulations and guidelines. A transfer of the manufacturing process for our product candidates would be time-consuming, and we or our partners may not be able to achieve such transfer. If we are unable to find an adequate replacement or another acceptable solution in time, clinical trials of our product candidates could be delayed or our commercial activities could be harmed.</div><div class="frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">Our third-party manufacturers may be unable to successfully scale up manufacturing of our product candidates in sufficient quality and quantity, which may impair the clinical advancement and commercialization of our product candidates.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">In order to conduct clinical trials of our product candidates and commercialize any approved product candidates, our manufacturing partners need to manufacture them in large quantities. However, they may be unable to successfully increase the manufacturing capacity for any of our product candidates in a timely or cost-effective manner, or at all. In addition, quality issues may arise during scale-up activities. Furthermore, due to the specific nature of our ADCs&#8217; components and availability of production capacity, there is significant lead time required by our third-party manufacturers to provide us with the needed manufacturing services. If we, or any manufacturing partners, are unable to successfully scale up the manufacture of our product candidates in sufficient quality and quantity, the development, testing and clinical trials of these product candidates may be delayed or infeasible, and regulatory approval or commercial launch of any resulting products may be delayed or not obtained, which could significantly harm our business. Supply sources could be interrupted from time to time and, if interrupted, it is not certain that supplies could be resumed (whether in part or in whole) within a reasonable timeframe and at an acceptable cost, or at all. If we are unable to obtain or maintain third-party manufacturing for commercial supply of our product candidates, or to do so on commercially reasonable terms, we may not be able to develop and commercialize our product candidates successfully.</div><div class="frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">We may not be successful in establishing commercialization collaborations and licensing agreements, which could adversely affect our ability to commercialize our product candidates, if approved.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">We expect to commercialize our product candidates, if approved, in the United States and may selectively pursue strategic collaborations and licensing agreements with third parties to commercialize our product candidates outside of the United States. We may not be successful in entering into such marketing and distribution arrangements with third parties or in entering in such marketing and distribution arrangements with third parties on favorable terms. Moreover, such arrangements are complex and time-consuming to negotiate, document and implement and they may require substantial resources to maintain.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">In addition, it is possible that a collaborator may not devote sufficient resources to the commercialization of our product candidates or may otherwise fail in its commercialization efforts, in which event the commercialization of such product candidates could be delayed or terminated and our business could be substantially harmed. In addition, the terms of any collaboration or other arrangement that we establish may not be favorable to us or may not be perceived as favorable, which may negatively impact our business, financial condition, results of operations and prospects. </div><div class="frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">We collaborate with third parties in the research, development and commercialization of certain of our product candidates and may enter into other collaborations in the future for our other product candidates. If our collaborators do not perform as expected or if we are unable to maintain existing or establish additional collaborations, our ability to develop and commercialize our product candidates may be adversely affected.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">From time to time, we may enter into collaboration agreements with third parties that have experience in product development, manufacturing and/or commercialization for other product candidates and/or research programs. We may face significant competition in seeking appropriate partners for our product candidates, and the negotiation process may be time-consuming and complex. In order for us to successfully partner our product candidates, potential collaborators must view these product candidates as economically valuable in markets they determine to be attractive in light of the terms that we are seeking and other available products for licensing by other companies. Even if we are successful in our efforts to establish collaborations, the terms that we agree upon may not be favorable to us, and we may not be able to maintain such collaborations if, for example, development or approval of a product candidate is delayed or sales of an approved product are disappointing. If we fail to establish and maintain collaborations related to our product candidates, we could bear all of the risk and costs related to the development of any such product candidate, and we may need to seek additional financing, hire additional employees and otherwise develop expertise for which we have not budgeted. This could negatively affect the development and commercialization of our product candidates.</div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 36pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">46<br></div></div></div>
<!--End Page 50-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 51-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 540pt;"><a name="nt10014672x1_drs_104-risk_pg34"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="block-frill" style="width: 540pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: Arial, Helvetica, sans-serif; font-size: 9pt; font-weight: bold; margin-top: 6pt; text-align: center;">Confidential Treatment Requested by ADC Therapeutics SA Pursuant to 17 C.F.R. &#167; 200.83<br></div></div><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 36pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">In such collaborations, we will depend on the performance of our collaborators. Our collaborators may fail to perform their obligations under the collaboration agreements or may not perform their obligations in a timely manner. If conflicts arise between our collaborators and us, the other party may act in a manner adverse to us and could limit our ability to implement our strategies. Furthermore, our collaborators may not properly obtain, maintain, enforce or defend our intellectual property or proprietary rights or may use our proprietary information in such a way as to invite litigation that could jeopardize or invalidate our proprietary information or expose us to potential litigation. In addition, we cannot control the amount and timing of resources our collaborators may devote to our product candidates. They may separately pursue competing products, therapeutic approaches or technologies to develop treatments for the diseases targeted by us. Competing products, either developed by the collaborators or to which the collaborators have rights, may result in the withdrawal of support for our product candidates. Even if our collaborators continue their contributions to the strategic collaborations, they may nevertheless determine not to actively pursue the development or commercialization of any resulting products. Additionally, if our collaborators pursue different clinical or regulatory strategies with their product candidates based on similar technology as used in our product candidates, adverse events with their product candidates could negatively affect our product candidates. Any of these developments could harm our product development efforts.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">We may be subject to exclusivity and other governance provisions within a collaboration agreement that may prevent us from pursuing certain alternative product candidates and exercising complete control over our product candidates&#8217; development and commercialization. For example, Cami is subject to a collaboration and license agreement with Genmab. See &#8220;Business&#8212;License and Collaboration Agreements&#8212;Genmab Collaboration and License Agreement.&#8221; In addition, our collaborators will likely have customary termination rights under these agreements. Any termination of an agreement by the relevant collaborators could affect our ability to develop further such product candidates or adversely affect how we are perceived in scientific and financial communities. Therefore, if our collaborators terminate or breach our agreements with them, or otherwise fail to complete their obligations in a timely manner, it may have a detrimental effect on our financial position by reducing or eliminating the potential for us to receive technology access and license fees, milestones and royalties, reimbursement of development costs, as well as possibly requiring us to devote additional efforts and incur costs associated with pursuing internal development of product candidates. Furthermore, if our collaborators do not prioritize and commit sufficient resources to our product candidates, we or our partners may be unable to develop or commercialize these product candidates, which would limit our ability to generate revenue and become profitable.</div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 18pt; margin-left: 0pt; text-align: left;">Risks Related to Intellectual Property</div><div class="frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 6pt; margin-left: 0pt; text-align: left;">If we are unable to obtain, maintain or protect our intellectual property rights in any products or technologies we develop, or if the scope of the intellectual property protection obtained is not sufficiently broad, third parties could develop and commercialize products and technology similar or identical to ours, and we may not be able to compete effectively in our market.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Our success depends in significant part on our own and any of our licensors&#8217; ability to obtain, maintain and protect patents and other intellectual property rights and operate without infringing, misappropriating, or otherwise violating the intellectual property rights of others. To protect our proprietary position, we have filed numerous patent applications both in the United States and in foreign jurisdictions to obtain patent rights to inventions we have developed that are important to our business, including Lonca and Cami. We have also licensed from third parties rights to patents and other intellectual property, including from MedImmune with respect to the PBD technology we use for our PBD-based ADCs, from Synaffix B.V. (&#8220;Synaffix&#8221;) for site-specific conjugation technology we use in ADCT-601 and ADCT-701, from Genmab with respect to the antibody we use in Cami and from other parties for some of our other product candidates and related technology. If we or our current or future licensors are unable to obtain or maintain patent protection with respect to such inventions and technology, our business, financial condition, results of operations and prospects could be materially harmed.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The patent prosecution process is expensive, time-consuming and complex, and we and our current or future licensors may not be able to prepare, file, prosecute, maintain and enforce all necessary or desirable patent applications at a reasonable cost or in a timely manner. Patents may be invalidated and patent applications may not be granted for a number of reasons, including known and unknown prior art (including our own prior art), deficiencies in the patent applications or the lack of novelty of the underlying inventions or technology. It is also </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 36pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">47<br></div></div></div>
<!--End Page 51-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 52-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 540pt;"><a name="nt10014672x1_drs_104-risk_pg35"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="block-frill" style="width: 540pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: Arial, Helvetica, sans-serif; font-size: 9pt; font-weight: bold; margin-top: 6pt; text-align: center;">Confidential Treatment Requested by ADC Therapeutics SA Pursuant to 17 C.F.R. &#167; 200.83<br></div></div><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 36pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">possible that we or our current and future licensors will fail to identify patentable aspects of inventions made in the course of research, development and commercialization activities in time to obtain patent protection. Although we enter into non-disclosure and confidentiality agreements with parties who have access to confidential or patentable aspects of our research, development and commercialization activities, such as our employees, corporate collaborators, outside scientific collaborators, CROs, consultants, advisors and other third parties, any of these parties may breach the agreements and disclose such activities before a patent application is filed, thereby jeopardizing our ability to seek patent protection. In addition, publications of discoveries in the scientific literature often lag behind actual discoveries, and patent applications in the United States and other jurisdictions are typically not published until 18 months after filing, or in some cases not at all. Therefore, we cannot be certain that we or our current or future licensors were the first to make the inventions claimed in our owned or licensed patents or patent applications, or that we or our current or future licensors were the first to file for patent protection of such inventions.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Moreover, in some circumstances, we may not have the right to control the preparation, filing, prosecution, maintenance, enforcement and defense of patents and patent applications covering technology that we license from third parties, and are reliant on our licensors. For example, pursuant to our agreements with MedImmune and Genmab, MedImmune and Genmab retain control of the preparation, filing, prosecution, maintenance, enforcement and defense of certain of the patents and patent applications licensed to us. Therefore, these patents and applications may not be prepared, filed, prosecuted, maintained, enforced and defended in a manner consistent with the best interests of our business. If our current or future licensors fail to prosecute, maintain, enforce or defend such patents and other intellectual property rights, are not fully cooperative or disagree with us as to the prosecution, maintenance or enforcement of any patent rights, or lose rights to those patents or patent applications, the rights that we have licensed may be reduced or eliminated, and our right to develop and commercialize any of our product candidates that are the subject of such licensed rights could be adversely affected.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The patent position of biotechnology companies generally is highly uncertain, involves complex legal and factual questions and has, in recent years, been the subject of much litigation. As a result, the issuance, scope, validity, enforceability and commercial value of our and our current or future licensors&#8217; patent rights are highly uncertain. For example, there is significant uncertainty, and there has been much litigation, regarding what is considered patentable subject matter under U.S. patent law, including with respect to diagnostics. Our owned and licensed pending and future patent applications may not result in patents being issued which protect the products or technologies we develop, in whole or in part, or which effectively prevent others from commercializing competitive technologies and products. Moreover, the patent examination process may require us or our current and future licensors to narrow the scope of the claims of our owned or licensed pending and future patent applications, which may limit the scope of patent protection that may be obtained. Additionally, the scope of patent protection can be reinterpreted after issuance. Even if our owned or licensed pending and future patent applications issue as patents, they may not issue in a form that will provide us with any meaningful protection, prevent competitors or other third parties from competing with us, or otherwise provide us with any competitive advantage. Any patents that we hold or in-license may be challenged, narrowed, circumvented or invalidated by third parties in court or in patent offices in the United States and abroad. Our owned or licensed patent applications cannot be enforced against third parties practicing the technology claimed in such applications unless and until a patent issues from such applications, and then, only to the extent the issued claims cover the technology. Our competitors or other third parties may also be able to circumvent our patents by developing similar or alternative technologies or products in a non-infringing manner.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">We may be subject to a third-party pre-issuance submission of prior art to the United States Patent and Trademark Office (&#8220;USPTO&#8221;). We cannot assure you that all of the potentially relevant prior art relating to our patents and patent applications has been found. If such prior art exists, it can invalidate a patent or prevent a patent from issuing from a pending patent application Even if patents do successfully issue and even if such patents cover our product candidates, third parties may initiate an opposition, interference, reexamination, post-grant review, <font style="font-style: italic;">inter partes</font> review, nullification or derivation action in court or before patent offices, or other proceedings challenging the inventorship, validity, enforceability or scope of such patents, which may result in the patent claims being narrowed or invalidated. An adverse determination in any such proceeding or litigation could reduce the scope of, or invalidate, the patent rights we own or license, allow third parties to commercialize the products or technologies we develop and compete directly with us, without payment to us, or result in our inability to manufacture or commercialize products without infringing third-party patent rights. Moreover, we, or </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 36pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">48<br></div></div></div>
<!--End Page 52-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 53-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 540pt;"><a name="nt10014672x1_drs_104-risk_pg36"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="block-frill" style="width: 540pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: Arial, Helvetica, sans-serif; font-size: 9pt; font-weight: bold; margin-top: 6pt; text-align: center;">Confidential Treatment Requested by ADC Therapeutics SA Pursuant to 17 C.F.R. &#167; 200.83<br></div></div><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 36pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">our current or future licensors, may have to participate in interference proceedings declared by the USPTO to determine priority of invention or in post-grant challenge proceedings, such as oppositions in foreign patent offices, that challenge priority of invention or other features of patentability. Such challenges may result in loss of patent rights, loss of exclusivity or in patent claims being narrowed, invalidated or held unenforceable, which could limit our ability to stop others from using or commercializing similar or identical technology and products, or limit the duration of the patent protection of the product candidates and technologies we develop, including Lonca or Cami. Such proceedings also may result in substantial cost and require significant time and attention from our scientific and management personnel, even if the eventual outcome is favorable to us. Consequently, there can be no assurance that any product candidates or technology we develop will be protectable or remain protected by valid and enforceable patents. In addition, if the breadth or strength of protection provided by our patents or patent applications is threatened, regardless of the outcome, it could dissuade companies from collaborating with us to license, develop or commercialize current or future product candidates.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Because patent applications in the United States and most other countries are confidential for a period of time after filing, and some remain so until issued, we cannot be certain that we or our current and future licensors were the first to file any patent application related to a product candidate. Furthermore, if third parties have filed such patent applications on or before March&#160;15, 2013, an interference proceeding in the United States can be initiated by such third parties to determine who was the first to invent any of the subject matter covered by the patent claims of our applications. If third parties have filed such applications after March&#160;15, 2013, a derivation proceeding in the United States can be initiated by such third parties to determine whether our invention was derived from theirs. Even where we have a valid and enforceable patent, we may not be able to exclude others from practicing our invention where the other party can show that they used the invention in commerce before our filing date or the other party benefits from a compulsory license. Any of the foregoing could have a material adverse effect on our business, results of operations, financial condition and prospects.</div><div class="frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">Issued patents covering one or more of our product candidates or technologies, including Lonca, Cami or the technology we use in our product candidates, could be found invalid or unenforceable if challenged in court.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">To protect our competitive position, we may, from time to time, resort to litigation in order to enforce or defend any patents or other intellectual property rights owned by or licensed to us, or to determine or challenge the scope or validity of patents or other intellectual property rights of third parties. Enforcement of intellectual property rights is difficult, unpredictable and expensive, and many of our or our licensors&#8217; or collaboration partners&#8217; adversaries in these proceedings may have the ability to dedicate substantially greater resources to prosecuting these legal actions than we or our licensors or collaboration partners can. Accordingly, despite our or our licensors&#8217; or collaboration partners&#8217; efforts, we or our licensors or collaboration partners may not prevent third parties from infringing upon or misappropriating intellectual property rights we own or control, particularly in countries where the laws may not protect those rights as fully as in the United States and the European Union. We may fail in enforcing our rights, in which case third parties, including our competitors, may be permitted to use our technology without being required to pay us any license fees.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">In addition, litigation involving our patents carries the risk that one or more of our patents will be held invalid (in whole or in part, on a claim-by-claim basis) or held unenforceable. Such an adverse court ruling could allow third parties, including our competitors, to commercialize or use our product candidates and technologies, including the PBD technology we use in our product candidates, and then compete directly with us, without payment to us.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">If we or one of our current or future licensors were to initiate legal proceedings against a third party to enforce a patent covering one of our product candidates, the defendant could counterclaim that such patent is invalid or unenforceable. In patent litigation in the United States and in Europe, defendant counterclaims alleging invalidity or unenforceability are commonplace. A claim for a validity challenge may be based on failure to meet any of several statutory requirements, for example, lack of novelty, obviousness or non-enablement. A claim for unenforceability could involve an allegation that someone connected with prosecution of the patent withheld relevant information from the USPTO or the European Patent Office or made a misleading statement during prosecution. Third parties may also raise similar claims before the USPTO or an equivalent foreign body, even outside the context of litigation. Potential proceedings include reexamination, post-grant review, <font style="font-style: italic;">inter parte</font>s review, interference proceedings, derivation proceedings and equivalent proceedings in foreign jurisdictions (e.g.,&#160;opposition proceedings). Such proceedings could result in the revocation of, cancellation of, or amendment to our patents in such a way that they no longer cover our technology or any product candidates that we may </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 36pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">49<br></div></div></div>
<!--End Page 53-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 54-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 540pt;"><a name="nt10014672x1_drs_104-risk_pg37"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="block-frill" style="width: 540pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: Arial, Helvetica, sans-serif; font-size: 9pt; font-weight: bold; margin-top: 6pt; text-align: center;">Confidential Treatment Requested by ADC Therapeutics SA Pursuant to 17 C.F.R. &#167; 200.83<br></div></div><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 36pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">develop. The outcome following legal assertions of invalidity and unenforceability during patent litigation is unpredictable. With respect to the validity question, for example, we cannot be certain that there is no invalidating prior art of which we or our licensing partners and the patent examiner were unaware during prosecution. If a defendant were to prevail on a legal assertion of invalidity or unenforceability, we would lose at least part, and perhaps all, of the patent protection on one or more of our product candidates or certain aspects of the PBD technology we use in our product candidates. Such a loss of patent protection could have a material adverse impact on our business, financial condition, results of operations and prospects. Further, litigation could result in substantial costs and diversion of management resources, regardless of the outcome, and this could harm our business and financial results. Patents and other intellectual property rights also will not protect our technology if competitors design around our protected technology without infringing our patents or other intellectual property rights.</div><div class="frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">We may become involved in lawsuits to protect or enforce our patents or other intellectual property, which could be expensive, time-consuming and unsuccessful.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Competitors and other third parties may infringe, misappropriate or otherwise violate our issued patents or other intellectual property or the patents or other intellectual property of our licensors, or we or our licensors may be required to defend against claims of infringement, misappropriation or other violations of intellectual property held by third parties. In addition, our patents or the patents of our licensors may become involved in inventorship or priority disputes. To counter infringement, misappropriation or other unauthorized use, we or our licensors may be required to file infringement claims, which can be expensive and time-consuming. Any claims we or our licensors assert against perceived infringers could provoke these parties to assert counterclaims alleging that we or our licensors infringe their patents or that our or our licensors&#8217; patents are invalid or unenforceable. In a patent infringement proceeding, a court may decide that a patent of ours or one of our licensors&#8217; is invalid or unenforceable, in whole or in part, construe the patent&#8217;s claims narrowly or refuse to stop the other party from using the technology at issue on the grounds that our or our licensors&#8217; patents do not cover the technology. An adverse result in any litigation proceeding could put one or more of our owned or licensed patents at risk of being invalidated, held unenforceable or interpreted narrowly. We may find it impractical or undesirable to enforce our intellectual property rights against some third parties. Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information could be compromised by disclosure during this type of litigation.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Interference proceedings provoked by third parties or brought by us or declared by the USPTO may be necessary to determine the priority of inventions with respect to our or our licensors&#8217; patents or patent applications. If we or our licensors are unsuccessful in any interference proceedings to which we or they are subject, we may lose valuable intellectual property rights through the loss of one or more patents owned or licensed or our owned or licensed patent claims may be narrowed, invalidated or held unenforceable. If we or our licensors are unsuccessful in any interference proceeding or other priority or inventorship dispute, we may be required to obtain and maintain licenses from third parties, including parties involved in any such interference proceedings or other priority of inventorship disputes. Such licenses may not be available on commercially reasonable terms or at all, or may be non-exclusive. If we are unable to obtain and maintain such licenses, we may need to cease the development, manufacture and commercialization of one or more of the product candidates we may develop. The loss of exclusivity or narrowing of our owned or licensed patent claims could limit our ability to stop others from using or commercializing similar or identical technology and products. Any of the foregoing could have a material adverse effect on our business, results of operations, financial condition and prospects.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information could be compromised by disclosure during this type of litigation. There could also be public announcements of the results of hearings, motions, or other interim proceedings or developments. If securities analysts or investors perceive these results to be negative, it could have a material adverse effect on the price of our common shares.</div><div class="frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">If we fail to comply with our obligations in the agreements under which we license intellectual property rights from third parties or otherwise experience disruptions to our business relationships with our licensors, we could lose the ability to continue the development and commercialization of our product candidates.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">We are party to a number of intellectual property and technology licenses that are important to our business. For example, the PBD technology we use to generate our PBD-based ADCs was developed by, and is licensed </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 36pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">50<br></div></div></div>
<!--End Page 54-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 55-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 540pt;"><a name="nt10014672x1_drs_104-risk_pg38"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="block-frill" style="width: 540pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: Arial, Helvetica, sans-serif; font-size: 9pt; font-weight: bold; margin-top: 6pt; text-align: center;">Confidential Treatment Requested by ADC Therapeutics SA Pursuant to 17 C.F.R. &#167; 200.83<br></div></div><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 36pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">on a target-exclusive basis from, MedImmune. All of our ADC product candidates and research programs utilize a PBD-based warhead. In addition, we license certain patents and know-how relating to the antibodies used and incorporated into Cami from Genmab and those used and incorporated into our other product candidates from other third-party licensors. For more information regarding these agreements, see &#8220;Business&#8212;License and Collaboration Agreements.&#8221; If we fail to comply with our obligations under these or our other agreements, including payment and diligence terms, our current and future licensors may have the right to terminate these agreements, in which event we may not be able to develop, manufacture, market or sell any product that is covered by these agreements or may face other penalties under these agreements. Such an occurrence could adversely affect the value of the product candidates being developed under any such agreement. Termination of these agreements or reduction or elimination of our rights under these agreements may result in our having to negotiate new or reinstated agreements, which may not be available to us on equally favorable terms, or at all, or cause us to lose our rights under these agreements, including our rights to intellectual property or technology important to our development programs. Accordingly, termination of these agreements may require us to cease the development of our product candidates, including Lonca or Cami.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Disputes may arise regarding intellectual property subject to a licensing agreement, including:</div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the scope of rights granted under the license agreement and other interpretation-related issues;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the extent to which our technology and processes infringe on intellectual property of the licensor that is not subject to the licensing agreement;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the sublicensing of patent and other rights under our existing collaborative development relationships and any collaboration relationships we might enter into in the future;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">our diligence obligations under the license agreement and what activities satisfy those diligence obligations;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the inventorship and ownership of inventions and know-how resulting from the joint creation or use of intellectual property by our current and future licensors and us; and</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the priority of invention of patented technology.</div></td></tr></table><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">In addition, the agreements under which we license intellectual property or technology from third parties are generally complex, and certain provisions in such agreements may be susceptible to multiple interpretations. The resolution of any contract interpretation disagreement that may arise could narrow what we believe to be the scope of our rights to the relevant intellectual property or technology, or increase what we believe to be our financial or other obligations under the relevant agreements. Moreover, if disputes over intellectual property that we have licensed prevent or impair our ability to maintain our current licensing arrangements on commercially acceptable terms, we may be unable to successfully develop and commercialize the affected product candidates. Any of the foregoing could have a material adverse effect on our business, financial condition, results of operations and prospects.</div><div class="frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">We may not be successful in obtaining additional intellectual property rights necessary or required to further develop our product candidates.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">A third party may hold intellectual property, including patent rights, that are important or necessary to the development of our product candidates. In order to avoid infringing these third-party patents, we may find it necessary or prudent to obtain licenses from such third-party intellectual property holders. Moreover, we may need to obtain additional licenses from our existing licensors and others to advance our research or allow commercialization of product candidates we may develop. In addition, many of our patents are co-owned with MedImmune, which licenses its interest in such patents to us. With respect to any patents we co-own with third parties, we may require licenses to such co-owners&#8217; interest to such patents. In addition, we may need the cooperation of any co-owners of our patents in order to enforce such patents against third parties, and such cooperation may not be provided to us. We may be unable to secure such licenses or otherwise acquire or in-license any compositions, methods of use, processes or other intellectual property rights from third parties that we identify as necessary for product candidates we develop, including Lonca or Cami. The licensing or acquisition of third-party intellectual property rights is a competitive area, and more established companies may pursue strategies to license or acquire third-party intellectual property rights that we may consider attractive or necessary. These established companies may have a competitive advantage over us due to their size, capital resources and greater clinical development or commercialization capabilities. In addition, companies that perceive us to be a competitor may be unwilling to assign or license rights to us. As a result, we may be unable to obtain </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 36pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">51<br></div></div></div>
<!--End Page 55-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 56-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 540pt;"><a name="nt10014672x1_drs_104-risk_pg39"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="block-frill" style="width: 540pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: Arial, Helvetica, sans-serif; font-size: 9pt; font-weight: bold; margin-top: 6pt; text-align: center;">Confidential Treatment Requested by ADC Therapeutics SA Pursuant to 17 C.F.R. &#167; 200.83<br></div></div><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 36pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">any such licenses at a reasonable cost or on reasonable terms, if at all. In that event, we may be required to expend significant time and resources to redesign our technology, product candidates or the methods for manufacturing them or to develop or license replacement technology, all of which may not be feasible on a technical or commercial basis. If we are unable to do so, we may be unable to develop or commercialize the affected product candidates, including Lonca or Cami, which could significantly harm our business, financial condition, results of operations and prospects. In&#160;addition, even if we obtain a license, it may be non-exclusive, thereby giving third parties, including our competitors, access to the same technologies licensed to us. In addition, any license we obtain could require us to make substantial licensing and royalty payments. If we are unable to obtain an exclusive license to any third-party or co-owned patents or patent applications, such parties may be able to license their rights to other third parties, including our competitors, and such third parties could market competing products and technology. Any of the foregoing could have a material adverse effect on our business, results of operations, financial condition and prospects. </div><div class="frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">Third parties may initiate legal proceedings against us alleging that we infringe, misappropriate, or otherwise violate their intellectual property rights or we may initiate legal proceedings against third parties to challenge the validity or scope of intellectual property rights controlled by third parties, the outcome of which would be uncertain and could have an adverse effect on the success of our business.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Our commercial success depends upon our ability to develop, manufacture, market and sell our product candidates and use our and our current or future licensors&#8217; proprietary technologies without infringing, misappropriating or otherwise violating the intellectual property rights of third parties. The biotechnology and pharmaceutical industries are characterized by extensive litigation regarding patents and other intellectual property rights. Third parties may initiate legal proceedings against us or our current and future licensors alleging that we or our current and future licensors infringe, misappropriate or otherwise violate their intellectual property rights. In&#160;addition, we and our licensors have initiated, and we and our current and future licensors may in the future initiate, legal proceedings against third parties to challenge the validity or scope of intellectual property rights controlled by third parties, including in oppositions, interferences, reexaminations, <font style="font-style: italic;">inter partes</font> reviews or derivation proceedings in the United States or other jurisdictions. These proceedings can be expensive and time-consuming, and many of our or our current and future licensors&#8217; adversaries in these proceedings may have the ability to dedicate substantially greater resources to prosecuting these legal actions than we or our current and future licensors. Numerous U.S.- and foreign-issued patents and pending patent applications which are owned by third parties exist in the fields in which we are pursuing our product candidates. We are aware of a patent family with issued claims that could be construed to cover the linker in ADCT-601 and ADCT-701. As&#160;the biotechnology and pharmaceutical industries expand and more patents are issued, the risk increases that we may be subject to claims of infringement of the patent rights of third parties.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">There are, and in the future, we may identify, other third-party patents or patent applications with claims to materials, formulations, methods of manufacture or methods for treatment related to the use or manufacture of one or more of our product candidates. Because patent applications can take many years to issue, there may be currently pending patent applications that may later result in issued patents that our product candidates may infringe. In addition, third parties may obtain patents in the future and claim that use of our technologies infringes upon these patents. Parties making infringement, misappropriation or other intellectual property claims against us may obtain injunctive or other equitable relief, which could effectively block our ability to further develop and commercialize one or more of our product candidates, including Lonca or Cami. Defense of these claims, regardless of their merit, would involve substantial litigation expense and would be a substantial diversion of management and employee resources. In addition, even if we believe any third-party intellectual property claims are without merit, there is no assurance that a court would find in our favor on questions of validity, enforceability, priority or non-infringement. A court of competent jurisdiction could hold that such third-party patents are valid, enforceable and infringed, which could materially and adversely affect our ability to commercialize any of our product candidates or technologies covered by the asserted third-party patents. In order to successfully challenge the validity of any such third-party U.S. patents in federal court, we would need to overcome a presumption of validity. As this burden is a high one requiring us to present clear and convincing evidence as to the invalidity of any such U.S. patent claim, there is no assurance that a court of competent jurisdiction would invalidate the claims of any such U.S. patent. An unfavorable outcome could require us or our current and future licensors to cease using the related technology or developing or commercializing our product candidates, or to attempt to license rights to it from the prevailing party. Our business could be harmed if the prevailing party does not offer us or our current and future licensors a license on commercially reasonable terms </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 36pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">52<br></div></div></div>
<!--End Page 56-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 57-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 540pt;"><a name="nt10014672x1_drs_104-risk_pg40"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="block-frill" style="width: 540pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: Arial, Helvetica, sans-serif; font-size: 9pt; font-weight: bold; margin-top: 6pt; text-align: center;">Confidential Treatment Requested by ADC Therapeutics SA Pursuant to 17 C.F.R. &#167; 200.83<br></div></div><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 36pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">or at all. Even if we or our current and future licensors obtain a license, it may be non-exclusive, thereby giving our competitors access to the same technologies licensed to us or our current and future licensors, and it could require us to make substantial licensing and royalty payments. In addition, we could be found liable for monetary damages, including treble damages and attorneys&#8217; fees, if we are found to have willfully infringed a patent. A finding of infringement, misappropriation or other violation of third-party intellectual property could prevent us from commercializing our product candidates or force us to cease some of our business operations, which could harm our business. Claims that we have misappropriated the confidential information or trade secrets of third parties could have a similar material adverse effect on our business, results of operations, financial condition and prospects. Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation or administrative proceedings, there is a risk that some of our confidential information could be compromised by disclosure. In&#160;addition, any uncertainties resulting from the initiation and continuation of any litigation could have a material adverse effect on our ability to raise additional funds or otherwise have a material adverse effect on our business, results of operations, financial condition and prospects.</div><div class="frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">We may be subject to claims by third parties asserting that we or our employees, consultants or advisors have misappropriated their intellectual property, or claiming ownership of what we regard as our own intellectual property.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Many of our employees, consultants, and advisors, including our senior management, were previously employed at other biopharmaceutical companies, including our competitors or potential competitors. Some of these employees executed proprietary rights, non-disclosure and/or non-competition agreements in connection with such previous employment. Although we try to ensure that our employees, consultants and advisors do not use the proprietary information or know-how of others in their work for us, we may be subject to claims that we or these individuals have used or disclosed confidential information or intellectual property, including trade secrets or other proprietary information, of any such individual&#8217;s current or former employer. Litigation may be necessary to defend against these claims. If we fail in defending against any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights or personnel. Such intellectual property rights could be awarded to a third party, and we could be required to obtain a license from such third party to commercialize our technology or products. Such a license may not be available on commercially reasonable terms, or at all. Even if we successfully prosecute or defend against such claims, litigation could result in substantial costs and distract management.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">In addition, while it is our policy to require our employees and contractors who may be involved in the conception or development of intellectual property to execute agreements assigning such intellectual property to us, we may be unsuccessful in executing such an agreement with each party who, in fact, conceives or develops intellectual property that we regard as our own. The assignment of intellectual property rights may not be self-executing, or the assignment agreements may be breached, and we may be forced to bring claims against third parties, or defend claims that they may bring against us, to determine the ownership of what we regard as our intellectual property. Such claims could have a material adverse effect on our business, results of operations, financial condition and prospects.</div><div class="frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">Intellectual property litigation or proceedings could cause us to spend substantial resources and distract our personnel.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Even if resolved in our favor, litigation or other legal proceedings relating to intellectual property claims could result in substantial costs and diversion of management resources, which could harm our business. In addition, the uncertainties associated with litigation could compromise our ability to raise the funds necessary to continue our clinical trials, continue our internal research programs or in-license needed technology or other product candidates. There could also be public announcements of the results of the hearing, motions or other interim proceedings or developments. If securities analysts or investors perceive those results to be negative, it could cause the price of our common shares to decline. Such litigation or proceedings could substantially increase our operating losses and reduce the resources available for development activities or any future sales, marketing, or distribution activities. We may not have sufficient financial or other resources to conduct such litigation or proceedings adequately. Most of our competitors are larger than we are and have substantially greater resources. They are, therefore, likely to be able to sustain the costs of complex patent litigation or proceedings more effectively than we can because of their greater financial resources and more mature and developed intellectual property portfolios. Accordingly, despite our efforts, we may not be able to prevent third parties from infringing upon, misappropriating or otherwise violating our intellectual property. Any of the foregoing events could harm our business, financial condition, results of operation and prospects.</div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 36pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">53<br></div></div></div>
<!--End Page 57-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 58-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 540pt;"><a name="nt10014672x1_drs_104-risk_pg41"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="block-frill" style="width: 540pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: Arial, Helvetica, sans-serif; font-size: 9pt; font-weight: bold; margin-top: 6pt; text-align: center;">Confidential Treatment Requested by ADC Therapeutics SA Pursuant to 17 C.F.R. &#167; 200.83<br></div></div><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 36pt;"><div class="frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">Changes in patent law could diminish the value of patents in general, thereby impairing our ability to protect our product candidates.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Obtaining and enforcing patents in the biopharmaceutical industry involves both technological and legal complexity and is therefore costly, time-consuming and inherently uncertain. Changes in either the patent laws or the interpretation of the patent laws in the United States or other jurisdictions could increase the uncertainties and costs surrounding the prosecution of patent applications and the enforcement or defense of issued patents. Recent patent reform legislation in the United States and other countries, including the Leahy-Smith America Invents Act (&#8220;the Leahy-Smith Act&#8221;) could increase those uncertainties and costs. The Leahy-Smith Act includes provisions that affect the way patent applications are prosecuted, redefine prior art and provide more efficient and cost-effective avenues for competitors to challenge the validity of patents, and may also affect patent litigation. These include allowing third-party submission of prior art to the USPTO during patent prosecution and additional procedures to attack the validity of a patent by USPTO-administered post-grant proceedings, including post-grant review,<font style="font-style: italic;"> inter partes</font> review and derivation proceedings. In addition, assuming that other requirements for patentability are met, prior to March&#160;15, 2013, in the United States, the first to invent the claimed invention was entitled to the patent, while outside the United States, the first to file a patent application was entitled to the patent. After March&#160;15, 2013, under the Leahy-Smith Act, the United States transitioned to a first inventor to file system in which, assuming that the other statutory requirements are met, the first inventor to file a patent application will be entitled to the patent on an invention regardless of whether a third party was the first to invent the claimed invention. The Leahy-Smith Act and its implementation could increase the uncertainties and costs surrounding the prosecution of our patent applications and the enforcement or defense of our issued patents, all of which could have a material adverse effect on our business, financial condition, results of operations and prospects.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">In addition, the U.S. Supreme Court has ruled on several patent cases in recent years, either narrowing the scope of patent protection available in certain circumstances or weakening the rights of patent owners in certain situations. This combination of events has created uncertainty with respect to the validity and enforceability of patents, once obtained. Depending on future actions by the U.S. Congress, the U.S. courts, the USPTO and the relevant law-making bodies in other countries, the laws and regulations governing patents could change in unpredictable ways that would weaken our ability to obtain new patents or to enforce our existing patents and patents that we might obtain in the future.</div><div class="frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">Obtaining and maintaining patent protection depends on compliance with various procedural, document submission, fee payment and other requirements imposed by governmental patent agencies, and our patent protection could be reduced or eliminated for non-compliance with these requirements.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Periodic maintenance fees, renewal fees, annuity fees and various other government fees on any issued patent or patent application are due to be paid to the USPTO and various government patent agencies outside of the United States in several stages over the lifetime of our owned or licensed patents and applications. The USPTO and various non-U.S. governmental patent agencies require compliance with a number of procedural, documentary, fee payment and other similar provisions during the patent application process. While an inadvertent lapse can, in some cases, be cured by payment of a late fee or by other means in accordance with the applicable rules, there are situations in which non-compliance can result in abandonment or lapse of the patent or patent application, resulting in a partial or complete loss of patent rights in the relevant jurisdiction. Non-compliance events that could result in abandonment or lapse of a patent or patent application include failure to respond to official actions within prescribed time limits, non-payment of fees and failure to properly legalize and submit formal documents. If we or our current and future licensors fail to maintain the patents and patent applications covering our product candidates, our patent protection could be reduced or eliminated and our competitors might be better able to enter the market with competing products or technology, which could have a material adverse effect on our business, financial condition, results of operation and prospects. </div><div class="frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">If we do not obtain patent term extension for any product candidates we may develop, our business may be materially harmed.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Patents have a limited lifespan. Due to the amount of time required for the development, testing and regulatory review of new product candidates, patents protecting such candidates might expire before or shortly after such candidates are commercialized. As a result, our owned and licensed patent portfolio may not provide us with sufficient rights to exclude others from commercializing products similar or identical to ours. In the </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 36pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">54<br></div></div></div>
<!--End Page 58-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 59-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 540pt;"><a name="nt10014672x1_drs_104-risk_pg42"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="block-frill" style="width: 540pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: Arial, Helvetica, sans-serif; font-size: 9pt; font-weight: bold; margin-top: 6pt; text-align: center;">Confidential Treatment Requested by ADC Therapeutics SA Pursuant to 17 C.F.R. &#167; 200.83<br></div></div><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 36pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">United States, if all maintenance fees are timely paid, the natural expiration of a patent is generally 20&#160;years from its earliest U.S. non-provisional filing date. Various extensions may be available, but the life of a patent, and the protection it affords, is limited. Even if patents covering our product candidates are obtained, once the patent life has expired for a product, we may be open to competition from competitive medications, including biosimilar or generic medications. At the time of the expiration of any relevant patents, the underlying technology covered by such patents can be used by any third party, including competitors. Although the patent term extensions under the Drug Price Competition and Patent Term Restoration Action of 1984 (the &#8220;Hatch-Waxman Amendments&#8221;) in the United States may be available to extend the patent term, we cannot provide any assurances that any such patent term extension will be obtained and, if so, for how long.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Given the amount of time required for the development, testing and regulatory review of new product candidates, patents protecting such product candidates might expire before or shortly after such product candidates are commercialized. Depending upon the timing, duration and specifics of any FDA marketing approval of any product candidates we may develop, one or more of our U.S. patents may be eligible for limited patent term extension under the Hatch-Waxman Amendments. The Hatch-Waxman Amendments permit a patent term extension of up to five years as compensation for patent term lost during the FDA regulatory review process. A patent term extension cannot extend the remaining term of a patent beyond a total of 14&#160;years from the date of product approval, only one patent may be extended and only those claims covering the approved drug, a method for using it or a method for manufacturing it may be extended. However, we may not be granted an extension because of, for example, failing to exercise due diligence during the testing phase or the regulatory review process, failing to apply within applicable deadlines, failing to apply prior to expiration of relevant patents or otherwise failing to satisfy applicable requirements. Moreover, the applicable time period or the scope of patent protection afforded could be less than we request. If we are unable to obtain patent term extension or term of any such extension is less than we request, our competitors may obtain approval of competing products following our patent expiration, and our business, financial condition, results of operations and prospects could be materially harmed.</div><div class="frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 20pt; margin-left: 0pt; text-align: left;">We may not be able to protect our intellectual property rights throughout the world.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Filing, prosecuting, enforcing and defending patents on product candidates in all countries throughout the world would be prohibitively expensive, and our owned or licensed intellectual property rights may not exist in some countries outside the United States or may be less extensive in some countries than in the United States. In addition, the laws of some foreign countries do not protect intellectual property rights to the same extent as federal and state laws in the United States. For example, in some jurisdictions, including Europe, it is more difficult to obtain patents protecting a medical method of use, and any such patents we are able to obtain in such jurisdictions may issue with narrower scope than their U.S. counterparts. Consequently, we and our current and future licensors may not be able to prevent third parties from practicing our owned or licensed inventions in all countries outside the United States, or from selling or importing products made using our owned or licensed inventions in and into the United States or other jurisdictions. Competitors may use our owned or licensed technologies to develop their own products in jurisdictions where we have not obtained patent protection and, further, may export otherwise infringing products to territories where we and our current and future licensors have patent protection, but enforcement is not as strong as that in the United States. These products may compete with our product candidates, including Lonca or Cami, and our owned and licensed patents or other intellectual property rights may not be effective or sufficient to prevent them from competing.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Many companies have encountered significant problems in protecting and defending intellectual property rights in foreign jurisdictions. The legal systems of certain countries, particularly certain developing countries, do not favor the enforcement of patents, trade secrets and other intellectual property protection, particularly those relating to biotechnology, which could make it difficult for us and our current and future licensors to stop the infringement of our owned or licensed patents or marketing of competing products in violation of our owned or licensed intellectual property and proprietary rights generally. Proceedings to enforce our owned or licensed intellectual property and proprietary rights in foreign jurisdictions could result in substantial costs and divert our and our current or future licensors&#8217; efforts and attention from other aspects of our business, could put our owned or licensed patents at risk of being invalidated or interpreted narrowly, could put our and our current or future licensors&#8217; patent applications at risk of not issuing, and could provoke third parties to assert claims against us or our current and future licensors. We or our current and future licensors may not prevail in any lawsuits that we or our current and future licensors initiate, and the damages or other remedies awarded, if any, may not be </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 36pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">55<br></div></div></div>
<!--End Page 59-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 60-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 540pt;"><a name="nt10014672x1_drs_104-risk_pg43"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="block-frill" style="width: 540pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: Arial, Helvetica, sans-serif; font-size: 9pt; font-weight: bold; margin-top: 6pt; text-align: center;">Confidential Treatment Requested by ADC Therapeutics SA Pursuant to 17 C.F.R. &#167; 200.83<br></div></div><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 36pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">commercially meaningful. Accordingly, our and our current and future licensors&#8217; efforts to enforce intellectual property and proprietary rights around the world may be inadequate to obtain a significant commercial advantage from the intellectual property that we develop or license.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Many countries have compulsory licensing laws under which a patent owner may be compelled to grant licenses to third parties. In addition, many countries limit the enforceability of patents against government agencies or government contractors. In these countries, the patent owner may have limited remedies, which could materially diminish the value of such patent. If we or our current and future licensors are forced to grant a license to third parties with respect to any patents relevant to our business, our competitive position may be impaired, and our business, financial condition, results of operations and prospects may be adversely affected.</div><div class="frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 20.5pt; margin-left: 0pt; text-align: left;">If we are unable to protect our confidential information and trade secrets, our business and competitive position would be harmed.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">In addition to seeking patents for some of our technology and product candidates, we also rely on trade secrets, including unpatented know-how, technology and other proprietary information to maintain our competitive position. Trade secrets can be difficult to protect. We seek to protect these trade secrets, in part, by entering into non-disclosure, confidentiality and invention assignment agreements with parties who have access to them, such as our employees, corporate collaborators, outside scientific collaborators, CROs, contract manufacturers, consultants, advisors and other third parties. We also enter into confidentiality agreements with our employees and consultants. However, there can be no assurance that we have entered into such agreements with each party that may have or have had access to our trade secrets or proprietary technology and processes. Despite these efforts, any of these parties may breach the agreements and disclose our proprietary information, including our trade secrets, and we may not be able to obtain adequate remedies for such breaches. Misappropriation or unauthorized disclosure of our trade secrets could significantly affect our competitive position and may have a material adverse effect on our business.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Enforcing a claim that a party illegally disclosed or misappropriated a trade secret is difficult, expensive and time-consuming, and the outcome is unpredictable. Some courts both within and outside the United States may be less willing or unwilling to protect trade secrets. Furthermore, trade secret protection does not prevent competitors from independently developing substantially equivalent information and techniques, and we cannot guarantee that our competitors will not independently develop substantially equivalent information and techniques. If a competitor lawfully obtained or independently developed any of our trade secrets, we would have no right to prevent such competitor from using that technology or information to compete with us. Failure on our part to adequately protect our trade secrets or confidential information could have a material adverse effect on our business, results of operations, financial condition and prospects.</div><div class="frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 20.5pt; margin-left: 0pt; text-align: left;">If our trademarks and trade names are not adequately protected, then we may not be able to build name recognition in our markets and our business may be adversely affected.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Our registered or unregistered trademarks or trade names may be challenged, circumvented, declared generic or determined to be infringing on other marks. There can be no assurance that competitors will not infringe our trademarks, that we will have adequate resources to enforce our trademarks or that any of our current or future trademark applications will be approved. During trademark registration proceedings, we may receive rejections and, although we are given an opportunity to respond, we may be unable to overcome such rejections. In addition, in proceedings before the USPTO and in proceedings before comparable agencies in many foreign jurisdictions, trademarks are examined for registrability against prior pending and registered third-party trademarks, and third parties are given an opportunity to oppose registration of pending trademark applications and/or to seek cancellation of registered trademarks. Applications to register our trademarks may be finally rejected, and opposition or cancellation proceedings may be filed against our trademarks, which may necessitate a change in branding strategy if such rejections and proceedings cannot be overcome or resolved. For example, in some jurisdictions the applicable trademark office has rejected our corporate name for registration, or a third party has objected to a published application for a product trademark, which, in some cases, has caused us to abandon or limit our applications, and/or rely more on the registration for our corporate logo.</div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 36pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">56<br></div></div></div>
<!--End Page 60-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 61-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 540pt;"><a name="nt10014672x1_drs_104-risk_pg44"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="block-frill" style="width: 540pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: Arial, Helvetica, sans-serif; font-size: 9pt; font-weight: bold; margin-top: 6pt; text-align: center;">Confidential Treatment Requested by ADC Therapeutics SA Pursuant to 17 C.F.R. &#167; 200.83<br></div></div><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 36pt;"><div class="frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">Intellectual property rights do not necessarily address all potential threats. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The degree of future protection afforded by our intellectual property rights is uncertain because intellectual property rights have limitations and may not adequately protect our business or permit us to maintain our competitive advantage. For example: </div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">others may be able to make products that are similar to any product candidates we may develop or utilize similar technology but that are not covered by the claims of the patents that we license or may own in the future;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">we, or our license partners or current or future collaborators, might not have been the first to make the inventions covered by the issued patent or pending patent application that we license or may own in the future; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">we, or our license partners or current or future collaborators, might not have been the first to file patent applications covering certain of our or their inventions;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">others may independently develop similar or alternative technologies or duplicate any of our technologies without infringing our owned or licensed intellectual property rights; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">it is possible that our pending licensed patent applications or those that we may own in the future will not lead to issued patents; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">issued patents that we hold rights to may be held invalid or unenforceable, including as a result of legal challenges by our competitors; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">our competitors might conduct research and development activities in countries where we do not have patent rights and then use the information learned from such activities to develop competitive products for sale in our major commercial markets;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">we may not develop additional proprietary technologies that are patentable;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the patents of others may harm our business; and </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">we may choose not to file a patent in order to maintain certain trade secrets or know-how, and a third party may subsequently file a patent covering such intellectual property.</div></td></tr></table><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Should any of these events occur, they could have a material adverse effect on our business, results of operations, financial condition and prospects. </div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 18pt; margin-left: 0pt; text-align: left;">Risks Related to Our Business and Industry</div><div class="frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 6pt; margin-left: 0pt; text-align: left;">If we fail to attract and retain senior management and key scientific personnel or fail to adequately plan for succession, we may be unable to successfully develop our product candidates, conduct our clinical trials and commercialize our product candidates.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Our ability to compete in the highly competitive biotechnology industry depends upon our ability to attract, motivate and retain highly qualified managerial, scientific and medical personnel. We are highly dependent on the performance and expertise of members of our senior management and key scientific personnel, including our co-founder and CEO, Dr. Christopher Martin, who was a co-founder of Spirogen Ltd., the company that developed the PBD technology that we use for all of our ADC product candidates and research programs. The loss of the services of Dr. Martin or any of our other senior management members, other key employees and scientific and medical advisors could impede the achievement of our research, development and commercialization objectives. Dr. Martin and other members of our senior management are employed pursuant to employment agreements with no term and that require advance notice (twelve months for Dr. Martin) for termination, but Dr. Martin and each of these other persons may terminate their employment with us at any time. In addition, laws and regulations on executive compensation, including legislation in our home country, Switzerland, may restrict our ability to attract, motivate and retain the required level of qualified personnel. In Switzerland, legislation affecting public companies has been passed that, among other things, (i)&#160;imposes an annual binding shareholders&#8217; &#8220;say-on-pay&#8221; vote with respect to the compensation of the members of (a)&#160;the executive committee and (b)&#160;the board of directors, (ii)&#160;prohibits severance, advances, transaction premiums and similar payments to executive officers and directors, and (iii)&#160;requires companies to specify various compensation-related matters in their articles of association, thus requiring them to be approved by a </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 36pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">57<br></div></div></div>
<!--End Page 61-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 62-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 540pt;"><a name="nt10014672x1_drs_104-risk_pg45"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="block-frill" style="width: 540pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: Arial, Helvetica, sans-serif; font-size: 9pt; font-weight: bold; margin-top: 6pt; text-align: center;">Confidential Treatment Requested by ADC Therapeutics SA Pursuant to 17 C.F.R. &#167; 200.83<br></div></div><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 36pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">shareholders&#8217; vote. Moreover, the United Kingdom&#8217;s exit from the European Union may result in difficulties in attracting and retaining qualified personnel for our research and development laboratories in London. We do not maintain &#8220;key person&#8221; insurance for any of our executives or other employees.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">In addition, our failure to put in place adequate succession plans for senior and key management roles or the failure of key employees to successfully transition into new roles could have an adverse effect on our business and operating results. The unexpected or abrupt departure of one or more of our key personnel and the failure to effectively transfer knowledge and effect smooth key personnel transitions may have an adverse effect on our business resulting from the loss of such person&#8217;s skills, knowledge of our business, and years of industry experience. If we cannot effectively manage leadership transitions and management changes in the future, our reputation and future business prospects could be adversely affected.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Competition for skilled personnel is intense, particularly in the biotechnology industry. We are headquartered in Lausanne, Switzerland, and maintain research and development laboratories in London, clinical development operations in New Jersey and in Lausanne, commercial operations in New Jersey and CMC operations in the San Francisco Bay Area. We face competition for personnel from other companies, universities, public and private research institutions and other organizations. This competition may limit our ability to hire and retain highly qualified personnel on acceptable terms, or at all. We may not be able to attract and retain these personnel on acceptable terms given the competition among numerous biotechnology companies for similar personnel. This possibility is further compounded by the novel nature of our product candidates, as fewer people are trained in or are experienced with product candidates of this type. In addition, we rely on consultants and advisors, including scientific and clinical advisors, to assist us in formulating our research and development and commercialization strategy. Our consultants and advisors may be employed or may have commitments under consulting or advisory contracts with other entities that may limit their availability to us.</div><div class="frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 20.5pt; margin-left: 0pt; text-align: left;">We may encounter difficulties in managing our growth and expanding our operations successfully.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">As we seek to advance our product candidates through clinical trials and commercialization, we are expanding our development, regulatory, manufacturing, marketing and sales capabilities and may need to further expand or contract with third parties to provide these capabilities. In addition, as our operations expand, we expect that we will need to manage additional relationships with various collaborators, suppliers and other third parties. Our growth will impose significant added responsibilities on members of management. Our management may have to divert a disproportionate amount of its attention away from our day-to-day activities and devote a substantial amount of time to these growth activities, including identifying, recruiting, integrating, maintaining and motivating additional employees, managing our research and development efforts effectively, including the clinical trials and the FDA&#8217;s, EMA&#8217;s or comparable regulatory authority in other jurisdictions&#8217; review process for our product candidates, while complying with our contractual obligations to contractors and other third parties and improving our operational, financial and management controls, reporting systems and procedures.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Our future financial performance and our ability to commercialize our product candidates and to compete effectively will depend, in part, on our ability to manage our growth effectively. To that end, we must be able to effectively manage our research and development efforts and hire, train and integrate additional management, administrative and sales and marketing personnel. We may not be able to accomplish these tasks, and our failure to accomplish any of them could prevent us from successfully growing our company or could disrupt our operations.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">In addition, we currently rely, and for the foreseeable future will continue to rely, in substantial part on certain independent organizations, advisors and consultants to provide certain services. There can be no assurance that the services of these independent organizations, advisors and consultants will continue to be available to us on a timely basis when needed or that we can find qualified replacements. Furthermore, if we are unable to effectively manage our outsourced activities or if the quality or accuracy of the services provided by consultants is compromised for any reason, our clinical trials may be extended, delayed or terminated, and we may not be able to obtain regulatory approval of our product candidates or otherwise advance our business. There can be no assurance that we will be able to manage our existing consultants or find other competent outside contractors and consultants on economically reasonable terms, if at all.</div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 36pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">58<br></div></div></div>
<!--End Page 62-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 63-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 540pt;"><a name="nt10014672x1_drs_104-risk_pg46"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="block-frill" style="width: 540pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: Arial, Helvetica, sans-serif; font-size: 9pt; font-weight: bold; margin-top: 6pt; text-align: center;">Confidential Treatment Requested by ADC Therapeutics SA Pursuant to 17 C.F.R. &#167; 200.83<br></div></div><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 36pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">If we are not able to effectively expand our organization by hiring new employees and expanding our groups of consultants and contractors, we may not be able to successfully implement the tasks necessary to further develop and commercialize our product candidates and, accordingly, may not achieve our research, development and commercialization goals.</div><div class="frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">As a result of being a public company, we have incurred costs and expect to continue to incur additional costs, and we may not manage to comply with our internal control procedures and corporate governance structures.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">To comply with the requirements imposed on us as a public company, we have incurred, and expect to continue to incur, significant legal, insurance, accounting and other expenses that we did not as a private company. The increased costs may require us to reduce costs in other areas of our business. In addition, our board of directors, management and administrative staff are required to perform additional tasks. For example, we bear all of the internal and external costs of preparing and distributing periodic public reports in compliance with our obligations under the securities laws. We have invested, and intend to continue to invest, resources to comply with evolving laws, regulations and standards, and this investment will result in increased general and administrative expenses and may divert management&#8217;s time and attention from research and development activities. These laws, regulations and standards are often subject to varying interpretations, in many cases due to their lack of specificity, and, as a result, their application in practice may evolve over time as new guidance is provided by regulatory and governing bodies. This could result in continuing uncertainty regarding compliance matters, enforcement proceedings and higher costs necessitated by ongoing revisions to disclosure and governance practices, which could have a material adverse impact on our business, financial condition, results of operations and prospects. </div><div class="frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">If we do not achieve our projected development and commercialization goals in the timeframes we announce and expect, the commercialization of any of our product candidates may be delayed, and our business will be harmed.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">For planning purposes, we sometimes estimate the timing of the accomplishment of various scientific, clinical, regulatory and other product development objectives. These milestones may include our expectations regarding the commencement or completion of scientific studies and clinical trials, the regulatory submissions or commercialization objectives. From time to time, we may publicly announce the expected timing of some of these milestones, such as the completion of an ongoing clinical trial, the initiation of other clinical trials, receipt of regulatory approval or the commercial launch of a product. The achievement of many of these milestones may be outside of our control. All of these milestones are based on a variety of assumptions which may cause the timing of achievement of the milestones to vary considerably from our estimates, including:</div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">our available capital resources or capital constraints we experience;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the rate of progress, costs and results of our clinical trials and research and development activities, including the extent of scheduling conflicts with participating clinicians and collaborators;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">our ability to identify and enroll patients who meet clinical trial eligibility criteria;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">our receipt of approvals by the FDA, EMA and comparable regulatory authorities in other jurisdictions, and the timing thereof;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">other actions, decisions or rules issued by regulators;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">our ability to access sufficient, reliable and affordable supplies of materials used in the manufacture of our product candidates;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">our ability to manufacture and supply clinical trial materials to our clinical sites on a timely basis;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the efforts of our collaborators with respect to the commercialization of our products; and</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the securing of, costs related to, and timing issues associated with, commercial product manufacturing as well as sales and marketing activities.</div></td></tr></table><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">If we fail to achieve announced milestones in the timeframes we expect, the commercialization of any of our product candidates may be delayed, and our business, results of operations, financial condition and prospects may be adversely affected.</div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 36pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">59<br></div></div></div>
<!--End Page 63-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 64-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 540pt;"><a name="nt10014672x1_drs_104-risk_pg47"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="block-frill" style="width: 540pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: Arial, Helvetica, sans-serif; font-size: 9pt; font-weight: bold; margin-top: 6pt; text-align: center;">Confidential Treatment Requested by ADC Therapeutics SA Pursuant to 17 C.F.R. &#167; 200.83<br></div></div><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 36pt;"><div class="frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">Failure to comply with health and data protection laws and regulations could lead to government enforcement actions, private litigation and/or adverse publicity and could negatively affect our operating results and business.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">We receive, generate and store significant and increasing volumes of sensitive information, such as employee and patient data. In addition, we actively seek access to medical information, including patient data, through research and development collaborations or otherwise. We have legal and contractual obligations regarding the protection of confidentiality and appropriate use of personal data. We and any potential collaborators may be subject to federal, state, local and foreign laws and regulations that apply to the collection, use, retention, protection, disclosure, transfer and other processing of personal data. In the United States, numerous federal and state laws and regulations, including federal health information privacy laws, state data breach notification laws, state health information privacy laws, and federal and state consumer protection laws (for example, Section 5 of the Federal Trade Commission Act), that govern the collection, use, disclosure and protection of health-related and other personal information could apply to our operations or the operations of our collaborators. In addition, we may obtain health information from third parties, including research institutions from which we obtain clinical trial data, that are subject to privacy and security requirements under federal Health Insurance Portability and Accountability Act of 1996 (&#8220;HIPAA&#8221;), as amended by the Health Information Technology for Economic and Clinical Health Act of 2009 (&#8220;HITECH&#8221;). Depending on the facts and circumstances, we could be subject to civil, criminal and administrative penalties if we knowingly obtain, use, or disclose individually identifiable health information maintained by a HIPAA-covered entity in a manner that is not authorized or permitted by HIPAA. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Several foreign jurisdictions, including the European Union, its member states and Australia, among others, have adopted legislation and regulations that increase or change the requirements governing the collection, use, disclosure and transfer of the personal information of individuals in these jurisdictions and place greater control with the data subject. In the United States, the California Consumer Privacy Act (&#8220;CCPA&#8221;), which went into effect on January 1, 2020, increased the requirements governing the collection, use, disclosure and transfer of the personal information of individuals in the state of California. The CCPA gives California residents expanded rights to access and request deletion of their personal information, opt out of certain sales of personal information and receive detailed information about how their personal information is used by requiring covered companies to provide new disclosures to California residents regarding such use. The CCPA provides for civil penalties for violations, as well as a private right of action for data breaches that is expected to increase data breach litigation. As we expand our operations and research and development efforts, the CCPA may increase our compliance costs and potential liability. Other states are considering similar laws.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">These laws and regulations are complex and change frequently, at times due to changes in political climate, and existing laws and regulations are subject to different and conflicting interpretations, which adds to the complexity of processing personal data from these jurisdictions. These laws have the potential to increase costs of compliance, risks of non-compliance and penalties for non-compliance. The Regulation 2016/679, known as the General Data Protection Regulation (&#8220;GDPR&#8221;), as well as European Union member state implementing legislations, apply to the collection and processing of personal data, including health-related information, by companies located in the European Union, or in certain circumstances, by companies located outside of the European Union and processing personal information of individuals located in the European Union. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">These laws impose strict obligations on the ability to process personal data, including health-related information, in particular in relation to their collection, use, disclosure and transfer. These include several requirements relating to (i)&#160;obtaining, in some situations, the consent of the individuals to whom the personal data relates, (ii)&#160;the information provided to the individuals about how their personal information is used, (iii)&#160;ensuring the security and confidentiality of the personal data, (iv)&#160;the obligation to notify regulatory authorities and affected individuals of personal data breaches, (v)&#160;extensive internal privacy governance obligations, and (vi)&#160;obligations to honor rights of individuals in relation to their personal data (for example, the right to access, correct and delete their data). The GDPR prohibits the transfer of personal data to countries outside of the European Economic Area, such as the United States, which are not considered by the European Commission to provide an adequate level of data protection. Switzerland has adopted similar restrictions. Although there are legal mechanisms to allow for the transfer of personal data from the EEA and Switzerland to the United States, they are subject to legal challenges and uncertainty about compliance with European Union data protection laws remains. For example, in July&#160;2020, the Court of Justice of the European Union invalidated the so-called Privacy Shield, which provided a framework for data transferred from the European Union to the </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 36pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">60<br></div></div></div>
<!--End Page 64-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 65-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 540pt;"><a name="nt10014672x1_drs_104-risk_pg48"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="block-frill" style="width: 540pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: Arial, Helvetica, sans-serif; font-size: 9pt; font-weight: bold; margin-top: 6pt; text-align: center;">Confidential Treatment Requested by ADC Therapeutics SA Pursuant to 17 C.F.R. &#167; 200.83<br></div></div><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 36pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">United States. To the extent that we were to rely on the EU-U.S. Privacy Shield Framework, we will not be able to do so in the future, which could increase our costs and limit our ability to process personal data from the EU. The same decision also cast doubt on the ability to use one of the primary alternatives to the Privacy Shield, namely, the European Commission&#8217;s Standard Contractual Clauses, to lawfully transfer personal data from Europe to the United States and most other countries. At present, there are few if any viable alternatives to the Privacy Shield and the Standard Contractual Clauses.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Potential pecuniary fines for noncompliant companies may be up to the greater of &#8364;20&#160;million or 4% of annual global revenue. The GDPR has increased our responsibility and liability in relation to personal data that we process, and we may be required to put in place additional potential mechanisms to ensure compliance with the new European Union data protection rules. The GDPR also contains a private right of action allowing data subjects and consumer associations to lodge complaints with supervisory authorities, seek judicial remedies, and obtain compensation for damages resulting from violations of the GDPR.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Compliance with U.S. and international data protection laws and regulations could require us to take on more onerous obligations in our contracts, restrict our ability to collect, use and disclose data, or in some cases, impact our ability to operate in certain jurisdictions. Failure to comply with these laws and regulations could result in government enforcement actions, which could include civil, criminal and administrative penalties, private litigation, and/or adverse publicity and could negatively affect our operating results and business. Moreover, clinical trial subjects, employees and other individuals about whom we or our potential collaborators obtain personal information, as well as the providers who share this information with us, may limit our ability to collect, use and disclose the information. Claims that we have violated individuals&#8217; privacy rights, failed to comply with data protection laws, or breached our contractual obligations, even if we are not found liable, could be expensive and time-consuming to defend and could result in adverse publicity that could harm our business.</div><div class="frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">Our current and future operations are subject to applicable fraud and abuse, transparency, government price reporting, privacy and security, and other healthcare laws. If we are unable to comply, or do not fully comply, with such laws, we could face substantial penalties.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Healthcare providers, physicians and third-party payors will play a primary role in the recommendation and prescription of any product candidates for which we obtain marketing approval. Our operations, including any arrangements with healthcare providers, physicians, third-party payors and customers may expose us to broadly applicable fraud and abuse and other healthcare laws that may affect the business or financial arrangements and relationships through which we would market, sell and distribute our products. The healthcare laws that may affect our ability to operate include, but are not limited to:</div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">The federal Anti-Kickback Statute, which prohibits any person or entity from, among other things, knowingly and willfully soliciting, receiving, offering or paying any remuneration, directly or indirectly, overtly or covertly, in cash or in kind, to induce or reward either the referral of an individual for, or the purchase, order or recommendation of an item or service reimbursable, in whole or in part, under a federal healthcare program, such as the Medicare and Medicaid programs. The term &#8220;remuneration&#8221; has been broadly interpreted to include anything of value. The federal Anti-Kickback Statute has also been interpreted to apply to arrangements between pharmaceutical manufacturers on the one hand and prescribers, purchasers, and formulary managers on the other hand. There are a number of statutory exceptions and regulatory safe harbors protecting some common activities from prosecution, but the exceptions and safe harbors are drawn narrowly and require strict compliance in order to offer protection.</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">Federal civil and criminal false claims laws, such as the False Claims Act (&#8220;FCA&#8221;), which can be enforced by private citizens through civil qui tam actions, and civil monetary penalty laws prohibit individuals or entities from, among other things, knowingly presenting, or causing to be presented, false, fictitious or fraudulent claims for payment of federal funds, and knowingly making, using or causing to be made or used a false record or statement material to a false or fraudulent claim to avoid, decrease or conceal an obligation to pay money to the federal government. For example, pharmaceutical companies have been prosecuted under the FCA in connection with their alleged off-label promotion of drugs, purportedly concealing price concessions in the pricing information submitted to the government for government price reporting purposes, and allegedly providing free product to customers with the expectation that the customers would bill federal healthcare programs for the product. In addition, a claim including items or services resulting from a violation of the federal </div></td></tr></table></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 36pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">61<br></div></div></div>
<!--End Page 65-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 66-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 540pt;"><a name="nt10014672x1_drs_104-risk_pg49"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="block-frill" style="width: 540pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: Arial, Helvetica, sans-serif; font-size: 9pt; font-weight: bold; margin-top: 6pt; text-align: center;">Confidential Treatment Requested by ADC Therapeutics SA Pursuant to 17 C.F.R. &#167; 200.83<br></div></div><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 36pt;"><div class="bl" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 40pt; text-align: left;">Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the FCA. As a result of a modification made by the Fraud Enforcement and Recovery Act of 2009, a&#160;claim includes &#8220;any request or demand&#8221; for money or property presented to the U.S. government. In addition, manufacturers can be held liable under the FCA even when they do not submit claims directly to government payors if they are deemed to &#8220;cause&#8221; the submission of false or fraudulent claims.</div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">HIPAA, among other things, imposes criminal liability for executing or attempting to execute a scheme to defraud any healthcare benefit program, including private third-party payors, knowingly and willfully embezzling or stealing from a healthcare benefit program, willfully obstructing a criminal investigation of a healthcare offense, and creates federal criminal laws that prohibit knowingly and willfully falsifying, concealing or covering up a material fact or making any materially false, fictitious or fraudulent statement or representation, or making or using any false writing or document knowing the same to contain any materially false, fictitious or fraudulent statement or entry in connection with the delivery of or payment for healthcare benefits, items or services.</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">HIPAA, as amended by HITECH, and their implementing regulations, which impose privacy, security and breach reporting obligations with respect to individually identifiable health information upon entities subject to the law, such as health plans, healthcare clearinghouses and certain healthcare providers, known as covered entities, and their respective business associates that perform services for them that involve individually identifiable health information. HITECH also created new tiers of civil monetary penalties, amended HIPAA to make civil and criminal penalties directly applicable to business associates, and gave state attorneys general new authority to file civil actions for damages or injunctions in U.S. federal courts to enforce HIPAA laws and seek attorneys&#8217; fees and costs associated with pursuing federal civil actions.</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">Federal and state consumer protection and unfair competition laws, which broadly regulate marketplace activities and activities that potentially harm consumers.</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">The federal transparency requirements under the Physician Payments Sunshine Act, created under the Health Care Reform Act, which requires, among other things, certain manufacturers of drugs, devices, biologics and medical supplies reimbursed under Medicare, Medicaid, or the Children&#8217;s Health Insurance Program to report annually to CMS information related to payments and other transfers of value provided to physicians, as defined by such law, and teaching hospitals and physician ownership and investment interests, including such ownership and investment interests held by a physician&#8217;s immediate family members.</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">State and foreign laws that are analogous to each of the above federal laws, such as anti-kickback and false claims laws, that may impose similar or more prohibitive restrictions, and may apply to items or services reimbursed by non-governmental third-party payors, including private insurers.</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">State and foreign laws that require pharmaceutical companies to implement compliance programs, comply with the pharmaceutical industry&#8217;s voluntary compliance guidelines and the relevant compliance guidance promulgated by the federal government, or to track and report gifts, compensation and other remuneration provided to physicians and other healthcare providers; state laws that require the reporting of marketing expenditures or drug pricing, including information pertaining to and justifying price increases; state and local laws that require the registration of pharmaceutical sales representatives; state laws that prohibit various marketing-related activities, such as the provision of certain kinds of gifts or meals; state laws that require the posting of information relating to clinical trials and their outcomes; and other federal, state and foreign laws that govern the privacy and security of health information or personally identifiable information in certain circumstances, including state health information privacy and data breach notification laws which govern the collection, use, disclosure, and protection of health-related and other personal information, many of which differ from each other in significant ways and often are not pre-empted by HIPAA, thus requiring additional compliance efforts.</div></td></tr></table><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">We have entered into consulting and scientific advisory board arrangements with physicians and other healthcare providers, including some who could influence the use of our drug candidates, if approved. Because of the complex and far-reaching nature of these laws, regulatory agencies may view these transactions as prohibited arrangements that must be restructured, or discontinued, or for which we could be subject to other significant penalties. We could be adversely affected if regulatory agencies interpret our financial relationships with providers who may influence the ordering and use of our drug candidates, if approved, to be in violation of applicable laws.</div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 36pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">62<br></div></div></div>
<!--End Page 66-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 67-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 540pt;"><a name="nt10014672x1_drs_104-risk_pg50"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="block-frill" style="width: 540pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: Arial, Helvetica, sans-serif; font-size: 9pt; font-weight: bold; margin-top: 6pt; text-align: center;">Confidential Treatment Requested by ADC Therapeutics SA Pursuant to 17 C.F.R. &#167; 200.83<br></div></div><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 36pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Ensuring that our business arrangements with third parties comply with applicable healthcare laws and regulations will likely be costly. It is possible that governmental authorities will conclude that our business practices do not comply with current or future statutes, regulations, agency guidance or case law involving applicable fraud and abuse or other healthcare laws. If our operations are found to be in violation of any of these laws or any other current or future healthcare laws that may apply to us, we may be subject to significant civil, criminal and administrative penalties, damages, fines, disgorgement, imprisonment, exclusion from government funded healthcare programs, such as Medicare and Medicaid, contractual damages, reputational harm, diminished profits and future earnings, additional reporting obligations and oversight if we become subject to a corporate integrity agreement or other agreement to resolve allegations of non-compliance with these laws, and the curtailment or restructuring of our operations, any of which could substantially disrupt our operations. Although effective compliance programs can mitigate the risk of investigation and prosecution for violations of these laws, these risks cannot be entirely eliminated. Any action against us for an alleged or suspected violation could cause us to incur significant legal expenses and could divert our management&#8217;s attention from the operation of our business, even if our defense is successful. In addition, if any of the physicians or other healthcare providers or entities with whom we expect to do business is found not to be in compliance with applicable laws, they may be subject to significant criminal, civil or administrative sanctions, including exclusions from government funded healthcare programs.</div><div class="frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 20pt; margin-left: 0pt; text-align: left;">Our employees, agents, contractors or collaborators may engage in misconduct or other improper activities.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">We cannot ensure that our compliance controls, policies and procedures will in every instance protect us from acts committed by our employees, agents, contractors or collaborators that would violate the laws or regulations of the jurisdictions in which we operate, including, without limitation, healthcare, employment, foreign corrupt practices, environmental, competition, and patient privacy and other privacy laws and regulations. Misconduct by these parties could include intentional failures to comply with FDA, EMA or other applicable regulations, provide accurate information to the FDA, EMA and comparable regulatory authorities in other jurisdictions, comply with healthcare fraud and abuse laws and regulations in the United States and abroad, report financial information or data accurately or disclose unauthorized activities to us.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Such misconduct also could involve the improper use of information obtained in the course of clinical trials or interactions with the FDA, EMA or comparable regulatory authorities in other jurisdictions. If we obtain FDA approval of any of our product candidates and begin commercializing those products in the United States, our potential exposure under these laws will increase significantly, and our costs associated with compliance with these laws are likely to increase. Such improper actions could subject us to civil or criminal investigations, and monetary and injunctive penalties, and could adversely impact our ability to conduct business, operating results and reputation.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">In addition, we are subject to the Foreign Corrupt Practices Act (&#8220;FCPA&#8221;) and similar anti-bribery or anti-corruption laws, regulations or rules of other countries in which we operate, including the UK Bribery Act. The FCPA generally prohibits offering, promising, giving, or authorizing others to give anything of value, either directly or indirectly, to a non-U.S. government official in order to influence official action, or otherwise obtain or retain business. The FCPA also requires public companies to make and keep books and records that accurately and fairly reflect the transactions of the corporation and to devise and maintain an adequate system of internal accounting controls. Our business is heavily regulated and therefore involves significant interaction with public officials, including officials of non-U.S. governments. Additionally, in many other countries, the healthcare providers who prescribe pharmaceuticals are employed by their government, and the purchasers of pharmaceuticals are government entities; therefore, our dealings with these prescribers and purchasers are subject to regulation under the FCPA. There is no certainty that all of our employees, agents, contractors, or collaborators, or those of our affiliates, will comply with all applicable laws and regulations, particularly given the high level of complexity of these laws. We have provisions in our Code of Business Conduct and Ethics, an anti-corruption policy and certain controls and procedures in place that are designed to mitigate the risk of non-compliance with anti-corruption and anti-bribery laws. However, it is not always possible to identify and deter employee misconduct, and the precautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from government investigations or other actions stemming from a failure to comply with these laws or regulations. Violations of these laws and regulations could result in, among other things, significant administrative, civil and criminal fines and sanctions against us, our officers, or our employees, the closing down of our facilities, exclusion from participation in </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 36pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">63<br></div></div></div>
<!--End Page 67-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 68-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 540pt;"><a name="nt10014672x1_drs_104-risk_pg51"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="block-frill" style="width: 540pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: Arial, Helvetica, sans-serif; font-size: 9pt; font-weight: bold; margin-top: 6pt; text-align: center;">Confidential Treatment Requested by ADC Therapeutics SA Pursuant to 17 C.F.R. &#167; 200.83<br></div></div><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 36pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">federal healthcare programs including Medicare and Medicaid, implementation of compliance programs, integrity oversight and reporting obligations, and prohibitions on the conduct of our business. Any such violations could include prohibitions on our ability to offer our products in one or more countries and could materially damage our reputation, our brand, our international expansion efforts, our ability to attract and retain employees, and our business, prospects, operating results and financial condition.</div><div class="frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">We and our third-party contractors must comply with environmental, health and safety laws and regulations. A failure to comply with these laws and regulations could expose us to significant costs or liabilities.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">We and our third-party contractors are subject to numerous environmental, health and safety laws and regulations, including those governing laboratory procedures and the use, generation, manufacture, distribution, storage, handling, treatment, remediation and disposal of hazardous materials and wastes. Hazardous chemicals, including flammable and biological materials, are involved in certain aspects of our business, and we cannot eliminate the risk of injury or contamination from the use, generation, manufacture, distribution, storage, handling, treatment or disposal of hazardous materials and wastes. In particular, our product candidates use PBDs, which are highly potent cytotoxins that require special handling by our and our contractors&#8217; staff. In the event of contamination or injury, or failure to comply with environmental, health and safety laws and regulations, we could be held liable for any resulting damages, fines and penalties associated with such liability could exceed our assets and resources.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Although we maintain workers&#8217; compensation insurance to cover us for costs and expenses we may incur due to injuries to our employees resulting from the use of biological or hazardous materials or wastes, this insurance may not provide adequate coverage against potential liabilities. We do not maintain insurance for environmental liability or toxic tort claims that may be asserted against us in connection with our storage or disposal of biological, hazardous or radioactive materials.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Environmental, health and safety laws and regulations are becoming increasingly more stringent. We may incur substantial costs in order to comply with current or future environmental, health and safety laws and regulations. These current or future laws and regulations may impair our research, development or production efforts. Our failure to comply with these laws and regulations also may result in substantial fines, penalties or other sanctions.</div><div class="frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">Product liability lawsuits could cause us to incur substantial liabilities and to limit development and/or commercialization of any products that we may develop.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">We face an inherent risk of product liability as a result of the clinical testing of our product candidates in human clinical trials and will face an even greater risk if we commercialize any products that we successfully develop. Any such product liability claims may include allegations of defects in manufacturing, defects in design, a failure to warn of dangers inherent in the product, negligence, strict liability and a breach of warranties. In particular, we believe that our highly potent PBD-based ADCs may increase our potential exposure to product liability claims. If we cannot successfully defend ourselves against product liability claims, we may incur substantial liabilities or be required to limit commercialization of our product candidates. Even a successful defense would require significant financial and management resources. Regardless of the merits or eventual outcome, liability claims may result in:</div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">decreased demand for our product candidates or products that we may develop;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">injury to our reputation and significant negative media attention;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">withdrawal of clinical trial sites and/or study participants;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">significant costs to defend the related litigations;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">a diversion of management&#8217;s time and our resources to pursue our business strategy;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">substantial monetary awards to study participants or patients;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">product recalls, withdrawals or labeling, marketing or promotional restrictions;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">loss of revenue;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the inability to commercialize our product candidates that we may develop; and</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">a decline in the price of our common shares.</div></td></tr></table></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 36pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">64<br></div></div></div>
<!--End Page 68-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 69-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 540pt;"><a name="nt10014672x1_drs_104-risk_pg52"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="block-frill" style="width: 540pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: Arial, Helvetica, sans-serif; font-size: 9pt; font-weight: bold; margin-top: 6pt; text-align: center;">Confidential Treatment Requested by ADC Therapeutics SA Pursuant to 17 C.F.R. &#167; 200.83<br></div></div><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 36pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Failure to obtain and retain sufficient product liability insurance at an acceptable cost to protect against potential product liability claims could prevent or inhibit the commercialization of products we develop. We currently carry product liability insurance covering our clinical trials in the amount of $10&#160;million in the aggregate. Although we maintain such insurance, any claim that may be brought against us could result in a court judgment or settlement in an amount that is not covered, in whole or in part, by our insurance or that is in excess of the limits of our insurance coverage. Our insurance policies also have various exclusions, and we may be subject to a product liability claim for which we have no coverage. In such instance, we may have to pay any amounts awarded by a court or negotiated in a settlement that exceed our coverage limitations or that are not covered by our insurance, and we may not have, or be able to obtain, sufficient capital to pay such amounts. If we are unable to obtain or maintain sufficient insurance coverage at an acceptable cost or to otherwise protect against potential product liability claims, it could prevent or inhibit the development and commercial production and sale of our product candidates, which could adversely affect our business, financial condition, results of operations and prospects.</div><div class="frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">If we engage in acquisitions and/or commercial collaborations in the future, we will incur a variety of costs and we may never realize the anticipated benefits of such acquisitions.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">We may acquire technologies and assets, form strategic alliances or create joint ventures with third parties that we believe will complement or augment our existing business. Such efforts may never result in a transaction, and any future growth through acquisition or in-licensing will depend upon the availability of suitable products, product candidates, research programs or companies for acquisition or in-licensing on acceptable prices, terms and conditions. Even if appropriate opportunities are available, we may not be able to acquire rights to them on acceptable terms, or at all. The competition to acquire or in-license rights to promising products, product candidates, research programs and companies is fierce, and many of our competitors are large, multinational pharmaceutical and biotechnology companies with considerably more financial, development and commercialization resources and personnel than we have. In order to compete successfully in the current business climate, we may have to pay higher prices for assets than may have been paid historically, which may make it more difficult for us to realize an adequate return on any acquisition.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Even if we are able to successfully identify and acquire or in-license new products, product candidates, research programs or companies, we may not be able to successfully manage the risks associated with integrating any products, product candidates, research programs or companies into our business or the risks arising from anticipated and unanticipated problems in connection with an acquisition or in-licensing. Further, while we seek to mitigate risks and liabilities of potential acquisitions through, among other things, due diligence, there may be risks and liabilities that such due diligence efforts fail to discover, that are not disclosed to us or that we inadequately assess. In any event, we may not be able to realize the anticipated benefits of any acquisition or in-licensing for a variety of reasons, including the possibility that a product candidate fails to advance to clinical development, proves not to be safe or effective in clinical trials, or fails to reach its forecasted commercial potential, or that the integration of a product, product candidate, research program or company gives rise to unforeseen difficulties and expenditures. Any failure in identifying and managing these risks and uncertainties would have a material adverse effect on our business, results of operations, financial condition and prospects.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">In addition, acquisitions create other uncertainties and risks, particularly when the acquisition takes the form of a merger or other business consolidation. We may encounter unexpected difficulties, or incur unexpected costs, in connection with transition activities and integration efforts, which include:</div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">high acquisition costs;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the need to incur substantial debt or engage in dilutive issuances of equity securities to pay for acquisitions;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the potential disruption of our historical business and our activities under our collaboration agreements;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the strain on, and need to expand, our existing operational, technical, financial and administrative infrastructure;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">our lack of experience in late-stage product development and commercialization;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the difficulties in assimilating employees and corporate cultures;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the difficulties in hiring qualified personnel and establishing necessary development and/or commercialization capabilities;</div></td></tr></table></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 36pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">65<br></div></div></div>
<!--End Page 69-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 70-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 540pt;"><a name="nt10014672x1_drs_104-risk_pg53"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="block-frill" style="width: 540pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: Arial, Helvetica, sans-serif; font-size: 9pt; font-weight: bold; margin-top: 6pt; text-align: center;">Confidential Treatment Requested by ADC Therapeutics SA Pursuant to 17 C.F.R. &#167; 200.83<br></div></div><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 36pt;"><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6.75pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the failure to retain key management and other personnel;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the challenges in controlling additional costs and expenses in connection with and as a result of the acquisition;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the need to write down assets or recognize impairment charges;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the diversion of our management&#8217;s attention to integration of operations and corporate and administrative infrastructures; and</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">any unanticipated liabilities for activities of or related to the acquired business or its operations, products or product candidates.</div></td></tr></table><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">If we fail to integrate or otherwise manage an acquired business successfully and in a timely manner, resulting operating inefficiencies could increase our costs more than we planned, could negatively impact the market price of our common shares and could otherwise distract us from execution of our strategy.</div><div class="frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 20.5pt; margin-left: 0pt; text-align: left;">Our internal computer systems, or those of our partners, third-party CROs or other contractors or consultants, may fail or suffer security incidents, which could result in a material disruption of our product development programs and significant monetary losses.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Despite the implementation of security measures, our internal computer systems and those of our current or future partners, third-party CROs and other contractors and consultants have been subject to attacks by, and may be vulnerable to damage from, various methods, including cybersecurity attacks, breaches, intentional or accidental mistakes or errors, or other technological failures which can include, among other things, computer viruses, malicious codes, employee theft or misuse, unauthorized copying of our website or its content, unauthorized access attempts including third parties gaining access to systems using stolen or inferred credentials, denial-of-service attacks, phishing attempts, service disruptions, natural disasters, fire, terrorism, war and telecommunication and electrical failures. As the cyber-threat landscape evolves, these attacks are growing in frequency, sophistication and intensity, and are becoming increasingly difficult to detect. Such attacks could include the use of keystroke loggers or other harmful and virulent malware, including ransomware or other denials of service, and can be deployed through malicious websites, the use of social engineering and/or other means. If a failure, accident or security breach were to occur and cause interruptions in our, our partners&#8217; or our CROs&#8217; operations, it could result in a misappropriation of confidential information, including our intellectual property or financial information, a material disruption of our programs and/or significant monetary losses. For example, the loss of clinical trial or CMC data for our product candidates could result in delays in our regulatory approval efforts and significantly increase our costs to recover or reproduce the data. In addition, because of our approach to running multiple clinical trials in parallel, any breach of our computer systems may result in a loss of data or compromised data integrity across many of our programs in many stages of development. Any such breach, loss or compromise of clinical trial participant personal data may also subject us to civil fines and penalties, including under the GDPR and relevant member state law in the European Union or the CCPA, HIPAA and other relevant state and federal privacy laws in the United States. Moreover, because we maintain sensitive company data on our computer networks, including our intellectual property and proprietary business information, any such security breach may compromise information stored on our networks and may result in significant data losses or theft of our intellectual property or proprietary business information. We currently carry cybersecurity liability insurance in the amount of CHF 5&#160;million in the aggregate. However, our current cybersecurity liability insurance, and any such insurance that we may obtain in the future, may not cover the damages we would sustain based on any breach of our computer security protocols or other cybersecurity attack. To the extent that any disruption or security breach results in a loss of or damage to our data or applications or other data or applications relating to our technology or product candidates, or inappropriate disclosure of confidential or proprietary information, our reputation could be harmed and we could incur significant liabilities and the further development of our product candidates could be disrupted.</div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 36pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">66<br></div></div></div>
<!--End Page 70-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 71-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 540pt;"><a name="nt10014672x1_drs_104-risk_pg54"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="block-frill" style="width: 540pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: Arial, Helvetica, sans-serif; font-size: 9pt; font-weight: bold; margin-top: 6pt; text-align: center;">Confidential Treatment Requested by ADC Therapeutics SA Pursuant to 17 C.F.R. &#167; 200.83<br></div></div><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 36pt;"><div class="frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">Our business is subject to economic, political, regulatory and other risks associated with conducting business internationally.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Because we plan to market our products, if approved, outside of the United States, our business is subject to risks associated with conducting business internationally. In addition, we and a number of our suppliers are located outside the United States. Our future results could be harmed by a variety of factors, including:</div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">economic weakness, including inflation, or political instability in particular non-U.S. economies and markets;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 4pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">global trends towards pharmaceutical pricing;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 4pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">differing regulatory requirements for drug approvals in non-U.S. countries;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 4pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">differing reimbursement, pricing and insurance regimes;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 4pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">potentially reduced protection for, and complexities and difficulties in obtaining, maintaining, protecting and enforcing, intellectual property rights;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 4pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">difficulties in compliance with non-U.S. laws and regulations;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 4pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">changes in non-U.S. regulations and customs, tariffs and trade barriers;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 4pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">changes in non-U.S. currency exchange rates and currency controls;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 4pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">changes in a specific country&#8217;s or region&#8217;s political or economic environment;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 4pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">trade protection measures, economic sanctions and embargoes, import or export licensing requirements or other restrictive actions by U.S. or non-U.S. governments;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 4pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">negative consequences from changes in tax laws;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 4pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">compliance with tax, employment, immigration and labor laws for employees living or traveling abroad;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 4pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">workforce uncertainty in countries where labor unrest is more common than in the United States;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 4pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">difficulties associated with staffing and managing international operations, including differing labor relations;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 4pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">production shortages resulting from any events affecting raw material supply or manufacturing capabilities abroad; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 4pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">business interruptions resulting from geopolitical actions, including war and terrorism, or natural disasters including earthquakes, typhoons, floods and fires; and </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 4pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the impact of public health epidemics on employees and the global economy, such as the COVID-19 pandemic.</div></td></tr></table><div class="frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 18pt; margin-left: 0pt; text-align: left;">The United Kingdom&#8217;s withdrawal from the European Union may have a negative effect on global economic conditions, financial markets and our business.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The United Kingdom left the European Union on January 31, 2020, an event commonly referred to as &#8220;Brexit,&#8221; under the terms of a withdrawal agreement, entering into a &#8220;transition period&#8221; set to end on December 31, 2020 during which the United Kingdom will essentially be treated as a member state of the European Union and the regulatory regime will remain the same across the United Kingdom and the European Union. The UK government passed a withdrawal agreement bill that prohibits any extension to the transition period beyond the end of 2020. After the transition period, the future relationship between the United Kingdom and the European Union will be governed by any agreements negotiated during the transition period.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Brexit imposes new regulatory costs and challenges that may have a material adverse effect on us and our operations. We may face decreased chances to obtain market approval for our products in the European Union, including the possibility that the EMA will not accept data from our clinical trials conducted in the United Kingdom or will only do so if we comply with certain conditions. Conversely, since a significant proportion of the United Kingdom&#8217;s regulatory framework affecting the pharmaceutical and biotechnological industry is derived from European Union directives and regulations, Brexit could materially alter the regulatory regime with respect to our product candidates in the United Kingdom, which may increase the time and costs associated with </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 36pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">67<br></div></div></div>
<!--End Page 71-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 72-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 540pt;"><a name="nt10014672x1_drs_104-risk_pg55"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="block-frill" style="width: 540pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: Arial, Helvetica, sans-serif; font-size: 9pt; font-weight: bold; margin-top: 6pt; text-align: center;">Confidential Treatment Requested by ADC Therapeutics SA Pursuant to 17 C.F.R. &#167; 200.83<br></div></div><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 36pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">obtaining regulatory approval from the relevant authorities. It may also be time-consuming and expensive for us to alter our internal operations in order to comply with new regulations. Altered regulations could also add time and expense to the process by which our product candidates receive regulatory approval in the United Kingdom and the European Union.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">In addition, following the Brexit vote, the European Union moved the EMA&#8217;s headquarters from the United Kingdom to the Netherlands. This transition may cause disruption in the administrative and medical scientific links between the EMA and the UK Medicines and Healthcare products Regulatory Agency, including delays in granting clinical trial authorization or marketing authorization, disruption of import and export of active substance and other components of new drug formulations and disruption of the supply chain for clinical trial product and final authorized formulations. The cumulative effects of the disruption to the regulatory framework may add considerably to the development lead time to marketing authorization and commercialization of products in the European Union and/or the United Kingdom.</div><div class="frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">Our business could be adversely affected by the effects of health epidemics, including the COVID-19 pandemic, in regions where we or third parties on which we rely have significant manufacturing facilities, concentrations of clinical trial sites or other business operations.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Our business could be adversely affected by health epidemics. For example, on March 11, 2020, the World Health Organization declared the outbreak of COVID-19 caused by a novel strain of coronavirus as a pandemic. Since then, COVID-19 has continued to spread, impacting the economies of most countries around the world. Our operations, similar to those of other life sciences companies, have been impacted by the COVID-19 pandemic. The outbreak has resulted in governments implementing numerous measures to contain the COVID-19 pandemic, which are subject to change and the respective government authorities may tighten the restrictions at any time.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The outbreak has caused us to modify our business practices including restricting employee travel, developing social distancing plans for our employees and cancelling physical participation in meetings, events and conferences, and we may take further actions as may be required by government authorities or as we determine are in the best interests of our employees and business partners. Such modifications may negatively impact productivity, divert resources away from product development, disrupt our business operations and delay and disrupt our clinical trials and preclinical programs.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">In addition, the outbreak and the resulting government actions may adversely impact our planned and ongoing clinical trials. Clinical site initiation, including difficulties in recruiting clinical site investigators and clinical site staff, and patient enrollment may be delayed due to prioritization of hospital resources toward the COVID-19 pandemic. For example, we have experienced delays in patient enrollment in our Phase 1/2 clinical trial of Lonca in combination with ibrutinib for the treatment of relapsed or refractory DLBCL and MCL and our Phase 1b clinical trial of Cami for the treatment of selected advanced solid tumors. Some patients may not be willing and/or able to comply with clinical trial protocols due to the COVID-19 pandemic, particularly if quarantines impede patient movement or interrupt healthcare services. Similarly, our ability to recruit and retain patients and principal investigators and site staff who, as healthcare providers, may have heightened exposure to COVID-19 may be impeded, which would adversely impact our clinical trial operations. The diversion of healthcare resources away from the conduct of clinical trials to focus on pandemic concerns, including the attention of physicians serving as our clinical trial investigators and hospitals serving as our clinical trial sites, diversion of hospitals and medical centers or sites serving as our clinical trial sites and hospital or other staff supporting the conduct of our clinical trials may significantly disrupt our research activities. As a result, the expected timeline for data readouts of our clinical trials and certain regulatory filings may be negatively impacted, which would adversely affect and delay our ability to obtain regulatory approvals for our product candidates, increase our operating expenses and have a material adverse effect on our financial condition. Furthermore, we could face the interruption of key clinical activities such as trial site data monitoring, which may impact the integrity of clinical data. As a result of disruptions caused by the COVID-19 pandemic, we may require additional capital to continue our research activities, which we may be unable to secure on favorable terms, if at all.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The response to the COVID-19 pandemic may redirect resources with respect to regulatory matters and intellectual property matters in a way that would adversely impact our ability to progress regulatory approvals and protect our intellectual property. In addition, we may face impediments to regulatory meetings and approvals due to measures intended to limit in-person interactions. For example, certain regulatory authorities have </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 36pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">68<br></div></div></div>
<!--End Page 72-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 73-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 540pt;"><a name="nt10014672x1_drs_104-risk_pg56"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="block-frill" style="width: 540pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: Arial, Helvetica, sans-serif; font-size: 9pt; font-weight: bold; margin-top: 6pt; text-align: center;">Confidential Treatment Requested by ADC Therapeutics SA Pursuant to 17 C.F.R. &#167; 200.83<br></div></div><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 36pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">postponed inspections of manufacturing facilities and products and are conducting only teleconference meetings. If global health concerns continue to prevent regulatory authorities from conducting their regular inspections, reviews or other regulatory activities, it could significantly impact the ability of regulatory authorities to timely review and process our regulatory submissions, including our planned BLA submission to the FDA in the second half of 2020 for Lonca for the treatment of relapsed or refractory DLBCL, which could have a material adverse effect on our business.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The outbreak and the resulting government actions may also adversely impact the operations of our CROs, CMOs, suppliers and other business partners due to staffing shortages, production slowdowns or stoppages and disruptions in delivery systems. For example, we have experienced delays in patient enrollment in our Phase 1b clinical trial of Cami for the treatment of selected advanced solid tumors. Furthermore, we may experience longer lead times in procuring raw materials or components necessary to manufacture our product candidates, and our CMOs may be unable to manufacture product candidates in sufficient quantities that meet our standards.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">As the COVID-19 pandemic continues to evolve, we believe that the extent of its impact to our operations, operating results, cash flows, liquidity and financial condition will be primarily driven by the severity and duration of the pandemic, the pandemic&#8217;s impact on the U.S. and global economies and the timing, scope and effectiveness of national and local governmental responses to the pandemic, especially in areas where the conditions have recently worsened. Those primary drivers are beyond our knowledge and control, and as a result, at this time, the COVID-19 pandemic&#8217;s ultimate impact on our results of operations, cash flows and financial position cannot be reasonably predicted. Any prolonged disruption of our clinical trials, suppliers or contract manufacturers, closures of facilities, such as clinical trial sites, would delay regulatory review and the commercialization of our product candidates, if approved. As a result, all anticipated milestones set forth in this prospectus are subject to further future adjustment based on the impact of the COVID-19 pandemic. There are no comparable recent events that provide guidance as to the likely effect of the COVID-19 pandemic, and, as a result, the ultimate impact of the outbreak is highly uncertain and subject to change. However, the COVID-19 pandemic could have a material adverse effect on our business, results of operations, financial condition and prospects and heighten many of our known risks described in this &#8220;Risk Factors&#8221; section.</div><div class="frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 18pt; margin-left: 0pt; text-align: left;">We or the third parties upon whom we depend may be adversely affected by natural disasters, medical epidemics and other natural or man-made accidents or incidents, and our business continuity and disaster recovery plans may not adequately protect us from a serious disaster.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Any unplanned event, such as a flood, fire, explosion, earthquake, extreme weather condition, medical epidemic, power shortage, telecommunication failure or other natural or man-made accidents or incidents that result in us being unable to fully use our facilities, or the manufacturing facilities of our third-party contract manufacturers, may have a material and adverse effect on our ability to operate our business, particularly on a daily basis, and have significant negative consequences on our financial and operating conditions. Loss of access to these facilities may result in increased costs, delays in the development of our product candidates or the interruption of our business operations for a substantial period of time.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The disaster recovery and business continuity plans we have in place may prove inadequate in the event of a serious disaster or similar event. As part of our risk management policy, we maintain insurance coverage at levels that we believe are appropriate for our business. However, in the event of an accident or incident at these facilities, there can be no assurance that the amounts of insurance will be sufficient to satisfy any damages and losses. If our facilities, or the manufacturing facilities of our third-party contract manufacturers, are unable to operate because of an accident or incident or for any other reason, even for a short period of time, any or all of our research and development programs and commercialization efforts may be harmed. </div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 20pt; margin-left: 0pt; text-align: left;">Risks Related to Our Common Shares and This Offering</div><div class="frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 7pt; margin-left: 0pt; text-align: left;">The market price of our common shares may be volatile and may fluctuate due to factors beyond our control.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The public offering price for our common shares will be determined by negotiations between us and the representatives of the underwriters and may not be indicative of prices that will prevail in the trading market. The market price of shares of our common shares could be subject to wide fluctuations in response to many risk factors listed in this &#8220;Risk Factors&#8221; section, and others beyond our control, including:</div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">results and timing of preclinical studies and clinical trials of our product candidates;</div></td></tr></table></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 36pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">69<br></div></div></div>
<!--End Page 73-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 74-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 540pt;"><a name="nt10014672x1_drs_104-risk_pg57"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="block-frill" style="width: 540pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: Arial, Helvetica, sans-serif; font-size: 9pt; font-weight: bold; margin-top: 6pt; text-align: center;">Confidential Treatment Requested by ADC Therapeutics SA Pursuant to 17 C.F.R. &#167; 200.83<br></div></div><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 36pt;"><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6.75pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">results of clinical trials of our competitors&#8217; products;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">public concern relating to the commercial value or safety of any of our product candidates;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">our inability to adequately protect our proprietary rights, including patents, trademarks and trade secrets;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">our inability to raise additional capital and the terms on which we raise it;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">commencement or termination of any strategic collaboration or licensing arrangement;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">regulatory developments, including actions with respect to our products or our competitors&#8217; products;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">actual or anticipated fluctuations in our financial condition and operating results;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">publication of research reports by securities analysts about us or our competitors or our industry;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">our failure or the failure of our competitors to meet analysts&#8217; projections or guidance that we or our competitors may give to the market;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">additions and departures of key personnel;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">strategic decisions by us or our competitors, such as acquisitions, divestitures, spin-offs, joint ventures, strategic investments or changes in business strategy;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the passage of legislation or other regulatory developments affecting us or our industry, including changes in the structure of healthcare payment systems;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">fluctuations in the valuation of companies perceived by investors to be comparable to us;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">sales of our common shares by us, our insiders or our other shareholders;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">speculation in the press or investment community;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">announcement or expectation of additional financing efforts; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">any default under the Facility Agreement or the timing of any conversion of the convertible notes issued thereunder into common shares;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">changes in market conditions for biopharmaceutical stocks; and</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">changes in general market and economic conditions.</div></td></tr></table><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">In addition, the stock market has historically experienced significant volatility, particularly with respect to pharmaceutical, biotechnology and other life sciences company stocks. The volatility of pharmaceutical, biotechnology and other life sciences company stocks often does not relate to the operating performance of the companies represented by the stock. As a result of this volatility, our investors may not be able to sell their common shares at or above the public offering price. As we operate in a single industry, we are especially vulnerable to these factors to the extent that they affect our industry or our product candidates, or to a lesser extent, our markets. In the past, securities class action litigation has often been initiated against companies following periods of volatility in their stock price. This risk is especially relevant for biotechnology companies, which have experienced significant stock price volatility in recent years. Securities litigation could result in substantial costs and divert our management&#8217;s attention and resources, and could also require us to make substantial payments to satisfy judgments or to settle litigation.</div><div class="frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">Our operating results may fluctuate significantly or may fall below the expectations of investors or securities analysts, each of which may cause the price of our common shares to fluctuate or decline.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 7pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">We expect our operating results to be subject to fluctuations by numerous factors, including: </div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">if any of our product candidates receives regulatory approval, the timing and the terms of such approval and market acceptance and demand for such product candidates;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">variations in the level of expense related to the ongoing development of our product candidates or research pipeline;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">results of clinical trials, or the addition or termination of clinical trials or funding support by us, or existing or future collaborators or licensing partners;</div></td></tr></table></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 36pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">70<br></div></div></div>
<!--End Page 74-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 75-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 540pt;"><a name="nt10014672x1_drs_104-risk_pg58"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="block-frill" style="width: 540pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: Arial, Helvetica, sans-serif; font-size: 9pt; font-weight: bold; margin-top: 6pt; text-align: center;">Confidential Treatment Requested by ADC Therapeutics SA Pursuant to 17 C.F.R. &#167; 200.83<br></div></div><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 36pt;"><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6.75pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">our execution of any additional collaboration, licensing or similar arrangements, and the timing of payments we may make or receive under existing or future arrangements, or the termination or modification of any such existing or future arrangements;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">developments or disputes concerning patents or other proprietary rights, including patents, litigation matters and our ability to obtain patent protection for our products;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">any intellectual property infringement lawsuit or any opposition, interference, cancellation or other intellectual-property-related proceeding in which we may become involved;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">additions and departures of key personnel;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">strategic decisions by us or our competitors, such as acquisitions, divestitures, spin-offs, joint ventures, strategic investments or changes in business strategy; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">fluctuations in the price of our common shares; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">regulatory developments affecting our product candidates or those of our competitors; and</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">changes in general market and economic conditions.</div></td></tr></table><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">If our operating results fall below the expectations of investors or securities analysts, the price of our common shares could decline substantially. Furthermore, any fluctuations in our operating results may, in turn, cause the price of our common shares to fluctuate substantially. We believe that quarterly comparisons of our financial results are not necessarily meaningful and should not be relied upon as an indication of our future performance.</div><div class="frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 20.5pt; margin-left: 0pt; text-align: left;">Our directors and executive officers and their affiliates will continue to be able to exercise significant influence over us, and their interests may conflict with the interests of other shareholders.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Following completion of this offering, our directors and executive officers and their affiliates are expected to own approximately &#8199;&#8199;&#8199;% of our common shares (or approximately &#8199;&#8199;&#8199;% if the underwriters exercise their option to purchase additional common shares in full), excluding any common shares purchased by any such holders in this offering. As a result, our directors and executive officers and their affiliates, if acting together, would be able to influence or control matters requiring approval by our shareholders, including the election of directors and the approval of certain types of capital increases, statutory mergers or other extraordinary transactions.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">In addition, our articles of association contain a provision stating that if an individual or legal entity acquires common shares and, as a result, directly or indirectly, has voting rights with respect to more than 15% of the registered share capital recorded in the commercial register, the registered shares exceeding the limit of 15% shall be entered in the share register as shares without voting rights. However, shareholders who held more than 15% prior to our initial public offering remain registered with voting rights for such shares. This may, in certain instances, allow our principal shareholders to exercise more influence over us than our other shareholders despite holding the same amount of common shares.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">To the extent that the interests of our principal shareholders may differ from the interests of our other shareholders, the latter may be disadvantaged by any action that our principal shareholders may seek to pursue. In addition, the concentration of ownership may have the effect of delaying, preventing or deterring a change of control of us, could deprive our shareholders of an opportunity to receive a premium for their common shares as part of a sale of our company and might ultimately affect the market price of our common shares. See &#8220;Principal Shareholders.&#8221;</div><div class="frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 20pt; margin-left: 0pt; text-align: left;">Future sales, or the possibility of future sales, of a substantial number of our common shares could adversely affect the price of our common shares.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Future sales of a substantial number of our common shares, or the perception that such sales will occur, could cause a decline in the market price of our common shares. Following the completion of this offering, we will have &#8195;&#8195;&#8195; common shares outstanding based on the number of common shares outstanding as of June 30, 2020. This includes the common shares in this offering, which may be resold in the public market immediately upon the closing of this offering without restriction, unless purchased by our affiliates. </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 36pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">71<br></div></div></div>
<!--End Page 75-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 76-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 540pt;"><a name="nt10014672x1_drs_104-risk_pg59"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="block-frill" style="width: 540pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: Arial, Helvetica, sans-serif; font-size: 9pt; font-weight: bold; margin-top: 6pt; text-align: center;">Confidential Treatment Requested by ADC Therapeutics SA Pursuant to 17 C.F.R. &#167; 200.83<br></div></div><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 36pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">In connection with our initial public offering, all of our directors and executive officers and the holders of substantially all of our share capital agreed, subject to limited exceptions, not to offer, pledge, announce the intention to sell, sell, contract to sell, sell any option or contract to purchase, purchase any option or contract to sell, grant any option, right or warrant to purchase or otherwise dispose of, directly or indirectly, or enter into any swap or other agreement that transfers, in whole or in part, any of the economic consequences of ownership of the common shares or such other securities for a period of 180 days after the date of our initial public offering without the prior written consent of Morgan Stanley &amp; Co. LLC and BofA Securities, Inc. Entities affiliated with Auven Therapeutics GP Ltd. have also agreed that they will not transfer, distribute or dispose of any common shares or securities convertible into common shares (other than those common shares or securities convertible into common shares for which such entity holds as nominee on behalf of equity incentive plan participants) to their partners, members, stockholders, beneficiaries or other equity holders and that they will not sell any common shares or securities convertible into common shares (other than those common shares or securities convertible into common shares for which such entity holds as nominee on behalf of equity incentive plan participants) prior to June 30, 2022 without the prior written consent of Morgan Stanley &amp; Co. LLC and BofA Securities, Inc. Morgan Stanley &amp; Co.LLC and BofA Securities, Inc. may waive the requirements of these lock-up agreements at any time in their sole discretion.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">In connection with this offering, all of our directors and executive officers and certain shareholders agreed, subject to limited exceptions, not to offer, pledge, announce the intention to sell, sell, contract to sell, sell any option or contract to purchase, purchase any option or contract to sell, grant any option, right or warrant to purchase or otherwise dispose of, directly or indirectly, or enter into any swap or other agreement that transfers, in whole or in part, any of the economic consequences of ownership of the common shares or such other securities for a period of 60 days after the date of this prospectus without the prior written consent of Morgan Stanley &amp; Co. LLC and BofA Securities, Inc. Morgan Stanley &amp; Co. LLC and BofA Securities, Inc. may waive the requirements of these lock-up agreements at any time in their sole discretion. See &#8220;Underwriters&#8221; for additional information regarding these lock-up agreements.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">After the end of such lock-up agreements or if such lock-up agreements are waived, if these shareholders sell substantial amounts of common shares in the public market or if the market perceives that such sales may occur, the market price of our common shares and our ability to raise capital through an issue of equity securities in the future could be adversely affected. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Certain of our shareholders have granted a security interest in at least some of our shares beneficially owned by them to secure certain of their debt instruments, each of which may include default provisions. In the event of a default under any such debt instruments, the secured parties may foreclose upon any and all shares pledged to them, the occurrence of which may result in the sale of substantial amounts of our common shares in the public market, which could adversely affect the market price of our common shares.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">If our outstanding senior secured convertible notes convert into common shares, or if we issue additional senior secured convertible notes in the future and such notes convert into common shares, then a substantial amount of our common shares may enter the public market, which could adversely affect the market price of our common shares. Such common shares issued or issuable upon the conversion of our outstanding senior secured convertible notes will be registered under the Securities Act pursuant to the Registration Rights Agreement, in which we granted Deerfield Partners, L.P. and Deerfield Private Design Fund IV, L.P. certain registration rights. See &#8220;Description of Description of Share Capital and Articles of Association&#8212;Registration Rights.&#8221; </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">In addition, we have registered under the Securities Act all common shares that we may issue under our 2019 Equity Incentive Plan. These common shares can be freely sold in the public market upon issuance, subject to volume limitations applicable to affiliates and the lock-up agreements described in the &#8220;Underwriters&#8221; section of this prospectus. If a large number of our common shares or securities convertible into our common shares are sold in the public market after they become eligible for sale, the sales could reduce the trading price of our common shares and impede our ability to raise future capital.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Under Swiss law, shareholders may receive certain pre-emptive rights to subscribe on a <font style="font-style: italic;">pro rata</font> basis for issuances of equity or other securities that are convertible into equity, which our board of directors has withdrawn for this offering. However, due to the laws and regulations in certain jurisdictions, shareholders in certain jurisdictions may not be able to exercise such rights, unless the company registers or otherwise qualifies the rights offering, including by complying with prospectus requirements under the laws of that jurisdiction. </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 36pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">72<br></div></div></div>
<!--End Page 76-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 77-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 540pt;"><a name="nt10014672x1_drs_104-risk_pg60"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="block-frill" style="width: 540pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: Arial, Helvetica, sans-serif; font-size: 9pt; font-weight: bold; margin-top: 6pt; text-align: center;">Confidential Treatment Requested by ADC Therapeutics SA Pursuant to 17 C.F.R. &#167; 200.83<br></div></div><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 36pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">There can be no assurance that we will take any action to register or otherwise qualify an offering of subscription rights or shares under the laws of any jurisdiction where the offering of such rights is restricted, other than the United States. If shareholders in such jurisdictions are unable to exercise their subscription rights, their ownership interest will be diluted.</div><div class="frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 16.5pt; margin-left: 0pt; text-align: left;">You will incur immediate and substantial dilution as a result of this offering.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The public offering price of our common shares is substantially higher than the as-adjusted net tangible book value per common share after the completion of this offering. Therefore, if you purchase common shares in this offering, you will pay a price per common share that substantially exceeds the as-adjusted net tangible book value per common share after this offering. To the extent options under our 2019 Equity Incentive Plan are exercised, you will incur further dilution. Based on a public offering price of $&#8194;&#8194;&#8194; per common share, which was the last reported sale price of our common shares on the NYSE on&#8195;&#8195;, 2020, you will experience immediate dilution of $&#8195;&#8195;&#8195; per common share, representing the difference between the as-adjusted net tangible book value per common share and the assumed public offering price. In addition, purchasers of common shares in this offering will have contributed approximately &#8195;&#8195;&#8195;% of the aggregate price paid by all purchasers of our common shares, but will own only approximately &#8195;&#8195;&#8195;% of our common shares outstanding after this offering.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Moreover, we issued options in the past to acquire common shares at prices significantly below the assumed public offering price. As a result of the dilution to investors purchasing shares in this offering, investors may receive significantly less than the purchase price paid in this offering, if anything, in the event of our liquidation. See&#160;&#8220;Dilution.&#8221;</div><div class="frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">Conversion of the senior secured convertible notes issued or to be issued under the Facility Agreement will dilute your ownership interest.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">On April&#160;24, 2020, we entered into the Facility Agreement with Deerfield. See &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8212;Liquidity and Capital Resources&#8212;$115.0 Million Facility Agreement.&#8221; The Facility Agreement provides for two separate disbursements of convertible loans , each subject to satisfaction of certain conditions precedent set forth in the Facility Agreement. On May&#160;19, 2020, Deerfield extended the initial disbursement to us in the amount of $65.0 million in connection with our initial public offering. The Facility Agreement provides for a subsequent disbursement in the amount of $50.0 million, which we will be required to draw down, upon receipt of regulatory approval for Lonca and satisfaction of certain other conditions. See &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8212;Liquidity and Capital Resources&#8212;$115.0 Million Facility Agreement.&#8221; Each convertible loan extended under the Facility Agreement is evidenced by a convertible note. If our outstanding senior secured convertible notes convert into common shares, or if we issue additional senior secured convertible notes in the future and such notes convert into common shares, your ownership interest will be diluted.</div><div class="frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 16.5pt; margin-left: 0pt; text-align: left;">We have broad discretion in the use of the net proceeds from this offering and may not use them effectively.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">We currently intend to use the net proceeds from this offering as described in &#8220;Use of Proceeds.&#8221; However, our board of directors and our management retains broad discretion in the application of the net proceeds from this offering and could spend the proceeds in ways that do not improve our results of operations or enhance the value of our common shares. Our failure to apply these funds effectively could result in financial losses, which could have a material adverse effect on our business, results of operations, financial condition and prospects, cause the price of our common shares to decline and delay the development of our product candidates. </div><div class="frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 16.5pt; margin-left: 0pt; text-align: left;">We have never paid dividends and do not expect to pay any dividends in the foreseeable future.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">We have not paid any cash dividends since our incorporation. Even if future operations lead to significant levels of distributable profits, we currently intend to reinvest any earnings in our business and do not anticipate declaring or paying any cash dividends until we have an established revenue stream to support continuing dividends. In&#160;addition, any proposal for the payment of future dividends will be at the discretion of our board of directors after taking into account various factors including our business prospects, liquidity requirements, financial performance and new product development. Furthermore, payment of future dividends is subject to certain limitations pursuant to our current and future debt instruments, Swiss law and our articles of association. See&#160;&#8220;Description of Share Capital and Articles of Association.&#8221; In addition, the Facility Agreement limits our </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 36pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">73<br></div></div></div>
<!--End Page 77-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 78-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 540pt;"><a name="nt10014672x1_drs_104-risk_pg61"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="block-frill" style="width: 540pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: Arial, Helvetica, sans-serif; font-size: 9pt; font-weight: bold; margin-top: 6pt; text-align: center;">Confidential Treatment Requested by ADC Therapeutics SA Pursuant to 17 C.F.R. &#167; 200.83<br></div></div><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 36pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">ability to pay dividends. See &#8220;&#8212;Risks Related to Our Financial Position and Capital Requirements&#8212;The Facility Agreement, our indebtedness and the associated restrictive covenants thereunder could adversely affect our financial condition and will restrict our ability to raise capital.&#8221; Accordingly, investors cannot rely on dividend income from our common shares, and any returns on an investment in our common shares will likely depend entirely upon any future appreciation in the price of our common shares.</div><div class="frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">If securities or industry analysts do not continue to publish research, or publish inaccurate or unfavorable research, about our business, the price of our common shares and our trading volume could decline.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The trading market for our common shares depends, in part, on the research and reports that securities or industry analysts publish about us or our business. If one or more of the analysts who cover us downgrade our common shares or publish inaccurate or unfavorable research about our business, the price of our common shares would likely decline. In&#160;addition, if our operating results fail to meet the forecast of analysts, the price of our common shares would likely decline. If one or more of these analysts cease coverage of our company or fail to publish reports on us regularly, demand for our common shares could decrease, which might cause the price of our common shares and trading volume to decline.</div><div class="frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 14pt; margin-left: 0pt; text-align: left;">The implementation of the authorized share capital increase may be delayed or blocked.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The common shares offered by us in this offering will be sourced through a share capital increase authorized by our board of directors. As with all share capital increases in Switzerland, a third party, such as shareholders or creditors, may at least temporarily block the registration of the capital increase in the commercial register of the Canton of Vaud and request the competent court to grant a preliminary injunction in a summary proceeding in which we would be entitled to appear and, therefore, prevent or delay the completion of this offering. In addition, as a result of the COVID-19 pandemic, the commercial register of the Canton of Vaud is significantly understaffed and may not review or record the capital increase within the anticipated timeframe, with the effect that the creation of the common shares and completion of this offering may be delayed. There can be no assurance that the implementation of the authorized share capital increase will not be delayed or blocked.</div><div class="frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">The rights of our shareholders may be different from the rights of shareholders in companies governed by the laws of U.S. jurisdictions.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">We are a Swiss corporation. Our corporate affairs are governed by our articles of association and by the laws governing companies, including listed companies, incorporated in Switzerland. The rights of our shareholders and the responsibilities of members of our board of directors may be different from the rights and obligations of shareholders and directors of companies governed by the laws of U.S. jurisdictions.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">In the performance of its duties, our board of directors is required by Swiss law to consider the interests of our company, our shareholders, our employees and other stakeholders, in all cases with due observation of the principles of reasonableness and fairness. It is possible that some of these parties will have interests that are different from, or in addition to, shareholders&#8217; interests. Swiss law limits the ability of our shareholders to challenge resolutions made or other actions taken by our board of directors in court. Our shareholders generally are not permitted to file a suit to reverse a decision or an action taken by our board of directors, but are instead only permitted to seek damages for breaches of fiduciary duty. As a matter of Swiss law, shareholder claims against a member of our board of directors for breach of fiduciary duty would have to be brought to the competent courts in Epalinges, Canton of Vaud, Switzerland, or where the relevant member of our board of directors is domiciled. In addition, under Swiss law, any claims by our shareholders against us must be brought exclusively to the competent courts in Epalinges, Canton of Vaud, Switzerland. For a further summary of applicable Swiss company law, see &#8220;Description of Share Capital and Articles of Association&#8221; and &#8220;Comparison of Swiss Law and Delaware Law.&#8221; However, there can be no assurance that Swiss law will not change in the future, which could adversely affect the rights of our shareholders, or that Swiss law will protect our shareholders in a similar fashion as under U.S. corporate law principles.</div><div class="frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">Our shareholders enjoy certain rights that may limit our flexibility to raise capital, issue dividends and otherwise manage ongoing capital needs.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Swiss law reserves for approval by shareholders certain corporate actions over which a board of directors would have authority in some other jurisdictions. For example, the payment of dividends and cancellation of treasury shares must be approved by shareholders. Swiss law also requires that our shareholders themselves </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 36pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">74<br></div></div></div>
<!--End Page 78-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 79-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 540pt;"><a name="nt10014672x1_drs_104-risk_pg62"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="block-frill" style="width: 540pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: Arial, Helvetica, sans-serif; font-size: 9pt; font-weight: bold; margin-top: 6pt; text-align: center;">Confidential Treatment Requested by ADC Therapeutics SA Pursuant to 17 C.F.R. &#167; 200.83<br></div></div><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 36pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">resolve to, or authorize our board of directors to, increase our share capital. While our shareholders may authorize share capital that can be issued by our board of directors without additional shareholder approval, Swiss law limits this authorization to 50% of the issued share capital at the time of the authorization. The authorization, furthermore, has a limited duration of up to two years and must be renewed by the shareholders from time to time thereafter in order to be available for raising capital. Additionally, subject to specified exceptions, including exceptions explicitly described in our articles of association, Swiss law grants pre-emptive subscription rights to existing shareholders to subscribe for new issuances of shares. Swiss law also does not provide as much flexibility in the various rights and regulations that can attach to different categories of shares as do the laws of some other jurisdictions. These Swiss law requirements relating to our capital management may limit our flexibility, and situations may arise where greater flexibility would have provided benefits to our shareholders. See &#8220;Description of Share Capital and Articles of Association&#8221; and &#8220;Comparison of Swiss Law and Delaware Law.&#8221;</div><div class="frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">Our shares are not listed in Switzerland, our home jurisdiction. As a result, our shareholders do not benefit from certain provisions of Swiss law that are designed to protect shareholders in a public takeover offer or a change-of-control transaction.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Because our common shares are listed exclusively on the NYSE and not in Switzerland, our shareholders do not benefit from the protection afforded by certain provisions of Swiss law that are designed to protect shareholders in the event of a public takeover offer or a change-of-control transaction. For example, Article 120 of the Swiss Financial Market Infrastructure Act and its implementing provisions require investors to disclose their interest in our company if they reach, exceed or fall below certain ownership thresholds. Similarly, the Swiss takeover regime imposes a duty on any person or group of persons who acquires more than one-third of a company&#8217;s voting rights to make a mandatory offer for all of the company&#8217;s outstanding listed equity securities. In addition, the Swiss takeover regime imposes certain restrictions and obligations on bidders in a voluntary public takeover offer that are designed to protect shareholders. However, these protections are applicable only to issuers that list their equity securities in Switzerland and, because our common shares are listed exclusively on the NYSE, are not be applicable to us. Furthermore, since Swiss law restricts our ability to implement rights plans or U.S.-style &#8220;poison pills,&#8221; our ability to resist an unsolicited takeover attempt or to protect minority shareholders in the event of a change of control transaction may be limited. Therefore, our shareholders may not be protected in the same degree in a public takeover offer or a change-of-control transaction as are shareholders in a Swiss company listed in Switzerland.</div><div class="frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">U.S. shareholders may not be able to obtain judgments or enforce civil liabilities against us or our executive officers or members of our board of directors.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">We are organized under the laws of Switzerland and our registered office and domicile is located in Epalinges, Canton of Vaud, Switzerland. Moreover, a number of our directors and executive officers are not residents of the United States, and all or a substantial portion of the assets of such persons are located outside the United States. As a result, it may not be possible for investors to effect service of process within the United States upon us or upon such persons or to enforce against them judgments obtained in U.S. courts, including judgments in actions predicated upon the civil liability provisions of the federal securities laws of the United States. We have been advised by our Swiss counsel that there is doubt as to the enforceability in Switzerland of original actions, or in actions for enforcement of judgments of U.S. courts, of civil liabilities to the extent solely predicated upon the federal and state securities laws of the United States. Original actions against persons in Switzerland based solely upon the U.S. federal or state securities laws are governed, among other things, by the principles set forth in the Swiss Federal Act on Private International Law (&#8220;PILA&#8221;). This statute provides that the application of provisions of non-Swiss law by the courts in Switzerland shall be precluded if the result is incompatible with Swiss public policy. Also, certain mandatory provisions of Swiss law may be applicable regardless of any other law that would otherwise apply.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Switzerland and the United States do not have a treaty providing for reciprocal recognition and enforcement of judgments in civil and commercial matters. The recognition and enforcement of a judgment of the courts of the United States in Switzerland is governed by the principles set forth in the PILA. This statute provides in principle that a judgment rendered by a non-Swiss court may be enforced in Switzerland only if:</div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the non-Swiss court had jurisdiction pursuant to the PILA;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the judgment of such non-Swiss court has become final and non-appealable;</div></td></tr></table></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 36pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">75<br></div></div></div>
<!--End Page 79-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 80-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 540pt;"><a name="nt10014672x1_drs_104-risk_pg63"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="block-frill" style="width: 540pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: Arial, Helvetica, sans-serif; font-size: 9pt; font-weight: bold; margin-top: 6pt; text-align: center;">Confidential Treatment Requested by ADC Therapeutics SA Pursuant to 17 C.F.R. &#167; 200.83<br></div></div><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 36pt;"><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6.75pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the judgment does not contravene Swiss public policy;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the court procedures and the service of documents leading to the judgment were in accordance with the due process of law; and</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">no proceeding involving the same parties and the same subject matter was first brought in Switzerland, or adjudicated in Switzerland, or was earlier adjudicated in a third state, and this decision is recognizable in Switzerland.</div></td></tr></table><div class="frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">Anti-takeover provisions in our articles of association could make an acquisition of us, which may be beneficial to our shareholders, more difficult.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Our articles of association contain provisions that may have the effect of discouraging, delaying or preventing a change in control of us that shareholders may consider favorable, including transactions in which our shareholders may receive a premium for their shares. Our articles of association include provisions that:</div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">in certain cases, allow our board of directors to place, upon the completion of this offering, up to &#8195;&#8195; common shares and rights to acquire an additional &#8195;&#8195;&#8195;&#8195; common shares with affiliates or third parties, without existing shareholders having statutory pre-emptive rights in relation to this share placement;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">allow our board of directors not to record any acquirer of common shares, or several acquirers acting in concert, in our share register as a shareholder with voting rights with respect to more than 15% of our share capital as set forth in the commercial register;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">limit the size of our board of directors to 11 members; and</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">require two-thirds of the votes represented at a shareholder meeting for amending or repealing the above-mentioned voting and recording restrictions, for amending the provision setting a maximum board size or providing for indemnification of our directors and members of our executive committee and for removing the chairman or any member of the board of directors before the end of his or her term of office.</div></td></tr></table><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">These and other provisions, alone or together, could delay or prevent takeovers and changes in control. See &#8220;Description of Share Capital and Articles of Association.&#8221; These provisions could also limit the price that investors might be willing to pay in the future for our common shares, thereby depressing the market price of our common shares.</div><div class="frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">We are a foreign private issuer, and, as a result, we are not subject to certain rules and obligations that are applicable to a U.S. domestic public company and are not subject to certain NYSE corporate governance listing standards that are applicable to a NYSE-listed U.S. domestic public company.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">We report under the Exchange Act as a non-U.S. company with foreign private issuer status. Because we qualify as a foreign private issuer under the Exchange Act and although we furnish quarterly financial information to the SEC, we are exempt from certain provisions of the Exchange Act that are applicable to U.S. domestic public companies, including (i)&#160;the sections of the Exchange Act regulating the solicitation of proxies, consents or authorizations in respect of a security registered under the Exchange Act; (ii)&#160;the sections of the Exchange Act requiring insiders to file public reports of their stock ownership and trading activities, and liability for insiders who profit from trades made in a short period of time; and (iii)&#160;the rules under the Exchange Act requiring the filing with the SEC of quarterly reports on Form 10-Q containing unaudited financial and other specified information, or current reports on Form 8-K upon the occurrence of specified significant events. In addition, foreign private issuers are not required to file their annual report on Form 20-F until four months after the end of each financial year, while U.S. domestic issuers are required to file their annual report on Form 10-K in less time. Foreign private issuers are also exempt from the Regulation Fair Disclosure, aimed at preventing issuers from making selective disclosures of material information.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Furthermore, because we are a foreign private issuer, we have elected to comply with our home country governance requirements and certain exemptions thereunder, rather than complying with certain of the NYSE corporate governance listing standards that are applicable to U.S. companies listed on the NYSE. For example, we are exempt from NYSE listing standards that require a listed U.S. company to have (i) a majority of the board of directors consist of independent directors, (ii) regularly scheduled executive sessions with only </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 36pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">76<br></div></div></div>
<!--End Page 80-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 81-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 540pt;"><a name="nt10014672x1_drs_104-risk_pg64"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="block-frill" style="width: 540pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: Arial, Helvetica, sans-serif; font-size: 9pt; font-weight: bold; margin-top: 6pt; text-align: center;">Confidential Treatment Requested by ADC Therapeutics SA Pursuant to 17 C.F.R. &#167; 200.83<br></div></div><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 36pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">independent directors and (iii) a compensation committee and a nomination and corporate governance committee consist entirely of independent directors. Our audit committee is required to comply with the provisions of Section 301 of the Sarbanes-Oxley Act and Rule 10A-3 of the Exchange Act, both of which are also applicable to NYSE-listed U.S. companies. Because we are a foreign private issuer, however, our audit committee is not subject to additional NYSE listing standards applicable to NYSE-listed U.S. companies, including an affirmative determination that all members of the audit committee are &#8220;independent.&#8221; Furthermore, NYSE listing standards generally require NYSE-listed U.S. companies to, among other things, seek shareholder approval for the implementation of certain equity compensation plans and issuances of securities, which we are not required to follow as a foreign private issuer. Accordingly, our shareholders may not have the same protections afforded to shareholders of companies that are not foreign private issuers. For an overview of our corporate governance principles, see &#8220;Description of Share Capital and Articles of Association.&#8221; </div><div class="frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 10.5pt; margin-left: 0pt; text-align: left;">We may lose our foreign private issuer status, which would then require us to comply with the Exchange Act&#8217;s domestic reporting regime and cause us to incur significant legal, accounting and other expenses.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">We qualify as a foreign private issuer and therefore we are not required to comply with all of the periodic disclosure and current reporting requirements of the Exchange Act applicable to U.S. domestic issuers. We may no longer be a foreign private issuer as of June&#160;30, 2021, which would require us to comply with all of the periodic disclosure and current reporting requirements of the Exchange Act applicable to U.S. domestic issuers, as of January&#160;1, 2022. In order to maintain our current status as a foreign private issuer, either (a) a majority of our common shares must be either directly or indirectly owned of record by nonresidents of the United States or (b)(i)&#160;a majority of our executive officers or directors may not be United States citizens or residents, (ii)&#160;more than 50% of our assets cannot be located in the United States and (iii)&#160;our business must be administered principally outside the United States. If we lose this status, we would be required to comply with the Exchange Act reporting and other requirements applicable to U.S. domestic issuers, which are more detailed and extensive than the requirements for foreign private issuers. We may also be required to make changes in our corporate governance practices in accordance with various SEC and stock exchange rules. The regulatory and compliance costs to us under U.S. securities laws if we are required to comply with the reporting requirements applicable to a U.S. domestic issuer may be significantly higher than the cost we would incur as a foreign private issuer. As a result, we expect that a loss of foreign private issuer status would increase our legal and financial compliance costs and would make some activities highly time-consuming and costly. We also expect that if we were required to comply with the rules and regulations applicable to U.S. domestic issuers, it would be more difficult and expensive for us to obtain director and officer liability insurance, and we may be required to accept reduced coverage or incur substantially higher costs to obtain coverage. These rules and regulations could also make it more difficult for us to attract and retain qualified members of our board of directors.</div><div class="frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 10.5pt; margin-left: 0pt; text-align: left;">We are an emerging growth company, and we cannot be certain if the reduced reporting requirements applicable to emerging growth companies make our common shares less attractive to investors.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">We are an &#8220;emerging growth company,&#8221; as defined in the JOBS Act. For as long as we continue to be an emerging growth company, we may take advantage of exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies, including, but not limited to, (i)&#160;not being required to comply with the auditor attestation requirements of Section 404 of the Sarbanes-Oxley Act, (ii)&#160;reduced disclosure obligations regarding executive compensation in this prospectus and our periodic reports and proxy statements and (iii)&#160;exemptions from the requirements of holding a nonbinding advisory vote on executive compensation. In addition, as an emerging growth company, we are required to provide only two years of audited financial statements and two years of selected financial data in our initial registration statement, compared to three and five years, respectively, for comparable data reported by other public companies.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">We could be an emerging growth company for up to five years from our initial public offering, although circumstances could cause us to lose that status earlier, including if the market value of our common shares held by non-affiliates exceeds $700&#160;million as of any June 30 (the end of our second fiscal quarter) before that time or if we have total annual gross revenues of $1.07&#160;billion or more during any fiscal year before that time, in which cases we would no longer be an emerging growth company as of the following December 31 (our fiscal year end) or, if we issue more than $1.0&#160;billion in non-convertible debt during any three-year period before that time, we would cease to be an emerging growth company immediately. Even after we no longer qualify as an emerging growth company, we may still qualify as a &#8220;smaller reporting company,&#8221; which would allow us to take advantage of many of the same exemptions from disclosure requirements, including not being required to comply </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 36pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">77<br></div></div></div>
<!--End Page 81-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 82-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 540pt;"><a name="nt10014672x1_drs_104-risk_pg65"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="block-frill" style="width: 540pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: Arial, Helvetica, sans-serif; font-size: 9pt; font-weight: bold; margin-top: 6pt; text-align: center;">Confidential Treatment Requested by ADC Therapeutics SA Pursuant to 17 C.F.R. &#167; 200.83<br></div></div><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 36pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">with the auditor attestation requirements of Section&#160;404 of the Sarbanes-Oxley Act and reduced disclosure obligations regarding executive compensation in our periodic reports and proxy statements. We cannot predict if investors will find our common shares less attractive because we may rely on these exemptions. If some investors find our common shares less attractive as a result, there may be a less active trading market for our common shares and the price of our common shares may be more volatile. When these exemptions cease to apply, we expect to incur additional expenses and devote increased management effort towards ensuring compliance with them, and we cannot predict or estimate the amount or timing of such additional costs. </div><div class="frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">We have identified material weaknesses in our internal control over financial reporting. If we are unable to remediate these material weaknesses or otherwise fail to maintain an effective system of internal controls, we may not be able to accurately or timely report our financial condition or results of operations, which may adversely affect our business and the price of our common shares. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">We have identified material weaknesses in our internal control over financial reporting. A company&#8217;s internal control over financial reporting is a process designed by, or under the supervision of, a company&#8217;s principal executive and principal financial officers, or persons performing similar functions, and effected by a company&#8217;s board of directors, management and other personnel to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements in accordance with IFRS. A material weakness is a deficiency, or a combination of deficiencies, in internal control over financial reporting, such that there is a reasonable possibility that a material misstatement of the annual or interim financial statements will not be prevented or detected on a timely basis.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">In June 2019, we identified an error related to the calculation of the expense charge for our historical share purchase plans, which, in accordance with IFRS 2, were required to be accounted for as if they were share option plans. While the share purchase plans were properly accounted for on the balance sheet, there was a material understatement of the share-based compensation expense, and the related disclosures were incomplete. This resulted in a restatement of the financial statements for the year ended December 31, 2018. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">During the first and second quarters of 2020, we identified errors related to the work performed by the independent valuation firm assisting us in calculating the fair value of the share-based compensation award grants per participant and our use thereof. Specifically, we identified errors in (i) our procedures for giving instructions to the independent valuation firm, (ii) our review of the work product delivered by such firm and (iii) our use of the information delivered by such firm. This resulted in audit adjustments to both our consolidated financial statements for the year ended December 31, 2019 and unaudited condensed consolidated interim financial statements for the three- and six-month periods ended June&#160;30, 2020. These errors are evidence that the Company has material weaknesses in its internal financial controls related to the accounting for share-based compensation. If these weaknesses are not remediated, they could lead to material misstatements in our future annual or interim consolidated financial statements. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">We have taken and continue to take steps to remediate the aforementioned material weaknesses and to enhance our overall control environment, including implementing changes in our internal control over financial reporting with regard to complex accounting matters such as share-based compensation plans.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">In addition, neither our management nor an independent registered public accounting firm has performed an evaluation of our internal control over financial reporting in accordance with the provisions of the Sarbanes-Oxley Act. Had we or our independent registered public accounting firm performed an evaluation of our internal control over financial reporting in accordance with the provisions of the Sarbanes-Oxley Act, additional material weaknesses may have been identified.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">We cannot assure you that the measures we have taken to date, and actions we may take in the future, will be sufficient to remediate the control deficiencies that led to these material weaknesses in our internal control over financial reporting or that they will prevent or avoid potential future material weaknesses.</div><div class="frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">We believe that we were a passive foreign investment company for U.S. federal income tax purposes (a &#8220;PFIC&#8221;) for our 2019 taxable year and it is possible that we will be a PFIC in future taxable years. If we are a PFIC, our U.S. shareholders may be subject to adverse U.S. federal income tax consequences. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Under the Internal Revenue Code of 1986, as amended (the &#8220;Code&#8221;), we will be a PFIC for any taxable year in which, after the application of certain look-through rules with respect to subsidiaries, either (i) 75% or more of our gross income consists of passive income or (ii) 50% or more of the average quarterly value of our </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 36pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">78<br></div></div></div>
<!--End Page 82-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 83-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 540pt;"><a name="nt10014672x1_drs_104-risk_pg66"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="block-frill" style="width: 540pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: Arial, Helvetica, sans-serif; font-size: 9pt; font-weight: bold; margin-top: 6pt; text-align: center;">Confidential Treatment Requested by ADC Therapeutics SA Pursuant to 17 C.F.R. &#167; 200.83<br></div></div><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 36pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">assets consists of assets that produce, or are held for the production of, passive income. Passive income generally includes dividends, interest, certain non-active rents and royalties, and capital gains. We believe that we were a PFIC for our 2019 taxable year and it is possible that we will be a PFIC for one or more subsequent taxable years. Whether we will be a PFIC in 2020 or any future years is uncertain because, among other things, (i)&#160;we currently own, and will own after the completion of this offering, a substantial amount of passive assets, including cash, (ii)&#160;the timing of our recognition of active income for U.S. federal income tax purposes, which may differ from the timing of the recognition of such income for financial accounting purposes, may result in our recognizing minimal amounts of active income for U.S. federal income tax purposes in certain taxable years and (iii) the valuation of our assets that generate non-passive income for PFIC purposes, including our intangible assets, is uncertain and may be determined in substantial part by our market capitalization, which may vary substantially over time. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">If we are a PFIC for any taxable year during which a U.S. investor holds common shares, we generally will continue to be treated as a PFIC with respect to that U.S. investor for all succeeding years during which the U.S. investor holds common shares, even if we cease to meet the threshold requirements for PFIC status. Such a U.S. investor may be subject to adverse U.S. federal income tax consequences, including (i)&#160;the treatment of all or a portion of any gain on disposition as ordinary income, (ii)&#160;the application of a deferred interest charge on such gain and on the receipt of certain dividends and (iii)&#160;compliance with certain reporting requirements. If we are a PFIC for any taxable year, the foregoing rules will also apply to a U.S. Holder&#8217;s indirect interest in any PFIC in which we hold a direct or indirect interest (a &#8220;Lower-tier PFIC&#8221;). If we determine that we are a PFIC for any taxable year, we will use our commercially reasonable efforts to, and currently expect to, provide the information necessary for U.S. Holders to make qualified electing fund elections (&#8220;QEF Elections&#8221;), which could mitigate the adverse U.S. federal income tax consequence of the PFIC rules. We also currently expect that we will provide the information necessary for U.S. Holders to make a QEF Election with respect to any Lower-tier PFIC, but there can be no assurance that we will be able to provide such information. See &#8220;Taxation&#8212;Material U.S. Federal Income Tax Consequences for U.S. Holders.&#8221;</div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 36pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">79<br></div></div></div>
<!--End Page 83-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 84-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 540pt;"><a name="nt10014672x1_drs_105-caution_pg1"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="block-frill" style="width: 540pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: Arial, Helvetica, sans-serif; font-size: 9pt; font-weight: bold; margin-top: 6pt; text-align: center;">Confidential Treatment Requested by ADC Therapeutics SA Pursuant to 17 C.F.R. &#167; 200.83<br></div></div><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 36pt;"><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: center;"><a name="tCSR"><!--Anchor--></a>CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">This prospectus contains statements that constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical facts contained in this prospectus, including statements regarding our future results of operations and financial position, business strategy, product candidates, research pipeline, ongoing and planned preclinical studies and clinical trials, regulatory submissions and approvals, research and development costs, timing and likelihood of success, as well as plans and objectives of management for future operations are forward-looking statements. Many of the forward-looking statements contained in this prospectus can be identified by the use of forward-looking words such as &#8220;anticipate,&#8221; &#8220;believe,&#8221; &#8220;could,&#8221; &#8220;expect,&#8221; &#8220;should,&#8221; &#8220;plan,&#8221; &#8220;intend,&#8221; &#8220;estimate,&#8221; &#8220;will&#8221; and &#8220;potential,&#8221; among others.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Forward-looking statements appear in a number of places in this prospectus and include, but are not limited to, statements regarding our intent, belief or current expectations. Forward-looking statements are based on our management&#8217;s beliefs and assumptions and on information currently available to our management. Such statements are subject to risks and uncertainties, and actual results may differ materially from those expressed or implied in the forward-looking statements due to various factors, including, but not limited to, those identified under the section entitled &#8220;Risk Factors&#8221; in this prospectus. These forward-looking statements include, among others:</div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the commencement, timing, progress and results of our research and development programs, preclinical studies and clinical trials;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the timing of IND, BLA, sBLA, MAA and other regulatory submissions with the FDA, EMA or comparable regulatory authorities in other jurisdictions;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the proposed clinical development pathway for our lead product candidates, Lonca and Cami, and our other product candidates, and the acceptability of the results of clinical trials for regulatory approval of such product candidates by the FDA, EMA or comparable regulatory authorities in other jurisdictions;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">assumptions relating to the identification of serious adverse, undesirable or unacceptable side effects related to our product candidates;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the timing of and our ability to obtain and maintain regulatory approval for our product candidates;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">our plan for the commercialization of Lonca and, subject to our collaboration and license agreement with Genmab, of Cami, if approved;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">our expectations regarding the size of the patient populations amenable to treatment with our product candidates, if approved, as well as the treatment landscape of the indications that we are targeting with our product candidates;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">assumptions relating to the rate and degree of market acceptance of any approved product candidates;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the pricing and reimbursement of our product candidates;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">our ability to identify and develop additional product candidates;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the ability of our competitors to discover, develop or commercialize competing products before or more successfully than we do;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">our competitive position and the development of and projections relating to our competitors or our industry;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">our estimates of our expenses, ongoing losses, future revenue, capital requirements and our needs for or ability to obtain additional financing;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">our ability to raise capital when needed in order to continue our research and development programs or commercialization efforts;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">assumptions regarding the receipt of the second disbursement under the Facility Agreement;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">our ability to identify and successfully enter into strategic collaborations or licensing opportunities in the future, and our assumptions regarding any potential revenue that we may generate thereunder;</div></td></tr></table></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 36pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">80<br></div></div></div>
<!--End Page 84-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 85-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 540pt;"><a name="nt10014672x1_drs_105-caution_pg2"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="block-frill" style="width: 540pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: Arial, Helvetica, sans-serif; font-size: 9pt; font-weight: bold; margin-top: 6pt; text-align: center;">Confidential Treatment Requested by ADC Therapeutics SA Pursuant to 17 C.F.R. &#167; 200.83<br></div></div><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 36pt;"><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6.75pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">our ability to obtain, maintain, protect and enforce intellectual property protection for our product candidates, and the scope of such protection;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">our ability to operate our business without infringing, misappropriating or otherwise violating the intellectual property rights of third parties;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">our expectations regarding the impact of the COVID-19 pandemic;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">our ability to attract and retain qualified key management and technical personnel; and</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">our expectations regarding the time during which we will be an emerging growth company under the JOBS&#160;Act and a foreign private issuer. </div></td></tr></table><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">These forward-looking statements speak only as of the date of this prospectus and are subject to a number of risks, uncertainties and assumptions described under the sections in this prospectus entitled &#8220;Risk Factors&#8221; and &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; and elsewhere in this prospectus. Because forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified and some of which are beyond our control, you should not rely on these forward-looking statements as predictions of future events. The events and circumstances reflected in our forward-looking statements may not be achieved or occur and actual results could differ materially from those projected in the forward-looking statements. Moreover, we operate in an evolving environment. New risk factors and uncertainties may emerge from time to time, and it is not possible for management to predict all risk factors and uncertainties. Except as required by applicable law, we do not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise. You should read this prospectus and the documents that we have filed as exhibits to the registration statement, of which this prospectus is a part, completely and with the understanding that our actual future results may be materially different from what we expect.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">In addition, statements that &#8220;we believe&#8221; and similar statements reflect our beliefs and opinions on the relevant subject. These statements are based upon information available to us as of the date of this prospectus, and while we believe such information forms a reasonable basis for such statements, such information may be limited or incomplete, and our statements should not be read to indicate that we have conducted an exhaustive inquiry into, or review of, all potentially available relevant information. These statements are inherently uncertain and investors are cautioned not to unduly rely upon these statements.</div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 36pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">81<br></div></div></div>
<!--End Page 85-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 86-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 540pt;"><a name="nt10014672x1_drs_105-caution_pg3"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="block-frill" style="width: 540pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: Arial, Helvetica, sans-serif; font-size: 9pt; font-weight: bold; margin-top: 6pt; text-align: center;">Confidential Treatment Requested by ADC Therapeutics SA Pursuant to 17 C.F.R. &#167; 200.83<br></div></div><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 36pt;"><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: center;"><a name="tMID"><!--Anchor--></a>MARKET AND INDUSTRY DATA</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">This prospectus contains industry, market and competitive position data that are based on general and industry publications, surveys and studies conducted by third parties, some of which may not be publicly available, and our own internal estimates and research. Third-party publications, surveys and studies generally state that they have obtained information from sources believed to be reliable, but do not guarantee the accuracy and completeness of such information. These data involve a number of assumptions and limitations and contain projections and estimates of the future performance of the industries in which we operate that are subject to a high degree of uncertainty. We&#160;caution you not to give undue weight to such projections, assumptions and estimates.</div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 36pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">82<br></div></div></div>
<!--End Page 86-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 87-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 540pt;"><a name="nt10014672x1_drs_105-caution_pg4"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="block-frill" style="width: 540pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: Arial, Helvetica, sans-serif; font-size: 9pt; font-weight: bold; margin-top: 6pt; text-align: center;">Confidential Treatment Requested by ADC Therapeutics SA Pursuant to 17 C.F.R. &#167; 200.83<br></div></div><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 36pt;"><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: center;"><a name="tUP"><!--Anchor--></a>USE OF PROCEEDS</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">We estimate that the net proceeds from the issuance and sale of &#8195;&#8195;&#8195; common shares by us in this offering will be approximately $&#8195;&#8195; million based on the assumed public offering price of $&#8195;&#8195; per common share, which was the last reported sale price of our common shares on the NYSE on &#8195;&#8195;, 2020, after deducting estimated underwriting discounts and commissions and estimated offering expenses payable by us. We will not receive any of the proceeds from the potential sale of common shares by the Selling Shareholder pursuant to the underwriters&#8217; option to purchase additional common shares.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Each $1.00 increase or decrease in the assumed public offering price would increase or decrease the net proceeds to us by $&#8195;&#8195; million, assuming that the number of common shares offered by us, as set forth on the cover page of this prospectus, remains the same and after deducting estimated underwriting discounts and commissions and estimated offering expenses payable by us. Each 1,000,000 share increase or decrease in the number of common shares offered by us would increase or decrease the net proceeds to us by $&#8195;&#8195; million, assuming the assumed public offering price remains the same and after deducting estimated underwriting discounts and commissions and estimated offering expenses payable by us.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">As of June 30, 2020, we had cash and cash equivalents of $348.6 million. We intend to use the net proceeds of this offering, together with our existing cash and cash equivalents, estimated revenue from Lonca, including revenue from potential commercial partnerships, and the second disbursement under the Facility Agreement, as follows:</div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">approximately $&#8195;&#8195; million to advance the clinical development of Lonca for the treatment of multiple hematological malignancies, including ongoing and new clinical trials; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">approximately $&#8195;&#8195; million to advance the clinical development of Cami for the treatment of both hematological malignancies and solid tumors;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">approximately $&#8195;&#8195; million to advance the clinical development of ADCT-602 for the treatment of relapsed or refractory ALL as well as ADCT-601 and ADCT-901 for the treatment of select advanced solid tumors, and to fund the research and development of our preclinical product candidates and preclinical pipeline;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">approximately $&#8195;&#8195;&#160;million to commercialize Lonca in the United States, if approved; and </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the remainder for working capital and other general corporate purposes.</div></td></tr></table><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Due to the uncertainties inherent in the product development process, it&#160;is difficult to estimate with certainty the exact amounts of the net proceeds from this offering that may be used for the above purposes. The amount and timing of our actual expenditures will depend upon numerous factors, including the results of our research and development efforts, the timing and success of our current and future preclinical studies and clinical trials, the timing and outcome of regulatory submissions and the nature of our late-stage manufacturing and commercialization activities for our product candidates. In addition, we might decide to postpone or not pursue certain preclinical studies or clinical trials if the net proceeds from this offering and our other sources of cash are less than expected.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The expected net proceeds from this offering, together with our existing cash and cash equivalents, estimated revenue from Lonca, including revenue from potential commercial partnerships, and the second disbursement under the Facility Agreement, will not be sufficient for us to advance all of our product candidates through regulatory approval for all indications that we are pursuing, and we will need to raise additional capital to complete the development and potential commercialization of our product candidates. We expect to finance our cash needs primarily through equity offerings and potentially through debt financings, collaborations and license and development agreements.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Our management will retain broad discretion in the application of the net proceeds we receive from this offering, and investors will be relying on the judgment of our management regarding the application of the net proceeds. Pending the use of the proceeds from this offering, we intend to invest the net proceeds in a variety of capital preservation instruments, which may include all or a combination of short-term and long-term interest-bearing instruments, investment-grade securities, and direct or guaranteed obligations of the U.S. government. We cannot predict whether the proceeds invested will yield a favorable return.</div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 36pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">83<br></div></div></div>
<!--End Page 87-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 88-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 540pt;"><a name="nt10014672x1_drs_105-caution_pg5"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="block-frill" style="width: 540pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: Arial, Helvetica, sans-serif; font-size: 9pt; font-weight: bold; margin-top: 6pt; text-align: center;">Confidential Treatment Requested by ADC Therapeutics SA Pursuant to 17 C.F.R. &#167; 200.83<br></div></div><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 36pt;"><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: center;"><a name="tDP"><!--Anchor--></a>DIVIDEND POLICY </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">We have never declared or paid cash dividends on our share capital. We intend to retain all available funds and any future earnings, if any, to fund the development and expansion of our business and we do not anticipate paying any cash dividends in the foreseeable future. In addition, the Facility Agreement limits our ability to pay dividends. Any future determination related to dividend policy will be made at the discretion of our board of directors and will depend upon, among other factors, our results of operations, financial condition, capital requirements, contractual restrictions, business prospects and other factors our board of directors may deem relevant.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Under Swiss law, any dividend must be approved by our shareholders. In addition, our auditors must confirm that the dividend proposal of our board of directors to the shareholders conforms to Swiss statutory law and our articles of association. A Swiss corporation may pay dividends only if it has sufficient distributable profits from the previous business year (<font style="font-style: italic;">b&#233;n&#233;fice de l&#8217;exercice</font>) or brought forward from previous business years (<font style="font-style: italic;">report des b&#233;n&#233;fices</font>) or if it has distributable reserves (<font style="font-style: italic;">r&#233;serves &#224; libre disposition</font>), each as evidenced by its audited stand-alone statutory balance sheet prepared pursuant to Swiss law and after allocations to reserves required by Swiss law and its articles of association have been deducted. Distributable reserves are generally booked either as free reserves (<font style="font-style: italic;">r&#233;serves libres</font>) or as reserves from capital contributions (<font style="font-style: italic;">apports de capital</font>). Distributions out of share capital, which is the aggregate par value of a corporation&#8217;s issued shares, may be made only by way of a share capital reduction. See &#8220;Description of Share Capital and Articles of Association.&#8221;</div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 36pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">84<br></div></div></div>
<!--End Page 88-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 89-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 540pt;"><a name="nt10014672x1_drs_105-caution_pg6"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="block-frill" style="width: 540pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: Arial, Helvetica, sans-serif; font-size: 9pt; font-weight: bold; margin-top: 6pt; text-align: center;">Confidential Treatment Requested by ADC Therapeutics SA Pursuant to 17 C.F.R. &#167; 200.83<br></div></div><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 36pt;"><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: center;"><a name="tC"><!--Anchor--></a>CAPITALIZATION</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 7.5pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The following table sets forth our cash and cash equivalents and our total capitalization as of June 30, 2020:</div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">on an actual basis;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">on an as-adjusted basis to give effect to our issuance and sale of common shares in this offering based on the assumed public offering price of $&#8195;&#8195; per common share, which was the last reported sale price of our common shares on the NYSE on &#8195;&#8195;, 2020, after deducting estimated underwriting discounts and commissions and estimated offering expenses payable by us.</div></td></tr></table><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">You should read this table in conjunction with our consolidated financial statements, including the notes thereto, included in this prospectus as well as &#8220;Use of Proceeds,&#8221; &#8220;Selected Consolidated Financial Data&#8221; and &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations.&#8221;</div><table cellspacing="0" cellpadding="0" class="fintab" style="margin-top: 5.25pt; border-collapse: collapse; width: 468pt; margin-left: auto; margin-right: auto;"><tr class="header"><td style="width: 64.1%; text-align: left; vertical-align: bottom; padding-top: 6pt; padding-bottom: 3.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 1.86%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 3.75pt;">&#8203;</td><td class="gutter" style="width: 1.86%; font-size: 2pt; padding-top: 6pt; padding-bottom: 3.75pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td colspan="4" style="width: 32.18%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 3.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">June 30, 2020</div></td></tr><tr class="header"><td style="width: 64.1%; text-align: left; vertical-align: bottom; padding-top: 3.75pt; padding-bottom: 3.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 1.86%; border-bottom: none; font-size: 2pt; padding-top: 3.75pt; padding-bottom: 3.75pt;">&#8203;</td><td class="gutter" style="width: 1.86%; font-size: 2pt; padding-top: 3.75pt; padding-bottom: 3.75pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 12.81%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 3.75pt; padding-bottom: 3.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Actual</div></td><td class="gutter" style="width: 1.86%; font-size: 2pt; padding-top: 3.75pt; padding-bottom: 3.75pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.86%; font-size: 2pt; padding-top: 3.75pt; padding-bottom: 3.75pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 15.66%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 3.75pt; padding-bottom: 3.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">As Adjusted<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(1)</sup></div></td></tr><tr class="header"><td style="width: 64.1%; text-align: left; vertical-align: bottom; padding-top: 3.75pt; padding-bottom: 3.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 1.86%; border-bottom: none; font-size: 2pt; padding-top: 3.75pt; padding-bottom: 3.75pt;">&#8203;</td><td class="gutter" style="width: 1.86%; border-bottom: none; font-size: 2pt; padding-top: 3.75pt; padding-bottom: 3.75pt;">&#8203;</td><td colspan="4" style="width: 32.18%; text-align: center; vertical-align: bottom; padding-top: 3.75pt; padding-bottom: 3.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">(in USD thousands except for share, <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">par value per share and per share data)</div></td></tr><tr><td style="width: 64.1%; text-align: left; vertical-align: bottom; padding-top: 3.75pt; padding-bottom: 3.75pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Cash and cash equivalents<font style="padding-left: 4.77pt;"></font></div></td><td class="gutter" style="width: 1.86%; border-bottom: none; font-size: 2pt; padding-top: 3.75pt; padding-bottom: 3.75pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.86%; border-bottom: none; font-size: 2pt; padding-top: 3.75pt; padding-bottom: 3.75pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 12.81%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3.75pt; padding-bottom: 3.75pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 12.05pt; text-align: left;"><font style="padding-left: 3.33pt; border-bottom: 1pt solid #000000; min-width: 35.83pt;">348,593</font></div></td><td class="gutter" style="width: 1.86%; border-bottom: none; font-size: 2pt; padding-top: 3.75pt; padding-bottom: 3.75pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.86%; border-bottom: none; font-size: 2pt; padding-top: 3.75pt; padding-bottom: 3.75pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 15.66%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3.75pt; padding-bottom: 3.75pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><font style="border-bottom: 1pt solid #000000; padding-left: 40pt; margin-left: 15.9pt;"></font></div></td></tr><tr><td style="width: 64.1%; text-align: left; vertical-align: bottom; padding-top: 3.75pt; padding-bottom: 2.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Convertible loans, short- and long-term<font style="padding-left: 1.16pt;"></font></div></td><td class="gutter" style="width: 1.86%; border-bottom: none; font-size: 2pt; padding-top: 3.75pt; padding-bottom: 2.5pt;">&#8203;</td><td class="gutter" style="width: 1.86%; border-bottom: none; font-size: 2pt; padding-top: 3.75pt; padding-bottom: 2.5pt;">&#8203;</td><td style="width: 12.81%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3.75pt; padding-bottom: 2.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 12.05pt; text-align: left;"><font style="padding-left: 8.33pt;">35,968</font></div></td><td class="gutter" style="width: 1.86%; border-bottom: none; font-size: 2pt; padding-top: 3.75pt; padding-bottom: 2.5pt;">&#8203;</td><td class="gutter" style="width: 1.86%; border-bottom: none; font-size: 2pt; padding-top: 3.75pt; padding-bottom: 2.5pt;">&#8203;</td><td style="width: 15.66%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3.75pt; padding-bottom: 2.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 64.1%; text-align: left; vertical-align: bottom; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Convertible loans, derivatives<font style="padding-left: 1.15pt;"></font></div></td><td class="gutter" style="width: 1.86%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.86%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 12.81%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 12.05pt; text-align: left;"><font style="padding-left: 3.33pt;">107,058</font></div></td><td class="gutter" style="width: 1.86%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.86%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 15.66%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 64.1%; text-align: left; vertical-align: bottom; padding-top: 2.5pt; padding-bottom: 2.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Shareholders&#8217; equity:<br></div></td><td class="gutter" style="width: 1.86%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td class="gutter" style="width: 1.86%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td style="width: 12.81%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.5pt; padding-bottom: 2.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.86%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td class="gutter" style="width: 1.86%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td style="width: 15.66%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.5pt; padding-bottom: 2.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 64.1%; text-align: left; vertical-align: bottom; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 20pt; text-indent: -10pt; text-align: left;">Common shares, par value CHF 0.08 per share; 70,715,852 shares outstanding, actual; &#8195;&#8195;shares outstanding, as adjusted<font style="padding-left: 4.24pt;"></font></div></td><td class="gutter" style="width: 1.86%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.86%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 12.81%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 12.05pt; text-align: left;"><font style="padding-left: 13.33pt;">5,795</font></div></td><td class="gutter" style="width: 1.86%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.86%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 15.66%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 64.1%; text-align: left; vertical-align: bottom; padding-top: 2.5pt; padding-bottom: 2.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Share premium <font style="padding-left: 1.97pt;"></font></div></td><td class="gutter" style="width: 1.86%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td class="gutter" style="width: 1.86%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td style="width: 12.81%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.5pt; padding-bottom: 2.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 12.05pt; text-align: left;"><font style="padding-left: 3.33pt;">792,605</font></div></td><td class="gutter" style="width: 1.86%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td class="gutter" style="width: 1.86%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td style="width: 15.66%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.5pt; padding-bottom: 2.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 64.1%; text-align: left; vertical-align: bottom; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Treasury shares<font style="padding-left: 4pt;"></font></div></td><td class="gutter" style="width: 1.86%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.86%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 12.81%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 12.05pt; text-align: left;"><font style="padding-left: 27.5pt;">(</font>4)</div></td><td class="gutter" style="width: 1.86%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.86%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 15.66%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 64.1%; text-align: left; vertical-align: bottom; padding-top: 2.5pt; padding-bottom: 2.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Other reserves<font style="padding-left: 3.65pt;"></font></div></td><td class="gutter" style="width: 1.86%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td class="gutter" style="width: 1.86%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td style="width: 12.81%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.5pt; padding-bottom: 2.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 12.05pt; text-align: left;"><font style="padding-left: 8.33pt;">16,654</font></div></td><td class="gutter" style="width: 1.86%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td class="gutter" style="width: 1.86%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td style="width: 15.66%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.5pt; padding-bottom: 2.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 64.1%; text-align: left; vertical-align: bottom; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Cumulative translation adjustments<font style="padding-left: 4.2pt;"></font></div></td><td class="gutter" style="width: 1.86%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.86%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 12.81%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 12.05pt; text-align: left;"><font style="padding-left: 17.5pt;">(146)</font></div></td><td class="gutter" style="width: 1.86%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.86%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 15.66%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 64.1%; text-align: left; vertical-align: bottom; padding-top: 2.5pt; padding-bottom: 3.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Accumulated losses<font style="padding-left: 1.98pt;"></font></div></td><td class="gutter" style="width: 1.86%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 3.75pt;">&#8203;</td><td class="gutter" style="width: 1.86%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 3.75pt;">&#8203;</td><td style="width: 12.81%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.5pt; padding-bottom: 3.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 12.05pt; text-align: left;"><font style="border-bottom: 1pt solid #000000; min-width: 35.83pt;">(</font><font style="border-bottom: 1pt solid #000000; min-width: 35.83pt;">618,602</font><font style="border-bottom: 1pt solid #000000; min-width: 35.83pt;"></font><font style="min-width: 35.83pt;">)</font></div></td><td class="gutter" style="width: 1.86%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 3.75pt;">&#8203;</td><td class="gutter" style="width: 1.86%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 3.75pt;">&#8203;</td><td style="width: 15.66%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.5pt; padding-bottom: 3.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><font style="border-bottom: 1pt solid #000000; padding-left: 40pt; margin-left: 15.9pt;"></font></div></td></tr><tr><td style="width: 64.1%; text-align: left; vertical-align: bottom; padding-top: 3.75pt; padding-bottom: 3.75pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Total equity<font style="padding-left: 3.76pt;"></font></div></td><td class="gutter" style="width: 1.86%; border-bottom: none; font-size: 2pt; padding-top: 3.75pt; padding-bottom: 3.75pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.86%; border-bottom: none; font-size: 2pt; padding-top: 3.75pt; padding-bottom: 3.75pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 12.81%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3.75pt; padding-bottom: 3.75pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 12.05pt; text-align: left;"><font style="padding-left: 3.33pt; border-bottom: 1pt solid #000000; min-width: 35.83pt;">196,302</font></div></td><td class="gutter" style="width: 1.86%; border-bottom: none; font-size: 2pt; padding-top: 3.75pt; padding-bottom: 3.75pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.86%; border-bottom: none; font-size: 2pt; padding-top: 3.75pt; padding-bottom: 3.75pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 15.66%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3.75pt; padding-bottom: 3.75pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><font style="border-bottom: 1pt solid #000000; padding-left: 40pt; margin-left: 15.9pt;"></font></div></td></tr><tr><td style="width: 64.1%; text-align: left; vertical-align: bottom; padding-top: 3.75pt; padding-bottom: 6pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Total capitalization<font style="padding-left: 4.89pt;"></font></div></td><td class="gutter" style="width: 1.86%; border-bottom: none; font-size: 2pt; padding-top: 3.75pt; padding-bottom: 6pt;">&#8203;</td><td class="gutter" style="width: 1.86%; border-bottom: none; font-size: 2pt; padding-top: 3.75pt; padding-bottom: 6pt;">&#8203;</td><td style="width: 12.81%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3.75pt; padding-bottom: 6pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 12.05pt; text-align: left;"><font style="padding-left: 3.33pt; border-bottom: 3pt double #000000; min-width: 35.83pt;">339,328</font></div></td><td class="gutter" style="width: 1.86%; border-bottom: none; font-size: 2pt; padding-top: 3.75pt; padding-bottom: 6pt;">&#8203;</td><td class="gutter" style="width: 1.86%; border-bottom: none; font-size: 2pt; padding-top: 3.75pt; padding-bottom: 6pt;">&#8203;</td><td style="width: 15.66%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3.75pt; padding-bottom: 6pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 16.65pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 40pt;">&#8195;&#8195;&#8195;&#8195;</font></div></td></tr></table><div><div class="rule-partial" style="height: 0pt; width: 72pt; border-bottom: 1pt solid #000000; margin-bottom: 1pt; margin-right: auto; margin-left: 0pt; margin-top: 13.25pt;"> </div></div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 3pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">(1)<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; text-align: left;">The as-adjusted information is illustrative only and will change based on the actual public offering price and other terms of this offering determined at pricing. Each $1.00 increase or decrease in the assumed public offering price would increase or decrease the as-adjusted amount of each of cash and cash equivalents, total equity and total capitalization by $&#8195;&#8195;million, assuming that the number of common shares offered by us, as set forth on the cover page of this prospectus, remains the same and after deducting estimated underwriting discounts and commissions and estimated offering expenses payable by us. Each 1,000,000 share increase or decrease in the number of common shares offered by us, as set forth on the cover page of this prospectus, would increase or decrease the as-adjusted amount of each of cash and cash equivalents, total equity and total capitalization by $ &#8195;&#8195;million, assuming the assumed public offering price remains the same, and after deducting estimated underwriting discounts and commissions and estimated offering expenses payable by us.</div></td></tr></table><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">There have been no material changes to our capitalization since June 30, 2020. We have not re-valued the liabilities resulting from our convertible loans since June 30, 2020. </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 36pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">85<br></div></div></div>
<!--End Page 89-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 90-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 540pt;"><a name="nt10014672x1_drs_105-caution_pg7"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="block-frill" style="width: 540pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: Arial, Helvetica, sans-serif; font-size: 9pt; font-weight: bold; margin-top: 6pt; text-align: center;">Confidential Treatment Requested by ADC Therapeutics SA Pursuant to 17 C.F.R. &#167; 200.83<br></div></div><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 36pt;"><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: center;"><a name="tD"><!--Anchor--></a>DILUTION</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">If you invest in our common shares, your interest will be diluted to the extent of the difference between the public offering price per share and the as-adjusted net tangible book value per share of our common shares immediately after this offering.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Net tangible book value is determined by dividing our tangible net worth (defined as total assets, less intangible assets, less total liabilities) by the number of our common shares outstanding. Our historical net tangible book value as of June 30, 2020 was $187.5 million, or $2.65 per share.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">After giving effect to our issuance and sale of common shares in this offering based on the assumed public offering price of $&#8195;&#8195; per common share, which was the last reported sale price of our common shares on the NYSE on &#8195;&#8195;, 2020, and after deducting estimated underwriting discounts and commissions and estimated offering expenses payable by us, the as-adjusted net tangible book value as of June 30, 2020 would have been $&#8195;&#8195; million, or $&#8195;&#8195; per common share. This amount represents an immediate increase in net tangible book value of $&#8195;&#8195; per common share to our existing shareholders and an immediate dilution in net tangible book value of $&#8195;&#8195; per common share to new investors.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8.5pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The following table illustrates this dilution on a per common share basis:</div><table cellspacing="0" cellpadding="0" class="fintab" style="margin-top: 11.25pt; border-collapse: collapse; width: 468pt; margin-left: auto; margin-right: auto;"><tr><td style="width: 76.92%; text-align: left; vertical-align: bottom; padding-top: 6pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Assumed public offering price per common share<font style="padding-left: 4.43pt;"></font></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.26%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 6pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.26%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 6pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 11.5pt; text-align: left;">$<font style="padding-left: 20pt;">&#8203;</font></div></td></tr><tr><td style="width: 76.92%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Historical net tangible book value per share as of June 30, 2020<font style="padding-left: 4pt;"></font></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 10.26%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 11.5pt; text-align: left;">$<font style="padding-left: 2.5pt;">&#8203;</font>2.65</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 10.26%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 76.92%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 20pt; text-indent: -10pt; text-align: left;">Increase in net tangible book value per share attributable to new investors participating in this offering<font style="padding-left: 2.72pt;"></font></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.26%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 11.5pt; text-align: left;"><font style="padding-left: 5pt; border-bottom: 1pt solid #000000; min-width: 25pt;">&#8195;&#8195;</font></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.26%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 76.92%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-indent: -10pt; text-align: left;">As-adjusted net tangible book value per common share after giving effect to this offering<font style="padding-left: 0.47pt;"></font></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 10.26%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 10.26%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 11.5pt; text-align: left;"><font style="padding-left: 5pt; border-bottom: 1pt solid #000000; min-width: 25pt;">&#8195;&#8195;</font></div></td></tr><tr><td style="width: 76.92%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Dilution per common share to investors participating in this offering<font style="padding-left: 1.67pt;"></font></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.26%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.26%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 11.5pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 25pt;">$</font><font style="border-bottom: 3pt double #000000; min-width: 25pt;">&#8195;&#8195;</font></div></td></tr></table><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The dilution information discussed above is illustrative only and will change based on the actual public offering price and other terms of this offering determined at pricing. Each $1.00 increase or decrease in the assumed public offering price would increase or decrease the as-adjusted net tangible book value per common share after this offering by $&#8195;&#8195; per share and dilution per common share to new investors participating in this offering by $&#8195;&#8195; per share, assuming that the number of common shares offered by us, as set forth on the cover page of this prospectus, remains the same and after deducting estimated underwriting discounts and commissions and estimated offering expenses payable by us. We may also increase or decrease the number of common shares we are offering. Each 1,000,000 share increase or decrease in the number of common shares offered by us, as&#160;set forth on the cover page of this prospectus, would increase or decrease the as-adjusted net tangible book value per common share after this offering by $&#8195;&#8195; per share and decrease or increase the dilution per common share to new investors participating in this offering by $&#8195;&#8195; per share, assuming the assumed public offering price remains the same, and after deducting estimated underwriting discounts and commissions and estimated offering expenses payable by us. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">To the extent that any outstanding options under our 2019 Equity Incentive Plan are exercised, new options are issued under our share-based compensation plans or we issue additional common shares in the future, there will be further dilution to investors participating in this offering.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">In addition, if our outstanding senior secured convertible notes convert into common shares, or if we issue additional senior secured convertible notes in the future and such notes convert into common shares, your ownership interest will be further diluted. See &#8220;Risk Factors&#8212;Risks Related to Our Common Shares and This Offering&#8212;Conversion of the senior secured convertible notes issued or to be issued under the Facility Agreement will dilute your ownership interest.&#8221;</div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 36pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">86<br></div></div></div>
<!--End Page 90-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 91-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 540pt;"><a name="nt10014672x1_drs_105-caution_pg8"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="block-frill" style="width: 540pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: Arial, Helvetica, sans-serif; font-size: 9pt; font-weight: bold; margin-top: 6pt; text-align: center;">Confidential Treatment Requested by ADC Therapeutics SA Pursuant to 17 C.F.R. &#167; 200.83<br></div></div><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 36pt;"><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: center;"><a name="tSCF"><!--Anchor--></a>SELECTED CONSOLIDATED FINANCIAL DATA</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The following selected consolidated financial data should be read in conjunction with &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; and our consolidated financial statements, including the notes thereto, included elsewhere in this prospectus. The selected consolidated income statement data for the years ended December&#160;31, 2019 and 2018 are derived from our audited consolidated financial statements included elsewhere in this prospectus. The selected consolidated income statement data for the six months ended June 30, 2020 and 2019 and the consolidated balance sheet data as of June 30, 2020 are derived from our unaudited condensed consolidated interim financial statements included elsewhere in this prospectus. The unaudited condensed consolidated interim financial statements have been prepared on the same basis as our audited consolidated financial statements and include all normal recurring adjustments that we consider necessary for a fair statement of our financial position and operating results as of the dates and for the periods presented. Our historical results are not necessarily indicative of the results that may be expected in the future, and our results for the six months ended June 30, 2020 are not necessarily indicative of the results that may be expected for the year ending December 31, 2020. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Our audited consolidated financial statements are prepared in accordance with IFRS and presented in USD. Our unaudited condensed consolidated interim financial statements are prepared in accordance with IAS 34 and presented in USD. </div><table cellspacing="0" cellpadding="0" class="fintab" style="margin-top: 11.25pt; border-collapse: collapse; width: 468pt; margin-left: auto; margin-right: auto;"><tr class="header"><td style="width: 51.28%; text-align: left; vertical-align: bottom; padding-top: 6pt; padding-bottom: 3.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 3.75pt;">&#8203;</td><td class="gutter" style="width: 1.28%; font-size: 2pt; padding-top: 6pt; padding-bottom: 3.75pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td colspan="4" style="width: 21.83%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 3.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Six Months Ended June&#160;30,</div></td><td class="gutter" style="width: 1.28%; font-size: 2pt; padding-top: 6pt; padding-bottom: 3.75pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.28%; font-size: 2pt; padding-top: 6pt; padding-bottom: 3.75pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td colspan="4" style="width: 21.78%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 3.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Year Ended December 31,</div></td></tr><tr class="header"><td style="width: 51.28%; text-align: left; vertical-align: bottom; padding-top: 3.75pt; padding-bottom: 3.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3.75pt; padding-bottom: 3.75pt;">&#8203;</td><td class="gutter" style="width: 1.28%; font-size: 2pt; padding-top: 3.75pt; padding-bottom: 3.75pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 9.64%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 3.75pt; padding-bottom: 3.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2020</div></td><td class="gutter" style="width: 1.28%; font-size: 2pt; padding-top: 3.75pt; padding-bottom: 3.75pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.28%; font-size: 2pt; padding-top: 3.75pt; padding-bottom: 3.75pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 9.64%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 3.75pt; padding-bottom: 3.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2019</div></td><td class="gutter" style="width: 1.28%; font-size: 2pt; padding-top: 3.75pt; padding-bottom: 3.75pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.28%; font-size: 2pt; padding-top: 3.75pt; padding-bottom: 3.75pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 9.62%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 3.75pt; padding-bottom: 3.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2019<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(2)</sup></div></td><td class="gutter" style="width: 1.28%; font-size: 2pt; padding-top: 3.75pt; padding-bottom: 3.75pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.28%; font-size: 2pt; padding-top: 3.75pt; padding-bottom: 3.75pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 9.61%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 3.75pt; padding-bottom: 3.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2018</div></td></tr><tr class="header"><td style="width: 51.28%; text-align: left; vertical-align: bottom; padding-top: 3.75pt; padding-bottom: 3.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Consolidated Income Statement Data:</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3.75pt; padding-bottom: 3.75pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3.75pt; padding-bottom: 3.75pt;">&#8203;</td><td colspan="10" style="width: 46.16%; text-align: center; vertical-align: bottom; padding-top: 3.75pt; padding-bottom: 3.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">(in USD thousands except for share and per share data)</div></td></tr><tr><td style="width: 51.28%; text-align: left; vertical-align: bottom; padding-top: 3.75pt; padding-bottom: 2.5pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Contract revenue<font style="padding-left: 3.09pt;"></font></div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3.75pt; padding-bottom: 2.5pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3.75pt; padding-bottom: 2.5pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.64%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3.75pt; padding-bottom: 2.5pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.05pt; text-align: left;"><font style="padding-left: 35pt;">&#8212;</font></div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3.75pt; padding-bottom: 2.5pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3.75pt; padding-bottom: 2.5pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.64%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3.75pt; padding-bottom: 2.5pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.05pt; text-align: left;"><font style="padding-left: 22.5pt;">2,340</font></div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3.75pt; padding-bottom: 2.5pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3.75pt; padding-bottom: 2.5pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.62%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3.75pt; padding-bottom: 2.5pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 22.5pt;">2,340</font></div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3.75pt; padding-bottom: 2.5pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3.75pt; padding-bottom: 2.5pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.61%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3.75pt; padding-bottom: 2.5pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 22.5pt;">1,140</font></div></td></tr><tr><td style="width: 51.28%; text-align: left; vertical-align: bottom; padding-top: 2.5pt; padding-bottom: 2.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Research and development expense<font style="padding-left: 2.56pt;"></font></div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td style="width: 9.64%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.5pt; padding-bottom: 2.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.05pt; text-align: left;"><font style="padding-left: 14.17pt;">(</font>61,325)</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td style="width: 9.64%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.5pt; padding-bottom: 2.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.05pt; text-align: left;"><font style="padding-left: 14.17pt;">(46,572)</font></div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td style="width: 9.62%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.5pt; padding-bottom: 2.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 9.17pt;">(</font>107,537)</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td style="width: 9.61%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.5pt; padding-bottom: 2.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 9.54pt;">(118,313)</font></div></td></tr><tr><td style="width: 51.28%; text-align: left; vertical-align: bottom; padding-top: 2.5pt; padding-bottom: 3.75pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">General and administrative expense<font style="padding-left: 2.01pt;"></font></div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 3.75pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 3.75pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.64%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.5pt; padding-bottom: 3.75pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.05pt; text-align: left;"><font style="padding-left: 14.17pt; border-bottom: 1pt solid #000000; min-width: 45pt;">(27,509</font><font style="min-width: 45pt;">)</font></div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 3.75pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 3.75pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.64%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.5pt; padding-bottom: 3.75pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.05pt; text-align: left;"><font style="padding-left: 19.17pt; border-bottom: 1pt solid #000000; min-width: 45pt;">(6,592</font><font style="min-width: 45pt;">)</font></div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 3.75pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 3.75pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.62%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.5pt; padding-bottom: 3.75pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 14.17pt; border-bottom: 1pt solid #000000; min-width: 45pt;">(</font><font style="border-bottom: 1pt solid #000000; min-width: 45pt;">14,202</font><font style="border-bottom: 1pt solid #000000; min-width: 45pt;"></font><font style="min-width: 45pt;">)</font></div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 3.75pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 3.75pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.61%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.5pt; padding-bottom: 3.75pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 19.17pt; border-bottom: 1pt solid #000000; min-width: 45pt;">(8,768</font><font style="min-width: 45pt;">)</font></div></td></tr><tr><td style="width: 51.28%; text-align: left; vertical-align: bottom; padding-top: 3.75pt; padding-bottom: 2.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Operating loss<font style="padding-left: 3.63pt;"></font></div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3.75pt; padding-bottom: 2.5pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3.75pt; padding-bottom: 2.5pt;">&#8203;</td><td style="width: 9.64%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3.75pt; padding-bottom: 2.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.05pt; text-align: left;"><font style="padding-left: 14.17pt;">(88,834)</font></div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3.75pt; padding-bottom: 2.5pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3.75pt; padding-bottom: 2.5pt;">&#8203;</td><td style="width: 9.64%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3.75pt; padding-bottom: 2.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.05pt; text-align: left;"><font style="padding-left: 14.17pt;">(50,824)</font></div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3.75pt; padding-bottom: 2.5pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3.75pt; padding-bottom: 2.5pt;">&#8203;</td><td style="width: 9.62%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3.75pt; padding-bottom: 2.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 9.54pt;">(</font>119,399)</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3.75pt; padding-bottom: 2.5pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3.75pt; padding-bottom: 2.5pt;">&#8203;</td><td style="width: 9.61%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3.75pt; padding-bottom: 2.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 9.17pt;">(125,941)</font> </div></td></tr><tr><td style="width: 51.28%; text-align: left; vertical-align: bottom; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Other income <font style="padding-left: 3.64pt;"></font></div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.64%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.05pt; text-align: left;"><font style="padding-left: 30pt;">278</font> </div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.64%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.05pt; text-align: left;"><font style="padding-left: 35pt;">&#8212;</font> </div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.62%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 22.5pt;">1,6</font>55 </div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.61%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 35pt;">&#8212;</font> </div></td></tr><tr><td style="width: 51.28%; text-align: left; vertical-align: bottom; padding-top: 2.5pt; padding-bottom: 2.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Convertible loans, derivatives, increase in fair value<font style="padding-left: 4.26pt;"></font></div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td style="width: 9.64%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.5pt; padding-bottom: 2.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.05pt; text-align: left;"><font style="padding-left: 14.17pt;">(79,261)</font></div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td style="width: 9.64%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.5pt; padding-bottom: 2.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.05pt; text-align: left;"><font style="padding-left: 35pt;">&#8212;</font></div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td style="width: 9.62%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.5pt; padding-bottom: 2.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 35pt;">&#8212;</font></div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td style="width: 9.61%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.5pt; padding-bottom: 2.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 35pt;">&#8212;</font></div></td></tr><tr><td style="width: 51.28%; text-align: left; vertical-align: bottom; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 20pt; text-indent: -10pt; text-align: left;">Convertible loans, first tranche, derivative, transaction costs<font style="padding-left: 2.51pt;"></font></div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.64%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.05pt; text-align: left;"><font style="padding-left: 19.17pt;">(1,571)</font></div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.64%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.05pt; text-align: left;"><font style="padding-left: 35pt;">&#8212;</font></div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.62%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 35pt;">&#8212;</font></div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.61%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 35pt;">&#8212;</font></div></td></tr><tr><td style="width: 51.28%; text-align: left; vertical-align: bottom; padding-top: 2.5pt; padding-bottom: 2.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Financial income<font style="padding-left: 2.52pt;"></font></div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td style="width: 9.64%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.5pt; padding-bottom: 2.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.05pt; text-align: left;"><font style="padding-left: 30pt;">569</font></div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td style="width: 9.64%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.5pt; padding-bottom: 2.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.05pt; text-align: left;"><font style="padding-left: 22.5pt;">1,306</font></div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td style="width: 9.62%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.5pt; padding-bottom: 2.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 22.5pt;">2,253</font></div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td style="width: 9.61%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.5pt; padding-bottom: 2.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 22.5pt;">2,856</font></div></td></tr><tr><td style="width: 51.28%; text-align: left; vertical-align: bottom; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Financial expense<font style="padding-left: 4.75pt;"></font></div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.64%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.05pt; text-align: left;"><font style="padding-left: 26.67pt;">(939)</font></div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.64%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.05pt; text-align: left;"><font style="padding-left: 31.67pt;">(</font>73)</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.62%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 26.67pt;">(</font>156)</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.61%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 35pt;">&#8212;</font></div></td></tr><tr><td style="width: 51.28%; text-align: left; vertical-align: bottom; padding-top: 2.5pt; padding-bottom: 3.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Exchange differences<font style="padding-left: 0.5pt;"></font></div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 3.75pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 3.75pt;">&#8203;</td><td style="width: 9.64%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.5pt; padding-bottom: 3.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.05pt; text-align: left;"><font style="padding-left: 31.67pt; border-bottom: 1pt solid #000000; min-width: 45pt;">(</font><font style="border-bottom: 1pt solid #000000; min-width: 45pt;">71</font><font style="border-bottom: 1pt solid #000000; min-width: 45pt;"></font><font style="min-width: 45pt;">)</font></div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 3.75pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 3.75pt;">&#8203;</td><td style="width: 9.64%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.5pt; padding-bottom: 3.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.05pt; text-align: left;"><font style="padding-left: 31.67pt; border-bottom: 1pt solid #000000; min-width: 45pt;">(</font><font style="border-bottom: 1pt solid #000000; min-width: 45pt;">68</font><font style="border-bottom: 1pt solid #000000; min-width: 45pt;"></font><font style="min-width: 45pt;">)</font></div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 3.75pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 3.75pt;">&#8203;</td><td style="width: 9.62%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.5pt; padding-bottom: 3.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 26.67pt; border-bottom: 1pt solid #000000; min-width: 45pt;">(</font><font style="border-bottom: 1pt solid #000000; min-width: 45pt;">255</font><font style="border-bottom: 1pt solid #000000; min-width: 45pt;"></font><font style="min-width: 45pt;">)</font></div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 3.75pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 3.75pt;">&#8203;</td><td style="width: 9.61%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.5pt; padding-bottom: 3.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 30pt; border-bottom: 1pt solid #000000; min-width: 45pt;">213</font></div></td></tr><tr><td style="width: 51.28%; text-align: left; vertical-align: bottom; padding-top: 3.75pt; padding-bottom: 2.5pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Loss before taxes<font style="padding-left: 0.87pt;"></font></div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3.75pt; padding-bottom: 2.5pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3.75pt; padding-bottom: 2.5pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.64%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3.75pt; padding-bottom: 2.5pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.05pt; text-align: left;"><font style="padding-left: 9.17pt;">(169,829)</font></div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3.75pt; padding-bottom: 2.5pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3.75pt; padding-bottom: 2.5pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.64%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3.75pt; padding-bottom: 2.5pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.05pt; text-align: left;"><font style="padding-left: 14.17pt;">(49,659)</font></div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3.75pt; padding-bottom: 2.5pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3.75pt; padding-bottom: 2.5pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.62%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3.75pt; padding-bottom: 2.5pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 9.54pt;">(</font>115,902)</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3.75pt; padding-bottom: 2.5pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3.75pt; padding-bottom: 2.5pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.61%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3.75pt; padding-bottom: 2.5pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 9.17pt;">(122,872)</font></div></td></tr><tr><td style="width: 51.28%; text-align: left; vertical-align: bottom; padding-top: 2.5pt; padding-bottom: 3.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Income tax expense<font style="padding-left: 1.43pt;"></font></div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 3.75pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 3.75pt;">&#8203;</td><td style="width: 9.64%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.5pt; padding-bottom: 3.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.05pt; text-align: left;"><font style="padding-left: 26.67pt; border-bottom: 1pt solid #000000; min-width: 45pt;">(</font><font style="border-bottom: 1pt solid #000000; min-width: 45pt;">204</font><font style="border-bottom: 1pt solid #000000; min-width: 45pt;"></font><font style="min-width: 45pt;">)</font></div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 3.75pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 3.75pt;">&#8203;</td><td style="width: 9.64%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.5pt; padding-bottom: 3.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.05pt; text-align: left;"><font style="padding-left: 26.67pt; border-bottom: 1pt solid #000000; min-width: 45pt;">(</font><font style="border-bottom: 1pt solid #000000; min-width: 45pt;">199</font><font style="border-bottom: 1pt solid #000000; min-width: 45pt;"></font><font style="min-width: 45pt;">)</font></div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 3.75pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 3.75pt;">&#8203;</td><td style="width: 9.62%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.5pt; padding-bottom: 3.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 26.67pt; border-bottom: 1pt solid #000000; min-width: 45pt;">(</font><font style="border-bottom: 1pt solid #000000; min-width: 45pt;">582</font><font style="border-bottom: 1pt solid #000000; min-width: 45pt;"></font><font style="min-width: 45pt;">)</font></div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 3.75pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 3.75pt;">&#8203;</td><td style="width: 9.61%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.5pt; padding-bottom: 3.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 26.67pt; border-bottom: 1pt solid #000000; min-width: 45pt;">(224</font><font style="min-width: 45pt;">)</font></div></td></tr><tr><td style="width: 51.28%; text-align: left; vertical-align: bottom; padding-top: 3.75pt; padding-bottom: 4.75pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Loss for the period<font style="padding-left: 4.2pt;"></font></div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3.75pt; padding-bottom: 4.75pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3.75pt; padding-bottom: 4.75pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.64%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3.75pt; padding-bottom: 4.75pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.05pt; text-align: left;"><font style="padding-left: 9.17pt; border-bottom: 3pt double #000000; min-width: 45pt;">(170,033</font><font style="min-width: 45pt;">)</font></div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3.75pt; padding-bottom: 4.75pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3.75pt; padding-bottom: 4.75pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.64%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3.75pt; padding-bottom: 4.75pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.05pt; text-align: left;"><font style="padding-left: 14.17pt; border-bottom: 3pt double #000000; min-width: 45pt;">(49,858</font><font style="min-width: 45pt;">)</font></div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3.75pt; padding-bottom: 4.75pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3.75pt; padding-bottom: 4.75pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.62%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3.75pt; padding-bottom: 4.75pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 9.54pt; border-bottom: 3pt double #000000; min-width: 45pt;">(</font><font style="border-bottom: 3pt double #000000; min-width: 45pt;">116,484</font><font style="border-bottom: 3pt double #000000; min-width: 45pt;"></font><font style="min-width: 45pt;">)</font></div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3.75pt; padding-bottom: 4.75pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3.75pt; padding-bottom: 4.75pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.61%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3.75pt; padding-bottom: 4.75pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 9.17pt; border-bottom: 3pt double #000000; min-width: 45pt;">(123,096</font><font style="min-width: 45pt;">)</font></div></td></tr><tr><td style="width: 51.28%; text-align: left; vertical-align: bottom; padding-top: 4.75pt; padding-bottom: 4.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Basic and diluted loss per share<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(1)</sup><font style="padding-left: 3.26pt;"></font></div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 4.75pt; padding-bottom: 4.75pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 4.75pt; padding-bottom: 4.75pt;">&#8203;</td><td style="width: 9.64%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.75pt; padding-bottom: 4.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.05pt; text-align: left;"><font style="padding-left: 24.17pt; border-bottom: 3pt double #000000; min-width: 45pt;">(</font><font style="border-bottom: 3pt double #000000; min-width: 45pt;">2.</font><font style="border-bottom: 3pt double #000000; min-width: 45pt;">97</font><font style="border-bottom: 3pt double #000000; min-width: 45pt;"></font><font style="min-width: 45pt;">)</font></div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 4.75pt; padding-bottom: 4.75pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 4.75pt; padding-bottom: 4.75pt;">&#8203;</td><td style="width: 9.64%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.75pt; padding-bottom: 4.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.05pt; text-align: left;"><font style="padding-left: 24.17pt; border-bottom: 3pt double #000000; min-width: 45pt;">(1.05</font><font style="min-width: 45pt;">)</font></div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 4.75pt; padding-bottom: 4.75pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 4.75pt; padding-bottom: 4.75pt;">&#8203;</td><td style="width: 9.62%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.75pt; padding-bottom: 4.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 24.17pt; border-bottom: 3pt double #000000; min-width: 45pt;">(</font><font style="border-bottom: 3pt double #000000; min-width: 45pt;">2.36</font><font style="border-bottom: 3pt double #000000; min-width: 45pt;"></font><font style="min-width: 45pt;">)</font></div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 4.75pt; padding-bottom: 4.75pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 4.75pt; padding-bottom: 4.75pt;">&#8203;</td><td style="width: 9.61%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.75pt; padding-bottom: 4.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 24.17pt; border-bottom: 3pt double #000000; min-width: 45pt;">(</font><font style="border-bottom: 3pt double #000000; min-width: 45pt;">2.</font><font style="border-bottom: 3pt double #000000; min-width: 45pt;">64</font><font style="border-bottom: 3pt double #000000; min-width: 45pt;"></font><font style="min-width: 45pt;">)</font></div></td></tr><tr><td style="width: 51.28%; text-align: left; vertical-align: bottom; padding-top: 4.75pt; padding-bottom: 6pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-indent: -10pt; text-align: left;">Weighted-average number of shares used to compute basic and diluted loss per share<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(1)</sup><font style="padding-left: 4.93pt;"></font></div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 4.75pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 4.75pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.64%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.75pt; padding-bottom: 6pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.05pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 45pt;">57,225,939</font></div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 4.75pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 4.75pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.64%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.75pt; padding-bottom: 6pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.05pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 45pt;">47,297,859</font></div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 4.75pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 4.75pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.62%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.75pt; padding-bottom: 6pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 45pt;">49,279,961</font></div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 4.75pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 4.75pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.61%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.75pt; padding-bottom: 6pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 45pt;">46,600,000</font></div></td></tr></table><div><div class="rule-partial" style="height: 0pt; width: 72pt; border-bottom: 1pt solid #000000; margin-bottom: 1pt; margin-right: auto; margin-left: 0pt; margin-top: 13.25pt;"> </div></div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 3pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">(1)<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; text-align: left;">See Note 28 to our audited consolidated financial statements and Note 15 to our unaudited condensed consolidated interim financial statements, each included elsewhere in this prospectus for a description of the method used to compute basic and diluted net loss per share.</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 3pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">(2)<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; text-align: left;">On January 1, 2019, we adopted IFRS 16 &#8220;Leases,&#8221; the impact of which is described in Note 17 to our audited consolidated financial statements.</div></td></tr></table></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 36pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">87<br></div></div></div>
<!--End Page 91-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 92-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 540pt;"><a name="nt10014672x1_drs_105-caution_pg9"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="block-frill" style="width: 540pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: Arial, Helvetica, sans-serif; font-size: 9pt; font-weight: bold; margin-top: 6pt; text-align: center;">Confidential Treatment Requested by ADC Therapeutics SA Pursuant to 17 C.F.R. &#167; 200.83<br></div></div><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 36pt;"><table cellspacing="0" cellpadding="0" class="fintab" style="margin-top: 4pt; border-collapse: collapse; width: 468pt; margin-left: auto; margin-right: auto;"><tr class="header"><td style="width: 66.67%; text-align: left; vertical-align: bottom; padding-top: 6pt; padding-bottom: 3.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 1.22%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 3.5pt;">&#8203;</td><td class="gutter" style="width: 1.22%; font-size: 2pt; padding-top: 6pt; padding-bottom: 3.5pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 10.68%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 3.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">As of June 30,</div></td><td class="gutter" style="width: 1.22%; font-size: 2pt; padding-top: 6pt; padding-bottom: 3.5pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.22%; font-size: 2pt; padding-top: 6pt; padding-bottom: 3.5pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td colspan="4" style="width: 17.76%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 3.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">As of December 31,</div></td></tr><tr class="header"><td style="width: 66.67%; text-align: left; vertical-align: bottom; padding-top: 3.5pt; padding-bottom: 3.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 1.22%; border-bottom: none; font-size: 2pt; padding-top: 3.5pt; padding-bottom: 3.5pt;">&#8203;</td><td class="gutter" style="width: 1.22%; font-size: 2pt; padding-top: 3.5pt; padding-bottom: 3.5pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 10.68%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 3.5pt; padding-bottom: 3.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2020</div></td><td class="gutter" style="width: 1.22%; font-size: 2pt; padding-top: 3.5pt; padding-bottom: 3.5pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.22%; font-size: 2pt; padding-top: 3.5pt; padding-bottom: 3.5pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 7.66%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 3.5pt; padding-bottom: 3.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2019</div></td><td class="gutter" style="width: 1.22%; font-size: 2pt; padding-top: 3.5pt; padding-bottom: 3.5pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.22%; font-size: 2pt; padding-top: 3.5pt; padding-bottom: 3.5pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 7.66%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 3.5pt; padding-bottom: 3.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2018</div></td></tr><tr class="header"><td style="width: 66.67%; text-align: left; vertical-align: bottom; padding-top: 3.5pt; padding-bottom: 3.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Consolidated Balance Sheet Data:</div></td><td class="gutter" style="width: 1.22%; border-bottom: none; font-size: 2pt; padding-top: 3.5pt; padding-bottom: 3.5pt;">&#8203;</td><td class="gutter" style="width: 1.22%; border-bottom: none; font-size: 2pt; padding-top: 3.5pt; padding-bottom: 3.5pt;">&#8203;</td><td colspan="7" style="width: 30.88%; text-align: center; vertical-align: bottom; padding-top: 3.5pt; padding-bottom: 3.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">(in USD thousands)</div></td></tr><tr><td style="width: 66.67%; text-align: left; vertical-align: bottom; padding-top: 3.5pt; padding-bottom: 4.5pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Cash and cash equivalents<font style="padding-left: 1.77pt;"></font></div></td><td class="gutter" style="width: 1.22%; border-bottom: none; font-size: 2pt; padding-top: 3.5pt; padding-bottom: 4.5pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.22%; border-bottom: none; font-size: 2pt; padding-top: 3.5pt; padding-bottom: 4.5pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.68%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3.5pt; padding-bottom: 4.5pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.07pt; text-align: left;"><font style="padding-left: 3.33pt; border-bottom: 3pt double #000000; min-width: 35.83pt;">348,593</font></div></td><td class="gutter" style="width: 1.22%; border-bottom: none; font-size: 2pt; padding-top: 3.5pt; padding-bottom: 4.5pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.22%; border-bottom: none; font-size: 2pt; padding-top: 3.5pt; padding-bottom: 4.5pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.66%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3.5pt; padding-bottom: 4.5pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;"><font style="padding-left: 3.7pt; border-bottom: 3pt double #000000; min-width: 35.83pt;">115,551</font></div></td><td class="gutter" style="width: 1.22%; border-bottom: none; font-size: 2pt; padding-top: 3.5pt; padding-bottom: 4.5pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.22%; border-bottom: none; font-size: 2pt; padding-top: 3.5pt; padding-bottom: 4.5pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.66%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3.5pt; padding-bottom: 4.5pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;"><font style="padding-left: 3.33pt; border-bottom: 3pt double #000000; min-width: 35.83pt;">138,807</font></div></td></tr><tr><td style="width: 66.67%; text-align: left; vertical-align: bottom; padding-top: 4.5pt; padding-bottom: 4.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Total assets<font style="padding-left: 2.44pt;"></font></div></td><td class="gutter" style="width: 1.22%; border-bottom: none; font-size: 2pt; padding-top: 4.5pt; padding-bottom: 4.5pt;">&#8203;</td><td class="gutter" style="width: 1.22%; border-bottom: none; font-size: 2pt; padding-top: 4.5pt; padding-bottom: 4.5pt;">&#8203;</td><td style="width: 10.68%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.5pt; padding-bottom: 4.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.07pt; text-align: left;"><font style="padding-left: 3.33pt; border-bottom: 3pt double #000000; min-width: 35.83pt;">373,842</font></div></td><td class="gutter" style="width: 1.22%; border-bottom: none; font-size: 2pt; padding-top: 4.5pt; padding-bottom: 4.5pt;">&#8203;</td><td class="gutter" style="width: 1.22%; border-bottom: none; font-size: 2pt; padding-top: 4.5pt; padding-bottom: 4.5pt;">&#8203;</td><td style="width: 7.66%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.5pt; padding-bottom: 4.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;"><font style="padding-left: 3.33pt; border-bottom: 3pt double #000000; min-width: 35.83pt;">137,682</font></div></td><td class="gutter" style="width: 1.22%; border-bottom: none; font-size: 2pt; padding-top: 4.5pt; padding-bottom: 4.5pt;">&#8203;</td><td class="gutter" style="width: 1.22%; border-bottom: none; font-size: 2pt; padding-top: 4.5pt; padding-bottom: 4.5pt;">&#8203;</td><td style="width: 7.66%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.5pt; padding-bottom: 4.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;"><font style="padding-left: 3.33pt; border-bottom: 3pt double #000000; min-width: 35.83pt;">150,558</font></div></td></tr><tr><td style="width: 66.67%; text-align: left; vertical-align: bottom; padding-top: 4.5pt; padding-bottom: 4.5pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Total liabilities<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(1)</sup><font style="padding-left: 4.8pt;"></font></div></td><td class="gutter" style="width: 1.22%; border-bottom: none; font-size: 2pt; padding-top: 4.5pt; padding-bottom: 4.5pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.22%; border-bottom: none; font-size: 2pt; padding-top: 4.5pt; padding-bottom: 4.5pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.68%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.5pt; padding-bottom: 4.5pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.07pt; text-align: left;"><font style="padding-left: 3.33pt; border-bottom: 3pt double #000000; min-width: 35.83pt;">177,540</font></div></td><td class="gutter" style="width: 1.22%; border-bottom: none; font-size: 2pt; padding-top: 4.5pt; padding-bottom: 4.5pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.22%; border-bottom: none; font-size: 2pt; padding-top: 4.5pt; padding-bottom: 4.5pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.66%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.5pt; padding-bottom: 4.5pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;"><font style="padding-left: 8.33pt; border-bottom: 3pt double #000000; min-width: 35.83pt;">26,526</font></div></td><td class="gutter" style="width: 1.22%; border-bottom: none; font-size: 2pt; padding-top: 4.5pt; padding-bottom: 4.5pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.22%; border-bottom: none; font-size: 2pt; padding-top: 4.5pt; padding-bottom: 4.5pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.66%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.5pt; padding-bottom: 4.5pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;"><font style="padding-left: 8.33pt; border-bottom: 3pt double #000000; min-width: 35.83pt;">24,315</font></div></td></tr><tr><td style="width: 66.67%; text-align: left; vertical-align: bottom; padding-top: 4.5pt; padding-bottom: 2.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Share capital<font style="padding-left: 1.75pt;"></font></div></td><td class="gutter" style="width: 1.22%; border-bottom: none; font-size: 2pt; padding-top: 4.5pt; padding-bottom: 2.25pt;">&#8203;</td><td class="gutter" style="width: 1.22%; border-bottom: none; font-size: 2pt; padding-top: 4.5pt; padding-bottom: 2.25pt;">&#8203;</td><td style="width: 10.68%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.5pt; padding-bottom: 2.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.07pt; text-align: left;"><font style="padding-left: 13.33pt;">5,795</font></div></td><td class="gutter" style="width: 1.22%; border-bottom: none; font-size: 2pt; padding-top: 4.5pt; padding-bottom: 2.25pt;">&#8203;</td><td class="gutter" style="width: 1.22%; border-bottom: none; font-size: 2pt; padding-top: 4.5pt; padding-bottom: 2.25pt;">&#8203;</td><td style="width: 7.66%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.5pt; padding-bottom: 2.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;"><font style="padding-left: 13.33pt;">4,361</font></div></td><td class="gutter" style="width: 1.22%; border-bottom: none; font-size: 2pt; padding-top: 4.5pt; padding-bottom: 2.25pt;">&#8203;</td><td class="gutter" style="width: 1.22%; border-bottom: none; font-size: 2pt; padding-top: 4.5pt; padding-bottom: 2.25pt;">&#8203;</td><td style="width: 7.66%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.5pt; padding-bottom: 2.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;"><font style="padding-left: 20.83pt;">401</font></div></td></tr><tr><td style="width: 66.67%; text-align: left; vertical-align: bottom; padding-top: 2.25pt; padding-bottom: 2.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Share premium<font style="padding-left: 2.3pt;"></font></div></td><td class="gutter" style="width: 1.22%; border-bottom: none; font-size: 2pt; padding-top: 2.25pt; padding-bottom: 2.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.22%; border-bottom: none; font-size: 2pt; padding-top: 2.25pt; padding-bottom: 2.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.68%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.25pt; padding-bottom: 2.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.07pt; text-align: left;"><font style="padding-left: 3.33pt;">792,605</font></div></td><td class="gutter" style="width: 1.22%; border-bottom: none; font-size: 2pt; padding-top: 2.25pt; padding-bottom: 2.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.22%; border-bottom: none; font-size: 2pt; padding-top: 2.25pt; padding-bottom: 2.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.66%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.25pt; padding-bottom: 2.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;"><font style="padding-left: 3.33pt;">549,922</font></div></td><td class="gutter" style="width: 1.22%; border-bottom: none; font-size: 2pt; padding-top: 2.25pt; padding-bottom: 2.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.22%; border-bottom: none; font-size: 2pt; padding-top: 2.25pt; padding-bottom: 2.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.66%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.25pt; padding-bottom: 2.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;"><font style="padding-left: 3.33pt;">452,268</font></div></td></tr><tr><td style="width: 66.67%; text-align: left; vertical-align: bottom; padding-top: 2.25pt; padding-bottom: 2.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Accumulated losses<font style="padding-left: 3.98pt;"></font></div></td><td class="gutter" style="width: 1.22%; border-bottom: none; font-size: 2pt; padding-top: 2.25pt; padding-bottom: 2.25pt;">&#8203;</td><td class="gutter" style="width: 1.22%; border-bottom: none; font-size: 2pt; padding-top: 2.25pt; padding-bottom: 2.25pt;">&#8203;</td><td style="width: 10.68%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.25pt; padding-bottom: 2.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.07pt; text-align: left;">(618,602)</div></td><td class="gutter" style="width: 1.22%; border-bottom: none; font-size: 2pt; padding-top: 2.25pt; padding-bottom: 2.25pt;">&#8203;</td><td class="gutter" style="width: 1.22%; border-bottom: none; font-size: 2pt; padding-top: 2.25pt; padding-bottom: 2.25pt;">&#8203;</td><td style="width: 7.66%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.25pt; padding-bottom: 2.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;">(448,569)</div></td><td class="gutter" style="width: 1.22%; border-bottom: none; font-size: 2pt; padding-top: 2.25pt; padding-bottom: 2.25pt;">&#8203;</td><td class="gutter" style="width: 1.22%; border-bottom: none; font-size: 2pt; padding-top: 2.25pt; padding-bottom: 2.25pt;">&#8203;</td><td style="width: 7.66%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.25pt; padding-bottom: 2.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;">(332,085)</div></td></tr><tr><td style="width: 66.67%; text-align: left; vertical-align: bottom; padding-top: 2.25pt; padding-bottom: 6pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Total equity<font style="padding-left: 0.76pt;"></font></div></td><td class="gutter" style="width: 1.22%; border-bottom: none; font-size: 2pt; padding-top: 2.25pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.22%; border-bottom: none; font-size: 2pt; padding-top: 2.25pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.68%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.25pt; padding-bottom: 6pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.07pt; text-align: left;"><font style="padding-left: 3.33pt; border-bottom: 3pt double #000000; min-width: 35.83pt;">196,302</font></div></td><td class="gutter" style="width: 1.22%; border-bottom: none; font-size: 2pt; padding-top: 2.25pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.22%; border-bottom: none; font-size: 2pt; padding-top: 2.25pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.66%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.25pt; padding-bottom: 6pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;"><font style="padding-left: 4.07pt; border-bottom: 3pt double #000000; min-width: 35.83pt;">111,156</font></div></td><td class="gutter" style="width: 1.22%; border-bottom: none; font-size: 2pt; padding-top: 2.25pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.22%; border-bottom: none; font-size: 2pt; padding-top: 2.25pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.66%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.25pt; padding-bottom: 6pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;"><font style="padding-left: 3.33pt; border-bottom: 3pt double #000000; min-width: 35.83pt;">126,243</font></div></td></tr></table><div><div class="rule-partial" style="height: 0pt; width: 72pt; border-bottom: 1pt solid #000000; margin-bottom: 1pt; margin-right: auto; margin-left: 0pt; margin-top: 13.25pt;"> </div></div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 3pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">(1)<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; text-align: left;">See Notes 3 and 11 to our unaudited condensed consolidated interim financial statements included elsewhere in this prospectus for further information related to the Facility Agreement and accounting for the convertible loans and associated derivative instruments, which were a significant cause of the increase in our total liabilities as of June 30, 2020 from December 31, 2019.</div></td></tr></table></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 36pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">88<br></div></div></div>
<!--End Page 92-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 93-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 540pt;"><a name="nt10014672x1_drs_106-mda_pg1"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="block-frill" style="width: 540pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: Arial, Helvetica, sans-serif; font-size: 9pt; font-weight: bold; margin-top: 6pt; text-align: center;">Confidential Treatment Requested by ADC Therapeutics SA Pursuant to 17 C.F.R. &#167; 200.83<br></div></div><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 36pt;"><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: center;"><a name="tMDA"><!--Anchor--></a>MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND <br></div><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">RESULTS OF OPERATIONS </div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 6pt; margin-left: 0pt; text-align: left;">You should read the following discussion of our financial condition and results of operations in conjunction with the section titled &#8220;Selected Consolidated Financial Data&#8221; and our consolidated financial statements, including the notes thereto, included elsewhere in this prospectus. In addition to historical information, the following discussion and analysis contains forward-looking statements that reflect our plans, estimates and beliefs. Our actual results and the timing of events could differ materially from those anticipated in the forward-looking statements. Factors that could cause or contribute to these differences include those discussed below and elsewhere in this prospectus, particularly in the sections titled &#8220;Risk Factors&#8221; and &#8220;Cautionary Statement Regarding Forward-Looking Statements.&#8221; The audited consolidated financial statements as of and for the years ended December&#160;31, 2019 and 2018 were prepared in accordance with the IFRS and presented in USD. Our unaudited condensed consolidated interim financial statements are prepared in accordance with IAS 34 and presented in USD.</div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">Overview</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">We are a late clinical-stage oncology-focused biotechnology company evolving into a commercial-stage company as we prepare for the launch of our lead product candidate, if approved. We are a pioneer in the development of highly potent and targeted ADCs for patients suffering from hematological malignancies and solid tumors. We develop our ADCs by applying our decades of experience in this field and using next-generation PBD technology to which we have proprietary rights for our targets. We are leveraging our R&amp;D strengths, our disciplined approach to target selection and our preclinical and clinical development strategy to generate a diverse and balanced portfolio and research pipeline. Our hematology franchise comprises three clinical-stage product candidates, Lonca, Cami and ADCT-602. Our solid tumor franchise comprises two clinical-stage product candidates, Cami and ADCT-601, and two preclinical product candidates, ADCT-901 and ADCT-701. We retain exclusive worldwide development and commercialization rights to all of our product candidates other than Cami, for which we have a collaboration and license agreement with Genmab. Our commercial organization has initiated pre-launch market activities and is leveraging our team&#8217;s deep industry experience to maximize the commercial potential of any approved products.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Our two lead product candidates, Lonca and Cami, have demonstrated significant clinical activity across a broad population of heavily pre-treated patients, while maintaining tolerability profiles that we believe are manageable. We have evaluated Lonca in a 145-patient pivotal Phase 2 clinical trial for the treatment of relapsed or refractory DLBCL that showed a 48.3% ORR and a 24.1% CRR as of April 2020. We intend to submit a BLA to the FDA in the second half of 2020 for Lonca for the treatment of relapsed or refractory DLBCL. Concurrently, we intend to commence a confirmatory Phase 3 clinical trial of Lonca in combination with rituximab that, if successful, may serve as the basis for an sBLA for Lonca for the treatment of relapsed or refractory DLBCL in transplant-ineligible patients. We are also conducting a Phase 1/2 clinical trial of Lonca in combination with ibrutinib for the treatment of relapsed or refractory DLBCL and MCL that showed a 75.0% ORR and a 58.3% CRR as of April 6, 2020 at the dose being used in the pivotal Phase 2 portion of the clinical trial. In July 2020, we dosed the first patient in the pivotal Phase 2 portion of this clinical trial. We also had an end-of-Phase 1 meeting with the FDA in the second quarter of 2020 to discuss a potential pivotal Phase 2 clinical trial of Lonca for the treatment of relapsed or refractory FL that we expect to commence in the first half of 2021.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">In addition, we are evaluating Cami in a 100-patient pivotal Phase 2 clinical trial for the treatment of relapsed or refractory HL and have enrolled 47 patients as of June 30, 2020. We have completed enrollment of a 133-patient Phase 1 clinical trial of Cami for the treatment of relapsed or refractory HL and NHL that has shown an 86.5% ORR and a 48.6% CRR in patients with HL at the initial dose for our pivotal Phase 2 clinical trial and a 44.0% ORR and an 8.0% CRR in a subset of patients with T-cell lymphoma as of April 2019. We anticipate reporting top-line response rate data from our pivotal Phase 2 clinical trial of Cami for the treatment of HL in the first half of 2021, and we believe that this clinical trial, if successful, will support a BLA submission. We are also evaluating Cami in a Phase 1b clinical trial as a novel immuno-oncology approach for the treatment of various advanced solid tumors.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">We began our operations in 2011. Since then, our operations have focused on organizing and staffing our company, business planning, raising capital, conducting research and development, including preclinical studies and clinical trials, and preparing for commercial activities. We do not have any products approved for sale. We </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 36pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">89<br></div></div></div>
<!--End Page 93-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 94-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 540pt;"><a name="nt10014672x1_drs_106-mda_pg2"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="block-frill" style="width: 540pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: Arial, Helvetica, sans-serif; font-size: 9pt; font-weight: bold; margin-top: 6pt; text-align: center;">Confidential Treatment Requested by ADC Therapeutics SA Pursuant to 17 C.F.R. &#167; 200.83<br></div></div><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 36pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">have funded our operations primarily through equity and convertible debt financing and, to a lesser extent, through revenue from license and collaboration agreements. Since inception, we have raised $891.2 million in gross cash proceeds from equity and convertible debt financings, and a total of $30.0&#160;million from a collaboration agreement. As of June 30, 2020, we had cash and cash equivalents of $348.6 million.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Since our inception, we have incurred net losses, which have been significant in recent periods. For the years ended December&#160;31, 2019 and 2018, our net losses were $116.5 million and $123.1 million, respectively. For the six months ended June 30, 2020 and 2019, our net losses were $170.0 million and $49.9 million, respectively. We expect to continue to incur significant expenses and increasing net losses for the foreseeable future as we continue our research and development efforts and seek to obtain regulatory approval for and commercialize our product candidates. Our future profitability will be dependent upon the successful development, approval and commercialization of our product candidates and achieving a level of revenues adequate to support our cost structure. We may never achieve profitability and, unless and until we do, we will continue to need to raise additional capital. Our net losses may fluctuate significantly from period to period and year to year, depending principally on the timing of our clinical trials, our expenditures on other research and development activities, the timing and amount of our CMC costs, subject to obtaining regulatory approval for our product candidates, revenues generated from the commercialization of any approved products, and the fair value adjustments associated with the derivatives under the Facility Agreement. We anticipate that our expenses will increase substantially in connection with our ongoing activities, as we:</div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">seek regulatory approval for Lonca and our other product candidates from applicable regulatory authorities; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">conduct a confirmatory clinical trial of Lonca in combination with rituximab for the treatment of relapsed or refractory DLBCL; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">conduct pivotal Phase 2 clinical trials of our product candidates, including the pivotal Phase 2 clinical trial of Lonca for the treatment of relapsed or refractory FL, the Phase 1/2 clinical trial of Lonca in combination with ibrutinib for the treatment of relapsed or refractory DLBCL and MCL and the pivotal Phase 2 clinical trial of Cami for the treatment of relapsed or refractory HL;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">conduct Phase 1 clinical trials of our current and future product candidates; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">conduct any required confirmatory clinical trials of any of our product candidates in anticipation of potential accelerated approval from the FDA or similar conditional approval from the EMA or comparable regulatory agencies in other jurisdictions;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">expand our research and development efforts for our preclinical product candidates and research pipeline;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">invest in our late-stage clinical development, manufacturing and commercialization activities, including launching commercial sales, marketing and distribution operations;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">continue to prepare, file, prosecute, maintain, protect and enforce our intellectual property rights and claims;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">add clinical, scientific, operational, financial and management information systems and personnel; and</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">continue to operate as a public company.</div></td></tr></table><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">We are subject to a number of risks comparable to those of other similar companies, including dependence on key individuals; the need to develop product candidates with the required safety and efficacy profile to seek regulatory approval and be commercially viable; competition from other companies, many of which are larger and better capitalized; and the need to obtain adequate additional financing to fund the research and development of our product candidates and research pipeline.</div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 15pt; margin-left: 0pt; text-align: left;">Financial Operations Overview</div><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 7pt; margin-left: 0pt; text-align: left;">Product Revenue</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">To date, we have not generated any revenue from the sale of product candidates. Our ability to generate product revenue and to become profitable will depend upon our ability to successfully develop, obtain regulatory approval for and commercialize our lead product candidates, Lonca and Cami, and our other product candidates. Because of the numerous risks and uncertainties associated with product development and regulatory approval, we are unable to predict the amount or timing of product revenue.</div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 36pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">90<br></div></div></div>
<!--End Page 94-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 95-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 540pt;"><a name="nt10014672x1_drs_106-mda_pg3"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="block-frill" style="width: 540pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: Arial, Helvetica, sans-serif; font-size: 9pt; font-weight: bold; margin-top: 6pt; text-align: center;">Confidential Treatment Requested by ADC Therapeutics SA Pursuant to 17 C.F.R. &#167; 200.83<br></div></div><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 36pt;"><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">Contract Revenue</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">In 2013, we entered into a license and joint collaboration agreement with MedImmune related to the joint clinical development of MEDI3726. To date, we have recognized minimal contract revenue, which has consisted of upfront license payments received in 2013 and a milestone payment received in 2016 under this agreement. In addition, we have, in the past, received cost reimbursement payments under this agreement, which were offset against the related expenses and were not reported as revenue. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">In accordance with IFRS, revenue arising from the provision of services under a license or collaboration agreement is recognized by reference to the stage of completion of the transaction at the end of the reporting period. This method requires judgment on the part of management and, in particular, requires management to make a reliable estimate of total transaction revenue, the stage of completion and the costs to complete the transaction. As a result of the discontinuance of the joint clinical development of MEDI3726 in June 2019, as of December&#160;31, 2019, we had no non-refundable upfront payment (consisting of deferred revenue and presented as a contract liability in our consolidated balance sheet) remaining. </div><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 20.5pt; margin-left: 0pt; text-align: left;">Research and Development Expense</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 7.5pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Research and development expense consists principally of:</div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">salaries for research and development staff and related expenses, including share-based compensation expense;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">costs for production of preclinical and clinical-stage product candidates by CMOs;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">fees and other costs paid to contract research organizations in connection with the performance of preclinical studies and clinical trials;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">costs of related facilities, materials and equipment;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">costs associated with depreciation of right-of-use assets;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">costs associated with obtaining and maintaining patents and other intellectual property; and</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">amortization and depreciation of tangible and intangible fixed assets used to develop our product candidates.</div></td></tr></table><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8.5pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Research and development costs are expensed in the period in which they are incurred. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">We expect that our total research and development expense will increase substantially in future periods. Our research and development expense primarily relates to the following key programs:</div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;"><font style="font-style: italic;">Lonca</font>. Our pivotal Phase 2 clinical trial of Lonca for the treatment of relapsed or refractory DLBCL and our Phase 1/2 clinical trial of Lonca in combination with ibrutinib for the treatment of relapsed or refractory DLBCL and MCL.</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;"><font style="font-style: italic;">Cami</font>. Our pivotal Phase&#160;2 clinical trial of Cami for the treatment of relapsed or refractory HL and our Phase 1b clinical trial of Cami for the treatment of selected advanced solid tumors.</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;"><font style="font-style: italic;">Other development programs</font>. Our other research and development expenses related to our Phase 1/2 clinical trial of ADCT-602 for the treatment of relapsed or refractory ALL, ADCT-601 for the treatment of selected advanced solid tumors and our preclinical studies of ADCT-701 and ADCT-901 for the treatment of selected advanced solid tumors. The expenses mainly consist of salaries, costs for production of our product candidates and costs paid to contract research organizations in conjunction with clinical trials and preclinical studies.</div></td></tr></table><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Our research and development expense may vary substantially from period to period according to the status of our research and development activities. The timing of expenses are impacted by the commencement of clinical trials and enrollment of patients in clinical trials. Research and development expense is expected to increase as we advance the clinical development of our lead product candidates, Lonca and Cami, and further advance the research and development of our other product candidates. The successful development of our product candidates is uncertain. </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 36pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">91<br></div></div></div>
<!--End Page 95-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 96-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 540pt;"><a name="nt10014672x1_drs_106-mda_pg4"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="block-frill" style="width: 540pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: Arial, Helvetica, sans-serif; font-size: 9pt; font-weight: bold; margin-top: 6pt; text-align: center;">Confidential Treatment Requested by ADC Therapeutics SA Pursuant to 17 C.F.R. &#167; 200.83<br></div></div><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 36pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">At this time, we cannot reasonably estimate the nature, timing and estimated costs of the efforts that will be necessary to complete the development of, or the period, if any, in which material net cash inflows may commence from, any of our product candidates. This is due to numerous risks and uncertainties associated with developing drugs, including the uncertainty of:</div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the scope, rate of progress, results and cost of our clinical trials, preclinical studies and other related activities;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the cost of manufacturing clinical supplies, and establishing commercial supplies, of any product candidates;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the number and characteristics of product candidates that we pursue;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the cost, timing and outcomes of regulatory approvals;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the cost and timing of establishing sales, marketing and distribution capabilities; and</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the terms and timing of any collaboration, licensing or other arrangements that we may establish, including any required milestone and royalty payments thereunder.</div></td></tr></table><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">A change in the outcome of any of these variables with respect to the development of our lead product candidates, Lonca and Cami, or any other current or future product candidates could mean a significant change in the costs and timing associated with the development of such product candidate. For example, if we are required to conduct additional clinical trials or other testing of any of our product candidates beyond those that are contemplated or if we experience significant delays in enrollment in any clinical trials, we could incur significant additional costs and the clinical development timeline for our product candidates may be delayed.</div><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">General and Administrative Expense</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">General and administrative expense includes employee expenses (including share-based compensation expense) for commercial employees and general and administrative employees, external costs (including in particular professional fees relating to commercialization, communications costs and IT costs, facility expenses and travel expenses), general and administrative costs charged by related parties (including telecommunications costs), depreciation of property, plant and equipment, depreciation of right-of-use assets and amortization of intangible assets. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">We have incurred and expect to continue to incur additional expenses as a result of operating as a public company, including expenses related to compliance with the rules and regulations of the SEC, additional insurance expenses, investor relations activities and other administrative and professional services.</div><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">Other Income and Expense </div><div class="h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 7pt; margin-left: 0pt; text-align: left;">R&amp;D Tax Credit </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">We recognize as other income amounts received and receivable by our subsidiary, ADC Therapeutics (UK) Limited, under the United Kingdom&#8217;s Research and Development Expenditure Credit scheme. Such amounts represent 12% of eligible expenditure for fiscal years 2018, 2019 and 2020 (11% for periods for fiscal years prior to and including fiscal year 2017). Due to the strictness of the eligibility criteria for these credits, we did not recognize any income under this scheme until we received confirmation in 2019 that our initial claims were approved for payment. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The claims are payable through the tax system, as a refund of corporation tax or of other taxes, including income tax and social security payments deducted from qualifying employees&#8217; payroll and VAT. The credit is independent of ADC Therapeutics (UK) Limited&#8217;s taxable profit and is designed to incentivize companies to invest in research and development activities and is itself taxable income. We therefore have recognized the income as government grants within other income and not as a credit to the tax charge. </div><div class="h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 12pt; margin-left: 0pt; text-align: left;">Convertible Loans</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">On April 24, 2020, we entered into a Facility Agreement with Deerfield. See &#8220;&#8212;Liquidity and Capital Resources&#8212;$115.0 Million Facility Agreement.&#8221; The first tranche of convertible loans amounting to $65.0 million issued on May 19, 2020 has been accounted for as comprising two components: a convertible loan and an embedded derivative conversion feature.</div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">The embedded conversion option derivative has been initially measured at fair value and is subsequently re-measured to fair value at each reporting date. Under IAS 32, this derivative could have </div></td></tr></table></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 36pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">92<br></div></div></div>
<!--End Page 96-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 97-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 540pt;"><a name="nt10014672x1_drs_106-mda_pg5"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="block-frill" style="width: 540pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: Arial, Helvetica, sans-serif; font-size: 9pt; font-weight: bold; margin-top: 6pt; text-align: center;">Confidential Treatment Requested by ADC Therapeutics SA Pursuant to 17 C.F.R. &#167; 200.83<br></div></div><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 36pt;"><div class="bl" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 40pt; text-align: left;">been classified as a component of equity only if in all cases the contract would be settled by us delivering a fixed number of its own equity instruments in exchange for a fixed amount of cash or debt redemption. However, the agreement foresees, in the event of a major transaction, the payment of &#8220;make-whole&#8221; amounts that would have to be computed in the light of the circumstances and are therefore not fixed. As a result, the derivative is presented in the balance sheet as a liability and classified as non-equity in accordance with IFRS 9. Changes in the fair value (gains or losses) of the derivative at the end of each period are recorded in the consolidated statement of income. </div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">The convertible loan&#8217;s initial fair value is the residual amount of the consideration received, net of attributable costs, after separating out the fair value of the embedded conversion option derivative. The loan is subsequently measured at its amortized cost in accordance with IFRS 9. It is presented in the consolidated balance sheet as a financial liability. </div></td></tr></table><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Expenses and fees payable upon the issuance of the convertible loans have been allocated pro rata to the above two components. The share of expenses allocated to the embedded conversion option derivative has been charged directly to the unaudited condensed consolidated interim statement of income, while the share of expenses allocated to the residual convertible loan has been deducted from the loan. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">We are obligated to draw down the second tranche in the amount of $50.0 million upon receipt of regulatory approval for Lonca. However, if we have not received such regulatory approval on or prior to December 31, 2021, our ability to draw down the second tranche will automatically terminate on such date. This obligation has been accounted for as a derivative and is presented in the unaudited condensed consolidated interim balance sheet as a financial liability with changes in its fair value being recorded directly in the consolidated statement of income at the end of each accounting period. </div><div class="h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 17.5pt; margin-left: 0pt; text-align: left;">Financial Income and Expense</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Financial income primarily consists of interest received from banks on our cash balances. Our policy is to invest funds in a variety of capital preservation instruments, which may include all or a combination of short-term and long-term interest-bearing instruments, investment-grade securities, and direct or guaranteed obligations of the U.S. government. Financial expense consists principally of commercial banking fees.</div><div class="h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 18pt; margin-left: 0pt; text-align: left;">Taxation</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">We are subject to corporate taxation in Switzerland. We are also subject to taxation in other jurisdictions in which we operate, in particular, the United States and the United Kingdom, where our two wholly-owned subsidiaries are incorporated.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">We are entitled under Swiss laws to carry forward any losses incurred for a period of seven years, which could be used to offset future taxable income. As of December&#160;31, 2019, we had tax loss carryforwards totaling $437.0 million that can be carried forward through future periods with the latest period ending in 2026. There is no certainty that we will make sufficient profits to be able to utilize these tax loss carryforwards in full.</div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 18pt; margin-left: 0pt; text-align: left;">Results of Operations </div><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 7pt; margin-left: 0pt; text-align: left;">Comparison of the Six Months Ended June 30, 2020 and 2019 </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 7pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The following table summarizes our results of operations for the six months ended June 30, 2020 and 2019: </div><table cellspacing="0" cellpadding="0" class="fintab" style="margin-top: 5.25pt; border-collapse: collapse; width: 468pt; margin-left: auto; margin-right: auto;"><tr class="header"><td style="width: 66.67%; text-align: left; vertical-align: bottom; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 1.45%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.45%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td colspan="4" style="width: 20.96%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Six Months Ended June 30,</div></td><td class="gutter" style="width: 1.45%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.45%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 6.59%; text-align: center; vertical-align: bottom; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td></tr><tr class="header"><td style="width: 66.67%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 1.45%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.45%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 9.03%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2020</div></td><td class="gutter" style="width: 1.45%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.45%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 9.03%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2019</div></td><td class="gutter" style="width: 1.45%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.45%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 6.59%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Change</div></td></tr><tr class="header"><td style="width: 66.67%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 1.45%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.45%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td colspan="7" style="width: 30.44%; text-align: center; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">(in USD thousands) </div></td></tr><tr><td style="width: 66.67%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Contract revenue<font style="padding-left: 0.09pt;"></font></div></td><td class="gutter" style="width: 1.45%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.45%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.03%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 5.73pt; text-align: left;"><font style="padding-left: 20.83pt;">&#8212;</font></div></td><td class="gutter" style="width: 1.45%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.45%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.03%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 5.72pt; text-align: left;"><font style="padding-left: 8.33pt;">2,340</font></div></td><td class="gutter" style="width: 1.45%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.45%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.59%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 5pt;">(2,340) </font></div></td></tr><tr><td style="width: 66.67%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Research and development expense<font style="padding-left: 4.56pt;"></font></div></td><td class="gutter" style="width: 1.45%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.45%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 9.03%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 5.73pt; text-align: left;">(61,325)</div></td><td class="gutter" style="width: 1.45%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.45%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 9.03%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 5.72pt; text-align: left;">(46,572)</div></td><td class="gutter" style="width: 1.45%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.45%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 6.59%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">(14,753)</div></td></tr><tr><td style="width: 66.67%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">General and administrative expense<font style="padding-left: 4.01pt;"></font></div></td><td class="gutter" style="width: 1.45%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.45%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.03%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 5.73pt; text-align: left;">(27,509)</div></td><td class="gutter" style="width: 1.45%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.45%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.03%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 5.72pt; text-align: left;"><font style="padding-left: 5pt;">(6,592)</font></div></td><td class="gutter" style="width: 1.45%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.45%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.59%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">(20,917)</div></td></tr><tr><td style="width: 66.67%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Operating loss<font style="padding-left: 0.63pt;"></font></div></td><td class="gutter" style="width: 1.45%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.45%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 9.03%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 5.73pt; text-align: left;">(88,834)</div></td><td class="gutter" style="width: 1.45%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.45%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 9.03%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 5.72pt; text-align: left;">(50,824)</div></td><td class="gutter" style="width: 1.45%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.45%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 6.59%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">(38,010)</div></td></tr><tr><td style="width: 66.67%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Other income<font style="padding-left: 3.97pt;"></font></div></td><td class="gutter" style="width: 1.45%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.45%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.03%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 5.73pt; text-align: left;"><font style="padding-left: 15.83pt;">278</font></div></td><td class="gutter" style="width: 1.45%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.45%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.03%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 5.72pt; text-align: left;"><font style="padding-left: 20.83pt;">&#8212;</font></div></td><td class="gutter" style="width: 1.45%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.45%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.59%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 15.83pt;">278</font></div></td></tr><tr><td style="width: 66.67%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Convertible loans, derivatives, increase in fair value<font style="padding-left: 1.26pt;"></font></div></td><td class="gutter" style="width: 1.45%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.45%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 9.03%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 5.73pt; text-align: left;">(79,261)</div></td><td class="gutter" style="width: 1.45%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.45%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 9.03%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 5.72pt; text-align: left;"><font style="padding-left: 20.83pt;">&#8212;</font></div></td><td class="gutter" style="width: 1.45%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.45%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 6.59%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">(79,261)</div></td></tr><tr><td style="width: 66.67%; text-align: left; vertical-align: bottom; padding-top: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Convertible loans, first tranche, derivative, transaction costs<font style="padding-left: 4.32pt;"></font></div></td><td class="gutter" style="width: 1.45%; border-bottom: none; font-size: 2pt; padding-top: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.45%; border-bottom: none; font-size: 2pt; padding-top: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.03%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 5.73pt; text-align: left;"><font style="padding-left: 5pt;">(1,571)</font></div></td><td class="gutter" style="width: 1.45%; border-bottom: none; font-size: 2pt; padding-top: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.45%; border-bottom: none; font-size: 2pt; padding-top: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.03%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 5.72pt; text-align: left;"><font style="padding-left: 20.83pt;">&#8212;</font></div></td><td class="gutter" style="width: 1.45%; border-bottom: none; font-size: 2pt; padding-top: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.45%; border-bottom: none; font-size: 2pt; padding-top: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.59%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 5pt;">(1,571)</font></div></td></tr></table></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 36pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">93<br></div></div></div>
<!--End Page 97-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 98-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 540pt;"><a name="nt10014672x1_drs_106-mda_pg6"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="block-frill" style="width: 540pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: Arial, Helvetica, sans-serif; font-size: 9pt; font-weight: bold; margin-top: 6pt; text-align: center;">Confidential Treatment Requested by ADC Therapeutics SA Pursuant to 17 C.F.R. &#167; 200.83<br></div></div><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 36pt;"><table cellspacing="0" cellpadding="0" class="fintab" style="margin-top: 4pt; border-collapse: collapse; width: 468pt; margin-left: auto; margin-right: auto;"><tr class="header"><td style="width: 66.67%; text-align: left; vertical-align: bottom; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 1.45%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.45%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td colspan="4" style="width: 20.96%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Six Months Ended June 30,</div></td><td class="gutter" style="width: 1.45%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.45%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 6.59%; text-align: center; vertical-align: bottom; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td></tr><tr class="header"><td style="width: 66.67%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 1.45%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.45%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 9.03%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2020</div></td><td class="gutter" style="width: 1.45%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.45%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 9.03%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2019</div></td><td class="gutter" style="width: 1.45%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.45%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 6.59%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Change</div></td></tr><tr class="header"><td style="width: 66.67%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 1.45%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.45%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td colspan="7" style="width: 30.44%; text-align: center; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">(in USD thousands) </div></td></tr><tr><td style="width: 66.67%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Financial income<font style="padding-left: 4.52pt;"></font></div></td><td class="gutter" style="width: 1.45%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.45%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.03%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.23pt; text-align: left;"><font style="padding-left: 20.83pt;">569</font></div></td><td class="gutter" style="width: 1.45%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.45%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.03%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 5.72pt; text-align: left;"><font style="padding-left: 8.33pt;">1,306</font></div></td><td class="gutter" style="width: 1.45%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.45%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.59%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -5pt; text-align: left;"><font style="padding-left: 17.5pt;">(737)</font></div></td></tr><tr><td style="width: 66.67%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Financial expense<font style="padding-left: 1.75pt;"></font></div></td><td class="gutter" style="width: 1.45%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.45%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 9.03%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.23pt; text-align: left;"><font style="padding-left: 17.5pt;">(939)</font></div></td><td class="gutter" style="width: 1.45%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.45%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 9.03%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 5.72pt; text-align: left;"><font style="padding-left: 17.5pt;">(73)</font></div></td><td class="gutter" style="width: 1.45%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.45%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 6.59%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -5pt; text-align: left;"><font style="padding-left: 17.5pt;">(866)</font></div></td></tr><tr><td style="width: 66.67%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Exchange differences <font style="padding-left: 4.17pt;"></font></div></td><td class="gutter" style="width: 1.45%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.45%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.03%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.23pt; text-align: left;"><font style="padding-left: 22.5pt; border-bottom: 1pt solid #000000; min-width: 35.83pt;">(71</font><font style="min-width: 35.83pt;">)</font></div></td><td class="gutter" style="width: 1.45%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.45%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.03%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 5.72pt; text-align: left;"><font style="padding-left: 17.5pt; border-bottom: 1pt solid #000000; min-width: 30.83pt;">(68</font><font style="min-width: 30.83pt;">)</font></div></td><td class="gutter" style="width: 1.45%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.45%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.59%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -5pt; text-align: left;"><font style="padding-left: 27.5pt; border-bottom: 1pt solid #000000; min-width: 35.83pt;">(3</font><font style="min-width: 35.83pt;">)</font></div></td></tr><tr><td style="width: 66.67%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Loss before taxes<font style="padding-left: 2.87pt;"></font></div></td><td class="gutter" style="width: 1.45%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.45%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 9.03%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.23pt; text-align: left;">(169,829)</div></td><td class="gutter" style="width: 1.45%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.45%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 9.03%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 5.72pt; text-align: left;">(49,659)</div></td><td class="gutter" style="width: 1.45%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.45%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 6.59%; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -5pt; text-align: justify;">(120,170)</div></td></tr><tr><td style="width: 66.67%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 20pt; text-align: left;">Income tax expense<font style="padding-left: 3.43pt;"></font></div></td><td class="gutter" style="width: 1.45%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.45%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.03%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.23pt; text-align: left;"><font style="padding-left: 17.5pt; border-bottom: 1pt solid #000000; min-width: 35.83pt;">(204</font><font style="min-width: 35.83pt;">)</font></div></td><td class="gutter" style="width: 1.45%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.45%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.03%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 5.72pt; text-align: left;"><font style="padding-left: 12.5pt; border-bottom: 1pt solid #000000; min-width: 30.83pt;">(199</font><font style="min-width: 30.83pt;">)</font></div></td><td class="gutter" style="width: 1.45%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.45%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.59%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -5pt; text-align: left;"><font style="padding-left: 27.5pt; border-bottom: 1pt solid #000000; min-width: 35.83pt;">(5</font><font style="min-width: 35.83pt;">)</font></div></td></tr><tr><td style="width: 66.67%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 6pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Loss for the year<font style="padding-left: 4.54pt;"></font></div></td><td class="gutter" style="width: 1.45%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt;">&#8203;</td><td class="gutter" style="width: 1.45%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt;">&#8203;</td><td style="width: 9.03%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 6pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.23pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 35.83pt;">(170,033</font><font style="min-width: 35.83pt;">)</font></div></td><td class="gutter" style="width: 1.45%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt;">&#8203;</td><td class="gutter" style="width: 1.45%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt;">&#8203;</td><td style="width: 9.03%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 6pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 5.72pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 30.83pt;">(49,858</font><font style="min-width: 30.83pt;">)</font></div></td><td class="gutter" style="width: 1.45%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt;">&#8203;</td><td class="gutter" style="width: 1.45%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt;">&#8203;</td><td style="width: 6.59%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 6pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -5pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 35.83pt;">(120,175</font><font style="min-width: 35.83pt;">)</font></div></td></tr></table><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The following table summarizes the notable items that impacted our results of operations for the six months ended June 30, 2020 compared to the six months ended June 30, 2019:</div><table cellspacing="0" cellpadding="0" class="fintab" style="margin-top: 5.25pt; border-collapse: collapse; width: 468pt; margin-left: auto; margin-right: auto;"><tr class="header"><td style="width: 66.67%; text-align: left; vertical-align: bottom; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 1.36%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.36%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td colspan="4" style="width: 22%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Six Months Ended June 30,</div></td><td class="gutter" style="width: 1.36%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.36%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 5.88%; text-align: center; vertical-align: bottom; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td></tr><tr class="header"><td style="width: 66.67%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 1.36%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.36%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 10.87%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2020</div></td><td class="gutter" style="width: 1.36%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.36%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 8.41%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2019</div></td><td class="gutter" style="width: 1.36%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.36%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 5.88%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Change</div></td></tr><tr class="header"><td style="width: 66.67%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 1.36%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.36%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td colspan="7" style="width: 30.61%; text-align: center; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">(in USD thousands)</div></td></tr><tr><td style="width: 66.67%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Research and development expense, share-based compensation<font style="padding-left: 2.67pt;"></font></div></td><td class="gutter" style="width: 1.36%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.36%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.87%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 11.68pt; text-align: left;"><font style="padding-left: 5pt;">3,974</font></div></td><td class="gutter" style="width: 1.36%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.36%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.41%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 14.68pt; text-align: left;">93</div></td><td class="gutter" style="width: 1.36%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.36%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.88%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 5pt;">3,881</font></div></td></tr><tr><td style="width: 66.67%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">General and administrative expense, share-based compensation<font style="padding-left: 2.11pt;"></font></div></td><td class="gutter" style="width: 1.36%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.36%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 10.87%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 11.68pt; text-align: left;">12,550</div></td><td class="gutter" style="width: 1.36%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.36%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 8.41%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 14.68pt; text-align: left;">47</div></td><td class="gutter" style="width: 1.36%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.36%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 5.88%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;">12,503</div></td></tr><tr><td style="width: 66.67%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Convertible loans, derivatives, increase in fair value<font style="padding-left: 1.26pt;"></font></div></td><td class="gutter" style="width: 1.36%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.36%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.87%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 11.68pt; text-align: left;">79,261</div></td><td class="gutter" style="width: 1.36%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.36%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.41%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 14.68pt; text-align: left;">&#8212;</div></td><td class="gutter" style="width: 1.36%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.36%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.88%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;">79,261</div></td></tr><tr><td style="width: 66.67%; text-align: left; vertical-align: bottom; padding-top: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Convertible loans, first tranche, derivative, transaction costs<font style="padding-left: 4.32pt;"></font></div></td><td class="gutter" style="width: 1.36%; border-bottom: none; font-size: 2pt; padding-top: 3pt;">&#8203;</td><td class="gutter" style="width: 1.36%; border-bottom: none; font-size: 2pt; padding-top: 3pt;">&#8203;</td><td style="width: 10.87%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 11.68pt; text-align: left;"><font style="padding-left: 5pt;">1,571</font></div></td><td class="gutter" style="width: 1.36%; border-bottom: none; font-size: 2pt; padding-top: 3pt;">&#8203;</td><td class="gutter" style="width: 1.36%; border-bottom: none; font-size: 2pt; padding-top: 3pt;">&#8203;</td><td style="width: 8.41%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 14.68pt; text-align: left;">&#8212;</div></td><td class="gutter" style="width: 1.36%; border-bottom: none; font-size: 2pt; padding-top: 3pt;">&#8203;</td><td class="gutter" style="width: 1.36%; border-bottom: none; font-size: 2pt; padding-top: 3pt;">&#8203;</td><td style="width: 5.88%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 5pt;">1,571</font></div></td></tr></table><div class="h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 18.5pt; margin-left: 0pt; text-align: left;">Contract Revenue </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Contract revenue decreased to nil for the six months ended June 30, 2020 from $2.3 million for the six months ended June 30, 2019, a decrease of $2.3 million, or 100.0%. The decrease was due to the discontinuance of the joint clinical development of MEDI3726 and the recognition during the six months ended June 30, 2019 of the remaining non-refundable upfront payment (consisting of deferred revenue and presented as a contract liability in our consolidated balance sheet) of $2.3 million that existed as of December 31, 2018. </div><div class="h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 20.5pt; margin-left: 0pt; text-align: left;">Research and Development Expense</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The following table summarizes our research and development expense for the six months ended June 30, 2020 and 2019:</div><table cellspacing="0" cellpadding="0" class="fintab" style="margin-top: 5.25pt; border-collapse: collapse; width: 468pt; margin-left: auto; margin-right: auto;"><tr class="header"><td style="width: 66.67%; text-align: left; vertical-align: bottom; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 1.36%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.36%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td colspan="4" style="width: 22%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Six Months Ended June 30,</div></td><td class="gutter" style="width: 1.36%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.36%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 5.88%; text-align: center; vertical-align: bottom; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td></tr><tr class="header"><td style="width: 66.67%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 1.36%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.36%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 9.64%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2020</div></td><td class="gutter" style="width: 1.36%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.36%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 9.64%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2019</div></td><td class="gutter" style="width: 1.36%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.36%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 5.88%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Change </div></td></tr><tr class="header"><td style="width: 66.67%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 1.36%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.36%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td colspan="7" style="width: 30.61%; text-align: center; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">(in USD thousands) </div></td></tr><tr><td style="width: 66.67%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">External costs<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(1)</sup><font style="padding-left: 3.56pt;"></font></div></td><td class="gutter" style="width: 1.36%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.36%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.64%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 8.81pt; text-align: left;">42,300</div></td><td class="gutter" style="width: 1.36%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.36%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.64%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 8.8pt; text-align: left;">36,041</div></td><td class="gutter" style="width: 1.36%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.36%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.88%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 5pt;">6,259</font> </div></td></tr><tr><td style="width: 66.67%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Employee expense<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(2)</sup><font style="padding-left: 4.67pt;"></font></div></td><td class="gutter" style="width: 1.36%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.36%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 9.64%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 8.81pt; text-align: left;"><font style="border-bottom: 1pt solid #000000; min-width: 27.5pt;">19,025</font></div></td><td class="gutter" style="width: 1.36%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.36%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 9.64%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 8.8pt; text-align: left;"><font style="border-bottom: 1pt solid #000000; min-width: 27.5pt;">10,531</font></div></td><td class="gutter" style="width: 1.36%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.36%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 5.88%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 5pt; border-bottom: 1pt solid #000000; min-width: 27.5pt;">8,494</font><font style="border-bottom: 1pt solid #000000; min-width: 27.5pt;"> </font></div></td></tr><tr><td style="width: 66.67%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Research and development expense<font style="padding-left: 4.56pt;"></font></div></td><td class="gutter" style="width: 1.36%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.36%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.64%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 8.81pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 27.5pt;">61,325</font></div></td><td class="gutter" style="width: 1.36%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.36%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.64%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 8.8pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 27.5pt;">46,572</font></div></td><td class="gutter" style="width: 1.36%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.36%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.88%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 27.5pt;">14,753</font></div></td></tr></table><div><div class="rule-partial" style="height: 0pt; width: 72pt; border-bottom: 1pt solid #000000; margin-bottom: 1pt; margin-right: auto; margin-left: 0pt; margin-top: 13.25pt;"> </div></div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 3pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">(1)<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; text-align: left;">External costs include depreciation expense. </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 3pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">(2)<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; text-align: left;">Employee expense includes share-based compensation expense. </div></td></tr></table><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Our research and development expense increased to $61.3 million for the six months ended June 30, 2020 from $46.6 million for the six months ended June 30, 2019, an increase of $14.7 million, or 31.7%. The increase was primarily due to increased external costs associated with our lead product candidates as clinical trials advanced and to increased employee expense associated with an increased number of research and development employees as a result of our expanding level of research and development activity and increased share-based compensation expense.</div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 36pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">94<br></div></div></div>
<!--End Page 98-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 99-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 540pt;"><a name="nt10014672x1_drs_106-mda_pg7"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="block-frill" style="width: 540pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: Arial, Helvetica, sans-serif; font-size: 9pt; font-weight: bold; margin-top: 6pt; text-align: center;">Confidential Treatment Requested by ADC Therapeutics SA Pursuant to 17 C.F.R. &#167; 200.83<br></div></div><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 36pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The following table summarizes our research and development expense for our major development programs for the six months ended June 30, 2020 and 2019:</div><table cellspacing="0" cellpadding="0" class="fintab" style="margin-top: 5.25pt; border-collapse: collapse; width: 468pt; margin-left: auto; margin-right: auto;"><tr class="header"><td style="width: 66.67%; text-align: left; vertical-align: bottom; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 1.36%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.36%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td colspan="4" style="width: 22%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Six Months Ended June 30,</div></td><td class="gutter" style="width: 1.36%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.36%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 5.88%; text-align: center; vertical-align: bottom; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td></tr><tr class="header"><td style="width: 66.67%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 1.36%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.36%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 9.64%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2020</div></td><td class="gutter" style="width: 1.36%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.36%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 9.64%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2019</div></td><td class="gutter" style="width: 1.36%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.36%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 5.88%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Change</div></td></tr><tr class="header"><td style="width: 66.67%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 1.36%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.36%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td colspan="7" style="width: 30.61%; text-align: center; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">(in USD thousands) </div></td></tr><tr><td style="width: 66.67%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Lonca<font style="padding-left: 4.51pt;"></font></div></td><td class="gutter" style="width: 1.36%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.36%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.64%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 8.81pt; text-align: left;">27,753</div></td><td class="gutter" style="width: 1.36%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.36%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.64%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 8.8pt; text-align: left;">18,820</div></td><td class="gutter" style="width: 1.36%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.36%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.88%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 5pt;">8,933</font> </div></td></tr><tr><td style="width: 66.67%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Cami<font style="padding-left: 2.84pt;"></font></div></td><td class="gutter" style="width: 1.36%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.36%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 9.64%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 8.81pt; text-align: left;">19,655</div></td><td class="gutter" style="width: 1.36%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.36%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 9.64%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 8.8pt; text-align: left;">13,880</div></td><td class="gutter" style="width: 1.36%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.36%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 5.88%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 5pt;">5,775</font></div></td></tr><tr><td style="width: 66.67%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">ADCT-602<font style="padding-left: 4.87pt;"></font></div></td><td class="gutter" style="width: 1.36%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.36%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.64%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 8.81pt; text-align: left;"><font style="padding-left: 5pt;">1,471</font></div></td><td class="gutter" style="width: 1.36%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.36%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.64%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 8.8pt; text-align: left;"><font style="padding-left: 12.5pt;">563</font></div></td><td class="gutter" style="width: 1.36%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.36%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.88%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 12.5pt;">908</font></div></td></tr><tr><td style="width: 66.67%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">ADCT-601<font style="padding-left: 4.87pt;"></font></div></td><td class="gutter" style="width: 1.36%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.36%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 9.64%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 8.81pt; text-align: left;"><font style="padding-left: 5pt;">2,400</font></div></td><td class="gutter" style="width: 1.36%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.36%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 9.64%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 8.8pt; text-align: left;"><font style="padding-left: 5pt;">2,937</font></div></td><td class="gutter" style="width: 1.36%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.36%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 5.88%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 9.17pt;">(537</font>)</div></td></tr><tr><td style="width: 66.67%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Preclinical product candidates and research pipeline<font style="padding-left: 2.38pt;"></font></div></td><td class="gutter" style="width: 1.36%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.36%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.64%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 8.81pt; text-align: left;"><font style="padding-left: 5pt;">7,979</font></div></td><td class="gutter" style="width: 1.36%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.36%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.64%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 8.8pt; text-align: left;"><font style="padding-left: 5pt;">9,177</font></div></td><td class="gutter" style="width: 1.36%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.36%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.88%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 1.67pt;">(1,198</font>)</div></td></tr><tr><td style="width: 66.67%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Not allocated to specific programs<font style="padding-left: 3.45pt;"></font></div></td><td class="gutter" style="width: 1.36%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.36%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 9.64%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 8.81pt; text-align: left;"><font style="padding-left: 5pt; border-bottom: 1pt solid #000000; min-width: 27.5pt;">2,067</font></div></td><td class="gutter" style="width: 1.36%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.36%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 9.64%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 8.8pt; text-align: left;"><font style="padding-left: 5pt; border-bottom: 1pt solid #000000; min-width: 27.5pt;">1,195</font></div></td><td class="gutter" style="width: 1.36%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.36%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 5.88%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 12.5pt; border-bottom: 1pt solid #000000; min-width: 27.5pt;">872</font></div></td></tr><tr><td style="width: 66.67%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Research and development expense<font style="padding-left: 4.56pt;"></font></div></td><td class="gutter" style="width: 1.36%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.36%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.64%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 8.81pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 27.5pt;">61,325</font></div></td><td class="gutter" style="width: 1.36%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.36%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.64%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 8.8pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 27.5pt;">46,572</font></div></td><td class="gutter" style="width: 1.36%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.36%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.88%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 27.5pt;">14,753</font></div></td></tr></table><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The increase in research and development expense related to Lonca was due to ongoing activities for the pivotal Phase 2 trial of Lonca for the treatment of relapsed or refractory DLBCL, increased activities in support of the BLA submission for Lonca, including CMC, and combination clinical trials for Lonca. The increase in research and development expense related to Cami was due to an increase in CMC activities, as well as the ramp-up related to the Phase 1b clinical trial of Cami for the treatment of selected advanced solid tumors. The decrease in research and development expense related to preclinical product candidates and research pipeline was due to the impact of the COVID-19 pandemic and the closing of our laboratories in the United Kingdom. Our UK laboratories have since reopened. </div><div class="h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 20.5pt; margin-left: 0pt; text-align: left;">General and Administrative Expense </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The following table summarizes our general and administrative expense for the six months ended June 30, 2020 and 2019: </div><table cellspacing="0" cellpadding="0" class="fintab" style="margin-top: 5.25pt; border-collapse: collapse; width: 468pt; margin-left: auto; margin-right: auto;"><tr class="header"><td style="width: 66.67%; text-align: left; vertical-align: bottom; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 1.36%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.36%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td colspan="4" style="width: 22%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Six Months Ended June 30,</div></td><td class="gutter" style="width: 1.36%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.36%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 5.88%; text-align: center; vertical-align: bottom; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td></tr><tr class="header"><td style="width: 66.67%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 1.36%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.36%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 10.17%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2020</div></td><td class="gutter" style="width: 1.36%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.36%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 9.1%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2019</div></td><td class="gutter" style="width: 1.36%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.36%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 5.88%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Change </div></td></tr><tr class="header"><td style="width: 66.67%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 1.36%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.36%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td colspan="7" style="width: 30.61%; text-align: center; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">(in USD thousands) </div></td></tr><tr><td style="width: 66.67%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">External costs<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(1)</sup><font style="padding-left: 3.56pt;"></font></div></td><td class="gutter" style="width: 1.36%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.36%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.17%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10.06pt; text-align: left;"><font style="padding-left: 5pt;">8,401</font></div></td><td class="gutter" style="width: 1.36%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.36%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.1%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10.05pt; text-align: left;">4,062</div></td><td class="gutter" style="width: 1.36%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.36%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.88%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 5pt;">4,339</font></div></td></tr><tr><td style="width: 66.67%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Employee expense<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(2)</sup><font style="padding-left: 4.67pt;"></font></div></td><td class="gutter" style="width: 1.36%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.36%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 10.17%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10.06pt; text-align: left;"><font style="border-bottom: 1pt solid #000000; min-width: 27.5pt;">19,108</font></div></td><td class="gutter" style="width: 1.36%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.36%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 9.1%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10.05pt; text-align: left;"><font style="border-bottom: 1pt solid #000000; min-width: 22.5pt;">2,530</font></div></td><td class="gutter" style="width: 1.36%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.36%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 5.88%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="border-bottom: 1pt solid #000000; min-width: 27.5pt;">16,578</font></div></td></tr><tr><td style="width: 66.67%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">General and administrative expense<font style="padding-left: 4.01pt;"></font></div></td><td class="gutter" style="width: 1.36%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.36%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.17%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10.06pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 27.5pt;">27,509</font></div></td><td class="gutter" style="width: 1.36%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.36%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.1%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10.05pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 22.5pt;">6,592</font></div></td><td class="gutter" style="width: 1.36%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.36%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.88%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 27.5pt;">20,917</font></div></td></tr></table><div><div class="rule-partial" style="height: 0pt; width: 72pt; border-bottom: 1pt solid #000000; margin-bottom: 1pt; margin-right: auto; margin-left: 0pt; margin-top: 13.25pt;"> </div></div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 3pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">(1)<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; text-align: left;">External costs include depreciation expense.</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 3pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">(2)<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; text-align: left;">Employee expense includes share-based compensation expense. </div></td></tr></table><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Our general and administrative expense increased to $27.5 million for the six months ended June 30, 2020 from $6.6 million for the six months ended June 30, 2019, an increase of $20.9 million, or 317.3%. The increase was primarily due to higher external costs associated with pre-launch commercial activities and higher employee expense associated with increased share-based compensation expense of $12.5 million. General and administrative expense also increased as a result of additional employee headcount, primarily relating to the recruitment of commercial employees as we prepare for the anticipated launch of Lonca in 2021, which resulted in employee expense of $1.8 million. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Employee expense for the six months ended June 30, 2020 includes share-based compensation expense relating to the 2014 Incentive Plan and the 2016 Share Purchase Plan, both of which terminated upon the effectiveness of the registration statement for our initial public offering, with all awards vesting as of that date and with all outstanding charges relating to those plans, which were being amortized over the vesting period, having to be recognized at that time. The amount of expense recognized for these plans in the six months ended June 30, 2020 was $7.5 million, which is included in the share-based compensation expense noted above. Share-based compensation expense under the 2019 Equity Incentive Plan was also recognized in the six months ended June 30, 2020 and will continue to arise in future. </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 36pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">95<br></div></div></div>
<!--End Page 99-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 100-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 540pt;"><a name="nt10014672x1_drs_106-mda_pg8"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="block-frill" style="width: 540pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: Arial, Helvetica, sans-serif; font-size: 9pt; font-weight: bold; margin-top: 6pt; text-align: center;">Confidential Treatment Requested by ADC Therapeutics SA Pursuant to 17 C.F.R. &#167; 200.83<br></div></div><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 36pt;"><div class="h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">Other Income and Expense </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The following table summarizes our other income and expense for the six months ended June 30, 2020 and 2019: </div><table cellspacing="0" cellpadding="0" class="fintab" style="margin-top: 5.25pt; border-collapse: collapse; width: 468pt; margin-left: auto; margin-right: auto;"><tr class="header"><td style="width: 66.67%; text-align: left; vertical-align: bottom; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 1.25%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.25%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td colspan="4" style="width: 21.76%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Six Months Ended June 30,</div></td><td class="gutter" style="width: 1.25%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.25%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 6.59%; text-align: center; vertical-align: bottom; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td></tr><tr class="header"><td style="width: 66.67%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 1.25%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.25%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 10.53%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2020</div></td><td class="gutter" style="width: 1.25%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.25%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 8.75%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2019</div></td><td class="gutter" style="width: 1.25%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.25%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 6.59%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Change</div></td></tr><tr class="header"><td style="width: 66.67%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 1.25%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.25%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td colspan="7" style="width: 30.84%; text-align: center; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">(in USD thousands) </div></td></tr><tr><td style="width: 66.67%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Other income<font style="padding-left: 3.97pt;"></font></div></td><td class="gutter" style="width: 1.25%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.25%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.53%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.22pt; text-align: left;"><font style="padding-left: 15.83pt;">278</font></div></td><td class="gutter" style="width: 1.25%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.25%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.75%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.22pt; text-align: left;"><font style="padding-left: 12.5pt;">&#8212;</font></div></td><td class="gutter" style="width: 1.25%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.25%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.59%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 15.83pt;">278 </font></div></td></tr><tr><td style="width: 66.67%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Convertible loans, derivatives, increase in fair value<font style="padding-left: 1.26pt;"></font></div></td><td class="gutter" style="width: 1.25%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.25%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 10.53%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.22pt; text-align: left;">(79,261)</div></td><td class="gutter" style="width: 1.25%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.25%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 8.75%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.22pt; text-align: left;"><font style="padding-left: 12.5pt;">&#8212;</font></div></td><td class="gutter" style="width: 1.25%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.25%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 6.59%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">(79,261)</div></td></tr><tr><td style="width: 66.67%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Convertible loans, first tranche, derivative, transaction costs<font style="padding-left: 4.32pt;"></font></div></td><td class="gutter" style="width: 1.25%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.25%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.53%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.22pt; text-align: left;"><font style="padding-left: 5pt;">(1,571)</font></div></td><td class="gutter" style="width: 1.25%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.25%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.75%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.22pt; text-align: left;"><font style="padding-left: 12.5pt;">&#8212;</font></div></td><td class="gutter" style="width: 1.25%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.25%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.59%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 5pt;">(1,571)</font></div></td></tr><tr><td style="width: 66.67%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Financial income<font style="padding-left: 4.52pt;"></font></div></td><td class="gutter" style="width: 1.25%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.25%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 10.53%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.22pt; text-align: left;"><font style="padding-left: 15.83pt;">569</font></div></td><td class="gutter" style="width: 1.25%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.25%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 8.75%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.22pt; text-align: left;">1,306</div></td><td class="gutter" style="width: 1.25%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.25%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 6.59%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 12.5pt;">(737</font>)</div></td></tr><tr><td style="width: 66.67%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Financial expense<font style="padding-left: 1.75pt;"></font></div></td><td class="gutter" style="width: 1.25%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.25%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.53%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.22pt; text-align: left;"><font style="padding-left: 12.5pt;">(939</font>)</div></td><td class="gutter" style="width: 1.25%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.25%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.75%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.22pt; text-align: left;"><font style="padding-left: 9.17pt;">(73)</font></div></td><td class="gutter" style="width: 1.25%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.25%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.59%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 12.5pt;">(866</font>)</div></td></tr><tr><td style="width: 66.67%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Exchange differences<font style="padding-left: 2.5pt;"></font></div></td><td class="gutter" style="width: 1.25%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.25%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 10.53%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.22pt; text-align: left;"><font style="padding-left: 17.5pt; border-bottom: 1pt solid #000000; min-width: 30.83pt;">(71</font><font style="min-width: 30.83pt;">)</font></div></td><td class="gutter" style="width: 1.25%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.25%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 8.75%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.22pt; text-align: left;"><font style="padding-left: 9.17pt; border-bottom: 1pt solid #000000; min-width: 22.5pt;">(68</font><font style="min-width: 22.5pt;">)</font></div></td><td class="gutter" style="width: 1.25%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.25%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 6.59%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 22.5pt; border-bottom: 1pt solid #000000; min-width: 30.83pt;">(3</font><font style="border-bottom: 1pt solid #000000; min-width: 30.83pt;"></font><font style="min-width: 30.83pt;">)</font></div></td></tr><tr><td style="width: 66.67%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Total other income (expense)<font style="padding-left: 0.25pt;"></font></div></td><td class="gutter" style="width: 1.25%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.25%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.53%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.22pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 30.83pt;">(80,995</font><font style="min-width: 30.83pt;">)</font></div></td><td class="gutter" style="width: 1.25%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.25%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.75%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.22pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 22.5pt;">1,165</font></div></td><td class="gutter" style="width: 1.25%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.25%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.59%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 30.83pt;">(82,160</font><font style="min-width: 30.83pt;">)</font></div></td></tr></table><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 12pt; margin-left: 20pt; text-align: left;">Other Income </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">We recognize as other income amounts received and receivable by our subsidiary, ADC Therapeutics (UK) Limited, under the United Kingdom&#8217;s Research and Development Expenditure Credit scheme. For the six months ended June 30, 2020, we recognized $0.3 million in respect of fiscal year 2020 in other income. For the six months ended June 30, 2019, we did not recognize any such income. </div><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 12pt; margin-left: 20pt; text-align: left;">Convertible Loans, Derivatives, Increase in Fair Value </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">This charge is explained in Note 11 to our unaudited condensed consolidated interim financial statements. Pursuant to the Facility Agreement, we drew down the first tranche amounting to $65.0 million on May 19, 2020 and we are obligated to draw down the second tranche amounting to $50.0 million upon the receipt of regulatory approval for Lonca. The conversion option derivative embedded in the first tranche is re-measured at fair value at the end of each accounting period. The obligation arising from the second tranche is accounted for as a derivative and is also re-measured at fair value at the end of each accounting period. Any movement in these fair values is recognized in the unaudited condensed consolidated interim statement of income. The significant increase in the fair values in the period is due to the increase in the price of our common shares since our initial public offering. </div><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 12pt; margin-left: 20pt; text-align: left;">Convertible Loans, First Tranche, Derivative, Transaction Costs </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">As explained in Note 11 to our unaudited condensed consolidated interim financial statements, transaction costs incurred on the issuance of the first tranche of the convertible notes have been allocated pro rata to the embedded conversion option derivative and to the residual convertible loan. The costs allocated to the loan have been deducted from the initial book value of the loan and will therefore be recognized over the life of the loan as part of the effective interest cost. See &#8220;&#8212;Financial Expense&#8221; below. The costs allocated to the embedded derivative feature of the first tranche have been recognized directly in the unaudited condensed consolidated interim statement of income. </div><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 12pt; margin-left: 20pt; text-align: left;">Financial Income </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Our financial income decreased to $0.6 million for the six months ended June 30, 2020 from $1.3 million for the six months ended June 30, 2019. The decrease was primarily due to decreases in amounts placed on short-term deposit and in interest rates. </div><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 12pt; margin-left: 20pt; text-align: left;">Financial Expense </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Our financial expense increased to $0.9 million for the six months ended June 30, 2020 from $0.1 million for the six months ended June 30, 2019. The increase was primarily due to interest on the convertible loans, calculated at the implied effective interest rate from May 19, 2020. </div><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 12pt; margin-left: 20pt; text-align: left;">Income Tax Expense </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Our income tax expense is primarily due to our internal arrangements to reimburse our foreign subsidiaries in the United States and the United Kingdom for the services they render on a cost-plus-margin basis. The net profit at each subsidiary is subject to local income tax and gives rise to minimal amounts of tax expense. </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 36pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">96<br></div></div></div>
<!--End Page 100-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 101-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 540pt;"><a name="nt10014672x1_drs_106-mda_pg9"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="block-frill" style="width: 540pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: Arial, Helvetica, sans-serif; font-size: 9pt; font-weight: bold; margin-top: 6pt; text-align: center;">Confidential Treatment Requested by ADC Therapeutics SA Pursuant to 17 C.F.R. &#167; 200.83<br></div></div><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 36pt;"><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">Comparison of the Years Ended December&#160;31, 2019 and 2018</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 7.5pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The following table summarizes our results of operations for the years ended December&#160;31, 2019 and 2018:</div><table cellspacing="0" cellpadding="0" class="fintab" style="margin-top: 5.25pt; border-collapse: collapse; width: 468pt; margin-left: auto; margin-right: auto;"><tr class="header"><td style="width: 66.67%; text-align: left; vertical-align: bottom; padding-top: 6pt; padding-bottom: 3.35pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 1.57%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 3.35pt;">&#8203;</td><td class="gutter" style="width: 1.57%; font-size: 2pt; padding-top: 6pt; padding-bottom: 3.35pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td colspan="4" style="width: 21.2%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 3.35pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Year Ended December&#160;31,</div></td><td class="gutter" style="width: 1.57%; font-size: 2pt; padding-top: 6pt; padding-bottom: 3.35pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.57%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 3.35pt;">&#8203;</td><td style="width: 5.88%; text-align: center; vertical-align: bottom; padding-top: 6pt; padding-bottom: 3.35pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td></tr><tr class="header"><td style="width: 66.67%; text-align: left; vertical-align: bottom; padding-top: 3.35pt; padding-bottom: 3.35pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 1.57%; border-bottom: none; font-size: 2pt; padding-top: 3.35pt; padding-bottom: 3.35pt;">&#8203;</td><td class="gutter" style="width: 1.57%; font-size: 2pt; padding-top: 3.35pt; padding-bottom: 3.35pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 9.03%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 3.35pt; padding-bottom: 3.35pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2019</div></td><td class="gutter" style="width: 1.57%; font-size: 2pt; padding-top: 3.35pt; padding-bottom: 3.35pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.57%; font-size: 2pt; padding-top: 3.35pt; padding-bottom: 3.35pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 9.03%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 3.35pt; padding-bottom: 3.35pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2018</div></td><td class="gutter" style="width: 1.57%; font-size: 2pt; padding-top: 3.35pt; padding-bottom: 3.35pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.57%; font-size: 2pt; padding-top: 3.35pt; padding-bottom: 3.35pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 5.88%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 3.35pt; padding-bottom: 3.35pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Change</div></td></tr><tr class="header"><td style="width: 66.67%; text-align: left; vertical-align: bottom; padding-top: 3.35pt; padding-bottom: 3.35pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 1.57%; border-bottom: none; font-size: 2pt; padding-top: 3.35pt; padding-bottom: 3.35pt;">&#8203;</td><td class="gutter" style="width: 1.57%; border-bottom: none; font-size: 2pt; padding-top: 3.35pt; padding-bottom: 3.35pt;">&#8203;</td><td colspan="7" style="width: 30.2%; text-align: center; vertical-align: bottom; padding-top: 3.35pt; padding-bottom: 3.35pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">(in USD thousands)</div></td></tr><tr><td style="width: 66.67%; text-align: left; vertical-align: bottom; padding-top: 3.35pt; padding-bottom: 2.1pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Contract revenue<font style="padding-left: 0.09pt;"></font></div></td><td class="gutter" style="width: 1.57%; border-bottom: none; font-size: 2pt; padding-top: 3.35pt; padding-bottom: 2.1pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.57%; border-bottom: none; font-size: 2pt; padding-top: 3.35pt; padding-bottom: 2.1pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.03%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3.35pt; padding-bottom: 2.1pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.22pt; text-align: left;"><font style="padding-left: 13.33pt;">2,340</font></div></td><td class="gutter" style="width: 1.57%; border-bottom: none; font-size: 2pt; padding-top: 3.35pt; padding-bottom: 2.1pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.57%; border-bottom: none; font-size: 2pt; padding-top: 3.35pt; padding-bottom: 2.1pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.03%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3.35pt; padding-bottom: 2.1pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.23pt; text-align: left;"><font style="padding-left: 13.33pt;">1,140</font></div></td><td class="gutter" style="width: 1.57%; border-bottom: none; font-size: 2pt; padding-top: 3.35pt; padding-bottom: 2.1pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.57%; border-bottom: none; font-size: 2pt; padding-top: 3.35pt; padding-bottom: 2.1pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.88%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3.35pt; padding-bottom: 2.1pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 5pt;">1,200</font></div></td></tr><tr><td style="width: 66.67%; text-align: left; vertical-align: bottom; padding-top: 2.1pt; padding-bottom: 2.1pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Research and development expense<font style="padding-left: 4.56pt;"></font></div></td><td class="gutter" style="width: 1.57%; border-bottom: none; font-size: 2pt; padding-top: 2.1pt; padding-bottom: 2.1pt;">&#8203;</td><td class="gutter" style="width: 1.57%; border-bottom: none; font-size: 2pt; padding-top: 2.1pt; padding-bottom: 2.1pt;">&#8203;</td><td style="width: 9.03%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.1pt; padding-bottom: 2.1pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.22pt; text-align: left;">(107,537)</div></td><td class="gutter" style="width: 1.57%; border-bottom: none; font-size: 2pt; padding-top: 2.1pt; padding-bottom: 2.1pt;">&#8203;</td><td class="gutter" style="width: 1.57%; border-bottom: none; font-size: 2pt; padding-top: 2.1pt; padding-bottom: 2.1pt;">&#8203;</td><td style="width: 9.03%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.1pt; padding-bottom: 2.1pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.23pt; text-align: left;"><font style="padding-left: 0.37pt;">(118,313)</font></div></td><td class="gutter" style="width: 1.57%; border-bottom: none; font-size: 2pt; padding-top: 2.1pt; padding-bottom: 2.1pt;">&#8203;</td><td class="gutter" style="width: 1.57%; border-bottom: none; font-size: 2pt; padding-top: 2.1pt; padding-bottom: 2.1pt;">&#8203;</td><td style="width: 5.88%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.1pt; padding-bottom: 2.1pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;">10,776</div></td></tr><tr><td style="width: 66.67%; text-align: left; vertical-align: bottom; padding-top: 2.1pt; padding-bottom: 2.1pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">General and administrative expense<font style="padding-left: 4.01pt;"></font></div></td><td class="gutter" style="width: 1.57%; border-bottom: none; font-size: 2pt; padding-top: 2.1pt; padding-bottom: 2.1pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.57%; border-bottom: none; font-size: 2pt; padding-top: 2.1pt; padding-bottom: 2.1pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.03%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.1pt; padding-bottom: 2.1pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.22pt; text-align: left;"><font style="padding-left: 5pt;">(14,202)</font></div></td><td class="gutter" style="width: 1.57%; border-bottom: none; font-size: 2pt; padding-top: 2.1pt; padding-bottom: 2.1pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.57%; border-bottom: none; font-size: 2pt; padding-top: 2.1pt; padding-bottom: 2.1pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.03%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.1pt; padding-bottom: 2.1pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.23pt; text-align: left;"><font style="padding-left: 10pt;">(8,768)</font></div></td><td class="gutter" style="width: 1.57%; border-bottom: none; font-size: 2pt; padding-top: 2.1pt; padding-bottom: 2.1pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.57%; border-bottom: none; font-size: 2pt; padding-top: 2.1pt; padding-bottom: 2.1pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.88%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.1pt; padding-bottom: 2.1pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 1.67pt;">(5,434)</font></div></td></tr><tr><td style="width: 66.67%; text-align: left; vertical-align: bottom; padding-top: 2.1pt; padding-bottom: 2.1pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Operating loss<font style="padding-left: 0.63pt;"></font></div></td><td class="gutter" style="width: 1.57%; border-bottom: none; font-size: 2pt; padding-top: 2.1pt; padding-bottom: 2.1pt;">&#8203;</td><td class="gutter" style="width: 1.57%; border-bottom: none; font-size: 2pt; padding-top: 2.1pt; padding-bottom: 2.1pt;">&#8203;</td><td style="width: 9.03%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.1pt; padding-bottom: 2.1pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.22pt; text-align: left;"><font style="padding-left: 0.37pt;">(119,399)</font></div></td><td class="gutter" style="width: 1.57%; border-bottom: none; font-size: 2pt; padding-top: 2.1pt; padding-bottom: 2.1pt;">&#8203;</td><td class="gutter" style="width: 1.57%; border-bottom: none; font-size: 2pt; padding-top: 2.1pt; padding-bottom: 2.1pt;">&#8203;</td><td style="width: 9.03%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.1pt; padding-bottom: 2.1pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.23pt; text-align: left;">(125,941)</div></td><td class="gutter" style="width: 1.57%; border-bottom: none; font-size: 2pt; padding-top: 2.1pt; padding-bottom: 2.1pt;">&#8203;</td><td class="gutter" style="width: 1.57%; border-bottom: none; font-size: 2pt; padding-top: 2.1pt; padding-bottom: 2.1pt;">&#8203;</td><td style="width: 5.88%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.1pt; padding-bottom: 2.1pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 5pt;">6,542</font></div></td></tr><tr><td style="width: 66.67%; text-align: left; vertical-align: bottom; padding-top: 2.1pt; padding-bottom: 2.1pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Other income<font style="padding-left: 3.97pt;"></font></div></td><td class="gutter" style="width: 1.57%; border-bottom: none; font-size: 2pt; padding-top: 2.1pt; padding-bottom: 2.1pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.57%; border-bottom: none; font-size: 2pt; padding-top: 2.1pt; padding-bottom: 2.1pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.03%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.1pt; padding-bottom: 2.1pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.22pt; text-align: left;"><font style="padding-left: 13.33pt;">1,655</font></div></td><td class="gutter" style="width: 1.57%; border-bottom: none; font-size: 2pt; padding-top: 2.1pt; padding-bottom: 2.1pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.57%; border-bottom: none; font-size: 2pt; padding-top: 2.1pt; padding-bottom: 2.1pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.03%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.1pt; padding-bottom: 2.1pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.23pt; text-align: left;"><font style="padding-left: 25.83pt;">&#8212;</font></div></td><td class="gutter" style="width: 1.57%; border-bottom: none; font-size: 2pt; padding-top: 2.1pt; padding-bottom: 2.1pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.57%; border-bottom: none; font-size: 2pt; padding-top: 2.1pt; padding-bottom: 2.1pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.88%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.1pt; padding-bottom: 2.1pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 5pt;">1,655</font></div></td></tr><tr><td style="width: 66.67%; text-align: left; vertical-align: bottom; padding-top: 2.1pt; padding-bottom: 2.1pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Financial income<font style="padding-left: 4.52pt;"></font></div></td><td class="gutter" style="width: 1.57%; border-bottom: none; font-size: 2pt; padding-top: 2.1pt; padding-bottom: 2.1pt;">&#8203;</td><td class="gutter" style="width: 1.57%; border-bottom: none; font-size: 2pt; padding-top: 2.1pt; padding-bottom: 2.1pt;">&#8203;</td><td style="width: 9.03%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.1pt; padding-bottom: 2.1pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.22pt; text-align: left;"><font style="padding-left: 13.33pt;">2,253</font></div></td><td class="gutter" style="width: 1.57%; border-bottom: none; font-size: 2pt; padding-top: 2.1pt; padding-bottom: 2.1pt;">&#8203;</td><td class="gutter" style="width: 1.57%; border-bottom: none; font-size: 2pt; padding-top: 2.1pt; padding-bottom: 2.1pt;">&#8203;</td><td style="width: 9.03%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.1pt; padding-bottom: 2.1pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.23pt; text-align: left;"><font style="padding-left: 13.33pt;">2,856</font></div></td><td class="gutter" style="width: 1.57%; border-bottom: none; font-size: 2pt; padding-top: 2.1pt; padding-bottom: 2.1pt;">&#8203;</td><td class="gutter" style="width: 1.57%; border-bottom: none; font-size: 2pt; padding-top: 2.1pt; padding-bottom: 2.1pt;">&#8203;</td><td style="width: 5.88%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.1pt; padding-bottom: 2.1pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 9.17pt;">(603)</font></div></td></tr><tr><td style="width: 66.67%; text-align: left; vertical-align: bottom; padding-top: 2.1pt; padding-bottom: 2.1pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Financial expense<font style="padding-left: 1.75pt;"></font></div></td><td class="gutter" style="width: 1.57%; border-bottom: none; font-size: 2pt; padding-top: 2.1pt; padding-bottom: 2.1pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.57%; border-bottom: none; font-size: 2pt; padding-top: 2.1pt; padding-bottom: 2.1pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.03%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.1pt; padding-bottom: 2.1pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.22pt; text-align: left;"><font style="padding-left: 17.5pt;">(156)</font></div></td><td class="gutter" style="width: 1.57%; border-bottom: none; font-size: 2pt; padding-top: 2.1pt; padding-bottom: 2.1pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.57%; border-bottom: none; font-size: 2pt; padding-top: 2.1pt; padding-bottom: 2.1pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.03%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.1pt; padding-bottom: 2.1pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.23pt; text-align: left;"><font style="padding-left: 25.83pt;">&#8212;</font></div></td><td class="gutter" style="width: 1.57%; border-bottom: none; font-size: 2pt; padding-top: 2.1pt; padding-bottom: 2.1pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.57%; border-bottom: none; font-size: 2pt; padding-top: 2.1pt; padding-bottom: 2.1pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.88%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.1pt; padding-bottom: 2.1pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 9.17pt;">(156)</font></div></td></tr><tr><td style="width: 66.67%; text-align: left; vertical-align: bottom; padding-top: 2.1pt; padding-bottom: 3.35pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Exchange differences<font style="padding-left: 2.5pt;"></font></div></td><td class="gutter" style="width: 1.57%; border-bottom: none; font-size: 2pt; padding-top: 2.1pt; padding-bottom: 3.35pt;">&#8203;</td><td class="gutter" style="width: 1.57%; border-bottom: none; font-size: 2pt; padding-top: 2.1pt; padding-bottom: 3.35pt;">&#8203;</td><td style="width: 9.03%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.1pt; padding-bottom: 3.35pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.22pt; text-align: left;"><font style="padding-left: 17.5pt; border-bottom: 1pt solid #000000; min-width: 35.83pt;">(255</font><font style="min-width: 35.83pt;">)</font></div></td><td class="gutter" style="width: 1.57%; border-bottom: none; font-size: 2pt; padding-top: 2.1pt; padding-bottom: 3.35pt;">&#8203;</td><td class="gutter" style="width: 1.57%; border-bottom: none; font-size: 2pt; padding-top: 2.1pt; padding-bottom: 3.35pt;">&#8203;</td><td style="width: 9.03%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.1pt; padding-bottom: 3.35pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.23pt; text-align: left;"><font style="padding-left: 20.83pt; border-bottom: 1pt solid #000000; min-width: 35.83pt;">213</font></div></td><td class="gutter" style="width: 1.57%; border-bottom: none; font-size: 2pt; padding-top: 2.1pt; padding-bottom: 3.35pt;">&#8203;</td><td class="gutter" style="width: 1.57%; border-bottom: none; font-size: 2pt; padding-top: 2.1pt; padding-bottom: 3.35pt;">&#8203;</td><td style="width: 5.88%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.1pt; padding-bottom: 3.35pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 9.17pt; border-bottom: 1pt solid #000000; min-width: 27.5pt;">(468</font><font style="min-width: 27.5pt;">)</font></div></td></tr><tr><td style="width: 66.67%; text-align: left; vertical-align: bottom; padding-top: 3.35pt; padding-bottom: 2.1pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Loss before taxes<font style="padding-left: 2.87pt;"></font></div></td><td class="gutter" style="width: 1.57%; border-bottom: none; font-size: 2pt; padding-top: 3.35pt; padding-bottom: 2.1pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.57%; border-bottom: none; font-size: 2pt; padding-top: 3.35pt; padding-bottom: 2.1pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.03%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3.35pt; padding-bottom: 2.1pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.22pt; text-align: left;"><font style="padding-left: 0.37pt;">(115,902)</font></div></td><td class="gutter" style="width: 1.57%; border-bottom: none; font-size: 2pt; padding-top: 3.35pt; padding-bottom: 2.1pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.57%; border-bottom: none; font-size: 2pt; padding-top: 3.35pt; padding-bottom: 2.1pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.03%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3.35pt; padding-bottom: 2.1pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.23pt; text-align: left;">(122,872)</div></td><td class="gutter" style="width: 1.57%; border-bottom: none; font-size: 2pt; padding-top: 3.35pt; padding-bottom: 2.1pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.57%; border-bottom: none; font-size: 2pt; padding-top: 3.35pt; padding-bottom: 2.1pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.88%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3.35pt; padding-bottom: 2.1pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 5pt;">6,970</font></div></td></tr><tr><td style="width: 66.67%; text-align: left; vertical-align: bottom; padding-top: 2.1pt; padding-bottom: 3.35pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Income tax expense<font style="padding-left: 3.43pt;"></font></div></td><td class="gutter" style="width: 1.57%; border-bottom: none; font-size: 2pt; padding-top: 2.1pt; padding-bottom: 3.35pt;">&#8203;</td><td class="gutter" style="width: 1.57%; border-bottom: none; font-size: 2pt; padding-top: 2.1pt; padding-bottom: 3.35pt;">&#8203;</td><td style="width: 9.03%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.1pt; padding-bottom: 3.35pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.22pt; text-align: left;"><font style="padding-left: 17.5pt; border-bottom: 1pt solid #000000; min-width: 35.83pt;">(582</font><font style="min-width: 35.83pt;">)</font></div></td><td class="gutter" style="width: 1.57%; border-bottom: none; font-size: 2pt; padding-top: 2.1pt; padding-bottom: 3.35pt;">&#8203;</td><td class="gutter" style="width: 1.57%; border-bottom: none; font-size: 2pt; padding-top: 2.1pt; padding-bottom: 3.35pt;">&#8203;</td><td style="width: 9.03%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.1pt; padding-bottom: 3.35pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.23pt; text-align: left;"><font style="padding-left: 17.5pt; border-bottom: 1pt solid #000000; min-width: 35.83pt;">(224</font><font style="min-width: 35.83pt;">)</font></div></td><td class="gutter" style="width: 1.57%; border-bottom: none; font-size: 2pt; padding-top: 2.1pt; padding-bottom: 3.35pt;">&#8203;</td><td class="gutter" style="width: 1.57%; border-bottom: none; font-size: 2pt; padding-top: 2.1pt; padding-bottom: 3.35pt;">&#8203;</td><td style="width: 5.88%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.1pt; padding-bottom: 3.35pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 9.17pt; border-bottom: 1pt solid #000000; min-width: 27.5pt;">(358</font><font style="min-width: 27.5pt;">)</font></div></td></tr><tr><td style="width: 66.67%; text-align: left; vertical-align: bottom; padding-top: 3.35pt; padding-bottom: 6pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Loss for the year<font style="padding-left: 4.54pt;"></font></div></td><td class="gutter" style="width: 1.57%; border-bottom: none; font-size: 2pt; padding-top: 3.35pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.57%; border-bottom: none; font-size: 2pt; padding-top: 3.35pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.03%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3.35pt; padding-bottom: 6pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.22pt; text-align: left;"><font style="padding-left: 0.37pt; border-bottom: 3pt double #000000; min-width: 35.83pt;">(116,484</font><font style="min-width: 35.83pt;">)</font></div></td><td class="gutter" style="width: 1.57%; border-bottom: none; font-size: 2pt; padding-top: 3.35pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.57%; border-bottom: none; font-size: 2pt; padding-top: 3.35pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.03%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3.35pt; padding-bottom: 6pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.23pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 35.83pt;">(123,096</font><font style="min-width: 35.83pt;">)</font></div></td><td class="gutter" style="width: 1.57%; border-bottom: none; font-size: 2pt; padding-top: 3.35pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.57%; border-bottom: none; font-size: 2pt; padding-top: 3.35pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.88%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3.35pt; padding-bottom: 6pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 5pt; border-bottom: 3pt double #000000; min-width: 27.5pt;">6,612</font></div></td></tr></table><div class="h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 18pt; margin-left: 0pt; text-align: left;">Contract Revenue</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Contract revenue increased to $2.3&#160;million for the year ended December&#160;31, 2019 from $1.1 million for the year ended December&#160;31, 2018, an increase of $1.2 million, or 105.3%. The increase was due to the discontinuance of the joint clinical development of MEDI3726 and the recognition of the remaining non-refundable upfront payment (consisting of deferred revenue and presented as a contract liability in our consolidated balance sheet) of $2.3&#160;million that existed as of December&#160;31, 2018.</div><div class="h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 20pt; margin-left: 0pt; text-align: left;">Research and Development Expense</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The following table summarizes our research and development expense for the years ended December&#160;31, 2019 and 2018:</div><table cellspacing="0" cellpadding="0" class="fintab" style="margin-top: 5.25pt; border-collapse: collapse; width: 468pt; margin-left: auto; margin-right: auto;"><tr class="header"><td style="width: 66.67%; text-align: left; vertical-align: bottom; padding-top: 6pt; padding-bottom: 3.35pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 1.45%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 3.35pt;">&#8203;</td><td class="gutter" style="width: 1.45%; font-size: 2pt; padding-top: 6pt; padding-bottom: 3.35pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td colspan="4" style="width: 20.96%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 3.35pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Year Ended December&#160;31,</div></td><td class="gutter" style="width: 1.45%; font-size: 2pt; padding-top: 6pt; padding-bottom: 3.35pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.45%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 3.35pt;">&#8203;</td><td style="width: 6.59%; text-align: center; vertical-align: bottom; padding-top: 6pt; padding-bottom: 3.35pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td></tr><tr class="header"><td style="width: 66.67%; text-align: left; vertical-align: bottom; padding-top: 3.35pt; padding-bottom: 3.35pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 1.45%; border-bottom: none; font-size: 2pt; padding-top: 3.35pt; padding-bottom: 3.35pt;">&#8203;</td><td class="gutter" style="width: 1.45%; font-size: 2pt; padding-top: 3.35pt; padding-bottom: 3.35pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 9.07%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 3.35pt; padding-bottom: 3.35pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2019</div></td><td class="gutter" style="width: 1.45%; font-size: 2pt; padding-top: 3.35pt; padding-bottom: 3.35pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.45%; font-size: 2pt; padding-top: 3.35pt; padding-bottom: 3.35pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 8.99%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 3.35pt; padding-bottom: 3.35pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2018</div></td><td class="gutter" style="width: 1.45%; font-size: 2pt; padding-top: 3.35pt; padding-bottom: 3.35pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.45%; font-size: 2pt; padding-top: 3.35pt; padding-bottom: 3.35pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 6.59%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 3.35pt; padding-bottom: 3.35pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Change</div></td></tr><tr class="header"><td style="width: 66.67%; text-align: left; vertical-align: bottom; padding-top: 3.35pt; padding-bottom: 3.35pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 1.45%; border-bottom: none; font-size: 2pt; padding-top: 3.35pt; padding-bottom: 3.35pt;">&#8203;</td><td class="gutter" style="width: 1.45%; border-bottom: none; font-size: 2pt; padding-top: 3.35pt; padding-bottom: 3.35pt;">&#8203;</td><td colspan="7" style="width: 30.44%; text-align: center; vertical-align: bottom; padding-top: 3.35pt; padding-bottom: 3.35pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">(in USD thousands) </div></td></tr><tr><td style="width: 66.67%; text-align: left; vertical-align: bottom; padding-top: 3.35pt; padding-bottom: 2.1pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">External costs<font style="padding-left: 2.3pt;"></font></div></td><td class="gutter" style="width: 1.45%; border-bottom: none; font-size: 2pt; padding-top: 3.35pt; padding-bottom: 2.1pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.45%; border-bottom: none; font-size: 2pt; padding-top: 3.35pt; padding-bottom: 2.1pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.07%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3.35pt; padding-bottom: 2.1pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.98pt; text-align: left;"><font style="padding-left: 5pt;">81,363</font></div></td><td class="gutter" style="width: 1.45%; border-bottom: none; font-size: 2pt; padding-top: 3.35pt; padding-bottom: 2.1pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.45%; border-bottom: none; font-size: 2pt; padding-top: 3.35pt; padding-bottom: 2.1pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.99%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3.35pt; padding-bottom: 2.1pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.98pt; text-align: left;"><font style="padding-left: 4.63pt;">98,493</font></div></td><td class="gutter" style="width: 1.45%; border-bottom: none; font-size: 2pt; padding-top: 3.35pt; padding-bottom: 2.1pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.45%; border-bottom: none; font-size: 2pt; padding-top: 3.35pt; padding-bottom: 2.1pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.59%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3.35pt; padding-bottom: 2.1pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">(17,130)</div></td></tr><tr><td style="width: 66.67%; text-align: left; vertical-align: bottom; padding-top: 2.1pt; padding-bottom: 2.1pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Employee expenses<font style="padding-left: 4.53pt;"></font></div></td><td class="gutter" style="width: 1.45%; border-bottom: none; font-size: 2pt; padding-top: 2.1pt; padding-bottom: 2.1pt;">&#8203;</td><td class="gutter" style="width: 1.45%; border-bottom: none; font-size: 2pt; padding-top: 2.1pt; padding-bottom: 2.1pt;">&#8203;</td><td style="width: 9.07%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.1pt; padding-bottom: 2.1pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.98pt; text-align: left;"><font style="padding-left: 5pt;">24,916</font></div></td><td class="gutter" style="width: 1.45%; border-bottom: none; font-size: 2pt; padding-top: 2.1pt; padding-bottom: 2.1pt;">&#8203;</td><td class="gutter" style="width: 1.45%; border-bottom: none; font-size: 2pt; padding-top: 2.1pt; padding-bottom: 2.1pt;">&#8203;</td><td style="width: 8.99%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.1pt; padding-bottom: 2.1pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.98pt; text-align: left;"><font style="padding-left: 4.63pt;">19,246</font></div></td><td class="gutter" style="width: 1.45%; border-bottom: none; font-size: 2pt; padding-top: 2.1pt; padding-bottom: 2.1pt;">&#8203;</td><td class="gutter" style="width: 1.45%; border-bottom: none; font-size: 2pt; padding-top: 2.1pt; padding-bottom: 2.1pt;">&#8203;</td><td style="width: 6.59%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.1pt; padding-bottom: 2.1pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 8.33pt;">5,670</font></div></td></tr><tr><td style="width: 66.67%; text-align: left; vertical-align: bottom; padding-top: 2.1pt; padding-bottom: 2.1pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Depreciation of property, plant and equipment<font style="padding-left: 0.49pt;"></font></div></td><td class="gutter" style="width: 1.45%; border-bottom: none; font-size: 2pt; padding-top: 2.1pt; padding-bottom: 2.1pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.45%; border-bottom: none; font-size: 2pt; padding-top: 2.1pt; padding-bottom: 2.1pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.07%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.1pt; padding-bottom: 2.1pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.98pt; text-align: left;"><font style="padding-left: 17.5pt;">407</font></div></td><td class="gutter" style="width: 1.45%; border-bottom: none; font-size: 2pt; padding-top: 2.1pt; padding-bottom: 2.1pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.45%; border-bottom: none; font-size: 2pt; padding-top: 2.1pt; padding-bottom: 2.1pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.99%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.1pt; padding-bottom: 2.1pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.98pt; text-align: left;"><font style="padding-left: 17.13pt;">330</font></div></td><td class="gutter" style="width: 1.45%; border-bottom: none; font-size: 2pt; padding-top: 2.1pt; padding-bottom: 2.1pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.45%; border-bottom: none; font-size: 2pt; padding-top: 2.1pt; padding-bottom: 2.1pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.59%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.1pt; padding-bottom: 2.1pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 20.83pt;">77</font></div></td></tr><tr><td style="width: 66.67%; text-align: left; vertical-align: bottom; padding-top: 2.1pt; padding-bottom: 2.1pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Depreciation of right-of-use assets<font style="padding-left: 4.02pt;"></font></div></td><td class="gutter" style="width: 1.45%; border-bottom: none; font-size: 2pt; padding-top: 2.1pt; padding-bottom: 2.1pt;">&#8203;</td><td class="gutter" style="width: 1.45%; border-bottom: none; font-size: 2pt; padding-top: 2.1pt; padding-bottom: 2.1pt;">&#8203;</td><td style="width: 9.07%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.1pt; padding-bottom: 2.1pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.98pt; text-align: left;"><font style="padding-left: 17.5pt;">837</font></div></td><td class="gutter" style="width: 1.45%; border-bottom: none; font-size: 2pt; padding-top: 2.1pt; padding-bottom: 2.1pt;">&#8203;</td><td class="gutter" style="width: 1.45%; border-bottom: none; font-size: 2pt; padding-top: 2.1pt; padding-bottom: 2.1pt;">&#8203;</td><td style="width: 8.99%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.1pt; padding-bottom: 2.1pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.98pt; text-align: left;"><font style="padding-left: 22.13pt;">&#8212;</font></div></td><td class="gutter" style="width: 1.45%; border-bottom: none; font-size: 2pt; padding-top: 2.1pt; padding-bottom: 2.1pt;">&#8203;</td><td class="gutter" style="width: 1.45%; border-bottom: none; font-size: 2pt; padding-top: 2.1pt; padding-bottom: 2.1pt;">&#8203;</td><td style="width: 6.59%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.1pt; padding-bottom: 2.1pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 15.83pt;">837</font></div></td></tr><tr><td style="width: 66.67%; text-align: left; vertical-align: bottom; padding-top: 2.1pt; padding-bottom: 2.1pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Amortization of intangible assets<font style="padding-left: 4.55pt;"></font></div></td><td class="gutter" style="width: 1.45%; border-bottom: none; font-size: 2pt; padding-top: 2.1pt; padding-bottom: 2.1pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.45%; border-bottom: none; font-size: 2pt; padding-top: 2.1pt; padding-bottom: 2.1pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.07%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.1pt; padding-bottom: 2.1pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.98pt; text-align: left;"><font style="padding-left: 22.5pt;">14</font></div></td><td class="gutter" style="width: 1.45%; border-bottom: none; font-size: 2pt; padding-top: 2.1pt; padding-bottom: 2.1pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.45%; border-bottom: none; font-size: 2pt; padding-top: 2.1pt; padding-bottom: 2.1pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.99%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.1pt; padding-bottom: 2.1pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.98pt; text-align: left;"><font style="padding-left: 22.13pt;">17</font></div></td><td class="gutter" style="width: 1.45%; border-bottom: none; font-size: 2pt; padding-top: 2.1pt; padding-bottom: 2.1pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.45%; border-bottom: none; font-size: 2pt; padding-top: 2.1pt; padding-bottom: 2.1pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.59%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.1pt; padding-bottom: 2.1pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 22.5pt;">(3)</font></div></td></tr><tr><td style="width: 66.67%; text-align: left; vertical-align: bottom; padding-top: 2.1pt; padding-bottom: 3.35pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Impairment of intangible assets<font style="padding-left: 1.22pt;"></font></div></td><td class="gutter" style="width: 1.45%; border-bottom: none; font-size: 2pt; padding-top: 2.1pt; padding-bottom: 3.35pt;">&#8203;</td><td class="gutter" style="width: 1.45%; border-bottom: none; font-size: 2pt; padding-top: 2.1pt; padding-bottom: 3.35pt;">&#8203;</td><td style="width: 9.07%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.1pt; padding-bottom: 3.35pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.98pt; text-align: left;"><font style="padding-left: 22.5pt; border-bottom: 1pt solid #000000; min-width: 32.5pt;">&#8212;</font></div></td><td class="gutter" style="width: 1.45%; border-bottom: none; font-size: 2pt; padding-top: 2.1pt; padding-bottom: 3.35pt;">&#8203;</td><td class="gutter" style="width: 1.45%; border-bottom: none; font-size: 2pt; padding-top: 2.1pt; padding-bottom: 3.35pt;">&#8203;</td><td style="width: 8.99%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.1pt; padding-bottom: 3.35pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.98pt; text-align: left;"><font style="padding-left: 17.13pt; border-bottom: 1pt solid #000000; min-width: 32.13pt;">227</font></div></td><td class="gutter" style="width: 1.45%; border-bottom: none; font-size: 2pt; padding-top: 2.1pt; padding-bottom: 3.35pt;">&#8203;</td><td class="gutter" style="width: 1.45%; border-bottom: none; font-size: 2pt; padding-top: 2.1pt; padding-bottom: 3.35pt;">&#8203;</td><td style="width: 6.59%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.1pt; padding-bottom: 3.35pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 12.5pt; border-bottom: 1pt solid #000000; min-width: 30.83pt;">(227</font><font style="min-width: 30.83pt;">)</font></div></td></tr><tr><td style="width: 66.67%; text-align: left; vertical-align: bottom; padding-top: 3.35pt; padding-bottom: 6pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Research and development expense<font style="padding-left: 4.56pt;"></font></div></td><td class="gutter" style="width: 1.45%; border-bottom: none; font-size: 2pt; padding-top: 3.35pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.45%; border-bottom: none; font-size: 2pt; padding-top: 3.35pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.07%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3.35pt; padding-bottom: 6pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.98pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 32.5pt;">107,537</font></div></td><td class="gutter" style="width: 1.45%; border-bottom: none; font-size: 2pt; padding-top: 3.35pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.45%; border-bottom: none; font-size: 2pt; padding-top: 3.35pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.99%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3.35pt; padding-bottom: 6pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.98pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 32.13pt;">118,313</font></div></td><td class="gutter" style="width: 1.45%; border-bottom: none; font-size: 2pt; padding-top: 3.35pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.45%; border-bottom: none; font-size: 2pt; padding-top: 3.35pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.59%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3.35pt; padding-bottom: 6pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 30.83pt;">(10,776</font><font style="min-width: 30.83pt;">)</font></div></td></tr></table><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Our research and development expense decreased to $107.5 million for the year ended December&#160;31, 2019 from $118.3 million for the year ended December&#160;31, 2018, a decrease of $10.8 million, or 9.1%. The decrease was primarily due to decreased CMC costs for our lead product candidates as clinical trials advanced.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The following table summarizes our research and development expense for our major development programs for the year ended December 31, 2019 and 2018: </div><table cellspacing="0" cellpadding="0" class="fintab" style="margin-top: 5.25pt; border-collapse: collapse; width: 468pt; margin-left: auto; margin-right: auto;"><tr class="header"><td style="width: 66.67%; text-align: left; vertical-align: bottom; padding-top: 6pt; padding-bottom: 3.35pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 1.45%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 3.35pt;">&#8203;</td><td class="gutter" style="width: 1.45%; font-size: 2pt; padding-top: 6pt; padding-bottom: 3.35pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td colspan="4" style="width: 20.96%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 3.35pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Year Ended December 31,</div></td><td class="gutter" style="width: 1.45%; font-size: 2pt; padding-top: 6pt; padding-bottom: 3.35pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.45%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 3.35pt;">&#8203;</td><td style="width: 6.59%; text-align: center; vertical-align: bottom; padding-top: 6pt; padding-bottom: 3.35pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td></tr><tr class="header"><td style="width: 66.67%; text-align: left; vertical-align: bottom; padding-top: 3.35pt; padding-bottom: 3.35pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 1.45%; border-bottom: none; font-size: 2pt; padding-top: 3.35pt; padding-bottom: 3.35pt;">&#8203;</td><td class="gutter" style="width: 1.45%; font-size: 2pt; padding-top: 3.35pt; padding-bottom: 3.35pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 9.07%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 3.35pt; padding-bottom: 3.35pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2019</div></td><td class="gutter" style="width: 1.45%; font-size: 2pt; padding-top: 3.35pt; padding-bottom: 3.35pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.45%; font-size: 2pt; padding-top: 3.35pt; padding-bottom: 3.35pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 8.99%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 3.35pt; padding-bottom: 3.35pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2018</div></td><td class="gutter" style="width: 1.45%; font-size: 2pt; padding-top: 3.35pt; padding-bottom: 3.35pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.45%; font-size: 2pt; padding-top: 3.35pt; padding-bottom: 3.35pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 6.59%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 3.35pt; padding-bottom: 3.35pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Change</div></td></tr><tr class="header"><td style="width: 66.67%; text-align: left; vertical-align: bottom; padding-top: 3.35pt; padding-bottom: 3.35pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 1.45%; border-bottom: none; font-size: 2pt; padding-top: 3.35pt; padding-bottom: 3.35pt;">&#8203;</td><td class="gutter" style="width: 1.45%; border-bottom: none; font-size: 2pt; padding-top: 3.35pt; padding-bottom: 3.35pt;">&#8203;</td><td colspan="7" style="width: 30.44%; text-align: center; vertical-align: bottom; padding-top: 3.35pt; padding-bottom: 3.35pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">(in USD thousands) </div></td></tr><tr><td style="width: 66.67%; text-align: left; vertical-align: bottom; padding-top: 3.35pt; padding-bottom: 2.1pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Lonca<font style="padding-left: 4.51pt;"></font></div></td><td class="gutter" style="width: 1.45%; border-bottom: none; font-size: 2pt; padding-top: 3.35pt; padding-bottom: 2.1pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.45%; border-bottom: none; font-size: 2pt; padding-top: 3.35pt; padding-bottom: 2.1pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.07%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3.35pt; padding-bottom: 2.1pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.98pt; text-align: left;"><font style="padding-left: 5pt;">42,123</font></div></td><td class="gutter" style="width: 1.45%; border-bottom: none; font-size: 2pt; padding-top: 3.35pt; padding-bottom: 2.1pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.45%; border-bottom: none; font-size: 2pt; padding-top: 3.35pt; padding-bottom: 2.1pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.99%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3.35pt; padding-bottom: 2.1pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.98pt; text-align: left;"><font style="padding-left: 4.63pt;">45,701</font></div></td><td class="gutter" style="width: 1.45%; border-bottom: none; font-size: 2pt; padding-top: 3.35pt; padding-bottom: 2.1pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.45%; border-bottom: none; font-size: 2pt; padding-top: 3.35pt; padding-bottom: 2.1pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.59%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3.35pt; padding-bottom: 2.1pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 5pt;">(3,578</font>)</div></td></tr><tr><td style="width: 66.67%; text-align: left; vertical-align: bottom; padding-top: 2.1pt; padding-bottom: 2.1pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Cami<font style="padding-left: 2.84pt;"></font></div></td><td class="gutter" style="width: 1.45%; border-bottom: none; font-size: 2pt; padding-top: 2.1pt; padding-bottom: 2.1pt;">&#8203;</td><td class="gutter" style="width: 1.45%; border-bottom: none; font-size: 2pt; padding-top: 2.1pt; padding-bottom: 2.1pt;">&#8203;</td><td style="width: 9.07%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.1pt; padding-bottom: 2.1pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.98pt; text-align: left;"><font style="padding-left: 5pt;">31,839</font></div></td><td class="gutter" style="width: 1.45%; border-bottom: none; font-size: 2pt; padding-top: 2.1pt; padding-bottom: 2.1pt;">&#8203;</td><td class="gutter" style="width: 1.45%; border-bottom: none; font-size: 2pt; padding-top: 2.1pt; padding-bottom: 2.1pt;">&#8203;</td><td style="width: 8.99%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.1pt; padding-bottom: 2.1pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.98pt; text-align: left;"><font style="padding-left: 4.63pt;">29,374</font></div></td><td class="gutter" style="width: 1.45%; border-bottom: none; font-size: 2pt; padding-top: 2.1pt; padding-bottom: 2.1pt;">&#8203;</td><td class="gutter" style="width: 1.45%; border-bottom: none; font-size: 2pt; padding-top: 2.1pt; padding-bottom: 2.1pt;">&#8203;</td><td style="width: 6.59%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.1pt; padding-bottom: 2.1pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 8.33pt;">2,465</font></div></td></tr><tr><td style="width: 66.67%; text-align: left; vertical-align: bottom; padding-top: 2.1pt; padding-bottom: 2.1pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">ADCT-602<font style="padding-left: 4.87pt;"></font></div></td><td class="gutter" style="width: 1.45%; border-bottom: none; font-size: 2pt; padding-top: 2.1pt; padding-bottom: 2.1pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.45%; border-bottom: none; font-size: 2pt; padding-top: 2.1pt; padding-bottom: 2.1pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.07%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.1pt; padding-bottom: 2.1pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.98pt; text-align: left;"><font style="padding-left: 10pt;">3,374</font></div></td><td class="gutter" style="width: 1.45%; border-bottom: none; font-size: 2pt; padding-top: 2.1pt; padding-bottom: 2.1pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.45%; border-bottom: none; font-size: 2pt; padding-top: 2.1pt; padding-bottom: 2.1pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.99%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.1pt; padding-bottom: 2.1pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.98pt; text-align: left;"><font style="padding-left: 9.63pt;">6,162</font></div></td><td class="gutter" style="width: 1.45%; border-bottom: none; font-size: 2pt; padding-top: 2.1pt; padding-bottom: 2.1pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.45%; border-bottom: none; font-size: 2pt; padding-top: 2.1pt; padding-bottom: 2.1pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.59%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.1pt; padding-bottom: 2.1pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 5pt;">(2,788</font>)</div></td></tr><tr><td style="width: 66.67%; text-align: left; vertical-align: bottom; padding-top: 2.1pt; padding-bottom: 2.1pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">ADCT-601<font style="padding-left: 4.87pt;"></font></div></td><td class="gutter" style="width: 1.45%; border-bottom: none; font-size: 2pt; padding-top: 2.1pt; padding-bottom: 2.1pt;">&#8203;</td><td class="gutter" style="width: 1.45%; border-bottom: none; font-size: 2pt; padding-top: 2.1pt; padding-bottom: 2.1pt;">&#8203;</td><td style="width: 9.07%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.1pt; padding-bottom: 2.1pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.98pt; text-align: left;"><font style="padding-left: 10pt;">7,183</font></div></td><td class="gutter" style="width: 1.45%; border-bottom: none; font-size: 2pt; padding-top: 2.1pt; padding-bottom: 2.1pt;">&#8203;</td><td class="gutter" style="width: 1.45%; border-bottom: none; font-size: 2pt; padding-top: 2.1pt; padding-bottom: 2.1pt;">&#8203;</td><td style="width: 8.99%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.1pt; padding-bottom: 2.1pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.98pt; text-align: left;"><font style="padding-left: 4.63pt;">14,250</font></div></td><td class="gutter" style="width: 1.45%; border-bottom: none; font-size: 2pt; padding-top: 2.1pt; padding-bottom: 2.1pt;">&#8203;</td><td class="gutter" style="width: 1.45%; border-bottom: none; font-size: 2pt; padding-top: 2.1pt; padding-bottom: 2.1pt;">&#8203;</td><td style="width: 6.59%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.1pt; padding-bottom: 2.1pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 5pt;">(7,067)</font></div></td></tr><tr><td style="width: 66.67%; text-align: left; vertical-align: bottom; padding-top: 2.1pt; padding-bottom: 2.1pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">MEDI3726<font style="padding-left: 3.95pt;"></font></div></td><td class="gutter" style="width: 1.45%; border-bottom: none; font-size: 2pt; padding-top: 2.1pt; padding-bottom: 2.1pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.45%; border-bottom: none; font-size: 2pt; padding-top: 2.1pt; padding-bottom: 2.1pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.07%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.1pt; padding-bottom: 2.1pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.98pt; text-align: left;"><font style="padding-left: 17.5pt;">915</font></div></td><td class="gutter" style="width: 1.45%; border-bottom: none; font-size: 2pt; padding-top: 2.1pt; padding-bottom: 2.1pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.45%; border-bottom: none; font-size: 2pt; padding-top: 2.1pt; padding-bottom: 2.1pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.99%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.1pt; padding-bottom: 2.1pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.98pt; text-align: left;"><font style="padding-left: 9.63pt;">2,389</font></div></td><td class="gutter" style="width: 1.45%; border-bottom: none; font-size: 2pt; padding-top: 2.1pt; padding-bottom: 2.1pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.45%; border-bottom: none; font-size: 2pt; padding-top: 2.1pt; padding-bottom: 2.1pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.59%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.1pt; padding-bottom: 2.1pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 5pt;">(1,474</font>)</div></td></tr><tr><td style="width: 66.67%; text-align: left; vertical-align: bottom; padding-top: 2.1pt; padding-bottom: 3.35pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Preclinical product candidates and research pipeline<font style="padding-left: 2.38pt;"></font></div></td><td class="gutter" style="width: 1.45%; border-bottom: none; font-size: 2pt; padding-top: 2.1pt; padding-bottom: 3.35pt;">&#8203;</td><td class="gutter" style="width: 1.45%; border-bottom: none; font-size: 2pt; padding-top: 2.1pt; padding-bottom: 3.35pt;">&#8203;</td><td style="width: 9.07%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.1pt; padding-bottom: 3.35pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.98pt; text-align: left;"><font style="padding-left: 5pt; border-bottom: 1pt solid #000000; min-width: 32.5pt;">22,103</font></div></td><td class="gutter" style="width: 1.45%; border-bottom: none; font-size: 2pt; padding-top: 2.1pt; padding-bottom: 3.35pt;">&#8203;</td><td class="gutter" style="width: 1.45%; border-bottom: none; font-size: 2pt; padding-top: 2.1pt; padding-bottom: 3.35pt;">&#8203;</td><td style="width: 8.99%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.1pt; padding-bottom: 3.35pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.98pt; text-align: left;"><font style="padding-left: 4.63pt; border-bottom: 1pt solid #000000; min-width: 32.13pt;">20,437</font></div></td><td class="gutter" style="width: 1.45%; border-bottom: none; font-size: 2pt; padding-top: 2.1pt; padding-bottom: 3.35pt;">&#8203;</td><td class="gutter" style="width: 1.45%; border-bottom: none; font-size: 2pt; padding-top: 2.1pt; padding-bottom: 3.35pt;">&#8203;</td><td style="width: 6.59%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.1pt; padding-bottom: 3.35pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 8.33pt; border-bottom: 1pt solid #000000; min-width: 30.83pt;">1,666</font></div></td></tr><tr><td style="width: 66.67%; text-align: left; vertical-align: bottom; padding-top: 3.35pt; padding-bottom: 6pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Total<font style="padding-left: 4.09pt;"></font></div></td><td class="gutter" style="width: 1.45%; border-bottom: none; font-size: 2pt; padding-top: 3.35pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.45%; border-bottom: none; font-size: 2pt; padding-top: 3.35pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.07%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3.35pt; padding-bottom: 6pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.98pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 32.5pt;">107,537</font></div></td><td class="gutter" style="width: 1.45%; border-bottom: none; font-size: 2pt; padding-top: 3.35pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.45%; border-bottom: none; font-size: 2pt; padding-top: 3.35pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.99%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3.35pt; padding-bottom: 6pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.98pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 32.13pt;">118,313</font></div></td><td class="gutter" style="width: 1.45%; border-bottom: none; font-size: 2pt; padding-top: 3.35pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.45%; border-bottom: none; font-size: 2pt; padding-top: 3.35pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.59%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3.35pt; padding-bottom: 6pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 30.83pt;">(10,776</font><font style="border-bottom: 3pt double #000000; min-width: 30.83pt;"></font><font style="min-width: 30.83pt;">)</font></div></td></tr></table></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 36pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">97<br></div></div></div>
<!--End Page 101-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 102-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 540pt;"><a name="nt10014672x1_drs_106-mda_pg10"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="block-frill" style="width: 540pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: Arial, Helvetica, sans-serif; font-size: 9pt; font-weight: bold; margin-top: 6pt; text-align: center;">Confidential Treatment Requested by ADC Therapeutics SA Pursuant to 17 C.F.R. &#167; 200.83<br></div></div><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 36pt;"><div class="h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">General and Administrative Expense</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The following table summarizes our general and administrative expense for the years ended December&#160;31, 2019 and 2018:</div><table cellspacing="0" cellpadding="0" class="fintab" style="margin-top: 5.25pt; border-collapse: collapse; width: 468pt; margin-left: auto; margin-right: auto;"><tr class="header"><td style="width: 66.67%; text-align: left; vertical-align: bottom; padding-top: 6pt; padding-bottom: 3.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 1.61%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 3.75pt;">&#8203;</td><td class="gutter" style="width: 1.61%; font-size: 2pt; padding-top: 6pt; padding-bottom: 3.75pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td colspan="4" style="width: 21.29%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 3.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Year Ended December&#160;31,</div></td><td class="gutter" style="width: 1.61%; font-size: 2pt; padding-top: 6pt; padding-bottom: 3.75pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.61%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 3.75pt;">&#8203;</td><td style="width: 5.6%; text-align: center; vertical-align: bottom; padding-top: 6pt; padding-bottom: 3.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td></tr><tr class="header"><td style="width: 66.67%; text-align: left; vertical-align: bottom; padding-top: 3.75pt; padding-bottom: 3.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 1.61%; border-bottom: none; font-size: 2pt; padding-top: 3.75pt; padding-bottom: 3.75pt;">&#8203;</td><td class="gutter" style="width: 1.61%; font-size: 2pt; padding-top: 3.75pt; padding-bottom: 3.75pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 9.57%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 3.75pt; padding-bottom: 3.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2019</div></td><td class="gutter" style="width: 1.61%; font-size: 2pt; padding-top: 3.75pt; padding-bottom: 3.75pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.61%; font-size: 2pt; padding-top: 3.75pt; padding-bottom: 3.75pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 8.5%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 3.75pt; padding-bottom: 3.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2018</div></td><td class="gutter" style="width: 1.61%; font-size: 2pt; padding-top: 3.75pt; padding-bottom: 3.75pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.61%; font-size: 2pt; padding-top: 3.75pt; padding-bottom: 3.75pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 5.6%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 3.75pt; padding-bottom: 3.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Change</div></td></tr><tr class="header"><td style="width: 66.67%; text-align: left; vertical-align: bottom; padding-top: 3.75pt; padding-bottom: 3.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 1.61%; border-bottom: none; font-size: 2pt; padding-top: 3.75pt; padding-bottom: 3.75pt;">&#8203;</td><td class="gutter" style="width: 1.61%; border-bottom: none; font-size: 2pt; padding-top: 3.75pt; padding-bottom: 3.75pt;">&#8203;</td><td colspan="7" style="width: 30.11%; text-align: center; vertical-align: bottom; padding-top: 3.75pt; padding-bottom: 3.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">(in USD thousands) </div></td></tr><tr><td style="width: 66.67%; text-align: left; vertical-align: bottom; padding-top: 3.75pt; padding-bottom: 2.5pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Employee expenses<font style="padding-left: 4.53pt;"></font></div></td><td class="gutter" style="width: 1.61%; border-bottom: none; font-size: 2pt; padding-top: 3.75pt; padding-bottom: 2.5pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.61%; border-bottom: none; font-size: 2pt; padding-top: 3.75pt; padding-bottom: 2.5pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.57%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3.75pt; padding-bottom: 2.5pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 8.64pt; text-align: left;"><font style="padding-left: 5pt;">5,135</font></div></td><td class="gutter" style="width: 1.61%; border-bottom: none; font-size: 2pt; padding-top: 3.75pt; padding-bottom: 2.5pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.61%; border-bottom: none; font-size: 2pt; padding-top: 3.75pt; padding-bottom: 2.5pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.5%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3.75pt; padding-bottom: 2.5pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 8.64pt; text-align: left;">4,936</div></td><td class="gutter" style="width: 1.61%; border-bottom: none; font-size: 2pt; padding-top: 3.75pt; padding-bottom: 2.5pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.61%; border-bottom: none; font-size: 2pt; padding-top: 3.75pt; padding-bottom: 2.5pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.6%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3.75pt; padding-bottom: 2.5pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.85pt; text-align: left;"><font style="padding-left: 7.5pt;">199</font></div></td></tr><tr><td style="width: 66.67%; text-align: left; vertical-align: bottom; padding-top: 2.5pt; padding-bottom: 2.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">External costs<font style="padding-left: 2.3pt;"></font></div></td><td class="gutter" style="width: 1.61%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td class="gutter" style="width: 1.61%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td style="width: 9.57%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.5pt; padding-bottom: 2.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 8.64pt; text-align: left;"><font style="padding-left: 5pt;">8,668</font></div></td><td class="gutter" style="width: 1.61%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td class="gutter" style="width: 1.61%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td style="width: 8.5%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.5pt; padding-bottom: 2.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 8.64pt; text-align: left;">3,628</div></td><td class="gutter" style="width: 1.61%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td class="gutter" style="width: 1.61%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td style="width: 5.6%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.5pt; padding-bottom: 2.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.85pt; text-align: left;">5,040</div></td></tr><tr><td style="width: 66.67%; text-align: left; vertical-align: bottom; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">General and administrative costs charged by related parties<font style="padding-left: 2.57pt;"></font></div></td><td class="gutter" style="width: 1.61%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.61%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.57%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 8.64pt; text-align: left;"><font style="padding-left: 17.87pt;">11</font></div></td><td class="gutter" style="width: 1.61%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.61%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.5%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 8.64pt; text-align: left;"><font style="padding-left: 12.5pt;">38</font></div></td><td class="gutter" style="width: 1.61%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.61%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.6%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.85pt; text-align: left;"><font style="padding-left: 9.17pt;">(27)</font></div></td></tr><tr><td style="width: 66.67%; text-align: left; vertical-align: bottom; padding-top: 2.5pt; padding-bottom: 2.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Depreciation of property, plant and equipment<font style="padding-left: 0.49pt;"></font></div></td><td class="gutter" style="width: 1.61%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td class="gutter" style="width: 1.61%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td style="width: 9.57%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.5pt; padding-bottom: 2.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 8.64pt; text-align: left;"><font style="padding-left: 12.5pt;">145</font></div></td><td class="gutter" style="width: 1.61%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td class="gutter" style="width: 1.61%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td style="width: 8.5%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.5pt; padding-bottom: 2.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 8.64pt; text-align: left;"><font style="padding-left: 7.5pt;">158</font></div></td><td class="gutter" style="width: 1.61%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td class="gutter" style="width: 1.61%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td style="width: 5.6%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.5pt; padding-bottom: 2.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.85pt; text-align: left;"><font style="padding-left: 9.17pt;">(13)</font></div></td></tr><tr><td style="width: 66.67%; text-align: left; vertical-align: bottom; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Depreciation of right-of-use assets<font style="padding-left: 4.02pt;"></font></div></td><td class="gutter" style="width: 1.61%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.61%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.57%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 8.64pt; text-align: left;"><font style="padding-left: 12.5pt;">227</font></div></td><td class="gutter" style="width: 1.61%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.61%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.5%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 8.64pt; text-align: left;"><font style="padding-left: 12.5pt;">&#8212;</font></div></td><td class="gutter" style="width: 1.61%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.61%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.6%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.85pt; text-align: left;"><font style="padding-left: 7.5pt;">227</font></div></td></tr><tr><td style="width: 66.67%; text-align: left; vertical-align: bottom; padding-top: 2.5pt; padding-bottom: 3.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Amortization of intangible assets<font style="padding-left: 4.55pt;"></font></div></td><td class="gutter" style="width: 1.61%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 3.75pt;">&#8203;</td><td class="gutter" style="width: 1.61%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 3.75pt;">&#8203;</td><td style="width: 9.57%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.5pt; padding-bottom: 3.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 8.64pt; text-align: left;"><font style="padding-left: 17.5pt; border-bottom: 1pt solid #000000; min-width: 27.5pt;">16</font></div></td><td class="gutter" style="width: 1.61%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 3.75pt;">&#8203;</td><td class="gutter" style="width: 1.61%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 3.75pt;">&#8203;</td><td style="width: 8.5%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.5pt; padding-bottom: 3.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 8.64pt; text-align: left;"><font style="padding-left: 17.5pt; border-bottom: 1pt solid #000000; min-width: 22.5pt;">8</font></div></td><td class="gutter" style="width: 1.61%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 3.75pt;">&#8203;</td><td class="gutter" style="width: 1.61%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 3.75pt;">&#8203;</td><td style="width: 5.6%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.5pt; padding-bottom: 3.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.85pt; text-align: left;"><font style="padding-left: 17.5pt; border-bottom: 1pt solid #000000; min-width: 22.5pt;">8</font></div></td></tr><tr><td style="width: 66.67%; text-align: left; vertical-align: bottom; padding-top: 3.75pt; padding-bottom: 6pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">General and administrative expenses<font style="padding-left: 0.12pt;"></font></div></td><td class="gutter" style="width: 1.61%; border-bottom: none; font-size: 2pt; padding-top: 3.75pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.61%; border-bottom: none; font-size: 2pt; padding-top: 3.75pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.57%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3.75pt; padding-bottom: 6pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 8.64pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 27.5pt;">14,202</font></div></td><td class="gutter" style="width: 1.61%; border-bottom: none; font-size: 2pt; padding-top: 3.75pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.61%; border-bottom: none; font-size: 2pt; padding-top: 3.75pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.5%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3.75pt; padding-bottom: 6pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 8.64pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 22.5pt;">8,768</font></div></td><td class="gutter" style="width: 1.61%; border-bottom: none; font-size: 2pt; padding-top: 3.75pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.61%; border-bottom: none; font-size: 2pt; padding-top: 3.75pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.6%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3.75pt; padding-bottom: 6pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.85pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 22.5pt;">5,434</font></div></td></tr></table><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Our general and administrative expense for the year ended December&#160;31, 2019 increased to $14.2 million from $8.8 million for the year ended December&#160;31, 2018, an increase of $5.4 million, or 62.0%. The increase was primarily due to costs incurred in preparation for a proposed public offering of securities.</div><div class="h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 18.5pt; margin-left: 0pt; text-align: left;">Other Income and Expense</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The following table summarizes our other income and expense for the year ended December 31, 2019 and 2018: </div><table cellspacing="0" cellpadding="0" class="fintab" style="margin-top: 5.25pt; border-collapse: collapse; width: 468pt; margin-left: auto; margin-right: auto;"><tr class="header"><td style="width: 66.67%; text-align: left; vertical-align: bottom; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 1.61%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.61%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td colspan="4" style="width: 21.29%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Year Ended December 31,</div></td><td class="gutter" style="width: 1.61%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.61%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 5.6%; text-align: center; vertical-align: bottom; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td></tr><tr class="header"><td style="width: 66.67%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 1.61%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.61%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 9.03%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2019</div></td><td class="gutter" style="width: 1.61%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.61%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 9.03%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2018</div></td><td class="gutter" style="width: 1.61%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.61%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 5.6%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Change</div></td></tr><tr class="header"><td style="width: 66.67%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 1.61%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.61%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td colspan="7" style="width: 30.11%; text-align: center; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">(in USD thousands) </div></td></tr><tr><td style="width: 66.67%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Other income<font style="padding-left: 3.97pt;"></font></div></td><td class="gutter" style="width: 1.61%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.61%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.03%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.89pt; text-align: left;">1,655</div></td><td class="gutter" style="width: 1.61%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.61%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.03%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.89pt; text-align: left;"><font style="padding-left: 12.5pt;">&#8212;</font></div></td><td class="gutter" style="width: 1.61%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.61%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.6%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.85pt; text-align: left;">1,655</div></td></tr><tr><td style="width: 66.67%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Financial income<font style="padding-left: 4.52pt;"></font></div></td><td class="gutter" style="width: 1.61%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.61%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 9.03%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.89pt; text-align: left;">2,253</div></td><td class="gutter" style="width: 1.61%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.61%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 9.03%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.89pt; text-align: left;">2,856</div></td><td class="gutter" style="width: 1.61%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.61%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 5.6%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.85pt; text-align: left;"><font style="padding-left: 4.17pt;">(603</font>)</div></td></tr><tr><td style="width: 66.67%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Financial expense<font style="padding-left: 1.75pt;"></font></div></td><td class="gutter" style="width: 1.61%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.61%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.03%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.89pt; text-align: left;"><font style="padding-left: 4.17pt;">(156</font>)</div></td><td class="gutter" style="width: 1.61%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.61%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.03%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.89pt; text-align: left;"><font style="padding-left: 12.5pt;">&#8212;</font></div></td><td class="gutter" style="width: 1.61%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.61%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.6%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.85pt; text-align: left;"><font style="padding-left: 4.17pt;">(156</font>)</div></td></tr><tr><td style="width: 66.67%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Exchange differences<font style="padding-left: 2.5pt;"></font></div></td><td class="gutter" style="width: 1.61%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.61%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 9.03%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.89pt; text-align: left;"><font style="padding-left: 4.17pt; border-bottom: 1pt solid #000000; min-width: 22.5pt;">(255</font><font style="min-width: 22.5pt;">)</font></div></td><td class="gutter" style="width: 1.61%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.61%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 9.03%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.89pt; text-align: left;"><font style="padding-left: 7.5pt; border-bottom: 1pt solid #000000; min-width: 22.5pt;">213</font></div></td><td class="gutter" style="width: 1.61%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.61%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 5.6%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.85pt; text-align: left;"><font style="padding-left: 4.17pt; border-bottom: 1pt solid #000000; min-width: 22.5pt;">(468</font><font style="border-bottom: 1pt solid #000000; min-width: 22.5pt;"></font><font style="min-width: 22.5pt;">)</font></div></td></tr><tr><td style="width: 66.67%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Total other income (expense)<font style="padding-left: 0.25pt;"></font></div></td><td class="gutter" style="width: 1.61%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.61%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.03%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.89pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 22.5pt;">3,497</font></div></td><td class="gutter" style="width: 1.61%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.61%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.03%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.89pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 22.5pt;">3,069</font></div></td><td class="gutter" style="width: 1.61%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.61%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.6%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.85pt; text-align: left;"><font style="padding-left: 7.5pt; border-bottom: 3pt double #000000; min-width: 22.5pt;">428</font></div></td></tr></table><div class="h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 16.5pt; margin-left: 0pt; text-align: left;">Other Income </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">We recognize as other income amounts received and receivable by our subsidiary, ADC Therapeutics (UK) Limited, under the United Kingdom&#8217;s Research and Development Expenditure Credit scheme. For the year ended December&#160;31, 2019, which was the first time we recognized such income, we recognized $1.7 million in respect of fiscal years 2016 to 2019 in other income. </div><div class="h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 18.5pt; margin-left: 0pt; text-align: left;">Financial Income </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Financial income decreased to $2.3&#160;million for the year ended December&#160;31, 2019 from $2.9&#160;million for the year ended December&#160;31, 2018, primarily due to decreases in amounts placed on deposit and in interest rates.</div><div class="h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 18.5pt; margin-left: 0pt; text-align: left;">Income Tax Expense</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Income tax expense increased to $0.6&#160;million for the year ended December&#160;31, 2019 from $0.2&#160;million for the year ended December&#160;31, 2018. This increase was primarily due to our internal arrangements to reimburse our foreign subsidiaries in the United States and the United Kingdom for the services they render on a cost-plus-margin basis. The net profit at each subsidiary is subject to local income tax and gives rise to minimal amounts of tax expense.</div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 18.5pt; margin-left: 0pt; text-align: left;">Liquidity and Capital Resources</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Since inception, we have incurred significant net losses. To date, we have not generated any product revenue and we have financed our operations through equity and convertible debt financings and additional funds provided by collaborations. As of June 30, 2020, we had cash and cash equivalents of $348.6 million. </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 36pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">98<br></div></div></div>
<!--End Page 102-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 103-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 540pt;"><a name="nt10014672x1_drs_106-mda_pg11"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="block-frill" style="width: 540pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: Arial, Helvetica, sans-serif; font-size: 9pt; font-weight: bold; margin-top: 6pt; text-align: center;">Confidential Treatment Requested by ADC Therapeutics SA Pursuant to 17 C.F.R. &#167; 200.83<br></div></div><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 36pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Our primary uses of capital are, and we expect will continue to be, research and development expenses, expenses associated with commercial launch preparations, compensation and related expenses and other operating expenses, including rent. Cash used to fund operating expenses is impacted by the timing of when we pay expenses, as reflected in the change in our outstanding accounts payable and accrued expenses. We expect to incur substantial expenses in connection with the advancement of clinical trials, including our pivotal clinical trials, and BLA preparations for our lead product candidates, Lonca and Cami, and the development of our other product candidates and our research pipeline. In addition, as we prepare for the potential approval of Lonca, we expect to incur substantial expense for commercial launch preparations.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">We plan to continue to fund our operating needs through the net proceeds of our initial public offering, this offering, the Facility Agreement, additional equity financings and/or other forms of financing. We may also pursue strategic collaborations and licensing opportunities for clinical development and commercialization of our product candidates in various geographical markets. The sale of additional equity and the issuance of senior secured convertible notes under the Facility Agreement and the conversion of such notes into common shares would result in additional dilution to our shareholders. </div><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 17.5pt; margin-left: 0pt; text-align: left;">Initial Public Offering </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">In May 2020, we completed our initial public offering, in which we issued and sold an aggregate of 14,082,475 common shares, including common shares issued and sold pursuant to the exercise in full of the underwriters&#8217; option to purchase additional common shares. We received net proceeds of $244.2 million from the offering, after deducting underwriting discounts and commissions and offering expenses payable by us. </div><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 17.5pt; margin-left: 0pt; text-align: left;">$115.0 Million Facility Agreement </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">On April 24, 2020, we entered into the Facility Agreement with Deerfield. The Facility Agreement provides for two separate disbursements of convertible loans, each subject to satisfaction of certain conditions precedent set forth in the Facility Agreement. On May 19, 2020, Deerfield extended the initial disbursement to us in the amount of $65.0 million in connection with our initial public offering (the &#8220;first tranche&#8221;). The Facility Agreement provides for a subsequent disbursement in the amount of $50.0 million, which we will be required to draw down, upon receipt of regulatory approval for Lonca and satisfaction of certain other conditions (the &#8220;second tranche&#8221;). If we have not received such regulatory approval on or prior to December 31, 2021, our ability to draw down the second tranche will automatically terminate on such date. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The outstanding principal amount of the convertible loans is due to be repaid in full on May 19, 2025. However, any conversion of the convertible loans into common shares pursuant to the senior secured convertible notes described below shall be deemed a repayment of the principal amount of the convertible loans so converted. The convertible loans bear interest at a rate of 5.95% per annum, with interest payable quarterly in arrears commencing July 1, 2020. In addition to accrued interest, upon any redemption of the convertible loans prior to maturity in connection with a major transaction or upon payment of the convertible loans following an event of default, we will be required to pay a make-whole amount equal to the amount of all remaining interest payments to maturity (or the discounted value thereof in certain limited circumstances). However, the convertible loans may not be voluntarily prepaid by us prior to maturity other than in connection with a forced conversion as described below. In addition, upon any payment of the convertible loans or conversion of the convertible notes, whether upon redemption or at maturity or at any other time, we will be required to pay an exit charge equal to 2.0% of the amount of the loans so paid or converted. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The Facility Agreement contains various covenants, including a requirement to retain $50.0 million in deposit and securities accounts as of the end of each fiscal quarter. In addition, the Facility Agreement restricts our and the guarantors&#8217; ability to, among other things, (i) declare or make any dividend payment, (ii) create or incur any lien on our assets beyond those outstanding on the date of the Facility Agreement and certain permitted licensing agreements, (iii) dispose of any assets or property, other than issuance and sale of common shares, certain financing transactions with respect to royalties on product sales, certain permitted licensing agreements and joint ventures or dispositions pursuant to the Genmab Collaboration and License Agreement, (iv) incur any indebtedness, (v) make any investments (other than investments in permitted joint ventures and other permitted transactions), (vi) amend our organizational documents or any material agreements in a manner that would reasonably be expected to be materially adverse to the rights of the lenders or (vii) change our reporting practices or fiscal year, in each case, subject to exceptions set forth in the Facility Agreement. Furthermore, </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 36pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">99<br></div></div></div>
<!--End Page 103-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 104-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 540pt;"><a name="nt10014672x1_drs_106-mda_pg12"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="block-frill" style="width: 540pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: Arial, Helvetica, sans-serif; font-size: 9pt; font-weight: bold; margin-top: 6pt; text-align: center;">Confidential Treatment Requested by ADC Therapeutics SA Pursuant to 17 C.F.R. &#167; 200.83<br></div></div><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 36pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">under the Facility Agreement, we are required to, among other things, (i) remain a reporting company and maintain the listing of our common shares on an eligible market, (ii) provide the lenders with information regarding any event of default or the occurrence of any material adverse event and (iii) publicly disclose material, nonpublic information that is provided to the lenders without their prior written consent. Subject to customary exceptions and exclusions, our obligations under the Facility Agreement are guaranteed by our wholly-owned subsidiaries and secured by a perfected, first-priority security interest in substantially all of our and our wholly-owned subsidiaries&#8217; personal property, including our intellectual property and the equity ownership interests directly and indirectly held by us in our wholly-owned subsidiaries.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Each convertible loan extended under the Facility Agreement is evidenced by a convertible note. The holder of each of the first tranche of convertible notes is entitled to convert the principal amount of convertible loans evidenced thereby, at its option, into our common shares at any time at a conversion price of $24.70 per share, which is 130% of the price at which our common shares were sold to the public in our initial public offering (subject to adjustment upon the occurrence of subdivisions or combinations of our common shares or similar events). The conversion price for the second tranche of convertible notes will be equal to the lesser of (i) $28.50, which is 150% of the price at which our common shares were sold to the public in our initial public offering, and (ii) 120% of the average of the volume weighted average prices of our common shares on each of the 15 trading days immediately prior to the disbursement date of the second tranche, but in no event less than a floor equal to $15.39, in each case subject to adjustment upon the occurrence of subdivisions or combinations of our common shares or similar events. If the conversion price of the second tranche of convertible notes would be less than the floor price but for the application of the floor, Deerfield will not be obligated to extend the second tranche. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The holders of the convertible notes are entitled to receive dividends (or cash amounts equal to such dividends) paid on our common shares as if the holders held the number of common shares into which the convertible notes are convertible.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Upon the occurrence of a major transaction, as defined under the convertible notes, the holders of the convertible notes may elect to require us to redeem all or any portion of the notes for an amount equal to the principal amount thereof (in addition to accrued and unpaid interest, the make-whole amount and the exit charge). Alternatively, if the holder of a convertible note does not elect to require us to redeem any portion of the note in connection with a major transaction, the holder may elect to convert the unredeemed portion and, in addition to the number of common shares otherwise deliverable upon conversion, receive a number of additional common shares determined as set forth in the convertible notes (in addition to accrued and unpaid interest and the exit charge). In the case of a successor major transaction, we may elect to require redemption of any portion of the convertible notes that the holder does not elect to convert in connection with such transaction. Major transactions include (i) mergers and similar transactions as a result of which the holders of common shares before the transaction no longer hold a majority of the common shares after the transaction or the common shares are changed into the securities of another entity, (ii) sales of assets exceeding 50% of our enterprise value, (iii) any person or group acquiring beneficial ownership of more than 50% of our common shares or (iv) the delisting of our common shares, subject in each case to the more detailed provisions contained in the convertible notes. Successor major transactions include any major transaction in which our common shares are converted into the right to receive cash, securities of another entity and/or other assets, and any asset sale major transaction in which we distribute assets to our shareholders.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">We have the right to force conversions of the convertible notes on and after the one-year anniversary of the date on which we have received regulatory approval of Lonca if each of the following is greater than 275% of the conversion price (among other conditions specified in the convertible notes): (1) the volume weighted average price of the common shares on at least 20 trading days during any period of 30 consecutive trading days, (2) the volume weighted average price of the common shares on the last trading day of such period and (3) the closing price of the common shares on the last trading day of such period. We will have the right to force conversions of the convertible notes on and after the three-year anniversary of the date on which we have received regulatory approval of Lonca if the same conditions above are satisfied, except that the applicable price described in the preceding sentence need only be greater than 175% of the conversion price. </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 36pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">100<br></div></div></div>
<!--End Page 104-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 105-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 540pt;"><a name="nt10014672x1_drs_106-mda_pg13"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="block-frill" style="width: 540pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: Arial, Helvetica, sans-serif; font-size: 9pt; font-weight: bold; margin-top: 6pt; text-align: center;">Confidential Treatment Requested by ADC Therapeutics SA Pursuant to 17 C.F.R. &#167; 200.83<br></div></div><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 36pt;"><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">Cash Flows</div><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 7pt; margin-left: 0pt; text-align: left;">Comparison of the Six Months Ended June 30, 2020 and 2019 </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 7pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The following table summarizes our cash flows for the six months ended June 30, 2020 and 2019:</div><table cellspacing="0" cellpadding="0" class="fintab" style="margin-top: 11.25pt; border-collapse: collapse; width: 468pt; margin-left: auto; margin-right: auto;"><tr class="header"><td style="width: 66.67%; text-align: left; vertical-align: bottom; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 1.19%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.19%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td colspan="4" style="width: 21.65%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Six Months Ended June 30,</div></td><td class="gutter" style="width: 1.19%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.19%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 6.94%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td></tr><tr class="header"><td style="width: 66.67%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 1.19%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.19%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 9.64%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2020</div></td><td class="gutter" style="width: 1.19%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.19%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 9.64%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2019</div></td><td class="gutter" style="width: 1.19%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.19%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 6.94%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Change </div></td></tr><tr class="header"><td style="width: 66.67%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 1.19%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.19%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td colspan="7" style="width: 30.96%; text-align: center; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">(in USD thousands) </div></td></tr><tr><td style="width: 66.67%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Net cash provided by (used in):<br></div></td><td class="gutter" style="width: 1.19%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.19%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.64%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.19%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.19%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.64%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.19%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.19%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.94%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 66.67%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Operating activities<font style="padding-left: 0.09pt;"></font></div></td><td class="gutter" style="width: 1.19%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.19%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 9.64%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 6.3pt; text-align: left;"><font style="padding-left: 1.67pt;">(72,688</font>)</div></td><td class="gutter" style="width: 1.19%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.19%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 9.64%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 6.3pt; text-align: left;"><font style="padding-left: 1.67pt;">(55,688</font>)</div></td><td class="gutter" style="width: 1.19%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.19%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 6.94%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 1.67pt;">(17,000</font>)</div></td></tr><tr><td style="width: 66.67%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Investing activities<font style="padding-left: 2.86pt;"></font></div></td><td class="gutter" style="width: 1.19%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.19%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.64%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 6.3pt; text-align: left;"><font style="padding-left: 14.17pt;">(634</font>)</div></td><td class="gutter" style="width: 1.19%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.19%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.64%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 6.3pt; text-align: left;"><font style="padding-left: 6.67pt;">(1,907</font>)</div></td><td class="gutter" style="width: 1.19%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.19%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.94%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 10pt;">1,273</font></div></td></tr><tr><td style="width: 66.67%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Financing activities<font style="padding-left: 0.08pt;"></font></div></td><td class="gutter" style="width: 1.19%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.19%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 9.64%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 6.3pt; text-align: left;"><font style="border-bottom: 1pt solid #000000; min-width: 32.5pt;">306,494</font></div></td><td class="gutter" style="width: 1.19%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.19%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 9.64%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 6.3pt; text-align: left;"><font style="border-bottom: 1pt solid #000000; min-width: 32.5pt;">100,931</font></div></td><td class="gutter" style="width: 1.19%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.19%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 6.94%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="border-bottom: 1pt solid #000000; min-width: 32.5pt;">205,563</font></div></td></tr><tr><td style="width: 66.67%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Net change in cash and cash equivalents<font style="padding-left: 3.47pt;"></font></div></td><td class="gutter" style="width: 1.19%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.19%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.64%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 6.3pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 32.5pt;">233,172</font></div></td><td class="gutter" style="width: 1.19%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.19%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.64%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 6.3pt; text-align: left;"><font style="padding-left: 5pt; border-bottom: 3pt double #000000; min-width: 32.5pt;">43,336</font></div></td><td class="gutter" style="width: 1.19%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.19%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.94%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 32.5pt;">189,836</font></div></td></tr></table><div class="h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 12pt; margin-left: 0pt; text-align: left;">Net Cash Used in Operating Activities</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Net cash used in operating activities increased to $72.7 million for the six months ended June 30, 2020 from $55.7 million for the six months ended June 30, 2019, an increase of $17.0 million, or 30.5%. The increase was primarily due to an increase in cash expenditure in the period on research and development, general and administrative costs and preparing for the commercial launch of Lonca.</div><div class="h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 14pt; margin-left: 0pt; text-align: left;">Net Cash Used in Investing Activities</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Net cash used in investing activities decreased to $0.6 million for the six months ended June 30, 2020 from $1.9 million for the six months ended June 30, 2019, a decrease of $1.3 million, or 66.8%. The decrease was primarily due to a reduction in amounts paid for intangible assets.</div><div class="h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 14pt; margin-left: 0pt; text-align: left;">Net Cash Provided by / Used in Financing Activities</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Net cash provided by financing activities increased to $306.5 million for the six months ended June 30, 2020 from $100.9 million for the six months ended June 30, 2019, an increase of $205.6 million, or 203.7%. The increase was primarily due to the completion of our initial public offering and the receipt of the first tranche under the Facility Agreement. </div><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 14pt; margin-left: 0pt; text-align: left;">Comparison of the Years Ended December&#160;31, 2019 and 2018</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 7pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The following table summarizes our cash flows for the years ended December&#160;31, 2019 and 2018:</div><table cellspacing="0" cellpadding="0" class="fintab" style="margin-top: 11.25pt; border-collapse: collapse; width: 468pt; margin-left: auto; margin-right: auto;"><tr class="header"><td style="width: 66.67%; text-align: left; vertical-align: bottom; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 1.39%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.39%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td colspan="4" style="width: 20.84%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Year Ended December&#160;31,</div></td><td class="gutter" style="width: 1.39%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.39%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 6.94%; text-align: center; vertical-align: bottom; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td></tr><tr class="header"><td style="width: 66.67%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 1.39%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.39%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 9.03%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2019</div></td><td class="gutter" style="width: 1.39%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.39%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 9.03%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2018</div></td><td class="gutter" style="width: 1.39%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.39%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 6.94%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Change</div></td></tr><tr class="header"><td style="width: 66.67%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 1.39%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.39%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td colspan="7" style="width: 30.56%; text-align: center; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">(in USD thousands)</div></td></tr><tr><td style="width: 66.67%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Net cash provided by (used in):<br></div></td><td class="gutter" style="width: 1.39%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.39%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.03%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.39%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.39%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.03%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.39%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.39%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.94%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 66.67%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Operating activities<font style="padding-left: 0.09pt;"></font></div></td><td class="gutter" style="width: 1.39%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.39%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 9.03%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.22pt; text-align: left;">(121,581)</div></td><td class="gutter" style="width: 1.39%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.39%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 9.03%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.22pt; text-align: left;">(121,362)</div></td><td class="gutter" style="width: 1.39%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.39%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 6.94%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 14.17pt;">(219)</font></div></td></tr><tr><td style="width: 66.67%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Investing activities<font style="padding-left: 2.86pt;"></font></div></td><td class="gutter" style="width: 1.39%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.39%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.03%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.22pt; text-align: left;"><font style="padding-left: 10pt;">(2,248)</font></div></td><td class="gutter" style="width: 1.39%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.39%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.03%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.22pt; text-align: left;"><font style="padding-left: 10pt;">(2,506)</font></div></td><td class="gutter" style="width: 1.39%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.39%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.94%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 17.5pt;">258</font></div></td></tr><tr><td style="width: 66.67%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Financing activities<font style="padding-left: 0.08pt;"></font></div></td><td class="gutter" style="width: 1.39%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.39%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 9.03%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.22pt; text-align: left;"><font style="padding-left: 3.33pt; border-bottom: 1pt solid #000000; min-width: 35.83pt;">100,512</font></div></td><td class="gutter" style="width: 1.39%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.39%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 9.03%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.22pt; text-align: left;"><font style="padding-left: 22.5pt; border-bottom: 1pt solid #000000; min-width: 35.83pt;">(24</font><font style="min-width: 35.83pt;">)</font></div></td><td class="gutter" style="width: 1.39%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.39%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 6.94%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="border-bottom: 1pt solid #000000; min-width: 32.5pt;">100,536</font></div></td></tr><tr><td style="width: 66.67%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Net change in cash and cash equivalents<font style="padding-left: 3.47pt;"></font></div></td><td class="gutter" style="width: 1.39%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.39%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.03%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.22pt; text-align: left;"><font style="padding-left: 5pt; border-bottom: 3pt double #000000; min-width: 35.83pt;">(23,317</font><font style="min-width: 35.83pt;">)</font></div></td><td class="gutter" style="width: 1.39%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.39%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.03%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.22pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 35.83pt;">(123,892</font><font style="min-width: 35.83pt;">)</font></div></td><td class="gutter" style="width: 1.39%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.39%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.94%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 32.5pt;">100,575</font></div></td></tr></table><div class="h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 12pt; margin-left: 0pt; text-align: left;">Net Cash Used in Operating Activities</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Net cash used in operating activities increased to $121.6&#160;million for the year ended December&#160;31, 2019 from $121.4&#160;million for the year ended December&#160;31, 2018, an increase of $0.2 million, or 0.2%.</div><div class="h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 13.5pt; margin-left: 0pt; text-align: left;">Net Cash Used in Investing Activities</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Net cash used in investing activities decreased to $2.2 million for the year ended December 31, 2019 from $2.5 million for the year ended December 31, 2018, a decrease of $0.3 million, or 10.3%, primarily due to a $0.6 million decrease in purchases of property, plant and equipment that was partially offset by a $0.3 million increase in purchases of intangible assets. </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 36pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">101<br></div></div></div>
<!--End Page 105-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 106-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 540pt;"><a name="nt10014672x1_drs_106-mda_pg14"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="block-frill" style="width: 540pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: Arial, Helvetica, sans-serif; font-size: 9pt; font-weight: bold; margin-top: 6pt; text-align: center;">Confidential Treatment Requested by ADC Therapeutics SA Pursuant to 17 C.F.R. &#167; 200.83<br></div></div><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 36pt;"><div class="h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">Net Cash Provided by / Used in Financing Activities</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Net cash provided by financing activities was $100.5 million for the year ended December 31, 2019 compared to $24 thousand of net cash used in financing activities for the year ended December 31, 2018. Net cash provided by financing activities for the year ended December 31, 2019 primarily resulted from the sale of Class E preferred shares. </div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 20pt; margin-left: 0pt; text-align: left;">Operating Capital Requirements</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">We expect our expenses to increase in connection with our ongoing activities, particularly as we continue the research and development of, continue or commence clinical trials of, and seek regulatory approval for, our product candidates, including confirmatory clinical trials following any conditional or accelerated approval that our product candidates may receive, and engage in commercial launch preparations. In addition, if we obtain regulatory approval for any of our product candidates, we expect to incur significant commercialization expenses related to sales, marketing, manufacturing and distribution. Accordingly, we will need to obtain substantial additional funding in connection with our continuing operations. If we are unable to raise capital when needed or on attractive terms, we would be forced to delay, reduce or eliminate our research and development programs or future commercialization efforts. Our future capital requirements will depend on many factors, including:</div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the outcome, timing and costs of obtaining regulatory approvals for Lonca and for our other product candidates if the requisite clinical trials are successful; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the progress, results and costs of our confirmatory clinical trial of Lonca in combination with rituximab for the treatment of relapsed or refractory DLBCL; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the progress, results and costs of our Phase 1 and potentially pivotal Phase 2 clinical trials of our product candidates;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the progress, results and costs of any required confirmatory clinical trials of any product candidates that receive accelerated approval from the FDA or similar conditional approval from the EMA or comparable regulatory agencies in other jurisdictions;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the scope, progress, results and costs of researching and developing product candidates in our research pipeline, including conducting preclinical studies and clinical trials of such product candidates;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the costs of outsourced manufacturing of our product candidates, which are complex biological molecules, for clinical trials and in preparation for regulatory approval and commercialization; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the size of the markets for approved indications in territories in which we receive regulatory approval, if any;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the timing and costs of commercialization activities for our product candidates, if any are approved for sale, including establishing our sales and marketing capabilities and engaging in the marketing, sales and distribution of our product candidates;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the revenue, if any, received from the commercialization of our product candidates, if any are approved for sale;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">our ability to maintain and establish collaboration, licensing or other arrangements and the financial terms of such agreements;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the costs involved in preparing, filing, prosecuting, maintaining, protecting and enforcing our intellectual property rights and claims, including any litigation costs and the outcome of such litigation;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the costs associated with potential product liability claims, including the costs associated with obtaining insurance against such claims and with defending against such claims;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the timing and amount of milestone payments we receive under our collaboration agreements;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the costs involved in maintaining and improving the technology we use in our product candidates;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">our efforts to enhance operational systems and hire additional personnel, including personnel to support the development and commercialization of our product candidates and to satisfy our obligations as a public company;</div></td></tr></table></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 36pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">102<br></div></div></div>
<!--End Page 106-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 107-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 540pt;"><a name="nt10014672x1_drs_106-mda_pg15"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="block-frill" style="width: 540pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: Arial, Helvetica, sans-serif; font-size: 9pt; font-weight: bold; margin-top: 6pt; text-align: center;">Confidential Treatment Requested by ADC Therapeutics SA Pursuant to 17 C.F.R. &#167; 200.83<br></div></div><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 36pt;"><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6.75pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the effect of competing technological and market developments; and</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the types of available sources of private and/or public market financing.</div></td></tr></table><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Identifying potential product candidates and conducting preclinical studies and clinical trials is a time-consuming, expensive and uncertain process that takes many years to complete, and we may never generate the necessary data or results required to obtain regulatory approval and commercialize our product candidates. In addition, our product candidates, if approved, may not achieve commercial success. Our commercial revenues, if any, will be derived from sales of products that we do not expect to be commercially available for many years, if at all. Accordingly, we will need to continue to rely on additional financing to achieve our business objectives. Adequate additional financing may not be available to us on acceptable terms, or at all.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Until such time, if ever, as we can generate substantial product revenues, we expect to finance our cash needs through the Facility Agreement and a combination of equity offerings, debt financings, convertible debt financings, strategic collaborations and licensing arrangements. To the extent that we raise additional capital through the sale of equity or debt securities, your ownership interest will be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect your rights as a common shareholder. Debt financing, if available, may involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">If we raise funds through additional strategic collaborations or licensing arrangements with third parties, we may have to relinquish valuable rights to our intellectual property, future revenue streams, research programs or product candidates or to grant licenses on terms that may not be favorable to us. If we are unable to raise additional funds through equity or debt financings when needed, we may be required to delay, limit, reduce or terminate our product development or future commercialization efforts or grant rights to develop and market product candidates that we would otherwise prefer to develop and market ourselves.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">For more information as to the risks associated with our future funding needs, see &#8220;Risk Factors.&#8221;</div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">Contractual Obligations and Other Commitments</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">We have entered into various agreements with collaborators, including in-licensing and manufacturing agreements. These agreements provide for us to make milestone and royalty payments that are conditional principally on success, and that are spread over various stages of development and commercialization, including achieving preclinical proof of concept, filing an IND or other regulatory submissions, commencing or completing multiple clinical development stages, obtaining regulatory approval in multiple countries, and achieving various levels of commercial sales. As of December&#160;31, 2019, the aggregate amount of such potential milestone payments, under all such collaboration agreements, was $324.0 million. Of this total, $132.5 million would become payable upon achieving milestones up to and including regulatory approval of a product candidate and $191.5 million would become payable after commencing sales of a product candidate. The timing of these payments, and whether they become due, is conditional on achieving the applicable milestones.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The following table summarizes our contractual obligations by period as of December&#160;31, 2019, and as such, the following table does not include obligations incurred under the Facility Agreement entered into on April&#160;24, 2020, which, as of June 30, 2020, comprised $3.1 million in current liabilities and $139.9 million in non-current liabilities:</div><table cellspacing="0" cellpadding="0" class="fintab" style="margin-top: 11.25pt; border-collapse: collapse; width: 468pt; margin-left: auto; margin-right: auto;"><tr class="header"><td style="width: 56.41%; text-align: left; vertical-align: bottom; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 1.33%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.33%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td colspan="13" style="width: 40.93%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Payments Due By Period<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(1)</sup> </div></td></tr><tr class="header"><td style="width: 56.41%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 1.33%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.33%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 4.81%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Total </div></td><td class="gutter" style="width: 1.33%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.33%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 7.12%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Less than <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">1&#160;year </div></td><td class="gutter" style="width: 1.33%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.33%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 4.81%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">1-3&#160;<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">years </div></td><td class="gutter" style="width: 1.33%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.33%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 4.81%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">3-5&#160;<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">years</div></td><td class="gutter" style="width: 1.33%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.33%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 8.76%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">More than <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">5&#160;years</div></td></tr><tr class="header"><td style="width: 56.41%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 1.33%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.33%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td colspan="13" style="width: 40.93%; text-align: center; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">(in USD thousands)</div></td></tr><tr><td style="width: 56.41%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Trade accounts payable<font style="padding-left: 0.78pt;"></font></div></td><td class="gutter" style="width: 1.33%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.33%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 4.81%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">3,329</div></td><td class="gutter" style="width: 1.33%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.33%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.12%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 5.41pt; text-align: left;">3,329</div></td><td class="gutter" style="width: 1.33%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.33%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 4.81%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;"><font style="padding-left: 12.5pt;">&#8212;</font></div></td><td class="gutter" style="width: 1.33%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.33%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 4.81%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;"><font style="padding-left: 12.5pt;">&#8212;</font></div></td><td class="gutter" style="width: 1.33%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.33%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.76%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.26pt; text-align: left;"><font style="padding-left: 12.5pt;">&#8212;</font></div></td></tr><tr><td style="width: 56.41%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Lease liabilities<font style="padding-left: 2.64pt;"></font></div></td><td class="gutter" style="width: 1.33%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.33%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 4.81%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="border-bottom: 1pt solid #000000; min-width: 22.5pt;">5,370</font></div></td><td class="gutter" style="width: 1.33%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.33%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 7.12%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 5.41pt; text-align: left;"><font style="border-bottom: 1pt solid #000000; min-width: 22.5pt;">1,246</font></div></td><td class="gutter" style="width: 1.33%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.33%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 4.81%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;"><font style="border-bottom: 1pt solid #000000; min-width: 22.5pt;">1,859</font></div></td><td class="gutter" style="width: 1.33%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.33%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 4.81%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;"><font style="border-bottom: 1pt solid #000000; min-width: 22.5pt;">1,204</font></div></td><td class="gutter" style="width: 1.33%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.33%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 8.76%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.26pt; text-align: left;"><font style="border-bottom: 1pt solid #000000; min-width: 22.5pt;">1,061</font></div></td></tr><tr><td style="width: 56.41%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Total<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(2)</sup><font style="padding-left: 2.35pt;"></font></div></td><td class="gutter" style="width: 1.33%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.33%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 4.81%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 22.5pt;">8,699</font></div></td><td class="gutter" style="width: 1.33%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.33%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.12%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 5.41pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 22.5pt;">4,575</font></div></td><td class="gutter" style="width: 1.33%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.33%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 4.81%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 22.5pt;">1,859</font></div></td><td class="gutter" style="width: 1.33%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.33%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 4.81%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 22.5pt;">1,204</font></div></td><td class="gutter" style="width: 1.33%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.33%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.76%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.26pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 22.5pt;">1,061</font></div></td></tr></table><div><div class="rule-partial" style="height: 0pt; width: 72pt; border-bottom: 1pt solid #000000; margin-bottom: 1pt; margin-right: auto; margin-left: 0pt; margin-top: 8.25pt;"> </div></div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 3pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">(1)<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; text-align: left;">The amounts of contractual obligations set forth in the table above are associated with contracts that are enforceable and legally binding and that specify all significant terms, fixed or minimum services to be used, fixed, minimum or variable price provisions, and the approximate timing of the actions under the contracts. The table does not include obligations under agreements that we can cancel without a significant penalty. </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 3pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">(2)<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; text-align: left;">Excludes collaboration agreements described in the preceding paragraphs above.</div></td></tr></table></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 36pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">103<br></div></div></div>
<!--End Page 107-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 108-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 540pt;"><a name="nt10014672x1_drs_106-mda_pg16"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="block-frill" style="width: 540pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: Arial, Helvetica, sans-serif; font-size: 9pt; font-weight: bold; margin-top: 6pt; text-align: center;">Confidential Treatment Requested by ADC Therapeutics SA Pursuant to 17 C.F.R. &#167; 200.83<br></div></div><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 36pt;"><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">Internal Control Over Financial Reporting</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">A company&#8217;s internal control over financial reporting is a process designed by, or under the supervision of, a company&#8217;s principal executive and principal financial officers, or persons performing similar functions, and effected by a company&#8217;s board of directors, management and other personnel to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements in accordance with IFRS. A material weakness is a deficiency, or a combination of deficiencies, in internal control over financial reporting, such that there is a reasonable possibility that a material misstatement of the annual or interim financial statements will not be prevented or detected on a timely basis.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">In June 2019, we identified an error related to the calculation of the expense charge for our historical share purchase plans, which, in accordance with IFRS&#160;2, were required to be accounted for as if they were share option plans. While the share purchase plans were properly accounted for on the balance sheet, there was a material understatement of the share-based compensation expense, and the related disclosures were incomplete. This resulted in a restatement of the financial statements for the year ended December&#160;31, 2018.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">During the first and second quarters of 2020, we identified errors related to the work performed by the independent valuation firm assisting us in calculating the fair value of the share-based compensation award grants per participant and our use thereof. Specifically, we identified errors in (i) our procedures for giving instructions to the independent valuation firm, (ii) our review of the work product delivered by such firm and (iii) our use of the information delivered by such firm. This resulted in audit adjustments to both our consolidated financial statements for the year ended December 31, 2019 and unaudited condensed consolidated interim financial statements for the three- and six-month periods ended June 30, 2020. These errors are evidence that the Company has material weaknesses in its internal financial controls related to the accounting for share-based compensation. If these weaknesses are not remediated, they could lead to material misstatements in our future annual or interim consolidated financial statements. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">We have taken and continue to take steps to remediate the aforementioned material weaknesses and to enhance our overall control environment, including implementing changes in our internal control over financial reporting with regard to complex accounting matters such as share-based compensation plans.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">In addition, neither our management nor an independent registered public accounting firm has performed an evaluation of our internal control over financial reporting in accordance with the provisions of the Sarbanes-Oxley Act. Had we or our independent registered public accounting firm performed an evaluation of our internal control over financial reporting in accordance with the provisions of the Sarbanes-Oxley Act, additional material weaknesses may have been identified. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">We cannot assure you that the measures we have taken to date, and actions we may take in the future, will be sufficient to remediate the control deficiencies that led to these material weaknesses in our internal control over financial reporting or that they will prevent or avoid potential future material weaknesses. See &#8220;Risk Factors&#8212;Risks Related to Our Common Shares and This Offering&#8212;We have identified material weaknesses in our internal control over financial reporting. If we are unable to remediate these material weaknesses or otherwise fail to maintain an effective system of internal controls, we may not be able to accurately or timely report our financial condition or results of operations, which may adversely affect our business and the price of our common shares.&#8221;</div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 18pt; margin-left: 0pt; text-align: left;">Off-Balance Sheet Arrangements</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">We did not have, during the periods presented, and we do not currently have, any off-balance sheet arrangements or commitments.</div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 18pt; margin-left: 0pt; text-align: left;">Quantitative and Qualitative Disclosures about Market Risk</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Our market risk arises primarily from changes in our share price and our exposure to fluctuation in currency exchange rates and to a significantly lesser extent, our exposure to interest rate movements. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">On April 24, 2020, we entered into a Facility Agreement with Deerfield. See &#8220;&#8212;Liquidity and Capital Resources&#8212;$115.0 Million Facility Agreement.&#8221; The first tranche of convertible loans amounting to $65.0 million issued on May 19, 2020 has been accounted for as comprising two components: a convertible loan and an embedded derivative conversion feature. The obligation to draw down the second tranche of $50.0 million has been accounted for </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 36pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">104<br></div></div></div>
<!--End Page 108-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 109-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 540pt;"><a name="nt10014672x1_drs_106-mda_pg17"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="block-frill" style="width: 540pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: Arial, Helvetica, sans-serif; font-size: 9pt; font-weight: bold; margin-top: 6pt; text-align: center;">Confidential Treatment Requested by ADC Therapeutics SA Pursuant to 17 C.F.R. &#167; 200.83<br></div></div><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 36pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">as a derivative. See &#8220;&#8212;Critical Accounting Policies and Significant Judgments and Estimates&#8212;Convertible Notes.&#8221; The embedded derivative conversion feature and the derivative associated with the second tranche are re-measured to fair value at each reporting date. Decreases in our share price and its expected volatility will tend to reduce the fair values of the derivatives and lead to gains in our consolidated income statement. However, increases in our share price and its expected volatility will tend to increase the fair values of the derivatives and lead to losses in our consolidated income statement. A hypothetical 10% increase (decrease) in our share price as of June 30, 2020 would have increased (decreased) the derivative values associated with the first and second tranches by $11.2 million ($11.0 million) and $2.4 million ($2.1 million), respectively. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">As of June 30, 2020, we had cash and cash equivalents of $348.6 million, which consisted exclusively of bank and money market deposits. Such interest-earning instruments carry a degree of interest rate risk. However, historical fluctuations of interest income have not been significant and have been principally impacted by the change in our cash balances as opposed to changes in interest rates received on the cash balances.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">We have not been exposed nor do we anticipate being exposed to material risks due to changes in interest rates. A hypothetical 10% change in interest rates during any of the periods presented would not have had a material impact on our consolidated financial statements.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">While we operate internationally and are exposed to foreign exchange risk arising from various currency exposures, primarily with respect to British pounds, Euros and Swiss francs, our foreign exchange risk is minimal. We primarily pay invoices in U.S. dollars and hold cash principally in U.S. dollars. Differences in exchange rates accounted for $0.1 million in expense for both the six months ended June 30, 2020 and 2019 and $0.3&#160;million in expense and $0.2&#160;million in income for the year ended December&#160;31, 2019 and 2018, respectively. A hypothetical 10% change in exchange rates during any of the periods presented would not have had a material impact on our consolidated financial statements. For more information, see Note 5.1 to our audited consolidated financial statements included elsewhere in this prospectus.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Inflation generally affects us by increasing our cost of labor and clinical trial costs. We do not believe that inflation had a material effect on our business, financial condition or results of operations for the periods presented.</div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 20.5pt; margin-left: 0pt; text-align: left;">Critical Accounting Policies and Significant Judgments and Estimates</div><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 7.5pt; margin-left: 0pt; text-align: left;">Revenue Recognition</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Revenue is measured at the fair value of the consideration received or receivable for the sale of services in the ordinary course of our activities. Revenue is shown net of value-added tax, rebates and discounts and after intra-company sales.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">We recognize revenue when our customer obtains control of promised goods or services, in an amount that reflects the consideration which we expect to receive in exchange for those goods or services. To determine revenue recognition, we perform the following five steps: (i)&#160;identify the contract(s) with our customer; (ii)&#160;identify the performance obligations in the contract; (iii)&#160;determine the transaction price; (iv)&#160;allocate the transaction price to the performance obligations in the contract; and (v)&#160;recognize revenue when (or as) we satisfy a performance obligation. We apply the five-step model to contracts only when it is probable that we will collect the consideration we are entitled to in exchange for the goods or services we transfer to the customer. At contract inception, we assess the goods or services promised within each contract, determine those that are performance obligations and assess whether each promised good or service is distinct. We then recognize as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied.</div><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 20.5pt; margin-left: 0pt; text-align: left;">Performance Obligation Satisfied to the State of Completion&#8212;Deferred Contract Revenue Amortization</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">When the outcome of a transaction involving the rendering of services can be estimated reliably, revenue is recognized according to the stage of completion of the transaction at the end of the period using the cost input method. Under this method, revenue is recognized in the accounting periods in which the services are rendered. The recognition of revenue on this basis provides full information on the extent of service activity and performance during a period.</div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 36pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">105<br></div></div></div>
<!--End Page 109-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 110-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 540pt;"><a name="nt10014672x1_drs_106-mda_pg18"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="block-frill" style="width: 540pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: Arial, Helvetica, sans-serif; font-size: 9pt; font-weight: bold; margin-top: 6pt; text-align: center;">Confidential Treatment Requested by ADC Therapeutics SA Pursuant to 17 C.F.R. &#167; 200.83<br></div></div><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 36pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">To be able to estimate the outcome of a transaction reliably, we must be able to make a reliable estimate of total transaction revenue, the stage of completion and the costs to complete the transaction. The stage of completion is determined as the proportion of the transaction costs incurred for services rendered to date compared to the estimated total transaction costs.</div><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 15pt; margin-left: 0pt; text-align: left;">Research and Development Expenses</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Research expenditure is recognized in expense in the year in which it is incurred. Internal development expenditure is capitalized only if it meets the recognition criteria of IAS 38 &#8220;Intangible Assets.&#8221; Where regulatory and other uncertainties are such that the criteria are not met, which is almost invariably the case prior to approval of the drug by the relevant regulatory authority, the expenditure is recognized in the income statement. Where, however, recognition criteria are met, internal development expenditure is capitalized and amortized on a straight-line basis over its useful economic life.</div><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 15pt; margin-left: 0pt; text-align: left;">Current, Deferred Income Tax and Tax Credit</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The tax expense for the period comprises current and deferred tax. Tax is recognized in the income statement, except to the extent that it relates to items recognized in other comprehensive income or directly in equity. In these cases, the related tax is recognized in other comprehensive income or directly in equity, respectively.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The current income tax charge is calculated on the basis of the tax laws enacted or substantively enacted at the balance sheet date in the countries where we and our subsidiaries operate and generate taxable income. We periodically evaluate positions taken in tax returns with respect to situations in which applicable tax regulation is subject to interpretation. We establish provisions where appropriate on the basis of amounts expected to be paid to the tax authorities.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Taxes on income are accrued in the same periods as the revenues and expenses to which they relate. Current income tax assets and liabilities for the current period are measured at the amount expected to be recovered from or paid to the taxation authorities.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Deferred income tax is recognized, using the liability method, on temporary differences arising between the tax bases of assets and liabilities and their carrying amounts in the consolidated financial statements. However, deferred tax liabilities are not recognized if they arise from the initial recognition of goodwill. The deferred income tax is not accounted for if it arises from initial recognition of an asset or liability in a transaction other than a business combination that at the time of the transaction affects neither accounting nor taxable profit nor loss. Deferred income tax is determined using tax rates that have been enacted or substantively enacted by the balance sheet date and are expected to apply when the related deferred income tax asset is realized or the deferred income tax liability is settled.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Deferred income tax assets are recognized only to the extent that it is probable that future taxable profit will be available against which the temporary differences or the unused tax losses can be utilized.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Deferred income tax assets from R&amp;D tax credit carryforwards are recognized to the extent that the national tax authority confirms the eligibility of such a claim and that the realization of the related tax benefit through future taxable profits is probable.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Deferred income tax assets and liabilities are offset when there is a legally enforceable right to offset current tax assets against current tax liabilities and when the deferred income tax assets and liabilities relate to income taxes levied by the same taxation authority on either the same taxable entity or different taxable entities where there is an intention to settle the balances on a net basis.</div><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 15pt; margin-left: 0pt; text-align: left;">Employee Benefits</div><div class="h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 7pt; margin-left: 0pt; text-align: left;">Pension Obligations</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">We operate defined benefit and defined contribution pension schemes in accordance with the local conditions and practices in the countries in which we operate. The schemes are generally funded through payments to insurance companies or trustee-administered funds, determined by periodic actuarial calculations. A defined contribution plan is a pension plan under which we pay fixed contributions into a separate entity (a fund) and have no legal or constructive obligations to pay further contributions if the fund does not hold sufficient </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 36pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">106<br></div></div></div>
<!--End Page 110-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 111-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 540pt;"><a name="nt10014672x1_drs_106-mda_pg19"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="block-frill" style="width: 540pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: Arial, Helvetica, sans-serif; font-size: 9pt; font-weight: bold; margin-top: 6pt; text-align: center;">Confidential Treatment Requested by ADC Therapeutics SA Pursuant to 17 C.F.R. &#167; 200.83<br></div></div><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 36pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">assets to pay all employees the benefits relating to the employees&#8217; service in previous, current and future periods. A defined benefit plan is a pension plan that is not a defined contribution plan. Typically, defined benefit plans define an amount of pension benefit that an employee will receive on retirement, usually dependent on one or more factors such as age, years of service and compensation. However, as is the case with many Swiss pension plans, although the amount of ultimate pension benefit is not defined, certain legal obligations of the plan nevertheless create constructive obligations on the employer to pay further contributions to fund an eventual deficit. This results in the plan being accounted for as a defined benefit plan under IFRS.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The liability recognized in the balance sheet in respect of defined benefit pension plans is the present value of the defined benefit obligation at the end of the reporting period less the fair value of plan assets. The defined benefit obligation is calculated annually by independent actuaries using the projected unit credit method. The present value of the defined benefit obligation is determined by discounting the estimated future cash outflows using interest rates of high-quality corporate bonds that are denominated in the currency in which the benefits will be paid, and that have terms to maturity that approximate to the terms of the related pension obligation. In countries where there is no deep market in such bonds, the market rates on government bonds are used.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The current service cost of the defined benefit plan, recognized in the income statement in employee benefit expense, except where included in the cost of an asset, reflects the increase in the defined benefit obligation resulting from employee service in the current year.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Past service costs, resulting from a plan amendment or curtailment, are recognized immediately in the income statement.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The net interest cost is calculated by applying the discount rate to the net balance of the present value of the defined benefit obligation and the fair value of plan assets. This cost is included in employee benefit expenses in the income statement.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Actuarial gains and losses arising from experience adjustments and changes in actuarial assumptions are charged or credited to equity in other comprehensive income in the period in which they arise.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">For defined contribution plans, we pay contributions to publicly or privately administered pension insurance plans on a mandatory, contractual or voluntary basis. Once the contributions have been paid, we have no further payment obligations. The contributions are recognized as employee benefit expenses when they are due and are included in staff costs. Prepaid contributions are recognized as an asset to the extent that a cash refund or a reduction in the future payments is available.</div><div class="h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 14.5pt; margin-left: 0pt; text-align: left;">Share-Based Compensation Expense</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The fair value of shares or options granted, respectively, under share purchase or share option plans is recognized as an employee share-based compensation expense with a corresponding increase in equity. The total amount to be expensed is determined by reference to the fair value of the shares or options granted:</div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">including any market performance conditions;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">excluding the impact of any service and non-market performance vesting conditions; and</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">including the impact of any non-vesting conditions.</div></td></tr></table><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The total expense is recognized over the vesting period, which is the period over which all of the specified vesting conditions are to be satisfied. At the end of each period, we revise our estimate of the number of options that are expected to vest based on the non-market vesting and service conditions. We recognize the impact of the revision to original estimate, if any, in profit or loss, with a corresponding adjustment to equity.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The proceeds received net of any directly attributable transaction costs are credited directly to equity. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The application of our accounting policy for share-based compensation is described below for each of our plans. </div><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 14.5pt; margin-left: 0pt; text-align: left;">2019 Equity Incentive Plan</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">In November 2019, we adopted the 2019 Equity Incentive Plan to motivate and reward our employees, directors, consultants and advisors to further our best interest and those of our shareholders. Under the 2019 Equity Incentive Plan, we may at our discretion grant to plan participants (directors, certain employees and </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 36pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">107<br></div></div></div>
<!--End Page 111-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 112-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 540pt;"><a name="nt10014672x1_drs_106-mda_pg20"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="block-frill" style="width: 540pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: Arial, Helvetica, sans-serif; font-size: 9pt; font-weight: bold; margin-top: 6pt; text-align: center;">Confidential Treatment Requested by ADC Therapeutics SA Pursuant to 17 C.F.R. &#167; 200.83<br></div></div><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 36pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">service providers working for the benefit of the Company at the time) awards in the form of restricted shares and restricted share units (&#8220;RSUs&#8221;), share options, share appreciation rights, performance awards and other share-based awards.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">For the periods presented, only share options have been granted under this plan. The exercise price per share option was set by us at the fair market value of the underlying common shares on the date of grant, as determined by us. The awards generally vest 25% on the first anniversary of the date of grant, and thereafter evenly on a monthly basis over the subsequent three years. The contractual term of each option award granted is ten years. Under the grant, the options may be settled only in shares. Therefore, the grants of share options under this plan have been accounted for as equity-settled under IFRS 2.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">In each accounting period, we take a charge for the vested portion of award grants and for partially earned but non-vested portions of award grants. This results in a front-loaded charge to the income statement. The charge to the income statement results in a corresponding credit being booked to &#8220;Other reserves&#8221; within equity.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The cumulative amounts credited to &#8220;Other reserves&#8221; with respect to the 2019 Equity Incentive Plan were $9.1 million and $0.3 million as of June 30, 2020 and December 31, 2019, respectively. The expense recognized for services received during the six months ended June 30, 2020 and the year ended December 31, 2019 was $8.8 million and $0.3 million, respectively.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The fair value of the option at grant date is independently determined using an adjusted form of the Black-Scholes option pricing model that takes into account the strike price, the term of the award, the impact of dilution (where material), the share price at grant date and expected price volatility of the underlying share, the expected dividend yield, the risk-free interest rate for the term of the award and the correlations and volatilities of the shares of peer group companies. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">For options granted prior to our initial public offering, the share price at grant date, which represents a critical input into this model, was itself determined using a probability-weighted expected returns method that takes account of both the value derived by using an adjusted form of the Black-Scholes option pricing model, as described above, and a discounted estimate of the price that might be achieved in a future transaction. The adjusted form of the Black-Scholes option pricing model used to derive a value for the common share price at grant date derives the implied equity value for one type of equity security from a contemporaneous transaction involving another type of security and considers the timing, amount, liquidation preferences and dividend rights of issues of preference shares. For options granted after the initial public offering, the share price at grant date was determined by reference to the market price of the underlying common shares on the date of grant.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">We used an independent valuation firm to assist us in calculating the fair value of the award grants per participant.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The assumptions used in an adjusted form of the Black-Scholes option pricing model for awards granted are as follows: </div><table cellspacing="0" cellpadding="0" class="fintab" style="margin-top: 11.25pt; border-collapse: collapse; width: 468pt; margin-left: auto; margin-right: auto;"><tr class="header"><td style="width: 66.67%; text-align: left; vertical-align: bottom; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 1.38%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.38%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 13.77%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Six Months Ended <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">June 30, 2020</div></td><td class="gutter" style="width: 1.38%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.38%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 14.06%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Year Ended <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">December 31, 2019</div></td></tr><tr><td style="width: 66.67%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Weighted average share price (in USD)<font style="padding-left: 3.16pt;"></font></div></td><td class="gutter" style="width: 1.38%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.38%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 13.77%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 8.05pt; text-align: left;">15.95-34.99</div></td><td class="gutter" style="width: 1.38%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.38%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 14.06%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 21.66pt; text-align: left;">16.31</div></td></tr><tr><td style="width: 66.67%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Strike price (in USD)<font style="padding-left: 1.21pt;"></font></div></td><td class="gutter" style="width: 1.38%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.38%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 13.77%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 8.05pt; text-align: left;">18.75-34.99</div></td><td class="gutter" style="width: 1.38%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.38%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 14.06%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 21.66pt; text-align: left;">18.75</div></td></tr><tr><td style="width: 66.67%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Expected volatility (%)<font style="padding-left: 4.53pt;"></font></div></td><td class="gutter" style="width: 1.38%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.38%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 13.77%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 8.05pt; text-align: left;"><font style="padding-left: 20pt;">85-206</font></div></td><td class="gutter" style="width: 1.38%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.38%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 14.06%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 21.66pt; text-align: left;">176.6</div></td></tr><tr><td style="width: 66.67%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Award life (years)<font style="padding-left: 0.47pt;"></font></div></td><td class="gutter" style="width: 1.38%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.38%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 13.77%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 8.05pt; text-align: left;"><font style="padding-left: 10pt;">5.02-5.85</font></div></td><td class="gutter" style="width: 1.38%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.38%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 14.06%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 21.66pt; text-align: left;"><font style="padding-left: 5pt;">5.65</font></div></td></tr><tr><td style="width: 66.67%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Expected dividend yield (%)<font style="padding-left: 2.32pt;"></font></div></td><td class="gutter" style="width: 1.38%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.38%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 13.77%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 8.05pt; text-align: left;"><font style="padding-left: 38.33pt;">&#8212;</font></div></td><td class="gutter" style="width: 1.38%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.38%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 14.06%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 21.66pt; text-align: left;"><font style="padding-left: 12.5pt;">&#8212;</font></div></td></tr><tr><td style="width: 66.67%; text-align: left; vertical-align: bottom; padding-top: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Risk-free interest rate (%)<font style="padding-left: 2.9pt;"></font></div></td><td class="gutter" style="width: 1.38%; border-bottom: none; font-size: 2pt; padding-top: 3pt;">&#8203;</td><td class="gutter" style="width: 1.38%; border-bottom: none; font-size: 2pt; padding-top: 3pt;">&#8203;</td><td style="width: 13.77%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 8.05pt; text-align: left;"><font style="padding-left: 10pt;">0.36-0.70</font></div></td><td class="gutter" style="width: 1.38%; border-bottom: none; font-size: 2pt; padding-top: 3pt;">&#8203;</td><td class="gutter" style="width: 1.38%; border-bottom: none; font-size: 2pt; padding-top: 3pt;">&#8203;</td><td style="width: 14.06%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 21.66pt; text-align: left;"><font style="padding-left: 5pt;">1.67</font></div></td></tr></table><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The expected volatility was based on historical volatility and selected volatility was based on median values observed among comparable public companies. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The award life is based on the time interval between the date of grant and the date during the ten-year life at which, when making the grant, we expected on average that participants would exercise their options. </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 36pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">108<br></div></div></div>
<!--End Page 112-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 113-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 540pt;"><a name="nt10014672x1_drs_106-mda_pg21"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="block-frill" style="width: 540pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: Arial, Helvetica, sans-serif; font-size: 9pt; font-weight: bold; margin-top: 6pt; text-align: center;">Confidential Treatment Requested by ADC Therapeutics SA Pursuant to 17 C.F.R. &#167; 200.83<br></div></div><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 36pt;"><div class="h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">2016 Share Purchase Plan</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">In November 2016, we adopted the 2016 Share Purchase Plan to provide participants the opportunity to buy our shares in accordance with plan rules and conditions under the 2016 Share Purchase Plan, which, among other things, specified the purchase price. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">For the years ended December 31, 2019 and 2018, participants acquired 584,460 and 450,000 common shares, respectively. Participants paid the par value of the common shares in cash and settled the balance between the purchase price and the par value in the form of a promissory note. In anticipation of our initial public offering, each of the participants holding promissory notes entered into a loan settlement agreement with us dated as of April 15, 2020, pursuant to which they repaid all amounts outstanding under the promissory notes, including accrued interest, by delivering such number of shares of equivalent value to cover the amount outstanding under the promissory notes. After consideration of all relevant factors, our board of directors determined the value of such shares delivered pursuant to the loan settlement agreements as of the settlement date to be $18.75 per share, resulting in the delivery of an aggregate of 597,774 common shares by all participants for the settlement of the promissory notes. We held these shares as treasury shares. These transactions resulted in the termination of the 2016 Share Purchase Plan on May 15, 2020. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The cumulative amounts credited to &#8220;Other reserves&#8221; as of June 30, 2020 and December 31, 2019 were $11.2 million and $3.8 million, respectively. The expense recognized for services received for the six months ended June 30, 2020 and the year ended December 31, 2019 was $7.4 million and $0.3 million, respectively.</div><div class="h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 12.5pt; margin-left: 0pt; text-align: left;">2014 Incentive Plan </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">In May 2014, we adopted the 2014 Incentive Plan to incentivize selected employees or service providers to accept employment or service, foster retention of such employees or service providers and encourage them to contribute maximum efforts to our success. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">All awards under the Incentive Plan 2014 vested and were settled in shares upon the completion of our initial public offering. We calculated for each participant the gain arising from the difference between the exercise price per share and the initial public offering price per share, undertook to settle in cash on behalf of the participant any associated tax and social charges liability and transferred to the participant the remaining balance in treasury shares, valued at $19.00 per share. A total of 356,144 shares were transferred to participants and an amount of $5.3 million was withheld for tax and social charges.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">For participants whose awards had an exercise price greater than $19.00 per share (i.e., were &#8220;out-of-the-money&#8221;), we made an equal number of new awards under the 2019 Equity Incentive Plan with an exercise price of $19.00 per share and with a vesting period of only three years instead of the usual four years. These new awards have been accounted for as a modification of the previous awards under the 2014 Incentive Plan. Accordingly, the original compensation expense calculated for the old awards that were &#8220;out-of-the-money&#8221; will continue to be recognized over their remaining vesting period, while the expense to be recognized for the new awards under the 2019 Equity Incentive Plan will be limited to the incremental fair value of the new awards over the fair value, as of May 15, 2020, of the old awards. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The cumulative amounts credited to &#8220;Other reserves&#8221; with respect to the 2014 Incentive Plan were $2.7 million and $2.3 million as of June 30, 2020 and December 31, 2019, respectively. The expense recognized for services received during the six months ended June 30, 2020 and the year ended December 31, 2019 was $0.4 million and $0.4 million, respectively.</div><div class="h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 12pt; margin-left: 0pt; text-align: left;">Leases</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">From January 1, 2019, leases are recognized as a right-of-use asset and a corresponding liability at the date at which the leased asset is available for use by the Company. Each lease payment is allocated between the liability and finance cost. The finance cost is charged to profit or loss over the lease period so as to produce a constant periodic rate of interest on the remaining balance of the liability for each period. The right-of-use asset is depreciated over the shorter of the asset&#8217;s useful life and the lease term on a straight-line basis.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The lease payments are discounted using the interest rate implicit in the lease. If that rate cannot be determined, the lessee&#8217;s incremental borrowing rate is used, being the rate that the lessee would have to pay to borrow the funds necessary to obtain an asset of similar value in a similar economic environment with similar terms and conditions.</div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 36pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">109<br></div></div></div>
<!--End Page 113-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 114-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 540pt;"><a name="nt10014672x1_drs_106-mda_pg22"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="block-frill" style="width: 540pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: Arial, Helvetica, sans-serif; font-size: 9pt; font-weight: bold; margin-top: 6pt; text-align: center;">Confidential Treatment Requested by ADC Therapeutics SA Pursuant to 17 C.F.R. &#167; 200.83<br></div></div><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 36pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Right-of-use assets are measured at cost and comprise the following:</div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the amount of the initial measurement of lease liability;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">any lease payments made at or before the commencement date less any lease incentives received;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">any initial direct costs; and</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">restoration costs.</div></td></tr></table><div class="h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 14.5pt; margin-left: 0pt; text-align: left;">Convertible Notes</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">We entered into the Facility Agreement on April 24, 2020, pursuant to which the counterparty agreed to extend senior secured convertible term loans to us in two separate disbursements:</div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(i)<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the first tranche of convertible loans in the amount of $65.0 million upon the completion of our initial public offering, and satisfaction of certain other conditions; and</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(ii)<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the second tranche of convertible loans in the amount of $50.0 million upon the receipt of regulatory approval for a specified product candidate, and satisfaction of certain other conditions.</div></td></tr></table><div class="h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 14.5pt; margin-left: 0pt; text-align: left;">Accounting for the First Tranche</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">On May 19, 2020, we received convertible loans in the amount of $65.0 million upon completion of our initial public offering. These convertible loans have been recognized as a hybrid financial instrument and accounted for as two separate components: (i) a loan and (ii) an embedded conversion option derivative.</div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">The embedded conversion option derivative has been initially measured at fair value and is subsequently re-measured to fair value at each reporting date. Under IAS 32, this derivative could have been classified as a component of equity only if in all cases the contract would be settled by us delivering a fixed number of its own equity instruments in exchange for a fixed amount of cash or debt redemption. However, the agreement foresees, in the event of a major transaction, the payment of &#8220;make-whole&#8221; amounts that would have to be computed in the light of the circumstances and are therefore not fixed. As a result, the derivative is presented in the balance sheet as a liability and classified as non-equity in accordance with IFRS 9. Changes in the fair value (gains or losses) of the derivative at the end of each period are recorded in the consolidated statement of income.</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">The convertible loan&#8217;s initial fair value is the residual amount of the consideration received, net of attributable costs, after separating out the fair value of the embedded conversion option derivative. The loan is subsequently measured at its amortized cost in accordance with IFRS 9. It is presented in the consolidated balance sheet as a financial liability.</div></td></tr></table><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Expenses and fees payable upon the issuance of the convertible loans have been allocated pro rata to the above two components.The share of expenses allocated to the embedded conversion option derivative has been charged directly to the unaudited condensed consolidated interim statement of income, while the share of expenses allocated to the residual convertible loan has been deducted from the loan.</div><div class="h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 15pt; margin-left: 0pt; text-align: left;">Accounting for Second Tranche</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">We are obligated to draw down the second tranche in the amount of $50.0 million upon receipt of regulatory approval for Lonca. This obligation has been accounted for as a derivative and is presented in the unaudited condensed consolidated interim balance sheet as a financial liability with changes in its fair value being recorded directly in the consolidated statement of income at the end of each accounting period.</div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 15pt; margin-left: 0pt; text-align: left;">Recent Accounting Pronouncements</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">See Note 4 to our audited consolidated financial statements and Note 3 to our unaudited condensed consolidated interim financial statements for a description of recent accounting pronouncements applicable to our consolidated financial statements.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">On January&#160;1, 2019, we adopted IFRS&#160;16, &#8220;Leases,&#8221; pursuant to which leases are recognized as a right-of-use asset and a corresponding liability at the adoption date. For the year ended December&#160;31, 2019, we applied the modified retrospective approach, which requires the recognition of the cumulative effect of initially </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 36pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">110<br></div></div></div>
<!--End Page 114-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 115-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 540pt;"><a name="nt10014672x1_drs_106-mda_pg23"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="block-frill" style="width: 540pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: Arial, Helvetica, sans-serif; font-size: 9pt; font-weight: bold; margin-top: 6pt; text-align: center;">Confidential Treatment Requested by ADC Therapeutics SA Pursuant to 17 C.F.R. &#167; 200.83<br></div></div><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 36pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">applying IFRS 16 as of January&#160;1, 2019 to accumulative losses. For the year ended December&#160;31, 2019, we recorded as of January&#160;1, 2019, $5.4&#160;million in right-of-use assets and in corresponding lease liabilities. See Note&#160;17 to our audited consolidated financial statements for more information.</div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 20.5pt; margin-left: 0pt; text-align: left;">JOBS Act</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">In April 2012, the JOBS Act was enacted. Section 107 of the JOBS Act provides that an emerging growth company can take advantage of an extended transition period for complying with new or revised accounting standards applicable to public companies. This provision allows an emerging growth company to delay the adoption of certain accounting standards until those standards would otherwise apply to private companies. This transition period is only applicable under U.S. GAAP. As a result, we will adopt new or revised accounting standards on the relevant dates on which adoption of such standards is required or permitted by the International Accounting Standards Board.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">We are in the process of evaluating the benefits of relying on other exemptions and reduced reporting requirements under the JOBS Act. Subject to certain conditions, as an emerging growth company, we intend to rely on certain of these exemptions, including without limitation, (i)&#160;providing an auditor&#8217;s attestation report on our system of internal controls over financial reporting pursuant to Section 404(b) of the Sarbanes-Oxley Act and (ii)&#160;complying with any requirement that may be adopted by the Public Company Accounting Oversight Board, regarding mandatory audit firm rotation or a supplement to the auditor&#8217;s report providing additional information about the audit and the financial statements, known as the auditor discussion and analysis. We will remain an emerging growth company until the earliest of (i)&#160;the last day of the fiscal year in which we have total annual gross revenues of $1.07&#160;billion or more; (ii)&#160;the last day of the fiscal year following the fifth anniversary of the completion of our initial public offering; (iii)&#160;the date on which we have issued more than $1.0&#160;billion in non-convertible debt during the previous three years; and (iv)&#160;the date on which we are deemed to be a large accelerated filer under the rules of the SEC, which means the market value of our common shares that are held by non-affiliates exceeds $700.0&#160;million as of the prior June 30<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">th</sup>.</div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 36pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">111<br></div></div></div>
<!--End Page 115-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 116-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 540pt;"><a name="nt10014672x1_drs_107-business_pg1"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="block-frill" style="width: 540pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: Arial, Helvetica, sans-serif; font-size: 9pt; font-weight: bold; margin-top: 6pt; text-align: center;">Confidential Treatment Requested by ADC Therapeutics SA Pursuant to 17 C.F.R. &#167; 200.83<br></div></div><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 36pt;"><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: center;"><a name="tB"><!--Anchor--></a>BUSINESS</div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">Overview</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">We are a late clinical-stage oncology-focused biotechnology company evolving into a commercial-stage company as we prepare for the launch of our lead product candidate, if approved. We are a pioneer in the development of highly potent and targeted ADCs for patients suffering from hematological malignancies and solid tumors. We develop our ADCs by applying our decades of experience in this field and using next-generation PBD technology to which we have proprietary rights for our targets. We are leveraging our R&amp;D strengths, our disciplined approach to target selection and our preclinical and clinical development strategy to generate a diverse and balanced portfolio and research pipeline. Our hematology franchise comprises three clinical-stage product candidates, Lonca, Cami and ADCT-602. Our solid tumor franchise comprises two clinical-stage product candidates, Cami and ADCT-601, and two preclinical product candidates, ADCT-901 and ADCT-701. We retain exclusive worldwide development and commercialization rights to all of our product candidates other than Cami, for which we have a collaboration and license agreement with Genmab. Our commercial organization has initiated pre-launch market activities and is leveraging our team&#8217;s deep industry experience to maximize the commercial potential of any approved products. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Our two lead product candidates, Lonca and Cami, have demonstrated significant clinical activity across a broad population of heavily pre-treated patients, while maintaining tolerability profiles that we believe are manageable. We have evaluated Lonca in a 145-patient pivotal Phase 2 clinical trial for the treatment of relapsed or refractory DLBCL that showed a 48.3% ORR and a 24.1% CRR as of April 2020. We intend to submit a BLA to the FDA in the second half of 2020 for Lonca for the treatment of relapsed or refractory DLBCL. Concurrently, we intend to commence a confirmatory Phase 3 clinical trial of Lonca in combination with rituximab that, if successful, may serve as the basis for an sBLA for Lonca for the treatment of relapsed or refractory DLBCL in transplant-ineligible patients. We are also conducting a Phase 1/2 clinical trial of Lonca in combination with ibrutinib for the treatment of relapsed or refractory DLBCL and MCL that showed a 75.0% ORR and a 58.3% CRR as of April 6, 2020 at the dose being used in the pivotal Phase 2 portion of the clinical trial. In July 2020, we dosed the first patient in the pivotal Phase 2 portion of this clinical trial. We also had an end-of-Phase 1 meeting with the FDA in the second quarter of 2020 to discuss a potential pivotal Phase 2 clinical trial of Lonca for the treatment of relapsed or refractory FL that we expect to commence in the first half of 2021.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">In addition, we are evaluating Cami in a 100-patient pivotal Phase 2 clinical trial for the treatment of relapsed or refractory HL and have enrolled 47 patients as of June 30, 2020. We have completed enrollment of a 133-patient Phase 1 clinical trial of Cami for the treatment of relapsed or refractory HL and NHL that has shown an 86.5% ORR and a 48.6% CRR in patients with HL at the initial dose for our pivotal Phase 2 clinical trial and a 44.0% ORR and an 8.0% CRR in a subset of patients with T-cell lymphoma as of April 2019. We anticipate reporting top-line response rate data from our pivotal Phase 2 clinical trial of Cami for the treatment of HL in the first half of 2021, and we believe that this clinical trial, if successful, will support a BLA submission. We are also evaluating Cami in a Phase 1b clinical trial as a novel immuno-oncology approach for the treatment of various advanced solid tumors.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Antibody drug conjugates are an established therapeutic approach in oncology. Currently, there are ten approved ADCs, six of which were approved by the FDA in the past two years. ADCs selectively deliver potent chemotherapeutic cytotoxins directly to tumor cells, with the goal of maximizing activity in tumor cells while minimizing toxicity to healthy cells. The antibody component is designed to selectively bind to a distinct antigen preferentially expressed on tumor cells or other cells in the tumor microenvironment. Upon binding to the antigen, most ADCs are internalized by the cell where the cytotoxic warhead is released, causing cell death.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">PBD warheads have a different mechanism of action from other warheads because they create cross-links in the cancer cells&#8217; DNA that do not distort the DNA helix, potentially evading the cells&#8217; natural DNA repair mechanisms. They have been shown preclinically to be approximately 100 times more potent than warheads used in currently marketed ADCs. Our ADCs use next-generation PBD technology, which is designed to produce warheads that are less hydrophobic, causing them to be easier to conjugate and, based on preclinical data, have less off-target toxicity than first-generation PBD warheads. Preclinical studies have further shown that our next-generation PBD warheads have improved therapeutic indices compared to first-generation PBDs. We believe that this mechanism of action has the potential to allow our ADCs to achieve significant clinical activity and durable responses in difficult-to-treat patients. </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 36pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">112<br></div></div></div>
<!--End Page 116-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 117-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 540pt;"><a name="nt10014672x1_drs_107-business_pg2"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="block-frill" style="width: 540pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: Arial, Helvetica, sans-serif; font-size: 9pt; font-weight: bold; margin-top: 6pt; text-align: center;">Confidential Treatment Requested by ADC Therapeutics SA Pursuant to 17 C.F.R. &#167; 200.83<br></div></div><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 36pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">We were founded in 2011 as a spinoff from Spirogen, which was founded in 2000 and was an early innovator in PBD-based ADC research. Our co-founder and CEO, Dr. Christopher Martin, was a founder and the CEO of Spirogen until its sale to AstraZeneca plc in 2013. We leverage Dr. Martin&#8217;s decades-long experience in the development and evolution of PBD-based ADC research. Our senior management team also brings extensive experience in oncology research and development, clinical development, CMC, medical affairs, commercialization and regulatory and compliance, having held senior positions in such companies as Ariad Pharmaceuticals, Inc., AstraZeneca plc, Bristol-Myers Squibb Company, Celgene Corporation, Daiichi Sankyo Company, Genentech, Inc., Genmab, ImmunoGen, Inc., MorphoSys AG and Wyeth Pharmaceuticals, Inc. Our board of directors includes former senior executives of Array BioPharma Inc., AstraZeneca plc, GlaxoSmithKline plc, Pfizer Inc., F. Hoffmann-La Roche AG and Serono S.A.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Since inception, we have raised $891.2 million in gross cash proceeds from equity and convertible debt financings. Our headquarters are located in Lausanne, Switzerland, our research and development team is based in London, our clinical development team is based in New Jersey and in Lausanne, our commercialization team is based in New Jersey and our CMC team is based in the San Francisco Bay Area. </div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 20.5pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Our Pipeline</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Our research and development operations have generated a diverse and balanced portfolio. Our hematology franchise comprises three clinical-stage product candidates, Lonca, Cami and ADCT-602. Our solid tumor franchise comprises two clinical-stage product candidates, Cami and ADCT-601, and two preclinical product candidates, ADCT-901 and ADCT-701. The figure below summarizes key information about our product candidates:</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 15.25pt; text-align: center;"><img style="height: 269px; width: 620px;" src="nt10014672x1_barchart1x1.jpg"><br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">&#8201;</div><div><div class="rule-partial" style="height: 0pt; width: 72pt; border-bottom: 1pt solid #000000; margin-bottom: 1pt; margin-right: auto; margin-left: 0pt; margin-top: 15.25pt;"> </div></div><div class="ftnote" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 3pt; margin-left: 0pt; text-align: left;">Anticipated milestones set forth in this chart and in this prospectus are subject to further future adjustment based on, among other factors, the impact of the COVID-19 pandemic. *We believe that our Phase 1/2 clinical trial of Lonca in combination with ibrutinib for the treatment of relapsed or refractory DLBCL and MCL, our Phase 2 clinical trial of Lonca for the treatment of relapsed or refractory FL and our Phase 2 clinical trial of Cami for the treatment of relapsed or refractory HL are pivotal clinical trials (i.e., a clinical trial intended to serve as the basis for BLA submission). Therefore, we believe that subsequent Phase 3 clinical trials will be confirmatory clinical trials. **We retain worldwide development and commercialization rights to Cami, subject to our collaboration and license agreement with Genmab. See &#8220;Recent Developments&#8221; and &#8220;&#8212;License and Collaboration Agreements&#8212;Genmab Collaboration and License Agreement.&#8221; </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">In addition, our preclinical research pipeline consists of research programs focused on five ADC targets (one&#160;hematological and four solid tumor targets) and ten XDC targets (four hematological and six solid tumor targets), with the goal of selecting clinical candidates for further development. We refer to those targets for which we are exploring the use of non-antibody protein scaffolds and peptides to deliver potent PBD cytotoxins to tumor cells as &#8220;XDC targets.&#8221;</div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 36pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">113<br></div></div></div>
<!--End Page 117-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 118-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 540pt;"><a name="nt10014672x1_drs_107-business_pg3"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="block-frill" style="width: 540pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: Arial, Helvetica, sans-serif; font-size: 9pt; font-weight: bold; margin-top: 6pt; text-align: center;">Confidential Treatment Requested by ADC Therapeutics SA Pursuant to 17 C.F.R. &#167; 200.83<br></div></div><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 36pt;"><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">Strengths</div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">We are a pioneer in developing highly potent and targeted PBD-based ADCs. We believe that our team, with decades of experience in this field, is well positioned to develop and commercialize PBD-based ADCs for the benefit of patients with cancer.</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">Our two lead product candidates, Lonca and Cami, have consistently demonstrated robust single-agent clinical activity across a broad population of heavily pre-treated patients, while maintaining tolerability profiles that we believe are manageable, and we are advancing the clinical development of Lonca to BLA submission in the second half of 2020 and of Cami to support BLA submission.</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">We are advancing a broad pipeline of four clinical-stage product candidates and two preclinical product candidates addressing multiple areas of unmet medical need across hematological malignancies and solid tumors, leveraging our R&amp;D strengths, our disciplined approach to target selection and our preclinical and clinical development strategy.</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">We retain exclusive worldwide development and commercialization rights to all of our product candidates other than Cami, for which we have a collaboration and license agreement with Genmab. Our commercial organization has initiated pre-launch market activities and is leveraging our team&#8217;s deep industry experience to maximize the commercial potential of any approved products.</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">Our experienced CMC team is highly proficient in the manufacturing of PBD-based ADCs and has developed a validated commercial supply chain that has been able to consistently produce Lonca at commercial scale to support BLA submission.</div></td></tr></table><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 20.5pt; margin-left: 0pt; text-align: left;">Strategy</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Our near-term goal is to leverage our expertise in next-generation PBD technology to develop and deliver innovative therapies to patients suffering from severe diseases who lack adequate treatment options, with a focus on oncology and immuno-oncology. Our long-term vision is to broaden the use of our ADCs to an extensive range of hematological and solid tumor indications, while also advancing any approved products through the treatment paradigm to become standard-of-care treatments in earlier lines of therapy. Key elements of our strategy to achieve our near-term goal and long-term vision include:</div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;"><font style="font-style: italic;">Continue to prepare for the near-term commercial launch of Lonca, if approved</font>. We intend to submit a BLA to the FDA in the second half of 2020 for Lonca for the treatment of relapsed or refractory DLBCL. To prepare for commercial launch, we have successfully recruited an experienced Chief Commercial Officer and senior commercial leadership team. We intend to continue to prepare for the commercial launch of Lonca by further enhancing our commercial team and commercial capabilities, including by building a highly talented and efficient U.S. customer-facing organization of more than 65&#160;cross-functional employees, which we believe has the potential to capture more than 80% of the DLBCL commercial opportunity.</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;"><font style="font-style: italic;">Expand the potential market opportunity by advancing Lonca into earlier lines of therapy</font><font style="font-style: italic;"> and for </font><font style="font-style: italic;">multiple indications</font>. Based on the significant single-agent clinical activity and promising combination data with ibrutinib observed in clinical trials to date, we believe that Lonca has the opportunity to advance into earlier lines of therapy in combination with other therapies, including into first-line therapy. Concurrently with our BLA submission in the second half of 2020, we intend to commence a confirmatory clinical trial of Lonca in combination with rituximab, which, if successful, we believe will support an sBLA for Lonca to be used as a second-line therapy for the treatment of relapsed or refractory DLBCL in transplant-ineligible patients. In addition, to further expand Lonca&#8217;s potential market opportunity, we are conducting a Phase 1/2 clinical trial of Lonca in combination with ibrutinib for the treatment of relapsed or refractory DLBCL and MCL and intend to commence a pivotal Phase 2 clinical trial of Lonca for the treatment of relapsed or refractory FL in the first half of 2021.</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;"><font style="font-style: italic;">Advance our second lead product candidate, </font><font style="font-style: italic;">Cami</font><font style="font-style: italic;">, to support BLA submission</font>. Based on promising results from our 133-patient Phase 1 clinical trial, we are currently evaluating Cami in a pivotal Phase&#160;2 clinical trial for the treatment of relapsed or refractory HL that, if successful, we believe will form the basis for a BLA submission. </div></td></tr></table></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 36pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">114<br></div></div></div>
<!--End Page 118-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 119-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 540pt;"><a name="nt10014672x1_drs_107-business_pg4"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="block-frill" style="width: 540pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: Arial, Helvetica, sans-serif; font-size: 9pt; font-weight: bold; margin-top: 6pt; text-align: center;">Confidential Treatment Requested by ADC Therapeutics SA Pursuant to 17 C.F.R. &#167; 200.83<br></div></div><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 36pt;"><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6.75pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;"><font style="font-style: italic;">Advance our two clinical-stage </font><font style="font-style: italic;">solid tumor </font><font style="font-style: italic;">product candidates</font><font style="font-style: italic;"> to address multiple indications in areas </font><font style="font-style: italic;">of high unmet medical need</font>. Our PBD-based ADCs have multiple mechanisms of action that we believe make them suitable for targeting solid tumors. We are therefore evaluating Cami, which targets the CD25-expressing Tregs that are part of the immunosuppressive tumor microenvironment, as a novel immuno-oncology approach for the treatment of various advanced solid tumors. We are also evaluating ADCT-601, which targets AXL-expressing solid tumors, for the treatment of various advanced solid tumors.</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;"><font style="font-style: italic;">Continue to build a divers</font><font style="font-style: italic;">e</font><font style="font-style: italic;"> and balanced portfolio of product candidates to address high unmet </font><font style="font-style: italic;">medical needs in oncology by leveraging our R&amp;D strengths, our disciplined approach to target </font><font style="font-style: italic;">selection and our preclinical and clinical development strategy</font>. In addition to the lead indications that we are pursuing for Lonca and Cami, we are also evaluating these two product candidates in various other disease settings, such as MCL and FL and, in the case of Cami, multiple solid tumors, both as monotherapies and when used in combination with other therapies. Furthermore, we are advancing our other product candidates, including ADCT-601 and ADCT-602, and research programs through preclinical and clinical development. To strike an optimized risk-reward balance, we intend to address both hematological malignancies and solid tumors, across both clinically validated and novel cancer targets.</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;"><font style="font-style: italic;">Maximize the commercial potential of our product candidates</font><font style="font-style: italic;"> </font><font style="font-style: italic;">t</font><font style="font-style: italic;">hrough both our own commercial </font><font style="font-style: italic;">organization and strategic collaborations</font><font style="font-style: italic;"> and licensing opportunities in select markets</font><font style="font-style: italic;">.</font> We currently hold exclusive worldwide development and commercialization rights to all of our product candidates other than Cami, for which we have a collaboration and license agreement with Genmab. We intend to commercialize Lonca in the United States through our own infrastructure and may selectively pursue strategic collaborations and licensing opportunities in other geographies. We have an experienced team with substantial expertise in the commercialization of oncology products to support our commercialization efforts for Lonca, if approved, which will also serve as the foundation of our U.S. commercialization efforts for our other product candidates in our hematology franchise.</div></td></tr></table><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 20.5pt; margin-left: 0pt; text-align: left;">Overview of Antibody Drug Conjugates</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Cancer is a broad group of diseases in which cells divide and grow in an uncontrolled fashion and which are usually classified as either hematological malignancies or solid tumors. In 2018, there were an estimated 18.1&#160;million new cases of cancer and 9.6&#160;million cancer-related deaths. Global spending on cancer treatment reached nearly $150 billion in 2018 and is expected to exceed $200&#160;billion by 2022, driven by an aging population and the development of improved treatment options. According to the National Cancer Institute, in the United States, most newly launched cancer treatments were priced at more than $100,000 per patient for one year of treatment. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The most common cancer treatments typically include a combination of surgery, radiation therapy and chemotherapy. In addition, several novel targeted therapies have also been approved. Each of these treatments have certain benefits but also certain limitations and may not be suitable for all patients. ADCs can complement other forms of treatment and are an important part of the cancer treatment paradigm.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Antibody drug conjugates are an established therapeutic approach in oncology. Currently, there are ten approved ADCs, six of which were approved by the FDA in the past two years. ADCs selectively deliver potent chemotherapeutic cytotoxins directly to tumor cells, with the goal of maximizing activity in tumor cells while minimizing toxicity to healthy cells. An ADC consists of three components: (i)&#160;a monoclonal antibody that selectively targets a distinct antigen preferentially expressed on tumor cells or other cells in the tumor microenvironment; (ii)&#160;a cytotoxic molecule, often referred to as the toxin or the warhead, that kills the target cell; and (iii)&#160;a chemical linker that joins together the antibody and the warhead. The warhead and the linker are together referred to as the payload. The figure below shows the three components of an ADC.</div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 36pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">115<br></div></div></div>
<!--End Page 119-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 120-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 540pt;"><a name="nt10014672x1_drs_107-business_pg5"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="block-frill" style="width: 540pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: Arial, Helvetica, sans-serif; font-size: 9pt; font-weight: bold; margin-top: 6pt; text-align: center;">Confidential Treatment Requested by ADC Therapeutics SA Pursuant to 17 C.F.R. &#167; 200.83<br></div></div><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 36pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; text-align: center;"><img style="height: 180px; width: 206px;" src="nt10014672x1_diagram1.jpg"><br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">&#8201;</div><div><div class="rule-partial" style="height: 0pt; width: 72pt; border-bottom: 1pt solid #000000; margin-bottom: 1pt; margin-right: auto; margin-left: 0pt; margin-top: 10.25pt;"> </div></div><div class="ftnote" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 4pt; margin-left: 0pt; text-align: left;">Schematic representation of an ADC, showing its three components.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Because the antibody is designed to selectively target a distinct antigen preferentially expressed on tumor cells or other cells in the tumor microenvironment, an ADC will bind preferentially to those cells that express the specific antigen. Upon binding to the antigen, most ADC molecules are internalized by the cell where the cytotoxic warhead is released through either cleavage of the linker or degradation of the entire antibody by cellular processes. Once a sufficient number of cytotoxic molecules have been released intracellularly, apoptosis occurs when the cell next attempts to replicate.</div><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12.5pt; margin-left: 0pt; text-align: left;">Components of Antibody Drug Conjugates</div><div class="h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 7pt; margin-left: 0pt; text-align: left;">Monoclonal Antibodies</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The first component of an ADC is the monoclonal antibody, which is a highly specific targeting agent that selectively binds to a distinct antigen preferentially expressed on tumor cells or other cells in the tumor microenvironment. Since ADCs are designed to selectively target an antigen that is expressed in the tumor microenvironment, ADCs have less effect on cells that do not express the target antigen. Due to this specificity, the cytotoxins used in ADCs can be much more potent than those used in traditional chemotherapies, allowing normally systemically intolerable doses of cytotoxins to be directed at tumors.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">In an ADC, two significant factors are considered in the selection of the antigen to which the antibody is targeted: (i)&#160;the preferential expression on tumor cells or other cells in the tumor microenvironment; and (ii)&#160;the level of antigen expression on these cells. As a result, it is generally recognized that high and consistent (i.e., homogeneous) antigen expression throughout the tumor microenvironment correlates with higher efficacy of the ADC. By contrast, the ability to achieve a therapeutic concentration of cytotoxins in the target cell diminishes as the level of antigen expression decreases.</div><div class="h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 12pt; margin-left: 0pt; text-align: left;">Chemotherapeutic Warheads</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The second component of an ADC is the cytotoxic warhead, or the cell-killing toxin. Cytotoxins commonly used in ADCs include tubulin inhibitors, such as maytansines and auristatins, and DNA-damaging toxins, such as calicheamicin. Because a warhead is conjugated to an antibody that selectively targets the tumor microenvironment, ADCs can use cytotoxins at levels that are normally too potent to be used as a stand-alone therapy. Once an ADC is internalized by the target cell, the warhead is released and ultimately causes cell death via a warhead-specific mechanism. Some warheads have the additional ability to diffuse into and kill neighboring cells in the tumor microenvironment. This bystander effect can be useful in enhancing the efficacy of ADCs in tumors with heterogeneous antigen expression by providing a mechanism to kill neighboring tumor cells that do not express the target antigen.</div><div class="h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 12pt; margin-left: 0pt; text-align: left;">Chemical Linkers</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The third component of an ADC is the chemical linker used to attach the warhead to the antibody. The chemical linker directly affects the efficacy, safety and tolerability of an ADC. Before an ADC is internalized by the target cell, it is critical that the chemical linker provides a stable connection between the warhead and the antibody in systemic circulation, as premature release of the warhead can cause significant off-target toxicity. After an ADC is internalized by the target cell, it is critical that the warhead is released from the antibody to promote rapid and efficient cell killing.</div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 36pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">116<br></div></div></div>
<!--End Page 120-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 121-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 540pt;"><a name="nt10014672x1_drs_107-business_pg6"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="block-frill" style="width: 540pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: Arial, Helvetica, sans-serif; font-size: 9pt; font-weight: bold; margin-top: 6pt; text-align: center;">Confidential Treatment Requested by ADC Therapeutics SA Pursuant to 17 C.F.R. &#167; 200.83<br></div></div><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 36pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Linkers used in ADCs fall into two categories: cleavable and non-cleavable. Cleavable linkers release the warhead intracellularly after proteolytic cleavage of the linker by intracellular enzymes such as cathepsin or after weakening of the linker by the intracellular environment. In contrast, non-cleavable linkers are resistant to this type of cleavage and instead rely on the degradation of the entire antibody. As a result, the released payload in ADCs that use non-cleavable linkers remains attached to a fragment of the antibody, which limits the warhead&#8217;s permeability to adjacent cells, reducing the bystander effect and potentially the ADC&#8217;s efficacy in tumors with heterogeneous target antigen expression.</div><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 20pt; margin-left: 0pt; text-align: left;">Key Strengths and Attributes of Antibody Drug Conjugates</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 7pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Antibody drug conjugates are an important part of the cancer treatment paradigm for the following reasons:</div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;"><font style="font-style: italic;">Selective Targeting</font>. Traditional chemotherapies are unable to distinguish between healthy cells and tumor cells. As a result, these therapies typically have a narrow therapeutic window (i.e., the dose range that can treat disease effectively without causing unacceptable toxic side effects). In contrast, ADCs, through their use of antigen-specific antibodies, target tumor cells or other cells in the tumor microenvironment with greater selectivity than do traditional chemotherapies. This selective targeting allows ADCs to use potent cytotoxins at dose levels that otherwise would not be tolerable. As a result, ADCs can represent a highly effective treatment approach while maintaining manageable side effects.</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;"><font style="font-style: italic;">Wide Addressable Patient Population.</font> ADCs represent a treatment approach that expands the treatment options available to cancer patients. Many therapies are not appropriate for certain patient populations. For example, surgery is not used when the cancer is widespread, chemotherapy may not be appropriate when the patient is too sick to tolerate or does not respond to available chemotherapeutics, stem cell transplant may not be appropriate when the patient is frail, and some novel targeted therapies such as CAR-T (i.e., a type of treatment in which a patient&#8217;s T cells are modified in the laboratory so they will attack cancer cells) may not be appropriate when there is significant comorbidity. As a result of these limitations, there remains a significant unmet medical need for patients for whom other treatment options are inappropriate or ineffective.</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;"><font style="font-style: italic;">Potential in Relapsed or Refractory Patients</font>. Traditional therapies typically have limited effectiveness for patients who exhibit relapsed (i.e., the cancer returns after an initial positive response to treatment) or refractory (i.e., the cancer is resistant to treatment) cancers. In contrast, some ADCs have proven efficacious in such patient populations while maintaining a manageable tolerability profile. Therefore, ADCs represent an important part of the cancer treatment paradigm, expanding the treatment options available to patients suffering from relapsed or refractory cancers.</div></td></tr></table><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 20pt; margin-left: 0pt; text-align: left;">The Antibody Drug Conjugates Landscape</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Currently, there are ten approved ADCs: (i)&#160;brentuximab vedotin (Adcetris&#174;), marketed by Seattle Genetics, Inc. and Takeda Pharmaceutical Company Ltd, (ii)&#160;ado-trastuzumab emtansine (Kadcyla&#174;), marketed by Genentech, Inc., (iii)&#160;inotuzumab ozogamicin (Besponsa&#174;), marketed by Pfizer Inc., (iv)&#160;gemtuzumab ozogamicin (Mylotarg&#174;), marketed by Pfizer Inc., (v)&#160;moxetumomab pasudotox (Lumoxiti&#174;), marketed by AstraZeneca plc, (vi)&#160;polatuzumab vedotin (Polivy&#174;), marketed by Genentech, Inc., (vii)&#160;enfortumab vedotin (Padcev&#174;), marketed by Astellas Pharma Inc., (viii)&#160;trastuzumab deruxtecan (Enhuertu&#174;), marketed by Daiichi Sankyo Company, (ix) sacituzumab govitecan (Trodelvy&#174;), marketed by Immunomedics, Inc., and (x)&#160;belantamab mafodotin (Blenrep&#174;), marketed by GlaxoSmithKline plc. We believe that the commercial success of previously approved ADCs demonstrates ADCs&#8217; potential to become an important part of the cancer treatment paradigm.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">While ADCs are an important part of the cancer treatment paradigm, there are certain challenges in developing ADCs that achieve the optimal therapeutic index (i.e., the balance between efficacy and tolerability). These challenges include (i)&#160;developing warheads that are sufficiently potent to target cancers with low or heterogeneous antigen expression without causing unacceptable toxic side effects, (ii)&#160;designing linkers that are stable in systemic circulation but that release the warhead once the ADC has been internalized by the target cell, and (iii)&#160;creating ADCs that achieve durable responses. We believe that our expertise in ADC research and development and access to next-generation PBD technology enables us to develop ADCs that overcome these challenges.</div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 36pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">117<br></div></div></div>
<!--End Page 121-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 122-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 540pt;"><a name="nt10014672x1_drs_107-business_pg7"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="block-frill" style="width: 540pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: Arial, Helvetica, sans-serif; font-size: 9pt; font-weight: bold; margin-top: 6pt; text-align: center;">Confidential Treatment Requested by ADC Therapeutics SA Pursuant to 17 C.F.R. &#167; 200.83<br></div></div><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 36pt;"><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">Our Next-Generation PBD-Based Antibody Drug Conjugates</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">We develop ADCs that use next-generation PBD warhead technology. Using this technology, we have developed a diverse and balanced portfolio of highly targeted ADCs with potential for improved therapeutic indices that may allow us to broaden the scope of addressable cancer patients for whom treatment with ADCs is feasible or appropriate.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">PBDs are a class of antibiotic or anti-tumor molecules. First-generation PBDs, developed in the early 2000s, were originally used as stand-alone chemotherapeutics. They were subsequently explored for use as ADC warheads. However, these first-generation PBD warheads&#8217; hydrophobicity generally resulted in manufacturability issues and they exhibited significant toxicities that resulted in very narrow therapeutic indices. In contrast, our ADCs use next-generation PBD technology, which is designed to produce warheads that are less hydrophobic, causing them to be easier to conjugate and, based on preclinical data, have less off-target toxicity than first-generation PBD warheads. Through further in-house development of conjugation technology and highly stable linker design, we aim to develop PBD-based ADCs that achieve significant clinical activity and durable responses in difficult-to-treat patients.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Our ADCs use PBD dimer warheads, which are two PBD monomer molecules bonded together. Once inside a target cell, these PBD dimers bind irreversibly to DNA without distorting the double helix, potentially evading DNA repair mechanisms that can otherwise reduce ADCs&#8217; effectiveness. PBD dimers do this by covalently binding two guanines from opposite DNA strands in the minor groove, forming highly cytotoxic <font style="font-style: italic;">inter</font>strand cross-links that block DNA strand separation, thus disrupting essential DNA metabolic processes such as replication, and ultimately resulting in cell death. The figure below shows the mechanism of action of our PBD-based ADCs.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 15.25pt; text-align: center;"><img style="height: 241px; width: 459px;" src="nt10014672x1_diagram2.jpg"><br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">&#8201;</div><div><div class="rule-partial" style="height: 0pt; width: 72pt; border-bottom: 1pt solid #000000; margin-bottom: 1pt; margin-right: auto; margin-left: 0pt; margin-top: 15.25pt;"> </div></div><div class="ftnote" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 4.5pt; margin-left: 0pt; text-align: left;">The mechanism of action of our PBD-based ADCs.</div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 36pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">118<br></div></div></div>
<!--End Page 122-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 123-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 540pt;"><a name="nt10014672x1_drs_107-business_pg8"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="block-frill" style="width: 540pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: Arial, Helvetica, sans-serif; font-size: 9pt; font-weight: bold; margin-top: 6pt; text-align: center;">Confidential Treatment Requested by ADC Therapeutics SA Pursuant to 17 C.F.R. &#167; 200.83<br></div></div><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 36pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">We believe that our ADCs, using next-generation PBD technology, have the potential to become an important part of the cancer treatment paradigm due to their following potential benefits:</div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;"><font style="font-style: italic;">Cytotoxic Potency</font>. The PBD dimer warheads used in our ADCs have been shown preclinically to be approximately 100 times more potent than warheads used in currently marketed ADCs, such as auristatin, maytansine and calicheamicin. The figure below shows the relative <font style="font-style: italic;">in vitro</font> cytotoxic potency of various ADC warheads and common chemotherapeutics in comparison to a PBD dimer. Despite their potency, however, the PBD dimer warheads used in our ADCs have demonstrated a manageable tolerability profile in our preclinical studies and clinical trials to date.</div></td></tr></table><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 15.25pt; text-align: center;"><img style="height: 244px; width: 450px;" src="nt10014672x1_diagram3.jpg"><br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 20pt; text-align: left;">&#8201;</div><div><div class="rule-partial" style="height: 0pt; width: 72pt; border-bottom: 1pt solid #000000; margin-bottom: 1pt; margin-right: auto; margin-left: 20pt; margin-top: 15.25pt;"> </div></div><div class="ftnote" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 3pt; margin-left: 20pt; text-align: left;">The relative <font style="font-style: italic;">in vitro</font> cytotoxic potency of various ADC warheads (in red) and common chemotherapeutics (in black) in comparison to a PBD dimer. &#8220;IC50&#8221; means the drug concentration causing 50% inhibition of the desired activity, and &#8220;M&#8221; means molar. Source: Spirogen, a subsidiary of AstraZeneca plc.</div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;"><font style="font-style: italic;">Activ</font><font style="font-style: italic;">ity</font><font style="font-style: italic;"> in Tumors with Low-Expressing Targets</font>. Tumor cells typically require a threshold number of warhead molecules to be internalized for efficient cell killing. The high potency of our PBD-based warheads means that, compared to other warheads, fewer molecules of warhead should be needed to be internalized into the cancer cell to kill it. In cancer cells with low levels of antigen expression, ADCs with less potent warheads cannot bind in sufficient quantities to be effective. We believe that the potency of our PBD-based warheads may allow us to develop ADCs that target antigens with low expression levels in the tumor microenvironment, potentially increasing the range of cancers amenable to treatment with ADCs.</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;"><font style="font-style: italic;">Durable Responses</font>. Cross-links in DNA occur when an agent reacts with two nucleotides of DNA, forming a covalent linkage between them. The cross-links can occur in the same strand (i.e.,&#160;<font style="font-style: italic;">intra</font>strand) or between opposite strands of DNA (i.e., <font style="font-style: italic;">inter</font>strand). Our PBD-based ADCs create <font style="font-style: italic;">inter</font>strand cross-links in the target cells&#8217; DNA. These <font style="font-style: italic;">inter</font>strand cross-links persist in target cells and can lie dormant, potentially for weeks. We believe that this allows our ADCs to target slowly proliferating cancer cells, including cancer stem cells. The persistence of the <font style="font-style: italic;">inter</font>strand cross-links is explained by the fact that these cross-links do not distort the DNA helix. Cells have natural DNA repair mechanisms that detect structural changes to DNA, including those caused by cytotoxic warheads, and repair the DNA back to its original state. Warheads that create <font style="font-style: italic;">intra</font>strand cross-links, and even some warheads that create <font style="font-style: italic;">inter</font>strand cross-links such as calicheamicin, distort the DNA helix, triggering the cells&#8217; DNA repair mechanisms, thereby reducing their efficacy and leading to drug resistance. As PBD cross-links are non-distortive, they are designed to be able to evade the cells&#8217; DNA repair mechanisms. In addition, tumor cells also induce the expression of certain transporter proteins (i.e., proteins that are able to transport warheads across the membrane outside the tumor cell) or the activation of detoxifying mechanisms that lead to inactive toxins. These potential resistance mechanisms limit traditional ADCs&#8217; </div></td></tr></table></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 36pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">119<br></div></div></div>
<!--End Page 123-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 124-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 540pt;"><a name="nt10014672x1_drs_107-business_pg9"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="block-frill" style="width: 540pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: Arial, Helvetica, sans-serif; font-size: 9pt; font-weight: bold; margin-top: 6pt; text-align: center;">Confidential Treatment Requested by ADC Therapeutics SA Pursuant to 17 C.F.R. &#167; 200.83<br></div></div><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 36pt;"><div class="bl" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 40pt; text-align: left;">efficacy, resulting in limited clinical responses and relapses. Based on data to date, very few resistance mechanisms have been reported for PBDs. We believe that all of these factors may contribute to the frequency and durability of responses in heavily pre-treated and primary refractory patients that we have observed in our clinical trials.</div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;"><font style="font-style: italic;">Bystander Effect</font>. The bystander effect occurs when a released warhead is able to diffuse into and kill neighboring cells in the tumor microenvironment, irrespective of those cells&#8217; antigen expression. Upon binding to the target antigen and internalization of our ADCs into the tumor cell, the warhead is designed to induce apoptosis. This is followed by the release of free PBD dimers into the tumor microenvironment. Since our PBD-based warheads are cell-permeable, they may be able to diffuse into adjacent cells and kill them in an antigen-independent manner. We believe that this may allow us to develop ADCs that target antigens with heterogeneous expression levels in the tumor microenvironment, potentially increasing the range of cancers amenable to treatment with ADCs. Once the PBD is released into circulation outside the tumor microenvironment, it is rapidly excreted with a short half-life, thus limiting overall systemic toxicity. We believe that this results in our ADCs&#8217; bystander effect being controlled and generally limited to tumor cells.</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;"><font style="font-style: italic;">Immunogenic Cell Death</font>. PBD warheads have been observed to induce immunogenic cell death, whereby a cancer cell&#8217;s death expresses certain stress signals that induce the body&#8217;s anti-tumor immune response through the activation of T cells and antigen-presenting cells. This opens up the potential for combining our ADCs with other therapies, particularly with immuno-oncology therapies such as checkpoint inhibitors, that are specifically designed to activate the patient&#8217;s own immune system to combat cancer.</div></td></tr></table><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 20.5pt; margin-left: 0pt; text-align: left;">Our Target Selection Strategy</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">While PBD warheads offer distinct benefits, they are not suitable for targeting all antigens expressed on a tumor or in the tumor microenvironment. Based on our extensive experience with PBD warheads, we have developed a disciplined target selection strategy, which involves:</div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">analysis of the relative overexpression of the target antigen on the membrane of cancer cells (as compared to healthy cells) and other target characteristics, such as internalization (i.e., how rapidly the antigen migrates from the membrane to the inside of the cell), recycling (i.e., whether or not the antigen recycles back to the membrane once internalized) and shedding (i.e., whether the antigen is cleaved off from the membrane to form a soluble antigen sink in the extracellular space and/or circulation) properties;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">review of whether an ADC that targets the antigen has the potential to address a clear unmet medical need and whether there is an established development path with the potential for accelerated regulatory approval;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">extensive in-house research and development focused on identifying preclinical <font style="font-style: italic;">in vivo</font> activity and on- and off-target toxicity to determine the therapeutic index of a PBD-based ADC aimed at the antigen target; and</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">determination of the potential product candidate&#8217;s placement in the overall risk-reward profile of our portfolio.</div></td></tr></table><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Our target selection strategy aims to optimize the balance between risk and reward associated with clinical development and commercialization by covering both hematological and solid tumor indications and both clinically validated and novel cancer targets. Consistent with this strategy, we initially focused on clinically validated targets in hematological indications, as they represented the fastest route to achieve clinical proof of concept. Since then, we have expanded our focus to novel targets and in solid tumor indications.</div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 36pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">120<br></div></div></div>
<!--End Page 124-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 125-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 540pt;"><a name="nt10014672x1_drs_107-business_pg10"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="block-frill" style="width: 540pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: Arial, Helvetica, sans-serif; font-size: 9pt; font-weight: bold; margin-top: 6pt; text-align: center;">Confidential Treatment Requested by ADC Therapeutics SA Pursuant to 17 C.F.R. &#167; 200.83<br></div></div><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 36pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Since inception, we have evaluated more than 170 targets and are currently pursuing 11 ADC targets and 10&#160;XDC targets in our clinical and preclinical programs. The figure below shows the ADC targets for our current research and development programs.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 15.25pt; text-align: center;"><img style="height: 285px; width: 324px;" src="nt10014672x1_diagram4.jpg"><br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">&#8201;</div><div><div class="rule-partial" style="height: 0pt; width: 72pt; border-bottom: 1pt solid #000000; margin-bottom: 1pt; margin-right: auto; margin-left: 0pt; margin-top: 15.25pt;"> </div></div><div class="ftnote" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 3pt; margin-left: 0pt; text-align: left;">ADC targets for our current research and development programs, which include both clinically validated and novel cancer targets in both hematological and solid tumor targets. Unlabeled circles represent undisclosed targets.</div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 19.5pt; margin-left: 0pt; text-align: left;">Our Development Strategy</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Once we have selected a target antigen that we believe is suitable for ADC development, we undertake research and development to advance the ADC through clinical development. Our development strategy involves:</div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">selecting the clinical product candidate that represents the optimal combination of antibody, linker and PBD dimer. We compare multiple candidates with different combinations of the target-specific antibodies, linkers and linker positions, conjugation chemistry and the PBD warhead. Our objective is to nominate product candidates that exhibit the optimal balance between efficacy and safety in preclinical models.</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">advancing our product candidates through IND-enabling preclinical studies, focusing on rapid execution of required pharmacology studies, non-clinical toxicology and pharmacokinetic studies and cGMP manufacturing of Phase 1 clinical material. Our efficient approach to preclinical development is evidenced by the following:</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 40pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 6pt;">&#9675;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 6pt; text-align: left;"><font style="font-size: 10pt;">We have consistently completed IND-enabling preclinical studies in </font><font style="font-size: 10pt;">13 to 22</font><font style="font-size: 10pt;"> months following </font><font style="font-size: 10pt;">selection of the clinical product candidate.</font></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 40pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 6pt;">&#9675;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 6pt; text-align: left;"><font style="font-size: 10pt;">Since 2015, we have submitted five INDs and worked with our collaborators to submit two </font><font style="font-size: 10pt;">additional INDs</font><font style="font-size: 10pt;"> for our product candidates</font><font style="font-size: 10pt;">.</font></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">designing clinical trials to efficiently advance our product candidates towards regulatory submission and potential approval. Our clinical trials have the following features:</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 40pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 6pt;">&#9675;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 6pt; text-align: left;"><font style="font-size: 10pt;">Our Phase 1 clinical trials enroll patients with different cancers that express the target antigen on the </font><font style="font-size: 10pt;">tumor cells or other cells in the tumor microenvironment. This allows us to conduct small </font><font style="font-size: 10pt;">dose-expansion studies simultaneously with dose-escalation studies, enabling signal searching and dose </font><font style="font-size: 10pt;">selection prior to concluding Phase 1 clinical trials. We have successfully used this method in our </font><font style="font-size: 10pt;">Phase 1 clinical trials </font><font style="font-size: 10pt;">of</font><font style="font-size: 10pt;"> </font><font style="font-size: 10pt;">Lonca</font><font style="font-size: 10pt;"> and </font><font style="font-size: 10pt;">Cami</font><font style="font-size: 10pt;">, which resulted in the early identification of DLBCL and HL </font><font style="font-size: 10pt;">as the initial indications to pursue in our pivotal Phase 2 clinical trials, respectively.</font><font style="font-size: 10pt;"> </font></div></td></tr></table></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 36pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">121<br></div></div></div>
<!--End Page 125-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 126-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 540pt;"><a name="nt10014672x1_drs_107-business_pg11"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="block-frill" style="width: 540pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: Arial, Helvetica, sans-serif; font-size: 9pt; font-weight: bold; margin-top: 6pt; text-align: center;">Confidential Treatment Requested by ADC Therapeutics SA Pursuant to 17 C.F.R. &#167; 200.83<br></div></div><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 36pt;"><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6.75pt; margin-left: 40pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 6pt;">&#9675;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 6pt; text-align: left;"><font style="font-size: 10pt;">Our </font><font style="font-size: 10pt;">approach allows us to identify opportunities that may expand the market opportunity for our </font><font style="font-size: 10pt;">product candidates. For example, while we are pursuing DLBCL as the lead indication for </font><font style="font-size: 10pt;">Lonca</font><font style="font-size: 10pt;">, </font><font style="font-size: 10pt;">the data generated from the Phase 1 clinical trial </font><font style="font-size: 10pt;">has allowed</font><font style="font-size: 10pt;"> us to </font><font style="font-size: 10pt;">efficiently advance </font><font style="font-size: 10pt;">pivotal </font><font style="font-size: 10pt;">clinical trials</font><font style="font-size: 10pt;"> of </font><font style="font-size: 10pt;">Lonca</font><font style="font-size: 10pt;"> for the treatment of other indications, such as MCL and FL</font><font style="font-size: 10pt;">.</font></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 40pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 6pt;">&#9675;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 6pt; text-align: left;"><font style="font-size: 10pt;">Our Phase 1 clinical trials involve a wide range of dosing regimens. Because the PBD cross-links </font><font style="font-size: 10pt;">persist in tumor cells, it is important to find the dose levels and intervals that result in optimal tumor </font><font style="font-size: 10pt;">shrinkage while minimizing cumulative toxicities due to accumulation of the cross-links between doses. </font><font style="font-size: 10pt;">The wide range of dosing regimens in our Phase 1 clinical trials enables us to select the dose level to </font><font style="font-size: 10pt;">be used in pivotal clinical trials without the need for separate dose-range finding studies.</font></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 40pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 6pt;">&#9675;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 6pt; text-align: left;"><font style="font-size: 10pt;">Our clinical trials are designed to balance risk and reward by enrolling patients with both cancers </font><font style="font-size: 10pt;">that are difficult to treat and those that are more responsive to treatment.</font></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">encouraging close collaboration between our preclinical and clinical teams. For example, when our clinical team provides emerging pharmacokinetic data to our preclinical team, this strengthens the predictive value of our preclinical animal models when switching between indications, such as from hematological tumors to solid tumors with Cami. Our preclinical team also analyze biomarkers that correlate with patient outcomes taken by our clinical team to monitor their pharmacodynamics effects and to inform patient selection and dosing strategies.</div></td></tr></table><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 7pt; margin-left: 0pt; text-align: left;">Our Product Candidates</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">We are leveraging next-generation PBD technology, to which we have proprietary rights for our targets, to develop a diverse and balanced portfolio of product candidates. Our hematology franchise comprises three clinical-stage product candidates, including our lead product candidate, Lonca, for which we intend to submit a BLA for the treatment of relapsed or refractory DLBCL in the second half of 2020, and our second lead product candidate, Cami, which we are currently evaluating in a 100-patient pivotal Phase 2 clinical trial for the treatment of relapsed or refractory HL. Our solid tumor franchise comprises two clinical-stage product candidates and two preclinical product candidates.</div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 7pt; margin-left: 0pt; text-align: left;">Our Hematology Franchise</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Our hematology franchise comprises three clinical-stage product candidates for the treatment of various hematological malignancies, including lymphoma and leukemia. The figure below summarizes the clinical-stage product candidates in our hematology franchise.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 14.75pt; text-align: center;"><img style="height: 154px; width: 623px;" src="nt10014672x1_barchart2.jpg"><br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">&#8201;</div><div><div class="rule-partial" style="height: 0pt; width: 72pt; border-bottom: 1pt solid #000000; margin-bottom: 1pt; margin-right: auto; margin-left: 0pt; margin-top: 3.75pt;"> </div></div><div class="ftnote" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Anticipated milestones set forth in this chart and in this prospectus are subject to further future adjustment based on, among other factors, the impact of the COVID-19 pandemic. *We believe that our Phase 1/2 clinical trial of Lonca in combination with ibrutinib for the treatment of relapsed or refractory DLBCL and MCL, our Phase 2 clinical trial of Lonca for the treatment of relapsed or refractory FL and our Phase 2 clinical trial of Cami for the treatment of relapsed or refractory HL are pivotal clinical trials (i.e., a clinical trial intended to serve as the basis for BLA submission). Therefore, we believe that subsequent Phase 3 clinical trials will be confirmatory clinical trials. **We retain worldwide development and commercialization rights to Cami, subject to our collaboration and license agreement with Genmab. See &#8220;Recent Developments&#8221; and &#8220;&#8212;License and Collaboration Agreements&#8212;Genmab Collaboration and License Agreement.&#8221;</div><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 13.5pt; margin-left: 0pt; text-align: left;">The Lymphoma Disease Setting</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Lymphoma is a group of several closely related blood cancers that develop in the lymphatic system, an interconnected network of vessels and nodes that circulate a fluid called lymph. The lymph is rich in lymphocytes, a type of white blood cells that help the body fight off infections and other diseases. Lymphoma occurs when lymphocytes become cancerous and are typically classified into two groups: non-Hodgkin lymphoma and Hodgkin lymphoma.</div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 36pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">122<br></div></div></div>
<!--End Page 126-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 127-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 540pt;"><a name="nt10014672x1_drs_107-business_pg12"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="block-frill" style="width: 540pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: Arial, Helvetica, sans-serif; font-size: 9pt; font-weight: bold; margin-top: 6pt; text-align: center;">Confidential Treatment Requested by ADC Therapeutics SA Pursuant to 17 C.F.R. &#167; 200.83<br></div></div><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 36pt;"><div class="h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">Non-Hodgkin Lymphoma</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Non-Hodgkin lymphoma is a heterogeneous group of cancers of the lymphatic system that is characterized by the overproduction and accumulation of lymphocytes, either B lymphocytes (&#8220;B cells&#8221;) or T lymphocytes (&#8220;T cells&#8221;). These cancerous lymphocytes travel to and accumulate in other organs, including the lymph nodes, bone marrow and spleen, and disrupt these organs&#8217; normal functioning. In 2018, there were an estimated 126,500 total new cases of NHL in the United States, France, Germany, Italy, Spain and the United Kingdom (&#8220;Europe&#8221;). The various types of NHL are distinguished by the characteristics of the cancer cells associated with each disease type. The designations &#8220;indolent&#8221; (i.e., slow growing) and &#8220;aggressive&#8221; (i.e., fast growing) are often applied to types of NHL based on the diseases&#8217; progression and prognosis. The figure below shows the distribution of NHL in the United States and Europe.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 15.25pt; text-align: center;"><img style="height: 321px; width: 445px;" src="nt10014672x1_piechart1.jpg"><br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">&#8201;</div><div><div class="rule-partial" style="height: 0pt; width: 72pt; border-bottom: 1pt solid #000000; margin-bottom: 1pt; margin-right: auto; margin-left: 0pt; margin-top: 4.25pt;"> </div></div><div class="ftnote" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">The distribution of NHL in the United States and Europe. Figures represent the estimated total number of new cases of the respective diseases in 2018.</div><div class="h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 15.5pt; margin-left: 20pt; text-align: left;">Diffuse Large B-Cell Lymphoma</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Diffuse large B-cell lymphoma is an aggressive type of NHL that develops from the B cells in the lymphatic system. It is the most common type of NHL, with an estimated 58,500 total new cases of <font style="font-style: italic;">de novo</font> or transformed DLBCL in the United States and Europe in 2018. Approximately 30,000 new cases were in the United States and approximately 28,500 new cases were in Europe. If left untreated, DLBCL is rapidly fatal.</div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 36pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">123<br></div></div></div>
<!--End Page 127-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 128-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 540pt;"><a name="nt10014672x1_drs_107-business_pg13"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="block-frill" style="width: 540pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: Arial, Helvetica, sans-serif; font-size: 9pt; font-weight: bold; margin-top: 6pt; text-align: center;">Confidential Treatment Requested by ADC Therapeutics SA Pursuant to 17 C.F.R. &#167; 200.83<br></div></div><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 36pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Treatments for DLBCL can be divided into first-line, second-line and third-line and later therapies. The figure below shows the current DLBCL treatment landscape.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.25pt; text-align: center;"><img style="height: 275px; width: 610px;" src="nt10014672x1_diagram5x1.jpg"><br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">&#8201;</div><div><div class="rule-partial" style="height: 0pt; width: 72pt; border-bottom: 1pt solid #000000; margin-bottom: 1pt; margin-right: auto; margin-left: 0pt; margin-top: 15.25pt;"> </div></div><div class="ftnote" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 3pt; margin-left: 0pt; text-align: left;">Current DLBCL treatment landscape. Patient population data presented are for the United States, France, Germany, Italy, Spain and the United Kingdom. Not all relapsing patients will receive treatment. The blue box represents the initial potential addressable patient population for Lonca, if approved as a third-line therapy. The green boxes represent the potential addressable patient population for Lonca, if approved as a second-line therapy in combination with other therapies. If our clinical trials are successful, we also intend to develop Lonca as a first-line therapy for the treatment of DLBCL. The gray box represents the potential addressable patient population for Lonca, if approved as a first-line therapy.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">First-line therapy generally involves chemotherapy with a rituximab backbone, such as R-CHOP (i.e., a chemotherapy regimen consisting of cyclophosphamide, doxorubicin hydrochloride, vincristine sulfate and prednisone, plus rituximab). Although first-line therapy is effective in some patients, approximately 40% of patients require second-line therapy. The prognosis is generally poor for patients who do not respond to first-line therapy. For example, a study of two large randomized trials and two academic databases found that for patients who exhibit primary refractory disease, only 20% displayed a response and only 3% displayed a complete response to subsequent chemotherapy.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Second-line therapy depends on whether the patient is eligible for stem cell transplant. Eligibility is determined by a patient&#8217;s physical fitness and response to high-dose salvage chemotherapy. For the patients who are ineligible for stem cell transplant, second-line therapy involves chemotherapy or Monjuvi&#174; in combination with lenalidomide. Of the patients who require treatment in the second-line setting, approximately 50% will require third-line therapy.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Current third-line therapies include cellular therapies such as CAR-T, allogeneic stem cell transplant (i.e., transplant involving a healthy donor&#8217;s stem cells), Polivy&#174; in combination with bendamustine and a rituximab product, XPOVIO&#174;, Monjuvi&#174; in combination with lenalidomide and chemotherapy using small molecules. Given the serious and potentially fatal side effects and the fitness required to undergo CAR-T and allogeneic stem cell transplant, patients who are ineligible to receive autologous stem cell transplant as a second-line therapy will likely also be ineligible to receive CAR-T or allogeneic stem cell transplant. Other treatment options are limited in efficacy or associated with severe side effects. The limited treatment options and generally poor outcomes observed in patients with relapsed or refractory DLBCL highlights the urgent need for alternative treatment strategies. We are developing Lonca to address this unmet medical need.</div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 36pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">124<br></div></div></div>
<!--End Page 128-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 129-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 540pt;"><a name="nt10014672x1_drs_107-business_pg14"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="block-frill" style="width: 540pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: Arial, Helvetica, sans-serif; font-size: 9pt; font-weight: bold; margin-top: 6pt; text-align: center;">Confidential Treatment Requested by ADC Therapeutics SA Pursuant to 17 C.F.R. &#167; 200.83<br></div></div><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 36pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The table below presents information about the clinical trials of approved treatments and treatments in development for relapsed or refractory DLBCL:</div><table cellspacing="0" cellpadding="0" class="fintab" style="margin-top: 11.25pt; border-collapse: collapse; width: 468pt; margin-left: auto; margin-right: auto;"><tr class="header"><td style="width: 51.28%; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Patient Characteristics</div></td><td class="gutter" style="width: 1.8%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.8%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 23.21%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Polatuzumab vedotin (Polivy&#174;) <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">in combination with rituximab <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">plus bendamustine</div></td><td class="gutter" style="width: 1.8%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.8%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 18.3%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Tafasitamab (Monjuvi&#174;) <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">in combination with <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">lenalidomide</div></td></tr><tr><td style="width: 51.28%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Median Number of Prior Lines of Therapy<font style="padding-left: 4.84pt;"></font></div></td><td class="gutter" style="width: 1.8%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.8%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 23.21%; text-align: center; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">2</div></td><td class="gutter" style="width: 1.8%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.8%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 18.3%; text-align: center; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">2</div></td></tr><tr><td style="width: 51.28%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">SCT eligible<font style="padding-left: 3.37pt;"></font></div></td><td class="gutter" style="width: 1.8%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.8%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 23.21%; text-align: center; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">Not Included</div></td><td class="gutter" style="width: 1.8%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.8%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 18.3%; text-align: center; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">Not Included</div></td></tr><tr><td style="width: 51.28%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Primary refractory disease<font style="padding-left: 0.43pt;"></font></div></td><td class="gutter" style="width: 1.8%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.8%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 23.21%; text-align: center; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">*</div></td><td class="gutter" style="width: 1.8%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.8%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 18.3%; text-align: center; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">Not Included***</div></td></tr><tr><td style="width: 51.28%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Double-hit and triple-hit DLBCL<font style="padding-left: 3.06pt;"></font></div></td><td class="gutter" style="width: 1.8%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.8%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 23.21%; text-align: center; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">Not Included</div></td><td class="gutter" style="width: 1.8%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.8%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 18.3%; text-align: center; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">Not Included</div></td></tr><tr><td style="width: 51.28%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Transformed disease<font style="padding-left: 2.73pt;"></font></div></td><td class="gutter" style="width: 1.8%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.8%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 23.21%; text-align: center; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">Not Included</div></td><td class="gutter" style="width: 1.8%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.8%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 18.3%; text-align: center; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">*</div></td></tr><tr><td style="width: 51.28%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Bulky disease<font style="padding-left: 3.4pt;"></font></div></td><td class="gutter" style="width: 1.8%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.8%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 23.21%; text-align: center; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">Included</div></td><td class="gutter" style="width: 1.8%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.8%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 18.3%; text-align: center; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">*</div></td></tr><tr><td style="width: 51.28%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Prior treatment with CAR-T<font style="padding-left: 2.08pt;"></font></div></td><td class="gutter" style="width: 1.8%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.8%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 23.21%; text-align: center; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">*</div></td><td class="gutter" style="width: 1.8%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.8%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 18.3%; text-align: center; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">Not Included</div></td></tr><tr><td style="width: 51.28%; text-align: left; vertical-align: bottom; padding-top: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Prior treatment with SCT<font style="padding-left: 3.35pt;"></font></div></td><td class="gutter" style="width: 1.8%; border-bottom: none; font-size: 2pt; padding-top: 3pt;">&#8203;</td><td class="gutter" style="width: 1.8%; border-bottom: none; font-size: 2pt; padding-top: 3pt;">&#8203;</td><td style="width: 23.21%; text-align: center; vertical-align: bottom; padding-top: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">Included</div></td><td class="gutter" style="width: 1.8%; border-bottom: none; font-size: 2pt; padding-top: 3pt;">&#8203;</td><td class="gutter" style="width: 1.8%; border-bottom: none; font-size: 2pt; padding-top: 3pt;">&#8203;</td><td style="width: 18.3%; text-align: center; vertical-align: bottom; padding-top: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">Included</div></td></tr></table><table cellspacing="0" cellpadding="0" class="fintab" style="margin-top: 6pt; border-collapse: collapse; width: 468pt; margin-left: auto; margin-right: auto;"><tr class="header"><td style="width: 31.84%; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Best Overall Response (%)</div></td><td class="gutter" style="width: 1.18%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.18%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 9.69%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Polatuzumab <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">vedotin <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">(Polivy&#174;)**</div></td><td class="gutter" style="width: 1.18%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.18%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 10.39%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Tafasitamab <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">(Monjuvi&#174;)**</div></td><td class="gutter" style="width: 1.18%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.18%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 13.86%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Polatuzumab <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">vedotin <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">(Polivy&#174;) in <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">combination <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">with rituximab <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">plus bendamustine</div></td><td class="gutter" style="width: 1.18%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.18%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 13.2%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Tafasitamab <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">(Monjuvi&#174;) <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">in combination <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">with lenalidomide</div></td><td class="gutter" style="width: 1.18%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.18%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 9.25%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Selinexor <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">(XPOVIO&#174;)</div></td></tr><tr><td style="width: 31.84%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Complete response (CR)<font style="padding-left: 0.98pt;"></font></div></td><td class="gutter" style="width: 1.18%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.18%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.69%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 17.66pt; text-align: left;">15%</div></td><td class="gutter" style="width: 1.18%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.18%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.39%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 19.31pt; text-align: left;"><font style="padding-left: 5pt;">6%</font></div></td><td class="gutter" style="width: 1.18%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.18%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 13.86%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 27.44pt; text-align: left;">50%</div></td><td class="gutter" style="width: 1.18%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.18%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 13.2%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 25.89pt; text-align: left;">37%</div></td><td class="gutter" style="width: 1.18%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.18%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.25%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 16.65pt; text-align: left;">13%</div></td></tr><tr><td style="width: 31.84%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Partial response (PR)<font style="padding-left: 4.87pt;"></font></div></td><td class="gutter" style="width: 1.18%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.18%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 9.69%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 17.66pt; text-align: left;">37%</div></td><td class="gutter" style="width: 1.18%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.18%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 10.39%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 19.31pt; text-align: left;">20%</div></td><td class="gutter" style="width: 1.18%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.18%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 13.86%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 27.44pt; text-align: left;">13%</div></td><td class="gutter" style="width: 1.18%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.18%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 13.2%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 25.89pt; text-align: left;">18%</div></td><td class="gutter" style="width: 1.18%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.18%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 9.25%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 16.65pt; text-align: left;">16%</div></td></tr><tr><td style="width: 31.84%; text-align: left; vertical-align: bottom; padding-top: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Overall response rate (CR + PR)<font style="font-weight: normal; padding-left: 4.35pt;"></font></div></td><td class="gutter" style="width: 1.18%; border-bottom: none; font-size: 2pt; padding-top: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.18%; border-bottom: none; font-size: 2pt; padding-top: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.69%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 17.66pt; text-align: left;"><font style="padding-left: 0.39pt;">52%</font></div></td><td class="gutter" style="width: 1.18%; border-bottom: none; font-size: 2pt; padding-top: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.18%; border-bottom: none; font-size: 2pt; padding-top: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.39%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 19.31pt; text-align: left;"><font style="padding-left: 0.39pt;">26%</font></div></td><td class="gutter" style="width: 1.18%; border-bottom: none; font-size: 2pt; padding-top: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.18%; border-bottom: none; font-size: 2pt; padding-top: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 13.86%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 27.44pt; text-align: left;"><font style="padding-left: 0.39pt;">63%</font></div></td><td class="gutter" style="width: 1.18%; border-bottom: none; font-size: 2pt; padding-top: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.18%; border-bottom: none; font-size: 2pt; padding-top: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 13.2%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 25.89pt; text-align: left;"><font style="padding-left: 0.39pt;">55</font>%</div></td><td class="gutter" style="width: 1.18%; border-bottom: none; font-size: 2pt; padding-top: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.18%; border-bottom: none; font-size: 2pt; padding-top: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.25%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 16.65pt; text-align: left;"><font style="padding-left: 0.39pt;">29%</font></div></td></tr></table><table cellspacing="0" cellpadding="0" class="fintab" style="margin-top: 6pt; border-collapse: collapse; width: 468pt; margin-left: auto; margin-right: auto;"><tr class="header"><td style="width: 30.77%; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Common Grade &#8805;3<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">TEAEs reported in &#8805;5% of patients (%)</div></td><td class="gutter" style="width: 1.28%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.28%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 9.69%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Polatuzumab <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">vedotin <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">(Polivy&#174;)**</div></td><td class="gutter" style="width: 1.28%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.28%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 10.39%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Tafasitamab <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">(Monjuvi&#174;)**</div></td><td class="gutter" style="width: 1.28%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.28%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 13.86%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Polatuzumab <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">vedotin <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">(Polivy&#174;) in <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">combination <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">with rituximab <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">plus bendamustine</div></td><td class="gutter" style="width: 1.28%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.28%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 13.2%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Tafasitamab <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">(Monjuvi&#174;) <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">in combination <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">with lenalidomide</div></td><td class="gutter" style="width: 1.28%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.28%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 9.25%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Selinexor <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">(XPOVIO&#174;)</div></td></tr><tr><td style="width: 30.77%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Neutropenia<font style="padding-left: 2.07pt;"></font></div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.69%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 17.66pt; text-align: left;">40%</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.39%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 19.31pt; text-align: left;">17%</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 13.86%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 27.44pt; text-align: left;">42%</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 13.2%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 25.89pt; text-align: left;">49%</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.25%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 16.65pt; text-align: left;"><font style="padding-left: 10pt;">*</font></div></td></tr><tr><td style="width: 30.77%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Anemia<font style="padding-left: 4.84pt;"></font></div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 9.69%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 17.66pt; text-align: left;"><font style="padding-left: 0.37pt;">11%</font></div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 10.39%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 19.31pt; text-align: left;"><font style="padding-left: 5pt;">9%</font></div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 13.86%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 27.44pt; text-align: left;">24%</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 13.2%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 25.89pt; text-align: left;"><font style="padding-left: 5pt;">7%</font></div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 9.25%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 16.65pt; text-align: left;"><font style="padding-left: 10pt;">*</font></div></td></tr><tr><td style="width: 30.77%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Peripheral sensory neuropathy<font style="padding-left: 3.22pt;"></font></div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.69%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 17.66pt; text-align: left;"><font style="padding-left: 5pt;">9%</font></div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.39%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 19.31pt; text-align: left;">26%</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 13.86%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 27.44pt; text-align: left;"><font style="padding-left: 10pt;">*</font></div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 13.2%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 25.89pt; text-align: left;"><font style="padding-left: 10pt;">*</font></div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.25%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 16.65pt; text-align: left;"><font style="padding-left: 10pt;">*</font></div></td></tr><tr><td style="width: 30.77%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Thrombocytopenia<font style="padding-left: 0.4pt;"></font></div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 9.69%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 17.66pt; text-align: left;"><font style="padding-left: 10pt;">*</font></div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 10.39%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 19.31pt; text-align: left;"><font style="padding-left: 5pt;">6%</font></div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 13.86%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 27.44pt; text-align: left;">40%</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 13.2%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 25.89pt; text-align: left;">17%</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 9.25%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 16.65pt; text-align: left;"><font style="padding-left: 10pt;">*</font></div></td></tr><tr><td style="width: 30.77%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Lymphopenia<font style="padding-left: 1.5pt;"></font></div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.69%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 17.66pt; text-align: left;"><font style="padding-left: 10pt;">*</font></div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.39%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 19.31pt; text-align: left;"><font style="padding-left: 10pt;">*</font></div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 13.86%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 27.44pt; text-align: left;">13%</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 13.2%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 25.89pt; text-align: left;"><font style="padding-left: 10pt;">*</font></div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.25%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 16.65pt; text-align: left;"><font style="padding-left: 10pt;">*</font></div></td></tr><tr><td style="width: 30.77%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Febrile neutropenia<font style="padding-left: 2.64pt;"></font></div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 9.69%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 17.66pt; text-align: left;"><font style="padding-left: 10pt;">*</font></div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 10.39%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 19.31pt; text-align: left;"><font style="padding-left: 10pt;">*</font></div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 13.86%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 27.44pt; text-align: left;"><font style="padding-left: 0.37pt;">11%</font></div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 13.2%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 25.89pt; text-align: left;">12%</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 9.25%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 16.65pt; text-align: left;"><font style="padding-left: 10pt;">*</font></div></td></tr><tr><td style="width: 30.77%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Pneumonia<font style="padding-left: 1.51pt;"></font></div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.69%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 17.66pt; text-align: left;"><font style="padding-left: 10pt;">*</font></div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.39%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 19.31pt; text-align: left;"><font style="padding-left: 10pt;">*</font></div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 13.86%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 27.44pt; text-align: left;">16%</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 13.2%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 25.89pt; text-align: left;"><font style="padding-left: 5pt;">7</font>%</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.25%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 16.65pt; text-align: left;"><font style="padding-left: 10pt;">*</font></div></td></tr><tr><td style="width: 30.77%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Fatigue<font style="padding-left: 1.51pt;"></font></div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 9.69%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 17.66pt; text-align: left;"><font style="padding-left: 10pt;">*</font></div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 10.39%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 19.31pt; text-align: left;"><font style="padding-left: 10pt;">*</font></div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 13.86%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 27.44pt; text-align: left;"><font style="padding-left: 10pt;">*</font></div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 13.2%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 25.89pt; text-align: left;"><font style="padding-left: 10pt;">*</font></div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 9.25%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 16.65pt; text-align: left;">15%</div></td></tr><tr><td style="width: 30.77%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Nausea<font style="padding-left: 2.07pt;"></font></div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.69%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 17.66pt; text-align: left;"><font style="padding-left: 10pt;">*</font></div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.39%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 19.31pt; text-align: left;"><font style="padding-left: 10pt;">*</font></div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 13.86%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 27.44pt; text-align: left;"><font style="padding-left: 10pt;">*</font></div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 13.2%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 25.89pt; text-align: left;"><font style="padding-left: 10pt;">*</font></div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.25%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 16.65pt; text-align: left;"><font style="padding-left: 5pt;">6%</font></div></td></tr><tr><td style="width: 30.77%; text-align: left; vertical-align: bottom; padding-top: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 10pt; text-indent: -10pt; text-align: left;">TEAEs leading to treatment discontinuation<font style="font-weight: normal; padding-left: 0.39pt;"></font></div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt;">&#8203;</td><td style="width: 9.69%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 17.66pt; text-align: left;"><font style="padding-left: 10pt;">*</font></div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt;">&#8203;</td><td style="width: 10.39%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 19.31pt; text-align: left;"><font style="padding-left: 10pt;">*</font></div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt;">&#8203;</td><td style="width: 13.86%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 27.44pt; text-align: left;">31%</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt;">&#8203;</td><td style="width: 13.2%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 25.89pt; text-align: left;">15%</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt;">&#8203;</td><td style="width: 9.25%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 16.65pt; text-align: left;">17%</div></td></tr></table><div><div class="rule-partial" style="height: 0pt; width: 72pt; border-bottom: 1pt solid #000000; margin-bottom: 1pt; margin-right: auto; margin-left: 0pt; margin-top: 8.25pt;"> </div></div><div class="ftnote" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 3pt; margin-left: 0pt; text-align: left;">Information about the competitive landscape for the treatment of relapsed or refractory DLBCL. Response rate data, duration of response data and TEAEs data are derived from different clinical trials conducted at different points in time: polatuzumab vedotin (Polivy&#174;) from NCT01290549; tafasitamab (Monjuvi&#174;) from NCT01685008; polatuzumab vedotin (Polivy&#174;) in combination with rituximab plus bendamustine from NCT02257567, based on the prescribing information for such product; tafasitamab (Monjuvi&#174;) in combination with lenalidomide from NCT02399085, based on the prescribing information for such product; selinexor (XPOVIO&#174;) from NCT02227251, based on the prescribing information for such product. Clinical trials vary in clinical trial design and patient inclusion criteria. Head-to-head clinical trials of these treatment options have not been conducted. *Not reported. **Treatments that have not been approved. ***The clinical trial excluded patients with primary refractory disease, defined as patients exhibiting no response to initial therapy. </div><div class="h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 12pt; margin-left: 20pt; text-align: left;">Follicular Lymphoma</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Follicular lymphoma is an indolent type of NHL that develops from B cells in the lymphatic system. It is the second most common type of NHL, with an estimated 25,500 total new cases in the United States and Europe in 2018. Approximately 13,000 new cases were in the United States and approximately 12,500 new cases were in Europe. FL is a highly variable disease, with uncertain prognosis and varying periods of progression.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Common therapies for FL include radiotherapy, R-CHOP and R-CVP (i.e., a chemotherapy regimen consisting of cyclophosphamide, vincristine sulfate and prednisone, plus rituximab). Although first-line therapy is </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 36pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">125<br></div></div></div>
<!--End Page 129-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 130-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 540pt;"><a name="nt10014672x1_drs_107-business_pg15"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="block-frill" style="width: 540pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: Arial, Helvetica, sans-serif; font-size: 9pt; font-weight: bold; margin-top: 6pt; text-align: center;">Confidential Treatment Requested by ADC Therapeutics SA Pursuant to 17 C.F.R. &#167; 200.83<br></div></div><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 36pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">effective in some patients, approximately 55% of patients require second-line therapy. These patients have limited treatment options. Generally, intensive chemotherapy regimens are not acceptable due to their toxicity, but less intensive chemotherapy regimens are not effective in such patients. Of the patients who require treatment in the second-line setting, approximately 65% will require third-line therapy. The limited treatment options and generally poor outcomes observed in patients with relapsed or refractory FL highlights the urgent need for alternative treatment strategies. We are developing Lonca to address this unmet medical need.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Treatments for FL can be divided into first-line and second-line and later therapies. The figure below shows the current FL treatment landscape. </div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 14.75pt; text-align: center;"><img style="height: 334px; width: 618px;" src="nt10014672x1_diagram12.jpg"><br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">&#8201; <br></div><div><div class="rule-partial" style="height: 0pt; width: 72pt; border-bottom: 1pt solid #000000; margin-bottom: 1pt; margin-right: auto; margin-left: 0pt; margin-top: 12.75pt;"> </div></div><div class="ftnote" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 3pt; margin-left: 0pt; text-align: left;">Current FL treatment landscape. Patient population data presented are for the United States, France, Germany, Italy, Spain and the United Kingdom. Not all relapsing patients will receive treatment.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 7pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The table below presents information about the approved treatments for relapsed or refractory FL: </div><table cellspacing="0" cellpadding="0" class="fintab" style="margin-top: 11.25pt; border-collapse: collapse; width: 468pt; margin-left: auto; margin-right: auto;"><tr class="header"><td style="width: 31.41%; text-align: left; vertical-align: bottom; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 0.71%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 0.71%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 9.06%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Duvelisib<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">(Copiktra&#174;)</div></td><td class="gutter" style="width: 0.71%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 0.71%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 12.82%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Copanlisib<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">(Aliqopa&#174;)</div></td><td class="gutter" style="width: 0.71%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 0.71%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 12.82%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Idelalisib <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">(Zydelig&#174;)</div></td><td class="gutter" style="width: 0.71%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 0.71%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 12.91%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Obinutuzumab <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">(Gazyva&#174;) in<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">combination with<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">bendamustine</div></td><td class="gutter" style="width: 0.71%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 0.71%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 13.89%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Lenalidomide<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">(Revlimid&#174;) in<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">combination<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">with rituximab</div></td></tr><tr><td style="width: 31.41%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Complete response (CR)<font style="padding-left: 3.98pt;"></font></div></td><td class="gutter" style="width: 0.71%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.71%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.06%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 12.45pt; text-align: left;"><font style="padding-left: 5pt;">1.2%</font></div></td><td class="gutter" style="width: 0.71%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.71%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 12.82%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 21.25pt; text-align: left;">14.4%</div></td><td class="gutter" style="width: 0.71%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.71%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 12.82%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 21.25pt; text-align: left;"><font style="padding-left: 5pt;">8.3%</font></div></td><td class="gutter" style="width: 0.71%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.71%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 12.91%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 21.47pt; text-align: left;">15.5%</div></td><td class="gutter" style="width: 0.71%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.71%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 13.89%; text-align: center; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">35%-46%</div></td></tr><tr><td style="width: 31.41%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Partial response (PR)<font style="padding-left: 2.87pt;"></font></div></td><td class="gutter" style="width: 0.71%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.71%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 9.06%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 12.45pt; text-align: left;">41.0%</div></td><td class="gutter" style="width: 0.71%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.71%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 12.82%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 21.25pt; text-align: left;">44.2%</div></td><td class="gutter" style="width: 0.71%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.71%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 12.82%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 21.25pt; text-align: left;">45.8%</div></td><td class="gutter" style="width: 0.71%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.71%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 12.91%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 21.47pt; text-align: left;">63.2%</div></td><td class="gutter" style="width: 0.71%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.71%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 13.89%; text-align: center; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">28%-46%</div></td></tr><tr><td style="width: 31.41%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Overall response rate (CR + PR)<font style="font-weight: normal; padding-left: 2.35pt;"></font></div></td><td class="gutter" style="width: 0.71%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.71%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.06%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 12.45pt; text-align: left;"><font style="padding-left: 0.39pt;">42.2</font><font style="padding-left: 0.39pt;">%</font></div></td><td class="gutter" style="width: 0.71%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.71%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 12.82%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 21.25pt; text-align: left;"><font style="padding-left: 0.39pt;">58.7</font><font style="padding-left: 0.39pt;">%</font></div></td><td class="gutter" style="width: 0.71%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.71%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 12.82%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 21.25pt; text-align: left;"><font style="padding-left: 0.39pt;">54.2</font><font style="padding-left: 0.39pt;">%</font></div></td><td class="gutter" style="width: 0.71%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.71%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 12.91%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 21.47pt; text-align: left;"><font style="padding-left: 0.39pt;">78.</font>7<font style="padding-left: 0.39pt;">%</font></div></td><td class="gutter" style="width: 0.71%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.71%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 13.89%; text-align: center; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">74%-80%</div></td></tr><tr><td style="width: 31.41%; text-align: left; vertical-align: bottom; padding-top: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Median duration of response<font style="font-weight: normal; padding-left: 4.45pt;"></font></div></td><td class="gutter" style="width: 0.71%; border-bottom: none; font-size: 2pt; padding-top: 3pt;">&#8203;</td><td class="gutter" style="width: 0.71%; border-bottom: none; font-size: 2pt; padding-top: 3pt;">&#8203;</td><td style="width: 9.06%; text-align: center; vertical-align: bottom; padding-top: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">*</div></td><td class="gutter" style="width: 0.71%; border-bottom: none; font-size: 2pt; padding-top: 3pt;">&#8203;</td><td class="gutter" style="width: 0.71%; border-bottom: none; font-size: 2pt; padding-top: 3pt;">&#8203;</td><td style="width: 12.82%; text-align: center; vertical-align: bottom; padding-top: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">12.2 months</div></td><td class="gutter" style="width: 0.71%; border-bottom: none; font-size: 2pt; padding-top: 3pt;">&#8203;</td><td class="gutter" style="width: 0.71%; border-bottom: none; font-size: 2pt; padding-top: 3pt;">&#8203;</td><td style="width: 12.82%; text-align: center; vertical-align: bottom; padding-top: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">not reached</div></td><td class="gutter" style="width: 0.71%; border-bottom: none; font-size: 2pt; padding-top: 3pt;">&#8203;</td><td class="gutter" style="width: 0.71%; border-bottom: none; font-size: 2pt; padding-top: 3pt;">&#8203;</td><td style="width: 12.91%; text-align: center; vertical-align: bottom; padding-top: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">not reached</div></td><td class="gutter" style="width: 0.71%; border-bottom: none; font-size: 2pt; padding-top: 3pt;">&#8203;</td><td class="gutter" style="width: 0.71%; border-bottom: none; font-size: 2pt; padding-top: 3pt;">&#8203;</td><td style="width: 13.89%; text-align: center; vertical-align: bottom; padding-top: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">36.6 months - <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">not reached</div></td></tr></table><div><div class="rule-partial" style="height: 0pt; width: 72pt; border-bottom: 1pt solid #000000; margin-bottom: 1pt; margin-right: auto; margin-left: 0pt; margin-top: 10.75pt;"> </div></div><div class="ftnote" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 3pt; margin-left: 0pt; text-align: left;">Information about the competitive landscape for the treatment of relapsed or refractory FL. Response rate data and duration of response data are derived from different clinical trials conducted at different points in time: duvelisib (Copiktra&#174;) (NCT02204982); copanlisib (Aliqopa&#174;) (NCT01660451); idelalisib (Zydelig&#174;) (NCT01282424); obinutuzumab (Gazyva&#174;) in combination with bendamustine (NCT01059630); lenalidomide (Revlimid&#174;) in combination with rituximab (NCT01938001 and NCT01996865). Clinical trials vary in clinical trial design and patient inclusion criteria. Head-to-head clinical trials of these treatment options have not been conducted. &#8722;*Not reported. </div><div class="h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 13pt; margin-left: 20pt; text-align: left;">Mantle Cell Lymphoma</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Mantle cell lymphoma is an aggressive type of NHL that develops from B cells in the mantle zone of the lymphatic system. It is a rare type of NHL, with an estimated 6,000 total new cases in the United States and Europe in 2018. Approximately 3,000 new cases were in the United States and approximately 3,000 new cases were in Europe. If left untreated, MCL is rapidly fatal.</div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 36pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">126<br></div></div></div>
<!--End Page 130-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 131-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 540pt;"><a name="nt10014672x1_drs_107-business_pg16"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="block-frill" style="width: 540pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: Arial, Helvetica, sans-serif; font-size: 9pt; font-weight: bold; margin-top: 6pt; text-align: center;">Confidential Treatment Requested by ADC Therapeutics SA Pursuant to 17 C.F.R. &#167; 200.83<br></div></div><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 36pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Common therapies for MCL include R-CHOP or R-DHAP (i.e., a chemotherapy regimen consisting of dexamethasone, cytarabine and cisplatin, plus rituximab). Although first-line therapy is effective in some patients, approximately 70% of patients require second-line therapy. These patients have limited treatment options. The efficacy of current second-line therapies is limited, with the majority of patients failing to achieve a durable response. Of the patients who require treatment in the second-line setting, approximately 65% will require third-line therapy. The limited treatment options and generally poor outcomes observed in patients with relapsed or refractory MCL highlights the urgent need for alternative treatment strategies. We are developing Lonca to address this unmet medical need.</div><div class="h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 12pt; margin-left: 20pt; text-align: left;">T-Cell Lymphoma</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">T-cell lymphoma is a group of aggressive NHLs that develops from the T cells of the lymphatic system. They are a rare type of NHL, with an estimated 11,000 total new cases in the United States and Europe in 2018. T-cell lymphoma comprises a diverse group of diseases with differing prognoses.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Common therapies for T-cell lymphoma include chemotherapy, such as CHOP (i.e., a chemotherapy regimen consisting of cyclophosphamide, doxorubicin hydrochloride, vincristine sulfate and prednisone) and CHOP-like regimens alone or in combination with other approved chemotherapeutics. Although first-line therapy is effective in some patients, approximately 70% of patients require second-line therapy. These patients have limited treatment options. The efficacy of current second-line therapies is limited, with the majority of patients failing to achieve a durable response. The National Comprehensive Cancer Network guidelines suggest that relapsed or refectory patients enroll in clinical trials, rather than receive treatment via standard therapy. In our experience, investigators have repeatedly stressed that novel therapies that are able to achieve an ORR above 40% are highly relevant and warrant further clinical development. The limited treatment options and generally poor outcomes observed in patients with relapsed or refractory T-cell lymphoma highlights the urgent need for alternative treatment strategies. Therefore, there is a significant unmet medical need for patients with relapsed or refractory T-cell lymphoma. We are developing Cami to address this unmet medical need.</div><div class="h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 12pt; margin-left: 20pt; text-align: left;">Hodgkin Lymphoma</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Hodgkin lymphoma is a rare but highly curable type of neoplasm of the lymph nodes. These lymphoid malignancies travel to other organs, such as the liver, lungs and bone marrow, and disrupt these organs&#8217; normal functioning. In 2015, there were an estimated 16,500 total new cases of HL in the United States and Europe. Approximately 8,500 new cases were in the United States and approximately 8,000 new cases were in Europe. Patients diagnosed with HL generally have good prognoses, with a five-year overall survival rate of approximately 87%.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Treatments for HL can be divided into first-line, second-line and third-line and later therapies. The figure below shows the current HL treatment landscape.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 14.75pt; text-align: center;"><img style="height: 251px; width: 560px;" src="nt10014672x1_diagram6.jpg"><br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">&#8201;</div><div><div class="rule-partial" style="height: 0pt; width: 72pt; border-bottom: 1pt solid #000000; margin-bottom: 1pt; margin-right: auto; margin-left: 0pt; margin-top: 10.25pt;"> </div></div><div class="ftnote" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 3pt; margin-left: 0pt; text-align: left;">Current HL treatment landscape. Patient population data presented are for the United States, France, Germany, Italy, Spain and the United Kingdom. Not all relapsing patients will receive treatment. The blue box represents the initial potential addressable patient population for Cami, if approved as a third-line therapy. The green boxes represent the potential addressable patient population for Cami, if approved as a second-line therapy in combination with other therapies.</div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 36pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">127<br></div></div></div>
<!--End Page 131-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 132-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 540pt;"><a name="nt10014672x1_drs_107-business_pg17"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="block-frill" style="width: 540pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: Arial, Helvetica, sans-serif; font-size: 9pt; font-weight: bold; margin-top: 6pt; text-align: center;">Confidential Treatment Requested by ADC Therapeutics SA Pursuant to 17 C.F.R. &#167; 200.83<br></div></div><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 36pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">First-line therapy generally involves ABVD (i.e., a chemotherapy regimen consisting of doxorubicin, bleomycin (which may be substituted by Adcetris&#174;, a CD30-directed ADC), vinblastine and dacarbazine), which may be combined with radiotherapy. Although first-line therapy is effective in most patients, approximately 15% of patients require second-line therapy.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Second-line therapy depends on whether the patient is eligible for stem cell transplant. Eligibility is determined by the patient&#8217;s physical fitness and response to salvage chemotherapy regimens not received in first-line therapy. For the patients who are ineligible for stem cell transplant, second-line therapy involves a chemotherapy regimen not already administered or Adcetris&#174;, with or without bendamustine. Of the patients who require treatment in the second-line setting, approximately 50% will require third-line therapy.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Current third-line therapies include an alternative chemotherapy regimen not previously used or immunotherapy with Adcetris&#174;. Although Adcetris&#174; and checkpoint inhibitors have achieved relatively high ORRs compared to traditional chemotherapy regimens, these therapies are moving into earlier lines of treatment. Other third-line chemotherapy regimens involving bendamustine, everolimus or lenalidomide have only shown limited efficacy. Other therapies include allogeneic stem cell transplantation. However, given that stem cell transplant requires patients to be physically fit, the proportion of eligible patients is small. The limited treatment options and generally poor outcomes observed in patients with relapsed or refractory HL highlights the urgent need for alternative treatment strategies. We are developing Cami to address this unmet medical need.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 8pt; margin-left: 0pt; text-align: left;">The Leukemia Disease Setting</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Leukemia is a group of several closely related blood cancers that develop in the bone marrow. Once the marrow cell undergoes a leukemic change, the leukemia cells may grow and survive better than healthy cells. Over time, the leukemia cells crowd out or suppress the development of healthy cells. Leukemia is classified into four groups: acute lymphoblastic leukemia, chronic lymphocytic leukemia, acute myeloid leukemia and chronic myeloid leukemia.</div><div class="h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 12pt; margin-left: 0pt; text-align: left;">Acute Lymphoblastic Leukemia</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Acute lymphoblastic leukemia is an aggressive form of blood cancer, characterized by the overproduction and accumulation of cancerous, immature white blood cells, known as leukemic blasts. These leukemic blasts are overproduced in the bone marrow affecting the synthesis of normal blood cells, causing a decrease in red blood cells, platelets and normal white blood cells. In 2016, there were an estimated 9,000 total new cases of ALL in the United States and Europe. ALL develops rapidly throughout the bone marrow and peripheral blood within a few days or a few weeks of the first symptoms. If left untreated, ALL is rapidly fatal.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Common therapies for ALL include multidrug chemotherapy regimens using available generic chemotherapeutics. Although first-line therapy is effective in some patients, approximately 30%-40% of patients require second-line therapy. For these patients, treatment options include targeted therapies such as tisagenlecleucel (Kymriah&#174;), a CD19-directed genetically modified autologous T cell immunotherapy, blinatumomab (Blincyto&#174;), a bispecific T cell engager targeting CD19, and Besponsa&#174;, a CD22-directed ADC. However, there remains a significant unmet medical need for patients who exhibit relapsed or refractory ALL due to the heterogeneity of and the existence of different subgroups within ALL. We are developing ADCT-602 to address this unmet medical need.</div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">Loncastuximab Tesirine: PBD-Based ADC Targeting CD19</div><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 7pt; margin-left: 0pt; text-align: left;">Overview</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Our lead product candidate, loncastuximab tesirine, or Lonca, is an ADC targeting CD19-expressing cancers. We are developing Lonca for the treatment of relapsed or refractory NHL, both when used as a monotherapy and when used in combination with other therapies. The following summary provides key information about Lonca:</div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">We retain exclusive worldwide development and commercialization rights to Lonca. We intend to commercialize Lonca in the United States through our own infrastructure and may selectively pursue strategic collaborations and licensing opportunities in other geographies.</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">We intend to submit a BLA to the FDA for Lonca for the treatment of relapsed or refractory DLBCL in the second half of 2020. Concurrently, we intend to commence a confirmatory clinical trial of Lonca in combination with rituximab, which, if successful, we believe will support an sBLA for Lonca to be used as a second-line therapy for the treatment of relapsed or refractory DLBCL in transplant-ineligible patients.</div></td></tr></table></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 36pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">128<br></div></div></div>
<!--End Page 132-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 133-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 540pt;"><a name="nt10014672x1_drs_107-business_pg18"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="block-frill" style="width: 540pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: Arial, Helvetica, sans-serif; font-size: 9pt; font-weight: bold; margin-top: 6pt; text-align: center;">Confidential Treatment Requested by ADC Therapeutics SA Pursuant to 17 C.F.R. &#167; 200.83<br></div></div><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 36pt;"><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6.75pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">We completed enrollment of a 145-patient pivotal Phase 2 clinical trial for the treatment of relapsed or refractory DLBCL.</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 40pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 6pt;">&#9675;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 6pt; text-align: left;"><font style="font-size: 10pt;">As of </font><font style="font-size: 10pt;">April 2020</font><font style="font-size: 10pt;">, we observed a </font><font style="font-size: 10pt;">48.3</font><font style="font-size: 10pt;">% </font><font style="font-size: 10pt;">ORR </font><font style="font-size: 10pt;">and a 24.1% CRR </font><font style="font-size: 10pt;">in 145 heavily pre-treated </font><font style="font-size: 10pt;">patients who </font><font style="font-size: 10pt;">had</font><font style="font-size: 10pt;"> received a median of three prior lines of therapy. </font><font style="font-size: 10pt;">The median duration of </font><font style="font-size: 10pt;">response was 10.25 months.</font><font style="font-size: 10pt;"> </font></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 40pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 6pt;">&#9675;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 6pt; text-align: left;"><font style="font-size: 10pt;">Lonca&#8217;s significant clinical activity was observed across a broad patient population in this clinical </font><font style="font-size: 10pt;">trial, including patients with primary refractory disease, bulky disease, double-hit or triple-hit </font><font style="font-size: 10pt;">disease and transformed disease, </font><font style="font-size: 10pt;">as well as </font><font style="font-size: 10pt;">elderly patients and patients who did not respond to</font><font style="font-size: 10pt;"> </font><font style="font-size: 10pt;">any</font><font style="font-size: 10pt;"> prior therapy.</font></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">Lonca is also being evaluated in a Phase 1/2 clinical trial in combination with ibrutinib for the treatment of relapsed or refractory DLBCL and MCL.</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 40pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 6pt;">&#9675;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 6pt; text-align: left;"><font style="font-size: 10pt;">As of </font><font style="font-size: 10pt;">April&#160;</font><font style="font-size: 10pt;">6</font><font style="font-size: 10pt;">, 2020</font><font style="font-size: 10pt;">, at the dose </font><font style="font-size: 10pt;">being</font><font style="font-size: 10pt;"> used in the pivotal Phase&#160;2 part of the clinical trial</font><font style="font-size: 10pt;">, we </font><font style="font-size: 10pt;">observed a </font><font style="font-size: 10pt;">75.0</font><font style="font-size: 10pt;">% ORR</font><font style="font-size: 10pt;"> and a </font><font style="font-size: 10pt;">58.3% CRR</font><font style="font-size: 10pt;"> in heavily pre-treated evaluable DLBCL patients who </font><font style="font-size: 10pt;">had</font><font style="font-size: 10pt;"> received a median of </font><font style="font-size: 10pt;">two</font><font style="font-size: 10pt;"> prior lines of therapy.</font></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">We also intend to commence an additional pivotal Phase 2 clinical trial of Lonca for the treatment of FL in the first half of 2021.</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 40pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 6pt;">&#9675;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 6pt; text-align: left;"><font style="font-size: 10pt;">In the Phase 1 clinical trial of Lonca for the treatment of relapsed or refractory </font><font style="font-size: 10pt;">B-NHL</font><font style="font-size: 10pt;">, we </font><font style="font-size: 10pt;">observed a 78.6% ORR </font><font style="font-size: 10pt;">and a 64.3% CRR </font><font style="font-size: 10pt;">in heavily pre-treated patients with relapsed or </font><font style="font-size: 10pt;">refractory FL who </font><font style="font-size: 10pt;">had</font><font style="font-size: 10pt;"> received a median of four prior lines of therapy.</font><font style="font-size: 10pt;"> </font></div></td></tr></table><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Of the estimated 58,500 total patients diagnosed with DLBCL each year in the United States and Europe, approximately 40% will exhibit relapsed or refractory DLBCL. We believe that the treatment of relapsed or refractory DLBCL remains an area of high unmet medical need. We expect that we would launch Lonca, if approved, as a third-line therapy for the treatment of DLBCL. Despite recent entrants, there is currently no leading therapeutic option for this patient population. Accordingly, we estimate that the initial addressable patient population is approximately 10,500 patients per year in the United States and Europe. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">We are also conducting a Phase 1/2 clinical trial of Lonca in combination with ibrutinib and intend to commence a confirmatory clinical trial of Lonca in combination with rituximab, which, if successful, may allow Lonca to be used as a second-line therapy for the treatment of relapsed or refractory DLBCL, thereby increasing the addressable patient population to approximately 22,000 patients per year in the United States and Europe. If our clinical trials are successful, we also intend to develop Lonca as a first-line therapy for the treatment of DLBCL.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">In addition to DLBCL, we are evaluating Lonca for the treatment of relapsed or refractory FL and MCL both as a monotherapy and in combination with other therapies. Of the estimated 25,500 total patients diagnosed with FL each year in the United States and Europe, approximately 55% will exhibit relapsed or refractory FL. Of the estimated 6,000 total patients who are diagnosed with MCL each year in the United States and Europe, approximately 70% will exhibit relapsed or refractory MCL. We believe that the treatment of relapsed or refractory FL and MCL remain areas of high unmet medical need. We intend to develop Lonca as a therapeutic option for relapsed or refractory MCL and FL to address the high unmet medical needs of these patient populations, including initiating a pivotal Phase 2 clinical trial of Lonca for the treatment of FL.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">We believe that the commercial potential of Lonca, if approved, is supported by the following key attributes observed to date:</div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">Favorable clinical activity across a broad patient population, including transplant eligible and ineligible patients, patients who have not responded to first-line therapy or any prior therapy and patients with bulky disease, double-hit and triple-hit disease and transformed disease;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">Significant single-agent clinical activity while maintaining a manageable tolerability profile with a low incidence of febrile neutropenia;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">Activity in heavily pretreated patients, including those who had received prior CD19 therapies, including CAR-T, and SCT;</div></td></tr></table></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 36pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">129<br></div></div></div>
<!--End Page 133-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 134-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 540pt;"><a name="nt10014672x1_drs_107-business_pg19"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="block-frill" style="width: 540pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: Arial, Helvetica, sans-serif; font-size: 9pt; font-weight: bold; margin-top: 6pt; text-align: center;">Confidential Treatment Requested by ADC Therapeutics SA Pursuant to 17 C.F.R. &#167; 200.83<br></div></div><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 36pt;"><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6.75pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">Promising clinical activity observed in our combination clinical trial with ibrutinib, which we believe demonstrates the opportunity to advance Lonca into earlier lines of therapy in combination with other therapies such as ibrutinib and rituximab; and</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">Convenient 30-minute intravenous infusions once every three weeks in the out-patient setting.</div></td></tr></table><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 17pt; margin-left: 0pt; text-align: left;">Commercialization Plan</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">If approved, we intend to commercialize Lonca in the United States through our own infrastructure and may selectively pursue strategic collaborations and licensing opportunities in other geographies. Our U.S. commercial organization buildout and launch-readiness activities are ongoing to enable commercialization of Lonca promptly following the receipt of accelerated approval, and include:</div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">Our successful recruitment of an experienced Chief Commercial Officer and senior commercial leadership team, including a Vice President of Sales, a Vice President of Marketing and a Vice President of Market Access, with broader organizational recruitment underway;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">Our successful recruitment of a Vice President of Medical Affairs, with broader organizational recruitment underway, including field-based medical science liaisons;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">Investing resources to assess the competitive landscape, supporting our differentiated profile and accelerating our launch readiness efforts;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">Increased scientific interactions with Key Opinion Leaders; and</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">Our plans to build a highly talented and efficient U.S. customer-facing organization of more than 65&#160;cross-functional employees, which we believe has the potential to capture more than 80% of the DLBCL commercial opportunity.</div></td></tr></table><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 17pt; margin-left: 0pt; text-align: left;">Structure and Mechanism of Action</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Lonca is composed of a humanized monoclonal antibody (RB4v1.2) directed against human CD19 and conjugated through a cathepsin-cleavable linker to SG3199, a PBD dimer cytotoxin. Once bound to a CD19-expressing cell, it is designed to be internalized by the cell, following which the warhead is released. The warhead is designed to bind irreversibly to DNA to create highly potent interstrand cross-links that block DNA strand separation, thus disrupting essential DNA metabolic processes such as replication and ultimately resulting in cell death. The figure below shows the structure of Lonca.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 14.75pt; text-align: center;"><img style="height: 140px; width: 264px;" src="nt10014672x1_diagram7.jpg"><br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">&#8201;</div><div><div class="rule-partial" style="height: 0pt; width: 72pt; border-bottom: 1pt solid #000000; margin-bottom: 1pt; margin-right: auto; margin-left: 0pt; margin-top: 14.75pt;"> </div></div><div class="ftnote" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 4pt; margin-left: 0pt; text-align: left;">Visual representation of Lonca.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The human CD19 antigen is involved in the recognition, binding and adhesion processes of cells, mediating direct interactions between surfaces of different cell types and pathogen recognition. CD19 is expressed only on B cells (i.e., a type of white blood cell that plays a significant role in protecting the body from infection by producing antibodies) throughout all stages of B cell development and differentiation. Its expression is maintained in high levels in hematologic B cell malignancies, including NHL and certain types of leukemia. For example, CD19 is expressed in activated B cells and memory B cells in DLBCL, in na&#239;ve B cells in MCL, and in memory B cells in FL.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">We believe that CD19 is an attractive target for ADCs developed to treat hematological malignancies for the following reasons:</div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">CD19 is a clinically validated target for the treatment of B cell malignancies.</div></td></tr></table></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 36pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">130<br></div></div></div>
<!--End Page 134-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 135-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 540pt;"><a name="nt10014672x1_drs_107-business_pg20"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="block-frill" style="width: 540pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: Arial, Helvetica, sans-serif; font-size: 9pt; font-weight: bold; margin-top: 6pt; text-align: center;">Confidential Treatment Requested by ADC Therapeutics SA Pursuant to 17 C.F.R. &#167; 200.83<br></div></div><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 36pt;"><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6.75pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">CD19 is expressed in B cell lineage at an earlier stage compared to CD20, which is another well-known target for the treatment of hematological malignancies.</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">The CD19 antigen is rapidly internalized by the cell. Therefore, it is an effective target for ADC therapy since ADCs bind only to antigens on the cell surface and the ADCs must be internalized to release the warhead inside the cell.</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">The CD19 antigen does not shed into the circulation. Therefore, there are no, or very low, levels of soluble CD19 to compete for binding of the ADC.</div></td></tr></table><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 20.5pt; margin-left: 0pt; text-align: left;">Pathway to Regulatory Approval</div><div class="h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 7.5pt; margin-left: 0pt; text-align: left;">BLA Submission</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">We have evaluated Lonca in a pivotal Phase 2 clinical trial for the treatment of relapsed or refractory DLBCL, which will form the basis of a BLA submission for accelerated approval of Lonca for the treatment of relapsed or refractory DLBCL in patients who have failed two or more treatment regimens. However, the FDA has not opined on whether our Phase 2 clinical trial will in fact be sufficient to support such approval. If we receive accelerated approval, we intend to commence the commercial launch of Lonca in 2021.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">To support the BLA submission, we have developed a validated commercial supply chain that has been able to consistently produce Lonca at commercial scale. We believe that we have a sufficient supply of commercial-grade drug product in stock to support our expected commercial launch for Lonca.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">In January 2020, we held a Type C meeting with the FDA to discuss a confirmatory clinical trial to support full approval. In April 2020, we held a Type B meeting with the FDA to discuss the content and format of our proposed BLA submission, during which the FDA agreed with the overall content of our proposed BLA submission, the plans for analysis and presentation of clinical data, the pharmacokinetic data analysis plan and that the CMC module could be submitted in advance of the complete BLA submission.</div><div class="h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 20.5pt; margin-left: 0pt; text-align: left;">Confirmatory Clinical Trial</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">We intend to commence the confirmatory trial concurrently with the BLA submission for the treatment of DLBCL in the second half of 2020. The confirmatory clinical trial will be a Phase 3, randomized, open-label, two-part, two-arm, multi-center clinical trial of Lonca combined with rituximab compared to immunochemotherapy in patients with relapsed or refractory DLBCL.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The primary objective of the clinical trial is to evaluate the efficacy of Lonca combined with rituximab compared to standard immunochemotherapy, as measured by progression-free survival (&#8220;PFS&#8221;). The secondary objectives of the clinical trial are to (i) characterize the safety profile of Lonca combined with rituximab, (ii)&#160;characterize the pharmacokinetic profile of Lonca combined with rituximab, (iii) evaluate the immunogenicity of Lonca combined with rituximab and (iv) evaluate the impact of Lonca combined with rituximab treatment on treatment-related and disease-related symptoms, patient-reported functions and overall health status.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The clinical trial will enroll patients with pathologically confirmed relapsed or refractory DLBCL who are not considered by the investigator to be a candidate for SCT and who had failed at least one multi-agent systemic treatment regime. The clinical trial is expected to enroll approximately 350 patients. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The clinical trial will be conducted in two parts: In the safety run-in, the first 20 patients will be non-randomly assigned to receive Lonca in combination with rituximab to compare the combination&#8217;s toxicity against historical safety data from monotherapy clinical trials of Lonca. In the randomized part of the clinical trial, which will be initiated after last patient in the safety run-in completes the first treatment cycle and it is observed that there is no significant increase in toxicity of the combination as compared to historical safety data of Lonca used as a monotherapy, patients will be randomly assigned 1:1 to receive either Lonca in combination with rituximab or rituximab in combination with gemcitabine and oxaliplatin. The randomized part of the clinical trial will enroll approximately 330 patients. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">We believe that this clinical trial, if successful, will support an sBLA for Lonca to be used as a second-line therapy for the treatment of relapsed or refractory DLBCL in transplant-ineligible patients.</div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 36pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">131<br></div></div></div>
<!--End Page 135-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 136-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 540pt;"><a name="nt10014672x1_drs_107-business_pg21"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="block-frill" style="width: 540pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: Arial, Helvetica, sans-serif; font-size: 9pt; font-weight: bold; margin-top: 6pt; text-align: center;">Confidential Treatment Requested by ADC Therapeutics SA Pursuant to 17 C.F.R. &#167; 200.83<br></div></div><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 36pt;"><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">Phase 1 Clinical Trial in Relapsed or Refractory Non-Hodgkin Lymphoma</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">We have conducted a Phase 1, open-label, dose escalation and dose expansion clinical trial of the safety and tolerability of Lonca, used as monotherapy, in 183 patients with relapsed or refractory B-NHL, which includes <font style="font-style: italic;">de novo</font> and transformed DLBCL, FL, chronic lymphocytic leukemia, MCL, marginal zone B-cell lymphoma, Burkitt&#8217;s lymphoma and lymphoplasmacytic lymphoma. We conducted the clinical trial at 12 sites in the United States and Europe, pursuant to an IND accepted by the FDA in December 2015. The first patient was dosed in March 2016. The results of the clinical trial showed encouraging anti-tumor activity and manageable tolerability profile in patients with relapsed or refractory B-NHL. The clinical trial&#8217;s design and our main findings are summarized below.</div><div class="h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 20pt; margin-left: 0pt; text-align: left;">Clinical Trial Design</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The primary objectives of the dose escalation stage of the clinical trial were to (i)&#160;evaluate the safety and tolerability, and determine, as appropriate, the maximum tolerated dose (&#8220;MTD&#8221;) of Lonca in patients with relapsed or refractory B-NHL and (ii)&#160;determine the recommended dose(s) of Lonca for the dose expansion stage of the clinical trial. The primary objective of the dose expansion stage was to evaluate the safety and tolerability of Lonca at the dose level(s) recommended from the results of the dose escalation stage. The secondary objectives of the clinical trial were to (i)&#160;evaluate the clinical activity of Lonca, as measured by ORR, DoR, overall survival (&#8220;OS&#8221;) and PFS, (ii)&#160;characterize the pharmacokinetic profile of Lonca and the free warhead SG3199 and (iii)&#160;evaluate anti-drug antibodies (&#8220;ADAs&#8221;) in patients&#8217; blood before, during and after treatment with Lonca.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The clinical trial enrolled patients with pathologically confirmed relapsed or refractory B-NHL who had failed or were intolerant to established therapy or for whom no other treatment options were available. Of the 183 patients who participated in the clinical trial, 139 patients were diagnosed with relapsed or refractory DLBCL, 15 patients were diagnosed with relapsed or refractory MCL, 14 patients were diagnosed with FL and the remaining 15 patients were diagnosed with other forms of relapsed or refractory B-NHL. The table below presents information about the patients&#8217; characteristics.</div><table cellspacing="0" cellpadding="0" class="fintab" style="margin-top: 5.25pt; border-collapse: collapse; width: 468pt; margin-left: auto; margin-right: auto;"><tr class="header"><td colspan="4" style="width: 85.9%; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 2.95pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Patient Characteristics</div></td><td class="gutter" style="width: 0.64%; font-size: 2pt; padding-top: 6pt; padding-bottom: 2.95pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 2.95pt;">&#8203;</td><td style="width: 2.56%; text-align: center; vertical-align: bottom; padding-top: 6pt; padding-bottom: 2.95pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 2.95pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 2.95pt;">&#8203;</td><td style="width: 8.97%; text-align: center; vertical-align: bottom; padding-top: 6pt; padding-bottom: 2.95pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td></tr><tr><td colspan="4" style="width: 85.9%; text-align: left; vertical-align: bottom; padding-top: 2.95pt; padding-bottom: 1.7pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Age, median (minimum, maximum)<font style="padding-left: 2.31pt;"></font></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 2.95pt; padding-bottom: 1.7pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 2.95pt; padding-bottom: 1.7pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 2.56%; text-align: right; vertical-align: bottom; padding-top: 2.95pt; padding-bottom: 1.7pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: right;">63 </div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 2.95pt; padding-bottom: 1.7pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 2.95pt; padding-bottom: 1.7pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.97%; text-align: right; vertical-align: bottom; padding-top: 2.95pt; padding-bottom: 1.7pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: right;">(20, 87)</div></td></tr><tr><td colspan="4" style="width: 85.9%; text-align: left; vertical-align: bottom; padding-top: 1.7pt; padding-bottom: 1.7pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Number of previous systemic therapies received, median (minimum, maximum)<font style="padding-left: 1.84pt;"></font></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 1.7pt; padding-bottom: 1.7pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 1.7pt; padding-bottom: 1.7pt;">&#8203;</td><td style="width: 2.56%; text-align: right; vertical-align: bottom; padding-top: 1.7pt; padding-bottom: 1.7pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: right;">3 </div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 1.7pt; padding-bottom: 1.7pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 1.7pt; padding-bottom: 1.7pt;">&#8203;</td><td style="width: 8.97%; text-align: right; vertical-align: bottom; padding-top: 1.7pt; padding-bottom: 1.7pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: right;">(1, 13)</div></td></tr><tr><td style="width: 64.1%; text-align: left; vertical-align: bottom; padding-top: 1.7pt; padding-bottom: 1.7pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Response to first-line systemic therapy, n (%)<font style="padding-left: 0.18pt;"></font></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 1.7pt; padding-bottom: 1.7pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 1.7pt; padding-bottom: 1.7pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 20.51%; text-align: left; vertical-align: bottom; padding-top: 1.7pt; padding-bottom: 1.7pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Relapsed<font style="padding-left: 1.85pt;"></font></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 1.7pt; padding-bottom: 1.7pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 1.7pt; padding-bottom: 1.7pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 2.56%; vertical-align: bottom; padding-top: 1.7pt; padding-bottom: 1.7pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -2.63pt; text-align: justify;">115 </div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 1.7pt; padding-bottom: 1.7pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 1.7pt; padding-bottom: 1.7pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.97%; text-align: right; vertical-align: bottom; padding-top: 1.7pt; padding-bottom: 1.7pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: right;">(62.8)</div></td></tr><tr><td style="width: 64.1%; text-align: left; vertical-align: bottom; padding-top: 1.7pt; padding-bottom: 1.7pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 1.7pt; padding-bottom: 1.7pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 1.7pt; padding-bottom: 1.7pt;">&#8203;</td><td style="width: 20.51%; text-align: left; vertical-align: bottom; padding-top: 1.7pt; padding-bottom: 1.7pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Refractory<font style="padding-left: 0.74pt;"></font></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 1.7pt; padding-bottom: 1.7pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 1.7pt; padding-bottom: 1.7pt;">&#8203;</td><td style="width: 2.56%; text-align: right; vertical-align: bottom; padding-top: 1.7pt; padding-bottom: 1.7pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: right;">43 </div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 1.7pt; padding-bottom: 1.7pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 1.7pt; padding-bottom: 1.7pt;">&#8203;</td><td style="width: 8.97%; text-align: right; vertical-align: bottom; padding-top: 1.7pt; padding-bottom: 1.7pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: right;">(23.5)</div></td></tr><tr><td style="width: 64.1%; text-align: left; vertical-align: bottom; padding-top: 1.7pt; padding-bottom: 1.7pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Response to last-line prior systemic therapy, n (%)<font style="padding-left: 4.63pt;"></font></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 1.7pt; padding-bottom: 1.7pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 1.7pt; padding-bottom: 1.7pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 20.51%; text-align: left; vertical-align: bottom; padding-top: 1.7pt; padding-bottom: 1.7pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Relapsed<font style="padding-left: 1.85pt;"></font></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 1.7pt; padding-bottom: 1.7pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 1.7pt; padding-bottom: 1.7pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 2.56%; text-align: right; vertical-align: bottom; padding-top: 1.7pt; padding-bottom: 1.7pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: right;">66 </div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 1.7pt; padding-bottom: 1.7pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 1.7pt; padding-bottom: 1.7pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.97%; text-align: right; vertical-align: bottom; padding-top: 1.7pt; padding-bottom: 1.7pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: right;">(36.1)</div></td></tr><tr><td style="width: 64.1%; text-align: left; vertical-align: bottom; padding-top: 1.7pt; padding-bottom: 1.7pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 1.7pt; padding-bottom: 1.7pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 1.7pt; padding-bottom: 1.7pt;">&#8203;</td><td style="width: 20.51%; text-align: left; vertical-align: bottom; padding-top: 1.7pt; padding-bottom: 1.7pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Refractory<font style="padding-left: 0.74pt;"></font></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 1.7pt; padding-bottom: 1.7pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 1.7pt; padding-bottom: 1.7pt;">&#8203;</td><td style="width: 2.56%; vertical-align: bottom; padding-top: 1.7pt; padding-bottom: 1.7pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -3pt; text-align: justify;">109 </div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 1.7pt; padding-bottom: 1.7pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 1.7pt; padding-bottom: 1.7pt;">&#8203;</td><td style="width: 8.97%; text-align: right; vertical-align: bottom; padding-top: 1.7pt; padding-bottom: 1.7pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: right;">(59.6)</div></td></tr><tr><td style="width: 64.1%; text-align: left; vertical-align: bottom; padding-top: 1.7pt; padding-bottom: 1.7pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Prior stem cell transplant, n (%)<font style="padding-left: 0.62pt;"></font></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 1.7pt; padding-bottom: 1.7pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 1.7pt; padding-bottom: 1.7pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 20.51%; text-align: left; vertical-align: bottom; padding-top: 1.7pt; padding-bottom: 1.7pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Yes<font style="padding-left: 3.95pt;"></font></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 1.7pt; padding-bottom: 1.7pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 1.7pt; padding-bottom: 1.7pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 2.56%; text-align: right; vertical-align: bottom; padding-top: 1.7pt; padding-bottom: 1.7pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: right;">42 </div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 1.7pt; padding-bottom: 1.7pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 1.7pt; padding-bottom: 1.7pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.97%; text-align: right; vertical-align: bottom; padding-top: 1.7pt; padding-bottom: 1.7pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: right;">(23.0)</div></td></tr><tr><td style="width: 64.1%; text-align: left; vertical-align: bottom; padding-top: 1.7pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 1.7pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 1.7pt;">&#8203;</td><td style="width: 20.51%; text-align: left; vertical-align: bottom; padding-top: 1.7pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">No<font style="padding-left: 1.28pt;"></font></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 1.7pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 1.7pt;">&#8203;</td><td style="width: 2.56%; vertical-align: bottom; padding-top: 1.7pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -3pt; text-align: justify;">141 </div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 1.7pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 1.7pt;">&#8203;</td><td style="width: 8.97%; text-align: right; vertical-align: bottom; padding-top: 1.7pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: right;">(77.0)</div></td></tr></table><div><div class="rule-partial" style="height: 0pt; width: 72pt; border-bottom: 1pt solid #000000; margin-bottom: 1pt; margin-right: auto; margin-left: 0pt; margin-top: 6.75pt;"> </div></div><div class="ftnote" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 4pt; margin-left: 0pt; text-align: left;">Information about the patients&#8217; characteristics.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">In the dose escalation stage, patients received intravenous infusions of Lonca, at escalating doses, on the first day of each 21-day treatment cycle. The initial dose was 15 &#181;g/kg and the highest allowed dose was planned at 300 &#181;g/kg. Dose escalation was conducted using a 3+3 design with oversight by a Dose Escalation Steering Committee (&#8220;DESC&#8221;). In the dose expansion stage, patients received 120 &#181;g/kg and 150 &#181;g/kg doses on the first day of each 21-day treatment cycle. The dose levels were determined by the DESC based on the anti-tumor activity and tolerability observed during the dose escalation stage. In this clinical trial, response to treatment was determined as complete response (&#8220;CR&#8221;), partial response (&#8220;PR&#8221;), stable disease (&#8220;SD&#8221;) or progressive disease (&#8220;PD&#8221;), based on the 2014 Lugano Classification Criteria.</div><div class="h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 20pt; margin-left: 0pt; text-align: left;">Clinical Trial Results</div><div class="h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 7pt; margin-left: 20pt; text-align: left;">Diffuse Large B-Cell Lymphoma</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">For patients with relapsed or refractory DLBCL (n=139), the median prior lines of therapy received was three. The median number of treatment cycles received was two and the maximum number of treatment cycles received was 13. The median duration of treatment was 64 days.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The main observed safety and tolerability findings in patients with relapsed or refractory DLBCL were as follows:</div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">The MTD was not reached in the dose escalation stage.</div></td></tr></table></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 36pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">132<br></div></div></div>
<!--End Page 136-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 137-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 540pt;"><a name="nt10014672x1_drs_107-business_pg22"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="block-frill" style="width: 540pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: Arial, Helvetica, sans-serif; font-size: 9pt; font-weight: bold; margin-top: 6pt; text-align: center;">Confidential Treatment Requested by ADC Therapeutics SA Pursuant to 17 C.F.R. &#167; 200.83<br></div></div><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 36pt;"><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6.75pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">Grade &#8805;3 TEAEs were reported in 108 patients, or 77.7% of patients. The table below presents the most common Grade &#8805;3 TEAEs that were reported in more than 5% of patients.</div></td></tr></table><table cellspacing="0" cellpadding="0" class="fintab" style="margin-top: 11.25pt; border-collapse: collapse; width: 428pt; margin-left: 40pt;"><tr class="header"><td rowspan="2" style="width: 36.45%; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Grade &#8805;3 TEAEs*, n (%)</div></td><td class="gutter" rowspan="2" style="width: 0.7%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 0.7%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td colspan="13" style="width: 62.15%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Dose Levels</div></td></tr><tr class="header"><td class="gutter" style="width: 0.7%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 11.31%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">&#8804;90 &#181;g/kg <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">(n=10)</div></td><td class="gutter" style="width: 0.7%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 0.7%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 11.31%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">120 &#181;g/kg <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">(n=32)</div></td><td class="gutter" style="width: 0.7%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 0.7%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 11.31%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">150 &#181;g/kg <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">(n=70)</div></td><td class="gutter" style="width: 0.7%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 0.7%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 11.31%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">200 &#181;g/kg <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">(n=27)</div></td><td class="gutter" style="width: 0.7%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 0.7%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 11.31%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">All Doses <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">(n=139)</div></td></tr><tr><td style="width: 36.45%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Neutrophil count decreased**<font style="padding-left: 3.09pt;"></font></div></td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 11.31%; text-align: center; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; text-align: center;">2 (20.0)</div></td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 11.31%; text-align: center; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; text-align: center;">10 (31.2)</div></td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 11.31%; text-align: center; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; text-align: center;">26 (37.1)</div></td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 11.31%; text-align: center; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; text-align: center;">15 (55.6)</div></td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 11.31%; text-align: center; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; text-align: center;">&#8199;53 (38.1)</div></td></tr><tr><td style="width: 36.45%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Platelet count decreased**<font style="padding-left: 0.75pt;"></font></div></td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 11.31%; text-align: center; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; text-align: center;">1 (10.0)</div></td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 11.31%; text-align: center; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; text-align: center;">&#8199;7 (21.9)</div></td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 11.31%; text-align: center; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; text-align: center;">18 (25.7)</div></td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 11.31%; text-align: center; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; text-align: center;">11 (40.7)</div></td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 11.31%; text-align: center; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; text-align: center;">&#8199;37 (26.6)</div></td></tr><tr><td style="width: 36.45%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Gamma-glutamyltransferase increased<font style="padding-left: 1.45pt;"></font></div></td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 11.31%; text-align: center; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; text-align: center;">1 (10.0)</div></td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 11.31%; text-align: center; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; text-align: center;">&#8199;7 (21.9)</div></td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 11.31%; text-align: center; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; text-align: center;">12 (17.1)</div></td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 11.31%; text-align: center; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; text-align: center;">&#8199;7 (25.9)</div></td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 11.31%; text-align: center; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; text-align: center;">&#8199;27 (19.4)</div></td></tr><tr><td style="width: 36.45%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Anemia<font style="padding-left: 3.55pt;"></font></div></td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 11.31%; text-align: center; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; text-align: center;">2 (20.0)</div></td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 11.31%; text-align: center; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; text-align: center;">&#8199;3 &#8199;(9.4)</div></td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 11.31%; text-align: center; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; text-align: center;">11 (15.7)</div></td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 11.31%; text-align: center; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; text-align: center;">&#8199;3 (11.1)</div></td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 11.31%; text-align: center; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; text-align: center;">&#8199;19 (13.7) </div></td></tr><tr><td style="width: 36.45%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Disease progression<font style="padding-left: 1.61pt;"></font></div></td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 11.31%; text-align: center; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; text-align: center;">0 &#8199;(0.0)</div></td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 11.31%; text-align: center; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; text-align: center;">&#8199;2 &#8199;(6.3)</div></td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 11.31%; text-align: center; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; text-align: center;">&#8199;8 (11.4)</div></td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 11.31%; text-align: center; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; text-align: center;">&#8199;0 &#8199;(0.0)</div></td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 11.31%; text-align: center; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; text-align: center;">&#8199;10 &#8199;(7.2)</div></td></tr><tr><td style="width: 36.45%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Hypokalemia<font style="padding-left: 2.44pt;"></font></div></td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 11.31%; text-align: center; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; text-align: center;">0 &#8199;(0.0)</div></td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 11.31%; text-align: center; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; text-align: center;">&#8199;0 &#8199;(0.0)</div></td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 11.31%; text-align: center; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; text-align: center;">&#8199;8 (11.4)</div></td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 11.31%; text-align: center; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; text-align: center;">&#8199;1 &#8199;(3.7)</div></td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 11.31%; text-align: center; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; text-align: center;">&#8199;&#8199;9 &#8199;(6.5)</div></td></tr><tr><td style="width: 36.45%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Alkaline phosphatase increased<font style="padding-left: 2.29pt;"></font></div></td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 11.31%; text-align: center; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; text-align: center;">1 (10.0)</div></td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 11.31%; text-align: center; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; text-align: center;">&#8199;3 &#8199;(9.4)</div></td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 11.31%; text-align: center; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; text-align: center;">&#8199;3 &#8199;(4.3)</div></td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 11.31%; text-align: center; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; text-align: center;">&#8199;1 &#8199;(3.7)</div></td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 11.31%; text-align: center; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; text-align: center;">&#8199;&#8199;8 &#8199;(5.8)</div></td></tr><tr><td style="width: 36.45%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Lymphocyte count decreased<font style="padding-left: 1.24pt;"></font></div></td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 11.31%; text-align: center; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; text-align: center;">0 &#8199;(0.0)</div></td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 11.31%; text-align: center; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; text-align: center;">&#8199;2 &#8199;(6.3)</div></td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 11.31%; text-align: center; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; text-align: center;">&#8199;4 &#8199;(5.7)</div></td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 11.31%; text-align: center; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; text-align: center;">&#8199;2 &#8199;(7.4)</div></td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 11.31%; text-align: center; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; text-align: center;">&#8199;&#8199;8 &#8199;(5.8)</div></td></tr><tr><td style="width: 36.45%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Alanine aminotransferase increased<font style="padding-left: 1.47pt;"></font></div></td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 11.31%; text-align: center; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; text-align: center;">0 &#8199;(0.0)</div></td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 11.31%; text-align: center; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; text-align: center;">&#8199;2 &#8199;(6.3)</div></td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 11.31%; text-align: center; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; text-align: center;">&#8199;3 &#8199;(4.3)</div></td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 11.31%; text-align: center; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; text-align: center;">&#8199;2 &#8199;(7.4)</div></td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 11.31%; text-align: center; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; text-align: center;">&#8199;&#8199;7 &#8199;(5.0)</div></td></tr><tr><td style="width: 36.45%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Fatigue<font style="padding-left: 0.13pt;"></font></div></td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 11.31%; text-align: center; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; text-align: center;">0 &#8199;(0.0)</div></td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 11.31%; text-align: center; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; text-align: center;">&#8199;2 &#8199;(6.3)</div></td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 11.31%; text-align: center; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; text-align: center;">&#8199;2 &#8199;(2.9)</div></td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 11.31%; text-align: center; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; text-align: center;">&#8199;3 (11.1)</div></td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 11.31%; text-align: center; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; text-align: center;">&#8199;&#8199;7 &#8199;(5.0)</div></td></tr><tr><td style="width: 36.45%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">White blood cell count decreased<font style="padding-left: 3.85pt;"></font></div></td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 11.31%; text-align: center; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; text-align: center;">0 &#8199;(0.0)</div></td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 11.31%; text-align: center; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; text-align: center;">&#8199;2 &#8199;(6.3)</div></td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 11.31%; text-align: center; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; text-align: center;">&#8199;3 &#8199;(4.3)</div></td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 11.31%; text-align: center; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; text-align: center;">&#8199;2 &#8199;(7.4)</div></td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 11.31%; text-align: center; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; text-align: center;">&#8199;&#8199;7 &#8199;(5.0)</div></td></tr><tr><td style="width: 36.45%; text-align: left; vertical-align: bottom; padding-top: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Patients with any Grade &#8805;3 TEAEs<font style="font-weight: normal; padding-left: 2.18pt;"></font></div></td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt;">&#8203;</td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt;">&#8203;</td><td style="width: 11.31%; text-align: center; vertical-align: bottom; padding-top: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; font-weight: bold; margin-top: 0pt; text-align: center;">4 (40.0)</div></td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt;">&#8203;</td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt;">&#8203;</td><td style="width: 11.31%; text-align: center; vertical-align: bottom; padding-top: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; font-weight: bold; margin-top: 0pt; text-align: center;">24 (75.0)</div></td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt;">&#8203;</td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt;">&#8203;</td><td style="width: 11.31%; text-align: center; vertical-align: bottom; padding-top: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; font-weight: bold; margin-top: 0pt; text-align: center;">56 (80.0)</div></td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt;">&#8203;</td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt;">&#8203;</td><td style="width: 11.31%; text-align: center; vertical-align: bottom; padding-top: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; font-weight: bold; margin-top: 0pt; text-align: center;">24 (88.9)</div></td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt;">&#8203;</td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt;">&#8203;</td><td style="width: 11.31%; text-align: center; vertical-align: bottom; padding-top: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; font-weight: bold; margin-top: 0pt; text-align: center;">108 (77.7)</div></td></tr></table><div><div class="rule-partial" style="height: 0pt; width: 72pt; border-bottom: 1pt solid #000000; margin-bottom: 1pt; margin-right: auto; margin-left: 40pt; margin-top: 13.25pt;"> </div></div><div class="ftnote" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 3pt; margin-left: 40pt; text-align: left;">The most common Grade &#8805;3 TEAEs for various administered dose levels. *Grade refers to the severity of the adverse event, with grade 1 adverse events generally including mild or asymptomatic conditions or clinical or diagnostic observations only, grade 2 adverse events generally including moderate events or minimal, local or non-invasive intervention events, grade 3 adverse events generally including severe or medically significant events that are not immediately life-threatening, events requiring hospitalization or prolongation of hospitalization or disabling events and grade 4 adverse events generally including life-threatening consequences or urgent intervention events. **Based on laboratory abnormality reporting.</div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">TEAEs in 26 patients, or 18.7% of patients, led to treatment discontinuation.</div></td></tr></table><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left; line-height: 12pt;">In our analysis, we highlight certain efficacy data for dose levels above &#8805;120 &#181;g/kg because (i) 120 &#181;g/kg was the dose level at which the first significant activity signal was observed and (ii)&#160;the majority of the patients were treated at dose levels &#8805;120 &#181;g/kg. The main observed efficacy findings from the Phase 1 clinical trial in patients with relapsed or refractory DLBCL were as follows:</div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 4pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top; line-height: 11.5pt;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">Across all dose levels, 32 patients, or 23.4% of patients, achieved a complete response and another 26 patients, or 19.0% of patients, achieved a partial response, resulting in a 42.3% ORR. At dose levels &#8805;120 &#956;g/kg, 31 patients, or 24.4% of patients, achieved a complete response and another 25 patients, or 19.7% of patients, achieved a partial response, resulting in a 44.1% ORR. The table below shows the response rate data from this clinical trial.</div></td></tr></table><table cellspacing="0" cellpadding="0" class="fintab" style="margin-top: 2.75pt; border-collapse: collapse; width: 428pt; margin-left: 40pt;"><tr class="header"><td rowspan="2" style="width: 39.25%; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 3.15pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Best Overall Response, n (%)</div></td><td class="gutter" rowspan="2" style="width: 0.7%; font-size: 2pt; padding-top: 6pt; padding-bottom: 3.15pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 0.7%; font-size: 2pt; padding-top: 6pt; padding-bottom: 3.15pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td colspan="13" style="width: 59.35%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 3.15pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Dose Levels</div></td></tr><tr class="header"><td class="gutter" style="width: 0.7%; font-size: 2pt; padding-top: 3.15pt; padding-bottom: 3.15pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 10.75%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 3.15pt; padding-bottom: 3.15pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">&#8804;90 &#181;g/kg <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">(n=10)</div></td><td class="gutter" style="width: 0.7%; font-size: 2pt; padding-top: 3.15pt; padding-bottom: 3.15pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 0.7%; font-size: 2pt; padding-top: 3.15pt; padding-bottom: 3.15pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 10.75%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 3.15pt; padding-bottom: 3.15pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">120 &#181;g/kg <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">(n=32)</div></td><td class="gutter" style="width: 0.7%; font-size: 2pt; padding-top: 3.15pt; padding-bottom: 3.15pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 0.7%; font-size: 2pt; padding-top: 3.15pt; padding-bottom: 3.15pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 10.75%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 3.15pt; padding-bottom: 3.15pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">150 &#181;g/kg <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">(n=70)</div></td><td class="gutter" style="width: 0.7%; font-size: 2pt; padding-top: 3.15pt; padding-bottom: 3.15pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 0.7%; font-size: 2pt; padding-top: 3.15pt; padding-bottom: 3.15pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 10.75%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 3.15pt; padding-bottom: 3.15pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">200 &#181;g/kg <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">(n=25)</div></td><td class="gutter" style="width: 0.7%; font-size: 2pt; padding-top: 3.15pt; padding-bottom: 3.15pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 0.7%; font-size: 2pt; padding-top: 3.15pt; padding-bottom: 3.15pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 10.75%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 3.15pt; padding-bottom: 3.15pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">All Doses <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">(n=137)</div></td></tr><tr><td style="width: 39.25%; text-align: left; vertical-align: bottom; padding-top: 3.15pt; padding-bottom: 1.9pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Complete response (CR)<font style="padding-left: 4.98pt;"></font></div></td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 3.15pt; padding-bottom: 1.9pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 3.15pt; padding-bottom: 1.9pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.75%; text-align: center; vertical-align: bottom; padding-top: 3.15pt; padding-bottom: 1.9pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">1 (10.0)</div></td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 3.15pt; padding-bottom: 1.9pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 3.15pt; padding-bottom: 1.9pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.75%; text-align: center; vertical-align: bottom; padding-top: 3.15pt; padding-bottom: 1.9pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">&#8199;6 (18.8)</div></td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 3.15pt; padding-bottom: 1.9pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 3.15pt; padding-bottom: 1.9pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.75%; text-align: center; vertical-align: bottom; padding-top: 3.15pt; padding-bottom: 1.9pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">15 (21.4)</div></td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 3.15pt; padding-bottom: 1.9pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 3.15pt; padding-bottom: 1.9pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.75%; text-align: center; vertical-align: bottom; padding-top: 3.15pt; padding-bottom: 1.9pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">10 (40.0)</div></td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 3.15pt; padding-bottom: 1.9pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 3.15pt; padding-bottom: 1.9pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.75%; text-align: center; vertical-align: bottom; padding-top: 3.15pt; padding-bottom: 1.9pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">32 (23.4)</div></td></tr><tr><td style="width: 39.25%; text-align: left; vertical-align: bottom; padding-top: 1.9pt; padding-bottom: 1.9pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Partial response (PR)<font style="padding-left: 3.87pt;"></font></div></td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 1.9pt; padding-bottom: 1.9pt;">&#8203;</td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 1.9pt; padding-bottom: 1.9pt;">&#8203;</td><td style="width: 10.75%; text-align: center; vertical-align: bottom; padding-top: 1.9pt; padding-bottom: 1.9pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">1 (10.0)</div></td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 1.9pt; padding-bottom: 1.9pt;">&#8203;</td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 1.9pt; padding-bottom: 1.9pt;">&#8203;</td><td style="width: 10.75%; text-align: center; vertical-align: bottom; padding-top: 1.9pt; padding-bottom: 1.9pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">&#8199;8 (25.0)</div></td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 1.9pt; padding-bottom: 1.9pt;">&#8203;</td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 1.9pt; padding-bottom: 1.9pt;">&#8203;</td><td style="width: 10.75%; text-align: center; vertical-align: bottom; padding-top: 1.9pt; padding-bottom: 1.9pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">14 (20.0)</div></td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 1.9pt; padding-bottom: 1.9pt;">&#8203;</td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 1.9pt; padding-bottom: 1.9pt;">&#8203;</td><td style="width: 10.75%; text-align: center; vertical-align: bottom; padding-top: 1.9pt; padding-bottom: 1.9pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">&#8199;3 (12.0)</div></td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 1.9pt; padding-bottom: 1.9pt;">&#8203;</td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 1.9pt; padding-bottom: 1.9pt;">&#8203;</td><td style="width: 10.75%; text-align: center; vertical-align: bottom; padding-top: 1.9pt; padding-bottom: 1.9pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">26 (19.0)</div></td></tr><tr><td style="width: 39.25%; text-align: left; vertical-align: bottom; padding-top: 1.9pt; padding-bottom: 1.9pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Stable disease<font style="padding-left: 3.3pt;"></font></div></td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 1.9pt; padding-bottom: 1.9pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 1.9pt; padding-bottom: 1.9pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.75%; text-align: center; vertical-align: bottom; padding-top: 1.9pt; padding-bottom: 1.9pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">2 (20.0)</div></td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 1.9pt; padding-bottom: 1.9pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 1.9pt; padding-bottom: 1.9pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.75%; text-align: center; vertical-align: bottom; padding-top: 1.9pt; padding-bottom: 1.9pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">&#8199;7 (21.9)</div></td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 1.9pt; padding-bottom: 1.9pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 1.9pt; padding-bottom: 1.9pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.75%; text-align: center; vertical-align: bottom; padding-top: 1.9pt; padding-bottom: 1.9pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">12 (17.1)</div></td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 1.9pt; padding-bottom: 1.9pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 1.9pt; padding-bottom: 1.9pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.75%; text-align: center; vertical-align: bottom; padding-top: 1.9pt; padding-bottom: 1.9pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">&#8199;2 &#8199;(8.0)</div></td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 1.9pt; padding-bottom: 1.9pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 1.9pt; padding-bottom: 1.9pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.75%; text-align: center; vertical-align: bottom; padding-top: 1.9pt; padding-bottom: 1.9pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">23 (16.8)</div></td></tr><tr><td style="width: 39.25%; text-align: left; vertical-align: bottom; padding-top: 1.9pt; padding-bottom: 1.9pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Progressive disease<font style="padding-left: 1.65pt;"></font></div></td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 1.9pt; padding-bottom: 1.9pt;">&#8203;</td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 1.9pt; padding-bottom: 1.9pt;">&#8203;</td><td style="width: 10.75%; text-align: center; vertical-align: bottom; padding-top: 1.9pt; padding-bottom: 1.9pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">6 (60.0)</div></td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 1.9pt; padding-bottom: 1.9pt;">&#8203;</td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 1.9pt; padding-bottom: 1.9pt;">&#8203;</td><td style="width: 10.75%; text-align: center; vertical-align: bottom; padding-top: 1.9pt; padding-bottom: 1.9pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">10 (31.3)</div></td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 1.9pt; padding-bottom: 1.9pt;">&#8203;</td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 1.9pt; padding-bottom: 1.9pt;">&#8203;</td><td style="width: 10.75%; text-align: center; vertical-align: bottom; padding-top: 1.9pt; padding-bottom: 1.9pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">28 (40.0)</div></td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 1.9pt; padding-bottom: 1.9pt;">&#8203;</td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 1.9pt; padding-bottom: 1.9pt;">&#8203;</td><td style="width: 10.75%; text-align: center; vertical-align: bottom; padding-top: 1.9pt; padding-bottom: 1.9pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">10 (40.0)</div></td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 1.9pt; padding-bottom: 1.9pt;">&#8203;</td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 1.9pt; padding-bottom: 1.9pt;">&#8203;</td><td style="width: 10.75%; text-align: center; vertical-align: bottom; padding-top: 1.9pt; padding-bottom: 1.9pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">54 (39.4)</div></td></tr><tr><td style="width: 39.25%; text-align: left; vertical-align: bottom; padding-top: 1.9pt; padding-bottom: 1.9pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Not evaluable<font style="padding-left: 3.86pt;"></font></div></td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 1.9pt; padding-bottom: 1.9pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 1.9pt; padding-bottom: 1.9pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.75%; text-align: center; vertical-align: bottom; padding-top: 1.9pt; padding-bottom: 1.9pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">0 &#8199;(0.0)</div></td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 1.9pt; padding-bottom: 1.9pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 1.9pt; padding-bottom: 1.9pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.75%; text-align: center; vertical-align: bottom; padding-top: 1.9pt; padding-bottom: 1.9pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">&#8199;1 &#8199;(3.1)</div></td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 1.9pt; padding-bottom: 1.9pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 1.9pt; padding-bottom: 1.9pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.75%; text-align: center; vertical-align: bottom; padding-top: 1.9pt; padding-bottom: 1.9pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">&#8199;1 &#8199;(1.4)</div></td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 1.9pt; padding-bottom: 1.9pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 1.9pt; padding-bottom: 1.9pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.75%; text-align: center; vertical-align: bottom; padding-top: 1.9pt; padding-bottom: 1.9pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">&#8199;0 &#8199;(0.0)</div></td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 1.9pt; padding-bottom: 1.9pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 1.9pt; padding-bottom: 1.9pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.75%; text-align: center; vertical-align: bottom; padding-top: 1.9pt; padding-bottom: 1.9pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">&#8199;2 &#8199;(1.5)</div></td></tr><tr><td style="width: 39.25%; text-align: left; vertical-align: bottom; padding-top: 1.9pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Overall response rate (CR + PR)<font style="font-weight: normal; padding-left: 2.27pt;"></font></div></td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 1.9pt;">&#8203;</td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 1.9pt;">&#8203;</td><td style="width: 10.75%; text-align: center; vertical-align: bottom; padding-top: 1.9pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">2 (20.0)</div></td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 1.9pt;">&#8203;</td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 1.9pt;">&#8203;</td><td style="width: 10.75%; text-align: center; vertical-align: bottom; padding-top: 1.9pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">14 (43.8)</div></td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 1.9pt;">&#8203;</td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 1.9pt;">&#8203;</td><td style="width: 10.75%; text-align: center; vertical-align: bottom; padding-top: 1.9pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">29 (41.4)</div></td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 1.9pt;">&#8203;</td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 1.9pt;">&#8203;</td><td style="width: 10.75%; text-align: center; vertical-align: bottom; padding-top: 1.9pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">13 (52.0)</div></td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 1.9pt;">&#8203;</td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 1.9pt;">&#8203;</td><td style="width: 10.75%; text-align: center; vertical-align: bottom; padding-top: 1.9pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">58 (42.3)</div></td></tr></table><div><div class="rule-partial" style="height: 0pt; width: 72pt; border-bottom: 1pt solid #000000; margin-bottom: 1pt; margin-right: auto; margin-left: 40pt; margin-top: 7.25pt;"> </div></div><div class="ftnote" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 3pt; margin-left: 40pt; text-align: left;">Response rate data. &#8220;Not evaluable&#8221; means that the patient met the criteria for inclusion in the efficacy analysis set, but the only scan obtained for disease assessment was indeterminate. As specified in the protocol definition of the efficacy analysis set, two patients were excluded from the efficacy analysis as they only received a single dose of study drug and did not have documented progression of disease at any point.</div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 4pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top; line-height: 11.5pt;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">In our post-hoc subset analysis that excluded patients with double-hit or triple-hit disease and patients with primary refractory and early relapsed disease, at dose levels &#8805;120 &#956;g/kg, 18 patients, or 45.0% of patients, achieved a complete response and another eight patients, or 20.0% of patients, achieved a partial response, resulting in a 65.0% ORR. </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 4pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top; line-height: 11.5pt;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">Lonca&#8217;s favorable clinical activity was observed across a broad patient population in this clinical trial, including transplant eligible and ineligible patients, patients who have not responded to first-line </div></td></tr></table></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 36pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">133<br></div></div></div>
<!--End Page 137-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 138-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 540pt;"><a name="nt10014672x1_drs_107-business_pg23"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="block-frill" style="width: 540pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: Arial, Helvetica, sans-serif; font-size: 9pt; font-weight: bold; margin-top: 6pt; text-align: center;">Confidential Treatment Requested by ADC Therapeutics SA Pursuant to 17 C.F.R. &#167; 200.83<br></div></div><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 36pt;"><div class="bl" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 40pt; text-align: left;">therapy or any prior therapy and patients with bulky disease, double-hit and triple-hit disease and transformed disease. The tables below show the effect of tumor characteristics, age and response to prior therapy on response rate data at dose levels &#8805;120 &#181;g/kg. </div><table cellspacing="0" cellpadding="0" class="fintab" style="margin-top: 4.75pt; border-collapse: collapse; width: 428pt; margin-left: 40pt;"><tr class="header"><td style="width: 56.07%; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 3.15pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Tumor Characteristics</div></td><td class="gutter" style="width: 0.7%; font-size: 2pt; padding-top: 6pt; padding-bottom: 3.15pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 0.7%; font-size: 2pt; padding-top: 6pt; padding-bottom: 3.15pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 42.52%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 3.15pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Overall Response Rate, <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">responders/total (%)</div></td></tr><tr><td style="width: 56.07%; text-align: left; vertical-align: bottom; padding-top: 3.15pt; padding-bottom: 1.9pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Bulky disease*<font style="padding-left: 0.85pt;"></font></div></td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 3.15pt; padding-bottom: 1.9pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 3.15pt; padding-bottom: 1.9pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 42.52%; text-align: center; vertical-align: bottom; padding-top: 3.15pt; padding-bottom: 1.9pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">4/18 (22.2), including 2/18 (11.1) CR</div></td></tr><tr><td style="width: 56.07%; text-align: left; vertical-align: bottom; padding-top: 1.9pt; padding-bottom: 1.9pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Double-hit or triple-hit disease**<font style="padding-left: 1.99pt;"></font></div></td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 1.9pt; padding-bottom: 1.9pt;">&#8203;</td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 1.9pt; padding-bottom: 1.9pt;">&#8203;</td><td style="width: 42.52%; text-align: center; vertical-align: bottom; padding-top: 1.9pt; padding-bottom: 1.9pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">5/22 (22.7), including 3/22 (13.6) CR</div></td></tr><tr><td style="width: 56.07%; text-align: left; vertical-align: bottom; padding-top: 1.9pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Transformed disease***<font style="padding-left: 4pt;"></font></div></td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 1.9pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 1.9pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 42.52%; text-align: center; vertical-align: bottom; padding-top: 1.9pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">16/31 (51.6), including 9/31 (29.0) CR</div></td></tr></table><table cellspacing="0" cellpadding="0" class="fintab" style="margin-top: 6pt; border-collapse: collapse; width: 428pt; margin-left: 40pt;"><tr class="header"><td style="width: 56.07%; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 3.15pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Age</div></td><td class="gutter" style="width: 0.7%; font-size: 2pt; padding-top: 6pt; padding-bottom: 3.15pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 0.7%; font-size: 2pt; padding-top: 6pt; padding-bottom: 3.15pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 42.52%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 3.15pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Overall Response Rate, <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">responders/total (%)</div></td></tr><tr><td style="width: 56.07%; text-align: left; vertical-align: bottom; padding-top: 3.15pt; padding-bottom: 1.9pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Less than 65<font style="padding-left: 0.3pt;"></font></div></td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 3.15pt; padding-bottom: 1.9pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 3.15pt; padding-bottom: 1.9pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 42.52%; text-align: center; vertical-align: bottom; padding-top: 3.15pt; padding-bottom: 1.9pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">25/69 (36.2), including 16/69 (23.2) CR</div></td></tr><tr><td style="width: 56.07%; text-align: left; vertical-align: bottom; padding-top: 1.9pt; padding-bottom: 1.9pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">65-74<font style="padding-left: 4.17pt;"></font></div></td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 1.9pt; padding-bottom: 1.9pt;">&#8203;</td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 1.9pt; padding-bottom: 1.9pt;">&#8203;</td><td style="width: 42.52%; text-align: center; vertical-align: bottom; padding-top: 1.9pt; padding-bottom: 1.9pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">18/36 (50.0), including 11/36 (30.6) CR</div></td></tr><tr><td style="width: 56.07%; text-align: left; vertical-align: bottom; padding-top: 1.9pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">More than 74<font style="padding-left: 1.97pt;"></font></div></td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 1.9pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 1.9pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 42.52%; text-align: center; vertical-align: bottom; padding-top: 1.9pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">13/22 (59.1), including 4/22 (18.2) CR</div></td></tr></table><table cellspacing="0" cellpadding="0" class="fintab" style="border-collapse: collapse; width: 428pt; margin-left: 40pt;"><tr class="header"><td colspan="4" style="width: 71.5%; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 3.15pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Response to Prior Therapy</div></td><td class="gutter" style="width: 0.7%; font-size: 2pt; padding-top: 6pt; padding-bottom: 3.15pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 0.7%; font-size: 2pt; padding-top: 6pt; padding-bottom: 3.15pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 27.1%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 3.15pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Overall Response Rate, <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">responders/total (%)</div></td></tr><tr><td style="width: 44.86%; text-align: left; vertical-align: bottom; padding-top: 3.15pt; padding-bottom: 1.9pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Response to first-line systemic therapy<font style="padding-left: 0.68pt;"></font></div></td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 3.15pt; padding-bottom: 1.9pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 3.15pt; padding-bottom: 1.9pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 25.23%; text-align: left; vertical-align: bottom; padding-top: 3.15pt; padding-bottom: 1.9pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Complete response<font style="padding-left: 3.3pt;"></font></div></td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 3.15pt; padding-bottom: 1.9pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 3.15pt; padding-bottom: 1.9pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 27.1%; text-align: center; vertical-align: bottom; padding-top: 3.15pt; padding-bottom: 1.9pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">32/49 (65.3)</div></td></tr><tr><td style="width: 44.86%; text-align: left; vertical-align: bottom; padding-top: 1.9pt; padding-bottom: 1.9pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 1.9pt; padding-bottom: 1.9pt;">&#8203;</td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 1.9pt; padding-bottom: 1.9pt;">&#8203;</td><td style="width: 25.23%; text-align: left; vertical-align: bottom; padding-top: 1.9pt; padding-bottom: 1.9pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Partial response<font style="padding-left: 1.09pt;"></font></div></td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 1.9pt; padding-bottom: 1.9pt;">&#8203;</td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 1.9pt; padding-bottom: 1.9pt;">&#8203;</td><td style="width: 27.1%; text-align: center; vertical-align: bottom; padding-top: 1.9pt; padding-bottom: 1.9pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">12/33 (36.4)</div></td></tr><tr><td style="width: 44.86%; text-align: left; vertical-align: bottom; padding-top: 1.9pt; padding-bottom: 1.9pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 1.9pt; padding-bottom: 1.9pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 1.9pt; padding-bottom: 1.9pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 25.23%; text-align: left; vertical-align: bottom; padding-top: 1.9pt; padding-bottom: 1.9pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Any response <font style="padding-left: 1.64pt;"></font></div></td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 1.9pt; padding-bottom: 1.9pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 1.9pt; padding-bottom: 1.9pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 27.1%; text-align: center; vertical-align: bottom; padding-top: 1.9pt; padding-bottom: 1.9pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">44/82 (53.7)</div></td></tr><tr><td style="width: 44.86%; text-align: left; vertical-align: bottom; padding-top: 1.9pt; padding-bottom: 1.9pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 1.9pt; padding-bottom: 1.9pt;">&#8203;</td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 1.9pt; padding-bottom: 1.9pt;">&#8203;</td><td style="width: 25.23%; text-align: left; vertical-align: bottom; padding-top: 1.9pt; padding-bottom: 1.9pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">No response<font style="padding-left: 4.97pt;"></font></div></td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 1.9pt; padding-bottom: 1.9pt;">&#8203;</td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 1.9pt; padding-bottom: 1.9pt;">&#8203;</td><td style="width: 27.1%; text-align: center; vertical-align: bottom; padding-top: 1.9pt; padding-bottom: 1.9pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">12/44 (27.3)</div></td></tr><tr><td style="width: 44.86%; text-align: left; vertical-align: bottom; padding-top: 1.9pt; padding-bottom: 1.9pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Response to last-line prior systemic therapy<font style="padding-left: 0.13pt;"></font></div></td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 1.9pt; padding-bottom: 1.9pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 1.9pt; padding-bottom: 1.9pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 25.23%; text-align: left; vertical-align: bottom; padding-top: 1.9pt; padding-bottom: 1.9pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Complete response<font style="padding-left: 3.3pt;"></font></div></td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 1.9pt; padding-bottom: 1.9pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 1.9pt; padding-bottom: 1.9pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 27.1%; text-align: center; vertical-align: bottom; padding-top: 1.9pt; padding-bottom: 1.9pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">16/21 (76.2)</div></td></tr><tr><td style="width: 44.86%; text-align: left; vertical-align: bottom; padding-top: 1.9pt; padding-bottom: 1.9pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 1.9pt; padding-bottom: 1.9pt;">&#8203;</td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 1.9pt; padding-bottom: 1.9pt;">&#8203;</td><td style="width: 25.23%; text-align: left; vertical-align: bottom; padding-top: 1.9pt; padding-bottom: 1.9pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Partial response<font style="padding-left: 1.09pt;"></font></div></td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 1.9pt; padding-bottom: 1.9pt;">&#8203;</td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 1.9pt; padding-bottom: 1.9pt;">&#8203;</td><td style="width: 27.1%; text-align: center; vertical-align: bottom; padding-top: 1.9pt; padding-bottom: 1.9pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">&#8199;9/24 (37.5)</div></td></tr><tr><td style="width: 44.86%; text-align: left; vertical-align: bottom; padding-top: 1.9pt; padding-bottom: 1.9pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 1.9pt; padding-bottom: 1.9pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 1.9pt; padding-bottom: 1.9pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 25.23%; text-align: left; vertical-align: bottom; padding-top: 1.9pt; padding-bottom: 1.9pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Any response <font style="padding-left: 1.64pt;"></font></div></td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 1.9pt; padding-bottom: 1.9pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 1.9pt; padding-bottom: 1.9pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 27.1%; text-align: center; vertical-align: bottom; padding-top: 1.9pt; padding-bottom: 1.9pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">25/45 (55.6)</div></td></tr><tr><td style="width: 44.86%; text-align: left; vertical-align: bottom; padding-top: 1.9pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 1.9pt;">&#8203;</td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 1.9pt;">&#8203;</td><td style="width: 25.23%; text-align: left; vertical-align: bottom; padding-top: 1.9pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">No response<font style="padding-left: 4.97pt;"></font></div></td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 1.9pt;">&#8203;</td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 1.9pt;">&#8203;</td><td style="width: 27.1%; text-align: center; vertical-align: bottom; padding-top: 1.9pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">31/82 (37.8)</div></td></tr></table><div><div class="rule-partial" style="height: 0pt; width: 72pt; border-bottom: 1pt solid #000000; margin-bottom: 1pt; margin-right: auto; margin-left: 40pt; margin-top: 7.25pt;"> </div></div><div class="ftnote" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 3pt; margin-left: 40pt; text-align: left;">Overall response rate data by various baseline patient characteristics at dose levels &#8805;120 &#181;g/kg. *Bulky disease is recorded for patients whose cancerous masses measure at least 10 cm in diameter. **Double-hit and triple-hit DLBCL are rare subtypes of DLBCL characterized by two or three recurrent chromosome translocations and are generally associated with poor prognosis. ***Transformed disease is recorded for patients who had another type of lymphoma that progressed to become DLBCL.</div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 5pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">Across all dose levels, the median DoR was not reached for patients who achieved a complete response (indicating that more than half of the patients continued to show a complete response as of their most recent assessment) and 2.86 months for patients who achieved a partial response, for an overall DoR of 4.47 months. At dose levels &#8805;120 &#181;g/kg, the median DoR was not reached for patients who achieved a complete response (indicating that more than half of the patients continued to show a complete response as of their most recent assessment) and was 2.69 months for patients who achieved a partial response, for an overall DoR of 4.17 months. The figure below shows the DoR by response at dose levels &#8805;120 &#181;g/kg.</div></td></tr></table><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 15.25pt; text-align: center;"><img style="height: 211px; width: 425px;" src="nt10014672x1_linechart1.jpg"><br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">&#8201;</div><div><div class="rule-partial" style="height: 0pt; width: 72pt; border-bottom: 1pt solid #000000; margin-bottom: 1pt; margin-right: auto; margin-left: 40pt; margin-top: 12.25pt;"> </div></div><div class="ftnote" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 4.5pt; margin-left: 40pt; text-align: left;">Duration of response by response at dose levels &#8805;120 &#181;g/kg.</div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">In our post-hoc subset analysis that excluded patients with double-hit or triple-hit disease and patients with primary refractory and early relapsed disease, at dose levels &#8805;120 &#956;g/kg, the median DoR was 10.6 months for patients who achieved a complete response and was 2.1 months for patients who achieved a partial response, for an overall DoR of 4.1 months.</div></td></tr></table></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 36pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">134<br></div></div></div>
<!--End Page 138-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 139-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 540pt;"><a name="nt10014672x1_drs_107-business_pg24"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="block-frill" style="width: 540pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: Arial, Helvetica, sans-serif; font-size: 9pt; font-weight: bold; margin-top: 6pt; text-align: center;">Confidential Treatment Requested by ADC Therapeutics SA Pursuant to 17 C.F.R. &#167; 200.83<br></div></div><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 36pt;"><div class="h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 6.75pt; margin-left: 20pt; text-align: left;">Mantle Cell Lymphoma</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">For patients with relapsed or refractory MCL (n=15), the median prior lines of therapy received was four. The median number of treatment cycles received was two and the maximum number of treatment cycles received was 11. The median duration of treatment was 65 days.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The main observed safety and tolerability findings in patients with relapsed or refractory MCL were similar in nature, frequency and severity to those in patients with relapsed or refractory DLBCL. The main observed efficacy findings from the Phase 1 clinical trial in patients with relapsed or refractory MCL were as follows:</div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 5pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">Across all dose levels, five patients, or 33.3% of patients, achieved a complete response and another two patients, or 13.3% of patients, achieved a partial response, resulting in a 46.7% ORR.</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 5pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">The median DoR was not reached (indicating that more than half of the patients continued to show a complete response as of their most recent assessment).</div></td></tr></table><div class="h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 20.5pt; margin-left: 20pt; text-align: left;">Follicular Lymphoma</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">For patients with relapsed or refractory FL (n=14), the median prior lines of therapy received was four. The median number of treatment cycles received was three and the maximum number of treatment cycles received was 12. The median duration of treatment was 79 days.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The main observed safety and tolerability findings in patients with relapsed or refractory FL were similar in nature, frequency and severity to those in patients with relapsed or refractory DLBCL. The main efficacy findings from the Phase 1 clinical trial in patients with relapsed or refractory FL were as follows:</div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">Across all dose levels, nine patients, or 64.3% of patients, achieved a complete response and another two patients, or 14.3% of patients, achieved a partial response, resulting in a 78.6% ORR.</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">The median DoR was not reached (indicating that more than half of the patients continued to show a complete response as of their most recent assessment).</div></td></tr></table><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 20.5pt; margin-left: 0pt; text-align: left;">Pivotal Phase 2 Clinical Trial in Relapsed or Refractory Diffuse Large B-Cell Lymphoma</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">We have conducted a 145-patient Phase 2, multi-center, open-label, single-arm clinical trial to evaluate the safety and efficacy of Lonca in patients with relapsed or refractory DLBCL, as defined according to the 2016 World Health Organization classification to include DLBCL not otherwise specified, primary mediastinal large B-cell lymphoma and high-grade B-cell lymphoma. We conducted the clinical trial at 37 sites in the United States and Europe, pursuant to an IND accepted by the FDA in December 2015 and an additional protocol submitted in April 2018. The first patient was dosed in August 2018. The results of the clinical trial showed significant anti-tumor activity and manageable tolerability profile across a broad population of patients with relapsed or refractory DLBCL. The clinical trial&#8217;s design and our main findings are summarized below.</div><div class="h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 20.5pt; margin-left: 0pt; text-align: left;">Clinical Trial Design</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The primary objective of the Phase 2 clinical trial was to evaluate the efficacy of Lonca in patients with relapsed or refractory DLBCL, measured by ORR based on the 2014 Lugano Classification Criteria. The secondary objectives were to (i)&#160;characterize the safety profile of Lonca, (ii)&#160;characterize the pharmacokinetic profile of Lonca, (iii)&#160;evaluate the immunogenicity of Lonca and (iv)&#160;evaluate the impact of Lonca treatment on health-related quality of life (&#8220;HRQoL&#8221;). </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 36pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">135<br></div></div></div>
<!--End Page 139-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 140-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 540pt;"><a name="nt10014672x1_drs_107-business_pg25"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="block-frill" style="width: 540pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: Arial, Helvetica, sans-serif; font-size: 9pt; font-weight: bold; margin-top: 6pt; text-align: center;">Confidential Treatment Requested by ADC Therapeutics SA Pursuant to 17 C.F.R. &#167; 200.83<br></div></div><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 36pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The clinical trial enrolled patients with pathologically confirmed relapsed or refractory DLBCL who have previously received two or more multi-agent systemic treatment regimens. The table below presents information about the patients&#8217; characteristics. </div><table cellspacing="0" cellpadding="0" class="fintab" style="margin-top: 5.25pt; border-collapse: collapse; width: 468pt; margin-left: auto; margin-right: auto;"><tr class="header"><td colspan="4" style="width: 85.9%; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Patient Characteristics</div></td><td class="gutter" style="width: 0.64%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 2.56%; text-align: center; vertical-align: bottom; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 8.97%; text-align: center; vertical-align: bottom; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td></tr><tr><td colspan="4" style="width: 85.9%; text-align: left; vertical-align: top; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Age, median (minimum, maximum)<font style="padding-left: 2.31pt;"></font></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 2.56%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -3.2pt; text-align: left;"><font style="padding-left: 5pt;">66</font> </div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.97%; text-align: right; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: right;">(23, 94)</div></td></tr><tr><td style="width: 51.28%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Histology, n (%)<font style="padding-left: 4.56pt;"></font></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 33.33%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">DLBCL Not otherwise specified<font style="padding-left: 1.14pt;"></font></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 2.56%; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -3.2pt; text-align: justify;">127</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 8.97%; text-align: right; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: right;">(87.6)</div></td></tr><tr><td style="width: 51.28%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 33.33%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">HGBCL*<font style="padding-left: 4.62pt;"></font></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 2.56%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -3.2pt; text-align: left;"><font style="padding-left: 5.37pt;">11</font></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.97%; text-align: right; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: right;">(7.6)</div></td></tr><tr><td style="width: 51.28%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 33.33%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">PMBCL**<font style="padding-left: 4.61pt;"></font></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 2.56%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -3.2pt; text-align: left;"><font style="padding-left: 10pt;">7</font></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 8.97%; text-align: right; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: right;">(4.8)</div></td></tr><tr><td style="width: 51.28%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Cancer characteristic, n (%)<font style="padding-left: 3.4pt;"></font></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 33.33%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Double-hit or triple-hit disease***<font style="padding-left: 2.99pt;"></font></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 2.56%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -3.2pt; text-align: left;"><font style="padding-left: 5pt;">15</font> </div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.97%; text-align: right; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: right;">(10.3)</div></td></tr><tr><td style="width: 51.28%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 33.33%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Double/triple expressor<font style="padding-left: 3.54pt;"></font></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 2.56%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -3.2pt; text-align: left;"><font style="padding-left: 5pt;">20</font></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 8.97%; text-align: right; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: right;">(13.8)</div></td></tr><tr><td style="width: 51.28%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 33.33%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Transformed disease****<font style="padding-left: 4.51pt;"></font></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 2.56%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -3.2pt; text-align: left;"><font style="padding-left: 5.39pt;">29</font> </div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.97%; text-align: right; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: right;">(20.0)</div></td></tr><tr><td style="width: 51.28%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Disease stage*****, n (%)<font style="padding-left: 3.29pt;"></font></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 33.33%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">I-II<font style="padding-left: 0.97pt;"></font></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 2.56%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -3.2pt; text-align: left;"><font style="padding-left: 5.39pt;">33</font></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 8.97%; text-align: right; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: right;">(22.8)</div></td></tr><tr><td style="width: 51.28%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 33.33%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">III-IV<font style="padding-left: 0.81pt;"></font></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 2.56%; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -3.2pt; text-align: justify;"><font style="padding-left: 0.96pt;">112</font></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.97%; text-align: right; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: right;">(77.2)</div></td></tr><tr><td colspan="4" style="width: 85.9%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Number of previous systemic therapies received, median (minimum, maximum)<font style="padding-left: 1.15pt;"></font></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 2.56%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -3.2pt; text-align: left;"><font style="padding-left: 10.2pt;">3 </font></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 8.97%; text-align: right; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: right;">(2, 7)</div></td></tr><tr><td style="width: 51.28%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Response to first-line systemic therapy, n (%)<font style="padding-left: 4.19pt;"></font></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 33.33%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Relapsed<font style="padding-left: 3.41pt;"></font></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 2.56%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -3.2pt; text-align: left;"><font style="padding-left: 5.39pt;">99 </font></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.97%; text-align: right; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: right;">(68.3)</div></td></tr><tr><td style="width: 51.28%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 33.33%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Refractory<font style="padding-left: 2.7pt;"></font></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 2.56%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -3.2pt; text-align: left;"><font style="padding-left: 5.39pt;">29 </font></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 8.97%; text-align: right; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: right;">(20.0)</div></td></tr><tr><td style="width: 51.28%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Response to last-line prior systemic therapy, n (%)<font style="padding-left: 4.63pt;"></font></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 33.33%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Relapsed<font style="padding-left: 3.41pt;"></font></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 2.56%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -3.2pt; text-align: left;"><font style="padding-left: 5.39pt;">43 </font></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.97%; text-align: right; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: right;">(29.7)</div></td></tr><tr><td style="width: 51.28%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 33.33%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Refractory<font style="padding-left: 2.7pt;"></font></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 2.56%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -3.2pt; text-align: left;"><font style="padding-left: 5.39pt;">84</font> </div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 8.97%; text-align: right; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: right;">(57.9)</div></td></tr><tr><td style="width: 51.28%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Refractory to all prior systemic therapies, n (%)<font style="padding-left: 0.26pt;"></font></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 33.33%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Yes<font style="padding-left: 4.54pt;"></font></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 2.56%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -3.2pt; text-align: left;"><font style="padding-left: 5.39pt;">25 </font></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.97%; text-align: right; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: right;">(17.2)</div></td></tr><tr><td style="width: 51.28%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 33.33%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">No<font style="padding-left: 1.67pt;"></font></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 2.56%; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -3.2pt; text-align: justify;"><font style="padding-left: 0.96pt;">115</font></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 8.97%; text-align: right; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: right;">(79.3)</div></td></tr><tr><td style="width: 51.28%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Prior stem cell transplant, n (%)<font style="padding-left: 2.09pt;"></font></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 33.33%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Autologous stem cell transplant<font style="padding-left: 0.17pt;"></font></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 2.56%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -3.2pt; text-align: left;"><font style="padding-left: 5.39pt;">21</font> </div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.97%; text-align: right; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: right;">(14.5)</div></td></tr><tr><td style="width: 51.28%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 33.33%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Allogeneic stem cell transplant<font style="padding-left: 2.96pt;"></font></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 2.56%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -3.2pt; text-align: left;"><font style="padding-left: 10.2pt;">2 </font></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 8.97%; text-align: right; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: right;">(1.4)</div></td></tr><tr><td style="width: 51.28%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 33.33%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Both autologous and allogeneic stem cell transplant<font style="padding-left: 4.24pt;"></font></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 2.56%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -3.2pt; text-align: left;"><font style="padding-left: 10.2pt;">1</font></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.97%; text-align: right; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: right;">(0.7)</div></td></tr><tr><td style="width: 51.28%; text-align: left; vertical-align: top; padding-top: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt;">&#8203;</td><td style="width: 33.33%; text-align: left; vertical-align: bottom; padding-top: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">No<font style="padding-left: 1.67pt;"></font></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt;">&#8203;</td><td style="width: 2.56%; vertical-align: bottom; white-space: nowrap; padding-top: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -3.2pt; text-align: justify;"><font style="padding-left: 0.59pt;">121 </font></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt;">&#8203;</td><td style="width: 8.97%; text-align: right; vertical-align: bottom; padding-top: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: right;">(83.4)</div></td></tr></table><div><div class="rule-partial" style="height: 0pt; width: 72pt; border-bottom: 1pt solid #000000; margin-bottom: 1pt; margin-right: auto; margin-left: 0pt; margin-top: 11.25pt;"> </div></div><div class="ftnote" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 3pt; margin-left: 0pt; text-align: left;">Information about the patients&#8217; characteristics. *High-grade diffuse large B-cell lymphoma. **Primary mediastinal large B-cell lymphoma. ***Double-hit and triple-hit DLBCL are rare subtypes of DLBCL characterized by two or three recurrent chromosome translocations and are generally associated with poor prognosis. ****Transformed disease is recorded for patients who had another type of lymphoma that progressed to become DLBCL. *****Disease stage is determined by the location of the tumor: Stage I means that the cancer is located in a single region, usually one lymph node and the surrounding area. Stage II means that the cancer is located in two separate regions, an affected lymph node or lymphatic organ and a second affected area, and that both affected areas are confined to one side of the diaphragm; Stage III means that the cancer has spread to both sides of the diaphragm, including one organ or area near the lymph nodes or the spleen; Stage IV means diffuse or disseminated involvement of one or more extralymphatic organs, including any involvement of the liver, bone marrow, or nodular involvement of the lungs.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The clinical trial used a two-stage design, with an interim analysis for futility based on data collected from the first 52 patients. The results of the interim analysis for futility in May 2019 showed that the clinical trial met the criteria to continue to full enrollment. Patients received a 150 &#181;g/kg dose on the first day of each 21-day treatment cycle for two treatment cycles, followed by a reduction to a 75 &#181;g/kg dose on the first day of each 21-day treatment cycle for up to one year. The decision for initial dosing at the 150 &#181;g/kg dose level was predicated on higher observed and predicted ORR as compared to lower dose levels. The decision to reduce the dose level after two treatment cycles was based on the rapid onset of initial response observed in the majority of patients in the Phase 1 clinical trial and the desire to optimize the risk-benefit profile for patients. Therefore, the dosing regimen was selected to optimize the frequency of objective response, while permitting continued exposure with manageable toxicity to optimize the durability of response. In this clinical trial, response to treatment was determined as CR, PR, SD or PD, based on the 2014 Lugano Classification Criteria. We also collected liquid biopsies from all patients before and after treatment with Lonca and we are applying multi-omics approaches (i.e., biological analysis approaches in which data sets of different &#8220;omic&#8221; groups, such as genome, proteome, and epigenome, are combined) to identify genetic signatures that may predict response to Lonca. </div><div class="h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 14pt; margin-left: 0pt; text-align: left;">Clinical Trial Results </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">In June 2020, we presented the results from this clinical trial at the virtual 25th Congress of the European Hematology Association. These data form the basis of our planned BLA submission.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The median number of treatment cycles received was 4.3 and the maximum number of treatment cycles received was 15. The median duration of treatment was 45 days.</div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 36pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">136<br></div></div></div>
<!--End Page 140-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 141-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 540pt;"><a name="nt10014672x1_drs_107-business_pg26"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="block-frill" style="width: 540pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: Arial, Helvetica, sans-serif; font-size: 9pt; font-weight: bold; margin-top: 6pt; text-align: center;">Confidential Treatment Requested by ADC Therapeutics SA Pursuant to 17 C.F.R. &#167; 200.83<br></div></div><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 36pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">As of April 6, 2020, the main observed safety and tolerability findings were as follows: </div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">Grade &#8805;3 TEAEs were reported in 105 patients, or 72.4% of patients. The table below presents the most common Grade &#8805;3 TEAEs that were reported in more than 10% of patients. </div></td></tr></table><table cellspacing="0" cellpadding="0" class="fintab" style="margin-top: 11.25pt; border-collapse: collapse; width: 428pt; margin-left: 40pt;"><tr class="header"><td style="width: 78.51%; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Grade &#8805;3 TEAEs*, n (%)</div></td><td class="gutter" style="width: 5.78%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 5.78%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 9.93%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">All Patients<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">(n=145)</div></td></tr><tr><td style="width: 78.51%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Neutropenia<font style="padding-left: 4.07pt;"></font></div></td><td class="gutter" style="width: 5.78%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 5.78%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.93%; text-align: center; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">&#8199;37 (25.5)</div></td></tr><tr><td style="width: 78.51%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Thrombocytopenia<font style="padding-left: 2.4pt;"></font></div></td><td class="gutter" style="width: 5.78%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 5.78%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 9.93%; text-align: center; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">&#8199;26 (17.9)</div></td></tr><tr><td style="width: 78.51%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Gamma-glutamyltransferase increased<font style="padding-left: 3.57pt;"></font></div></td><td class="gutter" style="width: 5.78%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 5.78%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.93%; text-align: center; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">&#8199;24 (16.6)</div></td></tr><tr><td style="width: 78.51%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Anemia<font style="padding-left: 1.84pt;"></font></div></td><td class="gutter" style="width: 5.78%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 5.78%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 9.93%; text-align: center; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">&#8199;15 (10.3)</div></td></tr><tr><td style="width: 78.51%; text-align: left; vertical-align: bottom; padding-top: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Patients with any Grade &#8805;3 TEAEs <font style="font-weight: normal; padding-left: 1.02pt;"></font></div></td><td class="gutter" style="width: 5.78%; border-bottom: none; font-size: 2pt; padding-top: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 5.78%; border-bottom: none; font-size: 2pt; padding-top: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.93%; text-align: center; vertical-align: bottom; padding-top: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">105 (72.4)</div></td></tr></table><div><div class="rule-partial" style="height: 0pt; width: 72pt; border-bottom: 1pt solid #000000; margin-bottom: 1pt; margin-right: auto; margin-left: 40pt; margin-top: 13.25pt;"> </div></div><div class="ftnote" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 3pt; margin-left: 40pt; text-align: left;">The most common Grade &#8805;3 TEAEs. *Grade refers to the severity of the adverse event, with grade 1 adverse events generally including mild or asymptomatic conditions or clinical or diagnostic observations only, grade 2 adverse events generally including moderate events or minimal, local or non-invasive intervention events, grade 3 adverse events generally including severe or medically significant events that are not immediately life-threatening, events requiring hospitalization or prolongation of hospitalization or disabling events and grade 4 adverse events generally including life-threatening consequences or urgent intervention events. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 7.5pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The main observed efficacy findings were as follows: </div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">Thirty-five patients, or 24.1% of patients, achieved a complete response and another 35 patients, or 24.1% of patients, achieved a partial response, resulting in a 48.3% ORR. The table below shows the response rate data.</div></td></tr></table><table cellspacing="0" cellpadding="0" class="fintab" style="margin-top: 11.25pt; border-collapse: collapse; width: 428pt; margin-left: 40pt;"><tr class="header"><td style="width: 39.25%; text-align: left; vertical-align: bottom; padding-top: 6pt; padding-bottom: 4pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 3.15%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 4pt;">&#8203;</td><td class="gutter" style="width: 3.15%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td colspan="10" style="width: 54.44%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Histology</div></td></tr><tr class="header"><td style="width: 39.25%; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4pt; padding-bottom: 4pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Best Overall Response, n (%)</div></td><td class="gutter" style="width: 3.15%; font-size: 2pt; padding-top: 4pt; padding-bottom: 4pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 3.15%; font-size: 2pt; padding-top: 4pt; padding-bottom: 4pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 10.9%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4pt; padding-bottom: 4pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">DLBCL-NOS <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">(n=127) </div></td><td class="gutter" style="width: 3.15%; font-size: 2pt; padding-top: 4pt; padding-bottom: 4pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 3.15%; font-size: 2pt; padding-top: 4pt; padding-bottom: 4pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 7.59%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4pt; padding-bottom: 4pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">HGBCL <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">(n=11)</div></td><td class="gutter" style="width: 3.15%; font-size: 2pt; padding-top: 4pt; padding-bottom: 4pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 3.15%; font-size: 2pt; padding-top: 4pt; padding-bottom: 4pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 7.59%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4pt; padding-bottom: 4pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">PMBCL <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">(n=17)</div></td><td class="gutter" style="width: 3.15%; font-size: 2pt; padding-top: 4pt; padding-bottom: 4pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 3.15%; font-size: 2pt; padding-top: 4pt; padding-bottom: 4pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 9.45%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4pt; padding-bottom: 4pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">All Patients <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">(n=145) </div></td></tr><tr><td style="width: 39.25%; text-align: left; vertical-align: bottom; padding-top: 4pt; padding-bottom: 2.75pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Complete response (CR) <font style="padding-left: 1.65pt;"></font></div></td><td class="gutter" style="width: 3.15%; border-bottom: none; font-size: 2pt; padding-top: 4pt; padding-bottom: 2.75pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 3.15%; border-bottom: none; font-size: 2pt; padding-top: 4pt; padding-bottom: 2.75pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.9%; text-align: center; vertical-align: bottom; padding-top: 4pt; padding-bottom: 2.75pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">30 (23.6)</div></td><td class="gutter" style="width: 3.15%; border-bottom: none; font-size: 2pt; padding-top: 4pt; padding-bottom: 2.75pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 3.15%; border-bottom: none; font-size: 2pt; padding-top: 4pt; padding-bottom: 2.75pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.59%; text-align: center; vertical-align: bottom; padding-top: 4pt; padding-bottom: 2.75pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">5 (45.5)</div></td><td class="gutter" style="width: 3.15%; border-bottom: none; font-size: 2pt; padding-top: 4pt; padding-bottom: 2.75pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 3.15%; border-bottom: none; font-size: 2pt; padding-top: 4pt; padding-bottom: 2.75pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.59%; text-align: center; vertical-align: bottom; padding-top: 4pt; padding-bottom: 2.75pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">0 &#8199;(0.0)</div></td><td class="gutter" style="width: 3.15%; border-bottom: none; font-size: 2pt; padding-top: 4pt; padding-bottom: 2.75pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 3.15%; border-bottom: none; font-size: 2pt; padding-top: 4pt; padding-bottom: 2.75pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.45%; text-align: center; vertical-align: bottom; padding-top: 4pt; padding-bottom: 2.75pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">35 (24.1)</div></td></tr><tr><td style="width: 39.25%; text-align: left; vertical-align: bottom; padding-top: 2.75pt; padding-bottom: 2.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Partial response (PR) <font style="padding-left: 0.54pt;"></font></div></td><td class="gutter" style="width: 3.15%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td class="gutter" style="width: 3.15%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td style="width: 10.9%; text-align: center; vertical-align: bottom; padding-top: 2.75pt; padding-bottom: 2.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">34 (26.8)</div></td><td class="gutter" style="width: 3.15%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td class="gutter" style="width: 3.15%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td style="width: 7.59%; text-align: center; vertical-align: bottom; padding-top: 2.75pt; padding-bottom: 2.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">0 &#8199;(0.0)</div></td><td class="gutter" style="width: 3.15%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td class="gutter" style="width: 3.15%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td style="width: 7.59%; text-align: center; vertical-align: bottom; padding-top: 2.75pt; padding-bottom: 2.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">1 (14.3)</div></td><td class="gutter" style="width: 3.15%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td class="gutter" style="width: 3.15%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td style="width: 9.45%; text-align: center; vertical-align: bottom; padding-top: 2.75pt; padding-bottom: 2.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">35 (24.1)</div></td></tr><tr><td style="width: 39.25%; text-align: left; vertical-align: bottom; padding-top: 2.75pt; padding-bottom: 2.75pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Stable disease<font style="padding-left: 3.3pt;"></font></div></td><td class="gutter" style="width: 3.15%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 3.15%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.9%; text-align: center; vertical-align: bottom; padding-top: 2.75pt; padding-bottom: 2.75pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">20 (15.7)</div></td><td class="gutter" style="width: 3.15%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 3.15%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.59%; text-align: center; vertical-align: bottom; padding-top: 2.75pt; padding-bottom: 2.75pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">1 &#8199;(9.1)</div></td><td class="gutter" style="width: 3.15%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 3.15%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.59%; text-align: center; vertical-align: bottom; padding-top: 2.75pt; padding-bottom: 2.75pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">1 (14.3)</div></td><td class="gutter" style="width: 3.15%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 3.15%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.45%; text-align: center; vertical-align: bottom; padding-top: 2.75pt; padding-bottom: 2.75pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">22 (15.2)</div></td></tr><tr><td style="width: 39.25%; text-align: left; vertical-align: bottom; padding-top: 2.75pt; padding-bottom: 2.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Progressive disease<font style="padding-left: 1.65pt;"></font></div></td><td class="gutter" style="width: 3.15%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td class="gutter" style="width: 3.15%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td style="width: 10.9%; text-align: center; vertical-align: bottom; padding-top: 2.75pt; padding-bottom: 2.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">23 (18.1)</div></td><td class="gutter" style="width: 3.15%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td class="gutter" style="width: 3.15%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td style="width: 7.59%; text-align: center; vertical-align: bottom; padding-top: 2.75pt; padding-bottom: 2.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">4 (36.4)</div></td><td class="gutter" style="width: 3.15%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td class="gutter" style="width: 3.15%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td style="width: 7.59%; text-align: center; vertical-align: bottom; padding-top: 2.75pt; padding-bottom: 2.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">3 (42.9)</div></td><td class="gutter" style="width: 3.15%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td class="gutter" style="width: 3.15%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td style="width: 9.45%; text-align: center; vertical-align: bottom; padding-top: 2.75pt; padding-bottom: 2.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">30 (20.7)</div></td></tr><tr><td style="width: 39.25%; text-align: left; vertical-align: bottom; padding-top: 2.75pt; padding-bottom: 2.75pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Not evaluable<font style="padding-left: 3.86pt;"></font></div></td><td class="gutter" style="width: 3.15%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 3.15%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.9%; text-align: center; vertical-align: bottom; padding-top: 2.75pt; padding-bottom: 2.75pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">20 (15.7)</div></td><td class="gutter" style="width: 3.15%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 3.15%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.59%; text-align: center; vertical-align: bottom; padding-top: 2.75pt; padding-bottom: 2.75pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">1 &#8199;(9.1)</div></td><td class="gutter" style="width: 3.15%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 3.15%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.59%; text-align: center; vertical-align: bottom; padding-top: 2.75pt; padding-bottom: 2.75pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">2 (28.6)</div></td><td class="gutter" style="width: 3.15%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 3.15%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.45%; text-align: center; vertical-align: bottom; padding-top: 2.75pt; padding-bottom: 2.75pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">23 (15.9)</div></td></tr><tr><td style="width: 39.25%; text-align: left; vertical-align: bottom; padding-top: 2.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Overall response rate (CR + PR)<font style="font-weight: normal; padding-left: 2.27pt;"></font></div></td><td class="gutter" style="width: 3.15%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt;">&#8203;</td><td class="gutter" style="width: 3.15%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt;">&#8203;</td><td style="width: 10.9%; text-align: center; vertical-align: bottom; padding-top: 2.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">64 (50.4)</div></td><td class="gutter" style="width: 3.15%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt;">&#8203;</td><td class="gutter" style="width: 3.15%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt;">&#8203;</td><td style="width: 7.59%; text-align: center; vertical-align: bottom; padding-top: 2.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">5 (45.5)</div></td><td class="gutter" style="width: 3.15%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt;">&#8203;</td><td class="gutter" style="width: 3.15%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt;">&#8203;</td><td style="width: 7.59%; text-align: center; vertical-align: bottom; padding-top: 2.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">1 (14.3)</div></td><td class="gutter" style="width: 3.15%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt;">&#8203;</td><td class="gutter" style="width: 3.15%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt;">&#8203;</td><td style="width: 9.45%; text-align: center; vertical-align: bottom; padding-top: 2.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">70 (48.3)</div></td></tr></table><div><div class="rule-partial" style="height: 0pt; width: 72pt; border-bottom: 1pt solid #000000; margin-bottom: 1pt; margin-right: auto; margin-left: 40pt; margin-top: 13.25pt;"> </div></div><div class="ftnote" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 3pt; margin-left: 40pt; text-align: left;">Response rate data. &#8220;Not evaluable&#8221; means that the patient met the criteria for inclusion in the efficacy analysis set, but the only scan obtained for disease assessment was indeterminate. </div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">Lonca&#8217;s favorable clinical activity was observed across a broad patient population in this clinical trial, including transplant eligible and ineligible patients, patients who have not responded to first-line therapy or any prior therapy, patients with bulky disease, double-hit and triple-hit disease and transformed disease and patients who had received prior CD19 therapies and SCT. The tables below show the effect of tumor characteristics, age, response to prior therapy and prior therapy (i.e., stem cell transplant or CAR-T) on response rate data. </div></td></tr></table><table cellspacing="0" cellpadding="0" class="fintab" style="margin-top: 11.25pt; border-collapse: collapse; width: 428pt; margin-left: 40pt;"><tr class="header"><td style="width: 78.5%; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Tumor Characteristics</div></td><td class="gutter" style="width: 1.28%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.28%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 18.94%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Overall Response Rate,<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">responders/total (%)</div></td></tr><tr><td style="width: 78.5%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Double-hit or triple-hit disease<font style="padding-left: 2.99pt;"></font></div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 18.94%; text-align: center; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">&#8199;5/15 (33.3)</div></td></tr><tr><td style="width: 78.5%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Transformed disease</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 18.94%; text-align: center; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">13/29 (44.8)</div></td></tr><tr><td style="width: 78.5%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Double/triple expressor<font style="padding-left: 3.54pt;"></font></div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 18.94%; text-align: center; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">10/20 (50.0)</div></td></tr><tr><td style="width: 78.5%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Germinal center B-cell DLBCL<font style="padding-left: 4.11pt;"></font></div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 18.94%; text-align: center; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">26/48 (54.2)</div></td></tr><tr><td style="width: 78.5%; text-align: left; vertical-align: bottom; padding-top: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Activated B-cell DLBCL<font style="padding-left: 0.76pt;"></font></div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 18.94%; text-align: center; vertical-align: bottom; padding-top: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">11/23 (47.8)</div></td></tr></table><table cellspacing="0" cellpadding="0" class="fintab" style="margin-top: 6pt; border-collapse: collapse; width: 428pt; margin-left: 40pt;"><tr class="header"><td style="width: 78.5%; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Age</div></td><td class="gutter" style="width: 0.7%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 0.7%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 20.09%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Overall Response Rate,<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">responders/total (%)</div></td></tr><tr><td style="width: 78.5%; text-align: left; vertical-align: top; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Less than 65<font style="padding-left: 1.3pt;"></font></div></td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 20.09%; text-align: center; vertical-align: top; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">32/65 (49.2)</div></td></tr><tr><td style="width: 78.5%; text-align: left; vertical-align: top; padding-top: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">More than or equal to 65<font style="padding-left: 0.21pt;"></font></div></td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt;">&#8203;</td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt;">&#8203;</td><td style="width: 20.09%; text-align: center; vertical-align: top; padding-top: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">38/80 (47.5)</div></td></tr></table></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 36pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">137<br></div></div></div>
<!--End Page 141-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 142-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 540pt;"><a name="nt10014672x1_drs_107-business_pg27"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="block-frill" style="width: 540pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: Arial, Helvetica, sans-serif; font-size: 9pt; font-weight: bold; margin-top: 6pt; text-align: center;">Confidential Treatment Requested by ADC Therapeutics SA Pursuant to 17 C.F.R. &#167; 200.83<br></div></div><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 36pt;"><table cellspacing="0" cellpadding="0" class="fintab" style="margin-top: 4pt; border-collapse: collapse; width: 428pt; margin-left: 40pt;"><tr class="header"><td colspan="4" style="width: 58.64%; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Response to Prior Therapy</div></td><td class="gutter" style="width: 0.7%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 0.7%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 39.95%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Overall Response Rate,<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">responders/total (%)</div></td></tr><tr><td style="width: 44.86%; text-align: left; vertical-align: top; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Response to first-line systemic therapy<font style="padding-left: 0.68pt;"></font></div></td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 12.38%; text-align: left; vertical-align: top; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Refractory<font style="padding-left: 2.74pt;"></font></div></td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 39.95%; text-align: center; vertical-align: top; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">11/29 (37.9), including 5/29 (17.2) CR</div></td></tr><tr><td style="width: 44.86%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 12.38%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Relapsed<font style="padding-left: 3.85pt;"></font></div></td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 39.95%; text-align: center; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">53/99 (53.5)</div></td></tr><tr><td style="width: 44.86%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Response to prior last-line systemic therapy<font style="padding-left: 0.13pt;"></font></div></td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 12.38%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Refractory<font style="padding-left: 2.74pt;"></font></div></td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 39.95%; text-align: center; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">31/84 (36.9), including 10/84 (11.9) CR</div></td></tr><tr><td style="width: 44.86%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 12.38%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Relapsed<font style="padding-left: 3.85pt;"></font></div></td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 39.95%; text-align: center; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">29/43 (67.4)</div></td></tr><tr><td style="width: 44.86%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Response to any prior line systemic therapy<font style="padding-left: 4.57pt;"></font></div></td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 12.38%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Refractory<font style="padding-left: 2.74pt;"></font></div></td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 39.95%; text-align: center; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">9/25 (36.0)</div></td></tr><tr><td style="width: 44.86%; text-align: left; vertical-align: top; padding-top: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt;">&#8203;</td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt;">&#8203;</td><td style="width: 12.38%; text-align: left; vertical-align: top; padding-top: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Relapsed<font style="padding-left: 3.85pt;"></font></div></td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt;">&#8203;</td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt;">&#8203;</td><td style="width: 39.95%; text-align: center; vertical-align: top; padding-top: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">60/115 (52.2)</div></td></tr></table><table cellspacing="0" cellpadding="0" class="fintab" style="margin-top: 6pt; border-collapse: collapse; width: 428pt; margin-left: 40pt;"><tr class="header"><td style="width: 78.5%; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Prior Therapy</div></td><td class="gutter" style="width: 0.7%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 0.7%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 20.09%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Overall Response Rate,<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">responders/total (%)</div></td></tr><tr><td style="width: 78.5%; text-align: left; vertical-align: top; padding-top: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Stem cell transplant<font style="padding-left: 2.42pt;"></font></div></td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 20.09%; text-align: center; vertical-align: top; padding-top: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">14/24 (58.3)</div></td></tr></table><div><div class="rule-partial" style="height: 0pt; width: 72pt; border-bottom: 1pt solid #000000; margin-bottom: 1pt; margin-right: auto; margin-left: 40pt; margin-top: 13.25pt;"> </div></div><div class="ftnote" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 4.5pt; margin-left: 40pt; text-align: left;">Overall response rate data by various baseline patient characteristics.</div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 40pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">The median DoR was 10.25 months for patients who achieved a response. The figure below shows the DoR. </div></td></tr></table><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 15.25pt; margin-left: 40pt; text-align: left;"><img style="height: 199px; width: 520px;" src="nt10014672x1_linechart1x1.jpg"><br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 40pt; text-align: left;">&#8201;</div><div><div class="rule-partial" style="height: 0pt; width: 72pt; border-bottom: 1pt solid #000000; margin-bottom: 1pt; margin-right: auto; margin-left: 40pt; margin-top: 15.25pt;"> </div></div><div class="ftnote" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 4.5pt; margin-left: 40pt; text-align: left;">Duration of response. </div><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 19.5pt; margin-left: 0pt; text-align: left;">Phase 1/2 Combination Clinical Trial with Ibrutinib</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Ibrutinib is a small-molecule inhibitor of Bruton&#8217;s tyrosine kinase (&#8220;BTK&#8221;), a mediator of the B cell receptor signaling pathway implicated in the pathogenesis of B cell cancers. BTK&#8217;s role in signaling results in activation of pathways necessary for B cell tracking, chemotaxis and adhesion. Ibrutinib forms a covalent bond with cysteine residue in the BTK active site, leading to inhibition of BTK enzymatic activity. Nonclinical studies have shown that ibrutinib inhibits malignant B cell proliferation and survival <font style="font-style: italic;">in vivo</font> as well as cell migration and substrate adhesion <font style="font-style: italic;">in vitro</font>. Currently, ibrutinib is indicated for the treatment of several types of B-NHL, including MCL.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Both Lonca and ibrutinib have demonstrated clinical activity as single agents for the treatment of relapsed or refractory B-NHL, including DLBCL and MCL. For example, ibrutinib has shown a 37% response rate, including a 16% complete response rate for patients with non-germinal center B-cell (&#8220;GCB&#8221;) DLBCL and a 5% response rate for patients with GCB DLBCL. In addition, in our preclinical studies in DLBCL models, we have observed synergistic effects when Lonca and ibrutinib were used in combination. We believe that combining these two targeted agents with different mechanisms of action has the potential to increase clinical activity compared to either agent alone.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">We are conducting a Phase 1/2 open-label, single-arm dose escalation and dose expansion clinical trial of the safety and efficacy of Lonca, used in combination with ibrutinib, in patients with relapsed or refractory DLBCL or MCL. We are conducting the clinical trial at 16 sites in the United States and Europe, pursuant to an </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 36pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">138<br></div></div></div>
<!--End Page 142-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 143-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 540pt;"><a name="nt10014672x1_drs_107-business_pg28"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="block-frill" style="width: 540pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: Arial, Helvetica, sans-serif; font-size: 9pt; font-weight: bold; margin-top: 6pt; text-align: center;">Confidential Treatment Requested by ADC Therapeutics SA Pursuant to 17 C.F.R. &#167; 200.83<br></div></div><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 36pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">IND accepted by the FDA in December 2015, an additional protocol submitted in July 2018 and amended protocols submitted in January and May 2020. The first patient was dosed in February 2019 and the first patient in the pivotal Phase 2 portion was dosed in July 2020. The clinical trial&#8217;s design and our interim findings are summarized below.</div><div class="h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 20.5pt; margin-left: 0pt; text-align: left;">Clinical Trial Design</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The primary objectives of the Phase 1 part of this clinical trial were to (i)&#160;characterize the safety and tolerability of Lonca in combination with ibrutinib and (ii)&#160;identify the MTD, recommended dose and dose schedule for Lonca in this clinical trial. The primary objective of the Phase 2 part of this clinical trial is to evaluate the efficacy of Lonca in combination with ibrutinib, as measured by ORR, DoR, OS and PFS. The secondary objectives of the Phase 1 part of this clinical trial were to (i)&#160;evaluate the anti-tumor effect of the combination of Lonca with ibrutinib, (ii)&#160;characterize the pharmacokinetic profile of Lonca when given in combination with ibrutinib and (iii)&#160;evaluate the immunogenicity of Lonca when given in combination with ibrutinib. The objectives of the Phase 2 part of this clinical trial are to (i)&#160;evaluate the safety and efficacy of Lonca in combination with ibrutinib, (ii)&#160;characterize the pharmacokinetic profile and immunogenicity of Lonca when given in combination with ibrutinib and (iii)&#160;evaluate the impact of Lonca in combination with ibrutinib on patient-reported outcomes, including symptoms, functions and overall status.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The clinical trial is enrolling patients with pathologically confirmed relapsed or refractory DLBCL who have failed or are intolerant to available standard therapy and patients with pathologically confirmed relapsed or refractory MCL who had received at least one prior line of therapy. The clinical trial is expected to enroll approximately 161 patients. The table below presents information about the first 25 patients&#8217; characteristics.</div><table cellspacing="0" cellpadding="0" class="fintab" style="margin-top: 11.25pt; border-collapse: collapse; width: 468pt; margin-left: auto; margin-right: auto;"><tr class="header"><td colspan="4" style="width: 80.77%; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Patient Characteristics</div></td><td class="gutter" style="width: 0.64%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 17.95%; text-align: center; vertical-align: bottom; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td></tr><tr><td colspan="4" style="width: 80.77%; text-align: left; vertical-align: top; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Age, median (minimum, maximum) <font style="padding-left: 4.98pt;"></font></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 17.95%; text-align: center; vertical-align: top; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">69 (39, 87)</div></td></tr><tr><td style="width: 46.15%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">ECOG performance status*, n (%)<font style="padding-left: 2.18pt;"></font></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 33.33%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">0<font style="padding-left: 3.5pt;"></font></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 17.95%; text-align: center; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">14 &#8199;&#8199;(56.0)</div></td></tr><tr><td style="width: 46.15%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 33.33%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">1<font style="padding-left: 3.5pt;"></font></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 17.95%; text-align: center; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">&#8199;8 &#8199;&#8199;(32.0)</div></td></tr><tr><td style="width: 46.15%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 33.33%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">2<font style="padding-left: 3.5pt;"></font></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 17.95%; text-align: center; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">&#8199;3 &#8199;&#8199;(12.0)</div></td></tr><tr><td style="width: 46.15%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">NHL subtype, n (%)<font style="padding-left: 4.74pt;"></font></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 33.33%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Double-hit or triple-hit DLBCL**<font style="padding-left: 4.09pt;"></font></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 17.95%; text-align: center; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">&#8199;1 &#8199;&#8199;&#8199;(4.0)</div></td></tr><tr><td style="width: 46.15%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 33.33%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Transformed DLBCL***<font style="padding-left: 1.1pt;"></font></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 17.95%; text-align: center; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">&#8199;3 &#8199;&#8199;(12.0)</div></td></tr><tr><td style="width: 46.15%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 33.33%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Total DLBCL<font style="padding-left: 1.99pt;"></font></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 17.95%; text-align: center; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">23 &#8199;&#8199;(92.0)</div></td></tr><tr><td style="width: 46.15%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 33.33%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">MCL<font style="padding-left: 1.84pt;"></font></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 17.95%; text-align: center; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">&#8199;2 &#8199;&#8199;&#8199;(8.0)</div></td></tr><tr><td style="width: 46.15%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Disease stage****, n (%)<font style="padding-left: 4.39pt;"></font></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 33.33%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Stage II<font style="padding-left: 1.3pt;"></font></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 17.95%; text-align: center; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">&#8199;3 &#8199;&#8199;(12.0)</div></td></tr><tr><td style="width: 46.15%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 33.33%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Stage III<font style="padding-left: 2.97pt;"></font></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 17.95%; text-align: center; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">&#8199;3 &#8199;&#8199;(12.0)</div></td></tr><tr><td style="width: 46.15%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 33.33%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Stage IV<font style="padding-left: 2.41pt;"></font></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 17.95%; text-align: center; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">19 &#8199;&#8199;(76.0)</div></td></tr><tr><td colspan="4" style="width: 80.77%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Number of previous systemic therapies received, median (minimum, maximum)<font style="padding-left: 2.84pt;"></font></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 17.95%; text-align: center; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">&#8199;2 &#8199;&#8199;(1, 5)</div></td></tr><tr><td style="width: 46.15%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Response to first-line systemic therapy, n (%)<font style="padding-left: 1.18pt;"></font></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 33.33%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Relapsed<font style="padding-left: 1.85pt;"></font></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 17.95%; text-align: center; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">18 &#8199;&#8199;(72.0)</div></td></tr><tr><td style="width: 46.15%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 33.33%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Refractory<font style="padding-left: 0.74pt;"></font></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 17.95%; text-align: center; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">&#8199;5 &#8199;&#8199;(20.0)</div></td></tr><tr><td style="width: 46.15%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Response to last-line systemic therapy, n (%)<font style="padding-left: 3.39pt;"></font></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 33.33%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Relapsed<font style="padding-left: 1.85pt;"></font></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 17.95%; text-align: center; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">11 &#8199;&#8199;(44.0)</div></td></tr><tr><td style="width: 46.15%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 33.33%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Refractory<font style="padding-left: 0.74pt;"></font></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 17.95%; text-align: center; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">12 &#8199;&#8199;(48.0)</div></td></tr><tr><td style="width: 46.15%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Prior stem cell transplant, n (%)<font style="padding-left: 1.62pt;"></font></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 33.33%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Autologous stem cell transplant<font style="padding-left: 4.1pt;"></font></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 17.95%; text-align: center; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">&#8199;1 &#8199;&#8199;&#8199;(4.0)</div></td></tr><tr><td style="width: 46.15%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 33.33%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Allogeneic stem cell transplant<font style="padding-left: 1.88pt;"></font></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 17.95%; text-align: center; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">&#8199;2 &#8199;&#8199;&#8199;(8.0)</div></td></tr><tr><td style="width: 46.15%; text-align: left; vertical-align: top; padding-top: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 33.33%; text-align: left; vertical-align: top; padding-top: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">No<font style="padding-left: 1.28pt;"></font></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 17.95%; text-align: center; vertical-align: top; padding-top: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">22 &#8199;&#8199;(88.0)</div></td></tr></table><div><div class="rule-partial" style="height: 0pt; width: 72pt; border-bottom: 1pt solid #000000; margin-bottom: 1pt; margin-right: auto; margin-left: 0pt; margin-top: 13.25pt;"> </div></div><div class="ftnote" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 3pt; margin-left: 0pt; text-align: left;">Information about the patients&#8217; characteristics. *ECOG performance status describes a patient&#8217;s level of functioning in terms of their ability to care for themself, daily activity and physical ability: Grade 0 means fully active, able to carry on all pre-disease performance without restriction; Grade 1 means restricted in physically strenuous activity but ambulatory and able to carry out work of a light or sedentary nature; Grade 2 means ambulatory and capable of all self-care but unable to carry out any work activities. **Double-hit and triple-hit DLBCL are rare subtypes of DLBCL characterized by two or three recurrent chromosome translocations and are generally associated with poor prognosis. ***Transformed disease is recorded for patients who had another type of lymphoma that progressed to become DLBCL. ****Disease stage is determined by the location of the tumor: Stage I means that the cancer is located in a single region, usually one lymph node and the surrounding area. Stage II means that the cancer is located in two separate regions, an affected lymph node or lymphatic organ and a second affected area, and that both affected areas are confined to one side of the diaphragm; Stage III means that the cancer has spread to both sides of the diaphragm, including one organ or area near the lymph nodes or the spleen; Stage IV means diffuse or disseminated involvement of one or more extralymphatic organs, including any involvement of the liver, bone marrow, or nodular involvement of the lungs.</div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 36pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">139<br></div></div></div>
<!--End Page 143-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 144-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 540pt;"><a name="nt10014672x1_drs_107-business_pg29"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="block-frill" style="width: 540pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: Arial, Helvetica, sans-serif; font-size: 9pt; font-weight: bold; margin-top: 6pt; text-align: center;">Confidential Treatment Requested by ADC Therapeutics SA Pursuant to 17 C.F.R. &#167; 200.83<br></div></div><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 36pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The clinical trial will have three stages: dose escalation, dose expansion and a pivotal Phase&#160;2 clinical trial to support our application for accelerated approval. In the dose escalation stage, patients received ibrutinib at 560&#160;mg/per day and received intravenous infusions of Lonca, at escalating doses, on the first day of each 21-day treatment cycle. The initial dose of Lonca was 60 &#181;g/kg and the highest allowed dose was 150&#160;&#181;g/kg. Dose escalation was conducted using a 3+3 design with oversight by a DESC. The initial dose escalation cohort received Lonca concurrently with ibrutinib for two treatment cycles and may then continue ibrutinib therapy for up to one year. In the dose expansion stage, patients received ibrutinib at 560 mg/per day and receive intravenous infusions of Lonca at 60 &#181;g/kg on the first day of each 21-day treatment cycle. The dose level was determined by the DESC based on the anti-tumor activity and tolerability observed during the dose escalation stage. The dose expansion stage has three cohorts, two for DLBCL (one for GCB and one for non-GCB) and one for MCL, to obtain additional safety and preliminary anti-tumor activity information at the recommended Phase 2 dose. The pivotal Phase 2 portion has three cohorts, two for DLBCL (one for GCB and one for non-GCB) and one for MCL. In the pivotal Phase 2 portion, patients receive ibrutinib at 560 mg/per day and receive intravenous infusions of Lonca at 60 &#956;g/kg on the first day of each 21-day treatment cycle. In this clinical trial, response to treatment is determined as CR, PR, SD or PD, based on the 2014 Lugano Classification Criteria.</div><div class="h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 20.5pt; margin-left: 0pt; text-align: left;">Interim Data </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">As of April 6, 2020, 25 patients have been enrolled, comprised of 23 DLBCL patients and two MCL patients. The median number of treatment cycles received was 2 and the maximum number of treatment cycles received was 4. The median duration of treatment was 42 days.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8.5pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The main observed safety and tolerability findings were as follows:</div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">Grade &#8805;3 TEAEs were reported in 14 patients, or 56.0% of patients. The table below presents the most common Grade &#8805;3 TEAEs that were reported in more than 5% of patients.</div></td></tr></table><table cellspacing="0" cellpadding="0" class="fintab" style="margin-top: 11.25pt; border-collapse: collapse; width: 428pt; margin-left: 40pt;"><tr class="header"><td style="width: 84.11%; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Grade &#8805;3 TEAEs*, n (%)</div></td><td class="gutter" style="width: 3.56%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 3.56%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 8.76%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">All Doses <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">(n=25)</div></td></tr><tr><td style="width: 84.11%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Thrombocytopenia<font style="padding-left: 1.4pt;"></font></div></td><td class="gutter" style="width: 3.56%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 3.56%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.76%; text-align: center; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">&#8199;5 (20.0)</div></td></tr><tr><td style="width: 84.11%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Anemia<font style="padding-left: 0.84pt;"></font></div></td><td class="gutter" style="width: 3.56%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 3.56%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 8.76%; text-align: center; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">&#8199;3 (12.0)</div></td></tr><tr><td style="width: 84.11%; text-align: left; vertical-align: bottom; padding-top: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Patients with any Grade &#8805;3 TEAEs <font style="font-weight: normal; padding-left: 0.02pt;"></font></div></td><td class="gutter" style="width: 3.56%; border-bottom: none; font-size: 2pt; padding-top: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 3.56%; border-bottom: none; font-size: 2pt; padding-top: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.76%; text-align: center; vertical-align: bottom; padding-top: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">14 (56.0)</div></td></tr></table><div><div class="rule-partial" style="height: 0pt; width: 72pt; border-bottom: 1pt solid #000000; margin-bottom: 1pt; margin-right: auto; margin-left: 40pt; margin-top: 13.25pt;"> </div></div><div class="ftnote" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 3pt; margin-left: 40pt; text-align: left;">The most common Grade &#8805;3 TEAEs. *Grade refers to the severity of the adverse event, with grade 1 adverse events generally including mild or asymptomatic conditions or clinical or diagnostic observations only, grade 2 adverse events generally including moderate events or minimal, local or non-invasive intervention events, grade 3 adverse events generally including severe or medically significant events that are not immediately life-threatening, events requiring hospitalization or prolongation of hospitalization or disabling events and grade 4 adverse events generally including life-threatening consequences or urgent intervention events.</div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">TEAEs in four patients, or 16.0% of patients, led to treatment discontinuation. </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">One DLT of Death Not Otherwise Specified was observed in a patient treated with Lonca at the 90 &#181;g/kg dose level in combination with ibrutinib, which the investigator assessed as unlikely to be related to Lonca and as possibly being related to ibrutinib, the disease and/or comorbidities. One DLT of anemia and thrombocytopenia was observed in a patient treated with Lonca at the 90 &#181;g/kg dose level in combination with ibrutinib, which the investigator assessed as possibly being related to Lonca, ibrutinib, the disease and/or comorbidities.</div></td></tr></table></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 36pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">140<br></div></div></div>
<!--End Page 144-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 145-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 540pt;"><a name="nt10014672x1_drs_107-business_pg30"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="block-frill" style="width: 540pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: Arial, Helvetica, sans-serif; font-size: 9pt; font-weight: bold; margin-top: 6pt; text-align: center;">Confidential Treatment Requested by ADC Therapeutics SA Pursuant to 17 C.F.R. &#167; 200.83<br></div></div><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 36pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Seventeen DLBCL patients and one MCL patient were evaluable for efficacy. The main observed efficacy findings were as follows:</div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">Across all dose levels, nine patients, or 50.0% of patients, achieved a complete response and another three patients, or 16.7% of patients, achieved a partial response, resulting in a 66.7% ORR. At the 60 &#956;g/kg dose level, which is being used in the pivotal Phase 2 portion of the clinical trial, seven patients, or 58.3% of patients, achieved a complete response and another two patients, or 16.7% of patients, achieved a partial response, resulting in a 75.0% ORR. The table below shows the response rate data from this clinical trial. </div></td></tr></table><table cellspacing="0" cellpadding="0" class="fintab" style="margin-top: 11.25pt; border-collapse: collapse; width: 428pt; margin-left: 40pt;"><tr class="header"><td style="width: 56.07%; text-align: left; vertical-align: bottom; padding-top: 6pt; padding-bottom: 4pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 1.66%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 4pt;">&#8203;</td><td class="gutter" style="width: 1.66%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td colspan="7" style="width: 40.61%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Dose Levels</div></td></tr><tr class="header"><td style="width: 56.07%; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4pt; padding-bottom: 4pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Best Overall Response, n (%) </div></td><td class="gutter" style="width: 1.66%; font-size: 2pt; padding-top: 4pt; padding-bottom: 4pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.66%; font-size: 2pt; padding-top: 4pt; padding-bottom: 4pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 12.6%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4pt; padding-bottom: 4pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Lonca 60 &#181;g/kg <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">+ ibrutinib<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">(n=12)</div></td><td class="gutter" style="width: 1.66%; font-size: 2pt; padding-top: 4pt; padding-bottom: 4pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.66%; font-size: 2pt; padding-top: 4pt; padding-bottom: 4pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 12.6%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4pt; padding-bottom: 4pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Lonca 90 &#181;g/kg <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">+ ibrutinib<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">(n=6)</div></td><td class="gutter" style="width: 1.66%; font-size: 2pt; padding-top: 4pt; padding-bottom: 4pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.66%; font-size: 2pt; padding-top: 4pt; padding-bottom: 4pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 8.76%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4pt; padding-bottom: 4pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">All Doses <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">(n=18)</div></td></tr><tr><td style="width: 56.07%; text-align: left; vertical-align: bottom; padding-top: 4pt; padding-bottom: 2.75pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Complete response (CR)<font style="padding-left: 1.98pt;"></font></div></td><td class="gutter" style="width: 1.66%; border-bottom: none; font-size: 2pt; padding-top: 4pt; padding-bottom: 2.75pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.66%; border-bottom: none; font-size: 2pt; padding-top: 4pt; padding-bottom: 2.75pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 12.6%; text-align: center; vertical-align: bottom; padding-top: 4pt; padding-bottom: 2.75pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">7 (58.3)</div></td><td class="gutter" style="width: 1.66%; border-bottom: none; font-size: 2pt; padding-top: 4pt; padding-bottom: 2.75pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.66%; border-bottom: none; font-size: 2pt; padding-top: 4pt; padding-bottom: 2.75pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 12.6%; text-align: center; vertical-align: bottom; padding-top: 4pt; padding-bottom: 2.75pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">2 (33.3)</div></td><td class="gutter" style="width: 1.66%; border-bottom: none; font-size: 2pt; padding-top: 4pt; padding-bottom: 2.75pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.66%; border-bottom: none; font-size: 2pt; padding-top: 4pt; padding-bottom: 2.75pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.76%; text-align: center; vertical-align: bottom; padding-top: 4pt; padding-bottom: 2.75pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">9 (50.0)</div></td></tr><tr><td style="width: 56.07%; text-align: left; vertical-align: bottom; padding-top: 2.75pt; padding-bottom: 2.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Partial response (PR) <font style="padding-left: 2.54pt;"></font></div></td><td class="gutter" style="width: 1.66%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td class="gutter" style="width: 1.66%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td style="width: 12.6%; text-align: center; vertical-align: bottom; padding-top: 2.75pt; padding-bottom: 2.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">2 (16.7)</div></td><td class="gutter" style="width: 1.66%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td class="gutter" style="width: 1.66%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td style="width: 12.6%; text-align: center; vertical-align: bottom; padding-top: 2.75pt; padding-bottom: 2.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">1 (16.7)</div></td><td class="gutter" style="width: 1.66%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td class="gutter" style="width: 1.66%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td style="width: 8.76%; text-align: center; vertical-align: bottom; padding-top: 2.75pt; padding-bottom: 2.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">3 (16.7)</div></td></tr><tr><td style="width: 56.07%; text-align: left; vertical-align: bottom; padding-top: 2.75pt; padding-bottom: 2.75pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Stable disease<font style="padding-left: 0.3pt;"></font></div></td><td class="gutter" style="width: 1.66%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.66%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 12.6%; text-align: center; vertical-align: bottom; padding-top: 2.75pt; padding-bottom: 2.75pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">0 &#8199;(0.0)</div></td><td class="gutter" style="width: 1.66%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.66%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 12.6%; text-align: center; vertical-align: bottom; padding-top: 2.75pt; padding-bottom: 2.75pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">0 &#8199;(0.0)</div></td><td class="gutter" style="width: 1.66%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.66%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.76%; text-align: center; vertical-align: bottom; padding-top: 2.75pt; padding-bottom: 2.75pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">0 &#8199;(0.0)</div></td></tr><tr><td style="width: 56.07%; text-align: left; vertical-align: bottom; padding-top: 2.75pt; padding-bottom: 2.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Progressive disease<font style="padding-left: 3.65pt;"></font></div></td><td class="gutter" style="width: 1.66%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td class="gutter" style="width: 1.66%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td style="width: 12.6%; text-align: center; vertical-align: bottom; padding-top: 2.75pt; padding-bottom: 2.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">3 (25.0)</div></td><td class="gutter" style="width: 1.66%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td class="gutter" style="width: 1.66%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td style="width: 12.6%; text-align: center; vertical-align: bottom; padding-top: 2.75pt; padding-bottom: 2.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">3 (50.0)</div></td><td class="gutter" style="width: 1.66%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td class="gutter" style="width: 1.66%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td style="width: 8.76%; text-align: center; vertical-align: bottom; padding-top: 2.75pt; padding-bottom: 2.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">6 (33.3)</div></td></tr><tr><td style="width: 56.07%; text-align: left; vertical-align: bottom; padding-top: 2.75pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Overall response rate (CR + PR) <font style="font-weight: normal; padding-left: 0.94pt;"></font></div></td><td class="gutter" style="width: 1.66%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.66%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 12.6%; text-align: center; vertical-align: bottom; padding-top: 2.75pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">9 (75.0)</div></td><td class="gutter" style="width: 1.66%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.66%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 12.6%; text-align: center; vertical-align: bottom; padding-top: 2.75pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">3 (50.0)</div></td><td class="gutter" style="width: 1.66%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.66%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.76%; text-align: center; vertical-align: bottom; padding-top: 2.75pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">12 (66.7)</div></td></tr></table><div><div class="rule-partial" style="height: 0pt; width: 72pt; border-bottom: 1pt solid #000000; margin-bottom: 1pt; margin-right: auto; margin-left: 40pt; margin-top: 13.25pt;"> </div></div><div class="ftnote" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 4.5pt; margin-left: 40pt; text-align: left;">Response rate data. The evaluable MCL patient received Lonca 60 &#956;g/kg + ibrutinib and displayed a partial response.</div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">The graph below shows the time to response for each patient.</div></td></tr></table><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 15.25pt; margin-left: 40pt; text-align: left;"><img style="height: 274px; width: 550px;" src="nt10014672x1_barchart6x1.jpg"><br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 40pt; text-align: left;">&#8201;</div><div><div class="rule-partial" style="height: 0pt; width: 72pt; border-bottom: 1pt solid #000000; margin-bottom: 1pt; margin-right: auto; margin-left: 40pt; margin-top: 15.25pt;"> </div></div><div class="ftnote" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 4.5pt; margin-left: 40pt; text-align: left;">Swimmer plot. </div><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 19.5pt; margin-left: 0pt; text-align: left;">Pivotal Phase 2 Clinical Trial in Relapsed or Refractory Follicular Lymphoma</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">We intend to conduct a 150-patient Phase 2, randomized, two-arm, multi-center, open-label clinical trial to evaluate the safety and efficacy of Lonca in patients with relapsed or refractory FL. This clinical trial will be conducted pursuant to an IND accepted by the FDA in December 2015 and an additional protocol submitted in September 2020. We intend to commence this clinical trial in the first half of 2021. We believe that this clinical trial, if successful, will form the basis of a BLA submission for accelerated approval of Lonca for the treatment of relapsed or refractory FL in patients who have failed two or more treatment regimens. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The primary objective of the Phase 2 clinical trial is to evaluate the efficacy of Lonca compared to idelalisib in patients with relapsed or refractory FL, measured by CR based on the 2014 Lugano Classification Criteria. The secondary objectives are to (i) further evaluate the additional efficacy of Lonca compared to idelalisib, </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 36pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">141<br></div></div></div>
<!--End Page 145-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 146-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 540pt;"><a name="nt10014672x1_drs_107-business_pg31"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="block-frill" style="width: 540pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: Arial, Helvetica, sans-serif; font-size: 9pt; font-weight: bold; margin-top: 6pt; text-align: center;">Confidential Treatment Requested by ADC Therapeutics SA Pursuant to 17 C.F.R. &#167; 200.83<br></div></div><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 36pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">(ii)&#160;assess the safety profile of Lonca, (iii) characterize the pharmacokinetic profile of Lonca, (iv) evaluate the immunogenicity of Lonca and (v) evaluate the impact of Lonca treatment compared to idelalisib on patient-reported outcomes, including symptoms, functions and overall status. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The clinical trial will enroll patients with pathologically confirmed relapsed or refractory FL who have previously received two or more treatment regimens, at least one of which must have contained an anti-CD20 therapy. The clinical trial is expected to enroll approximately 150 patients. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">In the clinical trial, patients will be randomly assigned 2:1 to receive either (i)&#160;a 150 &#956;g/kg dose of Lonca on the first day of each 21-day treatment cycle for two treatment cycles followed by a 75 &#956;g/kg dose on the first day of each 21-day treatment cycle for subsequent treatment cycles or (ii)&#160;150 mg dose of idelalisib twice daily. The decision for the initial dose level of Lonca is based on the observation in the Phase 1 clinical trial that there was a trend toward increased response with increased exposure and our ability to manage TEAEs at this dose level. In addition, we observed in our Phase 1 clinical trial that a substantial proportion of patients required a dose reduction after two cycles, while almost all of the responses were noted at the first disease assessment, which occurred after two cycles. Therefore, the dosing regimen for this pivotal Phase 2 clinical trial is selected to optimize potential response to treatment, while maintaining a manageable tolerability profile. In this clinical trial, response to treatment is determined as CR, PR, SD or PD, based on the 2014 Lugano Classification Criteria. </div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 15pt; margin-left: 0pt; text-align: left;">Camidanlumab Tesirine: PBD-Based ADC Targeting CD25</div><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 7pt; margin-left: 0pt; text-align: left;">Overview</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Our second lead product candidate, camidanlumab tesirine, or Cami, is an ADC targeting CD25-expressing cancers. We are developing Cami for the treatment of relapsed or refractory HL, NHL and solid tumors. The following summary provides key information about Cami:</div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">We retain worldwide development and commercialization rights to Cami, subject to our collaboration and license agreement with Genmab.</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">We are advancing Cami through clinical development to support a BLA submission for the treatment of relapsed or refractory HL. </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">Cami is being evaluated in a 100-patient pivotal Phase 2 clinical trial for the treatment of relapsed or refractory HL, for which we anticipate reporting top-line response rate data in the first half of 2021. </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 40pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 6pt;">&#9675;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 6pt; text-align: left;"><font style="font-size: 10pt;">As of </font><font style="font-size: 10pt;">June 30</font><font style="font-size: 10pt;">, 2</font><font style="font-size: 10pt;">020, </font><font style="font-size: 10pt;">47</font><font style="font-size: 10pt;"> patients have been </font><font style="font-size: 10pt;">enrolled</font><font style="font-size: 10pt;"> in this pivotal Phase&#160;2 clinical trial</font><font style="font-size: 10pt;">.</font><font style="font-size: 10pt;"> </font></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">Enrollment has been completed in a 133-patient Phase 1 clinical trial of Cami for the treatment of relapsed or refractory HL and NHL, including 77 patients with relapsed or refractory HL. In this clinical trial, Cami demonstrated significant clinical activity across a broad patient population and maintained a tolerability profile that we believe was manageable. More specifically, as of April 2019, we observed: </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 40pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 6pt;">&#9675;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 6pt; text-align: left;"><font style="font-size: 10pt;">A</font><font style="font-size: 10pt;">t the initial dose for our pivotal Phase 2 clinical trial, </font><font style="font-size: 10pt;">an 86.5% ORR </font><font style="font-size: 10pt;">and a 48.6% CRR </font><font style="font-size: 10pt;">in </font><font style="font-size: 10pt;">heavily pre-treated patients with relapsed or refractory HL who </font><font style="font-size: 10pt;">had</font><font style="font-size: 10pt;"> received a median of five </font><font style="font-size: 10pt;">prior lines of therapy</font><font style="font-size: 10pt;">, including patients who were relapsed or refractory to any or all of </font><font style="font-size: 10pt;">brentuximab vedotin, checkpoint inhibitors and stem cell transplant;</font><font style="font-size: 10pt;"> and</font><font style="font-size: 10pt;"> </font></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 40pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 6pt;">&#9675;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 6pt; text-align: left;"><font style="font-size: 10pt;">A</font><font style="font-size: 10pt;"> 44.0% ORR </font><font style="font-size: 10pt;">and an 8.0% CRR </font><font style="font-size: 10pt;">in heavily pre-treated patients with relapsed or refractory T-cell </font><font style="font-size: 10pt;">lymphoma who </font><font style="font-size: 10pt;">had</font><font style="font-size: 10pt;"> received a median of four prior lines of therapy.</font><font style="font-size: 10pt;"> </font></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">Cami is also being evaluated in a Phase 1b clinical trial for the treatment of selected advanced solid tumors by targeting Tregs, for which we anticipate reporting PK/PD data at a medical conference in the second half of 2020. </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 40pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 6pt;">&#9675;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 6pt; text-align: left;"><font style="font-size: 10pt;">In paired biopsies from three </font><font style="font-size: 10pt;">of six </font><font style="font-size: 10pt;">patients in the Phase&#160;1b clinical trial, we have observed a </font><font style="font-size: 10pt;">significant increase in the ratio of </font><font style="font-size: 10pt;">Teffs</font><font style="font-size: 10pt;"> to Tregs.</font></div></td></tr></table><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Of the estimated 16,500 total patients diagnosed with HL each year in the United States and Europe, approximately 15% will exhibit relapsed or refractory HL. We believe that the treatment of relapsed or refractory HL remains an area of high unmet medical need. We are developing Cami as a third-line therapy for the treatment of HL. Despite recent alterations in earlier lines of therapy due to the entry of Adcetris&#174;, there is </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 36pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">142<br></div></div></div>
<!--End Page 146-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 147-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 540pt;"><a name="nt10014672x1_drs_107-business_pg32"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="block-frill" style="width: 540pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: Arial, Helvetica, sans-serif; font-size: 9pt; font-weight: bold; margin-top: 6pt; text-align: center;">Confidential Treatment Requested by ADC Therapeutics SA Pursuant to 17 C.F.R. &#167; 200.83<br></div></div><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 36pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">currently no leading therapeutic option for this patient population. Accordingly, we estimate that the initial addressable patient population is approximately 1,300 patients per year in the United States and Europe. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">We may also undertake additional clinical trials of Cami in combination with other therapies, such as PD1-targeting agents, which, if successful, may allow Cami to be used as a second-line therapy for the treatment of relapsed or refractory HL, thereby increasing the addressable patient population to approximately 2,500 patients per year in the United States and Europe.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">In addition to HL, we are evaluating Cami for the treatment of relapsed or refractory T-cell lymphoma. Of the estimated 11,000 total patients diagnosed with T-cell lymphoma each year in the United States and Europe, approximately 70% will exhibit relapsed or refractory T-cell lymphoma. We believe that the treatment of relapsed or refractory T-cell lymphoma remains an area of high unmet medical need. We intend to develop Cami as a second-line therapy for the treatment of relapsed or refractory T-cell lymphoma to address the high unmet medical need of this patient population. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">We believe that the commercial potential of Cami, if approved, is supported by the following key attributes observed to date: </div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">At the initial dose for our pivotal Phase&#160;2 clinical trial, an 86.5% ORR and a 48.6% CRR in heavily pre-treated patients with relapsed or refractory HL who were relapsed or refractory to any or all of brentuximab vedotin, checkpoint inhibitors and stem cell transplant;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">Tolerability profile that we believe is manageable;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">The potential opportunity to advance Cami into earlier lines of therapy as a monotherapy or in combination with other therapies;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">Novel immuno-oncology approach targeting Tregs for the treatment of various advanced solid tumors; and</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">Convenient 30-minute intravenous infusions once every three weeks in the out-patient setting.</div></td></tr></table><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 20.5pt; margin-left: 0pt; text-align: left;">Structure and Mechanism of Action</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Cami is composed of a human monoclonal antibody (HuMax&#174;-TAC) directed against human CD25 and conjugated through a cathepsin-cleavable linker to SG3199, a PBD dimer cytotoxin. Once bound to a CD25-expressing cell, it is designed to be internalized by the cell, following which the warhead is released. The warhead is designed to bind irreversibly to DNA to create highly potent interstrand cross-links that block DNA strand separation, thus disrupting essential DNA metabolic processes such as replication and ultimately resulting in cell death. The figure below shows a visual representation of Cami and its mechanism of action.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 15.25pt; text-align: center;"><img style="height: 164px; width: 317px;" src="nt10014672x1_diagram11.jpg"><br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">&#8201;</div><div><div class="rule-partial" style="height: 0pt; width: 72pt; border-bottom: 1pt solid #000000; margin-bottom: 1pt; margin-right: auto; margin-left: 0pt; margin-top: 14.75pt;"> </div></div><div class="ftnote" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 4pt; margin-left: 0pt; text-align: left;">Visual representation of Cami.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">CD25, or T cell activation antigen, is the alpha chain of IL-2R. In normal human tissue, expression of CD25 is mainly limited to activated T cells and activated B cells. CD25 is involved in autoimmunity, organ transplantation, and graft rejection, and Tregs are involved in the prevention of autoimmune processes. The preponderance of CD25-expressing cells in hematological malignancies and the relationship between increased CD25 expression and poor prognosis raises the possibility of using an anti-CD25 antibody to deliver a potent cytotoxin to these cells in patients.</div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 36pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">143<br></div></div></div>
<!--End Page 147-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 148-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 540pt;"><a name="nt10014672x1_drs_107-business_pg33"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="block-frill" style="width: 540pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: Arial, Helvetica, sans-serif; font-size: 9pt; font-weight: bold; margin-top: 6pt; text-align: center;">Confidential Treatment Requested by ADC Therapeutics SA Pursuant to 17 C.F.R. &#167; 200.83<br></div></div><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 36pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">We believe that CD25 is an attractive target for ADCs developed to treat hematological malignancies and solid tumors for the following reasons:</div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">CD25 expression in healthy human tissue is mainly limited to activated T cells and activated B cells.</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">CD25 is expressed in a wide range of hematological malignancies.</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">The importance of CD25 overexpression as a prognosticator in hematological malignancies has been shown in multiple indications, including DLBCL.</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">CD25 positive Treg cells have been shown to play a role in undermining anti-tumor immune functions.</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">The safety profiles of monoclonal antibodies directed against CD25 have been well characterized.</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">Clinical proof of concept for treatment of CD25 positive malignancies has been established using radio-immunoconjugates and immunotoxins incorporating the anti-CD25 antibodies.</div></td></tr></table><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 20.5pt; margin-left: 0pt; text-align: left;">Phase 1 Clinical Trial in Relapsed or Refractory Hodgkin and Non-Hodgkin Lymphoma</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">We are conducting a Phase 1, open-label, dose escalation and dose expansion clinical trial of the safety and tolerability of Cami, used as monotherapy, in patients with relapsed or refractory HL or NHL. We have completed enrollment in this clinical trial, having treated 77 patients with relapsed or refractory HL and 51 patients with relapsed or refractory NHL. We are conducting the clinical trial at 12 sites in the United States and Europe, pursuant to an IND accepted by the FDA in April 2015. The first patient was dosed in October 2015. The results of the clinical trial showed encouraging anti-tumor activity and maintained a tolerability profile that we believe was manageable in patients with relapsed or refractory HL or NHL. The clinical trial&#8217;s design and our main findings are summarized below.</div><div class="h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 20.5pt; margin-left: 0pt; text-align: left;">Clinical Trial Design</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The primary objectives of the dose escalation stage of the clinical trial were to (i)&#160;evaluate the safety and tolerability, and determine, as appropriate, the MTD of Cami in patients with relapsed or refractory HL or NHL and (ii)&#160;determine the recommended dose(s) of Cami for the dose expansion stage of the clinical trial. The primary objective of the dose expansion stage was to evaluate the safety and tolerability of Cami at the dose level(s) recommended from the results of the dose escalation stage. The secondary objectives of the clinical trial were to (i)&#160;evaluate the clinical activity of Cami, as measured by ORR, DoR, OS and PFS, (ii)&#160;characterize the pharmacokinetic profile of Cami and the free warhead SG3199 and (iii)&#160;evaluate ADAs in patients&#8217; blood before, during and after treatment with Cami.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The clinical trial enrolled patients with pathologically confirmed relapsed or refractory HL who have failed or were intolerant to brentuximab vedotin and have received a checkpoint inhibitor and is enrolling patients with pathologically confirmed relapsed or refractory NHL who have failed or were intolerant to any established therapy. Of the 128 patients who participated in the clinical trial, 77 were diagnosed with relapsed or refractory HL and the remaining 51 were diagnosed with relapsed or refractory NHL, including 29 patients with relapsed or refractory T-cell lymphoma. The table below presents information about the patients&#8217; characteristics for all patients in the clinical trial and for HL patients.</div><table cellspacing="0" cellpadding="0" class="fintab" style="margin-top: 11.25pt; border-collapse: collapse; width: 468pt; margin-left: auto; margin-right: auto;"><tr class="header"><td style="width: 35.9%; text-align: left; vertical-align: bottom; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;"><u>Patient Characteristics</u></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 48.72%; text-align: center; vertical-align: bottom; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 2.56%; text-align: center; vertical-align: bottom; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 8.97%; text-align: center; vertical-align: bottom; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td></tr><tr><td colspan="4" style="width: 85.9%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Age, median (minimum, maximum)<font style="padding-left: 2.31pt;"></font></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 2.56%; text-align: right; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: right;">52 </div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.97%; text-align: right; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: right;">(19, 88) </div></td></tr><tr><td colspan="4" style="width: 85.9%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Number of previous systemic therapies received, median (minimum, maximum)<font style="padding-left: 1.84pt;"></font></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 2.56%; text-align: right; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: right;"><font style="padding-left: 5pt;">5</font> </div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 8.97%; text-align: right; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: right;">(1, 15)</div></td></tr><tr><td style="width: 35.9%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Prior stem cell transplant, n (%)<font style="padding-left: 3.62pt;"></font></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 48.72%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Yes<font style="padding-left: 0.95pt;"></font></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 2.56%; text-align: right; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: right;">57 </div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.97%; text-align: right; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: right;">(44.5)</div></td></tr><tr><td style="width: 35.9%; text-align: left; vertical-align: bottom; padding-top: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt;">&#8203;</td><td style="width: 48.72%; text-align: left; vertical-align: bottom; padding-top: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">No<font style="padding-left: 3.28pt;"></font></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt;">&#8203;</td><td style="width: 2.56%; text-align: right; vertical-align: bottom; white-space: nowrap; padding-top: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: right;">71 </div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt;">&#8203;</td><td style="width: 8.97%; text-align: right; vertical-align: bottom; padding-top: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: right;">(55.5)</div></td></tr></table><div><div class="rule-partial" style="height: 0pt; width: 72pt; border-bottom: 1pt solid #000000; margin-bottom: 1pt; margin-right: auto; margin-left: 0pt; margin-top: 13.25pt;"> </div></div><div class="ftnote" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 4.5pt; margin-left: 0pt; text-align: left;">Information about the patients&#8217; characteristics.</div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 36pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">144<br></div></div></div>
<!--End Page 148-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 149-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 540pt;"><a name="nt10014672x1_drs_107-business_pg34"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="block-frill" style="width: 540pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: Arial, Helvetica, sans-serif; font-size: 9pt; font-weight: bold; margin-top: 6pt; text-align: center;">Confidential Treatment Requested by ADC Therapeutics SA Pursuant to 17 C.F.R. &#167; 200.83<br></div></div><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 36pt;"><table cellspacing="0" cellpadding="0" class="fintab" style="margin-top: 4pt; border-collapse: collapse; width: 468pt; margin-left: auto; margin-right: auto;"><tr class="header"><td style="width: 35.9%; text-align: left; vertical-align: bottom; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;"><u>Patient Characteristics of HL Patients</u></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 48.72%; text-align: center; vertical-align: bottom; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 2.56%; text-align: center; vertical-align: bottom; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 8.97%; text-align: center; vertical-align: bottom; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td></tr><tr><td colspan="4" style="width: 85.9%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Age, median (minimum, maximum) <font style="padding-left: 3.98pt;"></font></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 2.56%; text-align: right; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: right;">38</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.97%; text-align: right; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: right;">(19, 80)</div></td></tr><tr><td colspan="4" style="width: 85.9%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Number of previous systemic therapies received, median (minimum, maximum)<font style="padding-left: 1.84pt;"></font></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 2.56%; text-align: right; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: right;"><font style="padding-left: 5pt;">5</font> </div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 8.97%; text-align: right; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: right;">(2, 15)</div></td></tr><tr><td style="width: 35.9%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Prior stem cell transplant, n (%) <font style="padding-left: 0.29pt;"></font></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 48.72%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Autologous stem cell transplant<font style="padding-left: 1.1pt;"></font></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 2.56%; text-align: right; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: right;">39 </div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.97%; text-align: right; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: right;">(50.6)</div></td></tr><tr><td style="width: 35.9%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 48.72%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Allogeneic stem cell transplant<font style="padding-left: 3.88pt;"></font></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 2.56%; text-align: right; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: right;"><font style="padding-left: 5pt;">3</font> </div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 8.97%; text-align: right; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: right;">(3.9) </div></td></tr><tr><td style="width: 35.9%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 48.72%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Both autologous and allogeneic stem cell transplant<font style="padding-left: 3.9pt;"></font></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 2.56%; text-align: right; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: right;"><font style="padding-left: 5pt;">5</font> </div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.97%; text-align: right; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: right;">(6.5)</div></td></tr><tr><td style="width: 35.9%; text-align: left; vertical-align: bottom; padding-top: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt;">&#8203;</td><td style="width: 48.72%; text-align: left; vertical-align: bottom; padding-top: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">No<font style="padding-left: 3.28pt;"></font></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt;">&#8203;</td><td style="width: 2.56%; text-align: right; vertical-align: bottom; white-space: nowrap; padding-top: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: right;">30 </div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt;">&#8203;</td><td style="width: 8.97%; text-align: right; vertical-align: bottom; padding-top: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: right;">(39.0)</div></td></tr></table><div><div class="rule-partial" style="height: 0pt; width: 72pt; border-bottom: 1pt solid #000000; margin-bottom: 1pt; margin-right: auto; margin-left: 0pt; margin-top: 12.75pt;"> </div></div><div class="ftnote" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 4pt; margin-left: 0pt; text-align: left;">Information about the HL patients&#8217; characteristics.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">In the dose escalation stage, patients received intravenous infusion of Cami, at escalating doses, on the first day of each 21-day treatment cycle. The initial dose was 3 &#181;g/kg and the highest given dose was 300 &#181;g/kg. Dose escalation was conducted using a continual reassessment method with oversight by a DESC. The MTD was defined as the highest dose level that has at least a 60% probability that the DLT rate is less than 30%. In the dose expansion stage, patients with HL received 30 &#181;g/kg or 45 &#181;g/kg doses on the first day of each 21-day treatment cycle, while patients with T-cell lymphoma received 60 &#181;g/kg or 80 &#181;g/kg doses on the first day of each 21-day treatment cycle. These dose levels were determined by the DESC based on the anti-tumor activity and tolerability observed during the dose escalation stage. In this clinical trial, response to treatment is determined as CR, PR, SD or PD, based on the 2014 Lugano Classification Criteria.</div><div class="h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 15pt; margin-left: 0pt; text-align: left;">Clinical Trial Results</div><div class="h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 14.5pt; margin-left: 20pt; text-align: left;">Hodgkin Lymphoma</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">For patients with relapsed or refractory HL (n=77), the median prior lines of therapy received was five. The median number of treatment cycles received was three and the maximum number of treatment cycles received was 15. The median duration of treatment was 50 days.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The main observed safety and tolerability findings in patients with relapsed or refractory HL were as follows:</div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">The MTD was not reached in the dose escalation stage.</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">Grade &#8805;3 TEAEs were reported in 51 patients, or 66.2% of patients. The table below presents the most common Grade &#8805;3 TEAEs that are reported in more than 5% of patients.</div></td></tr></table><table cellspacing="0" cellpadding="0" class="fintab" style="margin-top: 11.25pt; border-collapse: collapse; width: 428pt; margin-left: 40pt;"><tr class="header"><td rowspan="2" style="width: 44.86%; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Grade &#8805;3 TEAEs, n (%)</div></td><td class="gutter" rowspan="2" style="width: 0.7%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 0.7%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td colspan="13" style="width: 53.74%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Dose Levels</div></td></tr><tr class="header"><td class="gutter" style="width: 0.7%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 9.63%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">&#8804;20 &#181;g/kg <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">(n=3)</div></td><td class="gutter" style="width: 0.7%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 0.7%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 9.63%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">30 &#181;g/kg <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">(n=20)</div></td><td class="gutter" style="width: 0.7%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 0.7%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 9.63%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">45 &#181;g/kg <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">(n=37)</div></td><td class="gutter" style="width: 0.7%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 0.7%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 9.63%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">&#8805;60 &#181;g/kg <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">(n=17)</div></td><td class="gutter" style="width: 0.7%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 0.7%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 9.63%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">All Doses <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">(n=77)</div></td></tr><tr><td style="width: 44.86%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Gamma-glutamyltransferase increased<font style="padding-left: 4.57pt;"></font></div></td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.63%; text-align: center; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">1 (33.3)</div></td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.63%; text-align: center; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">&#8199;2 (10.0)</div></td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.63%; text-align: center; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">&#8199;3 &#8199;(8.1)</div></td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.63%; text-align: center; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">&#8199;7 (41.2)</div></td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.63%; text-align: center; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">13 (16.9)</div></td></tr><tr><td style="width: 44.86%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Maculopapular rash<font style="padding-left: 3.98pt;"></font></div></td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 9.63%; text-align: center; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">1 (33.3)</div></td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 9.63%; text-align: center; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">&#8199;2 (10.0)</div></td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 9.63%; text-align: center; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">&#8199;8 (21.6)</div></td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 9.63%; text-align: center; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">&#8199;2 (11.8)</div></td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 9.63%; text-align: center; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">13 (16.9)</div></td></tr><tr><td style="width: 44.86%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Alanine aminotransferase increased<font style="padding-left: 0.13pt;"></font></div></td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.63%; text-align: center; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">0 &#8199;(0.0)</div></td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.63%; text-align: center; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">&#8199;0 &#8199;(0.0)</div></td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.63%; text-align: center; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">&#8199;3 &#8199;(8.1)</div></td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.63%; text-align: center; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">&#8199;4 (23.5)</div></td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.63%; text-align: center; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">&#8199;7 &#8199;(9.1)</div></td></tr><tr><td style="width: 44.86%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Anemia<font style="padding-left: 2.84pt;"></font></div></td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 9.63%; text-align: center; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">1 (33.3)</div></td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 9.63%; text-align: center; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">&#8199;2 (10.0)</div></td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 9.63%; text-align: center; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">&#8199;3 &#8199;(8.1)</div></td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 9.63%; text-align: center; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">&#8199;0 &#8199;(0.0)</div></td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 9.63%; text-align: center; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">&#8199;6 &#8199;(7.8)</div></td></tr><tr><td style="width: 44.86%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Aspartate aminotransferase increased<font style="padding-left: 3.47pt;"></font></div></td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.63%; text-align: center; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">0 &#8199;(0.0)</div></td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.63%; text-align: center; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">&#8199;0 &#8199;(0.0)</div></td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.63%; text-align: center; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">&#8199;1 &#8199;(2.7)</div></td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.63%; text-align: center; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">&#8199;4 (23.5)</div></td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.63%; text-align: center; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">&#8199;5 &#8199;(6.5)</div></td></tr><tr><td style="width: 44.86%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Guillain&#8211;Barr&#233; syndrome/polyradiculopathy<font style="padding-left: 1.21pt;"></font></div></td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 9.63%; text-align: center; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">0 &#8199;(0.0)</div></td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 9.63%; text-align: center; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">&#8199;1 &#8199;(5.0)</div></td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 9.63%; text-align: center; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">&#8199;3 &#8199;(8.1)</div></td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 9.63%; text-align: center; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">&#8199;1 &#8199;(5.9)</div></td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 9.63%; text-align: center; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">&#8199;5 &#8199;(6.5)</div></td></tr><tr><td style="width: 44.86%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Lipase increased<font style="padding-left: 1.76pt;"></font></div></td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.63%; text-align: center; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">0 &#8199;(0.0)</div></td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.63%; text-align: center; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">&#8199;1 &#8199;(5.0)</div></td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.63%; text-align: center; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">&#8199;3 &#8199;(8.1)</div></td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.63%; text-align: center; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">&#8199;0 &#8199;(0.0)</div></td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.63%; text-align: center; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">&#8199;4 &#8199;(5.2)</div></td></tr><tr><td style="width: 44.86%; text-align: left; vertical-align: bottom; padding-top: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Patients with any Grade &#8805;3 TEAEs<font style="font-weight: normal; padding-left: 0.35pt;"></font></div></td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt;">&#8203;</td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt;">&#8203;</td><td style="width: 9.63%; text-align: center; vertical-align: bottom; padding-top: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">2 (66.7)</div></td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt;">&#8203;</td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt;">&#8203;</td><td style="width: 9.63%; text-align: center; vertical-align: bottom; padding-top: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">12 (60.0)</div></td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt;">&#8203;</td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt;">&#8203;</td><td style="width: 9.63%; text-align: center; vertical-align: bottom; padding-top: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">25 (67.6)</div></td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt;">&#8203;</td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt;">&#8203;</td><td style="width: 9.63%; text-align: center; vertical-align: bottom; padding-top: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">12 (70.6)</div></td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt;">&#8203;</td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt;">&#8203;</td><td style="width: 9.63%; text-align: center; vertical-align: bottom; padding-top: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">51 (66.2)</div></td></tr></table><div><div class="rule-partial" style="height: 0pt; width: 72pt; border-bottom: 1pt solid #000000; margin-bottom: 1pt; margin-right: auto; margin-left: 40pt; margin-top: 12.75pt;"> </div></div><div class="ftnote" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 4pt; margin-left: 40pt; text-align: left;">The most common Grade &#8805;3 TEAEs for various administered dose levels.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 40pt; text-align: left;">In August and September 2017, we informed the FDA that two patients with HL were diagnosed with Guillain&#8211;Barr&#233; syndrome and one HL patient was diagnosed with polyradiculopathy. The FDA issued a partial clinical hold on our clinical trial, pursuant to which we suspended the enrollment of new patients but continued the treatment of enrolled patients who would derive clinical benefit from continued treatment with Cami. We amended the clinical trial protocol and informed consent to include, among other things, additional risk factors to patient screening, additional exclusion criteria and routine neurologic evaluation prior to and during the clinical trial to monitor the occurrence of Guillain&#8211;Barr&#233; syndrome. In January 2018, the FDA lifted the partial clinical hold without condition. One of the patients diagnosed with Guillain&#8211;Barr&#233; </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 36pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">145<br></div></div></div>
<!--End Page 149-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 150-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 540pt;"><a name="nt10014672x1_drs_107-business_pg35"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="block-frill" style="width: 540pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: Arial, Helvetica, sans-serif; font-size: 9pt; font-weight: bold; margin-top: 6pt; text-align: center;">Confidential Treatment Requested by ADC Therapeutics SA Pursuant to 17 C.F.R. &#167; 200.83<br></div></div><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 36pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 40pt; text-align: left;">syndrome achieved a partial response, subsequently progressed and died in June 2019 while under the care at another facility. The other patient diagnosed with Guillain&#8211;Barr&#233; syndrome achieved a complete response and underwent, but died from complications related to, allogeneic stem cell transplant. </div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 40pt; text-align: left;">In September 2018, we informed the FDA that two additional patients with HL were diagnosed with Guillain&#8211;Barr&#233; syndrome. We voluntarily suspended patient enrollment and undertook a detailed safety review of our clinical trial in accordance with our clinical trial protocol and submitted it to the FDA. Our safety review showed with 99% confidence that HL patients were a distinct population at risk of developing Guillain&#8211;Barr&#233; syndrome and included input from a Clinical Advisory Panel that noted the potential positive benefit-risk ratio for patients with few alternative treatment options. Upon review, in October 2018, the FDA agreed that we can resume patient enrollment and made certain recommendations, including the expansion of the HL 30 &#956;g/kg dose cohort to ten additional patients, the continued assessment of pharmacokinetics and regulatory T cell profiles in the clinical trial and that we consult with the FDA regarding the decision of final dose selection before closing the 30 &#956;g/kg dose cohort. We subsequently implemented the FDA&#8217;s recommendations. As of May 2019, the two patients diagnosed with Guillain&#8211;Barr&#233; syndrome achieved a complete response and were alive.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 40pt; text-align: left;">There have been no cases of Guillain&#8211;Barr&#233; syndrome in the more than 130 patients with NHL, acute leukemia or solid tumors treated with Cami. Clinical literature suggests that patients with HL have a higher incidence of Guillain&#8211;Barr&#233; syndrome than patients with other cancers or otherwise healthy individuals. In March and May 2020, in our Phase 2 clinical trial of Cami for the treatment of relapsed or refractory HL, three patients were diagnosed with Guillain&#8211;Barr&#233; syndrome. See &#8220;&#8212;Pivotal Phase 2 Clinical Trial in Relapsed or Refractory Hodgkin Lymphoma.&#8221;</div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">TEAEs in 20 patients, or 26.0% of patients, led to treatment discontinuation.</div></td></tr></table><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">In our analysis, we highlight certain efficacy data for the 45 &#181;g/kg dose level because it is the initial dose in our pivotal Phase 2 clinical trial. The main observed efficacy findings in patients with relapsed or refractory HL were as follows:</div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">Across all dose levels, 30 patients, or 40.0% of patients, achieved a complete response and another 23 patients, or 30.7% of patients, achieved a partial response, resulting in a 70.7% ORR. At the 45&#160;&#181;g/kg dose level, 18 patients, or 48.6% of patients, achieved a complete response and another 14 patients, or 37.8% of patients achieved a partial response, resulting in an 86.5% ORR. The table below shows the response rate data from this clinical trial.</div></td></tr></table><table cellspacing="0" cellpadding="0" class="fintab" style="margin-top: 5.25pt; border-collapse: collapse; width: 428pt; margin-left: 40pt;"><tr class="header"><td rowspan="2" style="width: 44.86%; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Best Overall Response, n (%)</div></td><td class="gutter" rowspan="2" style="width: 1.32%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.32%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td colspan="13" style="width: 52.49%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Dose Levels</div></td></tr><tr class="header"><td class="gutter" style="width: 1.32%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 8.02%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">&#8804;20 &#181;g/kg <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">(n=3)</div></td><td class="gutter" style="width: 1.32%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.32%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 7.59%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">30 &#181;g/kg <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">(n=18)</div></td><td class="gutter" style="width: 1.32%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.32%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 8.76%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">45 &#181;g/kg <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">(n=37)</div></td><td class="gutter" style="width: 1.32%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.32%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 8.76%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">&#8805;60 &#181;g/kg <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">(n=17)</div></td><td class="gutter" style="width: 1.32%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.32%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 8.76%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">All Doses <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">(n=75)</div></td></tr><tr><td style="width: 44.86%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Complete response (CR)<font style="padding-left: 3.98pt;"></font></div></td><td class="gutter" style="width: 1.32%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.32%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.02%; text-align: center; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">0 &#8199;(0.0)</div></td><td class="gutter" style="width: 1.32%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.32%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.59%; text-align: center; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">5 (27.8)</div></td><td class="gutter" style="width: 1.32%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.32%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.76%; text-align: center; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">18 (48.6)</div></td><td class="gutter" style="width: 1.32%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.32%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.76%; text-align: center; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">&#8199;7 (41.1)</div></td><td class="gutter" style="width: 1.32%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.32%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.76%; text-align: center; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">30 (40.0)</div></td></tr><tr><td style="width: 44.86%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Partial response (PR)<font style="padding-left: 2.87pt;"></font></div></td><td class="gutter" style="width: 1.32%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.32%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 8.02%; text-align: center; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">1 (33.3)</div></td><td class="gutter" style="width: 1.32%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.32%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 7.59%; text-align: center; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">4 (22.2)</div></td><td class="gutter" style="width: 1.32%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.32%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 8.76%; text-align: center; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">14 (37.8)</div></td><td class="gutter" style="width: 1.32%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.32%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 8.76%; text-align: center; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">&#8199;4 (23.5)</div></td><td class="gutter" style="width: 1.32%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.32%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 8.76%; text-align: center; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">23 (30.7)</div></td></tr><tr><td style="width: 44.86%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Stable disease<font style="padding-left: 2.3pt;"></font></div></td><td class="gutter" style="width: 1.32%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.32%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.02%; text-align: center; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">1 (33.3)</div></td><td class="gutter" style="width: 1.32%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.32%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.59%; text-align: center; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">6 (33.3)</div></td><td class="gutter" style="width: 1.32%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.32%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.76%; text-align: center; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">&#8199;0 &#8199;(0.0)</div></td><td class="gutter" style="width: 1.32%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.32%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.76%; text-align: center; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">&#8199;1 &#8199;(5.9)</div></td><td class="gutter" style="width: 1.32%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.32%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.76%; text-align: center; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">&#8199;8 (10.7)</div></td></tr><tr><td style="width: 44.86%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Progressive disease<font style="padding-left: 0.65pt;"></font></div></td><td class="gutter" style="width: 1.32%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.32%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 8.02%; text-align: center; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">0 &#8199;(0.0)</div></td><td class="gutter" style="width: 1.32%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.32%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 7.59%; text-align: center; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">2 (11.1)</div></td><td class="gutter" style="width: 1.32%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.32%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 8.76%; text-align: center; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">&#8199;5 (13.5)</div></td><td class="gutter" style="width: 1.32%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.32%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 8.76%; text-align: center; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">&#8199;4 (23.5)</div></td><td class="gutter" style="width: 1.32%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.32%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 8.76%; text-align: center; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">11 (14.7)</div></td></tr><tr><td style="width: 44.86%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Not evaluable<font style="padding-left: 2.86pt;"></font></div></td><td class="gutter" style="width: 1.32%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.32%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.02%; text-align: center; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">1 (33.3)</div></td><td class="gutter" style="width: 1.32%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.32%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.59%; text-align: center; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">1&#8199; (5.6)</div></td><td class="gutter" style="width: 1.32%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.32%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.76%; text-align: center; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">&#8199;0 &#8199;(0.0)</div></td><td class="gutter" style="width: 1.32%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.32%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.76%; text-align: center; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">&#8199;1 &#8199;(5.9)</div></td><td class="gutter" style="width: 1.32%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.32%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.76%; text-align: center; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">&#8199;3 &#8199;(4.0)</div></td></tr><tr><td style="width: 44.86%; text-align: left; vertical-align: bottom; padding-top: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Overall response rate (CR + PR)<font style="font-weight: normal; padding-left: 1.27pt;"></font></div></td><td class="gutter" style="width: 1.32%; border-bottom: none; font-size: 2pt; padding-top: 3pt;">&#8203;</td><td class="gutter" style="width: 1.32%; border-bottom: none; font-size: 2pt; padding-top: 3pt;">&#8203;</td><td style="width: 8.02%; text-align: center; vertical-align: bottom; padding-top: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">1 (33.3)</div></td><td class="gutter" style="width: 1.32%; border-bottom: none; font-size: 2pt; padding-top: 3pt;">&#8203;</td><td class="gutter" style="width: 1.32%; border-bottom: none; font-size: 2pt; padding-top: 3pt;">&#8203;</td><td style="width: 7.59%; text-align: center; vertical-align: bottom; padding-top: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">9 (50.0)</div></td><td class="gutter" style="width: 1.32%; border-bottom: none; font-size: 2pt; padding-top: 3pt;">&#8203;</td><td class="gutter" style="width: 1.32%; border-bottom: none; font-size: 2pt; padding-top: 3pt;">&#8203;</td><td style="width: 8.76%; text-align: center; vertical-align: bottom; padding-top: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">32 (86.5)</div></td><td class="gutter" style="width: 1.32%; border-bottom: none; font-size: 2pt; padding-top: 3pt;">&#8203;</td><td class="gutter" style="width: 1.32%; border-bottom: none; font-size: 2pt; padding-top: 3pt;">&#8203;</td><td style="width: 8.76%; text-align: center; vertical-align: bottom; padding-top: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">11 (64.7)</div></td><td class="gutter" style="width: 1.32%; border-bottom: none; font-size: 2pt; padding-top: 3pt;">&#8203;</td><td class="gutter" style="width: 1.32%; border-bottom: none; font-size: 2pt; padding-top: 3pt;">&#8203;</td><td style="width: 8.76%; text-align: center; vertical-align: bottom; padding-top: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">53 (70.7)</div></td></tr></table><div><div class="rule-partial" style="height: 0pt; width: 72pt; border-bottom: 1pt solid #000000; margin-bottom: 1pt; margin-right: auto; margin-left: 40pt; margin-top: 12.25pt;"> </div></div><div class="ftnote" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 3pt; margin-left: 40pt; text-align: left;">Response rate data for various administered dose levels. &#8220;Not evaluable&#8221; means that the patient met the criteria for inclusion in the efficacy analysis set, but the only scan obtained for disease assessment was indeterminate. As specified in the protocol definition of the efficacy analysis set, two patients were excluded from the efficacy analysis as they only received a single dose of study drug and sufficient time has not passed for scans to determine response to treatment. </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 36pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">146<br></div></div></div>
<!--End Page 150-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 151-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 540pt;"><a name="nt10014672x1_drs_107-business_pg36"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="block-frill" style="width: 540pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: Arial, Helvetica, sans-serif; font-size: 9pt; font-weight: bold; margin-top: 6pt; text-align: center;">Confidential Treatment Requested by ADC Therapeutics SA Pursuant to 17 C.F.R. &#167; 200.83<br></div></div><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 36pt;"><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6.75pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">Cami&#8217;s favorable clinical activity was observed across a broad patient population in this clinical trial, including elderly patients and patients who have failed SCT. The table below shows the effect of age, prior therapy and response to prior therapy on response rate data at the 45 &#181;g/kg dose level. </div></td></tr></table><table cellspacing="0" cellpadding="0" class="fintab" style="margin-top: 5.25pt; border-collapse: collapse; width: 428pt; margin-left: 40pt;"><tr class="header"><td style="width: 56.07%; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Age </div></td><td class="gutter" style="width: 0.7%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 0.7%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 42.52%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Overall Response Rate, <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">responders/total (%) </div></td></tr><tr><td style="width: 56.07%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Less than or equal to 55<font style="padding-left: 2.54pt;"></font></div></td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 42.52%; text-align: center; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">25/28 (89.3), including 14/28 (50.0) CR </div></td></tr><tr><td style="width: 56.07%; text-align: left; vertical-align: bottom; padding-top: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">More than 55 <font style="padding-left: 3.64pt;"></font></div></td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt;">&#8203;</td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt;">&#8203;</td><td style="width: 42.52%; text-align: center; vertical-align: bottom; padding-top: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">7/9 (77.8), including 4/9 (44.4) CR</div></td></tr></table><table cellspacing="0" cellpadding="0" class="fintab" style="margin-top: 6pt; border-collapse: collapse; width: 428pt; margin-left: 40pt;"><tr class="header"><td style="width: 56.07%; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Prior Therapy</div></td><td class="gutter" style="width: 0.7%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 0.7%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 42.52%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Overall Response Rate, <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">responders/total (%)</div></td></tr><tr><td style="width: 56.07%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Brentuximab vedotin<font style="padding-left: 1.96pt;"></font></div></td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 42.52%; text-align: center; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">32/37 (86.5)</div></td></tr><tr><td style="width: 56.07%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Brentuximab vedotin and checkpoint inhibitor<font style="padding-left: 4.21pt;"></font></div></td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 42.52%; text-align: center; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">23/26 (88.5)</div></td></tr><tr><td style="width: 56.07%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Stem cell transplant<font style="padding-left: 1.42pt;"></font></div></td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 42.52%; text-align: center; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">16/18 (88.9)</div></td></tr><tr><td style="width: 56.07%; text-align: left; vertical-align: bottom; padding-top: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-indent: -10pt; text-align: left;">Brentuximab vedotin, checkpoint inhibitor and stem cell transplant<font style="padding-left: 3.07pt;"></font></div></td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt;">&#8203;</td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt;">&#8203;</td><td style="width: 42.52%; text-align: center; vertical-align: bottom; padding-top: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">13/14 (92.9)</div></td></tr></table><table cellspacing="0" cellpadding="0" class="fintab" style="margin-top: 6pt; border-collapse: collapse; width: 428.13pt; margin-left: 40pt;"><tr class="header"><td style="width: 39.24%; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Response to Prior Therapy </div></td><td class="gutter" style="width: 0.7%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 19.62%; text-align: center; vertical-align: bottom; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 0.7%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 38.34%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Overall Response Rate, <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">responders/total (%) </div></td></tr><tr><td style="width: 39.24%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Response to first-line therapy <font style="padding-left: 1.66pt;"></font></div></td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 19.62%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Refractory <font style="padding-left: 0.41pt;"></font></div></td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 38.34%; text-align: center; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">11/13 (84.6), including 6/13 (46.2) CR </div></td></tr><tr><td style="width: 39.24%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 19.62%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Relapsed <font style="padding-left: 1.52pt;"></font></div></td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 38.34%; text-align: center; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">21/24 (87.5), including 12/24 (50.0) CR </div></td></tr><tr><td style="width: 39.24%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Response to most recent therapy <font style="padding-left: 3.89pt;"></font></div></td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 19.62%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Refractory <font style="padding-left: 0.41pt;"></font></div></td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 38.34%; text-align: center; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">22/25 (88.0), including 11/25 (44.0) CR </div></td></tr><tr><td style="width: 39.24%; text-align: left; vertical-align: bottom; padding-top: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt;">&#8203;</td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt;">&#8203;</td><td style="width: 19.62%; text-align: left; vertical-align: bottom; padding-top: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Relapsed <font style="padding-left: 1.52pt;"></font></div></td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt;">&#8203;</td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt;">&#8203;</td><td style="width: 38.34%; text-align: center; vertical-align: bottom; padding-top: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">8/10 (80.0), including 6/10 (60.0) CR</div></td></tr></table><div><div class="rule-partial" style="height: 0pt; width: 72pt; border-bottom: 1pt solid #000000; margin-bottom: 1pt; margin-right: auto; margin-left: 40pt; margin-top: 12.25pt;"> </div></div><div class="ftnote" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 4.5pt; margin-left: 40pt; text-align: left;">Overall response rate data by various baseline patient characteristics at the 45 &#181;g/kg dose level.</div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">Across all dose levels, the median DoR was 8.1 months for patients who achieved a complete response and 5.1 months for patients who achieved a partial response, for an overall DoR of 6.4 months. At the 45 &#181;g/kg dose level, the median DoR was 7.2 months for patients who achieved a complete response and 5.6 months for patients who achieved a partial response, for an overall DoR of 6.6 months. The figure below shows the DoR by response at the 45 &#181;g/kg dose level.</div></td></tr></table><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 15.25pt; text-align: center;"><img style="height: 245px; width: 428px;" src="nt10014672x1_linechart2.jpg"><br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">&#8201;</div><div><div class="rule-partial" style="height: 0pt; width: 72pt; border-bottom: 1pt solid #000000; margin-bottom: 1pt; margin-right: auto; margin-left: 40pt; margin-top: 15.25pt;"> </div></div><div class="ftnote" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 4.5pt; margin-left: 40pt; text-align: left;">Duration of response by response at the 45 &#181;g/kg dose level. Circles represent censored patients.</div><div class="h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 19.5pt; margin-left: 20pt; text-align: left;">T-Cell Lymphoma</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">For patients with relapsed or refractory T-cell lymphoma (n=29), the median prior lines of therapy received was four. The median number of treatment cycles received was three and the maximum number of treatment cycles received was seven. The median duration of treatment was 38 days.</div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 36pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">147<br></div></div></div>
<!--End Page 151-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 152-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 540pt;"><a name="nt10014672x1_drs_107-business_pg37"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="block-frill" style="width: 540pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: Arial, Helvetica, sans-serif; font-size: 9pt; font-weight: bold; margin-top: 6pt; text-align: center;">Confidential Treatment Requested by ADC Therapeutics SA Pursuant to 17 C.F.R. &#167; 200.83<br></div></div><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 36pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The main observed safety and tolerability findings from the Phase 1 clinical trial in patients with relapsed or refractory T-cell lymphoma were as follows:</div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">The MTD was not reached in the dose escalation stage.</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">Grade &#8805;3 TEAEs were reported in 23 patients, or 79.3% of patients. The most common Grade &#8805;3 TEAEs, reported in more than 5% of patients, included hypercalcemia (10.3%), acute kidney injury (6.9%), back pain (6.9%), dehydration (6.9%), gamma-glutamyltransferase increased (6.9%), lung infection (6.9%), platelet count decreased (6.9%), pyrexia (6.9%), rash (6.9%) and maculopapular rash (6.9%).</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">TEAEs in two patients, or 6.9% of patients, led to treatment discontinuation.</div></td></tr></table><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The main observed efficacy findings from the Phase 1 clinical trial in patients with relapsed or refractory T-cell lymphoma were as follows:</div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">Across all dose levels, two patients, or 8.0% of patients, achieved a complete response and another nine patients, or 36.0% of patients, achieved a partial response, resulting in a 44.0% ORR.</div></td></tr></table><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 20.5pt; margin-left: 0pt; text-align: left;">Pivotal Phase 2 Clinical Trial in Relapsed or Refractory Hodgkin Lymphoma</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">We are currently conducting a 100-patient Phase 2, multi-center, open-label, single-arm clinical trial to evaluate the safety and efficacy of Cami in patients with relapsed or refractory HL. We are conducting the clinical trial at 29 sites in the United States and Europe as of February 2020, with additional sites being activated, pursuant to an IND accepted by the FDA in April&#160;2015 and an additional protocol submitted in March&#160;2019. The first patient was dosed in September&#160;2019. We anticipate reporting top-line response rate data in the first half of 2021. The clinical trial&#8217;s design is summarized below.</div><div class="h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 20.5pt; margin-left: 0pt; text-align: left;">Clinical Trial Design</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The primary objective of the Phase 2 clinical trial is to evaluate the efficacy of Cami in patients with relapsed or refractory HL, measured by ORR based on the 2014 Lugano Classification Criteria. The secondary objectives are to (i)&#160;characterize additional efficacy endpoints of Cami, including DoR, complete response rate, PFS and OS, (ii)&#160;characterize the safety profile of Cami, (iii)&#160;characterize the pharmacokinetic profile of Cami and (iv)&#160;evaluate the impact of Cami treatment on HRQoL.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The clinical trial is enrolling patients with pathologically confirmed relapsed or refractory HL who have failed three prior lines of therapy, including brentuximab vedotin and a checkpoint inhibitor approved for HL, such as nivolumab or pembrolizumab. The clinical trial is expected to enroll approximately 100 patients.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">In the clinical trial, patients receive a 45 &#181;g/kg dose of Cami on the first day of each 21-day treatment cycle for two treatment cycles and receive a 30 &#181;g/kg dose on the first day of each 21-day treatment cycle for subsequent treatment cycles. The decision for the initial dose level is based on the following observations from our Phase 1 clinical trial: (i)&#160;the favorable ORR and complete response rate together with Cami&#8217;s tolerability profile, (ii)&#160;the high fraction of patients with HL who could tolerate at least two cycles of Cami before an AE leading to a dose delay or modification occurred and (iii)&#160;the ability to manage some of the severe TEAEs at this dose level. The decision to reduce the subsequent dose level is based on the ability to mitigate the frequency and severity of AEs foreseen in patients treated with the 45 &#181;g/kg dose level beyond two treatment cycles and the significant clinical activity observed at the 30 &#181;g/kg dose level. Therefore, the dosing regimen is selected to optimize potential response to treatment, while maintaining a manageable tolerability profile. Because of the ORR observed in the Phase 1 clinical trial of Cami in patients with HL and the anticipated recruitment projections, we do not believe that an interim futility analysis is warranted. In this clinical trial, response to treatment is determined as CR, PR, SD or PD, based on the 2014 Lugano Classification Criteria. </div><div class="h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 20pt; margin-left: 0pt; text-align: left;">Interim Data</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">As of April&#160;15, 2020, which was the last data cutoff, 47 patients were enrolled in this pivotal Phase 2 clinical trial. Twelve patients reported Grade &#8805;3 TEAEs, with the most common being diarrhea, lymphopenia, neutropenia and pneumonia. </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 36pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">148<br></div></div></div>
<!--End Page 152-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 153-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 540pt;"><a name="nt10014672x1_drs_107-business_pg38"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="block-frill" style="width: 540pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: Arial, Helvetica, sans-serif; font-size: 9pt; font-weight: bold; margin-top: 6pt; text-align: center;">Confidential Treatment Requested by ADC Therapeutics SA Pursuant to 17 C.F.R. &#167; 200.83<br></div></div><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 36pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">In March 2020, two patients in this clinical trial were diagnosed with Guillain&#8211;Barr&#233; syndrome. Pursuant to the clinical trial protocol, which included specific stopping rules for Guillain&#8211;Barr&#233; syndrome, we suspended enrollment of new patients in this clinical trial but continued to treat enrolled patients who could derive clinical benefit from continued treatment with Cami. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Before we resumed enrollment pursuant to the recommendations of an independent DSMB, on April 17, 2020, the FDA issued a partial clinical hold on this clinical trial. The FDA agreed that, pending its review, we could continue to treat enrolled patients, including patients with stable disease, who could derive clinical benefit from continued treatment with Cami. In May 2020, an additional patient was diagnosed with Guillain&#8211;Barr&#233; syndrome. At the FDA&#8217;s request, we submitted certain information, including an updated investigator&#8217;s brochure, an updated clinical trial protocol, the DSMB meeting minutes, an updated informed consent form, dose and exposure analysis for safety and response and an updated safety monitoring plan. In July 2020, the FDA lifted the partial clinical hold. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">There have been no cases of Guillain&#8211;Barr&#233; syndrome in the more than 130 patients with NHL, acute leukemia or solid tumors treated with Cami. Clinical case literature suggests that patients with HL have a higher incidence of Guillain&#8211;Barr&#233; syndrome than patients with other cancers or otherwise healthy individuals.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">As of April 15, 2020, 24 patients have been assessed by the investigator for response to treatment. As of their first disease assessment, four patients, or 16.7% of patients, achieved a complete response and another 12 patients, or 50.0% of patients, achieved a partial response, resulting in a 66.7% ORR. These response rates are similar to those observed for HL patients at their first disease assessment in our Phase 1 clinical trial of Cami for the treatment of relapsed or refractory HL and NHL. Due to the mechanism of action of PBD warheads, we believe that the anti-tumor effects of Cami are realized over time. As such, we believe that the interim data may not reflect the data that would be obtained if the same patients were evaluated at a later date. Therefore, we believe that Cami may exhibit greater anti-tumor activity as we continue to follow the patients in the clinical trial. </div><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 20.5pt; margin-left: 0pt; text-align: left;">Pathway to Regulatory Approval</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">We have commenced a pivotal Phase 2 clinical trial, which, if successful, we believe will form the basis of a BLA submission for accelerated approval of Cami for the treatment of relapsed or refractory HL in patients who have failed or were intolerant to brentuximab vedotin and a checkpoint inhibitor approved for HL. However, the FDA has not opined on whether our Phase 2 clinical trial will in fact be sufficient to support such approval. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">To support the BLA submission,we have initiated the validation of the commercial supply chain for Cami. Based on our current clinical development timeline, we anticipate having data to support a BLA submission.</div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 20.5pt; margin-left: 0pt; text-align: left;">ADCT-602: PBD-Based ADC Targeting CD22</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">ADCT-602 is an ADC targeting CD22-expressing hematological malignancies. We have entered into a collaboration agreement with MD Anderson Cancer Center, pursuant to which they are conducting a Phase 1/2 clinical trial of ADCT-602 for the treatment of relapsed or refractory ALL.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Of the estimated 9,000 total patients diagnosed with ALL each year in the United States and Europe, approximately 30% will exhibit relapsed or refractory ALL. We believe that the treatment of relapsed or refractory ALL remains an area of high unmet medical need. New therapies for the treatment of ALL, such as Kymriah&#174;, Blincyto&#174; and Besponsa&#174;, are providing additional treatment options for patients with relapsed or refractory ALL. However, the heterogeneity of ALL and the existence of different subgroups within the disease mean there remains a high unmet medical need for portions of the ALL patient population. We intend to develop ADCT-602 as a therapeutic option for relapsed or refractory ALL to address the high unmet medical need of this patient population.</div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 36pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">149<br></div></div></div>
<!--End Page 153-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 154-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 540pt;"><a name="nt10014672x1_drs_107-business_pg39"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="block-frill" style="width: 540pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: Arial, Helvetica, sans-serif; font-size: 9pt; font-weight: bold; margin-top: 6pt; text-align: center;">Confidential Treatment Requested by ADC Therapeutics SA Pursuant to 17 C.F.R. &#167; 200.83<br></div></div><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 36pt;"><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">Structure and Mechanism of Action</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">ADCT-602 is composed of a humanized monoclonal antibody (hLL2-C220) directed against human CD22 and conjugated through a cathepsin-cleavable linker to SG3199, a PBD dimer cytotoxin. Once bound to a CD22-expressing cell, it is designed to be internalized by the cell, following which the warhead is released. The warhead is designed to bind irreversibly to DNA to create highly potent interstrand cross-links that block DNA strand separation, thus disrupting essential DNA metabolic processes such as replication and ultimately resulting in cell death. The figure below shows the structure of ADCT-602.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 14.75pt; text-align: center;"><img style="height: 196px; width: 331px;" src="nt10014672x1_diagram8.jpg"><br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">&#8201;</div><div><div class="rule-partial" style="height: 0pt; width: 72pt; border-bottom: 1pt solid #000000; margin-bottom: 1pt; margin-right: auto; margin-left: 0pt; margin-top: 10.25pt;"> </div></div><div class="ftnote" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 4pt; margin-left: 0pt; text-align: left;">Visual representation of ADCT-602.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The human CD22 antigen plays a pivotal role in the recognition, binding and adhesion processes of cells. CD22 is only expressed on B cells throughout all stages of B cell development and differentiation. Its expression is maintained in high levels in hematological B cell malignancies, including in NHL and certain types of leukemia, including B-cell ALL. We believe that CD22 is an attractive target for ADCs developed to treat hematological malignancies for the following reasons:</div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">The CD22 antigen is rapidly internalized by the cell.</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">An increasing number of reports describe the outgrowth of CD19-negative tumor cells in patients who initially respond to CD19-targeted therapy. We believe that given CD22&#8217;s broad and favorable expression profile, it may be a viable alternative B cell marker to CD19 for the targeted delivery of highly potent cytotoxic drugs.</div></td></tr></table><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12.5pt; margin-left: 0pt; text-align: left;">Preclinical Studies</div><div class="h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 7pt; margin-left: 0pt; text-align: left;">Preclinical Efficacy Studies</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">We evaluated the <font style="font-style: italic;">in vivo</font> efficacy of ADCT-602 in the Ramos xenograft model, in which mice received a single dose of (i)&#160;ADCT-602 at 0.3 mg/kg, (ii)&#160;ADCT-602 at 1 mg/kg, (iii)&#160;a non-targeted ADC at 1 mg/kg, or (iv)&#160;a vehicle control. We observed that ADCT-602 exhibited dose-dependent anti-tumor activity, while the non-targeted ADC and the vehicle control did not demonstrate any significant anti-tumor activity. The table below summarizes the response data and the figures below show the mean tumor volume in the Ramos xenograft model and the Kaplan-Meier plot from the Ramos xenograft model.</div><table cellspacing="0" cellpadding="0" class="fintab" style="margin-top: 11.25pt; border-collapse: collapse; width: 468pt; margin-left: auto; margin-right: auto;"><tr class="header"><td style="width: 43.59%; text-align: left; vertical-align: bottom; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 0.64%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td colspan="10" style="width: 55.13%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">n (%)</div></td></tr><tr class="header"><td style="width: 43.59%; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Response</div></td><td class="gutter" style="width: 0.64%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 0.64%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 11.75%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">ADCT-602 <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">0.3 mg/kg <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">(n=10)</div></td><td class="gutter" style="width: 0.64%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 0.64%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 11.75%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">ADCT-602 <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">1 mg/kg <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">(n=10)</div></td><td class="gutter" style="width: 0.64%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 0.64%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 16.03%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Non-Targeted ADC <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">1 mg/kg <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">(n=10)</div></td><td class="gutter" style="width: 0.64%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 0.64%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 11.75%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Vehicle Control <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">(n=10)</div></td></tr><tr><td style="width: 43.59%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Complete response<font style="padding-left: 4.3pt;"></font></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 11.75%; text-align: center; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">0 (0.0)</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 11.75%; text-align: center; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">10 (100.0)</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 16.03%; text-align: center; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">0 (0.0)</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 11.75%; text-align: center; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">0 (0.0)</div></td></tr><tr><td style="width: 43.59%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Partial response<font style="padding-left: 2.09pt;"></font></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 11.75%; text-align: center; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">0 (0.0)</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 11.75%; text-align: center; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">&#8199;0 &#8199;&#8199;(0.0)</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 16.03%; text-align: center; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">0 (0.0)</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 11.75%; text-align: center; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">0 (0.0)</div></td></tr><tr><td style="width: 43.59%; text-align: left; vertical-align: bottom; padding-top: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Tumor-free survivor<font style="padding-left: 4.31pt;"></font></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 11.75%; text-align: center; vertical-align: bottom; padding-top: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">0 (0.0)</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 11.75%; text-align: center; vertical-align: bottom; padding-top: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">&#8199;9 &#8199;(90.0)</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 16.03%; text-align: center; vertical-align: bottom; padding-top: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">0 (0.0)</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 11.75%; text-align: center; vertical-align: bottom; padding-top: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">0 (0.0)</div></td></tr></table><div><div class="rule-partial" style="height: 0pt; width: 72pt; border-bottom: 1pt solid #000000; margin-bottom: 1pt; margin-right: auto; margin-left: 0pt; margin-top: 8.25pt;"> </div></div><div class="ftnote" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 3pt; margin-left: 0pt; text-align: left;">Response data obtained in the Ramos xenograft model. Partial response is recorded when the tumor volume was 50% or less of its Day 1 volume for three consecutive measurements during the course of the study, and equal to or greater than 13.5 mm<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">3</sup> for one or more of these three measurements. Complete response is recorded when the tumor volume was &lt;13.5 mm<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">3</sup> for three consecutive measurements during the course of the study. Tumor-free survivor is recorded when a complete response is recorded at the termination of a study.</div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 36pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">150<br></div></div></div>
<!--End Page 154-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 155-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 540pt;"><a name="nt10014672x1_drs_107-business_pg40"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="block-frill" style="width: 540pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: Arial, Helvetica, sans-serif; font-size: 9pt; font-weight: bold; margin-top: 6pt; text-align: center;">Confidential Treatment Requested by ADC Therapeutics SA Pursuant to 17 C.F.R. &#167; 200.83<br></div></div><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 36pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; text-align: center;"><img style="height: 216px; width: 418px;" src="nt10014672x1_linechart3.jpg"><br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">&#8201;</div><div><div class="rule-partial" style="height: 0pt; width: 72pt; border-bottom: 1pt solid #000000; margin-bottom: 1pt; margin-right: auto; margin-left: 0pt; margin-top: 14.75pt;"> </div></div><div class="ftnote" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 4pt; margin-left: 0pt; text-align: left;">The anti-tumor activity of ADCT-602 in the Ramos xenograft model. Data represent the mean tumor volume &#177; SEM for each group of mice.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 13.75pt; text-align: center;"><img style="height: 220px; width: 488px;" src="nt10014672x1_linechart4.jpg"><br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">&#8201;</div><div><div class="rule-partial" style="height: 0pt; width: 72pt; border-bottom: 1pt solid #000000; margin-bottom: 1pt; margin-right: auto; margin-left: 0pt; margin-top: 14.75pt;"> </div></div><div class="ftnote" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 3pt; margin-left: 0pt; text-align: left;">The Kaplan-Meier plot of the activity of ADCT-602 in the Ramos xenograft model. Data represent Kaplan-Meier survival curves for each group of mice.</div><div class="h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 17pt; margin-left: 0pt; text-align: left;">Preclinical Safety Studies</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">We evaluated the toxicity of ADCT-602 primarily in non-human primates and with a single-dose MTD study in rats. In non-human primates, ADCT-602 was observed to be well tolerated at the 0.6 mg/kg dose. Toxicity was characterized by dose-dependent reversible myelosuppression, bodyweight loss, lymphocyte depletion with loss of germinal centers and CD20-positive cells and nephropathy. In rats, the MTD for ADCT-602 was 2 mg/kg.</div><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 18.5pt; margin-left: 0pt; text-align: left;">Phase 1/2 Clinical Trial in Relapsed or Refractory Acute Lymphoblastic Leukemia</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Pursuant to our collaboration agreement with MD Anderson Cancer Center, MD Anderson Cancer Center is conducting a Phase 1/2, open-label, dose escalation and dose expansion clinical trial of the safety and anti-tumor activity of ADCT-602, used as monotherapy, in patients with relapsed or refractory ALL. The clinical trial is being conducted at one site in the United States, pursuant to an IND submitted by MD Anderson Cancer Center and accepted by the FDA in July 2018. The first patient was dosed in November 2018. The clinical trial&#8217;s design and the interim findings are summarized below.</div><div class="h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 11.5pt; margin-left: 0pt; text-align: left;">Clinical Trial Design</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The primary objectives of the dose escalation stage are to (i)&#160;evaluate the safety and tolerability, and determine, as appropriate, the MTD of ADCT-602 in patients with relapsed or refractory ALL and (ii)&#160;determine the recommended dose(s) of ADCT-602 for the dose expansion stage. The primary objective of the dose expansion stage is to evaluate the efficacy of ADCT-602 at the dose level(s) recommended from the results of </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 36pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">151<br></div></div></div>
<!--End Page 155-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 156-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 540pt;"><a name="nt10014672x1_drs_107-business_pg41"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="block-frill" style="width: 540pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: Arial, Helvetica, sans-serif; font-size: 9pt; font-weight: bold; margin-top: 6pt; text-align: center;">Confidential Treatment Requested by ADC Therapeutics SA Pursuant to 17 C.F.R. &#167; 200.83<br></div></div><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 36pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">the dose escalation stage. The secondary objectives of the clinical trial are to (i)&#160;evaluate the clinical activity of ADCT-602, as measured by ORR, DoR, OS and PFS, (ii)&#160;characterize the pharmacokinetic profile of ADCT-602 and the free warhead SG3199, (iii)&#160;evaluate the immunogenicity of ADCT-602 and (iv)&#160;characterize the effect of ADCT-602 exposure on the QT interval.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The clinical trial will enroll patients with pathologically confirmed relapsed or refractory B-ALL and patients with pathologically confirmed relapsed or refractory Ph+ ALL who have failed either first- or second-generation tyrosine kinase inhibitor. The clinical trial is expected to enroll approximately 65 patients.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">In the dose escalation stage, patients receive intravenous infusions of ADCT-602, at escalating doses, on the first day of each 21-day treatment cycle. The initial dose of ADCT-602 is 30 &#181;g/kg and the highest allowed dose will be 150 &#181;g/kg. Dose escalation is conducted using a 3+3 design with oversight by a DESC. In the dose expansion stage, patients receive ADCT-602 at the recommended dose determined by the DESC based on the anti-tumor activity and tolerability observed during the dose escalation stage. Dose expansion is conducted according to Simon&#8217;s Minimax two-stage design. In the first stage, 22 patients (including six patients treated at the MTD in the dose escalation stage) will be dosed. If there are four or fewer responses in these patients, the clinical trial will stop. Otherwise, 19 additional patients will be dosed for a total of 41 patients. In this clinical trial, response to treatment is determined as CR, PR, SD or PD, based on the 2014 Lugano Classification Criteria.</div><div class="h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 13.5pt; margin-left: 0pt; text-align: left;">Interim Data</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">As of January 15, 2020, eight patients have been treated with ADCT-602. Five patients reported Grade &#8805;3 TEAEs, with the most common being infections and infestations and febrile neutropenia. No DLT has been observed. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">All enrolled patients have discontinued therapy. One patient achieved a complete response and subsequently underwent allogeneic stem cell transplant. Currently, the dose escalation stage of the Phase 1/2 clinical trial is ongoing. </div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 20.5pt; margin-left: 0pt; text-align: left;">Our Solid Tumor Franchise</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Our solid tumor franchise comprises two clinical-stage product candidates and two preclinical product candidates for the treatment of various solid tumor cancers, including colorectal cancer, head and neck cancer, non-small cell lung cancer, gastric and esophageal cancers, pancreatic cancer, bladder cancer, renal cell carcinoma, melanoma, triple negative breast cancer and ovarian cancer. The figure below summarizes the product candidates in our solid tumor franchise.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 15.25pt; text-align: center;"><img style="height: 142px; width: 618px;" src="nt10014672x1_barchart3.jpg"><br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">&#8201;</div><div><div class="rule-partial" style="height: 0pt; width: 72pt; border-bottom: 1pt solid #000000; margin-bottom: 1pt; margin-right: auto; margin-left: 0pt; margin-top: 6.25pt;"> </div></div><div class="ftnote" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 3pt; margin-left: 0pt; text-align: left;">*In certain cases, a Phase 2 clinical trial may be a pivotal clinical trial (i.e., a clinical trial intended to serve as the basis for BLA submission). **We retain worldwide development and commercialization rights to Cami, subject to our collaboration and license agreement with Genmab. See &#8220;Recent Developments&#8221; and &#8220;&#8212;License and Collaboration Agreements&#8212;Genmab Collaboration and License Agreement.&#8221;</div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 36pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">152<br></div></div></div>
<!--End Page 156-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 157-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 540pt;"><a name="nt10014672x1_drs_107-business_pg42"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="block-frill" style="width: 540pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: Arial, Helvetica, sans-serif; font-size: 9pt; font-weight: bold; margin-top: 6pt; text-align: center;">Confidential Treatment Requested by ADC Therapeutics SA Pursuant to 17 C.F.R. &#167; 200.83<br></div></div><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 36pt;"><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">The Solid Tumor Disease Setting</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">There are many different types of solid tumors and they account for the majority of cancers. The most commonly diagnosed solid tumor cancers include lung cancer, prostate cancer, breast cancer and colorectal cancer. The figure below presents the most common types of solid tumor cancers in the United States. The prognosis and treatment of solid tumor cancers vary based on the type of cancer.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 15.25pt; text-align: center;"><img style="height: 204px; width: 549px;" src="nt10014672x1_barchart4.jpg"><br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">&#8201;</div><div><div class="rule-partial" style="height: 0pt; width: 72pt; border-bottom: 1pt solid #000000; margin-bottom: 1pt; margin-right: auto; margin-left: 0pt; margin-top: 15.25pt;"> </div></div><div class="ftnote" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 4.5pt; margin-left: 0pt; text-align: left;">The most common solid tumor cancers in the United States. Source: National Cancer Institute.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Despite recent significant advances in the treatment of some solid tumor cancers, there remains a high medical need for novel therapies. One of the significant recent advances in the treatment of solid tumor cancers is the introduction of PD1 and PD-L1 checkpoint inhibitors, such as pembrolizumab (Keytruda&#174;), that leverages the body&#8217;s immune system to attack tumor cells. However, only 45% of cancer patients are eligible for treatment with checkpoint inhibitors and only 12% of cancer patients respond to treatment with checkpoint inhibitors. We are developing product candidates directed at different targets from those targeted by checkpoint inhibitors. We believe that our product candidates may enhance the efficacy of checkpoint inhibitors when they are used in combination and may provide a treatment option for patients who are not eligible for or do not respond to treatment with checkpoint inhibitors. We believe that there is a significant opportunity for our product candidates to address the high unmet medical need of these patient populations.</div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 20.5pt; margin-left: 0pt; text-align: left;">Camidanlumab Tesirine: PBD-Based ADC Targeting CD25</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">In addition to Cami&#8217;s hematological indications, we are also exploring its use as a novel immuno-oncology approach for the treatment of solid tumor cancers. Cami targets CD25 proteins expressed on Tregs, which contribute to the immunosuppressive tumor microenvironment in a variety of cancers, including colorectal, ovarian, lung, pancreatic cancers and melanoma, by allowing the tumor to evade immune surveillance. In recent years, a number of companies have begun exploring the therapeutic potential of approaches that deplete or reduce Tregs in the tumor microenvironment, while restoring the activity of cytotoxic Teffs. These approaches usually use a single mechanism of action. In contrast, Cami has three mechanisms of action that may enhance anti-tumor activity. First, Cami directly targets Tregs, with the goal of causing cell death. Second, after the target cell&#8217;s death, the PBD warhead is designed to diffuse into the tumor microenvironment, creating a bystander effect. Third, we believe that the target cell&#8217;s death triggers immunogenic cell death, which boosts the body&#8217;s anti-tumor immune response. We believe that these effects may further be enhanced by combining Cami with a checkpoint inhibitor. The figure below shows Cami&#8217;s proposed mechanisms of action in solid tumors.</div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 36pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">153<br></div></div></div>
<!--End Page 157-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 158-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 540pt;"><a name="nt10014672x1_drs_107-business_pg43"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="block-frill" style="width: 540pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: Arial, Helvetica, sans-serif; font-size: 9pt; font-weight: bold; margin-top: 6pt; text-align: center;">Confidential Treatment Requested by ADC Therapeutics SA Pursuant to 17 C.F.R. &#167; 200.83<br></div></div><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 36pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; text-align: center;"><img style="height: 324px; width: 587px;" src="nt10014672x1_diagram9.jpg"><br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">&#8201;</div><div><div class="rule-partial" style="height: 0pt; width: 72pt; border-bottom: 1pt solid #000000; margin-bottom: 1pt; margin-right: auto; margin-left: 0pt; margin-top: 13.75pt;"> </div></div><div class="ftnote" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 4pt; margin-left: 0pt; text-align: left;">Cami&#8217;s proposed mechanisms of action in solid tumors.</div><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 13pt; margin-left: 0pt; text-align: left;">Preclinical Immuno-Oncology Studies in Solid Tumors</div><div class="h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 7pt; margin-left: 0pt; text-align: left;">Preclinical Efficacy Studies</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Preclinical immuno-oncology models rely on mice that have a functional immune system and can only use murine cancer cells. The antibody in Cami does not bind to murine Tregs or any murine cell line expressing CD25 and thus cannot be used in preclinical immuno-oncology models. We therefore created the surrogate antibody Sur301, which binds to murine CD25, using the same PBD warhead as Cami.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">We evaluated the <font style="font-style: italic;">in vivo</font> efficacy of Sur301 in the CD25 negative MC38 syngeneic model, in which mice received (i)&#160;one dose of Sur301 at various dose levels, alone or in combination with three doses of an anti-PD1 antibody, or (ii)&#160;either three doses of an anti-PD1 antibody, a non-targeted ADC or a vehicle control. We observed that Sur301, when used as a monotherapy, exhibited strong and durable anti-tumor activity that is superior to that achieved by the anti-PD1 antibody. Furthermore, we observed that combining a low dose of Sur301 (0.1 mg/kg) with the anti-PD1 antibody resulted in anti-tumor activity that was synergistic (i.e., the total effect of the combined drug is greater than the sum of the individual effects of each drug). The figures below show the mean tumor volume in the CD25 negative MC38 syngeneic model and the synergistic effect of Sur301 and the anti-PD1 antibody.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 14.75pt; text-align: center;"><img style="height: 191px; width: 482px;" src="nt10014672x1_linechart5.jpg"><br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">&#8201;</div><div><div class="rule-partial" style="height: 0pt; width: 72pt; border-bottom: 1pt solid #000000; margin-bottom: 1pt; margin-right: auto; margin-left: 0pt; margin-top: 7.25pt;"> </div></div><div class="ftnote" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 3pt; margin-left: 0pt; text-align: left;">The anti-tumor activity of Sur301 in the CD25 negative MC38 syngeneic model. Data represent the mean tumor volume &#177; SEM for each group of mice.</div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 36pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">154<br></div></div></div>
<!--End Page 158-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 159-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 540pt;"><a name="nt10014672x1_drs_107-business_pg44"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="block-frill" style="width: 540pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: Arial, Helvetica, sans-serif; font-size: 9pt; font-weight: bold; margin-top: 6pt; text-align: center;">Confidential Treatment Requested by ADC Therapeutics SA Pursuant to 17 C.F.R. &#167; 200.83<br></div></div><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 36pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; text-align: center;"><img style="height: 189px; width: 423px;" src="nt10014672x1_linechart6.jpg"><br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">&#8201;</div><div><div class="rule-partial" style="height: 0pt; width: 72pt; border-bottom: 1pt solid #000000; margin-bottom: 1pt; margin-right: auto; margin-left: 0pt; margin-top: 0.75pt;"> </div></div><div class="ftnote" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 3pt; margin-left: 0pt; text-align: left;">The synergistic effect of Sur301 and the anti-PD1 antibody in the CD25 negative MC38 syngeneic model. Data represent the mean tumor volume &#177; SEM for each group of mice.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left; line-height: 11.7pt;">In addition, the tumor-free survivors from our preclinical studies were re-challenged by being re-grafted with MC38 cancer cells. These re-grafted tumor-free survivors did not develop any tumor, suggesting that immunological memory was induced by treatment with Sur301, both alone or in combination with an anti-PD1 antibody. The figure below shows the mean tumor volume in the re-challenge of tumor-free survivors.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 14.45pt; text-align: center;"><img style="height: 186px; width: 512px;" src="nt10014672x1_linechart7.jpg"><br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">&#8201;</div><div><div class="rule-partial" style="height: 0pt; width: 72pt; border-bottom: 1pt solid #000000; margin-bottom: 1pt; margin-right: auto; margin-left: 0pt; margin-top: 4.75pt;"> </div></div><div class="ftnote" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 3pt; margin-left: 0pt; text-align: left;">The immunological memory induced by Sur301 in the re-challenge of tumor-free survivors. Treatments indicated represent the treatment that the tumor-free survivors received before the re-challenge. Data represent the mean tumor volume &#177; SEM for each group of mice. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left; line-height: 11.7pt;">We undertook a preclinical study to assess Sur301&#8217;s mechanism of action by removing CD8+ Teffs, which generally play an important role in anti-tumor immunity. Mice were treated with a CD8-depleting antibody to remove these cells before they were treated with Sur301, alone or in combination with an anti-PD1 antibody. We observed that the anti-tumor activity of Sur301 was lost when CD8+ Teffs were depleted, indicating these cells play a key role in Sur301&#8217;s anti-tumor activity. The figure below shows the mean tumor volume in mice treated with a CD8-depleting antibody.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8.44pt; text-align: center;"><img style="height: 231px; width: 507px;" src="nt10014672x1_linechart8.jpg"><br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">&#8201;</div><div><div class="rule-partial" style="height: 0pt; width: 72pt; border-bottom: 1pt solid #000000; margin-top: 1pt; margin-bottom: 1pt; margin-right: auto; margin-left: 0pt;"> </div></div><div class="ftnote" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 4pt; margin-left: 0pt; text-align: left;">The anti-tumor activity of Sur301 depends on CD8+ Teffs. Data represent the mean tumor volume &#177; SEM for each group of mice.</div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 36pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">155<br></div></div></div>
<!--End Page 159-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 160-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 540pt;"><a name="nt10014672x1_drs_107-business_pg45"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="block-frill" style="width: 540pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: Arial, Helvetica, sans-serif; font-size: 9pt; font-weight: bold; margin-top: 6pt; text-align: center;">Confidential Treatment Requested by ADC Therapeutics SA Pursuant to 17 C.F.R. &#167; 200.83<br></div></div><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 36pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">We performed a longitudinal T cell immunophenotype study following a single dose of Sur301 at 0.5 mg/kg, either alone or in combination with an anti-PD1 antibody, in mice bearing established MC38 tumors. Following Sur301 treatment, the ratio of CD8+ Teffs to Tregs increased throughout the study, and a further increase in the ratio was observed in the combination therapy group. Tumor-infiltrating CD8+ Teffs from the Sur301 treatment groups (either alone or in combination with the anti-PD1 antibody) had higher activation and proliferation rates compared with CD8+ Teffs from the control groups. This study supports our hypothesis that Sur301 depletes Tregs, allowing Teffs to expand.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The conclusions from our preclinical studies with Sur301 suggest that targeting CD25 positive Tregs in the tumor microenvironment with Cami may be an attractive approach to induce an effective anti-tumor response, especially when combined with checkpoint inhibitors, because:</div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">Sur301 exhibited strong and durable anti-tumor activity that is superior to that achieved by an anti-PD1 antibody; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">Sur301 exhibited strong synergistic effects when tested at a low dose level in combination with an anti-PD1 regimen;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">Sur301&#8217;s observed anti-tumor activity was dependent on CD8 Teffs, and a statistically significant increase in the ratio of intratumoral CD8+ Teffs to Tregs was observed after administration of Sur301; and</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">Sur301 was associated with immunological memory in our re-challenge of tumor-free survivors.</div></td></tr></table><div class="h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 14.5pt; margin-left: 0pt; text-align: left;">Preclinical Safety Studies</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">We evaluated the toxicity of Cami primarily in non-human primates and with a single-dose MTD study in mice and rats. In non-human primates, Cami was observed to be well tolerated at 0.15 mg/kg. Toxicity was characterized by dose-dependent myelosuppression, increased liver enzymes, inflammation of the gastrointestinal tract, reduced bodyweight, nephropathy and skin toxicity. In mice and rats, the MTD for Cami was 9 mg/kg and 2 mg/kg, respectively.</div><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 14.5pt; margin-left: 0pt; text-align: left;">Phase 1b Clinical Trial in Selected Advanced Solid Tumors</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">We are conducting a Phase 1b, open-label, dose escalation and dose expansion clinical trial of the safety and tolerability of Cami used as monotherapy, in patients with selected advanced solid tumors, defined as those that literature evidence indicates contains CD25 positive Tregs, such as colorectal cancer, head and neck cancer, non-small cell lung cancer, gastric and esophageal cancers, pancreatic cancer, bladder cancer, renal cell carcinoma, melanoma, triple negative breast cancer and ovarian cancer. We are conducting the clinical trial at five sites in the United States and Europe, pursuant to an IND accepted by the FDA in June 2018. The first patient was dosed in January 2019. We anticipate reporting PK/PD data at a medical conference in the second half of 2020. The clinical trial&#8217;s design and our interim findings are summarized below.</div><div class="h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 15pt; margin-left: 0pt; text-align: left;">Clinical Trial Design</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The primary objectives of the clinical trial are to (i)&#160;evaluate the safety and tolerability of Cami in patients with selected advanced solid tumors and (ii)&#160;identify the recommended dose and dose schedule for future studies in patients with selected advanced solid tumors. The secondary objectives are to (i)&#160;evaluate the preliminary anti-tumor activity of Cami, (ii)&#160;characterize the pharmacokinetic profile of Cami and (iii)&#160;evaluate the immunogenicity of Cami.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The clinical trial will enroll patients with pathologically confirmed relapsed or refractory solid tumor malignancy that is locally advanced or metastatic at the time of screening and who have failed or are intolerant to existing therapies. The clinical trial is expected to enroll approximately 62 patients, with approximately 32 patients for the dose escalation stage and approximately 30 patients for the dose expansion stage.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">In the dose escalation stage, patients will receive intravenous infusion of Cami, at escalating doses, on the first day of each 21-day treatment cycle. The initial dose will be 20 &#181;g/kg and the highest allowed dose will be 300&#160;&#181;g/kg. Dose escalation will be conducted using a 3+3 design with oversight by a DESC. After completion of the dose escalation stage, we intend to amend the clinical trial protocol to allow patients in the dose expansion stage to receive Cami in combination with a checkpoint inhibitor. Patients will receive Cami at the recommended dose determined by the DESC based on the anti-tumor activity and tolerability observed during the dose </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 36pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">156<br></div></div></div>
<!--End Page 160-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 161-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 540pt;"><a name="nt10014672x1_drs_107-business_pg46"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="block-frill" style="width: 540pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: Arial, Helvetica, sans-serif; font-size: 9pt; font-weight: bold; margin-top: 6pt; text-align: center;">Confidential Treatment Requested by ADC Therapeutics SA Pursuant to 17 C.F.R. &#167; 200.83<br></div></div><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 36pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">escalation stage. The dose expansion stage may have two cohorts, one for an indication for which Cami was shown in the dose escalation stage to have preliminary activity and one for a basket arm with the same indications allowed in the dose escalation stage. In this clinical trial, response to treatment is determined as CR, PR, SD or PD, based on Response Evaluation Criteria in Solid Tumors (&#8220;RECIST&#8221;) and immune RECIST (&#8220;iRECIST&#8221;).</div><div class="h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 20.5pt; margin-left: 0pt; text-align: left;">Interim Data</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The dose escalation stage of the Phase 1b clinical trial is ongoing. As of July 31, 2020, 41 patients have been treated with Cami. Twenty-seven patients reported one or more Grade &#8805;3 TEAEs, with the most common being anemia and rash. No DLTs have been observed. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Thirty patients have been assessed by the investigator for response to treatment, 18 of whom displayed stable disease. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">In certain patients dosed with Cami, paired biopsies (i.e., one biopsy before dosing with Cami (baseline in the figure below) and one biopsy taken six weeks post the first dose of Cami (on-treatment in the figure below)) were analyzed by fluorescent multiplexing technology to quantify the number of CD8+ Teffs and Tregs in the tumor and in the tissue surrounding the tumor. In three of six paired biopsies analyzed to date, we observed a large increase in the ratio of CD8+ Teffs to Tregs in the local tumor environment following treatment with Cami. In two other paired biopsies, no Tregs were present at baseline. In the remaining paired biopsy, there was no observed increase in the ratio of CD8+ Teffs to Tregs. </div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 14.75pt; text-align: center;"><img style="height: 178px; width: 609px;" src="nt10014672x1_barchart5.jpg"><br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">&#8201; <br></div><div><div class="rule-partial" style="height: 0pt; width: 72pt; border-bottom: 1pt solid #000000; margin-bottom: 1pt; margin-right: auto; margin-left: 0pt; margin-top: 14.75pt;"> </div></div><div class="ftnote" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 3pt; margin-left: 0pt; text-align: left;">The ratio of CD8+ Teffs to Tregs in the local tumor environment at baseline and following treatment with Cami. In the figure, 0 means no Tregs were detected in the biopsy. <font style="font-size: 1pt;">&#8201;</font>&#x2610; means CD8+ Teffs and Tregs were detected in the biopsy, but the ratio of CD8+ Teffs to Tregs was less than 0.1. PC: Pancreatic cancer patient; HN: Head and neck cancer patient; CRC: Colorectal cancer patient; ES: Esophageal cancer patient. </div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 19pt; margin-left: 0pt; text-align: left;">ADCT-601: PBD-Based ADC Targeting AXL</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">ADCT-601 is an ADC targeting AXL-expressing cancers. Currently, we are conducting a Phase 1 clinical trial of ADCT-601 for the treatment of selected advanced tumors.</div><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 20pt; margin-left: 0pt; text-align: left;">Structure and Mechanism of Action</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">ADCT-601 is composed of a humanized monoclonal antibody (1H12-HAKB) directed against human AXL and conjugated through a cathepsin-cleavable linker to SG3199, a PBD dimer cytotoxin. Once bound to an AXL-expressing cell, it is designed to be internalized by the cell, following which the warhead is released. The warhead is designed to bind irreversibly to DNA to create highly potent interstrand cross-links that block DNA strand separation, thus disrupting essential DNA metabolic processes such as replication and ultimately resulting in cell death. The figure below shows the structure of ADCT-601. ADCT-601 also features the following unique technologies:</div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">ADCT-601 uses Glycoconnect<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">TM</sup> site-specific conjugation technology, which allows for fast and stable conjugation of the warhead to the antibody.</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">The PBD payload of ADCT-601 contains a unique spacer, Hydraspace<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">TM</sup>, which we have shown to provide an additional improvement in therapeutic index in preclinical models.</div></td></tr></table></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 36pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">157<br></div></div></div>
<!--End Page 161-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 162-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 540pt;"><a name="nt10014672x1_drs_107-business_pg47"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="block-frill" style="width: 540pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: Arial, Helvetica, sans-serif; font-size: 9pt; font-weight: bold; margin-top: 6pt; text-align: center;">Confidential Treatment Requested by ADC Therapeutics SA Pursuant to 17 C.F.R. &#167; 200.83<br></div></div><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 36pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; text-align: center;"><img style="height: 171px; width: 325px;" src="nt10014672x1_diagram10.jpg"><br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">&#8201;</div><div><div class="rule-partial" style="height: 0pt; width: 72pt; border-bottom: 1pt solid #000000; margin-bottom: 1pt; margin-right: auto; margin-left: 0pt; margin-top: 7.25pt;"> </div></div><div class="ftnote" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 4.5pt; margin-left: 0pt; text-align: left;">Visual representation of ADCT-601.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">AXL plays a pivotal role in various physiological and pathological processes. We believe that AXL is an attractive target for ADCs developed to treat solid tumors for the following reasons:</div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 4pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">AXL is highly overexpressed or ectopically expressed in a multitude of solid tumors, including in lung, breast, prostate, pancreas, glioma and esophageal cancers. Its overexpression is maintained in both primary tumors and metastasis.</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 4pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">AXL expression in healthy tissues is significantly lower than that in tumor cells.</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 4pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">AXL is expressed on M2 macrophages, which are part of the immunosuppressive tumor microenvironment.</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 4pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">Expression and activation of AXL is associated with poor clinical prognosis in many tumor indications and several studies suggest that expression of AXL is induced by both targeted and chemotherapy drugs. Therefore, AXL-based therapies may be efficacious even where traditional therapies have failed.</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 4pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">AXL is prevalent in tumors resistant to anti-PD1 therapy, and pre-clinical data have shown the benefit of combining AXL-targeted therapies with immunotherapies.</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 4pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">The extracellular portion of AXL can be cleaved off from the membrane to generate soluble AXL&#160;(&#8220;sAXL&#8221;), which can be detected in serum. Recent studies suggest that sAXL can be a potential circulating biomarker in certain tumors, representing a potentially attractive biomarker for clinical use.</div></td></tr></table><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 20.5pt; margin-left: 0pt; text-align: left;">Preclinical Studies</div><div class="h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 7.5pt; margin-left: 0pt; text-align: left;">Preclinical Efficacy Studies</div><div class="h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 7.5pt; margin-left: 20pt; text-align: left;">Breast Cancer</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">We evaluated the <font style="font-style: italic;">in vivo</font> efficacy of ADCT-601 in the MDA-MB-231 xenograft model, in which mice received a single dose of (i)&#160;ADCT-601 at 1 mg/kg, (ii)&#160;a non-targeted ADC at 1 mg/kg, or (iii)&#160;a vehicle control. We observed that ADCT-601 exhibited potent and sustained anti-tumor activity, while the non-targeted ADC and the vehicle control did not exhibit any significant anti-tumor activity. The table below summarizes the response data, and the figures below show the mean tumor volume in the MDA-MB-231 xenograft model and the Kaplan-Meier plot from the MDA-MB-231 xenograft model.</div><table cellspacing="0" cellpadding="0" class="fintab" style="margin-top: 5.25pt; border-collapse: collapse; width: 468pt; margin-left: auto; margin-right: auto;"><tr class="header"><td rowspan="2" style="width: 56.41%; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 3.75pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Response</div></td><td class="gutter" rowspan="2" style="width: 1.51%; font-size: 2pt; padding-top: 6pt; padding-bottom: 3.75pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.51%; font-size: 2pt; padding-top: 6pt; padding-bottom: 3.75pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td colspan="7" style="width: 40.57%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 3.75pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">n (%)</div></td></tr><tr class="header"><td class="gutter" style="width: 1.51%; font-size: 2pt; padding-top: 3.75pt; padding-bottom: 3.75pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 8.76%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 3.75pt; padding-bottom: 3.75pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">ADCT-601 <br></div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">1 mg/kg <br></div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">(n=10)</div></td><td class="gutter" style="width: 1.51%; font-size: 2pt; padding-top: 3.75pt; padding-bottom: 3.75pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.51%; font-size: 2pt; padding-top: 3.75pt; padding-bottom: 3.75pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 14.27%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 3.75pt; padding-bottom: 3.75pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Non-Targeted ADC <br></div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">1 mg/kg <br></div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">(n=10)</div></td><td class="gutter" style="width: 1.51%; font-size: 2pt; padding-top: 3.75pt; padding-bottom: 3.75pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.51%; font-size: 2pt; padding-top: 3.75pt; padding-bottom: 3.75pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 11.49%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 3.75pt; padding-bottom: 3.75pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Vehicle Control <br></div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">(n=10)</div></td></tr><tr><td style="width: 56.41%; text-align: left; vertical-align: bottom; padding-top: 3.75pt; padding-bottom: 2.5pt; background-color: #CCEEFF;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Complete response<font style="padding-left: 4.3pt;"></font></div></td><td class="gutter" style="width: 1.51%; border-bottom: none; font-size: 2pt; padding-top: 3.75pt; padding-bottom: 2.5pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.51%; border-bottom: none; font-size: 2pt; padding-top: 3.75pt; padding-bottom: 2.5pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.76%; text-align: center; vertical-align: bottom; padding-top: 3.75pt; padding-bottom: 2.5pt; background-color: #CCEEFF;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">4 (40.0)</div></td><td class="gutter" style="width: 1.51%; border-bottom: none; font-size: 2pt; padding-top: 3.75pt; padding-bottom: 2.5pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.51%; border-bottom: none; font-size: 2pt; padding-top: 3.75pt; padding-bottom: 2.5pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 14.27%; text-align: center; vertical-align: bottom; padding-top: 3.75pt; padding-bottom: 2.5pt; background-color: #CCEEFF;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">0 (0.0)</div></td><td class="gutter" style="width: 1.51%; border-bottom: none; font-size: 2pt; padding-top: 3.75pt; padding-bottom: 2.5pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.51%; border-bottom: none; font-size: 2pt; padding-top: 3.75pt; padding-bottom: 2.5pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 11.49%; text-align: center; vertical-align: bottom; padding-top: 3.75pt; padding-bottom: 2.5pt; background-color: #CCEEFF;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">0 (0.0)</div></td></tr><tr><td style="width: 56.41%; text-align: left; vertical-align: bottom; padding-top: 2.5pt; padding-bottom: 2.5pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Partial response<font style="padding-left: 2.09pt;"></font></div></td><td class="gutter" style="width: 1.51%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td class="gutter" style="width: 1.51%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td style="width: 8.76%; text-align: center; vertical-align: bottom; padding-top: 2.5pt; padding-bottom: 2.5pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">5 (50.0)</div></td><td class="gutter" style="width: 1.51%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td class="gutter" style="width: 1.51%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td style="width: 14.27%; text-align: center; vertical-align: bottom; padding-top: 2.5pt; padding-bottom: 2.5pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">0 (0.0)</div></td><td class="gutter" style="width: 1.51%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td class="gutter" style="width: 1.51%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td style="width: 11.49%; text-align: center; vertical-align: bottom; padding-top: 2.5pt; padding-bottom: 2.5pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">0 (0.0)</div></td></tr><tr><td style="width: 56.41%; text-align: left; vertical-align: bottom; padding-top: 2.5pt; background-color: #CCEEFF;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Tumor-free survivor<font style="padding-left: 4.31pt;"></font></div></td><td class="gutter" style="width: 1.51%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.51%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.76%; text-align: center; vertical-align: bottom; padding-top: 2.5pt; background-color: #CCEEFF;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">4 (40.0)</div></td><td class="gutter" style="width: 1.51%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.51%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 14.27%; text-align: center; vertical-align: bottom; padding-top: 2.5pt; background-color: #CCEEFF;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">0 (0.0)</div></td><td class="gutter" style="width: 1.51%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.51%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 11.49%; text-align: center; vertical-align: bottom; padding-top: 2.5pt; background-color: #CCEEFF;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">0 (0.0)</div></td></tr></table><div><div class="rule-partial" style="height: 0pt; width: 72pt; border-bottom: 1pt solid #000000; margin-bottom: 1pt; margin-right: auto; margin-left: 0pt; margin-top: 13.25pt;"> </div></div><div class="ftnote" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 3pt; margin-left: 0pt; text-align: left;">Response data obtained in the MDA-MB-231 xenograft model. Partial response is recorded when the tumor volume was 50% or less of its Day 1 volume for three consecutive measurements during the course of the study, and equal to or greater than 13.5 mm<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">3</sup> for one or more of these three measurements. Complete response is recorded when the tumor volume was &lt;13.5 mm<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">3</sup> for three consecutive measurements during the course of the study. Tumor-free survivor is recorded when a complete response is recorded at the termination of a study.</div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 36pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">158<br></div></div></div>
<!--End Page 162-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 163-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 540pt;"><a name="nt10014672x1_drs_107-business_pg48"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="block-frill" style="width: 540pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: Arial, Helvetica, sans-serif; font-size: 9pt; font-weight: bold; margin-top: 6pt; text-align: center;">Confidential Treatment Requested by ADC Therapeutics SA Pursuant to 17 C.F.R. &#167; 200.83<br></div></div><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 36pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; text-align: center;"><img style="height: 211px; width: 436px;" src="nt10014672x1_linechart9.jpg"><br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">&#8201;</div><div><div class="rule-partial" style="height: 0pt; width: 72pt; border-bottom: 1pt solid #000000; margin-bottom: 1pt; margin-right: auto; margin-left: 0pt; margin-top: 8.25pt;"> </div></div><div class="ftnote" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 3pt; margin-left: 0pt; text-align: left;">The anti-tumor activity of ADCT-601 in the MDA-MB-231 xenograft model. Data represent the mean tumor volume &#177; SEM for each group of mice.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 14.25pt; text-align: center;"><img style="height: 220px; width: 473px;" src="nt10014672x1_linechart10.jpg"><br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">&#8201;</div><div><div class="rule-partial" style="height: 0pt; width: 72pt; border-bottom: 1pt solid #000000; margin-bottom: 1pt; margin-right: auto; margin-left: 0pt; margin-top: 15.25pt;"> </div></div><div class="ftnote" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 3pt; margin-left: 0pt; text-align: left;">The Kaplan-Meier plot of the activity of ADCT-601 in the MDA-MB-231 xenograft model. Data represent Kaplan-Meier survival curves for each group of mice.</div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 36pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">159<br></div></div></div>
<!--End Page 163-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 164-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 540pt;"><a name="nt10014672x1_drs_107-business_pg49"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="block-frill" style="width: 540pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: Arial, Helvetica, sans-serif; font-size: 9pt; font-weight: bold; margin-top: 6pt; text-align: center;">Confidential Treatment Requested by ADC Therapeutics SA Pursuant to 17 C.F.R. &#167; 200.83<br></div></div><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 36pt;"><div class="h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 6.75pt; margin-left: 20pt; text-align: left;">Esophageal Cancer</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">We evaluated the <font style="font-style: italic;">in vivo</font> efficacy of ADCT-601 in the ES0195 patient-derived xenograft model, in which mice received a single dose of (i)&#160;ADCT-601 at 1 mg/kg, (ii)&#160;a non-targeted ADC at 1 mg/kg, or (iii)&#160;a vehicle control. We observed that ADCT-601 exhibited potent and sustained anti-tumor activity, while the non-targeted ADC and the vehicle control did not exhibit any significant anti-tumor activity. The table below summarizes the response data and the figures below show the mean tumor volume in the ES0195 patient-derived xenograft model and the Kaplan-Meier plot from the ES0195 patient-derived xenograft model.</div><table cellspacing="0" cellpadding="0" class="fintab" style="margin-top: 11.25pt; border-collapse: collapse; width: 468pt; margin-left: auto; margin-right: auto;"><tr class="header"><td rowspan="2" style="width: 53.85%; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Response</div></td><td class="gutter" rowspan="2" style="width: 1.94%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.94%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td colspan="7" style="width: 42.27%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">n (%)</div></td></tr><tr class="header"><td class="gutter" style="width: 1.94%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 8.76%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">ADCT-601 <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">1 mg/kg <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">(n=8)</div></td><td class="gutter" style="width: 1.94%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.94%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 14.27%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Non-Targeted ADC <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">1 mg/kg <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">(n=8)</div></td><td class="gutter" style="width: 1.94%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.94%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 11.49%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Vehicle Control <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">(n=8)</div></td></tr><tr><td style="width: 53.85%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Complete response<font style="padding-left: 2.3pt;"></font></div></td><td class="gutter" style="width: 1.94%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.94%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.76%; text-align: center; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">2 (25.0)</div></td><td class="gutter" style="width: 1.94%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.94%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 14.27%; text-align: center; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">0 (0.0)</div></td><td class="gutter" style="width: 1.94%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.94%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 11.49%; text-align: center; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">0 (0.0)</div></td></tr><tr><td style="width: 53.85%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Partial response<font style="padding-left: 0.09pt;"></font></div></td><td class="gutter" style="width: 1.94%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.94%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 8.76%; text-align: center; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">5 (62.5)</div></td><td class="gutter" style="width: 1.94%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.94%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 14.27%; text-align: center; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">0 (0.0)</div></td><td class="gutter" style="width: 1.94%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.94%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 11.49%; text-align: center; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">0 (0.0)</div></td></tr><tr><td style="width: 53.85%; text-align: left; vertical-align: bottom; padding-top: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Tumor-free survivor<font style="padding-left: 2.31pt;"></font></div></td><td class="gutter" style="width: 1.94%; border-bottom: none; font-size: 2pt; padding-top: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.94%; border-bottom: none; font-size: 2pt; padding-top: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.76%; text-align: center; vertical-align: bottom; padding-top: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">2 (25.0)</div></td><td class="gutter" style="width: 1.94%; border-bottom: none; font-size: 2pt; padding-top: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.94%; border-bottom: none; font-size: 2pt; padding-top: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 14.27%; text-align: center; vertical-align: bottom; padding-top: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">0 (0.0)</div></td><td class="gutter" style="width: 1.94%; border-bottom: none; font-size: 2pt; padding-top: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.94%; border-bottom: none; font-size: 2pt; padding-top: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 11.49%; text-align: center; vertical-align: bottom; padding-top: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">0 (0.0)</div></td></tr></table><div><div class="rule-partial" style="height: 0pt; width: 72pt; border-bottom: 1pt solid #000000; margin-bottom: 1pt; margin-right: auto; margin-left: 0pt; margin-top: 13.25pt;"> </div></div><div class="ftnote" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 3pt; margin-left: 0pt; text-align: left;">Response data obtained in the ES0195 patient-derived xenograft model. Partial response is recorded when the tumor volume was 50% or less of its Day 1 volume for three consecutive measurements during the course of the study, and equal to or greater than 13.5 mm<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">3</sup> for one or more of these three measurements. Complete response is recorded when the tumor volume was &lt;13.5 mm<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">3</sup> for three consecutive measurements during the course of the study. Tumor-free survivor is recorded when a complete response is recorded at the termination of a study.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 14.25pt; text-align: center;"><img style="height: 211px; width: 464px;" src="nt10014672x1_linechart11.jpg"><br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">&#8201;</div><div><div class="rule-partial" style="height: 0pt; width: 72pt; border-bottom: 1pt solid #000000; margin-bottom: 1pt; margin-right: auto; margin-left: 0pt; margin-top: 15.25pt;"> </div></div><div class="ftnote" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 3pt; margin-left: 0pt; text-align: left;">The anti-tumor activity of ADCT-601 in the ES0195 patient-derived xenograft model. Data represent the mean tumor volume &#177; SEM for each group of mice.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 14.25pt; text-align: center;"><img style="height: 209px; width: 447px;" src="nt10014672x1_linechart12.jpg"><br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">&#8201;</div><div><div class="rule-partial" style="height: 0pt; width: 72pt; border-bottom: 1pt solid #000000; margin-bottom: 1pt; margin-right: auto; margin-left: 0pt; margin-top: 15.25pt;"> </div></div><div class="ftnote" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 3pt; margin-left: 0pt; text-align: left;">The Kaplan-Meier plot of the activity of ADCT-601 in the ES0195 patient-derived xenograft model. Data represent Kaplan-Meier survival curves for each group of mice. </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 36pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">160<br></div></div></div>
<!--End Page 164-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 165-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 540pt;"><a name="nt10014672x1_drs_107-business_pg50"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="block-frill" style="width: 540pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: Arial, Helvetica, sans-serif; font-size: 9pt; font-weight: bold; margin-top: 6pt; text-align: center;">Confidential Treatment Requested by ADC Therapeutics SA Pursuant to 17 C.F.R. &#167; 200.83<br></div></div><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 36pt;"><div class="h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">Pancreatic Cancer</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">We evaluated the in vivo efficacy of ADCT-601 and that of AXL-107-MMAE, an AXL-targeted ADC similar to HuMax-AXL-ADC, which is currently in Phase 1/2 development by a third party for multiple types of solid tumors, in the PAXF1657 pancreatic cancer patient-derived xenograft model, in which mice received a single dose of (i) ADCT-601 at 0.075 mg/kg, (ii) ADCT-601 at 0.15 mg/kg, (iii) ADCT-601 at 0.3 mg/kg, (iv) AXL-107-MMAE at 0.3 mg/kg, (v) AXL-107-MMAE at 4 mg/kg, or (vi) a control vehicle. We observed that ADCT-601 exhibited dose-dependent anti-tumor activity and superior anti-tumor activity compared to AXL-107-MMAE when tested at the same low dose of 0.3 mg/kg. The table below summarizes the response data and the figures below show the mean tumor volume in the PAXF1657 xenograft model and the Kaplan-Meier plot from the PAXF1657 patient-derived xenograft model. </div><table cellspacing="0" cellpadding="0" class="fintab" style="margin-top: 11.25pt; border-collapse: collapse; width: 468pt; margin-left: auto; margin-right: auto;"><tr class="header"><td style="width: 23.08%; text-align: left; vertical-align: bottom; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 0.64%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td colspan="16" style="width: 75.64%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">n (%)</div></td></tr><tr class="header"><td style="width: 23.08%; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Response</div></td><td class="gutter" style="width: 0.64%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 0.64%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 9.62%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">ADCT-601<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">0.075 mg/kg<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">(n=8)</div></td><td class="gutter" style="width: 0.64%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 0.64%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 9.62%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">ADCT-601<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">0.15 mg/kg<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">(n=8)</div></td><td class="gutter" style="width: 0.64%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 0.64%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 9.62%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">ADCT-601<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">0.3 mg/kg<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">(n=8)</div></td><td class="gutter" style="width: 0.64%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 0.64%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 13.46%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">AXL-107-MMAE<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">0.3 mg/kg<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">(n=8)</div></td><td class="gutter" style="width: 0.64%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 0.64%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 13.46%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">AXL-107-MMAE<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">4 mg/kg<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">(n=8)</div></td><td class="gutter" style="width: 0.64%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 0.64%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 13.46%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Vehicle Control<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">&#8195;<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">(n=8)</div></td></tr><tr><td style="width: 23.08%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Complete response<font style="padding-left: 3.3pt;"></font></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.62%; text-align: center; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">0 (0.0)</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.62%; text-align: center; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">0 (0.0)</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.62%; text-align: center; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">3 (37.5)</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 13.46%; text-align: center; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">0 (0.0)</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 13.46%; text-align: center; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">8 (100.0)</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 13.46%; text-align: center; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">0 (0.0)</div></td></tr><tr><td style="width: 23.08%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Partial response<font style="padding-left: 1.09pt;"></font></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 9.62%; text-align: center; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">0 (0.0)</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 9.62%; text-align: center; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">0 (0.0)</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 9.62%; text-align: center; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">1 (12.5)</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 13.46%; text-align: center; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">0 (0.0)</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 13.46%; text-align: center; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">0 &#8199;&#8199;(0.0)</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 13.46%; text-align: center; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">0 (0.0)</div></td></tr><tr><td style="width: 23.08%; text-align: left; vertical-align: bottom; padding-top: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Tumor-free survivor<font style="padding-left: 3.31pt;"></font></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.62%; text-align: center; vertical-align: bottom; padding-top: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">0 (0.0)</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.62%; text-align: center; vertical-align: bottom; padding-top: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">0 (0.0)</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.62%; text-align: center; vertical-align: bottom; padding-top: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">3 (37.5)</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 13.46%; text-align: center; vertical-align: bottom; padding-top: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">0 (0.0)</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 13.46%; text-align: center; vertical-align: bottom; padding-top: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">8 (100.0)</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 13.46%; text-align: center; vertical-align: bottom; padding-top: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">0 (0.0)</div></td></tr></table><div><div class="rule-partial" style="height: 0pt; width: 72pt; border-bottom: 1pt solid #000000; margin-bottom: 1pt; margin-right: auto; margin-left: 0pt; margin-top: 9.75pt;"> </div></div><div class="ftnote" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 3pt; margin-left: 0pt; text-align: left;">Response data obtained in the PAXF1657 patient-derived xenograft model. Partial response is recorded when the tumor volume was 50% or less of its Day 1 volume for three consecutive measurements during the course of the study, and equal to or greater than 13.5 mm<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">3</sup> for one or more of these three measurements. Complete response is recorded when the tumor volume was &lt;13.5 mm<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">3</sup> for three consecutive measurements during the course of the study. Tumor-free survivor is recorded when a complete response is recorded at the termination of a study. </div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 13.75pt; text-align: center;"><img style="height: 188px; width: 470px;" src="nt10014672x1_linechart13.jpg"><br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">&#8201;</div><div><div class="rule-partial" style="height: 0pt; width: 72pt; border-bottom: 1pt solid #000000; margin-bottom: 1pt; margin-right: auto; margin-left: 0pt; margin-top: 11.75pt;"> </div></div><div class="ftnote" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 3pt; margin-left: 0pt; text-align: left;">The anti-tumor activity of ADCT-601 in the PAXF1657 patient-derived xenograft model. Data represent the mean tumor volume &#177; SEM for each group of mice.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 13.75pt; text-align: center;"><img style="height: 209px; width: 444px;" src="nt10014672x1_linechart14.jpg"><br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">&#8201;</div><div><div class="rule-partial" style="height: 0pt; width: 72pt; border-bottom: 1pt solid #000000; margin-bottom: 1pt; margin-right: auto; margin-left: 0pt; margin-top: 11.75pt;"> </div></div><div class="ftnote" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 3pt; margin-left: 0pt; text-align: left;">The Kaplan-Meier plot of the activity of ADCT-601 in the PAXF1657 patient-derived xenograft model. Data represent Kaplan-Meier survival curves for each group of mice.</div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 36pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">161<br></div></div></div>
<!--End Page 165-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 166-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 540pt;"><a name="nt10014672x1_drs_107-business_pg51"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="block-frill" style="width: 540pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: Arial, Helvetica, sans-serif; font-size: 9pt; font-weight: bold; margin-top: 6pt; text-align: center;">Confidential Treatment Requested by ADC Therapeutics SA Pursuant to 17 C.F.R. &#167; 200.83<br></div></div><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 36pt;"><div class="h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">Preclinical Safety Studies</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">We evaluated the toxicity of ADCT-601 primarily in non-human primates and with a single-dose MTD study in rats. In non-human primates, toxicity was observed in the immune system, bone marrow, kidney, mammary glands (females only), reproductive tract and skin. Most microscopic findings were not reversible after a six-week recovery phase, except for the morphologic effect on the hematopoietic system in the bone marrow in both sexes, and the immune system (spleen, thymus and gut-associated lymphoid tissue) in males. In rats, the MTD for ADCT-601 was 6 mg/kg.</div><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 20.5pt; margin-left: 0pt; text-align: left;">Phase 1 Clinical Trial in Selected Advanced Solid Tumors</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">We conducted a Phase 1, open-label, dose escalation and dose expansion clinical trial of the safety, tolerability, pharmacokinetics and anti-tumor activity of ADCT-601, used as monotherapy, in patients with selected advanced solid or metastatic tumors, including triple-negative breast cancer, colorectal cancer, esophageal cancer, gastric cancer, head and neck cancer, mesothelioma, non-small cell lung cancer, ovarian cancer, pancreatic cancer and soft tissue sarcoma. We conducted the clinical trial at four sites in the United States, pursuant to an IND accepted by the FDA in December 2018. The first patient was dosed in January 2019. The clinical trial&#8217;s design and our interim findings are summarized below.</div><div class="h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 20.5pt; margin-left: 0pt; text-align: left;">Clinical Trial Design</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The primary objectives of the clinical trial were to (i)&#160;evaluate the safety and tolerability of ADCT-601 in patients with selected advanced solid tumors and (ii)&#160;identify the recommended dose and dose schedule for future studies in patients with selected advanced solid tumors. The secondary objectives were to (i)&#160;evaluate the preliminary anti-tumor activity of ADCT-601, (ii)&#160;characterize the pharmacokinetic profile of ADCT-601 and (iii)&#160;evaluate the immunogenicity of ADCT-601.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The clinical trial enrolled patients with pathologically confirmed relapsed or refractory solid tumor malignancy that is locally advanced or metastatic at the time of screening and who have failed or are intolerant to existing therapies. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">In the dose escalation stage, patients received intravenous infusion of ADCT-601, at escalating doses, on the first day of each 21-day treatment cycle. The initial dose was 50 &#181;g/kg and the highest given dose was 150 &#181;g/kg. Dose escalation was conducted using a 3+3 design with oversight by a DESC. In this clinical trial, response to treatment was determined as CR, PR, SD or PD, based on RECIST and iRECIST. After completion of the dose escalation stage, we intend to update our clinical plan with respect to ADCT-601, including exploring its use in combination with other therapies and identifying solid tumors with high AXL expression that are potentially more susceptible to treatment with ADCT-601. We intend to commence a Phase 1b clinical trial of ADCT-601 in combination with other therapies in the second half of 2021.</div><div class="h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 20.5pt; margin-left: 0pt; text-align: left;">Interim Data</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The dose escalation stage of the Phase 1 clinical trial has been completed. As of November 4, 2019, 17 patients have been treated with ADCT-601. Ten patients experienced one or more Grade &#8805;3 TEAEs, with the most common being abdominal pain and urinary tract obstruction. One DLT of Grade 3 hematuria was observed in a colorectal cancer patient treated at the 100 &#181;g/kg dose level who had a history of radiotherapy involving the bladder. In addition, one DLT of hyponatremia was observed in an ovarian cancer patient treated at the 150 &#181;g/kg dose level, which the investigator assessed as probably being related to ADCT-601. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Thirteen patients have been assessed by the investigator for response to treatment, one of whom achieved a partial response and seven of whom displayed stable disease. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Following the dose escalation stage of the Phase 1 clinical trial, we intend to update our clinical plan with respect to ADCT-601, including exploring its use in combination with other therapies and identifying solid tumors with high AXL expression that are potentially more susceptible to treatment with ADCT-601. </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 36pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">162<br></div></div></div>
<!--End Page 166-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 167-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 540pt;"><a name="nt10014672x1_drs_107-business_pg52"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="block-frill" style="width: 540pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: Arial, Helvetica, sans-serif; font-size: 9pt; font-weight: bold; margin-top: 6pt; text-align: center;">Confidential Treatment Requested by ADC Therapeutics SA Pursuant to 17 C.F.R. &#167; 200.83<br></div></div><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 36pt;"><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">Our Preclinical Solid Tumor Product Candidates</div><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 7.5pt; margin-left: 0pt; text-align: left;">ADCT-901: PBD-Based ADC Targeting KAAG1</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">ADCT-901 is an ADC targeting KAAG1-expressing cancers. We are developing ADCT-901 for the treatment of advanced solid tumors with high unmet medical needs, including platinum resistant ovarian cancer and triple negative breast cancer. ADCT-901 is composed of a humanized monoclonal antibody (3A4) directed against human KAAG1 and conjugated through a cathepsin-cleavable linker to SG3199, a PBD dimer cytotoxin. KAAG1 is a novel tumor-associated antigen expressed in a high percentage of ovarian tumors and triple negative breast cancer, with limited expression in healthy cells. We believe that KAAG1 is an attractive target for ADC development as (i) it is an intracellular target by definition, but becomes exposed on the membrane of tumor cells, (ii) it has high expression in tumors with high unmet medical need, including ovarian cancer and triple negative breast cancer, while its expression on healthy tissue is very limited and (iii) it internalizes and co-localizes with lysosomal-associated membrane protein 1, a lysosomal marker, which shows that the target is efficiently transported to the cellular compartment where efficient release of the cytotoxin is expected. Currently, we are conducting preclinical development of ADCT-901 and expect to submit an IND in the first half of 2021. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">We evaluated the <font style="font-style: italic;">in vivo</font> efficacy of ADCT-901 in the CTG-0703 patient-derived ovarian cancer xenograft model, in which mice received a single dose of (i) ADCT-901 at 1 mg/kg, (ii) a non-targeted ADC at 1 mg/kg, or (iii) a vehicle control. We observed that ADCT-901 exhibited potent and specific anti-tumor activity, while the non-targeted ADC and the vehicle control did not exhibit any significant anti-tumor activity. The table below summarizes the response data and the figure below shows the mean tumor volume in the CTG-0703 patient-derived xenograft model. </div><table cellspacing="0" cellpadding="0" class="fintab" style="margin-top: 11.25pt; border-collapse: collapse; width: 468pt; margin-left: auto; margin-right: auto;"><tr class="header"><td style="width: 53.85%; text-align: left; vertical-align: bottom; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 1.69%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.69%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td colspan="7" style="width: 42.77%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">n (%)</div></td></tr><tr class="header"><td style="width: 53.85%; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Response</div></td><td class="gutter" style="width: 1.69%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.69%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 10.26%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">ADCT-901<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">1 mg/kg<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">(n=8)</div></td><td class="gutter" style="width: 1.69%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.69%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 14.27%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Non-Targeted ADC<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">1 mg/kg<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">(n=8)</div></td><td class="gutter" style="width: 1.69%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.69%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 11.49%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Vehicle Control<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">&#8195;<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">(n=8)</div></td></tr><tr><td style="width: 53.85%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Complete response<font style="padding-left: 2.3pt;"></font></div></td><td class="gutter" style="width: 1.69%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.69%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.26%; text-align: center; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">0 &#8199;(0.0)</div></td><td class="gutter" style="width: 1.69%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.69%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 14.27%; text-align: center; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">0 (0.0)</div></td><td class="gutter" style="width: 1.69%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.69%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 11.49%; text-align: center; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">0 (0.0)</div></td></tr><tr><td style="width: 53.85%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Partial response<font style="padding-left: 0.09pt;"></font></div></td><td class="gutter" style="width: 1.69%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.69%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 10.26%; text-align: center; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">7 (87.5)</div></td><td class="gutter" style="width: 1.69%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.69%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 14.27%; text-align: center; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">0 (0.0)</div></td><td class="gutter" style="width: 1.69%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.69%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 11.49%; text-align: center; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">0 (0.0)</div></td></tr><tr><td style="width: 53.85%; text-align: left; vertical-align: bottom; padding-top: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Tumor-free survivor<font style="padding-left: 2.31pt;"></font></div></td><td class="gutter" style="width: 1.69%; border-bottom: none; font-size: 2pt; padding-top: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.69%; border-bottom: none; font-size: 2pt; padding-top: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.26%; text-align: center; vertical-align: bottom; padding-top: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">0 &#8199;(0.0)</div></td><td class="gutter" style="width: 1.69%; border-bottom: none; font-size: 2pt; padding-top: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.69%; border-bottom: none; font-size: 2pt; padding-top: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 14.27%; text-align: center; vertical-align: bottom; padding-top: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">0 (0.0)</div></td><td class="gutter" style="width: 1.69%; border-bottom: none; font-size: 2pt; padding-top: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.69%; border-bottom: none; font-size: 2pt; padding-top: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 11.49%; text-align: center; vertical-align: bottom; padding-top: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">0 (0.0)</div></td></tr></table><div><div class="rule-partial" style="height: 0pt; width: 72pt; border-bottom: 1pt solid #000000; margin-bottom: 1pt; margin-right: auto; margin-left: 0pt; margin-top: 13.25pt;"> </div></div><div class="ftnote" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 3pt; margin-left: 0pt; text-align: left;">Response data obtained in the CTG-0703 patient-derived xenograft model. Partial response is recorded when the tumor volume was 50% or less of its Day 1 volume for three consecutive measurements during the course of the study, and equal to or greater than 13.5 mm<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">3</sup> for one or more of these three measurements. Complete response is recorded when the tumor volume was &lt;13.5 mm<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">3</sup> for three consecutive measurements during the course of the study. Tumor-free survivor is recorded when a complete response is recorded at the termination of a study.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 14.25pt; text-align: center;"><img style="height: 256px; width: 284px;" src="nt10014672x1_linechart16.jpg"><br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">&#8201;</div><div><div class="rule-partial" style="height: 0pt; width: 72pt; border-bottom: 1pt solid #000000; margin-bottom: 1pt; margin-right: auto; margin-left: 0pt; margin-top: 15.25pt;"> </div></div><div class="ftnote" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 3pt; margin-left: 0pt; text-align: left;">The anti-tumor activity of ADCT-901 in the CTG-0703 patient-derived xenograft model. Data represent the mean tumor volume &#177; SEM for each group of mice. </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 36pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">163<br></div></div></div>
<!--End Page 167-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 168-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 540pt;"><a name="nt10014672x1_drs_107-business_pg53"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="block-frill" style="width: 540pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: Arial, Helvetica, sans-serif; font-size: 9pt; font-weight: bold; margin-top: 6pt; text-align: center;">Confidential Treatment Requested by ADC Therapeutics SA Pursuant to 17 C.F.R. &#167; 200.83<br></div></div><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 36pt;"><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">ADCT-701: PBD-Based ADC Targeting DLK-1</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">ADCT-701 is an ADC targeting DLK-1-expressing cancers. We are developing ADCT-701 for the treatment of advanced solid tumors with high unmet medical needs, including hepatocellular carcinoma, neuroblastoma and small cell lung cancer (&#8220;SCLC&#8221;). ADCT-701 is composed of a humanized monoclonal antibody (HuBa-1-3D) directed against human DLK-1 and conjugated through a cathepsin-cleavable linker to SG3199, a PBD dimer cytotoxin. DLK-1 is widely expressed during fetal development, but its expression is highly restricted in adults. However, DKL-1 is expressed in adults in several tumors, such as neuroblastoma, hepatocellular carcinoma (&#8220;HCC&#8221;), SCLC and acute myeloid leukemia. Currently, we are evaluating collaboration options to further develop ADCT-701. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">We evaluated the <font style="font-style: italic;">in vivo</font> efficacy of ADCT-701 in the LI1097 patient-derived hepatocellular carcinoma xenograft model, in which mice received a single dose of (i) ADCT-701 at 0.1 mg/kg, (ii) ADCT-701 at 0.3 mg/kg, (iii) ADCT-701 at 1 mg/kg, (iv) a non-targeted ADC at 1 mg/kg, or (v) a vehicle control. We observed that ADCT-701 exhibited potent, specific and dose-dependent anti-tumor activity, while the non-targeted ADC and the vehicle control did not exhibit any significant anti-tumor activity. The table below summarizes the response data and the figure below shows the mean tumor volume in the LI1097 patient-derived xenograft model. </div><table cellspacing="0" cellpadding="0" class="fintab" style="border-collapse: collapse; width: 468pt; margin-left: auto; margin-right: auto;"><tr class="header"><td style="width: 33.33%; text-align: left; vertical-align: bottom; padding-top: 6pt; padding-bottom: 3.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 0.83%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 3.75pt;">&#8203;</td><td class="gutter" style="width: 0.83%; font-size: 2pt; padding-top: 6pt; padding-bottom: 3.75pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td colspan="13" style="width: 65%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 3.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">n (%)</div></td></tr><tr class="header"><td style="width: 33.33%; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 3.75pt; padding-bottom: 3.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Response </div></td><td class="gutter" style="width: 0.83%; font-size: 2pt; padding-top: 3.75pt; padding-bottom: 3.75pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 0.83%; font-size: 2pt; padding-top: 3.75pt; padding-bottom: 3.75pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 9.62%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 3.75pt; padding-bottom: 3.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">ADCT-701<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">0.1 mg/kg<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">(n=8) </div></td><td class="gutter" style="width: 0.83%; font-size: 2pt; padding-top: 3.75pt; padding-bottom: 3.75pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 0.83%; font-size: 2pt; padding-top: 3.75pt; padding-bottom: 3.75pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 9.62%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 3.75pt; padding-bottom: 3.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">ADCT-701<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">0.3 mg/kg<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">(n=8)</div></td><td class="gutter" style="width: 0.83%; font-size: 2pt; padding-top: 3.75pt; padding-bottom: 3.75pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 0.83%; font-size: 2pt; padding-top: 3.75pt; padding-bottom: 3.75pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 9.62%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 3.75pt; padding-bottom: 3.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">ADCT-701<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">1 mg/kg<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">(n=8)</div></td><td class="gutter" style="width: 0.83%; font-size: 2pt; padding-top: 3.75pt; padding-bottom: 3.75pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 0.83%; font-size: 2pt; padding-top: 3.75pt; padding-bottom: 3.75pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 14.74%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 3.75pt; padding-bottom: 3.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Non-Targeted ADC<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">1 mg/kg<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">(n=8)</div></td><td class="gutter" style="width: 0.83%; font-size: 2pt; padding-top: 3.75pt; padding-bottom: 3.75pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 0.83%; font-size: 2pt; padding-top: 3.75pt; padding-bottom: 3.75pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 14.74%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 3.75pt; padding-bottom: 3.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Vehicle Control<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">&#8195;<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">(n=8)</div></td></tr><tr><td style="width: 33.33%; text-align: left; vertical-align: bottom; padding-top: 3.75pt; padding-bottom: 2.5pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Complete response<font style="padding-left: 1.3pt;"></font></div></td><td class="gutter" style="width: 0.83%; border-bottom: none; font-size: 2pt; padding-top: 3.75pt; padding-bottom: 2.5pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.83%; border-bottom: none; font-size: 2pt; padding-top: 3.75pt; padding-bottom: 2.5pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.62%; text-align: center; vertical-align: bottom; padding-top: 3.75pt; padding-bottom: 2.5pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">0 (0.0) </div></td><td class="gutter" style="width: 0.83%; border-bottom: none; font-size: 2pt; padding-top: 3.75pt; padding-bottom: 2.5pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.83%; border-bottom: none; font-size: 2pt; padding-top: 3.75pt; padding-bottom: 2.5pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.62%; text-align: center; vertical-align: bottom; padding-top: 3.75pt; padding-bottom: 2.5pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">0 (0.0) </div></td><td class="gutter" style="width: 0.83%; border-bottom: none; font-size: 2pt; padding-top: 3.75pt; padding-bottom: 2.5pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.83%; border-bottom: none; font-size: 2pt; padding-top: 3.75pt; padding-bottom: 2.5pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.62%; text-align: center; vertical-align: bottom; padding-top: 3.75pt; padding-bottom: 2.5pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">2 (37.5) </div></td><td class="gutter" style="width: 0.83%; border-bottom: none; font-size: 2pt; padding-top: 3.75pt; padding-bottom: 2.5pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.83%; border-bottom: none; font-size: 2pt; padding-top: 3.75pt; padding-bottom: 2.5pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 14.74%; text-align: center; vertical-align: bottom; padding-top: 3.75pt; padding-bottom: 2.5pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">0 (0.0) </div></td><td class="gutter" style="width: 0.83%; border-bottom: none; font-size: 2pt; padding-top: 3.75pt; padding-bottom: 2.5pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.83%; border-bottom: none; font-size: 2pt; padding-top: 3.75pt; padding-bottom: 2.5pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 14.74%; text-align: center; vertical-align: bottom; padding-top: 3.75pt; padding-bottom: 2.5pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">0 (0.0)</div></td></tr><tr><td style="width: 33.33%; text-align: left; vertical-align: bottom; padding-top: 2.5pt; padding-bottom: 2.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Partial response <font style="padding-left: 0.76pt;"></font></div></td><td class="gutter" style="width: 0.83%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td class="gutter" style="width: 0.83%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td style="width: 9.62%; text-align: center; vertical-align: bottom; padding-top: 2.5pt; padding-bottom: 2.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">0 (0.0) </div></td><td class="gutter" style="width: 0.83%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td class="gutter" style="width: 0.83%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td style="width: 9.62%; text-align: center; vertical-align: bottom; padding-top: 2.5pt; padding-bottom: 2.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">0 (0.0)</div></td><td class="gutter" style="width: 0.83%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td class="gutter" style="width: 0.83%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td style="width: 9.62%; text-align: center; vertical-align: bottom; padding-top: 2.5pt; padding-bottom: 2.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">3 (62.5) </div></td><td class="gutter" style="width: 0.83%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td class="gutter" style="width: 0.83%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td style="width: 14.74%; text-align: center; vertical-align: bottom; padding-top: 2.5pt; padding-bottom: 2.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">0 (0.0) </div></td><td class="gutter" style="width: 0.83%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td class="gutter" style="width: 0.83%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td style="width: 14.74%; text-align: center; vertical-align: bottom; padding-top: 2.5pt; padding-bottom: 2.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">0 (0.0)</div></td></tr><tr><td style="width: 33.33%; text-align: left; vertical-align: bottom; padding-top: 2.5pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Tumor-free survivor <font style="padding-left: 2.98pt;"></font></div></td><td class="gutter" style="width: 0.83%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.83%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.62%; text-align: center; vertical-align: bottom; padding-top: 2.5pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">0 (0.0) </div></td><td class="gutter" style="width: 0.83%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.83%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.62%; text-align: center; vertical-align: bottom; padding-top: 2.5pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">0 (0.0)</div></td><td class="gutter" style="width: 0.83%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.83%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.62%; text-align: center; vertical-align: bottom; padding-top: 2.5pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">0 &#8199;(0.0)</div></td><td class="gutter" style="width: 0.83%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.83%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 14.74%; text-align: center; vertical-align: bottom; padding-top: 2.5pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">0 (0.0)</div></td><td class="gutter" style="width: 0.83%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.83%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 14.74%; text-align: center; vertical-align: bottom; padding-top: 2.5pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">0 (0.0)</div></td></tr></table><div><div class="rule-partial" style="height: 0pt; width: 72pt; border-bottom: 1pt solid #000000; margin-bottom: 1pt; margin-right: auto; margin-left: 0pt; margin-top: 13.25pt;"> </div></div><div class="ftnote" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 3pt; margin-left: 0pt; text-align: left;">Response data obtained in the LI1097 patient-derived xenograft model. Partial response is recorded when the tumor volume was 50% or less of its Day 1 volume for three consecutive measurements during the course of the study, and equal to or greater than 13.5 mm<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">3</sup> for one or more of these three measurements. Complete response is recorded when the tumor volume was &lt;13.5 mm<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">3</sup> for three consecutive measurements during the course of the study. Tumor-free survivor is recorded when a complete response is recorded at the termination of a study.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 14.25pt; text-align: center;"><img style="height: 293px; width: 315px;" src="nt10014672x1_linechart15.jpg"><br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">&#8201;</div><div><div class="rule-partial" style="height: 0pt; width: 72pt; border-bottom: 1pt solid #000000; margin-bottom: 1pt; margin-right: auto; margin-left: 0pt; margin-top: 15.25pt;"> </div></div><div class="ftnote" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 3pt; margin-left: 0pt; text-align: left;">The anti-tumor activity of ADCT-701 in the LI1097 patient-derived xenograft model. Data represent the mean tumor volume &#177; SEM for each group of mice. </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 36pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">164<br></div></div></div>
<!--End Page 168-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 169-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 540pt;"><a name="nt10014672x1_drs_107-business_pg54"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="block-frill" style="width: 540pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: Arial, Helvetica, sans-serif; font-size: 9pt; font-weight: bold; margin-top: 6pt; text-align: center;">Confidential Treatment Requested by ADC Therapeutics SA Pursuant to 17 C.F.R. &#167; 200.83<br></div></div><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 36pt;"><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">Our Research Pipeline</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">In addition to our product candidates described above, we have selected five additional ADC targets (one&#160;hematological and four solid tumor targets) and ten XDC targets (four hematological and six solid tumor targets) for which we are conducting preclinical research, with the aim of selecting clinical candidates for further development. For the XDC product candidates, we are exploring different non-antibody protein scaffolds as well as peptides for tumor targeting.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">We are also testing complementary technologies to expand the therapeutic index of our product candidates. For example, we are investigating novel conjugation and linker technologies to maximize the benefits of the PBD dimer technology. As an example, we benchmarked multiple site-specific conjugation technologies and identified GlycoConnect<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">TM</sup>/Hydraspace technology (licensed from Synaffix) to provide the enhanced therapeutic index for ADCT-601 and ADCT-701 that we observed in preclinical models. We are also exploring the use of a novel Silinol-based linker technology that we licensed from a third party. We continue to explore alternative conjugation and linker strategies as they become available and determine whether there is any merit in utilizing them in product candidates.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Moreover, we are exploring the development of ADCs that use tumor-conditional binding approaches, such as antibody masking, which depends on the unique proteolytic environment in the tumor. These tumor-specific proteases can be used to remove masking peptides engineered on a masked antibody. Such masked antibodies will not bind to healthy tissue expressing the target and will not bind to soluble target shed into circulation (as there is no expression of the tumor specific proteases and the mask prevents binding to target). However, once in the tumor microenvironment, tumor-specific proteases release the masking peptide from the antibody and it will bind to the target on the tumor cell membrane, allowing internalization of the ADC into the tumor. Another tumor conditional binding approach relies on the pH difference between tumor (more acidic) and healthy tissue (neutral pH), as it is possible to raise and select antibodies that only bind to their antigen at acidic pH, while there is little to no binding at neutral pH. Hence, we believe that ADCs developed using such antibodies will only bind to target expressed in the tumor and leave healthy tissue unaffected.</div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 18pt; margin-left: 0pt; text-align: left;">Commercial</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">As we near potential commercialization for our lead product candidate, Lonca, we have focused on preparing for our commercial launch. If approved, we intend to commercialize Lonca in the United States through our own infrastructure and may selectively pursue strategic collaborations and licensing opportunities in other geographies. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Our launch plan remains on track, and we have commercial-ready supply available. We are actively engaging with U.S. hematology oncologists to enhance our understanding of the unmet medical need in relapsed or refractory DLBCL, their assessment of the Lonca profile and how Lonca may fit into the treatment paradigm. Our commercial and medical affairs leadership teams are in place, including an experienced Chief Commercial Officer and senior commercial leadership team, including a Vice President of Sales, a Vice President of Marketing and a Vice President of Market Access. A broader organizational recruitment is underway. Despite the COVID-19 pandemic, we have recently added over 30 new employees focused on Lonca&#8217;s commercial launch. We are planning for a mix of virtual and face-to-face commercial launch for Lonca, if approved, which can be adapted to respond to the COVID-19 pandemic as appropriate. Our goal is to build a highly talented and efficient U.S. customer-facing organization with more than 65 cross-functional employees, which we believe has the potential to capture more than 80% of the DLBCL commercial opportunity.</div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 18pt; margin-left: 0pt; text-align: left;">Chemistry, Manufacturing and Controls</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">We believe that the manufacture of ADCs requires considerable expertise, know-how and resources. Since our inception, we have made significant financial and human resource investments to become a leader in the industry for ADC chemistry, manufacture and control processes. Currently, we have a 34-person, in-house team, based in the San Francisco Bay Area, overseeing our CMC operations for each of our product candidates.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">We do not own or operate, and do not plan to own or operate, manufacturing infrastructure for the manufacture of clinical or commercial supply of our product candidates. Instead, we contract with third party cGMP-compliant CMOs that have the facilities and capabilities to manufacture on our behalf the intermediate components and the final product candidates for use in clinical trials and future commercial supply. Our in-house </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 36pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">165<br></div></div></div>
<!--End Page 169-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 170-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 540pt;"><a name="nt10014672x1_drs_107-business_pg55"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="block-frill" style="width: 540pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: Arial, Helvetica, sans-serif; font-size: 9pt; font-weight: bold; margin-top: 6pt; text-align: center;">Confidential Treatment Requested by ADC Therapeutics SA Pursuant to 17 C.F.R. &#167; 200.83<br></div></div><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 36pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">team oversees all aspects of the CMO manufacturing process, including defining the scope of work and monitoring all aspects of the manufacturing process to ensure that they meet our specifications and quality requirements, including conducting routine site visits and audits. We also contract with external specialist quality control and stability-testing organizations to monitor the quality of the materials manufactured by the CMOs.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">To support BLA submission for Lonca, we have developed a validated commercial supply chain. The supply chain has been able to consistently produce drug product that complies with predefined specifications at commercial scale. We believe that we have a sufficient supply of commercial-grade drug product in stock to support our expected commercial launch for Lonca. For Cami, we have initiated the validation of the commercial supply chain. </div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 20.5pt; margin-left: 0pt; text-align: left;">License and Collaboration Agreements</div><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 7.5pt; margin-left: 0pt; text-align: left;">MedImmune License and Collaboration Agreement</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">In 2011, we (then operating under the name ADCT S&#224;rl) entered into a license and collaboration agreement with Spirogen (since renamed ADC Products UK Ltd.), pursuant to which Spirogen granted us access to its next-generation PBD-based warhead and linker technology. In connection with AstraZeneca plc&#8217;s acquisition of Spirogen S&#224;rl (which was at the time the direct parent company of Spirogen) and the transfer of certain of Spirogen&#8217;s intellectual property to Spirogen S&#224;rl, including its PBD-based warhead and linker technology, the agreement was subsequently amended and restated in October 2013 (with retroactive effect to September 2011), with Spirogen S&#224;rl also becoming a party to such agreement. Spirogen S&#224;rl subsequently transferred the PBD technology to MedImmune Limited, which, together with MedImmune LLC, is the global biologics research and development arm of AstraZeneca plc. Thereafter, Spirogen S&#224;rl transferred its rights and obligations under the agreement to MedImmune and the agreement was subsequently amended and restated again in May 2016 (with retroactive effect to September 2011), with MedImmune replacing Spirogen S&#224;rl as the licensor thereunder.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Under the terms of the agreement, MedImmune has granted us an exclusive, worldwide license under certain patent rights and related know-how to make, have made, use, sell, offer for sale and import product candidates in the field of human therapeutics and diagnostics that consist of (i)&#160;PBD-based molecules directly conjugated to an antibody (i.e., ADCs with a PBD-based warhead) that specifically bind to up to 11 approved targets (&#8220;ADC Targets&#8221;), and (ii)&#160;PBD-based molecules conjugated to a non-antibody (i.e., targeting-moiety conjugates with a PBD-based warhead) that specifically bind to up to ten approved targets (&#8220;XDC Targets&#8221;). As of the date hereof, there are 11 approved ADC Targets subject to the license, including CD19 (the target of Lonca) and CD25 (the target of Cami), and ten approved XDC Targets subject to the license.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Under the terms of the agreement, we have the right to grant sublicenses to affiliates and, subject to MedImmune&#8217;s approval (not to be unreasonably withheld), third parties. In addition, with respect to each licensed target, we agreed to use commercially reasonable efforts to develop and commercialize at least one product and submit an IND application with the FDA (or its equivalent in another jurisdiction) for one product within 48&#160;months after formal designation of the target as an approved target, which we have done with respect to CD19 and CD25 upon submitting the IND applications for Lonca and Cami, respectively.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">As consideration for the rights granted to us under the agreement, in 2011 we paid Spirogen an up-front licensing fee of $2.5 million. No further payments in consideration for the grant of such rights are required to be paid to Spirogen or MedImmune under the agreement.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">With respect to patent rights conceived during the course of our exercise of our rights under the agreement, rights are allocated as follows under the agreement: (i)&#160;we own any such patent that claims an antibody that binds to one of the ADC Targets approved under the agreement, (ii)&#160;we and MedImmune jointly own any such patent claiming any PBD-based ADC, with us owning the exclusive right to exploit such patent during the term of the agreement and (iii)&#160;MedImmune owns any such patent that claims a PBD or any PBD attached to an antibody that does not bind to one of the ADC Targets approved under the agreement. In addition, we have the right to prosecute and maintain all patents described in clauses (i)&#160;and (ii)&#160;above and are responsible for the costs of prosecuting and maintaining such patents. The ownership of any patent rights conceived during our exercise of our rights under the agreement in connection with non-ADC Targets will be determined under U.S. patent law.</div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 36pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">166<br></div></div></div>
<!--End Page 170-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 171-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 540pt;"><a name="nt10014672x1_drs_107-business_pg56"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="block-frill" style="width: 540pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: Arial, Helvetica, sans-serif; font-size: 9pt; font-weight: bold; margin-top: 6pt; text-align: center;">Confidential Treatment Requested by ADC Therapeutics SA Pursuant to 17 C.F.R. &#167; 200.83<br></div></div><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 36pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Unless earlier terminated, the agreement terminates on the date of expiration of the last to expire licensed patent right that covers a product being exploited under the license. The agreement (including the licenses granted thereunder) will terminate upon our material breach of any provision of the agreement that is not cured within an applicable cure period.</div><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 20.5pt; margin-left: 0pt; text-align: left;">Genmab Collaboration and License Agreement</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">In June 2013, we entered into a collaboration and license agreement with Genmab to collaborate on the development of Cami, which uses Genmab&#8217;s HuMax&#174;-TAC antibody that targets CD25.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Under the terms of the agreement, Genmab has granted us an exclusive, worldwide license or sublicense, as applicable, to certain patents covering, and know-how relating to, the HuMax&#174;-TAC antibody to make, develop, use, sell, offer for sale and import Cami for the treatment of conditions and diseases in humans.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">We were not required to pay any up-front licensing fees, and are not required to pay any ongoing royalty fees or milestone or other payments, to Genmab under the agreement. Rather, under the terms of the agreement, each party initially had a 50% interest in Cami and, subject to the oversight of the joint steering committee established thereunder, we were responsible for the execution of the preclinical work plan, together with technical support from Genmab. Upon the joint steering committee&#8217;s approval of the proposed IND application and clinical work plan for Cami in March 2015, Genmab exercised its option under the agreement to retain a 25% interest in Cami rather than pay us a specified fee necessary to retain its 50% interest. As a result of such exercise, we are the sole developing party, have the casting vote on the joint steering committee and have assumed all costs for the future development of Cami until the completion of a Phase 1/2 clinical trial based upon an agreed clinical plan framework. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">We may choose to discontinue our funding obligations under the agreement at any time upon prior written notice to Genmab. In such case, Genmab may choose to take over the development of Cami in return for increasing its interest in Cami from 25% to 75%, with us retaining a 25% interest and the licenses and sublicenses granted to us under the agreement terminating. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">On June 24, 2020, we and Genmab agreed to enter into a period of good faith negotiations regarding the key financial terms on which we would acquire Genmab&#8217;s share of Cami. If we and Genmab reach agreement, we and Genmab will have a further period of time to negotiate a license agreement for Genmab&#8217;s rights in Cami, which period may be extended by our and Genmab&#8217;s mutual written agreement. If we fail to agree on the key financial terms or if no license agreement has been entered into during the respective time periods to do so, a defined process to facilitate the divestment of Cami will be initiated. This process includes the opportunity for both parties to bid for the license rights alongside third parties. Both parties are required to use commercially reasonable efforts to complete and maximize the value obtained in this process. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Under the terms of the agreement, all patents directed to Cami that arose from the activities under the preclinical or clinical work plan (irrespective of the identity of the inventors) are our sole property, and we are responsible for the costs of prosecuting and maintaining such patents. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Unless earlier terminated (including, as described above), the agreement will expire upon the earlier of (i)&#160;following database lock for the Phase 1/2 clinical trial, upon the consummation of the divestment of Cami by licensing the rights thereto to a third party (or to either us or Genmab) and (ii)&#160;the expiration of the last valid patent claim included in any of the intellectual property claiming Cami (whether licensed by Genmab to us or by us to Genmab) that would preclude a third party from developing, making, using, selling and importing Cami in any country. Either party may terminate the agreement upon breach by the other party of any material provision of the agreement that is not cured within an applicable cure period. Either party may terminate the agreement upon written notice thereof upon the occurrence of certain insolvency events with respect to the other party.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Upon termination of the agreement, the licenses and sublicenses granted thereunder will terminate and we will be required to grant to Genmab a non-exclusive, worldwide, fully paid-up license to any claims in any new patents in any jurisdiction (irrespective of the identity of the inventors) arising from the activities under the preclinical work plan or clinical work plan to the extent that such claims are directed to Cami (or other antibody drug conjugates making use of Genmab&#8217;s CD25 antibody). Any proceeds from such patents will be shared between the parties as set forth in the agreement.</div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 36pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">167<br></div></div></div>
<!--End Page 171-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 172-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 540pt;"><a name="nt10014672x1_drs_107-business_pg57"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="block-frill" style="width: 540pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: Arial, Helvetica, sans-serif; font-size: 9pt; font-weight: bold; margin-top: 6pt; text-align: center;">Confidential Treatment Requested by ADC Therapeutics SA Pursuant to 17 C.F.R. &#167; 200.83<br></div></div><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 36pt;"><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">Synaffix Commercial License Agreement</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">In October&#160;2016, we entered into a commercial license agreement with Synaffix, under which we obtained a non-exclusive, royalty-bearing, sublicensable, worldwide license under certain patent rights and related know-how owned by Synaffix relating to site-specific conjugation technology to research, develop, manufacture, use, sell, import, distribute, commercialize and market antibody-drug conjugates for human therapeutic use that bind to three selected targets, including ADCT-601 and ADCT-701. In June 2020, we amended the agreement to grant us the option to extend this license to cover two additional targets.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">In consideration for the rights granted under the agreement, we paid an upfront fee and two additional six-figure fees upon our selection of licensed products binding the first three specific targets, and are required to pay a one-time fee upon the acceptance of a BLA (or foreign equivalent) for a licensed product and payments in the high eight figures upon the achievement of certain milestones (of which we have already paid a high six-figure amount). In addition, for the first and third such targets, we are required to pay tiered royalties in the low single-digit percentages on net sales of the applicable licensed products. For the second such target, we are required to pay royalties in the low to mid single-digit percentages on net sales of the applicable licensed products. In the event we select a fourth or fifth target, we will be required to pay a one-time license fee for each selected target, aggregate payments up to the mid eight figures upon the achievement of certain milestones and a royalty in the low single-digit percentages on net sales of each licensed product. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The agreement remains in effect on a country-by-country and licensed product-by-licensed product basis until the expiration of the last-to-expire valid claim in a patent licensed under the agreement covering such product in such country. Upon the expiration of the agreement for each licensed product in each country, the licenses granted to us for such product in such country will become fully paid-up and perpetual. We may terminate the agreement in its entirety or on a licensed product-by-licensed product basis at any time. Either party may terminate the agreement, subject to a specified notice and cure period, for a breach by the other party of a material provision of the agreement or upon an insolvency-related event experienced by the other party.</div><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 20.5pt; margin-left: 0pt; text-align: left;">Bergenbio License Agreement</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">In July 2014, we entered into a license agreement with Bergenbio AS (&#8220;Bergenbio&#8221;) under which we obtained an exclusive, royalty-bearing, sublicensable (subject to certain restrictions), worldwide license in certain patent rights and related know-how owned by Bergenbio relating to certain AXL-targeting antibodies used in ADCT-601 to conduct research, develop, make, use, sell, offer for sale, import and otherwise commercialize products for the treatment and/or prevention of diseases in humans (with an exception for certain types of products), as well as a similar non-exclusive license relating to companion diagnostics for such licensed products.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">In consideration for the rights granted under the agreement we paid an upfront fee, and we also paid a one-time low six-figure fee upon the filing of an IND application for ADCT-601 in 2018. Additionally, we are required to make payments in the low eight figures per licensed product upon the achievement of certain milestones, an additional one-time low eight-figure payment upon the achievement of a specified commercialization milestone, and tiered royalties in the mid-single digit percentages on net sales of licensed products.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The agreement remains in effect on a country-by-country and licensed product-by-licensed product basis until the latest of (i)&#160;the expiration of the last-to-expire valid claim in a patent covering such product licensed under the agreement in such country, (ii)&#160;the expiration of any other exclusivity protection of such licensed product in such country and (iii)&#160;the ten-year anniversary of the first commercial sale of such licensed product in such country. Upon the expiration of the agreement for each licensed product in each country, the licenses granted to us for such product in such country will become fully paid-up and irrevocable. We may terminate the agreement at any time effective immediately upon providing written notice to Bergenbio. Either party may terminate the agreement, subject to specified notice and cure periods, for a material breach by the other party of the agreement or upon an insolvency-related event experienced by the other party. Bergenbio may terminate the agreement, subject to a specified notice and cure period, if we fail to undertake any reasonable steps in the development and/or commercialization of at least one licensed product for a period of more than six consecutive months.</div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 36pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">168<br></div></div></div>
<!--End Page 172-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 173-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 540pt;"><a name="nt10014672x1_drs_107-business_pg58"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="block-frill" style="width: 540pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: Arial, Helvetica, sans-serif; font-size: 9pt; font-weight: bold; margin-top: 6pt; text-align: center;">Confidential Treatment Requested by ADC Therapeutics SA Pursuant to 17 C.F.R. &#167; 200.83<br></div></div><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 36pt;"><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">Intellectual Property</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Our success depends in part on our ability to obtain and maintain proprietary protection for our technology, programs and know-how related to our business, defend and enforce our intellectual property rights, in particular, our patent rights, preserve the confidentiality of our trade secrets, and operate without infringing valid and enforceable intellectual property rights of others. We seek to protect our proprietary position by, among other things, exclusively licensing and filing U.S. and foreign patent applications related to our technology, existing and planned programs and improvements that are important to the development of our business, where patent protection is available. We also rely on trade secrets, know-how, continuing technological innovation and confidential information to develop and maintain our proprietary position and protect aspects of our business that are not amenable to, or that we do not consider appropriate for, patent protection. We seek to protect our proprietary technology and processes, in part, by confidentiality agreements with our employees, consultants, scientific advisors, and contractors. We also seek to preserve the integrity and confidentiality of our data and trade secrets by maintaining physical security of our premises and physical and electronic security of our information technology systems. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Notwithstanding these efforts, we cannot be sure that patents will be granted with respect to any patent applications we have licensed or filed or may license or file in the future, and we cannot be sure that any patents we have licensed or patents that may be licensed or granted to us in the future will not be challenged, invalidated, or circumvented or that such patents will be commercially useful in protecting our technology. Moreover, trade secrets can be difficult to protect. While we have confidence in the measures we take to protect and preserve our trade secrets, such measures can be breached, and we may not have adequate remedies for any such breach. In addition, our trade secrets may otherwise become known or be independently discovered by competitors.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">In addition, we or our licensors may be subject to claims that former employees, collaborators, or other third parties have an interest in our owned or in-licensed patents or other intellectual property as an inventor or co-inventor. If we are unable to obtain an exclusive license to any such third party co-owners&#8217; interest in such patent applications, such co-owners may be able to license their rights to other third parties, including our competitors. In addition, we may need the cooperation of any such co-owners to enforce any patents that issue from such patent applications against third parties, and such cooperation may not be provided to us. For more information regarding the risks related to intellectual property, please see &#8220;Risk Factors&#8212;Risks Related to Intellectual Property.&#8221;</div><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">Patent Portfolio</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left; line-height: 11.7pt;">The term of individual utility patents depends upon the countries in which they are granted. In most countries, including the United States, the utility patent term is generally 20&#160;years from the earliest claimed filing date of a non-provisional utility patent application in the applicable country. United States provisional utility patent applications are not eligible to become issued patents until, among other things, non-provisional patent applications are filed within 12 months of the filing date of the applicable provisional patent applications and the failure to file such non-provisional patent applications within such timeline could cause us to lose the ability to obtain patent protection for the inventions disclosed in the associated provisional patent applications. In the United States, a patent&#8217;s term may, in certain cases, be lengthened by patent term adjustment, which compensates a patentee for administrative delays by the USPTO in examining and granting a patent, or may be shortened if a patent is terminally disclaimed over a commonly owned patent having an earlier expiration date. In certain circumstances, U.S. patents can also be eligible for patent term extension; for more information, see &#8220;&#8212;Government Regulation&#8212;Regulatory Approval in the United States&#8212;U.S. Patent Term Restoration and Marketing Exclusivity.&#8221; The expiration dates referred to below are without regard to potential patent term adjustment or extension that may be available to us.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left; line-height: 11.7pt;">In general, our licensed, owned or co-owned patents relate to our ADC products, the underlying antibodies, the PBD-based warhead, the linker used to connect such PBD warheads to the antibodies to form an ADC, modifications of the antibodies to enhance efficacy, and the methods to formulate, co-formulate, use and administer or co-administer such ADCs.</div><div class="h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 12pt; margin-left: 0pt; text-align: left;">&#8220;PBD Warhead,&#8221; &#8220;PBD Warhead with Linker&#8221; and Linker Patent Protection</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left; line-height: 11.7pt;">As of September 1, 2020, with respect to the PBD-based warhead and ADC technology we use to develop our product candidates, we have exclusively licensed from MedImmune 16 patent families directed to different </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 36pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">169<br></div></div></div>
<!--End Page 173-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 174-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 540pt;"><a name="nt10014672x1_drs_107-business_pg59"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="block-frill" style="width: 540pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: Arial, Helvetica, sans-serif; font-size: 9pt; font-weight: bold; margin-top: 6pt; text-align: center;">Confidential Treatment Requested by ADC Therapeutics SA Pursuant to 17 C.F.R. &#167; 200.83<br></div></div><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 36pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">aspects of the chemistry of the PBD molecules and methods of using the molecules in the treatment of proliferative diseases. These families include approximately 17 issued U.S. utility patents, 17 granted European patents, 12 granted Japanese patents, seven granted Chinese patents, and 63 granted utility patents in other jurisdictions, along with nine pending utility patent applications in non-U.S. jurisdictions. These issued utility patents, and any utility patents granted from such applications, are expected to expire between 2021 and 2033.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left; line-height: 11.7pt;">As of September 1, 2020, with respect to the &#8220;PBD warhead with linker&#8221; or linker technology we use to develop our product candidates, we have exclusively licensed from MedImmune 28 patent families directed to different aspects of the chemistry of the &#8220;PBD with linker&#8221; or linker molecules. Some of these patent families offer generic protection to the ADCs as well. These families include approximately 29 issued U.S. utility patents, 20 granted European patents, 24 granted Japanese patents, 10 granted Chinese patents and 146 granted utility patents in other jurisdictions, along with nine pending U.S. non-provisional utility patent applications and 143 pending utility patent applications in other jurisdictions. These issued utility patents, and any utility patents granted from such applications, are expected to expire between 2031 and 2038. The issued utility patents, and any utility patents granted from applications, more specifically directed to the &#8220;PBD warhead with linker&#8221; or linker present in Cami, Lonca and ADCT-602 are expected to expire between 2031 and 2033. Any utility patents granted from applications more specifically directed to the &#8220;PBD warhead with linker&#8221; or linker present in ADCT-601 are expected to expire in 2038.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">For more information on the license and collaboration agreement with MedImmune, see &#8220;&#8212;License and Collaboration Agreements&#8212;MedImmune License and Collaboration Agreement.&#8221;</div><div class="h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 17.5pt; margin-left: 0pt; text-align: left;">Antibody and Product-Specific Patent Protection</div><div class="h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 12.5pt; margin-left: 20pt; text-align: left;">Lonca</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 7pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The antibody for Lonca is in the public domain.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Patents more specifically directed to the Lonca ADC are co-owned by us and MedImmune, with us having the exclusive right to exploit the relevant patents during the term of our license and collaboration agreement with MedImmune. As of September 1, 2020, there are six such patent families directed to the ADC product, methods of using the ADC as a single agent or in combination with other named molecules in the treatment of proliferative diseases, and dosing regimens. The family having issued claims directed to the Lonca composition includes one issued U.S. utility patent, one granted utility patent in each of Europe, Japan and China and two pending U.S. non-provisional utility patent applications, along with six granted utility patents and two pending utility patent applications in other jurisdictions. The other families include two pending U.S. non-provisional utility patent applications, two pending European utility patent applications, two pending utility patent applications in Japan, one pending utility patent application in China, and 18 pending utility patent applications in other jurisdictions (including three Patent Cooperation Treaty (&#8220;PCT&#8221;) applications). These issued utility patents, and any utility patents granted from such applications, are expected to expire between 2033 and 2040.</div><div class="h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 18pt; margin-left: 20pt; text-align: left;">Cami</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">As of September 1, 2020, with respect to the antibody for Cami, we exclusively license an antibody utility patent family from Genmab that includes approximately five issued U.S. utility patents, one pending U.S. non-provisional utility patent application and 14 granted patents in foreign jurisdictions. These issued utility patents, and any utility patents granted from such applications, are expected to expire between 2023 and 2024. For more information on the collaboration and license agreement with Genmab, see &#8220;&#8212;License and Collaboration Agreements&#8212;Genmab Collaboration and License Agreement.&#8221;</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The patents more specifically directed to the Cami ADC are co-owned by us and MedImmune, with us having the exclusive right to exploit the relevant patents during the term of our license and collaboration agreement with MedImmune. As of September 1, 2020, there are 12 such patent families directed to the ADC product, methods of using the ADC as a single agent or in combination with other named molecules in the treatment of proliferative diseases, and dosing regimens. The family having issued claims directed to the Cami composition includes one issued U.S. utility patent, one granted utility patent in each of Europe, Japan and China, and six granted utility patents in other jurisdictions, along with two pending U.S.&#160;non-provisional utility patent applications and two pending utility patent applications in other jurisdictions. The other families include seven pending U.S. non-provisional utility patent applications, five pending European utility patent applications, </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 36pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">170<br></div></div></div>
<!--End Page 174-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 175-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 540pt;"><a name="nt10014672x1_drs_107-business_pg60"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="block-frill" style="width: 540pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: Arial, Helvetica, sans-serif; font-size: 9pt; font-weight: bold; margin-top: 6pt; text-align: center;">Confidential Treatment Requested by ADC Therapeutics SA Pursuant to 17 C.F.R. &#167; 200.83<br></div></div><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 36pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">three pending utility patent applications in Japan, two pending utility patent applications in China, and 29 pending utility patent applications in other jurisdictions (including four PCT applications). These issued utility patents, and any utility patents granted from such applications, are expected to expire between 2033 and&#160;2040. </div><div class="h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 18.5pt; margin-left: 20pt; text-align: left;">ADCT-602</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">As of September 1, 2020, we and MedImmune co-own three patent families relating specifically to the ADCT-602 ADC, along with methods of using the ADC as a single agent or in combination with other named molecules in the treatment of proliferative diseases; we have the exclusive right to exploit the relevant patents during the term of our license and collaboration agreement with MedImmune. The family having issued claims directed to the ADCT-602 composition includes one issued U.S. utility patent, one granted utility patent in each of Europe, Japan and China, and six granted utility patents in other jurisdictions, along with two pending U.S.&#160;non-provisional utility patent applications and two pending utility patent applications in other jurisdictions. The other families include two pending U.S. non-provisional utility patent applications, two pending utility patent applications in each of Europe, Japan, and China, and 16 pending utility patent applications in other jurisdictions. These issued utility patents, and any utility patents granted from such applications, are expected to expire between 2033 and 2038. </div><div class="h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 18.5pt; margin-left: 20pt; text-align: left;">ADCT-601</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">As of September 1, 2020, we and MedImmune co-own two patent families relating specifically to the ADCT-601 ADC, along with methods of using the ADC as a single agent or in combination with other named molecules in the treatment of proliferative diseases; we have the exclusive right to exploit the relevant patents during the term of our license and collaboration agreement with MedImmune. The family directed to the ADCT-601 ADC contains one pending U.S. non-provisional utility patent application, one pending utility patent application in each of Europe and China, one granted utility patent application in Japan, and two granted utility patents and ten pending utility patent applications in other jurisdictions, and the family directed to methods of use contains one issued U.S. utility patent, one pending U.S. non-provisional utility patent application, one pending utility patent application in each of Europe, Japan and China, and eight pending utility patent applications in other jurisdictions. These issued utility patents, and any utility patents granted from such applications, are expected to expire in 2038. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Additionally, we license several patent families relating to ADCT-601. As of September 1, 2020, this includes one patent family exclusively licensed from Bergenbio relating to the ADCT-601 antibody moiety as a product. This family includes one issued U.S. utility patent, one granted European utility patent application, and one pending utility patent application in each of the United States, Japan and China, along with four pending utility patent applications in other jurisdictions. The issued utility patent, and any utility patents granted from such applications, are expected to expire in 2035. We also non-exclusively license patent families from Synaffix relating to processes for producing ADCs with the ADCT-601 linker technology and linker synthesis intermediates. These families include seven issued U.S. utility patents, five granted European utility patents, one granted Japanese utility patent, two granted Chinese utility patents and two granted Indian utility patents, along with four pending U.S. non-provisional utility patent applications, four pending European utility patent applications, four pending Japanese utility patent applications and four pending Chinese utility patent applications. These issued utility patents, and any utility patents granted from such applications, are expected to expire between 2031 and 2037. Additionally, we exclusively license one patent family from MedImmune relating to the ADCT-601 ADC that contains one pending utility patent application in each of the United States, Europe, Japan, China and India. Any utility patents granted from these applications are expected to expire in 2038. For more information on the license agreements with Synaffix and Bergenbio, see &#8220;&#8212;License and Collaboration Agreements&#8212;Synaffix Commercial License Agreement&#8221; and &#8220;&#8212;License and Collaboration Agreements&#8212;Bergenbio License Agreement.&#8221;</div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 19pt; margin-left: 0pt; text-align: left;">Competition</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The biotechnology industry, and the oncology subsector, are characterized by rapid evolution of technologies, fierce competition and strong defense of intellectual property. While we believe that our technology, intellectual property, know-how, scientific expertise and leadership team provide us with certain competitive advantages, we face potential competition from many sources, including major pharmaceutical and </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 36pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">171<br></div></div></div>
<!--End Page 175-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 176-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 540pt;"><a name="nt10014672x1_drs_107-business_pg61"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="block-frill" style="width: 540pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: Arial, Helvetica, sans-serif; font-size: 9pt; font-weight: bold; margin-top: 6pt; text-align: center;">Confidential Treatment Requested by ADC Therapeutics SA Pursuant to 17 C.F.R. &#167; 200.83<br></div></div><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 36pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">biotechnology companies, academic institutions and public and private research organizations. Many competitors and potential competitors have substantially greater scientific, research and product development capabilities, as well as greater financial, marketing and human resources than we do.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Many companies are active in the oncology market and are developing or marketing products for the specific therapeutic markets that we target, including both antibody and non-antibody-based therapies. Similarly, we also face competition from other companies and institutions that continue to invest in innovation in the ADC field including new payload classes, new conjugation approaches and new targeting moieties. Specifically, we are aware of multiple companies with ADC technologies that may be competitive to our product candidates, including, but not limited to, AbbVie, Inc., Astellas Pharma Inc., AstraZeneca plc, BioAtla, LLC, Bristol-Myers Squibb Company, CytomX Therapeutics, Daiichi Sankyo Company, Eli Lilly and Company, Genentech, Inc., Genmab, GlaxoSmithKline plc, ImmunoGen, Inc., Immunomedics, Inc., Mersana Therapeutics Inc., Millennium Pharmaceuticals, Inc., MorphoSys AG, Novartis International AG, Pfizer Inc., F. Hoffmann-La Roche AG, Sanofi S.A., Seattle Genetics, Inc., Sutro Biopharma, Inc., Takeda Pharmaceutical Company Ltd and Wyeth Pharmaceuticals, Inc. Currently, there are ten approved ADCs: (i) brentuximab vedotin (Adcetris&#174;), marketed by Seattle Genetics, Inc. and Takeda Pharmaceutical Company Ltd, (ii) ado-trastuzumab emtansine (Kadcyla&#174;), marketed by Genentech, Inc., (iii) inotuzumab ozogamicin (Besponsa&#174;), marketed by Pfizer Inc., (iv)&#160;gemtuzumab ozogamicin (Mylotarg&#174;), marketed by Pfizer Inc., (v) moxetumomab pasudotox (Lumoxiti&#174;), marketed by AstraZeneca plc, (vi) polatuzumab vedotin (Polivy&#174;), marketed by Genentech, Inc., (vii) enfortumab vedotin (Padcev&#174;), marketed by Astellas Pharma Inc., (viii) trastuzumab deruxtecan (Enhuertu&#174;), marketed by Daiichi Sankyo Company, (ix) sacituzumab govitecan (Trodelvy&#174;), marketed by Immunomedics, Inc., and (x)&#160;belantamab mafodotin (Blenrep&#174;), marketed by GlaxoSmithKline plc. In addition, there are hundreds of ADCs in development, the vast majority of which were being developed for the treatment of cancer. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">In the relapsed or refractory DLBCL setting, for which we are developing Lonca, current third-line treatment options include CAR-T, allogeneic stem cell transplant, Polivy&#174; in combination with bendamustine and a rituximab product, XPOVIO&#174;, Monjuvi&#174; in combination with lenalidomide and chemotherapy using small molecules. In addition, we expect potential new competitors, including bispecific antibodies, to enter the market as potential treatment options for such patients in the future. In the relapsed or refractory HL setting, for which we are developing Cami, current third-line treatment options include chemotherapy, immunotherapy and Adcetris&#174;. In addition, we expect changes to the treatment paradigm, such as the movement of Adcetris&#174; to earlier lines of therapy and the potential expanded use of checkpoint inhibitors, and potential new entrants such as bispecific antibodies. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Any product candidates that we successfully develop and commercialize may compete directly with approved therapies and any new therapies that may be approved in the future. Competition will be based on their safety and effectiveness, the timing and scope of marketing approvals, the availability and cost of supply, marketing and sales capabilities, reimbursement coverage, price levels and discounts offered, patent position and other factors. Our competitors may succeed in developing competing products before we do, obtaining marketing approval for products and gaining acceptance for such products in the same markets that we are targeting.</div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 17.5pt; margin-left: 0pt; text-align: left;">Government Regulation</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Government authorities in the United States at the federal, state and local level and in other countries and jurisdictions, including the European Union, extensively regulate, among other things, the research, development, testing, manufacture, quality control, approval, labeling, packaging, storage, record-keeping, promotion, advertising, distribution, post-approval monitoring and reporting, marketing and export and import of drug and biological products, such as our investigational medicines and any future investigational medicines. Generally, before a new drug or biologic can be marketed, considerable data demonstrating its quality, safety and efficacy must be obtained, organized into a format specific for each regulatory authority, submitted for review and approved by the regulatory authority.</div><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 17.5pt; margin-left: 0pt; text-align: left;">Regulatory Approval in the United States</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">In the United States, pharmaceutical products are subject to extensive regulation by the FDA. The FDCA, and other federal and state statutes and regulations, govern, among other things, the research, development, testing, manufacture, storage, recordkeeping, approval, labeling, promotion and marketing, distribution, post-approval monitoring and reporting, sampling, and import and export of pharmaceutical products. Biological </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 36pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">172<br></div></div></div>
<!--End Page 176-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 177-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 540pt;"><a name="nt10014672x1_drs_107-business_pg62"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="block-frill" style="width: 540pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: Arial, Helvetica, sans-serif; font-size: 9pt; font-weight: bold; margin-top: 6pt; text-align: center;">Confidential Treatment Requested by ADC Therapeutics SA Pursuant to 17 C.F.R. &#167; 200.83<br></div></div><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 36pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">products used for the prevention, treatment or cure of a disease or condition of a human being are subject to regulation under the FDCA, except the section of the FDCA that governs the approval of new drug applications (&#8220;NDAs&#8221;). Biological products, such as our ADC product candidates, are approved for marketing under provisions of the Public Health Service Act (the &#8220;PHSA&#8221;), via a BLA. However, the application process and requirements for approval of BLAs are very similar to those for NDAs, and biologics are associated with similar approval risks and costs as drugs. Failure to comply with applicable U.S. requirements may subject a company to a variety of administrative or judicial sanctions, such as clinical hold, FDA refusal to approve pending NDAs or BLAs, warning or untitled letters, product recalls, product seizures, total or partial suspension of production or distribution, injunctions, fines, civil penalties, and criminal prosecution.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Our investigational medicines and any future investigational medicines must be approved by the FDA pursuant to a BLA before they may be legally marketed in the United States. The process generally involves the following:</div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">completion of extensive preclinical laboratory and animal studies in accordance with applicable regulations, including studies conducted in accordance with GLP requirements;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">submission to the FDA of an IND, which must become effective before human clinical trials may begin;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">approval by an IRB or independent ethics committee at each clinical trial site before each clinical trial may be commenced;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">performance of adequate and well-controlled human clinical trials in accordance with applicable IND regulations, GCP requirements and other clinical trial-related regulations to establish the safety and efficacy of the investigational product for each proposed indication;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">submission to the FDA of a BLA;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">a determination by the FDA within 60 days of its receipt of a BLA to accept the filing for review;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">satisfactory completion of one or more FDA pre-approval inspections of the manufacturing facility or facilities where the biologic, or components thereof, will be produced to assess compliance with cGMP requirements to assure that the facilities, methods and controls are adequate to preserve the biologic&#8217;s identity, strength, quality and purity;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">satisfactory completion of any potential FDA audits of the clinical trial sites that generated the data in support of the BLA to assure compliance with GCPs and integrity of the clinical data;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">payment of any user fees for FDA review of the BLA;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">FDA review and approval of the BLA, including consideration of the views of any FDA advisory committee; and</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">compliance with any post-approval requirements, including REMS, where applicable, and post-approval studies required by the FDA as a condition of approval.</div></td></tr></table><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The preclinical and clinical testing and approval process requires substantial time, effort and financial resources, and we cannot be certain that any approvals for our product candidates will be granted on a timely basis, or at all.</div><div class="h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 14pt; margin-left: 0pt; text-align: left;">Preclinical Studies</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Before testing any biological product candidates in humans, the product candidate must undergo rigorous preclinical testing. Preclinical studies include laboratory evaluation of product chemistry and formulation, as well as <font style="font-style: italic;">in vitro </font>and animal studies to assess the potential for adverse events and in some cases to establish a rationale for therapeutic use. The conduct of preclinical studies is subject to federal regulations and requirements, including GLP regulations for safety/toxicology studies. An IND sponsor must submit the results of the preclinical tests, together with manufacturing information, analytical data, any available clinical data or literature and plans for clinical studies, among other things, to the FDA as part of an IND. An IND is a request for authorization from the FDA to administer an investigational product to humans and must become effective before human clinical trials may begin. Some long-term preclinical testing may continue after the IND is submitted. An IND automatically becomes effective 30&#160;days after receipt by the FDA, unless before that time the FDA raises </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 36pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">173<br></div></div></div>
<!--End Page 177-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 178-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 540pt;"><a name="nt10014672x1_drs_107-business_pg63"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="block-frill" style="width: 540pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: Arial, Helvetica, sans-serif; font-size: 9pt; font-weight: bold; margin-top: 6pt; text-align: center;">Confidential Treatment Requested by ADC Therapeutics SA Pursuant to 17 C.F.R. &#167; 200.83<br></div></div><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 36pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">concerns or questions related to one or more proposed clinical trials and places the trial on clinical hold. In such a case, the IND sponsor and the FDA must resolve any outstanding concerns before the clinical trial can begin. As a result, submission of an IND may not result in the FDA allowing clinical trials to commence.</div><div class="h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 20.5pt; margin-left: 0pt; text-align: left;">Clinical Trials</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The clinical stage of development involves the administration of the investigational product to healthy volunteers or patients under the supervision of qualified investigators, generally physicians not employed by or under the trial sponsor&#8217;s control. Clinical trials must be conducted: (i)&#160;in compliance with federal regulations; (ii)&#160;in compliance with GCPs, an international standard meant to protect the rights and health of patients and to define the roles of clinical trial sponsors, administrators, and monitors; as well as (iii)&#160;under protocols detailing, among other things, the objectives of the trial, the parameters to be used in monitoring safety, and the effectiveness criteria to be evaluated in the trial. Each protocol involving testing on U.S. patients and subsequent protocol amendments must be submitted to the FDA as part of the IND. Furthermore, each clinical trial must be reviewed and approved by an IRB for each institution at which the clinical trial will be conducted to ensure that the risks to individuals participating in the clinical trials are minimized and are reasonable in relation to anticipated benefits. The IRB also approves the informed consent form that must be provided to each clinical trial subject or his or her legal representative and must monitor the clinical trial until completed.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">There also are requirements governing the reporting of ongoing clinical trials and completed clinical trial results to public registries. Information about certain clinical trials, including clinical trial results, must be submitted within specific timeframes for publication on the www.clinicaltrials.gov website. Information related to the product, patient population, phase of investigation, clinical trial sites and investigators, and other aspects of the clinical trial is then made public as part of the registration. Sponsors are also obligated to discuss the results of their clinical trials after completion. Disclosure of the results of these clinical trials can be delayed in certain circumstances for up to two years after the date of completion of the trial. Competitors may use this publicly available information to gain knowledge regarding the progress of development programs.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">A sponsor who wishes to conduct a clinical trial outside of the United States may, but need not, obtain FDA authorization to conduct the clinical trial under an IND. If a foreign clinical trial is not conducted under an IND, the sponsor may submit data from the clinical trial to the FDA in support of a BLA. The FDA will accept a well-designed and well-conducted foreign clinical trial not conducted under an IND if the clinical trial was conducted in accordance with GCP requirements, and the FDA is able to validate the data through an onsite inspection if deemed necessary.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8.5pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Clinical trials are generally conducted in three sequential phases, known as Phase 1, Phase 2 and Phase 3:</div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">Phase 1 clinical trials generally involve a small number of healthy volunteers or disease-affected patients who are initially exposed to a single dose and then multiple doses of the product candidate. The primary purpose of these clinical trials is to assess the metabolism, pharmacokinetics, pharmacologic action, side effect tolerability, safety of the product candidate, and, if possible, early evidence of effectiveness. Phase 1 clinical trials may be designated as Phase 1a, which may involve dose escalation to determine the maximum tolerated dose, or Phase 1b, which may involve dose expansion at one or more dose levels to determine the recommended dose level for Phase 2 clinical trials.</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">Phase 2 clinical trials generally involve studies in disease-affected patients to evaluate proof of concept and/or determine the dosing regimen(s) for subsequent investigations. At the same time, safety and further pharmacokinetic and pharmacodynamic information is collected, possible adverse effects and safety risks are identified, and a preliminary evaluation of efficacy is conducted.</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">Phase 3 clinical trials generally involve a large number of patients at multiple sites and are designed to provide the data necessary to demonstrate the effectiveness of the product for its intended use, its safety in use and to establish the overall benefit/risk relationship of the product, and provide an adequate basis for product labeling. In most cases, the FDA requires two adequate and well-controlled Phase 3 clinical trials to demonstrate the efficacy of the biologic.</div></td></tr></table></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 36pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">174<br></div></div></div>
<!--End Page 178-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 179-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 540pt;"><a name="nt10014672x1_drs_107-business_pg64"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="block-frill" style="width: 540pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: Arial, Helvetica, sans-serif; font-size: 9pt; font-weight: bold; margin-top: 6pt; text-align: center;">Confidential Treatment Requested by ADC Therapeutics SA Pursuant to 17 C.F.R. &#167; 200.83<br></div></div><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 36pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">These Phases may overlap or be combined. For example, a Phase 1/2 clinical trial may contain both a dose-escalation stage and a dose-expansion stage, the latter of which may confirm tolerability at the recommended dose for expansion in future clinical trials (as in traditional Phase 1 clinical trials) and provide insight into the anti-tumor effects of the investigational therapy in selected subpopulation(s).</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Typically, during the development of oncology therapies, all subjects enrolled in Phase 1 clinical trials are disease-affected patients and, as a result, considerably more information on clinical activity may be collected during such trials than during Phase 1 clinical trials for non-oncology therapies. A single Phase 3 or Phase 2 trial may be sufficient in rare instances, including (1) where the trial is a large, multicenter trial demonstrating internal consistency and a statistically very persuasive finding of a clinically meaningful effect on mortality, irreversible morbidity or prevention of a disease with a potentially serious outcome and confirmation of the result in a second trial would be practically or ethically impossible or (2) when in conjunction with other confirmatory evidence. Approval on the basis of a single trial may be subject to the requirement of additional post-approval studies. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Phase 1, Phase 2, Phase 3 and other types of clinical trials may not be completed successfully within any specified period, if at all. The FDA, the IRB, or the sponsor may suspend or terminate a clinical trial at any time on various grounds, including non-compliance with regulatory requirements or a finding that the patients are being exposed to an unacceptable health risk. Similarly, an IRB can suspend or terminate approval of a clinical trial at its institution if the clinical trial is not being conducted in accordance with the IRB&#8217;s requirements or if the drug or biologic has been associated with unexpected serious harm to patients. Additionally, some clinical trials are overseen by an independent group of qualified experts organized by the clinical trial sponsor, known as a data safety monitoring board or committee. This group provides authorization for whether a trial may move forward at designated checkpoints based on access to certain data from the trial.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Concurrent with clinical trials, companies usually complete additional animal studies and also must develop additional information about the chemistry and physical characteristics of the drug or biologic as well as finalize a process for manufacturing the product in commercial quantities in accordance with cGMP requirements. The manufacturing process must be capable of consistently producing quality batches of the product and, among other things, companies must develop methods for testing the identity, strength, quality, potency, and purity of the final product. Additionally, appropriate packaging must be selected and tested and stability studies must be conducted to demonstrate that the investigational medicines do not undergo unacceptable deterioration over their shelf life.</div><div class="h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 14pt; margin-left: 0pt; text-align: left;">FDA Review Process</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Following completion of the clinical trials, the results of preclinical studies and clinical trials are submitted to the FDA as part of a BLA, along with proposed labeling, chemistry and manufacturing information to ensure product quality and other relevant data. To support marketing approval, the data submitted must be sufficient in quality and quantity to establish the safety and efficacy of the investigational product to the satisfaction of the FDA. FDA approval of a BLA must be obtained before a biologic or drug may be marketed in the United States.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The cost of preparing and submitting a BLA is substantial. Under the Prescription Drug User Fee Act, as amended (the &#8220;PDUFA&#8221;), each BLA must be accompanied by a substantial user fee. The FDA adjusts the PDUFA user fees on an annual basis. Fee waivers or reductions are available in certain circumstances, including a waiver of the application fee for the first application filed by a small business. Additionally, no user fees are assessed on BLAs for products designated as orphan drugs, unless the product also includes a non-orphan indication. The applicant under an approved BLA is also subject to an annual program fee.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The FDA reviews all submitted BLAs before it accepts them for filing and may request additional information. The FDA must make a decision on accepting a BLA for filing within 60 days of receipt, and such decision could include a refusal to file by the FDA. Once the submission is accepted for filing, the FDA begins an in-depth review of the BLA. Under the goals and policies agreed to by the FDA under PDUFA, the FDA has 10 months, from the filing date, in which to complete its initial review of an original BLA for a new molecular entity and respond to the applicant, and six months from the filing date of an original BLA designated for priority review. The review process for both standard and priority review may be extended by the FDA for three additional months to consider certain late-submitted information, or information intended to clarify information already provided in the submission. The FDA does not always meet its PDUFA goal dates for standard and priority BLAs, and the review process can be extended by FDA requests for additional information or clarification.</div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 36pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">175<br></div></div></div>
<!--End Page 179-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 180-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 540pt;"><a name="nt10014672x1_drs_107-business_pg65"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="block-frill" style="width: 540pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: Arial, Helvetica, sans-serif; font-size: 9pt; font-weight: bold; margin-top: 6pt; text-align: center;">Confidential Treatment Requested by ADC Therapeutics SA Pursuant to 17 C.F.R. &#167; 200.83<br></div></div><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 36pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Before approving a BLA, the FDA will conduct a pre-approval inspection of the manufacturing facilities for the new product to determine whether they comply with cGMP requirements. The FDA will not approve the product unless it determines that the manufacturing processes and facilities are in compliance with cGMP requirements and adequate to assure consistent production of the product within required specifications.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The FDA also may audit data from clinical trials to ensure compliance with GCP requirements and the integrity of the data supporting safety and efficacy. Additionally, the FDA may refer applications for novel products or products that present difficult questions of safety or efficacy to an advisory committee, typically a panel that includes clinicians and other experts, for review, evaluation and a recommendation as to whether the application should be approved and under what conditions, if any. The FDA is not bound by recommendations of an advisory committee, but it generally follows such recommendations when making decisions on approval. The FDA likely will reanalyze the clinical trial data, which could result in extensive discussions between the FDA and the applicant during the review process.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">After the FDA evaluates a BLA, it will issue either an approval letter or a Complete Response Letter. An approval letter authorizes commercial marketing of the biologic with specific prescribing information for specific indications. A Complete Response Letter indicates that the review cycle of the application is complete, and the application will not be approved in its present form. A Complete Response Letter generally outlines the deficiencies in the BLA and may require additional clinical data, additional pivotal clinical trial(s), and/or other significant and time-consuming requirements related to clinical trials, preclinical studies or manufacturing in order for FDA to reconsider the application. If a Complete Response Letter is issued, the applicant may either resubmit the BLA, addressing all of the deficiencies identified in the letter, or withdraw the application or request an opportunity for a hearing. The FDA has committed to reviewing such resubmissions in two or six months, depending on the type of information included. Even if such data and information are submitted, the FDA may decide that the BLA does not satisfy the criteria for approval.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">As a condition of BLA approval, the FDA may require a risk evaluation and mitigation strategy (&#8220;REMS&#8221;) to help ensure that the benefits of the biologic outweigh the potential risks to patients. A REMS can include medication guides, communication plans for healthcare professionals, and elements to assure a product&#8217;s safe use (&#8220;ETASU&#8221;). An ETASU can include, but is not limited to, special training or certification for prescribing or dispensing the product, dispensing the product only under certain circumstances, special monitoring, and the use of patient-specific registries. The requirement for a REMS can materially affect the potential market and profitability of the product. Moreover, the FDA may require substantial post-approval testing and surveillance to monitor the product&#8217;s safety or efficacy.</div><div class="h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 12pt; margin-left: 0pt; text-align: left;">Orphan Drug Designation</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Under the Orphan Drug Act, the FDA may grant orphan designation to a drug or biological product intended to treat a rare disease or condition, which is generally a disease or condition that affects fewer than 200,000 individuals in the United States, or more than 200,000 individuals in the United States but for which there is no reasonable expectation that the cost of developing and making the product for this type of disease or condition will be recovered from sales of the product in the United States.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Orphan drug designation must be requested before submitting a BLA. After the FDA grants orphan drug designation, the identity of the therapeutic agent and its potential orphan use are disclosed publicly by the FDA. Orphan drug designation on its own does not convey any advantage in or shorten the duration of the regulatory review and approval process.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">If a product that has orphan designation subsequently receives the first FDA approval for the disease or condition for which it has such designation, the product is entitled to orphan drug exclusivity, which means that the FDA may not approve any other applications to market the same product for the same indication for seven years from the date of such approval, except in limited circumstances, such as a showing of clinical superiority to the product with orphan exclusivity by means of greater effectiveness, greater safety, or providing a major contribution to patient care, or in instances of drug supply issues. Competitors, however, may receive approval of either a different product for the same indication or the same product for a different indication. In the latter case, because healthcare professionals are free to prescribe products for off-label uses, the competitor&#8217;s product could be used for the orphan indication despite another product&#8217;s orphan exclusivity.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">FDA&#8217;s determination of whether two ADCs are the same product for purposes of orphan drug exclusivity is based on a determination of sameness of the monoclonal antibody element and the functional element of the </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 36pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">176<br></div></div></div>
<!--End Page 180-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 181-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 540pt;"><a name="nt10014672x1_drs_107-business_pg66"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="block-frill" style="width: 540pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: Arial, Helvetica, sans-serif; font-size: 9pt; font-weight: bold; margin-top: 6pt; text-align: center;">Confidential Treatment Requested by ADC Therapeutics SA Pursuant to 17 C.F.R. &#167; 200.83<br></div></div><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 36pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">conjugated molecule. Two ADCs are deemed to be the same product if the complementarity determining region sequences of the antibody and the functional element of the conjugated molecule are the same. A difference in either of those two elements can result in a determination that the molecules are different.</div><div class="h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 20pt; margin-left: 0pt; text-align: left;">Expedited Development and Review Programs</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The FDA is authorized to designate certain products for expedited review if they are intended to address an unmet medical need in the treatment of a serious or life-threatening disease or condition.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Fast track designation may be granted for products that are intended to treat a serious or life-threatening disease or condition for which there is no effective treatment and preclinical or clinical data demonstrate the potential to address unmet medical needs for the condition. Fast track designation applies to both the product and the specific indication for which it is being studied. The sponsor of a new biologic candidate can request the FDA to designate the candidate for a specific indication for fast track status concurrent with, or after, the submission of the IND for the candidate. The FDA must determine if the biologic candidate qualifies for fast track designation within 60 days of receipt of the sponsor&#8217;s request. For fast track products, sponsors may have greater interactions with the FDA and the FDA may initiate review of sections of a fast track product&#8217;s BLA before the application is complete. This &#8220;rolling review&#8221; is available if the FDA determines, after preliminary evaluation of clinical data submitted by the sponsor, that a fast track product may be effective. The sponsor must also provide, and the FDA must approve, a schedule for the submission of the remaining information and the sponsor must pay applicable user fees. Any product submitted to the FDA for marketing, including under a fast track program, may be eligible for other types of FDA programs intended to expedite development and review, such as priority review and accelerated approval.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Breakthrough therapy designation may be granted for products that are intended, alone or in combination with one or more other products, to treat a serious or life-threatening condition and preliminary clinical evidence indicates that the product may demonstrate substantial improvement over currently approved therapies on one or more clinically significant endpoints. Under the breakthrough therapy program, the sponsor of a new biologic candidate may request that the FDA designate the candidate for a specific indication as a breakthrough therapy concurrent with, or after, the submission of the IND for the biologic candidate. The FDA must determine if the biological product qualifies for breakthrough therapy designation within 60 days of receipt of the sponsor&#8217;s request. The FDA may take certain actions with respect to breakthrough therapies, including holding meetings with the sponsor throughout the development process, providing timely advice to the product sponsor regarding development and approval, involving more senior staff in the review process, assigning a cross-disciplinary project lead for the review team and taking other steps to design the clinical studies in an efficient manner.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Priority review may be granted for products that are intended to treat a serious or life-threatening condition and, if approved, would provide a significant improvement in safety and effectiveness compared to available therapies. The FDA will attempt to direct additional resources to the evaluation of an application designated for priority review in an effort to facilitate the review.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Accelerated approval may be granted for products that are intended to treat a serious or life-threatening condition and that generally provide a meaningful therapeutic advantage to patients over existing treatments. A product eligible for accelerated approval may be approved on the basis of either a surrogate endpoint that is reasonably likely to predict clinical benefit, or on a clinical endpoint that can be measured earlier than irreversible morbidity or mortality, that is reasonably likely to predict an effect on irreversible morbidity or mortality or other clinical benefit, taking into account the severity, rarity or prevalence of the condition and the availability or lack of alternative treatments. In clinical trials, a surrogate endpoint is a measurement of laboratory or clinical signs of a disease or condition that substitutes for a direct measurement of how a patient feels, functions, or survives. The accelerated approval pathway is most often used in settings in which the course of a disease is long and an extended period of time is required to measure the intended clinical benefit of a product, even if the effect on the surrogate or intermediate clinical endpoint occurs rapidly. Thus, accelerated approval has been used extensively in the development and approval of products for treatment of a variety of cancers in which the goal of therapy is generally to improve survival or decrease morbidity and the duration of the typical disease course requires lengthy and sometimes large studies to demonstrate a clinical or survival benefit. The accelerated approval pathway is contingent on a sponsor&#8217;s agreement to conduct additional post-approval confirmatory studies to verify and describe the product&#8217;s clinical benefit. These confirmatory trials must be completed with due diligence and, in some cases, the FDA may require that the trial be designed, </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 36pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">177<br></div></div></div>
<!--End Page 181-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 182-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 540pt;"><a name="nt10014672x1_drs_107-business_pg67"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="block-frill" style="width: 540pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: Arial, Helvetica, sans-serif; font-size: 9pt; font-weight: bold; margin-top: 6pt; text-align: center;">Confidential Treatment Requested by ADC Therapeutics SA Pursuant to 17 C.F.R. &#167; 200.83<br></div></div><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 36pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">initiated, and/or fully enrolled prior to approval. Failure to conduct required post-approval studies, or to confirm a clinical benefit during post-marketing studies, would allow the FDA to withdraw the product from the market on an expedited basis. All promotional materials for product candidates approved under accelerated regulations are subject to prior review by the FDA.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Even if a product qualifies for one or more of these programs, the FDA may later decide that the product no longer meets the conditions for qualification or the time period for FDA review or approval may not be shortened. Furthermore, fast track designation, breakthrough therapy designation, priority review and accelerated approval do not change the standards for approval, but may expedite the development or approval process.</div><div class="h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 16.5pt; margin-left: 0pt; text-align: left;">Additional Controls for Biologics</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">To help reduce the increased risk of the introduction of adventitious agents, the PHSA emphasizes the importance of manufacturing controls for products whose attributes cannot be precisely defined. The PHSA also provides authority to the FDA to immediately suspend licenses in situations where there exists a danger to public health, to prepare or procure products in the event of shortages and critical public health needs, and to authorize the creation and enforcement of regulations to prevent the introduction or spread of communicable diseases in the United States and between states.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">After a BLA is approved, the product may also be subject to official lot release as a condition of approval. As part of the manufacturing process, the manufacturer is required to perform certain tests on each lot of the product before it is released for distribution. If the product is subject to official release by the FDA, the manufacturer submits samples of each lot of product to the FDA together with a release protocol showing a summary of the history of manufacture of the lot and the results of all of the manufacturer&#8217;s tests performed on the lot. The FDA may also perform certain confirmatory tests on lots of some products, such as viral vaccines, before releasing the lots for distribution by the manufacturer. In addition, the FDA conducts laboratory research related to the regulatory standards on the safety, purity, potency, and effectiveness of biological products. As with drugs, after approval of biologics, manufacturers must address any safety issues that arise, are subject to recalls or a halt in manufacturing, and are subject to periodic inspection after approval.</div><div class="h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 16.5pt; margin-left: 0pt; text-align: left;">Pediatric Information</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Under the Pediatric Research Equity Act, or PREA, BLAs or supplements to BLAs must contain data to assess the safety and effectiveness of the biological product for the claimed indications in all relevant pediatric subpopulations and to support dosing and administration for each pediatric subpopulation for which the biological product is safe and effective. The FDA may grant full or partial waivers, or deferrals, for submission of data. Unless otherwise required by regulation, PREA generally does not apply to any biological product for an indication for which orphan designation has been granted. However, beginning in 2020, PREA will apply to BLAs for orphan-designated biologics if the biologic is a molecularly targeted cancer product intended for the treatment of an adult cancer and is directed at a molecular target that FDA has determined is substantially relevant to the growth or progression of a pediatric cancer. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The Best Pharmaceuticals for Children Act (the &#8220;BPCA&#8221;) provides a six-month extension of any exclusivity&#8212;patent or non-patent&#8212;for a biologic if certain conditions are met. Conditions for exclusivity include the FDA&#8217;s determination that information relating to the use of a new biologic in the pediatric population may produce health benefits in that population, FDA making a written request for pediatric studies, and the applicant agreeing to perform, and reporting on, the requested studies within the statutory timeframe. Applications under the BPCA are treated as priority applications, with all of the benefits that designation confers.</div><div class="h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 17pt; margin-left: 0pt; text-align: left;">Post-Approval Requirements</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Once a BLA is approved, a product will be subject to certain post-approval requirements. For instance, the FDA closely regulates the post-approval marketing and promotion of biologics, including standards and regulations for direct-to-consumer advertising, off-label promotion, industry-sponsored scientific and educational activities and promotional activities involving the Internet. Biologics may be marketed only for the approved indications and in a manner consistent with the provisions of the approved labeling.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Adverse event reporting and submission of periodic safety summary reports is required following FDA approval of a BLA. The FDA also may require post-marketing testing, known as Phase 4 testing, REMS, and </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 36pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">178<br></div></div></div>
<!--End Page 182-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 183-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 540pt;"><a name="nt10014672x1_drs_107-business_pg68"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="block-frill" style="width: 540pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: Arial, Helvetica, sans-serif; font-size: 9pt; font-weight: bold; margin-top: 6pt; text-align: center;">Confidential Treatment Requested by ADC Therapeutics SA Pursuant to 17 C.F.R. &#167; 200.83<br></div></div><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 36pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">surveillance to monitor the effects of an approved product, or the FDA may place conditions on an approval that could restrict the distribution or use of the product. In addition, quality control, biological product manufacture, packaging, and labeling procedures must continue to conform to cGMPs after approval. Biologic manufacturers and certain of their subcontractors are required to register their establishments with the FDA and certain state agencies. Registration with the FDA subjects entities to periodic unannounced inspections by the FDA, during which the agency inspects a biologic product&#8217;s manufacturing facilities to assess compliance with cGMPs. Accordingly, manufacturers must continue to expend time, money, and effort in the areas of production and quality-control to maintain compliance with cGMPs. Regulatory authorities may withdraw product approvals or request product recalls if a company fails to comply with required regulatory standards, if it encounters problems following initial marketing, or if previously unrecognized problems are subsequently discovered.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Once an approval is granted, the FDA may withdraw the approval if compliance with regulatory requirements and standards is not maintained or if problems occur after the product reaches the market. Later discovery of previously unknown problems with a product, including adverse events of unanticipated severity or frequency, or with manufacturing processes or failure to comply with regulatory requirements, may result in revisions to the approved labeling to add new safety information, imposition of post-market studies or clinical studies to assess new safety risks or imposition of distribution or other restrictions under a REMS program. Other potential consequences include, among other things:</div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">restrictions on the marketing or manufacturing of the product, suspension of the approval, complete withdrawal of the product from the market or product recalls; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">fines, warning or other enforcement-related letters or holds on post-approval clinical studies;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">refusal of the FDA to approve pending BLAs or supplements to approved BLAs, or suspension or revocation of product license approvals;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">product seizure or detention, or refusal to permit the import or export of products; or </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">injunctions or the imposition of civil or criminal penalties.</div></td></tr></table><div class="h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 14pt; margin-left: 0pt; text-align: left;">U.S. Patent Term Restoration and Marketing Exclusivity</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Depending upon the timing, duration, and specifics of FDA approval of our product candidates, some of our U.S. patents may be eligible for limited patent term extension under the Hatch Waxman Amendments. The Hatch Waxman Amendments permit a patent term extension of up to five years as compensation for patent term lost during the FDA regulatory review process. Patent term extension, however, cannot extend the remaining term of a patent beyond a total of 14&#160;years from the product&#8217;s approval date. The patent term extension period is generally one half the time between the effective date of an IND and the submission date of a BLA, plus the time between the submission date of a BLA and the approval of that application, except that the review period is reduced by any time during which the applicant failed to exercise due diligence. Only one patent applicable to an approved drug is eligible for such an extension, only those claims covering the approved drug, a method for using it, or a method for manufacturing it may be extended and the application for the extension must be submitted prior to the expiration of the patent. The USPTO, in consultation with the FDA, reviews and approves the application for any patent term extension or restoration. In the future, we or our licensors may apply for patent term extension for our owned or licensed patents to add patent life beyond their current expiration date, depending on the expected length of the clinical trials and other factors involved in the filing of the relevant BLA. However, an extension might not be granted because of, for example, failing to exercise due diligence during the testing phase or regulatory review process, failing to apply within applicable deadlines, failing to apply prior to expiration of relevant patents or otherwise failing to satisfy applicable requirements. Moreover, the applicable time period or the scope of patent protection afforded could be less than requested.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The BPCIA created an abbreviated approval pathway for biological products shown to be biosimilar to, or interchangeable with, an FDA-licensed reference biological product. Biosimilarity, which requires that the biological product be highly similar to the reference product notwithstanding minor differences in clinically inactive components and that there be no clinically meaningful differences between the biological product and the reference product in terms of safety, purity and potency, can be shown through analytical studies, animal studies and a clinical trial or trials. Interchangeability requires that a biological product be biosimilar to the reference product and that the product can be expected to produce the same clinical results as the reference product in any given patient and, for products administered multiple times to an individual, that the product and </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 36pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">179<br></div></div></div>
<!--End Page 183-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 184-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 540pt;"><a name="nt10014672x1_drs_107-business_pg69"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="block-frill" style="width: 540pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: Arial, Helvetica, sans-serif; font-size: 9pt; font-weight: bold; margin-top: 6pt; text-align: center;">Confidential Treatment Requested by ADC Therapeutics SA Pursuant to 17 C.F.R. &#167; 200.83<br></div></div><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 36pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">the reference product may be alternated or switched after one has been previously administered without increasing safety risks or risks of diminished efficacy relative to exclusive use of the reference biological product without such alternation or switch.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">A reference biological product is granted 12&#160;years of data exclusivity from the time of first licensure of the product and the FDA will not accept an application for a biosimilar or interchangeable product based on the reference biological product until four years after the date of first licensure of the reference product. &#8220;First licensure&#8221; typically means the initial date the particular product at issue was licensed in the United States. Date of first licensure does not include the date of licensure of (and a new period of exclusivity is not available for) a biological product if the licensure is for a supplement for the biological product or for a subsequent application by the same sponsor or manufacturer of the biological product (or licensor, predecessor in interest, or other related entity) for a change (not&#160;including a modification to the structure of the biological product) that results in a new indication, route of administration, dosing schedule, dosage form, delivery system, delivery device or strength, or for a modification to the structure of the biological product that does not result in a change in safety, purity or potency.</div><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 20.5pt; margin-left: 0pt; text-align: left;">Regulatory Approval in the European Union</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The EMA is a decentralized scientific agency of the European Union. It coordinates the evaluation and monitoring of centrally authorized medicinal products. It is responsible for the scientific evaluation of applications for EU marketing authorizations, as well as the development of technical guidance and the provision of scientific advice to sponsors. The EMA decentralizes its scientific assessment of medicines by working through a network of about 4,500 experts throughout the European Union, nominated by the member states. The EMA draws on resources of over 40 National Competent Authorities of European Union member states.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The process regarding approval of medicinal products in the European Union follows roughly the same lines as in the United States and likewise generally involves satisfactorily completing each of the following:</div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">preclinical laboratory tests, animal studies and formulation studies all performed in accordance with the applicable EU Good Laboratory Practice regulations;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">submission to the relevant national authorities of a clinical trial application (&#8220;CTA&#8221;) for each trial in humans, which must be approved before the trial may begin in each country where patient enrollment is planned;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">performance of adequate and well-controlled clinical trials to establish the safety and efficacy of the product for each proposed indication;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">submission to the relevant competent authorities of a MAA, which includes the data supporting safety and efficacy as well as detailed information on the manufacture and composition of the product in clinical development and proposed labelling;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">satisfactory completion of an inspection by the relevant national authorities of the manufacturing facility or facilities, including those of third parties, at which the product is produced to assess compliance with strictly enforced cGMP;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">potential audits of the non-clinical and clinical trial sites that generated the data in support of the MAA; and</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">review and approval by the relevant competent authority of the MAA before any commercial marketing, sale or shipment of the product.</div></td></tr></table><div class="h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 20.5pt; margin-left: 0pt; text-align: left;">Preclinical Studies</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Preclinical tests include laboratory evaluations of product chemistry, formulation and stability, as well as studies to evaluate toxicity in animal studies, in order to assess the quality and potential safety and efficacy of the product. The conduct of the preclinical tests and formulation of the compounds for testing must comply with the relevant international, EU and national legislation, regulations and guidelines. The results of the preclinical tests, together with relevant manufacturing information and analytical data, are submitted as part of the CTA.</div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 36pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">180<br></div></div></div>
<!--End Page 184-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 185-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 540pt;"><a name="nt10014672x1_drs_107-business_pg70"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="block-frill" style="width: 540pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: Arial, Helvetica, sans-serif; font-size: 9pt; font-weight: bold; margin-top: 6pt; text-align: center;">Confidential Treatment Requested by ADC Therapeutics SA Pursuant to 17 C.F.R. &#167; 200.83<br></div></div><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 36pt;"><div class="h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">Clinical Trials</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Pursuant to the Clinical Trials Directive 2001/20/EC, as amended (the &#8220;Clinical Trials Directive&#8221;), a system for the approval of clinical trials in the European Union has been implemented through national legislation of the member states. Under this system, approval must be obtained from the competent national authority of each European Union member state in which a clinical trial is planned to be conducted. To this end, a CTA is submitted, which must be supported by an investigational medicinal product dossier and further supporting information prescribed by the Clinical Trials Directive and other applicable guidance documents including but not being limited to the clinical trial protocol. Furthermore, a clinical trial may only be started after a competent ethics committee has issued a favorable opinion on the clinical trial application in that country.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Directive 2001/20/EC will be replaced by Regulation (EU) No. 536/2014, which became effective on June&#160;16, 2014. The Regulation introduces an authorization procedure based on a single submission via a single EU portal, an assessment procedure leading to a single decision, as well as transparency requirements (the proactive publication of clinical trial data in the EU database). Since October 2016, based on its Policy 0070, the EMA has been publishing clinical data submitted by pharmaceutical companies to support their MAA for human medicines under this centralized procedure.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Manufacturing and import into the EU of investigational medicinal products is subject to the holding of appropriate authorizations and must be carried out in accordance with cGMP.</div><div class="h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 15pt; margin-left: 0pt; text-align: left;">Review and Approval</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Authorization to market a product in the European Union member states proceeds under one of four procedures: a centralized authorization procedure, a mutual recognition procedure, a decentralized procedure or a national procedure. Since our products by their virtue of being antibody-based biologics fall under the centralized procedure, only this procedure will be described here.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Certain drugs, including medicinal products developed by means of biotechnological processes, must be approved via the centralized authorization procedure for marketing authorization. A successful application under the centralized authorization procedure results in a marketing authorization from the European Commission, which is automatically valid in all European Union member states. The other European Economic Area member states (namely Norway, Iceland and Liechtenstein) are also obligated to recognize the European Commission decision. The EMA and the European Commission administer the centralized authorization procedure.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Under the centralized authorization procedure, the Committee for Medicinal Products for Human Use (the &#8220;CHMP&#8221;) serves as the scientific committee that renders opinions about the safety, efficacy and quality of human products on behalf of the EMA. The CHMP is composed of experts nominated by each member state&#8217;s national drug authority, with one of them appointed to act as Rapporteur for the co-ordination of the evaluation with the possible assistance of a further member of the CHMP acting as a Co-Rapporteur. After approval, the Rapporteur(s) continue to monitor the product throughout its life cycle. The CHMP is required to issue an opinion within 210 days of receipt of a valid application, though the clock is stopped if it is necessary to ask the applicant for clarification or further supporting data. The process is complex and involves extensive consultation with the regulatory authorities of member states and a number of experts. Once the procedure is completed, a European Public Assessment Report is produced. If the CHMP concludes that the quality, safety and efficacy of the medicinal product is sufficiently proven, it adopts a positive opinion. The CHMP&#8217;s opinion is sent to the European Commission, which uses the opinion as the basis for its decision whether or not to grant a marketing authorization. If the opinion is negative, information is given as to the grounds on which this conclusion was reached.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">After a drug has been authorized and launched, it is a condition of maintaining the marketing authorization that all aspects relating to its quality, safety and efficacy must be kept under review. Sanctions may be imposed for failure to adhere to the conditions of the marketing authorization. In extreme cases, the authorization may be revoked, resulting in withdrawal of the product from sale.</div><div class="h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 15pt; margin-left: 0pt; text-align: left;">Conditional Approval and Accelerated Assessment</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">As per Article 14(7) of Regulation (EC) 726/2004, a medicine that would fulfill an unmet medical need may, if its immediate availability is in the interest of public health, be granted a conditional marketing authorization on the basis of less complete clinical data than are normally required, subject to specific obligations </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 36pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">181<br></div></div></div>
<!--End Page 185-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 186-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 540pt;"><a name="nt10014672x1_drs_107-business_pg71"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="block-frill" style="width: 540pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: Arial, Helvetica, sans-serif; font-size: 9pt; font-weight: bold; margin-top: 6pt; text-align: center;">Confidential Treatment Requested by ADC Therapeutics SA Pursuant to 17 C.F.R. &#167; 200.83<br></div></div><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 36pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">being imposed on the authorization holder. These specific obligations are to be reviewed annually by the EMA. The list of these obligations shall be made publicly accessible. Such an authorization shall be valid for one year, on a renewable basis.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">When an application is submitted for a marketing authorization in respect of a drug for human use which is of major interest from the point of view of public health and in particular from the viewpoint of therapeutic innovation, the applicant may request an accelerated assessment procedure pursuant to Article 14(9) of Regulation (EC) 726/2004. Under the accelerated assessment procedure, the CHMP is required to issue an opinion within 150 days of receipt of a valid application, subject to clock stops. We believe that some of the disease indications in which our product candidates are currently being or may be developed in the future qualify for this provision, and we will take advantage of this provision as appropriate.</div><div class="h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 12pt; margin-left: 0pt; text-align: left;">Period of Authorization and Renewals</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">A marketing authorization is initially valid for five years and may then be renewed on the basis of a re-evaluation of the risk-benefit balance by the EMA or by the competent authority of the authorizing member state. To this end, the marketing authorization holder shall provide the EMA or the competent authority with a consolidated version of the file in respect of quality, safety and efficacy, including all variants introduced since the marketing authorization was granted, at least six months before the marketing authorization ceases to be valid. Once renewed, the marketing authorization shall be valid for an unlimited period, unless the European Commission or the competent authority decides, on justified grounds relating to pharmacovigilance, to proceed with one additional five-year renewal. Any authorization which is not followed by the actual placing of the drug on the EU market (in case of centralized procedure) or on the market of the authorizing member state within three years after authorization shall cease to be valid (the so-called &#8220;sunset clause&#8221;).</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Without prejudice to the law on the protection of industrial and commercial property, marketing authorizations for new medicinal products benefit from an 8+2+1&#160;year period of regulatory protection. This regime consists of a regulatory data protection period of eight years plus a concurrent market exclusivity of 10&#160;years plus an additional market exclusivity of one further year if, during the first eight years of those 10&#160;years, the marketing approval holder obtains an approval for one or more new therapeutic indications which, during the scientific evaluation prior to their approval, are determined to bring a significant clinical benefit in comparison with existing therapies. Under the current rules, a third party may reference the preclinical and clinical data of the reference product beginning eight years after first approval, but the third party may market a generic version of the reference product after only 10 (or 11) years have lapsed.</div><div class="h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 12pt; margin-left: 0pt; text-align: left;">Orphan Drug Designation</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Regulation (EC) 141/2000 states that a drug shall be designated as an orphan drug if its sponsor can establish (i)&#160;that it is intended for the diagnosis, prevention or treatment of a life-threatening or chronically debilitating condition affecting not more than five in 10,000 persons in the European Union when the application is made, or that it is intended for the diagnosis, prevention or treatment of a life-threatening, seriously debilitating or serious and chronic condition in the European Union and that without incentives it is unlikely that the marketing of the drug in the European Union would generate sufficient return to justify the necessary investment; and (ii)&#160;that there exists no satisfactory method of diagnosis, prevention or treatment of the condition in question that has been authorized in the European Union or, if such method exists, the drug will be of significant benefit to those affected by that condition.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Regulation (EC) 847/2000 sets out criteria for the designation of orphan drugs. An application for designation as an orphan product can be made any time prior to the filing of an application for approval to market the product. Marketing authorization for an orphan drug leads to a 10-year period of market exclusivity, which means that no similar medicinal product can be authorized in the same indication. This period may, however, be reduced to six years if, at the end of the fifth year, it is established that the product no longer meets the criteria for orphan drug designation, for example because the product is sufficiently profitable not to justify continued market exclusivity. In addition, derogation from market exclusivity may be granted on an individual basis in very selected cases, such as consent from the marketing authorization holder, inability to supply sufficient quantities of the product or demonstration of &#8220;clinically relevant superiority&#8221; by a similar medicinal product. Medicinal products designated as orphan drugs pursuant to Regulation (EC) 141/2000 are eligible for incentives made available by the European Union and by the member states to support research into, and the development and availability of, orphan drugs.</div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 36pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">182<br></div></div></div>
<!--End Page 186-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 187-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 540pt;"><a name="nt10014672x1_drs_107-business_pg72"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="block-frill" style="width: 540pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: Arial, Helvetica, sans-serif; font-size: 9pt; font-weight: bold; margin-top: 6pt; text-align: center;">Confidential Treatment Requested by ADC Therapeutics SA Pursuant to 17 C.F.R. &#167; 200.83<br></div></div><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 36pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">If the MAA of a medicinal product designated as an orphan drug pursuant to Regulation (EC) 141/2000 includes the results of all studies conducted in compliance with an agreed PIP, and a corresponding statement is subsequently included in the marketing authorization granted, the 10-year period of market exclusivity will be extended to 12&#160;years.</div><div class="h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 14pt; margin-left: 0pt; text-align: left;">European Data Collection and Processing</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The collection, transfer, processing and other use of personal information, including health data, in the European Union is governed by the GDPR, which came into effect in May 2018. This directive imposes several requirements relating to (i)&#160;obtaining, in some situations, the consent of the individuals to whom the personal data relates, (ii)&#160;the information provided to the individuals about how their personal information is used, (iii)&#160;ensuring the security and confidentiality of the personal data, (iv)&#160;the obligation to notify regulatory authorities and affected individuals of personal data breaches, (v)&#160;extensive internal privacy governance obligations and (vi)&#160;obligations to honor rights of individuals in relation to their personal data (for example, the right to access, correct and delete their data). The GDPR prohibits the transfer of personal data to countries outside the European Economic Area, such as the United States, which are not considered by the European Commission to provide an adequate level of data protection. Switzerland has adopted similar restrictions. Failure to comply with the requirements of the GDPR and the related national data protection laws of the European Union member states may result in fines and other administrative penalties. The GDPR introduces new data protection requirements in the EU and substantial fines for breaches of the data protection rules. The GDPR and related data protection laws may impose additional responsibility and liability in relation to personal data that we collect and process and we may be required to put in place additional mechanisms ensuring compliance with such rules. This may be onerous and adversely affect our business, financial condition, results of operations, and prospects.</div><div class="h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 13.5pt; margin-left: 0pt; text-align: left;">Marketing</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Much like the Anti-Kickback Statute prohibition in the United States, the provision of benefits or advantages to physicians to induce or encourage the prescription, recommendation, endorsement, purchase, supply, order or use of medicinal products is also prohibited in the EU. The provision of benefits or advantages to physicians is governed by the national anti-bribery laws of European Union member states, such as the U.K. Bribery Act 2010. Infringement of these laws could result in substantial fines and imprisonment.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Payments made to physicians in certain European Union member states must be publicly disclosed. Moreover, agreements with physicians often must be the subject of prior notification and approval by the physician&#8217;s employer, his or her competent professional organization, and/or the regulatory authorities of the individual European Union member states. These requirements are provided in the national laws, industry codes or professional codes of conduct, applicable in the European Union member states. Failure to comply with these requirements could result in reputational risk, public reprimands, administrative penalties, fines or imprisonment.</div><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 13.5pt; margin-left: 0pt; text-align: left;">International Regulation</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">In addition to regulations in the United States and Europe, a variety of foreign regulations govern clinical trials, commercial sales and distribution of product candidates. The approval process varies from country to country and the time to approval may be longer or shorter than that required for FDA or European Commission approval.</div><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 13.5pt; margin-left: 0pt; text-align: left;">Other Healthcare Laws and Regulations and Legislative Reform</div><div class="h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 7pt; margin-left: 0pt; text-align: left;">Healthcare and Privacy Laws and Regulations</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Healthcare providers, physicians and third-party payors will play a primary role in the recommendation and prescription of any product candidates for which we obtain marketing approval. Our operations, including any arrangements with healthcare providers, physicians, third-party payors and customers may expose us to broadly applicable fraud and abuse and other healthcare laws that may affect the business or financial arrangements and relationships through which we would market, sell and distribute our products. The healthcare laws that may affect our ability to operate include, but are not limited to:</div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">The federal Anti-Kickback Statute, which prohibits any person or entity from, among other things, knowingly and willfully soliciting, receiving, offering or paying any remuneration, directly or indirectly, </div></td></tr></table></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 36pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">183<br></div></div></div>
<!--End Page 187-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 188-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 540pt;"><a name="nt10014672x1_drs_107-business_pg73"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="block-frill" style="width: 540pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: Arial, Helvetica, sans-serif; font-size: 9pt; font-weight: bold; margin-top: 6pt; text-align: center;">Confidential Treatment Requested by ADC Therapeutics SA Pursuant to 17 C.F.R. &#167; 200.83<br></div></div><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 36pt;"><div class="bl" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 40pt; text-align: left;">overtly or covertly, in cash or in kind, to induce or reward either the referral of an individual for, or the purchase, order or recommendation of an item or service reimbursable, in whole or in part, under a federal healthcare program, such as the Medicare and Medicaid programs. The term &#8220;remuneration&#8221; has been broadly interpreted to include anything of value. The federal Anti-Kickback Statute has also been interpreted to apply to arrangements between pharmaceutical manufacturers on the one hand and prescribers, purchasers, and formulary managers on the other hand. There are a number of statutory exceptions and regulatory safe harbors protecting some common activities from prosecution, but the exceptions and safe harbors are drawn narrowly and require strict compliance in order to offer protection.</div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">Federal civil and criminal false claims laws, such as the FCA, which can be enforced by private citizens through civil qui tam actions, and civil monetary penalty laws prohibit individuals or entities from, among other things, knowingly presenting, or causing to be presented, false, fictitious or fraudulent claims for payment of federal funds, and knowingly making, using or causing to be made or used a false record or statement material to a false or fraudulent claim to avoid, decrease or conceal an obligation to pay money to the federal government. For example, pharmaceutical companies have been prosecuted under the FCA in connection with their alleged off-label promotion of drugs, purportedly concealing price concessions in the pricing information submitted to the government for government price reporting purposes, and allegedly providing free product to customers with the expectation that the customers would bill federal healthcare programs for the product. In addition, a claim including items or services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the FCA. As a result of a modification made by the Fraud Enforcement and Recovery Act of 2009, a claim includes &#8220;any request or demand&#8221; for money or property presented to the U.S. government. In addition, manufacturers can be held liable under the FCA even when they do not submit claims directly to government payors if they are deemed to &#8220;cause&#8221; the submission of false or fraudulent claims.</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">HIPAA, among other things, imposes criminal liability for executing or attempting to execute a scheme to defraud any healthcare benefit program, including private third-party payors, knowingly and willfully embezzling or stealing from a healthcare benefit program, willfully obstructing a criminal investigation of a healthcare offense, and creates federal criminal laws that prohibit knowingly and willfully falsifying, concealing or covering up a material fact or making any materially false, fictitious or fraudulent statement or representation, or making or using any false writing or document knowing the same to contain any materially false, fictitious or fraudulent statement or entry in connection with the delivery of or payment for healthcare benefits, items or services.</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">HIPAA, as amended by HITECH, and their implementing regulations, which impose privacy, security and breach reporting obligations with respect to individually identifiable health information upon entities subject to the law, such as health plans, healthcare clearinghouses and certain healthcare providers, known as covered entities, and their respective business associates that perform services for them that involve individually identifiable health information. HITECH also created new tiers of civil monetary penalties, amended HIPAA to make civil and criminal penalties directly applicable to business associates, and gave state attorneys general new authority to file civil actions for damages or injunctions in U.S. federal courts to enforce HIPAA laws and seek attorneys&#8217; fees and costs associated with pursuing federal civil actions.</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">Federal and state consumer protection and unfair competition laws, which broadly regulate marketplace activities and activities that potentially harm consumers.</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">The federal transparency requirements under the Physician Payments Sunshine Act, created under the Health Care Reform Act, which requires, among other things, certain manufacturers of drugs, devices, biologics and medical supplies reimbursed under Medicare, Medicaid, or the Children&#8217;s Health Insurance Program to report annually to CMS information related to payments and other transfers of value provided to physicians, as defined by such law, and teaching hospitals and physician ownership and investment interests, including such ownership and investment interests held by a physician&#8217;s immediate family members.</div></td></tr></table></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 36pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">184<br></div></div></div>
<!--End Page 188-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 189-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 540pt;"><a name="nt10014672x1_drs_107-business_pg74"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="block-frill" style="width: 540pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: Arial, Helvetica, sans-serif; font-size: 9pt; font-weight: bold; margin-top: 6pt; text-align: center;">Confidential Treatment Requested by ADC Therapeutics SA Pursuant to 17 C.F.R. &#167; 200.83<br></div></div><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 36pt;"><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6.75pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">State and foreign laws that are analogous to each of the above federal laws, such as anti-kickback and false claims laws, that may impose similar or more prohibitive restrictions, and may apply to items or services reimbursed by non-governmental third-party payors, including private insurers.</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">State and foreign laws that require pharmaceutical companies to implement compliance programs, comply with the pharmaceutical industry&#8217;s voluntary compliance guidelines and the relevant compliance guidance promulgated by the federal government, or to track and report gifts, compensation and other remuneration provided to physicians and other healthcare providers; state laws that require the reporting of marketing expenditures or drug pricing, including information pertaining to and justifying price increases; state and local laws that require the registration of pharmaceutical sales representatives; state laws that prohibit various marketing-related activities, such as the provision of certain kinds of gifts or meals; state laws that require the posting of information relating to clinical trials and their outcomes; and other federal, state and foreign laws that govern the privacy and security of health information or personally identifiable information in certain circumstances, including state health information privacy and data breach notification laws which govern the collection, use, disclosure, and protection of health-related and other personal information, many of which differ from each other in significant ways and often are not pre-empted by HIPAA, thus requiring additional compliance efforts.</div></td></tr></table><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">If our operations are found to be in violation of any of these laws or any other current or future healthcare laws that may apply to us, we may be subject to significant civil, criminal and administrative penalties, damages, fines, disgorgement, imprisonment, exclusion from government funded healthcare programs, such as Medicare and Medicaid, contractual damages, reputational harm, diminished profits and future earnings, additional reporting obligations and oversight if we become subject to a corporate integrity agreement or other agreement to resolve allegations of non-compliance with these laws, and the curtailment or restructuring of our operations, any of which could substantially disrupt our operations. Although effective compliance programs can mitigate the risk of investigation and prosecution for violations of these laws, these risks cannot be entirely eliminated. Any action against us for an alleged or suspected violation could cause us to incur significant legal expenses and could divert our management&#8217;s attention from the operation of our business, even if our defense is successful. In addition, if any of the physicians or other healthcare providers or entities with whom we expect to do business is found not to be in compliance with applicable laws, they may be subject to significant criminal, civil or administrative sanctions, including exclusions from government funded healthcare programs.</div><div class="h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 12pt; margin-left: 0pt; text-align: left;">Legislative Reform</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">We operate in a highly regulated industry, and new laws, regulations and judicial decisions, or new interpretations of existing laws, regulations and decisions, related to healthcare availability, the method of delivery and payment for healthcare products and services could negatively affect our business, financial condition and prospects. There is significant interest in promoting healthcare reforms, and it is likely that federal and state legislatures within the United States and the governments of other countries will continue to consider changes to existing healthcare legislation.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">For example, the United States and state governments continue to propose and pass legislation designed to reduce the cost of healthcare. In 2010, the U.S. Congress enacted the Health Care Reform Act, which included changes to the coverage and reimbursement of drug products under government healthcare programs such as:</div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">increased the minimum Medicaid rebates owed by manufacturers under the Medicaid Drug Rebate Program;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">established a branded prescription drug fee that pharmaceutical manufacturers of certain branded prescription drugs must pay to the federal government;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">expanded the list of covered entities eligible to participate in the 340B drug pricing program by adding new entities to the program;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">established a new Medicare Part D coverage gap discount program, in which manufacturers must agree to offer 70% point-of-sale discounts off negotiated prices of applicable brand drugs to eligible beneficiaries during their coverage gap period, as a condition for the manufacturer&#8217;s outpatient drugs to be covered under Medicare Part D;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">extended manufacturers&#8217; Medicaid rebate liability to covered drugs dispensed to individuals who are enrolled in Medicaid managed care organizations;</div></td></tr></table></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 36pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">185<br></div></div></div>
<!--End Page 189-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 190-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 540pt;"><a name="nt10014672x1_drs_107-business_pg75"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="block-frill" style="width: 540pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: Arial, Helvetica, sans-serif; font-size: 9pt; font-weight: bold; margin-top: 6pt; text-align: center;">Confidential Treatment Requested by ADC Therapeutics SA Pursuant to 17 C.F.R. &#167; 200.83<br></div></div><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 36pt;"><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6.75pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">expanded eligibility criteria for Medicaid programs by, among other things, allowing states to offer Medicaid coverage to additional individuals and by adding new mandatory eligibility categories for individuals with income at or below 133% of the federal poverty level, thereby potentially increasing manufacturers&#8217; Medicaid rebate liability;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">created a new methodology by which rebates owed by manufacturers under the Medicaid Drug Rebate Program are calculated for certain drugs and biologics, including our product candidates, that are inhaled, infused, instilled, implanted or injected;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">established a new Patient-Centered Outcomes Research Institute to oversee, identify priorities in, and conduct comparative clinical effectiveness research, along with funding for such research;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">established a Center for Medicare and Medicaid Innovation at the CMS to test innovative payment and service delivery models to lower Medicare and Medicaid spending, potentially including prescription drug spending; and</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">created a licensure framework for follow-on biologic products.</div></td></tr></table><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">There remain judicial and congressional challenges to certain aspects of the Health Care Reform Act as well as efforts by the current U.S. Presidential Administration to repeal or replace certain aspects of the Health Care Reform Act. For example, in 2017, the U.S. Congress enacted the TCJA, which eliminated the tax-based shared responsibility payment imposed by the Health Care Reform Act on certain individuals who fail to maintain qualifying health coverage for all or part of a year that is commonly referred to as the &#8220;individual mandate.&#8221; On December&#160;14, 2018, the U.S. District Court for the Northern District of Texas held that the individual mandate is a critical and inseverable feature of the Health Care Reform Act, and therefore, because it was repealed by the TCJA, the remaining provisions of the Health Care Reform Act are invalid as well. On December&#160;18, 2019, the U.S. Court of Appeals for the Fifth Circuit upheld the District Court ruling that the individual mandate was unconstitutional and remanded the case back to the District Court to determine whether the remaining provisions of the Health Care Reform Act are invalid as well. On March 2, 2020, the Supreme Court of the United States granted the petitions for writ of certiorari to review this case. Oral arguments are expected to occur in the fall. It is unclear how this litigation and other efforts to repeal and replace the Health Care Reform Act will impact the Health Care Reform Act. It is difficult to predict the future legislative landscape in healthcare and the effect on our business, results of operations, financial condition and prospects.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">In addition, there have been and continue to be a number of initiatives at the United States federal and state levels that seek to reduce healthcare costs. In 2011, the U.S. Congress enacted the Budget Control Act, which included provisions intended to reduce the federal deficit. The Budget Control Act resulted in the imposition of 2% reductions in Medicare payments to providers beginning in 2013 and, due to subsequent legislative amendments to the statute, will remain in effect through 2030 absent additional congressional action. The CARES Act, which was signed into law on March 27, 2020, suspended the 2% Medicare sequester reductions under the Budget Control Act from May 1, 2020 through December 31, 2020 and extended the sequester by one year, through 2030. In 2012, the U.S. Congress enacted the American Taxpayer Relief Act, which, among other things, further reduced Medicare payments to several types of providers, including hospitals, imaging centers and cancer treatment centers, and increased the statute of limitations period for the government to recover overpayments to providers from three to five years. If government spending is further reduced, anticipated budgetary shortfalls may also impact the ability of relevant agencies, such as the FDA, to continue to function at current levels, which may impact the ability of relevant agencies to timely review and approve research and development, manufacturing and marketing activities, which may delay our ability to develop, market and sell any product candidates we may develop. In addition, any significant spending reductions affecting Medicare, Medicaid or other publicly funded or subsidized health programs that may be implemented, or any significant taxes or fees that may be imposed on us, as part of any broader deficit reduction effort or legislative replacement to the Budget Control Act, could have an adverse impact on our anticipated product revenues.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Furthermore, there has been heightened governmental scrutiny over the manner in which manufacturers set prices for their marketed products, which has resulted in several congressional inquiries and proposed legislation designed to, among other things, bring more transparency to product pricing, review the relationship between pricing and manufacturer patient programs and reform government program reimbursement methodologies for drug products. At the federal level, the U.S. Presidential Administration&#8217;s budget proposal for fiscal year 2021 includes a $135&#160;billion allowance to support legislative proposals seeking to reduce drug prices, increase competition, lower out-of-pocket </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 36pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">186<br></div></div></div>
<!--End Page 190-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 191-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 540pt;"><a name="nt10014672x1_drs_107-business_pg76"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="block-frill" style="width: 540pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: Arial, Helvetica, sans-serif; font-size: 9pt; font-weight: bold; margin-top: 6pt; text-align: center;">Confidential Treatment Requested by ADC Therapeutics SA Pursuant to 17 C.F.R. &#167; 200.83<br></div></div><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 36pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">drug costs for patients and increase patient access to lower-cost generic and biosimilar drugs. On March&#160;10, 2020, the current U.S. Presidential Administration sent &#8220;principles&#8221; for drug pricing to Congress, calling for legislation that would, among other things, cap Medicare Part D beneficiary out-of-pocket pharmacy expenses, provide an option to cap Medicare Part D beneficiary monthly out-of-pocket expenses and place limits on pharmaceutical price increases. Further, the current U.S. Presidential Administration previously released a &#8220;Blueprint&#8221; to lower drug prices and reduce out-of-pocket costs of drugs that contained proposals to increase drug manufacturer competition, increase the negotiating power of certain federal healthcare programs, incentivize manufacturers to lower the list price of their products, and reduce the out-of-pocket costs of drug products paid by consumers. HHS has solicited feedback on some of these measures and has implemented others under its existing authority. For example, CMS issued a final rule in May&#160;2019 to allow Medicare Advantage plans the option to use step therapy for Part&#160;B drugs beginning January&#160;1, 2020. This final rule codified CMS&#8217;s policy change that was effective January&#160;1, 2019. On July 24, 2020, the current U.S. Presidential Administration announced four executive orders related to prescription drug pricing that attempt to implement several of the administration&#8217;s proposals, including a policy that would tie Medicare Part B drug prices to international drug prices; one that directs HHS to finalize the Canadian drug importation proposed rule previously issued by HHS and makes other changes allowing for personal importation of drugs from Canada; one that directs HHS to finalize the rulemaking process for modifying the anti-kickback law safe harbors for discounts for plans, pharmacies, and pharmaceutical benefit managers; and one that reduces costs of insulin and some types of injectable epinephrine to patients of federally qualified health centers. While some of these and other measures may require additional authorization to become effective, Congress and the current U.S.&#160;Presidential Administration have each indicated that it will continue to seek new measures to control drug costs. Individual states in the United States have also become increasingly active in passing legislation and implementing regulations designed to control pharmaceutical product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing. In addition, regional healthcare authorities and individual hospitals are increasingly using bidding procedures to determine what pharmaceutical products and which suppliers will be included in their prescription drug and other healthcare programs. We expect that additional state and federal healthcare reform measures will be adopted in the future.</div><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 14.5pt; margin-left: 0pt; text-align: left;">Environmental, Health and Safety Laws and Regulations</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">We and our third-party contractors are subject to numerous environmental, health and safety laws and regulations, including those governing laboratory procedures and the use, generation, manufacture, distribution, storage, handling, treatment, remediation and disposal of hazardous materials and wastes. Hazardous chemicals, including flammable and biological materials, are involved in certain aspects of our business, and we cannot eliminate the risk of injury or contamination from the use, generation, manufacture, distribution, storage, handling, treatment or disposal of hazardous materials and wastes. In particular, our product candidates use PBDs, which are highly potent cytotoxins that require special handling by our and our contractors&#8217; staff. In the event of contamination or injury, or failure to comply with environmental, health and safety laws and regulations, we could be held liable for any resulting damages, fines and penalties associated with such liability could exceed our assets and resources. Environmental, health and safety laws and regulations are becoming increasingly more stringent. We may incur substantial costs in order to comply with current or future environmental, health and safety laws and regulations.</div><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 14.5pt; margin-left: 0pt; text-align: left;">Pharmaceutical Coverage, Pricing and Reimbursement</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The availability and extent of coverage and adequate reimbursement by governmental and private third-party payors are essential for most patients to be able to afford expensive medical treatments. In both domestic and foreign markets, sales of our product candidates will depend substantially on the extent to which the costs of our product candidates will be covered by third-party payors, such as government health programs, commercial insurance and managed healthcare organizations. These third-party payors decide which products will be covered and establish reimbursement levels for those products. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Coverage and reimbursement by a third-party payor may depend upon a number of factors, including the third-party payor&#8217;s determination that use of a product is:</div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">a covered benefit under its health plan;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">safe, effective and medically necessary;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">appropriate for the specific patient;</div></td></tr></table></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 36pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">187<br></div></div></div>
<!--End Page 191-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 192-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 540pt;"><a name="nt10014672x1_drs_107-business_pg77"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="block-frill" style="width: 540pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: Arial, Helvetica, sans-serif; font-size: 9pt; font-weight: bold; margin-top: 6pt; text-align: center;">Confidential Treatment Requested by ADC Therapeutics SA Pursuant to 17 C.F.R. &#167; 200.83<br></div></div><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 36pt;"><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6.75pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">cost-effective; and</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">neither experimental nor investigational.</div></td></tr></table><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Obtaining coverage approval and reimbursement for a product from a government or other third-party payor is a time-consuming and costly process that could require us to provide supporting scientific, clinical and cost-effectiveness data for the use of our products to the payor. We may not be able to provide data sufficient to gain acceptance with respect to coverage and reimbursement at a satisfactory level. If coverage and adequate reimbursement of our future products, if any, are unavailable or limited in scope or amount, such as may result where alternative or generic treatments are available, we may be unable to achieve or sustain profitability. Adverse coverage and reimbursement limitations may hinder our ability to recoup our investment in our product candidates, even if such product candidates obtain regulatory approval.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">There is significant uncertainty related to the insurance coverage and reimbursement of newly approved products. There is no uniform policy for coverage and reimbursement in the United States and, as a result, coverage and reimbursement can differ significantly from payor to payor. In the United States, the principal decisions about reimbursement for new medicines are typically made by the CMS, which decides whether and to what extent a new medicine will be covered and reimbursed under Medicare. Private payors often, but not always, follow the CMS&#8217;s decisions regarding coverage and reimbursement. It is difficult to predict what third-party payors will decide with respect to coverage and reimbursement for fundamentally novel products such as ours, as there is no body of established practices and precedents for these new products. Further, one payor&#8217;s determination to provide coverage and adequate reimbursement for a product does not assure that other payors will also provide coverage and adequate reimbursement for that product. We may need to conduct expensive pharmaco-economic studies in order to demonstrate the medical necessity and cost-effectiveness of our product candidates. There can be no assurance that our product candidates will be considered medically necessary or cost-effective. In addition to third-party payors, professional organizations and patient advocacy groups such as the National Comprehensive Cancer Network and the American Society of Clinical Oncology can influence decisions about reimbursement for new medicines by determining standards for care. Therefore, it is possible that any of our product candidates, even if approved, may not be covered by third-party payors or the reimbursement limit may be so restrictive that we cannot commercialize the product candidates profitably.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Reimbursement agencies in Europe may be more restrictive than payors in the United States. For example, a number of cancer products have been approved for reimbursement in the United States but not in certain European countries. In Europe, pricing and reimbursement schemes vary widely from country to country. For example, some countries provide that products may be marketed only after an agreement on reimbursement price has been reached. Such pricing negotiations with governmental authorities can take considerable time after receipt of marketing approval for a product. Political, economic and regulatory developments may further complicate pricing negotiations, and pricing negotiations may continue after reimbursement has been obtained. Other countries require the completion of additional health technology assessments that compare the cost-effectiveness of a particular product candidate to currently available therapies. In addition, the European Union provides options for its member states to restrict the range of products for which their national health insurance systems provide reimbursement and to control the prices of medicinal products for human use. European Union member states may approve a specific price for a product, may adopt a system of direct or indirect controls on the profitability of the company placing the product on the market or monitor and control prescription volumes and issue guidance to physicians to limit prescriptions. Reference pricing used by various European Union member states and parallel distribution, or arbitrage between low-priced and high-priced member states, can further reduce prices. Furthermore, many countries in the European Union have increased the amount of discounts required on pharmaceutical products, and these efforts could continue as countries attempt to manage healthcare expenditures, especially in light of the severe fiscal and debt crises experienced by many countries in the European Union. The downward pressure on healthcare costs in general, and prescription products in particular, has become increasingly intense. As a result, there are increasingly higher barriers to entry for new products. There can be no assurance that any country that has reimbursement limitations for pharmaceutical products will allow favorable reimbursement and pricing arrangements for any of our products, if approved in those countries. Accordingly, the reimbursement for any products in Europe may be reduced compared with the United States and may be insufficient to generate commercially reasonable revenues and profits.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Furthermore, the containment of healthcare costs has become a priority of foreign and domestic governments as well as private third-party payors. The prices of drugs have been a focus in this effort. Governments and private third-party payors have attempted to control costs by limiting coverage and the amount </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 36pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">188<br></div></div></div>
<!--End Page 192-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 193-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 540pt;"><a name="nt10014672x1_drs_107-business_pg78"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="block-frill" style="width: 540pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: Arial, Helvetica, sans-serif; font-size: 9pt; font-weight: bold; margin-top: 6pt; text-align: center;">Confidential Treatment Requested by ADC Therapeutics SA Pursuant to 17 C.F.R. &#167; 200.83<br></div></div><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 36pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">of reimbursement for particular medications, which could affect our ability to sell our product candidates profitably. We also expect to experience pricing pressures due to the trend towards managed healthcare, the increasing influence of health maintenance organizations and additional legislative changes. These and other cost-control initiatives could cause us to decrease the price we might establish for products, which could result in lower-than-anticipated product revenues. In addition, the publication of discounts by third-party payors or authorities may lead to further pressure on the prices or reimbursement levels within the country of publication and other countries. If pricing is set at unsatisfactory levels or if coverage and adequate reimbursement of our products is unavailable or limited in scope or amount, our revenues and the potential profitability of our product candidates in those countries would be negatively affected.</div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 20.5pt; margin-left: 0pt; text-align: left;">Facilities</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">We do not own any real property. We believe that our leased facilities meet our present needs and are continuously reviewing our space requirements. The table below sets forth the sizes and uses of our leased facilities:</div><table cellspacing="0" cellpadding="0" class="txttab" style="margin-top: 5.25pt; border-collapse: collapse; width: 468pt; margin-left: auto; margin-right: auto;"><tr class="header"><td style="width: 46.15%; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 3.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Location</div></td><td class="gutter" style="width: 1.28%; font-size: 2pt; padding-top: 6pt; padding-bottom: 3.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.28%; font-size: 2pt; padding-top: 6pt; padding-bottom: 3.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 24.36%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 3.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Primary Function</div></td><td class="gutter" style="width: 1.28%; font-size: 2pt; padding-top: 6pt; padding-bottom: 3.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.28%; font-size: 2pt; padding-top: 6pt; padding-bottom: 3.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 24.36%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 3.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Approximate Size</div></td></tr><tr><td style="width: 46.15%; text-align: left; vertical-align: top; padding-top: 3.25pt; padding-bottom: 2pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Biop&#244;le <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Route de la Corniche 3B <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">1066 Epalinges <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Switzerland</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3.25pt; padding-bottom: 2pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3.25pt; padding-bottom: 2pt;">&#8203;</td><td style="width: 24.36%; text-align: left; vertical-align: top; padding-top: 3.25pt; padding-bottom: 2pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Office</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3.25pt; padding-bottom: 2pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3.25pt; padding-bottom: 2pt;">&#8203;</td><td style="width: 24.36%; text-align: left; vertical-align: top; padding-top: 3.25pt; padding-bottom: 2pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">518 m<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">2</sup></div></td></tr><tr><td style="width: 46.15%; text-align: left; vertical-align: top; padding-top: 2pt; padding-bottom: 2pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2pt; padding-bottom: 2pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2pt; padding-bottom: 2pt;">&#8203;</td><td style="width: 24.36%; text-align: left; vertical-align: top; padding-top: 2pt; padding-bottom: 2pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2pt; padding-bottom: 2pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2pt; padding-bottom: 2pt;">&#8203;</td><td style="width: 24.36%; text-align: left; vertical-align: top; padding-top: 2pt; padding-bottom: 2pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 46.15%; text-align: left; vertical-align: top; padding-top: 2pt; padding-bottom: 2pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">430 Mountain Avenue, 4th Floor <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Murray Hill, New Jersey 07974 <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">United States</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2pt; padding-bottom: 2pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2pt; padding-bottom: 2pt;">&#8203;</td><td style="width: 24.36%; text-align: left; vertical-align: top; padding-top: 2pt; padding-bottom: 2pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Office</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2pt; padding-bottom: 2pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2pt; padding-bottom: 2pt;">&#8203;</td><td style="width: 24.36%; text-align: left; vertical-align: top; padding-top: 2pt; padding-bottom: 2pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">1038 m<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">2</sup></div></td></tr><tr><td style="width: 46.15%; text-align: left; vertical-align: top; padding-top: 2pt; padding-bottom: 2pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2pt; padding-bottom: 2pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2pt; padding-bottom: 2pt;">&#8203;</td><td style="width: 24.36%; text-align: left; vertical-align: top; padding-top: 2pt; padding-bottom: 2pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2pt; padding-bottom: 2pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2pt; padding-bottom: 2pt;">&#8203;</td><td style="width: 24.36%; text-align: left; vertical-align: top; padding-top: 2pt; padding-bottom: 2pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 46.15%; text-align: left; vertical-align: top; padding-top: 2pt; padding-bottom: 2pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">42 New Road <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">London, E1 2AX <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">United Kingdom</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2pt; padding-bottom: 2pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2pt; padding-bottom: 2pt;">&#8203;</td><td style="width: 24.36%; text-align: left; vertical-align: top; padding-top: 2pt; padding-bottom: 2pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Office and laboratory</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2pt; padding-bottom: 2pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2pt; padding-bottom: 2pt;">&#8203;</td><td style="width: 24.36%; text-align: left; vertical-align: top; padding-top: 2pt; padding-bottom: 2pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">284 m<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">2</sup></div></td></tr><tr><td style="width: 46.15%; text-align: left; vertical-align: top; padding-top: 2pt; padding-bottom: 2pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2pt; padding-bottom: 2pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2pt; padding-bottom: 2pt;">&#8203;</td><td style="width: 24.36%; text-align: left; vertical-align: top; padding-top: 2pt; padding-bottom: 2pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2pt; padding-bottom: 2pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2pt; padding-bottom: 2pt;">&#8203;</td><td style="width: 24.36%; text-align: left; vertical-align: top; padding-top: 2pt; padding-bottom: 2pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 46.15%; text-align: left; vertical-align: top; padding-top: 2pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">1510 Fashion Island Boulevard, Suite 205 <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">San Mateo, California 94404 <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">United States</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2pt;">&#8203;</td><td style="width: 24.36%; text-align: left; vertical-align: top; padding-top: 2pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Office</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2pt;">&#8203;</td><td style="width: 24.36%; text-align: left; vertical-align: top; padding-top: 2pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">390 m<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">2</sup></div></td></tr></table><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">We are not aware of any environmental issues or other constraints that would materially impact the intended use of our facilities.</div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 20.5pt; margin-left: 0pt; text-align: left;">Employees</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">As of September 1, 2020, we had 179 employees, 129 of whom have an advanced academic degree (Diploma/Master, D.Phil., Ph.D., M.D.). As of September 1, 2020, 122 of our employees were located in the United States, 26 in Switzerland and 31 in the United Kingdom. We are not subject to collective bargaining agreements or similar labor contracts and do not have a workers&#8217; council. We believe that our relationship with our employees is good.</div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 20.5pt; margin-left: 0pt; text-align: left;">Legal Proceedings</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">From time to time, we may be subject to various legal proceedings and claims that arise in the ordinary course of our business activities. The results of litigation and claims cannot be predicted with certainty. As of the date of this prospectus, we do not believe that we are party to any claim or litigation, the outcome of which would, individually or in the aggregate, be reasonably expected to have a material adverse effect on our business.</div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 36pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">189<br></div></div></div>
<!--End Page 193-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 194-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 540pt;"><a name="nt10014672x1_drs_108-management_pg1"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="block-frill" style="width: 540pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: Arial, Helvetica, sans-serif; font-size: 9pt; font-weight: bold; margin-top: 6pt; text-align: center;">Confidential Treatment Requested by ADC Therapeutics SA Pursuant to 17 C.F.R. &#167; 200.83<br></div></div><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 36pt;"><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: center;"><a name="tM"><!--Anchor--></a>MANAGEMENT</div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 15pt; margin-left: 0pt; text-align: left;">Executive Officers and Board of Directors</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The following table presents information about our current executive officers and directors. The term of each of our directors is one year and, accordingly, will expire at our annual general meeting of shareholders to be held in 2021. Ages are as of September 1, 2020.</div><table cellspacing="0" cellpadding="0" class="fintab" style="margin-top: 11.25pt; border-collapse: collapse; width: 468pt; margin-left: auto; margin-right: auto;"><tr class="header"><td style="width: 30.77%; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Name</div></td><td class="gutter" style="width: 1.28%; font-size: 2pt; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.28%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 53.85%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Position(s)</div></td><td class="gutter" style="width: 1.28%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.28%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 10.26%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Age</div></td></tr><tr><td style="width: 30.77%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Executive Officers and Directors <br></div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 53.85%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.26%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 30.77%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Christopher Martin<font style="padding-left: 3.75pt;"></font></div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 53.85%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Chief Executive Officer and Director</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 10.26%; text-align: center; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">62</div></td></tr><tr><td style="width: 30.77%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Michael Forer<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(1)</sup><font style="padding-left: 0.01pt;"></font></div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 53.85%; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: justify;">Executive Vice President and Vice&#160;Chairman of the Board of Directors</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.26%; text-align: center; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">55</div></td></tr><tr><td style="width: 30.77%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Jennifer Creel<font style="padding-left: 4.31pt;"></font></div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 53.85%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Chief Financial Officer</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 10.26%; text-align: center; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">49</div></td></tr><tr><td style="width: 30.77%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Jay Feingold<font style="padding-left: 4.29pt;"></font></div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 53.85%; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: justify;">Senior Vice President, Chief Medical Officer &amp; Head of Oncology</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.26%; text-align: center; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">64</div></td></tr><tr><td style="width: 30.77%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Dominique Graz<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(1)</sup></div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 53.85%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">General Counsel and Company Secretary</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 10.26%; text-align: center; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">59</div></td></tr><tr><td style="width: 30.77%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Peter Greaney<font style="padding-left: 3.76pt;"></font></div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 53.85%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Head of Corporate Development</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.26%; text-align: center; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">41</div></td></tr><tr><td style="width: 30.77%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Jennifer Herron<font style="padding-left: 2.65pt;"></font></div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 53.85%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Senior Vice President, Chief Commercial Officer</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 10.26%; text-align: center; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">50</div></td></tr><tr><td style="width: 30.77%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Richard Onyett<font style="padding-left: 4.3pt;"></font></div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 53.85%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Vice President, Business Development</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.26%; text-align: center; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">73</div></td></tr><tr><td style="width: 30.77%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Kimberly Pope<font style="padding-left: 4.85pt;"></font></div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 53.85%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Senior Vice President, Chief Human Resources Officer</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 10.26%; text-align: center; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">54</div></td></tr><tr><td style="width: 30.77%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Susan Romanus<font style="padding-left: 1.51pt;"></font></div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 53.85%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Chief Compliance Officer</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.26%; text-align: center; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">55</div></td></tr><tr><td style="width: 30.77%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Robert A. Schmidt<font style="padding-left: 0.12pt;"></font></div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 53.85%; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: justify;">Vice President, Corporate Controller &amp; Chief Accounting Officer</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 10.26%; text-align: center; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">43</div></td></tr><tr><td style="width: 30.77%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Patrick van Berkel<font style="padding-left: 0.42pt;"></font></div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 53.85%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Senior Vice President, Research and Development</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.26%; text-align: center; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">52</div></td></tr><tr><td style="width: 30.77%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Non-Executive Directors<br></div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 53.85%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 10.26%; text-align: center; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 30.77%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Ron Squarer<font style="padding-left: 0.41pt;"></font></div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 53.85%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Chairman of the Board of Directors</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.26%; text-align: center; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">53</div></td></tr><tr><td style="width: 30.77%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Peter B. Corr<font style="padding-left: 1.8pt;"></font></div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 53.85%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Director</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 10.26%; text-align: center; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">72</div></td></tr><tr><td style="width: 30.77%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Stephen Evans-Freke<font style="padding-left: 0.42pt;"></font></div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 53.85%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Director</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.26%; text-align: center; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">68</div></td></tr><tr><td style="width: 30.77%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Peter Hug<font style="padding-left: 0.41pt;"></font></div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 53.85%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Director</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 10.26%; text-align: center; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">61</div></td></tr><tr><td style="width: 30.77%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Thomas Pfisterer<font style="padding-left: 2.09pt;"></font></div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 53.85%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Director</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.26%; text-align: center; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">38</div></td></tr><tr><td style="width: 30.77%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Thomas M. Rinderknecht<font style="padding-left: 2.36pt;"></font></div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 53.85%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Director</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 10.26%; text-align: center; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">66</div></td></tr><tr><td style="width: 30.77%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Tyrell J. Rivers<font style="padding-left: 3.61pt;"></font></div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 53.85%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Director</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.26%; text-align: center; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">47</div></td></tr><tr><td style="width: 30.77%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Victor Sandor<font style="padding-left: 4.9pt;"></font></div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 53.85%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Director</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 10.26%; text-align: center; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">54</div></td></tr><tr><td style="width: 30.77%; text-align: left; vertical-align: top; padding-top: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Jacques Theurillat<font style="padding-left: 2.82pt;"></font></div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 53.85%; text-align: left; vertical-align: top; padding-top: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Director</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.26%; text-align: center; vertical-align: top; padding-top: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">60</div></td></tr></table><div><div class="rule-partial" style="height: 0pt; width: 72pt; border-bottom: 1pt solid #000000; margin-bottom: 1pt; margin-right: auto; margin-left: 0pt; margin-top: 12.75pt;"> </div></div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 3pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">(1)<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; text-align: left;">Mr. Graz has notified us of his decision to resign as General Counsel and Secretary to pursue a new opportunity, effective September&#160;30, 2020. Mr. Forer will, in addition to his current positions, assume the General Counsel role effective October 1, 2020.</div></td></tr></table><div class="ftnote" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 3pt; margin-left: 0pt; text-align: left;">Unless otherwise indicated, the current business address for our executive officers and directors and our non-executive directors is ADC Therapeutics SA, Biop&#244;le, Route de la Corniche 3B, 1066 Epalinges, Switzerland.</div><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 15pt; margin-left: 0pt; text-align: left;">Executive Officers and Executive Officer Nominees</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Christopher Martin<font style="font-weight: normal;">,</font> D.Phil.<font style="font-weight: normal;">, has been an Executive Director of our board of directors since our formation </font><font style="font-weight: normal;">and has been our Chief Executive Officer since June 2015. From 2000 to 2013, Dr. Martin was co-founder and </font><font style="font-weight: normal;">Chief Executive Officer of Spirogen, which was acquired by AstraZeneca plc in 2013, at which point he became </font><font style="font-weight: normal;">a member of both MedImmune&#8217;s management leadership team and AstraZeneca plc&#8217;s senior leaders group. Prior </font><font style="font-weight: normal;">to this acquisition, Dr. Martin led numerous Spirogen collaboration transactions, including agreements with </font><font style="font-weight: normal;">Genentech, Inc. and Seattle Genetics, Inc. He is currently a Non-Executive Chairman of Tokamak Energy Ltd. </font><font style="font-weight: normal;">Dr. Martin holds a B.Sc. in chemical engineering from Aston University, a D.Phil. in engineering science from </font><font style="font-weight: normal;">Oxford University and an M.B.A. from the International Institute for Management Development </font><font style="font-weight: normal;">Lausanne </font><font style="font-weight: normal;">and is </font><font style="font-weight: normal;">a Fellow of the Institution of Chemical Engineers.</font></div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Michael Forer<font style="font-weight: normal;">,</font> LL.B.<font style="font-weight: normal;">,</font><font style="font-weight: normal;"> has been Vice Chairman of our board of directors and our Executive Vice President</font><font style="font-weight: normal;"> </font><font style="font-weight: normal;">since June 2015</font><font style="font-weight: normal;">. From May 2016 to May 2020, Mr. Forer was</font><font style="font-weight: normal;"> </font><font style="font-weight: normal;">our </font><font style="font-weight: normal;">Chief Financial Officer</font><font style="font-weight: normal;">, and from</font><font style="font-weight: normal;"> our </font><font style="font-weight: normal;">formation to 2015, Mr.&#160;Forer was our Chief Executive Officer. From 2009 to 2013, Mr.&#160;Forer was a board </font></div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 36pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">190<br></div></div></div>
<!--End Page 194-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 195-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 540pt;"><a name="nt10014672x1_drs_108-management_pg2"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="block-frill" style="width: 540pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: Arial, Helvetica, sans-serif; font-size: 9pt; font-weight: bold; margin-top: 6pt; text-align: center;">Confidential Treatment Requested by ADC Therapeutics SA Pursuant to 17 C.F.R. &#167; 200.83<br></div></div><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 36pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">member and Executive Director of Spirogen. Previously, Mr.&#160;Forer was the Managing Director for the investment activities of Auven Therapeutics Holdings L.P. and the co-founder and Managing Director of Rosetta Capital Limited, after starting his career at Rothschild Asset Management. Mr.&#160;Forer holds a B.A. in economics from the University of Western Ontario, an LL.B. from the University of British Columbia and a Diploma in international business from the University of Copenhagen.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Jennifer Creel<font style="font-weight: normal;"> has been our Chief Financial Officer since May 2020. From 2008 to 2020, she served in </font><font style="font-weight: normal;">various senior positions at Celgene Corporation, including as Franchise Chief Financial Officer and Corporate </font><font style="font-weight: normal;">Vice President, Global Finance &amp; Business Planning, as Vice President of Finance, Hematology &amp; Oncology and </font><font style="font-weight: normal;">as Senior Director, Global Business Planning &amp; Analysis. Ms. Creel holds a B.A. in economics and French from </font><font style="font-weight: normal;">the College of William and Mary and an M.B.A. from the University of Virginia&#8217;s Darden Graduate School of </font><font style="font-weight: normal;">Business Administration.</font></div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Jay Feingold<font style="font-weight: normal;">,</font> M.D.<font style="font-weight: normal;">,</font> Ph.D.<font style="font-weight: normal;">, has been our Senior Vice President, Chief Medical Officer and Head of </font><font style="font-weight: normal;">Oncology Clinical Development since September 2014. From 2010 to 2014, he was Vice President of U.S. </font><font style="font-weight: normal;">Medical Affairs and Chairman of the Global Medical Affairs Oversight Committee at Daiichi Sankyo Company, </font><font style="font-weight: normal;">Ltd. From 2007 to 2010, Dr. Feingold was Vice President of Global Oncology Clinical Development and Global </font><font style="font-weight: normal;">Therapy Area Director of Oncology at Wyeth Pharmaceuticals, Inc. Dr. Feingold holds a B.S. in biology from </font><font style="font-weight: normal;">Stony Brook University and an M.D. and Ph.D. from the Albert Einstein College of Medicine and was trained in </font><font style="font-weight: normal;">pediatrics and pediatric hematology and oncology at the University of California Los Angeles Center for the </font><font style="font-weight: normal;">Health Sciences.</font></div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Dominique Graz, Dr. iur.<font style="font-weight: normal;">, has been our General Counsel and Company Secretary since April 2018. From </font><font style="font-weight: normal;">2016 to 2018, Mr. Graz was an independent counsel at Python. From 2003 to 2016, Mr. Graz was the group </font><font style="font-weight: normal;">general counsel and secretary to the board of Firmenich International SA. Mr. Graz holds a master in law and a </font><font style="font-weight: normal;">Dr. iur. from the University of Lausanne and is admitted to the bar of the Canton of Vaud, Switzerland.</font></div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Peter Greaney, Ph.D.<font style="font-weight: normal;">, has been our Head of Corporate Development since September 2018. From 2006 to </font><font style="font-weight: normal;">2018, he served in various positions at Celgene Corporation, including as Director of Business Development, </font><font style="font-weight: normal;">Strategy and Operations and Associate Director of Business Development. Dr. Greaney holds a B.S. in cell </font><font style="font-weight: normal;">biology from the University of East Anglia and a Ph.D. in molecular and cellular biology from the University of </font><font style="font-weight: normal;">Nottingham.</font></div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Jennifer Herron<font style="font-weight: normal;"> has been our Senior Vice President, Chief Commercial Officer since November&#160;2019. In </font><font style="font-weight: normal;">2019, she served as Executive Vice President and Chief Commercial Officer at ImmunoGen, Inc. In 2018, she </font><font style="font-weight: normal;">served as Executive Vice President, Global Commercial, at MorphoSys AG. From 2016 to 2017, she served as </font><font style="font-weight: normal;">Executive Vice President and Chief Commercial Officer at Ariad Pharmaceuticals, Inc. From 2006 to 2016, she </font><font style="font-weight: normal;">served in various positions at Bristol-Myers Squibb Company, including as Vice President, U.S.&#160;Immunology. </font><font style="font-weight: normal;">Ms. Herron holds a B.A. in biology </font><font style="font-weight: normal;">and economics </font><font style="font-weight: normal;">from Lehigh University and an M.B.A. from Georgetown </font><font style="font-weight: normal;">University.</font><font style="font-weight: normal;"> </font></div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Richard Onyett<font style="font-weight: normal;"> has been our Vice President of Business Development since April 2014. From </font><font style="font-weight: normal;">July 2006</font><font style="font-weight: normal;"> to </font><font style="font-weight: normal;">January 2012</font><font style="font-weight: normal;">, Mr.&#160;Onyett was the Commercial Director at Spirogen</font><font style="font-weight: normal;"> Limited and Commercial Director at Oxogen </font><font style="font-weight: normal;">Limited</font><font style="font-weight: normal;">. </font><font style="font-weight: normal;">Previously,</font><font style="font-weight: normal;"> he was Senior Vice President of Business Development of KuDOS Pharmaceuticals Limited</font><font style="font-weight: normal;">, </font><font style="font-weight: normal;">Senior Vice President of Corporate Development at Epidauros GmbH</font><font style="font-weight: normal;"> and</font><font style="font-weight: normal;"> Senior Vice President of Corporate </font><font style="font-weight: normal;">Development at Anthra Pharmaceuticals Inc. Mr.&#160;Onyett holds a B.Sc. in biological sciences from the University </font><font style="font-weight: normal;">of Nottingham and a M.Sc. in general virology from the University of Birmingham.</font><font style="font-weight: normal;"> </font></div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Kimberly Pope<font style="font-weight: normal;"> has been our </font><font style="font-weight: normal;">Senior Vice President, Chief Human Resources Officer since August 2020. </font><font style="font-weight: normal;">From 2016 to 2020, Ms. Pope was the Senior Vice President, Head of Human Resources at Array BioPharma </font><font style="font-weight: normal;">Inc. From 2013 to 2016, Ms. Pope was the Group Vice President, Human Resources at IDEX Corporation. </font><font style="font-weight: normal;">Previously, Ms. Pope served in various senior positions at Hospira, Inc., including Director of Human Resources. </font><font style="font-weight: normal;">Ms. Pope holds a B.B.A. in marketing and human resources management from the University of Iowa Tippie </font><font style="font-weight: normal;">College of Busines</font><font style="font-weight: normal;">.</font></div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 36pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">191<br></div></div></div>
<!--End Page 195-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 196-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 540pt;"><a name="nt10014672x1_drs_108-management_pg3"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="block-frill" style="width: 540pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: Arial, Helvetica, sans-serif; font-size: 9pt; font-weight: bold; margin-top: 6pt; text-align: center;">Confidential Treatment Requested by ADC Therapeutics SA Pursuant to 17 C.F.R. &#167; 200.83<br></div></div><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 36pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Susan Romanus<font style="font-weight: normal;"> has been our Chief Compliance Officer since June 2018. From 2015 to 2018, she served </font><font style="font-weight: normal;">as Vice President, Compliance at Taiho Oncology, Inc. From 2009 to 2012, she served as Vice President, Chief </font><font style="font-weight: normal;">Ethics &amp; Compliance Officer at Daiichi Sankyo Company. Ms.&#160;Romanus holds a B.S. in biochemistry and cell </font><font style="font-weight: normal;">biology</font><font style="font-weight: normal;"> from the University of California San Diego</font><font style="font-weight: normal;"> and an M.B.A. from the University of </font><font style="font-weight: normal;">San Diego and a </font><font style="font-weight: normal;">certificate in change leadership from Cornell University.</font></div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Robert A. Schmidt<font style="font-weight: normal;"> has been our Vice President, Corporate Controller and Chief Accounting Officer since </font><font style="font-weight: normal;">August 2020. From 2019 to 2020, Mr. Schmidt was the Senior Vice President and Chief Accounting Officer at </font><font style="font-weight: normal;">Newell Brands Inc. From 2016 to 2019, Mr. Schmidt was the Assistant Corporate Controller at Celgene </font><font style="font-weight: normal;">Corporation. Previously, Mr. Schmidt served in various senior positions, including Vice President and Controller, </font><font style="font-weight: normal;">at Tyco International plc. Mr. Schmidt holds a B.A. in accounting and economics from Muhlenberg College.</font></div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Patrick van Berkel, Ph.D.<font style="font-weight: normal;">, has been our Senior Vice President of Research &amp; Development since August </font><font style="font-weight: normal;">2012. From 2003 to 2012, Dr. van Berkel served in various roles at Genmab A/S, including as Vice President of </font><font style="font-weight: normal;">Antibody Technology and Vice President of Chemistry, Manufacturing and Control, Research and Development </font><font style="font-weight: normal;">and as Director of Technology for the Antibody Technology division. Dr. van Berkel holds a B.S. in chemistry </font><font style="font-weight: normal;">from the University of Nijmegen and a Ph.D. in chemistry from the University of Leiden.</font></div><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 20.5pt; margin-left: 0pt; text-align: left;">Non-Executive Directors </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Ron Squarer<font style="font-weight: normal;"> has been the Chairman of our board of directors since April 2020. From 2012 to its </font><font style="font-weight: normal;">acquisition by Pfizer, Inc. in August 2019, he served as the Chief Executive Officer at Array BioPharma Inc. </font><font style="font-weight: normal;">Previously, Mr. Squarer served in various senior positions at Hospira, Inc., which was later acquired by Pfizer, </font><font style="font-weight: normal;">Inc., including as Chief Commercial Officer</font><font style="font-weight: normal;">. In addition, Mr. Squarer has held leadership roles </font><font style="font-weight: normal;">at Pfizer Inc. </font><font style="font-weight: normal;">(focused on oncology) </font><font style="font-weight: normal;">and at SmithKline Beecham Pharmaceuticals (now GlaxoSmithKline plc). In addition to </font><font style="font-weight: normal;">our board of directors, Mr. Squarer also serves as a member of the board of directors of Deciphera </font><font style="font-weight: normal;">Pharmaceuticals, Inc. and Retrophin, Inc. Mr. Squarer holds a B.S. in biochemistry from the University of </font><font style="font-weight: normal;">California, Berkeley, and an M.B.A. from Northwestern University&#8217;s Kellogg School of Management.</font></div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Peter B. Corr<font style="font-weight: normal;">,</font> M.D.<font style="font-weight: normal;">,</font> Ph.D.<font style="font-weight: normal;">, has been </font><font style="font-weight: normal;">a Non-Executive Director</font><font style="font-weight: normal;"> of our board of directors since June 2011</font><font style="font-weight: normal;"> </font><font style="font-weight: normal;">and was the Chairman of our board of directors from June 2011 to April 2020</font><font style="font-weight: normal;">. He is the co-founder and </font><font style="font-weight: normal;">Managing General Partner of Auven Therapeutics Management L.L.L.P. From 2000 to 2006, he held various </font><font style="font-weight: normal;">senior positions at Pfizer Inc., including Executive Vice President for Science and Technology, Executive Vice </font><font style="font-weight: normal;">President for Global Research and Development and President for Worldwide Development. In addition to our </font><font style="font-weight: normal;">board of directors, Dr. Corr also serves as </font><font style="font-weight: normal;">Co-Founder and</font><font style="font-weight: normal;"> Chairman of the board of directors of Imvax Inc. and </font><font style="font-weight: normal;">as a member of the board of directors of Analytica Limited. Dr. Corr holds a </font><font style="font-weight: normal;">B.S. in pharmacy from Albany </font><font style="font-weight: normal;">College of Pharmacy and Health Sciences</font><font style="font-weight: normal;"> and </font><font style="font-weight: normal;">an M.D. and</font><font style="font-weight: normal;"> Ph.D. </font><font style="font-weight: normal;">from Georgetown University School of </font><font style="font-weight: normal;">Medicine.</font></div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Stephen Evans-Freke<font style="font-weight: normal;">,</font> LL.B.<font style="font-weight: normal;">, has been a Non-Executive Director of our board of directors since June 2011. </font><font style="font-weight: normal;">He is the co-founder and Managing General Partner of Auven Therapeutics Management L.L.L.P. </font><font style="font-weight: normal;">Mr.&#160;Evans-Freke was also the co-founder, Chairman and Chief Executive Officer of Sugen, Inc. until its sale to </font><font style="font-weight: normal;">Pharmacia Corporation. Previously, Mr.&#160;Evans-Freke was the President of PaineWebber Development </font><font style="font-weight: normal;">Corporation, Managing Director of BliteEastman PaineWebber Inc. and a member of the board of directors of </font><font style="font-weight: normal;">PaineWebber, Inc. In addition, he was the co-founder of CIBUS Global LLC, Fibrogen, Inc. and Royalty Pharma </font><font style="font-weight: normal;">AG. Mr.&#160;Evans-Freke holds a</font><font style="font-weight: normal;">n</font><font style="font-weight: normal;"> LL.B. from Cambridge University.</font></div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Peter Hug<font style="font-weight: normal;">,</font> Ph.D.<font style="font-weight: normal;">, has been a Non-Executive Director of our board of directors since June 2019. From 1983 </font><font style="font-weight: normal;">to 2018, Dr. Hug served in various positions at F. Hoffmann-La Roche Ltd., including as head of Roche Pharma </font><font style="font-weight: normal;">EEMEA region, head of Roche Pharma Europe region and Executive Vice President of Roche Pharma Partnering. </font><font style="font-weight: normal;">In addition to our board of directors, Dr. Hug also serves as a member of the board of directors of </font><font style="font-weight: normal;">Swiss Post </font><font style="font-weight: normal;">Ltd. Dr. Hug holds </font><font style="font-weight: normal;">a Ph.D. in economics from the University of Basel.</font></div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Thomas Pfisterer<font style="font-weight: normal;"> has been a Non-Executive Director of our board of directors since October 2016. Since </font><font style="font-weight: normal;">2015, Mr.&#160;Pfisterer has headed the direct investment activities of the WILD Family Office. From 2011 to 2015, </font><font style="font-weight: normal;">Mr.&#160;Pfisterer served as the head of strategic development of WILD Flavors GmbH, where he directed the </font><font style="font-weight: normal;">company&#8217;s global M&amp;A activities. </font><font style="font-weight: normal;">Previously, Mr. Pfisterer also worked in the investment banking division of </font></div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 36pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">192<br></div></div></div>
<!--End Page 196-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 197-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 540pt;"><a name="nt10014672x1_drs_108-management_pg4"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="block-frill" style="width: 540pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: Arial, Helvetica, sans-serif; font-size: 9pt; font-weight: bold; margin-top: 6pt; text-align: center;">Confidential Treatment Requested by ADC Therapeutics SA Pursuant to 17 C.F.R. &#167; 200.83<br></div></div><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 36pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">Morgan Stanley Bank AG. In addition to our board of directors, Mr.&#160;Pfisterer also serves as a Non-Executive Director of Sermonix Pharmaceuticals Inc., InSphero AG, Stade Fran&#231;ais Paris SASP and Imvax Inc. Mr.&#160;Pfisterer holds a B.A. in economics and a B.A. in administration finance from the University of St. Gallen and an M.Phil. in finance from Cambridge University.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Thomas M. Rinderknecht<font style="font-weight: normal;">,</font> Ph.D.<font style="font-weight: normal;">, has been a Non-Executive director of our board of directors since May </font><font style="font-weight: normal;">2016. Since 2008, Dr. Rinderknecht has been a senior partner at the law firm Badertscher Rechtsanw&#228;lte AG. In </font><font style="font-weight: normal;">addition to our board of directors, Dr. Rinderknecht also serves as a member of the board of directors of </font><font style="font-weight: normal;">Chocoladefabriken Lindt &amp; Spr&#252;ngli AG, Canyon Pharmaceuticals AG, APR Applied Pharma Research SA and </font><font style="font-weight: normal;">several other firms in the media, hotel and industry sectors. Dr. Rinderknecht holds a </font><font style="font-weight: normal;">master</font><font style="font-weight: normal;">s</font><font style="font-weight: normal;"> in law</font><font style="font-weight: normal;"> and a Ph.D. </font><font style="font-weight: normal;">in law from the University of Zurich and is admitted to the bar of the Canton of Zug, Switzerland.</font></div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Tyrell J. Rivers<font style="font-weight: normal;">,</font> Ph.D.<font style="font-weight: normal;">, has been a Non-Executive Director of our board of directors since June 2018. Since </font><font style="font-weight: normal;">2014, Dr. Rivers has been an Executive Director within AstraZeneca&#8217;s Corporate Development Group</font><font style="font-weight: normal;">. From </font><font style="font-weight: normal;">2009 to 2014, Dr. Rivers</font><font style="font-weight: normal;"> was at MedImmune Ventures specializing in biotechnology investing</font><font style="font-weight: normal;">. In addition to our </font><font style="font-weight: normal;">board of directors, Dr. Rivers also serves as a member of the board of directors of Armaron Bio Ltd, Cerapedics, </font><font style="font-weight: normal;">Inc., Corvidia Therapeutics, Inc. and Viela Bio, Inc. Dr. Rivers holds a B.S. in chemical engineering from the </font><font style="font-weight: normal;">Massachusetts Institute of Technology, </font><font style="font-weight: normal;">an</font><font style="font-weight: normal;"> </font><font style="font-weight: normal;">M.S. in engineering from the University of Texas at Austin</font><font style="font-weight: normal;">, an M.B.A. </font><font style="font-weight: normal;">from New York University Stern School of Business and a Ph.D. in chemical engineering from the University of </font><font style="font-weight: normal;">Texas at Austin.</font></div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Victor Sandor, M.D. C.M.<font style="font-weight: normal;">, has been a Non-Executive Director of our board of directors since April 2020. </font><font style="font-weight: normal;">From 2014 to its acquisition by Pfizer, Inc. in August 2019, he served as the Chief Medical Officer at Array </font><font style="font-weight: normal;">BioPharma Inc. Previously, Dr. Sandor served in various senior positions at Incyte Corporation, including as </font><font style="font-weight: normal;">Senior Vice President of Global Clinical Development, at Biogen Idec, including as Vice President and Chief </font><font style="font-weight: normal;">Medical Officer, and at AstraZeneca plc. In addition to our board of directors, Dr. Sandor also serves as a </font><font style="font-weight: normal;">member of the board of directors of Merus N.V. and Istari Oncology, Inc. Dr. Sandor holds a M.D. C.M from </font><font style="font-weight: normal;">McGill University.</font></div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Jacques Theurillat<font style="font-weight: normal;">,</font> LL.B.<font style="font-weight: normal;">, has been a Non-Executive Director of our board of directors since July 2015. </font><font style="font-weight: normal;">Since 2016, he has been a partner at the Sofinnova Crossover Fund. From 2008 to 2015, Mr.&#160;Theurillat served as </font><font style="font-weight: normal;">the Chief Executive Officer of Ares Life Sciences AG. Previously, Mr.&#160;Theurillat was the Chief Financial Officer </font><font style="font-weight: normal;">of Serono S.A. In addition to our board of directors, Mr.&#160;Theurillat also serves as a member of the board of </font><font style="font-weight: normal;">directors of Vifor Pharma AG, </font><font style="font-weight: normal;">Mundipharma</font><font style="font-weight: normal;"> Ltd and CNH Industrial N.V. Mr.&#160;Theurillat holds an LL.B. from </font><font style="font-weight: normal;">both Madrid University and Geneva University, an M.B.A. from Centro Estudios Financieros and a Swiss federal </font><font style="font-weight: normal;">diploma in tax.</font></div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 14.5pt; margin-left: 0pt; text-align: left;">Board Composition and Election of Directors</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Our board of directors is composed of 11 members. Each director is elected for a one-year term. The current members of our board of directors were appointed at our shareholders&#8217; meeting on April&#160;24, 2020 to serve until our annual general meeting of shareholders in 2021.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">We are a foreign private issuer under the rules of the SEC. As a result, in accordance with the NYSE listing standards, we rely on home country governance requirements and certain exemptions there under rather than on the stock exchange corporate governance requirements, including the requirement that within one year of the completion of this offering we have a board that is composed of a majority of independent directors. There are no family relationships among any of our directors or executive officers. For an overview of our corporate governance principles, see &#8220;Description of Share Capital and Articles of Association.&#8221;</div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 14.5pt; margin-left: 0pt; text-align: left;">Committees of the Board of Directors</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Our board of directors has established four separate committees: an audit committee, a compensation committee, a nomination and corporate governance committee and a science and technology committee.</div><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 15pt; margin-left: 0pt; text-align: left;">Audit Committee</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The audit committee, which consists of Jacques Theurillat (chair), Stephen Evans-Freke and Thomas M. Rinderknecht, assists our board of directors in overseeing our accounting and financial reporting processes and the audits of our consolidated financial statements. In addition, the audit committee is directly responsible for the </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 36pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">193<br></div></div></div>
<!--End Page 197-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 198-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 540pt;"><a name="nt10014672x1_drs_108-management_pg5"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="block-frill" style="width: 540pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: Arial, Helvetica, sans-serif; font-size: 9pt; font-weight: bold; margin-top: 6pt; text-align: center;">Confidential Treatment Requested by ADC Therapeutics SA Pursuant to 17 C.F.R. &#167; 200.83<br></div></div><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 36pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">compensation, retention and oversight of the work of our independent registered public accounting firm that our shareholders elect as our external auditors. The audit committee consists exclusively of members of our board of directors who are financially literate, and each of Jacques Theurillat, Stephen&#160;Evans-Freke and Thomas M. Rinderknecht is considered an &#8220;audit committee financial expert&#8221; as defined by the SEC. Our audit committee complies with Rule 10A-3(b)(1) of the Exchange Act, taking into account applicable transition periods under Rule 10A-3(b)(1)(iv)(A). Our board of directors has determined that each of Jacques Theurillat and Thomas M. Rinderknecht satisfies the &#8220;independence&#8221; requirements set forth in Rule 10A-3 under the Exchange Act. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The audit committee is governed by a charter that complies with the NYSE listing standards that apply to us. The audit committee has the responsibility to, among other things:</div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">pre-approve the audit services and non-audit services (including the fees and terms thereof) to be provided by the independent auditor pursuant to pre-approval policies and procedures;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">evaluate the independent auditor&#8217;s qualifications, performance and independence, and present its conclusions with respect to the independent auditor to the board of directors on at least an annual basis;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">confirm and evaluate the rotation of the audit partners on the audit engagement team as required by law;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">at least annually, review management&#8217;s plans with respect to the responsibilities, budget and staffing of the internal audit function and its plans for the implementation of the internal audit function, if any;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">review and discuss with management and the independent auditor the annual audited consolidated and stand-alone financial statements and unaudited quarterly financial statements;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">review with management, personnel responsible for the design and implementation of the internal audit function and the independent auditor (i) any analyses or other written communications prepared by management and/or the independent auditor setting forth significant financial reporting issues and judgments made in connection with the preparation of the financial statements, (ii) the Company&#8217;s critical accounting policies and practices, (iii) the effect of regulatory and accounting initiatives, as well as off-balance sheet transactions and structures, on the Company&#8217;s financial statements and (iv) any major issues regarding accounting principles and financial statement presentations;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">review the type and presentation of information included in the earnings press releases, as well as financial information and earnings guidance provided to analysts and rating agencies, and may review earnings press releases prior to public dissemination;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">in conjunction with the chief executive officer and chief financial officer, review disclosure controls and procedures and internal control over financial reporting;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">review policies and practices with respect to risk assessment and risk management; and</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">review any major litigation or investigations against the Company that may have a material impact on the Company&#8217;s financial statements.</div></td></tr></table><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The audit committee meets as often as it determines is appropriate to carry out its responsibilities, but in any event will meet at least four times per year. </div><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 20pt; margin-left: 0pt; text-align: left;">Compensation Committee</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The compensation committee, which consists of Peter Hug (chair), Peter B. Corr and Stephen&#160;Evans-Freke, supports our board of directors in establishing and reviewing the compensation and benefits strategy and guidelines as well as in preparing the proposals to the annual general meeting of shareholders regarding the compensation of the members of the board of directors and the executive officers. The compensation committee may submit proposals to the board of directors on other compensation-related matters. Swiss law requires that we have a compensation committee, so in accordance with NYSE listing standards, we follow home country requirements with respect to the compensation committee. As a result, our practice varies from NYSE listing standards, which set forth certain requirements as to the responsibilities, composition and independence of compensation committees for domestic issuers. Swiss law requires that our board of directors submit the aggregate amount of compensation of all members of our board of directors and of all executive officers to a binding shareholder vote every year and for the first time at our annual general meeting of shareholders in 2021. </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 36pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">194<br></div></div></div>
<!--End Page 198-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 199-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 540pt;"><a name="nt10014672x1_drs_108-management_pg6"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="block-frill" style="width: 540pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: Arial, Helvetica, sans-serif; font-size: 9pt; font-weight: bold; margin-top: 6pt; text-align: center;">Confidential Treatment Requested by ADC Therapeutics SA Pursuant to 17 C.F.R. &#167; 200.83<br></div></div><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 36pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">Commencing with our annual general meeting of shareholders in 2021, the members of the compensation committee will be elected by our annual general meeting of shareholders. The board of directors will appoint the chair of the compensation committee and fill any vacancies until the following annual general meeting of shareholders.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The compensation committee has the responsibility to, among other things:</div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">regularly review and make recommendations to the board of directors regarding our compensation and benefits strategy and guidelines;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">prepare the proposals to the shareholders&#8217; meeting regarding the compensation of the members of the board of directors and the executive committee;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">regularly review and make recommendations to the board of directors regarding the compensation of the members of the board of directors and of the executive committee;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">review and approve the recommendation of our chief executive officer regarding the fixed and variable compensation, including incentive plan participation and benefits, of the members of the management team other than members of the executive committee; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">review and make recommendations to the board of directors regarding our compensation and benefits plans (cash and/or equity-based plans) and, where appropriate or required, make recommendations to adopt, amend and terminate such plans; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">to the extent not delegated by the compensation committee to a different body or a third party, administer our compensation and benefits plans (other than equity-based plans); and</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">review and assess risks arising from our employee compensation policies and practices and whether any such risks are reasonably likely to have a material adverse effect on us.</div></td></tr></table><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 20pt; margin-left: 0pt; text-align: left;">Nomination and Corporate Governance Committee</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The nomination and corporate governance committee, which consists of Stephen Evans-Freke (chair), Peter Hug and Thomas M. Rinderknecht, is responsible for director and board committee nominations, succession planning, performance evaluation and reviewing and amending, if required, our corporate governance framework and guidelines. The members of the nomination and corporate governance committee and its chair are appointed by our board of directors.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The nomination and corporate governance committee has the responsibility to, among other things:</div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">determine selection criteria for the succession of the members of the board of directors and board committees, our chief executive officer, our chief financial officer and our executive vice president, and establish such succession planning (including for the event of the incapacitation, retirement or removal of such individuals) by making recommendations to the board of directors; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">oversee searches and identify qualified individuals for membership on the board of directors and for the position of chief executive officer; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">recommend individuals for membership on the board of directors and board committees and for the position of chief executive officer; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">at least annually, prepare the board of directors&#8217; assessment of the performance of the board of directors and board committees and of our chief executive officer and review the recommendations of the other board committees based on their evaluation of their own performance; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">review the recommendations of the other board committees based on their self-evaluations and discuss its self-evaluation with the board of directors; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">monitor and assess developments and trends in corporate governance to the extent that these do not have an impact on the activities and tasks of the audit and finance committee or the compensation committee; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">review proposals to be made to the board of directors for the amendment of our articles of association, our organizational regulations, any other rules or regulations and the Code of Conduct; </div></td></tr></table></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 36pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">195<br></div></div></div>
<!--End Page 199-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 200-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 540pt;"><a name="nt10014672x1_drs_108-management_pg7"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="block-frill" style="width: 540pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: Arial, Helvetica, sans-serif; font-size: 9pt; font-weight: bold; margin-top: 6pt; text-align: center;">Confidential Treatment Requested by ADC Therapeutics SA Pursuant to 17 C.F.R. &#167; 200.83<br></div></div><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 36pt;"><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6.75pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">periodically review and reassess the adequacy of the Code of Conduct and recommend any proposed changes to the board of directors;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">periodically review and assess the adequacy of the charter of the nomination and corporate governance committee and recommend any proposed changes to the board of directors for approval; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">if it deems advisable, develop and recommend to the board of directors corporate governance guidelines for the Company, and, if such guidelines are adopted, periodically review and reassess the adequacy of such guidelines, consider any requests for waivers of such guidelines and make recommendations to the board of directors regarding amendments and requests for waivers; and </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">oversee compliance with the Code of Conduct and report on such compliance to the board of directors. </div></td></tr></table><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 16.5pt; margin-left: 0pt; text-align: left;">Science and Technology Committee</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The science and technology committee, which consists of Victor Sandor (chair), Peter B. Corr, Peter Hug and Tyrell J. Rivers, is responsible for reviewing and making recommendations to the board of directors regarding our research and development activities, strategies, programs and objectives. The members of the science and technology committee and its chair are appointed by our board of directors.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The science and technology committee has the responsibility to, among other things.</div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">review and make recommendations to the board of directors regarding our preclinical and clinical research and development activities, including related CMC activities;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">review and make recommendations to the board of directors regarding preclinical and clinical research and development strategies;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">review and make recommendations to the board of directors regarding our preclinical and clinical research guidelines;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">provide strategic advice to the board of directors regarding emerging science and technology issues and trends;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">examine periodically our measures to keep the research and development personnel motivated, productive and entrepreneurially oriented;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">ensure, through regular review and consultation with the Chief Executive Officer and his team, that appropriate research and development objectives are in place that are aligned with our overall research and development strategy, and that progress against these objectives is being appropriately assessed; and</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">ensure that appropriate market potential assessments are being conducted.</div></td></tr></table><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 16.5pt; margin-left: 0pt; text-align: left;">Code of Business Conduct and Ethics</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">We have adopted a Code of Business Conduct and Ethics (the &#8220;Code of Conduct&#8221;) that is applicable to all of our employees, executive officers and directors. The Code of Conduct is available on our website <font style="font-style: italic;">www.adctherapeutics.com.</font> Our board of directors is responsible for overseeing the Code of Conduct and is required to approve any waivers of the Code of Conduct. We expect that any amendments to the Code of Conduct, or any waivers of its requirements, will be disclosed in our annual report on Form 20-F. </div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 17pt; margin-left: 0pt; text-align: left;">Corporate Governance Practices</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">As a &#8220;foreign private issuer,&#8221; as defined by the SEC, we are permitted to follow home country corporate governance practices, instead of certain corporate governance standards required by the NYSE for U.S. companies. Accordingly, we follow Swiss corporate governance rules in lieu of certain of the NYSE&#8217;s corporate governance requirements. The significant differences between our Swiss corporate governance rules and the NYSE&#8217;s corporate governance requirements are set forth below:</div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">Exemption from the requirement that a majority of the board of directors be comprised of independent directors and that there be regularly scheduled meetings with only the independent directors present. Swiss law does not have such a requirement.</div></td></tr></table></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 36pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">196<br></div></div></div>
<!--End Page 200-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 201-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 540pt;"><a name="nt10014672x1_drs_108-management_pg8"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="block-frill" style="width: 540pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: Arial, Helvetica, sans-serif; font-size: 9pt; font-weight: bold; margin-top: 6pt; text-align: center;">Confidential Treatment Requested by ADC Therapeutics SA Pursuant to 17 C.F.R. &#167; 200.83<br></div></div><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 36pt;"><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6.75pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">Exemption from the requirements that the compensation committee and the nomination and corporate governance committee be comprised of independent directors. Swiss law does not have such requirements.</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">Exemption from quorum requirements applicable to meetings of shareholders. Swiss law does not require such quorum requirements.</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">Exemption from the requirement that independent directors meet at regularly scheduled executive sessions. Swiss law does not have such a requirement.</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">Exemption from the requirement that listed companies adopt and disclose corporate governance guidelines that cover certain minimum specified subjects related to director qualifications and responsibilities. Swiss law does not require the adoption or disclosure of such guidelines. </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">Exemption from the requirement to disclose within four business days of any determination to grant a waiver of the Code of Conduct to directors and executive officers. Although we will require approval by our board of directors for any such waiver, we may choose not to disclose the waiver in the manner set forth in the NYSE listing standards.</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">Exemption from the requirement to obtain shareholder approval for certain issuances of securities, including shareholder approval of share option plans. Our articles of association provide that our board of directors is authorized, in certain instances, to issue a certain number of common shares without re-approval by our shareholders. </div></td></tr></table><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 17pt; margin-left: 0pt; text-align: left;">Compensation of Directors and Executive Officers</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">For the year ended December&#160;31, 2019, the aggregate compensation paid to the members of our board of directors and our executive officers for services in all capacities, including retirement and similar benefits, was $6.0 million. Pursuant to Swiss law, beginning at our annual general meeting of shareholders in 2021, we will be required to submit the aggregate amount of compensation of our board of directors and the aggregate amount of compensation of our executive officers to a binding say-on-pay vote by our shareholders.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">We granted Mr. Squarer options to acquire 1,125,545 common shares at $18.75 per share in connection with his election to our board of directors, representing approximately 2% of our then-outstanding share capital. These options are scheduled to vest upon Mr. Squarer&#8217;s continued service through designated dates over a three-year period, or immediately upon a change in control. On June 4, 2020, we provided Mr. Squarer with an additional grant of options to aquire 341,403 common shares in connection with our initial public offering. These options were granted with an exercise price equal to the grant date fair market value of our common shares on that date, and brought Mr. Squarer&#8217;s total rights to acquire our common shares to 2% of our then-outstanding share capital (measured without consideration of the shares underlying these grants).</div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 17pt; margin-left: 0pt; text-align: left;">Equity Incentive Plans</div><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 7pt; margin-left: 0pt; text-align: left;">Prior Plans</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Historically, we granted equity compensation through (i)&#160;the ADC Therapeutics Ltd 2013 Share Purchase Plan (the &#8220;2013 Share Purchase Plan&#8221;), (ii)&#160;the ADC Therapeutics Ltd 2016 Share Purchase Plan (the &#8220;2016 Share Purchase Plan&#8221;) and (iii)&#160;the ADC Therapeutics Incentive Plan dated May&#160;1, 2014 and Amended and Restated as of October&#160;1, 2015 (the &#8220;2014 Incentive Plan&#8221;). Each of these plans is described in more detail below.</div><div class="h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 17pt; margin-left: 0pt; text-align: left;">2013 Share Purchase Plan</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">In September 2013, our board of directors established the 2013 Share Purchase Plan as a one-off plan pursuant to which select eligible participants directly or indirectly purchased common shares at a purchase price determined by the board of directors. Participants paid the par value of the common shares in cash and settled the balance between the purchase price and the par value in the form of a promissory note. The terms of the plan and the promissory notes are described in more detail below.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Promissory Notes. <font style="font-style: normal;">The promissory notes with respect to the 2013 Share Purchase Plan (the &#8220;2013 </font><font style="font-style: normal;">Promissory Notes&#8221;) </font><font style="font-style: normal;">were</font><font style="font-style: normal;"> full recourse, repayable within ten years (subject to certain early repayment events) and </font></div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 36pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">197<br></div></div></div>
<!--End Page 201-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 202-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 540pt;"><a name="nt10014672x1_drs_108-management_pg9"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="block-frill" style="width: 540pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: Arial, Helvetica, sans-serif; font-size: 9pt; font-weight: bold; margin-top: 6pt; text-align: center;">Confidential Treatment Requested by ADC Therapeutics SA Pursuant to 17 C.F.R. &#167; 200.83<br></div></div><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 36pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">bore interest at the minimum interest rate pursuant to the guidelines for related party transactions as published by the Swiss Federal Tax Authority. Certain plan participants previously purchased our shares with such promissory notes. The largest aggregate amount outstanding under these notes since the first issuance was $2.3&#160;million immediately prior to the repayment of these notes. All promissory notes were repaid on April 15, 2020 as described below.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Repayment of the Promissory Notes. <font style="font-style: normal;">Under the terms of the 2013 Promissory Notes, the relevant plan </font><font style="font-style: normal;">participant </font><font style="font-style: normal;">could</font><font style="font-style: normal;"> repay outstanding amounts under the promissory note at any time in cash or repay the principal </font><font style="font-style: normal;">amount in whole or in part by delivering such number of shares as required to cover the amount to be repaid. In </font><font style="font-style: normal;">connection with </font><font style="font-style: normal;">our initial public</font><font style="font-style: normal;"> offering, </font><font style="font-style: normal;">all plan participants</font><font style="font-style: normal;"> </font><font style="font-style: normal;">who held 2013 Promissory Notes </font><font style="font-style: normal;">or 2016 </font><font style="font-style: normal;">Promissory Notes (as described below)</font><font style="font-style: normal;"> </font><font style="font-style: normal;">entered </font><font style="font-style: normal;">into </font><font style="font-style: normal;">a </font><font style="font-style: normal;">loan </font><font style="font-style: normal;">settlement</font><font style="font-style: normal;"> </font><font style="font-style: normal;">agreement</font><font style="font-style: normal;"> with us (the &#8220;Loan </font><font style="font-style: normal;">Settlement</font><font style="font-style: normal;"> </font><font style="font-style: normal;">Agreements&#8221;)</font><font style="font-style: normal;"> </font><font style="font-style: normal;">on </font><font style="font-style: normal;">April 15</font><font style="font-style: normal;">, </font><font style="font-style: normal;">2020</font><font style="font-style: normal;"> </font><font style="font-style: normal;">pursuant to which they </font><font style="font-style: normal;">repaid</font><font style="font-style: normal;"> all amounts outstanding under the 2013 </font><font style="font-style: normal;">Promissory Notes </font><font style="font-style: normal;">and</font><font style="font-style: normal;"> the</font><font style="font-style: normal;"> 2016 Promissory Notes </font><font style="font-style: normal;">by delivering such number of </font><font style="font-style: normal;">common shares necessary to </font><font style="font-style: normal;">cover the entire amounts outstanding under the 2013 Promissory Notes</font><font style="font-style: normal;"> and the 2016 Promissory Notes</font><font style="font-style: normal;">. After </font><font style="font-style: normal;">consideration of all relevant factors, our board of directors determined the value of such surrendered shares </font><font style="font-style: normal;">as of </font><font style="font-style: normal;">the </font><font style="font-style: normal;">settlement date</font><font style="font-style: normal;"> </font><font style="font-style: normal;">to be </font><font style="font-style: normal;">$</font><font style="font-style: normal;">18.75</font><font style="font-style: normal;"> per common share</font><font style="font-style: normal;">, </font><font style="font-style: normal;">resulting in the surrender of</font><font style="font-style: normal;"> </font><font style="font-style: normal;">an aggregate of </font><font style="font-style: normal;">597,774</font><font style="font-style: normal;"> common shares </font><font style="font-style: normal;">for </font><font style="font-style: normal;">the </font><font style="font-style: normal;">settlement of the 2013 Promissory Notes and the 2016 Promissory Notes</font><font style="font-style: normal;">. In the </font><font style="font-style: normal;">Loan </font><font style="font-style: normal;">Settlement</font><font style="font-style: normal;"> </font><font style="font-style: normal;">Agreements, we </font><font style="font-style: normal;">acknowledge</font><font style="font-style: normal;">d</font><font style="font-style: normal;"> and agree</font><font style="font-style: normal;">d</font><font style="font-style: normal;"> that all of the obligations under the 2013 Promissory </font><font style="font-style: normal;">Notes </font><font style="font-style: normal;">and the 2016 Promissory Notes were</font><font style="font-style: normal;"> satisfied and the loans </font><font style="font-style: normal;">are</font><font style="font-style: normal;"> extinguished.</font><font style="font-style: normal;"> </font></div><div class="h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 12pt; margin-left: 0pt; text-align: left;">2016 Share Purchase Plan</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">On November&#160;18, 2016, we implemented the 2016 Share Purchase Plan where the board of directors permitted select eligible participants to directly or indirectly purchase common shares. The purchase price of the common shares was determined by the board of directors in accordance with the Swiss tax authorities. Participants paid the par value of the common shares in cash and the balance between the purchase price and the par value in the form of a promissory note. The terms of the plan and the promissory notes are described in more detail below.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Promissory Notes. <font style="font-style: normal;">The promissory notes with respect to the 2016 Share Purchase Plan (the &#8220;2016 </font><font style="font-style: normal;">Promissory Notes&#8221;) </font><font style="font-style: normal;">bore</font><font style="font-style: normal;"> interest and </font><font style="font-style: normal;">had</font><font style="font-style: normal;"> a term of ten years, and we </font><font style="font-style: normal;">had</font><font style="font-style: normal;"> the right of</font><font style="font-style: normal;"> recourse</font><font style="font-style: normal;">. The 2016 </font><font style="font-style: normal;">Promissory Notes </font><font style="font-style: normal;">were</font><font style="font-style: normal;"> repayable within ten years (subject to certain early repayment events) and </font><font style="font-style: normal;">bore</font><font style="font-style: normal;"> interest at </font><font style="font-style: normal;">the minimum interest rate pursuant to the guidelines for related party transactions as published by the Swiss </font><font style="font-style: normal;">Federal Tax Authority. Certain </font><font style="font-style: normal;">plan participants</font><font style="font-style: normal;"> previously purchased our shares with such promissory notes. </font><font style="font-style: normal;">T</font><font style="font-style: normal;">he </font><font style="font-style: normal;">largest aggregate amount outstanding </font><font style="font-style: normal;">under these notes </font><font style="font-style: normal;">since the first issuance </font><font style="font-style: normal;">was $8.9 million immediately </font><font style="font-style: normal;">prior to the repayment of these notes. All</font><font style="font-style: normal;"> promissory notes</font><font style="font-style: normal;"> were repaid on April 15, 2020 as described above.</font><font style="font-style: normal;"> </font></div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Repayment of the Promissory Notes. <font style="font-style: normal;">As with the 2013 Promissory Notes, the 2016 Promissory Notes </font><font style="font-style: normal;">provided</font><font style="font-style: normal;"> that the relevant plan participant </font><font style="font-style: normal;">could</font><font style="font-style: normal;"> repay outstanding amounts under the promissory note at any </font><font style="font-style: normal;">time in cash or repay the principal amount in whole or in part by delivering such number of shares as required to </font><font style="font-style: normal;">cover the amount to be repaid. </font><font style="font-style: normal;">On April 15, 2020</font><font style="font-style: normal;">, the 2016 Promissory Notes </font><font style="font-style: normal;">were </font><font style="font-style: normal;">repaid</font><font style="font-style: normal;"> </font><font style="font-style: normal;">as described above.</font><font style="font-style: normal;"> </font></div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">From the beginning of the last fiscal year ended December&#160;31, 2019 to the final issuance under this plan, we issued and sold to members of our board of directors and to our executive officers, in the aggregate, 548,483 common shares at a price of $2.50 per common share under the 2016 Share Purchase Plan.</div><div class="h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 12pt; margin-left: 0pt; text-align: left;">2014 Incentive Plan</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Under the 2014 Incentive Plan, we granted options to plan participants with respect to common shares. The terms of the plan are described in more detail below. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Vesting<font style="font-style: normal;">. </font><font style="font-style: normal;">The awards for senior employees </font><font style="font-style: normal;">vested</font><font style="font-style: normal;"> 25% annually from the date of grant over a four-year </font><font style="font-style: normal;">period. We </font><font style="font-style: normal;">granted junior employees share option awards effective January 1, 2017</font><font style="font-style: normal;">,</font><font style="font-style: normal;"> 2018</font><font style="font-style: normal;"> and 2019</font><font style="font-style: normal;">, which vest </font><font style="font-style: normal;">100% upon the occurrence of a </font><font style="font-style: normal;">liquidity event, including our</font><font style="font-style: normal;"> initial public offering</font><font style="font-style: normal;">.</font><font style="font-style: normal;"> </font></div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">We settled the awards under the 2014 Incentive Plan upon the completion of our initial public offering by delivering 356,144 common shares.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">From the beginning of the last fiscal year ended December&#160;31, 2019 to the final grant under this plan, we granted our executive officers, in the aggregate, the right to acquire 56,525 common shares at a weighted-average price of $25.94 per common share under the 2014 Incentive Plan. </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 36pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">198<br></div></div></div>
<!--End Page 202-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 203-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 540pt;"><a name="nt10014672x1_drs_108-management_pg10"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="block-frill" style="width: 540pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: Arial, Helvetica, sans-serif; font-size: 9pt; font-weight: bold; margin-top: 6pt; text-align: center;">Confidential Treatment Requested by ADC Therapeutics SA Pursuant to 17 C.F.R. &#167; 200.83<br></div></div><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 36pt;"><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">2019 Equity Incentive Plan</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">In April 2020, we amended and restated the ADC Therapeutics SA 2019 Equity Incentive Plan (the &#8220;2019 Equity Incentive Plan&#8221;), which we originally adopted in November 2019. The purpose of the 2019 Equity Incentive Plan is to motivate and reward performance of our employees, directors, consultants and advisors and further the best interests of the Company and our shareholders. The 2019 Equity Incentive Plan is the sole means for the Company to grant new equity awards. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Plan Administration<font style="font-style: normal;">. The 2019 Equity Incentive Plan is </font><font style="font-style: normal;">administered by the compensation committee of our </font><font style="font-style: normal;">board of </font><font style="font-style: normal;">directors, subject to the board of directors&#8217; discretion to administer or appoint another committee to </font><font style="font-style: normal;">administer it.</font><font style="font-style: normal;"> </font></div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Eligible Participants<font style="font-style: normal;">. The administrator </font><font style="font-style: normal;">is</font><font style="font-style: normal;"> able offer equity awards at its discretion under the 2019 Equity </font><font style="font-style: normal;">Incentive Plan </font><font style="font-style: normal;">to: (1) any employees of us or any of our subsidiaries; (2) any non-employee directors serving on </font><font style="font-style: normal;">our board of directors; </font><font style="font-style: normal;">and </font><font style="font-style: normal;">(3) any consultants or other advisors to us or any of our subsidiaries.</font><font style="font-style: normal;"> The </font><font style="font-style: normal;">administrator of the plan may determine that an award for the benefit of a non-employee director will be granted </font><font style="font-style: normal;">to an affiliate of such director, but only to the extent consistent with the registration of shares offered under the </font><font style="font-style: normal;">plan on Form S-8 under the Securities Act.</font><font style="font-style: normal;"> </font></div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Awards<font style="font-style: normal;">. The maximum number of common shares in respect of which awards may be granted under the </font><font style="font-style: normal;">2019 Equity Incentive Plan is </font><font style="font-style: normal;">7,8</font><font style="font-style: normal;">20</font><font style="font-style: normal;">,000</font><font style="font-style: normal;"> common shares</font><font style="font-style: normal;">,</font><font style="font-style: normal;"> </font><font style="font-style: normal;">subject to adjustment in the event of certain corporate </font><font style="font-style: normal;">transactions or events if necessary to prevent dilution or </font><font style="font-style: normal;">enlargement of the benefits made available under the </font><font style="font-style: normal;">plan. Equity incentive awards under the 2019 Equity Incentive Plan may be </font><font style="font-style: normal;">granted in the form of options, share </font><font style="font-style: normal;">appreciation rights, restricted shares, restricted share units, performance awards or other </font><font style="font-style: normal;">share-based</font><font style="font-style: normal;"> awards but </font><font style="font-style: normal;">not &#8220;incentive stock options&#8221; for purposes of U.S. tax laws. Options and share appreciation rights will have an </font><font style="font-style: normal;">exercise price determined by the administrator but will not be less than fair market value of the underlying </font><font style="font-style: normal;">common shares on the date </font><font style="font-style: normal;">of grant.</font><font style="font-style: normal;"> </font></div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Vesting<font style="font-style: normal;">. The vesting conditions for grants under the equity incentive awards under the 2019 Equity Incentive </font><font style="font-style: normal;">Plan </font><font style="font-style: normal;">are</font><font style="font-style: normal;"> set forth in the applicable award documentation. </font></div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Termination of Service and Change in Control<font style="font-style: normal;">. In the event of a participant&#8217;s termination of employment, </font><font style="font-style: normal;">the compensation </font><font style="font-style: normal;">committee may, in its discretion, determine the extent to which an equity incentive award may </font><font style="font-style: normal;">be exercised, settled, vested, paid or </font><font style="font-style: normal;">forfeited. In the event of our termination of a participant&#8217;s employment </font><font style="font-style: normal;">without cause or a participant&#8217;s resignation for good reason </font><font style="font-style: normal;">(as defined in the 2019 Equity Incentive Plan) upon </font><font style="font-style: normal;">or within 18 months following a change in control of the company (as defined in </font><font style="font-style: normal;">the 2019 Equity Incentive </font><font style="font-style: normal;">Plan), any awards outstanding to the participant (unless otherwise provided in the award agreement) will </font><font style="font-style: normal;">immediately vest and settle, and options and share appreciation rights will become fully exercisable. In the event </font><font style="font-style: normal;">of a change in </font><font style="font-style: normal;">control that involves a merger, acquisition or other corporate transaction, any outstanding award </font><font style="font-style: normal;">not assumed, substituted, replaced or </font><font style="font-style: normal;">continued in connection with the transaction will immediately vest and </font><font style="font-style: normal;">settle, and options and share appreciation rights will become </font><font style="font-style: normal;">fully exercisable. In connection with a change of </font><font style="font-style: normal;">control of the Company, the compensation committee may, in its discretion, take any </font><font style="font-style: normal;">one or more of the </font><font style="font-style: normal;">following actions with respect to outstanding awards: (i) </font><font style="font-style: normal;">cancel</font><font style="font-style: normal;"> </font><font style="font-style: normal;">any such award, in exchange for a </font><font style="font-style: normal;">payment in </font><font style="font-style: normal;">cash, securities or other property or any combination thereof with a value equal to the value of such award based </font><font style="font-style: normal;">on the per share value of common shares received or to be received by other shareholders in the event</font><font style="font-style: normal;"> (or </font><font style="font-style: normal;">without payment of consideration</font><font style="font-style: normal;"> if the committee determines </font><font style="font-style: normal;">that no amount would have been realized upon the </font><font style="font-style: normal;">exercise of the award or other realization of the particip</font><font style="font-style: normal;">ant&#8217;s</font><font style="font-style: normal;"> rights); (ii) require the exercise of any outstanding </font><font style="font-style: normal;">option; (iii) provide for the assumption, substitution, replacement or continuation of any award by the </font><font style="font-style: normal;">successor </font><font style="font-style: normal;">or surviving corporation, along with appropriate adjustments with respect to the number and type of securities (or </font><font style="font-style: normal;">other </font><font style="font-style: normal;">consideration) of the successor or surviving corporation, subject to any replacement awards, the terms and </font><font style="font-style: normal;">conditions of the </font><font style="font-style: normal;">replacement awards (including performance targets) and the grant, exercise or purchase price </font><font style="font-style: normal;">per share for the replacement awards; </font><font style="font-style: normal;">(iv) make any other adjustments in the number and type of securities (or </font><font style="font-style: normal;">other consideration) subject to </font><font style="font-style: normal;">(a) </font><font style="font-style: normal;">such awards and in the terms and conditions of such awards</font><font style="font-style: normal;"> in order to </font><font style="font-style: normal;">prevent the dilution or enlargement of benefits intended to be made available under the 2019 Equity Plan and </font><font style="font-style: normal;">(b)</font><font style="font-style: normal;"> awards that may be granted in the future;</font><font style="font-style: normal;"> (v) provide that any such award shall be accelerated and become </font><font style="font-style: normal;">exercisable, payable and/or fully </font><font style="font-style: normal;">vested with respect to all shares covered thereby or (vi) provide that any award </font><font style="font-style: normal;">shall not vest, be exercised or become payable as a </font><font style="font-style: normal;">result of such event.</font><font style="font-style: normal;"> </font></div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 36pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">199<br></div></div></div>
<!--End Page 203-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 204-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 540pt;"><a name="nt10014672x1_drs_108-management_pg11"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="block-frill" style="width: 540pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: Arial, Helvetica, sans-serif; font-size: 9pt; font-weight: bold; margin-top: 6pt; text-align: center;">Confidential Treatment Requested by ADC Therapeutics SA Pursuant to 17 C.F.R. &#167; 200.83<br></div></div><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 36pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 6.75pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Termination and Amendment<font style="font-style: normal;">. Unless terminated earlier, the 2019 Equity Incentive Plan will continue for a </font><font style="font-style: normal;">term of </font><font style="font-style: normal;">ten</font><font style="font-style: normal;"> years. Our board of directors has the authority to amend or terminate the 2019 Equity Incentive Plan </font><font style="font-style: normal;">subject to shareholder approval with </font><font style="font-style: normal;">respect to certain amendments. However, no such action may impair the </font><font style="font-style: normal;">rights of the recipient of any options unless agreed </font><font style="font-style: normal;">to </font><font style="font-style: normal;">by the recipient.</font><font style="font-style: normal;"> </font></div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Since the beginning of the last fiscal year ended December&#160;31, 2019, we have granted to members of our board of directors and to our executive officers, in the aggregate, the right to acquire &#8195;&#8195;&#8195;&#8195; common shares at a price of $&#8195;&#8195; per common share under the 2019 Equity Incentive Plan. The expiration dates for these awards are &#8195;&#8195;&#8195;&#8195;&#8195;&#8195;. In July 2020, we granted to certain of our executive officers, in the aggregate, 149,984 restricted share units. The restricted share units vest ratably over a three-year period, subject to the executive officer&#8217;s continued employment with us, and any unvested restricted share units will be forefeited should the executive officer terminate his or her employment with us. </div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 20.5pt; margin-left: 0pt; text-align: left;">Employment Agreements</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">We have entered into employment agreements with certain of our executive officers. Each of these agreements provides for an initial salary and annual bonus opportunity, as well as participation in certain pension and welfare benefit plans. These agreements generally require advance notice of termination, from two to 12&#160;months, and in some cases provide for paid garden leave. Some of our executive officers have agreed to covenants not to compete against us or solicit our employees or customers during employment and for a period of up to one year following termination. We may be required to pay some of our executive officers compensation for their covenant not to compete with us following termination.</div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 36pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">200<br></div></div></div>
<!--End Page 204-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 205-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 540pt;"><a name="nt10014672x1_drs_108-management_pg12"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="block-frill" style="width: 540pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: Arial, Helvetica, sans-serif; font-size: 9pt; font-weight: bold; margin-top: 6pt; text-align: center;">Confidential Treatment Requested by ADC Therapeutics SA Pursuant to 17 C.F.R. &#167; 200.83<br></div></div><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 36pt;"><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: center;"><a name="tS"><!--Anchor--></a>PRINCIPAL AND SELLING SHAREHOLDERS</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The following table presents information relating to the beneficial ownership of our common shares as of June&#160;30, 2020 by:</div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">each person, or group of affiliated persons, known by us to own beneficially 5% or more of our outstanding common shares, including the Selling Shareholder;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">each of our executive officers and directors and persons nominated to serve in such positions; and</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">all executive officers and directors and persons nominated to serve in such positions as a group. </div></td></tr></table><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The number of common shares beneficially owned by each entity, person, executive officer or director is determined in accordance with the rules of the SEC, and the information is not necessarily indicative of beneficial ownership for any other purpose. Under such rules, beneficial ownership includes any common shares over which the individual has sole or shared voting power or investment power as well as any common shares that the individual has the right to acquire within 60 days from June 30, 2020 through the exercise of any option or other right. Except as otherwise indicated, and subject to applicable community property laws, we believe that the persons named in the table have sole voting and investment power with respect to all common shares held by that person based on information provided to us by such person.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The percentage of outstanding common shares beneficially owned before this offering is computed on the basis of the number of common shares outstanding as of June 30, 2020. Common shares that a person has the right to acquire within 60 days are deemed outstanding for purposes of computing the percentage ownership of the person holding such rights, but are not deemed outstanding for purposes of computing the percentage ownership of any other person, except with respect to the percentage ownership of all executive officers and directors as a group. Unless otherwise indicated below, the business address for each beneficial owner is ADC Therapeutics SA, Biop&#244;le, Route de la Corniche 3B, 1066 Epalinges, Switzerland. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The percentage of common shares beneficially owned after this offering is based on the number of common shares that will be outstanding upon the completion of this offering. The percentages assume no exercise by the underwriters of their option to purchase additional shares and do not give effect to any shares that may be acquired by our shareholders, directors or executive officers in this offering. </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 36pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">201<br></div></div></div>
<!--End Page 205-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 206-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 540pt;"><a name="nt10014672x1_drs_108-management_pg13"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="block-frill" style="width: 540pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: Arial, Helvetica, sans-serif; font-size: 9pt; font-weight: bold; margin-top: 6pt; text-align: center;">Confidential Treatment Requested by ADC Therapeutics SA Pursuant to 17 C.F.R. &#167; 200.83<br></div></div><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 36pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">As of June 30, 2020, to our knowledge, &#8195;&#8195; U.S. record holders held approximately &#8195;&#8195;% of our common shares.</div><table cellspacing="0" cellpadding="0" class="fintab" style="margin-top: 11.25pt; border-collapse: collapse; width: 468pt; margin-left: auto; margin-right: auto;"><tr class="header"><td style="width: 26.71%; text-align: left; vertical-align: bottom; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 2.67%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" rowspan="2" style="width: 2.67%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td rowspan="2" style="width: 20.82%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Number of Common Shares <br></div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Beneficially Owned</div></td><td class="gutter" rowspan="2" style="width: 2.67%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 2.67%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td colspan="4" style="width: 41.78%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Percentage of Common Shares Beneficially Owned</div></td></tr><tr class="header"><td style="width: 26.71%; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Principal Shareholders</div></td><td class="gutter" style="width: 2.67%; font-size: 2pt; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 2.67%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 18.69%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Before This Offering</div></td><td class="gutter" style="width: 2.67%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 2.67%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 17.74%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">After This Offering</div></td></tr><tr><td style="width: 26.71%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">5% Shareholders<br></div></td><td class="gutter" style="width: 2.67%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.67%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 20.82%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 2.67%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.67%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 18.69%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 2.67%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.67%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 17.74%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 26.71%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-indent: -10pt; text-align: left;">Entities affiliated with Auven Therapeutics GP Ltd.<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(1)</sup><font style="padding-left: 1.66pt;"></font></div></td><td class="gutter" style="width: 2.67%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.67%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 20.82%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 2.67%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.67%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 18.69%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 43.75pt; text-align: left;">%</div></td><td class="gutter" style="width: 2.67%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.67%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 17.74%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 41.52pt; text-align: left;">%</div></td></tr><tr><td style="width: 26.71%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">AstraZeneca UK Limited<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(2)</sup><font style="padding-left: 0.47pt;"></font></div></td><td class="gutter" style="width: 2.67%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.67%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 20.82%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 2.67%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.67%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 18.69%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 43.75pt; text-align: left;">%</div></td><td class="gutter" style="width: 2.67%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.67%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 17.74%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 41.52pt; text-align: left;">%</div></td></tr><tr><td style="width: 26.71%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">HPWH TH AG<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(3)</sup><font style="padding-left: 0.62pt;"></font></div></td><td class="gutter" style="width: 2.67%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.67%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 20.82%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 2.67%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.67%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 18.69%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 43.75pt; text-align: left;">%</div></td><td class="gutter" style="width: 2.67%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.67%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 17.74%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 41.52pt; text-align: left;">%</div></td></tr><tr><td style="width: 26.71%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 10pt; text-indent: -10pt; text-align: left;">Executive Officers and Directors<br></div></td><td class="gutter" style="width: 2.67%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.67%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 20.82%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 2.67%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.67%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 18.69%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 2.67%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.67%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 17.74%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 26.71%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Peter B. Corr<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(4)</sup><font style="padding-left: 4.06pt;"></font></div></td><td class="gutter" style="width: 2.67%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.67%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 20.82%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 2.67%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.67%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 18.69%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 43.75pt; text-align: left;">%</div></td><td class="gutter" style="width: 2.67%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.67%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 17.74%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 41.52pt; text-align: left;">%</div></td></tr><tr><td style="width: 26.71%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Jennifer Creel<font style="padding-left: 0.31pt;"></font></div></td><td class="gutter" style="width: 2.67%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.67%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 20.82%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 2.67%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.67%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 18.69%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 43.75pt; text-align: left;">%</div></td><td class="gutter" style="width: 2.67%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.67%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 17.74%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 41.52pt; text-align: left;">%</div></td></tr><tr><td style="width: 26.71%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Stephen Evans-Freke<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(4)</sup><font style="padding-left: 2.68pt;"></font></div></td><td class="gutter" style="width: 2.67%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.67%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 20.82%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 2.67%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.67%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 18.69%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 43.75pt; text-align: left;">%</div></td><td class="gutter" style="width: 2.67%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.67%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 17.74%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 41.52pt; text-align: left;">%</div></td></tr><tr><td style="width: 26.71%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Jay Feingold<font style="padding-left: 0.29pt;"></font></div></td><td class="gutter" style="width: 2.67%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.67%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 20.82%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 2.67%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.67%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 18.69%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 43.75pt; text-align: left;">%</div></td><td class="gutter" style="width: 2.67%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.67%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 17.74%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 41.52pt; text-align: left;">%</div></td></tr><tr><td style="width: 26.71%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Michael Forer<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(5)</sup><font style="padding-left: 1.01pt;"></font></div></td><td class="gutter" style="width: 2.67%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.67%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 20.82%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 2.67%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.67%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 18.69%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 43.75pt; text-align: left;">%</div></td><td class="gutter" style="width: 2.67%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.67%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 17.74%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 41.52pt; text-align: left;">%</div></td></tr><tr><td style="width: 26.71%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Dominique Graz<font style="padding-left: 4.75pt;"></font></div></td><td class="gutter" style="width: 2.67%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.67%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 20.82%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 2.67%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.67%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 18.69%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 43.75pt; text-align: left;">%</div></td><td class="gutter" style="width: 2.67%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.67%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 17.74%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 41.52pt; text-align: left;">%</div></td></tr><tr><td style="width: 26.71%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Peter Greaney<font style="padding-left: 4.76pt;"></font></div></td><td class="gutter" style="width: 2.67%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.67%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 20.82%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 2.67%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.67%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 18.69%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 43.75pt; text-align: left;">%</div></td><td class="gutter" style="width: 2.67%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.67%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 17.74%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 41.52pt; text-align: left;">%</div></td></tr><tr><td style="width: 26.71%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Jennifer Herron<font style="padding-left: 3.65pt;"></font></div></td><td class="gutter" style="width: 2.67%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.67%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 20.82%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 2.67%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.67%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 18.69%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 43.75pt; text-align: left;">%</div></td><td class="gutter" style="width: 2.67%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.67%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 17.74%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 41.52pt; text-align: left;">%</div></td></tr><tr><td style="width: 26.71%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Peter Hug<font style="padding-left: 1.41pt;"></font></div></td><td class="gutter" style="width: 2.67%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.67%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 20.82%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 2.67%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.67%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 18.69%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 43.75pt; text-align: left;">%</div></td><td class="gutter" style="width: 2.67%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.67%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 17.74%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 41.52pt; text-align: left;">%</div></td></tr><tr><td style="width: 26.71%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Christopher Martin<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(6)</sup><font style="padding-left: 1pt;"></font></div></td><td class="gutter" style="width: 2.67%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.67%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 20.82%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 2.67%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.67%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 18.69%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 43.75pt; text-align: left;">%</div></td><td class="gutter" style="width: 2.67%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.67%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 17.74%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 41.52pt; text-align: left;">%</div></td></tr><tr><td style="width: 26.71%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Richard Onyett<font style="padding-left: 0.3pt;"></font></div></td><td class="gutter" style="width: 2.67%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.67%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 20.82%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 2.67%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.67%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 18.69%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 43.75pt; text-align: left;">%</div></td><td class="gutter" style="width: 2.67%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.67%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 17.74%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 41.52pt; text-align: left;">%</div></td></tr><tr><td style="width: 26.71%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Thomas Pfisterer<font style="padding-left: 3.09pt;"></font></div></td><td class="gutter" style="width: 2.67%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.67%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 20.82%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 2.67%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.67%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 18.69%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 43.75pt; text-align: left;">%</div></td><td class="gutter" style="width: 2.67%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.67%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 17.74%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 41.52pt; text-align: left;">%</div></td></tr><tr><td style="width: 26.71%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Kimberly Pope<font style="padding-left: 0.85pt;"></font></div></td><td class="gutter" style="width: 2.67%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.67%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 20.82%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 2.67%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.67%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 18.69%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 43.75pt; text-align: left;">%</div></td><td class="gutter" style="width: 2.67%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.67%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 17.74%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 41.52pt; text-align: left;">%</div></td></tr><tr><td style="width: 26.71%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Thomas M. Rinderknecht<font style="padding-left: 3.36pt;"></font></div></td><td class="gutter" style="width: 2.67%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.67%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 20.82%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 2.67%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.67%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 18.69%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 43.75pt; text-align: left;">%</div></td><td class="gutter" style="width: 2.67%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.67%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 17.74%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 41.52pt; text-align: left;">%</div></td></tr><tr><td style="width: 26.71%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Tyrell J. Rivers<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(7)</sup><font style="padding-left: 0.87pt;"></font></div></td><td class="gutter" style="width: 2.67%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.67%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 20.82%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 2.67%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.67%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 18.69%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 43.75pt; text-align: left;">%</div></td><td class="gutter" style="width: 2.67%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.67%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 17.74%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 41.52pt; text-align: left;">%</div></td></tr><tr><td style="width: 26.71%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Susan Romanus<font style="padding-left: 2.51pt;"></font></div></td><td class="gutter" style="width: 2.67%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.67%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 20.82%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 2.67%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.67%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 18.69%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 43.75pt; text-align: left;">%</div></td><td class="gutter" style="width: 2.67%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.67%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 17.74%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 41.52pt; text-align: left;">%</div></td></tr><tr><td style="width: 26.71%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Victor Sandor<font style="padding-left: 0.9pt;"></font></div></td><td class="gutter" style="width: 2.67%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.67%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 20.82%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 2.67%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.67%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 18.69%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 43.75pt; text-align: left;">%</div></td><td class="gutter" style="width: 2.67%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.67%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 17.74%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 41.52pt; text-align: left;">%</div></td></tr><tr><td style="width: 26.71%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Robert A. Schmidt<font style="padding-left: 1.12pt;"></font></div></td><td class="gutter" style="width: 2.67%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.67%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 20.82%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 2.67%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.67%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 18.69%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 43.75pt; text-align: left;">%</div></td><td class="gutter" style="width: 2.67%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.67%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 17.74%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 41.52pt; text-align: left;">%</div></td></tr><tr><td style="width: 26.71%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Ron Squarer<font style="padding-left: 1.41pt;"></font></div></td><td class="gutter" style="width: 2.67%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.67%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 20.82%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 2.67%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.67%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 18.69%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 43.75pt; text-align: left;">%</div></td><td class="gutter" style="width: 2.67%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.67%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 17.74%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 41.52pt; text-align: left;">%</div></td></tr><tr><td style="width: 26.71%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Jacques Theurillat<font style="padding-left: 3.82pt;"></font></div></td><td class="gutter" style="width: 2.67%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.67%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 20.82%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 2.67%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.67%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 18.69%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 43.75pt; text-align: left;">%</div></td><td class="gutter" style="width: 2.67%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.67%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 17.74%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 41.52pt; text-align: left;">%</div></td></tr><tr><td style="width: 26.71%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Patrick van Berkel<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(8)</sup><font style="padding-left: 2.68pt;"></font></div></td><td class="gutter" style="width: 2.67%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.67%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 20.82%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 2.67%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.67%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 18.69%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 43.75pt; text-align: left;">%</div></td><td class="gutter" style="width: 2.67%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.67%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 17.74%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 41.52pt; text-align: left;">%</div></td></tr><tr><td style="width: 26.71%; text-align: left; vertical-align: bottom; padding-top: 3pt; background-color: #CCEEFF;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-indent: -10pt; text-align: left;">All executive officers and directors as a group <br></div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">(21 persons)<font style="padding-left: 1.97pt;"></font></div></td><td class="gutter" style="width: 2.67%; border-bottom: none; font-size: 2pt; padding-top: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.67%; border-bottom: none; font-size: 2pt; padding-top: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 20.82%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; background-color: #CCEEFF;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 2.67%; border-bottom: none; font-size: 2pt; padding-top: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.67%; border-bottom: none; font-size: 2pt; padding-top: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 18.69%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; background-color: #CCEEFF;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 43.75pt; text-align: left;">%</div></td><td class="gutter" style="width: 2.67%; border-bottom: none; font-size: 2pt; padding-top: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.67%; border-bottom: none; font-size: 2pt; padding-top: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 17.74%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; background-color: #CCEEFF;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 41.52pt; text-align: left;">%</div></td></tr></table><div><div class="rule-partial" style="height: 0pt; width: 72pt; border-bottom: 1pt solid #000000; margin-bottom: 1pt; margin-right: auto; margin-left: 0pt; margin-top: 13.25pt;"> </div></div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 3pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">*<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; text-align: left;">Less than 1% of our total outstanding common shares.</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 3pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">(1)<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; text-align: left;">This information is based on a Schedule 13D filed with the SEC on May 19, 2020 by A.T. Holdings II S&#224;rl (&#8220;A.T. Holdings&#8221;), C.T. Phinco S&#224;rl (&#8220;C.T. Phinco&#8221;), ADC Products Switzerland S&#224;rl (&#8220;ADC Products&#8221;), Auven Therapeutics Holdings L.P. (&#8220;Auven Therapeutics&#8221;), Auven Therapeutics General L.P. (&#8220;Auven Therapeutics General&#8221;), Auven Therapeutics GP Ltd. (&#8220;Auven Therapeutics GP&#8221;), Stephen Evans-Freke and Peter B. Corr. A.T. Holdings holds a 73.77% interest in ADC Products and is a wholly-owned subsidiary of C.T. Phinco, which is a wholly-owned subsidiary of Auven Therapeutics. Auven Therapeutics General is the general partner of Auven Therapeutics General L.P. Auven Therapeutics General L.P. is the general partner of Auven Therapeutics. Auven Therapeutics GP is the general partner of Auven Therapeutics General. Mr.&#160;Corr and Mr.&#160;Evans-Freke are directors and principals of Auven Therapeutics. All common shares held by A.T. Holdings have been pledged pursuant to lending arrangements. The address of each of A.T. Holdings and ADC Products is Biop&#244;le, Route de la Corniche 3B, 1066 Epalinges, Switzerland. The address of C.T. Phinco is 6 Rue Eugene Ruppert, L-2453 Luxembourg, Luxembourg. The address of each of Auven Therapeutics, Auven Therapeutics General and Auven Therapeutics GP is 171 Main Street, Road Town, Tortola, British Virgin Islands VG1110. The address of each of Mr.&#160;Corr and Mr.&#160;Evans-Freke is 6501 Redhook Plaza, Suite 201, St. Thomas, U.S. Virgin Islands 00802.</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 3pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">(2)<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; text-align: left;">AstraZeneca UK Limited (&#8220;AstraZeneca&#8221;) is a wholly-owned subsidiary of AstraZeneca plc, a public limited company organized under the laws of the United Kingdom, which may be deemed to have sole voting and investment power. The address of AstraZeneca is 1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge, United Kingdom, CB2 0AA. </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 3pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">(3)<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; text-align: left;">HPWH TH AG (&#8220;HPWH&#8221;) is a Swiss stock corporation. Dr.&#160;Hans-Peter Wild and Mr. Pfisterer are members of HPWH board of directors, and may be deemed to have shared voting and investment power with respect to such shares held of record by HPWH through a shareholders agreement. Mr.&#160;Pfisterer disclaims beneficial ownership of common shares held by HPWH, except to the extent of his pecuniary interest in such shares, if any. The address of HPWH is Neugasse 22, 6300 Zug, Switzerland. </div></td></tr></table></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 36pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">202<br></div></div></div>
<!--End Page 206-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 207-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 540pt;"><a name="nt10014672x1_drs_108-management_pg14"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="block-frill" style="width: 540pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: Arial, Helvetica, sans-serif; font-size: 9pt; font-weight: bold; margin-top: 6pt; text-align: center;">Confidential Treatment Requested by ADC Therapeutics SA Pursuant to 17 C.F.R. &#167; 200.83<br></div></div><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 36pt;"><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 5.25pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">(4)<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; text-align: left;">As described in footnote (1), as the directors and principals of Auven Therapeutics, Mr.&#160;Corr and Mr.&#160;Evans-Freke, may be deemed to have shared voting and investment power with respect to the common shares held by Auven Therapeutics.</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 3pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">(5)<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; text-align: left;">Does not include common shares held by Dune Capital Inc., a company which is wholly-owned by a trust whose beneficiaries include Mr. Forer and his family. Mr. Forer does not exercise investment or voting control over the trust, and therefore such shares do not appear in the table above. </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 3pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">(6)<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; text-align: left;">Does not include common shares held of record by Tuula Martin, spouse of Christopher Martin. Dr. Martin does not exercise investment or voting control over such shares, and therefore such shares do not appear in the table above. </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 3pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">(7)<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; text-align: left;">Mr. Rivers is an executive director within AstraZeneca&#8217;s corporate development group and disclaims beneficial ownership of common shares held by AstraZeneca, except to the extent of his pecuniary interest in such shares, if any. See footnote (2).</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 3pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">(8)<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; text-align: left;">Betulamab B.V. is a Dutch private limited liability company of which Dr.&#160;van Berkel is beneficial owner. The address of Betulamab B.V. is Neerdyck&#160;3, 3601 CZ Maarssen, The Netherlands.</div></td></tr></table></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 36pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">203<br></div></div></div>
<!--End Page 207-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 208-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 540pt;"><a name="nt10014672x1_drs_108-management_pg15"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="block-frill" style="width: 540pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: Arial, Helvetica, sans-serif; font-size: 9pt; font-weight: bold; margin-top: 6pt; text-align: center;">Confidential Treatment Requested by ADC Therapeutics SA Pursuant to 17 C.F.R. &#167; 200.83<br></div></div><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 36pt;"><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: center;"><a name="tRPT"><!--Anchor--></a>RELATED PARTY TRANSACTIONS</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The following is a description of certain related party transactions we have entered into since January&#160;1, 2017 with any of our executive officers, directors or their affiliates and holders of more than 10% of any class of our voting securities in the aggregate, which we refer to as related parties, other than compensation arrangements which are described under &#8220;Management.&#8221; </div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 20.5pt; margin-left: 0pt; text-align: left;">Sales of Securities</div><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 7.5pt; margin-left: 0pt; text-align: left;">Sale of Class&#160;E Preferred Shares</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">In October 2017, we entered into an investment and subscription agreement,which included customary representations and warranties and covenants, pursuant to which we issued and sold an aggregate of 617 Class&#160;E preferred shares at a purchase price of $324,292.00 per share (which is equal to 7,712,500 common shares at a purchase price of $25.94 per share after giving effect to the one-to-15,625 share split of all issued shares that was effected on September 19, 2019, the five-to-four reverse split of all issued shares that was effected on April 24, 2020 and the conversion on a one-to-one basis of our issued preferred shares into common shares that was effected on May 19, 2020 (collectively, the &#8220;Share Capital Reorganization&#8221;)) for an aggregate purchase price of $200.1&#160;million.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The following table sets forth the number of our Class&#160;E preferred shares (and the number of our common shares after giving effect to the Share Capital Reorganization) purchased by our related parties:</div><table cellspacing="0" cellpadding="0" class="fintab" style="margin-top: 11.25pt; border-collapse: collapse; width: 468pt; margin-left: auto; margin-right: auto;"><tr class="header"><td style="width: 56.41%; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Name of Shareholders</div></td><td class="gutter" style="width: 3.74%; font-size: 2pt; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 3.74%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td colspan="4" style="width: 36.12%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Number of Class&#160;E Preferred <br></div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Shares (Number of Common Shares <br></div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">After Giving Effect to the Share Capital <br></div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Reorganization) Purchased<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(1)</sup></div></td></tr><tr><td style="width: 56.41%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">A.T. Holdings II S&#224;rl<font style="padding-left: 4.49pt;"></font></div></td><td class="gutter" style="width: 3.74%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 3.74%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 11.3%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.69pt; text-align: left;">105.0000</div></td><td class="gutter" style="width: 3.74%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 3.74%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 17.35%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.68pt; text-align: left;">(1,312,500.0000)</div></td></tr><tr><td style="width: 56.41%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">ADC Products Switzerland S&#224;rl<font style="padding-left: 1.55pt;"></font></div></td><td class="gutter" style="width: 3.74%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 3.74%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 11.3%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.69pt; text-align: left;"><font style="padding-left: 5pt;">56.0000</font></div></td><td class="gutter" style="width: 3.74%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 3.74%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 17.35%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.68pt; text-align: left;"><font style="padding-left: 7.5pt;">(</font>700,000.0000)</div></td></tr><tr><td style="width: 56.41%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Michael Forer<font style="padding-left: 3.75pt;"></font></div></td><td class="gutter" style="width: 3.74%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 3.74%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 11.3%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.69pt; text-align: left;"><font style="padding-left: 10pt;">0.7709</font></div></td><td class="gutter" style="width: 3.74%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 3.74%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 17.35%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.68pt; text-align: left;"><font style="padding-left: 17.5pt;">(</font>9,636.2500)</div></td></tr><tr><td style="width: 56.41%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Tuula Martin<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(2)</sup><font style="padding-left: 4.23pt;"></font></div></td><td class="gutter" style="width: 3.74%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 3.74%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 11.3%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.69pt; text-align: left;"><font style="padding-left: 10pt;">1.5418</font></div></td><td class="gutter" style="width: 3.74%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 3.74%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 17.35%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.68pt; text-align: left;"><font style="padding-left: 12.5pt;">(</font>19,272.5000)</div></td></tr><tr><td style="width: 56.41%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Thomas Rinderknecht<font style="padding-left: 2.08pt;"></font></div></td><td class="gutter" style="width: 3.74%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 3.74%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 11.3%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.69pt; text-align: left;"><font style="padding-left: 10pt;">3.3421</font></div></td><td class="gutter" style="width: 3.74%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 3.74%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 17.35%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.68pt; text-align: left;"><font style="padding-left: 12.5pt;">(</font>41,776.2500)</div></td></tr><tr><td style="width: 56.41%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Jacques Theurillat<font style="padding-left: 2.82pt;"></font></div></td><td class="gutter" style="width: 3.74%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 3.74%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 11.3%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.69pt; text-align: left;"><font style="padding-left: 10pt;">1.5815</font></div></td><td class="gutter" style="width: 3.74%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 3.74%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 17.35%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.68pt; text-align: left;"><font style="padding-left: 12.5pt;">(</font>19,768.7500)</div></td></tr><tr><td style="width: 56.41%; text-align: left; vertical-align: bottom; padding-top: 3pt; background-color: #CCEEFF;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Barrie Ward<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(3)</sup><font style="padding-left: 3.21pt;"></font></div></td><td class="gutter" style="width: 3.74%; border-bottom: none; font-size: 2pt; padding-top: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 3.74%; border-bottom: none; font-size: 2pt; padding-top: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 11.3%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; background-color: #CCEEFF;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.69pt; text-align: left;"><font style="padding-left: 10pt;">0.4667</font></div></td><td class="gutter" style="width: 3.74%; border-bottom: none; font-size: 2pt; padding-top: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 3.74%; border-bottom: none; font-size: 2pt; padding-top: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 17.35%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; background-color: #CCEEFF;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.68pt; text-align: left;"><font style="padding-left: 17.5pt;">(</font>5,833.7500)</div></td></tr></table><div><div class="rule-partial" style="height: 0pt; width: 72pt; border-bottom: 1pt solid #000000; margin-bottom: 1pt; margin-right: auto; margin-left: 0pt; margin-top: 13.25pt;"> </div></div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 3pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">(1)<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; text-align: left;">Includes shares and fractional shares held by nominees on behalf of the shareholders set out in the table.</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 3pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">(2)<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; text-align: left;">Tuula Martin is the spouse of Christopher Martin, who is a member of our board of directors and CEO.</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 3pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">(3)<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; text-align: left;">Barrie Ward was a member of our board of directors from September 2014 to April 2020.</div></td></tr></table><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">In May 2019, we entered into an investment and subscription agreement, which included customary representations and warranties and covenants, pursuant to which we issued and sold an aggregate of 218 Class&#160;E preferred shares at a purchase price of $350,000.00 per share (which is equal to 2,725,000 common shares at a purchase price of $28.00 per share after giving effect to the Share Capital Reorganization) for an aggregate purchase price of $76.3&#160;million.</div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 36pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">204<br></div></div></div>
<!--End Page 208-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 209-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 540pt;"><a name="nt10014672x1_drs_108-management_pg16"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="block-frill" style="width: 540pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: Arial, Helvetica, sans-serif; font-size: 9pt; font-weight: bold; margin-top: 6pt; text-align: center;">Confidential Treatment Requested by ADC Therapeutics SA Pursuant to 17 C.F.R. &#167; 200.83<br></div></div><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 36pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The following table sets forth the number of our Class&#160;E preferred shares (and the number of our common shares after giving effect to the Share Capital Reorganization) purchased by our related parties:</div><table cellspacing="0" cellpadding="0" class="fintab" style="margin-top: 11.25pt; border-collapse: collapse; width: 468pt; margin-left: auto; margin-right: auto;"><tr class="header"><td style="width: 58.97%; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Name of Shareholders</div></td><td class="gutter" style="width: 3.09%; font-size: 2pt; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 3.09%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td colspan="4" style="width: 34.84%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Number of Class&#160;E Preferred Shares <br></div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">(Number of Common Shares <br></div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">After Giving Effect to the Share Capital <br></div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Reorganization) Purchased<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(1)</sup></div></td></tr><tr><td style="width: 58.97%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">A.T. Holdings II S&#224;rl<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(2)</sup><font style="padding-left: 2.75pt;"></font></div></td><td class="gutter" style="width: 3.09%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 3.09%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 11.57%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10.81pt; text-align: left;">62.0000</div></td><td class="gutter" style="width: 3.09%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 3.09%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 17.08%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10.81pt; text-align: left;">(775,000.0000)</div></td></tr><tr><td style="width: 58.97%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Michael Forer<font style="padding-left: 0.75pt;"></font></div></td><td class="gutter" style="width: 3.09%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 3.09%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 11.57%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10.81pt; text-align: left;"><font style="padding-left: 5pt;">0.4286</font></div></td><td class="gutter" style="width: 3.09%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 3.09%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 17.08%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10.81pt; text-align: left;"><font style="padding-left: 10pt;">(</font>5,357.5000)</div></td></tr><tr><td style="width: 58.97%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Dominique Graz<font style="padding-left: 0.75pt;"></font></div></td><td class="gutter" style="width: 3.09%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 3.09%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 11.57%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10.81pt; text-align: left;"><font style="padding-left: 5pt;">0.5700</font></div></td><td class="gutter" style="width: 3.09%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 3.09%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 17.08%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10.81pt; text-align: left;"><font style="padding-left: 10pt;">(</font>7,125.0000)</div></td></tr><tr><td style="width: 58.97%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">St&#233;phane Henchoz<font style="padding-left: 2.97pt;"></font></div></td><td class="gutter" style="width: 3.09%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 3.09%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 11.57%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10.81pt; text-align: left;"><font style="padding-left: 5pt;">0.1000</font></div></td><td class="gutter" style="width: 3.09%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 3.09%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 17.08%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10.81pt; text-align: left;"><font style="padding-left: 10pt;">(1,</font>250.0000)</div></td></tr><tr><td style="width: 58.97%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Thomas Rinderknecht<font style="padding-left: 4.08pt;"></font></div></td><td class="gutter" style="width: 3.09%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 3.09%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 11.57%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10.81pt; text-align: left;"><font style="padding-left: 5pt;">1.0000</font></div></td><td class="gutter" style="width: 3.09%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 3.09%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 17.08%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10.81pt; text-align: left;"><font style="padding-left: 5pt;">(1</font>2,500.0000)</div></td></tr><tr><td style="width: 58.97%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Jacques Theurillat<font style="padding-left: 4.82pt;"></font></div></td><td class="gutter" style="width: 3.09%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 3.09%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 11.57%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10.81pt; text-align: left;"><font style="padding-left: 5pt;">0.1800</font></div></td><td class="gutter" style="width: 3.09%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 3.09%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 17.08%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10.81pt; text-align: left;"><font style="padding-left: 10pt;">(2,</font>250.0000)</div></td></tr><tr><td style="width: 58.97%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Tuula Martin<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(3)</sup><font style="padding-left: 1.23pt;"></font></div></td><td class="gutter" style="width: 3.09%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 3.09%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 11.57%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10.81pt; text-align: left;"><font style="padding-left: 5pt;">0.4300</font></div></td><td class="gutter" style="width: 3.09%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 3.09%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 17.08%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10.81pt; text-align: left;"><font style="padding-left: 10pt;">(</font>5,375.0000)</div></td></tr><tr><td style="width: 58.97%; text-align: left; vertical-align: bottom; padding-top: 3pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Barrie Ward<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(4)</sup><font style="padding-left: 0.21pt;"></font></div></td><td class="gutter" style="width: 3.09%; border-bottom: none; font-size: 2pt; padding-top: 3pt;">&#8203;</td><td class="gutter" style="width: 3.09%; border-bottom: none; font-size: 2pt; padding-top: 3pt;">&#8203;</td><td style="width: 11.57%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10.81pt; text-align: left;"><font style="padding-left: 5pt;">0.0200</font></div></td><td class="gutter" style="width: 3.09%; border-bottom: none; font-size: 2pt; padding-top: 3pt;">&#8203;</td><td class="gutter" style="width: 3.09%; border-bottom: none; font-size: 2pt; padding-top: 3pt;">&#8203;</td><td style="width: 17.08%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10.81pt; text-align: left;"><font style="padding-left: 17.5pt;">(</font>250.0000)</div></td></tr></table><div><div class="rule-partial" style="height: 0pt; width: 72pt; border-bottom: 1pt solid #000000; margin-bottom: 1pt; margin-right: auto; margin-left: 0pt; margin-top: 13.25pt;"> </div></div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 3pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">(1)<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; text-align: left;">Includes shares and fractional shares held by nominees on behalf of the shareholders set out in the table.</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 3pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">(2)<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; text-align: left;">Includes 29.0000 Class&#160;E preferred shares (which is equal to 362,500.0000 common shares after giving effect to the Share Capital Reorganization) originally acquired by ADC Products Switzerland S&#224;rl and later transferred to A.T. Holdings II S&#224;rl.</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 3pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">(3)<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; text-align: left;">Tuula Martin is the spouse of Christopher Martin, who is a member of our board of directors and CEO.</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 3pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">(4)<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; text-align: left;">Barrie Ward was a member of our board of directors from September 2014 to April 2020. </div></td></tr></table><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 19.5pt; margin-left: 0pt; text-align: left;">Issuance of Class A Common Shares </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">In September&#160;2019, we issued 140 Class&#160;A common shares (which is equal to 1,750,000 common shares after giving effect to the Share Capital Reorganization) to A.T.&#160;Holdings II S&#224;rl at CHF 1,000 per Class A common share (CHF 0.08 per common share after giving effect to the Share Capital Reorganization), equal to the par value of such shares, and repurchased such shares from A.T.&#160;Holdings II S&#224;rl immediately upon their issuance and at the same price. Some of these shares were reserved to settle share grants and equity-linked instruments for directors, officers, employees and consultants, including to settle the outstanding awards under our 2014 Incentive Plan in connection with our initial public offering. </div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 20.5pt; margin-left: 0pt; text-align: left;">Shareholders&#8217; Agreement</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">In October 2017, we and our then-existing equity investors entered into a shareholders&#8217; agreement (the&#160;&#8220;Shareholders&#8217; Agreement&#8221;), which replaced our prior shareholders&#8217; agreements. In April 2020, we and our shareholders entered into an addendum to the Shareholders&#8217; Agreement. As consideration for the holders of our Class E preferred shares agreeing to convert their shares into common shares, we agreed to issue to such holders an aggregate of 4,777,996 common shares (after giving effect to the Share Capital Reorganization and accounting for the rounding of fractional shares) immediately prior to the completion of our initial public offering. These common shares were distributed among the holders of our Class E preferred shares pro rata based on their holdings of such shares. The Shareholders&#8217; Agreement terminated at the closing of our initial public offering.</div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 36pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">205<br></div></div></div>
<!--End Page 209-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 210-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 540pt;"><a name="nt10014672x1_drs_108-management_pg17"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="block-frill" style="width: 540pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: Arial, Helvetica, sans-serif; font-size: 9pt; font-weight: bold; margin-top: 6pt; text-align: center;">Confidential Treatment Requested by ADC Therapeutics SA Pursuant to 17 C.F.R. &#167; 200.83<br></div></div><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 36pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">In May 2020, to settle fractional holdings, we transferred the beneficial interest in (i) an aggregate of 6 Class C preferred shares, 12 Class D preferred shares and 26 Class E preferred shares we previously held in treasury to certain of our shareholders and (ii) an aggregate of 6.6 common shares to certain beneficiaries of our 2013 Share Purchase Plan and our 2016 Share Purchase Plan. We made such transfers without consideration. The following table sets forth the number of shares transferred to our related parties: </div><table cellspacing="0" cellpadding="0" class="fintab" style="margin-top: 11.25pt; border-collapse: collapse; width: 468pt; margin-left: auto; margin-right: auto;"><tr class="header"><td style="width: 69.23%; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Name of Shareholders</div></td><td class="gutter" style="width: 3.13%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 3.13%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 24.52%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Number of Shares Transferred<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">(After Giving Effect to the Share <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Capital Reorganization)</div></td></tr><tr><td style="width: 69.23%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">ADC Products Switzerland S&#224;rl<font style="padding-left: 1.55pt;"></font></div></td><td class="gutter" style="width: 3.13%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 3.13%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 24.52%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 43.62pt; text-align: left;">0.7727</div></td></tr><tr><td style="width: 69.23%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Betulamab B.V.<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(1)</sup><font style="padding-left: 3.51pt;"></font></div></td><td class="gutter" style="width: 3.13%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 3.13%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 24.52%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 43.62pt; text-align: left;">0.4000</div></td></tr><tr><td style="width: 69.23%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Michael Forer<font style="padding-left: 3.75pt;"></font></div></td><td class="gutter" style="width: 3.13%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 3.13%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 24.52%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 43.62pt; text-align: left;">1.2801</div></td></tr><tr><td style="width: 69.23%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Dominique Graz<font style="padding-left: 3.75pt;"></font></div></td><td class="gutter" style="width: 3.13%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 3.13%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 24.52%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 43.62pt; text-align: left;">0.8000</div></td></tr><tr><td style="width: 69.23%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Peter Greaney<font style="padding-left: 3.76pt;"></font></div></td><td class="gutter" style="width: 3.13%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 3.13%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 24.52%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 43.62pt; text-align: left;">0.4000</div></td></tr><tr><td style="width: 69.23%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">St&#233;phane Henchoz<font style="padding-left: 0.97pt;"></font></div></td><td class="gutter" style="width: 3.13%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 3.13%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 24.52%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 43.62pt; text-align: left;">0.9429</div></td></tr><tr><td style="width: 69.23%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Peter Hug<font style="padding-left: 0.41pt;"></font></div></td><td class="gutter" style="width: 3.13%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 3.13%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 24.52%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 43.62pt; text-align: left;">0.2000</div></td></tr><tr><td style="width: 69.23%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Christopher Martin<font style="padding-left: 3.75pt;"></font></div></td><td class="gutter" style="width: 3.13%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 3.13%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 24.52%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 43.62pt; text-align: left;">0.2000</div></td></tr><tr><td style="width: 69.23%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Thomas Pfisterer<font style="padding-left: 2.09pt;"></font></div></td><td class="gutter" style="width: 3.13%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 3.13%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 24.52%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 43.62pt; text-align: left;">0.2000</div></td></tr><tr><td style="width: 69.23%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Thomas Rinderknecht<font style="padding-left: 2.08pt;"></font></div></td><td class="gutter" style="width: 3.13%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 3.13%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 24.52%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 43.62pt; text-align: left;">1.5540</div></td></tr><tr><td style="width: 69.23%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Jacques Theurillat<font style="padding-left: 2.82pt;"></font></div></td><td class="gutter" style="width: 3.13%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 3.13%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 24.52%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 43.62pt; text-align: left;">1.1891</div></td></tr><tr><td style="width: 69.23%; text-align: left; vertical-align: bottom; padding-top: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Tuula Martin<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(2)</sup><font style="padding-left: 4.23pt;"></font></div></td><td class="gutter" style="width: 3.13%; border-bottom: none; font-size: 2pt; padding-top: 3pt;">&#8203;</td><td class="gutter" style="width: 3.13%; border-bottom: none; font-size: 2pt; padding-top: 3pt;">&#8203;</td><td style="width: 24.52%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 43.62pt; text-align: left;">0.2458</div></td></tr></table><div><div class="rule-partial" style="height: 0pt; width: 72pt; border-bottom: 1pt solid #000000; margin-bottom: 1pt; margin-right: auto; margin-left: 0pt; margin-top: 12.75pt;"> </div></div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 3pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">(1)<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; text-align: left;">Betulamab B.V. is a Dutch private limited liability company of which Dr. van Berkel, who is our Senior Vice President, Research and Development, is beneficial owner.</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 3pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">(2)<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; text-align: left;">Tuula Martin is the spouse of Christopher Martin, who is a member of our board of directors and CEO.</div></td></tr></table><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 13.5pt; margin-left: 0pt; text-align: left;">Director and Executive Officer Promissory Notes</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The following table sets forth the material terms of the promissory notes issued in connection with the share purchase plans between us and our directors and executive officers. All amounts outstanding under the promissory notes were repaid on April 15, 2020.</div><table cellspacing="0" cellpadding="0" class="fintab" style="margin-top: 11.25pt; border-collapse: collapse; width: 468pt; margin-left: auto; margin-right: auto;"><tr class="header"><td style="width: 76.92%; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Name of Director or Executive Officer</div></td><td class="gutter" style="width: 2.87%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 2.87%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 17.35%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Largest Amount<br></div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Previously Outstanding <br></div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">(in USD thousands)</div></td></tr><tr><td style="width: 76.92%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Michael Forer<font style="padding-left: 4.75pt;"></font></div></td><td class="gutter" style="width: 2.87%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.87%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 17.35%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 29.34pt; text-align: left;">3,307</div></td></tr><tr><td style="width: 76.92%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Dominique Graz<font style="padding-left: 4.75pt;"></font></div></td><td class="gutter" style="width: 2.87%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.87%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 17.35%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 29.34pt; text-align: left;"><font style="padding-left: 7.5pt;">20</font>7</div></td></tr><tr><td style="width: 76.92%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Peter Greaney<font style="padding-left: 4.76pt;"></font></div></td><td class="gutter" style="width: 2.87%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.87%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 17.35%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 29.34pt; text-align: left;"><font style="padding-left: 12.5pt;">7</font>1</div></td></tr><tr><td style="width: 76.92%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">St&#233;phane Henchoz<font style="padding-left: 1.97pt;"></font></div></td><td class="gutter" style="width: 2.87%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.87%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 17.35%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 29.34pt; text-align: left;"><font style="padding-left: 7.5pt;">33</font>6</div></td></tr><tr><td style="width: 76.92%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Peter Hug<font style="padding-left: 1.41pt;"></font></div></td><td class="gutter" style="width: 2.87%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.87%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 17.35%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 29.34pt; text-align: left;"><font style="padding-left: 7.5pt;">22</font>9</div></td></tr><tr><td style="width: 76.92%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Christopher Martin<font style="padding-left: 4.75pt;"></font></div></td><td class="gutter" style="width: 2.87%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.87%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 17.35%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 29.34pt; text-align: left;">4,148</div></td></tr><tr><td style="width: 76.92%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Thomas Pfisterer<font style="padding-left: 3.09pt;"></font></div></td><td class="gutter" style="width: 2.87%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.87%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 17.35%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 29.34pt; text-align: left;"><font style="padding-left: 7.5pt;">3</font>41</div></td></tr><tr><td style="width: 76.92%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Thomas M. Rinderknecht<font style="padding-left: 3.36pt;"></font></div></td><td class="gutter" style="width: 2.87%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.87%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 17.35%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 29.34pt; text-align: left;"><font style="padding-left: 7.5pt;">4</font>72</div></td></tr><tr><td style="width: 76.92%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Jacques Theurillat<font style="padding-left: 3.82pt;"></font></div></td><td class="gutter" style="width: 2.87%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.87%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 17.35%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 29.34pt; text-align: left;"><font style="padding-left: 7.5pt;">4</font>72</div></td></tr><tr><td style="width: 76.92%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Patrick van Berkel<font style="padding-left: 1.42pt;"></font></div></td><td class="gutter" style="width: 2.87%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.87%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 17.35%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 29.34pt; text-align: left;"><font style="padding-left: 7.5pt;">47</font>2</div></td></tr><tr><td style="width: 76.92%; text-align: left; vertical-align: bottom; padding-top: 3pt; background-color: #CCEEFF;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Barrie Ward<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(1)</sup><font style="padding-left: 4.21pt;"></font></div></td><td class="gutter" style="width: 2.87%; border-bottom: none; font-size: 2pt; padding-top: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.87%; border-bottom: none; font-size: 2pt; padding-top: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 17.35%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; background-color: #CCEEFF;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 29.34pt; text-align: left;"><font style="padding-left: 7.5pt;">38</font>5</div></td></tr></table><div><div class="rule-partial" style="height: 0pt; width: 72pt; border-bottom: 1pt solid #000000; margin-bottom: 1pt; margin-right: auto; margin-left: 0pt; margin-top: 12.75pt;"> </div></div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 3pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">(1)<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; text-align: left;">Barrie Ward was a member of our board of directors from September 2014 to April 2020. </div></td></tr></table><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 14pt; margin-left: 0pt; text-align: left;">Related Person Transaction Policy</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">We have adopted a related person transaction policy, which states that any related person transaction must be approved or ratified by our audit committee or board of directors. In determining whether to approve or ratify a transaction with a related person, our audit committee or board of directors will consider all relevant facts and circumstances, including, without limitation, the commercial reasonableness of the terms of the transaction, the benefit and perceived benefit, or lack thereof, to us, the opportunity costs of an alternative transaction, the </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 36pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">206<br></div></div></div>
<!--End Page 210-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 211-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 540pt;"><a name="nt10014672x1_drs_108-management_pg18"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="block-frill" style="width: 540pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: Arial, Helvetica, sans-serif; font-size: 9pt; font-weight: bold; margin-top: 6pt; text-align: center;">Confidential Treatment Requested by ADC Therapeutics SA Pursuant to 17 C.F.R. &#167; 200.83<br></div></div><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 36pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">materiality and character of the related person&#8217;s direct or indirect interest and the actual or apparent conflict of interest of the related person. Our audit committee or board of directors will not approve or ratify a related person transaction unless it has determined that, upon consideration of all relevant information, such transaction is in, or not inconsistent with, our best interests and the best interests of our shareholders. </div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 20.5pt; margin-left: 0pt; text-align: left;">Indemnification Agreements</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">We have entered into indemnification agreements with our executive officers and directors. The indemnification agreements and our articles of association require us to indemnify our executive officers and directors to the fullest extent permitted by law.</div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 36pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">207<br></div></div></div>
<!--End Page 211-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 212-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 540pt;"><a name="nt10014672x1_drs_109-description_pg1"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="block-frill" style="width: 540pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: Arial, Helvetica, sans-serif; font-size: 9pt; font-weight: bold; margin-top: 6pt; text-align: center;">Confidential Treatment Requested by ADC Therapeutics SA Pursuant to 17 C.F.R. &#167; 200.83<br></div></div><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 36pt;"><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: center;"><a name="tDSC"><!--Anchor--></a>DESCRIPTION OF SHARE CAPITAL AND ARTICLES OF ASSOCIATION </div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 19.5pt; margin-left: 0pt; text-align: left;">The Company</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">We are a Swiss stock corporation (<font style="font-style: italic;">soci&#233;t&#233; anonyme</font>) organized under the laws of Switzerland. We were incorporated as a Swiss limited liability company (<font style="font-style: italic;">soci&#233;t&#233; &#224; responsabilit&#233; limit&#233;e</font>) on June&#160;6, 2011 with our registered office and domicile in Epalinges, Canton of Vaud, Switzerland. We converted to a Swiss stock corporation under the laws of Switzerland on October&#160;13, 2015. Our domicile is in Epalinges, Canton of Vaud, Switzerland. Our registered office and head office is currently located at Biop&#244;le, Route de la Corniche 3B, 1066 Epalinges, Switzerland.</div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 20.5pt; margin-left: 0pt; text-align: left;">Share Capital</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">As of June 30, 2020, our share capital as registered with the commercial register of the Canton of Vaud, Switzerland (the &#8220;Commercial Register&#8221;) amounted to 70,770,000 common shares, 70,715,852 of which were outstanding, each with a par value of CHF 0.08 per share. Upon the closing of this offering, after giving effect to the issuance of the common shares to be sold in this offering, our outstanding fully paid-in share capital will consist of &#8195;&#8195;&#8195;&#8195; common shares, each with a par value of CHF 0.08 per share.</div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 20.5pt; margin-left: 0pt; text-align: left;">Changes in Our Share Capital During the Last Three Fiscal Years</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">In this section, share amounts are presented as of the date of the relevant transaction, without accounting for the Share Capital Reorganization. Since January 1, 2017, our share capital has changed as follows: </div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">On October&#160;11, 2017, our share capital as registered with the Commercial Register on October&#160;12, 2017, was increased by issuing 588 Class&#160;E preferred shares;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">On October&#160;24, 2017, our share capital as registered with the Commercial Register on October&#160;30, 2017, was increased by issuing 22 Class&#160;E preferred shares;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">On November&#160;10, 2017, our share capital as registered with the Commercial Register on November&#160;16, 2017, was increased by issuing 7 Class&#160;E preferred shares;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">On June&#160;19, 2018, our share capital as registered with the Commercial Register on June&#160;29, 2018, was increased by issuing 3 Class&#160;A common shares;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">On December&#160;10, 2018, our share capital as registered with the Commercial Register on December&#160;14, 2018, was increased by issuing 33 Class&#160;A common shares;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">On January&#160;30, 2019, our share capital as registered with the Commercial Register on February&#160;6, 2019, was increased by issuing 6 Class&#160;A common shares;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">On June&#160;4, 2019, our share capital as registered with the Commercial Register on June&#160;7, 2019, was increased by issuing 216 Class&#160;E preferred shares;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">On June&#160;7, 2019, our share capital as registered with the Commercial Register on June&#160;14, 2019, was increased by issuing 2 Class&#160;E preferred shares;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">On June&#160;28, 2019, our share capital as registered with the Commercial Register on July&#160;5, 2019, was increased by issuing 77 Class&#160;E preferred shares; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">On August 22, 2019, our share capital as registered with the Commercial Register on August&#160;28, 2019, was increased by an aggregate amount of CHF 3,714,300 through an increase of the par value of each of our Class A common shares and Class B, C, D and E preferred shares from CHF 100 to CHF&#160;1,000;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">On September&#160;19, 2019, our share capital as registered with the Commercial Register on September&#160;19, 2019, was increased by issuing 140 Class A common shares;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">In the one-to-15,625 share split of all issued shares effected on September&#160;19, 2019, each of our issued shares was split into 15,625 shares of the same class with a par value of CHF 0.064 per share; </div></td></tr></table></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 36pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">208<br></div></div></div>
<!--End Page 212-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 213-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 540pt;"><a name="nt10014672x1_drs_109-description_pg2"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="block-frill" style="width: 540pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: Arial, Helvetica, sans-serif; font-size: 9pt; font-weight: bold; margin-top: 6pt; text-align: center;">Confidential Treatment Requested by ADC Therapeutics SA Pursuant to 17 C.F.R. &#167; 200.83<br></div></div><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 36pt;"><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6.75pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">In the five-to-four reverse share split of all issued shares effected on April&#160;24, 2020, each of our issued shares was consolidated into 0.8&#160;shares of the same class with a par value of CHF 0.08 per share, and an aggregate of 44 common shares were converted into 6 Class C preferred shares, 12 Class D preferred shares and 26 Class E preferred shares, each with a par value of CHF 0.08; and</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">On May 15, 2020, our share capital as registered with the Commercial Register on May 15, 2020, was increased by issuing 17,432,500 common shares with a par value of CHF 0.08 per share.</div></td></tr></table><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 17pt; margin-left: 0pt; text-align: left;">Registration Rights</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">In connection with the initial disbursement under the Facility Agreement, we entered into an agreement with Deerfield Partners, L.P. and Deerfield Private Design Fund IV, L.P. that provides them with certain registration rights. Six months following the effectiveness of the registration statement for our initial public offering, we will be required to prepare and file a registration statement to register under the Securities Act common shares issued and issuable to them upon the conversion of their senior secured convertible notes issued under the Facility Agreement. The agreement also provides for piggyback registration rights pursuant to which such holders have the right to demand that we include any such shares in any registration statement that we file with the SEC, subject to certain exceptions.</div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 17pt; margin-left: 0pt; text-align: left;">Articles of Association</div><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 7pt; margin-left: 0pt; text-align: left;">Ordinary Capital Increase, Authorized and Conditional Share Capital</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Under Swiss law, we may increase our share capital (<font style="font-style: italic;">capital-actions</font>) with a resolution of the general meeting of shareholders (ordinary capital increase) that must be carried out by the board of directors within three months of the respective general meeting in order to become effective. Under our articles of association and Swiss law, in the case of subscription and increase against payment of contributions in cash, a resolution passed by an absolute majority of the shares represented at the general meeting of shareholders is required. In the case of subscription and increase against contributions in kind or to fund acquisitions in kind, when shareholders&#8217; statutory pre-emptive subscription rights or advance subscription rights are limited or withdrawn or where transformation of freely disposable equity into share capital is involved, a resolution passed by two-thirds of the shares represented at a general meeting of shareholders and the absolute majority of the par value of the shares represented is required.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Furthermore, under the Swiss Code of Obligations (the &#8220;CO&#8221;), our shareholders, by a resolution passed by two-thirds of the shares represented at a general meeting of shareholders and the absolute majority of the par value of the shares represented, may empower our board of directors to issue shares of a specific aggregate par value up to a maximum of 50% of the share capital in the form of: </div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">conditional share capital (<font style="font-style: italic;">capital-actions conditionnel</font>) for the purpose of issuing shares in connection with, among other things, (i)&#160;option and conversion rights granted in connection with warrants and convertible bonds of the Company or one of our subsidiaries or (ii)&#160;grants of rights to employees, members of our board of directors or consultants or to our subsidiaries or other persons providing services to the Company or a&#160;subsidiary to subscribe for new shares (conversion or option rights); or</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">authorized share capital (<font style="font-style: italic;">capital-actions autoris&#233;</font>) to be utilized by the board of directors within a period determined by the shareholders but not exceeding two years from the date of the shareholder approval.</div></td></tr></table><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 17pt; margin-left: 0pt; text-align: left;">Pre-Emptive and Advance Subscription Rights</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Pursuant to the CO, shareholders have pre-emptive subscription rights (<font style="font-style: italic;">droits de souscription</font>) to subscribe for new issuances of shares. With respect to conditional capital in connection with the issuance of conversion rights, convertible bonds or similar debt instruments, shareholders have advance subscription rights (<font style="font-style: italic;">droit de </font><font style="font-style: italic;">souscrire pr&#233;alablement</font>) for the subscription of such conversion rights, convertible bonds or similar debt instruments. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">A resolution passed at a general meeting of shareholders by two-thirds of the shares represented and the absolute majority of the par value of the shares represented may authorize our board of directors to withdraw or limit pre-emptive subscription rights or advance subscription rights in certain circumstances.</div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 36pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">209<br></div></div></div>
<!--End Page 213-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 214-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 540pt;"><a name="nt10014672x1_drs_109-description_pg3"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="block-frill" style="width: 540pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: Arial, Helvetica, sans-serif; font-size: 9pt; font-weight: bold; margin-top: 6pt; text-align: center;">Confidential Treatment Requested by ADC Therapeutics SA Pursuant to 17 C.F.R. &#167; 200.83<br></div></div><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 36pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">If pre-emptive subscription rights are granted, but not exercised, the board of directors may allocate the unexercised pre-emptive subscription rights at its discretion.</div><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12.5pt; margin-left: 0pt; text-align: left;">Our Authorized Share Capital</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Under our articles of association and immediately upon the completion of this offering, our board of directors is authorized at any time, including to prevent takeovers and changes in control, until April 23, 2022 to increase our nominal share capital by a maximum aggregate amount of CHF &#8195;&#8195;&#8195;&#8195; through the issuance of not more than &#8195;&#8195;&#8195;&#8195; shares, which would have to be fully paid-in, each with a&#160;par value of CHF 0.08 per share.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Increases in partial amounts are permitted. The board of directors has the power to determine the type of contributions, the issue price and the date on which the dividend entitlement starts.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">With respect to our authorized share capital, the board of directors is authorized by our articles of association to withdraw or to limit the pre-emptive subscription rights of shareholders, and to allocate them to third parties or to us, in the event that the newly issued shares are issued under the following circumstances:</div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">if the issue price of the new registered shares is determined by reference to the market price;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">for raising of capital (including private placements) in a fast and flexible manner, which would not be possible, or might only be possible with great difficulty or delays or at significantly less favorable conditions, without the exclusion of the statutory pre-emptive subscription rights of the existing shareholders; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">for the acquisition of an enterprise, parts of an enterprise or participations, for the acquisition of products, intellectual property or licenses by or for investment projects of the Company or any of its group companies, or for the financing or refinancing of any of such transactions through a placement of shares; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">for purposes of broadening the shareholder constituency of the Company in certain geographic, financial or investor markets, for purposes of the participation of strategic partners, or in connection with the listing of new shares on domestic or foreign stock exchanges; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">for purposes of granting an over-allotment option or an option to purchase additional shares in a placement or sale of shares to the respective initial purchaser(s) or underwriter(s);</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">for the participation of members of the board of directors, members of the executive committee, employees, contractors, consultants or other persons performing services for the benefit of the Company or any of its group companies;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">following a shareholder or a group of shareholders acting in concert having accumulated shareholdings in excess of 20% of our share capital registered in the Commercial Register without having submitted to all other shareholders a takeover offer recommended by the board of directors;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">for the defense of an actual, threatened or potential takeover bid, that the board of directors, upon consultation with an independent financial adviser retained by it, has not recommended to the shareholders acceptance on the basis that the board of directors has not found the takeover bid to be financially fair to the shareholders or not to be in the Company&#8217;s interest; or</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">for other valid grounds in the sense of Article 652b para. 2 of the CO.</div></td></tr></table><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">This authorization is exclusively linked to the particular available authorized share capital set out in the respective article. If the period to increase our share capital out of authorized share capital lapses without having been used by the board of directors, the authorization to withdraw or to limit the pre-emptive subscription rights lapses simultaneously with such capital.</div><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">Our Conditional Share Capital</div><div class="h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 7pt; margin-left: 0pt; text-align: left;">Conditional Share Capital for Warrants and Convertible Bonds</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Our nominal share capital may be increased, including to prevent takeovers and changes in control, by a&#160;maximum aggregate amount of CHF 1,624,000 through the issuance of not more than 20,300,000 common shares, which would have to be fully paid-in, each with a par value of CHF 0.08 per share, by the exercise of </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 36pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">210<br></div></div></div>
<!--End Page 214-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 215-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 540pt;"><a name="nt10014672x1_drs_109-description_pg4"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="block-frill" style="width: 540pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: Arial, Helvetica, sans-serif; font-size: 9pt; font-weight: bold; margin-top: 6pt; text-align: center;">Confidential Treatment Requested by ADC Therapeutics SA Pursuant to 17 C.F.R. &#167; 200.83<br></div></div><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 36pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">option and conversion rights granted in connection with warrants, convertible bonds or similar instruments of the Company or one of our subsidiaries. Shareholders will not have pre-emptive subscription rights in such circumstances, but will have advance subscription rights to subscribe for such warrants, convertible bonds or similar instruments. The holders of warrants, convertible bonds or similar instruments are entitled to the new shares upon the occurrence of the applicable conversion feature. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">When issuing convertible bonds, warrants or similar instruments, the board of directors is authorized to withdraw or to limit the advance subscription right of shareholders:</div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">for the purpose of financing or refinancing, or the payment for, the acquisition of enterprises, parts of enterprises, participations, intellectual property rights, licenses or investments;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">if the issuance occurs in domestic or international capital markets, including private placements;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">following a shareholder or a group of shareholders acting in concert having accumulated shareholdings in excess of 20% of the share capital registered in the Commercial Register without having submitted to all other shareholders a takeover offer recommended by the board of directors; or</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">for the defense of an actual, threatened or potential takeover bid that the board of directors, upon consultation with an independent financial adviser retained by it, has not recommended to the shareholders to accept on the basis that the board of directors has not found the takeover bid to be financially fair to the shareholders or not to be in the Company&#8217;s interest.</div></td></tr></table><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">To the extent that the advance subscription rights are withdrawn or limited, (i)&#160;the convertible bonds, warrants or similar instruments are to be issued at market conditions; (ii)&#160;the term to exercise the convertible bonds, warrants or similar instruments may not exceed ten years from the date of issue of the respective instrument and (iii) the conversion, exchange or exercise price of the convertible bonds, warrants or similar instruments has to be set with reference to or be subject to change based upon the valuation of the Company&#8217;s equity or market conditions.</div><div class="h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 20.5pt; margin-left: 0pt; text-align: left;">Conditional Share Capital for Equity Incentive Plans</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Our nominal share capital may, to the exclusion of the pre-emptive subscription rights and advance subscription rights of shareholders, be increased by a maximum aggregate amount of CHF 936,000 through the (direct or indirect) issuance of not more than 11,700,000 common shares, which would have to be fully paid-in, each with a par value of CHF 0.08 per share, by the exercise of options, other rights to receive shares or conversion rights that have been granted to employees, members of the board of directors, contractors or consultants of the Company or of one of our subsidiaries or other persons providing services to the Company or to a subsidiary through one or more equity incentive plans created by the board of directors.</div><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 20pt; margin-left: 0pt; text-align: left;">Uncertificated Securities</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Our shares are in the form of uncertificated securities (<font style="font-style: italic;">droits-valeurs</font>, within the meaning of Article 973c of the CO). In accordance with Article 973c of the CO, we will maintain a non-public register of uncertificated securities (<font style="font-style: italic;">registre des droits-valeurs</font>). We may at any time convert uncertificated securities into share certificates (including global certificates), one kind of certificate into another, or share certificates (including global certificates) into uncertificated securities. Following entry in the share register, a shareholder may at any time request from us a written confirmation in respect of his or her shares. Shareholders are not entitled, however, to request the conversion and/or printing and delivery of share certificates. We may print and deliver certificates for shares at any time.</div><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 20pt; margin-left: 0pt; text-align: left;">General Meeting of Shareholders</div><div class="h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 7pt; margin-left: 0pt; text-align: left;">Ordinary/Extraordinary Meetings, Powers</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The general meeting of shareholders is our supreme corporate body. Under Swiss law, an annual general meeting of shareholders must be held annually within six months after the end of a corporation&#8217;s financial year. In our case, this generally means on or before June 30. In addition, extraordinary general meetings of shareholders may be held.</div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 36pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">211<br></div></div></div>
<!--End Page 215-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 216-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 540pt;"><a name="nt10014672x1_drs_109-description_pg5"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="block-frill" style="width: 540pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: Arial, Helvetica, sans-serif; font-size: 9pt; font-weight: bold; margin-top: 6pt; text-align: center;">Confidential Treatment Requested by ADC Therapeutics SA Pursuant to 17 C.F.R. &#167; 200.83<br></div></div><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 36pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The following powers are vested exclusively in the general meeting of shareholders:</div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">adopting and amending the articles of association, including the change of a company&#8217;s purpose or domicile;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">electing the members of the board of directors, the chairman of the board of directors, the members of the compensation committee, the auditors and the independent proxy;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">approving the business report, the annual statutory and consolidated financial statements, and deciding on the allocation of profits as shown on the balance sheet, in particular with regard to dividends;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">approving the aggregate amount of compensation of members of the board of directors and the executive committee;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">discharging the members of the board of directors and the executive committee from liability with respect to their conduct of business;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">dissolving a company with or without liquidation; and</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">deciding matters reserved to the general meeting of shareholders by law or the articles of association or submitted to it by the board of directors.</div></td></tr></table><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">An extraordinary general meeting of shareholders may be called by a resolution of the board of directors or the general meeting of shareholders or, under certain circumstances, by a company&#8217;s auditor, liquidator or the representatives of bondholders, if any. In addition, the board of directors is required to convene an extraordinary general meeting of shareholders if shareholders representing at least 10% of our share capital request such general meeting of shareholders in writing. Such request must set forth the items to be discussed and the proposals to be acted upon. The board of directors must convene an extraordinary general meeting of shareholders and propose financial restructuring measures if, based on our stand-alone annual statutory balance sheet, half of our share capital and statutory reserves are not covered by our assets.</div><div class="h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 20pt; margin-left: 0pt; text-align: left;">Voting and Quorum Requirements </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Shareholder resolutions and elections (including elections of members of the board of directors) require the affirmative vote of the absolute majority of shares represented at the general meeting of shareholders, unless otherwise stipulated by law or our articles of association.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Under Swiss law and our articles of association, a resolution of the general meeting of the shareholders passed by two-thirds of the shares represented at the meeting, and the absolute majority of the par value of the shares represented is required for:</div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">amending the Company&#8217;s corporate purpose;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">creating shares with preference rights;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">cancelling or amending the transfer restrictions of shares;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">creating authorized or conditional share capital;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">increasing share capital out of equity, against contributions in-kind or for the purpose of acquiring specific assets and granting specific benefits;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">limiting or withdrawing shareholder&#8217;s pre-emptive subscription rights;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">changing a company&#8217;s domicile;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">amending or repealing the voting and recording restrictions, the provision setting a maximum board size or the indemnification provision for the board of directors and the executive committee set forth in our articles of association;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">converting registered shares into bearer shares; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">removing the chairman or any member of the board of directors before the end of his or her term of office; and</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">dissolving or liquidating the Company.</div></td></tr></table></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 36pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">212<br></div></div></div>
<!--End Page 216-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 217-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 540pt;"><a name="nt10014672x1_drs_109-description_pg6"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="block-frill" style="width: 540pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: Arial, Helvetica, sans-serif; font-size: 9pt; font-weight: bold; margin-top: 6pt; text-align: center;">Confidential Treatment Requested by ADC Therapeutics SA Pursuant to 17 C.F.R. &#167; 200.83<br></div></div><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 36pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The same voting requirements apply to resolutions regarding transactions among corporations based on Switzerland&#8217;s Federal Act on Mergers, Demergers, Transformations and the Transfer of Assets of 2003, as amended (the &#8220;Swiss Merger Act&#8221;). See &#8220;&#8212;Articles of Association&#8212;Compulsory Acquisitions; Appraisal Rights.&#8221;</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">In accordance with Swiss law and generally accepted business practices, our articles of association do not provide quorum requirements generally applicable to general meetings of shareholders. To this extent, our practice varies from NYSE listing standards, which require an issuer to provide in its bylaws for a generally applicable quorum, and that such quorum may not be less than one-third of the outstanding voting shares.</div><div class="h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 12pt; margin-left: 0pt; text-align: left;">Notice</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">General meetings of shareholders must be convened by the board of directors at least 20 days before the date of the meeting. The general meeting of shareholders is convened by way of a notice appearing in our official publication medium, currently the Swiss Official Gazette of Commerce. Registered shareholders may also be informed by ordinary mail or e-mail. The notice of a general meeting of shareholders must state the items on the agenda, the motions to the shareholders and, in case of elections, the names of the nominated candidates. A resolution on a matter which is not on the agenda may not be passed at a general meeting of shareholders, except for motions to convene an extraordinary general meeting of shareholders or to initiate a special investigation, on which the general meeting of shareholders may vote at any time. No previous notification is required for motions concerning items included in the agenda or for debates that do not result in a vote.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">All of the owners or representatives of our shares may, if no objection is raised, hold a general meeting of shareholders without complying with the formal requirements for convening general meetings of shareholders (a&#160;universal meeting). This universal meeting of shareholders may discuss and pass binding resolutions on all matters within the purview of the general meeting of shareholders, provided that the owners or representatives of all the shares are present at the meeting.</div><div class="h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 12pt; margin-left: 0pt; text-align: left;">Agenda Requests</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Pursuant to Swiss law and our articles of association, one or more shareholders, whose combined shareholdings represent the lower of (i)&#160;one tenth of our share capital and (ii)&#160;an aggregate par value of at least CHF 1,000,000 may request that an item be included in the agenda for a general meeting of shareholders. To be timely, the shareholder&#8217;s request must be received by us generally at least 45 calendar days in advance of the meeting. The request must be made in writing and contain, for each of the agenda items, the following information: </div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">a brief description of the business desired to be brought before the general meeting of shareholders and the reasons for conducting such business at the general meeting of shareholders;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the motions regarding the agenda item; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the name and address, as they appear in the share register, of the shareholder proposing such business;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the number of shares which are beneficially owned by such shareholder (including documentary support of such beneficial ownership);</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the dates upon which the shareholder acquired such shares;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">any material interest of the proposing shareholder in the proposed business;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">a statement in support of the matter; and </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">all other information required under the applicable laws and stock exchange rules.</div></td></tr></table><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">In addition, if the shareholder intends to solicit proxies from the shareholders of a company, such shareholder shall notify the company of this intent in accordance with SEC Rule 14a-4 and/or Rule 14a-8.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Our business report, the compensation report and the auditor&#8217;s report must be made available for inspection by the shareholders at our registered office no later than 20 days prior to the general meeting of shareholders. Shareholders of record may be notified of this in writing.</div><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">Voting Rights</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Each of our common shares entitles a holder to one vote. The common shares are not divisible. The right to vote and the other rights of share ownership may only be exercised by shareholders (including any nominees) or </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 36pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">213<br></div></div></div>
<!--End Page 217-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 218-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 540pt;"><a name="nt10014672x1_drs_109-description_pg7"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="block-frill" style="width: 540pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: Arial, Helvetica, sans-serif; font-size: 9pt; font-weight: bold; margin-top: 6pt; text-align: center;">Confidential Treatment Requested by ADC Therapeutics SA Pursuant to 17 C.F.R. &#167; 200.83<br></div></div><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 36pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">usufructuaries who are entered in the share register at a cut-off date determined by the board of directors. Those entitled to vote in the general meeting of shareholders may be represented by the independent proxy holder (annually elected by the general meeting of shareholders), by its legal representative or by another registered shareholder with written authorization to act as proxy. The chairman has the power to decide whether to recognize a power of attorney.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Our articles of association contain provisions that prevent investors from acquiring voting rights exceeding 15% of our issued share capital. Specifically, if an individual or legal entity acquires common shares and, as a result, directly or indirectly, has voting rights with respect to more than 15% of the registered share capital recorded in the Commercial Register, the registered shares exceeding the limit of 15% shall be entered in the share register as shares without voting rights (<font style="font-style: italic;">limitation &#224; l&#8217;inscription</font>). This restriction applies equally to parties acting in concert and to shares held or acquired via a nominee, including via Cede &amp; Co., New York (or any successor), as the nominee of The Depository Trust Company (&#8220;DTC&#8221;), New York, acting in its capacity as clearing nominee. Specifically, if shares are being held by a nominee for third-party beneficiaries, which control (alone or together with third parties) voting rights with respect to more than 15% of the share capital recorded in the Commercial Register, our articles of association provide that the board of directors may cancel the registration of the shares with voting rights held by such nominee in excess of the limit of 15%. Furthermore, our articles of association contain provisions that allow the board of directors to make the registration with voting rights of shares held by a nominee subject to conditions, limitations and reporting requirements or to impose or adjust such conditions, limitations and requirements once registered. However, any shareholders who held more than 15% prior to our initial public offering remain registered with voting rights for such shares. Furthermore, the board of directors may in special cases approve exceptions to these restrictions. </div><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 20pt; margin-left: 0pt; text-align: left;">Dividends and Other Distributions</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Our board of directors may propose to shareholders that a dividend or other distribution be paid but cannot itself authorize the distribution. Dividend payments require a resolution passed by an absolute majority of the shares represented at a general meeting of shareholders. In addition, our auditors must confirm that the dividend proposal of our board of directors conforms to Swiss statutory law and our articles of association.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Under Swiss law, we may pay dividends only if we have sufficient distributable profits from the previous business year (<font style="font-style: italic;">b&#233;n&#233;fice de l&#8217;exercice</font>) or brought forward from the previous business years (<font style="font-style: italic;">report des b&#233;n&#233;fices</font>), or if we have distributable reserves (<font style="font-style: italic;">r&#233;serves &#224; libre disposition</font>), each as evidenced by the Company&#8217;s audited stand-alone statutory balance sheet prepared pursuant to Swiss law, and after allocations to reserves required by Swiss law and by the articles of association have been deducted. We are not permitted to pay interim dividends out of profit of the current business year.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Distributable reserves are generally booked either as &#8220;free reserves&#8221; (<font style="font-style: italic;">r&#233;serves libres</font>) or as &#8220;reserve from capital contributions&#8221; (<font style="font-style: italic;">apports de capital</font>). Under the CO, if our general reserves (<font style="font-style: italic;">r&#233;serve g&#233;n&#233;rale</font>) amount to less than 20% of our share capital recorded in the Commercial Register (i.e., 20% of the aggregate par value of our issued capital), then at least 5% of our annual profit must be retained as general reserves. In addition, if our general reserves amount to less than 50% of our share capital recorded in the Commercial Register, 10% of the amounts distributed beyond payment of a dividend of 5% must be retained as general reserves. The CO permits us to accrue additional general reserves. Further, a purchase of our own shares (whether by us or a subsidiary) reduces the distributable reserves in an amount corresponding to the purchase price of such own shares. Finally, the CO under certain circumstances requires the creation of revaluation reserves which are not distributable.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Distributions out of issued share capital (i.e., the aggregate par value of our issued shares) are not allowed and may be made only by way of a share capital reduction. Such a capital reduction requires a resolution passed by an absolute majority of the shares represented at a general meeting of shareholders. The resolution of the shareholders must be recorded in a public deed and a special audit report must confirm that claims of our creditors remain fully covered despite the reduction in our share capital recorded in the Commercial Register. Our share capital may be reduced below CHF 100,000 only if and to the extent that at the same time the statutory minimum share capital of CHF 100,000 is reestablished by sufficient new fully paid-up capital. Upon approval by the general meeting of shareholders of the capital reduction, the board of directors must give public notice of the capital reduction resolution in the Swiss Official Gazette of Commerce three times and notify creditors that they may request, within two months of the third publication, satisfaction of or security for their claims. The reduction of our share capital may be implemented only after expiration of this time limit.</div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 36pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">214<br></div></div></div>
<!--End Page 218-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 219-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 540pt;"><a name="nt10014672x1_drs_109-description_pg8"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="block-frill" style="width: 540pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: Arial, Helvetica, sans-serif; font-size: 9pt; font-weight: bold; margin-top: 6pt; text-align: center;">Confidential Treatment Requested by ADC Therapeutics SA Pursuant to 17 C.F.R. &#167; 200.83<br></div></div><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 36pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Our board of directors determines the date on which the dividend entitlement starts. Dividends are usually due and payable shortly after the shareholders have passed the resolution approving the payment, but shareholders may also resolve at the annual general meeting of shareholders to pay dividends in quarterly or other installments.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">For a discussion of the taxation of dividends, see &#8220;Taxation&#8212;Swiss Tax Considerations&#8212;Swiss Federal, Cantonal and Communal Individual Income Tax and Corporate Income Tax.&#8221;</div><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 14pt; margin-left: 0pt; text-align: left;">Transfer of Shares</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Shares in uncertificated form (<font style="font-style: italic;">droits-valeurs</font>) may only be transferred by way of assignment. Shares or the beneficial interest in shares, as applicable, credited in a securities account may only be transferred when a credit of the relevant intermediated securities to the acquirer&#8217;s securities account is made in accordance with applicable rules. Our articles of association provide that in the case of securities held with an intermediary such as a registrar, transfer agent, trust corporation, bank or similar entity, any transfer, grant of a security interest or usufructuary right in such intermediated securities and the appurtenant rights associated therewith requires the cooperation of the intermediary in order for such transfer, grant of a security interest or usufructuary right to be valid against us.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Voting rights may be exercised only after a shareholder has been entered in the share register (<font style="font-style: italic;">registre des </font><font style="font-style: italic;">actions</font>) with his or her name and address (in the case of legal entities, the registered office) as a shareholder with voting rights. For a discussion of the restrictions applicable to the control and exercise of voting rights, see &#8220;Description of Share Capital and Articles of Association&#8212;Articles of Association&#8212;Voting Rights.&#8221;</div><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 14pt; margin-left: 0pt; text-align: left;">Inspection of Books and Records </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Under the CO, a shareholder has a right to inspect the share register with respect to his or her own shares and otherwise to the extent necessary to exercise his or her shareholder rights. No other person has a right to inspect the share register. Our books and correspondence may be inspected with the express authorization of the general meeting of shareholders or by resolution of the board of directors and subject to the safeguarding of our business secrets and other legitimate interests. See &#8220;Comparison of Swiss Law and Delaware Law&#8212;Inspection of books and records.&#8221;</div><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 16pt; margin-left: 0pt; text-align: left;">Special Investigation</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">If the shareholders&#8217; inspection rights as outlined above prove to be insufficient in the judgment of the shareholder, any shareholder may propose to the general meeting of shareholders that specific facts be examined by a special examiner in a special investigation. If the general meeting of shareholders approves the proposal, we or any shareholder may, within 30 calendar days after the general meeting of shareholders, request a court at our registered office (currently Epalinges, Canton of Vaud, Switzerland), to appoint a special examiner. If the general meeting of shareholders rejects the request, one or more shareholders representing at least 10% of our share capital or holders of shares in an aggregate par value of at least CHF 2,000,000 may request that the court appoint a special examiner. The court will issue such an order if the petitioners can demonstrate that the board of directors, any member of the board of directors or our executive committee infringed the law or our articles of association and thereby caused damages to the Company or the shareholders. The costs of the investigation would generally be allocated to us and only in exceptional cases to the petitioners. </div><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 15pt; margin-left: 0pt; text-align: left;">Compulsory Acquisitions; Appraisal Rights</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Business combinations and other transactions that are governed by the Swiss Merger Act (i.e., mergers, demergers, transformations and certain asset transfers) are binding on all shareholders. A statutory merger or demerger requires approval of two-thirds of the shares represented at a general meeting of shareholders and the absolute majority of the par value of the shares represented.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">If a transaction under the Swiss Merger Act receives all of the necessary consents, all shareholders are compelled to participate in such transaction.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Swiss corporations may be acquired by an acquirer through the direct acquisition of the shares of the Swiss corporation. The Swiss Merger Act provides for the possibility of a so-called &#8220;cash-out&#8221; or &#8220;squeeze-out&#8221; merger with the approval of holders of 90% of the issued shares. In these limited circumstances, minority </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 36pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">215<br></div></div></div>
<!--End Page 219-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 220-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 540pt;"><a name="nt10014672x1_drs_109-description_pg9"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="block-frill" style="width: 540pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: Arial, Helvetica, sans-serif; font-size: 9pt; font-weight: bold; margin-top: 6pt; text-align: center;">Confidential Treatment Requested by ADC Therapeutics SA Pursuant to 17 C.F.R. &#167; 200.83<br></div></div><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 36pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">shareholders of the corporation being acquired may be compensated in a form other than through shares of the acquiring corporation (for instance, through cash or securities of a parent corporation of the acquiring corporation or of another corporation). For business combinations effected in the form of a statutory merger or demerger and subject to Swiss law, the Swiss Merger Act provides that if equity rights have not been adequately preserved or compensation payments in the transaction are unreasonable, a shareholder may request the competent court to determine a reasonable amount of compensation.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">In addition, under Swiss law, the sale of &#8220;all or substantially all of our assets&#8221; by us may require the approval of two-thirds of the number of shares represented at a general meeting of shareholders and the absolute majority of the par value of the shares represented. Whether a shareholder resolution is required depends on the particular transaction, including whether the following test is satisfied:</div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">a core part of our business is sold without which it is economically impracticable or unreasonable to continue to operate the remaining business;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">our assets, after the divestment, are not invested in accordance with our corporate purpose as set forth in the articles of association; and</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the proceeds of the divestment are not earmarked for reinvestment in accordance with our corporate purpose but, instead, are intended for distribution to our shareholders or for financial investments unrelated to our corporate purpose.</div></td></tr></table><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">A shareholder of a Swiss corporation participating in certain major corporate transactions may, under certain circumstances, be entitled to appraisal rights. As a result, such shareholder may, in addition to the consideration (be it in shares or in cash) receive an additional amount to ensure that the shareholder receives the fair value of the shares held by the shareholder. Following a statutory merger or demerger, pursuant to the Swiss Merger Act, shareholders can file an appraisal action against the surviving company. If the consideration is deemed inadequate, the court will determine an adequate compensation payment.</div><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 14.5pt; margin-left: 0pt; text-align: left;">Board of Directors</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Our articles of association provide that the board of directors shall consist of at least three and not more than 11 members.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The members of the board of directors and the chairman are elected annually by the general meeting of shareholders for a period until the completion of the subsequent annual general meeting of shareholders and are eligible for re-election. Each member of the board of directors must be elected individually.</div><div class="h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 14.5pt; margin-left: 0pt; text-align: left;">Powers</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 7pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The board of directors has the following non-delegable and inalienable powers and duties:</div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the ultimate direction of the business of the Company and issuing of the relevant directives;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">laying down the organization of the Company;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">formulating accounting procedures, financial controls and financial planning;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">nominating and removing persons entrusted with the management and representation of the Company and regulating the power to sign for the Company;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the ultimate supervision of those persons entrusted with management of the Company, with particular regard to adherence to law, our articles of association, and regulations and directives of the Company;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">issuing the business report and the compensation report, and preparing for the general meeting of shareholders and carrying out its resolutions; and</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">informing the court in case of over-indebtedness.</div></td></tr></table><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The board of directors may, while retaining such non-delegable and inalienable powers and duties, delegate some of its powers, in particular direct management, to a single or to several of its members, committees or to third parties (such as executive officers) who need be neither members of the board of directors nor shareholders. Pursuant to Swiss law and our articles of association, details of the delegation and other procedural rules such as quorum requirements have been set in the organizational rules established by the board of directors. </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 36pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">216<br></div></div></div>
<!--End Page 220-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 221-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 540pt;"><a name="nt10014672x1_drs_109-description_pg10"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="block-frill" style="width: 540pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: Arial, Helvetica, sans-serif; font-size: 9pt; font-weight: bold; margin-top: 6pt; text-align: center;">Confidential Treatment Requested by ADC Therapeutics SA Pursuant to 17 C.F.R. &#167; 200.83<br></div></div><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 36pt;"><div class="h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">Indemnification of Executive Officers and Directors</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Subject to Swiss law, our articles of association provide for indemnification of the existing and former members of the board of directors and the executive committee and their heirs, executors and administrators, against liabilities arising in connection with the performance of their duties in such capacity, and permits us to advance the expenses of defending any act, suit or proceeding to our directors and executive officers to the extent not included in insurance coverage or advanced by third parties.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">In addition, under general principles of Swiss employment law, an employer may be required to indemnify an employee against losses and expenses incurred by such employee in the proper execution of his or her duties under the employment agreement with the employer. See &#8220;Comparison of Swiss Law and Delaware Law&#8212;Indemnification of directors and executive officers and limitation of liability.&#8221;</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">We have entered into indemnification agreements with each of the members of our board of directors and executive officers. See &#8220;Related Party Transactions&#8212;Indemnification Agreements.&#8221;</div><div class="h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 15pt; margin-left: 0pt; text-align: left;">Conflict of Interest, Management Transactions </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Swiss law does not have a general provision regarding conflicts of interest. However, the CO contains a provision that requires our directors and executive officers to safeguard the Company&#8217;s interests and imposes a duty of loyalty and duty of care on our directors and executive officers. This rule is generally understood to disqualify directors and executive officers from participation in decisions that directly affect them. Our directors and executive officers are personally liable to us for breaches of these obligations. In addition, Swiss law contains provisions under which directors and all persons engaged in the Company&#8217;s management are liable to the Company, each shareholder and the Company&#8217;s creditors for damages caused by an intentional or negligent violation of their duties. Furthermore, Swiss law contains a provision under which payments made to any of the Company&#8217;s shareholders or directors or any person related to any such shareholder or director, other than payments made at arm&#8217;s length, must be repaid to the Company if such shareholder or director acted in bad faith.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Our board of directors has adopted a Code of Business Conduct and Ethics and will adopt, upon the closing of this offering, other policies that will cover a broad range of matters, including the handling of conflicts of interest.</div><div class="h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 15pt; margin-left: 0pt; text-align: left;">Principles of the Compensation of the Board of Directors and the Executive Committee</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Pursuant to Swiss law, beginning at our annual general meeting of shareholders in 2021, our shareholders must annually approve the aggregate amount of compensation of the board of directors and the persons whom the board of directors has, fully or partially, entrusted with the management (which we refer to as our &#8220;executive committee&#8221;) of the Company. All of our executive officers named in &#8220;Management&#8221; are deemed to be members of our executive committee.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The board of directors must issue, on an annual basis, a written compensation report that must be reviewed by our auditors. The compensation report must disclose all compensation granted by the Company, directly or indirectly, to current members of the board of directors and the executive committee and, to the extent related to their former role within the Company or not on customary market terms, to former members of the board of directors and former executive officers.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The disclosure concerning compensation, loans and other forms of indebtedness must include the aggregate amount for the board of directors and the executive committee, respectively, as well as the particular amount for each member of the board of directors and for the highest paid executive officer, specifying the name and function of each of these persons.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">We are prohibited from granting certain forms of compensation to members of our board of directors and executive committee, such as:</div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">severance payments (compensation due until the termination of a contractual relationship does not qualify as severance payment);</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">advance compensation;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">incentive fees for the acquisition or transfer of companies, or parts thereof, by the Company or by companies being, directly or indirectly, controlled by us;</div></td></tr></table></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 36pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">217<br></div></div></div>
<!--End Page 221-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 222-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 540pt;"><a name="nt10014672x1_drs_109-description_pg11"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="block-frill" style="width: 540pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: Arial, Helvetica, sans-serif; font-size: 9pt; font-weight: bold; margin-top: 6pt; text-align: center;">Confidential Treatment Requested by ADC Therapeutics SA Pursuant to 17 C.F.R. &#167; 200.83<br></div></div><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 36pt;"><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6.75pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">loans, other forms of indebtedness, pension benefits not based on occupational pension schemes and performance-based compensation not provided for in the articles of association; and</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">equity-based compensation not provided for in the articles of association.</div></td></tr></table><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Compensation to members of the board of directors and the executive committee for activities in entities that are, directly or indirectly, controlled by the Company is prohibited if (i)&#160;the compensation would be prohibited if it were paid directly by the Company, (ii)&#160;the articles of association do not provide for it, or (iii)&#160;the compensation has not been approved by the general meeting of shareholders. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Beginning in 2021, the general meeting of shareholders will annually vote on the proposals of the board of directors with respect to:</div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the maximum aggregate amount of compensation of the board of directors for the term of office until the next annual general meeting of shareholders; and</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the maximum aggregate amount of fixed compensation of the executive committee for the following financial year; and</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the maximum aggregate amount of variable compensation of the executive committee for the current financial year.</div></td></tr></table><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The board of directors may submit for approval at the general meeting of shareholders deviating or additional proposals relating to the same or different periods.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">If, at the general meeting of shareholders, the shareholders do not approve a compensation proposal of the board of directors, the board of directors must prepare a new proposal, taking into account all relevant factors, and submit the new proposal for approval by the same general meeting of shareholders, at a subsequent extraordinary general meeting of shareholders or the next annual general meeting of shareholders.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">In addition to fixed compensation, members of the board of directors and the executive committee may be paid variable compensation, depending on the achievement of certain performance criteria. The performance criteria may include individual targets, targets of the Company or parts thereof and targets in relation to the market, other companies or comparable benchmarks, taking into account the position and level of responsibility of the recipient of the variable compensation. The board of directors or, where delegated to it, the compensation committee shall determine the relative weight of the performance criteria and the respective target values.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Compensation may be paid or granted in the form of cash, shares, financial instruments, in kind, or in the form of other types of benefits. The board of directors or, where delegated to it, the compensation committee shall determine grant, vesting, exercise and forfeiture conditions.</div><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">Borrowing Powers</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Neither Swiss law nor our articles of association restrict our power to borrow and raise funds. The decision to borrow funds is made by or under the direction of our board of directors, and no approval by the shareholders is required in relation to any such borrowing.</div><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">Repurchases of Shares and Purchases of Own Shares</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The CO limits our ability to repurchase and hold our own shares. We and our subsidiaries may repurchase shares only to the extent that (i)&#160;we have freely distributable reserves in the amount of the purchase price; and (ii)&#160;the aggregate par value of all shares held by us does not exceed 10% of our share capital. Pursuant to Swiss law, where shares are acquired in connection with a transfer restriction set out in the articles of association, the foregoing upper limit is 20%. If we own shares that exceed the threshold of 10% of our share capital, the excess must be sold or cancelled by means of a capital reduction within two years.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Shares held by us or our subsidiaries are not entitled to vote at the general meeting of shareholders but are entitled to the economic benefits applicable to the shares generally, including dividends and pre-emptive subscription rights in the case of share capital increases.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">In addition, selective share repurchases are only permitted under certain circumstances. Within these limitations, as is customary for Swiss corporations, we may, subject to applicable law, purchase and sell our own shares from time to time in order to meet imbalances of supply and demand, to provide liquidity and to even out variances in the market price of shares.</div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 36pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">218<br></div></div></div>
<!--End Page 222-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 223-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 540pt;"><a name="nt10014672x1_drs_109-description_pg12"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="block-frill" style="width: 540pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: Arial, Helvetica, sans-serif; font-size: 9pt; font-weight: bold; margin-top: 6pt; text-align: center;">Confidential Treatment Requested by ADC Therapeutics SA Pursuant to 17 C.F.R. &#167; 200.83<br></div></div><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 36pt;"><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">Notification and Disclosure of Substantial Share Interests </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The disclosure obligations generally applicable to shareholders of Swiss corporations under the Federal Act on Financial Market Infrastructures and Market Conduct in Securities and Derivatives Trading, or the Financial Market Infrastructure Act (the &#8220;FMIA&#8221;), do not apply to us since our shares are not listed on a Swiss exchange.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Pursuant to Article 663c of the CO, Swiss corporations whose shares are listed on a stock exchange must disclose their significant shareholders and their shareholdings in the notes to their statutory annual financial statements, to the extent that this information is known or ought to be known. Significant shareholders are defined as shareholders and groups of shareholders linked through voting rights who hold more than 5% of all voting rights.</div><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 20.5pt; margin-left: 0pt; text-align: left;">Mandatory Bid Rules</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The obligation of any person or group of persons that acquires more than one third of a company&#8217;s voting rights to submit a cash offer for all the outstanding listed equity securities of the relevant company at a minimum price pursuant to the FMIA does not apply to us since our shares are not listed on a Swiss exchange.</div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 20.5pt; margin-left: 0pt; text-align: left;">Stock Exchange Listing</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 7.5pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Our common shares are listed on the NYSE under the symbol &#8220;ADCT.&#8221;</div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 20.5pt; margin-left: 0pt; text-align: left;">The Depository Trust Company</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Initial settlement of the common shares issued in this offering will take place on the consummation date of this offering through DTC, in accordance with its customary settlement procedures for equity securities. Each person owning a beneficial interest in common shares held through DTC must rely on the procedures thereof and on institutions that have accounts therewith to exercise any rights of a holder of the shares.</div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 20.5pt; margin-left: 0pt; text-align: left;">Transfer Agent and Registrar of Shares</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Our share register is kept by Computershare Trust Company, N.A., which acts as transfer agent and registrar. The share register reflects only record owners of our shares. Swiss law does not recognize fractional share interests.</div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 36pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">219<br></div></div></div>
<!--End Page 223-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 224-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 540pt;"><a name="nt10014672x1_drs_110-comparision_pg1"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="block-frill" style="width: 540pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: Arial, Helvetica, sans-serif; font-size: 9pt; font-weight: bold; margin-top: 6pt; text-align: center;">Confidential Treatment Requested by ADC Therapeutics SA Pursuant to 17 C.F.R. &#167; 200.83<br></div></div><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 36pt;"><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: center;"><a name="tCOSL"><!--Anchor--></a>COMPARISON OF SWISS LAW AND DELAWARE LAW</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The Swiss laws applicable to Swiss corporations and their shareholders differ from laws applicable to U.S.&#160;corporations and their shareholders. The following table summarizes significant differences in shareholder rights between the provisions of the Swiss Code of Obligations (<font style="font-style: italic;">Code des obligations</font>) and the Swiss Ordinance against excessive compensation in listed stock corporations applicable to our Company and the Delaware General Corporation Law applicable to companies incorporated in Delaware and their shareholders. Please note that this is only a general summary of certain provisions applicable to companies in Delaware. Certain Delaware companies may be permitted to exclude certain of the provisions summarized below in their charter documents.</div><table cellspacing="0" cellpadding="0" class="txttab" style="margin-top: 11.25pt; border-collapse: collapse; width: 468pt; margin-left: auto; margin-right: auto;"><tr class="header"><td style="width: 48.72%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 3.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">DELAWARE CORPORATE LAW</div></td><td class="gutter" style="width: 1.28%; font-size: 2pt; padding-top: 6pt; padding-bottom: 3.75pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.28%; font-size: 2pt; padding-top: 6pt; padding-bottom: 3.75pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 48.72%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 3.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">SWISS CORPORATE LAW</div></td></tr><tr><td colspan="4" style="width: 100%; text-align: center; vertical-align: top; padding-top: 3.75pt; padding-bottom: 2.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 0pt; text-align: center;">Mergers and similar arrangements</div></td></tr><tr><td style="width: 48.72%; text-align: left; vertical-align: top; padding-top: 2.5pt; padding-bottom: 2.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td style="width: 48.72%; text-align: left; vertical-align: bottom; padding-top: 2.5pt; padding-bottom: 2.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 48.72%; text-align: left; vertical-align: top; padding-top: 2.5pt; padding-bottom: 2.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Under the Delaware General Corporation Law, with certain exceptions, a merger, consolidation, sale, lease or transfer of all or substantially all of the assets of a corporation must be approved by the board of directors and a majority of the outstanding shares entitled to vote thereon. A shareholder of a Delaware corporation participating in certain major corporate transactions may, under certain circumstances, be entitled to appraisal rights pursuant to which such shareholder may receive cash in the amount of the fair value of the shares held by such shareholder (as determined by a court) in lieu of the consideration such shareholder would otherwise receive in the transaction. The Delaware General Corporation Law also provides that a parent corporation, by resolution of its board of directors, may merge with any subsidiary, of which it owns at least 90.0% of each class of capital stock without a vote by the shareholders of such subsidiary. Upon any such merger, dissenting shareholders of the subsidiary would have appraisal rights.</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td style="width: 48.72%; text-align: left; vertical-align: top; padding-top: 2.5pt; padding-bottom: 2.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Under Swiss law, with certain exceptions, a merger or a demerger of the corporation or a sale of all or substantially all of the assets of a corporation must be approved by two-thirds of the voting rights represented at the respective general meeting of shareholders as well as the absolute majority of the par value of shares represented at such general meeting of shareholders. A&#160;shareholder of a Swiss corporation participating in a statutory merger or demerger pursuant to the Swiss Merger Act (<font style="font-style: italic;">Loi sur la fusion</font>) can file a lawsuit against the surviving company. If the consideration is deemed &#8220;inadequate,&#8221; such shareholder may, in addition to the consideration (be it in shares or in cash) receive an additional amount to ensure that such shareholder receives the fair value of the shares held by such shareholder. Swiss law also provides that if the merger agreement provides only for a compensation payment, at least 90.0% of all members in the transferring legal entity, who are entitled to vote, shall approve the merger agreement.</div></td></tr><tr><td style="width: 48.72%; text-align: left; vertical-align: top; padding-top: 2.5pt; padding-bottom: 2.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td style="width: 48.72%; text-align: left; vertical-align: top; padding-top: 2.5pt; padding-bottom: 2.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td colspan="4" style="width: 100%; text-align: center; vertical-align: top; padding-top: 2.5pt; padding-bottom: 2.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 0pt; text-align: center;">Shareholders&#8217; suits</div></td></tr><tr><td style="width: 48.72%; text-align: left; vertical-align: top; padding-top: 2.5pt; padding-bottom: 2.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td style="width: 48.72%; text-align: left; vertical-align: top; padding-top: 2.5pt; padding-bottom: 2.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 48.72%; text-align: left; vertical-align: top; padding-top: 2.5pt; padding-bottom: 2.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Class actions and derivative actions generally are available to shareholders of a Delaware corporation for, among other things, breach of fiduciary duty, corporate waste and actions not taken in accordance with applicable law. In such actions, the court has discretion to permit the winning party to recover attorneys&#8217; fees incurred in connection with such action.</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td style="width: 48.72%; text-align: left; vertical-align: top; padding-top: 2.5pt; padding-bottom: 2.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Class actions and derivative actions as such are not available under Swiss law. Nevertheless, certain actions may have a similar effect. A shareholder is entitled to bring suit against directors for breach of their duties and claim the payment of the company&#8217;s losses or damages to the corporation and, in some cases, to the individual shareholder. Likewise, an appraisal lawsuit won by a shareholder may indirectly compensate all shareholders. In addition, to the extent that U.S. laws and regulations provide a basis for liability and U.S. courts have jurisdiction, a class action may be available.</div></td></tr><tr><td style="width: 48.72%; text-align: left; vertical-align: top; padding-top: 2.5pt; padding-bottom: 2.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td style="width: 48.72%; text-align: left; vertical-align: top; padding-top: 2.5pt; padding-bottom: 2.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 48.72%; text-align: left; vertical-align: top; padding-top: 2.5pt; padding-bottom: 2.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td style="width: 48.72%; text-align: left; vertical-align: top; padding-top: 2.5pt; padding-bottom: 2.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Under Swiss law, the winning party is generally entitled to recover a limited amount of attorneys&#8217; fees incurred in connection with such action. The court has discretion to permit the shareholder who lost the lawsuit to recover attorneys&#8217; fees incurred to the extent that he acted in good faith.</div></td></tr><tr><td style="width: 48.72%; text-align: left; vertical-align: top; padding-top: 2.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt;">&#8203;</td><td style="width: 48.72%; text-align: left; vertical-align: top; padding-top: 2.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr></table></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 36pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">220<br></div></div></div>
<!--End Page 224-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 225-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 540pt;"><a name="nt10014672x1_drs_110-comparision_pg2"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="block-frill" style="width: 540pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: Arial, Helvetica, sans-serif; font-size: 9pt; font-weight: bold; margin-top: 6pt; text-align: center;">Confidential Treatment Requested by ADC Therapeutics SA Pursuant to 17 C.F.R. &#167; 200.83<br></div></div><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 36pt;"><table cellspacing="0" cellpadding="0" class="txttab" style="margin-top: 4pt; border-collapse: collapse; width: 468pt; margin-left: auto; margin-right: auto;"><tr class="header"><td style="width: 48.72%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 3.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">DELAWARE CORPORATE LAW</div></td><td class="gutter" style="width: 1.28%; font-size: 2pt; padding-top: 6pt; padding-bottom: 3.75pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.28%; font-size: 2pt; padding-top: 6pt; padding-bottom: 3.75pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 48.72%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 3.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">SWISS CORPORATE LAW</div></td></tr><tr><td colspan="4" style="width: 100%; text-align: center; vertical-align: top; padding-top: 3.75pt; padding-bottom: 2.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 0pt; text-align: center;">Shareholder vote on board and management compensation</div></td></tr><tr><td style="width: 48.72%; text-align: left; vertical-align: top; padding-top: 2.5pt; padding-bottom: 2.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td style="width: 48.72%; text-align: left; vertical-align: top; padding-top: 2.5pt; padding-bottom: 2.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 48.72%; text-align: left; vertical-align: top; padding-top: 2.5pt; padding-bottom: 2.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Under the Delaware General Corporation Law, the board of directors has the authority to fix the compensation of directors, unless otherwise restricted by the certificate of incorporation or bylaws.</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td style="width: 48.72%; text-align: left; vertical-align: top; padding-top: 2.5pt; padding-bottom: 2.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Pursuant to the Swiss Ordinance against excessive compensation in listed stock corporations (<font style="font-style: italic;">Ordonnance </font><font style="font-style: italic;">contre les r&#233;mun&#233;rations abusives dans les soci&#233;t&#233;s </font><font style="font-style: italic;">anonymes cot&#233;es en bourse</font>), the general meeting of shareholders has the non-transferable right, amongst others, to vote separately and bindingly on the aggregate amount of compensation of the members of the board of directors, of the executive committee and of the advisory boards.</div></td></tr><tr><td style="width: 48.72%; text-align: left; vertical-align: top; padding-top: 2.5pt; padding-bottom: 2.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td style="width: 48.72%; text-align: left; vertical-align: top; padding-top: 2.5pt; padding-bottom: 2.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td colspan="4" style="width: 100%; text-align: center; vertical-align: top; padding-top: 2.5pt; padding-bottom: 2.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 0pt; text-align: center;">Annual vote on board renewal</div></td></tr><tr><td style="width: 48.72%; text-align: left; vertical-align: top; padding-top: 2.5pt; padding-bottom: 2.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td style="width: 48.72%; text-align: left; vertical-align: top; padding-top: 2.5pt; padding-bottom: 2.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 48.72%; text-align: left; vertical-align: top; padding-top: 2.5pt; padding-bottom: 2.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Unless directors are elected by written consent in lieu of an annual meeting, directors are elected in an annual meeting of shareholders on a date and at a time designated by or in the manner provided in the bylaws. Re-election is possible.<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">&#8195;<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Classified boards are permitted.</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td style="width: 48.72%; text-align: left; vertical-align: top; padding-top: 2.5pt; padding-bottom: 2.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">The general meeting of shareholders elects the members of the board of directors, the chairperson of the board of directors and the members of the compensation committee individually and annually for a term of office until the end of the following general meeting of shareholders. Re-election is possible.</div></td></tr><tr><td style="width: 48.72%; text-align: left; vertical-align: top; padding-top: 2.5pt; padding-bottom: 2.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td style="width: 48.72%; text-align: left; vertical-align: top; padding-top: 2.5pt; padding-bottom: 2.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td colspan="4" style="width: 100%; text-align: center; vertical-align: top; padding-top: 2.5pt; padding-bottom: 2.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 0pt; text-align: center;">Indemnification of directors and executive officers and limitation of liability</div></td></tr><tr><td style="width: 48.72%; text-align: left; vertical-align: top; padding-top: 2.5pt; padding-bottom: 2.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td style="width: 48.72%; text-align: left; vertical-align: top; padding-top: 2.5pt; padding-bottom: 2.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 48.72%; text-align: left; vertical-align: top; padding-top: 2.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">The Delaware General Corporation Law provides that a certificate of incorporation may contain a provision eliminating or limiting the personal liability of directors (but not other controlling persons) of the corporation for monetary damages for breach of a fiduciary duty as a director, except no provision in the certificate of incorporation may eliminate or limit the liability of a director for:<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">&#8195;<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">&#8226;&#8199;&#8199;&#8201;&#8201;any breach of a director&#8217;s duty of loyalty to the <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">&#8199;&#8199;&#8201;&#8201;&#8199;corporation or its shareholders;<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">&#8195;<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">&#8226;&#8199;&#8199;&#8201;&#8201;acts or omissions not in good faith or which <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">&#8199;&#8199;&#8199;&#8201;&#8201;involve intentional misconduct or a knowing <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">&#8199;&#8199;&#8199;&#8201;&#8201;violation of law;<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">&#8195;<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">&#8226;&#8199;&#8199;&#8201;&#8201;statutory liability for unlawful payment of <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">&#8199;&#8199;&#8199;&#8201;&#8201;dividends or unlawful share purchase or <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">&#8199;&#8199;&#8199;&#8201;&#8201;redemption; or<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">&#8195;<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">&#8226;&#8199;&#8199;&#8201;&#8201;any transaction from which the director derived an <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">&#8199;&#8199;&#8199;&#8201;&#8201;improper personal benefit.<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">&#8195;<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">A Delaware corporation may indemnify any person who was or is a party or is threatened to be made a party to any proceeding, other than an action by or on behalf of the corporation, because the person is or was a director or officer, against liability incurred in connection with the proceeding if the director or officer acted in good faith and in a manner reasonably </div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt;">&#8203;</td><td style="width: 48.72%; text-align: left; vertical-align: top; padding-top: 2.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Under Swiss corporate law, an indemnification by the corporation of a director or member of the executive committee in relation to potential personal liability is not effective to the extent the director or member of the executive committee intentionally or negligently violated his or her corporate duties towards the corporation (certain views advocate that at least a grossly negligent violation is required to exclude the indemnification). Furthermore, the general meeting of shareholders may discharge (release) the directors and members of the executive committee from liability for their conduct to the extent the respective facts are known to shareholders. Such discharge is effective only with respect to claims of the company and of those shareholders who approved the discharge or who have since acquired their shares in full knowledge of the discharge. Most violations of corporate law are regarded as violations of duties towards the corporation rather than towards the shareholders. In addition, indemnification of other controlling persons is not permitted under Swiss corporate law, including shareholders of the corporation.<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">&#8195;<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">The articles of association of a Swiss corporation may also set forth that the corporation shall indemnify and hold harmless, to the extent permitted by the law, the directors and executive managers out of assets of the corporation against threatened, pending or completed actions.<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">&#8195;<br></div></td></tr></table></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 36pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">221<br></div></div></div>
<!--End Page 225-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 226-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 540pt;"><a name="nt10014672x1_drs_110-comparision_pg3"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="block-frill" style="width: 540pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: Arial, Helvetica, sans-serif; font-size: 9pt; font-weight: bold; margin-top: 6pt; text-align: center;">Confidential Treatment Requested by ADC Therapeutics SA Pursuant to 17 C.F.R. &#167; 200.83<br></div></div><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 36pt;"><table cellspacing="0" cellpadding="0" class="txttab" style="margin-top: 4pt; border-collapse: collapse; width: 468pt; margin-left: auto; margin-right: auto;"><tr class="header"><td style="width: 48.72%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 3.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">DELAWARE CORPORATE LAW</div></td><td class="gutter" style="width: 1.28%; font-size: 2pt; padding-top: 6pt; padding-bottom: 3.75pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.28%; font-size: 2pt; padding-top: 6pt; padding-bottom: 3.75pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 48.72%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 3.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">SWISS CORPORATE LAW</div></td></tr><tr><td style="width: 48.72%; text-align: left; vertical-align: top; padding-top: 3.75pt; padding-bottom: 2.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">believed to be in, or not opposed to, the best interests of the corporation; and the director or officer, with respect to any criminal action or proceeding, had no reasonable cause to believe his or her conduct was unlawful.<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">&#8195; <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Unless ordered by a court, any foregoing indemnification is subject to a determination that the director or officer has met the applicable standard of conduct:<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">&#8195; <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">&#8226; &#8199;&#8201;&#8201;by a majority vote of the directors who are not <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">&#8199;&#8199;&#8201;&#8201;&#8201;parties to the proceeding, even though less than a <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">&#8199;&#8199;&#8201;&#8201;&#8201;quorum; <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">&#8195; <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">&#8226;&#8199;&#8199;&#8201;by a committee of directors designated by a <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">&#8199;&#8199;&#8201;&#8201;&#8201;majority vote of the eligible directors, even though <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">&#8199;&#8199;&#8201;&#8201;&#8201;less than a quorum; <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">&#8195; <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">&#8226;&#8199;&#8199;&#8201;&#8201;by independent legal counsel in a written opinion <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">&#8199;&#8199;&#8201;&#8201;&#8201;&#8201;if there are no eligible directors, or if the eligible <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">&#8199;&#8199;&#8201;&#8201;&#8201;&#8201;directors so direct; or <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">&#8195; <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">&#8226;&#8199;&#8199;&#8201;&#8201;by the shareholders. <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">&#8195;<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Moreover, a Delaware corporation may not indemnify a director or officer in connection with any proceeding in which the director or officer has been adjudged to be liable to the corporation unless and only to the extent that the court determines that, despite the adjudication of liability but in view of all the circumstances of the case, the director or officer is fairly and reasonably entitled to indemnity for those expenses which the court deems proper. </div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3.75pt; padding-bottom: 2.5pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3.75pt; padding-bottom: 2.5pt;">&#8203;</td><td style="width: 48.72%; text-align: left; vertical-align: top; padding-top: 3.75pt; padding-bottom: 2.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Also, a corporation may enter into and pay for directors&#8217; and officers&#8217; liability insurance, which may cover negligent acts as well. </div></td></tr><tr><td style="width: 48.72%; text-align: left; vertical-align: top; padding-top: 2.5pt; padding-bottom: 2.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td style="width: 48.72%; text-align: left; vertical-align: top; padding-top: 2.5pt; padding-bottom: 2.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td colspan="4" style="width: 100%; text-align: center; vertical-align: top; padding-top: 2.5pt; padding-bottom: 2.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 0pt; text-align: center;">Directors&#8217; fiduciary duties</div></td></tr><tr><td style="width: 48.72%; text-align: left; vertical-align: top; padding-top: 2.5pt; padding-bottom: 2.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td style="width: 48.72%; text-align: left; vertical-align: top; padding-top: 2.5pt; padding-bottom: 2.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 48.72%; text-align: left; vertical-align: top; padding-top: 2.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">A director of a Delaware corporation has a fiduciary duty to the corporation and its shareholders. This duty has two components:<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">&#8195;<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">&#8226;&#8199;&#8199;&#8201;&#8201;the duty of care; and<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">&#8195;<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">&#8226;&#8199;&#8199;&#8201;&#8201;the duty of loyalty.<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">&#8195;<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">The duty of care requires that a director act in good faith, with the care that an ordinarily prudent person would exercise under similar circumstances. Under this duty, a director must inform himself or herself of, and disclose to shareholders, all material information reasonably available regarding a significant transaction.<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">&#8195;<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">&#8195;<br></div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt;">&#8203;</td><td style="width: 48.72%; text-align: left; vertical-align: top; padding-top: 2.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">The board of directors of a Swiss corporation manages the business of the corporation, unless responsibility for such management has been duly delegated to the executive committee based on organizational rules. However, there are several non-transferable duties of the board of directors:<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">&#8195;<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">&#8226;&#8199;&#8199;&#8201;&#8201;the overall management of the corporation and the <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">&#8199;&#8199;&#8199;&#8201;&#8201;issuing of all necessary directives;<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">&#8195; <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">&#8226;&#8199;&#8199;&#8201;&#8201;determination of the corporation&#8217;s organization;<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">&#8195; <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">&#8226;&#8199;&#8199;&#8201;&#8201;the organization of the accounting, financial <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">&#8199;&#8199;&#8199;&#8201;&#8201;control and financial planning systems as required <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">&#8199;&#8199;&#8199;&#8201;&#8201;for management of the corporation;<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">&#8195; <br></div></td></tr></table></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 36pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">222<br></div></div></div>
<!--End Page 226-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 227-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 540pt;"><a name="nt10014672x1_drs_110-comparision_pg4"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="block-frill" style="width: 540pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: Arial, Helvetica, sans-serif; font-size: 9pt; font-weight: bold; margin-top: 6pt; text-align: center;">Confidential Treatment Requested by ADC Therapeutics SA Pursuant to 17 C.F.R. &#167; 200.83<br></div></div><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 36pt;"><table cellspacing="0" cellpadding="0" class="txttab" style="margin-top: 4pt; border-collapse: collapse; width: 480pt; margin-left: auto; margin-right: auto;"><tr class="header"><td style="width: 47.5%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 3.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">DELAWARE CORPORATE LAW</div></td><td class="gutter" style="width: 1.25%; font-size: 2pt; padding-top: 6pt; padding-bottom: 3.75pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.25%; font-size: 2pt; padding-top: 6pt; padding-bottom: 3.75pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 47.5%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 3.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">SWISS CORPORATE LAW</div></td><td class="gutter" style="width: 1.25%; font-size: 2pt; padding-top: 6pt; padding-bottom: 3.75pt; border-bottom: 1px solid #ffffff;">&#8203;</td></tr><tr><td style="width: 47.5%; text-align: left; vertical-align: top; padding-top: 3.75pt; padding-bottom: 2.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">The duty of loyalty requires that a director act in a manner he or she reasonably believes to be in the best interests of the corporation. He or she must not use his or her corporate position for personal gain or advantage. This duty prohibits self-dealing by a director and mandates that the best interest of the corporation and its shareholders take precedence over any interest possessed by a director, officer or controlling shareholder and not shared by the shareholders generally. In general, actions of a director are presumed to have been made on an informed basis, in good faith and in the honest belief that the action taken was in the best interests of the corporation. However, this presumption may be rebutted by evidence of a breach of one of the fiduciary duties.<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">&#8195;<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Should such evidence be presented concerning a transaction by a director, a director must prove the procedural fairness of the transaction, and that the transaction was of fair value to the corporation.</div></td><td class="gutter" style="width: 1.25%; border-bottom: none; font-size: 2pt; padding-top: 3.75pt; padding-bottom: 2.5pt;">&#8203;</td><td class="gutter" style="width: 1.25%; border-bottom: none; font-size: 2pt; padding-top: 3.75pt; padding-bottom: 2.5pt;">&#8203;</td><td style="width: 47.5%; text-align: left; vertical-align: top; padding-top: 3.75pt; padding-bottom: 2.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">&#8226;&#8199;&#8199;&#8201;&#8201;the appointment and dismissal of persons <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">&#8199;&#8199;&#8199;&#8201;&#8201;entrusted with managing and representing the <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">&#8199;&#8199;&#8199;&#8201;&#8201;corporation;<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">&#8195; <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">&#8226;&#8199;&#8199;&#8201;&#8201;overall supervision of the persons entrusted with <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">&#8199;&#8199;&#8199;&#8201;&#8201;managing the corporation, in particular with <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">&#8199;&#8199;&#8199;&#8201;&#8201;regard to compliance with the law, articles of <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">&#8199;&#8199;&#8199;&#8201;&#8201;association, operational regulations and directives;<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">&#8195; <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">&#8226;&#8199;&#8199;&#8201;&#8201;compilation of the annual report, preparation for <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">&#8199;&#8199;&#8199;&#8201;&#8201;the general meeting of the shareholders, the <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">&#8199;&#8199;&#8199;&#8201;&#8201;compensation report and implementation of its <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">&#8199;&#8199;&#8199;&#8201;&#8201;resolutions; and<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">&#8195; <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">&#8226;&#8199;&#8199;&#8201;&#8201;notification of the court in the event that the <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">&#8199;&#8199;&#8199;&#8201;&#8201;company is over-indebted. <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">&#8195;<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">The members of the board of directors must perform their duties with all due diligence and safeguard the interests of the corporation in good faith. They must afford the shareholders equal treatment in equal circumstances.<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">&#8195;<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">The duty of care requires that a director act in good faith, with the care that an ordinarily prudent director would exercise under like circumstances<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">&#8195;<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">The duty of loyalty requires that a director safeguard the interests of the corporation and requires that directors act in the interest of the corporation and, if necessarily, put aside their own interests. If there is a risk of a conflict of interest, the board of directors must take appropriate measures to ensure that the interests of the company are duly taken into account.<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">&#8195;<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">The burden of proof for a violation of these duties is with the corporation or with the shareholder bringing a suit against the director.</div></td><td class="gutter" style="width: 1.25%; border-bottom: none; font-size: 2pt; padding-top: 3.75pt; padding-bottom: 2.5pt;">&#8203;</td></tr><tr><td style="width: 47.5%; text-align: left; vertical-align: top; padding-top: 2.5pt; padding-bottom: 2.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.25%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td class="gutter" style="width: 1.25%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td style="width: 47.5%; text-align: left; vertical-align: top; padding-top: 2.5pt; padding-bottom: 2.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.25%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td></tr><tr><td colspan="4" style="width: 97.5%; text-align: center; vertical-align: top; padding-top: 2.5pt; padding-bottom: 2.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 0pt; text-align: center;">Shareholder action by written consent</div></td><td class="gutter" style="width: 1.25%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td></tr><tr><td style="width: 47.5%; text-align: left; vertical-align: top; padding-top: 2.5pt; padding-bottom: 2.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.25%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td class="gutter" style="width: 1.25%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td style="width: 47.5%; text-align: left; vertical-align: top; padding-top: 2.5pt; padding-bottom: 2.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.25%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td></tr><tr><td style="width: 47.5%; text-align: left; vertical-align: top; padding-top: 2.5pt; padding-bottom: 2.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">A Delaware corporation may, in its certificate of incorporation, eliminate the right of shareholders to act by written consent.</div></td><td class="gutter" style="width: 1.25%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td class="gutter" style="width: 1.25%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td colspan="4" style="width: 50%; text-align: left; vertical-align: top; padding-top: 2.5pt; padding-bottom: 2.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Shareholders of a Swiss corporation may only exercise their voting rights in a general meeting of shareholders and may not act by written consents. The articles of association must allow for (independent) proxies to be present at a general meeting of shareholders. The instruction of such (independent) proxies may occur in writing or electronically.</div></td></tr><tr><td style="width: 47.5%; text-align: left; vertical-align: top; padding-top: 2.5pt; padding-bottom: 2.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.25%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td class="gutter" style="width: 1.25%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td style="width: 47.5%; text-align: left; vertical-align: top; padding-top: 2.5pt; padding-bottom: 2.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.25%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td></tr><tr><td colspan="4" style="width: 97.5%; text-align: center; vertical-align: top; padding-top: 2.5pt; padding-bottom: 2.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 0pt; text-align: center;">Shareholder proposals</div></td><td class="gutter" style="width: 1.25%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td></tr><tr><td style="width: 47.5%; text-align: left; vertical-align: top; padding-top: 2.5pt; padding-bottom: 2.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.25%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td class="gutter" style="width: 1.25%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td style="width: 47.5%; text-align: left; vertical-align: top; padding-top: 2.5pt; padding-bottom: 2.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.25%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td></tr><tr><td style="width: 47.5%; text-align: left; vertical-align: top; padding-top: 2.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">A shareholder of a Delaware corporation has the right to put any proposal before the annual meeting of shareholders, provided it complies with the notice</div></td><td class="gutter" style="width: 1.25%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt;">&#8203;</td><td class="gutter" style="width: 1.25%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt;">&#8203;</td><td style="width: 47.5%; text-align: left; vertical-align: top; padding-top: 2.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">At any general meeting of shareholders any shareholder may put proposals to the meeting if the proposal is part of an agenda item. No resolution may be taken on </div></td><td class="gutter" style="width: 1.25%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt;">&#8203;</td></tr></table></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 36pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">223<br></div></div></div>
<!--End Page 227-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 228-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 540pt;"><a name="nt10014672x1_drs_110-comparision_pg5"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="block-frill" style="width: 540pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: Arial, Helvetica, sans-serif; font-size: 9pt; font-weight: bold; margin-top: 6pt; text-align: center;">Confidential Treatment Requested by ADC Therapeutics SA Pursuant to 17 C.F.R. &#167; 200.83<br></div></div><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 36pt;"><table cellspacing="0" cellpadding="0" class="txttab" style="margin-top: 4pt; border-collapse: collapse; width: 468pt; margin-left: auto; margin-right: auto;"><tr class="header"><td style="width: 48.72%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 3.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">DELAWARE CORPORATE LAW</div></td><td class="gutter" style="width: 1.28%; font-size: 2pt; padding-top: 6pt; padding-bottom: 3.75pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.28%; font-size: 2pt; padding-top: 6pt; padding-bottom: 3.75pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 48.72%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 3.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">SWISS CORPORATE LAW</div></td></tr><tr><td style="width: 48.72%; text-align: left; vertical-align: top; padding-top: 3.75pt; padding-bottom: 2.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">provisions in the governing documents. A special meeting may be called by the board of directors or any other person authorized to do so in the governing documents, but shareholders may be precluded from calling special meetings.</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3.75pt; padding-bottom: 2.5pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3.75pt; padding-bottom: 2.5pt;">&#8203;</td><td style="width: 48.72%; text-align: left; vertical-align: top; padding-top: 3.75pt; padding-bottom: 2.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">proposals relating to the agenda items that were not duly notified. Unless the articles of association provide for a lower threshold or for additional shareholders&#8217; rights:<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">&#8195;<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">&#8226;&#8199;&#8199;&#8201;&#8201;shareholders together representing at least 10% of <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">&#8199;&#8199;&#8199;&#8201;&#8201;the share capital may demand that a general meeting <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">&#8199;&#8199;&#8199;&#8201;&#8201;of shareholders be called for specific agenda items <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">&#8199;&#8199;&#8199;&#8201;&#8201;and specific proposals; and<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">&#8195;<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">&#8226;&#8199;&#8199;&#8201;&#8201;shareholders together representing shares with a par <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">&#8199;&#8199;&#8199;&#8201;&#8201;value of at least CHF 1.0&#160;million or 10% of the <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">&#8199;&#8199;&#8199;&#8201;&#8201;share capital, whichever is lower, may demand that <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">&#8199;&#8199;&#8199;&#8201;&#8201;an agenda item including a specific proposal be put <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">&#8199;&#8199;&#8199;&#8201;&#8201;on the agenda for a scheduled general meeting of <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">&#8199;&#8199;&#8199;&#8201;&#8201;shareholders, provided such request is made with <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">&#8199;&#8199;&#8199;&#8201;&#8201;appropriate lead time.<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">&#8195;<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Any shareholder can propose candidates for election as directors or make other proposals within the scope of an agenda item without prior written notice.<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">&#8195;<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">In addition, any shareholder is entitled, at a general meeting of shareholders and without advance notice, to (i)&#160;request information from the board of directors on the affairs of the company (note, however, that the right to obtain such information is limited), (ii)&#160;request information from the auditors on the methods and results of their audit, (iii)&#160;request that the general meeting of shareholders resolve to convene an extraordinary general meeting, or (iv)&#160;request that the general meeting of shareholders resolve to appoint an examiner to carry out a special examination (&#8220;<font style="font-style: italic;">contr&#244;le sp&#233;cial</font>&#8221;).</div></td></tr><tr><td style="width: 48.72%; text-align: left; vertical-align: top; padding-top: 2.5pt; padding-bottom: 2.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td style="width: 48.72%; text-align: left; vertical-align: top; padding-top: 2.5pt; padding-bottom: 2.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td colspan="4" style="width: 100%; text-align: center; vertical-align: top; padding-top: 2.5pt; padding-bottom: 2.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 0pt; text-align: center;">Cumulative voting</div></td></tr><tr><td style="width: 48.72%; text-align: left; vertical-align: top; padding-top: 2.5pt; padding-bottom: 2.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td style="width: 48.72%; text-align: left; vertical-align: top; padding-top: 2.5pt; padding-bottom: 2.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 48.72%; text-align: left; vertical-align: top; padding-top: 2.5pt; padding-bottom: 2.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Under the Delaware General Corporation Law, cumulative voting for elections of directors is not permitted unless the corporation&#8217;s certificate of incorporation provides for it.</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td style="width: 48.72%; text-align: left; vertical-align: top; padding-top: 2.5pt; padding-bottom: 2.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Cumulative voting is not permitted under Swiss corporate law. Pursuant to Swiss law, shareholders can vote for each proposed candidate, but they are not allowed to cumulate their votes for single candidates. An annual individual election of (i)&#160;all members of the board of directors, (ii)&#160;the chairperson of the board of directors, (iii)&#160;the members of the compensation committee, (iv)&#160;the election of the independent proxy for a term of office of one year (i.e., until the following annual general meeting of shareholders), as well as the vote on the aggregate amount of compensation of the members of the board of directors, of the executive committee and of the members of any advisory board, is mandatory for listed companies. Re-election is permitted.</div></td></tr><tr><td style="width: 48.72%; text-align: left; vertical-align: top; padding-top: 2.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt;">&#8203;</td><td style="width: 48.72%; text-align: left; vertical-align: top; padding-top: 2.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr></table></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 36pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">224<br></div></div></div>
<!--End Page 228-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 229-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 540pt;"><a name="nt10014672x1_drs_110-comparision_pg6"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="block-frill" style="width: 540pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: Arial, Helvetica, sans-serif; font-size: 9pt; font-weight: bold; margin-top: 6pt; text-align: center;">Confidential Treatment Requested by ADC Therapeutics SA Pursuant to 17 C.F.R. &#167; 200.83<br></div></div><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 36pt;"><table cellspacing="0" cellpadding="0" class="txttab" style="margin-top: 4pt; border-collapse: collapse; width: 468pt; margin-left: auto; margin-right: auto;"><tr class="header"><td style="width: 48.72%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 3.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">DELAWARE CORPORATE LAW</div></td><td class="gutter" style="width: 1.28%; font-size: 2pt; padding-top: 6pt; padding-bottom: 3.75pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.28%; font-size: 2pt; padding-top: 6pt; padding-bottom: 3.75pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 48.72%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 3.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">SWISS CORPORATE LAW</div></td></tr><tr><td colspan="4" style="width: 100%; text-align: center; vertical-align: top; padding-top: 3.75pt; padding-bottom: 2.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 0pt; text-align: center;">Removal of directors</div></td></tr><tr><td style="width: 48.72%; text-align: left; vertical-align: top; padding-top: 2.5pt; padding-bottom: 2.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td style="width: 48.72%; text-align: left; vertical-align: top; padding-top: 2.5pt; padding-bottom: 2.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 48.72%; text-align: left; vertical-align: top; padding-top: 2.5pt; padding-bottom: 2.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">A Delaware corporation with a classified board may be removed only for cause with the approval of a majority of the outstanding shares entitled to vote, unless the certificate of incorporation provides otherwise.</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td style="width: 48.72%; text-align: left; vertical-align: top; padding-top: 2.5pt; padding-bottom: 2.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">A Swiss corporation may remove, with or without cause, any director at any time with a resolution passed by a majority of the shares represented at a general meeting of shareholders. The articles of association may require the approval by a supermajority of the shares represented at a meeting for the removal of a director.</div></td></tr><tr><td style="width: 48.72%; text-align: left; vertical-align: top; padding-top: 2.5pt; padding-bottom: 2.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td style="width: 48.72%; text-align: left; vertical-align: top; padding-top: 2.5pt; padding-bottom: 2.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td colspan="4" style="width: 100%; text-align: center; vertical-align: top; padding-top: 2.5pt; padding-bottom: 2.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 0pt; text-align: center;">Transactions with interested shareholders</div></td></tr><tr><td style="width: 48.72%; text-align: left; vertical-align: top; padding-top: 2.5pt; padding-bottom: 2.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td style="width: 48.72%; text-align: left; vertical-align: top; padding-top: 2.5pt; padding-bottom: 2.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 48.72%; text-align: left; vertical-align: top; padding-top: 2.5pt; padding-bottom: 2.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">The Delaware General Corporation Law generally prohibits a Delaware corporation from engaging in certain business combinations with an &#8220;interested shareholder&#8221; for three years following the date that such person becomes an interested shareholder. An interested shareholder generally is a person or group who or which owns or owned 15.0% or more of the corporation&#8217;s outstanding voting shares within the past three years.</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td style="width: 48.72%; text-align: left; vertical-align: top; padding-top: 2.5pt; padding-bottom: 2.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">No such rule applies to a Swiss corporation.</div></td></tr><tr><td colspan="4" style="width: 100%; text-align: left; vertical-align: top; padding-top: 2.5pt; padding-bottom: 2.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td colspan="4" style="width: 100%; text-align: center; vertical-align: top; padding-top: 2.5pt; padding-bottom: 2.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 0pt; text-align: center;">Dissolution; Winding up</div></td></tr><tr><td style="width: 48.72%; text-align: left; vertical-align: top; padding-top: 2.5pt; padding-bottom: 2.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td style="width: 48.72%; text-align: left; vertical-align: top; padding-top: 2.5pt; padding-bottom: 2.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 48.72%; text-align: left; vertical-align: top; padding-top: 2.5pt; padding-bottom: 2.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Unless the board of directors of a Delaware corporation approves the proposal to dissolve, dissolution must be approved by shareholders holding 100.0% of the total voting power of the corporation. Only if the dissolution is initiated by the board of directors may it be approved by a simple majority of the corporation&#8217;s outstanding shares. Delaware law allows a Delaware corporation to include in its certificate of incorporation a supermajority voting requirement in connection with dissolutions initiated by the board.</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td style="width: 48.72%; text-align: left; vertical-align: top; padding-top: 2.5pt; padding-bottom: 2.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">A dissolution of a Swiss corporation requires the approval by two-thirds of the voting rights represented at the respective general meeting of shareholders as well as the absolute majority of the par value of shares represented at such general meeting of shareholders. The articles of association may increase the voting thresholds required for such a resolution.</div></td></tr><tr><td colspan="4" style="width: 100%; text-align: left; vertical-align: top; padding-top: 2.5pt; padding-bottom: 2.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td colspan="4" style="width: 100%; text-align: center; vertical-align: top; padding-top: 2.5pt; padding-bottom: 2.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 0pt; text-align: center;">Variation of rights of shares</div></td></tr><tr><td style="width: 48.72%; text-align: left; vertical-align: top; padding-top: 2.5pt; padding-bottom: 2.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td style="width: 48.72%; text-align: left; vertical-align: top; padding-top: 2.5pt; padding-bottom: 2.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 48.72%; text-align: left; vertical-align: top; padding-top: 2.5pt; padding-bottom: 2.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">A Delaware corporation may vary the rights of a class of shares with the approval of a majority of the outstanding shares of such class, unless the certificate of incorporation provides otherwise.</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td style="width: 48.72%; text-align: left; vertical-align: top; padding-top: 2.5pt; padding-bottom: 2.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">The general meeting of shareholders of a Swiss corporation may resolve that preference shares be issued or that existing shares be converted into preference shares with a resolution passed by a majority of the shares represented at the general meeting of shareholders. Where a company has issued preference shares, further preference shares conferring preferential rights over the existing preference shares may be issued only with the consent of both a special meeting of the adversely affected holders of the existing preference shares and of a general meeting of all shareholders, unless otherwise provided in the articles of association.<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">&#8195;<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Shares with preferential voting rights are not regarded as preference shares for these purposes.</div></td></tr><tr><td style="width: 48.72%; text-align: left; vertical-align: top; padding-top: 2.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt;">&#8203;</td><td style="width: 48.72%; text-align: left; vertical-align: top; padding-top: 2.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr></table></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 36pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">225<br></div></div></div>
<!--End Page 229-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 230-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 540pt;"><a name="nt10014672x1_drs_110-comparision_pg7"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="block-frill" style="width: 540pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: Arial, Helvetica, sans-serif; font-size: 9pt; font-weight: bold; margin-top: 6pt; text-align: center;">Confidential Treatment Requested by ADC Therapeutics SA Pursuant to 17 C.F.R. &#167; 200.83<br></div></div><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 36pt;"><table cellspacing="0" cellpadding="0" class="txttab" style="margin-top: 4pt; border-collapse: collapse; width: 468pt; margin-left: auto; margin-right: auto;"><tr class="header"><td style="width: 48.72%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 3.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">DELAWARE CORPORATE LAW</div></td><td class="gutter" style="width: 1.28%; font-size: 2pt; padding-top: 6pt; padding-bottom: 3.75pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.28%; font-size: 2pt; padding-top: 6pt; padding-bottom: 3.75pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 48.72%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 3.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">SWISS CORPORATE LAW</div></td></tr><tr><td colspan="4" style="width: 100%; text-align: center; vertical-align: top; padding-top: 3.75pt; padding-bottom: 2.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 0pt; text-align: center;">Amendment of governing documents</div></td></tr><tr><td style="width: 48.72%; text-align: left; vertical-align: top; padding-top: 2.5pt; padding-bottom: 2.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td style="width: 48.72%; text-align: left; vertical-align: top; padding-top: 2.5pt; padding-bottom: 2.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 48.72%; text-align: left; vertical-align: top; padding-top: 2.5pt; padding-bottom: 2.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">A Delaware corporation&#8217;s governing documents may be amended with the approval of a majority of the outstanding shares entitled to vote, unless the certificate of incorporation provides otherwise.</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td style="width: 48.72%; text-align: left; vertical-align: top; padding-top: 2.5pt; padding-bottom: 2.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">The articles of association of a Swiss corporation may be amended with a resolution passed by a majority of the shares represented at a general meeting of shareholders, unless otherwise provided in the articles of association.<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">&#8195;<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">There are a number of resolutions, such as an amendment of the stated purpose of the corporation, the introduction of authorized and conditional capital and the introduction of shares with preferential voting rights that require the approval by two-thirds of the votes and an absolute majority of the par value of the shares represented at such general meeting of shareholders. The articles of association may increase these voting thresholds.</div></td></tr><tr><td style="width: 48.72%; text-align: left; vertical-align: top; padding-top: 2.5pt; padding-bottom: 2.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td style="width: 48.72%; text-align: left; vertical-align: top; padding-top: 2.5pt; padding-bottom: 2.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td colspan="4" style="width: 100%; text-align: center; vertical-align: top; padding-top: 2.5pt; padding-bottom: 2.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 0pt; text-align: center;">Inspection of books and records</div></td></tr><tr><td style="width: 48.72%; text-align: left; vertical-align: top; padding-top: 2.5pt; padding-bottom: 2.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td style="width: 48.72%; text-align: left; vertical-align: top; padding-top: 2.5pt; padding-bottom: 2.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 48.72%; text-align: left; vertical-align: top; padding-top: 2.5pt; padding-bottom: 2.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Shareholders of a Delaware corporation, upon written demand under oath stating the purpose thereof, have the right during the usual hours for business to inspect for any proper purpose, and to obtain copies of list(s) of shareholders and other books and records of the corporation and its subsidiaries, if any, to the extent the books and records of such subsidiaries are available to the corporation.</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td style="width: 48.72%; text-align: left; vertical-align: top; padding-top: 2.5pt; padding-bottom: 2.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Shareholders of a Swiss corporation may only inspect books and records if the general meeting of shareholders or the board of directors approved such inspection. The information may be refused where providing it would jeopardize the corporation&#8217;s trade secrets or other interests warranting protection. A shareholder is only entitled to receive information to the extent required to exercise his or her rights as a shareholder, subject to the interests of the corporation. A shareholder&#8217;s right to inspect the share register is limited to the right to inspect his or her own entry in the share register.</div></td></tr><tr><td style="width: 48.72%; text-align: left; vertical-align: top; padding-top: 2.5pt; padding-bottom: 2.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td style="width: 48.72%; text-align: left; vertical-align: top; padding-top: 2.5pt; padding-bottom: 2.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td colspan="4" style="width: 100%; text-align: center; vertical-align: top; padding-top: 2.5pt; padding-bottom: 2.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 0pt; text-align: center;">Payment of dividends</div></td></tr><tr><td style="width: 48.72%; text-align: left; vertical-align: top; padding-top: 2.5pt; padding-bottom: 2.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td style="width: 48.72%; text-align: left; vertical-align: top; padding-top: 2.5pt; padding-bottom: 2.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 48.72%; text-align: left; vertical-align: top; padding-top: 2.5pt; padding-bottom: 2.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">The board of directors may approve a dividend without shareholder approval. Subject to any restrictions contained in its certificate of incorporation, the board may declare and pay dividends upon the shares of its capital stock either:<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">&#8195;<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">&#8226;&#8199;&#8199;&#8201;&#8201;out of its surplus, or<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">&#8195;<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">&#8226;&#8199;&#8199;&#8201;&#8201;in case there is no such surplus, out of its net <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">&#8199;&#8199;&#8199;&#8201;&#8201;profits for the fiscal year in which the dividend is <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">&#8199;&#8199;&#8199;&#8201;&#8201;declared and/or the preceding fiscal year.<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">&#8195;<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Shareholder approval is required to authorize capital stock in excess of that provided in the charter. Directors may issue authorized shares without shareholder approval. </div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td style="width: 48.72%; text-align: left; vertical-align: top; padding-top: 2.5pt; padding-bottom: 2.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Dividend payments are subject to the approval of the general meeting of shareholders. The board of directors may propose to shareholders that a dividend shall be paid but cannot itself authorize the distribution.<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">&#8195;<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Payments out of a corporation&#8217;s share capital (in other words, the aggregate par value of the corporation&#8217;s registered share capital) in the form of dividends are not allowed and may be made only by way of a share capital reduction. Dividends may be paid only from the profits of the previous business year or brought forward from previous business years or if the corporation has distributable reserves, each as evidenced by the corporation&#8217;s audited stand-alone statutory balance sheet prepared pursuant to Swiss law and after allocations to reserves required by Swiss law and the articles of association have been deducted.</div></td></tr><tr><td style="width: 48.72%; text-align: left; vertical-align: top; padding-top: 2.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt;">&#8203;</td><td style="width: 48.72%; text-align: left; vertical-align: top; padding-top: 2.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr></table></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 36pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">226<br></div></div></div>
<!--End Page 230-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 231-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 540pt;"><a name="nt10014672x1_drs_110-comparision_pg8"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="block-frill" style="width: 540pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: Arial, Helvetica, sans-serif; font-size: 9pt; font-weight: bold; margin-top: 6pt; text-align: center;">Confidential Treatment Requested by ADC Therapeutics SA Pursuant to 17 C.F.R. &#167; 200.83<br></div></div><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 36pt;"><table cellspacing="0" cellpadding="0" class="txttab" style="margin-top: 4pt; border-collapse: collapse; width: 468pt; margin-left: auto; margin-right: auto;"><tr class="header"><td style="width: 48.72%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 3.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">DELAWARE CORPORATE LAW</div></td><td class="gutter" style="width: 1.28%; font-size: 2pt; padding-top: 6pt; padding-bottom: 3.75pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.28%; font-size: 2pt; padding-top: 6pt; padding-bottom: 3.75pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 48.72%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 3.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">SWISS CORPORATE LAW</div></td></tr><tr><td colspan="4" style="width: 100%; text-align: center; vertical-align: top; padding-top: 3.75pt; padding-bottom: 2.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 0pt; text-align: center;">Creation and issuance of new shares</div></td></tr><tr><td style="width: 48.72%; text-align: left; vertical-align: top; padding-top: 2.5pt; padding-bottom: 2.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td style="width: 48.72%; text-align: left; vertical-align: top; padding-top: 2.5pt; padding-bottom: 2.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 48.72%; text-align: left; vertical-align: top; padding-top: 2.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">All creation of shares require the board of directors to adopt a resolution or resolutions, pursuant to authority expressly vested in the board of directors by the provisions of the company&#8217;s certificate of incorporation.</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt;">&#8203;</td><td style="width: 48.72%; text-align: left; vertical-align: top; padding-top: 2.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">All creation of shares require a shareholders&#8217; resolution. The creation of authorized or contingent share capital requires at least two-thirds of the voting rights represented at the general meeting of shareholders and an absolute majority of the par value of shares represented at such meeting. The board of directors may issue shares out of the authorized share capital during a period of up to two years. Shares are created and issued out of contingent share capital through the exercise of options or of conversion rights that the board of director may grant in relation to, e.g., debt instruments or employees.</div></td></tr></table></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 36pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">227<br></div></div></div>
<!--End Page 231-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 232-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 540pt;"><a name="nt10014672x1_drs_110-comparision_pg9"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="block-frill" style="width: 540pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: Arial, Helvetica, sans-serif; font-size: 9pt; font-weight: bold; margin-top: 6pt; text-align: center;">Confidential Treatment Requested by ADC Therapeutics SA Pursuant to 17 C.F.R. &#167; 200.83<br></div></div><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 36pt;"><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: center;"><a name="tCSE"><!--Anchor--></a>COMMON SHARES ELIGIBLE FOR FUTURE SALE</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Future sales of substantial amounts of our common shares in the public market could adversely affect market prices prevailing from time to time. Furthermore, because only a limited number of common shares will be available for sale shortly after this offering due to existing contractual and legal restrictions on resale as described below, there may be sales of substantial amounts of our common shares in the public market after such restrictions lapse. This may adversely affect the prevailing market price and our ability to raise equity capital in the future.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Based on the number of common shares outstanding as of June&#160;30, 2020, we will have &#8195;&#8195;&#8195;&#8195; common shares outstanding after this offering. The common shares sold in our initial public offering and in this offering are freely transferable without restriction or registration under the Securities Act, except for any common shares purchased by one of our existing &#8220;affiliates,&#8221; as that term is defined in Rule 144 under the Securities Act. The remaining common shares are &#8220;restricted shares&#8221; as defined in Rule 144. Restricted shares may be sold in the public market only if registered or if they qualify for an exemption from registration under Rules 144 or 701 of the Securities Act. After the expiration of the contractual lock-up period described below, to the extent applicable, these common shares may be sold in the public market only if registered or pursuant to an exemption under Rules 144 or 701, each of which is summarized below. </div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 20.5pt; margin-left: 0pt; text-align: left;">Rule 144 </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">In general, a person who has beneficially owned our common shares that are restricted shares for at least six months would be entitled to sell such securities, provided that (i)&#160;such person is not deemed to have been one of our affiliates at the time of, or at any time during the 90 days preceding, the sale and (ii)&#160;we are subject to, and in compliance with certain of, the Exchange Act periodic reporting requirements for at least 90 days before the sale. If such person has beneficially owned such common shares for at least one year, then the requirement in clause (ii)&#160;will not apply to the sale. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Persons who have beneficially owned our common shares that are restricted shares for at least six months but who are our affiliates at the time of, or any time during the 90 days preceding, a sale, would be subject to additional restrictions, by which such person would be entitled to sell within any three-month period only a number of securities that does not exceed the greater of either of the following: </div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">1% of the number of our common shares then outstanding, which will equal approximately &#8195;&#8195;&#8195;&#8195; common shares immediately after this offering; or</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the average weekly trading volume of our common shares on the NYSE during the four calendar weeks preceding the filing of a notice on Form 144 with respect to the sale;</div></td></tr></table><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">provided, in each case, that we are subject to, and in compliance with certain of, the Exchange Act periodic reporting requirements for at least 90 days before the sale. Such sales must also comply with the manner of sale and notice provisions of Rule 144.</div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 20.5pt; margin-left: 0pt; text-align: left;">Rule 701</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">In general, under Rule 701, any of our employees, directors, officers, consultants or advisors who purchases shares from us in connection with a compensatory share or option plan or other written agreement before our initial public offering is entitled to resell such shares 90 days after the date of our initial public offering in reliance on Rule&#160;144, without having to comply with the holding period requirements or other restrictions contained in Rule 701. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The SEC has indicated that Rule 701 will apply to typical share options granted by an issuer before it becomes subject to the reporting requirements of the Exchange Act, along with the shares acquired upon exercise of such options, including exercises after the date of our initial public offering. Securities issued in reliance on Rule 701 are restricted securities and, subject to the contractual restrictions described below, beginning 90 days after the date of our initial public offering, may be sold by persons other than &#8220;affiliates,&#8221; as defined in Rule&#160;144, subject only to the manner of sale provisions of Rule 144 and by &#8220;affiliates&#8221; under Rule 144 without compliance with the one-year minimum holding period requirement. </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 36pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">228<br></div></div></div>
<!--End Page 232-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 233-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 540pt;"><a name="nt10014672x1_drs_110-comparision_pg10"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="block-frill" style="width: 540pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: Arial, Helvetica, sans-serif; font-size: 9pt; font-weight: bold; margin-top: 6pt; text-align: center;">Confidential Treatment Requested by ADC Therapeutics SA Pursuant to 17 C.F.R. &#167; 200.83<br></div></div><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 36pt;"><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">Equity Incentive Plan</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">We have filed a registration statement on Form S-8 under the Securities Act to register all common shares issued or issuable pursuant to the exercise of outstanding options and reserved for issuance under our 2019 Equity Incentive Plan. Shares covered by such registration statement are eligible for sale in the public markets, subject to vesting restrictions and any applicable holding periods, any applicable lock-up agreements described below and Rule 144 limitations applicable to affiliates. </div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 20.5pt; margin-left: 0pt; text-align: left;">Regulation S</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Regulation S provides generally that sales made in offshore transactions are not subject to the registration or prospectus-delivery requirements of the Securities Act. </div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 20.5pt; margin-left: 0pt; text-align: left;">Lock-up Agreements </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">In connection with our initial public offering, all of our directors and executive officers and the holders of substantially all of our share capital agreed, subject to limited exceptions, not to offer, pledge, announce the intention to sell, sell, contract to sell, sell any option or contract to purchase, purchase any option or contract to sell, grant any option, right or warrant to purchase or otherwise dispose of, directly or indirectly, or enter into any swap or other agreement that transfers, in whole or in part, any of the economic consequences of ownership of the common shares or such other securities for a period of 180 days after the date of our initial public offering without the prior written consent of Morgan Stanley &amp; Co. LLC and BofA Securities, Inc. Entities affiliated with Auven Therapeutics GP Ltd. have also agreed that they will not transfer, distribute or dispose of any common shares or securities convertible into common shares (other than those common shares or securities convertible into common shares for which such entity holds as nominee on behalf of equity incentive plan participants) to their partners, members, stockholders, beneficiaries or other equity holders and that they will not sell any common shares or securities convertible into common shares (other than those common shares or securities convertible into common shares for which such entity holds as nominee on behalf of equity incentive plan participants) prior to June 30, 2022 without the prior written consent of Morgan Stanley &amp; Co. LLC and BofA Securities, Inc. Morgan Stanley &amp; Co. LLC and BofA Securities, Inc. may waive the requirements of these lock-up agreements at any time in their sole discretion. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">In connection with this offering, all of our directors and executive officers and certain shareholders agreed, subject to limited exceptions, not to offer, pledge, announce the intention to sell, sell, contract to sell, sell any option or contract to purchase, purchase any option or contract to sell, grant any option, right or warrant to purchase or otherwise dispose of, directly or indirectly, or enter into any swap or other agreement that transfers, in whole or in part, any of the economic consequences of ownership of the common shares or such other securities for a period of 60 days after the date of this prospectus without the prior written consent of Morgan Stanley &amp; Co. LLC and BofA Securities, Inc. See &#8220;Underwriters.&#8221;</div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 20.5pt; margin-left: 0pt; text-align: left;">Registration Rights</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Holders of senior secured convertible notes issued under the Facility Agreement and their transferees are entitled to certain rights with respect to the registration of the offer and sale of our common shares issuable to them upon the conversion of their senior secured convertible notes under the Securities Act. Registration of these shares under the Securities Act would result in the shares becoming freely tradable without restriction under the Securities Act immediately on the effectiveness of the registration. See &#8220;Description of Share Capital and Articles of Association&#8212;Registration Rights&#8221; for additional information.</div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 36pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">229<br></div></div></div>
<!--End Page 233-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 234-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 540pt;"><a name="nt10014672x1_drs_110-comparision_pg11"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="block-frill" style="width: 540pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: Arial, Helvetica, sans-serif; font-size: 9pt; font-weight: bold; margin-top: 6pt; text-align: center;">Confidential Treatment Requested by ADC Therapeutics SA Pursuant to 17 C.F.R. &#167; 200.83<br></div></div><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 36pt;"><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: center;"><a name="tT"><!--Anchor--></a>TAXATION</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The following discussion is based on the tax laws, regulations and regulatory practices of Switzerland and the United States as in effect on the date hereof, which are subject to change (or subject to changes in interpretation), possibly with retroactive effect.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Current and prospective shareholders are advised to consult their own tax advisers in light of their particular circumstances as to the Swiss or U.S. tax laws, regulations and regulatory practices that could be relevant for them in connection with this offering, the acquiring, owning and selling or otherwise disposing of our common shares (such shares for purposes of this &#8220;Taxation&#8221; section, &#8220;common shares&#8221;) and receiving dividends and similar cash or in-kind distributions on our common shares (including dividends on liquidation proceeds and share dividends) or distributions on our common shares based upon a capital reduction or reserves paid out of capital contributions and the consequences thereof under the tax laws, regulations and regulatory practices of Switzerland or the United States.</div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 15pt; margin-left: 0pt; text-align: left;">Swiss Tax Considerations</div><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 7pt; margin-left: 0pt; text-align: left;">Withholding Tax</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Under present Swiss tax law, dividends due and similar cash or in-kind distributions made by the Company to a shareholder of common shares (including liquidation proceeds and bonus shares) are subject to Swiss federal withholding tax (&#8220;Withholding Tax&#8221;), currently at a rate of 35% (applicable to the gross amount of taxable distribution). However, the repayment of the par value of the common shares and any repayment of qualifying additional paid-in capital (capital contribution reserves), within the limitations accepted by the legislation in force when such Dividend becomes due and the respective administrative practice, are not subject to the Withholding Tax. The Company is obliged to deduct the Withholding Tax from the gross amount of any taxable distribution and to pay the tax to the Swiss Federal Tax Administration within 30 days of the due date of such distribution.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Swiss resident individuals who hold their common shares as private assets (&#8220;Resident Private Shareholders&#8221;) are in principle eligible for a full refund or credit against income tax of the Withholding Tax if they duly report the underlying income in their income tax return. In addition, (i)&#160;corporate and individual shareholders who are resident in Switzerland for tax purposes, (ii)&#160;corporate and individual shareholders who are not resident in Switzerland, and who, in each case, hold their common shares as part of a trade or business carried on in Switzerland through a permanent establishment with fixed place of business situated in Switzerland for tax purposes and (iii)&#160;Swiss resident private individuals who, for income tax purposes, are classified as &#8220;professional securities dealers&#8221; for reasons of, inter alia, frequent dealing, or leveraged investments, in shares and other securities (collectively, &#8220;Domestic Commercial Shareholders&#8221;) are in principle eligible for a full refund or credit against income tax of the Withholding Tax if they duly report the underlying income in their income statements or income tax return, as the case may be.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Shareholders who are not resident in Switzerland for tax purposes, and who, during the respective taxation year, have not engaged in a trade or business carried on through a permanent establishment with fixed place of business situated in Switzerland for tax purposes, and who are not subject to corporate or individual income taxation in Switzerland for any other reason (collectively, &#8220;Non-Resident Shareholders&#8221;) may be entitled to a total or partial refund of the Withholding Tax if the country in which such recipient resides for tax purposes maintains a bilateral treaty for the avoidance of double taxation with Switzerland and further conditions of such treaty are met. Non-Resident Shareholders should be aware that the procedures for claiming treaty benefits (and the time required for obtaining a refund) may differ from country to country. Non-Resident Shareholders should consult their own legal, financial or tax advisors regarding receipt, ownership, purchases, sale or other dispositions of common shares and the procedures for claiming a refund of the Withholding Tax.</div><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 15.5pt; margin-left: 0pt; text-align: left;">Swiss Federal Issue Stamp Tax</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The Company will be subject to the Swiss federal issue stamp tax (<font style="font-style: italic;">droit d&#8217;&#233;mission</font>) on the issuance of common shares of 1% of the offering price, net of certain deductions.</div><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 15.5pt; margin-left: 0pt; text-align: left;">Swiss Federal Securities Turnover Tax</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The delivery of common shares against payment of the offering price is not subject to Swiss securities turnover tax (<font style="font-style: italic;">droit de n&#233;gociation</font>). Any subsequent transactions in common shares in the secondary markets are </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 36pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">230<br></div></div></div>
<!--End Page 234-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 235-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 540pt;"><a name="nt10014672x1_drs_110-comparision_pg12"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="block-frill" style="width: 540pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: Arial, Helvetica, sans-serif; font-size: 9pt; font-weight: bold; margin-top: 6pt; text-align: center;">Confidential Treatment Requested by ADC Therapeutics SA Pursuant to 17 C.F.R. &#167; 200.83<br></div></div><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 36pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">subject to Swiss securities turnover tax at an aggregate rate of 0.15% of the consideration paid for such common shares, however, only if a bank or other securities dealer in Switzerland, as defined in the Swiss Federal Stamp Tax Act (<font style="font-style: italic;">loi f&#233;d&#233;rale sur les droits de timbre</font>), is a party or an intermediary to the transaction and no exemption applies.</div><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 14pt; margin-left: 0pt; text-align: left;">Swiss Federal, Cantonal and Communal Individual Income Tax and Corporate Income Tax</div><div class="h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 7pt; margin-left: 0pt; text-align: left;">Non-Resident Shareholders</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Non-Resident Shareholders are not subject to any Swiss federal, cantonal or communal income tax on dividend payments and similar distributions because of the mere holding of common shares. The same applies for capital gains on the sale of common shares except in certain cases if the Company would qualify as real estate company. For Withholding Tax consequences, see &#8220;&#8212;Swiss Tax Considerations&#8212;Withholding Tax.&#8221;</div><div class="h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 14pt; margin-left: 0pt; text-align: left;">Resident Private Shareholders and Domestic Commercial Shareholders</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Resident Private Shareholders who receive dividends and similar cash or in-kind distributions (including liquidation proceeds as well as bonus shares or taxable repurchases of common shares as described above), which are not repayments of the par value of common shares or, within the limitations accepted by the legislation in force and the respective administrative practice, qualifying additional paid-in capital, are required to report such receipts in their individual income tax returns and are subject to Swiss federal, cantonal and communal income tax on any net taxable income for the relevant tax period. A gain or a loss by Resident Private Shareholders realized upon the sale or other disposition of common shares to a third party will generally be a tax-free private capital gain or a not tax-deductible capital loss, as the case may be. Under exceptional circumstances the capital gain may be re-characterized into a taxable dividend, in particular upon taxable repurchase of common shares as described above. When a capital gain is re-characterized as a dividend, the relevant income for tax purposes corresponds to the difference between the repurchase price and the sum of the par value of common shares and, within the limitations accepted by the legislation in force and the respective administrative practice, qualifying additional paid-in capital.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Domestic Commercial Shareholders who receive dividends and similar cash or in-kind distributions (including liquidation proceeds as well as bonus shares) are required to recognize such payments in their income statements for the relevant tax period and are subject to Swiss federal, cantonal and communal individual or corporate income tax, as the case may be, on any net taxable earnings accumulated (including the dividends) for such period. On cantonal and communal level, similar provisions were introduced, but the regulations may vary depending on the canton of residency. Domestic Commercial Shareholders who are corporate taxpayers may qualify for participation relief on dividend distributions (<font style="font-style: italic;">r</font><font style="font-style: italic;">&#233;</font><font style="font-style: italic;">duction pour participations</font>), if common shares held have a market value of at least CHF 1&#160;million. For cantonal and communal income tax purposes, the regulations on participation relief are broadly similar, depending on the canton of residency.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Domestic Commercial Shareholders are required to recognize a gain or loss realized upon the disposal of common shares in their income statement for the respective taxation period and are subject to Swiss federal, cantonal and communal individual or corporate income tax, as the case may be, on any net taxable earnings (including the gain or loss realized on the sale or other disposition of common shares) for such taxation period.</div><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 14pt; margin-left: 0pt; text-align: left;">Swiss Wealth Tax and Capital Tax</div><div class="h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 7pt; margin-left: 0pt; text-align: left;">Non-Resident Shareholders</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Non-Resident Shareholders holding common shares are not subject to cantonal and communal wealth or annual capital tax because of the mere holding of common shares.</div><div class="h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 14pt; margin-left: 0pt; text-align: left;">Resident Private Shareholders</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Resident Private Shareholders are required to report their common shares as part of their private wealth and are subject to cantonal and communal wealth tax.</div><div class="h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 14pt; margin-left: 0pt; text-align: left;">Domestic Commercial Shareholders</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Domestic Commercial Shareholders are required to report their common shares as part of their business wealth or taxable capital, as defined, and are subject to cantonal and communal wealth or annual capital tax.</div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 36pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">231<br></div></div></div>
<!--End Page 235-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 236-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 540pt;"><a name="nt10014672x1_drs_110-comparision_pg13"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="block-frill" style="width: 540pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: Arial, Helvetica, sans-serif; font-size: 9pt; font-weight: bold; margin-top: 6pt; text-align: center;">Confidential Treatment Requested by ADC Therapeutics SA Pursuant to 17 C.F.R. &#167; 200.83<br></div></div><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 36pt;"><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">Automatic Exchange of Information in Tax Matters</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">On November&#160;19, 2014, Switzerland signed the Multilateral Competent Authority Agreement. The Multilateral Competent Authority Agreement is based on Article 6 of the OECD/Council of Europe administrative assistance convention and is intended to ensure the uniform implementation of Automatic Exchange of Information (the &#8220;AEOI&#8221;). The Federal Act on the International Automatic Exchange of Information in Tax Matters (the &#8220;AEOI Act&#8221;) entered into force on January&#160;1, 2017. The AEOI Act is the legal basis for the implementation of the AEOI standard in Switzerland.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The AEOI is being introduced in Switzerland through bilateral agreements or multilateral agreements. The agreements have been, and will be, concluded on the basis of guaranteed reciprocity, compliance with the principle of speciality (i.e., the information exchanged may only be used to assess and levy taxes (and for criminal tax proceedings)) and adequate data protection.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Based on such multilateral or bilateral agreements and the implementation of Swiss law, Switzerland collects and exchanges data in respect of financial assets, including common shares, held in, and income derived thereon and credited to, accounts or deposits with a paying agent in Switzerland for the benefit of individuals resident in a European Union member state or in a treaty state.</div><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 15pt; margin-left: 0pt; text-align: left;">Swiss Facilitation of the Implementation of the U.S. Foreign Account Tax Compliance Act</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Switzerland has concluded an intergovernmental agreement with the United States to facilitate the implementation of U.S. Foreign Account Tax Compliance Act. The agreement ensures that the accounts held by U.S. persons with Swiss financial institutions are disclosed to the U.S. tax authorities either with the consent of the account holder or by means of group requests within the scope of administrative assistance. Information will not be transferred automatically in the absence of consent, and instead will be exchanged only within the scope of administrative assistance on the basis of the double taxation agreement between the United States and Switzerland. On October&#160;8, 2014, the Swiss Federal Council approved a mandate for negotiations with the United States on changing the current direct-notification-based regime to a regime where the relevant information is sent to the Swiss Federal Tax Administration, which in turn provides the information to the U.S. tax authorities. </div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 15pt; margin-left: 0pt; text-align: left;">Material U.S. Federal Income Tax Consequences for U.S. Holders</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">In the opinion of Davis Polk &amp; Wardwell LLP, the following is a description of the material U.S. federal income tax consequences to the U.S. Holders, as defined below, of owning and disposing our common shares. It does not describe all tax considerations that may be relevant to a particular person&#8217;s decision to acquire common shares.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">This discussion applies only to a U.S. Holder that holds common shares as capital assets for U.S. federal income tax purposes (generally, property held for investment). In addition, it does not describe any tax consequences other than U.S. federal income tax consequences, including state and local tax consequences and estate tax consequences, and does not describe all of the U.S. federal income tax consequences that may be relevant in light of the U.S. Holder&#8217;s particular circumstances, including alternative minimum tax consequences, the potential application of the provisions of the Internal Revenue Code of 1986, as amended (the &#8220;Code&#8221;) known as the Medicare contribution tax and tax consequences applicable to U.S. Holders subject to special rules, such as:</div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">certain banks, insurance companies and other financial institutions;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">brokers, dealers or traders in securities who use a mark-to-market method of tax accounting;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">persons holding common shares as part of a straddle, wash sale, conversion transaction or other integrated transaction or persons entering into a constructive sale with respect to the common shares;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">persons whose functional currency for U.S. federal income tax purposes is not the U.S. dollar;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">entities or arrangements classified as partnerships or S corporations for U.S. federal income tax purposes;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">tax-exempt entities, including &#8220;individual retirement accounts&#8221; or &#8220;Roth IRAs,&#8221; and governmental entities;</div></td></tr></table></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 36pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">232<br></div></div></div>
<!--End Page 236-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 237-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 540pt;"><a name="nt10014672x1_drs_110-comparision_pg14"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="block-frill" style="width: 540pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: Arial, Helvetica, sans-serif; font-size: 9pt; font-weight: bold; margin-top: 6pt; text-align: center;">Confidential Treatment Requested by ADC Therapeutics SA Pursuant to 17 C.F.R. &#167; 200.83<br></div></div><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 36pt;"><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6.75pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">real estate investment trusts or regulated investment companies;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">former U.S. citizens or long-term residents of the United States;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">persons subject to Section 451(b) of the Code;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">persons that own or are deemed to own 10% or more of the voting power or value of our shares; or</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">persons holding common shares in connection with a trade or business conducted outside of the United States or in connection with a permanent establishment or other fixed place of business outside of the United States.</div></td></tr></table><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">If an entity or arrangement that is classified as a partnership for U.S. federal income tax purposes holds common shares, the U.S. federal income tax treatment of a partner will generally depend on the status of the partner and the activities of the partnership. Partnerships holding common shares and partners in such partnerships should consult their tax advisers as to the particular U.S. federal income tax consequences of owning and disposing of the common shares.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">This discussion is based on the Code, administrative pronouncements, judicial decisions, final, temporary and proposed Treasury regulations, and the income tax treaty between Switzerland and the United States (the &#8220;Treaty&#8221;), all as of the date hereof, any of which is subject to change or differing interpretations, possibly with retroactive effect.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">A &#8220;U.S. Holder&#8221; is a beneficial owner of our common shares who, for U.S. federal income tax purposes, is eligible for the benefits of the Treaty and is:</div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">a citizen or individual resident of the United States;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">a corporation, or other entity taxable as a corporation, created or organized in or under the laws of the United States, any state therein or the District of Columbia; or</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">an estate or trust the income of which is subject to U.S. federal income taxation regardless of its source.</div></td></tr></table><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">U.S. Holders should consult their tax advisers concerning the U.S. federal, state, local and non-U.S. tax consequences of owning and disposing of common shares in their particular circumstances.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The discussion under &#8220;Taxation of Distributions&#8221; and &#8220;Sale or Other Disposition of Common Shares&#8221; below describes certain consequences to U.S. Holders in the event that we are not a passive foreign investment company for U.S. federal income tax purposes (a &#8220;PFIC&#8221;) during any tax year in which a U.S. Holder holds our common shares. However, as discussed below under &#8220;Passive Foreign Investment Company Rules&#8221; below, we may be a PFIC for 2020 or one or more subsequent taxable years.</div><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 20.5pt; margin-left: 0pt; text-align: left;">Taxation of Distributions</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">As discussed above under &#8220;Dividend Policy,&#8221; we do not currently expect to make distributions on our common shares. In the event that we do make distributions of cash or other property, distributions paid on common shares, other than certain <font style="font-style: italic;">pro rata</font> distributions of common shares, will generally be treated as dividends to the extent paid out of our current or accumulated earnings and profits (as determined under U.S. federal income tax principles). Because we do not maintain calculations of our earnings and profits under U.S. federal income tax principles, we expect that distributions generally will be reported to U.S. Holders as dividends. If we were not a PFIC, as described below, and for so long as our common shares are listed on the NYSE or we are eligible for benefits under the Treaty, dividends paid to certain non-corporate U.S. Holders would be eligible for taxation as &#8220;qualified dividend income&#8221; and therefore, subject to applicable limitations, would be taxable at rates not in excess of the long-term capital gain rate applicable to such U.S. Holder. As discussed in &#8220;&#8212;Passive Foreign Investment Company Rules&#8221; below, however, if we are a PFIC (or, with respect to a particular U.S. Holder, are treated as a PFIC) for a taxable year in which we pay a dividend or for the prior taxable year, the dividend will not be eligible for taxation as &#8220;qualified dividend income.&#8221; U.S. Holders should consult their tax advisers regarding the availability of the reduced tax rate on dividends in their particular circumstances. </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 36pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">233<br></div></div></div>
<!--End Page 237-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 238-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 540pt;"><a name="nt10014672x1_drs_110-comparision_pg15"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="block-frill" style="width: 540pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: Arial, Helvetica, sans-serif; font-size: 9pt; font-weight: bold; margin-top: 6pt; text-align: center;">Confidential Treatment Requested by ADC Therapeutics SA Pursuant to 17 C.F.R. &#167; 200.83<br></div></div><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 36pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The amount of a dividend will include any amounts withheld by us in respect of Swiss income taxes. The amount of the dividend will be treated as foreign-source dividend income to U.S. Holders and will not be eligible for the dividends-received deduction generally available to U.S. corporations under the Code. Dividends will be included in a U.S. Holder&#8217;s income on the date of the U.S. Holder&#8217;s receipt of the dividend. The amount of any dividend income paid in Swiss francs will be the U.S. dollar amount calculated by reference to the exchange rate in effect on the date of actual or constructive receipt, regardless of whether the payment is in fact converted into U.S. dollars at that time. If the dividend is converted into U.S. dollars on the date of receipt, a U.S. Holder should not be required to recognize foreign currency gain or loss in respect of the dividend income. A U.S. Holder may have foreign currency gain or loss if the dividend is converted into U.S. dollars after the date of receipt.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Subject to applicable limitations, some of which vary depending upon the U.S. Holder&#8217;s particular circumstances, Swiss income taxes withheld from dividends on common shares (at a rate not exceeding the rate provided by the Treaty, in the case of a U.S. Holder eligible for a reduced rate under the Treaty) will be creditable against the U.S. Holder&#8217;s U.S. federal income tax liability. The rules governing foreign tax credits are complex and U.S. Holders should consult their tax advisers regarding the creditability of foreign taxes in their particular circumstances. In lieu of claiming a foreign tax credit, U.S. Holders may, at their election, deduct foreign taxes, including any Swiss income tax, in computing their taxable income, subject to generally applicable limitations under U.S. law. An election to deduct foreign taxes instead of claiming foreign tax credits applies to all foreign taxes paid or accrued in the taxable year.</div><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 17.5pt; margin-left: 0pt; text-align: left;">Sale or Other Disposition of Common Shares</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Gain or loss realized by a U.S. Holder on the sale or other disposition of common shares will be capital gain or loss, and will be long-term capital gain or loss if the U.S. Holder&#8217;s holding period for such common shares was more than one year as of the date of the sale or other disposition. The amount of the gain or loss will equal the difference between the U.S. Holder&#8217;s tax basis in the common shares disposed of and the amount realized on the disposition, in each case as determined in U.S. dollars. Long-term capital gain recognized by a non-corporate U.S. Holder is subject to U.S. federal income tax at rates lower than the rates applicable to ordinary income and short-term capital gains, while short-term capital gains are subject to U.S. federal income tax at the rates applicable to ordinary income. This gain or loss will generally be U.S.-source gain or loss for foreign tax credit purposes. The deductibility of capital losses is subject to various limitations.</div><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 17.5pt; margin-left: 0pt; text-align: left;">Passive Foreign Investment Company Rules</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Under the Code, we will be a PFIC for any taxable year in which, after the application of certain look-through rules with respect to subsidiaries, either (i) 75% or more of our gross income consists of &#8220;passive income&#8221; or (ii)&#160;50% or more of the average quarterly value of our assets consist of assets that produce, or are held for the production of, &#8220;passive income.&#8221; For purposes of the above calculations, we will be treated as if we hold our proportionate share of the assets of, and receive directly our proportionate share of the income of, any other corporation in which we directly or indirectly own at least 25%, by value, of the shares of such corporation. Passive income generally includes interest, dividends, certain non-active rents and royalties, and capital gains. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">We believe that we were a PFIC for our 2019 taxable year and it is possible that we will be a PFIC for one or more subsequent taxable years. Whether we will be a PFIC in 2020 or any future years is uncertain because, among other things, (i)&#160;we currently own, and will own after the completion of this offering, a substantial amount of passive assets, including cash, (ii)&#160;the timing of our recognition of active income for U.S. federal income tax purposes, which may differ from the timing of the recognition of such income for financial accounting purposes, may result in our recognizing minimal amounts of active income for U.S. federal income tax purposes in certain taxable years and (iii)&#160;the valuation of our assets that generate non-passive income for PFIC purposes, including our intangible assets, is uncertain and may be determined in substantial part by our market capitalization, which may vary substantially over time. Accordingly, there can be no assurance that we will not be a PFIC for 2020 or any future taxable year. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">If we are a PFIC for any year during which a U.S. Holder holds common shares, we will continue to be treated as a PFIC with respect to that U.S. Holder for all succeeding years during which the U.S. Holder holds common shares, even if we cease to meet the threshold requirements for PFIC status, unless the U.S. Holder </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 36pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">234<br></div></div></div>
<!--End Page 238-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 239-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 540pt;"><a name="nt10014672x1_drs_110-comparision_pg16"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="block-frill" style="width: 540pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: Arial, Helvetica, sans-serif; font-size: 9pt; font-weight: bold; margin-top: 6pt; text-align: center;">Confidential Treatment Requested by ADC Therapeutics SA Pursuant to 17 C.F.R. &#167; 200.83<br></div></div><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 36pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">elects to recognize gain, if any, as if it sold its common shares as of the last day of the last tax year in which we are a PFIC (such election, a &#8220;Purging Election&#8221;). In addition, the Company may, directly or indirectly, have held or hold equity interests in other PFICs<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;"> </sup>(collectively, &#8220;Lower-tier PFICs&#8221;). Under attribution rules, if the Company is a PFIC, U.S. Holders will be deemed to own their proportionate shares of the stock of Lower-tier PFICs and will be subject to U.S. federal income tax according to the rules described in the following paragraphs on (i)&#160;certain distributions by a Lower-tier PFIC and (ii)&#160;a disposition of shares of a Lower-tier PFIC, in each case as if the U.S. Holder held such shares directly, even though holders have not received the proceeds of those distributions or dispositions directly. U.S. Holders should consult their tax advisers about the consequences to them if we own one or more Lower-tier PFICs.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">If we are a PFIC for any taxable year during which a U.S. Holder held common shares (assuming such U.S. Holder has not made a timely mark-to-market election, or &#8220;qualified electing fund&#8221; election (a &#8220;QEF Election&#8221;), as described below), gain recognized by the U.S. Holder on sale or other disposition (including certain pledges) of common shares (including any gain recognized as a consequence of a Purging Election) will be allocated ratably over the U.S. Holder&#8217;s holding period for the common shares. The amounts allocated to the taxable year of the sale or other disposition and to any year before we became a PFIC will be taxed as ordinary income. The amount allocated to each other taxable year will be subject to tax at the highest rate in effect for individuals or corporations, as appropriate, for that taxable year, and an interest charge will be imposed on the resulting tax liability. Further, to the extent that any distribution received by a U.S. Holder on its common shares exceeds 125% of the average of the annual distributions on the common shares received during the preceding three years or the U.S. Holder&#8217;s holding period, whichever is shorter, that distribution will be subject to taxation in the same manner as gain, described immediately above.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">If we are a PFIC (or, with respect to a particular U.S. Holder, are treated as a PFIC) for a taxable year in which we pay a dividend or for the prior taxable year, the preferential dividend rates discussed above with respect to dividends paid to certain non-corporate U.S. Holders will not apply. </div><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 20.5pt; margin-left: 0pt; text-align: left;">Mark-to-Market Election</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">A U.S. Holder can avoid certain of the adverse rules described above by making a mark-to-market election with respect to its common shares, provided that the common shares are &#8220;marketable.&#8221; Common shares will be marketable if they are &#8220;regularly traded&#8221; on a &#8220;qualified exchange&#8221; or other market within the meaning of applicable Treasury regulations. If a U.S. Holder makes the mark-to-market election with respect to its common shares, it generally will recognize as ordinary income any excess of the fair market value of the common shares at the end of each taxable year over their adjusted tax basis, and will recognize an ordinary loss in respect of any excess of the adjusted tax basis of the common shares over their fair market value at the end of the taxable year (but only to the extent of the net amount of income previously included as a result of the mark-to-market election). If a U.S. Holder makes the election, the U.S. Holder&#8217;s tax basis in the common shares will be adjusted to reflect the income or loss amounts recognized. Any gain recognized by the U.S. Holder on the sale or other disposition of common shares in a year in which we are a PFIC will be treated as ordinary income and any such loss will be treated as an ordinary loss (but only to the extent of the net amount of income previously included as a result of the mark-to-market election).</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">In general, a U.S. Holder makes a mark-to-market election by attaching a properly executed Internal Revenue Service (&#8220;IRS&#8221;) Form 8621 to its U.S. federal income tax return for the first taxable year to which it wishes the election will apply. A U.S. Holder may make a mark-to-market election only if it holds common shares on the last day of such taxable year.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">A mark-to-market election generally cannot be made for equity interests in any Lower-tier PFIC unless shares of such Lower-tier PFIC are themselves &#8220;marketable.&#8221; As a result, if a U.S. Holder makes a mark-to-market election with respect to our common shares, the U.S. Holder will nevertheless be subject to the PFIC rules described above with respect to its indirect interest in any Lower-tier PFIC unless the U.S. Holder makes a QEF Election with respect to such Lower-tier PFIC, as discussed below. </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 36pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">235<br></div></div></div>
<!--End Page 239-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 240-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 540pt;"><a name="nt10014672x1_drs_110-comparision_pg17"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="block-frill" style="width: 540pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: Arial, Helvetica, sans-serif; font-size: 9pt; font-weight: bold; margin-top: 6pt; text-align: center;">Confidential Treatment Requested by ADC Therapeutics SA Pursuant to 17 C.F.R. &#167; 200.83<br></div></div><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 36pt;"><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">QEF Election</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">In order to avoid the application of the foregoing rules, a U.S. person that owns shares in a PFIC may make a QEF Election with respect to such PFIC if the PFIC provides the information necessary for such election to be made. If we determine that we are a PFIC for any taxable year, we will use our commercially reasonable efforts to, and currently expect to, provide the information necessary for U.S. Holders to make QEF Elections with respect to us.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">If a U.S. Holder makes a valid QEF Election with respect to its common shares, the U.S. Holder will be required to report on its U.S. federal income tax return, and thus to take into account in determining its U.S. federal income tax liability, its <font style="font-style: italic;">pro rata</font> share of our ordinary earnings and net capital gain (as ordinary income and long-term capital gain, respectively) for each taxable year in which we are classified as a PFIC, regardless of whether we make any distributions. U.S. Holders will not be entitled to claim deductions for any net losses we incur, and we will not be entitled to carry our net losses for any taxable year back or forward in computing our ordinary earnings and net capital gain for other taxable years. A U.S. Holder will also not be entitled to claim a foreign tax credit for any non-U.S. taxes we bear, but these taxes will reduce the amount of income the U.S. Holder would otherwise be required to include pursuant to the QEF Election.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Any distribution (or portion thereof) to a U.S. Holder that we make out of earnings and profits that were previously included in a U.S. person&#8217;s income pursuant to a QEF Election will not be subject to U.S. federal income tax, provided that the U.S. Holder can establish that such distribution (or portion thereof) is made out of such previously-taxed earnings and profits. If we are a PFIC (or, with respect to a particular U.S. Holder, are treated as a PFIC) for a taxable year in which we pay a dividend or for the prior taxable year, the preferential dividend rates discussed above with respect to dividends paid to certain non-corporate U.S. Holders will not apply to the portion of such dividend that the U.S. Holder includes in income after application of the foregoing exclusion. A U.S. Holder&#8217;s tax basis in its common shares will be increased by the amounts the U.S. Holder includes in income as a consequence of a QEF Election and decreased by the amount of distributions the U.S. Holder receives from us out of earnings and profits that a U.S. person previously included in income as a consequence of a QEF Election. If a U.S. Investor has made a QEF Election with respect to its common shares, any gain or loss recognized by the U.S. Holder on a sale or other disposition of such common shares will constitute capital gain or loss.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">A U.S. Holder that makes a QEF Election with respect to its common shares may also elect to defer the payment of taxes in respect of its share of our undistributed ordinary earnings and net capital gain, subject to the payment of an interest charge on the deferred tax liability. U.S. Holders should consult their tax advisors about this election.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">In general, a U.S. taxpayer makes a QEF Election with respect to a PFIC by attaching a properly executed IRS Form 8621 to its U.S. federal income tax return for the first taxable year to which it wishes the election to apply. Subject to the discussion below regarding retroactive QEF Elections, if a U.S. Holder does not make a QEF Election with respect to us for the first taxable year in which it holds common shares, a later QEF Election will not affect the U.S. federal income tax consequences to the U.S. Holder unless the U.S. Holder makes a Purging Election effective as of the first day of the first taxable year to which the QEF Election applies. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">A QEF Election with respect to us will not apply to any of our Lower-tier PFICs. If we determine that any of our current subsidiaries is a Lower-tier PFIC for any taxable year, we currently expect that we will provide the information necessary for U.S. Holders to make a QEF Election with respect to such Lower-tier PFIC, but there can be no assurance that we will be able to provide such information.</div><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">Information Returns</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">If a U.S. Holder owns common shares during any year in which we are a PFIC or in which we hold a direct or indirect equity interest in a Lower-tier PFIC, the U.S. Holder generally must file an annual report on IRS Form 8621 with respect to each such PFIC containing such information as the U.S. Treasury may require, generally with the U.S. Holder&#8217;s U.S. federal income tax return for the relevant year. A U.S. Holder&#8217;s failure to file the annual report will cause the statute of limitations for such U.S. Holder&#8217;s U.S. federal income tax return to remain open with respect to the items required to be included in such report until three years after the U.S. Holder files the annual report and, unless such failure is due to reasonable cause and not willful neglect, the statute of limitations for the U.S. Holder&#8217;s entire U.S. federal income tax return will remain open during such period. </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 36pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">236<br></div></div></div>
<!--End Page 240-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 241-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 540pt;"><a name="nt10014672x1_drs_110-comparision_pg18"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="block-frill" style="width: 540pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: Arial, Helvetica, sans-serif; font-size: 9pt; font-weight: bold; margin-top: 6pt; text-align: center;">Confidential Treatment Requested by ADC Therapeutics SA Pursuant to 17 C.F.R. &#167; 200.83<br></div></div><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 36pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Prospective U.S. holders should consult their tax advisers regarding the consequences of our potential PFIC status on an investment in common shares. </div><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 20.5pt; margin-left: 0pt; text-align: left;">Information Reporting and Backup Withholding</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Payments of dividends and sales proceeds that are made within the United States or through certain U.S.-related financial intermediaries generally are subject to information reporting, and may be subject to backup withholding, unless (i)&#160;the U.S. Holder is a corporation or other exempt recipient or (ii)&#160;in the case of backup withholding, the U.S. Holder provides a correct taxpayer identification number and certifies that it is not subject to backup withholding.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The amount of any backup withholding from a payment to a U.S. Holder will be allowed as a credit against the U.S. Holder&#8217;s U.S. federal income tax liability and may entitle it to a refund, provided that the required information is timely furnished to the IRS.</div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 36pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">237<br></div></div></div>
<!--End Page 241-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 242-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 540pt;"><a name="nt10014672x1_drs_111-under_pg1"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="block-frill" style="width: 540pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: Arial, Helvetica, sans-serif; font-size: 9pt; font-weight: bold; margin-top: 6pt; text-align: center;">Confidential Treatment Requested by ADC Therapeutics SA Pursuant to 17 C.F.R. &#167; 200.83<br></div></div><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 36pt;"><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: center;"><a name="tU"><!--Anchor--></a>UNDERWRITERS</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Under the terms and subject to the conditions in an underwriting agreement dated the date of this prospectus, the underwriters named below, for whom Morgan Stanley &amp; Co. LLC, BofA Securities, Inc. and Cowen and Company, LLC are acting as representatives, have severally agreed to purchase, and we have agreed to sell to them, severally, the number of shares indicated below:</div><table cellspacing="0" cellpadding="0" class="fintab" style="margin-top: 11.25pt; border-collapse: collapse; width: 468pt; margin-left: auto; margin-right: auto;"><tr class="header"><td style="width: 82.05%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Underwriter</div></td><td class="gutter" style="width: 1.3%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.3%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 15.35%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Number of Common <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Shares </div></td></tr><tr><td style="width: 82.05%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Morgan Stanley &amp; Co. LLC <font style="padding-left: 2.55pt;"></font></div></td><td class="gutter" style="width: 1.3%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.3%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 15.35%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 82.05%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">BofA Securities, Inc.<font style="padding-left: 0.97pt;"></font></div></td><td class="gutter" style="width: 1.3%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.3%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 15.35%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 82.05%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Cowen and Company, LLC <font style="padding-left: 0.79pt;"></font></div></td><td class="gutter" style="width: 1.3%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.3%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 15.35%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 15.91pt; text-align: left;"><font style="border-bottom: 1pt solid #000000; min-width: 40pt;">&#8199;&#8201;&#8199;&#8199;&#8199;&#8201;&#8199;&#8199;&#8199;</font></div></td></tr><tr><td style="width: 82.05%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 6pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Total<font style="font-weight: normal; padding-left: 4.64pt;"></font></div></td><td class="gutter" style="width: 1.3%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt;">&#8203;</td><td class="gutter" style="width: 1.3%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt;">&#8203;</td><td style="width: 15.35%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 6pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 15.91pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 40pt;">&#8199;&#8201;&#8199;&#8199;&#8199;&#8201;&#8199;&#8199;&#8199;</font></div></td></tr></table><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The underwriters and the representatives are collectively referred to as the &#8220;underwriters&#8221; and the &#8220;representatives,&#8221; respectively. The underwriters are offering the common shares subject to their acceptance of the shares from us and subject to prior sale. The underwriting agreement provides that the obligations of the several underwriters to pay for and accept delivery of the common shares offered by this prospectus are subject to the approval of certain legal matters by their counsel and to certain other conditions. The underwriters are obligated to take and pay for all of the common shares offered by this prospectus if any such shares are taken. However, the underwriters are not required to take or pay for the shares covered by the underwriters&#8217; option to purchase additional common shares described below.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The underwriters initially propose to offer part of the common shares directly to the public at the offering price listed on the cover page of this prospectus and part to certain dealers at a price that represents a concession not in excess of $&#8195;&#8195;per share under the public offering price. After the initial offering of the common shares, the offering price and other selling terms may from time to time be varied by the representatives.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The Selling Shareholder has granted to the underwriters an option, exercisable for 30 days from the date of this prospectus, to purchase up to &#8195;&#8195;&#8195;&#8195; additional common shares at the public offering price listed on the cover page of this prospectus, less underwriting discounts and commissions. To the extent the option is exercised, each underwriter will become obligated, subject to certain conditions, to purchase about the same percentage of the additional common shares as the number listed next to the underwriter&#8217;s name in the preceding table bears to the total number of common shares listed next to the names of all underwriters in the preceding table.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The following table shows the per share and total public offering price, underwriting discounts and commissions, and proceeds before expenses to us and the Selling Shareholder. These amounts are shown assuming both no exercise and full exercise of the underwriters&#8217; option to purchase &#8195;&#8195;&#8195;&#8195; additional common shares.</div><table cellspacing="0" cellpadding="0" class="fintab" style="margin-top: 11.25pt; border-collapse: collapse; width: 468pt; margin-left: auto; margin-right: auto;"><tr class="header"><td style="width: 69.23%; text-align: left; vertical-align: bottom; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 0.81%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 0.81%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 7.48%; text-align: center; vertical-align: bottom; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 0.81%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 0.81%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td colspan="4" style="width: 20.06%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Total</div></td></tr><tr class="header"><td style="width: 69.23%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 0.81%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 0.81%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 7.48%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Per Share</div></td><td class="gutter" style="width: 0.81%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 0.81%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 8.8%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">No Exercise</div></td><td class="gutter" style="width: 0.81%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 0.81%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 9.65%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Full Exercise</div></td></tr><tr><td style="width: 69.23%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Public offering price<font style="padding-left: 2.27pt;"></font></div></td><td class="gutter" style="width: 0.81%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.81%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.48%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;">$&#8195;&#8195;&#8195;</div></td><td class="gutter" style="width: 0.81%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.81%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.8%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.59pt; text-align: left;">$</div></td><td class="gutter" style="width: 0.81%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.81%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.65%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.59pt; text-align: left;">$<font style="padding-left: 35pt;">&#8203;</font></div></td></tr><tr><td style="width: 69.23%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Underwriting discounts and commissions to be paid by:<br></div></td><td class="gutter" style="width: 0.81%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.81%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 7.48%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.81%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.81%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 8.8%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.81%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.81%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 9.65%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 69.23%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Us<font style="padding-left: 0.39pt;"></font></div></td><td class="gutter" style="width: 0.81%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.81%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.48%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;">$</div></td><td class="gutter" style="width: 0.81%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.81%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.8%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.59pt; text-align: left;">$&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;</div></td><td class="gutter" style="width: 0.81%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.81%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.65%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.59pt; text-align: left;">$&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;</div></td></tr><tr><td style="width: 69.23%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">The Selling Shareholders<font style="padding-left: 3.76pt;"></font></div></td><td class="gutter" style="width: 0.81%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.81%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 7.48%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;">$</div></td><td class="gutter" style="width: 0.81%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.81%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 8.8%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.59pt; text-align: left;">$</div></td><td class="gutter" style="width: 0.81%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.81%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 9.65%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.59pt; text-align: left;">$</div></td></tr><tr><td style="width: 69.23%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Proceeds, before expenses, to us<font style="padding-left: 3.79pt;"></font></div></td><td class="gutter" style="width: 0.81%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.81%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.48%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;">$</div></td><td class="gutter" style="width: 0.81%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.81%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.8%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.59pt; text-align: left;">$</div></td><td class="gutter" style="width: 0.81%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.81%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.65%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.59pt; text-align: left;">$</div></td></tr><tr><td style="width: 69.23%; text-align: left; vertical-align: bottom; padding-top: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Proceeds, before expenses, to the Selling Shareholder<font style="padding-left: 2.15pt;"></font></div></td><td class="gutter" style="width: 0.81%; border-bottom: none; font-size: 2pt; padding-top: 3pt;">&#8203;</td><td class="gutter" style="width: 0.81%; border-bottom: none; font-size: 2pt; padding-top: 3pt;">&#8203;</td><td style="width: 7.48%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;">$</div></td><td class="gutter" style="width: 0.81%; border-bottom: none; font-size: 2pt; padding-top: 3pt;">&#8203;</td><td class="gutter" style="width: 0.81%; border-bottom: none; font-size: 2pt; padding-top: 3pt;">&#8203;</td><td style="width: 8.8%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.59pt; text-align: left;">$</div></td><td class="gutter" style="width: 0.81%; border-bottom: none; font-size: 2pt; padding-top: 3pt;">&#8203;</td><td class="gutter" style="width: 0.81%; border-bottom: none; font-size: 2pt; padding-top: 3pt;">&#8203;</td><td style="width: 9.65%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.59pt; text-align: left;">$</div></td></tr></table><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">We will not receive any of the proceeds from the potential sale of common shares by the Selling Shareholder. The estimated offering expenses payable by us, including stamp duty and exclusive of the underwriting discounts and commissions, are approximately $&#8195;&#8195; million. We have agreed to reimburse the underwriters for expense relating to clearance of this offering with the Financial Industry Regulatory Authority (&#8220;FINRA&#8221;) up to $35,000.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8.5pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Our common shares are listed on the NYSE under the symbol &#8220;ADCT.&#8221;</div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 36pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">238<br></div></div></div>
<!--End Page 242-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 243-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 540pt;"><a name="nt10014672x1_drs_111-under_pg2"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="block-frill" style="width: 540pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: Arial, Helvetica, sans-serif; font-size: 9pt; font-weight: bold; margin-top: 6pt; text-align: center;">Confidential Treatment Requested by ADC Therapeutics SA Pursuant to 17 C.F.R. &#167; 200.83<br></div></div><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 36pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">In connection with this offering, we and all directors and officers and certain shareholders have agreed that, without the prior written consent of Morgan Stanley &amp; Co. LLC and BofA Securities, Inc., on behalf of the underwriters, we and they will not, during the period ending 60 days (in the case of directors and officers and certain shareholders) or 90&#160;days (in the case of us) after the date of this prospectus (the &#8220;restricted period&#8221;):</div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">offer, pledge, sell, contract to sell, sell any option or contract to purchase, purchase any option or contract to sell, grant any option, right or warrant to purchase, lend or otherwise transfer or dispose of, directly or indirectly, any common shares or any securities convertible into or exercisable or exchangeable for common shares;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">file any registration statement with the SEC relating to the offering of any common shares or any securities convertible into or exercisable or exchangeable for common shares; or</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">enter into any swap or other arrangement that transfers to another, in whole or in part, any of the economic consequences of ownership of the common shares,</div></td></tr></table><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">whether any such transaction described above is to be settled by delivery of common shares or such other securities, in cash or otherwise. In addition, we and each such person agree that, without the prior written consent of Morgan Stanley &amp; Co. LLC and BofA Securities, Inc., on behalf of the underwriters, we or such other person will not, during the restricted period, make any demand for, or exercise any right with respect to, the registration of any common shares or any security convertible into or exercisable or exchangeable for common shares. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The restrictions described in the immediately preceding paragraph do not apply to our directors, officers and shareholders with respect to:</div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 30pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(i)<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">transactions relating to common shares or any security convertible into common shares acquired in this offering (other than any issuer-directed common shares purchased in the offering by our officers or directors) or in open market transactions after the completion of the offering;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 30pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(ii)<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">transfers or distributions as a bona fide gift or for bona fide estate planning purposes or to a charitable organization or educational institution; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 30pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(iii)<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">transfers or distributions to any immediate family member of such person, affiliate or any trust or trustee or beneficiary thereof for the direct or indirect benefit of such person or the immediate family of such person (for this purpose, &#8220;immediate family&#8221; means any relationship by blood, marriage, domestic partnership or adoption, not more remote than first cousin);</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 30pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(iv)<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">transfers or distributions to any corporation, partnership, limited liability company or other entity or affiliate of such person or the immediate family of such person; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 30pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(v)<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">transfers or distributions (a) by will, other testamentary document or intestate succession to the legal representative, heir, beneficiary or a member of the immediate family of such person upon the death of such person; (b) by operation of law pursuant to a domestic order or negotiated divorce settlement; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 30pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(vi)<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">transfers or distributions to another corporation, member, partnership, limited liability company, trust or other entity that is a direct or indirect affiliate (as defined under Rule 12b-2 of the Exchange Act), or to an investment fund or other entity that controls or manages, or is under common control with, such person, or distributions to partners, members, shareholders, beneficiaries or other equity holders of such person;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 30pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(vii)<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">transfers or distributions to us (a) in connection with the repurchase of such securities with respect to the termination of such person&#8217;s employment with us or (b) pursuant to contractual arrangements described in this prospectus; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 30pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(viii)<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">transfers or distributions (including through a &#8220;cashless&#8221; exercise or on a &#8220;net exercise basis&#8221;) to us in connection with the conversion of any convertible security into, or the exercise of any option or warrant for, common shares (including to satisfy withholding obligations or the payment of taxes in connection therewith); provided that (a) any such common shares received by such person shall be </div></td></tr></table></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 36pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">239<br></div></div></div>
<!--End Page 243-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 244-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 540pt;"><a name="nt10014672x1_drs_111-under_pg3"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="block-frill" style="width: 540pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: Arial, Helvetica, sans-serif; font-size: 9pt; font-weight: bold; margin-top: 6pt; text-align: center;">Confidential Treatment Requested by ADC Therapeutics SA Pursuant to 17 C.F.R. &#167; 200.83<br></div></div><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 36pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 50pt; text-align: left;">subject to the lock-up agreement and (b) no filing under Section 16(a) of the Exchange Act (or its foreign equivalent) reporting a reduction in beneficial ownership of common shares shall be required or shall be voluntarily made during the restricted period; </div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 30pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(ix)<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">transfers or distributions to a nominee or custodian of a person or entity to whom a disposition or transfer would be permissible under clauses (i) through (viii) above, provided that any common shares shall be subject to the terms of the lock-up agreement;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 30pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(x)<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">any pledge or transfer by such person (or any permitted transferee) of common shares or any security convertible into common shares pursuant to agreements governing indebtedness or commitments relating to indebtedness of such person (or any permitted transferee) or its affiliates (other than us and our subsidiaries) in effect on the date thereof (and any refinancing or replacement thereof) and described in this prospectus and any transfer upon foreclosure, provided that any required filing under Section 16(a) of the Exchange Act (or its foreign equivalent) reporting a reduction in beneficial ownership by such person or any party (pledgor or pledgee) shall indicate by footnote disclosure or otherwise the nature of the transfer and if any filing is required to be made under Section 16(a) of the Exchange Act (or its foreign equivalent) during the restricted period, and such person shall provide the representatives prior written notice informing them of such report;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 30pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(xi)<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the establishment of a trading plan pursuant to Rule 10b5-1 under the Exchange Act (or its foreign equivalent) for the transfer of common shares, provided that (a) such plan does not provide for the transfer of common shares during the restricted period and (b) to the extent a public announcement or filing under the Exchange Act (or its foreign equivalent), if any, is required of or voluntarily made by or on behalf of such person or us regarding the establishment of such plan, such announcement or filing shall include a statement to the effect that no transfer of common shares may be made under such plan during the restricted period;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 30pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(xii)<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">transfers or dispositions pursuant to a bona fide tender offer for our capital shares, merger, consolidation or other similar transaction made to all holders of our securities involving a change of control of us (including without limitation, the entering into of any lock-up, voting or similar agreement pursuant to which such person may agree to transfer, sell, tender or otherwise dispose of common shares or any security convertible into common shares in connection with such transaction) that has been approved by our board of directors; provided that, in the event that such change of control transaction is not consummated, this paragraph shall not be applicable and such person&#8217;s shares and other securities shall remain subject to the lock-up agreement (for this purpose, &#8220;change of control&#8221; means the transfer whether by tender offer, merger, consolidation or other similar transaction), in one transactions or a series of related transactions, to a person or group of affiliated persons (other than the underwriters pursuant to this offering), of our voting securities if, after such transfer, such person or group of affiliated persons would hold greater than 50% of our outstanding voting securities); or</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 30pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(xiii)<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the conversion, exercise or exchange of options to purchase common shares, warrants or any security convertible into common shares described in this prospectus; provided that any such securities shall remain subject to the lock-up agreement,</div></td></tr></table><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">provided that, (1) with respect to paragraphs (ii)-(iv) and (vi) above, the representatives receive a signed lock-up agreement for the balance of the restricted period from each done, trustee, distribute or transferee, as the case may be, and (2) with respect to paragraphs (ii)-(vii) above, no public announcement or filing under Section 16(a) of the Exchange Act reporting a reduction in beneficial ownership of common shares, shall be required or voluntarily made during the restricted period (other than, in the case of a transfer or other disposition pursuant to paragraphs (v) and (vii), any Form 4 or 5 required to be filed under the Exchange Act (or its foreign equivalent) if such person is subject to Section 16 reporting with respect to our shares under the Exchange Act (or its foreign equivalent) shall indicate by footnote the nature of the transfer or disposition. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">With respect to (x) above, certain of our shareholders have granted a security interest in all or a portion of our shares beneficially owned by them pursuant to certain of their debt instruments, each of which may include default provisions. As of the date of this prospectus, to our knowledge, 23,593,730 shares of our common shares are subject to a security interest.</div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 36pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">240<br></div></div></div>
<!--End Page 244-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 245-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 540pt;"><a name="nt10014672x1_drs_111-under_pg4"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="block-frill" style="width: 540pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: Arial, Helvetica, sans-serif; font-size: 9pt; font-weight: bold; margin-top: 6pt; text-align: center;">Confidential Treatment Requested by ADC Therapeutics SA Pursuant to 17 C.F.R. &#167; 200.83<br></div></div><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 36pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The restrictions on transfers or other dispositions by us described above do not apply to: </div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 30pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(i)<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the common shares to be sold in this offering; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 30pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(ii)<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the issuance by us of shares of common shares upon the exercise of an option or warrant or the conversion of a security outstanding on the date of this prospectus of which the underwriters have been advised in writing; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 30pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(iii)<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the grant of any options to purchase common shares, restricted shares or restricted units under an incentive compensation plan in effect or approved by our board of directors on the date of this prospectus and described in this prospectus; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 30pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(iv)<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">our filing of any registration statement on Form S-8 or a successor form relating to the common shares granted pursuant to or reserved for issuance under an incentive compensation plan described in this prospectus; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 30pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(v)<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the offer or issuance of common shares in connection with an acquisition, joint venture, commercial or collaborative relationship, or an acquisition or license by us of assets of another person or entity or pursuant to an employee benefit plan assumed by us in connection with any such acquisition, provided that (1) the aggregate number of shares issued does not exceed 5% of the total number of outstanding shares of our common shares immediately following the closing of this offering and (2) the recipient of any such shares during the restricted period enters into a lock-up agreement; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 30pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(vi)<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">facilitating the establishment of a trading plan on behalf of one of our shareholders, officers or directors pursuant to Rule 10b5-1 under the Exchange Act for the transfer of common shares, provided that such plan does not provide for the transfer of common shares during the restricted period and, to the extent a public announcement or filing under the Exchange Act is required of or voluntarily made by us regarding the establishment of such plan, such announcement or filing shall include a statement to the effect that no transfer of common shares may be made under such plan during the restricted period; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 30pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(vii)<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the issuance and sale of securities convertible into common shares pursuant to the Facility Agreement and the issuance of common shares upon the conversion of such securities; or</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 30pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(viii)<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the confidential submission of a registration statement with the SEC with respect to common shares issued and issuable upon the conversion of securities described in clause (vii) above exclusively as a result of contractual obligations contained in the Registration Rights Agreement to be entered into in connection with the Facility Agreement.</div></td></tr></table><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Morgan Stanley &amp; Co. LLC and BofA Securities, Inc., in their sole discretion, may release the common shares and other securities subject to the lock-up agreements described above in whole or in part at any time.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">In connection with our initial public offering, we and all of our directors and executive officers and substantially all of our shareholders agreed to 180-day lock-up agreements on substantially the same terms as the 90-day lock-up agreements for this offering. Morgan Stanley &amp; Co. LLC and BofA Securities, Inc. have waived the lock-up agreement from our initial public offering to the extent necessary to permit us to sell our common shares in this offering. Additionally, in connection with our initial public offering, entities affiliated with Auven Therapeutics GP Ltd. agreed that they will not transfer, distribute or dispose of any common shares or securities convertible into common shares (other than those common shares or securities convertible into common shares for which such entity holds as nominee on behalf of equity incentive plan participants) to their partners, members, stockholders, beneficiaries or other equity holders and that they will not sell any common shares or securities convertible into common shares (other than those common shares or securities convertible into common shares for which such entity holds as nominee on behalf of equity incentive plan participants) prior to June 30, 2022 without the prior written consent of Morgan Stanley &amp; Co. LLC and BofA Securities, Inc.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">In order to facilitate the offering of the common shares, the underwriters may engage in transactions that stabilize, maintain or otherwise affect the price of the common shares. Specifically, the underwriters may sell more common shares than they are obligated to purchase under the underwriting agreement, creating a short position. A short sale is covered if the short position is no greater than the number of shares available for purchase by the underwriters under the option to purchase additional common shares. The underwriters can close out a covered short sale by exercising the option to purchase additional common shares or purchasing shares in </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 36pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">241<br></div></div></div>
<!--End Page 245-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 246-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 540pt;"><a name="nt10014672x1_drs_111-under_pg5"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="block-frill" style="width: 540pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: Arial, Helvetica, sans-serif; font-size: 9pt; font-weight: bold; margin-top: 6pt; text-align: center;">Confidential Treatment Requested by ADC Therapeutics SA Pursuant to 17 C.F.R. &#167; 200.83<br></div></div><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 36pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">the open market. In determining the source of shares to close out a covered short sale, the underwriters will consider, among other things, the open market price of shares compared to the price available under the option to purchase additional common shares. The underwriters may also sell shares in excess of the option to purchase additional common shares, creating a naked short position. The underwriters must close out any naked short position by purchasing shares in the open market. A naked short position is more likely to be created if the underwriters are concerned that there may be downward pressure on the price of the common shares in the open market after pricing that could adversely affect investors who purchase in this offering. As an additional means of facilitating this offering, the underwriters may bid for, and purchase, common shares in the open market to stabilize the price of the common shares. These activities may raise or maintain the market price of the common shares above independent market levels or prevent or retard a decline in the market price of the common shares. The underwriters are not required to engage in these activities and may end any of these activities at any time.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">We, the Selling Shareholders and the underwriters have agreed to indemnify each other against certain liabilities, including liabilities under the Securities Act.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">A prospectus in electronic format may be made available on websites maintained by one or more underwriters, or selling group members, if any, participating in this offering. The representatives may agree to allocate a number of common shares to underwriters for sale to their online brokerage account holders. Internet distributions will be allocated by the representatives to underwriters that may make Internet distributions on the same basis as other allocations.</div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">Relationships</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The underwriters and their respective affiliates are full-service financial institutions engaged in various activities, which may include securities trading, commercial and investment banking, financial advisory, investment management, investment research, principal investment, hedging, financing and brokerage activities. Certain of the underwriters and their respective affiliates have, from time to time, performed, and may in the future perform, various financial advisory and investment banking services for us, for which they received or will receive customary fees and expenses. For example, certain of the underwriters also served as underwriters in our initial public offering in May 2020.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">In addition, in the ordinary course of their various business activities, the underwriters and their respective affiliates may make or hold a broad array of investments and actively trade debt and equity securities (or related derivative securities) and financial instruments (including bank loans) for their own accounts and for the accounts of their customers and may at any time hold long and short positions in such securities and instruments. Such investment and securities activities may involve our securities and instruments. The underwriters and their respective affiliates may also make investment recommendations or publish or express independent research views in respect of such securities or instruments and may at any time hold, or recommend to clients that they acquire, long or short positions in such securities and instruments.</div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">Selling Restrictions</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Other than in the United States, no action has been taken by us or the underwriters that would permit a public offering of the securities offered by this prospectus in any jurisdiction where action for that purpose is required. The securities offered by this prospectus may not be offered or sold, directly or indirectly, nor may this prospectus or any other offering material or advertisements in connection with the offer and sale of any such securities be distributed or published, in any jurisdiction, except under circumstances that will result in compliance with the applicable rules and regulations of that jurisdiction. Persons into whose possession this prospectus comes are advised to inform themselves about and to observe any restrictions relating to the offering and the distribution of this prospectus. This prospectus does not constitute an offer to sell or a solicitation of an offer to buy any securities offered by this prospectus in any jurisdiction in which such an offer or a solicitation is unlawful.</div><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">Australia</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">No placement document, prospectus, product disclosure statement or other disclosure document has been lodged with the Australian Securities and Investments Commission in relation to the offering. This prospectus does not constitute a prospectus, product disclosure statement or other disclosure document under the Corporations Act, and does not purport to include the information required for a prospectus, product disclosure statement or other disclosure document under the Corporations Act.</div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 36pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">242<br></div></div></div>
<!--End Page 246-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 247-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 540pt;"><a name="nt10014672x1_drs_111-under_pg6"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="block-frill" style="width: 540pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: Arial, Helvetica, sans-serif; font-size: 9pt; font-weight: bold; margin-top: 6pt; text-align: center;">Confidential Treatment Requested by ADC Therapeutics SA Pursuant to 17 C.F.R. &#167; 200.83<br></div></div><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 36pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Any offer in Australia of the common shares may only be made to persons, or to the Exempt Investors, who are &#8220;sophisticated investors&#8221; (within the meaning of section 708(8) of the Corporations Act), &#8220;professional investors&#8221; (within the meaning of section 708(11) of the Corporations Act) or otherwise pursuant to one or more exemptions contained in section 708 of the Corporations Act so that it is lawful to offer the common shares without disclosure to investors under Chapter 6D of the Corporations Act.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The common shares applied for by Exempt Investors in Australia must not be offered for sale in Australia in the period of 12 months after the date of allotment under the offering, except in circumstances where disclosure to investors under Chapter 6D of the Corporations Act would not be required pursuant to an exemption under section 708 of the Corporations Act or otherwise or where the offer is pursuant to a disclosure document which complies with Chapter 6D of the Corporations Act. Any person acquiring shares must observe such Australian on-sale restrictions.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">This prospectus contains general information only and does not take into account the investment objectives, financial situation or particular needs of any particular person. It does not contain any securities recommendations or financial product advice. Before making an investment decision, investors need to consider whether the information in this prospectus is appropriate for their needs, objectives and circumstances, and, if necessary, seek expert advice on those matters.</div><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">Canada</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The common shares may be sold only to purchasers purchasing, or deemed to be purchasing, as principal that are accredited investors, as defined in National Instrument 45-106 Prospectus Exemptions or subsection 73.3(1) of the Securities Act (Ontario), and are permitted clients, as defined in National Instrument 31-103 Registration Requirements, Exemptions and Ongoing Registrant Obligations. Any resale of the common shares must be made in accordance with an exemption from, or in a transaction not subject to, the prospectus requirements of applicable securities laws.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Securities legislation in certain provinces or territories of Canada may provide a purchaser with remedies for rescission or damages if this prospectus (including any amendment thereto) contains a misrepresentation, provided that the remedies for rescission or damages are exercised by the purchaser within the time limit prescribed by the securities legislation of the purchaser&#8217;s province or territory. The purchaser should refer to any applicable provisions of the securities legislation of the purchaser&#8217;s province or territory for particulars of these rights or consult with a legal advisor.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Pursuant to section 3A.3 of National Instrument 33-105 Underwriting Conflicts (NI 33-105), the underwriters are not required to comply with the disclosure requirements of NI 33-105 regarding underwriter conflicts of interest in connection with this offering.</div><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">European Economic Area and the United Kingdom</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">In relation to each Member State of the European Economic Area and the United Kingdom (each, a &#8220;Relevant State&#8221;), no shares have been offered or will be offered pursuant to this offering to the public in that Relevant State prior to the publication of a prospectus in relation to the common shares which has been approved by the competent authority in that Relevant State or, where appropriate, approved in another Relevant State and notified to the competent authority in that Relevant State, all in accordance with the Prospectus Regulation, except that it may make an offer to the public in that Relevant State of any common shares at any time under the following exemptions under the Prospectus Regulation:</div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(a)<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">to any legal entity which is a qualified investor as defined in the Prospectus Regulation;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(b)<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">to fewer than 150 natural or legal persons (other than qualified investors as defined in the Prospectus Regulation), subject to obtaining the prior consent of the representatives for any such offer; or</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(c)<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">in any other circumstances falling within Article 1(4) of the Prospectus Regulation,</div></td></tr></table><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">provided that no such offer of common shares shall require us or any underwriter to publish a prospectus pursuant to Article 3 of the Prospectus Regulation or supplement a prospectus pursuant to Article 23 of the Prospectus Regulation.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">For the purposes of this provision, the expression an &#8220;offer to the public&#8221; in relation to any of our common shares in any Relevant State means the communication in any form and by any means of sufficient information </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 36pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">243<br></div></div></div>
<!--End Page 247-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 248-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 540pt;"><a name="nt10014672x1_drs_111-under_pg7"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="block-frill" style="width: 540pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: Arial, Helvetica, sans-serif; font-size: 9pt; font-weight: bold; margin-top: 6pt; text-align: center;">Confidential Treatment Requested by ADC Therapeutics SA Pursuant to 17 C.F.R. &#167; 200.83<br></div></div><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 36pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">on the terms of the offer and any of our common shares to be offered so as to enable an investor to decide to purchase any of our common shares, and the expression &#8220;Prospectus Regulation&#8221; means Regulation (EU) 2017/1129.</div><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">Dubai International Financial Centre</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">This prospectus relates to an Exempt Offer in accordance with the Offered Securities Rules of the Dubai Financial Services Authority (&#8220;DFSA&#8221;). This prospectus is intended for distribution only to persons of a type specified in the Offered Securities Rules of the DFSA. It must not be delivered to, or relied on by, any other person. The DFSA has no responsibility for reviewing or verifying any documents in connection with Exempt Offers. The DFSA has not approved this prospectus nor taken steps to verify the information set forth herein and has no responsibility for the prospectus. The common shares to which this prospectus relates may be illiquid and/or subject to restrictions on their resale. Prospective purchasers of the common shares offered should conduct their own due diligence on the common shares. If you do not understand the contents of this prospectus you should consult an authorized financial advisor.</div><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">Hong Kong</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The common shares may not be offered or sold by means of any document other than (1) in circumstances which do not constitute an offer to the public within the meaning of the Companies Ordinance (Cap.32, Laws of Hong Kong); (2) to &#8220;professional investors&#8221; within the meaning of the Securities and Futures Ordinance (Cap.571, Laws of Hong Kong) and any rules made thereunder; or (3) in other circumstances which do not result in the document being a &#8220;prospectus&#8221; within the meaning of the Companies Ordinance (Cap.32, Laws of Hong Kong), and no advertisement, invitation, or document relating to the common shares may be issued or may be in the possession of any person for the purpose of issue (in each case whether in Hong Kong or elsewhere), which is directed at, or the contents of which are likely to be accessed or read by, the public in Hong Kong (except if permitted to do so under the laws of Hong Kong) other than with respect to common shares which are or are intended to be disposed of only to persons outside Hong Kong or only to &#8220;professional investors&#8221; within the meaning of the Securities and Futures Ordinance (Cap.571,&#160;Laws of Hong Kong) and any rules made thereunder.</div><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">Israel</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">In the State of Israel this prospectus shall not be regarded as an offer to the public to purchase shares of common stock under the Israeli Securities Law, 5728 &#8211; 1968, which requires a prospectus to be published and authorized by the Israel Securities Authority, if it complies with certain provisions of Section 15 of the Israeli Securities Law, 5728&#8211;1968, including, inter alia, if: (i) the offer is made, distributed or directed to not more than 35 investors, subject to certain conditions (the &#8220;Addressed Investors&#8221;); or (ii) the offer is made, distributed or directed to certain qualified investors defined in the First Addendum of the Israeli Securities Law, 5728 &#8211; 1968, subject to certain conditions (the &#8220;Qualified Investors&#8221;). The Qualified Investors shall not be taken into account in the count of the Addressed Investors and may be offered to purchase securities in addition to the 35 Addressed Investors. The company has not and will not take any action that would require it to publish a prospectus in accordance with and subject to the Israeli Securities Law, 5728 &#8211; 1968. We have not and will not distribute this prospectus or make, distribute or direct an offer to subscribe for our common stock to any person within the State of Israel, other than to Qualified Investors and up to 35 Addressed Investors. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Qualified Investors may have to submit written evidence that they meet the definitions set out in of the First Addendum to the Israeli Securities Law, 5728 &#8211; 1968. In particular, we may request, as a condition to be offered common stock, that Qualified Investors will each represent, warrant and certify to us and/or to anyone acting on our behalf: (i) that it is an investor falling within one of the categories listed in the First Addendum to the Israeli Securities Law, 5728 &#8211; 1968; (ii) which of the categories listed in the First Addendum to the Israeli Securities Law, 5728 &#8211; 1968 regarding Qualified Investors is applicable to it; (iii) that it will abide by all provisions set forth in the Israeli Securities Law, 5728 &#8211; 1968 and the regulations promulgated thereunder in connection with the offer to be issued common stock; (iv) that the shares of common stock that it will be issued are, subject to exemptions available under the Israeli Securities Law, 5728 &#8211; 1968: (a) for its own account; (b) for investment purposes only; and (c) not issued with a view to resale within the State of Israel, other than in accordance with the provisions of the Israeli Securities Law, 5728 &#8211; 1968; and (v) that it is willing to provide further evidence of its Qualified Investor status. Addressed Investors may have to submit written evidence in respect of their identity and may have to sign and submit a declaration containing, inter alia, the Addressed Investor&#8217;s name, address and passport number or Israeli identification number. </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 36pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">244<br></div></div></div>
<!--End Page 248-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 249-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 540pt;"><a name="nt10014672x1_drs_111-under_pg8"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="block-frill" style="width: 540pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: Arial, Helvetica, sans-serif; font-size: 9pt; font-weight: bold; margin-top: 6pt; text-align: center;">Confidential Treatment Requested by ADC Therapeutics SA Pursuant to 17 C.F.R. &#167; 200.83<br></div></div><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 36pt;"><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">Japan</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">No registration pursuant to Article 4, paragraph 1 of the Financial Instruments and Exchange Law of Japan (Law&#160;No. 25 of 1948, as amended) (the &#8220;FIEL&#8221;) has been made or will be made with respect to the solicitation of the application for the acquisition of the common shares.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Accordingly, the common shares have not been, directly or indirectly, offered or sold and will not be, directly or indirectly, offered or sold in Japan or to, or for the benefit of, any resident of Japan (which term as used herein means any person resident in Japan, including any corporation or other entity organized under the laws of Japan) or to others for re-offering or re-sale, directly or indirectly, in Japan or to, or for the benefit of, any resident of Japan except pursuant to an exemption from the registration requirements, and otherwise in compliance with, the FIEL and the other applicable laws and regulations of Japan.</div><div class="h5" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 15pt; margin-left: 20pt; text-align: left;"><u>For Qualified Institutional Investors (&#8220;QII&#8221;)</u></div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Please note that the solicitation for newly-issued or secondary securities (each as described in Paragraph 2, Article&#160;4 of the FIEL) in relation to the common shares constitutes either a &#8220;QII only private placement&#8221; or a &#8220;QII only secondary distribution&#8221; (each as described in Paragraph 1, Article 23-13 of the FIEL). Disclosure regarding any such solicitation, as is otherwise prescribed in Paragraph 1, Article 4 of the FIEL, has not been made in relation to the common shares. The common shares may only be transferred to QIIs.</div><div class="h5" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 15pt; margin-left: 20pt; text-align: left;"><u>For Non-QII Investors</u></div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Please note that the solicitation for newly-issued or secondary securities (each as described in Paragraph 2, Article&#160;4 of the FIEL) in relation to the common shares constitutes either a &#8220;small number private placement&#8221; or a &#8220;small number private secondary distribution&#8221; (each as is described in Paragraph 4, Article 23-13 of the FIEL). Disclosure regarding any such solicitation, as is otherwise prescribed in Paragraph 1, Article 4 of the FIEL, has not been made in relation to the common shares. The common shares may only be transferred en bloc without subdivision to a single investor.</div><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 15pt; margin-left: 0pt; text-align: left;">Singapore</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">This prospectus has not been registered as a prospectus with the Monetary Authority of Singapore. Accordingly, this prospectus and any other document or material in connection with the offer or sale, or invitation for subscription or purchase, of Non-CIS Securities may not be circulated or distributed, nor may the Non-CIS Securities be offered or sold, or be made the subject of an invitation for subscription or purchase, whether directly or indirectly, to persons in Singapore other than (i)&#160;to an institutional investor under Section 274 of the Securities and Futures Act, Chapter&#160;289 of Singapore (the &#8220;SFA&#8221;), (ii)&#160;to a relevant person pursuant to Section 275(1), or any person pursuant to Section 275(1A), and in accordance with the conditions specified in Section 275, of the SFA, or (iii)&#160;otherwise pursuant to, and in accordance with the conditions of, any other applicable provision of the SFA.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Where the Non-CIS Securities are subscribed or purchased under Section 275 of the SFA by a relevant person which is:</div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(a)<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">a corporation (which is not an accredited investor (as defined in Section 4A of the SFA)) the sole business of which is to hold investments and the entire share capital of which is owned by one or more individuals, each of whom is an accredited investor; or </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(b)<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">a trust (where the trustee is not an accredited investor) whose sole purpose is to hold investments and each beneficiary of the trust is an individual who is an accredited investor, </div></td></tr></table><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">securities (as defined in Section 239(1) of the SFA) of that corporation or the beneficiaries&#8217; rights and interest (howsoever described) in that trust shall not be transferred within six months after that corporation or that trust has acquired the Non-CIS Securities pursuant to an offer made under Section 275 of the SFA except:</div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(a)<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">to an institutional investor or to a relevant person defined in Section 275(2) of the SFA, or to any person arising from an offer referred to in Section 275(1A) or Section 276(4)(i)(B) of the SFA; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(b)<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">where no consideration is or will be given for the transfer; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(c)<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">where the transfer is by operation of law; </div></td></tr></table></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 36pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">245<br></div></div></div>
<!--End Page 249-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 250-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 540pt;"><a name="nt10014672x1_drs_111-under_pg9"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="block-frill" style="width: 540pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: Arial, Helvetica, sans-serif; font-size: 9pt; font-weight: bold; margin-top: 6pt; text-align: center;">Confidential Treatment Requested by ADC Therapeutics SA Pursuant to 17 C.F.R. &#167; 200.83<br></div></div><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 36pt;"><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6.75pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(d)<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">as specified in Section 276(7) of the SFA; or</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(e)<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">as specified in Regulation 37A of the Securities and Futures (Offers of Investments) (Securities and Securities-based Derivatives Contracts) Regulations 2018 of Singapore.</div></td></tr></table><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Singapore Securities and Futures Act Product Classification: Solely for the purposes of our obligations pursuant to sections 309B(1)(a) and 309B(1)(c) of the SFA, we have determined, and hereby notify all relevant persons (as defined in Section 309A of the SFA), that the common shares are &#8220;prescribed capital markets products&#8221; (as defined in the Securities and Futures (Capital Markets Products) Regulations 2018) and Excluded Investment Products (as defined in MAS Notice SFA 04-N12: Notice on the Sale of Investment Products and MAS Notice FAA-N16: Notice on Recommendations on Investment Products).</div><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 14pt; margin-left: 0pt; text-align: left;">Switzerland</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">This document is not intended to constitute an offer or solicitation to purchase or invest in the common shares described herein. The common shares may not be publicly offered, directly or indirectly, in Switzerland within the meaning of the Swiss Financial Services Act (&#8220;FinSA&#8221;) and will not be listed or admitted to trading on the SIX Swiss Exchange or on any trading venue (exchange or multilateral trading facility) in Switzerland. Neither this document nor any other offering or marketing material relating to the common shares constitutes a prospectus as such term is understood pursuant to the FinSA, and neither this document nor any other offering or marketing material relating to the common shares may be publicly distributed or otherwise made publicly available in Switzerland. </div><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 14pt; margin-left: 0pt; text-align: left;">United Kingdom</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 7pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Each underwriter has represented and agreed that:</div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 40pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(a)<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">it has only communicated or caused to be communicated and will only communicate or cause to be communicated an invitation or inducement to engage in investment activity (within the meaning of Section 21 of the Financial Services and Markets Act 2000 (&#8220;FSMA&#8221;) received by it in connection with the issue or sale of our common shares in circumstances in which Section 21(1) of the FSMA does not apply to us; and </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 40pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(b)<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">it has complied and will comply with all applicable provisions of the FSMA with respect to anything done by it in relation to our common shares in, from or otherwise involving the United Kingdom.</div></td></tr></table></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 36pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">246<br></div></div></div>
<!--End Page 250-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 251-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 540pt;"><a name="nt10014672x1_drs_111-under_pg10"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="block-frill" style="width: 540pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: Arial, Helvetica, sans-serif; font-size: 9pt; font-weight: bold; margin-top: 6pt; text-align: center;">Confidential Treatment Requested by ADC Therapeutics SA Pursuant to 17 C.F.R. &#167; 200.83<br></div></div><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 36pt;"><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: center;"><a name="tEO"><!--Anchor--></a>EXPENSES OF THE OFFERING</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">We expect that our expenses in connection with this offering, other than underwriting discounts and commissions, will be as follows:</div><table cellspacing="0" cellpadding="0" class="fintab" style="margin-top: 11.25pt; border-collapse: collapse; width: 471pt; margin-left: auto; margin-right: auto;"><tr class="header"><td style="width: 89.17%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Expenses</div></td><td class="gutter" style="width: 0.64%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 0.64%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 9.55%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Amount</div></td></tr><tr><td style="width: 89.17%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">SEC registration fee<font style="padding-left: 4.76pt;"></font></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.55%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">$<font style="padding-left: 40pt;">&#8203;</font>*</div></td></tr><tr><td style="width: 89.17%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">FINRA filing fee<font style="padding-left: 2.52pt;"></font></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 9.55%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 45pt;">*</font></div></td></tr><tr><td style="width: 89.17%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Printing and engraving expenses<font style="padding-left: 4.77pt;"></font></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.55%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 45pt;">*</font></div></td></tr><tr><td style="width: 89.17%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Legal fees and expenses<font style="padding-left: 3.11pt;"></font></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 9.55%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 45pt;">*</font></div></td></tr><tr><td style="width: 89.17%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Accounting fees and expenses<font style="padding-left: 4.22pt;"></font></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.55%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 45pt;">*</font></div></td></tr><tr><td style="width: 89.17%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Stamp duty<font style="padding-left: 0.84pt;"></font></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 9.55%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 45pt;">*</font></div></td></tr><tr><td style="width: 89.17%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Miscellaneous costs<font style="padding-left: 1.42pt;"></font></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.55%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 45pt; border-bottom: 1pt solid #000000; min-width: 45pt;"></font><font style="min-width: 45pt;">*</font></div></td></tr><tr><td style="width: 89.17%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 6pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Total<font style="font-weight: normal; padding-left: 0.64pt;"></font></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt;">&#8203;</td><td style="width: 9.55%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 6pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 45pt;">$</font><font style="border-bottom: 3pt double #000000; min-width: 45pt;">&#8195;&#8195;&#8195;&#8195;</font><font style="min-width: 45pt;">*</font></div></td></tr></table><div><div class="rule-partial" style="height: 0pt; width: 72pt; border-bottom: 1pt solid #000000; margin-bottom: 1pt; margin-right: auto; margin-left: 0pt; margin-top: 13.25pt;"> </div></div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 3pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">*<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; text-align: left;">To be provided by amendment.</div></td></tr></table><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">All amounts in the table are estimates except the SEC registration fee and the FINRA filing fee. The Company will pay all of the expenses of this offering.</div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 36pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">247<br></div></div></div>
<!--End Page 251-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 252-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 540pt;"><a name="nt10014672x1_drs_111-under_pg11"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="block-frill" style="width: 540pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: Arial, Helvetica, sans-serif; font-size: 9pt; font-weight: bold; margin-top: 6pt; text-align: center;">Confidential Treatment Requested by ADC Therapeutics SA Pursuant to 17 C.F.R. &#167; 200.83<br></div></div><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 36pt;"><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: center;"><a name="tLM"><!--Anchor--></a>LEGAL MATTERS</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The validity of the common shares and certain other matters with respect to Swiss law will be passed upon for us by Homburger AG, Zurich, Switzerland. Certain matters with respect to U.S. federal and New York State law will be passed upon for us by Davis Polk &amp; Wardwell LLP, New York, New York. Certain matters with respect to U.S.&#160;federal and New York State law will be passed upon for the underwriters by Cooley LLP, New York, New York. Lenz &amp; Staehelin, Geneva, Switzerland is representing the underwriters with respect to certain matters of Swiss law.</div><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 20.5pt; text-align: center;"><a name="tE"><!--Anchor--></a>EXPERTS</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The consolidated financial statements as of December&#160;31, 2019 and 2018 and for each of the two years in the period ended December&#160;31, 2019 included in this prospectus have been so included in reliance on the report of PricewaterhouseCoopers SA, an independent registered public accounting firm, given on the authority of said firm as experts in auditing and accounting. PricewaterhouseCoopers SA is a member of EXPERTsuisse &#8212; Swiss Expert Association for Audit, Tax and Fiduciary.</div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 36pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">248<br></div></div></div>
<!--End Page 252-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 253-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 540pt;"><a name="nt10014672x1_drs_111-under_pg12"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="block-frill" style="width: 540pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: Arial, Helvetica, sans-serif; font-size: 9pt; font-weight: bold; margin-top: 6pt; text-align: center;">Confidential Treatment Requested by ADC Therapeutics SA Pursuant to 17 C.F.R. &#167; 200.83<br></div></div><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 36pt;"><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: center;"><a name="tEJ"><!--Anchor--></a>ENFORCEMENT OF JUDGMENTS</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">We are organized under the laws of Switzerland and our registered office and domicile is located in Epalinges, Switzerland. Moreover, a number of our directors and executive officers are not residents of the United States, and all or a substantial portion of the assets of such persons are located outside the United States. As a result, it may not be possible for investors to effect service of process within the United States upon us or upon such persons or to enforce against them judgments obtained in U.S. courts, including judgments in actions predicated upon the civil liability provisions of the federal securities laws of the United States. We have been advised by our Swiss counsel that there is doubt as to the enforceability in Switzerland of original actions, or in actions for enforcement of judgments of U.S. courts, of civil liabilities to the extent solely predicated upon the federal and state securities laws of the United States. Original actions against persons in Switzerland based solely upon the U.S. federal or state securities laws are governed, among other things, by the principles set forth in the PILA. This statute provides that the application of provisions of non-Swiss law by the courts in Switzerland shall be precluded if the result would be incompatible with Swiss public policy. Also, mandatory provisions of Swiss law may be applicable regardless of any other law that would otherwise apply.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Switzerland and the United States do not have a treaty providing for reciprocal recognition of and enforcement of judgments in civil and commercial matters. The recognition and enforcement of a judgment of the courts of the United States in Switzerland is governed by the principles set forth in the PILA. This statute provides in principle that a judgment rendered by a non-Swiss court may be enforced in Switzerland only if:</div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the non-Swiss court had jurisdiction pursuant to the PILA; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the judgment of such non-Swiss court has become final and non-appealable; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the judgment does not contravene Swiss public policy; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the court procedures and the service of documents leading to the judgment were in accordance with the due process of law; and</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">no proceeding involving the same position and the same subject matter was first brought in Switzerland, or adjudicated in Switzerland, or was earlier adjudicated in a third state and this decision is recognizable in Switzerland.</div></td></tr></table></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 36pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">249<br></div></div></div>
<!--End Page 253-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 254-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 540pt;"><a name="nt10014672x1_drs_111-under_pg13"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="block-frill" style="width: 540pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: Arial, Helvetica, sans-serif; font-size: 9pt; font-weight: bold; margin-top: 6pt; text-align: center;">Confidential Treatment Requested by ADC Therapeutics SA Pursuant to 17 C.F.R. &#167; 200.83<br></div></div><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 36pt;"><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: center;"><a name="tWYC"><!--Anchor--></a>WHERE YOU CAN FIND MORE INFORMATION</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">We have filed with the SEC a registration statement (including amendments and exhibits to the registration statement) on Form F-1 under the Securities Act. This prospectus, which is part of the registration statement, does not contain all of the information set forth in the registration statement and the exhibits and schedules to the registration statement. For further information, we refer you to the registration statement and the exhibits and schedules filed as part of the registration statement. If a document has been filed as an exhibit to the registration statement, we refer you to the copy of the document that has been filed. Each statement in this prospectus relating to a document filed as an exhibit is qualified in all respects by the filed exhibit.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">We are subject to the informational requirements of the Exchange Act. Accordingly, we are required to file reports and other information with the SEC, including annual reports on Form 20-F and reports on Form 6-K. The SEC maintains an Internet site at www.sec.gov that contains reports, proxy and information statements and other information we have filed electronically with the SEC. As a foreign private issuer, we are exempt under the Exchange Act from, among other things, the rules prescribing the furnishing and content of proxy statements, and our executive officers, directors and principal shareholders are exempt from the reporting and short-swing profit recovery provisions contained in Section 16 of the Exchange Act. In addition, we are not required under the Exchange Act to file periodic reports and financial statements with the SEC as frequently or as promptly as U.S. companies whose securities are registered under the Exchange Act.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">We maintain a corporate website at www.adctherapeutics.com. The reference to our website is an inactive textual reference only, and information contained therein or connected thereto is not incorporated into this prospectus or the registration statement of which it forms a part.</div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 36pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">250<br></div></div></div>
<!--End Page 254-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 255-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 540pt;"><a name="nt10014672x1_drs_200-fintoc_pg1"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="block-frill" style="width: 540pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: Arial, Helvetica, sans-serif; font-size: 9pt; font-weight: bold; margin-top: 6pt; text-align: center;">Confidential Treatment Requested by ADC Therapeutics SA Pursuant to 17 C.F.R. &#167; 200.83<br></div></div><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 36pt;"><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: center;"><a name="fFINTOC"><!--Anchor--></a>INDEX TO FINANCIAL STATEMENTS</div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 19.5pt; margin-left: 0pt; text-align: left;">UNAUDITED CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS</div><table cellspacing="0" cellpadding="0" class="fintab" style="margin-top: 10.25pt; border-collapse: collapse; width: 468pt; margin-left: auto; margin-right: auto;"><tr><td style="width: 87.18%; text-align: left; vertical-align: bottom; padding-top: 6pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Unaudited Condensed Consolidated Interim Financial Statements<br></div></td><td class="gutter" style="width: 1.37%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.37%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.09%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 6pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 87.18%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 20pt; text-align: left;"><a href="#tF1SOI">- Condensed Consolidated Income Statement<font style="padding-left: 1.67pt;"></font></a></div></td><td class="gutter" style="width: 1.37%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.37%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 10.09%; text-align: right; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: right;"><a href="#tF1SOI">F-2</a></div></td></tr><tr><td style="width: 87.18%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 20pt; text-align: left;"><a href="#tF1SCI">- Condensed Consolidated Statement of Comprehensive Income<font style="padding-left: 3.92pt;"></font></a></div></td><td class="gutter" style="width: 1.37%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.37%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.09%; text-align: right; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: right;"><a href="#tF1SCI">F-3</a></div></td></tr><tr><td style="width: 87.18%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 20pt; text-align: left;"><a href="#tF1BS">- Condensed Consolidated Balance Sheet<font style="padding-left: 2.22pt;"></font></a></div></td><td class="gutter" style="width: 1.37%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.37%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 10.09%; text-align: right; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: right;"><a href="#tF1BS">F-4</a></div></td></tr><tr><td style="width: 87.18%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 20pt; text-align: left;"><a href="#tF1CIE">- Condensed Consolidated Statement of Changes in Equity<font style="padding-left: 4.46pt;"></font></a></div></td><td class="gutter" style="width: 1.37%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.37%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.09%; text-align: right; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: right;"><a href="#tF1CIE">F-5</a></div></td></tr><tr><td style="width: 87.18%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 20pt; text-align: left;"><a href="#tF1CF">- Condensed Consolidated Statement of Cash Flows<font style="padding-left: 2.23pt;"></font></a></div></td><td class="gutter" style="width: 1.37%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.37%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 10.09%; text-align: right; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: right;"><a href="#tF1CF">F-7</a></div></td></tr><tr><td style="width: 87.18%; text-align: left; vertical-align: bottom; padding-top: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 20pt; text-align: left;"><a href="#tF1NOTEE">- Notes to the Condensed Consolidated Interim Financial Statements<font style="padding-left: 4.48pt;"></font></a></div></td><td class="gutter" style="width: 1.37%; border-bottom: none; font-size: 2pt; padding-top: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.37%; border-bottom: none; font-size: 2pt; padding-top: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.09%; text-align: right; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: right;"><a href="#tF1NOTES">F-8</a> to <a href="#tF1NOTEE">F-23</a></div></td></tr></table><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 18.5pt; margin-left: 0pt; text-align: left;">CONSOLIDATED FINANCIAL STATEMENTS</div><table cellspacing="0" cellpadding="0" class="fintab" style="margin-top: 10.25pt; border-collapse: collapse; width: 468pt; margin-left: auto; margin-right: auto;"><tr><td style="width: 87.18%; text-align: left; vertical-align: bottom; padding-top: 6pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;"><a href="#tGI">Group Information<font style="padding-left: 3.86pt;"></font></a></div></td><td class="gutter" style="width: 0.83%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.83%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 11.16%; text-align: right; vertical-align: bottom; white-space: nowrap; padding-top: 6pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: right;"><a href="#tGI">F-24</a></div></td></tr><tr><td style="width: 87.18%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.83%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.83%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 11.16%; text-align: right; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 87.18%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;"><a href="#tRIR">Report of Independent Registered Public Accounting Firm<font style="padding-left: 1.68pt;"></font></a></div></td><td class="gutter" style="width: 0.83%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.83%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 11.16%; text-align: right; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: right;"><a href="#tRIR">F-25</a></div></td></tr><tr><td style="width: 87.18%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.83%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.83%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 11.16%; text-align: right; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 87.18%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Consolidated Financial Statements<br></div></td><td class="gutter" style="width: 0.83%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.83%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 11.16%; text-align: right; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 87.18%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 20pt; text-align: left;"><a href="#tCIS">- Consolidated Income Statement<font style="padding-left: 4.43pt;"></font></a></div></td><td class="gutter" style="width: 0.83%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.83%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 11.16%; text-align: right; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: right;"><a href="#tCIS">F-26</a></div></td></tr><tr><td style="width: 87.18%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 20pt; text-align: left;"><a href="#tCSCI">- Consolidated Statement of Comprehensive Income<font style="padding-left: 1.68pt;"></font></a></div></td><td class="gutter" style="width: 0.83%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.83%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 11.16%; text-align: right; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: right;"><a href="#tCSCI">F-27</a></div></td></tr><tr><td style="width: 87.18%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 20pt; text-align: left;"><a href="#tCBS">- Consolidated Balance Sheet<font style="padding-left: 4.99pt;"></font></a></div></td><td class="gutter" style="width: 0.83%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.83%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 11.16%; text-align: right; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: right;"><a href="#tCBS">F-28</a></div></td></tr><tr><td style="width: 87.18%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 20pt; text-align: left;"><a href="#tCSCE">- Consolidated Statement of Changes in Equity<font style="padding-left: 2.22pt;"></font></a></div></td><td class="gutter" style="width: 0.83%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.83%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 11.16%; text-align: right; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: right;"><a href="#tCSCE">F-29</a></div></td></tr><tr><td style="width: 87.18%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 20pt; text-align: left;"><a href="#tCSCF">- Consolidated Statement of Cash Flows<font style="padding-left: 5pt;"></font></a></div></td><td class="gutter" style="width: 0.83%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.83%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 11.16%; text-align: right; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: right;"><a href="#tCSCF">F-30</a></div></td></tr><tr><td style="width: 87.18%; text-align: left; vertical-align: bottom; padding-top: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 20pt; text-align: left;"><a href="#tNTC1">- Notes to the Consolidated Financial Statements<font style="padding-left: 0.01pt;"></font></a></div></td><td class="gutter" style="width: 0.83%; border-bottom: none; font-size: 2pt; padding-top: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.83%; border-bottom: none; font-size: 2pt; padding-top: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 11.16%; text-align: right; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: right;"><a href="#tNTC">F-31</a> to <a href="#tNTC1">F-69</a></div></td></tr></table></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 36pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">F-1<br></div></div></div>
<!--End Page 255-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 256-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 540pt;"><a name="nt10014672x1_drs_201-fintab01_pg1"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="block-frill" style="width: 540pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: Arial, Helvetica, sans-serif; font-size: 9pt; font-weight: bold; margin-top: 6pt; text-align: center;">Confidential Treatment Requested by ADC Therapeutics SA Pursuant to 17 C.F.R. &#167; 200.83<br></div></div><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 36pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: -22.25pt; margin-left: 0pt; text-align: left;"><a href="#tF1NOTEE"></a>&#8195;</div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 20.5pt; margin-left: 0pt; text-align: left;">ADC Therapeutics SA</div><div><div class="rule-full" style="height: 0pt; width: 100%; border-bottom: 1pt solid #000000; margin-bottom: 2pt; margin-left: auto; margin-right: auto; margin-top: 7.5pt;"> </div></div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 20.5pt; margin-left: 0pt; text-align: left;"><a name="tF1SOI"><!--Anchor--></a>Condensed Consolidated Interim Statement of Income<br></div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">(in KUSD except for share and per share data)</div><table cellspacing="0" cellpadding="0" class="fintab" style="margin-top: 10.25pt; border-collapse: collapse; width: 468pt; margin-left: auto; margin-right: auto;"><tr class="header"><td style="width: 47.22%; text-align: left; vertical-align: bottom; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 2.01%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 2.01%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 3.41%; text-align: center; vertical-align: bottom; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 2.01%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 2.01%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td colspan="4" style="width: 19.26%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">For the Three Months <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Ended June&#160;30,</div></td><td class="gutter" style="width: 2.01%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 2.01%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td colspan="4" style="width: 18.02%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">For the Six Months <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Ended June&#160;30,</div></td></tr><tr class="header"><td style="width: 47.22%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 2.01%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 2.01%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 3.41%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Note</div></td><td class="gutter" style="width: 2.01%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 2.01%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 7.99%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2020</div></td><td class="gutter" style="width: 2.01%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 2.01%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 7.25%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2019</div></td><td class="gutter" style="width: 2.01%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 2.01%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 7.36%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2020</div></td><td class="gutter" style="width: 2.01%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 2.01%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 6.63%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2019</div></td></tr><tr><td style="width: 47.22%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Contract revenue<font style="padding-left: 4.09pt;"></font></div></td><td class="gutter" style="width: 2.01%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.01%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 3.41%; text-align: center; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">6</div></td><td class="gutter" style="width: 2.01%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.01%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.99%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.45pt; text-align: left;"><font style="padding-left: 24.26pt;">&#8212;</font></div></td><td class="gutter" style="width: 2.01%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.01%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.25%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.46pt; text-align: left;"><font style="padding-left: 8.33pt;">1,962</font></div></td><td class="gutter" style="width: 2.01%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.01%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.36%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 24.26pt;">&#8212;</font></div></td><td class="gutter" style="width: 2.01%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.01%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.63%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 8.33pt;">2,340</font></div></td></tr><tr><td style="width: 47.22%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Operating expense<br></div></td><td class="gutter" style="width: 2.01%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.01%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 3.41%; text-align: center; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 2.01%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.01%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 7.99%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 2.01%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.01%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 7.25%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 2.01%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.01%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 7.36%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 2.01%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.01%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 6.63%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 47.22%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Research and development<font style="padding-left: 4.1pt;"></font></div></td><td class="gutter" style="width: 2.01%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.01%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 3.41%; text-align: center; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">7</div></td><td class="gutter" style="width: 2.01%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.01%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.99%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.45pt; text-align: left;"><font style="padding-left: 3.43pt;">(25,950</font><font style="padding-left: 0.2pt;">)</font></div></td><td class="gutter" style="width: 2.01%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.01%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.25%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.46pt; text-align: left;">(21,760<font style="padding-left: 0.2pt;">)</font></div></td><td class="gutter" style="width: 2.01%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.01%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.36%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 3.43pt;">(61,325</font><font style="padding-left: 0.2pt;">)</font></div></td><td class="gutter" style="width: 2.01%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.01%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.63%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">(46,572<font style="padding-left: 0.2pt;">)</font></div></td></tr><tr><td style="width: 47.22%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">General and administrative<font style="padding-left: 3.55pt;"></font></div></td><td class="gutter" style="width: 2.01%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 2.01%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 3.41%; text-align: center; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">8</div></td><td class="gutter" style="width: 2.01%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 2.01%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 7.99%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.45pt; text-align: left;"><font style="padding-left: 3.43pt; border-bottom: 1pt solid #000000; min-width: 34.46pt;">(18,999</font><font style="padding-left: 0.2pt; border-bottom: 1pt solid #000000; min-width: 34.46pt;"></font><font style="min-width: 34.46pt;">)</font></div></td><td class="gutter" style="width: 2.01%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 2.01%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 7.25%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.46pt; text-align: left;"><font style="padding-left: 5pt; border-bottom: 1pt solid #000000; min-width: 31.03pt;">(4,089</font><font style="padding-left: 0.2pt; border-bottom: 1pt solid #000000; min-width: 31.03pt;"></font><font style="min-width: 31.03pt;">)</font></div></td><td class="gutter" style="width: 2.01%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 2.01%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 7.36%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 3.43pt; border-bottom: 1pt solid #000000; min-width: 34.46pt;">(27,509</font><font style="padding-left: 0.2pt; border-bottom: 1pt solid #000000; min-width: 34.46pt;"></font><font style="min-width: 34.46pt;">)</font></div></td><td class="gutter" style="width: 2.01%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 2.01%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 6.63%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 5pt; border-bottom: 1pt solid #000000; min-width: 31.03pt;">(6,592</font><font style="padding-left: 0.2pt; border-bottom: 1pt solid #000000; min-width: 31.03pt;"></font><font style="min-width: 31.03pt;">)</font></div></td></tr><tr><td style="width: 47.22%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Total operating expense<font style="padding-left: 1.46pt;"></font></div></td><td class="gutter" style="width: 2.01%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.01%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 3.41%; text-align: center; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 2.01%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.01%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.99%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.45pt; text-align: left;"><font style="padding-left: 3.43pt; border-bottom: 1pt solid #000000; min-width: 34.46pt;">(44,949</font><font style="padding-left: 0.2pt; border-bottom: 1pt solid #000000; min-width: 34.46pt;"></font><font style="min-width: 34.46pt;">)</font></div></td><td class="gutter" style="width: 2.01%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.01%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.25%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.46pt; text-align: left;"><font style="border-bottom: 1pt solid #000000; min-width: 31.03pt;">(25,849</font><font style="padding-left: 0.2pt; border-bottom: 1pt solid #000000; min-width: 31.03pt;"></font><font style="min-width: 31.03pt;">)</font></div></td><td class="gutter" style="width: 2.01%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.01%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.36%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 3.43pt; border-bottom: 1pt solid #000000; min-width: 34.46pt;">(88,834</font><font style="padding-left: 0.2pt; border-bottom: 1pt solid #000000; min-width: 34.46pt;"></font><font style="min-width: 34.46pt;">)</font></div></td><td class="gutter" style="width: 2.01%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.01%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.63%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="border-bottom: 1pt solid #000000; min-width: 31.03pt;">(53,164</font><font style="padding-left: 0.2pt; border-bottom: 1pt solid #000000; min-width: 31.03pt;"></font><font style="min-width: 31.03pt;">)</font></div></td></tr><tr><td style="width: 47.22%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Loss from operations<font style="padding-left: 1.87pt;"></font></div></td><td class="gutter" style="width: 2.01%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 2.01%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 3.41%; text-align: center; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 2.01%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 2.01%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 7.99%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.45pt; text-align: left;"><font style="padding-left: 3.43pt; border-bottom: 1pt solid #000000; min-width: 34.46pt;">(44,949</font><font style="padding-left: 0.2pt; border-bottom: 1pt solid #000000; min-width: 34.46pt;"></font><font style="min-width: 34.46pt;">)</font></div></td><td class="gutter" style="width: 2.01%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 2.01%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 7.25%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.46pt; text-align: left;"><font style="border-bottom: 1pt solid #000000; min-width: 31.03pt;">(23,887</font><font style="padding-left: 0.2pt; border-bottom: 1pt solid #000000; min-width: 31.03pt;"></font><font style="min-width: 31.03pt;">)</font></div></td><td class="gutter" style="width: 2.01%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 2.01%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 7.36%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 3.43pt; border-bottom: 1pt solid #000000; min-width: 34.46pt;">(88,834</font><font style="padding-left: 0.2pt; border-bottom: 1pt solid #000000; min-width: 34.46pt;"></font><font style="min-width: 34.46pt;">)</font></div></td><td class="gutter" style="width: 2.01%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 2.01%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 6.63%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="border-bottom: 1pt solid #000000; min-width: 31.03pt;">(50,824</font><font style="padding-left: 0.2pt; border-bottom: 1pt solid #000000; min-width: 31.03pt;"></font><font style="min-width: 31.03pt;">)</font></div></td></tr><tr><td style="width: 47.22%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Other income (expense)<br></div></td><td class="gutter" style="width: 2.01%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.01%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 3.41%; text-align: center; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 2.01%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.01%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.99%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 2.01%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.01%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.25%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 2.01%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.01%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.36%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 2.01%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.01%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.63%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 47.22%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Other income<font style="padding-left: 2.97pt;"></font></div></td><td class="gutter" style="width: 2.01%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.01%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 3.41%; text-align: center; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 2.01%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.01%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 7.99%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.45pt; text-align: left;"><font style="padding-left: 19.26pt;">130</font></div></td><td class="gutter" style="width: 2.01%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.01%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 7.25%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.46pt; text-align: left;"><font style="padding-left: 20.83pt;">&#8212;</font></div></td><td class="gutter" style="width: 2.01%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.01%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 7.36%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 19.26pt;">278</font></div></td><td class="gutter" style="width: 2.01%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.01%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 6.63%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 20.83pt;">&#8212;</font></div></td></tr><tr><td style="width: 47.22%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Convertible loans, derivatives, increase in fair value<font style="padding-left: 0.85pt;"></font></div></td><td class="gutter" style="width: 2.01%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.01%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 3.41%; text-align: center; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">11</div></td><td class="gutter" style="width: 2.01%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.01%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.99%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.45pt; text-align: left;"><font style="padding-left: 4.8pt;">(79,261</font><font style="padding-left: 0.2pt;">)</font></div></td><td class="gutter" style="width: 2.01%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.01%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.25%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.46pt; text-align: left;"><font style="padding-left: 21.03pt;">&#8212;</font></div></td><td class="gutter" style="width: 2.01%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.01%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.36%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 4.8pt;">(79,261</font><font style="padding-left: 0.2pt;">)</font></div></td><td class="gutter" style="width: 2.01%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.01%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.63%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 21.03pt;">&#8212;</font></div></td></tr><tr><td style="width: 47.22%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 20pt; text-indent: -10pt; text-align: left;">Convertible loans, first tranche, derivative, transaction costs<font style="padding-left: 4.49pt;"></font></div></td><td class="gutter" style="width: 2.01%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.01%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 3.41%; text-align: center; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">11</div></td><td class="gutter" style="width: 2.01%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.01%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 7.99%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.45pt; text-align: left;"><font style="padding-left: 9.61pt;">(1,571</font><font style="padding-left: 0.2pt;">)</font></div></td><td class="gutter" style="width: 2.01%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.01%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 7.25%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.46pt; text-align: left;"><font style="padding-left: 21.03pt;">&#8212;</font></div></td><td class="gutter" style="width: 2.01%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.01%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 7.36%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 9.61pt;">(1,571</font><font style="padding-left: 0.2pt;">)</font></div></td><td class="gutter" style="width: 2.01%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.01%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 6.63%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 21.03pt;">&#8212;</font></div></td></tr><tr><td style="width: 47.22%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Financial income<font style="padding-left: 1.66pt;"></font></div></td><td class="gutter" style="width: 2.01%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.01%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 3.41%; text-align: center; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 2.01%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.01%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.99%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.45pt; text-align: left;"><font style="padding-left: 19.85pt;">195</font></div></td><td class="gutter" style="width: 2.01%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.01%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.25%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.46pt; text-align: left;"><font style="padding-left: 16.42pt;">659</font></div></td><td class="gutter" style="width: 2.01%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.01%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.36%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 19.85pt;">569</font></div></td><td class="gutter" style="width: 2.01%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.01%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.63%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 9.31pt;">1,306</font></div></td></tr><tr><td style="width: 47.22%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Financial expense<font style="padding-left: 4.08pt;"></font></div></td><td class="gutter" style="width: 2.01%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.01%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 3.41%; text-align: center; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 2.01%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.01%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 7.99%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.45pt; text-align: left;"><font style="padding-left: 16.72pt;">(897</font><font style="padding-left: 0.2pt;">)</font></div></td><td class="gutter" style="width: 2.01%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.01%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 7.25%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.46pt; text-align: left;"><font style="padding-left: 18.09pt;">(36</font><font style="padding-left: 0.2pt;">)</font></div></td><td class="gutter" style="width: 2.01%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.01%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 7.36%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 16.72pt;">(939</font><font style="padding-left: 0.2pt;">)</font></div></td><td class="gutter" style="width: 2.01%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.01%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 6.63%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 18.09pt;">(73</font><font style="padding-left: 0.2pt;">)</font></div></td></tr><tr><td style="width: 47.22%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Exchange differences<font style="padding-left: 0.42pt;"></font></div></td><td class="gutter" style="width: 2.01%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.01%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 3.41%; text-align: center; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 2.01%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.01%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.99%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.45pt; text-align: left;"><font style="padding-left: 16.72pt; border-bottom: 1pt solid #000000; min-width: 34.46pt;">(100</font><font style="padding-left: 0.2pt; border-bottom: 1pt solid #000000; min-width: 34.46pt;"></font><font style="min-width: 34.46pt;">)</font></div></td><td class="gutter" style="width: 2.01%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.01%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.25%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.46pt; text-align: left;"><font style="padding-left: 21.22pt; border-bottom: 1pt solid #000000; min-width: 31.03pt;">10</font></div></td><td class="gutter" style="width: 2.01%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.01%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.36%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 21.52pt; border-bottom: 1pt solid #000000; min-width: 34.46pt;">(71</font><font style="padding-left: 0.2pt; border-bottom: 1pt solid #000000; min-width: 34.46pt;"></font><font style="min-width: 34.46pt;">)</font></div></td><td class="gutter" style="width: 2.01%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.01%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.63%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 18.09pt; border-bottom: 1pt solid #000000; min-width: 31.03pt;">(68</font><font style="padding-left: 0.2pt; border-bottom: 1pt solid #000000; min-width: 31.03pt;"></font><font style="min-width: 31.03pt;">)</font></div></td></tr><tr><td style="width: 47.22%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Total other income (expense)<font style="padding-left: 4.74pt;"></font></div></td><td class="gutter" style="width: 2.01%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 2.01%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 3.41%; text-align: center; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 2.01%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 2.01%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 7.99%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.45pt; text-align: left;"><font style="padding-left: 4.8pt; border-bottom: 1pt solid #000000; min-width: 34.46pt;">(81,504</font><font style="padding-left: 0.2pt; border-bottom: 1pt solid #000000; min-width: 34.46pt;"></font><font style="min-width: 34.46pt;">)</font></div></td><td class="gutter" style="width: 2.01%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 2.01%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 7.25%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.46pt; text-align: left;"><font style="padding-left: 16.42pt; border-bottom: 1pt solid #000000; min-width: 31.03pt;">633</font></div></td><td class="gutter" style="width: 2.01%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 2.01%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 7.36%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 4.8pt; border-bottom: 1pt solid #000000; min-width: 34.46pt;">(80,995</font><font style="padding-left: 0.2pt; border-bottom: 1pt solid #000000; min-width: 34.46pt;"></font><font style="min-width: 34.46pt;">)</font></div></td><td class="gutter" style="width: 2.01%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 2.01%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 6.63%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 9.31pt; border-bottom: 1pt solid #000000; min-width: 31.03pt;">1,165</font></div></td></tr><tr><td style="width: 47.22%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Loss before taxes<font style="padding-left: 0.2pt;"></font></div></td><td class="gutter" style="width: 2.01%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.01%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 3.41%; text-align: center; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 2.01%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.01%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.99%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.45pt; text-align: left;">(126,453<font style="padding-left: 0.2pt;">)</font></div></td><td class="gutter" style="width: 2.01%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.01%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.25%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.46pt; text-align: left;"><font style="padding-left: 1.37pt;">(23,254</font><font style="padding-left: 0.2pt;">)</font></div></td><td class="gutter" style="width: 2.01%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.01%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.36%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">(169,829<font style="padding-left: 0.2pt;">)</font></div></td><td class="gutter" style="width: 2.01%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.01%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.63%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 1.37pt;">(49,659</font><font style="padding-left: 0.2pt;">)</font></div></td></tr><tr><td style="width: 47.22%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Income tax expense<font style="padding-left: 0.95pt;"></font></div></td><td class="gutter" style="width: 2.01%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 2.01%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 3.41%; text-align: center; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 2.01%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 2.01%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 7.99%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.45pt; text-align: left;"><font style="padding-left: 16.72pt; border-bottom: 1pt solid #000000; min-width: 34.46pt;">(104</font><font style="padding-left: 0.2pt; border-bottom: 1pt solid #000000; min-width: 34.46pt;"></font><font style="min-width: 34.46pt;">)</font></div></td><td class="gutter" style="width: 2.01%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 2.01%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 7.25%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.46pt; text-align: left;"><font style="padding-left: 18.09pt; border-bottom: 1pt solid #000000; min-width: 31.03pt;">(94</font><font style="padding-left: 0.2pt; border-bottom: 1pt solid #000000; min-width: 31.03pt;"></font><font style="min-width: 31.03pt;">)</font></div></td><td class="gutter" style="width: 2.01%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 2.01%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 7.36%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 16.72pt; border-bottom: 1pt solid #000000; min-width: 34.46pt;">(204</font><font style="padding-left: 0.2pt; border-bottom: 1pt solid #000000; min-width: 34.46pt;"></font><font style="min-width: 34.46pt;">)</font></div></td><td class="gutter" style="width: 2.01%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 2.01%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 6.63%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 13.28pt; border-bottom: 1pt solid #000000; min-width: 31.03pt;">(199</font><font style="padding-left: 0.2pt; border-bottom: 1pt solid #000000; min-width: 31.03pt;"></font><font style="min-width: 31.03pt;">)</font></div></td></tr><tr><td style="width: 47.22%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Net loss<font style="font-weight: normal; padding-left: 1.2pt;"></font></div></td><td class="gutter" style="width: 2.01%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.01%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 3.41%; text-align: center; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 2.01%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.01%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.99%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.45pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 34.46pt;">(126,557</font><font style="padding-left: 0.2pt; border-bottom: 3pt double #000000; min-width: 34.46pt;"></font><font style="min-width: 34.46pt;">)</font></div></td><td class="gutter" style="width: 2.01%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.01%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.25%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.46pt; text-align: left;"><font style="padding-left: 1.37pt; border-bottom: 3pt double #000000; min-width: 31.03pt;">(23,348</font><font style="padding-left: 0.2pt; border-bottom: 3pt double #000000; min-width: 31.03pt;"></font><font style="min-width: 31.03pt;">)</font></div></td><td class="gutter" style="width: 2.01%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.01%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.36%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 34.46pt;">(170,033</font><font style="padding-left: 0.2pt; border-bottom: 3pt double #000000; min-width: 34.46pt;"></font><font style="min-width: 34.46pt;">)</font></div></td><td class="gutter" style="width: 2.01%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.01%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.63%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 1.37pt; border-bottom: 3pt double #000000; min-width: 31.03pt;">(49,858</font><font style="padding-left: 0.2pt; border-bottom: 3pt double #000000; min-width: 31.03pt;"></font><font style="min-width: 31.03pt;">)</font></div></td></tr><tr><td style="width: 47.22%; text-align: left; vertical-align: bottom; padding-top: 5.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Net loss attributable to:<br></div></td><td class="gutter" style="width: 2.01%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.01%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 3.41%; text-align: center; vertical-align: bottom; padding-top: 5.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 2.01%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.01%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 7.99%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 5.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 2.01%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.01%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 7.25%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 5.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 2.01%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.01%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 7.36%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 5.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 2.01%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.01%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 6.63%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 5.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 47.22%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 5.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Owners of the parent<font style="padding-left: 0.8pt;"></font></div></td><td class="gutter" style="width: 2.01%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 5.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.01%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 5.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 3.41%; text-align: center; vertical-align: bottom; padding-top: 3pt; padding-bottom: 5.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 2.01%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 5.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.01%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 5.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.99%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 5.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.45pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 34.46pt;">(126,557</font><font style="padding-left: 0.2pt; border-bottom: 3pt double #000000; min-width: 34.46pt;"></font><font style="min-width: 34.46pt;">)</font></div></td><td class="gutter" style="width: 2.01%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 5.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.01%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 5.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.25%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 5.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.46pt; text-align: left;"><font style="padding-left: 1.37pt; border-bottom: 3pt double #000000; min-width: 31.03pt;">(23,348</font><font style="padding-left: 0.2pt; border-bottom: 3pt double #000000; min-width: 31.03pt;"></font><font style="min-width: 31.03pt;">)</font></div></td><td class="gutter" style="width: 2.01%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 5.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.01%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 5.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.36%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 5.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 34.46pt;">(170,033</font><font style="padding-left: 0.2pt; border-bottom: 3pt double #000000; min-width: 34.46pt;"></font><font style="min-width: 34.46pt;">)</font></div></td><td class="gutter" style="width: 2.01%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 5.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.01%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 5.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.63%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 5.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 1.37pt; border-bottom: 3pt double #000000; min-width: 31.03pt;">(49,858</font><font style="padding-left: 0.2pt; border-bottom: 3pt double #000000; min-width: 31.03pt;"></font><font style="min-width: 31.03pt;">)</font></div></td></tr><tr><td style="width: 47.22%; text-align: left; vertical-align: bottom; padding-top: 5.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Net loss per share, basic and diluted<font style="padding-left: 1.66pt;"></font></div></td><td class="gutter" style="width: 2.01%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt;">&#8203;</td><td class="gutter" style="width: 2.01%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt;">&#8203;</td><td style="width: 3.41%; text-align: center; vertical-align: bottom; padding-top: 5.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">15</div></td><td class="gutter" style="width: 2.01%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt;">&#8203;</td><td class="gutter" style="width: 2.01%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt;">&#8203;</td><td style="width: 7.99%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 5.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.45pt; text-align: left;"><font style="padding-left: 14.41pt;">(2.01</font><font style="padding-left: 0.2pt;">)</font></div></td><td class="gutter" style="width: 2.01%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt;">&#8203;</td><td class="gutter" style="width: 2.01%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt;">&#8203;</td><td style="width: 7.25%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 5.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.46pt; text-align: left;"><font style="padding-left: 10.98pt;">(0.49</font><font style="padding-left: 0.2pt;">)</font></div></td><td class="gutter" style="width: 2.01%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt;">&#8203;</td><td class="gutter" style="width: 2.01%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt;">&#8203;</td><td style="width: 7.36%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 5.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 14.41pt;">(2.97</font><font style="padding-left: 0.2pt;">)</font></div></td><td class="gutter" style="width: 2.01%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt;">&#8203;</td><td class="gutter" style="width: 2.01%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt;">&#8203;</td><td style="width: 6.63%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 5.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 10.98pt;">(1.05</font><font style="padding-left: 0.2pt;">)</font></div></td></tr></table></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 36pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 6.75pt; margin-left: 0pt; text-align: justify;">The accompanying notes on pages F-<a href="#tF1NOTES">8</a> to F-<a href="#tF1NOTEE">23</a> form an integral part of these condensed consolidated interim financial statements (Unaudited) <br></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 36pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">F-2<br></div></div></div>
<!--End Page 256-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 257-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 540pt;"><a name="nt10014672x1_drs_201-fintab01_pg2"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="block-frill" style="width: 540pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: Arial, Helvetica, sans-serif; font-size: 9pt; font-weight: bold; margin-top: 6pt; text-align: center;">Confidential Treatment Requested by ADC Therapeutics SA Pursuant to 17 C.F.R. &#167; 200.83<br></div></div><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 36pt;"><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">ADC Therapeutics SA</div><div><div class="rule-full" style="height: 0pt; width: 100%; border-bottom: 1pt solid #000000; margin-bottom: 2pt; margin-left: auto; margin-right: auto; margin-top: 7.5pt;"> </div></div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 20.5pt; margin-left: 0pt; text-align: left;"><a name="tF1SCI"><!--Anchor--></a>Condensed Consolidated Interim Statement of Comprehensive Income<br></div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">(in KUSD)</div><table cellspacing="0" cellpadding="0" class="fintab" style="margin-top: 10.25pt; border-collapse: collapse; width: 468pt; margin-left: auto; margin-right: auto;"><tr class="header"><td style="width: 56.41%; text-align: left; vertical-align: bottom; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 1.76%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.76%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td colspan="4" style="width: 18.76%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">For the Three Months <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Ended June&#160;30,</div></td><td class="gutter" style="width: 1.76%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.76%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td colspan="4" style="width: 17.77%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">For the Six Months <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Ended June&#160;30,</div></td></tr><tr class="header"><td style="width: 56.41%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 1.76%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.76%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 8.15%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2020</div></td><td class="gutter" style="width: 1.76%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.76%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 7.08%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2019</div></td><td class="gutter" style="width: 1.76%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.76%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 7.66%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2020</div></td><td class="gutter" style="width: 1.76%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.76%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 6.59%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2019</div></td></tr><tr><td style="width: 56.41%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Net Loss<font style="font-weight: normal; padding-left: 3.74pt;"></font></div></td><td class="gutter" style="width: 1.76%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.76%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.15%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.16pt; text-align: left;">(126,557)</div></td><td class="gutter" style="width: 1.76%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.76%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.08%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.16pt; text-align: left;">(23,348)</div></td><td class="gutter" style="width: 1.76%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.76%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.66%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;">(170,033)</div></td><td class="gutter" style="width: 1.76%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.76%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.59%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;">(49,858)</div></td></tr><tr><td style="width: 56.41%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Other comprehensive income<br></div></td><td class="gutter" style="width: 1.76%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.76%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 8.15%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.76%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.76%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 7.08%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.76%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.76%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 7.66%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.76%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.76%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 6.59%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 56.41%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 0pt; margin-left: 0pt; text-align: left;">Items that will not be reclassified to profit and loss<br></div></td><td class="gutter" style="width: 1.76%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.76%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.15%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.76%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.76%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.08%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.76%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.76%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.66%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.76%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.76%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.59%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 56.41%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Remeasurements of defined benefit plan<font style="padding-left: 1.57pt;"></font></div></td><td class="gutter" style="width: 1.76%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.76%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 8.15%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.16pt; text-align: left;"><font style="padding-left: 25.83pt;">&#8212;</font></div></td><td class="gutter" style="width: 1.76%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.76%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 7.08%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.16pt; text-align: left;"><font style="padding-left: 17.5pt;">(16)</font></div></td><td class="gutter" style="width: 1.76%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.76%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 7.66%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 25.83pt;">&#8212;</font></div></td><td class="gutter" style="width: 1.76%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.76%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 6.59%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 22.5pt;">(7)</font></div></td></tr><tr><td style="width: 56.41%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Total items that will not be reclassified to profit and loss<font style="padding-left: 2.85pt;"></font></div></td><td class="gutter" style="width: 1.76%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.76%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.15%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.16pt; text-align: left;"><font style="padding-left: 25.83pt;">&#8212;</font></div></td><td class="gutter" style="width: 1.76%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.76%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.08%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.16pt; text-align: left;"><font style="padding-left: 17.5pt;">(16)</font></div></td><td class="gutter" style="width: 1.76%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.76%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.66%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 25.83pt;">&#8212;</font></div></td><td class="gutter" style="width: 1.76%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.76%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.59%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 22.5pt;">(7)</font></div></td></tr><tr><td style="width: 56.41%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 0pt; margin-left: 0pt; text-align: left;">Items that may be reclassified to profit and loss<br></div></td><td class="gutter" style="width: 1.76%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.76%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 8.15%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.76%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.76%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 7.08%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.76%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.76%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 7.66%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.76%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.76%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 6.59%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 56.41%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Currency translation differences<font style="padding-left: 1.19pt;"></font></div></td><td class="gutter" style="width: 1.76%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.76%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.15%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.16pt; text-align: left;"><font style="padding-left: 22.5pt;">(13)</font></div></td><td class="gutter" style="width: 1.76%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.76%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.08%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.16pt; text-align: left;"><font style="padding-left: 17.5pt;">(42)</font></div></td><td class="gutter" style="width: 1.76%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.76%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.66%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 17.5pt;">(215)</font></div></td><td class="gutter" style="width: 1.76%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.76%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.59%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 22.5pt;">(8)</font></div></td></tr><tr><td style="width: 56.41%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Total items that may be reclassified to profit and loss<font style="padding-left: 2.29pt;"></font></div></td><td class="gutter" style="width: 1.76%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.76%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 8.15%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.16pt; text-align: left;"><font style="padding-left: 22.5pt;">(13)</font></div></td><td class="gutter" style="width: 1.76%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.76%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 7.08%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.16pt; text-align: left;"><font style="padding-left: 17.5pt;">(42)</font></div></td><td class="gutter" style="width: 1.76%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.76%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 7.66%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 17.5pt;">(215)</font></div></td><td class="gutter" style="width: 1.76%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.76%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 6.59%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 22.5pt;">(8)</font></div></td></tr><tr><td style="width: 56.41%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Other comprehensive loss for the period<font style="font-weight: normal; padding-left: 1.56pt;"></font></div></td><td class="gutter" style="width: 1.76%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.76%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.15%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.16pt; text-align: left;"><font style="padding-left: 22.5pt;">(13)</font></div></td><td class="gutter" style="width: 1.76%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.76%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.08%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.16pt; text-align: left;"><font style="padding-left: 17.5pt;">(58)</font></div></td><td class="gutter" style="width: 1.76%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.76%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.66%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 17.5pt;">(215)</font></div></td><td class="gutter" style="width: 1.76%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.76%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.59%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 17.5pt;">(15)</font></div></td></tr><tr><td style="width: 56.41%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Total comprehensive loss for the period<font style="font-weight: normal; padding-left: 0.07pt;"></font></div></td><td class="gutter" style="width: 1.76%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.76%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 8.15%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.16pt; text-align: left;">(126,570)</div></td><td class="gutter" style="width: 1.76%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.76%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 7.08%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.16pt; text-align: left;">(23,406)</div></td><td class="gutter" style="width: 1.76%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.76%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 7.66%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;">(170,248)</div></td><td class="gutter" style="width: 1.76%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.76%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 6.59%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;">(49,873)</div></td></tr><tr><td style="width: 56.41%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Total comprehensive loss attributable to:<br></div></td><td class="gutter" style="width: 1.76%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.76%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.15%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.76%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.76%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.08%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.76%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.76%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.66%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.76%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.76%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.59%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 56.41%; text-align: left; vertical-align: bottom; padding-top: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Owners of the parent<font style="padding-left: 4.88pt;"></font></div></td><td class="gutter" style="width: 1.76%; border-bottom: none; font-size: 2pt; padding-top: 3pt;">&#8203;</td><td class="gutter" style="width: 1.76%; border-bottom: none; font-size: 2pt; padding-top: 3pt;">&#8203;</td><td style="width: 8.15%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.16pt; text-align: left;">(126,570)</div></td><td class="gutter" style="width: 1.76%; border-bottom: none; font-size: 2pt; padding-top: 3pt;">&#8203;</td><td class="gutter" style="width: 1.76%; border-bottom: none; font-size: 2pt; padding-top: 3pt;">&#8203;</td><td style="width: 7.08%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.16pt; text-align: left;">(23,406)</div></td><td class="gutter" style="width: 1.76%; border-bottom: none; font-size: 2pt; padding-top: 3pt;">&#8203;</td><td class="gutter" style="width: 1.76%; border-bottom: none; font-size: 2pt; padding-top: 3pt;">&#8203;</td><td style="width: 7.66%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;">(170,248)</div></td><td class="gutter" style="width: 1.76%; border-bottom: none; font-size: 2pt; padding-top: 3pt;">&#8203;</td><td class="gutter" style="width: 1.76%; border-bottom: none; font-size: 2pt; padding-top: 3pt;">&#8203;</td><td style="width: 6.59%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;">(49,873)</div></td></tr></table></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 36pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 6.75pt; margin-left: 0pt; text-align: justify;">The accompanying notes on pages F-<a href="#tF1NOTES">8</a> to F-<a href="#tF1NOTEE">23</a> form an integral part of these condensed consolidated interim financial statements (Unaudited) <br></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 36pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">F-3<br></div></div></div>
<!--End Page 257-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 258-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 540pt;"><a name="nt10014672x1_drs_201-fintab01_pg3"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="block-frill" style="width: 540pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: Arial, Helvetica, sans-serif; font-size: 9pt; font-weight: bold; margin-top: 6pt; text-align: center;">Confidential Treatment Requested by ADC Therapeutics SA Pursuant to 17 C.F.R. &#167; 200.83<br></div></div><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 36pt;"><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">ADC Therapeutics SA</div><div><div class="rule-full" style="height: 0pt; width: 100%; border-bottom: 1pt solid #000000; margin-bottom: 2pt; margin-left: auto; margin-right: auto; margin-top: 7.5pt;"> </div></div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 20.5pt; margin-left: 0pt; text-align: left;"><a name="tF1BS"><!--Anchor--></a>Condensed Consolidated Interim Balance Sheet<br></div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">(in KUSD)</div><table cellspacing="0" cellpadding="0" class="fintab" style="margin-top: 10.25pt; border-collapse: collapse; width: 468pt; margin-left: auto; margin-right: auto;"><tr class="header"><td style="width: 66.67%; text-align: left; vertical-align: bottom; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 2.03%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 2.03%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 3.42%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Note</div></td><td class="gutter" style="width: 2.03%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 2.03%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 7.66%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">June&#160;30, <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2020</div></td><td class="gutter" style="width: 2.03%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 2.03%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 10.08%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">December&#160;31,<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2019</div></td></tr><tr><td style="width: 66.67%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">ASSETS<br></div></td><td class="gutter" style="width: 2.03%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.03%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 3.42%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 2.03%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.03%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.66%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 2.03%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.03%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.08%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 66.67%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Current assets<br></div></td><td class="gutter" style="width: 2.03%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.03%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 3.42%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 2.03%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.03%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 7.66%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 2.03%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.03%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 10.08%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 66.67%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Cash and cash equivalents<font style="padding-left: 1.77pt;"></font></div></td><td class="gutter" style="width: 2.03%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.03%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 3.42%; text-align: center; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">9</div></td><td class="gutter" style="width: 2.03%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.03%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.66%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;"><font style="padding-left: 3.33pt;">348,593</font></div></td><td class="gutter" style="width: 2.03%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.03%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.08%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 5.67pt; text-align: left;"><font style="padding-left: 3.7pt;">115,551</font></div></td></tr><tr><td style="width: 66.67%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Other current assets<font style="padding-left: 3.44pt;"></font></div></td><td class="gutter" style="width: 2.03%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 2.03%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 3.42%; text-align: center; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 2.03%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 2.03%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 7.66%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;"><font style="padding-left: 8.33pt; border-bottom: 1pt solid #000000; min-width: 35.83pt;">10,532</font></div></td><td class="gutter" style="width: 2.03%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 2.03%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 10.08%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 5.67pt; text-align: left;"><font style="padding-left: 13.33pt; border-bottom: 1pt solid #000000; min-width: 35.83pt;">7,055</font></div></td></tr><tr><td style="width: 66.67%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 20pt; text-align: left;">Total current assets<font style="padding-left: 0.8pt;"></font></div></td><td class="gutter" style="width: 2.03%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.03%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 3.42%; text-align: center; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 2.03%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.03%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.66%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;"><font style="padding-left: 3.33pt; border-bottom: 1pt solid #000000; min-width: 35.83pt;">359,125</font></div></td><td class="gutter" style="width: 2.03%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.03%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.08%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 5.67pt; text-align: left;"><font style="padding-left: 3.33pt; border-bottom: 1pt solid #000000; min-width: 35.83pt;">122,606</font></div></td></tr><tr><td style="width: 66.67%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Non-current assets<br></div></td><td class="gutter" style="width: 2.03%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.03%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 3.42%; text-align: center; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 2.03%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.03%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 7.66%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 2.03%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.03%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 10.08%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 66.67%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Property, plant and equipment<font style="padding-left: 1.57pt;"></font></div></td><td class="gutter" style="width: 2.03%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.03%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 3.42%; text-align: center; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 2.03%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.03%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.66%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;"><font style="padding-left: 13.33pt;">1,260</font></div></td><td class="gutter" style="width: 2.03%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.03%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.08%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 5.67pt; text-align: left;"><font style="padding-left: 13.33pt;">1,376</font></div></td></tr><tr><td style="width: 66.67%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Right-of-use assets<font style="padding-left: 2.31pt;"></font></div></td><td class="gutter" style="width: 2.03%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.03%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 3.42%; text-align: center; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 2.03%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.03%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 7.66%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;"><font style="padding-left: 13.33pt;">4,248</font></div></td><td class="gutter" style="width: 2.03%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.03%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 10.08%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 5.67pt; text-align: left;"><font style="padding-left: 13.33pt;">4,898</font></div></td></tr><tr><td style="width: 66.67%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Intangible assets<font style="padding-left: 2.31pt;"></font></div></td><td class="gutter" style="width: 2.03%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.03%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 3.42%; text-align: center; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">10</div></td><td class="gutter" style="width: 2.03%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.03%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.66%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;"><font style="padding-left: 13.33pt;">8,825</font></div></td><td class="gutter" style="width: 2.03%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.03%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.08%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 5.67pt; text-align: left;"><font style="padding-left: 13.33pt;">8,434</font></div></td></tr><tr><td style="width: 66.67%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Other long-term assets<font style="padding-left: 2.32pt;"></font></div></td><td class="gutter" style="width: 2.03%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 2.03%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 3.42%; text-align: center; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 2.03%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 2.03%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 7.66%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;"><font style="padding-left: 20.83pt; border-bottom: 1pt solid #000000; min-width: 35.83pt;">384</font></div></td><td class="gutter" style="width: 2.03%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 2.03%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 10.08%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 5.67pt; text-align: left;"><font style="padding-left: 20.83pt; border-bottom: 1pt solid #000000; min-width: 35.83pt;">368</font></div></td></tr><tr><td style="width: 66.67%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 20pt; text-align: left;">Total non-current assets<font style="padding-left: 2.47pt;"></font></div></td><td class="gutter" style="width: 2.03%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.03%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 3.42%; text-align: center; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 2.03%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.03%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.66%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;"><font style="padding-left: 8.33pt; border-bottom: 1pt solid #000000; min-width: 35.83pt;">14,717</font></div></td><td class="gutter" style="width: 2.03%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.03%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.08%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 5.67pt; text-align: left;"><font style="padding-left: 8.33pt; border-bottom: 1pt solid #000000; min-width: 35.83pt;">15,076</font></div></td></tr><tr><td style="width: 66.67%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 5.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Total assets<font style="font-weight: normal; padding-left: 4.88pt;"></font></div></td><td class="gutter" style="width: 2.03%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt;">&#8203;</td><td class="gutter" style="width: 2.03%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt;">&#8203;</td><td style="width: 3.42%; text-align: center; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 5.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 2.03%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt;">&#8203;</td><td class="gutter" style="width: 2.03%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt;">&#8203;</td><td style="width: 7.66%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 5.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0.01pt; text-align: left;"><font style="padding-left: 3.33pt; border-bottom: 3pt double #000000; min-width: 35.83pt;">373,842</font></div></td><td class="gutter" style="width: 2.03%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt;">&#8203;</td><td class="gutter" style="width: 2.03%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt;">&#8203;</td><td style="width: 10.08%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 5.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 5.67pt; text-align: left;"><font style="padding-left: 3.33pt; border-bottom: 3pt double #000000; min-width: 35.83pt;">137,682</font></div></td></tr><tr><td style="width: 66.67%; text-align: left; vertical-align: bottom; padding-top: 5.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">LIABILITIES AND SHAREHOLDERS&#8217; EQUITY<br></div></td><td class="gutter" style="width: 2.03%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.03%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 3.42%; text-align: center; vertical-align: bottom; padding-top: 5.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 2.03%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.03%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.66%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 5.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 2.03%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.03%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.08%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 5.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 66.67%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Current liabilities<br></div></td><td class="gutter" style="width: 2.03%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.03%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 3.42%; text-align: center; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 2.03%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.03%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 7.66%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 2.03%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.03%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 10.08%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 66.67%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Accounts payable<font style="padding-left: 2.31pt;"></font></div></td><td class="gutter" style="width: 2.03%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.03%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 3.42%; text-align: center; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 2.03%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.03%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.66%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;"><font style="padding-left: 13.33pt;">6,797</font></div></td><td class="gutter" style="width: 2.03%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.03%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.08%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 5.67pt; text-align: left;"><font style="padding-left: 13.33pt;">3,329</font></div></td></tr><tr><td style="width: 66.67%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Other current liabilities<font style="padding-left: 4.54pt;"></font></div></td><td class="gutter" style="width: 2.03%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.03%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 3.42%; text-align: center; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 2.03%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.03%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 7.66%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;"><font style="padding-left: 8.7pt;">20,211</font></div></td><td class="gutter" style="width: 2.03%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.03%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 10.08%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 5.67pt; text-align: left;"><font style="padding-left: 8.33pt;">15,430</font></div></td></tr><tr><td style="width: 66.67%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Lease liabilities, short-term<font style="padding-left: 3.16pt;"></font></div></td><td class="gutter" style="width: 2.03%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.03%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 3.42%; text-align: center; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 2.03%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.03%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.66%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;"><font style="padding-left: 13.33pt;">1,099</font></div></td><td class="gutter" style="width: 2.03%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.03%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.08%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 5.67pt; text-align: left;"><font style="padding-left: 13.33pt;">1,132</font></div></td></tr><tr><td style="width: 66.67%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Current income tax payable<font style="padding-left: 1.21pt;"></font></div></td><td class="gutter" style="width: 2.03%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.03%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 3.42%; text-align: center; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 2.03%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.03%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 7.66%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;"><font style="padding-left: 20.83pt;">148</font></div></td><td class="gutter" style="width: 2.03%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.03%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 10.08%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 5.67pt; text-align: left;"><font style="padding-left: 25.83pt;">52</font></div></td></tr><tr><td style="width: 66.67%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Convertible loans, short-term<font style="padding-left: 0.37pt;"></font></div></td><td class="gutter" style="width: 2.03%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.03%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 3.42%; text-align: center; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">11</div></td><td class="gutter" style="width: 2.03%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.03%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.66%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;"><font style="padding-left: 13.7pt; border-bottom: 1pt solid #000000; min-width: 35.83pt;">3,113</font></div></td><td class="gutter" style="width: 2.03%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.03%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.08%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 5.67pt; text-align: left;"><font style="padding-left: 25.83pt; border-bottom: 1pt solid #000000; min-width: 35.83pt;">&#8212;</font></div></td></tr><tr><td style="width: 66.67%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 20pt; text-align: left;">Total current liabilities<font style="padding-left: 1.9pt;"></font></div></td><td class="gutter" style="width: 2.03%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 2.03%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 3.42%; text-align: center; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 2.03%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 2.03%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 7.66%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;"><font style="padding-left: 8.33pt; border-bottom: 1pt solid #000000; min-width: 35.83pt;">31,368</font></div></td><td class="gutter" style="width: 2.03%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 2.03%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 10.08%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 5.67pt; text-align: left;"><font style="padding-left: 8.33pt; border-bottom: 1pt solid #000000; min-width: 35.83pt;">19,943</font></div></td></tr><tr><td style="width: 66.67%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Non-current liabilities<br></div></td><td class="gutter" style="width: 2.03%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.03%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 3.42%; text-align: center; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 2.03%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.03%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.66%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 2.03%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.03%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.08%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 66.67%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Convertible loans, long-term<font style="padding-left: 2.59pt;"></font></div></td><td class="gutter" style="width: 2.03%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.03%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 3.42%; text-align: center; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">11</div></td><td class="gutter" style="width: 2.03%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.03%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 7.66%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;"><font style="padding-left: 8.33pt;">32,855</font></div></td><td class="gutter" style="width: 2.03%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.03%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 10.08%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 5.67pt; text-align: left;"><font style="padding-left: 25.83pt;">&#8212;</font></div></td></tr><tr><td style="width: 66.67%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Convertible loans, derivatives<font style="padding-left: 3.15pt;"></font></div></td><td class="gutter" style="width: 2.03%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.03%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 3.42%; text-align: center; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">11</div></td><td class="gutter" style="width: 2.03%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.03%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.66%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;"><font style="padding-left: 3.33pt;">107,058</font></div></td><td class="gutter" style="width: 2.03%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.03%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.08%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 5.67pt; text-align: left;"><font style="padding-left: 25.83pt;">&#8212;</font></div></td></tr><tr><td style="width: 66.67%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Lease liabilities, long-term<font style="padding-left: 0.37pt;"></font></div></td><td class="gutter" style="width: 2.03%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.03%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 3.42%; text-align: center; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 2.03%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.03%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 7.66%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;"><font style="padding-left: 13.33pt;">3,334</font></div></td><td class="gutter" style="width: 2.03%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.03%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 10.08%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 5.67pt; text-align: left;"><font style="padding-left: 13.33pt;">3,899</font></div></td></tr><tr><td style="width: 66.67%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Defined benefit pension liabilities<font style="padding-left: 1.22pt;"></font></div></td><td class="gutter" style="width: 2.03%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.03%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 3.42%; text-align: center; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 2.03%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.03%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.66%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;"><font style="padding-left: 13.33pt; border-bottom: 1pt solid #000000; min-width: 35.83pt;">2,925</font></div></td><td class="gutter" style="width: 2.03%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.03%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.08%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 5.67pt; text-align: left;"><font style="padding-left: 13.33pt; border-bottom: 1pt solid #000000; min-width: 35.83pt;">2,684</font></div></td></tr><tr><td style="width: 66.67%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 20pt; text-align: left;">Total non-current liabilities<font style="padding-left: 3.57pt;"></font></div></td><td class="gutter" style="width: 2.03%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 2.03%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 3.42%; text-align: center; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 2.03%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 2.03%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 7.66%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;"><font style="padding-left: 3.33pt; border-bottom: 1pt solid #000000; min-width: 35.83pt;">146,172</font></div></td><td class="gutter" style="width: 2.03%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 2.03%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 10.08%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 5.67pt; text-align: left;"><font style="padding-left: 13.33pt; border-bottom: 1pt solid #000000; min-width: 35.83pt;">6,583</font></div></td></tr><tr><td style="width: 66.67%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Total liabilities<font style="font-weight: normal; padding-left: 0.43pt;"></font></div></td><td class="gutter" style="width: 2.03%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.03%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 3.42%; text-align: center; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 2.03%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.03%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.66%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0.01pt; text-align: left;"><font style="padding-left: 3.33pt; border-bottom: 1pt solid #000000; min-width: 35.83pt;">177,540</font></div></td><td class="gutter" style="width: 2.03%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.03%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.08%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 5.67pt; text-align: left;"><font style="padding-left: 8.33pt; border-bottom: 1pt solid #000000; min-width: 35.83pt;">26,526</font></div></td></tr><tr><td style="width: 66.67%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Equity attributable to owners of the parent<br></div></td><td class="gutter" style="width: 2.03%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.03%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 3.42%; text-align: center; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 2.03%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.03%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 7.66%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 2.03%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.03%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 10.08%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 66.67%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Share capital<font style="padding-left: 1.75pt;"></font></div></td><td class="gutter" style="width: 2.03%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.03%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 3.42%; text-align: center; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">13</div></td><td class="gutter" style="width: 2.03%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.03%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.66%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;"><font style="padding-left: 13.33pt;">5,795</font></div></td><td class="gutter" style="width: 2.03%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.03%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.08%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 5.67pt; text-align: left;"><font style="padding-left: 13.33pt;">4,361</font></div></td></tr><tr><td style="width: 66.67%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Share premium<font style="padding-left: 2.3pt;"></font></div></td><td class="gutter" style="width: 2.03%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.03%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 3.42%; text-align: center; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">13</div></td><td class="gutter" style="width: 2.03%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.03%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 7.66%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;"><font style="padding-left: 3.33pt;">792,605</font></div></td><td class="gutter" style="width: 2.03%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.03%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 10.08%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 5.67pt; text-align: left;"><font style="padding-left: 3.33pt;">549,922</font></div></td></tr><tr><td style="width: 66.67%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Treasury shares<font style="padding-left: 1pt;"></font></div></td><td class="gutter" style="width: 2.03%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.03%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 3.42%; text-align: center; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">13</div></td><td class="gutter" style="width: 2.03%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.03%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.66%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;"><font style="padding-left: 27.5pt;">(4)</font></div></td><td class="gutter" style="width: 2.03%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.03%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.08%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 5.67pt; text-align: left;"><font style="padding-left: 17.5pt;">(100)</font></div></td></tr><tr><td style="width: 66.67%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Other reserves<font style="padding-left: 0.65pt;"></font></div></td><td class="gutter" style="width: 2.03%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.03%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 3.42%; text-align: center; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 2.03%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.03%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 7.66%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;"><font style="padding-left: 8.33pt;">16,654</font></div></td><td class="gutter" style="width: 2.03%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.03%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 10.08%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 5.67pt; text-align: left;"><font style="padding-left: 13.33pt;">5,473</font></div></td></tr><tr><td style="width: 66.67%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Cumulative translation adjustment<font style="padding-left: 0.09pt;"></font></div></td><td class="gutter" style="width: 2.03%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.03%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 3.42%; text-align: center; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 2.03%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.03%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.66%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;"><font style="padding-left: 17.5pt;">(146)</font></div></td><td class="gutter" style="width: 2.03%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.03%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.08%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 5.67pt; text-align: left;"><font style="padding-left: 25.83pt;">69</font></div></td></tr><tr><td style="width: 66.67%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Accumulated losses<font style="padding-left: 3.98pt;"></font></div></td><td class="gutter" style="width: 2.03%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 2.03%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 3.42%; text-align: center; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 2.03%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 2.03%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 7.66%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;"><font style="border-bottom: 1pt solid #000000; min-width: 35.83pt;">(618,602</font><font style="min-width: 35.83pt;">)</font></div></td><td class="gutter" style="width: 2.03%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 2.03%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 10.08%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 5.67pt; text-align: left;"><font style="border-bottom: 1pt solid #000000; min-width: 35.83pt;">(448,569</font><font style="min-width: 35.83pt;">)</font></div></td></tr><tr><td style="width: 66.67%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 20pt; text-align: left;">Total equity attributable to owners of the parent<font style="padding-left: 3.05pt;"></font></div></td><td class="gutter" style="width: 2.03%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.03%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 3.42%; text-align: center; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 2.03%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.03%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.66%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;"><font style="padding-left: 3.33pt; border-bottom: 1pt solid #000000; min-width: 35.83pt;">196,302</font></div></td><td class="gutter" style="width: 2.03%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.03%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.08%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 5.67pt; text-align: left;"><font style="padding-left: 4.07pt; border-bottom: 1pt solid #000000; min-width: 35.83pt;">111,156</font></div></td></tr><tr><td style="width: 66.67%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 6pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Total liabilities and equity<font style="font-weight: normal; padding-left: 0.99pt;"></font></div></td><td class="gutter" style="width: 2.03%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt;">&#8203;</td><td class="gutter" style="width: 2.03%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt;">&#8203;</td><td style="width: 3.42%; text-align: center; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 6pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 2.03%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt;">&#8203;</td><td class="gutter" style="width: 2.03%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt;">&#8203;</td><td style="width: 7.66%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 6pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0.01pt; text-align: left;"><font style="padding-left: 3.33pt; border-bottom: 3pt double #000000; min-width: 35.83pt;">373,842</font></div></td><td class="gutter" style="width: 2.03%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt;">&#8203;</td><td class="gutter" style="width: 2.03%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt;">&#8203;</td><td style="width: 10.08%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 6pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 5.67pt; text-align: left;"><font style="padding-left: 3.33pt; border-bottom: 3pt double #000000; min-width: 35.83pt;">137,682</font></div></td></tr></table></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 36pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 6.75pt; margin-left: 0pt; text-align: justify;">The accompanying notes on pages F-<a href="#tF1NOTES">8</a> to F-<a href="#tF1NOTEE">23</a> form an integral part of these condensed consolidated interim financial statements (Unaudited) <br></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 36pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">F-4<br></div></div></div>
<!--End Page 258-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 259-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 540pt;"><a name="nt10014672x1_drs_201-fintab01_pg4"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="block-frill" style="width: 540pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: Arial, Helvetica, sans-serif; font-size: 9pt; font-weight: bold; margin-top: 6pt; text-align: center;">Confidential Treatment Requested by ADC Therapeutics SA Pursuant to 17 C.F.R. &#167; 200.83<br></div></div><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 36pt;"><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">ADC Therapeutics SA</div><div><div class="rule-full" style="height: 0pt; width: 100%; border-bottom: 1pt solid #000000; margin-bottom: 2pt; margin-left: auto; margin-right: auto; margin-top: 7.5pt;"> </div></div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 20.5pt; margin-left: 0pt; text-align: left;"><a name="tF1CIE"><!--Anchor--></a>Condensed Consolidated Interim Statement of Changes in Equity<br></div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">(in KUSD)</div><table cellspacing="0" cellpadding="0" class="fintab" style="margin-top: 10.25pt; border-collapse: collapse; width: 468pt; margin-left: auto; margin-right: auto;"><tr class="header"><td colspan="25" style="width: 100%; text-align: center; vertical-align: bottom; padding-top: 6pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">For the three and six months ended June&#160;30, 2019</div></td></tr><tr class="header"><td style="width: 34.4%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 0.66%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 0.66%; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 3.42%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Note</div></td><td class="gutter" style="width: 0.66%; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 0.66%; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 5.41%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Share<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Capital</div></td><td class="gutter" style="width: 0.66%; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 0.66%; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 6.94%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Share<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Premium</div></td><td class="gutter" style="width: 0.66%; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 0.66%; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 6.45%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Other<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Reserves</div></td><td class="gutter" style="width: 0.66%; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 0.66%; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 6.9%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Shares to<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">be issued</div></td><td class="gutter" style="width: 0.66%; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 0.66%; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 9.3%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Cumulative <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Translation<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Adjustments</div></td><td class="gutter" style="width: 0.66%; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 0.66%; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 9.68%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Accumulated<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Losses</div></td><td class="gutter" style="width: 0.66%; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 0.66%; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 6.94%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Total<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Equity</div></td></tr><tr><td style="width: 34.4%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">January&#160;1, 2019<font style="font-weight: normal; padding-left: 3.79pt;"></font></div></td><td class="gutter" style="width: 0.66%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.66%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 3.42%; text-align: center; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 0.66%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.66%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.41%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 5.17pt; text-align: left;">401</div></td><td class="gutter" style="width: 0.66%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.66%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.94%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0.01pt; text-align: left;">452,268</div></td><td class="gutter" style="width: 0.66%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.66%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.45%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 3.86pt; text-align: left;">5,702</div></td><td class="gutter" style="width: 0.66%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.66%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.9%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 2.4pt; text-align: left;"><font style="padding-left: 17.5pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.66%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.66%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.3%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 15.1pt; text-align: left;">(43)</div></td><td class="gutter" style="width: 0.66%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.66%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.68%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 4.74pt; text-align: left;">(332,085)</div></td><td class="gutter" style="width: 0.66%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.66%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.94%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: -0.01pt; text-align: left;">126,243</div></td></tr><tr><td style="width: 34.4%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Loss for the period<font style="padding-left: 0.2pt;"></font></div></td><td class="gutter" style="width: 0.66%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.66%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 3.42%; text-align: center; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.66%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.66%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 5.41%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 5.17pt; text-align: left;"><font style="padding-left: 5pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.66%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.66%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 6.94%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;"><font style="padding-left: 22.5pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.66%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.66%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 6.45%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.86pt; text-align: left;"><font style="padding-left: 12.5pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.66%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.66%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 6.9%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.4pt; text-align: left;"><font style="padding-left: 17.5pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.66%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.66%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 9.3%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 15.1pt; text-align: left;"><font style="padding-left: 3.33pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.66%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.66%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 9.68%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.74pt; text-align: left;"><font style="padding-left: 5pt;">(26,510)</font></div></td><td class="gutter" style="width: 0.66%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.66%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 6.94%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 1.67pt;">(26,510)</font></div></td></tr><tr><td style="width: 34.4%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Translation adjustment<font style="padding-left: 1.1pt;"></font></div></td><td class="gutter" style="width: 0.66%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.66%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 3.42%; text-align: center; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.66%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.66%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.41%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 5.17pt; text-align: left;"><font style="padding-left: 5pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.66%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.66%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.94%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;"><font style="padding-left: 22.5pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.66%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.66%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.45%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.86pt; text-align: left;"><font style="padding-left: 12.5pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.66%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.66%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.9%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.4pt; text-align: left;"><font style="padding-left: 17.5pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.66%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.66%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.3%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 15.1pt; text-align: left;"><font style="padding-left: 3.33pt;">34</font></div></td><td class="gutter" style="width: 0.66%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.66%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.68%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.74pt; text-align: left;"><font style="padding-left: 25.83pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.66%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.66%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.94%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 22.5pt;">34</font></div></td></tr><tr><td style="width: 34.4%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 20pt; text-indent: -10pt; text-align: left;">Remeasurement of defined benefit pension liability<font style="padding-left: 2.95pt;"></font></div></td><td class="gutter" style="width: 0.66%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 0.66%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 3.42%; text-align: center; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.66%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 0.66%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 5.41%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 5.17pt; text-align: left;"><font style="padding-left: 5pt; border-bottom: 1pt solid #000000; min-width: 15pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.66%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 0.66%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 6.94%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;"><font style="padding-left: 22.5pt; border-bottom: 1pt solid #000000; min-width: 32.5pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.66%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 0.66%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 6.45%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.86pt; text-align: left;"><font style="padding-left: 17.5pt; border-bottom: 1pt solid #000000; min-width: 22.5pt;">9</font></div></td><td class="gutter" style="width: 0.66%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 0.66%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 6.9%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.4pt; text-align: left;"><font style="padding-left: 17.5pt; border-bottom: 1pt solid #000000; min-width: 27.5pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.66%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 0.66%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 9.3%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 15.1pt; text-align: left;"><font style="padding-left: 3.33pt; border-bottom: 1pt solid #000000; min-width: 13.33pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.66%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 0.66%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 9.68%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.74pt; text-align: left;"><font style="padding-left: 25.83pt; border-bottom: 1pt solid #000000; min-width: 35.83pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.66%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 0.66%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 6.94%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 27.5pt; border-bottom: 1pt solid #000000; min-width: 32.5pt;">9</font></div></td></tr><tr><td style="width: 34.4%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 20pt; text-indent: -10pt; text-align: left;">Total other comprehensive income / (loss)<font style="font-weight: normal; padding-left: 0.18pt;"></font></div></td><td class="gutter" style="width: 0.66%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.66%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 3.42%; text-align: center; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 0.66%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.66%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.41%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 5.17pt; text-align: left;"><font style="padding-left: 5pt; border-bottom: 1pt solid #000000; min-width: 15pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.66%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.66%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.94%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0.01pt; text-align: left;"><font style="padding-left: 22.5pt; border-bottom: 1pt solid #000000; min-width: 32.5pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.66%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.66%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.45%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 3.86pt; text-align: left;"><font style="padding-left: 17.5pt; border-bottom: 1pt solid #000000; min-width: 22.5pt;">9</font></div></td><td class="gutter" style="width: 0.66%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.66%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.9%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 2.4pt; text-align: left;"><font style="padding-left: 17.5pt; border-bottom: 1pt solid #000000; min-width: 27.5pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.66%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.66%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.3%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 15.1pt; text-align: left;"><font style="padding-left: 3.33pt; border-bottom: 1pt solid #000000; min-width: 13.33pt;">34</font></div></td><td class="gutter" style="width: 0.66%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.66%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.68%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 4.74pt; text-align: left;"><font style="padding-left: 25.83pt; border-bottom: 1pt solid #000000; min-width: 35.83pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.66%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.66%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.94%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 22.5pt; border-bottom: 1pt solid #000000; min-width: 32.5pt;">43</font></div></td></tr><tr><td style="width: 34.4%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 20pt; text-indent: -10pt; text-align: left;">Total comprehensive income / (loss) for the period<font style="font-weight: normal; padding-left: 2.61pt;"></font></div></td><td class="gutter" style="width: 0.66%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.66%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 3.42%; text-align: center; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 0.66%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.66%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 5.41%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 5.17pt; text-align: left;"><font style="padding-left: 5pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.66%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.66%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 6.94%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0.01pt; text-align: left;"><font style="padding-left: 22.5pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.66%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.66%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 6.45%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 3.86pt; text-align: left;"><font style="padding-left: 17.5pt;">9</font></div></td><td class="gutter" style="width: 0.66%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.66%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 6.9%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 2.4pt; text-align: left;"><font style="padding-left: 17.5pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.66%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.66%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 9.3%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 15.1pt; text-align: left;"><font style="padding-left: 3.33pt;">34</font></div></td><td class="gutter" style="width: 0.66%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.66%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 9.68%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 4.74pt; text-align: left;"><font style="padding-left: 5pt;">(26,510)</font></div></td><td class="gutter" style="width: 0.66%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.66%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 6.94%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 1.67pt;">(26,467)</font></div></td></tr><tr><td style="width: 34.4%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Issuance of share capital<font style="padding-left: 3.01pt;"></font></div></td><td class="gutter" style="width: 0.66%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.66%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 3.42%; text-align: center; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">13</div></td><td class="gutter" style="width: 0.66%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.66%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.41%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 5.17pt; text-align: left;"><font style="padding-left: 10pt;">1</font></div></td><td class="gutter" style="width: 0.66%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.66%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.94%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;"><font style="padding-left: 22.5pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.66%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.66%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.45%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.86pt; text-align: left;"><font style="padding-left: 12.5pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.66%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.66%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.9%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.4pt; text-align: left;"><font style="padding-left: 17.5pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.66%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.66%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.3%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 15.1pt; text-align: left;"><font style="padding-left: 3.33pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.66%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.66%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.68%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.74pt; text-align: left;"><font style="padding-left: 25.83pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.66%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.66%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.94%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 27.5pt;">1</font></div></td></tr><tr><td style="width: 34.4%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Transaction costs<font style="padding-left: 3.32pt;"></font></div></td><td class="gutter" style="width: 0.66%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.66%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 3.42%; text-align: center; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">13</div></td><td class="gutter" style="width: 0.66%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.66%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 5.41%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 5.17pt; text-align: left;"><font style="padding-left: 5pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.66%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.66%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 6.94%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;"><font style="padding-left: 19.17pt;">(19)</font></div></td><td class="gutter" style="width: 0.66%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.66%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 6.45%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.86pt; text-align: left;"><font style="padding-left: 12.5pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.66%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.66%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 6.9%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.4pt; text-align: left;"><font style="padding-left: 17.5pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.66%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.66%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 9.3%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 15.1pt; text-align: left;"><font style="padding-left: 3.33pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.66%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.66%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 9.68%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.74pt; text-align: left;"><font style="padding-left: 25.83pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.66%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.66%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 6.94%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 19.17pt;">(19)</font></div></td></tr><tr><td style="width: 34.4%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Share-based compensation expense<font style="padding-left: 0.23pt;"></font></div></td><td class="gutter" style="width: 0.66%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.66%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 3.42%; text-align: center; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">12</div></td><td class="gutter" style="width: 0.66%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.66%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.41%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 5.17pt; text-align: left;"><font style="padding-left: 5pt; border-bottom: 1pt solid #000000; min-width: 15pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.66%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.66%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.94%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;"><font style="padding-left: 22.5pt; border-bottom: 1pt solid #000000; min-width: 32.5pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.66%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.66%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.45%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.86pt; text-align: left;"><font style="padding-left: 12.5pt; border-bottom: 1pt solid #000000; min-width: 22.5pt;">84</font></div></td><td class="gutter" style="width: 0.66%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.66%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.9%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.4pt; text-align: left;"><font style="padding-left: 17.5pt; border-bottom: 1pt solid #000000; min-width: 27.5pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.66%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.66%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.3%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 15.1pt; text-align: left;"><font style="padding-left: 3.33pt; border-bottom: 1pt solid #000000; min-width: 13.33pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.66%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.66%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.68%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.74pt; text-align: left;"><font style="padding-left: 25.83pt; border-bottom: 1pt solid #000000; min-width: 35.83pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.66%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.66%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.94%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 22.5pt; border-bottom: 1pt solid #000000; min-width: 32.5pt;">84</font></div></td></tr><tr><td style="width: 34.4%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 10pt; text-align: left;">Total transactions with owners<font style="font-weight: normal; padding-left: 0.02pt;"></font></div></td><td class="gutter" style="width: 0.66%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 0.66%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 3.42%; text-align: center; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 0.66%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 0.66%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 5.41%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 5.17pt; text-align: left;"><font style="padding-left: 10pt; border-bottom: 1pt solid #000000; min-width: 15pt;">1</font></div></td><td class="gutter" style="width: 0.66%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 0.66%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 6.94%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0.01pt; text-align: left;"><font style="padding-left: 19.17pt; border-bottom: 1pt solid #000000; min-width: 32.5pt;">(19</font><font style="min-width: 32.5pt;">)</font></div></td><td class="gutter" style="width: 0.66%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 0.66%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 6.45%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 3.86pt; text-align: left;"><font style="padding-left: 12.5pt; border-bottom: 1pt solid #000000; min-width: 22.5pt;">84</font></div></td><td class="gutter" style="width: 0.66%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 0.66%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 6.9%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 2.4pt; text-align: left;"><font style="padding-left: 17.5pt; border-bottom: 1pt solid #000000; min-width: 27.5pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.66%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 0.66%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 9.3%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 15.1pt; text-align: left;"><font style="padding-left: 3.33pt; border-bottom: 1pt solid #000000; min-width: 13.33pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.66%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 0.66%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 9.68%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 4.74pt; text-align: left;"><font style="padding-left: 25.83pt; border-bottom: 1pt solid #000000; min-width: 35.83pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.66%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 0.66%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 6.94%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 22.5pt; border-bottom: 1pt solid #000000; min-width: 32.5pt;">66</font></div></td></tr><tr><td style="width: 34.4%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">March&#160;31, 2019<font style="font-weight: normal; padding-left: 0.64pt;"></font></div></td><td class="gutter" style="width: 0.66%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.66%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 3.42%; text-align: center; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 0.66%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.66%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.41%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 5.17pt; text-align: left;">402</div></td><td class="gutter" style="width: 0.66%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.66%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.94%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0.01pt; text-align: left;">452,249</div></td><td class="gutter" style="width: 0.66%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.66%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.45%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 3.86pt; text-align: left;">5,795</div></td><td class="gutter" style="width: 0.66%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.66%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.9%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 2.4pt; text-align: left;"><font style="padding-left: 17.5pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.66%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.66%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.3%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 15.1pt; text-align: left;"><font style="padding-left: 5pt;">(9)</font></div></td><td class="gutter" style="width: 0.66%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.66%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.68%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 4.74pt; text-align: left;">(358,595)</div></td><td class="gutter" style="width: 0.66%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.66%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.94%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 5pt;">99,842</font></div></td></tr><tr><td style="width: 34.4%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Loss for the period<font style="padding-left: 0.2pt;"></font></div></td><td class="gutter" style="width: 0.66%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.66%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 3.42%; text-align: center; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.66%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.66%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 5.41%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 5.17pt; text-align: left;"><font style="padding-left: 5pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.66%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.66%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 6.94%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;"><font style="padding-left: 22.5pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.66%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.66%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 6.45%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.86pt; text-align: left;"><font style="padding-left: 12.5pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.66%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.66%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 6.9%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.4pt; text-align: left;"><font style="padding-left: 17.5pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.66%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.66%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 9.3%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 15.1pt; text-align: left;"><font style="padding-left: 3.33pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.66%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.66%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 9.68%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.74pt; text-align: left;"><font style="padding-left: 5pt;">(23,348)</font></div></td><td class="gutter" style="width: 0.66%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.66%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 6.94%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 1.67pt;">(23,348)</font></div></td></tr><tr><td style="width: 34.4%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Translation adjustment<font style="padding-left: 1.1pt;"></font></div></td><td class="gutter" style="width: 0.66%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.66%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 3.42%; text-align: center; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.66%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.66%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.41%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 5.17pt; text-align: left;"><font style="padding-left: 5pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.66%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.66%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.94%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;"><font style="padding-left: 22.5pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.66%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.66%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.45%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.86pt; text-align: left;"><font style="padding-left: 12.5pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.66%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.66%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.9%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.4pt; text-align: left;"><font style="padding-left: 17.5pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.66%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.66%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.3%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 15.1pt; text-align: left;">(42)</div></td><td class="gutter" style="width: 0.66%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.66%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.68%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.74pt; text-align: left;"><font style="padding-left: 25.83pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.66%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.66%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.94%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 19.17pt;">(42)</font></div></td></tr><tr><td style="width: 34.4%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 20pt; text-indent: -10pt; text-align: left;">Remeasurement of defined benefit pension liability<font style="padding-left: 2.95pt;"></font></div></td><td class="gutter" style="width: 0.66%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 0.66%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 3.42%; text-align: center; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.66%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 0.66%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 5.41%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 5.17pt; text-align: left;"><font style="padding-left: 5pt; border-bottom: 1pt solid #000000; min-width: 15pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.66%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 0.66%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 6.94%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;"><font style="padding-left: 22.5pt; border-bottom: 1pt solid #000000; min-width: 32.5pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.66%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 0.66%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 6.45%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.86pt; text-align: left;"><font style="padding-left: 9.17pt; border-bottom: 1pt solid #000000; min-width: 22.5pt;">(16</font><font style="min-width: 22.5pt;">)</font></div></td><td class="gutter" style="width: 0.66%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 0.66%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 6.9%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.4pt; text-align: left;"><font style="padding-left: 17.5pt; border-bottom: 1pt solid #000000; min-width: 27.5pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.66%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 0.66%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 9.3%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 15.1pt; text-align: left;"><font style="padding-left: 3.33pt; border-bottom: 1pt solid #000000; min-width: 13.33pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.66%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 0.66%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 9.68%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.74pt; text-align: left;"><font style="padding-left: 25.83pt; border-bottom: 1pt solid #000000; min-width: 35.83pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.66%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 0.66%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 6.94%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 19.17pt; border-bottom: 1pt solid #000000; min-width: 32.5pt;">(16</font><font style="min-width: 32.5pt;">)</font></div></td></tr><tr><td style="width: 34.4%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 10pt; text-align: left;">Total other comprehensive loss<font style="font-weight: normal; padding-left: 4.83pt;"></font></div></td><td class="gutter" style="width: 0.66%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.66%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 3.42%; text-align: center; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 0.66%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.66%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.41%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 5.17pt; text-align: left;"><font style="padding-left: 5pt; border-bottom: 1pt solid #000000; min-width: 15pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.66%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.66%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.94%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0.01pt; text-align: left;"><font style="padding-left: 22.5pt; border-bottom: 1pt solid #000000; min-width: 32.5pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.66%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.66%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.45%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 3.86pt; text-align: left;"><font style="padding-left: 9.17pt; border-bottom: 1pt solid #000000; min-width: 22.5pt;">(16</font><font style="min-width: 22.5pt;">)</font></div></td><td class="gutter" style="width: 0.66%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.66%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.9%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 2.4pt; text-align: left;"><font style="padding-left: 17.5pt; border-bottom: 1pt solid #000000; min-width: 27.5pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.66%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.66%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.3%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 15.1pt; text-align: left;"><font style="border-bottom: 1pt solid #000000; min-width: 13.33pt;">(42</font><font style="min-width: 13.33pt;">)</font></div></td><td class="gutter" style="width: 0.66%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.66%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.68%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 4.74pt; text-align: left;"><font style="padding-left: 25.83pt; border-bottom: 1pt solid #000000; min-width: 35.83pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.66%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.66%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.94%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 19.17pt; border-bottom: 1pt solid #000000; min-width: 32.5pt;">(58</font><font style="min-width: 32.5pt;">)</font></div></td></tr><tr><td style="width: 34.4%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 20pt; text-indent: -10pt; text-align: left;">Total comprehensive loss for the period<font style="font-weight: normal; padding-left: 0.73pt;"></font></div></td><td class="gutter" style="width: 0.66%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.66%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 3.42%; text-align: center; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 0.66%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.66%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 5.41%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 5.17pt; text-align: left;"><font style="padding-left: 5pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.66%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.66%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 6.94%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0.01pt; text-align: left;"><font style="padding-left: 22.5pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.66%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.66%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 6.45%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 3.86pt; text-align: left;"><font style="padding-left: 9.17pt;">(16)</font></div></td><td class="gutter" style="width: 0.66%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.66%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 6.9%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 2.4pt; text-align: left;"><font style="padding-left: 17.5pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.66%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.66%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 9.3%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 15.1pt; text-align: left;">(42)</div></td><td class="gutter" style="width: 0.66%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.66%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 9.68%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 4.74pt; text-align: left;"><font style="padding-left: 5pt;">(23,348)</font></div></td><td class="gutter" style="width: 0.66%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.66%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 6.94%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 1.67pt;">(23,406)</font></div></td></tr><tr><td style="width: 34.4%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Issuance of share capital<font style="padding-left: 3.01pt;"></font></div></td><td class="gutter" style="width: 0.66%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.66%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 3.42%; text-align: center; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">13</div></td><td class="gutter" style="width: 0.66%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.66%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.41%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 5.17pt; text-align: left;"><font style="padding-left: 5pt;">22</font></div></td><td class="gutter" style="width: 0.66%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.66%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.94%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;"><font style="padding-left: 5pt;">76,277</font></div></td><td class="gutter" style="width: 0.66%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.66%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.45%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.86pt; text-align: left;"><font style="padding-left: 12.5pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.66%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.66%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.9%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.4pt; text-align: left;">26,950</div></td><td class="gutter" style="width: 0.66%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.66%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.3%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 15.1pt; text-align: left;"><font style="padding-left: 3.33pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.66%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.66%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.68%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.74pt; text-align: left;"><font style="padding-left: 25.83pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.66%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.66%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.94%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;">103,249</div></td></tr><tr><td style="width: 34.4%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Transaction costs<font style="padding-left: 3.32pt;"></font></div></td><td class="gutter" style="width: 0.66%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.66%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 3.42%; text-align: center; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">13</div></td><td class="gutter" style="width: 0.66%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.66%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 5.41%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 5.17pt; text-align: left;"><font style="padding-left: 5pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.66%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.66%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 6.94%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;"><font style="padding-left: 6.67pt;">(1,443)</font></div></td><td class="gutter" style="width: 0.66%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.66%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 6.45%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.86pt; text-align: left;"><font style="padding-left: 12.5pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.66%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.66%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 6.9%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.4pt; text-align: left;"><font style="padding-left: 9.17pt;">(309)</font></div></td><td class="gutter" style="width: 0.66%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.66%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 9.3%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 15.1pt; text-align: left;"><font style="padding-left: 3.33pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.66%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.66%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 9.68%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.74pt; text-align: left;"><font style="padding-left: 25.83pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.66%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.66%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 6.94%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 6.67pt;">(1,752)</font></div></td></tr><tr><td style="width: 34.4%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Share-based compensation expense<font style="padding-left: 0.23pt;"></font></div></td><td class="gutter" style="width: 0.66%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.66%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 3.42%; text-align: center; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">12</div></td><td class="gutter" style="width: 0.66%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.66%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.41%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 5.17pt; text-align: left;"><font style="padding-left: 5pt; border-bottom: 1pt solid #000000; min-width: 15pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.66%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.66%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.94%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;"><font style="padding-left: 22.5pt; border-bottom: 1pt solid #000000; min-width: 32.5pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.66%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.66%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.45%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.86pt; text-align: left;"><font style="padding-left: 12.5pt; border-bottom: 1pt solid #000000; min-width: 22.5pt;">56</font></div></td><td class="gutter" style="width: 0.66%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.66%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.9%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.4pt; text-align: left;"><font style="padding-left: 17.5pt; border-bottom: 1pt solid #000000; min-width: 27.5pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.66%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.66%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.3%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 15.1pt; text-align: left;"><font style="padding-left: 3.33pt; border-bottom: 1pt solid #000000; min-width: 13.33pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.66%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.66%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.68%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.74pt; text-align: left;"><font style="padding-left: 25.83pt; border-bottom: 1pt solid #000000; min-width: 35.83pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.66%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.66%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.94%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 22.5pt; border-bottom: 1pt solid #000000; min-width: 32.5pt;">56</font></div></td></tr><tr><td style="width: 34.4%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 10pt; text-align: left;">Total transactions with owners<font style="font-weight: normal; padding-left: 0.02pt;"></font></div></td><td class="gutter" style="width: 0.66%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 0.66%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 3.42%; text-align: center; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 0.66%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 0.66%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 5.41%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 5.17pt; text-align: left;"><font style="padding-left: 5pt; border-bottom: 1pt solid #000000; min-width: 15pt;">22</font></div></td><td class="gutter" style="width: 0.66%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 0.66%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 6.94%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0.01pt; text-align: left;"><font style="padding-left: 5pt; border-bottom: 1pt solid #000000; min-width: 32.5pt;">74,834</font></div></td><td class="gutter" style="width: 0.66%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 0.66%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 6.45%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 3.86pt; text-align: left;"><font style="padding-left: 12.5pt; border-bottom: 1pt solid #000000; min-width: 22.5pt;">56</font></div></td><td class="gutter" style="width: 0.66%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 0.66%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 6.9%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 2.4pt; text-align: left;"><font style="border-bottom: 1pt solid #000000; min-width: 27.5pt;">26,641</font></div></td><td class="gutter" style="width: 0.66%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 0.66%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 9.3%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 15.1pt; text-align: left;"><font style="padding-left: 3.33pt; border-bottom: 1pt solid #000000; min-width: 13.33pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.66%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 0.66%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 9.68%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 4.74pt; text-align: left;"><font style="padding-left: 25.83pt; border-bottom: 1pt solid #000000; min-width: 35.83pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.66%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 0.66%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 6.94%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="border-bottom: 1pt solid #000000; min-width: 32.5pt;">101,553</font></div></td></tr><tr><td style="width: 34.4%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">June&#160;30, 2019<font style="font-weight: normal; padding-left: 3.79pt;"></font></div></td><td class="gutter" style="width: 0.66%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.66%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 3.42%; text-align: center; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 0.66%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.66%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.41%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 5.17pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 15pt;">424</font></div></td><td class="gutter" style="width: 0.66%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.66%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.94%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0.01pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 32.5pt;">527,083</font></div></td><td class="gutter" style="width: 0.66%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.66%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.45%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 3.86pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 22.5pt;">5,835</font></div></td><td class="gutter" style="width: 0.66%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.66%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.9%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 2.4pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 27.5pt;">26,641</font></div></td><td class="gutter" style="width: 0.66%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.66%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.3%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 15.1pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 13.33pt;">(51</font><font style="min-width: 13.33pt;">)</font></div></td><td class="gutter" style="width: 0.66%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.66%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.68%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 4.74pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 35.83pt;">(381,943</font><font style="min-width: 35.83pt;">)</font></div></td><td class="gutter" style="width: 0.66%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.66%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.94%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 32.5pt;">177,989</font></div></td></tr></table></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 36pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 6.75pt; margin-left: 0pt; text-align: justify;">The accompanying notes on pages F-<a href="#tF1NOTES">8</a> to F-<a href="#tF1NOTEE">23</a> form an integral part of these condensed consolidated interim financial statements (Unaudited) <br></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 36pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">F-5<br></div></div></div>
<!--End Page 259-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 260-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 540pt;"><a name="nt10014672x1_drs_201-fintab01_pg5"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="block-frill" style="width: 540pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: Arial, Helvetica, sans-serif; font-size: 9pt; font-weight: bold; margin-top: 6pt; text-align: center;">Confidential Treatment Requested by ADC Therapeutics SA Pursuant to 17 C.F.R. &#167; 200.83<br></div></div><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 36pt;"><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">ADC Therapeutics SA</div><div><div class="rule-full" style="height: 0pt; width: 100%; border-bottom: 1pt solid #000000; margin-bottom: 2pt; margin-left: auto; margin-right: auto; margin-top: 7.5pt;"> </div></div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 20.5pt; margin-left: 0pt; text-align: left;">Condensed Consolidated Interim Statement of Changes in Equity<br></div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">(in KUSD)</div><table cellspacing="0" cellpadding="0" class="fintab" style="margin-top: 10.25pt; border-collapse: collapse; width: 468.5pt; margin-left: auto; margin-right: auto;"><tr class="header"><td colspan="25" style="width: 100%; text-align: center; vertical-align: bottom; padding-top: 6pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">For the three and six months ended June&#160;30, 2020</div></td></tr><tr class="header"><td style="width: 34.36%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 0.64%; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 3.41%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Note</div></td><td class="gutter" style="width: 0.64%; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 0.64%; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 5.41%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Share<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Capital</div></td><td class="gutter" style="width: 0.64%; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 0.64%; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 6.94%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Share<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Premium</div></td><td class="gutter" style="width: 0.64%; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 0.64%; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 6.45%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Other<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Reserves</div></td><td class="gutter" style="width: 0.64%; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 0.64%; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 6.58%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Treasury<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Shares</div></td><td class="gutter" style="width: 0.64%; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 0.64%; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 9.29%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Cumulative <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Translation<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Adjustments</div></td><td class="gutter" style="width: 0.64%; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 0.64%; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 9.67%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Accumulated<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Losses</div></td><td class="gutter" style="width: 0.64%; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 0.64%; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 7.65%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Total<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Equity</div></td></tr><tr><td style="width: 34.36%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">January&#160;1, 2020<font style="font-weight: normal; padding-left: 3.79pt;"></font></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 3.41%; text-align: center; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.41%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 1.41pt; text-align: left;">4,361</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.94%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">549,922</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.45%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 1.34pt; text-align: left;"><font style="padding-left: 5pt;">5,473</font></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.58%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0.18pt; text-align: left;"><font style="padding-left: 12.13pt;">(100)</font></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.29%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 12.6pt; text-align: left;"><font style="padding-left: 8.33pt;">69</font></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.67%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 4.74pt; text-align: left;">(448,569)</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.65%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 4.43pt;">111,156</font></div></td></tr><tr><td style="width: 34.36%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Loss for the period<font style="padding-left: 0.2pt;"></font></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 3.41%; text-align: center; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 5.41%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.41pt; text-align: left;"><font style="padding-left: 12.5pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 6.94%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 22.5pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 6.45%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.34pt; text-align: left;"><font style="padding-left: 17.5pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 6.58%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.18pt; text-align: left;"><font style="padding-left: 20.46pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 9.29%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 12.6pt; text-align: left;"><font style="padding-left: 8.33pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 9.67%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.74pt; text-align: left;"><font style="padding-left: 5pt;">(43,476)</font></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 7.65%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 5pt;">(43,476)</font></div></td></tr><tr><td style="width: 34.36%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Translation adjustment<font style="padding-left: 1.1pt;"></font></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 3.41%; text-align: center; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.41%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.41pt; text-align: left;"><font style="padding-left: 12.5pt; border-bottom: 1pt solid #000000; min-width: 22.5pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.94%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 22.5pt; border-bottom: 1pt solid #000000; min-width: 32.5pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.45%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.34pt; text-align: left;"><font style="padding-left: 17.5pt; border-bottom: 1pt solid #000000; min-width: 27.5pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.58%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.18pt; text-align: left;"><font style="padding-left: 20.46pt; border-bottom: 1pt solid #000000; min-width: 30.46pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.29%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 12.6pt; text-align: left;"><font style="border-bottom: 1pt solid #000000; min-width: 18.33pt;">(202</font><font style="min-width: 18.33pt;">)</font></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.67%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.74pt; text-align: left;"><font style="padding-left: 25.83pt; border-bottom: 1pt solid #000000; min-width: 35.83pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.65%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 17.5pt; border-bottom: 1pt solid #000000; min-width: 35.83pt;">(202</font><font style="min-width: 35.83pt;">)</font></div></td></tr><tr><td style="width: 34.36%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 10pt; text-align: left;">Total other comprehensive loss<font style="font-weight: normal; padding-left: 4.83pt;"></font></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 3.41%; text-align: center; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 5.41%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 1.41pt; text-align: left;"><font style="padding-left: 12.5pt; border-bottom: 1pt solid #000000; min-width: 22.5pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 6.94%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 22.5pt; border-bottom: 1pt solid #000000; min-width: 32.5pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 6.45%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 1.34pt; text-align: left;"><font style="padding-left: 17.5pt; border-bottom: 1pt solid #000000; min-width: 27.5pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 6.58%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0.18pt; text-align: left;"><font style="padding-left: 20.46pt; border-bottom: 1pt solid #000000; min-width: 30.46pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 9.29%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 12.6pt; text-align: left;"><font style="border-bottom: 1pt solid #000000; min-width: 18.33pt;">(202</font><font style="min-width: 18.33pt;">)</font></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 9.67%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 4.74pt; text-align: left;"><font style="padding-left: 25.83pt; border-bottom: 1pt solid #000000; min-width: 35.83pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 7.65%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 17.5pt; border-bottom: 1pt solid #000000; min-width: 35.83pt;">(202</font><font style="min-width: 35.83pt;">)</font></div></td></tr><tr><td style="width: 34.36%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 20pt; text-indent: -10pt; text-align: left;">Total comprehensive loss for the period<font style="font-weight: normal; padding-left: 0.73pt;"></font></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 3.41%; text-align: center; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.41%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 1.41pt; text-align: left;"><font style="padding-left: 12.5pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.94%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 22.5pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.45%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 1.34pt; text-align: left;"><font style="padding-left: 17.5pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.58%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0.18pt; text-align: left;"><font style="padding-left: 20.46pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.29%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 12.6pt; text-align: left;">(202)</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.67%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 4.74pt; text-align: left;"><font style="padding-left: 5pt;">(43,476)</font></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.65%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 5pt;">(43,678)</font></div></td></tr><tr><td style="width: 34.36%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Share-based compensation expense<font style="padding-left: 0.23pt;"></font></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 3.41%; text-align: center; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">12</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 5.41%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.41pt; text-align: left;"><font style="padding-left: 12.5pt; border-bottom: 1pt solid #000000; min-width: 22.5pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 6.94%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 22.5pt; border-bottom: 1pt solid #000000; min-width: 32.5pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 6.45%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.34pt; text-align: left;"><font style="padding-left: 5pt; border-bottom: 1pt solid #000000; min-width: 27.5pt;">3,790</font></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 6.58%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.18pt; text-align: left;"><font style="padding-left: 20.46pt; border-bottom: 1pt solid #000000; min-width: 30.46pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 9.29%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 12.6pt; text-align: left;"><font style="padding-left: 8.33pt; border-bottom: 1pt solid #000000; min-width: 18.33pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 9.67%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.74pt; text-align: left;"><font style="padding-left: 25.83pt; border-bottom: 1pt solid #000000; min-width: 35.83pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 7.65%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 13.33pt; border-bottom: 1pt solid #000000; min-width: 35.83pt;">3,790</font></div></td></tr><tr><td style="width: 34.36%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 10pt; text-align: left;">Total transactions with owners<font style="font-weight: normal; padding-left: 0.02pt;"></font></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 3.41%; text-align: center; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.41%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 1.41pt; text-align: left;"><font style="padding-left: 12.5pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.94%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 22.5pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.45%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 1.34pt; text-align: left;"><font style="padding-left: 5pt;">3,790</font></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.58%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0.18pt; text-align: left;"><font style="padding-left: 20.46pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.29%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 12.6pt; text-align: left;"><font style="padding-left: 8.33pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.67%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 4.74pt; text-align: left;"><font style="padding-left: 25.83pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.65%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 13.33pt;">3,790</font></div></td></tr><tr><td style="width: 34.36%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">March&#160;31, 2020<font style="font-weight: normal; padding-left: 0.64pt;"></font></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 3.41%; text-align: center; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 5.41%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 1.41pt; text-align: left;">4,361</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 6.94%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">549,922</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 6.45%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 1.34pt; text-align: left;"><font style="padding-left: 5pt;">9,263</font></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 6.58%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0.18pt; text-align: left;"><font style="padding-left: 12.13pt;">(100)</font></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 9.29%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 12.6pt; text-align: left;">(133)</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 9.67%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 4.74pt; text-align: left;">(492,045)</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 7.65%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 8.33pt;">71,268</font></div></td></tr><tr><td style="width: 34.36%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Loss for the period<font style="padding-left: 0.2pt;"></font></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 3.41%; text-align: center; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.41%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.41pt; text-align: left;"><font style="padding-left: 12.5pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.94%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 22.5pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.45%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.34pt; text-align: left;"><font style="padding-left: 17.5pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.58%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.18pt; text-align: left;"><font style="padding-left: 20.46pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.29%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 12.6pt; text-align: left;"><font style="padding-left: 8.33pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.67%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.74pt; text-align: left;">(126,557)</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.65%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">(126,557)</div></td></tr><tr><td style="width: 34.36%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Translation adjustment<font style="padding-left: 1.1pt;"></font></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 3.41%; text-align: center; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 5.41%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.41pt; text-align: left;"><font style="padding-left: 12.5pt; border-bottom: 1pt solid #000000; min-width: 22.5pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 6.94%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 22.5pt; border-bottom: 1pt solid #000000; min-width: 32.5pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 6.45%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.34pt; text-align: left;"><font style="padding-left: 17.5pt; border-bottom: 1pt solid #000000; min-width: 27.5pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 6.58%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.18pt; text-align: left;"><font style="padding-left: 20.46pt; border-bottom: 1pt solid #000000; min-width: 30.46pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 9.29%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 12.6pt; text-align: left;"><font style="padding-left: 5pt; border-bottom: 1pt solid #000000; min-width: 18.33pt;">(13</font><font style="min-width: 18.33pt;">)</font></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 9.67%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.74pt; text-align: left;"><font style="padding-left: 25.83pt; border-bottom: 1pt solid #000000; min-width: 35.83pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 7.65%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 22.5pt; border-bottom: 1pt solid #000000; min-width: 35.83pt;">(13</font><font style="min-width: 35.83pt;">)</font></div></td></tr><tr><td style="width: 34.36%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 10pt; text-align: left;">Total other comprehensive loss<font style="font-weight: normal; padding-left: 4.83pt;"></font></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 3.41%; text-align: center; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.41%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 1.41pt; text-align: left;"><font style="padding-left: 12.5pt; border-bottom: 1pt solid #000000; min-width: 22.5pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.94%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 22.5pt; border-bottom: 1pt solid #000000; min-width: 32.5pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.45%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 1.34pt; text-align: left;"><font style="padding-left: 17.5pt; border-bottom: 1pt solid #000000; min-width: 27.5pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.58%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0.18pt; text-align: left;"><font style="padding-left: 20.46pt; border-bottom: 1pt solid #000000; min-width: 30.46pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.29%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 12.6pt; text-align: left;"><font style="padding-left: 5pt; border-bottom: 1pt solid #000000; min-width: 18.33pt;">(13</font><font style="min-width: 18.33pt;">)</font></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.67%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 4.74pt; text-align: left;"><font style="padding-left: 25.83pt; border-bottom: 1pt solid #000000; min-width: 35.83pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.65%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 22.5pt; border-bottom: 1pt solid #000000; min-width: 35.83pt;">(13</font><font style="min-width: 35.83pt;">)</font></div></td></tr><tr><td style="width: 34.36%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 20pt; text-indent: -10pt; text-align: left;">Total comprehensive loss for the period<font style="font-weight: normal; padding-left: 0.73pt;"></font></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 3.41%; text-align: center; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 5.41%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 1.41pt; text-align: left;"><font style="padding-left: 12.5pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 6.94%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 22.5pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 6.45%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 1.34pt; text-align: left;"><font style="padding-left: 17.5pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 6.58%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0.18pt; text-align: left;"><font style="padding-left: 20.46pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 9.29%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 12.6pt; text-align: left;"><font style="padding-left: 5pt;">(13)</font></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 9.67%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 4.74pt; text-align: left;">(126,557)</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 7.65%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">(126,570)</div></td></tr><tr><td style="width: 34.36%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 20pt; text-indent: -10pt; text-align: left;">Shares surrendered to redeem share purchase plan promissory notes<font style="padding-left: 4.66pt;"></font></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 3.41%; text-align: center; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">13</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.41%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.41pt; text-align: left;"><font style="padding-left: 12.5pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.94%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 5.37pt;">11,208</font></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.45%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.34pt; text-align: left;"><font style="padding-left: 17.5pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.58%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.18pt; text-align: left;">(11,208)</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.29%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 12.6pt; text-align: left;"><font style="padding-left: 8.33pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.67%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.74pt; text-align: left;"><font style="padding-left: 25.83pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.65%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 25.83pt;">&#8212;</font></div></td></tr><tr><td style="width: 34.36%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 20pt; text-indent: -10pt; text-align: left;">Issuance of shares through capitalization of reserves<font style="padding-left: 1.89pt;"></font></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 3.41%; text-align: center; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">13</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 5.41%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.41pt; text-align: left;"><font style="padding-left: 7.5pt;">393</font></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 6.94%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 14.17pt;">(393)</font></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 6.45%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.34pt; text-align: left;"><font style="padding-left: 17.5pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 6.58%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.18pt; text-align: left;"><font style="padding-left: 20.46pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 9.29%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 12.6pt; text-align: left;"><font style="padding-left: 8.33pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 9.67%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.74pt; text-align: left;"><font style="padding-left: 25.83pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 7.65%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 25.83pt;">&#8212;</font></div></td></tr><tr><td style="width: 34.36%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 20pt; text-indent: -10pt; text-align: left;">Issuance of shares to be held as treasury shares<font style="padding-left: 2.98pt;"></font></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 3.41%; text-align: center; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">13</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.41%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.41pt; text-align: left;"><font style="padding-left: 12.5pt;">34</font></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.94%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 22.5pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.45%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.34pt; text-align: left;"><font style="padding-left: 17.5pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.58%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.18pt; text-align: left;"><font style="padding-left: 17.13pt;">(34)</font></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.29%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 12.6pt; text-align: left;"><font style="padding-left: 8.33pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.67%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.74pt; text-align: left;"><font style="padding-left: 25.83pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.65%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 25.83pt;">&#8212;</font></div></td></tr><tr><td style="width: 34.36%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 20pt; text-indent: -10pt; text-align: left;">Grant of shares to settle 2014 incentive plan awards<font style="padding-left: 4.65pt;"></font></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 3.41%; text-align: center; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">13</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 5.41%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.41pt; text-align: left;"><font style="padding-left: 12.5pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 6.94%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 19.17pt;">(29)</font></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 6.45%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.34pt; text-align: left;"><font style="padding-left: 17.5pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 6.58%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.18pt; text-align: left;"><font style="padding-left: 20.46pt;">29</font></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 9.29%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 12.6pt; text-align: left;"><font style="padding-left: 8.33pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 9.67%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.74pt; text-align: left;"><font style="padding-left: 25.83pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 7.65%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 25.83pt;">&#8212;</font></div></td></tr><tr><td style="width: 34.36%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 20pt; text-indent: -10pt; text-align: left;">Issuance of shares at initial public offering<font style="padding-left: 1.47pt;"></font></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 3.41%; text-align: center; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">13</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.41%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.41pt; text-align: left;">1,007</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.94%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">231,661</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.45%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.34pt; text-align: left;"><font style="padding-left: 17.5pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.58%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.18pt; text-align: left;"><font style="padding-left: 20.46pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.29%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 12.6pt; text-align: left;"><font style="padding-left: 8.33pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.67%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.74pt; text-align: left;"><font style="padding-left: 25.83pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.65%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 3.33pt;">232,668</font></div></td></tr><tr><td style="width: 34.36%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 20pt; text-indent: -10pt; text-align: left;">Sale of shares under greenshoe option<font style="padding-left: 2.94pt;"></font></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 3.41%; text-align: center; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">13</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 5.41%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.41pt; text-align: left;"><font style="padding-left: 12.5pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 6.94%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 5pt;">23,591</font></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 6.45%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.34pt; text-align: left;"><font style="padding-left: 17.5pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 6.58%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.18pt; text-align: left;"><font style="padding-left: 3.33pt;">11,309</font></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 9.29%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 12.6pt; text-align: left;"><font style="padding-left: 8.33pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 9.67%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.74pt; text-align: left;"><font style="padding-left: 25.83pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 7.65%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 8.33pt;">34,900</font></div></td></tr><tr><td style="width: 34.36%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 20pt; text-indent: -10pt; text-align: left;">Transaction costs, initial public offering and greenshoe option<font style="padding-left: 0.95pt;"></font></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 3.41%; text-align: center; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">13</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.41%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.41pt; text-align: left;"><font style="padding-left: 12.5pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.94%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 1.67pt;">(23,355)</font></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.45%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.34pt; text-align: left;"><font style="padding-left: 17.5pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.58%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.18pt; text-align: left;"><font style="padding-left: 20.46pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.29%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 12.6pt; text-align: left;"><font style="padding-left: 8.33pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.67%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.74pt; text-align: left;"><font style="padding-left: 25.83pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.65%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 5pt;">(23,355)</font></div></td></tr><tr><td style="width: 34.36%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Share-based compensation expense<font style="padding-left: 0.23pt;"></font></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 3.41%; text-align: center; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">12</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 5.41%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.41pt; text-align: left;"><font style="padding-left: 12.5pt; border-bottom: 1pt solid #000000; min-width: 22.5pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 6.94%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 22.5pt; border-bottom: 1pt solid #000000; min-width: 32.5pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 6.45%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.34pt; text-align: left;"><font style="padding-left: 5pt; border-bottom: 1pt solid #000000; min-width: 27.5pt;">7,391</font></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 6.58%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.18pt; text-align: left;"><font style="padding-left: 20.46pt; border-bottom: 1pt solid #000000; min-width: 30.46pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 9.29%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 12.6pt; text-align: left;"><font style="padding-left: 8.33pt; border-bottom: 1pt solid #000000; min-width: 18.33pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 9.67%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.74pt; text-align: left;"><font style="padding-left: 25.83pt; border-bottom: 1pt solid #000000; min-width: 35.83pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 7.65%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 13.33pt; border-bottom: 1pt solid #000000; min-width: 35.83pt;">7,391</font></div></td></tr><tr><td style="width: 34.36%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 10pt; text-align: left;">Total transactions with owners<font style="font-weight: normal; padding-left: 0.02pt;"></font></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 3.41%; text-align: center; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.41%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 1.41pt; text-align: left;"><font style="border-bottom: 1pt solid #000000; min-width: 22.5pt;">1,434</font></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.94%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="border-bottom: 1pt solid #000000; min-width: 32.5pt;">242,683</font></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.45%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 1.34pt; text-align: left;"><font style="padding-left: 5pt; border-bottom: 1pt solid #000000; min-width: 27.5pt;">7,391</font></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.58%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0.18pt; text-align: left;"><font style="padding-left: 20.46pt; border-bottom: 1pt solid #000000; min-width: 30.46pt;">96</font></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.29%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 12.6pt; text-align: left;"><font style="padding-left: 8.33pt; border-bottom: 1pt solid #000000; min-width: 18.33pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.67%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 4.74pt; text-align: left;"><font style="padding-left: 25.83pt; border-bottom: 1pt solid #000000; min-width: 35.83pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.65%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 3.33pt; border-bottom: 1pt solid #000000; min-width: 35.83pt;">251,604</font></div></td></tr><tr><td style="width: 34.36%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 6pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">June&#160;30, 2020<font style="font-weight: normal; padding-left: 3.79pt;"></font></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt;">&#8203;</td><td style="width: 3.41%; text-align: center; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 6pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt;">&#8203;</td><td style="width: 5.41%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 6pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 1.41pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 22.5pt;">5,795</font></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt;">&#8203;</td><td style="width: 6.94%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 6pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 32.5pt;">792,605</font></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt;">&#8203;</td><td style="width: 6.45%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 6pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 1.34pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 27.5pt;">16,654</font></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt;">&#8203;</td><td style="width: 6.58%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 6pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0.18pt; text-align: left;"><font style="padding-left: 22.13pt; border-bottom: 3pt double #000000; min-width: 30.46pt;">(4</font><font style="min-width: 30.46pt;">)</font></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt;">&#8203;</td><td style="width: 9.29%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 6pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 12.6pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 18.33pt;">(146</font><font style="min-width: 18.33pt;">)</font></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt;">&#8203;</td><td style="width: 9.67%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 6pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 4.74pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 35.83pt;">(618,602</font><font style="min-width: 35.83pt;">)</font></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt;">&#8203;</td><td style="width: 7.65%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 6pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 3.33pt; border-bottom: 3pt double #000000; min-width: 35.83pt;">196,302</font></div></td></tr></table></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 36pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 6.75pt; margin-left: 0pt; text-align: justify;">The accompanying notes on pages F-<a href="#tF1NOTES">8</a> to F-<a href="#tF1NOTEE">23</a> form an integral part of these condensed consolidated interim financial statements (Unaudited) <br></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 36pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">F-6<br></div></div></div>
<!--End Page 260-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 261-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 540pt;"><a name="nt10014672x1_drs_201-fintab01_pg6"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="block-frill" style="width: 540pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: Arial, Helvetica, sans-serif; font-size: 9pt; font-weight: bold; margin-top: 6pt; text-align: center;">Confidential Treatment Requested by ADC Therapeutics SA Pursuant to 17 C.F.R. &#167; 200.83<br></div></div><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 36pt;"><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">ADC Therapeutics SA</div><div><div class="rule-full" style="height: 0pt; width: 100%; border-bottom: 1pt solid #000000; margin-bottom: 2pt; margin-left: auto; margin-right: auto; margin-top: 7.5pt;"> </div></div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 20.5pt; margin-left: 0pt; text-align: left;"><a name="tF1CF"><!--Anchor--></a>Condensed Consolidated Interim Statement of Cash Flows<br></div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">(in KUSD)</div><table cellspacing="0" cellpadding="0" class="fintab" style="margin-top: 4.25pt; border-collapse: collapse; width: 468pt; margin-left: auto; margin-right: auto;"><tr class="header"><td style="width: 66.67%; text-align: left; vertical-align: bottom; padding-top: 6pt; padding-bottom: 4pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 2.55%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 4pt;">&#8203;</td><td class="gutter" style="width: 2.55%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 4pt;">&#8203;</td><td style="width: 3.42%; text-align: center; vertical-align: bottom; padding-top: 6pt; padding-bottom: 4pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 2.55%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 4pt;">&#8203;</td><td class="gutter" style="width: 2.55%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td colspan="4" style="width: 19.71%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">For the Six Months <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Ended June&#160;30,</div></td></tr><tr class="header"><td style="width: 66.67%; text-align: left; vertical-align: bottom; padding-top: 4pt; padding-bottom: 4pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 2.55%; border-bottom: none; font-size: 2pt; padding-top: 4pt; padding-bottom: 4pt;">&#8203;</td><td class="gutter" style="width: 2.55%; font-size: 2pt; padding-top: 4pt; padding-bottom: 4pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 3.42%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4pt; padding-bottom: 4pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Note</div></td><td class="gutter" style="width: 2.55%; font-size: 2pt; padding-top: 4pt; padding-bottom: 4pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 2.55%; font-size: 2pt; padding-top: 4pt; padding-bottom: 4pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 7.66%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4pt; padding-bottom: 4pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2020</div></td><td class="gutter" style="width: 2.55%; font-size: 2pt; padding-top: 4pt; padding-bottom: 4pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 2.55%; font-size: 2pt; padding-top: 4pt; padding-bottom: 4pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 6.95%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4pt; padding-bottom: 4pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2019</div></td></tr><tr><td style="width: 66.67%; text-align: left; vertical-align: bottom; padding-top: 4pt; padding-bottom: 2.75pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Cash used in operating activities<br></div></td><td class="gutter" style="width: 2.55%; border-bottom: none; font-size: 2pt; padding-top: 4pt; padding-bottom: 2.75pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.55%; border-bottom: none; font-size: 2pt; padding-top: 4pt; padding-bottom: 2.75pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 3.42%; text-align: center; vertical-align: bottom; padding-top: 4pt; padding-bottom: 2.75pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 2.55%; border-bottom: none; font-size: 2pt; padding-top: 4pt; padding-bottom: 2.75pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.55%; border-bottom: none; font-size: 2pt; padding-top: 4pt; padding-bottom: 2.75pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.66%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4pt; padding-bottom: 2.75pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 2.55%; border-bottom: none; font-size: 2pt; padding-top: 4pt; padding-bottom: 2.75pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.55%; border-bottom: none; font-size: 2pt; padding-top: 4pt; padding-bottom: 2.75pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.95%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4pt; padding-bottom: 2.75pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 66.67%; text-align: left; vertical-align: bottom; padding-top: 2.75pt; padding-bottom: 2.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Loss for the period<font style="padding-left: 1.2pt;"></font></div></td><td class="gutter" style="width: 2.55%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td class="gutter" style="width: 2.55%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td style="width: 3.42%; text-align: center; vertical-align: bottom; padding-top: 2.75pt; padding-bottom: 2.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 2.55%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td class="gutter" style="width: 2.55%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td style="width: 7.66%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.75pt; padding-bottom: 2.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;">(170,033)</div></td><td class="gutter" style="width: 2.55%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td class="gutter" style="width: 2.55%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td style="width: 6.95%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.75pt; padding-bottom: 2.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;"><font style="padding-left: 1.67pt;">(49,858)</font></div></td></tr><tr><td style="width: 66.67%; text-align: left; vertical-align: bottom; padding-top: 2.75pt; padding-bottom: 2.75pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Adjustments for non-monetary items:<br></div></td><td class="gutter" style="width: 2.55%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.55%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 3.42%; text-align: center; vertical-align: bottom; padding-top: 2.75pt; padding-bottom: 2.75pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 2.55%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.55%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.66%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.75pt; padding-bottom: 2.75pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 2.55%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.55%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.95%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.75pt; padding-bottom: 2.75pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 66.67%; text-align: left; vertical-align: bottom; padding-top: 2.75pt; padding-bottom: 2.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Share-based compensation expense<font style="padding-left: 1.23pt;"></font></div></td><td class="gutter" style="width: 2.55%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td class="gutter" style="width: 2.55%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td style="width: 3.42%; text-align: center; vertical-align: bottom; padding-top: 2.75pt; padding-bottom: 2.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">12</div></td><td class="gutter" style="width: 2.55%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td class="gutter" style="width: 2.55%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td style="width: 7.66%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.75pt; padding-bottom: 2.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;"><font style="padding-left: 8.7pt;">11,181</font></div></td><td class="gutter" style="width: 2.55%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td class="gutter" style="width: 2.55%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td style="width: 6.95%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.75pt; padding-bottom: 2.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;"><font style="padding-left: 17.5pt;">140</font></div></td></tr><tr><td style="width: 66.67%; text-align: left; vertical-align: bottom; padding-top: 2.75pt; padding-bottom: 2.75pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Depreciation of property, plant and equipment<font style="padding-left: 0.49pt;"></font></div></td><td class="gutter" style="width: 2.55%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.55%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 3.42%; text-align: center; vertical-align: bottom; padding-top: 2.75pt; padding-bottom: 2.75pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 2.55%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.55%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.66%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.75pt; padding-bottom: 2.75pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;"><font style="padding-left: 20.83pt;">294</font></div></td><td class="gutter" style="width: 2.55%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.55%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.95%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.75pt; padding-bottom: 2.75pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;"><font style="padding-left: 17.5pt;">269</font></div></td></tr><tr><td style="width: 66.67%; text-align: left; vertical-align: bottom; padding-top: 2.75pt; padding-bottom: 2.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Amortization of intangible assets<font style="padding-left: 4.55pt;"></font></div></td><td class="gutter" style="width: 2.55%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td class="gutter" style="width: 2.55%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td style="width: 3.42%; text-align: center; vertical-align: bottom; padding-top: 2.75pt; padding-bottom: 2.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 2.55%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td class="gutter" style="width: 2.55%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td style="width: 7.66%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.75pt; padding-bottom: 2.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;"><font style="padding-left: 25.83pt;">17</font></div></td><td class="gutter" style="width: 2.55%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td class="gutter" style="width: 2.55%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td style="width: 6.95%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.75pt; padding-bottom: 2.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;"><font style="padding-left: 22.5pt;">13</font></div></td></tr><tr><td style="width: 66.67%; text-align: left; vertical-align: bottom; padding-top: 2.75pt; padding-bottom: 2.75pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Depreciation of right-of-use assets<font style="padding-left: 4.02pt;"></font></div></td><td class="gutter" style="width: 2.55%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.55%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 3.42%; text-align: center; vertical-align: bottom; padding-top: 2.75pt; padding-bottom: 2.75pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 2.55%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.55%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.66%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.75pt; padding-bottom: 2.75pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;"><font style="padding-left: 20.83pt;">569</font></div></td><td class="gutter" style="width: 2.55%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.55%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.95%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.75pt; padding-bottom: 2.75pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;"><font style="padding-left: 17.5pt;">513</font></div></td></tr><tr><td style="width: 66.67%; text-align: left; vertical-align: bottom; padding-top: 2.75pt; padding-bottom: 2.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Change in defined benefit pension liability<font style="padding-left: 4.55pt;"></font></div></td><td class="gutter" style="width: 2.55%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td class="gutter" style="width: 2.55%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td style="width: 3.42%; text-align: center; vertical-align: bottom; padding-top: 2.75pt; padding-bottom: 2.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 2.55%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td class="gutter" style="width: 2.55%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td style="width: 7.66%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.75pt; padding-bottom: 2.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;"><font style="padding-left: 20.83pt;">189</font></div></td><td class="gutter" style="width: 2.55%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td class="gutter" style="width: 2.55%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td style="width: 6.95%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.75pt; padding-bottom: 2.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;"><font style="padding-left: 17.5pt;">158</font></div></td></tr><tr><td style="width: 66.67%; text-align: left; vertical-align: bottom; padding-top: 2.75pt; padding-bottom: 2.75pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Convertible loans, derivatives, increase in fair value<font style="padding-left: 1.26pt;"></font></div></td><td class="gutter" style="width: 2.55%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.55%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 3.42%; text-align: center; vertical-align: bottom; padding-top: 2.75pt; padding-bottom: 2.75pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">11</div></td><td class="gutter" style="width: 2.55%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.55%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.66%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.75pt; padding-bottom: 2.75pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;"><font style="padding-left: 8.33pt;">79,261</font></div></td><td class="gutter" style="width: 2.55%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.55%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.95%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.75pt; padding-bottom: 2.75pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;"><font style="padding-left: 22.5pt;">&#8212;</font></div></td></tr><tr><td style="width: 66.67%; text-align: left; vertical-align: bottom; padding-top: 2.75pt; padding-bottom: 2.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Financial income<font style="padding-left: 4.52pt;"></font></div></td><td class="gutter" style="width: 2.55%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td class="gutter" style="width: 2.55%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td style="width: 3.42%; text-align: center; vertical-align: bottom; padding-top: 2.75pt; padding-bottom: 2.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 2.55%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td class="gutter" style="width: 2.55%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td style="width: 7.66%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.75pt; padding-bottom: 2.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;"><font style="padding-left: 17.5pt;">(569)</font></div></td><td class="gutter" style="width: 2.55%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td class="gutter" style="width: 2.55%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td style="width: 6.95%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.75pt; padding-bottom: 2.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;"><font style="padding-left: 14.17pt;">(852)</font></div></td></tr><tr><td style="width: 66.67%; text-align: left; vertical-align: bottom; padding-top: 2.75pt; padding-bottom: 2.75pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Interest expense on convertible loans<font style="padding-left: 2.9pt;"></font></div></td><td class="gutter" style="width: 2.55%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.55%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 3.42%; text-align: center; vertical-align: bottom; padding-top: 2.75pt; padding-bottom: 2.75pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">11</div></td><td class="gutter" style="width: 2.55%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.55%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.66%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.75pt; padding-bottom: 2.75pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;"><font style="padding-left: 20.83pt;">868</font></div></td><td class="gutter" style="width: 2.55%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.55%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.95%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.75pt; padding-bottom: 2.75pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;"><font style="padding-left: 22.5pt;">&#8212;</font></div></td></tr><tr><td style="width: 66.67%; text-align: left; vertical-align: bottom; padding-top: 2.75pt; padding-bottom: 2.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Exchange differences<font style="padding-left: 2.5pt;"></font></div></td><td class="gutter" style="width: 2.55%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td class="gutter" style="width: 2.55%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td style="width: 3.42%; text-align: center; vertical-align: bottom; padding-top: 2.75pt; padding-bottom: 2.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 2.55%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td class="gutter" style="width: 2.55%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td style="width: 7.66%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.75pt; padding-bottom: 2.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;"><font style="padding-left: 25.83pt;">&#8212;</font></div></td><td class="gutter" style="width: 2.55%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td class="gutter" style="width: 2.55%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td style="width: 6.95%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.75pt; padding-bottom: 2.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;"><font style="padding-left: 24.17pt;">(2)</font></div></td></tr><tr><td style="width: 66.67%; text-align: left; vertical-align: bottom; padding-top: 2.75pt; padding-bottom: 2.75pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Income taxes<font style="padding-left: 0.64pt;"></font></div></td><td class="gutter" style="width: 2.55%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.55%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 3.42%; text-align: center; vertical-align: bottom; padding-top: 2.75pt; padding-bottom: 2.75pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 2.55%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.55%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.66%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.75pt; padding-bottom: 2.75pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;"><font style="padding-left: 20.83pt;">204</font></div></td><td class="gutter" style="width: 2.55%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.55%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.95%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.75pt; padding-bottom: 2.75pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;"><font style="padding-left: 17.5pt;">199</font></div></td></tr><tr><td style="width: 66.67%; text-align: left; vertical-align: bottom; padding-top: 2.75pt; padding-bottom: 2.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Changes in assets and liabilities:<br></div></td><td class="gutter" style="width: 2.55%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td class="gutter" style="width: 2.55%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td style="width: 3.42%; text-align: center; vertical-align: bottom; padding-top: 2.75pt; padding-bottom: 2.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 2.55%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td class="gutter" style="width: 2.55%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td style="width: 7.66%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.75pt; padding-bottom: 2.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 2.55%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td class="gutter" style="width: 2.55%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td style="width: 6.95%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.75pt; padding-bottom: 2.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 66.67%; text-align: left; vertical-align: bottom; padding-top: 2.75pt; padding-bottom: 2.75pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Decrease in trade accounts receivable<font style="padding-left: 0.7pt;"></font></div></td><td class="gutter" style="width: 2.55%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.55%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 3.42%; text-align: center; vertical-align: bottom; padding-top: 2.75pt; padding-bottom: 2.75pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 2.55%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.55%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.66%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.75pt; padding-bottom: 2.75pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;"><font style="padding-left: 25.83pt;">&#8212;</font></div></td><td class="gutter" style="width: 2.55%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.55%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.95%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.75pt; padding-bottom: 2.75pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;"><font style="padding-left: 17.5pt;">182</font></div></td></tr><tr><td style="width: 66.67%; text-align: left; vertical-align: bottom; padding-top: 2.75pt; padding-bottom: 2.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">(Increase) in other current assets<font style="padding-left: 1.25pt;"></font></div></td><td class="gutter" style="width: 2.55%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td class="gutter" style="width: 2.55%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td style="width: 3.42%; text-align: center; vertical-align: bottom; padding-top: 2.75pt; padding-bottom: 2.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 2.55%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td class="gutter" style="width: 2.55%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td style="width: 7.66%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.75pt; padding-bottom: 2.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;"><font style="padding-left: 10pt;">(3,569)</font></div></td><td class="gutter" style="width: 2.55%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td class="gutter" style="width: 2.55%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td style="width: 6.95%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.75pt; padding-bottom: 2.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;"><font style="padding-left: 14.17pt;">(277)</font></div></td></tr><tr><td style="width: 66.67%; text-align: left; vertical-align: bottom; padding-top: 2.75pt; padding-bottom: 2.75pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">(Decrease) in contract liability<font style="padding-left: 0.12pt;"></font></div></td><td class="gutter" style="width: 2.55%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.55%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 3.42%; text-align: center; vertical-align: bottom; padding-top: 2.75pt; padding-bottom: 2.75pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">6</div></td><td class="gutter" style="width: 2.55%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.55%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.66%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.75pt; padding-bottom: 2.75pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;"><font style="padding-left: 25.83pt;">&#8212;</font></div></td><td class="gutter" style="width: 2.55%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.55%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.95%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.75pt; padding-bottom: 2.75pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;"><font style="padding-left: 6.67pt;">(2,340)</font></div></td></tr><tr><td style="width: 66.67%; text-align: left; vertical-align: bottom; padding-top: 2.75pt; padding-bottom: 2.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Increase / (Decrease) in accounts payable<font style="padding-left: 4.61pt;"></font></div></td><td class="gutter" style="width: 2.55%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td class="gutter" style="width: 2.55%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td style="width: 3.42%; text-align: center; vertical-align: bottom; padding-top: 2.75pt; padding-bottom: 2.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 2.55%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td class="gutter" style="width: 2.55%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td style="width: 7.66%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.75pt; padding-bottom: 2.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;"><font style="padding-left: 13.33pt;">3,468</font></div></td><td class="gutter" style="width: 2.55%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td class="gutter" style="width: 2.55%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td style="width: 6.95%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.75pt; padding-bottom: 2.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;"><font style="padding-left: 6.67pt;">(5,579)</font></div></td></tr><tr><td style="width: 66.67%; text-align: left; vertical-align: bottom; padding-top: 2.75pt; padding-bottom: 4pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Increase in other liabilities<font style="padding-left: 0.66pt;"></font></div></td><td class="gutter" style="width: 2.55%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 4pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.55%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 4pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 3.42%; text-align: center; vertical-align: bottom; padding-top: 2.75pt; padding-bottom: 4pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 2.55%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 4pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.55%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 4pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.66%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.75pt; padding-bottom: 4pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;"><font style="padding-left: 13.33pt; border-bottom: 1pt solid #000000; min-width: 35.83pt;">4,781</font></div></td><td class="gutter" style="width: 2.55%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 4pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.55%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 4pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.95%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.75pt; padding-bottom: 4pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;"><font style="padding-left: 17.5pt; border-bottom: 1pt solid #000000; min-width: 32.5pt;">906</font></div></td></tr><tr><td style="width: 66.67%; text-align: left; vertical-align: bottom; padding-top: 4pt; padding-bottom: 2.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Cash used in operating activities<font style="padding-left: 1.22pt;"></font></div></td><td class="gutter" style="width: 2.55%; border-bottom: none; font-size: 2pt; padding-top: 4pt; padding-bottom: 2.75pt;">&#8203;</td><td class="gutter" style="width: 2.55%; border-bottom: none; font-size: 2pt; padding-top: 4pt; padding-bottom: 2.75pt;">&#8203;</td><td style="width: 3.42%; text-align: center; vertical-align: bottom; padding-top: 4pt; padding-bottom: 2.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 2.55%; border-bottom: none; font-size: 2pt; padding-top: 4pt; padding-bottom: 2.75pt;">&#8203;</td><td class="gutter" style="width: 2.55%; border-bottom: none; font-size: 2pt; padding-top: 4pt; padding-bottom: 2.75pt;">&#8203;</td><td style="width: 7.66%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4pt; padding-bottom: 2.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;"><font style="padding-left: 5pt;">(73,339)</font></div></td><td class="gutter" style="width: 2.55%; border-bottom: none; font-size: 2pt; padding-top: 4pt; padding-bottom: 2.75pt;">&#8203;</td><td class="gutter" style="width: 2.55%; border-bottom: none; font-size: 2pt; padding-top: 4pt; padding-bottom: 2.75pt;">&#8203;</td><td style="width: 6.95%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4pt; padding-bottom: 2.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;"><font style="padding-left: 1.67pt;">(56,528)</font></div></td></tr><tr><td style="width: 66.67%; text-align: left; vertical-align: bottom; padding-top: 2.75pt; padding-bottom: 2.75pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Interest received<font style="padding-left: 2.32pt;"></font></div></td><td class="gutter" style="width: 2.55%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.55%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 3.42%; text-align: center; vertical-align: bottom; padding-top: 2.75pt; padding-bottom: 2.75pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 2.55%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.55%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.66%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.75pt; padding-bottom: 2.75pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;"><font style="padding-left: 20.83pt;">588</font></div></td><td class="gutter" style="width: 2.55%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.55%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.95%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.75pt; padding-bottom: 2.75pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;"><font style="padding-left: 17.5pt;">970</font></div></td></tr><tr><td style="width: 66.67%; text-align: left; vertical-align: bottom; padding-top: 2.75pt; padding-bottom: 2.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Interest expense on lease obligations<font style="padding-left: 4.57pt;"></font></div></td><td class="gutter" style="width: 2.55%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td class="gutter" style="width: 2.55%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td style="width: 3.42%; text-align: center; vertical-align: bottom; padding-top: 2.75pt; padding-bottom: 2.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 2.55%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td class="gutter" style="width: 2.55%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td style="width: 7.66%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.75pt; padding-bottom: 2.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;"><font style="padding-left: 25.83pt;">61</font></div></td><td class="gutter" style="width: 2.55%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td class="gutter" style="width: 2.55%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td style="width: 6.95%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.75pt; padding-bottom: 2.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;"><font style="padding-left: 22.5pt;">73</font></div></td></tr><tr><td style="width: 66.67%; text-align: left; vertical-align: bottom; padding-top: 2.75pt; padding-bottom: 4pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Tax refunded (paid)<font style="padding-left: 3.57pt;"></font></div></td><td class="gutter" style="width: 2.55%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 4pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.55%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 4pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 3.42%; text-align: center; vertical-align: bottom; padding-top: 2.75pt; padding-bottom: 4pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 2.55%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 4pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.55%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 4pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.66%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.75pt; padding-bottom: 4pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;"><font style="padding-left: 30.83pt; border-bottom: 1pt solid #000000; min-width: 35.83pt;">2</font></div></td><td class="gutter" style="width: 2.55%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 4pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.55%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 4pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.95%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.75pt; padding-bottom: 4pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;"><font style="padding-left: 14.17pt; border-bottom: 1pt solid #000000; min-width: 32.5pt;">(203</font><font style="min-width: 32.5pt;">)</font></div></td></tr><tr><td style="width: 66.67%; text-align: left; vertical-align: bottom; padding-top: 4pt; padding-bottom: 4pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Net cash used in operating activities<font style="font-weight: normal; padding-left: 2.34pt;"></font></div></td><td class="gutter" style="width: 2.55%; border-bottom: none; font-size: 2pt; padding-top: 4pt; padding-bottom: 4pt;">&#8203;</td><td class="gutter" style="width: 2.55%; border-bottom: none; font-size: 2pt; padding-top: 4pt; padding-bottom: 4pt;">&#8203;</td><td style="width: 3.42%; text-align: center; vertical-align: bottom; padding-top: 4pt; padding-bottom: 4pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 2.55%; border-bottom: none; font-size: 2pt; padding-top: 4pt; padding-bottom: 4pt;">&#8203;</td><td class="gutter" style="width: 2.55%; border-bottom: none; font-size: 2pt; padding-top: 4pt; padding-bottom: 4pt;">&#8203;</td><td style="width: 7.66%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4pt; padding-bottom: 4pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;"><font style="padding-left: 5pt; border-bottom: 1pt solid #000000; min-width: 35.83pt;">(72,688</font><font style="min-width: 35.83pt;">)</font></div></td><td class="gutter" style="width: 2.55%; border-bottom: none; font-size: 2pt; padding-top: 4pt; padding-bottom: 4pt;">&#8203;</td><td class="gutter" style="width: 2.55%; border-bottom: none; font-size: 2pt; padding-top: 4pt; padding-bottom: 4pt;">&#8203;</td><td style="width: 6.95%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4pt; padding-bottom: 4pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;"><font style="padding-left: 1.67pt; border-bottom: 1pt solid #000000; min-width: 32.5pt;">(55,688</font><font style="min-width: 32.5pt;">)</font></div></td></tr><tr><td style="width: 66.67%; text-align: left; vertical-align: bottom; padding-top: 4pt; padding-bottom: 2.75pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Cash used in investing activities<br></div></td><td class="gutter" style="width: 2.55%; border-bottom: none; font-size: 2pt; padding-top: 4pt; padding-bottom: 2.75pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.55%; border-bottom: none; font-size: 2pt; padding-top: 4pt; padding-bottom: 2.75pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 3.42%; text-align: center; vertical-align: bottom; padding-top: 4pt; padding-bottom: 2.75pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 2.55%; border-bottom: none; font-size: 2pt; padding-top: 4pt; padding-bottom: 2.75pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.55%; border-bottom: none; font-size: 2pt; padding-top: 4pt; padding-bottom: 2.75pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.66%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4pt; padding-bottom: 2.75pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 2.55%; border-bottom: none; font-size: 2pt; padding-top: 4pt; padding-bottom: 2.75pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.55%; border-bottom: none; font-size: 2pt; padding-top: 4pt; padding-bottom: 2.75pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.95%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4pt; padding-bottom: 2.75pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 66.67%; text-align: left; vertical-align: bottom; padding-top: 2.75pt; padding-bottom: 2.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Payment for purchase of property, plant and equipment<font style="padding-left: 3.29pt;"></font></div></td><td class="gutter" style="width: 2.55%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td class="gutter" style="width: 2.55%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td style="width: 3.42%; text-align: center; vertical-align: bottom; padding-top: 2.75pt; padding-bottom: 2.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 2.55%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td class="gutter" style="width: 2.55%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td style="width: 7.66%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.75pt; padding-bottom: 2.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;"><font style="padding-left: 17.5pt;">(226)</font></div></td><td class="gutter" style="width: 2.55%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td class="gutter" style="width: 2.55%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td style="width: 6.95%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.75pt; padding-bottom: 2.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;"><font style="padding-left: 14.17pt;">(150)</font></div></td></tr><tr><td style="width: 66.67%; text-align: left; vertical-align: bottom; padding-top: 2.75pt; padding-bottom: 4pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Payment for purchase of intangible assets<font style="padding-left: 4.02pt;"></font></div></td><td class="gutter" style="width: 2.55%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 4pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.55%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 4pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 3.42%; text-align: center; vertical-align: bottom; padding-top: 2.75pt; padding-bottom: 4pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">10</div></td><td class="gutter" style="width: 2.55%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 4pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.55%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 4pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.66%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.75pt; padding-bottom: 4pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;"><font style="padding-left: 17.5pt; border-bottom: 1pt solid #000000; min-width: 35.83pt;">(408</font><font style="min-width: 35.83pt;">)</font></div></td><td class="gutter" style="width: 2.55%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 4pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.55%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 4pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.95%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.75pt; padding-bottom: 4pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;"><font style="padding-left: 6.67pt; border-bottom: 1pt solid #000000; min-width: 32.5pt;">(1,757</font><font style="min-width: 32.5pt;">)</font></div></td></tr><tr><td style="width: 66.67%; text-align: left; vertical-align: bottom; padding-top: 4pt; padding-bottom: 4pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Net cash used in investing activities<font style="font-weight: normal; padding-left: 0.12pt;"></font></div></td><td class="gutter" style="width: 2.55%; border-bottom: none; font-size: 2pt; padding-top: 4pt; padding-bottom: 4pt;">&#8203;</td><td class="gutter" style="width: 2.55%; border-bottom: none; font-size: 2pt; padding-top: 4pt; padding-bottom: 4pt;">&#8203;</td><td style="width: 3.42%; text-align: center; vertical-align: bottom; padding-top: 4pt; padding-bottom: 4pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 2.55%; border-bottom: none; font-size: 2pt; padding-top: 4pt; padding-bottom: 4pt;">&#8203;</td><td class="gutter" style="width: 2.55%; border-bottom: none; font-size: 2pt; padding-top: 4pt; padding-bottom: 4pt;">&#8203;</td><td style="width: 7.66%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4pt; padding-bottom: 4pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;"><font style="padding-left: 17.5pt; border-bottom: 1pt solid #000000; min-width: 35.83pt;">(634</font><font style="min-width: 35.83pt;">)</font></div></td><td class="gutter" style="width: 2.55%; border-bottom: none; font-size: 2pt; padding-top: 4pt; padding-bottom: 4pt;">&#8203;</td><td class="gutter" style="width: 2.55%; border-bottom: none; font-size: 2pt; padding-top: 4pt; padding-bottom: 4pt;">&#8203;</td><td style="width: 6.95%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4pt; padding-bottom: 4pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;"><font style="padding-left: 6.67pt; border-bottom: 1pt solid #000000; min-width: 32.5pt;">(1,907</font><font style="min-width: 32.5pt;">)</font></div></td></tr><tr><td style="width: 66.67%; text-align: left; vertical-align: bottom; padding-top: 4pt; padding-bottom: 2.75pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Cash from financing activities<br></div></td><td class="gutter" style="width: 2.55%; border-bottom: none; font-size: 2pt; padding-top: 4pt; padding-bottom: 2.75pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.55%; border-bottom: none; font-size: 2pt; padding-top: 4pt; padding-bottom: 2.75pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 3.42%; text-align: center; vertical-align: bottom; padding-top: 4pt; padding-bottom: 2.75pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 2.55%; border-bottom: none; font-size: 2pt; padding-top: 4pt; padding-bottom: 2.75pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.55%; border-bottom: none; font-size: 2pt; padding-top: 4pt; padding-bottom: 2.75pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.66%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4pt; padding-bottom: 2.75pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 2.55%; border-bottom: none; font-size: 2pt; padding-top: 4pt; padding-bottom: 2.75pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.55%; border-bottom: none; font-size: 2pt; padding-top: 4pt; padding-bottom: 2.75pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.95%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4pt; padding-bottom: 2.75pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 66.67%; text-align: left; vertical-align: bottom; padding-top: 2.75pt; padding-bottom: 2.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Proceeds from capital contributions, net of transaction costs<font style="padding-left: 4.32pt;"></font></div></td><td class="gutter" style="width: 2.55%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td class="gutter" style="width: 2.55%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td style="width: 3.42%; text-align: center; vertical-align: bottom; padding-top: 2.75pt; padding-bottom: 2.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 2.55%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td class="gutter" style="width: 2.55%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td style="width: 7.66%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.75pt; padding-bottom: 2.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;"><font style="padding-left: 25.83pt;">&#8212;</font></div></td><td class="gutter" style="width: 2.55%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td class="gutter" style="width: 2.55%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td style="width: 6.95%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.75pt; padding-bottom: 2.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;"><font style="padding-left: 5pt;">74,838</font></div></td></tr><tr><td style="width: 66.67%; text-align: left; vertical-align: bottom; padding-top: 2.75pt; padding-bottom: 2.75pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 20pt; text-indent: -10pt; text-align: left;">Proceeds from public offering of common shares, net of underwriting fees and other transaction costs<font style="padding-left: 1.23pt;"></font></div></td><td class="gutter" style="width: 2.55%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.55%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 3.42%; text-align: center; vertical-align: bottom; padding-top: 2.75pt; padding-bottom: 2.75pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">13</div></td><td class="gutter" style="width: 2.55%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.55%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.66%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.75pt; padding-bottom: 2.75pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;"><font style="padding-left: 3.33pt;">244,213</font></div></td><td class="gutter" style="width: 2.55%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.55%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.95%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.75pt; padding-bottom: 2.75pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;"><font style="padding-left: 22.5pt;">&#8212;</font></div></td></tr><tr><td style="width: 66.67%; text-align: left; vertical-align: bottom; padding-top: 2.75pt; padding-bottom: 2.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Proceeds from convertible loans, net<font style="padding-left: 4.84pt;"></font></div></td><td class="gutter" style="width: 2.55%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td class="gutter" style="width: 2.55%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td style="width: 3.42%; text-align: center; vertical-align: bottom; padding-top: 2.75pt; padding-bottom: 2.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">11</div></td><td class="gutter" style="width: 2.55%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td class="gutter" style="width: 2.55%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td style="width: 7.66%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.75pt; padding-bottom: 2.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;"><font style="padding-left: 8.33pt;">62,896</font></div></td><td class="gutter" style="width: 2.55%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td class="gutter" style="width: 2.55%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td style="width: 6.95%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.75pt; padding-bottom: 2.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;"><font style="padding-left: 22.5pt;">&#8212;</font></div></td></tr><tr><td style="width: 66.67%; text-align: left; vertical-align: bottom; padding-top: 2.75pt; padding-bottom: 2.75pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Proceeds from shares to be issued, net of transaction costs<font style="padding-left: 4.9pt;"></font></div></td><td class="gutter" style="width: 2.55%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.55%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 3.42%; text-align: center; vertical-align: bottom; padding-top: 2.75pt; padding-bottom: 2.75pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 2.55%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.55%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.66%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.75pt; padding-bottom: 2.75pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;"><font style="padding-left: 25.83pt;">&#8212;</font></div></td><td class="gutter" style="width: 2.55%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.55%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.95%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.75pt; padding-bottom: 2.75pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;"><font style="padding-left: 5pt;">26,641</font></div></td></tr><tr><td style="width: 66.67%; text-align: left; vertical-align: bottom; padding-top: 2.75pt; padding-bottom: 4pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Principal payments of lease obligations<font style="padding-left: 4pt;"></font></div></td><td class="gutter" style="width: 2.55%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 4pt;">&#8203;</td><td class="gutter" style="width: 2.55%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 4pt;">&#8203;</td><td style="width: 3.42%; text-align: center; vertical-align: bottom; padding-top: 2.75pt; padding-bottom: 4pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 2.55%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 4pt;">&#8203;</td><td class="gutter" style="width: 2.55%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 4pt;">&#8203;</td><td style="width: 7.66%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.75pt; padding-bottom: 4pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;"><font style="padding-left: 17.5pt; border-bottom: 1pt solid #000000; min-width: 35.83pt;">(615</font><font style="min-width: 35.83pt;">)</font></div></td><td class="gutter" style="width: 2.55%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 4pt;">&#8203;</td><td class="gutter" style="width: 2.55%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 4pt;">&#8203;</td><td style="width: 6.95%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.75pt; padding-bottom: 4pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;"><font style="padding-left: 14.17pt; border-bottom: 1pt solid #000000; min-width: 32.5pt;">(548</font><font style="min-width: 32.5pt;">)</font></div></td></tr><tr><td style="width: 66.67%; text-align: left; vertical-align: bottom; padding-top: 4pt; padding-bottom: 4pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Net cash from financing activities<font style="font-weight: normal; padding-left: 3.63pt;"></font></div></td><td class="gutter" style="width: 2.55%; border-bottom: none; font-size: 2pt; padding-top: 4pt; padding-bottom: 4pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.55%; border-bottom: none; font-size: 2pt; padding-top: 4pt; padding-bottom: 4pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 3.42%; text-align: center; vertical-align: bottom; padding-top: 4pt; padding-bottom: 4pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 2.55%; border-bottom: none; font-size: 2pt; padding-top: 4pt; padding-bottom: 4pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.55%; border-bottom: none; font-size: 2pt; padding-top: 4pt; padding-bottom: 4pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.66%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4pt; padding-bottom: 4pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;"><font style="padding-left: 3.33pt; border-bottom: 1pt solid #000000; min-width: 35.83pt;">306,494</font></div></td><td class="gutter" style="width: 2.55%; border-bottom: none; font-size: 2pt; padding-top: 4pt; padding-bottom: 4pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.55%; border-bottom: none; font-size: 2pt; padding-top: 4pt; padding-bottom: 4pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.95%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4pt; padding-bottom: 4pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;"><font style="border-bottom: 1pt solid #000000; min-width: 32.5pt;">100,931</font></div></td></tr><tr><td style="width: 66.67%; text-align: left; vertical-align: bottom; padding-top: 4pt; padding-bottom: 2.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Net increase in cash and cash equivalents<font style="font-weight: normal; padding-left: 4.19pt;"></font></div></td><td class="gutter" style="width: 2.55%; border-bottom: none; font-size: 2pt; padding-top: 4pt; padding-bottom: 2.75pt;">&#8203;</td><td class="gutter" style="width: 2.55%; border-bottom: none; font-size: 2pt; padding-top: 4pt; padding-bottom: 2.75pt;">&#8203;</td><td style="width: 3.42%; text-align: center; vertical-align: bottom; padding-top: 4pt; padding-bottom: 2.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 2.55%; border-bottom: none; font-size: 2pt; padding-top: 4pt; padding-bottom: 2.75pt;">&#8203;</td><td class="gutter" style="width: 2.55%; border-bottom: none; font-size: 2pt; padding-top: 4pt; padding-bottom: 2.75pt;">&#8203;</td><td style="width: 7.66%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4pt; padding-bottom: 2.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;"><font style="padding-left: 3.33pt;">233,172</font></div></td><td class="gutter" style="width: 2.55%; border-bottom: none; font-size: 2pt; padding-top: 4pt; padding-bottom: 2.75pt;">&#8203;</td><td class="gutter" style="width: 2.55%; border-bottom: none; font-size: 2pt; padding-top: 4pt; padding-bottom: 2.75pt;">&#8203;</td><td style="width: 6.95%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4pt; padding-bottom: 2.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;"><font style="padding-left: 5pt;">43,336</font></div></td></tr><tr><td style="width: 66.67%; text-align: left; vertical-align: bottom; padding-top: 2.75pt; padding-bottom: 2.75pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Exchange gain / (losses) on cash and cash equivalents<font style="padding-left: 2.38pt;"></font></div></td><td class="gutter" style="width: 2.55%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.55%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 3.42%; text-align: center; vertical-align: bottom; padding-top: 2.75pt; padding-bottom: 2.75pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 2.55%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.55%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.66%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.75pt; padding-bottom: 2.75pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;"><font style="padding-left: 17.5pt;">(130)</font></div></td><td class="gutter" style="width: 2.55%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.55%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.95%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.75pt; padding-bottom: 2.75pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;"><font style="padding-left: 22.5pt;">13</font></div></td></tr><tr><td style="width: 66.67%; text-align: left; vertical-align: bottom; padding-top: 2.75pt; padding-bottom: 4pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Cash and cash equivalents at beginning of the period<font style="padding-left: 1.81pt;"></font></div></td><td class="gutter" style="width: 2.55%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 4pt;">&#8203;</td><td class="gutter" style="width: 2.55%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 4pt;">&#8203;</td><td style="width: 3.42%; text-align: center; vertical-align: bottom; padding-top: 2.75pt; padding-bottom: 4pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 2.55%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 4pt;">&#8203;</td><td class="gutter" style="width: 2.55%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 4pt;">&#8203;</td><td style="width: 7.66%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.75pt; padding-bottom: 4pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;"><font style="padding-left: 3.7pt; border-bottom: 1pt solid #000000; min-width: 35.83pt;">115,551</font></div></td><td class="gutter" style="width: 2.55%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 4pt;">&#8203;</td><td class="gutter" style="width: 2.55%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 4pt;">&#8203;</td><td style="width: 6.95%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.75pt; padding-bottom: 4pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;"><font style="border-bottom: 1pt solid #000000; min-width: 32.5pt;">138,807</font></div></td></tr><tr><td style="width: 66.67%; text-align: left; vertical-align: bottom; padding-top: 4pt; padding-bottom: 6pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Cash and cash equivalents at end of the period<font style="font-weight: normal; padding-left: 4.57pt;"></font></div></td><td class="gutter" style="width: 2.55%; border-bottom: none; font-size: 2pt; padding-top: 4pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.55%; border-bottom: none; font-size: 2pt; padding-top: 4pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 3.42%; text-align: center; vertical-align: bottom; padding-top: 4pt; padding-bottom: 6pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 2.55%; border-bottom: none; font-size: 2pt; padding-top: 4pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.55%; border-bottom: none; font-size: 2pt; padding-top: 4pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.66%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4pt; padding-bottom: 6pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;"><font style="padding-left: 3.33pt; border-bottom: 3pt double #000000; min-width: 35.83pt;">348,593</font></div></td><td class="gutter" style="width: 2.55%; border-bottom: none; font-size: 2pt; padding-top: 4pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.55%; border-bottom: none; font-size: 2pt; padding-top: 4pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.95%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4pt; padding-bottom: 6pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 32.5pt;">182,156</font></div></td></tr></table></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 36pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 6.75pt; margin-left: 0pt; text-align: justify;">The accompanying notes on pages F-<a href="#tF1NOTES">8</a> to F-<a href="#tF1NOTEE">23</a> form an integral part of these condensed consolidated interim financial statements (Unaudited) <br></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 36pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">F-7<br></div></div></div>
<!--End Page 261-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 262-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 540pt;"><a name="nt10014672x1_drs_202-finnotes01_pg1"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="block-frill" style="width: 540pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: Arial, Helvetica, sans-serif; font-size: 9pt; font-weight: bold; margin-top: 6pt; text-align: center;">Confidential Treatment Requested by ADC Therapeutics SA Pursuant to 17 C.F.R. &#167; 200.83<br></div></div><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 36pt;"><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">ADC Therapeutics SA <br></div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;"><div class="rule-full" style="height: 0pt; width: 100%; border-bottom: 1pt solid #000000; margin-top: 1pt; margin-bottom: 1pt; margin-left: auto; margin-right: auto;"> </div>Notes to the Condensed Consolidated Interim Financial Statements (Unaudited) &#8211; in KUSD except for share and per share data</div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"><a name="tF1NOTES"><!--Anchor--></a>1.<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; text-align: left;">Corporate information</div></td></tr></table><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: left;">ADC Therapeutics SA (the &#8220;Company&#8221; or &#8220;ADCT&#8221;) was incorporated on June&#160;6, 2011 under the laws of Switzerland. The registered office of the Company is located at Route de la Corniche 3B, 1066 Epalinges, Switzerland. The Company controls two wholly-owned subsidiaries: ADC Therapeutics America, Inc. (&#8220;ADCT America&#8221;), which was incorporated in Delaware, USA on December&#160;10, 2014, and ADC Therapeutics (UK) Ltd (&#8220;ADCT UK&#8221;), which was incorporated in England on December&#160;12, 2014. The Company and its two subsidiaries form the ADCT Group (the &#8220;Group&#8221;).</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: left;">The Group is focused on the development of antibody drug conjugates, including research, development, human clinical trials, regulatory approval and commercialization. Antibody drug conjugates (&#8220;ADCs&#8221;) are drug constructs which combine monoclonal antibodies specific to particular types of cells with cytotoxic molecules or warheads which seek to kill any cancer cell to which the ADC attaches. ADCs have extensive potential therapeutic applications in cancer.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: left;">These unaudited condensed consolidated interim financial statements were authorized for issue by the Board of Directors on August&#160;12, 2020.</div><div class="h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 12pt; margin-left: 20pt; text-align: left;"><u>Initial Public Offering (IPO)</u></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: left;">On May&#160;19, 2020, the Company completed an IPO on the New York Stock Exchange in which it issued and sold an aggregate of 14,082,475 common shares at USD 19.00 per share, which included 1,836,844 common shares issued and sold pursuant to the underwriters&#8217; exercise in full of their option to purchase additional common shares. The gross proceeds from the IPO were USD 267.6&#160;million, and net proceeds were USD 248.9&#160;million after deducting underwriting discounts and commissions and before deducting fees and expenses payable by the Company. The IPO resulted in a gross increase of USD 255.3&#160;million in the Company&#8217;s share premium account prior to transaction costs associated with the IPO share issuance of USD&#160;4.7&#160;million and underwriting discounts and commissions of USD 18.7&#160;million, both of which were charged directly against the Company&#8217;s share premium account. Further details are contained in note 13, &#8220;Share capital, share premium and treasury shares&#8221;.</div><div class="h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 12pt; margin-left: 20pt; text-align: left;"><u>Going concern basis</u></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: left;">ADC Therapeutics SA is a late-clinical-stage company developing innovative therapeutics. The Group is exposed to all risks inherent in establishing and developing its business, including the substantial uncertainty that current projects will succeed. The Group&#8217;s success may also depend on its ability to:</div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 40pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">establish and maintain a strong patent position and protection;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 40pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">enter into collaborations with partners in the pharmaceutical industry;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 40pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">acquire and retain key personnel; and</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 40pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">acquire additional funding to support its operations.</div></td></tr></table><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: left;">Since its incorporation, the Group has primarily funded its growth through capital increases and additional funds provided by research collaborations and, in the most recent quarter, by a public offering and the issuance of convertible loans (see note 11, &#8220;Convertible loans&#8221;). The Group does not have recourse to bank loans. As a result, the Group is not exposed to liquidity risk through requests for early repayment of loans, other than, pursuant to the convertible loans, it must maintain a balance of at least USD 50&#160;million in cash and cash equivalents at the end of each quarter.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: left;">As at June&#160;30, 2020, the Group&#8217;s cash and cash equivalents amounted to USD 348.6&#160;million (December&#160;31, 2019: USD 115.6&#160;million).</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: left;">The Board of Directors believes that the Group has sufficient financial resources to cover its operating costs for at least the next 12 months from the date of issuance of these unaudited condensed consolidated interim financial statements and, as a result, is presenting these unaudited condensed consolidated interim financial statements of the Group on a going concern basis.</div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 36pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">F-8<br></div></div></div>
<!--End Page 262-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 263-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 540pt;"><a name="nt10014672x1_drs_202-finnotes01_pg2"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="block-frill" style="width: 540pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: Arial, Helvetica, sans-serif; font-size: 9pt; font-weight: bold; margin-top: 6pt; text-align: center;">Confidential Treatment Requested by ADC Therapeutics SA Pursuant to 17 C.F.R. &#167; 200.83<br></div></div><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 36pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">ADC Therapeutics SA <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;"><div class="rule-full" style="height: 0pt; width: 100%; border-bottom: 1pt solid #000000; margin-top: 1pt; margin-bottom: 1pt; margin-left: auto; margin-right: auto;"> </div>Notes to the Condensed Consolidated Interim Financial Statements (Unaudited) &#8211; in KUSD except for share and per share data<font style="padding-left: 4pt;">(continued)</font><br></div><div class="h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 7pt; margin-left: 20pt; text-align: left;"><u>COVID &#8211; 19</u></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: left;">On March&#160;11, 2020, the World Health Organization declared the outbreak of the coronavirus disease (&#8220;COVID-19&#8221;) caused by a novel strain of coronavirus as a pandemic, which continues to spread throughout the United States, the European Union, Switzerland, the United Kingdom and around the world. Since then, COVID-19 has continued to spread, impacting the economies of most countries around the world. The Company&#8217;s operations, similar to those of other life sciences companies, have been impacted by the COVID-19 pandemic. As the Company advances its clinical programs, it is in close contact with its principal investigators and clinical sites, which are located in jurisdictions affected by the COVID-19 pandemic, and is assessing the impact of the COVID-19 pandemic on its clinical trials, expected timelines and costs on an ongoing basis. In light of recent developments relating to the COVID-19 pandemic, the primary focus of healthcare providers and hospitals is currently on fighting the novel coronavirus. In addition, in response to the spread of COVID-19, the Company has modified its business practices, including restricting employee travel, developing social distancing plans for its employees and cancelling physical participation in meetings, events and conferences. In addition, certain of the Company&#8217;s clinical trials have experienced delays or suspensions in patient enrollment as a result of the COVID-19 pandemic. This partial disruption, even temporary, may severely impact the Company&#8217;s operations and overall business by delaying the progress of its clinical trials and preclinical studies. As the COVID-19 pandemic continues to evolve, the Company believes the extent of the impact to its operations, operating results, cash flows, liquidity and financial condition will be primarily driven by the severity and duration of the pandemic, the pandemic&#8217;s impact on the U.S. and global economies and the timing, scope and effectiveness of national and local governmental responses to the pandemic, especially in areas where the conditions have recently worsened. Those primary drivers are beyond the Company&#8217;s knowledge and control, and as a result, at this time, the ultimate impact on the Company's results of operations, cash-flows and financial position in 2020 and thereafter cannot be reasonably predicted. Furthermore, the impact to the Company&#8217;s businesses, operating results, cash flows, liquidity and financial condition may be further impacted if the current circumstances continue to exist for a prolonged period of time. However, on the basis of the risk mitigation measures undertaken, the Company has concluded that there is no material uncertainty that may cast a significant doubt upon the Company&#8217;s ability to continue as a going concern.</div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 12pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">2.<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; text-align: left;">Basis of preparation</div></td></tr></table><div class="h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 7pt; margin-left: 20pt; text-align: left;"><u>Statement of Compliance</u></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: left;">These unaudited condensed consolidated interim financial statements as of June&#160;30, 2020 and December&#160;31, 2019 and for the three and six months ended June&#160;30, 2020 have been prepared in accordance with International Accounting Standard 34 <font style="font-style: italic;">Interim Financial Reporting</font> (&#8220;IAS 34&#8221;) and should be read in conjunction with the audited consolidated financial statements as of and for the year ended December&#160;31, 2019.</div><div class="h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 20pt; margin-left: 20pt; text-align: left;"><u>Functional and reporting currency</u></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: left;">These unaudited condensed consolidated interim financial statements are presented in United States Dollars (&#8220;USD&#8221;), which is the Company&#8217;s functional currency and the Group&#8217;s reporting currency.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: left;">A subsidiary of the Company, ADCT UK, has a functional currency of the British Pound (&#8220;GBP&#8221;). The following exchange rates have been used for the translation of the financial statements of ADCT UK:</div><table cellspacing="0" cellpadding="0" class="fintab" style="margin-top: 11.25pt; border-collapse: collapse; width: 428pt; margin-left: 20pt;"><tr class="header"><td style="width: 72.9%; text-align: left; vertical-align: bottom; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 1.51%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.51%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td colspan="4" style="width: 24.09%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Six Months Ended June&#160;30,</div></td></tr><tr class="header"><td style="width: 72.9%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 1.51%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.51%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 10.54%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2020</div></td><td class="gutter" style="width: 1.51%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.51%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 10.54%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2019</div></td></tr><tr><td style="width: 72.9%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">USD / GBP<br></div></td><td class="gutter" style="width: 1.51%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.51%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.54%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.51%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.51%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.54%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 72.9%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Closing rate, GBP 1<font style="padding-left: 1.84pt;"></font></div></td><td class="gutter" style="width: 1.51%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.51%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 10.54%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 6.3pt; text-align: left;">1.23272</div></td><td class="gutter" style="width: 1.51%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.51%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 10.54%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 6.3pt; text-align: left;">1.26898</div></td></tr><tr><td style="width: 72.9%; text-align: left; vertical-align: bottom; padding-top: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Weighted average exchange rate, GBP 1<font style="padding-left: 4.36pt;"></font></div></td><td class="gutter" style="width: 1.51%; border-bottom: none; font-size: 2pt; padding-top: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.51%; border-bottom: none; font-size: 2pt; padding-top: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.54%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 6.3pt; text-align: left;">1.23277</div></td><td class="gutter" style="width: 1.51%; border-bottom: none; font-size: 2pt; padding-top: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.51%; border-bottom: none; font-size: 2pt; padding-top: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.54%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 6.3pt; text-align: left;">1.29507</div></td></tr></table></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 36pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">F-9<br></div></div></div>
<!--End Page 263-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 264-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 540pt;"><a name="nt10014672x1_drs_202-finnotes01_pg3"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="block-frill" style="width: 540pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: Arial, Helvetica, sans-serif; font-size: 9pt; font-weight: bold; margin-top: 6pt; text-align: center;">Confidential Treatment Requested by ADC Therapeutics SA Pursuant to 17 C.F.R. &#167; 200.83<br></div></div><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 36pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">ADC Therapeutics SA <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;"><div class="rule-full" style="height: 0pt; width: 100%; border-bottom: 1pt solid #000000; margin-top: 1pt; margin-bottom: 1pt; margin-left: auto; margin-right: auto;"> </div>Notes to the Condensed Consolidated Interim Financial Statements (Unaudited) &#8211; in KUSD except for share and per share data<font style="padding-left: 4pt;">(continued)</font><br></div><div class="h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 7pt; margin-left: 20pt; text-align: left;"><u>Basis of Consolidation</u></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: left;">The unaudited condensed consolidated interim financial statements incorporate the financial statements of the Company and entities controlled by the Company. Control is achieved where the Company has the power to govern the financial and operating policies of an entity so as to obtain benefits from its activities.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8.5pt; margin-left: 20pt; text-align: left;">The consolidated entities include:</div><table cellspacing="0" cellpadding="0" class="fintab" style="margin-top: 11.25pt; border-collapse: collapse; width: 428pt; margin-left: 20pt;"><tr class="header"><td style="width: 72.9%; text-align: left; vertical-align: bottom; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 1.2%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.2%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td colspan="4" style="width: 24.71%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Ownership Interest</div></td></tr><tr class="header"><td style="width: 72.9%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 1.2%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.2%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 11.16%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">June&#160;30, 2020</div></td><td class="gutter" style="width: 1.2%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.2%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 11.16%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">June&#160;30, 2019</div></td></tr><tr><td style="width: 72.9%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">ADC Therapeutics America, Inc. (&#8220;ADCT America&#8221;)<font style="padding-left: 4.22pt;"></font></div></td><td class="gutter" style="width: 1.2%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.2%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 11.16%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 16.39pt; text-align: left;">100%</div></td><td class="gutter" style="width: 1.2%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.2%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 11.16%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 16.39pt; text-align: left;">100%</div></td></tr><tr><td style="width: 72.9%; text-align: left; vertical-align: bottom; padding-top: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">ADC Therapeutics (UK) Ltd (&#8220;ADCT UK&#8221;)<font style="padding-left: 0.32pt;"></font></div></td><td class="gutter" style="width: 1.2%; border-bottom: none; font-size: 2pt; padding-top: 3pt;">&#8203;</td><td class="gutter" style="width: 1.2%; border-bottom: none; font-size: 2pt; padding-top: 3pt;">&#8203;</td><td style="width: 11.16%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 16.39pt; text-align: left;">100%</div></td><td class="gutter" style="width: 1.2%; border-bottom: none; font-size: 2pt; padding-top: 3pt;">&#8203;</td><td class="gutter" style="width: 1.2%; border-bottom: none; font-size: 2pt; padding-top: 3pt;">&#8203;</td><td style="width: 11.16%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 16.39pt; text-align: left;">100%</div></td></tr></table><div class="h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 18.5pt; margin-left: 20pt; text-align: left;"><u>Use of estimates and judgements</u></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: left;">The preparation of the unaudited condensed consolidated interim financial statements in conformity with IFRS requires management to make judgements, estimates and assumptions that affect the application of accounting policies and the reported amounts of assets and liabilities, income and expense. Actual results may differ from these estimates.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: left;">Estimates are based on management&#8217;s best knowledge of current events and actions that the Company may undertake in the future. Estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognized in the period in which the estimate is revised if the revision affects only that period, or in the period of the revision and future periods if the revision affects both current and future periods.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: left;">In preparing these unaudited condensed consolidated interim financial statements, the significant judgements made by management in applying the Group&#8217;s accounting policies and the key sources of estimation uncertainty included those that applied to the consolidated financial statements for the year ended December&#160;31, 2019.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: left;">In addition, significant judgements were required in implementing the Company&#8217;s accounting policy for the convertible loans, as set out in note 3, &#8220;Significant accounting policies&#8221;. In particular, significant judgement was required in deciding whether the conversion option derivative embedded in the notes was of a liability or equity nature, in selecting the appropriate models to value the derivatives arising from the first and second tranches of the convertible notes and in identifying the appropriate key assumptions as inputs to the selected models. Details of the models and assumptions are set out in note 11, &#8220;Convertible loans&#8221;.</div><div class="h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 20.5pt; margin-left: 20pt; text-align: left;"><u>Share split and share consolidation</u></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: left;">As explained in note 13, &#8220;Share capital, share premium and treasury shares&#8221;, on September&#160;19, 2019, the Company effected a one to 15,625 share split of its outstanding shares and, on April&#160;24, 2020, the Company effected a five to four share consolidation of its outstanding shares. Accordingly, all share and per share amounts for all periods presented in these unaudited condensed consolidated interim financial statements and notes thereto have been adjusted retroactively, where applicable, to reflect the share split and share consolidation.</div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 12pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">3.<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; text-align: left;">Significant accounting policies</div></td></tr></table><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: left;">The accounting policies applied by the Company in these unaudited condensed consolidated interim financial statements are the same as those applied by the Company in its audited consolidated financial statements as of and for the year ended December&#160;31, 2019 and have been applied consistently to all periods presented in these unaudited condensed consolidated interim financial statements, except as disclosed below.</div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 36pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">F-10<br></div></div></div>
<!--End Page 264-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 265-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 540pt;"><a name="nt10014672x1_drs_202-finnotes01_pg4"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="block-frill" style="width: 540pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: Arial, Helvetica, sans-serif; font-size: 9pt; font-weight: bold; margin-top: 6pt; text-align: center;">Confidential Treatment Requested by ADC Therapeutics SA Pursuant to 17 C.F.R. &#167; 200.83<br></div></div><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 36pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">ADC Therapeutics SA <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;"><div class="rule-full" style="height: 0pt; width: 100%; border-bottom: 1pt solid #000000; margin-top: 1pt; margin-bottom: 1pt; margin-left: auto; margin-right: auto;"> </div>Notes to the Condensed Consolidated Interim Financial Statements (Unaudited) &#8211; in KUSD except for share and per share data<font style="padding-left: 4pt;">(continued)</font><br></div><div class="h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 7pt; margin-left: 20pt; text-align: left;"><u>Convertible loans</u></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: left;">The Company entered into a USD 115&#160;million Facility Agreement (see note 11, &#8220;Convertible loans&#8221;) on April&#160;24, 2020, pursuant to which the counterparty agreed to extend senior secured convertible term loans to the Company in two separate disbursements: </div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 40pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(i)<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">an initial disbursement of convertible loans in the amount of USD 65&#160;million upon the completion of the IPO, and satisfaction of certain other conditions (the &#8220;first tranche&#8221;) and</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 40pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(ii)<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">a subsequent disbursement of convertible loans amounting to USD 50&#160;million upon the receipt of regulatory approval for a specified product candidate, and satisfaction of certain other conditions (the &#8220;second tranche&#8221;).</div></td></tr></table><div class="h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 12pt; margin-left: 20pt; text-align: left;"><u>Accounting for the first tranche</u></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: left;">On May&#160;19, 2020 ADCT received convertible loans in the amount of USD 65&#160;million upon completion of the IPO. These convertible loans have been recognized as a hybrid financial instrument and accounted for as two separate components: (i)&#160;a loan and (ii)&#160;an embedded conversion option derivative.</div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 40pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(i)<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">The embedded conversion option derivative has been initially measured at fair value and is subsequently remeasured to fair value at each reporting date. Under IAS 32, this derivative could have been classified as a component of equity only if in all cases the contract would be settled by the Company delivering a fixed number of its own equity instruments in exchange for a fixed amount of cash or debt redemption. However, the agreement foresees, in the event of a major transaction, the payment of &#8220;make-whole&#8221; amounts that would have to be computed in the light of the circumstances and are therefore not fixed. As a result, the derivative is presented in the balance sheet as a liability and classified as non-equity in accordance with IFRS 9. Changes in the fair value (gains or losses) of the derivative at the end of each period are recorded in the consolidated statement of income.</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 40pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(ii)<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">The convertible loan&#8217;s initial fair value is the residual amount of the consideration received, net of attributable costs, after separating out the fair value of the embedded conversion option derivative. The loan is subsequently measured at its amortized cost in accordance with IFRS 9. It is presented in the unaudited condensed consolidated interim balance sheet as a financial liability.</div></td></tr></table><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: left;">Expenses and fees payable upon the issuance of the convertible loans have been allocated pro rata to the above two components. The share of expenses allocated to the embedded conversion option derivative has been charged directly to the unaudited condensed consolidated interim statement of income, while the share of expenses allocated to the residual convertible loan has been deducted from the loan.</div><div class="h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 12pt; margin-left: 20pt; text-align: left;"><u>Accounting for the second tranche</u></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: left;">The Company is obligated to draw down the second tranche in the amount of USD 50&#160;million upon receipt of regulatory approval for a specified drug candidate. This obligation has been accounted for as a derivative, and presented in the unaudited condensed consolidated interim balance sheet as a financial liability with changes in its fair value being recorded directly in the unaudited condensed consolidated interim statement of income at the end of each accounting period.</div><div class="h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 12pt; margin-left: 20pt; text-align: left;"><u>New and amended IFRS standards</u></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: left;">There are no new IFRS standards, amendments to standards or interpretations that are mandatory for the financial year beginning on January&#160;1, 2020, that are relevant to the Group and that have had any impact in the interim periods. New standards, amendments to standards and interpretations that are not yet effective, which have been deemed by the Group as currently not relevant, are not listed here.</div><div class="h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 12pt; margin-left: 20pt; text-align: left;"><u>Income tax expense</u></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: left;">Taxes on income in the interim periods are accrued using the tax rate that would be applicable to expected total annual profit or loss.</div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 36pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">F-11<br></div></div></div>
<!--End Page 265-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 266-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 540pt;"><a name="nt10014672x1_drs_202-finnotes01_pg5"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="block-frill" style="width: 540pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: Arial, Helvetica, sans-serif; font-size: 9pt; font-weight: bold; margin-top: 6pt; text-align: center;">Confidential Treatment Requested by ADC Therapeutics SA Pursuant to 17 C.F.R. &#167; 200.83<br></div></div><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 36pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">ADC Therapeutics SA <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;"><div class="rule-full" style="height: 0pt; width: 100%; border-bottom: 1pt solid #000000; margin-top: 1pt; margin-bottom: 1pt; margin-left: auto; margin-right: auto;"> </div>Notes to the Condensed Consolidated Interim Financial Statements (Unaudited) &#8211; in KUSD except for share and per share data<font style="padding-left: 4pt;">(continued)</font><br></div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 12pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">4.<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; text-align: left;">Financial risk management</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">4.1<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; text-align: left;">Financial risk factors</div></td></tr></table><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: left;">The Group&#8217;s activities are exposed to a variety of financial risks: market risk (including currency risk and interest rate risk), credit risk and liquidity risk.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: left;">The unaudited condensed consolidated interim financial statements do not include all financial risk management information and disclosures required in the annual financial statements, and should be read in conjunction with the Group&#8217;s consolidated financial statements as at December&#160;31, 2019.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: left;">There have been no changes in financial risk management since year-end, except with regard to the issuance of the convertible loans, as set out in note 11, &#8220;Convertible loans&#8221;, in connection with liquidity risk. Under the related agreement, the Company is subject to a covenant that requires it to maintain a balance of at least USD 50&#160;million in cash and cash equivalents at the end of each quarter.</div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 12pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">4.2<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; text-align: left;">Fair value estimation</div></td></tr></table><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: left;">At June&#160;30, 2020, the carrying amount is a reasonable approximation of fair value for the following financial assets and liabilities:</div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 40pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">Cash and cash equivalents</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 40pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">Trade accounts payable</div></td></tr></table><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: left;">In the six months ended June&#160;30, 2020, there were no significant changes in the business or economic circumstances that affected the fair value of the Group&#8217;s financial assets and financial liabilities.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: left;">Fair values have to be estimated on an ongoing basis with regard to awards under the ADC Therapeutics SA 2019 Equity Incentive Plan (the &#8220;Equity Incentive Plan 2019&#8221;), with regard to the convertible loan conversion option derivative related to the first tranche of the convertible loans and with regard to the derivative arising from the obligation related to the second tranche of the convertible loans. The approach to valuation and the key input factors are described for the share-based compensation awards in note 12, &#8220;Share-based compensation&#8221; and for the convertible loan derivatives in note 11, &#8220;Convertible loans&#8221;.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: left;">Commonly accepted pricing models (Hull and Goldman Sachs) have been used to calculate the fair value of the convertible loan derivatives. The valuation of the embedded derivative in the first tranche is classified as pertaining to level 2 of the valuation hierarchy set out below and the valuation of the derivative relating to the second tranche is classified as pertaining to level 3 of the valuation hierarchy set out below.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 20pt; text-align: left;">The different levels of the valuation hierarchy have been defined as follows:</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 20pt; text-align: left;">(a) Level 1: quoted prices (unadjusted) in active markets for identical assets or liabilities;</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: left;">(b) Level 2: inputs other than quoted prices that are observable for the asset or liability, either directly (for example, as prices) or indirectly (for example, derived from prices);</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 20pt; text-align: left;">(c) Level 3: inputs for the asset or liability that are not based on observable market data.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 20pt; text-align: left;">There were no transfers between the respective levels during the period.</div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 12pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">5.<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; text-align: left;">Segment information</div></td></tr></table><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: left;">Management considers the Group to have only a single segment: R&amp;D. This is consistent with the way that information is reported internally within the Group for the purpose of allocating resources and assessing performance.</div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 12pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">6.<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; text-align: left;">Contract Revenue</div></td></tr></table><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: left;">Contract revenue represents the amortization of upfront payments received under license and collaboration contracts in order to finance the research and development that is the subject of those contracts as well as associated milestone payments. In 2013, the Company entered into a license and joint collaboration </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 36pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">F-12<br></div></div></div>
<!--End Page 266-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 267-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 540pt;"><a name="nt10014672x1_drs_202-finnotes01_pg6"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="block-frill" style="width: 540pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: Arial, Helvetica, sans-serif; font-size: 9pt; font-weight: bold; margin-top: 6pt; text-align: center;">Confidential Treatment Requested by ADC Therapeutics SA Pursuant to 17 C.F.R. &#167; 200.83<br></div></div><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 36pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">ADC Therapeutics SA <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;"><div class="rule-full" style="height: 0pt; width: 100%; border-bottom: 1pt solid #000000; margin-top: 1pt; margin-bottom: 1pt; margin-left: auto; margin-right: auto;"> </div>Notes to the Condensed Consolidated Interim Financial Statements (Unaudited) &#8211; in KUSD except for share and per share data<font style="padding-left: 4pt;">(continued)</font><br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 7pt; margin-left: 20pt; text-align: left;">agreement which was subsequently discontinued in June 2019. As a result of the discontinuance of this joint development program, the remaining balance of the non-refundable upfront payment (consisting of deferred revenue and presented as a contract liability) received under the related license and collaboration agreement was recognized in the first half of 2019 as contract revenue and no additional contracts giving rise to current contract revenue have been entered into by the Company.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: left;">The movement in deferred contract revenue, for the three months ended June&#160;30, 2020 and 2019, previously presented under current liabilities, is shown below:</div><table cellspacing="0" cellpadding="0" class="fintab" style="margin-top: 11.25pt; border-collapse: collapse; width: 428pt; margin-left: 20pt;"><tr class="header"><td style="width: 72.9%; text-align: left; vertical-align: bottom; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 2.96%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 2.96%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td colspan="4" style="width: 21.19%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Three months ended</div></td></tr><tr class="header"><td style="width: 72.9%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">in KUSD</div></td><td class="gutter" style="width: 2.96%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 2.96%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 6.49%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2020</div></td><td class="gutter" style="width: 2.96%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 2.96%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 8.79%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2019</div></td></tr><tr><td style="width: 72.9%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">April&#160;1,<font style="padding-left: 2.57pt;"></font></div></td><td class="gutter" style="width: 2.96%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.96%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.49%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 8.89pt; text-align: left;">&#8212;</div></td><td class="gutter" style="width: 2.96%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.96%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.79%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 5.89pt; text-align: left;"><font style="padding-left: 3.33pt;">1,962</font></div></td></tr><tr><td style="width: 72.9%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Recognized as contract revenue<font style="padding-left: 0.12pt;"></font></div></td><td class="gutter" style="width: 2.96%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 2.96%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 6.49%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 8.89pt; text-align: left;"><font style="border-bottom: 1pt solid #000000; min-width: 10pt;">&#8212;</font></div></td><td class="gutter" style="width: 2.96%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 2.96%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 8.79%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 5.89pt; text-align: left;"><font style="border-bottom: 1pt solid #000000; min-width: 25.83pt;">(1,962</font><font style="min-width: 25.83pt;">)</font></div></td></tr><tr><td style="width: 72.9%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">June&#160;30,<font style="font-weight: normal; padding-left: 3.12pt;"></font></div></td><td class="gutter" style="width: 2.96%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.96%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.49%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 8.89pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 10pt;">&#8212;</font></div></td><td class="gutter" style="width: 2.96%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.96%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.79%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 5.89pt; text-align: left;"><font style="padding-left: 15.83pt; border-bottom: 3pt double #000000; min-width: 25.83pt;">&#8212;</font></div></td></tr></table><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: left;">The movement in deferred contract revenue, for the six months ended June&#160;30, 2020 and 2019, previously presented under current liabilities, is shown below:</div><table cellspacing="0" cellpadding="0" class="fintab" style="margin-top: 11.25pt; border-collapse: collapse; width: 428pt; margin-left: 20pt;"><tr class="header"><td style="width: 72.9%; text-align: left; vertical-align: bottom; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 3.52%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 3.52%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td colspan="4" style="width: 20.07%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Six months ended</div></td></tr><tr class="header"><td style="width: 72.9%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">in KUSD</div></td><td class="gutter" style="width: 3.52%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 3.52%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 5.37%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2020</div></td><td class="gutter" style="width: 3.52%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 3.52%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 7.66%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2019</div></td></tr><tr><td style="width: 72.9%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">January&#160;1,<font style="padding-left: 2.57pt;"></font></div></td><td class="gutter" style="width: 3.52%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 3.52%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.37%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 6.48pt; text-align: left;">&#8212;</div></td><td class="gutter" style="width: 3.52%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 3.52%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.66%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.49pt; text-align: left;"><font style="padding-left: 3.33pt;">2,340</font></div></td></tr><tr><td style="width: 72.9%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Recognized as contract revenue<font style="padding-left: 0.12pt;"></font></div></td><td class="gutter" style="width: 3.52%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 3.52%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 5.37%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 6.48pt; text-align: left;"><font style="border-bottom: 1pt solid #000000; min-width: 10pt;">&#8212;</font></div></td><td class="gutter" style="width: 3.52%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 3.52%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 7.66%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.49pt; text-align: left;"><font style="border-bottom: 1pt solid #000000; min-width: 25.83pt;">(2,340</font><font style="min-width: 25.83pt;">)</font></div></td></tr><tr><td style="width: 72.9%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">June&#160;30,<font style="font-weight: normal; padding-left: 3.12pt;"></font></div></td><td class="gutter" style="width: 3.52%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 3.52%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.37%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 6.48pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 10pt;">&#8212;</font></div></td><td class="gutter" style="width: 3.52%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 3.52%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.66%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.49pt; text-align: left;"><font style="padding-left: 15.83pt; border-bottom: 3pt double #000000; min-width: 25.83pt;">&#8212;</font></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 12pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">7.<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; text-align: left;">Research and development expense</div></td></tr></table><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: left;">The following table summarizes research and development expense for the three months ended June&#160;30, 2020 and 2019:</div><table cellspacing="0" cellpadding="0" class="fintab" style="margin-top: 11.25pt; border-collapse: collapse; width: 428pt; margin-left: 20pt;"><tr class="header"><td style="width: 72.9%; text-align: left; vertical-align: bottom; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 1.1%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.1%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td colspan="4" style="width: 24.9%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Three months ended June&#160;30,</div></td></tr><tr class="header"><td style="width: 72.9%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">in KUSD</div></td><td class="gutter" style="width: 1.1%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.1%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 11.35%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2020</div></td><td class="gutter" style="width: 1.1%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.1%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 11.35%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2019</div></td></tr><tr><td style="width: 72.9%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">External costs<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(1)</sup><font style="padding-left: 3.56pt;"></font></div></td><td class="gutter" style="width: 1.1%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.1%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 11.35%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10.54pt; text-align: left;">16,161</div></td><td class="gutter" style="width: 1.1%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.1%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 11.35%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10.54pt; text-align: left;">16,415</div></td></tr><tr><td style="width: 72.9%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Employee expense<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(2)</sup><font style="padding-left: 4.67pt;"></font></div></td><td class="gutter" style="width: 1.1%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.1%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 11.35%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10.54pt; text-align: left;"><font style="padding-left: 5pt; border-bottom: 1pt solid #000000; min-width: 27.5pt;">9,789</font></div></td><td class="gutter" style="width: 1.1%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.1%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 11.35%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10.54pt; text-align: left;"><font style="padding-left: 5pt; border-bottom: 1pt solid #000000; min-width: 27.5pt;">5,345</font></div></td></tr><tr><td style="width: 72.9%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Research and development expense<font style="padding-left: 4.56pt;"></font></div></td><td class="gutter" style="width: 1.1%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.1%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 11.35%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10.54pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 27.5pt;">25,950</font></div></td><td class="gutter" style="width: 1.1%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.1%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 11.35%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10.54pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 27.5pt;">21,760</font></div></td></tr></table><div><div class="rule-partial" style="height: 0pt; width: 72pt; border-bottom: 1pt solid #000000; margin-bottom: 1pt; margin-right: auto; margin-left: 20pt; margin-top: 9.25pt;"> </div></div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 3pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">(1)<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; text-align: left;">Includes depreciation expense</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 3pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">(2)<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; text-align: left;">Includes share-based compensation expense</div></td></tr></table><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: left;">The following table summarizes research and development expense for the six months ended June&#160;30, 2020 and 2019:</div><table cellspacing="0" cellpadding="0" class="fintab" style="margin-top: 11.25pt; border-collapse: collapse; width: 428pt; margin-left: 20pt;"><tr class="header"><td style="width: 72.9%; text-align: left; vertical-align: bottom; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 1.66%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.66%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td colspan="4" style="width: 23.78%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Six months ended June&#160;30,</div></td></tr><tr class="header"><td style="width: 72.9%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">in KUSD</div></td><td class="gutter" style="width: 1.66%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.66%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 10.22%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2020</div></td><td class="gutter" style="width: 1.66%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.66%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 10.22%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2019</div></td></tr><tr><td style="width: 72.9%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">External costs<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(1)</sup><font style="padding-left: 3.56pt;"></font></div></td><td class="gutter" style="width: 1.66%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.66%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.22%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 8.13pt; text-align: left;">42,300</div></td><td class="gutter" style="width: 1.66%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.66%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.22%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 8.13pt; text-align: left;">36,041</div></td></tr><tr><td style="width: 72.9%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Employee expense<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(2)</sup><font style="padding-left: 4.67pt;"></font></div></td><td class="gutter" style="width: 1.66%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.66%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 10.22%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 8.13pt; text-align: left;"><font style="border-bottom: 1pt solid #000000; min-width: 27.5pt;">19,025</font></div></td><td class="gutter" style="width: 1.66%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.66%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 10.22%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 8.13pt; text-align: left;"><font style="border-bottom: 1pt solid #000000; min-width: 27.5pt;">10,531</font></div></td></tr><tr><td style="width: 72.9%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Research and development expense<font style="padding-left: 4.56pt;"></font></div></td><td class="gutter" style="width: 1.66%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.66%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.22%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 8.13pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 27.5pt;">61,325</font></div></td><td class="gutter" style="width: 1.66%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.66%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.22%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 8.13pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 27.5pt;">46,572</font></div></td></tr></table><div><div class="rule-partial" style="height: 0pt; width: 72pt; border-bottom: 1pt solid #000000; margin-bottom: 1pt; margin-right: auto; margin-left: 20pt; margin-top: 8.75pt;"> </div></div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 3pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">(1)<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; text-align: left;">Includes depreciation expense</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 3pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">(2)<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; text-align: left;">Includes share-based compensation expense</div></td></tr></table><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: left;">The increases in employee expense in the three and six months ended June&#160;30, 2020 are due to an increased number of research and development employees and to increased share-based compensation expense.</div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 36pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">F-13<br></div></div></div>
<!--End Page 267-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 268-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 540pt;"><a name="nt10014672x1_drs_202-finnotes01_pg7"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="block-frill" style="width: 540pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: Arial, Helvetica, sans-serif; font-size: 9pt; font-weight: bold; margin-top: 6pt; text-align: center;">Confidential Treatment Requested by ADC Therapeutics SA Pursuant to 17 C.F.R. &#167; 200.83<br></div></div><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 36pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">ADC Therapeutics SA <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;"><div class="rule-full" style="height: 0pt; width: 100%; border-bottom: 1pt solid #000000; margin-top: 1pt; margin-bottom: 1pt; margin-left: auto; margin-right: auto;"> </div>Notes to the Condensed Consolidated Interim Financial Statements (Unaudited) &#8211; in KUSD except for share and per share data<font style="padding-left: 4pt;">(continued)</font><br></div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 12pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">8.<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; text-align: left;">General and administrative expense</div></td></tr></table><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: left;">The following table summarizes general and administrative expense for the three months ended June&#160;30, 2020 and 2019:</div><table cellspacing="0" cellpadding="0" class="fintab" style="margin-top: 11.25pt; border-collapse: collapse; width: 428pt; margin-left: 20pt;"><tr class="header"><td style="width: 72.9%; text-align: left; vertical-align: bottom; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 1.1%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.1%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td colspan="4" style="width: 24.9%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Three months ended June&#160;30,</div></td></tr><tr class="header"><td style="width: 72.9%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">in KUSD</div></td><td class="gutter" style="width: 1.1%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.1%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 11.93%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2020</div></td><td class="gutter" style="width: 1.1%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.1%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 10.77%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2019</div></td></tr><tr><td style="width: 72.9%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">External costs<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(1)</sup><font style="padding-left: 3.56pt;"></font></div></td><td class="gutter" style="width: 1.1%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.1%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 11.93%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 11.79pt; text-align: left;"><font style="padding-left: 5pt;">4,421</font></div></td><td class="gutter" style="width: 1.1%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.1%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.77%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 11.79pt; text-align: left;">2,843</div></td></tr><tr><td style="width: 72.9%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Employee expense<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(2)</sup><font style="padding-left: 4.67pt;"></font></div></td><td class="gutter" style="width: 1.1%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.1%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 11.93%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 11.79pt; text-align: left;"><font style="border-bottom: 1pt solid #000000; min-width: 27.5pt;">14,578</font></div></td><td class="gutter" style="width: 1.1%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.1%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 10.77%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 11.79pt; text-align: left;"><font style="border-bottom: 1pt solid #000000; min-width: 22.5pt;">1,246</font></div></td></tr><tr><td style="width: 72.9%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">General and administrative expense<font style="padding-left: 4.01pt;"></font></div></td><td class="gutter" style="width: 1.1%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.1%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 11.93%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 11.79pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 27.5pt;">18,999</font></div></td><td class="gutter" style="width: 1.1%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.1%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.77%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 11.79pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 22.5pt;">4,089</font></div></td></tr></table><div><div class="rule-partial" style="height: 0pt; width: 72pt; border-bottom: 1pt solid #000000; margin-bottom: 1pt; margin-right: auto; margin-left: 20pt; margin-top: 12.25pt;"> </div></div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 3pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">(1)<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; text-align: left;">Includes depreciation expense</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 3pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">(2)<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; text-align: left;">Includes share-based compensation expense</div></td></tr></table><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: left;">The following table summarizes general and administrative expense for the six months ended June&#160;30, 2020 and 2019:</div><table cellspacing="0" cellpadding="0" class="fintab" style="margin-top: 11.25pt; border-collapse: collapse; width: 428pt; margin-left: 20pt;"><tr class="header"><td style="width: 72.9%; text-align: left; vertical-align: bottom; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 1.66%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.66%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td colspan="4" style="width: 23.78%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Six months ended June&#160;30,</div></td></tr><tr class="header"><td style="width: 72.9%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">in KUSD</div></td><td class="gutter" style="width: 1.66%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.66%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 10.81%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2020</div></td><td class="gutter" style="width: 1.66%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.66%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 9.64%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2019</div></td></tr><tr><td style="width: 72.9%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">External costs<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(1)</sup><font style="padding-left: 3.56pt;"></font></div></td><td class="gutter" style="width: 1.66%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.66%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.81%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.38pt; text-align: left;"><font style="padding-left: 5pt;">8,401</font></div></td><td class="gutter" style="width: 1.66%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.66%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.64%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.38pt; text-align: left;">4,062</div></td></tr><tr><td style="width: 72.9%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Employee expense<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(2)</sup><font style="padding-left: 4.67pt;"></font></div></td><td class="gutter" style="width: 1.66%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.66%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 10.81%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.38pt; text-align: left;"><font style="border-bottom: 1pt solid #000000; min-width: 27.5pt;">19,108</font></div></td><td class="gutter" style="width: 1.66%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.66%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 9.64%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.38pt; text-align: left;"><font style="border-bottom: 1pt solid #000000; min-width: 22.5pt;">2,530</font></div></td></tr><tr><td style="width: 72.9%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">General and administrative expense<font style="padding-left: 4.01pt;"></font></div></td><td class="gutter" style="width: 1.66%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.66%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.81%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.38pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 27.5pt;">27,509</font></div></td><td class="gutter" style="width: 1.66%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.66%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.64%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.38pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 22.5pt;">6,592</font></div></td></tr></table><div><div class="rule-partial" style="height: 0pt; width: 72pt; border-bottom: 1pt solid #000000; margin-bottom: 1pt; margin-right: auto; margin-left: 20pt; margin-top: 12.75pt;"> </div></div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 3pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">(1)<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; text-align: left;">Includes depreciation expense</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 3pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">(2)<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; text-align: left;">Includes share-based compensation expense</div></td></tr></table><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: left;">The increase in external costs was due in particular to pre-launch commercial activities and to costs and professional fees, partially offset by savings in travel costs due to COVID-19.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: left;">The increase in employee expense was primarily due to increased share-based compensation expense and an increased number of general and administrative employees, reflecting principally the recruitment of employees for the Company&#8217;s commercial organization.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: left;">Employee expense for the three and six months ended June&#160;30, 2020 includes share-based compensation expense relating to the ADC Therapeutics Incentive Plan dated May 1, 2014 and Amended and Restated as of October 1, 2015 (the &#8220;Incentive Plan 2014&#8221;) and the ADC Therapeutics Ltd 2016 Share Purchase Plan (the &#8220;Share Purchase Plan 2016&#8221;), both of which terminated upon the effectiveness of the registration statement for the IPO, with all awards vesting as of that date and with all outstanding charges relating to those plans, which were being amortized over the vesting period, being recognized at that moment. The amounts of expense recognized for these plans in the three and six months ended June&#160;30, 2020 were KUSD 6,490 (2019: KUSD 56) and KUSD 7,548 (2019: KUSD 140).</div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 12pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">9.<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; text-align: left;">Cash and cash equivalents</div></td></tr></table><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: left;">Pursuant to the Facility Agreement entered into on April&#160;24, 2020 (see note 11, &#8220;Convertible loans&#8221;), the Company is subject to a covenant that requires it to maintain a balance of at least USD 50&#160;million in cash and cash equivalents at the end of each quarter, and such amounts are included in cash and cash equivalents on the unaudited condensed consolidated interim balance sheet.</div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 12pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">10.<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; text-align: left;">Intangible Assets</div></td></tr></table><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: left;">Licenses are amortized over their useful lives, which are determined on the basis of the expected pattern of consumption of the expected future economic benefits embodied in the licenses and which therefore commence only once the necessary regulatory and marketing approval has been received for the product </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 36pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">F-14<br></div></div></div>
<!--End Page 268-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 269-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 540pt;"><a name="nt10014672x1_drs_202-finnotes01_pg8"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="block-frill" style="width: 540pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: Arial, Helvetica, sans-serif; font-size: 9pt; font-weight: bold; margin-top: 6pt; text-align: center;">Confidential Treatment Requested by ADC Therapeutics SA Pursuant to 17 C.F.R. &#167; 200.83<br></div></div><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 36pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">ADC Therapeutics SA <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;"><div class="rule-full" style="height: 0pt; width: 100%; border-bottom: 1pt solid #000000; margin-top: 1pt; margin-bottom: 1pt; margin-left: auto; margin-right: auto;"> </div>Notes to the Condensed Consolidated Interim Financial Statements (Unaudited) &#8211; in KUSD except for share and per share data<font style="padding-left: 4pt;">(continued)</font><br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 7pt; margin-left: 20pt; text-align: left;">candidates to which they relate. To date, the Group has not received any regulatory and marketing approval for any of its product candidates. Consequently, the Group did not recognize any amortization expense of licenses.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 20pt; text-align: left;">During the six months ended June&#160;30, 2020, the Company capitalized the following license payments:</div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 40pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">An amount of KUSD 250 relating to a license agreement with a third party to acquire an antibody to be used in research, development, manufacturing and commercialization was capitalized as intangible assets.</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 40pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">An amount of KUSD 125 relating to a license agreement with a third party to use their technology to generate antibody-drug conjugates for up to five antibodies was capitalized as intangible assets.</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 12pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">11.<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; text-align: left;">Convertible Loans</div></td></tr></table><div class="h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 7pt; margin-left: 20pt; text-align: left;"><u>Facility agreement</u></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: left;">On April&#160;24, 2020, ADCT entered into a USD 115&#160;million Facility Agreement with Deerfield Partners, L.P. and certain of its affiliates (&#8220;Deerfield&#8221;). Pursuant to such agreement, Deerfield agreed to extend senior secured convertible term loans to the Company in two separate disbursements:</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: left;">(i)an initial disbursement of convertible loans in the amount of USD 65&#160;million upon the completion of the IPO, and satisfaction of certain other conditions (the &#8220;first tranche&#8221;) and</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: left;">(ii)a subsequent disbursement of convertible loans amounting to USD 50&#160;million upon the receipt of regulatory approval for a specified product candidate, loncastuximab tesirine (&#8220;Lonca&#8221; and previously known as ADCT-402), and satisfaction of certain other conditions (the &#8220;second tranche&#8221;).</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: left;">The outstanding principal amount of the convertible loans is due to be repaid in full on the fifth anniversary of the date on which the first tranche was funded being May&#160;19, 2020. However, any conversion of the convertible loans into common shares shall be deemed a repayment of the principal amount of the convertible loans so converted.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: left;">The convertible loans bear interest at a rate of 5.95% per annum, based on a 360-day year, with interest payable quarterly in arrears commencing July&#160;1, 2020.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: left;">Upon any payment of the convertible loans or conversion of the convertible notes, whether upon redemption or at maturity or at any other time, the Company will be required to pay an exit charge equal to 2.0% of the amount of the loans so paid or converted.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: left;">The Company&#8217;s obligations under the Facility Agreement are guaranteed by the Company&#8217;s wholly-owned subsidiaries and secured by a perfected, first-priority security interest in substantially all of the Company&#8217;s and its wholly-owned subsidiaries&#8217; personal property, including its intellectual property and the equity ownership interests directly and indirectly held by the Company in its wholly-owned subsidiaries.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: left;">Each convertible loan extended under the Facility Agreement is evidenced by a convertible note. The holder of each of the first tranche of convertible notes is entitled to convert the principal amount of convertible loans evidenced thereby, at its option, into the Company&#8217;s common shares at any time at a conversion price per share equal to 130% of the IPO share price, which was USD 19.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: left;">The conversion price for the second tranche of convertible notes is the lesser of (i) 150% of the IPO price and (ii) 120% of the average of the volume-weighted average prices of the Company&#8217;s common shares on each of the 15 trading days immediately prior to the disbursement date of the second tranche of convertible loans, but in no event less than a floor equal to 81% of the IPO price. If the conversion price of the second tranche of convertible notes is less than the floor price but for the application of the floor, the counterparty will not be obligated to extend the second tranche of convertible loans.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: left;">Upon the occurrence of a major transaction, as defined below, the holders of the convertible notes may elect to require the Company to redeem all or any portion of the notes for an amount equal to the principal amount thereof (in addition to accrued and unpaid interest, the make-whole amount and the exit charge) or </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 36pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">F-15<br></div></div></div>
<!--End Page 269-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 270-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 540pt;"><a name="nt10014672x1_drs_202-finnotes01_pg9"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="block-frill" style="width: 540pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: Arial, Helvetica, sans-serif; font-size: 9pt; font-weight: bold; margin-top: 6pt; text-align: center;">Confidential Treatment Requested by ADC Therapeutics SA Pursuant to 17 C.F.R. &#167; 200.83<br></div></div><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 36pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">ADC Therapeutics SA <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;"><div class="rule-full" style="height: 0pt; width: 100%; border-bottom: 1pt solid #000000; margin-top: 1pt; margin-bottom: 1pt; margin-left: auto; margin-right: auto;"> </div>Notes to the Condensed Consolidated Interim Financial Statements (Unaudited) &#8211; in KUSD except for share and per share data<font style="padding-left: 4pt;">(continued)</font><br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 7pt; margin-left: 20pt; text-align: left;">alternatively the holder may elect to require the Company to convert the unredeemed portion and, in addition, receive a number of additional common shares determined as set forth in the convertible notes (in&#160;addition to accrued and unpaid interest and the exit charge). In the case of a successor major transaction, as defined below, the Company may elect to require redemption of any portion of the convertible notes that the holder does not elect to convert in connection with such transaction.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: left;">Major transactions include (i)&#160;mergers and similar transactions as a result of which the holders of common shares before the transaction no longer hold a majority of the common shares after the transaction or the common shares are changed into the securities of another entity, (ii)&#160;sales of assets exceeding 50% of the Company&#8217;s enterprise value, (iii)&#160;any person or group acquiring beneficial ownership of more than 50% of the Company&#8217;s common shares or (iv)&#160;the delisting of the Company&#8217;s common shares, subject in each case to the more detailed provisions contained in the convertible notes. Successor major transactions include any major transaction in which the Company&#8217;s common shares are converted into the right to receive cash, securities of another entity and/or other assets, and any asset sale major transaction in which the Company distributes assets to its shareholders.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: left;">The Company will have the right to force conversions of the convertible notes on and after the one-year anniversary of the date on which it has received regulatory approval of Lonca if each of the following is greater than 275% of the conversion price (among other conditions specified in the convertible notes): (1)&#160;the volume weighted average price of the common shares on at least 20 trading days during any period of 30 consecutive trading days, (2) the volume weighted average price of the common shares on the last trading day of such period and (3) the closing price of the common shares on the last trading day of such period. The Company will have the right to force conversions of the convertible notes on and after the three-year anniversary of the date on which it has received regulatory approval of Lonca if the same conditions above are satisfied, except that the applicable price described in the preceding sentence need only be greater than 175% of the conversion price.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: left;">The Company is obligated to draw down the second tranche upon receipt of regulatory approval for Lonca. If the Company has not received the regulatory approval on or prior to December&#160;31, 2021, the second tranche will automatically terminate on such date.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: left;">The Facility Agreement contains various covenants, including a requirement to retain USD 50&#160;million in cash and cash equivalents as of the end of each fiscal quarter.</div><div class="h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 19.5pt; margin-left: 20pt; text-align: left;"><u>Bifurcation of first tranche</u></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: left;">The first tranche of convertible loans amounting to USD 65&#160;million issued on May&#160;19, 2020 has been accounted for as comprising two components: an embedded conversion option derivative and a loan, as explained in note 3, &#8220;Significant accounting policies&#8221;.</div><div class="h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 20pt; margin-left: 20pt; text-align: left;"><u>Valuation of derivative embedded in first tranche</u></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: left;">The Company has used an independent valuation firm to assist in calculating the fair value of the embedded conversion option derivative, which is based on the mean of values derived from application of the Hull and Goldman Sachs convertible bond pricing models. Key inputs for the valuations as of June&#160;30, 2020 and April&#160;24, 2020 were as follows: </div><table cellspacing="0" cellpadding="0" class="fintab" style="margin-top: 11.25pt; border-collapse: collapse; width: 428pt; margin-left: 20pt;"><tr class="header"><td style="width: 72.9%; text-align: left; vertical-align: bottom; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 1.09%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.09%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td colspan="4" style="width: 24.92%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">As of</div></td></tr><tr class="header"><td style="width: 72.9%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 1.09%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.09%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 11.16%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">June&#160;30, 2020</div></td><td class="gutter" style="width: 1.09%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.09%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 11.57%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">April&#160;24, 2020</div></td></tr><tr><td style="width: 72.9%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Exercise price, in USD<font style="padding-left: 4.82pt;"></font></div></td><td class="gutter" style="width: 1.09%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.09%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 11.16%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 12.64pt; text-align: left;">24.70</div></td><td class="gutter" style="width: 1.09%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.09%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 11.57%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 13.52pt; text-align: left;">22.10</div></td></tr><tr><td style="width: 72.9%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Forced conversion price, in USD<font style="padding-left: 4.28pt;"></font></div></td><td class="gutter" style="width: 1.09%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.09%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 11.16%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 12.64pt; text-align: left;">67.93</div></td><td class="gutter" style="width: 1.09%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.09%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 11.57%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 13.52pt; text-align: left;">60.78</div></td></tr><tr><td style="width: 72.9%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Share price in USD<font style="padding-left: 3.98pt;"></font></div></td><td class="gutter" style="width: 1.09%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.09%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 11.16%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 12.64pt; text-align: left;">46.81</div></td><td class="gutter" style="width: 1.09%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.09%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 11.57%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 13.52pt; text-align: left;">17.00</div></td></tr><tr><td style="width: 72.9%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Risk-free interest rate<font style="padding-left: 1.22pt;"></font></div></td><td class="gutter" style="width: 1.09%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.09%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 11.16%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 12.64pt; text-align: left;"><font style="padding-left: 10pt;">0.3%</font></div></td><td class="gutter" style="width: 1.09%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.09%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 11.57%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 13.52pt; text-align: left;"><font style="padding-left: 10pt;">0.4%</font></div></td></tr><tr><td style="width: 72.9%; text-align: left; vertical-align: bottom; padding-top: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Expected volatility<font style="padding-left: 2.85pt;"></font></div></td><td class="gutter" style="width: 1.09%; border-bottom: none; font-size: 2pt; padding-top: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.09%; border-bottom: none; font-size: 2pt; padding-top: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 11.16%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 12.64pt; text-align: left;"><font style="padding-left: 12.5pt;">75%</font></div></td><td class="gutter" style="width: 1.09%; border-bottom: none; font-size: 2pt; padding-top: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.09%; border-bottom: none; font-size: 2pt; padding-top: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 11.57%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 13.52pt; text-align: left;"><font style="padding-left: 12.5pt;">82%</font></div></td></tr></table></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 36pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">F-16<br></div></div></div>
<!--End Page 270-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 271-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 540pt;"><a name="nt10014672x1_drs_202-finnotes01_pg10"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="block-frill" style="width: 540pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: Arial, Helvetica, sans-serif; font-size: 9pt; font-weight: bold; margin-top: 6pt; text-align: center;">Confidential Treatment Requested by ADC Therapeutics SA Pursuant to 17 C.F.R. &#167; 200.83<br></div></div><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 36pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">ADC Therapeutics SA <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;"><div class="rule-full" style="height: 0pt; width: 100%; border-bottom: 1pt solid #000000; margin-top: 1pt; margin-bottom: 1pt; margin-left: auto; margin-right: auto;"> </div>Notes to the Condensed Consolidated Interim Financial Statements (Unaudited) &#8211; in KUSD except for share and per share data<font style="padding-left: 4pt;">(continued)</font><br></div><table cellspacing="0" cellpadding="0" class="fintab" style="border-collapse: collapse; width: 428pt; margin-left: 20pt;"><tr class="header"><td style="width: 72.9%; text-align: left; vertical-align: bottom; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 1.09%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.09%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td colspan="4" style="width: 24.92%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">As of</div></td></tr><tr class="header"><td style="width: 72.9%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 1.09%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.09%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 11.16%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">June&#160;30, 2020</div></td><td class="gutter" style="width: 1.09%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.09%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 11.57%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">April&#160;24, 2020</div></td></tr><tr><td style="width: 72.9%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Expected term<font style="padding-left: 0.63pt;"></font></div></td><td class="gutter" style="width: 1.09%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.09%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 11.16%; text-align: right; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: right;">58 months</div></td><td class="gutter" style="width: 1.09%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.09%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 11.57%; text-align: right; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: right;">61 months</div></td></tr><tr><td style="width: 72.9%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Dividend yield<font style="padding-left: 3.96pt;"></font></div></td><td class="gutter" style="width: 1.09%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.09%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 11.16%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 15.14pt; text-align: left;"><font style="padding-left: 7.5pt;">&#8212;</font></div></td><td class="gutter" style="width: 1.09%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.09%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 11.57%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 16.02pt; text-align: left;"><font style="padding-left: 7.5pt;">&#8212;</font></div></td></tr><tr><td style="width: 72.9%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Recovery rate<font style="padding-left: 2.86pt;"></font></div></td><td class="gutter" style="width: 1.09%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.09%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 11.16%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 15.14pt; text-align: left;"><font style="padding-left: 12.5pt;">5%</font></div></td><td class="gutter" style="width: 1.09%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.09%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 11.57%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 16.02pt; text-align: left;"><font style="padding-left: 12.5pt;">5%</font></div></td></tr><tr><td style="width: 72.9%; text-align: left; vertical-align: bottom; padding-top: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Implied bond yield<font style="padding-left: 1.74pt;"></font></div></td><td class="gutter" style="width: 1.09%; border-bottom: none; font-size: 2pt; padding-top: 3pt;">&#8203;</td><td class="gutter" style="width: 1.09%; border-bottom: none; font-size: 2pt; padding-top: 3pt;">&#8203;</td><td style="width: 11.16%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 15.14pt; text-align: left;">17.1%</div></td><td class="gutter" style="width: 1.09%; border-bottom: none; font-size: 2pt; padding-top: 3pt;">&#8203;</td><td class="gutter" style="width: 1.09%; border-bottom: none; font-size: 2pt; padding-top: 3pt;">&#8203;</td><td style="width: 11.57%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 16.02pt; text-align: left;">21.0%</div></td></tr></table><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 47.5pt; margin-left: 20pt; text-align: left;">On the basis of the valuation of the conversion option derivative at April&#160;24, 2020, the USD 65&#160;million amount of the convertible loans was accounted for on inception as follows:</div><table cellspacing="0" cellpadding="0" class="fintab" style="margin-top: 11.25pt; border-collapse: collapse; width: 428pt; margin-left: 20pt;"><tr class="header"><td style="width: 70.09%; text-align: left; vertical-align: bottom; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">in KUSD</div></td><td class="gutter" style="width: 1.32%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.32%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 8.62%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Embedded <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">derivative</div></td><td class="gutter" style="width: 1.32%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.32%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 6.96%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Residual<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">loan</div></td><td class="gutter" style="width: 1.32%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.32%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 6.43%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Total</div></td></tr><tr><td style="width: 70.09%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Gross proceeds<font style="padding-left: 0.31pt;"></font></div></td><td class="gutter" style="width: 1.32%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.32%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.62%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.69pt; text-align: left;">27,797</div></td><td class="gutter" style="width: 1.32%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.32%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.96%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.13pt; text-align: left;">37,203</div></td><td class="gutter" style="width: 1.32%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.32%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.43%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">65,000</div></td></tr><tr><td style="width: 70.09%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Less: transaction costs<font style="padding-left: 0.88pt;"></font></div></td><td class="gutter" style="width: 1.32%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.32%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 8.62%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.69pt; text-align: left;"><font style="padding-left: 1.67pt; border-bottom: 1pt solid #000000; min-width: 27.5pt;">(1,571</font><font style="min-width: 27.5pt;">)</font></div></td><td class="gutter" style="width: 1.32%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.32%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 6.96%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.13pt; text-align: left;"><font style="padding-left: 1.67pt; border-bottom: 1pt solid #000000; min-width: 27.5pt;">(2,102</font><font style="min-width: 27.5pt;">)</font></div></td><td class="gutter" style="width: 1.32%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.32%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 6.43%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 1.67pt; border-bottom: 1pt solid #000000; min-width: 27.5pt;">(3,673</font><font style="min-width: 27.5pt;">)</font></div></td></tr><tr><td style="width: 70.09%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Net<font style="padding-left: 3.06pt;"></font></div></td><td class="gutter" style="width: 1.32%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.32%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.62%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.69pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 27.5pt;">26,226</font></div></td><td class="gutter" style="width: 1.32%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.32%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.96%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.13pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 27.5pt;">35,101</font></div></td><td class="gutter" style="width: 1.32%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.32%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.43%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 27.5pt;">61,327</font></div></td></tr></table><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: left;">The transaction costs of the embedded derivative were charged directly to the unaudited condensed consolidated interim statement of income.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: left;">On the basis of the valuation of the conversion feature at June&#160;30, 2020, the movement in the value of the embedded derivative was:</div><table cellspacing="0" cellpadding="0" class="fintab" style="margin-top: 11.25pt; border-collapse: collapse; width: 428pt; margin-left: 20pt;"><tr class="header"><td style="width: 89.72%; text-align: left; vertical-align: bottom; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">in KUSD</div></td><td class="gutter" style="width: 1.93%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.93%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 6.43%; text-align: center; vertical-align: bottom; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td></tr><tr><td style="width: 89.72%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Liability related to embedded derivative as of April&#160;24, 2020<font style="padding-left: 1.31pt;"></font></div></td><td class="gutter" style="width: 1.93%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.93%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.43%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">27,797</div></td></tr><tr><td style="width: 89.72%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Increase in fair value of embedded derivative<font style="padding-left: 0.49pt;"></font></div></td><td class="gutter" style="width: 1.93%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.93%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 6.43%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="border-bottom: 1pt solid #000000; min-width: 27.5pt;">57,450</font></div></td></tr><tr><td style="width: 89.72%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Liability related to embedded derivative as of June&#160;30, 2020<font style="padding-left: 3.54pt;"></font></div></td><td class="gutter" style="width: 1.93%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.93%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.43%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 27.5pt;">85,247</font></div></td></tr></table><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: left;">The increase in fair value of the embedded derivative is primarily due to the increase in the fair value of the underlying shares from April&#160;24, 2020 to June&#160;30, 2020.</div><div class="h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 20.5pt; margin-left: 20pt; text-align: left;"><u>Accounting for residual loan of first tranche</u></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: left;">As illustrated in the table above and in accordance with IFRS 9, the transaction costs of the residual convertible loan (net of the value of the embedded derivative) were deducted from the loan to arrive at the deemed net present value as of May&#160;19, 2020 of all future cash outflows associated with the loan. The implied effective interest rate that would be needed to increase the book value of the loan to cover all future outflows, taking into account the deduction of transaction costs from the initial loan balance and based on a 365 day year, was computed at inception at 23% and will be applied over the life of the loan.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: left;">For both the three and six months ended June&#160;30, 2020, the Company recorded interest expense related to the interest payable on the residual convertible loan (net of the value of the embedded conversion option derivative) in the amount of KUSD 868, based on the implied effective interest rate.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: left;">The amount at which the convertible loan is presented as a liability in the unaudited condensed consolidated interim balance sheet represents the net present value of all future cash outflows associated with the loan discounted at the implied effective interest rate. The net present value of those cash outflows occurring within twelve months of the balance sheet date discounted at the same rate is presented as a short-term liability. The remainder of the amount is presented as a long-term liability.</div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 36pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">F-17<br></div></div></div>
<!--End Page 271-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 272-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 540pt;"><a name="nt10014672x1_drs_202-finnotes01_pg11"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="block-frill" style="width: 540pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: Arial, Helvetica, sans-serif; font-size: 9pt; font-weight: bold; margin-top: 6pt; text-align: center;">Confidential Treatment Requested by ADC Therapeutics SA Pursuant to 17 C.F.R. &#167; 200.83<br></div></div><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 36pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">ADC Therapeutics SA <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;"><div class="rule-full" style="height: 0pt; width: 100%; border-bottom: 1pt solid #000000; margin-top: 1pt; margin-bottom: 1pt; margin-left: auto; margin-right: auto;"> </div>Notes to the Condensed Consolidated Interim Financial Statements (Unaudited) &#8211; in KUSD except for share and per share data<font style="padding-left: 4pt;">(continued)</font><br></div><div class="h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 7pt; margin-left: 20pt; text-align: left;"><u>Accounting for second tranche</u></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: left;">The obligation to draw down the second tranche under the terms specified in the Facility Agreement has been accounted for as a derivative. The Company has used an independent valuation firm to assist in calculating the fair value of the derivative, which is based on the mean of values derived from application of the Hull and Goldman Sachs convertible bond pricing models. Key inputs for the valuation as of June&#160;30, 2020 were as follows:</div><table cellspacing="0" cellpadding="0" class="fintab" style="margin-top: 11.25pt; border-collapse: collapse; width: 437.77pt; margin-left: 20pt;"><tr class="header"><td style="width: 87.72%; text-align: left; vertical-align: bottom; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 0.69%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 0.69%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 10.91%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">As of<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">June&#160;30, 2020</div></td></tr><tr><td style="width: 87.72%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Exercise price, in USD<font style="padding-left: 1.82pt;"></font></div></td><td class="gutter" style="width: 0.69%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.69%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.91%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 12.63pt; text-align: left;">28.50</div></td></tr><tr><td style="width: 87.72%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Forced conversion price, in USD<font style="padding-left: 1.28pt;"></font></div></td><td class="gutter" style="width: 0.69%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.69%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 10.91%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 12.63pt; text-align: left;">78.38</div></td></tr><tr><td style="width: 87.72%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Share price in USD<font style="padding-left: 0.98pt;"></font></div></td><td class="gutter" style="width: 0.69%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.69%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.91%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 12.63pt; text-align: left;">46.81</div></td></tr><tr><td style="width: 87.72%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Risk-free interest rate<font style="padding-left: 3.22pt;"></font></div></td><td class="gutter" style="width: 0.69%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.69%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 10.91%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 12.63pt; text-align: left;"><font style="padding-left: 10pt;">0.3%</font></div></td></tr><tr><td style="width: 87.72%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Expected volatility<font style="padding-left: 4.85pt;"></font></div></td><td class="gutter" style="width: 0.69%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.69%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.91%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 12.63pt; text-align: left;"><font style="padding-left: 12.5pt;">75%</font></div></td></tr><tr><td style="width: 87.72%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Expected term<font style="padding-left: 2.63pt;"></font></div></td><td class="gutter" style="width: 0.69%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.69%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 10.91%; text-align: right; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: right;">11 months</div></td></tr><tr><td style="width: 87.72%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Dividend yield<font style="padding-left: 0.96pt;"></font></div></td><td class="gutter" style="width: 0.69%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.69%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.91%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 12.63pt; text-align: left;"><font style="padding-left: 12.5pt;">&#8212;</font></div></td></tr><tr><td style="width: 87.72%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Recovery rate<font style="padding-left: 4.86pt;"></font></div></td><td class="gutter" style="width: 0.69%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.69%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 10.91%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 12.63pt; text-align: left;"><font style="padding-left: 17.5pt;">5%</font></div></td></tr><tr><td style="width: 87.72%; text-align: left; vertical-align: bottom; padding-top: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Implied bond yield<font style="padding-left: 3.74pt;"></font></div></td><td class="gutter" style="width: 0.69%; border-bottom: none; font-size: 2pt; padding-top: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.69%; border-bottom: none; font-size: 2pt; padding-top: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.91%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 12.63pt; text-align: left;"><font style="padding-left: 10pt;">9.9%</font></div></td></tr></table><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: left;">In addition to the key inputs disclosed above for the second tranche, the Company estimated the probability of achieving regulatory approval for Lonca. For purposes of its June&#160;30, 2020 valuation, the Company estimated it was highly probable that it would receive regulatory approval for Lonca. Significant changes which increase or decrease the probabilities of achieving the related regulatory events, or shorten or lengthen the time required to achieve such events would result in a corresponding increase or decrease in the fair value of this derivative liability. On this basis, the fair value of the derivative has been calculated as of June&#160;30, 2020 at an amount of KUSD 21,811 and has been presented in the unaudited condensed consolidated interim balance sheet as a financial liability.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: left;">The value of the derivative is directly correlated with the estimate of probability. An increase or decrease of 10% in the estimated probability would have resulted in an increase or decrease in the value of the derivative of KUSD 2,181.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: left;">The increase in fair value of the derivative is primarily due to the increase in the fair value of the Company&#8217;s common shares from April&#160;24, 2020 to June&#160;30, 2020 and has been charged directly to the unaudited condensed consolidated interim statement of income.</div><div class="h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 20.5pt; margin-left: 20pt; text-align: left;"><u>Convertible loans, derivatives</u></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: left;">The convertible loan derivative liabilities presented in the unaudited condensed consolidated interim balance sheet comprise:</div><table cellspacing="0" cellpadding="0" class="fintab" style="margin-top: 11.25pt; border-collapse: collapse; width: 428pt; margin-left: 20pt;"><tr class="header"><td style="width: 72.9%; text-align: left; vertical-align: bottom; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 2.12%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 2.12%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td colspan="4" style="width: 22.86%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">As of</div></td></tr><tr class="header"><td style="width: 72.9%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">in KUSD</div></td><td class="gutter" style="width: 2.12%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 2.12%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 7.59%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">June&#160;30, <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2020</div></td><td class="gutter" style="width: 2.12%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 2.12%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 11.02%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">December&#160;31, <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2019</div></td></tr><tr><td style="width: 72.9%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">First tranche, embedded derivative<font style="padding-left: 3.17pt;"></font></div></td><td class="gutter" style="width: 2.12%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.12%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.59%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 5pt;">85,247</font></div></td><td class="gutter" style="width: 2.12%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.12%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 11.02%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 18.58pt; text-align: left;">&#8212;</div></td></tr><tr><td style="width: 72.9%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Second tranche, derivative<font style="padding-left: 1.49pt;"></font></div></td><td class="gutter" style="width: 2.12%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 2.12%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 7.59%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 5.37pt; border-bottom: 1pt solid #000000; min-width: 32.5pt;">21,811</font></div></td><td class="gutter" style="width: 2.12%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 2.12%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 11.02%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 18.58pt; text-align: left;"><font style="border-bottom: 1pt solid #000000; min-width: 10pt;">&#8212;</font></div></td></tr><tr><td style="width: 72.9%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 2.12%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.12%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.59%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 32.5pt;">107,058</font></div></td><td class="gutter" style="width: 2.12%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.12%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 11.02%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 18.58pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 10pt;">&#8212;</font></div></td></tr></table></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 36pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">F-18<br></div></div></div>
<!--End Page 272-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 273-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 540pt;"><a name="nt10014672x1_drs_202-finnotes01_pg12"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="block-frill" style="width: 540pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: Arial, Helvetica, sans-serif; font-size: 9pt; font-weight: bold; margin-top: 6pt; text-align: center;">Confidential Treatment Requested by ADC Therapeutics SA Pursuant to 17 C.F.R. &#167; 200.83<br></div></div><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 36pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">ADC Therapeutics SA <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;"><div class="rule-full" style="height: 0pt; width: 100%; border-bottom: 1pt solid #000000; margin-top: 1pt; margin-bottom: 1pt; margin-left: auto; margin-right: auto;"> </div>Notes to the Condensed Consolidated Interim Financial Statements (Unaudited) &#8211; in KUSD except for share and per share data<font style="padding-left: 4pt;">(continued)</font><br></div><div class="h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 7pt; margin-left: 20pt; text-align: left;"><u>Convertible loans, derivatives, increase in fair value</u></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: left;">The increase in fair value of the convertible loan derivatives presented in the unaudited condensed consolidated interim statement of income for the three and six months ended June 30 comprises:</div><table cellspacing="0" cellpadding="0" class="fintab" style="margin-top: 11.25pt; border-collapse: collapse; width: 428pt; margin-left: 20pt;"><tr class="header"><td style="width: 72.9%; text-align: left; vertical-align: bottom; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 1.35%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.35%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td colspan="4" style="width: 24.41%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Three and six months ended</div></td></tr><tr class="header"><td style="width: 72.9%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">in KUSD</div></td><td class="gutter" style="width: 1.35%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.35%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 10.86%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">June&#160;30, <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2020</div></td><td class="gutter" style="width: 1.35%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.35%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 10.86%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">June&#160;30, <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2019</div></td></tr><tr><td style="width: 72.9%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">First tranche, embedded derivative<font style="padding-left: 3.17pt;"></font></div></td><td class="gutter" style="width: 1.35%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.35%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.86%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.49pt; text-align: left;">57,450</div></td><td class="gutter" style="width: 1.35%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.35%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.86%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 18.24pt; text-align: left;">&#8212;</div></td></tr><tr><td style="width: 72.9%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Second tranche, derivative<font style="padding-left: 1.49pt;"></font></div></td><td class="gutter" style="width: 1.35%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.35%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 10.86%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.49pt; text-align: left;"><font style="padding-left: 0.37pt; border-bottom: 1pt solid #000000; min-width: 27.5pt;">21,811</font></div></td><td class="gutter" style="width: 1.35%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.35%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 10.86%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 18.24pt; text-align: left;"><font style="border-bottom: 1pt solid #000000; min-width: 10pt;">&#8212;</font></div></td></tr><tr><td style="width: 72.9%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.35%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.35%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.86%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.49pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 27.5pt;">79,261</font></div></td><td class="gutter" style="width: 1.35%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.35%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.86%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 18.24pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 10pt;">&#8212;</font></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 12pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">12.<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; text-align: left;">Share-based compensation</div></td></tr></table><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: left;">Share data have been revised to give effect to the share split and share consolidation as explained in note 2, &#8220;Share split and share consolidation&#8221;.</div><div class="h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 17.5pt; margin-left: 20pt; text-align: left;"><u>Share Purchase Plan 2013 and Share Purchase Plan 2016</u></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: left;">Under the terms of the 2013 and 2016 promissory notes issued in connection with the share purchase plans, in the case of an IPO the relevant plan participants were required to repay the outstanding amounts under the promissory notes prior to the IPO by delivering such number of shares of equivalent value to cover the amount to be repaid. In anticipation of the IPO, each of the plan participants holding promissory notes entered into loan settlement agreements with the Company dated as of April&#160;15, 2020 pursuant to which they repaid all amounts outstanding under the promissory notes, including accrued interest, by delivering such number of shares of equivalent value to cover the amount outstanding under the promissory notes.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: left;">After consideration of all relevant factors, the Board of Directors determined the value of such shares delivered pursuant to the loan settlement agreements as of the settlement date to be USD 18.75 per share, resulting in the delivery of an aggregate of 597,774 common shares by all plan participants for the settlement of the promissory notes. These shares were held by the Company as treasury shares.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: left;">These transactions resulted in the termination of both plans on May&#160;15, 2020. All compensation expense relating to the ADC Therapeutics Ltd 2013 Share Purchase Plan (the &#8220;Share Purchase Plan 2013&#8221;) was recognized in prior periods. Unrecognized expense relating to the Share Purchase Plan 2016 amounting to KUSD 6,425 was charged to the unaudited condensed consolidated interim statement of income and credited to &#8220;Other reserves&#8221; on completion of these transactions.</div><div class="h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 17.5pt; margin-left: 20pt; text-align: left;"><u>Incentive Plan 2014</u></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: left;">All existing awards under the Incentive Plan 2014 vested and were settled in shares upon the completion of the IPO. The Company calculated for each participant the gain arising from the difference between the exercise price and the USD 19 IPO price, undertook to settle in cash on behalf of the participant any associated tax and social charges liability, and transferred to the participant the remaining balance in treasury shares, valued at USD 19 per share. A total of 356,144 shares were transferred to participants and an amount of KUSD 5,343 was withheld for tax and social charges.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: left;">For participants whose awards had an exercise price greater than USD 19 &#8212; i.e., were &#8220;out-of-the-money&#8221; &#8212; the Company made an equal number of new awards under the Equity Incentive Plan 2019 (see below) with an exercise price of USD 19 and with a vesting period of only three years instead of the usual four years. These new awards have been accounted for as a modification of the previous awards under the Incentive Plan 2014. Accordingly, the original compensation expense calculated for the old awards that were &#8220;out-of-the-money&#8221; will continue to be recognized over their remaining vesting period while the expense to be recognized for the new awards under the Equity Incentive Plan 2019 will be limited to the incremental fair value of the new awards over the fair value, as of May&#160;15, 2020, of the old awards.</div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 36pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">F-19<br></div></div></div>
<!--End Page 273-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 274-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 540pt;"><a name="nt10014672x1_drs_202-finnotes01_pg13"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="block-frill" style="width: 540pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: Arial, Helvetica, sans-serif; font-size: 9pt; font-weight: bold; margin-top: 6pt; text-align: center;">Confidential Treatment Requested by ADC Therapeutics SA Pursuant to 17 C.F.R. &#167; 200.83<br></div></div><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 36pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">ADC Therapeutics SA <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;"><div class="rule-full" style="height: 0pt; width: 100%; border-bottom: 1pt solid #000000; margin-top: 1pt; margin-bottom: 1pt; margin-left: auto; margin-right: auto;"> </div>Notes to the Condensed Consolidated Interim Financial Statements (Unaudited) &#8211; in KUSD except for share and per share data<font style="padding-left: 4pt;">(continued)</font><br></div><div class="h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 7pt; margin-left: 20pt; text-align: left;"><u>Equity Incentive Plan 2019</u></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: left;">The cumulative amount credited to &#8220;Other reserves&#8221; in respect of the Equity Incentive Plan 2019 is KUSD&#160;9,094 as of June&#160;30, 2020. The amounts of expense recognized for services received during the three and six months ended June&#160;30, 2020 are KUSD 6,130 and KUSD 8,746, respectively. </div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 20pt; text-align: left;">The following table summarizes the awards outstanding as of June&#160;30, 2020:</div><table cellspacing="0" cellpadding="0" class="fintab" style="margin-top: 11.25pt; border-collapse: collapse; width: 428pt; margin-left: 20pt;"><tr class="header"><td style="width: 56.07%; text-align: left; vertical-align: bottom; padding-top: 6pt; padding-bottom: 3.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 1.31%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 3.5pt;">&#8203;</td><td class="gutter" style="width: 1.31%; font-size: 2pt; padding-top: 6pt; padding-bottom: 3.5pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 12.29%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 3.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Average strike <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">price per share <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">in USD</div></td><td class="gutter" style="width: 1.31%; font-size: 2pt; padding-top: 6pt; padding-bottom: 3.5pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.31%; font-size: 2pt; padding-top: 6pt; padding-bottom: 3.5pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 9.35%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 3.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Number of <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">awards</div></td><td class="gutter" style="width: 1.31%; font-size: 2pt; padding-top: 6pt; padding-bottom: 3.5pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.31%; font-size: 2pt; padding-top: 6pt; padding-bottom: 3.5pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 14.43%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 3.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Weighted average <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">remaining life in <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">years</div></td></tr><tr><td style="width: 56.07%; text-align: left; vertical-align: bottom; padding-top: 3.5pt; padding-bottom: 2.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">December&#160;31, 2019<font style="font-weight: normal; padding-left: 0.21pt;"></font></div></td><td class="gutter" style="width: 1.31%; border-bottom: none; font-size: 2pt; padding-top: 3.5pt; padding-bottom: 2.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.31%; border-bottom: none; font-size: 2pt; padding-top: 3.5pt; padding-bottom: 2.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 12.29%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3.5pt; padding-bottom: 2.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 15.04pt; text-align: left;">18.75</div></td><td class="gutter" style="width: 1.31%; border-bottom: none; font-size: 2pt; padding-top: 3.5pt; padding-bottom: 2.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.31%; border-bottom: none; font-size: 2pt; padding-top: 3.5pt; padding-bottom: 2.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.35%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3.5pt; padding-bottom: 2.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">1,020,434</div></td><td class="gutter" style="width: 1.31%; border-bottom: none; font-size: 2pt; padding-top: 3.5pt; padding-bottom: 2.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.31%; border-bottom: none; font-size: 2pt; padding-top: 3.5pt; padding-bottom: 2.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 14.43%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3.5pt; padding-bottom: 2.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 22.13pt; text-align: left;">9.96</div></td></tr><tr><td style="width: 56.07%; text-align: left; vertical-align: bottom; padding-top: 2.25pt; padding-bottom: 2.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Granted<font style="padding-left: 0.29pt;"></font></div></td><td class="gutter" style="width: 1.31%; border-bottom: none; font-size: 2pt; padding-top: 2.25pt; padding-bottom: 2.25pt;">&#8203;</td><td class="gutter" style="width: 1.31%; border-bottom: none; font-size: 2pt; padding-top: 2.25pt; padding-bottom: 2.25pt;">&#8203;</td><td style="width: 12.29%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 2.25pt; padding-bottom: 2.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 15.04pt; text-align: left;">21.26</div></td><td class="gutter" style="width: 1.31%; border-bottom: none; font-size: 2pt; padding-top: 2.25pt; padding-bottom: 2.25pt;">&#8203;</td><td class="gutter" style="width: 1.31%; border-bottom: none; font-size: 2pt; padding-top: 2.25pt; padding-bottom: 2.25pt;">&#8203;</td><td style="width: 9.35%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.25pt; padding-bottom: 2.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">2,247,074</div></td><td class="gutter" style="width: 1.31%; border-bottom: none; font-size: 2pt; padding-top: 2.25pt; padding-bottom: 2.25pt;">&#8203;</td><td class="gutter" style="width: 1.31%; border-bottom: none; font-size: 2pt; padding-top: 2.25pt; padding-bottom: 2.25pt;">&#8203;</td><td style="width: 14.43%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 2.25pt; padding-bottom: 2.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 22.13pt; text-align: left;">9.76</div></td></tr><tr><td style="width: 56.07%; text-align: left; vertical-align: bottom; padding-top: 2.25pt; padding-bottom: 3.5pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Forfeited<font style="padding-left: 0.85pt;"></font></div></td><td class="gutter" style="width: 1.31%; border-bottom: none; font-size: 2pt; padding-top: 2.25pt; padding-bottom: 3.5pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.31%; border-bottom: none; font-size: 2pt; padding-top: 2.25pt; padding-bottom: 3.5pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 12.29%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 2.25pt; padding-bottom: 3.5pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 15.04pt; text-align: left;"><font style="border-bottom: 1pt solid #000000; min-width: 22.5pt;">18.83</font></div></td><td class="gutter" style="width: 1.31%; border-bottom: none; font-size: 2pt; padding-top: 2.25pt; padding-bottom: 3.5pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.31%; border-bottom: none; font-size: 2pt; padding-top: 2.25pt; padding-bottom: 3.5pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.35%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.25pt; padding-bottom: 3.5pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 9.17pt; border-bottom: 1pt solid #000000; min-width: 40pt;">(19,985</font><font style="min-width: 40pt;">)</font></div></td><td class="gutter" style="width: 1.31%; border-bottom: none; font-size: 2pt; padding-top: 2.25pt; padding-bottom: 3.5pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.31%; border-bottom: none; font-size: 2pt; padding-top: 2.25pt; padding-bottom: 3.5pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 14.43%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 2.25pt; padding-bottom: 3.5pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 22.13pt; text-align: left;"><font style="padding-left: 7.5pt; border-bottom: 1pt solid #000000; min-width: 17.5pt;">&#8212;</font></div></td></tr><tr><td style="width: 56.07%; text-align: left; vertical-align: bottom; padding-top: 3.5pt; padding-bottom: 6pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">June&#160;30, 2020<font style="font-weight: normal; padding-left: 2.79pt;"></font></div></td><td class="gutter" style="width: 1.31%; border-bottom: none; font-size: 2pt; padding-top: 3.5pt; padding-bottom: 6pt;">&#8203;</td><td class="gutter" style="width: 1.31%; border-bottom: none; font-size: 2pt; padding-top: 3.5pt; padding-bottom: 6pt;">&#8203;</td><td style="width: 12.29%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3.5pt; padding-bottom: 6pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 15.04pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 22.5pt;">20.55</font></div></td><td class="gutter" style="width: 1.31%; border-bottom: none; font-size: 2pt; padding-top: 3.5pt; padding-bottom: 6pt;">&#8203;</td><td class="gutter" style="width: 1.31%; border-bottom: none; font-size: 2pt; padding-top: 3.5pt; padding-bottom: 6pt;">&#8203;</td><td style="width: 9.35%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3.5pt; padding-bottom: 6pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 40pt;">3,247,523</font></div></td><td class="gutter" style="width: 1.31%; border-bottom: none; font-size: 2pt; padding-top: 3.5pt; padding-bottom: 6pt;">&#8203;</td><td class="gutter" style="width: 1.31%; border-bottom: none; font-size: 2pt; padding-top: 3.5pt; padding-bottom: 6pt;">&#8203;</td><td style="width: 14.43%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3.5pt; padding-bottom: 6pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 22.13pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 17.5pt;">9.69</font></div></td></tr></table><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: left;">The awards granted during the six months ended June&#160;30, 2020 include 388,333 awards that were made to compensate holders of &#8220;out-of-the-money&#8221; awards under the Incentive Plan 2014 that expired on May&#160;15, 2020. Awards outstanding as of June&#160;30, 2020 and December&#160;31, 2019, expire in 2029. There were no awards exercised during the six months ended June&#160;30, 2020.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: left;">The fair values of the options granted during the three and six months ended June&#160;30, 2020 and 2019 were determined on the date of the grant using the Black-Scholes option-pricing model with the following assumptions:</div><table cellspacing="0" cellpadding="0" class="fintab" style="margin-top: 11.25pt; border-collapse: collapse; width: 428pt; margin-left: 20pt;"><tr class="header"><td style="width: 39.25%; text-align: left; vertical-align: bottom; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 1.01%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.01%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td colspan="4" style="width: 28.36%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Three Months Ended</div></td><td class="gutter" style="width: 1.01%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.01%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td colspan="4" style="width: 28.36%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Six Months Ended</div></td></tr><tr class="header"><td style="width: 39.25%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 1.01%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.01%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 15.18%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">June&#160;30, 2020</div></td><td class="gutter" style="width: 1.01%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.01%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 11.16%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">June&#160;30, 2019</div></td><td class="gutter" style="width: 1.01%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.01%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 15.18%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">June&#160;30, 2020</div></td><td class="gutter" style="width: 1.01%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.01%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 11.16%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">June&#160;30, 2019</div></td></tr><tr><td style="width: 39.25%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Weighted average share price<font style="padding-left: 0.26pt;"></font></div></td><td class="gutter" style="width: 1.01%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.01%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 15.18%; text-align: center; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">$15.95 - $34.99</div></td><td class="gutter" style="width: 1.01%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.01%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 11.16%; text-align: center; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">&#8212;</div></td><td class="gutter" style="width: 1.01%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.01%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 15.18%; text-align: center; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">$15.95 - $34.99</div></td><td class="gutter" style="width: 1.01%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.01%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 11.16%; text-align: center; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">&#8212;</div></td></tr><tr><td style="width: 39.25%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Strike price<font style="padding-left: 3.3pt;"></font></div></td><td class="gutter" style="width: 1.01%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.01%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 15.18%; text-align: center; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">$18.75 - $34.99</div></td><td class="gutter" style="width: 1.01%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.01%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 11.16%; text-align: center; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">&#8212;</div></td><td class="gutter" style="width: 1.01%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.01%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 15.18%; text-align: center; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">$18.75 - $34.99</div></td><td class="gutter" style="width: 1.01%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.01%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 11.16%; text-align: center; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">&#8212;</div></td></tr><tr><td style="width: 39.25%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Expected volatility<font style="padding-left: 3.85pt;"></font></div></td><td class="gutter" style="width: 1.01%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.01%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 15.18%; text-align: center; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">85% - 206%</div></td><td class="gutter" style="width: 1.01%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.01%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 11.16%; text-align: center; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">&#8212;</div></td><td class="gutter" style="width: 1.01%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.01%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 15.18%; text-align: center; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">85% - 206%</div></td><td class="gutter" style="width: 1.01%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.01%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 11.16%; text-align: center; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">&#8212;</div></td></tr><tr><td style="width: 39.25%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Award life<font style="padding-left: 2.55pt;"></font></div></td><td class="gutter" style="width: 1.01%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.01%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 15.18%; text-align: center; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">$5.02 - $5.85</div></td><td class="gutter" style="width: 1.01%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.01%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 11.16%; text-align: center; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">&#8212;</div></td><td class="gutter" style="width: 1.01%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.01%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 15.18%; text-align: center; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">$5.02 - $5.85</div></td><td class="gutter" style="width: 1.01%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.01%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 11.16%; text-align: center; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">&#8212;</div></td></tr><tr><td style="width: 39.25%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Expected dividends<font style="padding-left: 1.08pt;"></font></div></td><td class="gutter" style="width: 1.01%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.01%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 15.18%; text-align: center; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">0%</div></td><td class="gutter" style="width: 1.01%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.01%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 11.16%; text-align: center; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">&#8212;</div></td><td class="gutter" style="width: 1.01%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.01%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 15.18%; text-align: center; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">0%</div></td><td class="gutter" style="width: 1.01%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.01%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 11.16%; text-align: center; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">&#8212;</div></td></tr><tr><td style="width: 39.25%; text-align: left; vertical-align: bottom; padding-top: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Risk-free interest rate<font style="padding-left: 2.22pt;"></font></div></td><td class="gutter" style="width: 1.01%; border-bottom: none; font-size: 2pt; padding-top: 3pt;">&#8203;</td><td class="gutter" style="width: 1.01%; border-bottom: none; font-size: 2pt; padding-top: 3pt;">&#8203;</td><td style="width: 15.18%; text-align: center; vertical-align: bottom; padding-top: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">0.36% - 0.47%</div></td><td class="gutter" style="width: 1.01%; border-bottom: none; font-size: 2pt; padding-top: 3pt;">&#8203;</td><td class="gutter" style="width: 1.01%; border-bottom: none; font-size: 2pt; padding-top: 3pt;">&#8203;</td><td style="width: 11.16%; text-align: center; vertical-align: bottom; padding-top: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">&#8212;</div></td><td class="gutter" style="width: 1.01%; border-bottom: none; font-size: 2pt; padding-top: 3pt;">&#8203;</td><td class="gutter" style="width: 1.01%; border-bottom: none; font-size: 2pt; padding-top: 3pt;">&#8203;</td><td style="width: 15.18%; text-align: center; vertical-align: bottom; padding-top: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">0.36% - 0.70%</div></td><td class="gutter" style="width: 1.01%; border-bottom: none; font-size: 2pt; padding-top: 3pt;">&#8203;</td><td class="gutter" style="width: 1.01%; border-bottom: none; font-size: 2pt; padding-top: 3pt;">&#8203;</td><td style="width: 11.16%; text-align: center; vertical-align: bottom; padding-top: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">&#8212;</div></td></tr></table><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: left;">The Company has used an independent valuation firm to assist in calculating the fair value of the award grants per participant.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: left;">The expected volatility was based on historical volatility and selected volatility was based on median values observed among comparable public companies.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: left;">The award life is based on the time interval between the date of grant and the date during the ten-year life after which, when making the grant, the Company expected on average that participants would exercise their options.</div><div class="h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 14.5pt; margin-left: 20pt; text-align: left;"><u>Share-based Compensation Reserves</u></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 7pt; margin-left: 20pt; text-align: left;">The movement in the Share-based Compensation Reserves (included in &#8220;Other reserves&#8221;) is as follows:</div><table cellspacing="0" cellpadding="0" class="fintab" style="margin-top: 11.25pt; border-collapse: collapse; width: 428pt; margin-left: 20pt;"><tr class="header"><td style="width: 44.86%; text-align: left; vertical-align: bottom; padding-top: 6pt; padding-bottom: 3.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 1.31%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 3.5pt;">&#8203;</td><td class="gutter" style="width: 1.31%; font-size: 2pt; padding-top: 6pt; padding-bottom: 3.5pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td colspan="4" style="width: 24.95%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 3.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Three months ended</div></td><td class="gutter" style="width: 1.31%; font-size: 2pt; padding-top: 6pt; padding-bottom: 3.5pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.31%; font-size: 2pt; padding-top: 6pt; padding-bottom: 3.5pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td colspan="4" style="width: 24.95%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 3.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Six months ended</div></td></tr><tr class="header"><td style="width: 44.86%; text-align: left; vertical-align: bottom; padding-top: 3.5pt; padding-bottom: 3.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">in KUSD</div></td><td class="gutter" style="width: 1.31%; border-bottom: none; font-size: 2pt; padding-top: 3.5pt; padding-bottom: 3.5pt;">&#8203;</td><td class="gutter" style="width: 1.31%; font-size: 2pt; padding-top: 3.5pt; padding-bottom: 3.5pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 11.16%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 3.5pt; padding-bottom: 3.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">June&#160;30, 2020</div></td><td class="gutter" style="width: 1.31%; font-size: 2pt; padding-top: 3.5pt; padding-bottom: 3.5pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.31%; font-size: 2pt; padding-top: 3.5pt; padding-bottom: 3.5pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 11.16%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 3.5pt; padding-bottom: 3.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">June&#160;30, 2019</div></td><td class="gutter" style="width: 1.31%; font-size: 2pt; padding-top: 3.5pt; padding-bottom: 3.5pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.31%; font-size: 2pt; padding-top: 3.5pt; padding-bottom: 3.5pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 11.16%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 3.5pt; padding-bottom: 3.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">June&#160;30, 2020</div></td><td class="gutter" style="width: 1.31%; font-size: 2pt; padding-top: 3.5pt; padding-bottom: 3.5pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.31%; font-size: 2pt; padding-top: 3.5pt; padding-bottom: 3.5pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 11.16%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 3.5pt; padding-bottom: 3.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">June&#160;30, 2019</div></td></tr><tr><td style="width: 44.86%; text-align: left; vertical-align: bottom; padding-top: 3.5pt; padding-bottom: 2.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Share Purchase Plan 2013<font style="padding-left: 2.88pt;"></font></div></td><td class="gutter" style="width: 1.31%; border-bottom: none; font-size: 2pt; padding-top: 3.5pt; padding-bottom: 2.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.31%; border-bottom: none; font-size: 2pt; padding-top: 3.5pt; padding-bottom: 2.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 11.16%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3.5pt; padding-bottom: 2.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10.97pt; text-align: left;"><font style="padding-left: 15.83pt;">&#8212;</font></div></td><td class="gutter" style="width: 1.31%; border-bottom: none; font-size: 2pt; padding-top: 3.5pt; padding-bottom: 2.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.31%; border-bottom: none; font-size: 2pt; padding-top: 3.5pt; padding-bottom: 2.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 11.16%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3.5pt; padding-bottom: 2.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 18.89pt; text-align: left;">&#8212;</div></td><td class="gutter" style="width: 1.31%; border-bottom: none; font-size: 2pt; padding-top: 3.5pt; padding-bottom: 2.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.31%; border-bottom: none; font-size: 2pt; padding-top: 3.5pt; padding-bottom: 2.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 11.16%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3.5pt; padding-bottom: 2.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10.32pt; text-align: left;"><font style="padding-left: 17.13pt;">&#8212;</font></div></td><td class="gutter" style="width: 1.31%; border-bottom: none; font-size: 2pt; padding-top: 3.5pt; padding-bottom: 2.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.31%; border-bottom: none; font-size: 2pt; padding-top: 3.5pt; padding-bottom: 2.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 11.16%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3.5pt; padding-bottom: 2.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 16.39pt; text-align: left;"><font style="padding-left: 5pt;">&#8212;</font></div></td></tr><tr><td style="width: 44.86%; text-align: left; vertical-align: bottom; padding-top: 2.25pt; padding-bottom: 2.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Incentive Plan 2014<font style="padding-left: 2.86pt;"></font></div></td><td class="gutter" style="width: 1.31%; border-bottom: none; font-size: 2pt; padding-top: 2.25pt; padding-bottom: 2.25pt;">&#8203;</td><td class="gutter" style="width: 1.31%; border-bottom: none; font-size: 2pt; padding-top: 2.25pt; padding-bottom: 2.25pt;">&#8203;</td><td style="width: 11.16%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.25pt; padding-bottom: 2.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10.97pt; text-align: left;"><font style="padding-left: 10.83pt;">179</font></div></td><td class="gutter" style="width: 1.31%; border-bottom: none; font-size: 2pt; padding-top: 2.25pt; padding-bottom: 2.25pt;">&#8203;</td><td class="gutter" style="width: 1.31%; border-bottom: none; font-size: 2pt; padding-top: 2.25pt; padding-bottom: 2.25pt;">&#8203;</td><td style="width: 11.16%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 2.25pt; padding-bottom: 2.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 18.89pt; text-align: left;">10</div></td><td class="gutter" style="width: 1.31%; border-bottom: none; font-size: 2pt; padding-top: 2.25pt; padding-bottom: 2.25pt;">&#8203;</td><td class="gutter" style="width: 1.31%; border-bottom: none; font-size: 2pt; padding-top: 2.25pt; padding-bottom: 2.25pt;">&#8203;</td><td style="width: 11.16%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.25pt; padding-bottom: 2.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10.32pt; text-align: left;"><font style="padding-left: 12.13pt;">361</font></div></td><td class="gutter" style="width: 1.31%; border-bottom: none; font-size: 2pt; padding-top: 2.25pt; padding-bottom: 2.25pt;">&#8203;</td><td class="gutter" style="width: 1.31%; border-bottom: none; font-size: 2pt; padding-top: 2.25pt; padding-bottom: 2.25pt;">&#8203;</td><td style="width: 11.16%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 2.25pt; padding-bottom: 2.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 16.39pt; text-align: left;"><font style="padding-left: 5pt;">23</font></div></td></tr><tr><td style="width: 44.86%; text-align: left; vertical-align: bottom; padding-top: 2.25pt; padding-bottom: 2.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Share Purchase Plan 2016<font style="padding-left: 2.88pt;"></font></div></td><td class="gutter" style="width: 1.31%; border-bottom: none; font-size: 2pt; padding-top: 2.25pt; padding-bottom: 2.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.31%; border-bottom: none; font-size: 2pt; padding-top: 2.25pt; padding-bottom: 2.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 11.16%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.25pt; padding-bottom: 2.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10.97pt; text-align: left;"><font style="padding-left: 3.33pt;">6,425</font></div></td><td class="gutter" style="width: 1.31%; border-bottom: none; font-size: 2pt; padding-top: 2.25pt; padding-bottom: 2.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.31%; border-bottom: none; font-size: 2pt; padding-top: 2.25pt; padding-bottom: 2.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 11.16%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 2.25pt; padding-bottom: 2.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 18.89pt; text-align: left;">46</div></td><td class="gutter" style="width: 1.31%; border-bottom: none; font-size: 2pt; padding-top: 2.25pt; padding-bottom: 2.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.31%; border-bottom: none; font-size: 2pt; padding-top: 2.25pt; padding-bottom: 2.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 11.16%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.25pt; padding-bottom: 2.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10.32pt; text-align: left;"><font style="padding-left: 4.63pt;">7,417</font></div></td><td class="gutter" style="width: 1.31%; border-bottom: none; font-size: 2pt; padding-top: 2.25pt; padding-bottom: 2.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.31%; border-bottom: none; font-size: 2pt; padding-top: 2.25pt; padding-bottom: 2.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 11.16%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 2.25pt; padding-bottom: 2.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 16.39pt; text-align: left;"><font style="padding-left: 0.37pt;">117</font></div></td></tr><tr><td style="width: 44.86%; text-align: left; vertical-align: bottom; padding-top: 2.25pt; padding-bottom: 2.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Equity Incentive Plan 2019<font style="padding-left: 2.86pt;"></font></div></td><td class="gutter" style="width: 1.31%; border-bottom: none; font-size: 2pt; padding-top: 2.25pt; padding-bottom: 2.25pt;">&#8203;</td><td class="gutter" style="width: 1.31%; border-bottom: none; font-size: 2pt; padding-top: 2.25pt; padding-bottom: 2.25pt;">&#8203;</td><td style="width: 11.16%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.25pt; padding-bottom: 2.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10.97pt; text-align: left;"><font style="padding-left: 3.33pt;">6,130</font></div></td><td class="gutter" style="width: 1.31%; border-bottom: none; font-size: 2pt; padding-top: 2.25pt; padding-bottom: 2.25pt;">&#8203;</td><td class="gutter" style="width: 1.31%; border-bottom: none; font-size: 2pt; padding-top: 2.25pt; padding-bottom: 2.25pt;">&#8203;</td><td style="width: 11.16%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 2.25pt; padding-bottom: 2.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 18.89pt; text-align: left;">&#8212;</div></td><td class="gutter" style="width: 1.31%; border-bottom: none; font-size: 2pt; padding-top: 2.25pt; padding-bottom: 2.25pt;">&#8203;</td><td class="gutter" style="width: 1.31%; border-bottom: none; font-size: 2pt; padding-top: 2.25pt; padding-bottom: 2.25pt;">&#8203;</td><td style="width: 11.16%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.25pt; padding-bottom: 2.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10.32pt; text-align: left;"><font style="padding-left: 4.63pt;">8,746</font></div></td><td class="gutter" style="width: 1.31%; border-bottom: none; font-size: 2pt; padding-top: 2.25pt; padding-bottom: 2.25pt;">&#8203;</td><td class="gutter" style="width: 1.31%; border-bottom: none; font-size: 2pt; padding-top: 2.25pt; padding-bottom: 2.25pt;">&#8203;</td><td style="width: 11.16%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 2.25pt; padding-bottom: 2.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 16.39pt; text-align: left;"><font style="padding-left: 5pt;">&#8212;</font></div></td></tr><tr><td style="width: 44.86%; text-align: left; vertical-align: bottom; padding-top: 2.25pt; padding-bottom: 3.5pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-indent: -10pt; text-align: left;">Tax and social charge deductions - Incentive Plan 2014<font style="padding-left: 3.39pt;"></font></div></td><td class="gutter" style="width: 1.31%; border-bottom: none; font-size: 2pt; padding-top: 2.25pt; padding-bottom: 3.5pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.31%; border-bottom: none; font-size: 2pt; padding-top: 2.25pt; padding-bottom: 3.5pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 11.16%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.25pt; padding-bottom: 3.5pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10.97pt; text-align: left;"><font style="border-bottom: 1pt solid #000000; min-width: 25.83pt;">(5,343</font><font style="min-width: 25.83pt;">)</font></div></td><td class="gutter" style="width: 1.31%; border-bottom: none; font-size: 2pt; padding-top: 2.25pt; padding-bottom: 3.5pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.31%; border-bottom: none; font-size: 2pt; padding-top: 2.25pt; padding-bottom: 3.5pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 11.16%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 2.25pt; padding-bottom: 3.5pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 18.89pt; text-align: left;"><font style="border-bottom: 1pt solid #000000; min-width: 10pt;">&#8212;</font></div></td><td class="gutter" style="width: 1.31%; border-bottom: none; font-size: 2pt; padding-top: 2.25pt; padding-bottom: 3.5pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.31%; border-bottom: none; font-size: 2pt; padding-top: 2.25pt; padding-bottom: 3.5pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 11.16%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.25pt; padding-bottom: 3.5pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10.32pt; text-align: left;"><font style="padding-left: 1.3pt; border-bottom: 1pt solid #000000; min-width: 27.13pt;">(5,343</font><font style="min-width: 27.13pt;">)</font></div></td><td class="gutter" style="width: 1.31%; border-bottom: none; font-size: 2pt; padding-top: 2.25pt; padding-bottom: 3.5pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.31%; border-bottom: none; font-size: 2pt; padding-top: 2.25pt; padding-bottom: 3.5pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 11.16%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 2.25pt; padding-bottom: 3.5pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 16.39pt; text-align: left;"><font style="padding-left: 5pt; border-bottom: 1pt solid #000000; min-width: 15pt;">&#8212;</font></div></td></tr><tr><td style="width: 44.86%; text-align: left; vertical-align: bottom; padding-top: 3.5pt; padding-bottom: 6pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Total<font style="font-weight: normal; padding-left: 2.64pt;"></font></div></td><td class="gutter" style="width: 1.31%; border-bottom: none; font-size: 2pt; padding-top: 3.5pt; padding-bottom: 6pt;">&#8203;</td><td class="gutter" style="width: 1.31%; border-bottom: none; font-size: 2pt; padding-top: 3.5pt; padding-bottom: 6pt;">&#8203;</td><td style="width: 11.16%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3.5pt; padding-bottom: 6pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10.97pt; text-align: left;"><font style="padding-left: 3.33pt; border-bottom: 3pt double #000000; min-width: 25.83pt;">7,391</font></div></td><td class="gutter" style="width: 1.31%; border-bottom: none; font-size: 2pt; padding-top: 3.5pt; padding-bottom: 6pt;">&#8203;</td><td class="gutter" style="width: 1.31%; border-bottom: none; font-size: 2pt; padding-top: 3.5pt; padding-bottom: 6pt;">&#8203;</td><td style="width: 11.16%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3.5pt; padding-bottom: 6pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 18.89pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 10pt;">56</font></div></td><td class="gutter" style="width: 1.31%; border-bottom: none; font-size: 2pt; padding-top: 3.5pt; padding-bottom: 6pt;">&#8203;</td><td class="gutter" style="width: 1.31%; border-bottom: none; font-size: 2pt; padding-top: 3.5pt; padding-bottom: 6pt;">&#8203;</td><td style="width: 11.16%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3.5pt; padding-bottom: 6pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10.32pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 27.13pt;">11,181</font></div></td><td class="gutter" style="width: 1.31%; border-bottom: none; font-size: 2pt; padding-top: 3.5pt; padding-bottom: 6pt;">&#8203;</td><td class="gutter" style="width: 1.31%; border-bottom: none; font-size: 2pt; padding-top: 3.5pt; padding-bottom: 6pt;">&#8203;</td><td style="width: 11.16%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3.5pt; padding-bottom: 6pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 16.39pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 15pt;">140</font></div></td></tr></table></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 36pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">F-20<br></div></div></div>
<!--End Page 274-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 275-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 540pt;"><a name="nt10014672x1_drs_202-finnotes01_pg14"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="block-frill" style="width: 540pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: Arial, Helvetica, sans-serif; font-size: 9pt; font-weight: bold; margin-top: 6pt; text-align: center;">Confidential Treatment Requested by ADC Therapeutics SA Pursuant to 17 C.F.R. &#167; 200.83<br></div></div><div class="page-content"><div class="block-main" style="width: 528pt; margin-left: 6pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">ADC Therapeutics SA <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;"><div class="rule-full" style="height: 0pt; width: 100%; border-bottom: 1pt solid #000000; margin-top: 1pt; margin-bottom: 1pt; margin-left: auto; margin-right: auto;"> </div>Notes to the Condensed Consolidated Interim Financial Statements (Unaudited) &#8211; in KUSD except for share and per share data<font style="padding-left: 4pt;">(continued)</font><br></div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 12pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">13.<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; text-align: left;">Share Capital, share premium and treasury shares</div></td></tr></table><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: left;">Share data have been revised to give effect to the share split and share consolidation as explained in note 2, &#8220;Share split and share consolidation&#8221;.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: left;">The movements in the Company&#8217;s share capital, share premium and treasury shares accounts in the six months ended June&#160;30, 2020 are set out in the following table:</div><table cellspacing="0" cellpadding="0" class="fintab" style="margin-top: 11.25pt; border-collapse: collapse; width: 528pt; margin-left: auto; margin-right: auto;"><tr class="header"><td style="width: 11.36%; text-align: left; vertical-align: bottom; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 7pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 0.85%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 0.85%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 25%; text-align: center; vertical-align: bottom; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 7pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 0.85%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 0.85%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 3.83%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 7pt; font-weight: bold; margin-top: 0pt; text-align: center;">Issued <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 7pt; font-weight: bold; margin-top: 0pt; text-align: center;">share <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 7pt; font-weight: bold; margin-top: 0pt; text-align: center;">capital</div></td><td class="gutter" style="width: 0.85%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 0.85%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 5.2%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 7pt; font-weight: bold; margin-top: 0pt; text-align: center;">Share <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 7pt; font-weight: bold; margin-top: 0pt; text-align: center;">premium</div></td><td class="gutter" style="width: 0.85%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 0.85%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 5.11%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 7pt; font-weight: bold; margin-top: 0pt; text-align: center;">Treasury <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 7pt; font-weight: bold; margin-top: 0pt; text-align: center;">shares</div></td><td class="gutter" style="width: 0.85%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 0.85%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 5.94%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 7pt; font-weight: bold; margin-top: 0pt; text-align: center;">Increase / <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 7pt; font-weight: bold; margin-top: 0pt; text-align: center;">(Decrease) <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 7pt; font-weight: bold; margin-top: 0pt; text-align: center;">in net <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 7pt; font-weight: bold; margin-top: 0pt; text-align: center;">assets</div></td><td class="gutter" style="width: 0.85%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 0.85%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 6.44%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 7pt; font-weight: bold; margin-top: 0pt; text-align: center;">Price <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 7pt; font-weight: bold; margin-top: 0pt; text-align: center;">per <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 7pt; font-weight: bold; margin-top: 0pt; text-align: center;">share</div></td><td class="gutter" style="width: 0.85%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 0.85%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 6.82%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 7pt; font-weight: bold; margin-top: 0pt; text-align: center;">Issued <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 7pt; font-weight: bold; margin-top: 0pt; text-align: center;">share <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 7pt; font-weight: bold; margin-top: 0pt; text-align: center;">capital</div></td><td class="gutter" style="width: 0.85%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 0.85%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 7.61%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 7pt; font-weight: bold; margin-top: 0pt; text-align: center;">Treasury <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 7pt; font-weight: bold; margin-top: 0pt; text-align: center;">shares</div></td><td class="gutter" style="width: 0.85%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 0.85%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 7.34%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 7pt; font-weight: bold; margin-top: 0pt; text-align: center;">Outstanding <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 7pt; font-weight: bold; margin-top: 0pt; text-align: center;">share capital</div></td></tr><tr class="header"><td style="width: 11.36%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 7pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 0.85%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 0.85%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 25%; text-align: center; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 7pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 0.85%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 0.85%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td colspan="10" style="width: 25.2%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 7pt; font-weight: bold; margin-top: 0pt; text-align: center;">In KUSD</div></td><td class="gutter" style="width: 0.85%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 0.85%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 6.44%; text-align: center; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 7pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 0.85%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 0.85%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 6.82%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 7pt; font-weight: bold; margin-top: 0pt; text-align: center;">Number of <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 7pt; font-weight: bold; margin-top: 0pt; text-align: center;">shares <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 7pt; font-weight: bold; margin-top: 0pt; text-align: center;">issued</div></td><td class="gutter" style="width: 0.85%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 0.85%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 7.61%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 7pt; font-weight: bold; margin-top: 0pt; text-align: center;">Number of <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 7pt; font-weight: bold; margin-top: 0pt; text-align: center;">shares (held <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 7pt; font-weight: bold; margin-top: 0pt; text-align: center;">or received) / <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 7pt; font-weight: bold; margin-top: 0pt; text-align: center;">delivered</div></td><td class="gutter" style="width: 0.85%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 0.85%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 7.34%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 7pt; font-weight: bold; margin-top: 0pt; text-align: center;">Number of <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 7pt; font-weight: bold; margin-top: 0pt; text-align: center;">shares <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 7pt; font-weight: bold; margin-top: 0pt; text-align: center;">outstanding</div></td></tr><tr><td style="width: 11.36%; text-align: left; vertical-align: top; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">April&#160;15, 2020<font style="padding-left: 4.79pt;"></font></div></td><td class="gutter" style="width: 0.85%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.85%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 25%; text-align: left; vertical-align: top; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;">Shares surrendered by Share Purchase Plan 2013 and Share Purchase Plan 2016 participants to settle share purchase plan promissory notes (see note 12)</div></td><td class="gutter" style="width: 0.85%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.85%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 3.83%; text-align: left; vertical-align: top; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; margin-left: 1.11pt; text-align: left;"><font style="padding-left: 10pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.85%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.85%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.2%; text-align: left; vertical-align: top; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; margin-left: 0.74pt; text-align: left;"><font style="padding-left: 4.3pt;">11,208</font></div></td><td class="gutter" style="width: 0.85%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.85%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.11%; text-align: left; vertical-align: top; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; margin-left: 1.3pt; text-align: left;">(11,208)</div></td><td class="gutter" style="width: 0.85%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.85%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.94%; text-align: left; vertical-align: top; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; margin-left: 2.68pt; text-align: left;"><font style="padding-left: 18pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.85%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.85%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.44%; text-align: left; vertical-align: top; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;">USD 18.75</div></td><td class="gutter" style="width: 0.85%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.85%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.82%; text-align: left; vertical-align: top; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;"><font style="padding-left: 28pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.85%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.85%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.61%; text-align: left; vertical-align: top; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; margin-left: 2.76pt; text-align: left;"><font style="padding-left: 6pt;">(597,774)</font></div></td><td class="gutter" style="width: 0.85%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.85%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.34%; text-align: left; vertical-align: top; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; margin-left: 1.38pt; text-align: left;"><font style="padding-left: 7.34pt;">(597,774)</font></div></td></tr><tr><td style="width: 11.36%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">April&#160;16, 2020<font style="padding-left: 4.79pt;"></font></div></td><td class="gutter" style="width: 0.85%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.85%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 25%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;">Issuance of shares per shareholders' agreement addendum through capitalization of reserves</div></td><td class="gutter" style="width: 0.85%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.85%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 3.83%; text-align: left; vertical-align: top; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; margin-left: 1.11pt; text-align: left;"><font style="padding-left: 6pt;">393</font></div></td><td class="gutter" style="width: 0.85%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.85%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 5.2%; text-align: left; vertical-align: top; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; margin-left: 0.74pt; text-align: left;"><font style="padding-left: 11.34pt;">(393)</font></div></td><td class="gutter" style="width: 0.85%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.85%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 5.11%; text-align: left; vertical-align: top; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; margin-left: 1.3pt; text-align: left;"><font style="padding-left: 16.37pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.85%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.85%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 5.94%; text-align: left; vertical-align: top; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; margin-left: 2.68pt; text-align: left;"><font style="padding-left: 18pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.85%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.85%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 6.44%; text-align: left; vertical-align: top; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;"><font style="padding-left: 0.44pt;">CHF 0.08</font></div></td><td class="gutter" style="width: 0.85%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.85%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 6.82%; text-align: left; vertical-align: top; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;"><font style="padding-left: 4pt;">4,777,996</font></div></td><td class="gutter" style="width: 0.85%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.85%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 7.61%; text-align: left; vertical-align: top; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; margin-left: 2.76pt; text-align: left;"><font style="padding-left: 26.66pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.85%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.85%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 7.34%; text-align: left; vertical-align: top; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; margin-left: 1.38pt; text-align: left;"><font style="padding-left: 4pt;">4,777,996</font></div></td></tr><tr><td style="width: 11.36%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">April&#160;24, 2020<font style="padding-left: 4.79pt;"></font></div></td><td class="gutter" style="width: 0.85%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.85%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 25%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;">Elimination of fractional shareholdings</div></td><td class="gutter" style="width: 0.85%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.85%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 3.83%; text-align: left; vertical-align: top; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; margin-left: 1.11pt; text-align: left;"><font style="padding-left: 10pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.85%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.85%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.2%; text-align: left; vertical-align: top; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; margin-left: 0.74pt; text-align: left;"><font style="padding-left: 18pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.85%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.85%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.11%; text-align: left; vertical-align: top; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; margin-left: 1.3pt; text-align: left;"><font style="padding-left: 16.37pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.85%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.85%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.94%; text-align: left; vertical-align: top; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; margin-left: 2.68pt; text-align: left;"><font style="padding-left: 18pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.85%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.85%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.44%; text-align: left; vertical-align: top; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;"><font style="padding-left: 0.44pt;">CHF 0.08</font></div></td><td class="gutter" style="width: 0.85%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.85%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.82%; text-align: left; vertical-align: top; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;"><font style="padding-left: 28pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.85%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.85%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.61%; text-align: left; vertical-align: top; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; margin-left: 2.76pt; text-align: left;"><font style="padding-left: 26.66pt;">51</font></div></td><td class="gutter" style="width: 0.85%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.85%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.34%; text-align: left; vertical-align: top; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; margin-left: 1.38pt; text-align: left;"><font style="padding-left: 28pt;">51</font></div></td></tr><tr><td style="width: 11.36%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">May&#160;15, 2020<font style="padding-left: 2.01pt;"></font></div></td><td class="gutter" style="width: 0.85%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.85%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 25%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;">Issuance of shares to be held as treasury shares</div></td><td class="gutter" style="width: 0.85%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.85%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 3.83%; text-align: left; vertical-align: top; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; margin-left: 1.11pt; text-align: left;"><font style="padding-left: 10pt;">34</font></div></td><td class="gutter" style="width: 0.85%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.85%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 5.2%; text-align: left; vertical-align: top; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; margin-left: 0.74pt; text-align: left;"><font style="padding-left: 18pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.85%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.85%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 5.11%; text-align: left; vertical-align: top; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; margin-left: 1.3pt; text-align: left;"><font style="padding-left: 13.7pt;">(34)</font></div></td><td class="gutter" style="width: 0.85%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.85%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 5.94%; text-align: left; vertical-align: top; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; margin-left: 2.68pt; text-align: left;"><font style="padding-left: 18pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.85%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.85%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 6.44%; text-align: left; vertical-align: top; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;"><font style="padding-left: 0.44pt;">CHF 0.08</font></div></td><td class="gutter" style="width: 0.85%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.85%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 6.82%; text-align: left; vertical-align: top; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;"><font style="padding-left: 10pt;">408,873</font></div></td><td class="gutter" style="width: 0.85%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.85%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 7.61%; text-align: left; vertical-align: top; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; margin-left: 2.76pt; text-align: left;"><font style="padding-left: 6pt;">(408,873)</font></div></td><td class="gutter" style="width: 0.85%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.85%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 7.34%; text-align: left; vertical-align: top; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; margin-left: 1.38pt; text-align: left;"><font style="padding-left: 28pt;">&#8212;</font></div></td></tr><tr><td style="width: 11.36%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">May&#160;15, 2020<font style="padding-left: 2.01pt;"></font></div></td><td class="gutter" style="width: 0.85%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.85%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 25%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;">Grant of shares to settle Incentive Plan 2014 awards, net (see note 12)</div></td><td class="gutter" style="width: 0.85%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.85%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 3.83%; text-align: left; vertical-align: top; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; margin-left: 1.11pt; text-align: left;"><font style="padding-left: 10pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.85%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.85%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.2%; text-align: left; vertical-align: top; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; margin-left: 0.74pt; text-align: left;"><font style="padding-left: 15.34pt;">(29)</font></div></td><td class="gutter" style="width: 0.85%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.85%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.11%; text-align: left; vertical-align: top; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; margin-left: 1.3pt; text-align: left;"><font style="padding-left: 16.37pt;">29</font></div></td><td class="gutter" style="width: 0.85%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.85%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.94%; text-align: left; vertical-align: top; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; margin-left: 2.68pt; text-align: left;"><font style="padding-left: 18pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.85%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.85%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.44%; text-align: left; vertical-align: top; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;"><font style="padding-left: 0.44pt;">CHF 0.08</font></div></td><td class="gutter" style="width: 0.85%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.85%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.82%; text-align: left; vertical-align: top; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;"><font style="padding-left: 28pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.85%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.85%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.61%; text-align: left; vertical-align: top; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; margin-left: 2.76pt; text-align: left;"><font style="padding-left: 8.66pt;">356,144</font></div></td><td class="gutter" style="width: 0.85%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.85%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.34%; text-align: left; vertical-align: top; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; margin-left: 1.38pt; text-align: left;"><font style="padding-left: 10pt;">356,144</font></div></td></tr><tr><td style="width: 11.36%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">May&#160;15, 2020<font style="padding-left: 2.01pt;"></font></div></td><td class="gutter" style="width: 0.85%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.85%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 25%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;">Issuance of shares at IPO</div></td><td class="gutter" style="width: 0.85%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.85%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 3.83%; text-align: left; vertical-align: top; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; margin-left: 1.11pt; text-align: left;">1,007</div></td><td class="gutter" style="width: 0.85%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.85%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 5.2%; text-align: left; vertical-align: top; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; margin-left: 0.74pt; text-align: left;">231,661</div></td><td class="gutter" style="width: 0.85%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.85%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 5.11%; text-align: left; vertical-align: top; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; margin-left: 1.3pt; text-align: left;"><font style="padding-left: 16.37pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.85%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.85%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 5.94%; text-align: left; vertical-align: top; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; margin-left: 2.68pt; text-align: left;">232,668</div></td><td class="gutter" style="width: 0.85%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.85%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 6.44%; text-align: left; vertical-align: top; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;">USD 19.00</div></td><td class="gutter" style="width: 0.85%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.85%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 6.82%; text-align: left; vertical-align: top; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;">12,245,631</div></td><td class="gutter" style="width: 0.85%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.85%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 7.61%; text-align: left; vertical-align: top; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; margin-left: 2.76pt; text-align: left;"><font style="padding-left: 26.66pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.85%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.85%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 7.34%; text-align: left; vertical-align: top; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; margin-left: 1.38pt; text-align: left;">12,245,631</div></td></tr><tr><td style="width: 11.36%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">May&#160;15, 2020<font style="padding-left: 2.01pt;"></font></div></td><td class="gutter" style="width: 0.85%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.85%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 25%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;">Sale of shares under greenshoe option</div></td><td class="gutter" style="width: 0.85%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.85%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 3.83%; text-align: left; vertical-align: top; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; margin-left: 1.11pt; text-align: left;"><font style="padding-left: 10pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.85%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.85%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.2%; text-align: left; vertical-align: top; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; margin-left: 0.74pt; text-align: left;"><font style="padding-left: 4pt;">23,591</font></div></td><td class="gutter" style="width: 0.85%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.85%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.11%; text-align: left; vertical-align: top; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; margin-left: 1.3pt; text-align: left;"><font style="padding-left: 2.66pt;">11,309</font></div></td><td class="gutter" style="width: 0.85%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.85%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.94%; text-align: left; vertical-align: top; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; margin-left: 2.68pt; text-align: left;"><font style="padding-left: 4pt;">34,900</font></div></td><td class="gutter" style="width: 0.85%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.85%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.44%; text-align: left; vertical-align: top; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;">USD 19.00</div></td><td class="gutter" style="width: 0.85%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.85%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.82%; text-align: left; vertical-align: top; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;"><font style="padding-left: 28pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.85%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.85%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.61%; text-align: left; vertical-align: top; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; margin-left: 2.76pt; text-align: left;"><font style="padding-left: 2.66pt;">1,836,844</font></div></td><td class="gutter" style="width: 0.85%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.85%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.34%; text-align: left; vertical-align: top; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; margin-left: 1.38pt; text-align: left;"><font style="padding-left: 4pt;">1,836,844</font></div></td></tr><tr><td style="width: 11.36%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">May&#160;15, 2020<font style="padding-left: 2.01pt;"></font></div></td><td class="gutter" style="width: 0.85%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.85%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 25%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;">Transaction costs, IPO and greenshoe option</div></td><td class="gutter" style="width: 0.85%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.85%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 3.83%; text-align: left; vertical-align: top; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; margin-left: 1.11pt; text-align: left;"><font style="padding-left: 10pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.85%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.85%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 5.2%; text-align: left; vertical-align: top; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; margin-left: 0.74pt; text-align: left;"><font style="padding-left: 1.34pt;">(23,355)</font></div></td><td class="gutter" style="width: 0.85%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.85%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 5.11%; text-align: left; vertical-align: top; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; margin-left: 1.3pt; text-align: left;"><font style="padding-left: 16.37pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.85%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.85%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 5.94%; text-align: left; vertical-align: top; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; margin-left: 2.68pt; text-align: left;"><font style="padding-left: 1.34pt;">(23,355)</font></div></td><td class="gutter" style="width: 0.85%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.85%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 6.44%; text-align: left; vertical-align: top; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">&#160;</div></td><td class="gutter" style="width: 0.85%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.85%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 6.82%; text-align: left; vertical-align: top; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;"><font style="padding-left: 28pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.85%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.85%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 7.61%; text-align: left; vertical-align: top; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; margin-left: 2.76pt; text-align: left;"><font style="padding-left: 26.66pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.85%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.85%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 7.34%; text-align: left; vertical-align: top; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; margin-left: 1.38pt; text-align: left;"><font style="padding-left: 28pt;">&#8212;</font></div></td></tr><tr><td style="width: 11.36%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">&#160;</div></td><td class="gutter" style="width: 0.85%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.85%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 25%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; margin-left: -0.01pt; text-align: left;">Movements in the period</div></td><td class="gutter" style="width: 0.85%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.85%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 3.83%; text-align: left; vertical-align: top; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; margin-left: 1.11pt; text-align: left;"><font style="border-bottom: 1pt solid #000000; min-width: 18pt;">1,434</font></div></td><td class="gutter" style="width: 0.85%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.85%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.2%; text-align: left; vertical-align: top; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; margin-left: 0.74pt; text-align: left;"><font style="border-bottom: 1pt solid #000000; min-width: 26pt;">242,683</font></div></td><td class="gutter" style="width: 0.85%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.85%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.11%; text-align: left; vertical-align: top; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; margin-left: 1.3pt; text-align: left;"><font style="padding-left: 16.37pt; border-bottom: 1pt solid #000000; min-width: 24.37pt;">96</font></div></td><td class="gutter" style="width: 0.85%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.85%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.94%; text-align: left; vertical-align: top; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; margin-left: 2.68pt; text-align: left;"><font style="border-bottom: 1pt solid #000000; min-width: 26pt;">244,213</font></div></td><td class="gutter" style="width: 0.85%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.85%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.44%; text-align: left; vertical-align: top; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">&#160;</div></td><td class="gutter" style="width: 0.85%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.85%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.82%; text-align: left; vertical-align: top; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;"><font style="border-bottom: 1pt solid #000000; min-width: 36pt;">17,432,500</font></div></td><td class="gutter" style="width: 0.85%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.85%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.61%; text-align: left; vertical-align: top; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; margin-left: 2.76pt; text-align: left;"><font style="padding-left: 2.66pt; border-bottom: 1pt solid #000000; min-width: 34.66pt;">1,186,392</font></div></td><td class="gutter" style="width: 0.85%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.85%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.34%; text-align: left; vertical-align: top; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; margin-left: 1.38pt; text-align: left;"><font style="border-bottom: 1pt solid #000000; min-width: 36pt;">18,618,892</font></div></td></tr><tr><td style="width: 11.36%; text-align: left; vertical-align: top; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; margin-left: 8pt; text-indent: -8pt; text-align: left;">December&#160;31, 2019<font style="padding-left: 4pt;"></font></div></td><td class="gutter" style="width: 0.85%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.85%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 25%; text-align: left; vertical-align: top; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;">Balances reported at December&#160;31, 2019, revised for share consolidation</div></td><td class="gutter" style="width: 0.85%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.85%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 3.83%; text-align: left; vertical-align: top; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; margin-left: 1.11pt; text-align: left;">4,361</div></td><td class="gutter" style="width: 0.85%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.85%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 5.2%; text-align: left; vertical-align: top; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; margin-left: 0.74pt; text-align: left;">549,922</div></td><td class="gutter" style="width: 0.85%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.85%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 5.11%; text-align: left; vertical-align: top; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; margin-left: 1.3pt; text-align: left;"><font style="padding-left: 9.7pt;">(100)</font></div></td><td class="gutter" style="width: 0.85%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.85%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 5.94%; text-align: left; vertical-align: top; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">&#160;</div></td><td class="gutter" style="width: 0.85%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.85%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 6.44%; text-align: left; vertical-align: top; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">&#160;</div></td><td class="gutter" style="width: 0.85%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.85%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 6.82%; text-align: left; vertical-align: top; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;">53,337,500</div></td><td class="gutter" style="width: 0.85%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.85%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 7.61%; text-align: left; vertical-align: top; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; margin-left: 2.76pt; text-align: left;">(1,240,540)</div></td><td class="gutter" style="width: 0.85%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.85%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 7.34%; text-align: left; vertical-align: top; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; margin-left: 1.38pt; text-align: left;">52,096,960</div></td></tr><tr><td style="width: 11.36%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">&#160;</div></td><td class="gutter" style="width: 0.85%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.85%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 25%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">&#160;</div></td><td class="gutter" style="width: 0.85%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.85%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 3.83%; text-align: left; vertical-align: top; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">&#160;</div></td><td class="gutter" style="width: 0.85%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.85%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.2%; text-align: left; vertical-align: top; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">&#160;</div></td><td class="gutter" style="width: 0.85%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.85%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.11%; text-align: left; vertical-align: top; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">&#160;</div></td><td class="gutter" style="width: 0.85%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.85%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.94%; text-align: left; vertical-align: top; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">&#160;</div></td><td class="gutter" style="width: 0.85%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.85%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.44%; text-align: left; vertical-align: top; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">&#160;</div></td><td class="gutter" style="width: 0.85%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.85%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.82%; text-align: left; vertical-align: top; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">&#160;</div></td><td class="gutter" style="width: 0.85%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.85%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.61%; text-align: left; vertical-align: top; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">&#160;</div></td><td class="gutter" style="width: 0.85%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.85%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.34%; text-align: left; vertical-align: top; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">&#160;</div></td></tr><tr><td style="width: 11.36%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 6pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">&#160;</div></td><td class="gutter" style="width: 0.85%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 6pt;">&#8203;</td><td class="gutter" style="width: 0.85%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 6pt;">&#8203;</td><td style="width: 25%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 6pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; margin-left: -0.01pt; text-align: left;">Balance at June&#160;30, 2020</div></td><td class="gutter" style="width: 0.85%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 6pt;">&#8203;</td><td class="gutter" style="width: 0.85%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 6pt;">&#8203;</td><td style="width: 3.83%; text-align: left; vertical-align: top; white-space: nowrap; padding-top: 3pt; padding-bottom: 6pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; margin-left: 1.11pt; text-align: left;"><font style="border-bottom: 1pt solid #000000; min-width: 18pt;">5,795</font></div></td><td class="gutter" style="width: 0.85%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 6pt;">&#8203;</td><td class="gutter" style="width: 0.85%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 6pt;">&#8203;</td><td style="width: 5.2%; text-align: left; vertical-align: top; white-space: nowrap; padding-top: 3pt; padding-bottom: 6pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; margin-left: 0.74pt; text-align: left;"><font style="border-bottom: 1pt solid #000000; min-width: 26pt;">792,605</font></div></td><td class="gutter" style="width: 0.85%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 6pt;">&#8203;</td><td class="gutter" style="width: 0.85%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 6pt;">&#8203;</td><td style="width: 5.11%; text-align: left; vertical-align: top; white-space: nowrap; padding-top: 3pt; padding-bottom: 6pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; margin-left: 1.3pt; text-align: left;"><font style="padding-left: 17.7pt; border-bottom: 1pt solid #000000; min-width: 24.37pt;">(4</font><font style="min-width: 24.37pt;">)</font></div></td><td class="gutter" style="width: 0.85%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 6pt;">&#8203;</td><td class="gutter" style="width: 0.85%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 6pt;">&#8203;</td><td style="width: 5.94%; text-align: left; vertical-align: top; white-space: nowrap; padding-top: 3pt; padding-bottom: 6pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">&#160;</div></td><td class="gutter" style="width: 0.85%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 6pt;">&#8203;</td><td class="gutter" style="width: 0.85%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 6pt;">&#8203;</td><td style="width: 6.44%; text-align: left; vertical-align: top; white-space: nowrap; padding-top: 3pt; padding-bottom: 6pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">&#160;</div></td><td class="gutter" style="width: 0.85%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 6pt;">&#8203;</td><td class="gutter" style="width: 0.85%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 6pt;">&#8203;</td><td style="width: 6.82%; text-align: left; vertical-align: top; white-space: nowrap; padding-top: 3pt; padding-bottom: 6pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;"><font style="border-bottom: 1pt solid #000000; min-width: 36pt;">70,770,000</font></div></td><td class="gutter" style="width: 0.85%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 6pt;">&#8203;</td><td class="gutter" style="width: 0.85%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 6pt;">&#8203;</td><td style="width: 7.61%; text-align: left; vertical-align: top; white-space: nowrap; padding-top: 3pt; padding-bottom: 6pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; margin-left: 2.76pt; text-align: left;"><font style="padding-left: 10pt; border-bottom: 1pt solid #000000; min-width: 34.66pt;">(54,148</font><font style="min-width: 34.66pt;">)</font></div></td><td class="gutter" style="width: 0.85%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 6pt;">&#8203;</td><td class="gutter" style="width: 0.85%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 6pt;">&#8203;</td><td style="width: 7.34%; text-align: left; vertical-align: top; white-space: nowrap; padding-top: 3pt; padding-bottom: 6pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; margin-left: 1.38pt; text-align: left;"><font style="border-bottom: 1pt solid #000000; min-width: 36pt;">70,715,852</font></div></td></tr></table><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: left;">Upon the completion of the IPO, all of the Company&#8217;s issued Class&#160;B, C, D and E preferred shares were converted into common shares on a one-to-one basis.</div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 12pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">14.<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; text-align: left;">Related parties</div></td></tr></table><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: left;">Parties are considered to be related if one party has the ability, directly or indirectly, to control the other party or exercise significant influence over the other party in making financial and operating decisions.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: left;">A.T. Holdings II S&#224;rl (&#8220;AT Holdings II&#8221;) is a shareholder in the Company. AT Holdings II is in turn ultimately wholly owned by Auven Therapeutics Holdings, L.P. (&#8220;ATH&#8221;), a limited partnership registered in the British Virgin Islands. ATH&#8217;s General Partner is Auven Therapeutics General L.P., which itself is a limited partnership whose General Partner is Auven Therapeutics GP Ltd. The manager of ATH is Auven Therapeutics Management L.L.L.P. (&#8220;ATM&#8221;).</div><div class="h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 14pt; margin-left: 20pt; text-align: left;"><u>Services provided by the Company</u></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: left;">The Company provides registered office and other simple administrative services to four subsidiaries of ATH. The amounts invoiced for the three months and six months ended June&#160;30, 2020, recognized as general and administrative expense, amounted to KUSD 1 and KUSD 2 respectively (three and six months ended June&#160;30, 2019: KUSD 1 and KUSD 2).</div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 36pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">F-21<br></div></div></div>
<!--End Page 275-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 276-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 540pt;"><a name="nt10014672x1_drs_202-finnotes01_pg15"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="block-frill" style="width: 540pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: Arial, Helvetica, sans-serif; font-size: 9pt; font-weight: bold; margin-top: 6pt; text-align: center;">Confidential Treatment Requested by ADC Therapeutics SA Pursuant to 17 C.F.R. &#167; 200.83<br></div></div><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 36pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">ADC Therapeutics SA <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;"><div class="rule-full" style="height: 0pt; width: 100%; border-bottom: 1pt solid #000000; margin-top: 1pt; margin-bottom: 1pt; margin-left: auto; margin-right: auto;"> </div>Notes to the Condensed Consolidated Interim Financial Statements (Unaudited) &#8211; in KUSD except for share and per share data<font style="padding-left: 4pt;">(continued)</font><br></div><div class="h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 7pt; margin-left: 20pt; text-align: left;"><u>Other transactions with related parties</u></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: left;">Of the 597,774 shares surrendered by Share Purchase Plan 2013 and Share Purchase Plan 2016 participants to settle share purchase plan promissory notes on April&#160;15, 2020 (see note 13, &#8220;Share capital, share premium and treasury shares&#8221;), 556,799 were surrendered by related parties.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: left;">Of the 4,777,996 shares issued by way of capitalization of reserves on April&#160;16, 2020 (see note 13, &#8220;Share capital, share premium and treasury shares&#8221;), 1,222,966 shares were issued to related parties.</div><div class="h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 20pt; margin-left: 20pt; text-align: left;"><u>Chairman&#8217;s equity awards</u></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: left;">The Company granted the Chairman, Mr.&#160;Squarer, options to acquire 1,125,545 common shares at $18.75 per share in connection with his election to the Board of Directors, representing approximately 2% of our then-outstanding share capital. These options are scheduled to vest upon Mr.&#160;Squarer&#8217;s continued service through designated dates over a three-year period, or immediately upon a change in control. In accordance with its agreement with Mr.&#160;Squarer, the Company provided Mr.&#160;Squarer with an additional grant of 341,403 options on June&#160;4, 2020 with an exercise price equal to the fair market value of the Company&#8217;s shares on that date, to bring Mr.&#160;Squarer&#8217;s total rights to acquire the Company&#8217;s shares to 2% of the then-outstanding share capital (measured without consideration of the shares underlying these grants).</div><div class="h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 20pt; margin-left: 20pt; text-align: left;"><u>Key management compensation</u></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 7pt; margin-left: 20pt; text-align: left;">The compensation of key management is shown below:</div><table cellspacing="0" cellpadding="0" class="fintab" style="margin-top: 11.25pt; border-collapse: collapse; width: 428pt; margin-left: 20pt;"><tr class="header"><td style="width: 44.86%; text-align: left; vertical-align: bottom; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 1.31%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.31%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td colspan="4" style="width: 24.95%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Three months ended</div></td><td class="gutter" style="width: 1.31%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.31%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td colspan="4" style="width: 24.95%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Six months ended</div></td></tr><tr class="header"><td style="width: 44.86%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">in KUSD</div></td><td class="gutter" style="width: 1.31%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.31%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 11.16%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">June&#160;30, 2020</div></td><td class="gutter" style="width: 1.31%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.31%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 11.16%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">June&#160;30, 2019</div></td><td class="gutter" style="width: 1.31%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.31%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 11.16%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">June&#160;30, 2020</div></td><td class="gutter" style="width: 1.31%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.31%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 11.16%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">June&#160;30, 2019</div></td></tr><tr><td style="width: 44.86%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Salaries and other short-term employee costs<font style="padding-left: 0.69pt;"></font></div></td><td class="gutter" style="width: 1.31%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.31%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 11.16%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 12.64pt; text-align: left;">1,666</div></td><td class="gutter" style="width: 1.31%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.31%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 11.16%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 12.64pt; text-align: left;">1,242</div></td><td class="gutter" style="width: 1.31%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.31%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 11.16%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10.32pt; text-align: left;"><font style="padding-left: 4.63pt;">3,254</font></div></td><td class="gutter" style="width: 1.31%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.31%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 11.16%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 12.64pt; text-align: left;">2,477</div></td></tr><tr><td style="width: 44.86%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Pension costs<font style="padding-left: 4.52pt;"></font></div></td><td class="gutter" style="width: 1.31%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.31%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 11.16%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 12.64pt; text-align: left;"><font style="padding-left: 7.5pt;">107</font></div></td><td class="gutter" style="width: 1.31%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.31%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 11.16%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 12.64pt; text-align: left;"><font style="padding-left: 12.5pt;">98</font></div></td><td class="gutter" style="width: 1.31%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.31%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 11.16%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10.32pt; text-align: left;"><font style="padding-left: 12.13pt;">256</font></div></td><td class="gutter" style="width: 1.31%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.31%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 11.16%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 12.64pt; text-align: left;"><font style="padding-left: 7.5pt;">183</font></div></td></tr><tr><td style="width: 44.86%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Share-based compensation expense<font style="padding-left: 1.23pt;"></font></div></td><td class="gutter" style="width: 1.31%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.31%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 11.16%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 12.64pt; text-align: left;">6,025</div></td><td class="gutter" style="width: 1.31%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.31%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 11.16%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 12.64pt; text-align: left;"><font style="padding-left: 12.5pt;">42</font></div></td><td class="gutter" style="width: 1.31%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.31%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 11.16%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10.32pt; text-align: left;"><font style="padding-left: 4.63pt;">7,599</font></div></td><td class="gutter" style="width: 1.31%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.31%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 11.16%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 12.64pt; text-align: left;"><font style="padding-left: 7.5pt;">107</font></div></td></tr><tr><td style="width: 44.86%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Other compensation<font style="padding-left: 2.86pt;"></font></div></td><td class="gutter" style="width: 1.31%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.31%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 11.16%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 12.64pt; text-align: left;"><font style="padding-left: 12.5pt; border-bottom: 1pt solid #000000; min-width: 22.5pt;">22</font></div></td><td class="gutter" style="width: 1.31%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.31%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 11.16%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 12.64pt; text-align: left;"><font style="padding-left: 12.5pt; border-bottom: 1pt solid #000000; min-width: 22.5pt;">&#8212;</font></div></td><td class="gutter" style="width: 1.31%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.31%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 11.16%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10.32pt; text-align: left;"><font style="padding-left: 17.13pt; border-bottom: 1pt solid #000000; min-width: 27.13pt;">83</font></div></td><td class="gutter" style="width: 1.31%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.31%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 11.16%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 12.64pt; text-align: left;"><font style="padding-left: 12.5pt; border-bottom: 1pt solid #000000; min-width: 22.5pt;">&#8212;</font></div></td></tr><tr><td style="width: 44.86%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Total<font style="padding-left: 4.09pt;"></font></div></td><td class="gutter" style="width: 1.31%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.31%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 11.16%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 12.64pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 22.5pt;">7,820</font></div></td><td class="gutter" style="width: 1.31%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.31%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 11.16%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 12.64pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 22.5pt;">1,382</font></div></td><td class="gutter" style="width: 1.31%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.31%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 11.16%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10.32pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 27.13pt;">11,192</font></div></td><td class="gutter" style="width: 1.31%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.31%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 11.16%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 12.64pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 22.5pt;">2,767</font></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 12pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">15.<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; text-align: left;">Loss per share</div></td></tr></table><table cellspacing="0" cellpadding="0" class="fintab" style="margin-top: 10.25pt; border-collapse: collapse; width: 428pt; margin-left: 20pt;"><tr class="header"><td style="width: 44.86%; text-align: left; vertical-align: bottom; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 1.31%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.31%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td colspan="4" style="width: 24.95%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Three Months Ended</div></td><td class="gutter" style="width: 1.31%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.31%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td colspan="4" style="width: 24.95%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Six Months Ended</div></td></tr><tr class="header"><td style="width: 44.86%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">(in KUSD, except per share amounts)</div></td><td class="gutter" style="width: 1.31%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.31%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 11.16%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">June&#160;30, 2020</div></td><td class="gutter" style="width: 1.31%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.31%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 11.16%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">June&#160;30, 2019</div></td><td class="gutter" style="width: 1.31%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.31%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 11.16%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">June&#160;30, 2020</div></td><td class="gutter" style="width: 1.31%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.31%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 11.16%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">June&#160;30, 2019</div></td></tr><tr><td style="width: 44.86%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Loss attributable to owners<font style="padding-left: 3.43pt;"></font></div></td><td class="gutter" style="width: 1.31%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.31%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 11.16%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.39pt; text-align: left;"><font style="padding-left: 9.17pt;">(126,557)</font></div></td><td class="gutter" style="width: 1.31%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.31%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 11.16%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.39pt; text-align: left;"><font style="padding-left: 14.17pt;">(23,348)</font></div></td><td class="gutter" style="width: 1.31%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.31%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 11.16%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.39pt; text-align: left;"><font style="padding-left: 9.17pt;">(170,033)</font></div></td><td class="gutter" style="width: 1.31%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.31%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 11.16%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.39pt; text-align: left;"><font style="padding-left: 14.17pt;">(49,858)</font></div></td></tr><tr><td style="width: 44.86%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-indent: -10pt; text-align: left;">Weighted average number of shares outstanding<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(1)</sup><font style="padding-left: 4.09pt;"></font></div></td><td class="gutter" style="width: 1.31%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.31%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 11.16%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.39pt; text-align: left;"><font style="border-bottom: 1pt solid #000000; min-width: 45pt;">62,863,866</font></div></td><td class="gutter" style="width: 1.31%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.31%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 11.16%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.39pt; text-align: left;"><font style="border-bottom: 1pt solid #000000; min-width: 45pt;">47,654,258</font></div></td><td class="gutter" style="width: 1.31%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.31%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 11.16%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.39pt; text-align: left;"><font style="border-bottom: 1pt solid #000000; min-width: 45pt;">57,225,939</font></div></td><td class="gutter" style="width: 1.31%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.31%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 11.16%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.39pt; text-align: left;"><font style="border-bottom: 1pt solid #000000; min-width: 45pt;">47,297,859</font></div></td></tr><tr><td style="width: 44.86%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Basic and diluted loss per share<font style="padding-left: 4.01pt;"></font></div></td><td class="gutter" style="width: 1.31%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.31%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 11.16%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.39pt; text-align: left;"><font style="padding-left: 24.17pt; border-bottom: 3pt double #000000; min-width: 45pt;">(2.01</font><font style="min-width: 45pt;">)</font></div></td><td class="gutter" style="width: 1.31%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.31%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 11.16%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.39pt; text-align: left;"><font style="padding-left: 24.17pt; border-bottom: 3pt double #000000; min-width: 45pt;">(0.49</font><font style="min-width: 45pt;">)</font></div></td><td class="gutter" style="width: 1.31%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.31%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 11.16%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.39pt; text-align: left;"><font style="padding-left: 24.17pt; border-bottom: 3pt double #000000; min-width: 45pt;">(2.97</font><font style="min-width: 45pt;">)</font></div></td><td class="gutter" style="width: 1.31%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.31%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 11.16%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.39pt; text-align: left;"><font style="padding-left: 24.17pt; border-bottom: 3pt double #000000; min-width: 45pt;">(1.05</font><font style="min-width: 45pt;">)</font></div></td></tr></table><div><div class="rule-partial" style="height: 0pt; width: 72pt; border-bottom: 1pt solid #000000; margin-bottom: 1pt; margin-right: auto; margin-left: 20pt; margin-top: 12.75pt;"> </div></div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 3pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">(1)<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; text-align: left;">Share data have been revised to give effect to the share split and share consolidation as explained in note 2, &#8220;Share split and share consolidation&#8221;.</div></td></tr></table><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: left;">As all Class&#160;B, C, D and E preferred shares were converted into common shares upon the completion of the IPO, loss per share data are presented on that basis for all periods.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: left;">For the three and six months ended June&#160;30, 2020 and 2019, basic and diluted loss per share are calculated on the weighted average number of shares issued and outstanding and exclude shares to be issued under the Equity Incentive Plan 2019, as the effect of including those shares would be anti-dilutive.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: left;">Potentially dilutive securities that were not included in the diluted per share calculations because the effect of including them would be anti-dilutive were as follows:</div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 36pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">F-22<br></div></div></div>
<!--End Page 276-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 277-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 540pt;"><a name="nt10014672x1_drs_202-finnotes01_pg16"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="block-frill" style="width: 540pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: Arial, Helvetica, sans-serif; font-size: 9pt; font-weight: bold; margin-top: 6pt; text-align: center;">Confidential Treatment Requested by ADC Therapeutics SA Pursuant to 17 C.F.R. &#167; 200.83<br></div></div><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 36pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">ADC Therapeutics SA <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;"><div class="rule-full" style="height: 0pt; width: 100%; border-bottom: 1pt solid #000000; margin-top: 1pt; margin-bottom: 1pt; margin-left: auto; margin-right: auto;"> </div>Notes to the Condensed Consolidated Interim Financial Statements (Unaudited) &#8211; in KUSD except for share and per share data<font style="padding-left: 4pt;">(continued)</font><br></div><table cellspacing="0" cellpadding="0" class="fintab" style="margin-top: 3.25pt; border-collapse: collapse; width: 428pt; margin-left: 20pt;"><tr class="header"><td style="width: 44.86%; text-align: left; vertical-align: bottom; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 1.34%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.34%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td colspan="4" style="width: 26.01%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Three Months Ended June&#160;30,</div></td><td class="gutter" style="width: 1.34%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.34%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td colspan="4" style="width: 23.76%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Six Months Ended June&#160;30,</div></td></tr><tr class="header"><td style="width: 44.86%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 1.34%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.34%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 11.66%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2020</div></td><td class="gutter" style="width: 1.34%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.34%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 11.66%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2019</div></td><td class="gutter" style="width: 1.34%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.34%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 10.54%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2020</div></td><td class="gutter" style="width: 1.34%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.34%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 10.54%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2019</div></td></tr><tr><td style="width: 44.86%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Share options under the Incentive Plan 2014<font style="padding-left: 2.34pt;"></font></div></td><td class="gutter" style="width: 1.34%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.34%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 11.66%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.96pt; text-align: left;"><font style="padding-left: 30pt;">&#8212;</font></div></td><td class="gutter" style="width: 1.34%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.34%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 11.66%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.97pt; text-align: left;">2,137,437</div></td><td class="gutter" style="width: 1.34%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.34%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.54%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.56pt; text-align: left;"><font style="padding-left: 30pt;">&#8212;</font></div></td><td class="gutter" style="width: 1.34%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.34%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.54%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.56pt; text-align: left;">2,130,967</div></td></tr><tr><td style="width: 44.86%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Shares under the Share Purchase Plan 2016<font style="padding-left: 1.24pt;"></font></div></td><td class="gutter" style="width: 1.34%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.34%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 11.66%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.96pt; text-align: left;"><font style="padding-left: 30pt;">&#8212;</font></div></td><td class="gutter" style="width: 1.34%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.34%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 11.66%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.97pt; text-align: left;"><font style="padding-left: 7.5pt;">962,500</font></div></td><td class="gutter" style="width: 1.34%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.34%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 10.54%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.56pt; text-align: left;"><font style="padding-left: 30pt;">&#8212;</font></div></td><td class="gutter" style="width: 1.34%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.34%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 10.54%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.56pt; text-align: left;"><font style="padding-left: 7.5pt;">962,500</font></div></td></tr><tr><td style="width: 44.86%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-indent: -10pt; text-align: left;">Share options under the Equity Incentive Plan 2019<font style="padding-left: 4.5pt;"></font></div></td><td class="gutter" style="width: 1.34%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.34%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 11.66%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.96pt; text-align: left;">2,784,467</div></td><td class="gutter" style="width: 1.34%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.34%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 11.66%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.97pt; text-align: left;"><font style="padding-left: 30pt;">&#8212;</font></div></td><td class="gutter" style="width: 1.34%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.34%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.54%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.56pt; text-align: left;">1,999,022</div></td><td class="gutter" style="width: 1.34%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.34%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.54%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.56pt; text-align: left;"><font style="padding-left: 30pt;">&#8212;</font></div></td></tr><tr><td style="width: 44.86%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-indent: -10pt; text-align: left;">Conversion of the principal amount of convertible loans into the Company&#8217;s common shares<font style="padding-left: 1.19pt;"></font></div></td><td class="gutter" style="width: 1.34%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.34%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 11.66%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.96pt; text-align: left;"><font style="border-bottom: 1pt solid #000000; min-width: 40pt;">1,766,917</font></div></td><td class="gutter" style="width: 1.34%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.34%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 11.66%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.97pt; text-align: left;"><font style="padding-left: 30pt; border-bottom: 1pt solid #000000; min-width: 40pt;">&#8212;</font></div></td><td class="gutter" style="width: 1.34%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.34%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 10.54%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.56pt; text-align: left;"><font style="padding-left: 7.5pt; border-bottom: 1pt solid #000000; min-width: 40pt;">888,340</font></div></td><td class="gutter" style="width: 1.34%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.34%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 10.54%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.56pt; text-align: left;"><font style="padding-left: 30pt; border-bottom: 1pt solid #000000; min-width: 40pt;">&#8212;</font></div></td></tr><tr><td style="width: 44.86%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.34%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.34%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 11.66%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.96pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 40pt;">4,551,384</font></div></td><td class="gutter" style="width: 1.34%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.34%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 11.66%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.97pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 40pt;">3,099,937</font></div></td><td class="gutter" style="width: 1.34%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.34%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.54%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.56pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 40pt;">2,887,362</font></div></td><td class="gutter" style="width: 1.34%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.34%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.54%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.56pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 40pt;">3,093,467</font></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 12pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"><a name="tF1NOTEE"><!--Anchor--></a>16.<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; text-align: left;">Events after the reporting date</div></td></tr></table><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: left;">The Company has evaluated its subsequent events through August&#160;12, 2020, the date the unaudited condensed consolidated interim financial statements were available to be issued, and has concluded that there are no subsequent events requiring disclosure in these unaudited condensed consolidated interim financial statements.</div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 36pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">F-23<br></div></div></div>
<!--End Page 277-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 278-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 540pt;"><a name="nt10014672x1_drs_203-fintab02_pg1"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="block-frill" style="width: 540pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: Arial, Helvetica, sans-serif; font-size: 9pt; font-weight: bold; margin-top: 6pt; text-align: center;">Confidential Treatment Requested by ADC Therapeutics SA Pursuant to 17 C.F.R. &#167; 200.83<br></div></div><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 36pt;"><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">ADC Therapeutics SA, Epalinges<br></div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;"><div class="rule-full" style="height: 0pt; width: 100%; border-bottom: 1pt solid #000000; margin-top: 1pt; margin-bottom: 1pt; margin-left: auto; margin-right: auto;"> </div></div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 7.5pt; margin-left: 0pt; text-align: left;"><a name="tGI"><!--Anchor--></a>GROUP INFORMATION</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 7.5pt; margin-left: 0pt; text-align: left;">For the year ended December&#160;31, 2019</div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 20.5pt; margin-left: 0pt; text-align: left;">DIRECTORS:</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 7.5pt; margin-left: 20pt; text-align: left;">Peter B. Corr, Chairman of the Board<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 20pt; text-align: left;">Stephen Evans-Freke<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 20pt; text-align: left;">Michael Forer<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 20pt; text-align: left;">Peter Hug<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 20pt; text-align: left;">Chris J. Martin<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 20pt; text-align: left;">Thomas Pfisterer<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 20pt; text-align: left;">Thomas Rinderknecht<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 20pt; text-align: left;">Tyrell Rivers<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 20pt; text-align: left;">Jacques Theurillat<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 20pt; text-align: left;">Barrie Ward</div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 20.5pt; margin-left: 0pt; text-align: left;">SECRETARY:</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 7.5pt; margin-left: 20pt; text-align: left;">Dominique Graz</div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 20.5pt; margin-left: 0pt; text-align: left;">REGISTERED OFFICE:</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 7.5pt; margin-left: 20pt; text-align: left;">Route de la Corniche 3B<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 20pt; text-align: left;">1066 Epalinges<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 20pt; text-align: left;">Switzerland</div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 20.5pt; margin-left: 0pt; text-align: left;">AUDITORS:</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 7.5pt; margin-left: 20pt; text-align: left;">PricewaterhouseCoopers SA</div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 36pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">F-24<br></div></div></div>
<!--End Page 278-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 279-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 540pt;"><a name="nt10014672x1_drs_203-fintab02_pg2"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="block-frill" style="width: 540pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: Arial, Helvetica, sans-serif; font-size: 9pt; font-weight: bold; margin-top: 6pt; text-align: center;">Confidential Treatment Requested by ADC Therapeutics SA Pursuant to 17 C.F.R. &#167; 200.83<br></div></div><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 36pt;"><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: center;"><a name="tRIR"><!--Anchor--></a>Report of Independent Registered Public Accounting Firm </div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 7.5pt; margin-left: 0pt; text-align: left;">To the Board of Directors and Shareholders of ADC Therapeutics SA</div><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 20.5pt; margin-left: 0pt; text-align: left;">Opinion on the Financial Statements</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">We have audited the accompanying consolidated balance sheets of ADC Therapeutics SA and its subsidiaries (the&#160;&#8220;Company&#8221;) as of December&#160;31, 2019 and 2018, and the related consolidated income statements, the consolidated statements of comprehensive income, changes in equity and cash flows for the years then ended, including the related notes (collectively referred to as the &#8220;consolidated financial statements&#8221;). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company as of December&#160;31, 2019 and 2018, and the results of its operations and its cash flows for the years then ended in conformity with International Financial Reporting Standards as issued by the International Accounting Standards Board. </div><div class="h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 20.5pt; margin-left: 0pt; text-align: left;">Change in Accounting Principle</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">As discussed in Notes 4 and 17 to the consolidated financial statements, the Company changed the manner in which it accounts for leases in 2019.</div><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 20.5pt; margin-left: 0pt; text-align: left;">Basis for Opinion</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">These consolidated financial statements are the responsibility of the Company&#8217;s management. Our responsibility is to express an opinion on the Company&#8217;s consolidated financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB. </div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">We conducted our audits of these consolidated financial statements in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the consolidated financial statements are free of material misstatement, whether due to error or fraud.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Our audits included performing procedures to assess the risks of material misstatement of the consolidated financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the consolidated financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements. We believe that our audits provide a reasonable basis for our opinion.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8.5pt; margin-left: 0pt; text-align: left;">/s/ PricewaterhouseCoopers SA</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8.5pt; margin-left: 0pt; text-align: left;">Lausanne, Switzerland<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">March&#160;2, 2020, except for the effects of the share consolidation discussed in Note 2 (v) to the consolidated financial statements, as to which the date is April 24, 2020.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8.5pt; margin-left: 0pt; text-align: left;">We have served as the Company's auditor since 2015.</div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 36pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">F-25<br></div></div></div>
<!--End Page 279-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 280-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 540pt;"><a name="nt10014672x1_drs_203-fintab02_pg3"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="block-frill" style="width: 540pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: Arial, Helvetica, sans-serif; font-size: 9pt; font-weight: bold; margin-top: 6pt; text-align: center;">Confidential Treatment Requested by ADC Therapeutics SA Pursuant to 17 C.F.R. &#167; 200.83<br></div></div><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 36pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: -22.25pt; margin-left: 0pt; text-align: left;"><a href="#tNTC1"></a>&#8195;</div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 20.5pt; margin-left: 0pt; text-align: left;">ADC Therapeutics SA, Epalinges</div><div><div class="rule-full" style="height: 0pt; width: 100%; border-bottom: 1pt solid #000000; margin-bottom: 2pt; margin-left: auto; margin-right: auto; margin-top: 7.5pt;"> </div></div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 20.5pt; margin-left: 0pt; text-align: left;"><a name="tCIS"><!--Anchor--></a>CONSOLIDATED INCOME STATEMENT<br></div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">(in KUSD)</div><table cellspacing="0" cellpadding="0" class="fintab" style="margin-top: 10.25pt; border-collapse: collapse; width: 468pt; margin-left: auto; margin-right: auto;"><tr class="header"><td style="width: 66.67%; text-align: left; vertical-align: bottom; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 1.58%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.58%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 3.72%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Note</div></td><td class="gutter" style="width: 1.58%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.58%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 10.07%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Year ended <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">December&#160;31, <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2019</div></td><td class="gutter" style="width: 1.58%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.58%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 10.07%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Year ended <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">December&#160;31, <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2018</div></td></tr><tr><td style="width: 66.67%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Contract revenue<font style="font-weight: normal; padding-left: 4.16pt;"></font></div></td><td class="gutter" style="width: 1.58%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.58%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 3.72%; text-align: center; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">7</div></td><td class="gutter" style="width: 1.58%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.58%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.07%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 5.66pt; text-align: left;"><font style="padding-left: 13.33pt;">2,340</font></div></td><td class="gutter" style="width: 1.58%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.58%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.07%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 5.66pt; text-align: left;"><font style="padding-left: 13.33pt;">1,140</font></div></td></tr><tr><td style="width: 66.67%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Research and development expenses<font style="padding-left: 0.68pt;"></font></div></td><td class="gutter" style="width: 1.58%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.58%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 3.72%; text-align: center; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">9/11</div></td><td class="gutter" style="width: 1.58%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.58%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 10.07%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 5.66pt; text-align: left;">(107,537)</div></td><td class="gutter" style="width: 1.58%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.58%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 10.07%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 5.66pt; text-align: left;"><font style="padding-left: 0.37pt;">(118,313)</font></div></td></tr><tr><td style="width: 66.67%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">General and administrative expenses<font style="padding-left: 0.12pt;"></font></div></td><td class="gutter" style="width: 1.58%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.58%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 3.72%; text-align: center; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">11</div></td><td class="gutter" style="width: 1.58%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.58%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.07%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 5.66pt; text-align: left;"><font style="padding-left: 5pt;">(14,202)</font></div></td><td class="gutter" style="width: 1.58%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.58%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.07%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 5.66pt; text-align: left;"><font style="padding-left: 10pt;">(8,768)</font></div></td></tr><tr><td style="width: 66.67%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Operating loss<font style="font-weight: normal; padding-left: 1.74pt;"></font></div></td><td class="gutter" style="width: 1.58%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.58%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 3.72%; text-align: center; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.58%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.58%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 10.07%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 5.66pt; text-align: left;"><font style="padding-left: 0.55pt;">(119,399)</font></div></td><td class="gutter" style="width: 1.58%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.58%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 10.07%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 5.66pt; text-align: left;">(125,941)</div></td></tr><tr><td style="width: 66.67%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Other income<font style="padding-left: 3.97pt;"></font></div></td><td class="gutter" style="width: 1.58%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.58%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 3.72%; text-align: center; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">8</div></td><td class="gutter" style="width: 1.58%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.58%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.07%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 5.66pt; text-align: left;"><font style="padding-left: 13.33pt;">1,655</font></div></td><td class="gutter" style="width: 1.58%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.58%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.07%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 5.66pt; text-align: left;"><font style="padding-left: 25.83pt;">&#8212;</font></div></td></tr><tr><td style="width: 66.67%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Financial income<font style="padding-left: 4.52pt;"></font></div></td><td class="gutter" style="width: 1.58%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.58%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 3.72%; text-align: center; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.58%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.58%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 10.07%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 5.66pt; text-align: left;"><font style="padding-left: 13.33pt;">2,253</font></div></td><td class="gutter" style="width: 1.58%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.58%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 10.07%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 5.66pt; text-align: left;"><font style="padding-left: 13.33pt;">2,856</font></div></td></tr><tr><td style="width: 66.67%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Financial expense<font style="padding-left: 1.75pt;"></font></div></td><td class="gutter" style="width: 1.58%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.58%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 3.72%; text-align: center; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.58%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.58%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.07%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 5.66pt; text-align: left;"><font style="padding-left: 17.5pt;">(156)</font></div></td><td class="gutter" style="width: 1.58%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.58%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.07%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 5.66pt; text-align: left;"><font style="padding-left: 25.83pt;">&#8212;</font></div></td></tr><tr><td style="width: 66.67%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Exchange differences<font style="padding-left: 2.5pt;"></font></div></td><td class="gutter" style="width: 1.58%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.58%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 3.72%; text-align: center; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.58%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.58%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 10.07%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 5.66pt; text-align: left;"><font style="padding-left: 17.5pt; border-bottom: 1pt solid #000000; min-width: 35.83pt;">(255</font><font style="min-width: 35.83pt;">)</font></div></td><td class="gutter" style="width: 1.58%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.58%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 10.07%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 5.66pt; text-align: left;"><font style="padding-left: 20.83pt; border-bottom: 1pt solid #000000; min-width: 35.83pt;">213</font></div></td></tr><tr><td style="width: 66.67%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Loss before taxes<font style="font-weight: normal; padding-left: 4.72pt;"></font></div></td><td class="gutter" style="width: 1.58%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.58%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 3.72%; text-align: center; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.58%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.58%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.07%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 5.66pt; text-align: left;"><font style="padding-left: 0.55pt;">(115,902)</font></div></td><td class="gutter" style="width: 1.58%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.58%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.07%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 5.66pt; text-align: left;">(122,872)</div></td></tr><tr><td style="width: 66.67%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Income tax expenses<font style="padding-left: 4.54pt;"></font></div></td><td class="gutter" style="width: 1.58%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.58%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 3.72%; text-align: center; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">12</div></td><td class="gutter" style="width: 1.58%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.58%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 10.07%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 5.66pt; text-align: left;"><font style="padding-left: 17.5pt; border-bottom: 1pt solid #000000; min-width: 35.83pt;">(582</font><font style="min-width: 35.83pt;">)</font></div></td><td class="gutter" style="width: 1.58%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.58%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 10.07%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 5.66pt; text-align: left;"><font style="padding-left: 17.5pt; border-bottom: 1pt solid #000000; min-width: 35.83pt;">(224</font><font style="min-width: 35.83pt;">)</font></div></td></tr><tr><td style="width: 66.67%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Loss for the year<font style="font-weight: normal; padding-left: 0.27pt;"></font></div></td><td class="gutter" style="width: 1.58%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.58%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 3.72%; text-align: center; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.58%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.58%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.07%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 5.66pt; text-align: left;"><font style="padding-left: 0.55pt; border-bottom: 3pt double #000000; min-width: 35.83pt;">(116,484</font><font style="min-width: 35.83pt;">)</font></div></td><td class="gutter" style="width: 1.58%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.58%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.07%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 5.66pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 35.83pt;">(123,096</font><font style="min-width: 35.83pt;">)</font></div></td></tr><tr><td style="width: 66.67%; text-align: left; vertical-align: bottom; padding-top: 5.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.58%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.58%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 3.72%; text-align: center; vertical-align: bottom; padding-top: 5.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.58%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.58%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 10.07%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 5.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.58%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.58%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 10.07%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 5.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 66.67%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Attributable to:<br></div></td><td class="gutter" style="width: 1.58%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.58%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 3.72%; text-align: center; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.58%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.58%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.07%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.58%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.58%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.07%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 66.67%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Owners of the parent<font style="padding-left: 2.88pt;"></font></div></td><td class="gutter" style="width: 1.58%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.58%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 3.72%; text-align: center; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.58%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.58%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 10.07%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 5.66pt; text-align: left;"><font style="padding-left: 0.37pt;">(116,484)</font></div></td><td class="gutter" style="width: 1.58%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.58%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 10.07%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 5.66pt; text-align: left;">(123,096)</div></td></tr><tr><td style="width: 66.67%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.58%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.58%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 3.72%; text-align: center; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.58%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.58%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.07%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.58%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.58%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.07%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 66.67%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Loss per share<br></div></td><td class="gutter" style="width: 1.58%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.58%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 3.72%; text-align: center; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.58%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.58%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 10.07%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.58%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.58%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 10.07%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 66.67%; text-align: left; vertical-align: bottom; padding-top: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Basic and diluted loss per share (in USD)<font style="padding-left: 2.91pt;"></font></div></td><td class="gutter" style="width: 1.58%; border-bottom: none; font-size: 2pt; padding-top: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.58%; border-bottom: none; font-size: 2pt; padding-top: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 3.72%; text-align: center; vertical-align: bottom; padding-top: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">28</div></td><td class="gutter" style="width: 1.58%; border-bottom: none; font-size: 2pt; padding-top: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.58%; border-bottom: none; font-size: 2pt; padding-top: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.07%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 5.66pt; text-align: left;"><font style="padding-left: 15pt;">(</font>2.36)</div></td><td class="gutter" style="width: 1.58%; border-bottom: none; font-size: 2pt; padding-top: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.58%; border-bottom: none; font-size: 2pt; padding-top: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.07%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 5.66pt; text-align: left;"><font style="padding-left: 15pt;">(2.</font>64)</div></td></tr></table></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 36pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">The notes on pages F-<a href="#tNTC">31</a> to F-<a href="#tNTC1">69</a> form an integral part of these consolidated financial statements<br></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 36pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">F-26<br></div></div></div>
<!--End Page 280-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 281-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 540pt;"><a name="nt10014672x1_drs_203-fintab02_pg4"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="block-frill" style="width: 540pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: Arial, Helvetica, sans-serif; font-size: 9pt; font-weight: bold; margin-top: 6pt; text-align: center;">Confidential Treatment Requested by ADC Therapeutics SA Pursuant to 17 C.F.R. &#167; 200.83<br></div></div><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 36pt;"><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">ADC Therapeutics SA, Epalinges</div><div><div class="rule-full" style="height: 0pt; width: 100%; border-bottom: 1pt solid #000000; margin-bottom: 2pt; margin-left: auto; margin-right: auto; margin-top: 7.5pt;"> </div></div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 20.5pt; margin-left: 0pt; text-align: left;"><a name="tCSCI"><!--Anchor--></a>CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME<br></div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">(in KUSD)</div><table cellspacing="0" cellpadding="0" class="fintab" style="margin-top: 10.25pt; border-collapse: collapse; width: 468pt; margin-left: auto; margin-right: auto;"><tr class="header"><td style="width: 66.67%; text-align: left; vertical-align: bottom; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.63%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 3.42%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Note</div></td><td class="gutter" style="width: 1.63%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.63%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 10.08%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Year ended <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">December&#160;31, <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2019</div></td><td class="gutter" style="width: 1.63%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.63%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 10.08%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Year ended <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">December&#160;31, <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2018</div></td></tr><tr><td style="width: 66.67%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Loss for the year<font style="font-weight: normal; padding-left: 0.27pt;"></font></div></td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 3.42%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.08%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 5.85pt; text-align: left;"><font style="padding-left: 0.18pt;">(116,484)</font></div></td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.08%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 5.67pt; text-align: left;">(123,096)</div></td></tr><tr><td style="width: 66.67%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 3.42%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 10.08%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td></tr><tr><td style="width: 66.67%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Other comprehensive (loss) / profit:<br></div></td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 3.42%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.08%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.08%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 66.67%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><u>Items that will not be reclassified to profit or loss</u><br></div></td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 3.42%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 10.08%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 10.08%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 66.67%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Remeasurements of defined benefit plan<font style="padding-left: 4.57pt;"></font></div></td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 3.42%; text-align: center; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">22</div></td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.08%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 5.85pt; text-align: left;"><font style="padding-left: 9.63pt; border-bottom: 1pt solid #000000; min-width: 35.46pt;">(1,346</font><font style="min-width: 35.46pt;">)</font></div></td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.08%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 5.67pt; text-align: left;"><font style="padding-left: 17.5pt; border-bottom: 1pt solid #000000; min-width: 35.83pt;">(193</font><font style="min-width: 35.83pt;">)</font></div></td></tr><tr><td style="width: 66.67%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Total items that will not be reclassified to profit or loss<font style="padding-left: 1.96pt;"></font></div></td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 3.42%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 10.08%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 5.85pt; text-align: left;"><font style="padding-left: 9.63pt;">(1,346)</font></div></td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 10.08%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 5.67pt; text-align: left;"><font style="padding-left: 17.5pt;">(193)</font></div></td></tr><tr><td style="width: 66.67%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><u>Items that may be reclassified subsequently to profit or loss</u><br></div></td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 3.42%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.08%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.08%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 66.67%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Currency translation differences<font style="padding-left: 4.19pt;"></font></div></td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 3.42%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 10.08%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 5.85pt; text-align: left;"><font style="padding-left: 20.83pt; border-bottom: 1pt solid #000000; min-width: 35.46pt;">112</font></div></td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 10.08%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 5.67pt; text-align: left;"><font style="padding-left: 22.5pt; border-bottom: 1pt solid #000000; min-width: 35.83pt;">(79</font><font style="min-width: 35.83pt;">)</font></div></td></tr><tr><td style="width: 66.67%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Total items that may be reclassified subsequently to profit or loss<font style="padding-left: 0.86pt;"></font></div></td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 3.42%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.08%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 5.85pt; text-align: left;"><font style="padding-left: 20.83pt; border-bottom: 1pt solid #000000; min-width: 35.46pt;">112</font></div></td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.08%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 5.67pt; text-align: left;"><font style="padding-left: 22.5pt; border-bottom: 1pt solid #000000; min-width: 35.83pt;">(79</font><font style="min-width: 35.83pt;">)</font></div></td></tr><tr><td style="width: 66.67%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 3.42%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 10.08%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 10.08%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 66.67%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Other comprehensive loss for the year<font style="font-weight: normal; padding-left: 3.45pt;"></font></div></td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 3.42%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.08%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 5.85pt; text-align: left;"><font style="padding-left: 9.63pt; border-bottom: 1pt solid #000000; min-width: 35.46pt;">(1,234</font><font style="min-width: 35.46pt;">)</font></div></td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.08%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 5.67pt; text-align: left;"><font style="padding-left: 17.5pt; border-bottom: 1pt solid #000000; min-width: 35.83pt;">(272</font><font style="min-width: 35.83pt;">)</font></div></td></tr><tr><td style="width: 66.67%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 3.42%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 10.08%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 10.08%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 66.67%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 5.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Total comprehensive loss for the year<font style="font-weight: normal; padding-left: 1.96pt;"></font></div></td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 5.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 5.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 3.42%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 5.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 5.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 5.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.08%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 5.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 5.85pt; text-align: left;"><font style="padding-left: 0.18pt; border-bottom: 3pt double #000000; min-width: 35.46pt;">(117,718</font><font style="min-width: 35.46pt;">)</font></div></td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 5.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 5.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.08%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 5.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 5.67pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 35.83pt;">(123,368</font><font style="min-width: 35.83pt;">)</font></div></td></tr><tr><td style="width: 66.67%; text-align: left; vertical-align: bottom; padding-top: 5.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 3.42%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 5.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 10.08%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 5.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 10.08%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 5.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 66.67%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Attributable to:<br></div></td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 3.42%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.08%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.08%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 66.67%; text-align: left; vertical-align: bottom; padding-top: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Owners of the parent<font style="padding-left: 2.88pt;"></font></div></td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 3pt;">&#8203;</td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 3pt;">&#8203;</td><td style="width: 3.42%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 3pt;">&#8203;</td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 3pt;">&#8203;</td><td style="width: 10.08%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 5.85pt; text-align: left;">(117,718)</div></td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 3pt;">&#8203;</td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 3pt;">&#8203;</td><td style="width: 10.08%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 5.67pt; text-align: left;">(123,368)</div></td></tr></table></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 36pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">The notes on pages F-<a href="#tNTC">31</a> to F-<a href="#tNTC1">69</a> form an integral part of these consolidated financial statements<br></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 36pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">F-27<br></div></div></div>
<!--End Page 281-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 282-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 540pt;"><a name="nt10014672x1_drs_203-fintab02_pg5"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="block-frill" style="width: 540pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: Arial, Helvetica, sans-serif; font-size: 9pt; font-weight: bold; margin-top: 6pt; text-align: center;">Confidential Treatment Requested by ADC Therapeutics SA Pursuant to 17 C.F.R. &#167; 200.83<br></div></div><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 36pt;"><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">ADC Therapeutics SA, Epalinges</div><div><div class="rule-full" style="height: 0pt; width: 100%; border-bottom: 1pt solid #000000; margin-bottom: 2pt; margin-left: auto; margin-right: auto; margin-top: 7.5pt;"> </div></div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 20.5pt; margin-left: 0pt; text-align: left;"><a name="tCBS"><!--Anchor--></a>CONSOLIDATED BALANCE SHEET<br></div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">(in KUSD)</div><table cellspacing="0" cellpadding="0" class="fintab" style="margin-top: 10.25pt; border-collapse: collapse; width: 468pt; margin-left: auto; margin-right: auto;"><tr class="header"><td style="width: 66.67%; text-align: left; vertical-align: bottom; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 0.93%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 0.93%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 7.6%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Note</div></td><td class="gutter" style="width: 0.93%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 0.93%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 10.08%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">December&#160;31, <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2019</div></td><td class="gutter" style="width: 0.93%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 0.93%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 10.08%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">December&#160;31, <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2018</div></td></tr><tr><td style="width: 66.67%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">ASSETS<br></div></td><td class="gutter" style="width: 0.93%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.93%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.6%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.93%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.93%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.08%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.93%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.93%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.08%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 66.67%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Current assets<br></div></td><td class="gutter" style="width: 0.93%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.93%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 7.6%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.93%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.93%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 10.08%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.93%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.93%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 10.08%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 66.67%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Cash and cash equivalents<font style="padding-left: 1.77pt;"></font></div></td><td class="gutter" style="width: 0.93%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.93%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.6%; text-align: center; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">19</div></td><td class="gutter" style="width: 0.93%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.93%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.08%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 5.67pt; text-align: left;"><font style="padding-left: 3.7pt;">115,551</font></div></td><td class="gutter" style="width: 0.93%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.93%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.08%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 5.67pt; text-align: left;"><font style="padding-left: 3.33pt;">138,807</font></div></td></tr><tr><td style="width: 66.67%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Trade accounts receivable<font style="padding-left: 3.8pt;"></font></div></td><td class="gutter" style="width: 0.93%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.93%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 7.6%; text-align: center; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">13/19/27</div></td><td class="gutter" style="width: 0.93%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.93%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 10.08%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 5.67pt; text-align: left;"><font style="padding-left: 25.83pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.93%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.93%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 10.08%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 5.67pt; text-align: left;"><font style="padding-left: 20.83pt;">192</font></div></td></tr><tr><td style="width: 66.67%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Other current assets<font style="padding-left: 3.44pt;"></font></div></td><td class="gutter" style="width: 0.93%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.93%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.6%; text-align: center; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">14</div></td><td class="gutter" style="width: 0.93%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.93%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.08%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 5.67pt; text-align: left;"><font style="padding-left: 13.33pt; border-bottom: 1pt solid #000000; min-width: 35.83pt;">7,055</font></div></td><td class="gutter" style="width: 0.93%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.93%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.08%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 5.67pt; text-align: left;"><font style="padding-left: 13.33pt; border-bottom: 1pt solid #000000; min-width: 35.83pt;">3,081</font></div></td></tr><tr><td style="width: 66.67%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Total current assets<font style="font-weight: normal; padding-left: 4.53pt;"></font></div></td><td class="gutter" style="width: 0.93%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.93%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 7.6%; text-align: center; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.93%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.93%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 10.08%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 5.67pt; text-align: left;"><font style="padding-left: 3.33pt;">122,606</font></div></td><td class="gutter" style="width: 0.93%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.93%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 10.08%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 5.67pt; text-align: left;"><font style="padding-left: 3.33pt;">142,080</font></div></td></tr><tr><td style="width: 66.67%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Non-current assets<br></div></td><td class="gutter" style="width: 0.93%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.93%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.6%; text-align: center; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.93%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.93%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.08%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.93%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.93%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.08%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 66.67%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Property, plant and equipment<font style="padding-left: 1.57pt;"></font></div></td><td class="gutter" style="width: 0.93%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.93%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 7.6%; text-align: center; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">16</div></td><td class="gutter" style="width: 0.93%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.93%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 10.08%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 5.67pt; text-align: left;"><font style="padding-left: 13.33pt;">1,376</font></div></td><td class="gutter" style="width: 0.93%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.93%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 10.08%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 5.67pt; text-align: left;"><font style="padding-left: 13.33pt;">1,540</font></div></td></tr><tr><td style="width: 66.67%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Right-of-use assets<font style="padding-left: 2.31pt;"></font></div></td><td class="gutter" style="width: 0.93%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.93%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.6%; text-align: center; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">4/17</div></td><td class="gutter" style="width: 0.93%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.93%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.08%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 5.67pt; text-align: left;"><font style="padding-left: 13.33pt;">4,898</font></div></td><td class="gutter" style="width: 0.93%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.93%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.08%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 5.67pt; text-align: left;"><font style="padding-left: 25.83pt;">&#8212;</font></div></td></tr><tr><td style="width: 66.67%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Intangible assets<font style="padding-left: 2.31pt;"></font></div></td><td class="gutter" style="width: 0.93%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.93%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 7.6%; text-align: center; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">18</div></td><td class="gutter" style="width: 0.93%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.93%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 10.08%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 5.67pt; text-align: left;"><font style="padding-left: 13.33pt;">8,434</font></div></td><td class="gutter" style="width: 0.93%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.93%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 10.08%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 5.67pt; text-align: left;"><font style="padding-left: 13.33pt;">6,674</font></div></td></tr><tr><td style="width: 66.67%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Other long-term assets<font style="padding-left: 2.32pt;"></font></div></td><td class="gutter" style="width: 0.93%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.93%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.6%; text-align: center; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.93%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.93%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.08%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 5.67pt; text-align: left;"><font style="padding-left: 20.83pt; border-bottom: 1pt solid #000000; min-width: 35.83pt;">368</font></div></td><td class="gutter" style="width: 0.93%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.93%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.08%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 5.67pt; text-align: left;"><font style="padding-left: 20.83pt; border-bottom: 1pt solid #000000; min-width: 35.83pt;">264</font></div></td></tr><tr><td style="width: 66.67%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Total non-current assets<font style="font-weight: normal; padding-left: 0.09pt;"></font></div></td><td class="gutter" style="width: 0.93%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 0.93%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 7.6%; text-align: center; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.93%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 0.93%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 10.08%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 5.67pt; text-align: left;"><font style="padding-left: 8.33pt; border-bottom: 1pt solid #000000; min-width: 35.83pt;">15,076</font></div></td><td class="gutter" style="width: 0.93%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 0.93%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 10.08%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 5.67pt; text-align: left;"><font style="padding-left: 13.33pt; border-bottom: 1pt solid #000000; min-width: 35.83pt;">8,478</font></div></td></tr><tr><td style="width: 66.67%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.93%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.93%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.6%; text-align: center; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.93%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.93%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.08%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.93%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.93%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.08%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 66.67%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 5.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Total assets<font style="font-weight: normal; padding-left: 4.88pt;"></font></div></td><td class="gutter" style="width: 0.93%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 5.25pt;">&#8203;</td><td class="gutter" style="width: 0.93%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 5.25pt;">&#8203;</td><td style="width: 7.6%; text-align: center; vertical-align: bottom; padding-top: 3pt; padding-bottom: 5.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.93%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 5.25pt;">&#8203;</td><td class="gutter" style="width: 0.93%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 5.25pt;">&#8203;</td><td style="width: 10.08%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 5.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 5.67pt; text-align: left;"><font style="padding-left: 3.33pt; border-bottom: 3pt double #000000; min-width: 35.83pt;">137,682</font></div></td><td class="gutter" style="width: 0.93%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 5.25pt;">&#8203;</td><td class="gutter" style="width: 0.93%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 5.25pt;">&#8203;</td><td style="width: 10.08%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 5.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 5.67pt; text-align: left;"><font style="padding-left: 3.33pt; border-bottom: 3pt double #000000; min-width: 35.83pt;">150,558 </font></div></td></tr><tr><td style="width: 66.67%; text-align: left; vertical-align: bottom; padding-top: 5.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.93%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.93%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.6%; text-align: center; vertical-align: bottom; padding-top: 5.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.93%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.93%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.08%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 5.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.93%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.93%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.08%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 5.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 66.67%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">LIABILITIES AND EQUITY<br></div></td><td class="gutter" style="width: 0.93%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.93%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 7.6%; text-align: center; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.93%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.93%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 10.08%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.93%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.93%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 10.08%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 66.67%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Current liabilities<br></div></td><td class="gutter" style="width: 0.93%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.93%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.6%; text-align: center; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.93%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.93%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.08%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.93%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.93%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.08%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 66.67%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Trade accounts payable<font style="padding-left: 3.78pt;"></font></div></td><td class="gutter" style="width: 0.93%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.93%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 7.6%; text-align: center; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">19a/27</div></td><td class="gutter" style="width: 0.93%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.93%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 10.08%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 5.67pt; text-align: left;"><font style="padding-left: 13.33pt;">3,329</font></div></td><td class="gutter" style="width: 0.93%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.93%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 10.08%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 5.67pt; text-align: left;"><font style="padding-left: 13.33pt;">6,750</font></div></td></tr><tr><td style="width: 66.67%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Accrued liabilities and other payables<font style="padding-left: 0.12pt;"></font></div></td><td class="gutter" style="width: 0.93%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.93%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.6%; text-align: center; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">21</div></td><td class="gutter" style="width: 0.93%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.93%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.08%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 5.67pt; text-align: left;"><font style="padding-left: 8.33pt;">15,430</font></div></td><td class="gutter" style="width: 0.93%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.93%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.08%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 5.67pt; text-align: left;"><font style="padding-left: 8.33pt;">13,650</font></div></td></tr><tr><td style="width: 66.67%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Contract liability (short-term)<font style="padding-left: 3.99pt;"></font></div></td><td class="gutter" style="width: 0.93%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.93%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 7.6%; text-align: center; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">7</div></td><td class="gutter" style="width: 0.93%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.93%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 10.08%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 5.67pt; text-align: left;"><font style="padding-left: 25.83pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.93%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.93%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 10.08%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 5.67pt; text-align: left;"><font style="padding-left: 13.33pt;">1,765</font></div></td></tr><tr><td style="width: 66.67%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Lease liabilities (short-term)<font style="padding-left: 4pt;"></font></div></td><td class="gutter" style="width: 0.93%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.93%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.6%; text-align: center; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">4/17</div></td><td class="gutter" style="width: 0.93%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.93%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.08%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 5.67pt; text-align: left;"><font style="padding-left: 13.33pt;">1,132</font></div></td><td class="gutter" style="width: 0.93%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.93%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.08%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 5.67pt; text-align: left;"><font style="padding-left: 25.83pt;">&#8212;</font></div></td></tr><tr><td style="width: 66.67%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Current income tax payable<font style="padding-left: 1.21pt;"></font></div></td><td class="gutter" style="width: 0.93%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 0.93%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 7.6%; text-align: center; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.93%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 0.93%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 10.08%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 5.67pt; text-align: left;"><font style="padding-left: 25.83pt; border-bottom: 1pt solid #000000; min-width: 35.83pt;">52</font></div></td><td class="gutter" style="width: 0.93%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 0.93%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 10.08%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 5.67pt; text-align: left;"><font style="padding-left: 20.83pt; border-bottom: 1pt solid #000000; min-width: 35.83pt;">189</font></div></td></tr><tr><td style="width: 66.67%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Total current liabilities<font style="font-weight: normal; padding-left: 0.07pt;"></font></div></td><td class="gutter" style="width: 0.93%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.93%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.6%; text-align: center; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.93%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.93%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.08%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 5.67pt; text-align: left;"><font style="padding-left: 8.33pt;">19,943</font></div></td><td class="gutter" style="width: 0.93%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.93%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.08%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 5.67pt; text-align: left;"><font style="padding-left: 8.33pt;">22,354</font></div></td></tr><tr><td style="width: 66.67%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Non-current liabilities<br></div></td><td class="gutter" style="width: 0.93%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.93%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 7.6%; text-align: center; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.93%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.93%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 10.08%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.93%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.93%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 10.08%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 66.67%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Contract liability (long-term)<font style="padding-left: 1.2pt;"></font></div></td><td class="gutter" style="width: 0.93%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.93%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.6%; text-align: center; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">7</div></td><td class="gutter" style="width: 0.93%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.93%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.08%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 5.67pt; text-align: left;"><font style="padding-left: 25.83pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.93%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.93%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.08%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 5.67pt; text-align: left;"><font style="padding-left: 20.83pt;">575</font></div></td></tr><tr><td style="width: 66.67%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Lease liabilities (long-term)<font style="padding-left: 1.21pt;"></font></div></td><td class="gutter" style="width: 0.93%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.93%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 7.6%; text-align: center; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">4/17</div></td><td class="gutter" style="width: 0.93%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.93%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 10.08%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 5.67pt; text-align: left;"><font style="padding-left: 13.33pt;">3,899</font></div></td><td class="gutter" style="width: 0.93%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.93%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 10.08%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 5.67pt; text-align: left;"><font style="padding-left: 25.83pt;">&#8212;</font></div></td></tr><tr><td style="width: 66.67%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Defined benefit pension liabilities<font style="padding-left: 1.22pt;"></font></div></td><td class="gutter" style="width: 0.93%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.93%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.6%; text-align: center; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">22</div></td><td class="gutter" style="width: 0.93%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.93%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.08%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 5.67pt; text-align: left;"><font style="padding-left: 13.33pt; border-bottom: 1pt solid #000000; min-width: 35.83pt;">2,684</font></div></td><td class="gutter" style="width: 0.93%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.93%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.08%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 5.67pt; text-align: left;"><font style="padding-left: 13.33pt; border-bottom: 1pt solid #000000; min-width: 35.83pt;">1,386</font></div></td></tr><tr><td style="width: 66.67%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Total non-current liabilities<font style="font-weight: normal; padding-left: 0.63pt;"></font></div></td><td class="gutter" style="width: 0.93%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 0.93%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 7.6%; text-align: center; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.93%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 0.93%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 10.08%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 5.67pt; text-align: left;"><font style="padding-left: 13.33pt; border-bottom: 1pt solid #000000; min-width: 35.83pt;">6,583</font></div></td><td class="gutter" style="width: 0.93%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 0.93%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 10.08%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 5.67pt; text-align: left;"><font style="padding-left: 13.33pt; border-bottom: 1pt solid #000000; min-width: 35.83pt;">1,961</font></div></td></tr><tr><td style="width: 66.67%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.93%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.93%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.6%; text-align: center; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.93%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.93%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.08%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.93%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.93%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.08%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 66.67%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Total liabilities<font style="font-weight: normal; padding-left: 0.43pt;"></font></div></td><td class="gutter" style="width: 0.93%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.93%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 7.6%; text-align: center; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.93%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.93%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 10.08%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 5.67pt; text-align: left;"><font style="padding-left: 8.33pt;">26,526</font></div></td><td class="gutter" style="width: 0.93%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.93%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 10.08%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 5.67pt; text-align: left;"><font style="padding-left: 8.33pt;">24,315</font></div></td></tr><tr><td style="width: 66.67%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.93%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.93%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.6%; text-align: center; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.93%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.93%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.08%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.93%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.93%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.08%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 66.67%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Equity attributable to owners of the parent<br></div></td><td class="gutter" style="width: 0.93%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.93%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 7.6%; text-align: center; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.93%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.93%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 10.08%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.93%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.93%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 10.08%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 66.67%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Share capital<font style="padding-left: 1.75pt;"></font></div></td><td class="gutter" style="width: 0.93%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.93%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.6%; text-align: center; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">24</div></td><td class="gutter" style="width: 0.93%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.93%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.08%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 5.67pt; text-align: left;"><font style="padding-left: 13.33pt;">4,361</font></div></td><td class="gutter" style="width: 0.93%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.93%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.08%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 5.67pt; text-align: left;"><font style="padding-left: 20.83pt;">401</font></div></td></tr><tr><td style="width: 66.67%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Share premium<font style="padding-left: 2.3pt;"></font></div></td><td class="gutter" style="width: 0.93%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.93%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 7.6%; text-align: center; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">24</div></td><td class="gutter" style="width: 0.93%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.93%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 10.08%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 5.67pt; text-align: left;"><font style="padding-left: 3.33pt;">549,922</font></div></td><td class="gutter" style="width: 0.93%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.93%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 10.08%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 5.67pt; text-align: left;"><font style="padding-left: 3.33pt;">452,268</font></div></td></tr><tr><td style="width: 66.67%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Treasury shares<font style="padding-left: 1pt;"></font></div></td><td class="gutter" style="width: 0.93%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.93%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.6%; text-align: center; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">24</div></td><td class="gutter" style="width: 0.93%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.93%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.08%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 5.67pt; text-align: left;"><font style="padding-left: 17.5pt;">(100)</font></div></td><td class="gutter" style="width: 0.93%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.93%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.08%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 5.67pt; text-align: left;"><font style="padding-left: 25.83pt;">&#8212;</font></div></td></tr><tr><td style="width: 66.67%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Other reserves<font style="padding-left: 0.65pt;"></font></div></td><td class="gutter" style="width: 0.93%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.93%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 7.6%; text-align: center; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">22/23</div></td><td class="gutter" style="width: 0.93%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.93%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 10.08%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 5.67pt; text-align: left;"><font style="padding-left: 13.33pt;">5,473</font></div></td><td class="gutter" style="width: 0.93%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.93%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 10.08%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 5.67pt; text-align: left;"><font style="padding-left: 13.33pt;">5,702</font></div></td></tr><tr><td style="width: 66.67%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Cumulative translation adjustments<font style="padding-left: 1.2pt;"></font></div></td><td class="gutter" style="width: 0.93%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.93%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.6%; text-align: center; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.93%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.93%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.08%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 5.67pt; text-align: left;"><font style="padding-left: 25.83pt;">69</font></div></td><td class="gutter" style="width: 0.93%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.93%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.08%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 5.67pt; text-align: left;"><font style="padding-left: 22.5pt;">(43)</font></div></td></tr><tr><td style="width: 66.67%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Accumulated losses<font style="padding-left: 3.98pt;"></font></div></td><td class="gutter" style="width: 0.93%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 0.93%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 7.6%; text-align: center; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.93%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 0.93%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 10.08%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 5.67pt; text-align: left;"><font style="border-bottom: 1pt solid #000000; min-width: 35.83pt;">(448,569</font><font style="min-width: 35.83pt;">)</font></div></td><td class="gutter" style="width: 0.93%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 0.93%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 10.08%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 5.67pt; text-align: left;"><font style="border-bottom: 1pt solid #000000; min-width: 35.83pt;">(332,085</font><font style="min-width: 35.83pt;">)</font></div></td></tr><tr><td style="width: 66.67%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Total equity<font style="font-weight: normal; padding-left: 2.65pt;"></font></div></td><td class="gutter" style="width: 0.93%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.93%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.6%; text-align: center; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.93%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.93%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.08%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 5.67pt; text-align: left;"><font style="padding-left: 4.43pt; border-bottom: 1pt solid #000000; min-width: 35.83pt;">111,156</font></div></td><td class="gutter" style="width: 0.93%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.93%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.08%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 5.67pt; text-align: left;"><font style="padding-left: 3.33pt; border-bottom: 1pt solid #000000; min-width: 35.83pt;">126,243</font></div></td></tr><tr><td style="width: 66.67%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.93%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.93%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 7.6%; text-align: center; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.93%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.93%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 10.08%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.93%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.93%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 10.08%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 66.67%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 6pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Total liabilities and equity<font style="font-weight: normal; padding-left: 0.99pt;"></font></div></td><td class="gutter" style="width: 0.93%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.93%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.6%; text-align: center; vertical-align: bottom; padding-top: 3pt; padding-bottom: 6pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.93%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.93%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.08%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 6pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 5.67pt; text-align: left;"><font style="padding-left: 3.33pt; border-bottom: 3pt double #000000; min-width: 35.83pt;">137,682</font></div></td><td class="gutter" style="width: 0.93%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.93%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.08%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 6pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 5.67pt; text-align: left;"><font style="padding-left: 3.33pt; border-bottom: 3pt double #000000; min-width: 35.83pt;">150,558</font></div></td></tr></table></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 36pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">The notes on pages F-<a href="#tNTC">31</a> to F-<a href="#tNTC1">69</a> form an integral part of these consolidated financial statements<br></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 36pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">F-28<br></div></div></div>
<!--End Page 282-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 283-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 540pt;"><a name="nt10014672x1_drs_203-fintab02_pg6"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="block-frill" style="width: 540pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: Arial, Helvetica, sans-serif; font-size: 9pt; font-weight: bold; margin-top: 6pt; text-align: center;">Confidential Treatment Requested by ADC Therapeutics SA Pursuant to 17 C.F.R. &#167; 200.83<br></div></div><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 36pt;"><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">ADC Therapeutics SA, Epalinges</div><div><div class="rule-full" style="height: 0pt; width: 100%; border-bottom: 1pt solid #000000; margin-bottom: 2pt; margin-left: auto; margin-right: auto; margin-top: 7.5pt;"> </div></div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 20.5pt; margin-left: 0pt; text-align: left;"><a name="tCSCE"><!--Anchor--></a>CONSOLIDATED STATEMENT OF CHANGES IN EQUITY<br></div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">(in KUSD)</div><table cellspacing="0" cellpadding="0" class="fintab" style="margin-top: 10.25pt; border-collapse: collapse; width: 468pt; margin-left: auto; margin-right: auto;"><tr class="header"><td style="width: 34.4%; text-align: left; vertical-align: bottom; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 0.74%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 0.74%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 3.42%; text-align: center; vertical-align: bottom; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 0.74%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 0.74%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td colspan="19" style="width: 59.21%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Attributable to owners of the parent</div></td></tr><tr class="header"><td style="width: 34.4%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 0.74%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 0.74%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 3.42%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Note</div></td><td class="gutter" style="width: 0.74%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 0.74%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 4.94%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Share <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">capital</div></td><td class="gutter" style="width: 0.74%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 0.74%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 6.94%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Share <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">premium</div></td><td class="gutter" style="width: 0.74%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 0.74%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 5.95%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Other <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">reserves</div></td><td class="gutter" style="width: 0.74%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 0.74%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 6.59%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Treasury <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">shares</div></td><td class="gutter" style="width: 0.74%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 0.74%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 8.54%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Cumulative <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">translation <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">adjustment</div></td><td class="gutter" style="width: 0.74%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 0.74%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 9.68%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Accumulated <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">losses</div></td><td class="gutter" style="width: 0.74%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 0.74%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 7.65%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Total</div></td></tr><tr><td style="width: 34.4%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">January&#160;1, 2018<font style="font-weight: normal; padding-left: 3.79pt;"></font></div></td><td class="gutter" style="width: 0.74%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.74%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 3.42%; text-align: center; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.74%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.74%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 4.94%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0.31pt; text-align: left;"><font style="padding-left: 7.5pt;">397</font></div></td><td class="gutter" style="width: 0.74%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.74%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.94%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0.01pt; text-align: left;">452,296</div></td><td class="gutter" style="width: 0.74%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.74%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.95%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 1.01pt; text-align: left;"><font style="padding-left: 3.33pt;">5,426</font></div></td><td class="gutter" style="width: 0.74%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.74%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.59%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 6.25pt; text-align: left;"><font style="padding-left: 8.33pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.74%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.74%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.54%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 12.68pt; text-align: left;"><font style="padding-left: 4.63pt;">36</font></div></td><td class="gutter" style="width: 0.74%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.74%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.68%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 4.75pt; text-align: left;">(208,989)</div></td><td class="gutter" style="width: 0.74%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.74%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.65%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 3.33pt;">249,166</font></div></td></tr><tr><td style="width: 34.4%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Loss for the year<font style="padding-left: 3.54pt;"></font></div></td><td class="gutter" style="width: 0.74%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.74%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 3.42%; text-align: center; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.74%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.74%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 4.94%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.31pt; text-align: left;"><font style="padding-left: 12.5pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.74%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.74%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 6.94%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;"><font style="padding-left: 22.5pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.74%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.74%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 5.95%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.01pt; text-align: left;"><font style="padding-left: 15.83pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.74%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.74%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 6.59%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 6.25pt; text-align: left;"><font style="padding-left: 8.33pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.74%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.74%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 8.54%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 12.68pt; text-align: left;"><font style="padding-left: 4.63pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.74%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.74%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 9.68%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.75pt; text-align: left;">(123,096)</div></td><td class="gutter" style="width: 0.74%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.74%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 7.65%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;">(123,096)</div></td></tr><tr><td style="width: 34.4%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Translation adjustment<font style="padding-left: 1.1pt;"></font></div></td><td class="gutter" style="width: 0.74%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.74%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 3.42%; text-align: center; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.74%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.74%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 4.94%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.31pt; text-align: left;"><font style="padding-left: 12.5pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.74%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.74%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.94%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;"><font style="padding-left: 22.5pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.74%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.74%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.95%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.01pt; text-align: left;"><font style="padding-left: 15.83pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.74%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.74%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.59%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 6.25pt; text-align: left;"><font style="padding-left: 8.33pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.74%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.74%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.54%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 12.68pt; text-align: left;"><font style="padding-left: 1.3pt;">(79)</font></div></td><td class="gutter" style="width: 0.74%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.74%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.68%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.75pt; text-align: left;"><font style="padding-left: 25.83pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.74%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.74%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.65%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 22.5pt;">(79)</font></div></td></tr><tr><td style="width: 34.4%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 20pt; text-indent: -10pt; text-align: left;">Remeasurements of defined benefit pension<font style="padding-left: 2.39pt;"></font></div></td><td class="gutter" style="width: 0.74%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 0.74%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 3.42%; text-align: center; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">22</div></td><td class="gutter" style="width: 0.74%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 0.74%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 4.94%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.31pt; text-align: left;"><font style="padding-left: 12.5pt; border-bottom: 1pt solid #000000; min-width: 22.5pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.74%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 0.74%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 6.94%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;"><font style="padding-left: 22.5pt; border-bottom: 1pt solid #000000; min-width: 32.5pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.74%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 0.74%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 5.95%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.01pt; text-align: left;"><font style="padding-left: 7.5pt; border-bottom: 1pt solid #000000; min-width: 25.83pt;">(193</font><font style="min-width: 25.83pt;">)</font></div></td><td class="gutter" style="width: 0.74%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 0.74%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 6.59%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 6.25pt; text-align: left;"><font style="padding-left: 8.33pt; border-bottom: 1pt solid #000000; min-width: 18.33pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.74%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 0.74%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 8.54%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 12.68pt; text-align: left;"><font style="padding-left: 4.63pt; border-bottom: 1pt solid #000000; min-width: 14.63pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.74%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 0.74%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 9.68%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.75pt; text-align: left;"><font style="padding-left: 25.83pt; border-bottom: 1pt solid #000000; min-width: 35.83pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.74%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 0.74%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 7.65%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 17.5pt; border-bottom: 1pt solid #000000; min-width: 35.83pt;">(193</font><font style="min-width: 35.83pt;">)</font></div></td></tr><tr><td style="width: 34.4%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 10pt; text-align: left;">Total other comprehensive loss<font style="font-weight: normal; padding-left: 4.83pt;"></font></div></td><td class="gutter" style="width: 0.74%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.74%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 3.42%; text-align: center; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.74%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.74%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 4.94%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0.31pt; text-align: left;"><font style="padding-left: 12.5pt; border-bottom: 1pt solid #000000; min-width: 22.5pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.74%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.74%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.94%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0.01pt; text-align: left;"><font style="padding-left: 22.5pt; border-bottom: 1pt solid #000000; min-width: 32.5pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.74%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.74%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.95%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 1.01pt; text-align: left;"><font style="padding-left: 7.5pt; border-bottom: 1pt solid #000000; min-width: 25.83pt;">(193</font><font style="min-width: 25.83pt;">)</font></div></td><td class="gutter" style="width: 0.74%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.74%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.59%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 6.25pt; text-align: left;"><font style="padding-left: 8.33pt; border-bottom: 1pt solid #000000; min-width: 18.33pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.74%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.74%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.54%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 12.68pt; text-align: left;"><font style="padding-left: 1.3pt; border-bottom: 1pt solid #000000; min-width: 14.63pt;">(79</font><font style="min-width: 14.63pt;">)</font></div></td><td class="gutter" style="width: 0.74%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.74%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.68%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 4.75pt; text-align: left;"><font style="padding-left: 25.83pt; border-bottom: 1pt solid #000000; min-width: 35.83pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.74%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.74%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.65%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 17.5pt; border-bottom: 1pt solid #000000; min-width: 35.83pt;">(272</font><font style="min-width: 35.83pt;">)</font></div></td></tr><tr><td style="width: 34.4%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 10pt; text-indent: -10pt; text-align: left;">Total comprehensive loss for the year<font style="font-weight: normal; padding-left: 4.62pt;"></font></div></td><td class="gutter" style="width: 0.74%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.74%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 3.42%; text-align: center; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.74%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.74%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 4.94%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0.31pt; text-align: left;"><font style="padding-left: 12.5pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.74%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.74%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 6.94%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0.01pt; text-align: left;"><font style="padding-left: 22.5pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.74%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.74%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 5.95%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 1.01pt; text-align: left;"><font style="padding-left: 7.5pt;">(193)</font></div></td><td class="gutter" style="width: 0.74%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.74%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 6.59%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 6.25pt; text-align: left;"><font style="padding-left: 8.33pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.74%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.74%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 8.54%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 12.68pt; text-align: left;"><font style="padding-left: 1.3pt;">(79)</font></div></td><td class="gutter" style="width: 0.74%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.74%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 9.68%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 4.75pt; text-align: left;">(123,096)</div></td><td class="gutter" style="width: 0.74%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.74%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 7.65%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: -0.01pt; text-align: left;">(123,368)</div></td></tr><tr><td style="width: 34.4%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Issue of share capital<font style="padding-left: 1.89pt;"></font></div></td><td class="gutter" style="width: 0.74%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.74%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 3.42%; text-align: center; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">24</div></td><td class="gutter" style="width: 0.74%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.74%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 4.94%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.31pt; text-align: left;"><font style="padding-left: 17.5pt;">4</font></div></td><td class="gutter" style="width: 0.74%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.74%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.94%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;"><font style="padding-left: 22.5pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.74%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.74%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.95%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.01pt; text-align: left;"><font style="padding-left: 15.83pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.74%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.74%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.59%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 6.25pt; text-align: left;"><font style="padding-left: 8.33pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.74%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.74%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.54%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 12.68pt; text-align: left;"><font style="padding-left: 4.63pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.74%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.74%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.68%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.75pt; text-align: left;"><font style="padding-left: 25.83pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.74%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.74%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.65%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 30.83pt;">4</font></div></td></tr><tr><td style="width: 34.4%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Transaction costs<font style="padding-left: 3.32pt;"></font></div></td><td class="gutter" style="width: 0.74%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.74%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 3.42%; text-align: center; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">24</div></td><td class="gutter" style="width: 0.74%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.74%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 4.94%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.31pt; text-align: left;"><font style="padding-left: 12.5pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.74%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.74%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 6.94%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;"><font style="padding-left: 19.17pt;">(28)</font></div></td><td class="gutter" style="width: 0.74%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.74%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 5.95%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.01pt; text-align: left;"><font style="padding-left: 15.83pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.74%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.74%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 6.59%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 6.25pt; text-align: left;"><font style="padding-left: 8.33pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.74%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.74%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 8.54%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 12.68pt; text-align: left;"><font style="padding-left: 4.63pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.74%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.74%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 9.68%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.75pt; text-align: left;"><font style="padding-left: 25.83pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.74%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.74%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 7.65%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 22.5pt;">(28)</font></div></td></tr><tr><td style="width: 34.4%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Share-based compensation expense<font style="padding-left: 0.23pt;"></font></div></td><td class="gutter" style="width: 0.74%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.74%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 3.42%; text-align: center; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">23</div></td><td class="gutter" style="width: 0.74%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.74%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 4.94%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.31pt; text-align: left;"><font style="padding-left: 12.5pt; border-bottom: 1pt solid #000000; min-width: 22.5pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.74%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.74%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.94%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;"><font style="padding-left: 22.5pt; border-bottom: 1pt solid #000000; min-width: 32.5pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.74%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.74%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.95%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.01pt; text-align: left;"><font style="padding-left: 10.83pt; border-bottom: 1pt solid #000000; min-width: 25.83pt;">469</font></div></td><td class="gutter" style="width: 0.74%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.74%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.59%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 6.25pt; text-align: left;"><font style="padding-left: 8.33pt; border-bottom: 1pt solid #000000; min-width: 18.33pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.74%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.74%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.54%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 12.68pt; text-align: left;"><font style="padding-left: 4.63pt; border-bottom: 1pt solid #000000; min-width: 14.63pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.74%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.74%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.68%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.75pt; text-align: left;"><font style="padding-left: 25.83pt; border-bottom: 1pt solid #000000; min-width: 35.83pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.74%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.74%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.65%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 20.83pt; border-bottom: 1pt solid #000000; min-width: 35.83pt;">469</font></div></td></tr><tr><td style="width: 34.4%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Total transactions with owners<font style="font-weight: normal; padding-left: 0.02pt;"></font></div></td><td class="gutter" style="width: 0.74%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.74%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 3.42%; text-align: center; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.74%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.74%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 4.94%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0.31pt; text-align: left;"><font style="padding-left: 17.5pt;">4</font></div></td><td class="gutter" style="width: 0.74%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.74%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 6.94%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0.01pt; text-align: left;"><font style="padding-left: 19.17pt;">(28)</font></div></td><td class="gutter" style="width: 0.74%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.74%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 5.95%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 1.01pt; text-align: left;"><font style="padding-left: 10.83pt;">469</font></div></td><td class="gutter" style="width: 0.74%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.74%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 6.59%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 6.25pt; text-align: left;"><font style="padding-left: 8.33pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.74%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.74%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 8.54%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 12.68pt; text-align: left;"><font style="padding-left: 4.63pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.74%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.74%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 9.68%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 4.75pt; text-align: left;"><font style="padding-left: 25.83pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.74%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.74%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 7.65%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 20.83pt;">445</font></div></td></tr><tr><td style="width: 34.4%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 5.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">December&#160;31, 2018<font style="font-weight: normal; padding-left: 1.21pt;"></font></div></td><td class="gutter" style="width: 0.74%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 5.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.74%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 5.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 3.42%; text-align: center; vertical-align: bottom; padding-top: 3pt; padding-bottom: 5.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.74%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 5.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.74%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 5.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 4.94%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 5.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0.31pt; text-align: left;"><font style="padding-left: 7.5pt; border-bottom: 3pt double #000000; min-width: 22.5pt;">401</font></div></td><td class="gutter" style="width: 0.74%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 5.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.74%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 5.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.94%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 5.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0.01pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 32.5pt;">452,268</font></div></td><td class="gutter" style="width: 0.74%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 5.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.74%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 5.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.95%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 5.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 1.01pt; text-align: left;"><font style="padding-left: 3.33pt; border-bottom: 3pt double #000000; min-width: 25.83pt;">5,702</font></div></td><td class="gutter" style="width: 0.74%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 5.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.74%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 5.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.59%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 5.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 6.25pt; text-align: left;"><font style="padding-left: 8.33pt; border-bottom: 3pt double #000000; min-width: 18.33pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.74%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 5.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.74%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 5.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.54%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 5.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 12.68pt; text-align: left;"><font style="padding-left: 1.3pt; border-bottom: 3pt double #000000; min-width: 14.63pt;">(43</font><font style="min-width: 14.63pt;">)</font></div></td><td class="gutter" style="width: 0.74%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 5.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.74%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 5.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.68%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 5.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 4.75pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 35.83pt;">(332,085</font><font style="min-width: 35.83pt;">)</font></div></td><td class="gutter" style="width: 0.74%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 5.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.74%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 5.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.65%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 5.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 3.33pt; border-bottom: 3pt double #000000; min-width: 35.83pt;">126,243</font></div></td></tr><tr><td style="width: 34.4%; text-align: left; vertical-align: bottom; padding-top: 5.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Loss for the year<font style="padding-left: 3.54pt;"></font></div></td><td class="gutter" style="width: 0.74%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.74%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 3.42%; text-align: center; vertical-align: bottom; padding-top: 5.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.74%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.74%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 4.94%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 5.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.31pt; text-align: left;"><font style="padding-left: 12.5pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.74%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.74%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 6.94%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 5.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;"><font style="padding-left: 22.5pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.74%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.74%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 5.95%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 5.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.01pt; text-align: left;"><font style="padding-left: 15.83pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.74%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.74%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 6.59%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 5.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 6.25pt; text-align: left;"><font style="padding-left: 8.33pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.74%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.74%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 8.54%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 5.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 12.68pt; text-align: left;"><font style="padding-left: 4.63pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.74%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.74%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 9.68%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 5.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.75pt; text-align: left;"><font style="padding-left: 0.37pt;">(116,484)</font></div></td><td class="gutter" style="width: 0.74%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.74%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 7.65%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 5.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 0.37pt;">(116,484)</font></div></td></tr><tr><td style="width: 34.4%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Translation adjustment<font style="padding-left: 1.1pt;"></font></div></td><td class="gutter" style="width: 0.74%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.74%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 3.42%; text-align: center; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.74%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.74%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 4.94%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.31pt; text-align: left;"><font style="padding-left: 12.5pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.74%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.74%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.94%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;"><font style="padding-left: 22.5pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.74%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.74%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.95%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.01pt; text-align: left;"><font style="padding-left: 15.83pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.74%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.74%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.59%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 6.25pt; text-align: left;"><font style="padding-left: 8.33pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.74%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.74%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.54%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 12.68pt; text-align: left;">112</div></td><td class="gutter" style="width: 0.74%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.74%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.68%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.75pt; text-align: left;"><font style="padding-left: 25.83pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.74%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.74%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.65%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 21.2pt;">112</font></div></td></tr><tr><td style="width: 34.4%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 20pt; text-indent: -10pt; text-align: left;">Remeasurements of defined benefit pension<font style="padding-left: 2.39pt;"></font></div></td><td class="gutter" style="width: 0.74%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 0.74%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 3.42%; text-align: center; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">22</div></td><td class="gutter" style="width: 0.74%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 0.74%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 4.94%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.31pt; text-align: left;"><font style="padding-left: 12.5pt; border-bottom: 1pt solid #000000; min-width: 22.5pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.74%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 0.74%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 6.94%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;"><font style="padding-left: 22.5pt; border-bottom: 1pt solid #000000; min-width: 32.5pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.74%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 0.74%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 5.95%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.01pt; text-align: left;"><font style="border-bottom: 1pt solid #000000; min-width: 25.83pt;">(1,346</font><font style="min-width: 25.83pt;">)</font></div></td><td class="gutter" style="width: 0.74%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 0.74%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 6.59%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 6.25pt; text-align: left;"><font style="padding-left: 8.33pt; border-bottom: 1pt solid #000000; min-width: 18.33pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.74%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 0.74%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 8.54%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 12.68pt; text-align: left;"><font style="padding-left: 4.63pt; border-bottom: 1pt solid #000000; min-width: 14.63pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.74%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 0.74%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 9.68%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.75pt; text-align: left;"><font style="padding-left: 25.83pt; border-bottom: 1pt solid #000000; min-width: 35.83pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.74%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 0.74%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 7.65%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 10pt; border-bottom: 1pt solid #000000; min-width: 35.83pt;">(1,346</font><font style="min-width: 35.83pt;">)</font></div></td></tr><tr><td style="width: 34.4%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 10pt; text-align: left;">Total other comprehensive loss<font style="font-weight: normal; padding-left: 4.83pt;"></font></div></td><td class="gutter" style="width: 0.74%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.74%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 3.42%; text-align: center; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.74%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.74%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 4.94%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0.31pt; text-align: left;"><font style="padding-left: 12.5pt; border-bottom: 1pt solid #000000; min-width: 22.5pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.74%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.74%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.94%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0.01pt; text-align: left;"><font style="padding-left: 22.5pt; border-bottom: 1pt solid #000000; min-width: 32.5pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.74%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.74%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.95%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 1.01pt; text-align: left;"><font style="border-bottom: 1pt solid #000000; min-width: 25.83pt;">(1,346</font><font style="min-width: 25.83pt;">)</font></div></td><td class="gutter" style="width: 0.74%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.74%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.59%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 6.25pt; text-align: left;"><font style="padding-left: 8.33pt; border-bottom: 1pt solid #000000; min-width: 18.33pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.74%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.74%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.54%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 12.68pt; text-align: left;"><font style="padding-left: 0.18pt; border-bottom: 1pt solid #000000; min-width: 14.63pt;">112</font></div></td><td class="gutter" style="width: 0.74%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.74%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.68%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 4.75pt; text-align: left;"><font style="padding-left: 25.83pt; border-bottom: 1pt solid #000000; min-width: 35.83pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.74%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.74%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.65%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 10pt; border-bottom: 1pt solid #000000; min-width: 35.83pt;">(1,234</font><font style="min-width: 35.83pt;">)</font></div></td></tr><tr><td style="width: 34.4%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 10pt; text-indent: -10pt; text-align: left;">Total comprehensive loss for the year<font style="font-weight: normal; padding-left: 4.62pt;"></font></div></td><td class="gutter" style="width: 0.74%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.74%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 3.42%; text-align: center; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.74%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.74%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 4.94%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0.31pt; text-align: left;"><font style="padding-left: 12.5pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.74%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.74%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 6.94%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0.01pt; text-align: left;"><font style="padding-left: 22.5pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.74%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.74%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 5.95%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 1.01pt; text-align: left;">(1,346)</div></td><td class="gutter" style="width: 0.74%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.74%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 6.59%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 6.25pt; text-align: left;"><font style="padding-left: 8.33pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.74%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.74%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 8.54%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 12.68pt; text-align: left;"><font style="padding-left: 0.18pt;">112</font></div></td><td class="gutter" style="width: 0.74%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.74%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 9.68%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 4.75pt; text-align: left;"><font style="padding-left: 0.55pt;">(116,484)</font></div></td><td class="gutter" style="width: 0.74%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.74%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 7.65%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 0.55pt;">(117,718)</font></div></td></tr><tr><td style="width: 34.4%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 20pt; text-indent: -10pt; text-align: left;">Issue of share capital / capital contributions<font style="padding-left: 0.73pt;"></font></div></td><td class="gutter" style="width: 0.74%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.74%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 3.42%; text-align: center; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">24</div></td><td class="gutter" style="width: 0.74%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.74%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 4.94%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.31pt; text-align: left;"><font style="padding-left: 7.5pt;">171</font></div></td><td class="gutter" style="width: 0.74%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.74%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.94%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;">103,221</div></td><td class="gutter" style="width: 0.74%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.74%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.95%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.01pt; text-align: left;"><font style="padding-left: 15.83pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.74%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.74%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.59%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 6.25pt; text-align: left;"><font style="padding-left: 8.33pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.74%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.74%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.54%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 12.68pt; text-align: left;"><font style="padding-left: 4.63pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.74%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.74%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.68%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.75pt; text-align: left;"><font style="padding-left: 25.83pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.74%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.74%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.65%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 3.33pt;">103,392</font></div></td></tr><tr><td style="width: 34.4%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Transaction costs<font style="padding-left: 3.32pt;"></font></div></td><td class="gutter" style="width: 0.74%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.74%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 3.42%; text-align: center; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">24</div></td><td class="gutter" style="width: 0.74%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.74%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 4.94%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.31pt; text-align: left;"><font style="padding-left: 12.5pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.74%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.74%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 6.94%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;"><font style="padding-left: 6.67pt;">(1,778)</font></div></td><td class="gutter" style="width: 0.74%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.74%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 5.95%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.01pt; text-align: left;"><font style="padding-left: 15.83pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.74%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.74%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 6.59%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 6.25pt; text-align: left;"><font style="padding-left: 8.33pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.74%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.74%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 8.54%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 12.68pt; text-align: left;"><font style="padding-left: 4.63pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.74%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.74%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 9.68%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.75pt; text-align: left;"><font style="padding-left: 25.83pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.74%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.74%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 7.65%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 10pt;">(1,778)</font></div></td></tr><tr><td style="width: 34.4%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 20pt; text-indent: -10pt; text-align: left;">Transfer from share premium for par value increase<font style="padding-left: 4.66pt;"></font></div></td><td class="gutter" style="width: 0.74%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.74%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 3.42%; text-align: center; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">24</div></td><td class="gutter" style="width: 0.74%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.74%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 4.94%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.31pt; text-align: left;">3,789</div></td><td class="gutter" style="width: 0.74%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.74%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.94%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;"><font style="padding-left: 6.67pt;">(3,789)</font></div></td><td class="gutter" style="width: 0.74%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.74%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.95%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.01pt; text-align: left;"><font style="padding-left: 15.83pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.74%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.74%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.59%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 6.25pt; text-align: left;"><font style="padding-left: 8.33pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.74%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.74%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.54%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 12.68pt; text-align: left;"><font style="padding-left: 4.63pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.74%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.74%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.68%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.75pt; text-align: left;"><font style="padding-left: 25.83pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.74%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.74%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.65%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 25.83pt;">&#8212;</font></div></td></tr><tr><td style="width: 34.4%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Purchase of treasury shares<font style="padding-left: 1.9pt;"></font></div></td><td class="gutter" style="width: 0.74%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.74%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 3.42%; text-align: center; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">24</div></td><td class="gutter" style="width: 0.74%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.74%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 4.94%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.31pt; text-align: left;"><font style="padding-left: 12.5pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.74%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.74%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 6.94%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;"><font style="padding-left: 22.5pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.74%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.74%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 5.95%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.01pt; text-align: left;"><font style="padding-left: 15.83pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.74%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.74%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 6.59%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 6.25pt; text-align: left;">(141)</div></td><td class="gutter" style="width: 0.74%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.74%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 8.54%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 12.68pt; text-align: left;"><font style="padding-left: 4.63pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.74%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.74%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 9.68%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.75pt; text-align: left;"><font style="padding-left: 25.83pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.74%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.74%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 7.65%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 17.5pt;">(141)</font></div></td></tr><tr><td style="width: 34.4%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Sale of treasury shares<font style="padding-left: 0.78pt;"></font></div></td><td class="gutter" style="width: 0.74%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.74%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 3.42%; text-align: center; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">24</div></td><td class="gutter" style="width: 0.74%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.74%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 4.94%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.31pt; text-align: left;"><font style="padding-left: 12.5pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.74%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.74%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.94%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;"><font style="padding-left: 22.5pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.74%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.74%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.95%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.01pt; text-align: left;"><font style="padding-left: 15.83pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.74%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.74%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.59%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 6.25pt; text-align: left;"><font style="padding-left: 8.33pt;">41</font></div></td><td class="gutter" style="width: 0.74%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.74%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.54%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 12.68pt; text-align: left;"><font style="padding-left: 4.63pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.74%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.74%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.68%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.75pt; text-align: left;"><font style="padding-left: 25.83pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.74%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.74%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.65%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 25.83pt;">41</font></div></td></tr><tr><td style="width: 34.4%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Share-based compensation expense<font style="padding-left: 0.23pt;"></font></div></td><td class="gutter" style="width: 0.74%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 0.74%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 3.42%; text-align: center; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">23</div></td><td class="gutter" style="width: 0.74%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 0.74%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 4.94%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.31pt; text-align: left;"><font style="padding-left: 12.5pt; border-bottom: 1pt solid #000000; min-width: 22.5pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.74%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 0.74%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 6.94%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;"><font style="padding-left: 22.5pt; border-bottom: 1pt solid #000000; min-width: 32.5pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.74%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 0.74%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 5.95%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.01pt; text-align: left;"><font style="padding-left: 3.7pt; border-bottom: 1pt solid #000000; min-width: 25.83pt;">1,117</font></div></td><td class="gutter" style="width: 0.74%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 0.74%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 6.59%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 6.25pt; text-align: left;"><font style="padding-left: 8.33pt; border-bottom: 1pt solid #000000; min-width: 18.33pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.74%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 0.74%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 8.54%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 12.68pt; text-align: left;"><font style="padding-left: 4.63pt; border-bottom: 1pt solid #000000; min-width: 14.63pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.74%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 0.74%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 9.68%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.75pt; text-align: left;"><font style="padding-left: 25.83pt; border-bottom: 1pt solid #000000; min-width: 35.83pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.74%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 0.74%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 7.65%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 13.7pt; border-bottom: 1pt solid #000000; min-width: 35.83pt;">1,117</font></div></td></tr><tr><td style="width: 34.4%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Total transactions with owners<font style="font-weight: normal; padding-left: 0.02pt;"></font></div></td><td class="gutter" style="width: 0.74%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.74%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 3.42%; text-align: center; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.74%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.74%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 4.94%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0.31pt; text-align: left;">3,960</div></td><td class="gutter" style="width: 0.74%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.74%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.94%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0.01pt; text-align: left;"><font style="padding-left: 5pt;">97,654</font></div></td><td class="gutter" style="width: 0.74%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.74%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.95%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 1.01pt; text-align: left;"><font style="padding-left: 3.88pt;">1,117</font></div></td><td class="gutter" style="width: 0.74%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.74%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.59%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 6.25pt; text-align: left;">(100)</div></td><td class="gutter" style="width: 0.74%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.74%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.54%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 12.68pt; text-align: left;"><font style="padding-left: 4.63pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.74%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.74%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.68%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 4.75pt; text-align: left;"><font style="padding-left: 25.83pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.74%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.74%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.65%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 3.33pt;">102,631</font></div></td></tr><tr><td style="width: 34.4%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 6pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">December&#160;31, 2019<font style="font-weight: normal; padding-left: 1.21pt;"></font></div></td><td class="gutter" style="width: 0.74%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 6pt;">&#8203;</td><td class="gutter" style="width: 0.74%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 6pt;">&#8203;</td><td style="width: 3.42%; text-align: center; vertical-align: bottom; padding-top: 3pt; padding-bottom: 6pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.74%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 6pt;">&#8203;</td><td class="gutter" style="width: 0.74%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 6pt;">&#8203;</td><td style="width: 4.94%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 6pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0.31pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 22.5pt;">4,361</font></div></td><td class="gutter" style="width: 0.74%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 6pt;">&#8203;</td><td class="gutter" style="width: 0.74%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 6pt;">&#8203;</td><td style="width: 6.94%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 6pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0.01pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 32.5pt;">549,922</font></div></td><td class="gutter" style="width: 0.74%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 6pt;">&#8203;</td><td class="gutter" style="width: 0.74%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 6pt;">&#8203;</td><td style="width: 5.95%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 6pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 1.01pt; text-align: left;"><font style="padding-left: 3.33pt; border-bottom: 3pt double #000000; min-width: 25.83pt;">5,473</font></div></td><td class="gutter" style="width: 0.74%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 6pt;">&#8203;</td><td class="gutter" style="width: 0.74%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 6pt;">&#8203;</td><td style="width: 6.59%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 6pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 6.25pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 18.33pt;">(100</font><font style="min-width: 18.33pt;">)</font></div></td><td class="gutter" style="width: 0.74%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 6pt;">&#8203;</td><td class="gutter" style="width: 0.74%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 6pt;">&#8203;</td><td style="width: 8.54%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 6pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 12.68pt; text-align: left;"><font style="padding-left: 4.63pt; border-bottom: 3pt double #000000; min-width: 14.63pt;">69</font></div></td><td class="gutter" style="width: 0.74%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 6pt;">&#8203;</td><td class="gutter" style="width: 0.74%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 6pt;">&#8203;</td><td style="width: 9.68%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 6pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 4.75pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 35.83pt;">(448,569</font><font style="min-width: 35.83pt;">)</font></div></td><td class="gutter" style="width: 0.74%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 6pt;">&#8203;</td><td class="gutter" style="width: 0.74%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 6pt;">&#8203;</td><td style="width: 7.65%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 6pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 4.43pt; border-bottom: 3pt double #000000; min-width: 35.83pt;">111,156</font></div></td></tr></table></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 36pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">The notes on pages F-<a href="#tNTC">31</a> to F-<a href="#tNTC1">69</a> form an integral part of these consolidated financial statements<br></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 36pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">F-29<br></div></div></div>
<!--End Page 283-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 284-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 540pt;"><a name="nt10014672x1_drs_203-fintab02_pg7"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="block-frill" style="width: 540pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: Arial, Helvetica, sans-serif; font-size: 9pt; font-weight: bold; margin-top: 6pt; text-align: center;">Confidential Treatment Requested by ADC Therapeutics SA Pursuant to 17 C.F.R. &#167; 200.83<br></div></div><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 36pt;"><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">ADC Therapeutics SA, Epalinges</div><div><div class="rule-full" style="height: 0pt; width: 100%; border-bottom: 1pt solid #000000; margin-bottom: 2pt; margin-left: auto; margin-right: auto; margin-top: 7pt;"> </div></div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 14pt; margin-left: 0pt; text-align: left;"><a name="tCSCF"><!--Anchor--></a>CONSOLIDATED STATEMENT OF CASH FLOWS<br></div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">(in KUSD)</div><table cellspacing="0" cellpadding="0" class="fintab" style="margin-top: 4.25pt; border-collapse: collapse; width: 468pt; margin-left: auto; margin-right: auto;"><tr class="header"><td style="width: 66.67%; text-align: left; vertical-align: bottom; padding-top: 6pt; padding-bottom: 4pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 4pt;">&#8203;</td><td class="gutter" style="width: 1.63%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 3.42%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Note</div></td><td class="gutter" style="width: 1.63%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.63%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 10.08%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Year ended <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">December&#160;31, <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2019</div></td><td class="gutter" style="width: 1.63%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.63%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 10.08%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Year ended <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">December&#160;31, <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2018</div></td></tr><tr><td style="width: 66.67%; text-align: left; vertical-align: bottom; padding-top: 4pt; padding-bottom: 2.75pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Cash used in operating activities<br></div></td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 4pt; padding-bottom: 2.75pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 4pt; padding-bottom: 2.75pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 3.42%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4pt; padding-bottom: 2.75pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 4pt; padding-bottom: 2.75pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 4pt; padding-bottom: 2.75pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.08%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4pt; padding-bottom: 2.75pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 4pt; padding-bottom: 2.75pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 4pt; padding-bottom: 2.75pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.08%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4pt; padding-bottom: 2.75pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 66.67%; text-align: left; vertical-align: bottom; padding-top: 2.75pt; padding-bottom: 2.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Loss for the year<font style="padding-left: 4.54pt;"></font></div></td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td style="width: 3.42%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.75pt; padding-bottom: 2.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td style="width: 10.08%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.75pt; padding-bottom: 2.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 5.67pt; text-align: left;"><font style="padding-left: 0.37pt;">(116,484)</font></div></td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td style="width: 10.08%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.75pt; padding-bottom: 2.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 5.67pt; text-align: left;">(123,096)</div></td></tr><tr><td style="width: 66.67%; text-align: left; vertical-align: bottom; padding-top: 2.75pt; padding-bottom: 2.75pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Adjustments for non-monetary items:<br></div></td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 3.42%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.75pt; padding-bottom: 2.75pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.08%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.75pt; padding-bottom: 2.75pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.08%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.75pt; padding-bottom: 2.75pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 66.67%; text-align: left; vertical-align: bottom; padding-top: 2.75pt; padding-bottom: 2.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Share-based compensation expense<font style="padding-left: 1.23pt;"></font></div></td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td style="width: 3.42%; text-align: center; vertical-align: bottom; padding-top: 2.75pt; padding-bottom: 2.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">23</div></td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td style="width: 10.08%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.75pt; padding-bottom: 2.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 5.67pt; text-align: left;"><font style="padding-left: 13.7pt;">1,117</font></div></td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td style="width: 10.08%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.75pt; padding-bottom: 2.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 5.67pt; text-align: left;"><font style="padding-left: 20.83pt;">469</font></div></td></tr><tr><td style="width: 66.67%; text-align: left; vertical-align: bottom; padding-top: 2.75pt; padding-bottom: 2.75pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Depreciation of property, plant and equipment<font style="padding-left: 0.49pt;"></font></div></td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 3.42%; text-align: center; vertical-align: bottom; padding-top: 2.75pt; padding-bottom: 2.75pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">16</div></td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.08%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.75pt; padding-bottom: 2.75pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 5.67pt; text-align: left;"><font style="padding-left: 20.83pt;">552</font></div></td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.08%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.75pt; padding-bottom: 2.75pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 5.67pt; text-align: left;"><font style="padding-left: 20.83pt;">488</font></div></td></tr><tr><td style="width: 66.67%; text-align: left; vertical-align: bottom; padding-top: 2.75pt; padding-bottom: 2.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Depreciation of right-of-use assets<font style="padding-left: 4.02pt;"></font></div></td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td style="width: 3.42%; text-align: center; vertical-align: bottom; padding-top: 2.75pt; padding-bottom: 2.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">17</div></td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td style="width: 10.08%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.75pt; padding-bottom: 2.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 5.67pt; text-align: left;"><font style="padding-left: 13.33pt;">1,064</font></div></td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td style="width: 10.08%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.75pt; padding-bottom: 2.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 5.67pt; text-align: left;"><font style="padding-left: 25.83pt;">&#8212;</font></div></td></tr><tr><td style="width: 66.67%; text-align: left; vertical-align: bottom; padding-top: 2.75pt; padding-bottom: 2.75pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Amortization and impairment of intangible assets<font style="padding-left: 2.35pt;"></font></div></td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 3.42%; text-align: center; vertical-align: bottom; padding-top: 2.75pt; padding-bottom: 2.75pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">18</div></td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.08%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.75pt; padding-bottom: 2.75pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 5.67pt; text-align: left;"><font style="padding-left: 25.83pt;">30</font></div></td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.08%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.75pt; padding-bottom: 2.75pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 5.67pt; text-align: left;"><font style="padding-left: 20.83pt;">252</font></div></td></tr><tr><td style="width: 66.67%; text-align: left; vertical-align: bottom; padding-top: 2.75pt; padding-bottom: 2.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Change in defined benefit pension liabilities<font style="padding-left: 3.45pt;"></font></div></td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td style="width: 3.42%; text-align: center; vertical-align: bottom; padding-top: 2.75pt; padding-bottom: 2.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">22</div></td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td style="width: 10.08%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.75pt; padding-bottom: 2.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 5.67pt; text-align: left;"><font style="padding-left: 22.5pt;">(53)</font></div></td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td style="width: 10.08%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.75pt; padding-bottom: 2.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 5.67pt; text-align: left;"><font style="padding-left: 21.2pt;">119</font></div></td></tr><tr><td style="width: 66.67%; text-align: left; vertical-align: bottom; padding-top: 2.75pt; padding-bottom: 2.75pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Change in fair value measurement<font style="padding-left: 4.01pt;"></font></div></td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 3.42%; text-align: center; vertical-align: bottom; padding-top: 2.75pt; padding-bottom: 2.75pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.08%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.75pt; padding-bottom: 2.75pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 5.67pt; text-align: left;"><font style="padding-left: 20.83pt;">557</font></div></td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.08%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.75pt; padding-bottom: 2.75pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 5.67pt; text-align: left;"><font style="padding-left: 13.33pt;">1,009</font></div></td></tr><tr><td style="width: 66.67%; text-align: left; vertical-align: bottom; padding-top: 2.75pt; padding-bottom: 2.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Accrued withholding tax<font style="padding-left: 3.42pt;"></font></div></td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td style="width: 3.42%; text-align: center; vertical-align: bottom; padding-top: 2.75pt; padding-bottom: 2.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td style="width: 10.08%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.75pt; padding-bottom: 2.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 5.67pt; text-align: left;"><font style="padding-left: 20.83pt;">626</font></div></td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td style="width: 10.08%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.75pt; padding-bottom: 2.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 5.67pt; text-align: left;"><font style="padding-left: 21.2pt;">711</font></div></td></tr><tr><td style="width: 66.67%; text-align: left; vertical-align: bottom; padding-top: 2.75pt; padding-bottom: 2.75pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Accrued R&amp;D credit <font style="padding-left: 1.21pt;"></font></div></td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 3.42%; text-align: center; vertical-align: bottom; padding-top: 2.75pt; padding-bottom: 2.75pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.08%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.75pt; padding-bottom: 2.75pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 5.67pt; text-align: left;"><font style="padding-left: 17.5pt;">(437)</font> </div></td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.08%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.75pt; padding-bottom: 2.75pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 5.67pt; text-align: left;"><font style="padding-left: 25.83pt;">&#8212;</font> </div></td></tr><tr><td style="width: 66.67%; text-align: left; vertical-align: bottom; padding-top: 2.75pt; padding-bottom: 2.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Financial income <font style="padding-left: 1.19pt;"></font></div></td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td style="width: 3.42%; text-align: center; vertical-align: bottom; padding-top: 2.75pt; padding-bottom: 2.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td style="width: 10.08%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.75pt; padding-bottom: 2.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 5.67pt; text-align: left;"><font style="padding-left: 10pt;">(2,253)</font></div></td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td style="width: 10.08%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.75pt; padding-bottom: 2.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 5.67pt; text-align: left;"><font style="padding-left: 10pt;">(2,856)</font></div></td></tr><tr><td style="width: 66.67%; text-align: left; vertical-align: bottom; padding-top: 2.75pt; padding-bottom: 2.75pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Financial expense (including interest on lease obligations)<font style="padding-left: 1.81pt;"></font></div></td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 3.42%; text-align: center; vertical-align: bottom; padding-top: 2.75pt; padding-bottom: 2.75pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.08%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.75pt; padding-bottom: 2.75pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 5.67pt; text-align: left;"><font style="padding-left: 20.83pt;">156</font></div></td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.08%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.75pt; padding-bottom: 2.75pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 5.67pt; text-align: left;"><font style="padding-left: 25.83pt;">&#8212;</font></div></td></tr><tr><td style="width: 66.67%; text-align: left; vertical-align: bottom; padding-top: 2.75pt; padding-bottom: 2.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Exchange differences<font style="padding-left: 2.5pt;"></font></div></td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td style="width: 3.42%; text-align: center; vertical-align: bottom; padding-top: 2.75pt; padding-bottom: 2.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td style="width: 10.08%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.75pt; padding-bottom: 2.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 5.67pt; text-align: left;"><font style="padding-left: 20.83pt;">128</font></div></td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td style="width: 10.08%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.75pt; padding-bottom: 2.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 5.67pt; text-align: left;"><font style="padding-left: 22.5pt;">(29)</font></div></td></tr><tr><td style="width: 66.67%; text-align: left; vertical-align: bottom; padding-top: 2.75pt; padding-bottom: 4pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Income taxes<font style="padding-left: 0.64pt;"></font></div></td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 4pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 4pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 3.42%; text-align: center; vertical-align: bottom; padding-top: 2.75pt; padding-bottom: 4pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">12</div></td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 4pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 4pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.08%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.75pt; padding-bottom: 4pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 5.67pt; text-align: left;"><font style="padding-left: 20.83pt; border-bottom: 1pt solid #000000; min-width: 35.83pt;">582</font></div></td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 4pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 4pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.08%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.75pt; padding-bottom: 4pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 5.67pt; text-align: left;"><font style="padding-left: 20.83pt; border-bottom: 1pt solid #000000; min-width: 35.83pt;">224</font></div></td></tr><tr><td style="width: 66.67%; text-align: left; vertical-align: bottom; padding-top: 4pt; padding-bottom: 2.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Operating loss before working capital changes<font style="padding-left: 4.59pt;"></font></div></td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 4pt; padding-bottom: 2.75pt;">&#8203;</td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 4pt; padding-bottom: 2.75pt;">&#8203;</td><td style="width: 3.42%; text-align: center; vertical-align: bottom; padding-top: 4pt; padding-bottom: 2.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 4pt; padding-bottom: 2.75pt;">&#8203;</td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 4pt; padding-bottom: 2.75pt;">&#8203;</td><td style="width: 10.08%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4pt; padding-bottom: 2.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 5.67pt; text-align: left;"><font style="padding-left: 0.37pt;">(11</font>4,415)</div></td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 4pt; padding-bottom: 2.75pt;">&#8203;</td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 4pt; padding-bottom: 2.75pt;">&#8203;</td><td style="width: 10.08%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4pt; padding-bottom: 2.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 5.67pt; text-align: left;">(122,709)</div></td></tr><tr><td style="width: 66.67%; text-align: left; vertical-align: bottom; padding-top: 2.75pt; padding-bottom: 2.75pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Decrease in trade accounts receivable<font style="padding-left: 0.7pt;"></font></div></td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 3.42%; text-align: center; vertical-align: bottom; padding-top: 2.75pt; padding-bottom: 2.75pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.08%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.75pt; padding-bottom: 2.75pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 5.67pt; text-align: left;"><font style="padding-left: 20.83pt;">192</font></div></td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.08%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.75pt; padding-bottom: 2.75pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 5.67pt; text-align: left;"><font style="padding-left: 20.83pt;">895</font></div></td></tr><tr><td style="width: 66.67%; text-align: left; vertical-align: bottom; padding-top: 2.75pt; padding-bottom: 2.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">(Increase) in other current assets<font style="padding-left: 1.25pt;"></font></div></td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td style="width: 3.42%; text-align: center; vertical-align: bottom; padding-top: 2.75pt; padding-bottom: 2.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td style="width: 10.08%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.75pt; padding-bottom: 2.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 5.67pt; text-align: left;"><font style="padding-left: 10pt;">(4,030)</font></div></td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td style="width: 10.08%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.75pt; padding-bottom: 2.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 5.67pt; text-align: left;"><font style="padding-left: 10pt;">(1,678)</font></div></td></tr><tr><td style="width: 66.67%; text-align: left; vertical-align: bottom; padding-top: 2.75pt; padding-bottom: 2.75pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">(Decrease) in contract liability (short and long term)<font style="padding-left: 4.6pt;"></font></div></td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 3.42%; text-align: center; vertical-align: bottom; padding-top: 2.75pt; padding-bottom: 2.75pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.08%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.75pt; padding-bottom: 2.75pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 5.67pt; text-align: left;"><font style="padding-left: 10pt;">(2,340)</font></div></td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.08%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.75pt; padding-bottom: 2.75pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 5.67pt; text-align: left;"><font style="padding-left: 10pt;">(1,140)</font></div></td></tr><tr><td style="width: 66.67%; text-align: left; vertical-align: bottom; padding-top: 2.75pt; padding-bottom: 2.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">(Decrease) in trade accounts payable<font style="padding-left: 4.03pt;"></font></div></td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td style="width: 3.42%; text-align: center; vertical-align: bottom; padding-top: 2.75pt; padding-bottom: 2.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td style="width: 10.08%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.75pt; padding-bottom: 2.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 5.67pt; text-align: left;"><font style="padding-left: 10pt;">(3,425)</font></div></td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td style="width: 10.08%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.75pt; padding-bottom: 2.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 5.67pt; text-align: left;"><font style="padding-left: 17.5pt;">(858)</font></div></td></tr><tr><td style="width: 66.67%; text-align: left; vertical-align: bottom; padding-top: 2.75pt; padding-bottom: 4pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Increase in accrued liabilities and other payables<font style="padding-left: 0.16pt;"></font></div></td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 4pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 4pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 3.42%; text-align: center; vertical-align: bottom; padding-top: 2.75pt; padding-bottom: 4pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 4pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 4pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.08%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.75pt; padding-bottom: 4pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 5.67pt; text-align: left;"><font style="padding-left: 13.33pt; border-bottom: 1pt solid #000000; min-width: 35.83pt;">1,720</font></div></td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 4pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 4pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.08%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.75pt; padding-bottom: 4pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 5.67pt; text-align: left;"><font style="padding-left: 13.33pt; border-bottom: 1pt solid #000000; min-width: 35.83pt;">3,262</font></div></td></tr><tr><td style="width: 66.67%; text-align: left; vertical-align: bottom; padding-top: 4pt; padding-bottom: 2.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Cash used in operating activities<font style="padding-left: 1.22pt;"></font></div></td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 4pt; padding-bottom: 2.75pt;">&#8203;</td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 4pt; padding-bottom: 2.75pt;">&#8203;</td><td style="width: 3.42%; text-align: center; vertical-align: bottom; padding-top: 4pt; padding-bottom: 2.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 4pt; padding-bottom: 2.75pt;">&#8203;</td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 4pt; padding-bottom: 2.75pt;">&#8203;</td><td style="width: 10.08%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4pt; padding-bottom: 2.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 5.67pt; text-align: left;">(122,298)</div></td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 4pt; padding-bottom: 2.75pt;">&#8203;</td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 4pt; padding-bottom: 2.75pt;">&#8203;</td><td style="width: 10.08%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4pt; padding-bottom: 2.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 5.67pt; text-align: left;">(122,228)</div></td></tr><tr><td style="width: 66.67%; text-align: left; vertical-align: bottom; padding-top: 2.75pt; padding-bottom: 2.75pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 3.42%; text-align: center; vertical-align: bottom; padding-top: 2.75pt; padding-bottom: 2.75pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.08%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.75pt; padding-bottom: 2.75pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.08%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.75pt; padding-bottom: 2.75pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 66.67%; text-align: left; vertical-align: bottom; padding-top: 2.75pt; padding-bottom: 2.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Interest received<font style="padding-left: 2.32pt;"></font></div></td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td style="width: 3.42%; text-align: center; vertical-align: bottom; padding-top: 2.75pt; padding-bottom: 2.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td style="width: 10.08%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.75pt; padding-bottom: 2.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 5.67pt; text-align: left;"><font style="padding-left: 13.33pt;">1,164</font></div></td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td style="width: 10.08%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.75pt; padding-bottom: 2.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 5.67pt; text-align: left;"><font style="padding-left: 13.33pt;">1,051</font></div></td></tr><tr><td style="width: 66.67%; text-align: left; vertical-align: bottom; padding-top: 2.75pt; padding-bottom: 2.75pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Interest paid<font style="padding-left: 3.97pt;"></font></div></td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 3.42%; text-align: center; vertical-align: bottom; padding-top: 2.75pt; padding-bottom: 2.75pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.08%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.75pt; padding-bottom: 2.75pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 5.67pt; text-align: left;"><font style="padding-left: 17.5pt;">(157)</font></div></td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.08%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.75pt; padding-bottom: 2.75pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 5.67pt; text-align: left;"><font style="padding-left: 25.83pt;">&#8212;</font></div></td></tr><tr><td style="width: 66.67%; text-align: left; vertical-align: bottom; padding-top: 2.75pt; padding-bottom: 4pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Tax paid<font style="padding-left: 4.1pt;"></font></div></td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 4pt;">&#8203;</td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 4pt;">&#8203;</td><td style="width: 3.42%; text-align: center; vertical-align: bottom; padding-top: 2.75pt; padding-bottom: 4pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 4pt;">&#8203;</td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 4pt;">&#8203;</td><td style="width: 10.08%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.75pt; padding-bottom: 4pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 5.67pt; text-align: left;"><font style="padding-left: 17.5pt; border-bottom: 1pt solid #000000; min-width: 35.83pt;">(</font><font style="border-bottom: 1pt solid #000000; min-width: 35.83pt;">290</font><font style="border-bottom: 1pt solid #000000; min-width: 35.83pt;"></font><font style="min-width: 35.83pt;">)</font></div></td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 4pt;">&#8203;</td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 4pt;">&#8203;</td><td style="width: 10.08%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.75pt; padding-bottom: 4pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 5.67pt; text-align: left;"><font style="padding-left: 17.5pt; border-bottom: 1pt solid #000000; min-width: 35.83pt;">(185</font><font style="min-width: 35.83pt;">)</font></div></td></tr><tr><td style="width: 66.67%; text-align: left; vertical-align: bottom; padding-top: 4pt; padding-bottom: 2.75pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Net cash used in operating activities<font style="font-weight: normal; padding-left: 2.34pt;"></font></div></td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 4pt; padding-bottom: 2.75pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 4pt; padding-bottom: 2.75pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 3.42%; text-align: center; vertical-align: bottom; padding-top: 4pt; padding-bottom: 2.75pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 4pt; padding-bottom: 2.75pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 4pt; padding-bottom: 2.75pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.08%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4pt; padding-bottom: 2.75pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 5.67pt; text-align: left;">(121,581)</div></td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 4pt; padding-bottom: 2.75pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 4pt; padding-bottom: 2.75pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.08%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4pt; padding-bottom: 2.75pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 5.67pt; text-align: left;">(121,362)</div></td></tr><tr><td style="width: 66.67%; text-align: left; vertical-align: bottom; padding-top: 2.75pt; padding-bottom: 2.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td style="width: 3.42%; text-align: center; vertical-align: bottom; padding-top: 2.75pt; padding-bottom: 2.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td style="width: 10.08%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.75pt; padding-bottom: 2.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td style="width: 10.08%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.75pt; padding-bottom: 2.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 66.67%; text-align: left; vertical-align: bottom; padding-top: 2.75pt; padding-bottom: 2.75pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Cash used in investing activities<br></div></td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 3.42%; text-align: center; vertical-align: bottom; padding-top: 2.75pt; padding-bottom: 2.75pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.08%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.75pt; padding-bottom: 2.75pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.08%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.75pt; padding-bottom: 2.75pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 66.67%; text-align: left; vertical-align: bottom; padding-top: 2.75pt; padding-bottom: 2.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Payment for purchases of property, plant and equipment<font style="padding-left: 4.4pt;"></font></div></td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td style="width: 3.42%; text-align: center; vertical-align: bottom; padding-top: 2.75pt; padding-bottom: 2.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">16</div></td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td style="width: 10.08%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.75pt; padding-bottom: 2.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 5.67pt; text-align: left;"><font style="padding-left: 17.5pt;">(358)</font></div></td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td style="width: 10.08%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.75pt; padding-bottom: 2.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 5.67pt; text-align: left;"><font style="padding-left: 17.5pt;">(944)</font></div></td></tr><tr><td style="width: 66.67%; text-align: left; vertical-align: bottom; padding-top: 2.75pt; padding-bottom: 2.75pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Payment for purchases of intangible assets<font style="padding-left: 0.13pt;"></font></div></td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 3.42%; text-align: center; vertical-align: bottom; padding-top: 2.75pt; padding-bottom: 2.75pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">18</div></td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.08%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.75pt; padding-bottom: 2.75pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 5.67pt; text-align: left;"><font style="padding-left: 10pt;">(1,790)</font></div></td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.08%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.75pt; padding-bottom: 2.75pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 5.67pt; text-align: left;"><font style="padding-left: 10pt;">(1,526)</font></div></td></tr><tr><td style="width: 66.67%; text-align: left; vertical-align: bottom; padding-top: 2.75pt; padding-bottom: 4pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Payment for rent deposits<font style="padding-left: 4.54pt;"></font></div></td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 4pt;">&#8203;</td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 4pt;">&#8203;</td><td style="width: 3.42%; text-align: center; vertical-align: bottom; padding-top: 2.75pt; padding-bottom: 4pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 4pt;">&#8203;</td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 4pt;">&#8203;</td><td style="width: 10.08%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.75pt; padding-bottom: 4pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 5.67pt; text-align: left;"><font style="padding-left: 17.5pt; border-bottom: 1pt solid #000000; min-width: 35.83pt;">(100</font><font style="min-width: 35.83pt;">)</font></div></td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 4pt;">&#8203;</td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 4pt;">&#8203;</td><td style="width: 10.08%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.75pt; padding-bottom: 4pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 5.67pt; text-align: left;"><font style="padding-left: 22.5pt; border-bottom: 1pt solid #000000; min-width: 35.83pt;">(36</font><font style="min-width: 35.83pt;">)</font></div></td></tr><tr><td style="width: 66.67%; text-align: left; vertical-align: bottom; padding-top: 4pt; padding-bottom: 2.75pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Net cash used in investing activities<font style="font-weight: normal; padding-left: 0.12pt;"></font></div></td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 4pt; padding-bottom: 2.75pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 4pt; padding-bottom: 2.75pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 3.42%; text-align: center; vertical-align: bottom; padding-top: 4pt; padding-bottom: 2.75pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 4pt; padding-bottom: 2.75pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 4pt; padding-bottom: 2.75pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.08%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4pt; padding-bottom: 2.75pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 5.67pt; text-align: left;"><font style="padding-left: 10pt;">(2,248)</font></div></td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 4pt; padding-bottom: 2.75pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 4pt; padding-bottom: 2.75pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.08%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4pt; padding-bottom: 2.75pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 5.67pt; text-align: left;"><font style="padding-left: 10pt;">(2,506)</font></div></td></tr><tr><td style="width: 66.67%; text-align: left; vertical-align: bottom; padding-top: 2.75pt; padding-bottom: 2.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td style="width: 3.42%; text-align: center; vertical-align: bottom; padding-top: 2.75pt; padding-bottom: 2.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td style="width: 10.08%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.75pt; padding-bottom: 2.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td style="width: 10.08%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.75pt; padding-bottom: 2.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 66.67%; text-align: left; vertical-align: bottom; padding-top: 2.75pt; padding-bottom: 2.75pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Cash from / (used in) financing activities<br></div></td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 3.42%; text-align: center; vertical-align: bottom; padding-top: 2.75pt; padding-bottom: 2.75pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.08%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.75pt; padding-bottom: 2.75pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.08%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.75pt; padding-bottom: 2.75pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 66.67%; text-align: left; vertical-align: bottom; padding-top: 2.75pt; padding-bottom: 2.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Proceeds from capital contributions, net of transaction costs<font style="padding-left: 4.32pt;"></font></div></td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td style="width: 3.42%; text-align: center; vertical-align: bottom; padding-top: 2.75pt; padding-bottom: 2.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">24</div></td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td style="width: 10.08%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.75pt; padding-bottom: 2.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 5.67pt; text-align: left;"><font style="padding-left: 3.33pt;">101,614</font></div></td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td style="width: 10.08%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.75pt; padding-bottom: 2.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 5.67pt; text-align: left;"><font style="padding-left: 22.5pt;">(24)</font></div></td></tr><tr><td style="width: 66.67%; text-align: left; vertical-align: bottom; padding-top: 2.75pt; padding-bottom: 2.75pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Acquisition of treasury shares<font style="padding-left: 2.34pt;"></font></div></td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 3.42%; text-align: center; vertical-align: bottom; padding-top: 2.75pt; padding-bottom: 2.75pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">24</div></td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.08%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.75pt; padding-bottom: 2.75pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 5.67pt; text-align: left;"><font style="padding-left: 17.5pt;">(141)</font></div></td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.08%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.75pt; padding-bottom: 2.75pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 5.67pt; text-align: left;"><font style="padding-left: 25.83pt;">&#8212;</font></div></td></tr><tr><td style="width: 66.67%; text-align: left; vertical-align: bottom; padding-top: 2.75pt; padding-bottom: 2.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Sale of treasury shares<font style="padding-left: 1.78pt;"></font></div></td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td style="width: 3.42%; text-align: center; vertical-align: bottom; padding-top: 2.75pt; padding-bottom: 2.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">24</div></td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td style="width: 10.08%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.75pt; padding-bottom: 2.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 5.67pt; text-align: left;"><font style="padding-left: 25.83pt;">41</font></div></td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td style="width: 10.08%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.75pt; padding-bottom: 2.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 5.67pt; text-align: left;"><font style="padding-left: 25.83pt;">&#8212;</font></div></td></tr><tr><td style="width: 66.67%; text-align: left; vertical-align: bottom; padding-top: 2.75pt; padding-bottom: 4pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Principal portion of lease obligations payments<font style="padding-left: 1.78pt;"></font></div></td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 4pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 4pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 3.42%; text-align: center; vertical-align: bottom; padding-top: 2.75pt; padding-bottom: 4pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">17</div></td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 4pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 4pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.08%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.75pt; padding-bottom: 4pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 5.67pt; text-align: left;"><font style="padding-left: 10pt; border-bottom: 1pt solid #000000; min-width: 35.83pt;">(1,002</font><font style="min-width: 35.83pt;">)</font></div></td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 4pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 4pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.08%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.75pt; padding-bottom: 4pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 5.67pt; text-align: left;"><font style="padding-left: 25.83pt; border-bottom: 1pt solid #000000; min-width: 35.83pt;">&#8212;</font></div></td></tr><tr><td style="width: 66.67%; text-align: left; vertical-align: bottom; padding-top: 4pt; padding-bottom: 2.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Net cash from / (used in) financing activities<font style="font-weight: normal; padding-left: 1.43pt;"></font></div></td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 4pt; padding-bottom: 2.75pt;">&#8203;</td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 4pt; padding-bottom: 2.75pt;">&#8203;</td><td style="width: 3.42%; text-align: center; vertical-align: bottom; padding-top: 4pt; padding-bottom: 2.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 4pt; padding-bottom: 2.75pt;">&#8203;</td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 4pt; padding-bottom: 2.75pt;">&#8203;</td><td style="width: 10.08%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4pt; padding-bottom: 2.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 5.67pt; text-align: left;"><font style="padding-left: 3.33pt;">100,512</font></div></td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 4pt; padding-bottom: 2.75pt;">&#8203;</td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 4pt; padding-bottom: 2.75pt;">&#8203;</td><td style="width: 10.08%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4pt; padding-bottom: 2.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 5.67pt; text-align: left;"><font style="padding-left: 22.5pt;">(24)</font></div></td></tr><tr><td style="width: 66.67%; text-align: left; vertical-align: bottom; padding-top: 2.75pt; padding-bottom: 2.75pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 3.42%; text-align: center; vertical-align: bottom; padding-top: 2.75pt; padding-bottom: 2.75pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.08%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.75pt; padding-bottom: 2.75pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.08%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.75pt; padding-bottom: 2.75pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 66.67%; text-align: left; vertical-align: bottom; padding-top: 2.75pt; padding-bottom: 2.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Net decrease in cash and cash equivalents<font style="font-weight: normal; padding-left: 2.53pt;"></font></div></td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td style="width: 3.42%; text-align: center; vertical-align: bottom; padding-top: 2.75pt; padding-bottom: 2.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td style="width: 10.08%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.75pt; padding-bottom: 2.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 5.67pt; text-align: left;"><font style="padding-left: 5pt;">(23,317)</font></div></td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td style="width: 10.08%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.75pt; padding-bottom: 2.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 5.67pt; text-align: left;">(123,892)</div></td></tr><tr><td style="width: 66.67%; text-align: left; vertical-align: bottom; padding-top: 2.75pt; padding-bottom: 2.75pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Exchange gains / (losses) on cash and cash equivalents<font style="padding-left: 3.49pt;"></font></div></td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 3.42%; text-align: center; vertical-align: bottom; padding-top: 2.75pt; padding-bottom: 2.75pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.08%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.75pt; padding-bottom: 2.75pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 5.67pt; text-align: left;"><font style="padding-left: 25.83pt;">61</font></div></td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.08%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.75pt; padding-bottom: 2.75pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 5.67pt; text-align: left;"><font style="padding-left: 22.5pt;">(53)</font></div></td></tr><tr><td style="width: 66.67%; text-align: left; vertical-align: bottom; padding-top: 2.75pt; padding-bottom: 4pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Cash and cash equivalents at beginning of year<font style="padding-left: 0.69pt;"></font></div></td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 4pt;">&#8203;</td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 4pt;">&#8203;</td><td style="width: 3.42%; text-align: center; vertical-align: bottom; padding-top: 2.75pt; padding-bottom: 4pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 4pt;">&#8203;</td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 4pt;">&#8203;</td><td style="width: 10.08%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.75pt; padding-bottom: 4pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 5.67pt; text-align: left;"><font style="padding-left: 3.33pt; border-bottom: 1pt solid #000000; min-width: 35.83pt;">138,807</font></div></td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 4pt;">&#8203;</td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 4pt;">&#8203;</td><td style="width: 10.08%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.75pt; padding-bottom: 4pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 5.67pt; text-align: left;"><font style="padding-left: 3.33pt; border-bottom: 1pt solid #000000; min-width: 35.83pt;">262,752</font></div></td></tr><tr><td style="width: 66.67%; text-align: left; vertical-align: bottom; padding-top: 4pt; padding-bottom: 6pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Cash and cash equivalents at end of year<font style="font-weight: normal; padding-left: 0.12pt;"></font></div></td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 4pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 4pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 3.42%; text-align: center; vertical-align: bottom; padding-top: 4pt; padding-bottom: 6pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 4pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 4pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.08%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4pt; padding-bottom: 6pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 5.67pt; text-align: left;"><font style="padding-left: 3.88pt; border-bottom: 3pt double #000000; min-width: 35.83pt;">115,551</font></div></td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 4pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 4pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.08%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4pt; padding-bottom: 6pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 5.67pt; text-align: left;"><font style="padding-left: 3.33pt; border-bottom: 3pt double #000000; min-width: 35.83pt;">138,807</font></div></td></tr></table></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 36pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">The notes on pages F-<a href="#tNTC">31</a> to F-<a href="#tNTC1">69</a> form an integral part of these consolidated financial statements<br></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 36pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">F-30<br></div></div></div>
<!--End Page 284-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 285-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 540pt;"><a name="nt10014672x1_drs_204-finnotes02_pg1"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="block-frill" style="width: 540pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: Arial, Helvetica, sans-serif; font-size: 9pt; font-weight: bold; margin-top: 6pt; text-align: center;">Confidential Treatment Requested by ADC Therapeutics SA Pursuant to 17 C.F.R. &#167; 200.83<br></div></div><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 36pt;"><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; margin-left: 0pt; text-align: left;"><a name="tNCFS"><!--Anchor--></a>ADC Therapeutics SA, Epalinges <br></div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;"><div class="rule-full" style="height: 0pt; width: 100%; border-bottom: 1pt solid #000000; margin-top: 1pt; margin-bottom: 1pt; margin-left: auto; margin-right: auto;"> </div>NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS </div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"><a name="tNTC"><!--Anchor--></a>1.<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; text-align: left;">Corporate information</div></td></tr></table><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: left;">ADC Therapeutics SA (the &#8220;Company&#8221; or &#8220;ADCT&#8221;) was incorporated on June&#160;6, 2011 under the laws of Switzerland. The registered office of the Company is located at Route de la Corniche 3B, 1066 Epalinges, Switzerland. The Company controls two wholly-owned subsidiaries: ADC Therapeutics America, Inc. (&#8220;ADCT America&#8221;), which was incorporated in Delaware, USA on December&#160;10, 2014, and ADC Therapeutics (UK) Ltd (&#8220;ADCT UK&#8221;), which was incorporated in England on December&#160;12, 2014. The Company and its two subsidiaries form the ADCT Group (the &#8220;Group&#8221;).</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: left;">The Group is focused on the development of antibody drug conjugates, including research, development, human clinical trials, regulatory approval and commercialization. Antibody drug conjugates (&#8220;ADCs&#8221;) are drug constructs which combine monoclonal antibodies specific to particular types of cells with cytotoxic molecules or warheads which seek to kill cancer cells to which the ADC attaches. ADCs have extensive potential therapeutic applications in cancer.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: left;">The Group&#8217;s core technology platform is based on the development and commercial exploitation of chemistry acquired under license from Spirogen Ltd in 2011. The license agreement, as subsequently amended in 2013, gives the Company the right to develop up to eleven specific ADCs as well as ten non-ADCs using Spirogen Ltd's intellectual property and technology in warhead and linker chemistry.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: left;">These Group consolidated financial statements were authorized for issue by the Board of Directors on March&#160;2, 2020, except for the share consolidation disclosed in note 2 (v), &#8220;Basis of preparation &#8211; Share consolidation&#8221;, as to which the date is April 24, 2020.</div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 12pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">2.<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; text-align: left;">Basis of preparation</div></td></tr></table><div class="h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 7pt; margin-left: 20pt; text-align: left;"><u>(i) Compliance with International Financial Reporting Standards</u></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: left;">The ADCT Group consolidated financial statements have been prepared in accordance with International Financial Reporting Standards (IFRS) as issued by the International Accounting Standards Board (IASB). As of December&#160;31, 2019, the financial statements are presented in thousand dollars (KUSD).</div><div class="h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 16.5pt; margin-left: 20pt; text-align: left;"><u>(ii)&#160;Historical Cost Convention</u></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: left;">The consolidated financial statements have been prepared under the historical cost convention, except for the defined benefit pension liabilities, where plan assets are measured at fair value.</div><div class="h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 16.5pt; margin-left: 20pt; text-align: left;"><u>(iii)&#160;Going concern basis</u></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: left;">ADC Therapeutics SA is a late clinical-stage company developing innovative therapeutics. The Group is exposed to all risks inherent in establishing and developing its business, including the substantial uncertainty that current projects will succeed. The Group's success may also depend on its ability to:</div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 40pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">-<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">establish and maintain a strong patent position and protection;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 40pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">-<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">enter into collaborations with partners in the pharmaceutical industry;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 40pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">-<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">acquire and retain key personnel; and</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 40pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">-<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">acquire additional funding to support its operations.</div></td></tr></table><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: left;">Since its incorporation, the Company has primarily funded its growth through capital increases and additional funds provided by research collaborations. The Company never had recourse to bank loans. As a result, the Company is not exposed to liquidity risk through requests for early repayment of loans.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: left;">Significant R&amp;D expenses have been incurred from the start of the Company's activities, generating negative cash flows from operating activities since formation. Cash flows related to operating activities amounted to a negative KUSD 121,581 and negative KUSD 121,362 for the financial years ended December&#160;31, 2019 and 2018, respectively. As at December&#160;31, 2019, the Company&#8217;s cash and cash equivalents amounted to KUSD 115,551 (December&#160;31, 2018: KUSD 138,807).</div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 36pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">F-31<br></div></div></div>
<!--End Page 285-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 286-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 540pt;"><a name="nt10014672x1_drs_204-finnotes02_pg2"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="block-frill" style="width: 540pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: Arial, Helvetica, sans-serif; font-size: 9pt; font-weight: bold; margin-top: 6pt; text-align: center;">Confidential Treatment Requested by ADC Therapeutics SA Pursuant to 17 C.F.R. &#167; 200.83<br></div></div><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 36pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">ADC Therapeutics SA, Epalinges <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;"><div class="rule-full" style="height: 0pt; width: 100%; border-bottom: 1pt solid #000000; margin-top: 1pt; margin-bottom: 1pt; margin-left: auto; margin-right: auto;"> </div>NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS <font style="padding-left: 4pt;">(continued)</font><br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 7pt; margin-left: 20pt; text-align: left;">The Board of Directors believes that the Company has sufficient financial resources available to cover its planned cash outflows for the next twelve months from the date of issuance of these financial statements. To continue the development of current product candidates beyond that period, the Company will be required to raise additional capital within the next twelve months. The Company cannot be certain that additional funding will be available on acceptable terms, or at all. If the Company is unable to raise additional capital when required or on acceptable terms, it may have to (i)&#160;significantly delay, scale back or discontinue the development of one or more product candidates; (ii)&#160;seek collaborators for product candidates at an earlier stage than otherwise would be desirable and on terms that are less favorable than might otherwise be available; or (iii)&#160;relinquish or otherwise dispose of rights to product candidates that the Company would otherwise seek to develop itself, on unfavorable terms. As the Company has concluded that there is no substantial doubt about its ability to continue as a going concern within one year of the issuance of these financial statements without additional capital becoming available, the Company has prepared these financial statements under the going concern assumption.</div><div class="h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 16.5pt; margin-left: 20pt; text-align: left;"><u>(iv)&#160;Share split</u></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: left;">As explained in note 24, &#8220;Share capital&#8221;, on September&#160;19, 2019, the Company effected a one to 15,625 share split of its outstanding shares. Accordingly, all share and per share amounts for all periods presented in these consolidated financial statements and notes thereto have been adjusted retroactively, where applicable, to reflect this share split.</div><div class="h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 16.5pt; margin-left: 20pt; text-align: left;"><u>(v) Share consolidation</u></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: left;">On April 24, 2020, the Company effected a five to four share consolidation of its outstanding shares. Accordingly, all share and per share amounts for all periods presented in these consolidated financial statements and notes thereto have been adjusted retroactively, where applicable, to reflect this share consolidation.</div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 12pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">3.<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; text-align: left;">Significant accounting policies</div></td></tr></table><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: left;">The principal accounting policies applied in the preparation of these consolidated financial statements are set out below. These policies have been consistently applied to all the years presented, unless otherwise stated.</div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 12pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">3.1<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; text-align: left;">Consolidation</div></td></tr></table><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: left;">The annual closing date of the individual financial statements is December 31. Subsidiaries are all entities over which the Company has control. The Company controls an entity when the Company is exposed to, or has rights to, variable returns from its involvement with the entity and has the ability to affect those returns through its power over the entity. Subsidiaries are fully consolidated from the date on which control is transferred to the Company. They are de-consolidated from the date that control ceases.</div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 12pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">3.2<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; text-align: left;">Foreign currency translation</div></td></tr></table><div class="h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 7pt; margin-left: 20pt; text-align: left;"><u>Functional and presentation currency</u></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: left;">Items included in the financial statements of each of the Group entities are measured using the currency of the primary economic environment in which the entity operates (&#8220;the functional currency&#8221;). The consolidated financial statements are presented in US dollars (&#8220;USD&#8221; or &#8220;Dollars&#8221;), which is the Company's functional and the Group's presentation currency.</div><div class="h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 17pt; margin-left: 20pt; text-align: left;"><u>Transactions and balances</u></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: left;">Foreign currency transactions are translated into the functional currency using the exchange rates prevailing at the dates of the transactions. Foreign exchange gains and losses resulting from the settlement of such transactions and from the translation at year-end exchange rates of monetary assets and liabilities denominated in foreign currencies are recognized in the income statement.</div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 36pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">F-32<br></div></div></div>
<!--End Page 286-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 287-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 540pt;"><a name="nt10014672x1_drs_204-finnotes02_pg3"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="block-frill" style="width: 540pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: Arial, Helvetica, sans-serif; font-size: 9pt; font-weight: bold; margin-top: 6pt; text-align: center;">Confidential Treatment Requested by ADC Therapeutics SA Pursuant to 17 C.F.R. &#167; 200.83<br></div></div><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 36pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">ADC Therapeutics SA, Epalinges <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;"><div class="rule-full" style="height: 0pt; width: 100%; border-bottom: 1pt solid #000000; margin-top: 1pt; margin-bottom: 1pt; margin-left: auto; margin-right: auto;"> </div>NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS <font style="padding-left: 4pt;">(continued)</font><br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 7pt; margin-left: 20pt; text-align: left;">All foreign exchange gains and losses are presented in the income statement within &#8220;Exchange differences&#8221;.</div><div class="h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 14pt; margin-left: 20pt; text-align: left;"><u>Group companies</u></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: left;">The results and financial position of all the Group entities that have a functional currency different from the presentation currency are translated into the presentation currency as follows:</div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 40pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(i)<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">assets and liabilities for each balance sheet presented are translated at the closing rate at the date of that balance sheet;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 40pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(ii)<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">income and expenses for each income statement are translated at monthly average exchange rates; and</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 40pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(iii)<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">all resulting exchange differences are recognized in other comprehensive income, under &#8220;Cumulative translation adjustments&#8221;.</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 12pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">3.3<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; text-align: left;">Cash and cash equivalents</div></td></tr></table><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: left;">Cash and cash equivalents includes cash on hand, deposits held at call with external financial institutions and other short-term highly liquid investments with original maturities to the Company of three months or less. They are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Any bank overdrafts are not netted against cash and cash equivalents but are shown as part of current liabilities on the consolidated balance sheet.</div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 12pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">3.4<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; text-align: left;">Property, plant and equipment</div></td></tr></table><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: left;">All property, plant and equipment is stated at historical cost less accumulated depreciation. Historical cost includes expenditure that is directly attributable to the acquisition of the items.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: left;">Depreciation is calculated using the straight-line method to reduce the cost of each asset to its residual value over its estimated useful life, as follows:</div><table cellspacing="0" cellpadding="0" class="fintab" style="margin-top: 11.25pt; border-collapse: collapse; width: 428pt; margin-left: 20pt;"><tr><td style="width: 84.11%; text-align: left; vertical-align: bottom; padding-top: 6pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Leasehold improvements<font style="padding-left: 0.86pt;"></font></div></td><td class="gutter" style="width: 1.65%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.65%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 12.58%; text-align: right; vertical-align: bottom; padding-top: 6pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: right;">3 to 10&#160;years</div></td></tr><tr><td style="width: 84.11%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Laboratory equipment<font style="padding-left: 2.53pt;"></font></div></td><td class="gutter" style="width: 1.65%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.65%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 12.58%; text-align: right; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: right;">5&#160;years</div></td></tr><tr><td style="width: 84.11%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Office equipment<font style="padding-left: 1.6pt;"></font></div></td><td class="gutter" style="width: 1.65%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.65%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 12.58%; text-align: right; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: right;">5&#160;years</div></td></tr><tr><td style="width: 84.11%; text-align: left; vertical-align: bottom; padding-top: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Hardware<font style="padding-left: 3.08pt;"></font></div></td><td class="gutter" style="width: 1.65%; border-bottom: none; font-size: 2pt; padding-top: 3pt;">&#8203;</td><td class="gutter" style="width: 1.65%; border-bottom: none; font-size: 2pt; padding-top: 3pt;">&#8203;</td><td style="width: 12.58%; text-align: right; vertical-align: bottom; padding-top: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: right;">3&#160;years</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 12pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">3.5<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; text-align: left;">Intangible assets</div></td></tr></table><div class="h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 7pt; margin-left: 20pt; text-align: left;"><u>Licenses</u></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: left;">Licenses acquired are capitalized as intangible assets at historical cost and amortized over their useful lives, which are determined on a basis of the expected pattern of consumption of the expected future economic benefits embodied in the licenses and which therefore commence only once the necessary regulatory and marketing approval has been received. These licenses are tested for impairment in the last quarter of each financial period.</div><div class="h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 14.5pt; margin-left: 20pt; text-align: left;"><u>Amortization and impairment of licenses</u></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: left;">Amortization of capitalized licenses will be charged to research and development expenses. Impairment of capitalized licenses is charged to research and development expenses.</div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 12pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">3.6<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; text-align: left;">Impairment of non-financial assets</div></td></tr></table><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: left;">Assets that are subject to amortization are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of the asset may not be recoverable. An impairment loss is recognized for the amount by which the asset's carrying amount exceeds its recoverable amount. The recoverable amount is the higher of an asset's fair value less costs of disposal and value in use. In assessing </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 36pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">F-33<br></div></div></div>
<!--End Page 287-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 288-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 540pt;"><a name="nt10014672x1_drs_204-finnotes02_pg4"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="block-frill" style="width: 540pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: Arial, Helvetica, sans-serif; font-size: 9pt; font-weight: bold; margin-top: 6pt; text-align: center;">Confidential Treatment Requested by ADC Therapeutics SA Pursuant to 17 C.F.R. &#167; 200.83<br></div></div><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 36pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">ADC Therapeutics SA, Epalinges <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;"><div class="rule-full" style="height: 0pt; width: 100%; border-bottom: 1pt solid #000000; margin-top: 1pt; margin-bottom: 1pt; margin-left: auto; margin-right: auto;"> </div>NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS <font style="padding-left: 4pt;">(continued)</font><br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 7pt; margin-left: 20pt; text-align: left;">value in use, the estimated future cash flows, adjusted for the risks specific to each asset, are discounted to their present value using a discount rate that reflects current market assessments of the time value of money and the general risks affecting the pharmaceutical industry. For the purpose of impairment testing, assets are grouped together into the smallest group of assets that generates cash inflows from continuing use that are largely independent of the cash flows of other assets (&#8220;cash-generating units&#8221;).</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8.5pt; margin-left: 20pt; text-align: left;">Impairment losses are recognized in the income statement.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: left;">Prior impairments of non-financial assets are reviewed for possible reversal of the impairment at each reporting date.</div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 12pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">3.7<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; text-align: left;">Employee benefits</div></td></tr></table><div class="h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 7.5pt; margin-left: 20pt; text-align: left;"><u>Pension obligations</u></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: left;">Group companies operate defined benefit and defined contribution pension schemes in accordance with the local conditions and practices in the countries in which they operate. The schemes are generally funded through payments to insurance companies or trustee-administered funds, determined by periodic actuarial calculations. A defined contribution plan is a pension plan under which the Group pays fixed contributions into a separate entity (a fund) and has no legal or constructive obligations to pay further contributions if the fund does not hold sufficient assets to pay all employees the benefits relating to employee service in the current and prior periods. A defined benefit plan is a pension plan that is not a defined contribution plan. Typically, defined benefit plans define an amount of pension benefit that an employee will receive on retirement, usually dependent on one or more factors such as age, years of service and compensation. However, as is the case with many Swiss pension plans, although the amount of ultimate pension benefit is not defined, certain legal obligations of the plan nevertheless create constructive obligations on the employer to pay further contributions to fund an eventual deficit. This results in the plan being accounted for as a defined benefit plan.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: left;">The liability recognized in the balance sheet in respect of defined benefit pension plans is the present value of the defined benefit obligation at the end of the reporting period less the fair value of plan assets. The defined benefit obligation is calculated annually by independent actuaries using the projected unit credit method. The present value of the defined benefit obligation is determined by discounting the estimated future cash outflows using interest rates of high-quality corporate bonds that are denominated in the currency in which the benefits will be paid, and that have terms to maturity that approximate to the terms of the related pension obligation.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: left;">The current service cost of the defined benefit plan, recognized in the income statement in employee benefit expense, except where included in the cost of an asset, reflects the increase in the defined benefit obligation resulting from employee service in the current year.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: left;">Past service costs, resulting from a plan amendment or curtailment, are recognized immediately in the income statement.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: left;">The net interest cost is calculated by applying the discount rate to the net balance of the present value of the defined benefit obligation and the fair value of plan assets. This cost is included in employee benefit expenses in the income statement.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: left;">Actuarial gains and losses arising from experience adjustments and changes in actuarial assumptions are charged or credited to equity in other comprehensive income in the period in which they arise.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: left;">For defined contribution plans, the company pays contributions to publicly or privately administered pension insurance plans on a mandatory, contractual or voluntary basis. Once the contributions have been paid, the company has no further payment obligations. The contributions are recognized as employee benefit expenses when they are due and are included in staff costs. Prepaid contributions are recognized as an asset to the extent that a cash refund or a reduction in the future payments is available.</div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 36pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">F-34<br></div></div></div>
<!--End Page 288-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 289-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 540pt;"><a name="nt10014672x1_drs_204-finnotes02_pg5"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="block-frill" style="width: 540pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: Arial, Helvetica, sans-serif; font-size: 9pt; font-weight: bold; margin-top: 6pt; text-align: center;">Confidential Treatment Requested by ADC Therapeutics SA Pursuant to 17 C.F.R. &#167; 200.83<br></div></div><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 36pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">ADC Therapeutics SA, Epalinges <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;"><div class="rule-full" style="height: 0pt; width: 100%; border-bottom: 1pt solid #000000; margin-top: 1pt; margin-bottom: 1pt; margin-left: auto; margin-right: auto;"> </div>NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS <font style="padding-left: 4pt;">(continued)</font><br></div><div class="h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 7pt; margin-left: 20pt; text-align: left;"><u>Share-based compensation expense</u></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: left;">The fair value of shares or options granted, respectively, under share purchase or share option plans is recognized as an employee share-based compensation expense with a corresponding increase in equity. The total amount to be expensed is determined by reference to the fair value of the shares or options granted:</div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 40pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">-<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">including any market performance conditions;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 40pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">-<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">excluding the impact of any service and non-market performance vesting conditions; and</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 40pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">-<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">including the impact of any non-vesting conditions.</div></td></tr></table><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: left;">The total expense is recognized over the vesting period, which is the period over which all of the specified vesting conditions are to be satisfied. At the end of each period, the entity revises its estimate of the number of options that are expected to vest based on the non-market vesting and service conditions. It recognizes the impact of the revision to original estimate, if any, in profit or loss, with a corresponding adjustment to equity.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 20pt; text-align: left;">The proceeds received net of any directly attributable transaction costs are credited directly to equity.</div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 12pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">3.8<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; text-align: left;">Share capital and share premium</div></td></tr></table><div class="h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 7pt; margin-left: 20pt; text-align: left;"><u>Share capital</u></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: left;">The Company has issued five different classes of shares, all of which are classified as equity (see note 24, &#8220;Share Capital&#8221;).</div><div class="h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 18pt; margin-left: 20pt; text-align: left;"><u>Share premium</u></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: left;">Amounts of contribution in excess of par value are accounted for as share premium. Share premium also arises from additional capital contributions from shareholders. Incremental costs directly attributable to equity transactions such as the issue of new capital shares are shown in equity as a deduction, net of tax, from the proceeds within share premium. Transaction costs that relate to equity and non-equity transactions are allocated to those transactions using a basis of allocation that is rational and a consistent methodology with previous transactions.</div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 12pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">3.9<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; text-align: left;">Treasury shares</div></td></tr></table><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: left;">Treasury shares are recognized at acquisition cost and deducted from shareholders&#8217; equity at the time of acquisition, until they are cancelled. Where such shares are subsequently sold, any consideration received is included in shareholders&#8217; equity.</div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 12pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">3.10<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; text-align: left;">Leases</div></td></tr></table><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 7pt; margin-left: 20pt; text-align: left;">This policy concerns instances where a Group company is the lessee.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: left;">Leases are recognized as a right-of-use asset and a corresponding liability at the date at which the leased asset is available for use by the group. Each lease payment is allocated between the liability and the finance cost. The finance cost is charged to profit or loss over the lease period so as to produce a constant periodic rate of interest on the remaining balance of the liability for each period. The right-of-use asset is depreciated over the shorter of the asset's useful life and the lease term on a straight-line basis.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: left;">The lease payments are discounted using the interest rate implicit in the lease. If that rate cannot be determined, the lessee&#8217;s incremental borrowing rate is used, being the rate that the lessee would have to pay to borrow the funds necessary to obtain an asset of similar value in a similar economic environment with similar terms and conditions.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 20pt; text-align: left;">Right-of-use assets are measured at cost comprising the following:</div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 40pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">-<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the amount of the initial measurement of lease liability;</div></td></tr></table></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 36pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">F-35<br></div></div></div>
<!--End Page 289-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 290-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 540pt;"><a name="nt10014672x1_drs_204-finnotes02_pg6"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="block-frill" style="width: 540pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: Arial, Helvetica, sans-serif; font-size: 9pt; font-weight: bold; margin-top: 6pt; text-align: center;">Confidential Treatment Requested by ADC Therapeutics SA Pursuant to 17 C.F.R. &#167; 200.83<br></div></div><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 36pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">ADC Therapeutics SA, Epalinges <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;"><div class="rule-full" style="height: 0pt; width: 100%; border-bottom: 1pt solid #000000; margin-top: 1pt; margin-bottom: 1pt; margin-left: auto; margin-right: auto;"> </div>NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS <font style="padding-left: 4pt;">(continued)</font><br></div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 0pt; margin-left: 40pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">-<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">any lease payments made at or before the commencement date less any lease incentives received;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 40pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">-<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">any initial direct costs, and</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 40pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">-<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">restoration costs.</div></td></tr></table><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 20pt; text-align: left;">The lease term is considered to be the non-cancellable period of a lease, together with both:</div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 40pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">-<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">periods covered by an option to extend the lease if the Company is reasonably certain to exercise that option; and</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 40pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">-<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">periods covered by an option to terminate the lease if the Company is reasonably certain not to exercise that option.</div></td></tr></table><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: left;">The policy of recognizing right-of-use assets and lease liabilities is not applied to short-term (under 12&#160;months) or low value (under KUSD 5 when new) leases.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: left;">For deferred tax purposes, the Group considers the net effect of temporary differences arising from the right-of-use asset and the lease liabilities.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: left;">In 2018 and prior years, leases in which a significant portion of the risks and rewards of ownership are retained by the lessor were classified as operating leases. Payments made under operating leases (net of any incentives received from the lessor) were charged to the income statement on a straight-line basis over the period of the lease.</div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 12pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">3.11<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; text-align: left;">Revenue recognition</div></td></tr></table><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: left;">Revenue is measured at the fair value of the consideration received or receivable for the sale of services in the ordinary course of the Group's activities. Revenue is shown net of value-added tax, rebates and discounts and after eliminating sales within the Group.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: left;">The Company recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration which the entity expects to receive in exchange for those goods or services. To determine revenue recognition, the entity performs the following five steps: (i)&#160;identify the contract(s) with a customer; (ii)&#160;identify the performance obligations in the contract; (iii)&#160;determine the transaction price; (iv)&#160;allocate the transaction price to the performance obligations in the contract; and (v)&#160;recognize revenue when (or as) the entity satisfies a performance obligation. The Company applies the five-step model to contracts only when it is probable that the entity will collect the consideration it is entitled to in exchange for the goods or services it transfers to the customer. At contract inception, the Company assesses the goods or services promised within each contract, determines those that are performance obligations and assesses whether each promised good or service is distinct. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied.</div><div class="h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 12pt; margin-left: 20pt; text-align: left;"><u>Performance obligation satisfied to the state of completion - deferred contract revenue amortization</u></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: left;">When the outcome of a transaction involving the rendering of services can be estimated reliably, revenue is recognized according to the stage of completion of the transaction at the end of the period using the cost input method. Under this method, revenue is recognized in the accounting periods in which the services are rendered. The recognition of revenue on this basis provides full information on the extent of service activity and performance during a period.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: left;">To be able to estimate the outcome of a transaction reliably, the entity must be able to make a reliable estimate of total transaction revenue, the stage of completion and the costs to complete the transaction. The stage of completion is determined as the proportion of the transaction costs incurred for services rendered to date compared to the estimated total transaction costs.</div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 12pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">3.12<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; text-align: left;">Research and development expenses</div></td></tr></table><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: left;">Research expenditure is recognized in expense in the year in which it is incurred. Internal development expenditure is capitalized only if it meets the recognition criteria of IAS 38 &#8220;Intangible Assets&#8221;. Where </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 36pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">F-36<br></div></div></div>
<!--End Page 290-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 291-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 540pt;"><a name="nt10014672x1_drs_204-finnotes02_pg7"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="block-frill" style="width: 540pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: Arial, Helvetica, sans-serif; font-size: 9pt; font-weight: bold; margin-top: 6pt; text-align: center;">Confidential Treatment Requested by ADC Therapeutics SA Pursuant to 17 C.F.R. &#167; 200.83<br></div></div><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 36pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">ADC Therapeutics SA, Epalinges <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;"><div class="rule-full" style="height: 0pt; width: 100%; border-bottom: 1pt solid #000000; margin-top: 1pt; margin-bottom: 1pt; margin-left: auto; margin-right: auto;"> </div>NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS <font style="padding-left: 4pt;">(continued)</font><br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 7pt; margin-left: 20pt; text-align: left;">regulatory and other uncertainties are such that the criteria are not met, which is almost invariably the case prior to approval of the drug by the relevant regulatory authority, the expenditure is recognized in the income statement. Where, however, recognition criteria are met, internal development expenditure is capitalized and amortized on a straight-line basis over its useful economic life.</div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 12pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">3.13<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; text-align: left;">Current, deferred income tax and tax credit</div></td></tr></table><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: left;">The tax expense for the period comprises current and deferred tax. Tax is recognized in the income statement, except to the extent that it relates to items recognized in other comprehensive income or directly in equity; in this case the related tax is recognized in other comprehensive income or directly in equity, respectively.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: left;">The current income tax charge is calculated on the basis of the tax laws enacted or substantively enacted at the balance sheet date in the countries where the Company and its subsidiaries operate and generate taxable income. Management periodically evaluates positions taken in tax returns with respect to situations in which applicable tax regulation is subject to interpretation. It establishes provisions where appropriate on the basis of amounts expected to be paid to the tax authorities.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: left;">Taxes on income are accrued in the same periods as the revenues and expenses to which they relate. Current income tax assets and liabilities for the current period are measured at the amount expected to be recovered from or paid to the taxation authorities.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: left;">Deferred income tax is recognized, using the liability method, on temporary differences arising between the tax bases of assets and liabilities and their carrying amounts in the consolidated financial statements. However, deferred tax liabilities are not recognized if they arise from the initial recognition of goodwill. The deferred income tax is not accounted for if it arises from initial recognition of an asset or liability in a transaction other than a business combination that at the time of the transaction affects neither accounting nor taxable profit or loss. Deferred income tax is determined using tax rates (and laws) that have been enacted or substantively enacted by the balance sheet date and are expected to apply when the related deferred income tax asset is realized or the deferred income tax liability is settled.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: left;">Deferred income tax assets are recognized only to the extent that it is probable that future taxable profit will be available against which the temporary differences or the unused tax losses can be utilized.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: left;">Deferred income tax assets from tax credit carryforwards are recognized to the extent that the national tax authority confirms the eligibility of such a claim and that the realization of the related tax benefit through future taxable profits is probable.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: left;">Deferred income tax assets and liabilities are offset when there is a legally enforceable right to offset current tax assets against current tax liabilities and when the deferred income tax assets and liabilities relate to income taxes levied by the same taxation authority on either the same taxable entity or different taxable entities where there is an intention to settle the balances on a net basis.</div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 12pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">3.14<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; text-align: left;">Segment reporting</div></td></tr></table><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: left;">The Company is managed and operated as one business. A single management team that reports to the chief executive officer comprehensively manages the entire business. Accordingly, the Company views its business and manages its operations as one operating segment. Revenue is attributable to the Company&#8217;s country of domicile, Switzerland.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: left;">The Company has locations in three regions: Switzerland, the United Kingdom and the United States. An analysis of non-current assets by geographic region is presented in note 15, &#8220;Non-current assets by geographic area&#8221;.</div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 12pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">3.15<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; text-align: left;">Loss per share</div></td></tr></table><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: left;">Basic loss per share is calculated by dividing the net loss attributable to shareholders by the weighted average number of common shares in issue during the year, excluding common shares owned by the Company and held as treasury shares.</div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 36pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">F-37<br></div></div></div>
<!--End Page 291-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 292-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 540pt;"><a name="nt10014672x1_drs_204-finnotes02_pg8"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="block-frill" style="width: 540pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: Arial, Helvetica, sans-serif; font-size: 9pt; font-weight: bold; margin-top: 6pt; text-align: center;">Confidential Treatment Requested by ADC Therapeutics SA Pursuant to 17 C.F.R. &#167; 200.83<br></div></div><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 36pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">ADC Therapeutics SA, Epalinges <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;"><div class="rule-full" style="height: 0pt; width: 100%; border-bottom: 1pt solid #000000; margin-top: 1pt; margin-bottom: 1pt; margin-left: auto; margin-right: auto;"> </div>NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS <font style="padding-left: 4pt;">(continued)</font><br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 7pt; margin-left: 20pt; text-align: left;">The diluted loss per share is calculated by adjusting the weighted average number of common shares outstanding to assume conversion of all dilutive potential common shares (share option plans, see note 23, &#8220;Share-based compensation expense&#8221;).</div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 12pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">4.<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; text-align: left;">New and amended IFRS standards</div></td></tr></table><div class="h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 7.5pt; margin-left: 20pt; text-align: left;"><u>(i) New standards adopted by the Group</u></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: left;">The Group has applied all new standards, amendments to standards and interpretations that are mandatory for the financial year beginning on January&#160;1, 2019, to the extent that they are relevant to the Group. The only new standard adopted by the Group in 2019 is IFRS 16 &#8220;Leases&#8221;.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: left;">IFRS 16 &#8220;Leases&#8221; has been adopted by the Group from January&#160;1, 2019. Under IAS 17, lessees were required to make a distinction between a finance lease (on balance sheet) and an operating lease (off balance sheet). IFRS 16 now requires lessees to recognize an asset, being the right to use the leased item, and a financial liability, reflecting future lease payments, for virtually all lease contracts, though there is an optional exemption for certain short-term leases and leases of low-value assets.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: left;">The Group has applied the modified retrospective approach, which requires the recognition of the cumulative effect of initially applying IFRS 16 as of January&#160;1, 2019 to accumulated losses without restating prior years. Since the Group recognized the right-of-use assets at an amount equal to the lease liabilities there was no impact on accumulated losses. The new accounting policy for leases is set out in note 3.10, &#8220;Leases&#8221;.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: left;">The Group has elected to apply the following practical expedients in adopting IFRS 16: (i)&#160;not to recognize right-of-use assets and lease liabilities for leases of low value (i.e. approximate value of KUSD 5 when new), (ii)&#160;to apply hindsight in determining the lease term for contracts which contain certain options to extend or terminate the lease, (iii)&#160;to account for each lease component and any non-lease components as a single lease component, (iv)&#160;to rely on its assessment of whether leases were onerous by applying IAS&#160;37 Provisions, Contingent Liabilities and Contingent Assets immediately before the date of application, and (v)&#160;to exclude initial direct costs for the measurement of the right-of-use asset at the date of initial application. The Group&#8217;s weighted average incremental borrowing rate calculated as of January&#160;1, 2019 was&#160;2.66%.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: left;">The following table reconciles the Group's operating lease obligations at December&#160;31, 2018, as computed under the Group's previous accounting policy disclosed above in note 3.10, &#8220;Leases&#8221;, with the lease obligations recognized on initial application of IFRS 16 at January&#160;1, 2019.</div><table cellspacing="0" cellpadding="0" class="fintab" style="margin-top: 5.25pt; border-collapse: collapse; width: 428pt; margin-left: 20pt;"><tr class="header"><td style="width: 89.72%; text-align: left; vertical-align: bottom; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">(in KUSD)&#160;</div></td><td class="gutter" style="width: 2.51%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 2.51%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 5.26%; text-align: center; vertical-align: bottom; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td></tr><tr><td style="width: 89.72%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Operating lease commitments at December&#160;31, 2018<font style="padding-left: 1.31pt;"></font></div></td><td class="gutter" style="width: 2.51%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.51%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.26%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">4,378</div></td></tr><tr><td style="width: 89.72%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 2.51%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.51%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 5.26%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 89.72%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Discounted at the incremental borrowing rate as at January&#160;1, 2019<font style="padding-left: 0.23pt;"></font></div></td><td class="gutter" style="width: 2.51%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.51%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.26%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">3,976</div></td></tr><tr><td style="width: 89.72%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Short-term leases recognized on a straight-line basis as expenses<font style="padding-left: 1.63pt;"></font></div></td><td class="gutter" style="width: 2.51%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.51%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 5.26%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 9.17pt;">(15)</font></div></td></tr><tr><td style="width: 89.72%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Low-value leases recognized on a straight-line basis as expenses<font style="padding-left: 1.63pt;"></font></div></td><td class="gutter" style="width: 2.51%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.51%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.26%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 12.5pt;">&#8212;</font></div></td></tr><tr><td style="width: 89.72%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Extension options reasonably certain to be exercised<font style="padding-left: 1.59pt;"></font></div></td><td class="gutter" style="width: 2.51%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 2.51%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 5.26%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="border-bottom: 1pt solid #000000; min-width: 22.5pt;">1,462</font></div></td></tr><tr><td style="width: 89.72%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Lease obligations recognized at January&#160;1, 2019<font style="font-weight: normal; padding-left: 3.13pt;"></font></div></td><td class="gutter" style="width: 2.51%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.51%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.26%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 22.5pt;">5,423</font></div></td></tr><tr><td style="width: 89.72%; text-align: left; vertical-align: bottom; padding-top: 5.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 2.51%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.51%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 5.26%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 5.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 89.72%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Of which are:<br></div></td><td class="gutter" style="width: 2.51%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.51%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.26%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 89.72%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Lease liabilities (short-term)<font style="padding-left: 1pt;"></font></div></td><td class="gutter" style="width: 2.51%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.51%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 5.26%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 7.5pt;">924</font></div></td></tr><tr><td style="width: 89.72%; text-align: left; vertical-align: bottom; padding-top: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Lease liabilities (long-term)<font style="padding-left: 3.21pt;"></font></div></td><td class="gutter" style="width: 2.51%; border-bottom: none; font-size: 2pt; padding-top: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.51%; border-bottom: none; font-size: 2pt; padding-top: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.26%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">4,499</div></td></tr></table></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 36pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">F-38<br></div></div></div>
<!--End Page 292-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 293-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 540pt;"><a name="nt10014672x1_drs_204-finnotes02_pg9"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="block-frill" style="width: 540pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: Arial, Helvetica, sans-serif; font-size: 9pt; font-weight: bold; margin-top: 6pt; text-align: center;">Confidential Treatment Requested by ADC Therapeutics SA Pursuant to 17 C.F.R. &#167; 200.83<br></div></div><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 36pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">ADC Therapeutics SA, Epalinges <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;"><div class="rule-full" style="height: 0pt; width: 100%; border-bottom: 1pt solid #000000; margin-top: 1pt; margin-bottom: 1pt; margin-left: auto; margin-right: auto;"> </div>NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS <font style="padding-left: 4pt;">(continued)</font><br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 7pt; margin-left: 20pt; text-align: left;">The recognized right-of-use assets relate to the following types of assets:</div><table cellspacing="0" cellpadding="0" class="fintab" style="margin-top: 3.25pt; border-collapse: collapse; width: 428pt; margin-left: 20pt;"><tr class="header"><td style="width: 72.9%; text-align: left; vertical-align: bottom; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">(in KUSD) </div></td><td class="gutter" style="width: 1.85%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.85%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 11.02%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">December&#160;31, <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2019</div></td><td class="gutter" style="width: 1.85%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.85%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 8.67%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">January&#160;1, <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2019</div></td></tr><tr><td style="width: 72.9%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Properties (offices)<font style="padding-left: 1.95pt;"></font></div></td><td class="gutter" style="width: 1.85%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.85%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 11.02%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 12.34pt; text-align: left;">4,820</div></td><td class="gutter" style="width: 1.85%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.85%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.67%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.31pt; text-align: left;">5,399</div></td></tr><tr><td style="width: 72.9%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Vehicles<font style="padding-left: 0.63pt;"></font></div></td><td class="gutter" style="width: 1.85%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.85%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 11.02%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 12.34pt; text-align: left;"><font style="padding-left: 12.5pt; border-bottom: 1pt solid #000000; min-width: 22.5pt;">78 </font></div></td><td class="gutter" style="width: 1.85%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.85%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 8.67%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.31pt; text-align: left;"><font style="padding-left: 12.5pt; border-bottom: 1pt solid #000000; min-width: 22.5pt;">24 </font></div></td></tr><tr><td style="width: 72.9%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Total right-of-use assets<font style="font-weight: normal; padding-left: 1.58pt;"></font></div></td><td class="gutter" style="width: 1.85%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.85%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 11.02%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 12.34pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 22.5pt;">4,898</font></div></td><td class="gutter" style="width: 1.85%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.85%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.67%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 7.31pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 22.5pt;">5,423</font></div></td></tr></table><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: left;">In accordance with the adoption of IFRS 16 &#8220;Leases&#8221; as of January&#160;1, 2019, the Group recorded at initial recognition a non-cash KUSD 5,423 right-of-use asset and corresponding lease liability. Comparative information has not been restated. The Group&#8217;s income statement for the year ended December&#160;31, 2019 was impacted by an increase in depreciation of right-of-use leased assets of KUSD 1,064 and a reduction in operating lease expenses of KUSD 1,002. The increase in interest expense was KUSD 141. During the same periods, the Group&#8217;s cash flow statement was impacted by a shift of KUSD 1,143 from cash generated from operations to net cash used in financing activities. Overall, IFRS 16 was cash neutral for the Group.</div><div class="h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 19pt; margin-left: 20pt; text-align: left;"><u>(ii) New standards and interpretations not yet adopted</u></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: left;">There are new standards, amendments to standards and interpretations that are not yet effective, which have been deemed by the Group as currently not relevant, and hence are not listed here.</div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 12pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">5.<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; text-align: left;">Financial risk management</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">5.1<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; text-align: left;">Financial risk factors</div></td></tr></table><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: left;">The Board of Directors regularly reviews the Group cash forecast and related foreign exchange risk. It also performs the risk assessment, defines any necessary measures and ensures the monitoring of the internal control system. The Group does not use derivative financial instruments to hedge these exposures.</div><div class="h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 19.5pt; margin-left: 20pt; text-align: left;"><u>Foreign exchange risk</u></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: left;">The Group operates internationally and is exposed to foreign exchange risk arising from various currency exposures, primarily with respect to British pounds, Euros and Swiss francs. Transaction exposure arises because the amount of local currency paid or received in transactions denominated in foreign currencies may vary due to changes in exchange rates. Foreign exchange risk arises from:</div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 40pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">-<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">forecast costs denominated in a currency other than the entity&#8217;s functional currency;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 40pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">-<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">recognized assets and liabilities denominated in a currency other than the entity's functional currency; and</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 40pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">-<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">net investments in foreign operations.</div></td></tr></table><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: left;">Management believes that foreign exchange risk is minimal, as the Company pays invoices mainly in USD and holds cash principally in USD.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 20pt; text-align: left;">The Group's cash and cash equivalents are denominated in the following currencies:</div><table cellspacing="0" cellpadding="0" class="fintab" style="margin-top: 3.25pt; border-collapse: collapse; width: 428pt; margin-left: 20pt;"><tr class="header"><td style="width: 53.27%; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">December 31</div></td><td class="gutter" style="width: 0.7%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 0.7%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 10.28%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2019 <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">in KL/C<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(1)</sup></div></td><td class="gutter" style="width: 0.7%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 0.7%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 10.28%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2019 <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">in KUSD</div></td><td class="gutter" style="width: 0.7%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 0.7%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 10.28%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2018 <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">in KL/C<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(1)</sup></div></td><td class="gutter" style="width: 0.7%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 0.7%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 10.28%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2018 <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">in KUSD</div></td></tr><tr><td style="width: 53.27%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">In USD<font style="padding-left: 3.85pt;"></font></div></td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.28%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 5.75pt; text-align: left;">109,939</div></td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.28%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 5.75pt; text-align: left;">109,939</div></td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.28%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 5.75pt; text-align: left;">135,451</div></td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.28%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 5.75pt; text-align: left;">135,451</div></td></tr><tr><td style="width: 53.27%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">In CHF<font style="padding-left: 4.4pt;"></font></div></td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 10.28%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 5.75pt; text-align: left;"><font style="padding-left: 17.5pt;">457</font></div></td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 10.28%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 5.75pt; text-align: left;"><font style="padding-left: 17.5pt;">472</font></div></td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 10.28%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 5.75pt; text-align: left;"><font style="padding-left: 10pt;">1,143</font></div></td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 10.28%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 5.75pt; text-align: left;"><font style="padding-left: 10pt;">1,160</font></div></td></tr><tr><td style="width: 53.27%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">In GBP<font style="padding-left: 4.4pt;"></font></div></td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.28%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 5.75pt; text-align: left;"><font style="padding-left: 10pt;">3,529</font></div></td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.28%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 5.75pt; text-align: left;"><font style="padding-left: 10pt;">4,654</font></div></td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.28%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 5.75pt; text-align: left;"><font style="padding-left: 17.5pt;">929</font></div></td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.28%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 5.75pt; text-align: left;"><font style="padding-left: 10pt;">1,179</font></div></td></tr><tr><td style="width: 53.27%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">In EUR<font style="padding-left: 3.84pt;"></font></div></td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 10.28%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 5.75pt; text-align: left;"><font style="padding-left: 17.5pt;">433</font></div></td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 10.28%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 5.75pt; text-align: left;"><font style="padding-left: 17.5pt; border-bottom: 1pt solid #000000; min-width: 32.5pt;">486</font></div></td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 10.28%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 5.75pt; text-align: left;"><font style="padding-left: 17.5pt;">889</font></div></td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 10.28%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 5.75pt; text-align: left;"><font style="padding-left: 10pt; border-bottom: 1pt solid #000000; min-width: 32.5pt;">1,017 </font></div></td></tr><tr><td style="width: 53.27%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.28%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.28%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 5.75pt; text-align: left;"><font style="padding-left: 0.55pt; border-bottom: 3pt double #000000; min-width: 32.5pt;">115,551</font></div></td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.28%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.7%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.28%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 5.75pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 32.5pt;">138,807</font></div></td></tr></table><div><div class="rule-partial" style="height: 0pt; width: 72pt; border-bottom: 1pt solid #000000; margin-bottom: 1pt; margin-right: auto; margin-left: 20pt; margin-top: 12.75pt;"> </div></div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 3pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">(1)<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; text-align: left;">Thousands Local Currencies</div></td></tr></table></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 36pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">F-39<br></div></div></div>
<!--End Page 293-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 294-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 540pt;"><a name="nt10014672x1_drs_204-finnotes02_pg10"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="block-frill" style="width: 540pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: Arial, Helvetica, sans-serif; font-size: 9pt; font-weight: bold; margin-top: 6pt; text-align: center;">Confidential Treatment Requested by ADC Therapeutics SA Pursuant to 17 C.F.R. &#167; 200.83<br></div></div><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 36pt;"><div class="ftnote" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">ADC Therapeutics SA, Epalinges <br></div><div class="ftnote" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;"><div class="rule-full" style="height: 0pt; width: 100%; border-bottom: 1pt solid #000000; margin-top: 1pt; margin-bottom: 1pt; margin-left: auto; margin-right: auto;"> </div>NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS <font style="padding-left: 4pt;">(continued)</font><br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 7pt; margin-left: 20pt; text-align: left;">The Group has certain investments in foreign operations whose net assets are exposed to foreign currency translation risk. Currency exposure arising from these net assets of the Group&#8217;s foreign operations is managed primarily through purchasing goods and services denominated in the relevant foreign currencies.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: left;">At December&#160;31, 2019, if the USD had weakened / strengthened by 10% against the CHF with all other variables held constant, the pre-tax loss for the year would have been KUSD 201 higher / lower, as a result of foreign exchange losses / gains on translation of CHF-denominated net monetary liabilities (2018: KUSD 20 lower / higher on net monetary assets).</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: left;">At December&#160;31, 2019, if the USD had weakened / strengthened by 10% against the EUR with all other variables held constant, the pre-tax loss for the year would have been KUSD 95 higher / lower, mainly as a result of foreign exchange losses / gains on translation of EUR-denominated net monetary liabilities (2018:&#160;KUSD 158 higher / lower).</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: left;">At December&#160;31, 2019, if the USD had weakened / strengthened by 10% against the GBP with all other variables held constant, the pre-tax loss for the year would have been KUSD 290 higher / lower, mainly as a result of foreign exchange losses / gains on translation of GBP-denominated net monetary liabilities (2018:&#160;KUSD 100 higher / lower), and the gain on currency translation differences credited directly to equity and arising on the translation of the net assets of ADCT UK would have been KUSD 320 higher / lower (2018: KUSD 125 higher / lower).</div><div class="h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 20.5pt; margin-left: 20pt; text-align: left;"><u>Interest rate risk</u></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: left;">Interest rate risk arises from movements in interest rates which could have adverse effects on the Group's net income or financial position. Changes in interest rates cause variations in interest income and expenses on interest-bearing assets and liabilities, and on the value of the net defined benefit pension obligation.</div><div class="h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 20.5pt; margin-left: 20pt; text-align: left;"><u>Credit risk</u></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: left;">Credit risk is the risk that a counterparty will not meet its obligations under a financial instrument or customer contract, leading to a financial loss. The Group is exposed to credit risk from its operating activities and from its financing activities including deposits with banks and other financial institutions (see&#160;note 19b, &#8220;Credit quality of financial assets&#8221;). The Group&#8217;s cash and cash equivalents accounts are maintained with well established, highly rated financial institutions. The Company&#8217;s wholly-owned subsidiaries are solvent, are managed on a cost-plus service provider basis, and are supported by the Company as the parent.</div><div class="h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 20.5pt; margin-left: 20pt; text-align: left;"><u>Liquidity risk</u></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: left;">Liquidity risk is the risk that the Group may not be able to generate sufficient cash resources to settle its obligations in full as they fall due or can do so only on terms that are materially disadvantageous. Prudent liquidity risk management implies maintaining sufficient cash to cover working capital requirements. Cash is monitored by the Group management.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: left;">Funding and liquidity risks are reviewed regularly by the Board and management. The Board reviews the Group&#8217;s ongoing liquidity risks quarterly as part of the financial review process and on an ad hoc basis. To date, the Company has funded its capital requirements through capital raises or partnering of its programs.</div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 36pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">F-40<br></div></div></div>
<!--End Page 294-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 295-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 540pt;"><a name="nt10014672x1_drs_204-finnotes02_pg11"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="block-frill" style="width: 540pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: Arial, Helvetica, sans-serif; font-size: 9pt; font-weight: bold; margin-top: 6pt; text-align: center;">Confidential Treatment Requested by ADC Therapeutics SA Pursuant to 17 C.F.R. &#167; 200.83<br></div></div><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 36pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">ADC Therapeutics SA, Epalinges <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;"><div class="rule-full" style="height: 0pt; width: 100%; border-bottom: 1pt solid #000000; margin-top: 1pt; margin-bottom: 1pt; margin-left: auto; margin-right: auto;"> </div>NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS <font style="padding-left: 4pt;">(continued)</font><br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 7pt; margin-left: 20pt; text-align: left;">The table below analyses the Group's financial liabilities into relevant maturity groupings based on the remaining period at the balance sheet date to the contractual maturity date. </div><table cellspacing="0" cellpadding="0" class="fintab" style="margin-top: 11.25pt; border-collapse: collapse; width: 428pt; margin-left: 20pt;"><tr class="header"><td style="width: 42.06%; text-align: left; vertical-align: bottom; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">(in KUSD)</div></td><td class="gutter" style="width: 1.9%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.9%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 3.73%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Note</div></td><td class="gutter" style="width: 1.9%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.9%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 7.79%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Less than <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">3 months</div></td><td class="gutter" style="width: 1.9%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.9%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 9.55%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Between 3 <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">months and <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">1&#160;year</div></td><td class="gutter" style="width: 1.9%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.9%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 8.3%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Between 1 <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">year and <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">3&#160;years</div></td><td class="gutter" style="width: 1.9%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.9%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 9.58%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">More than <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">3 years</div></td></tr><tr><td style="width: 42.06%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Trade accounts payable<font style="padding-left: 1.78pt;"></font></div></td><td class="gutter" style="width: 1.9%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.9%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 3.73%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.9%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.9%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.79%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 5.41pt; text-align: left;">3,266</div></td><td class="gutter" style="width: 1.9%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.9%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.55%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 12.94pt; text-align: left;"><font style="padding-left: 5pt;">63</font></div></td><td class="gutter" style="width: 1.9%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.9%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.3%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 6.51pt; text-align: left;"><font style="padding-left: 12.5pt;">&#8212;</font></div></td><td class="gutter" style="width: 1.9%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.9%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.58%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.25pt; text-align: left;"><font style="padding-left: 12.5pt;">&#8212;</font></div></td></tr><tr><td style="width: 42.06%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Lease liabilities<font style="padding-left: 3.64pt;"></font></div></td><td class="gutter" style="width: 1.9%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.9%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 3.73%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.99pt; text-align: left;">17</div></td><td class="gutter" style="width: 1.9%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.9%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 7.79%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 5.41pt; text-align: left;"><font style="padding-left: 7.87pt; border-bottom: 1pt solid #000000; min-width: 22.5pt;">311</font></div></td><td class="gutter" style="width: 1.9%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.9%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 9.55%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 12.94pt; text-align: left;"><font style="border-bottom: 1pt solid #000000; min-width: 15pt;">935</font></div></td><td class="gutter" style="width: 1.9%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.9%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 8.3%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 6.51pt; text-align: left;"><font style="border-bottom: 1pt solid #000000; min-width: 22.5pt;">1,859</font></div></td><td class="gutter" style="width: 1.9%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.9%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 9.58%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.25pt; text-align: left;"><font style="border-bottom: 1pt solid #000000; min-width: 22.5pt;">2,265 </font></div></td></tr><tr><td style="width: 42.06%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">At December&#160;31, 2019<font style="font-weight: normal; padding-left: 1.34pt;"></font></div></td><td class="gutter" style="width: 1.9%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.9%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 3.73%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 1.9%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.9%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.79%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 5.41pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 22.5pt;">3,577</font></div></td><td class="gutter" style="width: 1.9%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.9%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.55%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 12.94pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 15pt;">998</font></div></td><td class="gutter" style="width: 1.9%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.9%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.3%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 6.51pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 22.5pt;">1,859</font></div></td><td class="gutter" style="width: 1.9%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.9%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.58%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 9.25pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 22.5pt;">2,265</font></div></td></tr><tr><td style="width: 42.06%; text-align: left; vertical-align: bottom; padding-top: 5.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.9%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.9%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 3.73%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 5.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.9%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.9%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 7.79%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 5.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.9%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.9%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 9.55%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 5.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.9%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.9%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 8.3%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 5.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.9%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.9%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 9.58%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 5.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 42.06%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Trade accounts payable<font style="padding-left: 1.78pt;"></font></div></td><td class="gutter" style="width: 1.9%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.9%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 3.73%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.9%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.9%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.79%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 5.41pt; text-align: left;">6,597</div></td><td class="gutter" style="width: 1.9%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.9%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.55%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 12.94pt; text-align: left;">153</div></td><td class="gutter" style="width: 1.9%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.9%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.3%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 6.51pt; text-align: left;"><font style="padding-left: 12.5pt;">&#8212;</font></div></td><td class="gutter" style="width: 1.9%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.9%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.58%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.25pt; text-align: left;"><font style="padding-left: 12.5pt;">&#8212;</font></div></td></tr><tr><td style="width: 42.06%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Lease liabilities<font style="padding-left: 3.64pt;"></font></div></td><td class="gutter" style="width: 1.9%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.9%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 3.73%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.99pt; text-align: left;">17</div></td><td class="gutter" style="width: 1.9%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.9%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 7.79%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 5.41pt; text-align: left;"><font style="padding-left: 12.5pt; border-bottom: 1pt solid #000000; min-width: 22.5pt;">&#8212;</font></div></td><td class="gutter" style="width: 1.9%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.9%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 9.55%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 12.94pt; text-align: left;"><font style="padding-left: 5pt; border-bottom: 1pt solid #000000; min-width: 15pt;">&#8212;</font></div></td><td class="gutter" style="width: 1.9%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.9%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 8.3%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 6.51pt; text-align: left;"><font style="padding-left: 12.5pt; border-bottom: 1pt solid #000000; min-width: 22.5pt;">&#8212;</font></div></td><td class="gutter" style="width: 1.9%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.9%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 9.58%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.25pt; text-align: left;"><font style="padding-left: 12.5pt; border-bottom: 1pt solid #000000; min-width: 22.5pt;">&#8212;</font></div></td></tr><tr><td style="width: 42.06%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">At December&#160;31, 2018<font style="font-weight: normal; padding-left: 1.34pt;"></font></div></td><td class="gutter" style="width: 1.9%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.9%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 3.73%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 1.9%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.9%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.79%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 5.41pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 22.5pt;">6,597</font></div></td><td class="gutter" style="width: 1.9%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.9%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.55%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 12.94pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 15pt;">153</font></div></td><td class="gutter" style="width: 1.9%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.9%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.3%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 6.51pt; text-align: left;"><font style="padding-left: 12.5pt; border-bottom: 3pt double #000000; min-width: 22.5pt;">&#8212;</font></div></td><td class="gutter" style="width: 1.9%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.9%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.58%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 9.25pt; text-align: left;"><font style="padding-left: 12.5pt; border-bottom: 3pt double #000000; min-width: 22.5pt;">&#8212;</font></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 12pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">5.2<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; text-align: left;">Capital management</div></td></tr></table><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: left;">The Group considers equity as equivalent to the IFRS equity on the balance sheet (including share capital, share premium and all other equity reserves attributable to the owners of the Company). The Group has no interest-bearing debt, other than lease liabilities.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: left;">The primary objective of the Group's capital management is to maximize shareholder value. The Board regularly reviews its shareholders' return strategy. For the foreseeable future, the Board will maintain a capital structure that supports the Group's strategic objectives through managing funding and liquidity risks and optimizing shareholder return.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: left;">The Company is a late clinical-stage biotechnology company with product candidates still at pre-clinical and clinical stages of development. As such, it does not expect to have significant revenues in the current year. It intends to continue to explore financing opportunities through cooperation and collaboration with pharmaceutical and biotechnology partners &#8211; potentially along the value chain from research alliances through co-development to commercialization &#8211; and through fund raising. As explained in note 2 (iii), &#8220;Going concern basis&#8221;, the Board of Directors believes that the Company has sufficient financial resources available to meet all of its obligations for at least the twelve months from the issuance of these consolidated financial statements without additional capital becoming available.</div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 12pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">5.3<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; text-align: left;">Fair value estimation</div></td></tr></table><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: left;">At December&#160;31, 2019, the carrying amount is a reasonable approximation of fair value for the following financial assets and liabilities:</div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 40pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">-<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">Cash and cash equivalents</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 40pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">-<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">Trade accounts receivable</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 40pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">-<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">Trade accounts payable</div></td></tr></table><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: left;">In 2019, there were no significant changes in the business or economic circumstances that affect the fair value of the Group's financial assets and financial liabilities.</div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 12pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">6<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; text-align: left;">Critical accounting estimates and judgements</div></td></tr></table><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: left;">Estimates and judgements are continually evaluated and are based on historical experience and other factors, including expectations of future events that are believed to be reasonable under the circumstances. The estimates, assumptions and judgements that have significantly affected reported results or that have a significant risk of causing a material adjustment to the carrying amounts of assets and liabilities within the next financial year are addressed below.</div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 36pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">F-41<br></div></div></div>
<!--End Page 295-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 296-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 540pt;"><a name="nt10014672x1_drs_204-finnotes02_pg12"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="block-frill" style="width: 540pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: Arial, Helvetica, sans-serif; font-size: 9pt; font-weight: bold; margin-top: 6pt; text-align: center;">Confidential Treatment Requested by ADC Therapeutics SA Pursuant to 17 C.F.R. &#167; 200.83<br></div></div><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 36pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">ADC Therapeutics SA, Epalinges <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;"><div class="rule-full" style="height: 0pt; width: 100%; border-bottom: 1pt solid #000000; margin-top: 1pt; margin-bottom: 1pt; margin-left: auto; margin-right: auto;"> </div>NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS <font style="padding-left: 4pt;">(continued)</font><br></div><div class="h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 7pt; margin-left: 20pt; text-align: left;"><u>Revenue recognition</u></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: left;">The Company was party to a long-term license and joint collaboration agreement with MedImmune for the joint clinical development a product candidate, MEDI3726. The license and joint collaboration agreement included both upfront and milestone payments receivable by the company in return for the satisfaction of certain performance obligations.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 20pt; text-align: left;"><u>Upfront payments for two programs</u></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: left;">The Company received an upfront payment in 2013 under the license and joint collaboration agreement. This related to two separate product candidate programs. In each case, MedImmune received, in addition to the license, a commitment from the Company to perform development work on a product candidate to be chosen by MedImmune from a specified list; in return, MedImmune agreed, inter alia, to make an upfront payment of KUSD 10,000 and to bear part of the development work costs.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 20pt; text-align: left;"><u>First program upfront payment</u></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: left;">The product candidate for the first program of work was immediately selected by MedImmune and the Company from inception recognized the upfront payment of KUSD 10,000 over the period of the related development work, based on the ratio of the costs of the work done to the total estimated costs to completion. This method requires that the entity be able to make a reliable estimate of total transaction revenue, the state of completion and the costs to complete the transaction, which involves some judgement. In 2019 MedImmune decided to discontinue its involvement in the development of this product candidate. As a consequence, the Company recognized the residual amount of the non-refundable upfront payment received under the related license and collaboration agreement (consisting of deferred revenue and presented as a contract liability at the end of 2019) in 2019 as contract revenue. The related revenue recognized in 2019 amounted to KUSD 2,340 (2018: KUSD 1,140). Please see also note 7, &#8220;Contract revenue and contract liability&#8221;.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 20pt; text-align: left;"><u>Second program upfront payment</u></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: left;">MedImmune deferred selection of a second program and finally decided definitively not to proceed with selection of a second program in 2015, when the upfront payment of KUSD 10,000 was entirely recognized in revenue, as there was no remaining performance obligation.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 20pt; text-align: left;"><u>Milestone payment</u></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: left;">Under the first program, the Company was also entitled to receive a milestone payment of KUSD 10,000 upon a successful IND filing. The performance obligation was deemed to be the development work to be performed in order to achieve this filing. This amount was not recognized over the period in which the work was performed, as there could be no confidence in advance a successful outcome would be achieved. Accordingly, the entire milestone payment was recognized in revenue in 2016 upon a successful IND filing.</div><div class="h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 12pt; margin-left: 20pt; text-align: left;"><u>Licenses</u></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: left;">The Company enters into collaboration, license and sublicense agreements with third parties, which grant the Company the right to use their antibodies with the Company's licensed warhead and linker technology to develop new ADCs for anti-cancer treatments. The license fees (upfront fees, signature fees, milestone payments) paid by the Company under the agreements are capitalized as intangible assets. The Company considers that those licenses have a finite life. However, they are not amortized until the commercialization phase. They are tested annually for impairment. An impairment loss is recognized for the amount by which the asset's carrying amount exceeds its recoverable amount (higher of an asset's fair value less costs of disposal and value in use). Impairment losses are recognized in the income statement. Testing for impairment inevitably involves the application of judgement. The license costs capitalized in 2019 amounted to KUSD 1,731 (2018: KUSD 1,481). The Company has performed a review of its licenses and concluded that no impairment was required under the provision of IAS 36. In 2018, in relation to the termination of one of the Company's programs, an impairment charge of KUSD 227 (corresponding to the entire carrying amount of the capitalized license) was recognized and charged to research and development expenses in the income statement. Please refer to note 18, &#8220;Intangible assets&#8221;.</div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 36pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">F-42<br></div></div></div>
<!--End Page 296-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 297-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 540pt;"><a name="nt10014672x1_drs_204-finnotes02_pg13"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="block-frill" style="width: 540pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: Arial, Helvetica, sans-serif; font-size: 9pt; font-weight: bold; margin-top: 6pt; text-align: center;">Confidential Treatment Requested by ADC Therapeutics SA Pursuant to 17 C.F.R. &#167; 200.83<br></div></div><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 36pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">ADC Therapeutics SA, Epalinges <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;"><div class="rule-full" style="height: 0pt; width: 100%; border-bottom: 1pt solid #000000; margin-top: 1pt; margin-bottom: 1pt; margin-left: auto; margin-right: auto;"> </div>NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS <font style="padding-left: 4pt;">(continued)</font><br></div><div class="h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 7pt; margin-left: 20pt; text-align: left;"><u>Share-based compensation expense</u></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: left;">The details of the Incentive Plan 2014, the Share Purchase Plan 2016 and the Equity Incentive Plan 2019 are explained in note 23, &#8220;Share-based compensation expense&#8221;. In all plans, the determination of the fair value of awards involved the application of an adjusted form of the Black-Scholes option pricing model. Significant judgement was required in estimating certain variables in that model, as explained in the notes regarding each plan. In addition, for awards granted on and subsequent to July&#160;1, 2019, the fair value of grants was based on a probability-weighted expected returns method that takes account of both the value derived by using an adjusted form of the Black-Scholes option pricing model and a discounted estimate of the price that might be achieved in a future transaction. This method entails further significant judgement, both in estimating a transaction price and in estimating the probabilities of different outcomes.</div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 12pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">7.<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; text-align: left;">Contract revenue and contract liability</div></td></tr></table><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: left;">Contract revenue represents the amortization of upfront payments received under the license and collaboration agreement with MedImmune for the joint clinical development of MEDI3726 in order to finance the research and development that is the subject of those contracts and a milestone payment related to the same agreement. Unamortized amounts are carried forward as a contract liability. No other upfront or milestone payment has been received or will become receivable under the terms of this or any other existing license and collaboration agreement.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8.5pt; margin-left: 20pt; text-align: left;">The movement in contract liability is as follows:</div><table cellspacing="0" cellpadding="0" class="fintab" style="margin-top: 11.25pt; border-collapse: collapse; width: 428pt; margin-left: 20pt;"><tr class="header"><td style="width: 72.9%; text-align: left; vertical-align: bottom; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">(in KUSD)</div></td><td class="gutter" style="width: 3.76%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 3.76%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 6.04%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2019</div></td><td class="gutter" style="width: 3.76%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 3.76%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 6.03%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2018</div></td></tr><tr><td style="width: 72.9%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">January 1<font style="padding-left: 0.07pt;"></font></div></td><td class="gutter" style="width: 3.76%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 3.76%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.04%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 3.33pt;">2,340</font></div></td><td class="gutter" style="width: 3.76%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 3.76%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.03%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 3.33pt;">3,480</font></div></td></tr><tr><td style="width: 72.9%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Recognized as contract revenue<font style="padding-left: 0.12pt;"></font></div></td><td class="gutter" style="width: 3.76%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 3.76%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 6.04%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="border-bottom: 1pt solid #000000; min-width: 25.83pt;">(2,340</font><font style="min-width: 25.83pt;">)</font></div></td><td class="gutter" style="width: 3.76%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 3.76%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 6.03%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="border-bottom: 1pt solid #000000; min-width: 25.83pt;">(1,140</font><font style="min-width: 25.83pt;">)</font></div></td></tr><tr><td style="width: 72.9%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">December 31<font style="font-weight: normal; padding-left: 3.04pt;"></font></div></td><td class="gutter" style="width: 3.76%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 3.76%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.04%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 15.83pt; border-bottom: 3pt double #000000; min-width: 25.83pt;">&#8212;</font></div></td><td class="gutter" style="width: 3.76%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 3.76%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.03%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 3.33pt; border-bottom: 3pt double #000000; min-width: 25.83pt;">2,340</font></div></td></tr><tr><td style="width: 72.9%; text-align: left; vertical-align: bottom; padding-top: 5.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 3.76%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 3.76%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 6.04%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 5.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 3.76%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 3.76%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 6.03%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 5.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 72.9%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><u>of which:</u><br></div></td><td class="gutter" style="width: 3.76%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 3.76%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.04%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 3.76%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 3.76%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.03%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 72.9%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Contract liability (short term)<font style="padding-left: 3.99pt;"></font></div></td><td class="gutter" style="width: 3.76%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 3.76%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 6.04%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 15.83pt;">&#8212;</font></div></td><td class="gutter" style="width: 3.76%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 3.76%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 6.03%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 3.33pt;">1,765</font></div></td></tr><tr><td style="width: 72.9%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Contract liability (long term)<font style="padding-left: 1.2pt;"></font></div></td><td class="gutter" style="width: 3.76%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 3.76%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.04%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 15.83pt; border-bottom: 1pt solid #000000; min-width: 25.83pt;">&#8212;</font></div></td><td class="gutter" style="width: 3.76%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 3.76%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.03%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 10.83pt; border-bottom: 1pt solid #000000; min-width: 25.83pt;">575 </font></div></td></tr><tr><td style="width: 72.9%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 6pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Contract liability (total)<font style="font-weight: normal; padding-left: 0.65pt;"></font></div></td><td class="gutter" style="width: 3.76%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt;">&#8203;</td><td class="gutter" style="width: 3.76%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt;">&#8203;</td><td style="width: 6.04%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 6pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 15.83pt; border-bottom: 3pt double #000000; min-width: 25.83pt;">&#8212;</font></div></td><td class="gutter" style="width: 3.76%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt;">&#8203;</td><td class="gutter" style="width: 3.76%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt;">&#8203;</td><td style="width: 6.03%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 6pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 3.33pt; border-bottom: 3pt double #000000; min-width: 25.83pt;">2,340</font></div></td></tr></table><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: left;">The amounts of deferred contract revenue arose entirely from an upfront payment received in 2013 under a license and joint collaboration agreement. The basis on which contract revenue had been recognized under this agreement is explained in note 6, &#8220;Critical accounting estimates and judgements&#8221; under &#8220;Revenue recognition&#8221;.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: left;">As a result of the discontinued involvement of MedImmune in the development of a product candidate, the residual amount of the non-refundable upfront payment received under the related license and collaboration agreement (consisting of deferred revenue and previously presented as a contract liability) was recognized in 2019 as contract revenue.</div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 36pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">F-43<br></div></div></div>
<!--End Page 297-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 298-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 540pt;"><a name="nt10014672x1_drs_204-finnotes02_pg14"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="block-frill" style="width: 540pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: Arial, Helvetica, sans-serif; font-size: 9pt; font-weight: bold; margin-top: 6pt; text-align: center;">Confidential Treatment Requested by ADC Therapeutics SA Pursuant to 17 C.F.R. &#167; 200.83<br></div></div><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 36pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">ADC Therapeutics SA, Epalinges <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;"><div class="rule-full" style="height: 0pt; width: 100%; border-bottom: 1pt solid #000000; margin-top: 1pt; margin-bottom: 1pt; margin-left: auto; margin-right: auto;"> </div>NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS <font style="padding-left: 4pt;">(continued)</font><br></div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 12pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">8.<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; text-align: left;">Other Income</div></td></tr></table><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: left;">The Group has for the first time recognized amounts received and receivable by ADCT UK under the UK&#8217;s Research and Development Expenditure Credit scheme. The amounts recognized are in respect of the years 2016 &#8211; 2019 and are set out below.</div><table cellspacing="0" cellpadding="0" class="fintab" style="margin-top: 11.25pt; border-collapse: collapse; width: 428pt; margin-left: 20pt;"><tr class="header"><td style="width: 72.9%; text-align: left; vertical-align: bottom; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">(in KUSD):</div></td><td class="gutter" style="width: 1.27%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.27%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 11.02%; text-align: center; vertical-align: bottom; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 1.27%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.27%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 11.02%; text-align: center; vertical-align: bottom; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td></tr><tr class="header"><td style="width: 72.9%; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Years</div></td><td class="gutter" style="width: 1.27%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.27%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 11.02%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">December&#160;31, <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2019</div></td><td class="gutter" style="width: 1.27%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.27%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 11.02%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">December&#160;31, <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2018</div></td></tr><tr><td style="width: 72.9%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">2016<font style="padding-left: 4.5pt;"></font></div></td><td class="gutter" style="width: 1.27%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.27%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 11.02%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 12.33pt; text-align: left;"><font style="padding-left: 7.5pt;">296</font></div></td><td class="gutter" style="width: 1.27%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.27%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 11.02%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 18.58pt; text-align: left;">&#8212;</div></td></tr><tr><td style="width: 72.9%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">2017<font style="padding-left: 4.5pt;"></font></div></td><td class="gutter" style="width: 1.27%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.27%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 11.02%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 12.33pt; text-align: left;"><font style="padding-left: 7.5pt;">350</font></div></td><td class="gutter" style="width: 1.27%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.27%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 11.02%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 18.58pt; text-align: left;">&#8212;</div></td></tr><tr><td style="width: 72.9%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">2018<font style="padding-left: 4.5pt;"></font></div></td><td class="gutter" style="width: 1.27%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.27%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 11.02%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 12.33pt; text-align: left;"><font style="padding-left: 7.5pt;">477</font></div></td><td class="gutter" style="width: 1.27%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.27%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 11.02%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 18.58pt; text-align: left;">&#8212;</div></td></tr><tr><td style="width: 72.9%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">2019<font style="padding-left: 4.5pt;"></font></div></td><td class="gutter" style="width: 1.27%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.27%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 11.02%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 12.33pt; text-align: left;"><font style="padding-left: 7.5pt; border-bottom: 1pt solid #000000; min-width: 22.5pt;">532</font></div></td><td class="gutter" style="width: 1.27%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.27%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 11.02%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 18.58pt; text-align: left;"><font style="border-bottom: 1pt solid #000000; min-width: 10pt;">&#8212; </font></div></td></tr><tr><td style="width: 72.9%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.27%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.27%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 11.02%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 12.33pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 22.5pt;">1,655</font></div></td><td class="gutter" style="width: 1.27%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.27%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 11.02%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 18.58pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 10pt;">&#8212;</font></div></td></tr></table><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: left;">The grants represent 12% of eligible expenditure (11% for periods prior to 2018). Because of the strictness of the eligibility criteria for these credits, the Group did not recognize any income under this scheme until it had positive confirmation that initial claims had been approved for payment. This occurred only in 2019.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: left;">The claims are payable through the tax system, as a refund of corporation tax or of other taxes, including income tax and social security payments deducted at source from qualifying (research) employees&#8217; payroll and VAT. The relevant amounts have been therefore presented net in the balance sheet. As the credit is independent of ADCT UK&#8217;s taxable profit, is clearly designed to incentivize companies to invest in research and development activities and is itself taxable income, the Group has recognized the income as government grants within other income and not as a credit to the tax charge.</div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 12pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">9.<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; text-align: left;">Research and development expenses</div></td></tr></table><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: left;">Throughout the period, the Company was ultimately responsible for paying all development costs and developing and maintaining the intellectual property of the Company. However, research and development (&#8220;R&amp;D&#8221;) expenses decreased from KUSD 118,313 in 2018 to KUSD 107,537 in 2019. This decrease of KUSD 10,776 is primarily due to a decrease in chemistry, manufacturing and controls (&#8220;CMC&#8221;) costs as the clinical trials advance.</div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 12pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">10<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; text-align: left;">Employee expenses</div></td></tr></table><table cellspacing="0" cellpadding="0" class="fintab" style="margin-top: 10.25pt; border-collapse: collapse; width: 428pt; margin-left: 20pt;"><tr class="header"><td style="width: 61.68%; text-align: left; vertical-align: bottom; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">(in KUSD)</div></td><td class="gutter" style="width: 2.09%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 2.09%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 3.74%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Note</div></td><td class="gutter" style="width: 2.09%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 2.09%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 11.02%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Year ended <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">December&#160;31, <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2019</div></td><td class="gutter" style="width: 2.09%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 2.09%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 11.02%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Year ended <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">December 31, <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2018</div></td></tr><tr><td style="width: 61.68%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 2.09%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.09%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 3.74%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 2.09%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.09%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 11.02%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 2.09%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.09%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 11.02%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 61.68%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Wages, salaries and other costs<br></div></td><td class="gutter" style="width: 2.09%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.09%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 3.74%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 2.09%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.09%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 11.02%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.82pt; text-align: left;">24,061</div></td><td class="gutter" style="width: 2.09%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.09%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 11.02%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.83pt; text-align: left;">19,245</div></td></tr><tr><td style="width: 61.68%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Social security costs<font style="padding-left: 3.2pt;"></font></div></td><td class="gutter" style="width: 2.09%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.09%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 3.74%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 2.09%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.09%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 11.02%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.82pt; text-align: left;"><font style="padding-left: 5pt;">3,871</font></div></td><td class="gutter" style="width: 2.09%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.09%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 11.02%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.83pt; text-align: left;"><font style="padding-left: 5pt;">3,452</font></div></td></tr><tr><td style="width: 61.68%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Share-based compensation expense<font style="padding-left: 3.23pt;"></font></div></td><td class="gutter" style="width: 2.09%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.09%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 3.74%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.99pt; text-align: left;">23</div></td><td class="gutter" style="width: 2.09%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.09%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 11.02%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.82pt; text-align: left;"><font style="padding-left: 5.37pt;">1,117</font></div></td><td class="gutter" style="width: 2.09%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.09%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 11.02%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.83pt; text-align: left;"><font style="padding-left: 12.5pt;">469</font></div></td></tr><tr><td style="width: 61.68%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Defined benefit plan - pension costs<font style="padding-left: 3.23pt;"></font></div></td><td class="gutter" style="width: 2.09%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.09%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 3.74%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.99pt; text-align: left;">22</div></td><td class="gutter" style="width: 2.09%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.09%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 11.02%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.82pt; text-align: left;"><font style="padding-left: 12.5pt;">462</font></div></td><td class="gutter" style="width: 2.09%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.09%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 11.02%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.83pt; text-align: left;"><font style="padding-left: 12.5pt;">535</font></div></td></tr><tr><td style="width: 61.68%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Defined contribution plan - pension costs<font style="padding-left: 2.12pt;"></font></div></td><td class="gutter" style="width: 2.09%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 2.09%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 3.74%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 2.09%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 2.09%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 11.02%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.82pt; text-align: left;"><font style="padding-left: 12.5pt; border-bottom: 1pt solid #000000; min-width: 27.5pt;">540</font></div></td><td class="gutter" style="width: 2.09%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 2.09%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 11.02%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.83pt; text-align: left;"><font style="padding-left: 12.5pt; border-bottom: 1pt solid #000000; min-width: 27.5pt;">481 </font></div></td></tr><tr><td style="width: 61.68%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Employee expenses<font style="font-weight: normal; padding-left: 3.75pt;"></font></div></td><td class="gutter" style="width: 2.09%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.09%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 3.74%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 2.09%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.09%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 11.02%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 9.82pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 27.5pt;">30,051</font></div></td><td class="gutter" style="width: 2.09%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.09%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 11.02%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 9.83pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 27.5pt;">24,182</font></div></td></tr></table><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: left;">Employee expenses increased from KUSD 24,182 in 2018 to KUSD 30,051 in 2019. This increase of KUSD 5,869 is mainly due to an increase in headcount.</div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 36pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">F-44<br></div></div></div>
<!--End Page 298-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 299-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 540pt;"><a name="nt10014672x1_drs_204-finnotes02_pg15"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="block-frill" style="width: 540pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: Arial, Helvetica, sans-serif; font-size: 9pt; font-weight: bold; margin-top: 6pt; text-align: center;">Confidential Treatment Requested by ADC Therapeutics SA Pursuant to 17 C.F.R. &#167; 200.83<br></div></div><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 36pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">ADC Therapeutics SA, Epalinges <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;"><div class="rule-full" style="height: 0pt; width: 100%; border-bottom: 1pt solid #000000; margin-top: 1pt; margin-bottom: 1pt; margin-left: auto; margin-right: auto;"> </div>NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS <font style="padding-left: 4pt;">(continued)</font><br></div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 12pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">11<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; text-align: left;">Expenses by nature</div></td></tr></table><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 7pt; margin-left: 20pt; text-align: left;">This note provides an analysis of expenses by nature.</div><table cellspacing="0" cellpadding="0" class="fintab" style="margin-top: 3.25pt; border-collapse: collapse; width: 428pt; margin-left: 20pt;"><tr class="header"><td style="width: 61.68%; text-align: left; vertical-align: bottom; padding-top: 6pt; padding-bottom: 3.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">(in KUSD) </div></td><td class="gutter" style="width: 2.09%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 3.75pt;">&#8203;</td><td class="gutter" style="width: 2.09%; font-size: 2pt; padding-top: 6pt; padding-bottom: 3.75pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 3.74%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 3.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Note</div></td><td class="gutter" style="width: 2.09%; font-size: 2pt; padding-top: 6pt; padding-bottom: 3.75pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 2.09%; font-size: 2pt; padding-top: 6pt; padding-bottom: 3.75pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 11.02%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 3.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Year ended <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">December&#160;31, <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2019</div></td><td class="gutter" style="width: 2.09%; font-size: 2pt; padding-top: 6pt; padding-bottom: 3.75pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 2.09%; font-size: 2pt; padding-top: 6pt; padding-bottom: 3.75pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 11.02%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 3.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Year ended <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">December&#160;31, <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2018</div></td></tr><tr><td style="width: 61.68%; text-align: left; vertical-align: bottom; padding-top: 3.75pt; padding-bottom: 2.5pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;"><u>R&amp;D</u><br></div></td><td class="gutter" style="width: 2.09%; border-bottom: none; font-size: 2pt; padding-top: 3.75pt; padding-bottom: 2.5pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.09%; border-bottom: none; font-size: 2pt; padding-top: 3.75pt; padding-bottom: 2.5pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 3.74%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3.75pt; padding-bottom: 2.5pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 2.09%; border-bottom: none; font-size: 2pt; padding-top: 3.75pt; padding-bottom: 2.5pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.09%; border-bottom: none; font-size: 2pt; padding-top: 3.75pt; padding-bottom: 2.5pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 11.02%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3.75pt; padding-bottom: 2.5pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 2.09%; border-bottom: none; font-size: 2pt; padding-top: 3.75pt; padding-bottom: 2.5pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.09%; border-bottom: none; font-size: 2pt; padding-top: 3.75pt; padding-bottom: 2.5pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 11.02%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3.75pt; padding-bottom: 2.5pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 61.68%; text-align: left; vertical-align: bottom; padding-top: 2.5pt; padding-bottom: 2.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">External costs<font style="padding-left: 4.3pt;"></font></div></td><td class="gutter" style="width: 2.09%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td class="gutter" style="width: 2.09%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td style="width: 3.74%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.5pt; padding-bottom: 2.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 2.09%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td class="gutter" style="width: 2.09%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td style="width: 11.02%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.5pt; padding-bottom: 2.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.32pt; text-align: left;"><font style="padding-left: 5pt;">81,363</font></div></td><td class="gutter" style="width: 2.09%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td class="gutter" style="width: 2.09%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td style="width: 11.02%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.5pt; padding-bottom: 2.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.33pt; text-align: left;"><font style="padding-left: 5pt;">98,493</font></div></td></tr><tr><td style="width: 61.68%; text-align: left; vertical-align: bottom; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Employee expenses<font style="padding-left: 1.53pt;"></font></div></td><td class="gutter" style="width: 2.09%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.09%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 3.74%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.99pt; text-align: left;">10</div></td><td class="gutter" style="width: 2.09%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.09%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 11.02%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.32pt; text-align: left;"><font style="padding-left: 5pt;">24,916</font></div></td><td class="gutter" style="width: 2.09%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.09%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 11.02%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.33pt; text-align: left;"><font style="padding-left: 5pt;">19,246</font></div></td></tr><tr><td style="width: 61.68%; text-align: left; vertical-align: bottom; padding-top: 2.5pt; padding-bottom: 2.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Depreciation of property, plant and equipment<font style="padding-left: 2.49pt;"></font></div></td><td class="gutter" style="width: 2.09%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td class="gutter" style="width: 2.09%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td style="width: 3.74%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.5pt; padding-bottom: 2.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.99pt; text-align: left;">16</div></td><td class="gutter" style="width: 2.09%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td class="gutter" style="width: 2.09%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td style="width: 11.02%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.5pt; padding-bottom: 2.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.32pt; text-align: left;"><font style="padding-left: 17.5pt;">407</font></div></td><td class="gutter" style="width: 2.09%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td class="gutter" style="width: 2.09%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td style="width: 11.02%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.5pt; padding-bottom: 2.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.33pt; text-align: left;"><font style="padding-left: 17.5pt;">330</font></div></td></tr><tr><td style="width: 61.68%; text-align: left; vertical-align: bottom; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Depreciation of right-of-use assets<font style="padding-left: 1.02pt;"></font></div></td><td class="gutter" style="width: 2.09%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.09%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 3.74%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.99pt; text-align: left;">17</div></td><td class="gutter" style="width: 2.09%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.09%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 11.02%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.32pt; text-align: left;"><font style="padding-left: 17.5pt;">837</font></div></td><td class="gutter" style="width: 2.09%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.09%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 11.02%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.33pt; text-align: left;"><font style="padding-left: 22.5pt;">&#8212;</font></div></td></tr><tr><td style="width: 61.68%; text-align: left; vertical-align: bottom; padding-top: 2.5pt; padding-bottom: 2.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Amortization of intangible assets<font style="padding-left: 1.55pt;"></font></div></td><td class="gutter" style="width: 2.09%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td class="gutter" style="width: 2.09%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td style="width: 3.74%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.5pt; padding-bottom: 2.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.99pt; text-align: left;">18</div></td><td class="gutter" style="width: 2.09%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td class="gutter" style="width: 2.09%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td style="width: 11.02%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.5pt; padding-bottom: 2.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.32pt; text-align: left;"><font style="padding-left: 22.5pt;">14</font></div></td><td class="gutter" style="width: 2.09%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td class="gutter" style="width: 2.09%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td style="width: 11.02%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.5pt; padding-bottom: 2.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.33pt; text-align: left;"><font style="padding-left: 22.5pt;">17</font></div></td></tr><tr><td style="width: 61.68%; text-align: left; vertical-align: bottom; padding-top: 2.5pt; padding-bottom: 3.75pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Impairment of intangible assets<font style="padding-left: 3.22pt;"></font></div></td><td class="gutter" style="width: 2.09%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 3.75pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.09%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 3.75pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 3.74%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.5pt; padding-bottom: 3.75pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.99pt; text-align: left;">18</div></td><td class="gutter" style="width: 2.09%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 3.75pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.09%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 3.75pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 11.02%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.5pt; padding-bottom: 3.75pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.32pt; text-align: left;"><font style="padding-left: 22.5pt; border-bottom: 1pt solid #000000; min-width: 32.5pt;">&#8212;</font></div></td><td class="gutter" style="width: 2.09%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 3.75pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.09%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 3.75pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 11.02%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.5pt; padding-bottom: 3.75pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.33pt; text-align: left;"><font style="padding-left: 17.5pt; border-bottom: 1pt solid #000000; min-width: 32.5pt;">227 </font></div></td></tr><tr><td style="width: 61.68%; text-align: left; vertical-align: bottom; padding-top: 3.75pt; padding-bottom: 2.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Research and development expenses<font style="font-weight: normal; padding-left: 4.52pt;"></font></div></td><td class="gutter" style="width: 2.09%; border-bottom: none; font-size: 2pt; padding-top: 3.75pt; padding-bottom: 2.5pt;">&#8203;</td><td class="gutter" style="width: 2.09%; border-bottom: none; font-size: 2pt; padding-top: 3.75pt; padding-bottom: 2.5pt;">&#8203;</td><td style="width: 3.74%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3.75pt; padding-bottom: 2.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 2.09%; border-bottom: none; font-size: 2pt; padding-top: 3.75pt; padding-bottom: 2.5pt;">&#8203;</td><td class="gutter" style="width: 2.09%; border-bottom: none; font-size: 2pt; padding-top: 3.75pt; padding-bottom: 2.5pt;">&#8203;</td><td style="width: 11.02%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3.75pt; padding-bottom: 2.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 7.32pt; text-align: left;">107,537</div></td><td class="gutter" style="width: 2.09%; border-bottom: none; font-size: 2pt; padding-top: 3.75pt; padding-bottom: 2.5pt;">&#8203;</td><td class="gutter" style="width: 2.09%; border-bottom: none; font-size: 2pt; padding-top: 3.75pt; padding-bottom: 2.5pt;">&#8203;</td><td style="width: 11.02%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3.75pt; padding-bottom: 2.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 7.33pt; text-align: left;"><font style="padding-left: 0.55pt;">118,313</font></div></td></tr><tr><td style="width: 61.68%; text-align: left; vertical-align: bottom; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 2.09%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.09%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 3.74%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 2.09%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.09%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 11.02%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 2.09%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.09%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 11.02%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 61.68%; text-align: left; vertical-align: bottom; padding-top: 2.5pt; padding-bottom: 2.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;"><u>G&amp;A</u> <br></div></td><td class="gutter" style="width: 2.09%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td class="gutter" style="width: 2.09%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td style="width: 3.74%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.5pt; padding-bottom: 2.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 2.09%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td class="gutter" style="width: 2.09%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td style="width: 11.02%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.5pt; padding-bottom: 2.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 2.09%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td class="gutter" style="width: 2.09%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td style="width: 11.02%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.5pt; padding-bottom: 2.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 61.68%; text-align: left; vertical-align: bottom; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">External costs<font style="padding-left: 4.3pt;"></font></div></td><td class="gutter" style="width: 2.09%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.09%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 3.74%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 2.09%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.09%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 11.02%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.32pt; text-align: left;"><font style="padding-left: 10pt;">8,668</font></div></td><td class="gutter" style="width: 2.09%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.09%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 11.02%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.33pt; text-align: left;"><font style="padding-left: 10pt;">3,628</font></div></td></tr><tr><td style="width: 61.68%; text-align: left; vertical-align: bottom; padding-top: 2.5pt; padding-bottom: 2.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Employee expenses<font style="padding-left: 1.53pt;"></font></div></td><td class="gutter" style="width: 2.09%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td class="gutter" style="width: 2.09%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td style="width: 3.74%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.5pt; padding-bottom: 2.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.99pt; text-align: left;">10</div></td><td class="gutter" style="width: 2.09%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td class="gutter" style="width: 2.09%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td style="width: 11.02%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.5pt; padding-bottom: 2.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.32pt; text-align: left;"><font style="padding-left: 10pt;">5,135</font></div></td><td class="gutter" style="width: 2.09%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td class="gutter" style="width: 2.09%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td style="width: 11.02%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.5pt; padding-bottom: 2.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.33pt; text-align: left;"><font style="padding-left: 10pt;">4,936</font></div></td></tr><tr><td style="width: 61.68%; text-align: left; vertical-align: bottom; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">General and administrative costs charged by related parties<font style="padding-left: 4.57pt;"></font></div></td><td class="gutter" style="width: 2.09%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.09%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 3.74%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.99pt; text-align: left;">27</div></td><td class="gutter" style="width: 2.09%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.09%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 11.02%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.32pt; text-align: left;"><font style="padding-left: 22.87pt;">11</font></div></td><td class="gutter" style="width: 2.09%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.09%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 11.02%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.33pt; text-align: left;"><font style="padding-left: 22.5pt;">38</font></div></td></tr><tr><td style="width: 61.68%; text-align: left; vertical-align: bottom; padding-top: 2.5pt; padding-bottom: 2.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Depreciation of property, plant and equipment<font style="padding-left: 2.49pt;"></font></div></td><td class="gutter" style="width: 2.09%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td class="gutter" style="width: 2.09%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td style="width: 3.74%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.5pt; padding-bottom: 2.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.99pt; text-align: left;">16</div></td><td class="gutter" style="width: 2.09%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td class="gutter" style="width: 2.09%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td style="width: 11.02%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.5pt; padding-bottom: 2.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.32pt; text-align: left;"><font style="padding-left: 17.5pt;">145</font></div></td><td class="gutter" style="width: 2.09%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td class="gutter" style="width: 2.09%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td style="width: 11.02%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.5pt; padding-bottom: 2.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.33pt; text-align: left;"><font style="padding-left: 17.5pt;">158</font></div></td></tr><tr><td style="width: 61.68%; text-align: left; vertical-align: bottom; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Depreciation of right-of-use assets<font style="padding-left: 1.02pt;"></font></div></td><td class="gutter" style="width: 2.09%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.09%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 3.74%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.99pt; text-align: left;">17</div></td><td class="gutter" style="width: 2.09%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.09%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 11.02%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.32pt; text-align: left;"><font style="padding-left: 17.5pt;">227</font></div></td><td class="gutter" style="width: 2.09%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.09%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 11.02%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.33pt; text-align: left;"><font style="padding-left: 22.5pt;">&#8212;</font></div></td></tr><tr><td style="width: 61.68%; text-align: left; vertical-align: bottom; padding-top: 2.5pt; padding-bottom: 3.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Amortization of intangible assets<font style="padding-left: 1.55pt;"></font></div></td><td class="gutter" style="width: 2.09%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 3.75pt;">&#8203;</td><td class="gutter" style="width: 2.09%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 3.75pt;">&#8203;</td><td style="width: 3.74%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.5pt; padding-bottom: 3.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.99pt; text-align: left;">18</div></td><td class="gutter" style="width: 2.09%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 3.75pt;">&#8203;</td><td class="gutter" style="width: 2.09%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 3.75pt;">&#8203;</td><td style="width: 11.02%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.5pt; padding-bottom: 3.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.32pt; text-align: left;"><font style="padding-left: 22.5pt; border-bottom: 1pt solid #000000; min-width: 32.5pt;">16</font></div></td><td class="gutter" style="width: 2.09%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 3.75pt;">&#8203;</td><td class="gutter" style="width: 2.09%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 3.75pt;">&#8203;</td><td style="width: 11.02%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.5pt; padding-bottom: 3.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.33pt; text-align: left;"><font style="padding-left: 27.5pt; border-bottom: 1pt solid #000000; min-width: 32.5pt;">8 </font></div></td></tr><tr><td style="width: 61.68%; text-align: left; vertical-align: bottom; padding-top: 3.75pt; padding-bottom: 3.75pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">General and administrative expenses<font style="font-weight: normal; padding-left: 1.55pt;"></font></div></td><td class="gutter" style="width: 2.09%; border-bottom: none; font-size: 2pt; padding-top: 3.75pt; padding-bottom: 3.75pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.09%; border-bottom: none; font-size: 2pt; padding-top: 3.75pt; padding-bottom: 3.75pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 3.74%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3.75pt; padding-bottom: 3.75pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 2.09%; border-bottom: none; font-size: 2pt; padding-top: 3.75pt; padding-bottom: 3.75pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.09%; border-bottom: none; font-size: 2pt; padding-top: 3.75pt; padding-bottom: 3.75pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 11.02%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3.75pt; padding-bottom: 3.75pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 7.32pt; text-align: left;"><font style="padding-left: 5pt; border-bottom: 1pt solid #000000; min-width: 32.5pt;">14,202</font></div></td><td class="gutter" style="width: 2.09%; border-bottom: none; font-size: 2pt; padding-top: 3.75pt; padding-bottom: 3.75pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.09%; border-bottom: none; font-size: 2pt; padding-top: 3.75pt; padding-bottom: 3.75pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 11.02%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3.75pt; padding-bottom: 3.75pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 7.33pt; text-align: left;"><font style="padding-left: 10pt; border-bottom: 1pt solid #000000; min-width: 32.5pt;">8,768</font></div></td></tr><tr><td style="width: 61.68%; text-align: left; vertical-align: bottom; padding-top: 3.75pt; padding-bottom: 6pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Total expenses by nature<font style="font-weight: normal; padding-left: 3.74pt;"></font></div></td><td class="gutter" style="width: 2.09%; border-bottom: none; font-size: 2pt; padding-top: 3.75pt; padding-bottom: 6pt;">&#8203;</td><td class="gutter" style="width: 2.09%; border-bottom: none; font-size: 2pt; padding-top: 3.75pt; padding-bottom: 6pt;">&#8203;</td><td style="width: 3.74%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3.75pt; padding-bottom: 6pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 2.09%; border-bottom: none; font-size: 2pt; padding-top: 3.75pt; padding-bottom: 6pt;">&#8203;</td><td class="gutter" style="width: 2.09%; border-bottom: none; font-size: 2pt; padding-top: 3.75pt; padding-bottom: 6pt;">&#8203;</td><td style="width: 11.02%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3.75pt; padding-bottom: 6pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 7.32pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 32.5pt;">121,739</font></div></td><td class="gutter" style="width: 2.09%; border-bottom: none; font-size: 2pt; padding-top: 3.75pt; padding-bottom: 6pt;">&#8203;</td><td class="gutter" style="width: 2.09%; border-bottom: none; font-size: 2pt; padding-top: 3.75pt; padding-bottom: 6pt;">&#8203;</td><td style="width: 11.02%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3.75pt; padding-bottom: 6pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 7.33pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 32.5pt;">127,081</font></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 12pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">12<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; text-align: left;">Income tax expenses</div></td></tr></table><table cellspacing="0" cellpadding="0" class="fintab" style="margin-top: 10.25pt; border-collapse: collapse; width: 428pt; margin-left: 20pt;"><tr class="header"><td style="width: 70.09%; text-align: left; vertical-align: bottom; padding-top: 6pt; padding-bottom: 3.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">(in KUSD)</div></td><td class="gutter" style="width: 1.97%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 3.75pt;">&#8203;</td><td class="gutter" style="width: 1.97%; font-size: 2pt; padding-top: 6pt; padding-bottom: 3.75pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 11.02%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 3.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Year ended <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">December&#160;31, <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2019</div></td><td class="gutter" style="width: 1.97%; font-size: 2pt; padding-top: 6pt; padding-bottom: 3.75pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.97%; font-size: 2pt; padding-top: 6pt; padding-bottom: 3.75pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 11.02%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 3.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Year ended <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">December&#160;31, <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2018</div></td></tr><tr><td style="width: 70.09%; text-align: left; vertical-align: bottom; padding-top: 3.75pt; padding-bottom: 2.5pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Current income taxes for the year<font style="padding-left: 4.24pt;"></font></div></td><td class="gutter" style="width: 1.97%; border-bottom: none; font-size: 2pt; padding-top: 3.75pt; padding-bottom: 2.5pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.97%; border-bottom: none; font-size: 2pt; padding-top: 3.75pt; padding-bottom: 2.5pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 11.02%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3.75pt; padding-bottom: 2.5pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 16.08pt; text-align: left;">572</div></td><td class="gutter" style="width: 1.97%; border-bottom: none; font-size: 2pt; padding-top: 3.75pt; padding-bottom: 2.5pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.97%; border-bottom: none; font-size: 2pt; padding-top: 3.75pt; padding-bottom: 2.5pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 11.02%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3.75pt; padding-bottom: 2.5pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 16.08pt; text-align: left;">218</div></td></tr><tr><td style="width: 70.09%; text-align: left; vertical-align: bottom; padding-top: 2.5pt; padding-bottom: 3.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Current income taxes related to prior years<font style="padding-left: 1.47pt;"></font></div></td><td class="gutter" style="width: 1.97%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 3.75pt;">&#8203;</td><td class="gutter" style="width: 1.97%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 3.75pt;">&#8203;</td><td style="width: 11.02%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 2.5pt; padding-bottom: 3.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 16.08pt; text-align: left;"><font style="padding-left: 5pt; border-bottom: 1pt solid #000000; min-width: 15pt;">10</font></div></td><td class="gutter" style="width: 1.97%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 3.75pt;">&#8203;</td><td class="gutter" style="width: 1.97%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 3.75pt;">&#8203;</td><td style="width: 11.02%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 2.5pt; padding-bottom: 3.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 16.08pt; text-align: left;"><font style="padding-left: 10pt; border-bottom: 1pt solid #000000; min-width: 15pt;">6</font></div></td></tr><tr><td style="width: 70.09%; text-align: left; vertical-align: bottom; padding-top: 3.75pt; padding-bottom: 6pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Income tax expenses<font style="font-weight: normal; padding-left: 3.65pt;"></font></div></td><td class="gutter" style="width: 1.97%; border-bottom: none; font-size: 2pt; padding-top: 3.75pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.97%; border-bottom: none; font-size: 2pt; padding-top: 3.75pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 11.02%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3.75pt; padding-bottom: 6pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 16.08pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 15pt;">582</font></div></td><td class="gutter" style="width: 1.97%; border-bottom: none; font-size: 2pt; padding-top: 3.75pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.97%; border-bottom: none; font-size: 2pt; padding-top: 3.75pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 11.02%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3.75pt; padding-bottom: 6pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 16.08pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 15pt;">224</font></div></td></tr></table><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: left;">The Group's expected tax expense for each year is based on the applicable tax rate in each individual jurisdiction, which in 2019 ranged between 11% and 27% (2018: between 11% and 27%) in the tax jurisdictions in which the Group operates. The weighted average tax rate applicable to the profits of the consolidated entities was 11.5% (2018: 11.3%). This small increase is due to changes in the mix of the taxable results of the individual group companies. The tax on the Group's profit/loss before tax differs from the theoretical amount that would arise using the weighted average applicable tax rate as follows:</div><table cellspacing="0" cellpadding="0" class="fintab" style="margin-top: 5.25pt; border-collapse: collapse; width: 428pt; margin-left: 20pt;"><tr class="header"><td style="width: 70.09%; text-align: left; vertical-align: bottom; padding-top: 6pt; padding-bottom: 3.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">(in KUSD)</div></td><td class="gutter" style="width: 1.97%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 3.5pt;">&#8203;</td><td class="gutter" style="width: 1.97%; font-size: 2pt; padding-top: 6pt; padding-bottom: 3.5pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 11.02%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 3.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Year ended <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">December&#160;31, <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2019</div></td><td class="gutter" style="width: 1.97%; font-size: 2pt; padding-top: 6pt; padding-bottom: 3.5pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.97%; font-size: 2pt; padding-top: 6pt; padding-bottom: 3.5pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 11.02%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 3.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Year ended <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">December&#160;31, <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2018</div></td></tr><tr><td style="width: 70.09%; text-align: left; vertical-align: bottom; padding-top: 3.5pt; padding-bottom: 2.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Loss before taxes<font style="padding-left: 0.87pt;"></font></div></td><td class="gutter" style="width: 1.97%; border-bottom: none; font-size: 2pt; padding-top: 3.5pt; padding-bottom: 2.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.97%; border-bottom: none; font-size: 2pt; padding-top: 3.5pt; padding-bottom: 2.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 11.02%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3.5pt; padding-bottom: 2.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.42pt; text-align: left;">115,902</div></td><td class="gutter" style="width: 1.97%; border-bottom: none; font-size: 2pt; padding-top: 3.5pt; padding-bottom: 2.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.97%; border-bottom: none; font-size: 2pt; padding-top: 3.5pt; padding-bottom: 2.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 11.02%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3.5pt; padding-bottom: 2.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.23pt; text-align: left;">122,872</div></td></tr><tr><td style="width: 70.09%; text-align: left; vertical-align: bottom; padding-top: 2.25pt; padding-bottom: 2.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-indent: -10pt; text-align: left;">Tax calculated at tax domestic rates applicable to profits in the respective countries<font style="padding-left: 1.98pt;"></font></div></td><td class="gutter" style="width: 1.97%; border-bottom: none; font-size: 2pt; padding-top: 2.25pt; padding-bottom: 2.25pt;">&#8203;</td><td class="gutter" style="width: 1.97%; border-bottom: none; font-size: 2pt; padding-top: 2.25pt; padding-bottom: 2.25pt;">&#8203;</td><td style="width: 11.02%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.25pt; padding-bottom: 2.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.42pt; text-align: left;"><font style="padding-left: 1.3pt;">(12,332</font><font style="padding-left: 0.2pt;">)</font></div></td><td class="gutter" style="width: 1.97%; border-bottom: none; font-size: 2pt; padding-top: 2.25pt; padding-bottom: 2.25pt;">&#8203;</td><td class="gutter" style="width: 1.97%; border-bottom: none; font-size: 2pt; padding-top: 2.25pt; padding-bottom: 2.25pt;">&#8203;</td><td style="width: 11.02%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.25pt; padding-bottom: 2.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.23pt; text-align: left;"><font style="padding-left: 1.67pt;">(13,321</font><font style="padding-left: 0.2pt;">)</font></div></td></tr><tr><td style="width: 70.09%; text-align: left; vertical-align: bottom; padding-top: 2.25pt; padding-bottom: 2.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.97%; border-bottom: none; font-size: 2pt; padding-top: 2.25pt; padding-bottom: 2.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.97%; border-bottom: none; font-size: 2pt; padding-top: 2.25pt; padding-bottom: 2.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 11.02%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.25pt; padding-bottom: 2.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.97%; border-bottom: none; font-size: 2pt; padding-top: 2.25pt; padding-bottom: 2.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.97%; border-bottom: none; font-size: 2pt; padding-top: 2.25pt; padding-bottom: 2.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 11.02%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.25pt; padding-bottom: 2.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 70.09%; text-align: left; vertical-align: bottom; padding-top: 2.25pt; padding-bottom: 2.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Tax effects of:<br></div></td><td class="gutter" style="width: 1.97%; border-bottom: none; font-size: 2pt; padding-top: 2.25pt; padding-bottom: 2.25pt;">&#8203;</td><td class="gutter" style="width: 1.97%; border-bottom: none; font-size: 2pt; padding-top: 2.25pt; padding-bottom: 2.25pt;">&#8203;</td><td style="width: 11.02%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.25pt; padding-bottom: 2.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.97%; border-bottom: none; font-size: 2pt; padding-top: 2.25pt; padding-bottom: 2.25pt;">&#8203;</td><td class="gutter" style="width: 1.97%; border-bottom: none; font-size: 2pt; padding-top: 2.25pt; padding-bottom: 2.25pt;">&#8203;</td><td style="width: 11.02%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.25pt; padding-bottom: 2.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 70.09%; text-align: left; vertical-align: bottom; padding-top: 2.25pt; padding-bottom: 2.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">- Tax losses for which no deferred income tax asset was recognized<font style="padding-left: 4.09pt;"></font></div></td><td class="gutter" style="width: 1.97%; border-bottom: none; font-size: 2pt; padding-top: 2.25pt; padding-bottom: 2.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.97%; border-bottom: none; font-size: 2pt; padding-top: 2.25pt; padding-bottom: 2.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 11.02%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.25pt; padding-bottom: 2.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.42pt; text-align: left;"><font style="padding-left: 4.63pt;">13,187</font></div></td><td class="gutter" style="width: 1.97%; border-bottom: none; font-size: 2pt; padding-top: 2.25pt; padding-bottom: 2.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.97%; border-bottom: none; font-size: 2pt; padding-top: 2.25pt; padding-bottom: 2.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 11.02%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.25pt; padding-bottom: 2.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.23pt; text-align: left;"><font style="padding-left: 5pt;">13,766</font></div></td></tr><tr><td style="width: 70.09%; text-align: left; vertical-align: bottom; padding-top: 2.25pt; padding-bottom: 2.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">- Utilization of R&amp;D tax credit (USA)<font style="padding-left: 4.79pt;"></font></div></td><td class="gutter" style="width: 1.97%; border-bottom: none; font-size: 2pt; padding-top: 2.25pt; padding-bottom: 2.25pt;">&#8203;</td><td class="gutter" style="width: 1.97%; border-bottom: none; font-size: 2pt; padding-top: 2.25pt; padding-bottom: 2.25pt;">&#8203;</td><td style="width: 11.02%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.25pt; padding-bottom: 2.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.42pt; text-align: left;"><font style="padding-left: 13.8pt;">(436</font><font style="padding-left: 0.2pt;">)</font></div></td><td class="gutter" style="width: 1.97%; border-bottom: none; font-size: 2pt; padding-top: 2.25pt; padding-bottom: 2.25pt;">&#8203;</td><td class="gutter" style="width: 1.97%; border-bottom: none; font-size: 2pt; padding-top: 2.25pt; padding-bottom: 2.25pt;">&#8203;</td><td style="width: 11.02%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.25pt; padding-bottom: 2.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.23pt; text-align: left;"><font style="padding-left: 14.17pt;">(310</font><font style="padding-left: 0.2pt;">)</font></div></td></tr><tr><td style="width: 70.09%; text-align: left; vertical-align: bottom; padding-top: 2.25pt; padding-bottom: 2.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">- Income not subject to tax / (expenses not deductible for tax purposes)<font style="padding-left: 2.86pt;"></font></div></td><td class="gutter" style="width: 1.97%; border-bottom: none; font-size: 2pt; padding-top: 2.25pt; padding-bottom: 2.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.97%; border-bottom: none; font-size: 2pt; padding-top: 2.25pt; padding-bottom: 2.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 11.02%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.25pt; padding-bottom: 2.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.42pt; text-align: left;"><font style="padding-left: 17.72pt;">156</font></div></td><td class="gutter" style="width: 1.97%; border-bottom: none; font-size: 2pt; padding-top: 2.25pt; padding-bottom: 2.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.97%; border-bottom: none; font-size: 2pt; padding-top: 2.25pt; padding-bottom: 2.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 11.02%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.25pt; padding-bottom: 2.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.23pt; text-align: left;"><font style="padding-left: 22.89pt;">83</font></div></td></tr><tr><td style="width: 70.09%; text-align: left; vertical-align: bottom; padding-top: 2.25pt; padding-bottom: 2.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">- Tax relating to prior years<font style="padding-left: 4.68pt;"></font></div></td><td class="gutter" style="width: 1.97%; border-bottom: none; font-size: 2pt; padding-top: 2.25pt; padding-bottom: 2.25pt;">&#8203;</td><td class="gutter" style="width: 1.97%; border-bottom: none; font-size: 2pt; padding-top: 2.25pt; padding-bottom: 2.25pt;">&#8203;</td><td style="width: 11.02%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.25pt; padding-bottom: 2.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.42pt; text-align: left;"><font style="padding-left: 22.52pt;">10</font></div></td><td class="gutter" style="width: 1.97%; border-bottom: none; font-size: 2pt; padding-top: 2.25pt; padding-bottom: 2.25pt;">&#8203;</td><td class="gutter" style="width: 1.97%; border-bottom: none; font-size: 2pt; padding-top: 2.25pt; padding-bottom: 2.25pt;">&#8203;</td><td style="width: 11.02%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.25pt; padding-bottom: 2.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.23pt; text-align: left;"><font style="padding-left: 27.7pt;">6</font></div></td></tr><tr><td style="width: 70.09%; text-align: left; vertical-align: bottom; padding-top: 2.25pt; padding-bottom: 3.5pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">- Other<font style="padding-left: 4.45pt;"></font></div></td><td class="gutter" style="width: 1.97%; border-bottom: none; font-size: 2pt; padding-top: 2.25pt; padding-bottom: 3.5pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.97%; border-bottom: none; font-size: 2pt; padding-top: 2.25pt; padding-bottom: 3.5pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 11.02%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.25pt; padding-bottom: 3.5pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.42pt; text-align: left;"><font style="padding-left: 24.19pt; border-bottom: 1pt solid #000000; min-width: 32.33pt;">(3</font><font style="padding-left: 0.2pt; border-bottom: 1pt solid #000000; min-width: 32.33pt;"></font><font style="min-width: 32.33pt;">)</font></div></td><td class="gutter" style="width: 1.97%; border-bottom: none; font-size: 2pt; padding-top: 2.25pt; padding-bottom: 3.5pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.97%; border-bottom: none; font-size: 2pt; padding-top: 2.25pt; padding-bottom: 3.5pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 11.02%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.25pt; padding-bottom: 3.5pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.23pt; text-align: left;"><font style="padding-left: 22.7pt; border-bottom: 1pt solid #000000; min-width: 32.7pt;">&#8212; </font></div></td></tr><tr><td style="width: 70.09%; text-align: left; vertical-align: bottom; padding-top: 3.5pt; padding-bottom: 6pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Income tax expenses<font style="font-weight: normal; padding-left: 2.38pt;"></font></div></td><td class="gutter" style="width: 1.97%; border-bottom: none; font-size: 2pt; padding-top: 3.5pt; padding-bottom: 6pt;">&#8203;</td><td class="gutter" style="width: 1.97%; border-bottom: none; font-size: 2pt; padding-top: 3.5pt; padding-bottom: 6pt;">&#8203;</td><td style="width: 11.02%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3.5pt; padding-bottom: 6pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 7.42pt; text-align: left;"><font style="padding-left: 17.72pt; border-bottom: 3pt double #000000; min-width: 32.33pt;">582</font></div></td><td class="gutter" style="width: 1.97%; border-bottom: none; font-size: 2pt; padding-top: 3.5pt; padding-bottom: 6pt;">&#8203;</td><td class="gutter" style="width: 1.97%; border-bottom: none; font-size: 2pt; padding-top: 3.5pt; padding-bottom: 6pt;">&#8203;</td><td style="width: 11.02%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3.5pt; padding-bottom: 6pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 7.23pt; text-align: left;"><font style="padding-left: 18.09pt; border-bottom: 3pt double #000000; min-width: 32.7pt;">224</font></div></td></tr></table></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 36pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">F-45<br></div></div></div>
<!--End Page 299-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 300-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 540pt;"><a name="nt10014672x1_drs_204-finnotes02_pg16"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="block-frill" style="width: 540pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: Arial, Helvetica, sans-serif; font-size: 9pt; font-weight: bold; margin-top: 6pt; text-align: center;">Confidential Treatment Requested by ADC Therapeutics SA Pursuant to 17 C.F.R. &#167; 200.83<br></div></div><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 36pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">ADC Therapeutics SA, Epalinges <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;"><div class="rule-full" style="height: 0pt; width: 100%; border-bottom: 1pt solid #000000; margin-top: 1pt; margin-bottom: 1pt; margin-left: auto; margin-right: auto;"> </div>NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS <font style="padding-left: 4pt;">(continued)</font><br></div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 12pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">13.<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; text-align: left;">Trade accounts receivable</div></td></tr></table><table cellspacing="0" cellpadding="0" class="fintab" style="margin-top: 10.25pt; border-collapse: collapse; width: 428pt; margin-left: 20pt;"><tr class="header"><td style="width: 70.09%; text-align: left; vertical-align: bottom; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">(in KUSD)</div></td><td class="gutter" style="width: 1.97%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.97%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 11.02%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">December&#160;31, <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2019</div></td><td class="gutter" style="width: 1.97%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.97%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 11.02%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">December&#160;31, <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2018</div></td></tr><tr><td style="width: 70.09%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Trade accounts receivable<font style="padding-left: 1.8pt;"></font></div></td><td class="gutter" style="width: 1.97%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.97%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 11.02%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 18.58pt; text-align: left;">&#8212;</div></td><td class="gutter" style="width: 1.97%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.97%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 11.02%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 16.08pt; text-align: left;">192</div></td></tr><tr><td style="width: 70.09%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Less: Allowance for doubtful accounts<font style="padding-left: 4.78pt;"></font></div></td><td class="gutter" style="width: 1.97%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.97%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 11.02%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 18.58pt; text-align: left;"><font style="border-bottom: 1pt solid #000000; min-width: 10pt;">&#8212;</font></div></td><td class="gutter" style="width: 1.97%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.97%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 11.02%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 16.08pt; text-align: left;"><font style="padding-left: 5pt; border-bottom: 1pt solid #000000; min-width: 15pt;">&#8212; </font></div></td></tr><tr><td style="width: 70.09%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Trade accounts receivable, net<font style="font-weight: normal; padding-left: 0.97pt;"></font></div></td><td class="gutter" style="width: 1.97%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.97%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 11.02%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 18.58pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 10pt;">&#8212;</font></div></td><td class="gutter" style="width: 1.97%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.97%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 11.02%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 16.08pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 15pt;">192</font></div></td></tr></table><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: left;">As at December&#160;31, 2019 and 2018, there were no trade accounts receivable past due and no provision for impairment. The credit status of receivables is considered in note 19b, &#8220;Credit quality of financial assets&#8221;.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8.5pt; margin-left: 20pt; text-align: left;">The carrying amounts of the Group's trade accounts receivables are denominated in USD.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: left;">The maximum exposure to credit risk at the reporting date is the carrying value of the receivables mentioned above.</div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 12pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">14.<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; text-align: left;">Other current assets</div></td></tr></table><table cellspacing="0" cellpadding="0" class="fintab" style="margin-top: 10.25pt; border-collapse: collapse; width: 428pt; margin-left: 20pt;"><tr class="header"><td style="width: 70.09%; text-align: left; vertical-align: bottom; padding-top: 6pt; padding-bottom: 4pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">(in KUSD)</div></td><td class="gutter" style="width: 1.97%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 4pt;">&#8203;</td><td class="gutter" style="width: 1.97%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 11.02%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">December 31, <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2019</div></td><td class="gutter" style="width: 1.97%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.97%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 11.02%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">December 31, <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2018</div></td></tr><tr><td style="width: 70.09%; text-align: left; vertical-align: bottom; padding-top: 4pt; padding-bottom: 2.75pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">VAT receivable, net<font style="padding-left: 2.06pt;"></font></div></td><td class="gutter" style="width: 1.97%; border-bottom: none; font-size: 2pt; padding-top: 4pt; padding-bottom: 2.75pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.97%; border-bottom: none; font-size: 2pt; padding-top: 4pt; padding-bottom: 2.75pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 11.02%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 4pt; padding-bottom: 2.75pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 12.33pt; text-align: left;"><font style="padding-left: 7.5pt;">471</font></div></td><td class="gutter" style="width: 1.97%; border-bottom: none; font-size: 2pt; padding-top: 4pt; padding-bottom: 2.75pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.97%; border-bottom: none; font-size: 2pt; padding-top: 4pt; padding-bottom: 2.75pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 11.02%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4pt; padding-bottom: 2.75pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 12.33pt; text-align: left;"><font style="padding-left: 7.5pt;">549</font></div></td></tr><tr><td style="width: 70.09%; text-align: left; vertical-align: bottom; padding-top: 2.75pt; padding-bottom: 2.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Withholding tax receivable<font style="padding-left: 2.38pt;"></font></div></td><td class="gutter" style="width: 1.97%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td class="gutter" style="width: 1.97%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td style="width: 11.02%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 2.75pt; padding-bottom: 2.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 12.33pt; text-align: left;"><font style="padding-left: 7.5pt;">626</font></div></td><td class="gutter" style="width: 1.97%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td class="gutter" style="width: 1.97%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td style="width: 11.02%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.75pt; padding-bottom: 2.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 12.33pt; text-align: left;"><font style="padding-left: 7.5pt;">968</font></div></td></tr><tr><td style="width: 70.09%; text-align: left; vertical-align: bottom; padding-top: 2.75pt; padding-bottom: 2.75pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Prepaid expenses<font style="padding-left: 2.53pt;"></font></div></td><td class="gutter" style="width: 1.97%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.97%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 11.02%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 2.75pt; padding-bottom: 2.75pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 12.33pt; text-align: left;">4,215</div></td><td class="gutter" style="width: 1.97%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.97%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 11.02%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.75pt; padding-bottom: 2.75pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 12.33pt; text-align: left;">1,384</div></td></tr><tr><td style="width: 70.09%; text-align: left; vertical-align: bottom; padding-top: 2.75pt; padding-bottom: 2.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">UK R&amp;D expenditure credits<font style="padding-left: 2.55pt;"></font></div></td><td class="gutter" style="width: 1.97%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td class="gutter" style="width: 1.97%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td style="width: 11.02%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 2.75pt; padding-bottom: 2.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 12.33pt; text-align: left;"><font style="padding-left: 7.5pt;">891</font></div></td><td class="gutter" style="width: 1.97%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td class="gutter" style="width: 1.97%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td style="width: 11.02%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.75pt; padding-bottom: 2.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 12.33pt; text-align: left;"><font style="padding-left: 12.5pt;">&#8212;</font></div></td></tr><tr><td style="width: 70.09%; text-align: left; vertical-align: bottom; padding-top: 2.75pt; padding-bottom: 4pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Other<font style="padding-left: 4.73pt;"></font></div></td><td class="gutter" style="width: 1.97%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 4pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.97%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 4pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 11.02%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 2.75pt; padding-bottom: 4pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 12.33pt; text-align: left;"><font style="padding-left: 7.5pt; border-bottom: 1pt solid #000000; min-width: 22.5pt;">852</font></div></td><td class="gutter" style="width: 1.97%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 4pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.97%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 4pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 11.02%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.75pt; padding-bottom: 4pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 12.33pt; text-align: left;"><font style="padding-left: 7.5pt; border-bottom: 1pt solid #000000; min-width: 22.5pt;">180 </font></div></td></tr><tr><td style="width: 70.09%; text-align: left; vertical-align: bottom; padding-top: 4pt; padding-bottom: 6pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.97%; border-bottom: none; font-size: 2pt; padding-top: 4pt; padding-bottom: 6pt;">&#8203;</td><td class="gutter" style="width: 1.97%; border-bottom: none; font-size: 2pt; padding-top: 4pt; padding-bottom: 6pt;">&#8203;</td><td style="width: 11.02%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 4pt; padding-bottom: 6pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 12.33pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 22.5pt;">7,055</font></div></td><td class="gutter" style="width: 1.97%; border-bottom: none; font-size: 2pt; padding-top: 4pt; padding-bottom: 6pt;">&#8203;</td><td class="gutter" style="width: 1.97%; border-bottom: none; font-size: 2pt; padding-top: 4pt; padding-bottom: 6pt;">&#8203;</td><td style="width: 11.02%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4pt; padding-bottom: 6pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 12.33pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 22.5pt;">3,081</font></div></td></tr></table><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: left;">The increase of KUSD 2,831 in prepaid expenses is due principally to an increase of KUSD 2,216 in prepaid research and development expenses. For further information regarding the UK R&amp;D expenditure credits, please refer to note 8, &#8220;Other Income&#8221;.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: left;">The maturity of other current assets is less than one year. The Company considers the counterparty risk as low and the carrying amount of these receivables is considered to approximate their fair value.</div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 12pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">15.<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; text-align: left;">Non-current assets by geographic area</div></td></tr></table><table cellspacing="0" cellpadding="0" class="fintab" style="margin-top: 10.25pt; border-collapse: collapse; width: 428pt; margin-left: 20pt;"><tr class="header"><td style="width: 70.09%; text-align: left; vertical-align: bottom; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">(in KUSD):</div></td><td class="gutter" style="width: 1.97%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.97%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 11.02%; text-align: center; vertical-align: bottom; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 1.97%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.97%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 11.02%; text-align: center; vertical-align: bottom; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td></tr><tr class="header"><td style="width: 70.09%; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Country</div></td><td class="gutter" style="width: 1.97%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.97%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 11.02%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">December&#160;31, <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2019</div></td><td class="gutter" style="width: 1.97%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.97%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 11.02%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">December&#160;31, <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2018</div></td></tr><tr><td style="width: 70.09%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Switzerland<font style="padding-left: 4.74pt;"></font></div></td><td class="gutter" style="width: 1.97%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.97%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 11.02%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.83pt; text-align: left;">10,903</div></td><td class="gutter" style="width: 1.97%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.97%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 11.02%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 12.33pt; text-align: left;"><font style="padding-left: 0.37pt;">7,112</font></div></td></tr><tr><td style="width: 70.09%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">United Kingdom<font style="padding-left: 4.18pt;"></font></div></td><td class="gutter" style="width: 1.97%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.97%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 11.02%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.83pt; text-align: left;"><font style="padding-left: 5pt;">2,032</font></div></td><td class="gutter" style="width: 1.97%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.97%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 11.02%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 12.33pt; text-align: left;"><font style="padding-left: 7.5pt;">885</font></div></td></tr><tr><td style="width: 70.09%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">United States<font style="padding-left: 3.07pt;"></font></div></td><td class="gutter" style="width: 1.97%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.97%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 11.02%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.83pt; text-align: left;"><font style="padding-left: 5pt; border-bottom: 1pt solid #000000; min-width: 27.5pt;">1,773</font></div></td><td class="gutter" style="width: 1.97%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.97%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 11.02%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 12.33pt; text-align: left;"><font style="padding-left: 7.5pt; border-bottom: 1pt solid #000000; min-width: 22.5pt;">217 </font></div></td></tr><tr><td style="width: 70.09%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 6pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.97%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt;">&#8203;</td><td class="gutter" style="width: 1.97%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt;">&#8203;</td><td style="width: 11.02%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 6pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 9.83pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 27.5pt;">14,708</font></div></td><td class="gutter" style="width: 1.97%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt;">&#8203;</td><td class="gutter" style="width: 1.97%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt;">&#8203;</td><td style="width: 11.02%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 6pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 12.33pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 22.5pt;">8,214</font></div></td></tr></table><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: left;">Non-current assets consist of property, plant and equipment, right-of-use assets and intangible assets. All intangible assets are located in Switzerland.</div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 36pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">F-46<br></div></div></div>
<!--End Page 300-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 301-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 540pt;"><a name="nt10014672x1_drs_204-finnotes02_pg17"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="block-frill" style="width: 540pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: Arial, Helvetica, sans-serif; font-size: 9pt; font-weight: bold; margin-top: 6pt; text-align: center;">Confidential Treatment Requested by ADC Therapeutics SA Pursuant to 17 C.F.R. &#167; 200.83<br></div></div><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 36pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">ADC Therapeutics SA, Epalinges <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;"><div class="rule-full" style="height: 0pt; width: 100%; border-bottom: 1pt solid #000000; margin-top: 1pt; margin-bottom: 1pt; margin-left: auto; margin-right: auto;"> </div>NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS <font style="padding-left: 4pt;">(continued)</font><br></div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 12pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">16.<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; text-align: left;">Property, plant and equipment</div></td></tr></table><table cellspacing="0" cellpadding="0" class="fintab" style="margin-top: 10.25pt; border-collapse: collapse; width: 428pt; margin-left: 20pt;"><tr class="header"><td style="width: 44.86%; text-align: left; vertical-align: bottom; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">(in KUSD)</div></td><td class="gutter" style="width: 1.51%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.51%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 8.1%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Leasehold <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">improve- <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">ments</div></td><td class="gutter" style="width: 1.51%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.51%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 9.24%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Laboratory <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">equipment</div></td><td class="gutter" style="width: 1.51%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.51%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 8.51%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Office <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">equipment</div></td><td class="gutter" style="width: 1.51%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.51%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 8.17%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Hardware</div></td><td class="gutter" style="width: 1.51%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.51%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 6.03%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Total</div></td></tr><tr><td style="width: 44.86%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Cost<br></div></td><td class="gutter" style="width: 1.51%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.51%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.1%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.51%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.51%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.24%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.51%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.51%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.51%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.51%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.51%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.17%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.51%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.51%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.03%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 44.86%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">January&#160;1, 2018<font style="padding-left: 4.24pt;"></font></div></td><td class="gutter" style="width: 1.51%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.51%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 8.1%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 8.17pt; text-align: left;"><font style="padding-left: 3.33pt;">291</font></div></td><td class="gutter" style="width: 1.51%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.51%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 9.24%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.08pt; text-align: left;"><font style="padding-left: 6.4pt;">671</font></div></td><td class="gutter" style="width: 1.51%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.51%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 8.51%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.06pt; text-align: left;"><font style="padding-left: 3.33pt;">340</font></div></td><td class="gutter" style="width: 1.51%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.51%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 8.17%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 8.32pt; text-align: left;"><font style="padding-left: 3.33pt;">388</font></div></td><td class="gutter" style="width: 1.51%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.51%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 6.03%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 3.33pt;">1,690</font></div></td></tr><tr><td style="width: 44.86%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Additions<font style="padding-left: 0.06pt;"></font></div></td><td class="gutter" style="width: 1.51%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.51%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.1%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 8.17pt; text-align: left;"><font style="padding-left: 3.33pt;">226</font></div></td><td class="gutter" style="width: 1.51%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.51%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.24%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.08pt; text-align: left;"><font style="padding-left: 6.4pt;">327</font></div></td><td class="gutter" style="width: 1.51%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.51%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.51%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.06pt; text-align: left;"><font style="padding-left: 3.33pt;">277</font></div></td><td class="gutter" style="width: 1.51%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.51%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.17%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 8.32pt; text-align: left;"><font style="padding-left: 3.7pt;">114</font></div></td><td class="gutter" style="width: 1.51%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.51%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.03%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 10.83pt;">944</font></div></td></tr><tr><td style="width: 44.86%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Disposals and scrapping<font style="padding-left: 0.65pt;"></font></div></td><td class="gutter" style="width: 1.51%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.51%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 8.1%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 8.17pt; text-align: left;"><font style="padding-left: 8.33pt;">&#8212;</font></div></td><td class="gutter" style="width: 1.51%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.51%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 9.24%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.08pt; text-align: left;"><font style="padding-left: 11.4pt;">&#8212;</font></div></td><td class="gutter" style="width: 1.51%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.51%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 8.51%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.06pt; text-align: left;"><font style="padding-left: 10pt;">(7)</font></div></td><td class="gutter" style="width: 1.51%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.51%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 8.17%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 8.32pt; text-align: left;"><font style="padding-left: 8.33pt;">&#8212;</font></div></td><td class="gutter" style="width: 1.51%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.51%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 6.03%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 17.5pt;">(7)</font></div></td></tr><tr><td style="width: 44.86%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Exchange difference<font style="padding-left: 1.39pt;"></font></div></td><td class="gutter" style="width: 1.51%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.51%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.1%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 8.17pt; text-align: left;"><font style="padding-left: 10pt; border-bottom: 1pt solid #000000; min-width: 18.33pt;">(3</font><font style="min-width: 18.33pt;">)</font></div></td><td class="gutter" style="width: 1.51%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.51%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.24%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.08pt; text-align: left;"><font style="padding-left: 8.07pt; border-bottom: 1pt solid #000000; min-width: 21.4pt;">(59</font><font style="min-width: 21.4pt;">)</font></div></td><td class="gutter" style="width: 1.51%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.51%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.51%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.06pt; text-align: left;"><font style="padding-left: 5pt; border-bottom: 1pt solid #000000; min-width: 18.33pt;">(13</font><font style="min-width: 18.33pt;">)</font></div></td><td class="gutter" style="width: 1.51%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.51%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.17%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 8.32pt; text-align: left;"><font style="padding-left: 10pt; border-bottom: 1pt solid #000000; min-width: 18.33pt;">(5</font><font style="min-width: 18.33pt;">)</font></div></td><td class="gutter" style="width: 1.51%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.51%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.03%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 12.5pt; border-bottom: 1pt solid #000000; min-width: 25.83pt;">(80</font><font style="min-width: 25.83pt;">)</font></div></td></tr><tr><td style="width: 44.86%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">December&#160;31, 2018<font style="font-weight: normal; padding-left: 2.21pt;"></font></div></td><td class="gutter" style="width: 1.51%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.51%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 8.1%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 8.17pt; text-align: left;"><font style="padding-left: 3.33pt;">514</font></div></td><td class="gutter" style="width: 1.51%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.51%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 9.24%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 9.08pt; text-align: left;"><font style="padding-left: 6.4pt;">939</font></div></td><td class="gutter" style="width: 1.51%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.51%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 8.51%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 9.06pt; text-align: left;"><font style="padding-left: 3.33pt;">597</font></div></td><td class="gutter" style="width: 1.51%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.51%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 8.17%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 8.32pt; text-align: left;"><font style="padding-left: 3.33pt;">497</font></div></td><td class="gutter" style="width: 1.51%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.51%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 6.03%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 3.33pt;">2,547</font></div></td></tr><tr><td style="width: 44.86%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Additions<font style="padding-left: 0.06pt;"></font></div></td><td class="gutter" style="width: 1.51%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.51%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.1%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 8.17pt; text-align: left;"><font style="padding-left: 8.33pt;">17</font></div></td><td class="gutter" style="width: 1.51%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.51%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.24%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.08pt; text-align: left;"><font style="padding-left: 6.4pt;">131</font></div></td><td class="gutter" style="width: 1.51%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.51%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.51%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.06pt; text-align: left;"><font style="padding-left: 8.33pt;">93</font></div></td><td class="gutter" style="width: 1.51%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.51%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.17%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 8.32pt; text-align: left;"><font style="padding-left: 3.7pt;">118</font></div></td><td class="gutter" style="width: 1.51%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.51%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.03%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 10.83pt;">359</font></div></td></tr><tr><td style="width: 44.86%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Exchange difference<font style="padding-left: 1.39pt;"></font></div></td><td class="gutter" style="width: 1.51%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.51%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 8.1%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 8.17pt; text-align: left;"><font style="padding-left: 13.33pt; border-bottom: 1pt solid #000000; min-width: 18.33pt;">2</font></div></td><td class="gutter" style="width: 1.51%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.51%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 9.24%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.08pt; text-align: left;"><font style="padding-left: 11.4pt; border-bottom: 1pt solid #000000; min-width: 21.4pt;">41</font></div></td><td class="gutter" style="width: 1.51%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.51%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 8.51%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.06pt; text-align: left;"><font style="padding-left: 13.33pt; border-bottom: 1pt solid #000000; min-width: 18.33pt;">8</font></div></td><td class="gutter" style="width: 1.51%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.51%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 8.17%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 8.32pt; text-align: left;"><font style="padding-left: 13.33pt; border-bottom: 1pt solid #000000; min-width: 18.33pt;">3</font></div></td><td class="gutter" style="width: 1.51%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.51%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 6.03%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 15.83pt; border-bottom: 1pt solid #000000; min-width: 25.83pt;">54 </font></div></td></tr><tr><td style="width: 44.86%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">December&#160;31, 2019<font style="font-weight: normal; padding-left: 2.21pt;"></font></div></td><td class="gutter" style="width: 1.51%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.51%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.1%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 8.17pt; text-align: left;"><font style="padding-left: 3.33pt; border-bottom: 3pt double #000000; min-width: 18.33pt;">533</font></div></td><td class="gutter" style="width: 1.51%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.51%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.24%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 9.08pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 21.4pt;">1,111</font></div></td><td class="gutter" style="width: 1.51%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.51%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.51%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 9.06pt; text-align: left;"><font style="padding-left: 3.33pt; border-bottom: 3pt double #000000; min-width: 18.33pt;">698</font></div></td><td class="gutter" style="width: 1.51%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.51%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.17%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 8.32pt; text-align: left;"><font style="padding-left: 3.33pt; border-bottom: 3pt double #000000; min-width: 18.33pt;">618</font></div></td><td class="gutter" style="width: 1.51%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.51%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.03%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 3.33pt; border-bottom: 3pt double #000000; min-width: 25.83pt;">2,960</font></div></td></tr><tr><td style="width: 44.86%; text-align: left; vertical-align: bottom; padding-top: 5.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.51%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.51%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 8.1%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 5.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.51%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.51%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 9.24%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 5.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.51%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.51%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 8.51%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 5.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.51%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.51%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 8.17%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 5.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.51%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.51%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 6.03%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 5.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 44.86%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Accumulated depreciation<br></div></td><td class="gutter" style="width: 1.51%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.51%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.1%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.51%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.51%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.24%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.51%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.51%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.51%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.51%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.51%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.17%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.51%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.51%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.03%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 44.86%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">January&#160;1, 2018<font style="padding-left: 4.24pt;"></font></div></td><td class="gutter" style="width: 1.51%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.51%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 8.1%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 8.17pt; text-align: left;"><font style="padding-left: 5pt;">(70)</font></div></td><td class="gutter" style="width: 1.51%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.51%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 9.24%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.08pt; text-align: left;"><font style="padding-left: 3.07pt;">(168)</font></div></td><td class="gutter" style="width: 1.51%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.51%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 8.51%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.06pt; text-align: left;">(136)</div></td><td class="gutter" style="width: 1.51%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.51%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 8.17%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 8.32pt; text-align: left;">(174)</div></td><td class="gutter" style="width: 1.51%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.51%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 6.03%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 7.5pt;">(548)</font></div></td></tr><tr><td style="width: 44.86%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Depreciation charge<font style="padding-left: 3.05pt;"></font></div></td><td class="gutter" style="width: 1.51%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.51%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.1%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 8.17pt; text-align: left;"><font style="padding-left: 5pt;">(57)</font></div></td><td class="gutter" style="width: 1.51%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.51%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.24%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.08pt; text-align: left;"><font style="padding-left: 3.07pt;">(159)</font></div></td><td class="gutter" style="width: 1.51%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.51%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.51%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.06pt; text-align: left;"><font style="padding-left: 0.37pt;">(118)</font></div></td><td class="gutter" style="width: 1.51%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.51%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.17%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 8.32pt; text-align: left;">(154)</div></td><td class="gutter" style="width: 1.51%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.51%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.03%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 7.5pt;">(488)</font></div></td></tr><tr><td style="width: 44.86%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Disposals and scrapping<font style="padding-left: 0.65pt;"></font></div></td><td class="gutter" style="width: 1.51%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.51%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 8.1%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 8.17pt; text-align: left;"><font style="padding-left: 8.33pt;">&#8212;</font></div></td><td class="gutter" style="width: 1.51%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.51%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 9.24%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.08pt; text-align: left;"><font style="padding-left: 11.4pt;">&#8212;</font></div></td><td class="gutter" style="width: 1.51%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.51%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 8.51%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.06pt; text-align: left;"><font style="padding-left: 13.33pt;">7</font></div></td><td class="gutter" style="width: 1.51%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.51%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 8.17%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 8.32pt; text-align: left;"><font style="padding-left: 8.33pt;">&#8212;</font></div></td><td class="gutter" style="width: 1.51%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.51%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 6.03%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 20.83pt;">7</font></div></td></tr><tr><td style="width: 44.86%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Exchange difference<font style="padding-left: 1.39pt;"></font></div></td><td class="gutter" style="width: 1.51%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.51%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.1%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 8.17pt; text-align: left;"><font style="padding-left: 13.33pt; border-bottom: 1pt solid #000000; min-width: 18.33pt;">1</font></div></td><td class="gutter" style="width: 1.51%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.51%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.24%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.08pt; text-align: left;"><font style="padding-left: 11.4pt; border-bottom: 1pt solid #000000; min-width: 21.4pt;">17</font></div></td><td class="gutter" style="width: 1.51%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.51%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.51%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.06pt; text-align: left;"><font style="padding-left: 13.33pt; border-bottom: 1pt solid #000000; min-width: 18.33pt;">2</font></div></td><td class="gutter" style="width: 1.51%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.51%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.17%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 8.32pt; text-align: left;"><font style="padding-left: 13.33pt; border-bottom: 1pt solid #000000; min-width: 18.33pt;">2</font></div></td><td class="gutter" style="width: 1.51%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.51%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.03%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 15.83pt; border-bottom: 1pt solid #000000; min-width: 25.83pt;">22 </font></div></td></tr><tr><td style="width: 44.86%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">December&#160;31, 2018<font style="font-weight: normal; padding-left: 2.21pt;"></font></div></td><td class="gutter" style="width: 1.51%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.51%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 8.1%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 8.17pt; text-align: left;">(126)</div></td><td class="gutter" style="width: 1.51%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.51%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 9.24%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 9.08pt; text-align: left;"><font style="padding-left: 3.07pt;">(310)</font></div></td><td class="gutter" style="width: 1.51%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.51%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 8.51%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 9.06pt; text-align: left;">(245)</div></td><td class="gutter" style="width: 1.51%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.51%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 8.17%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 8.32pt; text-align: left;">(326)</div></td><td class="gutter" style="width: 1.51%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.51%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 6.03%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: -0.01pt; text-align: left;">(1,007)</div></td></tr><tr><td style="width: 44.86%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Depreciation charge<font style="padding-left: 3.05pt;"></font></div></td><td class="gutter" style="width: 1.51%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.51%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.1%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 8.17pt; text-align: left;"><font style="padding-left: 5pt;">(82)</font></div></td><td class="gutter" style="width: 1.51%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.51%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.24%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.08pt; text-align: left;"><font style="padding-left: 3.07pt;">(204)</font></div></td><td class="gutter" style="width: 1.51%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.51%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.51%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.06pt; text-align: left;">(149)</div></td><td class="gutter" style="width: 1.51%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.51%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.17%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 8.32pt; text-align: left;"><font style="padding-left: 0.37pt;">(117)</font></div></td><td class="gutter" style="width: 1.51%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.51%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.03%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 7.5pt;">(552)</font></div></td></tr><tr><td style="width: 44.86%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Exchange difference<font style="padding-left: 1.39pt;"></font></div></td><td class="gutter" style="width: 1.51%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.51%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 8.1%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 8.17pt; text-align: left;"><font style="padding-left: 10pt; border-bottom: 1pt solid #000000; min-width: 18.33pt;">(1</font><font style="min-width: 18.33pt;">)</font></div></td><td class="gutter" style="width: 1.51%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.51%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 9.24%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.08pt; text-align: left;"><font style="padding-left: 8.07pt; border-bottom: 1pt solid #000000; min-width: 21.4pt;">(19</font><font style="min-width: 21.4pt;">)</font></div></td><td class="gutter" style="width: 1.51%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.51%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 8.51%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.06pt; text-align: left;"><font style="padding-left: 10pt; border-bottom: 1pt solid #000000; min-width: 18.33pt;">(3</font><font style="min-width: 18.33pt;">)</font></div></td><td class="gutter" style="width: 1.51%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.51%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 8.17%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 8.32pt; text-align: left;"><font style="padding-left: 10pt; border-bottom: 1pt solid #000000; min-width: 18.33pt;">(2</font><font style="min-width: 18.33pt;">)</font></div></td><td class="gutter" style="width: 1.51%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.51%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 6.03%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 12.5pt; border-bottom: 1pt solid #000000; min-width: 25.83pt;">(25</font><font style="min-width: 25.83pt;">)</font></div></td></tr><tr><td style="width: 44.86%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">December&#160;31, 2019<font style="font-weight: normal; padding-left: 2.21pt;"></font></div></td><td class="gutter" style="width: 1.51%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.51%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.1%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 8.17pt; text-align: left;"><font style="border-bottom: 1pt solid #000000; min-width: 18.33pt;">(209</font><font style="min-width: 18.33pt;">)</font></div></td><td class="gutter" style="width: 1.51%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.51%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.24%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 9.08pt; text-align: left;"><font style="padding-left: 3.07pt; border-bottom: 1pt solid #000000; min-width: 21.4pt;">(533</font><font style="min-width: 21.4pt;">)</font></div></td><td class="gutter" style="width: 1.51%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.51%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.51%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 9.06pt; text-align: left;"><font style="border-bottom: 1pt solid #000000; min-width: 18.33pt;">(397</font><font style="min-width: 18.33pt;">)</font></div></td><td class="gutter" style="width: 1.51%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.51%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.17%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 8.32pt; text-align: left;"><font style="border-bottom: 1pt solid #000000; min-width: 18.33pt;">(445</font><font style="min-width: 18.33pt;">)</font></div></td><td class="gutter" style="width: 1.51%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.51%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.03%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="border-bottom: 1pt solid #000000; min-width: 25.83pt;">(1,584</font><font style="min-width: 25.83pt;">)</font></div></td></tr><tr><td style="width: 44.86%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.51%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.51%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 8.1%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.51%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.51%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 9.24%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.51%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.51%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 8.51%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.51%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.51%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 8.17%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.51%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.51%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 6.03%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 44.86%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Net book amount<br></div></td><td class="gutter" style="width: 1.51%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.51%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.1%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.51%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.51%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.24%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.51%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.51%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.51%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.51%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.51%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.17%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.51%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.51%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.03%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 44.86%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 5.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">December&#160;31, 2018<font style="font-weight: normal; padding-left: 2.21pt;"></font></div></td><td class="gutter" style="width: 1.51%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 5.25pt;">&#8203;</td><td class="gutter" style="width: 1.51%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 5.25pt;">&#8203;</td><td style="width: 8.1%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 5.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 8.17pt; text-align: left;"><font style="padding-left: 3.33pt; border-bottom: 3pt double #000000; min-width: 18.33pt;">388</font></div></td><td class="gutter" style="width: 1.51%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 5.25pt;">&#8203;</td><td class="gutter" style="width: 1.51%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 5.25pt;">&#8203;</td><td style="width: 9.24%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 5.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 9.08pt; text-align: left;"><font style="padding-left: 6.4pt; border-bottom: 3pt double #000000; min-width: 21.4pt;">629</font></div></td><td class="gutter" style="width: 1.51%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 5.25pt;">&#8203;</td><td class="gutter" style="width: 1.51%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 5.25pt;">&#8203;</td><td style="width: 8.51%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 5.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 9.06pt; text-align: left;"><font style="padding-left: 3.33pt; border-bottom: 3pt double #000000; min-width: 18.33pt;">352</font></div></td><td class="gutter" style="width: 1.51%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 5.25pt;">&#8203;</td><td class="gutter" style="width: 1.51%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 5.25pt;">&#8203;</td><td style="width: 8.17%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 5.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 8.32pt; text-align: left;"><font style="padding-left: 3.33pt; border-bottom: 3pt double #000000; min-width: 18.33pt;">171</font></div></td><td class="gutter" style="width: 1.51%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 5.25pt;">&#8203;</td><td class="gutter" style="width: 1.51%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 5.25pt;">&#8203;</td><td style="width: 6.03%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 5.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 3.33pt; border-bottom: 3pt double #000000; min-width: 25.83pt;">1,540</font></div></td></tr><tr><td style="width: 44.86%; text-align: left; vertical-align: bottom; padding-top: 5.25pt; padding-bottom: 6pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">December&#160;31, 2019<font style="font-weight: normal; padding-left: 2.21pt;"></font></div></td><td class="gutter" style="width: 1.51%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.51%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.1%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 5.25pt; padding-bottom: 6pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 8.17pt; text-align: left;"><font style="padding-left: 3.33pt; border-bottom: 3pt double #000000; min-width: 18.33pt;">324</font></div></td><td class="gutter" style="width: 1.51%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.51%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.24%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 5.25pt; padding-bottom: 6pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 9.08pt; text-align: left;"><font style="padding-left: 6.4pt; border-bottom: 3pt double #000000; min-width: 21.4pt;">578</font></div></td><td class="gutter" style="width: 1.51%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.51%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.51%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 5.25pt; padding-bottom: 6pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 9.06pt; text-align: left;"><font style="padding-left: 3.33pt; border-bottom: 3pt double #000000; min-width: 18.33pt;">301</font></div></td><td class="gutter" style="width: 1.51%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.51%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.17%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 5.25pt; padding-bottom: 6pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 8.32pt; text-align: left;"><font style="padding-left: 3.33pt; border-bottom: 3pt double #000000; min-width: 18.33pt;">173</font></div></td><td class="gutter" style="width: 1.51%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.51%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.03%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 5.25pt; padding-bottom: 6pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 3.33pt; border-bottom: 3pt double #000000; min-width: 25.83pt;">1,376</font></div></td></tr></table><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: left;">In 2019, the investments in tangible fixed assets relate mainly to investments in the UK laboratory and in hardware. The 2018 &#8220;Additions&#8221; related principally to investments in the UK laboratory and offices, as well as to the offices in Switzerland.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 20pt; text-align: left;">Depreciation has been charged to the following categories in the income statement:</div><table cellspacing="0" cellpadding="0" class="fintab" style="margin-top: 11.25pt; border-collapse: collapse; width: 428pt; margin-left: 20pt;"><tr class="header"><td style="width: 70.09%; text-align: left; vertical-align: bottom; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">(in KUSD)</div></td><td class="gutter" style="width: 1.97%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.97%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 11.02%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Year ended <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">December&#160;31, <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2019</div></td><td class="gutter" style="width: 1.97%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.97%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 11.02%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Year ended <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">December 31, <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2018</div></td></tr><tr><td style="width: 70.09%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Research and development expenses<font style="padding-left: 3.68pt;"></font></div></td><td class="gutter" style="width: 1.97%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.97%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 11.02%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 16.08pt; text-align: left;">407</div></td><td class="gutter" style="width: 1.97%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.97%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 11.02%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 16.08pt; text-align: left;">330</div></td></tr><tr><td style="width: 70.09%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">General and administrative expenses<font style="padding-left: 3.12pt;"></font></div></td><td class="gutter" style="width: 1.97%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.97%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 11.02%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 16.08pt; text-align: left;"><font style="border-bottom: 1pt solid #000000; min-width: 15pt;">145</font></div></td><td class="gutter" style="width: 1.97%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.97%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 11.02%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 16.08pt; text-align: left;"><font style="border-bottom: 1pt solid #000000; min-width: 15pt;">158</font></div></td></tr><tr><td style="width: 70.09%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.97%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.97%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 11.02%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 16.08pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 15pt;">552</font></div></td><td class="gutter" style="width: 1.97%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.97%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 11.02%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 16.08pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 15pt;">488</font></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 12pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">17.<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; text-align: left;">Leases</div></td></tr></table><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 7pt; margin-left: 20pt; text-align: left;">The balance sheet shows the following amounts relating to leases:</div><table cellspacing="0" cellpadding="0" class="fintab" style="margin-top: 11.25pt; border-collapse: collapse; width: 428pt; margin-left: 20pt;"><tr class="header"><td style="width: 70.09%; text-align: left; vertical-align: bottom; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">(in KUSD)</div></td><td class="gutter" style="width: 2.55%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 2.55%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 11.02%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">December&#160;31, <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2019</div></td><td class="gutter" style="width: 2.55%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 2.55%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 8.67%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">January&#160;1, <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2019</div></td></tr><tr><td style="width: 70.09%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Properties (offices)<font style="padding-left: 4.95pt;"></font></div></td><td class="gutter" style="width: 2.55%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.55%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 11.02%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 12.34pt; text-align: left;">4,820</div></td><td class="gutter" style="width: 2.55%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.55%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.67%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.31pt; text-align: left;">5,399</div></td></tr><tr><td style="width: 70.09%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Vehicles<font style="padding-left: 3.63pt;"></font></div></td><td class="gutter" style="width: 2.55%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 2.55%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 11.02%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 12.34pt; text-align: left;"><font style="padding-left: 12.5pt; border-bottom: 1pt solid #000000; min-width: 22.5pt;">78</font></div></td><td class="gutter" style="width: 2.55%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 2.55%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 8.67%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.31pt; text-align: left;"><font style="padding-left: 12.5pt; border-bottom: 1pt solid #000000; min-width: 22.5pt;">24</font></div></td></tr><tr><td style="width: 70.09%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Total right-of-use assets<font style="font-weight: normal; padding-left: 4.58pt;"></font></div></td><td class="gutter" style="width: 2.55%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.55%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 11.02%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 12.34pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 22.5pt;">4,898</font></div></td><td class="gutter" style="width: 2.55%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.55%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.67%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 7.31pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 22.5pt;">5,423</font></div></td></tr></table></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 36pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">F-47<br></div></div></div>
<!--End Page 301-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 302-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 540pt;"><a name="nt10014672x1_drs_204-finnotes02_pg18"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="block-frill" style="width: 540pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: Arial, Helvetica, sans-serif; font-size: 9pt; font-weight: bold; margin-top: 6pt; text-align: center;">Confidential Treatment Requested by ADC Therapeutics SA Pursuant to 17 C.F.R. &#167; 200.83<br></div></div><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 36pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">ADC Therapeutics SA, Epalinges <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;"><div class="rule-full" style="height: 0pt; width: 100%; border-bottom: 1pt solid #000000; margin-top: 1pt; margin-bottom: 1pt; margin-left: auto; margin-right: auto;"> </div>NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS <font style="padding-left: 4pt;">(continued)</font><br></div><table cellspacing="0" cellpadding="0" class="fintab" style="border-collapse: collapse; width: 428pt; margin-left: 20pt;"><tr class="header"><td style="width: 70.09%; text-align: left; vertical-align: bottom; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">(in KUSD)</div></td><td class="gutter" style="width: 2.55%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 2.55%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 11.02%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">December&#160;31, <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2019</div></td><td class="gutter" style="width: 2.55%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 2.55%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 8.67%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">January&#160;1, <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2019</div></td></tr><tr><td style="width: 70.09%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Lease liabilities (short-term)<font style="padding-left: 2pt;"></font></div></td><td class="gutter" style="width: 2.55%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.55%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 11.02%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 12.34pt; text-align: left;">1,132</div></td><td class="gutter" style="width: 2.55%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.55%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.67%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.31pt; text-align: left;"><font style="padding-left: 7.5pt;">924</font></div></td></tr><tr><td style="width: 70.09%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Lease liabilities (long-term)<font style="padding-left: 4.21pt;"></font></div></td><td class="gutter" style="width: 2.55%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 2.55%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 11.02%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 12.34pt; text-align: left;"><font style="border-bottom: 1pt solid #000000; min-width: 22.5pt;">3,899</font></div></td><td class="gutter" style="width: 2.55%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 2.55%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 8.67%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.31pt; text-align: left;"><font style="border-bottom: 1pt solid #000000; min-width: 22.5pt;">4,499</font></div></td></tr><tr><td style="width: 70.09%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Total lease liabilities<font style="font-weight: normal; padding-left: 4.55pt;"></font></div></td><td class="gutter" style="width: 2.55%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.55%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 11.02%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 12.34pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 22.5pt;">5,031</font></div></td><td class="gutter" style="width: 2.55%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.55%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.67%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 7.31pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 22.5pt;">5,423</font></div></td></tr></table><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 37pt; margin-left: 20pt; text-align: left;">In the previous year, all leases were classified as &#8216;operating leases&#8217; under IAS 17 Leases and were accordingly not recognized as assets and liabilities. For adjustments recognized on adoption of IFRS 16 on 1&#160;January 2019, please refer to note 4 (i), &#8220;New standards adopted by the Group&#8221;.</div><table cellspacing="0" cellpadding="0" class="fintab" style="margin-top: 11.25pt; border-collapse: collapse; width: 428pt; margin-left: 20pt;"><tr class="header"><td style="width: 70.09%; text-align: left; vertical-align: bottom; padding-top: 6pt; padding-bottom: 3.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">(in KUSD)</div></td><td class="gutter" style="width: 1.89%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 3.75pt;">&#8203;</td><td class="gutter" style="width: 1.89%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 3.75pt;">&#8203;</td><td style="width: 6.04%; text-align: center; vertical-align: bottom; padding-top: 6pt; padding-bottom: 3.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 1.89%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 3.75pt;">&#8203;</td><td class="gutter" style="width: 1.89%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 3.75pt;">&#8203;</td><td style="width: 6.47%; text-align: center; vertical-align: bottom; padding-top: 6pt; padding-bottom: 3.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 1.89%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 3.75pt;">&#8203;</td><td class="gutter" style="width: 1.89%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 3.75pt;">&#8203;</td><td style="width: 6.03%; text-align: center; vertical-align: bottom; padding-top: 6pt; padding-bottom: 3.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td></tr><tr class="header"><td style="width: 70.09%; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 3.75pt; padding-bottom: 3.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Right-of-Use Assets<font style="font-weight: normal;"> </font></div></td><td class="gutter" style="width: 1.89%; font-size: 2pt; padding-top: 3.75pt; padding-bottom: 3.75pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.89%; font-size: 2pt; padding-top: 3.75pt; padding-bottom: 3.75pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 6.04%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 3.75pt; padding-bottom: 3.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Offices</div></td><td class="gutter" style="width: 1.89%; font-size: 2pt; padding-top: 3.75pt; padding-bottom: 3.75pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.89%; font-size: 2pt; padding-top: 3.75pt; padding-bottom: 3.75pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 6.47%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 3.75pt; padding-bottom: 3.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Vehicles</div></td><td class="gutter" style="width: 1.89%; font-size: 2pt; padding-top: 3.75pt; padding-bottom: 3.75pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.89%; font-size: 2pt; padding-top: 3.75pt; padding-bottom: 3.75pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 6.03%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 3.75pt; padding-bottom: 3.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Total</div></td></tr><tr><td style="width: 70.09%; text-align: left; vertical-align: bottom; padding-top: 3.75pt; padding-bottom: 2.5pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Cost<br></div></td><td class="gutter" style="width: 1.89%; border-bottom: none; font-size: 2pt; padding-top: 3.75pt; padding-bottom: 2.5pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.89%; border-bottom: none; font-size: 2pt; padding-top: 3.75pt; padding-bottom: 2.5pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.04%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3.75pt; padding-bottom: 2.5pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.89%; border-bottom: none; font-size: 2pt; padding-top: 3.75pt; padding-bottom: 2.5pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.89%; border-bottom: none; font-size: 2pt; padding-top: 3.75pt; padding-bottom: 2.5pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.47%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3.75pt; padding-bottom: 2.5pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.89%; border-bottom: none; font-size: 2pt; padding-top: 3.75pt; padding-bottom: 2.5pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.89%; border-bottom: none; font-size: 2pt; padding-top: 3.75pt; padding-bottom: 2.5pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.03%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3.75pt; padding-bottom: 2.5pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 70.09%; text-align: left; vertical-align: bottom; padding-top: 2.5pt; padding-bottom: 2.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">January&#160;1, 2019<font style="padding-left: 2.24pt;"></font></div></td><td class="gutter" style="width: 1.89%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td class="gutter" style="width: 1.89%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td style="width: 6.04%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.5pt; padding-bottom: 2.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 3.33pt;">5,399</font></div></td><td class="gutter" style="width: 1.89%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td class="gutter" style="width: 1.89%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td style="width: 6.47%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.5pt; padding-bottom: 2.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.18pt; text-align: left;"><font style="padding-left: 3.33pt;">24</font></div></td><td class="gutter" style="width: 1.89%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td class="gutter" style="width: 1.89%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td style="width: 6.03%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.5pt; padding-bottom: 2.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 3.33pt;">5,423</font></div></td></tr><tr><td style="width: 70.09%; text-align: left; vertical-align: bottom; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Additions<font style="padding-left: 3.06pt;"></font></div></td><td class="gutter" style="width: 1.89%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.89%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.04%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 10.83pt;">466</font></div></td><td class="gutter" style="width: 1.89%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.89%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.47%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.18pt; text-align: left;"><font style="padding-left: 3.33pt;">78</font></div></td><td class="gutter" style="width: 1.89%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.89%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.03%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 10.83pt;">544</font></div></td></tr><tr><td style="width: 70.09%; text-align: left; vertical-align: bottom; padding-top: 2.5pt; padding-bottom: 2.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Disposals<font style="padding-left: 3.63pt;"></font></div></td><td class="gutter" style="width: 1.89%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td class="gutter" style="width: 1.89%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td style="width: 6.04%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.5pt; padding-bottom: 2.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 15.83pt;">&#8212;</font></div></td><td class="gutter" style="width: 1.89%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td class="gutter" style="width: 1.89%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td style="width: 6.47%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.5pt; padding-bottom: 2.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.18pt; text-align: left;">(24)</div></td><td class="gutter" style="width: 1.89%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td class="gutter" style="width: 1.89%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td style="width: 6.03%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.5pt; padding-bottom: 2.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 12.5pt;">(24)</font></div></td></tr><tr><td style="width: 70.09%; text-align: left; vertical-align: bottom; padding-top: 2.5pt; padding-bottom: 3.75pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Exchange difference<font style="padding-left: 4.39pt;"></font></div></td><td class="gutter" style="width: 1.89%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 3.75pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.89%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 3.75pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.04%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.5pt; padding-bottom: 3.75pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 15.83pt; border-bottom: 1pt solid #000000; min-width: 25.83pt;">22</font></div></td><td class="gutter" style="width: 1.89%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 3.75pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.89%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 3.75pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.47%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.5pt; padding-bottom: 3.75pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.18pt; text-align: left;"><font style="padding-left: 3.33pt; border-bottom: 1pt solid #000000; min-width: 13.33pt;">&#8212;</font></div></td><td class="gutter" style="width: 1.89%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 3.75pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.89%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 3.75pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.03%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.5pt; padding-bottom: 3.75pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 15.83pt; border-bottom: 1pt solid #000000; min-width: 25.83pt;">22 </font></div></td></tr><tr><td style="width: 70.09%; text-align: left; vertical-align: bottom; padding-top: 3.75pt; padding-bottom: 3.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">December&#160;31, 2019<font style="font-weight: normal; padding-left: 0.21pt;"></font></div></td><td class="gutter" style="width: 1.89%; border-bottom: none; font-size: 2pt; padding-top: 3.75pt; padding-bottom: 3.75pt;">&#8203;</td><td class="gutter" style="width: 1.89%; border-bottom: none; font-size: 2pt; padding-top: 3.75pt; padding-bottom: 3.75pt;">&#8203;</td><td style="width: 6.04%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3.75pt; padding-bottom: 3.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 3.33pt; border-bottom: 1pt solid #000000; min-width: 25.83pt;">5,887</font></div></td><td class="gutter" style="width: 1.89%; border-bottom: none; font-size: 2pt; padding-top: 3.75pt; padding-bottom: 3.75pt;">&#8203;</td><td class="gutter" style="width: 1.89%; border-bottom: none; font-size: 2pt; padding-top: 3.75pt; padding-bottom: 3.75pt;">&#8203;</td><td style="width: 6.47%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3.75pt; padding-bottom: 3.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 7.18pt; text-align: left;"><font style="padding-left: 3.33pt; border-bottom: 1pt solid #000000; min-width: 13.33pt;">78</font></div></td><td class="gutter" style="width: 1.89%; border-bottom: none; font-size: 2pt; padding-top: 3.75pt; padding-bottom: 3.75pt;">&#8203;</td><td class="gutter" style="width: 1.89%; border-bottom: none; font-size: 2pt; padding-top: 3.75pt; padding-bottom: 3.75pt;">&#8203;</td><td style="width: 6.03%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3.75pt; padding-bottom: 3.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 3.33pt; border-bottom: 1pt solid #000000; min-width: 25.83pt;">5,965</font></div></td></tr><tr><td style="width: 70.09%; text-align: left; vertical-align: bottom; padding-top: 3.75pt; padding-bottom: 2.5pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Accumulated depreciation<br></div></td><td class="gutter" style="width: 1.89%; border-bottom: none; font-size: 2pt; padding-top: 3.75pt; padding-bottom: 2.5pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.89%; border-bottom: none; font-size: 2pt; padding-top: 3.75pt; padding-bottom: 2.5pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.04%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3.75pt; padding-bottom: 2.5pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.89%; border-bottom: none; font-size: 2pt; padding-top: 3.75pt; padding-bottom: 2.5pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.89%; border-bottom: none; font-size: 2pt; padding-top: 3.75pt; padding-bottom: 2.5pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.47%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3.75pt; padding-bottom: 2.5pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.89%; border-bottom: none; font-size: 2pt; padding-top: 3.75pt; padding-bottom: 2.5pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.89%; border-bottom: none; font-size: 2pt; padding-top: 3.75pt; padding-bottom: 2.5pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.03%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3.75pt; padding-bottom: 2.5pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 70.09%; text-align: left; vertical-align: bottom; padding-top: 2.5pt; padding-bottom: 2.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">January&#160;1, 2019<font style="padding-left: 2.24pt;"></font></div></td><td class="gutter" style="width: 1.89%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td class="gutter" style="width: 1.89%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td style="width: 6.04%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.5pt; padding-bottom: 2.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 15.83pt;">&#8212;</font></div></td><td class="gutter" style="width: 1.89%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td class="gutter" style="width: 1.89%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td style="width: 6.47%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.5pt; padding-bottom: 2.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.18pt; text-align: left;"><font style="padding-left: 3.33pt;">&#8212;</font></div></td><td class="gutter" style="width: 1.89%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td class="gutter" style="width: 1.89%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td style="width: 6.03%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.5pt; padding-bottom: 2.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 15.83pt;">&#8212;</font></div></td></tr><tr><td style="width: 70.09%; text-align: left; vertical-align: bottom; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Depreciation charge<font style="padding-left: 1.05pt;"></font></div></td><td class="gutter" style="width: 1.89%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.89%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.04%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">(1,051)</div></td><td class="gutter" style="width: 1.89%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.89%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.47%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.18pt; text-align: left;">(13)</div></td><td class="gutter" style="width: 1.89%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.89%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.03%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;">(1,064)</div></td></tr><tr><td style="width: 70.09%; text-align: left; vertical-align: bottom; padding-top: 2.5pt; padding-bottom: 2.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Disposals and scrapping<font style="padding-left: 3.65pt;"></font></div></td><td class="gutter" style="width: 1.89%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td class="gutter" style="width: 1.89%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td style="width: 6.04%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.5pt; padding-bottom: 2.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 15.83pt;">&#8212;</font></div></td><td class="gutter" style="width: 1.89%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td class="gutter" style="width: 1.89%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td style="width: 6.47%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.5pt; padding-bottom: 2.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.18pt; text-align: left;"><font style="padding-left: 3.33pt;">13</font></div></td><td class="gutter" style="width: 1.89%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td class="gutter" style="width: 1.89%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td style="width: 6.03%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.5pt; padding-bottom: 2.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 15.83pt;">13</font></div></td></tr><tr><td style="width: 70.09%; text-align: left; vertical-align: bottom; padding-top: 2.5pt; padding-bottom: 3.75pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Exchange difference<font style="padding-left: 4.39pt;"></font></div></td><td class="gutter" style="width: 1.89%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 3.75pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.89%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 3.75pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.04%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.5pt; padding-bottom: 3.75pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 12.5pt; border-bottom: 1pt solid #000000; min-width: 25.83pt;">(16</font><font style="min-width: 25.83pt;">)</font></div></td><td class="gutter" style="width: 1.89%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 3.75pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.89%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 3.75pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.47%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.5pt; padding-bottom: 3.75pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.18pt; text-align: left;"><font style="padding-left: 3.33pt; border-bottom: 1pt solid #000000; min-width: 13.33pt;">&#8212;</font></div></td><td class="gutter" style="width: 1.89%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 3.75pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.89%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 3.75pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.03%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.5pt; padding-bottom: 3.75pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 12.5pt; border-bottom: 1pt solid #000000; min-width: 25.83pt;">(16</font><font style="min-width: 25.83pt;">)</font></div></td></tr><tr><td style="width: 70.09%; text-align: left; vertical-align: bottom; padding-top: 3.75pt; padding-bottom: 4.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">December&#160;31, 2019<font style="font-weight: normal; padding-left: 0.21pt;"></font></div></td><td class="gutter" style="width: 1.89%; border-bottom: none; font-size: 2pt; padding-top: 3.75pt; padding-bottom: 4.75pt;">&#8203;</td><td class="gutter" style="width: 1.89%; border-bottom: none; font-size: 2pt; padding-top: 3.75pt; padding-bottom: 4.75pt;">&#8203;</td><td style="width: 6.04%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3.75pt; padding-bottom: 4.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 25.83pt;">(1,067</font><font style="min-width: 25.83pt;">)</font></div></td><td class="gutter" style="width: 1.89%; border-bottom: none; font-size: 2pt; padding-top: 3.75pt; padding-bottom: 4.75pt;">&#8203;</td><td class="gutter" style="width: 1.89%; border-bottom: none; font-size: 2pt; padding-top: 3.75pt; padding-bottom: 4.75pt;">&#8203;</td><td style="width: 6.47%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3.75pt; padding-bottom: 4.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 7.18pt; text-align: left;"><font style="padding-left: 3.33pt; border-bottom: 3pt double #000000; min-width: 13.33pt;">&#8212;</font></div></td><td class="gutter" style="width: 1.89%; border-bottom: none; font-size: 2pt; padding-top: 3.75pt; padding-bottom: 4.75pt;">&#8203;</td><td class="gutter" style="width: 1.89%; border-bottom: none; font-size: 2pt; padding-top: 3.75pt; padding-bottom: 4.75pt;">&#8203;</td><td style="width: 6.03%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3.75pt; padding-bottom: 4.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 25.83pt;">(1,067</font><font style="min-width: 25.83pt;">)</font></div></td></tr><tr><td style="width: 70.09%; text-align: left; vertical-align: bottom; padding-top: 4.75pt; padding-bottom: 2.5pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.89%; border-bottom: none; font-size: 2pt; padding-top: 4.75pt; padding-bottom: 2.5pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.89%; border-bottom: none; font-size: 2pt; padding-top: 4.75pt; padding-bottom: 2.5pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.04%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.75pt; padding-bottom: 2.5pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.89%; border-bottom: none; font-size: 2pt; padding-top: 4.75pt; padding-bottom: 2.5pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.89%; border-bottom: none; font-size: 2pt; padding-top: 4.75pt; padding-bottom: 2.5pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.47%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.75pt; padding-bottom: 2.5pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.89%; border-bottom: none; font-size: 2pt; padding-top: 4.75pt; padding-bottom: 2.5pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.89%; border-bottom: none; font-size: 2pt; padding-top: 4.75pt; padding-bottom: 2.5pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.03%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.75pt; padding-bottom: 2.5pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 70.09%; text-align: left; vertical-align: bottom; padding-top: 2.5pt; padding-bottom: 2.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Net book amount<br></div></td><td class="gutter" style="width: 1.89%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td class="gutter" style="width: 1.89%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td style="width: 6.04%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.5pt; padding-bottom: 2.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 1.89%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td class="gutter" style="width: 1.89%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td style="width: 6.47%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.5pt; padding-bottom: 2.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 1.89%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td class="gutter" style="width: 1.89%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td style="width: 6.03%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.5pt; padding-bottom: 2.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">&#160;</div></td></tr><tr><td style="width: 70.09%; text-align: left; vertical-align: bottom; padding-top: 2.5pt; padding-bottom: 4.75pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">January&#160;1, 2019<font style="font-weight: normal; padding-left: 2.79pt;"></font></div></td><td class="gutter" style="width: 1.89%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 4.75pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.89%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 4.75pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.04%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.5pt; padding-bottom: 4.75pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 3.33pt; border-bottom: 3pt double #000000; min-width: 25.83pt;">5,399</font></div></td><td class="gutter" style="width: 1.89%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 4.75pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.89%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 4.75pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.47%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.5pt; padding-bottom: 4.75pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 7.18pt; text-align: left;"><font style="padding-left: 3.33pt; border-bottom: 3pt double #000000; min-width: 13.33pt;">24</font></div></td><td class="gutter" style="width: 1.89%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 4.75pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.89%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 4.75pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.03%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.5pt; padding-bottom: 4.75pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 3.33pt; border-bottom: 3pt double #000000; min-width: 25.83pt;">5,423</font></div></td></tr><tr><td style="width: 70.09%; text-align: left; vertical-align: bottom; padding-top: 4.75pt; padding-bottom: 6pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">December&#160;31, 2019<font style="font-weight: normal; padding-left: 0.21pt;"></font></div></td><td class="gutter" style="width: 1.89%; border-bottom: none; font-size: 2pt; padding-top: 4.75pt; padding-bottom: 6pt;">&#8203;</td><td class="gutter" style="width: 1.89%; border-bottom: none; font-size: 2pt; padding-top: 4.75pt; padding-bottom: 6pt;">&#8203;</td><td style="width: 6.04%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.75pt; padding-bottom: 6pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 3.33pt; border-bottom: 3pt double #000000; min-width: 25.83pt;">4,820</font></div></td><td class="gutter" style="width: 1.89%; border-bottom: none; font-size: 2pt; padding-top: 4.75pt; padding-bottom: 6pt;">&#8203;</td><td class="gutter" style="width: 1.89%; border-bottom: none; font-size: 2pt; padding-top: 4.75pt; padding-bottom: 6pt;">&#8203;</td><td style="width: 6.47%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.75pt; padding-bottom: 6pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 7.18pt; text-align: left;"><font style="padding-left: 3.33pt; border-bottom: 3pt double #000000; min-width: 13.33pt;">78</font></div></td><td class="gutter" style="width: 1.89%; border-bottom: none; font-size: 2pt; padding-top: 4.75pt; padding-bottom: 6pt;">&#8203;</td><td class="gutter" style="width: 1.89%; border-bottom: none; font-size: 2pt; padding-top: 4.75pt; padding-bottom: 6pt;">&#8203;</td><td style="width: 6.03%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.75pt; padding-bottom: 6pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 3.33pt; border-bottom: 3pt double #000000; min-width: 25.83pt;">4,898</font></div></td></tr></table><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: left;">Depreciation has been charged to the following categories in the income statement:</div><table cellspacing="0" cellpadding="0" class="fintab" style="margin-top: 11.25pt; border-collapse: collapse; width: 428pt; margin-left: 20pt;"><tr class="header"><td style="width: 70.09%; text-align: left; vertical-align: bottom; padding-top: 6pt; padding-bottom: 3.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">(in KUSD)</div></td><td class="gutter" style="width: 1.97%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 3.75pt;">&#8203;</td><td class="gutter" style="width: 1.97%; font-size: 2pt; padding-top: 6pt; padding-bottom: 3.75pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 11.02%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 3.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Year ended <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">December&#160;31, <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2019</div></td><td class="gutter" style="width: 1.97%; font-size: 2pt; padding-top: 6pt; padding-bottom: 3.75pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.97%; font-size: 2pt; padding-top: 6pt; padding-bottom: 3.75pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 11.02%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 3.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Year ended <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">December&#160;31, <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2018</div></td></tr><tr><td style="width: 70.09%; text-align: left; vertical-align: bottom; padding-top: 3.75pt; padding-bottom: 2.5pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Research and development expenses<font style="padding-left: 3.68pt;"></font></div></td><td class="gutter" style="width: 1.97%; border-bottom: none; font-size: 2pt; padding-top: 3.75pt; padding-bottom: 2.5pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.97%; border-bottom: none; font-size: 2pt; padding-top: 3.75pt; padding-bottom: 2.5pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 11.02%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3.75pt; padding-bottom: 2.5pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 12.33pt; text-align: left;"><font style="padding-left: 7.5pt;">837</font></div></td><td class="gutter" style="width: 1.97%; border-bottom: none; font-size: 2pt; padding-top: 3.75pt; padding-bottom: 2.5pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.97%; border-bottom: none; font-size: 2pt; padding-top: 3.75pt; padding-bottom: 2.5pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 11.02%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3.75pt; padding-bottom: 2.5pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 18.58pt; text-align: left;">&#8212;</div></td></tr><tr><td style="width: 70.09%; text-align: left; vertical-align: bottom; padding-top: 2.5pt; padding-bottom: 3.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">General and administrative expenses<font style="padding-left: 3.12pt;"></font></div></td><td class="gutter" style="width: 1.97%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 3.75pt;">&#8203;</td><td class="gutter" style="width: 1.97%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 3.75pt;">&#8203;</td><td style="width: 11.02%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 2.5pt; padding-bottom: 3.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 12.33pt; text-align: left;"><font style="padding-left: 7.5pt; border-bottom: 1pt solid #000000; min-width: 22.5pt;">227</font></div></td><td class="gutter" style="width: 1.97%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 3.75pt;">&#8203;</td><td class="gutter" style="width: 1.97%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 3.75pt;">&#8203;</td><td style="width: 11.02%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 2.5pt; padding-bottom: 3.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 18.58pt; text-align: left;"><font style="border-bottom: 1pt solid #000000; min-width: 10pt;">&#8212;</font></div></td></tr><tr><td style="width: 70.09%; text-align: left; vertical-align: bottom; padding-top: 3.75pt; padding-bottom: 6pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.97%; border-bottom: none; font-size: 2pt; padding-top: 3.75pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.97%; border-bottom: none; font-size: 2pt; padding-top: 3.75pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 11.02%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3.75pt; padding-bottom: 6pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 12.33pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 22.5pt;">1,064</font></div></td><td class="gutter" style="width: 1.97%; border-bottom: none; font-size: 2pt; padding-top: 3.75pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.97%; border-bottom: none; font-size: 2pt; padding-top: 3.75pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 11.02%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3.75pt; padding-bottom: 6pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 18.58pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 10pt;">&#8212;</font></div></td></tr></table><table cellspacing="0" cellpadding="0" class="fintab" style="margin-top: 6pt; border-collapse: collapse; width: 428pt; margin-left: 20pt;"><tr class="header"><td style="width: 70.09%; text-align: left; vertical-align: bottom; padding-top: 6pt; padding-bottom: 3.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">(in KUSD)<font style="font-weight: normal;"> </font></div></td><td class="gutter" style="width: 1.89%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 3.75pt;">&#8203;</td><td class="gutter" style="width: 1.89%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 3.75pt;">&#8203;</td><td style="width: 6.04%; text-align: center; vertical-align: bottom; padding-top: 6pt; padding-bottom: 3.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 1.89%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 3.75pt;">&#8203;</td><td class="gutter" style="width: 1.89%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 3.75pt;">&#8203;</td><td style="width: 6.47%; text-align: center; vertical-align: bottom; padding-top: 6pt; padding-bottom: 3.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 1.89%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 3.75pt;">&#8203;</td><td class="gutter" style="width: 1.89%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 3.75pt;">&#8203;</td><td style="width: 6.03%; text-align: center; vertical-align: bottom; padding-top: 6pt; padding-bottom: 3.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td></tr><tr class="header"><td style="width: 70.09%; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 3.75pt; padding-bottom: 3.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Lease liabilities </div></td><td class="gutter" style="width: 1.89%; font-size: 2pt; padding-top: 3.75pt; padding-bottom: 3.75pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.89%; font-size: 2pt; padding-top: 3.75pt; padding-bottom: 3.75pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 6.04%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 3.75pt; padding-bottom: 3.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Offices</div></td><td class="gutter" style="width: 1.89%; font-size: 2pt; padding-top: 3.75pt; padding-bottom: 3.75pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.89%; font-size: 2pt; padding-top: 3.75pt; padding-bottom: 3.75pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 6.47%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 3.75pt; padding-bottom: 3.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Vehicles</div></td><td class="gutter" style="width: 1.89%; font-size: 2pt; padding-top: 3.75pt; padding-bottom: 3.75pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.89%; font-size: 2pt; padding-top: 3.75pt; padding-bottom: 3.75pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 6.03%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 3.75pt; padding-bottom: 3.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Total</div></td></tr><tr><td style="width: 70.09%; text-align: left; vertical-align: bottom; padding-top: 3.75pt; padding-bottom: 2.5pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">January&#160;1, 2019<font style="padding-left: 2.24pt;"></font></div></td><td class="gutter" style="width: 1.89%; border-bottom: none; font-size: 2pt; padding-top: 3.75pt; padding-bottom: 2.5pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.89%; border-bottom: none; font-size: 2pt; padding-top: 3.75pt; padding-bottom: 2.5pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.04%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3.75pt; padding-bottom: 2.5pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 3.33pt;">5,399</font></div></td><td class="gutter" style="width: 1.89%; border-bottom: none; font-size: 2pt; padding-top: 3.75pt; padding-bottom: 2.5pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.89%; border-bottom: none; font-size: 2pt; padding-top: 3.75pt; padding-bottom: 2.5pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.47%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3.75pt; padding-bottom: 2.5pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.18pt; text-align: left;"><font style="padding-left: 3.33pt;">24</font></div></td><td class="gutter" style="width: 1.89%; border-bottom: none; font-size: 2pt; padding-top: 3.75pt; padding-bottom: 2.5pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.89%; border-bottom: none; font-size: 2pt; padding-top: 3.75pt; padding-bottom: 2.5pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.03%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3.75pt; padding-bottom: 2.5pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 3.33pt;">5,423</font></div></td></tr><tr><td style="width: 70.09%; text-align: left; vertical-align: bottom; padding-top: 2.5pt; padding-bottom: 2.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Additions<font style="padding-left: 3.06pt;"></font></div></td><td class="gutter" style="width: 1.89%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td class="gutter" style="width: 1.89%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td style="width: 6.04%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.5pt; padding-bottom: 2.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 10.83pt;">466</font></div></td><td class="gutter" style="width: 1.89%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td class="gutter" style="width: 1.89%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td style="width: 6.47%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.5pt; padding-bottom: 2.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.18pt; text-align: left;"><font style="padding-left: 3.33pt;">78</font></div></td><td class="gutter" style="width: 1.89%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td class="gutter" style="width: 1.89%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td style="width: 6.03%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.5pt; padding-bottom: 2.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 10.83pt;">544</font></div></td></tr><tr><td style="width: 70.09%; text-align: left; vertical-align: bottom; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Disposals<font style="padding-left: 3.63pt;"></font></div></td><td class="gutter" style="width: 1.89%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.89%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.04%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 15.83pt;">&#8212;</font></div></td><td class="gutter" style="width: 1.89%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.89%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.47%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.18pt; text-align: left;">(12)</div></td><td class="gutter" style="width: 1.89%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.89%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.03%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 12.5pt;">(12)</font></div></td></tr><tr><td style="width: 70.09%; text-align: left; vertical-align: bottom; padding-top: 2.5pt; padding-bottom: 2.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Cash outflow (including interest)<font style="padding-left: 2.55pt;"></font></div></td><td class="gutter" style="width: 1.89%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td class="gutter" style="width: 1.89%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td style="width: 6.04%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.5pt; padding-bottom: 2.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">(1,130)</div></td><td class="gutter" style="width: 1.89%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td class="gutter" style="width: 1.89%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td style="width: 6.47%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.5pt; padding-bottom: 2.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.18pt; text-align: left;">(13)</div></td><td class="gutter" style="width: 1.89%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td class="gutter" style="width: 1.89%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td style="width: 6.03%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.5pt; padding-bottom: 2.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;">(1,143)</div></td></tr><tr><td style="width: 70.09%; text-align: left; vertical-align: bottom; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Interest<font style="padding-left: 2.52pt;"></font></div></td><td class="gutter" style="width: 1.89%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.89%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.04%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 10.83pt;">140</font></div></td><td class="gutter" style="width: 1.89%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.89%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.47%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.18pt; text-align: left;"><font style="padding-left: 8.33pt;">1</font></div></td><td class="gutter" style="width: 1.89%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.89%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.03%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 10.83pt;">141</font></div></td></tr><tr><td style="width: 70.09%; text-align: left; vertical-align: bottom; padding-top: 2.5pt; padding-bottom: 3.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Exchange difference<font style="padding-left: 4.39pt;"></font></div></td><td class="gutter" style="width: 1.89%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 3.75pt;">&#8203;</td><td class="gutter" style="width: 1.89%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 3.75pt;">&#8203;</td><td style="width: 6.04%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.5pt; padding-bottom: 3.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 15.83pt; border-bottom: 1pt solid #000000; min-width: 25.83pt;">78</font></div></td><td class="gutter" style="width: 1.89%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 3.75pt;">&#8203;</td><td class="gutter" style="width: 1.89%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 3.75pt;">&#8203;</td><td style="width: 6.47%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.5pt; padding-bottom: 3.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.18pt; text-align: left;"><font style="padding-left: 3.33pt; border-bottom: 1pt solid #000000; min-width: 13.33pt;">&#8212;</font></div></td><td class="gutter" style="width: 1.89%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 3.75pt;">&#8203;</td><td class="gutter" style="width: 1.89%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 3.75pt;">&#8203;</td><td style="width: 6.03%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.5pt; padding-bottom: 3.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 15.83pt; border-bottom: 1pt solid #000000; min-width: 25.83pt;">78 </font></div></td></tr><tr><td style="width: 70.09%; text-align: left; vertical-align: bottom; padding-top: 3.75pt; padding-bottom: 3.75pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">December&#160;31, 2019<font style="font-weight: normal; padding-left: 0.21pt;"></font></div></td><td class="gutter" style="width: 1.89%; border-bottom: none; font-size: 2pt; padding-top: 3.75pt; padding-bottom: 3.75pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.89%; border-bottom: none; font-size: 2pt; padding-top: 3.75pt; padding-bottom: 3.75pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.04%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3.75pt; padding-bottom: 3.75pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 3.33pt; border-bottom: 1pt solid #000000; min-width: 25.83pt;">4,953</font></div></td><td class="gutter" style="width: 1.89%; border-bottom: none; font-size: 2pt; padding-top: 3.75pt; padding-bottom: 3.75pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.89%; border-bottom: none; font-size: 2pt; padding-top: 3.75pt; padding-bottom: 3.75pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.47%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3.75pt; padding-bottom: 3.75pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 7.18pt; text-align: left;"><font style="padding-left: 3.33pt; border-bottom: 1pt solid #000000; min-width: 13.33pt;">78</font></div></td><td class="gutter" style="width: 1.89%; border-bottom: none; font-size: 2pt; padding-top: 3.75pt; padding-bottom: 3.75pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.89%; border-bottom: none; font-size: 2pt; padding-top: 3.75pt; padding-bottom: 3.75pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.03%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3.75pt; padding-bottom: 3.75pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 3.33pt; border-bottom: 1pt solid #000000; min-width: 25.83pt;">5,031</font></div></td></tr><tr><td style="width: 70.09%; text-align: left; vertical-align: bottom; padding-top: 3.75pt; padding-bottom: 2.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.89%; border-bottom: none; font-size: 2pt; padding-top: 3.75pt; padding-bottom: 2.5pt;">&#8203;</td><td class="gutter" style="width: 1.89%; border-bottom: none; font-size: 2pt; padding-top: 3.75pt; padding-bottom: 2.5pt;">&#8203;</td><td style="width: 6.04%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3.75pt; padding-bottom: 2.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.89%; border-bottom: none; font-size: 2pt; padding-top: 3.75pt; padding-bottom: 2.5pt;">&#8203;</td><td class="gutter" style="width: 1.89%; border-bottom: none; font-size: 2pt; padding-top: 3.75pt; padding-bottom: 2.5pt;">&#8203;</td><td style="width: 6.47%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3.75pt; padding-bottom: 2.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.89%; border-bottom: none; font-size: 2pt; padding-top: 3.75pt; padding-bottom: 2.5pt;">&#8203;</td><td class="gutter" style="width: 1.89%; border-bottom: none; font-size: 2pt; padding-top: 3.75pt; padding-bottom: 2.5pt;">&#8203;</td><td style="width: 6.03%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3.75pt; padding-bottom: 2.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 70.09%; text-align: left; vertical-align: bottom; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Lease liabilities (short-term)<font style="padding-left: 2pt;"></font></div></td><td class="gutter" style="width: 1.89%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.89%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.04%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 3.7pt;">1,114</font></div></td><td class="gutter" style="width: 1.89%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.89%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.47%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.18pt; text-align: left;"><font style="padding-left: 3.33pt;">18</font></div></td><td class="gutter" style="width: 1.89%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.89%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.03%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 3.33pt;">1,132</font></div></td></tr><tr><td style="width: 70.09%; text-align: left; vertical-align: bottom; padding-top: 2.5pt; padding-bottom: 3.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Lease liabilities (long-term)<font style="padding-left: 4.21pt;"></font></div></td><td class="gutter" style="width: 1.89%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 3.75pt;">&#8203;</td><td class="gutter" style="width: 1.89%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 3.75pt;">&#8203;</td><td style="width: 6.04%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.5pt; padding-bottom: 3.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 3.33pt; border-bottom: 1pt solid #000000; min-width: 25.83pt;">3,839</font></div></td><td class="gutter" style="width: 1.89%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 3.75pt;">&#8203;</td><td class="gutter" style="width: 1.89%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 3.75pt;">&#8203;</td><td style="width: 6.47%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.5pt; padding-bottom: 3.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.18pt; text-align: left;"><font style="padding-left: 3.33pt; border-bottom: 1pt solid #000000; min-width: 13.33pt;">60</font></div></td><td class="gutter" style="width: 1.89%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 3.75pt;">&#8203;</td><td class="gutter" style="width: 1.89%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 3.75pt;">&#8203;</td><td style="width: 6.03%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.5pt; padding-bottom: 3.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 3.33pt; border-bottom: 1pt solid #000000; min-width: 25.83pt;">3,899</font></div></td></tr><tr><td style="width: 70.09%; text-align: left; vertical-align: bottom; padding-top: 3.75pt; padding-bottom: 6pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Total lease liabilities<font style="font-weight: normal; padding-left: 4.55pt;"></font></div></td><td class="gutter" style="width: 1.89%; border-bottom: none; font-size: 2pt; padding-top: 3.75pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.89%; border-bottom: none; font-size: 2pt; padding-top: 3.75pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.04%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3.75pt; padding-bottom: 6pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 3.33pt; border-bottom: 3pt double #000000; min-width: 25.83pt;">4,953</font></div></td><td class="gutter" style="width: 1.89%; border-bottom: none; font-size: 2pt; padding-top: 3.75pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.89%; border-bottom: none; font-size: 2pt; padding-top: 3.75pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.47%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3.75pt; padding-bottom: 6pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 7.18pt; text-align: left;"><font style="padding-left: 3.33pt; border-bottom: 3pt double #000000; min-width: 13.33pt;">78</font></div></td><td class="gutter" style="width: 1.89%; border-bottom: none; font-size: 2pt; padding-top: 3.75pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.89%; border-bottom: none; font-size: 2pt; padding-top: 3.75pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.03%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3.75pt; padding-bottom: 6pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 3.33pt; border-bottom: 3pt double #000000; min-width: 25.83pt;">5,031</font></div></td></tr></table></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 36pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">F-48<br></div></div></div>
<!--End Page 302-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 303-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 540pt;"><a name="nt10014672x1_drs_204-finnotes02_pg19"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="block-frill" style="width: 540pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: Arial, Helvetica, sans-serif; font-size: 9pt; font-weight: bold; margin-top: 6pt; text-align: center;">Confidential Treatment Requested by ADC Therapeutics SA Pursuant to 17 C.F.R. &#167; 200.83<br></div></div><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 36pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">ADC Therapeutics SA, Epalinges <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;"><div class="rule-full" style="height: 0pt; width: 100%; border-bottom: 1pt solid #000000; margin-top: 1pt; margin-bottom: 1pt; margin-left: auto; margin-right: auto;"> </div>NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS <font style="padding-left: 4pt;">(continued)</font><br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 7pt; margin-left: 20pt; text-align: left;">The lease payments are discounted using the interest rate implicit in the lease. If that rate cannot be readily determined, which is generally the case for leases in the Group, the lessee&#8217;s incremental borrowing rate is used, being the rate that the individual lessee would have to pay to borrow the funds necessary to obtain an asset of similar value to the right-of-use asset in a similar economic environment with similar terms, security and conditions.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: left;">Assumptions as to whether the Company is reasonably likely to exercise any extension or termination options have been made case-by-case, on the basis of the Company&#8217;s plans.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: left;">The Company does not recognize right-of-use assets for short-term and low value leases. The Company has no low value leases. Expense relating to short-term leases incurred during 2019 is recorded in the income statement (included in research and development expenses and general and administrative expenses) in an amount of KUSD 28.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8.5pt; margin-left: 20pt; text-align: left;">The amount payable in 2020 under short-term leases (with a life of under 12 months) is KUSD 241.</div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 12pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">18.<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; text-align: left;">Intangible assets</div></td></tr></table><table cellspacing="0" cellpadding="0" class="fintab" style="margin-top: 10.25pt; border-collapse: collapse; width: 428pt; margin-left: 20pt;"><tr class="header"><td style="width: 70.09%; text-align: left; vertical-align: bottom; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">(in KUSD)</div></td><td class="gutter" style="width: 1.8%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.8%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 6.75%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Licenses</div></td><td class="gutter" style="width: 1.8%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.8%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 7.13%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Software</div></td><td class="gutter" style="width: 1.8%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.8%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 5.26%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Total</div></td></tr><tr><td style="width: 70.09%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Cost<br></div></td><td class="gutter" style="width: 1.8%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.8%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.75%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.8%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.8%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.13%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.8%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.8%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.26%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 70.09%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">January&#160;1, 2018<font style="padding-left: 2.24pt;"></font></div></td><td class="gutter" style="width: 1.8%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.8%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 6.75%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.19pt; text-align: left;">6,009</div></td><td class="gutter" style="width: 1.8%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.8%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 7.13%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.76pt; text-align: left;"><font style="padding-left: 5pt;">44</font></div></td><td class="gutter" style="width: 1.8%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.8%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 5.26%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;">6,053</div></td></tr><tr><td style="width: 70.09%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Additions<font style="padding-left: 3.06pt;"></font></div></td><td class="gutter" style="width: 1.8%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.8%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.75%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.19pt; text-align: left;">1,481</div></td><td class="gutter" style="width: 1.8%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.8%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.13%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.76pt; text-align: left;"><font style="padding-left: 5pt;">45</font></div></td><td class="gutter" style="width: 1.8%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.8%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.26%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;">1,526</div></td></tr><tr><td style="width: 70.09%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Exchange difference<font style="padding-left: 4.39pt;"></font></div></td><td class="gutter" style="width: 1.8%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.8%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 6.75%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.19pt; text-align: left;"><font style="padding-left: 12.5pt; border-bottom: 1pt solid #000000; min-width: 22.5pt;">&#8212;</font></div></td><td class="gutter" style="width: 1.8%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.8%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 7.13%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.76pt; text-align: left;"><font style="padding-left: 6.67pt; border-bottom: 1pt solid #000000; min-width: 15pt;">(2</font><font style="min-width: 15pt;">)</font></div></td><td class="gutter" style="width: 1.8%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.8%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 5.26%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 14.17pt; border-bottom: 1pt solid #000000; min-width: 22.5pt;">(2</font><font style="min-width: 22.5pt;">)</font></div></td></tr><tr><td style="width: 70.09%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">December&#160;31, 2018<font style="font-weight: normal; padding-left: 0.21pt;"></font></div></td><td class="gutter" style="width: 1.8%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.8%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.75%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 3.19pt; text-align: left;">7,490</div></td><td class="gutter" style="width: 1.8%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.8%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.13%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 7.76pt; text-align: left;"><font style="padding-left: 5pt;">87</font></div></td><td class="gutter" style="width: 1.8%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.8%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.26%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: -0.01pt; text-align: left;">7,577</div></td></tr><tr><td style="width: 70.09%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Additions<font style="padding-left: 3.06pt;"></font></div></td><td class="gutter" style="width: 1.8%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.8%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 6.75%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.19pt; text-align: left;">1,731</div></td><td class="gutter" style="width: 1.8%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.8%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 7.13%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.76pt; text-align: left;"><font style="padding-left: 5pt;">59</font></div></td><td class="gutter" style="width: 1.8%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.8%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 5.26%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;">1,790</div></td></tr><tr><td style="width: 70.09%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Exchange difference<font style="padding-left: 4.39pt;"></font></div></td><td class="gutter" style="width: 1.8%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.8%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.75%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.19pt; text-align: left;"><font style="padding-left: 12.5pt; border-bottom: 1pt solid #000000; min-width: 22.5pt;">&#8212;</font></div></td><td class="gutter" style="width: 1.8%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.8%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.13%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.76pt; text-align: left;"><font style="padding-left: 10pt; border-bottom: 1pt solid #000000; min-width: 15pt;">1</font></div></td><td class="gutter" style="width: 1.8%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.8%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.26%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 17.5pt; border-bottom: 1pt solid #000000; min-width: 22.5pt;">1 </font></div></td></tr><tr><td style="width: 70.09%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">December&#160;31, 2019<font style="font-weight: normal; padding-left: 0.21pt;"></font></div></td><td class="gutter" style="width: 1.8%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.8%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 6.75%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 3.19pt; text-align: left;"><font style="border-bottom: 1pt solid #000000; min-width: 22.5pt;">9,221</font></div></td><td class="gutter" style="width: 1.8%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.8%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 7.13%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 7.76pt; text-align: left;"><font style="border-bottom: 1pt solid #000000; min-width: 15pt;">147</font></div></td><td class="gutter" style="width: 1.8%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.8%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 5.26%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="border-bottom: 1pt solid #000000; min-width: 22.5pt;">9,368</font></div></td></tr><tr><td style="width: 70.09%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Accumulated amortization<br></div></td><td class="gutter" style="width: 1.8%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.8%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.75%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.8%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.8%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.13%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.8%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.8%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.26%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 70.09%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">January&#160;1, 2018<font style="padding-left: 2.24pt;"></font></div></td><td class="gutter" style="width: 1.8%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.8%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 6.75%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.19pt; text-align: left;"><font style="padding-left: 4.17pt;">(626)</font></div></td><td class="gutter" style="width: 1.8%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.8%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 7.13%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.76pt; text-align: left;"><font style="padding-left: 1.67pt;">(26)</font></div></td><td class="gutter" style="width: 1.8%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.8%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 5.26%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 4.17pt;">(652)</font></div></td></tr><tr><td style="width: 70.09%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Amortization charge<font style="padding-left: 4.38pt;"></font></div></td><td class="gutter" style="width: 1.8%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.8%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.75%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.19pt; text-align: left;"><font style="padding-left: 12.5pt;">&#8212;</font></div></td><td class="gutter" style="width: 1.8%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.8%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.13%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.76pt; text-align: left;"><font style="padding-left: 1.67pt;">(25)</font></div></td><td class="gutter" style="width: 1.8%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.8%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.26%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 9.17pt;">(25)</font></div></td></tr><tr><td style="width: 70.09%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Impairment loss<font style="padding-left: 1.97pt;"></font></div></td><td class="gutter" style="width: 1.8%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.8%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 6.75%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.19pt; text-align: left;"><font style="padding-left: 4.17pt;">(227)</font></div></td><td class="gutter" style="width: 1.8%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.8%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 7.13%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.76pt; text-align: left;"><font style="padding-left: 5pt;">&#8212;</font></div></td><td class="gutter" style="width: 1.8%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.8%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 5.26%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 4.17pt;">(227)</font></div></td></tr><tr><td style="width: 70.09%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Exchange difference<font style="padding-left: 4.39pt;"></font></div></td><td class="gutter" style="width: 1.8%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.8%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.75%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.19pt; text-align: left;"><font style="padding-left: 12.5pt; border-bottom: 1pt solid #000000; min-width: 22.5pt;">&#8212;</font></div></td><td class="gutter" style="width: 1.8%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.8%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.13%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.76pt; text-align: left;"><font style="padding-left: 10pt; border-bottom: 1pt solid #000000; min-width: 15pt;">1</font></div></td><td class="gutter" style="width: 1.8%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.8%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.26%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 17.5pt; border-bottom: 1pt solid #000000; min-width: 22.5pt;">1 </font></div></td></tr><tr><td style="width: 70.09%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">December&#160;31, 2018<font style="font-weight: normal; padding-left: 0.21pt;"></font></div></td><td class="gutter" style="width: 1.8%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.8%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 6.75%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 3.19pt; text-align: left;"><font style="padding-left: 4.17pt; border-bottom: 1pt solid #000000; min-width: 22.5pt;">(853</font><font style="min-width: 22.5pt;">)</font></div></td><td class="gutter" style="width: 1.8%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.8%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 7.13%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 7.76pt; text-align: left;"><font style="padding-left: 1.67pt; border-bottom: 1pt solid #000000; min-width: 15pt;">(50</font><font style="min-width: 15pt;">)</font></div></td><td class="gutter" style="width: 1.8%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.8%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 5.26%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 4.17pt; border-bottom: 1pt solid #000000; min-width: 22.5pt;">(903</font><font style="min-width: 22.5pt;">)</font></div></td></tr><tr><td style="width: 70.09%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Amortization charge<font style="padding-left: 4.38pt;"></font></div></td><td class="gutter" style="width: 1.8%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.8%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.75%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.19pt; text-align: left;"><font style="padding-left: 12.5pt;">&#8212;</font></div></td><td class="gutter" style="width: 1.8%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.8%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.13%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.76pt; text-align: left;"><font style="padding-left: 1.67pt;">(30)</font></div></td><td class="gutter" style="width: 1.8%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.8%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.26%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 9.17pt;">(30)</font></div></td></tr><tr><td style="width: 70.09%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Exchange difference<font style="padding-left: 4.39pt;"></font></div></td><td class="gutter" style="width: 1.8%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.8%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 6.75%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.19pt; text-align: left;"><font style="padding-left: 12.5pt; border-bottom: 1pt solid #000000; min-width: 22.5pt;">&#8212;</font></div></td><td class="gutter" style="width: 1.8%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.8%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 7.13%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.76pt; text-align: left;"><font style="padding-left: 6.67pt; border-bottom: 1pt solid #000000; min-width: 15pt;">(1</font><font style="min-width: 15pt;">)</font></div></td><td class="gutter" style="width: 1.8%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.8%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 5.26%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 14.17pt; border-bottom: 1pt solid #000000; min-width: 22.5pt;">(1</font><font style="min-width: 22.5pt;">)</font></div></td></tr><tr><td style="width: 70.09%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">December&#160;31, 2019<font style="font-weight: normal; padding-left: 0.21pt;"></font></div></td><td class="gutter" style="width: 1.8%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.8%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.75%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 3.19pt; text-align: left;"><font style="padding-left: 4.17pt; border-bottom: 1pt solid #000000; min-width: 22.5pt;">(853</font><font style="min-width: 22.5pt;">)</font></div></td><td class="gutter" style="width: 1.8%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.8%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.13%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 7.76pt; text-align: left;"><font style="padding-left: 1.67pt; border-bottom: 1pt solid #000000; min-width: 15pt;">(81</font><font style="min-width: 15pt;">)</font></div></td><td class="gutter" style="width: 1.8%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.8%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.26%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 4.17pt; border-bottom: 1pt solid #000000; min-width: 22.5pt;">(934</font><font style="min-width: 22.5pt;">)</font></div></td></tr><tr><td style="width: 70.09%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.8%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.8%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 6.75%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.8%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.8%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 7.13%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.8%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.8%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 5.26%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 70.09%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Net book amount<br></div></td><td class="gutter" style="width: 1.8%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.8%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.75%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.8%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.8%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.13%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.8%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.8%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.26%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 70.09%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 5.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">December&#160;31, 2018<font style="font-weight: normal; padding-left: 0.21pt;"></font></div></td><td class="gutter" style="width: 1.8%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 5.25pt;">&#8203;</td><td class="gutter" style="width: 1.8%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 5.25pt;">&#8203;</td><td style="width: 6.75%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 5.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 3.19pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 22.5pt;">6,637</font></div></td><td class="gutter" style="width: 1.8%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 5.25pt;">&#8203;</td><td class="gutter" style="width: 1.8%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 5.25pt;">&#8203;</td><td style="width: 7.13%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 5.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 7.76pt; text-align: left;"><font style="padding-left: 5pt; border-bottom: 3pt double #000000; min-width: 15pt;">37</font></div></td><td class="gutter" style="width: 1.8%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 5.25pt;">&#8203;</td><td class="gutter" style="width: 1.8%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 5.25pt;">&#8203;</td><td style="width: 5.26%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 5.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 22.5pt;">6,674</font></div></td></tr><tr><td style="width: 70.09%; text-align: left; vertical-align: bottom; padding-top: 5.25pt; padding-bottom: 6pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">December&#160;31, 2019<font style="font-weight: normal; padding-left: 0.21pt;"></font></div></td><td class="gutter" style="width: 1.8%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.8%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.75%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 5.25pt; padding-bottom: 6pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 3.19pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 22.5pt;">8,368</font></div></td><td class="gutter" style="width: 1.8%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.8%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.13%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 5.25pt; padding-bottom: 6pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 7.76pt; text-align: left;"><font style="padding-left: 5pt; border-bottom: 3pt double #000000; min-width: 15pt;">66</font></div></td><td class="gutter" style="width: 1.8%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.8%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.26%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 5.25pt; padding-bottom: 6pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 22.5pt;">8,434</font></div></td></tr></table><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.5pt; margin-left: 20pt; text-align: left;">Amortization has been charged to the following categories in the income statement:</div><table cellspacing="0" cellpadding="0" class="fintab" style="margin-top: 11.25pt; border-collapse: collapse; width: 428pt; margin-left: 20pt;"><tr class="header"><td style="width: 70.09%; text-align: left; vertical-align: bottom; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">(in KUSD)</div></td><td class="gutter" style="width: 1.97%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.97%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 11.02%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Year ended <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">December&#160;31, <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2019</div></td><td class="gutter" style="width: 1.97%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.97%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 11.02%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Year ended <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">December&#160;31, <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2018</div></td></tr><tr><td style="width: 70.09%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Research and development expenses<font style="padding-left: 3.68pt;"></font></div></td><td class="gutter" style="width: 1.97%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.97%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 11.02%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 18.58pt; text-align: left;">14</div></td><td class="gutter" style="width: 1.97%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.97%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 11.02%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 18.58pt; text-align: left;">17</div></td></tr><tr><td style="width: 70.09%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">General and administrative expenses<font style="padding-left: 3.12pt;"></font></div></td><td class="gutter" style="width: 1.97%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.97%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 11.02%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 18.58pt; text-align: left;"><font style="border-bottom: 1pt solid #000000; min-width: 10pt;">16</font></div></td><td class="gutter" style="width: 1.97%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.97%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 11.02%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 18.58pt; text-align: left;"><font style="padding-left: 5pt; border-bottom: 1pt solid #000000; min-width: 10pt;">8 </font></div></td></tr><tr><td style="width: 70.09%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.97%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.97%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 11.02%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 18.58pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 10pt;">30</font></div></td><td class="gutter" style="width: 1.97%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.97%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 11.02%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 18.58pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 10pt;">25</font></div></td></tr></table></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 36pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">F-49<br></div></div></div>
<!--End Page 303-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 304-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 540pt;"><a name="nt10014672x1_drs_204-finnotes02_pg20"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="block-frill" style="width: 540pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: Arial, Helvetica, sans-serif; font-size: 9pt; font-weight: bold; margin-top: 6pt; text-align: center;">Confidential Treatment Requested by ADC Therapeutics SA Pursuant to 17 C.F.R. &#167; 200.83<br></div></div><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 36pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">ADC Therapeutics SA, Epalinges <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;"><div class="rule-full" style="height: 0pt; width: 100%; border-bottom: 1pt solid #000000; margin-top: 1pt; margin-bottom: 1pt; margin-left: auto; margin-right: auto;"> </div>NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS <font style="padding-left: 4pt;">(continued)</font><br></div><div class="h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 7pt; margin-left: 20pt; text-align: left;"><u>Licenses</u></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: left;">Licenses are amortized over their useful lives, which are determined on the basis of the expected pattern of consumption of the expected future economic benefits embodied in the licenses and which therefore commence only once the necessary regulatory and marketing approval has been received for the product candidates to which they relate. To date, the Company has not received any regulatory and marketing approval for any of its product candidates. Consequently, the Company did not recognize any amortization expense of licenses.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: left;">The Company has capitalized certain payments for licenses, in accordance with its accounting policy note 3.5, &#8220;Intangible assets&#8221;. These licenses were acquired from six distinct third parties. The largest amount paid to any one party was KUSD 2,500 paid to Spirogen Ltd. in 2011 under a license and collaboration agreement, pursuant to which Spirogen Ltd. granted the Company access to its next-generation PBD-based warhead and linker technology. As a result of changes to the ownership of Spirogen Ltd. and of the applicable intellectual property rights, the agreement was subsequently amended and restated (with retroactive effect to September 2011) with MedImmune replacing Spirogen Ltd. as the licensor thereunder.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: left;">Under the terms of the agreement, MedImmune has granted the Company an exclusive, worldwide license under certain patent rights and related know-how to make, have made, use, sell, offer for sale and import product candidates in the field of human therapeutics and diagnostics that consist of (i)&#160;PBD-based molecules directly conjugated to an antibody (i.e., ADCs with a PBD-based warhead) that specifically bind to up to 11 approved targets (&#8220;ADC Targets&#8221;), and (ii)&#160;PBD-based molecules conjugated to a non-antibody (i.e., targeting-moiety conjugates with a PBD-based warhead) that specifically bind to up to ten approved targets (&#8220;XDC Targets&#8221;). As of December&#160;31, 2019, there are 11 approved ADC Targets subject to the license, including CD19 (the target of ADCT-402) and CD25 (the target of ADCT-301), and ten approved non-ADC Targets subject to the license.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: left;">Under the terms of the agreement, the Company has the right to grant sublicenses to affiliates and, subject to MedImmune&#8217;s approval (not to be unreasonably withheld), third parties. In addition, with respect to each licensed target, the Company has agreed to use commercially reasonable efforts to develop and commercialize at least one product and submit an IND application with the FDA (or its equivalent in another jurisdiction) for one product within 48 months after formal designation of the target as an approved replacement target, which the Company has done with respect to CD19 and CD25 upon submitting the IND applications for ADCT-402 and ADCT-301, respectively.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: left;">The Company is required to make no further payments to Spirogen Ltd or Medimmune, beyond the upfront licensing fee of $2.5&#160;million paid in 2011, in consideration for the rights granted under the agreement.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8.5pt; margin-left: 20pt; text-align: left;">In 2019, the Company capitalized the following license payments:</div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 40pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">-<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">An amount of KUSD 1,000 relating to a license agreement with a third party to acquire an antibody to be used in pre-clinical formalization, clinical testing, manufacturing and commercialization was capitalized as intangible assets.</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 40pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">-<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">An amount of KUSD 500 relating to a license agreement with a third party to use their technology to generate antibody-drug conjugates for up to five antibodies was capitalized as intangible assets.</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 40pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">-<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">An amount of KUSD 231 relating to a license agreement with a third party to use their technology for the production of antibodies was capitalized as intangible assets.</div></td></tr></table><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8.5pt; margin-left: 20pt; text-align: left;">In 2018, the Company capitalized the following license payments:</div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 40pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">-<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">An amount of KUSD 231 relating to a license agreement with a third party to use their technology for the production of antibodies was capitalized as intangible assets.</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 40pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">-<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">An amount of KUSD 750 relating to a license agreement with a third party to use their technology to generate antibody-drug conjugates for up to five antibodies was capitalized as intangible assets.</div></td></tr></table></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 36pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">F-50<br></div></div></div>
<!--End Page 304-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 305-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 540pt;"><a name="nt10014672x1_drs_204-finnotes02_pg21"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="block-frill" style="width: 540pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: Arial, Helvetica, sans-serif; font-size: 9pt; font-weight: bold; margin-top: 6pt; text-align: center;">Confidential Treatment Requested by ADC Therapeutics SA Pursuant to 17 C.F.R. &#167; 200.83<br></div></div><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 36pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">ADC Therapeutics SA, Epalinges <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;"><div class="rule-full" style="height: 0pt; width: 100%; border-bottom: 1pt solid #000000; margin-top: 1pt; margin-bottom: 1pt; margin-left: auto; margin-right: auto;"> </div>NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS <font style="padding-left: 4pt;">(continued)</font><br></div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 0pt; margin-left: 40pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">-<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">An amount of KUSD 250 relating to a license agreement with a third party to use their technology to generate antibody-drug conjugates for up to five antibodies was capitalized as intangible assets.</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 40pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">-<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">An amount of KUSD 250 relating to a license agreement with a third party to acquire an antibody to be used in pre-clinical formalization, clinical testing, manufacturing and commercialization was capitalized as intangible assets. </div></td></tr></table><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: left;">The Group performed an assessment of its licenses in the context of its annual impairment test. Given the stage of the Group's development activities, the Group performed the impairment test on the basis of a fair value model for the entire group using a market approach.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: left;">The group therefore performs their annual impairment tests on their entire portfolio of intangible assets, by deriving their fair value from an observable valuation for the entire group based on the latest rounds of external financing. The fair value of the intangible asset portfolio was derived by deducting the carrying value of its tangible assets, which consist primarily of cash and cash equivalents, from the Group valuation. This resulted in a derived fair value of its portfolio of intangibles that was multiple times the carrying value of its intangibles.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: left;">Each of the product candidates related to the capitalized intangible assets not yet available for use was additionally tested for impairment by assessing its probability of success. Assessments included reviews of the following indicators:</div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 40pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">-<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">Historical expenditure on clinical trials, future contractual commitments and internal budgets approved by the Board of Directors for ongoing and future trials;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 40pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">-<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">Consideration of the progress of clinical trials, including obtaining primary endpoint readout data, discussions with regulatory authorities for new trials and enrollment status for ongoing clinical trials;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 40pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">-<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">Consideration of market potential, supported where available by external market studies, and assessments of competitor products and product candidates.</div></td></tr></table><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: left;">If a candidate fails any of those indicators, the entire balance is written off. No impairment losses were recognized in 2019 (KUSD 227 in 2018).</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: left;">Management's estimate of the fair value is consistent with the approach taken in prior years and with external sources of information (level 3 assessment). </div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: left;">On April&#160;25, 2018, the Company announced the termination of one of its programs. Consequently, one license was terminated and an impairment charge of KUSD 227 (corresponding to the entire carrying amount of the capitalized license) was recognized and charged to research and development expenses in the income statement.</div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 12pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">19a.<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; text-align: left;">Financial instruments by class and by category</div></td></tr></table><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 7.5pt; margin-left: 20pt; text-align: left;">The accounting policies for financial instruments have been applied as indicated below:</div><table cellspacing="0" cellpadding="0" class="fintab" style="margin-top: 11.25pt; border-collapse: collapse; width: 428pt; margin-left: 20pt;"><tr class="header"><td style="width: 61.68%; text-align: left; vertical-align: bottom; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">(in KUSD)</div></td><td class="gutter" style="width: 2.09%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 2.09%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 3.74%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Note</div></td><td class="gutter" style="width: 2.09%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 2.09%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 11.02%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">December&#160;31, <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2019</div></td><td class="gutter" style="width: 2.09%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 2.09%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 11.02%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">December&#160;31, <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2018</div></td></tr><tr><td style="width: 61.68%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Financial assets - financial assets at amortized cost<br></div></td><td class="gutter" style="width: 2.09%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.09%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 3.74%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 2.09%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.09%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 11.02%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 2.09%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.09%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 11.02%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 61.68%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Cash and cash equivalents<font style="padding-left: 3.77pt;"></font></div></td><td class="gutter" style="width: 2.09%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.09%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 3.74%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 2.09%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.09%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 11.02%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.51pt; text-align: left;">115,551</div></td><td class="gutter" style="width: 2.09%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.09%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 11.02%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.33pt; text-align: left;">138,807</div></td></tr><tr><td style="width: 61.68%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Trade accounts receivable<font style="padding-left: 0.8pt;"></font></div></td><td class="gutter" style="width: 2.09%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.09%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 3.74%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.99pt; text-align: left;">13</div></td><td class="gutter" style="width: 2.09%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.09%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 11.02%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.51pt; text-align: left;"><font style="padding-left: 22.13pt;">&#8212;</font></div></td><td class="gutter" style="width: 2.09%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.09%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 11.02%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.33pt; text-align: left;"><font style="padding-left: 17.5pt;">192</font></div></td></tr><tr><td style="width: 61.68%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Other current assets (excluding prepaid expenses)<font style="padding-left: 3.27pt;"></font></div></td><td class="gutter" style="width: 2.09%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.09%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 3.74%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.99pt; text-align: left;">14</div></td><td class="gutter" style="width: 2.09%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.09%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 11.02%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.51pt; text-align: left;"><font style="padding-left: 9.63pt;">2,840</font></div></td><td class="gutter" style="width: 2.09%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.09%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 11.02%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.33pt; text-align: left;"><font style="padding-left: 10pt;">1,697</font></div></td></tr><tr><td style="width: 61.68%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Other long-term assets<font style="padding-left: 4.32pt;"></font></div></td><td class="gutter" style="width: 2.09%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.09%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 3.74%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 2.09%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.09%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 11.02%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.51pt; text-align: left;"><font style="padding-left: 17.13pt; border-bottom: 1pt solid #000000; min-width: 32.13pt;">368</font></div></td><td class="gutter" style="width: 2.09%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.09%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 11.02%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.33pt; text-align: left;"><font style="padding-left: 17.5pt; border-bottom: 1pt solid #000000; min-width: 32.5pt;">264 </font></div></td></tr><tr><td style="width: 61.68%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 6pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Total financial assets<font style="font-weight: normal; padding-left: 1.34pt;"></font></div></td><td class="gutter" style="width: 2.09%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt;">&#8203;</td><td class="gutter" style="width: 2.09%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt;">&#8203;</td><td style="width: 3.74%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 6pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 2.09%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt;">&#8203;</td><td class="gutter" style="width: 2.09%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt;">&#8203;</td><td style="width: 11.02%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 6pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 7.51pt; text-align: left;"><font style="padding-left: 0.18pt; border-bottom: 3pt double #000000; min-width: 32.13pt;">118,759</font></div></td><td class="gutter" style="width: 2.09%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt;">&#8203;</td><td class="gutter" style="width: 2.09%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt;">&#8203;</td><td style="width: 11.02%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 6pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 7.33pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 32.5pt;">140,960</font></div></td></tr></table></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 36pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">F-51<br></div></div></div>
<!--End Page 305-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 306-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 540pt;"><a name="nt10014672x1_drs_204-finnotes02_pg22"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="block-frill" style="width: 540pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: Arial, Helvetica, sans-serif; font-size: 9pt; font-weight: bold; margin-top: 6pt; text-align: center;">Confidential Treatment Requested by ADC Therapeutics SA Pursuant to 17 C.F.R. &#167; 200.83<br></div></div><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 36pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">ADC Therapeutics SA, Epalinges <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;"><div class="rule-full" style="height: 0pt; width: 100%; border-bottom: 1pt solid #000000; margin-top: 1pt; margin-bottom: 1pt; margin-left: auto; margin-right: auto;"> </div>NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS <font style="padding-left: 4pt;">(continued)</font><br></div><table cellspacing="0" cellpadding="0" class="fintab" style="border-collapse: collapse; width: 428pt; margin-left: 20pt;"><tr class="header"><td style="width: 61.68%; text-align: left; vertical-align: bottom; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">(in KUSD)</div></td><td class="gutter" style="width: 2.09%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 2.09%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 3.74%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Note</div></td><td class="gutter" style="width: 2.09%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 2.09%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 11.02%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">December&#160;31, <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2019</div></td><td class="gutter" style="width: 2.09%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 2.09%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 11.02%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">December&#160;31, <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2018</div></td></tr><tr><td style="width: 61.68%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Financial liabilities - financial liabilities at amortized cost<br></div></td><td class="gutter" style="width: 2.09%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.09%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 3.74%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 2.09%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.09%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 11.02%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 2.09%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.09%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 11.02%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 61.68%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Trade accounts payable<font style="padding-left: 0.78pt;"></font></div></td><td class="gutter" style="width: 2.09%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.09%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 3.74%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 2.09%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.09%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 11.02%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.82pt; text-align: left;"><font style="padding-left: 5pt;">3,329</font></div></td><td class="gutter" style="width: 2.09%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.09%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 11.02%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.33pt; text-align: left;"><font style="padding-left: 10pt;">6,750</font></div></td></tr><tr><td style="width: 61.68%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Accrued liabilities and other payables<font style="padding-left: 2.12pt;"></font></div></td><td class="gutter" style="width: 2.09%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.09%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 3.74%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.99pt; text-align: left;">21</div></td><td class="gutter" style="width: 2.09%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.09%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 11.02%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.82pt; text-align: left;">15,430</div></td><td class="gutter" style="width: 2.09%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.09%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 11.02%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.33pt; text-align: left;"><font style="padding-left: 5pt;">13,650</font></div></td></tr><tr><td style="width: 61.68%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Lease liabilities<font style="padding-left: 2.64pt;"></font></div></td><td class="gutter" style="width: 2.09%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 2.09%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 3.74%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.99pt; text-align: left;">17</div></td><td class="gutter" style="width: 2.09%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 2.09%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 11.02%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.82pt; text-align: left;"><font style="padding-left: 5pt; border-bottom: 1pt solid #000000; min-width: 27.5pt;">5,031</font></div></td><td class="gutter" style="width: 2.09%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 2.09%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 11.02%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.33pt; text-align: left;"><font style="padding-left: 22.5pt; border-bottom: 1pt solid #000000; min-width: 32.5pt;">&#8212; </font></div></td></tr><tr><td style="width: 61.68%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Total financial liabilities<font style="font-weight: normal; padding-left: 1.88pt;"></font></div></td><td class="gutter" style="width: 2.09%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.09%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 3.74%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 2.09%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.09%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 11.02%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 9.82pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 27.5pt;">23,790</font></div></td><td class="gutter" style="width: 2.09%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.09%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 11.02%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 7.33pt; text-align: left;"><font style="padding-left: 5pt; border-bottom: 3pt double #000000; min-width: 32.5pt;">20,400</font></div></td></tr><tr><td style="width: 61.68%; text-align: left; vertical-align: bottom; padding-top: 5.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 2.09%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.09%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 3.74%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 5.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 2.09%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.09%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 11.02%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 5.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 2.09%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.09%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 11.02%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 5.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 61.68%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 6pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Net financial position<font style="font-weight: normal; padding-left: 3.75pt;"></font></div></td><td class="gutter" style="width: 2.09%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.09%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 3.74%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 6pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 2.09%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.09%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 11.02%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 6pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 9.82pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 27.5pt;">94,969</font></div></td><td class="gutter" style="width: 2.09%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.09%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 11.02%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 6pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 7.33pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 32.5pt;">120,560</font></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 12pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">19b.<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; text-align: left;">Credit quality of financial assets</div></td></tr></table><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: left;">The credit quality of financial assets that are neither past due nor impaired is assessed below by reference to S&amp;P&#8217;s credit ratings (where available) or to historical information about counterparty default rates:</div><table cellspacing="0" cellpadding="0" class="fintab" style="margin-top: 5.25pt; border-collapse: collapse; width: 428pt; margin-left: 20pt;"><tr class="header"><td style="width: 72.9%; text-align: left; vertical-align: bottom; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">(in KUSD)</div></td><td class="gutter" style="width: 1.27%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.27%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 11.02%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">December&#160;31, <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2019</div></td><td class="gutter" style="width: 1.27%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.27%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 11.02%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">December&#160;31, <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2018</div></td></tr><tr><td style="width: 72.9%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Cash and cash equivalents<br></div></td><td class="gutter" style="width: 1.27%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.27%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 11.02%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.27%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.27%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 11.02%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 72.9%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">A+ UBS<font style="padding-left: 3.87pt;"></font></div></td><td class="gutter" style="width: 1.27%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.27%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 11.02%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.61pt; text-align: left;"><font style="padding-left: 4.45pt;">51,983</font></div></td><td class="gutter" style="width: 1.27%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.27%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 11.02%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.33pt; text-align: left;"><font style="padding-left: 5pt;">71,493</font></div></td></tr><tr><td style="width: 72.9%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">A+ Credit Suisse<font style="padding-left: 4.44pt;"></font></div></td><td class="gutter" style="width: 1.27%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.27%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 11.02%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.61pt; text-align: left;"><font style="padding-left: 4.45pt;">62,652</font></div></td><td class="gutter" style="width: 1.27%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.27%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 11.02%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.33pt; text-align: left;"><font style="padding-left: 5pt;">66,066</font></div></td></tr><tr><td style="width: 72.9%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">A+ JP Morgan Chase<font style="padding-left: 1.67pt;"></font></div></td><td class="gutter" style="width: 1.27%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.27%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 11.02%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.61pt; text-align: left;"><font style="padding-left: 16.95pt; border-bottom: 1pt solid #000000; min-width: 31.95pt;">916</font></div></td><td class="gutter" style="width: 1.27%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.27%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 11.02%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.33pt; text-align: left;"><font style="padding-left: 10pt; border-bottom: 1pt solid #000000; min-width: 32.5pt;">1,248 </font></div></td></tr><tr><td style="width: 72.9%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.27%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.27%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 11.02%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 7.61pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 31.95pt;">115,551</font></div></td><td class="gutter" style="width: 1.27%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.27%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 11.02%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 7.33pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 32.5pt;">138,807</font></div></td></tr></table><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: left;">Trade accounts receivable, other current assets (excluding prepaid expenses) and other long-term assets are fully performing, not past due and not impaired (see note 14, &#8220;Other current assets&#8221; and note 19a, &#8220;Financial instruments by class and by category&#8221;).</div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 12pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">20.<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; text-align: left;">Deferred income taxes and tax credit</div></td></tr></table><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 7pt; margin-left: 20pt; text-align: left;">Unrecognized temporary differences, unused tax losses and unused tax credits</div><table cellspacing="0" cellpadding="0" class="fintab" style="margin-top: 4.25pt; border-collapse: collapse; width: 428pt; margin-left: 20pt;"><tr class="header"><td style="width: 72.9%; text-align: left; vertical-align: bottom; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">(in KUSD)</div></td><td class="gutter" style="width: 1.27%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.27%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 11.02%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">December&#160;31, <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2019</div></td><td class="gutter" style="width: 1.27%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.27%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 11.02%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">December&#160;31, <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2018</div></td></tr><tr><td style="width: 72.9%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-indent: -10pt; text-align: left;">Deductible temporary differences, unused tax losses and unused tax credits for which no deferred tax assets have been recognized are attributable to the following:<br></div></td><td class="gutter" style="width: 1.27%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.27%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 11.02%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.27%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.27%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 11.02%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 72.9%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Taxes losses<font style="padding-left: 4.11pt;"></font></div></td><td class="gutter" style="width: 1.27%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.27%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 11.02%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.33pt; text-align: left;">437,013</div></td><td class="gutter" style="width: 1.27%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.27%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 11.02%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.33pt; text-align: left;">329,254</div></td></tr><tr><td style="width: 72.9%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Unused tax credit<font style="padding-left: 2.31pt;"></font></div></td><td class="gutter" style="width: 1.27%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.27%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 11.02%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.33pt; text-align: left;"><font style="padding-left: 5pt;">10,765</font></div></td><td class="gutter" style="width: 1.27%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.27%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 11.02%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.33pt; text-align: left;"><font style="padding-left: 10pt;">6,009</font></div></td></tr><tr><td style="width: 72.9%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Deductible temporary differences related to the retirement benefit plan<font style="padding-left: 0.37pt;"></font></div></td><td class="gutter" style="width: 1.27%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.27%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 11.02%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.33pt; text-align: left;"><font style="padding-left: 10pt;">2,684</font></div></td><td class="gutter" style="width: 1.27%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.27%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 11.02%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.33pt; text-align: left;"><font style="padding-left: 10pt;">1,386</font></div></td></tr><tr><td style="width: 72.9%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Deductible temporary differences related to IFRS 16<font style="padding-left: 4.22pt;"></font></div></td><td class="gutter" style="width: 1.27%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.27%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 11.02%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.33pt; text-align: left;"><font style="padding-left: 19.17pt;">(</font>39)</div></td><td class="gutter" style="width: 1.27%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.27%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 11.02%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.33pt; text-align: left;"><font style="padding-left: 22.5pt;">&#8212;</font></div></td></tr><tr><td style="width: 72.9%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Offset of recognized temporary differences related to intangible assets<font style="padding-left: 2.23pt;"></font></div></td><td class="gutter" style="width: 1.27%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.27%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 11.02%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.33pt; text-align: left;"><font style="padding-left: 6.67pt; border-bottom: 1pt solid #000000; min-width: 32.5pt;">(2,364</font><font style="min-width: 32.5pt;">)</font></div></td><td class="gutter" style="width: 1.27%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.27%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 11.02%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.33pt; text-align: left;"><font style="padding-left: 6.67pt; border-bottom: 1pt solid #000000; min-width: 32.5pt;">(2,364</font><font style="min-width: 32.5pt;">)</font></div></td></tr><tr><td style="width: 72.9%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Total<font style="font-weight: normal; padding-left: 2.64pt;"></font></div></td><td class="gutter" style="width: 1.27%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.27%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 11.02%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 7.33pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 32.5pt;">4</font><font style="border-bottom: 3pt double #000000; min-width: 32.5pt;">48,059</font></div></td><td class="gutter" style="width: 1.27%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.27%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 11.02%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 7.33pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 32.5pt;">334,285</font></div></td></tr></table><div class="h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 18pt; margin-left: 20pt; text-align: left;"><u>Tax loss carryforwards</u></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: left;">Potential deferred income tax assets from tax loss carryforwards exceed deferred tax liabilities. Deferred income tax assets from tax loss carryforwards are initially recognized to the extent of suitable deferred income tax liabilities, then to the extent that the realization of the related tax benefit through future taxable profits is probable. On this basis, the Company has decided not to recognize any deferred income tax assets at December&#160;31, 2019 or 2018. The amounts of deferred income tax assets that arise from sources other than tax loss carryforwards and the amounts of deferred income tax liabilities are insignificant in comparison to the unrecognized tax loss carryforwards.</div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 36pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">F-52<br></div></div></div>
<!--End Page 306-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 307-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 540pt;"><a name="nt10014672x1_drs_204-finnotes02_pg23"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="block-frill" style="width: 540pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: Arial, Helvetica, sans-serif; font-size: 9pt; font-weight: bold; margin-top: 6pt; text-align: center;">Confidential Treatment Requested by ADC Therapeutics SA Pursuant to 17 C.F.R. &#167; 200.83<br></div></div><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 36pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">ADC Therapeutics SA, Epalinges <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;"><div class="rule-full" style="height: 0pt; width: 100%; border-bottom: 1pt solid #000000; margin-top: 1pt; margin-bottom: 1pt; margin-left: auto; margin-right: auto;"> </div>NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS <font style="padding-left: 4pt;">(continued)</font><br></div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 7pt; margin-left: 20pt; text-align: left;">Tax losses not recognized and to be carried forward (in KUSD):</div><table cellspacing="0" cellpadding="0" class="fintab" style="margin-top: 4.25pt; border-collapse: collapse; width: 428pt; margin-left: 20pt;"><tr class="header"><td style="width: 72.9%; text-align: left; vertical-align: bottom; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Years of expiry</div></td><td class="gutter" style="width: 1.27%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.27%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 11.02%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">December&#160;31, <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2019</div></td><td class="gutter" style="width: 1.27%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.27%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 11.02%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">December&#160;31, <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2018</div></td></tr><tr><td style="width: 72.9%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">2019<font style="padding-left: 4.5pt;"></font></div></td><td class="gutter" style="width: 1.27%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.27%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 11.02%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.33pt; text-align: left;"><font style="padding-left: 22.5pt;">&#8212;</font></div></td><td class="gutter" style="width: 1.27%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.27%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 11.02%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.33pt; text-align: left;"><font style="padding-left: 10pt;">6,209</font></div></td></tr><tr><td style="width: 72.9%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">2020<font style="padding-left: 4.5pt;"></font></div></td><td class="gutter" style="width: 1.27%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.27%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 11.02%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.33pt; text-align: left;"><font style="padding-left: 5pt;">14,735</font></div></td><td class="gutter" style="width: 1.27%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.27%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 11.02%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.33pt; text-align: left;"><font style="padding-left: 5pt;">14,966</font></div></td></tr><tr><td style="width: 72.9%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">2021<font style="padding-left: 4.5pt;"></font></div></td><td class="gutter" style="width: 1.27%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.27%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 11.02%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.33pt; text-align: left;"><font style="padding-left: 5pt;">19,889</font></div></td><td class="gutter" style="width: 1.27%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.27%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 11.02%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.33pt; text-align: left;"><font style="padding-left: 5pt;">20,200</font></div></td></tr><tr><td style="width: 72.9%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">2022<font style="padding-left: 4.5pt;"></font></div></td><td class="gutter" style="width: 1.27%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.27%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 11.02%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.33pt; text-align: left;"><font style="padding-left: 5pt;">31,128</font></div></td><td class="gutter" style="width: 1.27%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.27%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 11.02%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.33pt; text-align: left;"><font style="padding-left: 5pt;">31,615</font></div></td></tr><tr><td style="width: 72.9%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">2023<font style="padding-left: 4.5pt;"></font></div></td><td class="gutter" style="width: 1.27%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.27%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 11.02%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.33pt; text-align: left;"><font style="padding-left: 5pt;">38,441</font></div></td><td class="gutter" style="width: 1.27%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.27%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 11.02%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.33pt; text-align: left;"><font style="padding-left: 5pt;">39,042</font></div></td></tr><tr><td style="width: 72.9%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Beyond 2024<font style="padding-left: 0.06pt;"></font></div></td><td class="gutter" style="width: 1.27%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.27%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 11.02%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.33pt; text-align: left;"><font style="border-bottom: 1pt solid #000000; min-width: 32.5pt;">332,820</font></div></td><td class="gutter" style="width: 1.27%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.27%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 11.02%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.33pt; text-align: left;"><font style="border-bottom: 1pt solid #000000; min-width: 32.5pt;">217,222</font></div></td></tr><tr><td style="width: 72.9%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.27%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.27%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 11.02%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 7.33pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 32.5pt;">437,013</font></div></td><td class="gutter" style="width: 1.27%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.27%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 11.02%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 7.33pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 32.5pt;">329,254</font></div></td></tr></table><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: left;">All of these carryforwards relate to the Company. In 2019, unused tax losses of KUSD 6,209 expired (2018: KUSD 1,727).</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: left;">Deferred income tax assets from USA R&amp;D tax credit carryforwards are recognized to the extent that the realization of the related tax benefit through future taxable profits is probable. On this basis, the Group has not recognized deferred tax assets related to the following tax credits carried forward:</div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 18pt; margin-left: 20pt; text-align: left;">R&amp;D USA tax credits carried forward (in KUSD):</div><table cellspacing="0" cellpadding="0" class="fintab" style="margin-top: 10.25pt; border-collapse: collapse; width: 428pt; margin-left: 20pt;"><tr class="header"><td style="width: 72.9%; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Years of expiry</div></td><td class="gutter" style="width: 1.27%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.27%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 11.02%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">December&#160;31, <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2019</div></td><td class="gutter" style="width: 1.27%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.27%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 11.02%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">December&#160;31, <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2018</div></td></tr><tr><td style="width: 72.9%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">2036<font style="padding-left: 4.5pt;"></font></div></td><td class="gutter" style="width: 1.27%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.27%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 11.02%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.83pt; text-align: left;"><font style="padding-left: 12.5pt;">783</font></div></td><td class="gutter" style="width: 1.27%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.27%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 11.02%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 12.33pt; text-align: left;"><font style="padding-left: 7.5pt;">783</font></div></td></tr><tr><td style="width: 72.9%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">2037<font style="padding-left: 4.5pt;"></font></div></td><td class="gutter" style="width: 1.27%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.27%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 11.02%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.83pt; text-align: left;"><font style="padding-left: 5pt;">1,839</font></div></td><td class="gutter" style="width: 1.27%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.27%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 11.02%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 12.33pt; text-align: left;">1,839</div></td></tr><tr><td style="width: 72.9%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">2038<font style="padding-left: 4.5pt;"></font></div></td><td class="gutter" style="width: 1.27%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.27%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 11.02%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.83pt; text-align: left;"><font style="padding-left: 5pt;">3,387</font></div></td><td class="gutter" style="width: 1.27%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.27%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 11.02%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 12.33pt; text-align: left;">3,387</div></td></tr><tr><td style="width: 72.9%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">2039<font style="padding-left: 4.5pt;"></font></div></td><td class="gutter" style="width: 1.27%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.27%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 11.02%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.83pt; text-align: left;"><font style="padding-left: 5pt; border-bottom: 1pt solid #000000; min-width: 27.5pt;">4,756</font></div></td><td class="gutter" style="width: 1.27%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.27%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 11.02%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 12.33pt; text-align: left;"><font style="padding-left: 12.5pt; border-bottom: 1pt solid #000000; min-width: 22.5pt;">&#8212; </font></div></td></tr><tr><td style="width: 72.9%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.27%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.27%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 11.02%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 9.83pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 27.5pt;">10,765</font></div></td><td class="gutter" style="width: 1.27%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.27%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 11.02%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 12.33pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 22.5pt;">6,009</font></div></td></tr></table><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: left;">An amount of KUSD 436 was utilized in 2019 (KUSD 310 in 2018), as per note 12 &#8220;Income tax expenses&#8221;.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 20pt; text-align: left;">These R&amp;D tax credits, which may be carried forward for up to 20&#160;years, relate entirely to ADCT America.</div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 12pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">21.<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; text-align: left;">Accrued liabilities and other payables</div></td></tr></table><table cellspacing="0" cellpadding="0" class="fintab" style="margin-top: 10.25pt; border-collapse: collapse; width: 428pt; margin-left: 20pt;"><tr class="header"><td style="width: 72.9%; text-align: left; vertical-align: bottom; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">(in KUSD)</div></td><td class="gutter" style="width: 1.27%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.27%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 11.02%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">December&#160;31, <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2019</div></td><td class="gutter" style="width: 1.27%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.27%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 11.02%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">December&#160;31, <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2018</div></td></tr><tr><td style="width: 72.9%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Payroll and social charges<font style="padding-left: 2.51pt;"></font></div></td><td class="gutter" style="width: 1.27%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.27%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 11.02%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.83pt; text-align: left;"><font style="padding-left: 5pt;">5,726</font></div></td><td class="gutter" style="width: 1.27%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.27%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 11.02%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.83pt; text-align: left;"><font style="padding-left: 5pt;">4,939</font></div></td></tr><tr><td style="width: 72.9%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Research and development costs<font style="padding-left: 1.78pt;"></font></div></td><td class="gutter" style="width: 1.27%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.27%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 11.02%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.83pt; text-align: left;"><font style="padding-left: 5pt;">8,922</font></div></td><td class="gutter" style="width: 1.27%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.27%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 11.02%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.83pt; text-align: left;"><font style="padding-left: 5pt;">8,124</font></div></td></tr><tr><td style="width: 72.9%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Other<font style="padding-left: 1.73pt;"></font></div></td><td class="gutter" style="width: 1.27%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.27%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 11.02%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.83pt; text-align: left;"><font style="padding-left: 12.5pt; border-bottom: 1pt solid #000000; min-width: 27.5pt;">782</font></div></td><td class="gutter" style="width: 1.27%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.27%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 11.02%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.83pt; text-align: left;"><font style="padding-left: 12.5pt; border-bottom: 1pt solid #000000; min-width: 27.5pt;">587 </font></div></td></tr><tr><td style="width: 72.9%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 6pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.27%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt;">&#8203;</td><td class="gutter" style="width: 1.27%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt;">&#8203;</td><td style="width: 11.02%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 6pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 9.83pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 27.5pt;">15,430</font></div></td><td class="gutter" style="width: 1.27%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt;">&#8203;</td><td class="gutter" style="width: 1.27%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt;">&#8203;</td><td style="width: 11.02%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 6pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 9.83pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 27.5pt;">13,650</font></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 12pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">22.<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; text-align: left;">Pension obligations</div></td></tr></table><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: left;">The Swiss pension plan is classified as a defined benefit plan under IFRS. Certain employees of the UK subsidiary are covered by local defined contribution plans. Pension costs for these plans are charged to the income statement when incurred.</div><div class="h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 18pt; margin-left: 20pt; text-align: left;"><u>Swiss pension plan</u></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: left;">The Company contracted with the Swiss Life Collective BVG Foundation based in Zurich for the provision of occupational benefits. All benefits in accordance with the regulations are reinsured in their entirety with Swiss Life SA within the framework of the corresponding contract. This pension solution fully reinsures the </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 36pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">F-53<br></div></div></div>
<!--End Page 307-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 308-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 540pt;"><a name="nt10014672x1_drs_204-finnotes02_pg24"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="block-frill" style="width: 540pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: Arial, Helvetica, sans-serif; font-size: 9pt; font-weight: bold; margin-top: 6pt; text-align: center;">Confidential Treatment Requested by ADC Therapeutics SA Pursuant to 17 C.F.R. &#167; 200.83<br></div></div><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 36pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">ADC Therapeutics SA, Epalinges <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;"><div class="rule-full" style="height: 0pt; width: 100%; border-bottom: 1pt solid #000000; margin-top: 1pt; margin-bottom: 1pt; margin-left: auto; margin-right: auto;"> </div>NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS <font style="padding-left: 4pt;">(continued)</font><br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 7pt; margin-left: 20pt; text-align: left;">risks of disability, death and longevity with Swiss Life. Swiss Life invests the vested pension capital and provides a 100% capital and interest guarantee. The pension plan is entitled to an annual bonus from Swiss Life comprising the effective savings, risk and cost results.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: left;">Although, as is the case with many Swiss pension plans, the amount of ultimate pension benefit is not defined, certain legal obligations of the plan create constructive obligations on the employer to pay further contributions to fund an eventual deficit; this results in the plan nevertheless being accounted for as a defined benefit plan.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: left;">In 2019, the guaranteed interest to be credited to employees' savings was 1% for mandatory retirement savings (2018: 1%) and 0.25% for supplementary retirement savings (2018: 0.25%). With regard to 2020 and subsequent years, while the rate for converting mandatory savings to an annuity remains fixed by statute at 6.8%, the rates for converting supplementary savings to an annuity at age 65 for male and 64 for female employees retiring in 2022 and onwards were reduced to 4.7120% (previously 4.9500% for 2021 and onwards) for male employees and to 4.7626% (previously 4.9954% for 2021 and onwards) for female employees. In the previous year, there had also been a reduction in such rates, for employees retiring in 2021 and onwards, to 4.9500% (previously 5.0980% for 2020 and onwards) for male employees and to 4.9954% (previously 5.0995% for 2020 and onwards) for female employees.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: left;">The Swiss defined benefit plan scheme is valued by independent actuaries every year using the projected unit credit method. The latest actuarial valuation was carried out as at December&#160;31, 2019.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8.5pt; margin-left: 20pt; text-align: left;">The net amount recognized on the balance sheet comprises:</div><table cellspacing="0" cellpadding="0" class="fintab" style="margin-top: 11.25pt; border-collapse: collapse; width: 428pt; margin-left: 20pt;"><tr class="header"><td style="width: 72.9%; text-align: left; vertical-align: bottom; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">(in KUSD)</div></td><td class="gutter" style="width: 1.27%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.27%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 11.02%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">December&#160;31, <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2019</div></td><td class="gutter" style="width: 1.27%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.27%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 11.02%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">December&#160;31, <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2018</div></td></tr><tr><td style="width: 72.9%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Present value of defined benefit obligation for funded plan<font style="padding-left: 3.49pt;"></font></div></td><td class="gutter" style="width: 1.27%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.27%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 11.02%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10.67pt; text-align: left;"><font style="padding-left: 3.33pt;">7,880</font></div></td><td class="gutter" style="width: 1.27%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.27%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 11.02%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10.67pt; text-align: left;"><font style="padding-left: 3.33pt;">4,372</font></div></td></tr><tr><td style="width: 72.9%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Fair value of plan assets<font style="padding-left: 4.55pt;"></font></div></td><td class="gutter" style="width: 1.27%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.27%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 11.02%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10.67pt; text-align: left;"><font style="border-bottom: 1pt solid #000000; min-width: 25.83pt;">(5,196</font><font style="min-width: 25.83pt;">)</font></div></td><td class="gutter" style="width: 1.27%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.27%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 11.02%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10.67pt; text-align: left;"><font style="border-bottom: 1pt solid #000000; min-width: 25.83pt;">(2,986</font><font style="min-width: 25.83pt;">)</font></div></td></tr><tr><td style="width: 72.9%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Deficit of funded plan: liability on the balance sheet<font style="font-weight: normal; padding-left: 2.91pt;"></font></div></td><td class="gutter" style="width: 1.27%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.27%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 11.02%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 10.67pt; text-align: left;"><font style="padding-left: 3.33pt; border-bottom: 3pt double #000000; min-width: 25.83pt;">2,684</font></div></td><td class="gutter" style="width: 1.27%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.27%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 11.02%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 10.67pt; text-align: left;"><font style="padding-left: 3.33pt; border-bottom: 3pt double #000000; min-width: 25.83pt;">1,386</font></div></td></tr></table><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.5pt; margin-left: 20pt; text-align: left;">The movement in the net defined benefit obligation over the year is as follows:</div><table cellspacing="0" cellpadding="0" class="fintab" style="margin-top: 11.25pt; border-collapse: collapse; width: 428pt; margin-left: 20pt;"><tr class="header"><td style="width: 61.68%; text-align: left; vertical-align: bottom; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">(in KUSD)</div></td><td class="gutter" style="width: 1.7%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.7%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 12.38%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Present value <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">of obligation</div></td><td class="gutter" style="width: 1.7%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.7%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 10.45%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Fair value of <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">plan assets</div></td><td class="gutter" style="width: 1.7%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.7%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 5.26%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Total</div></td></tr><tr><td style="width: 61.68%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">January&#160;1, 2018<font style="padding-left: 1.24pt;"></font></div></td><td class="gutter" style="width: 1.7%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.7%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 12.38%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 15.25pt; text-align: left;">3,070</div></td><td class="gutter" style="width: 1.7%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.7%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.45%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.45pt; text-align: left;">(1,994)</div></td><td class="gutter" style="width: 1.7%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.7%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.26%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;">1,076</div></td></tr><tr><td style="width: 61.68%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Defined benefit plan - pension costs:<br></div></td><td class="gutter" style="width: 1.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 12.38%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 10.45%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 5.26%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 61.68%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Current service cost<font style="padding-left: 4.88pt;"></font></div></td><td class="gutter" style="width: 1.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 12.38%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 15.25pt; text-align: left;"><font style="padding-left: 7.5pt;">527</font></div></td><td class="gutter" style="width: 1.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.45%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.45pt; text-align: left;"><font style="padding-left: 15.83pt;">&#8212;</font></div></td><td class="gutter" style="width: 1.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.26%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;"><font style="padding-left: 7.5pt;">527</font></div></td></tr><tr><td style="width: 61.68%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Interest cost / (income)<font style="padding-left: 1.55pt;"></font></div></td><td class="gutter" style="width: 1.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 12.38%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 15.25pt; text-align: left;"><font style="padding-left: 12.5pt; border-bottom: 1pt solid #000000; min-width: 22.5pt;">23</font></div></td><td class="gutter" style="width: 1.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 10.45%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.45pt; text-align: left;"><font style="padding-left: 12.5pt; border-bottom: 1pt solid #000000; min-width: 25.83pt;">(15</font><font style="min-width: 25.83pt;">)</font></div></td><td class="gutter" style="width: 1.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 5.26%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;"><font style="padding-left: 17.5pt; border-bottom: 1pt solid #000000; min-width: 22.5pt;">8 </font></div></td></tr><tr><td style="width: 61.68%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Defined benefit plan - pension costs<font style="font-weight: normal; padding-left: 1.56pt;"></font></div></td><td class="gutter" style="width: 1.7%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.7%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 12.38%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 15.25pt; text-align: left;"><font style="padding-left: 7.5pt; border-bottom: 3pt double #000000; min-width: 22.5pt;">550</font></div></td><td class="gutter" style="width: 1.7%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.7%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.45%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 9.45pt; text-align: left;"><font style="padding-left: 12.5pt; border-bottom: 3pt double #000000; min-width: 25.83pt;">(15</font><font style="min-width: 25.83pt;">)</font></div></td><td class="gutter" style="width: 1.7%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.7%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.26%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0.01pt; text-align: left;"><font style="padding-left: 7.5pt; border-bottom: 3pt double #000000; min-width: 22.5pt;">535 </font></div></td></tr><tr><td style="width: 61.68%; text-align: left; vertical-align: bottom; padding-top: 5.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Employee contributions<font style="padding-left: 4.85pt;"></font></div></td><td class="gutter" style="width: 1.7%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.7%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 12.38%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 5.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 15.25pt; text-align: left;"><font style="padding-left: 7.5pt;">208</font></div></td><td class="gutter" style="width: 1.7%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.7%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 10.45%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 5.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.45pt; text-align: left;"><font style="padding-left: 7.5pt;">(208)</font></div></td><td class="gutter" style="width: 1.7%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.7%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 5.26%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 5.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;"><font style="padding-left: 12.5pt;">&#8212;</font></div></td></tr><tr><td style="width: 61.68%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Employer contributions<font style="padding-left: 0.96pt;"></font></div></td><td class="gutter" style="width: 1.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 12.38%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 15.25pt; text-align: left;"><font style="padding-left: 12.5pt;">&#8212;</font></div></td><td class="gutter" style="width: 1.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.45%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.45pt; text-align: left;"><font style="padding-left: 7.5pt;">(416)</font></div></td><td class="gutter" style="width: 1.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.26%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;"><font style="padding-left: 4.17pt;">(416)</font></div></td></tr><tr><td style="width: 61.68%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Transfers from joiners' previous plans<font style="padding-left: 0.26pt;"></font></div></td><td class="gutter" style="width: 1.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 12.38%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 15.25pt; text-align: left;"><font style="padding-left: 7.5pt; border-bottom: 1pt solid #000000; min-width: 22.5pt;">382</font></div></td><td class="gutter" style="width: 1.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 10.45%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.45pt; text-align: left;"><font style="padding-left: 7.5pt; border-bottom: 1pt solid #000000; min-width: 25.83pt;">(382</font><font style="min-width: 25.83pt;">)</font></div></td><td class="gutter" style="width: 1.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 5.26%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;"><font style="padding-left: 12.5pt; border-bottom: 1pt solid #000000; min-width: 22.5pt;">&#8212; </font></div></td></tr><tr><td style="width: 61.68%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.7%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.7%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 12.38%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 15.25pt; text-align: left;"><font style="padding-left: 7.5pt; border-bottom: 3pt double #000000; min-width: 22.5pt;">590</font></div></td><td class="gutter" style="width: 1.7%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.7%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.45%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 9.45pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 25.83pt;">(1,006</font><font style="min-width: 25.83pt;">)</font></div></td><td class="gutter" style="width: 1.7%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.7%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.26%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0.01pt; text-align: left;"><font style="padding-left: 4.17pt; border-bottom: 3pt double #000000; min-width: 22.5pt;">(416</font><font style="min-width: 22.5pt;">)</font></div></td></tr><tr><td style="width: 61.68%; text-align: left; vertical-align: bottom; padding-top: 5.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Exchange differences<font style="padding-left: 4.5pt;"></font></div></td><td class="gutter" style="width: 1.7%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.7%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 12.38%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 5.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 15.25pt; text-align: left;"><font style="padding-left: 9.17pt;">(12)</font></div></td><td class="gutter" style="width: 1.7%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.7%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 10.45%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 5.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.45pt; text-align: left;"><font style="padding-left: 15.83pt;">10</font></div></td><td class="gutter" style="width: 1.7%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.7%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 5.26%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 5.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;"><font style="padding-left: 14.17pt;">(2)</font></div></td></tr><tr><td style="width: 61.68%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Remeasurements:<br></div></td><td class="gutter" style="width: 1.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 12.38%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.45%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.26%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 61.68%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Change in financial assumptions<font style="padding-left: 3.76pt;"></font></div></td><td class="gutter" style="width: 1.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 12.38%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 15.25pt; text-align: left;"><font style="padding-left: 9.17pt;">(99)</font></div></td><td class="gutter" style="width: 1.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 10.45%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.45pt; text-align: left;"><font style="padding-left: 15.83pt;">&#8212;</font></div></td><td class="gutter" style="width: 1.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 5.26%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;"><font style="padding-left: 9.17pt;">(99)</font></div></td></tr><tr><td style="width: 61.68%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Other actuarial losses<font style="padding-left: 3.77pt;"></font></div></td><td class="gutter" style="width: 1.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 12.38%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 15.25pt; text-align: left;"><font style="padding-left: 7.5pt;">295</font></div></td><td class="gutter" style="width: 1.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.45%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.45pt; text-align: left;"><font style="padding-left: 15.83pt;">&#8212;</font></div></td><td class="gutter" style="width: 1.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.26%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;"><font style="padding-left: 7.5pt;">295</font></div></td></tr><tr><td style="width: 61.68%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Plan asset losses<font style="padding-left: 3.76pt;"></font></div></td><td class="gutter" style="width: 1.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 12.38%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 15.25pt; text-align: left;"><font style="padding-left: 12.5pt;">&#8212;</font></div></td><td class="gutter" style="width: 1.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 10.45%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.45pt; text-align: left;"><font style="padding-left: 20.83pt;">5</font></div></td><td class="gutter" style="width: 1.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 5.26%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;"><font style="padding-left: 17.5pt;">5</font></div></td></tr><tr><td style="width: 61.68%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Exchange differences<font style="padding-left: 4.5pt;"></font></div></td><td class="gutter" style="width: 1.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 12.38%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 15.25pt; text-align: left;"><font style="padding-left: 9.17pt; border-bottom: 1pt solid #000000; min-width: 22.5pt;">(22</font><font style="min-width: 22.5pt;">)</font></div></td><td class="gutter" style="width: 1.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.45%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.45pt; text-align: left;"><font style="padding-left: 15.83pt; border-bottom: 1pt solid #000000; min-width: 25.83pt;">14</font></div></td><td class="gutter" style="width: 1.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.26%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;"><font style="padding-left: 14.17pt; border-bottom: 1pt solid #000000; min-width: 22.5pt;">(8</font><font style="min-width: 22.5pt;">)</font></div></td></tr><tr><td style="width: 61.68%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 5.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Remeasurements<font style="font-weight: normal; padding-left: 3.38pt;"></font></div></td><td class="gutter" style="width: 1.7%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt;">&#8203;</td><td class="gutter" style="width: 1.7%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt;">&#8203;</td><td style="width: 12.38%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 5.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 15.25pt; text-align: left;"><font style="padding-left: 7.5pt; border-bottom: 3pt double #000000; min-width: 22.5pt;">174</font></div></td><td class="gutter" style="width: 1.7%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt;">&#8203;</td><td class="gutter" style="width: 1.7%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt;">&#8203;</td><td style="width: 10.45%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 5.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 9.45pt; text-align: left;"><font style="padding-left: 15.83pt; border-bottom: 3pt double #000000; min-width: 25.83pt;">19</font></div></td><td class="gutter" style="width: 1.7%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt;">&#8203;</td><td class="gutter" style="width: 1.7%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt;">&#8203;</td><td style="width: 5.26%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 5.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0.01pt; text-align: left;"><font style="padding-left: 7.5pt; border-bottom: 3pt double #000000; min-width: 22.5pt;">193 </font></div></td></tr><tr><td style="width: 61.68%; text-align: left; vertical-align: bottom; padding-top: 5.25pt; padding-bottom: 6pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">December&#160;31, 2018<font style="font-weight: normal; padding-left: 4.21pt;"></font></div></td><td class="gutter" style="width: 1.7%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.7%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 12.38%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 5.25pt; padding-bottom: 6pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 15.25pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 22.5pt;">4,372</font></div></td><td class="gutter" style="width: 1.7%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.7%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.45%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 5.25pt; padding-bottom: 6pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 9.45pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 25.83pt;">(2,986</font><font style="min-width: 25.83pt;">)</font></div></td><td class="gutter" style="width: 1.7%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.7%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.26%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 5.25pt; padding-bottom: 6pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0.01pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 22.5pt;">1,386</font></div></td></tr></table></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 36pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">F-54<br></div></div></div>
<!--End Page 308-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 309-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 540pt;"><a name="nt10014672x1_drs_204-finnotes02_pg25"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="block-frill" style="width: 540pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: Arial, Helvetica, sans-serif; font-size: 9pt; font-weight: bold; margin-top: 6pt; text-align: center;">Confidential Treatment Requested by ADC Therapeutics SA Pursuant to 17 C.F.R. &#167; 200.83<br></div></div><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 36pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">ADC Therapeutics SA, Epalinges <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;"><div class="rule-full" style="height: 0pt; width: 100%; border-bottom: 1pt solid #000000; margin-top: 1pt; margin-bottom: 1pt; margin-left: auto; margin-right: auto;"> </div>NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS <font style="padding-left: 4pt;">(continued)</font><br></div><table cellspacing="0" cellpadding="0" class="fintab" style="border-collapse: collapse; width: 428pt; margin-left: 20pt;"><tr class="header"><td style="width: 61.68%; text-align: left; vertical-align: bottom; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">(in KUSD)</div></td><td class="gutter" style="width: 1.7%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.7%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 12.38%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Present value <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">of obligation</div></td><td class="gutter" style="width: 1.7%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.7%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 10.45%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Fair value of <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">plan assets</div></td><td class="gutter" style="width: 1.7%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.7%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 5.26%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Total</div></td></tr><tr><td style="width: 61.68%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Defined benefit plan - pension costs:<br></div></td><td class="gutter" style="width: 1.7%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.7%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 12.38%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.7%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.7%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.45%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.7%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.7%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.26%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 61.68%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Current service cost<font style="padding-left: 4.88pt;"></font></div></td><td class="gutter" style="width: 1.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 12.38%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 15.25pt; text-align: left;"><font style="padding-left: 7.5pt;">769</font></div></td><td class="gutter" style="width: 1.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 10.45%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.45pt; text-align: left;"><font style="padding-left: 15.83pt;">&#8212;</font></div></td><td class="gutter" style="width: 1.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 5.26%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;"><font style="padding-left: 7.5pt;">769</font></div></td></tr><tr><td style="width: 61.68%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Impact of plan changes<font style="padding-left: 0.99pt;"></font></div></td><td class="gutter" style="width: 1.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 12.38%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 15.25pt; text-align: left;"><font style="padding-left: 4.17pt;">(319)</font></div></td><td class="gutter" style="width: 1.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.45%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.45pt; text-align: left;"><font style="padding-left: 15.83pt;">&#8212;</font></div></td><td class="gutter" style="width: 1.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.26%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;"><font style="padding-left: 4.17pt;">(319)</font></div></td></tr><tr><td style="width: 61.68%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Interest cost / (income)<font style="padding-left: 1.55pt;"></font></div></td><td class="gutter" style="width: 1.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 12.38%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 15.25pt; text-align: left;"><font style="padding-left: 12.5pt; border-bottom: 1pt solid #000000; min-width: 22.5pt;">37</font></div></td><td class="gutter" style="width: 1.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 10.45%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.45pt; text-align: left;"><font style="padding-left: 12.5pt; border-bottom: 1pt solid #000000; min-width: 25.83pt;">(25</font><font style="min-width: 25.83pt;">)</font></div></td><td class="gutter" style="width: 1.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 5.26%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;"><font style="padding-left: 12.5pt; border-bottom: 1pt solid #000000; min-width: 22.5pt;">12 </font></div></td></tr><tr><td style="width: 61.68%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Defined benefit plan - pension costs<font style="font-weight: normal; padding-left: 1.56pt;"></font></div></td><td class="gutter" style="width: 1.7%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.7%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 12.38%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 15.25pt; text-align: left;"><font style="padding-left: 7.5pt; border-bottom: 3pt double #000000; min-width: 22.5pt;">487</font></div></td><td class="gutter" style="width: 1.7%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.7%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.45%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 9.45pt; text-align: left;"><font style="padding-left: 12.5pt; border-bottom: 3pt double #000000; min-width: 25.83pt;">(25</font><font style="min-width: 25.83pt;">)</font></div></td><td class="gutter" style="width: 1.7%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.7%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.26%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0.01pt; text-align: left;"><font style="padding-left: 7.5pt; border-bottom: 3pt double #000000; min-width: 22.5pt;">462 </font></div></td></tr><tr><td style="width: 61.68%; text-align: left; vertical-align: bottom; padding-top: 5.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Employee contributions<font style="padding-left: 4.85pt;"></font></div></td><td class="gutter" style="width: 1.7%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.7%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 12.38%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 5.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 15.25pt; text-align: left;"><font style="padding-left: 7.5pt;">257</font></div></td><td class="gutter" style="width: 1.7%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.7%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 10.45%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 5.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.45pt; text-align: left;"><font style="padding-left: 7.5pt;">(257)</font></div></td><td class="gutter" style="width: 1.7%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.7%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 5.26%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 5.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;"><font style="padding-left: 12.5pt;">&#8212;</font></div></td></tr><tr><td style="width: 61.68%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Employer contributions<font style="padding-left: 0.96pt;"></font></div></td><td class="gutter" style="width: 1.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 12.38%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 15.25pt; text-align: left;"><font style="padding-left: 12.5pt;">&#8212;</font></div></td><td class="gutter" style="width: 1.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.45%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.45pt; text-align: left;"><font style="padding-left: 7.5pt;">(515)</font></div></td><td class="gutter" style="width: 1.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.26%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;"><font style="padding-left: 4.17pt;">(515)</font></div></td></tr><tr><td style="width: 61.68%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Transfers from joiners' previous plans<font style="padding-left: 0.26pt;"></font></div></td><td class="gutter" style="width: 1.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 12.38%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 15.25pt; text-align: left;"><font style="border-bottom: 1pt solid #000000; min-width: 22.5pt;">1,302</font></div></td><td class="gutter" style="width: 1.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 10.45%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.45pt; text-align: left;"><font style="border-bottom: 1pt solid #000000; min-width: 25.83pt;">(1,302</font><font style="min-width: 25.83pt;">)</font></div></td><td class="gutter" style="width: 1.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 5.26%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;"><font style="padding-left: 12.5pt; border-bottom: 1pt solid #000000; min-width: 22.5pt;">&#8212; </font></div></td></tr><tr><td style="width: 61.68%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.7%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.7%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 12.38%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 15.25pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 22.5pt;">1,559</font></div></td><td class="gutter" style="width: 1.7%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.7%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.45%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 9.45pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 25.83pt;">(2,074</font><font style="min-width: 25.83pt;">)</font></div></td><td class="gutter" style="width: 1.7%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.7%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.26%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0.01pt; text-align: left;"><font style="padding-left: 4.17pt; border-bottom: 3pt double #000000; min-width: 22.5pt;">(515</font><font style="min-width: 22.5pt;">)</font></div></td></tr><tr><td style="width: 61.68%; text-align: left; vertical-align: bottom; padding-top: 5.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Exchange differences<font style="padding-left: 4.5pt;"></font></div></td><td class="gutter" style="width: 1.7%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.7%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 12.38%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 5.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 15.25pt; text-align: left;"><font style="padding-left: 12.5pt;">74</font></div></td><td class="gutter" style="width: 1.7%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.7%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 10.45%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 5.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.45pt; text-align: left;"><font style="padding-left: 12.5pt;">(69)</font></div></td><td class="gutter" style="width: 1.7%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.7%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 5.26%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 5.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;"><font style="padding-left: 17.5pt;">5</font></div></td></tr><tr><td style="width: 61.68%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Remeasurements:<br></div></td><td class="gutter" style="width: 1.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 12.38%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.45%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.26%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 61.68%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Change in financial assumptions<font style="padding-left: 3.76pt;"></font></div></td><td class="gutter" style="width: 1.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 12.38%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 15.25pt; text-align: left;"><font style="padding-left: 7.5pt;">686</font></div></td><td class="gutter" style="width: 1.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 10.45%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.45pt; text-align: left;"><font style="padding-left: 15.83pt;">&#8212;</font></div></td><td class="gutter" style="width: 1.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 5.26%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;"><font style="padding-left: 7.5pt;">686</font></div></td></tr><tr><td style="width: 61.68%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Other actuarial losses<font style="padding-left: 3.77pt;"></font></div></td><td class="gutter" style="width: 1.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 12.38%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 15.25pt; text-align: left;"><font style="padding-left: 7.5pt;">609</font></div></td><td class="gutter" style="width: 1.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.45%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.45pt; text-align: left;"><font style="padding-left: 15.83pt;">&#8212;</font></div></td><td class="gutter" style="width: 1.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.26%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;"><font style="padding-left: 7.5pt;">609</font></div></td></tr><tr><td style="width: 61.68%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Plan asset gains<font style="padding-left: 1.53pt;"></font></div></td><td class="gutter" style="width: 1.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 12.38%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 15.25pt; text-align: left;"><font style="padding-left: 12.5pt;">&#8212;</font></div></td><td class="gutter" style="width: 1.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 10.45%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.45pt; text-align: left;"><font style="padding-left: 17.5pt;">(2)</font></div></td><td class="gutter" style="width: 1.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 5.26%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;"><font style="padding-left: 14.17pt;">(2)</font></div></td></tr><tr><td style="width: 61.68%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Exchange differences<font style="padding-left: 4.5pt;"></font></div></td><td class="gutter" style="width: 1.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 12.38%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 15.25pt; text-align: left;"><font style="padding-left: 12.5pt; border-bottom: 1pt solid #000000; min-width: 22.5pt;">93</font></div></td><td class="gutter" style="width: 1.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.45%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.45pt; text-align: left;"><font style="padding-left: 12.5pt; border-bottom: 1pt solid #000000; min-width: 25.83pt;">(40</font><font style="min-width: 25.83pt;">)</font></div></td><td class="gutter" style="width: 1.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.26%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;"><font style="padding-left: 12.5pt; border-bottom: 1pt solid #000000; min-width: 22.5pt;">53 </font></div></td></tr><tr><td style="width: 61.68%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Remeasurements<font style="font-weight: normal; padding-left: 3.38pt;"></font></div></td><td class="gutter" style="width: 1.7%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.7%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 12.38%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 15.25pt; text-align: left;"><font style="border-bottom: 1pt solid #000000; min-width: 22.5pt;">1,388</font></div></td><td class="gutter" style="width: 1.7%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.7%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 10.45%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 9.45pt; text-align: left;"><font style="padding-left: 12.5pt; border-bottom: 1pt solid #000000; min-width: 25.83pt;">(42</font><font style="min-width: 25.83pt;">)</font></div></td><td class="gutter" style="width: 1.7%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.7%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 5.26%; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0.01pt; text-align: justify;"><font style="border-bottom: 1pt solid #000000; min-width: 22.5pt;">1,346 </font></div></td></tr><tr><td style="width: 61.68%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">December&#160;31, 2019<font style="font-weight: normal; padding-left: 4.21pt;"></font></div></td><td class="gutter" style="width: 1.7%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.7%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 12.38%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 15.25pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 22.5pt;">7,880</font></div></td><td class="gutter" style="width: 1.7%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.7%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.45%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 9.45pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 25.83pt;">(5,196</font><font style="min-width: 25.83pt;">)</font></div></td><td class="gutter" style="width: 1.7%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.7%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.26%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0.01pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 22.5pt;">2,684</font></div></td></tr></table><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: left;">The positive impact of plan changes in 2019 was due to the further decrease of conversion rates for the supplementary retirement savings.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: left;">The negative impact of changes in financial assumptions in 2019 was due principally to the net effect of the reductions in both the discount rate and the interest rate credited on savings used in calculating the present value of the obligation (see below).</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: left;">The other actuarial losses in 2019 were due to a variety of experience factors, including in particular the increase in 2019, after the service cost for 2019 had been determined, in the number of active employees covered by the pension plan.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: left;">The present value of the defined benefit obligation related to 22 active employees based in Switzerland (2018: 19 active employees).</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8.5pt; margin-left: 20pt; text-align: left;">The principal actuarial assumptions used for accounting purposes are as follows for all periods presented:</div><table cellspacing="0" cellpadding="0" class="fintab" style="margin-top: 11.25pt; border-collapse: collapse; width: 428pt; margin-left: 20pt;"><tr class="header"><td style="width: 72.9%; text-align: left; vertical-align: bottom; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 4.73%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 4.73%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 4.09%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2019</div></td><td class="gutter" style="width: 4.73%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 4.73%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 4.09%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2018</div></td></tr><tr><td style="width: 72.9%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Discount rate<font style="padding-left: 0.08pt;"></font></div></td><td class="gutter" style="width: 4.73%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 4.73%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 4.09%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">0.20%</div></td><td class="gutter" style="width: 4.73%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 4.73%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 4.09%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">0.85%</div></td></tr><tr><td style="width: 72.9%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Interest credited on savings accounts<font style="padding-left: 4.01pt;"></font></div></td><td class="gutter" style="width: 4.73%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 4.73%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 4.09%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">0.20%</div></td><td class="gutter" style="width: 4.73%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 4.73%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 4.09%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">1.00%</div></td></tr><tr><td style="width: 72.9%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Future salary increases<font style="padding-left: 1.22pt;"></font></div></td><td class="gutter" style="width: 4.73%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 4.73%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 4.09%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">1.50%</div></td><td class="gutter" style="width: 4.73%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 4.73%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 4.09%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">1.50%</div></td></tr><tr><td style="width: 72.9%; text-align: left; vertical-align: bottom; padding-top: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Future pension increases<font style="padding-left: 3.99pt;"></font></div></td><td class="gutter" style="width: 4.73%; border-bottom: none; font-size: 2pt; padding-top: 3pt;">&#8203;</td><td class="gutter" style="width: 4.73%; border-bottom: none; font-size: 2pt; padding-top: 3pt;">&#8203;</td><td style="width: 4.09%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">0.00%</div></td><td class="gutter" style="width: 4.73%; border-bottom: none; font-size: 2pt; padding-top: 3pt;">&#8203;</td><td class="gutter" style="width: 4.73%; border-bottom: none; font-size: 2pt; padding-top: 3pt;">&#8203;</td><td style="width: 4.09%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">0.00%</div></td></tr></table><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: left;">Assumptions regarding future mortality experience are set based on actuarial advice provided in accordance with published statistics and experience in each territory.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: left;">Mortality assumptions for Switzerland are based on the LPP 2015 mortality generational table. The average life expectancy in years after retirement of a pensioner retiring at age 65 (male) and 64 (female) on the balance sheet date is as follows:</div><table cellspacing="0" cellpadding="0" class="fintab" style="margin-top: 11.25pt; border-collapse: collapse; width: 428pt; margin-left: 20pt;"><tr class="header"><td style="width: 72.9%; text-align: left; vertical-align: bottom; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 4.15%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 4.15%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 5.26%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2019</div></td><td class="gutter" style="width: 4.15%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 4.15%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 5.26%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2018</div></td></tr><tr><td style="width: 72.9%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Male<font style="padding-left: 3.95pt;"></font></div></td><td class="gutter" style="width: 4.15%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 4.15%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.26%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">22.61</div></td><td class="gutter" style="width: 4.15%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 4.15%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.26%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">22.50</div></td></tr><tr><td style="width: 72.9%; text-align: left; vertical-align: bottom; padding-top: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Female<font style="padding-left: 0.07pt;"></font></div></td><td class="gutter" style="width: 4.15%; border-bottom: none; font-size: 2pt; padding-top: 3pt;">&#8203;</td><td class="gutter" style="width: 4.15%; border-bottom: none; font-size: 2pt; padding-top: 3pt;">&#8203;</td><td style="width: 5.26%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">25.64</div></td><td class="gutter" style="width: 4.15%; border-bottom: none; font-size: 2pt; padding-top: 3pt;">&#8203;</td><td class="gutter" style="width: 4.15%; border-bottom: none; font-size: 2pt; padding-top: 3pt;">&#8203;</td><td style="width: 5.26%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">25.53</div></td></tr></table></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 36pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">F-55<br></div></div></div>
<!--End Page 309-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 310-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 540pt;"><a name="nt10014672x1_drs_204-finnotes02_pg26"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="block-frill" style="width: 540pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: Arial, Helvetica, sans-serif; font-size: 9pt; font-weight: bold; margin-top: 6pt; text-align: center;">Confidential Treatment Requested by ADC Therapeutics SA Pursuant to 17 C.F.R. &#167; 200.83<br></div></div><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 36pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">ADC Therapeutics SA, Epalinges <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;"><div class="rule-full" style="height: 0pt; width: 100%; border-bottom: 1pt solid #000000; margin-top: 1pt; margin-bottom: 1pt; margin-left: auto; margin-right: auto;"> </div>NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS <font style="padding-left: 4pt;">(continued)</font><br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 7pt; margin-left: 20pt; text-align: left;">The sensitivity of the defined benefit obligation and of the service cost to changes in the weighted principal assumption is:</div><table cellspacing="0" cellpadding="0" class="fintab" style="margin-top: 11.25pt; border-collapse: collapse; width: 428pt; margin-left: 20pt;"><tr class="header"><td style="width: 53.27%; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">2019</div></td><td class="gutter" style="width: 1.25%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.25%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 9.14%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Increase in <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">assumption</div></td><td class="gutter" style="width: 1.25%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.25%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 9.13%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Impact on <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">defined <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">benefit <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">obligation <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">and service <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">cost</div></td><td class="gutter" style="width: 1.25%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.25%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 9.31%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Decrease in <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">assumption</div></td><td class="gutter" style="width: 1.25%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.25%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 9.13%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Impact on <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">defined <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">benefit <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">obligation <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">and service <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">cost</div></td></tr><tr><td style="width: 53.27%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Discount rate<font style="padding-left: 1.08pt;"></font></div></td><td class="gutter" style="width: 1.25%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.25%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.14%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10.8pt; text-align: left;">0.25%</div></td><td class="gutter" style="width: 1.25%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.25%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.13%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.13pt; text-align: left;">(5.40%)</div></td><td class="gutter" style="width: 1.25%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.25%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.31%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.5pt; text-align: left;">(0.25%)</div></td><td class="gutter" style="width: 1.25%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.25%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.13%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.13pt; text-align: left;"><font style="padding-left: 3.33pt;">5.90%</font></div></td></tr><tr><td style="width: 53.27%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Future salary increases<font style="padding-left: 2.22pt;"></font></div></td><td class="gutter" style="width: 1.25%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.25%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 9.14%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10.8pt; text-align: left;">0.50%</div></td><td class="gutter" style="width: 1.25%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.25%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 9.13%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.13pt; text-align: left;"><font style="padding-left: 3.33pt;">0.90%</font></div></td><td class="gutter" style="width: 1.25%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.25%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 9.31%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.5pt; text-align: left;">(0.50%)</div></td><td class="gutter" style="width: 1.25%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.25%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 9.13%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.13pt; text-align: left;">(0.90%)</div></td></tr><tr><td style="width: 53.27%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Interest credited on savings accounts<font style="padding-left: 0.01pt;"></font></div></td><td class="gutter" style="width: 1.25%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.25%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.14%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10.8pt; text-align: left;">0.50%</div></td><td class="gutter" style="width: 1.25%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.25%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.13%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.13pt; text-align: left;"><font style="padding-left: 3.33pt;">3.20%</font></div></td><td class="gutter" style="width: 1.25%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.25%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.31%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.5pt; text-align: left;">(0.50%)</div></td><td class="gutter" style="width: 1.25%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.25%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.13%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.13pt; text-align: left;">(3.00%)</div></td></tr><tr><td style="width: 53.27%; text-align: left; vertical-align: bottom; padding-top: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Future pension increases<font style="padding-left: 4.99pt;"></font></div></td><td class="gutter" style="width: 1.25%; border-bottom: none; font-size: 2pt; padding-top: 3pt;">&#8203;</td><td class="gutter" style="width: 1.25%; border-bottom: none; font-size: 2pt; padding-top: 3pt;">&#8203;</td><td style="width: 9.14%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10.8pt; text-align: left;">0.50%</div></td><td class="gutter" style="width: 1.25%; border-bottom: none; font-size: 2pt; padding-top: 3pt;">&#8203;</td><td class="gutter" style="width: 1.25%; border-bottom: none; font-size: 2pt; padding-top: 3pt;">&#8203;</td><td style="width: 9.13%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.13pt; text-align: left;"><font style="padding-left: 3.33pt;">7.00%</font></div></td><td class="gutter" style="width: 1.25%; border-bottom: none; font-size: 2pt; padding-top: 3pt;">&#8203;</td><td class="gutter" style="width: 1.25%; border-bottom: none; font-size: 2pt; padding-top: 3pt;">&#8203;</td><td style="width: 9.31%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.5pt; text-align: left;">(0.50%)</div></td><td class="gutter" style="width: 1.25%; border-bottom: none; font-size: 2pt; padding-top: 3pt;">&#8203;</td><td class="gutter" style="width: 1.25%; border-bottom: none; font-size: 2pt; padding-top: 3pt;">&#8203;</td><td style="width: 9.13%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.13pt; text-align: left;">(6.30%)</div></td></tr></table><table cellspacing="0" cellpadding="0" class="fintab" style="margin-top: 6pt; border-collapse: collapse; width: 428pt; margin-left: 20pt;"><tr class="header"><td style="width: 53.27%; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">2018</div></td><td class="gutter" style="width: 1.25%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.25%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 9.14%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Increase in <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">assumption</div></td><td class="gutter" style="width: 1.25%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.25%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 9.13%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Impact on <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">defined <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">benefit <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">obligation <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">and service <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">cost</div></td><td class="gutter" style="width: 1.25%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.25%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 9.31%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Decrease in <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">assumption</div></td><td class="gutter" style="width: 1.25%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.25%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 9.13%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Impact on <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">defined <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">benefit <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">obligation <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">and service <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">cost</div></td></tr><tr><td style="width: 53.27%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Discount rate<font style="padding-left: 1.08pt;"></font></div></td><td class="gutter" style="width: 1.25%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.25%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.14%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10.8pt; text-align: left;">0.25%</div></td><td class="gutter" style="width: 1.25%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.25%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.13%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.13pt; text-align: left;">(5.40%)</div></td><td class="gutter" style="width: 1.25%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.25%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.31%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.5pt; text-align: left;">(0.25%)</div></td><td class="gutter" style="width: 1.25%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.25%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.13%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.13pt; text-align: left;"><font style="padding-left: 3.33pt;">5.90%</font></div></td></tr><tr><td style="width: 53.27%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Future salary increases<font style="padding-left: 2.22pt;"></font></div></td><td class="gutter" style="width: 1.25%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.25%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 9.14%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10.8pt; text-align: left;">0.50%</div></td><td class="gutter" style="width: 1.25%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.25%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 9.13%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.13pt; text-align: left;"><font style="padding-left: 3.33pt;">1.00%</font></div></td><td class="gutter" style="width: 1.25%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.25%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 9.31%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.5pt; text-align: left;">(0.50%)</div></td><td class="gutter" style="width: 1.25%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.25%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 9.13%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.13pt; text-align: left;">(1.00%)</div></td></tr><tr><td style="width: 53.27%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Interest credited on savings accounts<font style="padding-left: 0.01pt;"></font></div></td><td class="gutter" style="width: 1.25%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.25%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.14%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10.8pt; text-align: left;">0.50%</div></td><td class="gutter" style="width: 1.25%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.25%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.13%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.13pt; text-align: left;"><font style="padding-left: 3.33pt;">3.20%</font></div></td><td class="gutter" style="width: 1.25%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.25%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.31%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.5pt; text-align: left;">(0.50%)</div></td><td class="gutter" style="width: 1.25%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.25%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.13%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.13pt; text-align: left;">(3.10%)</div></td></tr><tr><td style="width: 53.27%; text-align: left; vertical-align: bottom; padding-top: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Future pension increases<font style="padding-left: 4.99pt;"></font></div></td><td class="gutter" style="width: 1.25%; border-bottom: none; font-size: 2pt; padding-top: 3pt;">&#8203;</td><td class="gutter" style="width: 1.25%; border-bottom: none; font-size: 2pt; padding-top: 3pt;">&#8203;</td><td style="width: 9.14%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10.8pt; text-align: left;">0.50%</div></td><td class="gutter" style="width: 1.25%; border-bottom: none; font-size: 2pt; padding-top: 3pt;">&#8203;</td><td class="gutter" style="width: 1.25%; border-bottom: none; font-size: 2pt; padding-top: 3pt;">&#8203;</td><td style="width: 9.13%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.13pt; text-align: left;"><font style="padding-left: 3.33pt;">6.20%</font></div></td><td class="gutter" style="width: 1.25%; border-bottom: none; font-size: 2pt; padding-top: 3pt;">&#8203;</td><td class="gutter" style="width: 1.25%; border-bottom: none; font-size: 2pt; padding-top: 3pt;">&#8203;</td><td style="width: 9.31%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.5pt; text-align: left;">(0.50%)</div></td><td class="gutter" style="width: 1.25%; border-bottom: none; font-size: 2pt; padding-top: 3pt;">&#8203;</td><td class="gutter" style="width: 1.25%; border-bottom: none; font-size: 2pt; padding-top: 3pt;">&#8203;</td><td style="width: 9.13%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.13pt; text-align: left;">(5.60%)</div></td></tr></table><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: left;">The above sensitivity analyses are based on a change in an assumption while holding all other assumptions constant. In practice, this is unlikely to occur, and changes in some of the assumptions may be correlated. When calculating the sensitivity of the defined benefit obligation to significant actuarial assumptions the same method (present value of the defined benefit obligation calculated with the projected unit credit method at the end of the reporting period) has been applied as when calculating the pension liability recognized within the statement of financial position.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: left;">The methods and types of assumptions used in preparing the sensitivity analysis did not change compared to the prior period.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: left;">Expected employer contributions to the defined benefit plan for the year ending December&#160;31, 2020 amount to KUSD 598.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 20pt; text-align: left;">The weighted average duration of the defined benefit obligation is 22.7&#160;years (2018: 22.7&#160;years).</div><div class="h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 12pt; margin-left: 20pt; text-align: left;"><u>Asset-liability strategy</u></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: left;">The Swiss Life Collective BVG Foundation, to which the pension plan is affiliated, manages its funds in the interests of all members, with due attention to the priorities of liquidity, security and return. The Company&#8217;s pension plan benefits from the economies of scale and diversification of risk available through this affiliation.</div><div class="h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 12pt; margin-left: 20pt; text-align: left;"><u>Investments by asset class</u></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 7pt; margin-left: 20pt; text-align: left;">Investments by asset class in KUSD are as follows:</div><table cellspacing="0" cellpadding="0" class="fintab" style="margin-top: 11.25pt; border-collapse: collapse; width: 428pt; margin-left: 20pt;"><tr class="header"><td style="width: 72.9%; text-align: left; vertical-align: bottom; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 1.27%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.27%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 11.02%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">December&#160;31, <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2019</div></td><td class="gutter" style="width: 1.27%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.27%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 11.02%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">December&#160;31, <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2018</div></td></tr><tr><td style="width: 72.9%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Cash<font style="padding-left: 4.51pt;"></font></div></td><td class="gutter" style="width: 1.27%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.27%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 11.02%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 12.33pt; text-align: left;"><font style="padding-left: 7.5pt;">155</font></div></td><td class="gutter" style="width: 1.27%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.27%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 11.02%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 12.33pt; text-align: left;"><font style="padding-left: 12.5pt;">65</font></div></td></tr><tr><td style="width: 72.9%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Bonds<font style="padding-left: 3.95pt;"></font></div></td><td class="gutter" style="width: 1.27%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.27%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 11.02%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 12.33pt; text-align: left;">3,065</div></td><td class="gutter" style="width: 1.27%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.27%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 11.02%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 12.33pt; text-align: left;">1,919</div></td></tr><tr><td style="width: 72.9%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Shares<font style="padding-left: 2.85pt;"></font></div></td><td class="gutter" style="width: 1.27%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.27%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 11.02%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 12.33pt; text-align: left;"><font style="padding-left: 7.5pt;">329</font></div></td><td class="gutter" style="width: 1.27%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.27%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 11.02%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 12.33pt; text-align: left;"><font style="padding-left: 7.5pt;">147</font></div></td></tr><tr><td style="width: 72.9%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Real estates and mortgages<font style="padding-left: 3.44pt;"></font></div></td><td class="gutter" style="width: 1.27%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.27%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 11.02%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 12.33pt; text-align: left;">1,303</div></td><td class="gutter" style="width: 1.27%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.27%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 11.02%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 12.33pt; text-align: left;"><font style="padding-left: 7.5pt;">720</font></div></td></tr><tr><td style="width: 72.9%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Alternative investments<font style="padding-left: 3.42pt;"></font></div></td><td class="gutter" style="width: 1.27%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.27%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 11.02%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 12.33pt; text-align: left;"><font style="padding-left: 7.5pt; border-bottom: 1pt solid #000000; min-width: 22.5pt;">344</font></div></td><td class="gutter" style="width: 1.27%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.27%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 11.02%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 12.33pt; text-align: left;"><font style="padding-left: 7.5pt; border-bottom: 1pt solid #000000; min-width: 22.5pt;">135 </font></div></td></tr><tr><td style="width: 72.9%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 6pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.27%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt;">&#8203;</td><td class="gutter" style="width: 1.27%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt;">&#8203;</td><td style="width: 11.02%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 6pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 12.33pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 22.5pt;">5,196</font></div></td><td class="gutter" style="width: 1.27%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt;">&#8203;</td><td class="gutter" style="width: 1.27%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt;">&#8203;</td><td style="width: 11.02%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 6pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 12.33pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 22.5pt;">2,986</font></div></td></tr></table></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 36pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">F-56<br></div></div></div>
<!--End Page 310-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 311-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 540pt;"><a name="nt10014672x1_drs_204-finnotes02_pg27"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="block-frill" style="width: 540pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: Arial, Helvetica, sans-serif; font-size: 9pt; font-weight: bold; margin-top: 6pt; text-align: center;">Confidential Treatment Requested by ADC Therapeutics SA Pursuant to 17 C.F.R. &#167; 200.83<br></div></div><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 36pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">ADC Therapeutics SA, Epalinges <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;"><div class="rule-full" style="height: 0pt; width: 100%; border-bottom: 1pt solid #000000; margin-top: 1pt; margin-bottom: 1pt; margin-left: auto; margin-right: auto;"> </div>NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS <font style="padding-left: 4pt;">(continued)</font><br></div><div class="h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 7pt; margin-left: 20pt; text-align: left;"><u>Defined benefit plan reserves</u></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 7pt; margin-left: 20pt; text-align: left;">The movement in the defined benefit plan reserves (included in &#8220;Other reserves&#8221;) is as follows:</div><table cellspacing="0" cellpadding="0" class="fintab" style="margin-top: 11.25pt; border-collapse: collapse; width: 428pt; margin-left: 20pt;"><tr class="header"><td style="width: 72.9%; text-align: left; vertical-align: bottom; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">(in KUSD)</div></td><td class="gutter" style="width: 3.76%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 3.76%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 6.04%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2019</div></td><td class="gutter" style="width: 3.76%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 3.76%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 6.03%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2018</div></td></tr><tr><td style="width: 72.9%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">January 1<font style="padding-left: 0.07pt;"></font></div></td><td class="gutter" style="width: 3.76%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 3.76%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.04%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;">(1,043)</div></td><td class="gutter" style="width: 3.76%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 3.76%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.03%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 7.5pt;">(850)</font></div></td></tr><tr><td style="width: 72.9%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Remeasurements of defined benefit pension plan<font style="padding-left: 0.14pt;"></font></div></td><td class="gutter" style="width: 3.76%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 3.76%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 6.04%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="border-bottom: 1pt solid #000000; min-width: 25.83pt;">(1,346</font><font style="min-width: 25.83pt;">)</font></div></td><td class="gutter" style="width: 3.76%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 3.76%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 6.03%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 7.5pt; border-bottom: 1pt solid #000000; min-width: 25.83pt;">(193</font><font style="min-width: 25.83pt;">)</font></div></td></tr><tr><td style="width: 72.9%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">December 31<font style="font-weight: normal; padding-left: 3.04pt;"></font></div></td><td class="gutter" style="width: 3.76%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 3.76%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.04%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 25.83pt;">(2,389</font><font style="min-width: 25.83pt;">)</font></div></td><td class="gutter" style="width: 3.76%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 3.76%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.03%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 25.83pt;">(1,043</font><font style="min-width: 25.83pt;">)</font></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 12pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">23.<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; text-align: left;">Share-based compensation expense</div></td></tr></table><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: left;">Share data have been revised to give effect to the share split and share consolidation explained in note 2 (iv) &#8220;Share split&#8221; and in note 2 (v) &#8220;Share consolidation&#8221;.</div><div class="h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 12pt; margin-left: 20pt; text-align: left;"><u>Share Purchase Plan 2013</u></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: left;">The Board of Directors approved the &#8220;Share Purchase Plan 2013&#8221; in October 2012. The purpose of the plan was to allow participants the opportunity to buy shares from the Company.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: left;">Participants acquired 1,250,000 common shares in accordance with share purchase agreements executed on September&#160;19, 2013, at a purchase price determined by the board of directors. There is no contractual obligation on the part of the Company to buy back the shares issued. Participants paid the nominal value of the shares in cash and settled the balance between the purchase price and the nominal value in the form of a promissory note. These promissory notes bear interest, have a term of ten years and, give the Company the right of recourse. In accordance with IFRS, the Company has accounted for these share purchases as if the notes were non-recourse and the share purchases therefore, in substance, share options. To effect this, the Company has deemed the strike price to be equal to the purchase price plus accumulated interest up to the expected date of exercise and the life of the options to be equivalent to the period remaining until a likely Liquidity Event (see Incentive Plan 2014 below) and has offset the amount of outstanding promissory notes against share premium. The Company had the right for a period of time to repurchase the shares but, as it had not in the past demonstrated any practice of doing so and as those rights were cancelled as of December&#160;31, 2015, the plan has been accounted for since inception as equity-settled under IFRS 2.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: left;">The amount of promissory notes offset against share premium at December&#160;31, 2019 in respect of this plan is KUSD 2,150 (2018: KUSD 2,150). This amount excludes accumulated interest, as this expense has been recognized within the strike price in calculating the compensation expense.</div><div class="h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 12pt; margin-left: 20pt; text-align: left;"><u>Incentive Plan 2014</u></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: left;">Under the Incentive Plan dated May&#160;1, 2014, the Company may grant options to plan participants (certain employees and service providers working for the benefit of the Company at the time) entitling them to acquire upon the occurrence of a Liquidity Event a defined number of common shares at a defined strike price or an equivalent cash amount. A Liquidity Event is the first to occur of four possible events: the sale of the Company to a third party buyer, a merger of the Company with another entity, the sale of substantially all the Company's assets to a third party buyer or an initial public offering of the Company's shares. The strike price was set by the Company at the fair market value of the underlying common shares on the date of grant, as determined by the Company. The awards for senior employees vest 25% annually from date of grant, over a four-year period. In the event that a Liquidity Event takes place before the end of a plan participant&#8217;s vesting period, all of the awards granted to that plan participant vest as of the date of the Liquidity Event. In addition, the Company has granted junior employees share option awards effective January&#160;1, 2017, 2018 and 2019 which vest 100% on the occurrence of a Liquidity Event. Fair value of the awards is measured at each reporting date using an adjusted form of the Black-Scholes option pricing model, taking into account the terms and conditions upon which the awards were granted. The contractual term of each award granted is ten years.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: left;">The Company will be required to settle the awards under the Incentive Plan 2014 upon the occurrence of a Liquidity Event. The Company has made a significant investment in preparing itself for an IPO, including </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 36pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">F-57<br></div></div></div>
<!--End Page 311-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 312-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 540pt;"><a name="nt10014672x1_drs_204-finnotes02_pg28"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="block-frill" style="width: 540pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: Arial, Helvetica, sans-serif; font-size: 9pt; font-weight: bold; margin-top: 6pt; text-align: center;">Confidential Treatment Requested by ADC Therapeutics SA Pursuant to 17 C.F.R. &#167; 200.83<br></div></div><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 36pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">ADC Therapeutics SA, Epalinges <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;"><div class="rule-full" style="height: 0pt; width: 100%; border-bottom: 1pt solid #000000; margin-top: 1pt; margin-bottom: 1pt; margin-left: auto; margin-right: auto;"> </div>NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS <font style="padding-left: 4pt;">(continued)</font><br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 7pt; margin-left: 20pt; text-align: left;">legal, accounting and organizational matters. In the event of an IPO, the plan will be settled in shares rather than in cash. Therefore, the plan has been accounted for as equity-settled under IFRS 2.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: left;">For the awards that vest 25% annually from the date of grant, the Company annually takes a charge for the vested portion of award grants and for partially earned but non-vested portions of award grants. This results in a front-loaded charge to the income statement. For non-vested awards, the Company annually takes a pro rata charge to the income statement based on the expected date of an initial public offering. In all cases, the charge to the income statement results in a corresponding credit being booked to &#8220;Other reserves&#8221; within equity.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: left;">The cumulative amount credited to &#8220;Other reserves&#8221; at December&#160;31, 2019 in respect of the Incentive Plan 2014 is KUSD 2,308 (2018: KUSD 1,871). The expense recognized for services received during the year is KUSD 437 (2018: KUSD 108).</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: left;">Movements in the number of awards outstanding and their related weighted average strike prices are as follows:</div><table cellspacing="0" cellpadding="0" class="fintab" style="margin-top: 11.25pt; border-collapse: collapse; width: 428pt; margin-left: 20pt;"><tr class="header"><td style="width: 50.47%; text-align: left; vertical-align: bottom; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 1.95%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.95%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td colspan="4" style="width: 20.86%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2019</div></td><td class="gutter" style="width: 1.95%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.95%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td colspan="4" style="width: 20.86%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2018</div></td></tr><tr class="header"><td style="width: 50.47%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 1.95%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.95%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 7.61%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Average <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">strike <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">price in <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">USD <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">per share</div></td><td class="gutter" style="width: 1.95%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.95%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 9.35%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Number of <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">awards</div></td><td class="gutter" style="width: 1.95%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.95%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 7.61%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Average <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">strike <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">price in <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">USD <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">per share</div></td><td class="gutter" style="width: 1.95%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.95%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 9.34%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Number of <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">awards</div></td></tr><tr><td style="width: 50.47%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">At the beginning of the year<font style="padding-left: 1.88pt;"></font></div></td><td class="gutter" style="width: 1.95%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.95%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.61%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.54pt; text-align: left;">12.5</div></td><td class="gutter" style="width: 1.95%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.95%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.35%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;">1,982,375</div></td><td class="gutter" style="width: 1.95%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.95%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.61%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.54pt; text-align: left;"><font style="padding-left: 0.37pt;">11.8</font></div></td><td class="gutter" style="width: 1.95%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.95%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.34%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;">1,882,125</div></td></tr><tr><td style="width: 50.47%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Granted<font style="padding-left: 1.29pt;"></font></div></td><td class="gutter" style="width: 1.95%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.95%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 7.61%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.54pt; text-align: left;">26.6</div></td><td class="gutter" style="width: 1.95%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.95%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 9.35%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 7.5pt;">226,666</font></div></td><td class="gutter" style="width: 1.95%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.95%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 7.61%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.54pt; text-align: left;">25.9</div></td><td class="gutter" style="width: 1.95%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.95%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 9.34%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 7.5pt;">100,250</font></div></td></tr><tr><td style="width: 50.47%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Forfeited<font style="padding-left: 1.85pt;"></font></div></td><td class="gutter" style="width: 1.95%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.95%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.61%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.54pt; text-align: left;"><font style="padding-left: 5pt; border-bottom: 1pt solid #000000; min-width: 17.5pt;">9.8</font></div></td><td class="gutter" style="width: 1.95%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.95%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.35%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 4.17pt; border-bottom: 1pt solid #000000; min-width: 40pt;">(</font><font style="border-bottom: 1pt solid #000000; min-width: 40pt;">183,509</font><font style="border-bottom: 1pt solid #000000; min-width: 40pt;"></font><font style="min-width: 40pt;">)</font></div></td><td class="gutter" style="width: 1.95%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.95%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.61%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.54pt; text-align: left;"><font style="padding-left: 7.5pt; border-bottom: 1pt solid #000000; min-width: 17.5pt;">&#8212;</font></div></td><td class="gutter" style="width: 1.95%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.95%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.34%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 30pt; border-bottom: 1pt solid #000000; min-width: 40pt;">&#8212; </font></div></td></tr><tr><td style="width: 50.47%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 6pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">At the end of the year<font style="font-weight: normal; padding-left: 1.89pt;"></font></div></td><td class="gutter" style="width: 1.95%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt;">&#8203;</td><td class="gutter" style="width: 1.95%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt;">&#8203;</td><td style="width: 7.61%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 6pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 7.54pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 17.5pt;">1</font><font style="border-bottom: 3pt double #000000; min-width: 17.5pt;">4.3</font></div></td><td class="gutter" style="width: 1.95%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt;">&#8203;</td><td class="gutter" style="width: 1.95%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt;">&#8203;</td><td style="width: 9.35%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 6pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 40pt;">2,</font><font style="border-bottom: 3pt double #000000; min-width: 40pt;">025,532</font></div></td><td class="gutter" style="width: 1.95%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt;">&#8203;</td><td class="gutter" style="width: 1.95%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt;">&#8203;</td><td style="width: 7.61%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 6pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 7.54pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 17.5pt;">1</font><font style="border-bottom: 3pt double #000000; min-width: 17.5pt;">2.5</font></div></td><td class="gutter" style="width: 1.95%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt;">&#8203;</td><td class="gutter" style="width: 1.95%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt;">&#8203;</td><td style="width: 9.34%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 6pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 40pt;">1,982,375</font></div></td></tr></table><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: left;">Out of the total outstanding awards of 2,025,532 common shares as at December&#160;31, 2019 (2018: 1,982,375 awards), no awards are exercisable as there has been no Liquidity Event. No awards have expired.</div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 36pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">F-58<br></div></div></div>
<!--End Page 312-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 313-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 540pt;"><a name="nt10014672x1_drs_204-finnotes02_pg29"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="block-frill" style="width: 540pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: Arial, Helvetica, sans-serif; font-size: 9pt; font-weight: bold; margin-top: 6pt; text-align: center;">Confidential Treatment Requested by ADC Therapeutics SA Pursuant to 17 C.F.R. &#167; 200.83<br></div></div><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 36pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">ADC Therapeutics SA, Epalinges <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;"><div class="rule-full" style="height: 0pt; width: 100%; border-bottom: 1pt solid #000000; margin-top: 1pt; margin-bottom: 1pt; margin-left: auto; margin-right: auto;"> </div>NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS <font style="padding-left: 4pt;">(continued)</font><br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 7pt; margin-left: 20pt; text-align: left;">Awards outstanding at the end of the year have the following expiry date and strike prices:</div><table cellspacing="0" cellpadding="0" class="fintab" style="margin-top: 11.25pt; border-collapse: collapse; width: 428pt; margin-left: 20pt;"><tr class="header"><td style="width: 50.47%; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Grant date</div></td><td class="gutter" style="width: 1.63%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.63%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 9.55%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Expiry date</div></td><td class="gutter" style="width: 1.63%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.63%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 4.88%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Strike <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">price <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">in <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">USD</div></td><td class="gutter" style="width: 1.63%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.63%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 11.02%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Awards <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">December&#160;31, <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2019</div></td><td class="gutter" style="width: 1.63%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.63%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 11.02%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Awards <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">December&#160;31, <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2018</div></td></tr><tr><td style="width: 50.47%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Feb - Sep 2014<font style="padding-left: 0.19pt;"></font></div></td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.55%; text-align: center; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">2024</div></td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 4.88%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.69pt; text-align: left;"><font style="padding-left: 5pt;">9.3</font></div></td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 11.02%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.57pt; text-align: left;"><font style="padding-left: 7.5pt;">602,375</font></div></td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 11.02%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.57pt; text-align: left;"><font style="padding-left: 7.5pt;">602,375</font></div></td></tr><tr><td style="width: 50.47%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Mar - Jul 2015<font style="padding-left: 1.86pt;"></font></div></td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 9.55%; text-align: center; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">2025</div></td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 4.88%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.69pt; text-align: left;"><font style="padding-left: 5pt;">9.3</font></div></td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 11.02%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.57pt; text-align: left;"><font style="padding-left: 7.5pt;">144,875</font></div></td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 11.02%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.57pt; text-align: left;"><font style="padding-left: 7.5pt;">144,875</font></div></td></tr><tr><td style="width: 50.47%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Oct - Nov 2015<font style="padding-left: 3.53pt;"></font></div></td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.55%; text-align: center; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">2025</div></td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 4.88%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.69pt; text-align: left;"><font style="padding-left: 0.37pt;">11.2</font></div></td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 11.02%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.57pt; text-align: left;"><font style="padding-left: 12.87pt;">11,875</font></div></td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 11.02%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.57pt; text-align: left;"><font style="padding-left: 12.87pt;">11,875</font></div></td></tr><tr><td style="width: 50.47%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Jan - Jul 2016<font style="padding-left: 0.19pt;"></font></div></td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 9.55%; text-align: center; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">2026</div></td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 4.88%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.69pt; text-align: left;"><font style="padding-left: 0.37pt;">11.2</font></div></td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 11.02%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.57pt; text-align: left;"><font style="padding-left: 7.5pt;">151,375</font></div></td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 11.02%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.57pt; text-align: left;"><font style="padding-left: 7.5pt;">151,375</font></div></td></tr><tr><td style="width: 50.47%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Jan - Oct 2017<font style="padding-left: 2.42pt;"></font></div></td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.55%; text-align: center; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">2027</div></td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 4.88%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.69pt; text-align: left;">13.4</div></td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 11.02%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.57pt; text-align: left;"><font style="padding-left: 7.5pt;">938,250</font></div></td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 11.02%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.57pt; text-align: left;"><font style="padding-left: 7.5pt;">938,250</font></div></td></tr><tr><td style="width: 50.47%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Nov - Dec 2017<font style="padding-left: 1.86pt;"></font></div></td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 9.55%; text-align: center; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">2027</div></td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 4.88%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.69pt; text-align: left;">25.9</div></td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 11.02%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.57pt; text-align: left;"><font style="padding-left: 12.5pt;">33,375</font></div></td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 11.02%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.57pt; text-align: left;"><font style="padding-left: 12.5pt;">33,375</font></div></td></tr><tr><td style="width: 50.47%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Jan - Dec 2018<font style="padding-left: 0.76pt;"></font></div></td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.55%; text-align: center; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">2028</div></td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 4.88%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.69pt; text-align: left;">25.9</div></td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 11.02%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.57pt; text-align: left;"><font style="padding-left: 7.5pt;">100,250</font></div></td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 11.02%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.57pt; text-align: left;"><font style="padding-left: 7.5pt;">100,250</font></div></td></tr><tr><td style="width: 50.47%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Jan - Apr 2019<font style="padding-left: 1.86pt;"></font></div></td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 9.55%; text-align: center; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">2029</div></td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 4.88%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.69pt; text-align: left;">25.9</div></td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 11.02%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.57pt; text-align: left;"><font style="padding-left: 7.5pt;">155,062</font></div></td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 11.02%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 50.47%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Jul - Sep 2019<font style="padding-left: 3.52pt;"></font></div></td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.55%; text-align: center; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">2029</div></td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 4.88%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.69pt; text-align: left;">28.0</div></td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 11.02%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.57pt; text-align: left;"><font style="padding-left: 12.5pt;">71,604</font></div></td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 11.02%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 50.47%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Jul 2019 forfeited<font style="padding-left: 0.75pt;"></font></div></td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 9.55%; text-align: center; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 4.88%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 11.02%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.57pt; text-align: left;"><font style="padding-left: 4.17pt; border-bottom: 1pt solid #000000; min-width: 40pt;">(</font><font style="border-bottom: 1pt solid #000000; min-width: 40pt;">183,509</font><font style="border-bottom: 1pt solid #000000; min-width: 40pt;"></font><font style="min-width: 40pt;">)</font></div></td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 11.02%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.57pt; text-align: left;"><font style="padding-left: 30pt; border-bottom: 1pt solid #000000; min-width: 40pt;">&#8195;</font></div></td></tr><tr><td style="width: 50.47%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Total<font style="font-weight: normal; padding-left: 1.64pt;"></font></div></td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.55%; text-align: center; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 4.88%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 11.02%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 3.57pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 40pt;">2,</font><font style="border-bottom: 3pt double #000000; min-width: 40pt;">025,532</font></div></td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 11.02%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 3.57pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 40pt;">1,982,375</font></div></td></tr><tr><td style="width: 50.47%; text-align: left; vertical-align: bottom; padding-top: 5.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-indent: -10pt; text-align: left;">Weighted average remaining contractual life of awards outstanding at end of period<font style="padding-left: 1.34pt;"></font></div></td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt;">&#8203;</td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt;">&#8203;</td><td style="width: 9.55%; text-align: center; vertical-align: bottom; padding-top: 5.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt;">&#8203;</td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt;">&#8203;</td><td style="width: 4.88%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 5.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt;">&#8203;</td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt;">&#8203;</td><td style="width: 11.02%; text-align: center; vertical-align: bottom; padding-top: 5.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">6.64&#160;years</div></td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt;">&#8203;</td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt;">&#8203;</td><td style="width: 11.02%; text-align: center; vertical-align: bottom; padding-top: 5.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">7.17&#160;years</div></td></tr></table><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: left;">The average assessed fair value at grant date of awards granted during the year ended December&#160;31, 2019 was USD 15.13 per award (2018: USD 0.31). For awards up to June&#160;30, 2019, the fair value at grant date is independently determined using an adjusted form of the Black-Scholes option pricing model that takes into account the strike price, the term of the award, the impact of dilution (where material), the share price at grant date and expected price volatility of the underlying share, the expected dividend yield, the risk free interest rate for the term of the award and the correlations and volatilities of the shares of peer group companies. For awards granted on and subsequent to July&#160;1, 2019, the fair value at grant date is based on a probability-weighted expected returns method that takes account of both the value derived by using an adjusted form of the Black-Scholes option pricing model, as described above, and a discounted estimate of the price that might be achieved in a future transaction.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: left;">The Company has used an independent valuation firm to assist in calculating the fair value of the award grants per participant.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8.5pt; margin-left: 20pt; text-align: left;">The model inputs for awards granted during the following years included:</div><table cellspacing="0" cellpadding="0" class="fintab" style="margin-top: 11.25pt; border-collapse: collapse; width: 428pt; margin-left: 20pt;"><tr class="header"><td style="width: 44.86%; text-align: left; vertical-align: bottom; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 2.24%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 2.24%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 12.2%; text-align: center; vertical-align: bottom; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 2.24%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 2.24%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 15.64%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Year ended <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">December&#160;31, <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2019</div></td><td class="gutter" style="width: 2.24%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 2.24%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 13.89%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Year ended <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">December 31, <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2018</div></td></tr><tr><td style="width: 44.86%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">a) weighted average share price<font style="padding-left: 4.58pt;"></font></div></td><td class="gutter" style="width: 2.24%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.24%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 12.2%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">in USD</div></td><td class="gutter" style="width: 2.24%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.24%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 15.64%; text-align: center; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">0.80 to 27.50</div></td><td class="gutter" style="width: 2.24%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.24%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 13.89%; text-align: center; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">0.79 to 1.91</div></td></tr><tr><td style="width: 44.86%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">b) strike price<font style="padding-left: 2.31pt;"></font></div></td><td class="gutter" style="width: 2.24%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.24%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 12.2%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">in USD</div></td><td class="gutter" style="width: 2.24%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.24%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 15.64%; text-align: center; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">26.00 to 28.00</div></td><td class="gutter" style="width: 2.24%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.24%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 13.89%; text-align: center; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">25.94</div></td></tr><tr><td style="width: 44.86%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">c) expected volatility<font style="padding-left: 3.42pt;"></font></div></td><td class="gutter" style="width: 2.24%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.24%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 12.2%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">in %</div></td><td class="gutter" style="width: 2.24%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.24%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 15.64%; text-align: center; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">201.9 to 4,612.8</div></td><td class="gutter" style="width: 2.24%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.24%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 13.89%; text-align: center; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">146.4 to 201.9</div></td></tr><tr><td style="width: 44.86%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">d) award life<font style="padding-left: 1.76pt;"></font></div></td><td class="gutter" style="width: 2.24%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.24%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 12.2%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">in # of years</div></td><td class="gutter" style="width: 2.24%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.24%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 15.64%; text-align: center; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">0.08 to 1.02</div></td><td class="gutter" style="width: 2.24%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.24%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 13.89%; text-align: center; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">1.02 to 1.75</div></td></tr><tr><td style="width: 44.86%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">e) expected dividends<font style="padding-left: 0.65pt;"></font></div></td><td class="gutter" style="width: 2.24%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.24%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 12.2%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">in %</div></td><td class="gutter" style="width: 2.24%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.24%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 15.64%; text-align: center; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">0</div></td><td class="gutter" style="width: 2.24%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.24%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 13.89%; text-align: center; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">0</div></td></tr><tr><td style="width: 44.86%; text-align: left; vertical-align: bottom; padding-top: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">f) risk-free interest rate<font style="padding-left: 4.57pt;"></font></div></td><td class="gutter" style="width: 2.24%; border-bottom: none; font-size: 2pt; padding-top: 3pt;">&#8203;</td><td class="gutter" style="width: 2.24%; border-bottom: none; font-size: 2pt; padding-top: 3pt;">&#8203;</td><td style="width: 12.2%; text-align: left; vertical-align: bottom; padding-top: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">in %</div></td><td class="gutter" style="width: 2.24%; border-bottom: none; font-size: 2pt; padding-top: 3pt;">&#8203;</td><td class="gutter" style="width: 2.24%; border-bottom: none; font-size: 2pt; padding-top: 3pt;">&#8203;</td><td style="width: 15.64%; text-align: center; vertical-align: bottom; padding-top: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">2.08 to 2.57</div></td><td class="gutter" style="width: 2.24%; border-bottom: none; font-size: 2pt; padding-top: 3pt;">&#8203;</td><td class="gutter" style="width: 2.24%; border-bottom: none; font-size: 2pt; padding-top: 3pt;">&#8203;</td><td style="width: 13.89%; text-align: center; vertical-align: bottom; padding-top: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">1.84 to 2.57</div></td></tr></table><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: left;">The expected volatility was based on historical volatility and selected volatility determined by median values observed among comparable public companies.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: left;">The award life was based on the time interval between the date of grant and the date at which, when making the grant, the Company expected a Liquidity Event to occur.</div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 36pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">F-59<br></div></div></div>
<!--End Page 313-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 314-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 540pt;"><a name="nt10014672x1_drs_204-finnotes02_pg30"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="block-frill" style="width: 540pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: Arial, Helvetica, sans-serif; font-size: 9pt; font-weight: bold; margin-top: 6pt; text-align: center;">Confidential Treatment Requested by ADC Therapeutics SA Pursuant to 17 C.F.R. &#167; 200.83<br></div></div><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 36pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">ADC Therapeutics SA, Epalinges <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;"><div class="rule-full" style="height: 0pt; width: 100%; border-bottom: 1pt solid #000000; margin-top: 1pt; margin-bottom: 1pt; margin-left: auto; margin-right: auto;"> </div>NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS <font style="padding-left: 4pt;">(continued)</font><br></div><div class="h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 7pt; margin-left: 20pt; text-align: left;"><u>Share Purchase Plan 2016</u></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: left;">On November&#160;18, 2016, the Company implemented the Share Purchase Plan 2016 to provide participants the opportunity to buy shares from the Company in accordance with plan rules, which specified the purchase price. </div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: left;">For the year ended December&#160;31, 2019, participants acquired 584,460 common shares (2018: 450,000) in accordance with share purchase agreements. The Share Purchase Plan 2016 does not oblige the Company to buy back the shares issued. Participants paid the nominal value of the shares in cash and settled the balance between the purchase price and the nominal value in the form of a promissory note. These promissory notes bear interest and have a term of ten years, and the Company has the right of recourse. In accordance with IFRS, the Company has accounted for these share purchases as if the notes were non-recourse and the share purchases therefore, in substance, share options. To effect this, the Company has deemed the strike price to be equal to the purchase price plus accumulated interest up to the expected date of exercise and the life of the options to be equivalent to the period remaining until a likely Liquidity Event (see Incentive Plan 2014 above) and has offset the amount of outstanding promissory notes against share premium. </div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: left;">The terms also include leaver provisions, giving the Company has a call right over 100%, 75%, 50% or 25% if the date of termination occurs after the first, second, third or fourth anniversary of the award, respectively. Since the Company has not in the past demonstrated any practice of exercising this call right, the plan is considered as equity-settled under IFRS 2.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: left;">The cumulative amount credited to &#8220;Other reserves&#8221; at December&#160;31, 2019 in respect of the Share Purchase Plan 2016 is KUSD 3,816 (2018: KUSD 3,483). The expense recognized for services received during the year is KUSD 332 (2018: KUSD 361).</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: left;">Movements in the number of awards outstanding and their related weighted average strike prices are as follows:</div><table cellspacing="0" cellpadding="0" class="fintab" style="margin-top: 11.25pt; border-collapse: collapse; width: 428pt; margin-left: 20pt;"><tr class="header"><td style="width: 50.47%; text-align: left; vertical-align: bottom; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 1.95%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.95%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td colspan="4" style="width: 20.86%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2019</div></td><td class="gutter" style="width: 1.95%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.95%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td colspan="4" style="width: 20.86%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2018</div></td></tr><tr class="header"><td style="width: 50.47%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 1.95%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.95%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 7.61%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Average <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">strike <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">price in <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">USD <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">per share</div></td><td class="gutter" style="width: 1.95%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.95%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 9.35%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Number of <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">awards</div></td><td class="gutter" style="width: 1.95%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.95%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 7.61%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Average <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">strike <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">price in <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">USD <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">per share</div></td><td class="gutter" style="width: 1.95%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.95%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 9.34%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Number of <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">awards</div></td></tr><tr><td style="width: 50.47%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">At the beginning of the year<font style="padding-left: 1.88pt;"></font></div></td><td class="gutter" style="width: 1.95%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.95%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.61%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10.04pt; text-align: left;">2.7</div></td><td class="gutter" style="width: 1.95%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.95%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.35%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;">2,762,500</div></td><td class="gutter" style="width: 1.95%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.95%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.61%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10.04pt; text-align: left;">2.7</div></td><td class="gutter" style="width: 1.95%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.95%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.34%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;">2,312,500</div></td></tr><tr><td style="width: 50.47%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Granted<font style="padding-left: 1.29pt;"></font></div></td><td class="gutter" style="width: 1.95%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.95%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 7.61%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10.04pt; text-align: left;">2.5</div></td><td class="gutter" style="width: 1.95%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.95%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 9.35%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 7.5pt;">584,460</font></div></td><td class="gutter" style="width: 1.95%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.95%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 7.61%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10.04pt; text-align: left;">2.6</div></td><td class="gutter" style="width: 1.95%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.95%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 9.34%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 7.5pt;">450,000</font></div></td></tr><tr><td style="width: 50.47%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Forfeited<font style="padding-left: 1.85pt;"></font></div></td><td class="gutter" style="width: 1.95%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.95%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.61%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10.04pt; text-align: left;"><font style="padding-left: 2.5pt; border-bottom: 1pt solid #000000; min-width: 12.5pt;">&#8212;</font></div></td><td class="gutter" style="width: 1.95%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.95%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.35%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 30pt; border-bottom: 1pt solid #000000; min-width: 40pt;">&#8212;</font></div></td><td class="gutter" style="width: 1.95%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.95%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.61%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10.04pt; text-align: left;"><font style="padding-left: 2.5pt; border-bottom: 1pt solid #000000; min-width: 12.5pt;">&#8212;</font></div></td><td class="gutter" style="width: 1.95%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.95%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.34%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 30pt; border-bottom: 1pt solid #000000; min-width: 40pt;">&#8212; </font></div></td></tr><tr><td style="width: 50.47%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 6pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">At the end of the year<font style="font-weight: normal; padding-left: 1.89pt;"></font></div></td><td class="gutter" style="width: 1.95%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt;">&#8203;</td><td class="gutter" style="width: 1.95%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt;">&#8203;</td><td style="width: 7.61%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 6pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 10.04pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 12.5pt;">2.</font><font style="border-bottom: 3pt double #000000; min-width: 12.5pt;">6</font></div></td><td class="gutter" style="width: 1.95%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt;">&#8203;</td><td class="gutter" style="width: 1.95%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt;">&#8203;</td><td style="width: 9.35%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 6pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 40pt;">3,346,960</font></div></td><td class="gutter" style="width: 1.95%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt;">&#8203;</td><td class="gutter" style="width: 1.95%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt;">&#8203;</td><td style="width: 7.61%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 6pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 10.04pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 12.5pt;">2.</font><font style="border-bottom: 3pt double #000000; min-width: 12.5pt;">7</font></div></td><td class="gutter" style="width: 1.95%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt;">&#8203;</td><td class="gutter" style="width: 1.95%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt;">&#8203;</td><td style="width: 9.34%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 6pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 40pt;">2,762,500</font></div></td></tr></table><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: left;">Out of the total outstanding awards of 3,346,960 common shares as at December&#160;31, 2019 (2018: 2,762,500 awards), no awards are exercisable as there has been no Liquidity Event. No awards have expired.</div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 36pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">F-60<br></div></div></div>
<!--End Page 314-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 315-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 540pt;"><a name="nt10014672x1_drs_204-finnotes02_pg31"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="block-frill" style="width: 540pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: Arial, Helvetica, sans-serif; font-size: 9pt; font-weight: bold; margin-top: 6pt; text-align: center;">Confidential Treatment Requested by ADC Therapeutics SA Pursuant to 17 C.F.R. &#167; 200.83<br></div></div><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 36pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">ADC Therapeutics SA, Epalinges <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;"><div class="rule-full" style="height: 0pt; width: 100%; border-bottom: 1pt solid #000000; margin-top: 1pt; margin-bottom: 1pt; margin-left: auto; margin-right: auto;"> </div>NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS <font style="padding-left: 4pt;">(continued)</font><br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 7pt; margin-left: 20pt; text-align: left;">Awards outstanding at the end of the year have the following expiry date and strike prices:</div><table cellspacing="0" cellpadding="0" class="fintab" style="margin-top: 11.25pt; border-collapse: collapse; width: 428pt; margin-left: 20pt;"><tr class="header"><td style="width: 50.47%; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Grant date</div></td><td class="gutter" style="width: 1.63%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.63%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 9.55%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Expiry date</div></td><td class="gutter" style="width: 1.63%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.63%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 4.88%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Strike <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">price <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">in <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">USD</div></td><td class="gutter" style="width: 1.63%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.63%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 11.02%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Awards <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">December&#160;31, <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2019</div></td><td class="gutter" style="width: 1.63%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.63%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 11.02%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Awards <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">December&#160;31, <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2018</div></td></tr><tr><td style="width: 50.47%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">May 2014<font style="padding-left: 1.84pt;"></font></div></td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.55%; text-align: center; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">2024</div></td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 4.88%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.19pt; text-align: left;">2.8</div></td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 11.02%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.57pt; text-align: left;"><font style="padding-left: 12.5pt;">63,750</font></div></td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 11.02%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.57pt; text-align: left;"><font style="padding-left: 12.5pt;">63,750</font></div></td></tr><tr><td style="width: 50.47%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Sep 2014<font style="padding-left: 0.17pt;"></font></div></td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 9.55%; text-align: center; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">2024</div></td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 4.88%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.19pt; text-align: left;">2.8</div></td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 11.02%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.57pt; text-align: left;"><font style="padding-left: 7.5pt;">102,500</font></div></td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 11.02%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.57pt; text-align: left;"><font style="padding-left: 7.5pt;">102,500</font></div></td></tr><tr><td style="width: 50.47%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">May 2015<font style="padding-left: 1.84pt;"></font></div></td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.55%; text-align: center; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">2025</div></td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 4.88%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.19pt; text-align: left;">2.7</div></td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 11.02%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.57pt; text-align: left;">1,047,375</div></td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 11.02%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.57pt; text-align: left;">1,047,375</div></td></tr><tr><td style="width: 50.47%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Sep 2015<font style="padding-left: 0.17pt;"></font></div></td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 9.55%; text-align: center; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">2025</div></td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 4.88%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.19pt; text-align: left;">2.7</div></td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 11.02%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.57pt; text-align: left;"><font style="padding-left: 7.5pt;">160,500</font></div></td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 11.02%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.57pt; text-align: left;"><font style="padding-left: 7.5pt;">160,500</font></div></td></tr><tr><td style="width: 50.47%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">May 2016<font style="padding-left: 1.84pt;"></font></div></td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.55%; text-align: center; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">2026</div></td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 4.88%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.19pt; text-align: left;">2.7</div></td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 11.02%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.57pt; text-align: left;"><font style="padding-left: 7.5pt;">101,125</font></div></td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 11.02%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.57pt; text-align: left;"><font style="padding-left: 7.5pt;">101,125</font></div></td></tr><tr><td style="width: 50.47%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">May 2016<font style="padding-left: 1.84pt;"></font></div></td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 9.55%; text-align: center; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">2026</div></td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 4.88%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.19pt; text-align: left;">2.7</div></td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 11.02%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.57pt; text-align: left;"><font style="padding-left: 7.5pt;">160,500</font></div></td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 11.02%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.57pt; text-align: left;"><font style="padding-left: 7.5pt;">160,500</font></div></td></tr><tr><td style="width: 50.47%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Oct 2016<font style="padding-left: 0.73pt;"></font></div></td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.55%; text-align: center; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">2026</div></td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 4.88%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.19pt; text-align: left;">2.6</div></td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 11.02%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.57pt; text-align: left;"><font style="padding-left: 7.87pt;">112,500</font></div></td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 11.02%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.57pt; text-align: left;"><font style="padding-left: 7.87pt;">112,500</font></div></td></tr><tr><td style="width: 50.47%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Dec 2016<font style="padding-left: 4.07pt;"></font></div></td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 9.55%; text-align: center; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">2026</div></td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 4.88%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.19pt; text-align: left;">2.6</div></td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 11.02%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.57pt; text-align: left;"><font style="padding-left: 7.5pt;">564,250</font></div></td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 11.02%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.57pt; text-align: left;"><font style="padding-left: 7.5pt;">564,250</font></div></td></tr><tr><td style="width: 50.47%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Jun 2018<font style="padding-left: 1.28pt;"></font></div></td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.55%; text-align: center; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">2028</div></td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 4.88%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.19pt; text-align: left;">2.6</div></td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 11.02%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.57pt; text-align: left;"><font style="padding-left: 12.5pt;">37,500</font></div></td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 11.02%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.57pt; text-align: left;"><font style="padding-left: 12.5pt;">37,500</font></div></td></tr><tr><td style="width: 50.47%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Dec 2018<font style="padding-left: 4.07pt;"></font></div></td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 9.55%; text-align: center; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">2028</div></td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 4.88%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.19pt; text-align: left;">2.6</div></td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 11.02%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.57pt; text-align: left;"><font style="padding-left: 7.5pt;">412,500</font></div></td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 11.02%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.57pt; text-align: left;"><font style="padding-left: 7.5pt;">412,500</font></div></td></tr><tr><td style="width: 50.47%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Jan 2019<font style="padding-left: 1.84pt;"></font></div></td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.55%; text-align: center; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">2029</div></td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 4.88%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.19pt; text-align: left;">2.6</div></td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 11.02%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.57pt; text-align: left;"><font style="padding-left: 12.5pt;">75,000</font></div></td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 11.02%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 50.47%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Dec 2019<font style="padding-left: 4.07pt;"></font></div></td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 9.55%; text-align: center; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">2029</div></td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 4.88%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.19pt; text-align: left;">2.5</div></td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 11.02%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.57pt; text-align: left;"><font style="padding-left: 7.5pt; border-bottom: 1pt solid #000000; min-width: 40pt;">509,460</font></div></td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 11.02%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.57pt; text-align: left;"><font style="padding-left: 30pt; border-bottom: 1pt solid #000000; min-width: 40pt;">&#8195;</font></div></td></tr><tr><td style="width: 50.47%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Total<font style="font-weight: normal; padding-left: 1.64pt;"></font></div></td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.55%; text-align: center; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 4.88%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 11.02%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 3.57pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 40pt;">3,346,960</font></div></td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 11.02%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 3.57pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 40pt;">2,762,500</font></div></td></tr><tr><td style="width: 50.47%; text-align: left; vertical-align: bottom; padding-top: 5.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-indent: -10pt; text-align: left;">Weighted average remaining contractual life of awards outstanding at end of period<font style="padding-left: 1.34pt;"></font></div></td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt;">&#8203;</td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt;">&#8203;</td><td style="width: 9.55%; text-align: center; vertical-align: bottom; padding-top: 5.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt;">&#8203;</td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt;">&#8203;</td><td style="width: 4.88%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 5.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt;">&#8203;</td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt;">&#8203;</td><td style="width: 11.02%; text-align: center; vertical-align: bottom; padding-top: 5.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">6.97&#160;years</div></td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt;">&#8203;</td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt;">&#8203;</td><td style="width: 11.02%; text-align: center; vertical-align: bottom; padding-top: 5.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">7.37&#160;years</div></td></tr></table><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: left;">The average assessed fair value at grant date of awards granted during the year ended December&#160;31, 2019 was USD 12.86 per award (2018: USD 0.28). For awards up to June&#160;30, 2019, the fair value at grant date is independently determined using an adjusted form of the Black-Scholes option pricing model that takes into account the strike price, the term of the award, the impact of dilution (where material), the share price at grant date and expected price volatility of the underlying share, the expected dividend yield, the risk free interest rate for the term of the award and the correlations and volatilities of the shares of peer group companies. For awards granted on and subsequent to July&#160;1, 2019, the fair value at grant date is based on a probability-weighted expected returns method that takes account of both the value derived by using an adjusted form of the Black-Scholes option pricing model, as described above, and a discounted estimate of the price that might be achieved in a future transaction. The adjusted form of the Black-Scholes option pricing model used to derive a value for the common share price at grant date derives the implied equity value for one type of equity security from a contemporaneous transaction involving another type of security and considers the timing, amount, liquidation preferences and dividend rights of issues of preference shares.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: left;">The Company has used an independent valuation firm to assist in calculating the fair value of the award grants per participant. </div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: left;">The assumptions used in an adjusted form of the Black-Scholes option pricing model for awards granted are as follows:</div><table cellspacing="0" cellpadding="0" class="fintab" style="margin-top: 11.25pt; border-collapse: collapse; width: 428pt; margin-left: 20pt;"><tr class="header"><td style="width: 44.86%; text-align: left; vertical-align: bottom; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 2.53%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 2.53%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 12.2%; text-align: center; vertical-align: bottom; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 2.53%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 2.53%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 13.89%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Year ended <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">December&#160;31, <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2019</div></td><td class="gutter" style="width: 2.53%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 2.53%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 13.89%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Year ended <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">December 31, <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2018</div></td></tr><tr><td style="width: 44.86%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">a) weighted average share price<font style="padding-left: 4.58pt;"></font></div></td><td class="gutter" style="width: 2.53%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.53%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 12.2%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">in USD</div></td><td class="gutter" style="width: 2.53%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.53%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 13.89%; text-align: center; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">0.51 to 16.31</div></td><td class="gutter" style="width: 2.53%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.53%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 13.89%; text-align: center; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">0.50 to 1.25</div></td></tr><tr><td style="width: 44.86%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">b) strike price<font style="padding-left: 2.31pt;"></font></div></td><td class="gutter" style="width: 2.53%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.53%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 12.2%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">in USD</div></td><td class="gutter" style="width: 2.53%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.53%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 13.89%; text-align: center; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">2.50 to 2.56</div></td><td class="gutter" style="width: 2.53%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.53%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 13.89%; text-align: center; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">2.58 to 2.63</div></td></tr><tr><td style="width: 44.86%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">c) expected volatility<font style="padding-left: 3.42pt;"></font></div></td><td class="gutter" style="width: 2.53%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.53%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 12.2%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">in %</div></td><td class="gutter" style="width: 2.53%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.53%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 13.89%; text-align: center; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">176.6 to 233.1</div></td><td class="gutter" style="width: 2.53%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.53%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 13.89%; text-align: center; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">170.0 to 233.1</div></td></tr><tr><td style="width: 44.86%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">d) award life<font style="padding-left: 1.76pt;"></font></div></td><td class="gutter" style="width: 2.53%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.53%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 12.2%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">in # of years</div></td><td class="gutter" style="width: 2.53%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.53%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 13.89%; text-align: center; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">0.83 to 1.29</div></td><td class="gutter" style="width: 2.53%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.53%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 13.89%; text-align: center; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">0.83 to 1.33</div></td></tr><tr><td style="width: 44.86%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">e) expected dividends<font style="padding-left: 0.65pt;"></font></div></td><td class="gutter" style="width: 2.53%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.53%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 12.2%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">in %</div></td><td class="gutter" style="width: 2.53%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.53%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 13.89%; text-align: center; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">0</div></td><td class="gutter" style="width: 2.53%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.53%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 13.89%; text-align: center; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">0</div></td></tr><tr><td style="width: 44.86%; text-align: left; vertical-align: bottom; padding-top: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">f) risk-free interest rate<font style="padding-left: 4.57pt;"></font></div></td><td class="gutter" style="width: 2.53%; border-bottom: none; font-size: 2pt; padding-top: 3pt;">&#8203;</td><td class="gutter" style="width: 2.53%; border-bottom: none; font-size: 2pt; padding-top: 3pt;">&#8203;</td><td style="width: 12.2%; text-align: left; vertical-align: bottom; padding-top: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">in %</div></td><td class="gutter" style="width: 2.53%; border-bottom: none; font-size: 2pt; padding-top: 3pt;">&#8203;</td><td class="gutter" style="width: 2.53%; border-bottom: none; font-size: 2pt; padding-top: 3pt;">&#8203;</td><td style="width: 13.89%; text-align: center; vertical-align: bottom; padding-top: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">1.55 to 2.60</div></td><td class="gutter" style="width: 2.53%; border-bottom: none; font-size: 2pt; padding-top: 3pt;">&#8203;</td><td class="gutter" style="width: 2.53%; border-bottom: none; font-size: 2pt; padding-top: 3pt;">&#8203;</td><td style="width: 13.89%; text-align: center; vertical-align: bottom; padding-top: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">2.32 to 2.60</div></td></tr></table><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: left;">The expected volatility was based on historical volatility and selected volatility determined by median values observed among comparable public companies.</div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 36pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">F-61<br></div></div></div>
<!--End Page 315-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 316-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 540pt;"><a name="nt10014672x1_drs_204-finnotes02_pg32"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="block-frill" style="width: 540pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: Arial, Helvetica, sans-serif; font-size: 9pt; font-weight: bold; margin-top: 6pt; text-align: center;">Confidential Treatment Requested by ADC Therapeutics SA Pursuant to 17 C.F.R. &#167; 200.83<br></div></div><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 36pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">ADC Therapeutics SA, Epalinges <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;"><div class="rule-full" style="height: 0pt; width: 100%; border-bottom: 1pt solid #000000; margin-top: 1pt; margin-bottom: 1pt; margin-left: auto; margin-right: auto;"> </div>NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS <font style="padding-left: 4pt;">(continued)</font><br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 7pt; margin-left: 20pt; text-align: left;">The award life is based on the time interval between the date of grant and the date at which, when making the grant, the Company expected a Liquidity Event to occur.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: left;">The amount of promissory notes offset against share premium at December&#160;31, 2019 in respect of this plan is KUSD 8,311 (2018: KUSD 6,891). This amount excludes accumulated interest, as this expense has been recognized within the strike price in calculating the compensation expense.</div><div class="h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 18.5pt; margin-left: 20pt; text-align: left;"><u>Equity Incentive Plan 2019</u></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: left;">Under the Equity Incentive Plan 2019 dated July&#160;1, 2019, the Company, at its discretion, may grant to plan participants (directors, certain employees and service providers working for the benefit of the Company at the time) awards in the form of restricted shares and restricted share units (&#8220;RSUs&#8221;), share options, share appreciation rights, performance awards and other share-based awards.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: left;">To date, only share options have been granted under this plan. The strike price was set by the Company at the fair market value of the underlying common shares on the date of grant, as determined by the Company. The awards vest 25% on the first anniversary of the date of grant, and thereafter evenly on a monthly basis over the subsequent three years. The contractual term of each award granted is ten years. </div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: left;">Under the grant, the options may be settled only in shares. Therefore, the grant of options issued under this plan has been accounted for as equity-settled under IFRS 2.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: left;">The Company annually takes a charge for the vested portion of award grants and for partially earned but non-vested portions of award grants. This results in a front-loaded charge to the income statement. In all cases, the charge to the income statement results in a corresponding credit being booked to &#8220;Other reserves&#8221; within equity.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: left;">The cumulative amount credited to &#8220;Other reserves&#8221; in respect of the Equity Incentive Plan 2019 is KUSD 348 as of December&#160;31, 2019. The expense recognized for services received during the year is KUSD 348.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: left;">Movements in the number of awards outstanding and their related weighted average strike prices are as follows:</div><table cellspacing="0" cellpadding="0" class="fintab" style="margin-top: 5.25pt; border-collapse: collapse; width: 428pt; margin-left: 20pt;"><tr class="header"><td style="width: 56.07%; text-align: left; vertical-align: bottom; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 1.32%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.32%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td colspan="4" style="width: 19.6%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2019</div></td><td class="gutter" style="width: 1.32%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.32%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td colspan="4" style="width: 19.04%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2018</div></td></tr><tr class="header"><td style="width: 56.07%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 1.32%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.32%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 7.61%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Average <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">strike <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">price in <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">USD <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">per share</div></td><td class="gutter" style="width: 1.32%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.32%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 9.35%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Number of <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">awards</div></td><td class="gutter" style="width: 1.32%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.32%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 7.61%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Average <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">strike <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">price in <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">USD <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">per share</div></td><td class="gutter" style="width: 1.32%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.32%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 8.79%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Number of <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">awards</div></td></tr><tr><td style="width: 56.07%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">At the beginning of the year<font style="padding-left: 0.88pt;"></font></div></td><td class="gutter" style="width: 1.32%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.32%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.61%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.55pt; text-align: left;"><font style="padding-left: 7.5pt;">&#8212;</font></div></td><td class="gutter" style="width: 1.32%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.32%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.35%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 30pt;">&#8212;</font></div></td><td class="gutter" style="width: 1.32%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.32%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.61%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 11.29pt; text-align: left;">&#8212;</div></td><td class="gutter" style="width: 1.32%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.32%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.79%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 13.8pt; text-align: left;">&#8212;</div></td></tr><tr><td style="width: 56.07%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Granted<font style="padding-left: 0.29pt;"></font></div></td><td class="gutter" style="width: 1.32%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.32%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 7.61%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.55pt; text-align: left;">18.8</div></td><td class="gutter" style="width: 1.32%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.32%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 9.35%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">1,020,434</div></td><td class="gutter" style="width: 1.32%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.32%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 7.61%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 11.29pt; text-align: left;">&#8212;</div></td><td class="gutter" style="width: 1.32%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.32%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 8.79%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 13.8pt; text-align: left;">&#8212;</div></td></tr><tr><td style="width: 56.07%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Forfeited<font style="padding-left: 0.85pt;"></font></div></td><td class="gutter" style="width: 1.32%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.32%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.61%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.55pt; text-align: left;"><font style="padding-left: 7.5pt; border-bottom: 1pt solid #000000; min-width: 17.5pt;">&#8212;</font></div></td><td class="gutter" style="width: 1.32%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.32%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.35%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 30pt; border-bottom: 1pt solid #000000; min-width: 40pt;">&#8212;</font></div></td><td class="gutter" style="width: 1.32%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.32%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.61%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 11.29pt; text-align: left;"><font style="border-bottom: 1pt solid #000000; min-width: 10pt;">&#8212;</font></div></td><td class="gutter" style="width: 1.32%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.32%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.79%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 13.8pt; text-align: left;"><font style="border-bottom: 1pt solid #000000; min-width: 10pt;">&#8212; </font></div></td></tr><tr><td style="width: 56.07%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 6pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">At the end of the year<font style="font-weight: normal; padding-left: 0.89pt;"></font></div></td><td class="gutter" style="width: 1.32%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt;">&#8203;</td><td class="gutter" style="width: 1.32%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt;">&#8203;</td><td style="width: 7.61%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 6pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 7.55pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 17.5pt;">1</font><font style="border-bottom: 3pt double #000000; min-width: 17.5pt;">8</font><font style="border-bottom: 3pt double #000000; min-width: 17.5pt;">.</font><font style="border-bottom: 3pt double #000000; min-width: 17.5pt;">8</font></div></td><td class="gutter" style="width: 1.32%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt;">&#8203;</td><td class="gutter" style="width: 1.32%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt;">&#8203;</td><td style="width: 9.35%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 6pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 40pt;">1,</font><font style="border-bottom: 3pt double #000000; min-width: 40pt;">020</font><font style="border-bottom: 3pt double #000000; min-width: 40pt;">,</font><font style="border-bottom: 3pt double #000000; min-width: 40pt;">434</font></div></td><td class="gutter" style="width: 1.32%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt;">&#8203;</td><td class="gutter" style="width: 1.32%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt;">&#8203;</td><td style="width: 7.61%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 6pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 11.29pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 10pt;">&#8212;</font></div></td><td class="gutter" style="width: 1.32%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt;">&#8203;</td><td class="gutter" style="width: 1.32%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt;">&#8203;</td><td style="width: 8.79%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 6pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 13.8pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 10pt;">&#8212;</font></div></td></tr></table><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: left;">Out of the total outstanding awards of 1,020,434 common shares as at December&#160;31, 2019, no awards are exercisable as no awards have vested. No awards have expired.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 20pt; text-align: left;">Awards outstanding at the end of the year have the following expiry date and strike prices:</div><table cellspacing="0" cellpadding="0" class="fintab" style="margin-top: 5.25pt; border-collapse: collapse; width: 440.06pt; margin-left: 20pt;"><tr class="header"><td style="width: 54.54%; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Grant date</div></td><td class="gutter" style="width: 0.68%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 0.68%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 9.29%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Expiry date</div></td><td class="gutter" style="width: 0.68%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 0.68%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 9.29%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Strike price <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">in USD</div></td><td class="gutter" style="width: 0.68%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 0.68%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 10.72%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Awards <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">December&#160;31, <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2019</div></td><td class="gutter" style="width: 0.68%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 0.68%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 10.72%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Awards <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">December&#160;31, <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2018</div></td></tr><tr><td style="width: 54.54%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Dec 2019<font style="padding-left: 3.07pt;"></font></div></td><td class="gutter" style="width: 0.68%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.68%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.29%; text-align: center; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">2029</div></td><td class="gutter" style="width: 0.68%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.68%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.29%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 11.68pt; text-align: left;">18.8</div></td><td class="gutter" style="width: 0.68%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.68%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.72%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.58pt; text-align: left;"><font style="border-bottom: 1pt solid #000000; min-width: 40pt;">1,</font><font style="border-bottom: 1pt solid #000000; min-width: 40pt;">020,434</font></div></td><td class="gutter" style="width: 0.68%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.68%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.72%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 18.58pt; text-align: left;"><font style="border-bottom: 1pt solid #000000; min-width: 10pt;">&#8212;</font></div></td></tr><tr><td style="width: 54.54%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 5.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Total<font style="font-weight: normal; padding-left: 0.64pt;"></font></div></td><td class="gutter" style="width: 0.68%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt;">&#8203;</td><td class="gutter" style="width: 0.68%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt;">&#8203;</td><td style="width: 9.29%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 5.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 0.68%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt;">&#8203;</td><td class="gutter" style="width: 0.68%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt;">&#8203;</td><td style="width: 9.29%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 5.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 0.68%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt;">&#8203;</td><td class="gutter" style="width: 0.68%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt;">&#8203;</td><td style="width: 10.72%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 5.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 3.58pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 40pt;">1,</font><font style="border-bottom: 3pt double #000000; min-width: 40pt;">020,434</font></div></td><td class="gutter" style="width: 0.68%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt;">&#8203;</td><td class="gutter" style="width: 0.68%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt;">&#8203;</td><td style="width: 10.72%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 5.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 18.58pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 10pt;">&#8212;</font></div></td></tr><tr><td style="width: 54.54%; text-align: left; vertical-align: bottom; padding-top: 5.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-indent: -10pt; text-align: left;">Weighted average remaining contractual life of awards outstanding at end of period<font style="padding-left: 1.98pt;"></font></div></td><td class="gutter" style="width: 0.68%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.68%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.29%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 5.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.68%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.68%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.29%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 5.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.68%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.68%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.72%; text-align: center; vertical-align: bottom; padding-top: 5.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">9.96&#160;years</div></td><td class="gutter" style="width: 0.68%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.68%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.72%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 5.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 18.58pt; text-align: left;">&#8212;</div></td></tr></table><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: left;">The average assessed fair value at grant date of awards granted during the year ended December&#160;31, 2019 was USD 15.71 per award. The fair value of the option at grant date is independently determined using an </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 36pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">F-62<br></div></div></div>
<!--End Page 316-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 317-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 540pt;"><a name="nt10014672x1_drs_204-finnotes02_pg33"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="block-frill" style="width: 540pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: Arial, Helvetica, sans-serif; font-size: 9pt; font-weight: bold; margin-top: 6pt; text-align: center;">Confidential Treatment Requested by ADC Therapeutics SA Pursuant to 17 C.F.R. &#167; 200.83<br></div></div><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 36pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">ADC Therapeutics SA, Epalinges <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;"><div class="rule-full" style="height: 0pt; width: 100%; border-bottom: 1pt solid #000000; margin-top: 1pt; margin-bottom: 1pt; margin-left: auto; margin-right: auto;"> </div>NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS <font style="padding-left: 4pt;">(continued)</font><br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 7pt; margin-left: 20pt; text-align: left;">adjusted form of the Black-Scholes option pricing model that takes into account the strike price, the term of the award, the impact of dilution (where material), the share price at grant date and expected price volatility of the underlying share, the expected dividend yield, the risk free interest rate for the term of the award and the correlations and volatilities of the shares of peer group companies. The share price at grant date, which represents a critical input into this model, is itself determined using a probability-weighted expected returns method that takes account of both the value derived by using an adjusted form of the Black-Scholes option pricing model, as described above, and a discounted estimate of the price that might be achieved in a future transaction. The adjusted form of the Black-Scholes option pricing model used to derive a value for the common share price at grant date derives the implied equity value for one type of equity security from a contemporaneous transaction involving another type of security and considers the timing, amount, liquidation preferences and dividend rights of issues of preference shares.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: left;">The Company has used an independent valuation firm to assist in calculating the fair value of the award grants per participant.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: left;">The assumptions used in an adjusted form of the Black-Scholes option pricing model for awards granted are as follows:</div><table cellspacing="0" cellpadding="0" class="fintab" style="margin-top: 5.25pt; border-collapse: collapse; width: 428pt; margin-left: 20pt;"><tr class="header"><td style="width: 56.08%; text-align: left; vertical-align: bottom; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 1.62%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.62%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 12.2%; text-align: center; vertical-align: bottom; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 1.62%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.62%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 11.02%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Year <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">ended <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">December&#160;31, <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2019</div></td><td class="gutter" style="width: 1.62%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.62%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 11.02%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Year <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">ended <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">December 31, <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2018</div></td></tr><tr><td style="width: 56.08%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">a) weighted average share price<font style="padding-left: 2.58pt;"></font></div></td><td class="gutter" style="width: 1.62%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.62%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 12.2%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;">in USD</div></td><td class="gutter" style="width: 1.62%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.62%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 11.02%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 12.33pt; text-align: left;">16.31</div></td><td class="gutter" style="width: 1.62%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.62%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 11.02%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 18.58pt; text-align: left;">&#8212;</div></td></tr><tr><td style="width: 56.08%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">b) strike price<font style="padding-left: 0.31pt;"></font></div></td><td class="gutter" style="width: 1.62%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.62%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 12.2%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;">in USD</div></td><td class="gutter" style="width: 1.62%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.62%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 11.02%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 12.33pt; text-align: left;">18.75</div></td><td class="gutter" style="width: 1.62%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.62%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 11.02%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 18.58pt; text-align: left;">&#8212;</div></td></tr><tr><td style="width: 56.08%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">c) expected volatility<font style="padding-left: 1.42pt;"></font></div></td><td class="gutter" style="width: 1.62%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.62%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 12.2%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;">in %</div></td><td class="gutter" style="width: 1.62%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.62%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 11.02%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 12.33pt; text-align: left;">176.6</div></td><td class="gutter" style="width: 1.62%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.62%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 11.02%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 18.58pt; text-align: left;">&#8212;</div></td></tr><tr><td style="width: 56.08%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">d) award life<font style="padding-left: 4.76pt;"></font></div></td><td class="gutter" style="width: 1.62%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.62%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 12.2%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;">in # of years</div></td><td class="gutter" style="width: 1.62%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.62%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 11.02%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 12.33pt; text-align: left;"><font style="padding-left: 5pt;">5.65</font></div></td><td class="gutter" style="width: 1.62%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.62%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 11.02%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 18.58pt; text-align: left;">&#8212;</div></td></tr><tr><td style="width: 56.08%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">e) expected dividends<font style="padding-left: 3.65pt;"></font></div></td><td class="gutter" style="width: 1.62%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.62%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 12.2%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;">in %</div></td><td class="gutter" style="width: 1.62%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.62%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 11.02%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 12.33pt; text-align: left;"><font style="padding-left: 17.5pt;">0</font></div></td><td class="gutter" style="width: 1.62%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.62%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 11.02%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 18.58pt; text-align: left;">&#8212;</div></td></tr><tr><td style="width: 56.08%; text-align: left; vertical-align: bottom; padding-top: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">f) risk-free interest rate<font style="padding-left: 2.57pt;"></font></div></td><td class="gutter" style="width: 1.62%; border-bottom: none; font-size: 2pt; padding-top: 3pt;">&#8203;</td><td class="gutter" style="width: 1.62%; border-bottom: none; font-size: 2pt; padding-top: 3pt;">&#8203;</td><td style="width: 12.2%; text-align: left; vertical-align: bottom; padding-top: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;">in %</div></td><td class="gutter" style="width: 1.62%; border-bottom: none; font-size: 2pt; padding-top: 3pt;">&#8203;</td><td class="gutter" style="width: 1.62%; border-bottom: none; font-size: 2pt; padding-top: 3pt;">&#8203;</td><td style="width: 11.02%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 12.33pt; text-align: left;"><font style="padding-left: 5pt;">1.67</font></div></td><td class="gutter" style="width: 1.62%; border-bottom: none; font-size: 2pt; padding-top: 3pt;">&#8203;</td><td class="gutter" style="width: 1.62%; border-bottom: none; font-size: 2pt; padding-top: 3pt;">&#8203;</td><td style="width: 11.02%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 18.58pt; text-align: left;">&#8212;</div></td></tr></table><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: left;">The expected volatility was based on historical volatility and selected volatility was based on median values observed among comparable public companies. </div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: left;">The award life is based on the time interval between the date of grant and the date during the ten-year life at which, when making the grant, the Company expected on average that participants would exercise their options.</div><div class="h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 20.5pt; margin-left: 20pt; text-align: left;"><u>Share-based Compensation Reserves</u></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 7.5pt; margin-left: 20pt; text-align: left;">The movement in the Share-based Compensation Reserves (included in &#8220;Other reserves&#8221;) is as follows:</div><table cellspacing="0" cellpadding="0" class="fintab" style="margin-top: 11.25pt; border-collapse: collapse; width: 428pt; margin-left: 20pt;"><tr class="header"><td style="width: 78.5%; text-align: left; vertical-align: bottom; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">(in KUSD)</div></td><td class="gutter" style="width: 2.75%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 2.75%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 5.26%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2019</div></td><td class="gutter" style="width: 2.75%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 2.75%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 5.26%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2018</div></td></tr><tr><td style="width: 78.5%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">January 1<font style="padding-left: 4.07pt;"></font></div></td><td class="gutter" style="width: 2.75%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.75%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.26%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">6,745</div></td><td class="gutter" style="width: 2.75%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.75%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.26%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">6,276</div></td></tr><tr><td style="width: 78.5%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Share Purchase Plan 2013<font style="padding-left: 1.88pt;"></font></div></td><td class="gutter" style="width: 2.75%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.75%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 5.26%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 12.5pt;">&#8212;</font></div></td><td class="gutter" style="width: 2.75%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.75%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 5.26%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 12.5pt;">&#8212;</font></div></td></tr><tr><td style="width: 78.5%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Incentive Plan 2014<font style="padding-left: 1.86pt;"></font></div></td><td class="gutter" style="width: 2.75%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.75%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.26%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 7.5pt;">437</font></div></td><td class="gutter" style="width: 2.75%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.75%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.26%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 7.5pt;">108</font></div></td></tr><tr><td style="width: 78.5%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Share Purchase Plan 2016<font style="padding-left: 1.88pt;"></font></div></td><td class="gutter" style="width: 2.75%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.75%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 5.26%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 7.5pt;">332</font></div></td><td class="gutter" style="width: 2.75%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.75%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 5.26%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 7.5pt;">361</font></div></td></tr><tr><td style="width: 78.5%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Equity Incentive Plan 2019<font style="padding-left: 1.86pt;"></font></div></td><td class="gutter" style="width: 2.75%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.75%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.26%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 7.5pt; border-bottom: 1pt solid #000000; min-width: 22.5pt;">348</font></div></td><td class="gutter" style="width: 2.75%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.75%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.26%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 12.5pt; border-bottom: 1pt solid #000000; min-width: 22.5pt;">&#8212; </font></div></td></tr><tr><td style="width: 78.5%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 6pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">December 31<font style="font-weight: normal; padding-left: 2.04pt;"></font></div></td><td class="gutter" style="width: 2.75%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt;">&#8203;</td><td class="gutter" style="width: 2.75%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt;">&#8203;</td><td style="width: 5.26%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 6pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 22.5pt;">7,862</font></div></td><td class="gutter" style="width: 2.75%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt;">&#8203;</td><td class="gutter" style="width: 2.75%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt;">&#8203;</td><td style="width: 5.26%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 6pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 22.5pt;">6,745</font></div></td></tr></table></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 36pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">F-63<br></div></div></div>
<!--End Page 317-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 318-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 540pt;"><a name="nt10014672x1_drs_204-finnotes02_pg34"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="block-frill" style="width: 540pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: Arial, Helvetica, sans-serif; font-size: 9pt; font-weight: bold; margin-top: 6pt; text-align: center;">Confidential Treatment Requested by ADC Therapeutics SA Pursuant to 17 C.F.R. &#167; 200.83<br></div></div><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 36pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">ADC Therapeutics SA, Epalinges <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;"><div class="rule-full" style="height: 0pt; width: 100%; border-bottom: 1pt solid #000000; margin-top: 1pt; margin-bottom: 1pt; margin-left: auto; margin-right: auto;"> </div>NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS <font style="padding-left: 4pt;">(continued)</font><br></div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 12pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">24.<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; text-align: left;">Share capital</div></td></tr></table><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: left;">Share data have been revised to give effect to the share split and share consolidation as explained in note 2 (iv) &#8220;Share split&#8221; and in note 2 (v) &#8220;Share consolidation&#8221;.</div><table cellspacing="0" cellpadding="0" class="fintab" style="margin-top: 11.25pt; border-collapse: collapse; width: 438.9pt; margin-left: 20pt;"><tr class="header"><td style="width: 32.81%; text-align: left; vertical-align: bottom; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 0.68%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 0.68%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 10.13%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Number of<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">shares <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">issued<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Common</div></td><td class="gutter" style="width: 0.68%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 0.68%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 10.25%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Number of<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">shares <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">issued<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Class&#160;B</div></td><td class="gutter" style="width: 0.68%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 0.68%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 9.11%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Number of<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">shares <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">issued<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Class&#160;C</div></td><td class="gutter" style="width: 0.68%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 0.68%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 9.11%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Number of<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">shares <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">issued<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Class&#160;D</div></td><td class="gutter" style="width: 0.68%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 0.68%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 10.13%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Number of<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">shares <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">issued<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Class&#160;E</div></td><td class="gutter" style="width: 0.68%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 0.68%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 10.25%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Number of<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">shares <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">issued<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Total</div></td></tr><tr><td style="width: 32.81%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">January&#160;1, 2018<font style="font-weight: normal; padding-left: 1.79pt;"></font></div></td><td class="gutter" style="width: 0.68%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.68%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.13%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 4.45pt;">9,487,500</font></div></td><td class="gutter" style="width: 0.68%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.68%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.25%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">14,262,500</div></td><td class="gutter" style="width: 0.68%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.68%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.11%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">8,075,000</div></td><td class="gutter" style="width: 0.68%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.68%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.11%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">7,837,500</div></td><td class="gutter" style="width: 0.68%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.68%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.13%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 4.45pt;">7,712,500</font></div></td><td class="gutter" style="width: 0.68%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.68%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.25%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">47,375,000</div></td></tr><tr><td style="width: 32.81%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-indent: -10pt; text-align: left;">Issuance of share capital / capital contributions<font style="padding-left: 3.73pt;"></font></div></td><td class="gutter" style="width: 0.68%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 0.68%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 10.13%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 11.95pt; border-bottom: 1pt solid #000000; min-width: 44.45pt;">450,000</font><font style="border-bottom: 1pt solid #000000; min-width: 44.45pt;"> </font></div></td><td class="gutter" style="width: 0.68%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 0.68%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 10.25%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 35pt; border-bottom: 1pt solid #000000; min-width: 45pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.68%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 0.68%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 9.11%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 30pt; border-bottom: 1pt solid #000000; min-width: 40pt;">&#8212; </font></div></td><td class="gutter" style="width: 0.68%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 0.68%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 9.11%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 30pt; border-bottom: 1pt solid #000000; min-width: 40pt;">&#8212; </font></div></td><td class="gutter" style="width: 0.68%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 0.68%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 10.13%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 34.45pt; border-bottom: 1pt solid #000000; min-width: 44.45pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.68%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 0.68%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 10.25%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 12.5pt; border-bottom: 1pt solid #000000; min-width: 45pt;">450,000</font><font style="border-bottom: 1pt solid #000000; min-width: 45pt;"> </font></div></td></tr><tr><td style="width: 32.81%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">December&#160;31, 2018<font style="font-weight: normal; padding-left: 4.21pt;"></font></div></td><td class="gutter" style="width: 0.68%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.68%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.13%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 4.45pt;">9,937,500</font></div></td><td class="gutter" style="width: 0.68%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.68%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.25%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">14,262,500</div></td><td class="gutter" style="width: 0.68%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.68%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.11%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">8,075,000</div></td><td class="gutter" style="width: 0.68%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.68%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.11%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">7,837,500</div></td><td class="gutter" style="width: 0.68%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.68%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.13%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 4.45pt;">7,712,500</font></div></td><td class="gutter" style="width: 0.68%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.68%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.25%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">47,825,000</div></td></tr><tr><td style="width: 32.81%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-indent: -10pt; text-align: left;">Issuance of share capital / capital contributions<font style="padding-left: 3.73pt;"></font></div></td><td class="gutter" style="width: 0.68%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 0.68%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 10.13%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 4.45pt; border-bottom: 1pt solid #000000; min-width: 44.45pt;">1,825,000</font><font style="border-bottom: 1pt solid #000000; min-width: 44.45pt;"> </font></div></td><td class="gutter" style="width: 0.68%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 0.68%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 10.25%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 35pt; border-bottom: 1pt solid #000000; min-width: 45pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.68%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 0.68%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 9.11%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 30pt; border-bottom: 1pt solid #000000; min-width: 40pt;">&#8212; </font></div></td><td class="gutter" style="width: 0.68%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 0.68%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 9.11%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 30pt; border-bottom: 1pt solid #000000; min-width: 40pt;">&#8212; </font></div></td><td class="gutter" style="width: 0.68%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 0.68%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 10.13%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 4.45pt; border-bottom: 1pt solid #000000; min-width: 44.45pt;">3,687,500</font></div></td><td class="gutter" style="width: 0.68%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 0.68%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 10.25%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 5pt; border-bottom: 1pt solid #000000; min-width: 45pt;">5,512,500</font><font style="border-bottom: 1pt solid #000000; min-width: 45pt;"> </font></div></td></tr><tr><td style="width: 32.81%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">December&#160;31, 2019<font style="font-weight: normal; padding-left: 4.21pt;"></font></div></td><td class="gutter" style="width: 0.68%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.68%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.13%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 44.45pt;">1</font><font style="border-bottom: 3pt double #000000; min-width: 44.45pt;">1,762,500</font></div></td><td class="gutter" style="width: 0.68%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.68%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.25%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 45pt;">1</font><font style="border-bottom: 3pt double #000000; min-width: 45pt;">4,262,500</font></div></td><td class="gutter" style="width: 0.68%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.68%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.11%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 40pt;">8,075,000</font></div></td><td class="gutter" style="width: 0.68%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.68%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.11%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 40pt;">7,837,500</font></div></td><td class="gutter" style="width: 0.68%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.68%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.13%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 44.45pt;">1</font><font style="border-bottom: 3pt double #000000; min-width: 44.45pt;">1,400,000</font></div></td><td class="gutter" style="width: 0.68%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.68%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.25%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 45pt;">53,337,500</font></div></td></tr><tr><td style="width: 32.81%; text-align: left; vertical-align: bottom; padding-top: 5.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">of which, treasury shares:<font style="padding-left: 1.28pt;"></font></div></td><td class="gutter" style="width: 0.68%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt;">&#8203;</td><td class="gutter" style="width: 0.68%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt;">&#8203;</td><td style="width: 10.13%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 5.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 4.45pt;">1,</font>240,540</div></td><td class="gutter" style="width: 0.68%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt;">&#8203;</td><td class="gutter" style="width: 0.68%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt;">&#8203;</td><td style="width: 10.25%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 5.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.68%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt;">&#8203;</td><td class="gutter" style="width: 0.68%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt;">&#8203;</td><td style="width: 9.11%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 5.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.68%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt;">&#8203;</td><td class="gutter" style="width: 0.68%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt;">&#8203;</td><td style="width: 9.11%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 5.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.68%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt;">&#8203;</td><td class="gutter" style="width: 0.68%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt;">&#8203;</td><td style="width: 10.13%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 5.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.68%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt;">&#8203;</td><td class="gutter" style="width: 0.68%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt;">&#8203;</td><td style="width: 10.25%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 5.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr></table><table cellspacing="0" cellpadding="0" class="fintab" style="margin-top: 6pt; border-collapse: collapse; width: 428pt; margin-left: 20pt;"><tr class="header"><td style="width: 50.47%; text-align: left; vertical-align: bottom; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 1.88%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.88%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 8.61%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Share <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">capital<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">(in KUSD)</div></td><td class="gutter" style="width: 1.88%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.88%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 8.61%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Share <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">premium<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">(in KUSD)</div></td><td class="gutter" style="width: 1.88%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.88%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 8.61%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Treasury <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">shares <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">(in KUSD)</div></td><td class="gutter" style="width: 1.88%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.88%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 8.61%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Total <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">(in KUSD)</div></td></tr><tr><td style="width: 50.47%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">January&#160;1, 2018<font style="font-weight: normal; padding-left: 3.79pt;"></font></div></td><td class="gutter" style="width: 1.88%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.88%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.61%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 7.18pt; text-align: left;"><font style="padding-left: 7.5pt;">397</font></div></td><td class="gutter" style="width: 1.88%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.88%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.61%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 2.18pt; text-align: left;">452,296</div></td><td class="gutter" style="width: 1.88%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.88%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.61%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 9.27pt; text-align: left;"><font style="padding-left: 8.33pt;">&#8212;</font></div></td><td class="gutter" style="width: 1.88%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.88%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.61%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 2.18pt; text-align: left;">452,693</div></td></tr><tr><td style="width: 50.47%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Issuance of share capital /capital contributions<font style="padding-left: 4.14pt;"></font></div></td><td class="gutter" style="width: 1.88%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.88%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 8.61%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.18pt; text-align: left;"><font style="padding-left: 17.5pt; border-bottom: 1pt solid #000000; min-width: 22.5pt;">4 </font></div></td><td class="gutter" style="width: 1.88%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.88%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 8.61%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.18pt; text-align: left;"><font style="padding-left: 19.17pt; border-bottom: 1pt solid #000000; min-width: 32.5pt;">(28</font><font style="min-width: 32.5pt;">)</font></div></td><td class="gutter" style="width: 1.88%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.88%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 8.61%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.27pt; text-align: left;"><font style="padding-left: 8.33pt; border-bottom: 1pt solid #000000; min-width: 18.33pt;">&#8212; </font></div></td><td class="gutter" style="width: 1.88%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.88%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 8.61%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.18pt; text-align: left;"><font style="padding-left: 19.17pt; border-bottom: 1pt solid #000000; min-width: 32.5pt;">(24</font><font style="min-width: 32.5pt;">)</font></div></td></tr><tr><td style="width: 50.47%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">December&#160;31, 2018<font style="font-weight: normal; padding-left: 1.21pt;"></font></div></td><td class="gutter" style="width: 1.88%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.88%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.61%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 7.18pt; text-align: left;"><font style="padding-left: 7.5pt;">401</font></div></td><td class="gutter" style="width: 1.88%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.88%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.61%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 2.18pt; text-align: left;">452,268</div></td><td class="gutter" style="width: 1.88%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.88%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.61%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 9.27pt; text-align: left;"><font style="padding-left: 8.33pt;">&#8212;</font></div></td><td class="gutter" style="width: 1.88%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.88%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.61%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 2.18pt; text-align: left;">452,669</div></td></tr><tr><td style="width: 50.47%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Issuance of share capital /capital contributions<font style="padding-left: 4.14pt;"></font></div></td><td class="gutter" style="width: 1.88%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.88%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 8.61%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.18pt; text-align: left;"><font style="padding-left: 7.5pt;">171</font></div></td><td class="gutter" style="width: 1.88%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.88%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 8.61%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.18pt; text-align: left;">101,443</div></td><td class="gutter" style="width: 1.88%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.88%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 8.61%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.27pt; text-align: left;"><font style="padding-left: 8.33pt;">&#8212;</font></div></td><td class="gutter" style="width: 1.88%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.88%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 8.61%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.18pt; text-align: left;">101,614</div></td></tr><tr><td style="width: 50.47%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Change in par value<font style="padding-left: 0.76pt;"></font></div></td><td class="gutter" style="width: 1.88%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.88%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.61%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.18pt; text-align: left;">3,789</div></td><td class="gutter" style="width: 1.88%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.88%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.61%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.18pt; text-align: left;"><font style="padding-left: 6.67pt;">(3,789)</font></div></td><td class="gutter" style="width: 1.88%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.88%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.61%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.88%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.88%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.61%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.18pt; text-align: left;"><font style="padding-left: 22.5pt;">&#8212;</font></div></td></tr><tr><td style="width: 50.47%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Treasury shares - additions<font style="padding-left: 3.35pt;"></font></div></td><td class="gutter" style="width: 1.88%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.88%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 8.61%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.18pt; text-align: left;"><font style="padding-left: 12.5pt;">&#8212;</font></div></td><td class="gutter" style="width: 1.88%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.88%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 8.61%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.18pt; text-align: left;"><font style="padding-left: 22.5pt;">&#8212;</font></div></td><td class="gutter" style="width: 1.88%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.88%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 8.61%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.27pt; text-align: left;">(141)</div></td><td class="gutter" style="width: 1.88%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.88%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 8.61%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.18pt; text-align: left;"><font style="padding-left: 14.17pt;">(141)</font></div></td></tr><tr><td style="width: 50.47%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Treasury shares - disposals<font style="padding-left: 3.36pt;"></font></div></td><td class="gutter" style="width: 1.88%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.88%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.61%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.18pt; text-align: left;"><font style="padding-left: 12.5pt; border-bottom: 1pt solid #000000; min-width: 22.5pt;">&#8212;</font></div></td><td class="gutter" style="width: 1.88%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.88%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.61%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.18pt; text-align: left;"><font style="padding-left: 22.5pt; border-bottom: 1pt solid #000000; min-width: 32.5pt;">&#8212;</font></div></td><td class="gutter" style="width: 1.88%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.88%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.61%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.27pt; text-align: left;"><font style="padding-left: 8.33pt; border-bottom: 1pt solid #000000; min-width: 18.33pt;">41</font></div></td><td class="gutter" style="width: 1.88%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.88%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.61%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.18pt; text-align: left;"><font style="padding-left: 22.5pt; border-bottom: 1pt solid #000000; min-width: 32.5pt;">41</font></div></td></tr><tr><td style="width: 50.47%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 6pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">December&#160;31, 2019<font style="font-weight: normal; padding-left: 1.21pt;"></font></div></td><td class="gutter" style="width: 1.88%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt;">&#8203;</td><td class="gutter" style="width: 1.88%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt;">&#8203;</td><td style="width: 8.61%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 6pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 7.18pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 22.5pt;">4,361</font></div></td><td class="gutter" style="width: 1.88%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt;">&#8203;</td><td class="gutter" style="width: 1.88%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt;">&#8203;</td><td style="width: 8.61%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 6pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 2.18pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 32.5pt;">549,922</font></div></td><td class="gutter" style="width: 1.88%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt;">&#8203;</td><td class="gutter" style="width: 1.88%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt;">&#8203;</td><td style="width: 8.61%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 6pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 9.27pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 18.33pt;">(100</font><font style="min-width: 18.33pt;">)</font></div></td><td class="gutter" style="width: 1.88%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt;">&#8203;</td><td class="gutter" style="width: 1.88%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt;">&#8203;</td><td style="width: 8.61%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 6pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 2.18pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 32.5pt;">554,183</font></div></td></tr></table><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: left;">All issuances of share capital or capital contributions are shown net of transaction costs. Par value of all classes of shares is CHF 0.08 per share and each registered share carries one voting right. Common shares were previously described as Class&#160;A shares.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: left;">At December&#160;31, 2019, the share capital of the Company amounts to CHF 4,267,000, consisting of 53,337,500 issued and fully paid-in registered shares with a nominal value of CHF 0.08 each.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: left;">Pursuant to the Company's Share Purchase Plan 2016, on February&#160;6, 2019, the Company increased its share capital by CHF 600 (USD 603) through the issuance of 75,000 common shares at a par value of CHF&#160;0.008.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: left;">Pursuant to an investment agreement, on June&#160;7, 2019, the Company increased its share capital by CHF&#160;21,600 (USD 21,761) through the issuance of 2,700,000 Class&#160;E shares at a par value of CHF 0.008 for a total consideration (nominal value and share premium) of KUSD 75,600.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: left;">Pursuant to an investment agreement, on June&#160;14, 2019, the Company increased its share capital by CHF 200 (USD 202) through the issuance of 25,000 Class&#160;E shares at a par value of CHF 0.008 for a total consideration (nominal value and share premium) of KUSD 700.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: left;">Pursuant to an investment agreement, on July&#160;5, 2019, the Company increased its share capital by CHF 7,700 (USD 7,889) through the issuance of 962,500 Class&#160;E shares at a par value of CHF 0.008 for a total consideration (nominal value and share premium) of KUSD 26,950.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: left;">On August&#160;22, 2019, the par value of each of the shares was increased from CHF 0.008 to CHF 0.08 (CHF 100 to CHF 1,000 before share split and share consolidation) by transferring an amount of KCHF 3,714 (KUSD 3,789) from share premium to share capital.</div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 36pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">F-64<br></div></div></div>
<!--End Page 318-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 319-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 540pt;"><a name="nt10014672x1_drs_204-finnotes02_pg35"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="block-frill" style="width: 540pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: Arial, Helvetica, sans-serif; font-size: 9pt; font-weight: bold; margin-top: 6pt; text-align: center;">Confidential Treatment Requested by ADC Therapeutics SA Pursuant to 17 C.F.R. &#167; 200.83<br></div></div><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 36pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">ADC Therapeutics SA, Epalinges <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;"><div class="rule-full" style="height: 0pt; width: 100%; border-bottom: 1pt solid #000000; margin-top: 1pt; margin-bottom: 1pt; margin-left: auto; margin-right: auto;"> </div>NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS <font style="padding-left: 4pt;">(continued)</font><br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 7pt; margin-left: 20pt; text-align: left;">Under the terms of the 2013 and 2016 Promissory Notes issued in connection with the share purchase plans, the relevant plan participant had to repay in the case of an IPO outstanding amounts under the promissory note at any time in cash or repay the principal amount in whole or in part by delivering such number of shares as required to cover the amount to be repaid. In anticipation of an offering planned for October 2019, each of the executive officers and directors and their respective related parties who held Promissory Notes entered into loan settlement agreements with the Company dated as of August&#160;31, 2019 pursuant to which they repaid all amounts outstanding under the Promissory Notes, including accrued interest, by delivering such number of shares necessary to cover the entire amounts outstanding under the Promissory Notes. The IPO finally did not occur in October 2019 and therefore the loan settlement agreements were cancelled.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: left;">In order to have available treasury shares to meet the demand for shares when share options are exercised, the Company, on September&#160;2, 2019, increased its share capital by KCHF 140 (KUSD 141) through the issuance to a related party of 1,750,000 common shares at par value of CHF 0.08 per share and repurchased these shares from the same related party at the same price on September&#160;19, 2019. These shares are reserved for issuance on the exercise of share options.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: left;">The total consideration of 2019 capital increases was reduced by an amount of KUSD 1,778 relating to transaction costs.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: left;">On September&#160;19, 2019, the Company effected a one to 15,625 share split of its outstanding common and preferred shares. Accordingly, all share and per share amounts for all periods presented in these consolidated financial statements and notes thereto have been adjusted retroactively, where applicable, to reflect this share&#160;split.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: left;">Pursuant to the Articles of Incorporation, in the event of certain defined liquidation events, the liquidation proceeds will be distributed to the holders of shares in the following order of priority:</div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 40pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">1.<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">First, to the Class&#160;E shareholders, an amount equal to the total price paid for the Class&#160;E shares, plus an 8% per annum return;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 40pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">2.<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">Second, to the Class&#160;D shareholders, an amount equal to the total price paid for the Class&#160;D shares, plus an 8% per annum return;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 40pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">3.<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">Third, to the Class&#160;C shareholders, an amount equal to the total price paid for the Class&#160;C shares;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 40pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">4.<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">Fourth, pari passu, to the Class&#160;B shareholders, an amount equal to the total price paid for the Class&#160;B shares, plus an 8% per annum return, and, to the Class&#160;C shareholders, an 8% per annum return on the total price paid for the Class&#160;C shares; and</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 40pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">5.<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">Thereafter, to all shareholders, the remaining proceeds in proportion to the nominal value of their shares.</div></td></tr></table><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8.5pt; margin-left: 20pt; text-align: left;">All references above to total price paid for shares include any share premium paid.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: left;">Pursuant to the Company's shareholder agreement, the above liquidation preferences may not apply to a change of control or initial public offering event.</div><div class="h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 20.5pt; margin-left: 20pt; text-align: left;"><u>Treasury shares</u></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: left;">As explained above in this note, shares were issued to and repurchased at the same price from a related party in September 2019 in order to have available treasury shares to meet the demand for shares when share options are exercised.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: left;">Pursuant to the Company's Share Purchase Plan 2016, on December&#160;16, 2019, the Company re-issued 509,460 treasury shares (common) to plan participants for a consideration of KCHF 41 (KUSD 41).</div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 36pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">F-65<br></div></div></div>
<!--End Page 319-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 320-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 540pt;"><a name="nt10014672x1_drs_204-finnotes02_pg36"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="block-frill" style="width: 540pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: Arial, Helvetica, sans-serif; font-size: 9pt; font-weight: bold; margin-top: 6pt; text-align: center;">Confidential Treatment Requested by ADC Therapeutics SA Pursuant to 17 C.F.R. &#167; 200.83<br></div></div><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 36pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">ADC Therapeutics SA, Epalinges <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;"><div class="rule-full" style="height: 0pt; width: 100%; border-bottom: 1pt solid #000000; margin-top: 1pt; margin-bottom: 1pt; margin-left: auto; margin-right: auto;"> </div>NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS <font style="padding-left: 4pt;">(continued)</font><br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 7pt; margin-left: 20pt; text-align: left;">Movements on the treasury shares position are as follows:</div><table cellspacing="0" cellpadding="0" class="fintab" style="margin-top: 11.25pt; border-collapse: collapse; width: 428pt; margin-left: 20pt;"><tr class="header"><td style="width: 30.84%; text-align: left; vertical-align: bottom; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 1.62%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.62%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td colspan="7" style="width: 31.61%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2019</div></td><td class="gutter" style="width: 1.62%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.62%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td colspan="7" style="width: 31.05%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2018</div></td></tr><tr class="header"><td style="width: 30.84%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 1.62%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.62%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 7.16%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Price <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">(in USD)</div></td><td class="gutter" style="width: 1.62%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.62%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 9.35%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Number of <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">treasury <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">shares</div></td><td class="gutter" style="width: 1.62%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.62%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 8.61%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Value <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">(in KUSD)</div></td><td class="gutter" style="width: 1.62%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.62%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 7.16%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Price <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">(in USD)</div></td><td class="gutter" style="width: 1.62%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.62%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 8.79%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Number of <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">treasury <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">shares</div></td><td class="gutter" style="width: 1.62%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.62%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 8.62%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Value <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">(in KUSD)</div></td></tr><tr><td style="width: 30.84%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">At the beginning of the year<font style="padding-left: 2.88pt;"></font></div></td><td class="gutter" style="width: 1.62%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.62%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.16%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 6.58pt; text-align: left;"><font style="padding-left: 7.5pt;">&#8212;</font></div></td><td class="gutter" style="width: 1.62%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.62%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.35%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 30pt;">&#8212;</font></div></td><td class="gutter" style="width: 1.62%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.62%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.61%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10.94pt; text-align: left;"><font style="padding-left: 5pt;">&#8212;</font></div></td><td class="gutter" style="width: 1.62%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.62%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.16%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10.33pt; text-align: left;">&#8212;</div></td><td class="gutter" style="width: 1.62%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.62%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.79%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 13.81pt; text-align: left;">&#8212;</div></td><td class="gutter" style="width: 1.62%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.62%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.62%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 13.44pt; text-align: left;">&#8212;</div></td></tr><tr><td style="width: 30.84%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Additions<font style="padding-left: 0.06pt;"></font></div></td><td class="gutter" style="width: 1.62%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.62%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 7.16%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 6.58pt; text-align: left;">0.08</div></td><td class="gutter" style="width: 1.62%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.62%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 9.35%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;">1,750,000</div></td><td class="gutter" style="width: 1.62%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.62%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 8.61%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10.94pt; text-align: left;">141</div></td><td class="gutter" style="width: 1.62%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.62%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 7.16%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10.33pt; text-align: left;">&#8212;</div></td><td class="gutter" style="width: 1.62%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.62%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 8.79%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 13.81pt; text-align: left;">&#8212;</div></td><td class="gutter" style="width: 1.62%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.62%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 8.62%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 13.44pt; text-align: left;">&#8212;</div></td></tr><tr><td style="width: 30.84%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Disposals<font style="padding-left: 0.63pt;"></font></div></td><td class="gutter" style="width: 1.62%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.62%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.16%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 6.58pt; text-align: left;">0.08</div></td><td class="gutter" style="width: 1.62%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.62%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.35%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 4.17pt; border-bottom: 1pt solid #000000; min-width: 40pt;">(</font><font style="border-bottom: 1pt solid #000000; min-width: 40pt;">509,460</font><font style="border-bottom: 1pt solid #000000; min-width: 40pt;"></font><font style="min-width: 40pt;">)</font></div></td><td class="gutter" style="width: 1.62%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.62%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.61%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10.94pt; text-align: left;"><font style="padding-left: 1.67pt; border-bottom: 1pt solid #000000; min-width: 15pt;">(41</font><font style="min-width: 15pt;">)</font></div></td><td class="gutter" style="width: 1.62%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.62%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.16%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10.33pt; text-align: left;"><font style="border-bottom: 1pt solid #000000; min-width: 10pt;">&#8212;</font></div></td><td class="gutter" style="width: 1.62%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.62%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.79%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 13.81pt; text-align: left;"><font style="border-bottom: 1pt solid #000000; min-width: 10pt;">&#8212;</font></div></td><td class="gutter" style="width: 1.62%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.62%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.62%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 13.44pt; text-align: left;"><font style="border-bottom: 1pt solid #000000; min-width: 10pt;">&#8212;</font></div></td></tr><tr><td style="width: 30.84%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 6pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">At the end of the year<font style="padding-left: 3.44pt;"></font></div></td><td class="gutter" style="width: 1.62%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt;">&#8203;</td><td class="gutter" style="width: 1.62%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt;">&#8203;</td><td style="width: 7.16%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 6pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 6.58pt; text-align: left;">0.08</div></td><td class="gutter" style="width: 1.62%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt;">&#8203;</td><td class="gutter" style="width: 1.62%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt;">&#8203;</td><td style="width: 9.35%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 6pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="border-bottom: 1pt solid #000000; min-width: 40pt;">1,240,540</font></div></td><td class="gutter" style="width: 1.62%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt;">&#8203;</td><td class="gutter" style="width: 1.62%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt;">&#8203;</td><td style="width: 8.61%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 6pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10.94pt; text-align: left;"><font style="border-bottom: 1pt solid #000000; min-width: 15pt;">100</font></div></td><td class="gutter" style="width: 1.62%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt;">&#8203;</td><td class="gutter" style="width: 1.62%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt;">&#8203;</td><td style="width: 7.16%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 6pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10.33pt; text-align: left;"><font style="border-bottom: 1pt solid #000000; min-width: 10pt;">&#8212;</font></div></td><td class="gutter" style="width: 1.62%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt;">&#8203;</td><td class="gutter" style="width: 1.62%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt;">&#8203;</td><td style="width: 8.79%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 6pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 13.81pt; text-align: left;"><font style="border-bottom: 1pt solid #000000; min-width: 10pt;">&#8212;</font></div></td><td class="gutter" style="width: 1.62%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt;">&#8203;</td><td class="gutter" style="width: 1.62%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt;">&#8203;</td><td style="width: 8.62%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 6pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 13.44pt; text-align: left;"><font style="border-bottom: 1pt solid #000000; min-width: 10pt;">&#8212;</font></div></td></tr></table><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: left;">As at December&#160;31, 2019, the Company owns 1,240,540 own shares for a value of KUSD 100 (2018: no own shares).</div><div class="h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 20pt; margin-left: 20pt; text-align: left;"><u>Authorized Capital</u></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: left;">As of September&#160;19, 2019, the Board of Directors was authorized, subject to compliance with the Company's shareholder agreement, to increase the share capital at any time until March&#160;31, 2020, by a maximum amount of CHF 1,647,000, by issuing a maximum of 20,587,500 common shares, fully paid up, with a par value of CHF 0.08 each. An increase of the share capital in partial amounts is permissible. As at December&#160;31, 2019, the remaining maximum amount is CHF 1,647,000, which may be raised by issuing a maximum of 20,587,500 common shares.</div><div class="h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 20pt; margin-left: 20pt; text-align: left;"><u>Dividend</u> </div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: left;">At the next ordinary Annual General Meeting, the Board of Directors will not propose any dividend in respect of fiscal year 2019 (2018: 0).</div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 12pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">25.<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; text-align: left;">Commitments</div></td></tr></table><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 7pt; margin-left: 20pt; text-align: left;">The Company has contractual obligations as follows:</div><div class="h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 20pt; margin-left: 20pt; text-align: left;"><u>a) Collaborations and co-operations with development partners</u></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: left;">The Company has entered into various collaborations with development partners, including in-licensing and manufacturing agreements. These agreements provide for the Company to make milestone payments that are conditional on success, and that are spread over various stages of development and commercialization, including achieving preclinical proof of concept, filing an investigational new drug (&#8220;IND&#8221;) application, commencing or completing multiple clinical development stages, obtaining regulatory approval in multiple countries, and achieving various levels of commercial sales. As of December&#160;31, 2019, the aggregate amount of such potential milestone payments, under all such collaboration agreements, was KUSD 323,973 (2018: KUSD 331,130). These milestone payments relate to product candidates in the following phases:</div><table cellspacing="0" cellpadding="0" class="fintab" style="margin-top: 11.25pt; border-collapse: collapse; width: 428pt; margin-left: 20pt;"><tr class="header"><td style="width: 67.29%; text-align: left; vertical-align: bottom; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">(in KUSD):</div></td><td class="gutter" style="width: 2.67%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 2.67%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 11.02%; text-align: center; vertical-align: bottom; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 2.67%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 2.67%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 11.02%; text-align: center; vertical-align: bottom; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td></tr><tr class="header"><td style="width: 67.29%; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">R&amp;D Phase</div></td><td class="gutter" style="width: 2.67%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 2.67%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 11.02%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">December&#160;31, <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2019</div></td><td class="gutter" style="width: 2.67%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 2.67%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 11.02%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">December&#160;31, <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2018</div></td></tr><tr><td style="width: 67.29%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Pre-clinical<font style="padding-left: 4.41pt;"></font></div></td><td class="gutter" style="width: 2.67%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.67%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 11.02%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.33pt; text-align: left;">192,290</div></td><td class="gutter" style="width: 2.67%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.67%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 11.02%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.33pt; text-align: left;">275,602</div></td></tr><tr><td style="width: 67.29%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Phase I<font style="padding-left: 0.52pt;"></font></div></td><td class="gutter" style="width: 2.67%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.67%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 11.02%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.33pt; text-align: left;"><font style="padding-left: 0.74pt;">116,115</font></div></td><td class="gutter" style="width: 2.67%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.67%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 11.02%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.33pt; text-align: left;"><font style="padding-left: 5pt;">49,959</font></div></td></tr><tr><td style="width: 67.29%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Phase II<font style="padding-left: 2.19pt;"></font></div></td><td class="gutter" style="width: 2.67%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.67%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 11.02%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.33pt; text-align: left;"><font style="padding-left: 5pt; border-bottom: 1pt solid #000000; min-width: 32.5pt;">15,568</font></div></td><td class="gutter" style="width: 2.67%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.67%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 11.02%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.33pt; text-align: left;"><font style="padding-left: 10pt; border-bottom: 1pt solid #000000; min-width: 32.5pt;">5,569 </font></div></td></tr><tr><td style="width: 67.29%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 6pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 2.67%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt;">&#8203;</td><td class="gutter" style="width: 2.67%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt;">&#8203;</td><td style="width: 11.02%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 6pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 7.33pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 32.5pt;">323,973</font></div></td><td class="gutter" style="width: 2.67%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt;">&#8203;</td><td class="gutter" style="width: 2.67%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt;">&#8203;</td><td style="width: 11.02%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 6pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 7.33pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 32.5pt;">331,130</font></div></td></tr></table><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: left;">As at December&#160;31, 2019, the Company had two product candidates in phase II clinical trials: ADCT-301 and ADCT-402. Product candidate ADCT-301 is the subject of a collaboration and license agreement with Genmab A/S, under which there are no upfront or future milestone payments payable and no revenue </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 36pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">F-66<br></div></div></div>
<!--End Page 320-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 321-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 540pt;"><a name="nt10014672x1_drs_204-finnotes02_pg37"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="block-frill" style="width: 540pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: Arial, Helvetica, sans-serif; font-size: 9pt; font-weight: bold; margin-top: 6pt; text-align: center;">Confidential Treatment Requested by ADC Therapeutics SA Pursuant to 17 C.F.R. &#167; 200.83<br></div></div><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 36pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">ADC Therapeutics SA, Epalinges <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;"><div class="rule-full" style="height: 0pt; width: 100%; border-bottom: 1pt solid #000000; margin-top: 1pt; margin-bottom: 1pt; margin-left: auto; margin-right: auto;"> </div>NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS <font style="padding-left: 4pt;">(continued)</font><br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 7pt; margin-left: 20pt; text-align: left;">receivable. Product candidate ADCT-402 is not linked to any collaboration agreement regarding the in-licensing of intellectual property. Both product candidates are linked to manufacturing agreements under which payment of the amounts indicated above under Phase II could become payable upon the achievement of certain milestones.</div><div class="h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 20.5pt; margin-left: 20pt; text-align: left;"><u>b) Future minimum lease payments under non-cancellable operating leases</u> </div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: left;">The group leases various offices and vehicles under non-cancellable operating leases expiring within six months to eight years. The leases have varying terms, escalation clauses and renewal rights. On renewal, the terms of the leases are renegotiated.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: left;">From 1 January 2019, the group has recognized right-of-use assets for these leases, except for short-term and low-value leases. See note 4 (i) &#8220;New standards adopted by the Group&#8221;, note 3.10 &#8220;Leases&#8221; and note 17 &#8220;Leases&#8221; for further information. The principal portion of future lease payments is now recognized as lease liabilities.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: left;">Future minimum lease payments under non-cancellable operating leases at December&#160;31, 2018, as reported under IAS 17, before the change in accounting policy as from January&#160;1, 2019, were as follows:</div><table cellspacing="0" cellpadding="0" class="fintab" style="margin-top: 11.25pt; border-collapse: collapse; width: 428pt; margin-left: 20pt;"><tr class="header"><td style="width: 78.5%; text-align: left; vertical-align: bottom; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">(in KUSD)</div></td><td class="gutter" style="width: 5.24%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 5.24%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 11.02%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">December&#160;31, <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2018</div></td></tr><tr><td style="width: 78.5%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Not later than 1&#160;year<font style="padding-left: 2.99pt;"></font></div></td><td class="gutter" style="width: 5.24%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 5.24%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 11.02%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 12.33pt; text-align: left;">1,084</div></td></tr><tr><td style="width: 78.5%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Later than 1&#160;year and not later than 5&#160;years<font style="padding-left: 4.7pt;"></font></div></td><td class="gutter" style="width: 5.24%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 5.24%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 11.02%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 12.33pt; text-align: left;">3,163</div></td></tr><tr><td style="width: 78.5%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">More than 5&#160;years<font style="padding-left: 3.54pt;"></font></div></td><td class="gutter" style="width: 5.24%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 5.24%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 11.02%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 12.33pt; text-align: left;"><font style="padding-left: 7.5pt; border-bottom: 1pt solid #000000; min-width: 22.5pt;">131 </font></div></td></tr><tr><td style="width: 78.5%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 6pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 5.24%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt;">&#8203;</td><td class="gutter" style="width: 5.24%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt;">&#8203;</td><td style="width: 11.02%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 6pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 12.33pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 22.5pt;">4,378</font></div></td></tr></table><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: left;">In 2018, lease payments incurred for all non-cancellable operating leases were recorded in the income statement in an amount of KUSD 869.</div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 12pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">26.<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; text-align: left;">Contingent liabilities</div></td></tr></table><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: left;">The Group has no contingent liabilities in respect of legal claims arising in the ordinary course of business. There are no material legal proceedings to which the Company is a party. In the opinion of the Board of Directors, the disposition of such legal proceedings should not have a material impact on the Company&#8217;s results of operations, financial position and cash flows.</div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 12pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">27.<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; text-align: left;">Related parties</div></td></tr></table><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: left;">Share data have been revised to give effect to the share split and share consolidation explained in note 2 (iv) &#8220;Share split&#8221; and in note 2 (v) &#8220;Share consolidation&#8221;.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: left;">Parties are considered to be related if one party has the ability, directly or indirectly, to control the other party or exercise significant influence over the other party in making financial and operating decisions.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: left;">A.T. Holdings II S&#224;rl (&#8220;AT Holdings II&#8221;) is a shareholder in the Company. AT Holdings II is in turn ultimately entirely owned by Auven Therapeutics Holdings, L.P. (&#8220;ATH&#8221;), a limited partnership registered in the British Virgin Islands. ATH&#8217;s General Partner is Auven Therapeutics General L.P., which itself is a limited partnership whose General Partner is Auven Therapeutics GP Ltd. The manager of ATH is Auven Therapeutics Management L.L.L.P. (&#8220;ATM&#8221;).</div><div class="h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 20pt; margin-left: 20pt; text-align: left;"><u>Services provided by the Company</u></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: left;">The Company provides registered office and simple administrative services to four subsidiaries of ATH. The amounts invoiced in 2019, recognized as general and administrative (&#8220;G&amp;A&#8221;) expenses, amounted to KUSD 4 (2018: KUSD 7).</div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 36pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">F-67<br></div></div></div>
<!--End Page 321-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 322-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 540pt;"><a name="nt10014672x1_drs_204-finnotes02_pg38"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="block-frill" style="width: 540pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: Arial, Helvetica, sans-serif; font-size: 9pt; font-weight: bold; margin-top: 6pt; text-align: center;">Confidential Treatment Requested by ADC Therapeutics SA Pursuant to 17 C.F.R. &#167; 200.83<br></div></div><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 36pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">ADC Therapeutics SA, Epalinges <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;"><div class="rule-full" style="height: 0pt; width: 100%; border-bottom: 1pt solid #000000; margin-top: 1pt; margin-bottom: 1pt; margin-left: auto; margin-right: auto;"> </div>NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS <font style="padding-left: 4pt;">(continued)</font><br></div><div class="h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 7pt; margin-left: 20pt; text-align: left;"><u>Services provided to the Company</u></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: left;">Auven affiliated companies incurred expenses on behalf of the Company, relating to a telecommunication contract with a third-party vendor, and recharged these at cost. The costs incurred in 2019, recognized as G&amp;A expenses, amounted to KUSD 11 (2018: KUSD 38).</div><div class="h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 20.5pt; margin-left: 20pt; text-align: left;"><u>Other transactions with related parties</u></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 7.5pt; margin-left: 20pt; text-align: left;">- Out of the 3,687,500 class E shares issued in 2019, 809,107 shares were purchased by related parties.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: left;">- Shares were issued to and repurchased at the same price from a related party in September 2019 in order to have available treasury shares to meet the demand for shares when share options are exercised.</div><div class="h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 20.5pt; margin-left: 20pt; text-align: left;"><u>Related party balances at year-end</u> </div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: left;">Trade accounts receivable at December&#160;31, 2019, include amounts receivable from Auven companies amounting to KUSD 0 (2018: KUSD 2).</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: left;">Trade accounts payable at December&#160;31, 2019, include amounts payable to Auven companies amounting to KUSD 1 (2018: KUSD 10).</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8.5pt; margin-left: 20pt; text-align: left;">All amounts due to affiliates have no defined payment terms and are non-interest bearing.</div><div class="h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 20.5pt; margin-left: 20pt; text-align: left;"><u>Key management compensation</u></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 7.5pt; margin-left: 20pt; text-align: left;">Key management compensation was:</div><table cellspacing="0" cellpadding="0" class="fintab" style="margin-top: 11.25pt; border-collapse: collapse; width: 428pt; margin-left: 20pt;"><tr class="header"><td style="width: 67.29%; text-align: left; vertical-align: bottom; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">(in KUSD)</div></td><td class="gutter" style="width: 2.67%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 2.67%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 11.02%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Year ended <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">December&#160;31, <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2019</div></td><td class="gutter" style="width: 2.67%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 2.67%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 11.02%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Year ended <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">December&#160;31, <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2018</div></td></tr><tr><td style="width: 67.29%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Salaries and other short-term employee benefits<font style="padding-left: 0.03pt;"></font></div></td><td class="gutter" style="width: 2.67%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.67%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 11.02%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 12.33pt; text-align: left;">5,364</div></td><td class="gutter" style="width: 2.67%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.67%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 11.02%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 12.33pt; text-align: left;">4,512</div></td></tr><tr><td style="width: 67.29%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Pension costs<font style="padding-left: 0.52pt;"></font></div></td><td class="gutter" style="width: 2.67%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.67%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 11.02%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 12.33pt; text-align: left;"><font style="padding-left: 7.5pt;">407</font></div></td><td class="gutter" style="width: 2.67%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.67%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 11.02%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 12.33pt; text-align: left;"><font style="padding-left: 7.5pt;">299</font></div></td></tr><tr><td style="width: 67.29%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Share-based compensation expenses<font style="padding-left: 3.34pt;"></font></div></td><td class="gutter" style="width: 2.67%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.67%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 11.02%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 12.33pt; text-align: left;"><font style="padding-left: 7.5pt;">396</font></div></td><td class="gutter" style="width: 2.67%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.67%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 11.02%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 12.33pt; text-align: left;"><font style="padding-left: 7.5pt;">341</font></div></td></tr><tr><td style="width: 67.29%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Other compensation<font style="padding-left: 3.86pt;"></font></div></td><td class="gutter" style="width: 2.67%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 2.67%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 11.02%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 12.33pt; text-align: left;"><font style="padding-left: 12.5pt; border-bottom: 1pt solid #000000; min-width: 22.5pt;">73</font></div></td><td class="gutter" style="width: 2.67%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 2.67%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 11.02%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 12.33pt; text-align: left;"><font style="padding-left: 7.5pt; border-bottom: 1pt solid #000000; min-width: 22.5pt;">183 </font></div></td></tr><tr><td style="width: 67.29%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 2.67%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.67%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 11.02%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 12.33pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 22.5pt;">6,240</font></div></td><td class="gutter" style="width: 2.67%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.67%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 11.02%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 12.33pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 22.5pt;">5,335</font></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 12pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">28.<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; text-align: left;">Loss per share</div></td></tr></table><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: left;">Share data have been revised to give effect to the share split and share consolidation explained in note 2 (iv), &#8220;Share split&#8221; and in note 2 (v) &#8220;Share consolidation&#8221;.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: left;">The Company's shares comprise 5 classes of common and preferred shares. The net loss is allocated to each class pro rata to its weighted average number of shares in issue during the period. The basic loss per share is calculated by dividing the net loss attributable to shareholders by the weighted average number of shares in issue during the period, excluding common shares owned by the Company and held as treasury shares, as follows:</div><table cellspacing="0" cellpadding="0" class="fintab" style="margin-top: 11.25pt; border-collapse: collapse; width: 428pt; margin-left: 20pt;"><tr class="header"><td style="width: 44.86%; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Year Ended December&#160;31, 2019</div></td><td class="gutter" style="width: 0.72%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 0.72%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 9.35%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Common <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Shares</div></td><td class="gutter" style="width: 0.72%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 0.72%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 10.51%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Class&#160;B <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Preferred <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Shares</div></td><td class="gutter" style="width: 0.72%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 0.72%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 9.35%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Class&#160;C <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Preferred <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Shares</div></td><td class="gutter" style="width: 0.72%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 0.72%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 9.35%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Class&#160;D <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Preferred <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Shares</div></td><td class="gutter" style="width: 0.72%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 0.72%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 9.35%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Class&#160;E <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Preferred <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Shares</div></td></tr><tr><td style="width: 44.86%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-indent: -10pt; text-align: left;">Net loss attributable to shareholders (in&#160;KUSD)<font style="padding-left: 4.52pt;"></font></div></td><td class="gutter" style="width: 0.72%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.72%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.35%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 9.17pt;">(22,137)</font></div></td><td class="gutter" style="width: 0.72%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.72%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.51%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 14.17pt;">(33,713)</font></div></td><td class="gutter" style="width: 0.72%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.72%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.35%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 9.17pt;">(19,087)</font></div></td><td class="gutter" style="width: 0.72%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.72%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.35%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 9.17pt;">(18,526)</font></div></td><td class="gutter" style="width: 0.72%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.72%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.35%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 9.17pt;">(23,021)</font></div></td></tr><tr><td style="width: 44.86%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Weighted average number of shares in issue<font style="padding-left: 3.72pt;"></font></div></td><td class="gutter" style="width: 0.72%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.72%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 9.35%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">9,365,406</div></td><td class="gutter" style="width: 0.72%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.72%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 10.51%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">14,262,500</div></td><td class="gutter" style="width: 0.72%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.72%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 9.35%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">8,075,000</div></td><td class="gutter" style="width: 0.72%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.72%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 9.35%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">7,837,500</div></td><td class="gutter" style="width: 0.72%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.72%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 9.35%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">9,739,555</div></td></tr><tr><td style="width: 44.86%; text-align: left; vertical-align: bottom; padding-top: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Basic and diluted loss per share (in USD)<font style="padding-left: 2.91pt;"></font></div></td><td class="gutter" style="width: 0.72%; border-bottom: none; font-size: 2pt; padding-top: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.72%; border-bottom: none; font-size: 2pt; padding-top: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.35%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 19.17pt;">(</font>2.36)</div></td><td class="gutter" style="width: 0.72%; border-bottom: none; font-size: 2pt; padding-top: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.72%; border-bottom: none; font-size: 2pt; padding-top: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.51%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 24.17pt;">(</font>2.36)</div></td><td class="gutter" style="width: 0.72%; border-bottom: none; font-size: 2pt; padding-top: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.72%; border-bottom: none; font-size: 2pt; padding-top: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.35%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 19.17pt;">(</font>2.36)</div></td><td class="gutter" style="width: 0.72%; border-bottom: none; font-size: 2pt; padding-top: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.72%; border-bottom: none; font-size: 2pt; padding-top: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.35%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 19.17pt;">(</font>2.36)</div></td><td class="gutter" style="width: 0.72%; border-bottom: none; font-size: 2pt; padding-top: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.72%; border-bottom: none; font-size: 2pt; padding-top: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.35%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 19.17pt;">(</font>2.36)</div></td></tr></table></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 36pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">F-68<br></div></div></div>
<!--End Page 322-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 323-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 540pt;"><a name="nt10014672x1_drs_204-finnotes02_pg39"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="block-frill" style="width: 540pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: Arial, Helvetica, sans-serif; font-size: 9pt; font-weight: bold; margin-top: 6pt; text-align: center;">Confidential Treatment Requested by ADC Therapeutics SA Pursuant to 17 C.F.R. &#167; 200.83<br></div></div><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 36pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">ADC Therapeutics SA, Epalinges <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;"><div class="rule-full" style="height: 0pt; width: 100%; border-bottom: 1pt solid #000000; margin-top: 1pt; margin-bottom: 1pt; margin-left: auto; margin-right: auto;"> </div>NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS <font style="padding-left: 4pt;">(continued)</font><br></div><table cellspacing="0" cellpadding="0" class="fintab" style="margin-top: 3.25pt; border-collapse: collapse; width: 428pt; margin-left: 20pt;"><tr class="header"><td style="width: 44.86%; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Year Ended December&#160;31, 2018</div></td><td class="gutter" style="width: 0.72%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 0.72%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 9.35%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Common <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Shares</div></td><td class="gutter" style="width: 0.72%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 0.72%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 10.51%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Class&#160;B <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Preferred <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Shares</div></td><td class="gutter" style="width: 0.72%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 0.72%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 9.35%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Class&#160;C <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Preferred <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Shares</div></td><td class="gutter" style="width: 0.72%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 0.72%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 9.35%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Class&#160;D <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Preferred <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Shares</div></td><td class="gutter" style="width: 0.72%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 0.72%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 9.35%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Class&#160;E <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Preferred <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Shares</div></td></tr><tr><td style="width: 44.86%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-indent: -10pt; text-align: left;">Net loss attributable to shareholders (in KUSD)<font style="padding-left: 3.96pt;"></font></div></td><td class="gutter" style="width: 0.72%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.72%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.35%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 9.17pt;">(23,014)</font></div></td><td class="gutter" style="width: 0.72%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.72%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.51%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 14.17pt;">(37,676)</font></div></td><td class="gutter" style="width: 0.72%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.72%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.35%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 9.17pt;">(21,330)</font></div></td><td class="gutter" style="width: 0.72%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.72%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.35%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 9.17pt;">(20,703)</font></div></td><td class="gutter" style="width: 0.72%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.72%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.35%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 9.17pt;">(20,373)</font></div></td></tr><tr><td style="width: 44.86%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Weighted average number of shares in issue<font style="padding-left: 3.72pt;"></font></div></td><td class="gutter" style="width: 0.72%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.72%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 9.35%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">8,712,500</div></td><td class="gutter" style="width: 0.72%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.72%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 10.51%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">14,262,500</div></td><td class="gutter" style="width: 0.72%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.72%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 9.35%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">8,075,000</div></td><td class="gutter" style="width: 0.72%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.72%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 9.35%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">7,837,500</div></td><td class="gutter" style="width: 0.72%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.72%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 9.35%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">7,712,500</div></td></tr><tr><td style="width: 44.86%; text-align: left; vertical-align: bottom; padding-top: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Basic and diluted loss per share (in USD)<font style="padding-left: 2.91pt;"></font></div></td><td class="gutter" style="width: 0.72%; border-bottom: none; font-size: 2pt; padding-top: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.72%; border-bottom: none; font-size: 2pt; padding-top: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.35%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 19.17pt;">(2.</font>64)</div></td><td class="gutter" style="width: 0.72%; border-bottom: none; font-size: 2pt; padding-top: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.72%; border-bottom: none; font-size: 2pt; padding-top: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.51%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 24.17pt;">(2.</font>64)</div></td><td class="gutter" style="width: 0.72%; border-bottom: none; font-size: 2pt; padding-top: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.72%; border-bottom: none; font-size: 2pt; padding-top: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.35%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 19.17pt;">(2.</font>64)</div></td><td class="gutter" style="width: 0.72%; border-bottom: none; font-size: 2pt; padding-top: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.72%; border-bottom: none; font-size: 2pt; padding-top: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.35%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 19.17pt;">(2.</font>64)</div></td><td class="gutter" style="width: 0.72%; border-bottom: none; font-size: 2pt; padding-top: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.72%; border-bottom: none; font-size: 2pt; padding-top: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.35%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 19.17pt;">(2.</font>64)</div></td></tr></table><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: left;">For the years ended December&#160;31, 2019 and 2018, the potential impact, on the calculation of earnings per share, of the existing potential common shares related to the Incentive Plans 2014 and 2019 (see note 23, &#8220;Share-based compensation expenses&#8221;) is not presented, as the impact would be to dilute a loss, which causes them to be deemed &#8220;not dilutive&#8221; for the purposes of the required disclosure.</div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 12pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">29.<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; text-align: left;">Foreign currency exchange rate</div></td></tr></table><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: left;">The following exchange rates have been used for the translation of the financial statements of ADCT UK, the functional currency of which is the British pound:</div><table cellspacing="0" cellpadding="0" class="fintab" style="margin-top: 11.25pt; border-collapse: collapse; width: 428pt; margin-left: 20pt;"><tr class="header"><td style="width: 61.68%; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">USD / GBP</div></td><td class="gutter" style="width: 1.94%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.94%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 4.67%; text-align: center; vertical-align: bottom; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 1.94%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.94%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 11.02%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Year ended <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">December&#160;31, <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2019</div></td><td class="gutter" style="width: 1.93%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.93%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 11.02%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Year ended <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">December&#160;31, <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2018</div></td></tr><tr><td style="width: 61.68%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Closing rate, GBP 1<font style="padding-left: 3.84pt;"></font></div></td><td class="gutter" style="width: 1.94%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.94%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 4.67%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;">USD</div></td><td class="gutter" style="width: 1.94%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.94%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 11.02%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.33pt; text-align: left;">1.31858</div></td><td class="gutter" style="width: 1.93%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.93%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 11.02%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.33pt; text-align: left;">1.26902</div></td></tr><tr><td style="width: 61.68%; text-align: left; vertical-align: bottom; padding-top: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Weighted average exchange rate, GBP 1<font style="padding-left: 1.36pt;"></font></div></td><td class="gutter" style="width: 1.94%; border-bottom: none; font-size: 2pt; padding-top: 3pt;">&#8203;</td><td class="gutter" style="width: 1.94%; border-bottom: none; font-size: 2pt; padding-top: 3pt;">&#8203;</td><td style="width: 4.67%; text-align: left; vertical-align: bottom; padding-top: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;">USD</div></td><td class="gutter" style="width: 1.94%; border-bottom: none; font-size: 2pt; padding-top: 3pt;">&#8203;</td><td class="gutter" style="width: 1.94%; border-bottom: none; font-size: 2pt; padding-top: 3pt;">&#8203;</td><td style="width: 11.02%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.33pt; text-align: left;">1.27468</div></td><td class="gutter" style="width: 1.93%; border-bottom: none; font-size: 2pt; padding-top: 3pt;">&#8203;</td><td class="gutter" style="width: 1.93%; border-bottom: none; font-size: 2pt; padding-top: 3pt;">&#8203;</td><td style="width: 11.02%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.33pt; text-align: left;">1.35009</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 12pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"><a name="tNTC1"><!--Anchor--></a>30.<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; text-align: left;">Events after the reporting date</div></td></tr></table><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: left;">The Company has evaluated its subsequent events through March&#160;2, 2020, the date the financial statements were available to be issued, and has concluded that there are no subsequent events requiring disclosure in the financial statements.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: left;">On April 24, 2020 the Company effected a five to four share consolidation of its outstanding shares. Accordingly, all share and per share amounts for all periods presented in these consolidated financial statements and notes thereto have been adjusted retroactively, where applicable, to reflect this share consolidation.</div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 36pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">F-69<br></div></div></div>
<!--End Page 323-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 324-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 540pt;"><a name="nt10014672x1_drs_300-bcv_pg1"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="block-frill" style="width: 540pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; font-weight: bold; margin-top: 6pt; text-align: center;">Confidential Treatment Requested by ADC Therapeutics SA Pursuant to 17 C.F.R. &#167; 200.83<br></div></div><div class="block-frill" style="width: 456pt; margin-left: 42pt;"><div><div class="rule-full" style="height: 0pt; width: 100%; border-bottom: 2pt solid #000000; margin-top: 1pt; margin-bottom: 1pt; margin-left: auto; margin-right: auto;"> </div><div class="rule-full" style="height: 0pt; width: 100%; border-bottom: 1pt solid #000000; margin-bottom: 1pt; margin-left: auto; margin-right: auto; margin-top: 4pt;"> </div></div></div><div class="page-content"><div class="block-main" style="width: 456pt; margin-left: 42pt;"><div class="h1" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 16pt; font-style: italic; font-weight: bold; margin-top: 34.75pt; text-align: center;">&#8195;&#8195;&#8195;&#8195;&#8195;&#8195; Shares</div><div class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10pt; margin-top: 24.75pt; text-align: center;"><img style="height: 103px; width: 180px;" src="logo_adc2x1.jpg"><br></div><div class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">&#8201;</div><div class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 14pt; font-style: italic; margin-top: 8pt; text-align: center;">Common Shares</div><div><div class="rule-partial" style="height: 0pt; width: 96pt; border-bottom: 1pt solid #000000; margin-bottom: 2pt; margin-left: auto; margin-right: auto; margin-top: 60.75pt;"> </div></div><div class="h1" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 16pt; font-style: italic; margin-top: 3pt; text-align: center;">Prospectus</div><div><div class="rule-partial" style="height: 0pt; width: 96pt; border-bottom: 1pt solid #000000; margin-bottom: 2pt; margin-left: auto; margin-right: auto; margin-top: 12.75pt;"> </div></div><div class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 16pt; font-style: italic; font-weight: bold; margin-top: 152pt; text-align: center;">MORGAN STANLEY<br></div><div class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 16pt; font-style: italic; font-weight: bold; margin-top: 0pt; text-align: center;">&#8195;<br></div><div class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 16pt; font-style: italic; font-weight: bold; margin-top: 0pt; text-align: center;">BofA SECURITIES<br></div><div class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 16pt; font-style: italic; font-weight: bold; margin-top: 0pt; text-align: center;">&#8195;<br></div><div class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 16pt; font-style: italic; font-weight: bold; margin-top: 0pt; text-align: center;">COWEN</div><div class="fpara" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 180pt; text-align: center;">&#8195;&#8195;, 2020</div></div></div><div class="block-frill" style="width: 456pt; margin-top: 12pt; margin-left: 42pt;"><div><div class="rule-full" style="height: 0pt; width: 100%; border-bottom: 1pt solid #000000; margin-top: 1pt; margin-bottom: 1pt; margin-left: auto; margin-right: auto;"> </div><div class="rule-full" style="height: 0pt; width: 100%; border-bottom: 2pt solid #000000; margin-bottom: 1pt; margin-left: auto; margin-right: auto; margin-top: 4pt;"> </div></div></div></div>
<!--End Page 324-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 325-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 540pt;"><a name="nt10014672x1_drs_301-part2_pg1"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="block-frill" style="width: 540pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: Times New Roman, Times, Serif; font-size: 9pt; font-weight: bold; margin-top: 6pt; text-align: center;">Confidential Treatment Requested by ADC Therapeutics SA Pursuant to 17 C.F.R. &#167; 200.83<br></div></div><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 36pt;"><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: center;">PART II<br></div><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">INFORMATION NOT REQUIRED IN THE PROSPECTUS</div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 12pt; margin-left: 0pt;"><tr><td style="width: 40pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Item 6.<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; text-align: left;">Indemnification of Directors and Officers</div></td></tr></table><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Under Swiss law, a corporation may indemnify its directors or officers against losses and expenses (except for such losses and expenses arising from willful misconduct or negligence, although legal scholars advocate that at least gross negligence be required), including attorney&#8217;s fees, judgments, fines and settlement amounts actually and reasonably incurred in a civil or criminal action, suit or proceeding by reason of having been the representative of, or serving at the request of, the corporation. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Subject to Swiss law, our articles of association provide for indemnification of the existing and former members of our board of directors and our executive committee as well as their heirs, executors and administrators, against liabilities arising in connection with the performance of their duties in such capacity, and our articles of association require us to advance the expenses of defending any action, suit or proceeding to existing and former members of our board of directors and our executive committee to the extent not included in insurance coverage or advanced by third parties.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">In addition, under general principles of Swiss employment law, an employer may be required to indemnify an employee against losses and expenses incurred by such employee in the proper execution of their duties under the employment agreement with the company.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">We have entered into indemnification agreements with each of the members of our board of directors and executive officers, the form of which has been filed as an exhibit to this Registration Statement.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">In the underwriting agreement that we enter into in connection with the sale of the common shares being registered hereby, a form of which has been filed as Exhibit 1.1 to this Registration Statement, the underwriters will agree to indemnify, under certain conditions, us, our directors, our officers and persons who control us within the meaning of the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;), against certain liabilities. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers and controlling persons of the Company, the Company has been advised that, in the opinion of the U.S. Securities and Exchange Commission (the &#8220;SEC&#8221;), such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable.</div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 12pt; margin-left: 0pt;"><tr><td style="width: 40pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Item 7.<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; text-align: left;">Recent Sales of Unregistered Securities</div></td></tr></table><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">During the past three years, we have issued and sold the securities described below without registering the securities under the Securities Act. In this section, share amounts are presented as of the date of the relevant transaction, without accounting for (i)&#160;with respect to transactions that occurred prior to September&#160;19, 2019, the one-to-15,625&#160;share split of all issued shares that was effected on September&#160;19, 2019, (ii)&#160;with respect to transactions that occurred prior to April&#160;24, 2020, the five-to-four reverse share split of all issued shares, which was effected on April&#160;24, 2020, and (iii)&#160;the conversion on a one-to-one basis of our issued Class&#160;B, C, D and E preferred shares into common shares that was effected on May&#160;19, 2020.</div><table cellspacing="0" cellpadding="0" class="fintab" style="margin-top: 5.25pt; border-collapse: collapse; width: 468pt; margin-left: auto; margin-right: auto;"><tr class="header"><td style="width: 32.69%; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 3.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Name or Class of Purchasers</div></td><td class="gutter" style="width: 0.49%; font-size: 2pt; padding-top: 6pt; padding-bottom: 3.75pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 0.49%; font-size: 2pt; padding-top: 6pt; padding-bottom: 3.75pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 15.75%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 3.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Date of Issuance</div></td><td class="gutter" style="width: 0.49%; font-size: 2pt; padding-top: 6pt; padding-bottom: 3.75pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 0.49%; font-size: 2pt; padding-top: 6pt; padding-bottom: 3.75pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 19.87%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 3.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Title of Securities</div></td><td class="gutter" style="width: 0.49%; font-size: 2pt; padding-top: 6pt; padding-bottom: 3.75pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 0.49%; font-size: 2pt; padding-top: 6pt; padding-bottom: 3.75pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 13.24%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 3.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Number of <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Securities</div></td><td class="gutter" style="width: 0.49%; font-size: 2pt; padding-top: 6pt; padding-bottom: 3.75pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 0.49%; font-size: 2pt; padding-top: 6pt; padding-bottom: 3.75pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 14.53%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 3.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Consideration<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">(in USD thousands)</div></td></tr><tr><td style="width: 32.69%; text-align: left; vertical-align: top; background-color: #FFFFFF; padding-top: 3.75pt; padding-bottom: 2.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Deerfield Partners, L.P. and certain of its affiliates</div></td><td class="gutter" style="width: 0.49%; border-bottom: none; font-size: 2pt; background-color: #FFFFFF; padding-top: 3.75pt; padding-bottom: 2.5pt;">&#8203;</td><td class="gutter" style="width: 0.49%; border-bottom: none; font-size: 2pt; background-color: #FFFFFF; padding-top: 3.75pt; padding-bottom: 2.5pt;">&#8203;</td><td style="width: 15.75%; text-align: left; vertical-align: top; background-color: #FFFFFF; padding-top: 3.75pt; padding-bottom: 2.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">May 19, 2020</div></td><td class="gutter" style="width: 0.49%; border-bottom: none; font-size: 2pt; background-color: #FFFFFF; padding-top: 3.75pt; padding-bottom: 2.5pt;">&#8203;</td><td class="gutter" style="width: 0.49%; border-bottom: none; font-size: 2pt; background-color: #FFFFFF; padding-top: 3.75pt; padding-bottom: 2.5pt;">&#8203;</td><td style="width: 19.87%; text-align: left; vertical-align: top; background-color: #FFFFFF; padding-top: 3.75pt; padding-bottom: 2.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Senior secured convertible notes</div></td><td class="gutter" style="width: 0.49%; border-bottom: none; font-size: 2pt; background-color: #FFFFFF; padding-top: 3.75pt; padding-bottom: 2.5pt;">&#8203;</td><td class="gutter" style="width: 0.49%; border-bottom: none; font-size: 2pt; background-color: #FFFFFF; padding-top: 3.75pt; padding-bottom: 2.5pt;">&#8203;</td><td style="width: 13.24%; text-align: right; vertical-align: top; background-color: #FFFFFF; padding-top: 3.75pt; padding-bottom: 2.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; text-align: right;">$65,000,000<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; text-align: right;">principal amount</div></td><td class="gutter" style="width: 0.49%; border-bottom: none; font-size: 2pt; background-color: #FFFFFF; padding-top: 3.75pt; padding-bottom: 2.5pt;">&#8203;</td><td class="gutter" style="width: 0.49%; border-bottom: none; font-size: 2pt; background-color: #FFFFFF; padding-top: 3.75pt; padding-bottom: 2.5pt;">&#8203;</td><td style="width: 14.53%; text-align: left; vertical-align: top; background-color: #FFFFFF; white-space: nowrap; padding-top: 3.75pt; padding-bottom: 2.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 19.38pt; text-align: left;"><font style="padding-left: 4.5pt;">65,000</font></div></td></tr><tr><td style="width: 32.69%; text-align: left; vertical-align: top; background-color: #FFFFFF; padding-top: 2.5pt; padding-bottom: 2.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"></div></td><td class="gutter" style="width: 0.49%; border-bottom: none; font-size: 2pt; background-color: #FFFFFF; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td class="gutter" style="width: 0.49%; border-bottom: none; font-size: 2pt; background-color: #FFFFFF; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td style="width: 15.75%; text-align: left; vertical-align: top; background-color: #FFFFFF; padding-top: 2.5pt; padding-bottom: 2.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"></div></td><td class="gutter" style="width: 0.49%; border-bottom: none; font-size: 2pt; background-color: #FFFFFF; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td class="gutter" style="width: 0.49%; border-bottom: none; font-size: 2pt; background-color: #FFFFFF; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td style="width: 19.87%; text-align: left; vertical-align: top; background-color: #FFFFFF; padding-top: 2.5pt; padding-bottom: 2.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"></div></td><td class="gutter" style="width: 0.49%; border-bottom: none; font-size: 2pt; background-color: #FFFFFF; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td class="gutter" style="width: 0.49%; border-bottom: none; font-size: 2pt; background-color: #FFFFFF; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td style="width: 13.24%; text-align: right; vertical-align: top; background-color: #FFFFFF; padding-top: 2.5pt; padding-bottom: 2.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; text-align: right;"></div></td><td class="gutter" style="width: 0.49%; border-bottom: none; font-size: 2pt; background-color: #FFFFFF; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td class="gutter" style="width: 0.49%; border-bottom: none; font-size: 2pt; background-color: #FFFFFF; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td style="width: 14.53%; text-align: left; vertical-align: top; background-color: #FFFFFF; white-space: nowrap; padding-top: 2.5pt; padding-bottom: 2.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 19.38pt; text-align: left;"></div></td></tr><tr><td style="width: 32.69%; text-align: left; vertical-align: top; background-color: #FFFFFF; padding-top: 2.5pt; padding-bottom: 2.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Directors, officers, employees and consultants </div></td><td class="gutter" style="width: 0.49%; border-bottom: none; font-size: 2pt; background-color: #FFFFFF; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td class="gutter" style="width: 0.49%; border-bottom: none; font-size: 2pt; background-color: #FFFFFF; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td style="width: 15.75%; text-align: left; vertical-align: top; background-color: #FFFFFF; padding-top: 2.5pt; padding-bottom: 2.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">December&#160;16, 2019</div></td><td class="gutter" style="width: 0.49%; border-bottom: none; font-size: 2pt; background-color: #FFFFFF; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td class="gutter" style="width: 0.49%; border-bottom: none; font-size: 2pt; background-color: #FFFFFF; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td style="width: 19.87%; text-align: left; vertical-align: top; background-color: #FFFFFF; padding-top: 2.5pt; padding-bottom: 2.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Common shares </div></td><td class="gutter" style="width: 0.49%; border-bottom: none; font-size: 2pt; background-color: #FFFFFF; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td class="gutter" style="width: 0.49%; border-bottom: none; font-size: 2pt; background-color: #FFFFFF; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td style="width: 13.24%; text-align: right; vertical-align: top; background-color: #FFFFFF; padding-top: 2.5pt; padding-bottom: 2.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; text-align: right;">&#8203;636,825 </div></td><td class="gutter" style="width: 0.49%; border-bottom: none; font-size: 2pt; background-color: #FFFFFF; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td class="gutter" style="width: 0.49%; border-bottom: none; font-size: 2pt; background-color: #FFFFFF; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td style="width: 14.53%; text-align: left; vertical-align: top; background-color: #FFFFFF; white-space: nowrap; padding-top: 2.5pt; padding-bottom: 2.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 19.38pt; text-align: left;">&#8203;<font style="padding-left: 9pt;">1,274</font></div></td></tr><tr><td style="width: 32.69%; text-align: left; vertical-align: top; background-color: #FFFFFF; padding-top: 2.5pt; padding-bottom: 2.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"></div></td><td class="gutter" style="width: 0.49%; border-bottom: none; font-size: 2pt; background-color: #FFFFFF; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td class="gutter" style="width: 0.49%; border-bottom: none; font-size: 2pt; background-color: #FFFFFF; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td style="width: 15.75%; text-align: left; vertical-align: top; background-color: #FFFFFF; padding-top: 2.5pt; padding-bottom: 2.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"></div></td><td class="gutter" style="width: 0.49%; border-bottom: none; font-size: 2pt; background-color: #FFFFFF; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td class="gutter" style="width: 0.49%; border-bottom: none; font-size: 2pt; background-color: #FFFFFF; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td style="width: 19.87%; text-align: left; vertical-align: top; background-color: #FFFFFF; padding-top: 2.5pt; padding-bottom: 2.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"></div></td><td class="gutter" style="width: 0.49%; border-bottom: none; font-size: 2pt; background-color: #FFFFFF; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td class="gutter" style="width: 0.49%; border-bottom: none; font-size: 2pt; background-color: #FFFFFF; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td style="width: 13.24%; text-align: right; vertical-align: top; background-color: #FFFFFF; padding-top: 2.5pt; padding-bottom: 2.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; text-align: right;"></div></td><td class="gutter" style="width: 0.49%; border-bottom: none; font-size: 2pt; background-color: #FFFFFF; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td class="gutter" style="width: 0.49%; border-bottom: none; font-size: 2pt; background-color: #FFFFFF; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td style="width: 14.53%; text-align: left; vertical-align: top; background-color: #FFFFFF; white-space: nowrap; padding-top: 2.5pt; padding-bottom: 2.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 19.38pt; text-align: left;"></div></td></tr><tr><td style="width: 32.69%; text-align: left; vertical-align: top; background-color: #FFFFFF; padding-top: 2.5pt; padding-bottom: 2.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">A.T.&#160;Holdings II S&#224;rl (for the creation of treasury shares to settle share grants and equity-linked instruments for directors, officers employees and consultants)</div></td><td class="gutter" style="width: 0.49%; border-bottom: none; font-size: 2pt; background-color: #FFFFFF; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td class="gutter" style="width: 0.49%; border-bottom: none; font-size: 2pt; background-color: #FFFFFF; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td style="width: 15.75%; text-align: left; vertical-align: top; background-color: #FFFFFF; padding-top: 2.5pt; padding-bottom: 2.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">September 19, 2019</div></td><td class="gutter" style="width: 0.49%; border-bottom: none; font-size: 2pt; background-color: #FFFFFF; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td class="gutter" style="width: 0.49%; border-bottom: none; font-size: 2pt; background-color: #FFFFFF; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td style="width: 19.87%; text-align: left; vertical-align: top; background-color: #FFFFFF; padding-top: 2.5pt; padding-bottom: 2.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Class A common shares</div></td><td class="gutter" style="width: 0.49%; border-bottom: none; font-size: 2pt; background-color: #FFFFFF; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td class="gutter" style="width: 0.49%; border-bottom: none; font-size: 2pt; background-color: #FFFFFF; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td style="width: 13.24%; text-align: right; vertical-align: top; background-color: #FFFFFF; padding-top: 2.5pt; padding-bottom: 2.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; text-align: right;">140</div></td><td class="gutter" style="width: 0.49%; border-bottom: none; font-size: 2pt; background-color: #FFFFFF; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td class="gutter" style="width: 0.49%; border-bottom: none; font-size: 2pt; background-color: #FFFFFF; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td style="width: 14.53%; text-align: left; vertical-align: top; background-color: #FFFFFF; white-space: nowrap; padding-top: 2.5pt; padding-bottom: 2.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 19.38pt; text-align: left;"><font style="padding-left: 15.75pt;">141</font></div></td></tr><tr><td style="width: 32.69%; text-align: left; vertical-align: top; background-color: #FFFFFF; padding-top: 2.5pt; padding-bottom: 2.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"></div></td><td class="gutter" style="width: 0.49%; border-bottom: none; font-size: 2pt; background-color: #FFFFFF; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td class="gutter" style="width: 0.49%; border-bottom: none; font-size: 2pt; background-color: #FFFFFF; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td style="width: 15.75%; text-align: left; vertical-align: top; background-color: #FFFFFF; padding-top: 2.5pt; padding-bottom: 2.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"></div></td><td class="gutter" style="width: 0.49%; border-bottom: none; font-size: 2pt; background-color: #FFFFFF; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td class="gutter" style="width: 0.49%; border-bottom: none; font-size: 2pt; background-color: #FFFFFF; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td style="width: 19.87%; text-align: left; vertical-align: top; background-color: #FFFFFF; padding-top: 2.5pt; padding-bottom: 2.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"></div></td><td class="gutter" style="width: 0.49%; border-bottom: none; font-size: 2pt; background-color: #FFFFFF; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td class="gutter" style="width: 0.49%; border-bottom: none; font-size: 2pt; background-color: #FFFFFF; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td style="width: 13.24%; text-align: right; vertical-align: top; background-color: #FFFFFF; padding-top: 2.5pt; padding-bottom: 2.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; text-align: right;"></div></td><td class="gutter" style="width: 0.49%; border-bottom: none; font-size: 2pt; background-color: #FFFFFF; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td class="gutter" style="width: 0.49%; border-bottom: none; font-size: 2pt; background-color: #FFFFFF; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td style="width: 14.53%; text-align: left; vertical-align: top; background-color: #FFFFFF; white-space: nowrap; padding-top: 2.5pt; padding-bottom: 2.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 19.38pt; text-align: left;"></div></td></tr><tr><td style="width: 32.69%; text-align: left; vertical-align: top; background-color: #FFFFFF; padding-top: 2.5pt; padding-bottom: 2.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Various private equity investment funds, institutional investors and other persons</div></td><td class="gutter" style="width: 0.49%; border-bottom: none; font-size: 2pt; background-color: #FFFFFF; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td class="gutter" style="width: 0.49%; border-bottom: none; font-size: 2pt; background-color: #FFFFFF; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td style="width: 15.75%; text-align: left; vertical-align: top; background-color: #FFFFFF; padding-top: 2.5pt; padding-bottom: 2.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">June&#160;7, 2019 <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">June&#160;14, 2019<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">July&#160;5, 2019</div></td><td class="gutter" style="width: 0.49%; border-bottom: none; font-size: 2pt; background-color: #FFFFFF; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td class="gutter" style="width: 0.49%; border-bottom: none; font-size: 2pt; background-color: #FFFFFF; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td style="width: 19.87%; text-align: left; vertical-align: top; background-color: #FFFFFF; padding-top: 2.5pt; padding-bottom: 2.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Class&#160;E preferred shares</div></td><td class="gutter" style="width: 0.49%; border-bottom: none; font-size: 2pt; background-color: #FFFFFF; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td class="gutter" style="width: 0.49%; border-bottom: none; font-size: 2pt; background-color: #FFFFFF; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td style="width: 13.24%; text-align: right; vertical-align: top; background-color: #FFFFFF; padding-top: 2.5pt; padding-bottom: 2.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; text-align: right;">&#8203;295</div></td><td class="gutter" style="width: 0.49%; border-bottom: none; font-size: 2pt; background-color: #FFFFFF; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td class="gutter" style="width: 0.49%; border-bottom: none; font-size: 2pt; background-color: #FFFFFF; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td style="width: 14.53%; text-align: left; vertical-align: top; background-color: #FFFFFF; white-space: nowrap; padding-top: 2.5pt; padding-bottom: 2.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 19.38pt; text-align: left;">&#8203;103,250</div></td></tr><tr><td style="width: 32.69%; text-align: left; vertical-align: top; background-color: #FFFFFF; padding-top: 2.5pt; padding-bottom: 2.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"></div></td><td class="gutter" style="width: 0.49%; border-bottom: none; font-size: 2pt; background-color: #FFFFFF; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td class="gutter" style="width: 0.49%; border-bottom: none; font-size: 2pt; background-color: #FFFFFF; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td style="width: 15.75%; text-align: left; vertical-align: top; background-color: #FFFFFF; padding-top: 2.5pt; padding-bottom: 2.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"></div></td><td class="gutter" style="width: 0.49%; border-bottom: none; font-size: 2pt; background-color: #FFFFFF; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td class="gutter" style="width: 0.49%; border-bottom: none; font-size: 2pt; background-color: #FFFFFF; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td style="width: 19.87%; text-align: left; vertical-align: top; background-color: #FFFFFF; padding-top: 2.5pt; padding-bottom: 2.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"></div></td><td class="gutter" style="width: 0.49%; border-bottom: none; font-size: 2pt; background-color: #FFFFFF; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td class="gutter" style="width: 0.49%; border-bottom: none; font-size: 2pt; background-color: #FFFFFF; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td style="width: 13.24%; text-align: right; vertical-align: top; background-color: #FFFFFF; padding-top: 2.5pt; padding-bottom: 2.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; text-align: right;"></div></td><td class="gutter" style="width: 0.49%; border-bottom: none; font-size: 2pt; background-color: #FFFFFF; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td class="gutter" style="width: 0.49%; border-bottom: none; font-size: 2pt; background-color: #FFFFFF; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td style="width: 14.53%; vertical-align: top; background-color: #FFFFFF; white-space: nowrap; padding-top: 2.5pt; padding-bottom: 2.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 19.38pt; text-align: justify;"></div></td></tr></table></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 36pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">II-1<br></div></div></div>
<!--End Page 325-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 326-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 540pt;"><a name="nt10014672x1_drs_301-part2_pg2"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="block-frill" style="width: 540pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: Arial, Helvetica, sans-serif; font-size: 9pt; font-weight: bold; margin-top: 6pt; text-align: center;">Confidential Treatment Requested by ADC Therapeutics SA Pursuant to 17 C.F.R. &#167; 200.83<br></div></div><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 36pt;"><table cellspacing="0" cellpadding="0" class="fintab" style="margin-top: 4pt; border-collapse: collapse; width: 468pt; margin-left: auto; margin-right: auto;"><tr class="header"><td style="width: 32.69%; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 3.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Name or Class of Purchasers</div></td><td class="gutter" style="width: 0.49%; font-size: 2pt; padding-top: 6pt; padding-bottom: 3.75pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 0.49%; font-size: 2pt; padding-top: 6pt; padding-bottom: 3.75pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 15.75%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 3.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Date of Issuance</div></td><td class="gutter" style="width: 0.49%; font-size: 2pt; padding-top: 6pt; padding-bottom: 3.75pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 0.49%; font-size: 2pt; padding-top: 6pt; padding-bottom: 3.75pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 19.87%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 3.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Title of Securities</div></td><td class="gutter" style="width: 0.49%; font-size: 2pt; padding-top: 6pt; padding-bottom: 3.75pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 0.49%; font-size: 2pt; padding-top: 6pt; padding-bottom: 3.75pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 13.24%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 3.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Number of <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Securities</div></td><td class="gutter" style="width: 0.49%; font-size: 2pt; padding-top: 6pt; padding-bottom: 3.75pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 0.49%; font-size: 2pt; padding-top: 6pt; padding-bottom: 3.75pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 14.53%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 3.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Consideration<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">(in USD thousands)</div></td></tr><tr><td style="width: 32.69%; text-align: left; vertical-align: top; background-color: #FFFFFF; padding-top: 3.75pt; padding-bottom: 2.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Directors and officers</div></td><td class="gutter" style="width: 0.49%; border-bottom: none; font-size: 2pt; background-color: #FFFFFF; padding-top: 3.75pt; padding-bottom: 2.5pt;">&#8203;</td><td class="gutter" style="width: 0.49%; border-bottom: none; font-size: 2pt; background-color: #FFFFFF; padding-top: 3.75pt; padding-bottom: 2.5pt;">&#8203;</td><td style="width: 15.75%; text-align: left; vertical-align: top; background-color: #FFFFFF; padding-top: 3.75pt; padding-bottom: 2.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">June&#160;29, 2018 <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">December&#160;14, 2018 <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">February&#160;6, 2019</div></td><td class="gutter" style="width: 0.49%; border-bottom: none; font-size: 2pt; background-color: #FFFFFF; padding-top: 3.75pt; padding-bottom: 2.5pt;">&#8203;</td><td class="gutter" style="width: 0.49%; border-bottom: none; font-size: 2pt; background-color: #FFFFFF; padding-top: 3.75pt; padding-bottom: 2.5pt;">&#8203;</td><td style="width: 19.87%; text-align: left; vertical-align: top; background-color: #FFFFFF; padding-top: 3.75pt; padding-bottom: 2.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Class&#160;A common shares</div></td><td class="gutter" style="width: 0.49%; border-bottom: none; font-size: 2pt; background-color: #FFFFFF; padding-top: 3.75pt; padding-bottom: 2.5pt;">&#8203;</td><td class="gutter" style="width: 0.49%; border-bottom: none; font-size: 2pt; background-color: #FFFFFF; padding-top: 3.75pt; padding-bottom: 2.5pt;">&#8203;</td><td style="width: 13.24%; text-align: right; vertical-align: top; background-color: #FFFFFF; padding-top: 3.75pt; padding-bottom: 2.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; text-align: right;">42</div></td><td class="gutter" style="width: 0.49%; border-bottom: none; font-size: 2pt; background-color: #FFFFFF; padding-top: 3.75pt; padding-bottom: 2.5pt;">&#8203;</td><td class="gutter" style="width: 0.49%; border-bottom: none; font-size: 2pt; background-color: #FFFFFF; padding-top: 3.75pt; padding-bottom: 2.5pt;">&#8203;</td><td style="width: 14.53%; text-align: center; vertical-align: top; background-color: #FFFFFF; white-space: nowrap; padding-top: 3.75pt; padding-bottom: 2.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 19.38pt; text-align: left;">&#8203;<font style="padding-left: 9pt;">1,314</font></div></td></tr><tr><td style="width: 32.69%; text-align: left; vertical-align: top; background-color: #FFFFFF; padding-top: 2.5pt; padding-bottom: 2.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"></div></td><td class="gutter" style="width: 0.49%; border-bottom: none; font-size: 2pt; background-color: #FFFFFF; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td></tr><tr><td style="width: 32.69%; text-align: left; vertical-align: top; background-color: #FFFFFF; padding-top: 2.5pt; padding-bottom: 2.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Various private equity investment funds, institutional investors and other persons</div></td><td class="gutter" style="width: 0.49%; border-bottom: none; font-size: 2pt; background-color: #FFFFFF; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td class="gutter" style="width: 0.49%; border-bottom: none; font-size: 2pt; background-color: #FFFFFF; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td style="width: 15.75%; text-align: left; vertical-align: top; background-color: #FFFFFF; padding-top: 2.5pt; padding-bottom: 2.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">October&#160;12, 2017 <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">October&#160;30, 2017 <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">November&#160;16, 2017</div></td><td class="gutter" style="width: 0.49%; border-bottom: none; font-size: 2pt; background-color: #FFFFFF; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td class="gutter" style="width: 0.49%; border-bottom: none; font-size: 2pt; background-color: #FFFFFF; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td style="width: 19.87%; text-align: left; vertical-align: top; background-color: #FFFFFF; padding-top: 2.5pt; padding-bottom: 2.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Class&#160;E preferred shares</div></td><td class="gutter" style="width: 0.49%; border-bottom: none; font-size: 2pt; background-color: #FFFFFF; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td class="gutter" style="width: 0.49%; border-bottom: none; font-size: 2pt; background-color: #FFFFFF; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td style="width: 13.24%; text-align: right; vertical-align: top; background-color: #FFFFFF; padding-top: 2.5pt; padding-bottom: 2.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; text-align: right;">617</div></td><td class="gutter" style="width: 0.49%; border-bottom: none; font-size: 2pt; background-color: #FFFFFF; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td class="gutter" style="width: 0.49%; border-bottom: none; font-size: 2pt; background-color: #FFFFFF; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td style="width: 14.53%; text-align: center; vertical-align: top; background-color: #FFFFFF; white-space: nowrap; padding-top: 2.5pt; padding-bottom: 2.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 19.38pt; text-align: left;">200,088</div></td></tr></table><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The offers, sales and issuances of the securities described in the preceding table were exempt from registration either (i)&#160;under Section 4(a)(2) of the Securities Act and the rules and regulations promulgated thereunder in that the transactions were between an issuer and sophisticated investors or members of its senior executive management and did not involve any public offering within the meaning of Section 4(a)(2), (ii)&#160;under Regulation S promulgated under the Securities Act in that offers, sales and issuances were not made to persons in the United States and no directed selling efforts were made in the United States, (iii)&#160;under Rule 144A under the Securities Act in that the shares were offered and sold by the initial purchasers to qualified institutional buyers or (iv)&#160;under Rule 701 promulgated under the Securities Act in that the transactions were under compensatory benefit plans and contracts relating to compensation.</div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 12pt; margin-left: 0pt;"><tr><td style="width: 40pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Item 8.<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; text-align: left;">Exhibits and Financial Statement Schedules</div></td></tr></table><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 7pt; margin-left: 0pt; text-align: left;">Exhibits</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 7pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The exhibit index attached hereto is incorporated herein by reference.</div><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 17pt; margin-left: 0pt; text-align: left;">Financial Statements Schedules</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">All schedules have been omitted because they are not required or are not applicable, or the information is otherwise set forth in the consolidated financial statements and related notes thereto.</div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 12pt; margin-left: 0pt;"><tr><td style="width: 40pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Item 9.<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; text-align: left;">Undertakings</div></td></tr></table><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 7pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The undersigned hereby undertakes:</div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(a)<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">for purposes of determining any liability under the Securities Act, the information omitted from the form of prospectus filed as part of this registration statement in reliance upon Rule 430A and contained in a form of prospectus filed by the Registrant pursuant to Rule 424(b)(1) or (4) or 497(h) under the Securities Act shall be deemed to be part of this registration statement as of the time it was declared effective;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(b)<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">for the purpose of determining any liability under the Securities Act, each post-effective amendment that contains a form of prospectus shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(c)<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers and controlling persons of the registrant pursuant to the foregoing provisions, or otherwise, the registrant has been advised that, in the opinion of the SEC, such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the registrant of expenses incurred or paid by a director, officer, or controlling person of the registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the registrant will, unless, in the opinion of its counsel, the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question of whether such indemnification by it is against public policy as expressed in the Securities Act and will be governed by the final adjudication of such issue; and</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(d)<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">to provide to the underwriters at the closing specified in the underwriting agreement, certificates in such denominations and registered in such names as required by the underwriters to permit prompt delivery to each purchaser.</div></td></tr></table></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 36pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">II-2<br></div></div></div>
<!--End Page 326-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 327-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 540pt;"><a name="nt10014672x1_drs_302-exindx_pg1"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="block-frill" style="width: 540pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: Arial, Helvetica, sans-serif; font-size: 9pt; font-weight: bold; margin-top: 6pt; text-align: center;">Confidential Treatment Requested by ADC Therapeutics SA Pursuant to 17 C.F.R. &#167; 200.83<br></div></div><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 36pt;"><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: center;">EXHIBIT INDEX</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 5.5pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The following documents are filed as part of this registration statement:</div><table cellspacing="0" cellpadding="0" class="txttab" style="margin-top: 3.25pt; border-collapse: collapse; width: 468pt; margin-left: auto; margin-right: auto;"><tr><td style="width: 7.69%; text-align: left; vertical-align: top; padding-top: 6pt; padding-bottom: 2.35pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">1.1*</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 2.35pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 2.35pt;">&#8203;</td><td style="width: 89.74%; text-align: left; vertical-align: bottom; padding-top: 6pt; padding-bottom: 2.35pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Form of Underwriting Agreement</div></td></tr><tr><td style="width: 7.69%; text-align: left; vertical-align: top; padding-top: 2.35pt; padding-bottom: 2.35pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">3.1</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.35pt; padding-bottom: 2.35pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.35pt; padding-bottom: 2.35pt;">&#8203;</td><td style="width: 89.74%; text-align: left; vertical-align: bottom; padding-top: 2.35pt; padding-bottom: 2.35pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Articles of Association of ADC Therapeutics SA </div></td></tr><tr><td style="width: 7.69%; text-align: left; vertical-align: top; padding-top: 2.35pt; padding-bottom: 2.35pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">5.1*</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.35pt; padding-bottom: 2.35pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.35pt; padding-bottom: 2.35pt;">&#8203;</td><td style="width: 89.74%; text-align: left; vertical-align: bottom; padding-top: 2.35pt; padding-bottom: 2.35pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Opinion of Homburger AG, Swiss counsel of ADC Therapeutics SA, as to the validity of the common shares</div></td></tr><tr><td style="width: 7.69%; text-align: left; vertical-align: top; padding-top: 2.35pt; padding-bottom: 2.35pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">10.1#</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.35pt; padding-bottom: 2.35pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.35pt; padding-bottom: 2.35pt;">&#8203;</td><td style="width: 89.74%; text-align: left; vertical-align: bottom; padding-top: 2.35pt; padding-bottom: 2.35pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Second Amended and Restated License Agreement among ADC Products (UK) Limited, ADC Therapeutics SA and MedImmune Limited, dated May&#160;9, 2016 (incorporated herein by reference to Exhibit 10.1 to the Registrant&#8217;s Registration Statement on Form F-1 (File No. 333-237841), filed with the SEC on April&#160;24, 2020)</div></td></tr><tr><td style="width: 7.69%; text-align: left; vertical-align: top; padding-top: 2.35pt; padding-bottom: 2.35pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">10.2#</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.35pt; padding-bottom: 2.35pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.35pt; padding-bottom: 2.35pt;">&#8203;</td><td style="width: 89.74%; text-align: left; vertical-align: bottom; padding-top: 2.35pt; padding-bottom: 2.35pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Amendment #1 to the Second Amended and Restated License Agreement among ADC Products (UK) Limited, ADC Therapeutics SA and MedImmune Limited, dated September&#160;19, 2018 (incorporated herein by reference to Exhibit 10.2 to the Registrant&#8217;s Registration Statement on Form F-1 (File No. 333-237841), filed with the SEC on April&#160;24, 2020)</div></td></tr><tr><td style="width: 7.69%; text-align: left; vertical-align: top; padding-top: 2.35pt; padding-bottom: 2.35pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">10.3#</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.35pt; padding-bottom: 2.35pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.35pt; padding-bottom: 2.35pt;">&#8203;</td><td style="width: 89.74%; text-align: left; vertical-align: bottom; padding-top: 2.35pt; padding-bottom: 2.35pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Collaboration and License Agreement between ADC Therapeutics Sarl and Genmab A/S, dated June&#160;14, 2013 (incorporated herein by reference to Exhibit 10.3 to the Registrant&#8217;s Registration Statement on Form F-1 (File No. 333-237841), filed with the SEC on April&#160;24, 2020)</div></td></tr><tr><td style="width: 7.69%; text-align: left; vertical-align: top; padding-top: 2.35pt; padding-bottom: 2.35pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">10.4#</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.35pt; padding-bottom: 2.35pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.35pt; padding-bottom: 2.35pt;">&#8203;</td><td style="width: 89.74%; text-align: left; vertical-align: bottom; padding-top: 2.35pt; padding-bottom: 2.35pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Amendment to the Collaboration and License Agreement between ADC Therapeutics Sarl and Genmab A/S, dated November&#160;20, 2013 (incorporated herein by reference to Exhibit 10.4 to the Registrant&#8217;s Registration Statement on Form F-1 (File No. 333-237841), filed with the SEC on April&#160;24, 2020)</div></td></tr><tr><td style="width: 7.69%; text-align: left; vertical-align: top; padding-top: 2.35pt; padding-bottom: 2.35pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">10.5</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.35pt; padding-bottom: 2.35pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.35pt; padding-bottom: 2.35pt;">&#8203;</td><td style="width: 89.74%; text-align: left; vertical-align: bottom; padding-top: 2.35pt; padding-bottom: 2.35pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Second Amendment to the Collaboration and License Agreement between ADC Therapeutics SA and Genmab A/S, dated April 16, 2020 (incorporated herein by reference to Exhibit 10.5 to the Registrant&#8217;s Registration Statement on Form F-1 (File No. 333-237841), filed with the SEC on April&#160;24, 2020)</div></td></tr><tr><td style="width: 7.69%; text-align: left; vertical-align: top; padding-top: 2.35pt; padding-bottom: 2.35pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">10.6</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.35pt; padding-bottom: 2.35pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.35pt; padding-bottom: 2.35pt;">&#8203;</td><td style="width: 89.74%; text-align: left; vertical-align: bottom; padding-top: 2.35pt; padding-bottom: 2.35pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Third Amendment to the Collaboration and License Agreement between ADC Therapeutics SA and Genmab A/S, dated August&#160;10, 2020</div></td></tr><tr><td style="width: 7.69%; text-align: left; vertical-align: top; padding-top: 2.35pt; padding-bottom: 2.35pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">10.7</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.35pt; padding-bottom: 2.35pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.35pt; padding-bottom: 2.35pt;">&#8203;</td><td style="width: 89.74%; text-align: left; vertical-align: bottom; padding-top: 2.35pt; padding-bottom: 2.35pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Lease Relating to Suite 5, 1<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">st</sup> Floor, The Queen Mary BioEnterprises Innovation Centre between Queen Mary Bioenterprises Limited and ADC Therapeutics (UK) Limited, dated September&#160;14, 2017 (incorporated herein by reference to Exhibit 10.6 to the Registrant&#8217;s Registration Statement on Form F-1 (File No. 333-237841), filed with the SEC on April&#160;24, 2020) </div></td></tr><tr><td style="width: 7.69%; text-align: left; vertical-align: top; padding-top: 2.35pt; padding-bottom: 2.35pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">10.8</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.35pt; padding-bottom: 2.35pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.35pt; padding-bottom: 2.35pt;">&#8203;</td><td style="width: 89.74%; text-align: left; vertical-align: bottom; padding-top: 2.35pt; padding-bottom: 2.35pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Lease Relating to Lab 11b, Suite 11 Write Up Space and Suite 12, 1<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">st</sup> Floor, The Queen Mary BioEnterprises Innovation Centre between Queen Mary Bioenterprises Limited and ADC Therapeutics (UK) Limited, dated December&#160;20, 2017 (incorporated herein by reference to Exhibit 10.7 to the Registrant&#8217;s Registration Statement on Form F-1 (File No. 333-237841), filed with the SEC on April&#160;24, 2020)</div></td></tr><tr><td style="width: 7.69%; text-align: left; vertical-align: top; padding-top: 2.35pt; padding-bottom: 2.35pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">10.9</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.35pt; padding-bottom: 2.35pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.35pt; padding-bottom: 2.35pt;">&#8203;</td><td style="width: 89.74%; text-align: left; vertical-align: bottom; padding-top: 2.35pt; padding-bottom: 2.35pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Counterpart Lease Relating to Suite 8, First Floor, The Queen Mary BioEnterprises Innovation Centre between Queen Mary Bioenterprises Limited and ADC Therapeutics (UK) Limited, dated July&#160;9, 2018 (incorporated herein by reference to Exhibit 10.8 to the Registrant&#8217;s Registration Statement on Form F-1 (File No. 333-237841), filed with the SEC on April&#160;24, 2020) </div></td></tr><tr><td style="width: 7.69%; text-align: left; vertical-align: top; padding-top: 2.35pt; padding-bottom: 2.35pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">10.10</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.35pt; padding-bottom: 2.35pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.35pt; padding-bottom: 2.35pt;">&#8203;</td><td style="width: 89.74%; text-align: left; vertical-align: bottom; padding-top: 2.35pt; padding-bottom: 2.35pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Deed of Variation Relating to Lease of Suite 5, 1<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">st</sup> Floor, The Queen Mary BioEnterprises Innovation Centre between Queen Mary Bioenterprises Limited and ADC Therapeutics (UK) Limited, dated July&#160;1, 2019 (incorporated herein by reference to Exhibit 10.9 to the Registrant&#8217;s Registration Statement on Form F-1 (File No. 333-237841), filed with the SEC on April&#160;24, 2020) </div></td></tr><tr><td style="width: 7.69%; text-align: left; vertical-align: top; padding-top: 2.35pt; padding-bottom: 2.35pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">10.11</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.35pt; padding-bottom: 2.35pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.35pt; padding-bottom: 2.35pt;">&#8203;</td><td style="width: 89.74%; text-align: left; vertical-align: bottom; padding-top: 2.35pt; padding-bottom: 2.35pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Deed of Variation Relating to Lease of Lab 11b, Suite 11 Write Up Space and Suite 12, 1<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">st</sup> Floor, The Queen Mary BioEnterprises Innovation Centre between Queen Mary Bioenterprises Limited and ADC Therapeutics (UK) Limited, dated July&#160;1, 2019 (incorporated herein by reference to Exhibit 10.10 to the Registrant&#8217;s Registration Statement on Form F-1 (File No. 333-237841), filed with the SEC on April&#160;24, 2020) </div></td></tr><tr><td style="width: 7.69%; text-align: left; vertical-align: top; padding-top: 2.35pt; padding-bottom: 2.35pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">10.12</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.35pt; padding-bottom: 2.35pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.35pt; padding-bottom: 2.35pt;">&#8203;</td><td style="width: 89.74%; text-align: left; vertical-align: bottom; padding-top: 2.35pt; padding-bottom: 2.35pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Deed of Variation Relating to Lease of Suite 8, First Floor, The Queen Mary BioEnterprises Innovation Centre between Queen Mary Bioenterprises Limited and ADC Therapeutics (UK) Limited, dated July&#160;1, 2019 (incorporated herein by reference to Exhibit 10.11 to the Registrant&#8217;s Registration Statement on Form F-1 (File No. 333-237841), filed with the SEC on April&#160;24, 2020) </div></td></tr><tr><td style="width: 7.69%; text-align: left; vertical-align: top; padding-top: 2.35pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">10.13</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.35pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.35pt;">&#8203;</td><td style="width: 89.74%; text-align: left; vertical-align: bottom; padding-top: 2.35pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Form of Indemnity Agreement with directors and officers (incorporated herein by reference to Exhibit 10.12 to the Registrant&#8217;s Registration Statement on Form F-1 (File No. 333-237841), filed with the SEC on April&#160;24, 2020) </div></td></tr></table></div></div></div>
<!--End Page 327-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 328-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 540pt;"><a name="nt10014672x1_drs_302-exindx_pg2"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="block-frill" style="width: 540pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: Arial, Helvetica, sans-serif; font-size: 9pt; font-weight: bold; margin-top: 6pt; text-align: center;">Confidential Treatment Requested by ADC Therapeutics SA Pursuant to 17 C.F.R. &#167; 200.83<br></div></div><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 36pt;"><table cellspacing="0" cellpadding="0" class="txttab" style="margin-top: 4pt; border-collapse: collapse; width: 468pt; margin-left: auto; margin-right: auto;"><tr><td style="width: 7.69%; text-align: left; vertical-align: top; padding-top: 6pt; padding-bottom: 2.35pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">10.14</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 2.35pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 2.35pt;">&#8203;</td><td style="width: 89.74%; text-align: left; vertical-align: bottom; padding-top: 6pt; padding-bottom: 2.35pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">2019 Equity Incentive Plan (incorporated herein by reference to Exhibit 10.16 to the Registrant&#8217;s Registration Statement on Form F-1 (File No. 333-237841), filed with the SEC on April&#160;24, 2020)</div></td></tr><tr><td style="width: 7.69%; text-align: left; vertical-align: top; padding-top: 2.35pt; padding-bottom: 2.35pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">10.15</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.35pt; padding-bottom: 2.35pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.35pt; padding-bottom: 2.35pt;">&#8203;</td><td style="width: 89.74%; text-align: left; vertical-align: bottom; padding-top: 2.35pt; padding-bottom: 2.35pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Facility Agreement among ADC Therapeutics SA, the other Loan Parties party thereto, the Lenders and Deerfield Partners, L.P., as agent for itself and the Secured Parties thereto, dated April&#160;24, 2020 (incorporated herein by reference to Exhibit 10.17 to the Registrant&#8217;s Registration Statement on Form F-1 (File No. 333-237841), filed with the SEC on April 27, 2020) </div></td></tr><tr><td style="width: 7.69%; text-align: left; vertical-align: top; padding-top: 2.35pt; padding-bottom: 2.35pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">10.16</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.35pt; padding-bottom: 2.35pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.35pt; padding-bottom: 2.35pt;">&#8203;</td><td style="width: 89.74%; text-align: left; vertical-align: bottom; padding-top: 2.35pt; padding-bottom: 2.35pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Form of Senior Secured Convertible Note (incorporated herein by reference to Exhibit 99.1 to the Registrant&#8217;s Report on Form 6-K (File No. 001-39071), filed with the SEC on May&#160;19, 2020)</div></td></tr><tr><td style="width: 7.69%; text-align: left; vertical-align: top; padding-top: 2.35pt; padding-bottom: 2.35pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">10.17</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.35pt; padding-bottom: 2.35pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.35pt; padding-bottom: 2.35pt;">&#8203;</td><td style="width: 89.74%; text-align: left; vertical-align: bottom; padding-top: 2.35pt; padding-bottom: 2.35pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Registration Rights Agreement between ADC Therapeutics SA and Deerfield Partners, L.P. and Deerfield Private Design Fund IV, L.P., dated May&#160;19, 2020 </div></td></tr><tr><td style="width: 7.69%; text-align: left; vertical-align: top; padding-top: 2.35pt; padding-bottom: 2.35pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">21.1</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.35pt; padding-bottom: 2.35pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.35pt; padding-bottom: 2.35pt;">&#8203;</td><td style="width: 89.74%; text-align: left; vertical-align: bottom; padding-top: 2.35pt; padding-bottom: 2.35pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">List of subsidiaries</div></td></tr><tr><td style="width: 7.69%; text-align: left; vertical-align: top; padding-top: 2.35pt; padding-bottom: 2.35pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">23.1*</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.35pt; padding-bottom: 2.35pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.35pt; padding-bottom: 2.35pt;">&#8203;</td><td style="width: 89.74%; text-align: left; vertical-align: bottom; padding-top: 2.35pt; padding-bottom: 2.35pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Consent of PricewaterhouseCoopers SA</div></td></tr><tr><td style="width: 7.69%; text-align: left; vertical-align: top; padding-top: 2.35pt; padding-bottom: 2.35pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">23.2*</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.35pt; padding-bottom: 2.35pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.35pt; padding-bottom: 2.35pt;">&#8203;</td><td style="width: 89.74%; text-align: left; vertical-align: bottom; padding-top: 2.35pt; padding-bottom: 2.35pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Consent of Homburger AG, Swiss counsel of ADC Therapeutics SA (included in Exhibit 5.1)</div></td></tr><tr><td style="width: 7.69%; text-align: left; vertical-align: top; padding-top: 2.35pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">24.1*</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.35pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.35pt;">&#8203;</td><td style="width: 89.74%; text-align: left; vertical-align: bottom; padding-top: 2.35pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Powers of attorney (included on signature page to the registration statement)</div></td></tr></table><div><div class="rule-partial" style="height: 0pt; width: 72pt; border-bottom: 1pt solid #000000; margin-bottom: 1pt; margin-right: auto; margin-left: 0pt; margin-top: 13.25pt;"> </div></div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 12pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">*<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; text-align: left;">To be filed by amendment.</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 12pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">#<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; text-align: left;">Portions of this exhibit have been omitted because they are both (i)&#160;not material and (ii)&#160;would likely cause competitive harm to the Company if publicly disclosed.</div></td></tr></table></div></div></div>
<!--End Page 328-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 329-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 540pt;"><a name="nt10014672x1_drs_303-sig_pg1"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="block-frill" style="width: 540pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: Arial, Helvetica, sans-serif; font-size: 9pt; font-weight: bold; margin-top: 6pt; text-align: center;">Confidential Treatment Requested by ADC Therapeutics SA Pursuant to 17 C.F.R. &#167; 200.83<br></div></div><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 36pt;"><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: center;"><a name="tSIGN"><!--Anchor--></a>SIGNATURES</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Pursuant to the requirements of the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;), the registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form F-1 and has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the municipality of Epalinges, Switzerland on &#8195;&#8195;&#8195;&#8195;&#8195;&#8195;, 2020.</div><table cellspacing="0" cellpadding="0" class="txttab" style="margin-top: 5.25pt; border-collapse: collapse; width: 468pt; margin-left: auto; margin-right: auto;"><tr><td style="width: 46.15%; text-align: left; vertical-align: top; padding-top: 6pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 3pt;">&#8203;</td><td colspan="7" style="width: 51.28%; text-align: left; vertical-align: bottom; padding-top: 6pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">ADC THERAPEUTICS SA</div></td></tr><tr><td style="width: 46.15%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 2.56%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 5.13%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 38.46%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 46.15%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 2.56%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">By:</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.28%; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td colspan="4" style="width: 46.15%; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 46.15%; text-align: left; vertical-align: top; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 2.56%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 5.13%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Name:</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 38.46%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Christopher Martin</div></td></tr><tr><td style="width: 46.15%; text-align: left; vertical-align: top; padding-top: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt;">&#8203;</td><td style="width: 2.56%; text-align: left; vertical-align: bottom; padding-top: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt;">&#8203;</td><td style="width: 5.13%; text-align: left; vertical-align: bottom; padding-top: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Title:</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt;">&#8203;</td><td style="width: 38.46%; text-align: left; vertical-align: bottom; padding-top: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Chief Executive Officer</div></td></tr></table><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0.5pt; margin-left: 0pt; text-align: left;"> </div></div></div></div>
<!--End Page 329-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 330-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 540pt;"><a name="nt10014672x1_drs_303-sig_pg2"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="block-frill" style="width: 540pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: Arial, Helvetica, sans-serif; font-size: 9pt; font-weight: bold; margin-top: 6pt; text-align: center;">Confidential Treatment Requested by ADC Therapeutics SA Pursuant to 17 C.F.R. &#167; 200.83<br></div></div><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 36pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below hereby constitutes and appoints Christopher Martin, Michael Forer, Jennifer Creel and Dominique Graz and each of them, individually, as his true and lawful attorneys-in-fact and agents, with full power of substitution and resubstitution, for him and in his name, place and stead in any and all capacities, in connection with this registration statement, including to sign in the name and on behalf of the undersigned, this registration statement and any and all amendments thereto, including post-effective amendments and registrations filed pursuant to Rule 462 under the Securities Act, and to file the same, with all exhibits thereto, and other documents in connection therewith, with the U.S. Securities and Exchange Commission, granting unto such attorneys-in-fact and agents full power and authority to do and perform each and every act and thing requisite and necessary to be done in and about the premises, as fully to all intents and purposes as he might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents, or his substitute, may lawfully do or cause to be done by virtue hereof. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Pursuant to the requirements of the Securities Act, this registration statement has been signed by the following persons on &#8195;&#8195;&#8195;&#8195;&#8195;&#8195;, 2020 in the capacities indicated:</div><table cellspacing="0" cellpadding="0" class="txttab" style="margin-top: 11.25pt; border-collapse: collapse; width: 468pt; margin-left: auto; margin-right: auto;"><tr class="header"><td style="width: 46.15%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 3.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Name</div></td><td class="gutter" style="width: 1.28%; font-size: 2pt; padding-top: 6pt; padding-bottom: 3.75pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 3.75pt;">&#8203;</td><td style="width: 2.56%; text-align: center; vertical-align: bottom; padding-top: 6pt; padding-bottom: 3.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 3.75pt;">&#8203;</td><td class="gutter" style="width: 1.28%; font-size: 2pt; padding-top: 6pt; padding-bottom: 3.75pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 46.15%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 3.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Title</div></td></tr><tr><td style="width: 46.15%; text-align: center; vertical-align: top; padding-top: 3.75pt; padding-bottom: 2.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3.75pt; padding-bottom: 2.5pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3.75pt; padding-bottom: 2.5pt;">&#8203;</td><td style="width: 2.56%; text-align: center; vertical-align: bottom; padding-top: 3.75pt; padding-bottom: 2.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3.75pt; padding-bottom: 2.5pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3.75pt; padding-bottom: 2.5pt;">&#8203;</td><td style="width: 46.15%; text-align: center; vertical-align: bottom; padding-top: 3.75pt; padding-bottom: 2.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 46.15%; text-align: center; vertical-align: top; border-bottom: 1pt solid #000000; padding-top: 2.5pt; padding-bottom: 3.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 3.75pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 3.75pt;">&#8203;</td><td style="width: 2.56%; text-align: center; vertical-align: bottom; padding-top: 2.5pt; padding-bottom: 3.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 3.75pt;">&#8203;</td><td class="gutter" rowspan="2" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 3.75pt;">&#8203;</td><td rowspan="2" style="width: 46.15%; text-align: center; vertical-align: middle; padding-top: 2.5pt; padding-bottom: 3.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">Chief Executive Officer and Director<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">(principal executive officer)</div></td></tr><tr><td style="width: 46.15%; text-align: center; vertical-align: top; padding-top: 3.75pt; padding-bottom: 2.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">Christopher Martin</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3.75pt; padding-bottom: 2.5pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3.75pt; padding-bottom: 2.5pt;">&#8203;</td><td style="width: 2.56%; text-align: center; vertical-align: bottom; padding-top: 3.75pt; padding-bottom: 2.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3.75pt; padding-bottom: 2.5pt;">&#8203;</td></tr><tr><td style="width: 46.15%; text-align: center; vertical-align: top; padding-top: 2.5pt; padding-bottom: 2.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td style="width: 2.56%; text-align: center; vertical-align: bottom; padding-top: 2.5pt; padding-bottom: 2.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td style="width: 46.15%; text-align: center; vertical-align: middle; padding-top: 2.5pt; padding-bottom: 2.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 46.15%; text-align: center; vertical-align: top; border-bottom: 1pt solid #000000; padding-top: 2.5pt; padding-bottom: 3.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 3.75pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 3.75pt;">&#8203;</td><td style="width: 2.56%; text-align: center; vertical-align: bottom; padding-top: 2.5pt; padding-bottom: 3.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 3.75pt;">&#8203;</td><td class="gutter" rowspan="2" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 3.75pt;">&#8203;</td><td rowspan="2" style="width: 46.15%; text-align: center; vertical-align: middle; padding-top: 2.5pt; padding-bottom: 3.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">Chief Financial Officer <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">(principal financial officer)</div></td></tr><tr><td style="width: 46.15%; text-align: center; vertical-align: top; padding-top: 3.75pt; padding-bottom: 2.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">Jennifer Creel</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3.75pt; padding-bottom: 2.5pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3.75pt; padding-bottom: 2.5pt;">&#8203;</td><td style="width: 2.56%; text-align: center; vertical-align: bottom; padding-top: 3.75pt; padding-bottom: 2.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3.75pt; padding-bottom: 2.5pt;">&#8203;</td></tr><tr><td style="width: 46.15%; text-align: center; vertical-align: top; padding-top: 2.5pt; padding-bottom: 2.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td style="width: 2.56%; text-align: center; vertical-align: bottom; padding-top: 2.5pt; padding-bottom: 2.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td></tr><tr><td style="width: 46.15%; text-align: center; vertical-align: top; border-bottom: 1pt solid #000000; padding-top: 2.5pt; padding-bottom: 3.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 3.75pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 3.75pt;">&#8203;</td><td style="width: 2.56%; text-align: center; vertical-align: bottom; padding-top: 2.5pt; padding-bottom: 3.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 3.75pt;">&#8203;</td><td class="gutter" rowspan="2" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 3.75pt;">&#8203;</td><td rowspan="2" style="width: 46.15%; text-align: center; vertical-align: middle; padding-top: 2.5pt; padding-bottom: 3.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">Corporate Controller and Chief Accounting Officer (principal accounting officer)</div></td></tr><tr><td style="width: 46.15%; text-align: center; vertical-align: top; padding-top: 3.75pt; padding-bottom: 2.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">Robert A. Schmidt</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3.75pt; padding-bottom: 2.5pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3.75pt; padding-bottom: 2.5pt;">&#8203;</td><td style="width: 2.56%; text-align: center; vertical-align: bottom; padding-top: 3.75pt; padding-bottom: 2.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3.75pt; padding-bottom: 2.5pt;">&#8203;</td></tr><tr><td style="width: 46.15%; text-align: center; vertical-align: top; padding-top: 2.5pt; padding-bottom: 2.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td style="width: 2.56%; text-align: center; vertical-align: bottom; padding-top: 2.5pt; padding-bottom: 2.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td></tr><tr><td style="width: 46.15%; text-align: center; vertical-align: top; border-bottom: 1pt solid #000000; padding-top: 2.5pt; padding-bottom: 3.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 3.75pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 3.75pt;">&#8203;</td><td style="width: 2.56%; text-align: center; vertical-align: bottom; padding-top: 2.5pt; padding-bottom: 3.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 3.75pt;">&#8203;</td><td class="gutter" rowspan="2" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 3.75pt;">&#8203;</td><td rowspan="2" style="width: 46.15%; text-align: center; vertical-align: middle; padding-top: 2.5pt; padding-bottom: 3.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">Chairman of the Board of Directors</div></td></tr><tr><td style="width: 46.15%; text-align: center; vertical-align: top; padding-top: 3.75pt; padding-bottom: 2.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">Ron Squarer</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3.75pt; padding-bottom: 2.5pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3.75pt; padding-bottom: 2.5pt;">&#8203;</td><td style="width: 2.56%; text-align: center; vertical-align: bottom; padding-top: 3.75pt; padding-bottom: 2.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3.75pt; padding-bottom: 2.5pt;">&#8203;</td></tr><tr><td style="width: 46.15%; text-align: center; vertical-align: top; padding-top: 2.5pt; padding-bottom: 2.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td style="width: 2.56%; text-align: center; vertical-align: bottom; padding-top: 2.5pt; padding-bottom: 2.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td style="width: 46.15%; text-align: center; vertical-align: middle; padding-top: 2.5pt; padding-bottom: 2.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 46.15%; text-align: center; vertical-align: top; border-bottom: 1pt solid #000000; padding-top: 2.5pt; padding-bottom: 3.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 3.75pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 3.75pt;">&#8203;</td><td style="width: 2.56%; text-align: center; vertical-align: bottom; padding-top: 2.5pt; padding-bottom: 3.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 3.75pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 3.75pt;">&#8203;</td><td style="width: 46.15%; text-align: center; vertical-align: middle; padding-top: 2.5pt; padding-bottom: 3.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">Vice Chairman of the Board of Directors</div></td></tr><tr><td style="width: 46.15%; text-align: center; vertical-align: top; padding-top: 3.75pt; padding-bottom: 2.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">Michael Forer</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3.75pt; padding-bottom: 2.5pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3.75pt; padding-bottom: 2.5pt;">&#8203;</td><td style="width: 2.56%; text-align: center; vertical-align: bottom; padding-top: 3.75pt; padding-bottom: 2.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3.75pt; padding-bottom: 2.5pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3.75pt; padding-bottom: 2.5pt;">&#8203;</td><td style="width: 46.15%; text-align: center; vertical-align: middle; padding-top: 3.75pt; padding-bottom: 2.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 46.15%; text-align: center; vertical-align: top; padding-top: 2.5pt; padding-bottom: 2.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td style="width: 2.56%; text-align: center; vertical-align: bottom; padding-top: 2.5pt; padding-bottom: 2.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td style="width: 46.15%; text-align: center; vertical-align: middle; padding-top: 2.5pt; padding-bottom: 2.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 46.15%; text-align: center; vertical-align: top; border-bottom: 1pt solid #000000; padding-top: 2.5pt; padding-bottom: 3.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 3.75pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 3.75pt;">&#8203;</td><td style="width: 2.56%; text-align: center; vertical-align: bottom; padding-top: 2.5pt; padding-bottom: 3.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 3.75pt;">&#8203;</td><td class="gutter" rowspan="2" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 3.75pt;">&#8203;</td><td rowspan="2" style="width: 46.15%; text-align: center; vertical-align: middle; padding-top: 2.5pt; padding-bottom: 3.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">Director</div></td></tr><tr><td style="width: 46.15%; text-align: center; vertical-align: top; padding-top: 3.75pt; padding-bottom: 2.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">Peter B. Corr</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3.75pt; padding-bottom: 2.5pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3.75pt; padding-bottom: 2.5pt;">&#8203;</td><td style="width: 2.56%; text-align: center; vertical-align: bottom; padding-top: 3.75pt; padding-bottom: 2.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3.75pt; padding-bottom: 2.5pt;">&#8203;</td></tr><tr><td style="width: 46.15%; text-align: center; vertical-align: top; padding-top: 2.5pt; padding-bottom: 2.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td style="width: 2.56%; text-align: center; vertical-align: bottom; padding-top: 2.5pt; padding-bottom: 2.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td style="width: 46.15%; text-align: center; vertical-align: middle; padding-top: 2.5pt; padding-bottom: 2.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 46.15%; text-align: center; vertical-align: top; border-bottom: 1pt solid #000000; padding-top: 2.5pt; padding-bottom: 3.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 3.75pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 3.75pt;">&#8203;</td><td style="width: 2.56%; text-align: center; vertical-align: bottom; padding-top: 2.5pt; padding-bottom: 3.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 3.75pt;">&#8203;</td><td class="gutter" rowspan="2" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 3.75pt;">&#8203;</td><td rowspan="2" style="width: 46.15%; text-align: center; vertical-align: middle; padding-top: 2.5pt; padding-bottom: 3.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">Director</div></td></tr><tr><td style="width: 46.15%; text-align: center; vertical-align: top; padding-top: 3.75pt; padding-bottom: 2.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">Stephen Evans-Freke</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3.75pt; padding-bottom: 2.5pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3.75pt; padding-bottom: 2.5pt;">&#8203;</td><td style="width: 2.56%; text-align: center; vertical-align: bottom; padding-top: 3.75pt; padding-bottom: 2.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3.75pt; padding-bottom: 2.5pt;">&#8203;</td></tr><tr><td style="width: 46.15%; text-align: center; vertical-align: top; padding-top: 2.5pt; padding-bottom: 2.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td style="width: 2.56%; text-align: center; vertical-align: bottom; padding-top: 2.5pt; padding-bottom: 2.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td style="width: 46.15%; text-align: center; vertical-align: middle; padding-top: 2.5pt; padding-bottom: 2.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 46.15%; text-align: center; vertical-align: top; border-bottom: 1pt solid #000000; padding-top: 2.5pt; padding-bottom: 3.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 3.75pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 3.75pt;">&#8203;</td><td style="width: 2.56%; text-align: center; vertical-align: bottom; padding-top: 2.5pt; padding-bottom: 3.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 3.75pt;">&#8203;</td><td class="gutter" rowspan="2" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 3.75pt;">&#8203;</td><td rowspan="2" style="width: 46.15%; text-align: center; vertical-align: middle; padding-top: 2.5pt; padding-bottom: 3.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">Director</div></td></tr><tr><td style="width: 46.15%; text-align: center; vertical-align: top; padding-top: 3.75pt; padding-bottom: 2.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">Peter Hug</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3.75pt; padding-bottom: 2.5pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3.75pt; padding-bottom: 2.5pt;">&#8203;</td><td style="width: 2.56%; text-align: center; vertical-align: bottom; padding-top: 3.75pt; padding-bottom: 2.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3.75pt; padding-bottom: 2.5pt;">&#8203;</td></tr><tr><td style="width: 46.15%; text-align: center; vertical-align: top; padding-top: 2.5pt; padding-bottom: 2.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td style="width: 2.56%; text-align: center; vertical-align: bottom; padding-top: 2.5pt; padding-bottom: 2.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td style="width: 46.15%; text-align: center; vertical-align: middle; padding-top: 2.5pt; padding-bottom: 2.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 46.15%; text-align: center; vertical-align: top; border-bottom: 1pt solid #000000; padding-top: 2.5pt; padding-bottom: 3.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 3.75pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 3.75pt;">&#8203;</td><td style="width: 2.56%; text-align: center; vertical-align: bottom; padding-top: 2.5pt; padding-bottom: 3.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 3.75pt;">&#8203;</td><td class="gutter" rowspan="2" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 3.75pt;">&#8203;</td><td rowspan="2" style="width: 46.15%; text-align: center; vertical-align: middle; padding-top: 2.5pt; padding-bottom: 3.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">Director</div></td></tr><tr><td style="width: 46.15%; text-align: center; vertical-align: top; padding-top: 3.75pt; padding-bottom: 2.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">Thomas Pfisterer</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3.75pt; padding-bottom: 2.5pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3.75pt; padding-bottom: 2.5pt;">&#8203;</td><td style="width: 2.56%; text-align: center; vertical-align: bottom; padding-top: 3.75pt; padding-bottom: 2.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3.75pt; padding-bottom: 2.5pt;">&#8203;</td></tr><tr><td style="width: 46.15%; text-align: center; vertical-align: top; padding-top: 2.5pt; padding-bottom: 2.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td style="width: 2.56%; text-align: center; vertical-align: bottom; padding-top: 2.5pt; padding-bottom: 2.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td style="width: 46.15%; text-align: center; vertical-align: middle; padding-top: 2.5pt; padding-bottom: 2.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 46.15%; text-align: center; vertical-align: top; border-bottom: 1pt solid #000000; padding-top: 2.5pt; padding-bottom: 3.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 3.75pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 3.75pt;">&#8203;</td><td style="width: 2.56%; text-align: center; vertical-align: bottom; padding-top: 2.5pt; padding-bottom: 3.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 3.75pt;">&#8203;</td><td class="gutter" rowspan="2" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 3.75pt;">&#8203;</td><td rowspan="2" style="width: 46.15%; text-align: center; vertical-align: middle; padding-top: 2.5pt; padding-bottom: 3.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">Director</div></td></tr><tr><td style="width: 46.15%; text-align: center; vertical-align: top; padding-top: 3.75pt; padding-bottom: 2.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">Thomas M. Rinderknecht</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3.75pt; padding-bottom: 2.5pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3.75pt; padding-bottom: 2.5pt;">&#8203;</td><td style="width: 2.56%; text-align: center; vertical-align: bottom; padding-top: 3.75pt; padding-bottom: 2.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3.75pt; padding-bottom: 2.5pt;">&#8203;</td></tr><tr><td style="width: 46.15%; text-align: center; vertical-align: top; padding-top: 2.5pt; padding-bottom: 2.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td style="width: 2.56%; text-align: center; vertical-align: bottom; padding-top: 2.5pt; padding-bottom: 2.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td style="width: 46.15%; text-align: center; vertical-align: middle; padding-top: 2.5pt; padding-bottom: 2.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 46.15%; text-align: center; vertical-align: top; border-bottom: 1pt solid #000000; padding-top: 2.5pt; padding-bottom: 3.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 3.75pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 3.75pt;">&#8203;</td><td style="width: 2.56%; text-align: center; vertical-align: bottom; padding-top: 2.5pt; padding-bottom: 3.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 3.75pt;">&#8203;</td><td class="gutter" rowspan="2" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 3.75pt;">&#8203;</td><td rowspan="2" style="width: 46.15%; text-align: center; vertical-align: middle; padding-top: 2.5pt; padding-bottom: 3.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">Director</div></td></tr><tr><td style="width: 46.15%; text-align: center; vertical-align: top; padding-top: 3.75pt; padding-bottom: 2.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">Tyrell J. Rivers</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3.75pt; padding-bottom: 2.5pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3.75pt; padding-bottom: 2.5pt;">&#8203;</td><td style="width: 2.56%; text-align: center; vertical-align: bottom; padding-top: 3.75pt; padding-bottom: 2.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3.75pt; padding-bottom: 2.5pt;">&#8203;</td></tr><tr><td style="width: 46.15%; text-align: center; vertical-align: top; padding-top: 2.5pt; padding-bottom: 2.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td style="width: 2.56%; text-align: center; vertical-align: bottom; padding-top: 2.5pt; padding-bottom: 2.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td style="width: 46.15%; text-align: center; vertical-align: middle; padding-top: 2.5pt; padding-bottom: 2.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 46.15%; text-align: center; vertical-align: top; border-bottom: 1pt solid #000000; padding-top: 2.5pt; padding-bottom: 3.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 3.75pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 3.75pt;">&#8203;</td><td style="width: 2.56%; text-align: center; vertical-align: bottom; padding-top: 2.5pt; padding-bottom: 3.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 3.75pt;">&#8203;</td><td class="gutter" rowspan="2" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 3.75pt;">&#8203;</td><td rowspan="2" style="width: 46.15%; text-align: center; vertical-align: middle; padding-top: 2.5pt; padding-bottom: 3.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">Director</div></td></tr><tr><td style="width: 46.15%; text-align: center; vertical-align: top; padding-top: 3.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">Victor Sandor</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3.75pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3.75pt;">&#8203;</td><td style="width: 2.56%; text-align: center; vertical-align: bottom; padding-top: 3.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3.75pt;">&#8203;</td></tr></table></div></div></div>
<!--End Page 330-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 331-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 540pt;"><a name="nt10014672x1_drs_303-sig_pg3"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="block-frill" style="width: 540pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: Arial, Helvetica, sans-serif; font-size: 9pt; font-weight: bold; margin-top: 6pt; text-align: center;">Confidential Treatment Requested by ADC Therapeutics SA Pursuant to 17 C.F.R. &#167; 200.83<br></div></div><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 36pt;"><table cellspacing="0" cellpadding="0" class="txttab" style="margin-top: 4pt; border-collapse: collapse; width: 468pt; margin-left: auto; margin-right: auto;"><tr class="header"><td style="width: 46.15%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 3.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Name</div></td><td class="gutter" style="width: 1.28%; font-size: 2pt; padding-top: 6pt; padding-bottom: 3.75pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 3.75pt;">&#8203;</td><td style="width: 2.56%; text-align: center; vertical-align: bottom; padding-top: 6pt; padding-bottom: 3.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 3.75pt;">&#8203;</td><td class="gutter" style="width: 1.28%; font-size: 2pt; padding-top: 6pt; padding-bottom: 3.75pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 46.15%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 3.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Title</div></td></tr><tr><td style="width: 46.15%; text-align: center; vertical-align: top; padding-top: 3.75pt; padding-bottom: 2.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3.75pt; padding-bottom: 2.5pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3.75pt; padding-bottom: 2.5pt;">&#8203;</td><td style="width: 2.56%; text-align: center; vertical-align: bottom; padding-top: 3.75pt; padding-bottom: 2.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3.75pt; padding-bottom: 2.5pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3.75pt; padding-bottom: 2.5pt;">&#8203;</td><td style="width: 46.15%; text-align: center; vertical-align: middle; padding-top: 3.75pt; padding-bottom: 2.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 46.15%; text-align: center; vertical-align: top; border-bottom: 1pt solid #000000; padding-top: 2.5pt; padding-bottom: 3.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 3.75pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 3.75pt;">&#8203;</td><td style="width: 2.56%; text-align: center; vertical-align: bottom; padding-top: 2.5pt; padding-bottom: 3.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 3.75pt;">&#8203;</td><td class="gutter" rowspan="2" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 3.75pt;">&#8203;</td><td rowspan="2" style="width: 46.15%; text-align: center; vertical-align: middle; padding-top: 2.5pt; padding-bottom: 3.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">Director</div></td></tr><tr><td style="width: 46.15%; text-align: center; vertical-align: top; padding-top: 3.75pt; padding-bottom: 2.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">Jacques Theurillat</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3.75pt; padding-bottom: 2.5pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3.75pt; padding-bottom: 2.5pt;">&#8203;</td><td style="width: 2.56%; text-align: center; vertical-align: bottom; padding-top: 3.75pt; padding-bottom: 2.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3.75pt; padding-bottom: 2.5pt;">&#8203;</td></tr><tr><td style="width: 46.15%; text-align: center; vertical-align: top; padding-top: 2.5pt; padding-bottom: 2.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td style="width: 2.56%; text-align: center; vertical-align: bottom; padding-top: 2.5pt; padding-bottom: 2.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td style="width: 46.15%; text-align: center; vertical-align: middle; padding-top: 2.5pt; padding-bottom: 2.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 46.15%; text-align: center; vertical-align: top; border-bottom: 1pt solid #000000; padding-top: 2.5pt; padding-bottom: 3.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 3.75pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 3.75pt;">&#8203;</td><td style="width: 2.56%; text-align: center; vertical-align: bottom; padding-top: 2.5pt; padding-bottom: 3.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 3.75pt;">&#8203;</td><td class="gutter" rowspan="2" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 3.75pt;">&#8203;</td><td rowspan="2" style="width: 46.15%; text-align: center; vertical-align: middle; padding-top: 2.5pt; padding-bottom: 3.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">Authorized Representative in the United States</div></td></tr><tr><td style="width: 46.15%; text-align: center; vertical-align: top; padding-top: 3.75pt; padding-bottom: 2.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">Jennifer Creel</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3.75pt; padding-bottom: 2.5pt;">&#8203;</td></tr><tr><td style="width: 46.15%; text-align: center; vertical-align: top; padding-top: 2.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">ADC Therapeutics America, Inc.</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt;">&#8203;</td><td style="width: 2.56%; text-align: center; vertical-align: bottom; padding-top: 2.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt;">&#8203;</td></tr></table></div></div></div>
<!--End Page 331-->
</body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-3.1
<SEQUENCE>2
<FILENAME>filename2.htm
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: Broadridge Financial Soultions, Inc.
         Document created using EDGARfilings PROfile 7.1.0.0
         Copyright 1995 - 2020 Broadridge -->
  </head>
<body style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000;" bgcolor="#ffffff">
  <hr style="height: 4px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;" align="center" noshade="noshade">
  <div>
    <div style="text-align: right; font-weight: bold;">Exhibit 3.1</div>
    <div><br>
    </div>
    <div style="text-align: justify;">Articles of Association of ADC Therapeutics SA</div>
    <div><br>
    </div>
    <div style="text-align: center; font-weight: bold;">Articles of Association</div>
    <div style="text-align: center; font-weight: bold;">of ADC Therapeutics SA</div>
    <div style="text-align: center; font-weight: bold;">(ADC Therapeutics AG)</div>
    <div style="text-align: center; font-weight: bold;">(ADC Therapeutics Ltd)</div>
    <div>&#160;</div>
    <div style="text-align: center; font-weight: bold;">Statuts</div>
    <div style="text-align: center; font-weight: bold;">de ADC Therapeutics SA</div>
    <div style="text-align: center; font-weight: bold;">(ADC Therapeutics AG)</div>
    <div style="text-align: center; font-weight: bold;">(ADC Therapeutics Ltd)</div>
    <div>&#160;</div>
    <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div id="DSPFPageBreak" style="page-break-after:always;">
        <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
    </div>
    <table id="z62b059c5295d4c97a8604b2f62635bfc" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;" border="0" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 15%; vertical-align: top;">&#160;</td>
          <td style="width: 35%; vertical-align: top; border-top: 2px solid rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0);">
            <div style="font-weight: bold;">Section 1</div>
            <div style="font-style: italic;">Name, Registered Office, Purpose and Duration of the Company</div>
          </td>
          <td style="width: 2%; vertical-align: top;">&#160;</td>
          <td style="width: 13%; vertical-align: top;">&#160;</td>
          <td style="width: 35%; vertical-align: top; border-top: 2px solid rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0);">
            <div style="font-weight: bold;">Section 1</div>
            <div style="font-style: italic;">Raison sociale, si&#232;ge, but de la soci&#233;t&#233;, dur&#233;e</div>
            <div style="font-style: italic;"> <br>
            </div>
          </td>
        </tr>
        <tr>
          <td style="width: 15%; vertical-align: top;">&#160;</td>
          <td style="width: 35%; vertical-align: top; border-top: 2px solid rgb(0, 0, 0);">&#160;</td>
          <td style="width: 2%; vertical-align: top;">&#160;</td>
          <td style="width: 13%; vertical-align: top;">&#160;</td>
          <td style="width: 35%; vertical-align: top; border-top: 2px solid rgb(0, 0, 0);">&#160;</td>
        </tr>
        <tr>
          <td style="width: 15%; vertical-align: top;">&#160;</td>
          <td style="width: 35%; vertical-align: top;">
            <div style="font-weight: bold;">Article 1</div>
          </td>
          <td style="width: 2%; vertical-align: top;">&#160;</td>
          <td style="width: 13%; vertical-align: top;">&#160;</td>
          <td style="width: 35%; vertical-align: top;">
            <div style="font-weight: bold;">Article 1</div>
          </td>
        </tr>
        <tr>
          <td style="width: 15%; vertical-align: top;" rowspan="1">&#160;</td>
          <td style="width: 35%; vertical-align: top;" rowspan="1">&#160;</td>
          <td style="width: 2%; vertical-align: top;" rowspan="1">&#160;</td>
          <td style="width: 13%; vertical-align: top;" rowspan="1">&#160;</td>
          <td style="width: 35%; vertical-align: top;" rowspan="1">&#160;</td>
        </tr>
        <tr>
          <td style="width: 15%; vertical-align: top;">
            <div>Name, Place of In-</div>
            <div>corporation</div>
          </td>
          <td style="width: 35%; vertical-align: top;">
            <div>Under the name ADC Therapeutics SA (ADC Therapeutics AG) (ADC Therapeutics Ltd) (the <font style="font-weight: bold;">Company</font>) shall exist a corporation with its registered office in Epalinges, canton of Vaud.</div>
          </td>
          <td style="width: 2%; vertical-align: top;">&#160;</td>
          <td style="width: 13%; vertical-align: top;">
            <div>Raison sociale, </div>
            <div>si&#232;ge</div>
          </td>
          <td style="width: 35%; vertical-align: top;">
            <div>Sous la raison sociale ADC Therapeutics SA (ADC Therapeutics AG), (ADC Therapeutics Ltd) (la <font style="font-weight: bold;">Soci&#233;t&#233;</font>) existe une soci&#233;t&#233; anonyme avec si&#232;ge &#224;<font style="font-weight: bold;">&#160;</font>Epalinges,
              canton de Vaud.</div>
          </td>
        </tr>
        <tr>
          <td style="width: 15%; vertical-align: top;">&#160;</td>
          <td style="width: 35%; vertical-align: top;">&#160;</td>
          <td style="width: 2%; vertical-align: top;">&#160;</td>
          <td style="width: 13%; vertical-align: top;">&#160;</td>
          <td style="width: 35%; vertical-align: top;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 15%; vertical-align: top;">&#160;</td>
          <td style="width: 35%; vertical-align: top;">
            <div style="font-weight: bold;">Article 2</div>
          </td>
          <td style="width: 2%; vertical-align: top;">&#160;</td>
          <td style="width: 13%; vertical-align: top;">&#160;</td>
          <td style="width: 35%; vertical-align: top;">
            <div style="font-weight: bold;">Article 2</div>
          </td>
        </tr>
        <tr>
          <td style="width: 15%; vertical-align: top;" rowspan="1">&#160;</td>
          <td style="width: 35%; vertical-align: top;" rowspan="1">&#160;</td>
          <td style="width: 2%; vertical-align: top;" rowspan="1">&#160;</td>
          <td style="width: 13%; vertical-align: top;" rowspan="1">&#160;</td>
          <td style="width: 35%; vertical-align: top;" rowspan="1">&#160;</td>
        </tr>
        <tr>
          <td style="width: 15%; vertical-align: top;">
            <div>Purpose</div>
          </td>
          <td style="width: 35%; vertical-align: top;">
            <div><sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">1</sup> The Company's purpose is to research, develop, produce and sell products in the fields of biotechnology, pharmaceutics, medical technology, diagnosis and
              therapy as well as to purchase, sell and use patents and licenses in these fields. The Company may engage in all types of transactions that appear appropriate to promote the purpose of the Company or that are related thereto.</div>
          </td>
          <td style="width: 2%; vertical-align: top;">&#160;</td>
          <td style="width: 13%; vertical-align: top;">
            <div>But</div>
          </td>
          <td style="width: 35%; vertical-align: top;">
            <div><sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">1</sup> La Soci&#233;t&#233; a pour but la recherche, le d&#233;veloppement, la production et la vente de produits dans les domaines de la biotechnologie, de la pharmaceutique, de
              la technologie m&#233;dicale, du diagnostic et de la th&#233;rapie ainsi que l&#8217;acquisition, la vente et l'utilisation de brevets et de licences dans ces domaines. La Soci&#233;t&#233; peut exercer toutes activit&#233;s aptes &#224; favoriser son but ou en rapport avec ce
              dernier.</div>
          </td>
        </tr>
        <tr>
          <td style="width: 15%; vertical-align: top;" rowspan="1">&#160;</td>
          <td style="width: 35%; vertical-align: top;" rowspan="1">&#160;</td>
          <td style="width: 2%; vertical-align: top;" rowspan="1">&#160;</td>
          <td style="width: 13%; vertical-align: top;" rowspan="1">&#160;</td>
          <td style="width: 35%; vertical-align: top;" rowspan="1">&#160;</td>
        </tr>
        <tr>
          <td style="width: 15%; vertical-align: top;">&#160;</td>
          <td style="width: 35%; vertical-align: top;">
            <div><sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">2</sup> The Company may open branch offices and subsidiaries in Switzerland and abroad. It may also acquire participations or otherwise invest in other companies in
              Switzerland and abroad.</div>
          </td>
          <td style="width: 2%; vertical-align: top;">&#160;</td>
          <td style="width: 13%; vertical-align: top;">&#160;</td>
          <td style="width: 35%; vertical-align: top;">
            <div><sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">2</sup> La Soci&#233;t&#233; peut constituer des succursales et des filiales en Suisse et &#224; l'&#233;tranger et participer &#224; ou investir autrement dans d'autres entreprises en
              Suisse et &#224; l'&#233;tranger.</div>
          </td>
        </tr>
        <tr>
          <td style="width: 15%; vertical-align: top;" rowspan="1">&#160;</td>
          <td style="width: 35%; vertical-align: top;" rowspan="1">&#160;</td>
          <td style="width: 2%; vertical-align: top;" rowspan="1">&#160;</td>
          <td style="width: 13%; vertical-align: top;" rowspan="1">&#160;</td>
          <td style="width: 35%; vertical-align: top;" rowspan="1">&#160;</td>
        </tr>
        <tr>
          <td style="width: 15%; vertical-align: top;">&#160;</td>
          <td style="width: 35%; vertical-align: top;">
            <div><sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">3</sup> The Company may acquire, hold, manage, mortgage, exploit and sell real estate and intellectual property rights in Switzerland and abroad and may also
              finance other companies.</div>
          </td>
          <td style="width: 2%; vertical-align: top;">&#160;</td>
          <td style="width: 13%; vertical-align: top;">&#160;</td>
          <td style="width: 35%; vertical-align: top;">
            <div><sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">3</sup> La Soci&#233;t&#233; peut acqu&#233;rir, d&#233;tenir, g&#233;rer, gager, mettre en valeur et ali&#233;ner des immeubles et des droits de propri&#233;t&#233; intellectuelle en Suisse et &#224;
              l'&#233;tranger, ainsi que financer d'autres soci&#233;t&#233;s.</div>
          </td>
        </tr>
        <tr>
          <td style="width: 15%; vertical-align: top;">&#160;</td>
          <td style="width: 35%; vertical-align: top;">&#160;</td>
          <td style="width: 2%; vertical-align: top;">&#160;</td>
          <td style="width: 13%; vertical-align: top;">&#160;</td>
          <td style="width: 35%; vertical-align: top;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 15%; vertical-align: top;">&#160;</td>
          <td style="width: 35%; vertical-align: top;">
            <div style="font-weight: bold;">Article 3</div>
          </td>
          <td style="width: 2%; vertical-align: top;">&#160;</td>
          <td style="width: 13%; vertical-align: top;">&#160;</td>
          <td style="width: 35%; vertical-align: top;">
            <div style="font-weight: bold;">Article 3</div>
          </td>
        </tr>
        <tr>
          <td style="width: 15%; vertical-align: top;" rowspan="1">&#160;</td>
          <td style="width: 35%; vertical-align: top;" rowspan="1">&#160;</td>
          <td style="width: 2%; vertical-align: top;" rowspan="1">&#160;</td>
          <td style="width: 13%; vertical-align: top;" rowspan="1">&#160;</td>
          <td style="width: 35%; vertical-align: top;" rowspan="1">&#160;</td>
        </tr>
        <tr>
          <td style="width: 15%; vertical-align: top;">
            <div>Duration</div>
          </td>
          <td style="width: 35%; vertical-align: top;">
            <div>The duration of the Company shall be unlimited.</div>
          </td>
          <td style="width: 2%; vertical-align: top;"><br>
          </td>
          <td style="width: 13%; vertical-align: top;">
            <div>Dur&#233;e</div>
          </td>
          <td style="width: 35%; vertical-align: top;">
            <div>La dur&#233;e de la Soci&#233;t&#233; est illimit&#233;e.</div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <div>&#160;</div>
    <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div id="DSPFPageBreak" style="page-break-after:always;">
        <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
    </div>
    <table id="z42f49a6b7170466ea43e3d93bbcb93a8" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 15%; vertical-align: top;">&#160;</td>
          <td style="width: 35%; vertical-align: top; border-top: 2px solid rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0);">
            <div style="font-weight: bold;">Section 2</div>
            <div style="font-style: italic;">Share Capital, Shares, Restrictions of Transferability</div>
            <div style="font-style: italic;"> <br>
            </div>
          </td>
          <td style="width: 2%; vertical-align: top;">&#160;</td>
          <td style="width: 13%; vertical-align: top;">&#160;</td>
          <td style="width: 35%; vertical-align: top; border-top: 2px solid rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0);">
            <div style="font-weight: bold;">Section 2</div>
            <div style="font-style: italic;">Capital-actions, actions et restrictions &#224; la transmissibilit&#233;</div>
          </td>
        </tr>
        <tr>
          <td style="width: 15%; vertical-align: top;">&#160;</td>
          <td style="width: 35%; vertical-align: top;">&#160;</td>
          <td style="width: 2%; vertical-align: top;">&#160;</td>
          <td style="width: 13%; vertical-align: top;">&#160;</td>
          <td style="width: 35%; vertical-align: top;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 15%; vertical-align: top;">&#160;</td>
          <td style="width: 35%; vertical-align: top;">
            <div style="font-weight: bold;">Article 4</div>
          </td>
          <td style="width: 2%; vertical-align: top;">&#160;</td>
          <td style="width: 13%; vertical-align: top;">&#160;</td>
          <td style="width: 35%; vertical-align: top;">
            <div style="font-weight: bold;">Article 4</div>
          </td>
        </tr>
        <tr>
          <td style="width: 15%; vertical-align: top;" rowspan="1">&#160;</td>
          <td style="width: 35%; vertical-align: top;" rowspan="1">&#160;</td>
          <td style="width: 2%; vertical-align: top;" rowspan="1">&#160;</td>
          <td style="width: 13%; vertical-align: top;" rowspan="1">&#160;</td>
          <td style="width: 35%; vertical-align: top;" rowspan="1">&#160;</td>
        </tr>
        <tr>
          <td style="width: 15%; vertical-align: top;">
            <div>Share Capital</div>
          </td>
          <td style="width: 35%; vertical-align: top;">
            <div>The share capital of the Company is CHF 5,661,600 and is divided into 70,770,000<font style="font-weight: bold;"></font> fully paid in registered shares with a par value of CHF 0.08 each.</div>
          </td>
          <td style="width: 2%; vertical-align: top;"><br>
          </td>
          <td style="width: 13%; vertical-align: top;">
            <div>Capital-actions</div>
          </td>
          <td style="width: 35%; vertical-align: top;">
            <div>Le capital-actions de la Soci&#233;t&#233; s'&#233;l&#232;ve &#224; CHF 5,661,600 et est divis&#233; en 70,770,000<font style="font-weight: bold;"></font> actions nominatives enti&#232;rement lib&#233;r&#233;es d'une valeur nominale de CHF 0.08 chacune.</div>
          </td>
        </tr>
        <tr>
          <td style="width: 15%; vertical-align: top;">&#160;</td>
          <td style="width: 35%; vertical-align: top;">&#160;</td>
          <td style="width: 2%; vertical-align: top;">&#160;</td>
          <td style="width: 13%; vertical-align: top;">&#160;</td>
          <td style="width: 35%; vertical-align: top;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 15%; vertical-align: top;">&#160;</td>
          <td style="width: 35%; vertical-align: top;">
            <div style="font-weight: bold;">Article 4a</div>
          </td>
          <td style="width: 2%; vertical-align: top;">&#160;</td>
          <td style="width: 13%; vertical-align: top;">&#160;</td>
          <td style="width: 35%; vertical-align: top;">
            <div style="font-weight: bold;">Article 4a</div>
          </td>
        </tr>
        <tr>
          <td style="width: 15%; vertical-align: top;" rowspan="1">&#160;</td>
          <td style="width: 35%; vertical-align: top;" rowspan="1">&#160;</td>
          <td style="width: 2%; vertical-align: top;" rowspan="1">&#160;</td>
          <td style="width: 13%; vertical-align: top;" rowspan="1">&#160;</td>
          <td style="width: 35%; vertical-align: top;" rowspan="1">&#160;</td>
        </tr>
        <tr>
          <td style="width: 15%; vertical-align: top;">
            <div>Authorized Share </div>
            <div>Capital</div>
          </td>
          <td style="width: 35%; vertical-align: top;">
            <div><sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">1 </sup>The Board of Directors shall be authorized to increase the share capital at any time, including in connection with an intended takeover, until April 23,
              2022 by a maximum amount of CHF 32,000,000 by issuing a maximum of 2,560,000 fully paid in registered shares with a par value of CHF 0.08 each. Increases in partial amounts shall be permissible.</div>
          </td>
          <td style="width: 2%; vertical-align: top;">&#160;</td>
          <td style="width: 13%; vertical-align: top;">
            <div>Capital-actions auto-ris&#233;</div>
            <div><br>
            </div>
          </td>
          <td style="width: 35%; vertical-align: top;">
            <div><sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">1 </sup>Le Conseil d'administration est autoris&#233; &#224; augmenter le capital-actions d'un montant maximum de CHF 2'560'000, en tout temps, y inclus en lien avec une
              future offre publique d'acquisition, mais jusqu'au 23 avril 2022 au plus tard, par l'&#233;mission d'un maximum de 32'000'000 actions nominatives d'une valeur nominale de CHF 0.08 chacune, qui doivent &#234;tre int&#233;gralement lib&#233;r&#233;es. Des augmentations
              par montants partiels sont autoris&#233;es.</div>
          </td>
        </tr>
        <tr>
          <td style="width: 15%; vertical-align: top;" rowspan="1">&#160;</td>
          <td style="width: 35%; vertical-align: top;" rowspan="1">&#160;</td>
          <td style="width: 2%; vertical-align: top;" rowspan="1">&#160;</td>
          <td style="width: 13%; vertical-align: top;" rowspan="1">&#160;</td>
          <td style="width: 35%; vertical-align: top;" rowspan="1">&#160;</td>
        </tr>
        <tr>
          <td style="width: 15%; vertical-align: top;">&#160;</td>
          <td style="width: 35%; vertical-align: top;">
            <div><sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">2</sup> The subscription and acquisition of the new shares as well as any subsequent transfer of the shares shall be subject to the restrictions pursuant to Article
              6 of these articles of association.</div>
          </td>
          <td style="width: 2%; vertical-align: top;">&#160;</td>
          <td style="width: 13%; vertical-align: top;">&#160;</td>
          <td style="width: 35%; vertical-align: top;">
            <div><sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">2</sup> La souscription et l'acquisition des nouvelles actions ainsi que tout transfert ult&#233;rieur des actions sont assujettis aux restrictions &#224; la transmissibilit&#233;
              conform&#233;ment &#224; l'article 6 des pr&#233;sents statuts.</div>
          </td>
        </tr>
        <tr>
          <td style="width: 15%; vertical-align: top;" rowspan="1">&#160;</td>
          <td style="width: 35%; vertical-align: top;" rowspan="1">&#160;</td>
          <td style="width: 2%; vertical-align: top;" rowspan="1">&#160;</td>
          <td style="width: 13%; vertical-align: top;" rowspan="1">&#160;</td>
          <td style="width: 35%; vertical-align: top;" rowspan="1">&#160;</td>
        </tr>
        <tr>
          <td style="width: 15%; vertical-align: top;">&#160;</td>
          <td style="width: 35%; vertical-align: top;">
            <div><sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">3 </sup>The Board of Directors shall determine the issue price, the type of contribution, the date of issue, the conditions for the exercise of pre-emptive rights
              and the beginning date for dividend entitlement. In this regard, the Board of Directors may issue new shares by means of a firm underwriting through a financial institution, a syndicate of financial institutions or another third party and a
              subsequent offer of these shares to the existing shareholders or third parties (if the pre-emptive rights of the existing shareholders have been withdrawn or have not been duly exercised). The Board of Directors is entitled to permit, to
              restrict or to exclude the trading of pre-emptive rights. It may permit the expiration of pre-emptive rights that have not been exercised, or it may place such rights or shares as to which pre-emptive rights have been granted, but not
              exercised, at market conditions or may use them otherwise in the interest of the Company.</div>
          </td>
          <td style="width: 2%; vertical-align: top;">&#160;</td>
          <td style="width: 13%; vertical-align: top;">&#160;</td>
          <td style="width: 35%; vertical-align: top;">
            <div><sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">3 </sup>Le Conseil d'administration d&#233;termine le prix d'&#233;mission, la nature des apports, le moment de l'&#233;mission, les conditions de l'exercice du droit de
              souscription pr&#233;f&#233;rentiel et le moment &#224; partir duquel les actions donneront droit &#224; des dividendes. A cet effet, le Conseil d'administration peut &#233;mettre des nouvelles actions par voie de prise ferme par un &#233;tablissement financier, un
              consortium bancaire ou un tiers et d'offre subs&#233;quente de ces actions aux actionnaires actuels ou &#224; des tiers (si les droits de souscription pr&#233;f&#233;rentiels des actionnaires actuels ont &#233;t&#233; supprim&#233;s ou qu'ils n'ont pas &#233;t&#233; valablement
              exerc&#233;s). Le Conseil d'administration est en droit d'autoriser, de limiter ou d'exclure le n&#233;goce des droits de souscription pr&#233;f&#233;rentiels. Le Conseil d'administration peut laisser s'&#233;teindre les droits de souscription pr&#233;f&#233;rentiels non
              exerc&#233;s; il peut aussi ali&#233;ner ceux-ci, respectivement les actions pour lesquelles des droits de souscription ont &#233;t&#233; accord&#233;s sans toutefois &#234;tre exerc&#233;s, aux conditions du march&#233; ou les utiliser autrement dans l'int&#233;r&#234;t de la Soci&#233;t&#233;.</div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div id="DSPFPageBreak" style="page-break-after:always;">
        <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
    </div>
    <table id="z71e89d8c74d543deb50a6931a76c8729" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 15%; vertical-align: top;">&#160;</td>
          <td style="width: 35%; vertical-align: top;">
            <div><sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">4 </sup>The Board of Directors is further authorized to withdraw or restrict pre-emptive rights of existing shareholders and to allocate such rights to third
              parties, the Company or any of its group companies:</div>
          </td>
          <td style="width: 2%; vertical-align: top;">&#160;</td>
          <td style="width: 13%; vertical-align: top;">&#160;</td>
          <td style="width: 35%; vertical-align: top;">
            <div><sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">4 </sup>Le Conseil d'administration peut aussi exclure ou limiter les droits de souscription pr&#233;f&#233;rentiels des actionnaires actuels et les attribuer &#224; des tiers, &#224;
              la Soci&#233;t&#233; ou &#224; une des soci&#233;t&#233;s du groupe:</div>
          </td>
        </tr>
        <tr>
          <td style="width: 15%; vertical-align: top;" rowspan="1">&#160;</td>
          <td style="width: 35%; vertical-align: top;" rowspan="1">&#160;</td>
          <td style="width: 2%; vertical-align: top;" rowspan="1">&#160;</td>
          <td style="width: 13%; vertical-align: top;" rowspan="1">&#160;</td>
          <td style="width: 35%; vertical-align: top;" rowspan="1">&#160;</td>
        </tr>
        <tr>
          <td style="width: 15%; vertical-align: top;">&#160;</td>
          <td style="width: 35%; vertical-align: top;">
            <div style="text-indent: -27pt; margin-left: 27pt;">(a)&#160;&#160; &#160; &#160; if the issue price of the new shares is determined by reference to the market price; or</div>
          </td>
          <td style="width: 2%; vertical-align: top; text-indent: -27pt; margin-left: 27pt;">&#160;</td>
          <td style="width: 13%; vertical-align: top; text-indent: -27pt; margin-left: 27pt;">&#160;</td>
          <td style="width: 35%; vertical-align: top;">
            <div style="text-indent: -27pt; margin-left: 27pt;">(a) &#160; &#160;&#160; si le prix d'&#233;mission des nouvelles actions est d&#233;termin&#233; en fonction du prix du march&#233;; ou</div>
          </td>
        </tr>
        <tr>
          <td style="width: 15%; vertical-align: top;" rowspan="1">&#160;</td>
          <td style="width: 35%; vertical-align: top;" rowspan="1">&#160;</td>
          <td style="width: 2%; vertical-align: top;" rowspan="1">&#160;</td>
          <td style="width: 13%; vertical-align: top; text-indent: -27pt; margin-left: 27pt;" rowspan="1">&#160;</td>
          <td style="width: 35%; vertical-align: top; text-indent: -27pt; margin-left: 27pt;" rowspan="1">&#160;</td>
        </tr>
        <tr>
          <td style="width: 15%; vertical-align: top;">&#160;</td>
          <td style="width: 35%; vertical-align: top;">
            <div style="text-indent: -27pt; margin-left: 27pt;">(b)&#160; &#160; &#160; for raising capital in a fast and flexible manner, which would not be possible, or might only be possible with great difficulty or delays or at significantly less favorable
              conditions, without the exclusion of the pre-emptive rights of existing shareholders; or</div>
          </td>
          <td style="width: 2%; vertical-align: top;">&#160;</td>
          <td style="width: 13%; vertical-align: top; text-indent: -27pt; margin-left: 27pt;">&#160;</td>
          <td style="width: 35%; vertical-align: top;">
            <div style="text-indent: -27pt; margin-left: 27pt;">(b) &#160; &#160;&#160; pour cr&#233;er des fonds de mani&#232;re rapide et flexible, ce qui ne serait pas possible ou possible qu'avec difficult&#233; ou tardivement ou &#224; des conditions nettement plus d&#233;favorables sans
              l'exclusion des droits de souscription pr&#233;f&#233;rentiels des actionnaires actuels; ou</div>
          </td>
        </tr>
        <tr>
          <td style="width: 15%; vertical-align: top;" rowspan="1">&#160;</td>
          <td style="width: 35%; vertical-align: top;" rowspan="1">&#160;</td>
          <td style="width: 2%; vertical-align: top;" rowspan="1">&#160;</td>
          <td style="width: 13%; vertical-align: top; text-indent: -27pt; margin-left: 27pt;" rowspan="1">&#160;</td>
          <td style="width: 35%; vertical-align: top; text-indent: -27pt; margin-left: 27pt;" rowspan="1">&#160;</td>
        </tr>
        <tr>
          <td style="width: 15%; vertical-align: top;">&#160;</td>
          <td style="width: 35%; vertical-align: top;">
            <div style="text-indent: -27pt; margin-left: 27pt;">(c)&#160;&#160;&#160;&#160;&#160; for the acquisition of companies, part(s) of companies or participations, for the acquisition of products, intellectual property or licenses by or for investment projects of the
              Company or any of its group companies, or for the financing or refinancing of any of such transactions through a placement of shares; or</div>
          </td>
          <td style="width: 2%; vertical-align: top; text-indent: -27pt; margin-left: 27pt;">&#160;</td>
          <td style="width: 13%; vertical-align: top; text-indent: -27pt; margin-left: 27pt;">&#160;</td>
          <td style="width: 35%; vertical-align: top;">
            <div style="text-indent: -27pt; margin-left: 27pt;">(c)&#160;&#160; &#160;&#160; pour l'acquisition de soci&#233;t&#233;s, de partie(s) de soci&#233;t&#233;s ou de participations, pour l'acquisition de produits, de droits de propri&#233;t&#233; intellectuelle, ou licences par ou pour des
              projets d'investissement de la Soci&#233;t&#233; ou de l'une des soci&#233;t&#233;s du groupe, ou pour le financement ou le refinancement de telles transactions par le placement d'actions; ou</div>
          </td>
        </tr>
        <tr>
          <td style="width: 15%; vertical-align: top;" rowspan="1">&#160;</td>
          <td style="width: 35%; vertical-align: top;" rowspan="1">&#160;</td>
          <td style="width: 2%; vertical-align: top; text-indent: -27pt; margin-left: 27pt;" rowspan="1">&#160;</td>
          <td style="width: 13%; vertical-align: top; text-indent: -27pt; margin-left: 27pt;" rowspan="1">&#160;</td>
          <td style="width: 35%; vertical-align: top; text-indent: -27pt; margin-left: 27pt;" rowspan="1">&#160;</td>
        </tr>
        <tr>
          <td style="width: 15%; vertical-align: top;">&#160;</td>
          <td style="width: 35%; vertical-align: top;">
            <div style="text-indent: -27pt; margin-left: 27pt;">(d)&#160;&#160;&#160;&#160;&#160; for purposes of broadening the shareholder constituency of the Company in certain geographic, financial or investor markets, for purposes of the participation of strategic partners,
              or in connection with the listing of new shares on domestic or foreign stock exchanges; or</div>
          </td>
          <td style="width: 2%; vertical-align: top; text-indent: -27pt; margin-left: 27pt;">&#160;</td>
          <td style="width: 13%; vertical-align: top; text-align: justify; text-indent: -27pt; margin-left: 27pt;">&#160;</td>
          <td style="width: 35%; vertical-align: top;">
            <div style="text-align: justify; text-indent: -27pt; margin-left: 27pt;">(d)&#160;&#160;&#160; pour &#233;largir le cercle des actionnaires de la Soci&#233;t&#233; dans certains march&#233;s g&#233;ographiques, financiers ou d'investisseurs, pour permettre la participation de
              partenaires strat&#233;giques, ou en relation avec la cotation de nouvelles actions sur des bourses nationales ou &#233;trang&#232;res; ou</div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div id="DSPFPageBreak" style="page-break-after:always;">
        <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
    </div>
    <table id="z9fe75e6ca24149cd85350f3cbbe953b9" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 15%; vertical-align: top; text-indent: -27pt; margin-left: 27pt;">&#160;</td>
          <td style="width: 35%; vertical-align: top;">
            <div style="text-indent: -27pt; margin-left: 27pt;">(e)&#160;&#160;&#160;&#160;&#160; for purposes of granting an over-allotment option (<font style="font-style: italic;">Greenshoe</font>)&#160; or an option to subscribe for additional shares in a placement or sale of
              shares to the respective initial purchaser(s) or underwriter(s); or</div>
          </td>
          <td style="width: 2%; vertical-align: top; text-indent: -27pt; margin-left: 27pt;">&#160;</td>
          <td style="width: 13%; vertical-align: top; text-indent: -27pt; margin-left: 27pt;">&#160;</td>
          <td style="width: 35%; vertical-align: top;">
            <div style="text-indent: -27pt; margin-left: 27pt;">(e)&#160;&#160;&#160;&#160;&#160; pour octroyer une option de surallocation (<font style="font-style: italic;">Greenshoe</font>) ou une option de souscription d'actions suppl&#233;mentaires lors d'un placement ou de la
              vente d'actions &#224; un ou plusieurs acheteurs initiaux ou souscripteurs; ou</div>
          </td>
        </tr>
        <tr>
          <td style="width: 15%; vertical-align: top; text-indent: -27pt; margin-left: 27pt;" rowspan="1">&#160;</td>
          <td style="width: 35%; vertical-align: top;" rowspan="1">&#160;</td>
          <td style="width: 2%; vertical-align: top; text-indent: -27pt; margin-left: 27pt;" rowspan="1">&#160;</td>
          <td style="width: 13%; vertical-align: top; text-indent: -27pt; margin-left: 27pt;" rowspan="1">&#160;</td>
          <td style="width: 35%; vertical-align: top;" rowspan="1">&#160;</td>
        </tr>
        <tr>
          <td style="width: 15%; vertical-align: top; text-indent: -27pt; margin-left: 27pt;">&#160;</td>
          <td style="width: 35%; vertical-align: top;">
            <div style="text-indent: -27pt; margin-left: 27pt;">(f)&#160;&#160;&#160;&#160;&#160; for the participation of members of the Board of Directors, members of the executive management, employees, contractors, consultants or other persons performing services for the
              benefit of the Company or any of its group companies; or</div>
          </td>
          <td style="width: 2%; vertical-align: top; text-indent: -27pt; margin-left: 27pt;">&#160;</td>
          <td style="width: 13%; vertical-align: top; text-indent: -27pt; margin-left: 27pt;">&#160;</td>
          <td style="width: 35%; vertical-align: top;">
            <div style="text-indent: -27pt; margin-left: 27pt;">(f)&#160;&#160;&#160; &#160;&#160; pour la participation de membres du Conseil d'administration, de membres de la direction, d'employ&#233;s, de co-contractants, de consultants ou d'autres personnes exer&#231;ant des services
              au b&#233;n&#233;fice de la Soci&#233;t&#233; ou de l'une des soci&#233;t&#233;s du groupe; ou</div>
          </td>
        </tr>
        <tr>
          <td style="width: 15%; vertical-align: top; text-indent: -27pt; margin-left: 27pt;" rowspan="1">&#160;</td>
          <td style="width: 35%; vertical-align: top;" rowspan="1">&#160;</td>
          <td style="width: 2%; vertical-align: top; text-indent: -27pt; margin-left: 27pt;" rowspan="1">&#160;</td>
          <td style="width: 13%; vertical-align: top; text-indent: -27pt; margin-left: 27pt;" rowspan="1">&#160;</td>
          <td style="width: 35%; vertical-align: top;" rowspan="1">&#160;</td>
        </tr>
        <tr>
          <td style="width: 15%; vertical-align: top; text-indent: -27pt; margin-left: 27pt;">&#160;</td>
          <td style="width: 35%; vertical-align: top;">
            <div style="text-indent: -27pt; margin-left: 27pt;">(g)&#160;&#160;&#160;&#160;&#160; following a shareholder or a group of shareholders acting in concert having accumulated shareholdings in excess of 20% of the share capital registered in the commercial register
              without having submitted to all other shareholders a takeover offer recommended by the Board of Directors; or</div>
          </td>
          <td style="width: 2%; vertical-align: top; text-indent: -27pt; margin-left: 27pt;">&#160;</td>
          <td style="width: 13%; vertical-align: top; text-indent: -27pt; margin-left: 27pt;">&#160;</td>
          <td style="width: 35%; vertical-align: top;">
            <div style="text-indent: -27pt; margin-left: 27pt;">(g)&#160;&#160; &#160;&#160; si un actionnaire ou un groupe d'actionnaires agissant de concert a acquis ou r&#233;uni une participation de plus de 20% du capital-actions inscrit au registre du commerce sans avoir
              pr&#233;sent&#233; &#224; tous les autres actionnaires une offre publique d'achat dont l'acceptation a &#233;t&#233; recommand&#233;e par le Conseil d'administration; ou</div>
          </td>
        </tr>
        <tr>
          <td style="width: 15%; vertical-align: top; text-indent: -27pt; margin-left: 27pt;" rowspan="1">&#160;</td>
          <td style="width: 35%; vertical-align: top;" rowspan="1">&#160;</td>
          <td style="width: 2%; vertical-align: top; text-indent: -27pt; margin-left: 27pt;" rowspan="1">&#160;</td>
          <td style="width: 13%; vertical-align: top; text-indent: -27pt; margin-left: 27pt;" rowspan="1">&#160;</td>
          <td style="width: 35%; vertical-align: top;" rowspan="1">&#160;</td>
        </tr>
        <tr>
          <td style="width: 15%; vertical-align: top; text-indent: -27pt; margin-left: 27pt;">&#160;</td>
          <td style="width: 35%; vertical-align: top;">
            <div style="text-indent: -27pt; margin-left: 27pt;">(h)&#160;&#160;&#160;&#160;&#160; for the defense of an actual, threatened or potential takeover bid that the Board of Directors, upon consultation with an independent financial adviser retained by it, has not
              recommended or will not recommend to the shareholders to accept on the basis that the Board of Directors does not find such takeover bid to be financially fair to the shareholders or not to be in the Company's interest.</div>
          </td>
          <td style="width: 2%; vertical-align: top; text-indent: -27pt; margin-left: 27pt;">&#160;</td>
          <td style="width: 13%; vertical-align: top; text-indent: -27pt; margin-left: 27pt;">&#160;</td>
          <td style="width: 35%; vertical-align: top;">
            <div style="text-indent: -27pt; margin-left: 27pt;">(h)&#160;&#160; &#160;&#160; pour se d&#233;fendre contre une offre publique d'achat hostile pr&#233;sent&#233;e, mena&#231;ante ou potentielle dont le rejet est, respectivement sera, recommand&#233; par le Conseil d'administration,
              apr&#232;s consultation d'un conseiller financier ind&#233;pendant qu'il aura choisi, dans la mesure o&#249; le Conseil d'administration estime que l'offre publique d'achat n'est pas &#233;quitable d'un point de vue financier vis-&#224;-vis des actionnaires ou n'est
              pas dans l'int&#233;r&#234;t de la Soci&#233;t&#233;.</div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div id="DSPFPageBreak" style="page-break-after:always;">
        <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
    </div>
    <table id="z770779914e094a8bb5393fbe8632acd1" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 15%; vertical-align: top;">&#160;</td>
          <td style="width: 35%; vertical-align: top;">
            <div style="font-weight: bold;">Article 4b</div>
          </td>
          <td style="width: 2%; vertical-align: top;">&#160;</td>
          <td style="width: 13%; vertical-align: top;">&#160;</td>
          <td style="width: 35%; vertical-align: top;">
            <div style="font-weight: bold;">Article 4b</div>
          </td>
        </tr>
        <tr>
          <td style="width: 15%; vertical-align: top;" rowspan="1">&#160;</td>
          <td style="width: 35%; vertical-align: top;" rowspan="1">&#160;</td>
          <td style="width: 2%; vertical-align: top;" rowspan="1">&#160;</td>
          <td style="width: 13%; vertical-align: top;" rowspan="1">&#160;</td>
          <td style="width: 35%; vertical-align: top;" rowspan="1">&#160;</td>
        </tr>
        <tr>
          <td style="width: 15%; vertical-align: top;">
            <div>Conditional Share</div>
            <div>Capital for Em</div>
            <div>ployee Participation</div>
          </td>
          <td style="width: 35%; vertical-align: top;">
            <div><sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">1 </sup>The share capital may be increased in an amount not to exceed CHF 936,000 through the issuance of up to 11,700,000 fully paid in registered shares with a
              par value of CHF 0.08 per share through the direct or indirect issuance of shares, options or related subscription rights to members of the Board of Directors, members of the executive management, employees, contractors or consultants of the
              Company or its group companies, or other persons providing services to the Company or its group companies.</div>
          </td>
          <td style="width: 2%; vertical-align: top;">&#160;</td>
          <td style="width: 13%; vertical-align: top;">
            <div>Capital-actions</div>
            <div> conditionnel pour</div>
            <div> la participation</div>
            <div> des employ&#233;s</div>
          </td>
          <td style="width: 35%; vertical-align: top;">
            <div><sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">1 </sup>Le capital-actions peut &#234;tre augment&#233; d'un montant maximum de CHF 936'000 par l'&#233;mission de 11'700'000 actions nominatives au plus, d'une valeur nominale
              de CHF 0.08 chacune, qui doivent &#234;tre int&#233;gralement lib&#233;r&#233;es, par l'&#233;mission directe ou indirecte d'actions, d'options ou de droits de souscription y relatifs, octroy&#233;s aux membres du Conseil d'administration, aux membres de la direction, ou
              aux employ&#233;s, co-contractants ou consultants de la Soci&#233;t&#233; ou de l'une des soci&#233;t&#233;s du groupe, ou d'autres personnes exer&#231;ant des services au b&#233;n&#233;fice de la Soci&#233;t&#233; ou de l'une des soci&#233;t&#233;s du groupe.</div>
          </td>
        </tr>
        <tr>
          <td style="width: 15%; vertical-align: top;" rowspan="1">&#160;</td>
          <td style="width: 35%; vertical-align: top;" rowspan="1">&#160;</td>
          <td style="width: 2%; vertical-align: top;" rowspan="1">&#160;</td>
          <td style="width: 13%; vertical-align: top;" rowspan="1">&#160;</td>
          <td style="width: 35%; vertical-align: top;" rowspan="1">&#160;</td>
        </tr>
        <tr>
          <td style="width: 15%; vertical-align: top;">&#160;</td>
          <td style="width: 35%; vertical-align: top;">
            <div><sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">2</sup> The pre-emptive rights and advance subscription rights of the shareholders of the Company shall be excluded in connection with the issuance of any shares,
              options, other rights to receive shares, or subscription rights therefor. Shares, options, other rights to receive shares, or subscription rights therefor shall be issued pursuant to one or more regulations to be issued by the Board of
              Directors or, to the extent delegated to it, the Compensation Committee, and to the extent applicable, taking into account the compensation principles pursuant to Article 28 of these articles of association.<font style="font-weight: bold;">&#160;</font>Shares,



              options, other rights to receive shares, or subscription rights therefor may be issued at a price or with an exercise price lower than the market price.</div>
          </td>
          <td style="width: 2%; vertical-align: top;">&#160;</td>
          <td style="width: 13%; vertical-align: top;">&#160;</td>
          <td style="width: 35%; vertical-align: top;">
            <div><sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">2</sup> Le droit de souscription pr&#233;f&#233;rentiel ainsi que le droit de souscription pr&#233;alable des actionnaires de la Soci&#233;t&#233; sont exclus en relation avec l'&#233;mission de
              toutes actions, options, autres droits &#224; recevoir des actions ou des droits de souscription qui y sont attach&#233;s. L'&#233;mission d'actions, d'options, d'autres droits &#224; recevoir des actions ou des droits de souscription qui y sont attach&#233;s est
              faite selon un ou plusieurs r&#232;glements adopt&#233;s par le Conseil d'administration ou le Comit&#233; de r&#233;mun&#233;ration, dans la mesure o&#249; cette comp&#233;tence lui a &#233;t&#233; d&#233;l&#233;gu&#233;e, et le cas &#233;ch&#233;ant en tenant compte des principes de r&#233;mun&#233;ration selon
              l'article 28 des pr&#233;sents statuts. L'&#233;mission d'actions, d'options, d'autres droits &#224; recevoir des actions ou des droits de souscription qui y sont attach&#233;s peut se faire &#224; un prix ou avec un prix d'exercice en-dessous du prix du march&#233;.</div>
          </td>
        </tr>
        <tr>
          <td style="width: 15%; vertical-align: top;" rowspan="1">&#160;</td>
          <td style="width: 35%; vertical-align: top;" rowspan="1">&#160;</td>
          <td style="width: 2%; vertical-align: top;" rowspan="1">&#160;</td>
          <td style="width: 13%; vertical-align: top;" rowspan="1">&#160;</td>
          <td style="width: 35%; vertical-align: top;" rowspan="1">&#160;</td>
        </tr>
        <tr>
          <td style="width: 15%; vertical-align: top;">&#160;</td>
          <td style="width: 35%; vertical-align: top;">
            <div><sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">3 </sup>The direct or indirect acquisition of the new shares by persons listed in paragraph 1 in connection with an employee participation program and any
              subsequent transfer of such shares shall be subject to the restrictions of Article 6 of these articles of association.</div>
          </td>
          <td style="width: 2%; vertical-align: top;">&#160;</td>
          <td style="width: 13%; vertical-align: top;">&#160;</td>
          <td style="width: 35%; vertical-align: top;">
            <div><sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">3 </sup>L'acquisition directe ou indirecte de nouvelles actions par des personnes mentionn&#233;es &#224; l'alin&#233;a 1 dans le cadre d'un programme de participation des
              collaborateurs ainsi que le transfert subs&#233;quent de ces actions sont assujettis aux restrictions &#224; la transmissibilit&#233; conform&#233;ment &#224; l'article 6 des pr&#233;sents statuts.</div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div id="DSPFPageBreak" style="page-break-after:always;">
        <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
    </div>
    <table id="z1a0eb6b69b2445c8b309e4a1459a4464" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 15%; vertical-align: top;">&#160;</td>
          <td style="width: 35%; vertical-align: top;">
            <div style="font-weight: bold;">Article 4c</div>
          </td>
          <td style="width: 2%; vertical-align: top;">&#160;</td>
          <td style="width: 13%; vertical-align: top;">&#160;</td>
          <td style="width: 35%; vertical-align: top;">
            <div style="font-weight: bold;">Article 4c</div>
          </td>
        </tr>
        <tr>
          <td style="width: 15%; vertical-align: top;" rowspan="1">&#160;</td>
          <td style="width: 35%; vertical-align: top;" rowspan="1">&#160;</td>
          <td style="width: 2%; vertical-align: top;" rowspan="1">&#160;</td>
          <td style="width: 13%; vertical-align: top;" rowspan="1">&#160;</td>
          <td style="width: 35%; vertical-align: top;" rowspan="1">&#160;</td>
        </tr>
        <tr>
          <td style="width: 15%; vertical-align: top;">
            <div>Conditional Share </div>
            <div>Capital for Financing, </div>
            <div>Acquisitions and other </div>
            <div>Purposes</div>
          </td>
          <td style="width: 35%; vertical-align: top;">
            <div><sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">1 </sup>The share capital may be increased including in connection with an intended takeover in an amount not to exceed CHF 1,624,000 through the issuance of up to
              20,300,000 fully paid in registered shares with a par value of CHF 0.08 per share through the exercise or mandatory exercise of conversion, exchange, option, warrant or similar rights or obligations for the subscription of shares granted to
              shareholders or third parties on a stand-alone basis or in connection with bonds, notes, options, warrants or other securities or contractual obligations of the Company or any of its group companies, including without limitation a convertible
              debenture to be entered into by the Company, as may be amended or novated from time to time (hereinafter collectively, the <font style="font-weight: bold;">Financial Instruments</font>).</div>
          </td>
          <td style="width: 2%; vertical-align: top;">&#160;</td>
          <td style="width: 13%; vertical-align: top;">
            <div>Capital-actions </div>
            <div>conditionnel aux</div>
            <div> fins de financement,</div>
            <div> acquisitions ou </div>
            <div>d'autres buts</div>
          </td>
          <td style="width: 35%; vertical-align: top;">
            <div><sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">1 </sup>Le capital-actions peut &#234;tre augment&#233;, y compris en lien avec une future offre publique d'acquisition, d'un montant maximum de CHF 1'624'000 par l'&#233;mission
              de 20'300'000 actions nominatives au plus, d'une valeur nominale de CHF 0.08 chacune, qui doivent &#234;tre int&#233;gralement lib&#233;r&#233;es par l'exercice ou l'exercice obligatoire de droits de conversion, d'&#233;change, d'option, de warrant ou d'autres droits
              ou obligations similaires pour la souscription d'actions octroy&#233;s aux actionnaires ou &#224; des tiers de mani&#232;re autonome ou en rapport avec des obligations, effets, options, warrants ou autres instruments financiers ou obligations contractuelles
              de la Soci&#233;t&#233; ou de l'une des soci&#233;t&#233;s du groupe, y compris, mais sans s'y limiter, une d&#233;benture convertible de la soci&#233;t&#233;, laquelle peut &#234;tre amen&#233;e &#224; &#234;tre modifi&#233;e ou actualis&#233;e (ci-apr&#232;s d&#233;sign&#233;s collectivement les <font style="font-weight: bold;">Instruments Financiers</font>).</div>
          </td>
        </tr>
        <tr>
          <td style="width: 15%; vertical-align: top;" rowspan="1">&#160;</td>
          <td style="width: 35%; vertical-align: top;" rowspan="1">&#160;</td>
          <td style="width: 2%; vertical-align: top;" rowspan="1">&#160;</td>
          <td style="width: 13%; vertical-align: top;" rowspan="1">&#160;</td>
          <td style="width: 35%; vertical-align: top;" rowspan="1">&#160;</td>
        </tr>
        <tr>
          <td style="width: 15%; vertical-align: top;">&#160;</td>
          <td style="width: 35%; vertical-align: top;">
            <div><sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">2</sup> The pre-emptive rights of shareholders shall be excluded for the exercise of any Financial Instruments in connection with the issuance of shares. The
              then-current owners of such Financial Instruments shall be entitled to acquire the new shares issued upon conversion, exchange or exercise of any Financial Instruments. The key conditions of the Financial Instruments shall be determined by
              the Board of Directors.</div>
          </td>
          <td style="width: 2%; vertical-align: top;">&#160;</td>
          <td style="width: 13%; vertical-align: top;">&#160;</td>
          <td style="width: 35%; vertical-align: top;">
            <div><sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">2</sup> Le droit de souscription pr&#233;f&#233;rentiel des actionnaires est exclu en relation avec l'&#233;mission d'actions &#224; l'occasion de l'exercice d'Instruments Financiers.
              Les personnes qui d&#233;tiendront alors de tels Instruments Financiers seront en droit d'acqu&#233;rir les nouvelles actions &#233;mises &#224; l'occasion de la conversion, de l'&#233;change ou de l'exercice d'Instruments Financiers. Le Conseil d'administration
              d&#233;termine les principales conditions des Instruments Financiers.</div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <div>&#160;</div>
    <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div id="DSPFPageBreak" style="page-break-after:always;">
        <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
    </div>
    <table id="z9b87ead8e8034cdaac83d4c4a2f4259d" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 15%; vertical-align: top;">&#160;</td>
          <td style="width: 35%; vertical-align: top;">
            <div><sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">3 </sup>The Board of Directors shall be authorized to restrict or withdraw advance subscription rights of shareholders in connection with the issuance of Financial
              Instruments by the Company or one of its group companies (1) if the issuance is for purposes of financing or refinancing, or the payment for, the acquisition of companies, parts of a company, participations, intellectual property rights,
              licenses or investments, (2) if the issuance occurs in domestic or international capital markets or through a private placement, (3) following a shareholder or a group of shareholders acting in concert having accumulated shareholdings in
              excess of 20% of the share capital registered in the commercial register without having submitted to all other shareholders a takeover offer recommended by the Board of Directors, or (4) for the defense of an actual, threatened or potential
              takeover bid that the Board of Directors, upon consultation with an independent financial adviser retained by it, has not recommended or will not recommend to the shareholders to accept on the basis that the Board of Directors does not find
              such takeover bid to be financially fair to the shareholders or not in the Company's interest. If the advance subscription rights are neither granted directly nor indirectly by the Board of Directors, the following shall apply:</div>
          </td>
          <td style="width: 2%; vertical-align: top;">&#160;</td>
          <td style="width: 13%; vertical-align: top;">&#160;</td>
          <td style="width: 35%; vertical-align: top;">
            <div><sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">3 </sup>Le Conseil d'administration est autoris&#233; &#224; limiter ou retirer le droit de souscription pr&#233;alable des actionnaires en relation avec l'&#233;mission d'Instruments
              Financiers par la Soci&#233;t&#233; ou une des soci&#233;t&#233;s du groupe (1) si l'&#233;mission a pour but le financement, le refinancement ou le paiement de l'acquisition d'entreprises, de parties d'une entreprise, de participations, de droits de propri&#233;t&#233;
              intellectuelle, de licences ou d'investissements, (2) si l'&#233;mission a lieu sur les march&#233;s de capitaux nationaux ou internationaux ou par le biais d'un placement priv&#233;, (3) si un actionnaire ou un groupe d'actionnaires agissant de concert a
              acquis ou r&#233;uni une participation de plus de 20% du capital-actions inscrit au registre du commerce sans avoir pr&#233;sent&#233; &#224; tous les autres actionnaires une offre publique d'achat dont l'acceptation a &#233;t&#233; recommand&#233;e par le Conseil
              d'administration, ou (4) pour se d&#233;fendre contre une offre publique d'achat hostile pr&#233;sent&#233;e, mena&#231;ante ou potentielle dont le rejet est, respectivement sera, recommand&#233; par le Conseil d'administration, apr&#232;s consultation d'un conseiller
              financier ind&#233;pendant qu'il aura choisi, dans la mesure o&#249; le Conseil d'administration estime que l'offre publique d'achat n'est pas &#233;quitable d'un point de vue financier vis-&#224;-vis des actionnaires ou n'est pas dans l'int&#233;r&#234;t de la Soci&#233;t&#233;.
              Si le droit de souscription pr&#233;alable n'est pas accord&#233;, de mani&#232;re directe ou indirecte, par le Conseil d'administration, les r&#232;gles suivantes s'appliquent:</div>
          </td>
        </tr>
        <tr>
          <td style="width: 15%; vertical-align: top;" rowspan="1">&#160;</td>
          <td style="width: 35%; vertical-align: top;" rowspan="1">&#160;</td>
          <td style="width: 2%; vertical-align: top;" rowspan="1">&#160;</td>
          <td style="width: 13%; vertical-align: top;" rowspan="1">&#160;</td>
          <td style="width: 35%; vertical-align: top;" rowspan="1">&#160;</td>
        </tr>
        <tr>
          <td style="width: 15%; vertical-align: top; text-indent: -27pt; margin-left: 27pt;">&#160;</td>
          <td style="width: 35%; vertical-align: top;">
            <div style="text-indent: -27pt; margin-left: 27pt;">(a)&#160;&#160;&#160;&#160;&#160; the Financial Instruments shall be issued or entered into at market conditions;</div>
          </td>
          <td style="width: 2%; vertical-align: top; text-indent: -27pt; margin-left: 27pt;">&#160;</td>
          <td style="width: 13%; vertical-align: top; text-indent: -27pt; margin-left: 27pt;">&#160;</td>
          <td style="width: 35%; vertical-align: top;">
            <div style="text-indent: -27pt; margin-left: 27pt;">(a)&#160;&#160;&#160; &#160; les Instruments Financiers sont &#233;mis ou conclus aux conditions du march&#233;;</div>
          </td>
        </tr>
        <tr>
          <td style="width: 15%; vertical-align: top; text-indent: -27pt; margin-left: 27pt;" rowspan="1">&#160;</td>
          <td style="width: 35%; vertical-align: top;" rowspan="1">&#160;</td>
          <td style="width: 2%; vertical-align: top; text-indent: -27pt; margin-left: 27pt;" rowspan="1">&#160;</td>
          <td style="width: 13%; vertical-align: top; text-indent: -27pt; margin-left: 27pt;" rowspan="1">&#160;</td>
          <td style="width: 35%; vertical-align: top;" rowspan="1">&#160;</td>
        </tr>
        <tr>
          <td style="width: 15%; vertical-align: top; text-indent: -27pt; margin-left: 27pt;">&#160;</td>
          <td style="width: 35%; vertical-align: top;">
            <div style="text-indent: -27pt; margin-left: 27pt;">(b)&#160;&#160;&#160;&#160;&#160; the Financial Instruments may be converted, exchanged or exercised during a maximum period of 10 years from the date of issuance or contract conclusion; and</div>
          </td>
          <td style="width: 2%; vertical-align: top; text-indent: -27pt; margin-left: 27pt;">&#160;</td>
          <td style="width: 13%; vertical-align: top; text-indent: -27pt; margin-left: 27pt;">&#160;</td>
          <td style="width: 35%; vertical-align: top;">
            <div style="text-indent: -27pt; margin-left: 27pt;">(b)&#160; &#160; &#160; les Instruments Financiers peuvent &#234;tre convertis, &#233;chang&#233;s ou exerc&#233;s durant une p&#233;riode maximale de 10 ans suivant la date de l'&#233;mission ou de la conclusion du contrat; et</div>
          </td>
        </tr>
        <tr>
          <td style="width: 15%; vertical-align: top; text-indent: -27pt; margin-left: 27pt;" rowspan="1">&#160;</td>
          <td style="width: 35%; vertical-align: top; text-indent: -27pt; margin-left: 27pt;" rowspan="1">&#160;</td>
          <td style="width: 2%; vertical-align: top; text-indent: -27pt; margin-left: 27pt;" rowspan="1">&#160;</td>
          <td style="width: 13%; vertical-align: top; text-indent: -27pt; margin-left: 27pt;" rowspan="1">&#160;</td>
          <td style="width: 35%; vertical-align: top; text-indent: -27pt; margin-left: 27pt;" rowspan="1">&#160;</td>
        </tr>
        <tr>
          <td style="width: 15%; vertical-align: top; text-indent: -27pt; margin-left: 27pt;">&#160;</td>
          <td style="width: 35%; vertical-align: top;">
            <div style="text-indent: -27pt; margin-left: 27pt;">(c)&#160;&#160;&#160;&#160;&#160; <font style="color: rgb(0, 0, 0);">the conversion, exchange or exercise price </font>of the Financial Instruments shall be set with reference to, and/or shall be subject to change
              based upon, the valuation <font style="color: rgb(0, 0, 0);">of the Company's equity and/or market conditions.</font></div>
          </td>
          <td style="width: 2%; vertical-align: top; text-indent: -27pt; margin-left: 27pt;">&#160;</td>
          <td style="width: 13%; vertical-align: top; text-indent: -27pt; margin-left: 27pt;">&#160;</td>
          <td style="width: 35%; vertical-align: top;">
            <div style="text-indent: -27pt; margin-left: 27pt;">(c)&#160;&#160;&#160;&#160;&#160; le prix de conversion, d'&#233;change ou d'exercice des Instruments Financiers est fix&#233; en prenant en compte, et/ou peut &#234;tre modifi&#233; en fonction, de la valorisation des fonds propres de
              la soci&#233;t&#233; et/ou des conditions du march&#233;.</div>
          </td>
        </tr>
        <tr>
          <td style="width: 15%; vertical-align: top;" rowspan="1">&#160;</td>
          <td style="width: 35%; vertical-align: top;" rowspan="1">&#160;</td>
          <td style="width: 2%; vertical-align: top;" rowspan="1">&#160;</td>
          <td style="width: 13%; vertical-align: top;" rowspan="1">&#160;</td>
          <td style="width: 35%; vertical-align: top;" rowspan="1">&#160;</td>
        </tr>
        <tr>
          <td style="width: 15%; vertical-align: top;">&#160;</td>
          <td style="width: 35%; vertical-align: top;">
            <div><sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">4 </sup>The direct or indirect acquisition of the new shares acquired through the exercise of Financial Instruments and any subsequent transfer of such shares
              shall be subject to the restrictions of Article 6 of these articles of association.</div>
          </td>
          <td style="width: 2%; vertical-align: top;">&#160;</td>
          <td style="width: 13%; vertical-align: top;">&#160;</td>
          <td style="width: 35%; vertical-align: top;">
            <div><sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">4 </sup>L'acquisition de nouvelles actions acquises directement ou indirectement par l'exercice d'Instruments Financiers ainsi que le transfert subs&#233;quent de ces
              actions sont assujettis aux restrictions &#224; la transmissibilit&#233; conform&#233;ment &#224; l'article 6 des pr&#233;sents statuts.</div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div id="DSPFPageBreak" style="page-break-after:always;">
        <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
    </div>
    <table id="zf55848836db645f0abdbaf9b0cd7e225" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 15%; vertical-align: top;">&#160;</td>
          <td style="width: 35%; vertical-align: top;">
            <div style="font-weight: bold;">Article 5</div>
          </td>
          <td style="width: 2%; vertical-align: top;">&#160;</td>
          <td style="width: 13%; vertical-align: top;">&#160;</td>
          <td style="width: 35%; vertical-align: top;">
            <div style="font-weight: bold;">Article 5</div>
          </td>
        </tr>
        <tr>
          <td style="width: 15%; vertical-align: top;" rowspan="1">&#160;</td>
          <td style="width: 35%; vertical-align: top;" rowspan="1">&#160;</td>
          <td style="width: 2%; vertical-align: top;" rowspan="1">&#160;</td>
          <td style="width: 13%; vertical-align: top;" rowspan="1">&#160;</td>
          <td style="width: 35%; vertical-align: top;" rowspan="1">&#160;</td>
        </tr>
        <tr>
          <td style="width: 15%; vertical-align: top;">
            <div>Share Certificates and Intermediated Securities</div>
          </td>
          <td style="width: 35%; vertical-align: top;">
            <div><sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">1 </sup>The Company may issue its registered shares in the form of single certificates, global certificates and uncertificated securities. Subject to applicable
              law, the Company may convert its registered shares from one form into another form at any time and without the approval of the shareholders. The Company shall bear the cost associated with any such conversion.</div>
          </td>
          <td style="width: 2%; vertical-align: top;"><br>
          </td>
          <td style="width: 13%; vertical-align: top;">
            <div>Certificats d'actions et titres interm&#233;di&#233;s</div>
          </td>
          <td style="width: 35%; vertical-align: top;">
            <div><sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">1 </sup>La Soci&#233;t&#233; &#233;met ses actions nominatives sous forme de certificats individuels, de certificats globaux ou de droits-valeurs. La Soci&#233;t&#233; est libre, dans les
              limites du droit applicable, en tout temps et sans l'approbation des actionnaires, de convertir ses actions nominatives &#233;mises sous l'une des formes ci-dessus, en une autre forme. La Soci&#233;t&#233; supporte les co&#251;ts d'une telle conversion.</div>
          </td>
        </tr>
        <tr>
          <td style="width: 15%; vertical-align: top;" rowspan="1">&#160;</td>
          <td style="width: 35%; vertical-align: top;" rowspan="1">&#160;</td>
          <td style="width: 2%; vertical-align: top;" rowspan="1">&#160;</td>
          <td style="width: 13%; vertical-align: top;" rowspan="1">&#160;</td>
          <td style="width: 35%; vertical-align: top;" rowspan="1">&#160;</td>
        </tr>
        <tr>
          <td style="width: 15%; vertical-align: top;">&#160;</td>
          <td style="width: 35%; vertical-align: top;">
            <div><sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">2</sup> A shareholder has no right to request a conversion of the registered shares issued in one form into another form. Each shareholder may, however, at any time
              request from the Company a written confirmation of the registered shares held by such shareholder, as reflected in the share register.</div>
          </td>
          <td style="width: 2%; vertical-align: top;">&#160;</td>
          <td style="width: 13%; vertical-align: top;">&#160;</td>
          <td style="width: 35%; vertical-align: top;">
            <div><sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">2</sup> Un actionnaire n'a pas le droit de r&#233;clamer la conversion d'actions nominatives &#233;mises sous une certaine forme en une autre forme. Chaque actionnaire peut
              toutefois exiger en tout temps que la Soci&#233;t&#233; &#233;tablisse une attestation relative aux actions nominatives qu'il d&#233;tient selon le registre des actions.</div>
          </td>
        </tr>
        <tr>
          <td style="width: 15%; vertical-align: top;" rowspan="1">&#160;</td>
          <td style="width: 35%; vertical-align: top;" rowspan="1">&#160;</td>
          <td style="width: 2%; vertical-align: top;" rowspan="1">&#160;</td>
          <td style="width: 13%; vertical-align: top;" rowspan="1">&#160;</td>
          <td style="width: 35%; vertical-align: top;" rowspan="1">&#160;</td>
        </tr>
        <tr>
          <td style="width: 15%; vertical-align: top;">&#160;</td>
          <td style="width: 35%; vertical-align: top;">
            <div><sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">3</sup> Intermediated securities based on registered shares of the Company cannot be transferred by way of assignment. A security interest in any such intermediated
              securities also cannot be granted by way of assignment.</div>
          </td>
          <td style="width: 2%; vertical-align: top;">&#160;</td>
          <td style="width: 13%; vertical-align: top;">&#160;</td>
          <td style="width: 35%; vertical-align: top;">
            <div><sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">3</sup> Les titres interm&#233;di&#233;s fond&#233;s sur des actions nominatives de la Soci&#233;t&#233; ne peuvent pas &#234;tre transf&#233;r&#233;s par cession. Il ne peut pas non plus &#234;tre constitu&#233;
              de s&#251;ret&#233;s par cession sur ces titres interm&#233;di&#233;s.</div>
          </td>
        </tr>
        <tr>
          <td style="width: 15%; vertical-align: top;">&#160;</td>
          <td style="width: 35%; vertical-align: top;">&#160;</td>
          <td style="width: 2%; vertical-align: top;">&#160;</td>
          <td style="width: 13%; vertical-align: top;">&#160;</td>
          <td style="width: 35%; vertical-align: top;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 15%; vertical-align: top;">&#160;</td>
          <td style="width: 35%; vertical-align: top;">
            <div style="font-weight: bold;">Article 6</div>
          </td>
          <td style="width: 2%; vertical-align: top;">&#160;</td>
          <td style="width: 13%; vertical-align: top;">&#160;</td>
          <td style="width: 35%; vertical-align: top;">
            <div style="font-weight: bold;">Article 6</div>
          </td>
        </tr>
        <tr>
          <td style="width: 15%; vertical-align: top;" rowspan="1">&#160;</td>
          <td style="width: 35%; vertical-align: top;" rowspan="1">&#160;</td>
          <td style="width: 2%; vertical-align: top;" rowspan="1">&#160;</td>
          <td style="width: 13%; vertical-align: top;" rowspan="1">&#160;</td>
          <td style="width: 35%; vertical-align: top;" rowspan="1">&#160;</td>
        </tr>
        <tr>
          <td style="width: 15%; vertical-align: top;">
            <div>Share Register, Re</div>
            <div>strictions on Regis</div>
            <div>tration, Nominees</div>
          </td>
          <td style="width: 35%; vertical-align: top;">
            <div><sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">1 </sup>The Company shall maintain, itself or through a third party, a share register for the registered shares that lists the surname and name (the name of the
              company in case of a legal entity), the address and domicile (the registered office in case of a legal entity) of the shareholders or usufructuaries. A person registered in the share register shall notify the share registrar of any change of
              address. Until such notification has occurred, all written communications from the Company to persons registered in the share register shall be deemed to have validly been made if sent to the address previously recorded in the share register.</div>
          </td>
          <td style="width: 2%; vertical-align: top;"><br>
          </td>
          <td style="width: 13%; vertical-align: top;">
            <div>Registre des ac</div>
            <div>tions, limitations &#224; </div>
            <div>l'inscription, Nomin</div>
            <div>ees</div>
          </td>
          <td style="width: 35%; vertical-align: top;">
            <div><sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">1 </sup>La Soci&#233;t&#233; ou un tiers mandat&#233; par elle tient un registre des actions qui mentionne le nom et le pr&#233;nom (la raison sociale pour les personnes morales),
              l'adresse et le domicile (le si&#232;ge pour les personnes morales) des propri&#233;taires et des usufruitiers. Si une personne inscrite au registre des actions change d'adresse, elle doit le communiquer &#224; la personne en charge de la tenue du registre.
              Aussi longtemps que cette communication n'a pas eu lieu, toutes les communications &#233;crites de la Soci&#233;t&#233; aux personnes inscrites au registre des actions seront valablement envoy&#233;es &#224; l'adresse inscrite au registre des actions.</div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div id="DSPFPageBreak" style="page-break-after:always;">
        <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
    </div>
    <table id="z0ea38e01d4d44d26b92ddf97ddf00df5" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 15%; vertical-align: top;">&#160;</td>
          <td style="width: 35%; vertical-align: top;">
            <div><sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">2</sup> Persons acquiring shares shall be registered in the share register as shareholders with voting rights upon their request if they expressly declare to have
              acquired these shares in their own name and for their own account. Subject to paragraph 4 of this Article 6 and article 685<font style="font-style: italic;">d</font> para. 3 of the Swiss Code of Obligations, no person or entity shall be
              registered in the share register as a shareholder with voting rights for, and no person or entity may directly or indirectly, formally, constructively or beneficially own, or otherwise control alone or together with third parties voting
              rights (whether exercisable or not) with respect to more than 15% of the share capital as set forth in the commercial register as a shareholder with voting rights. This restriction shall also apply to persons or entities who hold some or all
              of their shares through Nominees (as defined in paragraph 4 of this Article 6).</div>
          </td>
          <td style="width: 2%; vertical-align: top;">&#160;</td>
          <td style="width: 13%; vertical-align: top;">&#160;</td>
          <td style="width: 35%; vertical-align: top;">
            <div><sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">2</sup> Les personnes qui acqui&#232;rent des actions sont inscrites dans le registre des actions, &#224; leur demande, comme actionnaires avec droit de vote, pour autant
              qu'ils d&#233;clarent express&#233;ment avoir acquis les actions en leur nom et pour leur propre compte. Sous r&#233;serve de l'alin&#233;a 4 du pr&#233;sent article 6 et de l'article 685d al. 3 du Code des obligations, aucune personne physique ou morale ne peut &#234;tre
              inscrite au registre des actions comme actionnaire avec droit de vote et aucune personne physique ou morale ne peut d&#233;tenir, directement ou indirectement, formellement, de fait ou comme ayant droit &#233;conomique, ou contr&#244;ler autrement, seul ou
              avec des tiers, des droits de vote (exer&#231;ables ou non), par rapport &#224; plus de 15% du capital-actions inscrit au registre du commerce en tant qu'actionnaire avec droit de vote. Cette restriction s'applique &#233;galement aux personnes ou entit&#233;s
              qui d&#233;tiennent tout ou partie de leurs actions par l'interm&#233;diaire de Nominees (tels que d&#233;finis &#224; l'alin&#233;a 4 du pr&#233;sent article 6).</div>
          </td>
        </tr>
        <tr>
          <td style="width: 15%; vertical-align: top;" rowspan="1">&#160;</td>
          <td style="width: 35%; vertical-align: top;" rowspan="1">&#160;</td>
          <td style="width: 2%; vertical-align: top;" rowspan="1">&#160;</td>
          <td style="width: 13%; vertical-align: top;" rowspan="1">&#160;</td>
          <td style="width: 35%; vertical-align: top;" rowspan="1">&#160;</td>
        </tr>
        <tr>
          <td style="width: 15%; vertical-align: top;">&#160;</td>
          <td style="width: 35%; vertical-align: top;">
            <div><sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">3 </sup>Subject to Art. 652b para. 3 of the Swiss Code of Obligations, this transfer restriction also applies in the case of the acquisition of shares by the
              exercise of subscription, option and conversion rights. The transfer restriction does not apply to acquisitions by inheritance, division of an estate or matrimonial property law.</div>
          </td>
          <td style="width: 2%; vertical-align: top;">&#160;</td>
          <td style="width: 13%; vertical-align: top;">&#160;</td>
          <td style="width: 35%; vertical-align: top;">
            <div><sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">3 </sup>Sous r&#233;serve de l'art. 652b al. 3 CO, les restrictions au transfert s'appliquent &#233;galement lors de l'acquisition d'actions dans le cadre de l'exercice d'un
              droit de souscription, d'option ou de conversion. Les restrictions au transfert ne s'appliquent pas lors d'acquisitions par succession, partage successoral ou en vertu du droit matrimonial.</div>
          </td>
        </tr>
        <tr>
          <td style="width: 15%; vertical-align: top;" rowspan="1">&#160;</td>
          <td style="width: 35%; vertical-align: top;" rowspan="1">&#160;</td>
          <td style="width: 2%; vertical-align: top;" rowspan="1">&#160;</td>
          <td style="width: 13%; vertical-align: top;" rowspan="1">&#160;</td>
          <td style="width: 35%; vertical-align: top;" rowspan="1">&#160;</td>
        </tr>
        <tr>
          <td style="width: 15%; vertical-align: top;">&#160;</td>
          <td style="width: 35%; vertical-align: top;">
            <div><sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">4</sup> The Board of Directors may, in its own discretion, register persons who declare in the registration application that they hold the shares as nominees (each
              a <font style="font-weight: bold;">Nominee</font>) on behalf of third party beneficiaries (each a <font style="font-weight: bold;">Beneficial Owner</font>) in the share register as shareholders with voting rights. If, however, any
              Beneficial Owner should as a result of such registration being made or upheld, directly or indirectly, formally, constructively or beneficially own, or otherwise control or direct, alone or together with third parties, voting rights (whether
              exercisable or not) with respect to more than 15% of the share capital as set forth in the commercial register, the Board of Directors may cancel the registration of the Nominee holding shares for the account of such Beneficial Owner with
              respect to any shares in excess of such limit. The Board of Directors may make the registration with voting rights of the shares held by a Nominee subject to conditions, limitations and reporting requirements or may impose or adjust such
              conditions, limitations and requirements once registered.</div>
          </td>
          <td style="width: 2%; vertical-align: top;">&#160;</td>
          <td style="width: 13%; vertical-align: top;">&#160;</td>
          <td style="width: 35%; vertical-align: top;">
            <div><sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">4</sup> Le Conseil d'administration peut, &#224; son enti&#232;re discretion inscrire les personnes qui d&#233;clarent dans leur requ&#234;te d'inscription qu'elles d&#233;tiennent les
              actions en tant que nominees (chacun un <font style="font-weight: bold;">Nominee</font>) pour le compte de tiers ayants droit &#233;conomiques (chacun un <font style="font-weight: bold;">Ayant Droit Economique</font>) en tant qu'actionnaires
              avec droit de vote. Toutefois, si suite &#224; l'inscription ou &#224; la confirmation de l'inscription, un Ayant Droit Economique d&#233;tient directement ou indirectement, formellement, de fait ou comme ayant droit &#233;conomique, ou contr&#244;le ou dirige
              autrement, seul ou avec des tiers, des droits de votes (exer&#231;ables ou non) par rapport &#224; plus de 15% du capital-actions inscrit au registre du commerce, le Conseil d'administration peut annuler l'inscription du Nominee d&#233;tenant les actions
              pour le compte d'un tel Ayant Droit Economique pour les actions d&#233;passant cette limite. Le Conseil d'administration peut soumettre l'inscription avec droit de vote des actions d&#233;tenues par un Nominee &#224; des conditions, limitations, exigences
              de rapports ou peut imposer de telles conditions, limitiations ou exigences suite &#224; l'inscription.</div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div id="DSPFPageBreak" style="page-break-after:always;">
        <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
    </div>
    <table id="z4961019a32164a41937e9f00d8c7485c" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 15%; vertical-align: top;">&#160;</td>
          <td style="width: 35%; vertical-align: top;">
            <div><sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">5 </sup>Legal entities and partnerships or other groups of persons or joint owners who are interrelated to one another through capital ownership, voting rights,
              uniform management or are otherwise linked, as well as individuals or legal entities or partnerships who act in concert or otherwise act in a coordinated manner or acquire shares indirectly, thereby circumventing the restrictions or limits
              pursuant to paragraph 2 or 4 of this article 6 shall be treated as one single person, entity, Nominee or as a person acquiring shares, as applicable, for purposes of paragraphs 2 and 4 of this article 6.</div>
          </td>
          <td style="width: 2%; vertical-align: top;">&#160;</td>
          <td style="width: 13%; vertical-align: top;">&#160;</td>
          <td style="width: 35%; vertical-align: top;">
            <div><sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">5 </sup>Les personnes morales et communaut&#233;s de personnes ou autres groupes de personnes ou de copropri&#233;taires qui sont li&#233;s par le capital, les droits de vote, la
              gestion commune ou de toute autre mani&#232;re, de m&#234;me que les personnes physiques ou morales ou communaut&#233;s de personnes qui agissent de concert ou de mani&#232;re coordonn&#233;e ou acqui&#232;rent indirectement des actions, et contournent ainsi les
              restrictions ou limites vis&#233;es aux alin&#233;as 2 ou 4 du pr&#233;sent article 6 sont trait&#233;s comme une seule personne, personne morale, Nominee ou comme une personne acqu&#233;rant des actions, selon le cas, aux fins des alin&#233;as 2 et 4 du pr&#233;sent article
              6.</div>
          </td>
        </tr>
        <tr>
          <td style="width: 15%; vertical-align: top;" rowspan="1">&#160;</td>
          <td style="width: 35%; vertical-align: top;" rowspan="1">&#160;</td>
          <td style="width: 2%; vertical-align: top;" rowspan="1">&#160;</td>
          <td style="width: 13%; vertical-align: top;" rowspan="1">&#160;</td>
          <td style="width: 35%; vertical-align: top;" rowspan="1">&#160;</td>
        </tr>
        <tr>
          <td style="width: 15%; vertical-align: top;">&#160;</td>
          <td style="width: 35%; vertical-align: top;">
            <div><sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">6 </sup>The Board of Directors may grant exceptions from the restrictions or limits pursuant to paragraph 2 or 4 of this article 6 for justified reasons with the
              majority vote of two thirds of all its members. A justified reason may include the situation where a person extends an offer to purchase with respect to all other shares of the Company, which the Board of Directors, after having consulted an
              independent financial advisor, recommends to the shareholders. Shareholders, other than Nominees, already being registered directly or through a Nominee with more than 15% at the time that this article takes effect remain registered with
              voting rights for such shares.</div>
          </td>
          <td style="width: 2%; vertical-align: top;">&#160;</td>
          <td style="width: 13%; vertical-align: top;">&#160;</td>
          <td style="width: 35%; vertical-align: top;">
            <div><sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">6 </sup>Le Conseil d'administration peut octroyer des d&#233;rogations aux restrictions et limites mentionn&#233;es aux alin&#233;as 2 ou 4 du pr&#233;sent article 6 pour des raisons
              justifi&#233;es, &#224; la majorit&#233; des deux tiers de l'ensemble de ses membres. Peut aussi &#234;tre consid&#233;r&#233;e comme une raison justifi&#233;e le fait qu'une personne &#233;tende une offre d'achat par rapport &#224; l'ensemble des autres actions de la Soci&#233;t&#233; et que le
              Conseil d'administration, apr&#232;s avoir consult&#233; un conseiller financier ind&#233;pendant, recommande aux actionnaires d'accepter cette offre. Les actionnaires autres que les Nominees d&#233;j&#224; inscrits directement ou par l'interm&#233;diaire d'un Nominee
              pour plus de 15% au moment o&#249; le pr&#233;sent article entre en vigueur demeurent enregistr&#233;s avec droit de vote pour ces actions.</div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div id="DSPFPageBreak" style="page-break-after:always;">
        <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
    </div>
    <table id="zbe6f94b1959746a8a5087a5f1b2f460b" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 15%; vertical-align: top;">&#160;</td>
          <td style="width: 35%; vertical-align: top;">
            <div><sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">7 </sup>After hearing the registered shareholder or Nominee, the Board of Directors may cancel such person's registration in the share register with retroactive
              effect as of the date of registration if such registration was made based on false or misleading information or if such information becomes untrue or misleading. The relevant shareholder or Nominee shall be promptly informed of the
              cancellation.</div>
          </td>
          <td style="width: 2%; vertical-align: top;">&#160;</td>
          <td style="width: 13%; vertical-align: top;">&#160;</td>
          <td style="width: 35%; vertical-align: top;">
            <div><sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">7 </sup>Le Conseil d'administration peut, apr&#232;s avoir entendu l'actionnaire ou le Nominee, radier du registre des actions l'inscription qui a &#233;t&#233; faite sur la base
              d'informations fausses ou trompeuses donn&#233;es par l'acqu&#233;reur, ou si les informations deviennent fausses ou trompeuses. L'actionnaire ou le Nominee doit &#234;tre inform&#233; imm&#233;diatement de la radiation.</div>
          </td>
        </tr>
        <tr>
          <td style="width: 15%; vertical-align: top;" rowspan="1">&#160;</td>
          <td style="width: 35%; vertical-align: top;" rowspan="1">&#160;</td>
          <td style="width: 2%; vertical-align: top;" rowspan="1">&#160;</td>
          <td style="width: 13%; vertical-align: top;" rowspan="1">&#160;</td>
          <td style="width: 35%; vertical-align: top;" rowspan="1">&#160;</td>
        </tr>
        <tr>
          <td style="width: 15%; vertical-align: top;">&#160;</td>
          <td style="width: 35%; vertical-align: top;">
            <div><sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">8 </sup>The Board of Directors shall regulate all details and issue the instructions necessary to ensure compliance with the preceding provisions. The Board of
              Directors may delegate its duties.</div>
          </td>
          <td style="width: 2%; vertical-align: top;">&#160;</td>
          <td style="width: 13%; vertical-align: top;">&#160;</td>
          <td style="width: 35%; vertical-align: top;">
            <div><sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">8 </sup>Le Conseil d'administration r&#232;gle les d&#233;tails et prend les mesures n&#233;cessaires au respect des dispositions ci-dessus. Le Conseil d'administration peut
              d&#233;l&#233;guer ses t&#226;ches.</div>
          </td>
        </tr>
        <tr>
          <td style="width: 15%; vertical-align: top;">&#160;</td>
          <td style="width: 35%; vertical-align: top;">&#160;</td>
          <td style="width: 2%; vertical-align: top;">&#160;</td>
          <td style="width: 13%; vertical-align: top;">&#160;</td>
          <td style="width: 35%; vertical-align: top;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 15%; vertical-align: top;">&#160;</td>
          <td style="width: 35%; vertical-align: top;">
            <div style="font-weight: bold;">Article 7</div>
          </td>
          <td style="width: 2%; vertical-align: top;">&#160;</td>
          <td style="width: 13%; vertical-align: top;">&#160;</td>
          <td style="width: 35%; vertical-align: top;">
            <div style="font-weight: bold;">Article 7</div>
          </td>
        </tr>
        <tr>
          <td style="width: 15%; vertical-align: top;" rowspan="1">&#160;</td>
          <td style="width: 35%; vertical-align: top;" rowspan="1">&#160;</td>
          <td style="width: 2%; vertical-align: top;" rowspan="1">&#160;</td>
          <td style="width: 13%; vertical-align: top;" rowspan="1">&#160;</td>
          <td style="width: 35%; vertical-align: top;" rowspan="1">&#160;</td>
        </tr>
        <tr>
          <td style="width: 15%; vertical-align: top;">
            <div>Exercise of Rights</div>
          </td>
          <td style="width: 35%; vertical-align: top;">
            <div><sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">1 </sup>The Company shall only accept one representative per share.</div>
          </td>
          <td style="width: 2%; vertical-align: top;">
            <div><br>
            </div>
          </td>
          <td style="width: 13%; vertical-align: top;">
            <div>Exercice des droits</div>
          </td>
          <td style="width: 35%; vertical-align: top;">
            <div><sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">1 </sup>La Soci&#233;t&#233; ne reconna&#238;t qu'un repr&#233;sentant par action.</div>
          </td>
        </tr>
        <tr>
          <td style="width: 15%; vertical-align: top;" rowspan="1">&#160;</td>
          <td style="width: 35%; vertical-align: top;" rowspan="1">&#160;</td>
          <td style="width: 2%; vertical-align: top;" rowspan="1">&#160;</td>
          <td style="width: 13%; vertical-align: top;" rowspan="1">&#160;</td>
          <td style="width: 35%; vertical-align: top;" rowspan="1">&#160;</td>
        </tr>
        <tr>
          <td style="width: 15%; vertical-align: top;">&#160;</td>
          <td style="width: 35%; vertical-align: top;">
            <div><sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">2</sup> The voting right and the rights associated therewith may be exercised vis-&#224;-vis the Company by a shareholder, usufructuary or Nominee only to the extent
              that such person is registered in the share register with voting rights.</div>
          </td>
          <td style="width: 2%; vertical-align: top;">&#160;</td>
          <td style="width: 13%; vertical-align: top;">&#160;</td>
          <td style="width: 35%; vertical-align: top;">
            <div><sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">2</sup> Le droit de vote et les droits y relatifs ne peuvent &#234;tre exerc&#233;s &#224; l'&#233;gard de la Soci&#233;t&#233; que par un actionnaire, un usufruitier ou un Nominee uniquement
              dans la mesure o&#249; celui-ci est inscrit avec droit de vote au registre des actions.</div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <table id="z69018a8bb6dd49a6b67b1008052d3e8b" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 15%; vertical-align: top;">&#160;</td>
          <td style="width: 35%; vertical-align: top; border-top: 2px solid rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0);">
            <div style="font-weight: bold;">Section 3</div>
            <div style="font-style: italic;">Corporate Bodies</div>
          </td>
          <td style="width: 2%; vertical-align: top;">&#160;</td>
          <td style="width: 13%; vertical-align: top;">&#160;</td>
          <td style="width: 35%; vertical-align: top; border-top: 2px solid rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0);">
            <div style="font-weight: bold;">Section 3</div>
            <div style="font-style: italic;">Organes</div>
          </td>
        </tr>
        <tr>
          <td style="width: 15%; vertical-align: middle;">&#160;</td>
          <td style="width: 35%; vertical-align: middle; border-top: 2px solid rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0);">
            <div><font style="font-weight: bold;">A.</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-weight: bold;">The General Meeting of Shareholders</font></div>
          </td>
          <td style="width: 2%; vertical-align: middle;">&#160;</td>
          <td style="width: 13%; vertical-align: middle;">&#160;</td>
          <td style="width: 35%; vertical-align: middle; border-top: 2px solid rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0);">
            <div><font style="font-weight: bold;">A.</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-weight: bold;">L'Assembl&#233;e g&#233;n&#233;rale</font></div>
          </td>
        </tr>
        <tr>
          <td style="width: 15%; vertical-align: top;">&#160;</td>
          <td style="width: 35%; vertical-align: top;">&#160;</td>
          <td style="width: 2%; vertical-align: top;">&#160;</td>
          <td style="width: 13%; vertical-align: top;">&#160;</td>
          <td style="width: 35%; vertical-align: top;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 15%; vertical-align: top;">&#160;</td>
          <td style="width: 35%; vertical-align: top;">
            <div style="font-weight: bold;">Article 8</div>
          </td>
          <td style="width: 2%; vertical-align: top;">&#160;</td>
          <td style="width: 13%; vertical-align: top;">&#160;</td>
          <td style="width: 35%; vertical-align: top;">
            <div style="font-weight: bold;">Article 8</div>
          </td>
        </tr>
        <tr>
          <td style="width: 15%; vertical-align: top;" rowspan="1">&#160;</td>
          <td style="width: 35%; vertical-align: top;" rowspan="1">&#160;</td>
          <td style="width: 2%; vertical-align: top;" rowspan="1">&#160;</td>
          <td style="width: 13%; vertical-align: top;" rowspan="1">&#160;</td>
          <td style="width: 35%; vertical-align: top;" rowspan="1">&#160;</td>
        </tr>
        <tr>
          <td style="width: 15%; vertical-align: top;"><br>
          </td>
          <td style="width: 35%; vertical-align: top;">
            <div><sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">1 </sup>The General Meeting of Shareholders is the supreme corporate body of the Company.</div>
          </td>
          <td style="width: 2%; vertical-align: top;"><br>
          </td>
          <td style="width: 13%; vertical-align: top;"><br>
          </td>
          <td style="width: 35%; vertical-align: top;">
            <div><sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">1 </sup>L'Assembl&#233;e g&#233;n&#233;rale est l'organe supr&#234;me de la Soci&#233;t&#233;.</div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
      <div style="page-break-after: always;" id="DSPFPageBreak">
        <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;" noshade="noshade"></div>
    </div>
    <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 15%; vertical-align: top;">
            <div>&#160;Powers of the Gen</div>
            <div>eral Meeting of </div>
            <div>Shareholders</div>
          </td>
          <td style="width: 35%; vertical-align: top;">
            <div><sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">2</sup> The General Meeting of Shareholders shall have the following inalienable powers:</div>
          </td>
          <td style="width: 2%; vertical-align: top;">&#160;</td>
          <td style="width: 13%; vertical-align: top;">
            <div>Pouvoirs de</div>
            <div> l'Assembl&#233;e g&#233;n&#233;</div>
            <div>rale</div>
          </td>
          <td style="width: 35%; vertical-align: top;">
            <div><sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">2</sup> L'Assembl&#233;e g&#233;n&#233;rale a le droit inali&#233;nable:</div>
          </td>
        </tr>
        <tr>
          <td style="width: 15%; vertical-align: top; text-indent: -27pt; margin-left: 27pt;">&#160;</td>
          <td style="width: 35%; vertical-align: top;">
            <div style="text-indent: -27pt; margin-left: 27pt;">1.&#160;&#160;&#160;&#160;&#160;&#160;&#160; the adoption and amendment of these articles of association;</div>
          </td>
          <td style="width: 2%; vertical-align: top; text-indent: -27pt; margin-left: 27pt;">&#160;</td>
          <td style="width: 13%; vertical-align: top; text-indent: -27pt; margin-left: 27pt;">&#160;</td>
          <td style="width: 35%; vertical-align: top;">
            <div style="text-indent: -27pt; margin-left: 27pt;">1.&#160;&#160;&#160;&#160;&#160;&#160;&#160; d'adopter et de modifier les pr&#233;sents statuts;</div>
          </td>
        </tr>
        <tr>
          <td style="width: 15%; vertical-align: top; text-indent: -27pt; margin-left: 27pt;" rowspan="1">&#160;</td>
          <td style="width: 35%; vertical-align: top;" rowspan="1">&#160;</td>
          <td style="width: 2%; vertical-align: top; text-indent: -27pt; margin-left: 27pt;" rowspan="1">&#160;</td>
          <td style="width: 13%; vertical-align: top; text-indent: -27pt; margin-left: 27pt;" rowspan="1">&#160;</td>
          <td style="width: 35%; vertical-align: top;" rowspan="1">&#160;</td>
        </tr>
        <tr>
          <td style="width: 15%; vertical-align: top; text-indent: -27pt; margin-left: 27pt;">&#160;</td>
          <td style="width: 35%; vertical-align: top;">
            <div style="text-indent: -27pt; margin-left: 27pt;">2.&#160;&#160;&#160;&#160;&#160;&#160;&#160; the election of the members of the Board of Directors, the Chairman of the Board of Directors and the members of the Compensation Committee;</div>
          </td>
          <td style="width: 2%; vertical-align: top; text-indent: -27pt; margin-left: 27pt;">&#160;</td>
          <td style="width: 13%; vertical-align: top; text-indent: -27pt; margin-left: 27pt;">&#160;</td>
          <td style="width: 35%; vertical-align: top;">
            <div style="text-indent: -27pt; margin-left: 27pt;">2.&#160;&#160;&#160;&#160;&#160;&#160;&#160; de nommer les membres du Conseil d'administration, le pr&#233;sident du Conseil d'administration et les membres du Comit&#233; de r&#233;mun&#233;ration;</div>
          </td>
        </tr>
        <tr>
          <td style="width: 15%; vertical-align: top; text-indent: -27pt; margin-left: 27pt;" rowspan="1">&#160;</td>
          <td style="width: 35%; vertical-align: top;" rowspan="1">&#160;</td>
          <td style="width: 2%; vertical-align: top; text-indent: -27pt; margin-left: 27pt;" rowspan="1">&#160;</td>
          <td style="width: 13%; vertical-align: top; text-indent: -27pt; margin-left: 27pt;" rowspan="1">&#160;</td>
          <td style="width: 35%; vertical-align: top;" rowspan="1">&#160;</td>
        </tr>
        <tr>
          <td style="width: 15%; vertical-align: top; text-indent: -27pt; margin-left: 27pt;">&#160;</td>
          <td style="width: 35%; vertical-align: top;">
            <div style="text-indent: -27pt; margin-left: 27pt;">3.&#160;&#160;&#160;&#160;&#160;&#160;&#160; the election of the Auditors;</div>
          </td>
          <td style="width: 2%; vertical-align: top; text-indent: -27pt; margin-left: 27pt;">&#160;</td>
          <td style="width: 13%; vertical-align: top; text-indent: -27pt; margin-left: 27pt;">&#160;</td>
          <td style="width: 35%; vertical-align: top;">
            <div style="text-indent: -27pt; margin-left: 27pt;">3.&#160;&#160;&#160;&#160;&#160;&#160;&#160; de nommer l'organe de r&#233;vision;</div>
          </td>
        </tr>
        <tr>
          <td style="width: 15%; vertical-align: top; text-indent: -27pt; margin-left: 27pt;" rowspan="1">&#160;</td>
          <td style="width: 35%; vertical-align: top;" rowspan="1">&#160;</td>
          <td style="width: 2%; vertical-align: top; text-indent: -27pt; margin-left: 27pt;" rowspan="1">&#160;</td>
          <td style="width: 13%; vertical-align: top; text-indent: -27pt; margin-left: 27pt;" rowspan="1">&#160;</td>
          <td style="width: 35%; vertical-align: top;" rowspan="1">&#160;</td>
        </tr>
        <tr>
          <td style="width: 15%; vertical-align: top; text-indent: -27pt; margin-left: 27pt;">&#160;</td>
          <td style="width: 35%; vertical-align: top;">
            <div style="text-indent: -27pt; margin-left: 27pt;">4.&#160;&#160;&#160;&#160;&#160;&#160;&#160; the election of the independent voting rights representative;</div>
          </td>
          <td style="width: 2%; vertical-align: top; text-indent: -27pt; margin-left: 27pt;">&#160;</td>
          <td style="width: 13%; vertical-align: top; text-indent: -27pt; margin-left: 27pt;">&#160;</td>
          <td style="width: 35%; vertical-align: top;">
            <div style="text-indent: -27pt; margin-left: 27pt;">4.&#160;&#160;&#160;&#160;&#160;&#160;&#160; de nommer le repr&#233;sentant ind&#233;pendant;</div>
          </td>
        </tr>
        <tr>
          <td style="width: 15%; vertical-align: top; text-indent: -27pt; margin-left: 27pt;" rowspan="1">&#160;</td>
          <td style="width: 35%; vertical-align: top;" rowspan="1">&#160;</td>
          <td style="width: 2%; vertical-align: top; text-indent: -27pt; margin-left: 27pt;" rowspan="1">&#160;</td>
          <td style="width: 13%; vertical-align: top; text-indent: -27pt; margin-left: 27pt;" rowspan="1">&#160;</td>
          <td style="width: 35%; vertical-align: top;" rowspan="1">&#160;</td>
        </tr>
        <tr>
          <td style="width: 15%; vertical-align: top; text-indent: -27pt; margin-left: 27pt;">&#160;</td>
          <td style="width: 35%; vertical-align: top;">
            <div style="text-indent: -27pt; margin-left: 27pt;">5.&#160;&#160;&#160;&#160;&#160;&#160;&#160; the approval of the annual management report and the consolidated financial statements;</div>
          </td>
          <td style="width: 2%; vertical-align: top; text-indent: -27pt; margin-left: 27pt;">&#160;</td>
          <td style="width: 13%; vertical-align: top; text-indent: -27pt; margin-left: 27pt;">&#160;</td>
          <td style="width: 35%; vertical-align: top;">
            <div style="text-indent: -27pt; margin-left: 27pt;">5.&#160;&#160;&#160;&#160;&#160;&#160;&#160; d&#8217;approuver le rapport annuel et les comptes consolid&#233;s;</div>
          </td>
        </tr>
        <tr>
          <td style="width: 15%; vertical-align: top; text-indent: -27pt; margin-left: 27pt;" rowspan="1">&#160;</td>
          <td style="width: 35%; vertical-align: top;" rowspan="1">&#160;</td>
          <td style="width: 2%; vertical-align: top; text-indent: -27pt; margin-left: 27pt;" rowspan="1">&#160;</td>
          <td style="width: 13%; vertical-align: top; text-indent: -27pt; margin-left: 27pt;" rowspan="1">&#160;</td>
          <td style="width: 35%; vertical-align: top;" rowspan="1">&#160;</td>
        </tr>
        <tr>
          <td style="width: 15%; vertical-align: top; text-indent: -27pt; margin-left: 27pt;">&#160;</td>
          <td style="width: 35%; vertical-align: top;">
            <div style="text-indent: -27pt; margin-left: 27pt;">6.&#160;&#160;&#160;&#160;&#160;&#160;&#160; the approval of the annual financial statements as well as the resolution on the allocation of profit shown on the balance sheet, in particular the determination of dividends;</div>
          </td>
          <td style="width: 2%; vertical-align: top; text-indent: -27pt; margin-left: 27pt;">&#160;</td>
          <td style="width: 13%; vertical-align: top; text-indent: -27pt; margin-left: 27pt;">&#160;</td>
          <td style="width: 35%; vertical-align: top;">
            <div style="text-indent: -27pt; margin-left: 27pt;">6.&#160;&#160;&#160;&#160;&#160;&#160;&#160; d'approuver les comptes annuels et de d&#233;terminer l'emploi du b&#233;n&#233;fice r&#233;sultant du bilan, en particulier de fixer le dividende;</div>
          </td>
        </tr>
        <tr>
          <td style="width: 15%; vertical-align: top; text-indent: -27pt; margin-left: 27pt;" rowspan="1">&#160;</td>
          <td style="width: 35%; vertical-align: top;" rowspan="1">&#160;</td>
          <td style="width: 2%; vertical-align: top; text-indent: -27pt; margin-left: 27pt;" rowspan="1">&#160;</td>
          <td style="width: 13%; vertical-align: top; text-indent: -27pt; margin-left: 27pt;" rowspan="1">&#160;</td>
          <td style="width: 35%; vertical-align: top;" rowspan="1">&#160;</td>
        </tr>
        <tr>
          <td style="width: 15%; vertical-align: top; text-indent: -27pt; margin-left: 27pt;">&#160;</td>
          <td style="width: 35%; vertical-align: top;">
            <div style="text-indent: -27pt; margin-left: 27pt;">7.&#160;&#160;&#160;&#160;&#160;&#160;&#160; the discharge from liability of the members of the Board of Directors and the persons entrusted with management;</div>
          </td>
          <td style="width: 2%; vertical-align: top; text-indent: -27pt; margin-left: 27pt;">&#160;</td>
          <td style="width: 13%; vertical-align: top; text-indent: -27pt; margin-left: 27pt;">&#160;</td>
          <td style="width: 35%; vertical-align: top;">
            <div style="text-indent: -27pt; margin-left: 27pt;">7.&#160;&#160;&#160;&#160;&#160;&#160;&#160; de donner d&#233;charge aux membres du Conseil d'administration et aux personnes charg&#233;es de la gestion;</div>
          </td>
        </tr>
        <tr>
          <td style="width: 15%; vertical-align: top; text-indent: -27pt; margin-left: 27pt;" rowspan="1">&#160;</td>
          <td style="width: 35%; vertical-align: top;" rowspan="1">&#160;</td>
          <td style="width: 2%; vertical-align: top; text-indent: -27pt; margin-left: 27pt;" rowspan="1">&#160;</td>
          <td style="width: 13%; vertical-align: top; text-indent: -27pt; margin-left: 27pt;" rowspan="1">&#160;</td>
          <td style="width: 35%; vertical-align: top;" rowspan="1">&#160;</td>
        </tr>
        <tr>
          <td style="width: 15%; vertical-align: top; text-indent: -27pt; margin-left: 27pt;">&#160;</td>
          <td style="width: 35%; vertical-align: top;">
            <div style="text-indent: -27pt; margin-left: 27pt;">8.&#160;&#160;&#160;&#160;&#160;&#160;&#160; the approval of the compensation of the Board of Directors and of the Executive Committee pursuant to Article 26 of these articles of association; and</div>
          </td>
          <td style="width: 2%; vertical-align: top; text-indent: -27pt; margin-left: 27pt;">&#160;</td>
          <td style="width: 13%; vertical-align: top; text-indent: -27pt; margin-left: 27pt;">&#160;</td>
          <td style="width: 35%; vertical-align: top;">
            <div style="text-indent: -27pt; margin-left: 27pt;">8.&#160;&#160;&#160;&#160;&#160;&#160;&#160; d'approuver la r&#233;mun&#233;ration du Conseil d'administration et de la Direction ex&#233;cutive selon l'article 26 des pr&#233;sents statuts; et</div>
          </td>
        </tr>
        <tr>
          <td style="width: 15%; vertical-align: top; text-indent: -27pt; margin-left: 27pt;" rowspan="1">&#160;</td>
          <td style="width: 35%; vertical-align: top;" rowspan="1">&#160;</td>
          <td style="width: 2%; vertical-align: top; text-indent: -27pt; margin-left: 27pt;" rowspan="1">&#160;</td>
          <td style="width: 13%; vertical-align: top; text-indent: -27pt; margin-left: 27pt;" rowspan="1">&#160;</td>
          <td style="width: 35%; vertical-align: top;" rowspan="1">&#160;</td>
        </tr>
        <tr>
          <td style="width: 15%; vertical-align: top; text-indent: -27pt; margin-left: 27pt;">&#160;</td>
          <td style="width: 35%; vertical-align: top;">
            <div style="text-indent: -27pt; margin-left: 27pt;">9.&#160;&#160;&#160;&#160;&#160;&#160;&#160; the adoption of resolutions on matters that are reserved to the General Meeting of Shareholders by law or these articles of association or that are, subject to article 716a CO,
              submitted to the General Meeting of Shareholders by the Board of Directors.</div>
          </td>
          <td style="width: 2%; vertical-align: top; text-indent: -27pt; margin-left: 27pt;">&#160;</td>
          <td style="width: 13%; vertical-align: top; text-indent: -27pt; margin-left: 27pt;">&#160;</td>
          <td style="width: 35%; vertical-align: top;">
            <div style="text-indent: -27pt; margin-left: 27pt;">9.&#160;&#160;&#160;&#160;&#160;&#160;&#160; de prendre toutes les d&#233;cisions qui lui sont r&#233;serv&#233;es par la loi ou les pr&#233;sents statuts ou qui lui sont soumises par le Conseil d&#8217;administration, sous r&#233;serve de l&#8217;article 716a CO.</div>
          </td>
        </tr>
        <tr>
          <td style="width: 15%; vertical-align: top;">&#160;</td>
          <td style="width: 35%; vertical-align: top;">&#160;</td>
          <td style="width: 2%; vertical-align: top;">&#160;</td>
          <td style="width: 13%; vertical-align: top;">&#160;</td>
          <td style="width: 35%; vertical-align: top;">&#160;</td>
        </tr>

    </table>
    <div><br>
    </div>
    <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div id="DSPFPageBreak" style="page-break-after:always;">
        <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
    </div>
    <table id="zda01906ecaea499a8c875800e36d1a3c" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 15%; vertical-align: top;">&#160;</td>
          <td style="width: 35%; vertical-align: top;">
            <div style="font-weight: bold;">Article 9</div>
          </td>
          <td style="width: 2%; vertical-align: top;">&#160;</td>
          <td style="width: 13%; vertical-align: top;">&#160;</td>
          <td style="width: 35%; vertical-align: top;">
            <div style="font-weight: bold;">Article 9</div>
          </td>
        </tr>
        <tr>
          <td style="width: 15%; vertical-align: top;" rowspan="1">&#160;</td>
          <td style="width: 35%; vertical-align: top;" rowspan="1">&#160;</td>
          <td style="width: 2%; vertical-align: top;" rowspan="1">&#160;</td>
          <td style="width: 13%; vertical-align: top;" rowspan="1">&#160;</td>
          <td style="width: 35%; vertical-align: top;" rowspan="1">&#160;</td>
        </tr>
        <tr>
          <td style="width: 15%; vertical-align: top;">
            <div>Ordinary and Ex</div>
            <div>traordinary General</div>
            <div> Meetings of Share</div>
            <div>holders</div>
          </td>
          <td style="width: 35%; vertical-align: top;">
            <div><sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">1 </sup>The Ordinary General Meeting of Shareholders shall be held each year within six months of the close of the financial year of the Company.</div>
          </td>
          <td style="width: 2%; vertical-align: top;">&#160;</td>
          <td style="width: 13%; vertical-align: top;">
            <div>Assembl&#233;es g&#233;n&#233;</div>
            <div>rales ordinaires et </div>
            <div>extraordinaires</div>
          </td>
          <td style="width: 35%; vertical-align: top;">
            <div><sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">1 </sup>L'Assembl&#233;e g&#233;n&#233;rale ordinaire a lieu chaque ann&#233;e dans les six mois qui suivent la cl&#244;ture de l'exercice de la Soci&#233;t&#233;.</div>
          </td>
        </tr>
        <tr>
          <td style="width: 15%; vertical-align: top;" rowspan="1">&#160;</td>
          <td style="width: 35%; vertical-align: top;" rowspan="1">&#160;</td>
          <td style="width: 2%; vertical-align: top;" rowspan="1">&#160;</td>
          <td style="width: 13%; vertical-align: top;" rowspan="1">&#160;</td>
          <td style="width: 35%; vertical-align: top;" rowspan="1">&#160;</td>
        </tr>
        <tr>
          <td style="width: 15%; vertical-align: top;">&#160;</td>
          <td style="width: 35%; vertical-align: top;">
            <div><sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">2</sup> Extraordinary General Meetings of Shareholders shall be held if</div>
          </td>
          <td style="width: 2%; vertical-align: top;">&#160;</td>
          <td style="width: 13%; vertical-align: top;">&#160;</td>
          <td style="width: 35%; vertical-align: top;">
            <div><sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">2</sup> Des Assembl&#233;es g&#233;n&#233;rales extraordinaires ont lieu lorsque</div>
          </td>
        </tr>
        <tr>
          <td style="width: 15%; vertical-align: top;" rowspan="1">&#160;</td>
          <td style="width: 35%; vertical-align: top;" rowspan="1">&#160;</td>
          <td style="width: 2%; vertical-align: top;" rowspan="1">&#160;</td>
          <td style="width: 13%; vertical-align: top;" rowspan="1">&#160;</td>
          <td style="width: 35%; vertical-align: top;" rowspan="1">&#160;</td>
        </tr>
        <tr>
          <td style="width: 15%; vertical-align: top; text-indent: -27pt; margin-left: 27pt;">&#160;</td>
          <td style="width: 35%; vertical-align: top;">
            <div style="text-indent: -27pt; margin-left: 27pt;">(a)&#160;&#160;&#160;&#160;&#160; the Board of Directors or the Auditors deem it necessary;</div>
          </td>
          <td style="width: 2%; vertical-align: top; text-indent: -27pt; margin-left: 27pt;">&#160;</td>
          <td style="width: 13%; vertical-align: top; text-indent: -27pt; margin-left: 27pt;">&#160;</td>
          <td style="width: 35%; vertical-align: top;">
            <div style="text-indent: -27pt; margin-left: 27pt;">(a)&#160;&#160;&#160;&#160;&#160; le Conseil d'administration ou l'organe de r&#233;vision l'estime n&#233;cessaire;</div>
          </td>
        </tr>
        <tr>
          <td style="width: 15%; vertical-align: top; text-indent: -27pt; margin-left: 27pt;" rowspan="1">&#160;</td>
          <td style="width: 35%; vertical-align: top; text-indent: -27pt; margin-left: 27pt;" rowspan="1">&#160;</td>
          <td style="width: 2%; vertical-align: top; text-indent: -27pt; margin-left: 27pt;" rowspan="1">&#160;</td>
          <td style="width: 13%; vertical-align: top; text-indent: -27pt; margin-left: 27pt;" rowspan="1">&#160;</td>
          <td style="width: 35%; vertical-align: top; text-indent: -27pt; margin-left: 27pt;" rowspan="1">&#160;</td>
        </tr>
        <tr>
          <td style="width: 15%; vertical-align: top; text-indent: -27pt; margin-left: 27pt;">&#160;</td>
          <td style="width: 35%; vertical-align: top;">
            <div style="text-indent: -27pt; margin-left: 27pt;">(b)&#160;&#160;&#160;&#160;&#160; so resolved by a General Meeting of Shareholders; or</div>
          </td>
          <td style="width: 2%; vertical-align: top; text-indent: -27pt; margin-left: 27pt;">&#160;</td>
          <td style="width: 13%; vertical-align: top; text-indent: -27pt; margin-left: 27pt;">&#160;</td>
          <td style="width: 35%; vertical-align: top;">
            <div style="text-indent: -27pt; margin-left: 27pt;">(b)&#160;&#160;&#160;&#160;&#160; une Assembl&#233;e g&#233;n&#233;rale le d&#233;cide; ou</div>
          </td>
        </tr>
        <tr>
          <td style="width: 15%; vertical-align: top; text-indent: -27pt; margin-left: 27pt;" rowspan="1">&#160;</td>
          <td style="width: 35%; vertical-align: top; text-indent: -27pt; margin-left: 27pt;" rowspan="1">&#160;</td>
          <td style="width: 2%; vertical-align: top; text-indent: -27pt; margin-left: 27pt;" rowspan="1">&#160;</td>
          <td style="width: 13%; vertical-align: top; text-indent: -27pt; margin-left: 27pt;" rowspan="1">&#160;</td>
          <td style="width: 35%; vertical-align: top; text-indent: -27pt; margin-left: 27pt;" rowspan="1">&#160;</td>
        </tr>
        <tr>
          <td style="width: 15%; vertical-align: top; text-indent: -27pt; margin-left: 27pt;">&#160;</td>
          <td style="width: 35%; vertical-align: top;">
            <div style="text-indent: -27pt; margin-left: 27pt;">(c)&#160;&#160;&#160;&#160;&#160; shareholders who hold, alone or together, shares representing at least 10% of the share capital so request in writing, indicating the matters to be discussed and the corresponding
              proposals and, in case of elections, the names of the nominated candidates.</div>
          </td>
          <td style="width: 2%; vertical-align: top; text-indent: -27pt; margin-left: 27pt;">&#160;</td>
          <td style="width: 13%; vertical-align: top; text-indent: -27pt; margin-left: 27pt;">&#160;</td>
          <td style="width: 35%; vertical-align: top;">
            <div style="text-indent: -27pt; margin-left: 27pt;">(c)&#160;&#160;&#160;&#160;&#160; des actionnaires repr&#233;sentant seuls ou ensemble 10% au moins du capital-actions le requi&#232;rent par &#233;crit en indiquant les objets de discussion et les propositions, et en cas
              d'&#233;lections, les noms des candidats propos&#233;s.</div>
          </td>
        </tr>
        <tr>
          <td style="width: 15%; vertical-align: top;">&#160;</td>
          <td style="width: 35%; vertical-align: top;">&#160;</td>
          <td style="width: 2%; vertical-align: top;">&#160;</td>
          <td style="width: 13%; vertical-align: top;">&#160;</td>
          <td style="width: 35%; vertical-align: top;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 15%; vertical-align: top;">&#160;</td>
          <td style="width: 35%; vertical-align: top;">
            <div style="font-weight: bold;">Article 10</div>
          </td>
          <td style="width: 2%; vertical-align: top;">&#160;</td>
          <td style="width: 13%; vertical-align: top;">&#160;</td>
          <td style="width: 35%; vertical-align: top;">
            <div style="font-weight: bold;">Article 10</div>
          </td>
        </tr>
        <tr>
          <td style="width: 15%; vertical-align: top;" rowspan="1">&#160;</td>
          <td style="width: 35%; vertical-align: top;" rowspan="1">&#160;</td>
          <td style="width: 2%; vertical-align: top;" rowspan="1">&#160;</td>
          <td style="width: 13%; vertical-align: top;" rowspan="1">&#160;</td>
          <td style="width: 35%; vertical-align: top;" rowspan="1">&#160;</td>
        </tr>
        <tr>
          <td style="width: 15%; vertical-align: top;">
            <div>Notice</div>
          </td>
          <td style="width: 35%; vertical-align: top;">
            <div><sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">1 </sup>Notice of a General Meeting of Shareholders shall be given by the Board of Directors or, if necessary, by the Auditors, no later than 20 calendar days
              prior to the date of the meeting. Liquidators and representatives of bond-holders are also entitled to call a General Meeting of Shareholders.</div>
          </td>
          <td style="width: 2%; vertical-align: top;"><br>
          </td>
          <td style="width: 13%; vertical-align: top;">
            <div>Convocation</div>
          </td>
          <td style="width: 35%; vertical-align: top;">
            <div><sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">1 </sup>L'Assembl&#233;e g&#233;n&#233;rale est convoqu&#233;e par le Conseil d'administration ou, si n&#233;cessaire, par l'organe de r&#233;vision au plus tard 20 jours calendaires avant le
              jour de l'assembl&#233;e. Les liquidateurs et les repr&#233;sentants de d&#233;tenteurs d'obligations ont &#233;galement le droit de convoquer l'Assembl&#233;e g&#233;n&#233;rale.</div>
          </td>
        </tr>
        <tr>
          <td style="width: 15%; vertical-align: top;" rowspan="1">&#160;</td>
          <td style="width: 35%; vertical-align: top;" rowspan="1">&#160;</td>
          <td style="width: 2%; vertical-align: top;" rowspan="1">&#160;</td>
          <td style="width: 13%; vertical-align: top;" rowspan="1">&#160;</td>
          <td style="width: 35%; vertical-align: top;" rowspan="1">&#160;</td>
        </tr>
        <tr>
          <td style="width: 15%; vertical-align: top;">&#160;</td>
          <td style="width: 35%; vertical-align: top;">
            <div><sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">2</sup> Notice of the General Meeting of Shareholders shall be given by way of a single announcement in the official means of publication of the Company pursuant to
              Article 36 of these articles of association. Registered shareholders may in addition be notified in writing.</div>
          </td>
          <td style="width: 2%; vertical-align: top;">&#160;</td>
          <td style="width: 13%; vertical-align: top;">&#160;</td>
          <td style="width: 35%; vertical-align: top;">
            <div><sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">2</sup> La convocation &#224; l'Assembl&#233;e g&#233;n&#233;rale a lieu par une annonce unique dans l'organe de publication de la Soci&#233;t&#233; selon l'article<font style="font-weight: bold;">&#160;</font>36 des pr&#233;sents statuts. La convocation peut &#233;galement &#234;tre envoy&#233;e par &#233;crit aux actionnaires inscrits.</div>
          </td>
        </tr>
        <tr>
          <td style="width: 15%; vertical-align: top;" rowspan="1">&#160;</td>
          <td style="width: 35%; vertical-align: top;" rowspan="1">&#160;</td>
          <td style="width: 2%; vertical-align: top;" rowspan="1">&#160;</td>
          <td style="width: 13%; vertical-align: top;" rowspan="1">&#160;</td>
          <td style="width: 35%; vertical-align: top;" rowspan="1">&#160;</td>
        </tr>
        <tr>
          <td style="width: 15%; vertical-align: top;">&#160;</td>
          <td style="width: 35%; vertical-align: top;">
            <div><sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">3 </sup>The annual report, the compensation report and the Auditors' reports shall be made available for inspection by the shareholders at the registered office of
              the Company no later than 20 calendar days prior to the Ordinary General Meeting of Shareholders. Registered shareholders shall be informed in writing in the notice.</div>
          </td>
          <td style="width: 2%; vertical-align: top;">&#160;</td>
          <td style="width: 13%; vertical-align: top;">&#160;</td>
          <td style="width: 35%; vertical-align: top;">
            <div><sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">3 </sup>Le rapport de gestion, le rapport de r&#233;mun&#233;ration et les rapports de r&#233;vision sont mis &#224; la disposition des actionnaires au si&#232;ge de la Soci&#233;t&#233; au plus
              tard 20 jours calendaires avant l'Assembl&#233;e g&#233;n&#233;rale ordinaire. Les actionnaires inscrits doivent en &#234;tre inform&#233;s par &#233;crit dans la convocation.</div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div id="DSPFPageBreak" style="page-break-after:always;">
        <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
    </div>
    <table id="ze226fa093dbc4b2dbe0e1c927852322f" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 15%; vertical-align: top;">&#160;</td>
          <td style="width: 35%; vertical-align: top;">
            <div><sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">4 </sup>The notice shall specify the items on the agenda as well as the proposals of the Board of Directors and the shareholder(s) who requested that a General
              Meeting of Shareholders be held or an item be included on the agenda and, in the event of elections, the names of the proposed candidates.</div>
          </td>
          <td style="width: 2%; vertical-align: top;">&#160;</td>
          <td style="width: 13%; vertical-align: top;">&#160;</td>
          <td style="width: 35%; vertical-align: top;">
            <div><sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">4 </sup>La convocation mentionne les objets port&#233;s &#224; l'ordre du jour ainsi que les propositions du Conseil d'administration et du ou des actionnaires qui ont
              demand&#233; la convocation de l'Assembl&#233;e g&#233;n&#233;rale ou l'inscription d'un objet &#224; l'ordre du jour et, en cas d'&#233;lections, les noms des candidats propos&#233;s.</div>
          </td>
        </tr>
        <tr>
          <td style="width: 15%; vertical-align: top;">&#160;</td>
          <td style="width: 35%; vertical-align: top;">&#160;</td>
          <td style="width: 2%; vertical-align: top;">&#160;</td>
          <td style="width: 13%; vertical-align: top;">&#160;</td>
          <td style="width: 35%; vertical-align: top;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 15%; vertical-align: top;">&#160;</td>
          <td style="width: 35%; vertical-align: top;">
            <div style="font-weight: bold;">Article 11</div>
          </td>
          <td style="width: 2%; vertical-align: top;">&#160;</td>
          <td style="width: 13%; vertical-align: top;">&#160;</td>
          <td style="width: 35%; vertical-align: top;">
            <div style="font-weight: bold;">Article 11</div>
          </td>
        </tr>
        <tr>
          <td style="width: 15%; vertical-align: top;" rowspan="1">&#160;</td>
          <td style="width: 35%; vertical-align: top;" rowspan="1">&#160;</td>
          <td style="width: 2%; vertical-align: top;" rowspan="1">&#160;</td>
          <td style="width: 13%; vertical-align: top;" rowspan="1">&#160;</td>
          <td style="width: 35%; vertical-align: top;" rowspan="1">&#160;</td>
        </tr>
        <tr>
          <td style="width: 15%; vertical-align: top;">
            <div>Agenda</div>
          </td>
          <td style="width: 35%; vertical-align: top;">
            <div><sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">1 </sup>Shareholders who, alone or together, either hold shares with a par value of at least CHF 1,000,000 or who represent at least 10% of the share capital may
              request that an item be included on the agenda.<font style="font-weight: bold;">&#160;</font>Such request must be made in writing and be received at the registered office of the Company at least 45 calendar days prior to the General Meeting of
              Shareholders, specifying the agenda item and the proposals of the shareholders.</div>
          </td>
          <td style="width: 2%; vertical-align: top;"><br>
          </td>
          <td style="width: 13%; vertical-align: top;">
            <div>Objets &#224; l'ordre du </div>
            <div>jour</div>
          </td>
          <td style="width: 35%; vertical-align: top;">
            <div><sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">1 </sup>Des actionnaires qui repr&#233;sentent seuls ou ensemble des actions totalisant une valeur nominale d'au moins CHF 1'000'000 ou qui repr&#233;sentent au moins 10% du
              capital-actions peuvent requ&#233;rir l'inscription d'un objet &#224; l'ordre du jour. La demande doit &#234;tre faite par &#233;crit et re&#231;ue au si&#232;ge de la Soci&#233;t&#233; au moins 45 jours calendaires avant l'Assembl&#233;e g&#233;n&#233;rale avec indication des objets &#224; l'ordre du
              jour et des propositions des actionnaires.</div>
          </td>
        </tr>
        <tr>
          <td style="width: 15%; vertical-align: top;" rowspan="1">&#160;</td>
          <td style="width: 35%; vertical-align: top;" rowspan="1">&#160;</td>
          <td style="width: 2%; vertical-align: top;" rowspan="1">&#160;</td>
          <td style="width: 13%; vertical-align: top;" rowspan="1">&#160;</td>
          <td style="width: 35%; vertical-align: top;" rowspan="1">&#160;</td>
        </tr>
        <tr>
          <td style="width: 15%; vertical-align: top;">&#160;</td>
          <td style="width: 35%; vertical-align: top;">
            <div><sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">2</sup> No resolutions may be passed at a General Meeting of Shareholders on proposals concerning agenda items for which proper notice was not given. This provision
              shall not apply, however, to proposals made during a General Meeting of Shareholders to convene an Extraordinary General Meeting of Shareholders or to initiate a special audit. Each request for inclusion of an item on the agenda shall include
              (i) a brief description of the agenda item and the reason for which it is to be discussed at the meeting; (ii) the motions regarding the agenda item; (iii) the name and address, as they appear on the Company&#8217;s register of shareholders, of the
              shareholder proposing such business; (iv) the number of shares of the Company which are beneficially owned by such shareholder; (v) the dates upon which the shareholder acquired such shares; (vi) documentary support for any claim of
              beneficial ownership; (vii) any material interest of such shareholder in including the item in the agenda; (viii) a statement in support of the matter; and (ix) all other information required under applicable law and stock exchange rules.</div>
          </td>
          <td style="width: 2%; vertical-align: top;">&#160;</td>
          <td style="width: 13%; vertical-align: top;">&#160;</td>
          <td style="width: 35%; vertical-align: top;">
            <div><sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">2</sup> Aucune d&#233;cision ne peut &#234;tre prise par l'Assembl&#233;e g&#233;n&#233;rale sur des objets qui n'ont pas &#233;t&#233; d&#251;ment port&#233;s &#224; l'ordre du jour, &#224; l'exception des propositions
              de convoquer une Assembl&#233;e g&#233;n&#233;rale extraordinaire et d'instituer un contr&#244;le sp&#233;cial. Toute requ&#234;te visant l'inscription d'un objet &#224; l'ordre du jour doit inclure (i) une br&#232;ve description de cet objet et la raison pour laquelle il doit &#234;tre
              discut&#233; lors de l'Asembl&#233;e g&#233;n&#233;rale; (ii) les propositions relatives &#224; cet objet; (iii) le nom et l'adresse, tels qu'ils apparaissent dans le registre des actions, de l'actionnaire proposant un tel objet; (iv) le nombre d'actions de la
              Soci&#233;t&#233; dont cet actionnaire est ayant droit &#233;conomique; (v) les dates auxquelles l'actionnaire a acquis ces actions; (vi) les pi&#232;ces justificatives d&#233;montrant le statut d'ayant droit &#233;conomique; (vii) l'int&#233;r&#234;t important de l'actionnaire &#224;
              l'inscription de l'objet &#224; l'ordre du jour; (viii) une d&#233;claration &#224; l'appui de la requ&#234;te; et (ix) toute autre information requise par la loi ou les r&#232;gles boursi&#232;res applicables.</div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div id="DSPFPageBreak" style="page-break-after:always;">
        <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
    </div>
    <table id="z70c20ec09ced4e9e8fe684d227ca96f8" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 15%; vertical-align: top;">&#160;</td>
          <td style="width: 35%; vertical-align: top;">
            <div><sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">3 </sup>No prior notice is required to bring motions related to items already on the agenda or for the discussion of matters on which no resolution is to be taken.</div>
          </td>
          <td style="width: 2%; vertical-align: top;">&#160;</td>
          <td style="width: 13%; vertical-align: top;">&#160;</td>
          <td style="width: 35%; vertical-align: top;">
            <div><sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">3 </sup>En revanche, il n'est pas n&#233;cessaire d'annoncer &#224; l'avance les propositions entrant dans le cadre des objets port&#233;s &#224; l'ordre du jour ni les d&#233;lib&#233;rations
              qui ne doivent pas &#234;tre suivies d'un vote.</div>
          </td>
        </tr>
        <tr>
          <td style="width: 15%; vertical-align: top;">&#160;</td>
          <td style="width: 35%; vertical-align: top;">&#160;</td>
          <td style="width: 2%; vertical-align: top;">&#160;</td>
          <td style="width: 13%; vertical-align: top;">&#160;</td>
          <td style="width: 35%; vertical-align: top;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 15%; vertical-align: top;">&#160;</td>
          <td style="width: 35%; vertical-align: top;">
            <div style="font-weight: bold;">Article 12</div>
          </td>
          <td style="width: 2%; vertical-align: top;">&#160;</td>
          <td style="width: 13%; vertical-align: top;">&#160;</td>
          <td style="width: 35%; vertical-align: top;">
            <div style="font-weight: bold;">Article 12</div>
          </td>
        </tr>
        <tr>
          <td style="width: 15%; vertical-align: top;" rowspan="1">&#160;</td>
          <td style="width: 35%; vertical-align: top;" rowspan="1">&#160;</td>
          <td style="width: 2%; vertical-align: top;" rowspan="1">&#160;</td>
          <td style="width: 13%; vertical-align: top;" rowspan="1">&#160;</td>
          <td style="width: 35%; vertical-align: top;" rowspan="1">&#160;</td>
        </tr>
        <tr>
          <td style="width: 15%; vertical-align: top;">
            <div>Chairman, Vote </div>
            <div>Counters, Minutes</div>
          </td>
          <td style="width: 35%; vertical-align: top;">
            <div><sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">1 </sup>The Chairman of the Board of Directors shall chair the General Meeting of Shareholders. In his absence, the Vice-Chairman of the Board of Directors,
              another member or a person designated by the Board of Directors shall chair the General Meeting of Shareholders. If no member of the Board of Directors is available and no other person has been designated by the Board of Directors, the acting
              chair shall be elected by the General Meeting of Shareholders.</div>
          </td>
          <td style="width: 2%; vertical-align: top;"><br>
          </td>
          <td style="width: 13%; vertical-align: top;">
            <div>Pr&#233;sidence, scruta</div>
            <div>teurs, proc&#232;s-verbal</div>
          </td>
          <td style="width: 35%; vertical-align: top;">
            <div><sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">1 </sup>Le pr&#233;sident du Conseil d'administration pr&#233;side l'Assembl&#233;e g&#233;n&#233;rale. En son absence, le vice-pr&#233;sident du Conseil d'administration, un autre membre ou
              une personne d&#233;sign&#233;e par le Conseil d'administration pr&#233;side l'Assembl&#233;e g&#233;n&#233;rale. Si aucun membre du Conseil d'administration n'est disponible et aucune personne n'a &#233;t&#233; d&#233;sign&#233;e par le Conseil d'administration, l'Assembl&#233;e g&#233;n&#233;rale &#233;lit
              son pr&#233;sident.</div>
          </td>
        </tr>
        <tr>
          <td style="width: 15%; vertical-align: top;" rowspan="1">&#160;</td>
          <td style="width: 35%; vertical-align: top;" rowspan="1">&#160;</td>
          <td style="width: 2%; vertical-align: top;" rowspan="1">&#160;</td>
          <td style="width: 13%; vertical-align: top;" rowspan="1">&#160;</td>
          <td style="width: 35%; vertical-align: top;" rowspan="1">&#160;</td>
        </tr>
        <tr>
          <td style="width: 15%; vertical-align: top;">&#160;</td>
          <td style="width: 35%; vertical-align: top;">
            <div><sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">2</sup> The acting chair of the General Meeting of Shareholders shall appoint the secretary and the vote counter(s), none of whom need be shareholders. The minutes
              shall be signed by the acting chair of the General Meeting of Shareholders and the secretary.</div>
          </td>
          <td style="width: 2%; vertical-align: top;">&#160;</td>
          <td style="width: 13%; vertical-align: top;">&#160;</td>
          <td style="width: 35%; vertical-align: top;">
            <div><sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">2</sup> Le pr&#233;sident de l'Assembl&#233;e g&#233;n&#233;rale d&#233;signe un r&#233;dacteur du proc&#232;s-verbal et le ou les scrutateurs, qui ne doivent pas n&#233;cessairement &#234;tre des
              actionnaires. Le proc&#232;s-verbal doit &#234;tre sign&#233; par le pr&#233;sident de l'Assembl&#233;e g&#233;n&#233;rale et le secr&#233;taire.</div>
          </td>
        </tr>
        <tr>
          <td style="width: 15%; vertical-align: top;" rowspan="1">&#160;</td>
          <td style="width: 35%; vertical-align: top;" rowspan="1">&#160;</td>
          <td style="width: 2%; vertical-align: top;" rowspan="1">&#160;</td>
          <td style="width: 13%; vertical-align: top;" rowspan="1">&#160;</td>
          <td style="width: 35%; vertical-align: top;" rowspan="1">&#160;</td>
        </tr>
        <tr>
          <td style="width: 15%; vertical-align: top;">&#160;</td>
          <td style="width: 35%; vertical-align: top;">
            <div><sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">3 </sup>The acting chair of the General Meeting of Shareholders shall have all powers and authority necessary and appropriate to ensure the orderly conduct of the
              General Meeting of Shareholders.</div>
          </td>
          <td style="width: 2%; vertical-align: top;">&#160;</td>
          <td style="width: 13%; vertical-align: top;">&#160;</td>
          <td style="width: 35%; vertical-align: top;">
            <div><sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">3 </sup>Le pr&#233;sident de l'Assembl&#233;e g&#233;n&#233;rale a tous les pouvoirs n&#233;cessaires et appropri&#233;s pour s'assurer de la conduite r&#233;guli&#232;re de l'Assembl&#233;e g&#233;n&#233;rale.</div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div id="DSPFPageBreak" style="page-break-after:always;">
        <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
    </div>
    <table id="zf035e3224a8448aea559348abbdeb432" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 15%; vertical-align: top;">&#160;</td>
          <td style="width: 35%; vertical-align: top;">
            <div style="font-weight: bold;">Article 13</div>
          </td>
          <td style="width: 2%; vertical-align: top;">&#160;</td>
          <td style="width: 13%; vertical-align: top;">&#160;</td>
          <td style="width: 35%; vertical-align: top;">
            <div style="font-weight: bold;">Article 13</div>
          </td>
        </tr>
        <tr>
          <td style="width: 15%; vertical-align: top;" rowspan="1">&#160;</td>
          <td style="width: 35%; vertical-align: top;" rowspan="1">&#160;</td>
          <td style="width: 2%; vertical-align: top;" rowspan="1">&#160;</td>
          <td style="width: 13%; vertical-align: top;" rowspan="1">&#160;</td>
          <td style="width: 35%; vertical-align: top;" rowspan="1">&#160;</td>
        </tr>
        <tr>
          <td style="width: 15%; vertical-align: top;" rowspan="3">
            <div>Voting Rights, Rep</div>
            <div>resentation</div>
          </td>
          <td style="width: 35%; vertical-align: top;">
            <div><sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">1 </sup>Each share shall convey the right to one vote. The voting rights are subject to the conditions of Articles 6 and 7 of these articles of association.</div>
          </td>
          <td style="width: 2%; vertical-align: top;"><br>
          </td>
          <td style="width: 13%; vertical-align: top;">
            <div>Droit de vote, repr&#233;<br>
              sentation</div>
          </td>
          <td style="width: 35%; vertical-align: top;">
            <div><sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">1 </sup>Chaque action donne droit &#224; une voix. Les droits de vote sont soumis aux conditions des articles 6<font style="font-weight: bold;">&#160;</font>et 7 des
              pr&#233;sents statuts.</div>
          </td>
        </tr>
        <tr>
          <td style="width: 35%; vertical-align: top;" rowspan="1">&#160;</td>
          <td style="width: 2%; vertical-align: top;" rowspan="1">&#160;</td>
          <td style="width: 13%; vertical-align: top;" rowspan="1">&#160;</td>
          <td style="width: 35%; vertical-align: top;" rowspan="1">&#160;</td>
        </tr>
        <tr>
          <td style="width: 35%; vertical-align: top;">
            <div><sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">2</sup> The Board of Directors shall issue the rules regarding the participation in and representation at the General Meeting of Shareholders and determine the
              requirements as to proxies and instructions. A shareholder may only be represented at the General Meeting of Shareholders by the independent voting rights representative, its legal representative or, by means of a written proxy, by another
              shareholder with the right to vote. All shares held by a shareholder may only be represented by one person.</div>
          </td>
          <td style="width: 2%; vertical-align: top;">&#160;</td>
          <td style="width: 13%; vertical-align: top;">&#160;</td>
          <td style="width: 35%; vertical-align: top;">
            <div><sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">2</sup> Le Conseil d'administration prend les dispositions relatives &#224; la participation et &#224; la repr&#233;sentation &#224; l'Assembl&#233;e g&#233;n&#233;rale et d&#233;termine les exigences
              applicables aux procurations et instructions. Un actionnaire ne peut &#234;tre repr&#233;sent&#233; &#224; l'Assembl&#233;e g&#233;n&#233;rale que par le repr&#233;sentant ind&#233;pendant, par son repr&#233;sentant l&#233;gal ou, au moyen d'une procuration &#233;crite, par un autre actionnaire ayant
              droit de vote. Toutes les actions d&#233;tenues par un actionnaire ne peuvent &#234;tre repr&#233;sent&#233;es que par une seule personne.</div>
          </td>
        </tr>
        <tr>
          <td style="width: 15%; vertical-align: top;" rowspan="1">&#160;</td>
          <td style="width: 35%; vertical-align: top;" rowspan="1">&#160;</td>
          <td style="width: 2%; vertical-align: top;" rowspan="1">&#160;</td>
          <td style="width: 13%; vertical-align: top;" rowspan="1">&#160;</td>
          <td style="width: 35%; vertical-align: top;" rowspan="1">&#160;</td>
        </tr>
        <tr>
          <td style="width: 15%; vertical-align: top;">&#160;</td>
          <td style="width: 35%; vertical-align: top;">
            <div><sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">3 </sup>The General Meeting of Shareholders shall elect the independent voting rights representative for a term of office until completion of the next Ordinary
              General Meeting of Shareholders. Re-election is possible.</div>
          </td>
          <td style="width: 2%; vertical-align: top;">&#160;</td>
          <td style="width: 13%; vertical-align: top;">&#160;</td>
          <td style="width: 35%; vertical-align: top;">
            <div><sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">3 </sup>L'Assembl&#233;e g&#233;n&#233;rale nomme le repr&#233;sentant ind&#233;pendant pour une dur&#233;e de fonctions s&#8217;achevant &#224; la fin de l&#8217;Assembl&#233;e g&#233;n&#233;rale ordinaire suivante. La
              r&#233;&#233;lection est possible.</div>
          </td>
        </tr>
        <tr>
          <td style="width: 15%; vertical-align: top;" rowspan="1">&#160;</td>
          <td style="width: 35%; vertical-align: top;" rowspan="1">&#160;</td>
          <td style="width: 2%; vertical-align: top;" rowspan="1">&#160;</td>
          <td style="width: 13%; vertical-align: top;" rowspan="1">&#160;</td>
          <td style="width: 35%; vertical-align: top;" rowspan="1">&#160;</td>
        </tr>
        <tr>
          <td style="width: 15%; vertical-align: top;">&#160;</td>
          <td style="width: 35%; vertical-align: top;">
            <div><sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">4 </sup>If the Company does not have an independent voting rights representative, the Board of Directors shall appoint the independent voting rights representative
              for the next General Meeting of Shareholders.</div>
          </td>
          <td style="width: 2%; vertical-align: top;">&#160;</td>
          <td style="width: 13%; vertical-align: top;">&#160;</td>
          <td style="width: 35%; vertical-align: top;">
            <div><sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">4 </sup>Dans le cas o&#249; la Soci&#233;t&#233; n'a pas de repr&#233;sentant ind&#233;pendant, le Conseil d'administration nommera le repr&#233;sentant ind&#233;pendant pour l'Assembl&#233;e g&#233;n&#233;rale
              suivante.</div>
          </td>
        </tr>
        <tr>
          <td style="width: 15%; vertical-align: top;">&#160;</td>
          <td style="width: 35%; vertical-align: top;">&#160;</td>
          <td style="width: 2%; vertical-align: top;">&#160;</td>
          <td style="width: 13%; vertical-align: top;">&#160;</td>
          <td style="width: 35%; vertical-align: top;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 15%; vertical-align: top;">&#160;</td>
          <td style="width: 35%; vertical-align: top;">
            <div style="font-weight: bold;">Article 14</div>
          </td>
          <td style="width: 2%; vertical-align: top;">&#160;</td>
          <td style="width: 13%; vertical-align: top;">&#160;</td>
          <td style="width: 35%; vertical-align: top;">
            <div style="font-weight: bold;">Article 14</div>
          </td>
        </tr>
        <tr>
          <td style="width: 15%; vertical-align: top;" rowspan="1">&#160;</td>
          <td style="width: 35%; vertical-align: top;" rowspan="1">&#160;</td>
          <td style="width: 2%; vertical-align: top;" rowspan="1">&#160;</td>
          <td style="width: 13%; vertical-align: top;" rowspan="1">&#160;</td>
          <td style="width: 35%; vertical-align: top;" rowspan="1">&#160;</td>
        </tr>
        <tr>
          <td style="width: 15%; vertical-align: top;">
            <div>Resolutions, Elec</div>
            <div>tions</div>
          </td>
          <td style="width: 35%; vertical-align: top;">
            <div><sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">1 </sup>The General Meeting of Shareholders shall pass its resolutions and decide its elections by the absolute majority of the votes attached to the shares
              represented, unless required otherwise by law or these articles of association. In the event of a tie, the resolution shall be deemed refused.</div>
          </td>
          <td style="width: 2%; vertical-align: top;"><br>
          </td>
          <td style="width: 13%; vertical-align: top;">
            <div>D&#233;cisions, &#233;lections</div>
          </td>
          <td style="width: 35%; vertical-align: top;">
            <div><sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">1 </sup>Les d&#233;cisions de l'Assembl&#233;e g&#233;n&#233;rale sont prises &#224; la majorit&#233; absolue des voix attribu&#233;es aux actions repr&#233;sent&#233;es, &#224; moins que la loi ou les pr&#233;sents
              statuts n'en disposent autrement. En cas d'&#233;galit&#233; de voix, la d&#233;cision est refus&#233;e.</div>
          </td>
        </tr>

    </table>
    <div>'</div>
    <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div id="DSPFPageBreak" style="page-break-after:always;">
        <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
    </div>
    <table id="z88dd15acd53f4e03a924bbc7fcbf24f0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 15%; vertical-align: top;">&#160;</td>
          <td style="width: 35%; vertical-align: top;">
            <div><sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">2</sup> Two thirds of the votes represented and the absolute majority of the par value of shares represented shall be required for the General Meeting of
              Shareholders to adopt resolutions on the following matters:</div>
          </td>
          <td style="width: 2%; vertical-align: top;">&#160;</td>
          <td style="width: 13%; vertical-align: top;">&#160;</td>
          <td style="width: 35%; vertical-align: top;">
            <div><sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">2</sup> Une d&#233;cision de l'Assembl&#233;e g&#233;n&#233;rale recueillant au moins les deux tiers des voix attribu&#233;es aux actions repr&#233;sent&#233;es et la majorit&#233; absolue des valeurs
              nominales repr&#233;sent&#233;es est n&#233;cessaire pour:</div>
          </td>
        </tr>
        <tr>
          <td style="width: 15%; vertical-align: top;" rowspan="1">&#160;</td>
          <td style="width: 35%; vertical-align: top;" rowspan="1">&#160;</td>
          <td style="width: 2%; vertical-align: top;" rowspan="1">&#160;</td>
          <td style="width: 13%; vertical-align: top;" rowspan="1">&#160;</td>
          <td style="width: 35%; vertical-align: top;" rowspan="1">&#160;</td>
        </tr>
        <tr>
          <td style="width: 15%; vertical-align: top; text-indent: -27pt; margin-left: 27pt;">&#160;</td>
          <td style="width: 35%; vertical-align: top;">
            <div style="text-indent: -27pt; margin-left: 27pt;">1.&#160;&#160;&#160;&#160;&#160;&#160;&#160; the amendment of the purpose of the Company;</div>
          </td>
          <td style="width: 2%; vertical-align: top; text-indent: -27pt; margin-left: 27pt;">&#160;</td>
          <td style="width: 13%; vertical-align: top; text-indent: -27pt; margin-left: 27pt;">&#160;</td>
          <td style="width: 35%; vertical-align: top;">
            <div style="text-indent: -27pt; margin-left: 27pt;">1.&#160;&#160;&#160;&#160;&#160;&#160; la modification du but social de la Soci&#233;t&#233;;</div>
          </td>
        </tr>
        <tr>
          <td style="width: 15%; vertical-align: top; text-indent: -27pt; margin-left: 27pt;" rowspan="1">&#160;</td>
          <td style="width: 35%; vertical-align: top; text-indent: -27pt; margin-left: 27pt;" rowspan="1">&#160;</td>
          <td style="width: 2%; vertical-align: top; text-indent: -27pt; margin-left: 27pt;" rowspan="1">&#160;</td>
          <td style="width: 13%; vertical-align: top; text-indent: -27pt; margin-left: 27pt;" rowspan="1">&#160;</td>
          <td style="width: 35%; vertical-align: top; text-indent: -27pt; margin-left: 27pt;" rowspan="1">&#160;</td>
        </tr>
        <tr>
          <td style="width: 15%; vertical-align: top; text-indent: -27pt; margin-left: 27pt;">&#160;</td>
          <td style="width: 35%; vertical-align: top;">
            <div style="text-indent: -27pt; margin-left: 27pt;">2.&#160;&#160;&#160;&#160;&#160;&#160;&#160; the creation of shares with privileged voting rights;</div>
          </td>
          <td style="width: 2%; vertical-align: top; text-indent: -27pt; margin-left: 27pt;">&#160;</td>
          <td style="width: 13%; vertical-align: top; text-indent: -27pt; margin-left: 27pt;">&#160;</td>
          <td style="width: 35%; vertical-align: top;">
            <div style="text-indent: -27pt; margin-left: 27pt;">2.&#160;&#160;&#160;&#160;&#160;&#160; l'introduction d'actions &#224; droit de vote privil&#233;gi&#233;;</div>
          </td>
        </tr>
        <tr>
          <td style="width: 15%; vertical-align: top; text-indent: -27pt; margin-left: 27pt;" rowspan="1">&#160;</td>
          <td style="width: 35%; vertical-align: top; text-indent: -27pt; margin-left: 27pt;" rowspan="1">&#160;</td>
          <td style="width: 2%; vertical-align: top; text-indent: -27pt; margin-left: 27pt;" rowspan="1">&#160;</td>
          <td style="width: 13%; vertical-align: top; text-indent: -27pt; margin-left: 27pt;" rowspan="1">&#160;</td>
          <td style="width: 35%; vertical-align: top; text-indent: -27pt; margin-left: 27pt;" rowspan="1">&#160;</td>
        </tr>
        <tr>
          <td style="width: 15%; vertical-align: top; text-indent: -27pt; margin-left: 27pt;">&#160;</td>
          <td style="width: 35%; vertical-align: top;">
            <div style="text-indent: -27pt; margin-left: 27pt;">3.&#160;&#160;&#160;&#160;&#160;&#160;&#160; the restriction on the transferability of registered shares or their registration with voting rights and the cancelation of such a restriction;</div>
          </td>
          <td style="width: 2%; vertical-align: top; text-indent: -27pt; margin-left: 27pt;">&#160;</td>
          <td style="width: 13%; vertical-align: top; text-indent: -27pt; margin-left: 27pt;">&#160;</td>
          <td style="width: 35%; vertical-align: top;">
            <div style="text-indent: -27pt; margin-left: 27pt;">3.&#160;&#160;&#160;&#160;&#160;&#160;&#160; la restriction de la transmissibilit&#233; des actions nominatives ou leur inscription avec droit de vote ainsi que la suppression d'une telle restriction;</div>
          </td>
        </tr>
        <tr>
          <td style="width: 15%; vertical-align: top; text-indent: -27pt; margin-left: 27pt;" rowspan="1">&#160;</td>
          <td style="width: 35%; vertical-align: top; text-indent: -27pt; margin-left: 27pt;" rowspan="1">&#160;</td>
          <td style="width: 2%; vertical-align: top; text-indent: -27pt; margin-left: 27pt;" rowspan="1">&#160;</td>
          <td style="width: 13%; vertical-align: top; text-indent: -27pt; margin-left: 27pt;" rowspan="1">&#160;</td>
          <td style="width: 35%; vertical-align: top; text-indent: -27pt; margin-left: 27pt;" rowspan="1">&#160;</td>
        </tr>
        <tr>
          <td style="width: 15%; vertical-align: top; text-indent: -27pt; margin-left: 27pt;">&#160;</td>
          <td style="width: 35%; vertical-align: top;">
            <div style="text-indent: -27pt; margin-left: 27pt;">4.&#160;&#160;&#160;&#160;&#160;&#160;&#160; an authorized or conditional increase in share capital;</div>
          </td>
          <td style="width: 2%; vertical-align: top; text-indent: -27pt; margin-left: 27pt;">&#160;</td>
          <td style="width: 13%; vertical-align: top; text-indent: -27pt; margin-left: 27pt;">&#160;</td>
          <td style="width: 35%; vertical-align: top;">
            <div style="text-indent: -27pt; margin-left: 27pt;">4.&#160;&#160;&#160;&#160;&#160;&#160;&#160; l'augmentation autoris&#233;e ou conditionnelle du capital-actions;</div>
          </td>
        </tr>
        <tr>
          <td style="width: 15%; vertical-align: top; text-indent: -27pt; margin-left: 27pt;" rowspan="1">&#160;</td>
          <td style="width: 35%; vertical-align: top; text-indent: -27pt; margin-left: 27pt;" rowspan="1">&#160;</td>
          <td style="width: 2%; vertical-align: top; text-indent: -27pt; margin-left: 27pt;" rowspan="1">&#160;</td>
          <td style="width: 13%; vertical-align: top; text-indent: -27pt; margin-left: 27pt;" rowspan="1">&#160;</td>
          <td style="width: 35%; vertical-align: top; text-indent: -27pt; margin-left: 27pt;" rowspan="1">&#160;</td>
        </tr>
        <tr>
          <td style="width: 15%; vertical-align: top; text-indent: -27pt; margin-left: 27pt;">&#160;</td>
          <td style="width: 35%; vertical-align: top;">
            <div style="text-indent: -27pt; margin-left: 27pt;">5.&#160;&#160;&#160;&#160;&#160;&#160;&#160; an increase in share capital through the conversion of equity surplus, against contributions in kind or for purposes of an acquisition of assets, or the granting of special benefits;</div>
          </td>
          <td style="width: 2%; vertical-align: top; text-indent: -27pt; margin-left: 27pt;">&#160;</td>
          <td style="width: 13%; vertical-align: top; text-indent: -27pt; margin-left: 27pt;">&#160;</td>
          <td style="width: 35%; vertical-align: top;">
            <div style="text-indent: -27pt; margin-left: 27pt;">5.&#160;&#160;&#160;&#160;&#160;&#160;&#160; l'augmentation du capital-actions au moyen de la conversion de fonds propres, contre apport en nature ou en vue d'une reprise de biens et l'octroi d'avantages particuliers;</div>
          </td>
        </tr>
        <tr>
          <td style="width: 15%; vertical-align: top; text-indent: -27pt; margin-left: 27pt;" rowspan="1">&#160;</td>
          <td style="width: 35%; vertical-align: top; text-indent: -27pt; margin-left: 27pt;" rowspan="1">&#160;</td>
          <td style="width: 2%; vertical-align: top; text-indent: -27pt; margin-left: 27pt;" rowspan="1">&#160;</td>
          <td style="width: 13%; vertical-align: top; text-indent: -27pt; margin-left: 27pt;" rowspan="1">&#160;</td>
          <td style="width: 35%; vertical-align: top; text-indent: -27pt; margin-left: 27pt;" rowspan="1">&#160;</td>
        </tr>
        <tr>
          <td style="width: 15%; vertical-align: top; text-indent: -27pt; margin-left: 27pt;">&#160;</td>
          <td style="width: 35%; vertical-align: top;">
            <div style="text-indent: -27pt; margin-left: 27pt;">6.&#160;&#160;&#160;&#160;&#160;&#160;&#160; the limitation or withdrawal of pre-emptive rights;</div>
          </td>
          <td style="width: 2%; vertical-align: top; text-indent: -27pt; margin-left: 27pt;">&#160;</td>
          <td style="width: 13%; vertical-align: top; text-indent: -27pt; margin-left: 27pt;">&#160;</td>
          <td style="width: 35%; vertical-align: top;">
            <div style="text-indent: -27pt; margin-left: 27pt;">6.&#160;&#160;&#160;&#160;&#160;&#160;&#160; la limitation ou la suppression du droit de souscription pr&#233;f&#233;rentiel;</div>
          </td>
        </tr>
        <tr>
          <td style="width: 15%; vertical-align: top; text-indent: -27pt; margin-left: 27pt;" rowspan="1">&#160;</td>
          <td style="width: 35%; vertical-align: top; text-indent: -27pt; margin-left: 27pt;" rowspan="1">&#160;</td>
          <td style="width: 2%; vertical-align: top; text-indent: -27pt; margin-left: 27pt;" rowspan="1">&#160;</td>
          <td style="width: 13%; vertical-align: top; text-indent: -27pt; margin-left: 27pt;" rowspan="1">&#160;</td>
          <td style="width: 35%; vertical-align: top; text-indent: -27pt; margin-left: 27pt;" rowspan="1">&#160;</td>
        </tr>
        <tr>
          <td style="width: 15%; vertical-align: top; text-indent: -27pt; margin-left: 27pt;">&#160;</td>
          <td style="width: 35%; vertical-align: top;">
            <div style="text-indent: -27pt; margin-left: 27pt;">7.&#160;&#160;&#160;&#160;&#160;&#160;&#160; the relocation of the registered office of the Company;</div>
          </td>
          <td style="width: 2%; vertical-align: top; text-indent: -27pt; margin-left: 27pt;">&#160;</td>
          <td style="width: 13%; vertical-align: top; text-indent: -27pt; margin-left: 27pt;">&#160;</td>
          <td style="width: 35%; vertical-align: top;">
            <div style="text-indent: -27pt; margin-left: 27pt;">7.&#160;&#160;&#160;&#160;&#160;&#160;&#160; le transfert du si&#232;ge de la Soci&#233;t&#233;;</div>
          </td>
        </tr>
        <tr>
          <td style="width: 15%; vertical-align: top; text-indent: -27pt; margin-left: 27pt;" rowspan="1">&#160;</td>
          <td style="width: 35%; vertical-align: top; text-indent: -27pt; margin-left: 27pt;" rowspan="1">&#160;</td>
          <td style="width: 2%; vertical-align: top; text-indent: -27pt; margin-left: 27pt;" rowspan="1">&#160;</td>
          <td style="width: 13%; vertical-align: top; text-indent: -27pt; margin-left: 27pt;" rowspan="1">&#160;</td>
          <td style="width: 35%; vertical-align: top; text-indent: -27pt; margin-left: 27pt;" rowspan="1">&#160;</td>
        </tr>
        <tr>
          <td style="width: 15%; vertical-align: top; text-indent: -27pt; margin-left: 27pt;">&#160;</td>
          <td style="width: 35%; vertical-align: top;">
            <div style="text-indent: -27pt; margin-left: 27pt;">8.&#160;&#160;&#160;&#160;&#160;&#160;&#160; the dissolution of the Company;</div>
          </td>
          <td style="width: 2%; vertical-align: top; text-indent: -27pt; margin-left: 27pt;">&#160;</td>
          <td style="width: 13%; vertical-align: top; text-indent: -27pt; margin-left: 27pt;">&#160;</td>
          <td style="width: 35%; vertical-align: top;">
            <div style="text-indent: -27pt; margin-left: 27pt;">8.&#160;&#160;&#160;&#160;&#160;&#160;&#160; la dissolution de la Soci&#233;t&#233;;</div>
          </td>
        </tr>
        <tr>
          <td style="width: 15%; vertical-align: top; text-indent: -27pt; margin-left: 27pt;" rowspan="1">&#160;</td>
          <td style="width: 35%; vertical-align: top; text-indent: -27pt; margin-left: 27pt;" rowspan="1">&#160;</td>
          <td style="width: 2%; vertical-align: top; text-indent: -27pt; margin-left: 27pt;" rowspan="1">&#160;</td>
          <td style="width: 13%; vertical-align: top; text-indent: -27pt; margin-left: 27pt;" rowspan="1">&#160;</td>
          <td style="width: 35%; vertical-align: top; text-indent: -27pt; margin-left: 27pt;" rowspan="1">&#160;</td>
        </tr>
        <tr>
          <td style="width: 15%; vertical-align: top; text-indent: -27pt; margin-left: 27pt;">&#160;</td>
          <td style="width: 35%; vertical-align: top;">
            <div style="text-indent: -27pt; margin-left: 27pt;">9.&#160;&#160;&#160;&#160;&#160;&#160;&#160; mergers, demergers and conversions pursuant to the Merger Act;</div>
          </td>
          <td style="width: 2%; vertical-align: top; text-indent: -27pt; margin-left: 27pt;">&#160;</td>
          <td style="width: 13%; vertical-align: top; text-indent: -27pt; margin-left: 27pt;">&#160;</td>
          <td style="width: 35%; vertical-align: top;">
            <div style="text-indent: -27pt; margin-left: 27pt;">9.&#160;&#160;&#160;&#160;&#160;&#160;&#160; une fusion, scission ou transformation conform&#233;ment &#224; la Loi sur la fusion;</div>
          </td>
        </tr>
        <tr>
          <td style="width: 15%; vertical-align: top; text-indent: -27pt; margin-left: 27pt;" rowspan="1">&#160;</td>
          <td style="width: 35%; vertical-align: top; text-indent: -27pt; margin-left: 27pt;" rowspan="1">&#160;</td>
          <td style="width: 2%; vertical-align: top; text-indent: -27pt; margin-left: 27pt;" rowspan="1">&#160;</td>
          <td style="width: 13%; vertical-align: top; text-indent: -27pt; margin-left: 27pt;" rowspan="1">&#160;</td>
          <td style="width: 35%; vertical-align: top; text-indent: -27pt; margin-left: 27pt;" rowspan="1">&#160;</td>
        </tr>
        <tr>
          <td style="width: 15%; vertical-align: top; text-indent: -27pt; margin-left: 27pt;" rowspan="1">&#160;</td>
          <td style="width: 35%; vertical-align: top;" rowspan="1">
            <div style="text-indent: -27pt; margin-left: 27pt;">10.&#160;&#160;&#160;&#160;&#160; the conversion of registered shares into bearer shares;</div>
          </td>
          <td style="width: 2%; vertical-align: top; text-indent: -27pt; margin-left: 27pt;" rowspan="1">&#160;</td>
          <td style="width: 13%; vertical-align: top; text-indent: -27pt; margin-left: 27pt;" rowspan="1">&#160;</td>
          <td style="width: 35%; vertical-align: top;" rowspan="1">
            <div style="text-indent: -27pt; margin-left: 27pt;">10.&#160;&#160;&#160;&#160;&#160;&#160; la conversion d'actions nominatives en actions au porteur;</div>
          </td>
        </tr>
        <tr>
          <td style="width: 15%; vertical-align: top; text-indent: -27pt; margin-left: 27pt;" rowspan="1">&#160;</td>
          <td style="width: 35%; vertical-align: top; text-indent: -27pt; margin-left: 27pt;" rowspan="1">&#160;</td>
          <td style="width: 2%; vertical-align: top; text-indent: -27pt; margin-left: 27pt;" rowspan="1">&#160;</td>
          <td style="width: 13%; vertical-align: top; text-indent: -27pt; margin-left: 27pt;" rowspan="1">&#160;</td>
          <td style="width: 35%; vertical-align: top; text-indent: -27pt; margin-left: 27pt;" rowspan="1">&#160;</td>
        </tr>
        <tr>
          <td style="width: 15%; vertical-align: top; text-indent: -27pt; margin-left: 27pt;">&#160;</td>
          <td style="width: 35%; vertical-align: top;">
            <div style="text-indent: -27pt; margin-left: 27pt;">11.&#160;&#160;&#160;&#160;&#160; the removal of any member of the Board of Directors or of its Chairman before the end of his or her term of office; and</div>
          </td>
          <td style="width: 2%; vertical-align: top; text-indent: -27pt; margin-left: 27pt;">&#160;</td>
          <td style="width: 13%; vertical-align: top; text-indent: -27pt; margin-left: 27pt;">&#160;</td>
          <td style="width: 35%; vertical-align: top;">
            <div style="text-indent: -27pt; margin-left: 27pt;">11.&#160;&#160;&#160;&#160;&#160; la r&#233;vocation de tout membre du Conseil d'administration ou de son pr&#233;sident avant la fin de son mandat; et</div>
          </td>
        </tr>
        <tr>
          <td style="width: 15%; vertical-align: top;" rowspan="1">&#160;</td>
          <td style="width: 35%; vertical-align: top;" rowspan="1">&#160;</td>
          <td style="width: 2%; vertical-align: top;" rowspan="1">&#160;</td>
          <td style="width: 13%; vertical-align: top;" rowspan="1">&#160;</td>
          <td style="width: 35%; vertical-align: top;" rowspan="1">&#160;</td>
        </tr>
        <tr>
          <td style="width: 15%; vertical-align: top;">&#160;</td>
          <td style="width: 35%; vertical-align: top;">
            <div style="text-indent: -27pt; margin-left: 27pt;">12.&#160;&#160;&#160;&#160;&#160; the amendment or repeal of the following provisions of these articles of association, with the exception of editorial amendments that do not effectively change their content:</div>
          </td>
          <td style="width: 2%; vertical-align: top;">&#160;</td>
          <td style="width: 13%; vertical-align: top;">&#160;</td>
          <td style="width: 35%; vertical-align: top;">
            <div style="text-indent: -27pt; margin-left: 27pt;">12.&#160;&#160;&#160;&#160;&#160; la modification ou la suppression des dispositions suivantes des pr&#233;sents statuts, &#224; l'exception des modifications r&#233;dactionnelles qui ne modifient pas effectivement leur contenu:</div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div id="DSPFPageBreak" style="page-break-after:always;">
        <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
    </div>
    <table id="zf12e2eed60494ea695578fad62bcdb34" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 15%; vertical-align: top;" rowspan="1">&#160;</td>
          <td style="width: 35%; vertical-align: top;" rowspan="1">
            <div style="margin-left: 27pt;">(i)&#160;&#160;&#160;&#160;&#160; article 6;</div>
            <div style="margin-left: 27pt;">(ii)&#160;&#160;&#160;&#160; article 14;</div>
            <div style="margin-left: 27pt;">(iii)&#160;&#160;&#160; article 15; and</div>
            <div style="margin-left: 27pt;">(iv)&#160;&#160;&#160; article 18.</div>
          </td>
          <td style="width: 2%; vertical-align: top;" rowspan="1">&#160;</td>
          <td style="width: 13%; vertical-align: top;" rowspan="1">&#160;</td>
          <td style="width: 35%; vertical-align: top;" rowspan="1">
            <div style="margin-left: 27pt;">(i)&#160;&#160;&#160;&#160;&#160;&#160; article 6;</div>
            <div style="margin-left: 27pt;">(ii)&#160;&#160;&#160;&#160;&#160; article 14;</div>
            <div style="margin-left: 27pt;">(iii)&#160;&#160; &#160; article 15; et</div>
            <div style="margin-left: 27pt;">(iv)&#160;&#160;&#160;&#160; article 18.</div>
          </td>
        </tr>
        <tr>
          <td style="width: 15%; vertical-align: top;" rowspan="1">&#160;</td>
          <td style="width: 35%; vertical-align: top;" rowspan="1">&#160;</td>
          <td style="width: 2%; vertical-align: top;" rowspan="1">&#160;</td>
          <td style="width: 13%; vertical-align: top;" rowspan="1">&#160;</td>
          <td style="width: 35%; vertical-align: top;" rowspan="1">&#160;</td>
        </tr>
        <tr>
          <td style="width: 15%; vertical-align: top;">&#160;</td>
          <td style="width: 35%; vertical-align: top;">
            <div><sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">3 </sup>Resolutions and elections shall be decided by open ballot, unless the acting chair of the General Meeting of Shareholders decides that a secret ballot be
              held or that it be voted by electronic means. The acting chair may at any time order that a resolution or election be repeated if he considers the vote to be in doubt. The resolution or election previously held shall then be deemed not to
              have taken place.</div>
          </td>
          <td style="width: 2%; vertical-align: top;">&#160;</td>
          <td style="width: 13%; vertical-align: top;">&#160;</td>
          <td style="width: 35%; vertical-align: top;">
            <div><sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">3 </sup>Les d&#233;cisions et &#233;lections ont lieu &#224; main lev&#233;e, &#224; moins qu'un vote &#224; bulletins secrets ou &#233;lectronique ne soit ordonn&#233; par le pr&#233;sident de l'Assembl&#233;e
              g&#233;n&#233;rale. Le pr&#233;sident peut en tout temps ordonner qu'une d&#233;cision ou &#233;lection soit r&#233;p&#233;t&#233;e s'il estime qu'il existe des doutes sur le r&#233;sultat. Dans ce cas, la d&#233;cision ou l'&#233;lection pr&#233;c&#233;dente est r&#233;put&#233;e ne pas avoir eu lieu.</div>
          </td>
        </tr>
        <tr>
          <td style="width: 15%; vertical-align: top;">&#160;</td>
          <td style="width: 35%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">&#160;</td>
          <td style="width: 2%; vertical-align: top;">&#160;</td>
          <td style="width: 13%; vertical-align: top;">&#160;</td>
          <td style="width: 35%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">&#160;</td>
        </tr>
        <tr>
          <td style="width: 15%; vertical-align: middle;">&#160;</td>
          <td style="width: 35%; vertical-align: middle; border-top: 2px solid rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0);">
            <div><font style="font-weight: bold;">B.</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-weight: bold;">The Board of Directors</font></div>
          </td>
          <td style="width: 2%; vertical-align: middle;">&#160;</td>
          <td style="width: 13%; vertical-align: middle;">&#160;</td>
          <td style="width: 35%; vertical-align: middle; border-top: 2px solid rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0);">
            <div><font style="font-weight: bold;">B.</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-weight: bold;">Le Conseil d'administration</font></div>
          </td>
        </tr>
        <tr>
          <td style="width: 15%; vertical-align: top;">&#160;</td>
          <td style="width: 35%; vertical-align: top;">&#160;</td>
          <td style="width: 2%; vertical-align: top;">&#160;</td>
          <td style="width: 13%; vertical-align: top;">&#160;</td>
          <td style="width: 35%; vertical-align: top;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 15%; vertical-align: top;">&#160;</td>
          <td style="width: 35%; vertical-align: top;">
            <div style="font-weight: bold;">Article 15</div>
          </td>
          <td style="width: 2%; vertical-align: top;">&#160;</td>
          <td style="width: 13%; vertical-align: top;">&#160;</td>
          <td style="width: 35%; vertical-align: top;">
            <div style="font-weight: bold;">Article 15</div>
          </td>
        </tr>
        <tr>
          <td style="width: 15%; vertical-align: top;" rowspan="1">&#160;</td>
          <td style="width: 35%; vertical-align: top;" rowspan="1">&#160;</td>
          <td style="width: 2%; vertical-align: top;" rowspan="1">&#160;</td>
          <td style="width: 13%; vertical-align: top;" rowspan="1">&#160;</td>
          <td style="width: 35%; vertical-align: top;" rowspan="1">&#160;</td>
        </tr>
        <tr>
          <td style="width: 15%; vertical-align: top;">
            <div>Number of Directors</div>
          </td>
          <td style="width: 35%; vertical-align: top;">
            <div>The Board of Directors shall consist of not less than 3 and no more than 11 members.</div>
          </td>
          <td style="width: 2%; vertical-align: top;"><br>
          </td>
          <td style="width: 13%; vertical-align: top;">
            <div>Nombre de membres</div>
          </td>
          <td style="width: 35%; vertical-align: top;">
            <div>Le Conseil d'administration se compose de 3 membres au moins et de 11 membres au plus.</div>
          </td>
        </tr>
        <tr>
          <td style="width: 15%; vertical-align: top;">&#160;</td>
          <td style="width: 35%; vertical-align: top;">&#160;</td>
          <td style="width: 2%; vertical-align: top;">&#160;</td>
          <td style="width: 13%; vertical-align: top;">&#160;</td>
          <td style="width: 35%; vertical-align: top;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 15%; vertical-align: top;">&#160;</td>
          <td style="width: 35%; vertical-align: top;">
            <div style="font-weight: bold;">Article 16</div>
          </td>
          <td style="width: 2%; vertical-align: top;">&#160;</td>
          <td style="width: 13%; vertical-align: top;">&#160;</td>
          <td style="width: 35%; vertical-align: top;">
            <div style="font-weight: bold;">Article 16</div>
          </td>
        </tr>
        <tr>
          <td style="width: 15%; vertical-align: top;" rowspan="1">&#160;</td>
          <td style="width: 35%; vertical-align: top;" rowspan="1">&#160;</td>
          <td style="width: 2%; vertical-align: top;" rowspan="1">&#160;</td>
          <td style="width: 13%; vertical-align: top;" rowspan="1">&#160;</td>
          <td style="width: 35%; vertical-align: top;" rowspan="1">&#160;</td>
        </tr>
        <tr>
          <td style="width: 15%; vertical-align: top;">
            <div>Election and Term </div>
            <div>of Office</div>
          </td>
          <td style="width: 35%; vertical-align: top;">
            <div><sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">1 </sup>The General Meeting of Shareholders shall elect the members of the Board of Directors and the Chairman of the Board of Directors individually and for a
              term of office until the completion of the next Ordinary General Meeting of Shareholders. Re-election is possible.</div>
          </td>
          <td style="width: 2%; vertical-align: top;">
            <div><br>
            </div>
          </td>
          <td style="width: 13%; vertical-align: top;">
            <div>&#201;lection et dur&#233;e</div>
            <div> des fonctions</div>
          </td>
          <td style="width: 35%; vertical-align: top;">
            <div><sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">1 </sup>Les membres du Conseil d&#8217;administration et le pr&#233;sident du Conseil d&#8217;administration sont &#233;lus individuellement par l&#8217;Assembl&#233;e g&#233;n&#233;rale pour une dur&#233;e de
              fonctions s&#8217;achevant &#224; la fin de l&#8217;Assembl&#233;e g&#233;n&#233;rale ordinaire suivante. La r&#233;&#233;lection est possible.</div>
          </td>
        </tr>
        <tr>
          <td style="width: 15%; vertical-align: top;" rowspan="1">&#160;</td>
          <td style="width: 35%; vertical-align: top;" rowspan="1">&#160;</td>
          <td style="width: 2%; vertical-align: top;" rowspan="1">&#160;</td>
          <td style="width: 13%; vertical-align: top;" rowspan="1">&#160;</td>
          <td style="width: 35%; vertical-align: top;" rowspan="1">&#160;</td>
        </tr>
        <tr>
          <td style="width: 15%; vertical-align: top;">&#160;</td>
          <td style="width: 35%; vertical-align: top;">
            <div><sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">2</sup> If the office of the Chairman of the Board of Directors is vacant, the Board of Directors shall appoint a new Chairman from among its members for a term of
              office extending until completion of the next Ordinary General Meeting of Shareholders.</div>
          </td>
          <td style="width: 2%; vertical-align: top;">&#160;</td>
          <td style="width: 13%; vertical-align: top;">&#160;</td>
          <td style="width: 35%; vertical-align: top;">
            <div><sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">2</sup> Lorsque la fonction de pr&#233;sident du Conseil d&#8217;administration est vacante, le Conseil d&#8217;administration d&#233;signe un nouveau pr&#233;sident parmi ses membres pour
              une dur&#233;e de fonctions s&#8217;achevant &#224; la fin de l&#8217;Assembl&#233;e g&#233;n&#233;rale ordinaire suivante.</div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div id="DSPFPageBreak" style="page-break-after:always;">
        <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
    </div>
    <table id="z777ebe86688242ca99b49191c6656977" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 15%; vertical-align: top;">&#160;</td>
          <td style="width: 35%; vertical-align: top;">
            <div style="font-weight: bold;">Article 17</div>
          </td>
          <td style="width: 2%; vertical-align: top;">&#160;</td>
          <td style="width: 13%; vertical-align: top;">&#160;</td>
          <td style="width: 35%; vertical-align: top;">
            <div style="font-weight: bold;">Article 17</div>
          </td>
        </tr>
        <tr>
          <td style="width: 15%; vertical-align: top;" rowspan="1">&#160;</td>
          <td style="width: 35%; vertical-align: top;" rowspan="1">&#160;</td>
          <td style="width: 2%; vertical-align: top;" rowspan="1">&#160;</td>
          <td style="width: 13%; vertical-align: top;" rowspan="1">&#160;</td>
          <td style="width: 35%; vertical-align: top;" rowspan="1">&#160;</td>
        </tr>
        <tr>
          <td style="width: 15%; vertical-align: top;">
            <div>Organization of the</div>
            <div> Board of Directors</div>
          </td>
          <td style="width: 35%; vertical-align: top;">
            <div><sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">1 </sup>Except for the election of the Chairman of the Board of Directors and the members of the Compensation Committee by the General Meeting of Shareholders, the
              Board of Directors shall constitute itself. The Board of Directors may elect one or several Vice-Chairmen. The Board of Directors shall further appoint a secretary who need not be member of the Board of Directors.</div>
          </td>
          <td style="width: 2%; vertical-align: top;"><br>
          </td>
          <td style="width: 13%; vertical-align: top;">
            <div>Organisation du </div>
            <div>Conseil d'adminis</div>
            <div>tration</div>
          </td>
          <td style="width: 35%; vertical-align: top;">
            <div><sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">1 </sup>A l'exception de l'&#233;lection par l'Assembl&#233;e g&#233;n&#233;rale du pr&#233;sident du Conseil d'administration et des membres du Comit&#233; de r&#233;mun&#233;ration, le Conseil
              d'administration se constitue lui-m&#234;me. Il peut d&#233;signer au besoin, un ou plusieurs vice-pr&#233;sidents. Le Conseil d'administration d&#233;signe en outre un secr&#233;taire, qui ne doit pas n&#233;cessairement &#234;tre membre du Conseil d'administration.</div>
          </td>
        </tr>
        <tr>
          <td style="width: 15%; vertical-align: top;" rowspan="1">&#160;</td>
          <td style="width: 35%; vertical-align: top;" rowspan="1">&#160;</td>
          <td style="width: 2%; vertical-align: top;" rowspan="1">&#160;</td>
          <td style="width: 13%; vertical-align: top;" rowspan="1">&#160;</td>
          <td style="width: 35%; vertical-align: top;" rowspan="1">&#160;</td>
        </tr>
        <tr>
          <td style="width: 15%; vertical-align: top;">&#160;</td>
          <td style="width: 35%; vertical-align: top;">
            <div><sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">2</sup> Subject to these articles of association, the Board of Directors shall regulate its organization and the adoption of resolutions in the organizational
              regulations.</div>
          </td>
          <td style="width: 2%; vertical-align: top;">&#160;</td>
          <td style="width: 13%; vertical-align: top;">&#160;</td>
          <td style="width: 35%; vertical-align: top;">
            <div><sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">2</sup> Le Conseil d'administration r&#232;gle en outre son organisation et la mani&#232;re de prendre des d&#233;cisions dans un r&#232;glement d'organisation, sous r&#233;serve des
              pr&#233;sents statuts.</div>
          </td>
        </tr>
        <tr>
          <td style="width: 15%; vertical-align: top;">&#160;</td>
          <td style="width: 35%; vertical-align: top;">&#160;</td>
          <td style="width: 2%; vertical-align: top;">&#160;</td>
          <td style="width: 13%; vertical-align: top;">&#160;</td>
          <td style="width: 35%; vertical-align: top;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 15%; vertical-align: top;">&#160;</td>
          <td style="width: 35%; vertical-align: top;">
            <div style="font-weight: bold;">Article 18</div>
          </td>
          <td style="width: 2%; vertical-align: top;">&#160;</td>
          <td style="width: 13%; vertical-align: top;">&#160;</td>
          <td style="width: 35%; vertical-align: top;">
            <div style="font-weight: bold;">Article 18</div>
          </td>
        </tr>
        <tr>
          <td style="width: 15%; vertical-align: top;" rowspan="1">&#160;</td>
          <td style="width: 35%; vertical-align: top;" rowspan="1">&#160;</td>
          <td style="width: 2%; vertical-align: top;" rowspan="1">&#160;</td>
          <td style="width: 13%; vertical-align: top;" rowspan="1">&#160;</td>
          <td style="width: 35%; vertical-align: top;" rowspan="1">&#160;</td>
        </tr>
        <tr>
          <td style="width: 15%; vertical-align: top;">
            <div>Reimbursement of </div>
            <div>Expenses, Indemni</div>
            <div>fication</div>
          </td>
          <td style="width: 35%; vertical-align: top;">
            <div><sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">1 </sup>The members of the Board of Directors shall be entitled to the reimbursement of all expenses incurred in the interest of the Company.</div>
          </td>
          <td style="width: 2%; vertical-align: top;"><br>
          </td>
          <td style="width: 13%; vertical-align: top;">
            <div>Remboursement</div>
            <div> des frais, indemni</div>
            <div>sation</div>
          </td>
          <td style="width: 35%; vertical-align: top;">
            <div><sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">1 </sup>Les membres du Conseil d'administration ont droit au remboursement de tous les frais engag&#233;s dans l'int&#233;r&#234;t de la Soci&#233;t&#233;.</div>
          </td>
        </tr>
        <tr>
          <td style="width: 15%; vertical-align: top;">&#160;</td>
          <td style="width: 35%; vertical-align: top;" rowspan="1">&#160;</td>
          <td style="width: 2%; vertical-align: top;" rowspan="1">&#160;</td>
          <td style="width: 13%; vertical-align: top;">&#160;</td>
          <td style="width: 35%; vertical-align: top;" rowspan="1">&#160;</td>
        </tr>
        <tr>
          <td style="width: 15%; vertical-align: top;">&#160;</td>
          <td style="width: 35%; vertical-align: top;">
            <div><sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">2</sup> To the extent not included in insurance coverage or paid by third parties, the Company shall indemnify and hold harmless, to the extent permitted by law,
              the existing and former members of the Board of Directors and Executive Committee, and their heirs, executors and administrators, out of the assets of the Company from and against all threatened, pending or completed actions, suits or
              proceedings &#8211; whether civil, criminal, administrative or investigative &#8211; and all costs, charges, losses, damages, and expenses which they or any of them, their heirs, executors or administrators, shall or may incur or sustain by or by reason
              of any actual or alleged actions, consents or omissions in or about the execution of their duty, or alleged duty, or by reason of the fact that he is or was a member of the Board of Directors or Executive Committee of the Company or one of
              its subsidiaries, or, while serving as a member of the Board of Directors or Executive Committee of the Company, is or was serving at the request of the Company as a director, member of the executive management, employee or agent of another
              corporation, partnership, joint venture, trust or other enterprise; provided, however, that this indemnity shall not extend to any matter in which any of said persons is found, in a final judgment or decree of a court or governmental or
              administrative authority of competent jurisdiction not subject to appeal, to have committed an intentional or grossly negligent breach of his statutory duties as a member of the Board of Directors or Executive Committee.</div>
          </td>
          <td style="width: 2%; vertical-align: top;">&#160;</td>
          <td style="width: 13%; vertical-align: top;">&#160;</td>
          <td style="width: 35%; vertical-align: top;">
            <div><sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">2</sup> Dans la mesure o&#249; la loi le permet, la Soci&#233;t&#233; indemnisera, &#224; concurrence de la portion non couverte par une assurance ou pay&#233;e par un tiers, sur ses
              propres biens les membres actuels et pass&#233;s du Conseil d'administration et de la Direction ex&#233;cutive ainsi que leurs h&#233;ritiers, masse en faillite ou masse successorale contre toutes actions, proc&#232;s ou poursuites, mena&#231;ants, en cours ou
              termin&#233;s, de nature civile, p&#233;nale, administrative ou autre, et tous les co&#251;ts, d&#233;penses, pertes, dommages et frais qu'ils (ou leurs h&#233;ritiers, masse en faillite ou masse successorale) subiraient ou pourraient subir en raison d'actions,
              consentements ou omissions, effectifs ou pr&#233;sum&#233;s, en relation avec l'exercice de leurs fonctions, leurs fonctions suppos&#233;es ou en raison du fait d'&#234;tre ou d'avoir &#233;t&#233; membres du Conseil d'administration ou de la Direction ex&#233;cutive de la
              Soci&#233;t&#233; ou de l'une de ses filiales ou, sur instruction de la Soci&#233;t&#233; en tant que membres du Conseil d'administration ou de la Direction ex&#233;cutive, en raison du fait d'&#234;tre ou d'avoir &#233;t&#233; administrateur, membre de la direction, employ&#233; ou
              mandataire d'une autre soci&#233;t&#233;, entreprise, coentreprise, personne morale d&#233;nu&#233;e de la personnalit&#233; ou trust. L'obligation d'indemnisation s'&#233;teint d&#232;s qu'un jugement d&#233;finitif et ex&#233;cutoire d'un tribunal ou d'une autorit&#233; comp&#233;tente a d&#233;cid&#233;
              que la personne en question a viol&#233;, volontairement ou par grave n&#233;gligence, ses devoirs de membre du Conseil d'administration ou de la Direction ex&#233;cutive.</div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div id="DSPFPageBreak" style="page-break-after:always;">
        <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
    </div>
    <table id="z495698626944434b812d845b38c70dd6" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 15%; vertical-align: top;">&#160;</td>
          <td style="width: 35%; vertical-align: top;">
            <div><sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">3 </sup>Without limiting the foregoing paragraph 2 of this Article 18, the Company shall advance costs and expenses idemnifiable thereunder to the existing and
              former members of the Board of Directors and Executive Committee to the extent not included in insurance coverage or advanced by third parties. The Company may however recover such advanced costs if any of said persons is found, in a final
              judgment or decree of a court or governmental or administrative authority of competent jurisdiction not subject to appeal, to have committed an intentional or grossly negligent breach of his statutory duties as a member of the Board of
              Directors or Executive Committee.</div>
          </td>
          <td style="width: 2%; vertical-align: top;">&#160;</td>
          <td style="width: 13%; vertical-align: top;">&#160;</td>
          <td style="width: 35%; vertical-align: top;">
            <div><sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">3 </sup>Sans pr&#233;judice de l'alin&#233;a 2 du pr&#233;sent article 18, la Soci&#233;t&#233; avancera les frais et les co&#251;ts indemnisables en vertu de la disposition pr&#233;cit&#233;e aux
              membres actuels et pass&#233;s du Conseil d'administration et de la Direction ex&#233;cutive, &#224; concurrence de la portion non couverte par une assurance ou pay&#233;e par un tiers. La Soci&#233;t&#233; peut cependant recouvrer ces avances de frais si l'une de ces
              personnes a &#233;t&#233; reconnue coupable de violation intentionnelle ou par n&#233;gligence grave de ses devoirs de membre du Conseil d'administration ou de la Direction ex&#233;cutive par un jugement ou une d&#233;cision final et ex&#233;cutoire d'un tribunal ou d'une
              autorit&#233; gouvernementale ou administrative comp&#233;tente.</div>
          </td>
        </tr>
        <tr>
          <td style="width: 15%; vertical-align: top;">&#160;</td>
          <td style="width: 35%; vertical-align: top;">&#160;</td>
          <td style="width: 2%; vertical-align: top;">&#160;</td>
          <td style="width: 13%; vertical-align: top;">&#160;</td>
          <td style="width: 35%; vertical-align: top;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 15%; vertical-align: top;">&#160;</td>
          <td style="width: 35%; vertical-align: top;">
            <div style="font-weight: bold;">Article 19</div>
          </td>
          <td style="width: 2%; vertical-align: top;">&#160;</td>
          <td style="width: 13%; vertical-align: top;">&#160;</td>
          <td style="width: 35%; vertical-align: top;">
            <div style="font-weight: bold;">Article 19</div>
          </td>
        </tr>
        <tr>
          <td style="width: 15%; vertical-align: top;" rowspan="1">&#160;</td>
          <td style="width: 35%; vertical-align: top;" rowspan="1">&#160;</td>
          <td style="width: 2%; vertical-align: top;" rowspan="1">&#160;</td>
          <td style="width: 13%; vertical-align: top;" rowspan="1">&#160;</td>
          <td style="width: 35%; vertical-align: top;" rowspan="1">&#160;</td>
        </tr>
        <tr>
          <td style="width: 15%; vertical-align: top;">
            <div>Convening of Meet</div>
            <div>ings, Resolutions, </div>
            <div>Minutes</div>
          </td>
          <td style="width: 35%; vertical-align: top;">
            <div><sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">1 </sup>The Board of Directors shall meet at the invitation of its Chairman or, if not available, of the Vice-Chairman or of another member of the Board of
              Directors as often as the business of the Company shall require or if a member requests it in writing or via telefax, e-mail or another form of electronic communication, indicating the reasons.</div>
          </td>
          <td style="width: 2%; vertical-align: top;"><br>
          </td>
          <td style="width: 13%; vertical-align: top;">
            <div>Convocation, d&#233;ci</div>
            <div>sions, proc&#232;s-verbal</div>
          </td>
          <td style="width: 35%; vertical-align: top;">
            <div><sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">1 </sup>Le Conseil d'administration est convoqu&#233; par son pr&#233;sident ou, en cas d'emp&#234;chement de ce dernier, par son vice-pr&#233;sident ou par un autre membre du Conseil
              d'administration, aussi souvent que cela appara&#238;t n&#233;cessaire ou lorsqu'un membre du Conseil d'administration le demande par &#233;crit, par t&#233;l&#233;copie, courriel ou par un autre moyen de communication &#233;lectronique, avec indication des motifs.</div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div id="DSPFPageBreak" style="page-break-after:always;">
        <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
    </div>
    <table id="z9c4ddb7fc7ee4edcb1e5c61f7468b0d1" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 15%; vertical-align: top;">&#160;</td>
          <td style="width: 35%; vertical-align: top;">
            <div><sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">2</sup> Unless the organizational regulations adopted by the Board of Directors or a board resolution taken with the applicable attendance quorum provide otherwise,
              the Board of Directors shall only have a quorum if a majority of the members of the Board of Directors is present. No attendance quorum shall be required for resolutions of the Board of Directors providing for the amendment and ascertainment
              of a capital increase.</div>
          </td>
          <td style="width: 2%; vertical-align: top;">&#160;</td>
          <td style="width: 13%; vertical-align: top;">&#160;</td>
          <td style="width: 35%; vertical-align: top;">
            <div><sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">2</sup> A moins que le contraire ne r&#233;sulte d'une disposition du r&#232;glement d'organisation adopt&#233; par le Conseil d'administration ou d'une d&#233;cision du Conseil
              d'administration prise conform&#233;ment aux dispositions applicables au quorum de pr&#233;sence, la majorit&#233; des membres du Conseil d'administration doivent &#234;tre pr&#233;sents afin de pouvoir prendre une d&#233;cision. Ce quorum de pr&#233;sence n'est pas n&#233;cessaire
              pour les d&#233;cisions de modification et de constatation du Conseil d'administration en lien avec les augmentations du capital-actions.</div>
          </td>
        </tr>
        <tr>
          <td style="width: 15%; vertical-align: top;" rowspan="1">&#160;</td>
          <td style="width: 35%; vertical-align: top;" rowspan="1">&#160;</td>
          <td style="width: 2%; vertical-align: top;" rowspan="1">&#160;</td>
          <td style="width: 13%; vertical-align: top;" rowspan="1">&#160;</td>
          <td style="width: 35%; vertical-align: top;" rowspan="1">&#160;</td>
        </tr>
        <tr>
          <td style="width: 15%; vertical-align: top;">&#160;</td>
          <td style="width: 35%; vertical-align: top;">
            <div><sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">3 </sup>The Board of Directors shall adopt its resolutions by a majority of votes cast. In the case of a tie, the Chairman of the Board of Directors shall have the
              casting vote.</div>
          </td>
          <td style="width: 2%; vertical-align: top;">&#160;</td>
          <td style="width: 13%; vertical-align: top;">&#160;</td>
          <td style="width: 35%; vertical-align: top;">
            <div><sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">3 </sup>Les d&#233;cisions du Conseil d'administration sont prises &#224; la majorit&#233; des voix exprim&#233;es. En cas d'&#233;galit&#233; des voix, la voix du pr&#233;sident du Conseil
              d'administration pr&#233;vaut.</div>
          </td>
        </tr>
        <tr>
          <td style="width: 15%; vertical-align: top;" rowspan="1">&#160;</td>
          <td style="width: 35%; vertical-align: top;" rowspan="1">&#160;</td>
          <td style="width: 2%; vertical-align: top;" rowspan="1">&#160;</td>
          <td style="width: 13%; vertical-align: top;" rowspan="1">&#160;</td>
          <td style="width: 35%; vertical-align: top;" rowspan="1">&#160;</td>
        </tr>
        <tr>
          <td style="width: 15%; vertical-align: top;">&#160;</td>
          <td style="width: 35%; vertical-align: top;">
            <div><sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">4 </sup>Resolutions may also be adopted by way of written consent or by approval via telefax, e-mail or another form of electronic communication, unless a member
              requests discussion thereof.</div>
          </td>
          <td style="width: 2%; vertical-align: top;">&#160;</td>
          <td style="width: 13%; vertical-align: top;">&#160;</td>
          <td style="width: 35%; vertical-align: top;">
            <div><sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">4 </sup>Les d&#233;cisions du Conseil d'administration peuvent &#233;galement &#234;tre prises par voie de circulation ou &#234;tre adopt&#233;es par t&#233;l&#233;copie, courriel ou par un autre
              moyen de communication &#233;lectronique, &#224; moins qu'une discussion ne soit requise par l'un des membres du Conseil d'administration.</div>
          </td>
        </tr>
        <tr>
          <td style="width: 15%; vertical-align: top;" rowspan="1">&#160;</td>
          <td style="width: 35%; vertical-align: top;" rowspan="1">&#160;</td>
          <td style="width: 2%; vertical-align: top;" rowspan="1">&#160;</td>
          <td style="width: 13%; vertical-align: top;" rowspan="1">&#160;</td>
          <td style="width: 35%; vertical-align: top;" rowspan="1">&#160;</td>
        </tr>
        <tr>
          <td style="width: 15%; vertical-align: top;">&#160;</td>
          <td style="width: 35%; vertical-align: top;">
            <div><sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">5 </sup>The decisions of the Board of Directors shall be recorded in minutes to be signed by the acting chair and the secretary.</div>
          </td>
          <td style="width: 2%; vertical-align: top;">&#160;</td>
          <td style="width: 13%; vertical-align: top;">&#160;</td>
          <td style="width: 35%; vertical-align: top;">
            <div><sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">5 </sup>Les d&#233;cisions du Conseil d'administration sont consign&#233;es dans un proc&#232;s-verbal sign&#233; par le pr&#233;sident et par le secr&#233;taire.</div>
          </td>
        </tr>
        <tr>
          <td style="width: 15%; vertical-align: top;">&#160;</td>
          <td style="width: 35%; vertical-align: top;">&#160;</td>
          <td style="width: 2%; vertical-align: top;">&#160;</td>
          <td style="width: 13%; vertical-align: top;">&#160;</td>
          <td style="width: 35%; vertical-align: top;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 15%; vertical-align: top;">&#160;</td>
          <td style="width: 35%; vertical-align: top;">
            <div style="font-weight: bold;">Article 20</div>
          </td>
          <td style="width: 2%; vertical-align: top;">&#160;</td>
          <td style="width: 13%; vertical-align: top;">&#160;</td>
          <td style="width: 35%; vertical-align: top;">
            <div style="font-weight: bold;">Article 20</div>
          </td>
        </tr>
        <tr>
          <td style="width: 15%; vertical-align: top;" rowspan="1">&#160;</td>
          <td style="width: 35%; vertical-align: top;" rowspan="1">&#160;</td>
          <td style="width: 2%; vertical-align: top;" rowspan="1">&#160;</td>
          <td style="width: 13%; vertical-align: top;" rowspan="1">&#160;</td>
          <td style="width: 35%; vertical-align: top;" rowspan="1">&#160;</td>
        </tr>
        <tr>
          <td style="width: 15%; vertical-align: top;">
            <div>Powers of the Board </div>
            <div>of Directors</div>
          </td>
          <td style="width: 35%; vertical-align: top;">
            <div><sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">1 </sup>The Board of Directors may pass resolutions with respect to all matters which are not delegated to another corporate body of the Company by law, by these
              articles of association or by regulations.</div>
          </td>
          <td style="width: 2%; vertical-align: top;"><br>
          </td>
          <td style="width: 13%; vertical-align: top;">
            <div>Attributions du Con</div>
            <div>seil d'administration</div>
          </td>
          <td style="width: 35%; vertical-align: top;">
            <div><sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">1 </sup>Le Conseil d'administration peut prendre des d&#233;cisions sur toutes les affaires qui ne sont pas attribu&#233;es &#224; un autre organe de la Soci&#233;t&#233; par la loi, les
              pr&#233;sents statuts ou un r&#232;glement.</div>
          </td>
        </tr>
        <tr>
          <td style="width: 15%; vertical-align: top;" rowspan="1">&#160;</td>
          <td style="width: 35%; vertical-align: top;" rowspan="1">&#160;</td>
          <td style="width: 2%; vertical-align: top;" rowspan="1">&#160;</td>
          <td style="width: 13%; vertical-align: top;" rowspan="1">&#160;</td>
          <td style="width: 35%; vertical-align: top;" rowspan="1">&#160;</td>
        </tr>
        <tr>
          <td style="width: 15%; vertical-align: top;">&#160;</td>
          <td style="width: 35%; vertical-align: top;">
            <div><sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">2</sup> It shall have the following non-transferable and inalienable duties:</div>
          </td>
          <td style="width: 2%; vertical-align: top;">&#160;</td>
          <td style="width: 13%; vertical-align: top;">&#160;</td>
          <td style="width: 35%; vertical-align: top;">
            <div><sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">2</sup> Il a les attributions intransmissibles et inali&#233;nables suivantes:</div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div id="DSPFPageBreak" style="page-break-after:always;">
        <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
    </div>
    <table id="zb52636723c3941f0939fe0c1103e3b7f" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 15%; vertical-align: top; text-indent: -27pt; margin-left: 27pt;">&#160;</td>
          <td style="width: 35%; vertical-align: top;">
            <div style="text-indent: -27pt; margin-left: 27pt;">1.&#160;&#160;&#160;&#160;&#160;&#160;&#160; the ultimate management of the Company and the issuance of necessary instructions;</div>
          </td>
          <td style="width: 2%; vertical-align: top; text-indent: -27pt; margin-left: 27pt;">&#160;</td>
          <td style="width: 13%; vertical-align: top; text-indent: -27pt; margin-left: 27pt;">&#160;</td>
          <td style="width: 35%; vertical-align: top;">
            <div style="text-indent: -27pt; margin-left: 27pt;">1.&#160;&#160;&#160;&#160; &#160;&#160; exercer la haute direction de la Soci&#233;t&#233; et &#233;tablir les instructions n&#233;cessaires;</div>
          </td>
        </tr>
        <tr>
          <td style="width: 15%; vertical-align: top; text-indent: -27pt; margin-left: 27pt;" rowspan="1">&#160;</td>
          <td style="width: 35%; vertical-align: top; text-indent: -27pt; margin-left: 27pt;" rowspan="1">&#160;</td>
          <td style="width: 2%; vertical-align: top; text-indent: -27pt; margin-left: 27pt;" rowspan="1">&#160;</td>
          <td style="width: 13%; vertical-align: top; text-indent: -27pt; margin-left: 27pt;" rowspan="1">&#160;</td>
          <td style="width: 35%; vertical-align: top; text-indent: -27pt; margin-left: 27pt;" rowspan="1">&#160;</td>
        </tr>
        <tr>
          <td style="width: 15%; vertical-align: top; text-indent: -27pt; margin-left: 27pt;">&#160;</td>
          <td style="width: 35%; vertical-align: top;">
            <div style="text-indent: -27pt; margin-left: 27pt;">2.&#160;&#160;&#160;&#160;&#160;&#160;&#160; the determination of the organization of the Company;</div>
          </td>
          <td style="width: 2%; vertical-align: top; text-indent: -27pt; margin-left: 27pt;">&#160;</td>
          <td style="width: 13%; vertical-align: top; text-indent: -27pt; margin-left: 27pt;">&#160;</td>
          <td style="width: 35%; vertical-align: top;">
            <div style="text-indent: -27pt; margin-left: 27pt;">2.&#160;&#160;&#160;&#160;&#160;&#160;&#160; fixer l'organisation de la Soci&#233;t&#233;;</div>
          </td>
        </tr>
        <tr>
          <td style="width: 15%; vertical-align: top; text-indent: -27pt; margin-left: 27pt;" rowspan="1">&#160;</td>
          <td style="width: 35%; vertical-align: top; text-indent: -27pt; margin-left: 27pt;" rowspan="1">&#160;</td>
          <td style="width: 2%; vertical-align: top; text-indent: -27pt; margin-left: 27pt;" rowspan="1">&#160;</td>
          <td style="width: 13%; vertical-align: top; text-indent: -27pt; margin-left: 27pt;" rowspan="1">&#160;</td>
          <td style="width: 35%; vertical-align: top; text-indent: -27pt; margin-left: 27pt;" rowspan="1">&#160;</td>
        </tr>
        <tr>
          <td style="width: 15%; vertical-align: top; text-indent: -27pt; margin-left: 27pt;">&#160;</td>
          <td style="width: 35%; vertical-align: top;">
            <div style="text-indent: -27pt; margin-left: 27pt;">3.&#160;&#160;&#160;&#160;&#160;&#160;&#160; the structuring of the accounting system, of the financial controls and of the financial planning;</div>
          </td>
          <td style="width: 2%; vertical-align: top; text-indent: -27pt; margin-left: 27pt;">&#160;</td>
          <td style="width: 13%; vertical-align: top; text-indent: -27pt; margin-left: 27pt;">&#160;</td>
          <td style="width: 35%; vertical-align: top;">
            <div style="text-indent: -27pt; margin-left: 27pt;">3.&#160;&#160;&#160;&#160;&#160;&#160;&#160; fixer les principes de la comptabilit&#233; et du contr&#244;le financier ainsi que le plan financier;</div>
          </td>
        </tr>
        <tr>
          <td style="width: 15%; vertical-align: top; text-indent: -27pt; margin-left: 27pt;" rowspan="1">&#160;</td>
          <td style="width: 35%; vertical-align: top; text-indent: -27pt; margin-left: 27pt;" rowspan="1">&#160;</td>
          <td style="width: 2%; vertical-align: top; text-indent: -27pt; margin-left: 27pt;" rowspan="1">&#160;</td>
          <td style="width: 13%; vertical-align: top; text-indent: -27pt; margin-left: 27pt;" rowspan="1">&#160;</td>
          <td style="width: 35%; vertical-align: top; text-indent: -27pt; margin-left: 27pt;" rowspan="1">&#160;</td>
        </tr>
        <tr>
          <td style="width: 15%; vertical-align: top; text-indent: -27pt; margin-left: 27pt;">&#160;</td>
          <td style="width: 35%; vertical-align: top;">
            <div style="text-indent: -27pt; margin-left: 27pt;">4.&#160;&#160;&#160;&#160;&#160;&#160;&#160; the appointment and dismissal of the persons entrusted with management and representation of the Company, and issuance of rules on the signature authority;</div>
          </td>
          <td style="width: 2%; vertical-align: top; text-indent: -27pt; margin-left: 27pt;">&#160;</td>
          <td style="width: 13%; vertical-align: top; text-indent: -27pt; margin-left: 27pt;">&#160;</td>
          <td style="width: 35%; vertical-align: top;">
            <div style="text-indent: -27pt; margin-left: 27pt;">4.&#160;&#160;&#160;&#160;&#160;&#160;&#160; nommer et r&#233;voquer les personnes charg&#233;es de la gestion et de la repr&#233;sentation de la Soci&#233;t&#233; et r&#233;glementer le droit de signature;</div>
          </td>
        </tr>
        <tr>
          <td style="width: 15%; vertical-align: top; text-indent: -27pt; margin-left: 27pt;" rowspan="1">&#160;</td>
          <td style="width: 35%; vertical-align: top; text-indent: -27pt; margin-left: 27pt;" rowspan="1">&#160;</td>
          <td style="width: 2%; vertical-align: top; text-indent: -27pt; margin-left: 27pt;" rowspan="1">&#160;</td>
          <td style="width: 13%; vertical-align: top; text-indent: -27pt; margin-left: 27pt;" rowspan="1">&#160;</td>
          <td style="width: 35%; vertical-align: top; text-indent: -27pt; margin-left: 27pt;" rowspan="1">&#160;</td>
        </tr>
        <tr>
          <td style="width: 15%; vertical-align: top; text-indent: -27pt; margin-left: 27pt;">&#160;</td>
          <td style="width: 35%; vertical-align: top;">
            <div style="text-indent: -27pt; margin-left: 27pt;">5.&#160;&#160;&#160;&#160;&#160;&#160;&#160; the ultimate supervision of the persons entrusted with management, in particular in view of compliance with the law, these articles of association, regulations and directives;</div>
          </td>
          <td style="width: 2%; vertical-align: top; text-indent: -27pt; margin-left: 27pt;">&#160;</td>
          <td style="width: 13%; vertical-align: top; text-indent: -27pt; margin-left: 27pt;">&#160;</td>
          <td style="width: 35%; vertical-align: top;">
            <div style="text-indent: -27pt; margin-left: 27pt;">5.&#160;&#160;&#160;&#160;&#160;&#160;&#160; exercer la haute surveillance sur les personnes charg&#233;es de la gestion pour s'assurer notamment qu'elles observent la loi, les pr&#233;sents statuts, les r&#232;glements et les instructions
              donn&#233;es;</div>
          </td>
        </tr>
        <tr>
          <td style="width: 15%; vertical-align: top; text-indent: -27pt; margin-left: 27pt;" rowspan="1">&#160;</td>
          <td style="width: 35%; vertical-align: top; text-indent: -27pt; margin-left: 27pt;" rowspan="1">&#160;</td>
          <td style="width: 2%; vertical-align: top; text-indent: -27pt; margin-left: 27pt;" rowspan="1">&#160;</td>
          <td style="width: 13%; vertical-align: top; text-indent: -27pt; margin-left: 27pt;" rowspan="1">&#160;</td>
          <td style="width: 35%; vertical-align: top; text-indent: -27pt; margin-left: 27pt;" rowspan="1">&#160;</td>
        </tr>
        <tr>
          <td style="width: 15%; vertical-align: top; text-indent: -27pt; margin-left: 27pt;">&#160;</td>
          <td style="width: 35%; vertical-align: top;">
            <div style="text-indent: -27pt; margin-left: 27pt;">6.&#160;&#160;&#160;&#160;&#160;&#160;&#160; the preparation of the annual report and the compensation report;</div>
          </td>
          <td style="width: 2%; vertical-align: top; text-indent: -27pt; margin-left: 27pt;">&#160;</td>
          <td style="width: 13%; vertical-align: top; text-indent: -27pt; margin-left: 27pt;">&#160;</td>
          <td style="width: 35%; vertical-align: top;">
            <div style="text-indent: -27pt; margin-left: 27pt;">6.&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#233;tablir le rapport de gestion et le rapport de r&#233;mun&#233;ration;</div>
          </td>
        </tr>
        <tr>
          <td style="width: 15%; vertical-align: top; text-indent: -27pt; margin-left: 27pt;" rowspan="1">&#160;</td>
          <td style="width: 35%; vertical-align: top; text-indent: -27pt; margin-left: 27pt;" rowspan="1">&#160;</td>
          <td style="width: 2%; vertical-align: top; text-indent: -27pt; margin-left: 27pt;" rowspan="1">&#160;</td>
          <td style="width: 13%; vertical-align: top; text-indent: -27pt; margin-left: 27pt;" rowspan="1">&#160;</td>
          <td style="width: 35%; vertical-align: top; text-indent: -27pt; margin-left: 27pt;" rowspan="1">&#160;</td>
        </tr>
        <tr>
          <td style="width: 15%; vertical-align: top; text-indent: -27pt; margin-left: 27pt;">&#160;</td>
          <td style="width: 35%; vertical-align: top;">
            <div style="text-indent: -27pt; margin-left: 27pt;">7.&#160;&#160;&#160;&#160;&#160;&#160;&#160; the preparation of the General Meeting of Shareholders and the implementation of its resolutions;</div>
          </td>
          <td style="width: 2%; vertical-align: top; text-indent: -27pt; margin-left: 27pt;">&#160;</td>
          <td style="width: 13%; vertical-align: top; text-indent: -27pt; margin-left: 27pt;">&#160;</td>
          <td style="width: 35%; vertical-align: top;">
            <div style="text-indent: -27pt; margin-left: 27pt;">7.&#160;&#160;&#160;&#160;&#160;&#160;&#160; pr&#233;parer l'Assembl&#233;e g&#233;n&#233;rale et ex&#233;cuter ses d&#233;cisions;</div>
          </td>
        </tr>
        <tr>
          <td style="width: 15%; vertical-align: top; text-indent: -27pt; margin-left: 27pt;" rowspan="1">&#160;</td>
          <td style="width: 35%; vertical-align: top; text-indent: -27pt; margin-left: 27pt;" rowspan="1">&#160;</td>
          <td style="width: 2%; vertical-align: top; text-indent: -27pt; margin-left: 27pt;" rowspan="1">&#160;</td>
          <td style="width: 13%; vertical-align: top; text-indent: -27pt; margin-left: 27pt;" rowspan="1">&#160;</td>
          <td style="width: 35%; vertical-align: top; text-indent: -27pt; margin-left: 27pt;" rowspan="1">&#160;</td>
        </tr>
        <tr>
          <td style="width: 15%; vertical-align: top; text-indent: -27pt; margin-left: 27pt;">&#160;</td>
          <td style="width: 35%; vertical-align: top;">
            <div style="text-indent: -27pt; margin-left: 27pt;">8.&#160;&#160;&#160;&#160;&#160;&#160;&#160; the adoption of resolutions on the increase of the share capital to the extent that such power is vested in the Board of Directors, the ascertainment of capital increases, the
              preparation of the report on the capital increase, and the respective amendments of the articles of association (including deletions);</div>
          </td>
          <td style="width: 2%; vertical-align: top; text-indent: -27pt; margin-left: 27pt;">&#160;</td>
          <td style="width: 13%; vertical-align: top; text-indent: -27pt; margin-left: 27pt;">&#160;</td>
          <td style="width: 35%; vertical-align: top;">
            <div style="text-indent: -27pt; margin-left: 27pt;">8.&#160;&#160;&#160;&#160;&#160;&#160;&#160; prendre les d&#233;cisions relatives aux augmentations du capital-actions, dans la mesure o&#249; elles sont de la comp&#233;tence du Conseil d'administration, ainsi que les d&#233;cisions relatives &#224;
              la constatation d'augmentations de capital, &#224; l'&#233;tablissement du rapport d'augmentation du capital-actions et aux modifications des statuts qui en r&#233;sultent (radiation comprise);</div>
          </td>
        </tr>
        <tr>
          <td style="width: 15%; vertical-align: top; text-indent: -27pt; margin-left: 27pt;" rowspan="1">&#160;</td>
          <td style="width: 35%; vertical-align: top; text-indent: -27pt; margin-left: 27pt;" rowspan="1">&#160;</td>
          <td style="width: 2%; vertical-align: top; text-indent: -27pt; margin-left: 27pt;" rowspan="1">&#160;</td>
          <td style="width: 13%; vertical-align: top; text-indent: -27pt; margin-left: 27pt;" rowspan="1">&#160;</td>
          <td style="width: 35%; vertical-align: top; text-indent: -27pt; margin-left: 27pt;" rowspan="1">&#160;</td>
        </tr>
        <tr>
          <td style="width: 15%; vertical-align: top; text-indent: -27pt; margin-left: 27pt;">&#160;</td>
          <td style="width: 35%; vertical-align: top;">
            <div style="text-indent: -27pt; margin-left: 27pt;">9.&#160;&#160;&#160;&#160;&#160;&#160;&#160; the non-transferable and inalienable duties and powers of the Board of Directors pursuant to the Merger Act;</div>
          </td>
          <td style="width: 2%; vertical-align: top; text-indent: -27pt; margin-left: 27pt;">&#160;</td>
          <td style="width: 13%; vertical-align: top; text-indent: -27pt; margin-left: 27pt;">&#160;</td>
          <td style="width: 35%; vertical-align: top;">
            <div style="text-indent: -27pt; margin-left: 27pt;">9.&#160;&#160;&#160;&#160;&#160;&#160;&#160; les attributions et comp&#233;tences intransmissibles et inali&#233;nables du Conseil d'administration selon la Loi sur la fusion;</div>
          </td>
        </tr>
        <tr>
          <td style="width: 15%; vertical-align: top; text-indent: -27pt; margin-left: 27pt;" rowspan="1">&#160;</td>
          <td style="width: 35%; vertical-align: top; text-indent: -27pt; margin-left: 27pt;" rowspan="1">&#160;</td>
          <td style="width: 2%; vertical-align: top; text-indent: -27pt; margin-left: 27pt;" rowspan="1">&#160;</td>
          <td style="width: 13%; vertical-align: top; text-indent: -27pt; margin-left: 27pt;" rowspan="1">&#160;</td>
          <td style="width: 35%; vertical-align: top; text-indent: -27pt; margin-left: 27pt;" rowspan="1">&#160;</td>
        </tr>
        <tr>
          <td style="width: 15%; vertical-align: top; text-indent: -27pt; margin-left: 27pt;">&#160;</td>
          <td style="width: 35%; vertical-align: top;">
            <div style="text-indent: -27pt; margin-left: 27pt;">10.&#160;&#160;&#160;&#160;&#160; the notification of the judge if liabilities exceed assets; and</div>
          </td>
          <td style="width: 2%; vertical-align: top; text-indent: -27pt; margin-left: 27pt;">&#160;</td>
          <td style="width: 13%; vertical-align: top; text-indent: -27pt; margin-left: 27pt;">&#160;</td>
          <td style="width: 35%; vertical-align: top;">
            <div style="text-indent: -27pt; margin-left: 27pt;">10.&#160;&#160;&#160;&#160;&#160; informer le juge en cas de surendettement; et</div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div id="DSPFPageBreak" style="page-break-after:always;">
        <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
    </div>
    <table id="z2a2c8a16d1814b84b1b5404f6fed9101" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 15%; vertical-align: top; text-indent: -27pt; margin-left: 27pt;">&#160;</td>
          <td style="width: 35%; vertical-align: top;">
            <div style="text-indent: -27pt; margin-left: 27pt;">11.&#160;&#160;&#160;&#160;&#160; other powers and duties reserved to the Board of Directors by law or these articles of association.</div>
          </td>
          <td style="width: 2%; vertical-align: top; text-indent: -27pt; margin-left: 27pt;">&#160;</td>
          <td style="width: 13%; vertical-align: top; text-indent: -27pt; margin-left: 27pt;">&#160;</td>
          <td style="width: 35%; vertical-align: top;">
            <div style="text-indent: -27pt; margin-left: 27pt;">11.&#160;&#160;&#160;&#160;&#160; d'autres attributions et comp&#233;tences r&#233;serv&#233;es au Conseil d'administration par la loi ou les pr&#233;sents statuts.</div>
          </td>
        </tr>
        <tr>
          <td style="width: 15%; vertical-align: top;" rowspan="1">&#160;</td>
          <td style="width: 35%; vertical-align: top;" rowspan="1">&#160;</td>
          <td style="width: 2%; vertical-align: top;" rowspan="1">&#160;</td>
          <td style="width: 13%; vertical-align: top;" rowspan="1">&#160;</td>
          <td style="width: 35%; vertical-align: top;" rowspan="1">&#160;</td>
        </tr>
        <tr>
          <td style="width: 15%; vertical-align: top;">&#160;</td>
          <td style="width: 35%; vertical-align: top;">
            <div style="margin-left: 2.2pt;"><sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">3 </sup>In all other respects, the Board of Directors may delegate in whole or in part the management and the representation of the
              Company within the framework set forth by these articles of association and the law to one or several of its members or to third parties by means of organizational regulations.</div>
          </td>
          <td style="width: 2%; vertical-align: top;">&#160;</td>
          <td style="width: 13%; vertical-align: top;">&#160;</td>
          <td style="width: 35%; vertical-align: top;">
            <div style="margin-left: 2.85pt;"><sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">3 </sup>En outre, le Conseil d'administration peut d&#233;l&#233;guer en tout ou en partie la gestion ainsi que la repr&#233;sentation de la Soci&#233;t&#233;,
              dans le cadre des pr&#233;sents statuts et de la loi, &#224; un ou plusieurs de ses membres ou &#224; des tiers conform&#233;ment au r&#232;glement d'organisation.</div>
          </td>
        </tr>
        <tr>
          <td style="width: 15%; vertical-align: top;">&#160;</td>
          <td style="width: 35%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">&#160;</td>
          <td style="width: 2%; vertical-align: top;">&#160;</td>
          <td style="width: 13%; vertical-align: top;">&#160;</td>
          <td style="width: 35%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">&#160;</td>
        </tr>
        <tr>
          <td style="width: 15%; vertical-align: middle;">&#160;</td>
          <td style="width: 35%; vertical-align: middle; border-top: 2px solid rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0);">
            <div><font style="font-weight: bold;">C.</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-weight: bold;">The Compensation Committee</font></div>
          </td>
          <td style="width: 2%; vertical-align: middle;">&#160;</td>
          <td style="width: 13%; vertical-align: middle;">&#160;</td>
          <td style="width: 35%; vertical-align: middle; border-top: 2px solid rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0);">
            <div><font style="font-weight: bold;">C.</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-weight: bold;">Le Comit&#233; de r&#233;mun&#233;ration</font></div>
          </td>
        </tr>
        <tr>
          <td style="width: 15%; vertical-align: top;">&#160;</td>
          <td style="width: 35%; vertical-align: top;">&#160;</td>
          <td style="width: 2%; vertical-align: top;">&#160;</td>
          <td style="width: 13%; vertical-align: top;">&#160;</td>
          <td style="width: 35%; vertical-align: top;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 15%; vertical-align: top;">&#160;</td>
          <td style="width: 35%; vertical-align: top;">
            <div style="font-weight: bold;">Article 21</div>
          </td>
          <td style="width: 2%; vertical-align: top;">&#160;</td>
          <td style="width: 13%; vertical-align: top;">&#160;</td>
          <td style="width: 35%; vertical-align: top;">
            <div style="font-weight: bold;">Article 21</div>
          </td>
        </tr>
        <tr>
          <td style="width: 15%; vertical-align: top;" rowspan="1">&#160;</td>
          <td style="width: 35%; vertical-align: top;" rowspan="1">&#160;</td>
          <td style="width: 2%; vertical-align: top;" rowspan="1">&#160;</td>
          <td style="width: 13%; vertical-align: top;" rowspan="1">&#160;</td>
          <td style="width: 35%; vertical-align: top;" rowspan="1">&#160;</td>
        </tr>
        <tr>
          <td style="width: 15%; vertical-align: top;">
            <div>Number of Members</div>
          </td>
          <td style="width: 35%; vertical-align: top;">
            <div>The Compensation Committee shall consist of at least two members of the Board of Directors.</div>
          </td>
          <td style="width: 2%; vertical-align: top;"><br>
          </td>
          <td style="width: 13%; vertical-align: top;">
            <div>Nombre de membres</div>
          </td>
          <td style="width: 35%; vertical-align: top;">
            <div>Le Comit&#233; de r&#233;mun&#233;ration se compose d'au moins deux membres du Conseil d'administration.</div>
          </td>
        </tr>
        <tr>
          <td style="width: 15%; vertical-align: top;">&#160;</td>
          <td style="width: 35%; vertical-align: top;">&#160;</td>
          <td style="width: 2%; vertical-align: top;">&#160;</td>
          <td style="width: 13%; vertical-align: top;">&#160;</td>
          <td style="width: 35%; vertical-align: top;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 15%; vertical-align: top;">&#160;</td>
          <td style="width: 35%; vertical-align: top;">
            <div style="font-weight: bold;">Article 22</div>
          </td>
          <td style="width: 2%; vertical-align: top;">&#160;</td>
          <td style="width: 13%; vertical-align: top;">&#160;</td>
          <td style="width: 35%; vertical-align: top;">
            <div style="font-weight: bold;">Article 22</div>
          </td>
        </tr>
        <tr>
          <td style="width: 15%; vertical-align: top;" rowspan="1">&#160;</td>
          <td style="width: 35%; vertical-align: top;" rowspan="1">&#160;</td>
          <td style="width: 2%; vertical-align: top;" rowspan="1">&#160;</td>
          <td style="width: 13%; vertical-align: top;" rowspan="1">&#160;</td>
          <td style="width: 35%; vertical-align: top;" rowspan="1">&#160;</td>
        </tr>
        <tr>
          <td style="width: 15%; vertical-align: top;">
            <div>Election and Term </div>
            <div>of Office</div>
          </td>
          <td style="width: 35%; vertical-align: top;">
            <div><sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">1 </sup>The General Meeting of Shareholders shall elect the members of the Compensation Committee individually for a term of office until the completion of the
              subsequent Ordinary General Meeting of Shareholders. Only members of the Board of Directors may be elected. Re-election is possible.</div>
          </td>
          <td style="width: 2%; vertical-align: top;"><br>
          </td>
          <td style="width: 13%; vertical-align: top;">
            <div>Election et dur&#233;e de </div>
            <div>fonctions</div>
          </td>
          <td style="width: 35%; vertical-align: top;">
            <div><sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">1 </sup>L'Assembl&#233;e g&#233;n&#233;rale &#233;lit individuellement les membres du Comit&#233; de r&#233;mun&#233;ration pour une dur&#233;e de fonctions s'achevant &#224; la fin de l'Assembl&#233;e g&#233;n&#233;rale
              ordinaire suivante. Seuls des membres du Conseil d'administration sont &#233;ligibles. La r&#233;&#233;lection est possible.</div>
          </td>
        </tr>
        <tr>
          <td style="width: 15%; vertical-align: top;" rowspan="1">&#160;</td>
          <td style="width: 35%; vertical-align: top;" rowspan="1">&#160;</td>
          <td style="width: 2%; vertical-align: top;" rowspan="1">&#160;</td>
          <td style="width: 13%; vertical-align: top;" rowspan="1">&#160;</td>
          <td style="width: 35%; vertical-align: top;" rowspan="1">&#160;</td>
        </tr>
        <tr>
          <td style="width: 15%; vertical-align: top;">&#160;</td>
          <td style="width: 35%; vertical-align: top;">
            <div><sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">2 </sup>If there are vacancies on the Compensation Committee, the Board of Directors may appoint substitute members from among its members for a term of office
              extending until completion of the next Ordinary General Meeting of Shareholders.</div>
          </td>
          <td style="width: 2%; vertical-align: top;">&#160;</td>
          <td style="width: 13%; vertical-align: top;">&#160;</td>
          <td style="width: 35%; vertical-align: top;">
            <div><sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">2 </sup>En cas de vacance au sein du Comit&#233; de r&#233;mun&#233;ration, le Conseil d'administration peut d&#233;signer des substituts parmi ses membres pour une dur&#233;e de fonctions
              s'achevant &#224; la fin de l'Assembl&#233;e g&#233;n&#233;rale ordinaire suivante.</div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div id="DSPFPageBreak" style="page-break-after:always;">
        <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
    </div>
    <table id="z2af2b0bed6b64438a29cc48d41ebc02f" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 15%; vertical-align: top;">&#160;</td>
          <td style="width: 35%; vertical-align: top;">
            <div style="font-weight: bold;">Article 23</div>
          </td>
          <td style="width: 2%; vertical-align: top;">&#160;</td>
          <td style="width: 13%; vertical-align: top;">&#160;</td>
          <td style="width: 35%; vertical-align: top;">
            <div style="font-weight: bold;">Article 23</div>
          </td>
        </tr>
        <tr>
          <td style="width: 15%; vertical-align: top;" rowspan="1">&#160;</td>
          <td style="width: 35%; vertical-align: top;" rowspan="1">&#160;</td>
          <td style="width: 2%; vertical-align: top;" rowspan="1">&#160;</td>
          <td style="width: 13%; vertical-align: top;" rowspan="1">&#160;</td>
          <td style="width: 35%; vertical-align: top;" rowspan="1">&#160;</td>
        </tr>
        <tr>
          <td style="width: 15%; vertical-align: top;">
            <div>Organization of the</div>
            <div> Compensation </div>
            <div>Committee</div>
          </td>
          <td style="width: 35%; vertical-align: top;">
            <div><sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">1 </sup>The Compensation Committee shall constitute itself. Unless the organizational regulations provide otherwise, the Board of Directors shall elect a chairman
              from among the Compensation Committee's members.</div>
          </td>
          <td style="width: 2%; vertical-align: top;"><br>
          </td>
          <td style="width: 13%; vertical-align: top;">
            <div>Organisation du Co</div>
            <div>mit&#233; de r&#233;mun&#233;ra</div>
            <div>tion</div>
          </td>
          <td style="width: 35%; vertical-align: top;">
            <div><sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">1 </sup>Le Comit&#233; de r&#233;mun&#233;ration se constitue lui-m&#234;me. A moins que le r&#232;glement d'organisation n'en dispose autrement, le Conseil d'administration &#233;lit le
              Pr&#233;sident du Comit&#233; de r&#233;mun&#233;ration parmi les membres du Comit&#233; de r&#233;mun&#233;ration.</div>
          </td>
        </tr>
        <tr>
          <td style="width: 15%; vertical-align: top;">&#160;</td>
          <td style="width: 35%; vertical-align: top;" rowspan="1">&#160;</td>
          <td style="width: 2%; vertical-align: top;" rowspan="1">&#160;</td>
          <td style="width: 13%; vertical-align: top;">&#160;</td>
          <td style="width: 35%; vertical-align: top;" rowspan="1">&#160;</td>
        </tr>
        <tr>
          <td style="width: 15%; vertical-align: top;">&#160;</td>
          <td style="width: 35%; vertical-align: top;">
            <div><sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">2</sup> The Board of Directors shall issue regulations establishing the organization and decision-making process of the Compensation Committee, which may be part of
              the organizational regulations.</div>
          </td>
          <td style="width: 2%; vertical-align: top;">&#160;</td>
          <td style="width: 13%; vertical-align: top;">&#160;</td>
          <td style="width: 35%; vertical-align: top;">
            <div><sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">2</sup> Le Conseil d'administration &#233;tablit un r&#232;glement concernant l'organisation et le processus de d&#233;cision du Comit&#233; de r&#233;mun&#233;ration, qui peut &#234;tre int&#233;gr&#233; au
              r&#232;glement d'organisation.</div>
          </td>
        </tr>
        <tr>
          <td style="width: 15%; vertical-align: top;">&#160;</td>
          <td style="width: 35%; vertical-align: top;">&#160;</td>
          <td style="width: 2%; vertical-align: top;">&#160;</td>
          <td style="width: 13%; vertical-align: top;">&#160;</td>
          <td style="width: 35%; vertical-align: top;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 15%; vertical-align: top;">&#160;</td>
          <td style="width: 35%; vertical-align: top;">
            <div style="font-weight: bold;">Article 24</div>
          </td>
          <td style="width: 2%; vertical-align: top;">&#160;</td>
          <td style="width: 13%; vertical-align: top;">&#160;</td>
          <td style="width: 35%; vertical-align: top;">
            <div style="font-weight: bold;">Article 24</div>
          </td>
        </tr>
        <tr>
          <td style="width: 15%; vertical-align: top;" rowspan="1">&#160;</td>
          <td style="width: 35%; vertical-align: top;" rowspan="1">&#160;</td>
          <td style="width: 2%; vertical-align: top;" rowspan="1">&#160;</td>
          <td style="width: 13%; vertical-align: top;" rowspan="1">&#160;</td>
          <td style="width: 35%; vertical-align: top;" rowspan="1">&#160;</td>
        </tr>
        <tr>
          <td style="width: 15%; vertical-align: top;">
            <div>Duties and Powers</div>
          </td>
          <td style="width: 35%; vertical-align: top;">
            <div><sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">1 </sup>The Compensation Committee shall support the Board of Directors in establishing and reviewing the compensation strategy and guidelines as well as in
              preparing the proposals to the General Meeting of Shareholders regarding the compensation of the Board of Directors and the Executive Committee. It may submit proposals to the Board of Directors in other compensation-related issues.</div>
          </td>
          <td style="width: 2%; vertical-align: top;">&#160;</td>
          <td style="width: 13%; vertical-align: top;">
            <div>Attributions</div>
          </td>
          <td style="width: 35%; vertical-align: top;">
            <div><sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">1 </sup>Le Comit&#233; de r&#233;mun&#233;ration assiste le Conseil d'administration dans l'&#233;tablissement et la r&#233;vision de la strat&#233;gie et des directives de r&#233;mun&#233;ration, ainsi
              que dans la pr&#233;paration des propositions &#224; soumettre &#224; l'Assembl&#233;e g&#233;n&#233;rale concernant la r&#233;mun&#233;ration du Conseil d'administration et de la Direction ex&#233;cutive. Il peut soumettre au Conseil d'administration des propositions en toutes autres
              mati&#232;res relatives &#224; la r&#233;mun&#233;ration.</div>
          </td>
        </tr>
        <tr>
          <td style="width: 15%; vertical-align: top;" rowspan="1">&#160;</td>
          <td style="width: 35%; vertical-align: top;" rowspan="1">&#160;</td>
          <td style="width: 2%; vertical-align: top;" rowspan="1">&#160;</td>
          <td style="width: 13%; vertical-align: top;" rowspan="1">&#160;</td>
          <td style="width: 35%; vertical-align: top;" rowspan="1">&#160;</td>
        </tr>
        <tr>
          <td style="width: 15%; vertical-align: top;">&#160;</td>
          <td style="width: 35%; vertical-align: top;">
            <div><sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">2 </sup>The Board of Directors shall determine in regulations for which positions of the Board of Directors, the Executive Committee and other member of management
              (if any) the Compensation Committee<font style="font-weight: bold;">&#160;</font>shall submit proposals for the performance metrics, target values and/or the compensation of the members of the Board of Directors and the Executive Committee, and
              for which positions it shall itself determine, in accordance with these articles of association and the compensation guidelines established by the Board of Directors, such performance metrics, target values and/or the compensation.</div>
          </td>
          <td style="width: 2%; vertical-align: top;">&#160;</td>
          <td style="width: 13%; vertical-align: top;">&#160;</td>
          <td style="width: 35%; vertical-align: top;">
            <div><sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">2 </sup>Le Conseil d'administration d&#233;termine dans un r&#232;glement pour quelles fonctions du Conseil d'administration, de la Direction ex&#233;cutive et d'autres membres
              de la direction (si applicable) le Comit&#233; de r&#233;mun&#233;ration proposera au Conseil d'administration les mesures de performances, les valeurs cibles et/ou la r&#233;mun&#233;ration des membres du Conseil d'administration et de la Direction ex&#233;cutive, et
              pour quelles fonctions il aura la comp&#233;tence de d&#233;terminer de son propre chef, en accord avec les statuts et les directives de r&#233;mun&#233;ration &#233;tablies par le Conseil d'administration, les mesures de performances, les valeurs cibles et/ou la
              r&#233;mun&#233;ration.</div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div id="DSPFPageBreak" style="page-break-after:always;">
        <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
    </div>
    <table id="z9f28c8fd81d34fab95a173c732e85db7" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 15%; vertical-align: top;">&#160;</td>
          <td style="width: 35%; vertical-align: top;">
            <div><sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">3 </sup>The Board of Directors may delegate further tasks to the Compensation Committee.</div>
          </td>
          <td style="width: 2%; vertical-align: top;">&#160;</td>
          <td style="width: 13%; vertical-align: top;">&#160;</td>
          <td style="width: 35%; vertical-align: top;">
            <div><sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">3 </sup>Le Conseil d&#8217;administration peut d&#233;l&#233;guer d'autres t&#226;ches au Comit&#233; de r&#233;mun&#233;ration.</div>
          </td>
        </tr>
        <tr>
          <td style="width: 15%; vertical-align: top;">&#160;</td>
          <td style="width: 35%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">&#160;</td>
          <td style="width: 2%; vertical-align: top;">&#160;</td>
          <td style="width: 13%; vertical-align: top;">&#160;</td>
          <td style="width: 35%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">&#160;</td>
        </tr>
        <tr>
          <td style="width: 15%; vertical-align: middle;">&#160;</td>
          <td style="width: 35%; vertical-align: middle; border-top: 2px solid rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0);">
            <div><font style="font-weight: bold;">D.</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-weight: bold;">The Auditors</font></div>
          </td>
          <td style="width: 2%; vertical-align: middle;">&#160;</td>
          <td style="width: 13%; vertical-align: middle;">&#160;</td>
          <td style="width: 35%; vertical-align: middle; border-top: 2px solid rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0);">
            <div><font style="font-weight: bold;">D.</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-weight: bold;">L'organe de r&#233;vision</font></div>
          </td>
        </tr>
        <tr>
          <td style="width: 15%; vertical-align: top;">&#160;</td>
          <td style="width: 35%; vertical-align: top;">&#160;</td>
          <td style="width: 2%; vertical-align: top;">&#160;</td>
          <td style="width: 13%; vertical-align: top;">&#160;</td>
          <td style="width: 35%; vertical-align: top;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 15%; vertical-align: top;">&#160;</td>
          <td style="width: 35%; vertical-align: top;">
            <div style="font-weight: bold;">Article 25</div>
          </td>
          <td style="width: 2%; vertical-align: top;">&#160;</td>
          <td style="width: 13%; vertical-align: top;">&#160;</td>
          <td style="width: 35%; vertical-align: top;">
            <div style="font-weight: bold;">Article 25</div>
          </td>
        </tr>
        <tr>
          <td style="width: 15%; vertical-align: top;" rowspan="1">&#160;</td>
          <td style="width: 35%; vertical-align: top;" rowspan="1">&#160;</td>
          <td style="width: 2%; vertical-align: top;" rowspan="1">&#160;</td>
          <td style="width: 13%; vertical-align: top;" rowspan="1">&#160;</td>
          <td style="width: 35%; vertical-align: top;" rowspan="1">&#160;</td>
        </tr>
        <tr>
          <td style="width: 15%; vertical-align: top;">&#160;</td>
          <td style="width: 35%; vertical-align: top;">
            <div><sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">1 </sup>The General Meeting of Shareholders shall elect the Auditors for a term of office until the completion of the next Ordinary General Meeting of
              Shareholders. Re-election is possible.</div>
          </td>
          <td style="width: 2%; vertical-align: top;">&#160;</td>
          <td style="width: 13%; vertical-align: top;">&#160;</td>
          <td style="width: 35%; vertical-align: top;">
            <div><sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">1 </sup>L'Assembl&#233;e g&#233;n&#233;rale &#233;lit l'organe de r&#233;vision pour une dur&#233;e de fonctions s&#8217;achevant &#224; la fin de l&#8217;Assembl&#233;e g&#233;n&#233;rale ordinaire suivante. La r&#233;&#233;lection
              est possible.</div>
          </td>
        </tr>
        <tr>
          <td style="width: 15%; vertical-align: top;" rowspan="1">&#160;</td>
          <td style="width: 35%; vertical-align: top;" rowspan="1">&#160;</td>
          <td style="width: 2%; vertical-align: top;" rowspan="1">&#160;</td>
          <td style="width: 13%; vertical-align: top;" rowspan="1">&#160;</td>
          <td style="width: 35%; vertical-align: top;" rowspan="1">&#160;</td>
        </tr>
        <tr>
          <td style="width: 15%; vertical-align: top;">&#160;</td>
          <td style="width: 35%; vertical-align: top;">
            <div><sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">2</sup> The Auditors shall have the powers and duties vested in them by law.</div>
          </td>
          <td style="width: 2%; vertical-align: top;">&#160;</td>
          <td style="width: 13%; vertical-align: top;">&#160;</td>
          <td style="width: 35%; vertical-align: top;">
            <div><sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">2</sup> L'organe de r&#233;vision a les pouvoirs et obligations que lui conf&#232;re la loi.</div>
          </td>
        </tr>
        <tr>
          <td style="width: 15%; vertical-align: top;" rowspan="1">&#160;</td>
          <td style="width: 35%; vertical-align: top;" rowspan="1">&#160;</td>
          <td style="width: 2%; vertical-align: top;" rowspan="1">&#160;</td>
          <td style="width: 13%; vertical-align: top;" rowspan="1">&#160;</td>
          <td style="width: 35%; vertical-align: top;" rowspan="1">&#160;</td>
        </tr>
        <tr>
          <td style="width: 15%; vertical-align: top;">&#160;</td>
          <td style="width: 35%; vertical-align: top;">
            <div><sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">3 </sup>The Board of Directors may mandate the Auditors at any time to perform special investigations, in particular interim audits, and to prepare a report on
              their findings.</div>
          </td>
          <td style="width: 2%; vertical-align: top;">&#160;</td>
          <td style="width: 13%; vertical-align: top;">&#160;</td>
          <td style="width: 35%; vertical-align: top;">
            <div><sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">3 </sup>Le Conseil d'administration peut en tout temps charger l'organe de r&#233;vision de proc&#233;der &#224; des contr&#244;les sp&#233;ciaux, notamment des r&#233;visions interm&#233;diaires,
              et de lui en soumettre un rapport.</div>
          </td>
        </tr>
        <tr>
          <td style="width: 15%; vertical-align: top;">&#160;</td>
          <td style="width: 35%; vertical-align: top;">&#160;</td>
          <td style="width: 2%; vertical-align: top;">&#160;</td>
          <td style="width: 13%; vertical-align: top;">&#160;</td>
          <td style="width: 35%; vertical-align: top;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 15%; vertical-align: top;">&#160;</td>
          <td style="width: 35%; vertical-align: top; border-top: 2px solid rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0);">
            <div style="font-weight: bold;">Section 4</div>
            <div style="font-style: italic;">Compensation of the Members of the Board of Directors and the Executive Committee and Related Matters</div>
          </td>
          <td style="width: 2%; vertical-align: top;">&#160;</td>
          <td style="width: 13%; vertical-align: top;">&#160;</td>
          <td style="width: 35%; vertical-align: top; border-top: 2px solid rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0);">
            <div style="font-weight: bold;">Section 4</div>
            <div style="font-style: italic;">R&#233;mun&#233;ration des membres du Conseil d'administration et de la Direction ex&#233;cutive et affaires connexes</div>
          </td>
        </tr>
        <tr>
          <td style="width: 15%; vertical-align: top;">&#160;</td>
          <td style="width: 35%; vertical-align: top; border-top: 2px solid rgb(0, 0, 0);">&#160;</td>
          <td style="width: 2%; vertical-align: top;">&#160;</td>
          <td style="width: 13%; vertical-align: top;">&#160;</td>
          <td style="width: 35%; vertical-align: top; border-top: 2px solid rgb(0, 0, 0);">&#160;</td>
        </tr>
        <tr>
          <td style="width: 15%; vertical-align: top;">&#160;</td>
          <td style="width: 35%; vertical-align: top;">
            <div style="font-weight: bold;">Article 26</div>
          </td>
          <td style="width: 2%; vertical-align: top;">&#160;</td>
          <td style="width: 13%; vertical-align: top;">&#160;</td>
          <td style="width: 35%; vertical-align: top;">
            <div style="font-weight: bold;">Article 26</div>
          </td>
        </tr>
        <tr>
          <td style="width: 15%; vertical-align: top;" rowspan="1">&#160;</td>
          <td style="width: 35%; vertical-align: top;" rowspan="1">&#160;</td>
          <td style="width: 2%; vertical-align: top;" rowspan="1">&#160;</td>
          <td style="width: 13%; vertical-align: top;" rowspan="1">&#160;</td>
          <td style="width: 35%; vertical-align: top;" rowspan="1">&#160;</td>
        </tr>
        <tr>
          <td style="width: 15%; vertical-align: top;">
            <div>Approval of the </div>
            <div>Compensation by</div>
            <div> the General Meeting </div>
            <div>of Shareholders</div>
          </td>
          <td style="width: 35%; vertical-align: top;">
            <div><sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">1 </sup>The General Meeting of Shareholders shall approve the proposals of the Board of Directors in relation to the aggregate amounts of:</div>
          </td>
          <td style="width: 2%; vertical-align: top;">&#160;</td>
          <td style="width: 13%; vertical-align: top;">
            <div>Approbation de la<br>
            </div>
            <div>r&#233;mun&#233;ration par </div>
            <div>l'Assembl&#233;e g&#233;n&#233;</div>
            <div>rale</div>
          </td>
          <td style="width: 35%; vertical-align: top;">
            <div><sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">1 </sup>L'Assembl&#233;e g&#233;n&#233;rale approuve les propositions du Conseil d'administration en relation avec les montants maximaux suivants:</div>
          </td>
        </tr>
        <tr>
          <td style="width: 15%; vertical-align: top;">&#160;</td>
          <td style="width: 35%; vertical-align: top;" rowspan="1">&#160;</td>
          <td style="width: 2%; vertical-align: top;" rowspan="1">&#160;</td>
          <td style="width: 13%; vertical-align: top;">&#160;</td>
          <td style="width: 35%; vertical-align: top;" rowspan="1">&#160;</td>
        </tr>
        <tr>
          <td style="width: 15%; vertical-align: top; text-indent: -27pt; margin-left: 27pt;">&#160;</td>
          <td style="width: 35%; vertical-align: top;">
            <div style="text-indent: -27pt; margin-left: 27pt;">1.&#160;&#160;&#160;&#160;&#160;&#160;&#160; the maximum compensation of the Board of Directors until the completion of the next Ordinary General Meeting of Shareholders;</div>
          </td>
          <td style="width: 2%; vertical-align: top; text-indent: -27pt; margin-left: 27pt;">&#160;</td>
          <td style="width: 13%; vertical-align: top; text-indent: -27pt; margin-left: 27pt;">&#160;</td>
          <td style="width: 35%; vertical-align: top;">
            <div style="text-indent: -27pt; margin-left: 27pt;">1.&#160;&#160;&#160;&#160;&#160;&#160;&#160; la r&#233;mun&#233;ration maximale du Conseil d'administration jusqu'&#224; la fin de l'Assembl&#233;e g&#233;n&#233;rale ordinaire des actionnaires suivante;</div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div id="DSPFPageBreak" style="page-break-after:always;">
        <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
    </div>
    <table id="zeed4f27e86ce45ebb52730ef63e9b1b4" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 15%; vertical-align: top; text-indent: -27pt; margin-left: 27pt;">&#160;</td>
          <td style="width: 35%; vertical-align: top;">
            <div style="text-indent: -27pt; margin-left: 27pt;">2.&#160;&#160;&#160;&#160;&#160;&#160;&#160; the maximum fixed compensation of the Executive Committee for the following financial year; and</div>
          </td>
          <td style="width: 2%; vertical-align: top; text-indent: -27pt; margin-left: 27pt;">&#160;</td>
          <td style="width: 13%; vertical-align: top; text-indent: -27pt; margin-left: 27pt;">&#160;</td>
          <td style="width: 35%; vertical-align: top;">
            <div style="text-indent: -27pt; margin-left: 27pt;">2.&#160;&#160;&#160;&#160;&#160;&#160;&#160; la r&#233;mun&#233;ration fixe maximale de la Direction ex&#233;cutive pour l'ann&#233;e comptable suivante; et</div>
          </td>
        </tr>
        <tr>
          <td style="width: 15%; vertical-align: top; text-indent: -27pt; margin-left: 27pt;" rowspan="1">&#160;</td>
          <td style="width: 35%; vertical-align: top; text-indent: -27pt; margin-left: 27pt;" rowspan="1">&#160;</td>
          <td style="width: 2%; vertical-align: top; text-indent: -27pt; margin-left: 27pt;" rowspan="1">&#160;</td>
          <td style="width: 13%; vertical-align: top; text-indent: -27pt; margin-left: 27pt;" rowspan="1">&#160;</td>
          <td style="width: 35%; vertical-align: top; text-indent: -27pt; margin-left: 27pt;" rowspan="1">&#160;</td>
        </tr>
        <tr>
          <td style="width: 15%; vertical-align: top; text-indent: -27pt; margin-left: 27pt;">&#160;</td>
          <td style="width: 35%; vertical-align: top;">
            <div style="text-indent: -27pt; margin-left: 27pt;">3.&#160;&#160;&#160;&#160;&#160;&#160;&#160; the maximum variable compensation of the Executive Committee for the current financial year.</div>
          </td>
          <td style="width: 2%; vertical-align: top; text-indent: -27pt; margin-left: 27pt;">&#160;</td>
          <td style="width: 13%; vertical-align: top; text-indent: -27pt; margin-left: 27pt;">&#160;</td>
          <td style="width: 35%; vertical-align: top;">
            <div style="text-indent: -27pt; margin-left: 27pt;">3.&#160;&#160;&#160;&#160;&#160;&#160;&#160; la r&#233;mun&#233;ration variable maximale de la Direction ex&#233;cutive pour l'exercice en cours.</div>
          </td>
        </tr>
        <tr>
          <td style="width: 15%; vertical-align: top;" rowspan="1">&#160;</td>
          <td style="width: 35%; vertical-align: top;" rowspan="1">&#160;</td>
          <td style="width: 2%; vertical-align: top;" rowspan="1">&#160;</td>
          <td style="width: 13%; vertical-align: top;" rowspan="1">&#160;</td>
          <td style="width: 35%; vertical-align: top;" rowspan="1">&#160;</td>
        </tr>
        <tr>
          <td style="width: 15%; vertical-align: top;">&#160;</td>
          <td style="width: 35%; vertical-align: top;">
            <div><sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">2 </sup>The Board of Directors may submit for approval by the General Meeting of Shareholders deviating, additional or conditional proposals relating to the
              maximum aggregate amount or maximum partial amounts for the same or different periods and/or specific compensation components and/or in relation to additional amounts for specific compensation components.</div>
          </td>
          <td style="width: 2%; vertical-align: top;">&#160;</td>
          <td style="width: 13%; vertical-align: top;">&#160;</td>
          <td style="width: 35%; vertical-align: top;">
            <div><sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">2 </sup>Le Conseil d'administration peut soumettre &#224; l'approbation de l'Assembl&#233;e g&#233;n&#233;rale des propositions divergentes, suppl&#233;mentaires ou conditionnelles
              concernant le montant maximal total ou les montants maximaux partiels pour les m&#234;mes p&#233;riodes ou des p&#233;riodes diff&#233;rentes et/ou des &#233;l&#233;ments de r&#233;mun&#233;ration sp&#233;cifiques et/ou en relation avec des montants additionnels pour des &#233;l&#233;ments de
              r&#233;mun&#233;ration sp&#233;cifiques.</div>
          </td>
        </tr>
        <tr>
          <td style="width: 15%; vertical-align: top;" rowspan="1">&#160;</td>
          <td style="width: 35%; vertical-align: top;" rowspan="1">&#160;</td>
          <td style="width: 2%; vertical-align: top;" rowspan="1">&#160;</td>
          <td style="width: 13%; vertical-align: top;" rowspan="1">&#160;</td>
          <td style="width: 35%; vertical-align: top;" rowspan="1">&#160;</td>
        </tr>
        <tr>
          <td style="width: 15%; vertical-align: top;">&#160;</td>
          <td style="width: 35%; vertical-align: top;">
            <div><sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">3 </sup>In the event that the General Meeting of Shareholders does not approve a proposal of the Board of Directors, the Board of Directors shall determine, taking
              into account all relevant factors, the respective (maximum) aggregate amount or (maximum) partial amounts, and submit the amount(s) so determined for approval by a General Meeting of Shareholders.</div>
          </td>
          <td style="width: 2%; vertical-align: top;">&#160;</td>
          <td style="width: 13%; vertical-align: top;">&#160;</td>
          <td style="width: 35%; vertical-align: top;">
            <div><sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">3 </sup>Si l'Assembl&#233;e g&#233;n&#233;rale n'approuve pas une proposition du Conseil d'administration, le Conseil d'administration d&#233;termine, en prenant en compte tous les
              crit&#232;res pertinents, le montant (maximal) total ou des montants (maximaux) partiels respectifs, et soumet le(s) montant(s) ainsi d&#233;termin&#233;(s) &#224; l'approbation d'une Assembl&#233;e g&#233;n&#233;rale.</div>
          </td>
        </tr>
        <tr>
          <td style="width: 15%; vertical-align: top;" rowspan="1">&#160;</td>
          <td style="width: 35%; vertical-align: top;" rowspan="1">&#160;</td>
          <td style="width: 2%; vertical-align: top;" rowspan="1">&#160;</td>
          <td style="width: 13%; vertical-align: top;" rowspan="1">&#160;</td>
          <td style="width: 35%; vertical-align: top;" rowspan="1">&#160;</td>
        </tr>
        <tr>
          <td style="width: 15%; vertical-align: top;">&#160;</td>
          <td style="width: 35%; vertical-align: top;">
            <div><sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">4 </sup>The Company or companies controlled by it may pay or grant compensation prior to approval by the General Meeting of Shareholders, subject to subsequent
              approval.</div>
          </td>
          <td style="width: 2%; vertical-align: top;">&#160;</td>
          <td style="width: 13%; vertical-align: top;">&#160;</td>
          <td style="width: 35%; vertical-align: top;">
            <div><sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">4 </sup>La r&#233;mun&#233;ration peut &#234;tre vers&#233;e ou octroy&#233;e par la Soci&#233;t&#233; ou les soci&#233;t&#233;s qu'elle contr&#244;le avant l'approbation de l'Assembl&#233;e g&#233;n&#233;rale, sous r&#233;serve
              d'une approbation ult&#233;rieure.</div>
          </td>
        </tr>
        <tr>
          <td style="width: 15%; vertical-align: top;">&#160;</td>
          <td style="width: 35%; vertical-align: top;">&#160;</td>
          <td style="width: 2%; vertical-align: top;">&#160;</td>
          <td style="width: 13%; vertical-align: top;">&#160;</td>
          <td style="width: 35%; vertical-align: top;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 15%; vertical-align: top;">&#160;</td>
          <td style="width: 35%; vertical-align: top;">
            <div style="font-weight: bold;">Article 27</div>
          </td>
          <td style="width: 2%; vertical-align: top;">&#160;</td>
          <td style="width: 13%; vertical-align: top;">&#160;</td>
          <td style="width: 35%; vertical-align: top;">
            <div style="font-weight: bold;">Article 27</div>
          </td>
        </tr>
        <tr>
          <td style="width: 15%; vertical-align: top;" rowspan="1">&#160;</td>
          <td style="width: 35%; vertical-align: top;" rowspan="1">&#160;</td>
          <td style="width: 2%; vertical-align: top;" rowspan="1">&#160;</td>
          <td style="width: 13%; vertical-align: top;" rowspan="1">&#160;</td>
          <td style="width: 35%; vertical-align: top;" rowspan="1">&#160;</td>
        </tr>
        <tr>
          <td style="width: 15%; vertical-align: top;">
            <div>Supplementary </div>
            <div>Amount for </div>
            <div>Changes to the Ex</div>
            <div>ecutive Committee</div>
          </td>
          <td style="width: 35%; vertical-align: top;">
            <div>If the maximum aggregate amount of compensation already approved by the General Meeting of Shareholders is not sufficient to also cover the compensation of one or more persons who become members of the Executive Committee or are being
              promoted within the Executive Committee after the General Meeting of Shareholders has approved the compensation of the Executive Committee for the relevant period, then the Company or companies controlled by it shall be authorized to pay such
              member(s) a supplementary amount during the compensation period(s) already approved. The supplementary amount per compensation period per member shall not exceed 100% of the aggregate amount of (maximum) compensation of the Executive
              Committee last approved.</div>
          </td>
          <td style="width: 2%; vertical-align: top;">&#160;</td>
          <td style="width: 13%; vertical-align: top;">
            <div>Montant compl&#233;</div>
            <div>mentaire en cas de </div>
            <div>changements au </div>
            <div>sein de la Direction </div>
            <div>ex&#233;cutive</div>
          </td>
          <td style="width: 35%; vertical-align: top;">
            <div>Si le montant global maximal de la r&#233;mun&#233;ration d&#233;j&#224; approuv&#233; par l'Assembl&#233;e g&#233;n&#233;rale n'est pas suffisant pour couvrir &#233;galement la r&#233;mun&#233;ration d'une ou plusieurs personnes devenant membre(s) de la Direction ex&#233;cutive ou &#233;tant promue(s)
              au sein de la Direction ex&#233;cutive apr&#232;s que l'Assembl&#233;e g&#233;n&#233;rale a approuv&#233; la r&#233;mun&#233;ration de la Direction ex&#233;cutive pour la p&#233;riode vis&#233;e, la Soci&#233;t&#233; ou toute autre soci&#233;t&#233; qu'elle contr&#244;le est alors autoris&#233;e &#224; verser &#224; ce(s) membre(s) un
              montant compl&#233;mentaire au cours de la (ou les) p&#233;riode(s) de r&#233;mun&#233;ration d&#233;j&#224; approuv&#233;e(s). Le montant compl&#233;mentaire par p&#233;riode de compensation par membre ne doit pas d&#233;passer 100%<font style="font-weight: bold;">&#160;</font>du montant global
              de la r&#233;mun&#233;ration (maximale) de la Direction ex&#233;cutive approuv&#233;e en dernier.</div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div id="DSPFPageBreak" style="page-break-after:always;">
        <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
    </div>
    <table id="zca27b0d517ed45d79ec11ca9a1323a7f" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 15%; vertical-align: top;">&#160;</td>
          <td style="width: 35%; vertical-align: top;">
            <div style="font-weight: bold;">Article 28</div>
          </td>
          <td style="width: 2%; vertical-align: top;">&#160;</td>
          <td style="width: 13%; vertical-align: top;">&#160;</td>
          <td style="width: 35%; vertical-align: top;">
            <div style="font-weight: bold;">Article 28</div>
          </td>
        </tr>
        <tr>
          <td style="width: 15%; vertical-align: top;" rowspan="1">&#160;</td>
          <td style="width: 35%; vertical-align: top;" rowspan="1">&#160;</td>
          <td style="width: 2%; vertical-align: top;" rowspan="1">&#160;</td>
          <td style="width: 13%; vertical-align: top;" rowspan="1">&#160;</td>
          <td style="width: 35%; vertical-align: top;" rowspan="1">&#160;</td>
        </tr>
        <tr>
          <td style="width: 15%; vertical-align: top;">
            <div>General Compensa</div>
            <div>tion Principles</div>
          </td>
          <td style="width: 35%; vertical-align: top;">
            <div><sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">1 </sup>The compensation of the non-executive members of the Board of Directors may consist of fixed and variable compensation elements. Total compensation shall
              take into account the position and level of responsibility of the recipient.</div>
          </td>
          <td style="width: 2%; vertical-align: top;">&#160;</td>
          <td style="width: 13%; vertical-align: top;">
            <div>Principes g&#233;n&#233;raux </div>
            <div>de r&#233;mun&#233;ration</div>
          </td>
          <td style="width: 35%; vertical-align: top;">
            <div><sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">1 </sup>La r&#233;mun&#233;ration des membres non-ex&#233;cutifs du Conseil d'administration peut &#234;tre constitu&#233;e d'&#233;l&#233;ments de r&#233;mun&#233;rations fixes et variables. La r&#233;mun&#233;ration
              totale prend en compte la position et le niveau de responsabilit&#233; du b&#233;n&#233;ficiaire.</div>
          </td>
        </tr>
        <tr>
          <td style="width: 15%; vertical-align: top;">&#160;</td>
          <td style="width: 35%; vertical-align: top;" rowspan="1">&#160;</td>
          <td style="width: 2%; vertical-align: top;" rowspan="1">&#160;</td>
          <td style="width: 13%; vertical-align: top;">&#160;</td>
          <td style="width: 35%; vertical-align: top;" rowspan="1">&#160;</td>
        </tr>
        <tr>
          <td style="width: 15%; vertical-align: top;">&#160;</td>
          <td style="width: 35%; vertical-align: top;">
            <div><sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">2 </sup>The compensation of the members of the Executive Committee may consist of fixed and variable compensation elements. Fixed compensation comprises the base
              salary and may consist of other compensation elements. Variable compensation may take into account the achievement of specific performance targets. Total compensation shall take into account the position and level of responsibility of the
              recipient.</div>
          </td>
          <td style="width: 2%; vertical-align: top;">&#160;</td>
          <td style="width: 13%; vertical-align: top;">&#160;</td>
          <td style="width: 35%; vertical-align: top;">
            <div><sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">2 </sup>La r&#233;mun&#233;ration des membres de la Direction ex&#233;cutive peut &#234;tre constitu&#233;e d'&#233;l&#233;ments de r&#233;mun&#233;ration fixes et variables. La r&#233;mun&#233;ration fixe comprend le
              salaire de base et peut &#234;tre constitu&#233;e d'autres &#233;l&#233;ments de r&#233;mun&#233;ration. La r&#233;mun&#233;ration variable peut prendre en compte l'accomplissement d'objectifs de performance sp&#233;cifiques. La r&#233;mun&#233;ration totale prend en compte la position et le
              niveau de responsabilit&#233; du b&#233;n&#233;ficiaire.</div>
          </td>
        </tr>
        <tr>
          <td style="width: 15%; vertical-align: top;" rowspan="1">&#160;</td>
          <td style="width: 35%; vertical-align: top;" rowspan="1">&#160;</td>
          <td style="width: 2%; vertical-align: top;" rowspan="1">&#160;</td>
          <td style="width: 13%; vertical-align: top;" rowspan="1">&#160;</td>
          <td style="width: 35%; vertical-align: top;" rowspan="1">&#160;</td>
        </tr>
        <tr>
          <td style="width: 15%; vertical-align: top;">&#160;</td>
          <td style="width: 35%; vertical-align: top;">
            <div><sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">3 </sup>The performance targets may include individual targets, targets of the Company, group or parts thereof or targets in relation to the market, other
              companies or comparable benchmarks, taking into account the position and level of responsibility of the recipient. The Board of Directors or, to the extent delegated to it, the Compensation Committee shall determine the relative weight of the
              performance targets and the respective target values.</div>
          </td>
          <td style="width: 2%; vertical-align: top;">&#160;</td>
          <td style="width: 13%; vertical-align: top;">&#160;</td>
          <td style="width: 35%; vertical-align: top;">
            <div><sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">3 </sup>Les objectifs de performance peuvent comprendre des objectifs personnels, des objectifs li&#233;s &#224; la performance de la Soci&#233;t&#233; ou de tout ou partie du groupe
              ou des buts en relation avec le march&#233;, d'autres soci&#233;t&#233;s ou d'autres rep&#232;res comparables, prenant en compte la position et le niveau de responsabilit&#233; du b&#233;n&#233;ficiaire. Le Conseil d'administration ou le Comit&#233; de r&#233;mun&#233;ration, dans la mesure
              o&#249; cette comp&#233;tence lui est d&#233;l&#233;gu&#233;e, d&#233;termine le poids relatif des objectifs de performance et les valeurs cibles respectives.</div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div id="DSPFPageBreak" style="page-break-after:always;">
        <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
    </div>
    <table id="z511f853343f34c00b14706d50d3b9a2d" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 15%; vertical-align: top;">&#160;</td>
          <td style="width: 35%; vertical-align: top;">
            <div><sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">4 </sup>Compensation may be paid in the form of cash, shares, options or other share-based instruments or units, or in the form of other types of benefits. The
              Board of Directors or, to the extent delegated to it, the Compensation Committee shall determine grant, vesting, exercise, restriction and forfeiture conditions and periods. In particular, they may provide for continuation, acceleration or
              removal of vesting, exercise, restriction and forfeiture conditions and periods, for payment or grant of compensation based upon assumed target achievement, or for forfeiture, in each case in the event of pre-determined events such as a
              change of control or termination of an employment or mandate agreement. The Company may procure the required shares or other securities through purchases in the market, from treasury shares or by using conditional or authorized share capital.</div>
          </td>
          <td style="width: 2%; vertical-align: top;">&#160;</td>
          <td style="width: 13%; vertical-align: top;">&#160;</td>
          <td style="width: 35%; vertical-align: top;">
            <div><sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">4 </sup>La r&#233;mun&#233;ration peut &#234;tre vers&#233;e en esp&#232;ces, sous forme d'actions, d'options ou d'instruments ou unit&#233;s sur base d'actions ou d'autres types de
              prestations. Le Conseil d'administration ou le Comit&#233; de r&#233;mun&#233;ration, dans la mesure o&#249; cette comp&#233;tence lui a &#233;t&#233; d&#233;l&#233;gu&#233;e, d&#233;termine les conditions et p&#233;riodes d'octroi, d'acquisition (<font style="font-style: italic;">vesting</font>),
              d'exercice, de restriction et de p&#233;remption. Ils peuvent en particulier pr&#233;voir la continuation, l'acc&#233;l&#233;ration ou la suppression des conditions ou p&#233;riodes d'acquisition (<font style="font-style: italic;">vesting</font>), d'exercice, de
              restriction et de p&#233;remption, le versement ou l'octroi d'une r&#233;mun&#233;ration supposant l'atteinte des objectifs ou encore la d&#233;ch&#233;ance des droits, dans chaque cas lors d'&#233;v&#233;nements pr&#233;d&#233;termin&#233;s tels que, notamment, un changement de contr&#244;le ou
              la fin d'un contrat de travail ou de mandat. La Soci&#233;t&#233; peut se procurer les actions ou autres instruments des march&#233;s financiers requis par le biais d'achats sur le march&#233; ou d'actions propres, ou en utilisant son capital-actions
              conditionnel ou autoris&#233;.</div>
          </td>
        </tr>
        <tr>
          <td style="width: 15%; vertical-align: top;" rowspan="1">&#160;</td>
          <td style="width: 35%; vertical-align: top;" rowspan="1">&#160;</td>
          <td style="width: 2%; vertical-align: top;" rowspan="1">&#160;</td>
          <td style="width: 13%; vertical-align: top;" rowspan="1">&#160;</td>
          <td style="width: 35%; vertical-align: top;" rowspan="1">&#160;</td>
        </tr>
        <tr>
          <td style="width: 15%; vertical-align: top;">&#160;</td>
          <td style="width: 35%; vertical-align: top;">
            <div><sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">5 </sup>Compensation may be paid by the Company or companies controlled by it.</div>
          </td>
          <td style="width: 2%; vertical-align: top;">&#160;</td>
          <td style="width: 13%; vertical-align: top;">&#160;</td>
          <td style="width: 35%; vertical-align: top;">
            <div><sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">5 </sup>La r&#233;mun&#233;ration peut &#234;tre vers&#233;e par la Soci&#233;t&#233; ou tout autre soci&#233;t&#233; qu'elle contr&#244;le.</div>
          </td>
        </tr>
        <tr>
          <td style="width: 15%; vertical-align: top;">&#160;</td>
          <td style="width: 35%; vertical-align: top;">&#160;</td>
          <td style="width: 2%; vertical-align: top;">&#160;</td>
          <td style="width: 13%; vertical-align: top;">&#160;</td>
          <td style="width: 35%; vertical-align: top;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 15%; vertical-align: top;">&#160;</td>
          <td style="width: 35%; vertical-align: top;">
            <div style="font-weight: bold;">Article 29</div>
          </td>
          <td style="width: 2%; vertical-align: top;">&#160;</td>
          <td style="width: 13%; vertical-align: top;">&#160;</td>
          <td style="width: 35%; vertical-align: top;">
            <div style="font-weight: bold;">Article 29</div>
          </td>
        </tr>
        <tr>
          <td style="width: 15%; vertical-align: top;" rowspan="1">&#160;</td>
          <td style="width: 35%; vertical-align: top;" rowspan="1">&#160;</td>
          <td style="width: 2%; vertical-align: top;" rowspan="1">&#160;</td>
          <td style="width: 13%; vertical-align: top;" rowspan="1">&#160;</td>
          <td style="width: 35%; vertical-align: top;" rowspan="1">&#160;</td>
        </tr>
        <tr>
          <td style="width: 15%; vertical-align: top;">
            <div>Agreements with </div>
            <div>Members of the </div>
            <div>Board of Directors</div>
            <div> and the Executive </div>
            <div>Committee</div>
          </td>
          <td style="width: 35%; vertical-align: top;">
            <div><sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">1 </sup>The Company or companies controlled by it may enter into agreements with non-executive members of the Board of Directors relating to their compensation for
              a fixed term or for an indefinite term. The duration and termination are subject to the term of office and the law.</div>
          </td>
          <td style="width: 2%; vertical-align: top;">&#160;</td>
          <td style="width: 13%; vertical-align: top;">
            <div>Contrats avec les</div>
            <div> membres du Con</div>
            <div>seil d'administration </div>
            <div>et de la Direction </div>
            <div>ex&#233;cutive</div>
          </td>
          <td style="width: 35%; vertical-align: top;">
            <div><sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">1 </sup>La Soci&#233;t&#233;, ou toute soci&#233;t&#233; qu'elle contr&#244;le, peut conclure des contrats de dur&#233;e d&#233;termin&#233;e ou ind&#233;termin&#233;e avec les membres non-ex&#233;cutifs du Conseil
              d'administration en relation avec leur r&#233;mun&#233;ration. La dur&#233;e et la r&#233;siliation doivent &#234;tre conformes avec la dur&#233;e des fonctions ainsi qu'avec les dispositions l&#233;gales applicables.</div>
          </td>
        </tr>
        <tr>
          <td style="width: 15%; vertical-align: top;" rowspan="1">&#160;</td>
          <td style="width: 35%; vertical-align: top;" rowspan="1">&#160;</td>
          <td style="width: 2%; vertical-align: top;" rowspan="1">&#160;</td>
          <td style="width: 13%; vertical-align: top;" rowspan="1">&#160;</td>
          <td style="width: 35%; vertical-align: top;" rowspan="1">&#160;</td>
        </tr>
        <tr>
          <td style="width: 15%; vertical-align: top;">&#160;</td>
          <td style="width: 35%; vertical-align: top;">
            <div><sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">2 </sup>The Company or companies controlled by it may enter into employment agreements with executive members of the Board of Directors and other members of the
              Executive Committee for a fixed term or for an indefinite term. Fixed term agreements may have a maximum duration of one year; renewal is possible. Agreements for an indefinite term may have a notice period of maximum twelve months.</div>
          </td>
          <td style="width: 2%; vertical-align: top;">&#160;</td>
          <td style="width: 13%; vertical-align: top;">&#160;</td>
          <td style="width: 35%; vertical-align: top;">
            <div><sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">2 </sup>La Soci&#233;t&#233;, ou toute soci&#233;t&#233; qu'elle contr&#244;le, peut conclure des contrats de travail de dur&#233;e d&#233;termin&#233;e ou ind&#233;termin&#233;e avec les membres ex&#233;cutifs du
              conseil d'administration et les autres membres de la Direction ex&#233;cutive. Les contrats de dur&#233;e d&#233;termin&#233;e peuvent avoir une dur&#233;e maximale d'une ann&#233;e; le renouvellement est possible. Les contrats de dur&#233;e ind&#233;termin&#233;e peuvent pr&#233;voir un
              d&#233;lai de cong&#233; d'au maximum douze mois.</div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div id="DSPFPageBreak" style="page-break-after:always;">
        <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
    </div>
    <table id="zef979c58c0684895aad8a3329c8de553" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 15%; vertical-align: top;">&#160;</td>
          <td style="width: 35%; vertical-align: top;">
            <div><sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">3 </sup>The Company or companies controlled by it may enter into non-compete agreements with members of the Executive Committee for the time after termination of
              employment. Their duration shall not exceed two years, and consideration paid per year for such non-compete undertaking shall not exceed the sum of the total annual compensation of such member last paid or payable for the first time.</div>
          </td>
          <td style="width: 2%; vertical-align: top;">&#160;</td>
          <td style="width: 13%; vertical-align: top;">&#160;</td>
          <td style="width: 35%; vertical-align: top;">
            <div><sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">3 </sup>La Soci&#233;t&#233;, ou toute soci&#233;t&#233; qu'elle contr&#244;le, peut conclure des accords de non-concurrence avec les membres de la Direction ex&#233;cutive pour la p&#233;riode
              suivant la fin des rapports de travail. Leur dur&#233;e ne peut exc&#233;der deux ans, et l'indemnisation par an vers&#233;e en contrepartie d'un tel accord de non concurrence ne peut exc&#233;der la somme de la derni&#232;re r&#233;mun&#233;ration annuelle totale vers&#233;e ou &#224;
              verser pour la premi&#232;re fois au membre concern&#233;.</div>
          </td>
        </tr>
        <tr>
          <td style="width: 15%; vertical-align: top;">&#160;</td>
          <td style="width: 35%; vertical-align: top;">&#160;</td>
          <td style="width: 2%; vertical-align: top;">&#160;</td>
          <td style="width: 13%; vertical-align: top;">&#160;</td>
          <td style="width: 35%; vertical-align: top;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 15%; vertical-align: top;">&#160;</td>
          <td style="width: 35%; vertical-align: top;">
            <div style="font-weight: bold;">Article 30</div>
          </td>
          <td style="width: 2%; vertical-align: top;">&#160;</td>
          <td style="width: 13%; vertical-align: top;">&#160;</td>
          <td style="width: 35%; vertical-align: top;">
            <div style="font-weight: bold;">Article 30</div>
          </td>
        </tr>
        <tr>
          <td style="width: 15%; vertical-align: top;" rowspan="1">&#160;</td>
          <td style="width: 35%; vertical-align: top;" rowspan="1">&#160;</td>
          <td style="width: 2%; vertical-align: top;" rowspan="1">&#160;</td>
          <td style="width: 13%; vertical-align: top;" rowspan="1">&#160;</td>
          <td style="width: 35%; vertical-align: top;" rowspan="1">&#160;</td>
        </tr>
        <tr>
          <td style="width: 15%; vertical-align: top;">
            <div>Mandates Outside</div>
            <div> of the Group</div>
          </td>
          <td style="width: 35%; vertical-align: top;">
            <div><sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">1</sup> The number of mandates on the board of directors or the executive committee of legal entities that have to be registered in a Swiss commercial register or a
              similar foreign register outside the group is limited:</div>
          </td>
          <td style="width: 2%; vertical-align: top;">&#160;</td>
          <td style="width: 13%; vertical-align: top;">
            <div>Mandats en dehors </div>
            <div>du groupe</div>
          </td>
          <td style="width: 35%; vertical-align: top;">
            <div><sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">1 </sup>Le nombre de mandats d'administrateur et/ou au sein de la Direction ex&#233;cutive d'entit&#233;s juridiques tenues d'&#234;tre inscrites au registre du commerce suisse
              ou dans un registre similaire &#233;tranger est limit&#233;:</div>
          </td>
        </tr>
        <tr>
          <td style="width: 15%; vertical-align: top;" rowspan="1">&#160;</td>
          <td style="width: 35%; vertical-align: top;" rowspan="1">&#160;</td>
          <td style="width: 2%; vertical-align: top;" rowspan="1">&#160;</td>
          <td style="width: 13%; vertical-align: top;" rowspan="1">&#160;</td>
          <td style="width: 35%; vertical-align: top;" rowspan="1">&#160;</td>
        </tr>
        <tr>
          <td style="width: 15%; vertical-align: top; text-indent: -27pt; margin-left: 27pt;">&#160;</td>
          <td style="width: 35%; vertical-align: top;">
            <div style="text-indent: -27pt; margin-left: 27pt;">(a)&#160;&#160;&#160;&#160;&#160; for members of the Executive Committee, to seven mandates, of which no more than two in a listed company; and</div>
          </td>
          <td style="width: 2%; vertical-align: top; text-indent: -27pt; margin-left: 27pt;">&#160;</td>
          <td style="width: 13%; vertical-align: top; text-indent: -27pt; margin-left: 27pt;">&#160;</td>
          <td style="width: 35%; vertical-align: top;">
            <div style="text-indent: -27pt; margin-left: 27pt;">(a)&#160;&#160;&#160;&#160;&#160; pour les membres de la Direction ex&#233;cutive, &#224; sept mandats, dont pas plus de deux au sein de soci&#233;t&#233;s cot&#233;es; et</div>
          </td>
        </tr>
        <tr>
          <td style="width: 15%; vertical-align: top; text-indent: -27pt; margin-left: 27pt;" rowspan="1">&#160;</td>
          <td style="width: 35%; vertical-align: top; text-indent: -27pt; margin-left: 27pt;" rowspan="1">&#160;</td>
          <td style="width: 2%; vertical-align: top; text-indent: -27pt; margin-left: 27pt;" rowspan="1">&#160;</td>
          <td style="width: 13%; vertical-align: top; text-indent: -27pt; margin-left: 27pt;" rowspan="1">&#160;</td>
          <td style="width: 35%; vertical-align: top; text-indent: -27pt; margin-left: 27pt;" rowspan="1">&#160;</td>
        </tr>
        <tr>
          <td style="width: 15%; vertical-align: top; text-indent: -27pt; margin-left: 27pt;">&#160;</td>
          <td style="width: 35%; vertical-align: top;">
            <div style="text-indent: -27pt; margin-left: 27pt;">(b)&#160;&#160;&#160;&#160;&#160; for members of the Board of Directors, to fifteen mandates, of which no more than five in listed companies.</div>
          </td>
          <td style="width: 2%; vertical-align: top; text-indent: -27pt; margin-left: 27pt;">&#160;</td>
          <td style="width: 13%; vertical-align: top; text-indent: -27pt; margin-left: 27pt;">&#160;</td>
          <td style="width: 35%; vertical-align: top;">
            <div style="text-indent: -27pt; margin-left: 27pt;">(b)&#160;&#160;&#160;&#160;&#160; pour les membres du Conseil d'administration &#224; quinze mandats, dont pas plus de cinq au sein de soci&#233;t&#233;s cot&#233;es.</div>
          </td>
        </tr>
        <tr>
          <td style="width: 15%; vertical-align: top;" rowspan="1">&#160;</td>
          <td style="width: 35%; vertical-align: top;" rowspan="1">&#160;</td>
          <td style="width: 2%; vertical-align: top;" rowspan="1">&#160;</td>
          <td style="width: 13%; vertical-align: top;" rowspan="1">&#160;</td>
          <td style="width: 35%; vertical-align: top;" rowspan="1">&#160;</td>
        </tr>
        <tr>
          <td style="width: 15%; vertical-align: top;">&#160;</td>
          <td style="width: 35%; vertical-align: top;">
            <div><sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">2 </sup>Mandates in different legal entities being part of the same group or for the same group are deemed to be one mandate.</div>
          </td>
          <td style="width: 2%; vertical-align: top;">&#160;</td>
          <td style="width: 13%; vertical-align: top;">&#160;</td>
          <td style="width: 35%; vertical-align: top;">
            <div><sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">2 </sup>Les mandats dans diff&#233;rentes entit&#233;s juridiques appartenant au m&#234;me groupe ou assum&#233;s pour le m&#234;me groupe sont consid&#233;r&#233;s comme un mandat.</div>
          </td>
        </tr>
        <tr>
          <td style="width: 15%; vertical-align: top;" rowspan="1">&#160;</td>
          <td style="width: 35%; vertical-align: top;" rowspan="1">&#160;</td>
          <td style="width: 2%; vertical-align: top;" rowspan="1">&#160;</td>
          <td style="width: 13%; vertical-align: top;" rowspan="1">&#160;</td>
          <td style="width: 35%; vertical-align: top;" rowspan="1">&#160;</td>
        </tr>
        <tr>
          <td style="width: 15%; vertical-align: top;">&#160;</td>
          <td style="width: 35%; vertical-align: top;">
            <div><sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">3 </sup>Mandates in associations, charitable organizations, family trusts and foundations relating to post-retirement benefits are not subject to the above
              limitations. No member of the Board of Directors or the Executive Committee shall hold more than 10 such mandates.</div>
          </td>
          <td style="width: 2%; vertical-align: top;">&#160;</td>
          <td style="width: 13%; vertical-align: top;">&#160;</td>
          <td style="width: 35%; vertical-align: top;">
            <div><sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">3 </sup>Les mandats dans des associations, organisations caritatives, fondations de famille et fondations de pr&#233;voyance professionnelle ne sont pas soumis aux
              limites mentionn&#233;es ci-dessus. Aucun membre du Conseil d'administration ou de la Direction ex&#233;cutive ne peut exercer plus de 10<font style="font-weight: bold;">&#160;</font>mandats de ce genre.</div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div id="DSPFPageBreak" style="page-break-after:always;">
        <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
    </div>
    <table id="ze3fdbc4810044f58bdac3d568c842d02" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 15%; vertical-align: top;">&#160;</td>
          <td style="width: 35%; vertical-align: top;">
            <div style="font-weight: bold;">Article 31</div>
          </td>
          <td style="width: 2%; vertical-align: top;">&#160;</td>
          <td style="width: 13%; vertical-align: top;">&#160;</td>
          <td style="width: 35%; vertical-align: top;">
            <div style="font-weight: bold;">Article 31</div>
          </td>
        </tr>
        <tr>
          <td style="width: 15%; vertical-align: top;" rowspan="1">&#160;</td>
          <td style="width: 35%; vertical-align: top;" rowspan="1">&#160;</td>
          <td style="width: 2%; vertical-align: top;" rowspan="1">&#160;</td>
          <td style="width: 13%; vertical-align: top;" rowspan="1">&#160;</td>
          <td style="width: 35%; vertical-align: top;" rowspan="1">&#160;</td>
        </tr>
        <tr>
          <td style="width: 15%; vertical-align: top;">
            <div>Post-Retirement </div>
            <div>Benefits</div>
          </td>
          <td style="width: 35%; vertical-align: top;">
            <div>The Company or companies controlled by it may grant to members of the Board of Directors and the Executive Committee post-retirement benefits beyond the occupational benefit schemes which do not exceed the annual compensation of the
              respective member of the Board of Directors or the Executive Committee last paid or payable for the first time.</div>
          </td>
          <td style="width: 2%; vertical-align: top;">&#160;</td>
          <td style="width: 13%; vertical-align: top;">
            <div>Prestations de re</div>
            <div>traite</div>
          </td>
          <td style="width: 35%; vertical-align: top;">
            <div>La Soci&#233;t&#233; ou toute soci&#233;t&#233; qu'elle contr&#244;le peut octroyer aux membres du Conseil d'administration et de la Direction ex&#233;cutive des prestations de retraite allant au-del&#224; du r&#233;gime de pr&#233;voyance professionnelle n'exc&#233;dant pas la
              r&#233;mun&#233;ration annuelle<font style="font-weight: bold;">&#160;</font>du membre du Conseil d'administration ou de la Direction ex&#233;cutive concern&#233; vers&#233;e ou &#224; verser pour la premi&#232;re fois.</div>
          </td>
        </tr>
        <tr>
          <td style="width: 15%; vertical-align: top;">&#160;</td>
          <td style="width: 35%; vertical-align: top;">&#160;</td>
          <td style="width: 2%; vertical-align: top;">&#160;</td>
          <td style="width: 13%; vertical-align: top;">&#160;</td>
          <td style="width: 35%; vertical-align: top;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 15%; vertical-align: top;">&#160;</td>
          <td style="width: 35%; vertical-align: top;">&#160;</td>
          <td style="width: 2%; vertical-align: top;">&#160;</td>
          <td style="width: 13%; vertical-align: top;">&#160;</td>
          <td style="width: 35%; vertical-align: top;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 15%; vertical-align: top;">&#160;</td>
          <td style="width: 35%; vertical-align: top; border-top: 2px solid rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0);">
            <div style="font-weight: bold;">Section 5</div>
            <div style="font-style: italic;">Financial Year, Profit Allocation</div>
            <div style="font-style: italic;"> <br>
            </div>
          </td>
          <td style="width: 2%; vertical-align: top;">&#160;</td>
          <td style="width: 13%; vertical-align: top;">&#160;</td>
          <td style="width: 35%; vertical-align: top; border-top: 2px solid rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0);">
            <div style="font-weight: bold;">Section 5</div>
            <div style="font-style: italic;">Exercice, r&#233;partition du b&#233;n&#233;fice</div>
          </td>
        </tr>
        <tr>
          <td style="width: 15%; vertical-align: top;">&#160;</td>
          <td style="width: 35%; vertical-align: top; border-top: 2px solid rgb(0, 0, 0);">&#160;</td>
          <td style="width: 2%; vertical-align: top;">&#160;</td>
          <td style="width: 13%; vertical-align: top;">&#160;</td>
          <td style="width: 35%; vertical-align: top; border-top: 2px solid rgb(0, 0, 0);">&#160;</td>
        </tr>
        <tr>
          <td style="width: 15%; vertical-align: top;">&#160;</td>
          <td style="width: 35%; vertical-align: top;">
            <div style="font-weight: bold;">Article 32</div>
          </td>
          <td style="width: 2%; vertical-align: top;">&#160;</td>
          <td style="width: 13%; vertical-align: top;">&#160;</td>
          <td style="width: 35%; vertical-align: top;">
            <div style="font-weight: bold;">Article 32</div>
          </td>
        </tr>
        <tr>
          <td style="width: 15%; vertical-align: top;" rowspan="1">&#160;</td>
          <td style="width: 35%; vertical-align: top;" rowspan="1">&#160;</td>
          <td style="width: 2%; vertical-align: top;" rowspan="1">&#160;</td>
          <td style="width: 13%; vertical-align: top;" rowspan="1">&#160;</td>
          <td style="width: 35%; vertical-align: top;" rowspan="1">&#160;</td>
        </tr>
        <tr>
          <td style="width: 15%; vertical-align: top;">
            <div>Financial Year, An</div>
            <div>nual and Compen</div>
            <div>sation Report</div>
          </td>
          <td style="width: 35%; vertical-align: top;">
            <div><sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">1 </sup>The Company's financial year shall be determined by the Board of Directors.</div>
          </td>
          <td style="width: 2%; vertical-align: top;">&#160;</td>
          <td style="width: 13%; vertical-align: top;">
            <div>Exercice social, rap</div>
            <div>port de gestion et de </div>
            <div>r&#233;mun&#233;ration</div>
          </td>
          <td style="width: 35%; vertical-align: top;">
            <div><sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">1 </sup>L'exercice est fix&#233; par le Conseil d'administration.</div>
            <div>&#160;</div>
          </td>
        </tr>
        <tr>
          <td style="width: 15%; vertical-align: top;">&#160;</td>
          <td style="width: 35%; vertical-align: top;" rowspan="1">&#160;</td>
          <td style="width: 2%; vertical-align: top;" rowspan="1">&#160;</td>
          <td style="width: 13%; vertical-align: top;">&#160;</td>
          <td style="width: 35%; vertical-align: top;" rowspan="1">&#160;</td>
        </tr>
        <tr>
          <td style="width: 15%; vertical-align: top;">&#160;</td>
          <td style="width: 35%; vertical-align: top;">
            <div><sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">2</sup> The Board of Directors shall prepare an annual report for each financial year, comprising the annual financial statements, if required, the management
              report and the consolidated financial statements, as well as a compensation report.</div>
          </td>
          <td style="width: 2%; vertical-align: top;">&#160;</td>
          <td style="width: 13%; vertical-align: top;">&#160;</td>
          <td style="width: 35%; vertical-align: top;">
            <div><sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">2</sup> Le Conseil d'administration &#233;tablit pour chaque exercice un rapport de gestion, qui se compose des comptes annuels et, cas &#233;ch&#233;ant, du rapport annuel et des
              comptes de groupe, ainsi qu'un rapport de r&#233;mun&#233;ration.</div>
          </td>
        </tr>
        <tr>
          <td style="width: 15%; vertical-align: top;">&#160;</td>
          <td style="width: 35%; vertical-align: top;">&#160;</td>
          <td style="width: 2%; vertical-align: top;">&#160;</td>
          <td style="width: 13%; vertical-align: top;">&#160;</td>
          <td style="width: 35%; vertical-align: top;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 15%; vertical-align: top;">&#160;</td>
          <td style="width: 35%; vertical-align: top;">
            <div style="font-weight: bold;">Article 33</div>
          </td>
          <td style="width: 2%; vertical-align: top;">&#160;</td>
          <td style="width: 13%; vertical-align: top;">&#160;</td>
          <td style="width: 35%; vertical-align: top;">
            <div style="font-weight: bold;">Article 33</div>
          </td>
        </tr>
        <tr>
          <td style="width: 15%; vertical-align: top;" rowspan="1">&#160;</td>
          <td style="width: 35%; vertical-align: top;" rowspan="1">&#160;</td>
          <td style="width: 2%; vertical-align: top;" rowspan="1">&#160;</td>
          <td style="width: 13%; vertical-align: top;" rowspan="1">&#160;</td>
          <td style="width: 35%; vertical-align: top;" rowspan="1">&#160;</td>
        </tr>
        <tr>
          <td style="width: 15%; vertical-align: top;">
            <div>Allocation of Profit </div>
            <div>Shown on the Bal</div>
            <div>ance Sheet, Re</div>
            <div>serves</div>
          </td>
          <td style="width: 35%; vertical-align: top;">
            <div><sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">1 </sup>The General Meeting of Shareholders shall resolve on the allocation of the profit as shown on the balance sheet in accordance with applicable law. The
              Board of Directors shall submit its proposals to the General Meeting of Shareholders.</div>
          </td>
          <td style="width: 2%; vertical-align: top;">&#160;</td>
          <td style="width: 13%; vertical-align: top;">
            <div>Utilisation du b&#233;n&#233;</div>
            <div>fice r&#233;sultant du</div>
            <div> bilan, r&#233;serves</div>
          </td>
          <td style="width: 35%; vertical-align: top;">
            <div><sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">1 </sup>L'Assembl&#233;e g&#233;n&#233;rale d&#233;termine l'emploi du b&#233;n&#233;fice r&#233;sultant du bilan, sous r&#233;serve des prescriptions l&#233;gales concernant la r&#233;partition du b&#233;n&#233;fice. Le
              Conseil d'administration lui soumet ses propositions.</div>
          </td>
        </tr>
        <tr>
          <td style="width: 15%; vertical-align: top;">&#160;</td>
          <td style="width: 35%; vertical-align: top;" rowspan="1">&#160;</td>
          <td style="width: 2%; vertical-align: top;" rowspan="1">&#160;</td>
          <td style="width: 13%; vertical-align: top;">&#160;</td>
          <td style="width: 35%; vertical-align: top;" rowspan="1">&#160;</td>
        </tr>
        <tr>
          <td style="width: 15%; vertical-align: top;">&#160;</td>
          <td style="width: 35%; vertical-align: top;">
            <div><sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">2</sup> In addition to the reserves required by law, the General Meeting of Shareholders may create other reserves.</div>
          </td>
          <td style="width: 2%; vertical-align: top;">&#160;</td>
          <td style="width: 13%; vertical-align: top;">&#160;</td>
          <td style="width: 35%; vertical-align: top;">
            <div><sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">2</sup> En sus des r&#233;serves l&#233;gales, l'Assembl&#233;e g&#233;n&#233;rale peut constituer des r&#233;serves suppl&#233;mentaires.</div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div id="DSPFPageBreak" style="page-break-after:always;">
        <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
    </div>
    <table id="z2855446513ac432d8506f4e3ee1e90f8" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 15%; vertical-align: top;">&#160;</td>
          <td style="width: 35%; vertical-align: top;">
            <div><sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">3 </sup>Dividends that have not been collected within five years after their payment date shall inure to the Company and be allocated to the general statutory
              reserves.</div>
          </td>
          <td style="width: 2%; vertical-align: top;">&#160;</td>
          <td style="width: 13%; vertical-align: top;">&#160;</td>
          <td style="width: 35%; vertical-align: top;">
            <div><sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">3 </sup>Les dividendes qui n'ont pas &#233;t&#233; per&#231;us dans un d&#233;lai de cinq ans apr&#232;s leur date de paiement sont prescrits et sont allou&#233;s aux r&#233;serves statutaires de la
              Soci&#233;t&#233;.</div>
          </td>
        </tr>
        <tr>
          <td style="width: 15%; vertical-align: top;">&#160;</td>
          <td style="width: 35%; vertical-align: top;">&#160;</td>
          <td style="width: 2%; vertical-align: top;">&#160;</td>
          <td style="width: 13%; vertical-align: top;">&#160;</td>
          <td style="width: 35%; vertical-align: top;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 15%; vertical-align: top;">&#160;</td>
          <td style="width: 35%; vertical-align: top; border-top: 2px solid rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0);">
            <div style="font-weight: bold;">Section 6</div>
            <div style="font-style: italic;">Dissolution, Liquidation</div>
            <div style="font-style: italic;"> <br>
            </div>
          </td>
          <td style="width: 2%; vertical-align: top;">&#160;</td>
          <td style="width: 13%; vertical-align: top;">&#160;</td>
          <td style="width: 35%; vertical-align: top; border-top: 2px solid rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0);">
            <div style="font-weight: bold;">Section 6</div>
            <div style="font-style: italic;">Dissolution, liquidation</div>
          </td>
        </tr>
        <tr>
          <td style="width: 15%; vertical-align: top;">&#160;</td>
          <td style="width: 35%; vertical-align: top; border-top: 2px solid rgb(0, 0, 0);">&#160;</td>
          <td style="width: 2%; vertical-align: top;">&#160;</td>
          <td style="width: 13%; vertical-align: top;">&#160;</td>
          <td style="width: 35%; vertical-align: top; border-top: 2px solid rgb(0, 0, 0);">&#160;</td>
        </tr>
        <tr>
          <td style="width: 15%; vertical-align: top;">&#160;</td>
          <td style="width: 35%; vertical-align: top;">
            <div style="font-weight: bold;">Article 34</div>
          </td>
          <td style="width: 2%; vertical-align: top;">&#160;</td>
          <td style="width: 13%; vertical-align: top;">&#160;</td>
          <td style="width: 35%; vertical-align: top;">
            <div style="font-weight: bold;">Article 34</div>
          </td>
        </tr>
        <tr>
          <td style="width: 15%; vertical-align: top;" rowspan="1">&#160;</td>
          <td style="width: 35%; vertical-align: top;" rowspan="1">&#160;</td>
          <td style="width: 2%; vertical-align: top;" rowspan="1">&#160;</td>
          <td style="width: 13%; vertical-align: top;" rowspan="1">&#160;</td>
          <td style="width: 35%; vertical-align: top;" rowspan="1">&#160;</td>
        </tr>
        <tr>
          <td style="width: 15%; vertical-align: top;">
            <div>Dissolution, Liquida</div>
            <div>tion</div>
          </td>
          <td style="width: 35%; vertical-align: top;">
            <div><sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">1 </sup>The General Meeting of Shareholders may at any time resolve to dissolve and liquidate the Company in accordance with the law and the provisions set forth
              in these articles of association.</div>
          </td>
          <td style="width: 2%; vertical-align: top;">&#160;</td>
          <td style="width: 13%; vertical-align: top;">
            <div>Dissolution, liquida</div>
            <div>tion</div>
          </td>
          <td style="width: 35%; vertical-align: top;">
            <div><sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">1 </sup>L'Assembl&#233;e g&#233;n&#233;rale peut d&#233;cider en tout temps de la dissolution et de la liquidation de la Soci&#233;t&#233; en conformit&#233; avec les prescriptions l&#233;gales et
              statutaires.</div>
          </td>
        </tr>
        <tr>
          <td style="width: 15%; vertical-align: top;" rowspan="1">&#160;</td>
          <td style="width: 35%; vertical-align: top;" rowspan="1">&#160;</td>
          <td style="width: 2%; vertical-align: top;" rowspan="1">&#160;</td>
          <td style="width: 13%; vertical-align: top;" rowspan="1">&#160;</td>
          <td style="width: 35%; vertical-align: top;" rowspan="1">&#160;</td>
        </tr>
        <tr>
          <td style="width: 15%; vertical-align: top;">&#160;</td>
          <td style="width: 35%; vertical-align: top;">
            <div><sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">2</sup> The liquidation shall be effected by the Board of Directors, unless the General Meeting of Shareholders appoints other persons as liquidators.</div>
          </td>
          <td style="width: 2%; vertical-align: top;">&#160;</td>
          <td style="width: 13%; vertical-align: top;">&#160;</td>
          <td style="width: 35%; vertical-align: top;">
            <div><sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">2</sup> La liquidation a lieu par les soins du Conseil d'administration, &#224; moins que l'Assembl&#233;e g&#233;n&#233;rale ne d&#233;signe d'autres liquidateurs.</div>
          </td>
        </tr>
        <tr>
          <td style="width: 15%; vertical-align: top;" rowspan="1">&#160;</td>
          <td style="width: 35%; vertical-align: top;" rowspan="1">&#160;</td>
          <td style="width: 2%; vertical-align: top;" rowspan="1">&#160;</td>
          <td style="width: 13%; vertical-align: top;" rowspan="1">&#160;</td>
          <td style="width: 35%; vertical-align: top;" rowspan="1">&#160;</td>
        </tr>
        <tr>
          <td style="width: 15%; vertical-align: top;">&#160;</td>
          <td style="width: 35%; vertical-align: top;">
            <div><sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">3 </sup>The liquidation of the Company shall be effected pursuant to applicable law. The liquidators shall be entitled to sell assets (real estate included) in
              private transactions.</div>
          </td>
          <td style="width: 2%; vertical-align: top;">&#160;</td>
          <td style="width: 13%; vertical-align: top;">&#160;</td>
          <td style="width: 35%; vertical-align: top;">
            <div><sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">3 </sup>La liquidation de la Soci&#233;t&#233; s'effectue conform&#233;ment au droit applicable. Les liquidateurs sont autoris&#233;s &#224; vendre des actifs (immeubles y compris) de gr&#233;
              &#224; gr&#233;.</div>
          </td>
        </tr>
        <tr>
          <td style="width: 15%; vertical-align: top;" rowspan="1">&#160;</td>
          <td style="width: 35%; vertical-align: top;" rowspan="1">&#160;</td>
          <td style="width: 2%; vertical-align: top;" rowspan="1">&#160;</td>
          <td style="width: 13%; vertical-align: top;" rowspan="1">&#160;</td>
          <td style="width: 35%; vertical-align: top;" rowspan="1">&#160;</td>
        </tr>
        <tr>
          <td style="width: 15%; vertical-align: top;">&#160;</td>
          <td style="width: 35%; vertical-align: top;">
            <div><sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">4 </sup>Upon discharge of all liabilities of the Company, the assets shall be distributed to the shareholders in proportion to the share capital, unless these
              articles of association provide otherwise.</div>
          </td>
          <td style="width: 2%; vertical-align: top;">&#160;</td>
          <td style="width: 13%; vertical-align: top;">&#160;</td>
          <td style="width: 35%; vertical-align: top;">
            <div><sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">4 </sup>Apr&#232;s paiement des dettes de la Soci&#233;t&#233;, l'actif est r&#233;parti entre les actionnaires au prorata du capital-actions, &#224; moins que les pr&#233;sents statuts n'en
              disposent autrement.</div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div id="DSPFPageBreak" style="page-break-after:always;">
        <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
    </div>
    <table id="z3e5113df5b5945f09d14d62bbc5f6fa4" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 15%; vertical-align: top;">&#160;</td>
          <td style="width: 35%; vertical-align: top; border-top: 2px solid rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0);">
            <div style="font-weight: bold;">Section 7</div>
            <div style="font-style: italic;">Notices, Communications</div>
            <div style="font-style: italic;"> <br>
            </div>
          </td>
          <td style="width: 2%; vertical-align: top;">&#160;</td>
          <td style="width: 13%; vertical-align: top;">&#160;</td>
          <td style="width: 35%; vertical-align: top; border-top: 2px solid rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0);">
            <div style="font-weight: bold;">Section 7</div>
            <div style="font-style: italic;">Communications, organe de publication</div>
          </td>
        </tr>
        <tr>
          <td style="width: 15%; vertical-align: top;">&#160;</td>
          <td style="width: 35%; vertical-align: top; border-top: 2px solid rgb(0, 0, 0);">&#160;</td>
          <td style="width: 2%; vertical-align: top;">&#160;</td>
          <td style="width: 13%; vertical-align: top;">&#160;</td>
          <td style="width: 35%; vertical-align: top; border-top: 2px solid rgb(0, 0, 0);">&#160;</td>
        </tr>
        <tr>
          <td style="width: 15%; vertical-align: top;">&#160;</td>
          <td style="width: 35%; vertical-align: top;">
            <div style="font-weight: bold;">Article 35</div>
          </td>
          <td style="width: 2%; vertical-align: top;">&#160;</td>
          <td style="width: 13%; vertical-align: top;">&#160;</td>
          <td style="width: 35%; vertical-align: top;">
            <div style="font-weight: bold;">Article 35</div>
          </td>
        </tr>
        <tr>
          <td style="width: 15%; vertical-align: top;" rowspan="1">&#160;</td>
          <td style="width: 35%; vertical-align: top;" rowspan="1">&#160;</td>
          <td style="width: 2%; vertical-align: top;" rowspan="1">&#160;</td>
          <td style="width: 13%; vertical-align: top;" rowspan="1">&#160;</td>
          <td style="width: 35%; vertical-align: top;" rowspan="1">&#160;</td>
        </tr>
        <tr>
          <td style="width: 15%; vertical-align: top;">
            <div>Notices, Communi</div>
            <div>cations</div>
          </td>
          <td style="width: 35%; vertical-align: top;">
            <div><sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">1 </sup>The official means of publication of the Company shall be the Swiss Official Gazette of Commerce.</div>
          </td>
          <td style="width: 2%; vertical-align: top;">&#160;</td>
          <td style="width: 13%; vertical-align: top;">
            <div>Communications, </div>
            <div>organe de publica</div>
            <div>tion</div>
          </td>
          <td style="width: 35%; vertical-align: top;">
            <div><sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">1 </sup>L'organe de publication de la Soci&#233;t&#233; est la Feuille officielle suisse du commerce.</div>
          </td>
        </tr>
        <tr>
          <td style="width: 15%; vertical-align: top;">&#160;</td>
          <td style="width: 35%; vertical-align: top;" rowspan="1">&#160;</td>
          <td style="width: 2%; vertical-align: top;" rowspan="1">&#160;</td>
          <td style="width: 13%; vertical-align: top;">&#160;</td>
          <td style="width: 35%; vertical-align: top;" rowspan="1">&#160;</td>
        </tr>
        <tr>
          <td style="width: 15%; vertical-align: top;">&#160;</td>
          <td style="width: 35%; vertical-align: top;">
            <div><sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">2 </sup>To the extent that personal notification is not mandated by law, all communications to the shareholders shall be deemed valid if published in the Swiss
              Official Gazette of Commerce. Written communications by the Company to its shareholders shall be sent by ordinary mail to the last address of the shareholder or authorized recipient entered in the share register. If neither these articles of
              association nor the law mandatorily require a communication to be in written form, the Company can validly send communications to the shareholders to the last e-mail address of the shareholder or authorized recipient communicated to the
              Company, through the banking system, electronically, by publication in the Swiss Official Gazette of Commerce or in any other way. To comply with a written form, a facsimile or electronic copy of a signature shall be sufficient.</div>
          </td>
          <td style="width: 2%; vertical-align: top;">&#160;</td>
          <td style="width: 13%; vertical-align: top;">&#160;</td>
          <td style="width: 35%; vertical-align: top;">
            <div><sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">2 </sup>Dans la mesure o&#249; la loi n&#8217;exige pas de notification personnelle, toutes les communications aux actionnaires publi&#233;es dans la Feuille officielle suisse du
              commerce seront r&#233;put&#233;es valides. Les communications &#233;crites adress&#233;es par la Soci&#233;t&#233; &#224; ses actionnaires seront envoy&#233;es par courrier ordinaire &#224; la derni&#232;re adresse de l&#8217;actionnaire ou de son b&#233;n&#233;ficiaire autoris&#233; qui figure sur le registre
              des actions. Si ni la loi ni les pr&#233;sents statuts n'imposent qu'une communication rev&#234;te la forme &#233;crite, la Soci&#233;t&#233; peut valablement envoyer une telle communication aux actionnaires par courriel, &#224; la derni&#232;re adresse e-mail de l&#8217;actionnaire
              ou de son b&#233;n&#233;ficiaire autoris&#233; communiqu&#233;e &#224; la Soci&#233;t&#233;, par l'interm&#233;diraire du syst&#232;me bancaire, &#233;lectroniquement, par publication dans la Feuille officielle suisse du commerce ou de toute autre mani&#232;re. Un t&#233;l&#233;fax ou une copie
              &#233;lectronique de la signature suffisent pour se conformer &#224; la forme &#233;crite.</div>
          </td>
        </tr>
        <tr>
          <td style="width: 15%; vertical-align: top;">&#160;</td>
          <td style="width: 35%; vertical-align: top;">&#160;</td>
          <td style="width: 2%; vertical-align: top;">&#160;</td>
          <td style="width: 13%; vertical-align: top;">&#160;</td>
          <td style="width: 35%; vertical-align: top;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 15%; vertical-align: top;">&#160;</td>
          <td style="width: 35%; vertical-align: top; border-top: 2px solid rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0);">
            <div style="font-weight: bold;">Section 8</div>
            <div style="font-style: italic;">Authoritative Language</div>
            <div style="font-style: italic;"> <br>
            </div>
          </td>
          <td style="width: 2%; vertical-align: top;">&#160;</td>
          <td style="width: 13%; vertical-align: top;">&#160;</td>
          <td style="width: 35%; vertical-align: top; border-top: 2px solid rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0);">
            <div style="font-weight: bold;">Section 8</div>
            <div style="font-style: italic;">Langue faisant foi</div>
          </td>
        </tr>
        <tr>
          <td style="width: 15%; vertical-align: top;">&#160;</td>
          <td style="width: 35%; vertical-align: top; border-top: 2px solid rgb(0, 0, 0);">&#160;</td>
          <td style="width: 2%; vertical-align: top;">&#160;</td>
          <td style="width: 13%; vertical-align: top;">&#160;</td>
          <td style="width: 35%; vertical-align: top; border-top: 2px solid rgb(0, 0, 0);">&#160;</td>
        </tr>
        <tr>
          <td style="width: 15%; vertical-align: top;">&#160;</td>
          <td style="width: 35%; vertical-align: top;">
            <div style="font-weight: bold;">Article 36</div>
          </td>
          <td style="width: 2%; vertical-align: top;">&#160;</td>
          <td style="width: 13%; vertical-align: top;">&#160;</td>
          <td style="width: 35%; vertical-align: top;">
            <div style="font-weight: bold;">Article 36</div>
          </td>
        </tr>
        <tr>
          <td style="width: 15%; vertical-align: top;" rowspan="1">&#160;</td>
          <td style="width: 35%; vertical-align: top;" rowspan="1">&#160;</td>
          <td style="width: 2%; vertical-align: top;" rowspan="1">&#160;</td>
          <td style="width: 13%; vertical-align: top;" rowspan="1">&#160;</td>
          <td style="width: 35%; vertical-align: top;" rowspan="1">&#160;</td>
        </tr>
        <tr>
          <td style="width: 15%; vertical-align: top;">
            <div>Authoritative Lan</div>
            <div>guage</div>
          </td>
          <td style="width: 35%; vertical-align: top;">
            <div>In the event of discrepancies between the French and English version of these articles of association, the French version shall prevail.</div>
          </td>
          <td style="width: 2%; vertical-align: top;">&#160;</td>
          <td style="width: 13%; vertical-align: top;">
            <div>Langue faisant foi</div>
          </td>
          <td style="width: 35%; vertical-align: top;">
            <div>En cas de d&#233;saccord entre la version fran&#231;aise et la version anglaise, la version fran&#231;aise des pr&#233;sents statuts pr&#233;vaut.</div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <div>&#160;</div>
    <div>
      <hr style="height: 2px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;" align="center" noshade="noshade"> </div>
  </div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.6
<SEQUENCE>3
<FILENAME>filename3.htm
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: Broadridge Financial Soultions, Inc.
         Document created using EDGARfilings PROfile 7.1.0.0
         Copyright 1995 - 2020 Broadridge -->
  </head>
<body style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000;" bgcolor="#ffffff">
  <div>
    <div style="text-align: right; font-weight: bold;">
      <hr style="height: 4px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;" align="center" noshade="noshade">Exhibit 10.6</div>
    <div><br>
    </div>
    <div style="text-align: center; font-weight: bold;">THIRD AMENDMENT TO COLLABORATION AND LICENSE AGREEMENT</div>
    <div style="text-align: center; font-weight: bold;"> <br>
    </div>
    <div style="text-align: center; font-weight: bold;">BETWEEN</div>
    <div style="text-align: center; font-weight: bold;"> <br>
    </div>
    <div style="text-align: center; font-weight: bold;">ADC THERAPEUTICS SA</div>
    <div style="text-align: center; font-weight: bold;"> <br>
    </div>
    <div style="text-align: center; font-weight: bold;">AND</div>
    <div style="text-align: center; font-weight: bold;"> <br>
    </div>
    <div style="text-align: center; font-weight: bold;">GENMAB A/S</div>
    <div style="text-align: center; font-weight: bold;"> <br>
    </div>
    <div style="text-align: center; font-weight: bold;"> <br>
    </div>
    <div style="text-align: center; font-weight: bold;"> <br>
    </div>
    <div style="text-align: center; font-weight: bold;"> <br>
    </div>
    <div style="text-align: center; font-weight: bold;"> <br>
    </div>
    <div style="text-align: center; font-weight: bold;"> <br>
    </div>
    <div style="text-align: center; font-weight: bold;"> <br>
    </div>
    <div style="text-align: center; font-weight: bold;"> <br>
    </div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
      <div style="page-break-after:always;" id="DSPFPageBreak">
        <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
    </div>
    <div style="text-align: center; font-weight: bold;">THIRD AMENDMENT TO COLLABORATION AND LICENSE AGREEMENT</div>
    <div style="text-align: center; font-weight: bold;"> <br>
    </div>
    <div style="text-align: justify; font-family: 'Times New Roman',Times,serif;"><font style="font-weight: bold;">THIS THIRD AMENDMENT TO COLLABORATION AND LICENSE AGREEMENT</font> (&#8220;<font style="font-weight: bold;">Third Amendment</font>&#8221;) made and
      entered into, effective as of June 24, 2020 (&#8220;<font style="font-weight: bold;">Amendment Effective Date</font>&#8221;), amends that certain <font style="font-weight: bold;">COLLABORATION AND LICENSE AGEEMENT</font> entered into by and between <font style="font-weight: bold;">ADC Therapeutics SA</font>, a Swiss Corporation, having its principal place of business at Biopole, rte de la Corniche 3B, 1066 Epalinges, Switzerland (formerly ADC Therapeutics Sarl) and its Affiliates (&#8220;<font style="font-weight: bold;">ADCT</font>&#8221;), and <font style="font-weight: bold;">GENMAB A/S</font> a Danish corporation, having its principal place of business at Kalvebod Brygge 43, 1560 Copenhagen V, Denmark, CVR no. 2102 3884 (&#8220;<font style="font-weight: bold;">Genmab</font>&#8221;) on 14 June 2013, as amended (&#8220;<font style="font-weight: bold;">Agreement</font>&#8221;). Genmab and ADCT are sometimes referred to herein individually as a &#8220;<font style="font-weight: bold;">Party</font>&#8221; and
      collectively as the &#8220;<font style="font-weight: bold;">Parties</font>.&#8221;</div>
    <div><br>
    </div>
    <div style="text-align: center; font-weight: bold;">BACKGROUND</div>
    <div><br>
    </div>
    <div style="text-align: justify;"><font style="font-family: 'Times New Roman',Times,serif; font-weight: bold;">WHEREAS</font>, the Parties entered into the Collaboration and License Agreement on 13 June 2013,</div>
    <div><br>
    </div>
    <div style="text-align: justify;"><font style="font-family: 'Times New Roman',Times,serif; font-weight: bold;">WHEREAS</font>, the Parties subsequently amended the Collaboration and License Agreement on November 20, 2013, and on April 17, 2020,
      respectively,</div>
    <div><br>
    </div>
    <div style="text-align: justify;"><font style="font-weight: bold;">WHEREAS, Article 9</font> of the <font style="font-weight: bold;">Agreement</font> defines a certain divestment process with respect to license rights conveyed pursuant to the <font style="font-weight: bold;">Agreement</font>,</div>
    <div><br>
    </div>
    <div style="text-align: justify;"><font style="font-family: 'Times New Roman',Times,serif; font-weight: bold;">WHEREAS</font>, ADCT has decided not to exercise the Grace Period under Section 9.2, and Genmab has waived its exclusive option for a two (2)
      month period to negotiate with ADCT to acquire ADCT&#8217;s share of the ADC under Section 9.4.1, and</div>
    <div><br>
    </div>
    <div style="text-align: justify;"><font style="font-family: 'Times New Roman',Times,serif; font-weight: bold;">WHEREAS</font>, the Parties now desire to further amend the <font style="font-family: 'Times New Roman',Times,serif; font-weight: bold;">Agreement</font>,</div>
    <div><br>
    </div>
    <div style="text-align: justify;"><font style="font-family: 'Times New Roman',Times,serif; font-weight: bold;">NOW THEREFORE</font>, the Parties for good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, agree to
      amend the <font style="font-family: 'Times New Roman',Times,serif; font-weight: bold;">Agreement</font> as follows:</div>
    <div><br>
    </div>
    <div style="text-align: center; font-weight: bold;">SECTION 1</div>
    <div style="text-align: center; font-weight: bold;">AMENDMENT</div>
    <div><br>
    </div>
    <div style="text-align: justify;"><font style="font-family: 'Times New Roman',Times,serif; font-weight: bold;">1. </font></div>
    <div style="margin: -12pt 0px 0px; text-align: justify; text-indent: 36pt;"><font style="font-family: 'Times New Roman',Times,serif; font-weight: bold;">Amendment</font>. The <font style="font-family: 'Times New Roman',Times,serif; font-weight: bold;">Parties</font>
      hereby agree to amend <font style="font-family: 'Times New Roman',Times,serif; font-weight: bold;">Article 9</font> of the <font style="font-family: 'Times New Roman',Times,serif; font-weight: bold;">Agreement</font>,</div>
    <div><br>
    </div>
    <div style="text-align: justify;">(i) by adding a new Section 9.4A after Section 9.4:</div>
    <div style="text-align: justify;"> <br>
    </div>
    <div style="text-align: justify; text-indent: 36pt;">&#8220;9.4A <font style="font-family: 'Times New Roman',Times,serif; font-weight: bold;"></font></div>
    <div style="margin: -12pt 0px 0px 0px; text-align: justify; text-indent: 72pt;"><font style="font-family: 'Times New Roman',Times,serif; font-weight: bold;">ADCT Right to negotiate acquisition of Genmab&#8217;s share</font></div>
    <div><br>
    </div>
    <div style="margin: 0px 0px 0px 36pt; text-align: justify; text-indent: 36pt;">9.4A.1 </div>
    <div style="margin: -12pt 0px 0px 36pt; text-align: justify; text-indent: 72pt;">The Parties agree to negotiate for a period ending on 31 August 2020 with the intent to agree in good faith on a non-binding term sheet that includes all key financial
      terms for a license agreement between the Parties whereby ADCT acquires Genmab&#8217;s share of the ADC (the &#8220;Term Sheet&#8221;).</div>
    <div><br>
    </div>
    <div style="margin: 0px 0px 0px 36pt; text-align: justify; text-indent: 36pt;">9.4A.2 </div>
    <div style="margin: -12pt 0px 0px 36pt; text-align: justify; text-indent: 72pt;">If the Parties mutually agree on a Term Sheet by 31 August 2020, the Parties shall negotiate in good faith a license agreement in accordance with the Term Sheet for a
      period of sixty (60) calendar days starting on 1 September 2020, which sixty (60) calendar day period may be extended by prior mutual written agreement by the Parties (the &#8220;Negotiation Period&#8221;).</div>
    <div><br>
    </div>
    <div style="margin: 0px 0px 0px 36pt; text-align: justify; text-indent: 36pt;">9.4.A.3 </div>
    <div style="margin: -12pt 0px 0px 36pt; text-align: justify; text-indent: 72pt;">If no license agreement has been entered into by the Parties within the Negotiation Period, the Divestment Process shall be initiated immediately following the end of the
      Negotiation Period.</div>
    <div><br>
    </div>
    <div style="margin: 0px 0px 0px 36pt; text-align: justify; text-indent: 36pt;">9.4A.4 </div>
    <div style="margin: -12pt 0px 0px 36pt; text-align: justify; text-indent: 72pt;">If by 31 August 2020 the Parties have not agreed on a Term Sheet, ADCT may elect a subsequent ninety (90) calendar day waiting period by giving written notice to Genmab by
      31 August 2020. ADCT can request initiation of the Divestment Process at any time during this waiting period, but otherwise the Divestment Process shall be initiated immediately following the end of the waiting period.</div>
    <div><br>
    </div>
    <div style="margin: 0px 0px 0px 36pt; text-align: justify; text-indent: 36pt;">9.4A.5 </div>
    <div style="margin: -12pt 0px 0px 36pt; text-align: justify; text-indent: 72pt;">If by 31 August 2020 the Parties have not agreed on a Term Sheet, and if ADCT does not elect the ninety (90) calendar day waiting period pursuant to Section 9.4A.4, the
      Divestment Process shall be initiated immediately after 31 August 2020.&#8221;</div>
    <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div id="DSPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;" noshade="noshade"></div>
    </div>
    <div style="text-align: justify;">and (ii) by replacing Sections 9.5.1 and 9.5.2 in their entirety with new Section 9.5:</div>
    <div><br>
    </div>
    <div style="margin: 0px 0px 0px 0px; text-align: justify; text-indent: 36pt;">&#8220;9.5. </div>
    <div style="margin: -12pt 0px 0px; text-align: justify; text-indent: 72pt;"><font style="font-family: 'Times New Roman',Times,serif; font-weight: bold;">Initiation of Divestment Process</font> The Divestment Process shall commence immediately (i) if a
      Term Sheet has been mutually agreed by 31 August 2020, upon the expiration of the Negotiation Period without a license agreement having been entered into by the Parties, (ii) if no Term Sheet has been mutually agreed by 31 August 2020 and if the
      waiting period has been requested by ADCT, at any time during the waiting period at the request of ADCT or otherwise following the end of the waiting period, or (iii) if no Term Sheet has been mutually agreed by 31 August 2020 and no waiting period
      has been elected by ADCT by 31 August 2020, immediately after 31 August 2020.&#8221;</div>
    <div style="text-align: center; font-weight: bold;"> <br>
    </div>
    <div style="text-align: center; font-weight: bold;">THE REMAINDER OF ARTICLE 9 SHALL REMAIN UNCHANGED.</div>
    <div><br>
    </div>
    <div style="text-align: justify;"><font style="font-family: 'Times New Roman',Times,serif; font-weight: bold;">2. </font></div>
    <div style="margin: -12pt 0px 0px; text-align: justify; text-indent: 36pt;"><font style="font-family: 'Times New Roman',Times,serif; font-weight: bold;">No Other Changes.</font> This Amendment contemplates only the changes in Section 1 above and the
      remainder of the Agreement shall be unaltered by the Amendment. The Agreement shall be read and interpreted, to the extent necessary, consistent with the amendment to Section 9 herein.</div>
    <div><br>
    </div>
    <div style="text-align: justify;"><font style="font-family: 'Times New Roman',Times,serif; font-weight: bold;">3. </font></div>
    <div style="margin: -12pt 0px 0px; text-align: justify; text-indent: 36pt;"><font style="font-family: 'Times New Roman',Times,serif; font-weight: bold;">Counterparts.</font> This Amendment may be executed in two or more counterparts, each of which will
      be deemed an original, but all of which together will constitute one and the same instrument. For purposes hereof, a PDF copy of this Amendment, including the signature pages hereto, will be deemed to be an original. Notwithstanding the foregoing,
      the Parties shall deliver original execution copies of this Amendment to one another as soon as practicable following execution thereof.</div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
      <div style="page-break-after:always;" id="DSPFPageBreak">
        <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
    </div>
    <div style="text-align: justify;"><font style="font-weight: bold;">IN WITNESS WHEREOF</font>, ADCT and Genmab have executed this Amendment by their respective officers hereunto duly authorized, on August 11, 2020.</div>
    <div><br>
    </div>
    <table style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: rgb(0, 0, 0);" id="z6079f6e8f7164e3aa44646a1b7906f73" border="0" cellpadding="3" cellspacing="0">

        <tr>
          <td colspan="2" style="vertical-align: top;">
            <div style="font-family: 'Times New Roman', Times, serif; font-weight: bold;">ADC Therapeutics SA</div>
          </td>
          <td style="width: 70%; vertical-align: top;">&#160;</td>
        </tr>
        <tr>
          <td rowspan="1" colspan="2" style="vertical-align: top;">&#160;</td>
          <td rowspan="1" style="width: 70%; vertical-align: top;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 5%; vertical-align: top; padding-bottom: 2px;">
            <div style="font-family: 'Times New Roman', Times, serif;">By:</div>
          </td>
          <td style="width: 25%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">
            <div style="font-family: 'Times New Roman', Times, serif;">/s/ Michael Forer</div>
          </td>
          <td style="width: 70%; vertical-align: top; padding-bottom: 2px;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 5%; vertical-align: top; padding-bottom: 2px;">
            <div style="font-family: 'Times New Roman', Times, serif;">Name:</div>
          </td>
          <td style="width: 25%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">
            <div style="font-family: 'Times New Roman', Times, serif;">Michael Forer</div>
          </td>
          <td style="width: 70%; vertical-align: top; padding-bottom: 2px;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 5%; vertical-align: top; padding-bottom: 2px;">
            <div style="font-family: 'Times New Roman', Times, serif;">Title:</div>
          </td>
          <td style="width: 25%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">
            <div style="font-family: 'Times New Roman', Times, serif;">Vice Chairman &amp; EVP</div>
          </td>
          <td style="width: 70%; vertical-align: top; padding-bottom: 2px;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 5%; vertical-align: top;">&#160;</td>
          <td style="width: 25%; vertical-align: top;">&#160;</td>
          <td style="width: 70%; vertical-align: top;">&#160;</td>
        </tr>
        <tr>
          <td colspan="2" rowspan="1" style="vertical-align: top;">
            <div style="font-family: 'Times New Roman', Times, serif; font-weight: bold;">Genmab A/S</div>
          </td>
          <td style="width: 70%; vertical-align: top;">&#160;</td>
        </tr>
        <tr>
          <td colspan="2" rowspan="1" style="vertical-align: top;">&#160;</td>
          <td rowspan="1" style="width: 70%; vertical-align: top;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 5%; vertical-align: top; padding-bottom: 2px;">
            <div style="font-family: 'Times New Roman', Times, serif;">By:</div>
          </td>
          <td style="width: 25%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">
            <div style="font-family: 'Times New Roman', Times, serif;">/s/ Birgitte Stephensen</div>
          </td>
          <td style="width: 70%; vertical-align: top; padding-bottom: 2px;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 5%; vertical-align: top; padding-bottom: 2px;">
            <div style="font-family: 'Times New Roman', Times, serif;">Name:</div>
          </td>
          <td style="width: 25%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">
            <div style="font-family: 'Times New Roman', Times, serif;">Birgitte Stephensen</div>
          </td>
          <td style="width: 70%; vertical-align: top; padding-bottom: 2px;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 5%; vertical-align: top; padding-bottom: 2px;">
            <div style="font-family: 'Times New Roman', Times, serif;">Title:</div>
          </td>
          <td style="width: 25%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">
            <div style="font-family: 'Times New Roman', Times, serif;">SVP, IPR &amp; Legal</div>
          </td>
          <td style="width: 70%; vertical-align: top; padding-bottom: 2px;">&#160;</td>
        </tr>

    </table>
    <div><br>
    </div>
    <div>
      <hr style="height: 2px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;" align="center" noshade="noshade"></div>
  </div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.17
<SEQUENCE>4
<FILENAME>filename4.htm
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: Broadridge Financial Soultions, Inc.
         Document created using EDGARfilings PROfile 7.1.0.0
         Copyright 1995 - 2020 Broadridge -->
  </head>
<body style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000;" bgcolor="#ffffff">
  <div>
    <div style="text-align: right; font-family: 'Times New Roman',Times,serif; font-size: 12pt; font-weight: bold;">
      <hr style="height: 4px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;" align="center" noshade="noshade"> <font style="font-size: 10pt;">Exhibit 10.17<br>
      </font></div>
    <div style="text-align: center; font-size: 12pt; font-weight: bold;"> <font style="font-size: 10pt;"><br>
      </font></div>
    <div style="text-align: center; font-family: 'Times New Roman',Times,serif; font-weight: bold;">REGISTRATION RIGHTS AGREEMENT</div>
    <div><br>
    </div>
    <div style="text-align: justify; font-family: 'Times New Roman',Times,serif;">REGISTRATION RIGHTS AGREEMENT (this &#8220;<font style="font-weight: bold;">Agreement</font>&#8221;), dated as of May 19, 2020, by and among ADC Therapeutics SA, a Swiss stock
      corporation <font style="font-style: italic;">(soci&#233;t&#233; anonyme)</font> (the &#8220;<font style="font-weight: bold;">Company</font>&#8221;), and Deerfield Partners, L.P. and Deerfield Private Design Fund IV, L.P (each individually, a &#8220;<font style="font-weight: bold;">Lender</font>&#8221; and together, the &#8220;<font style="font-weight: bold;">Lenders</font>&#8221;).</div>
    <div><br>
    </div>
    <div style="text-align: justify; font-family: 'Times New Roman',Times,serif; font-weight: bold;">WHEREAS:</div>
    <div><br>
    </div>
    <div style="text-align: justify; font-size: 12pt;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;">A. In connection with the Facility Agreement, dated as of April 24, 2020, by and among the Company, the Lenders, the other
        Loan Parties (as defined therein) and Cortland Capital Market Services LLC, as agent for itself and the Secured Parties (as defined therein) (as the same has heretofore been amended, modified, restated or otherwise supplemented, the &#8220;</font><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif; font-weight: bold;">Facility Agreement</font><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;">&#8221;), the Company (i) is on the date hereof issuing</font><font style="font-size: 10pt;">&#160;<font style="font-family: 'Times New Roman',Times,serif;">senior secured convertible notes to the Lenders (such senior secured convertible notes, together with any notes issued in exchange or substitution therefor or
          replacement thereof, as the same may be amended, restated or modified and in effect from time to time, the &#8220;</font><font style="font-family: 'Times New Roman',Times,serif; font-weight: bold;">Initial Notes</font><font style="font-family: 'Times New Roman',Times,serif;">&#8221;; and the Common Shares issuable upon conversion of the Initial Notes, without regard to any limitation on conversion thereof, being referred to as the &#8220;</font><font style="font-family: 'Times New Roman',Times,serif; font-weight: bold;">Initial Note Conversion Shares</font><font style="font-family: 'Times New Roman',Times,serif;">&#8221;) and (ii) subject to the terms and conditions set forth in the Facility Agreement may issue additional senior secured convertible
          notes to the Lenders (such senior secured convertible notes, together with any notes issued in exchange or substitution therefor or replacement thereof, as the same may be amended, restated or modified and in effect from time to time, the &#8220;</font><font style="font-family: 'Times New Roman',Times,serif; font-weight: bold;">Subsequent Notes,</font><font style="font-family: 'Times New Roman',Times,serif;">&#8221; and together with the Initial Notes, the &#8220;</font><font style="font-family: 'Times New Roman',Times,serif; font-weight: bold;">Notes</font><font style="font-family: 'Times New Roman',Times,serif;">&#8221;; and the Common Shares issuable upon conversion of the Subsequent Notes, without regard to any limitation on conversion thereof, being
          referred to as the &#8220;</font><font style="font-family: 'Times New Roman',Times,serif; font-weight: bold;">Subsequent Note Conversion Shares</font><font style="font-family: 'Times New Roman',Times,serif;">&#8221; and, together with the Initial Note
          Conversion Shares, the &#8220;</font><font style="font-family: 'Times New Roman',Times,serif; font-weight: bold;">Shares</font><font style="font-family: 'Times New Roman',Times,serif;">&#8221;).</font></font></div>
    <div><br>
    </div>
    <div style="text-align: justify; font-family: 'Times New Roman',Times,serif;">B. To induce the Lenders to execute and deliver the Facility Agreement, the Company has agreed to provide certain registration rights under the Securities Act of 1933, as
      amended, and the rules and regulations thereunder, or any similar successor statute (collectively, the &#8220;<font style="font-weight: bold;">Securities Act</font>&#8221;), and applicable state securities laws.</div>
    <div><br>
    </div>
    <div style="text-align: justify; font-size: 12pt;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif; font-weight: bold;">NOW, THEREFORE</font><font style="font-size: 10pt;">, in consideration of the premises and the mutual
        covenants contained herein and other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Company and each of the Lenders hereby agree as follows:</font></div>
    <div><br>
    </div>
    <div style="text-align: justify; font-family: 'Times New Roman',Times,serif; font-weight: bold;">1. DEFINITIONS.</div>
    <div><br>
    </div>
    <div style="text-align: justify; font-family: 'Times New Roman',Times,serif;">a. As used in this Agreement, the following terms shall have the following meanings (all capitalized terms used and not otherwise defined herein having the respective
      meanings set forth in the Facility Agreement):</div>
    <div><br>
    </div>
    <div style="text-align: justify; font-family: 'Times New Roman',Times,serif;">(i) &#8220;<font style="font-weight: bold;">Additional Filing Deadline</font>&#8221; means, with respect to any Registration Statements that may be required pursuant to Section 2(a)(iv),
      (A) the tenth (10th) Business Day following the first date on which the applicable Registrable Securities may then be included in a Registration Statement if such Registration Statement is required to be filed because the SEC shall have notified the
      Company in writing that certain Registrable Securities were not eligible for inclusion in a previously filed Registration Statement, or (B) if such additional Registration Statement is required for a reason other than as described in (A) above, the
      thirtieth (30<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">th</sup>) day following the date on which the Company first knows that such additional Registration Statement is required.</div>
    <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div id="DSPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;" noshade="noshade"></div>
    </div>
    <!--PROfilePageNumberReset%Num%2%%%-->
    <div style="text-align: justify; font-family: 'Times New Roman',Times,serif;">(ii) &#8220;<font style="font-weight: bold;">Additional Registration Deadline</font>&#8221; means, with respect to any additional Registration Statement(s) required to be filed pursuant
      to Section 2(a)(iv), the forty fifth (45th) day following the applicable Additional Filing Deadline.</div>
    <div><br>
    </div>
    <div style="text-align: justify; font-family: 'Times New Roman',Times,serif;">(iii) &#8220;<font style="font-weight: bold;">Common Shares</font>&#8221; means the common shares, par value CHF 0.064 per share, of the Company.</div>
    <div><br>
    </div>
    <div style="text-align: justify; font-family: 'Times New Roman',Times,serif;">(iv) &#8220;<font style="font-weight: bold;">Exchange Act</font>&#8221; means the Securities Exchange Act of 1934, as amended, together with the rules and regulations promulgated
      thereunder, and any successor statute.</div>
    <div><br>
    </div>
    <div style="text-align: justify; font-family: 'Times New Roman',Times,serif;">(v) &#8220;<font style="font-weight: bold;">FINRA</font>&#8221; means the Financial Industry Regulatory Authority, Inc. (or successor thereto).</div>
    <div><br>
    </div>
    <div style="text-align: justify; font-family: 'Times New Roman',Times,serif;">(vi) &#8220;<font style="font-weight: bold;">Filing Deadline</font>,&#8221; for the Mandatory Registration Statement required pursuant to Section 2(a)(i), shall mean the Mandatory
      Registration Filing Deadline, for the Subsequent Mandatory Registration Statement required pursuant to Section 2(a)(ii), shall mean the Subsequent Filing Deadline, and for each Registration Statement required pursuant to Section 2(a)(iv) shall mean
      the Additional Filing Deadline.</div>
    <div><br>
    </div>
    <div style="text-align: justify; font-family: 'Times New Roman',Times,serif;">(vii) &#8220;<font style="font-weight: bold;">Foreign Private Issuer</font>&#8221; has the meaning set forth in Rule 405 of Regulation C under the Securities Act or any successor rule
      thereto.</div>
    <div><br>
    </div>
    <div style="text-align: justify; font-size: 12pt;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;">(viii) &#8220;</font><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif; font-weight: bold;">Form S-1</font><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;">&#8221; means a Registration Statement on Form S-1,</font><font style="font-size: 10pt;">&#160;<font style="font-family: 'Times New Roman',Times,serif;">or if the Company is a Foreign
          Private Issuer, Form F-1, or in each case,</font> any successor form of registration statement<font style="font-family: 'Times New Roman',Times,serif;">.</font></font></div>
    <div><br>
    </div>
    <div style="text-align: justify; font-size: 12pt;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;">(ix) &#8220;</font><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif; font-weight: bold;">Form S-3</font><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;">&#8221; means a Registration Statement on Form S-3, or if the Company is a Foreign Private Issuer, Form F-3, </font><font style="font-size: 10pt;">or in each case, any successor form
        of registration statement<font style="font-family: 'Times New Roman',Times,serif;">.</font></font></div>
    <div><br>
    </div>
    <div style="text-align: justify; font-family: 'Times New Roman',Times,serif;">(xi) &#8220;<font style="font-weight: bold;">Investor</font>&#8221; means any Lender and any transferee or assignee who agrees in writing to become bound by the provisions of this
      Agreement in accordance with Section 10 hereof.</div>
    <div><br>
    </div>
    <div style="text-align: justify; font-family: 'Times New Roman',Times,serif;">(xii) &#8220;<font style="font-weight: bold;">Person</font>&#8221; means and includes any natural person, partnership, joint venture, corporation, trust, limited liability company,
      limited company, joint stock company, unincorporated organization, government entity or any political subdivision or agency thereof, or any other entity.</div>
    <div><br>
    </div>
    <div style="text-align: justify; font-family: 'Times New Roman',Times,serif;">(xiii) &#8220;<font style="font-weight: bold;">Prospectus</font>&#8221; means (i) any prospectus (preliminary or final) included in any Registration Statement, as may be amended or
      supplemented by any prospectus supplement with respect to the terms of the offering of any portion of the Registrable Securities covered by such Registration Statement and by all other amendments and supplements to such prospectus, including
      post-effective amendments, and all material incorporated by reference in such prospectus, and (ii) any &#8220;free writing prospectus&#8221; as defined in Rule 405 under the Securities Act relating to any offering of Registrable Securities pursuant to a
      Registration Statement.</div>
    <div><br>
    </div>
    <div style="text-align: justify; font-family: 'Times New Roman',Times,serif;">(xiv) &#8220;<font style="font-weight: bold;">Register</font>,&#8221; &#8220;<font style="font-weight: bold;">Registered</font>,&#8221; and &#8220;<font style="font-weight: bold;">Registration</font>&#8221;
      refer to a registration effected by preparing and filing a Registration Statement or Statements in compliance with the Securities Act and pursuant to Rule 415, and the declaration of effectiveness of such Registration Statement (to the extent
      required, by declaration or ordering of effective, of such Registration Statement by the United States Securities and Exchange Commission (the &#8220;<font style="font-weight: bold;">SEC</font>&#8221;)).</div>
    <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-weight: normal; font-style: normal;">2</font></div>
      <div id="DSPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;" noshade="noshade"></div>
    </div>
    <div style="text-align: justify; font-family: 'Times New Roman',Times,serif;">(xv) &#8220;<font style="font-weight: bold;">Registrable Securities</font>,&#8221; for a given Registration, means (a) any Shares issued or issuable upon conversion of, or otherwise
      pursuant to, the Initial Notes (without giving effect to any limitations on conversion set forth in the Initial Notes) and, following the Subsequent Note Issuance Date, the Subsequent Notes (without giving effect to any limitations on conversion set
      forth in the Subsequent Notes), (b) any shares of capital stock issued or issuable as a dividend on or in exchange for or otherwise with respect to any of the foregoing, (c) any additional Common Shares issuable in connection with any anti-dilution
      provisions in the Notes, (d) any other Common Shares issuable pursuant to the terms of the Notes, and (e) any securities issued or issuable upon any stock split, dividend or other distribution, recapitalization or similar event with respect to any of
      the foregoing.</div>
    <div><br>
    </div>
    <div style="text-align: justify; font-family: 'Times New Roman',Times,serif;">(xvi) &#8220;<font style="font-weight: bold;">Registration Deadline</font>&#8221; shall mean, for purposes of any Registration Statement required pursuant to Section 2(a)(i) or 2(a)(ii),
      the date that is seventy-five (75) days after the applicable Filing Deadline, and with respect to any Registration Statement required pursuant to Section 2(a)(iv), the Additional Registration Deadline. Any Registration Deadline (or any extension
      thereof) shall be automatically extended if the Company has, and continues to use, its commercially reasonable efforts to respond and resolve any comments to the Registration Statement received from the SEC. Notwithstanding the foregoing, at any time
      that the Company (A) is not a Foreign Private Issuer and (B) is required to comply with Rule 3-01 of SEC Regulation S-X but is not eligible to rely upon paragraph (c) thereof, if a Registration Deadline would otherwise occur during the period
      beginning 45 days after the end of any fiscal year of the Company and ending on the date the Company files its Annual Report on Form 10-K for the previously completed fiscal year (the &#8220;<font style="font-weight: bold;">Prior Year Annual Report</font>&#8221;),


      the Registration Deadline shall be automatically extended until the Company files its Prior Year Annual Report, provided that the Company uses commercially reasonable efforts to file the Prior Year Annual Report as soon as practicable, and in no
      event shall such extension of a Registration Deadline extend past the due date for the applicable Prior Year Annual Report.</div>
    <div><br>
    </div>
    <div style="text-align: justify; font-family: 'Times New Roman',Times,serif;">(xvii) &#8220;<font style="font-weight: bold;">Registration Failure</font>&#8221; means that (A) the Company fails to file with the SEC on or before the Filing Deadline any Registration
      Statement required to be filed pursuant to Section 2 hereof, (B) the Company fails to use its commercially reasonable efforts to obtain effectiveness with the SEC, prior to the Registration Deadline, and if such Registration Statement does not become
      effective prior to the Registration Deadline, as soon as possible thereafter, of any Registration Statement that is required to be filed pursuant to Section 2(a) hereof, or fails to use its commercially reasonable efforts to keep such Registration
      Statement current and effective as required in Section 3 hereof, (C) the Company fails to file any additional Registration Statement required to be filed pursuant to Section 2(a)(ii) hereof on or before the Additional Filing Deadline or fails to use
      its commercially reasonable efforts to cause such additional Registration Statement to become effective on or before the Additional Registration Deadline, and if such effectiveness does not occur within such period, as soon as possible thereafter, or
      (D) the Registration Statement required to be filed hereunder, after its initial effectiveness and during the applicable Registration Period, lapses in effect or, other than on a day during an Allowable Grace Period, sales of all of the Registrable
      Securities cannot otherwise be made thereunder (whether by reason of the Company&#8217;s failure to amend or supplement the prospectus included therein in accordance herewith, the Company&#8217;s failure to file and use its commercially reasonable efforts to
      obtain effectiveness with the SEC of an additional Registration Statement or amended Registration Statement required pursuant to Section 2(a)(ii) or 3(b) hereof, as applicable, or otherwise).</div>
    <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-weight: normal; font-style: normal;">3</font></div>
      <div id="DSPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;" noshade="noshade"></div>
    </div>
    <div style="text-align: justify; font-family: 'Times New Roman',Times,serif;">(xviii) &#8220;<font style="font-weight: bold;">Registration Statement(s)&#8221;</font> means any registration statement(s) of the Company filed under the Securities Act that covers the
      resale of any of the Registrable Securities pursuant to the provisions of this Agreement, all amendments and supplements to such Registration Statement, including post-effective amendments, and all exhibits to, and all material incorporated by
      reference in, such Registration Statement.</div>
    <div style="text-align: justify; font-family: 'Times New Roman',Times,serif;"> <br>
    </div>
    <div style="text-align: justify; font-family: 'Times New Roman',Times,serif;">(xix) &#8220;<font style="font-weight: bold;">Rule 415</font>&#8221; means Rule 415 under the Securities Act or any successor rule providing for the offering of securities on a
      continuous basis.</div>
    <div><br>
    </div>
    <div style="text-align: justify; font-family: 'Times New Roman',Times,serif;">(xx) &#8220;<font style="font-weight: bold;">Subsequent Note Issuance Date</font>&#8221; means the date of issuance of the Subsequent Notes.</div>
    <div><br>
    </div>
    <div style="text-align: justify; font-family: 'Times New Roman',Times,serif; font-weight: bold;">2. REGISTRATION.</div>
    <div><br>
    </div>
    <div style="text-align: justify; font-family: 'Times New Roman',Times,serif; font-weight: bold;">a. MANDATORY REGISTRATION / SUBSEQUENT REGISTRATION.</div>
    <div><br>
    </div>
    <div style="text-align: justify; font-size: 12pt;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;">(i) On or prior to the date that is forty-five (45) days after the six (6) month anniversary of the effective date of the
        registration statement for the Qualifying IPO (the &#8220;</font><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif; font-weight: bold;">Mandatory Registration Filing Deadline</font><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;">&#8221;),</font><font style="background-color: rgb(255, 255, 255); font-size: 10pt; font-family: 'Times New Roman',Times,serif;">&#160;</font><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;">the Company shall
        prepare and file with the SEC a Registration Statement (the &#8220;</font><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif; font-weight: bold;">Mandatory Registration Statement</font><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;">&#8221;) on Form S-</font><font style="font-size: 10pt;">1<font style="font-family: 'Times New Roman',Times,serif;">, covering (x) if the Subsequent Note Issuance Date has not occurred prior to the Mandatory Registration
          Filing Deadline, the resale of all of the Registrable Securities relating to the Initial Notes, or (y) if the Subsequent Note Issuance Date has occurred prior to the Mandatory Registration Filing Deadline, the resale of all of the Registrable
          Securities relating to the Notes. The Mandatory Registration Statement, to the extent allowable under the Securities Act and the rules and regulations promulgated thereunder (including Rule 416), shall state that such Registration Statement also
          covers such indeterminate number of additional Common Shares as may become issuable upon exercise of or otherwise pursuant to (x) if the Subsequent Note Issuance Date has not occurred prior to the Mandatory Registration Filing Deadline, the
          Initial Notes or (y) if the Subsequent Note Issuance Date has occurred prior to the Mandatory Registration Filing Deadline, the Notes.&#160; Notwithstanding the foregoing, if the Subsequent Note Issuance Date occurs subsequent to the Mandatory
          Registration Filing Deadline but prior to the date of the submission of the Company&#8217;s acceleration request with respect to the Mandatory Registration Statement, the Company shall cause all Registrable Securities relating to the Notes to be
          included in the Mandatory Registration Statement, which Registration Statement, to the extent allowable under the Securities Act and the rules and regulations promulgated thereunder (including Rule 416), shall state that such Registration
          Statement also covers such indeterminate number of additional Common Shares as may become issuable upon exercise of or otherwise pursuant to the Notes.</font></font></div>
    <div><br>
    </div>
    <div style="text-align: justify; font-size: 12pt;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;">(ii) If the Subsequent Note Issuance Date has not occurred prior to the date of the submission of the Company&#8217;s acceleration
        request with respect to the Mandatory Registration Statement, the Company shall prepare, and, on or prior to the date that is thirty (30) days following the Subsequent Note Issuance Date (the &#8220;</font><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif; font-weight: bold;">Subsequent Filing Deadline</font><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;">&#8221;), file with the SEC a Registration Statement (the &#8220;</font><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif; font-weight: bold;">Subsequent</font><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;">&#160;</font><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif; font-weight: bold;">Mandatory</font><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;">&#160;</font><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif; font-weight: bold;">Registration Statement</font><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;">&#8221;) on Form S-1, covering the resale of all of the Registrable Securities that are not at that time covered by the Mandatory Registration Statement (as then in effect and available
        for resale of the Registrable Securities covered thereby), which Registration Statement, to the extent allowable under the Securities Act and the rules and regulations promulgated thereunder (including Rule 416), shall state that such Registration
        Statement also covers such indeterminate number of additional Common Shares as may become issuable upon exercise of or otherwise pursuant to the Notes. To the extent allowable under the Securities Act and the rules and regulations promulgated
        thereunder, the Subsequent Mandatory Registration Statement shall include a combined prospectus for the resale</font><font style="font-size: 10pt;">&#160;<font style="font-family: 'Times New Roman',Times,serif;">of the Registrable Securities</font>&#160;<font style="font-family: 'Times New Roman',Times,serif;">registered by the Mandatory Registration Statement and the Subsequent Mandatory Registration Statement and shall be deemed a post-effective amendment to the Mandatory Registration Statement in
          accordance with Rule 429 under the Securities Act.</font></font></div>
    <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-weight: normal; font-style: normal;">4</font></div>
      <div id="DSPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;" noshade="noshade"></div>
    </div>
    <div style="text-align: justify; font-family: 'Times New Roman',Times,serif;">(iii) Subject to any SEC comments, any Registration Statement pursuant to this Section 2(a) shall include a &#8220;plan of distribution&#8221; approved by the holders of a
      majority-in-interest of the Registrable Securities to be in included in such Registration Statement. No Investor shall be named as an &#8220;underwriter&#8221; in the Registration Statement without the Investor&#8217;s prior written consent; provided, that
      notwithstanding any other provision in this Agreement, if despite the Company&#8217;s compliance with Section 3(p), the SEC or the Securities Act requires such Investor(s) to be named as an &#8220;underwriter&#8221; in the Registration Statement and such Investor(s)
      withhold written consent to be so named, the Company&#8217;s failure to fulfill its obligations under this Section 2(a) solely as a result thereof shall not constitute a Registration Failure.&#160; Each Registration Statement (and each amendment or supplement
      thereto, and each request for acceleration of effectiveness thereof) shall be provided to (and shall be subject to the approval, which shall not be unreasonably withheld or delayed, of) the Investors and Legal Counsel (as defined below) prior to its
      filing or other submission.</div>
    <div><br>
    </div>
    <div style="text-align: justify; font-family: 'Times New Roman',Times,serif;">(iv) If for any reason, despite the Company&#8217;s use of its commercially reasonable efforts to include all of the Registrable Securities requested or required to be included in
      any Registration Statement filed pursuant to Section 2(a)(i) or Section 2(a)(ii) (and subject to Section 3(p) below), the SEC does not permit all such Registrable Securities to be included in such Registration Statement, or for any other reason any
      such Registrable Securities are not then included in a Registration Statement, then the Company shall prepare, and, as soon as practicable but in no event later than the Additional Filing Deadline, file with the SEC an additional Registration
      Statement on Form S-1 covering the resale of all Registrable Securities requested or required to be included in such Registration Statement filed pursuant to Section 2(a)(i) or Section 2(a)(ii) and not already covered by an existing and effective
      Registration Statement for an offering to be made on a continuous basis pursuant to Rule 415.</div>
    <div><br>
    </div>
    <div style="text-align: justify; font-family: 'Times New Roman',Times,serif;">(v) Notwithstanding the foregoing, if at the time the Company is required to file a Mandatory Registration Statement pursuant to Section 2(a)(i), a Subsequent Mandatory
      Registration Statement pursuant to Section 2(a)(ii) or an additional Registration Statement pursuant to Section 2(a)(iv), the Company is eligible to use Form S-3 to register the resale of securities by the Investors, then the Company shall file such
      Registration Statement on Form S-3.</div>
    <div><br>
    </div>
    <div style="text-align: justify; font-size: 12pt;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif; font-weight: bold;">b. PIGGY-BACK REGISTRATIONS.</font><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"> If at any time subsequent to </font><font style="font-size: 10pt;">the effective date of the registration statement in respect of the Qualifying IPO<font style="font-family: 'Times New Roman',Times,serif;"> but prior to the
          expiration of the Registration Period (as defined below) the Company shall determine (i) to file with the SEC a registration statement under the Securities Act relating (in whole or in part) to an offering of Common Shares for its own account or
          for the account of any other holder of its equity securities (other than securities being registered on Form S-4, Form F-4 or Form S-8 or their then equivalents relating to equity securities to be issued solely in connection with any acquisition
          of any entity or business or equity securities issuable in connection with stock option or other employee benefit plans), and/or (ii) otherwise </font>to effect an underwritten offering of any securities of the Company of a type included in a
        then effective Registration Statement (other than &#8220;at the market&#8221; or &#8220;registered direct&#8221; offerings on behalf of the Company), the Company shall send to each Investor written notice of such determination at least ten (10) days prior to the
        anticipated filing date of the registration statement <font style="font-family: 'Times New Roman',Times,serif;">and, if within five (5) days after the receipt of such notice, the Investor shall so request in writing, the Company shall </font><font style="font-family: 'Times New Roman',Times,serif;">use commercially reasonable efforts to include in such Registration Statement and/or include in such underwritten offering, as applicable, all or any part of such Investor&#8217;s Registrable
          Securities that the Investor requests to be registered and/or included in the underwritten offering, as applicable, except that if, in connection with any underwritten offering for the account of the Company, the managing underwriter(s) thereof
          shall advise the Company in writing, in good faith, a limitation on the number of Registrable Securities which may be included in such offering is desirable because, in such underwriter(s)&#8217; judgment, marketing or other factors dictate the
          inclusion of such Registrable Securities would interfere with the public distribution, then the Company shall be obligated to include in such underwritten offering only such limited portion of the Registrable Securities with respect to which the
          Investor has requested inclusion hereunder as the underwriter(s) shall permit;</font></font></div>
    <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-weight: normal; font-style: normal;">5</font></div>
      <div id="DSPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;" noshade="noshade"></div>
    </div>
    <div style="text-align: justify; font-size: 12pt;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif; font-weight: bold; font-style: italic;">provided, however</font><font style="font-size: 10pt;">, that the Company shall not
        exclude any Registrable Securities unless the Company has first excluded all outstanding securities to be sold for the accounts of any holders of the Company&#8217;s equity securities which are not entitled by contract to inclusion of such securities in
        an underwritten offering or are not entitled to pro rata inclusion with the Registrable Securities; and</font></div>
    <div><br>
    </div>
    <div style="text-align: justify; font-size: 12pt;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif; font-weight: bold; font-style: italic;">provided, further, however</font><font style="font-size: 10pt;">, that, after giving
        effect to the immediately preceding proviso, any exclusion of Registrable Securities shall be made pro rata with holders of other securities having the contractual right to include such securities in such underwritten offering. No right to
        registration of Registrable Securities under this Section 2(b) shall be construed to limit any registration required under Section 2(a) hereof. If an Investor&#8217;s Registrable Securities are included in an underwritten offering pursuant to this
        Section 2(b), then such Investor shall, unless otherwise agreed by the Company, offer and sell such Registrable Securities in such underwritten offering using the same underwriter or underwriters and, subject to the provisions of this Agreement, on
        the same terms and conditions as other Common Shares included in such underwritten offering.</font></div>
    <div><br>
    </div>
    <div style="text-align: justify; font-family: 'Times New Roman',Times,serif;">Notwithstanding the foregoing, if, prior to the effectiveness of the registration statement described in Section 2(b) above, the Company determines for any reason not to
      proceed with the offering, the Company shall give notice to the Investors and shall be relieved of its obligation to register any Registrable Securities in connection with such registration statement (but, for the avoidance of doubt, shall not
      relieve the Company of its obligations pursuant to Section 6).</div>
    <div><br>
    </div>
    <div style="text-align: justify; font-family: 'Times New Roman',Times,serif;">c. <font style="font-weight: bold;">NOTICES</font>. Each Investor acknowledges and agrees that, in the event the Company would be required by the terms of this Section 2 to
      provide notice to such Investor of the filing of any Registration Statement (including for purposes of an underwritten offering pursuant to Section 2(b) hereof) in which any Registrable Securities of any Investor are eligible to be included, the
      Company shall provide such notice only to counsel to such Investor (which shall be Katten Muchin Rosenman LLP (Attn: Mark D. Wood and Mark I. Fisher) or such other counsel as shall have been designated by such Investor), unless such Investor has
      given prior written instructions to the contrary to the Company.</div>
    <div><br>
    </div>
    <div style="text-align: justify; font-size: 12pt;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif; font-weight: bold;">3.&#160; OBLIGATIONS OF THE COMPANY.</font><font style="font-size: 10pt;"> In connection with any registration
        of the Registrable Securities hereunder, the Company shall have the following obligations:</font></div>
    <div><br>
    </div>
    <div style="text-align: justify; font-size: 12pt;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;">a. The Company shall </font><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;">prepare promptly, and
        file with the SEC as soon as practicable after such registration obligation arises hereunder (but in no event later than the applicable Filing Deadline), such Registration Statements with respect to the Registrable Securities as provided in Section
        2(a), and thereafter use its commercially reasonable efforts to cause each such Registration Statement relating to Registrable Securities to become effective as soon as possible after such filing, but in any event shall use its commercially
        reasonable efforts to cause each such Registration Statement relating to Registrable Securities to become effective no later than the applicable Registration Deadline, and shall use its commercially reasonable efforts to keep the Registration
        Statement current and effective pursuant to Rule 415 at all times after its effective date until such date as is the earlier of (i) the date on which all of the Registrable Securities included in such Registration Statement have been sold pursuant
        to such Registration Statement or pursuant to Rule 144 and (ii) the date on which all of the Registrable Securities included in such Registration Statement (in the opinion of counsel to the Investors) may be immediately sold to the public without
        registration or restriction (including without limitation as to volume by each holder thereof),</font><font style="font-size: 10pt;">&#160;<font style="font-family: 'Times New Roman',Times,serif;">and without compliance with any &#8220;current public
          information&#8221; requirement, pursuant to Rule 144 under the Securities Act (the &#8220;</font><font style="font-family: 'Times New Roman',Times,serif; font-weight: bold;">Registration Period</font><font style="font-family: 'Times New Roman',Times,serif;">&#8221;),


          which Registration Statement (including any amendments or supplements thereto and prospectuses contained therein), except for information provided in writing by an Investor pursuant to Section 4(a), shall not contain any untrue statement of a
          material fact or omit to state a material fact required to be stated therein, or necessary to make the statements therein not misleading.&#160; In the event that Form S-3 is not available for the registration of the resale of any Registrable
          Securities hereunder (but, for the avoidance of doubt, without in any way affecting the Company&#8217;s obligation to register the resale of the Registrable Securities on such other form as is available, as provided in Section 2(a)), (i) the Company
          shall undertake to file, within thirty (30) days of such time as such form is available for such registration, a post-effective amendment to the Registration Statement then in effect, or otherwise file a Registration Statement on Form S-3,
          registering such Registrable Securities on Form S-3; provided that the Company shall maintain the effectiveness of the Registration Statement then in effect until such time as a Registration Statement (or post-effective amendment) on Form S-3
          covering such Registrable Securities has been declared effective by the SEC, and (ii) the Company shall provide that any Registration Statement on Form S-1 filed hereunder shall incorporate documents by reference (including by way of forward
          incorporation by reference) to the maximum extent possible. If the Company is a &#8220;well-known seasoned issuer&#8221; (as defined in Rule 405 under the Securities Act) and to the extent permitted by the rules and regulations of the SEC applicable to the
          Company, at the time the Company is requested or required hereunder to file a Registration Statement or amendment to a Registration Statement hereunder, the Company shall use its commercially reasonable efforts to file the Registration Statement
          or amendment as an &#8220;automatic shelf registration statement&#8221; (as defined in Rule 405 under the Securities Act).</font></font></div>
    <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-weight: normal; font-style: normal;">6</font></div>
      <div id="DSPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;" noshade="noshade"></div>
    </div>
    <div style="text-align: justify; font-family: 'Times New Roman',Times,serif;">b. The Company shall prepare and file with the SEC such amendments (including post-effective amendments) and supplements to each Registration Statement and the prospectus
      used in connection with each Registration Statement as may be necessary to keep each Registration Statement current and effective at all times during the Registration Period, and, during the Registration Period, shall comply with the provisions of
      the Securities Act with respect to the disposition of all Registrable Securities of the Company covered by each Registration Statement until such time as all of such Registrable Securities have been disposed of in accordance with the intended methods
      of disposition by the seller or sellers thereof as set forth in such Registration Statement.</div>
    <div><br>
    </div>
    <div style="text-align: justify; font-size: 12pt;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;">c. The Company shall furnish to each Investor and Legal Counsel (i) promptly after the same is prepared and publicly
        distributed, publicly filed with the SEC or received by the Company, one copy of each Registration Statement and any amendment thereto, each preliminary prospectus and prospectus and each amendment or supplement thereto,</font><font style="font-size: 10pt;">&#160;<font style="font-family: 'Times New Roman',Times,serif;">and, each letter written by or on behalf of the Company to the SEC or the staff of the SEC, and each item of correspondence from the SEC or the staff of the SEC, in
          each case relating to such Registration Statement (other than any portion of any thereof which contains information for which the Company has sought or intends to seek confidential treatment, which contains or reflects any material non-public
          information with respect to the Company or its securities), and (ii) such number of copies of a prospectus, including a preliminary prospectus, and all amendments and supplements thereto and such other documents as an Investor may reasonably
          request in order to facilitate the disposition of the Registrable Securities owned by such Investor; provided that the Company may provide any such copies in electronic form only.&#160; The Company will promptly notify each of the Investors by
          electronic mail of the effectiveness of each Registration Statement or any post-effective amendment thereto. The Company will </font><font style="font-family: 'Times New Roman',Times,serif;">use commercially reasonable efforts to promptly
          respond to any and all comments received from the SEC with respect to any Registration Statement filed pursuant to this Agreement, with a view towards causing each Registration Statement or any amendment thereto to be declared effective by the
          SEC</font>&#160;<font style="font-family: 'Times New Roman',Times,serif;">(to the extent required, by declaration or ordering of effective, of such Registration Statement or amendment by the SEC) as soon as practicable, and, as soon as practicable,
          but in no event later than five (5) Business Days, following the resolution or clearance of all SEC comments or, if applicable, following notification by the SEC that any such Registration Statement or any amendment thereto will not be subject to
          review, shall file </font>a request for acceleration of effectiveness of such Registration Statement (<font style="font-family: 'Times New Roman',Times,serif;">to the extent required, by declaration or ordering of effective, of such Registration
          Statement or amendment by the SEC</font>) to a time and date not later than two (2) Business Days after the submission of such request.&#160; No later than two (2) Business Days after the Registration Statement becomes effective, the Company shall
        file with the SEC the final prospectus included in the Registration Statement pursuant to Rule 424 (or successor thereto) under the Securities Act.</font></div>
    <div><br>
    </div>
    <div style="text-align: justify; font-family: 'Times New Roman',Times,serif;">d. The Company shall use its commercially reasonable efforts to (i) register and qualify, in any jurisdiction in the United States where registration and/or qualification is
      required, the Registrable Securities covered by the Registration Statements under such other securities or &#8220;blue sky&#8221; laws of such jurisdictions in the United States as the Investors shall reasonably request, (ii) prepare and file in those
      jurisdictions such amendments (including post-effective amendments) and supplements to such registrations and qualifications as may be reasonably necessary to maintain the effectiveness thereof during the Registration Period, (iii) take such other
      actions as may be reasonably necessary to maintain such registrations and qualifications in effect at all times during the Registration Period, and (iv) take all other actions reasonably necessary or advisable to qualify the Registrable Securities
      for sale in such jurisdictions; except that in no event shall the Company be required to qualify to do business as a foreign corporation in any jurisdiction where it would not, but for the requirements of this paragraph (d), be required to be so
      qualified, to subject itself to taxation in any such jurisdiction or to consent to general service of process in any such jurisdiction, except where the Company is then already required to be so qualified, already subject to taxation or required to
      consent to general service of process.</div>
    <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-weight: normal; font-style: normal;">7</font></div>
      <div id="DSPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;" noshade="noshade"></div>
    </div>
    <div style="text-align: justify; font-family: 'Times New Roman',Times,serif;">e.&#160; As promptly as practicable after becoming aware of such event, the Company shall notify each Investor that holds Registrable Securities of the happening of any event, of
      which the Company has knowledge, as a result of which the prospectus included in any Registration Statement, as then in effect, includes an untrue statement of a material fact or omits to state a material fact required to be stated therein or
      necessary to make the statements therein not misleading, and, subject to Section 3(r), use its commercially reasonable efforts to promptly prepare a supplement or amendment to any Registration Statement to correct such untrue statement or omission,
      and deliver such number of copies of such supplement or amendment to each Investor as such Investor may reasonably request.</div>
    <div><br>
    </div>
    <div style="text-align: justify; font-family: 'Times New Roman',Times,serif;">f. The Company shall use its commercially reasonable efforts to prevent the issuance of any stop order or other suspension of effectiveness of any Registration Statement,
      and, if such an order is issued, to obtain the withdrawal of such order as promptly as reasonably practicable, and to notify each Investor that holds Registrable Securities covered by such Registration Statement (and, in the event of an underwritten
      offering, the managing underwriters) of the issuance of such order and the resolution thereof, in each case as promptly as reasonably practicable.</div>
    <div><br>
    </div>
    <div style="text-align: justify; font-family: 'Times New Roman',Times,serif;">g. The Company shall permit one outside legal counsel designated by the Investors (which shall be Katten Muchin Rosenman LLP (Attn: Mark D. Wood) or such other counsel as
      shall have been designated by the Investors) (&#8220;<font style="font-weight: bold;">Legal Counsel</font>&#8221;) to review such Registration Statement and all amendments and supplements thereto (as well as all requests for acceleration or effectiveness thereof
      but excluding the Company&#8217;s filings under the Exchange Act), a reasonable period of time prior to their filing with the SEC (not less than five (5) Business Days) and not file any documents in a form to which Legal Counsel reasonably objects and will
      not request acceleration of such Registration Statement without prior notice to Legal Counsel; provided that, notwithstanding the foregoing, in no event shall the Company be (i) required to file any document with the SEC which in the view of the
      Company or its counsel contains any untrue statement of a material fact or omits to state a material fact required to be stated therein or necessary to make any statement therein not misleading or (ii) prohibited from filing any document with the SEC
      which the Company or its counsel reasonably believes to be required by law to be so filed.</div>
    <div><br>
    </div>
    <div style="text-align: justify; font-family: 'Times New Roman',Times,serif;">h. The Company shall hold in confidence and not make any disclosure of information concerning an Investor provided to the Company unless (i) disclosure of such information is
      necessary to comply with federal or state securities laws or otherwise required in the context of any Registration Statement or offering of securities in which any Investor participates, (ii) the disclosure of such information is necessary to avoid
      or correct a misstatement or omission in any Registration Statement, (iii) the release of such information is ordered pursuant to a subpoena or other order from a court or governmental body of competent jurisdiction, or (iv) such information has been
      made generally available to the public other than by disclosure in violation of this Agreement or any other agreement. The Company agrees that it shall, upon learning that disclosure of such information concerning any Investor is sought in or by a
      court or governmental body of competent jurisdiction or through other means, give prompt notice to such Investor prior to making such disclosure, and allow such Investor, at its expense, to undertake appropriate action to prevent disclosure of, or to
      obtain a protective order for, such information.</div>
    <div><br>
    </div>
    <div style="text-align: justify; font-family: 'Times New Roman',Times,serif;">i. The Company shall use its commercially reasonable efforts to cause all the Registrable Securities covered by each Registration Statement to be listed on the principal U.S.
      securities exchange on which securities of the same class or series issued by the Company are then listed, and, to arrange for at least two market makers to register with FINRA as such with respect to such Registrable Securities.</div>
    <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-weight: normal; font-style: normal;">8</font></div>
      <div id="DSPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;" noshade="noshade"></div>
    </div>
    <div style="text-align: justify; font-family: 'Times New Roman',Times,serif;">j. The Company shall provide a transfer agent and registrar, which may be a single entity, for the Registrable Securities not later than the effective date of the initial
      Registration Statement.</div>
    <div><br>
    </div>
    <div style="text-align: justify; font-size: 12pt;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;">k. The Company shall cooperate with each Investor that holds Registrable Securities being offered and the managing underwriter
        or underwriters with respect to an applicable Registration Statement, if any, to facilitate the timely (i) preparation and delivery of certificates (not bearing any restrictive legends) representing Registrable Securities to be offered pursuant to
        such Registration Statement, and enable such certificates to be registered in such names and in such denominations or amounts, as the case may be, or (ii) crediting of the Registrable Securities to be offered pursuant to a Registration Statement to
        the applicable account (or accounts) with DTC through its Deposit/Withdrawal At Custodian (DWAC) system, in any such case as such Investor or the managing underwriter or underwriters, if any, may reasonably request.&#160; Within two (2) Business Days
        after a Registration Statement which includes Registrable Securities becomes effective, the Company shall deliver,</font><font style="font-size: 10pt;">&#160;<font style="font-family: 'Times New Roman',Times,serif;">and, if required by the transfer
          agent, shall cause legal counsel selected by the Company to deliver, to the transfer agent for the Registrable Securities (with copies to each Investor) an appropriate instruction and an opinion of such counsel in the form required by the
          transfer agent in order to issue or transfer (as applicable) such the Registrable Securities free of restrictive legends.</font></font></div>
    <div><br>
    </div>
    <div style="text-align: justify; font-family: 'Times New Roman',Times,serif;">l. At the reasonable request of an Investor, the Company shall prepare and file with the SEC such amendments (including post-effective amendments) and supplements to a
      Registration Statement and any prospectus used in connection with the Registration Statement as may be necessary in order to change the plan of distribution set forth in such Registration Statement, in each case as promptly as is reasonably
      practicable.</div>
    <div><br>
    </div>
    <div style="text-align: justify; font-family: 'Times New Roman',Times,serif;">m. The Company shall not, and shall not agree to, allow the holders of any Common Shares or other securities of the Company to include any of their securities (other than
      Registrable Securities) in any Registration Statement filed pursuant to Section 2(a) or any amendment or supplement thereto under Section 3(b) hereof without the consent of Investors holding a majority-in-interest of the then outstanding Registrable
      Securities.&#160; In addition, the Company shall not include any securities for its own account or the account of others in any Registration Statement filed pursuant to Section 2(a) or any amendment or supplement thereto filed pursuant to Section 3(b)
      hereof without the consent of Investors holding a majority-in-interest of the then outstanding Registrable Securities.</div>
    <div><br>
    </div>
    <div style="text-align: justify; font-family: 'Times New Roman',Times,serif;">n. The Company shall comply in all material respects with all applicable laws related to a Registration Statement and offering and sale of securities and all applicable rules
      and regulations of governmental authorities in connection therewith (including the Securities Act and the Exchange Act and the rules and regulations promulgated by the SEC).</div>
    <div><br>
    </div>
    <div style="text-align: justify; font-family: 'Times New Roman',Times,serif;">o.&#160; If required by the FINRA Corporate Financing Department, the Company shall promptly effect a filing with FINRA pursuant to FINRA Rule 5110 (or successor thereto) with
      respect to the public offering contemplated by resales of securities under the Registration Statement (an &#8220;<font style="font-weight: bold;">Issuer Filing</font>&#8221;), and pay the filing fee required by such Issuer Filing. The Company shall use its
      commercially reasonable efforts to pursue the Issuer Filing until FINRA issues a letter confirming that it does not object to the terms of the offering contemplated by the Registration Statement.</div>
    <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-weight: normal; font-style: normal;">9</font></div>
      <div id="DSPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;" noshade="noshade"></div>
    </div>
    <div style="text-align: justify; font-size: 12pt;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;">p.&#160; </font><font style="font-size: 10pt;">If at any time the SEC advises the Company in writing that the offering of some or
        all of the Registrable Securities in a Registration Statement is not eligible to be made on a delayed or continuous basis under the provisions of Rule 415 under the Securities Act, the Company shall use its commercially reasonable efforts to
        persuade the SEC that the offering contemplated by a Registration Statement is a bona fide secondary offering and not an offering &#8220;by or on behalf of the issuer&#8221; as defined in Rule 415 and that none of the Investors is an &#8220;underwriter.&#8221;&#160; The
        Investors shall have the right to participate or have their respective legal counsel be advised of, and consulted with regarding any meetings or discussions with the SEC regarding the SEC&#8217;s position and to comment or have their respective legal
        counsel comment on any written submission made to the SEC with respect to such matters.&#160; In the event that, despite the Company&#8217;s commercially reasonable efforts and compliance with the terms of this Section 3(p), the SEC refuses to alter its
        position, the Company shall remove from the Registration Statement such portion of the Registrable Securities as the SEC requires in writing be removed therefrom.&#160; Any such cut-back imposed by the SEC as contemplated by this Section 3(p) shall be
        imposed on a pro rata basis (based upon the Registrable Securities held by each of the Investors).</font></div>
    <div><br>
    </div>
    <div style="text-align: justify; font-family: 'Times New Roman',Times,serif;">q. Subject to the limitations contained herein, the Company shall use commercially reasonable efforts to take all other reasonable actions arising out of its obligations
      under this Agreement and necessary to facilitate the disposition by the Investors of the Registrable Securities pursuant to a Registration Statement.</div>
    <div><br>
    </div>
    <div style="text-align: justify; font-size: 12pt;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;">r.&#160; </font><font style="font-size: 10pt;">Notwithstanding anything to the contrary in Section 3(e), the Company may postpone
        effecting a Registration or, at any time after the effective date of the applicable Registration Statement, the Company may suspend the use of any prospectus forming a part of such Registration Statement, if (i) the Board of Directors of the
        Company determines that any registration or offering of Registrable Securities should not be made or continued because it would materially and adversely interfere with any existing or potential material financing, acquisition, corporate
        reorganization, merger, share exchange or other transaction or event involving the Company or any of its subsidiaries or because the Company does not have appropriate financial statement of any acquired or to-be-acquired entities available for
        filing, or (ii) the Board of Directors of the Company determines that the Company would otherwise be required to disclose material non-public information concerning the Company, the disclosure of which is not otherwise required and which the
        Company has a bona fide business purpose for preserving in confidence (the period of such postponement or suspension, a &#8220;<font style="font-family: 'Times New Roman',Times,serif; font-weight: bold;">Grace Period</font>&#8221;); provided, that the Company
        shall (i) promptly notify the Investors in writing of the existence of the Grace Period (provided that in each notice the Company shall not disclose the content of any material non-public information to any Investor unless otherwise requested in
        writing by such Investor) and the date on which the Grace Period will begin, and (ii) as soon as such date may be determined, promptly notify the Investors in writing of the date on which the Grace Period ends; and, provided, further, that (A) no
        Grace Period shall exceed forty-five (45) consecutive days, (B) during any three hundred sixty five (365) day period, such Grace Periods shall not exceed an aggregate of ninety (90) days, (C) the first day of any Grace Period must be at least
        forty-five (45) days after the last day of any prior Grace Period, and (D) no Grace Period may postpone the effectuation of any Registration or otherwise affect the Filing Deadline in respect of any Registration as to which the Registration
        Deadline has been otherwise extended pursuant to the last sentence of the definition thereof (each Grace Period that satisfies all of the requirements of this Section 3(r) being referred to as an &#8220;<font style="font-family: 'Times New Roman',Times,serif; font-weight: bold;">Allowable Grace Period</font>&#8221;).&#160; For purposes of determining the length of a Grace Period above, the Grace Period shall begin on and include the date the Investors receive the notice referred to in clause
        (i) and shall end on and include the later of the date the Investors receive the notice referred to in clause (ii) and the date referred to in such notice.&#160; The provisions of Section 3(e) hereof shall not be applicable during the period of any
        Allowable Grace Period, and the unavailability of a Registration Statement for resales of the Registrable Securities on any day during an Allowable Grace Period shall not constitute a &#8220;<font style="font-family: 'Times New Roman',Times,serif; font-weight: bold;">Registration Failure.</font>&#8221;&#160; Upon expiration of the Grace Period, the Company shall again be bound by the first sentence of Section 3(e) with respect to the information giving rise thereto unless such material non-public
        information is no longer applicable.</font></div>
    <div><br>
    </div>
    <div style="text-align: justify; font-family: 'Times New Roman',Times,serif;">s.&#160; The Company shall not grant any Person any registration rights with respect to Common Shares or any other securities of the Company other than registration rights that
      will not adversely affect the rights of the Investors hereunder (including by limiting in any way the number of Registrable Securities that could be included in any Registration Statement pursuant to Rule 415) and shall not otherwise enter into any
      agreement that is inconsistent with the rights granted to the Investors hereunder; provided that the grant of registration rights to other current or future securityholders shall not in and of itself be deemed to adversely affect the rights of the
      Investors hereunder.</div>
    <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-weight: normal; font-style: normal;">10</font></div>
      <div id="DSPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;" noshade="noshade"></div>
    </div>
    <div style="text-align: justify; font-size: 12pt;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif; font-weight: bold;">4. OBLIGATIONS OF THE INVESTOR.</font><font style="font-size: 10pt;"> In connection with the registration
        of the Registrable Securities, each Investor shall have the following obligations:</font></div>
    <div><br>
    </div>
    <div style="text-align: justify; font-family: 'Times New Roman',Times,serif;">a. It shall be a condition precedent to the obligations of the Company to complete the registration pursuant to this Agreement with respect to the Registrable Securities of
      an Investor that such Investor shall furnish to the Company such information regarding itself, the Registrable Securities held by it and the intended method of disposition of the Registrable Securities held by it as shall be reasonably required to
      effect the registration of such Registrable Securities and shall execute such documents in connection with such registration as the Company may reasonably request. At least five (5) Business Days prior to the first anticipated filing date of a
      Registration Statement, the Company shall notify each Investor of the information the Company requires from such Investor.&#160; Any such information shall not contain any untrue statement of a material fact or omit to state a material fact required to be
      stated therein, or necessary to make the statements therein not misleading.</div>
    <div><br>
    </div>
    <div style="text-align: justify; font-family: 'Times New Roman',Times,serif;">b. Each Investor, by such Investor&#8217;s acceptance of the Registrable Securities, agrees to cooperate with the Company as reasonably requested by the Company in connection with
      the preparation and filing of a Registration Statement hereunder, unless such Investor has notified the Company in writing of such Investor&#8217;s election to exclude all of the Investor&#8217;s Registrable Securities from such Registration Statement.</div>
    <div><br>
    </div>
    <div style="text-align: justify; font-family: 'Times New Roman',Times,serif;">c. Upon request, in the event of an underwritten offering pursuant to Section 2(b) in which any Registrable Securities of any Investor are to be included, such Investor
      agrees to enter into and perform the Investor&#8217;s obligations under an underwriting agreement, in usual and customary form, including customary indemnification and contribution obligations (as applicable to selling security holders generally), with the
      managing underwriter of such offering; provided, that no Investor including Registrable Securities in any underwritten offering shall be required to make any representations or warranties to the Company or the underwriters other than representations
      and warranties regarding such Investor, such Investor&#8217;s ownership of its Registrable Securities to be sold in the offering and such Investor&#8217;s intended method of distribution or to undertake any indemnification obligations to the Company or the
      underwriters with respect thereto except to the extent expressly set forth in Section 7 hereof.</div>
    <div><br>
    </div>
    <div style="text-align: justify; font-family: 'Times New Roman',Times,serif;">d. Each Investor agrees that, upon receipt of any notice from the Company of the happening of any event of the kind described in Section 3(e) or 3(f), such Investor will
      immediately discontinue disposition of Registrable Securities pursuant to the Registration Statement covering such Registrable Securities until such Investor&#8217;s receipt of the copies of the supplemented or amended prospectus contemplated by Section
      3(e) or 3(f).</div>
    <div><br>
    </div>
    <div style="text-align: justify; font-size: 12pt;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif; font-weight: bold;">5. REGISTRATION FAILURE.</font><font style="font-size: 10pt;">&#160; In the event of a Registration Failure, the
        Investors shall be entitled to additional damages as set forth in Section 4 of the Notes and such other rights as set forth in the Notes.</font></div>
    <div><br>
    </div>
    <div style="text-align: justify; font-size: 12pt;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif; font-weight: bold;">6. EXPENSES OF REGISTRATION.</font><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"> All reasonable expenses, other than underwriting discounts and commissions or other charges of any broker-dealer acting on behalf of the Investors, incurred in connection with registrations, filings or qualifications pursuant
        to Sections 2 and 3, including all registration, listing and qualification fees, printers and accounting fees, and the fees and disbursements of counsel for the Company shall be borne by the Company.&#160; </font><font style="font-size: 10pt;">The
        Company shall also reimburse the Investors for the reasonable and documented fees and disbursements of Legal Counsel in connection with registrations pursuant to Section 2 or 3 of this Agreement, provided that the amount of such reimbursements
        shall not exceed $35,000 per Registration in connection with Registrations involving an underwritten offering and $25,000 per Registration in connection with Registrations that do not involve an underwritten offering.&#160; For the avoidance of doubt,
        any documentation required under this Agreement with respect to any legal fees and expenses shall not be required to include any detailed time entries or description of work.</font></div>
    <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-weight: normal; font-style: normal;">11</font></div>
      <div id="DSPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;" noshade="noshade"></div>
    </div>
    <div style="text-align: justify; font-size: 12pt;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif; font-weight: bold;">7. INDEMNIFICATION.</font><font style="font-size: 10pt;"> In the event any Registrable Securities are
        included in a Registration Statement under this Agreement:</font></div>
    <div><br>
    </div>
    <div style="text-align: justify; font-family: 'Times New Roman',Times,serif;">a. The Company will indemnify, hold harmless and defend (i) each Investor, (ii) the directors, officers, partners, managers, members, employees and agents of each Investor,
      and each Person who controls any Investor within the meaning of the Securities Act or the Exchange Act, if any, (iii) any underwriter (as defined in the Securities Act) for each Investor in connection with an underwritten offering pursuant to Section
      2(b) hereof, and (iv) the directors, officers, partners and employees of, and each Person who controls, any such underwriter within the meaning of the Securities Act or the Exchange Act, if any (each, an &#8220;<font style="font-weight: bold;">Indemnified
        Person</font>&#8221;), against any joint or several losses, claims, damages, liabilities or expenses (collectively, together with actions, proceedings or inquiries by any regulatory or self-regulatory organization, whether commenced or threatened, in
      respect thereof, &#8220;<font style="font-weight: bold;">Claims</font>&#8221;) to which any of them may become subject insofar as such Claims arise out of or are based upon: (i) any untrue statement or alleged untrue statement of a material fact in any
      Registration Statement, or any amendment as supplement thereto, or any filing made under state securities laws as required hereby, or the omission or alleged omission to state therein a material fact required to be stated or necessary to make the
      statements therein not misleading; (ii) any untrue statement or alleged untrue statement of a material fact contained in any Prospectus, or any amendment or supplement thereto, or the omission or alleged omission to state therein any material fact
      necessary to make the statements made therein, in the light of the circumstances under which the statements therein were made, not misleading; or (iii) any violation or alleged violation by the Company of the Securities Act, the Exchange Act, any
      other law, including any state securities law, or any rule or regulation thereunder relating to the offer or sale of the Registrable Securities, and relating to any action required by or inaction by the Company in connection with the offer or sale of
      the Registrable Securities (the matters in the foregoing clauses (i) through (iii) being, collectively, &#8220;<font style="font-weight: bold;">Violations</font>&#8221;). The Company shall reimburse the Indemnified Person, promptly as such expenses are incurred
      and are due and payable, for any reasonable and documented legal fees and other reasonable and documented expenses incurred by them in connection with investigating or defending any such Claim.&#160; Notwithstanding anything to the contrary contained
      herein, the indemnification agreement contained in this Section 7(a) shall not apply to a Claim arising out of or based upon a Violation to the extent that such Violation occurs in reliance upon and in conformity with information furnished in writing
      to the Company by or on behalf of any Indemnified Person expressly for use in connection with the preparation of such Registration Statement or related prospectus or any such amendment thereof or supplement thereto, or to any amounts paid in
      settlement of any Claim effected without the prior written consent of the Company, which consent shall not be unreasonably withheld, conditioned or delayed.&#160; Such indemnity shall remain in full force and effect regardless of any investigation made by
      or on behalf of the Indemnified Person and shall survive the transfer of the Registrable Securities by any of the Investors pursuant to Section 10.</div>
    <div><br>
    </div>
    <div style="text-align: justify; font-family: 'Times New Roman',Times,serif;">b. Promptly after receipt by an Indemnified Person under this Section 7 of notice of the commencement of any action (including any governmental action), such Indemnified
      Person shall, if a Claim in respect thereof is to be made against the Company under this Section 7, deliver to the Company a written notice of the commencement thereof, and the Company shall have the right to participate in, and, to the extent the
      Company so desires, to assume control of the defense thereof with counsel mutually satisfactory to the Company and the Indemnified Person, as the case may be;</div>
    <div><br>
    </div>
    <div style="text-align: justify; font-size: 12pt;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif; font-weight: bold; font-style: italic;">provided, however</font><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;">, that an Indemnified Person shall have the right to retain its own counsel with the reasonable and documented fees and expenses to be paid by the Company, if, in the opinion of counsel for such Indemnified Person, the
        representation by such counsel of the Indemnified Person and the Company would be inappropriate due to actual or potential differing interests between such Indemnified Person and any other party represented by such counsel in such proceeding. The
        Company shall pay for only one separate legal counsel (in addition to one separate local counsel, if required) for the Indemnified Persons, and such legal counsel shall be selected by the Investors. The failure to deliver written notice to the
        Company within a reasonable time of the commencement of any such action shall not relieve the Company of any liability to the Indemnified Person under this Section 7, except to the extent that the Company is actually prejudiced in its ability to
        defend such action, and shall not relieve the Company of any liability to the Indemnified Person otherwise than pursuant to this Section 7.&#160; The Company </font><font style="font-size: 10pt;">shall not, without the prior written consent of the
        Indemnified Persons, consent to entry of any judgment or enter into any settlement or other compromise with respect to any Claim in respect of which indemnification or contribution may be or has been sought hereunder (whether or not any such
        Indemnified Party is an actual or potential party to such action or claim) which does not include as an unconditional term thereof the giving by the claimant or plaintiff to the Indemnified Persons of a full release from all liability with respect
        to such Claim or which includes any admission as to fault or culpability on the part of any Indemnified Person.&#160; <font style="font-family: 'Times New Roman',Times,serif;">The indemnification required by this Section 7 shall be made by periodic
          payments of the amount thereof during the course of the investigation or defense, as any expense, loss, damage or liability is incurred and is due and payable.</font></font></div>
    <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-weight: normal; font-style: normal;">12</font></div>
      <div id="DSPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;" noshade="noshade"></div>
    </div>
    <div style="text-align: justify; font-family: 'Times New Roman',Times,serif;">c.&#160; Each Investor will indemnify, hold harmless and defend (i)&#160;the Company, and (ii)&#160;the directors, officers, partners, managers, members, employees and agents of the
      Company, if any (each, a &#8220;<font style="font-weight: bold;">Company Indemnified Person</font>&#8221;), against any Claims to which any of them may become subject insofar as such Claims arise out of or are based upon any violation or alleged violation by the
      Company of the Securities Act, the Exchange Act, any other law, including any state securities law, or any rule or regulation thereunder relating to the offer or sale of the Registrable Securities, which occurs due to the inclusion by the Company in
      a Registration Statement or prospectus, or any amendment or supplement thereto, of false or misleading information about an Investor, where such information was furnished in writing to the Company by or on behalf of such Investor expressly for the
      purpose of inclusion in such Registration Statement or prospectus.&#160; Notwithstanding anything herein to the contrary, the indemnity agreement contained in this Section&#160;7(c) shall not apply to amounts paid in settlement of any Claim if such settlement
      is effected without the prior written consent of the Investors, which consent shall not be unreasonably withheld or delayed; and provided, further, however, that&#160;an Investor shall be liable under this Section&#160;7(c) for only that amount of a Claim as
      does not exceed the net amount of proceeds received by such Investor as a result of the sale of Registrable Securities pursuant to such Registration Statement.</div>
    <div><br>
    </div>
    <div style="text-align: justify; font-family: 'Times New Roman',Times,serif;">d.&#160; Promptly after receipt by a Company Indemnified Person under this Section&#160;7 of notice of the commencement of any action (including any governmental action), such Company
      Indemnified Person shall, if a Claim in respect thereof is to be made against any Investor under this Section&#160;7, deliver to such Investor a written notice of the commencement thereof, and such Investor shall have the right to participate in, and, to
      the extent such Investor so desires, to assume control of the defense thereof with counsel mutually satisfactory to such Investor and such Company Indemnified Person. No Investor shall, without the prior written consent of the Company, consent to
      entry of any judgment or enter into any settlement or other compromise with respect to any Claim in respect of which indemnification or contribution may be or has been sought by any Company Indemnified Person hereunder (whether or not any such
      Company Indemnified Person is an actual or potential party to such action or claim) which does not include as an unconditional term thereof the giving by the claimant or plaintiff to the Company Indemnified Persons of a full release from all
      liability with respect to such Claim or which includes any admission as to fault or culpability on the part of any Company Indemnified Person.</div>
    <div><br>
    </div>
    <div style="text-align: justify; font-size: 12pt;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif; font-weight: bold;">8.&#160; CONTRIBUTION.&#160; </font><font style="font-size: 10pt;">If for any reason the indemnification provided
        for in Section 7(a) or 7(c) (as applicable) is unavailable to an Indemnified Person or Company Indemnified Person (as applicable) or insufficient to hold it harmless, other than as expressly specified therein, then the indemnifying party shall
        contribute to the amount paid or payable by the Indemnified Person or Company Indemnified Person (as applicable) as a result of the Claim in such proportion as is appropriate to reflect the relative fault of the Indemnified Person or Company
        Indemnified Person (as applicable) and the indemnifying party (provided that the relative fault of any Company Indemnified Person shall be deemed to include the fault of all other Company Indemnified Persons), as well as any other relevant
        equitable considerations.&#160; No Person guilty of fraudulent misrepresentation within the meaning of Section&#160;11(f) of the Securities Act shall be entitled to contribution from any Person not guilty of such fraudulent misrepresentation.&#160; In no event
        shall the contribution obligation of an Investor be greater in amount than the net amount of proceeds received by such Investor as a result of the sale of Registrable Securities giving rise to such contribution obligation pursuant to the applicable
        Registration Statement (net of the aggregate amount of any damages or other amounts such Investor has otherwise been required to pay (pursuant to Section 7(c) or otherwise) by reason of such Investor&#8217;s untrue or alleged untrue statement or omission
        or alleged omission).</font></div>
    <div style="text-align: justify; font-size: 12pt;"><font style="font-size: 10pt;"> <br>
      </font></div>
    <div style="text-align: justify; font-size: 12pt;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif; font-weight: bold;">9.&#160; REPORTS UNDER THE 1934 ACT.&#160; </font><font style="font-size: 10pt;">With a view to making available to
        the Investors the benefits of Rule&#160;144 promulgated under the Securities Act or any other similar rule or regulation of the SEC that may at any time permit the Investors to sell securities of the Company to the public without registration, the
        Company agrees to, at all times following the effective date of the registration statement in respect of the Qualifying IPO:</font></div>
    <div style="text-align: justify; font-size: 12pt;"><font style="font-size: 10pt;"> <br>
      </font></div>
    <div style="text-align: justify; font-family: 'Times New Roman',Times,serif;">a.&#160; make and keep public information available, as those terms are understood and defined in Rule&#160;144;</div>
    <div style="text-align: justify; font-family: 'Times New Roman',Times,serif;"> <br>
    </div>
    <div style="text-align: justify; font-family: 'Times New Roman',Times,serif;">b.&#160; file with the SEC in a timely manner all reports and other documents required of the Company under the Exchange Act so long as the Company remains subject to such
      requirements and the filing of such reports and other documents is required for the applicable provisions of Rule&#160;144; and</div>
    <div style="text-align: justify; font-family: 'Times New Roman',Times,serif;"> <br>
    </div>
    <div style="text-align: justify; font-family: 'Times New Roman',Times,serif;">c.&#160; so long as any of the Investors owns Registrable Securities, promptly upon request, furnish to such Investor (i) a written statement by the Company that it has complied
      with the reporting requirements of the Exchange Act as required for applicable provisions of Rule&#160;144 and (ii)&#160;such other information as may be reasonably requested to permit such Investor to sell such Registrable Securities pursuant to Rule&#160;144
      without registration.</div>
    <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-weight: normal; font-style: normal;">13</font></div>
      <div id="DSPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;" noshade="noshade"></div>
    </div>
    <div style="text-align: justify; font-size: 12pt;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif; font-weight: bold;">10.&#160; ASSIGNMENT OF REGISTRATION RIGHTS.&#160; </font><font style="font-size: 10pt;">The rights under this
        Agreement shall be automatically assignable by each Investor to any transferee of all or any portion of the Registrable Securities if:&#160; (i)&#160;such Investor agrees in writing with the transferee or assignee to assign such rights, and a copy of such
        agreement is furnished to the Company within a reasonable time after such assignment, (ii)&#160;the Company is, within a reasonable time after such transfer or assignment, furnished with written notice of (a)&#160;the name and address of such transferee or
        assignee, and (b)&#160;the securities with respect to which such registration rights are being transferred or assigned, and (iii) at or before the time the Company receives the written notice contemplated in clause (ii) of this sentence, the&#160;transferee
        or assignee agrees in writing with the Company to be bound by all of the provisions contained herein as applicable to an Investor.&#160; In the event that the Company receives written notice from an Investor that it has transferred all or any portion of
        its Registrable Securities pursuant to this Section, the Company shall have up to ten (10) days to file any amendments or supplements necessary to keep a Registration Statement current, effective and available for the resale of all of the
        Registrable Securities pursuant to Rule 415.&#160; The Company shall not assign this Agreement (or any rights or obligations hereunder) without the prior written consent of <font style="font-family: 'Times New Roman',Times,serif;">the holders of a </font>majority-in-interest


        of the then-outstanding Registrable Securities.</font></div>
    <div style="text-align: justify; font-size: 12pt;"><font style="font-size: 10pt;"> <br>
      </font></div>
    <div style="text-align: justify; font-size: 12pt;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif; font-weight: bold;">11.&#160; AMENDMENT OF REGISTRATION RIGHTS.&#160; </font><font style="font-size: 10pt;">Provisions of this Agreement
        may be amended and the observance thereof may be waived (either generally or in a particular instance and either retroactively or prospectively), only with written consent of the Company and the holders of a majority in interest of then-outstanding
        Registrable Securities.&#160; Any amendment or waiver effected in accordance with this Section&#160;11 shall be binding upon each of the Investors and the Company.</font></div>
    <div style="text-align: justify; font-size: 12pt;"><font style="font-size: 10pt;"> <br>
      </font></div>
    <div style="text-align: justify; font-family: 'Times New Roman',Times,serif; font-weight: bold;">12.&#160; MISCELLANEOUS.</div>
    <div style="text-align: justify; font-family: 'Times New Roman',Times,serif; font-weight: bold;"> <br>
    </div>
    <div style="text-align: justify; font-family: 'Times New Roman',Times,serif;">a.&#160; A Person is deemed to hold, and be a holder of, Common Shares or other Registrable Securities whenever such Person owns of record or beneficially through a &#8220;street name&#8221;
      holder such Common Shares or other Registrable Securities (or the Notes or other securities upon exercise, conversion or exchange of which such Registrable Securities are directly or indirectly issuable, without giving effect to any limitations on
      conversion of the Notes or other securities), and solely for purposes hereof, Registrable Securities shall be deemed outstanding to the extent they are directly or indirectly issuable upon conversion of the Notes or other outstanding securities,
      Registrable Securities, without giving effect to any limits on exercise, conversion or exchange of the Notes or other securities.&#160; If the Company receives conflicting instructions, notices or elections from two or more Persons with respect to the
      same Registrable Securities, the Company shall act upon the basis of instructions, notice or election received from the registered owner of such Registrable Securities (or the Notes or other securities upon exercise, conversion or exchange of which
      such Registrable Securities are directly or indirectly issuable).</div>
    <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-weight: normal; font-style: normal;">14</font></div>
      <div id="DSPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;" noshade="noshade"></div>
    </div>
    <div style="text-align: justify; font-family: 'Times New Roman',Times,serif;">b.&#160; Any notices required or permitted to be given under the terms hereof shall be sent by certified or registered mail (return receipt requested) or delivered personally or
      by courier (including a recognized overnight delivery service) or by electronic mail and shall be effective upon receipt, in each case addressed to a party.&#160; The addresses for such communications shall be:</div>
    <div style="text-align: justify; font-family: 'Times New Roman',Times,serif;"> <br>
    </div>
    <div style="text-align: justify; font-family: 'Times New Roman',Times,serif;">If to the Company:</div>
    <div style="text-align: justify; font-family: 'Times New Roman',Times,serif;"> <br>
    </div>
    <br>
    <table style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: rgb(0, 0, 0);" id="z36625a8febb1457c8480d76e006870ea" border="0" cellpadding="0" cellspacing="0">

        <tr>
          <td colspan="2" style="vertical-align: top;">
            <div style="text-align: justify;">ADC Therapeutics SA</div>
          </td>
        </tr>
        <tr>
          <td colspan="2" style="vertical-align: top;">
            <div style="text-align: justify;">Biop&#244;le</div>
          </td>
        </tr>
        <tr>
          <td colspan="2" style="vertical-align: top;">
            <div style="text-align: justify;">Route de la Corniche 3B</div>
          </td>
        </tr>
        <tr>
          <td colspan="2" style="vertical-align: top;">
            <div style="text-align: justify;">1066 Epalinges</div>
          </td>
        </tr>
        <tr>
          <td colspan="2" style="vertical-align: top;">
            <div style="text-align: justify;">Switzerland</div>
          </td>
        </tr>
        <tr>
          <td style="width: 5%; vertical-align: top;">
            <div style="text-align: justify;">E-mail:</div>
          </td>
          <td style="width: 95%; vertical-align: top;">
            <div style="text-align: justify;">Michael.Forer@adctherapeutics.com</div>
          </td>
        </tr>
        <tr>
          <td style="width: 5%; vertical-align: top;">&#160;</td>
          <td style="width: 95%; vertical-align: top;">
            <div style="text-align: justify;">Dominique.Graz@adctherapeutics.com</div>
          </td>
        </tr>
        <tr>
          <td style="width: 5%; vertical-align: top;">
            <div style="text-align: justify;">Attn:</div>
          </td>
          <td style="width: 95%; vertical-align: top;">
            <div style="text-align: justify;">Michael Forer</div>
          </td>
        </tr>
        <tr>
          <td style="width: 5%; vertical-align: top;">&#160;</td>
          <td style="width: 95%; vertical-align: top;">
            <div style="text-align: justify;">Dominique Graz</div>
          </td>
        </tr>
        <tr>
          <td style="width: 5%; vertical-align: top;">&#160;</td>
          <td style="width: 95%; vertical-align: top;">&#160;</td>
        </tr>
        <tr>
          <td colspan="2" style="vertical-align: top;">
            <div style="text-align: justify;">With copy to:</div>
          </td>
        </tr>
        <tr>
          <td rowspan="1" colspan="2" style="vertical-align: top;">&#160;</td>
        </tr>
        <tr>
          <td colspan="2" style="vertical-align: top;">
            <div style="text-align: justify;">Davis Polk &amp; Wardwell LLP</div>
          </td>
        </tr>
        <tr>
          <td colspan="2" style="vertical-align: top;">
            <div style="text-align: justify;">450 Lexington Avenue</div>
          </td>
        </tr>
        <tr>
          <td colspan="2" style="vertical-align: top;">
            <div style="text-align: justify;">New York, NY 10017</div>
          </td>
        </tr>
        <tr>
          <td style="vertical-align: top;">
            <div style="text-align: justify;">Email: <br>
            </div>
          </td>
          <td style="vertical-align: top;">deanna.kirkpatrick@davispolk.com <br>
          </td>
        </tr>
        <tr>
          <td style="width: 5%; vertical-align: top;">&#160;</td>
          <td style="width: 95%; vertical-align: top;">
            <div style="text-align: justify;">Yasin.keshvargar@davispolk.com</div>
          </td>
        </tr>
        <tr>
          <td style="width: 5%; vertical-align: top;">
            <div style="text-align: justify;">Attn:</div>
          </td>
          <td style="width: 95%; vertical-align: top;">
            <div style="text-align: justify;">Deanna L. Kirkpatrick</div>
          </td>
        </tr>
        <tr>
          <td style="width: 5%; vertical-align: top;">&#160;</td>
          <td style="width: 95%; vertical-align: top;">
            <div style="text-align: justify;">Yasin Keshvargar</div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <div style="text-align: justify; font-family: 'Times New Roman',Times,serif;">If to an Investor:</div>
    <div style="text-align: justify; font-family: 'Times New Roman',Times,serif;">c/o Deerfield Mgmt, L.P.<br>
      780 Third Avenue, 37<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">th</sup> Floor<br>
      New York, NY 10017<br>
      Fax:&#160; (212) 599-1248<br>
      E-mail: dclark@deerfield.com</div>
    <div style="text-align: justify; font-family: 'Times New Roman',Times,serif;">Attn: David J. Clark, Esq.</div>
    <div><br>
    </div>
    <div style="text-align: justify; font-family: 'Times New Roman',Times,serif;">With a copy to:</div>
    <div style="text-align: justify; font-family: 'Times New Roman',Times,serif;">Katten Muchin Rosenman LLP</div>
    <div style="text-align: justify; font-family: 'Times New Roman',Times,serif;">525 West Monroe Street</div>
    <div style="text-align: justify; font-family: 'Times New Roman',Times,serif;">Chicago, Il 60661</div>
    <div style="text-align: justify; font-family: 'Times New Roman',Times,serif;">Email: mark.wood@katten.com</div>
    <div style="text-align: justify; font-family: 'Times New Roman',Times,serif;">Attn: Mark D. Wood, Esq.</div>
    <div><br>
    </div>
    <div style="text-align: justify; font-family: 'Times New Roman',Times,serif;">Each party shall provide notice to the other party of any change in address.</div>
    <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-weight: normal; font-style: normal;">15</font></div>
      <div id="DSPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;" noshade="noshade"></div>
    </div>
    <div style="text-align: justify; font-family: 'Times New Roman',Times,serif;">c.&#160; Failure of any party to exercise any right or remedy under this Agreement or otherwise, or delay by a party in exercising such right or remedy, shall not operate as a
      waiver thereof.</div>
    <div style="text-align: justify; font-family: 'Times New Roman',Times,serif;"> <br>
    </div>
    <div style="text-align: justify; font-family: 'Times New Roman',Times,serif;">d.&#160; Governing Law.&#160; All questions concerning the construction, validity, enforcement and interpretation of this Agreement shall be governed by and construed and enforced in
      accordance with the internal laws of the State of New York, without regard to the principles of conflicts of law thereof.&#160; Each party agrees that all legal proceedings concerning the interpretations, enforcement and defense of the transactions
      contemplated by this Agreement (whether brought against a party hereto or its respective affiliates, directors, officers, shareholders, employees or agents) shall be commenced exclusively in the state and federal courts sitting in the City of New
      York, borough of Manhattan (and, in each case, the applicable state and federal appeals courts sitting in the City of New York or, if not available or applicable, the State of New York).&#160; Each party hereby irrevocably submits to the exclusive
      jurisdiction of the state and federal courts sitting in the City of New York, Borough of Manhattan for the adjudication of any dispute hereunder or in connection herewith or with any transaction contemplated hereby or discussed herein, and hereby
      irrevocably waives, and agrees not to assert in any suit, action or proceeding, any claim that it is not personally subject to the jurisdiction of any such court, that such suit, action or proceeding is improper or is an inconvenient venue for such
      proceeding.&#160; Each party hereby irrevocably waives personal service of process and consents to process being served in any such suit, action or proceeding by mailing a copy thereof via registered or certified mail or overnight delivery (with evidence
      of delivery) to such party at the address in effect for notices to it under this Agreement and agrees that such service shall constitute good and sufficient service of process and notice thereof.&#160; Nothing contained herein shall be deemed to limit in
      any way any right to serve process in any other manner permitted by law.&#160; The parties hereby waive all rights to a trial by jury.&#160; If either party shall commence an action or proceeding to enforce any provision of this Agreement, then the prevailing
      party in such action or proceeding shall be reimbursed by the other party for its reasonable attorneys&#8217; fees and other costs and expenses incurred with the investigation, preparation and prosecution of such action or proceeding.</div>
    <div style="text-align: justify; font-family: 'Times New Roman',Times,serif;"> <br>
    </div>
    <div style="text-align: justify; font-family: 'Times New Roman',Times,serif;">e.&#160; This Agreement, the Facility Agreement, the Notes and the instruments referenced herein and therein, including the Facility Documents (as defined in the Facility
      Agreement) (collectively, the &#8220;<font style="font-weight: bold;">Transaction Documents</font>&#8221;), constitute the entire agreement among the parties hereto with respect to the subject matter hereof and thereof.&#160; This Agreement and the other Transaction
      Documents (including all schedules and exhibits hereto and thereto) supersedes all prior agreements and understandings among the parties hereto with respect to the subject matter hereof and thereof.</div>
    <div style="text-align: justify; font-family: 'Times New Roman',Times,serif;"> <br>
    </div>
    <div style="text-align: justify; font-family: 'Times New Roman',Times,serif;">f.&#160; Subject to the requirements of Section&#160;10 hereof, this Agreement shall inure to the benefit of and be binding upon the successors and permitted assigns of each of the
      parties hereto, and the provisions of Sections 7 and 8 hereof shall inure to the benefit of, and be enforceable by, each Indemnified Person and Company Indemnified Person (as applicable).</div>
    <div style="text-align: justify; font-family: 'Times New Roman',Times,serif;"> <br>
    </div>
    <div style="text-align: justify; font-family: 'Times New Roman',Times,serif;">g.&#160; The headings in this Agreement are for convenience of reference only and shall not limit or otherwise affect the meaning hereof.</div>
    <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-weight: normal; font-style: normal;">16</font></div>
      <div id="DSPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;" noshade="noshade"></div>
    </div>
    <div style="text-align: justify; font-family: 'Times New Roman',Times,serif;">h.&#160; This Agreement and any amendments hereto may be executed and delivered in two or more counterparts, and by the different parties hereto in separate counterparts, each of
      which when executed shall be deemed to be an original, but all of which taken together shall constitute one and the same agreement, and shall become effective when counterparts have been signed by each party hereto and delivered to the other parties
      hereto, it being understood that all parties need not sign the same counterpart.&#160; In the event that any signature to this Agreement or any amendment hereto is delivered by facsimile transmission, by e-mail delivery of a &#8220;.pdf&#8221; format data file or by
      other electronic means, such signature shall create a valid and binding obligation of the party executing (or on whose behalf such signature is executed) with the same force and effect as if such facsimile, &#8220;.pdf&#8221; or other electronic signature page
      were an original thereof.&#160; No party hereto shall raise the use of a facsimile machine, e-mail delivery of a &#8220;.pdf&#8221; format data file or other electronic means to deliver a signature to this Agreement or any amendment hereto or the fact that such
      signature was transmitted or communicated through the use of a facsimile machine, e-mail delivery of a &#8220;.pdf&#8221; format data file or other electronic means as a defense to the formation or enforceability of a contract, and each party hereto forever
      waives any such defense.</div>
    <div style="text-align: justify; font-family: 'Times New Roman',Times,serif;"> <br>
    </div>
    <div style="text-align: justify; font-family: 'Times New Roman',Times,serif;">i.&#160; The parties hereto acknowledge that a breach by it of its obligations hereunder will cause irreparable harm to the non-breaching party hereto by vitiating the intent and
      purpose of the transactions contemplated hereby.&#160; Accordingly, the parties hereto acknowledge that the remedy at law for breach of its obligations hereunder will be inadequate and agrees, in the event of a breach or threatened breach by any other
      party hereto of any of the provisions hereunder, that the non-breaching party hereto shall be entitled, in addition to all other available remedies in law or in equity, to an injunction or injunctions to prevent or cure breaches of the provisions of
      this Agreement and to enforce specifically the terms and provisions hereof, without the necessity of showing economic loss and without any bond or other security being required.</div>
    <div style="text-align: justify; font-family: 'Times New Roman',Times,serif;"> <br>
    </div>
    <div style="text-align: justify; font-family: 'Times New Roman',Times,serif;">j.&#160; The language used in this Agreement will be deemed to be the language chosen by the parties to express their mutual intent, and no rules of strict construction will be
      applied against any party.</div>
    <div style="text-align: justify; font-family: 'Times New Roman',Times,serif;"> <br>
    </div>
    <div style="text-align: justify; font-family: 'Times New Roman',Times,serif;">k.&#160; In the event that any provision of this Agreement is invalid or unenforceable under any applicable statute or rule of law, then such provision shall be deemed inoperative
      to the extent that it may conflict therewith and shall be deemed modified to conform with such statute or rule of law.&#160; Any provision hereof which may prove invalid or unenforceable under any law shall not affect the validity or enforceability of any
      other provision hereof.</div>
    <div style="text-align: justify; font-family: 'Times New Roman',Times,serif;"> <br>
    </div>
    <div style="text-align: justify; font-family: 'Times New Roman',Times,serif;">l.&#160; In the event an Investor shall sell or otherwise transfer any of such holder&#8217;s Registrable Securities, each transferee shall be allocated a pro rata portion of the number
      of Registrable Securities included in a Registration Statement for such transferor.</div>
    <div style="text-align: justify; font-family: 'Times New Roman',Times,serif;"> <br>
    </div>
    <div style="text-align: justify; font-family: 'Times New Roman',Times,serif;">m.&#160; There shall be no oral modifications or amendments to this Agreement.&#160; This Agreement may be modified or amended only in writing.</div>
    <div style="text-align: justify; font-family: 'Times New Roman',Times,serif;"> <br>
    </div>
    <div style="text-align: justify; font-family: 'Times New Roman',Times,serif;">p.&#160; The obligations of each Investor hereunder are several and not joint with the obligations of any other Investor, and no provision of this Agreement is intended to confer
      any obligations on any Investor vis-&#224;-vis any other Investor.&#160; Nothing contained herein, and no action taken by any Investor pursuant hereto, shall be deemed to constitute the Investors as a partnership, an association, a joint venture or any other
      kind of entity, or create a presumption that the Investors are in any way acting in concert or as a group with respect to such obligations or the transactions contemplated herein.</div>
    <div style="text-align: justify; font-family: 'Times New Roman',Times,serif;"> <br>
    </div>
    <div style="text-align: justify; font-family: 'Times New Roman',Times,serif;">o.&#160; Unless the context otherwise requires, (i) all references to Sections, Schedules or Exhibits are to Sections, Schedules or Exhibits contained in or attached to this
      Agreement, (ii) words in the singular or plural include the singular and plural, and pronouns stated in either the masculine, the feminine or neuter gender shall include the masculine, feminine and neuter, and (iii) the use of the word &#8220;including&#8221; in
      this Agreement shall be by way of example rather than limitation.</div>
    <div><br>
    </div>
    <div style="text-align: center; font-family: 'Times New Roman',Times,serif; font-weight: bold;">[Remainder of page left intentionally blank]</div>
    <div style="text-align: center; font-family: 'Times New Roman',Times,serif; font-weight: bold;"> <br>
    </div>
    <div style="text-align: center; font-family: 'Times New Roman',Times,serif; font-weight: bold;">[Signature page follows]</div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
      <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-weight: normal; font-style: normal;">17</font></div>
      <div style="page-break-after:always;" id="DSPFPageBreak">
        <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
    </div>
    <div style="text-indent: 36pt; font-family: 'Times New Roman',Times,serif;">IN WITNESS WHEREOF, the undersigned Investors and the Company have caused this Registration Rights Agreement to be duly executed as of the date first written above.</div>
    <div style="text-indent: 36pt; font-family: 'Times New Roman',Times,serif;"> <br>
    </div>
    <div>
      <table style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: rgb(0, 0, 0);" id="z1f8a716dcbc544dead9b4d80dc4b2d3b" border="0" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 50%; vertical-align: top;">&#160;</td>
            <td colspan="2" style="vertical-align: top;">
              <div style="font-weight: bold;">COMPANY:</div>
            </td>
          </tr>
          <tr>
            <td style="width: 50%; vertical-align: top;">&#160;</td>
            <td style="width: 5%; vertical-align: top;">&#160;</td>
            <td style="width: 45%; vertical-align: top;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 50%; vertical-align: top;">&#160;</td>
            <td colspan="2" style="vertical-align: top;">
              <div style="font-weight: bold;">ADC THERAPEUTICS SA</div>
            </td>
          </tr>
          <tr>
            <td rowspan="1" style="width: 50%; vertical-align: top;">&#160;</td>
            <td rowspan="1" colspan="2" style="vertical-align: top;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 50%; vertical-align: top; padding-bottom: 2px;">&#160;</td>
            <td style="width: 5%; vertical-align: top; padding-bottom: 2px;">
              <div>By:</div>
            </td>
            <td style="width: 45%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">/s/ Michael Forer<br>
            </td>
          </tr>
          <tr>
            <td style="width: 50%; vertical-align: top;">&#160;</td>
            <td style="width: 5%; vertical-align: top;">
              <div>Name:</div>
            </td>
            <td style="width: 45%; vertical-align: top;">Michael Forer</td>
          </tr>
          <tr>
            <td style="width: 50%; vertical-align: top;">&#160;</td>
            <td style="width: 5%; vertical-align: top;">
              <div style="margin-right: 14.6pt;">Title:</div>
            </td>
            <td style="width: 45%; vertical-align: top;">Vice Chairman &amp; EVP <br>
            </td>
          </tr>

      </table>
    </div>
    <div style="text-indent: 36pt; font-family: 'Times New Roman',Times,serif;"> <br>
    </div>
    <div style="text-indent: 36pt; font-family: 'Times New Roman',Times,serif;">
      <div style="text-align: center; font-family: 'Times New Roman', Times, serif;"> <br>
      </div>
      <div style="text-align: center; font-family: 'Times New Roman', Times, serif;">[Signature Page to Registration Rights Agreement]</div>
    </div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
      <div style="page-break-after:always;" id="DSPFPageBreak">
        <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
    </div>
    <div style="text-indent: 36pt; font-family: 'Times New Roman',Times,serif;">IN WITNESS WHEREOF, the undersigned Investors and the Company have caused this Registration Rights Agreement to be duly executed as of the date first written above.</div>
    <div><br>
    </div>
    <div>
      <table style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: rgb(0, 0, 0);" id="z0b033023f442415d9a036a73ab3fce1c" border="0" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 50%; vertical-align: top;">&#160;</td>
            <td colspan="3" style="vertical-align: top;">
              <div style="font-weight: bold;">INVESTORS:</div>
            </td>
          </tr>
          <tr>
            <td style="width: 50%; vertical-align: top;">&#160;</td>
            <td colspan="3" style="vertical-align: top;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 50%; vertical-align: top;">&#160;</td>
            <td colspan="3" style="vertical-align: top;">
              <div style="font-weight: bold;">DEERFIELD PARTNERS, L.P.</div>
            </td>
          </tr>
          <tr>
            <td style="width: 50%; vertical-align: top;">&#160;</td>
            <td style="width: 5%; vertical-align: top;">&#160;</td>
            <td style="width: 5%; vertical-align: top;">&#160;</td>
            <td style="width: 40%; vertical-align: top;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 50%; vertical-align: top;">&#160;</td>
            <td style="width: 5%; vertical-align: top;">
              <div>By:</div>
            </td>
            <td colspan="2" style="vertical-align: top;">
              <div>Deerfield Mgmt, L.P.,</div>
            </td>
          </tr>
          <tr>
            <td style="width: 50%; vertical-align: top;">&#160;</td>
            <td style="width: 5%; vertical-align: top;">&#160;</td>
            <td colspan="2" style="vertical-align: top;">
              <div>its General Partner</div>
            </td>
          </tr>
          <tr>
            <td style="width: 50%; vertical-align: top;">&#160;</td>
            <td style="width: 5%; vertical-align: top;">&#160;</td>
            <td style="width: 5%; vertical-align: top;">&#160;</td>
            <td style="width: 40%; vertical-align: top;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 50%; vertical-align: top;">&#160;</td>
            <td style="width: 5%; vertical-align: top;">
              <div>By:</div>
            </td>
            <td colspan="2" style="vertical-align: top;">
              <div>J.E. Flynn Capital, LLC,</div>
            </td>
          </tr>
          <tr>
            <td style="width: 50%; vertical-align: top;">&#160;</td>
            <td style="width: 5%; vertical-align: top;">&#160;</td>
            <td colspan="2" style="vertical-align: top;">
              <div>its General Partner</div>
            </td>
          </tr>
          <tr>
            <td style="width: 50%; vertical-align: top;">&#160;</td>
            <td style="width: 5%; vertical-align: top;">&#160;</td>
            <td colspan="2" style="vertical-align: top;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 50%; vertical-align: top; padding-bottom: 2px;">&#160;</td>
            <td style="width: 5%; vertical-align: top; padding-bottom: 2px;">
              <div>By:</div>
            </td>
            <td colspan="2" style="vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">
              <div>/s/ David J. Clark </div>
            </td>
          </tr>
          <tr>
            <td style="width: 50%; vertical-align: top;">&#160;</td>
            <td style="width: 5%; vertical-align: top;">&#160;</td>
            <td style="width: 5%; vertical-align: top;">
              <div>Name:</div>
            </td>
            <td style="width: 40%; vertical-align: top;">
              <div>David J. Clark</div>
            </td>
          </tr>
          <tr>
            <td style="width: 50%; vertical-align: top;">&#160;</td>
            <td style="width: 5%; vertical-align: top;">&#160;</td>
            <td style="width: 5%; vertical-align: top;">
              <div>Title:</div>
            </td>
            <td style="width: 40%; vertical-align: top;">
              <div>&#160;Authorized Signatory</div>
            </td>
          </tr>

      </table>
      <div> <br>
      </div>
      <div>
        <table style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: rgb(0, 0, 0);" id="zf9111f047a8d4589a9526d94130996ee" border="0" cellpadding="0" cellspacing="0">

            <tr>
              <td style="width: 50%; vertical-align: top;">&#160;</td>
              <td colspan="3" style="vertical-align: top;">
                <div style="font-weight: bold;">DEERFIELD PRIVATE DESIGN FUND IV, L.P.</div>
              </td>
            </tr>
            <tr>
              <td style="width: 50%; vertical-align: top;">&#160;</td>
              <td colspan="3" style="vertical-align: top;">&#160;</td>
            </tr>
            <tr>
              <td style="width: 50%; vertical-align: top;">&#160;</td>
              <td colspan="3" style="vertical-align: top;">
                <div>By: Deerfield Mgmt IV, L.P., General Partner</div>
              </td>
            </tr>
            <tr>
              <td style="width: 50%; vertical-align: top;">&#160;</td>
              <td colspan="3" style="vertical-align: top;">&#160;</td>
            </tr>
            <tr>
              <td style="width: 50%; vertical-align: top;">&#160;</td>
              <td colspan="3" style="vertical-align: top;">
                <div>By: J.E. Flynn Capital IV, LLC, General Partner</div>
              </td>
            </tr>
            <tr>
              <td style="width: 50%; vertical-align: top;">&#160;</td>
              <td colspan="3" style="vertical-align: top;">&#160;</td>
            </tr>
            <tr>
              <td style="width: 50%; vertical-align: top; padding-bottom: 2px;">&#160;</td>
              <td style="width: 5%; vertical-align: top; padding-bottom: 2px;">
                <div>By: <br>
                </div>
              </td>
              <td colspan="2" style="vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">
                <div>/s/ David J. Clark </div>
              </td>
            </tr>
            <tr>
              <td style="width: 50%; vertical-align: top;">&#160;</td>
              <td style="width: 5%; vertical-align: top;">&#160;</td>
              <td style="width: 5%; vertical-align: top;">
                <div>Name:</div>
              </td>
              <td style="width: 40%; vertical-align: top;">
                <div>David J. Clark</div>
              </td>
            </tr>
            <tr>
              <td style="width: 50%; vertical-align: top;">&#160;</td>
              <td style="width: 5%; vertical-align: top;">&#160;</td>
              <td style="width: 5%; vertical-align: top;">
                <div>Title:</div>
              </td>
              <td style="width: 40%; vertical-align: top;">
                <div>Authorized Signatory</div>
              </td>
            </tr>

        </table>
        <div> <br>
        </div>
        <div>
          <div style="text-align: center;"> <br>
          </div>
          <div style="text-align: center;">[Signature Page to Registration Rights Agreement]</div>
        </div>
        <div>
          <hr style="height: 2px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;" align="center" noshade="noshade"> </div>
      </div>
    </div>
  </div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-21.1
<SEQUENCE>5
<FILENAME>filename5.htm
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: Broadridge Financial Soultions, Inc.
         Document created using EDGARfilings PROfile 7.1.0.0
         Copyright 1995 - 2020 Broadridge -->
  </head>
<body style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000;" bgcolor="#ffffff">
  <div style="text-align: right; font-weight: bold;">
    <hr style="height: 4px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;" align="center" noshade="noshade">Exhibit 21.1</div>
  <div style="text-align: center; font-weight: bold;">Subsidiaries of ADC Therapeutics SA</div>
  <div style="text-align: center; font-weight: bold;"> <br>
  </div>
  <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;" id="z985eebd9d0e44f3198cdd5a08382b650" border="0" cellpadding="0" cellspacing="0">

      <tr>
        <td style="width: 50%; vertical-align: middle;">
          <div style="text-align: center; font-weight: bold;"><u>Name of Subsidiary</u></div>
        </td>
        <td style="width: 50%; vertical-align: middle;">
          <div style="text-align: center; font-weight: bold;"><u>Jurisdiction of Organization</u></div>
        </td>
      </tr>
      <tr>
        <td rowspan="1" style="width: 50%; vertical-align: middle;">&#160;</td>
        <td rowspan="1" style="width: 50%; vertical-align: middle;">&#160;</td>
      </tr>
      <tr>
        <td style="width: 50%; vertical-align: middle;">
          <div style="text-align: center;">&#160;ADC Therapeutics America, Inc.</div>
        </td>
        <td style="width: 50%; vertical-align: middle;">
          <div style="text-align: center;">&#160;United States</div>
        </td>
      </tr>
      <tr>
        <td style="width: 50%; vertical-align: middle;">
          <div style="text-align: center;">ADC Therapeutics (UK) Limited</div>
        </td>
        <td style="width: 50%; vertical-align: middle;">
          <div style="text-align: center;">England</div>
        </td>
      </tr>

  </table>
  <div><br>
  </div>
  <div>
    <hr style="height: 2px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;" align="center" noshade="noshade"></div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>logo_adc2.jpg
<TEXT>
begin 644 logo_adc2.jpg
M_]C_X  02D9)1@ ! 0$ P #   #_[0 V4&AO=&]S:&]P(#,N,  X0DE- ^T*
M4F5S;VQU=&EO;@     0 ,     !  $ P     $  ?_B"^!)0T-?4%)/1DE,
M10 ! 0  "]!N;VYE @   &UN=')21T(@6%E:( ?4  < %0 3  L (6%C<W
M         $E%0R!S4D="     0            #VU@ !     -,M2% @(
M
M$&1E<V,   %$    =&)865H   &X    %&)44D,   ',   (#&1M9&0   G8
M    B&=865H   I@    %&=44D,   ',   (#&QU;6D   IT    %&UE87,
M  J(    )&)K<'0   JL    %')865H   K     %')44D,   ',   (#'1E
M8V@   K4    #'9U960   K@    AW=T<'0   MH    %&-P<G0   M\
M*&-H860   ND    +&1E<V,         &G-21T(@245#-C$Y-C8M,BTQ('=I
M=&A"4$,
M                                                    6%E:(
M     "2@   /A   ML]C=7)V        !      %  H #P 4 !D '@ C "@
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M;W5R(%-P86-E("T@<U)'0@
M
M      !865H@        8ID  +>%   8VEA96B            !0
M;65A<P         !                               "6%E:(
M  ,6   #,P   J1865H@        ;Z(  #CU   #D'-I9R      0U)4(&1E
M<V,         +5)E9F5R96YC92!6:65W:6YG($-O;F1I=&EO;B!I;B!)14,@
M-C$Y-C8M,BTQ
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MU=;7V-G:X>+CY.7FY^CIZO'R\_3U]O?X^?K_Q  ? 0 # 0$! 0$! 0$!
M     0(#! 4&!P@)"@O_Q "U$0 " 0($! ,$!P4$!  ! G<  0(#$00%(3$&
M$D%1!V%Q$R(R@0@40I&AL<$)(S-2\!5B<M$*%B0TX27Q%Q@9&B8G*"DJ-38W
M.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U=G=X>7J"@X2%AH>(B8J2
MDY25EI>8F9JBHZ2EIJ>HJ:JRL[2UMK>XN;K"P\3%QL?(R<K2T]35UM?8V=KB
MX^3EYN?HZ>KR\_3U]O?X^?K_V@ , P$  A$#$0 _ /[^**** "BBB@ HHHH
M**** "BBOPW_ ."X/_!3.W_88^ 3?#GX::S"G[2OQPTO4M*\%"VFC>\^'WA+
M*6/B'XC7L2%I+6[C2>32O!GG"+[5KS3ZE T\/AZ^@?VN'LAS'B?.<!D>54G5
MQF/KQI0O?V=&FKRK8FO))\E##TE.M6G9M0@^52DXQ?G9OFN#R3+L7FF/JJEA
M<'2=6I+3FD]%"E33:YZM:;C3I03O*<HKJ+^T9_P<$_L&?LV?&7QS\$/$-O\
M&/QYXE^'FJMH/B37/AGX4\):[X0CU^WC0ZIHUEK&K^/?#\][=Z+=,^FZJ\.G
MFU@U*WNK2*XG>WD*_/4W_!T!^PF)&%O\-_VCWCS\K2^"_ R.1_M*OQ,< _0D
M>]?P97-S<WMS<7EY<37=W=S2W-U=7,KSW%S<3NTLT\\TK-)---(S22RR,SR.
MS.[%B34%?VAAOH\< TL/0AB?[7Q.(A1IQKUUC_8QK5HPBJE6-&-*4:4:DU*<
M::E)04N3FE:[_F6OXT<5SKUI4*.54:$JLY4:4\+5JSITG-NG3G5^L1]I*,+1
ME/EBIN\E&*:BO[S_ /B*!_89_P"B:_M%_P#A'>"/_GE5W_PP_P"#CS]C+XK^
M,]+\#:!X!^.UAJNK)>O;7.M>%/"D&GI]ALY[V59I;#QYJ-RI>*!UCV6D@,A4
M.44EQ_GXU]2?L9_\G#>"?^N/B'_U']2KJI?1Y\.JE2$'1SE*4HQ;69NZ3:5U
M>@U?U37=.[O\SQ;X\\=9)PQG^;X*.2O%Y9E&.QN&5;+ZU2DZV&P\ZM/VD%C(
M.<.:"YHJ46TVKJY_H.?\/=_V?/\ H7_'W_@DLO\ Y<4?\/=_V?/^A?\ 'W_@
MDLO_ )<5_-O17=_Q+;X;]L^_\.E/R_Z@_+\7W/Y&_P")Y?&W_GWP9_X8<7_\
M]_+\^[/Z4;?_ (*X?L[S-B72_&UH,XW3Z"KC''S8M;^Y; R?X=W!PIXSZ'X>
M_P""GO[+6N21PS>+KC2)7(XU71==L(US@'?=3Z;]C3!(^]<CN>@)K^6NBN7$
M_1E\/JT6J&,XEPD[>[*GF&"JQ3M]J-?+*CDM-4IQ;ULU<]# _3P\8</4B\7E
M' N84KKGA4RG-\/4:ZJ%7#Y]&,';9RHU$GJXO6_]E?@S]I[X'^/E0^%_B'X9
MU8OT2RU>PNI ?[K1P3O(C Y!5T5U((*@@@>UV.L:7J2"2QO[6Y5@"#%,C<'I
MQG/>OX;89IK>5)H)9()HVW1RPNT<L;#HR2(596]U(-?1/PW_ &L?CU\+KB!_
M#_Q UF\L8&0G2=?N9M:L'1""(U:\D:]M4P" MG=VX&<X) Q^=Y]]%K'4H5*O
M#7$N'Q<DG*&#S?"SP<VEKR+&X6>*ISG):1Y\+0AS/WIQCJOVCA#Z?V2XFI1P
M_'' V/RN,G&-7,^',?2S6E%MQ3J2RS'4\OKTJ4=925/'XRJHKW(5)6B_[&Z*
M_$?]GW_@JOI&K366@_%S3QX>O)#'"-764SZ),Y"+O>Z8+/IY8AB1>(UO&N ;
MUW/'[!>#/B#X7\>:;;ZEX>U2UO8;B))4$,T<A*.H964HS*RD'*E20001UK^<
M>)N#^).#\9]1XBRK$Y=5ES>QJ5(J>&Q,8M7GA<72<\-B8J\>;V-6<J;DHU%"
M7NG]M\"^(_!/B3E?]K\%\0X#/,+#D6)IT)RI8[ SFFXTLPR[$1HX[ U)6ER1
MQ6'I>U47.DZE.TGVU%%8OB/Q'H'A#0=7\4>*M9TWP]X<T"PN=5UK7-8O(-/T
MO2].LXVFN;V^O;EXX+>WAC4L\DCJ!P!DD _-PA.I.-.G&4YSE&$(0BY3G.34
M8QC&*;E*3:48I-MM)*[/M9SA3A.I4G&G3IQE.I4G)0A"$$Y2G.4FHQC&*;E)
MM))-MI(VJ^7/VB/VS_V:_P!EG3VN?C-\4-#\/ZL\!GL/!]@TNO>-]54@>7]B
M\+:0EUJBPRLRH-0OH;+2HF93<7\*'=7X$?MV_P#!;KQ+XBN]9^&/['D\_A?P
MY"\VGZG\:;VU0>)=<V/LF/@73+R)T\/::X5TAU[4(9=;NHI//L+31)8X;F3^
M>;7->USQ/J]_K_B76=5\0Z[JMP]WJFM:WJ%WJNK:C=R?ZRYOM1OII[N[N'P-
M\UQ-)(V!ECBOZ7X#^CKF>;TJ&9\98FMDF"JJ-2GE.&C!YO6INS3Q-2K&I0R[
MF335*5+$XE7<:M+#31_&_BE]+G(N':^)R7P_P>'XGS.BYTJV=XN=2/#V&K1;
MBUA84)T\3G#A)-2J4:V#P;O"=#%XJ/-%?TB?'#_@X+U S7FF?LZ?!"RB@4R1
MVOBWXNZC<7,DO+HLR>"_"E[9K""NV6)KCQA,0?EFL^JU^9'Q$_X*U_M[_$62
MY6?XY7_@ZPN!(@TSX>Z#X?\ "4,$<F<I!J5GITGB$;02%DEUJ6< \RD@$?F[
M17]*9+X4^'V0PA'!\+Y97JP2_P!IS.@LUQ,I*WO^TS#ZPJ<FU>U"-*"?PQBM
M#^-^)/'GQ:XIJU)X_C7.,%1FW;!9'7>182G"[M2Y,K^JU:T%=J^*JXBI)64Y
MRLK>\:S^U-^TUXB>1]=_:'^-^J^:27COOBKXYG@Y.2%MWUPP1KGD)'&J#LHK
M!TWX^_';1IOM&D?&KXM:5/D'SM-^(_C&QFR""#YEKK,3Y! (.[@@'L*\EHK[
M2.597"'LX9;@(4[6]G'!X>,++9<JIJ-EVL?G,^(N(*E15JF>9Q4JIMJK/,\;
M*HG+634Y5W*[>[O=]3[3\%?\%%OVX? #Q-H'[37Q4GCA*[;?Q1KY\;VK $'$
MEOXSAUZ-\XP6*[R.-PK] _@[_P %[OVF_",UM:?%[P/\/?B[HZF-;B^LK6Y\
M >+F4'$CK?Z0;[PU(=GS"(^$X6>0 &YC5B1^%-%?-YMX=\#9Y"<,RX5R6K*=
M^:O1P5+!8O7=K&8)8?%1?I61]AD/C!XH<-5*=3*..>(Z4:7+R8;%YC6S3 I1
MT4?J&:/&8+EMHU[#:W96_N,_9D_X*V?LB_M(3:?H$GBJX^$7C^^9((O!_P 3
MOLND0WUTY"+#H?BN&>;PUJ;2N0MM;3WVG:M<$X32Q7Z=(Z2(LD;*Z.JNCHP9
M'1@&5E920RL""K D$$$'!K_,YK]7/V'O^"L/QS_93O=(\(>-+_5?BY\$(I(;
M:?PAK=^UUXA\*V!<"2;P+KE_(TUHEO&6>+P[?7#:',P\N :6\LEW7\\<<_1N
M5.E6S#@7%U:DH*5260YE5C*<TM7#+\P:A>2VA0QJ;EJY8V]HO^M_#+Z8<<37
MPV4>)V7T,*JCC2AQ1D]*I&A"3M%3S7*DZLZ<'K*KBLNG*,6TEET*?-4A_;91
M7E'P3^-OPV_:%^''A[XJ?"CQ):>)O"/B.V66WN83Y=YIUXJK]LT;6K!R+G2M
M:TV5O(O]/ND26&0!U\R"2&:0K^4,3AL1@\17PF+H5<-BL-5G0Q&'KTY4JU&M
M2DX5*56G-*<)PDG&49)----']TX3%X7'X7#X[ XBAB\'BZ%+$X7%8:K"MA\3
MAZT%4HUZ%:FY4ZM*K3E&=.I"3C*+33:9ZO1116!T!1110 4444 %%%0W%Q;V
MEO/=W<\-K:VL,MQ<W-Q*D-O;V\*-)-//-(RQQ0PQJTDLLC*D:*SNP4$@2;=D
MKMZ)+=OL!\^?M6_M.?#+]C[X#^/_ (__ !8U(67A;P/I3W$.GPR1C5?$^O71
M%MH/A30H7.;G6->U*2"RME"M';1O-J%V8K&SNIXO\O?]K3]J'XF?MC_'WQ_^
MT%\5]0^U>)O&^I^9:Z;!)*VE>%O#EC&MGX=\)Z%#(Q%OI.A:7%!:1!0KW=P+
MG4KOS+Z^NII/U&_X+D_\%-;G]M_X]2?"SX8ZW._[-7P.U?4M*\+"UG<6'Q%\
M;6\D^G:[\1[A$*QW6GE5DTGP8)A+Y&BBZU2%HI/$-U!'^%5?W=X)^'*X1R;^
MV\TH<O$.=T(2G"I&U3+<NDXU:."LU>%>LU#$8U:-35'#RC?#.4_Y1\5.-?\
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M+B*2&9#Z/'(JNI]F4&O[E7T[3Y/OV5JWU@B_^)KA/%7P>^%OCBUDLO%WP_\
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M%U9)#XG^+/B"QMYO$NHSR1PF\L]"$GGKX6\/-/$&ATC3) \JK$^JWFI7,:W
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MJ[8:D\1A\7@4[<F&Q/U6"DL'*<J=?!G[0?A/_A"_'>G^-=.C,6C>,7:WU9%
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MVT17OM1E<117XAD$<<CL$0:7:NHGFN')40W5U%%)$[_N+)+B.&['@O[1VO\
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MG72:_P P2O\ 3[_X+!?\HROVS/\ LCFJ?^G72:_S!*_M+Z-/_))9[_V44_\
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M_;#_ &8O@'97-U\5?C9X \,W5NDC_P!@C7[/5O%=P8P24M/"FBOJ'B&Y8GY
M8]-,8<A7=<U_/K^V=_P71U_Q?8ZKX _9'T74_!>D7<<]E??%SQ1#!'XMNH)
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M 'Q<?_)%=O\ Q-)PA_T3_$G_ (#EG_S?_5GY7_EO_B0+Q%_Z+3@S_P !SO\
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/L="K3K8E5<9A\53Q,__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>logo_adc2x1.jpg
<TEXT>
begin 644 logo_adc2x1.jpg
M_]C_X  02D9)1@ ! 0$ P #   #_[0 V4&AO=&]S:&]P(#,N,  X0DE- ^T*
M4F5S;VQU=&EO;@     0 ,     !  $ P     $  ?_B"^!)0T-?4%)/1DE,
M10 ! 0  "]!N;VYE @   &UN=')21T(@6%E:( ?4  < %0 3  L (6%C<W
M         $E%0R!S4D="     0            #VU@ !     -,M2% @(
M
M$&1E<V,   %$    =&)865H   &X    %&)44D,   ',   (#&1M9&0   G8
M    B&=865H   I@    %&=44D,   ',   (#&QU;6D   IT    %&UE87,
M  J(    )&)K<'0   JL    %')865H   K     %')44D,   ',   (#'1E
M8V@   K4    #'9U960   K@    AW=T<'0   MH    %&-P<G0   M\
M*&-H860   ND    +&1E<V,         &G-21T(@245#-C$Y-C8M,BTQ('=I
M=&A"4$,
M                                                    6%E:(
M     "2@   /A   ML]C=7)V        !      %  H #P 4 !D '@ C "@
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M;W5R(%-P86-E("T@<U)'0@
M
M      !865H@        8ID  +>%   8VEA96B            !0
M;65A<P         !                               "6%E:(
M  ,6   #,P   J1865H@        ;Z(  #CU   #D'-I9R      0U)4(&1E
M<V,         +5)E9F5R96YC92!6:65W:6YG($-O;F1I=&EO;B!I;B!)14,@
M-C$Y-C8M,BTQ
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MU=;7V-G:X>+CY.7FY^CIZO'R\_3U]O?X^?K_Q  ? 0 # 0$! 0$! 0$!
M     0(#! 4&!P@)"@O_Q "U$0 " 0($! ,$!P4$!  ! G<  0(#$00%(3$&
M$D%1!V%Q$R(R@0@40I&AL<$)(S-2\!5B<M$*%B0TX27Q%Q@9&B8G*"DJ-38W
M.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U=G=X>7J"@X2%AH>(B8J2
MDY25EI>8F9JBHZ2EIJ>HJ:JRL[2UMK>XN;K"P\3%QL?(R<K2T]35UM?8V=KB
MX^3EYN?HZ>KR\_3U]O?X^?K_V@ , P$  A$#$0 _ /[^**** "BBB@ HHHH
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MVH/&$EU:?"CP3\//A#I$OF+!<SV]WX]\50H3A"-5U;^S= #A/O$>$]V[#(Z
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MZ_#'_@N-_P %,+7]A_X -\-?AMK$)_:1^-^GWVC^$XK:=?M?@#P9)%-::_\
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MMV32T3:E)+].J***_B$_U*"BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHK\Y/VY?V__  E^RYI%QX0\)BP\6?&K5+,-IVA/+YFE^$X+A<Q:WXJ\EQ+]
MP^;IVC1O#<Z@VV26:UM 97^<XKXLR#@K),9Q#Q)F%++LLP4+SJ3O*K7JR3]E
MA<)0C>IB<77:<:-"E&4Y.\GRTXSG'ZG@S@OB7Q XAP'"_"F65LUSC,)VIT:=
MHTJ%&+BJV,QN(E:EA,%AHR4\1B:THTZ<;*\IRA"7T;^T;^U1\(/V8/# U[XD
MZ^B:G>PS/X>\'Z8T-UXJ\22Q97;IVFF5&CM%EQ'<:K>-;Z;:LP66Y$K)&_\
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M/CHYEPAQ+G/#N,4HRG4RO'5\-3K\NT<5AX3^K8REI9T<52K4I+24&M#^K/\
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M%K0_(KXC_L9_$SPOY]YX4^S^.M*4NP33PMGKD:=0)-*N)2+E@.,6%Q<R.>1
MN<#XL\0Z5JFAWDVG:UIM_I.H0,1/8ZE:3V-W$R\$26]S'%*G((&4 )!Q7])%
M<OXH\$^$/&MFUAXL\-:+XAM64J(]5T^WNVC!&"899$,T#="'ADC=2 P8$ C^
M8^*?HG<-8N=7%<'9QB^'ZLKN.6X^,LTRQ/[-.C7E.&88:%]Y5:N8-;1@E9+^
MAN%/I)YYEJI8?BC*L/G=&/+%X[ RCEV8**M>=2ER5,%B)I+2-.G@4_M3O=O^
M:2_;J/10/S.3^E,T?XD>/? \RW'@_P 9>)/#DBDMMTC6;ZR@?DX$EM#,MO,!
MG($L3J#@XS7[3^-OV"/@QXF,L^@S^(_!5W)N*KIE\FI:8&;."]CJT5S/A3@!
M(-0MUVY!!.&'R%X\_P""<?B?28+J]T/XK>$+NT@CDE!\26%]X<,42@L3/-;3
MZ[ JHO#S812%+^6HRJ_BN/\ H_\ BYP[B%7RO+XYC*C+]UCN'<VI1K)JW*Z=
M*O4P&8\S[4\/)I]=F_Z'R3Q]\(<^P_U?.<P_LZ%5+VN"XCRBM/#M62DJM6A2
MS#+N1+FNZN(BK--VU2^;--_;^_:<\,H(SXVL/$$4?"1^(O#>B7;[1_"]U96F
MGWDQ(()::YED)Z. ,#:F_P""JO[15FA0^'OA5<L.?,G\/>(U8CIR+?Q=!'R>
M>%')QTQ7Q#\3K?0? OB*Z\-7'COP;XDO;,L+F\\'7VJZ_I44JNT9@_M*+1H;
M:29=I,D<32&/A9-C':?&KW5=%G+B/6[+YA@,UKK('3O_ ,2MFZ@8^6OLL)X?
M?34H4Z4<NX*\<J]"K"#H5)</<29A0G3DH\DZ>*Q&#Q-)4VG>,O:J+CK%N.I\
M]7\8?V>LL176>>*/T;<)B\-5E3QF&GQGPAE>*I58-*I3K8+#YCA:ZK1:E&=-
MT744KJ2YM#5^-/QB\5?&'QSKOQ$\=)8:KXFUIT$DY_M)+2PM(%,=GIVF67]H
MM;6NGV4?R6]L8Y?O/+,\T\LLK_/%]K^K3B2V^V/!;X,;P64<%A%*O3$\=C%;
MK<'  W3B1N.M=QJ$6F3J^[4I9),G:+2P9XF Q@/-=SV,D>[^\MK+MQRIZ'-A
MCTVS<R66FQ&4E66XU-DU.:-A][RXGA@T\*W!4R6$D\1Y2<-@C]2RSZ+/[0;Q
MOI8/(N,\^XOX6X+5.GAI4O$#CS$X#(\/A(*$(T8<&93C<=C:CHT5:E3J9#1H
MRLJ;Q%-<SC^(9Y].7]E#]&O$YCQ3X?\ #? '''B14K5\=]8\*?##!YMQ/C<P
MJMU)8BKXC9WEN6Y93=>O*3KUJ?%-?$)-U5A:KC%2YK3/#]S>HEW=.-.TTY87
M<Z$R7*JQ5UTZUW))?2!E,996CM(I,+=7=N"&J]XF\1Z/X0\-:EJ4J_8-#T:U
MFO[@-(K75]+"C"-[J;;&MQ=REOL]I$J)!;^<R6\2&6XDFV)YY[F5IKB62>5\
M;I)79W.  HW,2<*H"JHX50%4  "OAW]IWQ1KNI^)K;X61V&HZ39::MGJVN&]
MM;BSDU26ZACN=-$<<R1M+I<$#BY290\5W<2(R'%LC/\ Z:_1D^A#X7_1EC1X
MAE67'7BGB,/.A'BW-L+2PU/+?:TU2Q6'X4RCVF(64X>4*CIXO,*F(QF:UL/.
MI2>,H87$2P3_ ,9OIB_M(_'#Z;N)K\&4,-+PO\"\)C*.*Q'!&0XROC:V:PH5
MO;8+%\=<0>QPG]N8M5:*J99E%+"X#)*&-A1K+ 8O&82.8Q\)LKZ_\9^*-=\;
MZP/]*U>_ENDCR2MO#@16EI%D9$5I9I#;QG[Q5,N2^YCV=4["SBL;6*WB4*J*
M!P,9..2?<G)/N35RO[2I4_9P4;\TG[TY/>4Y:SD_-R;?7RTL?P]5G&4DH15.
ME3C"E1IQ^&G2IPC3I4X^4*<8P7?EONS^BG_@B_\ \%"K#P->V'[(_P 8]=CL
M?#&N:C,WP>\3:M<B*QT77=0E>>X\$7UY.XCL['7+MWFT!Y72V36)GTY6CEU&
MV27^I^O\SN*66"6.:&1X9H726*6)VCDBDC8,DD;J0R.C ,K*0RL 0017]*G_
M  3@_P""R=GI&G:)\#OVN]7DCMK-;;2_!OQLN6DE2"S14@MM(^(BX=PEN %M
MO%L1"+;A8M9MP8FU27^4/&SP:Q>-Q6*XQX2PDL15K\U?/,GP\;UZE;>IF6 I
M15ZTZJ][&8:"=6=12Q%*-252K&/]X_1M^D1@,'@<#X><>X^&$CA>3"\,\08N
M:AA8X9)1HY/FF(F^7#JA_#R_&57&A['DPE>=)TJ,ZW].%%9VDZOI6OZ98:UH
M>I6.L:/JEK#?:;JFF7<%]I]_9W,:RV]U9WEL\MO<V\T;*\4T,CHZL&5B#6C7
M\ARC*,I1E%QE%N,HR34HR3LXR3LTTTTTU=/1G]\QE&48RC)2C)*491:<91:N
MI1:NFFFFFG9K5!1112&%%%% !63KVO:+X6T35O$GB/5+'1- T+3KO5M9UC4[
MF*ST_3--L('N;R^O;J=DAM[:V@C>6661U5$4DFL3Q]\0O _PL\)ZOXY^(OBG
M1?!OA'0;9KK5M?U^^AL-/M(E!P#+,P,L\K?N[>U@66YN92L5O#)*RH?Y"?\
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MO\*?\E3PU_V/\G_]6.&/.SC_ )%.:?\ 8NQO_J-5/\N^BBBO]03^" K]W/\
M@@;^T!X,_9X_:1^*'BKQK->Q6&H_#&WTVV-C87%_(UQ'XDL+E@T=NK,@\I&(
M9L*3\N<D5^$=??W_  3V_P"2E^+_ /L45_\ 3G;5Y>=</X'BG*\;P_F4L1#
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M?#E[*0+>[>:RD86E\7A_6SX??#;0/ &DVUAIEE!$\,2)NCC10@48"H%
M '   %>C5_!.?>,'%><<9X3C"EB?J57*ZLXY1EL)2J8+!X&;2JX.I%\OUGZY
M37+F%>485,0^5P5&%+#PH_[!<$_1V\/^$/#;&^',L%_:=#.Z-.?$>=5J<*.9
MYKFD(IT<QA4BZCP2R^M[^486$ZE/ I-R=>M6Q5;$?YI6M:-JWAS5]3T#7M.O
M-'UO1KZZTS5M*U&WDM;[3M0LIGM[NSN[:95E@N+>>-XI8W4,KJ01697]F/\
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ME_>9X2_X*C_L$>,K>.;3_P!I'P5I3R %K7Q;;Z_X.N(6(!*2?\)+H^F0,PR
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MDE:+. HK],O^'4W[2O\ T$/A[_X-]?\ _F9H_P"'4W[2O_00^'O_ (-]?_\
MF9KTO^(N^&G_ $663?\ @VI_\J\U]Y_&'_$MGCI_T;3B/_P7A/\ YJ\_S[,_
M,VBOTR_X=3?M*_\ 00^'O_@WU_\ ^9FNAT[_ (),?'2X91J'BOP?8J<;FMX=
M7OB">P5[:QS^++653QB\,J4>:7&&5R6KM26*KRTM]BCAZDWNOLZ]#?#_ $9/
M'C$S]G3\-L\C+37$5LKPD-?^GF*S"C3]?>TZV/RLHK]L_#'_  1[U1W63Q5\
M4+F:+*[H-%\.P6#*!RP^UWVIZGOR, ?Z'&5Y/S9&/JOP)_P2O^ _AEX9]:LK
M_P 4W$>PL^OZC-<PNP )W6-H+.Q9<Y^22U?CY7WCK\IFOTB_#;+XR^IXO,\Z
MJ)>['+\MK4(N5M$ZF:/+THWT<HQGW2DC]$X=^A-XWYS.#S/!</\ "U&33G/-
M\\P^+JQA>UXT<@CG'-.VJA.I2TTE*#NE_-OHN@:YXCO8]-\/Z/JFN:A+CR[+
M2;"ZU"Z;)P"(+2*63;D@;MNT=S7W9\'/^"=WQH^(UQ:W/B>U_P"$)T:4H[I.
MBWNM21MR46UB?[-:,R]'N;AWC.=UJV-I_HX\$?L^?"_P!:167ASPOI&F6T6-
ML%AI]K9Q9484E((D#$# RP)( !/ Q[':V%G9(([6VA@5>@CC5<?D/Y>WI7XI
MQ3])OB',(5,-POE6&R&E)2BL=BIQS+,+/13I0G2I8+#RMO&I0QMG\-1-7/ZD
MX ^@CP3DM6CCN/,^Q_&.(IN$WE>"I2R')>9.[IXB5'$8C-<9!-)*5/&9<IJZ
MJ46GRKX'_9]_8,^&?P?MH+E-,6\U8JANM6U'9=ZI<L,%@T[(HAC)Y$%LEO;
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M1[#5--A344QK4%S&@MY/.@DAN%65MKD5\XZI_P $\_AKI>H7>N_ KXE_&/\
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G<MRE4Z^,JSRBMF&%HTX9#'.:^ M4Q<N&H1RV5&6&E67]H_6T?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>nt10014672x1_barchart1.jpg
<TEXT>
begin 644 nt10014672x1_barchart1.jpg
M_]C_X  02D9)1@ ! 0$ P #   #_[0 V4&AO=&]S:&]P(#,N,  X0DE- ^T*
M4F5S;VQU=&EO;@     0 ,     !  $ P     $  ?_B"^!)0T-?4%)/1DE,
M10 ! 0  "]!N;VYE @   &UN=')21T(@6%E:( ?4  < %0 3  L (6%C<W
M         $E%0R!S4D="     0            #VU@ !     -,M2% @(
M
M$&1E<V,   %$    =&)865H   &X    %&)44D,   ',   (#&1M9&0   G8
M    B&=865H   I@    %&=44D,   ',   (#&QU;6D   IT    %&UE87,
M  J(    )&)K<'0   JL    %')865H   K     %')44D,   ',   (#'1E
M8V@   K4    #'9U960   K@    AW=T<'0   MH    %&-P<G0   M\
M*&-H860   ND    +&1E<V,         &G-21T(@245#-C$Y-C8M,BTQ('=I
M=&A"4$,
M                                                    6%E:(
M     "2@   /A   ML]C=7)V        !      %  H #P 4 !D '@ C "@
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M;W5R(%-P86-E("T@<U)'0@
M
M      !865H@        8ID  +>%   8VEA96B            !0
M;65A<P         !                               "6%E:(
M  ,6   #,P   J1865H@        ;Z(  #CU   #D'-I9R      0U)4(&1E
M<V,         +5)E9F5R96YC92!6:65W:6YG($-O;F1I=&EO;B!I;B!)14,@
M-C$Y-C8M,BTQ
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MU=;7V-G:X>+CY.7FY^CIZO'R\_3U]O?X^?K_Q  ? 0 # 0$! 0$! 0$!
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M?E;^9;_AQ#\6O^B\?#K_ ,)SQ+_\71_PXA^+7_1>/AU_X3GB7_XNOZ::*/\
MB9#Q9_Z'N"_\,>4?_,@?\2@>!/\ T3.9?^)+GW_S?_5WY6_F6_X<0_%K_HO'
MPZ_\)SQ+_P#%T?\ #B'XM?\ 1>/AU_X3GB7_ .+K^FFBC_B9#Q9_Z'N"_P##
M'E'_ ,R!_P 2@>!/_1,YE_XDN??_ #?_ %=^5OYEO^'$/Q:_Z+Q\.O\ PG/$
MO_Q='_#B'XM?]%X^'7_A.>)?_BZ_IIHH_P")D/%G_H>X+_PQY1_\R!_Q*!X$
M_P#1,YE_XDN??_-_]7?E;^9;_AQ#\6O^B\?#K_PG/$O_ ,71_P .(?BU_P!%
MX^'7_A.>)?\ XNOZ::*/^)D/%G_H>X+_ ,,>4?\ S('_ !*!X$_]$SF7_B2Y
M]_\ -_\ 5WY6_F6_X<0_%K_HO'PZ_P#"<\2__%T?\.(?BU_T7CX=?^$YXE_^
M+K^FFBC_ (F0\6?^A[@O_#'E'_S('_$H'@3_ -$SF7_B2Y]_\W_U=^5OYEO^
M'$/Q:_Z+Q\.O_"<\2_\ Q='_  XA^+7_ $7CX=?^$YXE_P#BZ_IIHH_XF0\6
M?^A[@O\ PQY1_P#,@?\ $H'@3_T3.9?^)+GW_P W_P!7?E;^9;_AQ#\6O^B\
M?#K_ ,)SQ+_\71_PXA^+7_1>/AU_X3GB7_XNOZ::*/\ B9#Q9_Z'N"_\,>4?
M_,@?\2@>!/\ T3.9?^)+GW_S?_5WY6_F6_X<0_%K_HO'PZ_\)SQ+_P#%T?\
M#B'XM?\ 1>/AU_X3GB7_ .+K^FFBC_B9#Q9_Z'N"_P##'E'_ ,R!_P 2@>!/
M_1,YE_XDN??_ #?_ %=^5OYEO^'$/Q:_Z+Q\.O\ PG/$O_Q='_#B'XM?]%X^
M'7_A.>)?_BZ_IIHH_P")D/%G_H>X+_PQY1_\R!_Q*!X$_P#1,YE_XDN??_-_
M]7?E;^9;_AQ#\6O^B\?#K_PG/$O_ ,71_P .(?BU_P!%X^'7_A.>)?\ XNOZ
M::*/^)D/%G_H>X+_ ,,>4?\ S('_ !*!X$_]$SF7_B2Y]_\ -_\ 5WY6_F6_
MX<0_%K_HO'PZ_P#"<\2__%T?\.(?BU_T7CX=?^$YXE_^+K^FFBC_ (F0\6?^
MA[@O_#'E'_S('_$H'@3_ -$SF7_B2Y]_\W_U=^5OYEO^'$/Q:_Z+Q\.O_"<\
M2_\ Q='_  XA^+7_ $7CX=?^$YXE_P#BZ_IIHH_XF0\6?^A[@O\ PQY1_P#,
M@?\ $H'@3_T3.9?^)+GW_P W_P!7?E;^9;_AQ#\6O^B\?#K_ ,)SQ+_\71_P
MXA^+7_1>/AU_X3GB7_XNOZ::*/\ B9#Q9_Z'N"_\,>4?_,@?\2@>!/\ T3.9
M?^)+GW_S?_5WY6_F6_X<0_%K_HO'PZ_\)SQ+_P#%T?\ #B'XM?\ 1>/AU_X3
MGB7_ .+K^FFBC_B9#Q9_Z'N"_P##'E'_ ,R!_P 2@>!/_1,YE_XDN??_ #?_
M %=^5OYEO^'$/Q:_Z+Q\.O\ PG/$O_Q='_#B'XM?]%X^'7_A.>)?_BZ_IIHH
M_P")D/%G_H>X+_PQY1_\R!_Q*!X$_P#1,YE_XDN??_-_]7?E;^9;_AQ#\6O^
MB\?#K_PG/$O_ ,77/:S_ ,$0OBIHU_H%A+\</A_,^OZ@^GPR1^'O$:K;ND)F
M,DH9\LI VX3G/-?U%5YIXY_Y&/X;_P#8RS?^D34?\3(>+/\ T/<%_P"&/*/_
M )D#_B4#P)_Z)G,O_$ES[_YO_J[\K?SP_P##B'XM?]%X^'7_ (3GB7_XNC_A
MQ#\6O^B\?#K_ ,)SQ+_\77]--%'_ !,AXL_]#W!?^&/*/_F0/^)0/ G_ *)G
M,O\ Q)<^_P#F_P#J[\K?S+?\.(?BU_T7CX=?^$YXE_\ BZ/^'$/Q:_Z+Q\.O
M_"<\2_\ Q=?TTT4?\3(>+/\ T/<%_P"&/*/_ )D#_B4#P)_Z)G,O_$ES[_YO
M_J[\K?S+?\.(?BU_T7CX=?\ A.>)?_BZ/^'$/Q:_Z+Q\.O\ PG/$O_Q=?TTT
M4?\ $R'BS_T/<%_X8\H_^9 _XE \"?\ HF<R_P#$ES[_ .;_ .KORM_,M_PX
MA^+7_1>/AU_X3GB7_P"+H_X<0_%K_HO'PZ_\)SQ+_P#%U_3311_Q,AXL_P#0
M]P7_ (8\H_\ F0/^)0/ G_HF<R_\27/O_F_^KORM_,M_PXA^+7_1>/AU_P"$
MYXE_^+H_X<0_%K_HO'PZ_P#"<\2__%U_3311_P 3(>+/_0]P7_ACRC_YD#_B
M4#P)_P"B9S+_ ,27/O\ YO\ ZN_*W\RW_#B'XM?]%X^'7_A.>)?_ (NC_AQ#
M\6O^B\?#K_PG/$O_ ,77]--%'_$R'BS_ -#W!?\ ACRC_P"9 _XE \"?^B9S
M+_Q)<^_^;_ZN_*W\O>K_ /!#WXJZ1<:);R_''X?3-K>JQZ5$T?AWQ&H@DDMK
MBY$L@9\L@6W*E5^;+ ] :V_^'$/Q:_Z+Q\.O_"<\2_\ Q=?T5>-?^0GX!_['
M&W_]->IUW]'_ !,AXL_]#W!?^&/*/_F0/^)0/ G_ *)G,O\ Q)<^_P#F_P#J
M[\K?S+?\.(?BU_T7CX=?^$YXE_\ BZ/^'$/Q:_Z+Q\.O_"<\2_\ Q=?TTT4?
M\3(>+/\ T/<%_P"&/*/_ )D#_B4#P)_Z)G,O_$ES[_YO_J[\K?S+?\.(?BU_
MT7CX=?\ A.>)?_BZ/^'$/Q:_Z+Q\.O\ PG/$O_Q=?TTT4?\ $R'BS_T/<%_X
M8\H_^9 _XE \"?\ HF<R_P#$ES[_ .;_ .KORM_,M_PXA^+7_1>/AU_X3GB7
M_P"+H_X<0_%K_HO'PZ_\)SQ+_P#%U_3311_Q,AXL_P#0]P7_ (8\H_\ F0/^
M)0/ G_HF<R_\27/O_F_^KORM_,M_PXA^+7_1>/AU_P"$YXE_^+H_X<0_%K_H
MO'PZ_P#"<\2__%U_3311_P 3(>+/_0]P7_ACRC_YD#_B4#P)_P"B9S+_ ,27
M/O\ YO\ ZN_*W\RW_#B'XM?]%X^'7_A.>)?_ (NC_AQ#\6O^B\?#K_PG/$O_
M ,77]--%'_$R'BS_ -#W!?\ ACRC_P"9 _XE \"?^B9S+_Q)<^_^;_ZN_*W\
MRW_#B'XM?]%X^'7_ (3GB7_XNN>UG_@B%\5-&O\ 0+"7XX?#^9]?U!]/ADC\
M/>(U6W=(3,9)0SY92!MPG.>:_J*KS3QS_P C'\-_^QEF_P#2)J/^)D/%G_H>
MX+_PQY1_\R!_Q*!X$_\ 1,YE_P")+GW_ ,W_ -7?E;^>'_AQ#\6O^B\?#K_P
MG/$O_P 71_PXA^+7_1>/AU_X3GB7_P"+K^FFBC_B9#Q9_P"A[@O_  QY1_\
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M/_F0/^)0/ G_ *)G,O\ Q)<^_P#F_P#J[\K?S+?\.(?BU_T7CX=?^$YXE_\
MBZ/^'$/Q:_Z+Q\.O_"<\2_\ Q=?TTT4?\3(>+/\ T/<%_P"&/*/_ )D#_B4#
MP)_Z)G,O_$ES[_YO_J[\K?S+?\.(?BU_T7CX=?\ A.>)?_BZ/^'$/Q:_Z+Q\
M.O\ PG/$O_Q=?TTT4?\ $R'BS_T/<%_X8\H_^9 _XE \"?\ HF<R_P#$ES[_
M .;_ .KORM_,M_PXA^+7_1>/AU_X3GB7_P"+H_X<0_%K_HO'PZ_\)SQ+_P#%
MU_3311_Q,AXL_P#0]P7_ (8\H_\ F0/^)0/ G_HF<R_\27/O_F_^KORM_,M_
MPXA^+7_1>/AU_P"$YXE_^+H_X<0_%K_HO'PZ_P#"<\2__%U_3311_P 3(>+/
M_0]P7_ACRC_YD#_B4#P)_P"B9S+_ ,27/O\ YO\ ZN_*W\RW_#B'XM?]%X^'
M7_A.>)?_ (NL[4_^"'7Q'T2*"?5?CUX(6&[O;33+;^S_  CKUW(;_4)1;V0G
M2YU+3UBLS,RBZN(Y)YH(LR16=TX$1_IZK@/B)_R#-#_[''PM_P"G2*D_I'>+
M4ERK/\'%O3FCD>3<R\US8*4;^L6O(J'T0O B,E)\+9A42=W"?$O$"C+R;AF,
M)V_PRB_,_G5_X<0_%K_HO'PZ_P#"<\2__%T?\.(?BU_T7CX=?^$YXE_^+K^F
MFBG_ ,3(>+/_ $/<%_X8\H_^9"?^)0/ G_HF<R_\27/O_F_^KORM_,M_PXA^
M+7_1>/AU_P"$YXE_^+H_X<0_%K_HO'PZ_P#"<\2__%U_337\A'_!SOJ?PKLO
MVE_^"-=M\?=0\26G[/NH?%K]H"+XXV_A>[\8V^J7OPQ7Q'^R@OBZ*UB\ R)X
MON;Q=!FU);-/#BOK@DE8:4/M;ID_XF0\6?\ H>X+_P ,>4?_ #('_$H'@3_T
M3.9?^)+GW_S?_5WY6^CO^'$/Q:_Z+Q\.O_"<\2__ !='_#B'XM?]%X^'7_A.
M>)?_ (NORK_9!U#Q+/X&_P""W^H?L;V_[6GAO_@DY8_\$TOVHK[X9Z3^TOJ>
MN26=E^T1JGPQU*Y@NOA#%XANKC5+72X-*TWXE0W=S:ZEK?B%-(M?"<_Q/U(>
M(-1\+0VWU-_P35_X*C_M7?LU?!/_ ()!?!_XP_LM^%8_V4_VNM2T']FCX4?&
M)?B5K%_\7[GQS/XW3PC%XX\5>&Y-$?1-)\,:YXA\16,OA?P]<7+ZMK/A*RO/
M$\7B %TTF _XF0\6?^A[@O\ PQY1_P#,@?\ $H'@3_T3.9?^)+GW_P W_P!7
M?E;ZN_X<0_%K_HO'PZ_\)SQ+_P#%T?\ #B'XM?\ 1>/AU_X3GB7_ .+K/_;>
M_P""[/[1G[#WQN^(D/Q,_9J_9HT_X&?#/XH#P ?AY>?MB_#6_P#VT?B7X-O[
M^P30OCCX-^#OA?4]=D\.>#M2T6Z76X?"WB_1H]<^SW]D-5U708;/5;FWB_;(
M_P""^_Q$^"G[8_QJ_9B^#WPU_9=6+X /\,?MEE^U%\?-=^ /C+X_Q?$#P3IG
MC?4)?A'XC\3^$-*^#'@*U\+6NLZ987%Q\5_B':7FNQ:AINM^&M(U>UN=2LM$
M/^)D/%G_ *'N"_\ #'E'_P R!_Q*!X$_]$SF7_B2Y]_\W_U=^5M7_AQ#\6O^
MB\?#K_PG/$O_ ,71_P .(?BU_P!%X^'7_A.>)?\ XNN^_;N_X+8?%+X'?&3X
M4?LS_LX_!?X$7_QM\2_LX>&/VI/BI=_M.?M,_"SX8?#3X>>&M=!DM_@YHOC*
M'QMIW@[QW\6M:\M;/2=2\-^.[[PP(]6T#Q-H\'C'PG-KNJ^'OU(_X)T_MN^%
M_P#@HC^Q]\+?VJ_"'ABX\ MX]A\1Z9K_ ($U+5K;Q'<^"O&/A#Q%JOA;7M&E
MU:R@TQ=6T][W2QK&B7TECHU[J7AS5-(O;S3-(O+J:QMC_B9#Q9_Z'N"_\,>4
M?_,@?\2@>!/_ $3.9?\ B2Y]_P#-_P#5WY6_'G_AQ#\6O^B\?#K_ ,)SQ+_\
M71_PXA^+7_1>/AU_X3GB7_XNO@C4_@?\3OV%O^"O/[$7A"']JO\ ;7G\=_$O
MX[W5M^T]^V;^TX?&'AO]E7]JO2/'+Z1XK\'_ +*WPD\.Z?;:[X/\0>,KC1M4
MOO!EM;W_ (F7PWX3^(]];ZOH<&GW^E:9X?\ !O[=_P#!>KQ/KMS^P?#^S=X+
MU"?2_B)^W5^T-^SY^QCX$OK=RHMM0^+7Q#T_4O$1O0IW'2;WP)X2\6:/J38\
MM;?4]LI"O@G_ !,AXL_]#W!?^&/*/_F0/^)0/ G_ *)G,O\ Q)<^_P#F_P#J
M[\K?'?\ PXA^+7_1>/AU_P"$YXE_^+H_X<0_%K_HO'PZ_P#"<\2__%U_27X5
M\,:%X)\+^&_!GA?3H-(\->$= T?PQX=TFU0):Z9H6@:=;Z5I.G6R  )!96%I
M;VT*  +'$H P*WJ/^)D/%G_H>X+_ ,,>4?\ S('_ !*!X$_]$SF7_B2Y]_\
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M]%X^'7_A.>)?_BZ/^'$/Q:_Z+Q\.O_"<\2__ !=?TTU_.[^R]\?_ (X>)?\
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MPQX<\/OXETJZCTBSCM[&/3M)^RVT*.( OWW^SI_P6V^$WQQ_:7^'7[//C/\
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M=N)4UJ/P7KGAV^M= \86UYX?L?Z8J/\ B9#Q9_Z'N"_\,>4?_,@?\2@>!/\
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M?^B9S+_Q)<^_^;_ZN_*W\RW_  XA^+7_ $7CX=?^$YXE_P#BZ/\ AQ#\6O\
MHO'PZ_\ "<\2_P#Q=?TTT4?\3(>+/_0]P7_ACRC_ .9 _P")0/ G_HF<R_\
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M.(?BU_T7CX=?^$YXE_\ BZ/^'$/Q:_Z+Q\.O_"<\2_\ Q=?TTT4?\3(>+/\
MT/<%_P"&/*/_ )D#_B4#P)_Z)G,O_$ES[_YO_J[\K?S+?\.(?BU_T7CX=?\
MA.>)?_BZ/^'$/Q:_Z+Q\.O\ PG/$O_Q=?TTT4?\ $R'BS_T/<%_X8\H_^9 _
MXE \"?\ HF<R_P#$ES[_ .;_ .KORM_,M_PXA^+7_1>/AU_X3GB7_P"+K]6_
M^">7[%WBC]B_P;\1/#'B?QKH/C2?QKXFTK7K6ZT'3]0L(;*'3]*?3WM[A-0)
M>221V\Q6C^4*,'FOT.HKY[BCQG\0.,LFQ&09_FN&Q668JIAZM:C2RO+\+.4\
M+7AB*+5;#X>G5CRU:<9-1DE)+EE=-H^LX)^CMX5>'O$.$XIX6R3&X+.<%2Q5
M'#XBMG6;8VG"GC<-4PF(3P^*Q=6A-SHU:D4Y0;@Y<T;22:****_*S]P"BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "O-/'/_(Q_#?_ +&6;_TB:O2Z\T\<
M_P#(Q_#?_L99O_2)J /2Z_FY^,O_  4L_P""GWBW_@I]^V!_P3\_8>^"W[''
MC1?V8?A9X$^+%C=_';4/BIX>\3^+]'\2?#+X-^)]1T*SUCP[XSLO"TOB2X\7
M?%6/2=!CU.S\*Z%'I<,,FM:]:M;W%]/_ $C5_(%X^_X)9>)_VU_^"]G_  4;
MO/C=IG[8_P '/V8?&/P"^#<GASXQ?!Z?Q5\)_ 'QAUG1OA5^RUX<U3X<S_$K
M4?!VL>"?B%HD%U8>))]7\&V5U=SPZ_X.DN)UAN?#EW'" ?JO^PQ_P6F^ O[1
M7[(UI^TC^TS<^#OV1M3TG]I+4/V/_%]CXL\;V>L_#^\^/&F^%M-\80V7@[QY
M!;1:9=:#X@\.WTNL6EQJ$RVNCKIVKVUSKFJZ?8VGB+5OH_Q%_P %<?\ @FKX
M3^%_@OXRZ_\ MD_!>Q^'/Q%\0ZKX7\$:XNNW=Y=^(]7T'58-%U_^S_#=CI]U
MXI;2_#^HW5I%K_B"718O#^APWEG>ZKJ=I8W=M<R_CY_P5D_X)C^#?@Y_P3[_
M &'/V1_V)_V:_'/COX=^#_\ @I3\$_B#\0?"7@WP9XH^+WB/4?#.I>"OC99?
M$'XD_%BXTK2M:U34M'8:OHV@:[XG\1Q1Z%I&CR>&_"T<FG:)::)I<'S)_P %
M,_V1/&OP8_X*D>$_BKX9_9T^*$_['NO_ +%&O?"+X>']D_\ 8-^%G[5WAOX9
M^+I?%/C#Q1XK^&-U\&?$W@/6O ?@O4/B9K.O^)K]?%D.F:5JFI7?Q2U!8M;;
M19/B(VG ']2WQ8_;5_9,^!WP-TG]I7XI?M"?"SPO\"?$=OIESX3^)I\56&M>
M'/&R:U"]UI,7@.3P\^K7?CN\U&SBN+^TL/"%KK=]-IUI?:BEN;*QO+B#\\/^
M"@/_  5GT/X'_LU?LN_M'_L9>)_@3^T=X2^/7[:GPC_9CUCQ%'KMWXR\+:5H
M7CSPK\0?$'B-[*?P3XGT>XTGQ_H4OA;1HFTG7YGDTJ/4+B+6- ^T26YA_!_0
M_P!B[XZ?LE?#;_@B/^T'\1/V1OVE?VA?V;/V:M8_:6U7XJ_LD7_PV\/_ !I^
M./P4N/VA'U#Q/X/\4:]\-?#>E:5;ZE/IOB:\3QRD6M:?IFH>!-4\,>&=)\60
M^&?&&H2>'M.],_:R^'?Q%_:C_8X^%'C7]G;_ ()4?%C]E'2M7_X+:_"[XIR>
M -!^'/C:]^+?Q)^&^@^"_B_:ZK^U#\6/@YH?PZL)/@QH-X^N:'HE^9-4\1^'
M++58[F.#7ET:7P[J&N '[OW/_!1JS^%_[8/[<_P[_:/^)7[,/PY_9@_93\$_
M CQ%8>)[/Q'XFE^,_AJ_^+FE?#6VW_&G1I+J_P!%T?1=7\8^/K?2_!4VBZ1;
M37EAJ7A^2]>22>XF;Z7^"/\ P40_8?\ VDOBGXE^"7P*_:?^$?Q/^*OA--2E
MU;P5X6\307>K36^C2)%J]YH!E2"S\6V&E.Z#4K_PI=:U96(.^ZGB3+#^5'_@
MJ)^R?^U-\0/V@?\ @X2UKP%^S3\?_&^C_&GX.?\ !-W2_@YJWA'X-_$7Q)IG
MQ9U/P-XV_8[N_&VG?#._T;PY>VOCR^\'6OACQ+<^*;3PM+JMQX>M_#VN3:M'
M:1Z3?M;_ '1HW[&?B;X5?\%7_P#@AQXW^%/[,GB[P;\,_AO^Q1\1? ?QS^('
MA'X1:]I?A3PGK5G^S3\2-$\,>'?C/XUTS0(=,TOQ))XCU.#3]/M/'FIPZS>^
M(=2C@C6;4[Q%D /T]_89_P""A47Q0_82U#]L3]L+XG?LI^ ]'\.>*/&>F^*_
M'OP9\;ZI/\$-,TC0=0L['28(=?\ &6JZAJ5SXHO;BZCT]M%M[FYO-2UFYL-*
MT6PN;^\M[6;Z4^&G_!0+]B7XP?!?Q7^T/\.?VH_@KXB^#'@"TL[WXA>/1XYT
M?2=,^'<6HOY>FQ?$.TUR?3-6\!WVIR8CTW3/%VG:-J6H2O''9VD[RQJW\<7P
MT_8D_:\T;_@B[^Q#/XJ_9,^-WC1/V7?^"FL?[1'[0'[&?B3X/^)K3XF_%3X-
M6&M_9;J:T^%/BG1]/\1>+;*:PO+_ $1M$CTN:SU30/%NLZQ<$Z9H=Y<0_?OQ
MM^)OC7XU_LO_ /!3CXP?L@?\$/U\%76KVW[./A?2KG]IC]G?5YOB3^U%#;ZQ
MX:MM9U>Q_8SA^'>H:-XFO/V=[F"7Q-H.JCQAKFB^=:Z)XMN]*U/4M(\1^%H
M#]I_$?\ P5+_ &7OB-^R5^V'\??V-?CI\'OC[XS_ &8/V>OC?\7F\(6NKWLL
MD.K_  Q\!^*_$>AMXK\*--X=\9+X+UK7?#\5A_;MBEC8:Q92NVA:X6FMKJO;
M?^">/[2'B[]KW]BC]G']I?Q[HOASPYXP^,GP[LO&'B#0_",6IP>&M-O[F_U"
MT>VT>'6=2UC5([-4M(V5;W4[V;>SYF(V@?Q]_!SX$_M,^*_VB?\ @HSX_/P.
M_;8\:>&_BI_P1'_:O^!?P[^*GCC]A'_AEVP^+7QCU/PIX:O](^'OAKX0?"?X
M9^'O#7AV*9+#4/"/P_\ ">IW/B7QOXPUSPS87FFZOJ]CJ7AS3;+^JC_@CQX$
M\;_#+_@F/^QEX!^)/@WQ5\/?'7A;X.:;I?B;P7XX\/:OX3\6^'-3CU;5Y'T[
M7?#FO6=AK&D7R1RQR/::A9V]PJ2(YC"NI(!]U>-?^0GX!_['&W_]->IUW]<!
MXU_Y"?@'_L<;?_TUZG7?T ?G=_P5>_; \>_L$_L!_'O]K'X8>'/"'BWQS\*?
M^%6_V'X?\>0:S<^%-0_X3KXT_#GX;:G_ &K!X>UG0-8?[)H_C'4+VQ^QZO:;
M=2MK-[CS[59[:;\I?AE_P5^_X* ?";XJ?L V'[>7[-O[,Z_ O_@I-+\+M#^!
M7Q&_9B\=^,%\4^#?$_Q9'A2;P[:^// OQ%U36=9UA=/A\<^$1XIAT&TL='T:
M#6?M6G>,/$6IVG_"-W7W!_P7[^&/Q*^,G_!)+]K+X;_"#X>>.?BK\1/$?_"B
M/^$>\!?#?PGK_CGQIKW]C_M+_!K7M6_L;PMX8T_5-<U3^R]#TO4]9U'[#8S_
M &+2=.OM1N?*L[2XFC^>_P#@G)_P0_\ V8/A78_LB?M@?%M/VC?B?^T[X-^"
M/P=U[3/#W[3'Q U/Q/I7P-\>-\--&CO/#_AGX>ZIX>T.Z\+O\.-3O+G3/"7A
MOQ.=5F^'=_HFD3:5!IVO^'[&_M@"_P#LY?\ !=+X)77QF_;@^%_[;GQ6_9[_
M &<8_@'^VS\4_P!F/X%B;4]>T?6?'_A'X>^)O$>AGQ5XOCU;6O$4=O-;QZ7I
MBZ[XIAM?#'@VRO\ 4$MY/L<EU:6]?IQ^T-_P4*_8C_90C\%O^T+^TW\)?AE)
M\1=/TS6? ]GJ_B6&_P!3\3^'M8NDLM.\5:5I6@QZMJ=QX.GN'VMXP^R+X8MX
MXY[BYU:&WMYY8_Y:Y?V!?B-XD_9V_P"#E76?$_[(/Q.U;XK_ !C_ &P/BOX@
M_9UN]5^"OC>?QO\ $WPIIGQI\8^-?!FN_ Y9O#_]L>+= N[W5Y-:MM5^'R7U
MAXBL[N 7EQJ6FBVB3)_:$\/?M@:'8?L&_#S6/V3?BOX>\/:3_P $<?@+X.U/
MXN_!G_@GKH7[3'[47Q!^,J_#[2M&UW]CCXF_$3XO?#'Q?IW[-UG::U8ZW<ZD
MLWA^\U3P1<:K>ZUXAM[P>*KFR\) ']5_Q=_X*"_L2? ?X5^!/C;\5_VH?@UX
M4^%?Q2@GNOACXR/C/3-;T[XCVMI';R7]WX!@\.2:OJ/C&UTQ;RS_ +6N?#ME
MJ4&DO>6<>I26LEU;K)O1?MO?LA3?L\-^UG'^T?\ " _LW)'*6^,A\:Z.G@D7
M<-ZVF/HIU)[A6_X2;^U5.CIX4\G_ (26362ND1Z4^I.EJW\4OAW]E'XU>#OV
M!O\ @D@?%_PD_P""E/[./QM^"GB']MKP3J_QE^"OP*\;?$/7/V?H/B9\4O&_
MB*>P^(W[+6H>%M \<^*O!?Q/\+ZIX8L-'UCP]XS\-Z!KVA:Y\4K/Q!:>+18:
M)H&H5_%O[.?_  4/^*/_  2S^#&L>+OV4/$X\*_ S_@J4?B[K/P_^&O[%?@3
MX:?''XU_!B'PM9Z-;_'WQM^QWI'@*P\&^+-;TN[?6_#5U%XETG68/%V@ZS9V
MOC>WUCP5X6O/&6J ']P?[-G[5_[./[87@ ?%#]F;XQ>"OC'X)2\_LV^U7PEJ
M+2W>AZKY$=T-'\4:!?PV/B+PGK1M)H+P:-XETG2=4-G/;W8M#;3PRO\ EQ_P
M68_X+*Z'_P $RO [^$_AOX!OOBW^U#K?A'0_B+HWA;5/"WBVZ^%G@'X8:EX\
MC\!R_$KXK^*M%ETB"ST6_P#$L-QX+\.Z/I6OPZQ>^,=1T*#43IEAJ%A+J?B?
M_!#WX >)?"GQZ_;Z_:/7P)^T?X!\#_&SQ'\+_#ECJ7Q_^ /PY_93B^,VL> ]
M"OKF3XD^"?V=_!/A'PE=>!--L;CQ+KUE?ZM=:;#I?C6\UX^(1<WGC"?QOH_A
M/ZA_X+\?"'QY\8?^"4'[77@KX._##Q=\4OBOXNM/V?;#1_"7PT\%:SXW^(?B
M>Q\,?M._"?Q-<66FZ#X6TS4_$FM6GA[2E\2>()K:UM;F'2=/&N:LZ6]L+^XH
M ^O_ !S^WE^SA^SU^SU\'_CK^UI\9?AO\#++XH^ O"_B:RA\0:I/;2:WK6I^
M%-&\1:[I?@CPU$=6\5^)O[).K1&2ST>QUF^M+6>S:\8M/')+]!?!?XY_!S]H
MOP!I7Q3^!'Q-\%?%KX=ZU)<0:=XO\!^(-/\ $6BRWEFRI?:=-=:?--]BU73W
M=(]1TF^6VU+3Y66*\M8)"%K^<W_@IE!^TAX;T?\ X)/:'X5_9[UQO VC_#'5
M[/XJ_M)^ OV$[+]MW]IG]F?Q#IOPI\#:9%X,\(_#;QIX/\0>'_AS%\2]3>ST
M#5]4U&QN-;N]1T.2[AMK*3P$VE>*O5_^#;/X4_%WX/?LT_M;>'OC/\%_CS\#
M?$GBK]N+XE_$WP_X6^.GPVOOAMJ6H^!?&'P]^%MMH&N:991>$O!G@_4[R6]T
M'6M-\17/@'1+#PM;7>F6=IIFFZ58)8V,0!_1A7FGCG_D8_AO_P!C+-_Z1-7I
M=>:>.?\ D8_AO_V,LW_I$U 'I=?._P"U[\8-?_9Z_9-_:A^/OA33='UCQ1\#
MOV=OC7\8/#>D>(8[V70-5U_X:?#7Q-XTT?3=<BTV\T[49-'OM1T6VM=3CL-0
ML;U[*6=;6\M9S'.GT17QS_P42\,>)?&W_!/W]NGP9X,\/:YXN\8>+OV.?VF_
M#'A3PIX8TF_U_P 2^)_$NO\ P4\;Z5H7A[P]H6E6]WJFM:YK6J7=KINDZ3IM
MK<W^HW]S;V=G;S7$T<; '\ZGAO\ X+M_\%(?A?\ LN_LZ_\ !1']IW]EO]D[
MQ)^PQ\=/%UYX-U"Z^!?CKQWX7^.G@N[C\4>(O"=O?W7ASXC^(M>TC6KF6Y\'
M^*=4TWP_X;@UT:KI^CNNM^(?!$=Q'J"_HEJ'_!:;X<_!S_@H[^V]^RO^UGXW
M^"7P+_9__9Q\+?L^7GPM^(>N2>)K'Q]XY\6?&+X;> ?'&J:%JEF^K:K!K TR
M3Q1JTT,/ASPA83:3H>G+?Z[/Y%I>WS?!7_!)C_@@O\!?&_[+'['/QW_;9\-_
MM4ZK\8O G_"1>(%_9?\ V@/%7B+0OA/\-=8T+XP>+[W0;&/X$^(_"VBZUH6C
M:W:6.F>*-7\*:U?3>'?%KZ]J%]J^D:EI>NO;R][??L6^(?B-_P %=/\ @N%\
M4?B9^S%XR\5^ ?B'^Q3\/_ GP.^(7B?X5^*+SP;XVUW4_P!F?X3Z#XKT/X3>
M*;O1_P"PO$7BZ'6_#$.B7+>#;Z\\3:/JFEW>F6\UC=?;H' /W4^*_P#P4$_8
MF^!_P=\$_'_XI?M._"#PM\'_ (F6$FI_#7QN_BVRU>P^(UG#;PW5S)X!LM .
MJZOXTDLX)X&O[;PUIVIW-@TL<5Y#!*ZH9M3_ &_?V)]'_9_M/VJ-1_:C^"<'
M[/.H:HF@Z?\ %=?'FB7'A;4?$KQW$W_"(Z?-;7,UW?>,TAM+R:7P=:6DWB>"
M&RO9IM)CCL[EHOY$O W@7]L_X-_\$_O^"+_PX\1_LG_$OP3;>&=0_;4_X6_\
M;D_X)Z7?[6W[7O[+=Q=_'#XAWG@SPOX8^#GQ2\":E9?#+2/C+H>K^%DM-=U7
M2)M2U[3K33=?TB*&Q\'VUEXN\7^%_P"R;\<-+_X)M^.(?B;^RY_P4I^%WC_P
MM_P6(E_:)\ :S\*OAAJ7AOXV?!G0O$_PS\":)X5^/EG\([+X;>&]$^*VE>%S
MIWBN+78?@W)\-UTGQ[I'@/3]!\0>#_"^HZB+, _MH^$7[<G['_QW^#OBK]H'
MX3_M'?"7Q=\&/ :WK^/OB)#XOTW2?#_@$:=91ZE>CQY-KTNE7'@IK?39H=0=
M/$]OI3FPFAO$5K:6.1HOV8/VY_V1/VT+3Q1=?LN_'_X>?&5O!5\UCXKTWPMJ
MDJ:_H)^U7%E;7^H^&M7MM,\00:%J=S:72:'XD.F'P_KZV\TNB:G?Q1NX_BUB
M_9I_X*.?'3_@G3_P5B^%/AWX+^,_'7A^Z^)O[-OBWX?_ !4\0_L4:7^R'^U!
M^V/HW@#QE>:[XYTS4_AAH'A6#Q?\4V\+HFD>.-%O/%6N>(_&$6IVVK:%H^I>
M(=;\6WGAO0?TY_X(]? #Q1K/_!0C6OVH=,^$7[5GPP\,>%?V-_"GP@\4>*OC
M7^R1\'OV*/ 7B74]>U72]37X0^'_ (6^ / GA"X\>Z_\-9_#&A0W/Q1TN.[M
M)++PLGA[6;O3M'L_AX?&(!]Z_P#!9C_@LKH?_!,KP._A/X;^ ;[XM_M0ZWX1
MT/XBZ-X6U3PMXMNOA9X!^&&I>/(_ <OQ*^*_BK19=(@L]%O_ !+#<>"_#NCZ
M5K\.L7OC'4="@U$Z98:A82ZFS]LG_@K/X@_9%^(7_!*"V\96_P '/"OPA_;<
MT/X@^)?VB/'_ ([D\06$/PMT/P3X%^#?BLW_ (*OX?$UE8V,;W/Q&U:UDB\1
M6?B>XNQ:Z1:6$37TD@O.X_X+\?"'QY\8?^"4'[77@KX._##Q=\4OBOXNM/V?
M;#1_"7PT\%:SXW^(?B>Q\,?M._"?Q-<66FZ#X6TS4_$FM6GA[2E\2>()K:UM
M;F'2=/&N:LZ6]L+^XK\PO^"LWP8^*M]XX_X($_$+_AC/X[?M4?#O]FC3O&GB
MK]HOX:?#;X*^)OB;J6@:%HGA7]E34KK1?%/AM+2WT>W\27*>#_$C^%_!7C74
M='@\;>(/#5UX4$-Z[7MB0#^E#]F[]JW]G']K_P !'XF_LS_&+P3\9/!45Z=+
MO]5\'ZI]HN=#U80I<_V/XFT.\BL_$'A;6#:RPWB:3XCTO2]1>RN+>]2U:UN(
M9I/H.OYJ_P#@B5\+?'^I_MJ_\%2_VP=-_9C^*?[&_P"S/^T3XP^$6F_!GX.?
M%+X;77PFUGQ5J'@W3O$__"4?$,^!M0LK>72!<ZEJ-[KTW]DR3^'DUKXC>(-%
ML;W4IO#]Q):_TJ4 </\ $K_D1/$W_8-?_P!&Q5TNB_\ (&TG_L&6'_I+%7-?
M$K_D1/$W_8-?_P!&Q5TNB_\ (&TG_L&6'_I+%3Z+U?Y1 TZ***0'X=?\%</^
M"BW[5/[&?QP_X)[_   _91\ _ ;QIXW_ &X?B'\2/AG#=?'I?'L?A[0?$.@:
MU\$="\'S)?\ @/Q%H][IVEW=[\4M1;Q#<S:9K]PEO8V+Z?:(\=Q'=^"?#_\
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M+:CXETK4KO1K)=)LR+O4S<WL0L+8B>Z,41#T <=^T[\&?^&COV:_VA?V>?\
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MI+0OC$^E?%2[@^%5SJ6B>*CX9TNXL5L?"6D>.-(.NO#:G7%T]GU2/Z^\>?\
M!,GXL^,_VY_^"8_[1NH:K\(=4^#W[''[+?Q2^ _QL\%WVK>*6\4^-+_Q[\!_
M&WPIC@\!Z.?!/_".:SX:GU#Q-;C4I/%'B7P?=+HOVN2/3I[E8[*;]OJ* /\
M, ^-7CGXDZE^P!X>_P""8GPR_:Y^ /Q<^&W@?]L>W\.? WX :/\ "/\ :3\"
M_MV^*/'_ (K\<>(&/PY^+G@?QIX7T3X>^$_"6@>*_B5KVMZE;>'KWX@37/Q8
MLK'PGH/BO6$L'^S?Z?\ 7)?\(!X$_P"$I_X3G_A"O"7_  FWV3^S_P#A,?\
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M8=+\/>%_#.F6VC:#HNGQ,SNEGIFF6=K9VX=Y)/*A4R2.Y9B =71110 4444
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MG^(G_1+_ /R]M#_^1Z/^$G^(G_1+_P#R]M#_ /D>BS\OO7^8'I5%>:_\)/\
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M9=.MO^$HTJZ_M.Y-JRM:^=%"J66U,R>?.&C.-H&:+/R^]?Y@?05%>:_\)/\
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M-8IAXLT&,31K;QA)?+<[X_,4!]C?,N=K<@T[.RVW?5>7F!ZG17G?_"3>/?\
MHF<W_A7^'_\ &C_A)O'O_1,YO_"O\/\ ^-*S\OO7^8'HE%>=_P#"3>/?^B9S
M?^%?X?\ \:/^$F\>_P#1,YO_  K_  __ (T6?E]Z_P P/1**\[_X2;Q[_P!$
MSF_\*_P__C1_PDWCW_HF<W_A7^'_ /&BS\OO7^8'HE%>=_\ "3>/?^B9S?\
MA7^'_P#&C_A)O'O_ $3.;_PK_#_^-%GY?>O\P/1**\[_ .$F\>_]$SF_\*_P
M_P#XT?\ "3>/?^B9S?\ A7^'_P#&BS\OO7^8'HE%>=_\)-X]_P"B9S?^%?X?
M_P :/^$F\>_]$SF_\*_P_P#XT6?E]Z_S ]$KSKXG2/#H6F3HH9H/%/AR8 @E
M<QZC&5WX((4MM4\CJ ""12_\)-X]_P"B9S?^%?X?_P :X_QUKWC"Z\/M%?\
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MK;28)&+/R^]?Y@>S6?[/WP4_9[^&7Q"T?X'_  R\(_"K0_&7BGPWXM\0^'_
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MZ=I5AHOBNXU;3;/3;"RL;>VCM;6"*,L_+[U_F!_()^R)?_&7X&^+OVR_AG\
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M39<EGY?>O\P/X'?"7ACXJ>$/^")W@7_@J'I_[4?[3X_:@^%'[7L/P^^&%_\
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M-_X5_A__ !H_X2;Q[_T3.;_PK_#_ /C19^7WK_,#T2BO._\ A)O'O_1,YO\
MPK_#_P#C1_PDWCW_ *)G-_X5_A__ !HL_+[U_F!Z)17G?_"3>/?^B9S?^%?X
M?_QH_P"$F\>_]$SF_P#"O\/_ .-%GY?>O\P/1**\[_X2;Q[_ -$SF_\ "O\
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M'4[.[T&2/Q%;^&]%\9PVR6"Z;;WU[#<Z7:64,-I#!^;'_!-3X7?#7PG\3?\
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M?CM_V'/@)_ZTA\(J2U:7=H#]-****0!1110 5YIXV_>>*?AM;KS*VOW]P%Z
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MXN? WX0ZIH'QP^/=EX"U6TGU/XH?!&UU*SU'Q-91:[<^*XKS3M$U?3KK\C?
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M+6VA5(;>VMH(TA@@B1(XHD6-%55 'S?^V)^SG_PUE^SMX[^ ?_"8_P#" _\
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ML>'C\/=2\.6_C30? 4-K9^*3K(@N]:U+Q#XCTZ#2[*U@G@OHS,(KS[4L=K*
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MG[9/_B3WQM_^;BC_ (>+_P#!0?\ Z/L_;)_\2>^-O_S<4_\ B"V:?]#K ?\
MA/B/\R?^(RY9_P!"7'_^%&'_ ,O7^GI_J_T5_E ?\/%_^"@__1]G[9/_ (D]
M\;?_ )N*/^'B_P#P4'_Z/L_;)_\ $GOC;_\ -Q1_Q!;-/^AU@/\ PGQ'^8?\
M1ERS_H2X_P#\*,/_ )>O]/3_ %?Z*_R@/^'B_P#P4'_Z/L_;)_\ $GOC;_\
M-Q1_P\7_ ."@_P#T?9^V3_XD]\;?_FXH_P"(+9I_T.L!_P"$^(_S#_B,N6?]
M"7'_ /A1A_\ +U_IZ?ZO]%?Y0'_#Q?\ X*#_ /1]G[9/_B3WQM_^;BC_ (>+
M_P#!0?\ Z/L_;)_\2>^-O_S<4?\ $%LT_P"AU@/_  GQ'^8?\1ERS_H2X_\
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M_P H#_AXO_P4'_Z/L_;)_P#$GOC;_P#-Q1_P\7_X*#_]'V?MD_\ B3WQM_\
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M]"7'_P#A1A_\O7^GI_J_UYIXY_Y&/X;_ /8RS?\ I$U?Y9?_  \7_P""@_\
MT?9^V3_XD]\;?_FXJM/_ ,%"OV^KJ2VFN?VX?VP+B:SE,UG+/^TO\:)I+28K
MM,UL\GC5F@E*_*9(BCE>,XXH_P"(+9I_T.L!_P"$^(_S#_B,N6?]"7'_ /A1
MA_\ +U_IZ?ZQ%%?Y0'_#Q?\ X*#_ /1]G[9/_B3WQM_^;BC_ (>+_P#!0?\
MZ/L_;)_\2>^-O_S<4?\ $%LT_P"AU@/_  GQ'^8?\1ERS_H2X_\ \*,/_EZ_
MT]/]7^BO\H#_ (>+_P#!0?\ Z/L_;)_\2>^-O_S<4?\ #Q?_ (*#_P#1]G[9
M/_B3WQM_^;BC_B"V:?\ 0ZP'_A/B/\P_XC+EG_0EQ_\ X48?_+U_IZ?ZO]%?
MY0'_  \7_P""@_\ T?9^V3_XD]\;?_FXH_X>+_\ !0?_ */L_;)_\2>^-O\
M\W%'_$%LT_Z'6 _\)\1_F'_$9<L_Z$N/_P#"C#_Y>O\ 3T_U?Z*_R@/^'B__
M  4'_P"C[/VR?_$GOC;_ /-Q1_P\7_X*#_\ 1]G[9/\ XD]\;?\ YN*/^(+9
MI_T.L!_X3XC_ ##_ (C+EG_0EQ__ (48?_+U_IZ?ZO\ 17^4!_P\7_X*#_\
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MPZ^)/B725F:_T#X:?&+7/!NF_"/XB:M&L(-O9>"_&^N3:B;BT33!>R7<"/\
M6GPF^-OPQ^.5AXWU3X6^)O\ A*+'X<_%7XC_  2\9S_V+XAT3^QOB=\)?$MW
MX0^(/AGRO$6DZ1-J/_"/^(K&ZT[^VM*COO#VJ^5]KT35M2L7CN7_ !]\ ?\
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MRK5\76C44J:O"C45/VD91M&I-Q;A%2_H*_9P_P"#C_QM\=/%VM^&K_\ 9?\
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M@_\ T6+]C;_PX/QM_P#H>:_OMHH_XBSQ?_S^P'_A##_Y(/\ B%/"/_/G'_\
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M\%!_^BQ?L;?^'!^-O_T/-?WVT4?\19XO_P"?V _\(8?_ "0?\0IX1_Y\X_\
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M_P#X6S_^1_J[\K?P)?\ $*]_P4'_ .BQ?L;?^'!^-O\ ]#S1_P 0KW_!0?\
MZ+%^QM_X<'XV_P#T/-?WVT4?\19XO_Y_8#_PAA_\D'_$*>$?^?./_P#"V?\
M\C_5WY6_@2_XA7O^"@__ $6+]C;_ ,.#\;?_ *'FC_B%>_X*#_\ 18OV-O\
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M_P"%9[O^$8^V_M:^!_VI/^%>_P#"+?\ "P1_;7E_\(9_P@O_  EG_"1:3O\
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M-W::+9W!LHX;>>6*7]"OBQ^Q_=_LR?L??&_1_&-]X9\-?LSCP=XDU?XN^"O
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M\,Z?M!_]$)^,G_AL/&W_ ,HZ/]1> O\ H5X#_P +L3Y?]1GI]_GJ?Z\<>?\
M0SQ__A#AO_F3S7WG]+?_ !%>_M"?]&G_  :_\+3QO_\ &J/^(KW]H3_HT_X-
M?^%IXW_^-5_-)_PSI^T'_P!$)^,G_AL/&W_RCH_X9T_:#_Z(3\9/_#8>-O\
MY1T?ZB\!?]"O ?\ A=B?+_J,]/O\]3_7CCS_ *&>/_\ "'#?_,GFOO/Z6_\
MB*]_:$_Z-/\ @U_X6GC?_P"-4?\ $5[^T)_T:?\ !K_PM/&__P :K^:3_AG3
M]H/_ *(3\9/_  V'C;_Y1T?\,Z?M!_\ 1"?C)_X;#QM_\HZ/]1> O^A7@/\
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M7_PWY;Y?]0/I]_GK_7!_Q%G^+/\ HQKP[_XD'J7_ ,YVC_B+/\6?]&->'?\
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M&:-)$91O_%?_ )$+6O\ KMHG_J0:53CNO5?F!Z)1112 **** "BBB@ HHHH
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MWGB6-]<T'P]XGF63Q+H&CZM8@'Y*^,O^"A_[>^@_#K]M?]I#3[O]E&/X/_\
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MCW:V>L:EX+@T_P /> VOKV*"S/D_Q6_9]\<K\:XO@S-\*?BU\0=9TO\ 9O\
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ME_95^#T+:)JL>JQ+'XR\:,)Y([:XMA%(6BRJ%;@L67YLJ!T)K;_XBO?VA/\
MHT_X-?\ A:>-_P#XU1_Q"SC/_H7X?_PX8+_Y<'_$4.#?^AA7_P##?C?_ )2?
MW$T5_#M_Q%>_M"?]&G_!K_PM/&__ ,:H_P"(KW]H3_HT_P"#7_A:>-__ (U1
M_P 0LXS_ .A=A_\ PX8+_P"7_P!6?E<_XBAP;_T,*_\ X;\;_P#*#^XFBOX=
MO^(KW]H3_HT_X-?^%IXW_P#C5'_$5[^T)_T:?\&O_"T\;_\ QJC_ (A9QG_T
M+L/_ .'#!?\ R_\ JS\KG_$4.#?^AA7_ /#?C?\ Y0?W$T5_#M_Q%>_M"?\
M1I_P:_\ "T\;_P#QJC_B*]_:$_Z-/^#7_A:>-_\ XU1_Q"SC/_H78?\ \.&"
M_P#E_P#5GY7/^(H<&_\ 0PK_ /AOQO\ \H/[B:*_AV_XBO?VA/\ HT_X-?\
MA:>-_P#XU1_Q%>_M"?\ 1I_P:_\ "T\;_P#QJC_B%G&?_0NP_P#X<,%_\O\
MZL_*Y_Q%#@W_ *&%?_PWXW_Y0?W$T5_#M_Q%>_M"?]&G_!K_ ,+3QO\ _&J/
M^(KW]H3_ *-/^#7_ (6GC?\ ^-4?\0LXS_Z%V'_\.&"_^7_U9^5S_B*'!O\
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M *L_*Y_Q%#@W_H85_P#PWXW_ .4']Q-%?P[?\17O[0G_ $:?\&O_  M/&_\
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MO_LF_'#X<_M>?%'6O@K!_P ,^_"SXJ_![XS?#KQ:/".K^)O#/C1?!/C?X_\
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M,/$>H>-%^"]]\7KGX:WOB,HFMZ!J_AGS/#3@%C_@H/H-I;^&M)^*?Q8_;/\
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MWB3P3\5=.\??!7Q?\-O&>EKJ^D6.O>'PO@#2F\->)+>/7-*$5WYPG]I^ ?\
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M]B\.>(+TB8BTT35;HBVN9+*X/V>QGEQ!>1!I;28[,17,:M) ^V5 60"OY_\
MX-?\%*_VGM6^$_PY\/?L\?LN>&OBCI'PX_X)G?L[?MO?$'Q9^T'^USXX?QW=
MZ)X_TKX@G_A5MOXON?@CXVU+XE_%K7+'X8:L^E>/_'>K>#M%U?53?ZKXLN],
M542[_<7X=?#/5?!7PRB^'/BOXM?$SXU7WV;7K34/B5\4A\.HOB!K%OKEU?3K
M%J/_  K#X>?#3P,@T>UO5TK26T[P/I[C3[*S.IMJ=_\ :KZZ^5O@K_P3C^"'
MP(\-:[X6\(^*?BKJ.G^(?V.?@W^Q%>S>(]<\(WEY%\*?@?8?%'3O"?B"UDTS
MP-H\"?$+4(/BUXC?Q%JLMO/X;NY;+1&TWPGI*6U^FI 'UC\$_BCI7QP^#/PD
M^-6@Z=J&CZ'\7_ACX"^*.C:3JYMCJNEZ5X_\*Z5XLT[3M3-G-<69U"RL]6AM
MKTVMQ/;&YBE\B:6+:[>G5YS\'?AAH'P2^$?PL^#'A2\UC4/"_P (OAQX(^&'
MAN_\0W%E=Z_?:!X!\,Z9X4T>\URZTW3])TZYUBYT[2;:;4[BPTK3;*:]>>2U
MT^S@:.VC]&H \[^+'_)/O$?_ %QL?_3K8UWMK_Q[6_\ UPA_]%K7!?%C_DGW
MB/\ ZXV/_IUL:[VU_P"/:W_ZX0_^BUI]%ZO\H@3T444@"BBB@ HHHH ****
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M9_U_PZ^\#I:*YK_A,_!__0V>&O\ P>Z7_P#)5'_"9^#_ /H;/#7_ (/=+_\
MDJBS[/\ K_AU]X'2T5S7_"9^#_\ H;/#7_@]TO\ ^2J/^$S\'_\ 0V>&O_![
MI?\ \E46?9_U_P .OO Z6BN:_P"$S\'_ /0V>&O_  >Z7_\ )5'_  F?@_\
MZ&SPU_X/=+_^2J+/L_Z_X=?>!TM%<U_PF?@__H;/#7_@]TO_ .2J/^$S\'_]
M#9X:_P#![I?_ ,E46?9_U_PZ^\#I:*YK_A,_!_\ T-GAK_P>Z7_\E4?\)GX/
M_P"AL\-?^#W2_P#Y*HL^S_K_ (=?>!TM%<U_PF?@_P#Z&SPU_P"#W2__ )*H
M_P"$S\'_ /0V>&O_  >Z7_\ )5%GV?\ 7_#K[P.EHKFO^$S\'_\ 0V>&O_![
MI?\ \E4?\)GX/_Z&SPU_X/=+_P#DJBS[/^O^'7W@?'7[9?PY^*'Q&\:_L>6G
MPKU23PKK&A_'OQGK&J?$"Z^&Y^*/ASP)I#_LR?'O26U7Q3X;FO\ 2-+73=:O
M]2L?!VGWVKZSIEK;^(O$FC?9I;G4VL;"[^8/B;=?M@_#GXI:AX?M/B-\5/$_
MC&QL?V:K+]G_ $_X9_!!]-_9^^)MQXC^(=]8_M#2_&)=+\'>,_#O@F33M$L)
M[[7;C6_B'X<NO!W@FYTCQ!X)U5O$6IW,0_63_A,_!_\ T-GAK_P>Z7_\E4?\
M)GX/_P"AL\-?^#W2_P#Y*HL^WX>G_ ^_S _G!G^$/[6&A:A^RU??##X8?$K1
M/&6C6GQ#TY]3U7X?>,8_#WA[4-9_X*#7?C#1T\>R+I*)IGAR\\-M:>+M374)
M+5+CP0)M>5_[)/VROKOPQXV^-VE?!OX8:Y9ZY^W#XHU?PQ\1OV.O&7[1-_\
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M79W3^)%?4M(UN!/U\_X3/P?_ -#9X:_\'NE__)5'_"9^#_\ H;/#7_@]TO\
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M;_Y1T?\ #.G[0?\ T0GXR?\ AL/&W_RCK_6__P"$S\'_ /0V>&O_  >Z7_\
M)5'_  F?@_\ Z&SPU_X/=+_^2JK_ (C5B_\ HGJ'_APJ>7_4)Y_BOG/_ !!C
M"_\ 0_Q'_AOI_P#S7Z_TM?\ ) _X9T_:#_Z(3\9/_#8>-O\ Y1T?\,Z?M!_]
M$)^,G_AL/&W_ ,HZ_P!;_P#X3/P?_P!#9X:_\'NE_P#R51_PF?@__H;/#7_@
M]TO_ .2J/^(U8O\ Z)ZA_P"'"IY?]0GG^*^9_P 08PO_ $/\1_X;Z?\ \U^O
M]+7_ "0/^&=/V@_^B$_&3_PV'C;_ .4='_#.G[0?_1"?C)_X;#QM_P#*.O\
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M#7_@]TO_ .2J/^(U8O\ Z)ZA_P"'"IY?]0GG^*^9_P 08PO_ $/\1_X;Z?\
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M=?ZW_P#PF?@__H;/#7_@]TO_ .2J/^$S\'_]#9X:_P#![I?_ ,E4?\1JQ?\
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M (<*GE_U"?U=?,_X@QA?^A_7_P##?3_^:_7^EK_E!?\ #.G[0?\ T0GXR?\
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M!^5_[;'QW^*/P>_X*%_\$X-'\$>'/CC\3O"OC7X5?M[W'C7X*_!GQ#X8L/\
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MXK:O\*_"/[1OBO\ :Z\(?LJ:MXJ^$-S\ O#/[17C$>*;_5?'NFI'\-X/BO\
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M_;0.EHK _P"$K\+?]#+H'_@XT[_Y)H_X2OPM_P!#+H'_ (.-._\ DFBS[/\
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M36MW'X@U?P]JOB'XL-:-$)9[*]"E/Z;O^"?7[0W[1_Q\^'/Q0L?VK?@]X?\
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M6WB%-9TK3-9T L-'TKPY9^%[:WFUNZ29:Z:[[:OO;TZ=^GH!^G7_  AG@_\
MZ%/PU_X(M+_^1:/^$,\'_P#0I^&O_!%I?_R+7XA:#_P6=U"X_9Z_:T^+&I?!
MSP-KWBO]E'Q=\&M!U.S^'/Q?_P"$H^&OQ TGXR^*;SPYINL>%O'4?A 2J='_
M +*U:2YC_LF]M[V6&U2.ZMO/G6UD\<_\%5?VK_A]?_M,Z!KW[$/@M_$'[(]K
MX!\6_&LZ?^TC8W6E:-X(^)>FZ3KOA:VT:5OA]#=^(?$DFC:I)<:A<Z= ^F6"
MZ;>R/;/<O8Z9>.TOZ=NWGZ?@!^W/_"&>#_\ H4_#7_@BTO\ ^1:/^$,\'_\
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M#7_@BTO_ .1:/^$,\'_]"GX:_P#!%I?_ ,BUTM%%WW?]?\,ON YK_A#/!_\
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M_(M'_"&>#_\ H4_#7_@BTO\ ^1:Z6BB[[O\ K_AE]P'-?\(9X/\ ^A3\-?\
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M%/PU_P""+2__ )%K ^+'_)/O$?\ UQL?_3K8UZ)1=V6O5_\ MH'-?\(9X/\
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M23:Y))Y)/)-8WQ8_Y)]XC_ZXV/\ Z=;&N]M?^/:W_P"N$/\ Z+6B[LM>K_\
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MV$\?[N802EXA*GR2;=Z_*PK[SCG%8:M'+8X2IAY03Q:Y<+C<JQ"H8."PJP&
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M(-"BM;:[\/7NH)+J<WZ3447?Y?AL!^:EO_P2_P#A'X>\!?LX^$OAS\6OCO\
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M4 >=_%C_ ))]XC_ZXV/_ *=;&O1*\[^+'_)/O$?_ %QL?_3K8UZ)3Z+U?Y1
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M7P__ &+/#?BKXC?M#_&6U\5R> [*'QCHEE\*[;X6>+/A_ITEAX=M_&=Y\<O
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MUWQ?K^H:M::YIVI>,[A-4CTBTL(QI1^SJ*0'XN?M.?LK_'#5/$WCKP#^SO\
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MGCL?#1?^$1@\8Q:%'XAMK%FO+:_BUACJ5=);?LS?!&STRUT>V\$^7IMGX.^
M_@"VMO\ A)/%S^7X2_9E\7:OX[^"&D^=)KS3O_PA/BK7M5U7[?)*VI^)/M7V
M'Q=>Z_IL%M9PFGG_ $]?P_$#Q#X0_MO^'/BY^T9KWP!T[PA;V3:;H7Q#U2R\
M2Z;\2/ GC:Z@U/X6^+_#WA#Q9X=\:Z#X)U#7++P3K,DWB?2M5T33)?$^LZV=
M-:XB\6:-X/U:*+3)_P 5_P#@Z)^.'Q<^%OP!_9V\&_#CQ#KWA'PY\6?&'Q,T
M7XC:YX;U>XT:_P!3T72O#?AU;7P->W%E)#>S:!XKAUK5I];LHYDMM1MM!73-
M12XL+VXM9OWR\!_L>? +X:^/M!^)7@_PUXGT[Q+X2M?&FG>#+>Y^*7Q4U;PE
MX*T?XB:B=8\9Z%X0^'^K>-+WP'X>T+7=6\K4I])TWPY!8VMQ9:0NGPVEOH&@
MP:9PG[:7[*7P3_;/\.>$?@/\??"\GB;P)X@F\4ZA&;&_N-'U_P .^(-*T:*;
M1O%'AC6K0BXTK7=)FDD,$I6XL;ZTGO-(UJPU30]1U+3+SW.&,QPF4Y]EF98_
M#O%83"8CVE:BHQG)Q]G.$:D(3<8SJ4)RC7IQE**E.G%<T;W7A\2Y=B\VR+,L
MNP.(6%Q>*P_LZ-9RE"*DJD)RISG!2G&G7A"5"I*,9.,*DGRRM9_Y1U%?WHW'
M_!JM^P\\\S6OQX_:L@MVD<P0S>(/A'<2Q1%B4CDG3X16RS.JX#2+!"'(W"-<
MX$/_ !"J?L2_]%]_:G_\'/PE_P#G45_17_$5^#O^@K&_^$%?R\OZL_*_\\_\
M0KXO_P"@;!O_ +GJ/ZG\&E%?WE_\0JG[$O\ T7W]J?\ \'/PE_\ G44?\0JG
M[$O_ $7W]J?_ ,'/PE_^=13_ .(K\'?]!6-_\(*_^7]6?E<_XA7Q?_T"X/\
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M*_\ %S17]HW_ !"8>$_^CY?$7_B/FF__ #XJ/^(3#PG_ -'R^(O_ !'S3?\
MY\5'_$3^"?\ H<3_ /#=FG_S'_5GY7/^(9\:?]"B'_AQRS_YL_JS\K_Q<T5_
M:-_Q"8>$_P#H^7Q%_P"(^:;_ //BH_XA,/"?_1\OB+_Q'S3?_GQ4?\1/X)_Z
M'$__  W9I_\ ,?\ 5GY7/^(9\:?]"B'_ (<<L_\ FS^K/RO_ !<T5_9Q?_\
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M+<V2^;> 2^\/^(;<;1U62M-=8YCE5_E;'W^X_D-_X2_Q9_T-'B+_ ,'>I?\
MR31_PE_BS_H:/$7_ (.]2_\ DFOZX/\ B$P\6?\ 1\OAW_Q'S4O_ )\5'_$)
MAXL_Z/E\._\ B/FI?_/BH_XB/P-_T.:7_ANS+R_Z@?3[O+0_XAWQQ_T)ZO\
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M!AD>N#S3J0!1110 4444 %%%% !1110 4444 %%%% 'G?Q8_Y)]XC_ZXV/\
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M,;KQ]!+J#:7^BG[*/[.W_#,/PS\1_#K_ (3#_A-_^$@^./[1/QF_MC_A'_\
MA&OLG_"_/CCX]^,W_"-_V?\ VWK_ -H_X13_ (3C_A&_[8^W0_V[_9?]L?V7
MHWVW^R[3X@\7_P#!/_\ :QU/]M3QU^VCX8_;#^!K^*;[0F\!_!3PU\6_V.?B
M!\4[7]G'X8W-I8P:YX4^&LVD_MK?#;PY%KGCF\L!J_Q"^(3^";7Q?XENKJZT
M>VOM%\%FW\*6P!\\_M(_M>?MKV:_M]_M:? 7XL^ +#X%?\$U?BK/\--=_95U
MKX3Z5J)_:*TWX;_"#X2_%SX]^(O%?QIU;5;3Q?X!UG3])^+.K:;\-;7P+IBZ
M7!JGPYL;G7;7QE9^*)K./TG]N[XT?M]? 9=<^/W@'XS?">U\-ZE\:_@E\*?V
M/?V.-!^%D'C37OVL?^%BIX+LM=TCXF?$+Q+-X?\ &7@WQ_?ZA??$+7M!@^&T
M.E>&_AKX#\$2>(_&MQX\BDU$Z5Z1^T%_P37^(/QG\4_M$^$M$_:(\-^$/V3_
M -LCXF?"7XH?M/?!34?@M?>)?B#KFJ?#[1?A=X-\=Z)\,?C%9?%KPO9^!]$^
M.GP_^$/@KPGXT_M[X<^-[SPT;'4M8\(36EYKMW';5/%__!/_ /:QU/\ ;4\=
M?MH^&/VP_@:_BF^T)O ?P4\-?%O]CGX@?%.U_9Q^&-S:6,&N>%/AK-I/[:WP
MV\.1:YXYO+ :O\0OB$_@FU\7^);JZNM'MK[1?!9M_"EL =%I7[1/[8EU_P %
M2_!?P%\?^#?!'PJ_9:\0_L[?M/>*?A[H.G>)]*\>?$CXM^)/A%\4O@#X<L/B
MYXWO;?PS;VOPV\-W&@?$=H/A]\//#_B?4]9DCU+Q-JWQ,<:B?"NA>%_U4KYH
M\4_L[?\ "2_M;_!O]J;_ (3#[%_PJ3X'?'3X,_\ ""_\(_\ :?\ A(/^%T^+
M_@GXJ_X23_A)_P"VX/[*_P"$:_X4[]@_L?\ X1[4O[9_X2+[5_:FE?V1]GU3
MZ7H **** "BBB@#SOXL?\D^\1_\ 7&Q_].MC7>VO_'M;_P#7"'_T6M<%\6/^
M2?>(_P#KC8_^G6QKO;7_ (]K?_KA#_Z+6GT7J_RB!/1112 ***_,7_@L?\=/
MB'^SE_P3H^/WQ1^%WCJ\^%GBZWO/@]X)3XIZ?90W]]\-/#_Q5^.?PU^%OC+Q
MQ86\FZ9=5T#PAXQURZT2\T^&;4M,UO\ L[4[)(YK-;B  _382Q-*\ EC,\<<
M4LD(=3+'%,TJ0RO&#O6.5[>=(G8!9&AE5"3&X5Y .,]O\D?C7\PG[=_P'_X)
M^_\ !.2S\)>._ O[+'[='PS^)'PKM?#WQN_X>"?LJ^!_$'Q:UOPE#:^,XK+Q
MCX;^/GQ?^(OQ5L8/']EX^T71+_0?&_@/XKKXH\(OX7\:07MI86T]U;10>E?M
M2_\ !6W]I#PK\;OVP/"_[.]I^S1;>#OV+-8T7PN?A_\ %GP=^T#XQ^+/[6/C
MS3?!'ASXA?$OP/\ #GQ-\,/L?@[X+W.FZ5XD?P7X&OO%>@_$1?$GQ"L]'O=4
M_L;PCJFH-IH!_0^=&THW)O#IUG]K:]74C=?9H?M!U!=/_LE;WS=F_P"UKI>=
M-%QN\X6)-H'\@E#D1>!_!T$AFA\,:#%,S6;M+'I-@DC/IZVBV#,ZVX):Q2PL
M4M&SFW2SM4B*K;PA/Y[O%O\ P4^_X*">/-._;9^,O[//PL_9B\*_ 3]B/X0_
M K]H[Q!X9_: TKXMQ?&GXC>!/BA^QK\*?VL?%_PDC7PIXKL=&^'_ ,2/ NDZ
MU\0+,^,-9T#5-&U'5-4\ ^%F\%VS^'/&'B;6O9_V@OV\/VZ=9^.]]\-/V1?#
M/[+WASP9X?\ ^":_P[_X*"^(O$?[0N@_$WQ=K"7OB3Q?\7]&G^$5C!\//B!X
M,BE'B2Q\&>'FL/%1TTQ^$UTCQ?/>VGB&X\1^&K/P_C+#X>=N>A1E9S:YJ4)6
M=16FU>+LYK2;WDM'<VCB,1"_)7K1O&,7RU9QO&'P1=I+W8?96T>B1^V[>&/#
M[_:]VC::QOIK:XO6:RMBUY/9WLVHVDUR3%F>2VU"XGOH'DW-#>3S7,96:1W)
M=>&/#MZ-.%YHFEW/]D1&#2_/L;:4Z= PM@T%B7B)M(7%G:AXX#&C?9H,@^3'
MM_"/]DW_ (*5_MF^/?BY_P $]T_:0^&W[.>C?"+_ (*>?#GXT>.?@9X:^$$_
MQ!D^)OP=B^$GPIMOC3I4OQ.\5^+M>N_"'CM/'O@J=HS:^'/#G@N3PMJL]A;7
M4NHBWU"27Y6^&G_!:?X]^//CO\'_ (7^+?&7[%/Q"T/X[?%#Q3\%/'OP:_9V
M\+_M >+_ !'^SQ+JW@KXEZ_X*O[C]L9M5UC]EKXT:U:'PG%I_C#2O!-KI\FN
M2+->>!K%=(T[Q%K&EMT*#33HTFFDFG3A9J,_:137+9I5/?7:?O+WM1*O734E
M6JJ2O:2J3NKP5)V=[J]-*F^\$H?"K']/UIX.\*V#7K6?A[1[9M2DBEU!H=.M
M(VO98+I[Z&2Y*0J9GAO9)+R(R;MEU++<+B:1W:&;POX-U*_$TVBZ!>:EI=RM
MSYALK":\L+RXG75%G8^6TUM<SW)34E=MCR7'EWBYD"R5_,C_ ,$L/VCOVS_V
M7/V(O^"86M?&KPI^S]JO['WQ\\1_"C]EOP-X<\"_\)PO[1GP\U+XRZS+I'P4
M^,?C'Q1J.N7GPX\9>'_&GC*2_P!-\8_#K0O"_AO6O /A?Q'X)\00^*O$&JZ+
MXV\/'[$\"_\ !*[]HGP-\9OVV/BI#^US\0M5TK]I;X>_$S3?AGX37XU_M!>'
MM6^&'Q&BUU[#X(>(]=^(FA^+8?%'C&TT?X>Z?X>TS5M4U47OB7X:O!?^#OA+
M=VG@:8VEQ/U7#<JA]7H<BU4/94^5/F<[J/+9>^W/;XFY;ML?UG$<SG]8K<[T
M<_:U.9KE4+.7-=^XE#?X4H[*Q^U_A[P]X5TF%[KPSINC6<%^(F>YT>VLHHKR
M.W,H@4S6:*DT,#2S^2@8QQ-)+L"EWSTM?G7_ ,$S_P!BWXA?L*? G7?@M\1/
MC;K'QWF@^(6NZEX*\5ZC>^)+:WTSX<SVNG'PYX<MO!.IZKJ'A7P'=Z9>OK8U
M+2_AY:Z5X:U>22W\075I)XAU+6+F;]%*TITZ=*"A2A"G"-[0IQC""NVW:,4D
MKMMNRU;;W9%2I4JS=2K.=2<K<TZDI3G*R45>4FV[))*[T226B"BBBK("BBB@
M J.::&WAEN+B6."""-YIYYG6*&&&)2\DLLCE4CCC16=W=@J*"S$ $U)7R!^V
MK^V-X+_8C^%6A_%3QW\+/C?\7=&\2>/=,^',7AGX">!])\?>+[6^UCPYXK\1
MIK.JZ+K'B?PG:P>%X+7PG>:??:@NHSS1:GJ>C6@L98[V6>VWPN&KXS$4L+AJ
M<JU>O-0I4HM*4Y/7E3DU&]D]VD88G$T,)0JXG$U(TJ%&//4J23<81NE=J*;:
MNULFS^+G1O$7P4\$ZEXFM_!_QD_X+C:!^R_X=\#O\9_#7Q.\,_'#3-#N/%_P
MY\1?&:'P+XK^,NC?"'3_ (>VMGHWPVN_&NJ^+?$%QXVU_P 9:3>:[J<<*:MI
M&G>)/$\MM9?W[Z7'#%ING16]X^H01V-I'!J$DZW4E]"EO&L=Y)<I\EP]R@69
MIT^65G,B\,*_SUM N_\ @G-KGQ=UR^TK1/\ @M1XB_9HT*6X\#:G^RAHGPJ^
M']UX?T+0[+XFP_&6\^ FO^,;/]H"]O;;X2VWQ"D3Q/=?#B;PSIGBF#6IHO%+
M^,8_&I7Q2_\ H5Z=<17FGV%W!!+:P75E:W$-M-$L$UO%/!'+'!+"C,D,L*,L
M<D2,RQNI16( )_2/$B,8O)[0QD926-G.6+I>SD^:&!Y8SN[SQ>DZF+E3_P!E
M<JE-X:3BY*/YSX<RE)9M>>#E&/U*$(X2K[6*<98SF=.R2CA+.$,+&I;%)4ZB
MQ$5*SE7U?6M*T&U6]UB^AL+5IDMUGG+!#,ZNZ1@JK'<RQR,.,84\US?_  LK
MP)_T,VF_]]R__&J[&XMK:[0175O!<QA@XCN(HYD#@$!@DBLH8!F ;&0"0#R:
MI_V+HW_0)TS_ , +7_XU7YAI_3_X'K_6_P"FG-?\+*\"?]#-IO\ WW+_ /&J
M/^%E>!/^AFTW_ON7_P"-5TO]BZ-_T"=,_P# "U_^-4?V+HW_ $"=,_\  "U_
M^-4]//[_ /@>O]+4.:_X65X$_P"AFTW_ +[E_P#C5'_"RO G_0S:;_WW+_\
M&JZ7^Q=&_P"@3IG_ ( 6O_QJFII&AR M'I>E.H9T+)96; /$[1R(2L1 :.1'
MC=>J.K*P#*0#3S^__@>O]+4.<_X65X$_Z&;3?^^Y?_C521_$7P-*VQ?$^D@X
M)S+<>2O'^W,L:9]!NR>P-=#_ &+HW_0)TS_P M?_ (U4<OA_09EV3:)I$J9!
MV2Z;9R+D=#M:$C([''%&GG]_IY>OX=M0RO\ A//!?_0U:#_X,[3_ ..T?\)Y
MX+_Z&K0?_!G:?_':N_\ "*>%O^A:T#_P3Z=_\C4?\(IX6_Z%K0/_  3Z=_\
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M[_Y&H_X13PM_T+6@?^"?3O\ Y&HT\_P\O^#^'F!2_P"$\\%_]#5H/_@SM/\
MX[1_PGG@O_H:M!_\&=I_\=J[_P (IX6_Z%K0/_!/IW_R-1_PBGA;_H6M _\
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M>7_!_#S /^$S\'_]#9X:_P#![I?_ ,E4?\)GX/\ ^AL\-?\ @]TO_P"2J/\
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M@7?^$K\+?]#+H'_@XT[_ .2:/^$K\+?]#+H'_@XT[_Y)JE_P@?@O_H5=!_\
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M_!SJW_R91IW?W+_,#TNBO-/^%1^!O^@=>_\ @YU;_P"3*/\ A4?@;_H'7O\
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M-G_T-OCW_P *63_Y&IK?#2R4@?\ "6^/,GL?$\@/U_X]?;V[^AHT[]NC\O\
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M2B^ ?BF/XQ16W@>SD\07A\$Q&YL9/!TO@*UBUZ66ZN[.]TUETE/ ] _X(U^
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M]GCX/? [7/BMXC^%OA#_ (1?6?C?X_U;XH_%"\_X2#Q1K?\ PD_CK7+N]O\
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MQKT2N!^*,7G> ?$J;MNVSAESC.?L][:SE<9'WA'MSVSG!Q@N.Z]5^8';VO\
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M0:O8?%'Q+^SK\';'Q5X0^.5OX!^';>#)[CQ8GQF_X6W\9O$O@LCQ193^-?\
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M75A;^7,<Q=]M^?%3[=+;ORM<?$[C.-[YG2G>WQ9?EZMZ<F&AOUO?RL?W$?\
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M .C8J<=UZK\P.QM?^/:W_P"N$/\ Z+6IZ@M?^/:W_P"N$/\ Z+6IZ0!1110
M4444 %%%% !1110 4444 %%%% 'G?Q8_Y)]XC_ZXV/\ Z=;&O1*\[^+'_)/O
M$?\ UQL?_3K8UZ)3Z+U?Y1 ****0'Y!?\%;K/QO?ZC_P3$L_AMXA\*^$_'5Q
M_P %1?A''X9\1^./!NK_ !"\):1J9_9N_:N*7>N^"]!\=_#+6/$=BL8D1].T
M_P ?>%KAW=)!JD:QM'+\6?\ !0O]ACXF67@GQ[^T=^T#^TNGQ,^/GQJ^-/\
MP3=_9J\'>,O@[\)I/V>]$^ ?PET_]OOX=>*_[.^&.AWGQ.^,/B"7Q'/XR\8Q
M^*7\6>*?&^N:M%J7AW1$MWBM;<PG^E"B@#^6S]HKQ<O[%FF_\%(?@5X8\>?M
M02_ C1/BO_P3?O\ PTDO[6_C+PO>?">[_:C\1ZYH/Q6D\;?M@?%U/B]\5?@A
M^S[XSU7P1I#_ !%\9:1<Z]XH\-ZGXPUN7PQ>Z OBB]OM-_-_2/C+XMUSQO\
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M 'G?Q8_Y)]XC_P"N-C_Z=;&N]M?^/:W_ .N$/_HM:X+XL?\ )/O$?_7&Q_\
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M5T'_ ,%EI_\ &J/^$#\%_P#0JZ#_ ."RT_\ C5&GG]W_  ?7^GH&S_;6C?\
M06TS_P #[7_X[1_;6C?]!;3/_ ^U_P#CM8W_  @?@O\ Z%70?_!9:?\ QJC_
M (0/P7_T*N@_^"RT_P#C5&GG]W_!]?Z>@;/]M:-_T%M,_P# ^U_^.T?VUHW_
M $%M,_\  ^U_^.UC?\('X+_Z%70?_!9:?_&J/^$#\%_]"KH/_@LM/_C5&GG]
MW_!]?Z>@;/\ ;6C?]!;3/_ ^U_\ CM']M:-_T%M,_P# ^U_^.UC?\('X+_Z%
M70?_  66G_QJC_A _!?_ $*N@_\ @LM/_C5&GG]W_!]?Z>@;/]M:-_T%M,_\
M#[7_ ..T?VUHW_06TS_P/M?_ ([6-_P@?@O_ *%70?\ P66G_P :H_X0/P7_
M -"KH/\ X++3_P"-4:>?W?\ !]?Z>@;/]M:-_P!!;3/_  /M?_CM']M:-_T%
MM,_\#[7_ ..USC?#?P*[,Y\,:6"Q+$+$Z*"3D[41U11Z*JA0.  *;_PK7P)_
MT+.F_P#?$O\ \=HT\_N_X/K_ $] Z7^VM&_Z"VF?^!]K_P#':/[:T;_H+:9_
MX'VO_P =KFO^%:^!/^A9TW_OB7_X[1_PK7P)_P!"SIO_ 'Q+_P#':-//[O\
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MIY_=_P 'U_IZ!V/VJV_Y^(/^_P!'_P#%4?:K;_GX@_[_ $?_ ,57'?\ "M?
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M^$9\$_\ 0O\ A;_P5:3_ /(]4/\ A6O@3_H6=-_[XE_^.T?\*U\"?]"SIO\
MWQ+_ /':I3DK6G-6MLWIMMKTMIZ+Y3R0_DC_ . K_+R7W%__ (1GP3_T+_A;
M_P %6D__ "/1_P (SX)_Z%_PM_X*M)_^1ZH?\*U\"?\ 0LZ;_P!\2_\ QVC_
M (5KX$_Z%G3?^^)?_CM'//\ GG][\O/R_!?)>SA_)#_P%?Y>2^XXO_AGW]G+
M_HB'P3_\-KX$_P#E+1_PS[^SE_T1#X)_^&U\"?\ REKM/^%:^!/^A9TW_OB7
M_P".T?\ "M? G_0LZ;_WQ+_\=K7ZUB?^@G$?^#:GE_?\OP7RS^JX;_H'H?\
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M^PNI?#H\RYLK6>3;JVN!=\T$<C[1_:? W,<#L*N?\*@^'?\ T+W_ )5M<_\
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M[XZS\2O'7C"1M6\#6OCB/7++3(X_#MC$-$MS\VF07^F+XFUGZ<^-W[?7BO\
M9/\ "'A-?CG^SA\6_&_BS1OA5X<\=?'#Q[\%/#]LWP!\*:C+*VD^)=/\,^/?
MB)K/A1M?UF'5(&U6T\%6$6I:O9:!J%I)>:E.;6\N1Y1XZ_X)E?&J/Q-^T1IW
M[//[;7B'X"? []J?Q;XE\=_%;X41_!_P_P"-[^T\5>-[:&W\=ZAX+\<7OBK1
M=7\-IXNC22RN$TJ#39M,TT6MHMQJ:6&GBSROVD/^"2#_ !O\6V^I:/\ '2PB
M\+I^SAX>_9WM=-^.'PH_X:%\2^"8O#[HLWQ+^&GB37OB#X6MO#/Q%\36=M;0
MZWXDFT6_UB+5+SQ#XCL-4CU75=..@UHVKM6LKZ.^ROLNK\P/3_BO_P %6OA7
M\.]5TK2_"WP7^.OQ?75/V6O#?[8\FI> =%\(C3M#^!&O++=7?BGQ&VO^+](O
M=+_X1_3(X;O58A97,:SZAIUE#/(\\\MKYMKO_!5OP9\0O GQ6TSPKX'_ &AO
MV?=:O/V2_B+^T?\ !3XK^.OACX$U5/%'AGPKIL@E\2^"?!NJ^-9M(\2:AI\L
MG]NZ'I'B6]T[0?$>F:=-/?ZEIME?:2^J]K9?\$P6M)]4G?XXK*=2_P""7X_X
M)N!5^&1B$"II]AIZ?&4D_$*4RL$L%D?X>_NPS2$#QP@49I^+?^"6O_"4>$/A
M)X4_X7I]A_X59^P_X]_8T^W_ /"LOM7]N_\ ";^%K;PU_P +'^R_\+"M_P"S
M/[,^S_;?^$/^TZC]MW_9O^$HM-OGL>[IZJ[^Z^EO5=?GH!A^(O\ @I?9>"?A
M+\'_  7H7ACXV_'SXX^+OV(O"?[2_C'QOX)^'/@FQE\%>%];^'UM-#\6_B#X
M0MO$5QX:T.ZO?$\L6M:OX&\+R>(=-T6WO%L].DU6WFT6SU?R?X&_\%6/&/@C
M]C/X(_%?X[?![]H/XY>(M7^'GB;XA_%7XT^"_A[X(\*_#'2](L?BSXY\&V]C
M_;UQ>^!/"6I>--.TO1-*FG\'>$M*DNCI,L&JWDRSG47C]9U__@EOXWL]9^&.
MM_"/]J$_#"_TC]BOP=^PY\9;J'X/:;KEQ\4?AYX;T:VT:]\8Z&]YXVB;P%XV
MO;:QL!H]X'\23>'CINEQQZEJ%C;:CI^L_/T__!#;4U\(>%_!"?M+^%?$VDZ1
M\"-:^"4MS\3/V<[?Q\_@^76OB'XF\=7GC[X*Z3J7Q<ATSX8^*KVVUVWT">^7
M^W=2LI8]:\2:9J]OJ>L:=#X<%R]6MT]G?;5;=^P'V3\1_P#@J9\,?"'B+0/"
MO@CX*_'KXTZSXJ_9A\-?M:Z%%\./#GANYB;X1^)(;J^74M7&K>*=-O=)N-*T
MRU2ZU&$V-TTEU?Z9I&E#4M4OH[4?/_QK_P""FTND?$+]@;XS?#G6_$A_9?\
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M7;2/'6J> /&GBY/A3XZOFMK^]T'P3\2HM!O=6T^R@D>>VO-7TK3;SR7]DO\
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M".3P)IU]JGCTZAJT\4<R>);"T%UI>C7<::=I>M:S!>KX_P"!/V';+QE\/_\
M@HO^PY\2?#?B;PO\,_BA^T!??'WX6?$[1M"FM/#4VB_&!/#_ (R\/:?X3O)3
M_9NH:[\&O'W@"YT3Q3X>^UVLT^BMH8NH+;3/$EI>W7IWPK_80_:*MOB9X2^(
MO[2O[=WQ!^.2_#3X>^.OA_\ #?1/"'@'2_@G_9TGCC2;?0+SQKXIU+P[XEUO
M_A,_$MIID$-YIYU^POI;+Q-IF@^(VU:[O=+=;QNUM+=/GHMNVM[[?,#D+O\
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M *\O%G_INBKTNO-/$/\ R4KX>?\ 7EXL_P#3=%36_P I?DP/2Z***0!1110
M4444 %%%% !1110 4444 <!XU_Y"?@'_ +'&W_\ 37J==_7 >-?^0GX!_P"Q
MQM__ $UZG7?T %%%% !1110 4444 %%%% !1110 5YIXY_Y&/X;_ /8RS?\
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M4/%=OJ&I6L4N?](<:5)<1]+>U:O*_@3_ ,$P?^"@'[,O[6?AFQ^$GQ(M]"\
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MEUJ'AC5O!2ZUXE\7ZA<:5=>&+C1W;4'\1ZG;:I>?:M2T]X-/N[6TM_5*\/\
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M_A*O^%-_%[QI\!OB1_Q(_$FA_P#".?%?X>?V;_PF'A7_ (J/1]'_ +8_L?\
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MY)]XC_ZXV/\ Z=;&N]M?^/:W_P"N$/\ Z+6GT7J_RB!/1112 *_GC_X*W?\
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M<UK6-6M(I!!+JGB"73[5;>)KA8%MTT;3]*::]N;Z6QM3_:B1QSRS1-&?1/\
M@BE^UIX2\:67QC_9[N]1M+77-#\:7/C;X<Q2>7!_PD_@NXTK2/#^L_V87\NX
MOI])UG0FUF9IH8KB;2?$UA<)%MM+Y;7N?V8?^"6-S;W]IXT_:>GM-==(F,'P
MWMK[^U;%UFA=&A\3ZA\\5XJ"0B33]/F>!I5#->R1@QO^=G[5G_!'K]H'X ?$
M)/BQ^QG)K_C'PEIVL+KGA[2=!U:.Q^*/P[N8I6N+:*Q'F69\1:;8-_HUI>Z9
M+)J_V?RX]1TZ91<WLGWO#^5\.9IEL_#GBSQ3RO,\1E."G#A/,<GX>K\,<#X'
M-\5F$L9F&+KRQ^?9WC<]SK%?[FLTQ>-PN6X?+,7B<'D> HXBIB:^8?F&=YEQ
MMDV?KQJX0\$,XR.EQ)F%!<=Y)GO%F'XT\2\PX<P&54<NRG!82EE7#'#F7<,Y
M#@[?VC+A[ 9=F6=8S.<%A,QXFS;$X:A@\'E']:JMN&?<C\OQ-<]/XL\.6FOV
M'A2[U[1K;Q/JUC?:II?A^?4K.+6M1T[39+>*_OK+3'F6\N;.REN[5+JXAADB
MA:>-9'4LN?Y&K+_@H-_P5]\(::O@.^\*^-]0U6")[*/5M:^ UUJ7B<-M/[[^
MT8-%6SO)T$BE;F:UN<%$+LWS;M/]G+]@/]O_ /:R^/6@_'OX]^)?B)\*(M+U
M/2=6N?BIXHOO[+^(AM=/D+VVF?#[0 HN-/D2*2:.%[O3].\/V*3W+R1W\TLE
ME<<<_!193A<=F/%?'/">49=0PM:K@JV!QL\TQ.8UXQOAXT,(HX:K.E5;3DJ/
MUC$M/EIX>7-[2/T]/Z1,L]QF6Y5P1X9\>9]FV)QN%HYG0S++8Y%A,FPLZG+B
MJN+Q]2>,H0KT8J?LXUWAL+)QDZF+IN*IS_KS4DY.1CC&/?/7GZ?EQ3JS],M7
ML;*TLFN;F]^QVEK:_;+Z59[V[-O"L1NKR94C66ZG*&6XD6.,22N[A%#!1H5^
M&=[:J[L]KKH[/5773IL?TFKM)M6=E=;V?:ZT=@HHHH&%%%% !7YK_MQ?$_X1
MZUX<U/PS/\:=0^$GQ%^!/Q1^'.J1^(H/!/B?Q+;:/XO\;> /&^K^%=-GATW3
MY4NK?6/"*>(+[^U=,-X=$O;&UCN0L\XL[G]**^5_VJ_C#X_^%7A;P6OPKB\!
M2>+?&?Q.\,?#^?5?B+<W\?@[P?8^)+/5GC\0>)&T>]M=1L[07]KIMA#=L);9
M)M1B0V]W=3V-C=_6\#S<.)<O=+#5<3BO:1^J*&/P>7T:=15(2KSQ=3'Y3G.%
MK86I@8XO#3P]3!R4YUZ<W[94WA,3^?\ B?3C5X,S>-;&4,'@?8R^ORJ95F.;
M8BM1E2JPPE/+Z.59]PYC<-CJ6:RR_&4L72S&'LZ6%K4O]GE6CC\'\4_L)M\!
M#\8-"TGX7_&N\^(4G@+]GV]\'Z'X8NOA[XE\,/#+JOCJP\7?$?Q?-JFK6-K:
MA-0\3WUJND:6]QJ%_!IFI-827DEOHMM)/^OU?'GP%L_VPX/&MT_QY^(/P%\4
M^"CX?OEM=-^&8UC_ (2%-?-YIIL;N;[?X7T:#^RXK,:E'<XNVD^T36FV!QN>
M/[#KK\0L<LQXBGB5BZ>-4L)0O7I9C0S6,JDYUJM:4L7A\BX=IRJU:U2I7K)Y
M<INM5G4G7JN?N\'A'ECRCA"G@Y8"MEKAC\3RX6ODV*R*<*-.EAZ&&A'+\7Q3
MQA5A1H8:C1PN&DLX=-8>A2I4\+0C27.4445\.?IX4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 445Y%\>_A>WQG^#GQ"^&EMJTGA[6/$WA
MZ=/"GBB$S"?PAXZTJ:#7/ /C.V\AED:[\'^--,T'Q-:QC<LEQI44<B21L\;
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MG_SF_J[\K'_$YGBI_P!"C@;_ ,-.=_\ T1G]2?\ P\Q_8X_Z*7J?_A >/O\
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M (0'C[_YG*/^'F/[''_12]3_ /" \??_ #.5_+911_Q+=P)_T,>*?_"_+/\
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MS_PJO'W_ ,U='_#O3]CC_HBFF?\ A5>/O_FKKZ%_X1CXB?\ 14/_ "R=#_\
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MI_T6/$__ (D&;_\ S5Y+[@_XACX:_P#1O.!O_$3R#_YW^2^X\S_X=Z?L<?\
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MET>626*V:RA,$<L@;#R)$55W'#,"PZT^BU6[[]H^73K^%P/8J*\T_LOXJ?\
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M\B'98^ RGE1["USK>XKL7:6QQG&,XXSTIVT6JW?X\OY7U^8'J%%>:>?\7?\
MGQ\!?^!.N4>?\7?^?'P%_P"!.N4K>:^_T_S_  ?8#TNH;F)Y[>>&.>6UDFAE
MBCNH!$TUL\B,B3PK/'-"986(DC$T4L1=0)(W3*GSL3_%PD V7@%02 6-SKN
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M4L.G6CV L=2AN[FZ^V![.))?U@KX4_9W_9:OO@]\6-1\5?\ "V+'Q9X*\/\
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MZO/#<EIICLGA&RE\">&]=&FZQJ4%F:26GJKKR>WZ;=];6 _;/X*?\%!?@/\
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M%\.?VOXROO#WP]BU9+;2_,U&ZU?Q+I^EZA!!?:C!;QRFETMMKN_>U_2VO]:
M?7\7_!5K]F^+P1XF\2>(/!W[0W@WQOX<\;^ _AO#\ O%OP8U[2?CWXH\<?%+
M3M4UCX;^'?"?@-;FY@U>]\:Z3HNIZAH;-K=K;2016B74]K<ZOHD&I>IZ3_P4
M-_9?U+]FKQ1^U/>^,;[PM\/_  5J>N^%/%N@>,]+;PM\1- ^)GAVQ2^U/X0W
M?A'5[BWEG^)RB6"WM?#FGWEY'?27$5Q:7\VG"2^C_!K5?"_[1-]\1_#_ ,;_
M  YX#_;P\>?LI? O]MO]D7XD^ O!7QP\/?%?QK\8[7P^G@?Q=>?M&^--&\+^
M*;?5O&6M:=H?C2#3EFGL7ET/^TM;N$TV6&.YUJZM?T$_9 _9PU#QG^RI^U]X
MY^,7P,U*UU'XT_M4_M0?M2_ _P"&'Q+\"31>,/!\WB7PK>^%_ .OKX UBQN+
MWPYX\?S->BT)8([N\33[S1=1T:Z=KBRN:+*U_P!?):;>;]+6U _6'X!_&KPM
M^T7\'/A]\;_!-AX@TOPI\2?#\/B/0M/\56NG6/B&TL9YY[=(M6M-(U77--@N
MP]NY9+/5K^$*4(G))5?7J^(_^";OA/Q3X%_87_9F\(^-O#7B#P=XKT'X:V-A
MKOACQ5HVH^'O$.BWR:AJ+O9ZMHNKVUGJ6G7:HZ.UO>6T,RJZ,4 8$_;E2!X+
M\!?V@_"O[0</Q?G\*Z/X@T=?@S\>OB;^SYXA'B"+3HFU/Q5\+;^RT_6M8T;^
MSM1U$2>'[^6^B?2Y;XV6HO&DAN].M&"JW1_%SXF:S\+M$LM:T?X0?$[XP?:+
MN:&^TSX82_#*"_T*RM[2:[EUG6)OBC\2OAEI":6OE"W+6.JW]\)I49K%;59K
MF+XB_P""9?\ QX?MX_\ :33]L+_U)?#U>_\ [>&K^.='_8Y_:-_X5EX0\8>.
MOB!KOPM\1^"?"'AOP%HFJ>(O%EQKOQ!@3P)8ZGI.DZ+;7>HS_P#".R>(AXCO
MIX;=X]/TW2;S4;LQV=I<2([:I=[;^:0$G[.G[5]M^T;X;TGQYI_P*^./PL^&
M?B+P3;^//#/Q)^+L?P=T;POX@T:]EL/[.BLK;PC\8?&WBNSN]1L+YM8M)-;\
M-:3I;:797,TNIQ3RZ?;7WU3/=VMLJ/<W-O;I)OV//-'$K^7#)<2;&D90VR"*
M69\$[88Y)&PB,P_'/]KWX:3>%?"?[(/[.%Q\/)/$7PG^%WPQO9-/\?7'[-GQ
MH_:X\/0?$+X6>%?!OPX\#>"I_@7\,==T?P?-X@\1^'/$'B?6?"GB?XV6GB#P
M=IEUHMVNDZ9!JT5S?P?/W[,'[+?B'XX:9^P_\-?VBO@[\1M'^'GPY\._MC_M
M'_$3P)XO^&FO_#7X81>./B#\<)/!OPC^$$WA.&"S\/\ A2PT?P9K?C+Q;9_"
M6QN/[&;PJUO"-.O/!6M7%GJ1;2^VMOP_']';9,#]_IM?T&WFMK>XUO2(+B\L
MI=3M()M2LXIKK383$)M0MHGF5Y[*(SP"6[B5H(S-$'D'F)NOM=VBW4=BUS;K
M>RP2W45FTT8NI;:!XHIKB.W+><\$,L\$<LRH8XWFB1V#2(#_ #3?$/X._"SQ
M7H7@_P""GCK]F*]O_P!H#XX_\%!M&\'0_&=?AE<IX/T7]GCPW\09O$_A(_!#
MXOOH[Z!J?PFTK]DCX?6O@#0OA;X9\1SQ^'(++Q->>*/#^BWT7VC4>WNO@E\4
M/'/QK\5V7BCX<SW7[17B+]M6_P#B#>?%6X_9"\=ZYX@^&7PJ^&OC>+Q;\,-4
M\'?M@>)/B)IGPI/PEU?X3>"/"W@#3?AUI7ANZU_4Y_%'B+PGK/A*37I-:U]"
MWG^'I^&N_6WF!^T^@?M)>!_&8O9/A_H_C'Q_::7\=M2_9^UB_P##6DZ>EEI/
MBCP['*OC+Q-=RZ_K&AM)X"\%ZE9ZKH>N:_8I>7-UK&D7UOX;TK7X'L+F]]TM
M=5TN^GFM;+4K"\N;>"TNKBWM;RWN)X+:_61K&XFBBD>2*"]6&9K29U6.X6*0
MPLX1B/YB_"7PD\<^%OV;?@2?A3\!/C#H_C;X;?LJ?MF?&OQK;^&OV<_''@:[
MUS]KSX^QZ?\  SP-X,_LEO!VAW6I^)/A;;?$3QX-&-M;W:Z9\*_!NFW^@W,/
MA&SL[A/K/Q1^QWJW[.@ET7]EKX>6G@GQY\&_^"</Q2\'6WQSTZR;PCJ/QD^/
MOQ6U'P#X/\#Z7JWCPKIUIXO\9Z!_PJ3Q'KGAK0-<U>\T[P5K_CKP))!IVAZ5
M=Z*K%EWZV7^;[?CU _;V#6]&NKNXL+75],N;ZTNC8W=E!?VLUW:WJVRWC6=Q
M;1RM-#=+9LMV;>1%E%LRSE/*(<^!?M4?M1_#G]D3X4WOQ9^)&G^+]?TV&^&F
MZ9X5^'^C6FO^-?$5U!I>J>)-:_L32]0U70]->V\,>#/#WBCQSXEOM2UG3+'2
MO"?A;7=2DN7EMH;6Y_,+]F7X8_L]ZS^WK\%C\$?V9_$7P-T_]F[]CK5O$WBG
M6_%_PLU;X5^-O$?CKXM:QHWP\\(:=X\TOQ#H>AZ]XF\3:%X<\._&(7WQ#U2*
M^G\7:OJ>O3V&M:YI4<>J7/JOCKX#?'O]M+XT_'7QOK$^@_"+X1>"O /Q7_9*
M^"GAGXS?!KQ=XFUOQ/9_$30H="^./Q[T'2HOB'\+[KPJOBI2GP_^'WB6=_$U
MOX@\!Z9J.J0:+IUGK;R:\TE?5Z;NZM]UF]_^"!^AOQ*^/7@?X5Z1\,O%'B.+
M6[KP7\3_ !SX0\!V?CC1;*TO_"OA.]\?PSQ^"M>\<7\FH6LVA^$O$FOMHW@^
MR\06]IJ-K;^)O%/ANUU);&POY=2M?"?BM^WW\'?A;J7Q?LH_#7Q-^).G_ BQ
M\-1?%+Q-\,]#\-ZSX8\-^._&?BG0_"/A+X/)JNN>+_#8UGXKZYJGB+26;POH
M<.I0Z!;W<0\6:IH%W-;VDWQ];-\>_CM^Q9^S1^Q7I?P<\=>%/&'Q0_9X\)>"
M/VD?B7\9?AEXFT+PA\$O /A+1[7X?^-]1MV\2Z9IECXJ^./BC4M&GN/A9X,T
MB:XO=--U9?$;Q!)X?\-6VE:I>^0_\(QX^^$_[/7P)_9MUSX)?&*.7X-_M_\
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M *Y/QY_R)?BK_L ZG_Z22UUE<GX\_P"1+\5?]@'4_P#TDEIQW7JOS N^%/\
MD5O#7_8 T?\ ]-UM6_6!X4_Y%;PU_P!@#1__ $W6U;]( HHHH **** "BBB@
M HHHH **** "BBB@#SOXL?\ )/O$?_7&Q_\ 3K8UZ)7G?Q8_Y)]XC_ZXV/\
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MBATK6KK2_+\1^(-0L)=MQ:V8^VIIUO<M]FS&8(YI8F^KJ^1?@1^QQX*_9_\
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M>%;."[M)IP#[YHK\[_!/_!0SX8'X<>"?$_Q"@\83>(O$GA[XN_$#Q#IOP_\
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M7_YB*/\ A\IHW_1OVI_^'*M?_F(H_P"()>)__1+5/_#MD7_ST\_S[,/^)F?
M_P#Z+FC_ .&'BC_YR>?Y]F?MC17XP:=_P60\'RF7^UO@9XEL@H3R#IWC72]4
M,A.[S!*+G0-($(4!-A0S^9N8,(]@+Z?_  ^*^&W_ $1OQQ_X/M!_^-UC+P9\
M3(2<7PKB6U;6..RF<=4GI*&/E%Z/6S=G=.S31T0^DAX)U(J<>.\$D[V4\LS^
ME+1VUA4RJ$XZ[<T5=:JZU/V,HK\<_P#A\5\-O^B-^./_  ?:#_\ &Z/^'Q7P
MV_Z(WXX_\'V@_P#QNI_X@WXE_P#1*8O_ ,*\L_\ FXK_ (F-\%?^B\R__P -
M^=__ #L\_P ^S/V,HK\<_P#A\5\-O^B-^./_  ?:#_\ &Z/^'Q7PV_Z(WXX_
M\'V@_P#QNC_B#?B7_P!$IB__  KRS_YN#_B8WP5_Z+S+_P#PWYW_ /.SS_/L
MS]3?&O\ R$_ /_8XV_\ Z:]3KOZ_%#7O^"M_P[U>[\.7$?PB\:0C1-<BU657
MUS0V,\<=I=VQBC*IA7+7"L&;Y<*1U(KH_P#A\5\-O^B-^./_  ?:#_\ &Z/^
M(-^)?_1*8O\ \*\L_P#FX/\ B8WP5_Z+S+__  WYW_\ .SS_ #[,_8RBOQS_
M .'Q7PV_Z(WXX_\ !]H/_P ;H_X?%?#;_HC?CC_P?:#_ /&Z/^(-^)?_ $2F
M+_\ "O+/_FX/^)C?!7_HO,O_ /#?G?\ \[//\^S/V,HK\<_^'Q7PV_Z(WXX_
M\'V@_P#QNC_A\5\-O^B-^./_  ?:#_\ &Z/^(-^)?_1*8O\ \*\L_P#FX/\
MB8WP5_Z+S+__  WYW_\ .SS_ #[,_8RBOQ]LO^"P_P *)+A%U'X1_$*UM"'\
MR>RU+PW?W"D(2@2UGN]-BD#/M5RUY&40EP)"HC;<_P"'P'P$_P"B<_%[_P
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M_P#"U_ 7_0:F_P#!)X@_^55'_"U_ 7_0:F_\$GB#_P"55%GV?W,#T2BO._\
MA:_@+_H-3?\ @D\0?_*JC_A:_@+_ *#4W_@D\0?_ "JHL^S^Y@>B45YW_P +
M7\!?]!J;_P $GB#_ .55'_"U_ 7_ $&IO_!)X@_^55%GV?W,#T2BO._^%K^
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M36SZMX2^'WA'Q'XPU/5?"FCVWA>76_'&K^(M3;1;K5Q<7%UJFMZMJEY]!?\
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MXC1Y,2'"[=Q&K]I_9S_Z%_P!_P"$):__ "AK6'TG,*X_O.#<5&750SJG./\
MX%+*Z;?_ ("C"I]"+,%*U+Q%P<X67O5.&*]*5^JY8YY55ET?/KV1_'I17]A?
MVG]G/_H7_ '_ (0EK_\ *&C[3^SG_P!"_P" /_"$M?\ Y0U7_$S>"_Z([&?^
M'BE_\[C/_B2+-/\ HX>7_P#B.8C_ .>_K_3T_CTHK^PO[3^SG_T+_@#_ ,(2
MU_\ E#5F-?V>)4#KH/PW .<"3PAI,+\$@YCETA''(XRHR,$9!!H_XF;P7_1'
MXS_P\4?_ )W!_P 219I_T</+_P#Q',1_\]_7^GI_'717]B_E?L]?] +X:?\
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M97@3_H9M-_[[E_\ C5%GV?\ 7_#K[P-/QG_R)_BS_L6M=_\ 37=4>#/^1/\
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M?_!G:?\ QVBS[/\ K_AU]X'645R?_">>"_\ H:M!_P#!G:?_ !VC_A//!?\
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M@L?$GA3P%X=T77+.&^MWM+V*UU*PL(;J!+NTEEMK@12)YMO+)"^Y)&4^P?\
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MRS0>'-)_36D 4444 %%%% !1110 5YIJG_)5/"W_ &+6M_\ HY*]+KS35/\
MDJGA;_L6M;_]')0!Z71110 4444 %%%% !1110 4444 %%%% ' >-?\ D)^
M?^QQM_\ TUZG7?UP'C7_ )"?@'_L<;?_ -->IUW] !1110 5$\$#L6>&)V.,
ML\:,QQP,D@G@=*EHH @^RVW_ #[P?]^8_P#XFC[+;?\ /O!_WYC_ /B:GHH
M@^RVW_/O!_WYC_\ B:/LMM_S[P?]^8__ (FIZ* (/LMM_P ^\'_?F/\ ^)H^
MRVW_ #[P?]^8_P#XFIZ* (/LMM_S[P?]^8__ (FO-O&\$"^(OAR%AB4-XDF#
M 1H P^Q-PP P1['(KU"O-/'/_(Q_#?\ [&6;_P!(FH ]$^RVW_/O!_WYC_\
MB:/LMM_S[P?]^8__ (FIZ* (/LMM_P ^\'_?F/\ ^)H^RVW_ #[P?]^8_P#X
MFIZ* (/LMM_S[P?]^8__ (FC[+;?\^\'_?F/_P")J>B@"#[+;?\ /O!_WYC_
M /B:/LMM_P ^\'_?F/\ ^)J>B@"#[+;?\^\'_?F/_P")H^RVW_/O!_WYC_\
MB:GHH @^RVW_ #[P?]^8_P#XFC[+;?\ /O!_WYC_ /B:GHH Y3QE;6Z^$/%;
M+!"&'AO7""(D!!&EW1!!"Y!!Y!'(-'@VVMV\(>%&:"$L?#>ADDQ(22=+M222
M5R23R2>2:F\9_P#(G^+/^Q:UW_TUW5'@S_D3_"?_ &+6A?\ IKM:?1>K_*(&
M]]EMO^?>#_OS'_\ $T?9;;_GW@_[\Q__ !-3T4@(/LMM_P ^\'_?F/\ ^)H^
MRVW_ #[P?]^8_P#XFIZ* (/LMM_S[P?]^8__ (FC[+;?\^\'_?F/_P")J>B@
M"#[+;?\ /O!_WYC_ /B:/LMM_P ^\'_?F/\ ^)J>B@"#[+;?\^\'_?F/_P")
MH^RVW_/O!_WYC_\ B:GHH @^RVW_ #[P?]^8_P#XFC[+;?\ /O!_WYC_ /B:
MGHH IRZ=I\X GL;.8*<J);6"0*3P2 Z, 2.,BN5\8:1I,7A+Q3)'I>G1R1^'
M-;>.1+*V1T=-,NF5T98@RLK ,K*05(!!!%=M7->,_P#D3_%G_8M:[_Z:[JG'
M=>J_,"GX6TC2)?#'AR5],TV1I-!TB1I&LK5VD9]/MV+LYB)8L26+$DL3DDYK
M>_L71O\ H$Z9_P" %K_\:K-\&?\ (G^$_P#L6M"_]-=K72T@,S^Q=&_Z!.F?
M^ %K_P#&J/[%T;_H$Z9_X 6O_P :K3HH S/[%T;_ *!.F?\ @!:__&J/[%T;
M_H$Z9_X 6O\ \:K3HH S/[%T;_H$Z9_X 6O_ ,:H_L71O^@3IG_@!:__ !JM
M.B@#,_L71O\ H$Z9_P" %K_\:H_L71O^@3IG_@!:_P#QJM.B@#,_L71O^@3I
MG_@!:_\ QJC^Q=&_Z!.F?^ %K_\ &JTZ* ,S^Q=&_P"@3IG_ ( 6O_QJC^Q=
M&_Z!.F?^ %K_ /&JTZ* /./B+I6EP>"/$DL.FV$,J:<[))%9V\<B-YD8RKI&
M&4X)Y!!KKK;1='-M;DZ3IA)@B))L+4DDQKDD^5R36!\2O^1$\3?]@U__ $;%
M78VO_'M;_P#7"'_T6M/HO5_E$"G_ &+HW_0)TS_P M?_ (U1_8NC?] G3/\
MP M?_C5:=%(#,_L71O\ H$Z9_P" %K_\:H_L71O^@3IG_@!:_P#QJM.B@#,_
ML71O^@3IG_@!:_\ QJC^Q=&_Z!.F?^ %K_\ &JTZ* ,S^Q=&_P"@3IG_ ( 6
MO_QJC^Q=&_Z!.F?^ %K_ /&JTZ* ,S^Q=&_Z!.F?^ %K_P#&J/[%T;_H$Z9_
MX 6O_P :K3HH S/[%T;_ *!.F?\ @!:__&J/[%T;_H$Z9_X 6O\ \:K3HH S
M/[%T;_H$Z9_X 6O_ ,:H_L71O^@3IG_@!:__ !JM.B@#,_L71O\ H$Z9_P"
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M8:K3KTI.+:DHU*4I0E9IIVD[--/4****R-PHHHH X#QK_P A/P#_ -CC;_\
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M/2%\;.NG):IXO7P2GC9=1O ZZ:/$(\'QB[_L&U /TRHHHH \[^+'_)/O$?\
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MG%,HHHKX\_1 HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MCAA0R.TCE8HU5%+R.\CD*-SLS'+,27"&%9GN%BB$\D<<4DXC43211-(T4;R
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M'/\ \!/^BC?%[_P.\&?_ #'5?_$?_#C_ *#LS_\ #5BO\OZL_*\?\2F>,O\
MT*\E_P##]@?\S^?CPYXD\0^$-;T[Q+X4UO5?#GB#2)_M.F:UHE_<Z9JEA/L:
M,R6M[9R0W$+/$\D4FR0"2&22*0-&[J?[)/@UXJUCQS\(?A;XU\16RV>O^+OA
MWX+\3:U;1Q""*+5==\.:=J=^L-N'<V\)NKF5H8';S88BD4RI*CHOPAX(_P""
M47[-OA3Q#8:]K&J_$3QU!IT\=S'X=\2ZQH</A^\EB)=!JD&A>'=)U*]@601R
M?94U2WM9PC0WT-Y;2R0']-D1(T6.-51$541$4*B(H"JJJH 55  50    !@5
M^">-?B)POQRLCI9!A\15K9?+%3Q&9XK"K"S]E7C25/!4E*3K5(*<9UJCJ1A3
MIS4/8\[JU7'^K?HT>#_'/A>^)\1Q9C,)0PV;QP-+"9)@L:\=3^L865:57,Z\
MH1CAJ-3V52&&HJE*I5K0=1XCV4:-!5'4445^"']6A1110!P'C7_D)^ ?^QQM
M_P#TUZG7?UP'C7_D)^ ?^QQM_P#TUZG7?T %%%% !1110 4444 %%%% !111
M0 5YIXY_Y&/X;_\ 8RS?^D35Z77FGCG_ )&/X;_]C+-_Z1-0!Z71110 4444
M %%%% !1110 4444 %%%% &!XK_Y%;Q+_P!@#6/_ $W7-0^#/^1/\)_]BUH7
M_IKM:F\5_P#(K>)?^P!K'_INN:A\&?\ (G^$_P#L6M"_]-=K3Z+U?Y1 Z6BB
MBD 4444 %%%% !1110 4444 %%%% !7->,_^1/\ %G_8M:[_ .FNZKI:YKQG
M_P B?XL_[%K7?_37=4X[KU7Y@'@S_D3_  G_ -BUH7_IKM:Z6N:\&?\ (G^$
M_P#L6M"_]-=K72T@"BBB@ HHHH **** "BBB@ HHHH **** .'^)7_(B>)O^
MP:__ *-BKL;7_CVM_P#KA#_Z+6N.^)7_ "(GB;_L&O\ ^C8J[&U_X]K?_KA#
M_P"BUI]%ZO\ *($]%%%( HHHH **** "BBB@ HHHH **** "BBB@ HHHH \[
M^+'_ "3[Q'_UQL?_ $ZV-=[:_P#'M;_]<(?_ $6M<%\6/^2?>(_^N-C_ .G6
MQKO;7_CVM_\ KA#_ .BUI]%ZO\H@3T444@"OY8O^"\W[,_[>G[9/Q/\  ?P^
M_9O_ &<_%/B7X6?#WPS)_;WCV#Q1X(TFU\:Z]XBDL=4DTC3K'5?$]AJ(T3PY
M%;VD5Y+=VD#:AKGVJ)('M--MKF\_J=II4'J3],\5Z^0YK2R/-L#G$LHRG.:^
M68BECL!A\YP]7%83#9AAJD:N#S"%&E7P]\7@JL56P=2<I+#XA0Q-.*KT:-2G
MRXZAB,7@<9@:&9YCE4,PPF(R_&5\KKQPV)KY?C:,\/CL!*LZ=1K"X[#5*F&Q
ME.*7M\-4JX>;=&K4A+\<?^",_P#P37LOV OV>X]0\<Z9:M^T?\7K?3M<^+6H
M":RU ^&+>!)9="^&ND:A:B2,Z?X<BN9)];FM+JYMM6\37%]<)<W6G6>C?9_V
M-<@ DG^%O7VI0N#G/3VP /0#^O7M39!D<8Z-U_#_ ">/K4YYG68\19MCLZS6
MM[?'9AB'7K2BFH0O94Z-&#<G"A0IQA1HPN^2E"$;NS;SRW+L)E&!PV78&DJ.
M%PE*-*E!6;=M95)RTYZM6;E4JS:3G4E*5M3_ #]!_P $K/\ @I9X>_;MU'XW
M>%?V=?&VGZ-IO[46M_$GP_XQL]8\'A;;21\3;[Q%I?B&V5]?:X"BR:"^B1K9
MIE!0&#S!L'[GW?@3_@K'XCA_LJYO/BI'%<L%+)XIT#1&&X%3G4K?4+*2!0"2
M6$\8!P<DA:_<F/QSXWLO%5_I&I:9HNKZ9'XXC\*V5MX?MI[/5VMKCP%=>-XK
MR:;6M<ATR26%5MK"94>!&(N)XQEHX(^#M/C9XTO[35;RUTKP];"TC\)6]IIE
MPC76HR:CXGL/!MR3*MOXFBNIHK2?Q3.JP6^EK%.EDJKJR-([I]_7^DUBHPPL
M,PX0X.S#$8*%?"X>MF?#F,QV(H0RN,?;RIUZN/E"$8<GM.6E43G.2E&-Y1/R
MGB#Z*V'XJQ;Q6'X^\1>':%6AAYXG!\+<88;)<#C?[6JRE1GB\-'+:DJM>IS_
M %?VE6/N4::A)I)GY5?!S_@E1\5_&&NIXB_:1\8MI&GS7<=[J.C:7K[>)?%>
MLR%LS?VAK<C7FGVDDN/+DN$GU2>1)&8-'(!M]F_;6_X(]?"7]H#PQHFK?!A]
M-^$OQ4\(Z!:Z!I]RMN7\*^---TV%ELK3QA%!#)J"ZO$<0VWBBW>XO%MV>WU.
MSU.*.Q:Q_1BT^+VL+-HEEJ>B1K<BYUJQ\5W<%GJ<-KHLZ:UJ_A[PG(Z,;M+1
M?$.KZ1-#Y%W?2/#'+$Z32+*CG(LOBC\1W_X0^'4=*\-6#^*+2YU,:C<6=W8V
M\EA;P^%Y&BL]-U;Q1IUU%+!-X@FA:[DN+A[H6JR6NF21EG/SF/\ I#<6X_.<
MOSNEG-?#5<!RK Y;E6 5#*L+#%1PM*5&K@/?I5J=;V\,/4J8N5=*I2J8?V\*
MM"$8]^1_11\-\AX<S;AE<-8?'4<XAS9MG&=YC/&9_F,\)+%5H8B&;MPKX>KA
MO8U<32IY>L'%PJPQ*P]2&(E4G_,1X5^ G_!9/]C@3^%_AII?Q.3PO SBTL?!
M>O:%\1/!)1YFF>XTG2YKS4AI"7,F^66/^S-(NW:1FNK59)"6;JO[&W_!6G]M
MSQ!I-M\;8?&=AX;MKR"5K_XJ>)--\->$M#5MT;ZA:>#=.N#<WVH1P-,(Y+#P
M_<79#^5+<V\,[R'^IF]^)NOWVCV<_A9O"S:Q'IVD7NNV^I"^U&'3+C4==BT&
M33IH-.OK*XM+R.XDF=$NW5\6%U"\.X!HI$^)6MKK(TJZF\)Z;_9U]';7[:B^
MIQ2^(3)XIU3PVUOX8B6X>1;NW.G+=2QRQ:D3+JFFVLD<"RBY;ZQ_26Q*Q#Q]
M#A+@FGG]:G!KB.GD518F<JT9\U:%:>,YHXB"IU9U)5:KAS1E3]G4DXTG\E'Z
M(V62PL<HQ/'GB7B>%Z%1I\(U^*(2RZ%.C*DZ>%J4*>7Q;PDG4IQHQHJ,TI>V
M56#C*NO-OV)?V2M'_8U^"NE?"G3/&'B3QM>R7TFMZ_K.NZA<R:<=9O%1;JV\
M*Z'+-):>&M 0H/L^FV@,D\YGU"^GN+^[F<_8U>0_#'QY?^,O[6BU7^Q([RQ&
MF7L<&C3/=1V]AJIO?LL5Q?1W>H6%[*#8S_O[6ZAE=-OVS2=)EVPR^O5^3U\]
MK\38C$9]BL34QF*S3$5\5B<15A&E4JXB56<:SG2A&$*4HU(R@Z4805+E]FH0
MY>5?O&"X>P?">"P?#>7X2G@<#DV%P^!P>%I3G4IT<-2HP]A&-6I*=2JG3<9.
MM.<YUFW4E.;DYR****R.H**** "OSV^/S_$6S\9^/WL?V"_@_P#%_P  R2>&
M_$.J?$[QKX[^#7A]?%$WAKP@+>+7/$VG^,K"2^@D\#V^J^(O#.F:GKDKM8:,
ME\]A/;:7J+QO^A-?#?[?GA+Q-XM^$7@^/2O"?BWX@>$-#^+_ (%\0_%SP!X(
MEO5\1>,/A?IS:F->TFSM],NK74]04WTVDSO9V#"X@>*+6A<:>FCOJ-K]AP+6
MI0XDP6&KT\%.CF,H8&I/'5\SP]*@I5Z.(C5I2RO.L@JU,6ZF'A2PM+$YA#!R
MK58.JHSC2KT?SSQ2PU>IP;F>-PU;,J>(R>$\SI4\KPN28NMBG##8C"3P^(CG
MG#7%E&E@%2QE2OCJ^"RBKF,,-0J+#NI3E7PN)Y;]D769_%7BV_\ $&E_L@?
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M_LOXJ?\ 0T^&O_!+-_\ %T?V7\5/^AI\-?\ @EF_^+KD/V8OV@_"O[5/P*\
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M )'KT2BB_DON]/\ +\7W \[W?%G_ )Y?#O\ [_\ B7_Y'HW?%G_GE\._^_\
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M6UBU&QGU30;&ZFWE8X)/%5M%"Q:.Y>V^=1[U^P?^T9_P5"\!?M.:9^S-\9O
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MB/0+V6\MX-1L6EBN%3[5I]S9ZA9SP7,$%U:7MA=VM[9W<$-U:7$-Q#'(I?\
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ME=L/^Q"N?_3Y36TO3]4!Z71112 **** "BBB@ HHHH **** "BBB@#@/&O\
MR$_ /_8XV_\ Z:]3KOZX#QK_ ,A/P#_V.-O_ .FO4Z[^@ HHHH **** "BBB
M@ HHHH **** "O-/'/\ R,?PW_[&6;_TB:O2Z\T\<_\ (Q_#?_L99O\ TB:@
M#TNBBB@ HHHH **** "BBB@ HHHH **** ,#Q7_R*WB7_L :Q_Z;KFH?!G_(
MG^$_^Q:T+_TUVM3>*_\ D5O$O_8 UC_TW7-0^#/^1/\ "?\ V+6A?^FNUI]%
MZO\ *('2T444@"BBB@ HHHH **** "BBB@ HHHH *Y_Q8 ?"OB4$ @^']9!!
M&00=.N000>""."#UKH*P/%?_ "*WB7_L :Q_Z;KFG'=>J_,"OX)</X-\*,N<
M#PYHJ<^L>G6\;?AN4X]1@UT]<GX#_P"1+\*_]@'3/_22*NLI %%%% !1110
M4444 %%%% !1110 4444 </\2O\ D1/$W_8-?_T;%78VO_'M;_\ 7"'_ -%K
M7'?$K_D1/$W_ &#7_P#1L5=C:_\ 'M;_ /7"'_T6M/HO5_E$#XR_;9_:>\7?
ML[>%_A-X7^$7@G1_B1^T/^TK\9/#GP$^ _A'Q/JEYHW@>V\4ZQI&O>+O$_Q
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MJVGW=EXCL=1\-S%==TO4M.M/F_X6?\$[_P!H*V^)/PP^.WQ6\0?!9/B!J?\
MP4L^*'[=_P 8_!'@[4_%6H>#_!'A'Q%^R5XR_9@^'?PT^&OB&_\  GA^;XE>
M+?#D"?#_ ,2^)_''B3P;\*5US4KGQ7>QVLEWH^C'7OE*[_X)6_MT^+OC-\%O
M''Q,\9?#CXD>(_@A^W_X>_:>G_:'^(?[87[4?B:\\>?!#2/CSJ'CJW^&7@']
MC6'X86/[-_[/7BJV^&^HPZ?>7?A:]UW2Y/%FA1Z9IFHP:/XIU#Q+X? /L3]G
M?_@JSIW[1OB'285T2;X"Z0O[=/QO_9>ETOXU?!?X^Z)J/CSP;\*_AU\;?$FG
M2^&/%GB/PY\/O#?@7XK-)\'[_P <?$_P]XTL-1MO@YH<%[\*_&NG6GQ U+P]
MK=]]+_!'_@IY^QG^T-XSTKP1\+_B-XGO;[Q9X>\6>*OAEKOBGX/_ !A^'7@K
MXTZ#X!CDE\>:A\$/&WQ"\"^&/#'Q;3P;'#//KL?@74]:FAL;>YU:UCN]'MKC
M4(O@2+_@EY^T%XQU[Q/\/_B+J/PCTSX'7'_!1+]L[]JNV\4^$_B+XWF^)OB'
MX1_MG?!;]JGP#KV@)X=E^%FF:1X3^(/@76OCCX2BT\1>,=6TG4K&S\3:JFN6
M=UI&BV'B3H_@/^PC^VV[_L > /VB+S]F3P]\-?\ @G%X ^(/AKP?XM^$/BOQ
MWXH\7?M#:_>_ /6OV:_A3=:MX4U[X3_#ZT^!?A[PW\//%&J>(/'MGI/C;XH)
MXL\9:?I^G6FBVFA&#4;$ ^SOV=/^"H7['W[4OC#X=^"_A/XL^(GV[XR>%_$O
MBWX*ZU\0?@7\:?A/X.^-.F>!H8+CX@0?"3QC\3/ GA7PY\0]3\ VUU:W/B[3
M_"^HZC/I=M+)<@3P66HR6?K/C_XS^.;']L#]G3]G;P/#X8FT#Q3\,?CQ\;?C
MA?:K;7]WK>C>!OAY+\._ 7P_TGP[):7UM9Z1K'C/XE_%2UU*&\U:VU"&_P##
M7PW\;V-A;QW:M>V?R1\"?V#/BM\+/"?_  2&T#5M=^&DMQ^P)\/?%GA;XRG0
M]3\2/:>)M9\1?LR:Q\'!>?#4W/@_3WUJUD\9:E_:]]<>*H?!MT^BM<7XMY]5
M;^RY/LSP!\&O$6E_M1?M$_M">+I='E_X3GP9\$/@S\+K73[B6[NM,^%OPIL_
M&OC?4;[5TN-/M1I'B'Q)\6?C-\0[34;+3[O4K2_\,>#O %_<W27JOI^G 'Y;
M_M>?\%-_VF?@D_\ P55TWX4?#[X-^*_$?[%/B3_@G)X;^ VD>*M,\6Q1^-M2
M_;'\2^!O#_C6P^)&H6OQ#T.UN)+*7Q5/#X)O]#?P?9Z',+2Y\2IXDMX+B.?Z
M(\-_\%(/^%L^/?\ @FQ:?"70M(L?"/[7_P 2/VC/AG\=?"GC_2=;M_BQ\$/'
M?P#_ &?/B7\0_$WPMOK*#6-'M_"OQ%\$?%/P&?!OC:W\1Z#KMG?Z/#=7>@00
MVVK:-XB/C7[1?_!-3XZ_%WQC_P %*_$/AOQ9\)K&R_;)^(__  3(\7_#&+7-
M=\86UUH6F?L7^./AYXF^*,'CQ+#P'J<6EWVO6'A+48? ,7A^?Q1;ZI=SV4?B
M*Y\+0R3W%MZ%X_\ ^":GB1?^"H?[-7[<WP:\9>'O"?PE\/\ B3XM?$']I[X+
MZI>:O;0>*?B_XC_9P\>? 3P;\:/AAI-EH&JZ1;>.O$NB^+]'\/?&-;K6/!VG
M^(M!\">$O$<O_"0^*[&<70!\M?#K_@HE_P %%-)_X)_?"?\ X*??%'PY^RC\
M6O@+JGA;0/B;\;_@7\&/A3\7OA?\:? OP?O=7NM(\9>-O 'C_P ;?M#_ !7\
M%^.]>^'-K%'XJO/!6N>"?!%EXG\/6VM+%XW\-WNGVJ:E_0EI&K:;KVE:9KFC
M7UMJ>CZUI]EJVDZE9R+-::AINHVT5Y8WUK,N5EMKNUFBG@D4[7BD5AP17\^?
M@G_@GW_P45OO^"=_PF_X)>^-IOV2/AC\&;7P9H?PC^.W[07PT^.OQD^)?Q;\
M2?"2'Q!_;7C/2?AE\+/$W[+'PK\(>&O$7CK2!<>"+G4?%'Q)\2Z?HFB:UJFI
MP:?J.H0V=N/Z"]'TC3/#^DZ7H.BV5OINC:)IUEI&DZ=:(([73],TVVBL["RM
MHQD1V]K:PQ00H.$CC5>U '&?%C_DGWB/_KC8_P#IUL:[VU_X]K?_ *X0_P#H
MM:X+XL?\D^\1_P#7&Q_].MC7>VO_ ![6_P#UPA_]%K3Z+U?Y1 GHHHI %)D9
MQD?Y_P#UTM?#O[<G[86B_LE?#J/5+:WM-;^)'BM[FQ\!^&KQY%M)9;:.'^T/
M$&L>2RS#1-$2>%I8HFCGU&^GM--BFM4GN+ZT\7B'B#*>%LFQ^?YYBXX++,MH
M^VQ->493E9RC3IT:-*"=2MB,16G3H8:A3C*K7KU*=*G&4YQB_>X7X9SOC+/\
MKX9X=P4\PSG.,5'"X+#0<8)R<95*M:M5FXTZ&&PU"%3$XK$590HX?#TJM:K.
M-.$I+KOVT_VI-+_9(^ ?C#XK?\([J?CSQ?;VW]D_#CX=:%#=76L>.O'>H13#
M0M%1+**>>TTF.2&34?$6L%!'I6A65_<@RW0M;6X_BV_8Y_8P^)?[6WQ\_:/_
M &N?V^Y3976A^"?B!\1-)\,>/)[.TU/XM_%O5/"^OCP9I.E:&UR9!X1\!36E
ME>P:/%$MH)-/\*^$[6RN],?4K6W],\%_M8_&7]M7]K?PC\%OAJ]Y\;/C!X^\
M27-OKOC/Q/J-Z/AW\,/"VGS+=>(M<ALK)T\[PYX4TZ.\NGTG1I=#L)YXK2PT
MF[O]1U.WC?\ J/\ '_[&7PH^&'P>\?>+-(N/$U[K_@CX=>*_%%K<7NIV_P!D
MU#4_#GAK4-6A2[M(K!#'97-U: 200RI*L$C1I<!@LHGAOQ*^D+PUE'M^'?!_
MA_AI<:4:-;+JW&_$%? <<8K('7IPP\HY;@E-<,4\TM65.&:X66*N_K*=2GA\
M+57T?%WAMX"RS!9?F_BQG/%^;<+8BK1S.'!&38?&<#X7.X4[UJ2S+'14N(IY
M;/E4J^78F&'3O2G1I59XBBOY"/\ @VUADM_^"ED,%Q$\,T/P,^*L4T,T;1RQ
M21W/A='CEC<*T;HP*LC ,K J0#D5_H*,%93M"L3Z 9../;./<_3G%?QD_P#!
M*/\ ;@\+?M)?M56^O>'?V:O#V@?M3:!\./%M\?$F@RVTVG^,_ ROI,7BS3KW
M4,:1K$6H!I=.N-)L=53Q,T9BN&M-3BD=[2[_ *EO"O[6?PJU*5-*\8ZC)\-?
M%,1$5]HGC**73(K>Y&0Z1:O/%#8M%N&(WO383.I#&VC)('TOB7XOXC...HY;
MXF<%YMX.<8T,JP6%GD?$^89;F.29JJ=7$RCCN%N,\KJSR'/<'7C5CRT'6P6<
M8>JJE'&951=-2G^<\"^'JP_"\L3P+G='Q$X?6.Q=99CDV!QF%S/!*;I\U+.>
M',4GFF65*33YZO)B,#*-IT\;-22/R0_X*V_ +PQX-U[P+\9/"VEV>CR^.KW5
M?#OC"SL;>.UL[W7+2&'4=.ULV\8$0U'4;8WUOJ4\<0^UFQM9YLW#S33;?_!$
M/]F/PAX,\.?&7X[76D6=QXIUSXAWO@?P;>SVZ23>&_!%GHOA[Q'?6FE2R!S;
M?VKK?B":QO7@*&2R\/:=;[@J3*^G_P %:_C-X+\;Z?\ "3X9>#?$.C>([VWU
M74_&.KW>C:E;:I:V43VIT32+99;"6=;F[G$^KW,UI;">ZMH+6&66)4N81+TG
M_!&#X_>#O&O@GXT_!>PN[6+Q!\-_B/-K=G;>>&N==\+ZQH^BZ1/K4.#Y$RZ=
MXKT36=+O#9M+!:Q2:+*9774())?WO$^(,LX\"\OX:RS-7G>;X24:_$+RW$0Q
M\LBX3CFM;#Y7'/\ $T*L_P"SGFF*E@:&3X'$RAC,RR[#8O$X>A5R[ 8ZM3_C
MK*O"NED'TLN(.,LRR.'#W#F9X".'X7>;X6IEM/B;Q EDV"Q6=U>$\)B:-+^U
MO[%R^GF>)XAS+ *IE^3YMC\-@\96I9OF> H3_<' Z8&!T&!Q48@@$C3"&(3.
MB1/*(T\QXXVD:.-I-NYD1II61"2JM+(5 +ME?,7.,$9!(/&"!UYS_P#KQQ49
MN8@Q3.7"AR@QOVDL Q3[P4LI4,0 6!4$L"*_GOH][6UWM;3?RVOT778_LEVT
MO;?2_?R\]RQTZ44 Y /J,T4#"BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *P?%6GZWJWA?Q)I7AK7Y/
M"?B/4] UC3_#_BF+3K#5Y?#6MWNG7%MI6OQZ3JL-SI>IR:-?RP:BFG:E;SV%
MZUL+:\AEMY9$;>HH _+O2_VUO%^OVWPJOGMHM(G^%7P0^(GQK_;2T2T_X133
M(]$\2> M1\0? \?!^W\5?$+5?#_@[PG'J?QO\.?%;Q$OB35O$F@&+P[\"KL2
MZE;:1K]PTTG@/_@HY??$O7/ GA#P3\#X/$GBSQK\:/&?PD0:+\7_  [J/@R*
MR\*?"#2/C;%XYTCQO!X<^Q^(=$U'P9K$,3P0:?9-'K=O/::5=Z]8RV&IWOU_
MJ/[+'P!U6V^-UK>?#?2]G[1=WI6H?&*6VU'7K&[\5ZAH5I';:'?V]]9:M;WG
MA>]T>='US2[KPA/H$]CXLN]2\9VSQ^+-5U/6KO \"_L<? #X>>.[?XH:%X:\
M57_Q%@\3:CXS;QGXP^*_Q9\>:U=^*M6\$3_#?4=;OG\:>-]=M+NYN/ TX\-)
M#-:-8VFEVFE06-I:_P!BZ.;$T_KO_5P/C;X,_P#!26'4_"&K:EXJ^'GQ'\6>
M'OAEXC@T?XW?%N.X^'-E9^!)/'WQP\8?#KX?*OABTN/"NH>*]+TG2=*L-4\5
MWOA?0'O]$\/FUE2S\6^(&U!&]-N/^"@Z)\/O!GCG3O@=XQ\3W?C3X<?M4>/[
M'PEX1U1O$7B&-_V9?B_X$^$D^F0V5EX=^V:E;>)Y_'*>*=0U&PLI;SPKH6BZ
MD+?1/%-V88F]EM_V&OV9[&]T*ZT[P/K>F6FAW^B:E+X?L/B3\3K?PIXIN_"_
MQ)\3_&#PJWC_ ,++XP.@_$&+PO\ $OQEXD\7:!;>,[#6[;3+W419P1#2++3]
M.M&6_P"PM^S+!-XB9_!'B"]L?$6A?$;PR-!U+XH_%6_\+^&-#^+?B?3O&OQ$
ML?A]X9N?&LFA?#AO$GC#1])\3/?^!K#0-3TG6-*TNZT"]TH:;8);&G]+_@^O
M]/0.P_9[_:&T;X^?!]_BS:VOAO0+&TN]=L-1FT[XC^#_ !WX/CET"&.>]U"U
M\:^%[N:.'288Y0M_#XIT7PEXKT2>VOX->\)Z6UO"UU^:7P[_ &[?BY\&?MGB
M']K/5O'$^IZS\*=5\=7GPEUGX5>"_#^EZGXWM[OP]/I.D?L8_%WX9:CXB^&O
MQ>^'%U#XDGTW5;'XG_$_4OB)8:1!X5\<2ZQ8V/\ PE>EM^L'PU^"GP]^%.A>
M*_#_ (6T[5[NU\>>(]1\7>.+WQEXK\4_$'7/%_B/5M$T;PU?:EX@UWQQK'B#
M5M0,OAWP]H>AQV<EV-.M-)TNSL+2S@MHA&?)M%_8D_9RT71M1\,_\(EXEU[P
MK>?#G7?A%IGA7QG\4OBIXX\.^#/AKXGL-.TO7_"'PYTOQ=XSUJW^'6EZEIVC
MZ/89\%C1+NPL-(TK3]*NK"QTZSMH7_7?^OZ75@?G[^UC_P %#_B7X$GT'P_H
M>@^*?@KX_P#!>L>.M,^-'@2^_P"%:>,;V2VE^!4GQ/\ AYJ_A+Q>+/QIX:O=
M(N;J0J;E[#3M3&HZ+K.F:MH<=B+"[U#Z3US]K[XA>*_V@_A9\/\ X<^ -4TG
MX10?M;>*_P!GOQ_\5[W6/"%_!XKUSP1\!?BYXO\ %'@F'P9,L_B[PS:VOC31
M/#\^D^,8Q NK?\(GJMK(]AI>M:0/$GK.K?L#_LN>)=+N=,\8>!?$/CB:_P#$
M&O>*-5\0^,_BK\6O$?C'6=:\1^#+#X=ZA<:UXRU'QQ+XFU6W@\#:5IOAC1M.
MOM4GTWP_IME$=#M-/NVFN9>]_P"&5/@A_P +8B^-*^&M;A\;P>-I?B9;PVOC
M_P"(5EX)B^)%SX#E^&%_X_\ ^%9V7BFW^'4_C#4O 4S>&]1U^Z\+SW]W:E[J
M27^TKBZO9S3SZ_\  Z][_AH!X3XFLOCM#^V)X)^%]A^U#\1]/\ >-_A1\;/C
M3/X>A\!? *<:/-\/_BC\#?#VA^!]+U:\^$ESK<GA5M%^*NL6-Y=:GJ-_XKF_
MLS2;D>(DNUOI[WA/%_\ P4ET_P *?"+PW\5_^%.ZEJB>(OAM^U#\1(_#UOXT
MMH;J%?V:?C3\/?@[<:+'?2>&FBN+CQG/X^CUVTNS;V\>BKIC:9+!J37@O[;]
M";KP!X2O/B!H?Q2N=)\SQWX<\'>*? &C:[]OU-/L?A+QKK?@[Q%XFTG^S([U
M-&N/[3UGP#X2O/M]WI\^IV?]D_9]/O;2UO\ 4X+SYLD_8)_9=N1XB@OO WB+
M4=*\1Z1X\T!_#>H?%?XN7/A3P_H7Q0\8Z1\0/B%I/@CPN_CG^PO =EXM\9Z#
MH^OZK'X0L-%;[3IUI:VKVVF01V*GK^"7]?,#SL?MWWWA_P 6:QH'Q0_9]\<>
M =%\'>+=9^'7C[QE#XQ\ >+=&\/_ !!L/@'?_M.66@:78:-K">(?$=E<?!ZU
ML-0U+7(-(L;;3/%.NZ7X;M8-8ACU;6=+XK4?^"D5Q8Z9X#LY/V</'6G?$7XJ
MO\#-9^&?@3Q!XV\"VD/BWP!\?_&5UX*\)^*!XHT"\\4V.A:KH&IIIK>-/"VO
MV6G2:3'K>GMINK:U#'J$]E]R7/P-^%=YX@O?%%WX4BN=;U+XGV_QEOKJ;5M>
MDANOB1:_"&R^ T/B";3VU0Z:T0^$^GVGA.30OL@\.3)$=:FTB3Q%+-J\GDWA
M7]B#]FWP@^E2Z=X,U_49?#NI_"O4/"D_BCXF_%#Q;<>$+7X(:EJ.L_"?PSX4
MN/$OC'5)] \$^"=5U?4[_3?!.G20>%KNXO)#K&E:DL=NL)IY]/\ @]?N Y7]
MEK]LA_VC?%_C[P+K/PNNOA7XK\!K=3:IX8UGQUX;U/QEH\5IKDNA?9?&_P /
MKN'PU\0/"%]J3HFK>']07POKG@?7M#E2[T_QM)>-'ITOI_Q>^)OA?X-:SKOQ
M.\9SW$'ASPA\+[K4+X6<(GO;N6;Q)!8Z;IEA"[Q12:AJ^J7=EI5@MQ/;6OVR
M\A-U=6ML);B._P##K]F/X-_"KQO>?$+P3H&MZ?XBGTGQ5X?TZ._\=>._$'A[
MPKH'CGQ;9>//&&A>"/"/B#Q)J?A;P3I'B'QAINGZY?Z?X7T?2[=9;#3[&T2V
MTG3['3[?S;]JCX/3?'K1/&WPLL[R.PU7Q%\+/M&A7<Y*VR>(- \86/B+0X;R
M0*[0V%[J>E6UAJ%PD<LEO8W5Q/%#++&D;>GDM++J^<971S>M/#Y56S' TLSK
MTW^\HY?4Q=&.,JP?+*TJ>'=2<7RS::3Y9M<K\7B2OF^&X=S[$\/X>GB\^P^3
M9I6R3"UE>EB<VI8*O/+J%5<T+TZV,C1IS3G!.,FG."?,ORP\3?\ !8'XV3ZS
M?2>#OAO\+=+\/&YF_LRT\36GBW7M92TWG[/]NU#2_%OANQEN3'@S?9],AB#D
MJFY5#-@?\/>OVE/^A(^!W_A->/?_ )Y=?(&J_L<_M3:-J-WIEW\!/B=/<6<S
MP2RZ5X7U#7=.=T."UIJVB1ZAI=]">JSV5Y<0N.4D(K/_ .&3/VGO^C?_ (O?
M^$!XD_\ E?7]V4>"O!54:2I8/A&K35."A4EFM"M*I#E7+-UI8Z<JKDFGSN4G
M*][NY_ECB?$KZ2T\17E6S'Q!HUG5J>UHPR'%8:-*IS/GIQP]/*Z<**A+W52C
M"*A;E45:Q]G_ /#WK]I3_H2/@=_X37CW_P">71_P]Z_:4_Z$CX'?^$UX]_\
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M@ HHHH **** "BBB@ HHHH **** "O-/'/\ R,?PW_[&6;_TB:O2Z\T\<_\
M(Q_#?_L99O\ TB:@#TNBBB@ HHHH **** "BBB@ HHHH **** ,#Q7_R*WB7
M_L :Q_Z;KFH?!G_(G^$_^Q:T+_TUVM3>*_\ D5O$O_8 UC_TW7-0^#/^1/\
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M/XE?"?XS_LF:=\-?%GP&_:+UC7=*\+>-/#OA'Q?XD\6>'IK_ $O5_"K>(8-
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M"G_@IE^TU^U1I/[5/CGQE\0OA-H,=U86WBCQCXMTE_#UEXC\$6DDMPWP_P#
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M^?Y^5OQ\_P"']6@?]&QZQ_X=BR_^=[1_P_JT#_HV/6/_  [%E_\ .]K]@_\
MAD']DS_HU[]G;_PR?PU_^9FC_AD']DS_ *->_9V_\,G\-?\ YF:/]5/"'_HV
MM7_Q-.(O_D_ZN_*PN./'W3_C<5'I_P VZX1Z\O\ T[\_S\K?CY_P_JT#_HV/
M6/\ P[%E_P#.]H_X?U:!_P!&QZQ_X=BR_P#G>U^P?_#(/[)G_1KW[.W_ (9/
MX:__ #,T?\,@_LF?]&O?L[?^&3^&O_S,T?ZJ>$/_ $;6K_XFG$7_ ,G_ %=^
M5A<<>/NG_&XJ/3_FW7"/7E_Z=^?Y^5OQ\_X?U:!_T;'K'_AV++_YWM'_  _J
MT#_HV/6/_#L67_SO:_8/_AD']DS_ *->_9V_\,G\-?\ YF:/^&0?V3/^C7OV
M=O\ PR?PU_\ F9H_U4\(?^C:U?\ Q-.(O_D_ZN_*PN./'W3_ (W%1Z?\VZX1
MZ\O_ $[\_P _*WX^?\/ZM _Z-CUC_P .Q9?_ #O:/^']6@?]&QZQ_P"'8LO_
M )WM?L'_ ,,@_LF?]&O?L[?^&3^&O_S,T?\ #(/[)G_1KW[.W_AD_AK_ /,S
M1_JIX0_]&UJ_^)IQ%_\ )_U=^5A<<>/NG_&XJ/3_ )MUPCUY?^G?G^?E;\?/
M^']6@?\ 1L>L?^'8LO\ YWM'_#^K0/\ HV/6/_#L67_SO:_8/_AD']DS_HU[
M]G;_ ,,G\-?_ )F:/^&0?V3/^C7OV=O_  R?PU_^9FC_ %4\(?\ HVM7_P 3
M3B+_ .3_ *N_*PN./'W3_C<5'I_S;KA'KR_]._/\_*WX^?\ #^K0/^C8]8_\
M.Q9?_.]H_P"']6@?]&QZQ_X=BR_^=[7[!_\ #(/[)G_1KW[.W_AD_AK_ /,S
M1_PR#^R9_P!&O?L[?^&3^&O_ ,S-'^JGA#_T;6K_ .)IQ%_\G_5WY6%QQX^Z
M?\;BH]/^;=<(]>7_ *=^?Y^5OQ\_X?U:!_T;'K'_ (=BR_\ G>T?\/ZM _Z-
MCUC_ ,.Q9?\ SO:_8/\ X9!_9,_Z->_9V_\ #)_#7_YF:/\ AD']DS_HU[]G
M;_PR?PU_^9FC_53PA_Z-K5_\33B+_P"3_J[\K"XX\?=/^-Q4>G_-NN$>O+_T
M[\_S\K?CY_P_JT#_ *-CUC_P[%E_\[VC_A_5H'_1L>L?^'8LO_G>U^P?_#(/
M[)G_ $:]^SM_X9/X:_\ S,T?\,@_LF?]&O?L[?\ AD_AK_\ ,S1_JIX0_P#1
MM:O_ (FG$7_R?]7?E87''C[I_P ;BH]/^;=<(]>7_IWY_GY6_'S_ (?U:!_T
M;'K'_AV++_YWM'_#^K0/^C8]8_\ #L67_P [VOV#_P"&0?V3/^C7OV=O_#)_
M#7_YF:/^&0?V3/\ HU[]G;_PR?PU_P#F9H_U4\(?^C:U?_$TXB_^3_J[\K"X
MX\?=/^-Q4>G_ #;KA'KR_P#3OS_/RM^/G_#^K0/^C8]8_P##L67_ ,[VC_A_
M5H'_ $;'K'_AV++_ .=[7[!_\,@_LF?]&O?L[?\ AD_AK_\ ,S1_PR#^R9_T
M:]^SM_X9/X:__,S1_JIX0_\ 1M:O_B:<1?\ R?\ 5WY6%QQX^Z?\;BH]/^;=
M<(]>7_IWY_GY6_'S_A_5H'_1L>L?^'8LO_G>T?\ #^K0/^C8]8_\.Q9?_.]K
M]@_^&0?V3/\ HU[]G;_PR?PU_P#F9H_X9!_9,_Z->_9V_P##)_#7_P"9FC_5
M3PA_Z-K5_P#$TXB_^3_J[\K"XX\?=/\ C<5'I_S;KA'KR_\ 3OS_ #\K?CY_
MP_JT#_HV/6/_  [%E_\ .]H_X?U:!_T;'K'_ (=BR_\ G>U^P?\ PR#^R9_T
M:]^SM_X9/X:__,S1_P ,@_LF?]&O?L[?^&3^&O\ \S-'^JGA#_T;6K_XFG$7
M_P G_5WY6%QQX^Z?\;BH]/\ FW7"/7E_Z=^?Y^5OQ\_X?U:!_P!&QZQ_X=BR
M_P#G>T?\/ZM _P"C8]8_\.Q9?_.]K]@_^&0?V3/^C7OV=O\ PR?PU_\ F9H_
MX9!_9,_Z->_9V_\ #)_#7_YF:/\ 53PA_P"C:U?_ !-.(O\ Y/\ J[\K"XX\
M?=/^-Q4>G_-NN$>O+_T[\_S\K?CY_P /ZM _Z-CUC_P[%E_\[VC_ (?U:!_T
M;'K'_AV++_YWM?L'_P ,@_LF?]&O?L[?^&3^&O\ \S-'_#(/[)G_ $:]^SM_
MX9/X:_\ S,T?ZJ>$/_1M:O\ XFG$7_R?]7?E87''C[I_QN*CT_YMUPCUY?\
MIWY_GY6_'S_A_5H'_1L>L?\ AV++_P"=[1_P_JT#_HV/6/\ P[%E_P#.]K]@
M_P#AD']DS_HU[]G;_P ,G\-?_F9H_P"&0?V3/^C7OV=O_#)_#7_YF:/]5/"'
M_HVM7_Q-.(O_ )/^KORL+CCQ]T_XW%1Z?\VZX1Z\O_3OS_/RM^/G_#^K0/\
MHV/6/_#L67_SO:/^']6@?]&QZQ_X=BR_^=[7[!_\,@_LF?\ 1KW[.W_AD_AK
M_P#,S1_PR#^R9_T:]^SM_P"&3^&O_P S-'^JGA#_ -&UJ_\ B:<1?_)_U=^5
MA<<>/NG_ !N*CT_YMUPCUY?^G?G^?E;\?/\ A_5H'_1L>L?^'8LO_G>US,G_
M  7(T%_&%OXJ_P"&;]7"P:!+HGV'_A:5D2QDOOMOVG[1_P (&  /]7Y/D'/W
M_-'W:_:G_AD']DS_ *->_9V_\,G\-?\ YF:/^&0?V3/^C7OV=O\ PR?PU_\
MF9H_U5\(?^C:U/\ Q-.(O+^_Y N./'W3_C<5'I_S;KA'KR_]._/\_*WX^?\
M#^K0/^C8]8_\.Q9?_.]H_P"']6@?]&QZQ_X=BR_^=[7[!_\ #(/[)G_1KW[.
MW_AD_AK_ /,S1_PR#^R9_P!&O?L[?^&3^&O_ ,S-'^JGA#_T;6K_ .)IQ%_\
MG_5WY6%QQX^Z?\;BH]/^;=<(]>7_ *=^?Y^5OQ\_X?U:!_T;'K'_ (=BR_\
MG>T?\/ZM _Z-CUC_ ,.Q9?\ SO:_8/\ X9!_9,_Z->_9V_\ #)_#7_YF:/\
MAD']DS_HU[]G;_PR?PU_^9FC_53PA_Z-K5_\33B+_P"3_J[\K"XX\?=/^-Q4
M>G_-NN$>O+_T[\_S\K?CY_P_JT#_ *-CUC_P[%E_\[VC_A_5H'_1L>L?^'8L
MO_G>U^P?_#(/[)G_ $:]^SM_X9/X:_\ S,T?\,@_LF?]&O?L[?\ AD_AK_\
M,S1_JIX0_P#1M:O_ (FG$7_R?]7?E87''C[I_P ;BH]/^;=<(]>7_IWY_GY6
M_'S_ (?U:!_T;'K'_AV++_YWM'_#^K0/^C8]8_\ #L67_P [VOV#_P"&0?V3
M/^C7OV=O_#)_#7_YF:/^&0?V3/\ HU[]G;_PR?PU_P#F9H_U4\(?^C:U?_$T
MXB_^3_J[\K"XX\?=/^-Q4>G_ #;KA'KR_P#3OS_/RM^/G_#^K0/^C8]8_P##
ML67_ ,[VC_A_5H'_ $;'K'_AV++_ .=[7[!_\,@_LF?]&O?L[?\ AD_AK_\
M,S1_PR#^R9_T:]^SM_X9/X:__,S1_JIX0_\ 1M:O_B:<1?\ R?\ 5WY6%QQX
M^Z?\;BH]/^;=<(]>7_IWY_GY6_'S_A_5H'_1L>L?^'8LO_G>T?\ #^K0/^C8
M]8_\.Q9?_.]K]@_^&0?V3/\ HU[]G;_PR?PU_P#F9H_X9!_9,_Z->_9V_P##
M)_#7_P"9FC_53PA_Z-K5_P#$TXB_^3_J[\K"XX\?=/\ C<5'I_S;KA'KR_\
M3OS_ #\K?BYK?_!<[0=8NO#]R/V;=7M_[#UF/5BA^*=E+]I$=K=6WD!O^$"C
M\DG[1O\ -(DQLV^6=V1T'_#^K0/^C8]8_P##L67_ ,[VOV#_ .&0?V3/^C7O
MV=O_  R?PU_^9FC_ (9!_9,_Z->_9V_\,G\-?_F9H_U4\(?^C:U/_$TXB_\
MDP7''C[I_P ;BH]/^;=<(]>7_IWY_GY6_'S_ (?U:!_T;'K'_AV++_YWM'_#
M^K0/^C8]8_\ #L67_P [VOV#_P"&0?V3/^C7OV=O_#)_#7_YF:/^&0?V3/\
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M8]8_\.Q9?_.]K]@_^&0?V3/^C7OV=O\ PR?PU_\ F9H_X9!_9,_Z->_9V_\
M#)_#7_YF:/\ 53PA_P"C:U?_ !-.(O\ Y/\ J[\K"XX\?=/^-Q4>G_-NN$>O
M+_T[\_S\K?CY_P /ZM _Z-CUC_P[%E_\[VN9UW_@N1H.M:EX:U ?LWZO;CP_
MJ;ZB8C\4K*4W8> P^2'_ .$#C\@C.[>4ESTV=Z_:G_AD']DS_HU[]G;_ ,,G
M\-?_ )F:/^&0?V3/^C7OV=O_  R?PU_^9FC_ %4\(?\ HVM3_P 33B+_ .3_
M *OZ N./'W3_ (W%1Z?\VZX1Z\O_ $[\_P _*WX^?\/ZM _Z-CUC_P .Q9?_
M #O:/^']6@?]&QZQ_P"'8LO_ )WM?L'_ ,,@_LF?]&O?L[?^&3^&O_S,T?\
M#(/[)G_1KW[.W_AD_AK_ /,S1_JIX0_]&UJ_^)IQ%_\ )_U=^5A<<>/NG_&X
MJ/3_ )MUPCUY?^G?G^?E;\?/^']6@?\ 1L>L?^'8LO\ YWM'_#^K0/\ HV/6
M/_#L67_SO:_8/_AD']DS_HU[]G;_ ,,G\-?_ )F:/^&0?V3/^C7OV=O_  R?
MPU_^9FC_ %4\(?\ HVM7_P 33B+_ .3_ *N_*PN./'W3_C<5'I_S;KA'KR_]
M._/\_*WX^?\ #^K0/^C8]8_\.Q9?_.]H_P"']6@?]&QZQ_X=BR_^=[7[!_\
M#(/[)G_1KW[.W_AD_AK_ /,S1_PR#^R9_P!&O?L[?^&3^&O_ ,S-'^JGA#_T
M;6K_ .)IQ%_\G_5WY6%QQX^Z?\;BH]/^;=<(]>7_ *=^?Y^5OQ\_X?U:!_T;
M'K'_ (=BR_\ G>T?\/ZM _Z-CUC_ ,.Q9?\ SO:_8/\ X9!_9,_Z->_9V_\
M#)_#7_YF:/\ AD']DS_HU[]G;_PR?PU_^9FC_53PA_Z-K5_\33B+_P"3_J[\
MK"XX\?=/^-Q4>G_-NN$>O+_T[\_S\K?CY_P_JT#_ *-CUC_P[%E_\[VC_A_5
MH'_1L>L?^'8LO_G>U^P?_#(/[)G_ $:]^SM_X9/X:_\ S,T?\,@_LF?]&O?L
M[?\ AD_AK_\ ,S1_JIX0_P#1M:O_ (FG$7_R?]7?E87''C[I_P ;BH]/^;=<
M(]>7_IWY_GY6_'S_ (?U:!_T;'K'_AV++_YWM'_#^K0/^C8]8_\ #L67_P [
MVOV#_P"&0?V3/^C7OV=O_#)_#7_YF:/^&0?V3/\ HU[]G;_PR?PU_P#F9H_U
M4\(?^C:U?_$TXB_^3_J[\K"XX\?=/^-Q4>G_ #;KA'KR_P#3OS_/RM^-NK?\
M%W- U32]2TW_ (9HUB#^T=/O+'S_ /A:ME+Y/VNWDM_-\O\ X0"/S/+\S?L\
MQ-^-N]<[@S1?^"[.@:1H^DZ3_P ,TZQ<?V7IEAIWVC_A:EE#Y_V*UBMO.\K_
M (0&7RO-\K?Y?F2;-VW>^-Q_97_AD']DS_HU[]G;_P ,G\-?_F9H_P"&0?V3
M/^C7OV=O_#)_#7_YF:/]5?"+_HVM7_Q-.(O+^]Y?BP7''C[I_P ;BH]/^;=<
M(]>7_IWY_GY6_'S_ (?U:!_T;'K'_AV++_YWM'_#^K0/^C8]8_\ #L67_P [
MVOV#_P"&0?V3/^C7OV=O_#)_#7_YF:/^&0?V3/\ HU[]G;_PR?PU_P#F9H_U
M4\(?^C:U?_$TXB_^3_J[\K"XX\?=/^-Q4>G_ #;KA'KR_P#3OS_/RM^/G_#^
MK0/^C8]8_P##L67_ ,[VC_A_5H'_ $;'K'_AV++_ .=[7[!_\,@_LF?]&O?L
M[?\ AD_AK_\ ,S1_PR#^R9_T:]^SM_X9/X:__,S1_JIX0_\ 1M:O_B:<1?\
MR?\ 5WY6%QQX^Z?\;BH]/^;=<(]>7_IWY_GY6_'S_A_5H'_1L>L?^'8LO_G>
MT?\ #^K0/^C8]8_\.Q9?_.]K]@_^&0?V3/\ HU[]G;_PR?PU_P#F9H_X9!_9
M,_Z->_9V_P##)_#7_P"9FC_53PA_Z-K5_P#$TXB_^3_J[\K"XX\?=/\ C<5'
MI_S;KA'KR_\ 3OS_ #\K?CY_P_JT#_HV/6/_  [%E_\ .]H_X?U:!_T;'K'_
M (=BR_\ G>U^P?\ PR#^R9_T:]^SM_X9/X:__,S1_P ,@_LF?]&O?L[?^&3^
M&O\ \S-'^JGA#_T;6K_XFG$7_P G_5WY6%QQX^Z?\;BH]/\ FW7"/7E_Z=^?
MY^5OQ\_X?U:!_P!&QZQ_X=BR_P#G>T?\/ZM _P"C8]8_\.Q9?_.]K]@_^&0?
MV3/^C7OV=O\ PR?PU_\ F9H_X9!_9,_Z->_9V_\ #)_#7_YF:/\ 53PA_P"C
M:U?_ !-.(O\ Y/\ J[\K"XX\?=/^-Q4>G_-NN$>O+_T[\_S\K?CY_P /ZM _
MZ-CUC_P[%E_\[VC_ (?U:!_T;'K'_AV++_YWM?L'_P ,@_LF?]&O?L[?^&3^
M&O\ \S-'_#(/[)G_ $:]^SM_X9/X:_\ S,T?ZJ>$/_1M:O\ XFG$7_R?]7?E
M87''C[I_QN*CT_YMUPCUY?\ IWY_GY6_'S_A_5H'_1L>L?\ AV++_P"=[5/4
M/^"[?AO5;"^TN?\ 9KURT@U*SN;":ZB^*-A=RVT5Y"]O)<16K^!K1+F2%)#(
MEN]W:K,RB-KB$,9%_8__ (9!_9,_Z->_9V_\,G\-?_F9H_X9!_9,_P"C7OV=
MO_#)_#7_ .9FE_JIX16T\-JJ?1KC3B&Z?=7DU=;ZIKNFAQXY\?$TWXPT9)--
MI^'7"5G\.CY8)V=[.S3WLT[-?C7I/_!=7PSH6EV&BVO[-^NW]MI=I!807T_Q
M-T^PGNXK6-88[B6RC\$ZA':22JH=[=+Z[6)B46XF"AVT?^']6@?]&QZQ_P"'
M8LO_ )WM?L'_ ,,@_LF?]&O?L[?^&3^&O_S,T?\ #(/[)G_1KW[.W_AD_AK_
M /,S0N%/")))^&U6322;?&G$-W:VKY9)7=KNR2U=DE9)OCGQ\E)M>,-"*;NH
MQ\.N$W&*;B^5<T)2LN:RYI.5MVWJOQ\_X?U:!_T;'K'_ (=BR_\ G>T?\/ZM
M _Z-CUC_ ,.Q9?\ SO:_8/\ X9!_9,_Z->_9V_\ #)_#7_YF:/\ AD']DS_H
MU[]G;_PR?PU_^9FG_JIX0_\ 1M:O_B:<1?\ R?\ 5WY6E<<>/NG_ !N*CT_Y
MMUPCUY?^G?G^?E;\?/\ A_5H'_1L>L?^'8LO_G>T?\/ZM _Z-CUC_P .Q9?_
M #O:_8/_ (9!_9,_Z->_9V_\,G\-?_F9H_X9!_9,_P"C7OV=O_#)_#7_ .9F
MC_53PA_Z-K5_\33B+_Y/^KORL+CCQ]T_XW%1Z?\ -NN$>O+_ -._/\_*WX^?
M\/ZM _Z-CUC_ ,.Q9?\ SO:/^']6@?\ 1L>L?^'8LO\ YWM?L'_PR#^R9_T:
M]^SM_P"&3^&O_P S-'_#(/[)G_1KW[.W_AD_AK_\S-'^JGA#_P!&UJ_^)IQ%
M_P#)_P!7?E87''C[I_QN*CT_YMUPCUY?^G?G^?E;\?/^']6@?]&QZQ_X=BR_
M^=[1_P /ZM _Z-CUC_P[%E_\[VOV#_X9!_9,_P"C7OV=O_#)_#7_ .9FC_AD
M']DS_HU[]G;_ ,,G\-?_ )F:/]5/"'_HVM7_ ,33B+_Y/^KORL+CCQ]T_P"-
MQ4>G_-NN$>O+_P!._/\ /RM^/G_#^K0/^C8]8_\ #L67_P [VC_A_5H'_1L>
ML?\ AV++_P"=[7[!_P##(/[)G_1KW[.W_AD_AK_\S-'_  R#^R9_T:]^SM_X
M9/X:_P#S,T?ZJ>$/_1M:O_B:<1?_ "?]7?E87''C[I_QN*CT_P";=<(]>7_I
MWY_GY6_'S_A_5H'_ $;'K'_AV++_ .=[1_P_JT#_ *-CUC_P[%E_\[VOV#_X
M9!_9,_Z->_9V_P##)_#7_P"9FC_AD']DS_HU[]G;_P ,G\-?_F9H_P!5/"'_
M *-K5_\ $TXB_P#D_P"KORL+CCQ]T_XW%1Z?\VZX1Z\O_3OS_/RM^,'B7_@N
MCH'B'0M3T3_AFS6+/^T;8V_VG_A:5E<>3EE;?Y/_  @<'F?=QM\V/KG=Q6S%
M_P %Y] CBCC_ .&9=8;RXT3=_P +8LAG8H7./^%?'&<9QDX]37[#?\,@_LF?
M]&O?L[?^&3^&O_S,T?\ #(/[)G_1KW[.W_AD_AK_ /,S1_JKX1?]&UJ_^)IQ
M%Y?WO+\6"XX\?=/^-Q4>G_-NN$>O+_T[\_S\K?CY_P /ZM _Z-CUC_P[%E_\
M[VC_ (?U:!_T;'K'_AV++_YWM?L'_P ,@_LF?]&O?L[?^&3^&O\ \S-'_#(/
M[)G_ $:]^SM_X9/X:_\ S,T?ZJ>$/_1M:O\ XFG$7_R?]7?E87''C[I_QN*C
MT_YMUPCUY?\ IWY_GY6_'S_A_5H'_1L>L?\ AV++_P"=[1_P_JT#_HV/6/\
MP[%E_P#.]K]@_P#AD']DS_HU[]G;_P ,G\-?_F9H_P"&0?V3/^C7OV=O_#)_
M#7_YF:/]5/"'_HVM7_Q-.(O_ )/^KORL+CCQ]T_XW%1Z?\VZX1Z\O_3OS_/R
MM^/G_#^K0/\ HV/6/_#L67_SO:/^']6@?]&QZQ_X=BR_^=[7[!_\,@_LF?\
M1KW[.W_AD_AK_P#,S1_PR#^R9_T:]^SM_P"&3^&O_P S-'^JGA#_ -&UJ_\
MB:<1?_)_U=^5A<<>/NG_ !N*CT_YMUPCUY?^G?G^?E;\?/\ A_5H'_1L>L?^
M'8LO_G>T?\/ZM _Z-CUC_P .Q9?_ #O:_8/_ (9!_9,_Z->_9V_\,G\-?_F9
MH_X9!_9,_P"C7OV=O_#)_#7_ .9FC_53PA_Z-K5_\33B+_Y/^KORL+CCQ]T_
MXW%1Z?\ -NN$>O+_ -._/\_*WX^?\/ZM _Z-CUC_ ,.Q9?\ SO:/^']6@?\
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M+ ,O@%772A;3SV_]D*PTPV\TT!M/)EDC;]O?^&0?V3/^C7OV=O\ PR?PU_\
MF9H_X9!_9,_Z->_9V_\ #)_#7_YF:F? _@K4454\*Z<U"/+!3XNSZ7+'3W8\
MS?+'1:*R+I^(OTB*3DZ?C;.FYRC*;AP!PM!SDN6TI<L5S25WJ[O?773\>D_X
M+S^'HT1$_9BU=515157XKV*JJJ   !\/0     !@#@4[_A_5H'_1L>L?^'8L
MO_G>U^P?_#(/[)G_ $:]^SM_X9/X:_\ S,T?\,@_LF?]&O?L[?\ AD_AK_\
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GREB<JCP;P]D[KU*>7UJF'G]?R^"Q5+V%=0K<L&HU>1TY^Y)I?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>nt10014672x1_barchart1x1.jpg
<TEXT>
begin 644 nt10014672x1_barchart1x1.jpg
M_]C_X  02D9)1@ ! 0$ P #   #_[0 V4&AO=&]S:&]P(#,N,  X0DE- ^T*
M4F5S;VQU=&EO;@     0 ,     !  $ P     $  ?_B"^!)0T-?4%)/1DE,
M10 ! 0  "]!N;VYE @   &UN=')21T(@6%E:( ?4  < %0 3  L (6%C<W
M         $E%0R!S4D="     0            #VU@ !     -,M2% @(
M
M$&1E<V,   %$    =&)865H   &X    %&)44D,   ',   (#&1M9&0   G8
M    B&=865H   I@    %&=44D,   ',   (#&QU;6D   IT    %&UE87,
M  J(    )&)K<'0   JL    %')865H   K     %')44D,   ',   (#'1E
M8V@   K4    #'9U960   K@    AW=T<'0   MH    %&-P<G0   M\
M*&-H860   ND    +&1E<V,         &G-21T(@245#-C$Y-C8M,BTQ('=I
M=&A"4$,
M                                                    6%E:(
M     "2@   /A   ML]C=7)V        !      %  H #P 4 !D '@ C "@
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M;W5R(%-P86-E("T@<U)'0@
M
M      !865H@        8ID  +>%   8VEA96B            !0
M;65A<P         !                               "6%E:(
M  ,6   #,P   J1865H@        ;Z(  #CU   #D'-I9R      0U)4(&1E
M<V,         +5)E9F5R96YC92!6:65W:6YG($-O;F1I=&EO;B!I;B!)14,@
M-C$Y-C8M,BTQ
M                                                          !8
M65H@        ]M8  0    #3+71E>'0     0V]P>7)I9VAT($AE=VQE='0@
M4&%C:V%R9"P@,C P- !S9C,R       !#$0   7?___S)@  !Y0  /V/___[
MH?___:(   /;  # =?_; $,  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! ?_; $,! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! ?_  !$( AH$V ,!(@ "$0$#$0'_Q  ?   !!0$!
M 0$! 0           0(#! 4&!P@)"@O_Q "U$  " 0,# @0#!04$!    7T!
M @, !!$%$B$Q008346$'(G$4,H&1H0@C0K'!%5+1\"0S8G*""0H6%Q@9&B4F
M)R@I*C0U-C<X.3I#1$5&1TA)2E-455976%E:8V1E9F=H:6IS='5V=WAY>H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:X>+CY.7FY^CIZO'R\_3U]O?X^?K_Q  ? 0 # 0$! 0$! 0$!
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MXDW\#_\ H4Y[_P")%C_\S^6K_AQ=^TI_T5;X'?\ @P\>_P#S"T?\.+OVE/\
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M-_ __H4Y[_XD6/\ \S^6K_AQ=^TI_P!%6^!W_@P\>_\ S"T?\.+OVE/^BK?
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M_AFP?^7]7?E8_P")-_ __H4Y[_XD6/\ \S^6K_AQ=^TI_P!%6^!W_@P\>_\
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M_@P\>_\ S"T?\.+OVE/^BK? [_P8>/?_ )A:_J5HH_XF6\5?^ACE/_AFP?\
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MQ,MXJ_\ 0QRG_P ,V#_R_J[\K'_$F_@?_P!"G/?_ !(L?_F?RU?\.+OVE/\
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M ,2+'_YG\M7_  XN_:4_Z*M\#O\ P8>/?_F%H_X<7?M*?]%6^!W_ (,/'O\
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MU_4K11_Q,MXJ_P#0QRG_ ,,V#_R_J[\K'_$F_@?_ -"G/?\ Q(L?_F?RU?\
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M^(GW/!7_ &43PI_Z47%"^DMXJ72_M'*=6E_R)L'Y>7]7#_B3?P/_ .A3GO\
MXD6/_P S^:[_ (<7?M*?]%6^!W_@P\>__,+1_P .+OVE/^BK? [_ ,&'CW_Y
MA:_J5HH_XF6\5?\ H8Y3_P"&;!_Y?U=^5C_B3?P/_P"A3GO_ (D6/_S/Y:O^
M'%W[2G_15O@=_P"##Q[_ /,+1_PXN_:4_P"BK? [_P &'CW_ .86OZE:*/\
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MM-+?5?[5U'3K*[/^)EO%7_H8Y3_X9L'_ )?U=^5C_B3?P/\ ^A3GO_B18_\
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M*_9,^#7[1UW=>&OA?\<K[PS\0O#GC^QBT0^-_A_;6/PK^W_V?XI\9:9XBN-
M\!ZEIND_$C3]!MFU#6_!6CV5I=26_P!,?!#_ (*.?L1?M$?L\^*_VJ_A9^T5
MX"U+X"^ );^V^(7CSQ)<:CX @^'U[IOD?:;'QSH_CW3_  UK_A:[F^U6C:3'
MK&EVJ^(8;[3[KPZ^JVFHV$]R?\3+>*O_ $,<I_\ #-@_\OZN_*Q_Q)OX'_\
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M^'%W[2G_ $5;X'?^##Q[_P#,+7]2M%'_ !,MXJ_]#'*?_#-@_P#+^KORL?\
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M/['/Q]_:'_:(^ _@7_@K-X6\&>%_%7[1ELZZWX;N-.^"_P <K^^\%?#[4IO
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M_(&U;_L&7_\ Z2RU_,E_P00_Y/V_X.#/^TA&O?\ JYOVK:_IMUK_ ) VK?\
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MCXVA\,^/?"?_  A-BWPZ_2'_ (*2?$GPW^V)_P %/?V3O"W[2>A>%=8_8_\
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M"WBW_@E]\,/%6C_$/]KSX1_'3X?? CQU^U+9>)/&\WP;*_%/3M0\)?!GX\^
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MT74M8N=-B_X1[0_+ME_LFP^S['Q(^&/PU^,G@O6OAO\ %_X>>!OBK\._$?\
M9W_"0^ OB1X3T#QSX+U[^Q]6L=>TG^VO"WB?3]4T/5/[+US2],UG3OMUC/\
M8M6TZQU&V\J\M+>:/3_X3/P?_P!#9X:_\'NE_P#R51_PF?@__H;/#7_@]TO_
M .2J+/L_Z_X=?>!PU]^SY\!-3OOA%J>I?!#X0ZCJ7[/UL]E\!M0OOAKX,N[[
MX)6<FGZ/I,EI\(KNXT62X^&UM)I7A[0-,>#P;)HL3:?H>CV3(;;3+*.#PF?_
M ()M?\$\+K4?$>K7G["7['E_J'BZ=+KQ-<ZA^S7\'-0;6[E;E+TSZ@EYX-GB
MGFFOXTU&YD,8:[U%%U"Z,UZHG'U?_P )GX/_ .AL\-?^#W2__DJC_A,_!_\
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M+HS7JB<?5_\ PF?@_P#Z&SPU_P"#W2__ )*H_P"$S\'_ /0V>&O_  >Z7_\
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M/_Z&SPU_X/=+_P#DJBS[/^O^'7W@=+7%_$/X;_#OXN^#=;^'7Q7\!>"_B?\
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MPS-J5OJ>KVESJVEV<&MG3]=U_3$U---UW5K2\+/L_P"O^'7W@?S2V-C^UO\
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M_ALC^Q_ OAJS_P"'@'V[_AKC_B\/Q#N/^%M?VE_PG/VW_CZ^(D__  @?G_\
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M_%?BC6=-31XM)TN.P2Q\/:!;Z9\[?\%MOAO^V%^V%\"K;]C?]E3P;^S=XO\
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MO^$S\'_]#9X:_P#![I?_ ,E4?\)GX/\ ^AL\-?\ @]TO_P"2J5GV?]?\.OO
MZ6BN:_X3/P?_ -#9X:_\'NE__)5'_"9^#_\ H;/#7_@]TO\ ^2J+/L_Z_P"'
M7W@=+17-?\)GX/\ ^AL\-?\ @]TO_P"2J/\ A,_!_P#T-GAK_P 'NE__ "51
M9]G_ %_PZ^\#I:*YK_A,_!__ $-GAK_P>Z7_ /)5'_"9^#_^AL\-?^#W2_\
MY*HL^S_K_AU]X'2T5S7_  F?@_\ Z&SPU_X/=+_^2J/^$S\'_P#0V>&O_![I
M?_R519]G_7_#K[P.EHKFO^$S\'_]#9X:_P#![I?_ ,E4?\)GX/\ ^AL\-?\
M@]TO_P"2J+/L_P"O^'7W@=+17-?\)GX/_P"AL\-?^#W2_P#Y*H_X3/P?_P!#
M9X:_\'NE_P#R519]G_7_  Z^\#I:*YK_ (3/P?\ ]#9X:_\ ![I?_P E4?\
M"9^#_P#H;/#7_@]TO_Y*HL^S_K_AU]X'2T5S7_"9^#_^AL\-?^#W2_\ Y*H_
MX3/P?_T-GAK_ ,'NE_\ R519]G_7_#K[P.EHK&L?$?A[4YQ:Z;KVBZA=%6<6
MUCJEC=SE$&7<0P3R2%4'+,%PHY)%%("'_A%/"W_0M:!_X)]._P#D:C_A%/"W
M_0M:!_X)]._^1JWZ*=WW?]?\,ON P/\ A%/"W_0M:!_X)]._^1J/^$4\+?\
M0M:!_P""?3O_ )&K?HHN^[_K_AE]P&!_PBGA;_H6M _\$^G?_(U'_"*>%O\
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M4C7PIZY_P5(_9IM_ 'P4\<^ ])^,GQMU#X_1>++GX??#+X,_#'4_%_Q7ELO
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M:-I[>&I/!=EJ\_A.:\M6U.WUZ8S"X8U\_P ?+_@?AY ?I'_PBGA;_H6M _\
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M.GM-;@MA<WGTUUMTM^GX ?I-_P (IX6_Z%K0/_!/IW_R-1_PBGA;_H6M _\
M!/IW_P C5C?#'Q_H?Q8^&WP]^*?A@7:^&OB5X'\)^/\ P\M_''#?+H?C+0;#
MQ%I(O(8I9XHKL6&I6XN(XYIHTFWJDLB@.>1_:.\7Z_\ #W]GKX\>/O"EXFG^
M*/ _P9^*'B_PW?R6MK?1V.O^&O!&N:UH]Y)97L5Q9W:6VHV5M,UK=P36MPJ&
M*XBDB=T85^C?W^G^2^X#T?\ X13PM_T+6@?^"?3O_D:C_A%/"W_0M:!_X)].
M_P#D:O)/V5?'/B7XG_LO_LW_ !*\9WT>J>,/B'\!/@_XY\5ZE%9V>GQ:CXE\
M6_#WP[K^NWT=AI\%M86,=WJFH75PEG8VUO9VRR"&V@BA1(U]ZHN^[_K_ (9?
M<!@?\(IX6_Z%K0/_  3Z=_\ (U'_  BGA;_H6M _\$^G?_(U;]%%WW?]?\,O
MN P/^$4\+?\ 0M:!_P""?3O_ )&H_P"$4\+?]"UH'_@GT[_Y&K?HHN^[_K_A
ME]P'COPS\/Z#>:!>RWFB:1=RKXAUR)9+G3;*>18HKPK'$KRPNPCC7Y40':@X
M4 5Z'_PBGA;_ *%K0/\ P3Z=_P#(U<G\)/F\$V<AYDFU'6I97/+22'5;M2[M
MU9RJJ"QR2% ["O2Z-5I?9_U^0&!_PBGA;_H6M _\$^G?_(U'_"*>%O\ H6M
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M5OT47?=_U_PR^X# _P"$4\+?]"UH'_@GT[_Y&H_X13PM_P!"UH'_ ()]._\
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MT?\ "&>#_P#H4_#7_@BTO_Y%KI:*+ON_Z_X9?<!S7_"&>#_^A3\-?^"+2_\
MY%H_X0SP?_T*?AK_ ,$6E_\ R+72T47?=_U_PR^X#FO^$,\'_P#0I^&O_!%I
M?_R+1_PAG@__ *%/PU_X(M+_ /D6NEHHN^[_ *_X9?<!S7_"&>#_ /H4_#7_
M ((M+_\ D6C_ (0SP?\ ]"GX:_\ !%I?_P BUTM%%WW?]?\ #+[@.:_X0SP?
M_P!"GX:_\$6E_P#R+1_PAG@__H4_#7_@BTO_ .1:Z6BB[[O^O^&7W <U_P (
M9X/_ .A3\-?^"+2__D6C_A#/!_\ T*?AK_P1:7_\BUTM%%WW?]?\,ON YK_A
M#/!__0I^&O\ P1:7_P#(M>>_$3PSX;LK3PPUEX>T.T:X\:^'K2=K72;"W:>U
MGDN!-;3&*W0R6\P51+"^Z.0 ;U.!7L]>:?$[_CR\)?\ 8^^&O_1ES3BW=:O=
M?H!TW_"&>#_^A3\-?^"+2_\ Y%H_X0SP?_T*?AK_ ,$6E_\ R+72T4KON_Z_
MX9?<!S7_  AG@_\ Z%/PU_X(M+_^1:/^$,\'_P#0I^&O_!%I?_R+72T47?=_
MU_PR^X#FO^$,\'_]"GX:_P#!%I?_ ,BT?\(9X/\ ^A3\-?\ @BTO_P"1:Z6B
MB[[O^O\ AE]P'-?\(9X/_P"A3\-?^"+2_P#Y%H_X0SP?_P!"GX:_\$6E_P#R
M+72T47?=_P!?\,ON YK_ (0SP?\ ]"GX:_\ !%I?_P BT?\ "&>#_P#H4_#7
M_@BTO_Y%KI:*+ON_Z_X9?<!S7_"&>#_^A3\-?^"+2_\ Y%H_X0SP?_T*?AK_
M ,$6E_\ R+72T47?=_U_PR^X#FO^$,\'_P#0I^&O_!%I?_R+1_PAG@__ *%/
MPU_X(M+_ /D6NEHHN^[_ *_X9?<!S7_"&>#_ /H4_#7_ ((M+_\ D6N$\=^%
M_#5FGA VGAW0K4W/CSPU9W)MM)L(/M%I//.)[6?RK=?-MI@ )8)-T4@ #JP
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M4OVT_#'B;]G[]B'7-;_X)[?#;P[^TU\=]?T'XJ_&S2_#GQ)^ GC3P3XP\?\
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MW["/P#O?%WP@E\8?LP?M@Z/^T#X^U*UU_P 9OX:U?P;I_CKQOXGFTSP?>2^
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M9\/WMQ:3IXEUJWN='FLI6AM+J26&&]J_[+__  4&T+X]^&/VSO!>I_L@ZO\
MM#^)?V<M<^ /QL\ ZG>?&32/A)!<P>/+OQ1X*\:?#'6YK#7/%DZ0V=GX+B\4
M>&M?M-#@DET+Q"-.U&YN/$]G?>'?V.55151%5$10J(H"JJJ %55  55
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MEH YKX:_\B)X9_[!J?\ HV6NXKA_AK_R(GAG_L&I_P"C9:[B@ HHHH ****
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ME>&K7QUH@T37[7PSXBG\)Z!9VFOZU;VGQH\0^ ]$UVRO/#MQKMS:@&O\!_\
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M?!OCW7M4NOB?XV7XE>'=!7P69M2\#_#[1] N?$GBVYG_ '1HHH;_ .&UT^\
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M?_\ R]H_L?-_^A5F7_A#BO\ Y5YK[P_MC*?^AIEW_A;AO_EI]UT5\*?\//\
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MH_X>?_\ !.;_ */C_98_\/?\/_\ Y>T?V/F__0JS+_PAQ7_RKS7WA_;&4_\
M0TR[_P +<-_\M/NNBOA3_AY__P $YO\ H^/]EC_P]_P__P#E[1_P\_\ ^"<W
M_1\?[+'_ (>_X?\ _P O:/['S?\ Z%69?^$.*_\ E7FOO#^V,I_Z&F7?^%N&
M_P#EI]UT5\*?\//_ /@G-_T?'^RQ_P"'O^'_ /\ +VC_ (>?_P#!.;_H^/\
M98_\/?\ #_\ ^7M']CYO_P!"K,O_  AQ7_RKS7WA_;&4_P#0TR[_ ,+<-_\
M+3[KKS3XN?\ (C:C_P!?NC?^G>SKY?\ ^'G_ /P3F_Z/C_98_P##W_#_ /\
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M /E[1_8^;_\ 0JS+_P (<5_\J\U]X?VQE/\ T-,N_P#"W#?_ "T^ZZ*^%/\
MAY__ ,$YO^CX_P!EC_P]_P /_P#Y>T?\//\ _@G-_P!'Q_LL?^'O^'__ ,O:
M/['S?_H59E_X0XK_ .5>:^\/[8RG_H:9=_X6X;_Y:?==%?"G_#S_ /X)S?\
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M6/\ P]_P_P#_ )>T?\//_P#@G-_T?'^RQ_X>_P"'_P#\O:/['S?_ *%69?\
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M?#]P+63]B_V$M,^)>A?LM_#/0/BU^S;X!_9(\8Z#%XBTB7X _##6?"^O>"?
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M]4\>:OX4N9;7XO\ P,^*FH6.I6=S\2/%*7$VD:IIUK>P7-JMU9R26<,H^=/
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MQ^,G_A%>"?\ X]1_Q%/@S_H8XC_PWXW_ .4?U9^5S_B%_&7_ $+\/_X7X/\
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M/^(7\9?]"_#_ /A?@_\ Y=_5GY7_ (=Z*_N(_P"(4+]GS_H['XR?^$5X)_\
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M3_\ 'J/^(4+]GS_H['XR?^$5X)_^/4?\13X,_P"ACB/_  WXW_Y1_5GY7/\
MB%_&7_0OP_\ X7X/_P"7?U9^5_X=Z*_N(_XA0OV?/^CL?C)_X17@G_X]1_Q"
MA?L^?]'8_&3_ ,(KP3_\>H_XBGP9_P!#'$?^&_&__*/ZL_*Y_P 0OXR_Z%^'
M_P#"_!__ "[^K/RO_#O17]Q'_$*%^SY_T=C\9/\ PBO!/_QZL;Q#_P &JOP
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M9\_Z.Q^,G_A%>"?_ (]1_P 0H7[/G_1V/QD_\(KP3_\ 'J/^(I\&?]#'$?\
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MWQ ^'O@OQ%X9U;X@Z%9:K=VUIIO]I^')=9M;G1VOC<K-:-K3:=%<PH[PR/\
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M $-7P;_\-%I'_P GT?\ $(.*_P#GYE'_ (65O_F3^K/RN?\ $6^%?^?>;?\
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M?V-O_#??&W_Z(:C_ (BH?^"@_P#T1W]C;_PWWQM_^B&H_P"(3<7_ //G ?\
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M:_[ &C_^FZVK?K^"C3O^#IW]M;3=/L=.A^ O[+;PZ?9VME$\NC?%DR/':P)
MC2%?BJJEV6,%RJJNXG"@8 N?\15?[;7_ $0+]EC_ ,$WQ:_^>O2_XA1QC_T"
MX+_POH?Y_P!6]+O_ (BIPA_T%8S_ ,(:_P#D?WET5_!I_P 15?[;7_1 OV6/
M_!-\6O\ YZ]'_$57^VU_T0+]EC_P3?%K_P">O1_Q"CC'_H%P7_A?0_S_ *L_
M*Y_Q%3A#_H*QG_A#7_R/[RZ*_@T_XBJ_VVO^B!?LL?\ @F^+7_SUZ/\ B*K_
M &VO^B!?LL?^";XM?_/7H_XA1QC_ - N"_\ "^A_G_5GY7/^(J<(?]!6,_\
M"&O_ )']Y=%?PM^#O^#K3]J>T\0Z=/\ $#]FG]G_ %_PJMS:G5M,\'7OQ%\(
M^(9[,7=NUXNG:YK7BKQOIMK<O8+=PVKW/AZ\BBNY;>YE2:&WEM+G^QS]E']I
M[X7_ +9/P ^'7[1WP=N=4E\"?$?3+N[L;+7[*+3?$>@ZII&J7V@^(O#7B+3[
M>ZOK:UUKP_KVF:CI5Z;&^U#2[QK9=1T;4M3T>\L-1NOGL_X.S_AJE1KYKA(T
M\/7J>RIXBC6IUZ7M>5S5*<J<FZ<Y0C*4%.,5-0FX.7)*WT&0\7Y#Q)5K4,KQ
M<JF(H4_:U,/6HU*%7V/-&#JPC4BE4A&<HQFX2DX2G!34>>'-]$45^*UA_P %
M-_VMOB-JW[6<_P"SG_P3=NOCUX)_9*_:8^*?[,WB?4M(_:N\$>#O'OC'Q)\)
M1X=O_$.K>$OAUXH^&<$=YY_AWQ3I&L6&AIXMGU#4+EKC0M*DU/54MX;KWG]E
M3_@I7X,_:P@\&_$+PWX 7X<?LZ^+/@'<_$Z[^*_Q:^*WPQ\&^,O!OQ8T?X[>
M(O@1XG^!'C+X&W.M2^.M&GT77?#LUU;_ !5>:3X>Z[?WEEX7TF\GUR9(6^7/
MIC],**RKW7M#TW4=&T?4=9TJPU;Q'/>6OA[2[W4;.UU'7KG3K"?5-0M]&LIY
MH[G5)[#3+:YU&\AL8IY+6PMY[R=4MXI)%Y+2/BY\*/$%UX[L=!^)WP\UN]^%
MMS<6?Q-L](\:>&]2NOAU=VEJ]]=6OCNWLM2FF\(W-M91R7EQ!X@33Y8;6-[B
M15A5G !Z%17QY^R/^W'\"OVQ_P!FG2OVJ_A[K$GA3X7ZAK/Q T>^/Q%U+PKH
M>L>%F\ >/_$G@*YN/&*Z9XCUO1O#BZVWA^+Q/HL-[K7GR^&=>T&_N4MY+[R$
MH_M)?ML?#GX(_LM:I^U5X F\,?'_ ,$V7C;X*^#=/?X>_$#0KK0=:;XQ_&_X
M;?!B/4;#QEHMOXITF5/#LOQ%@\1S6T$%P=1ATTZ:L]BU\E_;@'VC7FGQ5_Y%
MRQ_[&70/_2U:]+KS3XJ_\BY8_P#8RZ!_Z6K3CNO5?F!Z71112 **** "BBB@
M HHHH **** "BBB@ HHHH *\T^)W_'EX2_['WPU_Z,N:]+KS3XG?\>7A+_L?
M?#7_ *,N:<=UZK\P/2ZS-9UK1O#FE7^N^(=6TS0=#TJVEO=4UG6;^UTO2M-L
MX1NFN[_4;Z6"TL[:)?FEGN)HXHQRS@5IU^+'_!0;PQX,^,W_  4(_P""97[.
M7[1MIIVN_LL>.;+]J;Q^/AGXEL;+7/AO\;_VDOAGX1\#_P#"K_!7Q4T75;0:
M5>:7X3\'^)_B'X[\%:'?W5_9>,O%%A/I]_X>U"#1U94!^P7A'QGX/^(&@6'B
MOP'XK\->-O"VJQ^=I?B7PCKNE^)- U*+C][8:SHUU>Z=>1\CY[>YD7D<UTM?
MA=^TQXM_8M_X)53?MM_'S]FCP[X:\%?M+Z?^QEIOQ>\3_LG_  X\/+H/PD\8
MV.D_$;6O!/PJ^.WC7X=>"/#^D6UA>VOQ'\57WA7QCXMT;Q+H5_=^"'UFXU2T
M:YM;/7[7Y[_:R_:Q_P""BW[!D7BRQ^(O[3'PX_:.N/V@_P!A_P#;0^/'PJUC
MP3^SMX4^&T7[+/Q=_9<^&OA7X@:7>:(B^+O'<'Q%^"WBF'QF="B/Q,@\3:Z/
M%%CX4+^)$L=6OM(U4 _I5HK^=/PI\1/^"K7Q!_:/^'_[-^G_ +;_ ,%?#Z_M
M&?L6I^W+I'Q$A_8^T.[U#X+R^'?%_@?P5J7P.\%^%;WXG7.G>(_!>OZK\5/!
M^H7_ (T^(6K^+/&R:9H?B2PTAM#O-3TW5-.\+^'7_!03_@H5^V;ISZU\&?CM
M\-?V<#I'_!*OX*?MP:WI,_P&T'XGVFM?&*V\5_'+PYXX\):%?^(O$<-WX2^'
M'Q(U'P3I@U5M4B\>^)?#>A:=I47A&]TC6'U[5-< /ZH**_ ?]E[]M;]L?3O'
MG['?CC]I'Q_X&^,'PV_X*%_L/?%W]KKPE\(?A5\$_P#A!=;_ &>-?^$_@CX&
M_%*P\!>#_$LGCCQ1KGQ4TOQ3X'^,4F@WZ^+T.NS^.]&MM4T6_P!&T&_?PY#\
M4_LQ_P#!3S_@HCXJ\=?LM?&KQ;>?%#XH? O]L'Q!9Z%XI^%=_P#L&ZO\(OA/
M^SM8_$GPOXBU_P ">(?@A^U8VO7#?&>R\!:];:)H_BR?QS9ZHOBKPE9^(]:T
M/3K6Y"ZIHP!_6=17\R_[)'[:/_!0U/!G_!-#]J[X^_'_ , _&?X0?MMZ'X^\
M">/OV??"G[.VC^#=?\&:QX)_9\^+7Q@\,_$?P/XX\.Z[>^(/%/Q$\3WOP-U.
MV\8:)=Z?I_@";_A-)]%\%_#[1)K72M:TSZC_ &2_CK^W-K'@_P#9O_; ^-7[
M3W[.OQ!^"_[6OPIUSXRM^R;9_#6Q^'GQ/^'NGWOP7UCXQ^#?AU^RUXITG7M;
MU_\ : \?Z!#9Q:9\2=&^(<-A.V@Z=K_B31YM'N-(?2[L _<6O#OB1^T[^S7\
M&_$NG>#/B]^T+\#OA5XPU?3+36M)\*?$CXL^ O WB75-&U"_OM*L-6T[0O$^
MOZ7JE[IE[JFEZGIMI?VUK+:W-_IU]9PRO<6EQ''_ #??L>_\%+_^"A'CSXO?
ML<_%GQS<_%'XJ? #]M#QYX=\*^,_A/??L(:S\'OA1^SSI'Q3T;6]8\%Z]\#_
M -K!?$$\OQDL_ FM1:-HWBNZ\;6NI?\ "4>$K3Q'KF@Z?:7075=%]@_:\AU^
M[_X+GZCIV@?L7>'_ -N5M3_X(^>&=.U/X3>)_$7P:\-Z)IVEWG[8'Q0@N?$.
MH7'QN?\ X1B\LIBZ>&KVQL+>^U:2TU^>065QI\=^A /Z'+[XE_#G3(?!5QJ7
MC_P3I]O\2=5L]!^'4]]XJT*TA\?:YJ&G7>L:?HW@J6>_C3Q5JM]I.GW^J6>G
M:$U_>7.G65W>PPO;6TTJ=M7\H7A_]GC]HW]CKP%^S+X#U#P=\"OV9O%_[9'_
M  6%^)GCGX:?"OPAX5^'/[1'A/\ 8K\*_%#]FCXB67@K2_A-JGQ#\!S^'="\
M;^#_ !)X*/BNXU?X;:7X8\.R0:MJ'A[0M-\/^'->U_PT_P!:? #_ (*7?'+X
MJ?\ #.OA_7S<:=XT_9C_ &6_VGOCG_P5(\,:1X-TG5_$M[X^_9TUKQ;^S7H?
MPH\.Q:;IMSIWA77_ (K_ !R\"?%7XMZ3H_AVWL=:;PG\-M*TG3TCT7Q*\=P
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M;SZ*^'7AO]HWP%XZ^&_Q2B/[4WBW6OB%\2_^"@VA_%;P;XB\6^/_ !!X8MO
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MU_T9W^U/_P"(^?%K_P"9&C_AA?\ ;:_Z,[_:G_\ $?/BU_\ ,C7^M#17J_\
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M^&O_ "(GAG_L&I_Z-EKN*O\ XC7BO^B?P_\ X<:G_P R>O\ 2UG_ (@QA?\
MH?XC_P -]/\ ^:_7^EK_ )#?_#.G[0?_ $0GXR?^&P\;?_*.C_AG3]H/_HA/
MQD_\-AXV_P#E'7^O)11_Q&O%?]$_A_\ PXU/_F3U_I:G_$&,+_T/\1_X;Z?_
M ,U^O]+7_(;_ .&=/V@_^B$_&3_PV'C;_P"4='_#.G[0?_1"?C)_X;#QM_\
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M#_HHY_\ AI7_ ,\O7^EK_CL_\(AXL_Z%?Q%_X)-2_P#D:D/A'Q6H+-X8\0@
M9).BZD  .I)-M@ >IK_8GKD_'G_(E^*O^P#J?_I)+0O&R;:7^K<-6E_R-WY?
M]2WU_I:G_$%X?]%'/_PTK_YY>O\ 2U_R!!X1\6$ CPQXA((!!&BZD00>001;
M8((Z&E_X1#Q9_P!"OXB_\$FI?_(U?[ _A3_D5O#7_8 T?_TW6U;]'_$;)_\
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M?P_X;_M73;W3H+G6/$5KJ>K7-GJ*^'=)UHZ1JXL?R[_XBO?V?/\ HT[XR?\
MA:^"?_C-?B/_ ,' /P;^)W@G]M=?BQXI34+WX<?&OP-X>NOA;J[B>32=/C\!
M6-MX/\8^#+:>11##J6E^(;63Q=?V$!*QVOCS3+YB9-0E"_A?7]%<*^&_"N89
M#EN8XN-?,,1CL-3Q-:I'%U:-*E5GK4PU.&'E32^KS4J%3VCG-U83?-%-1C_/
M7%7B-Q3E^?YEE^$E0P&'P.*J8>E3EA*5:I5IP:]GB*DZ\:C?UB'+6I\BA!4J
MD%:37._[B/\ B*]_9\_Z-.^,G_A:^"?_ (S1_P 17O[/G_1IWQD_\+7P3_\
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M3_\ &:J7_P#P=:_L_7EC>VB_LH?&-&NK2XMU=O&O@DJC3PO$&($.2%+9(')
MXK^(*BC_ (A9P9_T+L1_X<,;_P#+_P"KORL?\10XR_Z&%#_P@P7_ ,I_J_I;
M^VGPM_P=2_ 'P_X>TG19OV5/C#<2Z=:K;O/'XS\%I'(P=VW*K0E@/FQ@\\5O
M_P#$5[^SY_T:=\9/_"U\$_\ QFOX=Z*/^(6<&?\ 0NQ'_APQO_R_^KORL?\
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M;^XC_B*]_9\_Z-.^,G_A:^"?_C-'_$5[^SY_T:=\9/\ PM?!/_QFOX=Z*/\
MB%G!G_0NQ'_APQO_ ,O_ *N_*Q_Q%#C+_H88?_P@P?\ \I_J[\K?W$?\17O[
M/G_1IWQD_P#"U\$__&:/^(KW]GS_ *-.^,G_ (6O@G_XS7\.]%'_ !"S@S_H
M78C_ ,.&-_\ E_\ 5WY6/^(H<9?]###_ /A!@_\ Y3_5WY6_N(_XBO?V?/\
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MT+L1_P"'#&__ "_^KORL?\10XR_Z&&'_ /"#!_\ RG^KORM_<1_Q%>_L^?\
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MOAWQY!IVJW'@^YU*WTV\%M_530 4444 %%%% !1110 5YI\5?^1<L?\ L9=
M_P#2U:]+KS3XJ_\ (N6/_8RZ!_Z6K3CNO5?F!Z71112 **** "BBB@ HHHH
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M"G_(K>&O^P!H_P#Z;K:GT7J_RB!OT444@"BBB@ HHHH **** "BBB@ HHHH
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M_P#<%'_"MO\ J?OB5_X5/_W!19=_P]/\W]WF!Z517FO_  K;_J?OB5_X5/\
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M8GPU\()X:/C"/2AH*>*3HZZ0+$^(5\/JOAT:P8?[0_X1T?V#]H_LC_0JZ_\
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M35_#7C/X/?#'Q3H&O^+C\0-;T?7O OAG4]/U;QZ;&/2SXXU"VN],EBNO&/\
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M^C'/V6/_  R'P_\ _E%1_P .P/\ @G-_T8Y^RQ_X9#X?_P#RBKZA_P"%;?\
M4_?$K_PJ?_N"C_A6W_4_?$K_ ,*G_P"X*/[8S;_H;9ET_P"8W%>7_3WI_P"V
M^@?V/E/_ $*\N_\ "+#?_*CY>_X=@?\ !.;_ *,<_98_\,A\/_\ Y14?\.P/
M^"<W_1CG[+'_ (9#X?\ _P HJ^H?^%;?]3]\2O\ PJ?_ +@H_P"%;?\ 4_?$
MK_PJ?_N"C^V,V_Z&V9=/^8W%>7_3WI_[;Z!_8^4_]"O+O_"+#?\ RH^7O^'8
M'_!.;_HQS]EC_P ,A\/_ /Y14?\ #L#_ ()S?]&.?LL?^&0^'_\ \HJ^H?\
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M]6] _L?*?^A7EW_A%AO_ )4?+W_#L#_@G-_T8Y^RQ_X9#X?_ /RBH_X=@?\
M!.;_ *,<_98_\,A\/_\ Y15]0_\ "MO^I^^)7_A4_P#W!1_PK;_J?OB5_P"%
M3_\ <%']L9M_T-LRZ?\ ,;BO+_I[T_\ ;?0/['RG_H5Y=_X18;_Y4?+W_#L#
M_@G-_P!&.?LL?^&0^'__ ,HJ/^'8'_!.;_HQS]EC_P ,A\/_ /Y15]0_\*V_
MZG[XE?\ A4__ '!1_P *V_ZG[XE?^%3_ /<%']L9M_T-LRZ?\QN*\O\ I[T_
M]M] _L?*?^A7EW_A%AO_ )4?+W_#L#_@G-_T8Y^RQ_X9#X?_ /RBH_X=@?\
M!.;_ *,<_98_\,A\/_\ Y15]0_\ "MO^I^^)7_A4_P#W!1_PK;_J?OB5_P"%
M3_\ <%']L9M_T-LRZ?\ ,;BO+_I[T_\ ;?0/['RG_H5Y=_X18;_Y4?+W_#L#
M_@G-_P!&.?LL?^&0^'__ ,HJ/^'8'_!.;_HQS]EC_P ,A\/_ /Y15]0_\*V_
MZG[XE?\ A4__ '!1_P *V_ZG[XE?^%3_ /<%']L9M_T-LRZ?\QN*\O\ I[T_
M]M] _L?*?^A7EW_A%AO_ )4?+W_#L#_@G-_T8Y^RQ_X9#X?_ /RBH_X=@?\
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MW_#T_P W]WF!Z717FG_"N[S_ **#X]_\',?_ ,BT?\*[O/\ HH/CW_P<Q_\
MR+19=_P]/\W]WF!Z77Y^?\%2?V4OB)^VY^PS\8_V9?A3K/@OP_X\^(>L?!?4
M-%U;XA:CKFE>$;6'X=?'GX8?%'6UU2_\-^'/%FLP2W7A_P %:K9Z4MIH%ZD^
ML7&GV]V]C92W.H6GUQ_PKN\_Z*#X]_\ !S'_ /(M'_"N[S_HH/CW_P ',?\
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MX!_LU_L[>$? C6^E_#;P/^S/\5O'_P 5_#<NC3I+>ZSJ_BC6?B'\$/@IK?\
MPEVJZ[/<ZGK6K7=KXMUCQ;JE]J/B7Q)XCN==O[V6X]W_ .%=WG_10?'O_@YC
M_P#D6C_A7=Y_T4'Q[_X.8_\ Y%HLN_X>G^;^[S ^=O\ @G1^SCXW_9$_8@_9
ML_9J^).J^%=;\=?!WX<67A#Q-JW@>^U?4O"5]J=MJ&HW;SZ%?Z]H?AK6+JQ,
M=W&J2ZAH.EW!=7!ME4*S?:E>:?\ "N[S_HH/CW_P<Q__ "+1_P *[O/^B@^/
M?_!S'_\ (M%EW_#T_P W]WF!Z717FG_"N[S_ **#X]_\',?_ ,BT?\*[O/\
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M!>/XR\,0VNHMXBT'2SI6IBT^#?VG/V+_ (O>)/VF?C9XO^$/PNT^7X:^)_\
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M4Z(UL;<L]HMW<7<L1MHIY82RYDMU=?GY?TO/=AY/XJ_X* ?MD>/?&_QST_\
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M:"\":;X7^,FA>,/$?PT\2^=J=[X?\5Z9X"A$GBQ;36=/TV[TVTU72K@C2/\
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M/_TDEIQW7JOS N^%/^16\-?]@#1__3=;5OU@>%/^16\-?]@#1_\ TW6U;](
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M&-'^(.H^)+J]U"+1=*MM7EAGNT^OOA1^W_\ "_XK>./AG:6UQX"\'?";XX?
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MZ/;)LQL7:[9SQ7\W&L?L8>/](_8.'[>?CJYO+#1O'O[06@?"/X;Z=?+/)?\
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M HHHH **** "BBB@ HHHH *\T^+G_(C:C_U^Z-_Z=[.O2Z\T^+G_ "(VH_\
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M+M+^!=C<>%-#\%)\4)?&M]J<=I\,])\'/J6J0(G"_!7X:_#+XV?#[]HWX/\
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M>H?#77;OXYZY^P!^S1\5/"/@/P?^S)_PKR_1-2U'Q,G@+P1)\8M9\,_V>?\
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M2&-Y[;ST$<_V>5E,D/G1@)+Y;+YB *^5&*GHHH **** "BBB@ HHHH ****
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MD_\ AOO@E_\ 1#4?\14/_!/C_HCO[9/_ (;[X)?_ $0U+_43B_\ Z$&/_P#
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M ,$8#_YX^O\ 3T/^(.\1_P#0PR3_ ,'X[_YW^O\ 3T_S)Z*_TR;_ /X()?\
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M>?VFO_GST?\ $/Y_P2,_Z-*_\SS^TU_\^>C_ (C+PQ_T 9]_X2Y?_P#/0/\
MB#W$W_0=D7_A3F'_ ,[#_-)HK_2V_P"(?S_@D9_T:5_YGG]IK_Y\]'_$/Y_P
M2,_Z-*_\SS^TU_\ /GH_XC+PQ_T 9]_X2Y?_ //0/^(/<3?]!V1?^%.8?_.P
M_P TFBO])9_^#>/_ ().N[LO[.WB"-69F$:?'#XX%(P22$0R?$&20J@.U3)(
M[D ;G9LDM_XAX?\ @D]_T;SXB_\ #X?&[_YOZO\ XC'PM_T"9Y_X28+_ .>/
M]6?E>?\ B$'$_P#T%Y)_X58W_P"=W]6]+_YM=%?Z2G_$/#_P2>_Z-Y\1?^'P
M^-W_ ,W]'_$/#_P2>_Z-Y\1?^'P^-W_S?T?\1CX6_P"@3//_  DP7_SQ_JS\
MKK_B$'$__07DG_A5C/\ YW_U9^5_\VNBO])3_B'A_P""3W_1O/B+_P /A\;O
M_F_H_P"(>'_@D]_T;SXB_P##X?&[_P";^C_B,?"W_0)GG_A)@O\ YX_U9^5S
M_B$'$_\ T%Y)_P"%6,_^=_\ 5GY7_P VNBO])3_B'A_X)/?]&\^(O_#X?&[_
M .;^N?\ %?\ P;X?\$J-+\,Z]J5E^S[XABN['2;ZZMI&^-OQKD"3PV\DD;F.
M3QZR.%=0=KJRG&"".*%XQ<+O_F$SS7_J%P7E_P!3'^K/RN?\0@XG_P"@O)/_
M  JQG_SO_JS\K_YQ=%?Z/V@?\&]G_!*6_P!"T2^N?V?/$+W-YI&FW=PX^-OQ
ML0//<6<,TKA$\>JB!I'8A54*N<*  !4&N_\ !N5_P2NU>&"+3_A%X_\ "SPR
M-))<:%\9_B/<372LNT0SKXFUSQ%;K&A^=3;06TQ;AY63Y*:\8N%FTGALZBG]
MIX3"67KRYA*7W18GX0\4)-K$Y+)]EBL7=[;<V 2Z]6MGY7_SB**_T4?^(:S_
M ()A?]"M\9?_  [NK?\ ROH_XAK/^"87_0K?&7_P[NK?_*^M/^(O\*?\^\W_
M /".C_\ -?\ 5GY7C_B$?%7_ #\RG_PKK_\ S(?YUU%?Z*/_ !#6?\$PO^A6
M^,O_ (=W5O\ Y7T?\0UG_!,+_H5OC+_X=W5O_E?1_P 1?X4_Y]YO_P"$='_Y
MK_JS\KG_ !"/BK_GYE/_ (5U_P#YD/\ .P1WC=9(V9'1E='1BKHZD,K*RD%6
M4@%6!!! (.17^MU^Q]??$S4_V3/V8M2^-":JGQ>U#]G[X.WOQ/77HI[?7QX^
MNOA[X>G\6_\ "06]S'#/;>(/[<>^.N6TD:FWU7[7",J@)_//X*_\$"_^"9'P
M1\;:/\0--^">K^/?$7AW4K+6/#R?%/QYXG\8>']*U.PD,MO=2>$C>:?X6UX+
M)MD^R>*]'U^P26**>*UCGB20?LQ7YCXB<;99Q5#+</EN%Q,(8*=>K4Q.,ITJ
M=24JT:<52HQIU:S5.T.:HYRBY3C!*%H<TOTKP]X+S+A:>8XC,L3AYSQL*%*G
MAL)4JU*<8T95).K6E4I4DZEY<M-0C)1A*;<[SY8_S-_L%Z[^V<=:_P""O?@O
M]G#]G;]F'XL>$?$O_!6G]LBQU7Q7^T-^T-XW\ :;8>(-7\,_"'3-8\/ZW\)?
M"G[-WQ37QIX+C\/KI=U=W2_$/0+S6FU?5-%?0[6'2XK_ %GQ/X&?LW?MC?LN
M>/?$7_!*GX1?M.:_HOC/P?\ \$7?%O[0W@:]^'4EKX7\ Z5^V5XW_;M^*OC*
MWUWPGI]_HI72?"$M_?V/PHF631["'4/AQ'<SW'AW3=1U&YMXOZ:?@W^SU\'_
M -G^7XMS_"/PA_PB4OQU^-'C+]H7XJ-_;_BC7O\ A*?C!\0+/0=/\7>+]OB;
M6M970_[6L_#.B0_V!X<&D>%[#[%YFF:+92W-V]P)^SU\'T_:'N/VK5\(8^/M
MU\%[3]GJ?Q[_ &_XH._X/V/CB]^)%KX0_P"$6.M'P6OE>--1O-9_M]/#B^*'
M\[^SI-:?2HXK%/R\_3C^<_6_^"NWQ<_:+^&.N_M2?LU:AJECX:_8O_X)B>-_
MVD?VB?!FB6L-UX9N?VVOB]!JWPZ\ ?!CXC^'-8MK/Q)J'A#X 3?#+XV?$_6Q
MINH:?;WEO'X6U#4)YO(M8*^ECX2_:2_9I^+?[%EC/_P4(_:/_:<TC_@HGXH\
M:?"7XN^'O&!^"\)\,WFM_LU?$OXHV?[0O[*C^&O"&B6WP7T_X9ZAX1TB\_X1
M'38_&_@>YT76/M5QIVH>(#I$MW^KWPO_ &*OV6O@SHW[0WA[X<?!OPWH&A_M
M7>.O'?Q'_:$TF>ZUWQ!8_$SQ5\2[&73?&KZK;^)=6UB/3= UBQN;VW3P7X?&
MD>#-*74M5;1?#^G/JNHM=><_L_?\$W?V1?V9/&?A3Q_\*_ OC)O$_P ._!NM
M?#GX57/Q&^-OQO\ C)IWP>^'_B&XLKC6/!_PAT#XN?$3QKH'PSTB_P#[/MK6
MY?P=IFD:E/I8ET6?4)='GFL7 /YVOV&O'.K? ;_@B#^R%I^A_M/_ +4?@KQ3
M^T1^U/\ '+1-%\%?L^_"OP]\>/VF/&^A^&_C=\?X/%?P:_90T74-*M?#GPPU
M'Q!:^ S\2_%GQ.^(-CXNT/PQ>WOCF=393>*?#>FZ=P>I_'C]H+Q7^SG_ ,%5
M_P!F/XP>*/VFM:\#?LS_ !T_X(QZU\'M"_;1U'X2>)?VJ?!FF?'G]J#X5>*?
M$FC_ !:\8?!V[U'P_K4E_-X8T/7_  UI^J:C?>)?#^B:K#9Z_,NKS7L,7]%V
MG?\ !)[]AW1OA/!\$=&^''CO1OASHWQFM?V@O .D:3\?_P!H#3M1^#WQ?L9]
M>O+/QE\$O$UI\3HO$_P@N8-2\4^)M6?3OA_J^@Z->:GK^K7FH:==R7;U<\.?
M\$I?V$/"VE?$[2=-^#6MW*_&RX^&&H_&35=>^-?Q[\3>)?BKKOP:^+#_ !O^
M&_BOX@>*O$/Q/U/Q'XJ\9>&_B6[:S'XPU?4[GQ+J.DB/P5JVJ7_@:"#PU& ?
MHA7FGQ<_Y$;4?^OW1O\ T[V=>EUYK\7N/ &M2]X)M'F4=F(UK3TP?08<GCG(
M%..Z]5^8'I5%%%( HHHH **** "BBB@ HHHH **** "BBB@ K@/B)_R#-#_[
M''PM_P"G2*N_K@/B)_R#-#_[''PM_P"G2*G'=>J_,#OZ***0!1110 5\._\
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M>+O$'PGC^'-H/#RIX.\2FV\/W?AF[:[U.P2[1+G\Y/C7_P %!?VFKO\ 9O\
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M==OQ]/\ )_?Y 9/_  LZS_Z%+Q[_ .$U)_\ )-'_  LZS_Z%+Q[_ .$U)_\
M)-5O'GQU^"/PLU.TT7XG?&/X5?#G6;^P75+'2?'GQ"\(^$-3O=,>XN+1-1M+
M#Q!J^GW5S8/=6MU;+=PQ/;M<6UQ")#)#(JZ/@#XN_"?XKQZI+\+?B?\ #SXE
M1:&]I'K4O@#QKX;\8QZ1)J"W+6$>J/X=U/45T][U;.[:T6[,+7*VMR80X@E*
MFG;\7Y7_ %^_R K_ /"TM&3BZT/QA9,>52[\.W*,X[L@C>4%0>#D@Y[4?\+5
M\.?\^/B7_P $%[_\377:CXH\,Z1JVB:!JWB+0M+UWQ-+=0^'-%U'5]/LM6\0
M36-NUW>PZ)IUS<17FJRV=JCW-U'80W#V]NK33!(U+"#4_&7A#1=;T7PUK/BO
MPWI/B/Q(TB>'?#^IZ[I=AK>OO"KO,FBZ5=745_JC1)%(\BV,$Y18W9@ C$&G
MG]__  /7^EJ',?\ "U?#G_/CXE_\$%[_ /$T?\+5\.?\^/B7_P $%[_\374:
MQXQ\(^'M2T31=?\ %7AS0]8\2W:V'AS2=8US3-,U+Q!?MPMEHEA>W4%UJMVQ
M!VVUA%<3'LE='1IY_?\ \#U_I:AYI_PM7PY_SX^)?_!!>_\ Q-'_  M7PY_S
MX^)?_!!>_P#Q-=[JFJ:9H>F:CK6M:C8:/HVCV%WJFK:MJEW;Z?IFEZ9I]O)=
MW^HZC?W<D-K96%E:PRW-W=W,L5O;6\4DTTB1HS!FCZQI'B+2-*\0>']5TW7=
M!UW3;'6-$UO1[ZUU/2-8TC4[6*]TW5=*U*REGL]0TW4+.>&[L;ZTFFM;NUFB
MN+>62*1')IY_?_P/7^EJ'"_\+5\.?\^/B7_P07O_ ,31_P +5\.?\^/B7_P0
M7O\ \34OQ ^,/PC^$_\ 9/\ PM/XI?#GX:?V_P#;_P"PO^%@>-_#/@W^VO[*
M^Q?VG_9/_"1:GIO]I?V;_:6G?;_L?G?8_M]E]H\O[5!YE;P%\;?@Q\5;R_T_
MX7_%WX8?$B_TJVBO-4L? 7C[PIXPO--M)I3!#=7]MX>U;49K.VEF!ABGN$CB
MDE!C1B_%'R?]6\OZNOF$G_"U?#G_ #X^)?\ P07O_P 31_PM7PY_SX^)?_!!
M>_\ Q->ET4:>?W_\#U_I:AYI_P +5\.?\^/B7_P07O\ \31_PM7PY_SX^)?_
M  07O_Q->EU4OK^QTRUN+[4KVTT^RM;>XNKJ\OKF&TM;:UM()+FZN;BXG>.*
M&WMK:*6XN)I'6.&"*261EC1F!IY_?_P/7^EJ'G__  M7PY_SX^)?_!!>_P#Q
M-'_"U?#G_/CXE_\ !!>__$UW6CZQI'B+2-*\0>']5TW7=!UW3;'6-$UO1[ZU
MU/2-8TC4[6*]TW5=*U*REGL]0TW4+.>&[L;ZTFFM;NUFBN+>62*1'.C1IY_?
M_P #U_I:AYI_PM7PY_SX^)?_  07O_Q-'_"V?""<73ZQ9,>52[T/4D9QW9!'
M;R@J#P<D'/:O2ZX_0?B'X \5:QK7A[POXY\'^)-?\-RM!XBT/0?$VBZQK&@S
MH8E>'6M,TZ]N+W2Y4,\ :.^@@=3-$" 9$R:=G]__  /7^MPQ/^%N>!O^@C>_
M^";5O_D.C_A;G@;_ *"-[_X)M6_^0ZKW/QS^"=GXX_X5C=_&'X66OQ)^V6FG
M_P#"O;GX@^$H/''V^_MX+NQL?^$3EU==>^V7EK=6MS:6W]G^=<6]S!-"CQS1
MLW<:YXF\-^&(K.?Q+X@T3P]!J-_;Z7I\VN:M8:3%?:G=L5M-.LY+^XMTN;^Z
M8%;>S@+W$S B.-CQ1IV?WK_(#C_^%N>!O^@C>_\ @FU;_P"0Z/\ A;G@;_H(
MWO\ X)M6_P#D.NTUWQ!H/A?3+G6_$NMZ1X=T:S"&\U?7=2L](TRU$DBQ1FYO
M]0FM[2 22ND:&65-\C*BY9@#I0S0W,,5Q;S17%O<11S03PR)+#-#*@DBFBEC
M+))%(C*\<B,R.C!E)!!HT[/[U_D!YS_PMSP-_P!!&]_\$VK?_(='_"W/ W_0
M1O?_  3:M_\ (=>ET4:=G]Z_R \T_P"%N>!O^@C>_P#@FU;_ .0Z/^%N>!O^
M@C>_^";5O_D.O2Z*-.S^]?Y >:?\+<\#?]!&]_\ !-JW_P AT?\ "W/ W_01
MO?\ P3:M_P#(=>ET4:=G]Z_R \T_X6YX&_Z"-[_X)M6_^0Z/^%N>!O\ H(WO
M_@FU;_Y#KTNBC3L_O7^0'FG_  MSP-_T$;W_ ,$VK?\ R'1_PMSP-_T$;W_P
M3:M_\AUZ711IV?WK_(#Y]^''Q'\':!X,T;2M7U9K*^M?[1\V)M.U2=<3ZK?7
M,92:ULIX7!BFC)VR$JQ*, RD#N/^%O\ P[_Z&'_RDZY_\K*/A!_R3OP]_P!Q
M;_T^:G7I5-VN]'N^J[^@'FO_  M_X=_]##_Y2=<_^5E'_"W_ (=_]##_ .4G
M7/\ Y65Z512T[/[U_D!YK_PM_P"'?_0P_P#E)US_ .5E'_"W_AW_ -##_P"4
MG7/_ )65Z511IV?WK_(#S7_A;_P[_P"AA_\ *3KG_P K*/\ A;_P[_Z&'_RD
MZY_\K*]*HHT[/[U_D!YK_P +?^'?_0P_^4G7/_E91_PM_P"'?_0P_P#E)US_
M .5E>E44:=G]Z_R \U_X6_\ #O\ Z&'_ ,I.N?\ RLH_X6_\._\ H8?_ "DZ
MY_\ *RO2J*-.S^]?Y >:_P#"W_AW_P!##_Y2=<_^5E4=4^+/P_N-,U&WAU_?
M-/8W<,2?V5K:[Y);>1(UW/IJJNYF RS!1G)(&37K%9FM?\@;5O\ L&7_ /Z2
MRT:=G]Z_R \>\$?$WP1H_A/0M,U'6_L]]9V*PW,']FZO-Y<@DD8KYD%A+"_#
M YCD9>>N<UUJ?%OX>."1XB08X^?3=8C/X!]/4GZC(J_\-?\ D1/#/_8-3_T;
M+7:/%%(09(HY". 716('H-P./PHT[/[U_D!Y_P#\+8^'W_0QP_\ @#JO_P @
MT?\ "V/A]_T,</\ X ZK_P#(-=[]EMO^?>#_ +\Q_P#Q-'V6V_Y]X/\ OS'_
M /$T:=G]Z_R X+_A;'P^_P"ACA_\ =5_^0:/^%L?#[_H8X?_  !U7_Y!KO?L
MMM_S[P?]^8__ (FC[+;?\^\'_?F/_P")HT[/[U_D!P7_  MCX??]#'#_ . .
MJ_\ R#1_PMCX??\ 0QP_^ .J_P#R#7>_9;;_ )]X/^_,?_Q-'V6V_P"?>#_O
MS'_\31IV?WK_ " X+_A;'P^_Z&.'_P  =5_^0:/^%L?#[_H8X?\ P!U7_P"0
M:[W[+;?\^\'_ 'YC_P#B:/LMM_S[P?\ ?F/_ .)HT[/[U_D!P7_"V/A]_P!#
M'#_X ZK_ /(-'_"V/A]_T,</_@#JO_R#7>_9;;_GW@_[\Q__ !-'V6V_Y]X/
M^_,?_P 31IV?WK_(#@O^%L?#[_H8X?\ P!U7_P"0:X7XC_$+P=K?A.]T[2]:
MBN[V6ZTR2.!;6_C+)!J-K/,V^:TCC&R*-W(+@D+A06(!]W^RVW_/O!_WYC_^
M)KS;XM00)X(U!DAB1OMNCC<L:*<'5K,$9 !Y'!]::M=:/==5W] +G_"V/A]_
MT,</_@#JO_R#1_PMCX??]#'#_P" .J__ "#7>_9;;_GW@_[\Q_\ Q-'V6V_Y
M]X/^_,?_ ,32T[/[U_D!Q,7Q0\ S E/$MDH4X/FQ7D!YYX$]M&6'NH('0G-2
M_P#"RO G_0S:;_WW+_\ &JZJ73--G(,^GV,Q484RVEO(5!Y(!>-B 3S@5%_8
MNC?] G3/_ "U_P#C5&G9_?\ \#U_I:AS7_"RO G_ $,VF_\ ?<O_ ,:H_P"%
ME>!/^AFTW_ON7_XU72_V+HW_ $"=,_\  "U_^-4?V+HW_0)TS_P M?\ XU1I
MY_?_ ,#U_I:AS7_"RO G_0S:;_WW+_\ &J/^%E>!/^AFTW_ON7_XU72_V+HW
M_0)TS_P M?\ XU1_8NC?] G3/_ "U_\ C5&GG]__  /7^EJ'-?\ "RO G_0S
M:;_WW+_\:H_X65X$_P"AFTW_ +[E_P#C5=+_ &+HW_0)TS_P M?_ (U1_8NC
M?] G3/\ P M?_C5&GG]__ ]?Z6H<U_PLKP)_T,VF_P#?<O\ \:H_X65X$_Z&
M;3?^^Y?_ (U72_V+HW_0)TS_ , +7_XU1_8NC?\ 0)TS_P  +7_XU1IY_?\
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M/_CM7?\ A%/"W_0M:!_X)]._^1J/^$4\+?\ 0M:!_P""?3O_ )&HT\_P\O\
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MP?\ ]"GX:_\ !%I?_P BT?\ "&>#_P#H4_#7_@BTO_Y%HT\_P\O^#^'F ?\
M"9^#_P#H;/#7_@]TO_Y*H_X3/P?_ -#9X:_\'NE__)5'_"&>#_\ H4_#7_@B
MTO\ ^1:/^$,\'_\ 0I^&O_!%I?\ \BT:>?X>7_!_#S /^$S\'_\ 0V>&O_![
MI?\ \E5Q'CSQ1X9O-.T9+3Q%H5T\7BOPY<RI;:OI\[1V\&HQO//(L5PQ2&%
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MRZ!_X.-._P#DFC_A*_"W_0RZ!_X.-._^2:I?\('X+_Z%70?_  66G_QJC_A
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MHW_06TS_ ,#[7_X[1_;6C?\ 06TS_P #[7_X[7-?\*U\"?\ 0LZ;_P!\2_\
MQVC_ (5KX$_Z%G3?^^)?_CM&GG]W_!]?Z>@>1_&W]FC]D3]I1M,E_:&^!7[/
MGQPN=$@^RZ'??%?X=_#_ ,?:EHEJ;@W;VVBZEXGTK4K_ $FVFN&>2X@T^YMH
MKCS9DG21)I5?J=&^#_[.7ASX5W/P+\/?"WX)Z%\$KS2]1T2[^#NC>"/ NE_"
MNZT76&E;5M(N?A[8Z9!X2GTO5&FF;4=/ETAK2]::4W,,ID<GL_\ A6O@3_H6
M=-_[XE_^.TC?#;P( 3_PC.F\ G[DIZ#T$N3^%&GG]W_!]?Z>@>)?#O\ 9/\
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MCU&"V:M?LEK;]-^OS^ZX'$^-/VSOVP]6U#XG>/OA0NKW'A+X,?&W4_@=X(\
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M9P,^E=%2 **** "BBB@ HHHH **** "BBB@ HHHH *\U^+__ "3OQ#_W"?\
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MK?*_F?Z%?@S_ (./O^"9NB>%]%TF_P#%'QA6\L;-8+@1?"759(Q('=B%<:@
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M8K W_'+6OPZ^EFO&#B=/7!Y(_)X7&V_#,4_/?\#_ $MO^(@/_@D9_P!':_\
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MS3XN?\B-J/\ U^Z-_P"G>SKTNO-/BY_R(VH_]?NC?^G>SIQW7JOS ]+HHHI
M%%%% !1110 4444 %%%% !1110 5S7C/_D3_ !9_V+6N_P#IKNJZ6N:\9_\
M(G^+/^Q:UW_TUW5..Z]5^8!X,_Y$_P )_P#8M:%_Z:[6NEKFO!G_ ")_A/\
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M_P#D6C_A7=Y_T4'Q[_X.8_\ Y%IV7?\ #T_S?W>8'I=%>:?\*[O/^B@^/?\
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M3+#O$*RR!0\BQ"201!V(CWOL W-GSG_A!O$?_12/$O\ WYLO_B:/^$&\1_\
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M>16JP2-+J-M&CL8U#[H782I@X+HH/&:%NM>J[]UY?U;TN'T'17FG_"#>(_\
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MQS_T4Z]_\)K2?_CM'_"(^.?^BG7O_A-:3_\ ':++NOQ_R ]+HKS3_A$?'/\
MT4Z]_P#":TG_ ..T?\(CXY_Z*=>_^$UI/_QVBR[K\?\ (#TNBO-/^$1\<_\
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M^TP?@3KVB:!HW@NV_9SN_P!H/5_C+K'Q*\*Z3IFC65EXRO\ PO=:+J'A"_\
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M:C_U^Z-_Z=[.O2Z\T^+G_(C:C_U^Z-_Z=[.G'=>J_,#TNBBBD 4444 %%%%
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MKTNO-/BK_P BY8_]C+H'_I:M..Z]5^8'I=%%%( HHHH **** "BBB@ HHHH
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M,)=!?P]&GBF?0]3\3:DNM+X#\%Z5?&37H+<LM+>5]5VN_2WS\[ ?LIXB^/\
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M[?2[RUO(I88_^$8B6.[LH;=[]]9F:1[*'^BR"3S8U?:R%TC<HXPZ;E!VN 2
MX.0PR<'(R>I^9XHX+XCX-J9?2XBP'U"IF>$CC<+!UJ-6;I-152G5C2J3E1KT
M9R4*U*HE*$_=UU9]EP7XA\)>(5#-,3PEFBS2AD^83RW&U8X?$4:<:\4W"=&=
M>E3AB,/7@G4H5Z+G"=.SNF[$]%%%?+'VH4444 %%%% !7B7[2'Q)USX/_ SX
MF?$KPSI<6L:_X2\-7&HZ597,$ES9B\>XM[..]O[>&XM)9M-TO[4=4U&.*Y@D
M:QL[@)(K8KVVOF3XX:!^T'K5[KT/P_U[X-67PRO/A7KVEZKI7Q.LKV\6?QC=
M37R/=:W%_P ([J^ES^!6\/R);:Q;7<\GFC[6LVG2V[%V]KAZAAJ^<Y?]<G@5
MA*.*P^)Q-+,:]7#X;%T*%>G.M@I5:5&O.,L534J,6J;^)NZL?-\78G&X;AW-
MO[.IYG+'XG XO!X*OE&&HXO&8#%8G#5J6'S*-"OB,-2G# UG#$3YJJ^!*SN[
M?F!X2_:0^,,OQNT;Q;IWC[X5W7AK2_B[\&/V?]5T_0/!WA1%^->K>*+*QTSX
MM^+O"_B;3]%L_$5Y;6FO:?#XDLI%EM],L;#Q)X>40P*!IFL_NU7X@?"[P[XY
MT'QM\*M#;XT?\$TGT?PG\1[+6+#PMX1\1:4_B6/5-?U32+37I_"NF-X;B,WC
MK5+"SM=,T*[E8:A;W-OI=I875G%;VXB_;^OO_%:&70Q>21R_"9?AJ=/ 5:"G
M@**H^VH4)4:6'>(4<!@55KS49XNK5E[>:K8RMAX5/JV'PZ?Y+X"U,XJ9?Q/4
MS?'YOC*M;-:&*=/-<1+$K#XK%TZ]?%QP;EFF9^PPM.4Z6 HX>"PM-X?+\/BY
MT?KF+Q;11117Y,?OQS7C#P7X.^(?AO5/!OC_ ,)^&O'/A#7(H8-:\*>,-"TO
MQ-X;UB&WNH+ZWAU30M:M;W2]0B@O;6VO(8[NUF2*ZMX+A LL,;KB_$CX4?##
MXQ>'4\(_%CX>>"OB5X7BU"VU>#P_XZ\,:-XITBVU:RBN+>SU6UL-:L[RWM=4
MM(+R[@M=0MXXKRWAN[F*&9([B57[^B@#RKPE\"?@AX!?2I/ OP;^%7@N30=4
MN=<T.3PE\//"/AQ]&UJ]\,P>"KS6-*?1]'LVT[5+OP;:VOA*YU"S,-W/X9MH
M-!EF?2H8[1?@WXV?\$Z=8_:(^(NLW?Q?^)GPP\;?";6/B!IWBZ.SUK]F_P +
M77[0F@^!].US1/$P^ GAK]H9O%0OM(^%%WX@TF[N;OR?!;>)Y=!U_7?"#ZM)
MI-W!+:?J/11>W]?U]X'C_B?]GSX#>-?'VB_%3QC\%_A7XJ^)GAP:>-!\?^(O
M 'A;6O&.CG2+EKS1VT[Q'J.EW&K6LFCW<DMUH\D5TLFE7,T\^GM;2S2N[?'O
M[/'P#^*FOIXJ^)WP4^%'Q%\21^'F\(C7/'/P^\*>*]3?PJU[/J0\-S7>NZ5?
MRW&A1ZC=7=_#I4[26,%[=W=U!!'/=7$DGL5% 'FUQ\&OA!=Z#XR\*W7PJ^&U
MSX8^(WB*X\8?$+PY<>!O#$V@^._%MU+ID]UXH\9:/)I;:?XH\17,^B:--<:W
MK=O?:G-+I&F2273/86K1? /QL_X)TZQ^T1\1=9N_B_\ $SX8>-OA-K'Q T[Q
M='9ZU^S?X6NOVA-!\#Z=KFB>)A\!/#7[0S>*A?:1\*+OQ!I-W<W?D^"V\3RZ
M#K^N^$'U:32;N"6T_4>BB]OZ_K[P(YH8KB*6">*.>">-X9H9D62*:*12DD4L
M;ADDCD1BCHZE74E6!!(KQOX;_LX?L^?!W5]2\0?"7X&_"/X9:[K$+6VIZSX!
M^'7A'PCJE[:/()VL9K_0=(L+IK SC[1]@$HL_M+/<"#SI'=O:** /FX_L;?L
M@G76\4G]E3]FX^)FU9M>;Q&?@;\,#KK:X]V=0;66U<^%_P"T#JS7Y-ZVHFX-
MXUV3<F8S$O73?$7]FO\ 9S^,&N6_B?XM? 'X*?%'Q+::9!HEKXA^(OPK\"^-
MM<MM&M;F\O;72+?5O$N@ZG?PZ9;7FHZA=P6$=PMK#<WUY/'$LMS.[^UT4 >/
M^+/V>_@/X[\!>'_A9XR^#'PM\3_#3PD^FR>$_ &M> _#%_X/\*R:/9SZ=I3^
M&?#L^F/I7A]]-TVZNM-LFTBULVMM.N[JPA*6ES/#)Z'X9\+^&O!7A_2/"?@W
MP[H7A+PMH%E#IF@^&O#.D:?H/A_1--MQMM]/TC1M*M[33M-LH%^6&TL[:&"(
M<)&HK=HH **** "BBB@ HHHH ***\LN?BQHEC\:=(^"%_IFLV>O^)/AIKGQ-
M\,:[-%9#PWK^G^$_$NB>&O&.A6-PMZ;\>(?#,OBSP=J=]:3Z?%;3Z5XFM+BQ
MN[E[+4XK, ]3HKY0\)?MI_L]Z[\/]/\ BCXK^(O@WX1^!O$_C_X@^ _AUKWQ
M8\<>"/!5I\35^'GB[4/!E]XH\$OJ?B)!J?A_6-2TRYO=$9C#J<VB266K7FG6
M5M?6Y;L];_:9^"NGZ_-X-T3XE_#7Q?X]T_Q5X%\,:_X T/XJ_"ZV\8>&AXZ\
M=>&O -IJNM:)K_C'1KJV@L=6\5:4!I$:S>)O$%W<V/AWPAHGB'Q9K.A:#J8!
M[Y17E>G_ !T^"6K:!XM\5Z5\8OA9J7A?P#?S:5XZ\26'Q!\)WF@>"]4MWBCG
MT[Q7K-OJ\FG>';Z"2>&.:TU>YLYXI)8XWC5W4&MXZ_: ^ _PO;4X_B5\:_A-
M\/I-$NM!L=:C\;?$7PAX6DTB\\4V^HWGAFVU2/7-8L7T^?Q!9Z/K%[HT=VL+
M:E9:3JEW9B:VTZ\EA /7:*\6^,_QS\*_!CX377Q>O;'5_&VB/>>!])\.Z9X'
M;1M0O_%VL_$KQ7X>\%>!;#1=0U35]'\,Q6VO^(O%.AVT>MZOKVFZ%:VEW]ON
M=1CMU!?G?A_^T5INO>'O'FK?%KP'XQ_9JO\ X7?V7)X^MOC5-X5TOPMINGZQ
M9&]T_7]$^*?A_P 1Z_\ "[Q3X=E5)[:ZOM(\6R7VAWT!L?$^E:%=W%E#= 'T
M717RMXJ_:[^&&@:O?:9HLT'C:QA_9T\6_M+Z7XNT#Q?\.;#P!KG@?PCK^C>'
MKBUM/'_BGQCX?\&Z?<ZA=:W:W-KK>NZWI7@ZUT^.YO-6\2:=#$6*ZM^V/\#K
M+]HKX:_LP:)XNT3QM\4OB!=?$>QU/2?!GBCPCKUQ\,KWX:^%QXJU"T^)ND6F
MOMXA\+W.M6B75GH,$^CRR75_I]_%.MM':RRJ ?5%%?$GC#]KSQMX4^-EC\#+
M?]D3XZ^)/$NOZ;XU\2>#M5T?QC^S5;:'XO\ !'@#7/#.@^(?&>GR:[\=M(O]
M+TV&Z\9>&);?2/$UAH?BJY@U53#H#R66I1V?U!8_%/X8ZG%X;FTWXC> ]0A\
M97?B2P\(2V/B_P /W<7BJ^\&KJ3^+[/PW)!J$B:Y=^%4T;5V\26^EFZFT-=*
MU)M42U%C=&( [NBOFS3?VS/V0=8N%M-)_:I_9QU.Z?5K#0HK>P^-WPUNY9M:
MU5)7TO2H$@\3.T^H:B(+A;&TA#S7<MM<PP))+;3I'ZC8?%SX4ZIK?C/PUIGQ
M-^'VH^(_AQ;F[^(6@6/C/PY=ZUX$M1%-.USXRTNWU*2]\,0+!;SS-+K<%C&L
M,,DK,$1F !Z%4%U_Q[7'_7";_P!%M7@GAS]K7]E;QCX@T/PEX1_:6^ /BGQ3
MXFNIK#PYX<\.?&+X>:YKFOWT#;9;'1M*TSQ%=7VIWJ'=_HEE!-<,J2,L96.0
MK[W=?\>UQ_UPF_\ 1;4 <%\)_P#DGWAS_KC??^G6^KT2OQP_:)_X*$:G^SII
MGA7X5_#+PUH/B#QS'HBZSXBUOQ-)>W.B>'(M3U35);+1DT73+K3+V^UJYT\6
M^K-<RZK:V-A9WFG_ .BZI)>3II_Q!_P]._:S_P"@QX'_ /"*LO\ Y(K]>X>\
M$N.>)<KPV<X2CEN#P6.@J^#>8XV5&MB,/._L\1&C0H8F4*51+FINM[*=2#C4
MC!TYPG+^?.,/I,^%_!>?8[AS'XG.<PS++*TL-F*RC+(XG#X3%TVE5PD\1B<5
M@X5:]%OEK+#^VITJD9T9U(UJ<Z<?Z;J*_F1_X>G?M9_]!CP/_P"$59?_ "11
M_P /3OVL_P#H,>!__"*LO_DBO;_XET\0/^?W#W_AQQ/_ ,[SY?\ XG$\)O\
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M\#_^$59?_)%'_$NGB!_S^X>_\..)_P#G>'_$XGA-_P! W%__ (9L%_\ /?\
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MV+^UMXI_;2TE(O@?\5-'^.5UILW[,GQ4^/O[5O[3=AHW[+_A1_ACX"\,>(_
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M?!_XE^.O&OPUGT328+GQ)\.?#.O_  ODUGQ7I.F:MJNM:O)>VVH>#N#\$?\
M!-OXHZ;^Q_XI_9ZU_P 7> =%\=>,OC[^S_\ $?4_'?@O5O$4DVF>$/AG#^SM
M:^*7TK7+[P;I6L2>,((OA+XEN_!MO-IT.ESWTWAM]1U71A<ZB^E?LE]JMO\
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M:4_Z-Z^./_AIO'O_ ,H*_L7HH_XF9SW_ *)C*?\ PLQG^0?\23\+?]%OG_\
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M\3,Y[_T3&4_^%F,_R#_B2?A;_HM\_P#_  WY=_\ )'\>EM^S9^T7>P175G\
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M^TI_T;U\<?\ PTWCW_Y05_8O11_Q,SGO_1,93_X68S_(/^))^%O^BWS_ /\
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M1110 4444 %%%% !1110 4444 %%%% ')^//^1+\5?\ 8!U/_P!)):N^%/\
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MJ$/A2U^S:YXHNTET_3I+6WT[7M4T5IR>S>OFP/J;_A4_P^_Z%R'_ ,#M5_\
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MU;_Y,KTNBB[[O[V!YI_PJ/P-_P! Z]_\'.K?_)E'_"H_ W_0.O?_  <ZM_\
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M<_Y_O$O_ (/[W_XJO2Z*+ON_Z_X9?<!YI_PJKPY_S_>)?_!_>_\ Q5</\1?
M&BZ)X5O=0M+O7))XKK3(U2\U>ZNH"L^HVT+EH9#L9@CDH3RCA7'(%?0=>:?%
MS_D1M1_Z_=&_].]G0F[K7JOS7^2^X _X55X<_P"?[Q+_ .#^]_\ BJ/^%5>'
M/^?[Q+_X/[W_ .*KTNBB[[O^O^&7W >:?\*J\.?\_P!XE_\ !_>__%4?\*J\
M.?\ /]XE_P#!_>__ !5>ET47?=_U_P ,ON \T_X55X<_Y_O$O_@_O?\ XJC_
M (55X<_Y_O$O_@_O?_BJ]+HHN^[_ *_X9?<!YI_PJKPY_P _WB7_ ,'][_\
M%4?\*J\.?\_WB7_P?WO_ ,57I=%%WW?]?\,ON \T_P"%5>'/^?[Q+_X/[W_X
MJC_A5FAIS;ZQXMM).@FMO$-TLH'=0761=K=_ESZ$5Z711=]_ZT_R7W >:?\
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MUD+E&$IG=5570Q,7#Q_SO?\ !*+X/?\ !1WX1?&[Q)X,\;+K/A;X!^"M3NM
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MCAFBEDM95M[I(Y$=[:=H(;I8;A58M#*UM<V]PL<@5S!/#,%\N5&;^7CX@_\
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M\&? +XJ_#OQ]\=?V:?!O[)_QMDTSXP2?$_0]=\/>)_A+X$U^_P!+LO"5K?\
MPRM=:\"W/B?PUX,^(R1:YK<?B>QU;2I/"]]%^W= !1110!R?CS_D2_%7_8!U
M/_TDEJ[X4_Y%;PU_V -'_P#3=;52\>?\B7XJ_P"P#J?_ *22U=\*?\BMX:_[
M &C_ /INMJ?1>K_*(&_1112 *;O7GG[N<\'C')[=A3J^$?VX_P!LSP_^R=X&
MA:SAM]<^*'BQ+N#P5X;E;]Q$D&([OQ)K@C97CT;379$6$,DVIWK):0,D:7ES
M:^'Q'Q'D_">29AQ#GV,IX#*LLH.OBL1-.3UE&%*C2IQ3G6Q&(JSA0P]"FG4K
M5JD*<$W)'T/"O"V>\:\097POPU@*N99UF^)6&P>%I62;Y93JUJU235.AAL-1
MA/$8K$U7&E0P].I5J248MGJO[6W[2OAK]E;X&^,_BYK6EZAXKU/1K P>$/ F
MA1_:/$/CGQ;>L+;0O#FE6X!<"[OI(WU._*-#I.DQ7NI3JT=L8W_AP_9M_9#^
M.G_!0K_@H!_PN?\ ;T^T>"/A]XB\23?$GXH:KXOOET2#Q!HVD7-G%H?PC\(0
MBX-S96MQ;C3?#MM CVS:/X0T_4+J.Z;4+>U%SZ[XL_;J\??&_P"/>@_#W2(_
M%'[1_P"T'\2_%=KX9\.^%K35%LO#&C:A>RF*UT];E_,T[1M*T]/.N;NWTFT%
MIINFVU]?ZM?6FR6XE_J[^'W_  3[\":-X0T"U\6Z[JEYXSCT731XDOM"ECM]
M#?75M8CJIT>VN[9[M=,-\9A8"[D-S]F\LSXE+ <'"_BQ](+A_(J^=\)^#N3<
M-8+C'!5O["SKQ S:M@.*\5DJY8T<;E^386O"OD]#$SDL1A\1CL+5HXN?U>OA
M\1B:-",X_8<:>$W@10S.GD7$WB[FG%7$'"^-C#.\JX RZAB^%,!G$(QE6P&.
MS;&4*M/-Z^#DI4*U/"8G#U:"=6CBL+A:M2<%_GZ_M6:'8>'_ /@IG\:],T72
M;?1?#D7[9/BX^%;&QLUL-*3PN?C%>KX??1((XXK?^Q6TQ+8:7):J;5K-8O(8
MH!7^HK$ZE(P#GY%Z!O3'ITX[U_"[\9_VQ_V7M=_:P^*/[+?[07P/6X7X5?M"
M^+_AOX#^*-E#;:OJ$&J>"OB%=^'O#6KW36D%CXDT*YO9=,LGO[C1KK4+:5I9
M+6YT\Z=)< ?UU>$?VIM%L;M?#'Q@TF\^'7BFU\N&6XU"WF&A7S#:KSPW(0O9
MH7 ;,XDM6SB.\D;,:_8^(GCIG&,EP%PQXP^'&?\ @[Q#A,JQ%'+<SSG&X#/.
M ^+J%:AE3HXGA_C?+*DLNCC9QHRJXK),XCE^98-5:$6L3*LFOR;@[PRP%&MQ
M9F?AUQ7@?$/*J^80K8K!X#!XC+N)\DG3J8MU:.9\/8F^*G0IRK>SI8_ ?6<-
M6=*M)JA&G)+WSXH_#;PK\6O OB+P!XRTR#5=!\1:?/97$,RJ7MI7C86NH6<G
M$EO?:?<^5>6=Q"R2PW$*.C ;@?XC/B_\);W6=4\0?"J-HI-=TGQU_P (WIUT
MZXV:SI'B4Z+YL:J6*)<+'=6TH&<VMW(GS%RM?V]7_P 1_ ]GX:U/Q;)XJT%_
M#^CZ9>:QJ.IVVJV5S;6NGV-K+=W,\DD,[*-EO%(P0L&) 3&X[:_C%^*/Q2MO
M#_C/QK\;;RQ:2(^/-0\9Z;HUS)]EO)K[6O%;WVB6URD3"6W,LUW$J)&S33B&
M:[B22RM;NXB_H7P%XYPO#64<95<5F,*F%QL<KP_#>5T:U&MB\]XKQBQE+ Y7
MD&#E5A]>S+'QA1C4IT)*%.A1IXK&U*&#PT\12_C+Z6OAIB^-N)?"N&6Y1*.8
MY9CLXQG%V>5L/6P^"X:X$RZ>5U\USGBG,H4I?V9DN63J572J8I\U7$XJM@<N
MHXG,,93PF(_LE^#WPM\)_!;X9>"?A=X&TN#2_"_@CP]IF@Z5;0H%>5+*V2*>
M_O'+![C4M2N?/U#4;N4M/=7US/<3.\DA8>GUQ7P_\<^'/B-X'\(^/?"-_#JO
MAGQEX;T?Q-H.H6\BO'=:7K-A#J%G+E2Q5_)F5)4/SQ3*\4@$B.H[1F"@L>U?
MSYC)8J>,Q<\=*M+&SQ->>,EB')UWBI5)/$.NY^_[5U7)U.?WN:]S^RL!3P5+
M X.GET:$,OAA,/# QPJ@L-'!QHPCA8X=4_<5"-!05)0M!0MRJPM%1K(&SC''
MOWX]NV03['O3P<YXQ@X_0?U_SVKFO?\ K^OZOV9UBT444P"BBB@ HHHH *^(
M_P!H+]DWQQ\7/B_X8^,GP]^/FI?!?Q'X9\"OX'BDTKP1'XEN[BTFU?5]4NKA
M;^7Q;H*V\=RFJ+:O:?89R!;"47)\WRX_MRO#OVE?#/C/QC\"/B=X9^'<6JS>
M.=7\,SVWA6/1=?MO"^I'6EN+::S-OKMY=6-M8*DD0>X,U[9I<VJS6GVJ W E
M3Z'A?,\=EF=8.> Q^%RRIC)QRROC<=A,!CL%0P>83AAL5/%X;,Z5;!3P\:4Y
M3K>V@HJG&3<X*\E\EQQDV69WPUF-+-<JQV=4LNI2SK"Y;EF89KEF98G,<HA/
M&X"G@,9DM?#YE2Q<\12A3P_U:<IRJSBE2JNT'\6_"3]@#XQ_"&_\&V^@_MH^
M.X_ _A3Q)IVN3?#[3?"&KZ+X>U>RAUN/6=8T62V@^*=S96MOK[?:X+Z4Z==H
MQO9YIK6Y+/')^H=?FQ\*?B]^WFNH>"O _BO]G+P1=V6B3^$_#WCSQ4/C+X)U
M?Q%8Z9$VGV&M^)]3TR#QYJ>I3:J;'[1J\EO(EU=7MRQ5%N))E#_I/7M\?8GB
M+%9AAZG$6;</YQB9+$3HXK(:O#=95(5*L9SK8R7#M.FO:XAN-6F\??$2BVXO
MEYCY?PHP?!^"RC%T>#L@XMX>P<98.GB,!Q50XSH2I5*-"5.GA\NCQA5JR^KX
M.*EAZL<K<<)"<(QFN90"BBBO@S]5"BBB@ HHHH **** "BBB@ HHHH ****
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MU*)K886K?L@_VIXUO/&'_"P_(^U_MI>%/VOO[._X1+S?+_X1C]G_ ,,? O\
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M\OZN_*Q_Q-'XX?\ 184?_$;X7_\ G-_5WY6_=?\ X?*:-_T;]J?_ (<JU_\
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MZ(WXX_\ !]H/_P ;K\ Z*/\ B WAI_T)\7_X=\S_ /FH/^)J_&K_ **++_\
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MP>+PD,5-1GF5"KAI17+E\.;%XJ-:G5I/!TL1I3GRU8?U5T445_'1_HJ%%%%
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MMI]Y;>&M/T_2;7ZXHHH **** .3\>?\ (E^*O^P#J?\ Z22U=\*?\BMX:_[
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M1_P@?@O_ *%70?\ P66G_P :HT\_P\O^#^'F!=_X2OPM_P!#+H'_ (.-._\
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M9TW_ +XE_P#CM&GG]W_!]?Z>@=+_ &UHW_06TS_P/M?_ ([1_;6C?]!;3/\
MP/M?_CM<U_PK7P)_T+.F_P#?$O\ \=H_X5KX$_Z%G3?^^)?_ ([1IY_=_P '
MU_IZ!TO]M:-_T%M,_P# ^U_^.T?VUHW_ $%M,_\  ^U_^.US7_"M? G_ $+.
MF_\ ?$O_ ,=H_P"%:^!/^A9TW_OB7_X[1IY_=_P?7^GH'2_VUHW_ $%M,_\
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M_P#QVK_UCXA_Z'V=?^'3'>7_ %$>7X+Y9_ZF\(?]$KPW_P"&/*__ )E/(/\
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M\#O_  C_  A_\B5V7@/P'X/U+PAH%_?Z!875Y=6"RW%Q*LADED,D@+,1(!G
M X Z5UO_  K7P)_T+.F_]\2__':/]8^(?^A_G7_ASQWE_P!1'E^"^1_J;PA_
MT2O#?_ACRO\ ^93R#_AF;]DC_HBWP._\(_PA_P#(E'_#,W[)'_1%O@=_X1_A
M#_Y$KU__ (5KX$_Z%G3?^^)?_CM'_"M? G_0LZ;_ -\2_P#QVC_6/B'_ *'V
M=?\ ATQWE_U$>7X+Y'^IO"'_ $2O#?\ X8\K_P#F4\A'[,O[))( ^"OP/))
M '@_PB22>  !:9))X '6K?\ PRM^RQ_T0CX-?^$-X7_^0:]2/PT\"$$'PSIV
M""#A9@>>.")00?0@@CJ"#53_ (5/\/O^A<A_\#M5_P#DZC_6/B#_ *'^=?\
MASQOE_U$>7X(/]3>$/\ HE>&_P#PQY7_ /,IY'J/['G[)FJ/')<_ WX7Q-$I
M11IVB6>D(0QW$R1Z2]E',V>CS*[J/E5@O%9W_#%/[(?_ $1+P!_W[NO_ )85
M[;_PJ?X??]"Y#_X':K_\G4?\*G^'W_0N0_\ @=JO_P G5M'BOBB$5&'$W$$(
MK:,<WS",5K?1+%)+771;G//@+@6I)SJ<%\)U)RLY3GPYD\I2:22;E+!MNR22
MN]DET1XE_P ,4_LA_P#1$O '_?NZ_P#EA1_PQ3^R'_T1+P!_W[NO_EA7MO\
MPJ?X??\ 0N0_^!VJ_P#R=1_PJ?X??]"Y#_X':K_\G57^MW%7_14<1?\ AYS'
M_P":R/\ B'W 7_1$<(?^(UDW_P Q>2^X\2_X8I_9#_Z(EX _[]W7_P L*/\
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MO^?B#_O]'_\ %5P7_"I_A]_T+D/_ (':K_\ )U'_  J?X??]"Y#_ .!VJ_\
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MJC5E7#8SGM[ #GZX_+%>8I\*O <BATT^[=#G#IKFJNIP<<%;P@Y]B>>,5/\
M\*C\#?\ 0.O?_!SJW_R96^'P.&PM2M4HJJJE?D]M*I5JU93=*/+!OVM6=I*.
MCE%)R5N=RY8VQQ&-KXJ%"G6E!PPZG&C&%&C24(U&I22]E3A>+:ND[J+<N5+F
M=_2Z*\T_X5'X&_Z!U[_X.=6_^3*/^%1^!O\ H'7O_@YU;_Y,KKT[O[E_F<IZ
M717FG_"H_ W_ $#KW_P<ZM_\F4?\*C\#?] Z]_\ !SJW_P F4:=W]R_S ]+H
MKA]'^'7A30=1M]5TVSNHKVU\[R9)-3U&X1?/@EMI-T,]S)$^8II%&]#M)#+A
ME!!2TZ?E;]6!W%?./[7F@ZUXG_9G^,^@>'8/%-WKFJ>"K^VTS3_!>FSZOXBU
M6Z,UNZ:/::9:_P"E7EIK 1M+UB&V62X.BW>H&&&:0+$_T=7E7QP32Y/A-X[3
M6OB%JOPHTIM#E%]\1=#O;C3M6\)0^=!G5K"^M)(KFVGC;;$)(9$?;*P!Y->M
MD%>>&SW)<3!7GA\VRVO!>QJ8B\Z6,HU(KV%&%2M7NXI>QI4YU*GP0A*4E%^!
MQ7AJ>-X6XEP=5\M+%Y!G&&J2^L4<)RTZ^78FE-_6L14HX?#6C-OZQ7JTJ-'^
M)5J0A&4E^1_P2\ ?L\Z9KOPJ^W_\$^/VL] \>6&O^#C+XVU71_BC)X<T7Q+;
M:M8&+Q3JEW-XIT;2QHVFWZ1ZM?O/X8M;&&SAF$VFO C1R?N+7X0IKGA7PK\3
M?@5)X%_X* _''XYG7?C)X$\,:Y\.(O'WB];C4=-UK6K:VCU&6\FO=2TF;2+"
M^^R1ZYX=U+2V_P"$FTR[N--M-4TB<_:J_=ZOT7Q76)J8K)<97Q.:XB&,P^/J
M4EFM?B6=2@X8J,:E*CA^*.7&8>BGRN/U>FL-4BXJ-2=2G.-/\?\  26"I8#B
M3+\+@LBP=3+\7E5*O+(L-P53HXI5,!*='$8C%\#\V78S$2CS1F\75>-I3C-R
MI4J-6E*J4445^2'[^4-4U33M$TS4=:UB]MM-TG2+"\U35-1O)4@L[#3K"WDN
M[V]NYY"$AMK6VBEGGE<A(XHW=B I-?D1_P $W_\ @ISXA_;6^*?Q@^'GCSX>
MZ7\-Q9Z+_P +4^ *VEKK=OJ/C?X*?\)IKG@R\UC7WU:_O;2ZUC1-2B\-V5QJ
M&BI8Z9JM[?ZN;33;2'2\R_3G_!2'PC^T'\2?V1_B3\)_V9_"4OBKXC_%P:9\
M.+V4>)/"GABT\-> O$=UL^(.NZG>>+=;T.WNM/N?"MOJ/A:6PTB34-=>7Q+#
M=66EW,%I=O!^=^K?\$W_ -I3]FGXS_L6?'KX%?$76OVEIOV?;S0?@?XA\ :I
MX7^"WPHO]&_9GOM/U^Q\0-I6K6]_X#T_Q=>:-!KFOW-O#XNUC7O$][XHU[3=
M=%Y=O::M.])*SO:[V^7X:[:VL!S'P_\ ^"I7[>47[,WA[]N+X@_LV? +QS^R
M[=7^HVOB]?A5XU\4^$?BGX*L=.\<77PYFU>^TCQSJ&O:9JL;^)5M)+*Q\/#6
M7GL;B)]4N] MWO\ 4='^U_CS^WW\0KGX@_!7X%?L1_"?0OCM\7OC9\&M-_:%
MM-6\<>()?!WP]\"?!CQ"Z6GAOQGXF+/9:K?OJ-Y*LMQH5K>:;J]M:K:0P07M
M_K6GVZ_FC\//V=O^"EEE_P $\[7_ ()SC]C:S\%#Q5JE[HWB+]H/7OVC?@O?
MZ!X;\,>*/BO)X]UV]N/ 'A;6]<\37L<.E3S:#<Q:5>:G>RV\MS>VFGW%QY.G
MM]A^/?V4?VA?V0OV@_V</VD/V2?AG#^TEHW@G]E;PQ^QU\8OAC<>+O#GPX\6
M:GX.\!V^B_\ "*?$+0=>\5:D^CR7]U<:!H*:MI"1WD]L/#MI:PQ7-OXAU#7?
M#3:7EUMKH[6M?732_:[W ]T^'_[17_!0CXQ_"?QM9>'_ -E7P-\#/VD?AI\4
M+'PEK>G_ !_U#QZ?@AX^\%M8:\-1\7?"SQ9X7TZTU+7IH=:T^QM8UL9]=\/#
M3+B#4X/$>H?VM;6]EY9_P3<_;*_;B_;4D'Q)\:^!/V8O#7P!T/QIXU^'GC"?
MPK<_$VU^*2>)O#?AJSU*QDT#3=7U;7/#4^D3ZMKFA0W=S?7L5T;#^TS#:Q3Q
M6[2_77[%U[^VOXBT_P"+'C?]LG2/"_@!_%WCV:]^#OP6T.\\*^)-7^%'P_@-
M\(=)\3>//!Z)I7C"_OUGT\17<C2WR?V;<7]V-,?6!X=T/Y4_X)G_ +'WQM^$
M/[%?QL^ OQM@\6_ OQI\2/BQ\6=3TC7O 7CCPM/XV\.^'/&7A/PAHND^,O"?
MBKP9K/B73]$\06=WIVH7&E/+<#4M.O+&&YGLHT>!I5I:6U]+?A???;\[:,#U
MW]LK]M'XO?"'XS_![]F']F;X,^'_ (Q?'OXM>%_%GQ AL_&_B^/P3X2T3P=X
M/2YFN%CO;EK&#6M;UM=)U^*WM8M;T\Z)_9UM>7MO?V^I1K!\TZ=_P5J\7_&O
MX=?LE67[+'P8\-^+_P!H?]J6X^+>GOX#\?\ C5M"\)_#C4_@;H@USQQ!JNLV
MUO;3ZS'K-A_Q-/!SQSZ2+K2&5]2:TU7.DUS?[1W[!?Q*^'^C_!,^$_"/[0/_
M  4"N_"WCKXIZ_KGQ%^(7[5NK?#[]I?X<Z/XS\">&?#-IX(\"?$@>)_!5E<?
M"_Q5J&AE/%>AW5GK.H:+8ZEXM?0X;:;QE?:KI'AGPB_X)U_M&?L:>&_^"??Q
MV^'_ ,&K7XR_&;X':A^T#>?'SX4>'?'7A+PUJ-U+\=O".K^'_#<VF>)/$6LP
M^%]1/PZL;FST/7WTNYU*ZU>\\B;39;K0K9K[3Q6LKVOK^3WU[V[?/4#ZT\9_
M\%=M.T[]A?P3^TEX0^#_ (DUSXV_$OPS\4[KP]\'K'3/$7BS0/"6H?!77[7P
M[\5?%_Q!\5>']-MXM'^''@9=1TKQ)<7-[-HNJ:WI^L:1ID#Z6TVKZUH/Z>?L
MY?$?5_C'^SU\"/B[X@LM-TW7OBI\&?A?\1];T[1TNH](L-7\<>"-#\3ZE9:5
M'>W-[>)IMK>:I-!8I=WEW=+:QQ+<7,\H>5_S7^"7[&GQE^&7_!(WXE?LT:EX
M8LI_VA/B/\*?CS<ZGX/T[Q!HC6A^('Q0;Q/-HGAI?$-WKK>%(IK33[S0=&O-
M0AUN'P\E[;7%PNH30&34KC]#_P!E#P3XG^&G[+7[-?PY\;:9_8OC/P!\ ?@Y
MX)\7:-]MT_4O[)\3^%?AWX<T+7],_M'2;N_TJ_\ L&JV%W:_;=,OKW3[KRO/
MLKNXMI(YG3MT[OKTTL![]7R+^R9^T'XJ^/US^U)!XHT?P_I"_ S]KKXL_L^>
M&CH$6HQ-JOA7P!I/@K4-+UC7/[1U'4!)X@O)?$MXE_+8"PTYHX+86^G6[+*T
MOUU7YE_\$UO^/_\ X*(?]I-/VE/_ %&OA/0NODOU0'W7\7#\7QX US_A0Z_#
M9OBF7TL>&S\7'\3IX 2/^U[$ZVVN+X-C?Q%*YT$:FFEI8-"HU=[&6[D-E'<1
M2_G#^RM^TM^W'\79/&GQ(^+G_#&'@7]G;X1_%?XN?#SXD>,-*;XN6.NZGHOP
M:EO]-\3>._!E]XBUYO"MGX1FUJPNH8]:\6W.FRV6EZ;JNIWND*8+>VN?U*\4
M7VM:7X9\1:GX<T23Q-XAT[0M7OM!\.17=CI\OB#6K33[BXTO1([_ %2[L-,L
MI-5OHX+!+O4;^RL;9K@37=W;6Z23)^5N@?LS_M ?"W_@EW\/?@)X7T!/$GQG
M-MX0USXP^%;J'X2^*_$NJCQ[\6;;XB_'G0?#5]\3GUCX+ZAX[TJQ\1^*+/PU
MKOBY/$/A:6_TFWFL7NKE])U&$6UM-]WY^?E;\6!]A>#OVXOV4?'WAKXG^+O"
M7QH\-ZMH?P:\-:IXS^(\OV+Q#8:AX?\ !^D6EW>W?BN+0]3T:RUS7O#4MO8W
M)TO7?#FFZOI>MS1K;:+=7]S+##)SLG_!0W]C1/"L7C9?CIX?NO"USXEUSPI9
M:OI^A^,M3AU'5/"^E^']9\57>E0:?X;NKO5?#/A33?%7AVY\5>--.M[KP=X9
M.KV<&N:]87#F)?S"E_8A_: ^*?BS]H;5/%?@;]HJV\.?&'P?^R_\!/#6N?'C
MX^_##Q_\2(?@KJ7Q]@\=?M5ZWKEKX9\;ZIH/@J>V\*Z!:S>'? GA%KZP*:\C
M:' FJ7FN^&=$][_:%^*,O[*_[0G[1W[0_@;P/X*^,=I\,/V0_AY\/)/"UG\1
M/AI\/]2_9PC\-:CX]^(-CHGB'P]XFO\ 0==D^''Q;TJ^T?4O#W_"N;+QGXIU
M_P 2>!)?"5GX9D%CI$FFNRTUNWT^[3RW>K[ ?<&O_MS_ +)OAGP1I_Q%U;XV
M>&%\(ZWXK\8^"O#&H:?:>(-;O/&OB#X?:L^A^-8_ &A:)H^H>(/'^E>&]2C:
M/4_$?@O2]=\.0V^V_&K-I\B73<-^T'^WS\(/@GH'[.WB#0[J'XHZ;^TC\0_#
M_A?P=J_@M]:\0:%!X'G=+GQM\2TU/PEX=\51:O;>"M$+:A#X4M?LVN>*+M)=
M/TZ2UM].U[5-%_+/X*_L??M"_ _P]^SCXS\+?"SXT^,V;]A70_!^E:?\%OBE
M\-/A#XA^'/QN\9_$WQC\</'/@_X@K\0?$&@Q:9X \3:KX^TN'6?$?A.U\3:G
MIE_X%AL'\-W$%KHD-U]=1?LU?%?X"ZE_P3YC\"?"/7/B-HG[.?@[]ISQ!XKT
M7P#XP\(R:;IWQU^,7ARR@TVVN]2^*WC#P9JLG@"6^\:_%VWT[7=,BU._L%_L
M6UO-%T:PN(TI66G5:O>U[=.Z?Y].X'T1:_MW_!WP''XQO?C[\7?A5X:L;SXK
M?&WPY\)1X.TSXHZC/K/@GX)Z]X9\"^);373JWA&!]9^(VE^/-3OM(U"S\%6N
MH>'-7N+BRTGP-?>++C2=9U ^DZ[^V_\ LJ>&_AU\/_BOJWQF\.IX"^*=MJ]]
MX"UJRL/$6KW&OZ;X<N([/Q5JJ:%H^BW_ (AT_2/!UW-#:>-=7U;2;#3?!MU-
M%;^*+K29I41OSV_8?_9$_:!^!'B;3OB1\1O 6I:CXD^#7[$6G^ ? &BZCXQ\
M ZG_ ,+ ^//QC^(OCW]HCX]16EYI_BF_MM U;2O&NI^'/AC<^*-;GTC1M>A^
MT:GI6K:AH(GOQX1\.H_%7_!.W0?$OQ$_X0KPS\:/'/P@_82^&GAKXJ>'+GXM
M_"WP_P")/V=_BGJ^O?$KX_?$;3/%T>N:SI^J:[X ^,7B[QI>ZQH6J?#'_A/O
M$/BWQ+X'F\-Z;H5Y%;:-=6!9;>EO.]M/)_>OU#]YOAI\6OAS\8O#-WXS^&7B
MO3_&'A&T\0^)_"Y\3:6EV-#O-7\':S>>'_$7]D:G=6UM9Z[I=CJ^GWMG%K^B
MRW^@:BUM+-I>IWMNOFU^7OPV_P""E'Q"^-7PM^'>E_!SX;>%/'W[5GQTO_'_
M (D\"_"R*ZU72O!WP7^!^E>.]9\/>#_B]^TCK_\ :.J7N@Z+>>&+31?$45II
MG]G:Q\0KW7M,T7P1HUO+?VTU>C_ ;X+_ !2^$/\ P2;\/?"/X:^%KNZ^.%_^
MR_XKNO#_ (36ZT/PW>:?\7/C!HNO^+YM.GN=?U'2-!TIO#GC3QO<+>+=ZC96
M<,>F306\B#R(SYQ\//V!]>_8X@_9,^*7[+_@NVUGXD^ O"WAKX/_ +6'@^P\
M1:=IES\=_AWXL73)?&OC)-8\9:U9Z)<>-?A7XVC;QKX(M+O5=&2[\(VUQ\/=
M/U2UT73O#.@(*WXZ=-N_:]U]SU6X':_M\_MZ_$']C_P[\._"_@;PCX1^,/QP
MD\)7?Q8^,5A':ZGH_A'P=\$? \=II7C[XC2:5%XIO/$/AJW\2>,M1L?#OPVM
M=3U+Q#;S7:ZQ8W6H:QJ.D)#J7UK^UM^T=8_LT_ O7?B78:;'XP\:ZQ=Z+X'^
M"_@2TECFO/B=\7_'=RNC_#KP=I4"7EI<:C'J>K3IJ6KII<\FH0>%=,UW5;*&
MX>P$3_ ,?[#WQZ^,'PI_:Z^,/Q3\9^./AO\ M-?M:?#_ .)/@V\^#.E:C\#O
M%7@CP?\ #[3=(\5^&_@A\%KKQ?K'@#QO<6]C%IEY9:GXY\1_#GQ?X-36M?UV
M\UB26#7-*M-;CW?AS^S%^TU\=?'WP%\4_M(WOCCX"Z9^R7\#?A)IOPNA\*:]
M\#_&NI^.?VCO$WPXM--^.7Q0UO3]0T3XK>#8+3P3(K> ?!5KK.@7-XE^^L>.
M/"FHZ2M]'YSTT\M_P_6ZNNFM@/H#X-_MK-JG[#>G?M8_'#PW#H7B/2YO%GAC
MQCX#^'%K?Z_<7?Q)\._%W6_@QI'@CP;I\UW?WESJ_C7QK8Z-HWAZWO\ 4FM$
MO?$-C)?:O#I*RZHE>T^-_P"W3X4U_P"'OBCXM?LN_#P_";Q]X@\,^%O$7A3X
M)_$/Q=\5OC;\$)/$W[J/QAXYA?P)X<\)>-_"?A^_>&R\;)\/_.N_#EJTNN:7
M<^+-.MYE7Y27]C[]J32_V=OCKX*L[<^*/'OP[_X**W?[6_[/FG^*/$7@+3]*
M^.G@/2?B#X/^+-GX?\5S>%(M&\/>&;OQ5XAN/'#7&E:IX?\ "&D6/B^VTMXK
M'1/"LEK>66_XM^"7Q,_:&_:T^!?Q=TK]EKX[?L\)X8^*7@_XD?&SXK?$K]HW
M0KG2]=TCX:^&)[71_A9X5^!?PZ^.?Q*\&W=CXCU^S\(R:EXJ@\,^'(I;;1-4
MN+I9K_6M0FNBRUV>_7;;;5=WO?:UMP/IW4?VUYM9_:]^%7[+/P[^&'CFYL-=
MU'XMW/Q&^+/C;P9XB\*>"8=$^$6@:I9>(-+^%TVM#1K[QQJEG\2KWP5X=U?Q
M=96-WX"M+/4KF#1-1\3:A<2R:%][U\=Z;\(?&6I_MZ^*OC_K>EW6G> _"?[+
M'A/X*_#R\FU/1KNU\2>)/%WQ/\1^/OB?J%KI5IJ=SK&CMH5CX8^&FDM<ZMI>
MEKJK7UT-.N-2@LIOLGV)4_U_7Y %%%% !1110 4444 %9FM?\@;5O^P9?_\
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MJXKAS)<KS?"1J_VEF^6TJE&MFLYNT/:TN;EA3C!1DU5EB:BK<SHU:-&3H/\
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M7X7PU.]-0K/$X:MGV>K%5ZG+34:T*F'Y804)0J>[*)1117@'U@4444 %%%%
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M8?VU.E4C.C.I&M3G3C_3=17\R/\ P]._:S_Z#'@?_P (JR_^2*/^'IW[6?\
MT&/ _P#X15E_\D5[G_$NGB!_S^X>_P##CB?_ )WGR_\ Q.)X3?\ 0-Q?_P"&
M;!?_ #W_ *L_*_\ 3=17\V5O_P %9_VH88(HI-*^$UU)'&B/<W'A/75GN&50
M&FE6U\7VULLDA&YQ!;PQ!B1'$BX42_\ #VS]I[_H!?"'_P )7Q)_\VM8/Z/7
MB&FUR9*TG:ZS-V?FKX=.SWU2?=7.I?2\\(&DW5XE3:3:>2*ZOT=L8U=;.S:[
M-K4_I(HK^;?_ (>V?M/?] +X0_\ A*^)/_FUKT/X:?\ !7KXH6GB2RC^+/@+
MP5K7A">9(M0F\%6FLZ%XDTZ*1XT>]L_[5U_6]+U);6/?*-,FM]/DO'_=C5[1
M<,,,3X >(N'H5:T<'EF*E2A*:H8;,Z3KU>57<*4:L*-.4WKRQ=2/,U9-MI/J
MP?TL_!W%XJAAIYAG>"C7JPI/%8S):T<+0YVHJI7E0JXBK"DF_?G&C/E5Y22B
MFU_0+16?I.JZ=KNE:9K>CWD.H:3K.GV>JZ7?VS;[>^T[4+:.[LKR!\#=#<VT
MT4T38&Y'4X&:T*_%I1E"4H3C*$XR<91DG&491=I1E%V:DFFFFDTU9ZG]*PG"
MI"%2G.-2G4C&<)PDI0G"24HSA*+<91E%IQDFTTTTVF%%%%24%9FM?\@;5O\
ML&7_ /Z2RUIUF:U_R!M6_P"P9?\ _I++0!S7PU_Y$3PS_P!@U/\ T;+7<5P_
MPU_Y$3PS_P!@U/\ T;+7<4 %%%% !1110 4444 %%%% !1110 5YI\7/^1&U
M'_K]T;_T[V=>EUYI\7/^1&U'_K]T;_T[V=..Z]5^8'I=%%%( HHHH **** "
MBBB@ HHHH **** "L#Q7_P BMXE_[ &L?^FZYK?K \5_\BMXE_[ &L?^FZYI
MQW7JOS I> _^1+\*_P#8!TS_ -)(JZRN3\!_\B7X5_[ .F?^DD5=92 ****
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M7X6ZM=Z%X6T&RDT*[\/Z?X=L/&.D:%:_UOT4 ?R-?L\?LZZ3XG^'_P#P2O\
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M13QD21J1L_\ "5^%O^AET#_P<:=_\DT?\)7X6_Z&70/_  <:=_\ )-%GV?\
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M  :QIY))X  %QDDG@ =:M_VUHW_06TS_ ,#[7_X[2 TZ*S/[:T;_ *"VF?\
M@?:__':/[:T;_H+:9_X'VO\ \=H TZ*S/[:T;_H+:9_X'VO_ ,=H_MK1O^@M
MIG_@?:__ !V@#3HK,_MK1O\ H+:9_P"!]K_\=H_MK1O^@MIG_@?:_P#QV@#3
MKS3XN?\ (C:C_P!?NC?^G>SKN/[:T;_H+:9_X'VO_P =KSGXK:IIEQX*U"*W
MU&QGE-YI!$<-W;RR$+JMFS$(DC,0J@LQ P "3@"G'=>J_,#UFBLS^VM&_P"@
MMIG_ ('VO_QVC^VM&_Z"VF?^!]K_ /':0&G169_;6C?]!;3/_ ^U_P#CM']M
M:-_T%M,_\#[7_P".T :=%9G]M:-_T%M,_P# ^U_^.T?VUHW_ $%M,_\  ^U_
M^.T :=%9G]M:-_T%M,_\#[7_ ..T?VUHW_06TS_P/M?_ ([0!IT5F?VUHW_0
M6TS_ ,#[7_X[1_;6C?\ 06TS_P #[7_X[0!IT5F?VUHW_06TS_P/M?\ X[1_
M;6C?]!;3/_ ^U_\ CM &G6!XK_Y%;Q+_ -@#6/\ TW7-7/[:T;_H+:9_X'VO
M_P =K"\4:QI,GAGQ%''JFG.[Z%JZ(B7MLSN[:?<*JJJRDLS$@*H!))  S3CN
MO5?F!)X#_P"1+\*_]@'3/_22*NLK@_ ^K:5%X.\,12ZGI\4D>AZ:DD<E[;(Z
M.MK$&5T:4,K \%2 0>"*ZG^VM&_Z"VF?^!]K_P#':0&G169_;6C?]!;3/_ ^
MU_\ CM']M:-_T%M,_P# ^U_^.T :=%9G]M:-_P!!;3/_  /M?_CM']M:-_T%
MM,_\#[7_ ..T :=%9G]M:-_T%M,_\#[7_P".T?VUHW_06TS_ ,#[7_X[0!IT
M5F?VUHW_ $%M,_\  ^U_^.T?VUHW_06TS_P/M?\ X[0!IT5F?VUHW_06TS_P
M/M?_ ([1_;6C?]!;3/\ P/M?_CM &G169_;6C?\ 06TS_P #[7_X[1_;6C?]
M!;3/_ ^U_P#CM &G7)^//^1+\5?]@'4__226N@BU'3YP3!?6<P4X8Q74$@4G
MD E'8 D<X-<SXZN+=O!GBE5GA9CH6I@*LJ$D_9)>  V2?84X[KU7Y@:?A3_D
M5O#7_8 T?_TW6U;]<UX5N;<>%_#8,\((T'1P094!!&GVX((+9!!X(/2M[[5;
M?\_$'_?Z/_XJD!/14'VJV_Y^(/\ O]'_ /%4?:K;_GX@_P"_T?\ \50!/14'
MVJV_Y^(/^_T?_P 51]JMO^?B#_O]'_\ %4 3T5!]JMO^?B#_ +_1_P#Q5'VJ
MV_Y^(/\ O]'_ /%4 3T5!]JMO^?B#_O]'_\ %4?:K;_GX@_[_1__ !5 $]%0
M?:K;_GX@_P"_T?\ \51]JMO^?B#_ +_1_P#Q5 $]%0?:K;_GX@_[_1__ !5'
MVJV_Y^(/^_T?_P 50!/7FGQ<_P"1&U'_ *_=&_\ 3O9UZ)]JMO\ GX@_[_1_
M_%5YM\6IX'\$:@J31.WVW1SM61&.!JUF2< D\#D^E..Z]5^8'J%%0?:K;_GX
M@_[_ $?_ ,51]JMO^?B#_O\ 1_\ Q5(">BH/M5M_S\0?]_H__BJ/M5M_S\0?
M]_H__BJ )Z*@^U6W_/Q!_P!_H_\ XJC[5;?\_$'_ '^C_P#BJ )Z*@^U6W_/
MQ!_W^C_^*H^U6W_/Q!_W^C_^*H GHJ#[5;?\_$'_ '^C_P#BJ/M5M_S\0?\
M?Z/_ .*H GHJ#[5;?\_$'_?Z/_XJC[5;?\_$'_?Z/_XJ@">BH/M5M_S\0?\
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M[2)KE[=KJY,MU/--(:VO?:W]?A^0'UW_ ,(9X/\ ^A3\-?\ @BTO_P"1:/\
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MU_PR^X#A_P#A6O@3_H6=-_[XE_\ CM'_  K7P)_T+.F_]\2__':[BBB[[O\
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M_P#PK7P)_P!"SIO_ 'Q+_P#':/\ A6O@3_H6=-_[XE_^.UW%%%WW?]?\,ON
MX?\ X5KX$_Z%G3?^^)?_ ([1_P *U\"?]"SIO_?$O_QVNXHHN^[_ *_X9?<!
MP_\ PK7P)_T+.F_]\2__ !VC_A6O@3_H6=-_[XE_^.UW%%%WW?\ 7_#+[@.'
M_P"%:^!/^A9TW_OB7_X[6-XC^'O@JT\/:]=6WAW3X;BVT;5+B"5$DWQ30V,\
MD4BYD(W(ZJRY!&0.*]1K \5_\BMXE_[ &L?^FZYH3=UKU7YK_)?<!P7@_P
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M9TW_ +XE_P#CM'_"M? G_0LZ;_WQ+_\ ':[BBB[[O^O^&7W </\ \*U\"?\
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MK]G:(FF74.M(([6UT?2H[6SU1+J9=-_7VBB[O?\ IZWU[Z@?#NM?LGZK8?\
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MI&F^)XK34K07%K8VMUJ5F/TPHH3M]]_N _#3PY_P2_\ &5]K_P <-4UOX?\
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M+'4VU.;4_!6L03V5M8<)XD_X)">!_B9JWBGQ-\<OVNOVO_C/XI\6_LI?%/\
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MUM5+QY_R)?BK_L ZG_Z22U=\*?\ (K>&O^P!H_\ Z;K:GT7J_P H@;]%%%(
MI&8+C.3DXX^A/\@:6N%^)OCO1/AA\/\ Q?\ $7Q(TRZ#X*\/ZIXDU;[-&9KE
M[+2;.:[FBMHA_K+B81B&!&(0RNA9D4%AAB<30P>&Q&+Q56%##86C5Q.(KU&H
MTZ-"A"56K5J2>D84Z<93G)Z**;>B.C"X7$8[%8;!82C4Q&+QF(HX7"X>E%SJ
MU\1B*D:5"C3@KN52K4G&$(K64I)+5C?B#\3O 7PK\/7'BKXA^*]&\(:#;D(=
M1UJ\BM8YYW#&.TLHBQN-0OI0K&&PL8KB\FP?*@>OXQ/^"GO@W]H;_@IU^T$-
M>L/'?A3P7^SY\-Y+_P /?!GPAJ+Z_=ZC)87#VJ^(?B!K-A:Z5#:#Q%XRGL(;
MF&V^U-)I6@VFBZ)*\=S!J-U<>(?\%!/^"G'B+QI\2+GQ#XDE_P"$A\0P27H\
M"_#*#4#'X:^'>A715[+^TWMXT:2]N8OL\U_*+>/5_$,T*2S2Z98?V?Y']$W_
M  2,_8_^(&D_L]V/QF_; T^P\1?%7XRQZ=XF\/\ P]UGPYIMGI7PC^'XB>3P
MSHHT8VH8^*_$%O<_V]XBN]6-SJEG;SZ/H-P8+O2M1-Q\9PGQ'](#&X"'B?P#
ME_"_A[P9C:DL%P9Q!QUE]3,^)^+Z%5*.)S?(>'I4JM/+LIGAU.4,?F5"A*MA
M:M-83$5HXN5%?KW%_!O@)PC4GX>^(&9\0^(GB%AZ%'%\7<.<$X^.7<,<&8EM
M5*&2YUQ#3J4IYCG%*?(L3A,OKUH4,1"I2Q&%@L/&O5_!+_@J=^RE8ZM^S1^Q
M1\+/V-OA5XQU_P )_LT^'/BK9?$!&L=(/B_6]>\;/X O[SQO<Z3IVJW]_K^H
M>)M5T#7=1U)=)CO&TM#:6$,$&FPV4<?] /\ P;[VMWIG_!+WX,6&H6EU97UG
MXQ^-5M>65W!):W=K<P?%OQ?%/;7-O<+'+!<0R*R2PRHCQN"K ,"!^=__  <%
M_'3QY^Q5XJ_9&U;]G9O#W@>'QM9_&1O&>B1^%]#O-%\3KX>N_AJ^DIJ%K/9&
M>!K(:MJ<<%QI5UIMXJ7TZBZ 92OW!_P3*^.'[1GQB_8\^&W[2GACPWH&H:7X
MPU/QC;^*/A;IUU((HM2\+>+=8\-ZCJ^@3WP%W;_VW)I0U/[+#<7<MK+<FWFM
M]5:-KR7[W/>-OI"\.>%7#;\3.%,@XZX"S'B+%8V'B!X?8K&SXKRC'SQF?RK0
MXJX'S"C'$9EA<95JXJO#,>%,3C:N#IT%3Q&5S52-:/XO@.'_  DSOQ$SFGP)
MFV;<+<2X;)J&$GPOQ:L(LBQ.$5')_8/)N),/)4L'4H4H86C+#YW"C3K5*C=/
M&4U%J?[K2)YH([$ $$D'^]P1GV]QR?8_RB_\%*_AWH7A+]JWXC:=IEK;V^E>
M,M.T?Q/=6$<:"W6\\1Z4L&O )@+G4-0@U#49P0,O>3$@H5!_>=/VZ/A3X?\
M,M/BGI/C/X4:M ,SVOB7PSK%W:LZK\XM+K3;*:ZE08&U[C3;/<""JMN%?SC?
MMP?'[1?B=\9?BC\;\2'PI81PV/A>UO+=[4W>EZ'IL&C:&@^UI$]SJ&N:C%]O
MAT^""ZBLY=22&]F!C>&3[SZ._B]P9@.+,?B,#GM/-\7C,AQ&#P7"N4QJXKB;
M.\UK8S O 99ALA<(XW#UY5(3=?&YE1P.69105;%YOC\OP4:V(C^$?3&\#^-^
M)/#?)\+B.'*F3X3!\79=F>,XXSQT\NX1X7R3#X#,H9OG>.XEG-8*M0AAZT*6
M&RO**V89WGF,J8; Y'E69YC*AAW_ $G_ + GP\T;X6_L;?LU>#]$MH8(K;X0
M>"M5U*2%1B]\0^)-$M?$7B34I'V*\DFHZ]J>HW9=P#ME5<!0H'V'7Y6_\$E_
MVKO#_P"T-^RSX&\,WVMV+?%CX0:'9>!_'GAYKB)=1-EHR+9>'/%%M9DK/-H^
MLZ0ME&]ZJ-%'K%MJ-E)*TL0+_J9YIYR , '.200<].F,8/<\<\9Q7S_%6$SC
M \1YWA^(,/+"YRLRQ=7,:+J3K)8G$5IXBI.G7J4Z,\11JNK[6AB'2I_6*,X5
ME"*GRK]0X(QV0YEPAPWBN&,9''9!+)LOHY5B52AAI2PF&PU/#4X5L+"I5C@\
M325+V6)P?M)O"8B%3#RG)TVR:BO/-,^*WPZUKQMXA^&VD>-_"NI>/_"=EI^H
M^)?!EGKEA/XET.QU2,2V%UJ6D1SF\MX+F,JZRO$%198/-V>?#O\ 0AR ?4"O
M$J4JM%QC6I5*4ITZ=6,:L)0<J56"J4JD5)+FA4A)3A-7C.#4HMQ:;^DI5Z->
M,I4*U*M&%2I1G*E4A4C&M1FZ=:E)P<E&I2J1E3JP;4J=2,H32E%I+11169J%
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %?+O[1GCWQ?\ "?Q#\ _B+9:U/;_"[_A;>D_##XTZ
M&;72GL7\/_&1!X&\ ^,IK^\@_M#3YO"'QBN_A[97$MC>VUF/#'BKQ3<ZI!<B
MSLY;3ZBKC/B+\//!OQ9\"^*_AK\0M$A\2>"?&VB7WA[Q+HDUS?6(O]+U"(Q3
MQPZAI5U8ZKIEY'E9['5=)OK'5=+O8K?4-,O;2^MK>XC/4#\S[3]M/XA>%?AY
MXC_:!O\ _A"_%OA'X]?M&^)_ _[-?ASQW\2M(^%'@[P[\'? >DZAX2T+Q;'>
MV7@/QC\3_&6K_%SQ/X,U[QUI>B^$? OQ"OY-$\:>'+Z:7PMX1TO4M5M.&T[_
M (*8^-OC1\&/C_X_\"_ W4O!?@_X._LX:C\3_&_B_P#X7'IFA_$KP[XJO-#^
M*EM:>'/ 7AO7O@7XY\.:A>Z;XM^%NKV">)O&%I#:VFF7NE>(+_P)?W2WW@]/
MT:\1?LN_!7Q)X:^$_A5_#FM>'-.^!NE)H'PFO? 7CSQ]\._$W@?P]_PB\7@J
MY\/Z-XP\#^)M \5KHNH^%8+;2-2T^XUF>"^%EINI3AM8TG2]1L^-\$?L,_LL
M_#CX<?$;X2>#/A>='^'OQ9\&K\/OB!X?/C?XC:E_;_A!)O&$Z:.-6U;Q=?ZW
MI*I)X^\6%+W0]2TW44355B6\$6GZ6EDTUU7;;MU_#\W<#QCPI_P4"/B*ST/Q
M;>?!V_T?X8_%6U^.+_L^>+SXUMKS5?B!>? C0/&GB?7;;QSX4_X1JTG^&$7B
MW0O ?B+5_!5Q;ZIX[>YT[3ISXBMO#FI2Z?I=]S/Q)_X*,:OX+\-_"C5] ^ M
M_P"+;_XI_LQ>!OVD'AM/%7B:]TSP)8>,O%7@'P[>6OBQO!?PH\<>*7\(>%;7
MQK/K&L>-]%\(:A=-'I"6P\)6\6HRZAI?U;X/_9%^ G@7XA?\+,\/>$-3'B*V
MN/B'>:!I^L^-_'?B7P5X)OOBWJW]N?$^^^'GP\\1^)-5\"_#Z[\=:FTTWB&;
MP;X>T5KF&\U2RA%O8ZSJ]M?>;:?_ ,$[?V3],^P2VW@CQB^I:#X5\*>!O!^O
M7GQJ^-NH>(OA]X/\!>*M$\:^ _#OPYUV^^(5QJ?@/3O!?B/P]IE[X=7PM<Z7
M-8P?VGIC33:7X@\066J&G7R^??K_ %Y 6=/_ &B_$?Q;_8H\:?'GX=W_ ,,/
M GCR]^'?Q-/@C4[KXH^"?'GPJTOQ]H;>(?#_ (0U"?XCK)HWARX\.:IXALM)
MO5;Q9IOA?6-(@U"/2_''A/P]KMGJWA^U^1_ ?[5WBG]G&'XPR?'SQA^TIK.H
M^!?A+8>.H?@C^T;\/?@S;?%'Q-XKN_&&B^$I-;^"WQ?^ ]Y!\*/%_P --0\4
M>+-!\*ZQH=XFMZOX&U/6- U.XU?1-"EETF7])M)_9\^$6C_"3Q'\#8?",=]\
M-?&5GXSM?&FC:WJVN:[J'C*7XBW6J7_CS5?%?B?5M3O/%&O>(/%FH:UJE_K7
MB'4=9GUJYO+Q[A;Z-XX#%YKHG[$G[.ND6?C^SU'PQXL\>_\ "ROA]=?";Q/?
M_%GXL?%GXNZXGPNO9);BX^'_ (<\0?$GQMXHUSP=X9EO9%U*:T\*:AHT]SJU
MGI6KW=S/J6B:-=6"_K:_]?T@/F+4?VO_ (I:E^U#\%/@+XE\,/\ "+QII5[X
M^U+XQ^!] \3Z/\0O"OB;PEKOP!^)?CGX6ZEX<\?WW@_0=2E:T\0^!-7BU2%O
M"V@7%AX@T"ZM9(M?\.SV-_JGS-X:_P""A/QX^,O@?]B[Q1\*_!NL>&?A-XD_
M:>_9;^"7Q3^+GBWQ[X2\0?$/QKK'B?P+H6M?$GPAJO@?3_A'X:T"30;_ %/Q
M"-+O/B;X:G\$W&H>(-$GGT'P!X8T75K>&P_4/P=^QI^SWX)\46GCO3O"GB'6
M?']IK6JZ]_PL#QO\2_B=X^\<WU]JW@&7X721ZUXK\9^,-<UO7M-T_P  SW'A
MW0M'UN\U#2O#\=U?:IHMG8ZYJ%_JESROA_\ X)^_LI>%=1\&7OAWX>ZWI%A\
M/?$7PX\:>$/"EG\4OBRG@72?'GPF\.:+X/\  GQ ;P.?&[>%M2\=:7X4\.Z1
MX?U'Q9JVE7VM>*-.M73Q7=ZW-=WLUPU9/7;3SUZ]5Y]_0#BOV]8?BEX9\)^#
M_B+\-?VA/BU\*;BY^*O[/OPGOO"_@RQ^$%]X6O\ 2_BG\=/"/@+Q'XCN8_'G
MPG\:^(4\4VWA_P 7W::3-:>(;;0+:ZTS29[OP_?!-0CU&EXF_:HO_P!G?PI^
MU#X;UBQ\5_&34?V1/ ?PD\77/C7QWXO\*:1XK^*[?&._\5W,%CJZ^"?A?X<\
M+^%Y?#":1'IEG=Z3X8O$U>T%L)[&VOH+F\O_ +7^(/PW\%_%/0[+PWX\T;^W
M=%T[Q5X,\;6=E_:.JZ9Y/B?X?>*M(\;>$-3^T:-?:==R?V1XGT+2M3^Q2SOI
M]_\ 9?L6J6E[I\]S:3>-_&/]CWX _'O6]8UWXH>%O$&M3>)?#7A;PCXNTS2?
MB3\3/!WAWQIH/@77];\5>![/QCX;\%^+_#^B>)9/!WB/Q)KNL^'+W5[&ZO=-
MO]0,T5P?L>G"S$UU77_+]$_O ^3X?V\_CYK/C/P_X<\)?LL^ =8TGX@:]^U)
MH?PWU?4_VD]0T.\U$?LE?$'4? GCZ_\ &.F+\!-4C\+)XEGTZ63P=::1?^,'
M>]>VM];GTO3KBXUC3M0?\%([#4?#E[\2/#?P:UC5_A)\/?@Q\"OC7\>/%=UX
MPLM*\1?#W0_C]X/M?'?AS2_"'@]] NH?B5?^%O"E]:^(/&\K>)?!T%CI;M%H
M \2:Z/[$K[(TC]F_X+Z#J'A+5=)\&_9+_P "WWQIU+PK/_PD7BN?^R[W]H?Q
M/<^,OC#-Y5SKLT-]_P )?XDO+C4O+U&.\B\/^9]C\+QZ)8)':KYKJ?["O[,.
MJQ>$+*X\!:M#H?@WP3\*OAQ!X5L?B/\ $VQ\'>*O OP/O#J'PF\-?$[PE:^,
M(O#WQ8L/ ]ZSS:5)\2=.\4WL\<MQ9:I=7^GW=U:3FG73TZ_>P/E35_\ @HY\
M4](^#VB_&S4/V:/#.C^!?%OQ*\:^"/#GB;6/C1XTN?"FAZ)\/->\<^&?$'BS
MXNZ_X2_9R\5GX6VNL:[X-M[#P>]UI^OZ!>)K3WGB?Q-X3CTEHM1_0KPQXYA^
M)WP-T;XBV]E:Z;%XY^&-MXJ73K+Q)X;\8V>G-KOAH:C)86WBSP=J6L^%/$D%
ME)<-;1ZYX=U74-&U18A>:==S6LT;GB+_ /9*^!=WX,\#^!;'PYXB\,:3\-/$
M_BWQAX U/P7\1_B1X.\8^$]?\>3>*9O&EQI/COP[XLT[QFEEXF/C3Q)'JVBW
M&N7&B7$5];QC3D&D:)_9WI5EX(\)_#7X3+\/_ FA6'ACP;X-\"S^'/#/A_3(
MVCL=(T72=%EL["R@\QY)I!%!$HDN+B6:ZN92]Q=3S7$LLKM6O'O=?I_P0/R'
M_;+_ &]?B'\([GPQ\%/@Q>6/A[6M(\'>%=3\9>,IM.LM6U6SO=8TN'4[+P]H
M]CJ]K>Z1;Q'1+G3=0OM3GLKVZD.I0VU@=-DLIKBZ_.#_ (;?_:R_Z+KXY_\
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M *+KXY_\"[/_ .0JZ;_AWI^V/_T134__  JO /\ \U='_#O3]L?_ *(IJ?\
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MZ-\0=>^&>@?#KQ7\3[2^O-/-_P"/_$NCZ>/#&H^&K/Q)HVD6/BWPM<?$;4?
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M %:C_P"9U_\ Q.4?\/\ '_JU'_S.O_XG*_9O_AD']DS_ *->_9V_\,G\-?\
MYF:/^&0?V3/^C7OV=O\ PR?PU_\ F9K^T/\ 5CP?_P"C7_\ FZ\4?_-!_G7_
M *Z?2 _Z/5V_YMQP5UY?^H7^]^!^,G_#_'_JU'_S.O\ ^)RC_A_C_P!6H_\
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M?_Q.5^S?_#(/[)G_ $:]^SM_X9/X:_\ S,T?\,@_LF?]&O?L[?\ AD_AK_\
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M ,,@_LF?]&O?L[?^&3^&O_S,T?\ #(/[)G_1KW[.W_AD_AK_ /,S1_JQX/\
M_1K_ /S=>*/_ )H#_73Z0'_1ZNW_ #;C@KKR_P#4+_>_ _&3_A_C_P!6H_\
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M?]&O?L[?^&3^&O\ \S-'_#(/[)G_ $:]^SM_X9/X:_\ S,T?ZL>#_P#T:_\
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MG;_PR?PU_P#F9H_U8\'_ /HU_P#YNO%'_P T!_KI](#_ */5V_YMQP5UY?\
MJ%_O?@?C)_P_Q_ZM1_\ ,Z__ (G*/^'^/_5J/_F=?_Q.5^S?_#(/[)G_ $:]
M^SM_X9/X:_\ S,T?\,@_LF?]&O?L[?\ AD_AK_\ ,S1_JQX/_P#1K_\ S=>*
M/_F@/]=/I ?]'J[?\VXX*Z\O_4+_ 'OP/QD_X?X_]6H_^9U__$Y1_P /\?\
MJU'_ ,SK_P#B<K]F_P#AD']DS_HU[]G;_P ,G\-?_F9H_P"&0?V3/^C7OV=O
M_#)_#7_YF:/]6/!__HU__FZ\4?\ S0'^NGT@/^CU=O\ FW'!77E_ZA?[WX'X
MR?\ #_'_ *M1_P#,Z_\ XG*/^'^/_5J/_F=?_P 3E?LW_P ,@_LF?]&O?L[?
M^&3^&O\ \S-'_#(/[)G_ $:]^SM_X9/X:_\ S,T?ZL>#_P#T:_\ \W7BC_YH
M#_73Z0'_ $>KM_S;C@KKR_\ 4+_>_ _&3_A_C_U:C_YG7_\ $Y5:]_X+T?;+
M.[M/^&5/+^U6MQ;>9_PO/?Y?GQ/%OV?\*>7=MW;MNY=V,;AG(_:3_AD']DS_
M *->_9V_\,G\-?\ YF:/^&0?V3/^C7OV=O\ PR?PU_\ F9H_U8\'_P#HU_\
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M_AD_AK_\S-'_  R#^R9_T:]^SM_X9/X:_P#S,T?ZL>#Z_P";7_\ FZ\4?_-
M?ZZ?2 _Z/5V_YMQP5UY?^H7^]^!^,G_#_'_JU'_S.O\ ^)RC_A_C_P!6H_\
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M?_Q.5^S?_#(/[)G_ $:]^SM_X9/X:_\ S,T?\,@_LF?]&O?L[?\ AD_AK_\
M,S1_JQX/_P#1K_\ S=>*/_F@/]=/I ?]'J[?\VXX*Z\O_4+_ 'OP/QD_X?X_
M]6H_^9U__$Y1_P /\?\ JU'_ ,SK_P#B<K]F_P#AD']DS_HU[]G;_P ,G\-?
M_F9H_P"&0?V3/^C7OV=O_#)_#7_YF:/]6/!__HU__FZ\4?\ S0'^NGT@/^CU
M=O\ FW'!77E_ZA?[WX'XR?\ #_'_ *M1_P#,Z_\ XG*H:K_P7C&IZ9J6FG]E
M4PC4+"\L3,/CEYAB%W;R6YE"'X/(',8DW!-Z[L8W+G(_:K_AD']DS_HU[]G;
M_P ,G\-?_F9H_P"&0?V3/^C7OV=O_#)_#7_YF:/]6/!__HU__F[<4?\ S0'^
MNGT@/^CU=O\ FW'!77E_ZA?[WX'XGZ'_ ,%W1HFC:7I"_LKFX73+"VL1.?CB
M(C,+:)8O,,8^#\@C+[=VP.^W.-QQFM7_ (?X_P#5J/\ YG7_ /$Y7[-_\,@_
MLF?]&O?L[?\ AD_AK_\ ,S1_PR#^R9_T:]^SM_X9/X:__,S1_JQX/_\ 1K__
M #=>*/\ YH#_ %T^D!_T>KM_S;C@KKR_]0O][\#\9/\ A_C_ -6H_P#F=?\
M\3E'_#_'_JU'_P SK_\ B<K]F_\ AD']DS_HU[]G;_PR?PU_^9FC_AD']DS_
M *->_9V_\,G\-?\ YF:/]6/!_P#Z-?\ ^;KQ1_\ - ?ZZ?2 _P"CU=O^;<<%
M=>7_ *A?[WX'XR?\/\?^K4?_ #.O_P")RC_A_C_U:C_YG7_\3E?LW_PR#^R9
M_P!&O?L[?^&3^&O_ ,S-'_#(/[)G_1KW[.W_ (9/X:__ #,T?ZL>#_\ T:__
M ,W7BC_YH#_73Z0'_1ZNW_-N."NO+_U"_P![\#\9/^'^/_5J/_F=?_Q.4?\
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M(S-$&WK^U?\ PR#^R9_T:]^SM_X9/X:__,S1_P ,@_LF?]&O?L[?^&3^&O\
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M_,S1_P ,@_LF?]&O?L[?^&3^&O\ \S-'^K'@_P#]&O\ _-UXH_\ F@/]=/I
M?]'J[?\ -N."NO+_ -0O][\#\9/^'^/_ %:C_P"9U_\ Q.5S?BS_ (+GKXIT
M2XT9_P!EMK(3S6<WVA?C>+@H;2[AN@OE'X0PAO,\G83Y@V[MV&QM/[?_ /#(
M/[)G_1KW[.W_ (9/X:__ #,T?\,@_LF?]&O?L[?^&3^&O_S,T?ZL>#Z_YM?_
M .;KQ1_\T!_KI](#_H]7;_FW'!77E_ZA?[WX'XR?\/\ '_JU'_S.O_XG*/\
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M[]G;_P ,G\-?_F9H_P"&0?V3/^C7OV=O_#)_#7_YF:/]6/!__HU__FZ\4?\
MS0'^NGT@/^CU=O\ FW'!77E_ZA?[WX'XR?\ #_'_ *M1_P#,Z_\ XG*/^'^/
M_5J/_F=?_P 3E?LW_P ,@_LF?]&O?L[?^&3^&O\ \S-'_#(/[)G_ $:]^SM_
MX9/X:_\ S,T?ZL>#_P#T:_\ \W7BC_YH#_73Z0'_ $>KM_S;C@KKR_\ 4+_>
M_ _&3_A_C_U:C_YG7_\ $Y1_P_Q_ZM1_\SK_ /B<K]F_^&0?V3/^C7OV=O\
MPR?PU_\ F9H_X9!_9,_Z->_9V_\ #)_#7_YF:/\ 5CP?_P"C7_\ FZ\4?_-
M?ZZ?2 _Z/5V_YMQP5UY?^H7^]^!^,G_#_'_JU'_S.O\ ^)RC_A_C_P!6H_\
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M>,:9IFFZ:/V53,-/L+.Q$Q^.7EF46EO';B4H/@\X0R"/<4WMMSC<V,G]JO\
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M<H_X?X_]6H_^9U__ !.5^S?_  R#^R9_T:]^SM_X9/X:_P#S,T?\,@_LF?\
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
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>nt10014672x1_barchart2.jpg
<TEXT>
begin 644 nt10014672x1_barchart2.jpg
M_]C_X  02D9)1@ ! 0$ P #   #_[0 V4&AO=&]S:&]P(#,N,  X0DE- ^T*
M4F5S;VQU=&EO;@     0 ,     !  $ P     $  ?_B"^!)0T-?4%)/1DE,
M10 ! 0  "]!N;VYE @   &UN=')21T(@6%E:( ?4  < %0 3  L (6%C<W
M         $E%0R!S4D="     0            #VU@ !     -,M2% @(
M
M$&1E<V,   %$    =&)865H   &X    %&)44D,   ',   (#&1M9&0   G8
M    B&=865H   I@    %&=44D,   ',   (#&QU;6D   IT    %&UE87,
M  J(    )&)K<'0   JL    %')865H   K     %')44D,   ',   (#'1E
M8V@   K4    #'9U960   K@    AW=T<'0   MH    %&-P<G0   M\
M*&-H860   ND    +&1E<V,         &G-21T(@245#-C$Y-C8M,BTQ('=I
M=&A"4$,
M                                                    6%E:(
M     "2@   /A   ML]C=7)V        !      %  H #P 4 !D '@ C "@
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M;W5R(%-P86-E("T@<U)'0@
M
M      !865H@        8ID  +>%   8VEA96B            !0
M;65A<P         !                               "6%E:(
M  ,6   #,P   J1865H@        ;Z(  #CU   #D'-I9R      0U)4(&1E
M<V,         +5)E9F5R96YC92!6:65W:6YG($-O;F1I=&EO;B!I;B!)14,@
M-C$Y-C8M,BTQ
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MU=;7V-G:X>+CY.7FY^CIZO'R\_3U]O?X^?K_Q  ? 0 # 0$! 0$! 0$!
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MXDW\#_\ H4Y[_P")%C_\S^6K_AQ=^TI_T5;X'?\ @P\>_P#S"T?\.+OVE/\
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M-_ __H4Y[_XD6/\ \S^6K_AQ=^TI_P!%6^!W_@P\>_\ S"T?\.+OVE/^BK?
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M_AFP?^7]7?E8_P")-_ __H4Y[_XD6/\ \S^6K_AQ=^TI_P!%6^!W_@P\>_\
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M_@P\>_\ S"T?\.+OVE/^BK? [_P8>/?_ )A:_J5HH_XF6\5?^ACE/_AFP?\
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M#O\ P8>/?_F%H_X<7?M*?]%6^!W_ (,/'O\ \PM?U*T4?\3+>*O_ $,<I_\
M#-@_\OZN_*Q_Q)OX'_\ 0ISW_P 2+'_YG\M7_#B[]I3_ **M\#O_  8>/?\
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M *&.4_\ AFP?^7]7?E8_XDW\#_\ H4Y[_P")%C_\S^6K_AQ=^TI_T5;X'?\
M@P\>_P#S"T?\.+OVE/\ HJWP._\ !AX]_P#F%K^I6BC_ (F6\5?^ACE/_AFP
M?^7]7?E8_P")-_ __H4Y[_XD6/\ \S^6K_AQ=^TI_P!%6^!W_@P\>_\ S"T?
M\.+OVE/^BK? [_P8>/?_ )A:_J5HH_XF6\5?^ACE/_AFP?\ E_5WY6/^)-_
M_P#Z%.>_^)%C_P#,_EJ_X<7?M*?]%6^!W_@P\>__ #"T?\.+OVE/^BK? [_P
M8>/?_F%K^I6BC_B9;Q5_Z&.4_P#AFP?^7]7?E8_XDW\#_P#H4Y[_ .)%C_\
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M /,+7]2M%/\ XF6\5?\ H8Y3_P"&;!_Y?U=^5I_XDW\#_P#H4Y[_ .)%C_\
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M_!B.?P[=6]I>23WWCA89I+E)G1K8Q^"Y'9 (6#&5(F!*X4Y..B_X<7?M*?\
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MP7)K_A70I%1/$?B#01J6F>&_M>F2:]<Z=#K.CR7Y_P 3+>*O_0QRG_PS8/\
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M::/*^H1'_$RWBK_T,<I_\,V#_P OZN_*Q_Q)OX'_ /0ISW_Q(L?_ )GY2_\
M#B[]I3_HJWP._P#!AX]_^86C_AQ=^TI_T5;X'?\ @P\>_P#S"U^S_P"TG_P4
M[_8:_9(LO@/K7QX^/GAOPIX4_:8\/^+/%GP6\<Z78:]XU\">-?"_@S0O"OB3
M5O$.G^,/!&E>(=!&DW>C>-O"UYX:NGO0OB\ZS96WA8:O=3) ?E:X_P"#A3_@
MCW;> =.^([_ME^'9-!U3Q??^"K;3(/AI\:Y_',6J:7::5J-]J-_\-HOALWQ
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M*?\ 15O@=_X,/'O_ ,PM?KI\0_\ @K[_ ,$S_A/X[\8?#'XC_MD?![PAX^\
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MA5?(Y.&D9/6+U04445^3G[J%%%% !1110 4444 %%%% !1110 4444 %%%%
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MXK;_ (6O<MK5E'?:39?%Z2VN-.\5:Y%%X<U"/0'@\#?F?_P2'_Y/V_X(#?\
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M38[[PS?:1=SW4TX!Y-_P^*^&O_#I+_A[9_PISQS_ ,*[_P"B1_V]H'_":?\
M)R__  S1_P AO9_8?_(<_P"*F^Y_R"?]$_X_.:_3;X&?%;3/CG\%_A#\9M(T
MZYT33_BY\*_AW\5+'0+^YM[K4]#T[XB>$]+\6:?IFHRVN();JRM]4%G-/"JP
M3SV\SP?)C'\9G_.EY_G_ *2M5X9\$O G[,?[.7[6_P#P0$\4?\$O_BYK'BO]
MH#]IO2_"4/[=>G^$/B_=_$34/$?PXO;#X1ZQ\5H/C1\/K7Q/XKM? %[8:-/\
M8);GP4\%CHOA&]^%C:G-86?B7P!'XCH _O[HHHH \N\)_N_B+\4(6Y9V\)3
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M\:^(O'">*3H<O@O4+B_!U>P6Y\$^*[#55GBL-5T6]T:>/5-*M8[FPEN_W1H
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MVOO'NE^"M78JDUIXAL=#\1Z7I7B.W5 =*U_^TM/BDN%LDNI_J'XV_L_?'/\
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MR^#]*^)'CCPK=V6F^#[;PK>>,?#WCVYLO ]G%XIT/6W\<07*Z5JWA_P-"_\
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M)]&A0M]5QD#OWKTJO-/%W_(\_#'_ *_?$O\ Z:(J:W^4OR8'I=%%%( HHHH
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M[)X<U'Q!H;W^J:G>PW</B_Q=JVKV>J>)=837+/\ 7N@ HHHH **** "BBB@
MHKFO^$S\'_\ 0V>&O_![I?\ \E4?\)GX/_Z&SPU_X/=+_P#DJG9]G_7_  Z^
M\#I:*YK_ (3/P?\ ]#9X:_\ ![I?_P E4?\ "9^#_P#H;/#7_@]TO_Y*HL^S
M_K_AU]X'2T5S7_"9^#_^AL\-?^#W2_\ Y*H_X3/P?_T-GAK_ ,'NE_\ R519
M]G_7_#K[P.EHKFO^$S\'_P#0V>&O_![I?_R51_PF?@__ *&SPU_X/=+_ /DJ
MBS[/^O\ AU]X'2T5S7_"9^#_ /H;/#7_ (/=+_\ DJC_ (3/P?\ ]#9X:_\
M![I?_P E46?9_P!?\.OO Z6BN:_X3/P?_P!#9X:_\'NE_P#R51_PF?@__H;/
M#7_@]TO_ .2J+/L_Z_X=?>!TM%<U_P )GX/_ .AL\-?^#W2__DJC_A,_!_\
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MU#4=2DN;^]M6-I=7,MM^ZKZ3_P"$S\'_ /0V>&O_  >Z7_\ )5'_  F?@_\
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MK%K;Z5KT5_I\$.L:O'#;(NJ7XN/=?^$S\'_]#9X:_P#![I?_ ,E4?\)GX/\
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M/3/^$S\'_P#0V>&O_![I?_R53:=]GLOR0'*?%OX(?!;X_>%X/!'QW^$/PO\
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M3O$^F:/XPTG6-.L/$-AIVL:O866M6EM%J5K9:KJ5K!<QP7UU'+V/_"5^%O\
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M:OJ5V;[3H)Z_<K6/^";'_!./7OV5/AG^Q)JWPMT"[_9A^#OCF;XD?#CX9?\
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MS_PLC_A5_P#PNWXM_P#(Z?;?[0_MG_A-O^%H_P#"Q/\ C\_??V=_PEO]D_\
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M4B\$^&] TOPGX9M_[/2PO-5TA;;5IM3TBWTS6];@TW1].EU?4I[OYTG_ ."
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M _\ !QIW_P DT6?9_P!?\.OO WZ*P/\ A*_"W_0RZ!_X.-._^2:/^$K\+?\
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MFM7.FZ=%<64O@^:^UTW$4VCV4\.NVVH:7;_HS^RS^VK\*/VL[SXF:!X-\/\
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MT6_U0VEU')<Z-'=?9)UD>*0&NF^NWX?\#\ /H_\ X0SP?_T*?AK_ ,$6E_\
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MNEHHN^[_ *_X9?<!S7_"&>#_ /H4_#7_ ((M+_\ D6C_ (0SP?\ ]"GX:_\
M!%I?_P BUTM%%WW?]?\ #+[@/#OA9X;\.ZAHVMRW^@:+?2Q>*]8MHI+S2K&Y
MDBMXEM/*@C>:!V2&/<WEQ*0B;FVJ,G/IG_"&>#_^A3\-?^"+2_\ Y%KC?A#_
M ,@/7_\ L<=<_P#0+*O5Z;;ON]E^2 YK_A#/!_\ T*?AK_P1:7_\BT?\(9X/
M_P"A3\-?^"+2_P#Y%KI:*5WW?]?\,ON YK_A#/!__0I^&O\ P1:7_P#(M'_"
M&>#_ /H4_#7_ ((M+_\ D6NEHHN^[_K_ (9?<!S7_"&>#_\ H4_#7_@BTO\
M^1::_@GP:XVGPIX< Z_)HNG1GC_:2V5OJ,X/>NGHHN^[_K_AE]P')_\ "!^"
M_P#H5=!_\%EI_P#&J/\ A _!?_0JZ#_X++3_ .-5UE%%WW?]?\,ON Y/_A _
M!?\ T*N@_P#@LM/_ (U1_P ('X+_ .A5T'_P66G_ ,:KK**+ON_Z_P"&7W <
MG_P@?@O_ *%70?\ P66G_P :H_X0/P7_ -"KH/\ X++3_P"-5UE%%WW?]?\
M#+[@/#=!\+>&)?B+X\TNXT'29+2VM?#D^G6<EA ]O;))IT?VQ[>,QF.$RW$B
MM*!M:1SOPV"1Z-_P@?@O_H5=!_\ !9:?_&JY30O^2M>.?^P-H/\ Z2V=>KT-
MN^_2/Y+_ "0')_\ "!^"_P#H5=!_\%EI_P#&J/\ A _!?_0JZ#_X++3_ .-5
MUE%%WW?]?\,ON Y/_A _!?\ T*N@_P#@LM/_ (U1_P ('X+_ .A5T'_P66G_
M ,:KK**+ON_Z_P"&7W <G_P@?@O_ *%70?\ P66G_P :H_X0/P7_ -"KH/\
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M_P"QEA_](EKTNAMWWZ1_)?Y(#D_^$#\%_P#0JZ#_ ."RT_\ C5'_  @?@O\
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ME?PM^RY8_$/XR?\ !'K]C7XP_%2V^/-_\6;7X/:!?>,/B/\ %S7XO!G@?2/
M>IZCXOM-<\5ZM=W4&F>)-8O-:T_PUX>\-ZG/JUIXAU&?2[&Y+ON_Z_X9?<!_
M43_P@?@O_H5=!_\ !9:?_&J/^$#\%_\ 0JZ#_P""RT_^-5_/-X:_X+"_M;_M
M/6=[KO[&WP0_9SATC1OV"? '[;7B;3?CWXT^)$>LZ1J5EX]^-_@#XR?!7P_=
M^"=&M],\8:H_B3X5KH'@'QSJ:_#_ $;3#97_ (CU_2==M-?LM&\._3?[/?\
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M3J7Q,\.Z[I?PK\-VVC^$=+\/? S0OAYH?Q!34]$U"35XK^[O?$]UZ?\ $/\
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M^$#\%_\ 0JZ#_P""RT_^-4?\('X+_P"A5T'_ ,%EI_\ &JZRBB[[O^O^&7W
M<G_P@?@O_H5=!_\ !9:?_&J/^$#\%_\ 0JZ#_P""RT_^-5UE%%WW?]?\,ON
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M34#^=7]HW_@D3\6?%WA'X.>'/AAX0_9>O[KX9_ NR\!Z-XIG\;?M#?#7Q_\
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M1+7I=-[_ "C^2 ****0!1110 4444 %%%% !1110 4444 >4?"'_ ) >O_\
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M^"J?P_\ &OQ=^"/CG4=1_:;_ &:O@9>_!S]L'XE^)/AQ\>/V24\,2_%SP/\
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MV/F__0JS+_PAQ7_RKS7WA_;&4_\ 0TR[_P +<-_\M/NNBOA3_AY__P $YO\
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M(20H3L8[6P>*] _X>?\ _!.;_H^/]EC_ ,/?\/\ _P"7M#R?-[_\BO,=H_\
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M%?"G_#S_ /X)S?\ 1\?[+'_A[_A__P#+VC_AY_\ \$YO^CX_V6/_  ]_P_\
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M_P#^7M-Y/F^G_"5F6R_Y@<5V7_3H/[8RG_H:9=_X6X;_ .6GW717PI_P\_\
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M/Z7^S_:?"V[UB.35M;\$>,;+4[S7H_B=;)8Q2R:/%:2:4XFGF2\WVGFWP_\
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M"UW>ZE?>R_#C_@H+\7G^(?PM\,?M._L&?'#]E/P-^T#XUL? 'P/^)WB7Q_\
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M^&?C6PMIIXK3Q!X0\6:+J6G2NC^1J=@+#6K+.GZG:.P!](UYI\1/^/WX??\
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MC?P_\4?#W!XNK&C2S?BGA.OA<N4Y-+WW"K/%M*]Y?5\)B))+2'1?TL%B">.
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M7/!%MX USQ-I^IZ'H/BW4Y5TZ74_3O@!^VC\&OVCO$4GA;P.WB+3=:N_!_\
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M'KP;X:^-WB^+QG\3/ACX7/P0B\(Z_J+^ _!OPSU>UM/$.L_!+6OB[X8M-?\
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MT62\\0>%/C'X6^*7PD\,R^$M>N_#7BN?PUJVDP^$/B3!JOVGPGK>MZ-JYO\
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M%EY#2OV+]0\8?&'XV>-/BWXU\7R?#K6OVH/"WQX^'/PFT34?"</@W4M:\%?
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M)X*\2^%?'1CU?P%JF@ZCXV>;P/:Z-K@O=%D\':WX;U[Q1HUWX0\C5(WL_0O
M7['_ ($\$:AX'\1W'C#XA^+O&_A/XY?$#]HK6?&GB34?#G]J_$'XG?$?X7^+
M/@[K%WXLL='\+Z5H=GH.D^ ?%,6A^%O#W@O2_"=GHUMX5\*QEKR*TU2/6%_5
MM?ZU]?N \7\*?\%*_AKXN\,Z=XIL?@;^TK9VOB?X=R_$_P"'MC?^#? !O_B#
MX5TWQSX1^''BF\TI]/\ BAJ&E>%+7P1XJ\:Z'%XNU[XI:I\/_".E:'+)XL3Q
M)<^%1%K$OTS^S;^T?X&_:?\  6I^.O ]IJVE#P[XR\0?#WQ7H&MW7A?4[_P]
MXQ\,?8Y-4TLZYX&\1^,/!/B"U:SU+3-2L-9\*>*M=TB[L=0MP;N&_BOK"S^;
M/%7_  3-^!?BKP7\%O!5WXH^)2V?P$\(:KX/\#3WMQX \06FHV6K_$CX>_$^
MXN/'OA?Q%\/M5\&>.0NN?#?1K!='UOPZ_ALZ7>ZC<G1?^$FMO#OB/0/HS]FW
M]FWPI^S)X8\:^&?"OBGQKXO7Q_\ $OQ!\5?$&K>.'\'K?+XE\2Z5X?TG4+/2
M+#P+X.\#>&]%\.00>'+)M)T'3M!@L]&66:PTW[/I$.G:;8/3^O\ /_@?\ /X
MU_\ @Z1^,_Q);]JOX8? .+7=7TWX4VGP2\-?$R?PY:7T]KI/B?Q?KWB_QMH+
MZMK=G:W/V;5VT#3_  A8VV@+JENUQHEQ?:]/8+#'K,DUS_+/7^F-_P %%O\
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M"3?]9 /_ #53_P#*1H_XA)O^L@'_ )JI_P#E(U]9_P 1-X(_Z'?_ )C<W_\
MF ^4_P"(:\;?]"7_ ,R.4_\ S>?QMT5_9)_Q"3?]9 /_ #53_P#*1H_XA)O^
ML@'_ )JI_P#E(T?\1-X(_P"AW_YC<W_^8 _XAKQM_P!"7_S(Y3_\WG\;=%?V
M2?\ $)-_UD _\U4__*1H_P"(2;_K(!_YJI_^4C1_Q$W@C_H=_P#F-S?_ .8
M_P"(:\;?]"7_ ,R.4_\ S>?QMT5_9)_Q"3?]9 /_ #53_P#*1H_XA)O^L@'_
M )JI_P#E(T?\1-X(_P"AW_YC<W_^8 _XAKQM_P!"7_S(Y3_\WG\;=%?V2?\
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M_H2_^9'*?_F\_C;HK^R3_B$F_P"L@'_FJG_Y2-'_ !"3?]9 /_-5/_RD:/\
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M0#_B&O&W_0E_\R.4_P#S>?QMT5_9)_Q"3?\ 60#_ ,U4_P#RD:/^(2;_ *R
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MOP&_;3^*W_!2+]HK]K/X6?#;]H[XOZ)^WQ^T/^R=H=K\;/!>A_$VQ^"OP(^
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MXB\7>(-.M]4\)ZQ>Q?$+3KWPGIT7AS5;G4+OPW:6LUZFI^$]7FD@GMO (_\
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M\&QW6MZY:^&O >CWVE7/A*]\$6$&N7.I7-YIE]836NF6?E?BK_@E)^SQXO\
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M\+7_ ,+-4OO#GA74IO R7FC_ !$M=!\2VMC9^)]$\0Z/K]U=>&C1ORZZK_@
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M_B*W"/\ S^Q__A%/_P"2_JS\K_WVT5_ E_Q%0_\ !0?_ *([^QM_X;[XV_\
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M\%!_^B._L;?^&^^-O_T0U+_B$W%__/G ?^%T/_D0_P"(K<(_\_L?_P"$4_\
MY+^K/RO_ 'VT5_ E_P 14/\ P4'_ .B._L;?^&^^-O\ ]$-1_P 14/\ P4'_
M .B._L;?^&^^-O\ ]$-1_P 0FXO_ .?. _\ "Z'_ ,B'_$5N$?\ G]C_ /PB
MG_\ )?U9^5_[[:*_@2_XBH?^"@__ $1W]C;_ ,-]\;?_ *(:C_B*A_X*#_\
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M175QIT<$B6T[I(RPR%0#T*BOEW]E7]IBV_:?T+XTZW:^#Y_!B_!W]J+]H?\
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MNN21>(]-@N-9MKH?6G[:4WBY?BMX8/BBY_:PL?@=I_P&^*6K>'$_8];XN?\
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M $0CX-?^&P\$?_*.C_AG/]GO_HA'P:_\-AX(_P#E'5_\1KPO_1/XC_PXT_\
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M $/Z'_ANJ?\ S6?Y#E%?Z\?_  SG^SW_ -$(^#7_ (;#P1_\HZ/^&<_V>_\
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MAZ^_M_P=K'V?3=6O+K2O[/UJ#3=4L6_M:_\ !/WP[\%?V9?^"GO[77CWX_\
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M^2E?$/\ Z\O"?_INEKTNO-/#W_)2OB'_ ->7A/\ ]-TM>ETWO\H_D@"BBBD
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M/ARV-X';^NNMO\_S _0BBOP'^"'[=OQ4LO OQO\ B!\;/B'XEUOPS\._B_\
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M?"7_ .>O7\&E%?8_\0HX._Z!<;_X7U_\_P"KORM\?_Q%3B__ *"L'_X0T/\
M(_O+_P"(JO\ 8E_Z(%^U/_X)OA+_ //7H_XBJ_V)?^B!?M3_ /@F^$O_ ,]>
MOX-**/\ B%'!W_0+C?\ POK_ .?]7?E8_P"(J<7_ /05@_\ PAH?Y']Y?_$5
M7^Q+_P!$"_:G_P#!-\)?_GKT?\15?[$O_1 OVI__  3?"7_YZ]?P:44?\0HX
M._Z!<;_X7U_\_P"KORL?\14XO_Z"L'_X0T/\C^\O_B*K_8E_Z(%^U/\ ^";X
M2_\ SUZ/^(JO]B7_ *(%^U/_ .";X2__ #UZ_@THH_XA1P=_T"XW_P +Z_\
MG_5WY6/^(J<7_P#05@__  AH?Y']Y?\ Q%5_L2_]$"_:G_\ !-\)?_GKT?\
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MX-**/^(4<'?] N-_\+Z_^?\ 5WY6/^(J<7_]!6#_ /"&A_D?WE_\15?[$O\
MT0+]J?\ \$WPE_\ GKT?\15?[$O_ $0+]J?_ ,$WPE_^>O7\&E%'_$*.#O\
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MIQ?_ -!6#_\ "&A_D?WE_P#$57^Q+_T0+]J?_P $WPE_^>O1_P 15?[$O_1
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MO;::WNX;74-,U32]1M;O3-9T75K.QUC1=5M+O2]5L;._M;BVC^-/''_!0O\
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M:_MK^#_VQOC+XQT+X0?\(QX/\<6GPW^"GBSX#_#'X%?#SPA-\2-:U3X:^ _
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M@_X0#[/K_P 2-<_X6=_:'_"=:)_PE6__ (6%]E_X0O[%X;V_V1Y__"6-]O\
M)LOU HH ^,/#/[(?_"._&W]ECXQ_\+"^V?\ #-'[*OQ'_9E_X1S_ (1/[/\
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M7.K/K-QY]QKHM8]0>***W22.'S5E_H<_8_\ #?[4_A/X!>#]"_;/\?\ P_\
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M36D__':/^$1\<_\ 13KW_P )K2?_ ([19=U^/^0'I=%>:?\ "(^.?^BG7O\
MX36D_P#QVC_A$?'/_13KW_PFM)_^.T67=?C_ ) >ET5YI_PB/CG_ **=>_\
MA-:3_P#':/\ A$?'/_13KW_PFM)_^.T67=?C_D!Z717FG_"(^.?^BG7O_A-:
M3_\ ':/^$1\<_P#13KW_ ,)K2?\ X[19=U^/^0'I=%>:?\(CXY_Z*=>_^$UI
M/_QVC_A$?'/_ $4Z]_\ ":TG_P".T67=?C_D!Z717FG_  B/CG_HIU[_ .$U
MI/\ \=H_X1'QS_T4Z]_\)K2?_CM%EW7X_P"0'I=%>:?\(CXY_P"BG7O_ (36
MD_\ QVC_ (1'QS_T4Z]_\)K2?_CM%EW7X_Y >ET5YI_PB/CG_HIU[_X36D__
M !VC_A$?'/\ T4Z]_P#":TG_ ..T67=?C_D!Z717FG_"(^.?^BG7O_A-:3_\
M=H_X1'QS_P!%.O?_  FM)_\ CM%EW7X_Y >ET5YI_P (CXY_Z*=>_P#A-:3_
M /':/^$1\<_]%.O?_":TG_X[19=U^/\ D!IV'PW\%Z9\1/$OQ7L=&\CQ_P",
M/"OA3P3XBU_^T=5E_M'PQX(U'Q1JWA?3/[+FOI-%M/[,U#QIXEN/MMCIUKJ%
M[_:7E:C=W<%G81VOD][^R5\"-1^*J?&.\\*:M/XM7QQI_P 4'TQ_'7CT_#N?
MXI:1X5@\$Z3\3;CX3_\ "2_\*RF^(&F>&+:UTZS\6OX3.M12VECJQNVUO3M/
MU*U]%_X1'QS_ -%.O?\ PFM)_P#CM'_"(^.?^BG7O_A-:3_\=H_[>7;[6W;8
M#R+P_P#L3_LP^%].UW2-%^%T$&E^)?%7P]\:Z]877BOQUJEMJ?B3X5_$35_B
MOX$OKB+5?$]ZOD:+X]UW5M<FTM-FD:U'>-HVO6.J:#%!ID6/IG["'[,^D:%J
MWA^S\)>+7MM1TCX9>'M.U+4?B[\7M:\2>"O#WP8\7'Q[\*- ^&OBK6?'-_XB
M^&^B> O&17Q!H.E^"=3T.R6[@L[>^AO=.L+&RMO=?^$1\<_]%.O?_":TG_X[
M1_PB/CG_ **=>_\ A-:3_P#':?\ V]_Z5_D!\_:3_P $_/V2]'L_'=I%\,;[
M4)?B=I7BC2O'^JZ_\1_BEXBUWQ.?&FN>$_%'B;6KW7-<\:W^J6_BO4O%/@;P
MKXH3Q?IMU8^)],\1:3'K6D:MI^H7%W<7&YX,_8B_9O\  OQ3M?CAI'A#Q/J7
MQ?MM8C\0-\0_&/Q9^+OCOQ#>:U%X&\3?#6*_U!_&7CK7+&^:#P+XOU[PW:VM
MQ9/866G7%DEE:6SZ)H;Z;[+_ ,(CXY_Z*=>_^$UI/_QVC_A$?'/_ $4Z]_\
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M^+_QA^(YOO&]_P"-?C?IOQ>\#>')_%?CA? WA*[T?X*^ /A5I.L7GPY;7D\
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M(?S_ ()&?]&E?^9Y_::_^?/1_P 0_G_!(S_HTK_S//[37_SYZ_4?_A$?'/\
MT4Z]_P#":TG_ ..T?\(CXY_Z*=>_^$UI/_QVC_6GB?\ Z*7/?_#OF7_R\/\
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M (36D_\ QVF^*>)_^BDSW9?\S?,>R_Z?]0_U7X9_Z)W(O_#1E_\ \SGY<?\
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M;:RM8(5=W8)N9B?=J^>)-"\9#XEP61\=;M7/@UKE=;_X1C2ALT_^UYHSIO\
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MQ\1/^BH?^63H?_R119=U^/\ D FE_P#)5/%/_8M:)_Z.>O2Z^?;#0O&;^/\
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M /)%%EW7X_Y >E45YK_PC'Q$_P"BH?\ EDZ'_P#)%'_",?$3_HJ'_EDZ'_\
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M_P LG0__ )(HLNZ_'_(#\N?BQ_P3^TK]H+_@KO+^T'^T!^S/\)?CA^RU8?\
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M?VG/A3XJT#0_ OA/]FW1?AKKU]\4=8^(_A:33M<TWQWX,/B_5+W6_#I%I?\
MP[L/"D:26LNH>)[TVNLV\;ZM9R06:D#^:?\ ;9_9V^-?AGX^_$;Q9I7P6^+?
MQ[\?^*+7]GJ;Q1X:^*/['_\ PN'X9_'#Q%X8\+^%M"U>^^'GQ_\ !'B/Q/XZ
M^%5A;W>FQWOB;P5I/C7PA>/:3ZAX/NO$^K>'[;3;/4_OCQ?\(/CIJGQ _P""
MV>K:G\'_ !S#??%_]E'X!Z)X%70?#7B_Q%H'C[QIIG[+UWH?B?PQ\+?$4VAV
MTGQ)N-#\4R2>'Y3HL%QJCWPA@O[&TU"<VBG*N^Z7R^']'_70/TWUK]M+X>3_
M !Q_9]^#_P +=1^'?QCT_P"-%[\0K+Q)XR\%?&?P!>M\,F\&^$-(\7Z*UUX5
ML;K5-6\5OXPM-486D.E3V<FEV5NNK7/VBRN8B/<_#WQ]^!/B[6O#7AOPI\:O
MA+XG\1>,]*U'7/!^@>'OB/X.UK6O%>B:/>ZIIVK:QX:TO3=9N;[7=*TO4-#U
MNPU'4-+@NK2RO='U2UN9HI]/NXX?PF^"_P"QY<_"OXI_\$3_ !GX*_9PU_P3
MK.G?#GXQZE^U#XETKX::]IEYH/C+5/@5X,M-+F^-.I#2D;PYKE[XBO?$>FZ9
M'XOET^ZEU%M0TNRC,EN]M%\V_!G]B'Q/X+_8W_X)O_$#3OV6_''AW]IS1/\
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M]?OAK_TT2UZ77FGA'_D>?B=_U^^&O_31+7I=-[_*/Y( HHHI %%%% !1110
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M(C<3Q16L_CGP[_X*)_"CQ=\3O WP2^('PJ_:0_9Q^,?Q7TSQQJOPA^'7Q_\
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M/C/Q)]MM_#7]E?VU/-_PB'AWQ!_9L-G_ &UIV)=4^Q)=>=+]C:X^R7GV?*^
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M0 4444 %%%% !1110 4444 >:>$?^1Y^)W_7[X:_]-$M>EUYIX1_Y'GXG?\
M7[X:_P#31+7I=-[_ "C^2 ****0!1110 4444 %%%% !1110 4444 >4?"'_
M ) >O_\ 8XZY_P"@65>KUY1\(?\ D!Z__P!CCKG_ *!95ZO3>_RC^2 ****0
M!1110 4444 %%%% !1110 4444 >4:C_ ,ECT#_L3KS_ -++ZO5Z\HU'_DL>
M@?\ 8G7G_I9?5ZO3>_RC^2 ****0!1110 4444 %%%% !1110 4444 %%%%
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M>&5#'+#-%(&22*1&9)(W5D=&*L""17SG^U)^RY\//VMO@XWP0^(>I>*_#OA
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MZ->HK*EYI6M:1X9L]2TZZ1695N+2YAE568!P"<[OQ%_9K_9S^,&N6_B?XM?
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M$W#^65WAL?F^ PN(23E0J8B'M8)I->TIQ<I4^9-.*FHN2=U=:G]'-%?SC?\
M$4-_P3F_Z$S]J?\ \-I\/_\ Y[U'_$4-_P $YO\ H3/VI_\ PVGP_P#_ )[U
M=O\ J/Q=_P!$_F7_ ()_^V\_S[,XO]=N$_\ H?Y=_P"#O^ ?T<T5_.-_Q%#?
M\$YO^A,_:G_\-I\/_P#Y[U7]+_X.>_\ @F]?W]O:7>@_M,:);S%Q)JFJ?##P
ME+86@6)Y%:XCT7XF:OJ;"1T6%/LNG7+"61#(L<(DEC3X'XN2;_U?S*R5]*#;
M^23;;\DFWLE<:XVX3;26?Y;=M+6NDM>[:22[MM);MV/Z*J*_ C_B)3_X)A?]
M#3\9?_#1:M_\L*/^(E/_ ()A?]#3\9?_  T6K?\ RPK/_4WBO_HGLW_\(JW_
M ,CY_GV9I_KCPK_T4&4_^%M#_P"3/WWHK\"/^(E/_@F%_P!#3\9?_#1:M_\
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M.&\1?^&/^-W_ ,P%'_$0]_P2>_Z.&\1?^&/^-W_S 4?ZI<4_]$YGG_AKQO\
M\I\_S[,/]:^&/^BAR3_PYX/_ .7>?Y]F?MI17XE_\1#W_!)[_HX;Q%_X8_XW
M?_,!1_Q$/?\ !)[_ *.&\1?^&/\ C=_\P%'^J7%/_1.9Y_X:\;_\I\_S[,/]
M:^&/^BAR3_PYX/\ ^7>?Y]F?MI17XE_\1#W_  2>_P"CAO$7_AC_ (W?_,!1
M_P 1#W_!)[_HX;Q%_P"&/^-W_P P%'^J7%/_ $3F>?\ AKQO_P I\_S[,/\
M6OAC_HH<D_\ #G@__EWG^?9G[:45^)\7_!PW_P $G))8XW_:+UZ!'D1&GE^!
MWQR,4*LP5I9!!\/)IC'&"7<0PRRE01'&[X4[W_$0'_P2,_Z.U_\ ,#?M-?\
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M9>'/^A_DG_AUP/\ \O\ -?>?KA17Y'_\/V_^"3W_ $=]X=_\-K\;O_G9T?\
M#]O_ ()/?]'?>'?_  VOQN_^=G1_JSQ)_P!$_GG_ (:<?_\ ,_FOO#_67AS_
M *'^2?\ AUP/_P O\U]Y^C.H_P#)8] _[$Z\_P#2R^KU>OQ,U/\ X+@_\$L9
M/B1X:UZV_:T\/MIMOHNI:?J5W_PKGXSA8MZW4MK$8G^&XF):>13OAB;[V'8*
M#CT/_A^W_P $GO\ H[[P[_X;7XW?_.SH?#/$CM_QC^=[+_F4X_HDO^@?T^37
M</\ 67AS_H?Y)_X=<#_\O\U]Y^N%%?F@O_!8_P#X)@LJL/VT/@X P# -J&LH
MP!&1N1]&5E//*L RG@@$$4O_  ^._P""87_1Z/P;_P#!EJ__ ,IZR_L#/O\
MH29O_P"&W&?_ "GS7WFO]O9'_P!#G*?_  XX/_Y=YK[S]+J*_-'_ (?'?\$P
MO^CT?@W_ .#+5_\ Y3T?\/CO^"87_1Z/P;_\&6K_ /RGH_L#/?\ H29O_P"&
MW&?_ "GS7WA_;V1_]#G*?_#C@_\ Y=YK[S]+J*_-FS_X+"?\$QKZ[M;*']M/
MX)I->7$%K$]YKUYI]HDMQ*L4;75_?Z=;6-C;J[@SWE[<V]I;1!IKF>*%'D7[
M_P#!GC;P9\1_"VB>.?A[XM\,^._!7B6R74?#OB_P;KNE^)O#&O:>[O$M]HVO
M:+=7NE:G:-+%)$+FRNIX?,CD3?O1@.3%9=F&"C&6-P&,PD9OEA+%86OAXSE:
M]HNK""D[)NRN[:['5ALQR_&N4<'CL'BY02E..&Q-&NX1=DG)4IS<4VTDW9:H
MZ>BO)?BI\??@3\"HM$G^-WQJ^$OP<@\2R7\/AR;XJ?$?P=\/8O$$NE+:/JD6
MB2>+M9TA-5DTU-0L'OTL&G:S6]M&N!&+F$O#X3_:%^ 7CWP/XF^)O@7XX_!_
MQI\-O!=IJE_XQ^(7A/XE^"_$?@?PG8Z'I\NK:U>^)O%FCZU>:#H-IH^E03ZG
MJESJE_:PZ?I\,M[=O#;1O(.,[#V"BLS1-;T7Q-HND>(_#FKZ7X@\/>(-+L-;
MT'7M$O[35=%UO1=5M(K_ $O5](U2PEN+'4M+U*QN(+RPO[.>:TO+2:*XMY9(
M9$=M.@ HJ-Y8HVB226.-[B0Q0([JK32K%+.8HE8@R2""&:8H@9A%%+(1LC<B
M2@ HKG/#7C'PCXSAU>Y\'^*O#GBNW\/^(]=\':]<>&M<TS78=$\7>%K^72O$
MWA75Y=+NKI--\1^'-4@FTW7=#O&AU/2+^&6SU"UM[B-XQT= 'FO_ #6'_NFO
M_NT5Z57FO_-8?^Z:_P#NT5Z53>_RC^2 ****0!1110 4444 %%%% !1110 4
M444 %%%% 'E&H_\ )8] _P"Q.O/_ $LOJ]7KRC4?^2QZ!_V)UY_Z67U>KTWO
M\H_D@/Y5OV._ /[?GQ>\(?\ !73X0?LU2_L8Z#\(_B;_ ,%5/^"C'@7QAXP_
M:%T_XH^.?&VDR>+O$UGH'C Z1\+-!T2/X=^*;*/P[?:>^A0>+_$\FDW.JO?1
M>)O#>KZ+'_9VHRP_L):O;?\ !0+5?V9_!?[5?[1/P3TK]E[_ ((Q_LG>#]*\
M;_ /Q1!\-_&/CKQ%\+_'7Q:\'>"]<\6:O)!X@U)_!]A+I6HZ]J?PSM=1CT+Q
M#>WVEV6LWUUI6@065W_3AX+^&_P[^&Z>*(_AWX"\%^ D\<>-/$/Q(\:IX+\+
M:'X63QA\1/%LT5SXK\>^*%T.QL1X@\:>)KBW@G\0^*=6%WKFM30Q2ZE?7+QH
MR@^&_P .QXTU?XD#P%X+'Q$\0>%;'P)KWCT>%M#'C36_!&EWU_JFF>#=7\4B
MQ_MS4O"NG:GJNJ:C8^'KV^FTBTOM2O[NWLX[B\N))$!_*3X]_:?^/_[3_P &
MO@OXI;XG_MF:YXX^'O\ P2U_9W_:8^-L7P _:$^$7[ WP5^'7B;XL^&O'^K^
M)_VC_BI\6KS7D^(OQ7O;L> 5O5^''@GX/>*?@_\ #JUT.Z1[.\UGQGJOARQY
M+QC^T#^VG\6/A'\&/VB]0_:(^.7BS0_!'_!,G]FWX_?$C2_V6/VB?AQ\ /BM
M\!?B!K'A?Q/XM\=_M3?%;]G?XC:#X+^&7[8/P^\8W6@VMC;^#;?XF:9X3M&\
M/>.O 8\#6'B.^TC6;?\ IK\4_L)?L2^-[_X?ZIXQ_9"_9E\47WPI\+:)X&^&
M<^N_ SX9ZH? 7@CPQ<W%[X8\&^$X[SPS+%H7A/PQ?7=U?^&O#>GQP:-X?O[J
MXOM'LK*[GEF>EXE_8 _85\96/@72_%7[&?[+.OZ7\,-+30?AUIFJ? +X67>G
M>!_#T>L7WB)?#GA:QD\+&UT/PV?$&IZCKS^'M/A@T636K^[U62Q>_N);A@#\
M*_VB?CC^T%^U=^TAI/PZ\+?&S]I?X;?"?PU_P3F^ 7[7_@"\^#OQ]^&G[#NO
M^,[7XH?\)RWQ#_:(^*8\;>&O$.KR>'_ DNG>#M$U+X1:IK\/A/P+J46H7'B.
MUO;?63--^JWP(\=:?\=/^"4?A3QS_P %"O$?@#Q!X6\<?LOZW<_M.>.M US4
MM"^'/CWX<KH6KV/B;XA0:SX4L_!=S9:!\2? EJGB^]7PA8:+I;Q>(KFR\*VH
MT:33HI/K7XU_LF?LN?M)W7AJ]_:%_9T^"'QPO?!OVA?"MW\6/A;X*^(%UX?@
MO7BDO['2KCQ3HNJ2V>F:C)!;OJ>E1.NFZD]O;-?6MP;>$IZ'XG^$_P +/&WP
MZN?A!XS^&GP_\7?"6\T73O#=W\+O$_@WP[KWPZNO#ND&S.DZ#<^"=5TV[\-3
MZ+I9T^P.G:7+IC6-D;&S^S01?9H=@!^3'['FEZS^U1^UAX(_;7T;0[+X*_LD
M?!C]FOQ+^SO^Q!\'[I;?PU\3_B3X2\=^(O ^L>+OCYXU\%Z>UMJ/@?X4:UX>
M^&_@31?@E\+?&SW?B$Z19?\ "Q=>\)^ -4NM(M=2\N^*NC?'76_^"_UY;? +
MXC?"7X:>*(O^"/'@^?5]8^,'P6\8?''0+[0!^VG\08Y=,TWPWX+^/G[/6HZ5
MK#ZB^GW4>N77BO6+*.RM;RP;P]+/?0:EIWZN?"O]B?\ 8T^!?BV'Q]\$OV2/
MV9/@[XZM[&]TNW\:?"OX"_"OX>^+8-,U)%CU'3H?$?A+PII&L16-_&B1WMHE
MXMO=(BI/'(J@#V<?#?X=K\1)/B\O@+P6OQ8E\%P_#>7XH#PMH8^(DGP[M]<G
M\3P> I/&HL?^$E?P7!XEN;GQ##X6;4SH<>N7$^K)8K?RR7# '\J7[2-E\1]'
M\$?\%PK7XQ^+_ GC7X@6G[<'_!&Y_$OBWX=?#[7?A/X(U%&U3]@ZXTM](\">
M*?B?\9-;\/KI^@OINGZFU_\ $GQ&-3U2SO\ 6K<Z/9ZC;Z#I?]96G^(-!U:5
MX-*UO2-3GCC,LD.GZE9WLL<094,KQVTTKK&'=$+L NYE7.6 /F?B[]G;]G[X
M@:9\3-%\>_ OX.>-]'^--]X6U3XQZ3XN^&/@GQ)IGQ9U/P-;Z':>"=1^)EAK
M.B7MKX\OO!UKX8\-6WA:[\4Q:K<>'K?P]H<.DR6D>DV"V_-?!_\ 9"_9-_9Z
MU_4O%?P"_9>_9V^!WBC6-'D\/:OXD^#_ ,%/AK\--?U70);VSU*70]2UCP7X
M9T34;[1Y-1T[3[^33+JYELGO;&SNF@,]K!(@!_-1^W]XJ\<?'WX+_P#!;[XI
M_&;]K;X[? EOV.=<\:_LV_"K]F/P-XV\*Z)\'M>^&'C+X'^"X/ >L_%KX>7O
MA36S\1[K]J3Q+\2M7BT3Q%KM\/$'@]%T\?#_ %3PI?\ A^.XM^?_ ."C'[17
MQZTC3_VUOCI\$OBM^VM80?L9V7PI\$Z7XO\ #_[1'PA_9;_96_9\\=67PB^$
MWC;1?#%Q\$KG7/&/Q)_;(UOXB^,/'=NNIW7Q/^$^G^%O&<GBNW^&?@G5[;P[
MX>T_Q9'_ $T?%/\ 8O\ V/\ XY^,X?B+\:OV6/V=_BYX]@TA] 7QC\2_@S\.
M_''B6706M;NQ&B7>L>)?#NIWU[I$5I?W]O;:;>33V=K'?7JVT,7VJ?S,KQO^
MPE^Q+\3/'FJ_%#XC_LA?LR^/_B+KVEP:)KOC7QK\#/AGXI\2:WI5KX?B\)6M
MEK.JZYX9OKO5(K7PG##X4M3?R7$EOX8BC\/0NFCHMD #\ /VJM:LO@U_P5O_
M &A_VJM1^-WQM^'>I>$O^"$.J?'K3M;\'2O\2+/0/%$'Q \<_#:WT_PG\%_$
M&L:-X(\<>%_#BPV_Q;T?X4^)]8TKX=M\85?XE^+=3TJUEU?5K?U/_@GS\0?V
M@_AY_P %*O"7[/7CCQ5^U?8> _B?^Q)X_P#C/?\ @']KK]L+X:?M6^.?%FI^
M&OB;\+M%\ ?&G3M!^'EWXPT#X!V_B.P\1_$#2%\+^#/B3JOA/Q=%I\[CPYIT
M_@VTU/4OW3\4_LD?LK^.-;\*>)/&7[-WP)\5:]X%^'FM_"'P;JWB'X3^!=7O
M?#/PG\2>&M9\&Z]\,-%FOM"G:P^'FK^$?$?B+PQ?^"K?9X:N= U_6](DTPV.
MK7\%QC?"C]B7]C?X$Z[I'BGX+_LI?LY_"KQ7H']M#0_%GP_^"_P[\*>*]('B
M2QMM+\0)IOB;1?#MGKMDFM:7966E:I';ZA&E[I=E9:;<+)96EO!& ?@5_P %
M8_VCOVE/AY^U'^TUX*^$G[0/Q4^%.G:1^SA_P39U;P@/!_B6YAL/!WBKXF_\
M%"+WX>>,O%FD>';[[7X;GU7Q#X0\GP]XABU+2KVP\2Z#;IH.OVNHZ,\ME)^D
M?[#WA3XA?L\?MF_M8?LC:E^TE^T7^T?\+?"_P(_9;^/7@_5/VHO'UA\5OB/X
M5\:?%?Q1^T-X(\?6&E>/E\.Z!K3>#]:L_A!X1U:U\(WS7FB>'-:_MBY\+6FB
MV^M:E:W'Z)>,?V?/@)\1-;U3Q+\0/@A\(?'7B/7-,\):+K7B#QC\-?!GB;6]
M7T;P#XH/C?P+I.J:KK>BWU_J&F>"O&C-XO\ "5A=SS6OASQ0QU_1XK/5B;NN
MXM?!?@ZQ\7:SX_LO"?AFS\>>(]#T+PQXA\;6N@Z7;^+M>\->%[S6]0\,^'M9
M\20VJ:SJFA^';_Q-XCOM"TF^O9[#2+SQ!K=SI]O;S:K?O< '35YI\7/^1&U'
M_K]T;_T[V=>EUYI\7/\ D1M1_P"OW1O_ $[V=..Z]5^8'I=%%%( HHHH _F]
M_P""R_\ P38_;F_X*)_%+P39_"_5?@WX8^"'POT.2'P[!XE\7:]9^)?$_B;Q
M#'87?B+6M<LK+PQ>6EG::;+:6^CZ%IZW5X52TO=7>>-]6^QV?W1_P28_X)MZ
M%_P3L^ !\.:U)H7B+XZ_$&\CUSXO>-](A=K6>XM9+I?#_A'0;NY@BO7\->%[
M"Y=(VF2$ZEK-WJVKF"".[M;.S_5DJ"<D?J:"N3DD\?3USZ?_ %Z^KK\9YU5X
M8H\'TOJ6!R*GB(XJMA\#A*>&JX_$JTG6S"O%NIBYU*BA5J.H[2J4J+Y4J-)0
M\2.08!9U+B"J\5BLS6'>$H5L7B:M>G@\+S.2H8*C-^RPM.+E4Y52BFO:UG?F
MKUG-&.,'W_H?_P!=?R5?\%9?^"*7[77[:W[:GCCX_P#PAU#X70^"/$7A7X?Z
M-91>*/%-[I6L)=^%_"UCHNH?:+2'1[N-(GN[21K=UN'WPLKL$8LJ_P!:C\@
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M3-#:P)&_Z_K_ (?_ ((?YVO_  <46_Q%A_X*I?&J3QR-8_L&Z\'?!V;X4-J
MNAIC?#M?AIX=M[C_ (1@7+.@TA/B-!\04U#[(1:MXL7Q+(J)+),H_#NO]3C]
MJ?\ 8%_9._;H\:7V@_M,?";3/'<GAC0-*N/"WB6SU37/"GC/PX\YN8IH--\5
M^%=2T?6GTJ<W#SW/A[4+J^\.7=ZEM?W>D3WME9W$'PQ_Q#6?\$PO^A6^,O\
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M-_T.?[4__AR_A_\ _.AH_P"(M\(_SYE_X1?_ '7^K/RN?\0GXL_DR[_PM_\
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M"_9\_P"CL?C)_P"$5X)_^/4?\0H7[/G_ $=C\9/_  BO!/\ \>JO^(I\&?\
M0QQ'_AOQO_RC^K/RO/\ Q"_C+_H7X?\ \+\'_P#+OZL_*_\ #O17]Q'_ !"A
M?L^?]'8_&3_PBO!/_P >H_XA0OV?/^CL?C)_X17@G_X]1_Q%/@S_ *&.(_\
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M\_8^OOC5J'PTTG0M1T.V\(ZY-\=_ALWPN\7+XZL-0\.:GK.IQ:=X?8WGAQ=
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MLJ^,_P!GM?&@T[QAJ_\ PADGA'Q7\1]$'CE[B#QK>>#;?^T_$?AOP_K%UIL
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M-HVB:+8P:;I6E:3H^DVMCI6E:9IUA;06=AINF65II]C:PQ6ME:V]M%'$FS3
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M:/KMQI_@/P1X3\IM0L[_ $?3DCNM(U6RTW][O^"<T?[)3?L<_"#4/V'-#O\
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M%_PMCX??]#'#_P" .J__ "#1_P +8^'W_0QP_P#@#JO_ ,@UWOV6V_Y]X/\
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MC3O_ ))J$^"_!Q!'_"*>&N>.-"TL'\Q:Y'U'-0?\('X+_P"A5T'_ ,%EI_\
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M+?\ 0RZ!_P"#C3O_ ))JE_P@?@O_ *%70?\ P66G_P :H_X0/P7_ -"KH/\
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M ).HT[O[E_F!CZ[/"?BQX'<31%%T?70SB1"JDVMW@%LX!.1@$\YKU7[5;?\
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M-M*B\1C2_&>H>,[+2[6;6-<^(%GXKUQ]7>^\00:C!K^J:GJ5Y[2WPSLE /\
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M[V]FLK?4+BR%_=(7FE+K;I=WTZ:;=M@/P2_:-_X*$?$/Q=^U/\>;WP3^UO\
M$[X,_ []GV[^#FF?#O7/@9\ +#]H7X6W^C_$31;>7Q9\;?COK<5Q'HU]\,TU
M"^L]&\+)::EK%WK:^(O#>I^ /#][JFD:E=ZW[]^V1^T#^T)\3OVE/B#\)/@E
M^TCK?P;\+_L]?\$]?$'[9;:O\-=$TFYL_B?\1]$U#2]1TO3-2N];6]NI/A[J
MN@:SH<MOIXGO;?RWO5U&VU<W(6V]U^.G_!*&]\=>,_C/+\#_ (^0_L^_!_\
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MB?P^OQ!'C/0_ GC:UL+"\\8^$=&TS7-0M97N8=6U;B/C[^QQ\=?V@_A]\(/
M'BG]HSX:V>@^ ]=UG6_B-X(L?V=?%-G\(/C5# MK#\-_#GBGP%H?[26@Z];>
M#_A^L,FHS^#;KX@Z]X4\:>((]*U#Q!HO]F:+9Z$?MGX8Z#XX\,>"])T/XA^*
M/"/B_P 2Z<)[>76? O@"Z^&'A;^SHYG31[#2O!=YXT^(,^DQ:;IBVME)GQ3?
M1W,T,ES!!I\$L=A;KIT_RVZ^?W(#OZ***0!1110 4444 %%%% !1110!YII?
M_)5/%/\ V+6B?^CGKTNO--+_ .2J>*?^Q:T3_P!'/7I=-[_*/Y( HHHI %%%
M% !1110 4444 %%%% !1110!YIX1_P"1Y^)W_7[X:_\ 31+7I=>:>$?^1Y^)
MW_7[X:_]-$M>ETWO\H_D@"BBBD 4444 %%%% !1110 4444 %%%% 'E'PA_Y
M >O_ /8XZY_Z!95ZO7E'PA_Y >O_ /8XZY_Z!95ZO3>_RC^2 ****0!1110
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MC(EU;I>W%G>+!<*HEA6[M+6Y6-U$]O!*'B7^<C_@YINOB?)_P46AM?&!OE\
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M%?>F]=]C_24_XB'O^"3W_1PWB+_PQ_QN_P#F H_XB'O^"3W_ $<-XB_\,?\
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M5/\ Q!KAO_H8YY_X/P'_ ,[O7^EK7_$8N(_^A?DG_@C'?_/#U_I:_P"FRO\
MP7:_X)/LRJ/VO_#@+$*"WPW^-B*"3@;G?X:*JCGEF(51R2 ":]!_X?'?\$PO
M^CT?@W_X,M7_ /E/7^7+142\&>'G;DS/.8]^:I@9WVVM@H6Z[WW7;6X^,>?J
M_/EN3RVMRT\;"W>]\9.]^FUO,_TW?#7_  5[_P"":-GXN\?WUS^V/\'X;34[
MO07L)WU'5O+NDMM-DAG:(C2"2(I"$;('S'C-=[_P^._X)A?]'H_!O_P9:O\
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M_0+*O5Z\H^$/_(#U_P#[''7/_0+*O5Z;W^4?R0!1112 **** "BBB@ HHHH
M**** "BBB@#R[Q+_ ,E.^&G_ %P\7?\ IF:O4:\N\5?NOB/\,)OO;_\ A+8=
MO3&=)A7=GG/^OSMP/NXS\V1ZC3>T?3]6 4444@"BBB@ HHHH **** "BBB@
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M#I/$<4<:9?@\1SYECJ^,EC)T<OQJA@Z.6TL+A\5#$UL9"C@OMJ7C=Q!PSD6
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MZUT'4ET+PI>:-K6GZA>Z]);/%IUG,U[80V,4(NY(GO)C>;([:.<QM)*$C?\
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MIQGTWQ-XY\;?$Z;Q3XHU&W6"ZO?%'A_2/$TMQ/KB_;H_=KCX;?#J[FN[B[\
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M_P"B^_M3_P#@Y^$O_P ZBOUK_P"'K_[ 7_1>_P#S%OQI_P#G<T?\/7_V O\
MHO?_ )BWXT__ #N:KZKXZ_\ 0@\0?_$6S;R_ZE?E^?=D_P"LGT=O^BT\+O\
MQ-\@_P#GP?DI_P 0JG[$O_1??VI__!S\)?\ YU%86N_\&IG[)=Q# OAG]I3]
MHK2+A9&-S+KMM\-/$4,T)7")!!I_A'PL]M(K_,TLEQ=*R_((4/SU^Q'_  ]?
M_8"_Z+W_ .8M^-/_ ,[FC_AZ_P#L!?\ 1>__ #%OQI_^=S51PWCK%IK(./[K
M^;A3-)+YQEE33^:8GQ%]'62:?&GA?9]N.,AB^^\<Y37R?EL?BC_Q"A?L^?\
M1V/QD_\ "*\$_P#QZC_B%"_9\_Z.Q^,G_A%>"?\ X]7[7?\ #U_]@+_HO?\
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M-NMOA_,B[S&_[MV65<?.BY&?0?\ AZ_^P%_T7O\ \Q;\:?\ YW--^&_B)?\
MY(+C39?\TMGG9?\ 4"'_ !&#PE_Z.CX=?^)MPU_\\S]$J*_.W_AZ_P#L!?\
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M\1/^B"XT_P#$6SS_ .80_P"(P>$O_1T?#K_Q-N&O_GF?HE17YV_\/7_V O\
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M *.CX=?^)MPU_P#/,_1*BOSM_P"'K_[ 7_1>_P#S%OQI_P#G<T?\/7_V O\
MHO?_ )BWXT__ #N:/^(;^(G_ $07&G_B+9Y_\PA_Q&#PE_Z.CX=?^)MPU_\
M/,_1*BOSM_X>O_L!?]%[_P#,6_&G_P"=S1_P]?\ V O^B]_^8M^-/_SN:/\
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M #"'_$8/"7_HZ/AU_P")MPU_\\S]$J*_.W_AZ_\ L!?]%[_\Q;\:?_G<T?\
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M1@\)?^CH^'7_ (FW#7_SS/T2HK\[?^'K_P"P%_T7O_S%OQI_^=S1_P /7_V
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MN3X=,K;64C*L5.,@D8-7O^'K_P"P%_T7O_S%OQI_^=S2_P"(;^(G_1!<:?\
MB+9Y_P#,(?\ $8/"7_HZ/AU_XFW#7_SS/T2HK\[?^'K_ .P%_P!%[_\ ,6_&
MG_YW-'_#U_\ 8"_Z+W_YBWXT_P#SN:/^(;^(G_1!<:?^(MGG_P PA_Q&#PE_
MZ.CX=?\ B;<-?_/,_1' ]!^5(%5?N@#Z5^=__#U_]@+_ *+W_P"8M^-/_P [
MFC_AZ_\ L!?]%[_\Q;\:?_G<T?\ $-O$3_H@>-/_ !%L\Z;?\P ?\1@\)?\
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MQC+_ (Q[C9S4GRSEP7F\U*,G)OFI_4H04[>S4>6T5R2=K5))>O+QR\"W*/\
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MT07&G_B+9Y_\PA_Q&#PE_P"CH^'7_B;<-?\ SS/T2HK\[?\ AZ_^P%_T7O\
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M6G_&+<.=/^9)EG]S_J%\W][#_AQI^R9_T4/]HG_PK?AK_P#.DH_X<:?LF?\
M10_VB?\ PK?AK_\ .DHHH_UDXB_Z'^=?^'3'?_+P7!_"6G_&+<.=/^9)EG]S
M_J%\W][#_AQI^R9_T4/]HG_PK?AK_P#.DH_X<:?LF?\ 10_VB?\ PK?AK_\
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M/^9)EG]S_J%\W][#_AQI^R9_T4/]HG_PK?AK_P#.DH_X<:?LF?\ 10_VB?\
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M6G_&+<.=/^9)EG]S_J%\W][#_AQI^R9_T4/]HG_PK?AK_P#.DH_X<:?LF?\
M10_VB?\ PK?AK_\ .DHHH_UDXB_Z'^=?^'3'?_+P7!_"6G_&+<.=/^9)EG]S
M_J%\W][#_AQI^R9_T4/]HG_PK?AK_P#.DH_X<:?LF?\ 10_VB?\ PK?AK_\
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M/^9)EG]S_J%\W][#_AQI^R9_T4/]HG_PK?AK_P#.DH_X<:?LF?\ 10_VB?\
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M6G_&+<.=/^9)EG]S_J%\W][#_AQI^R9_T4/]HG_PK?AK_P#.DH_X<:?LF?\
M10_VB?\ PK?AK_\ .DHHH_UDXB_Z'^=?^'3'?_+P7!_"6G_&+<.=/^9)EG]S
M_J%\W][#_AQI^R9_T4/]HG_PK?AK_P#.DH_X<:?LF?\ 10_VB?\ PK?AK_\
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M/^9)EG]S_J%\W][#_AQI^R9_T4/]HG_PK?AK_P#.DH_X<:?LF?\ 10_VB?\
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M6G_&+<.=/^9)EG]S_J%\W][#_AQI^R9_T4/]HG_PK?AK_P#.DH_X<:?LF?\
M10_VB?\ PK?AK_\ .DHHH_UDXB_Z'^=?^'3'?_+P7!_"6G_&+<.=/^9)EG]S
M_J%\W][#_AQI^R9_T4/]HG_PK?AK_P#.DH_X<:?LF?\ 10_VB?\ PK?AK_\
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M/^9)EG]S_J%\W][#_AQI^R9_T4/]HG_PK?AK_P#.DH_X<:?LF?\ 10_VB?\
MPK?AK_\ .DHHH_UDXB_Z'^=?^'3'?_+P7!_"6G_&+<.=/^9)EG]S_J%\W][#
M_AQI^R9_T4/]HG_PK?AK_P#.DH_X<:?LF?\ 10_VB?\ PK?AK_\ .DHHH_UD
MXB_Z'^=?^'3'?_+P7!_"6G_&+<.=/^9)EG]S_J%\W][#_AQI^R9_T4/]HG_P
MK?AK_P#.DH_X<:?LF?\ 10_VB?\ PK?AK_\ .DHHH_UDXB_Z'^=?^'3'?_+P
M7!_"6G_&+<.=/^9)EG]S_J%\W][#_AQI^R9_T4/]HG_PK?AK_P#.DH_X<:?L
MF?\ 10_VB?\ PK?AK_\ .DHHH_UDXB_Z'^=?^'3'?_+P7!_"6G_&+<.=/^9)
MEG]S_J%\W][#_AQI^R9_T4/]HG_PK?AK_P#.DH_X<:?LF?\ 10_VB?\ PK?A
MK_\ .DHHH_UDXB_Z'^=?^'3'?_+P7!_"6G_&+<.=/^9)EG]S_J%\W][#_AQI
M^R9_T4/]HG_PK?AK_P#.DH_X<:?LF?\ 10_VB?\ PK?AK_\ .DHHH_UDXB_Z
M'^=?^'3'?_+P7!_"6G_&+<.=/^9)EG]S_J%\W][#_AQI^R9_T4/]HG_PK?AK
M_P#.DH_X<:?LF?\ 10_VB?\ PK?AK_\ .DHHH_UDXB_Z'^=?^'3'?_+P7!_"
M6G_&+<.=/^9)EG]S_J%\W][#_AQI^R9_T4/]HG_PK?AK_P#.DH_X<:?LF?\
M10_VB?\ PK?AK_\ .DHHH_UDXB_Z'^=?^'3'?_+P7!_"6G_&+<.=/^9)EG]S
M_J%\W][#_AQI^R9_T4/]HG_PK?AK_P#.DH_X<:?LF?\ 10_VB?\ PK?AK_\
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M/^9)EG]S_J%\W][#_AQI^R9_T4/]HG_PK?AK_P#.DH_X<:?LF?\ 10_VB?\
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E/)\!B8Y=F<8XC!99@L+7C&>%BIQ5:A0IU%&:;4DI6DG9IG__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>nt10014672x1_barchart3.jpg
<TEXT>
begin 644 nt10014672x1_barchart3.jpg
M_]C_X  02D9)1@ ! 0$ P #   #_[0 V4&AO=&]S:&]P(#,N,  X0DE- ^T*
M4F5S;VQU=&EO;@     0 ,     !  $ P     $  ?_B"^!)0T-?4%)/1DE,
M10 ! 0  "]!N;VYE @   &UN=')21T(@6%E:( ?4  < %0 3  L (6%C<W
M         $E%0R!S4D="     0            #VU@ !     -,M2% @(
M
M$&1E<V,   %$    =&)865H   &X    %&)44D,   ',   (#&1M9&0   G8
M    B&=865H   I@    %&=44D,   ',   (#&QU;6D   IT    %&UE87,
M  J(    )&)K<'0   JL    %')865H   K     %')44D,   ',   (#'1E
M8V@   K4    #'9U960   K@    AW=T<'0   MH    %&-P<G0   M\
M*&-H860   ND    +&1E<V,         &G-21T(@245#-C$Y-C8M,BTQ('=I
M=&A"4$,
M                                                    6%E:(
M     "2@   /A   ML]C=7)V        !      %  H #P 4 !D '@ C "@
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M;W5R(%-P86-E("T@<U)'0@
M
M      !865H@        8ID  +>%   8VEA96B            !0
M;65A<P         !                               "6%E:(
M  ,6   #,P   J1865H@        ;Z(  #CU   #D'-I9R      0U)4(&1E
M<V,         +5)E9F5R96YC92!6:65W:6YG($-O;F1I=&EO;B!I;B!)14,@
M-C$Y-C8M,BTQ
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MU=;7V-G:X>+CY.7FY^CIZO'R\_3U]O?X^?K_Q  ? 0 # 0$! 0$! 0$!
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M?$7_ ,2K\=?_ "\H_P"&*/\ @L7_ -'"?$7_ ,2K\=?_ "\K^FFBOW7_ (F
MXI_Z)GP^_P#$6A_\V'\Q_P#$JO!/_19^*_\ XFU3_P"=WDON/YEO^&*/^"Q?
M_1PGQ%_\2K\=?_+RC_ABC_@L7_T<)\1?_$J_'7_R\K^FFBC_ (F XI_Z)GP^
M_P#$6A_\V!_Q*KP3_P!%GXK_ /B;5/\ YW>2^X_F6_X8H_X+%_\ 1PGQ%_\
M$J_'7_R\H_X8H_X+%_\ 1PGQ%_\ $J_'7_R\K^FFBC_B8#BG_HF?#[_Q%H?_
M #8'_$JO!/\ T6?BO_XFU3_YW>2^X_F6_P"&*/\ @L7_ -'"?$7_ ,2K\=?_
M "\H_P"&*/\ @L7_ -'"?$7_ ,2K\=?_ "\K^FFBC_B8#BG_ *)GP^_\1:'_
M ,V!_P 2J\$_]%GXK_\ B;5/_G=Y+[C^9;_ABC_@L7_T<)\1?_$J_'7_ ,O*
M/^&*/^"Q?_1PGQ%_\2K\=?\ R\K^FFBC_B8#BG_HF?#[_P 1:'_S8'_$JO!/
M_19^*_\ XFU3_P"=WDON/YEO^&*/^"Q?_1PGQ%_\2K\=?_+RC_ABC_@L7_T<
M)\1?_$J_'7_R\K^FFBC_ (F XI_Z)GP^_P#$6A_\V!_Q*KP3_P!%GXK_ /B;
M5/\ YW>2^X_F6_X8H_X+%_\ 1PGQ%_\ $J_'7_R\H_X8H_X+%_\ 1PGQ%_\
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M_G=Y+[C^9;_ABC_@L7_T<)\1?_$J_'7_ ,O*/^&*/^"Q?_1PGQ%_\2K\=?\
MR\K^FFBC_B8#BG_HF?#[_P 1:'_S8'_$JO!/_19^*_\ XFU3_P"=WDON/YEO
M^&*/^"Q?_1PGQ%_\2K\=?_+RC_ABC_@L7_T<)\1?_$J_'7_R\K^FFBC_ (F
MXI_Z)GP^_P#$6A_\V!_Q*KP3_P!%GXK_ /B;5/\ YW>2^X_F6_X8H_X+%_\
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M-.U!7_:F\?1"*ZC9U9$9]:"RJ=A(>,LI&,D'@;/_  Q1_P %B_\ HX3XB_\
MB5?CK_Y>5_0E\./^0Y\2_P#L<;O_ -#GKU>F_'_BE?\ -,^'VR_YI:'5)_\
M08'_ !*KP3_T6?BO_P")M4_^=WDON/YEO^&*/^"Q?_1PGQ%_\2K\=?\ R\H_
MX8H_X+%_]'"?$7_Q*OQU_P#+ROZ::*7_ !,!Q3_T3/A]_P"(M#_YL#_B57@G
M_HL_%?\ \3:I_P#.[R7W'\RW_#%'_!8O_HX3XB_^)5^.O_EY1_PQ1_P6+_Z.
M$^(O_B5?CK_Y>5_3311_Q,!Q3_T3/A]_XBT/_FP/^)5>"?\ HL_%?_Q-JG_S
MN\E]Q_,M_P ,4?\ !8O_ *.$^(O_ (E7XZ_^7E'_  Q1_P %B_\ HX3XB_\
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M?CK_ .7E?TB>#/\ D3_"?_8M:%_Z:[6NEI?\3 <4_P#1,^'W_B+0_P#FP/\
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M\,4?\%B_^CA/B+_XE7XZ_P#EY1_PQ1_P6+_Z.$^(O_B5?CK_ .7E?TTT4?\
M$P'%/_1,^'W_ (BT/_FP/^)5>"?^BS\5_P#Q-JG_ ,[O)?<?S+?\,4?\%B_^
MCA/B+_XE7XZ_^7E8^L_LB_\ !7O04T]]1_:(^),:ZGJEIH]H8_VIO'LNZ^O1
M*8$<)K9*1D0OND/RK@9ZBOZ@:\N^*7_'MX*_[*'X;_\ 1>H4UX_\4MI?ZL^'
MVK7_ #2T/_FP/^)5>"?^BS\5_P#Q-JG_ ,[O)?<?SS_\,4?\%B_^CA/B+_XE
M7XZ_^7E'_#%'_!8O_HX3XB_^)5^.O_EY7]--%+_B8#BG_HF?#[_Q%H?_ #8'
M_$JO!/\ T6?BO_XFU3_YW>2^X_F6_P"&*/\ @L7_ -'"?$7_ ,2K\=?_ "\H
M_P"&*/\ @L7_ -'"?$7_ ,2K\=?_ "\K^FFBC_B8#BG_ *)GP^_\1:'_ ,V!
M_P 2J\$_]%GXK_\ B;5/_G=Y+[C^9;_ABC_@L7_T<)\1?_$J_'7_ ,O*/^&*
M/^"Q?_1PGQ%_\2K\=?\ R\K^FFBC_B8#BG_HF?#[_P 1:'_S8'_$JO!/_19^
M*_\ XFU3_P"=WDON/YEO^&*/^"Q?_1PGQ%_\2K\=?_+RC_ABC_@L7_T<)\1?
M_$J_'7_R\K^FFBC_ (F XI_Z)GP^_P#$6A_\V!_Q*KP3_P!%GXK_ /B;5/\
MYW>2^X_F6_X8H_X+%_\ 1PGQ%_\ $J_'7_R\H_X8H_X+%_\ 1PGQ%_\ $J_'
M7_R\K^FFBC_B8#BG_HF?#[_Q%H?_ #8'_$JO!/\ T6?BO_XFU3_YW>2^X_F6
M_P"&*/\ @L7_ -'"?$7_ ,2K\=?_ "\H_P"&*/\ @L7_ -'"?$7_ ,2K\=?_
M "\K^FFBC_B8#BG_ *)GP^_\1:'_ ,V!_P 2J\$_]%GXK_\ B;5/_G=Y+[C^
M9;_ABC_@L7_T<)\1?_$J_'7_ ,O*R-8_9%_X*]:$E@^H_M$_$B)=2U.UTBTV
M?M3>/I3)?7HD,$;"/6F\M6$4A:1\(NWELD _U 5Y=\4O^/;P5_V4/PW_ .B]
M0IKQ_P"*6TO]6?#[5K_FEH?_ #8'_$JO!/\ T6?BO_XFU3_YW>2^X_GG_P"&
M*/\ @L7_ -'"?$7_ ,2K\=?_ "\H_P"&*/\ @L7_ -'"?$7_ ,2K\=?_ "\K
M^FFBE_Q,!Q3_ -$SX??^(M#_ .; _P")5>"?^BS\5_\ Q-JG_P [O)?<?S+?
M\,4?\%B_^CA/B+_XE7XZ_P#EY1_PQ1_P6+_Z.$^(O_B5?CK_ .7E?TTT4?\
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M)@.*?^B9\/O_ !%H?_-@?\2J\$_]%GXK_P#B;5/_ )W>2^X]/_X8H_X+%_\
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M^(M#_P"; _XE5X)_Z+/Q7_\ $VJ?_.[R7W'DO_#%'_!8O_HX3XB_^)5^.O\
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MLOP^\-^#].UWQ/XOBNM,O[/4[FXT31[NTT?2IO[6UVXTS2X;B\B/^)@.*?\
MHF?#[_Q%H?\ S8'_ !*KP3_T6?BO_P")M4_^=WDON/QH_P"&*/\ @L7_ -'"
M?$7_ ,2K\=?_ "\H_P"&*/\ @L7_ -'"?$7_ ,2K\=?_ "\K]=OV1_\ @IS^
MPU^W;XK\7^"?V4/CM:?%SQ+X#\,:#XQ\66%EX"^*?A:'2/#_ (E,":3=/J?C
MOP/X7TF[NWFN$M+_ $>POKK6=%ODN;#6M/T^]L[N"'[SH_XF XI_Z)GP^_\
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ME5X)_P"BS\5__$VJ?_.[R7W'\]'_  Q1_P %B_\ HX3XB_\ B5?CK_Y>4?\
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MMKXDTDZ:?#7C.:/76DOO%^BZY?76E>'[NXGT'3?S7_:Z_;F_;C\'I_P5%N_
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M$[N&8:AXCT36/"TL-[X<L-(\87>AW^@^(]1TS46 /]!BBOY3OC)KEK_P3!\
M_MT_#+Q%_P %X/C#XDDM/@CX#O\ PW\-_B_X0L?VJ_VT?@+XG\4:WX1TVV\:
M^!=9OOBCX(?4;;QW!K]YX<TOPYJ.@>$]!\%)XX^'_C;5/&WA\:#'KGBCPG_@
MF9\:_P!L;X1?\%??A5^RKX@\6?\ !0.Y_9W^._[)FM?&C4? G_!1SXW^!_BY
M\8IQ8KX[?1OC%IOAW09=;N?@9'KWB_PP_AR;X/W'B*\\8Q&ZU;Q-XOU/5M,N
MO#<&D@']+_[#G[=OP!_X*&_!S4OCK^SAJ/BC4_ .E>.]:^'-W<>+O#5SX5U1
M?$N@:1X>UO48H]-NIIY'LUL?$^E-%=APDLKSQA086)^G/'G_ ")?BK_L ZG_
M .DDM?S5_P#!I1_RC#\<_P#9WGQ4_P#5;?!6OZ5/'G_(E^*O^P#J?_I)+3CN
MO5?F!/X,_P"1/\)_]BUH7_IKM:Z6N:\&?\B?X3_[%K0O_37:UTM(#\;_ -K+
M_@NO^P7^Q?\ '_QI^S1\:-4^+P^*7@#3/#>L>)+'P9\*=9\6Z3:Z=XJ\-:-X
MLTNYCU6PNDCEB&D:]IS7;F)$M;F5K>1MRY/6>*O^"VG_  3N\._LO>!_VP=*
M^,5]X^^"GCOXRZ/\ ;*_\">$]:U/Q5X>^*NM^&O$WBVU\+^-_!&J0Z+XF\'W
M2Z%X4U+4&;7-.M1<65QI&HZ>+W2M7T^_G_"'XD^)/VU_#/\ P<H_M]7/[!?P
MQ^"7Q4^-E_\ L3_#O2[_ $7X_>(M8\/> -(\"W&@_LC3ZMXA=="U70M1UW5+
M?7;7PSI<&@QZWI2W-CJ^HWK78_L]8I?@W_@IO_P3:^-G[!7_  3'O?%'QO\
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M,^%L9\*V>F7VA7>H^!]2\2>*+K2K?P9K.I:?X'^WIJ7C7P\ ?V&5\2?M*_\
M!0S]EO\ 9/\ C-^S9^SY\7O&]W:?&+]J[Q_X=^'OPC\#>'M&NO$.KW%]XH\5
M:-X)TCQ!XG6R(B\*>$;GQ1KUCH]OKFKR0IJ-S%JXT>WU)?#^OMIGRG_P0U^+
MO[4/Q>_86TRZ_:Q\6:1\1O'G@3XG>,_ASX1^*>G_ !'^$GQ6U7XF_"S0]/\
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M-3\2Z<^A>'9)7\0V5K-97OV&^NQ-MBF,?MU '\C_ .UA\(/BQ^SE_P %/OV
M/V[_ (F?\$\O&WQH_9H\,_L/^$_@MXH^"?[,?PLL?V@K/]BWXL^'++QIJ$.@
M_#;P/X.TWPOHS>$OA_JGB;0]+\,>,=8T;3=%FTC4O&-]X-L[;7?#WA/1;/\
M*+Q+_P $Y_VJ/'GP#^+WQCL/V,/C;X$^%'[7G_!;3X$?%?X;_LE6WP>\7VGQ
M#^%'[-?A+1?VPTUSQQX\^%/A'3-1F^%7@>;3_C%X6\$RW$PTG1]/;PQ#+IL6
MG^$=2\#WVL?Z'M-+*I4,RJ78J@) +L%9RJ@G+,$1W(&3M5FQA20 ?S*>!/V8
M_B;J'_!Q7_P4*^,OBSX ?$&Z^!?C3_@GW#X0\(?%/7OA?XF?X1^,_&M]X2_9
M7\,ZIX3T+QK?:)_PAGBGQ'=Z+8>-=%OO#MIJ6H:A-9:;XBM)[)DTV_2W_)#X
MJ?L>?M=:C_P;F?\ !/+X'V'[+7[1U_\ &CP1_P %!]4\9^,/A!:?!'XFW7Q0
M\(^#)-4_:YE3Q7XE^'\/AB3Q7H'AB1?$WAZ5-=U32;32F7Q!HSBZ(U:Q-Q_>
MY10!_'9^S?\ L@_&VTT+_@ZPN_%_[-'Q>L=9_:$U[]J)OV>9=?\ A'XYLK_X
MW6MW<?MB:_X+;X*_;M!AF^(]OJWB#7/!>HZ*? @UB/6[[5/"CPF\:[T8/XKX
M]_9\_:/^#/P7_P"#>#]IKQ'^S)\9/CO_ ,,@^'?$WA_XV_L@VO@+5=9^/GAV
MVU/7/#'V3QCX3^!>KP:9XSU?7/#$<6G/<K>V]IH_A[Q'HOPELM<ETG3-=%XO
M]OM?#W[;W_!/7]G+]O\ \-_#[1_CII_C/3/$OP@\52^./@_\4_A=XRU/X?\
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MK,7@C7?!)\/6_AGPW)%X1U7P-9:OK?B&7X6Z/+JWQY_P4O\ @KHG[#_[1_\
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M#[7_ ..T?VUHW_06TS_P/M?_ ([0!IT5F?VUHW_06TS_ ,#[7_X[1_;6C?\
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M8P\BEHV# JX!5N<$X./3/[:T;_H+:9_X'VO_ ,=IO?Y1_) >0_LW?LW?!?\
M9%^"_@S]GG]GGP9_PK[X/_#[_A(O^$0\(?\ "1>*_%G]D?\ "6>*]=\;Z_\
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MCO8);SBR^SG4=2-W^@7]M:-_T%M,_P# ^U_^.T?VUHW_ $%M,_\  ^U_^.T
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M2V>EV&DQM#H]I!IZ?L/_ &UHW_06TS_P/M?_ ([1_;6C?]!;3/\ P/M?_CM
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MV@GNM/TXOH">%_\ A&OL.G:;HHT<:#I]EI<'?_M4?\$>/^"=G[:'Q7N/C?\
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MB'4;'6=.O_&^OR^*/%\WB?4_$6@ZW9:[/XN\0W%[ICSWD4EOX=\._P#@B?\
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MO_5"^/J^S_[:T;_H+:9_X'VO_P =KP[]IWX9Z-^T=^S7^T+^SS_PG6F>#?\
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M (5+_:?Q7^%WQ._X0/\ X1/_ (6]!_PGGD?\*V_L/_A*/^$F\&>9_;7]I?\
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M'_P.U7_Y.H_X5/\ #[_H7(?_  .U7_Y.KT2BE=]W][ \[_X5/\/O^A<A_P#
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M#_X':K_\G5Z)11=]W][ \[_X5/\ #[_H7(?_  .U7_Y.H_X5/\/O^A<A_P#
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M_O8'G?\ PJ?X??\ 0N0_^!VJ_P#R=1_PJ?X??]"Y#_X':K_\G5Z)11=]W][
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M2>//'%M>3,TCJTEJ+:ZBFMI[RSD\Z^'.K> _'O[(OP\\9?M1_M4_%W4_V=_
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MO=WMKJ=UXQ\::-<:-)IOBGQ5<ZE8V6H7'B'7+:^U>:]L[6[DO&GMXI$];HH
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MR$1VP.=JL>@- 'IM%%% !1110 4444 %%%% !1110 4444 %%%% !7E&H_\
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M_#=K=PV[VJ7>H)I^J7.IZM(4C=]*M+6WA@MIO-N=6AND%C)\Y?\ #XKXE_\
M1'/ W_@]U_\ ^)K]/R;P>\0<_P OPV:X#(U'!8RE"MA:F+QV!P<\11G%.%:%
M#$8B%=4JD;2I5*E.$:M.4:E)SIRC)_B7$OTB/"3A3.,9D.:\3N69Y?5GA\?1
MR_+,TS&EA,33?+4PU7%83"5<++$497A7I4JU2>'JPG1KJG6A*FOW]HK\ O\
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MWRS_ .:@_P")J_!7_HHLP_\ $>SO_P"8OZL_*_[^T5^ 7_#XKXE_]$<\#?\
M@]U__P")H_X?%?$O_HCG@;_P>Z__ /$T?\0&\2_^A/A/_#OEG_S4'_$U?@K_
M -%%F'_B/9W_ /,7]6?E?]_:*_ +_A\5\2_^B.>!O_![K_\ \31_P^*^)?\
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M *$^$_\ #OEG_P U!_Q-7X*_]%%F'_B/9W_\Q?U9^5_W]HK\ O\ A\5\2_\
MHCG@;_P>Z_\ _$T?\/BOB7_T1SP-_P"#W7__ (FC_B WB7_T)\)_X=\L_P#F
MH/\ B:OP5_Z*+,/_ !'L[_\ F+^K/RO^_M%?@%_P^*^)?_1'/ W_ (/=?_\
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M[KGB[QQKECHMS\6[CXG:WX.L%L1XP^(=II6N:WX),OO/_!-/X!?$CX>?M)_
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MUX5'&E7J%%%%?FA^U!1110 4444 %%%% !1110 4444 %%%% !1110 4444
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ML]-L-:AM>N_9I\(_%75/VK?V??'/Q87]IO7/C/H,7[8NG_M MXZT7XLO\!O
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M%_\ 0L?RLT5_5-_P[=_8N_Z(S_YD3XK_ /S=4?\ #MW]B[_HC/\ YD3XK_\
MS=4?\3)\"_\ 0JXL_P#"')__ )^A_P 27^*/_0^X!_\ #IQ%_P#0L?RLT5_5
M-_P[=_8N_P"B,_\ F1/BO_\ -U1_P[=_8N_Z(S_YD3XK_P#S=4?\3)\"_P#0
MJXL_\(<G_P#GZ'_$E_BC_P!#[@'_ ,.G$7_T+'\K-%?U3?\ #MW]B[_HC/\
MYD3XK_\ S=4?\.W?V+O^B,_^9$^*_P#\W5'_ !,GP+_T*N+/_"')_P#Y^A_Q
M)?XH_P#0^X!_\.G$7_T+'\K-%?U3?\.W?V+O^B,_^9$^*_\ \W5'_#MW]B[_
M *(S_P"9$^*__P W5'_$R? O_0JXL_\ "')__GZ'_$E_BC_T/N ?_#IQ%_\
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MX=N_L7?]$9_\R)\5_P#YNJ/^)D^!?^A5Q9_X0Y/_ //T/^)+_%'_ *'W /\
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MX/B>5]*L+^;58H=9NKNZ@>WBN+&\L;P1WB?N=7X0?"7XE^&]-\9?#/PSHO\
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MB_B[]NS]F;P=^RU:_MB7WQ"M=0^"FJZ,FI^&]2TJ'S=?\5ZG->SZ5#X.\/\
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MH_L+XM?]#SHW_@AM?_D.O5Z*+OR^Y?Y >4?V%\6O^AYT;_P0VO\ \AT?V/\
M%Z'F/Q=X;NR>"MWI(MU0?WD-K9%F8]"&X Y'->KT47]/N7Z(#RC^SOC'_P!!
M_P '?^ =Y_\ (-']G?&/_H/^#O\ P#O/_D&O5Z*+^2^[T_R_%]P/*/[.^,?_
M $'_  =_X!WG_P @UP7Q(L_B-#X;W^(M6\.7>G?VE8#RM.MKF.X^T&4^0^Z2
MUB7RU;)D&[)'0&OI2O*/C-_R)O\ W&=)_P#1[4T]5HMU^G^7XON ?V=\8_\
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MY*UX&_[ VO?^DMY33UV6SZ>7_ _%]P)O.^,O_/K\//\ OK7_ /Y(H\[XR_\
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M \H_M'XQ_P#0 \'?^!EY_P#)U']H_&/_ * '@[_P,O/_ ).KU>BB_DON]/\
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M _\ :"^*O['OQ,^*D%H/BW)^SGXTT>V\"?%;5['3%T*U\8^.?AA\5_A;\4O
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M_#?_ *+U"O4:\N^*7_'MX*_[*'X;_P#1>H4X[KU7Y@>HT444@"BBB@ HHHH
M**** "BBB@ HHHH *\H^,W_(F_\ <9TG_P!'M7J]>5?&52?!%Q-QLM=3TJ>0
M?Q%!=I%A!T+;I5X) QDYR "X[KU7Y@>JT444@"BBB@ HHHH **** "BBB@ H
MHHH **** "O,O%R@^._A@^/F6[\3J#[-I,!88Z<E%^F..IKTVO,/&4BQ>-_A
M@SYP=1\01C S\TVFV\*?@7D7)[#)[4UO\I?DP/3Z***0!1110 4444 %%%%
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M45^)_P /O^"OGB>[_:6^'GP+^._['GB3X!:%\<+?XF3_  7O;SX\?"GX@_M
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M^@OXY_\ "+O/_DFC_AZ=^R;_ -!?QS_X1=Y_\DU_,E167_$NGA__ ,_N(?\
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M_P#)-?S)44?\2Z>'_P#S^XA_\..&_P#G>'_$XGBS_P! W"'_ (9L;_\ /?\
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M%5/$2PV<95P]3Q$\1F6 R;$4HO$86KG$UA:>-Q%"=*JL)AI4:,XU:T*U'/\
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M3]\2O_"I_P#N"OS!6ZNWR]/^#]WF?N)Z517FO_"MO^I^^)7_ (5/_P!P4?\
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MXE?^%3_]P467?\/3_-_=Y@>E45YK_P *V_ZG[XE?^%3_ /<%-?X;.1^[\?\
MQ(5L]7\3%QCN-JVD9S[[OP-%EW_#T_S?W>8'IE%>7?\ "M+G_HH?Q#_\*&3_
M .-4?\*TN?\ HH?Q#_\ "AD_^-467?\ #T_S?W>8'J-%>7?\*TN?^BA_$/\
M\*&3_P"-5(GPYNT! ^(7C\@G/SZX)#^!>W8@>P..^,T67?\ !^7_  ?N\P/3
M:*\T_P"%=WG_ $4'Q[_X.8__ )%H_P"%=WG_ $4'Q[_X.8__ )%HLN_X>G^;
M^[S ]+HKS3_A7=Y_T4'Q[_X.8_\ Y%H_X5W>?]%!\>_^#F/_ .1:++O^'I_F
M_N\P/2Z*\T_X5W>?]%!\>_\ @YC_ /D6C_A7=Y_T4'Q[_P"#F/\ ^1:++O\
MAZ?YO[O,#TNBO-/^%=WG_10?'O\ X.8__D6C_A7=Y_T4'Q[_ .#F/_Y%HLN_
MX>G^;^[S ]+HKS3_ (5W>?\ 10?'O_@YC_\ D6C_ (5W>?\ 10?'O_@YC_\
MD6BR[_AZ?YO[O,#TNBO-/^%=WG_10?'O_@YC_P#D6C_A7=Y_T4'Q[_X.8_\
MY%HLN_X>G^;^[S ]+HKS3_A7=Y_T4'Q[_P"#F/\ ^1:/^%=WG_10?'O_ (.8
M_P#Y%HLN_P"'I_F_N\P/2Z*\T_X5W>?]%!\>_P#@YC_^1:/^%=WG_10?'O\
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M8_\ @6__ ,?JO^(X>*'_ $5/_F$X>\O^I3YO[O,S_P")8/ S_HA__-EXP_\
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M]^;+_P")H_XCGXG_ /124_\ PRY%Y?\ 4L]?Q\@_XE<\#_\ HCJO_B2<4_\
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M1UG_ ,%<'_R=1_P@?C+_ **CK/\ X*X/_DZBR[K\?\@/5Z\N^,G_ "3[6/\
MKOI?_ISM*A_X0/QE_P!%1UG_ ,%<'_R=7#?$?PGXETOPCJ-[J/CO4M;M(I;%
M9--N;"*"*8R7UO'&S2K=2LIA=EE7"'+( < YII*ZU6Z[]_0#Z0HKRC_A _&7
M_14=9_\ !7!_\G4?\('XR_Z*CK/_ (*X/_DZE9=U^/\ D!ZO17E'_"!^,O\
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MGIG_ ,FT?\(?\0?^BI3_ /A)Z9_\FT67=?C_ ) >HT5Y=_PA_P 0?^BI3_\
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MO)JMR+]DND&J?02\*O7[HZ]>G?WKRT>'/B8>GQ,@[?\ ,HZ/WZ8^7GZBG?\
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M>L?\)/<_#W3?"NH2>+(0FF:;_9,&JCQ.L2:,YU&2S-DSMJ=SYX6'Z3K\R_\
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M2O\ @I=X.\1_!3X>_$?PA\,?$GC;XE?'KQG\1_"_[-GP!\)ZS:ZCX^^*^D>
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MJR::GA^:'4==\/:SIZ6-KJT^JP/9--=6,%M+;S2@'JU%%% !1110!YK\2?\
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M[$/[-OQD\=:W\1/'_@S7M2U[Q;8>&-+\>V&E_$OXG^%_!_Q*TSP4+X>$M/\
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MP9_R)_A/_L6M"_\ 37:UTM<UX,_Y$_PG_P!BUH7_ *:[6NEI %%%% !1110
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M;QGXI^'>NZY\-?VA_'GP:^%VJ^,EM/CKX?NWD\5Z)<>)K^^M-$UT^)-(M_Z
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M'9$MO%7CN^MH+OQKX@@$>J^+)XD?7[O4"* /Y]?B)\<?VG/VK?V??^"<VI_
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M[>MKDEU\0M OK;6KK5[35_$-[=V?B#4;'5YHI[S4(H[ZS;5HYXY'>Z@E6/\
M!W]G[P%\:?\ @J)^U%X._9W\"2ZAX4\ ZOJ!U7Q9<6:RW-AX/^'>C7,4NM>+
M_%!C*6^HW\4+PVVD6-P5M)O$=_I.G0G,INA_HZ?!+X-> OV?/A3X#^#'PPT*
MV\.> _AUX?L?#GA[2[944BVM@7N+^\D15-WJNK7TMSJNLW\H\_4=5O;R^N&:
M:XD8^1F'@KXGY-E>$QWB?XN<5<.\8<3TJ>/Q/AUX9YQ5R/).%<GE":PN"SG-
ML-5JO/<S<YU*<HJC*A0E#$26/QM-T:E3[S%^,OA/+%8O(_"'PLX>S[A?(9K
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M8\&?&'2[/PWXAT7P_H<6F_&+P3XT^%L/BE-5\.O)+8:Y9:=^O?P=T+QKX/\
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M]/3^4:BOZJ'_ ."<'[%[NSGX,J"[,Q"?$'XJ1J"Q)(5$\<*B+D_*B*J*,!5
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MO_@YC_\ D6O2Z*+OO_6G^2 \T_X5W>?]%!\>_P#@YC_^1:/^%=WG_10?'O\
MX.8__D6O2Z*+OO\ UI_D@/-/^%=WG_10?'O_ (.8_P#Y%H_X5W>?]%!\>_\
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MO_?FR_\ B:/^$&\1_P#12/$O_?FR_P#B:]+HHOZ?<OZZ?GW8'FG_  @WB/\
MZ*1XE_[\V7_Q-'_"#>(_^BD>)?\ OS9?_$UZ711?T^Y?UT_/NP/-/^$&\1_]
M%(\2_P#?FR_^)H_X0;Q'_P!%(\2_]^;+_P")KTNBB_I]R_KI^?=@>:?\(-XC
M_P"BD>)?^_-E_P#$T?\ "#>(_P#HI'B7_OS9?_$UZ711?T^Y?UT_/NP/-/\
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MWM?"97AL)F&=8[ZWB*Z>=<0XZG7S'-98=0H<[H0BZLH2J2****^%/U$^"?\
M@ICXK^+OAW]C?XKZ'\"/ ?CWX@_%?XHV5K\(_"VE_#[PKX@\4ZKI,/CYY-)\
M4>);\^';.\N/#FG:+X._X2&:W\4WQL]-TKQ ^AI-?6]Q=VI;\H] _9"_:[_8
M2^/_ .P_\;[#P]X+^*G@/P'HFC?LC_%#1?V7_AU\7;CQ/<?";Q'+X@U>\^)/
MQ1T WGC2[\3G2/$FJZAXZUK7=&TOP_I?_"1Z+X9T]]*MHKO2H;+^E*BFG;HO
M.ZW_ %^[J!_)I\--8_:!_P"'54?_  3STK]B#]L4_'3QQJ>I^&(O$/B_]GSQ
M'X8^#>BVOBWXV/XT;6=:\=^*/L$6CQ:;X=F.-3U'2K*TTK6_(NY+Z"ULVOU^
MVM=^%OQ2_P""??[4?[,'[04OPN^*_P"TC\*=._88\%?L8?$>Y^"7A;4_B)XS
M\ >*_AR?#EY9^-(/"(BM+E/!OBF7P_8I%<PW-F;>ZN/%,U\8M3O-%T?Q'^^-
M%-N_31[_ #M?\5=?J@/R]\/_ !>_:,_:G_8[_;7UWQ]^SCXL^#MGKG@OX\>$
M/V>O 7B'0/$>F_&KQMX0F^'GB&RT"_\ %WPZN8K^YTOQ+KE[=V=AIFGZ+=WR
MZQJ)O8-+M)M.ATC6?$'(_L._!O\ :0L_^"5OP2^$W@OQAK_[*/Q]LM.UT)X@
M\=_">U\0:_X+0?&KQ3KE]::M\-/B#:6432>(?#$CVMJVJ6D4EM:ZO;:O9AF6
MVD;]<**5]+65KW_J]P/QR_:5^!?[17Q-\.?L)?L@_&GQ;XK_ &AM"\;?&_Q1
MXV_:S^,WAKX6)X'\$^(_A[\(Y-7^(OA/P1\0;/P9%_PB/@32/%$M]X7\(Z7!
M<7%E<^*==\)P:GI=Q_;L<L4OS[^WCX1^)GPD_;*^._Q>T#X)?&[XO>$OVD?^
M";7Q&_9G\'W'PF\ :_\ $*TT#XQZUKMG#HWA_7HO#NG3OX6T*YTS2;"_2>=;
MN6ZN=1OY]/ANEM[V"Q_H/HH3M_7FG\MDO0#\EM9_9IU[PI_P24_X5;J'P^N/
M%7QW\&?L->-? >CV%KX?C\6?$+2?%/C;X<0S>+/ ?@^;3]-GUP_VCKUIINB2
M:+H2L=7&@Z):S+J4FGV<U?:W[&>A:WX7_8__ &4O#/B;1M5\.^)/#O[-GP+T
M+Q!X?UW3KO2-<T+6](^%_A;3]6T;6=)U"&WO],U73+^WN++4=.O;>"[LKN":
MVN88IHG1?I.BETMZ_C;_ " *_,O_ (([_P#*.WX$_P#8<^/?_K2'Q=K]-*\L
M^"OP7^'?[/?PU\/_  C^%.BS>'O ?A>X\0W6BZ1<:KJNMS6LWBKQ/K/C#6V;
M4];O-0U.X%UX@U_5;Q%N+N5;9+A;6W$5K!##&^C7FOPO_F!YY^V5K_C+PU^R
MC^T-J?PZ\.>+?%GQ!D^$?C?1_ N@^!?#VK>*_%5YXP\1Z'=^'?#,NE>']#LM
M0U34#I^M:K9:E>K;6DOV?3[.[NYS%;6\TT?Q'^T/\+/%/PE_8R_9$_9SM/!E
MMXG\$>'KWX0> OC-XJA^$/Q+_: LO!%K\.? %[K]EXVU+X#_  NU?2K_ .(^
MBZI\4?"FAQ:I:^)Y/$'@;2[K5+34/$/@WQ.AM8K3]<J*$]O)W\^G^0'\Z'PQ
M_9Y^+>K_ +/G[>GARQ\/_&30[G]JK]HKX"? 7PQ'K/[.<'P0NT^#MR?AGX7\
M=?',_"OP;X4\-^'_  QX>O\ P%XT\=W7B+5)M(T^X@B\&06/CQ=,\5)K%C;>
MT_&OX>?L^?LN?&+XE>+O'7[)\7Q._9H^&?[+=E'\*/ /PU^#%I\1OAQX,\=V
MEYXAUKXZWWQ-T2*UU?POX#^(7C+P+IGPLO;[XT_$RPT&WUKX>Z%+I<_BV\GT
M[4++5/W&KY-^*/[$/[-OQD\=:W\1/'_@S7M2U[Q;8>&-+\>V&E_$OXG^%_!_
MQ*TSP4+X>$M/^)7@/POXQT?P7X]LO#ZZEJ$-E;^*-"U..6SO+G3;Y;O3)GLR
M[]_P7HGZ:+]-GH'X'_"3X+?$WX4^%?V3-<\8^ M=\9^!;/\ 8?U#QS\,M'O_
M -D;Q_\ MB^'I/CE\;_BSXL^+7Q \*'PKH'B;08_AY\7=8\):_\ #[P_IWCC
MQ]=V6E3^%])U/1;KQ%9&SUZ0^H?\*9^)W[-]E;Z9=?"KXF>,OB3\./\ @F+X
M\T+X(6_A;X'^+_B/+H_[0'QJ^-'COQU;^&_#WB/P9HWC?POH.J_L_6FE>"?"
M^GPW'BH:RN@7,-QH-Q>:;-->77])L,,-M#%;V\,5O;V\4<,$$,:10PPQ((XH
M8HHPJ1Q1HJI'&BJB(H50  *EHYGY?U_GK=;.[T _G2TK]D[7=#^"?[<OBOQO
M^S]K/Q5\8?"?X ?"+]CO]E#0=?\ @WJGB?Q,-7^$_P"SQ8^!M:^(_P *]!UG
M0[N;5O#/B;XP?$C7M=M?'/ANPE272M(\27,.L"S34VKV+XK^%/ 7[-?C%M2_
M:*^#'BS]J7X&?LY_L(_#SX9_"/3],^&DOQC\'>%/$_@.PUF;XUS_ !$T>Z77
MO"OPP\7^,O!FD_#?6'^)_CS3O#&AW/P_TZ[TB#Q#(]CJ-AJG[EU\F_%']B']
MFWXR>.M;^(GC_P &:]J6O>+;#PQI?CVPTOXE_$_POX/^)6F>"A?#PEI_Q*\!
M^%_&.C^"_'MEX?74M0ALK?Q1H6IQRV=Y<Z;?+=Z9,]F5?OZ:;VT7Y+\7W ^2
M_P!ESPUX[_9\_P""0'AU_!_AWQ/X@^*TG[-?C_XH^%_#7AW1M>\1^+]2^(?Q
M=M/%'Q+\+:-#I-A;WOB2_P!4M=;\9Z3I=RAANM3M8[.1KEI'M9'KQ#2)O&_B
M7]@[X:_\$\_@'\%_C[HWQ#\9_ GP?\(_B%\4_B5^S[\5?A/\&/AQ9^(M+TZV
M^/WB+6?$?Q8\/> [O6M0EL]1\;1^'-$\*V&MW^L:WJ>GFR^T6<5Q./W0AAAM
MH8K>WABM[>WBCA@@AC2*&&&)!'%#%%&%2.*-%5(XT541%"J  !4M%^O6][^8
M'XV_L5?$RV^"OB/]J"Q^(?P7_:ATG7?B'^U1XG@\!75K^RA^TAX@T^?X)^!/
M#/@CX0?!:;4/&MA\-+_0S9'PSX+.IK=76NO9:?::D]U<3V\<D\AX+XS_ +!?
MB+]N?]I']N7Q7\1KGXA> -"\,^%?@Y\(_P!EK4-2MM5T'P?K/B[P3X:D^(=[
M\0=7T/4]*>'XA^#/#OQ(\3ZCX>LXX1J/A35-/UGQHT5M/XGLM%U7P]^Y]%%W
M^"7W6_R _)_X\7_QJ_:=_P"">4_AO5?A'X[^'7[1_P 4=0\%?LW>/="'@/76
MN_!UQXG^,'@OP)\;/%6FW=O87Q;X):IX3TS6_&]OXQL+Z\\)W_@L:1-?:UYU
MK)):?JO9V=KI]I:V%C;Q6EE8VT%G9VL"+'!;6MM$L-O;PQJ L<4,*)'&B@*J
M*J@8%6:*+_FW]]O\@"BBBD 4444 %%%% !1110 5S7C/_D3_ !9_V+6N_P#I
MKNJZ6N:\9_\ (G^+/^Q:UW_TUW5..Z]5^8$'@/\ Y$OPK_V =,_])(JZRN3\
M!_\ (E^%?^P#IG_I)%764@"BBB@ HHHH **** "BBB@ HHHH *Y/QY_R)?BK
M_L ZG_Z22UUE<GX\_P"1+\5?]@'4_P#TDEIQW7JOS G\&?\ (G^$_P#L6M"_
M]-=K72US7@S_ )$_PG_V+6A?^FNUKI:0!1110 4444 %%%% !1110 4444 %
M>7?%+_CV\%?]E#\-_P#HO4*]1KR[XI?\>W@K_LH?AO\ ]%ZA3CNO5?F!ZC11
M12 **** "BBB@ HHHH **** "BBB@ KS7XO_ /)._$/_ '"?_3YIE>E5YU\6
ME#?#WQ&&&0(M/;J1RFKV#J>,=&4''0XP<CBG'=>J_,#OK7_CVM_^N$/_ *+6
MIZS])D>72M,ED.Z273[*1VP!N=[:-F.% 498DX  '0 "M"D 4444 %%%% !1
M110 4444 %%%% !1110 5Y9\75C'AS3;B5RB6GBC0[ECC(VB6:)L@ G"I*S_
M "@DE0 #FO4Z\H^,W_(F_P#<9TG_ -'M3CNO5?F!ZO1112 **** "BBB@ HH
MHH **** "BBB@ HHHH *\N\8?\E!^%O_ %W\6?\ ILLJ]1KRKQRQC\;?"Z5#
MA_[5UJ'=@']W<6MC',N#D?.G&<;EZJ5/--;_ "E^3 ]5K\V?VT_VB_C[I'QM
M_9K_ &+_ -DJX\#>'OCI^T?I_P 5?'OBCXO?$;PM>?$+P?\ L_\ P-^#VE:+
M'XB\=7WP^TKQ7X/U#Q/XJ\6>,_&/A'P7\.[&[UBW\-RZM+J\GB"1+:UCW?I-
M7Y_?MF?LQ_&'XB_$/]G;]J']ES7/AII'[3O[,-]\1=)\+:'\:YO%MG\'/B;\
M+?C7HNC^'_BEX \=ZEX!L=2\8:%?1/X;\*>,O ?BK3-*\11:!XH\,K:7_AG5
M-+U_46MD!S?PI\??MA_LPR_'.?\ ;]^(OP@^*/[-/PE^"MG\7]$_;,\$?#]?
M@WJ\;^&V\1W'Q3\%?%7X)V'Q"^)%_-KFC:#8:5XH\,^(?AQI-OH&KZ<;W2?L
M<OBB[M-%M/F#XY?\%?\ P#K_ .SE^V2OP:T/X_? #]H;X9?LF_&?]H+]GR7]
MI;]GKQ)\*K?XQ>&? ?A"74+;XM?!W3/B1I4VG>.O"NA:O?:%)J6B^)=,TGQ$
M+:\CO;WPA)HJWEW#H?%O]A[]MS]NCX:?MF>&_P!KSXI^ _@QHOQT_9VL_@9\
M"?V>_@#\1_'GQ!^%'P^\1Z1XFO\ Q_;?&SXK^*?$WP_^&FM>,?'6K>*X/#'A
M?4]*\+^'=&\/GX6:5J>BW:ZIJ>NJ^B^;?M&?\$_?VX_V\/#NH:G^TM;_ ++'
MPN\??"G]BW]J+]G?X$:=\*_B1\3O'7AKQS\<?VI? .D?#GQO\8/B%XBUKX+^
M ]3^&OPQTWPWX8T^T\,_#70/"GQ+UP77B?6=7UC77F\+Z!I^I@'T]\,OVZM3
M\$Z9_P %#_B)^T#JOB#Q1X(_9M_:&^%?PV^&GA?P!X#AUWQWJT?Q#_9H_9?\
M4>'_ (<>#_#GA?3[;5/&?C'QW\8_BYJ.F^'5U6=C'?>);.TO]8T?PQIAN=,^
M5?VO?^"QD>F?L>?M ?$WX4^#_P!H+]E7XZ?LW?$W]DA_B;\-/VF_@;IWAWXD
MZ9\&_CC\;/"GAQO&NC^%Y[GX@>$_$WASQQX3L_B-X=TNXT36+[Q3H>NZ!J,6
MH:1X>U,Z!<:A[)\3/V#/VL3\*/VXM'^#WQ.\*^&/'7[1/[5?[.7QP\'P>'OB
M[\5O@\WB;X4_"[X9_LN?#[XJ_"/QM\7?AWX-/Q*^%5Y\2M.^#7C[1K?7OA;_
M &I?G1=;T&WOM;T^SUGQ+ING_ ^O?\$;/VPK[P]^V'-\*?#G['?[/FH_'N+]
MAK6_A%X./QQ^/_QP@\%>+?V3?CU>_%C7[_XS_$WQ_P#!"+Q;\7-6\:V^H7.H
MQ^)I[#SXKB+2OAW>:=<:'H\?CJ^ /UH\&_\ !67]EO6?AK\4OB#\3-"_:!_9
MKUOX-Q?#R\\=?!7]HCX"?$#P1\>H=+^,7BR?P+\'M7\,?##1M.\5:O\ $"P^
M)_C"VG\-^&/^$!E\37=MK<4NE>)K3P]?PS6T?"7?_!:#]E/0/A1\8/B7\0O
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M1I6H7AT.*^NK?30#[B\3_%W]M;]@;XX_LOZ3^TK^T1X'_:]_9G_:S_:&\/\
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M".DV6A>&/"VCZ;H6@Z/I\*6]GINE:9:16=C:01(JJJ0P1(O0LS;G<L[.QZG
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M_P#$OACXG^ ?'7P_U[Q(;$C6;+Q5<>#X]?T?Q.)M3TJ^M;35->TS5^+^&O\
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M:1R3SW,B6UIIS00))<W4DUS<.L4:*T]Q-+/*P,DTDDC,Q%NO5?H!^,G[1O\
MP4O\6?#N^@^$GP.TO0XKOP=8V&C>*/'FO6SZNTNNVME;+J6D>']$E^S6ELNA
MWPGTS4-2U4:DM]?0W45E86UM:P:CJ/Q]_P /,?VQ_P#HI>F?^$!X!_\ F<KR
MG]KCX/\ BOX3?&'Q!-KME=?V)\0;J?X@>$M=,$XT_5],\5%-=N;6VNY=PGOO
M#]YJ;Z/JL32&XCGMX[IT^RWUG-/\P5_H-P3X>^'<N%LCQ&%X>R/-X8O+<'B9
MYCC\%ALRQ&*KU:,)8BI.MBH5I4Y>W]I&>&I^SIX><9452I\C@O\ (WQ,\7?&
M"''7$^$QO%W$_#U3+\ZS#!4LGRK,L;DV#P.%P^)J0PE*EA\#5P\*T'AE1G3Q
ME7VU7&4YQQ,J]95N>7WK_P /,?VQ_P#HI>F?^$!X!_\ F<H_X>8_MC_]%+TS
M_P (#P#_ /,Y7P517U7_ !#[@3_HC.%O_##EG_S-Y?GW9\)_Q%WQ4_Z./QS_
M .)3G7_S;Y?GW9]Z_P##S']L?_HI>F?^$!X!_P#F<H_X>8_MC_\ 12],_P#"
M \ __,Y7P511_P 0^X$_Z(SA;_PPY9_\S>7Y]V'_ !%WQ4_Z./QS_P")3G7_
M ,V^7Y]V?>O_  \Q_;'_ .BEZ9_X0'@'_P"9RO>/@=_P5>^+>B>)]*L/CA9Z
M'XV\%WMU!:ZOK>EZ/!X?\4Z'!<WL0EUBVBT:%=(U>'3+1YW?1?[(M+K41%"D
M6K6LPD:X_)*NY^&WPY\6_%GQMX=^'_@C2;G5_$7B74K73K.&""YFAM$GGCBN
M-5U.2V@N&L=&TN)VOM7U*6/[/I]A#/=SLL43&O-S?PX\.:V6XR..X7X>P&$C
MAZM2OC<+@,)EE;"TH4Y2GB(XW#4Z-2C[&*=3F<^1<MYQE&Z?L9!XR>,6'SG+
MIY9QQQ=FN/EBZ%+"Y;CLUS#.L-CJU6K"%/"5,MQM;$T<3]8FXTN3V?M'SOV<
MX3:DO[2+6ZMKZUMKVSGBNK.\@ANK6Y@=98+BVN(UE@GAD0E)(IHG62-U)5T8
M,I((-3US_A/P_#X3\*^&?"UM/-=6_AKP_HWA^"ZN'EDN+F'1M.MM.BGGDFEG
MFDFF2V625Y9II6=F:261R7/05_G)55.-6I&C.4Z2J35*<H\LITU)J$Y1^S*4
M;-QZ-M=#_9##RK3H49XBG&E7E2IRKTH2YX4ZTH1=2G&=ESQA-RC&5ES))VU"
MBBBLS4*Y/QY_R)?BK_L ZG_Z22UUE<GX\_Y$OQ5_V =3_P#226G'=>J_,"?P
M9_R)_A/_ +%K0O\ TUVM=+7->#/^1/\ "?\ V+6A?^FNUKI:0!1110 4444
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M.OVT_@[\4_A3\2?V7?VAOAO\&/VL_ /@K2?V,[3X0>+?C!\!M?\ $OQ(\/\
M@V2]TWQ/;:E\-_&WPE^,EO9P>/\ PEXEO-3T;2[A](TN_E /U4\7_P#!5O\
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M?_\ R71_P^5_8G_Z#GQ%_P#" O\ _P"2Z/\ AS5^Q/\ ] /XB_\ A?W_ /\
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M?_\ R71_P^5_8G_Z#GQ%_P#" O\ _P"2Z/\ AS5^Q/\ ] /XB_\ A?W_ /\
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M?_\ R71_P^5_8G_Z#GQ%_P#" O\ _P"2Z/\ AS5^Q/\ ] /XB_\ A?W_ /\
M(E'_  YJ_8G_ .@'\1?_  O[_P#^1*/]7O '_H#\3O\ PHX?_P#EX?ZV_2G_
M .AAX,=/^83BK^[_ -0WG^?D'_#Y7]B?_H.?$7_P@+__ .2Z/^'RO[$__0<^
M(O\ X0%__P#)='_#FK]B?_H!_$7_ ,+^_P#_ )$H_P"'-7[$_P#T _B+_P"%
M_?\ _P B4?ZO> /_ $!^)W_A1P__ /+P_P!;?I3_ /0P\&.G_,)Q5_=_ZAO/
M\_(/^'RO[$__ $'/B+_X0%__ /)=8/BC_@L+^Q?J_AS7-+M-;^(7VK4-+O;2
MW\WP%?I'YT]N\<>]_M3;5W,,M@X'.*WO^'-7[$__ $ _B+_X7]__ /(E'_#F
MK]B?_H!_$7_PO[__ .1*/]7O %?\P?B=_P"%'#__ ,O#_6WZ4_\ T,/!CI_S
M"<5?W?\ J&\_S\CCH?\ @K-^P?JG@[1_"WB\>*O$-G:Z-IEC?Z7K/PO;6=+E
MGM=.CLYPUKJ$D]M,A_?1AGA^>)V!&UV!Y+_AXG_P2L_Z)9HW_B.WAO\ ^0*]
M>_X<U?L3_P#0#^(O_A?W_P#\B4?\.:OV)_\ H!_$7_PO[_\ ^1*[,/EW@AA(
M.GA9>+6&@WS.&'S'):,'+3WG&GBHIO1:VOHNQY^*S?Z26.J1JXV'@1C*JBHQ
MJXK*.(L144;Q:BIU<%.2BF[V3LFVTMCR'_AXG_P2L_Z)9HW_ (CMX;_^0*/^
M'B?_  2L_P"B6:-_XCMX;_\ D"O7O^'-7[$__0#^(O\ X7]__P#(E'_#FK]B
M?_H!_$7_ ,+^_P#_ )$K?ZOX,_\ 05XP_P#AVRG_ .;/)?<<JQ7TAM/]A^C]
MT_YD&>_W?^I?YK\>R/(?^'B?_!*S_HEFC?\ B.WAO_Y H_X>)_\ !*S_ *)9
MHW_B.WAO_P"0*]>_X<U?L3_] /XB_P#A?W__ ,B4?\.:OV)_^@'\1?\ PO[_
M /\ D2CZOX,_]!7C#_X=LI_^;/)?<"Q7TAM/]A^C]T_YD&>_W?\ J7^:_'LC
MR'_AXG_P2L_Z)9HW_B.WAO\ ^0*[3PQ_P5;_ .">'@F*>#P9I.M^$8;G;]HA
M\,?!^WT"*XVLS+Y\>E?9$EVL[LOF!L,S$<L2>J_X<U?L3_\ 0#^(O_A?W_\
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M/_\ R\/];?I3_P#0P\&.G_,)Q5_=_P"H;S_/R#_A\K^Q/_T'/B+_ .$!?_\
MR76#XH_X+"_L7ZOX<US2[36_B%]JU#2[VTM_-\!7Z1^=/;O''O?[4VU=S#+8
M.!SBM[_AS5^Q/_T _B+_ .%_?_\ R)1_PYJ_8G_Z ?Q%_P#"_O\ _P"1*/\
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MCA__ .7A_K;]*?\ Z&'@QT_YA.*O[O\ U#>?Y^0?\/E?V)_^@Y\1?_" O_\
MY+H_X?*_L3_]!SXB_P#A 7__ ,ET?\.:OV)_^@'\1?\ PO[_ /\ D2C_ (<U
M?L3_ /0#^(O_ (7]_P#_ ")1_J]X _\ 0'XG?^%'#_\ \O#_ %M^E/\ ]##P
M8Z?\PG%7]W_J&\_S\@_X?*_L3_\ 0<^(O_A 7_\ \ET?\/E?V)_^@Y\1?_"
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M_P"7A_K;]*?_ *&'@QT_YA.*O[O_ %#>?Y^0?\/E?V)_^@Y\1?\ P@+_ /\
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MDUWXAF2VL[6WD*> -0*%X8$C<H6NE8J64E254D8R >*N?\/E?V)_^@Y\1?\
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M_P"7A_K;]*?_ *&'@QT_YA.*O[O_ %#>?Y^0?\/E?V)_^@Y\1?\ P@+_ /\
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M@'\1?_"_O_\ Y$H_X<U?L3_] /XB_P#A?W__ ,B4?ZO> /\ T!^)W_A1P_\
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M%'#_ /\ +P_UM^E/_P!##P8Z?\PG%7]W_J&\_P _(/\ A\K^Q/\ ]!SXB_\
MA 7_ /\ )='_  ^5_8G_ .@Y\1?_  @+_P#^2Z/^'-7[$_\ T _B+_X7]_\
M_(E'_#FK]B?_ * ?Q%_\+^__ /D2C_5[P!_Z _$[_P *.'__ )>'^MOTI_\
MH8>#'3_F$XJ_N_\ 4-Y_GY!_P^5_8G_Z#GQ%_P#" O\ _P"2Z/\ A\K^Q/\
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M7]__ /(E'^KW@#_T!^)W_A1P_P#_ "\/];?I3_\ 0P\&.G_,)Q5_=_ZAO/\
M/R#_ (?*_L3_ /0<^(O_ (0%_P#_ "71_P /E?V)_P#H.?$7_P ("_\ _DNC
M_AS5^Q/_ - /XB_^%_?_ /R)1_PYJ_8G_P"@'\1?_"_O_P#Y$H_U>\ ?^@/Q
M._\ "CA__P"7A_K;]*?_ *&'@QT_YA.*O[O_ %#>?Y^0?\/E?V)_^@Y\1?\
MP@+_ /\ DNC_ (?*_L3_ /0<^(O_ (0%_P#_ "71_P .:OV)_P#H!_$7_P +
M^_\ _D2C_AS5^Q/_ - /XB_^%_?_ /R)1_J]X _] ?B=_P"%'#__ ,O#_6WZ
M4_\ T,/!CI_S"<5?W?\ J&\_S\@_X?*_L3_]!SXB_P#A 7__ ,ET?\/E?V)_
M^@Y\1?\ P@+_ /\ DNC_ (<U?L3_ /0#^(O_ (7]_P#_ ")1_P .:OV)_P#H
M!_$7_P +^_\ _D2C_5[P!_Z _$[_ ,*.'_\ Y>'^MOTI_P#H8>#'3_F$XJ_N
M_P#4-Y_GY!_P^5_8G_Z#GQ%_\("__P#DNC_A\K^Q/_T'/B+_ .$!?_\ R71_
MPYJ_8G_Z ?Q%_P#"_O\ _P"1*/\ AS5^Q/\ ] /XB_\ A?W_ /\ (E'^KW@#
M_P! ?B=_X4</_P#R\/\ 6WZ4_P#T,/!CI_S"<5?W?^H;S_/R#_A\K^Q/_P!!
MSXB_^$!?_P#R71_P^5_8G_Z#GQ%_\("__P#DNC_AS5^Q/_T _B+_ .%_?_\
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M7]__ /(E'^KW@#_T!^)W_A1P_P#_ "\/];?I3_\ 0P\&.G_,)Q5_=_ZAO/\
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M)]IAO'6X$FR(Q]Y_PYJ_8G_Z ?Q%_P#"_O\ _P"1*/\ AS5^Q/\ ] /XB_\
MA?W_ /\ (E/_ %-^CG:4?[(\1[2J2JO]YPY=U9N+E5O[;F55N$&ZB:DY1C*_
M,DTO]??I:.49/.O!]RC"G2B_8\6Z4J?P4K?5[.G'VDDJ;3BE*44N5V.#T_\
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MY\1?_" O_P#Y+H_X<U?L3_\ 0#^(O_A?W_\ \B4?\.:OV)_^@'\1?_"_O_\
MY$K?_5[P!_Z _$[_ ,*.'_\ Y>8?ZV_2G_Z&'@QT_P"83BK^[_U#>?Y^0?\
M#Y7]B?\ Z#GQ%_\ " O_ /Y+H_X?*_L3_P#0<^(O_A 7_P#\ET?\.:OV)_\
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F2ME6!JYIB> 99A.C%XN6#HYTL*ZKE9NBJM)5%"SC\:3OS>1__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>nt10014672x1_barchart4.jpg
<TEXT>
begin 644 nt10014672x1_barchart4.jpg
M_]C_X  02D9)1@ ! 0$ P #   #_[0 V4&AO=&]S:&]P(#,N,  X0DE- ^T*
M4F5S;VQU=&EO;@     0 ,     !  $ P     $  ?_B"^!)0T-?4%)/1DE,
M10 ! 0  "]!N;VYE @   &UN=')21T(@6%E:( ?4  < %0 3  L (6%C<W
M         $E%0R!S4D="     0            #VU@ !     -,M2% @(
M
M$&1E<V,   %$    =&)865H   &X    %&)44D,   ',   (#&1M9&0   G8
M    B&=865H   I@    %&=44D,   ',   (#&QU;6D   IT    %&UE87,
M  J(    )&)K<'0   JL    %')865H   K     %')44D,   ',   (#'1E
M8V@   K4    #'9U960   K@    AW=T<'0   MH    %&-P<G0   M\
M*&-H860   ND    +&1E<V,         &G-21T(@245#-C$Y-C8M,BTQ('=I
M=&A"4$,
M                                                    6%E:(
M     "2@   /A   ML]C=7)V        !      %  H #P 4 !D '@ C "@
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M;W5R(%-P86-E("T@<U)'0@
M
M      !865H@        8ID  +>%   8VEA96B            !0
M;65A<P         !                               "6%E:(
M  ,6   #,P   J1865H@        ;Z(  #CU   #D'-I9R      0U)4(&1E
M<V,         +5)E9F5R96YC92!6:65W:6YG($-O;F1I=&EO;B!I;B!)14,@
M-C$Y-C8M,BTQ
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MU=;7V-G:X>+CY.7FY^CIZO'R\_3U]O?X^?K_Q  ? 0 # 0$! 0$! 0$!
M     0(#! 4&!P@)"@O_Q "U$0 " 0($! ,$!P4$!  ! G<  0(#$00%(3$&
M$D%1!V%Q$R(R@0@40I&AL<$)(S-2\!5B<M$*%B0TX27Q%Q@9&B8G*"DJ-38W
M.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U=G=X>7J"@X2%AH>(B8J2
MDY25EI>8F9JBHZ2EIJ>HJ:JRL[2UMK>XN;K"P\3%QL?(R<K2T]35UM?8V=KB
MX^3EYN?HZ>KR\_3U]O?X^?K_V@ , P$  A$#$0 _ /[^**** "BBB@ HHHH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M<6.F7%MX<OO$BZG=Z+#<:=87$>G36ZSV=M*'A3T&BB@ HHHH **** "BBB@
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M+J&.XMKJVN(VBGM[B"57BG@GB=XIH94:.2-F1U96((!^9O[%O_!6W]DC]O\
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MM[M+ZZ_9G_@OQIGA?P?_ ,$L?A5J'PGG.G>*OA3^T!^QUK/[)@T*VW2Q^/M
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M[6?_  1$\5>$+NZM_B_:_P#!1/0O"&BQV,,DEU-\&/'NA6NE?M";FAL[J5+
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M[X3^.?#4.F?'B"9X8'E33)_#]GX=L=7_ -*L[<:=>W$MU/!!"U_8^2?\$.M
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M(M/$%E=6VH^!!J-HWC:T\.^'?$5SHTLJZ?'%>ZN1IQ\6_:RN+_P__P %^/\
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M:7UT ?T5_ S_ (+<?LO_ !K^*_PG^&VH?"']KOX$>&OVB-1CT7]FCX]?M%_
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MO^U;\ H8(((46.&&&&/QZL<444:JD<:*J(BJJJ% %?<]% 'P[_P\Z_X)L?\
M20K]AW_Q++X"_P#S?4?\/.O^";'_ $D*_8=_\2R^ O\ \WU?<5% 'P[_ ,/.
MO^";'_20K]AW_P 2R^ O_P WU'_#SK_@FQ_TD*_8=_\ $LO@+_\ -]7W%10!
M\._\/.O^";'_ $D*_8=_\2R^ O\ \WU'_#SK_@FQ_P!)"OV'?_$LO@+_ /-]
M7W%10!_'?\/_ (7Z)\,OCQ\8_P!IOPI_P="?\$]?^%Z_'2XB3QQ\2?$OP5_8
MR\<>)[?PW:/$^F?#[P=JOC;]K7Q!>>!?AMI0MK%;+P+X3GTGP\QTS2IKVRO+
MG2[">W^QOVL]3_8A_:S^ /[,.E>*_P#@MS^Q+H7[;?[)/Q'\-?&+X6_MGZ#\
M1?V5]/2?XA:-<DZXFL_!"'XO_P#".Q>"O&-A%I*:SX2T_P 5163ZQX:\-:EJ
M+ZYHMGJWA37OZ2J* /YTO@#KG_!/#3OB[\9/VE/VV_\ @KG^P3^V)\?OC%\%
MV_9E-[;_ !<_9S^$'PH^'O[-E[/<ZIXC^$_@_P"'5C\9O&-S=?\ ";>(]1U7
M6/&?BS7O$UYJ6J0SVNDZ98Z':)J[Z[\5?#_]GC]CO1_@SX:_8;^)O_!P-^QS
M\3O^";'A#XEKXQM?V=7\<?LP>&OBWXP\ Z9XZE^)GA?X)>.OV@K'XZ75S<^"
M--\<1Z=J_B#4-!\":1K7B&"WO-*T"3P%I,FA6'AG^P*B@#^<5/\ @HE^S9\0
M?^"O-OJUG_P4A^ O@+]BG]F#]C_0K*+PS:_M>?#'P1\&?C%^TU\5O%'C*SMQ
M;:7%XWT_PG\7=(^'7PB*OJH2;6[+P!XXC\'$V^FZTL#CY.C^"?[)'@?3_P!I
M_P#9]^ 7_!P)^Q;\%_V"?VL_B7XM\>^/OV>K#Q7^ROXB^(W@30/BE%:V/QA^
M&'P?^,U_\<+6T\(^%_&VAQW'AK2+N_\ A[K9\':!_9\46CZYKL?B+Q'XL_K8
ME_Y#-A_V#-6_]*M%K3H%??R=OP3_ %/YF?VD_#G_  33\2^+?V+/C!^Q-_P5
MO_81_8X^-_["_@JZ^#OPPU^?XR_L[_&/P7XM^ =]X:3PR_PE^(/A;6/C'X9U
M35[/3+47EQH6OMXDFO+"?Q%XOOI;*Y\3ZMHGBKPK[-^REXL_X)??!BT_:>\7
M_M"_\%3_ -A[]J[]H#]M6Y@M_P!I[XIZ_P#'O]G+X?\ AOQAX(T7PM>^ O!G
MPF\*?#32/BIKECX0^''A+P)?76@QZ=)K^MZQKMS?:CJ>KZP\+Z1I6B?T 44#
M/X_?A_\ L\?L=Z/\&?#7[#?Q-_X.!OV.?B=_P38\(?$M?&-K^SJ_CC]F#PU\
M6_&'@'3/'4OQ,\+_  2\=?M!6/QTNKFY\$:;XXCT[5_$&H:#X$TC6O$,%O>:
M5H$G@+29-"L/#/\ 0W;_ /!3+_@FC:P0VMK_ ,% _P!ABVMK:*.WM[>W_:M^
M 4,$$$*+'####'X]6.***-52.-%5$1555"@"ON>B@#X=_P"'G7_!-C_I(5^P
M[_XEE\!?_F^H_P"'G7_!-C_I(5^P[_XEE\!?_F^K[BHH ^'?^'G7_!-C_I(5
M^P[_ .)9? 7_ .;ZC_AYU_P38_Z2%?L._P#B67P%_P#F^K[BHH ^'?\ AYU_
MP38_Z2%?L._^)9? 7_YOJ/\ AYU_P38_Z2%?L._^)9? 7_YOJ^XJ* /P6^$O
MQ+_X)L?"[_@HA^U?^WO_ ,/7OV'==_X:>^&?PC^'?_"J/^%]? 73/^$'_P"%
M5Z!X?T/^V/\ A.O^%W:A_P )+_;O]A?:O[/_ .$.\/\ ]E_:O(^W:CY'G3>(
M?M(:M^QSXB_;5M_V]/V+_P#@MK^P3^RG\:_%7P=7X&_'32/%/C[]FSXX_#_X
MO^%=,U"VO_"7B6^T2Z^./@6^TCQQX56RTS3TU8:EJ U+2?#GA32K9M"TVS\4
M6GC/^EBB@#^=;X<:!_P1M\-_L0_'[]C?XD_\%-/V1/B]?_M:ZC\2?'W[3_QU
MUG]J+]FK1_'?Q,^.GQ5DM]1U_P",.EZ+'XVU7PUX/U'PUX@T[0M8^&_AN&VU
MC1_"C^&="%^WB34%UC5=9^>?@OX0_95%U^R7X3_;1_X+X_L.?M6? 7]AW7_#
M'C7X$?"+1?%_[-/P=EU_XB_#72W\/_!OQO\ &;QI!\?_ !QJ_CC_ (59H%S>
M6^B>'K:VTL:UJ?V'5O&&O^(V36;7Q!_5?10!_*G^S#^T?^QA^V;\ ?\ @I7I
MO[=O_!1_X*I\/_VV_P!H/XX^$/@K\*_BA^V#\*-)U7X'_LP^"_$>M^'/@?XB
M\$?"[QWXM_L_X6>-VUU;[XAZ;/)X7V^(;?0_AEXCUF#6[2WL0S/@OX0_95%U
M^R7X3_;1_P""^/[#G[5GP%_8=U_PQXU^!'PBT7Q?^S3\'9=?^(OPUTM_#_P;
M\;_&;QI!\?\ QQJ_CC_A5F@7-Y;Z)X>MK;2QK6I_8=6\8:_XC9-9M?$']3EA
M_P ?6M?]A.+_ -,VDUITVK?<G]ZN!_-/^TAJW['/B+]M6W_;T_8O_P""VO[!
M/[*?QK\5?!U?@;\=-(\4^/OV;/CC\/\ XO\ A73-0MK_ ,)>);[1+KXX^!;[
M2/''A5;+3-/35AJ6H#4M)\.>%-*MFT+3;/Q1:>,^(\3_  (_X(\^,OV ?BE^
MQUXE_P""L7[)NL?%WXR?%O4/VI/'G[7]Y^TE^S:/B'J7[8&I:W:^(KKXX6?A
M&T^)=II&BZ69[5O"D/@'0];TV2T^'%]JGA^Q\86OBC4;KQU)_4?12 _FV^!7
MBG]DEOVC?A+^U/\ MW?\%P_V$_VO/B7^SAX'\3>#_P!G+1?#/Q _9F^ _@7X
M=ZU\0=,M]!^)OQ5U[2='^-7BZ?QO\2O&OA[3M,T>.Z,OAWPQX8MAJ,FE^&Y[
MV?1[S0/UG_X>=?\ !-C_ *2%?L._^)9? 7_YOJ^XJ* /AW_AYU_P38_Z2%?L
M._\ B67P%_\ F^H_X>=?\$V/^DA7[#O_ (EE\!?_ )OJ^XJ* /AW_AYU_P $
MV/\ I(5^P[_XEE\!?_F^H_X>=?\ !-C_ *2%?L._^)9? 7_YOJ^XJ* /AW_A
MYU_P38_Z2%?L._\ B67P%_\ F^H_X>=?\$V/^DA7[#O_ (EE\!?_ )OJ^XJ*
M /AW_AYU_P $V/\ I(5^P[_XEE\!?_F^H_X>=?\ !-C_ *2%?L._^)9? 7_Y
MOJ^XJ* /AW_AYU_P38_Z2%?L._\ B67P%_\ F^K\Y?\ @HSXZ_X)K_MS^$_@
MOJO@C_@K/^Q9^SM^T;^S)\8?#_QO_9Z^/.E_M ?LW^/Y?!OBG2'B75]!UWP?
MK'Q-TFV\2^#?%EM;Z>^LZ+_:^G13ZQH'AF]U-=;T/3M5\*Z_^_E% 'Y<?L7?
ML9ZMI/QBUW]O[X\?M1>'/VT?CW\7O@WX2^&_PL^+'P^\">'OAQ\%?!'[-5U<
MV_Q!TG0/@]X=\.>+O'MIK]AX]\0Z@?&^I_$>\\7ZN_B*QN=)@T"#2M,;4YM?
M_4>LS1?^0-I/_8,L/_26*M.@2=TGW5PHHHH&%%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5\0_\%#OV
M'? __!0O]ESQG^S?XQ\3:IX U'4M2\/>,OAQ\4M!TZVU;Q!\+/B?X,U)-5\)
M^-](TZYNM/6^%N_VS1-=TZWU31-0U7PIKGB#2=,\0>'=2OK77=.^WJ* /YTO
MABW[-W@O]K+P-\=/^"D/_!:']B_]H[X]_LA:)X\^%'P=^'1\5?LZ_LT:5\%/
M'WB*/_A#/C5XT\?^#$^,7B/6]=^,^MV6B6WA74K/4XO"FC^!YK76;>W\)_VJ
M=,N/#WZE_P##SK_@FQ_TD*_8=_\ $LO@+_\ -]7U+/XX\&Z#JVN:?K7BC0M*
MODU"VE>SO]3M+6X6.71=):-S#-*CA77E&(PPY%+_ ,+1^&__ $/7A7_P>:?_
M /'Z\RKG634:DZ57-\LIU:<G"I3J8_"PJ4YQ=IPG"552A.$DXRC))IIII/0G
MFBMY1^]?YGRS_P /.O\ @FQ_TD*_8=_\2R^ O_S?4?\ #SK_ ()L?])"OV'?
M_$LO@+_\WU?4W_"T?AO_ -#UX5_\'FG_ /Q^C_A:/PW_ .AZ\*_^#S3_ /X_
M4?V_D7_0ZRG_ ,..#_\ EP<\/YH_^!+_ #/EG_AYU_P38_Z2%?L._P#B67P%
M_P#F^H_X>=?\$V/^DA7[#O\ XEE\!?\ YOJ^IO\ A:/PW_Z'KPK_ .#S3_\
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M $.LI_\ #C@__EP<\/YH_P#@2_S/PN_95^(_["7PS_:'\??ME_M5_P#!8O\
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M'KPK_P"#S3__ (_1_;^1?]#K*?\ PXX/_P"7!SPU]Z/_ ($M=$?@'^V/IO\
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M>O"O_@\T_P#^/T?\+1^&_P#T/7A7_P 'FG__ !^C^W\B_P"AUE/_ (<<'_\
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M);3Q%86SZ/K6FWK>%_\ !Q)\1?!VO_\ !+S]LOX)>%?B#X/U'XMZ5X5^"'Q
M\9_"W0_$FE:M\6M$^$.G?M*?!5O$GCU_AYIVJQ^)X?"FFQ7NGMK&O:E8VOAR
M/2;R:.\U& 74$A^&?^"D?[/'@;_@G3^S+\#O^"AG[&'[3_[27B7]IZ7XF_L_
M^%? OB+Q9^T!XU^)GA;]M?1?B%J<&I6/PV\4> [G4#\/)O"NJ^"HO$'BCPGX
M<^&_ASP=X4TC0K2_M]$T2$+HUQI(!^Q_[3'_  ^O_P"%Q^)O^&./^'6O_#/O
MV70/^$._X:8_X:R_X7']L_L#3?\ A*?^$F_X5;_Q1/V7_A*/[7_L#^R_WO\
M8']F_P!H_P#$Q^U5\0_L6?\ !77]H/4OV,/V[_VY/V]=#_9QC^!_[+?Q!UOX
M<_"+QI^RCI7Q0T[PU\?]9\$ZG<>$]<OO!%]\6?%?B&Y\1>%/'_Q"U[X>^"/A
M3XO-IX6L+K6=2\00^([.P_LFY-A]5?\ !9?]H[X@_#3]G3PM^S#^SQ=9_:Y_
M;_\ '-K^RS\ K>WN;F"]\,V7B^.&U^+GQ>NIM.==7TGP]\+_  !J%U-?^+],
M6:7P3K_B+PKXDN86L+*[9/D+_@L5^R-H/[.7_!O1\6_V7?@/I>HW'A/X"?#W
MX#1+;6%@BZEXFTGP7\=OAGXG^(WC?Q#:Z;Y-J-0U6Z3Q+\6/&MZD)M!J2:OJ
M?DQ*%DA -G1?^"C?_!2_X ZG^R=\;?V^?@1^R7X9_8^_;&^(_P ,OA3I-M\"
M?$7Q4D^/?[,?BCXYV7]I_"Z]^/$WQ%N;?P%XAT33HE?2OB)<^#+:Q71[R.^O
M;.<W-II'AOQ/^G?[67_(Q>$O^P+>_P#I<*_+3_@N;XY\*?M(_P#!+W]G3P-\
M)(M,UWQ!^W9\>?V.?"/[-Z:?-";F&_\ '.M:3\1=&\0:(J65W)!:6'A/2;K3
M;[44M$M]+L]:"WA59UL[G]2_VLO^1B\)?]@6]_\ 2X5^5>-/_)OLV_["<K_]
M6.&,,3_"?K'\S[-\.?\ (O:#_P!@;2__ $A@K9K&\.?\B]H/_8&TO_TA@K9K
M]2I_PZ?^"/\ Z2C:.R]%^044458PHHHH **** "BBB@ HHHH *_$#]O3]J7]
MLG3?^"BO[&G[!/[+7Q2^%OP1M/VCOA-\:/B-KWQ-\=?!J7XRZGIVK?"S0O$N
MNV&C6V@S>/O!6GKHVMQ:(EC>3I+_ &EI]Q.FI0RWD%M+H]]^W]?S)?\ !2KX
M00?'?_@N=_P3)^%MQ\1_B]\)$\3_ +,7[5T:_$'X$>/]0^&/Q3\.2V7@_P <
M7\-WX7\9Z9#<W&ES/+;)#=QR6MW9ZA8R7&GW]I<V=S/!( ?;/[#'[:O[67B'
M]MG]I#_@GG^VIH_P(\1_%KX*_"OP7\<?"GQB_9AM/%ME\/=<\!>+M5LM+'AO
MXE>'_&&O^(-5\ _$]6UW0M4T?P[<3VAUGP^FL:O96EWHMGI7B3Q%^AN@?M=?
MLH^*_%?A;P)X5_::_9^\4>-_'&K>)-!\&^#O#?QC^'FO>*?%>M^#3JB^,-)\
M.^'])\17>K:SJ'A1]$UF/Q+::?:7$VA2Z5J$6J):R6DZI^#O_!/KPE>_\$_O
M^"O_ ,<O^"?'A[QW+^U/H'QZ_9PLOVNO'_[1'Q/5/%?[7W@SQ;H6O:=X!\-?
M#SX\?%VWO[>'QCX-M_#\4FM>%-+U#P]8:MI5U\1O#^H:?::;I>LW]SK_ ,0?
M\$U_@)X%T/\ X)S?\%AOVT? OPVTK6?VS/ WQ4_X**^&_@U\86TF#6OB9\,+
M;PG\*)]9\/6WP>U&YMKN^\&ZK;:YXP\3ZX'\*)::SXBU75'L+ZXU"V-C8P '
M]7^F?M>_LGZU\8+O]GO1_P!IO]G_ %7X\6%_>Z3>_!?3OC%\/;WXJ6NKZ9%=
M7&J:/-X!MO$,GBF/6-+MK*YNM4TEM+&HZ;:Q&ZOK:"!DD:G\8OVS?V0OV>-?
MLO"GQ[_:E_9X^"WBK4K>UO+'PQ\4_C-\._ 7B*YT^\F,%OJ<>B>*/$6F:F=)
M>4,K:J;4:=$%=YKJ-$9A_)W\ _\ @G-^UK^V'_P2)_9R^&/P+^"__!*[PYX5
M\3?#KP+\3?AA^TW!\6?C[!^TYX*^*PUO2?%?BOQ]?>*M&_9MUT^'_BR/&6DZ
MOX3^(&E:'XQU&PT,VNI>!M,UB71]"TMH/T/^*GC3XH?M2_M%?&/]DCX3?L??
M\$^/C;^U/^RE^SI^SYX!_;F_:]_;G\+R2?#+76^)7@:;XA6_P\^%W@CP?X4U
M;XK>*/ NIZO<Z[XS-WKFO^#/"_A^_M-1L;S2?M$OAC7M4 /Z"-;^+?PI\-?#
M=OC)XC^)WP]T#X0IH&G^+'^*NM^-/#>E?#=?"VK0VUQI7B5O'-_J4'AA= U.
MWO;.?3]9.J#3KR&[MI;:YD2>)G^+_BW_ ,%2/V*? ?[+WQW_ &GO ?[2?[.G
MQBT#X*^%_%EQ!H_A3X^_#>.'QM\3M)\"^*/&W@OX,:3X@@U35[>'QY\3T\*Z
MAIO@O2K;3]7U?6GBO+G1-%UH:?<VX_G*_8!_8O\ B#_P4<_X-\_A3\!/!/C_
M ,#:+X[^!/[8'C?X@_!@_$&TOM<^#?BR[^'GQ$\6^((O OQ,TJWM/$5SX@^'
M/B(?$/Q7<3V;:3KT*RC1KFYTK4[:QEAF^Q-:^.'@O]JC]@3_ (+"_LS_ !\_
M8+^$?[./[6O[%/[+OB[6_BI\/_"^A?#7X@_#FX\9:I^R=\29?V?OBS\*O$>A
M:3(]EKFC>$/#2Q>#;>;[5XG^&WA^?P[H>D^)[J07EKI@!^UW["/[<WP7_;R^
M!'@/XL?#7QK\+KSQIJWPY^'/C7XL?!_P)\6O"GQ2\3_ ;7OB+HMSJMGX%^(C
M: +#5M%UBTN],U_2(&\2^&/"MYJMUX=UEHM&M9+"]M;3[5K\K?\ @C!\+?@]
MX)_X)P?L=>,_AK\.OAKX1\3?$O\ 9>^ VH_$WQ7X&\(^%] UWX@>)-'\$0I+
M?>.]=T#3[34/%>MZ5J^J>(TDN?$%U?W]CJ6HZTK/%=7=\)/U2H **** "BBB
M@ HHHH **** "BBB@ HHHH _-']H;_DKGBC_ *YZ#_ZCNE5XK7M7[0W_ "5S
MQ1_UST'_ -1W2J\5K_/GCK_DM.+/^RBSC_U/KGEU?XL_\3"BBBOE3,**** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH *_1?X'3:M;? ZSN-!T^QU;78+;Q5-H
MNEZGJ<VB:;J6K1:EJKZ=I^H:S;Z9K<^D6-Y>+#;W>IP:-J\UA!))=1Z9?O$M
MK+^=%?I3^SK_ ,DF\._]?.N?^GO4*_;_  "_Y+/'?]DYC?\ U8Y2=.%_B2_P
M/_TJ)^$O[07_  4,_P""Q_["O@/2?VR/VROV6/V,;G]CX>,_#>C_ !2^#WP)
M^(7Q-UO]J+X#^%?'6JMX>\-:SXI\?:[<2_!7QIJFB>)-6T#0==_X0O3KW2?$
MVL7>CZ=I3^$]/UG4?$_A[]1?VW/V^M _90MOA/X"^'_PS\5?M*?M3?M):EJV
M@_LV_LW_  ]O=*TS7O'=YH^BS:WK/B_Q9XDUR>#2OA]\)_"=H+6X\9^/=3BO
M(]$M+L7JZ9<Z?8:Y?:/^<OQ_UR\_X+-_M/>"OV5?A1IEUK?_  35_9<^*VE?
M$3]L?X^1F;_A OVE_C#\-=06Z\)_LD_#.\$\%CX]\$:3K3+K/QB\0:9%K.C>
M;::>+#5?#6I:/X,O_B%YW^UA^SQX2_:._P"#@[X:_#WXR_$?XJ?#;P)XA_X)
M9W4?@:Q^%7C[Q%\)[[XSZOX=_:.\6ZIXV^%4_C_P]=Z=XKA\GP[J$_C/Q=H/
MPZUG0/$&I^%?#^D1ZUK,'AE]8TK7O[!.\_1F_P#VH/VP_P!DK]CO]J']J_\
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MDO\ R&;#_L&:M_Z5:+6G69+_ ,AFP_[!FK?^E6BUIT"6\O7]$%%%% PHHHH
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M=-,C\4>(OMOC?Q%XDU"Q_M1-'TX?V1IMW9Z%9?9\Z=IEH9IS+]"44 ?DL/\
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M4^(/#NL:=XCN;V&ZL;II=,L],FM3'=:'I,D85[K6+.8NJ\.# %!^ZS#FL/\
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M_P +\/\ _,/]7?E8^JT^\_O7^7]7?E;\YO\ AFGXH_\ /IHW_@XA_P#B*/\
MAFGXH_\ /IHW_@XA_P#B*_1FBC_B _!'_/W/?_"_#_\ S#_5WY6/JM/O/[U_
ME_5WY6_.;_AFGXH_\^FC?^#B'_XBC_AFGXH_\^FC?^#B'_XBOT9HH_X@/P1_
MS]SW_P +\/\ _,/]7?E8^JT^\_O7^7]7?E;\YO\ AFGXH_\ /IHW_@XA_P#B
M*/\ AFGXH_\ /IHW_@XA_P#B*_1FBC_B _!'_/W/?_"_#_\ S#_5WY6/JM/O
M/[U_E_5WY6_.;_AFGXH_\^FC?^#B'_XBC_AFGXH_\^FC?^#B'_XBOT9HH_X@
M/P1_S]SW_P +\/\ _,/]7?E8^JT^\_O7^7]7?E;\X)?V</B;"]O&]IH^ZZF:
M"+&KPD&1;>>Y.X[/E'E6\AS_ '@H[U-_PS3\4?\ GTT;_P '$/\ \17Z#7__
M !]:+_V$Y?\ TS:M6G3_ .(#\$?\_<\_\+\/_P#,(+#4]=9:/NNR?;U^_P!#
M\YO^&:?BC_SZ:-_X.(?_ (BC_AFGXH_\^FC?^#B'_P"(K]&:*7_$!^"/^?N>
M_P#A?A__ )A_J[\K'U6GWG]Z_P OZN_*WYS?\,T_%'_GTT;_ ,'$/_Q%'_#-
M/Q1_Y]-&_P#!Q#_\17Z,T4?\0'X(_P"?N>_^%^'_ /F'^KORL?5:?>?WK_+^
MKORM^<W_  S3\4?^?31O_!Q#_P#$4?\ #-/Q1_Y]-&_\'$/_ ,17Z,T4?\0'
MX(_Y^Y[_ .%^'_\ F'^KORL?5:?>?WK_ "_J[\K?G-_PS3\4?^?31O\ P<0_
M_$4?\,T_%'_GTT;_ ,'$/_Q%?HS11_Q ?@C_ )^Y[_X7X?\ ^8?ZN_*Q]5I]
MY_>O\OZN_*WYS?\ #-/Q1_Y]-&_\'$/_ ,17T]H'P<T[7O@+K_P2^*.GO?\
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MX\#1W7@GX?V/PWCTN_N(O$5CI/@OQ&GABP>ZO-._-O\ X*8_\$Y/VJ?V"?\
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M#;X<>+-$T;PO'JUK=6$M_J&I0/\ ;+>:TB@ENE\@^B>*/^"@7['/@_\ 9P\
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MV1:\6_X)*?%7X"? /]IC_@M#X/\ VF_'?PU^$_[3;_\ !0/XN?$?Q7J_Q?\
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M_P -_#,7A"Q<ZE#!JVD>*_#ZZFUGH^M64<%@ ?TQ_L??\%%/V/?V\6^(-O\
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M[JJ^'_%FBZ[X,N_"FDC7M=LO$7@K7M"TWQE87=MHS)J=K ="=M7LY(Y='_M
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M>)/$FHZ7!%#%I'AVRGT^.\O;Q+F[O?LEE-:7?Y ?\%:O^4F?_!!/_LY?X_\
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MFL:1H5_X:\*:)"WA[5[*TO\ Q;K6AP:KJUJNBZ2]]J]U9V-Q^0GP%_XV/?\
M!6[XK?M3W?\ Q-_V6O\ @EU_PE7[+/[->[]]HGC3]K?Q=8VG_#27Q1L<X6?_
M (5_H#Z9\.[19DO]&U2.;P1XZ\+7\%_:WN #Z?\ V^/%W_!1SX'?L.6NN_LX
M>+_@'KGQ@^%OP#\7^+OVDOV@/BUI.HVK0R_"OX0R:]XE\7_"+X5>&=#E\*ZA
MX[\=^*-*U?4?#VD^*+>W^'OA@^1::IH>H:=<+;VFC^PY^V+XGU7_ ()'?"K]
MN7]IWQ)J/C;7]#_9=\6_'SXR>)=(\.>'=*U;7;+P#I'BGQ/XDNM+\,>%].\.
M>&H-1DT3P]+'9:;I>G:5937*Q($B:5Y*^D/^"@O_ "83^V[_ -FA_M*?^J9\
M:5^5G[(?PM\3_&[_ (-L/#GP@\$:;<:SXW^)/_!/#XO^#?!6C6KQQSZSXQUW
MP=X_L/"ND)),K1I_:FOS:?8.S8PEPQ#HV'4 ^5M7_:M_X+ >%/V(M%_X+.:K
M^T)\+]4^#UW;Z'\:=5_X)I1_ ?P=9^'8/V;?%WC:VT'1[?3/VH(S/\5)_'EM
MX"U?2?B!)K-YI$&E07,ERTVF:A9:=_PBFL_U'>!/&OAOXD^"/!OQ%\&ZC%K'
MA#Q]X5\/>-?"NK0X\G5/#?BK2+/7=#U&+!(\J^TR_M;F/!(V2CD]:_E*U#]O
M3X->//\ @VH\"?#WX=^,/!_BWX]>//V7/AK^P-X3^ VDZUI6I_%?Q!\9)H/#
M?[.EWX9TSX?6>H/XFD\02:)'<_$+3(6L5>Y\/3:7K\,,UIJ%C'=?TS?LK?"C
M4/@/^S!^SA\#M6NX;_5?@S\!?@_\*-3O[=Y)(+W4/AW\/?#OA"]NX'FFN)GA
MN;G1Y9HWEN)Y&1U+S2L2[ 'O-%%% &9?_P#'UHO_ &$Y?_3-JU:=9E__ ,?6
MB_\ 83E_],VK5IT"6\O7]$%%%% PHHHH **** "BBB@ HHHH **** "LS6O^
M0-JW_8,O_P#TEEK3K,UK_D#:M_V#+_\ ])9:<=UZK\P-.BBBD 4444 %%%%
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M7+?_ ,'NA?\ RQKZ[_X:*^$W_0PW/_@CUO\ ^0*/^&BOA-_T,-S_ ."/6_\
MY K\L_XAUX,?]%U_YL_#W_S"8>RP_P#S]?\ X'#_ .1\_P ^S/C^/]GSXK2O
M/&GAZW+6TH@F']MZ(-LC00W(4$Z@ P\JXB;*Y&6*YW*0)?\ AG;XM?\ 0N6_
M_@]T+_Y8U]6VG[0?PJBN-3=_$%R%N;Z.:$_V)K1W1KINGVY8@6!*XFMY5PV#
MA=V-K*3>_P"&BOA-_P!##<_^"/6__D"A^'7@Q_T771?\U/P]VU_Y@0]EA_\
MGZ__  ./_P C_7R9\B?\,[?%K_H7+?\ \'NA?_+&C_AG;XM?]"Y;_P#@]T+_
M .6-?7?_  T5\)O^AAN?_!'K?_R!1_PT5\)O^AAN?_!'K?\ \@4?\0Z\&/\
MHNO_ #9^'O\ YA#V6'_Y^O\ \#A_\CY_GV9\B?\ #.WQ:_Z%RW_\'NA?_+&C
M_AG;XM?]"Y;_ /@]T+_Y8U]=_P##17PF_P"AAN?_  1ZW_\ (%'_  T5\)O^
MAAN?_!'K?_R!1_Q#KP8_Z+K_ ,V?A[_YA#V6'_Y^O_P.'_R/G^?9GR)_PSM\
M6O\ H7+?_P 'NA?_ "QH_P"&=OBU_P!"Y;_^#W0O_EC7UW_PT5\)O^AAN?\
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M_"O]7^(K-:NWC[5/!G_"-?\ ".7_ (U9[*S=O%-WILNNEK2U8WY-O$4^B**
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M_P# &Q_^*H_X9-\/?]#;K/\ X V/_P 57UG17+_Q"GP^_P"B:PO_ (59C_\
M-GE^?=B]A2_D7WR_S\OS[L^3/^&3?#W_ $-NL_\ @#8__%4?\,F^'O\ H;=9
M_P# &Q_^*KZSHH_XA3X??]$UA?\ PJS'_P";/+\^[#V%+^1??+_/R_/NSY,_
MX9-\/?\ 0VZS_P" -C_\51_PR;X>_P"AMUG_ , ;'_XJOK.BC_B%/A]_T36%
M_P#"K,?_ )L\OS[L/84OY%]\O\_+\^[/DS_ADWP]_P!#;K/_ ( V/_Q5'_#)
MOA[_ *&W6?\ P!L?_BJ^LZ*/^(4^'W_1-87_ ,*LQ_\ FSR_/NP]A2_D7WR_
MS\OS[L^3/^&3?#W_ $-NL_\ @#8__%4?\,F^'O\ H;=9_P# &Q_^*KZSHH_X
MA3X??]$UA?\ PJS'_P";/+\^[#V%+^1??+_/R_/NSY,_X9-\/?\ 0VZS_P"
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M\OC"Q\/P:[#KGB--3U,>(=8@OH]2US^TM0.JW-V;VY,OT[110 4444 9E_\
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M^#_PZ\?:9;:?+X6B\.Z#XD\8V5G)>ZJ-7NM%O?#/B+5>_P#VX_BY^V%\3?\
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M.:;^V5\%/'-\38QI"=.A2SU'5/$]Q:211/!#?2RK$D3QK0!_5=X)_P""M/[
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MN/B6= ATG5O*OM)7X8_!G2/!G@1/"R>3:Z7?>%;RTLHXUE)9 ?EC_P %.O\
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M9FM?\@;5O^P9?_\ I++6G69K7_(&U;_L&7__ *2RTX[KU7Y@:=%%%( HHHH
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M*6L_^!UC_P#$T?\ #67A[_H4M9_\#K'_ .)H_LSZ/O\ T,/_ "[XA\O^G?\
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MUU93@@BK5 'S/X<_8N_9 \(?"'Q#^S]X:_9<_9]T;X%^+M<;Q/XL^#UG\'_
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MF5<;F5=S!5W$#<QZ*,]6/8#D]J6@844BLK9VLK;6*MM(.UAU4XZ,.X/([TM
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M &[_ .E1/BNBBBOX8/-"BBB@ HHHH **** "BBB@ HHHH _7_P .?\B]H/\
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M]1T6YFBU*QAU"TNK&6YMHDN[>:W:2-OYC/\ @EQ\"5_9M_X+E?\ !2[X1?\
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M7'Q<\6VW[3?C#_@JQ:_\$:/B9\?Y=3!^)5OX67Q3J5[J'C#1/$-H9(SXLB\
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M_P"#M+T.6:R7Q"]SJVDV>O\ ]$- !1110 4444 %%%% !1110 4444 9E_\
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M6A%Z?U-GGAMH9KFYFBM[>WBDGGGGD2*&"&)#)+--+(52.*-%9Y)'941%+,0
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MQ<^+/@+X<7OB)(IEMY7T.T\8Z_HT^JQQ3LL$LEC'.D4S+'(RNP4_(_\ $,.
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M )3T?VK]'W_H&P7_ (:N(?\ YF#FPO9?=/\ K_AGY7[/_AE+P1_T,'BK_O\
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MO_RGH_X:VO/^A%MO_"AE_P#E/1_K?X$_] '#G_B%U?\ YRA[3#?RP_\ !?\
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M% &9?_\ 'UHO_83E_P#3-JU:=9E__P ?6B_]A.7_ -,VK5IT"6\O7]$%%%%
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M^)'B?PAX/GE\0:AH]E=RRV?A?X?^$\6V@V=_<W1DU3Q!J?B?Q'KL?@7X9?\
M!0[_ ()O?M9?\%"3^SC^QC??MF_L]_MH?%:^_:K^#VOZ+\=_A!\,)/AG\>_'
M]K=R_%/PC\4-+^(^M>']6A\-7_B66WN;+6/#L6IVUEX1T/PW%I\^K:_K?B#3
M/!X!V'_!$WQ;XPD_X)O_ !^^ 7C'6-1\22_L4?M*_M5_L?>&_$^JZGJ&L7FN
M^#?A?J=EKWAEH]1U)5EFTOP_I_C=?!WAZVM\6&E^'?#>E:18PV=MI\=C:^UU
MZ7^P/^Q5J_[!O_!/BY^#'C7Q!H_C#XP^((?B;\7OCQXRT"*:+1O$WQB^)MU=
MZ[XHN-+DN;>SN[[3-"M!H_@_2]5O++3[K6-,\-V>JSZ9I,EXVF6?FE?RC](3
M_D>Y!_V*:_\ ZF3.'%?''_#^K"BBBOY].4**** "BBB@ HHHH _7_P .?\B]
MH/\ V!M+_P#2&"MFL;PY_P B]H/_ &!M+_\ 2&"MFO\ 2VG_  Z?^"/_ *2C
MUX[+T7Y!1115C/Y$/^#FOX??$#XR?'G_ ()Q>!?A3KWB#PW\0/ 'PS_X*,_M
M)>&M6\.HW]K6WB?]G;X+_#CXV^#!HDL,BW,6NWVO?#(Z#IEQ %EL[[6[.Y@,
MDH C^K/VY?VW+S]M/_@E)^R)X1^!FM6>B?%W_@K[K_P=_9HT^/P_)=7R?#VS
M\;7<=M^UI=7%DZ'4-3\'_#+3= \=?#3QK=1@_9K76DO&F:%EF;ZK^-OPC^(7
MQ&_X+?\ [&/CN3X<>/M3^#WP'_8O_:*UZ]^)%WX:\2M\(M+\??%/7X/ATG@^
MV\66UM+X4G^(FJ>&A->:EX0UBX@N[CPH+/6K>"[:RMVM/SD_X)3_ /!/#]H+
MX-_\%#OB1X!^,?@OQ7I_[(W_  3.\1_M&3?\$_?$'B71O$5II/B1/VX-<T;7
M%O\ P?XKO].MO#GCZ/P%\+]!\2Z)X];0)IO^$8\?^/GL[[[-?QR0, ;G_!,C
M]M/X>_\ !.C_ ((F_#[4/'>A>,OB7XG^'/[4WQX_9+^%WPM\ VT-_P"*/C!\
M<O$G[0/Q-U;P7\/_  3<7HLHO(UF*_OM9O\ 6-0LX+RSTS3?$%QI_A_6-5@T
MO0-6_2OX;_\ !1[XR^&/VFO@Y^RS^W9^R G[)OBW]IFR\0O^SAX\\'?'SPM^
MT'\+O'?BCPAH:^)?%_PR\4:[8>$?ASK'@/QYH>F7NEV6E)<^']7\/>-M8N);
M3P]K(9].CU#\"];_ .">_P"TWXT_X)U_''PY#\"/C9XNUC]D'_@N9\5_VIO#
M7P)\1V'Q"^$OCK]IG]FKPV=/M=5'P*U6P_X1_P 3$^,]+\:ZYXB\&>-? &H6
M]YJ%]I'C"W^'5YJ/C.;18KG]#_V2_@U_P2M^*'[0/[.NL>#/V!?^"D_@KXW^
M%?&^J>-_!5[^U1X9_P""A"^$O@)XJ\!^'=9\4VGB[Q_KGQE^+/BSX':7+/?:
M%;>&_#HM=6\6W5[XVU;PSI?]GQ27*7=H +_P0=\3>-?!G[!7[??B[X<?#N?X
MN^/?#7_!0+]LC7/"/PNM?$VE>#;SX@Z]IFB_#J[T[PA9>*M=AGT30+[7KB)-
M.LM3U=!IEM=3Q/?2P6WFSQ_6_P -O^"FO[1_AS]KK]GK]DS]N7]A)?V5-2_:
MVT3QU=_ #X@>#/VEO _[0GAB^\7_  Y\)V'C#Q?\./'D.C>$/ ]WX;UC2-.N
MXM/77M-.NZ9K'B75M"TK0;/4M'EU3Q3IGY6_L^?#G_@H7\ /^"+O_!3JV_9Z
M^%_QR^%_[6.L?MR?'+QG\*="?X6^)],^+7B#X;>)O&?P3L_$_BKX4>%_$'A[
M^V-:NM:^'</C?_A#O$?AO2;^^EN[*XNO!-Y'XHL=,O+/YVTK]GOX7W__  45
M_P""6'Q@_8W_ &#?^"B]AHW@_P",&G:S^U_^U+^TG\+_ -IW6/$'B3Q5X_T/
M1[?2F\;ZU\7Y-3N4E\#:V/&5_P#%CX@:!HOA;X4Z?JFLQ2:5J>K:;+ITEJ ?
ML?J?_!7K]I3Q]^TS^UG^R5^R1_P3@\2_M&_%#]E+Q^?#'BCQ'/\ M&>"OA=\
M,D\+7?A\ZAX>\3>(_%7C3P3;0Z%XJ\6:[!JNB>%OAIIG_"27>JVVA:UKMUXI
MTG3=/NWM^L\ _P#!<3X&ZU_P3SUK]N7X@_"OXC>"/%OA'XRW7[+_ (J_9@T[
M[)X@^*3?M20:GIEA#\&O"<^J0^$[7Q%J-SI^LZ?XKEO);+2KW3O#,>M276BM
MK6B7.C2Y?_!,+X2?%;P!_P %#/\ @M?XU\=_#'XA>"O!OQ5_:$^"&M?"_P 6
M^+?!?B3PWX9^)&C:3X7^)-OJNK> =>UG3;+2O&&F:9<7]C!J%_X>N]1M;*:\
MM(KF6-[B%7_+?Q7^Q1^UMKG[,W[='Q-^'GP)\?ZC\7OV:O\ @X_^-/\ P4>^
M#'P8\7^$M=\,2_M+_"WP+>>#8+*Y\ V7B2VTRV\8^&_%&B:OKFO^$=>\/VFO
MQ^,H_"NJ^%?!$>MZYK4.FW0!^LFD_P#!4G]I?X.?%OX!^!?^"AO_  3[U']D
M3X?_ +4/Q TGX.?"7XQ>"OVD/ G[2'A?1/C;XHNHXO!GPO\ BW;>&?"G@\^#
M'\46=KK-_IOB^QO]=T^4VR0C2!INE^+]>\,+^T3_ ,%7/C=X _;I\=?\$_/V
M;/V#M?\ VJ/C3X:^$W@GXOZ/=Z?\?/"7PH\.3^$_$(EC\4ZQXTU/QGX+GT?P
M3H_@Z^N_#.F6MTNNZ_?>+=5\26>FV.F:;<K&+GY)_;D^(7CC_@L /V0/V2_@
M5^RM^US\,?"R?M(?"O\ :#_:8^,'[2W[.OQ#^ 'AWX%_#_X61:_<^(? .G>)
M_%NG64^H?'75I]5BT[0H?AAJNJV32A[&/Q@FAZEKVL:'],_"CX2?%;3O^#@_
M]J/XT:A\,?B%8?!WQ!_P3X^'O@O0/BS>>"_$EK\--;\8V7Q#^'-[>>$](\=S
MZ:GA;4O$UI96-[=W6@V6JS:I;VMG=7$MJD5O*Z 'E?PW_P""TG[6/[1OAOXK
M>&?V9?\ @EA\1/&G[3'[,7C;QCX'_:T^$GB[]H/X:>%O WPFUWPS?:YINE^&
M_ WQ7ETLO\:O%WBB[\.ZW'9Z/X7\$Z;#IYT>YEGOKG3M7\*:EXA^YO@O_P %
M"O''[5G_  3K\ _MR_LC?LNZS\:O'7Q"M_L^D_LTZK\7/!OPRUB+Q!I'Q&O_
M (9^.--N/BCXFTRX\+6^F>%=5TC5]?AUB_TFPGUSPC:0ZG!H]IJ=[!HE>7_\
M$U/AC\2O G[6_P#P5[\2>./AYXY\&^'?B7^V-X=\3_#C7_%?A/7_  [HOQ \
M-0?#/3;";Q#X)U75]/L['Q7H<-]&]E+JVA3W]A'=H]L]P)E*#\+_ (,_#O\
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M+S:+_@LA\9/B-\/?BS^U5^S)^P'XJ^._[!?P5\5>+=%\1_'I_COX0^'GQ/\
MB#X2^&8EE^*_Q9^"7P+U[PC>6WCKP#X-MM.U:71SJ?Q.\,:]XWD@.GVVE:!K
M6E^(-)TOT[]N'X2?$7QU_P %8/\ @B_X[\.> /'VN_#CX<6?_!2>R^*OQ$\,
M>%M>U+PI\,X_B#^S%X9\-^"W\;^+]/TZZT/P7-XLUN.ZTCP@_B*]L!KNM02V
M&D+>7D4D _"S]C_]C_\ 9:_9,\ >)OV/O^"C'[#/_!13Q!\3_A)XO^*.B:;^
MT%^SXW_!0;QC^S)^T1\.-5\3:EXC\&^(?!6F_LU_$Z+PGX?U'5M#\1)I&K>%
MD\!Z9!9"TMKOQSJL'C75?%&GZ< ?V*? OXT_#[]HWX-_#'X\?"G5SKOPY^+?
M@KP_X]\'ZE+%]FNY-&\1:?#J%O;:G9%Y'TW6=.,KZ=K>E3.;G2=7M+W3;H+<
MVLJC\L/"_P#P4X_:5_:"_:2_:6^#'['/[$7AWXK^ _V0_C+9_!#XQ_$OXJ?M
M0>&_@OK^H^,K7Q+!X?\ %T'@;X7I\.O'6L7&BZ':1ZYXFT3Q5XBUG1='\9:%
MX<U6'0DD\1?8M O/T4_8^^&OPA^$?[,'P-\"_ 3X4>*O@9\(K+X>:%KG@GX0
M>.[/Q+IWCSX=Z?XUA;QM=^%_'FF^,=9\0^*M,\<Z=JOB+4(_&6F^(-<U35=/
M\2G5+*\O9Y8&8_S1?\%!]/3Q]\=?B!\;/^":W[,W_!2O]GS_ (*KZ+\>]#^%
M/_"6>%_@9\3?A_\ LX?M)>&?#7CS1_"M[\1_CMXGUVUU/]G_ ,0_ .Y\(:7<
M:QX6\6^(]6\(ZKK+ZKX8O_'FCWGAV,W.C 'N?BG]HCX1?LH?\%\?V^?V@?CK
MXMM/!/PN^&W_  2Y^&FL^)=<N8Y;F8^;\5?A18:9I&DZ?;J]WJ^OZ_JUW8Z+
MH&C64<EYJFKW]G96Z&28$==_P4&_:TTOXK_\$E_#W[1W[>O_  3LO8O ?Q!^
M._P=NO!'[,&H_M2>+?"/CM_"WB#7@/AU\1OB/XL\&_"S0;SP+XEN(9)];NOA
M"EKXK2UTF]TZW\1>(]-\1M?:-H/SU^V3_P $J_%G[?W_  5\_:LN/&OAOXO_
M  R\/67[!WPQUS]F_P#:>T70O'6B_#'PA^U9X+\8^")O"FH:=XMMK2T\->+M
M5\/V\OB&VU?P@FK3ZW;^&-1\07^FQZ1XALM*\0:-3_;M\8_MQ_MR_P#!':;X
M8_%W]CO]HS1OVU_@I^U)\%O /QE\&Z#\#/'^JZ1\4IO 7BV]MK_X[?!;4/#'
MAFZ\/>/_ (8^*+*R?6M6UKP)+?\ AWPSJIOHX9!X/OO!NO\ B( _37]H'_@J
M_P#%SX>_MV^./^"?/[/O["WBS]J#XU:#\*O 7Q7\-7FB?&KPS\-_"]UX=\2S
M,GBS6?B-K?BWP9<:3\,_"O@G[1HMG#KJZIXNU#Q9KWB#2/#^F>'K2]O(6?W/
M_@G%_P %#=7_ &VY/VB_AM\5O@/K7[,?[3O[)?Q'T[X=?'?X+:IXKL_']AHK
M^)+75KSP7XG\.>.=,TC1=-\0Z%XJ@\/>(&L9[.S>V>+2EU+3M0U;0]6T?5K[
MYH^%'PD^*VG?\'!_[4?QHU#X8_$*P^#OB#_@GQ\/?!>@?%F\\%^)+7X::WXQ
MLOB'\.;V\\)Z1X[GTU/"VI>)K2RL;V[NM!LM5FU2WM;.ZN);5(K>5T]!_8L^
M&'Q)\*?\%;?^"UWQ(\3?#SQQX;^'7Q5/_!.$_"_Q[KOA+7M'\%?$@^!_V:?%
M6A>-SX"\4ZAI]MH7C ^$->N8-'\5'P]?:C_8&KW$6GZO]DO)4A8 _8RBBB@
MHHHH _-']H;_ )*YXH_ZYZ#_ .H[I5>*U[5^T-_R5SQ1_P!<]!_]1W2J\5K_
M #YXZ_Y+3BS_ +*+./\ U/KGEU?XL_\ $PHHHKY4S"BBB@#]0?A18V6I_"'P
MMINI6EM?Z=J'AR2QO[&\ACN;2]LKLW-O=6EU;S*\5Q;7,$DD,\,J-'+$[1NK
M*Q!_CY_;>\'?L)^,?VI/V1/V#?V<?V+V_P"":WQ3^$/[7?A358OVWOB[\,O!
M?[)>B:S\/_@EXMO]%U.3X _%;4;B^\2?M+^+_B5?V6GZW\(+SQ9'?6OBW71X
M<UY[J6[U75-5T7^M33=:\=^&_P!F&_\ $/PM\%6WQ)^)FA_"[Q/J_P ._AY>
M^(;#PC9>.O'.G:3JMWX3\(7WBO5,Z=X9LO$>O16&D7GB"]62VT:VNY=1EAF2
MW,3_ (2_M^>'O^"G/_!5/X :7^Q'>?\ !-U_V1/#OQ+^(7P\U#XV?M!?%_\
M:(_9]^+7A[X3>%_!?BFQ\7R7GPQT/X:^);CQAXR\37]SHUI9)J>EZ=I/_$MF
MU3PO>PVFG^*+GQ%H?^B?"_\ R3/#O_8BRC_U7X<]6G_#I_X(_P#I*'?\%#O$
M?P&/_!:K]D?P;_P4=/@I?V&9OV.OB!XC_9^B^.-UI>G_ +-DO[8ME\29D\8:
MK\0I?%LECX#U77-*^$<.CZ39:?XUDU30]+O?$_@AK&"WUGQ,5F\\_P""7/Q
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M%%% !69K7_(&U;_L&7__ *2RUIUF:U_R!M6_[!E__P"DLM..Z]5^8&G1112
M**** "BBB@ HHHH **** ,R__P"/K1?^PG+_ .F;5JTZS+__ (^M%_["<O\
MZ9M6K3H$MY>OZ(****!A1110 4444 %%%% !1110 4444 %%%% &9+_R&;#_
M +!FK?\ I5HM:=9DO_(9L/\ L&:M_P"E6BUIT"6\O7]$%%%% PHHHH ****
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M74%G:P_\,]?M4Q^;<W4J001^9+\#DB3?*ZKOD=(USN=E4$C0#]N0
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M\/\ 4-/FU/;]HGU34/#US<_VAK,PDOK[4KFXU.Z>:[GED?\ !#P7_P $N/\
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MB^+/P:\*Z3\/+K5?AU!^T&L^@^)O"7C_ ,,6T>I:UI_AG5M-OM7\2QH-;O\
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MWXEN/!_@?Q7\0;^#4_%FA*9;:WTZTU:'6SX=N=>UW]#OVA?V$_CW^U#\?/\
M@GFGQJ^)G@;QQ^RW^QX--^-OQ>L[T7>D_$S]I#]K[PAX?_L'X=>*]9\!^'?
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M;R]?T04444#"BBB@ HHHH **** "BBB@ HHHH **** ,R7_D,V'_ &#-6_\
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MM&_[]S?_ !ZOB+_AHGXM?]#';_\ @BT+_P"5U'_#1/Q:_P"ACM__  1:%_\
M*ZC_ (BKX3?]$?7_ /$;X?\ _F[R7W![>A_S[?\ X!#_ #\E]Q^BVAJ%T71U
M485=+T]0!T %I" !]!6I61X?8OH&ANQRSZ1IK,>F2UE 2<#@<GM6O7]%Q:<4
MULTFNFC6FGH=<=EZ+\@HHKY:_:&_;#^"_P"S!XU_9Q\ _%6^\0VGB']JCXO:
M7\$/A+'HF@3ZS:7GCO6)+..RM]=NH98UT73&:^M_,U*998XP7)0[3EC/J6BO
MD+XM_MO_  (^#W[1WP._9)UB_P#$OBO]H/X_P:EJ_@_X;_#[P]-XLUG0?!NC
MS>1J?Q%^(AM;B&W\!?#^W:'5#!XE\02VUMJA\/\ B.+1DU&XT/488.M_9C_:
MU^ O[8GA'QIXZ_9[\:3^./#/P^^*GC/X+^+-0G\,>*_"QT[XA> SIS^(-(AM
MO%NBZ)<ZG:QV>LZ/J%IK.EQ7ND7=OJ,<,=Z-0M=1L;( ^D**^/?VQ/VT/AY^
MQ9I?[/FJ_$3PSXS\30?M&_M2?"?]D_PE'X+M]#N)=%\<?%ZW\3W.@^(/$0US
M6]$2+PIIR>%;U=7GTQ]2U>-KBU^QZ3>!IC%]A4 %%%% !1110 4444 %%%%
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MHA_PC?AW_H :+_X*['_XQ6O'''%&D42)%%$BQQQQJJ1QQHH5$1% 5$10%55
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M0S8?]@S5O_2K1:!/;YQ_-&G1110,**** "BBB@ HHHH **** "BBB@ HHHH
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M_#$NO:M9^%_[2O=*MO!]JNN_'W[/7_!$#]L#X4_"O_@GC\//%_Q+_9SUV_\
MV-_^"DOB3]K7QGKVB>(_B1 GC+X2:Q?^$=6BMM L+GX4VR1?$R;4-+U[[3X:
MO7TSPE9V[Z4EOXUNWENC; 'TK\-OB7_P46_8U_X*@?LF?LJ?M4?M::1^VK\$
M_P!O#X8_'.;PKXEN_@A\-_@5K_PI^+?[._@)_B-XN31=%^'4$ZWWA34-"&BV
M%G'K6K7DERWB=RZ0ZCX7NM4\39?P\^+W_!2#_@IO\?/VQ-3_ &8OVN_"_P"P
M=^S5^QY^T5X^_90\#VVF_L\> OV@O&OQR^*?PRBTV/QUXQ^(]Q\3I;6RT/P?
M"=2T^[\*Z+X,GT>_DTCQ/#;ZW''KWARVU_4?T*_:6_9"^)7QE_X*"_\ !,S]
MJ_PQKG@:P^'?[&/_  V;_P +0T;7M2U^U\::]_PT3\$]!^&_@G_A M.T_P ,
MZIH>J?V7KFEW%WXI_P"$A\1^%OL6DO#/I/\ ;=XSV,?Q5X4_8L_X*3?L4_M+
M?MB>*/V"=2_8Y\?_ +.?[9'Q7U/]HJ3P7^U!XE^,/A7Q/\%?CQXQMF/Q&U/3
M/^%7^"]<M/%?@3Q'JIAOH-'_ +0T[48M,T_0?#MBWATZ'J&O^+0#C?\ @WM'
MQ$72?^"JR_%Z3PC+\65_X*S_ +4@^*$O@"'5;?P')\1!;>#!XUD\$P:]-<ZY
M#X1?Q+_:;>&X=9N+C58]&-DFHS2WBS2-K_\ !2C]H[_@H#8?\%)OV+?V(/V*
M_CEX0^"MI^T[\%OBWJWB7Q)XV^&G@CXAZ3X-O_ =W=>)[_XC6FGZ]H-WKNL^
M(-)\'^&=9T/P[X337++PMJNLZU9S:_:B"W?4K/ZE_P""3?["OQ\_89\+?M<:
M=^T3\5? GQG\<?M$_MA?$K]I)?B'X(L=1T.3Q+#\0=#\)PZKK7BOPG=>']%T
MKP5XHUKQ+I.N:S>>$O"U[XH\-Z%;7]I8Z;XEU%(F,>Y\</V(OBM\2_\ @JK^
MQ+^W)H7B#X>VGPF_9M^$/QT\ >.?#VK:KXD@^(FJZS\3?#'BC1=!N?">DV?A
M._\ #5]IEI=:W:2:O-K'BW0KJWMX[A[*ROY$CBE /R.^-W_!2;XG>&/VQ?'W
M[!WQ8_X*C>"/V*_"_P"QM\%OA!I7Q _:@U'X*_"O7?B[^V#^T=\0/A]X?\8W
M>N6'@3Q=X;\:?#;X?_#7PM!J$5[XJ\+^%=*TW5TUYY-"B\0WF@>);%O"WB/C
M+_@N!^U5>_\ !-W]HGQ]\-/BQX!\=?M"?LC?ML_!WX#1?M&?#WX<^'K/X7?M
M1_!SQEJ=U)X:\:Q^&/%^G>*/#7@_Q'\2-,T75K;QUH?A@6TG@PSZ9J&@S^'C
MJMM:67[ ?%S]C3]MKX&?MX_%C]N'_@GQJW[.7BG3/VJ_!'PS\.?M7_ 3]IG7
M?B%X0L-8\5_!JSC\,_#_ .(GPG\:_#KPKXI?1M8'@B:ZT+4]*\1:5+I%I=3:
M]K\EMXHU'Q)8V_A3G/V]/V-_V^/^"C?["7B7X(?$K3/V3_@U\9[C]I3X=>/_
M  ;I'A?XH?%CQA\/=-^$'@,:!?R6WBSQY>?!S3M=U/XDZCXB/B^:"#1/AW8>
M&$T"3PQ;37T.J)J\U '@'Q3^(/\ P5;_ & OVC/^"?GQ _:*_;(\!_M4?!G]
ML#]J7P!^R'\9O@IH7P#\!?"/PI\(_'?QQFOSX"U+X2^*=(AOOB#XHT3PJ;/Q
M!(VK>,=1M]4U6V\*VT6N6EP_BR!/"GN'_!5+XW^(/@1\0-/UK4_^"SNA?\$_
MO#FN_#O3XOA]\"-*_9=^%W[0WQ$\0_$2UUK6IIOB1J6D7?A_QM\6-?\ AI<6
M.GP:!-X?T/PMINDMK=O>_:/%KO+;^'YOL#_@HK^R%\2OVNO^&%/^%;ZYX&T3
M_AF+_@HW^S%^U[X]_P"$WU+7]-_M?X:_!;_A-_\ A*=#\(?V#X9\2_;_ !S?
M_P#"2V/]@:;K/]@:!=>5=_VCXFTKRX?/^-?%G[%7_!07X*?\%#OVV?VQ?V0M
M-_8T^(%G^V=\.O@MX:T?7?VDO%WQ/T+QM\ /%/PF\&:3X,N9["R\&?"WQ;)X
MK^'OB&WLGUC4/!VD^+_#$NO:M9^%_P"TKW2K;P?:KKH!^0/[9'[:GQ%_;W_X
M-R?A1\>OC"NB/\74_:N^&?P\^)%_X<T6;P]HNN>(/ /Q9UG1;/Q%;:++(\>G
M7OB#PROA_6-?M;&.RTF+Q)>:PFCZ1H>E"ST73_[#?CMXDUKP;\$/C)XO\-WO
M]F^(O"GPJ^(?B30-1^S6EY]@UK0_".L:II5[]DOX+JQNOLM]:P3_ &:]MKFT
MG\ORKF":%GC;^:_3O^"('[8%O_P2"O\ _@GKJ/Q+_9SU+XN6O[8\'QWT?QW'
MXC^)%CX!U;X>Q>)=-\2S?VU*GPIGUW2/'-W=?VLO]@:;X;U/PY;1_8(T\42[
MYY(OZ-/VG?\ DVO]H7_LAWQ9_P#4"U^@#^<_]C3Q/_P7"_;T_8+^&7[:W@K]
MNKX:?"_QD/">M3?#/X$?\,S_  G\0Z1^T3JGPT\4>(O#VMZ_\=?B)=6EC/X)
MU'XJ:YI'B'PUIOA[X4>%?"OAWP?X7M?".L?O?%KZKK\>;\9?^"[?BWQU^R3_
M ,$N_%/@7XB?##]C[Q=_P4#OOB?;?&_]HOQQH-OXQ\+?LQZ+^S=JUCX8^,^J
M>!/ _B&77]+U?Q!XV\8-<6GP?M?'L7B?2O[(DM=,\16C:IK-IXDT;Q[_ ()(
M>#?^"R7B#_@D7\+/AQ^S'XF_8C'P>^+O@[XK:7\)/BG\5?$'QC\,?&C]GW2O
M$/C_ .)'A[QK$WA[P5X$U_POXVU?2_$YUCQ;\+-=N=7)TG4+R&R\5Z;JVAVE
MCI=E^C/C'_@CKX]^#_[.O_!-RT_8;^)7@#PU^UC_ ,$RKKQ->_#?Q-\9++Q.
MOP:^,4'QMM)5_:@\/_$*P\+1Z[XQ\-Z1\4M<U#5M>T6XT)]6O_"=A?ZMX6TN
M6SEUN+Q9H !\>?!C_@J#JWB?XZ?'[]AD_MJ>#_\ @HY\'_BI^Q=^T#\4_A1^
MT-X>^&7AGP!\2_A;XT\%^"O$;ZW\'/BQ:_#?2O#?@37/#\W@_2[KQ+HOQ!_X
M1/P]J=SK^IV/A^X^W-?01:=XY_P3Z_:E^.G[&G[#W_!!3XFIX\-M^Q1\9_B'
M\9OV6/VF?!%WH'@%K+1O'?Q3^,/QA7X"_$Z/QEJ>@KXT\-Z7HOB*WUJZ\=SQ
M>+K7PQ'X>\-65N=&?4]6DN)OW[\%VG_!2CXO^%/BC\._VG?AA^QO\,/"WBG]
MGGXC^#;'6O@_\8_B]\0M?U[XR^*;2PT7PS?-I?B?X1>$=.\&?#&QT6Z\5R^(
MX7U+QQXJ;5)?#/\ 9+SVD.KJ_P @>%/^"2'CG4O^"%]M_P $N?BOXF^'%U\9
M=&^'/C.'PWXY\*ZOXFNOAUI/Q:M/B]XH^,7PHUNW\0ZIX+TKQA;>'[77+GPW
MIOC&\M?!::NNC3>);'3;#4HY83>@&WKG[7G[1OQ9_;__ &]_!WP:^)?_  C/
M[+'_  3W_8\DT[QQI%GX6^'6N1_$#]L[X@>%O$_C[PY=Q>*-;\*^(->;P_\
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M(/#OAI[2]U;Q!<S:ZWA3QIIMMXC\"Z=/I?AFZAN+VTU'6]:_0ROQ\_X)B_\
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M^M%_["<O_IFU:M.LR_\ ^/K1?^PG+_Z9M6K3H$MY>OZ(****!A1110 4444
M%%%% !1110 4444 %%%% &9+_P AFP_[!FK?^E6BUIUF2_\ (9L/^P9JW_I5
MHM:= EO+U_1!1110,**** "BBB@ HHHH **** "BBB@ HHHH S+#_CZUK_L)
MQ?\ IFTFM.LRP_X^M:_["<7_ *9M)K3IO?Y1_) %%%%( HHHH **** $(# J
MP!4@@@@$$$8((/!!'!!X(KE?^$#\#_\ 0F>%/_"=TC_Y#KJZ*YZ^$PF*Y?K.
M%P^)Y.;D]O1IUN3FMS<OM(RY>;ECS6M?E5]D)I/=)^JO_6R^XY3_ (0/P/\
M]"9X4_\ "=TC_P"0Z/\ A _ _P#T)GA3_P )W2/_ )#KJZ_*'X$?\%<O@/\
M&O\ X*%_'_\ X)P7/AOQ'X ^,GP9GU>'POK7B+4M&F\-_&*3PM:6FI>,-/\
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MUT7W'TI_P@?@?_H3/"G_ (3ND?\ R'1_P@?@?_H3/"G_ (3ND?\ R'7YL?\
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M9RC[).S:O=:^?POLNO0_67_A _ __0F>%/\ PG=(_P#D.C_A _ __0F>%/\
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M_P $[O%G[.WQX_:!_; _:/\ VA[C]JO]K?\ :(TGPCX,UKXD0?#/2?@[X.\
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M/5+&TU+3[B.[L;ZWBN[2YB),<]O.@DAEC) )21&#+D X/(%6ZX/X7?\ )-_
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MQ/\ ^W_^$9^R_P#$N_M2NT9^C5%?FA_P4C_;H\:_L@:?^S?\./@M\/\ P?\
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M:+6G69+_ ,AFP_[!FK?^E6BUIT"6\O7]$%%%% PHHHH **** "BBB@ HHHH
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MPHHHH **** "BBB@ K^?#]K/_E8A_P""4/\ V;1^US_Z@/Q K^@^OS)_;/\
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M_A'XA\/^*9_$'AG6_"T ^)WBC0O@WX<^)/Q"M= @UV37]$L-9\:+8VOC#2M
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MG:9X"\&ZYXB^'&NX^&.BZ9X*T33]/L_%EGXL\<RP+=2ZKX]U*\G%U& ?)_\
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MW_@FK\;_ (C?$;XG^/?V?M0.N_&+Q(GC+XNZ-X0^,GQQ^'/@+XF^+HY7NO\
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MOPYT_P  7?Q'FTBUTK3O"XU7P1XCUU?&VHZ%IJW'ARVL?.T?3M;U2#28^/\
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M]7/^%H_#?_H>O"O_ (/-/_\ C]'_  M'X;_]#UX5_P#!YI__ ,?K\HZ*\?\
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M"BBB@ HHHH **** "BBB@ HHHH **** ,R__ ./K1?\ L)R_^F;5JTZS+_\
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M4GS25*C"<W&/VFHV75F.(3=)I)MW6B5^I\;45Z9_PIOXH?\ 0E:U_P!^HO\
MX]1_PIOXH?\ 0E:U_P!^HO\ X]7\@_ZK\2_]$[GO_AIQ_P#\S^:^\\_DG_++
M_P !?^1YG17IG_"F_BA_T)6M?]^HO_CU'_"F_BA_T)6M?]^HO_CU'^J_$O\
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M9^(_BY\0_#'A_7+.?0]3U+3?B?XPT18_$)L+V\\.ZEXUU+28+V"_L0T/$?\
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M\ _#C]CBWUNZ^(FG_"W4_AMH7AF_\&_'GQ8= \&^"_&MOX)\.^*X/#G@6\\
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MA;5;+X)_#'0_A=\+=#\=2"X'@S4/&VG>';;X=^"]2TAT\=>5?:]%X.U'2?$
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M444 %%%% !1110 4444 %%%% &9?_P#'UHO_ &$Y?_3-JU:=9E__ ,?6B_\
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M?^"A7[./[4/[87Q%_:KE^&_P#_9]\56MYJ]H_@#X8Z5XB\>:3X:\2:C+\/\
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M9JW_ *5:+0)[?./YHTZ***!A1110 4444 %%%% !1110 4444 %%%% &9?\
M_'UHO_83E_\ 3-JU:=9E_P#\?6B_]A.7_P!,VK5IT"6\O7]$%%%% PHHHH *
M*** "BBB@ HHHH **** "LS6O^0-JW_8,O\ _P!)9:TZS-:_Y VK?]@R_P#_
M $EEIQW7JOS TZ***0!1110 4444 %%%% !1110!F7__ !]:+_V$Y?\ TS:M
M6G69?_\ 'UHO_83E_P#3-JU:= EO+U_1!1110,**** "BBB@ HHHH **** "
MBBB@ HHHH S)?^0S8?\ 8,U;_P!*M%K3K,E_Y#-A_P!@S5O_ $JT6M.@2WEZ
M_H@HHHH&%%%% !1110 4444 %%%% !1110 4444 9EA_Q]:U_P!A.+_TS:36
MG698?\?6M?\ 83B_],VDUITWO\H_D@"BBBD 4444 ?SX?LF?\K$/_!5[_LVC
M]D;_ -0'X?U\[?M$_P#!,[]M']EC]CG_ (*I_%"S_P""A_PY^($7Q^^#W[4G
MQQ_:0?Q#^PSIL/Q*^+.GQ?!?QFLWPY@^*DG[2FJ7/@SPSHWA&/4/"/PVL=*\
M,7?AKX8V^K7M]X;\);;B\L;S^IBB@#^=7]@C]IO5/^"=W_!(W]B7XF?M3_$K
MQ[^TO8_'B']FOX9_LR_#?X/_  0\$^&_'?A)/BS\,-%3X8_L_P"G1OXZTC2O
MB)>Z3-X=U^=_B5XLUOPWJ6L&[CM;K3XI(;99N$_X+._\%>OAW\,OB#=?\$U/
MAK^T9H/[,GQ1\>Z+96O[27[5GB/0/'>O6?[,'PP\6Z'I^MRZ5X!T#P'H>J^*
M/%7QV\=^"=:M;GPF^EMHNF>$-.US3M7_ .$S\->(+NT\1>#OW-^._P"RE\,_
MVC?'_P"S5X\^)MWXGOX_V6?BW+\<_ /@FRO=&A\$:Y\4;3POK'ACP?XJ\:V%
MYH-_K.I7OPY.NZCXB\$#1->\.I8>))([[51K-K#'8#Z8H _C[_:QU']@3XM?
M\$Q_V2V_8&MHOVI_V-/^"6G[:_[-'Q/_ &G_ (9:1X$\;W5WKWP1T:U\;1_%
M[6]?\'>+O!_AD^/_ !#K)\>WWCKQY<FQ/AD:3K'CW7_$YMO#\&JP)Z#^TG^T
M1^R+_P %!OV^O^"1GA?_ ()HWOA7XF_%GX,_M Z!\</B]\7OA-X*UKPI;?!W
M]D3P)8V5[XP^'7CWQ#=^&/#2:9HWQ(T[5=1\-Z;X+O;HRZ/K<,OA34]'TK5_
M'.E:=KG]8=4[+3M/TU9DTZPLK!+B=[FX6RM8+59[F0 /<3+!'&)9W"J'E<-(
MP4 L0!0!_+/^R#^VI\!O^"3/[4'_  5F_9A_;:\:+\%X/%O[7/Q"_;L^ &H:
MGX?\5ZC:?&3X9?M"V-I=C3/AS=6.BWJ>*?$?AF/POX:\*7>FV]Y)/J/B]?$N
MC::+B[\)>*O[+^W_ /@D9\ _BO\ !?\ X)S_ !4\<_';PSJO@?XR?M=?%S]H
M3]L;X@^!->LHM.UWP;J/QHN;9=#T76[!+:TN-.UB7P=X9\-:QJFD:C;P:KH-
M_JMQH.I6FGWFF2Z=9_MU<6%C=36MS=65I<W%B[R65Q<6T,TUG)(%622UED1I
M+=W55#O"R,P50Q( K#\:Z/=^(?"/B70K%H5O=7T34M.M6N':.!9[NUEAB,SH
MDKI&'<%V6-V"Y(1CQ7FYS2J5\GS6A1A*I6K9;CJ5*G%7E.I4PM6$(1764I-1
M2ZMDR5XR2W<6OP/R.HKZ0_X9;^)'_/YX5_\ !GJ'_P J*/\ AEOXD?\ /YX5
M_P#!GJ'_ ,J*_A?_ (AOQU_T2^;?^$__ -L>;[*K_)+[C[O\.?\ (O:#_P!@
M;2__ $A@K9K(\/J4T'1$;&4TC35..F5LX0<=.,CCBM>O[X@FH03T:C%->:2N
M>G'9>B_(****H84444 %%%% !1110 4444 %?SX?\&XO_)J_[7W_ &DM_:M_
M](_AI7]!]?/?[.'[*WP%_9(\*^,/!/[/?@3_ (5_X8\>_$OQ7\8/%FF?\)1X
MR\5_VK\1O&Z:9'XH\1?;?&_B+Q)J%C_:B:/IP_LC3;NST*R^SYT[3+0S3F4
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M+\1=4\5ZKXGT;Q#=>)M=35-/\2:CJMM<V.I3Z6T?]F"*TC /YY?^"L'[*_[
M'P?_ ."(,'Q>^ /@7X7?#_5/A?X(_9G^(7[)?[0?PY\'>&O#?Q:U3QEJ'B3X
M7Q>#?%^E>-/#XT7Q+X@\0?$KPO,U[XNU>[U;5[RYM;F\\=W<&HZSX9TZ^M.[
M_9,UCXC:Q_P7O^.^O^/-&L--^+>J?\$@/@-K'C+P_;F:+2[#XC7WB#X/WOB+
M1H#=1:=<1V%KXFEO+*,W$%C,EO&IEBM7#(GZ*?#C_@BY_P $YOA7XK^&OBKP
MM\#_ !%=Q?!?Q;)X]^#G@CQG\=/C]\1/A3\+/&DUX-2F\3^"/A1X\^)WB/X>
MZ1J[:J%U:*Y/AV?['JL5MJ-BMK=V=G-;_9.C?LK? 7P_^TOXO_;!TCP)]D_:
M+\>?#33/@_XK^(G_  E'C*X_M7X<Z/J>EZSIOAW_ (1*Z\13>!;'[-J6BZ9<
M_P!KZ;X9L]=F^S>3/J<L$UQ%* ?SG_\ !%+]EK]AG]I;_@EOX^^/_P"V3\-/
MA'\7?C%\4/B)^TKK_P"VY\9?CSH^@ZG\0O"OBSP_XR\47&HW.O?$3Q,6\2?"
MF?PO\-#X9\=?:M&U/P?+X6OM:NO&%LMAJ-W)K%Q]E?\ !L]_RAR_9H_[&;X_
M?^K[^(]?4WBW_@C'_P $WO&_QC\:_''Q'^SPMSXM^)GC*U^(?Q-\/V?Q.^+V
MD?"CXE>-[755US_A(/B!\&-(\>V/PJ\7R7VKJ^IZYI.N>$+WP]XDU"ZU*^\1
M:/JMWJVJS7OVC^SC^S7\$_V2/A+H7P+_ &>O!*_#SX5^&=1\2ZKH?A1/$'BK
MQ.EA?^+_ !'JGBSQ#,FL>--<\1^()EO_ !!K.I7ZV]SJLUM9"X%GI\-K806]
MK$ >YT444 %%%% !1110 4444 %%%% !1110!^:/[0W_ "5SQ1_UST'_ -1W
M2J\5K]"?&7P$TCX@^+O$'B2\U_4=.GFN=/M3;6UK;2Q*MIH6DQJX>4A\N#E@
M> >E<W_PR;X>_P"AMUG_ , ;'_XJOY#XJ\)..,TXES_,L'EN'J83'YQF.,PU
M2698"G*>'Q.+JUJ,W"==3@Y4YQDXR2E'522:L<%2A4E.4E'1R;6JV^_^K>A\
M-45]R_\ #)OA[_H;=9_\ ;'_ .*H_P"&3?#W_0VZS_X V/\ \57@?\06\0?^
MA5A?_#IEW_S1_5GY7CZO5_E7_@4?\_ZL_*_PU17W+_PR;X>_Z&W6?_ &Q_\
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MR_\ ^/K1?^PG+_Z9M6K3H$MY>OZ(****!A1110 4444 %%%% !1110 4444
M%9FM?\@;5O\ L&7_ /Z2RUIUF:U_R!M6_P"P9?\ _I++3CNO5?F!IT444@"B
MBB@ HHHH **** "BBB@#,O\ _CZT7_L)R_\ IFU:M.BB@2WEZ_H@HHHH&%%%
M% !1110 4444 %%%% !1110 4444 9DO_(9L/^P9JW_I5HM:=%% EO+U_1!1
M110,**** "BBB@ HHHH **** "BBB@ HHHH S+#_ (^M:_["<7_IFTFM.BBF
M]_E'\D 4444@"BBB@ HHHH **** "BBB@ HHHH **** ,S1?^0-I/_8,L/\
MTEBK3HHH%'9>B_(****!A1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% &98?\?6M?]A.+_TS:36G
M113>_P H_D@"BBBD 4444 %%%% !1110 4444 %%%% !69+_ ,AFP_[!FK?^
ME6BT44">WSC^:-.BBB@84444 %%%% !1110 4444 %%%% !1110!F7__ !]:
M+_V$Y?\ TS:M6G110);R]?T04444#"BBB@ HHHH **** "BBB@ HHHH *S-:
E_P"0-JW_ &#+_P#])9:**<=UZK\P-.BBBD 4444 %%%% '__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>nt10014672x1_barchart5.jpg
<TEXT>
begin 644 nt10014672x1_barchart5.jpg
M_]C_X  02D9)1@ ! 0$ P #   #_[0 V4&AO=&]S:&]P(#,N,  X0DE- ^T*
M4F5S;VQU=&EO;@     0 ,     !  $ P     $  ?_B"^!)0T-?4%)/1DE,
M10 ! 0  "]!N;VYE @   &UN=')21T(@6%E:( ?4  < %0 3  L (6%C<W
M         $E%0R!S4D="     0            #VU@ !     -,M2% @(
M
M$&1E<V,   %$    =&)865H   &X    %&)44D,   ',   (#&1M9&0   G8
M    B&=865H   I@    %&=44D,   ',   (#&QU;6D   IT    %&UE87,
M  J(    )&)K<'0   JL    %')865H   K     %')44D,   ',   (#'1E
M8V@   K4    #'9U960   K@    AW=T<'0   MH    %&-P<G0   M\
M*&-H860   ND    +&1E<V,         &G-21T(@245#-C$Y-C8M,BTQ('=I
M=&A"4$,
M                                                    6%E:(
M     "2@   /A   ML]C=7)V        !      %  H #P 4 !D '@ C "@
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M;W5R(%-P86-E("T@<U)'0@
M
M      !865H@        8ID  +>%   8VEA96B            !0
M;65A<P         !                               "6%E:(
M  ,6   #,P   J1865H@        ;Z(  #CU   #D'-I9R      0U)4(&1E
M<V,         +5)E9F5R96YC92!6:65W:6YG($-O;F1I=&EO;B!I;B!)14,@
M-C$Y-C8M,BTQ
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MU=;7V-G:X>+CY.7FY^CIZO'R\_3U]O?X^?K_Q  ? 0 # 0$! 0$! 0$!
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M:PVU[+/>6L4W\ O_ #KU?]YQ/_>+U]??\%@+GX1_ '_@HK^W-X\\-?%_P?\
M";XG?$'X9?#OQ=\1/V=_V\?V/]!^-WPD_:CTG3O#4FDVMA^S-\;M$TWXU^,/
M#6F>*8?#>F1-9MI_P1N- \<>7I47Q%TFT\)7>F_"T _O?\/^(-!\6:#HGBGP
MMK>D>)?#'B72--\0>'/$?A_4K/6=!\0:#K-G#J.D:WHFKZ=-<Z?JND:KI]S;
MW^FZE87$]G?6<\-U:S2P2H[?D==_\%+/%DG[:G[>GP^T;PEX=U']D'_@FQ^R
MI!\3OVC?&MAHFJ:O\7_$7QZU/0-:^)EA\/?AG*GC;3/"LWA[3_A9X<\0IK$6
MI^&[C6$^(&B3:'-J6FV&H6=X/=O^"3'Q&U_XM?\ !.7]DOX@^(O@5X?_ &;;
MKQ#\+;673/@_X1M=0L/!WA[PI9:QJVG>"=7\&Z=J]_JFL:;X1\;>#K/0_'/A
MO3M5U'4+ZQT?Q)9VLVHZD(EU&Z_('_@F9XJ\4>%O'7_!QUHME\'H_CK\?O!O
M[8OQH^(1^$WB&?\ LVT^-_@GQ78?%2X^#?PN6QU31]>%CI?C72_"OB'1M!:_
MM]=TB]T[Q1IUM]FFTZWDN+X \Y^'W_!;#_@K7\4/A5H'[<?PL_X)Y_!#XY?L
M4^(_B)JGA&'X1_!'Q[XT^(/[8>A:;#K.K^&K"Z\2Q^$[[Q-::==KK%G;27"'
MX)BZELF@NKG1]%T/6M/\2P?TP6?[3/P(N/B+\//@QJ'Q.\*^&/C?\4_ %G\3
M_!/P-\8ZI;^$OC1JW@F[LM:OGUD_"_7WL/&=HFG1^&_$L&LP76CQ3Z1>^'->
MLM0CM[G2;Z*'_.*\8?%?_@G/IGP8\._M0_\ !/WQI^TW_P $_O\ @K#I_C?2
M/#,?[%OP>E^,/CKP'XF\1W'Q*M](U;2]$\1Z]X;FDMM(UO2KN'58/!&I>.[W
M3YI]/N?AA<_"+6$NX-0D_<3]JKXUZO\ LJ?\%E?^"/7[<_[?CS?"/PCXD_X)
MNV_P\^,?CW_A&-;O?#_AO]H>+P1\=KOXG^&9M%\,Z3J.JVD>C^,/C1X.LI;;
M3])N#IL/B&UGN;>UTRSO;NU /Z<M7_;V_8FT"?Q?:ZY^UC^SYH]Q\/\ XIV'
MP/\ ',.I_%CP79/X0^,6J/XLCTWX8>)!<:O'_8WCF^?P'XU6U\-7_D:K,?"G
MB );'^R;WR>4M?\ @IA_P3SO/#6D>,;?]MC]F!O"NOZSX]\/:+X@D^-/@*#2
M=4UOX7:9HNN?$+3;*]GUN*&XNO"6@^)?#7B#64C8BW\/^(_#^N@OI.MZ7>7?
M^=#^TWXL\.?&;X5?\%/?'^@Q:TG@SXO_ /!<GX&^.O#R:[H^I^&->D\'_$?P
MK_P4I\2:#-J6A:Q;6FKZ'J-UH&MV=Q-IVHVMO?6,LIAN88YHV4?T:?\ !:3]
MD7]F'P)^VI_P0'_9T\"? ;X5^!O@7XU_:W^*]OXR^%/@[P3H'AOP/XL@UWQU
M^Q=I/B*/Q'H&DV-K8:RWB71].M-(\17&H0W%UK6G1"VOYYUY !_21XB_X*#_
M +#7A+X-^#_VA/$W[6O[/VA_!?XAQ:X_P^^(6H_%+PE;:'X\G\,7$MGXETOP
M67U,7GBK7O#M];SZ=KOAW0;34-=TC4X)M-U#3K>^B>W7N$_:\_97E^!EY^TY
M!^T5\%KC]G73IH+;4/CA;?$GPG<_"RPNKGQ%8^$8+2^\;P:K)X?M+N3Q3J>G
M^'?LMQ?QW"ZU>VNFO&MW/'$W\M7_  4J^&?[)O[(O_!7/]B7QY^V?\#/#-E_
MP2K\,_LO>*?AW\*= TKX1WFL?LS?!OXX3>)_B5XKUFP\4_!_P;X<\5:)XBO/
M$-WJNE:I=:;:^#K)=9D\0>%]7N[+5K#X9:O.OYZ^!?@WXC^,'_!-'_@XI^(/
M[)?PW\6:1^P_\4/C3\'/'/[)OAHZ=J6F>'M9\*? ?]H.7XD_&CQA\/O">HVV
MEZGH/A_0_A9H_AN^N[:3P];O;Z;INE^"KK4+G6?AWJ]K8@']V&N_M2?LW>%[
MKX(6/B/XZ_"G0[S]I?['_P ,]6NJ^.?#MC/\;/[0C\-S6/\ PJ^*XOXW\:_:
MXO&/A22V_L 7WG)XCT5DW#4;4R^7>,O^"B?[!GP\'BC_ (3K]L7]FWPE)X)^
M(6J?";Q;;:_\8O NFWOAWXEZ%=FRU_P-JMA<ZU'>VGB;P_<*X\0:5) +K0H8
MIKG5DL[:&69/XXO'7[:?[/7[6/QR_P"#7;P7\"O%FK>+]<_9L\5?![P#\:O-
M\'>+="TKP7\0-0'[)&@/X&?7M=T;3]%USQ'IM[\-/$D^IP>&[_6+*WTV31=4
MCOI['6]/GFZ;]G_]G_X(_$NY_P"#M[XF_$CX3_#KX@^//AAXJ_;*NOAAXI\;
M^"_#7BK6_AKJ44O[;7B%M:\ :IK>EWNH>$=<N-9T3P]J,^K:%<V5\UUX<T*=
M)HY=-A< ']I7Q(_:A_9Q^$'PBL_C[\3?CE\+/!7P4U2TTJ]T7XHZYXWT"V\$
M^(;?7K8WF@GPUKXOGL?$LVNVBM<Z+:Z#+J-UJT"M+I\-RBL1^._A+_@L)XM^
M+W[:_P"WU\ /@5<_LS_$7X(_LW_L*:G^U#\"_C+I_B]Y_#_CCQQ:>#?AWJR:
M=X]^(T?C^W^'EK\/-/\ $WBW6=+\2:E9GPU-H%II$G]K:_I\NG:E<5_.7#HW
M@[P]^PQ_P;??'_\ :L\-'QQ_P3^^&/Q'_:/\.?M!Z9>Z)J'B'PIX;\0^+_CI
MKMQX-UWXB>'K"VUVX\8^$I+;PM>7<WAE?#&J1ZAHOA'Q3X4:.[?QO;:9=>J_
MLZ^,/V:OB#_P4'_X+U^-OV/_  ;I'@?]G#Q)_P $EOCS>_#/3?#?@>7X;^$M
M7L[;X;?"+3/$/C#P?X+ET3P]_8_A?QGXPL/$/B;1WCTJVAU:WU/^VX8X4U(6
M\(!_5G^R?_P4 \'^*_V7?V8?B9^V'\7OV4OA#\9_VB-,^)U[HV@^!?C3X(U/
MX8^+9/AGXNUG3?$$GPM\5GQ[XMTSQ=8^&?#*>'=0\976E>+-;@\/ZCJ%U!J4
M^GF,VEO],_"+]LC]DWX^Z#XX\4?!/]I/X'_%/PY\,X[FX^(>N>!OB=X/\1:5
MX(LK6.^GDU7Q5?:=JT]OH>BO;:9J%Y:ZWJ+V^D7MC97-_9WL]G"\Z_PBV7@3
MPC\3_P!GW_@TL^'WC[0-*\5^"/%_[0?[3NA>+/"VNV%GJN@^)O#][^V)\#X]
M5\/:]I6H07-CJFAZW9^=IFLZ9>02VVH:;=75I,ACF:H_^"B'[/?B>U_X* ?\
M%Z?@M^Q]\.-&\(:%X>_8X_9B\3WOPF^$/@VR\.V4WPZT35?V#?B#\3+?PEX7
M\(0Z3IVF,B?VSXV\3)8Z=-_;&D6WBRTDLKJ[UR5V /[>_ G_  4@_8#^)^H>
M%=(^'W[9'[.'B_6/'/C=_AMX-T?0_BWX-O-8\4^.Q=6EG#X6T#2DU;^T-5U:
M^FO[ Z5;V=M,-8M[ZRN]+:\M+NWGDV_VU/$?[:OA?X1Z=J/[!OP]^"GQ+^-+
M^-]&M=3\/?'G6];T#P5#X ETK7Y-<U2UO= USP_>OK]MK$/ARWL;=KY[>2SN
M]2>2WD>*-XOX?+OXN?\ !/KXQ?MC?\&]VH_L*_ BT^%>K>"?BM\%_!/[1WB'
M0OA7J7@/3+CXG6GB7X&.OPQ\6>-+_P )^'8_C)\4?A]=V_B;6?%7CVWN];EU
M"Q\=:/JE]K>J3:\D>F?Z'M '\I/[&_\ P5*_X+;?M@?'CX^_!SPC^S!^P:@_
M9%^.>G_!?]I.YE\1?%'2;G1+^'QEXM\+>(Y?!%Q??%*\M?$C6O\ P@/BR33K
MM;8VTTEOI[O;R1W8CK]:?V8_VZ_&7B_XH_\ !1*S_:>\4_LD_#+X)_LB_&&R
M\&^!_'7A'XV>"+O4=)\$7/B#Q]HQU#]I S_$_P 1VWPL\5.?#_AVWM]*\4Z;
M\/YYM4NM;LDTB2XLI+>Q_,S_ (((?\G[?\'!G_:0C7O_ %<W[5M?E9J_@+X;
M?$;P1_P=+:)\6K#XW2^!=._;-\">+=4UWX ^%]"\=^.?!$_@_P"+GQY\1Z9X
MVU#P#XC\??#?2?&G@?0M2TZU;QUI$_B6U:R\-7%_XBCN=";0_P#A*_#P!_9A
M\ OVW?V/_P!J?5M;\/\ [.7[3'P3^-/B/PY;7VH:YX:^'GQ%\,^)/$NF:1IV
MJPZ'=:_<^';#4)-:7PW_ &K<V=G;>)%L6T&^>_TY['4;B+4;*2XY+P[_ ,%&
M_P!@3Q?\5;;X(>%OVS/V9_$/Q8O]4T_0-+\#Z/\ &?P%J&LZSXDU34+C2K'P
MKH0MM<DM==\73:E;/8MX4TBYO?$4%U):PW&F1/>V8G_D@_X(_P#[0,NN_P#!
M1S2/@=X4T/\ 97_;V\+^)_V5?'T6N?M8?LP_LV7?[)?QP^$?PPTKPGJ*Z7\/
M?&5I:>%/@+X'@OM5\167@[X?273VVL:C:ZCXW\#RCXQP3Z)>Z#9?F3\./BSX
M'_91\8_!;P!^SF?@Q^VO9^&?VP;WPMX+_8(_:O\ V)8/A3^WA\-/B/\ \+#U
M#3]+U"X^+WPYT/58M9\4?VE8Z7H>GWFJ_'W5]/M-9N?"(N?@A8?V%J?A7P6
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M\4<+GP[XJ^-/Q*\4>$)%2.213#-X2UC1);:4L))[=XII8XI9'B0 _9"BBB@
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M=6>EKV;3Y<6K4E--J4*E)Q:DU:]6$7>S2:<9-6=T?O#1117&=04444 %%%%
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M=:^(/Q"U+XI>'/A%XB\2Z]X7@M-2\.7.D^%=)\ 1>(M=BN]<BTS4)7\/--J
M!_1I17R#^PG^U9+^VA^S+X"^/>H?#'Q1\&?$FOS>(-"\9?##Q<)IM2\)>+?"
M6NW_ (>UJVL=4EL-+_X2#PUJ4UBFN>$_$*:=8'6?#6J:5>W%AIU[+=:?:_7U
M 'E^F?!#X+:+\5_$/QXT?X0_"_2?CCXM\/0>$?%?QFTSP!X4L/BOXF\*6W]A
M_9O#'B'XB6NDQ>+]:\/6_P#PC/AOR-%U+6+G38O^$>T/R[9?[)L/L_B&L_\
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MM7LYO^$JT.?7_%MAL\1VOAD _HGT;]F_]GCPY<_&"\\/? 7X+Z%>?M"_:O\
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M_@OOXI_:$^#OCNS^"'@2_P#V>O'<6J?LE?%CX4^-M)^)7PI^-TGB'X#?$O\
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MEU;2;CX>7UMKOBSQQX"\>1?%+7(M7\9:7H/@[7$L_A&-7\BSNOB#<^]^&_\
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M34UQ;P74$MM=00W-M<1O#/;W$:30312*5DBEBD5HY(W4E71U964D,"#BI:*
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M%]#8Z08[*WET#0)-+_2.B@#\X/#O_!)7]@KP=8_LT:;X-^#FO^$K3]D'Q/\
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M9>'+WXC^*/%FJ:!H#R627<?AW2KZUT5-5N=6UPV3:YKNMZEJ/TM110 4444
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M^,_[$@\81^'$_LGX;WUUX<_X1V/2%\*7_F_VOJ6A7FO)'JB?7E% 'YL>,O\
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M!J(L[2$7VMZ]JFI:UJMSYM_JFH7E]//<R;]%% !1110 4444 %%%% !1110
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M/'\\A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7\N?_!
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MJB;Q-)\:_CA-\7Y/VDC8KILGQN;XWS?$63XM_P#"P9K)3;RZLOC$1-&\BBU
M<B@#BO\ @BG^T=\7?VK_ /@FI^SK\;/CMXH_X3KXHZX_Q7\-^(O'BZ9I>DQ>
M-H?AY\:/B%\/]#\1QVFBV=AIAEN_#_AG2X+^[M;2$7^JVM_?2J9[B5C)\1/^
M"ETOPC_;0T+]EGXD?L]^+_#7@?QAXMT?P5X'^/,NM:J^D^,=;UW1/#<]H/#_
M (6N/ -G8ZI9V/BGQ7I'A;7[O3/'-\FA"?\ M2] 8KIA^\/@+\!OA+^S%\(?
M WP&^!7@VS^'_P )_AMI4NC>#?"-C?:OJD.DV-SJ%[J]X9-4U_4-6US5;W4-
M6U'4-4U+5-8U._U/4=1O;J]O;N>XGDD;\>_^"N__ "=-_P $J/\ LO\ KW_J
MQ?V;JZ<)"G4K>SJ1YE*G5L^9Q<)1IRFIJS5VN6UI7CK=IV1SXF4X4U.$N5QJ
M4[JT6I1E.,'%W3LO>O=6>FY^\-%%%<QT!1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5RWCGQ=IOP_P#!
M/C'QYK45Y/H_@GPMXA\7:M!I\<4U_-IOAO2;S6;^*QAGFMH);R2ULI4MHYKB
M")YBBR31(2Z]37AW[3O_ ";7^T+_ -D.^+/_ *@6OT ?SD:!_P '0&E^+-'L
M/$?A3_@FA^V#XB\.:O!]KT?7-*E\/WNG:G9L[I'=6MU::;<6TT;E&&Z&>5 R
MLHD;;FM?_B)>O?\ I%M^VC_WZT?_ .5%?C7^PW_R:3\"/^Q&M?\ TNOJ^K:_
MRVXO^GQQOPYQ9Q1P]A^!>%<1A\AXBSK):&(K8O-XUJ]'*\RQ.!IUJL85U"-2
MK"@IS4$HJ4FHJR/]%N%OH6\(Y_PSP[GM?C+B.A6SK(LHS:M0I87+'2HU<QR_
M#XRI2IN=)S=.G.LX0<FY.*3DV[GZS_LC_P#!?WPG^TW^U1\&OV5_%'[%?[2?
MP"\0?'2X\9:=X'\7?$3_ (1_^P)=4\%>#M6\;ZE;W=NW]E7[VITK1IK=[K3$
MU*>UO[W3$GLA:W4UW:_T(U_#9\!/^4NG_!*;_L>?VG__ %GG7:_N3K^ZO CQ
M'S#Q:\+>'./LTR[!Y5CL[J9U"M@<!.O4PE%97GN9933=*>(E.L_:TL#"K/GD
M[5)R4?=21_'/C+P'@O#/Q%S_ (+R['8K,L'E$,IE2QF-A1IXFL\QR7+\SJ*I
M"A&-)>SJ8R=*'*E>$(N7O-L****_7S\O"BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHKP_]H_\ :*^%'[*'P7\<?'SXV>(6\-_#OP#I\%WJMW;65QJF
MJZE?ZC>VVD>'_#?AW1[-7N]:\3^*=>OM.\/^'-(ME$NHZQJ-G:[XDD>:, ]P
MHK\:?%'_  6A^%&G?#3]B+Q]X#_9N_:5^,>M_MX^#/B#XZ^$_P ,/AUI?PPN
M/'>@:)\.+OPA8:LWC>+Q#\3-!\/Z=-J5]XTTJPT%=,UW5H]5U!9M.@D_M![2
MUN>D^.G_  63_9U_9O\ B-X3^&_Q9^%_[0NCWC?"WX,_%/X[>(M(\#^'?$'A
MG]DG3?CUXGL/!?P[T;]HBZT[QFVI:#K%UXIOET758O"&E>,X=/NI]),,E[%K
M=C(P!^N5?RY_\$ _^3X?^"Z/_9UGA?\ ]6[^V)7]1E?RY_\ ! /_ )/A_P""
MZ/\ V=9X7_\ 5N_MB5]/D_\ R3_%W_8)E'_JYPI\?GO_ "5' _\ V&9]_P"J
M'%']1E%%%?,'V 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M:MI5Y;ZAIFIZ;?0)<V6H:??VDDUK>V5Y;2QW%K=VTLL%Q!(DL,CQNK'\+/\
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M2%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !7AW[3O_)M?[0O_9#OBS_Z@6OU[C7AW[3O_)M?[0O_ &0[
MXL_^H%K] '\)?[#?_)I/P(_[$:U_]+KZOJVOE+]AO_DTGX$?]B-:_P#I=?5]
M6U_SA>*7_)S?$;_LN^+O_6@S _WE\./^3><!_P#9&<+_ /JCP)B? 3_E+I_P
M2F_['G]I_P#]9YUVO[DZ_AL^ G_*73_@E-_V//[3_P#ZSSKM?W)U_LQ]"_\
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MOB-_V7?%W_K09@?[R^''_)O. _\ LC.%_P#U1X$Q/@)_RET_X)3?]CS^T_\
M^L\Z[7]R=?PV? 3_ )2Z?\$IO^QY_:?_ /6>==K^Y.O]F/H7_P#*./ /_7_B
M[_UL^(#_ "E^EA_R?GC;_KUPQ_ZR61A1117]2G\Z!1110 4444 %%%% !111
M0 4444 %%%% !7\GG_!1W]N?]E33_P!KSPU^TA^S)_P54^%?[*W[37PM^&7Q
MF_8T^)?A_P"*_P"S-\9OC'X,U[PY8?$RSU76[&R6Q\#7MCX;\5?#WXF>'Y[T
M:OIFFZO9^*[BPT:TNM0N?"^GWNFZ]_6'7\C/_!2GXD?'[]B7_@HA)\0_'_\
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M ))G-_\ L&7_ *>I']L>-'_)KN,_^Q4O_4O#'^FY1117\V'^7P4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %?Q/?\'*__*0_]@K_ +(%\8O_ $[Z
MA7]L-?Q/?\'*_P#RD/\ V"O^R!?&+_T[ZA7L\._\C_)/^QK@/_4JD?;>&O\
MR<3@7_LKN'?_ %;80_("O+?C?_R1WXG_ /8B^)O_ $TW5>I5Y;\;_P#DCOQ/
M_P"Q%\3?^FFZK^DLR_Y%V/\ ^P+%?^F*A_I[Q1_R3/$7_8BS?_U7X@_T=O\
M@GU_R83^Q%_V:'^S7_ZIGP77UY7R'_P3Z_Y,)_8B_P"S0_V:_P#U3/@NOKRO
MY4/\C HHHH **** "BBB@ HHHH **** "BBB@ HHHH _-;]O?_@FIX3_ &\?
M&?[//Q'O/VC/VF/V9_B'^S4GQ:C^'WCS]F#QWI7PX\9B+XR:?X*TGQ;#=^*)
M_#NLZY:POI7@J#3$AT6^TJ*[T_6=;LM534+:ZBB@]>_9A_9(\1_LW_"+Q_\
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MH **** "BBB@ HHHH *\._:=_P"3:_VA?^R'?%G_ -0+7Z]QKP[]IW_DVO\
M:%_[(=\6?_4"U^@#^$O]AO\ Y-)^!'_8C6O_ *77U?5M?*7[#?\ R:3\"/\
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MQ"\*^"_$G]AZS);7?V'7[;19=&OKB*:.&_DG#+7VQ0 4444 %?RY_P#! /\
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MII_\GAPW_9&Y)_ZG9R%%%%?VT?R.%%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 5X=^T[_R;7^T+_P!D.^+/_J!:_7N->'?M._\ )M?[0O\
MV0[XL_\ J!:_0!_"7^PW_P FD_ C_L1K7_TNOJ^K:^4OV&_^32?@1_V(UK_Z
M77U?5M?\X7BE_P G-\1O^R[XN_\ 6@S _P!Y?#C_ )-YP'_V1G"__JCP)B?
M3_E+I_P2F_['G]I__P!9YUVO[DZ_AL^ G_*73_@E-_V//[3_ /ZSSKM?W)U_
MLQ]"_P#Y1QX!_P"O_%W_ *V?$!_E+]+#_D_/&W_7KAC_ -9+(PHHHK^I3^=
MHHHH **** "BBB@ HHHH **** "BBB@ K^<S_@L+XZ;X&?MC_L6_%7X/_M3^
M%/@O^TY\3_!WB[]E.S^'GCOX$^(_VB_#OB'X5_&#XJ_"NPM_'T>A6VJZ9X8^
M%(\-?$J?0-(UKQ3J5[I%_P#$>+5M&\-I/KFG>#KS0Y?Z,Z_C\_X+<:+XK\<?
M\%"O@[XU^'5O^V+#X"TG]ES0_#'BCXU?L+_L[S_M7:@/B7\*OVP-'^,_A'X5
M?$'PY?Z]H7P\TF/P1XU^&6F>/$\G7U\8Z3XMM=!M_%/AS6O"]S'9Q@'Z!_\
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M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K^)[_@Y7_P"4A_[!7_9
MOC%_Z=]0K^V&OXGO^#E?_E(?^P5_V0+XQ?\ IWU"O9X=_P"1_DG_ &-<!_ZE
M4C[;PU_Y.)P+_P!E=P[_ .K;"'Y 5Y;\;_\ DCOQ/_[$7Q-_Z:;JO4J\M^-_
M_)'?B?\ ]B+XF_\ 33=5_269?\B['_\ 8%BO_3%0_P!/>*/^29XB_P"Q%F__
M *K\0?Z.W_!/K_DPG]B+_LT/]FO_ -4SX+KZ\KY#_P""?7_)A/[$7_9H?[-?
M_JF?!=?7E?RH?Y&!1110 4444 %%%% !1110 4444 %%%% !1110!^5GP?\
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MZP=.TI[NSO=1\*S:QIWG6$-Q!INI6EM<F6XAEFD_+/\ X*E_&'X;^./VX_\
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M+?"OP4\<?L1?"7XFZG>Z1XE^,WB+5M.^(^G>,?B3:Q>(M4\.^/M/N;36="=
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M]87$C>XT ?RJ^./^"+/[;7ASX _LM^%/@=XU_9JN/C!X=_X)T?M!_P#!-O\
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M]K-HUMX?L]'U'1M5U_3M4M]?U0 _6.BBB@ K\'O^"N__ "=-_P $J/\ LO\
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M<D_]3LY"BBBO[:/Y'"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH *\._:=_Y-K_:%_[(=\6?_4"U^O<:\._:=_Y-K_:%_P"R'?%G_P!0+7Z
M/X2_V&_^32?@1_V(UK_Z77U?5M?*7[#?_)I/P(_[$:U_]+KZOJVO^<+Q2_Y.
M;XC?]EWQ=_ZT&8'^\OAQ_P F\X#_ .R,X7_]4>!,3X"?\I=/^"4W_8\_M/\
M_K/.NU_<G7\-GP$_Y2Z?\$IO^QY_:?\ _6>==K^Y.O\ 9CZ%_P#RCCP#_P!?
M^+O_ %L^(#_*7Z6'_)^>-O\ KUPQ_P"LED84445_4I_.@4444 %%%% !7Y[_
M /!6;_E&'^W_ /\ 9H?Q]_\ 5;>(:_0BOSW_ ."LW_*,/]O_ /[-#^/O_JMO
M$- '\CG[+_\ R;3^SQ_V0SX2_P#J ^'Z]SKPS]E__DVG]GC_ +(9\)?_ % ?
M#]>YU_S7<;?\EGQ=_P!E/G__ *M<6?[[<(?\DEPO_P!D[DG_ *K,*6OV.?\
ME-/_ ,$YO^Q%_;(_]4=?U_;=7\2/['/_ "FG_P""<W_8B_MD?^J.OZ_MNK_;
MKZ'O_*./AM_UXXF_];/B,_R*^E-_R?GC[_K[P]_ZR60A1117]+G\_!7\LO\
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M7#/_ %ZSW_UG\T/.*D^&?_)[G_!,K_M(Y^R+_P"K;\/U'4GPS_Y/<_X)E?\
M:1S]D7_U;?A^OV/C#_DF<W_[!E_Z>I']L>-'_)KN,_\ L5+_ -2\,?Z;E%%%
M?S8?Y?!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5_$]_P '*_\
MRD/_ &"O^R!?&+_T[ZA7]L-?Q/?\'*__ "D/_8*_[(%\8O\ T[ZA7L\._P#(
M_P D_P"QK@/_ %*I'VWAK_R<3@7_ +*[AW_U;80_("O+?C?_ ,D=^)__ &(O
MB;_TTW5>I5Y;\;_^2._$_P#[$7Q-_P"FFZK^DLR_Y%V/_P"P+%?^F*A_I[Q1
M_P DSQ%_V(LW_P#5?B#_ $=O^"?7_)A/[$7_ &:'^S7_ .J9\%U]>5\A_P#!
M/K_DPG]B+_LT/]FO_P!4SX+KZ\K^5#_(P**** "BBB@ HHHH **** "BBB@
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MXV_;FC^*7_!!WP#^VC<?&C]K']I/XS:_^T'\3?C=^R#8W/B7X/>//B1J6M^
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M<_\ @@'_ ,GP_P#!='_LZSPO_P"K=_;$KZ?)_P#DG^+O^P3*/_5SA3X_/?\
MDJ.!_P#L,S[_ -4.*/ZC****^8/L HHHH *_S9OVQ/\ E*K_ ,%.O^R^Z-_Z
MC]Q7^DS7^;-^V)_RE5_X*=?]E]T;_P!1^XK[#@+_ )*K+?\ #C?_ % Q)^T_
M1[_Y.UPS_P!>L]_]9_-#SBI/AG_R>Y_P3*_[2.?LB_\ JV_#]1U)\,_^3W/^
M"97_ &D<_9%_]6WX?K]CXP_Y)G-_^P9?^GJ1_;'C1_R:[C/_ +%2_P#4O#'^
MFY1117\V'^7P4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %?Q/?\
M!RO_ ,I#_P!@K_L@7QB_].^H5_;#7\3W_!RO_P I#_V"O^R!?&+_ -.^H5[/
M#O\ R/\ )/\ L:X#_P!2J1]MX:_\G$X%_P"RNX=_]6V$/R KRWXW_P#)'?B?
M_P!B+XF_]--U7J5>6_&__DCOQ/\ ^Q%\3?\ IINJ_I+,O^1=C_\ L"Q7_IBH
M?Z>\4?\ ),\1?]B+-_\ U7X@_P!';_@GU_R83^Q%_P!FA_LU_P#JF?!=?7E?
M(?\ P3Z_Y,)_8B_[-#_9K_\ 5,^"Z^O*_E0_R,"BBB@ HHHH **** "BBB@
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M5_Y/SXJ?]E=F'_N,_P!N? '_ ),QX<?]DQ@?_<A\H?M<?\B[\$?^SJ_V<?\
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MAV^$_P#VC2\"?^LN:57,_P#!;[_E$U^W7_V0[5?_ $\Z)73?!?\ Y0[?"?\
M[1I>!/\ UES2J /Y!_V&_P#DTGX$?]B-:_\ I=?5]6U\I?L-_P#)I/P(_P"Q
M&M?_ $NOJ^K:_P"<+Q2_Y.;XC?\ 9=\7?^M!F!_O+X<?\F\X#_[(SA?_ -4>
M!,3X"?\ *73_ ()3?]CS^T__ .L\Z[7]R=?PV? 3_E+I_P $IO\ L>?VG_\
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MMD?^J.OZ_MNK_;KZ'O\ RCCX;?\ 7CB;_P!;/B,_R*^E-_R?GC[_ *^\/?\
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MK_\ *0_]@K_L@7QB_P#3OJ%>SP[_ ,C_ "3_ +&N _\ 4JD?;>&O_)Q.!?\
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M?_5;>(:_0BOSW_X*S?\ *,/]O_\ [-#^/O\ ZK;Q#0!_(Y^R_P#\FT_L\?\
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MZU;X4> ?C#\*/$?P._:=_9D_X)^? ;]L[Q]\3M?\9VWQ>F\2_L/^+?"-W/\
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MGQ-_;:\ >/(M#B\>> /$MGI-SXF\&>'+_4;"VM]2&F0V]W 6W/\ AK+X]?\
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M75I/Y-QX@E@E\J>*.3RYXI(7V[9(W0LI_P!)/_@DY(\G_!,7_@G^TCO(P_9
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MII_^"<W_ &(O[9'_ *HZ_K^VZO\ ;KZ'O_*./AM_UXXF_P#6SXC/\BOI3?\
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MX*=?^O)_VLJ^XJ /AWQ]_P I)_V3?^S'?^"A7_J^O^"8M?S ?\'*_P#RD/\
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MV)_].TS\]^EA_P CK@__ +%>9_\ J7AS]"****_+#^2PHHHH **** "BBB@
MK\'O^"N__)TW_!*C_LO^O?\ JQ?V;J_>&OP>_P""N_\ R=-_P2H_[+_KW_JQ
M?V;JZ\#_ +S#_!7_ /3%4YL7_ E_CH_^GJ9^\-%%%<ATA1110 4444 ?Y_OP
M1_Y*K^WW_P!I'/VOO_5@)7T57SK\$?\ DJO[??\ VD<_:^_]6 E?15?\^_TE
M?^3\^*G_ &5V8?\ N,_VY\ ?^3,>''_9,8'_ -R'RA^UQ_R+OP1_[.K_ &<?
M_5E:37^A/7^>Q^UQ_P B[\$?^SJ_V<?_ %96DU_H3U_I=] 7_DQN,_[+S/\
M_P!5N0G^?WTT_P#D\.&_[(W)/_4[.0HHHK^VC^1PHHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH _!7_@G%_P IC?\ @OM_V,W_  3K_P#5"?$ZOWJK
M\%?^"<7_ "F-_P""^W_8S?\ !.O_ -4)\3J_>J@#\K/^"WW_ "B:_;K_ .R'
M:K_Z>=$KIO@O_P H=OA/_P!HTO G_K+FE5S/_!;[_E$U^W7_ -D.U7_T\Z)7
M3?!?_E#M\)_^T:7@3_UES2J /Y!_V&_^32?@1_V(UK_Z77U?5M?*7[#?_)I/
MP(_[$:U_]+KZOJVO^<+Q2_Y.;XC?]EWQ=_ZT&8'^\OAQ_P F\X#_ .R,X7_]
M4>!,3X"?\I=/^"4W_8\_M/\ _K/.NU_<G7\-GP$_Y2Z?\$IO^QY_:?\ _6>=
M=K^Y.O\ 9CZ%_P#RCCP#_P!?^+O_ %L^(#_*7Z6'_)^>-O\ KUPQ_P"LED84
M445_4I_.@4444 %%%% !7Y[_ /!6;_E&'^W_ /\ 9H?Q]_\ 5;>(:_0BOSW_
M ."LW_*,/]O_ /[-#^/O_JMO$- '\CG[+_\ R;3^SQ_V0SX2_P#J ^'Z]SKP
MS]E__DVG]GC_ +(9\)?_ % ?#]>YU_S7<;?\EGQ=_P!E/G__ *M<6?[[<(?\
MDEPO_P!D[DG_ *K,*6OV.?\ E-/_ ,$YO^Q%_;(_]4=?U_;=7\2/['/_ "FG
M_P""<W_8B_MD?^J.OZ_MNK_;KZ'O_*./AM_UXXF_];/B,_R*^E-_R?GC[_K[
MP]_ZR60A1117]+G\_!1110 4444 %%%% !7\N?\ P0#_ .3X?^"Z/_9UGA?_
M -6[^V)7]1E?RY_\$ _^3X?^"Z/_ &=9X7_]6[^V)7T^3_\ )/\ %W_8)E'_
M *N<*?'Y[_R5' __ &&9]_ZH<4?U&5A^)_$_AKP3X:\0^,_&?B'0_"/@_P (
MZ'JWB?Q7XK\3ZM8:!X:\,>&M L+C5==\0^(==U6XM-+T70]%TNTNM2U;5M2N
MK:PTZPMKB\O+B&WADD7<KX=_X*=?\HV/^"A7_9CO[67_ *H7Q]7S!]@'_#SK
M_@FQ_P!)"OV'?_$LO@+_ /-]1_P\Z_X)L?\ 20K]AW_Q++X"_P#S?5]Q44 >
M5?"#X[?!#]H/PU?>,_@'\9/A5\;_  ?IFN7/AC4O%?P@^(?A'XE>&M/\2V5A
MIFJWGAZ^UWP9J^M:7::Y::7K6C:E<Z3<74=_!8:MIEY+;I;W]K)+_G=_MB?\
MI5?^"G7_ &7W1O\ U'[BO[M_V3?^2]?\%.O^SXO '_KMC_@GK7\)'[8G_*57
M_@IU_P!E]T;_ -1^XK[#@+_DJLM_PXW_ -0,2?M/T>_^3M<,_P#7K/?_ %G\
MT/.*D^&?_)[G_!,K_M(Y^R+_ .K;\/U'4GPS_P"3W/\ @F5_VD<_9%_]6WX?
MK]CXP_Y)G-_^P9?^GJ1_;'C1_P FNXS_ .Q4O_4O#'^FY1117\V'^7P4444
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M7N1((PHOH-I;+;?D[_A]]_P2;_Z/K^!W_@UUG_Y2U^:__!>_PCX4\??MQ_\
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MTG4=,U*2S2RU*QGN/"/^(A?_ ((Y?]'K>&?_  UGQ[_^=50!^SU%?DK\./\
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MM.T'0/A-\2_$WBOPM::SHA^(TTW@_P (R:_IFCS^((=0_._]L3_@E9\:/^"
MOPP\.?\ !1?]@3]LGXEZU/\ #'Q-\.=)_:&^%OQ3LK.+P5\6;3Q5KA\+2W>J
MZ'X4O]&TSQ%X*O\ 7]=TK1Y/AYXDLM7\3^'8-:N?&WA7XJZ5XK\-:1>Q@']T
M]%>,_LY?&*Q_:'_9Z^ _[0&F:1<^']-^.?P9^%_QBT_0;V>.YO-$L?B;X(T/
MQK::1=W$($-Q<Z;;ZW'93SQ 1RRPO)& K 5[-0 4444 %%%% 'P[_P $]?\
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M8M9TZ266630;](XXXTN2[R.Y"HB@LS$*H)(%?Z&/_!)G_E&'^P!_V:'\ O\
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MT_X8/_X+1?\ 2>O_ ,Y;_LI?_-A7[B44 ?AW_P ,'_\ !:+_ *3U_P#G+?\
M92_^;"ON;_@G%^QG%_P3Z_8P^#'[(4/Q%D^+*?"*/Q^#\09?":^!V\0R^//B
MEXW^)L[CPJGB/Q<-(CTZ?QG)H\41\1ZHUQ%IZ7KRQ/<M;0_;U% '\MWBS_@W
MA_:#/Q8^/?CWX0_\%09?A/X2^-_QY^*_QU/@&?\ 8L\">/YO#FI?%'Q7>^(I
M])E\6^(/C-;7FMOI=K-9:4VHQ:7H=I?FP-_%H>F/=2VZYW_$/G^VK_TF'_\
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MWC[4Y/$GB-_ %SH6IZ5Y?C'PG'H][X:O_ T=Y%+.NJ)=R7D8\J 6K>?\;?\
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MO+>:WFDC;XY_X=B_\$V/^D>O[#O_ (B;\!?_ )@:^XJ* /AW_AV+_P $V/\
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MJRM_*C_PYX_X+3_])GOB)_X7?QZ_^:.C_ASQ_P %I_\ I,]\1/\ PN_CU_\
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M_P +OX]?_-'1_P .>/\ @M/_ -)GOB)_X7?QZ_\ FCK^JZBC_7'./^?>5?\
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MT,;G>%E&K2G*<<YS*JYTX3C*I1<:N)E&*JQBX.<4IP3YH-22M_*C_P .>/\
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MV;^7_47Y?U96_E1_X<\?\%I_^DSWQ$_\+OX]?_-'1_PYX_X+3_\ 29[XB?\
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MB?\ A=_'K_YHZ/\ ASQ_P6G_ .DSWQ$_\+OX]?\ S1U_5=11_KCG'_/O*O\
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M0MK2+Q/;7NL?&+Q6O@]Y?%/B'PKX-@LY=&L;K1+.+4M2U:]U>P\/'^NO$O\
MT,*?_ANRO_YB#_B'_"?_ $+*O_AUSCR_ZC_)'X^?\0UOQ9_Z2R?M%?\ A%>)
M?_H@*/\ B&M^+/\ TED_:*_\(KQ+_P#1 5_45X3\9>$?'NB1^)? _BCP]XQ\
M.RZCKVCQ:]X6UG3M?T:75?"VO:EX6\2Z;%J>E7%U927WA_Q+HVK^']9M4F:;
M3=:TO4-,O$AO+.XACZ2C_77B7_H84_\ PW97_P#,0?\ $/\ A/\ Z%E7_P .
MN<>7_4?Y(_E1_P"(:WXL_P#263]HK_PBO$O_ -$!1_Q#6_%G_I+)^T5_X17B
M7_Z("OZKJ*/]=>)?^AA3_P##=E?_ ,Q!_P 0_P"$_P#H65?_  ZYQY?]1_DC
M^5'_ (AK?BS_ -)9/VBO_"*\2_\ T0%?*?[2O_!OQ_P4#^'NK?":U_9L_;)^
M-O[0VD^)_$5]8?%C5-9\9+\)I/A?X=AN?#\=CK]A9>(OCE>R^-IKRVOO$%PV
ME:6UO<6[:%%"\A;4X"O]K5%:T..N(Z-6-2>)PV)C%2O1KY?@52GS0E%.3H8>
MA5O!M3CRU8KGC'F4H<T)8XCPZX5K4I4J>$Q>%E)P:KX?-,Q=:').$FHK$XG$
M4;34/9SYZ,GR2DX.$^6<?Y4?^(:WXL_])9/VBO\ PBO$O_T0%'_$-;\6?^DL
MG[17_A%>)?\ Z("OZKJ*R_UUXE_Z&%/_ ,-V5_\ S$;?\0_X3_Z%E7_PZYQY
M?]1_DC^5'_B&M^+/_263]HK_ ,(KQ+_]$!1_Q#6_%G_I+)^T5_X17B7_ .B
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M1<^,=7^/5SIOA^.2%YI3J%Y!+"AA"%29!6=\!?\ @W6_:V\;?"3P=XH^//\
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M_P#T0%'_ !#6_%G_ *2R?M%?^$5XE_\ H@*_JNHH_P!=>)?^AA3_ /#=E?\
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M$6M:?H-]I'A?68M6MM!\1VMSX=MC_77B7_H84_\ PW97_P#,0?\ $/\ A/\
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M1117QQ]V%%%% !1110 4444 %-=TC1Y)'6..-6>21V"(B("S.[,0JJJ@EF)
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MCM9ATRPT3Q)?::-%T;X@6FH7>H>(-6T][OQW9_$C]M* "BBB@ HHHH ****
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M\./B#=1W3ZK\!]>M-7UW7=7TSQ3KEUK=GK^E>%K9+:^FL;WQ)J?[9T %%%%
M!1110 4444 %%%% !7S?^UO^U;\'/V)?V??B)^TM\>-:O=&^'/PXTR"[OTTB
MP;5O$6OZOJ=[;Z1X;\)^%])66!=0\1^*-=O;#1M*CN[O3])M9[O^T=>U;1M
MLM3U>Q^D*X[XA?#WP/\ %CP/XK^&GQ+\*:'XX\ >.-#U#PUXN\(^)=/M]5T+
MQ!H6JP/;7^FZE87*/#/;SPN1R!)%($FA>.:..10#^4KXN_M%_P#!0O\ X*&?
M&;X>?L[7W[*_P;_9]_:L_9G;X<?\%;/V3_#M]\;="^+W@_Q+X,\"^*_^%8Z'
M\"OVBGT&PO-(\*>-/B'H'Q"\0>*?"OCO3=2\-_8=1M/"FFKIO@M-1U+QSHWZ
MJ_LQVG_!0/\ :"_;NL_VHOVC?@7XR_8G^!OPO_97O/@QI7P!U;]H+P9\8XOB
MQ\9_'7C?0_%?C'QR^E?#C6]7\#Z;X8\#6GAR'P[H/B>XT7PWX[\5B/0]3DOI
M/#\]YX2\/'_!.'_@F'KG_!-G]H/]J.S^%'B#P%X@_8]^.-CX(\7>!;3Q38ZO
MJ7[3?P[\;>&('\,VGPDU#XBSVT@\;? 3P7X1B9OATOB36[O7_#DVI?V3;Z6M
MY_PEGC#QM^R- !1110 4444 %%%% !1110 5\L?MJ_M<?#C]A?\ 9F^*/[47
MQ6T[Q1K'@WX8Z1:W=QH_@_1;S6=;UG6-9U.ST#PSHD)@B>RT>/6_$6IZ7I#^
M(-=N-/T#2&O4N=3OX(@JR?4]8OB3PWX>\8^'M=\(^+M"T?Q3X4\4Z/J?AWQ-
MX9\1:99:UH'B'0-:LIM.UC0]<T?48;G3]5TC5=/N;BQU+3;ZWGL[VSGFMKF&
M6&5T8 _EEUGQ_P"&?^"B?AB'Q'^T3\>/&?A#]HK]C7P-\7?VLT_:1_X)X_%[
MX5?#/X'?LE^$/CUX%TWPYX=_8JUC]LCXAZ[K_P +/'OQ>\<?#&\:^UWXJ^&[
M;0M"\.WT4DT?B_3_  UI>H7WB;W7_@CU_P $^_C'\!?VE?'G[1WB3]F/6_V$
M/AU)^S;HWP$O_@1XB_:8L?VI?'O[1?QEN/B5-\2_&O[5'Q5^(7AO4&\*MJFG
M-)<>!/!X&F)JVHZ;JFLW^G0^%/"ATO0+SK?AW_P0*^'/@/XSZQX.;XS^+=9_
MX)AQ_$6S_:-\,_\ !//4E>_\&77[1DL-EIDZ_$+Q9?/<:]X\^!OABU\.^'_$
M'AKX7Z_?ZAI^M>)6MX_%R7UAX?U*3Q__ $'1116\44$$4<,$,:10PQ(L<444
M:A(XHHT"I''&BA$1 %50%4  "@"2BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH _#7_@L;^W=\7/V4KOX!_#/PYX^OOV-?A)\:]:UB/XC_P#!1W6_
MA''^T%X/^#LWAK2M6UG3_@[X6^$FEVGB">Z^*_Q-?3;=-/\ $7Q#TC3/!^G>
M%/[;E\(IXL\2V>N7GPX^</V3?V1_^"B_Q8\(_#C_ (*-> /VD?#_ .R_^U[^
MTS\+3X/_ &J?!'Q3_9YBUKX=?'[P9X1\1^*_"_[-7[0OBGX3:3X[TI_A/\?]
M ^!TWA#74\/:1JU[X=EN5TOPSJ^G^&=.N?'NA>(_Z&/BM\*?AQ\<OASXP^$?
MQ=\&Z%\0?AMX_P!#O/#OB_P?XDLUO=(UK2;U )(9H\I-;W,$BQ7>G:E936VI
M:3J-O:ZGI=Y9ZC:6MU%Q/[,G[/?@_P#92^ _PV_9W^'VO>//$?@;X4:')X8\
M(ZA\2O%,_C+Q=;^'(]2OKW1]"NM?GMK-IM)\+V%Y!X:\+6$5K;VNB>%M)T;1
M+2(6VG1$@'!?L+?LD>$OV%?V4/@U^ROX,U_4?%FE?"OP_?V^H^+=4MWL+KQ9
MXO\ %'B#5_&OCWQ4FCMJ&K1^';+Q)XW\1^(-:T_PU;ZGJ-MX=L;ZWT:#4+]+
M(7D_UI110 4444 %%%% !1110 5\;_MR?MG^$?V#O@WIOQY^(OPZ^*'CKX:P
M?$3P9X0^(FN_#+0+?Q'_ ,*C\(^*+V:UU/XM>.K$WUOJ:> _"WE10:G+H=CK
M&JS:IJ>BZ;!8 :@UW;?9%9NLZ-H_B/1]5\/>(=*TW7= UW3;[1M<T/6;&UU3
M1]9T?5+66QU/2M5TR^BGLM1TW4;*>>SOK&\@FM;NUFEM[B*2*1T(!_"W\;_#
M]S^VG\4AK?Q<T+6OC-\&_%'[4/C3P-_P2M_X*A_'+X)>%?$_@KQIXUU+Q!-?
M:A^R!^U1X#\%Z5--X]_8L^)?Q#U?Q;X*_9^^-MIX-\-ZM\.=;L]0\0_#JVL/
M"Z>(?#G@[^F;_@GA_P $Q_V7_P!C^/3?C]\/_P!EO1/V7/VCOBG\)]#\._&O
MP-X$^.7Q9^*7@#P_?WUQIGB/7O"VDQ>*_%-YX0OUTW7K"SBAU;2?#L4=A]BG
MM/#^HSZ?>ZAJ.N>U?L0_L%?#;]@;3?C'X*^"?C;XC3?!CXD_$NY^)/@7X(>*
M=4TC5_ ?P"FU>R3_ (2?P[\*;HZ-%XPM_#_B36VFU>[TOQ#XGUO3-/6VTQ-&
MT[3M7D\6:]XP^YJ "BBB@ HHHH **** "BBB@#E_&WB9_!OA'Q-XIA\/Z[XO
MN_#^@:SK-AX.\*)I4WBSQA?Z5IEWJ-KX4\)VVMZKH>CW?B;Q!+:C2]"M=3UK
M2=/GU*YMX[W4K"U,UW#_ !:^+/\ @HM\4OVZ$T?PI^U1XNUCQY^Q[^T1X,_:
M"\,_MN?L<?LR_LD?$3XF^)?^"='AGPYJNKZ)^SCXJ^)WQ7T_P=??%BP_:7TW
MXN^#$\4:]9^*O#MA\.)=*\"ZMXC\._#]-,O/"Z>(?O?_ (*!:E^SC\(O^"JW
MAWXP?\%9-#U[Q+^QE_PI_P"&6O?L*_$O4T^+FL_ CX#_ +1'PX\5WFK?$GP)
MXZ^&_P -;75]%\2?$WXE2MIWCBS\7^.=&GT:\\$^&](\"SV?B&SL+E/#?U=_
MP31^$=M^TG\2]0_X*U/97GP0\4_&[5OCCX#MO#GPHTC4/ /PZ_:]_9KT;QRV
MA_LW?&[X[?"KX@VOB?Q%X?\ B?%H>@W?B;1M<T+7M'\0:QI>J:+>W.M-X0U>
M[\(70!RG[$O[('QZ_:&\5_L/?M@_M&_MF6G[2OPF_99\%^/=2_9+N;7]F3XA
M_LV?%WXER?$[PVG@6+XJ_M 77Q(UV/Q=/=#P1:BVTW1M&\-Z=X<^(]I+H?CS
M4=;\3V-Y)?\ BO\ ?BBB@ HHHH **** "BBB@ HHHH _EX_X*B_\%"OVY?AU
M^U+\0O@)\&_B5J/[(^J> ? '@/Q#^R)\.8OV<]&_:,\:?\%2/BAXT\3:'HFI
M>#?"WB'58YO"GPP\&> ]?OM*\*^(-#T/6+;XK:?I&JZ_\2-9M+WP[!!HOAWT
MV#_@C_\ M=7GP6^(/[-GA7]JOX=_!C]DK]KN72_B-^TI^SE<_!L?$_7O@-X_
M\;VFB^(OV@?A_P#LI?$C4?&L%G8_#GQ_XV76(M%C\7Z7JK?#:WCM/$'A 7_B
M*]U[5-<_8W]L#]C/X*_MM_#&T^&OQBL_$6FW/ASQ)I'CGX9_%#X>:T/"'Q@^
M#'Q&\/745YX?^(WPE\=QV=]=>$?&&CW,2-;WJVM[87<6ZTU73M0LV:W/T_IE
MDVFZ;IVG-?7VIM86-I9-J6J2QSZEJ#6MO' ;[49X8;>&:^NS&9[N6*W@CDN)
M)'2&)2$4 ;I.EV6B:7INBZ;$\&G:1I]GI>GPR7%S=R0V6GV\=I:Q27=Y-<7E
MT\<$4:/<7<\]S,P,D\TLK.[:%%% !1110 4444 %%%% !7XY_P#!7[]M'XQ_
MLF>"?@OH?P^UJ3]GCP-\;/B'%X&^*'_!0#7_ (>V_P 8_A]^R+INV*ZT>^U7
MX3VMOK%YXD\2_$34(SX2\-:IXLTBR^&N@7=V+CQ!J[7$UNEG^QE<UXR\&^$O
MB)X3\1^ _'OAG0O&?@KQAHNH^'/%?A/Q/I=EK?AWQ'H&KVLEEJFC:UI&HPW%
MCJ6FZA:32VUW9W<$L$\,C)(C*<4 ?S,_L5_L\?\ !1']J/P+\/?^"EG@?]I;
MPU\%?VJ?%&C^./@I+XH^)O[.RV?@/]MW]C_PYXNEF^ 7Q=^.WP,T3Q5HG_"K
M/B^CRZ]XF\*>(/!MS<3W/@:3PEHD-R?"NLZC<ZO^W?[!/['MC^Q%^SW9?!]_
M'=[\5/&NN>.?B%\6_BW\4KW1E\+#XA_%?XI^*+[Q3XP\2V'@JUU75]&\$:0T
MUU:Z7I/A?0+D:;9:?IEO<3?:M7O-5U&^]2_9B_9R\$?LF_!CPO\  7X:ZWX_
MUGX>^!KCQ!#X)@^)'C'4?'>M^%/"NJ^(-2UG0/A[I/B#5E_M-O!'P[TN_M?!
M7P_TS4)[^_T?P9H6B:9?:KJUY:W&IW?OU !1110 4444 %%%% !1110!X]^T
M'XR^)_P\^!_Q5\<_!7X8_P#"Z/BSX4\#>(-<^'WPJ_MZT\,_\)YXIT^PEGTK
MP[_;=ZK6]E]MN%4<@2W.W[);,ES<1.O\BWP+^.WP9_:=_9Q^.^N_MJ^'=3_:
M2^"T'C'2=8^-7B+]I'0_&VI?'SQ]_P %:/&WA[PGI_PS_95_8B_8S\%?$'P[
MK_@7PW\#_"W]I?![7M(L=>\&:Q\7KFXO],MO$MA\,/"?C+Q)I_\ :57P_#_P
M3E_8[MOVS7_;ZM_@YH5O^TS+X8D\.R>,86FBTR2_FMI]+E\>/X:C9=%?XER^
M&[JY\)2>.FM3KS^&+B?2FN3'-([ 'S-_P3O_ .";7BO]E[XF^*/VA?C?\1OA
M;\1OBM>?!CPM^S9\)M+^"?[/WA_]F;X8_"+]GWPYXKU+Q[?>'],^&OA34KG2
M6\5?$OQQ>67CGQW<W%OMT/6[&/0?#D_]B1'SOUYHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "OSX_:B_X)B_LJ?M:_%'1_C;\0],^)O@_P"+
M>G^"Y?ACJ_Q"^"?QB^(WP7\3>-_A3=7=S>W_ ,,/'E]\/]?T8>)_!NH7%Y<&
MZM;R,:F8'%G#JD-DB6ZE% 'V%\(OA+\.?@-\,/ ?P9^$7A33_ _PR^&?AC2?
M!W@CPIIDEY/:Z+X?T6U2TL;4WNI7-]JNIW;(AGU'6-8O]0UG6=0FNM5UC4+[
M4[RZNYO1:** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@"M=V=IJ%O+9W]K;7MI,%$UK=P17-O*%
M=9%$L$RO%(%=5=0ZD!U5A@@$6:** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
2**** "BBB@ HHHH **** /_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>nt10014672x1_barchart6x1.jpg
<TEXT>
begin 644 nt10014672x1_barchart6x1.jpg
M_]C_X  02D9)1@ ! 0$ P #   #_[0 V4&AO=&]S:&]P(#,N,  X0DE- ^T*
M4F5S;VQU=&EO;@     0 ,     !  $ P     $  ?_B"^!)0T-?4%)/1DE,
M10 ! 0  "]!N;VYE @   &UN=')21T(@6%E:( ?4  < %0 3  L (6%C<W
M         $E%0R!S4D="     0            #VU@ !     -,M2% @(
M
M$&1E<V,   %$    =&)865H   &X    %&)44D,   ',   (#&1M9&0   G8
M    B&=865H   I@    %&=44D,   ',   (#&QU;6D   IT    %&UE87,
M  J(    )&)K<'0   JL    %')865H   K     %')44D,   ',   (#'1E
M8V@   K4    #'9U960   K@    AW=T<'0   MH    %&-P<G0   M\
M*&-H860   ND    +&1E<V,         &G-21T(@245#-C$Y-C8M,BTQ('=I
M=&A"4$,
M                                                    6%E:(
M     "2@   /A   ML]C=7)V        !      %  H #P 4 !D '@ C "@
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M;W5R(%-P86-E("T@<U)'0@
M
M      !865H@        8ID  +>%   8VEA96B            !0
M;65A<P         !                               "6%E:(
M  ,6   #,P   J1865H@        ;Z(  #CU   #D'-I9R      0U)4(&1E
M<V,         +5)E9F5R96YC92!6:65W:6YG($-O;F1I=&EO;B!I;B!)14,@
M-C$Y-C8M,BTQ
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MU=;7V-G:X>+CY.7FY^CIZO'R\_3U]O?X^?K_Q  ? 0 # 0$! 0$! 0$!
M     0(#! 4&!P@)"@O_Q "U$0 " 0($! ,$!P4$!  ! G<  0(#$00%(3$&
M$D%1!V%Q$R(R@0@40I&AL<$)(S-2\!5B<M$*%B0TX27Q%Q@9&B8G*"DJ-38W
M.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U=G=X>7J"@X2%AH>(B8J2
MDY25EI>8F9JBHZ2EIJ>HJ:JRL[2UMK>XN;K"P\3%QL?(R<K2T]35UM?8V=KB
MX^3EYN?HZ>KR\_3U]O?X^?K_V@ , P$  A$#$0 _ /[^**** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBOAW]CG]OSX.?MN^)?VG?"WPI\-?$OP_J'[)_QQ\0_ 'XBS?$+1O"VE6>
MM>,?#5_JVG7VI>"I/#?C+Q9/J/AF6?1[I[2\URW\.:I)%) TVC0.TB1 'W%1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 45\:
M?M^_M'?%/]DS]E3XM_'_ .$7P0/QW\1_#'P9XR\;ZKX?N_&WASP'X<\*>$?
M_@;Q3XZ\3>/?%VJ:W>Q:QJFA:)I_AAK"'PQX$TGQ#XS\1^(=9T+2[:QT?0I]
M?\9>%_K;0=1?5]#T;5I(UADU32M.U&2%"62)[VSAN6C1F^9E1I2JD\D $\T
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M *.$^.'_ (=CQ[_\OZ/^&F_VDO\ HX3XX?\ AV/'O_R_H_XJ(<&?]&ZXG_\
M#KE7_P B'_$BO%G_ $7?#O\ X;<R_P#DO7^GI_8A17\=_P#PTW^TE_T<)\</
M_#L>/?\ Y?T?\--_M)?]'"?'#_P['CW_ .7]'_%1#@S_ *-UQ/\ ^'7*O_D0
M_P")%>+/^B[X=_\ #;F7_P EZ_T]/[$**_CO_P"&F_VDO^CA/CA_X=CQ[_\
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M'#_P['CW_P"7]'_#3?[27_1PGQP_\.QX]_\ E_1_Q40X,_Z-UQ/_ .'7*O\
MY$/^)%>+/^B[X=_\-N9?_)>O]/3^Q"BOX[_^&F_VDO\ HX3XX?\ AV/'O_R_
MH_X:;_:2_P"CA/CA_P"'8\>__+^C_BHAP9_T;KB?_P .N5?_ "(?\2*\6?\
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MT<)\</\ P['CW_Y?T?\ #3?[27_1PGQP_P##L>/?_E_1_P 5$.#/^C=<3_\
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M_P --_M)?]'"?'#_ ,.QX]_^7]'_ !40X,_Z-UQ/_P"'7*O_ )$/^)%>+/\
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M%I=V\B30321NK$ \^U3]G;]G[6]3U'6M:^!?P<U?6-7OKO5-6U;5/ACX)O\
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M7_5;_P!7?;3Y$_X=:?M8_P#0(\#_ /A:67_R-1_PZT_:Q_Z!'@?_ ,+2R_\
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M_AUI^UC_ - CP/\ ^%I9?_(U'_#K3]K'_H$>!_\ PM++_P"1J^N_^'R.C?\
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M -7?;0_UN^FS_P!&WX2_\'9%Y?\ 5;_U=]M/D3_AUI^UC_T"/ __ (6EE_\
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MI_\ AR;7_P"8FC_A\CHW_1O^I_\ AR;7_P"8FC_4GZ 7_1T^-/\ P1Q'Y?\
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MW_P^1T;_ *-_U/\ \.3:_P#S$T?\/D=&_P"C?]3_ /#DVO\ \Q-'^I/T O\
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M0GP._P"@OCO_ ,/^7?\ SB_J[\K'_$Z?C#_T"\&?^&7'_P#SY_J[\K?S+_\
M#K3]K'_H$>!__"TLO_D:C_AUI^UC_P! CP/_ .%I9?\ R-7]-%%'_$A/@=_T
M%\=_^'_+O_G%_5WY6/\ B=/QA_Z!>#/_  RX_P#^?/\ 5WY6_F7_ .'6G[6/
M_0(\#_\ A:67_P C4?\ #K3]K'_H$>!__"TLO_D:OZ:**/\ B0GP._Z"^.__
M  _Y=_\ .+^KORL?\3I^,/\ T"\&?^&7'_\ SY_J[\K?S+_\.M/VL?\ H$>!
M_P#PM++_ .1J/^'6G[6/_0(\#_\ A:67_P C5_3111_Q(3X'?]!?'?\ X?\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M%_\ ,-4?\8&?]6B_^8:H_P")&O\ J^'A]_X!Z?\ 4T\_R[Z'_$XG_5G^./\
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M1?\ S#5'_$C7_5\/#[_P#T_ZFGG^7?0_XG$_ZL_QQ_X%_P#@X_DYHK^L;_C
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M'ZDFM>$OAI\/_"^L1PRVZ:MX=\&^'-$U)+>X 6>!+_3--M;I89E 66(2A)
M'5@!7H%?Z!^#' F=>&W >6\'9WF>59M5RFK4IX/%91@*F6X98*=.A)0JX:<Y
M0^LRQ?US$5)T(4:/+7IPC2YX3JU/X@\6.,\IX_XTQ_%649?F664\SITYXO#Y
MIC88^O\ 7(SK1<J=>,5)T(X7ZK1A&M.K5YJ-2<JG+.-.F4445^K'YL%%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110!\;_ +<R>-8O@?=ZKX*F_:^N)=#U
M7^U-;\-_L1K\$E^-WBK2+;1-:D72[*Y^-D<=K!I$&J+INHSP^ M2T[QWJ>IV
MFDZ1;C4_#E_XCT>_Q_\ @FO\8?&/Q\_82_9A^+'Q&\=Z=\2?B1XH^&&FP_$G
MQ?INA77AG[9\1_#=[?\ A3Q]IFK:!>:!X4DTGQ3X8\7Z'K/A?QE9P^&M!L8O
M%NC:U_9FE6.G&UMT]Q^-7[/W@7X\V_AB+QAK/Q6\.WG@[4;_ %+0-;^$7QM^
M+WP/\0V\NJV#:9J=I>ZW\(?&O@O4=:TJ]LRJRZ3K<^HZ='<PVVH6UM!J-K;7
M<73?!_X0?#CX!_#3PA\'_A'X8M_!WPZ\":8VD^&?#]O>ZKJK6EO+=W.H7MU?
MZSKU_JNOZ]K.K:I>WVL:]XAU_5-4U[Q!K5_?ZSK>I7^J7UW=S 'X,?&__@LG
M_P %%/A?\:?B]\-/!'_!"3]J7XO>"_AW\4/'_@7PC\6?#WCOX@6>@?%#POX2
M\5ZMH&@?$30[2R_94\16=KH_C72M/M/$NF6]IX@UVV@LM3@B@UC4XE2]G_F9
M_8:\8>(?B'\5/V\_'_B[P-JGPQ\5^.?VLOB#XP\3_#76Y[BZUKX>^(?$WB/Q
M+K6M>!M7N;O2]#NKC5/">I7MSH%_/<Z)H]Q-=Z?+)-I>GR,UI#_I+5_%1_P2
MS_8;_P"&L?VA_P#@KGXA_P"%H?\ " _\(E_P41^,^C?8_P#A"?\ A*O[0^V^
M./'-]]I^T?\ "6^'/LGE8\KR?(N=^=_FI]ROY\^E#P/Q1XB^#?$/"G!N5_VQ
MG^.QV05L+@/KN79?[6G@LZP6+Q4OK6:XO X*'LL/1J5+5,3"4^7DIJ<W&+_<
M?HZ<8<.<">*V1\2\5YC_ &5DF#P6=T<3C?JF/QWLZF+RG%X;#Q^K9;A<9BY^
MTKU80O3H2C#FYIN,$Y+EJ*_<#_AS3_U<?_YB#_\ &C1_PYI_ZN/_ /,0?_C1
MK_*[_B3?Z2'_ $;G_P V_@/_ .B@_P!(?^)K/ /_ *+S_P U?C/_ .AT_#^B
MOW _X<T_]7'_ /F(/_QHT?\ #FG_ *N/_P#,0?\ XT:/^)-_I(?]&Y_\V_@/
M_P"B@/\ B:SP#_Z+S_S5^,__ *'3\/Z*_<#_ (<T_P#5Q_\ YB#_ /&C1_PY
MI_ZN/_\ ,0?_ (T:/^)-_I(?]&Y_\V_@/_Z* _XFL\ _^B\_\U?C/_Z'3\8?
M"_A^;Q'JT-BFY+=?WU].N!Y%JC .5+ CS9"1%"-K?O'#LIC20KZS\0?",$^D
MPZCIENL4VC6RPO#&,>;ID*@8YY9K)09%).YH3,"781@?KIX?_P""3FH>&K:6
MWT_]H'2G,\@EGN+GX,W4ES*5&V-'DB^+L*^7$"WEH$"J7D;EY'8[Y_X)?^(2
M"#^T#HA!&"#\%[X@@]01_P +BY!K[;*?HA>-.'R7%8+'>'E>6,S"-Z]:'$O
MLWAI0;>'C0D^*5?V,K5)-652<I0DY4U$_B[Q4^D'G>>>,G#7&G!'&.28?A'@
M2O[/)<IQ<.+<(N(,/C8TX<0ULXP\.&*BA_:]#FR_#0G[6>7X2AA\50C0Q\ZS
M?\^-%?N-<?\ !&X3SS3C]HF&W$TLDH@M_@\R00[V+>7"K_%21UB3.U%9W*J
M-QQ4/_#FG_JX_P#\Q!_^-&OBI?0V^D>I-+PZYDFTI+B[@1*23T=GQ.FKK6S5
MUU/[-H_2N\!ZE&E4J\;NA5G3A.I0EPSQA4E1J2BI3I2G3X>E3FZ<FX.=.4H2
M:O%N+3/P_HK]P/\ AS3_ -7'_P#F(/\ \:-'_#FG_JX__P Q!_\ C1I?\2;_
M $D/^C<_^;?P'_\ 10:?\36> ?\ T7G_ )J_&?\ ]#I^']%?N!_PYI_ZN/\
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M_P#10'_$UG@'_P!%Y_YJ_&?_ -#I^']%?N!_PYI_ZN/_ /,0?_C1H_X<T_\
M5Q__ )B#_P#&C1_Q)O\ 20_Z-S_YM_ ?_P!% ?\ $UG@'_T7G_FK\9__ $.G
MX?T5^X'_  YI_P"KC_\ S$'_ .-&C_AS3_U<?_YB#_\ &C1_Q)O])#_HW/\
MYM_ ?_T4!_Q-9X!_]%Y_YJ_&?_T.GX?T5^X'_#FG_JX__P Q!_\ C1H_X<T_
M]7'_ /F(/_QHT?\ $F_TD/\ HW/_ )M_ ?\ ]% ?\36> ?\ T7G_ )J_&?\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH \N^
M-?QD^'O[/?PI\=_&GXJZZGAWP!\.] N?$'B'41!->WLD<3QVUAH^B:5:K)?Z
M]XG\1:K<V'A[PIX:TJ"YUGQ-XEU32M T:TO-5U*SM93X(_&#P5^T'\'?A?\
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M !%X;TWQAX=UBU\<Z1XIT1?[7LM-:_MKC2=6-GJ4=G*9(;>_CWM$9HV/M/\
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M;_P\N_8Z_P"BEZG_ .$#X]_^9RC_ (>7?L=?]%+U/_P@?'O_ ,SE?RY44?\
M%0#QI_Z$7AO_ .&3B+_Z+/ZN_*Q_Q)'X2?\ 0YX^_P##OD7_ -#/]7?E;^HW
M_AY=^QU_T4O4_P#P@?'O_P SE'_#R[]CK_HI>I_^$#X]_P#F<K^7*BC_ (J
M>-/_ $(O#?\ \,G$7_T6?U=^5C_B2/PD_P"ASQ]_X=\B_P#H9_J[\K?U&_\
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MC6OCL%B\OP.;K#X?%.<X8EN*_P!IP^)P^,BY4\3"4OZ,/^':/['7_1--3_\
M"^\>_P#S1T?\.T?V.O\ HFFI_P#A?>/?_FCK^<__ (:!^/7_ $6WXN_^')\9
M?_+JC_AH'X]?]%M^+O\ X<GQE_\ +JO+_P")GOHU_P#2+?#'_AGX,\O^I'_7
MS9^H?\2[^/\ _P!)&\1?^'7BS_Y\>7Y]V?T8?\.T?V.O^B::G_X7WCW_ .:.
MC_AVC^QU_P!$TU/_ ,+[Q[_\T=?SG_\ #0/QZ_Z+;\7?_#D^,O\ Y=4?\- _
M'K_HMOQ=_P##D^,O_EU1_P 3/?1K_P"D6^&/_#/P9Y?]2/\ KYL/^)=_'_\
MZ2-XB_\ #KQ9_P#/CR_/NS^C#_AVC^QU_P!$TU/_ ,+[Q[_\T='_  [1_8Z_
MZ)IJ?_A?>/?_ )HZ_G/_ .&@?CU_T6WXN_\ AR?&7_RZH_X:!^/7_1;?B[_X
M<GQE_P#+JC_B9[Z-?_2+?#'_ (9^#/+_ *D?]?-A_P 2[^/_ /TD;Q%_X=>+
M/_GQY?GW9_1A_P .T?V.O^B::G_X7WCW_P":.C_AVC^QU_T334__  OO'O\
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M_P 2W/?_ )N\OS[L_?3_ (=H_L=?]$TU/_POO'O_ ,T='_#M']CK_HFFI_\
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MW%C!<K^@M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!\:?M7_ +,'
MBGXY^*?V:?BQ\+_'?@_X>?&7]ECXK>)?B5X!UCXA?#S5_BCX&UJR\;?"3Q_\
M(?&'A+Q'X4T/XA?#+54CU+2?'$&MZ7XATWQ1%?Z'K7AO3I(;.[@N+J.NQ_9!
M_9UD_9;^!FC?">_\86WQ \2/XQ^*_P 2O''C6P\)VW@+2?$GQ ^-7Q5\9?%_
MQQ?Z!X%L=6UVR\%^&H_$_C?4[+PSX7M=9U2/1- M-.L)-2U"XAFO;C:_:"_:
MI_9Z_94T+0/$O[0OQ4\-_"S1/%&K3:'X?OO$1U!UU;5;:S>_N+2T@TRQO[EV
M@M(S--*T*P1!HD>59)H4?K/@K\;OA1^T7\-]"^+WP1\<Z+\1_AKXFGURVT'Q
M?X?>X?2]2N/#6OZGX7UZ"$W=O:W*RZ5XAT;5-)NXYK>-H[NRG3!4!B >7^(?
MV&_V*/%NOZYXK\5_L??LM>)O%'B;6-3\0^)/$GB']G[X3:UK_B'7]:O9]2UC
M7-<UC4O"5SJ.K:QJVHW-S?ZGJ=_<W%[?WMQ/=74\L\LDC?QB_P#!/']CKXJ_
M%[X_?\%1;3X#?#[03X-^'W[>/Q>\(VVCZ9JGA+P=H_ARRM/&GC.+1-#T;1KR
M^TBVM-*T_2K:"UL+/3+5+"QM8(;2%(HXTC7^]ZOXL_\ @E7^W#8_LH?M"_\
M!77P]=_#>[\<-XL_X*)?&;64N[?Q3#X?6Q6R\;^.;$V[0RZ!K!N#(3Y@E$L(
M4?)Y;?>K\5^D%EOAUFWA=G6!\5<\S+AS@JKC,FEF.;91"K4QU#$4\UPE3+H4
MXT<ISNHXU\=&A1JM9=52ISDW.BKU8_K?@?C^/,L\1<IQGAMDV7Y]Q;3PN:QP
M&69I.G#!UJ%3+L1#'3J2JYGD\%*CA)5JL+X^D^>*M&H_<E]?_P##M']L7_HF
MFF?^%]X"_P#FCH_X=H_MB_\ 1--,_P#"^\!?_-'7W!_P^1T;_HW_ %/_ ,.3
M:_\ S$T?\/D=&_Z-_P!3_P##DVO_ ,Q-?YX?\0_^@3_T>7Q!_P#"3,O+_JV'
M]7?;3^Z?]=_II_\ 1J.!_P#PIP'E_P!7$_J[[:?#_P#P[1_;%_Z)IIG_ (7W
M@+_YHZ/^':/[8O\ T333/_"^\!?_ #1U]P?\/D=&_P"C?]3_ /#DVO\ \Q-'
M_#Y'1O\ HW_4_P#PY-K_ /,31_Q#_P"@3_T>7Q!_\),R\O\ JV']7?;0_P!=
M_II_]&HX'_\ "G >7_5Q/ZN^VGP__P .T?VQ?^B::9_X7W@+_P":.O1_!?\
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MZ/+X@_\ A)F7E_U;#^KOMI^Y_P"N_P!-/_HU' __ (4X#R_ZN)_5WVT^'_\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M_P &8;_Y1Z_T]/Y)Z*_K8_X5C^Q'_P!$]_97_P#"3^$G_P KZ/\ A6/[$?\
MT3W]E?\ \)/X2?\ ROH_XD*SK_H[G G_ (*Q?_S1YK[P_P")TLI_Z-AQG_X,
MPW_RCU_IZ?R3UHZ5IESK&HVNFVB@SW4H0,?N1H 6EFDQSY<,2O*^,L50A0S$
M*?ZQ_P#A6/[$?_1/?V5__"3^$G_ROH_X5C^Q'_T3W]E?_P )/X2?_*^M*7T"
M\VC4IRJ^+/ U2DIQ=2G&.*IRJ04DY0C4]K/D<H^ZI\D^5M/EEL^+,?IFX>OE
M^.H99X><69?F5;"8FE@,?B,/A\PP^"QM2C.&&Q=; *>">-I8>LX5JF$6+POU
MB,'2^L4>?VD?YY=)TNUT;3K73;1<0VT80L0-\TAYEGEQP9)I"TCXPH+;5"HJ
MJ/GSQ]X:_L'53<6T>W3-19YK8*H"6\V<SVF%P$5&;S(%VJOD.(TW&&0U_4[_
M ,*Q_8C_ .B>_LK_ /A)_"3_ .5]'_"L?V(_^B>_LK_^$G\)/_E?7UF=?0QQ
M^<9?1P*\0^ \(\*Z?U.K"OBJBP\8J,'35/V=/FI3I)0</:17,J<[MP2?\I>#
M/'>:>$?'N:\;5,PXYXJAQ+#&+BS*L;PG1P4L^KXFK4QE+'U,P?$^/6'S'"YC
M4EB:>+E@L3*5&MC<(HPAC:E2'\D]%?UL?\*Q_8C_ .B>_LK_ /A)_"3_ .5]
M'_"L?V(_^B>_LK_^$G\)/_E?7Q__ !(5G7_1W.!/_!6+_P#FCS7WG]=?\3I9
M3_T;#C/_ ,&8;_Y1Z_T]/Y)Z*_K8_P"%8_L1_P#1/?V5_P#PD_A)_P#*^K5C
M\(_V,=3NX+#3?AC^S#J%]=2"*ULK'P7\*KN[N92"1'!;0:;)--(0"0D:,Q )
M XJH?0(SRI*,(>+7 TYSE&,(0H8R4IRDTHQC%5VY2DVE%)-MM)*[1,OIJ9/"
M,IS\,N,80A%RG.5;"QC&,5>4I2=%)1BDVVVDDKMI7M_#)JGP,^*$_P 7? _B
M&+X_?&2YT?2_AQ\5-&O_ !7)IG[.4>IZ+J>O>)_@Y?:3X>M-/7X(P6MU8^)K
M7PYK6I:C>S:!J=Q87'A+2X+;6-#CU&[LO$/[/?\ !+VTN-/_ &LOA)87>J7V
MMW5EX>\9VESK6J1Z9#J>KW%M\.M?AFU348M%T[2-'BOM0D1KN[CTG2=+TQ+B
M:1;#3K*U$5M%_17_ ,,R?LV_]&]_ _\ \-/X"_\ E!5RR^$_[/OPH:[^(6G?
M#3X-_#5O"VF:IJE]XXLO!O@GP<WAS1H-/N3K>HW?B6#3=..D:9#I7VLZI=S7
MMO:QZ?\ :3=R"V\VOV/AGZ'?'N5\9>&_$>;\:<"U\%P!G^39K'"Y+PC3R7%X
MW"Y;Q%5S^O0E7P.%PT/:U9XBO1I0:IX.'[NK*@\1+$8BM^4\0_2HX*S'A3C[
M(<LX3XRHXOC;)<URV6)S;BBIFV&P>(Q^14LEHUHT<9B:\O9TX8>C5JSO/%3]
M^G&M[!4:%'X1\;_L.?MO^)?&GB[Q'X;_ ."N7[0_@/P[K_B?7];T#P/I/[/_
M .RSJNE^#-%U75;N^TKPIINJ:U\.+O6=2T_P[8SP:19W^K7=SJ=Y;V<=Q?W$
MUU)+(W":W^P[^W!X9T;5O$?B/_@MI^T'X?\ #V@:;?:SKNO:W\ /V/-*T;1=
M'TRVEO=2U75M4O\ X:V]CIVFZ?9PS7=]?7D\-K:6T,L]Q+'%&[C]B8I8KB**
M>"6.:":-)89HG62*6*10\<L4B%DDCD1@Z.A*LI#*2"#7.^-/!?A'XC^$?$O@
M#Q_X:T/QGX(\9Z'J7AKQ;X2\2Z;::SX>\2>'M9M);#5M$UO2;^*>RU+2]2LI
MYK6]LKJ&6WN;>5XI49&(/^AQ_#!_"W^U7\!_C;_P5/\ B1H/P9_8Y_:R^-W_
M  45\5?"+Q;#;ZK^VAXQ^"7[-_P'_9F_9SU32]66>[M_"_[4_@KX10_%;Q]J
MUO?1:9KEQX+^!L]UI7B/2[W2/&&AZKXLCTB>VM/["_V&/@)\=?V;/V<_!GPI
M_:,_:C\8?M=_%#0Q<OJWQ9\9Z'INBWYM;@H;+PW:31OJ'B?Q%9:)$IA/BOQ_
MXD\3^,?$5[)=ZE>W^FV$VG>'-%^E? _@3P1\,O">A> OAOX.\+?#_P #>%[%
M-,\->#/!/A_2?"OA7P]IJ.\J6&B>'M#M+'2=*LEEEED%M8VD$(DDD?9O=B>J
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHKX(^-G_!27]F/
MX!W7C"P\;7WQ&U/4_ /Q'\0?#WQ?I/@+X7>,OB!K.AVO@;X5?##XU?%/XFWN
MC>%--U/54^$/PB^'GQ@\":O\2?B!]C.EZ#=ZQ!HD":AK5UIUA? 'WO14%K<P
M7MM;WEK*D]K=P0W-M/&<I-!/&LL,J$@$I)&ZNI(&01Q4] !1110 4444 %%%
M% 'Y._\ !63XU?%_X2^#?V7-"^#GB?XXZ?>_%O\ :?TGP#\1O!_[*OAOP1XJ
M_:F\<?")OA1\5=:\6GX,:;X^^'WQ)T*SE\#ZQIGA7Q]XWULZ-H5W9>#?#VJ6
M5EXZ\)W>J07-U[K_ ,$S?BAXY^,G[#/[/OQ#^)OQ(A^*WQ$UGPWKEIXS\6MH
MDOAW6X-?T'QGXE\/WG@WQSHT_AWP@]I\3OAN-+C^'GQ3D7PIX:M[_P"(OA?Q
M/J5GH6EV=Y;V<7MGQY_9A^#_ .T@?AU=_$W2O%"^(OA#XNNO'?PM\;^ /B-\
M1/A-\0/ ?BC4/#>L^#]5OO#WCCX7^*/"/B>&RUOPOX@U?0O$'A^YU.Z\-^(=
M.NQ!KFCZ@+:T-OU/P/\ @?\ #']G'X8^'/@[\'?#DOA7X?>%9=>NM)TFZU[Q
M)XJU!M0\5>)-8\8^*-8UCQ1XQUCQ!XJ\1ZYXC\5:_K?B'7-<\0ZWJFK:IJVJ
M7E[>WDTTS-0!^ WQV_X+O_M6?"#XW_&3X2^'?^"+G[8WQ3\/_"[XJ_$/X=:%
M\3O#'_"Q_P#A&OB-HW@GQ=J_AK3/'GA[[#^SCKEE_8?B^RTR#Q!I/V/6]8M?
ML&HV_P!GU34(=EW-_-M^PIXYU7XG_$_]N[XE:[X-UCX=:W\0_P!J_P ?>.=8
M^'WB'[3_ &_X$U7Q;XA\2:_J'@W7/MFG:/=_VQX8N]0FT34_M6DZ7<_;;&?S
M].LI=UM%_I-5_%1_P2S_ &&_^&L?VA_^"N?B'_A:'_" _P#")?\ !1'XSZ-]
MC_X0G_A*O[0^V^./'-]]I^T?\);X<^R>5CRO)\BYWYW^:GW*_GSZ4/ _%'B+
MX-\0\*<&Y7_;&?X['9!6PN ^NY=E_M:>"SK!8O%2^M9KB\#@H>RP]&I4M4Q,
M)3Y>2FIS<8O]Q^CIQAPYP)XK9'Q+Q7F/]E9)@\%G='$XWZIC\=[.IB\IQ>&P
M\?JV6X7&8N?M*]6$+TZ$HPYN:;C!.2Y:BOW _P"'-/\ U<?_ .8@_P#QHT?\
M.:?^KC__ #$'_P"-&O\ *[_B3?Z2'_1N?_-OX#_^B@_TA_XFL\ _^B\_\U?C
M/_Z'3\/Z*_<#_AS3_P!7'_\ F(/_ ,:-'_#FG_JX_P#\Q!_^-&C_ (DW^DA_
MT;G_ ,V_@/\ ^B@/^)K/ /\ Z+S_ ,U?C/\ ^AT_#^BOW _X<T_]7'_^8@__
M !HT?\.:?^KC_P#S$'_XT:NE]#;Z1DJE.-;P\E3I2G!5:D.+. ZLZ=-R2G.%
M)\5TU4E&-Y1@ZE-3:47.-^915^E;X#QIU)4>.8U*L83=*G/AKC2E"I446X0G
M57#51TXRE:,IJG4<$W)0E;E?X?\ 7_/^![CI17[?_P##F@_]'('_ ,,^/_GH
M4H_X(T_]7'D_7X0?_C0K^U?I-?1NX-XN\.O"#)OH]>"?B3PWQIX=Y-#A3B?,
M^+<1X-Y1@^/\IJ_6LSQ'$N<XO(_%C/<0^*Z?$6(QF(IIX%T*N69S5R[ZY0P>
M0Y+@E_$/T7_'/Q.X/\1_&/.OI%>,?AGQ+P3XCYS/BWA?+.$'XNYQC?#[-Z7U
M7*\-PSDV$SSPJR'#KA.IPYAL%AZK6/5>EF>2TLR^I5\;G^=XU_A_7S%^T1\7
M?B#\/_AY\8;SPC\*?B/+=>%_AQXOUG0OB?IUW\%Y_"6E:G9>#;W5K7Q#)H_B
M7XFVOBV[L?#.H /JEE<> ;VXO'TR[CT[1]=M9K/[?_2[_P .:?\ JX__ ,Q!
M_P#C1K#\4?\ !$31?&?AKQ%X/\2_M!?VEX=\5Z%JWAK7]._X51=V?V_1==L+
MC2]5LOM=A\6+6^M?M5C=3P?:;*ZMKN#S/-MIX9E21?Y'X7^B5X^Y/GN6X_.?
M"#!Y[EM#&8.IC,!C>+>#JD)8:EC,/6Q$J5'"\<9;#$5Y8>E5HTZ&-K5,!55:
M<,30FG&=/^QN(OI-^"F:9/C\%E7BEB\FS"MA<5#"XW"<,<50G&O4PM>E0C4J
MXC@_'RH456J4ZLZV$HPQM)THRP]:+4HS_"+P7XMU_P 4_P!I?VY\,/'/PW^P
M_8_LO_"::A\-+[^V?M7VKS_[-_X5W\0_'OE?V=]GA^V?VQ_96_[=:_V?]NV7
MOV/[A_8B_P"3L?@7_P!CQ:_^D5[7Z,?\.:?^KC__ #$'_P"-&O5/@A_P2U_X
M4W\6/ OQ0_X7I_PD?_"%:Y%K/]A_\*R_L?\ M/RH9X?LW]I_\+"U3['N\[=Y
MW]GW>-N/*.<CUN#OHI>/N7^(?!_$&,\,L+DF499Q9PSF>.IX+BWA;%8; X'+
MLTP%?&5Z<,3QAFF9U[4J%7$SIJMBJTZDIT\/3472H1\SBGZ2O@GCN!N*,DPO
MB%B,WS/,.&>(,OP=3%\,<28?$8S&8_+L91PM&I.APMEV7T;U:U.A&HZ6'I1@
MHSKSYE4JRP/B=_P6$_X5E\2OB'\-_P#AUM_P6,^(/_"OO'/BSP1_PGOPQ_8C
M_P"$L^&OC?\ X1/7]0T'_A+_ (>^*?\ A9MA_P )+X&\2_8/[9\)Z_\ 8;+^
MV= O=/U'[);?:?)3R'QG_P %B?"7Q&\(^)_ /CW_ ((Q_P#!:GQCX(\::#JO
MA?Q;X3\2?\$\K76/#_B3PYKEE-INL:)K6E7WQ4FL]1TS4["XGM+VSN8I(9X)
M7CD0JQ%?O37"_$\?$MOAQX[7X,OX'C^+C>$?$"_#.7XFIKTGPZB\=MI=TOA:
M7QS%X6:/Q+-X3BUHV<FOP:#+#J\VF+<Q:?/!=/%*G^SQ_DV?Q">*/^"D'QG_
M ."4MSI7Q _9!_9-_P""I_@7]B.7Q';:;XP_9,_X*2_LW:[X.^!_PSBU>YEG
MMK/]FS]IJX\?>./'/PJFNF@DLM$^'7B;2?&WA62]U#6_$5W%K6HFUL;;^M_]
M@3]MWP?_ ,% ?V=O#/[0_@KX7_&3X3:3X@D>U_X1OXR>"+[PK>W,T$432:QX
M.UT?:/#?Q"\$7TCR#0_&/A?4;JUO$BDM]4LM"UF"]T:S^-_@[_P2*TSQI\1M
M _:7_P""FGQ=U#]O_P#:2T6234/"'AWQ?I$&A?LG_ :>]6-KC2/@M^S["/\
MA&KI[=8K&RO/&/CVUUC4_$UQH&@^+9]"T'Q9;2WS_LXB)&B1QHL<<:JD<:*$
M1$0!51%4!555 "J      !0 ZBBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M-86,R1"!);.VE2 0RVXA62%&6(6\\5O/ (P0GDS00RQ;=DD4;J46W0 4444
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MX1\ > _AIX&\(_"O0(?"_P .]%\,Z5;^#]#ALM4T][+19K5+NU:]MM=1-?\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MAGQ=XH;1_"^L 'D@_89_8KC^&4OP6M?V1_V:=-^$,WC9/B6_PQT?X'?#31O
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MNS^Y?^(#?2-_Z2%S'_PLX@_^7^O]/3]^/^'6G[)W_0(\<?\ A:7O_P C4?\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M**_I ]D**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M(T(SJ1G]&45\_P#_  UE^RQ_T<O^S_\ ^'E^'7_S1T?\-9?LL?\ 1R_[/_\
MX>7X=?\ S1U_3/\ 8F=?]"C-/_"#%_\ RKS7WG\^?ZQ\/?\ 0^R7_P .F!_^
M7^:^\^@**^?_ /AK+]EC_HY?]G__ ,/+\.O_ )HZ/^&LOV6/^CE_V?\ _P /
M+\.O_FCH_L3.O^A1FG_A!B__ )5YK[P_UCX>_P"A]DO_ (=,#_\ +_-?>?0%
M%?/_ /PUE^RQ_P!'+_L__P#AY?AU_P#-'1_PUE^RQ_T<O^S_ /\ AY?AU_\
M-'1_8F=?]"C-/_"#%_\ RKS7WA_K'P]_T/LE_P##I@?_ )?YK[SZ HKY_P#^
M&LOV6/\ HY?]G_\ \/+\.O\ YHZ?)^U=^RW%(\4O[2?P"BEB=HY(Y/C%\.TD
MCD1BKHZ-XC#(Z,"K*P#*P((!%3_8V<<RA_969<\HRE&/U'%<THQ<%*2C[*[C
M%U(*32LG."=G)7?^L7#]F_[=R:R:3?\ :F"LF[M)OV]KM)M+K9VV/?:*^?\
M_AK+]EC_ *.7_9__ /#R_#K_ .:.C_AK+]EC_HY?]G__ ,/+\.O_ )HZK^Q,
MZ_Z%&:?^$&+_ /E7FOO%_K'P]_T/LE_\.F!_^7^:^\^@**^?_P#AK+]EC_HY
M?]G_ /\ #R_#K_YHZ/\ AK+]EC_HY?\ 9_\ _#R_#K_YHZ/[$SK_ *%&:?\
MA!B__E7FOO#_ %CX>_Z'V2_^'3 __+_-?>?0%%?/_P#PUE^RQ_T<O^S_ /\
MAY?AU_\ -'1_PUE^RQ_T<O\ L_\ _AY?AU_\T=']B9U_T*,T_P#"#%__ "KS
M7WA_K'P]_P!#[)?_  Z8'_Y?YK[SZ HKY_\ ^&LOV6/^CE_V?_\ P\OPZ_\
MFCH_X:R_98_Z.7_9_P#_  \OPZ_^:.C^Q,Z_Z%&:?^$&+_\ E7FOO#_6/A[_
M *'V2_\ ATP/_P O\U]Y] 45\_\ _#67[+'_ $<O^S__ .'E^'7_ ,T='_#6
M7[+'_1R_[/\ _P"'E^'7_P T=']B9U_T*,T_\(,7_P#*O-?>'^L?#W_0^R7_
M ,.F!_\ E_FOO/H"BOG_ /X:R_98_P"CE_V?_P#P\OPZ_P#FCH_X:R_98_Z.
M7_9__P##R_#K_P":.C^Q,Z_Z%&:?^$&+_P#E7FOO#_6/A[_H?9+_ .'3 _\
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MUXF\1^#==O/ &BZUI^I^!? =KXT^,?A;0/AO9-;Z=+/ILVBWH_\ @I;^WO\
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M>^+OA;P1\5?"UQHFJZEJG@/Q1I/BCPT;.;6/#<FO^&-?UG1];A@TO\Q/#O\
MP4__ &[->\!_L]7FC?LW? ?QU\6/V@_V5;_]O7PS\._!&L?'_5+2Y^ <UE\(
M8O!GP4L=;T+X8^+[BT^/7BW5?B%J']K?$7Q9I7A?X)> [A_#6@7LWB%+NX\4
MO^VOPO\ @1\%?@EX<U7PA\'_ (4_#_X9>%]=N8;W6] \#>$]%\,Z7J]U;:!I
M7A2UN-3L])L[6*_EL_"V@Z'X9LFNEE-GX>T;2=%M?*TW3K.VAX[QC^R)^RO\
M0_"_PZ\$^._V<_@GXP\(_"'PO=>!_A7X<\2?#/PAK.D?#KP3?^'K#PCJ7@WP
M797^DSP^&_"6J^%=*TOPWJ_AK25M=%U;0M,T_2M2L;JQLK:"( _,3XO_ /!3
M/]I#X<?&?Q=\*[KX%^"? .N:W\0?@K\/_P!GWP'\8[3XK:+J/Q-T7XJ?'7]D
M_P""=[\98?C1X1T'Q1\%-?\ #'A+7OVF+G1/B5\,/".J7GQ/^$?B'POX9;5+
M?QCIGCVZ?P7Z7:?M_?'+Q/+\,_@QX/\ AW\*5_:,\;_M>?M&_LFWWC#Q%JWC
M&']GN*[_ &:/AWXM^*OB3QSH*:9;77C;5KGQ7X8\/V.@V?@3[<C>$?&J^/M+
MU3QEK<'PZ:7Q3]*?&O\ X)Q_L??''2=9TS7_ ('_  ST&7Q=\1OAG\0OB'JW
MAGX<^ +75/B5#\._C)X(^-VH^!O'4U_X8U&+7_ GQ/\ %G@+1X?BIH5S#_Q6
M-G+=7-[<+K0M=6MO6-5_8^_91UWX5:%\#-9_9M^!VJ?!OPOXBE\8>&?AA??"
M_P &W/@CP]XPN+C6;NZ\7Z'X<ET=M,TKQ9>77B/Q'<7WB6QMX-<O9O$.O27=
M_,^LZD;H _(OP[_P5_\ CGXLT7_A:=I^S_\ "K0/A!\.O!/[)7C3XXP7OQ,\
M7Z]XYN+?]IS]K3XR?LJ0'X)3VG@/1?#?B[P[:'X3WOQ:\->+/%9\)G7_  O=
M:%H7_"/Q3>+)?$?@Y=6_X*L_M0P_%IOV<E^!?P[\&_M%>./B?K_A[P/\,_B%
MX3_::=_AU\._#NF?M&Z_I7CWQ/JO@#X9>,X?VB_"WQ?\._ 2'4_AI\0?V=8I
M_"VEWFL^/M'\:VNF_P#"IXM2^(G[(I^S/^SK%HEYX9@^!7PBMO#5_P"&?A;X
M+O/#EI\//"EIX?N/!WP0US4/$WP;\)R:);:5%IA\,_"WQ!JVJ:SX T$6HTOP
MIJ.HWMUHEK9RW,S/PZ_L-?L8IHUSX>C_ &4_V>H=%NO$_ASQJ^G0?"'P)!;P
M^+?!J:Y%X.\1V(AT-'T[6/"$'BCQ/;>%+[3VM9_#=KXE\16NBO8V^N:I%=@'
MDWQ2_:=_:.\-_L8?#GX^^&OV8?%&F?&CQC'\)D^(GP9OM+U_XK>(?@7:^,]4
MTS3OB3XID\ _#2*T^('QSM/A/;7.H:['X&\ 6_A_QSXUT6R6X%KX3G35(-*^
M*-._X*!?'^V^)WQ;^+6K?$S]F"X_9)\+?\$R/V5/VPM*NQ8?%Q?#D/B#XR1_
MM'6<GBG0]8TSX97_ ,8]2TKQ9X\^'NF:3+X;U#P/J7B2#X>:1X-A\.?#G3OB
MIK/C'3=0_7#Q#^SE\ ?%?PV\*?!SQ)\%OA=K?PH\!IHD?@;X<ZCX&\-W/@OP
M6GAK2KC0M 7PEX=?3CI?AS^Q]"O+W0]..C6UD;71;Z_TF(KIU[=6TW/^)OV1
M?V5/&=QH5UXO_9I^ OBB;PQ\-W^#GAP^(/A'X"U>/0_A(^FZCHH^&.E0W^@3
MPV/@"'1M9UO2+7PA;1QZ#9Z5KFN:=:V$-GK6J0W8!^4'P6_X*-_MM_M&?&:T
M_9H^'GPB_9T\$_%?P?J_Q^D^*_BGXL#]H#PYX;E\)_!;1_V,?%&E7?A'X9:K
MX2\,_$OP]XL\8Z3^V9X2TK4_#'CZ6QB\'7_AKQ!K$6K^++2/2M)UK[R_X)B_
M%7X]?'3]A/\ 9F^,W[1VN^#_ !/\2?BE\(/AUX\N/$?A#2SHG]NZ=XG\#^'=
M6CU;Q/H]OI^DZ#IGC#4-2NM4NM;L?".EZ=X3M3+;0Z'96UNAA3WKX5?LL?LU
M? O4VUKX,? 3X0_"G6'3Q3')JGP]^'OA?PCJ$P\<?\(&?&KSWFAZ993SS>,)
M/A;\.)_%-Q+(\_B"Y\#>%KG5I+NXT6PEA[#X5_!GX1? SPY=>$/@M\+_ (?_
M  E\*7VM7OB.\\-?#?PAH/@K0;G7=0@L[2\U:;2?#MAIU@]_-9:=ING_ &@P
M>9'IVFZ=IT12RL+."$ ]*HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "O,_C%X:^)?C'X:^*?#'P
M?^)MA\&OB)K5M966@?$[4/ 5E\35\'Q/JM@VN:EI_@K5-=\/:/JNOR>'DU:R
M\,W.N7E]H.A^(KK2]?USPUXQTG2[SPEK?IE</\2/AYH'Q5\%ZUX"\3ZAXYTO
M0]>_L[[=??#?XG?$KX-^-(/[+U:QUFV_L;XD?"#Q9X&^(GASS;S3K>'4?^$>
M\4Z7_;&DR7V@ZM]MT/5-3TZ[ /R9\!>/OC3\5/\ @D?^QW\9-2\4?MG>-OB'
MXC_9[^#/Q"^)LO['1^!S?M!?$N^U;X4_VKJ\KWOQGM[:QCM+GQ%-9ZU?Q_#^
M]TKQQJNL0:7I-JFI>&[_ ,1Z-?\ U]_P37^,/C'X^?L)?LP_%CXC>.].^)/Q
M(\4?##38?B3XOTW0KKPS]L^(_AN]O_"GC[3-6T"\T#PI)I/BGPQXOT/6?"_C
M*SA\-:#8Q>+=&UK^S-*L=.-K;I%X=_X)V?LV>"OA5X&^#'@&Y_:*\!> _AEJ
MUSJ?P]MO"?[9/[7>GZ]X-M+KPQI7@Z3PCX>\7S?&ZZ\5Z;\-[?P_HFG6^E_"
M^WUE/AYH5_%-KV@^&=,\07M]JES].?!_X0?#CX!_#3PA\'_A'X8M_!WPZ\":
M8VD^&?#]O>ZKJK6EO+=W.H7MU?ZSKU_JNOZ]K.K:I>WVL:]XAU_5-4U[Q!K5
M_?ZSK>I7^J7UW=S 'X<?&G_@N;\5OA)\8_BS\*=._P""2'_!0?XDZ?\ #'XE
M^._A[8_$7P7\,O$E_P"#O'UGX+\4ZKX;M?&OA.^@\&74%[X9\4P::FN:#=PW
M5S%<Z7?VLT<\R.)&_C ^&7C>Z^)GQU_;3^)%]X3U_P !7OQ _:A^*'C>\\#>
M++:2R\4^"[KQ7XP\2Z]<>$_$MG-#;S6FO^'9K]]'UFVEMX)(-1L[F)X8F0HO
M^J?7\)7_  3\_P""8O\ PWG^TI_P5@\7?\+N_P"%5?\ "!?\%!_C;X<_L_\
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M_P YS^;?^)8/'/\ Z(?_ ,V7@_\ ^B _F7HK^FC_ (AT?^KQ/_-?/_QWT?\
M$.C_ -7B?^:^?_COH_XCSX4?]%5_Y@^)/_G.'_$L'CG_ -$/_P";+P?_ /1
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M?/\ \=]'_$.C_P!7B?\ FOG_ ..^C_B//A1_T57_ )@^)/\ YSA_Q+!XY_\
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MYIOP\U3Q/+XM7XF^.O@M\:?AA\8_'VL_$7P'/XP'Q0T"_P!*T[X>:IH,U_\
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MGXL6OP+^*?[!OAR3PK\-M2_9L\;Z#\9_AO\ $F_M/@=9?!W2/BEX[T?]H/\
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MSU^?_P"(B>/?_13>)/\ X/SO_P"1\OS[L_0'_A^/^WG_ -#!\,O_  W&G?\
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M5F-+V.88FI4R[#3G7QU'VM?V6,K2;J8JE[>M[.O*</:U+<[****\@]\****
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MI7C&ZA\(_P!A:]TO[%__  4-T;]HGQ)J?PD^(WAGQ#X(^+X^)W[9?AOPA?\
M_"NO%WA3X2_$SPI^R]^TWXK^$,Z_#3QEXEU#5K3QKXJ\-^!+CX8:K\2&TC4&
MTJ3Q5K/BR'P]%;_\(GXL\.>#0#],**** "BBB@ HHHH **** "BBB@ HHHH
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M_P"'S_\ P3P_Z+/K7_AJOBI_\Q]?P^T4?\2R^'__ $,>*_\ PX97_P#.0/\
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M_P -5\5/_F/H_P"'S_\ P3P_Z+/K7_AJOBI_\Q]?P^T4?\2R^'__ $,>*_\
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M=+,,=CI58U_91JX7$X>I&A4A*I25ZM"JH_7U%%%?D9^\A1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% '\[*?L@_&[XV?M'7O[<6D_L]
M#PS^SCKWQW\!>-]6_P"">7CW5];^'OB7X^:SX2.K^&E_;M^(O@SQ#XFTCX5^
M"_VA-$GO?#OC+PA\%?'_ (>M8/&WA?X?:!KGQ;U_P_\ '"'P7<^ /Z)J** /
M&/VC/@?X9_:8^ ?QD_9Y\::GKNB^$OC9\-?&7PO\2:OX8FT^W\1:9HOC70KW
M0-1O]$GU73M6TR+5+6VOI)K)[_3+^T6=$,]K-'N0T_'G[/\ X+\>>//V=_'U
MQ-J.@WW[-GQ,\6?%/P;I/AV/2;#1=8U[QC\%/BG\#-2M/$EL^F3S3:;%X9^+
M6O:K;+I5QI5Y_;VGZ1-/>3Z?%>:?>^.?\%(_B#XT^$W_  3^_;0^)WPX\1:A
MX0\?> /V9OC-XN\&^*=)>./5/#WB70/ FMZEHVL:?)+'+$EYI]];PW5NTD4B
M++&I9& Q7S[_ ,%)O^"A'BO]B6WTVY^'_ASP#\2-8\._"7XE_M!_$3X:ZSI_
MQJN?&=]\'OA7?^%[/Q+K&A>(?AS\-_&'P^^'-GNU^;3[/Q?\7M?T31;WQ6V@
M^&]/TR^M=0U_Q#X3 /#OVEO^".<'C?X(_$+X?_"/XR>.M>\M/C</@)\&_BYK
MGP\\/_!KX0P_M1?%[2_B!^T'::)XM\'_ +/_ (F^)=Q=ZIX5N_'_ ($^&.K?
M$=/C#9> M#\;:GHVI^&_%VB7,UHGO7[)?[!_BWX=Z;\,I?B]J6@^'K7]G?\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MO_$W_P ./J/_ ,AT?\../V#/^A?^)O\ X<?4?_D.OY2O^&UOVR?^CM?VFO\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %</\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M\S^,7AKXE^,?AKXI\,?!_P")MA\&OB)K5M966@?$[4/ 5E\35\'Q/JM@VN:E
MI_@K5-=\/:/JNOR>'DU:R\,W.N7E]H.A^(KK2]?USPUXQTG2[SPEK?IE</\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %?R(?\ !&/]LG]DW]F/X[_\%A]"_:*_:0^"OP0UKQ1_P4=^,.K>'-*^*7Q&
M\+>"=0US2[/QCXYL[O4-*M/$&I6,U]9V]V1;37%NDD4<Y$;,'XK^N^OY-/\
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M\%6L_P#RZH ]+_X>S?\ !,/_ */_ /V0_P#P_OPV_P#FAH_X>S?\$P_^C_\
M]D/_ ,/[\-O_ )H:_#__ ((K_P#!"'X2^&_V1_$-A_P4O_8<\!W'[0C_ !N\
M8W.CR>/=0T3Q5K8^&,GA7P#'X<6+4O ?B_6-%CT\:]%XL,%I+=+J$4QN9)X4
MAFMFD_77_AR#_P $F_\ HQ3X'?\ @JUG_P"75 'I?_#V;_@F'_T?_P#LA_\
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MS3_AR#_P2;_Z,4^!W_@JUG_Y=4?\.0?^"3?_ $8I\#O_  5:S_\ +J@#TO\
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M,4^!W_@JUG_Y=4 >E_\ #V;_ ()A_P#1_P#^R'_X?WX;?_-#1_P]F_X)A_\
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M)O\ Z,4^!W_@JUG_ .75'_#D'_@DW_T8I\#O_!5K/_RZH ]+_P"'LW_!,/\
MZ/\ _P!D/_P_OPV_^:&C_A[-_P $P_\ H_\ _9#_ /#^_#;_ .:&O-/^'(/_
M  2;_P"C%/@=_P""K6?_ )=4?\.0?^"3?_1BGP._\%6L_P#RZH ]+_X>S?\
M!,/_ */_ /V0_P#P_OPV_P#FAH_X>S?\$P_^C_\ ]D/_ ,/[\-O_ )H:_*S_
M (*I?\$*_P!E?7/V"_COI?[!W[#7PT@_:NNO^%8?\*JE\'RV?A[Q&OD?&7X>
M7/CG^SM8\8>*=,\.V>[X;P^,%N_[1OH/M%B;JUM/-OI[6&3Z:_9G_P""&_\
MP3ILOV</V?K/XV_L+_!Y_C/:?!'X4VWQ<?5K6ZO]4?XG0>!-!B\?-J5]I/B&
MYTN]U!O%2:L;R[TVXGT^YN3)-9S2VSQNP!]<_P##V;_@F'_T?_\ LA_^']^&
MW_S0T?\ #V;_ ()A_P#1_P#^R'_X?WX;?_-#7FG_  Y!_P""3?\ T8I\#O\
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M?^"K6?\ Y=4 >E_\/9O^"8?_ $?_ /LA_P#A_?AM_P#-#1_P]F_X)A_]'_\
M[(?_ (?WX;?_ #0UYI_PY!_X)-_]&*? [_P5:S_\NJ/^'(/_  2;_P"C%/@=
M_P""K6?_ )=4 >E_\/9O^"8?_1__ .R'_P"']^&W_P T-'_#V;_@F'_T?_\
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M^"8?_1__ .R'_P"']^&W_P T-'_#V;_@F'_T?_\ LA_^']^&W_S0U\Y?%O\
MX(=_\$RKCX4_$ZW^'W["WP77Q]/\/?&D/@=K*QU"VO%\7R^&]23PT;2YO=>B
ML[>Y&M-9&">[EBMHI=DD\B1*[#\]_P#@CS_P0E^ WA[]B_1-._X*+?L-_#VX
M_:57XA>/9M3D\<7FE>)]>/A"6_M3X3$FJ>"/%NK:$UL+07'V:".\-S"N1<QH
MQ4$ _97_ (>S?\$P_P#H_P#_ &0__#^_#;_YH:/^'LW_  3#_P"C_P#]D/\
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MX:?\/+SQ+I3RZ-K^M^"M'\=Z?X>\1:IH4UWX?GU^PU-=!U+6='CLM9U#[5H
M**** /F']H[]L3X ?LIWOPDT;XS>,SHGB7XZ?$3PS\,OA7X3TO2M1U[Q)XK\
M0^)?&/@[P,;^'3=,MYVT[PIX=U[Q]X0M_%?B[6)-/\/Z'-XBT#3;B_;7?$7A
MS2=7+;]L3X :C^U9<?L6:1XS.M?M!:7\.];^)OB;PKI.E:C=Z;X/\/:(WP^D
M:P\4>)5MUT/3?%>H:9\3_!GB&Q\(K>W'B"/PQK>E>(M3L--TC7O#=WK7@_\
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M,^)09-)U3X?^*=?M5TCQ5#<6C6^H!+"Y,K:=>6U[$DL#2O%]EU^,O_!/_P"
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M:UX@\1:L ?+?Q&_X*8V/P[NO"/Q4\6^$OB%X5^&D7[&7[8?[4VK_  OTVS^
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MO]HGX;^(O!GA[0O&/Q]\.ZW??LVRZM^SUX-\4>._&7@3P[XG\66-E^T/-?\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M1IPY@%W<"/:)7S^ _P#PWI^VO_T==^T!_P"'5\8__+:OV:_X.)_^1B_9/_[
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MV'@:+5]&CT&2]\'WOBR]TK6[;0=.\91>']0U*;PYXH2VM7/ACQ!_9OY_^/\
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MCQ_XMTWP=I?PROM#MO'MEKL>D_#[4SX?MYM(N&\?W#3V_@U-4FLF2?.^,_\
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MPQ_4E !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M5PA&G!U*U;#SJ3Y*<(4X\TGRPC&*M&*2^2_^&"_V*/\ HU']G_\ \-5X._\
ME37T/X%\!>"?ACX5TOP/\.O"?A_P/X-T/[=_8_A?PMI5GHF@Z7_:6HWFKZA]
MATO3X8+2U^VZKJ%]J-UY,2>=>7=Q<2;I978];16>,SC-LPI1HX_-,QQU&$U5
MC2QF.Q.)I1J1C*$:D:=:K.*FH3G%324E&4HIVDT],!D&1956EB,KR3*,MQ$Z
M4J,Z^ RW!X.M.C*<)RI2JX>C3G*E*=.G.5-R<7.G"35XQ:****\X]<**** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ K\R]8_X)C^$=6^'>M_"&7]I;]H^?X1:
MK\:_&7QYMOA-J]G^S7KOPZM?%WQ ^-_BOX^>+M US1;_ /9T;4OB;\.-9\:>
M./$\$WP_^+^N?$#P_%IMYIMW;P1>)_#'A7Q'HGZ:44 ?DUX#_P""0WP9^%OP
M@\5_ CX<_&7XY^$_AA\2_@GI/P3^+N@V?_"G+FX^)^G^'O"7Q!\%>'_&6N:K
M??"*XU#1?&6G^'_'=A9377@^;P[I%_;_  U^&MC<:1_9NF^*;+Q?]0^*/V*_
MAUXJ^'/[:_PTN?%7CRPTC]NCQ1XD\6?$O5-.O/#BZWX0U+Q/\!_A9^S]>K\/
M9;SPW>:=9PVOA;X2Z#K5@OB;3?$YC\1W^JS71O-+>TTNU^Q** /QG\=?\$5_
M@Y\5_%_B#XA_%K]HC]HOXE^/?&WCGPW\1?'?B3Q3:_L]2+K'BWP9<?!.#PIK
MWA70=/\ @-8^'?A-K^F^%/@#X!^'NI>(OA3I?@_7O%O@8ZYHGB[4=<^W6=QI
MGW3>?L@?#V]_9=^*G[)\OB#QFO@+XN?\+^_X2'7H[O1!XOL/^&B?B'X]^)/C
M'^QKMM";1H?[)UGXAZQ9^&?MVB7_ -FTRTTV/5/[7NXKJ[N_J^B@#X$^)_\
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M7Q'\0?$,.F_"3P3>:#XX\,$ZAX;^*?@WPG\-OA=X.^%]A\6K?QDEK\2_$'Q
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
*%%% !1110!__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>nt10014672x1_diagram1.jpg
<TEXT>
begin 644 nt10014672x1_diagram1.jpg
M_]C_X  02D9)1@ ! 0$ P #   #_[0 V4&AO=&]S:&]P(#,N,  X0DE- ^T*
M4F5S;VQU=&EO;@     0 ,     !  $ P     $  ?_B"^!)0T-?4%)/1DE,
M10 ! 0  "]!N;VYE @   &UN=')21T(@6%E:( ?4  < %0 3  L (6%C<W
M         $E%0R!S4D="     0            #VU@ !     -,M2% @(
M
M$&1E<V,   %$    =&)865H   &X    %&)44D,   ',   (#&1M9&0   G8
M    B&=865H   I@    %&=44D,   ',   (#&QU;6D   IT    %&UE87,
M  J(    )&)K<'0   JL    %')865H   K     %')44D,   ',   (#'1E
M8V@   K4    #'9U960   K@    AW=T<'0   MH    %&-P<G0   M\
M*&-H860   ND    +&1E<V,         &G-21T(@245#-C$Y-C8M,BTQ('=I
M=&A"4$,
M                                                    6%E:(
M     "2@   /A   ML]C=7)V        !      %  H #P 4 !D '@ C "@
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M;W5R(%-P86-E("T@<U)'0@
M
M      !865H@        8ID  +>%   8VEA96B            !0
M;65A<P         !                               "6%E:(
M  ,6   #,P   J1865H@        ;Z(  #CU   #D'-I9R      0U)4(&1E
M<V,         +5)E9F5R96YC92!6:65W:6YG($-O;F1I=&EO;B!I;B!)14,@
M-C$Y-C8M,BTQ
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MU=;7V-G:X>+CY.7FY^CIZO'R\_3U]O?X^?K_Q  ? 0 # 0$! 0$! 0$!
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ME?MJ?%3]B_X#>'-9_9W^%VE_&[]I3XH^.9?"/PA^%>K1ZE>6.MVO@WP3XO\
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M^'_^">7[8/@;X,?L8_LKV'PN?Q/\,?V%_P#@MYX%^.'PF\:W7Q#^&5Q=ZO\
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M6KZA%JEQ:Z%#X4OM&\3S>F?L/_\ !5']E3]K#3/@7\+8OCS\.+_]K'QY\ _
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M+X#>++_5=EHD-GXOU.PL=4\ ZE>73Q16-QJ%J^FVDHAE_P"$UANU2./\;O\
M@M%_P1OU+_@EQKT'[47[,K:WXD_8A\;>)H=(\:^!KZ[OM;U;]G_7]<NHTT54
MU6[:>YU/P-K-W<-I_A_6M1NIM2M-22W\.^(;R\N]2T;4[_\ '?QEX-T;QQHE
MUHFL0*RS1N;6[6/_ $K3[O81#=VLI!*/&^UF7(2504D!4G']BO\ P04_:/L?
M^"FO_!/+]I+_ ()H_M<7K^+_ !=\#?#,OP;U2_U66.ZU_P 3_ GQUIFHZ?\
M#SQ-%+J!GGN_$7PYU72+O3;'6_*?[!#8^ ;V=Y=1F:XG_".-N"<\\(<^RK.,
MGS2M6PM6M*IE>:PA["O2Q%%1G5P&.I1<J515*4]5_ QN']K&5&/)5IQ_;>#.
M,LE\5LDS+*LURRE1Q5*E"GF65SG[:A4H5TXTL=@ZLH0JPY:D79I>VPE>-)QJ
M7E3J2_D.M;J"^M;>\M)EN+6[@BN;>>)D>.6&=%DBD1APRNC*RD=00:L<_P"U
M_P".5QFD>"?%/P2\=?&K]F_XA;8O&O[.7Q8\;?"K73*2JO\ \(MK^HZ0+N,R
M,?\ 0I[G3[R2QF$C0RV+VKPNR,K'RWXA_'O2O#D%Q;^$[1?$]_;W$%K>:A$D
MLF@:7+.S"..ZO8,)-<3&.2."WBE4,Z29ES&4;^KL)XG<-0X,RCB[.<?A\NI9
MC@XU/JBDZN*J8ZG*5#&83!X:'-7Q#HXNE6I)QC:,(QJ5I4X-RC_,&)\-^(9\
M7YKPKE&"KXZIE^,]G]:E!4L-3P=6-.OA,5B\3)1H4%5PM2E4<7+FE-NG1A4G
M&,7]"\_[7_CE'/\ M?\ CE5[5Y9;6VEGC2*>2"%YHU1BL<SQJTL8S\V$<L@W
M<X&3UJ? ]!_WP:_1*=15(0J134:D(32DI1DE-1DE*+2<9)25XNS3T=G>WP$X
M2IU)TY6<J<Y4Y./+*+<)*+<91;4HMIM23::U6B0O/^U_XY1S_M?^.4F!Z#_O
M@T8'H/\ O@U=_3IWZV\O/^M;0NF_3[*_N_UY:_RH7G_:_P#'*.?]K_QRDP/0
M?]\&C ]!_P!\&B_IT[];>7G_ %K873?I]E?W?Z\M?Y4<3XK\*W^HW>B^*_"6
MM:CX-^)7@W4;37O OCK0KR?2M>\/:_ID\5[IMW9ZI820WUJT%Y;P313V\BSV
MLJ+/ 0ZX/]ZG_!!3_@L3)_P4"^&VI_L_?M"7MOH_[:GP*T>!/&L<R6EA;_&/
MP?;2PV%K\3_#UK!Y4:ZI \MG:>.M+M+=+2VU&]L-=TP+IFNK8:1_##^7_?#5
MF^'OB5\4/V8_C)\,_P!KWX!ZG+HOQ>^!_B"T\2V@C\];/Q/H,&8M<\,Z]! T
M;ZAHNL:/+?:1J]BS8O-$O[^U^^873^=/&[PQH9S@,1QAD>&C#.<!2=7-L/0C
M;^U<!3BG4Q')%+FQV"IWJ<Z3GB<-&5)\U6G0B_Z \&O$BME.-P_"F=8B4\IQ
MU6-'*\17D[99C*K2IX?F=^7!8NH^11OR8?$S4THPJUI+_75HKY-_8;_:]^&_
M[=O[+/PA_:A^%US'_8'Q+\-6]YJNB?:H[J^\&^,K G3O&7@G5G18S_:/ACQ#
M;W^F/*\$ O[6*UU6WB%G?VS/]95_&9_784444 %%%% %:]O;33;.[U'4+FWL
MK"PMI[V]O+N:.VM;2TM8GGN;FYN)F2&"W@AC>6::5TCBC1GD954D?YQ__!:O
M_@K-XJ_X*<?&;6OV;?@)XFU30?V$_@]XC>QU_4].FFLG_:*\<:)<RQR>(;QX
M75IO!&G72-_PA6ES[H;BV6/Q;J, U"_TBST;]F/^#G/_ (*5ZW\./ _A_P#X
M)N_L_P#B);3XN?M":*NK_'C7M*NV&H> /@7<SR0#PXTMHZR6&I?$EK6^CU*.
M22.=?!>GW=G)!)!XNL[A/X_O#'AO3/">AZ?H&DPB.SL(%C#,A,EQ,0#/=3D
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MXK#5(WZ*V)AAK-]';=N_]"?[6O\ P;+^%?VP_P#@HC\9_P!JGQG^T-JOP^^
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M[77Q-^W^,4LKM!=P_";X1W&CZQJ-M>VD?[]+/6O&VL>$;J":1HH+NW\*ZW:
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M_P!GOM"DE_LZ^LYM@CN;:^L[N&XB9HKA98B4/](G[#__  <U>+-/O;+X!?\
M!6KX=>%_$'P\\7QMX2NOVD?!7A*"Z\/WEAJJ&RG;XM?#*QMKK2=0T:[@G:+6
M;KPKHVG&&S$S?\(;?!96E_G*Y_VO_'*SM5TG3M<T^ZTK5K*&_P!/O(FAN+6Y
MCBDBD0]/E8':Z'#1NN'C<!T96 (^/XO\ ^%,YPU:MP[3_P!7<U492HJC.I4R
MNO46JIXC"5)5'0A.W*JF#E2]E?G=&M;D?U?"GCCQ/E&(HTL^J_V_ECE&-5U8
M4Z>94*;Y4ZF'Q5.%-5IQNI.GBXU'5LH*M0NYQ_H._P""P'_!$;P?\.O UY_P
M4B_X)81:;XA^"VH:&/B+\8?@=X-U./7_  A<^![J%=2N?BA\'&MI+@R:!;64
M\VI:_P"&+::Y_L.TCN=8\/;=,M[W1;+^>#PKXGTOQAH-AX@TB4O:7L661W(E
MMKA/EN+2=1G;-!)E&'1AM="R.K']XO\ @W7_ ."C/B?]F3]H[3O^";GQQ\1W
M7B;]G']HB?48/V>+GQ/="]M?AQ\2KN.[N7^']O\ ;GEC3PO\2'>XT@:'&&M!
MXTN='O+.UMV\2Z\\OP%_P5>_8PL_^"<O_!2KXB_"/PAIZ:3\ _VC-/E^.WP*
MT^VB:/3?#EOK5[J*>)? M@H#16T'A3Q!IVMZ3I]H)))(O#4?A.68"6[./R/P
MEXLSC@/C&? O$+JT<OQN82RVKA*\W.&69Q.4887$85W<%A\=-TZ51TW[&M"O
M0Q:E:G[_ .I^*?"^4\:\)0XUR)4ZN/P6 CF-/%T(6EF.44H\^)P^)C&*DZ^#
M@JE2E&:=6E4I5L*XJ55J'QWD>H_[[-&1ZC_OLTIR"?O?^.4<_P"U_P".5_:A
M_'R>VKZ=7_=\OZN^[LF1ZC_OLT9'J/\ OLTO/^U_XY1S_M?^.4 GMJ^G5_W?
M+^KON[9>M:7;ZYH^J:/=*KV^IZ?=V,JER?EN8'BSTZJ6# ]B :_N1_X-8?CU
M>?%G_@ESI/PTUR\2;Q%^S#\9_B9\&)K5Y-]Y!X?N+RP^)'AR28%F/V6(>.]2
MT*P<'88] DA3Y8*_B"&1_>_\=_I7]*/_  :-^./[(^+/_!27X*23NL$VH_!;
MXK:/9,["-6NYOB)I/B&>& DJC!=3\+P33KEKA%MA(0((Q7\L_27RN#P_"^=1
MBE4IU\?E=:=M9PK4Z6+PT6[;4Y8?%-)_\_7;J?TQ]'7,Y^WXER>4FZ<Z.!S.
MC&^D9TY3PN)=K)WG&MA;OHJ?G9?VXT445_)I_485_FX?\%^?C--\>O\ @LS\
M2_#T=Y'?^%OV4/A-\/\ X2:'Y;DV\/B+6-$3Q[XH;9T6[@UKQ_K&C7;LH)DT
M&)%#+"CU_I'U_DI_&+QU_P +?_;:_;]^,ADDN4\>_M;_ !CETVYD)<G0K#QQ
MX@.AQ(SY*+'H]WI\?E@JD<<44<:*B(H_2?"'+(9MXC<,8>I%2I8?&5<SG=72
M>5X6OCJ#:[/$T*$?5J^E[?GOBKF4\JX XCQ%-M5:^$I9=#E=G;,\31P-:S[Q
MP]>M+36T79IF1D>H_P"^S1D>H_[[-+S_ +7_ (Y1S_M?^.5_H>?P,GMJ^G5_
MW?+^KON[)D>H_P"^S1D>H_[[-+S_ +7_ (Y1S_M?^.4 GMJ^G5_W?+^KON[)
MD>H_[[-0>#O 'QD_:0^-?P\_93_9F\.OXL^.7Q7OUL=-B#"/3?"FC!3-JWBG
M7[^7_1]+TC1=,CN]6U'4;DF.QT^TDN!#<3M:VT]/7-7MO#^CZIK=\S+::58W
M-].?E)*6\3R[% Y+R%1&B_Q.P%?U-?\ !!GX2_#/_@GE_P $V_VAO^"R?[3>
MF0-XR^*GAOQ+XI\+M<QPC7M'^#'AC6;C1?"'@OPO<7D0:QU?XR_$"*T@ME0_
M9-1TZ'P!*72!;C=^#>.G'^*X6RC"Y'E%>6'SC/85I5,33DXUL#E=)JG5JT9)
MJ5/$8NK)T*%:+O2A3Q4X<E:-&I']O\%>!<-Q+FM?.\VHJOE.2SHJEAZJYJ&-
MS.HE.E3K1:M4H82FHXBK3=E.I5PT9J5*52#^E/A_\$?^"8O_  ;2?L[Z1\8O
MCIJ-I\7/VS_&^CW/E^(_L,.N_%SXF^+9K=(M5\-_"'1+E)(?A]\.[">Z-GJ/
MBB_>P>>R:637-7U+4[W3_#;?@'^UI_P75_X*>?MN7NJZ9X-\9)^Q3\"K]Y8M
M.\'_  JE\OXF:UI;L_E2>*/B)/N\2>=-;RO#<V>AR>%M'E1MD^BWC)'>'\YO
MBW\<_B_^W9\>?&7[8_[2NK3:_P"-/'>H7$W@/PM+<3W7AOX8^ X[F<^&_"?A
M2QNG:&PTC2;*1%LTBCCENYVN]<OWGUC5KZZ>+G_:XXYVFOSOPS\"Z&=8##<1
M<8U,5##XV$,3@<FH5'0JU\/52J4L5F.)5ZT(XB#52GAZ$J=9TY4ZE3$1<IT%
M][XB^--7)\?B,@X2AAIXG!SEA\=F]>"K4J&(IM0J87 8=WI3J8>:Y*M>LITE
M4C.G"C)+VIY-J/PAT3Q1JDVO_$7Q#XQ^)_B.Z<RW>N^./%6K:OJ%Q*S%V9[B
M2X%RZLY+>7-<3)DXQMXI^E_"?3/"6KP^)?AGXG\:_"OQ1:2++9Z]X$\5:OHU
M];R(_F(4FAN1/&BR -Y4$\*$$J058@>K<_[7_CE'/^U_XY7] /PN\/7@_J/^
MJ.2JA:W.L*EB]K7^OI_7N:VG/]8YNO-?4_"UXE<>?6UC?]:LW]NFFH_6+X6]
MXO\ W%T_J+5WI%X=QL[<J6D?T._9N_X+@_\ !4O]DVU7PQXN\;Z)^VW\$WM9
M-+UCP)\:[?S_ !U'H=U&+>^@T;XA6<EKXH+M8A[*&'6K_P 4:9!"[BVT&%G>
MX'XT? +7;2X_X3WP[9Z7J&AV&F>+=1U71='U5]U]I>AZW=7$EAIMW,D,"2W=
MDML4N)$BACE=_-CB16*K]$\_[7_CE1);PQR2S1PI'--M\Z5(X5DEV A/-=5#
M2;02%WD[03C&:^8R/P<RKA7B_ <3<-9CBL'A:4,70Q^3XM?7*5;#XG#U*:AA
M<4Y4\115.O["MRXAXMR=*ZJ17NOZ3.?%O,N)^%<=P[Q%E^%Q6)JSPE; YKA&
M\)4I5\/B*-24\5AN2=&JZE'VM+FH?5DE5:]GO)29'J/^^S1D>H_[[-+S_M?^
M.4<_[7_CE?LA^1I[:OIU?]WR_J[[NR9'J/\ OLT9'J/^^S2\_P"U_P".4<_[
M7_CE )[:OIU?]WR_J[[NR9'J/^^S1D>H_P"^S2\_[7_CE<MXP\8:/X(T2YUS
M69BD,(*6]LI0W%]=L&\FTMH\@O+*P()R%C4-(Y"J37)C\?@\LP>)S#,,12PF
M"P=&=?$XFM)0IT:5-7E.3?W**3E*348IR:3Z\#@L7F6+PV P%"KB\9BZL*.&
MP]).52K5FXJ,8JUEWE*348QYI3<8J3C0\4+XT\5:SX.^#OPGT6]\5?&'XQ^(
M]+\!_#WPQI*&?4]1UGQ!?0:7!]G4LB1.TUTD,4\TD4$$CFZGD2WM9W3_ $]?
M^"7O["GA;_@G3^Q?\)?V:=#^Q7OB71].?Q1\6?$UDOR>,?BWXGBMKKQIKJRF
M.&2:P@N(;;P]X>:>)+B+POH6B6]P#/#(S?S_ '_!N'_P21\2>#7M?^"F'[6/
MAC[%\5_'NB21_LR_#K6[*477PP^'NMVAAE^(E_9WB12V'BGQEH]S/8>'K9[>
M*?2_"U]>:I,SWGB6.+2_[!J_ST\2^.:W'G$E;,8JI2RK"1E@\FPU325/!1ES
M/$58)N,<1C*EZU9:N$?94.::H1D_[T\.^"Z/!/#U'+Y.%7,L5*.+S;$PU53%
MRA&,:-.35W0PD$J-*]N:7M:W+"5:444445^>GW@4444 %%%% !1110!\N_MB
M?L>? K]NGX#^+OV=_P!H7PHGBCP)XJCCG@N+>2.S\1>$_$-G'.NC^,/!^KM!
M<MHOB?1'N)GL+Y8)X9(I[K3]0M;W2[V]L;G_ #>OV_O^";'[4W_!)CQQ-I/Q
M-TC5_BW^R=JFJSV7PQ_:-\.:5-<V5C:/([Z;X?\ B#96TER?"/B2.SV;],OF
M73[]H[J;PQJ>K6MI=0V7^I/7,>,O!7@_XB^&-:\%>/O"^@>-/!_B.QFTS7_#
M'BC2;'7-!UC3[@;9K/4M+U*"XL[N!\ F.:%P&577#JK#W>'>),YX4S.EF^1X
MR>#Q=)<DK)3H8FBVG/#8NA+W*]";2<H25XR4:E.5.K&$X^)G_#V4<3Y=5RO.
ML)#%X2H^>-[QK8>LDU#$86LO?H5H)M*<&N:+E3FI4YSA+_)0TC6M(U^QAU/1
M;^TU&QN%#17%JPE7!_A<*=T;CH\;JLD;95U5@16G@>@_[X-?V$?ME_\ !JO^
MSA\2==U?XA?L/?%/Q!^R!XNU-Y+R?P"\6H^-_@U<7[;I&.GZ3=ZDOB+PQ:3R
MDE["TU#5](LUD,6E:38V4,5@?Q.^('_!O!_P6F^&VHS:?X9\+_LU_M"Z8A#6
MVN>!?BQ9>$Y[F)LA!=V?Q0LOAHUO=QA0]S%!;7%LK.5M[VY"[Z_J?(/I'Y'7
MP\(<2Y3C\NQD4E4K99"GCL#5:MS3C"I6HXO#WUM2<<2E=WKNRO\ S/GGT?,Z
MH5Y3X>S;!8_!MN4*693J8/&TDVN6G*=*A6PV(LE:55/#7O=45=V_*C ]!_WP
M:,#T'_?!K]2_!O\ P;U_\%G/'<LP\:>&_P!G']G'P_;6MU>ZMXC\:?%73O&%
MS96-G$TUPUA8?#&V^)+W5XT"2/;0S06D#N L]]9@[U_$/X ZCK^L>#=0U37]
M6NM9N;GQ)JD<,]S(698;06]LP0' C1YXY7$:?*N< #!S]UPOXP</<8<0T.'\
MDP>:U)U,+B<55QN+H4,+AZ4,-&F[1A]8J5ZCG*:A=TZ:C*:LY)-KXGB3PGS_
M (2R"MGN=8W+(1IXG"8:E@\+6Q&)K5IXF:BVZCPU&C3Y(QE.RE/G49IN#LG[
MC@>@_P"^#1@>@_[X-'/]T_\ ?9_QHY_NG_OL_P"-?K%WW[=O[OGYO[_2_P"6
MKIOT^TO[O]>>O\R# ]!_WP:,#T'_ 'P:.?[I_P"^S_C1S_=/_?9_QHN^_;M_
M=\_-_?Z7%TWZ?:7]W^O/7^9!@>@_[X-&!Z#_ +X-'/\ =/\ WV?\:.?[I_[[
M/^-%WW[=O[OGYO[_ $N+IOT^TO[O]>>O\R/+?BM<:]X>TKP_\2O!]Y/I7C;X
M2>+?#OQ%\):S9O+!>Z3J_AO5;2_M[^VEC971[&>"WU!2C*5ELHG!#(M?UF?\
M'$\&D?MB_P#!*#]@#_@IQX*LX)=7\%:O\+?&^KRZ4JRVVB^#?VB/!^D+XPT2
M_GVO.I\/_$[0O"'AAH9IL66H7&H6LB&XF=A_+IK&FPZSH^JZ3<H3!J>GWEA*
MI.[*7=O) W?@@2$CW (Y%?TZ?\$V;6__ &Z?^#7W]K']E220:GXZ^ 5C\=?
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M_!2;]M&V4@P77[+^@W4^!@">T\?_  Z@MNAP#Y5U./F!8X."/FS^#_/]T_\
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M#1S_ '3_ -]G_&CG^Z?^^S_C7]Y7??MV_N^?F_O]+_Q NF_3[2_N_P!>>O\
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MYRE.<Y.<Y2GS2E*3C*4I-ZR;;;;;;;;;;<@P/0?]\&C ]!_WP:.?[I_[[/\
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M"594Z3ES2HU(/EHR^1>?]K_QRCG_ &O_ !RN6\,>-/"_C&T6[\/:O9WZ%<O
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M-Z*O@?QM?7EW;PV;3-]DC-JR6,LUG<_HK_P54_X)Q_LZ_P#!)7]CSQE^WO\
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MZO /49_SC^1(KLK^/_B)5@XPQ&489M-<]#*XRFMM5]9KXB%U;K!KNG=G'A_
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M6\57!CU_]CK]K+Q4MI]LN=GD^#/':7FDVR6UO,Q\G3D\3?#7Q5KGVE6,,O\
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MFV%IX[+,9AL?@ZJO3Q.$K0KTI;7CSP;49QO:4)6E%Z22>A])4445P':%%%%
M!1110 450U+5=+T:TEU#5]2L-*L(?]=>ZE>6]C:19Z>;<W4D4,?_  -Q6?HO
MBOPOXEMIKSPWXDT#Q!:6XS/<Z)K.G:K;P\%AYL]C<SQ1Y )R[J, GH#0!^3W
M[<W_  7,_P""?7_!/[Q[K7P@^,OC[Q=XH^->@6NAW6I?![X3^"[SQAXUM?\
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M]^65SEGED9I'8EG8L2:NV]O;VD$-K:Q0V]M;Q)#!!#B****-0J1QQHJJJJH
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M0:/K5Q9>'-'MWF%MHW@*87=SJFKB^U74?]$RO'/CW^S_ /![]I_X6^)_@O\
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MG_[&DR/4?]]FC(]1_P!]FA+;Y=5_<_K_ (= NF_3[*_N_P!>6O\ *A<^[?\
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M0?\ ?!HP/0?]\&@%TT[=_P"YY_U;U%Y_VO\ QRCG_:_\<I,#T'_?!HP/0?\
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MS\1ZM(Q(WWNL^.]9UBY?.3@M=:G<GJ1@@9/6O]=>O\C/Q=X2OOAO^U'^V_\
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M (Y1S_M?^.47?Y=5_=\O-_TU85M-NG?^Y_P/P\Q,CU'_ 'V:,CU'_?9I>?\
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M$?Q+\$M)CUC3/B0-7'CW7OB/>Z!XO\-:S:^&=9OK#5/LK_@E'+\6_BY\8O\
M@H3\;_BG^T=\=_'EG\*O^"@O[=?[*'PP^"VO>,H+KX*>#?AIX<^+_A'Q?H&K
M6_A>72I-:U'QUX=/G>#O"FM7_B:71O"'PZED\(^&/#6E)>:Q?ZJ ?MQ1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 5SGC#QAX5^'WA7Q#XX\<>(='\)^#O">D7VO^)O$WB#4+;2M$T'1-,MWN
MM0U35-1O)(K:SLK.VCDFGGFD5$12<DX!Z.O\]S_@X)_X*;^*_P!M7]H_Q/\
ML%_!#Q;<Z7^RQ^SUX@?2_CEKOAW4)4A^,7Q;T6\\O4_#=Y<P,(;SPM\/]7LY
M-(TZQ5GM+SQ1I^L:_<&\CL?#;VWHY3E6/SS,L%E&68>6*Q^85X8?#4(V7-.6
MKE*3M&%*E!2JUJLFH4J4)U)M1BVN#,\SP639?B\TS*O'#8' T95\36GJH0C9
M)1BO>G4J2<:=*E!.=6I*-."<I)/Y3_X+H?MK?L6?\%$/C[9>(/V%_@'J]O\
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M^&6H:=X G'E,8?B3XYO++P%\/;KR9PT5Q'I_C#Q-H^I7-NR.);2SG4J1FO\
M+R^$6@7&B^#+&[U%[BXU[Q/)+XI\07UTQDO;W4]:;[8\MY-*6DEN!%)&LSNS
M,TXED8^8[D_V[_\ !V[XSN--_P""=7PD^&MI<20-\7/VMOAMHFH1H[JM[H_A
M_P (_$'Q#)9R!2-R_P!MVWA^[7<2%>S5@I8*R?QI1QI#%'#&$$<4:1H#CY41
M0JJ,        8'0=*_I3Z-N34<3G?$.>581E4RO X/!824K/DJ9I5KSKU(=5
M45' ^QYOY*\X[39_._TALWK8;)\AR6E*4:>:8W%8S$\OVJ>6PP\:5*>NM.57
M&JK9Z<]"$DKQ3)>?]K_QRCG_ &O_ !RF_P#?NC_OW7]A?-=.K_N^?]77=W_D
MQ=-^GV5_=_KRU_E0[G_:_P#'*.?]K_QRF_\ ?NC_ +]T?-=.K_N^?]77=W%T
MWZ?97]W^O+7^5#N?]K_QRJUY9VNH6MQ8WUM'=V=U$\%S;7$<4L,\3C#QR1N"
MK*PZ@BI_^_='_?NHJ4Z=:G.E6A3JTJL)4ZM*HE4IU*<THSA.$KQG"<6XRC).
M,E*S34G>Z=2I1J4ZM*<Z56E.%2G4IMPJ4YP<)0G"<6I0G"24HRBTXM733BC[
M:_X)9?\ !47XH?\ !(CXOVVDZY=>(O'G[!_Q+\0P+\3OAS$SZIJ7PMU;4)8;
M4_$;P!#-(KV^I6<(B&K:5%<067B[3XEL+]5U>ST34K?^]/\ :_\ ^"H7[*G[
M'_['5K^VAXF\<Z;XU^'7C'0K"^^"^G>#[ZVO-5^,VO:_IDFH^&O#_A ,V,WD
M:>?K6I7,:V_AK3H;V[U-%FMA9S?YHVH:?9:K8W>FZC;P75C>P26UU;RJ&CFA
ME4HZ.#V921D<@X(((!KS#3?!_CZ\3P=X/\=_$;Q'XS^$?P>E\0R_!7X>:UK>
MH:EX<\$/XMU0:WKS:5HMW-)I^E&\U+-W??8XE_M&]$=U,0(EC;^1>/? C'OB
M7 U.#:%..39UB>3$TI2_<\/5G^\K597ESO+94U.IAXP4ITZJ6#2O4PRG_5G
M_C9@?]7<9#BVO+^U\FPREAZD8/VN?4ERPHTXI7C_ &A&;A3Q#ERQG3D\4VHP
MQ$J7T=^U!^TW^T)_P4>^.=]^TO\ M7ZL]RJR2P_"3X06<LD7@GX5>$3,9=-T
MC2]()6.2<KBZU+4;X3ZKKE^\FH:M<NQ@M+3C0-H"J"JJ %4!   ,  #@ #@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110!_)#_P=YZ9<R_LG_L;:Z#*FGZ-^V'I%O?RK_J8F
MU+X>>,)+9I3N&&QIMQY?!X\PY&.?Y&^?]K_QRO[B?^#J+X47OQ$_X)*>./%V
MG0^;=_ CXS_!OXN$*I:9;-]=O/A=?21X_@MX/B8;VX#9006CN071,?PR:1J$
M6KZ3I>JP,'AU/3K+4(7P7#17EM%<(00!_#(.H!SG-?U5]&;%4^;B_ MI5)+)
M<7!:7E"#S&C5?>T92H+UGT=F_P"9/I&8:3CPGC$E[.,LWPU26NDZCRVK27:\
ME3K/_MU7ZFES_M?^.4<_[7_CE)@>@_[X-&!Z#_O@U_5MOZLO+R\OZLK?R^K:
M;=._]S_@?AYB\_[7_CE'/^U_XY28'H/^^#1@>@_[X-%OZLO+R\OZLK"MIMT[
M_P!S_@?AYB\_[7_CE'/^U_XY28'H/^^#1@>@_P"^#1;^K+R\O+^K*PK:;=._
M]S_@?AYB\_[7_CE'/^U_XY28'H/^^#1@>@_[X-%OZLO+R\OZLK"MIMT[_P!S
M_@?AYB\_[7_CE'/^U_XY28'H/^^#1@>@_P"^#1;^K+R\O+^K*PK:;=._]S_@
M?AYB\_[7_CE'/^U_XY28'H/^^#1@>@_[X-%OZLO+R\OZLK"MIMT[_P!S_@?A
MYB\_[7_CE'/^U_XY28'H/^^#1@>@_P"^#1;^K+R\O+^K*PK:;=._]S_@?AYB
M\_[7_CE>)?'<$^%_#RJ&,K>//#"P*,;C*9KE4"A>2Q)   )R1CFO;,#T'_?!
MJ#P;X E^,O[47[%_P.M-IN?BK^U'\(/#<B^7O\O3+WQMH.E:G=21$D20V=MJ
M[74JD9*0D#J17YSXN5Z>%\..*ZE1I*>7T\-&Z7\3%XO"X6GII=^TJQLN_31(
M_0?"JA/$>(/"\*>\,=.N[7OR87!UL34W_P"G=*6_EYG^N);B86\ N"#<"&(3
ME<;3,$7S2N !@ON(P ,=!4U%%?YW']]!1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!\S_
M +9W[/VG?M5_LF?M&?LXZDL!3XS?!SQ[X#T^>XQY6G>(-;\/7L/A?6"65E#Z
M)XD&E:O$65E$MDA96 (/^3[\'I-5L?#-[X+\1V<^F>*OAMK^M> _$NDW:2V]
MWI>J>'K^6TEL;J"14>*>T*FREC=5=)K65&52A4?[#5?YL?\ P7<_9+N?V*O^
M"I/C'QSI&F-8?!?]N>UN_B_X9NX5D&G67Q7%T(_BEH<DTL:0C4)O%=S)XH:"
MW:18;'Q_HT0$8B>.+]5\&>)8<-<>9;/$5%3P.<0J9)C)R=HP6-G2EA*LF[1C
M&&/HX53G)I4Z,ZLKI7/S+Q=X>GQ#P3F$*$'4QF52AG.$A%.4YO!QFL53A&*<
MI3G@JN)Y(13<ZJIQLVT?FQD>H_[[-&1ZC_OLTO/^U_XZ/\_YZ4<_[7_CE?Z!
MW7=?U_PZ^\_A&^VJZ=6_Y?\ /\5YB9'J/^^S1D>H_P"^S2\_[7_CE'/^U_XY
M1==U_7_#K[P3VU73^;^[_G^.O43(]1_WV:,CU'_?9I>?]K_QRCG_ &O_ !RB
MZ[K^O^'7W@GMJNG\W]W_ #_'7J)D>H_[[-&1ZC_OLTO/^U_XY1S_ +7_ (Y1
M==U_7_#K[P3VU73^;^[_ )_CKU$R/4?]]FC(]1_WV:7G_:_\<HY_VO\ QRBZ
M[K^O^'7W@GMJNG\W]W_/\=>HF1ZC_OLT9'J/^^S2\_[7_CE'/^U_XY1==U_7
M_#K[P3VU73^;^[_G^.O43(]1_P!]FC(]1_WV:7G_ &O_ !RCG_:_\<HNNZ_K
M_AU]X)[:KI_-_=_S_'7J)D>H_P"^S7Z4_P#!!/X&R_M%_P#!9+X6^(9[$7W@
M[]D3X:^-?C%K\K _9XO%&I:6O@WP=;O+R/M</B/QCHFN6<:[7<^'KLN3'#(!
M^8>MZO::!I&I:U?N8[/2[*XO9V^4DI!&7V(!RTDC 1QJ.6=E4<D5_:%_P:K?
ML@ZI\(_V-?B%^UUX[TXVWQ"_;2\='Q%HYNHQ]LL?@[\/;O6]$\$P*98TGMH]
M:\0:CXRUR-(R+:^T*7PO=KO"0^7_ #9]([B.GALCRKABC47UG-<6LQQ<8O6&
M R^ZI*:[8C&U*<J<M;O!U5I9G]$?1\X?GB<XS/B6K#_9\LPO]GX2;3M+'8WD
ME6<)?S8?"0E&I&^V,IMIO;^I2BBBOXZ/ZS"BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M[I/ /PF\/7-I?>*-8O2"MM!=#3Y$M]'AO9[:&^\2ZGX9TOS%?4P:_P!5_P
M>!?"OPP\"^#?AMX&T>T\/>"_ 'A;0/!?A+0K",16>C>&_#&E6NBZ)IEK&/NP
M66G65M;Q@Y8K&"Q+$D_A/_P;^_\ !*V]_P""?_[.5]\6?C7I,1_:]_:7MM-\
M3_%26Z\NXO?A[X2W/J'A3X56LWS"UNK!+K^V/&L=JR13^)9XM*D-U:^%]*GK
M^@6O\Y.->*L5QGQ)F&?8I2IQQ$U2P6&DTU@\OHWCA<,K>ZI1A^\KN*4:F)J5
MJMESG^@G!W#.%X1X>R_(\,XS>'I^TQF(C%Q>+Q]:T\5B97;E:53W*,9-NG0A
M3I\TE!,****^5/IPHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** .=\7>$?"WC[POX
M@\$^-O#VC>+/"'BO1]1\/>)?#/B'3K75M$UW0]6M9++4M*U73;V*>TO;"^M9
MI+>YMKB*2*6)V5E(-?YOW_!73_@D9\1O^"4OQ(U/XP?"#3?$'Q%_8)^(GB!Y
MK:X@ANM4UK]GK7M6N&\GPGXKE!G>3P^\KK#X9\571AAU:)X-&U*1/$4,,^L?
MZ4=<SXT\%^$_B+X3\1>!/'?AW1_%W@WQ;I%]H/B;PQX@T^VU71-<T;4H'MK[
M3=3TZ\CEMKNTN879)(IHV4Y###*K#U<DSO,^'<SPF<91BIX/'X.HITJL+.,H
MZ<]&M3=X5J%:-X5J,TX5(-IK9KS,XR?+<_RW%93FV%AB\#BX<E6E.ZDFM85:
M52-IT:U*5ITJL&ITYI2B[H_R4],U/3M:L;?4])N[>_L+N,207-L1+&Z]QE2=
MKH<JZ,%9&!#*""*OX'H/^^#7[[_\%._^#<7XR_LX:UXH_:"_X)FZ9JGQ0^$5
MW/>>(?&?[*M_?_;_ !KX0B.ZXU%_A3<W$D5UXQT:&-6.G^'"\_C.SC,=A9)X
MK\N)%_G)\/\ Q%T;5]1N_#FJ0:AX3\9Z5<266L^$/%%K=:-K>G7\#&.YM)+6
M^CA=YH) 5DB $\7_ "UB0%2W]O\ A_XR</<7T:."S&K0R/B%1C"I@L355/"8
MVHDDZF6XFK)1J>T;NL)5DL5!MQBJ\8.M+^,^._"//N%*U;&9?2K9UD3E*<,7
MAJ7M,5@Z;=U#,</33G!4TK/%THO#324YNA*4:2[_  /0?]\&C ]!_P!\&C\1
MSR/G/3UHR/4?]]FOV0_(U;35/;^7^[V?]=-E<P/0?]\&C ]!_P!\&C(]1_WV
M:,CU'_?9H!=-NG2/]WS_ *Z;*Y@>@_[X-&!Z#_O@T9'J/^^S1D>H_P"^S0"Z
M;=.D?[OG_7397,#T'_?!HP/0?]\&CUZ<=<.Q_I7#W?BZ]U/Q/H_PW^&GAC7_
M (I?%?Q1?0:3X7^'_@G3K_7];U75+MTCM;46NEP75P)99'7;;QQ27+*=XC6,
MB0^+GW$62\,X"KF6>9AA\OPE).TJTTJE::5U1PU%7JXFO)?#1H0G4:N^7E3:
M]C),@SCB/'4LOR7 5\?B:CC>-&FO9T8-Q7M<16;5+#T4T[U:LXP3T3;Y4[OC
M#QCHG@C1YM7UF=%4 I9V:!1>:C=%28[2SB8YDD<@!FQLC4[W( K^I[_@W^_X
M(L>)M5\4>$_^"D?[;_A'[#KD,<&M_LL? ;Q3IA<^%;9Q%<Z5\8/%FF:@N;76
M K+=> M)N["&]L;GR_&-UY-VGA];7T?_ ((^_P#!NE?^"?$GAC]KS_@I9INE
M^+/B_I\EIK?PR_9M$^GZQX$^&$ZF.[L]7^((MWOM-\4>++.01-9^'+:[N_#N
MCSQ-<:M/K^I"V32?["      !T & /H!7\.>)_BGCN/<5'!X6%7 <-X.JYX3
M!3DE6QE6-U'&YAR-Q=1*_L,-&4Z6&4F^:I5;J']G^&WAG@N!\*\7BI4L=Q#B
MJ2ABL:H?NL)2DHN6#P"DE)4W))UL1)1J5W%>[3IQC3BM%%%?DA^J!1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 5^7'[=G_!'+]@K_@H1:W6I?&SX
M/:=HGQ0>-_[/^-OPT,7@GXHVD^/W3ZGK>FP?9/%MM$X#)9>+]/UR*V#3-IS6
M%Q/)<$HH _F&^.?_  :I_MD?#6YO]1_9"_:U^'7Q;\+0_:)['P'\?=.UOP9X
MJCB#9M["P\2:'I_BS0]4N6&%WWTO@^R7#M)*685^=GB;_@C#_P %K/!MV]E>
M_L:Z)XJ/F,D6H>#_ (J> M8L)EW;$G7[%XDN)(4?B01W*PRHA EB1@P!17U^
M6<?\:Y/2CA\NXHSG#X>"4:="6,GB:%**VC2HXKV].DET5.,4CY;,>!N#\WJN
MMF/#>48BO.5YUUA*=&O-MZNI6PZI5:C?5SE)O?<]2^&'_!OS_P %F_C!J%K8
MZ_X ^"7[-V@W8 N?%7Q&^)6E:Y<646&>1H-"\"0>-M<:\51Y=O#=:);V\T[Q
MK-=P0^;<1^;_ +37_!%?_@J_^QKJ-[]H^#]M^UW\-()));#XD_ 66YU75S:,
M0X76_!$]C:^*M)NH R1S*=&O=.$K-%8:UJB(;BBBNBGXD\>TL?#,H\69U+%4
MTXQ]IBY5<,X-IN$L#54\#.#:3<98=JZ3W.>?AYP/6P4LNEPOD\<-4E!R]EA8
MT,1S17+&4<91=/&0DDVN:-=.S:O9M/\ ,C7?%'C[P?J$NC>./V?/V@O!^N0.
M$FTC7?AEK6F7L;D<*;?5(]/NLL00F;<!U 8'!Q7IGP[^%G[8/QOFM[3X&?L3
M_M*_$">]D1+*]_X5KXBTW19C(VU3_;$M@VE8!#&3.H*(U 8L=RBBBOIZGCQX
MDUZ'L5F^$HR<7%XBCE67JN]E>\Z%2E&3N]84HM;QLTK?-T/!'P\I5O;/*L56
MBI1<:%7,\>Z*^%I6A6A5DEVJ59II6DI*Z?['_LQ_\&TW_!1K]I"?3]:_:G\?
M^!_V//AA=-#/>>$]!NE\??&34[.39+Y"V.C2KX=T'<F^*675_%D%_:2D+-X8
MO%!=/Z]/V O^"2?[%/\ P3DT&./X#_#*UO\ XCWEH;?Q/\;_ !YY/BCXK>)'
ME4"YC_X2&ZA">'=)E;<!H/A>UTC39%VRW\>H7QFOIBBOS3-LZS?/<4\;G.98
MW,\4TTJV-Q%6O*$79\E*,Y.%&FFKJG2C"";=HI'Z)E>495DF&6#RC+L'EN&3
M3='!X>G0C.25N>HX14JLVEK.HY3?5GZ8T445YAZ(4444 %%%% !1110 4444
? %%%% !1110 4444 %%%% !1110 4444 %%%% '_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>nt10014672x1_diagram2.jpg
<TEXT>
begin 644 nt10014672x1_diagram2.jpg
M_]C_X  02D9)1@ ! 0$ P #   #_[0 V4&AO=&]S:&]P(#,N,  X0DE- ^T*
M4F5S;VQU=&EO;@     0 ,     !  $ P     $  ?_B"^!)0T-?4%)/1DE,
M10 ! 0  "]!N;VYE @   &UN=')21T(@6%E:( ?4  < %0 3  L (6%C<W
M         $E%0R!S4D="     0            #VU@ !     -,M2% @(
M
M$&1E<V,   %$    =&)865H   &X    %&)44D,   ',   (#&1M9&0   G8
M    B&=865H   I@    %&=44D,   ',   (#&QU;6D   IT    %&UE87,
M  J(    )&)K<'0   JL    %')865H   K     %')44D,   ',   (#'1E
M8V@   K4    #'9U960   K@    AW=T<'0   MH    %&-P<G0   M\
M*&-H860   ND    +&1E<V,         &G-21T(@245#-C$Y-C8M,BTQ('=I
M=&A"4$,
M                                                    6%E:(
M     "2@   /A   ML]C=7)V        !      %  H #P 4 !D '@ C "@
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M;W5R(%-P86-E("T@<U)'0@
M
M      !865H@        8ID  +>%   8VEA96B            !0
M;65A<P         !                               "6%E:(
M  ,6   #,P   J1865H@        ;Z(  #CU   #D'-I9R      0U)4(&1E
M<V,         +5)E9F5R96YC92!6:65W:6YG($-O;F1I=&EO;B!I;B!)14,@
M-C$Y-C8M,BTQ
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MU=;7V-G:X>+CY.7FY^CIZO'R\_3U]O?X^?K_Q  ? 0 # 0$! 0$! 0$!
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M=$USPA>:=I^MZ-XB\!^)](UJSL=0@U>Q@_+WXF>//@+^QI_P<+>*/&__  5
MU^/5_A/X5_8/^$FA?LA_$?XB?#OQ-\2]'OO%GA7PS\*-,O\ Q1X?\,:-I/Q#
MU30?$M_X]T']I&XTH6-M--9^*M<NQ#=RZ_XCTV\U/VO_ (-@/!_A+XB?$[_@
MJG^VQX ^'5A\-OA3\:?VFAX)^"_@R#3-/TF;X?>%M-UKQU\5=6\"1Z9ILL]A
MI$&E^'_BE\*;*?2M(:/1;2XTA;;2XUL;2UAMP#^N>BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '\EW
M[8G[*'[<O_!7[_@J->:=H5_\2OV)/V6/^"<,FCZI\"/C3\7OV:K[QCX<^+W[
M0\/B[2M1U3QOX%^''Q.O/ WA7XL^&Y]5\)SV=CXA34O&/@2U\&^!_#6IW6G2
M0_%Y+.[\Y\#_ +/_ /P4._8 _P""MO[67[0OQ"G^-'[?_BKXR?\ !,?XJ:QI
M7[1OPZ_9$UKX?^"_%WQE\"Z!HFH_"WX1:OX?^#-AXE^'>D?$9H/V==$\&Z#I
ML>KV^N^((/%?A@+9#5?$UF+_ /L7HH _A?\ ^"6G[3G[:?\ P39_X)\^)/V9
M_A3_ ,$E?^"C7Q _:U^)7Q3^(?CZ#Q/X_P#V8?'G@G]GSPQXT\;:-X9\">"M
M6U7Q/=:>?$.L^'_#NC>#O"^N>)M/UO2_ ]I=W?\ ;&D'QEH>E^5XEM_L_0_^
M")7Q\\$?\$&OVKOV:-2OK7Q?^W!^T[KVB_M5>/\ 2S<:5<2?\+*\+^)OASX^
MB^!UGXCTVZDTKQ'K#:3X#U?0;;67U-_"\GQ0\:ZS>V.K-X4%IJDG]:-% '\:
M_@[_ (*4?\%8]3_8V_9;_85_8[_X)B?M7? 7]K?P3X0^#?P.\4?'#XO?!+4]
M/^!_@/PS\+]$\/>&D\5:7>?$CP7#X4TN'QUI'AZ/^UV^(MC9Z1X(T?5-2L?#
MEYXOUUM!U^TYG_@J/X+^,OC3X^_#^R_:%_9P_P""C'A']K?]GK]G7POH?P2_
MX*8_\$P_".H?%C1OCGXHUO33=>,=)\6_#GP_X5^#-_\ #;2=+\7ZOXYL_#_@
MO0/C)I?B;0$\1ZD-5U#4/"_B72M5U+^TZB@#\I_^"+5W^W#??\$^?A'=?\%
MQXK7X\R7_BF.T3XD6-_IOQ>3X;VVKO:^"!\7[35+6TU)?'KVL%W+--JT1\17
M7AR3PY=>+I9?%\VOR-^K%%% !1110 5_%[_P<L?LA^(=*^.'P[_;"L?#?]O_
M  E^*'@+P]\%/BC.-.COM-\(?$KP/K/B#4_ >J^*!/+,J6/Q,\-^)F\+Z1>-
M8IIEAKGPWT[2;V^76/&'ARSO?[0J\U^,/P=^%_[0'PS\8_!OXT>!_#_Q(^&'
MC[2CHWBWP9XGLQ>Z3J]DMS;WUK(0&CN;+4M*U.SL=9T+6M.N+/6?#^NZ?INN
MZ)?Z?J^G65[![O#6>UN&\[P&<T*4,0\)4FJV&JV]GBL+7I3P^+PT[QFDJ^&J
MU::DX34)2C4Y)<O*_&X@R:CQ!D^-RFM5G06*A!TL32O[3#8FA4A7PN(A:4&W
M1Q%*G4<5.#G&+ASQYKK_ "Q/"OQ&^(GP#?3/&7P2\;^._AEKO@_6=-\1:*WP
M[\0>(]&@MKR"\LH[V0^&M"NETO5X+[2XY-.U;2KO2-0LM<T<RZ-J=E?:;+)9
MO^@GCK]DW]B_XM?$KQCX7_X)@_M6ZCXUU!HX[_X6?LH?M(_"OXN?"CQI\2+3
M0_#MC_;OAWX"?'GXDPZ'X*\5>)[JYADN/!'PD\9>$OA[XEU...]L+2]N[:SE
M\1S_ *!?\%J?^"1/PG_8@^'WPT_:)_97T#XG0_"L^-/$WA#XY:-KGC#Q7\2=
M%^'.F^)=-L-1^&?BLW^NP:KJ_ASP/H^JZ!KO@S6/$WBWQ+?R/KOC3P18WVJ3
MW5]YLO\ /[H?BOQ'X"\1>$?B1X)^S/XU^&?C'P?\3_ YND66U/C#X=^)-+\:
M>%A."RJUM+K>B6,=QEMK6TDJMN1F5OZ1P='"<:X?$<:\"XVOPSG&58.O@GE.
M&P> Y<;BJ"EC:,<PH4KQKTL9[58:E4G3GI&32DX3I'\^8NKBN$:]#@_C3"4.
M(LJS/%T,6LTQ&+QU\'AJ_)A*TL#6JVE1J83V?MZL(3CJXIN,9PJ$WP[^+_C'
MX0>*OAU^T5\'=2%E\0OA/KFA_%KX;ZDPN5M[K4]#5=4AT;58;:XLKJZ\-^,=
M)>\\)>+M(%S NL>%M=UC2+AA%=OC^^'_ (*G?MTGX;_\$G=7_:,^#OB6[\(>
M*OVG?!/P>\)? [6/.OM-\2Z<W[2$>A7%[K/A^\T^:TO=)\;>#?A!J?C?QUX>
MU"*6,Z5K_A6UO71TMFB?^-GQO^QMK^M?%WP/?? )=6U3]C3]HWQIX?\ $7P@
M_:1'A;4/&_@[X.?#/Q[K<6K^,_AW\:;7PSKEY_8WQK_98TN^UKP7XU^%FK^*
M])\<>.-1\&07VC6D-SX@ELM,_IG_ ."C?[.GPG^)/_!)G]DS]F/X6?M+^![[
M6?V<-%^#M[\)M7\2Z%X@"_&RX_9]^!GBGX-KH>LZ3X8MM>UCX9WWB;^W?MKZ
MIK.FW^F^&?$-O;Z-JJB.66^M?SSQ#S[A?B3..!\T]O!5*^$PJXIC3HU+X*A'
M&454H5Z<+U98G#O^TH2HKFJ^PCAITYU*5:A)_><!Y+Q'P]E7&.6^QDX4<3B7
MPY*I6II8RM+"U?9UZ,Y<M*.'KKZA*-5\M/V\J\)QIU*5:"_CB^'OP_UCQGXE
M\*?#+P#9:!;:KK;ZA:Z9_;VMV/A+P?X=T+PQX<UGQEXQ\6^+O$VH V/AGP1X
M \!^&?%'CSQKK]Q'<-I7A7PWK.H16FH7<,-E<^N^&]7_ &8_AE\*/VA/%FG?
M%OX^^,_VK[[PMX+\!_LZ>(?"OP:U7P#\ =(TWQ;\3- \!_M"Z_X2U2Z\?^)?
MBWJ/B?Q7^SYXL^)6G^"/&GQ1^%'[/+:/X1GULOH4/Q#UGPKI_A[A;+1?%WP[
M\(ZOX[\6:+K7PX\9_$/P!XW^%7PC\"^-= UC0_'>M:'\6-$U#X6?'_XJW/A/
M58=*U'2OA5X5^#^M_%/X+Z7XOU^"#3/'?QC\?Q:)\/[/Q8/A5\6+SP+YW-<1
MP-;1MYCSWUY:Z=I]G;Q2W5]J>IWTJV]AI>EV%LDMYJ6JZA<NEKI^FV,%Q?7]
MU)';6EO-/(D;?KV+P]#C^MFZCGE3 \%9&LNH8*>!CA*659GBZ,/K693Q=6M3
M_P!IR[!TG0P7LJ=6AAN9U)1E^[DZGY7A:];@>CE3ED]/&\7YR\?6Q<,:\34S
M++L+6G'#Y='"4J-3]QC\745?%^UJ4ZV(Y?9Q<??BJ>%J&D>%[72K<:IINFMH
MWAY;F]LK:\M4N[#26ES)=W&GV4J316US<')E>S@6YNI6P?,EDPW^@9_P0E_8
MQ\8?LD?L8KK?Q7\.ZMX2^,O[1GC"Z^,'C3PAK]H=/UWP'X<?3+#PU\,? VL:
M<Y%QIFM6/@S2+/Q5XGT?4HHM8\/^,O&?B7PWJ*HVC0V]OX%_P2F_X(I_ +X4
M_!G]F[]H#]J;X%WM]^V?H&H^(_B??0^,/B+X^\0Z'X'UO4OB+XJ\2?".2\^&
M4OB8_#*R\??#KX=WW@K3ID7PS>)X4\=:/=:KI=S+XATNR\0C^B6OPOQ%X^PG
M$T:.4Y+EE'*\HPF*EB*SIPH0GF.*I*IA\/6DL/"$%0HT9U'0BW.4G6E*7+RP
M2_:. >",5P[*KFF;YC5S+-,5AHT*,:DJTXX##573KUZ*=><Y.O5K0IJM)*,8
MJC&,>;FFV4445^5'Z8%%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M!4O["QU6QO=+U2RM-2TS4K2YL-1TZ_MH;RQO[&\A>WN[*]M+A)+>ZM+JWDD@
MN;:>.2&>&1XI49&93^2'B_\ X(0?\$L?%NM:GKZ?LQKX+O=6N9KFYL/AG\6/
MC5\.?"-L+B.9)K?1/AWX1^(>E?#KPQ;,TQF2+PSX4T?R)XXY;9H2&W_KU7/^
M+/$VD^"O"OB;QEKTS6^A^$O#^L^)M9N$C>5X-)T'3KG5=1F2*,-)*T5G:3.L
M:*SN5"J"Q KHPV+Q>"J>UP>)Q&$JN/*ZN&K5*%3E;3<>>E*$N5M)VO:Z3W2,
M,1A<-BX>RQ6'H8FFGS*GB*-.M!22:4N2I&4;I-J]KV;74_FP_;;\ _\ !+G_
M ()#?#6QT_X*V&D_##X^^+O&W@SXE:=\(-(\1_$+XV_&/XT:7H1\0>%K2[UU
MOB%X\\1ZYX8\$:%#J7B.[TSQIXM\1>'/!5K=:1KOAS0KU_$^I06@_(;X9?\
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MBX2Y8<SA$HHHKY4^F"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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ME%NMGI6NZ+>Z7J%TT[/$L*V]I=32F5I(Q&$WET"[AV%? G_!5/P_XO\ %/\
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MC22OV2^-/[>G_!"K_@J+\1= TW]JOX7_ !]_9X\=GPK+X%^'_P"U)\0H=/\
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MZ<)*"@XOVGMZE;]T/C7_ ,'!_P"VQXZ\+7?P]^ ?@/X&_LA>#)M+M-+L-0\
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M)^.&K>"K;3+/Q7%IGAV/4]1\*R^"].MM(BDOXM8\3:=$OAB]\7UOA#_P< ?
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M/,$"^*/B)J]KX6TN]OI(HYFMM)TB34FUK6[\QM%IFBZ=J&I7&VWM)6'Z#_\
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M;\(OV6_A/^SM^R_\7_B1XW\%^*O'7Q7\3:?\//A_X2^)7Q:O-)\.>+O$.O\
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MWC?4+WQM%%I6JZ)I7Q"N+#XB:K:>%OA[]L7_ ()F_P#!2S]K?XD^(?B'=_\
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M*^'8M3O$GBTNQN-5OXKWQ!K*V>ISZ!X7LM<UZ#1]8ETQ=,N_P$\"^*OVG?\
M@LU^QM\:]$U6]^''P.\5>#OB]H&F-XE\--XOO/A9\:]8T;1KOQCK?PLU_P /
M7>HZEXL\%^&?#TOB'X;27_B:'7?'ZWVNVC7'_"()#IEWX:?]Q/VIOV?/@O\
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MNW,=Q:_#3XPZT'5I([7PMXRU&1S(DC/M&E>(+R1F!MVW+]CU.<J+(*T-W(;
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MA&$$HHHHHK(P"BBB@ HHHH **** "BBO+_C?XSUKX<?!?XO?$/PW:6.H>(O
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110!_)9_P<^_&:]D_X9&_9IM9(&T2\U'X@?M"^*[=H)UN3K?A
M&TT[X;?#)H[HJMM-8&V\>_%6YO;$-/(NIZ?X?U"5+5[6RDN/Y0J_I*_X.<]
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M]5@H)X(SVX..1CMG\#U^M?N^28]5J<(N5[K35WZ)K72^G?IYZY'5T4=:*^F
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M.K.4VDN9Z16T8I)1BO*$4HKR2"BBBO5(.1\8>&?^$BL(GLYEL=?TJ4WN@ZH
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MJ+5IS%<"+Q?]G/\ X+#?\$WOVM/BWX=^!7[//[3FA_$CXK^+;;7;OP]X0LO
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MU:=.,*DHXFK*.(AB)12=:4:GLY4JD^:HJ;E2<O94J,(?L/1117\\G[P%%%%
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MG%?92G**V=KW/W(HID<B2HLD;*Z, 593D$'_ #R.H/!YI]?LVVYV;[!1110
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M/$4J,ZE.%6<)U(1E52C4I:SC9/125FOO6WDG9L^HJ*S?[9T?_H*Z;_X'6O\
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M-;))))1C%*,4HI)<[/\ ?E^K5SL_5_J/YBNBG^_+]6KG9^K_ %'\Q7T^#_\
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M]>B[GTN,_@O_ !1^6I]T?\,$?LD?]$=T[_PI_'/_ ,U%'_#!'[)'_1'=._\
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MI H'58Y)6!P&!_86LY_$_E^2-Z2]Q>K?X_\  N>$?"_]F7X&_!C7[SQ1\,O
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M-R[%83,\OQF.SO&9GBJ%'"_TT_#;Q"SB#YR/ND=,>_4GKGGI].*^]/AWK/\
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M#/=VVE>17?P9O-$^+/A'XDZ;XKBU+7ETOQIIOQ<U:6>2^B^(8\47:>(=*O\
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M.4^'US\!_P!LOXD?"GX$_'GX%6ND^%KS6/&OB7PE\+O ?Q@\$16YL_!OQ%\
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MI[6,X1_:JBBBOWX^7"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M&*^"/B'X18O-^[R?F'0]/FX/8C)&,_3@U_2WASP)X=Y=5RVM'AW"XVKEG/\
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MG\(:=>ZA;V,_B3Q'X7\6W&GMHNEK(1?7M_'X?US7M<EMM'_XF4.E:+J6I?\
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MO#WC#Q%XAL;T0/(DNHV_B#34B<R,L]EY4UF\:L' _,3_ ()W?L:2_&K]G?\
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M$ETT]4UL>'?\%!_^"E_[87@[]FCX5?%7X>?"C7_V<]=T/X^>%-"U[QU/X_\
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MRROK626VN[6YB<2V]Q;R20RQLLD;LI!/PC\>_P#@LO\ \$Z?V1/C-XP_9_\
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M\W3'>OV!\5_#G>9"8,YSSMYZ'L.OZGGMFOGW7OA@2S[;<X^;/R].,>G4G/\
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M\/M3U_XEV6M7L^D0?$?P/I6C>./ FMZW\7+8ZGH&G:;XT\)V&H>)'@GTDO\
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M)5T=2&5E)#*002#3ZXCS@HHHH **** &21I*C1R*'1AAE(R"/\]#V->>^(/
MT-^CO:A6/)\IL!N>,*Q(5L9)Y*L ,#><5Z+171A\36PLU.C-Q:=VNC]5^JL_
M,YL3A,/BZ;IUZ:G%II/JK]GT_(^//$GP[=7D62V96'.&0AL'D'D=^O QQD9Q
MQXSJ_P . S.3;@D\9VCJ>N"!SVQSQCC)YK](YK>"X39/#%,G]V5%<#W&X'!]
MQ@US-[X*T*\R?(>W;GF%\@D^HE$G'LI4>E?89?QE7PZC&JIJUM8/F3\[-IKT
MU]3X+-. ,+BW*5!TVG?W*BY7TLDTFGM;5Q]$?F)>?#%"Q_T;Z_)G_'L>?IR.
MF**?#! W_'N.3_<_ST[=_?U_22;X7:9(Q*7C("> UJLA SG&1.@/H?EY':H!
M\*-.!!^WYQC_ )<E'3Z7(_,YKZ.'B!!1LZ]1>7)5OLM+J+5^F_SL?)3\+9N3
MM0IM=U4HI?=S7^]+;4^ M.^&:JP/D'@]-@[_ (>_Z#&<UX_XQ^&&OZ/\9?"T
M.E^+[OP#I/Q2TH:#)K5MI6GZDMWXJT$32V6CRRWYBBTRYU72K@0Z+<QR/=W.
MH6TEK;P3,^(?UOM/AKH\!!EGEEP01Y<4</0D_P 1F]?S&>:Y3XM_ OPQ\4/A
M[J_@X[](U5O)U3PMXEA>7[?X;\6:7OGT+7;62-ED0VMT3%>+;-!/<:=<7MK#
M/;O.LT?YGXGYE5XMX>C0P:Q=?,\IS'!Y[E4,/F..R:K7Q6 ]I3Q.7PS3+\3@
M\=@%G&58G,LFGB</7INC3S"4ZBG152E4^MX7X(_L;%3J36%A1Q&&JX2O&=&C
MBHNG4<)PFZ%6G6H570Q-*AB8QJ0DG*C&UI)-?*7A_P#8NMM:5#XI^)/QB\26
ML@Q=V-]XS?3]"N R@2I]ALK*"2*%F"LT,-XS@Q1J20&W>/?&?]F_X0^"/VB?
MV'OAO\./":V?C+7_ (W7?Q>U[6I-9US6)[;PI\$- G\17T=\NLZGJ2V<.L:O
MJ6G"RG$-LEUJ6FB&W9;A2!V7PB^'&E>-K7QAX:^.WQP_:&\.?$SX8QSW7Q*\
M(Z[\:C;>$D\/1Q_;X_&&A2FRC,G@B^TS[-/?WCZBYTE]BWEU'#<:=>WN#^P)
M\+O!7C3XS?&O]K#P?8ZY!\.6ED^"OP&N?$-UK]YJ'B7PMHDMA?\ CSXGRS>(
MXQ=7,'C7Q1#$-!GA6Q?3+>#Q!HU[I\-U'*!_/^6PRKB;$9)B,)X?Y#ERQN,5
M6.:YCFBSCBG+(Y3B85<SH5(8W+L5CL%B*%6A/*L;"KFN%K83&XE0G1J3YHGZ
M/3PCR^G*A]=KU9/EYH0@J&&G%I-3C3I2A2<9*S@_9SNK-22L?K71117[B(**
M** "BBN*\>>)SX9T1Y+3;)K6I.=/T2W+1@O?3*1]I?S/W:VUBA-S/)-MMQLC
MBEDC$RM50A*<HPBKRDTEVUZM]$MV]DDV]$73IRJSC3@KRFTE=V2OU;Z)+5O9
M)-O8\>\=WESXS\:6V@:8^Z*TN)?#5E(!N1;ZYB6;Q9J8X*2II&EK'83P2%)8
MY;@7-JWF1@GZ-L[2WL+2UL;2,0VMG;PVMM$N2(X+>-8HD!.20D:*N223C))-
M>+_"#PX%CN/%,^Z5)HI-*T2:4-YMQ9I<O-JFL2>8J2E]8U+?)"+A3=6UK$+8
MS2PE&/N-=.*G%.%"'PT(\K?>;LYNW2SW6MIN=G9G9CIQBZ>%IN\,-'E;[U)6
M<W\GNM>6HZEG9A1117(< 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M>%?M#?&R'X$>!+3Q.GA^3Q3KFO\ B?1_!?A30/[071[/4/$6M1WMU"=5UEK3
M4#I6E66G:9J>H7EW%IVH7++:+:6EG/=7,*U\:>'_ -MOXN>'M6TZ[^*7P]\(
MZ]X,O+B.'6[GX4Q^)3XH\&02^?G44T36[O4W\>Z=:M]F2^71U\/ZVL'GW>GZ
M#J4@6P5I-ZI7)<HII-I-['Z@45\L7W[;?[*=CH">(F^-_@J]@EMH[F/1M)N[
MK5_&)\UG5;:3P+IMI=>,K:^1HV^U6%WH4%W8J/-OX;:']Y7T3X5\2:5XR\,>
M'/%^A2RSZ)XKT'1_$FCS3PR6TTVE:YI]OJFGRS6\H$L$LEI=0O)#(!)$Y*.
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MO_UJYR]T4$$A0P['C(ZGC&#P!QWYKYW'Y)3K)N,4[].[=MG\GUV5W<#YMOM
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M**B&1TB5G*(BEB=JJ, ?BI\3'2+X<?$"1SM2/P1XK=VP3M1-!OV8X ). "<
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M+:\LKRVF5X;FUNK>62"X@E1XIH9'CD5E8@W:*11^#OQK_P""<?Q:\#:Y-<?
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M_P#A-_'OA;X<Z/\ V5IFKZWX=TZZ\O7O%VES7WVC6;/R=-CO+B'[1/%%:S_
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M9]G_ %_PZ^\+KNOO1TE%<W_PF7A#_H:O#?\ X/-+_P#DJC_A,O"'_0U>&_\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M_P )#P]_\KJ[RBB[[O[V+EC_ "Q^Y?UT7W'!_P#"K/AC_P!$X\!_^$AX>_\
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M8!E((!KURN;\9?\ (H>*O^Q;US_TUW5--W6KW75]Q.,;/W8[/HNW_ 7W&/\
M"S_DF'PX_P"Q#\(?^H]IU=Y7!_"S_DF'PX_[$/PA_P"H]IU=Y2EN_5_F.'P1
M_P ,?R04444B@HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** (YI5@AEF?)2&-Y7"@%BL:EVV@D G . 2 3W%>/Z/\4O$O
MB#2-*U[2/@WX[N])UO3;'5]+N_[<^%]O]JT[4K6*\LKCR+GQ_#<P>=;312>3
M<0Q3Q[MDL:2*RCUC4?\ D'WW_7G=?^B'KA/@Y_R2+X5_]DX\#_\ J,:736S=
MKZKOUOV:[$.[DDI.*M)NW+K9QMNGW>W<I_\ "=^-O^B)^.__  HOA3_\\.C_
M (3OQM_T1/QW_P"%%\*?_GAUZG11==E^/^8<K_Y^3^Z'_P A_5WY6\L_X3OQ
MM_T1/QW_ .%%\*?_ )X='_"=^-O^B)^._P#PHOA3_P#/#KU.BBZ[+\?\PY7_
M ,_)_=#_ .0_J[\K>6?\)WXV_P"B)^.__"B^%/\ \\.C_A._&W_1$_'?_A1?
M"G_YX=>IT4779?C_ )ARO_GY/[H?_(?U=^5O+/\ A._&W_1$_'?_ (47PI_^
M>'1_PG?C;_HB?CO_ ,*+X4__ #PZ]3HHNNR_'_,.5_\ /R?W0_\ D/ZN_*WE
MG_"=^-O^B)^._P#PHOA3_P#/#H_X3OQM_P!$3\=_^%%\*?\ YX=>IT4779?C
M_F'*_P#GY/[H?_(?U=^5O+/^$[\;?]$3\=_^%%\*?_GAT?\ "=^-O^B)^.__
M  HOA3_\\.O4Z*+KLOQ_S#E?_/R?W0_^0_J[\K>6?\)WXV_Z(GX[_P#"B^%/
M_P \.C_A._&W_1$_'?\ X47PI_\ GAUZG11==E^/^8<K_P"?D_NA_P#(?U=^
M5O+/^$[\;?\ 1$_'?_A1?"G_ .>'1_PG?C;_ *(GX[_\*+X4_P#SPZ]3HHNN
MR_'_ ##E?_/R?W0_^0_J[\K>6?\ "=^-O^B)^.__  HOA3_\\.C_ (3OQM_T
M1/QW_P"%%\*?_GAUZG11==E^/^8<K_Y^3^Z'_P A_5WY6\L_X3OQM_T1/QW_
M .%%\*?_ )X='_"=^-O^B)^._P#PHOA3_P#/#KU.BBZ[+\?\PY7_ ,_)_=#_
M .0_J[\K>6?\)WXV_P"B)^.__"B^%/\ \\.C_A._&W_1$_'?_A1?"G_YX=>I
MT4779?C_ )ARO_GY/[H?_(?U=^5O+/\ A._&W_1$_'?_ (47PI_^>'1_PG?C
M;_HB?CO_ ,*+X4__ #PZ]3HHNNR_'_,.5_\ /R?W0_\ D/ZN_*WEG_"=^-O^
MB)^._P#PHOA3_P#/#H_X3OQM_P!$3\=_^%%\*?\ YX=>IT4779?C_F'*_P#G
MY/[H?_(?U=^5O+/^$[\;?]$3\=_^%%\*?_GAT?\ "=^-O^B)^.__  HOA3_\
M\.O4Z*+KLOQ_S#E?_/R?W0_^0_J[\K>6?\)WXV_Z(GX[_P#"B^%/_P \.C_A
M._&W_1$_'?\ X47PI_\ GAUZG11==E^/^8<K_P"?D_NA_P#(?U=^5O+/^$[\
M;?\ 1$_'?_A1?"G_ .>'1_PG?C;_ *(GX[_\*+X4_P#SPZ]3HHNNR_'_ ##E
M?_/R?W0_^0_J[\K>6?\ "=^-O^B)^.__  HOA3_\\.C_ (3OQM_T1/QW_P"%
M%\*?_GAUZG11==E^/^8<K_Y^3^Z'_P A_5WY6\L_X3OQM_T1/QW_ .%%\*?_
M )X='_"=^-O^B)^._P#PHOA3_P#/#KU.BBZ[+\?\PY7_ ,_)_=#_ .0_J[\K
M?/'CC]H%?AIIMKK'CSX8^._#^EWUZNFVEW]N^'^K>=?O!/=);^1HWC6^N(]U
MO;7$GG21)"/+V&0.Z*Q7DO[>/_),O"?_ &/=M_ZC^OT5O3IQG&[6MWLW_P $
MX:^(JTJCA&5TE'XHQOJDWLDOPZ^EOM74?^0???\ 7G=?^B'KA/@Y_P DB^%?
M_9./ _\ ZC&EUW>H_P#(/OO^O.Z_]$/7"?!S_DD7PK_[)QX'_P#48TNL.C]5
M^4CO?QQ_PR_.!Z/7\\W_  <N?M,?M&?LH_L#_#GXI?LR_%KQ-\&_&\O[5/P_
M\+Z]XE\)W,%KJNI>#-7^%WQJNKWP_ON;*^A>VN?$&F^&M3FC9(3NTF.19]T8
MAF_H9K^?#_@YB_9\^*W[1W_!-F+PG\%_AI\2_BYX^\-?M"?"SQII_@;X4>!?
M$GQ$\5:E9VVE>-O#.IW!\.^%-,U?6CIFFV?BJ2_O+Z"R:*U>"W%Q)'%*QI%'
MY/\ _!P9_P %BOVG?AI^T?H7P6_89^)'CCP3X#_9ET3PCKG[3WQ"\ I%;Z?J
MOQ!^,RV6M> OAKKVMW^BW]O81:3X*TM+^QCLKE;C4=:\6>*-,U'3FO/ <XM?
MTQ_:"_;)^,OQQ_X+&^'?V;_@_P#'/6O@K^QM_P $Z?A+J/[1/_!0CQ_X=NDT
M_1O$NHK:Z?XPL_A7XIUV;3M4T^XT6UTRT\(V&H:;IMUI.MQZ/JWQQ59I-6\&
MVT=C^7'Q>_X)7?M&>$?^#?WXIZSJGPR^)WQ4_;Y_:V^/'PH_:T_:!\)>'_AW
MXD\6?&?4[G7?'/D^'_ %UX/\->'1XJM]0\ >&/&&H>./&.@7>AK)X,\7^(?B
M;8RI;V-M%Y'V;\!/V1OV\?V*?^"(O[3/QP^#&D^.=2_X*N_M=WND_M+_ !5O
MX_"%MK?QJM+CQ;\0=#OM0\$V7A'5/#$]_>>/_"OP@UGQSKLO@VZT ^(O#7Q5
M\;>.K'PW VLV>B6A /M#X,?\'#_[&/QE^,'P;^&2?"3]KWX9>$/VC/&S?#GX
M _M!_%CX*V'A3X$_%OQ@OB%/"L6G>$_%=OXUU;5[JVO/$%WI.D17K>'0NDZA
MJ26WC"+PJ869]G7?^#@G]BK3?VE?B=^R'X?\ ?M-?$+]H+X<_'S3OV=-/\ ^
M ?AMX2UZZ^)OCIO$VM>$_%E_\/[T_$FUL8?"_P .M8T22'QEK'Q#F^'[0I>V
M<^AVFN6T&LSZ1_-O\"_V?/VIOC5_P4"_X)>_$WXI^ O^"S7Q,^$'PAU;0OC+
M\9?BS^VCX+^+?C;2?#_Q_P#AOI(^)^IZ!\)/!=OHFLK\,OA3<>/_  IX1\'Z
M)J'B+5Y=4\;7^H:A!#/)::#!+/\ NM_P;F?LH?%CX0_ _P#:=_:P_:D^%'C3
MX8_M.?M>_M$^.O''BK2/B+X(USPC\0['P'I-Y-J.GP7OA?Q!HNF>*M)_MWX@
M^(/B-K\=FUA!'KVF3>&=2MK2:(6,S@'RUKW_  6CU#X(_P#!9#_@HCI_Q \8
M_M#_ !I_9E_9X^$.E>!_AQ^S!^S]\-Y_B1J8^('AC3/AA??&KXH75M:MHF@^
M'M&^%>J:%\4+/QCXE\<^,M(TZPL=<C%N+BXLX[2V_7SQ!_P6P_80\/\ [)/P
M0_:]/C#QIK?AW]I*_P!5T#X%?!GPSX.DU_\ :,^)OC'P[XFF\'^*_!GAGX5V
M&HR37.L>%/$4!TS7M3FUB#PA;75YH4%OXGNIO%GA&/7?P]_8Y^"G[3GPZ_X)
M>_\ !:O]L+Q?^R1\?_#_ .VI^WC\4/CQIOAGX0#X1?$-/C<WA'XK)#H?A;4/
M#GPZF\.2^.O[/\.>._CG\2O%5_+9Z-);W>@^#X=;NYY-.TE+NT^/O&7_  3D
M_:'_ &2[O_@B9\<M4\ _MT7/P?\ A;^R+K7ASXSR_L7_  ZM/%?[5O[-GQO^
M*GB'XU_''7I[KP1XR\$>+-)\-QKXL_:&TOP1K%YKNB7-[9:7X \4Z9:IH_B^
MW\*1ZJ ?UC?LA_\ !5?]E7]L'P'\=_&.A2_$CX):W^RW:RW_ .TG\+OVC/ M
MW\,?B3\%-+CLO$>HIJWC321>:WHRZ?-8>$?$EVQT?7]5O=-CTN2#7;+2+Z>U
MM)_C[X,?\'#_ .QC\9?C!\&_ADGPD_:]^&7A#]HSQLWPY^ /[0?Q8^"MAX4^
M!/Q;\8+XA3PK%IWA/Q7;^-=6U>ZMKSQ!=Z3I$5ZWAT+I.H:DEMXPB\*F%F?\
MT/AG\"?VS/!O[)?_  4]_P""A'[)OPL_X*$^!?VU/C3;^!/AU\+7_;"U_P"&
MGCS]IGXL?##X;^.?!MAKOQ1L?@#X7_9<^&$O@+QQ+\([/4-%\(^';G5OB/K&
MI7EIJ-UX2N+J]T[PKX@\7?"/[.?[-/[57[0?_!1C_@E3XV^)O@S_ (+$^/\
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MU[XW\(VVD)X7OO$-C>SZ_:0)?+/;ZC%9?S)_M"?!7_@H=^SK\;M3_8YTL?\
M!7-_V3?@U^R7X(T#]A_PC^P5KER=!\<?%R\\!^#IO$?A?X__ +2'@/X9_#K1
M]7\(:+\2K[XC)XNUG6/ 6G>)[7PG9Z0V@^'_  UIU[HMIJ_JW[*GP#^+?[-?
M_!OOXE^&OQ:_X)Y_M(_M)2?M+_M%?$#5OVM/@0;7QM\)OVE?A;H^KZYX6\*^
M&?C!\./A[XK^$7B_7O'NH^'+#X6?#[QMI4PT^PMM.\07MEXAO[B[\.Z5XHN]
M( /W)_9@_P""V_[-O[2O[0'@O]F[5/@?^V!^S-X_^*_A[5O%?P4N_P!J?X(P
M?"SPS\8M T71)?$-]?>"-8M?%WB;SHGT>UN]2T^[U.WT[2-3M?L%M8ZK/K>I
MVFC-YWXQ_P"#B'_@GGX0^(E_X?1OCWXO^"FA>.D^&7BK]L[P%\'-4\6?LA>&
M?'<ENLZ>'[GXIZ;J;ZIKKOB9;:_\'>$?$FFZK;QIK6@W>K>&YXM;/XL_\$[_
M ('?\%#/%7Q*_:S_ &8/@!XJ_P""AFF_\$]?'O["OQJ^%_@6;_@II\-/$?PL
MNOAE\3_%7@+6_ OPA\+_  @EGU;QCI,LW@W6-7TJYUC5OA_I?@KP_/X4B\50
M:U\.(;S0O .HZS\F?LU_LH?&KQI^R7\(?^":OQ*_9O\ ^"UH\9^*OC#>^%OC
MQ\)D3X5?L^?L$^!- _X6EK/CW3_C):_&CQ1^RE\;==O=.TUK7PCKMU%?37;^
M(]:L?$0\)Z_=:2O@K0_$P!_7E^W?_P %;/V5/V /$/PR^'7Q!M_BC\9/CA\8
M#:W?P_\ V?/V;_!]A\3?C%K?AN]DU&TM?&)\/WGB+POI-GX;O=5TVXT?1C<Z
M\FM^)]1BU!?"6B:];>'_ !1<Z'^6'[ W_!3?Q[_P4T_X+.^/9?@;\0_B;HW[
M"WP4_8YT7Q#'\-]9TM_#5AKOQ;UZ3P=:ZA'\0M":*Z:V\:^'=?\ B3XT\,21
M0:Q?:)>R_"2/4M!O]8TN&QU6[\A\3>%/BG_P3<_X+K_$7]IGQ/\ LF?M>_M5
M?L]?$G]B;X:_!?X">+_V=/@UJ?QK\0^#]=\)>#O@QX&;0O$]U81^&_#&E^*]
M8OO@QXR.I!M4TRYAL_B+HNJ_8[;P[JNIS:?[]_P;N_ 3X^Z9XV_X*:_MG_M)
M? +Q[^S9X[_:^_:D?6='^$_Q)\!^*/ .N>']$L-1\<?$_4KO0[+Q9X=\,ZCK
M7A.\U7XUQ^'++Q1!IPM-<U+P1J+L_P!OM;U5 /Z:ZYOQE_R*'BK_ +%O7/\
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M$?$#WKV4<=W:2N ?07PP_P""T_[+GQ*\<_#C0KSX6_M<_"GX6?&_QG8_#_X
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M_9\L5M<Z]H<EV ?<GPP_X+3_ ++GQ*\<_#C0KSX6_M<_"GX6?&_QG8_#_P"
M/[4GQG_9U\3_  \_9G^.GBWQ!="+P-I7P^\?ZC>SZU$OQ'LR-6\!W_C7PCX/
MTW7;$3P&\M=7LK_2[7%^(7_!<#]EOX<>-/BWI^I_!K]LS7_@I\!/B7JWPA^-
M/[7W@O\ 9QUOQ7^RW\-_'OAG7H_#/C+1]=\;:7K4OC&\B\&:W+%8>(-1\/\
MP^UK3O-N-/&D7.K?VQHO]H_@WX#_ &9M4^.?PB_8^_9HUKP5_P %VO%OQC3Q
MG\&/"GQB^!OQO^('CGX(_LF_LT'X66&F7FN_%G3OBIXF_9S\=?#AOAQX.O\
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M &/=M_ZC^OT4?MX_\DR\)_\ 8]VW_J/Z_1771^!>K/(Q?\>7I'_TE'VKJ/\
MR#[[_KSNO_1#UPGP<_Y)%\*_^R<>!_\ U&-+KN]1_P"0???]>=U_Z(>N$^#G
M_)(OA7_V3CP/_P"HQI=<O1^J_*1ZK^./^&7YP/1Z*0D $D@  DDG  ')))X
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M'WP,^)_Q,\*Z</#W@3X3ZAI>H>$(;G2C'J7C'6[^PT6+3]:ADA_J-_X)1_\
M!*SP5^P'X$T/X@>*O&'Q'^*O[4OCCX'?";X;_$SQG\1_%$/B&P\ >'_!6@Z;
MY/P8^#^FVME:V_A+X5^%M1MK/3M,TDW.K3W4'AS193?16MI:6-M]$:M_P2]_
M80UKX/?L^?L_W_[/VC_\*9_9:\>:;\3_ ((?#VR\8_$K2M \+^/M*N[Z_MO%
M&M1Z5XSLKGXB:E/>ZIJMWJK?$NY\7PZY<:MJTNM0Z@^J7YN/OF@#^6']F_Q]
MHOQ%_P""]_\ P5T_;,\4ZO!J?P@_8!_99\.? ZWNKHP,_@^YMM&T;Q+XX?3I
M<^3 VGZ]\(OC[!.\UQ&R)KMY%,@W2?9_YXM,_95\-ZO_ ,$&?VGO^"E'[0_B
MCXC^(_C/\=?VIYO$_P  /#Z^/]9\/_#6S\::Q\8_!_@GQQ\69_!V@7&FV_BC
MXCZB=+^-6F+?>*Y->TW2-%T.T'A[1M&OKK5M8N_[X_"?_!.G]C?P-H/[77AO
MPM\'?[*TK]N_4?&NJ_M8 ?$'XIWFH_%R]^(</BRW\8->:YJ'C>[UOPI;ZO%X
MZ\7*+'P'J/A:QTXZ_?OI5M8R.C)RWC;_ ():_L'_ !$_98^%_P"Q/XO^ MMJ
M?[,'P:\36?C'X=?"NW^(GQ:T:ST3Q)8GQ<T.I7GB70_'NF^-?$IEF\=^++N^
MM/%7B36['4[[5WO]1MKJ]M;">U /Y'O%7["/@C]KK_@K1_P2H_93_:7TSQ'X
MQU/2_P#@E?\  ;Q9^VBVJ?$+Q;!XNU#Q?X(^#OCFSL_!EQ>IKRWNB3:?K6B_
M#\ZQ<>'9=*UKQ!)XG\2>*M8FN-3U"XOG^8_"4/QQ_P""DGP'_;&_;B^.OP6^
M+OCSQSX'^)&M?##]F7XXVW[;7[.G[)?[.W[ &N^$=.\*W_PL\$:/X%^*7QF^
M&<FFQ:3KOC7PEH>IZG=6=['K]G>VEUI>OZG\5]5U_P 12?W#?'#_ ()B_L3?
MM%?M-_";]L3XL_!M?$'[0_P4NO =YX"\>6?C/QYH$5K+\,O%EQXW\"G6?"FA
M>)M/\'>)&\/^([NXNX9]=T"_N[RU:WTC4[B]T>PTVPL_"_'W_!"[_@EI\3OC
M/XH^/'C7]EO3M6\=>.?&P^)'C:TB^)/Q@TKP'XO\>?VI<ZS)XE\1?#32/']A
MX!U.XN]2O;Z[U+3)O#W]@ZO+J.JOJVDWK:MJ9NP#^<K]L[0OVG_VT/C?_P &
M\G[ ?Q(^(OB;P=^TG9_!N']H#XS?%;P3X_\ #?CGQ!96L/\ 9W]E_&WP_P#$
MSPOXD\6^%O$WQ"L?!7[//CSQIX:\>:5X@U:PU+Q=XD@U2RU"\FOEB36\4?\
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M>5P?PL_Y)A\./^Q#\(?^H]IU=Y1+=^K_ #%#X(_X8_D@HHHI%!1110 4444
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M_P"21?"O_LG'@?\ ]1C2Z[O4?^0???\ 7G=?^B'KA/@Y_P DB^%?_9./ _\
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MOA3XRE\,>.M7\374Z^,K[3? /Q0M;S6==\+^%?#D+>(].6TT72-3TW6+2>R
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M\!>$X-77QCHOPC\+Z!<^(]:G\//X"UC4[74H;:]R_!O_  6=^)W[0W_!%O\
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M\5?%'A)/#FM>(+/7/$_A?1=-N8;_ %'29=6T765/A4 _>BD) Y) &0,DXY)
M Y[DD #N2 .37\ZWQI_X+%_M!?!G]A3_ (*!>.?&?P=^$?@_]O7_ ()R_$#]
MGOP)\8OABVI>+?'?P+\5:1\>/B%\,-*\&?%7P9>V6I^"_%T7@_XD^ /%OBC6
MO!^@:KKR^)O"FK:+:CQ5_:, :QO_ )T_:J\;?\%NM;_:;_X)G'QGIW_!/CX3
M^+/&OQZ^+VJ?!;X:V&O_ +37BSPM9:[#^S7XVUF33?VE+JPO?#L'B:7PEX-U
M/Q1HEB_@/3X4A^(MG%K-A=GPQ?RP4 ?U,Z'XG\->)_[8_P"$;\0Z'XA_X1[7
M-0\,:_\ V'JUAJW]A^)=)\G^U?#VL?8+BX_LS7-,^T0?VAI-[Y%_9^?#]IMX
M_,3=N5_,9\(/^"D.I? WP;^V9H7P=_9@^#5Y^T5\8O\ @N_^U#^Q/\"_A_X'
MOO$OP\\)_$CXC-:^"+W4OVD/VB];UOQ!X_UJ:[L-+5M6^+.M^ -(TG3M8EM?
M#&CZ1X8\%V^HWWB33_O_ .!W[97[7GPX_:^^''[%7_!0SP%^SOI?C/\ :-\!
M?$+Q_P#LR_&3]EO5OB*WPW\;ZG\(]-T;6OBC\(/$7@_XGKJ'B_1?&?A'PYJ4
MOB^W\6G58?#'B'0$MX+?3M.UJ633XP#]=**_E+^&_P#P5^_X*P^+?^"=WAK_
M (*CW7[-G[$>J?LW^$+/4KKXK^ -.\7_ !H\-?&CXDZ/X6^+GB'X?^./&_PH
M;4+GQ)X'^&NA: +6RT.VT#Q?JWQ0UW5;SPWXM\90SQ0W^@> %_JFTO4(=6TS
M3M5MEE2WU.QM-0@2=469(;VWCN8EF6-Y$654D42*DDB!P0KN,,0"]1110 44
M44 %%%% !1110 4444 %%%% !1110!\/?MX_\DR\)_\ 8]VW_J/Z_11^WC_R
M3+PG_P!CW;?^H_K]%=='X%ZL\C%_QY>D?_24?:NH_P#(/OO^O.Z_]$/7"?!S
M_DD7PK_[)QX'_P#48TNN[U'_ )!]]_UYW7_HAZX3X.?\DB^%?_9./ __ *C&
MEUR]'ZK\I'JOXX_X9?G ]'K^-']H/_@WU_;;\;?&'_@HM>_#B]_X)^^*_"W[
M;/Q2\1_%/PC\??C_ *'\0?$?[2'P?TSQ!XJ\2^,]0^&O@)H/AQXD\,?#:7Q!
M?^((_"/B3QSX835=3'@G3DNM(6VU.>RT70?[+J*11_-9^S[_ ,$9/C]X!_:D
M_P""3WQ,^(?B']GU/@9_P3I_9+N_AYX@^'_@_P 1>/=>UOQ3^TSKEO\ % ^*
MOB3X5M=<^%WAC2CX:UOQ)XI\%>.O[3U;5])U^V\1>&[J(:!)$UO=2^S_  3_
M ."2/Q'NOVF/^"QOQL_:@\6?#74M._X*-^#_ !!\"/A-JGPLU;Q3JOCCX>?L
M^>)=!\:^!]6L/%T7BGP;X8TG3/%=UX/C^$<IT_P_J7BK2(];\(7J?VO):1V<
MUW^]E% '\9>O?\$;/^"V_B3_ ()N:%_P2QC^+O\ P3UT#]GSP/XXN-=M_%EK
MXF^/EO\ $#XE>&9?B%KOQ6T_PEXHOU^$>M:-8:'H_P 0]83Q418^%++6[R[T
M;PKIIUI;#2-9?Q/_ $R_%W]G#Q=9_P#!/SQW^R%^S1J?A_PUXL@_90U3]FOX
M-:]XRUC6-!T+PO(OPM;X6^%?$&JZQX;\/^)M8LCX<L?L^KQ2:9X>U&9[VQ@A
M6W1)&EB^SZ* /X\?!G_!%S_@L+X-_8DF_P""6EC^TE^QO'^Q_P#$/Q/X4\6?
M$/XIPI\8I_C;X&TC6[SPUXP^+WPF^'VBMX9T_P ,^(?!/_"R--U;6?#<^J3^
M%=9\;6-]J:^)-9\%Z=XMO/"?AK]/]<_X)4>/;7_@I#_P3P^/O@/6_AKI?[%W
M_!/+]E2_^"_PW^%&M>(?%M[\4KSQ^?!_Q#\"Z7K,L7_"$7/AR71X]&U;X<7M
M]XDN_&+^(KG6_!US?3:)<M=J9?W/HH _F7^ 7_!'3]L/X-_\$IOV^OV6[[XE
M?L\ZU^VG^W+\3O&?B[Q-\38-?^(D?PI'AKX@3>!=#\2:+K/B9_A=%XX><>%+
M;XH:E810?#^[MHO$GC-+%I_[/DN]3@E_:2_X(J_'FY_90_X)'Z)^REXO^"&@
M?M4_\$M]8\(^+K"W^(M]XQ@^!?C_ ,7WZ^!/''Q>U+[3HGA2\\67B:_\:/AU
MHVO:3#>:3X;DU'PYK7B1+V^T#59;(Q_TQT4 ?S*>!O\ @EE_P4\^+'_!17QA
M_P %$/VK_P!H']F+X;_$O2/V6O&?PF_9ANOV:8/%WCH?L\_$;6-"E\,^%+A/
M!'QR^%<GAWQ;X-TZQ\9_%C7/&,NM>*-7U+7_ !)XOO8-$L- T>]L%\,_(FK?
M\$+/^"B/[2GQN_9N^(/[45E_P3E^%OBWX1_&+PU\1OC!^U[^RM#\6? G[47Q
MPM= \3-XBO-1U+PWH'@7P5\#M0^(6LWJ0:@/'NH^!?#GB6PU>STC58-36TM-
M:\->(O[)J* /$OVEO!WQ'^(G[.GQ[^'WP>U?0/#_ ,6?'?P:^)O@SX9^(/%5
M[J6G>&M \>^*?!>M:%X2UW7KW1](U_5;?2-&UV_L=2U!]-T75+W[-:R+;64\
MQ1#_ #D>'/\ @A!^T38? 3_@CE^SAK7Q!^ =]\./V(/V@O'G[0O[7UDNL>.[
MI/BWX@U[XO:1\0O#>D?#:QG^&=M#XAM-.\+-XJ\!:C>>,Y_ LC:;JMI/#;3M
M#*I_JDHH _&W0/\ @G?\8M3_ ."U_C?_ (*2_$_7OA-K/P5\.?LR6'P3_9R\
M+Z5JWBVZ^+'A3Q1<6GAB/Q#K_B;2+[P;I_A'3=.E.M_&W3;.71O&FNWEQIOB
MK1Y)["TFFU&&QP?^"GW_  39^-/[?'[5?_!-KQ[HOB;X4:/^SO\ LA_&2]^+
M/QG\,^,-:\7)XT^('G>+OA?KL.@^&/#FE>"-9\,ZC ='^'E_HLESKGB[PXT<
M?BW4BL<RV\1E_;"B@#\$/A]_P30_:R\*?\%'?^"F/_!16\\<_ R+Q[^T+^SY
MK?P4_8YT73_$GCN^M_!MY;>%O!?A_P &>(?C";[X8V</A8P3_"7X?W>L)X&'
MQ#>,:WXR\A-1>"U_MGX5?_@@'^U)I?\ P1P^'7_!./PA\4O@)H7Q2\5_M?\
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MA=K.M2>&_BM9^,]=U'1X8K&VN=)\0FUM];^TSSM;_P!+%% '\D5__P $<_\
M@JU^U%\)OV-_V&?VWOC1^QAI_P"PC^R/XE^'%UJ,WP'E^,U[\;_C#X/^&'AN
MY\'^%?#.KW'BGPUX?\/VMW9>!;G4?!5IK%C-X2M] DUL^++O1/B#J6AZ9:C]
M1/\ @F'_ ,$W?B;^Q_\ M"?\%$_VF?CEKGPNU_X@_MG?M!:EXU\%V?PSU+Q'
MKNG^ /@W:^(O&?B3POX0NM2\4^"O!-Y8ZJDOC-=+U72-)L]1T5;#PAX8DBUB
M]EB\NT_9FB@ KF_&7_(H>*O^Q;US_P!-=U725S?C+_D4/%7_ &+>N?\ IKNJ
M<=UZK\Q2V?H_R,?X6?\ ),/AQ_V(?A#_ -1[3J[RN#^%G_),/AQ_V(?A#_U'
MM.KO*);OU?YBA\$?\,?R04444B@HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** *>H_P#(/OO^O.Z_]$/7"?!S_DD7PK_[
M)QX'_P#48TNN[U'_ )!]]_UYW7_HAZX3X.?\DB^%?_9./ __ *C&ET^C]5^4
MB7\<?\,OS@:%S\,OAM>>/--^*=Y\/O ]U\3]&TB\\/Z1\1[GPGH,_CS2M!U#
M'V_1--\7RV#>(;'2+[ ^V:;:ZC%97.!YT+XKMZ**11^<O_!2/]D+XE?MA^$_
MV4="^&>N>!M#O/@5^W7^S=^T[XND\=:EK^F6VH^ O@]J7B*\\3:1X<?P_P"&
M?$\MWXOOHM7MET*PU.'2-&N9$G&H:_IBK&TOQS_P6Z_X(_Z[_P %+OA[X8\3
M_ /QIX2^$W[4/@VQ?P#)XI\87WB#0O!7Q2^!^N:W9Z]K_P *_B7JO@_P_P")
M_$-QIGA_Q/8:?X_\!&;P_P"(]/TGQ+:ZM:+I5C-XID\2Z%^\%% 'XFV7['W[
M=7[)_P"U+^TU\<_V*XOV8/B=X$_;$\,_"G5?'OPU_:"^(7Q.^&$?PE^/WPT\
M%2^ _P#A8OA"Z^'?PK^(,'C+P'XOL!!K?Q T*_B\-^,M8UB&TBTK6K"WMO-/
MUY_P3D_8VU7]BK]GW4O!GCGQK;?$OXY_&#XJ_$+]I']I?XC:;;2V&A^-?V@?
MC!?VFJ>/=5\-:;-!9O8^&[%+#2?#NA[[#3)M1T_1(=9O-)TJ^U.YTZU^]J*
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M>^&VLZ=:ZQX*\*>+=1M]3BL-=N7B\ZSM(H5D-_%=3W%C%I>H?J510!_.%/\
M\$>_VF++P9\:O&OA#XE?!+PW^TWI?_!9[XO_ /!4S]EO49]4\=ZK\-KKP?\
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M3+_P':7>E?#[3-.N1<W'Q<U6*R^%'EVFKLGC1UT#7CIO\PO[$W[0?PO\2?\
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M=J5AX1\3:3H'B+P[::-X)NM)LK^UU_0M%UE;K3KRXU32=.O99[.'^7S]EO\
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MX,\:>/)M$-OHWQ*\3RZ;X.\&W6AZE:^)=5TZXN(HF\I_;N_X*\_L;?LJ:/\
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M\&/B7\1-)?5Y=+LVN1!%H_@OPC'=:C+$7DN9+:XN=GF2E:_,K3OV;?BM9_\
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M?!75_&O@K2="\5Z7X:N_C5XK^$7A;QIXX\$:-XU'AX_"J+Q78^(=4O\ 1Y/
M-EXWN/$.D^(PO@>73E\4Q?V/7R=^U=^V)^QC^UQH7_!46?\ 9A\ ^'_C9XP^
M''_!&S]H_2_B%^W5X":VU7P/H6B>)/!OQ!UWPU^RT?%<=J%U77]1EDN?B>UE
MIEY=:9:C2]7T_4)H?$'AR_TVQX7XG^!O!^E?\$=/^"%5_IGAK1M/OO#'QR_X
M(\>-?#MY96,%K=:+XM\:7WP]O?%WB+39X$26TU;Q)>^*?$5YK-Y"RRZA=ZQ?
M75RTD\QD !^L'QY_X*^_\$WOV9OBGJGP6^,_[4_@[PQ\2/#_ -A7Q7H6D^'/
MB'X\M/!%QJ4]Q;VFG_$#Q+\//!WBKPKX U9Y+<F71_&>MZ%JEK#<:?<75G#;
MZIILMUZ?\=O^"C'[$7[,^F_"'7?C;^T9X#\$^&OCYX&\>?$KX->+R=:\1^"O
MB+X*^''ACPWXP\1ZUX:\:^$M(U[PK>"\T'QAX5F\%:>VL1ZK\3-0\0Z/H7PW
ML?%FO7]OIDG\HOQ;_:_UGQ7X'_X*K^ K']IGX+_L#ZGK/QW_ &L?A4/^"<WP
M7_9=TKXD_M6?MA_$_P ;>'+[PG8>+/B%XE\;/XWU.77/CI+!IOAOQ)XS^#_@
MB7POH^ER2ZVWB3P[J M=5NOICX!S^#OB-\3?^#1=XCI7BK1+#]F[]M2V??&E
MY9VWB_X7_LA?#2UN$*2IM75/"'C[PE(BN%W6>M:()(F+P(] 'ZU?';_@JG^S
M3\2?V#_VD/VCOV0?VUOA+X$N?@AK'PST'Q=\5?'WPD^+'CB'X,ZKXP^*GA'P
MK:V_Q&_9^M/!UM\9U3QK!>:WX/\ #%V?!*6:Z])>ZF+A[/PEXBDT[WS]HK_@
MK'_P3T_9/^+-Q\#?CY^TKX<\#_%+3M,TS6?$'A:V\)?$GQF?!VFZW;V-YH]U
MX_UGP%X+\4>'OAZNJV.J:7J&G1^-]6T":\TW4]-U&WCDLK^TGF_G!_X+3:+I
M&DP_\'"5QI>EZ?IT^O?L]_\ !'S6M;FL;2"UDU;5V_::72VU347AC1KS4&T[
M2].L6N[@R3M:V-I TAC@C5?H/]L[X@_![X!?MX?MZ^,?!'[?%]^P/\7/%'@G
MX2^+?V@/@!^VG\"OAO\ &/\ 9-_;D\%Z9\*)/!GA:]^#&FV6O_\ "?ZIH5WH
MFG7/@OQ[:>%'NOB#-XD'B31HO#$ME'>6&G@'[T_M _\ !2K]A?\ 9;T;X.>)
M?CG^T?X'\&^%?V@_"7B_QU\%?&%I;^)/&?@WXD>$_ VB^%O$.NZSX9\7^ ]"
M\3^&KN"?2?&WA2X\,0OJD5UXYEUVQLO!%OXAOG:V3P&;_@N7_P $I8?AGIWQ
M;/[8?@Z7PCJGBG6/!MM9VO@GXMWGQ BUSP[I>GZSKYU'X16GP^G^+&D:)HFG
M:KIL^K^*M6\$V7A;3FO;>WO-9ANI%AK\L]/O=<^+?[6'_!K?K_QB_9T^'_[/
MFOZQ\/O^"A?C"X_9_P#!WA./POX!^&U]X=_9O\#>)_A\?"O@:XB$G@B"S;1_
M"_C?0_"MT'U/P-J4MKI-S<S:GHTET_V'^RAX*\(-_P %/_\ @X+W^&-!D35]
M/_89TK5(9=*LI;:_TWQ%^QWJ>L^(K&ZM9(6MYK7Q#JNHWNHZ_"\136KR=KC4
MQ=2)&R '[B>"O&OA#XD>$/#/Q ^'_B;0_&G@?QIH>F>)O"7BWPSJ=IK/A[Q)
MX>UFTBO])UG1M6L)9[/4--U"SGAN;2[MII(IHI%=&(-=/7Y6?\$0?^437["G
M_9#M*_\ 3SK=?JG0!\/?MX_\DR\)_P#8]VW_ *C^OT4?MX_\DR\)_P#8]VW_
M *C^OT5UT?@7JSR,7_'EZ1_])1]JZC_R#[[_ *\[K_T0]<)\'/\ DD7PK_[)
MQX'_ /48TNN[U'_D'WW_ %YW7_HAZX3X.?\ )(OA7_V3CP/_ .HQI=<O1^J_
M*1ZK^./^&7YP/1Z***105^/7[:'_  33_:-^/'[4?A+]JO\ 98_X*)_$G]C3
MQ7I/@"#P/XN\"'X4:3^T%\(_&USIKZ_#HGB^\^%OC;Q_X:\ +XGT_2O$E[IW
MV_7?#7BIX)=.\/ZQH1T#6M+EO[[]A:* /S(_X)@_\$T_#?\ P3>^&WQ4T>Y^
M+?B7]H;XT_'WXI:I\7OCE\>O&>@VOAWQ%X]\4W\12W@.F1:QXEO[;2K&ZN==
MU\)K?BOQ1JUSXH\7^+=6FU<0:I;:;I_Z;T44 58;&RM[B[O+>SM8+N_,)OKJ
M&WABN+PVZ-';F[G1%EN#!&S)"9F?RD9E3:"02ZL;*]-L;VSM;LV=S'>6ANK>
M&X-K=PY,-U;&5',%S$23'/%MECR=K#)JU10 4444 5(["QBNY]0BLK2._NDC
MCNKV.VA2[N8X0%BCGN5033)$JA8TD=E0 !0 !5NBB@"J+&R%Z=2%G:C43;?8
MS?BWA%Z;3S!-]E-UL\\VWF@2^09/*\P!]NX U:HHH **** "BBB@ HHHH **
M** "N;\9?\BAXJ_[%O7/_37=5TE<WXR_Y%#Q5_V+>N?^FNZIQW7JOS%+9^C_
M ",?X6?\DP^''_8A^$/_ %'M.KO*X/X6?\DP^''_ &(?A#_U'M.KO*);OU?Y
MBA\$?\,?R04444B@HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** *>H_\ (/OO^O.Z_P#1#UPGP<_Y)%\*_P#LG'@?_P!1
MC2Z] NXFGM;F!"H>:WFB4L2%#21LBEB 2%!(R0"<= 3Q7B'@Y/C'X2\(^%?"
MO_"!>!-0_P"$9\-Z'X?^W_\ "S]7M/MO]C:9:Z;]K^R_\*QN?LWVG[-YWV?[
M1<>3O\OSI=OF,UL]MUNTN_<B3M*+:=N62TC*6K<-[)V_X<]VHKRS^W?C'_T3
M?P)_X=?5_P#YU=']N_&/_HF_@3_PZ^K_ /SJZ+/R^]?YASKM/_P7/_Y'S_/L
MSU.BO+/[=^,?_1-_ G_AU]7_ /G5T?V[\8_^B;^!/_#KZO\ _.KHL_+[U_F'
M.NT__!<__D?/\^S/4ZK7-E9WOV?[9:6MW]DNHKVU^TV\4_V:\@W>1=V_FH_D
MW4.]O*N(]LL>YMCKN.?-?[=^,?\ T3?P)_X=?5__ )U=']N_&/\ Z)OX$_\
M#KZO_P#.KHL_+[U_F'.NT_\ P7/_ .1\_P ^S/4ZK2V5G/<VMY/:6LUY8^?]
MANI;>*2YL_M48BN?LL[H9;?[1$!'/Y+)YL8"2;E %>:_V[\8_P#HF_@3_P .
MOJ__ ,ZNC^W?C'_T3?P)_P"'7U?_ .=719^7WK_,.==I_P#@N?\ \CY_GV9Z
M)J&E:7JT20:KIMAJ<$<@FCAU"SM[V))0K()4CN8Y460([H'50P5V7.&(-X
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MSVXM6O;03&XCZ#^W?C'_ -$W\"?^'7U?_P"=71_;OQC_ .B;^!/_  Z^K_\
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MIVR(KKAE!$Z(D:)'&BQQQJJ1QHH1$1 %5$50%554 *H      %>7?V[\8_\
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M[ZXL7\VRGO+.VN9K.3?')YEK+-&[V[[XHGWPLC;XXVSE%(\\_MWXQ_\ 1-_
MG_AU]7_^=71_;OQC_P"B;^!/_#KZO_\ .KHL_+[U_F'.NT__  7/_P"1\_S[
M,]3HKRS^W?C'_P!$W\"?^'7U?_YU=']N_&/_ *)OX$_\.OJ__P ZNBS\OO7^
M8<Z[3_\ !<__ )'S_/LSU.BO+/[=^,?_ $3?P)_X=?5__G5T?V[\8_\ HF_@
M3_PZ^K__ #JZ+/R^]?YASKM/_P %S_\ D?/\^S/G']O'_DF7A/\ ['NV_P#4
M?U^BNA^.OPT^,/QO\-:3X;?P]X"\*#2]=CUO[<WCW6=;%P8]/O[#[)]F3X>Z
M68BWVXS>?YT@'D^7Y1,@=2NBE*,8V<DG=];_ )'G8BG4J592A";BU&SY6MDE
MLTG_ $^S/K:^YLKP'D?9;C_T2]?SX0^*_%%O#%;V_B37X+>"-(8((=8U&*&&
M&)0D44427*I''&BJB1HH5% 50  ***FCM+UA^;-\7O2]*GYTR3_A,?%W_0T^
M(_\ P>:G_P#)5'_"8^+O^AI\1_\ @\U/_P"2J**U73Y?^XSD#_A,?%W_ $-/
MB/\ \'FI_P#R51_PF/B[_H:?$?\ X/-3_P#DJBBA=/E_[C /^$Q\7?\ 0T^(
M_P#P>:G_ /)5'_"8^+O^AI\1_P#@\U/_ .2J**%T^7_N, _X3'Q=_P!#3XC_
M /!YJ?\ \E4?\)CXN_Z&GQ'_ .#S4_\ Y*HHH73Y?^XP#_A,?%W_ $-/B/\
M\'FI_P#R51_PF/B[_H:?$?\ X/-3_P#DJBBA=/E_[C /^$Q\7?\ 0T^(_P#P
M>:G_ /)5'_"8^+O^AI\1_P#@\U/_ .2J**%T^7_N, _X3'Q=_P!#3XC_ /!Y
MJ?\ \E4?\)CXN_Z&GQ'_ .#S4_\ Y*HHH73Y?^XP#_A,?%W_ $-/B/\ \'FI
M_P#R51_PF/B[_H:?$?\ X/-3_P#DJBBA=/E_[C /^$Q\7?\ 0T^(_P#P>:G_
M /)5'_"8^+O^AI\1_P#@\U/_ .2J**%T^7_N, _X3'Q=_P!#3XC_ /!YJ?\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
%BB@#_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>nt10014672x1_diagram3.jpg
<TEXT>
begin 644 nt10014672x1_diagram3.jpg
M_]C_X  02D9)1@ ! 0$ P #   #_[0 V4&AO=&]S:&]P(#,N,  X0DE- ^T*
M4F5S;VQU=&EO;@     0 ,     !  $ P     $  ?_B"^!)0T-?4%)/1DE,
M10 ! 0  "]!N;VYE @   &UN=')21T(@6%E:( ?4  < %0 3  L (6%C<W
M         $E%0R!S4D="     0            #VU@ !     -,M2% @(
M
M$&1E<V,   %$    =&)865H   &X    %&)44D,   ',   (#&1M9&0   G8
M    B&=865H   I@    %&=44D,   ',   (#&QU;6D   IT    %&UE87,
M  J(    )&)K<'0   JL    %')865H   K     %')44D,   ',   (#'1E
M8V@   K4    #'9U960   K@    AW=T<'0   MH    %&-P<G0   M\
M*&-H860   ND    +&1E<V,         &G-21T(@245#-C$Y-C8M,BTQ('=I
M=&A"4$,
M                                                    6%E:(
M     "2@   /A   ML]C=7)V        !      %  H #P 4 !D '@ C "@
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M;W5R(%-P86-E("T@<U)'0@
M
M      !865H@        8ID  +>%   8VEA96B            !0
M;65A<P         !                               "6%E:(
M  ,6   #,P   J1865H@        ;Z(  #CU   #D'-I9R      0U)4(&1E
M<V,         +5)E9F5R96YC92!6:65W:6YG($-O;F1I=&EO;B!I;B!)14,@
M-C$Y-C8M,BTQ
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MU=;7V-G:X>+CY.7FY^CIZO'R\_3U]O?X^?K_Q  ? 0 # 0$! 0$! 0$!
M     0(#! 4&!P@)"@O_Q "U$0 " 0($! ,$!P4$!  ! G<  0(#$00%(3$&
M$D%1!V%Q$R(R@0@40I&AL<$)(S-2\!5B<M$*%B0TX27Q%Q@9&B8G*"DJ-38W
M.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U=G=X>7J"@X2%AH>(B8J2
MDY25EI>8F9JBHZ2EIJ>HJ:JRL[2UMK>XN;K"P\3%QL?(R<K2T]35UM?8V=KB
MX^3EYN?HZ>KR\_3U]O?X^?K_V@ , P$  A$#$0 _ /[^**** "BBB@ HHHH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M]DS_ .A3H_X9>^)7_1]?[7__ (#_ +)G_P!"G7U_11_8^"_FQ_\ X=LV\O\
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M"?\ T-^7Y]V?('_#+WQ*_P"CZ_VO_P#P'_9,_P#H4Z/^&7OB5_T?7^U__P"
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M]DS_ .A3H_X9>^)7_1]?[7__ (#_ +)G_P!"G7U_11_8^"_FQ_\ X=LV\O\
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M+FR\16_AC3='\,G4-*O;2PDTC1-+$FD/?Q3WUS^[E% 'R[\._P!B?]DSX7>
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MWJD&DZIXCCNDU2ZU?4?#^A3-=00:9;6L?Z[T44 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110!\M_L-_\F4_L??]FM_L_?\ JIO"5?4E?+?[#?\
MR93^Q]_V:W^S]_ZJ;PE7U)7FY-_R)\J_[%N!_P#46D?8>(?_ "7_ !S_ -EA
MQ-_ZNL:%%%%>D?'A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %?('AG_D_KXV?]F@?LO?\ JY_VOJ^OZ^0/#/\ R?U\;/\
MLT#]E[_U<_[7U>7F/^\9-_V-'_ZK<R/N>#_^13XC?]D-#_UMN##Z_HHHKU#X
M8**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ^6_V&_^3*?V/O\
MLUO]G[_U4WA*OJ2OEO\ 8;_Y,I_8^_[-;_9^_P#53>$J^I*\W)O^1/E7_8MP
M/_J+2/L/$/\ Y+_CG_LL.)O_ %=8T****](^/"BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH *^0/#/\ R?U\;/\ LT#]E[_U
M<_[7U?7]?('AG_D_KXV?]F@?LO?^KG_:^KR\Q_WC)O\ L:/_ -5N9'W/!_\
MR*?$;_LAH?\ K;<&'U_1117J'PP4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M#'XA^$?'MO8AI&B4WDWA76-5CM@TJ/$#.R9D5D'S*0/5:_F1_P""R7_!./\
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M +7U?7]?('AG_D_KXV?]F@?LO?\ JY_VOJ\O,?\ >,F_[&C_ /5;F1]SP?\
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M[48QIWE:E?I<_5,<<<,<<44:111(L<44:JD<<:*%2.-% 5$10%55 55
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MSX4UZ\\9:3=ZWX:G>Y:70M7NM*TRXU+2WM;V?3[.69K:/K/^'S/Q&_Z0Z?\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** /EO]AO\ Y,I_8^_[-;_9^_\ 53>$J^I*^6_V
M&_\ DRG]C[_LUO\ 9^_]5-X2KZDKS<F_Y$^5?]BW _\ J+2/L/$/_DO^.?\
MLL.)O_5UC0HHHKTCX\**** "BBB@ HHHH ^0OCG_ ,G)?L=?]A_XP_\ J"6=
M?7M?(7QS_P"3DOV.O^P_\8?_ %!+.OKVM)_!2_PR_P#3DB(_%4_QK_TW3"BB
MBLRPHHHH **** "BBB@ HHHH **** "BBB@ KY \,_\ )_7QL_[- _9>_P#5
MS_M?5]?U\@>&?^3^OC9_V:!^R]_ZN?\ :^KR\Q_WC)O^QH__ %6YD?<\'_\
M(I\1O^R&A_ZVW!A]?T445ZA\,%%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 ?+?[#?_ "93^Q]_V:W^S]_ZJ;PE7U)7RW^PW_R93^Q]_P!FM_L_
M?^JF\)5]25YN3?\ (GRK_L6X'_U%I'V'B'_R7_'/_98<3?\ JZQH4445Z1\>
M%%%% !1110 4444 ?(7QS_Y.2_8Z_P"P_P#&'_U!+.OKVOD+XY_\G)?L=?\
M8?\ C#_Z@EG7U[6D_@I?X9?^G)$1^*I_C7_INF%%%%9EA1110 4444 %%%%
M!1110 4444 %%%% !7R!X9_Y/Z^-G_9H'[+W_JY_VOJ^OZ^0/#/_ "?U\;/^
MS0/V7O\ U<_[7U>7F/\ O&3?]C1_^JW,C[G@_P#Y%/B-_P!D-#_UMN##Z_HH
MHKU#X8**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ^6_P!AO_DR
MG]C[_LUO]G[_ -5-X2KZDKY;_8;_ .3*?V/O^S6_V?O_ %4WA*OJ2O-R;_D3
MY5_V+<#_ .HM(^P\0_\ DO\ CG_LL.)O_5UC0HHHKTCX\**** "BBB@ HHHH
M ^0OCG_R<E^QU_V'_C#_ .H)9U]>U\A?'/\ Y.2_8Z_[#_QA_P#4$LZ^O:TG
M\%+_  R_].2(C\53_&O_ $W3"BBBLRPHHHH **** "BBB@ HHHH **** "BB
MB@ KY \,_P#)_7QL_P"S0/V7O_5S_M?5]?U\@>&?^3^OC9_V:!^R]_ZN?]KZ
MO+S'_>,F_P"QH_\ U6YD?<\'_P#(I\1O^R&A_P"MMP8?7]%%%>H?#!7F7QK^
M)$'P;^#?Q:^+USIDNMVWPJ^&7CSXD7&C03I:SZO!X&\*ZKXGETR&ZD22.VEO
MX]+:TCG>-TA>42,C*I4^FUR?CWP=I7Q$\"^-/A_KPD.A^.O"?B/P=K(B$9E.
ME>)]'O-$U$1B57B,AL[Z;8)$>,M@.K+D''$JM+#UXX:2AB'1JJA.23C&LX25
M*4DTTU&?*VFFFEJK'I9-/+:><954SFE4Q&44\RP,\UH4I3A5K9;'%4I8ZE3G
M3<:D*E3"JK"$J<HSC*2<6I),_%[]G+]A2P_;F^ G@[]HS]NCXF_%WXL?$'XV
MZ./B%X=\*Z1\1O$/@GX9?!_0-?CC;P?;?#GP3X8O;/1+#4E\.0Z?J.H7E];7
M<%U>ZA*NHZ??ZE#>:SJOUY\)'^+'["?[/7QNUC]JOXI77QG^%WPD\0^(=?\
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M[P,\JPU6-'*<9A93Q5/$XMRIX/ 8:MCE@?9X.KAZ[:J<G"?AYX.9_B<3G/\
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M,5/!5*&79?\ H_1117W)_+P4444 %%%% !1110 4444 %%%% !1110 4444
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M^#B'_I%#^S1_XESX!_\ G@4 ?T'T5_/A_P -9_\ !Q#_ -(H?V:/_$N? /\
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MBBB@#Y;_ &&_^3*?V/O^S6_V?O\ U4WA*OJ2OEO]AO\ Y,I_8^_[-;_9^_\
M53>$J^I*\W)O^1/E7_8MP/\ ZBTC[#Q#_P"2_P".?^RPXF_]76-"BBBO2/CP
MHHHH **** "BBLG7I-9AT/6)O#EM8WGB"+2[^70[/4YI;?3KO5X[65].M;^Y
MA#36UG<78AAN;B)7D@A=Y5CD9 C 'RQ\<_\ DY+]CK_L/_&'_P!02SKZ]K\#
MO'W[=/CGQ#\2_AGXPUCX<:'HVM?!O5O&+)H;WVK)]KO?$.E)X?U"SU5;A$N;
M.733;LPC1!(+@/%,J[2*_6;]F'XM>-OC=\-U^(GB_P +Z3X3M=6U6]MO#-EI
MES=W3:AI6FO]CN=7GDNWW1I/JL=]8VT'E1MLTY[HM+#=P%=ZE.4:=-NUHIIZ
MK5N<FDN^CN8TZD)3FDVVWS+1K10A%WNM-4T?1=%%%8&P4444 %%%% !1110
M4444 %%%% !1110 5\@>&?\ D_KXV?\ 9H'[+W_JY_VOJ^OZ^0/#/_)_7QL_
M[- _9>_]7/\ M?5Y>8_[QDW_ &-'_P"JW,C[G@__ )%/B-_V0T/_ %MN##Z_
MHHHKU#X8**** "BBB@ K!T[PKX7TC5M7U[2?#>@Z7KOB!H7U[6M.T?3[+5M;
M>WW"!M7U&VMXKS4F@#N(6O9IC%O;85W'.]12<8MIN*;B[Q;2;BVFFTWLVFU=
M=&ULRXU*D(U(0J3A&K%0JQC.48U(*<:BA42:4XJ<(349)I3C&25XIHHHHID!
M1110 4444 %8/B#PKX8\66]K:>*?#F@^);2RO(M1L[7Q!H^GZS;VFH0!UAOK
M6'4;>YCM[R%7=8KF)4FC#N$<!CG>HI2C&2<914HO>,DFGZIW3+IU*E&<:E*I
M.E4@[PJ4YRA.+LU>,XM2B[-JZ:T;0@         &  .  !P !T%+113("BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** .9TWP5X-T;Q!K?BW2/"7AG2O%7B5;=/$?B;3=!TJQ\0>
M($M%1+5-;UFUM(M1U5;9(XTMUO[F<0JB+&%"@#IJ** "BBB@ HHHH **** .
M:\4^#/!_CG34T;QMX4\->,=(CNH;Z/2O%.A:7XATV.^MMWV>\2QU:UN[5;JW
MWOY-PL0FBWMY;KN.>C1$C1(XT6..-52.-%"(B( JHBJ JJJ@!5       IU%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MU>7F/^\9-_V-'_ZK<R/N>#_^13XC?]D-#_UMN##Z_HHHKU#X8**** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH ^6_V&_^3*?V/O\ LUO]G[_U4WA*
MOJ2OEO\ 8;_Y,I_8^_[-;_9^_P#53>$J^I*\W)O^1/E7_8MP/_J+2/L/$/\
MY+_CG_LL.)O_ %=8T****](^/"BBB@ K^9S_ (./OB:UIX%_9H^#5M=Q.GB#
MQ;XV^)NLV*R1F:W;PAH^G>%?#-W-%GS4BO!XX\60VTFT1R/8W:@EHB!_3'7\
MY'[6OP0^,O[1O_!:/]FN];X,_%%?@?\ !2+X7#4/BC>?#WQ7)\)M1E\$2>(?
MCMJ#'QJ^D2>$Y8[_ %/4M/\  4\4FI".XU^S&@2(;TF!O@/$J&)Q7#$\IP<:
MCQ&>YEE63PG3ISJ^QCB<;2J5:LXP6E)4:%2-24Y0@HS:<XMH_J[Z&-?),E\;
M<-QYQ%6P=/*/"_@WCGQ!Q%#&8O#X*./K9-P[C,)@,%AZN(=Y8V>8YGA*N$I8
M>EB,1*M1C*&'J1C.WS;^T1_P5]_9\^)7[(]S^QI^SO\ L^_$SQK?ZO\ #+0O
M@GX6N?B9X<\)-8Z/8:=X?L_"VG>(_#_A[0=<\<:MJ_BW2K:UBN/"!2'1[S3-
M>&GZY%=)<Z<EC<\/\?OA=X[_ &)/^")WA'X/?$"272/B%^U+^T)H/C?Q3X)O
M5N;75?"GA^;0K#Q?;:#J%AJ'E7=KJ6CM\,/ 4_B>P%G:-HGB77;G2+F*2>VE
MO+O^O*STK2]/9WL--L+%Y%"R/9V=O;,Z@Y"NT,:%E!Y 8D \@9K^:W_@O1\/
M_CQ\:OB7^S3X'^&?[/?QQ^+'@WX?^'/%GC+Q1K7PR^&WC?Q9HMQ>^.-?T;2#
MX;DUWPWH&LZ?8:_INE> 9[LV\Y^U6=IXEL;R2W>"[@W?'<7\-9IEF2YUGF/S
M5YWFDLEAPWE6&R_*/[.H83!YABZ-'%VHX>OC:V(DL+*M[U25HTE.%FW!P_HG
MZ/OC+P3QKXD>''ACPIP+#PTX'H>)&(\9>.LYXJ\0'Q;FG$'$7">18_'Y"YYA
MF^6\.Y?E5*6>4,N7L,'1Y\3C98:NYTHT\3&OXO\ "#_@I9\7/V3_ -ACPM\&
MW_X)S?%.?PGX,^'%YHEU\3/B=!XNMOA+J]YXZU*_O;OQ#XETO4?A8NGWGA;Q
M#XA\5RNOAZ3Q7!;ZS;ZA!HMOK%NM[#,GJ_\ P2=T#PM^S+_P3H_;!_;!T;XD
M^&/$OCCQ)X/\3ZG>Z3X?GF@@^'NL?"WP=XDO_!/@S6[6^L],%IXRU3Q#XR-U
M-;6]J^E2V&J>&ET:\OK>8W$WIOQE_P""D_[9_P 2_A#X_P#A5X1_X)*?M.>'
M-0\?^"?$/@"UUCQ)X3^(^N:#H-GXHT.]\/RW]QX?D^!>G66KQV5O>DIIFH:A
M8Z7*!_I\SVB2VT_S!%^Q7^T;^S-_P2 ^*_P\;X.?$CQ?\??VK?C%X%.O?#WX
M=^'M<^('B/X?^ O#>HV/B'1V\0Z1X+7Q!!9FYMO VJ2:QJ-NNVU_X3[P_P"&
M]::WUBQ^R0>-1JXFAF>%QF!QN8<38/A?@_.HX'$5^'\3DL<FQGU&.$P-'"VP
M>&>.KXQ1I8:%.K&K4I4G4KQFW"?+^D8[ Y)FO!6<\/\ $_#7"/@MQ)XW?2%\
M-:W%&4Y9XLY-XEUO$7(%Q++B#B;,\\53B'.H\,99D%2MC\[KXO!8C 8?&XZ.
M#RVMA:5/$87V_P!=_P#!N[\+XO#O[+OQ;^*=S:30:G\3OB\VA0S2%3!?^%OA
MUX;TV+2IX5QG]WXC\6^-+.4L2&:V  &W+?(5UX6\*_"W_@X8\(^%_@/X>TWP
MS8G7-,D\4>&-&L;;1O#EE<>+/V?+S7?B ^E6&G7-O:K;SZ#JEQXEFA6.WA3Q
M++>!=/E$,:3]O^RC^V5^VO\ LI?LH^ OV;OA]_P2R_:6UWQ?X/L/$UM8^//%
M?@OXJZ?X:NO$/BSQ7XA\52:UJ_ANV^$UK=S:?9W^O+:MIS>,M+:2PM$0Z[8(
MB;/K3_@F#_P3C^,'PU^*OC+]MG]M'4GU;]I?QW<>()=!\-RZEI>KW'@__A*A
M)%XE\5>(M1T&6;0CXGUJPFGT#1/#OAZ9O#_A#PG/=V9,U[J=OI?A'LRS#PSC
M*O#KAS)L%C)U\AS#*\[SO,ZV78O!8?*OJ_/B\=A(8G%X>BJV*QF+KSA2AAO;
M0JNC[2I[BYX?.\9YOB/#[CSZ7WC%XB\2</8?*_%+A'C7PU\->"\NXPX?XDS;
MCQYNL)D7#&>XC)N'\WS*6 R3A_(,LP^(Q];.5@,3@:>9_5<,E7E]6Q/[MT44
M5^^G^404444 %%%% !1110 4444 %%%% !7R!X9_Y/Z^-G_9H'[+W_JY_P!K
MZOK^OD#PS_R?U\;/^S0/V7O_ %<_[7U>7F/^\9-_V-'_ .JW,C[G@_\ Y%/B
M-_V0T/\ UMN##Z_K^:'_ ()&^/?%/PO_ &I?BAX*\7:K=7?@3]KO7OCEJWPU
MGU"YNIU@^*O[./Q*\10^+/"6E027$T<;7'PW\4Q>*=4O3';K-%I^E6*J[68=
MOZ7J_G'\._ 7XX^"_P!C;P[\:O#7PA^)+?'S]EG]OSXA?'CP?\.%\$^);'XA
M?$CX9^)?B2WASQUX.T#2Y=,&NR>'_'O@O6_[:GOM-TR_35=*\. 6,=RLBM7R
MO%\,33S7A[-,-"O.62TLWS*I&C"<_:8>G4RFECZ#A!-U*M;*JN8+#4DG.>(C
M3<(3E'E?[K]'S$9+B^ _%_@G.L3EF&I^).-\/^#,)5S"OAL.\+F^,PW'F.X5
MS*-?$3@L+@<OXYP/"57.<:Y0H8?*9XJ.)K4*5;VL8_VA_B%XJ^+?_!77]G+Q
M!H^KWB?"'X%_'+PS^S3IL-K>2RZ-XB^*<O@G7OB=\6;N)(IUBM]0\+QZUX*\
M':[:S02&:XTZS9'C^RR";]'OB-^W/\5;?QM\3?#O[._[&?Q0_:,\+_!#Q#=>
M$?BUX\L_&_@SX:V.G^*=+L++5M=\/?#_ ,/^*EN?$GQ,U31M-U&S>YAT>PL8
M[J[E2#3I;RWN+"]O?C#PW^S5\7?!FA_\$L=2USP/XL\0?$;5?VFO'7[1O[3N
MO:5X.UB23PSXX^,^A:QXO\0ZA\1GL;*:#PY+H$^LZ=X%N+_6)+.U\_P]!:+,
MSJ@/!:Y=?$7X@_$[]I&/]K_P1_P4'^(7Q!T?XN>,/"GP'_9Z^!<7QD\%_LN>
M-OA7&MJWPNOAXS^&MKX3\/,\VH/=S^+_ (A>,/'&DS6^D'3[S48))])O;&R^
M9P^,S?+UF=1UL9@,9GN<PS&I6=&CRX=8C(L%C*> GB<7@\RI4OJOM*6!A1H9
M=C<1BY82I1P_)5YZK_;,VX=X XN?!6$C@.'.*^'_  P\.,7P?A<OI9CF3K9K
M/*?%+/N'<5Q30R?(.(.#,PQZSM87'\3U\?FG%_#>3Y%1S["YEFSKY<J.!7Z-
M_##_ (*)_#[XL^(_V1AX<\$^(K'X;_MD>&/BK<?#KQYKU]:6%_H?Q%^$%[>V
M_BCX;>*_#%O;7UG9W-S%I>J#0]?M/%=W:ZWJ-C)I^FV%S&Z7Q^=_^"@O[=?Q
M4\)>&/VP?A/^SE\.-;U;6_@!\*? >H_%#XY:/\0- \*W/P>USXL1:GJ.CC3/
M#FN:0]SXFN[#PE8V^K/>>'-9;5[2[UJ""UT^WNM-DOD^:_ OP/\ B?X6_P""
M+_PTO-6\&>)?AO\ M!?L0^.O&G[2OAO1OB#HFK^$KO3M?^$GQJ^(?Q$U(RVF
MIPV,VL:%XB^%FO:[;V+P&;2-;N+ZU%O-=+"C5ZAX:^"?Q*^('_!*/]JCXBOX
M7U77/CO^VWIOQ(_:9U'PKI<5QK^M2V7C6[M-8^&W@?PQ#:)=ZKJ<-C\+]'\.
MKX:\.0Q27D&I:I<:+9VJSN(VZ:F<<39CECP,JN(PV-QO"\.)*F)PN$I4JM&A
M4R!X>OE%%3HU/98U<1VJIN+Q=/!594:4XU::KT_!P?A[X*<(\;PXHI8+)\WX
M<X;\<*W@W@\FSS/L;CL!F69X3Q7IYKE7B!F-3"YEA5CN&Y>#[G@:D(UZ>0XG
MB3!4LPQN'JX#&3RW%_6FC?MB?$7X>?LW?LSW7B[]G3XA^)OVC_C;IJ^&/A[\
M#_#_ (V\*>*-4\4W'ACP^VJW'C+Q1\59+J+P?X:T?5O"-E;>--3N]7N;K5M+
M.L+IUY8W5S8:S=V-3P9_P41UB74OCS\.OC7^S3XY^!7QZ^!?[/WC#]I2?X;:
MOXR\+>,_#'C;X;>%$>#[?X6^)WA>*33;A[O63;:/.[:"\%G<37 ADU&YTO5+
M.T^//BQ\8OCI\1?A7^PI867A#]M3X'?LSZWHWB+P9^T[=?!WX:^-="_:5\+^
M*_ /A/3-*\%VS0:'X;U_Q=H7PWU?Q/8R7;>(_"UM<GQ5H#ZCIE]%9:A#!I,W
MA/@[X/\ B'_AHG]J;Q=\*_V<OVNM%^%7Q#_X)E?'_P"$W@GQO\;]&^+_ (N\
M;?%CXJ3:SI^N2ZAJO_"<W6O^(_".J^+OLMQI?A'P;J$/AR;Q(-)MM=T+PNDW
MB:1[@K<1YQ2Q.#I9?C<7B*%*.782<,1A,+%XBGB,FI8EY@J-++IXFJ_K-:FG
MCI8G+,OAB.;+XY=6JTW.L\M\'_#S&Y-G^-XMX8R+*,SQU?BW/</B,IX@SVI3
MR;&95XCXS)H<)2S#&\84,FP,%DF!Q=2'"T,GXWXLKY0J/%E3C#+L%C(X7+_M
M./\ X*YZG8?#GX??M"^*_P!C3XT^'?V5/%UOX2L]?^.Z^(O"FHQ^%O$OB2*W
ML;Q(/ ;+8>)-9\"Z/XL>Z\,P_$*\;P]8:_+;6\^C:5<7FKZ/I-]]#_%#]N/X
M@:;\</B3\#?V=_V4_&W[2NN? FP\&:C\=M4TGXC_  ]^&]KX+C^(&A2>)_"N
MG^%[#QE=G4/B'KE]H%M>7DNF:3%IZQ7,,>G17=Q>3&.+Y)_:+^$?Q3UK_@A;
MX>^$6A_#'X@:M\5H?@1^RUI,_P ,-)\%^(K_ .(46L:!\0?A%?\ B'3)?!5G
MILOB2/4M%M=.U.]UJR?3!=:=!87]Q?1PQVMP\?._M<> OAOXC_:Y^)>M?%GX
M ?MC?!CQCIOA+P;-\'/VP?V'(?B=XA\2_%W28-&E75_"_BU? GAS7M&\-^*=
M U-=-\,:;!KFC/K%[8:3;RZEXDTGPQ'X1:\UKYKQ-A*5.G6S6K+V^#X:S"IB
MJN#P>!G2J9G0XA_M#+\/BO[(QN7X6-*MEN!J4I9IA9RY:T\%/'4L1C,'6AQ9
M5P)X*9]C\9C,#P)@J*RSB'QEX3PN28#B+B+B7#X[#<%YMX1+A3BS-\E?'_#?
M%N=UL9EG&G%.$QU'@?.\-3=3+\-Q+A^&<9E/#_$. Q/T_P#M/_'CX2?$KX$?
ML7_%SQ#\-?BC>^'?B9^UY^SW!X*\-:SJ.H?!_P :>#/&NH:SXFL=%UKQEI-Q
MI>LR:IIN@7UC?&^\,QNNE>*K66TOM,\02:7+9W]U@7__  4Q^(VM>*OV@O!O
MP8_8G^*?QKUC]FSXL>._ ?Q$N?#?CCPWH^AP^%O!QB2R\4:9?ZSI,=[KGBWQ
M++:>(C8?"[P[I6MZW#;Z-;3-JL[ZW8P+\[:[X1_:Z^)'[#7_  3T_P"%S^#/
MBCXM^,/A[]N7X%>*_%MIJ7A'4]1^)/A_X4^&?&_CJ'0/%7Q;LM&LKB?3-0TS
MP6?#]UXO\0ZY!975JUW;3>,YX_$TVK3S?:7_  3Z\">-/!?BW]OR[\8>#?%'
MA.'QG^W?\8?%WA&Y\2^'M6T&+Q7X1U+3?"Z:7XG\.3:I9VJ:[X;OY(;I=/UK
M3&NM,NGBN%MKF1DD Z</C,[S'-,'##XC%953S3 Y97Q>*64X*&+4GDN)Q7+4
MABJ&,I4:D<4H1G1JRQ"H*53#PDI251>3F_#OAEPAP)Q#B<WRG(N/,7P1Q/QM
MEF19%/C[B2OD%2FO$C)LC5?!ULCS+(,=F&$JY(\36H8_!4,IEF52EA<VQ-*=
M&C4PE2/6/^"FGPFF^ 7P$^,WPU\ ?$WXI^*_VH+[Q'HWP/\ @?X?TO3X?B-X
MGUOP5?ZAIGCJ'4E6_OM)T?1O!-[IEPGB77X;O5;.S@EL[V".ZLYWGA]+_9Y_
M;#U#XI_$_P 1?L^_&7X(^,/V;?VA_#G@RV^)0^'/B7Q#X;\=:%XG^'-WJ=OH
MJ>+?!7Q#\(2MH7B*VL=9N(]*UFS%M97.G7Y>U47<]EK$>E_B#\//V8OBUX2_
M91_X);_$[Q]\%OVC;S1O@#X@_:K\)_';X6?#*W^*7@#]HGPKX;^-7Q*\7MX8
M\;:#H/A";PQ\28;'26L;+5O$=GIT\5SK?AG5-,3[+)H5_?7\'Z%_LD>"O!OB
M/]L36_'_ ,.?V=/VGM(^'WPZ^%%WX>T?]I3]J'XC_M%V^L>(]=\4:M ^I^!/
MA_\ #+XZZM>ZKJGA1[: W]_X@ELM.32=<T.[ANK*WEU#P_<ZECE'$'$N-QN4
MRQ=2EAOK-/(.?+9X:K#ZU0Q^1X/'9ECHTJ>68C$QE0QU;&4(5GF.%P.%E@_J
MV,H\]2-:7;Q_X3>"_#G#7'T.'\'CLX_L;%^*SPO&6'SG!8A9'FG"WBAG_"_!
MG#5;&XKC7*<EKT,TX7P/#V9XK+EP?G?$V?4^(?[:X<S)8;!U\NH_L91117ZF
M?PP%%%% !1110 4444 %<A\0? OAOXH> O&_PT\96EQ?^$/B)X0\2^!?%=A:
M:A?Z1=7OAOQ;HU[H&N6EMJNE7-GJFF7%SI>H74,.H:;=VM_92.MS9W,%Q%'*
MO7T4 ?QY?MD?\$:_V!_A%^W[_P $I_@5X#^'?Q#TCX9_M/\ C?\ :HT7XT:%
M-\?/CCJ<_B?3OAC\%M-\8^#(;76-3\?W>L>'FTOQ!<37DLOA^^TR74$86NH/
M<VJK"/T;\*^.?#G_  3=\5_$C]@[_@E=_P $]/C9^U3XD\&W>B?'[X_:=J/[
M0EIX"\!_#_4/BMX8TO1O"\,'Q=_:,U_Q/?\ B;Q3XF\,?#BTN;/P1X1M)='M
M8[&2=+U=8F\1V]A[/^WA\,?B5XP_X*8?\$8O'GA+X>>.?%'@;X6_$/\ ;*O?
MB;XS\.^$]?UOPI\.K/Q1\ =)T;PS=^._$6F:?=:/X1M?$6L1R:5H5QX@O-/B
MU?4HWL=/>XNE:(?GM^UCK_Q=\:?\%!_VH/!W[<-I_P %38/V6? F@?"N;]C#
MX:?\$\O"GQY;X0?'C0?$'A>=OBSI'Q:\5_ /PS!XA\4?$"[\4+I=EI^E^*O&
M7A73_"48\2Z5:ZQ;Z7>:5>ZN ?7VI_\ !;_P]%^Q]<?MI:1^RA\89_A[\'?V
MH+G]E[]MSP/X@U?3- ^+'[*/B#0;GPS9^-?%A\+6>D>(--^*7A_PE=^*]#LK
MZUL/$'A'5_MVM:/;WMII:KXFF\+?1O@W_@JE\&_B=^T%\<_ ?POL-'\:?LQ_
MLK_L_P!A\=/VDOVU+'QQ!-\)/ D^N>&I_'>@^ ?"EAHOAS7I/B1K<GP]@E\;
M>(-3T;7;'2_#&F:?K6E7S3>*;"VT#4?P2_90L/VO/V>?^">W[=7[*?P\_P""
M?7[0OA[X\?MN_P#!1+XZ>#/A%\-OBW\*?B?\2?A)\(/@9^T3\-OA/X3G^)_Q
MI^-GB'2/&?@OQ;\//AMX;MM6\/ZKXK\6>+?%0\:^*((;K6?^$JTVT\<S6'T9
M^SU_P3X^/7[*/P#_ &T/^"*L_AW7_&_PH_::_9Y^(WQ)_9@_;4\)?#+Q1X>\
M#2_&+Q;\-K/PK\0/A%^TQXG\$Z9J6G^!M6A\7>'-/UCP)>^,M:O[?Q;\)L>!
MY?$FK:H?#_@.V /LX_\ !:_Q!H7@GPC^U+\3?^"??[2GPK_X)U>.KOPI#H?[
M8/B?Q+\,;SQ!I&B^.;NQTOPA\2/'G[.'A_7-6^(?A'X1>)-5U+3QHOCS^U=6
M&I:3J6C:G9Z---XA\/:=JN]^QMJ=Q>_\%L/^"Q<*ZA-=Z9#\,?\ @GC<:=$+
MM[BPB2\^#'B:9Y[*,2/;HMUE97D@ $^5<LW!K\_?B]\6?CI^TO\ \$CO /\
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M%;ZEHUO8W7PE\3W6G+I5E\4;J:/X<M)<;[KQ'%:I-*GZ7^+_ !9XN_X*2_\
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M[\6/F:;-+IOV1V /INBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M11_PE7AC_H8]!_\ !QI__P D5U^TA_/#_P "7^?FOO/ ^KXC_GQ6_P#!4_\
MY$WJ*P?^$J\,?]#'H/\ X.-/_P#DBC_A*O#'_0QZ#_X.-/\ _DBCVD/YX?\
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MDM/%&L6\VGZC]MTNPBDL4TFRL!HVC?8,[PQ^QO\ LR^#4^$$?AKX1^'],B^
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M .>K1_Q#T?\ !'+_ *,I\,_^'3^/?_SU:_9ZB@#\8?\ B'H_X(Y?]&4^&?\
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M4WGANUN+NZT_6+/Q5H&CZKJ&GSZ2UA+HNHVNJ22V/U[_ ,$/O^"0EW_P2?\
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M_P#U6YD?<\'_ /(I\1O^R&A_ZVW!A]?T445ZA\,%%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 ?+?[#?_)E/['W_9K?[/W_ *J;PE7U)7RW^PW_
M ,F4_L??]FM_L_?^JF\)5]25YN3?\B?*O^Q;@?\ U%I'V'B'_P E_P <_P#9
M8<3?^KK&A1117I'QX4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !7R!X9_Y/Z^-G_9H'[+W_ *N?]KZOK^OD#PS_ ,G]?&S_
M +- _9>_]7/^U]7EYC_O&3?]C1_^JW,C[G@__D4^(W_9#0_];;@P^OZ***]0
M^&"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M+?\ Y35]'T47A_++_P "7_R 6J_\_(?^"WY?]//)_?Y'SA_PUA\$?^ABU?\
M\(_Q;_\ *:C_ (:P^"/_ $,6K_\ A'^+?_E-7T?11>'\LO\ P)?_ " 6J_\
M/R'_ (+?E_T\\G]_D?.'_#6'P1_Z&+5__"/\6_\ RFH_X:P^"/\ T,6K_P#A
M'^+?_E-7T?11>'\LO_ E_P#(!:K_ ,_(?^"WY?\ 3SR?W^1\X?\ #6'P1_Z&
M+5__  C_ !;_ /*:C_AK#X(_]#%J_P#X1_BW_P"4U?1]%%X?RR_\"7_R 6J_
M\_(?^"WY?]//)_?Y'SA_PUA\$?\ H8M7_P#"/\6__*:C_AK#X(_]#%J__A'^
M+?\ Y35]'T47A_++_P "7_R 6J_\_(?^"WY?]//)_?Y'SA_PUA\$?^ABU?\
M\(_Q;_\ *:F+^UK\#'9T3Q-JCO&0)%7PEXK9HR<X#J-')4G!P& )P<=*^DJ^
M6/@9_P EA_:<_P"QO\+_ /I%KE-<C3=I:*_Q+NE_)YDOVJE!<\'S-K^&]+1Y
MO^?G7E?W^1L?\-8?!'_H8M7_ /"/\6__ "FH_P"&L/@C_P!#%J__ (1_BW_Y
M35]'T4KP_EE_X$O_ ) JU7_GY#_P6_+_ *>>3^_R/G#_ (:P^"/_ $,6K_\
MA'^+?_E-1_PUA\$?^ABU?_PC_%O_ ,IJ^CZ*+P_EE_X$O_D M5_Y^0_\%OR_
MZ>>3^_R/G#_AK#X(_P#0Q:O_ .$?XM_^4U'_  UA\$?^ABU?_P (_P 6_P#R
MFKZ/HHO#^67_ ($O_D M5_Y^0_\ !;\O^GGD_O\ (^</^&L/@C_T,6K_ /A'
M^+?_ )34?\-8?!'_ *&+5_\ PC_%O_RFKZ/HHO#^67_@2_\ D M5_P"?D/\
MP6_+_IYY/[_(^</^&L/@C_T,6K_^$?XM_P#E-1_PUA\$?^ABU?\ \(_Q;_\
M*:OH^BB\/Y9?^!+_ .0"U7_GY#_P6_+_ *>>3^_R/G#_ (:P^"/_ $,6K_\
MA'^+?_E-1_PUA\$?^ABU?_PC_%O_ ,IJ^CZ*+P_EE_X$O_D M5_Y^0_\%OR_
MZ>>3^_R/G#_AK#X(_P#0Q:O_ .$?XM_^4U'_  UA\$?^ABU?_P (_P 6_P#R
MFKZ/HHO#^67_ ($O_D M5_Y^0_\ !;\O^GGD_O\ (^</^&L/@C_T,6K_ /A'
M^+?_ )34?\-8?!'_ *&+5_\ PC_%O_RFKZ/HHO#^67_@2_\ D M5_P"?D/\
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M>%=/C\ > M86",Z?XD\0>,K&4 _K.HK^/O\ X+P?LV_"K4_BMJ45O\5OC_\
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MPMX=\."V /ZE:*_EJ^,WPM_:2\(?\'#_ /P2_P#B'\?_ -H*R^*6B?$[4O\
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M4]0USY _X*H?MF_LU?\ !3K7O^">.@_LF7_C3_@H3\']>^._[1/@?XI_L*>
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MA^._@9OA_P"+F\=:9J'A;4_$&IRZ=HS&Y\.-H'B?PREGJ>)M336+7_0J^MP
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MUKQ%I7B/6/%WB.;4=/\ $&J:G:/::I-I,4,>DQV]C" ?P=?MP_M"_##XK?\
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M6FTS1])TYK^]N#8:986GDVD/O5% !1110 4444 %%%% !1110 4444 %%%%
M' >._#GAZXTS7O%=QH6C3^*=*\">,-#TOQ)-I=C+K^FZ)K-I;WNL:/8:P\#:
MC9Z5JUYHVCW>I:?;W,=I?7.E:;/=0RRV-J\7\Q__  :+VJWO_!,OX\V337%N
MMW^VS\4;5KBTE,%U MQ\ /V:XC-;3@$PW$0??#* 3'(JN <8K^J:]L[;4;.[
MT^\C\ZSOK6XL[J'?)'YMM=1/!/'YD3)*F^)V7?&Z2+G<C*P!'R_^R%^Q-^S%
M^P9\-=<^$'[*'PS_ .%5?#OQ'XYU+XD:SX>_X3/X@^.?MGC36- \,^&-1UG^
MUOB1XK\8:Y;_ &C0_!_ARQ_LZTU.#28?[.^TP6,5Y=WUQ= '\//_  2&^,/@
M/]EO_@FA_P %ZOV=?C3XC\/^ /C7X'^'GQ-\/2^!?&FI:7I-[K?BK6/A;\4/
M@C:^&](TR_U&SU#7K^R^)]C8^&-?T_3X&ELKCQ#X?MR[W&L6\0_H._X-E/@O
M?^#/^"2?PNU#QOI4]U%\6/BE\6?BSH.D^)[8W::=H5UKT?@72+C3-/U.S0:=
MINM6_@F;Q)IQ@$T&HV^OMK=M<O#K 5?J+]I/_@A#_P $P?VKOC5J'Q^^+G[.
MYD^(GB/59-;\>W/@KQ[X^^'NB_$;5)HW6XU'Q?H7@[Q%H^GOJ]]<.VH:OK^@
M1Z#XBU_4B]]K^K:I/-.TOZL^"_!OA3X<^#O"GP^\">']+\)^"/ OAO0_!_@[
MPMH=I'8:+X;\+>&M,M=&T#0=(L80L-GIFD:596FGV-K$!'!:V\42 *HH _(;
M]KK_ ((>_LV?M;_&?XD_&6[^,O[3_P "+CX[^"?!7P]_:*\!_L_?$3PUX+^'
MGQV\,_#P:=!X1B\?>']8\"^)_MEYI>F:/I&B+-!<QVBZ1IEO!:6%G=7&J7FH
M_KYX.\(>&?A]X1\+> O!>BV/AOP=X(\.:'X0\)^'=,C,.FZ#X9\-:9:Z-H.B
MZ?$6<Q6.EZ796MC:1EF*001J6)&3T=% !1110!\M_L-_\F4_L??]FM_L_?\
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M1_M9_P#SGJ/^&UOAK_T2S]K_ /\ $(_VL_\ YSU']MY/_P!#3 ?^%5'R_O\
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MO)_^AI@/_"JCY?W_ #0?\0R\1/\ HB.*?_#)F'_RCS7WGU_17R!_PVM\-?\
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M$<4_^&3,/_E'FOO/K^BOD#_AM;X:_P#1+/VO_P#Q"/\ :S_^<]1_PVM\-?\
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M=2<*46YRC3G)1:C)K[KHHHKZ$_(PHHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@#*.N:4"0;M<@X/[N;J/\ MG2?VYI7_/VO_?J?_P"-5YN_WV_W
MF_F:;09<[[+\?\STK^W-*_Y^U_[]3_\ QJC^W-*_Y^U_[]3_ /QJO-:* YWV
M7X_YGI7]N:5_S]K_ -^I_P#XU1_;FE?\_:_]^I__ (U7FM% <[[+\?\ ,]*_
MMS2O^?M?^_4__P :H_MS2O\ G[7_ +]3_P#QJO-:* YWV7X_YGI7]N:5_P _
M:_\ ?J?_ .-4?VYI7_/VO_?J?_XU7FM% <[[+\?\STK^W-*_Y^U_[]3_ /QJ
MC^W-*_Y^U_[]3_\ QJO-:* YWV7X_P"9Z5_;FE?\_:_]^I__ (U1_;FE?\_:
M_P#?J?\ ^-5YK10'.^R_'_,]*_MS2O\ G[7_ +]3_P#QJC^W-*_Y^U_[]3__
M !JO-:* YWV7X_YGI7]N:5_S]K_WZG_^-4?VYI7_ #]K_P!^I_\ XU7FM% <
M[[+\?\STK^W-*_Y^U_[]3_\ QJC^W-*_Y^U_[]3_ /QJO-:* YWV7X_YGI7]
MN:5_S]K_ -^I_P#XU1_;FE?\_:_]^I__ (U7FM% <[[+\?\ ,]*_MS2O^?M?
M^_4__P :H_MS2O\ G[7_ +]3_P#QJO-:* YWV7X_YGI7]N:5_P _:_\ ?J?_
M .-4?VYI7_/VO_?J?_XU7FM% <[[+\?\STK^W-*_Y^U_[]3_ /QJC^W-*_Y^
MU_[]3_\ QJO-:* YWV7X_P"9Z5_;FE?\_:_]^I__ (U1_;FE?\_:_P#?J?\
M^-5YK10'.^R_'_,]*_MS2O\ G[7_ +]3_P#QJC^W-*_Y^U_[]3__ !JO-:*
MYWV7X_YGI7]N:5_S]K_WZG_^-4?VYI7_ #]K_P!^I_\ XU7FM% <[[+\?\ST
MK^W-*_Y^U_[]3_\ QJC^W-*_Y^U_[]3_ /QJO-:* YWV7X_YGI7]N:5_S]K_
M -^I_P#XU1_;FE?\_:_]^I__ (U7FM% <[[+\?\ ,]*_MS2O^?M?^_4__P :
MH_MS2O\ G[7_ +]3_P#QJO-:* YWV7X_YGI7]N:5_P _:_\ ?J?_ .-4?VYI
M7_/VO_?J?_XU7FM% <[[+\?\STK^W-*_Y^U_[]3_ /QJC^W-*_Y^U_[]3_\
MQJO-:* YWV7X_P"9Z5_;FE?\_:_]^I__ (U1_;FE?\_:_P#?J?\ ^-5YK10'
M.^R_'_,]*_MS2O\ G[7_ +]3_P#QJC^W-*_Y^U_[]3__ !JO-:* YWV7X_YG
MI7]N:5_S]K_WZG_^-4?VYI7_ #]K_P!^I_\ XU7FM% <[[+\?\STK^W-*_Y^
MU_[]3_\ QJC^W-*_Y^U_[]3_ /QJO-:* YWV7X_YGI7]N:5_S]K_ -^I_P#X
MU1_;FE?\_:_]^I__ (U7FM% <[[+\?\ ,]*_MS2O^?M?^_4__P :H_MS2O\
MG[7_ +]3_P#QJO-:* YWV7X_YGI7]N:5_P _:_\ ?J?_ .-4?VYI7_/VO_?J
M?_XU7FM% <[[+\?\STK^W-*_Y^U_[]3_ /QJC^W-*_Y^U_[]3_\ QJO-:* Y
MWV7X_P"9Z5_;FE?\_:_]^I__ (U1_;FE?\_:_P#?J?\ ^-5YK10'.^R_'_,]
M*_MS2O\ G[7_ +]3_P#QJC^W-*_Y^U_[]3__ !JO-:* YWV7X_YGI7]N:5_S
M]K_WZG_^-4?VYI7_ #]K_P!^I_\ XU7FM% <[[+\?\STK^W-*_Y^U_[]3_\
MQJC^W-*_Y^U_[]3_ /QJO-:* YWV7X_YGI7]N:5_S]K_ -^I_P#XU1_;FE?\
M_:_]^I__ (U7FM% <[[+\?\ ,]*_MS2O^?M?^_4__P :H_MS2O\ G[7_ +]3
M_P#QJO-:* YWV7X_YGI7]N:5_P _:_\ ?J?_ .-4?VYI7_/VO_?J?_XU7FM%
M <[[+\?\STK^W-*_Y^U_[]3_ /QJC^W-*_Y^U_[]3_\ QJO-:* YWV7X_P"9
MZ5_;FE?\_:_]^I__ (U1_;FE?\_:_P#?J?\ ^-5YK10'.^R_'_,]*_MS2O\
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M /QJO-:* YWV7X_YGI7]N:5_S]K_ -^I_P#XU1_;FE?\_:_]^I__ (U7FM%
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M-;WZ?%Z%[R- 6GCU+_28[EKNTF_*'_@IC^TYX;_;X^.'[5G[6OC;5_B%JO[
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MI4VDZ1XFMK6*77UU'-Y::YX>@TS2[[Q)KFG>&IP.5]O+\+_D?M=17XN_L/\
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M@DL/"WAKQ7IGA72YM6!\J6[\M%?72_W7_P" ?V345_)-_P %C/CW^V%^R?\
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M5\7>*OAWKOBRWU+Q-97.E>#-"TSQ+Y=W%);:?-[+_P $JOV=_BYXM_X*G_\
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M:SI;Z[K/CKQAHE_<Z1I/@OPIKGBZZ_IU_8S_ &^M8_:H_:6_;9_9O?\ 9O\
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M3?B-8:#9^"+:]S([KJ%Y\.O#7@_6-1M)H;2ZTF^U.XT6\MEO--GDE^Q_VO\
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9** /0O#?_(,3_KM-_,4444&\=EZ+\C__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>nt10014672x1_diagram4.jpg
<TEXT>
begin 644 nt10014672x1_diagram4.jpg
M_]C_X  02D9)1@ ! 0$ P #   #_[0 V4&AO=&]S:&]P(#,N,  X0DE- ^T*
M4F5S;VQU=&EO;@     0 ,     !  $ P     $  ?_B"^!)0T-?4%)/1DE,
M10 ! 0  "]!N;VYE @   &UN=')21T(@6%E:( ?4  < %0 3  L (6%C<W
M         $E%0R!S4D="     0            #VU@ !     -,M2% @(
M
M$&1E<V,   %$    =&)865H   &X    %&)44D,   ',   (#&1M9&0   G8
M    B&=865H   I@    %&=44D,   ',   (#&QU;6D   IT    %&UE87,
M  J(    )&)K<'0   JL    %')865H   K     %')44D,   ',   (#'1E
M8V@   K4    #'9U960   K@    AW=T<'0   MH    %&-P<G0   M\
M*&-H860   ND    +&1E<V,         &G-21T(@245#-C$Y-C8M,BTQ('=I
M=&A"4$,
M                                                    6%E:(
M     "2@   /A   ML]C=7)V        !      %  H #P 4 !D '@ C "@
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M;W5R(%-P86-E("T@<U)'0@
M
M      !865H@        8ID  +>%   8VEA96B            !0
M;65A<P         !                               "6%E:(
M  ,6   #,P   J1865H@        ;Z(  #CU   #D'-I9R      0U)4(&1E
M<V,         +5)E9F5R96YC92!6:65W:6YG($-O;F1I=&EO;B!I;B!)14,@
M-C$Y-C8M,BTQ
M                                                          !8
M65H@        ]M8  0    #3+71E>'0     0V]P>7)I9VAT($AE=VQE='0@
M4&%C:V%R9"P@,C P- !S9C,R       !#$0   7?___S)@  !Y0  /V/___[
MH?___:(   /;  # =?_; $,  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! ?_; $,! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! ?_  !$( CH"B ,!(@ "$0$#$0'_Q  ?   !!0$!
M 0$! 0           0(#! 4&!P@)"@O_Q "U$  " 0,# @0#!04$!    7T!
M @, !!$%$B$Q008346$'(G$4,H&1H0@C0K'!%5+1\"0S8G*""0H6%Q@9&B4F
M)R@I*C0U-C<X.3I#1$5&1TA)2E-455976%E:8V1E9F=H:6IS='5V=WAY>H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:X>+CY.7FY^CIZO'R\_3U]O?X^?K_Q  ? 0 # 0$! 0$! 0$!
M     0(#! 4&!P@)"@O_Q "U$0 " 0($! ,$!P4$!  ! G<  0(#$00%(3$&
M$D%1!V%Q$R(R@0@40I&AL<$)(S-2\!5B<M$*%B0TX27Q%Q@9&B8G*"DJ-38W
M.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U=G=X>7J"@X2%AH>(B8J2
MDY25EI>8F9JBHZ2EIJ>HJ:JRL[2UMK>XN;K"P\3%QL?(R<K2T]35UM?8V=KB
MX^3EYN?HZ>KR\_3U]O?X^?K_V@ , P$  A$#$0 _ /[^**** "BBB@ HHHH
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M=6^HX7 X?"RQE#+Z"KU:N%QU>IBGB*<FG0G&E@J<X5HSI0JN5I+^??\ 8O\
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MO^#C#X=Z/_P36^"7_!1+PK^S-XG\7Q?$7]J32_V5?B'\%3\3;'2==^''C%_
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M%<^&H_"6F:?&?%[7UF+2?^PRB@#\)/VUO^">W[8O_#Q+X2?\%,/^">_B_P"
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M<)1Q%;#4J^(C24\1@<53C'VLM:3:T:;_ %OHHHK\N/V\**** "BBB@ HHHH
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MTCPW;:E/IZ^(]=,/A_0Y=0URYMM.F^#/^#M?_E&'X&_[.\^%?_JMOC57Q?\
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M5Y(_)+_AS=^SG_T5G]I?_P +OP+_ /.OJ%O^".7[.:]/BS^TM[?\5WX%R?\
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M-OR_$QEX+>$JM;@;)E\L5MI_U$OY?)Z]/S9/_!+'X&_]%/\ V@P/?QKX0_\
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M'-O[.?\ T5G]I?\ \+OP+_\ .OK]78Y>W^?P_GC_ .N:NHX8>_\ /_Z_J/\
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MPOT75KJR\-: [F#;)!XS\9Z1?7=VUI>13P6G@2;3KZ&73_$+(_\ 'C7Z4?\
M!7CXKWWQ<_X*&_M'ZG<37!L/!?BRW^%6B64T\LT6FV/PTTJR\)ZA#9K*!]GM
M]0\2Z?K^O201@1+>ZQ=NA?S#(_R[_P ,H_M!OX*_9\^(-K\-=2U+PM^U3XD\
M3>$/@!<:/JOAS6M5^(_B;P?XLA\#>(-&T[PQI.LWOBC2KRS\53PZ1 OB/1M&
M34Y)%N=*>^LLW(_1_#C*<MX/X*X>PN(KX7!XG-:,,PQ$\36HT)XO,L;@:F9U
MJ,74E%5JN$R[#5(N%/F<<'EU6N[TZ56HOC.-,?CN).)\XKT:6(Q5#+ZDL)1C
M1I5*L<-@<-BH8"E5DH*7LJ>(QM>%I3LI8G&TZ2M.I3IGSS17U!=_L:?M'VO[
M2EE^R#%\/[35_P!HJ^UE/#L?PZ\,^//AQXM>WUS^SY]5N],U/Q3X7\7ZOX)T
M>[T?3;6[O?$<>K>)++_A&(+2\?Q$=+%I<>5XY\4?AAX\^"WQ$\9?"?XH>'+O
MPC\0?A_X@U#POXM\.7LUE=3:5K.F3&&YA2^TRZOM*U.TDPMQ8:MI-]?Z3JUC
M-;:EI=]>:?=6US+]WA\TRS%U:5'"YC@<36KX*GF5"CA\7AZU6MEU:?LZ684J
M=.I*=3!5:GN4\5!.A.?NQJ.6A\I6R_'X:G4JXC!8NA2HXJ>!JU*V&K4J=+'4
MX\]3!U)SA&,,53A[\\/)JM"/O2@EJ<%17T-^T+^RA^T+^RGJ/@?2?V@OAEJ_
MPUU#XC^#++Q]X-MM4O\ 0=2;5?#-]/-;)-,_A_5M7BTC5[2>$QZOX6UN33O%
M.AF:S.M:-8+?V37'T5X+_P""3_\ P4*^(GP7T[X_^#/V9O%^N_#76_#J>+_#
M]S;:SX+C\7>)?"\L+7-MKOAOX:W/B:#XCZ]8ZA:FUO-%_LOPI=7'B'3]0T[4
MO#T&J:?=Q71XZ_$O#N&P>$S#$Y_DM# 8^K[# XZMFF!I83&U^:<'1PF)G7C1
MQ%52ISBZ=&<Y)PFFO=E;JI9%G=?$XG!4,GS6MC,'3]MB\)2R_%U,3A:5HR]K
MB:$*+JT*;4X-3JPC%J<6G[RO^=]?:/\ P3[_ &N->_8E_:N^%OQWTZ;4)/#6
ME:NOA_XGZ%I[S%O$_P +O$<D5AXQTHV:7=G!J-]9V1C\1^&[:^F%E#XNT+P_
M?W"LMF!7D7P)_9H^.7[3&L^+=!^!_P /M1\=ZCX#\%ZU\0_&(M]0T+1+#P[X
M/\/HCZIJ^IZQXFU31=(@V>8L=GI_VXZIJL^ZWTJRO9T>-?"ZUQ]'*L\PV:Y!
MBYX;&0K8-X7-,!&M3G7I8;,:-6%/V]*,I5,/[>G&K+#U)QBY.G*=)MTVUEA*
MN8Y37R[.,/"OAIT\2L1E^,=*<:52O@JM.4_8U)15.M[&;IQKPC*2BIJ%1)32
M?^BW\<M<TGQ-_P %'?\ @GYXCT#4;35]"U_X?_$+6M%U:PF2XL=4TG5?"'BF
M^TW4;*XC)CGM+ZSN(;FVF0E)894=258&OUMK^4'_ ()I?&/5OC+J?_!)6\U^
MZ-[K?PZ\$?'/X/W5P4"#^R_AS!X[T7P9;JH S]@\ CPII\DA+M--:RS,P:0H
MG]7U?YY^+F3U.'Y\$Y'5ESU,HX6S#+I5-E56$XYXPHQJI:>[5C!5(Z+W9+1'
M]5^">90SG&^+6;4X\D,R\1<%C8PW=/ZSX:>'E5TWJ_>IN3A+5^]%ZA1117Y
M?NH4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M 'Y>?\%?O^3--:_[*#X#_P#2Z[K]#=&?_B2:-C_H%:?CV'V2'GZ_Y^OYY?\
M!7[_ ),TUK_LH/@/_P!+KNOT&T5L:)I!/_0+T_\ ])(OZ5^G8]-^%_!27_15
M\=?^H7!I^*Y.[>.'B6_^J"\+?_5GXC&E(^T$]^O/^?\ /4UERRY/7GM_C_\
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M.:."R^A4P6"P6$I.>:5E3JTHY76]M6>(S6M7EF>$>7YQSRKPAF%.EBJE./\
M>]X5\<_#6]^&_P"RLGQ2AL)-/_8*_P""?_[*O_!1'P]8%8FU?Q-#:_ G]I_X
M9>+=.MVDC9K>W\/:KH?PS\26TJ;]^MQ:4AC#B/?\5Z_X0\*>,?\ @K);_MJ?
MM$:G::;\'?V0_P!B3X!_M)_$[Q1J.CW-_I+_ !$UGP0;/X<V$=GI4<EXOB"7
MQ;?ZAXX\)Z?IEI=WFHZOX%BTFPLIY[J*,_QV45Y&"\%5@*^9UL/Q17IRS3*<
M=DLG3RN,98/ 9K7H5LT6!E+,9JAB,7)YA4]O*%1T\5C:5=PJ0P5.A4]/%>*C
MQE+ 4JW#]&HL!F&$S2*GCW*.)QF74JM++WBXQP4'6HX9+!0=%2@JF'PM2ES0
MEBJE6']'/_!4/2?!/[8'[$/P._;8^%_QHM_VEO&W[-GB:\_9E_:2^*UA\,_%
M/PLN]:T3Q'>_\);\,M?U;P;XNN9-1T?3?#&H>)+7PPVI0OJ%KXC\1_$&:2"\
MC;3[JPL/YQJ**_3^%.'7PME4LGAF%3,,'1QV-Q&7NMAL/AJV$P>,K/%?49K"
M1I86I&AB:N)="6&PN"H4<+.AA*6$IT\-&4_@.(L[7$&81S.6"A@L34PF%HXU
M4L17Q%+$XG"TEA_K<7B95,1"5:A2H>V5?$8NM5Q$*V)J8F<Z\E'^PS_@W4LM
M4B_97^-FIS78?1+S]H"[L-/L?(@4V^J:;\.O =QJ]U]I4_:9A>VFJ:'"+>4"
M"V-@9+<F2ZN=O] S,3[#^?UK\OO^"//P0?X'_L$_"&*_M9+3Q!\5EU'XU^($
M>8RI(WC[[*_A2:),G[/O^'6F>"_M%MP4O5NFD5)'=5_3EF)]A_/ZU_&7'N*I
M9CQIQ)BZ#C.E+-*]*$XJ*A)87EPOM(\NDHS=!SC/>::F]9,_H/A>A/!\.Y/0
MK)J<<%2FXMMRBZ]Z_*T]4X*HHN.T6N5:)#B_4#\_\]:C)ZDGZTUF ]S_ "^M
M1$D]:^6M&.^K_K;HOZU/:E)OR78>7/;CW/7_ #^=1TA('6HRS'@?_7_^M_3U
MI>]/R7]??^1)(6 Z_EWIA<G@#\N33< ?>.3Z#^I_GCFC<>@X'M_C5*"7G_78
M+I;NP%?[S<^G4_C_ )Q1D#HN?<\_I3:*HAS737^OZ[#BQ/?_ #_GUIM-+*.^
M?IS_ /6IID/8?G5*+?0ASEWMZ$E%1%V]A^'^.:;D^I_.FH/JTB;M[LGR!U.*
M3(]1^8J"BG[-=_Z_J_\ 6X?GG^W@1_PEW[('/3]HGPOG_P &>B5^B>X>H_.O
MSH_;N_Y&W]D'_LXCPO\ ^G/1:_1"OM,]@GPEP,KO2CQ%^.<RO_7YGYGPI_R<
M/Q6_["N#/_69I'$ZN"-1NLG.60@\=#$A4<>@('J<9/-9M;6N0[+L2@';/&I)
M]7C^1@/H@C/U-8M?SMFE*5',<;3DFG]9JR5[W<:DW4@]==83B[];W/ZYR:K&
MME.75(M-?4Z$':R7/2IJE422T5IPDK+:UC\;/^"V?Q/^($'[,7AS]DWX&V5U
MKGQ__;F\>6'P(\#>'M+U6RTK59?!JB+7OBOJS3ZB\.GIX=/AR"S\$^++S4+J
MRT_2M&\?2ZI?7EO;6DD@_//]B/XYV7_!+_\ :&_:Y^ ?[5GPH7]DOX _%7X7
M7'[8'P5^&6M?$WP7\6K/2KOPCI9\&_$OP3X<\4^&H[32?%OBKXCP^'VNM \)
M2_V?J5O:^#=)T)+"XN->T^[U/^I^BO/:UO?7TTMV[]^OY'IG\=O_  2H\/M^
MR7^V9\+?C%^T)\!U^$WPN_X*$^$/'&E_L):OJ7BR]\2:9^SK8^)_B9KWCOP[
M\ )XM8N(8?#UU\3_  YKFA7WA75!;?VSKDNOZ-9:9&E[XQ^*-CH7T[_P1"_X
M*,_L7?"G]BW]G/\ 9?\ B!\<-+\.?'?4?'OC7PU9?#^;PG\0;V[GUSXB?&3Q
M)-X,L!K.E^$K[PTCZW'K^D-%-)K26UI]L4:A-:&*<1?TZT4E&UK/OT[V_P O
M/\ "BBBJ Z_PSE8;IB?D:6-5&!PRH2Q]>0R#TXX[U_GS_P#!0/3-2TG]N+]K
M.UU8YNIOV@/BEJ<1VPK_ ,2S6O%NIZSHHQ SH0-'O[ !F(F8#=<*EP947_0E
MT.$0Z?&6!#3LTY]@V%3'^R8T5N_WC@<U_%I_P72^"TWPS_;=U+Q[:PW!T'XZ
M^"/#'CFVN/LQBL+?Q#H5FO@3Q+I%M/DBXNHU\-:1XDU#)#1/XK@7:$:.OZY^
MCKB*>"S:I@:K4:F89'.='FUE*K2Q-'%>R75/V%2M4:>B5*VZ2/Y6\:(/&0JX
MVE[T,+FJIS:TBJ;H2PWM';1KVM.G%2Z^TOU9^,U%%%?U^?SP%%%% !1110 5
M_:)_P;H6][:_L6_$ZXGDQ97W[3/B^:QM_+BR##\,?A%;75V)58R,+B2)+?R9
M0OE&Q,L8Q.S-_%W7]_W_  2%^$$OP8_X)_? /3;ZU2VUOQ[HM_\ %S6F1R_V
MG_A9.I7'B+PU.ZDGR9X_ L_A.SN(1C9/:R;U61G _%/'G&4J'!=+"2:=7,,W
MP=.E#3FY</3Q&)JU%U48>SIP;6J=6*LTV?I?A51G/B6>(6D,+E^(E.73FJSH
MT80\W)3E)+M"36J1_%1^W/:7MC^VM^UW;ZC)YUX/VFOCK--<;(XOM)NOB?XG
MNDNQ%$3'"+J*9+D0J0(A*(R%*E1_2]^QE^U5^SI^RI^P3_P2)UGXX^#;N?5O
MB;XH_;+^%'AGXT0:C;:>W[/'A3QE\;/&>D^._B)ID]W,R6&N/J]U\/+"?7K6
MR74]#\!'X@W-EJJ"2?PSXM_&7_@MM\'I?A/_ ,% _B;J<-JEKH?QAT/PG\7M
M"5',GF?VYIK>'/%$TK$DI/=>._"OBN],!VF*"ZM]JB)HRWY*5[6+X9R_Q'X,
MX/IXC&5\+@:='"9G66#<Z=>LZO#.:9-/"1K4JU/ZNZ%?-75J\T<31K1PE3 U
M\/4H8FI*/#@L_P 9P1Q+Q'5H86CB,74G7P%)XGEG1I>SSW+\TCB)4JE*I[=5
M:67>RIVE0JTI8B&+I5H5:$(R_J5_9F_8TOO^"<?QH_;]_:2_:W^*][\/+;X5
M:!K/P;_9R_:3\1^#/$?CNZ\6?%#]I6QU,Z!\<_#.CZ1=7VN>+/%7AKPE<++X
MST"POM0E@N?&/BW3]3UR%_#^IZE%ZK\8_P!CWX9?MZ_M9_L)?MU^#_%ND_$[
M]F[Q_P"$9[[]LKXL-X*UOP?X2NO$?[(&G;O%VN^-_#'B:YAU?P7I'Q@TSPS;
M?#^PTF]7_B4Z/HBZN+S4K>]MKZ\_D5HKDK>&V<ULPJ9\^-:M+B*MEL\EJXVA
MD.$I8".45<E67U*&'P,<9]=H8A9I&/$%&;S>IE]''15-99*%YOLI<=972P4,
MG7"M.IDE+'0S6GA:V<8FIC'F5/-'C85:^+>%^JUJ+R]RR:K%993QE3"/G>/C
M+W3^M+]N'Q?\#?\ @I+^Q]\:?B;\-_C8_P"TWXW_ &+/C[K'[00TO3?A=XU^
M%'B?PO\ LD_%_7YHO$?PGMI/&:QQ^(CX,T?P\?$6K>/K&V,=KI7@+3H+G1-+
MDO[=;_W^X^ _CK]H3_@IG-^U_IFE_&WXG_LE>._A]\(_$W[,?[2'P1^/NA?"
M7P?\ / ]QX,\.>%OB/-J%GXBUK3+_2+72[FR\5/XK^%NEZ-;^(;^2YU&YUKP
M^^HW^K6L'\5U3+<7"02VR3S);3O')/;K*ZP3/#O\EY8@PCD>+>_ELZDIO?:1
MN.>5>$E7!X&6793Q-4HX6G0SO 9?',<IAB9Y?EO$2R6OFE"B\IQ^0TE7EF.3
MRQ=&O1HX>C+#YCCL!CL+CH5(UX]#\2*6)Q<<=F600JXB=;*<9C'@LQG0AC,=
MDCS.EE]6JLQP><3E16!S*.'JTJM2O5C7P6$QF$Q&$E3=*7]*G[ 7QX\8:'^V
MM^W=^RS\.?B:WBK]FG4=1_X*!?%&SU&._P!%\7:G\4KZQT'6/#'@WQIXA^*4
M4%UKGCJPE\-:/9:WI<RZW-H&I:KK.H^*A;W5_J,-[%_-+117W^1\,X?(\PS/
M'T*M.<LTP.2X;$QCA:="I5Q.4T\=3J9AB*U.;^L8C&K%P]HY4XRIK#QC[2I%
MQ5/XW-L^K9M@L!@ZU.<5E^+S7$4)2Q$ZT*=#,I82<,'0I3C^XHX1X63@HU)1
MJ.M*7)3DI.I_31_P0_TK5=.\:_L>W>H$FTUWXT?M+:MH65@4#2H?A/X?T.8
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M5D[?:E.3ZWOJ?.RX+X7J3<YY5!-N_P"[Q.-I0OV]G2Q,()>48I>5C\;?@?\
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M;Q0\0,THRP^*XFQT*4DTXX&&$RR4HM6E"=7+</A*LH26CC*HXR3L[Q;1OEO
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M>#YK[PW9-)/#I_\ 3A10!_%]9?\ !$#_ (+"> _V&?CQ_P $Q?A=\7?V!/\
MAF#XE?&FX^)4'Q-\3ZM\;?#_ ,:_%7A]=;\*:K8>&]<_X1SX4Z_X>T=+V;P#
MX4U;Q CV7B#5K2XCU#PE8>,M<\(RV@L/Z^/@U\,/#WP1^$'PI^"_A%&C\*?"
M+X;>!OAAX8C?.]/#W@'PQI?A314?+,=RZ;I-LK99CD'+'K7I-% 'X[?$S_@G
MC\7OBQ_P6>_9^_X*'>)?%/PX@^ 7[-?[-WB#X:^!/ UOK/BB]^).I_%/Q-'\
M3M-U'Q%JGAZX\&P>#]/T!='^*=\L6H6OC>_U7[;X4\/2KHL3S37-E\H_M5_\
M$Y?^"FDO_!2/]HK]M[]BKXL?LN6:?M _L?P_LS>'-3^/^L?%?2_%?[/3>1X.
M?5=2^'6F^ O!WB33+W4+C7/!,?BKPWXEU.\N8M(USQCXB;4_".H6>C6]MXJ_
MHWHH _EJ\5?\$+/VA]7_ ."37[%G_!-C1_B#\#=,O?A_^TS:?&G]KWQI#XC\
M?6.D>-_"=QXL^)&M:MH/P^CMOAE/>^,=7M-,\;>'[72?^$VT_P $6<UQX T'
M[1>6D;B2T^W+[_@G[^UJO_!3C]LS_@H#I?COX'O:^)_V(+O]F3]A_P ,:GK7
MC235OAUXU;1?!FLV6N_$N.+X<MIWACPQ'\3]&\7:A+/X,O\ QSJO_".>,KT+
MI3W:/82_MS10!_)'X?\ ^" '[3OP>_8\_P""=EI\$?B+^S?:_MR_L*_M+?%'
M]I'5[KQA/\0-7_9[^*NM?$7QIX8U=K&\UB#P38^./M-CX0^$OP<\->>_@_1K
MJ7^SM>&FZ[X<N8]*UY/H3PM_P2B_;M^)OCG_ (*%?ME_M2?$/]FIOVVOVG_V
M4?&?[)G[-WA'X4:W\2+3X _ ;P;XS\$Q>$KWQ'K/B7Q%X"U+Q^_BFW:VM+JR
M;1]'UZVM99_%UU<7&J)XRLM,\%?TL44 ?@I;?\$V?VM_@)_P2<_9N_8H_95\
M;?LT:C\4_A:-'NOCQX _:#\!P?%']F']I&P\5^)]8\=_&KX<>))?$'@2_P#&
M=GX4U;QAXAO6\-Z_IN@^'/$ESX9L5T?/@_4[_3-?\)^>_P#!'/\ X))?M!?L
M+?M-?M-?M(_%:;]GSX/>$?C=X)T/PCX8_95_91\6_&;Q=\(M$U.SUO3M6U#Q
MQK5W\:(SKEEKFG2:->Q^%--TW5?$.E6%E\1/&5EIW_"*Z1;:7X=3^BVB@#\O
M/^"OW_)FFM?]E!\!_P#I==U]C:.<:+I/J=,L /\ P%B_S]<5\<_\%?O^3--:
M_P"R@^ __2Z[KZ^TE\:)I'_8+L /_ 2'/KU/'_ZJ_88*_ACP>O\ JJN-[^GU
M+@\_GZ#MXX>(E_\ H@O#%_\ F3\0_P#,M2OEL=A_G_/U]JS9G_SZ>GY#\\\U
M9D; /J>3_GW/'YUEROG/?.1_B?3_ "/2O&I1T3[VM\O\E^+2>A]A7J=_F^O3
M]=%TT^Z!VZGL/\_Y]JSI'Y+?@/\ /YG]*L3/_"/Q_P _I^?I5%FR?8?K[_Y_
MK7?2AY>?RZ+RO_6QX]:?,[7O?OV_X+7W?(C9L#W/3_&H"<#)_P#UFGL<GV'3
M_&J[')]ATKMBN5.3[?AT^_\ KJ<<W=VZ+\Q"<DGUJ)SD[1^/U]*<QP/<]*C'
MRC=W/W?ZG'TZ=>M$5=\SU[>O?_+_ (! I.!M'7^(_P!/\_U-,HICMC@=3_*M
M4FW9&4Y7=ELOQ8UVSP.G\S_A_GTIE%%;))*R_P"'?G_6A 4445G*5]%KW??R
M7E^?XL"D) Y-!( R:A))/\AZ4?#_ (O_ $G_ (/];;@K,3]/3_&FT4QG X')
M_E346]97_5_Y(F4DM-W_ %N.) Y-1L_8<>_K_A_.FDD\DU&7 Z<G]*TVV7W&
M3;>X\GU/YTPN.W/Z?Y_*HR2>II*EM+=V\E?R[:_EIT$.+D^WT_QIM%%3S/[,
M=/3_ "T0!1113]]]E]WEZ^OW^2 _/?\ ;F_Y&W]D;_LX3PQ_Z<]%K]"*_/?]
MN;_D;?V1O^SA/#'_ *<]%K]"*^SSU2_U2X&LU?V/$5__  \RMTZ'YIPK_P G
M"\5/^PG@S_UFJ84445\9>:Z)_P!>37]>1^EB@D=#3PY[\^_?_/Y5'12Y^DDU
MY]>GS2 F# ]Z>"1T/X=JK4\.1UY^O7\__P!=6G=:._\ 7Y_=\@+8<'KQ]?\
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M$[V_/I9V_P"'_ _/;XQ'_C9?^P^/^I9^)Q_/POXO_P *_86OQW^,!S_P4O\
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MG*W4XJ>:Y96G[*CF&"K5;\OLZ6+P]2?-TCRPJ.5WV2;\CZ0HHII91WS].?\
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M_N/AO_V0O_OV\5'C>#3OFWC,_P#JZ?X?\0^X"M^ 4445^5G[B%%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!^7G_  5^_P"3
M--:_[*#X#_\ 2Z[KZHTML:-I(SC_ (EEA_Z2Q$_T'O7RO_P5^_Y,TUK_ +*#
MX#_]+KNOJ#3&_P")/I/_ &#+#/I_QZQ$_P!*_:<+_P FQX1\N*N-?_4/A"WX
MV/YUK.WC=XA>? ?ADO\ S)^(7Z$TC9)_,^F3S6=(Q)8GMG'U_P#U_I5R5L!C
MZ]/\_3BLUST'X_Y_SVKRZ4=M+[+Y+?7^M4?15Y7;7?\ X#_R1"QP#[\?G_\
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M?-JJDU&4?=A&4RG*<'V/6FT5]7NFGZ/_ #_7R/C"Q7Y^_MV?\%%O@I^PWX3
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MMNM&O)I4L/B9._M859/EIUY?O(5)*-64X3YJ7[P_%8@_\%+/V(2/^A:^)O\
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M#N/\7*OGTL.Y/DP.&H4HQN^53JP6)G*VW-)581DUNH03^$****_6CX@****
M"BBB@#^E?_@WU^/&IG5?C9^S;J^J7%QI;:5I_P 7O!&G3.GD:7<6=]:>%?'R
MVS,IF/\ :PU7P/<I9I(+>!],U&\C@$U[>3-_3C7\/G_!&OQ+/X?_ ."A7P6M
M$G:&T\5:9\3/#6HX&X302?#/Q7K5G ZB*5RKZSHFED%##L95DDE$"2H_]P=?
MR)XQY=3P'&=6M2BHK-,OPF8345:/M;UL%4=EIS3E@_:S>\IU)3E=R;?[=P+B
MIXG(84YMMX/$U\+%MW?):GB(+O:*K\D>T8**T21^??[<G_(U?LE_]G >&O\
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MCI^NZ.NX[O\ 0>>:_H>K^+#_ ((H^,[CQ1XQ_8@T.9RT?PX^(_[2G@RT4_\
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MZ[KZ.THXT72_^P;8_P#I+$?Z5^VX'_DV/"7_ &5?&G_J'PB?S=C7;QM\0/\
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M4P\^;#R]D?1?[6_Q^_X:F_:2^,'[0G_")_\ ""_\+7\77'BK_A$/[>_X2?\
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M2;7Q4*\G6HR3V?N349-:*<91T::11117U1X@4444 %%%>D?![X5>+_CE\4_
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M2;_A0/[)MMNAQ^5XO&^?/CH[H_+:3T^5[N]_AO\ DU^/4#Y)G_X+)_%&RO\
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MB,54;MR8>C4JM><N2,N5+=RE9):MI:GY^ $D  DD@  9))X  '))/05_8?\
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M .EUW7T/I?\ R!]'_P"P78?^DL5?/'_!7[_DS36O^R@^ _\ TNNZN:=^U/\
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MG^H609[R/_A%S;=?\RW&>7_3D/\ 6[A3_HI^'O\ P]9;_P#-)[E43_>^@_\
MK_UKP[_AJ#]G+_HN7PK_ /"X\/\ _P G5$W[3_[.9)(^./PL_P#"W\/^G_7]
M5PR#/5%?\(N;:Z_\B[&?_*3.?%O"FG_&3\/=?^9UEOE_U$GMS]1]/ZFF5X<W
M[3O[.I/_ "7#X68[?\5OX>_^3_6F_P##3G[.O_1</A9_X7'A[_Y/J99!GS4?
M^$7-WIK_ ,)N,WLM_P!SZF?^MW"G_13\/?\ AZRW_P":3W.BO#/^&G/V=?\
MHN'PL_\ "X\/?_)]'_#3G[.O_1</A9_X7'A[_P"3ZT_L#/?^A+FW_ANQG_RD
MRGQ;PJW_ ,E-P_I_U.<N_P#FD]L/))]2:2O#?^&F_P!G;_HM_P +?_"W\/\
M_P GTG_#3G[.W_1;_A=_X6V@?_)U']@9[_T)<V_\-V,_^4D_ZV<*_P#13</_
M /AYR[_YI/<7^Z?P_F*AKQ%_VF_V=B./C=\+CS_T.N@>_P#T_5'_ ,--_L[_
M /1;?A?_ .%KH/\ \FT_[ SW_H29O_X;<9_\I\U]X?ZV<*_]%-P__P"'G+O_
M )I/:9;.TGF@N)[6VFN+4LUM/+!%)-;L^-Y@E=6>$MM7<8V4MM&<X%.)R2?6
MO$S^TU^SO@X^-OPOS@X_XK70?_DZH?\ AIG]GC_HMGPP_P#"TT'_ .3:N&0Y
M[?7)LWLDTKY=C++5.R_<]W][,Y\6<*Z6XEX?UU=LYR[5Z)-_[3\OP/;7/0?B
M?\_YZ5'7B3?M+_L]$DCXV?##';_BM-!_^3J;_P -+_L]?]%K^&'_ (6N@?\
MR=5+(<\=W_8V:ZO3_A.QFRLO^?/?7Y^9F^+.%K.W$N0/M_PLY<_3_F)\U]Y[
M<QP,_E4))/6O$G_:6_9[)_Y+5\,<#_J=-!_^3?\ .*;_ ,-*_L]_]%J^&/\
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MAWV_Z?ZE7]J7]FT'GX[?"CI_T/7AWV_Z?ZC^P,^<VWDF;NZW_LW&N^W7V/\
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MF4Q_V-OV7QC'P6\&#K_R[7GM_P!/E?3E1OT!_P _YXK=<4<3<C?^L6>WOO\
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MWGK_ -?E3?\ #'O[,G_1&?!W_@-=_P#R97T:OWA_GIS4U+_6CB7_ **+/?\
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MHO!'_1'<*_\ B/91_P#,9\W)^QQ^S!C)^"_@T_\ ;M>?3_G\Q3O^&-_V7_\
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M7:_GW FIP^ZWN0!^'--IQX4>Y)_+BL#2"W?R_K\"1/NCWS_.I4ZGZ?U%1J,
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M$O\ LJ^-/_4/A$_FW&K_ (W=X@?]D'X:?^K/Q!_R8U^H/^?\\UR/BF<QVB0
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MA3<.6G0IO&4TGS2=:I3G5=.C>,%_1S:?L=_L%W?B7X,_L[7?[,$4?C#XQ_\
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M_45"1@XKE8KF> CRI74 YVYRA]<H<J<]SC/H0>:W+748[C$<NV*7@*<_(Y]
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M$B1Q11HJ1QQHH5(XT4!41% 5$4!54    "BGT5_*Y_0H4444 %%%% !1110
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M JG$N>?7^0Z_G6K$N!D_Y]?KV&?:O/J2W;^?GL_\DO5K3KZN'ALOF]_Z[O\
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M  ?UMTA(')( R!DG')( '/<D@ =R0!R:_CH_;J_X.#/VM?V7OC;\8!X9O_\
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M/([CK[,/Z<5]5PHVL?7_ )7A))]N;VU'EO\ +F_JY\7QPHO+,*M.?Z]!QO\
MR_5\1S_BX?@3$=0?QJ,H>W/L>O\ G\JME0>OYU$5(]Q_GK7Z!Z=?Z_(_+&FM
M&5:*G(!ZTPIZ'\__ *U2XI[K7:Z_KY7:_01'12D$=125/+);2NNGIZ:H HHH
MIWFMU?\ I=OZ^0'Y[_MS?\C;^R-_V<)X8_\ 3GHM?H17Y[_MS?\ (V_LC?\
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M%%%% !1110 5_9U_P0#\)7>@_L2>(-<O+.6W3QS\=_'&OZ;<RJ%%]I&F^&?
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M:+Q,6U'S=._9NB@#^3Z#_@V;\=VGPU\+? 6Q_P""@FGQ?L__  U_:6L_VB/
MGPVU+]CCP#?W'B*^MY]9D>U^.7C/1?B?X2\7_&#Q#;Z;JL?A?1=?UO6+?2M$
M\.G7K*R\+K9ZUHNG>#/U#\4_\$PO'Z?\%7--_P""FGPH_:GO_ -OXE^&?AKX
M2_&KX*ZU\*M \>CQAX(\/3:+<7>@>!_'6OZX5^&VE>*I/"'@U]7_ +'\(3>(
MM/O;3Q7J.D^*8_\ A,KFQTS]?J* /Y?+W_@WE^-&C_#?XP_LB?"S_@I5XO\
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M ,%1?B5K'[.'_!3/]M+XS?"_XP?M4_L%_&7QC^SII'PHBT[PE^RM;?&SX?\
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M6\,.#O/BOC?[OJ7!^I^!4(\WC?XC>7 7AAKVOF?B)_7I<2:/(/YCZ?\ UO\
M/6LV5-P/J/\ /Z=_;-;3+D>X_P X_P ]ZSI4P2>QX_S_ "__ %UX%*=FO+\O
M^!_D?;UH73TUV?ET_';[NIA2H1V[G']1_G\*H3)D;AVZ_3U_R?U-;<T?_P!;
M^A^O8UG2)@G(X/4>_P#GG_(KT*<NO2_RMIHOT3\M['D5Z6_=?*]]/^!Z_,QW
M7!SV/\ZKNN#D=#_/T_S_ $K1E3!.>0?\_P"??/I51EQD'G^O^?YUWTY[>7XK
M^OTZGF2CNG\G^O\ 7H4G7N/Q_P ?\_XU&1D$>M62,$@__K%0,N/IV/\ C6TE
MS+FCO^/_  Z_KH<[5FUV(/ND@\@]?IZ_A7"Z[:FWOFD _=7(\U".F[@2K[MN
M^<G&,2+WS7?,,CW[5FW]DE];M YVNIWPN<X20 @;L<E&!*L.1@[@-P!'FYM@
MGF&"G3A;V])JK1N[7G%-./:U2+E%7LE-Q;T5SV<AS)99F$*M1OV%6+H8BUWR
MTYN+51)7NZ<XQD[)R<%.,=9'G5%/EC>&1XI%*21L593V(/KT(/56!(8$,I((
M-,K\V:<6XR3C*+:E%IIIIV::>J:>C3U3/UZ,HSC&<6I1DE*,HM.,HR5TTUHT
MTTTUHUJ%%%%(84444 2P0O<31PH/FD8*/8?Q,?95RQ[X!QS7>B((JJ@PJ*%5
M?15   ^@&*RM'L/(3[3*")I5PBG@QQG!Y!Z.^ 3GE5PO!+BMNOT+AW+WA,-*
MM6BX5L4XRL]'"E%/V<9)[2DY.<ENDXJ5G%GY3Q7FL,PQL,/0DIX?!*<%-.\:
ME>;C[646M)0CR1IQ?5QG*+<9INO14Y4'K^?>HRA'3G_/I_AFOH?>CKNOO7]?
M<?*-)[JY$54]L?3BF%#VY_G4M%4IKKI^)#AV?R?^?_#E?!'48I-H]!^56:3:
MI[#^7\JK1[-?)Z]/GV)<9+I?TU*Q1?<?C_CFF^6.Q_K_ (59*#L2/\_Y[TGE
M^_Z?_7HMYO\ /\[_ -7ZDV?9_P!?\.OO/SN_;H7;XL_9&.<_\9"^&!T_ZB6B
M^]?H3Y?O^G_UZ_/K]NM=OBO]D7G.?VA?#'_IRT6OT-\OW_2OLL\7_&)\#ZO^
M#Q%V_P"AS+R/S7A7_DX/BI_V%<&_^LU2_P R#8/4_I_A2[5';^O\ZF\OW_2G
M;%^OX_X8KXVWF_OM^5K_ #/TNS[/[B' '0 4X*3V_/\ S_*IL = !11>*ZK3
M\OZL-0;\OZ[# @[\^W^?_K4X #H,4M* 3T%0ZG9??_E_P2U!+?7\A*4 GI3U
M3N?R_P :DI6;UD[>N_R7]>A8U5 ]S_+Z5\^?M3_LX^#/VL/@5X[^!GCF2:QT
MSQ=8P-INO6=O#<:EX6\2Z5=PZGX=\2:<DQ0/-INIVT!N[5)[7^U=)EU'1IKF
M&UU*X:OH6BM\+BZ^"Q.'Q>#J3H8G"UJ6(P]:#_>4ZU&<:E*I&Z:O"<5))IIV
MU5FT\JU&EB*-7#UX1J4:U.=*K3E\,Z=2+C.+V=I1;3LT]=&F?YOO[1/[/OQ*
M_9>^+OBSX,?%72!IGBGPM=@1W=LSSZ+XDT.ZW2Z+XJ\-WS)']OT'7+/;=6<K
M1PWEI+]HTK5[/3M;T[4M-L_$:_T*/VR_V'/@E^VUX!_X13XFZ4=-\5:/%._@
M3XG:'!;)XQ\%7\N6*VUQ(H35_#M[(%&M^%=29],U*/;=6YTW7+32M;TW^1#]
MJ[_@DO\ M<?LOZA?ZA;>"[_XT?#2)YY+/XB_"S2=0UT6]C$MQ.9O%OA"T2\\
M3>$)+>S@$^I7EU:W_A6UDF2UM?%6H3!L?U[P3XG9/Q)AJ&%S+$4,LSV,(TZV
M'KSC1P^,J)).M@:LVH/VK][ZI.:KTY.4(*M3@JTOP?B+@W,,HK5:V$I5<9EK
MDY4ZM*+J5</!NZIXF$4Y+D6GMU'V4TE)NG*7LU^8U%/DCDBD>*5'BEB=HY(Y
M%9)(Y$8JZ.C ,CHP*LK ,K @@$4ROU$^,"BO0/AQ\)_B?\8=?C\*_"GX>^,_
MB-XBD"O_ &/X*\-ZMXDOH8&D2(W=Y#I5I=&QL(F=3<:A>&"RM8\RW-Q%$K./
MZ-?V&/\ @@]JD&JZ%\3?VUKK3H["SQ?V7P!\.:FNHW%[=I*/LR?$?QCH]T=-
MBL(?+DFF\-^#KW5%U-)[)KWQ791V^I:#>_,\1\7Y!PMAIU\VQU*G5Y7*C@:4
MHU<?B96O&-'#1ESVD[1]M5]GAX.2=2K!-,]G*,@S3.ZT:6!PTY0YDJF)FG#"
MT5?652LURW2N_9PYZLK/DA)JQX__ ,$3?^">.I_$GQOX?_;&^*VF3V?PU^'V
MLO??!S1[J*)1X^^(&BW4]JGBQUF1YO\ A&/A_JMN]QI\\"V[:IXXL;18;UK/
MPUK>G:A_7.B_Q'KV_P :R]#T/1O#FCZ7X?\ #VDZ;H/A_0]/L])T71-&L;;3
M-(TC2M/MX[2PTS2].LHH;2PT^QM8HK:TM+6&*WMX(TAAC1$51L5_&?&?%N-X
MPSFKF6*7LJ27U? X.,N:&#PD92E"DI67M*TW)U,16:7M*DFHQA2C3IT_Z#X?
MR/#9!E]/!4'[2HW[7%8AJTL1B))*4[7?+3BDH4J=WR02NY3<YR4#)QZU,!@
M#_\ 6::BXY/4_H*G1>Y_#_&OEO@CW;_K[E_5KGO1CS/RZCE7 ]S_ )Q_GO5I
M$Y"CJ>O^?Y5&B]_R_E_]:K\2;1D]3_G_ /5^/K7+4G:_EOKN_P#@=?RT.FG&
M[79?U^&[)43HHZ#J?\_E_P#JK1ACY'X?_6_(<GIZ5!%'G'3W]S_@/U].36G&
MFT#U/ '^/U_2O/JRM?\ K=_TO2^FJ/5H4MO+??\ K3=^=D3Q)D@=A_GTQ_\
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M#S3C.%*3E5G%[QG6:B^5K1JG&GS)M3YHNP445AZKJ9M_]'MV'GD9D?KY2D<
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M-_A9VU6OHT*6WR_KY=>[TZ$L,>,$CI_G\SW_ *9K0A3)R1]/\^_\OK44:9(
M''?W_P ]_;\*THUVC./I_C_G^6*X*M3M\M[?\,MDOZ7K4::2_/S\O\_N[#U7
M''<U=ACS]!SGU/\ GI_/@U!&A)^O3_'^@]?QK2C3 "CZG^OK]/3-<%6=M%O^
M;_X'Y]-#TJ4-G;7]>B^77S[GYK?&T8_X*8_L.'L?#'Q0Q^'ACQ?7Z]5^1'QP
MX_X*8_L-_P#8L?%#_P!1CQ=7Z[U[OB+_ ,BSPT_[(1_^M=Q4?%^$6F>>-2[>
M*:_]=YP"%%%%?F!^UA1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 ?EY_P5^_Y,TUK_LH/@/_ -+KNONK1EVZ-I''']EZ?^!^
MR1<?Y_#I7PK_ ,%?O^3--:_[*#X#_P#2Z[K[VTF+&B:.<9!TK3L_^ D7/K_A
M[ "OU7$RY?##@OSXKXY_]0N#M/GZ'X=EL;^.'B5V_P!0O"[\<T\1;/[Q'7KQ
MP?T/^>1_]:L^:/!_/'^'I@]O3\*UF7J#59T!R"/H?Y'O_GWKY2G.S3Z/^O\
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MD]>PKDJU-[:)=?ZZ_ELM3U*-&UM/\OGY?B_P"&+OC)/^<_3T]?RJZJXP!_\
MK/K2*N.!R3^M6XHL_P!3_GL.Y[_RX:E3_@+]7_7ZL]"G3O9=/S[_ "_X9:BQ
M19^G<GO_ )]/_KFKZ+^0_7_/>FHG0#IW/^?R%657/ X_H*X:D[MMO3\W_6W9
M=M3T*5/:RT_/_@+_ (&NHJKN/M_,^E:4$6 "1_GTX_R.O<5'!"3]!Z^_J?4^
MW_ZM!5Z ?Y]S_GVKSZU2^VOY?\,OQ?WGI4J=[;?UN_\ +]+'Y??'[_E)I^PQ
M_P!BM\4?_49\75^M-?DS^T$N/^"FG["WI_PBOQ1Q_P"$UXNY_&OUFK[#C_\
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M'XC_  ]O\_2!D!S@<_H:[85//3\5_7_#>?#4I]']]NW1K^K?>84D0.?3N?\
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MSI<Z\_Z^8R,$]E&?8$G^M+M9NI_/_#_]52T4N=O1+]?Z^8# @[Y/Z?Y_.G@
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MYBNR%3:S^71^G]7^1Q3I-=+K\?E^&WS1CO'CAA^/Z?YZCZU4DA!S@?\ UO\
M#^7M6Z\8/0?XCZ53>$C)7IW'3'^?\>@KJA5Z?@_O^:\GVZ''4HIW:7]:;_\
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M[%/XI?\ J-^+Z_5BORG_ &D/^4G'["G_ &*?Q2_]1OQ?7ZL5^@\=?\B/PO\
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M'/N*J/"1G'(]_P#/?\O>ORW/_!83]F;MX'^.OX^&? '_ ,\ZF'_@L%^S,?\
MF1OCH/IX9\ ?_/-K>/A3XD:7X0S?_P %TDUM_P!/?Z[Z&$O'WP7?_-P^'O55
MJ]OG_L_=^OG9'ZAO$#U&#_GIZ?AQ[56>#_\ 7_\ 7']1ZU^8#?\ !7[]F9NO
M@;XY_P#A,^ 0?_5FG_&H3_P5Z_9I[>"/CG^/AGP#_3XF<?K6\?"SQ'Z\(YM;
MLZ5+RZ>UL_\ /KH<T_'GP8>J\0^'G_W&Q'EO_L]_SZH_3QH3SQ^/0_GT/^>*
M@,9'_P!?_'O7YC'_ (*\?LU'_F2/CB/IX:\!?_/+J-O^"NG[-1Z>"/CC]/\
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M?C?^'AOP$/\ WI52C_@KE^S6/^9)^.'_ (37@+^OQ+-0_"[Q$?\ S2>;:_\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M#JX@B\3>._$.F^&/BYH&G^*-<^(_BWQ+_:>GZ)XCT.UBTW0/#_A*S\,T+O\
MX*?_ +7&B?L-_P#!2']M_P"$GQY^(.KWO[6/_!4ZW_8Z_93O/B7XRU34? O[
M-/PBM_#_ (L^(.D^+?AWHGBZ[U'P3\.&U/P7XCLO"FKZQ%:Z-HUIJVF:3XBO
MY9]6T"R0@']U]%?ST? OX8VO[ '[2'QR\4^(?^"T?Q5_:+\)? S]D[Q%\2_V
MMOV5OVH_'7_#07Q8\+WVAZ,WC.3XY>!M%L?'7A_7/A/X4L=*O?")T[PI9^!?
M%5YJ>D:O!X9O_$>I7/C'P3JGAG^?SX=?M+?MJ0?ME_\ !,_XB^#_ (Y?\%,?
M$DW[9G[6FAZQH6O_ +3_ ,9? 7AOX-_%W]F_5_'V@6?CZT\,?L.^"-6\>S_#
M?P);^&/$HO--\=7WC"U\&ZEH5I?:S\,O#5M<6=O>^$P#^R#X^_\ !2C]E_\
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MOZ3\4O%GCC1K"\LK;PQ=^!OB1X>\4^*]/T:UN_A]X=U;2Q_9]MHTOBRRO;$
M_JK^'O[9GP8^*'[5GQ[_ &./!TOBS4/B_P#LT^'/ GB3XMS2>&;FW\%:%!\2
M="T7Q)X.TNV\5O,;74-;U71=;CO5T^W@)B73=9CEE6;3I8S]75_+=_P; :/X
M[^)OPO\ VWOVX/BQXVU_XD?$7]IC]I'2O T_C_Q+I-EI6H^./"7P"\$VEMX>
M\8B"QMK:VB;5;WXCZ[H]];VZ+#!>^&'@8--#)(_]2- !1110 4444 %%%% !
M7SG^UG^U/\(OV*OV?_'O[2_QVU+5]*^%WPW'AK_A)+O0-'G\0:T)/%OB_0/
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M</#LWPKTQK!=4?0+9O%6O:X^K^)DU\ _KZHHHH **** "BBB@ HHHH ****
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0% !1110 4444 %%%% '_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>nt10014672x1_diagram5x1.jpg
<TEXT>
begin 644 nt10014672x1_diagram5x1.jpg
M_]C_X  02D9)1@ ! 0$ P #   #_[0 V4&AO=&]S:&]P(#,N,  X0DE- ^T*
M4F5S;VQU=&EO;@     0 ,     !  $ P     $  ?_B"^!)0T-?4%)/1DE,
M10 ! 0  "]!N;VYE @   &UN=')21T(@6%E:( ?4  < %0 3  L (6%C<W
M         $E%0R!S4D="     0            #VU@ !     -,M2% @(
M
M$&1E<V,   %$    =&)865H   &X    %&)44D,   ',   (#&1M9&0   G8
M    B&=865H   I@    %&=44D,   ',   (#&QU;6D   IT    %&UE87,
M  J(    )&)K<'0   JL    %')865H   K     %')44D,   ',   (#'1E
M8V@   K4    #'9U960   K@    AW=T<'0   MH    %&-P<G0   M\
M*&-H860   ND    +&1E<V,         &G-21T(@245#-C$Y-C8M,BTQ('=I
M=&A"4$,
M                                                    6%E:(
M     "2@   /A   ML]C=7)V        !      %  H #P 4 !D '@ C "@
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M;W5R(%-P86-E("T@<U)'0@
M
M      !865H@        8ID  +>%   8VEA96B            !0
M;65A<P         !                               "6%E:(
M  ,6   #,P   J1865H@        ;Z(  #CU   #D'-I9R      0U)4(&1E
M<V,         +5)E9F5R96YC92!6:65W:6YG($-O;F1I=&EO;B!I;B!)14,@
M-C$Y-C8M,BTQ
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MU=;7V-G:X>+CY.7FY^CIZO'R\_3U]O?X^?K_Q  ? 0 # 0$! 0$! 0$!
M     0(#! 4&!P@)"@O_Q "U$0 " 0($! ,$!P4$!  ! G<  0(#$00%(3$&
M$D%1!V%Q$R(R@0@40I&AL<$)(S-2\!5B<M$*%B0TX27Q%Q@9&B8G*"DJ-38W
M.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U=G=X>7J"@X2%AH>(B8J2
MDY25EI>8F9JBHZ2EIJ>HJ:JRL[2UMK>XN;K"P\3%QL?(R<K2T]35UM?8V=KB
MX^3EYN?HZ>KR\_3U]O?X^?K_V@ , P$  A$#$0 _ /[^**** "BBB@ HHHH
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M%1_Q#M_\%)_^D[_[2W_F>O\ Z**OZ\J* /Y#?^(=O_@I/_TG?_:6_P#,]?\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110!\Y>)_B+8:9^US\$/A+)H>N7&J>-OV<OVI
MOB+9^);?Q_XET[PUI-A\+OB9^QWX:U+0]6^%EJP\'^,M<\0W'Q@TJ_\ #WC_
M %U3XE^&MAX8\3^'?"C+I?Q8\9A_HVOE;Q?X(^W_ +;W[/7Q(_X2_P #67_"
M)_LJ_MC^"/\ A M0U_[-\2O$O_"P?BY^PIKW_"7^$_"WV1_[9\#>"/\ A67]
MC?$/7_MUM_PC6O\ Q!^&.G?9+W_A+/.L/JF@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ KR7X^_%2+X%? GXU?&Z?1)/$L'P<^$O
MQ'^*DWAR&_72I?$$7P]\':SXNDT2+5'M-0339-532#8)?O87JV;3BX:TN1&8
M7]:KY#_X*"_\F$_MN_\ 9H?[2G_JF?&E 'XV?"O_ (+??MX?&[X>>$_BQ\)_
M^"'_ .T%XZ^'/CK2H]<\(^+M#_:#\+2Z3KVDRRRPQW]A)-\)H)7@>6"5 7B1
MMR-\N*] _P"'M7_!3/\ Z0)_M+_^'_\ "/\ \ZNOKS_@B#_RB:_84_[(=I7_
M *>=;K]4Z /Y\/\ A[5_P4S_ .D"?[2__A__  C_ /.KK\F/^"R/_!6C_@IC
M!^S)\/M;C_81_:5_X)NZCX6_:%\">(M&_:"E^-VFZQ;:EJ=EX2^(<$?PTOM'
MT3P9X=76-.\4VUW=:EJ.D:Y-J?AS5+'P[/8:QHNH6]P%C_MVKYC_ &JOV._V
M>?VV/!'A+X:?M,> H_B7\/?!WQ'T+XJV/@^\UC6]'T?4O%OAK1_$>C:*VOC0
M-0TN\U?1[:#Q/J,]QH-Q=C2M5F2W@U>UO]-^TV%R ?YXW[4G_!:/]LK_ (*&
M?\$P/B)\%OVB_P!GN3Q5IG@OXC?":_U#]L7X?>'M2\*^"EUS2=5A%CX0^)^B
M0Z9+X#M_'?BY+Z^U/3YO!>L>%HWALQ%9?#5=.BU'7+'_ $&?^"?7_)A/[$7_
M &:'^S7_ .J9\%U^+?\ P<R> _ _PQ_X(W:GX"^&W@WPK\/O WACXR?!/3?#
M?@WP3X?TGPKX5\/Z='KFJ.EAHOA[0K2QTG2[-7=W6VL;2"$.[OLW,Q/[2?\
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MI:W5GI/B'4O!GBZPT6_FM]2O/#&OV]M)I5W]C4 %%%% !1110 4444 %%%%
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M_P"T!^U+JNA>(?#VNZ5<7>EZUH>M:7=VNI:3JVFW5S8:C87-O>6=Q-;S1R,
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M_P#!3K_E&Q_P4*_[,=_:R_\ 5"^/J^XJ "BBB@ HHHH **** "BBB@ HHHH
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M?C?Q+X@CTTV<OB76&=]-6U>Z^TJ+IIA;VXC^_P"B@ HHHH *^5O%^O>"[?\
M;>_9Z\,7W@+^T?B)K'[*O[8^O>%OBA_PE.K6G_"'^"_#GQ<_84T_Q[X"_P"$
M)AA;0_$'_"R-<\5?#?Q#_P )3J-Q%JW@_P#X55_9.C0SV?CG7GM_JFOE;Q?H
M/@NX_;>_9Z\3WWCW^SOB)H_[*O[8^@^%OA?_ ,(MJUW_ ,)AX+\1_%S]A34/
M'OCW_A-H9ET/P_\ \*WUSPK\-_#W_"+:C;RZMXP_X6K_ &MHTT%GX&UY+@ ^
MJ:*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /E;]NOXD>-/@W^Q%^V
M/\7_ (;ZS_PCGQ$^%7[*O[0OQ(\!>(?[.TG6/[!\:>!OA'XO\3^%M9_LG7K'
M5-#U3^R]<TNQOO[.UG3-1TF]\C[-J-C=V<LUO)]4U\K?MUZ]X+\*_L1?MC^)
M_B1X"_X6K\._#G[*O[0NO>/?A?\ \)3JW@;_ (61X+T?X1^+]0\4^ O^$VT&
M&XUSP?\ \)AH=O?>'O\ A*=&MY]6\/\ ]H_VMIT,MY:0HWU30 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?'/C?PQXEN_\
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M**_DS_XB_P#]@G_HW/\ :\_\$7P9_P#GQ4?\1?\ ^P3_ -&Y_M>?^"+X,_\
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M\(MJ-O+JWC#_ (6K_:VC306?@;7DN/JF@ HHHH **** "BBB@ HHHH ****
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M_20K]AW_ ,2R^ O_ ,WU 'W%17P[_P /.O\ @FQ_TD*_8=_\2R^ O_S?4?\
M#SK_ ()L?])"OV'?_$LO@+_\WU 'W%17P[_P\Z_X)L?])"OV'?\ Q++X"_\
MS?4?\/.O^";'_20K]AW_ ,2R^ O_ ,WU 'W%17P[_P /.O\ @FQ_TD*_8=_\
M2R^ O_S?4?\ #SK_ ()L?])"OV'?_$LO@+_\WU 'W%17P[_P\Z_X)L?])"OV
M'?\ Q++X"_\ S?4?\/.O^";'_20K]AW_ ,2R^ O_ ,WU 'W%17P[_P /.O\
M@FQ_TD*_8=_\2R^ O_S?4?\ #SK_ ()L?])"OV'?_$LO@+_\WU 'W%17P[_P
M\Z_X)L?])"OV'?\ Q++X"_\ S?5[C\&?VG?V:_VCO^$D_P"&>?VA?@=\>/\
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M )X]?H1_P3%_Y1L?\$]?^S'?V3?_ %0O@&ON*@#\%?\ B&>_X(Y?]&T>)O\
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M"U@A@CCC6E_P=K_\HP_ W_9WGPK_ /5;?&JOW$_X)]?\F$_L1?\ 9H?[-?\
MZIGP70!^:/\ Q#/?\$<O^C:/$W_A_?CW_P#/'H_XAGO^".7_ $;1XF_\/[\>
M_P#YX]?O510!^"O_ !#/?\$<O^C:/$W_ (?WX]__ #QZ/^(9[_@CE_T;1XF_
M\/[\>_\ YX]?O510!^"O_$,]_P $<O\ HVCQ-_X?WX]__/'H_P"(9[_@CE_T
M;1XF_P##^_'O_P">/7[U44 ?@K_Q#/?\$<O^C:/$W_A_?CW_ //'H_XAGO\
M@CE_T;1XF_\ #^_'O_YX]?O510!^"O\ Q#/?\$<O^C:/$W_A_?CW_P#/'H_X
MAGO^".7_ $;1XF_\/[\>_P#YX]?O510!^"O_ !#/?\$<O^C:/$W_ (?WX]__
M #QZ/^(9[_@CE_T;1XF_\/[\>_\ YX]?O510!^"O_$,]_P $<O\ HVCQ-_X?
MWX]__/'K\M/^#3[PSHW@KXV?\%@?!OARU:R\/>$OBG\ /#.A63W%Q=O::-H/
MBW]KK2M+M7NKN6:ZN6M[&U@B:XN9I;B8H9)I9)&9S_9K7\='_!K1_P G*?\
M!:7_ ++C\%__ %/?VPJ /[%Z*** "OCGQOX8\2W?_!0+]F3QG:^'M<N?!^@?
ML<_MT^&-=\5V^DW\WAK1?$OB[XU_\$[=5\*>'M6UV.W;2].USQ/I?@GQGJ7A
M[2;RZAO]:L/"/B>\TVWN;?0-5DM/L:OAWQ]_RDG_ &3?^S'?^"A7_J^O^"8M
M 'W%1110 5_)G_P=_P#_ "83^SG_ -G>:%_ZIGXQ5_697\F?_!W_ /\ )A/[
M.?\ V=YH7_JF?C%0!^TE%%%?N!^+A1110 4444 %%%% !1110 4444 %%%%
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M$&K2F*QTVPM_@)\/PTC[%DFGFED>.VL[.UBGO;^\FM[*QM[B[N(()-WXC?\
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M_$71/!_C]M&\#?$:3X=>+M7NO!>OZK#HNO2Z3J[QVU2ZQ^RU\8M)_:R\;?M
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MCV/C31-;M=,OKFU MI[NRB@N)H (9)&C&VOZ=?\ AV=_P3@_Z1^?L1_^(I?
MC_Y@J /D_P#XB ?^"/G_ $>WX'_\(7XR?_.XKYL_;,_X+F?\$I/B5^Q_^U;\
M.? _[8G@WQ!XU\?_ +-GQT\%>$-!M_!?Q:M[C6_%'BKX7^*="\/Z1!<7WP_M
M;&";4M6O[2SBFO+JVM8GF5[B>&%7D7]0_P#AV=_P3@_Z1^?L1_\ B*7P(_\
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M:?)H46KW&B:U>:=8Z?, ?SF_\%I_^"U/['W_  4]_P""8?@[PC\*;OQ7\/\
MX\:#^TE\,?%WB_X&_$'2)(M<T_0].\ ?$_2M7\0^&?%NDK>>#_&'AFVUS7;+
M3[:XM]3TSQ4898+_ %KP9H$-Q&E?V<?L!3);?L!?L47$BRM'!^Q]^S?,ZP6\
M]U.R1?!;P:[+#:VL<US<RE5(CM[>&6>9]L<,;R,JG^23_@O!_P $H_V)_P#@
MG!_P2J\&1_LX?"U(O'^J_M1?"O0?%?QM\=WB>+OC#XMTU_A]\7KNZL+_ ,4S
M6EG9^']%U"[TW2[S4?"W@31O"/A&^O\ 2M,U*[T&;4K.*\'];?[ 2SM^P%^Q
M0MK)%#<M^Q]^S>MO-<0O<P13GX+>#1#)-;QW%K)/$DFUI(4NK9Y4#(MQ"S"1
M0#.\$?\ !0K]D;XD_#VP^*7@/XG:MXI\&:WJ<.D>%;O2?A1\99]:\>7\G@>W
M^)5S'\-O!Y^'R>,?B7#H_@.X_P"$J\2WG@'0/$=EX5TBUU.X\2W&E?V1JBV?
MDWPH_P""B7P]\8>//VH+WQ-XM\$-\!_AIXG_ &4=$^ WCGP1I/BSQ+X@^+L7
M[47P8\%_$OPC:Z3HFA/XEUGQSXA\3:MXUT[2_!6A>!_"J:MJ%EMD?3;N=II+
M;SN3_@F=XMT/]G[_ ()]_#OP5\:?AU<?&#_@GYI$7A'PKX_^)7P&UCQI\)_B
MEX&U#X5ZC\)/%?AWQQ\$++XV>';VWEU?23X5\5:?JEE\4;BZT3QCX.L[JP$>
MG:G=65O8C_X)Q?%7PS#\=+_X;?M.Z%X/\0?&OXB?LD>/=1@TSX'/X9\(R6G[
M.G@+PEX%\=^!O$6B^ OBIX3U27P1\8V\.7'B Z5\-M?^$]]X0-U;>%9]6\6^
M%/[<L-? /?/$?_!2W]B?PKX/\&^/-8^,TI\,>/OAQXT^+7A>\TGX9_%_Q'>7
MGP_^&OBK2/!/Q*UZ_P!#\.^ -5U[0'^&_B?6['2_B'H_B'3-*U[P,T>IW?BK
M3-)L-$UJZT_L])_;O_9*UVYU1=)^-&A7NB:-X'O/B+J'Q CT?Q8GPBB\*Z=H
MOA7Q%J5Q%\:)?#\?PEN]8TS0O''@[5]4\*6?C2X\6:;8>)M$N;[1((]1MFD_
M([X9?L6?&_\ 9U^/'[-W[+GAKQC#KN@:=^QA_P %+/AR/CCI7[(/Q+A^"?@J
M']IGX]_!#XJ^ /!6N2VOBCQ-\,;/Q1HMUX>\9^(]/T;6OB'X=TKQ/H7@FW^'
MTFE:%?>+/#^M:AZ/_P .._"G_"N_%/PJT[X]>(?!WA?5O@#J7P @U+P+X?U3
MPWJGCC1O"'A'X<^%_P!E_P 7_'[PU8>.+?X:?%;XC?LV7'@!M7T_XBZ3X*\
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MK^#/_P Q= 'X2_\ !1;_ (.7/@+^S)XH_9PUK]D#Q-\'/VR? _B74/B99?M
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MX,\4CPE=?%6;PF/B.Z:MI.OZ@R77@SP)X7U'Q!\:/%^F"YNM"^%]XVF:M#8
M'Z)T5^:\'_!4?X%ZCX9\4^.O#_P^^-WBSP#X=^-/PZ^ 6F^,O"GA_P  :_IW
MC#XD?$CXT?\ "@-/T+0]'L/B7)XPT35] ^)<EEIOBCPE\0_#/@?Q]8Z3K&A>
M(K#PAJFB:YI5[=Z?A+_@I;\(/'.C6MIX:^&/QQNOC3=?'SXA_LSK^S!J&C?#
M7P[\<XOBW\*_AM<?&'QSI5ROB7XIZ1\)X/#^C_#&.S\7Q^-W^*P\&ZE:Z[X:
MTK2]<O/$7B+1]&O #]%:*_(;4/\ @M?^Q_;:3:^*M-\/?'WQ%X M_!/PE^(W
MCGXBZ3\+H[;P?\)_!WQ7^-OCK]G,:E\2KGQ#XDT+5M%U+P!\:/AWXG\#^.O"
M6FZ/K7C0WVGWU]X(\.^-M(T+Q/J&A?0?BG_@HU^S_P""_&OQ^\+^)+3QWI_A
MS]F2RN1\8_B<NE>'+[PAX4\31Z?X,U/3? U[X>T_Q9=?%ZU\2>+;/Q]X;D^'
M]YJ/POL/!_Q&::_C\"^*O$,FDZFMJ ?>U?SX?\%:O^4F?_!!/_LY?X__ /J(
M_"NOV1^ ?[1/A+]H.R\>2^'O#_B[PEJ_PU\:GP+XM\.^,HO"\M[!J<GAS0/%
M>GZIHNN^!?%7CCP-XN\,:MHOB.P>P\1>$O%NN:8NJ6VM^';^:R\1^'==TG3O
MQN_X*U?\I,_^""?_ &<O\?\ _P!1'X5T ?T'T444 %?@K_P<P_\ *'+]I?\
M[&;X _\ J^_AQ7[U5^"O_!S#_P H<OVE_P#L9O@#_P"K[^'% 'Z$?\$Q?^4;
M'_!/7_LQW]DW_P!4+X!K[BK^,S]CO_@Z6_X)^_L^?LC?LL_ /QG\'_VQM3\8
M?!#]G+X(?"#Q7J7ACX?_  4O?#6H>)?AK\,_#'@S7;[P]>:K^T)HNJ7>AW>J
M:+=7&DW.I:-I-_/826\MYIEA</):Q?1O_$7K_P $V/\ HB/[<7_AM?@+_P#1
M+T ?U345_*S_ ,1>O_!-C_HB/[<7_AM?@+_]$O1_Q%Z_\$V/^B(_MQ?^&U^
MO_T2] ']4U%?RL_\1>O_  38_P"B(_MQ?^&U^ O_ -$O1_Q%Z_\ !-C_ *(C
M^W%_X;7X"_\ T2] ']4U%?RL_P#$7K_P38_Z(C^W%_X;7X"__1+T?\1>O_!-
MC_HB/[<7_AM?@+_]$O0!_5-17\K/_$7K_P $V/\ HB/[<7_AM?@+_P#1+T?\
M1>O_  38_P"B(_MQ?^&U^ O_ -$O0!_5-17\K/\ Q%Z_\$V/^B(_MQ?^&U^
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M(FCBN)XT=4ED#>;?\,Q?LU_]&]? [_PTW@+_ .4%>XT4 >'?\,Q?LU_]&]?
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M  G/_"X/^&5?VQ_^$%_L_P#L#_A6O_"M?^%N?L*?\+7_ .$L^T?\51_PG/\
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M9?VSH%[J&G?:[;[3YR?5- !1110 4444 %%%% !1110 4444 %%%% !1110
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M (787_Y;YK[S/ZQ0_P"?]'_P9#_Y+S7WG]PU%?P\_P##_P"_X+L_](N_!?\
MX8?]IO\ ^>51_P /_O\ @NS_ -(N_!?_ (8?]IO_ .>51_;&4?\ 0URW_P +
ML+_\M\U]X?6*'_/^C_X,A_\ )>:^\_N&HK^'G_A_]_P79_Z1=^"__##_ +3?
M_P \JC_A_P#?\%V?^D7?@O\ \,/^TW_\\JC^V,H_Z&N6_P#A=A?_ );YK[P^
ML4/^?]'_ ,&0_P#DO-?>?W#45_#S_P /_O\ @NS_ -(N_!?_ (8?]IO_ .>5
M1_P_^_X+L_\ 2+OP7_X8?]IO_P">51_;&4?]#7+?_"["_P#RWS7WA]8H?\_Z
M/_@R'_R7FOO/[AJ*_AY_X?\ W_!=G_I%WX+_ /##_M-__/*H_P"'_P!_P79_
MZ1=^"_\ PP_[3?\ \\JC^V,H_P"AKEO_ (787_Y;YK[P^L4/^?\ 1_\ !D/_
M )+S7WG]PU%?P\_\/_O^"[/_ $B[\%_^&'_:;_\ GE4?\/\ [_@NS_TB[\%_
M^&'_ &F__GE4?VQE'_0URW_PNPO_ ,M\U]X?6*'_ #_H_P#@R'_R7FOO/[AJ
M*_AY_P"'_P!_P79_Z1=^"_\ PP_[3?\ \\JOT'_X(W?\%I/VSOV]?VW/BS^R
M3^U5^S[\*?@==?#+]GKQ)\6[S3?#'ACXF>&/'MEXCTSQ[\&_#NE:5KEAXZ\<
M>(HK;2K[P_\ $RZU9H?[*MKZ61-)N(+Q+5IHKG>AC\#BINGA<;A,3.,>>4*&
M)HUIJ":3DXTYR:BG**YFK7DE>[1<:M.;M"I";2NU&<9.VFMDWIJM?-=S^G^B
MBBNLL*_GP_X*U?\ *3/_ (()_P#9R_Q__P#41^%=?T'U_/A_P5J_Y29_\$$_
M^SE_C_\ ^HC\*Z /Z#Z*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "OE;Q?\-_&FJ?MO?L]?%^QT;S_AWX&_95_;'^&_BGQ#_:
M.DQ?V7XT^*OQ<_84\3^ M&_LF:^CUR]_M[0_@W\2+[^T=.TR[TG2_P#A'/LV
MLWVG7FL:#;ZI]4U\.^/O^4D_[)O_ &8[_P %"O\ U?7_  3%H ^XJ*** "OY
M,_\ @[__ .3"?V<_^SO-"_\ 5,_&*OZS*_DS_P"#O_\ Y,)_9S_[.\T+_P!4
MS\8J /VDHHHK]P/Q<**** "BOSC^%VO^*_VK/C9^VGX?\8>.?B1\-_#'[/\
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M5K_PV]^SU_:G_"<_\+@_X95_;'_X07^S_P"P/^%:_P#"M?\ A;G["G_"U_\
MA+/M'_%4?\)S_P )1_PIG_A7O]C_ /$@_L#_ (6=_P ))_Q,?^$5KZIH ***
MP_$7B?PUX/TS^V_%OB'0_"^C?VCHFC_VOXBU:PT33/[7\3:WI_AKPWI?V_4[
MBUM/[1\0>(]7TKP_HECYOVG5M;U/3]*L(KB_O;:"4 _'W_@X7_Y0Y?MK?]BS
M\+/_ %??PJK\>O\ @C[_ ,HX/V9?^P)X]_\ 5M>/J_87_@X7_P"4.7[:W_8L
M_"S_ -7W\*J_'K_@C[_RC@_9E_[ GCW_ -6UX^K\B\9?^2<R[_L=T?\ U S
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !7RMXO^)'C32_VWOV>OA!8ZSY'P[\<_LJ_MC_$CQ3X>_L[29?[
M4\:?"KXN?L*>&/ 6L_VM-8R:Y9?V#H?QD^)%C_9VG:G::3JG_"1_:=9L=1O-
M'T&XTOZIKY6\7_\ "M?^&WOV>O[4_P"$Y_X7!_PRK^V/_P (+_9_]@?\*U_X
M5K_PMS]A3_A:_P#PEGVC_BJ/^$Y_X2C_ (4S_P *]_L?_B0?V!_PL[_A)/\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M3=:%I;>][SBS[@\+?!OX1>!FT^3P9\+OAYX4ETKPA%\/M-N/#O@SP[H]S8^
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M5_M.6S?6+3^QM'^*GCRS^PV.H6VFZC_;OVC5;.^NM+T:?3OZ=Z_EQ_X+YSZ
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M]?P[Z>+_ &!B?^?U#[ZG_P @?JLJJBJB*J(BA410%5548554 !54      8
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M1_:#&(3/Y:^<859G6(RXWF-79G$9;:&9F R2:_*O_AR#_P %]O\ I)K\%?\
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M]%^1_I=T444AA1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?#O\
MP4Z_Y1L?\%"O^S'?VLO_ %0OCZON*OE;]NOXD>-/@W^Q%^V/\7_AOK/_  CG
MQ$^%7[*O[0OQ(\!>(?[.TG6/[!\:>!OA'XO\3^%M9_LG7K'5-#U3^R]<TNQO
MO[.UG3-1TF]\C[-J-C=V<LUO)]4T %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M^"B/A;PC_P (9>ZUY'CW7_\ A-OC#^R_K/\ PD_AKP[]F?\ M7PAX1_X5_\
MV5XWUK[9!_8&M>-OA]8_9KO_ (23S;+^G>OY6?\ @OU_RDG_ .#=;_L^*_\
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MW?J_S/V>.R]%^1_I=T444AA1110 4444 %%%% !1110 4444 %%%% !1110
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MH.N?M/\ Q$^/WQ OOAW\0OVNK#XN_"O_ (*B_LM>%+SX/7GCSQ'XH^"_@_\
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M_$7I_P!8T?B9_P"'V_\ Q#4?\1>G_6-'XF?^'V__ !#5_9Y10!_&'_Q%Z?\
M6-'XF?\ A]O_ ,0U'_$7I_UC1^)G_A]O_P 0U?V>44 ?QA_\1>G_ %C1^)G_
M (?;_P#$-1_Q%Z?]8T?B9_X?;_\ $-7]GE% '\8?_$7I_P!8T?B9_P"'V_\
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MI7<)QFD]FXM.S];'X2V_[/\ \1OA7^S)^S9^TUHZ?&V_^+!^!?[ /[._QO\
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M %%%% !1110 4444 %%%% !1110!_&'_ ,[C7_=,_P#WPBO[/*_C#_YW&O\
MNF?_ +X17]GE !1110!_,1_P7M\(_;?VZO\ @W[\>?\ "3^$+3_A&_\ @HCX
M6\(_\(9>ZUY'CW7_ /A-OC#^R_K/_"3^&O#OV9_[5\(>$?\ A7_]E>-]:^V0
M?V!K7C;X?6/V:[_X23S;+^G>OY<?^"^?A[7[G_@H3_P;T>*[;0]8N/"^B_M]
M67A[6/$D&F7LN@:3K_B;XW?L?:EX;T/4]8C@;3K#6/$.G>$O%=_H>F75S%>Z
MM9>&?$-U807$&BZE);?U'4 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !7\^'_!6K_E)G_P03_[.7^/_ /ZB/PKK^@^OP8_X+$_
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M=/\ Z09>&?\ Q8Y^S-_\=H_X;F_X+I_](,O#/_BQS]F;_P".T ?O517X*_\
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MO>*=-\(>+?"/B?2/B1H7@BXAL%O@#]P:*_-Y_P!N_P 8V/BWX>_!/Q+\ /\
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M2Z+IFF_$OQAI^@:=XH@3XM:E\+=6L+K2SM_M2_MG?M0_ +4?V?)M<^#7P>\
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MHHH **** "BBB@ HHHH **** /E;]NO_ (5K_P ,1?MC_P#"YO\ A.?^%/\
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MQ)YAUJT@OD[!OV:_V>7^(\GQ@;X&_"5OBI-'ID<_Q#/P^\+?\)A<'1?">K^
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MHNH:IX=N=/6Z\.W>E7-Q=RW'\VO_  =_ #]@C]G(   ?M=Z$  ,  ?!GXQ
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M+O\ V<CX^_\ 43^'E%?B$MWZO\S]GCLO1?D?Z7=%%%(84444 %%%% !1110
M4444 %%%% !1110 4444 %%%% 'P[_P4Z_Y1L?\ !0K_ +,=_:R_]4+X^K[B
MKY6_;K^)'C3X-_L1?MC_ !?^&^L_\(Y\1/A5^RK^T+\2/ 7B'^SM)UC^P?&G
M@;X1^+_$_A;6?[)UZQU30]4_LO7-+L;[^SM9TS4=)O?(^S:C8W=G+-;R?5-
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M.\?^B+_LT?\ @U_9J_\ GL5_7C10!_(=_P )W_P=X_\ 1%_V:/\ P:_LU?\
MSV*/^$[_ .#O'_HB_P"S1_X-?V:O_GL5_7C10!_(=_PG?_!WC_T1?]FC_P &
MO[-7_P ]BC_A._\ @[Q_Z(O^S1_X-?V:O_GL5_7C10!_(=_PG?\ P=X_]$7_
M &:/_!K^S5_\]BC_ (3O_@[Q_P"B+_LT?^#7]FK_ .>Q7]>-% '\AW_"=_\
M!WC_ -$7_9H_\&O[-7_SV*/^$[_X.\?^B+_LT?\ @U_9J_\ GL5_7C10!_(=
M_P )W_P=X_\ 1%_V:/\ P:_LU?\ SV*^@?\ @W;_ ."?'[;O[$OB[]OOQO\
MMI_#?1?A_KO[27B/X'>*O#4FB>./ 'C"VUS5O#^I_M ZOX\=;;P+XD\0KH<%
MC>?$+06M8-2-JMQ'?-'8FX%E=F'^G"B@ HHHH *^5O%^@^"[C]M[]GKQ/?>/
M?[.^(FC_ +*O[8^@^%OA?_PBVK7?_"8>"_$?Q<_84U#Q[X]_X3:&9=#\/_\
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ME_@;X??\+!_95_:%\$?\)[\3M?\ ^$3^&O@C_A+/A'XOT'_A+_B'XI^R7_\
MPC7@;PU]O_MGQ9K_ -AO?[&T"RU#4?LES]F\E_JF@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH *_GP_X..O^35_V0?^TEO[*7_I
M'\2Z_H/K^?#_ (..O^35_P!D'_M);^RE_P"D?Q+H _H/HHHH **** "BBB@
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MQ;XKL-#U.ZMI;W2;+Q-XAM;">W@UK4H[G^HZOYB/^"]OB[[%^W5_P;]^ _\
MA&/"%W_PDG_!1'PMXN_X3.]T7S_'N@?\(3\8?V7]&_X1CPUXB^TI_97A#Q=_
MPL#^U?&^B_8Y_P"W]:\$_#Z^^TVG_"-^5>_T[T %%%% !1110 4444 %%%%
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MI+?V4O\ TC^)= ']!]%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 >4?%GX(_#+XY6G@.Q^)_A^Z\0VOPR^*W@#XV^"HK7Q+XK\,_P!D_$SX
M7:ROB#P-X@N)/"FN:'+K=MHNL*EZ_AS7GU/PMJ[)'%K>BZE B1#Q_6/V&_V:
M]:^'%[\*YO!_B:R\*W?Q]UC]J*VN-)^*WQ9TWQ?X>^//B'X@:E\4->^(O@SX
M@6WC=/'7@;5-7\:ZWX@U2[L?!_B'0]&$'B/Q%I5MIL&E:YJ5E<_6]% 'P3\/
M/^"97[&/PNT7XA>'_"/PT\50Z5\4OA!X^^ GC>UUGXW_ !X\3+J7PA^)OB_Q
MAX[\8^"K#_A(OB9J8\-VVH^*?'OB_5H-8\,#1_$FF7.O:A)INM6KW$C-]J>#
M_"FA> _"?ACP/X6M)K#PSX-\/:-X5\.V%QJ.IZO/9:%X?TZVTG2;.;5=:O-1
MUC4Y;:PM+>%[_5;^]U&[9#/>W=Q<222OT5% '\Q'_!>W1O"D_P"W5_P;]^(;
MSQG]A\<Z7_P41\+:-X=^'G_".ZE<_P#"4>%-=^,/[+]]XS\9_P#"6Q2C1]$_
MX0/6/#G@/0_^$=OH)-2\4?\ "Q_[3TJ6&U\(:RD_].]?RX_\%\_#VOW/_!0G
M_@WH\5VVAZQ<>%]%_;ZLO#VL>)(-,O9= TG7_$WQN_8^U+PWH>IZQ' VG6&L
M>(=.\)>*[_0],NKF*]U:R\,^(;JP@N(-%U*2V_J.H **** "BOS1_P""PW[1
MGQ;_ &2_^";W[3G[0WP*\1VWA+XK_#?0_ 5[X0\0W>A:'XEM]-N-<^+7@'PK
MJ3RZ'XDT_5=$OQ/HFNZG:JE_I]PD+SK<PJEQ##*G\B_P6_X*'_\ !S5^T%\,
M?"OQA^%7Q"\">(/ 'C2#4;GP[K%QX'_8_P!$FO8=*UC4=!O6?2]:T"PU2T,6
MJ:5?0!;NTA:18A-&&ADC=N+'9CE^64HU\QQN$P%&=14H5<9B*6&ISJN,IJG&
M=:<(RFXPG)13;Y8RE:T6UG4JTJ,5*K4A3BWRJ4Y**;LW9.32O9-V[)G^@M17
M\'7_  U5_P '5G_0U?#[_P )S]BK_P"5E'_#57_!U9_T-7P^_P#"<_8J_P#E
M97E_ZV\+?]%'D?\ X=,%_P#+O/\ /LS'Z]@_^@K#_P#@ZG_\D?WBT5_!U_PU
M5_P=6?\ 0U?#[_PG/V*O_E91_P -5?\ !U9_T-7P^_\ "<_8J_\ E91_K;PM
M_P!%'D?_ (=,%_\ +O/\^S#Z]@_^@K#_ /@ZG_\ )']XM%?P=?\ #57_  =6
M?]#5\/O_  G/V*O_ )64?\-5?\'5G_0U?#[_ ,)S]BK_ .5E'^MO"W_11Y'_
M .'3!?\ R[S_ #[,/KV#_P"@K#_^#J?_ ,D?WBT5_!U_PU5_P=6?]#5\/O\
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M=I7VNUW/ZYZ***]0V"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **_"W_@X2_;8_:-_8*_89\*_&K]E
M_P :V/@+XBZG^T3X"\ 7NM7_ (3\)^,H)?"VN>"OB;K.IZ>-)\9:-KFDQR3Z
MAX;TB9;V.S6]A6V:*&=(IYTD_&+X<>/_ /@[Q^+'P\\!_%/P-J'PWU;P3\2O
M!GA?Q_X.U66R_85TV74_"WC+0['Q%X>U"73M2@M=1L)+S2=1M+E[*_M;:]M6
MD,%U!#/')&H!_;?17\8?_'8U_P!4S_\ -"*/^.QK_JF?_FA% ']GE%?QA_\
M'8U_U3/_ ,T(H_X[&O\ JF?_ )H10!_9Y17\8?\ QV-?]4S_ /-"*/\ CL:_
MZIG_ .:$4 ?V>45_&'_QV-?]4S_\T(H_X[&O^J9_^:$4 ?V>45_&'_QV-?\
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M!^XE%?AW_P 1(?\ P1=_Z/+_ /-=_P!JW_YQE'_$2'_P1=_Z/+_\UW_:M_\
MG&4 ?N)17X=_\1(?_!%W_H\O_P UW_:M_P#G&4?\1(?_  1=_P"CR_\ S7?]
MJW_YQE '[B45^'?_ !$A_P#!%W_H\O\ \UW_ &K?_G&4?\1(?_!%W_H\O_S7
M?]JW_P"<90!^XE%?AW_Q$A_\$7?^CR__ #7?]JW_ .<97M'[//\ P6__ ."7
MO[5?QC\$_ #X!_M._P#">?%SXBW6JV?@[PE_PI;]H7PO_;%SHF@:KXHU./\
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M45_2A]:%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M** "OAWQ]_RDG_9-_P"S'?\ @H5_ZOK_ ()BU]Q5\K>+_&_V#]M[]GKX;_\
M"(>!KW_A+/V5?VQ_&_\ PGNH:!]I^)7AK_A7WQ<_84T'_A$/"?BG[6G]C>!O
M&_\ PLW^V?B'H'V&Y_X277_A]\,=1^UV7_")^3?@'U31110 5_)G_P '?_\
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MV0__  P7PV_^9ZC_ (=,_P#!,/\ Z, _9#_\,%\-O_F>K]"** /SW_X=,_\
M!,/_ *, _9#_ /#!?#;_ .9ZC_ATS_P3#_Z, _9#_P##!?#;_P"9ZOT(HH _
M/?\ X=,_\$P_^C /V0__  P7PV_^9ZC_ (=,_P#!,/\ Z, _9#_\,%\-O_F>
MK]"** /SW_X=,_\ !,/_ *, _9#_ /#!?#;_ .9ZC_ATS_P3#_Z, _9#_P##
M!?#;_P"9ZOT(HH _/?\ X=,_\$P_^C /V0__  P7PV_^9ZC_ (=,_P#!,/\
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M<>G6MWJ6H7-O9K*((I[VZE1 \\A;^SG]IW_DVO\ :%_[(=\6?_4"U^OY6_\
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M[_\ 9 ;K_P!0/]K*@N&_R_R/[1****#4*_GP_P"#CK_DU?\ 9!_[26_LI?\
MI'\2Z_H/K^?#_@XZ_P"35_V0?^TEO[*7_I'\2Z /Z#Z*** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#\+/^"M?_!/K5/V]OVCO
M^"?K?##]K>P_9?\ VC_V89/CM^TA\'(]0^!UQ\8(O$47@CQW^RD=5\;)-?\
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M]?\ !'W_ )1P?LR_]@3Q[_ZMKQ]7Y%XR_P#).9=_V.Z/_J!F!X>?_P"Z4O\
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MO=/T?1=,N+W4GTK1-!L-1UK4+E-.MIUM]*T+3KW5-08+8Z?975S-%;R?E_\
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M\1N'_P!$O1_PYT_X*M?]+!_[0G_B-P_^B7K^DBBOZ3/K3^;?_ASI_P %6O\
MI8/_ &A/_$;A_P#1+T?\.=/^"K7_ $L'_M"?^(W#_P"B7K^DBB@#^;?_ (<Z
M?\%6O^E@_P#:$_\ $;A_]$O1_P .=/\ @JU_TL'_ +0G_B-P_P#HEZ_I(HH
M_FW_ .'.G_!5K_I8/_:$_P#$;A_]$O1_PYT_X*M?]+!_[0G_ (C</_HEZ_I(
MHH _FW_X<Z?\%6O^E@_]H3_Q&X?_ $2]'_#G3_@JU_TL'_M"?^(W#_Z)>OZ2
M** /YM_^'.G_  5:_P"E@_\ :$_\1N'_ -$O1_PYT_X*M?\ 2P?^T)_XC</_
M *)>OZ2** /YM_\ ASI_P5:_Z6#_ -H3_P 1N'_T2]'_  YT_P""K7_2P?\
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M_AW%_P %C?\ I/MXF_\ %=GP$_\ GG5^]5% 'X*_\.XO^"QO_2?;Q-_XKL^
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M/?[6'@GX4:IH7Q \5_V#I<^MZU_PC_A7XXZ%K.J_V5H]L5N-3U#[':3?9+&
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M      8 Q3J_+#_B#\L?^DD7Q!_\,##_ //VH_X@_+'_ *21?$'_ ,,##_\
M/VK/_B"<_P#HI(?^&A__ #R]?Z>B_P!7W_T%K_P0_P#Y:?J?17Y8?\0?EC_T
MDB^(/_A@8?\ Y^U'_$'Y8_\ 22+X@_\ A@8?_G[4?\03G_T4D/\ PT/_ .>7
MK_3T/]7W_P!!:_\ !#_^6GZGT5^6'_$'Y8_])(OB#_X8&'_Y^U'_ !!^6/\
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M@:TJKKJKS4I4^7V?):\X2O?GEMR6M;KOH?T+T445^F'KA1110 4444 %%%%
M!1110 4444 %%%% 'R'_ ,%!?^3"?VW?^S0_VE/_ %3/C2OFC_@B#_RB:_84
M_P"R':5_Z>=;KZ7_ ."@O_)A/[;O_9H?[2G_ *IGQI7S1_P1!_Y1-?L*?]D.
MTK_T\ZW0!^J=%%% !1110 4444 %%%% !1110 4444 %%%% '\O_ /P=K_\
M*,/P-_V=Y\*__5;?&JOW$_X)]?\ )A/[$7_9H?[-?_JF?!=>$_\ !5S_ ()P
MZ;_P5%_9HT3]G+5/BW??!>VT7XM>%_BHOBVP\%P>.Y[B7PSX<\9^'ET0Z+<>
M)_"<<4=XOB][IK\:F[0-8+"+247)DA_GQB_X-!HK>**"#_@I5\2(8(8TBAAB
M^ RQQ111J$CBBC3X\*D<<:*$1$ 55 50  * /[0**_C#_P"(0O\ ZR7?$S_P
MQ/\ ^/FC_B$+_P"LEWQ,_P##$_\ X^: /[/**_C#_P"(0O\ ZR7?$S_PQ/\
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MFTTOZU/[NJ*_E<_XB+?VE/\ I#_\<?\ PY_CW_Z%*C_B(M_:4_Z0_P#QQ_\
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M#DEV_%?YG]4=%?RN?\1%O[2G_2'_ ../_AS_ ![_ /0I4?\ $1;^TI_TA_\
MCC_X<_Q[_P#0I4!R2[?BO\S^J.OYH_C'_P K4'_!/?\ [(#=?^H'^UE7G'_$
M1;^TI_TA_P#CC_X<_P >_P#T*5>#?LC_ +0GQR_;Q_X+_?L._M/^+/V0/BO^
MSGX?\+>$/%7PXU*P\0VWB_Q3HUNFB_"OX_:E!KM[XQU+X:_#VRT]-2NO&,&F
M1:?/II$=Q;1%-0N)+Y+> *C%IZKIY>1_H"4444&@5_/A_P ''7_)J_[(/_:2
MW]E+_P!(_B77]!]?SX?\''7_ ":O^R#_ -I+?V4O_2/XET ?T'T444 %%%%
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110!\A_\%!?^3"?VW?\ LT/]I3_U3/C2OFC_ ((@_P#*)K]A
M3_LAVE?^GG6Z^E_^"@O_ "83^V[_ -FA_M*?^J9\:5\T?\$0?^437["G_9#M
M*_\ 3SK= 'ZIT444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M;OU?YG[)'9>B_(_TO:***0PHHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** /E;]NOQO_PK+]B+]L?XD?\ "(>!OB#_ ,*^_95_:%\;_P#"!?$[0/\
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MXZII'B#]JG1+W4+"SUK5]871FUM=#L;F^MK2Y<,;>UBFGN1:0R  _L5HHHH
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M/_H>?VO/_#J?#;_YRM'_ !"4?\$P_P#H>?VO/_#J?#;_ .<K7]0%% '\O_\
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M7$MG8>+-!T>ZO;:(WEG%<6;QW#_UI?LQ?\FU_L]?]D.^$W_J!:!0![C1110
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M_P#A.?\ A%_[4_X1/_A)/^)!_;_]G_VQ_P 2[[17U30 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %?SX?\ !QU_R:O^R#_VDM_9
M2_\ 2/XEU_0?7\^'_!QU_P FK_L@_P#:2W]E+_TC^)= ']!]%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!\.^/O^4D_[)O\
MV8[_ ,%"O_5]?\$Q:^XJ^5O%_P 2/&FE_MO?L]?""QUGR/AWXY_95_;'^)'B
MGP]_9VDR_P!J>-/A5\7/V%/#'@+6?[6FL9-<LO[!T/XR?$BQ_L[3M3M-)U3_
M (2/[3K-CJ-YH^@W&E_5- !1110 4444 %%%% !1110 4444 %%%% !1110
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 ?*W[=?PW\:?&3]B+]L?X0?#?1O\
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M9?V-\0]?^W6W_"-:_P#$'X8Z=]DO?^$L\ZP /JFBBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@#Y6_;K^)'C3X-_L1?MC_%_P"&^L_\(Y\1/A5^RK^T
M+\2/ 7B'^SM)UC^P?&G@;X1^+_$_A;6?[)UZQU30]4_LO7-+L;[^SM9TS4=)
MO?(^S:C8W=G+-;R?5-?*W[=?_"M?^&(OVQ_^%S?\)S_PI_\ X95_:%_X6O\
M\*Q_L#_A97_"M?\ A4?B_P#X3K_A7O\ PE7_ !2__"<_\(O_ &I_PB?_  DG
M_$@_M_\ L_\ MC_B7?:*^J: "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ K^>[_@X]=(_P!E3]D.21UCCC_X*5_LJ/)([!$1%LOB
M6S.[,0JJJ@EF)  !)( K^A&OE_\ :V_8R_9K_;I^&%C\&OVJ/AO_ ,+2^&VF
M^+]*\>67AO\ X3#Q[X(\CQ7HFFZWI&F:K_;'PY\4^$=>D^RZ=XBUBW^PS:I)
MILWVSSKBSEGM[66  ]Z_X37P;_T-OAG_ ,'VE?\ R71_PFO@W_H;?#/_ (/M
M*_\ DNOQA_XAO/\ @B[_ -&:?^;$?M6__/SH_P"(;S_@B[_T9I_YL1^U;_\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M (:SX]__ #JJ/^(A?_@CE_T>MX9_\-9\>_\ YU5 '[/45^,/_$0O_P $<O\
MH];PS_X:SX]__.JH_P"(A?\ X(Y?]'K>&?\ PUGQ[_\ G54 ?C#_ ,[C7_=,
M_P#WPBO[/*_A3_9T_:1^"?[6G_!U_P"'/CK^SSXZM?B1\*/%OP\UVT\/>+[+
M2?$.AV^I7'AK]B74/#6N1)IOBK2-"UN V&MZ5J%@[76F0),]N9K9IK9XIG_N
MLH **** /E;Q?KW@NW_;>_9Z\,7W@+^T?B)K'[*O[8^O>%OBA_PE.K6G_"'^
M"_#GQ<_84T_Q[X"_X0F&%M#\0?\ "R-<\5?#?Q#_ ,)3J-Q%JW@__A57]DZ-
M#/9^.=>>W^J:^5O%_@C[?^V]^SU\2/\ A+_ UE_PB?[*O[8_@C_A M0U_P"S
M?$KQ+_PL'XN?L*:]_P )?X3\+?9'_MGP-X(_X5E_8WQ#U_[=;?\ "-:_\0?A
MCIWV2]_X2SSK#ZIH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH *^5O%^O>"[?]M[]GKPQ?> O[1^(FL?LJ_MCZ]X6^*'_  E.
MK6G_  A_@OPY\7/V%-/\>^ O^$)AA;0_$'_"R-<\5?#?Q#_PE.HW$6K>#_\
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M\0]'_!'+_HRGPS_X=/X]_P#SU:/^(>C_ ((Y?]&4^&?_  Z?Q[_^>K7[/44
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M]B+]L?X;_P#"7^!OA]_PL']E7]H7P1_PGOQ.U_\ X1/X:^"/^$L^$?B_0?\
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MB3Q);W^H:9IFD2:Q!)=:/X8\*>-/'VKW[6N@^%O!.O:U>PV8 /?:*_$?6_\
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M8\0)^QUJOP9N)_'UWI&A?%/0OVQ/C%X.^#^A::?%.N?#33=-T'X@?#6_\?\
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M6W'XZZ5X@\6^&O\ @H%HT=CHGC70/V5[;]J#X%?#;P_\2O#WA^XM_B%^S_\
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MDN-=\%Z)X.\(^'OA[J/A/0?"^@Z;I_Q%I/\ P4&_:<T#Q/O\=^%?@WXB\/\
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M>FQ1VUGIWBVULK.TMX?YC?AE^TM^TQXT_8T_:I^-'Q \6_$C5/BU^S7^S_\
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MK&O6^J=Q110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MGU?1_!?B#7O!NE:O-=OJ6G>$M<UCPS9W4.B:G>V,^+K?[*G[,/B73+'1]?\
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M:/7KJ_&E6'V<HH P_$G[)?P?UK0/"/P]T?P?X0\%?"'1?'O@/XD>*OAIX/\
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M^%?@C3[N/0TN;/P;\./&&B:1XG\#^%K>6/0?"^NZ;9:GHNGV=W;QRKZ7X_\
MAYX ^*_A#6_A]\4O W@[XE> ?$MO%:>(_!'C_P ,Z+XQ\(>(+2"Y@O8;;6_#
M7B*RU'1=5MX;RVMKN*&_LIXX[FW@G11+%&ZE% &+X\^#7PD^*6G:#I'Q)^&?
M@3QYI/A>Z-YX=TOQ;X6T77].T:=K&32Y#IUEJ=G<VUM%/ILTFG7-M'$+:ZL7
M-I<12V^(Z^>=3_X)]?LC>*_'7Q<^(?Q)^!OPR^*VN_&7QUX3^(7B>V^(?P]\
M#>(=#M/$/@GP5>> -!OM,T>?PXMM-JC^'=7\0VVN>)==.M>*O$,'B&_T35=<
MG\):?X;\-Z"44 ?0_C[X.?";XJV&AZ5\3/AKX&\?:9X:O&O] T[Q?X7T;Q#8
M:1<O92Z;,UA9ZI9W-O;QW&G32Z?=6Z1BWN[)VM;F*6#]W4DWPA^%=S\1K;XO
M7'PY\%3_ !3LM/32[/XAS>&M(E\8VEC'9ZEIL<%MXA>T;4X-FF:QJ^EI+%<)
M,NEZKJ6F+(+&^N;>4HH ^:?B[^QS:?&?]K/X3_M!^-]9^'7B;X;?#CX#?&_X
M&:K\$_&'PCN/%<_BRS^.FK_#W5?$NMMXWNOB+::%I]NEM\--&\,7?AO4?A?X
MDT[7_!WB'Q[X>UB>>#Q):S:)ZG\0/V1?V5OBQXMM?'OQ0_9O^!OQ%\;6-AX6
MTNS\6>-_A9X)\4>(+33?!&LW/B'P?86^K:UHM[>PV?AG6KR[U+1+>.98M.NK
MJX>V2/SY0Q10!+I7[)7[+&B>'_"_A/2OV;?@19>&?!&@^//"O@W0(OA+X#.D
M^$_"_P 4[,Z=\3/#7ANQ?07M]#\/?$'33_9?C71-,CMM,\3Z6L>FZU:WMC''
M L_@K]E3]F'X<>'O!/A/P#^SM\#_  ;X9^&OBZZ^('P\T+PW\*_ ^CZ7X&\>
MWNEW6AWGCGPC9V.APP^'?&-WHE]>Z-<^*-)6TUR?2;NYTZ6^>SFDA8HH P;7
M]BO]CVPL!I.G_LK_ +.^FZ./ US\,!HNF_!KX>:=HO\ PKB\\8ZG\0[SP$='
MLO#T&F'P?=^/-;USQC=>'#:G2+CQ-KFMZU-:/J&KZC/<ZNH?LV_#_4O&OPIU
M]]+TBQ\(_!;Q-XM^)W@/X?Z1HD&F:3'\</&]KXKTC7OC!XBO+>YW^(_$R:)X
F[\=QZ;%>6:1MXF\>^+?'GB*;Q)XP_P"$1U;P>44 ?0M%%% '_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>20
<FILENAME>nt10014672x1_diagram6.jpg
<TEXT>
begin 644 nt10014672x1_diagram6.jpg
M_]C_X  02D9)1@ ! 0$ P #   #_[0 V4&AO=&]S:&]P(#,N,  X0DE- ^T*
M4F5S;VQU=&EO;@     0 ,     !  $ P     $  ?_B"^!)0T-?4%)/1DE,
M10 ! 0  "]!N;VYE @   &UN=')21T(@6%E:( ?4  < %0 3  L (6%C<W
M         $E%0R!S4D="     0            #VU@ !     -,M2% @(
M
M$&1E<V,   %$    =&)865H   &X    %&)44D,   ',   (#&1M9&0   G8
M    B&=865H   I@    %&=44D,   ',   (#&QU;6D   IT    %&UE87,
M  J(    )&)K<'0   JL    %')865H   K     %')44D,   ',   (#'1E
M8V@   K4    #'9U960   K@    AW=T<'0   MH    %&-P<G0   M\
M*&-H860   ND    +&1E<V,         &G-21T(@245#-C$Y-C8M,BTQ('=I
M=&A"4$,
M                                                    6%E:(
M     "2@   /A   ML]C=7)V        !      %  H #P 4 !D '@ C "@
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M;W5R(%-P86-E("T@<U)'0@
M
M      !865H@        8ID  +>%   8VEA96B            !0
M;65A<P         !                               "6%E:(
M  ,6   #,P   J1865H@        ;Z(  #CU   #D'-I9R      0U)4(&1E
M<V,         +5)E9F5R96YC92!6:65W:6YG($-O;F1I=&EO;B!I;B!)14,@
M-C$Y-C8M,BTQ
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MU=;7V-G:X>+CY.7FY^CIZO'R\_3U]O?X^?K_Q  ? 0 # 0$! 0$! 0$!
M     0(#! 4&!P@)"@O_Q "U$0 " 0($! ,$!P4$!  ! G<  0(#$00%(3$&
M$D%1!V%Q$R(R@0@40I&AL<$)(S-2\!5B<M$*%B0TX27Q%Q@9&B8G*"DJ-38W
M.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U=G=X>7J"@X2%AH>(B8J2
MDY25EI>8F9JBHZ2EIJ>HJ:JRL[2UMK>XN;K"P\3%QL?(R<K2T]35UM?8V=KB
MX^3EYN?HZ>KR\_3U]O?X^?K_V@ , P$  A$#$0 _ /[^**** "BBB@ HHHH
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MD?S_ '_$,#_P1>_Z-@\3_P#B0G[0?_SRZ/\ B&!_X(O?]&P>)_\ Q(3]H/\
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MI-*TGP%/^P5^Q%XCU'3_  0E]_HT'AB3XGZ_\1]5NXM'_P"):?&FI^+II?\
MB;S:K0!]>4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7R=^
MS3\-O%W@'X@?MJZUXGL;6ST[XL?M8_\ "R?!$MOJFF:C)J/A'_AF3]FCX?\
MVZ\@T^[N9]'NO^$H\ ^)[/\ LO5X[+4_LUG;ZE]D_L[4=/N;GZQKY._9H^&?
MC?X?_$#]M76_%VB?V1I?Q;_:Q_X69\/;K^TM(O\ _A(/!'_#,G[-'P]_MOR=
M,O[VXTK_ (K#X?\ B[2/[-UN'3=7_P")1_:'V#^R[_3+V] /K&BBB@ HHHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M%FARZ/IGQ4_:V_X6-X NI+O3[I?$7@O_ (9@_9D\!?VY#'8W=U-91?\ "6^
M_%FC_9-4CL=0\S1Y+K[)]AN;&ZNOK:OD3]F#P7XU\)_$3]N'4_%NC:II6F>/
MOVN_^$T^']SJ)!@U[P5_PRW^S!X2_MG1\2R;=+_X2[PGXMTG!6$_VCI6HGRL
M$22 'UW1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M_L^>2Z26XA:2W@DB_L5H5[R=FKVW] 5[R=FKVW] HHHJBCY(_:0^'/C3QO\
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MA^Q1\6KW2I[S2].LK[7I9O'_ ,4?'.MC5O$=SJ^LPPZS#H<&HQ>'M%T'2=,
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MK:BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MO4==>WT;3=2U^[NK5[466G6%W++ T4,DZ_$/_$0G^W)_T@/_ &SO_"M\5?\
MT-]3_P#!3K_E8-_X(]_]D(_:V_\ 53?&"OUSKZ?),@HYKA:N(J8BM2E3Q,J"
MC3C3<7&-*C4YFY)N[=5KM9(^8SG/*^6XJ%"G2IU(RH0JWFY)IRG4@UII:T$^
M]VS\A?\ B(3_ &Y/^D!_[9W_ (5OBK_Z&^C_ (B$_P!N3_I ?^V=_P"%;XJ_
M^AOK]>J*]C_4["_]!N)_\ H__(GD_P"MF+_Z!J'WS_S/R%_XB$_VY/\ I ?^
MV=_X5OBK_P"AOH_XB$_VY/\ I ?^V=_X5OBK_P"AOK]>J*/]3L+_ -!N)_\
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MA?\ !"K_ )1$_L$_]D)TK_T]ZY2ZKT?YQ%U7H_SB?K)1113&%?C1_P %"O\
M@N7^R!_P34^.WA7]G?X[^"_VB/%?Q \8?"G1OC'I)^#WP^\+>,='7PEKGBWQ
MQX,M8KNXUCXA>%=1BU:+5O &MRW5M%I<]I%8S:=,M_)+<306W[+U_-=\7O\
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M/!6J_#?QC=6?Q6U/P=\5;.[A\2WGB'P=X$LOB3X)L_AT ?TPU_-=_P %\O\
MDYS_ ((+_P#:6/X"?^K!^&U>Z_LS?M8?&?XN?MG?LT>%OBK\<O#UE#:>#?\
M@J]\&M>\->!-'TWPAX"^/?Q._9)_;2^"WP?\+^(+'P;KNM^-]8T[Q5J7PEBN
M?B3<>'](\6ZYJ?A+2[7Q/J>C:I:>"M?\3PW7R+_P<I:K\2M"^(/_  1IUOX,
M^%M&\<?&#1O^"CWPZU7X4^"O$6JQZ%X?\8?$K3];\%7?@7PMKNMRW-E%H^C>
M(/%$.EZ3J>JR7EI'I]E=SW;W,"PF5%+;YK\T)[?-?FC^I:BOYU?^&I_^#DS_
M *1=_L<_^)2:%_\ /)H_X:G_ .#DS_I%W^QS_P")2:%_\\FES>4ON?\ 7_#/
MRN77G]S_ ,C^@/QM_P B9XN_[%C7_P#TU7=?F%_P0J_Y1$_L$_\ 9"=*_P#3
MWKE?%&K_ +2W_!R1J^DZII,O_!+_ /8\ABU33KW3I)8_VI- ,D4=[;2VSR(&
M^))4NBREE# J6 R,5YQ^Q'I?_!?K]C[]E#X&?LRZ!^PK^QGK^C_!KP1:^#M/
MUGQ9^U'=VGB/4+>VO;V[%QJ]MX<M=3T.&[9KQE9--O[JV"*A64L6 +ZIV>SZ
M/K;_ (/W>@KZK?9]'U:\C^H*BOPD_P"%_?\ !PE_TC]_82_\2L\2_P#RGH_X
M7]_P<)?](_?V$O\ Q*SQ+_\ *>CF\I?<_P"O^&?E=W]?N?\ 77\^S/W:R,D9
M&0 2,\@'(!(Z@$@@'O@XZ&OYK_B]_P K5G[+7_:)SQ#_ .KE_:,K^=#_ (*U
M?ME?\%K?A+_P53^!6NZ-X;O/V=/VM_%'[+WPY\.>$?@S^R#XO\0?'WPU\7?!
M%E\7?V@;KPV_BSX?WFAZSH_Q$UEO$6I>.+6+PCKOA#Q#;:7:Z7I^MV$4%[<^
M?#^F/[%_Q+_;P^+'_!P-^QOXO_X*+?!'P-\!?VA[G_@EOXPMQX2\"ZM'>6^L
M^!4^*/QQN?#?B_Q)H46O^*X_ GB_6+JZUFUUOP4/$NJ2::=-MK^YM_#EUJD_
MA'P^N:^EFM8[KS6_83=]+/>.MG;=?<?VGTC,J L[*JCJS$*!DX&2< 9) ^IQ
M7Y_?MI_&?XU?#SXJ_L1_"OX.?$SX3_#"3]ICXW?$?X4>)M>^)GPYOOB/<6L6
MA_LW_&#XK^&+WPWI=K\4_AE$;A_%OP]TCPS-8SW%Y)JFI^*] 6"ZMA:3:%XI
M_'?XY_MN>*OVG?A3XAO?BKKO[+_AWPW\(/VL_P!F.Y\8?!T7&IWW[1?[)7Q6
M^#7_  5\^!'P;5_B_K:7VO?#GX?Z7XG^$#^)Y[75-8UW0O$'CZWM/&?B[X;K
MJ?POE\7:7X)LH_J*HK^;?Q+_ ,%:OC3?^%/V_&^%7COX1>(==_9]_9$^*G[2
M/P^UCQ'\,SIMSHWC+X/_ !S^,7@'Q?\ #37OA7I_QDO/&FCVA\"^#O ;0P?%
M6\\(?%#PQXJUF\\9^,?AY9^'/%?AGX;:+U'Q6_X*'_MG_"/0/VB?"_B#5?@[
M\2/^%2?$K5(/#7[1'P1^'^EZ#<>,OA=IG[)/@?\ :3\7>(O WP%^)7QV\2Z/
M\0Y?@9XH^(7A&P^)N@>'OC%)XS^('P0U76K[X2Z5<_$?P7XKU/1 #^B"HWFA
M0X>6)#OCCP\BJ?,F(6*/!(^>5B%C7[SD@*"37X :%_P5-^/^N_"K]KCXRZ59
M_L_:K?? +X1_M(ZMXA_9FTV#QCXA_:!_9H^*?P4^/VK?"_3KC]I+3] UU_"^
ME?#JV^'EG>_$;6]'F\2^&_B!\4=/\"^,O%'P2M]2\-G4]*\#87[(NI:'XP_:
MJ_X**CX9_$GX)>,-$^$'[0L7[7%Y\1?A]8:3!\-=1^(GQ$_X)Y?L]>$?A!XN
M\1^#/"/C)]'\8^$_%^I:_P#M$>.O'6JZ?XXTR;Q#\5?A@OBN'5?#VK7[/I@!
M_1!30Z%VC#J9$5':,,"ZI(76-V7.X*[1R!&( 8QN 24;'\Y>A_\ !2_]JZT^
M$?['&H>)OBO^R%HGCG]KK]D#2/VJ?A]X_P#B9X/\6^"_A=XQ^(D"_L_V'B;]
MCOP/X>\$_$CXC?$/Q]\9]*?QWXKNXM)\):(/&?CO7?%/AK3/ ?@N.Z^'OBCP
MAXE\N^#7C7XLV?[3=KXR\-_'CX-:A\<_C9_P4W_;O_81U;XQ_&3X->$OB!X[
M\"?#/X3_  F\;_$+P?X-\+S^"_&_P=O+33-4U'X$_!S2[GP%JM[?:6NL:AX4
MUGPW;Z+<ZWXFT[XB ']0]%?S:_\ #YKQCI7Q3\7^$YO%?PLUKX9P>)/A!9>*
M_C!K_A[1/AS9_LX:)XJ_;<\;_LS_ !-\0_$#P)J/Q@U/Q+H'AGP?X/M_AC$L
M7Q:N?!_Q$\%>.O&$7Q*^)_@31_AKK-KX$\.])K_[=OQJ^%?BS]O+XMK\:="^
M.M[\*_\ @GI^S]\8_A'\/O"7@R;2?A5XIC'QO_;&\!^//VA_"7@?4M>'C7QG
M\,_ =IX1\)>*O&OC?P5XTL= ^+'A2XT:Y\.Z];Z%K7PDBTD _HFHK\(_A!^V
MG^UU\1O^"F.K_L:I\6?V?KKX$^%O ^N_$SPA\9+'X3RZKKO[0GA_PSHO[%'C
MS6/"OAR\T[XZVF@66O#0?VA_&^D1>./#'AK5?"D&E:'%K-IH7B'6=-\2:?X1
M^BOV3_BI^UGXJ_:*\??L]?&?QM<:UJG[+7B3XD7?QE\96_PUT'P?X0^-'@GX
MMV7@K6OV-=1^'L":#FQLAX-D^*:_%(:!XKUC4?#?Q=^%^N>']5N+WPKXK\+)
MI@!\ ?\ !SM_R;'^P#_VEC_95_\ 5??'VOZ4:_F5_P"#IB/7IOV0_P!AZ+PK
M<Z79>*)?^"I7[-,?AN\UNVN;W1;37G^&/[0BZ/<ZO9V<]K=W>EP:@;>6_MK6
MZMKF>T26*">&5UD7[?\ ^$ _X+S?]')_\$PO_$:?VCO_ )^U0G[TM_L_U^/X
M,E/66CW7Y(_8NBOQT_X0#_@O-_T<G_P3"_\ $:?VCO\ Y^U'_" ?\%YO^CD_
M^"87_B-/[1W_ ,_:JOY/[O3_ #_!]A_)_A_G_5GY7^U/VD/B-XT\$?&/]@+P
MSX6UR72=#^,/[6_C/X<_$BPCM-/N4\3^"],_80_;7^+ECH<\U[:7-S816_Q$
M^%G@+Q*+O2)M/U!YO#T-C+=OI5[J=A>_6]?SZ?&75?\ @O!\/?B-^R;X2E_:
M;_X)U0/\=/V@/$GPKMXM _9J^,HTF\FTC]E?]I?XW-;^-QX@^+&KZL?"ZV_P
M<GN[0>!]0\+>*/\ A-+7P@;O7KCP4/&'ACQ'] ?\(!_P7F_Z.3_X)A?^(T_M
M'?\ S]J2>^^_;;2.GXW^\%UWW\M-%Y_/[_G^Q=9;ZYHD6M6WAN36-*C\17FF
M7FM6>@/J%HFM7>C:==65CJ&K6VE-,+Z?3+&]U+3K2\OXH'M;:ZO[*WGE26Z@
M23\B/^$ _P""\W_1R?\ P3"_\1I_:._^?M7\O/\ P7X^$W_!8WQ)^TQ_P3TT
M?4/%'@WXO?M'QZ?\>M7^ =S_ ,$]_AI\;_AMX]\%+8ZG\(+?Q=X@UW5K_P >
M>+=:TRW@:^T"2'Q58:EX;TGPUI\6L7&OWZVEPDUL.5E>S_JW^?X,&[*]GT[>
M7^?X>A^NW_!3K_E8-_X(]_\ 9"/VMO\ U4WQ@K]<Z_D_\#>%/^"G?A#_ (*V
M?\$<]+_X*F>,_A_XP^,__"GOVKY/!J^&GT;4?'WA_P #I\$?BK;QZ%\8O$O@
MZSL?A]XE\9VNI0W)BU/PB=>^T:<T5YK_ (S\2:W>W1T_^L"OT?@]WRW$;K_;
MZN^_^[84_/N*O^1C2_[ Z7_I[$!1117U9\R%%%% !1110 4444 %%%% !7XF
M_P#!PW_RB@_:%_[&+X(?^KM\ U^V5?B;_P '#?\ RB@_:%_[&+X(?^KM\ UY
M^;?\BO,?^P'%_P#IB9VY;_R,,#_V%X?_ -.P/ZVJ***_'S];"BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ KY-_9S\2>$=<^,'[>VE^&_ -KX.UGP;^UE
MX.\-^/\ Q%;Z]J>L2_%;Q==?L+_L7>+[+Q]?:??HEKX5NM.\!^*O!/PN30=%
M:73+BR^&UGXHE<:SXDU:*/ZRKY-_9S\0>"-9^,'[>^G>%/A__P (9KWA/]K+
MP=X?^)GB/_A*]7\1?\+9\;W/["_[%WBFP^(']D:E#%9^ _[-^&_B7X?_  K_
M .$4\/O<Z1>?\*S_ .$XFF77O&>MV\ !]94444 %%%% !1110 4444 %%%%
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M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /QT\?_\
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MVL%L)%MH$MK97$,:!EM[:..W@#9$4$:11[8T51B?\)MX,_Z&[PQ_X/\ 2O\
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M$/\ U=O@&OVRK\3?^#AO_E%!^T+_ -C%\$/_ %=O@&O/S;_D5YC_ -@.+_\
M3$SMRW_D88'_ +"\/_Z=@?UM4445^/GZV%%%% !1110 4444 %%%% !1110
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MP%\6/"WA>S^P:#H^G6&^PT2UDNOL_P!JO7N+R:>XE^?O^(:#_@B3_P!&5?\
MFQ_[6O\ \_FOW:HI679?<A679?<C\)?^(:#_ ((D_P#1E7_FQ_[6O_S^:/\
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M;"'Y[Q7_ ,C*E_V!TO\ T]B HHHKZL^9"BBB@ HHHH **** "BBB@ K\3?\
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M"?\ "FO^%2?VA_PEO_%0?\+._P"%C?9O^*5_X1FOK*ODW]G.+X:Q_&#]O9_
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MXZ^%G[96C^)/$ECYGC2P\"?$SP5\:_!#? ?Q/%\6V^&^AZEJ'AS5O"C^,(_
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MT'6FBTRWLOB3>>*(G.L^&])BD^LJ2Z^OZ(2Z^OZ(****8S^63_@IU_RL&_\
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M?^1A@?\ L+P__IV!_6U1117X^?K84444 %%%% !1110 4444 %%%% !1110
M4444 %?)O[.>G_#VS^,'[>]SX+\0:]K/B35OVLO!VH?%S3M7TF+3M/\ "7Q"
MC_86_8NTK3?#_A:\C=WU[0;GX4Z9\,?%5QJTZQ2P^)_$WB/0PAAT:&23ZRKY
M-_9ST7P)I7Q@_;VOO"/C:Z\5>(/$G[67@[6OBCH5QX;OM#B^&GCN#]A?]B[P
M[I_@FQU.[ED@\96M_P##+0/AU\1G\2:8D%C:WOC^\\(21'4O"NH3S 'UE111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %?RECX-O^VW_P6[_X
M*%? '1OVDOVZ_P!D'P!\'OA%\$/'OB32/V1_VP?B'\*](^*_QJ\2Z7HVC:U\
M5?$?AM++4?#ND:A>?#J#P!X#DTO1]-4O;_#W3=5GU2>6_EL[7^K2OYV_V/-7
M\&:I_P '#/\ P5&M_"?A&Y\+ZCHG[+?[.&D>.]0GU^\UI/&WC,:E%J3>+K6U
MNHXX_#=LWA;4O"_AK^P+%I;,3^&I]9$GVG6;F..9=/\ $A/IZ_DFSW+_ (<F
MZ3_TE3_X+9?^+$O&G_S(T?\ #DW2?^DJ?_!;+_Q8EXT_^9&OVRHIV7;^M/\
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M).E!4U.[J*4&G2PU.*C-8AMMRLX1NER04W+F4FTHMVD[67>Z:/UG\$:#X/\
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M_P#E%!^T+_V,7P0_]7;X!K]LJ_$W_@X;_P"44'[0O_8Q?!#_ -7;X!K+-O\
MD5YC_P!@.+_],3+RW_D88'_L+P__ *=@?UM4445^/GZV%%%% !1110 4444
M%%%% !1110 4444 %%%% !7R;^SGX?\ !&C?&#]O?4?"GQ _X3/7O%G[67@[
MQ!\3/#G_  BFK^'?^%3>-[;]A?\ 8N\+6'P__M?4II;/QY_:7PW\-?#_ .*G
M_"5^'TMM(L_^%F?\(/-"VO>#-;N)_K*ODW]G/PWX1T/XP?M[:IX;\?6OC'6?
M&7[67@[Q)X_\.V^@ZGH\OPI\76O["_[%WA"R\ WVH7[O:^*KK4? ?A7P3\44
MU[15BTRWLOB39^%Y4.L^&]6ED /K*BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@#YS^(?[5?P9^&7Q%T'X3Z]?>/M;\?>(+[PWI\>@_#3X,?&7XPMH
M5SXO77KCPT?&]_\ "?P%XTTSX>VFK:=X4\5:W;ZCXYO/#VG)H/AK6M;N+J'3
M;,W+>Z:'XAT'Q/93ZEX<UG2]>T^VUCQ%X>N+[2+ZVU&T@U[PCX@U/PIXIT:6
MXM))8H]4\.>)]%U?P]K=B["YTO6M+O\ 3;R.&\M)X4_"_P"*'[&GQVTWXX_M
M_?%WX1_!+Q5IGB;XF?M3_P#!-[XD?"3QIX!^)GP_\#ZK\2OA;X!\7_ #4_VN
M-&=Q\5O"]VND/HG@GXB+XK\%_%.WT/2?'M]>Z7-X=T_Q+<O;W6G_ '1_P3A^
M#'B;X"?!3XD?#WQA\+;GX:Z[%^U?^V#XIBO)]0\,:E;?$7PE\0?VFOBI\0OA
MEX]T:?PYKVNW0T2]^%OBKP5HEI!XLC\/>+;*ZT._T[4O#5E:66G7VJ 'Z 5_
M.W^QY?>!KS_@X9_X*C1>#M#UK1]3T_\ 9;_9PL?B'<ZMJ4>H6WB'QR-2BNWU
MS08453I.BGPC=^$=)&FREY!JNDZI?[ME^BK_ $25_.W^QY+\/Y/^#AG_ (*C
M+X(MO%=OJL7[+?[.$7Q+?Q+-I<MC=_$#^THI'N?!JZ<!/!X4_P"$,D\&6ZPZ
MOG5/^$B@\12D_P!GRZ>!,OL_XD)[KU_1G]$E%%%4,*_@P^-G[</[-G[%O_!;
MW_@KC>_M$^.+[P7;_$/4OV4[7PF]EX1\7>*SJ,WAGX$:'+K*R)X4T767L1:Q
MZ[IA5KY;=;CSV%N93#,$_O/K!O/"OAC4+F6\O_#F@WUW,5,UU>:/I]S<RE$6
M-#+/-;O+(5C1$4NQVHJJ,*H \G/,GPV?Y7BLIQDZ]/#8OV/M9X>4(5E[&O2Q
M$.252G5@KSI14N:G*\7)*S:DL,3AX8JC*A4<E";BVXV4O=DI*S::W2OH]+G\
M5G_#]7_@F;_T737?_#/?%_\ ^8BC_A^K_P $S?\ HNFN_P#AGOB__P#,17]I
M7_"$^#/^A1\,?^"#2O\ Y$H_X0GP9_T*/AC_ ,$&E?\ R)7YY_Q!SAC_ *#<
M[_\ "G!?_.\\K^P<)_S]Q'_@5/\ ^5_U=^5OXM?^'ZO_  3-_P"BZ:[_ .&>
M^+__ ,Q%'_#]7_@F;_T737?_  SWQ?\ _F(K^TK_ (0GP9_T*/AC_P $&E?_
M ")1_P (3X,_Z%'PQ_X(-*_^1*/^(.<,?]!N=_\ A3@O_G>']@X3_G[B/_ J
M?_RO^KORM_%K_P /U?\ @F;_ -%TUW_PSWQ?_P#F(H_X?J_\$S?^BZ:[_P"&
M>^+_ /\ ,17]I7_"$^#/^A1\,?\ @@TK_P"1*/\ A"?!G_0H^&/_  0:5_\
M(E'_ !!SAC_H-SO_ ,*<%_\ .\/[!PG_ #]Q'_@5/_Y7_5WY6_BU_P"'ZO\
MP3-_Z+IKO_AGOB__ /,11_P_5_X)F_\ 1=-=_P##/?%__P"8BO[2O^$)\&?]
M"CX8_P#!!I7_ ,B4?\(3X,_Z%'PQ_P""#2O_ )$H_P"(.<,?]!N=_P#A3@O_
M )WA_8.$_P"?N(_\"I__ "O^KORM_%K_ ,/U?^"9O_1=-=_\,]\7_P#YB*/^
M'ZO_  3-_P"BZ:[_ .&>^+__ ,Q%?VE?\(3X,_Z%'PQ_X(-*_P#D2C_A"?!G
M_0H^&/\ P0:5_P#(E'_$'.&/^@W._P#PIP7_ ,[P_L'"?\_<1_X%3_\ E?\
M5WY6_BU_X?J_\$S?^BZ:[_X9[XO_ /S$4?\ #]7_ ()F_P#1=-=_\,]\7_\
MYB*_M*_X0GP9_P!"CX8_\$&E?_(E'_"$^#/^A1\,?^"#2O\ Y$H_X@YPQ_T&
MYW_X4X+_ .=X?V#A/^?N(_\  J?_ ,K_ *N_*W\*_P $_P!N']FS]M+_ (+>
M_P#!(Z]_9V\<7WC2W^'FI?M66OBQ[WPCXN\*'3IO$WP(UR71EC3Q7HNC/?"Z
MCT+4RS6*W"V_D*+@Q&:$/_>?6#9^%?#&GW,5Y8>'-!L;N$L8;JST?3[:YB+H
MT;F*>&W26,M&[HQ1AN1F4Y5B#O5^AY'D^&R#*\+E.#G7J8;">V]E/$2A.L_;
M5ZN(GSRITZ4':=62CRTXVBHIW:<GZN&P\,+1A0@Y2C#FLYV<O>DY.[22W;V2
MT^\****]8W/QT\?_ /*>;]FS_M&%^TM_ZT=\":_8NOQT\?\ _*>;]FS_ +1A
M?M+?^M'? FOV+I+>7K^B$MY>OZ(****8PHHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH ^3?VC-0^'MG\8/V"+;QIX?U[6?$FK?M9>,=/\ A'J.D:M%
MIVG^$OB%'^PM^VCJNI>(/%-G(COKV@W/PITSXG>%;?28&BEA\3^)O#FN%S#H
MTT<GUE7R;^T9+\-8_C!^P2GCJT\8W/BB?]K+QC%\&9O#$^D0Z)8?$I?V%_VT
M9]4N_B+'J0-Y=>#G^#\/Q7L;&#P^1JZ_$&]\"W,Q_L&WUL'ZRI+KZ_HM_P"M
MK"[[;_HM_/\ 2P4444QG\LG_  4Z_P"5@W_@CW_V0C]K;_U4WQ@K]<Z_(S_@
MIU_RL&_\$>_^R$?M;?\ JIOC!7ZYU^B\'_\ (MQ'_8?4_P#4;"'Y[Q7_ ,C*
ME_V!TO\ T]B KF_&7B[P]\/_  AXK\>>+M2AT;PGX)\-ZYXN\3ZQ<!V@TKP]
MX;TNZUG6M2G6)7D:&QTVRN;J41H[E(F"*S8!Z2O-/BQ\+]*^,'A2V\&:]KGB
M/1M"7Q;X&\4ZM;^')M&A/B>U\#>+]&\9)X,\1#6M$UR"]\$^*[S0[71O&VC6
M\%G<>(?"]SJGA^34+>PU2]2;ZF?,HR<$G/E?*GLY6]U/;2]KZ['S<.5RBIMJ
M',N9K=1O[S6^MKVTW/ES]G;]L&_\3? SXQ_$/]J'PO;? 7Q_^SMXO\=Z;\=/
M Y:XUP>!= @LK;XE?#NZLCI#ZSJ/BM]:^"_BWP%>"YT.TGF\1>+Y=<TK0M(2
M[BCTF'#^&'[:\<_C3]I#PU\7#]D?P!\?Y_AK\(?#WASX5^/M!^(/B'PO!^S5
MX _:.U>'Q)X.U+6/%FHW6M>#]%\2^([34_&=L/#7A'Q/::/H-[H6DV-]XO\
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M;2V]U1W=VROQ-_X.&_\ E%!^T+_V,7P0_P#5V^ :_;*OQ-_X.&_^44'[0O\
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M3^,[)M5DT+4KS]._@IXR\-:)^RG\)?B#J&LV9\(:/^SYX$\87_B"UG6_T_\
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M+962W@A@1YIKATAC2)7GN97GN)V5%4--<3R2332$%Y97>21F=F8@'X\^/_\
ME/-^S9_VC"_:6_\ 6CO@37[%U^.GC_\ Y3S?LV?]HPOVEO\ UH[X$U^Q=);R
M]?T0EO+U_1!1113&%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !7\LG[6OP8^#WQY_P"#GW]F#X??'+X4?#7XS^ KG_@E7J>JW'@C
MXL>!?"_Q%\(3ZGIGQH_:.ETW49O#7B_2]8T:6_T^5WDL;Q[)KBT=V>"2-F)/
M]3=?S7?%[_E:L_9:_P"T3GB'_P!7+^T92>WSC^:$]OG'\T?K)_PZV_X)D_\
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M)TWQ=\+](N/"=MJGB"VUG6?#>GZ/87VG2>.O![7_ (4U:^L/&%E!XBTRZN]
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MK]B_V!_C9\1_VF/AAJ?[0'BF3Q7HO@/QZW@_3/AA\//'OA?2/#7CSP;<>!_
M^A>%_C5_PG$%CX<\,7T?BB3]H&T^*'A:[T^>Q?0_[/\ !.E^)?![V_ASQ79V
M%I_/K_P5$'[4Q_X.._\ @GK_ ,,8GX +^T-_PPY\1?\ A##^T\OQ%;X,?8OM
M/[3W_"5?\).OPJ9/'!NO^$5_MC_A'O[*81#Q!_9IU+.G?:A2>WSC^:$]OG'\
MT?U[45^%>W_@YD_YZ_\ !"O_ +\?M^__ "11M_X.9/\ GK_P0K_[\?M^_P#R
M11?R?W>G^?X/L%_)_=Z?Y_@^Q^ZE?SM_L>:1X,TO_@X9_P""HUQX3\77/BC4
M=;_9;_9PU?QWI\^@7FBIX)\9G4HM-;PC:W5U))'XDME\+:;X7\2_V_8K%9F?
MQ+/HPC^TZ-<R2>H;?^#F3_GK_P $*_\ OQ^W[_\ )%?"O_!)G2OVFM-_X+H_
M\%+9_P!JSQ-^S+X@^-^K_LR_!35/BS9_LN6GQGMOAMX6\1'6] T_PCX<T9_C
M3HVD>(9[I/!NG1ZYXEFMKGQ)HS7.O:+%I6OB[M]>T;2I;^'1_$M_Z\[??V%?
M5:/?KZ?\&WW]C^KZBBBK*"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** /Q%_;=\$?MU?#S_ (*+_ ;]LK]DK]CO2/VOO#OA7]D7XL_L^^+O
M"^H_M(_#;]G631-:\>_%;P'XYL=6CUCQQIGB6ZU5+:Q\%& V5CX;>WE;4?,D
MU:TDLQ;7=C_AMS_@M!_T@T\+_P#BTW]G[_YSU?ME12MOJU?T].J\A6WU:OZ>
MG5>1^)O_  VY_P %H/\ I!IX7_\ %IO[/W_SGJ/^&W/^"T'_ $@T\+_^+3?V
M?O\ YSU?ME119]W^'^06?=_A_D?B;_PVY_P6@_Z0:>%__%IO[/W_ ,YZC_AM
MS_@M!_T@T\+_ /BTW]G[_P"<]7[9446?=_A_D%GW?X?Y'XF_\-N?\%H/^D&G
MA?\ \6F_L_?_ #GJ/^&W/^"T'_2#3PO_ .+3?V?O_G/5^V5%%GW?X?Y!9]W^
M'^1^)O\ PVY_P6@_Z0:>%_\ Q:;^S]_\YZC_ (;<_P""T'_2#3PO_P"+3?V?
MO_G/5^V5%%GW?X?Y!9]W^'^1^)O_  VY_P %H/\ I!IX7_\ %IO[/W_SGJ/^
M&W/^"T'_ $@T\+_^+3?V?O\ YSU?ME119]W^'^06?=_A_D?B;_PVY_P6@_Z0
M:>%__%IO[/W_ ,YZC_AMS_@M!_T@T\+_ /BTW]G[_P"<]7[9446?=_A_D%GW
M?X?Y'XF_\-N?\%H/^D&GA?\ \6F_L_?_ #GJ/^&W/^"T'_2#3PO_ .+3?V?O
M_G/5^V5%%GW?X?Y!9]W^'^1^)O\ PVY_P6@_Z0:>%_\ Q:;^S]_\YZC_ (;<
M_P""T'_2#3PO_P"+3?V?O_G/5^V5%%GW?X?Y!9]W^'^1^)O_  VY_P %H/\
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MW]^GP8NK,Z.;6?X6B]U74KD^ Y87\,--?W;OIC&>3< ?G=\/O^"@O[2?C?\
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MXWO](T_Q!XGZW_@X;_Y10?M"_P#8Q?!#_P!7;X!K]LJ_$W_@X;_Y10?M"_\
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M\06^E:O+_8']KPV$F@ZKHFJ:D ?65%%% !1110 4444 %%%% !1110 4444
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MMW60XU?^$V\&?]#=X8_\'^E?_)='_";>#/\ H;O#'_@_TK_Y+H =X-\(Z#X
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MK2Z9H&F>*#):%[7^RO$^EQ[OM$=PJS+I_B0GT]?T9_1)1115#"BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "OYKOB]_P K5G[+7_:)
MSQ#_ .KE_:,K^E&OQH_;Q_X(O?"[]NO]J+P9^UU>_M2?M=?LV?%WP/\ !73/
M@3I.K?LQ_$3P[\.)W\':=XP\>^,Y9)]:E\'ZOXG6\U.^^(&IV6J0VVN6^EW6
MGV.FQMIXFCN)KA/]5^#0G^J_!H_9>BOYU_\ B'M_ZR]_\%C/_$N__P #J/\
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M1X#\?-X8N_%G]BOP9\7/BQJ?Q9U#XD?%'PE?ZS%^S//JOAWP?/X!30=0U_\
M9-^,_B+XW_"+Q%.WBKP#XJU=+NS\3>*-7TK6].M-3MM$UG0+A8IM.358+75K
M?QWXK?\ !+[X0?&'QW\4_'/BOXJ?&Z%_BQI'QCT+6-'TS4OAK(FD:5\<_AQX
M9^&OC6QT?Q+X@^&.O^.9["TTKPKI-[X.TCQ!XHUW0O \UK#I'A32M)\*_:M
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M+X-O4M?$EYK.LW^A^"/&%SH_AW2=1\4ZI;/8Z-H&K7J>)O%GA'3_ !%!<_\
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M:21@H"@N[DL[G&6=B69LDDDDT^O5/,"OQ-_X.&_^44'[0O\ V,7P0_\ 5V^
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MEV7W(++LON1_/]_Q# _\$7O^C8/$_P#XD)^T'_\ /+KZ+_92_P""%W_!,_\
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M?ME7XF_\'#?_ "B@_:%_[&+X(?\ J[? ->?FW_(KS'_L!Q?_ *8F=N6_\C#
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M'%_^F)G;EO\ R,,#_P!A>'_].P/ZVJ*\(_X:E_9C_P"CC/@1_P"'>^'_ /\
M-#1_PU+^S'_T<9\"/_#O?#__ .:&OQZZ[K^O^'7WGZV>[T5X1_PU+^S'_P!'
M&? C_P .]\/_ /YH:/\ AJ7]F/\ Z.,^!'_AWOA__P#-#1==U_7_  Z^\#W>
MBO"/^&I?V8_^CC/@1_X=[X?_ /S0T?\ #4O[,?\ T<9\"/\ P[WP_P#_ )H:
M+KNOZ_X=?>![O17A'_#4O[,?_1QGP(_\.]\/_P#YH:/^&I?V8_\ HXSX$?\
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M=S!=1)+$\EO+LE19(V9 '4G^._P%_P IQ_\ @M/_ -?7[&O_ *HR*OA/$O\
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M\FZW^UM\7_C\_@_QGX<EOOAMX3EU/_@EKX^\,_#T:YXJ\*:ZGB7XY?M4^-_
M'CWP_P"(?%^@RV \9_#OQ-HWA?4M$O(]3\*ZWX6\5>$6\*>+]'\-V]UYTFH/
M#\,YE5:=6-+#4G3P=959U:512I9A76'P<X1I3DY1KU/:6E=1C&C5<W&2A&;A
MA*LFN9*$6J<N9M.ZJRY*;7*W=2=];VM&5WHD_P!R**_,NR_;S\?ZA8KX?TWX
M'Z%J?Q7\-Z+^T#XA^(.AR?%.U\*_#J'2OV;OC]+\"O'MUX1^)_C?PUX=TK4+
M8?9;KQI<S:Y9:+=>&=-N/#ECK>F_9?$3:_I'>7G[57Q.M_%7QETVZ\'_  D\
M/^%_AS^T'X?_ &=O#FKZEX]\>ZWXN\5^*/%7A?X/^.-&N],^'_A[X63WFOWI
M\(_$C4K^3POH6M27SZKHTMC/J&G^%M-U?Q[%SRR#,X2<9T:49+VEXO%85S:I
M8BGA925.-:52495JL(TIQBXUES2I.<82:CZM6NURJZOISPO:,HP;2YKM<TDD
M[6EKRWLS[XHK\A/#?_!2/XM>)M(M_'VF_L[^$K[X=:9X2_92\5^+K'3OBKXB
MOOBBL'[37Q3\5_!F+3O!'A.'X4'1O%6M^'?&GA/5;RST>\\2Z!+KV@6^E);7
M,>N^)9-+\,_3?P)_:%^+7Q'^)^L_"+QEH'@+2/&WPG\0_$;3OCYIWAV/7;JR
M\,Z9';^#;_X"W_AK4K_6/M5W#\9/#7BFX\<:9?:KHD%NNG^'/%_A>2"PU_PI
M<3ZG6)X>S3!PKSQ-*C36'4G62Q6&JSI\E*E5DIPHU:DH<JQ&%@W-1C[;%X6D
MI.I6A%N>%K04G-17*FY>_%M6C&3NHMVMSP3O9<TX1OS22/N"BO(_!L^I^(?B
M5\3_ !-)>ZB/#6BGPY\-/#.F-<K+HEU?^'+>]\1>-/%^EB"4QM<W^M^+K;X?
M:M'=1FYL-2^%ES#$T2W-PDGKE>15I^RDH-IODIS=NCJ4XU.1WUYH<W+-65IJ
M2Z7>$E9VO?1-^5TG;U5[/SNC\W?'O_*<?_@BQ_U]?ME?^J,EK^QJOXY?'O\
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M_P#R+<1_V'U/_4;"'Y[Q7_R,J7_8'2_]/8@****^K/F0HHHH **** "BBB@
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MG@S0;G[-KWC/Q)??VE=Z7/J\W]I?99[^6SL["WM?[>:_FN_X-B?^38_V_O\
MM+'^U5_ZK[X!4FDVKJ^C_-":3:NKZ/\ -'N__$-!_P $2?\ HRK_ ,V/_:U_
M^?S1_P 0T'_!$G_HRK_S8_\ :U_^?S7V;XK_ &T_$'AK]O;X>?LVR>";-_@'
MXITOQ!\)M:^-:78DFTC]M.[\"Z7\?_ _P)U"S>\MAH]I??LTZ;X@\>?VO)9:
MC#K^N>+/!/A[3KRPU"WO;34/AG]I'_@I]\?_ -F7XH_MD0^(;WX!>,O"/[-'
MQH_9Y\ ?#CX*Z7\(OBEX=^,?[0=E^T5X2\ ^)])\&>%_BH_QM\4^#-'^(G@Q
M?&-W%>:K)\)=4T#Q'#IUG=:EHWP]L]4CO(2R[+[D%EV7W(V?^(:#_@B3_P!&
M5?\ FQ_[6O\ \_FC_B&@_P"")/\ T95_YL?^UK_\_FOHGQ/^U/\ M-?#'XY_
MMH?!OXC:K\"I[KPY\!-"^.?["47AOX1_$.SUOXFIXM\5>)?AK!X%\>IJ_P =
MI]'\>^-O WQ=N?A'\.=9T3P9J/PP;QE+\6_ .O6-QX+;Q>F@^'?./!_[0_\
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M9H_V35(['4/,T>2Z^R?8;FQNKI-7MY.XFKV\G<^ _LG_  <;_P#0?_X(F_\
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MEG;SW5S(5AMX99G1&_);2](^-GPW^*_P^_:M\+?"WQ;JWBK]KS0O'GA/XO\
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M_P#Y_E'_  ^BU;_I$!_P6R_\0O\ !?\ \_ROVRHIV??\/3_)_?Y!9]_P]/\
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MB3Q?H'Q*^%WP^\:3^%? WQY6\D^#'COX@^(?#.E?&+]G_P &_ G6->\&:_\
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M?"&OZ>*B-_>U^T_S7_!7S)UN]>OZ1_X*^9^%?_#\I_\ I#O_ ,%U/_$ +?\
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MU^$O_$,#_P $7O\ HV#Q/_XD)^T'_P#/+H_XA@?^"+W_ $;!XG_\2$_:#_\
MGET:]E][_P @U[+[W_D?NU_PFW@S_H;O#'_@_P!*_P#DNC_A-O!G_0W>&/\
MP?Z5_P#)=?A+_P 0P/\ P1>_Z-@\3_\ B0G[0?\ \\NC_B&!_P""+W_1L'B?
M_P 2$_:#_P#GET:]E][_ ,@U[+[W_D?NU_PFW@S_ *&[PQ_X/]*_^2Z/^$V\
M&?\ 0W>&/_!_I7_R77X2_P#$,#_P1>_Z-@\3_P#B0G[0?_SRZ/\ B&!_X(O?
M]&P>)_\ Q(3]H/\ ^>71KV7WO_(->R^]_P"1^[7_  FW@S_H;O#'_@_TK_Y+
MH_X3;P9_T-WAC_P?Z5_\EU^$O_$,#_P1>_Z-@\3_ /B0G[0?_P \NC_B&!_X
M(O?]&P>)_P#Q(3]H/_YY=&O9?>_\@U[+[W_D>+_\',WB+P_J_P"S5^P';:5K
MNCZG<)_P5>_97G>WT_4[*]F2%? /QZC:9HK:>618EDEC1I"H0/(BD@NH/]--
M?@]X3_X-J?\ @CQX(\5>&?&GAO\ 9J\2V/B+PAX@T;Q1H%[)\?/CW=I9ZUH&
MHVVK:7=/:7?Q&FM+I+>^M()6M[J&6WF"&.:*2-F0_O#22=VW;6WX?) KZWZO
M]$O+L%%%%4,^0_VE/!?C7Q3\9O\ @GWKGA71M4U30OAO^UYXT\:?$J^T\@6G
MASP5??L%?MN_#RPUG7!YL>[2Y_B-X]\ >'H0$G/]M:[I#>4 #-#]>5\A_M*:
M)X]U7XS?\$^[[P?I_B>]\/>&OVO/&FM_%2YT"+4I-*TGP%/^P5^V[X<T[4/&
M[V/^C0>&)/B?K_PXTJTEUC_B6GQIJ?A&&+_B;S:57UY277U_1"77U_1;?UO<
M****8S^63_@IU_RL&_\ !'O_ +(1^UM_ZJ;XP5^N=?D9_P %.O\ E8-_X(]_
M]D(_:V_]5-\8*_7.OT7@_P#Y%N(_[#ZG_J-A#\]XK_Y&5+_L#I?^GL0%%%%?
M5GS(4444 %%%% !1110 4444 %?B;_P<-_\ **#]H7_L8O@A_P"KM\ U^V5?
MB;_P<-_\HH/VA?\ L8O@A_ZNWP#7GYM_R*\Q_P"P'%_^F)G;EO\ R,,#_P!A
M>'_].P/HG_@U"_Y1$^#_ /LN_P ;O_3UIE?THU_(U^RA_P $9O\ @N1^P]\(
MK/X#_LN_\%8_@1\,/A3I^O:YXFM/"O\ PR_X#\:^5KGB.>*XUF]_MSXA_#+Q
M;XDD^V30QO\ 9I=8>TM]NVTMX$+*?I3_ (8D_P"#E'_I-+\"/_$,_@5_\XRO
MQU.R2Y7LNWEY_P!?)GZRKI)6>B7;_,_I1HK^:[_AB3_@Y1_Z32_ C_Q#/X%?
M_.,H_P"&)/\ @Y1_Z32_ C_Q#/X%?_.,HO\ W9?A_GY_GV8[OL_P_P S^E&B
MOYKO^&)/^#E'_I-+\"/_ !#/X%?_ #C*/^&)/^#E'_I-+\"/_$,_@5_\XRB_
M]V7X?Y^?Y]F%WV?X?YG]*-%?S7?\,2?\'*/_ $FE^!'_ (AG\"O_ )QE'_#$
MG_!RC_TFE^!'_B&?P*_^<91?^[+\/\_/\^S"[[/\/\S^E&BOYKO^&)/^#E'_
M *32_ C_ ,0S^!7_ ,XRC_AB3_@Y1_Z32_ C_P 0S^!7_P XRB_]V7X?Y^?Y
M]F%WV?X?YG]*-%?S7?\ #$G_  <H_P#2:7X$?^(9_ K_ .<91_PQ)_P<H_\
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MR/.V>;Y/VF*7RO-\J+S-FW?Y:;L[%Q_.#_PQ)_P<H_\ 2:7X$?\ B&?P*_\
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M])XBTLVNJCP^$T-+I=*CCLU_#S_AB3_@Y1_Z32_ C_Q#/X%?_.,H_P"&)/\
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MK^:[_AB3_@Y1_P"DTOP(_P#$,_@5_P#.,H_X8D_X.4?^DTOP(_\ $,_@5_\
M.,HO_=E^'^?G^?9A=]G^'^9S'@#_ )6P?C?_ -HP])_]3+X0U_3Q7\\7[ /_
M  2G_;M^"?\ P48\7_\ !0C]N#]LGX9?M1^._%?[.6K? .:;P?\ "NP^&6JB
MT?Q+X$UGP]<2:=X6\.^%?""V6DV7A2^LYG@T9-2NY;Z"6XN)_*9A_0[1&^M]
M+MOY,%UTM=_HET] HHHJAGXF_L1_\IH/^"YG_8K_ /!++_UG[XPU^V5?B;^Q
M'_RF@_X+F?\ 8K_\$LO_ %G[XPU^V5);?.7YL2V^<OS84444QA1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %?)/[,D'Q'A^(7[;;>/(?&T6BW'[
M6WG_  J;Q='KJ:7/\./^&8/V9(?.^'QUD"TE\$_\)]#X\B\SPX6T+_A+XO%R
M9_MI-9 ^MJ^2?V9)_B/-\0OVVU\>3>-I=%M_VMO(^%2^+I-=?2X/AQ_PS!^S
M)-Y/P^&LDVD7@G_A/IO'DOE^' NA?\)?+XN?']M/K)(!];4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M_P"$GB\.,OUO2[[[_HMO+];B[[[_ *+;R_6X4444QG\LG_!3K_E8-_X(]_\
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M$^D:[X\@U+]AW]C3XJMXK^)>H->W2^*/&UG<_$VX\#6&NQP::EO\./!GP_\
M#)LI)/#KZC?@'U;1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110!^)O[$?\ RF@_X+F?]BO_ ,$LO_6?OC#7[95^)O[$?_*:#_@N9_V*
M_P#P2R_]9^^,-?ME26WSE^;$MOG+\V%%%%,84444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !7R3^S)/\ $>;XA?MMKX\F\;2Z+;_M;>1\*E\72:Z^
MEP?#C_AF#]F2;R?A\-9)M(O!/_"?3>/)?+\.!="_X2^7Q<^/[:?62?K:OD3]
MF#6O'NK?$3]N&U\::AXGO=)\/_M=_P!B_#:'Q%+J4ECIG@+_ (9;_9@U?^S_
M  @M_P#N8?#'_":ZMXTOO*TK_B6_\)'?>(I/^/\ DOZ /KNBBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** /A+_@J3_RC)_X*+_\ 9B7[77_K/_Q"KJ/^"=W_ "C]_87_ .S.OV9/
M_5*>":Y?_@J3_P HR?\ @HO_ -F)?M=?^L__ !"KJ/\ @G=_RC]_87_[,Z_9
MD_\ 5*>":75>C_.(NJ]'^<3[%HHHIC"BBB@ HHHH **** "BBB@ HHHH *_.
M?]J__@K5_P $\OV'?B98_!W]JC]I'1?A+\2=2\):7X[L?#&H>!_BGXCGG\)Z
MUJ6M:1IFKB_\%^!?$FD)'=:CX>UFV6VDU!+Z-K)I)K:.*6WDE_1BOY@_B_\
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MH>]_=^Y_Y^O]/3XZ_P"(C#_@B_\ ]'P>%_\ PU'[0/\ \Z:C_B(P_P""+_\
MT?!X7_\ #4?M _\ SIJ^Q?\ AUM_P3)_Z1T?L)?^(B_L_P#_ ,[ZC_AUM_P3
M)_Z1T?L)?^(B_L__ /SOJ/>_N_<_\_7^GH>]_=^Y_P"?K_3T^.O^(C#_ ((O
M_P#1\'A?_P -1^T#_P#.FH_XB,/^"+__ $?!X7_\-1^T#_\ .FK[%_X=;?\
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M%'X'F\;1>&+G]K?QG!\8T\*2:ZFA7'PX7]A#]M>YTN'XF+I!&GR^"5^+MO\
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MHH ^$O\ @J3_ ,HR?^"B_P#V8E^UU_ZS_P#$*NH_X)W?\H_?V%_^S.OV9/\
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MO_G/477G]S_R"Z\_N?\ D?ME17XF_P##;G_!:#_I!IX7_P#%IO[/W_SGJ/\
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M#^:[_@YV_P"38_V ?^TL?[*O_JOOC[7]*-?S7?\ !SM_R;'^P#_VEC_95_\
M5??'VOZ4:E?%+_MW\A+>7K^B"BBBJ&?(?[2GC3QKX6^,W_!/O0_"NLZII>A?
M$C]KSQIX+^)5CIX!M/$?@JQ_8*_;=^(=AHVN'RI-NEP?$;P%X \0PD/ ?[:T
M+2%\T@F&;Z\KY(_:0^(WC3P1\8_V O#/A;7)=)T/XP_M;^,_AS\2+".TT^Y3
MQ/X+TS]A#]M?XN6.ASS7MI<W-A%;_$3X6> O$HN](FT_4'F\/0V,MV^E7NIV
M%[];TEU]?T0EU]?T04444QA1110 4444 %%%% !1110 4444 %%%% !1110
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MNOOW_AW!_P %U/\ I/?_ .:%_!+_ .7=2G?5)_A_F2G?5)_A_F?T445_.O\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M/)[GX$?!>]^,UI^T5??"SP'J'QWT[P-9_#/2OB]J'AC2;[XA:+X L=5\1ZW%
MX0T'Q3=VLVK:%H4VJ^+?$-[J-AH]S91:M-J)_M07B6UFMO\ A?\ \[2W_>'/
M_P!^;K^BBOYU_P#G:6_[PY_^_-TG^L?S0GM\X_FC^BBBBBF,**** ,7Q)X;\
M.^,O#NO^$/%^@Z+XJ\)^*M%U3PWXH\+^)-+L=<\.^)/#NN6,^F:WH.OZ)J<%
MUINL:+K&FW5SIVJ:7J-M<6.H6-Q/:7<$UO-)&WB4O[(W[+$WPQ\)_!2;]G+X
M(S?!_P ":VGB7P;\+I?AAX-D\ ^&O$*VFKV#ZYH_A-]'.AV6JW-AXA\06%_?
MPV2W.HV.O:W9W\EQ;:MJ$5Q]#T4 ?/?@S]DC]E;X=>'M;\)^ OV:O@)X-\,^
M)OA_)\*/$^A>&?A#X T72_%'POFFURYN/AWXFL[#P_!#XA\$W5UXG\2W=WX7
MUE;W1;N[\1Z_=7-E+<:SJ4ESZ%\+/A)\+/@;X(T?X9_!CX<^!_A1\//#YO&T
M3P/\._"^B^#O"NER:C>3ZCJ,UEH6@65AIL%SJ6HW-SJ&HW*6XN+^_N;B]NY)
MKF>65_0J* "BBB@ HHHH _FN_P"#G;_DV/\ 8!_[2Q_LJ_\ JOOC[7]*-?S7
M?\'.W_)L?[ /_:6/]E7_ -5]\?:_I1J5\4O^W?R$MY>OZ(****H9\F_M&?$S
MQOX#^,'[!'A;PIK?]E:#\:?VLO&/PS^)EC_9ND7W_"2^"-*_87_;1^,=AHGV
MK4K"\O-&\CXD?";X?^(_[2\/W&E:O+_8']D37\F@ZKK>EZE]95\F_M&?$GQ=
MX&^,'[!/A?PW?6MIHWQE_:R\8_#;Q_;W&EZ9J$NI^$=+_87_ &T?C!96-C=W
M]I<76AW4?CSX4^"=2?5-%FL-3FLM.O-$ENWT;6-6L;SZRI+KZ_HA+KZ_H@HH
MHIC"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "ODW]G/Q!X(UGXP?M[Z=X4^'_ /PAFO>$_P!K
M+P=X?^)GB/\ X2O5_$7_  MGQO<_L+_L7>*;#X@?V1J4,5GX#_LWX;^)?A_\
M*_\ A%/#[W.D7G_"L_\ A.)IEU[QGK=O!]95\F_LYZUX$U7XP?M[6/A'P3=>
M%?$'AO\ :R\':+\4==N/$E]KD7Q+\=S_ +"_[%WB+3_&UCIEW%'!X-M;#X9:
M_P##KX<OX;TQY[&ZO? %YXODE&I>*M0@A /K*BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@#\3?V(_^4T'_!<S_L5_^"67_K/WQAK]
MLJ_GK_9\_:)_9^^ ?_!:#_@M9_PO7XZ?!SX+?\)9X7_X)C_\(M_PMGXF^"OA
MS_PDO]A?L_?$_P#MO^P/^$PUO1O[9_L;^V=(_M7^SOM/]G?VKIOVOR?MUKYO
MZG_\/$?^"?W_ $?1^QU_XDW\%/\ YMJ2:[]9?G_P5]XDUWZR_/\ X*^\^Q:*
M^.O^'B/_  3^_P"CZ/V.O_$F_@I_\VU?D%\(_P#@YR_8 U_]J+XS_LO?'/7H
M?@E+X ^,_COX<?#;X_0:]8?$+]G+XM^&-!\63:#X3\6?\+#\,12-X&D\2V(3
M5)KS7-.NOAO8Z?#)JLOQ,CANH;*$NNZU"Z[K4\B_X-^/^4@7_!Q+_P!I%?$'
M_JZ_VM:_J?K^4C_@W7\0Z!XN_;B_X."?%?A37-'\3^%O$_[?M[XA\->)?#VI
MV6M:!XAT#6OB]^U=J6C:YH>LZ;/<Z=JVCZMIUS;7^F:G87-Q97]E<075K/+!
M+'(W]6]*'PKY_FQ0^%?/\V%%%%44%%%<WXL\8^%/ >AS>)?&GB+1O"V@07ND
M:8^K:]J-KIEDVJ^(=8L?#WAW2()KJ2-;G5_$7B'5-+\/^'])M_-U'6]=U/3M
M&TNVN]2O[2UF .DHKY0M?VY?V3=0EOX]-^-WA358]*U_X0>&=2O](AUO5M'L
M=9^/GB/7_!GP@ANM<T[2;K1X;7QQXX\+>(O .FZH]\-*MOB!HU_X$U.]L/%L
M#:-3M$_;J_8S\2Z'XI\3>'_VH?@9K7AWP3?SZ9XKUS3/B3X7O-*T*_M?^$Y>
MZM;Z^@U%[9)+6R^&7Q"UFYV2.MOX<\&>(_$TS)X>TNZU., ^K:*S-%UK1O$F
MC:3XB\.ZMIFO^']?TRPUK0M=T6_M=5T;6M&U6UBOM,U;2=3L99[+4=,U*RG@
MO+"_LYYK6\M9HKBWEDAD1VTZ "BBB@ K^8C]J;_E:B_X)G?]F)?&;_TT?M85
M_3O7\Q'[4W_*U%_P3._[,2^,W_IH_:PI/;YQ_-">WSC^:/Z=Z***8PKY._9I
M^(>M^.?B!^VKH^KVF@VMK\+OVL?^%>>'I-&T:TTJ[OM$_P"&9/V:/'7VOQ)<
MVRB37M>_MCQSJ]K_ &S>EKO^Q;71M)W?9=)M57ZQKY._9I\>W/C3X@?MJZ3<
M>&O!V@)\-OVL?^$"M+WPKH,>BZEXLMO^&9/V:/&O_"2^.[M)YCXD\8_:/&EQ
MX?\ [>D2VD_X130/"NB>1LT5)I@#ZQHHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH *_&']M[_@BS\,_P!M7]J73?VO/^&L?VQO
MV9_BUIWP<T7X'?;_ -F#XEZ!\-/MG@G1O$_B'Q9]FO=6_P"$/U3Q+-_:6JZ_
MOU*R_MQ=)N?[)TB7^SEN;3SG_9ZBC^ON#^ON/YU_^(>W_K+W_P %C/\ Q+O_
M / ZC_B'M_ZR]_\ !8S_ ,2[_P#P.K^BBBE9=OZT_P D*R[?UI_DC^=?_B'M
M_P"LO?\ P6,_\2[_ /P.H_XA[?\ K+W_ ,%C/_$N_P#\#J_HHHHLNW]:?Y(+
M+M_6G^2/YU_^(>W_ *R]_P#!8S_Q+O\ _ ZC_B'M_P"LO?\ P6,_\2[_ /P.
MK^BBBBR[?UI_D@LNW]:?Y(_G7_XA[?\ K+W_ ,%C/_$N_P#\#J/^(>W_ *R]
M_P#!8S_Q+O\ _ ZOZ***++M_6G^2"R[?UI_DC^=?_B'M_P"LO?\ P6,_\2[_
M /P.H_XA[?\ K+W_ ,%C/_$N_P#\#J_HHHHLNW]:?Y(++M_6G^2/YU_^(>W_
M *R]_P#!8S_Q+O\ _ ZC_B'M_P"LO?\ P6,_\2[_ /P.K^BBBBR[?UI_D@LN
MW]:?Y(_F\U+_ (-N/A=XNUWX>:K\5O\ @HU_P4V^-VE?#/XD>$OBIX<\&_&3
MX_\ AWXB>#T\8>#+R2YTC5&T/Q)X OK:"]6VN=1TIM2L1::I%I>K:I9VM[!'
M?3[_ .D.BBA)+;^K: DEM_73] HHHIC/DW]HSXAZWX*^,'[!'AO2;30;FP^+
MO[67C'X>>)IM7T:SU34-/T33/V%OVT?BO;W?A:^N5:;PYKS^)/AAX?L+C6=/
M*7D_AB]\1^'G8V&O7RM]95\F_M&>/;GP?\8/V"?#T'AKP=KL7Q5_:R\8^ KW
M5/$^@QZQK?@RVT[]A?\ ;1^*">)?AUJ#SPMX5\8W5Y\-[3P??:]%'=27'P^\
M5^.O"Y@6+Q))<VWUE277U^[1?\/\Q=_7[M%_P_S"BBBF,**** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M:I+%>1S?#[Q[XZT06RRZQ'=VOUE2[^OW:+_A_F+OZ_=HO^'^84444QA1110
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MZ6I9]W^'^1_-=_P^(_X*[?\ 2NW\=_\ Q+/1?_H;Z/\ A\1_P5V_Z5V_CO\
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M>.PURPTS4XH?MMC<I#)<64*74*)=VK36D\$\H!V]%%% !1110 4444 %%%%
M!1110 4444 %%%% !7R3^S)KW@_6OB%^VW:>%O <7@S4O#?[6W]@^.M6C\2Z
MSX@;XD^,/^&8/V9-:_X3R:QU7_1O"4O_  BNM>%O!7_"-:#C1O+\&1^(?^0M
MX@U8U];5\G?LT:_X(UOX@?MJVGA'X?\ _"$:IX9_:Q_L#XA:O_PE>K^)/^%F
M^-_^&9/V:-;_ .%@?V?J<,5OX+_XH_6_"/@?_A%-$:XTC_BB/^$F\[^U/$NI
MPQ 'UC1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !117CM]^T'\$M+\9>)/ &J?%#P=IGBKP=X,\2_$+Q98ZEK%O86?
MAOP;X*D\.IXUUO6]<NS#H.FP^"X_&'@^]\8VUWJ<5]X5TOQAX2U?7[73]+\3
MZ%=WX![%17SJ_P"UW^RW'I)UU_V@_A FE1:QXF\/WEVWC[PX!I6L^"M6\.Z#
MXUL-=A-_]HT";P7K?C#PAI/C$ZU%81^%M0\6^%[37GT^?Q%HZ7N=KO[:'[)?
MAB/XA2^)/VC/@]H,7PITWQ5K'Q!EUCQWH&G1^&]+\">++/P!XWO[F2[O(DNK
M7P=\0-1T_P"'WBJ73C>+X?\ ']_9>"-6-IXINH-)D /INBOEH_MD?LX>(?AE
MK7Q*^&/QZ^ 7CK3(?$WB/X:>&M5;XOZ%8^!=;^,.A>%KWQ>/AWJ/C/0+/QC/
MI5U'X>LV\6:]<Z3X:\4:GH?P\COOB#%X?U;P]9&6;QR/]N+6+_\ X)A'_@HO
MH_PFTRYOX_V0)?VMYO@SJ7Q%NM,M%TO3OAF_Q3USP7'\2;7X?ZQ-+J%KH=KJ
M%CI.L-\/X;;5M6ALX[RQT.SO9[S3P#]"**^/H_VT_@=X;TWXB^*OBW\9/V=_
MAQX"\$_$KP#\)HO$MQ\;-.N)M.^('C7P/X2\2MX!^)EMK?A[POHOP^^(5KJO
MB*Y6Q\)6/B?QG-<^"8=,\;:U>^&GO=4T#0NS3]L#]E5_ /@[XJ?\-%_!B/X:
M_$%-0D\&>.I_B-X6M_"WB&'1_%&G^!M:N;#6I]3CL6M="\;ZMI'@O7KJ6:*W
MT/Q?J^E>&-5EL]<U.QL)P#Z.HKYB^*O[4?@_X<?%OP_^SY9Z=?Z[\:O'7P-^
M,GQM\ Z)=6NO:9X)O]/^$-]X)T>?2O%_CO1_#?BL^#8-?UKQWIEM#K8\.:]!
MI=K8:E)=V4FJWGA71/$_GG[+'[?7P _:7_9\\$_&F+XC_##POKUW\)OV>_B#
M\7_AU:_$C0_$>I?!/Q+^T5X(\.^*_!7P_P#%%XL>DWKZOJ^IZ\WA7PDUUH>D
M7WC/7+*;3=(T==9$^D6P!]P45\=P?\%"?V%;J_?3+/\ :]_9TOKV+PNOC2:&
MP^+O@F_6#PJVC>)O$+:[<36>L3006$.B^#?$NHW4DTJ&TM]+<W2PM<6:W%3Q
M7_P48_8-\!7&C67CS]K[]GKP)?Z]!K=QI^G>-OBEX3\(ZFJ^&?%USX!\31:G
MIOB+4M-OM#O/#/C.PU;PUXDL-;M]/O= U;0O$=KJ]O9MX<UW^SP#[/HKYLT;
M]K[]G/Q%K.N:!H/Q*M-9U7PW\<;+]FS78--\/>+[V'3/CC?V-YJD/P[N;ZW\
M/O8+J\6D63ZS?W*W+:3I>BW6E:SJ>H6FF:UH]W??2= !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% 'R1^TAKW@_1_C
M'^P%I_B;P%%XPUKQ5^UOXST'X>>(9/$NLZ$_PK\86_["'[:_B>]\>P:7I9^P
M^-)=1\ >'/'/PP/AKQ'G1K6'XCS>,8!_PD/A/02/K>ODW]HSQ!X(T;XP?L$:
M=XK^'_\ PF>O>+/VLO&/A_X9^(_^$KU?P[_PJ;QO;?L+_MH^*;_X@?V1IL,M
MGX\_M+X;^&OB!\*_^$4\0/;:19_\+,_X3B&9M>\&:);S]Y^T/^T3\._V8O V
MB?$'XF-KW]A>(/BA\)?A)IL7AK0-3\2ZK-XH^,?Q%\.?#?PV4TO28+B\EL[/
M4O$<6IZD((I;V73K&ZM=&LM6UZYTK1M12Z^OZ(2Z^OZ(]VHK\SO@Y_P4L^%'
MQ+^!OQ/\8^*_%_[/'PD^._PHTK]I;6/&'P8\:_M"06GAWPKHWP"_:!^)_P"S
MOIWC?QCX^O/A]IGBWP]\+O%_B[P%HUQ?^,Y/@_<ZAX9M_&6E6J^%-;U.?2;#
M6_HGQ!^VQ^REX&\96WPN^(O[1/P1\&_%O^SO!=WJ/PXO?B3H?_"16MWX_P!/
MN[[PE86FG7W]E:U?3>*!8SIX4MY=%L-6\1?:-&6STA+O7]'L[QC/JBBOD+]D
MK]IG7_VJ/@)X@^+6G>"?!>A^)M(^)W[0_P *M-\/:)\4-0\9_#SQ!K?P)^+O
MCSX16>N:7\45^&_A_5)_!WCG4/!2>(++6T^&C7^EZ'K,3KH6K7-J(KOR#X8?
M\%&?A;XH^"'[-'Q[^*GB;X&_ 7PI\;/V5&_:G\>^'_B%\<XK/QK\,_"MY:_#
MC^RKC0M'N/ NGV7CWP7;ZYXZD\*>)/'.JZI\.VL/$3>$=,T#PWXHU'Q9<:?X
M> /T<HKYMTG]L?\ 9/U[X?:K\6-#_:/^"NL_#/0_%.N^"-6\=Z5\2/"NH^%K
M'Q=X8\/S>+_$7AZ;6;34YK+^U-$\&6]QXWU.V65GL_!$$WC.;9X8B?55])\2
M_&+X6>$/ ^C?$KQ#X_\ "MCX#\2R>%X/"WBF/5[34-)\777CB>RM?!-CX/GT
MV2\/BW4/&5SJ6GV_A/3O#BZG?>))[ZTBT6WO7N85< ])HKY.M?V\?V*K[QEX
M0^'=E^U;^S_>>.?B!#\.I_ _A2T^*W@VYUOQ9%\7+>>Z^&#:!80ZN\VJ'QY!
M#&_A=+197U=M1T2.T627Q!H::AS,'[9WA?6OVS/ O[*G@Q?A_P".=(\6?"/X
M^>/-:\?>%OB>NK>(O!'CC]GKXC?##X=^,?AWXD^'UGX1ETR"WFU/XFQV4'B:
M'XB2ZA8^+?!/C_P5K/@[3-1\.27<X!]KT5\*Z'^W;\-]'\=?M1>#OCUJ/@#X
M&VO[/'QSM/A#HNOZM\1O[6M/B+H]U^S;\,_VH+CQM]FU'PKX4N?#*^&/AS\1
M9]0^(&FHOB+0_ VE^$/$7B?5/&<WAFUFU2W])\$?MA_ GQSK7[0>D6?BI]$M
M_P!FOXH>&_A'\0/$GBBQNM \)WGB[Q;X,^'7B_P_:^%/$E^D>E>(GU:;XF^'
M_"VF:=8W+:WJGB5H(-,TJ\TW7O">I>( #ZAHKYB\"_MJ_LA_%#QUH7PR^&O[
M2_P0^(/Q!\3:79ZUH'A#P5\2?"OBC7=6TN_TKQ-KEM>65CHFIWTLT?\ 9'@[
MQ+J$X \RTMM*EDNT@\ZU$_R[\2?^"H_P<^'WQWTCX5W=OINE^!?#?[1/Q$_9
MR^/_ ,7OB#K^K?#W0OA3XD\&_L<:[^V!I6O>'TU+P=?>&_'_ (?U31M!O/ ^
MOFX\;>#=9\-ZX=/U2PT7Q3H6O:)?W@!^G]%?/NO_ +6/[+_A6Q\(:KXG_:'^
M"WA[2?'_ (=\/>+O!6L:U\2_!^F:/XG\+>,-*UG7?!_B+1]6O-7ATZ\T;QAH
MWAOQ)JGA'48[DVOBBQ\.>(+G09=0BT35&M.-\+?MX_L9>-[7PU?>#_VG/@QX
MFLO%^H:=I?A^\T3QUHFHVE]>ZO<^!M/TN.2YM;F2'3X]0UGXG?#GPU:76I/9
MVL_BWQWX2\(QS-XF\0:7I-R ?6E%?#'CS_@IM_P3W^&6N>-?"WCC]L?]GW0O
M%?PZU+6-'\:^$7^)'A^_\7>']5\.K9R>(-.N_"VEW5]K\E[H,%XUWK=M:Z=<
M2Z38Z7XBOK];>S\+>))]*^H?!?Q9\!?$'7O%OACPIK-U?Z_X%MO!MWXMTR[\
M/^)-#N-#3Q]X=B\6>%8;O^WM(TR-KZ_\/SP:A=:; \VHZ+YT5KKEKIM[(ML0
M#T:OSN^/_P"P3)^T5X%_;)\/^,OBY=Z?XU_:57P/8?"[XB>'?#?B#1+_ /9Y
MT'X-Z;HNN_ ;2[?2])^)6G_\+(F^%/QWC\:_'[3]0OM3\)OJ7B[XB>(-'2#2
M]%@L$B_1&B@#\-O&O[+_ (S_ &F/VN/VJ/A3\8%UU_AIXG_9Z_X)?+\1OB?'
M\!_BQX.\)?%GQM^R;^T=\9_CO\0_#WPB\32ZFWAG1!K">(O">E:A9:)X]\8^
M(_#5OX^BNO">N:SK_P -_%$,?C'PM_X)TZ[^V7^S3XOL_B1JGB/X':]I^H_\
M%A/A'\*H?''P*^)WACQ;X:T#]OS]J37O&%K\4_$7A7QQKWPRU'Q?;1_"=(K_
M ,+Z)%'8>'KP?$2VCUR73O&WPUG@K^C"B@#\P/C+_P $Y[OXU_$+X[ZQXI^+
MQ?X<?M06/[&5Y\8O!=KX<\06.LZ5XQ_8Y^*EE\1+#6?A+XIB^($LO@30_BAI
MEA9^&-8T2.QN]:\%:I8P>/\ PUXONO$5Q?17'8_#G]C/XJ_![X\_M%?M!_#S
MX]>#X?$/[3/@6<_$;P3KGP1NYO 5W\=_"NHZW8?!KXPZ=::1\6=)U71=.\)_
M#"^T+X8?$/P597S7?Q9A\*:1XWO_ !CX>\7RZG>7_P"AU% 'SI^U9\$?$?[1
M?[/WCKX->&_'.B?#OQ!XP7PI]F\::YX(OO'^CZ2WA[QEX<\4W9G\&6'CGX?W
MNIKJ5MH=QIELL?C73#IT]]#J,K:E'9/IU[\]_&_]@;2OC'\6?B/X\_X3.TT'
MP[\9S^QAJ'Q)T5/##W'B.+Q-^Q1\>M4^-'@OQ+X+\60:Y93:%J/C72=7E^'&
MOS26,][X<T_3=%\3^%K^VU:#4;35/T/HH ^ O&?P4_:8_:8^#GB_X.?'_P 2
M?!#1OAS\5K7XT_#KXH>'M*^#OB$>-[SX7>(/&O\ 97@'5?!^L)^T)XW\*>#O
M'7_"J8M4$FJ7L'C>'2?'>L^%OB!:6.G/X4U+X;ZMPGB?_@F?X!\9_$?7[GQ)
MK]OJ'P+\4?M6:_\ MH>(/A0-&O(-1UGXR>(OV98?V9M1T'4/$T.N);7?PTO[
M:XU[XMZUI5SH4^OZ[\2M8BCO-;3PO97FCZS^G%% 'P'^RA^Q)#^S7XETGQSX
MC\?W'Q#\0^ ?V3O@'^QAX N[71+_ $1+3X,?L]2>*]3T[7O$6F)K.LPZ[\4/
MB#KGBJ74/&.J:9:Z;H\%KX?\-:/X:T.R:/6;W7?SM_9]_88^(G[1/P97QMJ7
MB[QO^S=\3?AAX_\ ^"KOASX"7VO_  8^(W@3QWX63]LS]L&^^*>A?$CQ'I7C
MVY\$:WK.D7_PRTFUBTR'PW:Z!?0:3\4)+K1?%'@+XR_"[2O$.C_T'44 ?A&G
M_!'CXE?V)\7M'D_:F\(+-\=OA)_P4D^$/C[4Q\"?%NHM8Z/_ ,%"KWX1^);S
M5?#">(OVB-<UQ]6^&_C?X5IJ#77B[Q7XHN_&'A?6I?#][>Z;XCMW\>7?TKXC
M_P"">'B;6?VB;KXS1?%3X77?AGQQX&_9VL?BGX7\;?L]_P#"Q_$]C\4OV:)/
M$9\*?$3]GKQ5XQ^*NJ:#\![3QK::QHVD>.-%C\"^-]<L]-\++JO@CQEX7^(V
MN'XBZ'^H]% 'XN6O_!)[QAX?\#_"[0/#'[1?A=?$?P?_ &>_^"7OP5\)ZMJ_
MP.U.30[S7O\ @F?^T7K/Q[T'QUXBT.Q^,]M>WFF_%G^W[_PYKG@W3M<TJ[\.
MS16VLVGC74PT^G-]<_L??L<ZM^RWXE^+/B&Y^*%UXHL?BO;>&KW4? NE6.OZ
M1\/='^(%AXQ^+'B[QQ\2_"'A77O%WBS3_AW??%.3XCZ0?&'@'X<Q^%?AI%XJ
M\*:MXYT+PSI=WX]O=$T#[JHH *^3?V<]%\":5\8/V]K[PCXVNO%7B#Q)^UEX
M.UKXHZ%<>&[[0XOAIX[@_87_ &+O#NG^";'4[N62#QE:W_PRT#X=?$9_$FF)
M!8VM[X_O/"$D1U+PKJ$\WUE7A/PB^"G_  JOX@?M2>.O^$F_M[_AI7X[^'OC
M7_9?]C?V7_PA?]@_LR?LZ?LY_P#",_;O[5U'_A(_M7_"@?\ A,?[9^QZ#Y'_
M  EG_"/?V5-_8/\ ;FL@'NU%%% !1110 4444 %%%% !1110 4444 %%>(_M
M*_';PO\ LP_L_?&3]H7QG:W6H^'/@Y\.?%7C^^T73I;>'5O$DWA[2;F]TSPG
MH;W;);-X@\6ZJECX:\/PS,J7&M:K86Y/[VO&/$G[8G@OX"S>%/ _[2&IZY%\
M1-7^QZ;?^(/A[\%/BK<?#;4O'7B#PK\1?B1X?^&?@>>UM_&>H>+?%\_@GX:>
M+8[/3?#M]K]_J.IZ-I5KJ=GX9\1_$/P)X1U< ^U:_.;]IG]@O5_VAOB!^TYX
MQM_C#IW@S3/VD?\ @G?XP_8.N-$F^&=SXFO_  A=^*M?^(FJQ?%J'7$^(_AR
MWUNWTZQ^(^IV$GP]?0M*DOKNPL-17QW90_:-,FXS2?\ @LA^P]K'A?3O%%KK
M?QUC_MNR^ >M^'?#-S^RI^TG!XV\6^$/VFM?N/"/P7\?^"?")^%YUKQS\/\
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MSVFHZ5JEI%?:??6LR%DFMKNTGAN()4)62*174D$&M2@ HHHH **** "BBB@
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MK+QCI_PCU'2-6BT[3_"7Q"C_ &%OVT=5U+Q!XILY$=]>T&Y^%.F?$[PK;Z3
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M<OA2#PIXV\0^-+#XT>!_$?AR'0=8NK2]\!SZG\3Y+NW^&6EW/C  'SQ\6O\
M@F5XT\:?&GQ7^T%X/^-GPOL_'NN?M&6/QKL/"/Q2_9^\1_$SX)R^$=5_8T\
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MU;QI\./%GP^T_3+CQ_+X%D?Q[X<2[EUKP[8^*M=G\3:7]6_LO_&'QU\7]/\
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MQEI_(_ ?_@H#X:^.OC;PEIMW%J'P6M+Z3]N9[GP?\1OA_JUZ_C;PE^R#\?\
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MXYO_ !XVH>,M4NO%/@_]L#P;\3/#=X/ T?A/XK6G[</Q3\,_%KXXZAXX@MO
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MI?%=Q/))H<P?QZ?"+Z"[1MX1.JDZM7S-X;_81NO@YHG@\_ /XP^.M \=^$?
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MK?L\>%?A[?:-X3^#_A70-9TK1/A[\8_%TM[XRN]*'Q9\8>(8?#ESXT^(6O\
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MM;_$CQ!X+^)_ASQGK-C9Z):Z7XFT-/"?@X^'BB@#EV_9B^*7Q&\":GX"^/\
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M:6L,4$$:C:D4:J. *T*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH \K^(7P@\+?$OQ;\"_&GB&XUF'5OV>_BIJ_Q?\"Q
MZ9=VMM977BG6O@C\8_@%>6_B*&XL;N6_T9?!/QP\8W4%I97&F72>(+;0KY[Z
M2SLKO3=0]4HHH ^$_P!M7X=Z;9:C\ OVQ8+2WO?%'[#OCCQG\3I=.FO)["3Q
M+\(_B'\,?%7PG^-_ABPNH;2]0Z_;>$?$UM\1_!>FWL5II7B7Q_\ #;PEX2US
M7_"&A>(-4\8:#^.G_!0/]DSX.?L$>'O GQZT[XK_ +0_BCQ=\3OVM/V5_#-O
M+J]O\'?%!T'0?!_[<>F?MJ:OJ5[J=QX'\+>+_'WC+1AHGC?3O"_BKXI>,?'G
MB#Q3JFI:-I7Q$UO4],2WUGPZ44 >F_$OX*?!.Q_X*3^!?V(;#4OB)H-M^T;^
MQK_P4BO?CCXMT/2O D>K^/M8_;D^,/P\^)_C>:779[)I=):QTGX1^.]&T'5X
M/#]UK'A*TTCX0^&K>7Q)H<'B"XL/T;UG_@FM\$[[0_'NBZ)XL^(WA'_A*/VH
M_@U^V#X&G\.I\,[2W^!OQC^ W@SX5_#OP OPITG_ (5L=*MO R^!/@]X3\':
MYX0\8VOC"#4?#=UXCTZUO=,;6I+B$HH H>./^"8GP,\=>"=1\'R^-/BYX/N;
M[XQ^,_VEK;QAX UGP7X?\6^'_P!J'QK\7=/^+\W[1?AW4K[P'K:6_P 3_#%S
MI_\ PK?P5=ZO!K>@Z!\'+_5_AX^A7^GZOJ=S=_>WAW0=7T6[\37&I^,_$'BR
M#7-9L]2TFRURS\+6L'A&PMO#/A_0Y]!T1_#?AW0;B\T[4-6TC4_%]U<>(9M:
MU6/7/$^KV=EJ%IX<M=#T322B@#Y=C_9D\<?#WPO\0-+^!WQT^(&@>(_BO^U5
M%^T/XJ\2^*(OA-?OX?T'Q-XJ\,:A\1_AEX7T\?!'4=/OO!5[X8T.]T70K+6K
M4?$,3ZH\T_QDL9(8;N+B+G_@GUX;\2^'/C;X'^*O[1?[2'QF^'_[0/A[XGZ)
M\1O!7CBZ^ VB6.HWWQ0TV+09_$__  DGPI^ OPV^(&H:WX#\,QKX8^%EEXB\
M8Z[X2\!:+;Z+#H_AA;KPEX,N_#I10!J-^P/\._\ A*+SXLP^-?&-M^T7??&J
M\^/4_P ?[?3_  ./& \;3_L^:E^RO8V2Z!+X4E\#OX0T#X%ZB?#.B>%;KPY<
MZ7'K]G:^.]3CU7Q;+J>IZC\2?\%++?X1?L/?L)_LD_!'X?Z5XE\(^ O ?[5W
M["?A;X='PQ9Z+XBU?P]H_P "_CO\/OC!J6K7K>*;ZVM-=\37GAKX8:]<V]WK
M"7\?B?QYJ%DWB9[>PU35M7M"B@#V3XI?\$?_ (!?%)HI;CXE_&7PA/?^*_BG
MX_\ &DGA63X57,?C3Q]\6?VAO#W[2VN>,KBU\;_"WQG;>%?$6F>./#.A^'=-
MU[P+'X9\0ZM\,O#_ (2^''CK6O&7A7PGHVGP^J^ O^";?PB\%^+=+\1:EX^^
M*?C[0=&F_;CL+/X9^-#\,K_X=W7@;_@H!\3O#WQ?^.'PZUNQLOAI8>)-:\-6
MWCKP['J7A2ZN_%'_  D=O::GJNB>(M;\2:"^GZ7IQ10!!\'_ /@G)X3^$]I^
MS7;WO[1G[2_Q/E_9)UVPNO@;/\0=<^$KV_AKP?H'P,^*W[/'A7X>WVC>$_@_
MX5T#6=*T3X>_&/Q=+>^,KO2A\6?&'B&'PY<^-/B%K_A_PGX9\-:3YYX=_P""
M2'P1\+:'X9\&6'Q-^*WB#X;Z/^SU^SQ^S7XI^&'Q$TSX->// /Q>\ ?LQZG\
M5KWX:?\ "V_#^J_">&#Q)=)8?&'Q5H^L6FD-X;T2<P>'_%>FZ5I7Q$\->'?&
M>E%% '?_  -^ .C:1^T%\.M.T2_O[[X:_P#!.W]G1?V1OAG)XRU&?Q+\1O%?
MC7XJ>$_@'XT\6^._%&LO;6U@(_#GPK^'_P +/#GA_5=/6VO]?\0>/OC%;:CH
0/A_0]$\)3:_^C5%% '__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>21
<FILENAME>nt10014672x1_diagram7.jpg
<TEXT>
begin 644 nt10014672x1_diagram7.jpg
M_]C_X  02D9)1@ ! 0$ P #   #_[0 V4&AO=&]S:&]P(#,N,  X0DE- ^T*
M4F5S;VQU=&EO;@     0 ,     !  $ P     $  ?_B"^!)0T-?4%)/1DE,
M10 ! 0  "]!N;VYE @   &UN=')21T(@6%E:( ?4  < %0 3  L (6%C<W
M         $E%0R!S4D="     0            #VU@ !     -,M2% @(
M
M$&1E<V,   %$    =&)865H   &X    %&)44D,   ',   (#&1M9&0   G8
M    B&=865H   I@    %&=44D,   ',   (#&QU;6D   IT    %&UE87,
M  J(    )&)K<'0   JL    %')865H   K     %')44D,   ',   (#'1E
M8V@   K4    #'9U960   K@    AW=T<'0   MH    %&-P<G0   M\
M*&-H860   ND    +&1E<V,         &G-21T(@245#-C$Y-C8M,BTQ('=I
M=&A"4$,
M                                                    6%E:(
M     "2@   /A   ML]C=7)V        !      %  H #P 4 !D '@ C "@
M+0 R #< .P!  $4 2@!/ %0 60!> &, : !M '( =P!\ ($ A@"+ )  E0":
M )\ I "I *X L@"W +P P0#& ,L T #5 -L X #E .L \ #V /L! 0$' 0T!
M$P$9 1\!)0$K 3(!. $^ 44!3 %2 5D!8 %G 6X!=0%\ 8,!BP&2 9H!H0&I
M ;$!N0'! <D!T0'9 >$!Z0'R ?H" P(, A0"'0(F B\". )! DL"5 )= F<"
M<0)Z H0"C@*8 J("K *V L$"RP+5 N "ZP+U P #"P,6 R$#+0,X T,#3P-:
M V8#<@-^ XH#E@.B ZX#N@/' ],#X /L _D$!@03!" $+00[!$@$501C!'$$
M?@2,!)H$J 2V!,0$TP3A!/ $_@4-!1P%*P4Z!4D%6 5G!7<%A@66!:8%M07%
M!=4%Y07V!@8&%@8G!C<&2 99!FH&>P:,!IT&KP; !M$&XP;U!P<'&0<K!ST'
M3P=A!W0'A@>9!ZP'OP?2!^4'^ @+"!\(,@A&"%H(;@B"")8(J@B^"-((YPC[
M"1 ))0DZ"4\)9 EY"8\)I FZ"<\)Y0G["A$*)PH]"E0*:@J!"I@*K@K%"MP*
M\PL+"R(+.0M1"VD+@ N8"[ +R OA"_D,$@PJ#$,,7 QU#(X,IPS #-D,\PT-
M#28-0 U:#70-C@VI#<,-W@WX#A,.+@Y)#F0.?PZ;#K8.T@[N#PD/)0]!#UX/
M>@^6#[,/SP_L$ D0)A!#$&$0?A";$+D0UQ#U$1,1,1%/$6T1C!&J$<D1Z!('
M$B8211)D$H02HQ+#$N,3 Q,C$T,38Q.#$Z03Q1/E% 84)Q1)%&H4BQ2M%,X4
M\!42%3055A5X%9L5O17@%@,6)A9)%FP6CQ:R%M86^A<=%T$791>)%ZX7TA?W
M&!L80!AE&(H8KQC5&/H9(!E%&6L9D1FW&=T:!!HJ&E$:=QJ>&L4:[!L4&SL;
M8QN*&[(;VAP"'"H<4AQ['*,<S!SU'1X=1QUP'9D=PQWL'A8>0!YJ'I0>OA[I
M'Q,?/A]I'Y0?OQ_J(!4@02!L()@@Q"#P(1PA2"%U(:$ASB'[(B<B52*"(J\B
MW2,*(S@C9B.4(\(C\"0?)$TD?"2K)-HE"24X)6@EER7')?<F)R97)H<FMR;H
M)Q@G22=Z)ZLGW"@-*#\H<2BB*-0I!BDX*6LIG2G0*@(J-2IH*ILJSRL"*S8K
M:2N=*]$L!2PY+&XLHBS7+0PM02UV+:LMX2X6+DPN@BZW+NXO)"]:+Y$OQR_^
M,#4P;#"D,-LQ$C%*,8(QNC'R,BHR8S*;,M0S#3-&,W\SN#/Q-"LT932>--@U
M$S5--8<UPC7]-C<V<C:N-NDW)#=@-YPWUS@4.% XC#C(.04Y0CE_.;PY^3HV
M.G0ZLCKO.RT[:SNJ.^@\)SQE/*0\XSTB/6$]H3W@/B ^8#Z@/N _(3]A/Z(_
MXD C0&1 ID#G02E!:D&L0>Y",$)R0K5"]T,Z0WU#P$0#1$=$BD3.11)%546:
M1=Y&(D9G1JM&\$<U1WM'P$@%2$M(D4C721U)8TFI2?!*-TI]2L1+#$M32YI+
MXDPJ3'),NDT"34I-DTW<3B5.;DZW3P!/24^33]U0)U!Q4+M1!E%049M1YE(Q
M4GQ2QU,34U]3JE/V5$)4CU3;52A5=57"5@]67%:I5O=71%>25^!8+UA]6,M9
M&EEI6;A:!UI66J9:]5M%6Y5;Y5PU7(9<UETG77A=R5X:7FQ>O5\/7V%?LV %
M8%=@JF#\84]AHF'U8DEBG&+P8T-CEV/K9$!DE&3I93UEDF7G9CUFDF;H9SUG
MDV?I:#]HEFCL:4-IFFGQ:DAJGVKW:T]KIVO_;%=LKVT(;6!MN6X2;FMNQ&\>
M;WAOT7 K<(9PX'$Z<95Q\')+<J9S 7-=<[AT%'1P=,QU*'6%=>%V/G:;=OAW
M5G>S>!%X;GC,>2IYB7GG>D9ZI7L$>V-[PGPA?(%\X7U!?:%^ 7YB?L)_(W^$
M?^6 1X"H@0J!:X'-@C""DH+T@U>#NH0=A("$XX5'A:N&#H9RAM>'.X>?B 2(
M:8C.B3.)F8G^BF2*RHLPBY:+_(QCC,J-,8V8C?^.9H[.CS:/GI &D&Z0UI$_
MD:B2$9)ZDN.339.VE""4BI3TE5^5R98TEI^7"I=UE^"83)BXF229D)G\FFB:
MU9M"FZ^<')R)G/>=9)W2GD">KI\=GXN?^J!IH-BA1Z&VHB:BEJ,&HW:CYJ16
MI,>E.*6IIAJFBZ;]IVZGX*A2J,2I-ZFIJARJCZL"JW6KZ:Q<K-"M1*VXKBVN
MH:\6KXNP +!UL.JQ8+'6LDNRPK,XLZZT);2<M1.UBK8!MGFV\+=HM^"X6;C1
MN4JYPKH[NK6[+KNGO"&\F[T5O8^^"KZ$OO^_>K_UP'# [,%GP>/"7\+;PUC#
MU,11Q,[%2\7(QD;&P\=!Q[_(/<B\R3K)N<HXRK?+-LNVS#7,M<TUS;7.-LZV
MSS?/N- YT+K1/-&^TC_2P=-$T\;42=3+U4[5T=95UMC77-?@V&38Z-ELV?':
M=MK[VX#<!=R*W1#=EMX<WJ+?*=^OX#;@O>%$X<SB4^+;XV/CZ^1SY/SEA.8-
MYI;G'^>IZ#+HO.E&Z=#J6^KEZW#K^^R&[1'MG.XH[K3O0._,\%CPY?%R\?_R
MC/,9\Z?T-/3"]5#UWO9M]OOWBO@9^*CY./G'^E?ZY_MW_ ?\F/TI_;K^2_[<
M_VW__V1E<V,         +DE%0R V,3DV-BTR+3$@1&5F875L="!21T(@0V]L
M;W5R(%-P86-E("T@<U)'0@
M
M      !865H@        8ID  +>%   8VEA96B            !0
M;65A<P         !                               "6%E:(
M  ,6   #,P   J1865H@        ;Z(  #CU   #D'-I9R      0U)4(&1E
M<V,         +5)E9F5R96YC92!6:65W:6YG($-O;F1I=&EO;B!I;B!)14,@
M-C$Y-C8M,BTQ
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MU=;7V-G:X>+CY.7FY^CIZO'R\_3U]O?X^?K_Q  ? 0 # 0$! 0$! 0$!
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MI]+^-^B:FD; _9KRZ^(-CJOB^SAD VRR:!XLT6\96;;=*VUE_/:BOW?$^&7
M&*H/#U.$LDA!QY.?#X*GA*Z35KK$X94L0I6^U[3FZWN?B6'\1^.\-65>GQ5G
M,I\RGRU\7+%46TT[/#XI5L.XZ6<'2Y&M+']M'_!.7_@X9\ ?M#>+/#7P-_;!
M\)Z!\!?BWXHO;30_!WQ)\-WU]/\  _X@>(;V5(+#0+AM:GN]<^&'B759Y%@T
MFP\0ZEKGAK5+D+:0>+[;5KS3M&NOZ6 <U_D;7EI;WUI<6=U&);>XB:*1#T*M
MW!'*LI^9&'S(X5E(8 C^WS_@FW_P6Y_9-\,_L(? ^S_;3_:A\,^'_CUX1C\5
M?#?Q1IU[#XF\=^/]=T[P'XEO]$\(^,?$'A_P'HGBSQ)9R:_X.7P_+>:QK]A8
MG6M:@UF^@>>,F4_R=XO>%]#@C&8#&9).O7RC-ZE6C1PM5RKXG!8NE%5'055+
MFKT:E-N5"4DZL53J0JRFU&I/^H?"KQ(K<9X3&X3.(4*.;953I5JV(I)4</C,
M+5E*FJ_LW)QHUJ4XJ.(C%JE)U:<Z48)RIP_I-HKY3_9P_;D_9#_:ZBO3^SA^
MT)\,_BMJ&F0FYU7PUH&OQVWC71[4.L8O-9\":U'I?C/2+)W8)%>:EH5K:S,<
M0S.:^K*_$Y1E%N,DXR3LXR3336Z:>J?DS]A332::::NFG=-=TUHT%%%%(844
M5\H_M'_MS_LA?LB1V@_:0_:$^&GPIU'48%NM+\-:]KT=UXVU:S9RGVW1_ FB
MQZIXSU:Q5U9)+W3M"N;6)@1)*A%.,93:C&+E)M)1BFVV]$DE=MMZ)(3:2<FT
ME%-MMV22W;;T275O1'U:6"C). .?RK^:7_@HQ_P<-^ OV?/%GB;X'?L=^$O#
M_P >?BQX8O;O1/&/Q,\37U[%\$/ /B"SEDM[_0K/^Q+FUUSXG^(]*GC-OJME
MX?U/0?#>EW):TE\77.J66H:/;6?^"D__  6[_9/\3_L(_&NP_8J_:A\,>(?C
MQXT/A?X9>&=/LXO$W@;Q_H6F>.O$-GI'C#Q?H'A[QSHOA3Q+=MHG@T>(/LFM
M:'87BZ)K5UI%[-)" C'^(BSM+:QMH+2TB6&WMXEBAC7HJ*,#DY+,?O,Q)9V)
M9B2<U^V>$/A=0XVQF/QN>3KT,HRBK1H5<)2;H8G&XNK!U?82G*+G0HTJ7+.M
M*,55G[6G"G*#<JD?QWQ5\2JW!N$P.#R:%"OFV:PJUJ6(K6JX?!X2E*--XA4X
MOEKUJM23A0A)^RC[.I.JII0IS_1'XL_\%9_^"E_QJU":]\5_MD_%?PE:/-))
M:^'_ ()W&F? _1=,C<Y^RVEU\/++2?%M[!&,K%)K_BO6KU5"[KIWW,?#M._;
M>_;MTFZ6]L?V[OVV#<JX<?VE^U5\<->M 5;<,Z;X@\;:KI;ID8:*2R>)URKQ
MLO%?-%%?UCA_#+@#"T/J]/A+))4^7DYL1@J>*KM+OB<2JN(<O[SJN3>K=S^7
ML1XC<=XFN\14XKSJ$VW+EP^+EA:%V[V6&PRI8=)=(JE:VEGH?IIX2_X+0_\
M!5?P;=Z5<VG[9?BCQ/::0L$4>A^/?AE\$/$NE:G;6XPMMKE['\-M,\6:@9E&
MRYU!/$]KK$P+2?VDL^V5?Z__ /@D%_P503_@H]\/?'&C^.O!=A\/_C_\&#X=
M7XC:3X<DO;KP+XFT7Q2FHIX=\<^#)M1EN-3TRRU2\T36K#4?"^K75_?Z#>V
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M-WMQ:_8]8O%>PFM9)C!</+;0_P M_CO]H+P/XX_;H_9V^)?PJ@^%WP.^-?\
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MW%J<<14JPC6J1Y$JDE?_ $5J***_AP_L\**** "BBB@ HHHH **** "BBB@
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M^T%-9^,/%'_!;3X _M,?M%?M>KX2\&> XM'^(OQ1^('Q$\4^-/CG'X.\6?\
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M3_@D3_T?M\"/_!OK7_RDHNNZ_K_AU]X'ZQT5^3G_  _4_P""1/\ T?M\"/\
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MPK\*> O#6HZU/K>M-\4IK+X?:U<6,7]F6BN="\.^)=7\0W EG2 6NDSM<++
M)(G\E_X(4_\ !7K_ ()Y? C_ ()5_LI_!S]H7]K7X7?"WXN_#S3OBIH/BGP1
MXNU/6(];T>V;XX_$O4_"S3JFF7:"&_\ !^H:!J%JD<QC@M[J.W18TA"*KZVZ
M6O\ >U;^NMP/ZTJIV6G:?IJS)IUA96"7$[W-PME:P6JSW,@ >XF6".,2SN%4
M/*X:1@H!8@"ORH_X?J?\$B?^C]O@1_X-]:_^4E'_  _4_P""1/\ T?M\"/\
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M^)OAKPW$--\.>*/'VN>([4F]UJ_\1:-X@U35IK^-_P#P]W_X):?])#/V.?\
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MJWCGPCXA\5_#2+XY?M)^!?&/PB^'W@3PC\4?B]8ZWHGQ?\2Z+XC^+7PY\!^
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M#X2_X=;?\$R?^D='["7_ (B+^S__ /.^H_X=;?\ !,G_ *1T?L)?^(B_L_\
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M-)JEWI7AK7=)TGQ1$=;^&O@V\&G>*;+6-/ TI[86PM=0U*&[&DULNGZ7_!6
MX[_AUM_P3)_Z1T?L)?\ B(O[/_\ \[ZC_AUM_P $R?\ I'1^PE_XB+^S_P#_
M #OJ^[:*++LOZ_X9?<!\)?\ #K;_ ()D_P#2.C]A+_Q$7]G_ /\ G?5OVO\
MP3A_X)XV/AK6?!EE^P9^QC9^#_$>K:#K_B'PI:_LN_ ^W\-:]KOA6VUZS\+Z
MUK.A0^!DTO5-6\-V?BGQ/::#J5]:SWFCVWB/7H-/FMXM7U!+C[.HIV7;^OZ2
M ^$O^'6W_!,G_I'1^PE_XB+^S_\ _.^H_P"'6W_!,G_I'1^PE_XB+^S_ /\
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M-6AP3,SOIVE^%]3\)^-KNR,BZGJUI+GQ+\0?$%Z7TZ[DLMUXRI)=RK-?W?\
M1!7SI^SG^RE\#OV4+'XO:=\#?"EWX3M/CK\=O'_[27Q-CN_$GB/Q(==^,'Q.
MAT.#QGXE@D\2:IJLFCVVJ1>'-(6+0=':QT'3_LS-I^G6S3SF0MK\G^G^0'T7
M1113 **** "BBB@#"\4>*/#G@GPYKOC#Q?KND^&/"OA?2-1U_P 1^(M>U"UT
MK1=#T32;26^U/5M5U*]EAM+#3["S@FN;N[N98X+>"-Y9'5%)K^-?_@H%_P '
M&_Q-\;:YKOPS_P"">ZVG@#X?6%S=Z7<_M*^*_#MIK/C/QF8)C"^H_"GP1XFM
M)]%\,>&YQ&YL/$OCG1M8US6+.X2YM/#'AF6&"[N.,_X.#_\ @I!J_P 9_BQJ
MW["'PBU^:W^#?PBU*R?X_P"J:1>,(/B9\488[/5+/X>3SVY43>%/AFS0S>)-
M/,KP:KXYE6QOH ?""BX_FV "@*H "@  <  <  =@!@ 5_2/A#X.X;B'"T>)^
M*:=265U92>696I3H_7XTY\KQ>+J0<:L<(YJ4:-&FX2K\KJ2FJ#@JW\]^*WBU
MB<@Q53AOAF=..9TXQ_M+,Y0A66 =2*G#"X6G-2I3Q;A)2K5:D*E/#J2IQ@\1
MS.AZ5X_^/W[0GQ+U7Q)X@^)GQE^+_P 7?%7B?PM:^%+?Q7\0_BUXTUO5_!26
M_P 4OAG\3UU3P=_:&HW5OX8"WWPZBMELO",/AX1RWT,\#1+:A:]$^!G[;'[8
M_P"SKK5EXC^"7Q\^(7POUVU\/Q^'_$%]%K&F^/+3XE2V_P 2?BE\1X]=\?:1
MX^T;Q%IWB2\^W?%/6;:&?6X=0UBW$U_*FJA[LR#YRHK]XJ^#W %;'RQ\\CH)
M2DG]1IQIT< DL%'!*$:%&G3DERQ6(NJJD\8WB7)U&[_B=+Q:X[HX!8"&=5FX
MII8ZJZE;'MO&O&N4J]6I.,W=_54ITI06"2PW)R(_L"_X)Y_\''5EXQ\0^'/@
M]_P4!T/PO\/M7UNZL]$\/?M)>"H)])^&=[JEU*EK90?%;PQ?7=_+\-WO9FC6
M3QEIVIW_ ('CN)GGUBU\%Z5%]IK^K>UNK:^MK>]LKB"[L[N"*YM;JVFCN+:Y
MMYXUE@G@GB9XIH9HG62*6-VCD1E=&*D$_P"2'+''-')#,B2Q2HT<D<BADD1P
M5='5@0R,I*LI!5@2""#7]7G_  ;R_P#!3/7K;Q'IO_!/+XZ^)+C5=+N],O;S
M]E/Q7K5XTUYI\6AV=UJ?B#X'ZA?W3F2XL]/T>VFUWX9B9WEM=,L-;\*)*UM9
M>&K*+^>O%OP>I\*4)\1\-^VJ9&JD(X_ U9.K5RN56484JM*J[U*V"G4:IR=5
MRJT)SAS5*L)N5/\ >O"SQ8GQ16AP_P 0>QIYW[.4\%C*48TJ.:*E!SJTIT8V
MA1QL*<95K4E&C6I1GR0ISI\M3^P>BBBOY[/W8*^3+G]G/XNZAJCZAJ'[=/[4
M<5A-<+--X5T+PK^QYHOAP0H5V65K>_\ #*=]X^M;=MB23R+X[DO996F"WD5G
M(+./ZSHH ^)]/^+^E?LM^-?^%2_M#_%NP@\ >)=$U?QG\%?C?\7_ !1H^A75
M_%H,NBP?$3X6_$GQ=J9T7PQ/XR\.ZIX@LO%?P^U2+^PY_&'P[UG4O#]OX;DO
MO@OXH\8>+?M);BW:W%VL\+6K0BX6Y65#;M;E/,$XF#>683'^\$H;84^<-MYK
MY5_:<_9KUCX^3>#M1\.?$"R^'>N>$]'\>^'X]8?P]XON=5.E^/HO#/\ :#:+
MXM^&'Q4^"?Q-\.7%O<>%---SI%G\09_ 'BNVE>/QWX$\4W^C^#=4\*\_-_P3
MU_8U\1M#J?Q7_9T^#GQX\8S:?I]MKWCCXW?#/P1\2M<U^_M--TC3[K5WM/%&
MA:AH'A^74Y=%MM1GTKPCH^@>'K._FO)=*TBP6\N4D-?Z_KU_+S \E\#_  +^
M%O[=-WJG[4_QL\(-XH\+>)U@TO\ 8_+:CK_A/Q1\-_@7ITS3V/Q@\"^+/"NL
MZ3XS\!>-?VE=9W?$NY\1^$]?\+Z[>?!JV^ GA7Q-I.D>*?!GB"&X\7_:P_8@
MTB^\:?L2>"-!^/7[6&E_"SQ%^U#-H_COP=XC^._C'XU:--:Z'^S]\>_BSX7\
M3W/B7X_S?%7QY9>,-+^*/PS\!67@'Q/-XRE/P[\0ZO:^+?AQ9>&?BOHWPZ\<
M^#O6'^,_A+_@F]K/A3X)?&?Q7X@U']G+QY/JFG?LI>)['PUXH^(7COX>W.D'
M1K:S_92\1^%/ FB>)/'OC2QMAJ^GZ7^S3X\TO0-<U+Q'8OI_P&^($T?Q6LOA
M7XB_:'@^+VC_ +6?Q\\>_"SXU_!/PW\0_@QI7P@\ ?M*#1_AI\9/$GASPUX=
M^/'BGQ)J?[.,?PPN/&O@;PWXA\7ZKX%'B#P39?'6S^&OCGQ%INB?%KX'>)W@
MU+Q7X/LM%\2>*_AKXRGUW5KVWZ?G^*] /T2\ _#_ ,$_"SP?H/P_^'/A?1?!
M?@OPS:-9:%X:\/6,.G:7IT$MQ->7+16\*J)+J_O[FZU+4[Z<RWVJ:G>7FIZC
M<7-_=W-Q+U]?G-\+OVR?AO\  /X;?#OX4_ML^-+S]F_XO>"/AMX.T#6?$W[2
MOB;0-#\,?&W6O#7A32].\1^,OA=\:9_$VN> OBOJ>M:M9:EJVI>$;;Q@_P ;
M-'AGMM8\??#KPW!KVB7>K=Y#\:/VG_C1&/$/[.7P=\.>!/AUIK#4M.\6?M;6
M?COX>^(?C5%;QQR1^'_!7PJT2P/Q+^#?AK76EGL9?B[\:O#MKXP\+WVF-=Z5
M^R]\2_"^M:5XFIJWIY=OE\T!]NU\'?M#_MR6'[/_ (K^//A.Z^$_C3QG<?!G
M]G+X9?'ZTU3P[:>([S0]>?XB^*OV@/#!\*>)M9TCP;KNF?#>TT9O@:E^/%>M
MWFH6^I6_B>ZQH]E%X8GN-5TKG]OSX#?#M3H?[4NMVO[(/Q*CD6SM/ /QVUO0
M=#7XB:@PD$4?[/GC*RO[OPG^T7_:3)!)IWA[X4ZAKGQ-TP:QX;T?Q_\ #CP'
MXSU^S\)5\7?''X;?M>_M)^(/VB/CE\ O#/Q&^&_A;XH?LO?"?]GCPO\ "3X\
M:CI?PTD^*&FVOCO]IS4_$OQ;TOPI%K.L^,_@IXW\)Z;\3/AKXI\%1_$[1O G
MC/Q#H/\ PF7PR^)GP]\*>()?#WB'X?C>FGY:KKMZ=_N>S#]L**^2M7_;9^ 7
M@76O$'A3XV>)9?V>/&FC:GJ-GH_@_P"-7]F>%]8^)NFP:S'I&BZ_\$;K3M4U
MS0/CA:^)S?\ AR6RT'X4:UXO\<>'M3\8>%?!/C_PIX.^(^KQ>#$Y^;XJ_M=?
M$F-/%_P0^"?@?P5X TIQ?Z=HW[46J^,/ 7Q,^-UB\<\:V>D>'/"FD>(-2_9M
MTB>&YT_7=)\5?%KP[XU^(UQ=6&I>!_&'[.?P[DO+;QO8L#[5HKXFU+]MW0=!
MLO%,_B;X$?M!>'+WX6^ ;3XG_'G3-6T'X<6TWP.\"7NH>,;.W\4>(KR7XH)I
MGQ(T:>U^'?C_ %FVO?V>[WXRBXTWPCJ<$:?VY<:3HNHS?\+1_;"\=RIXZ^%O
MP,\"^$?AEI3[['P'^T%XBU[P?\;_ (SZ;<N8WU?28O"UIXDT+]G>UTZP6+7O
M"ND?$[2O'7CCQ_<WK>#?B/X,_9EO=+N/$-T ?:=%?&2?MZ_LYZ-!)I7Q5\1:
MO\"_BO;)''-^SU\5=%FL?CYK&IRQH8=)^%WPY\)R^+K_ /:)EOKMFT?0M5_9
MIN?C%X:\5>(8+OP[X4US6]=LKS3X/EGXA:/^UQ\3-/\ CMX^\,_"W]IWPO\
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MMKNCRYX#0R7=DEO=PMF*ZLYKBUG5X)I4;)J*=D2"9I"!&L4C.20 $"$L220
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M+P)X,TK0?#FI^._'&L6L>F^%K74+S5?%VMWNKZAJ,DML+7V>DM$EV2 ^!_\
M@FI\/OA_H'[%G[)'CW0/!GA/2/'?CW]C?]D2U\>>,M+T'2K+Q7XN@\)_ /P5
MIWA6R\4:_;6L>K:S:^&],N9;;0+/4KJ>WTBVO+H:?%;B]N#-:_X*, ']G[X?
M@@$']NS_ ();@@C((/\ P4U_9%!!!X((X(/6OG3QA_P3]^(W[/7B";XI?L">
M/=4\&3P6FDP:Q\%M9UC[38ZYH7AC2M%T/0?#>@ZYXEN+KPYXXTG0?"^@V?A7
MPMX"^/=KK&MZ#X3T[PU\(OV?/VG_ -B;X;6-Y?+[QJGPF^/7[77AK1M _:/M
M(/@5\'[/4_!GB'5/A?X3?P_+\<OB)XN\ :SH/BO0O$OBCQ_X;\6?$CPY^SGI
MNC?$/08?&7@G1/V?_B/X^^,GAG5- ^'?CWPY^U9X$\3Z;K7A!!:)+\OE=].O
MW@=Y_P $[O\ E'[^PO\ ]F=?LR?^J4\$U]BU\%6/PE^+O['?A>PM?V<+P_%K
M]G7P)H5I96_[,?Q'\0O'XZ^'?@KPWIT,,6D_LY?&_7;B>;4+31](L;B'P_\
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M(Y'2REP =&""&UABM[>-8H((DAAC10J1Q1J%1%4<*JJ  !VJ0@'@_3\/2O\
M1_(>'<UR;A+#9!_K%B\1F6'P<:%'.J^'PM>IA9QA!4XT:%2E[.OA\/RN%*.+
M=:M*G93K/W>3_/G.\_RS..*<1GW^KV$HY;B<6Z]?)Z.)Q>&CBZ<IMSG6Q-*I
MST,3B(MSK2PD*%%57S0H_&Y_V7?\$FO^"&W[.NBZ/X _:R^.OQ3^&'[8FNZC
M;6_B3X;Z#\-KJ/Q+^S3X6N<@V^L0W%_$MW\5_$^ESI*D-]XGTS1-#T*^#K'X
M)37--MM8A\8_X*<?\&]VC:*GC7]HK]A[Q1X!^&_AVUAU'Q7X]_9\^)OB/3_
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M?=[[A1117 =H4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M?W5O;R=L0""" 00001D$'@@@\$$<$'K7X:? WP]H^A?\%;O&'PZM+/[7X"\
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M%0O^E?O]I[_Q(7P=_P#.HH_X>]_\%0O^E?O]I[_Q(7P=_P#.HK^BBBBS[O\
M#_(#^5K]GK_@XJ_:I_:Z\+ZYXX_9;_X(N_'_ .-'@[PKXA_X0CQ3KWA_X_>%
M[:#0O'EGHNCZUK?A>ZANOA291<:;!K=A+'*XAFN;*ZM+FXL]/GFDL;?WW_A[
MW_P5"_Z5^_VGO_$A?!W_ ,ZBON?_ ()3?\$[)_\ @FM\'_CW\*9?B!HWQ MO
MC#^US\8OVCM&?0/"C^$-,\(^&_'VF>"/#'AKP3'IS:EJ,<T^D:#X"TZ[O;BU
M^QV%O>ZG/I.GVTUEID&HW_Z@T).RNW?KM_D!_.O_ ,/>_P#@J%_TK]_M/?\
MB0O@[_YU%'_#WO\ X*A?]*_?[3W_ (D+X._^=17]%%%%GW?X?Y ?SZ?\$4OA
M!^UC<_M!?\%2?VY/VLO@7XK_ &:/$G[:7QK^#4?@KX+>-]1LM9\2>'?!7P/\
M$^+-/T>_DUNQBLX=7TV73?B)IWAJTOAI>EB:^\(ZJ8[../8J_P!!=%%"5E8
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?S1^'_ (^_#O\
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M-'MD3)VL,F@#\GO^"*?A[X@VO[%$WQ'^(J7$.H?M%_M$_M,_M+>'(;KPA?\
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MB/\ P3^_Z/H_8Z_\2;^"G_S;477=?U_PZ^\#[%HKXZ_X>(_\$_O^CZ/V.O\
MQ)OX*?\ S;4?\/$?^"?W_1]'['7_ (DW\%/_ )MJ+KNOZ_X=?>!]BT5\=?\
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MK^RMKB+\Z?\ AQ7_ ,$B?^C"?@1_X*-:_P#EW7ZQT4 ?DY_PXK_X)$_]&$_
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M_P ,ON _)S_AQ7_P2)_Z,)^!'_@HUK_Y=T?\.*_^"1/_ $83\"/_  4:U_\
M+NOUCHHLNR_K_AE]P'Y.?\.*_P#@D3_T83\"/_!1K7_R[H_X<5_\$B?^C"?@
M1_X*-:_^7=?K'119=E_7_#+[@/R<_P"'%?\ P2)_Z,)^!'_@HUK_ .7='_#B
MO_@D3_T83\"/_!1K7_R[K]8Z*++LOZ_X9?<!^3G_  XK_P""1/\ T83\"/\
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M]&$_ C_P4:U_\NZ/^'%?_!(G_HPGX$?^"C6O_EW7ZQT4679?U_PR^X#\G/\
MAQ7_ ,$B?^C"?@1_X*-:_P#EW1_PXK_X)$_]&$_ C_P4:U_\NZ_6.BBR[+^O
M^&7W ?DY_P .*_\ @D3_ -&$_ C_ ,%&M?\ R[H_X<5_\$B?^C"?@1_X*-:_
M^7=?K'119=E_7_#+[@/R<_X<5_\ !(G_ *,)^!'_ (*-:_\ EW1_PXK_ ."1
M/_1A/P(_\%&M?_+NOUCHHLNR_K_AE]P'Y.?\.*_^"1/_ $83\"/_  4:U_\
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MB7XGRVWAOP?XM^,?B#PM9^%](\917=KK^CI;7EAX3F7Q?K7A]E^J_B'\/?\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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FD$4?TM110 4444 %%%% !1110 4444 %%%% !1110 4444 ?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>22
<FILENAME>nt10014672x1_diagram8.jpg
<TEXT>
begin 644 nt10014672x1_diagram8.jpg
M_]C_X  02D9)1@ ! 0$ P #   #_[0 V4&AO=&]S:&]P(#,N,  X0DE- ^T*
M4F5S;VQU=&EO;@     0 ,     !  $ P     $  ?_B"^!)0T-?4%)/1DE,
M10 ! 0  "]!N;VYE @   &UN=')21T(@6%E:( ?4  < %0 3  L (6%C<W
M         $E%0R!S4D="     0            #VU@ !     -,M2% @(
M
M$&1E<V,   %$    =&)865H   &X    %&)44D,   ',   (#&1M9&0   G8
M    B&=865H   I@    %&=44D,   ',   (#&QU;6D   IT    %&UE87,
M  J(    )&)K<'0   JL    %')865H   K     %')44D,   ',   (#'1E
M8V@   K4    #'9U960   K@    AW=T<'0   MH    %&-P<G0   M\
M*&-H860   ND    +&1E<V,         &G-21T(@245#-C$Y-C8M,BTQ('=I
M=&A"4$,
M                                                    6%E:(
M     "2@   /A   ML]C=7)V        !      %  H #P 4 !D '@ C "@
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M;W5R(%-P86-E("T@<U)'0@
M
M      !865H@        8ID  +>%   8VEA96B            !0
M;65A<P         !                               "6%E:(
M  ,6   #,P   J1865H@        ;Z(  #CU   #D'-I9R      0U)4(&1E
M<V,         +5)E9F5R96YC92!6:65W:6YG($-O;F1I=&EO;B!I;B!)14,@
M-C$Y-C8M,BTQ
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MU=;7V-G:X>+CY.7FY^CIZO'R\_3U]O?X^?K_Q  ? 0 # 0$! 0$! 0$!
M     0(#! 4&!P@)"@O_Q "U$0 " 0($! ,$!P4$!  ! G<  0(#$00%(3$&
M$D%1!V%Q$R(R@0@40I&AL<$)(S-2\!5B<M$*%B0TX27Q%Q@9&B8G*"DJ-38W
M.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U=G=X>7J"@X2%AH>(B8J2
MDY25EI>8F9JBHZ2EIJ>HJ:JRL[2UMK>XN;K"P\3%QL?(R<K2T]35UM?8V=KB
MX^3EYN?HZ>KR\_3U]O?X^?K_V@ , P$  A$#$0 _ /[DOVA/C]\+/V7/@S\0
M/CY\:O$]MX1^&OPUT*;7O$FLSH\TQ02Q6EAI>EV46;C4]<US4[FST;0M)M5:
MZU35[ZSL;=3+.M?PI_M@?\' ?[=_[2_B76+3]GSQ--^QY\#6N+B#PWIGAC2?
M#NM_''Q)I <BUU7QIXXUVQUJR\(ZC>QJES_87@6TL9M($K6%SXAUAXGN9?W$
M_P""Z?Q_^%'[3?\ P3H_;M^&OP.\<6_C/QE^QC\9?V>H_P!HS0--M=20>%UM
M_B)X1U^_LY;F6VCLM6@TNSDN+G5Y]/DO;;3+_P .:S87K17NE7$4?\14;!E#
M Y! P<DY!&0>?K_D8K]Z\#^ N'N,<3G&+SZ,\;3REX*-'+(U9TJ55XOZP_K&
M)E1G"M.G#V#C3IQG"G.7-[7GBE!_A_C/QSG_  CA\GPF1M82>;?7)5<S]G"K
M4H+"?5N6C0C5C.C&I4]NY.I.$I)1BJ?*VY'T5KW[9_[=GBG2[[0O$?[=G[7^
MKZ)J3!]1TZ7X\>,[&.[)5U9'N-)O;"^2V99"'LH+J&T<@%X"50K\I:[X4TKQ
M7++<^+Y-;\97=PS27%WXP\2^(O%%[/+(6:2::[UW5;^X>61F9I)&D+L3C(&0
M>FHK^J<)X<<"8)MX?A3(DV[MU<NP^)?16B\1"JXII:J+2>]M[_S-B_$#CC&J
M*Q'%>>-1=TJ..JX5-].985T>>UW;GYFE97LD87A[P_;>#IX+OP1J7B?P+?6K
MB6TOO!'B_P 4>$;ZTF7_ %<T%WX?U?3I8Y8R 4</E2.N,@_HC\!?^"K7_!2W
M]FB]LY?A[^UMX[\?>'[5X#/X!_:'\GXV>&-0M[<@#3QK'B@GX@:';21@QM)X
M=\8:9,JMN^=D11\%T#_.1G],C/YUSYGX8< YM2E2Q7"^54FT_P!]@,-#+<1%
MO[4:V!5"=UT4G*.]XN[OMEOB/QUE52-3#\3YM6Y6G[/'XAYC1DD[N#HXU5J7
MO*\7)1C)*SC*,DI+^W+_ ()^?\'&/P1_:$U_PY\'/VO/"NG?LM?&/79[;2-
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MNP0B8>'? /A&UD74O$.J%7A-S)&(=+TF*>*[US4=,L6-TOJ7[1OQX\"?LP?
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M6O)-KF45HEPC_#/P*]W_ &@_AVT?4-V\7SR737GF9W>9]J,YG\S< WF%R^X
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M7Q*N/A#<:W>.6\_5KGPWI<GP_P!2GO;AI/,E?6O%OB&Z8\37\BHAKGA\4O\
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M_:'Q1^#EI-+LTC6]/4M>^(_"-LT&B>,+%)E:&TUN.PU2U_T8_AM\1_ _Q?\
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M?^-]IX#_ &AO"3,"8KQ?%_ANU\,>.)(I#G=)'\1/"/B2>91@H+ZW5@,JQ_,
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MH3KQNE*Z_P!:H<@'UHKB/AGX_P##?Q7^'/@+XH^#KO[?X2^(_@WPSX[\,7V
M/MGA_P 6Z-9:]H]R0"P4SZ??V\C+D[68KGBNWK_/X_ND^9?VR?VG_!'[&7[,
MGQB_:7^(.9] ^%7A&[UN#2(Y?)N_$_B2YEATKPCX0T]Q',5U#Q9XHO\ 2?#]
MI)Y,JP2Z@+F5###*1_E_?$#XE_$7XZ_$WXB?'KXR:O)X@^+'QB\4WWC7QKJ<
MDCM#:W5ZVS2_#.D1N6^P^&_!VD)9>&_#NF18M['2M.@CB7)=V_J3_P"#I/\
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MQK8^'M?L]<T+7M'NM+AU'0]5MK,NNZ^] ?K'17XF_P#$1A_P1?\ ^CX/"_\
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M1[^&7_S.4?\ #HC_ ():?](\_P!CG_Q'OX9?_,Y7Z*44679?<@/SK_X=$?\
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MXN<)1G!8[&8K$4HRB[J]!5:=":O;W:M.<7973L?B3^Q7_P $4?A'^PG^S?\
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MA?:?B+I]N=!,5_8>?H/BF(:T9-+@6^ /LJBBB@ HHHH **** "BBB@ HHHH
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MEJNGF_'BOXV>-M6E^%]GXP?6/BMJ=[X%T#78]!USX=?"3X<^)]&FUS4O?/\
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MGX6^)_$OC3P':>'=5TWPU\+(O@EI6DFXG-KON_\ )?/^M&!]U?\ !07Q=9>
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M\4?"OQ4TEQ'XM\!:];7E[;W)K^6G;OW_ *0'UA7R]\3?VS_V9O@]XPN_ WQ
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M*>/Q$HIVI8;!7KU9S:3M%QA[/6W-*<8)WDC_ $N:***_SK/[["BBB@ HHHH
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MR9%U#XD?!FWNI3!H'BG3U9K[6_#-NUKHGC:VA:VNTM-573M8L/ZL_P#@H_\
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MUN6_TZRT9?B!J<$NC7UOITL^J5?BO^UYXR\/? _6-$TG1=%\,_MD>+_&>A?
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M@M?I6N7\:^-_!?PV\)Z_X\^(OB[PQX"\#^%=.GUCQ/XR\9Z]I?A?PKX<TFV
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M  0/_P"";6L_L8_L_P"K_'#XUZ -+_:>_:9MM(UWQ3I%]"G]I?"KX862-=>
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MP4(\37?AKS/WMKX?_9U\+Z+XCEMMWS1Q:UJ'Q%U[3;6X9,K]I/A^Y17^<6I
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MWL?A31K6V\1^*M6TJU.M0:<GB36?HJBB@ HHHH **** "BBB@ HHHH ****
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MB*ZE1-_P\1_X)_?]'T?L=?\ B3?P4_\ FVHNNZ_K_AU]X'V+17QU_P /$?\
M@G]_T?1^QU_XDW\%/_FVH_X>(_\ !/[_ */H_8Z_\2;^"G_S;477=?U_PZ^\
M#[%HKXZ_X>(_\$_O^CZ/V.O_ !)OX*?_ #;5JZ%^WI^PSXHUK2_#GAG]L_\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MJ4,, E1!-)]??\0P/_!%[_HV#Q/_ .)"?M!__/+K]UO ?@;PC\,/ W@SX:>
M-!L?"W@/X>>$_#O@;P3X8TQ9$TWPYX1\):/9Z!X;T'3DEDEE2QTC1M/LM/M%
MDEDD6WMXP\CL"QZNA179?U;_ "_/NP/Y_O\ B&!_X(O?]&P>)_\ Q(3]H/\
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MW_T*M)3C97>O71@?UC45_)S_ ,1'O[9W_2 C]N[\OBM_]"K1_P 1'O[9W_2
MC]N[\OBM_P#0JT<\>_X/_(#^L:BOY.?^(CW]L[_I 1^W=^7Q6_\ H5:/^(CW
M]L[_ *0$?MW?E\5O_H5:.>/?\'_D!_6-17\G/_$1[^V=_P!("/V[OR^*W_T*
MM'_$1[^V=_T@(_;N_+XK?_0JT<\>_P"#_P @/ZQJ*_DY_P"(CW]L[_I 1^W=
M^7Q6_P#H5:/^(CW]L[_I 1^W=^7Q6_\ H5:.>/?\'_D!_6-17\G/_$1[^V=_
MT@(_;N_+XK?_ $*M'_$1[^V=_P!("/V[OR^*W_T*M'/'O^#_ ,@/ZQJ*_DY_
MXB/?VSO^D!'[=WY?%;_Z%6O/?&?_  =?Z]\&)FTK]HW_ (),_M6? OQ-XDT6
MZN?A1H7C/Q->:%-\0=>L]1TVRGTUO^$[^$/@'4+'18([\?:M>\-Z5XXO;;49
M--TU_#I74OMEJ<\>_P"#_P @/["**_DY_P"(CW]L[_I 1^W=^7Q6_P#H5:/^
M(CW]L[_I 1^W=^7Q6_\ H5:.>/?\'_D!_6-17\G/_$1[^V=_T@(_;N_+XK?_
M $*M'_$1[^V=_P!("/V[OR^*W_T*M'/'O^#_ ,@/ZQJ*_DY_XB/?VSO^D!'[
M=WY?%;_Z%6C_ (B/?VSO^D!'[=WY?%;_ .A5HYX]_P '_D!_6-17\G/_ !$>
M_MG?]("/V[OR^*W_ -"K1_Q$>_MG?]("/V[OR^*W_P!"K1SQ[_@_\@/ZQJ*_
MDY_XB/?VSO\ I 1^W=^7Q6_^A5H_XB/?VSO^D!'[=WY?%;_Z%6CGCW_!_P"0
M']8U%?R<_P#$1[^V=_T@(_;N_+XK?_0JT?\ $1[^V=_T@(_;N_+XK?\ T*M'
M/'O^#_R _K&KX\L_V^/V4;_]LC5_V K;XI++^UCHG@VV\?:A\+D\(^.95@\+
MW.A6GB87LOC2'PW+X"MKJ/0=0TW4WTB]\3VVL/:ZC9O;V$_G87^?S_B(]_;.
M_P"D!'[=WY?%;_Z%6O-/^"1>D?M+_MG_ /!<C]KS_@IO\;/V,OC#^R-\/;K]
MF7PI\/\ PAX6^-/A7Q1IFI6OC>]TGX/^!+.+P]XA\8>"_ <GBF>Z\/?"[XB:
MMK%_X>\/PKX<L->T?0M6<'5+6ZU8YD[):W>NCV _L1HHHJ@"BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "OY8?^#AG]D3XU_M.
M?M>_\$3M2^&'P>^(GQ&\$>#_ -J/Q7H?QF\5?#_PQJ&MP_#OPSXK^(7[,.L6
MVM>,-5L+"_A\+:!!X<\$_$'5QXBUY(M TI=$U"6\N8FE2*X_J>HI-75MMOSN
M 4444P"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?CU_P5._9;_:
M4^)'C[]B7]L3]DGP5X"^-/QI_84^*'Q"\66W[.GQ/\1V?A'PK\8?!?Q>\'Z?
MX/\ %J:)XDU91X>T/XI>$#HND:M\.M;\276FZ3X?NKG5O$2WE[JND:7X:\0_
MCS^W-^VU\+?VR/@!\/?V<=$^$/C+]BGXN_'[_@IY^Q/^R]_P50^$.H^%-,\)
M_%C0O!GQDMO'.JP-K7Q!T;0]*D^(^B^-K#X<VUUX4^(=NJW^L>#_  __ &5K
M^CZ/HOBFRTG5?Z*_VM?@?^V1\3/$_P +/%_[(_[9&D_LR3^"[?Q3IWCWP9XR
M^!.A?'+P%\5].U^Y\-WNERZK8ZAXJ\(ZQX;U;PQ-H%W;6&I^']4@OKG3_$>K
M6OVNS7/VCX7\/_\ !$KP3\1/A;^VEHW[;7QX\2_M+_'3]N[Q+\)?$7Q:^/?@
M_P !>%/@;JG@Q?@%IEGIOP1L_A!X3LIO'>B^$+_P!!%<V5QK\CWTOC/2IH]-
M\2Z9-:K=17@!D_\ !1']H[X6_P#!/C]G[Q7\-O%'_!**7XN_\$\OAMX3\ 0>
M*=>\/S?LYV/P0TM_%?BK2/"6C:#'\(/$^JR>)]2U"P\5ZSX:MFUD>$3(VMZB
MFK"\5+2XUE?N/]L7Q-\;_@[XD\%?&']EG_@G/X:_;7^-6J^'?$/@'Q%XQA^+
M_P "_@!XV^'_ ($TV>WUW0O#4_Q"^*FGS^(-=\)>(_$.KZS=CPQX<FN+'2KZ
MUO\ 5;RP:YU&W^T?GU^T%_P2A_X*!?M6_!&;]DW]H;_@JQIWC_\ 9I\07GA;
M_A8*6O[%/@#PY\;?'GA[P9XS\-^-/#N@ZK\1;7XHWNDVNKZ;JGA+1+L>-M+\
M*6-]J>H1W$_B31=?L[FZTZY_1G]H'X.?MT^(_C+I/Q)_9A_;&^''PF\ )\.+
M#P9XB^ GQ?\ V9XOC-X+U3Q;9>(_$>LM\5=+\7^'?BO\*/'VA^(;C2=8TSPM
M<>'8M7N?#%Q8Z+;:C<VLVH^480#\J/\ @AC\-OA#\5_V(/VW/V?/BI91P^/O
MBI^UE^TM/^VQ^RQ8>'M>^#^G_L[>*_C!8:9X0\0_ ?P9#X<\3-JUM\-$\+^%
M6?P9XL\(^)K>*6&_U;3-/O++4] OH+7M/^"6?P@^%WP$_P""K?\ P7!^$/P7
M\!>%OAC\,?!%C_P2\T[PKX'\&:1::'X>T6WNOV8/'6JW[VUA9QQH][JNKW^H
M:UK6I7!FU'6M;U'4=9U:ZO-4O[R[F^T?V2/^"?7C;]E'X=?M6ZO9?M%V_C_]
MLC]KSQUXF^*'Q%_:EU[X-:3IN@V7C>XTBXTGX=V^E_ W3/&HTUO GPT6ZN[S
M3_",WCT76L7>K:ZLWB'3["]T^PT?PG]G'_@FO^VO\"/VOOC5^UKJ_P#P42^'
M?CS5/VH/$?P!U#]I/P?!^PY8>$H?'GAK]GOPO<^!?"_ASPAKB_M+>(A\.;R_
M\'7^H:;>Z_::'KSK?SQ:L^F7+VXMI #X#^'=[XU_8MU;_@JA^S?^T;_P33_:
MX_:C;]M/]KW]H[XU^$/BE\$_@=X<^+/P=^+7P1^,-K8VOP[\+_%;XI7OC#1]
M#^'4W@IEUVZU+1_%)TC3/ UKJ]_J&CVBZB\\NJ?+O[,&B?M%?\,@_P#!O1^W
M9K_[/7QC_:T^%_['.A?M@:%\4_A=\)_"UE\2_B]H>A>+[[5OA?\ LR?$'P'\
M,+V_T*]\:'P/H_@[PS>V$EBNH77A'2=(T?4M&"7LEOK4?[K_ +1G[%/_  48
M_:$M_B[\+3_P4O\ "GPZ_9T^+6O^/[6]T/PG^QGX2E^-6D?!?X@>?I5W\#[#
MXI7OQ8_L."'1?"5Y?:)H_P 5;3P!:?$%;ZX;7+V>ZN$MK>T]_P#B#^S!^T!X
M$^&7[/WPH_8 ^/WPZ_97\ _ OP3J/PZD\"?$'X!1_'OPYXQ\,6_AS0/#O@.6
M74Y?B+\/_%V@:]X _LK4]935+?7=3'C;6=:>Y\:0:I':O'>@'Y,_L$?&G4OB
MY_P7._:D\8^$/V9OCM^RE\._B]_P3X^'WCWX@^"?CS\/;#X3^//B'\3O!GQU
M_P"$*\%?%OQ=\/[#5-=NM'O]6\,:AXZ\-^'I?$UYI7B?4-*\/:CJM[HJQ:E'
M.O\ 2[7Y[?L1?L->(/V9/%/QV^-WQO\ CM>_M4?M7?M):UX3E^*?QXO_ (=:
M'\);)O!7PX\/Q^&_AK\-O!7PR\-:UKWA[P7X7\*V#:A>7K:9?/?^+-=U.XUK
MQ%-=7-OIZV?Z$T %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MU_\ 1DG["/\ X5G@O_Z+JCF_NR^X#^L:BOY.?^%^?\'=?_1DG["/_A6>"_\
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MY_P=U_\ 1DG["/\ X5G@O_Z+JC_A?G_!W7_T9)^PC_X5G@O_ .BZHYO[LON
M_K&HK^3G_A?G_!W7_P!&2?L(_P#A6>"__HNJ/^%^?\'=?_1DG["/_A6>"_\
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M]U&2&,A7E2RMI;EXT9OE#NL152W )!/%?RE?\+\_X.Z_^C)/V$?_  K/!?\
M]%U7%?$KXA_\';?Q0^'/C_X::O\ L;_L6:+I/Q$\%>*O NIZSX9\;^ ]/\2:
M3IWBW0K_ $"]U/P_?W?[5VHVECK=A;:A+=:3>76GW]O;7\5O--9W4:- YS?W
M9?<!^Z__  2S_P""D7@K_@J5^S;K'[27@+X9^+/A5H>D?%7Q/\*V\.>,=5TG
M6-4N;[PQH'A#7KC6(;S1D2S^PW,?BZ"TBB(,R3V-R7.&0 KA/^")?[$7CO\
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MK.K7"VFE:3:2WT\$=SJ>IW3I;:?80L]U>W#K#;122,%.O7X;?M@2_P##6_\
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M&&WM+>*/6_H']BKX*:K\(OC7XE'@G_@J'\2OVRO@GJ?POO$N_@?\<O'7PO\
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MGB"XL]=\0W-O<7%LEG%9>*_'O^"<_P ,?A[KW_!8?XA_M%?LI?L'?%W]CO\
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MAWXW\50VFGAQI]FVO>)/#NI:G-9:<TCR:=9SW,MM83D7%I%#.JR HH ^EP
M       ,  <  #@ #@ =*6BB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
3"BBB@ HHHH **** "BBB@#__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>23
<FILENAME>nt10014672x1_diagram9.jpg
<TEXT>
begin 644 nt10014672x1_diagram9.jpg
M_]C_X  02D9)1@ ! 0$ P #   #_[0 V4&AO=&]S:&]P(#,N,  X0DE- ^T*
M4F5S;VQU=&EO;@     0 ,     !  $ P     $  ?_B"^!)0T-?4%)/1DE,
M10 ! 0  "]!N;VYE @   &UN=')21T(@6%E:( ?4  < %0 3  L (6%C<W
M         $E%0R!S4D="     0            #VU@ !     -,M2% @(
M
M$&1E<V,   %$    =&)865H   &X    %&)44D,   ',   (#&1M9&0   G8
M    B&=865H   I@    %&=44D,   ',   (#&QU;6D   IT    %&UE87,
M  J(    )&)K<'0   JL    %')865H   K     %')44D,   ',   (#'1E
M8V@   K4    #'9U960   K@    AW=T<'0   MH    %&-P<G0   M\
M*&-H860   ND    +&1E<V,         &G-21T(@245#-C$Y-C8M,BTQ('=I
M=&A"4$,
M                                                    6%E:(
M     "2@   /A   ML]C=7)V        !      %  H #P 4 !D '@ C "@
M+0 R #< .P!  $4 2@!/ %0 60!> &, : !M '( =P!\ ($ A@"+ )  E0":
M )\ I "I *X L@"W +P P0#& ,L T #5 -L X #E .L \ #V /L! 0$' 0T!
M$P$9 1\!)0$K 3(!. $^ 44!3 %2 5D!8 %G 6X!=0%\ 8,!BP&2 9H!H0&I
M ;$!N0'! <D!T0'9 >$!Z0'R ?H" P(, A0"'0(F B\". )! DL"5 )= F<"
M<0)Z H0"C@*8 J("K *V L$"RP+5 N "ZP+U P #"P,6 R$#+0,X T,#3P-:
M V8#<@-^ XH#E@.B ZX#N@/' ],#X /L _D$!@03!" $+00[!$@$501C!'$$
M?@2,!)H$J 2V!,0$TP3A!/ $_@4-!1P%*P4Z!4D%6 5G!7<%A@66!:8%M07%
M!=4%Y07V!@8&%@8G!C<&2 99!FH&>P:,!IT&KP; !M$&XP;U!P<'&0<K!ST'
M3P=A!W0'A@>9!ZP'OP?2!^4'^ @+"!\(,@A&"%H(;@B"")8(J@B^"-((YPC[
M"1 ))0DZ"4\)9 EY"8\)I FZ"<\)Y0G["A$*)PH]"E0*:@J!"I@*K@K%"MP*
M\PL+"R(+.0M1"VD+@ N8"[ +R OA"_D,$@PJ#$,,7 QU#(X,IPS #-D,\PT-
M#28-0 U:#70-C@VI#<,-W@WX#A,.+@Y)#F0.?PZ;#K8.T@[N#PD/)0]!#UX/
M>@^6#[,/SP_L$ D0)A!#$&$0?A";$+D0UQ#U$1,1,1%/$6T1C!&J$<D1Z!('
M$B8211)D$H02HQ+#$N,3 Q,C$T,38Q.#$Z03Q1/E% 84)Q1)%&H4BQ2M%,X4
M\!42%3055A5X%9L5O17@%@,6)A9)%FP6CQ:R%M86^A<=%T$791>)%ZX7TA?W
M&!L80!AE&(H8KQC5&/H9(!E%&6L9D1FW&=T:!!HJ&E$:=QJ>&L4:[!L4&SL;
M8QN*&[(;VAP"'"H<4AQ['*,<S!SU'1X=1QUP'9D=PQWL'A8>0!YJ'I0>OA[I
M'Q,?/A]I'Y0?OQ_J(!4@02!L()@@Q"#P(1PA2"%U(:$ASB'[(B<B52*"(J\B
MW2,*(S@C9B.4(\(C\"0?)$TD?"2K)-HE"24X)6@EER7')?<F)R97)H<FMR;H
M)Q@G22=Z)ZLGW"@-*#\H<2BB*-0I!BDX*6LIG2G0*@(J-2IH*ILJSRL"*S8K
M:2N=*]$L!2PY+&XLHBS7+0PM02UV+:LMX2X6+DPN@BZW+NXO)"]:+Y$OQR_^
M,#4P;#"D,-LQ$C%*,8(QNC'R,BHR8S*;,M0S#3-&,W\SN#/Q-"LT932>--@U
M$S5--8<UPC7]-C<V<C:N-NDW)#=@-YPWUS@4.% XC#C(.04Y0CE_.;PY^3HV
M.G0ZLCKO.RT[:SNJ.^@\)SQE/*0\XSTB/6$]H3W@/B ^8#Z@/N _(3]A/Z(_
MXD C0&1 ID#G02E!:D&L0>Y",$)R0K5"]T,Z0WU#P$0#1$=$BD3.11)%546:
M1=Y&(D9G1JM&\$<U1WM'P$@%2$M(D4C721U)8TFI2?!*-TI]2L1+#$M32YI+
MXDPJ3'),NDT"34I-DTW<3B5.;DZW3P!/24^33]U0)U!Q4+M1!E%049M1YE(Q
M4GQ2QU,34U]3JE/V5$)4CU3;52A5=57"5@]67%:I5O=71%>25^!8+UA]6,M9
M&EEI6;A:!UI66J9:]5M%6Y5;Y5PU7(9<UETG77A=R5X:7FQ>O5\/7V%?LV %
M8%=@JF#\84]AHF'U8DEBG&+P8T-CEV/K9$!DE&3I93UEDF7G9CUFDF;H9SUG
MDV?I:#]HEFCL:4-IFFGQ:DAJGVKW:T]KIVO_;%=LKVT(;6!MN6X2;FMNQ&\>
M;WAOT7 K<(9PX'$Z<95Q\')+<J9S 7-=<[AT%'1P=,QU*'6%=>%V/G:;=OAW
M5G>S>!%X;GC,>2IYB7GG>D9ZI7L$>V-[PGPA?(%\X7U!?:%^ 7YB?L)_(W^$
M?^6 1X"H@0J!:X'-@C""DH+T@U>#NH0=A("$XX5'A:N&#H9RAM>'.X>?B 2(
M:8C.B3.)F8G^BF2*RHLPBY:+_(QCC,J-,8V8C?^.9H[.CS:/GI &D&Z0UI$_
MD:B2$9)ZDN.339.VE""4BI3TE5^5R98TEI^7"I=UE^"83)BXF229D)G\FFB:
MU9M"FZ^<')R)G/>=9)W2GD">KI\=GXN?^J!IH-BA1Z&VHB:BEJ,&HW:CYJ16
MI,>E.*6IIAJFBZ;]IVZGX*A2J,2I-ZFIJARJCZL"JW6KZ:Q<K-"M1*VXKBVN
MH:\6KXNP +!UL.JQ8+'6LDNRPK,XLZZT);2<M1.UBK8!MGFV\+=HM^"X6;C1
MN4JYPKH[NK6[+KNGO"&\F[T5O8^^"KZ$OO^_>K_UP'# [,%GP>/"7\+;PUC#
MU,11Q,[%2\7(QD;&P\=!Q[_(/<B\R3K)N<HXRK?+-LNVS#7,M<TUS;7.-LZV
MSS?/N- YT+K1/-&^TC_2P=-$T\;42=3+U4[5T=95UMC77-?@V&38Z-ELV?':
M=MK[VX#<!=R*W1#=EMX<WJ+?*=^OX#;@O>%$X<SB4^+;XV/CZ^1SY/SEA.8-
MYI;G'^>IZ#+HO.E&Z=#J6^KEZW#K^^R&[1'MG.XH[K3O0._,\%CPY?%R\?_R
MC/,9\Z?T-/3"]5#UWO9M]OOWBO@9^*CY./G'^E?ZY_MW_ ?\F/TI_;K^2_[<
M_VW__V1E<V,         +DE%0R V,3DV-BTR+3$@1&5F875L="!21T(@0V]L
M;W5R(%-P86-E("T@<U)'0@
M
M      !865H@        8ID  +>%   8VEA96B            !0
M;65A<P         !                               "6%E:(
M  ,6   #,P   J1865H@        ;Z(  #CU   #D'-I9R      0U)4(&1E
M<V,         +5)E9F5R96YC92!6:65W:6YG($-O;F1I=&EO;B!I;B!)14,@
M-C$Y-C8M,BTQ
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MU=;7V-G:X>+CY.7FY^CIZO'R\_3U]O?X^?K_Q  ? 0 # 0$! 0$! 0$!
M     0(#! 4&!P@)"@O_Q "U$0 " 0($! ,$!P4$!  ! G<  0(#$00%(3$&
M$D%1!V%Q$R(R@0@40I&AL<$)(S-2\!5B<M$*%B0TX27Q%Q@9&B8G*"DJ-38W
M.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U=G=X>7J"@X2%AH>(B8J2
MDY25EI>8F9JBHZ2EIJ>HJ:JRL[2UMK>XN;K"P\3%QL?(R<K2T]35UM?8V=KB
MX^3EYN?HZ>KR\_3U]O?X^?K_V@ , P$  A$#$0 _ /[^**** "BBB@ HHHH
M**** "BBF>9'O\O>GF$;A'N7?M_O;<[L>^,4 /HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HIAD0.L9=!(P+*A8!V4=2JYW$#N0,#
MO3Z "BBB@ HHHH **** "BBB@ HHHH **** "BFNZ1J6D=448RSL%49.!DL0
M!D\#GK3NO2@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M6H7D CBA"75E+<^0^,?^"[_[/^B?"3]DWXP>$/A#\9/B-IW[4_Q!^(WPJL?
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M]OB1X>L?#%Q+:Z5H6NW5U.+33KF&SNK<PN&MD0K7YX?$W_@F%^T+\5OVB?\
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MZ;P5)X+C6'_A7\NLS2ZAJ<ZZA<7/VS^T_L]R'&F?86EM[6_-S;Q_(?PVU?\
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MA2=)&U&'4+LJ\2QQ6MFI+34_Z_K:P)6]/QZ=[VVMU/R?^"7_  5@_:]\"?\
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M-=Q\-+K4)_$.H>"/);SI_&:W=_=JE[GR 2]MIEP;P7@6R-F+::3[1H&%%%%
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MX6OV-G'VB&_)_M+RM#+I9)<?*7[>G[)G_!4/]M[X"_%KX4?$/PE\"IO^$?\
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MM==+-?FO^"P?-T\]-+VLK._D[]>G8Z3_ ()O?\%>=$M/ _\ P30_96^,_P
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M>'3;5M!TBXF6)0+^YN+E;#3K:T/POIK^OD/5::O71ZZ*ZT>NO7>_6VJ/E_\
M9=_;Q^.7QW_:Y\2>"/C#_P %;_&O[-'B6?\ :B\=^$OAO^RKXC_8_P#A_+X3
M\;_#;PWXFCL/#.D:;\;_ !%X6\/VHOO%J0WVFV]I%J6H:Y"(K>>.YNI[V&-?
MZ,/VH_VR/#_[-GC+]F;PA)HNG>*YOVA?C_X6^!UU<)XILM*?P.OB17+>)[VV
M:UO7O8K':-]A(^G"0$DWD=?D?^T%^R5_P4Z_X*/?$'X$_#_]JGX0_LX?L[?!
M+X'_ !CTOXI:Q\4/ ?Q,G^(WCWQI%X>O?-L=-\"Z5'I-G?>$Y-3@CB2]_MF:
MVC="QFE&Q;<^Q_MU_P#!&GX"_'?XR_L\?$[X>_L^^&M2O[O]I[PSXX_:DU>\
M\>>*M+G\1_"TJ_\ PE02SOO&,$/GW!" 6OA.VLM5).;0I\QI?U]W_ &E9OM?
M[MO)Z6OMZ6[?KA\=?A>O[0_P?\5_#;0?BY\0/A0?%5O%:0_$WX+>([#1O'7A
M][>YBN'E\/:[+::K:6EQ((_(G9K64F"5T 5F##^5C]DSX._&O4_VM/\ @HOH
M'C[_ (*&?M^^(? /_!/'Q/\ \)!X5T.+XTV<MS\2-$\+Z+>>*K_1?'":EH,^
MFWBZK'I3V#II]OI%NT5PRR #+C^K+X#_ +/GP=_9D\ 6_P +?@9X)M/ '@*T
MU/4-9M_#UEJ>NZM#'J6J>3]ONOMGB+5-8U)FN/L\.Y'O6B01@11H"<_DS\#/
MV$?V@O GQ]_X+"_$#Q#HFA0>&_VR+?Q)%\$+B'Q)I%S/K#:KX)UG1;4ZQ:P7
M+SZ O]H7T$3G5$MBB[I<>6NZB_\ 5E_7]>;!I-KU77I=7.2^%/\ P7\^"_Q!
M^!7BO]HS7OV<?VA_ _PJT+3?"VC>&/%&I>&K*ZTOXL?&KQ1X@FT*'X(_"W44
MO(+#Q-XML#$+V_NGN;+3H+82L\JA8S+[A\,/^"R'P@U%_C[H7[2/PF^)_P"R
M7\0/V>?AA;_&CQ5X)^*#>%]6NM=^&VHI$=*U?PKJ?@_7-;TW5-2N;FZL=,GT
M1IX+ZTU2]@M)5SYCI\$ZC_P1K^/?Q*_X(Y? K]CWQ+-X/\)_M#_ [XC0_%73
M_#^J^*+V7P+XFO=.UO4[N7PEK7BKP-=M?Z>NN:9>+%!KNCW?VG2[I0$GMO,:
M[MN)\(_\$B[KQK\ /VO]%^-?[''P:_85\2^,?V>KKP?I'QVT[]LCXR_M$F:;
M1=8L/&.IW?B33_'GB?7M)\'^ A+X9L;F]NO,OM6TVQ>\*)/Y91S_ "6VO3^K
M^8:_EK_P-?+[_(^O/!O_  7;TGQ#XY_9J\*^*OV)_P!IOX5:#^UOXYMO#OP*
M\>?$2P\+Z5X9\8^&KA-S^*()K36K^>WGM%DL[BZT*>)+P6.HV-W%++'.M?37
MP0_X*FZ7^T?^U1XV^ /P7_9K^,_C7X<?#3XDZY\)/B!^T5:S>";/P)X7\9Z!
M975W>2WOA^]\30^-'\,/);"R@UV/0R);NYMD6TV2^8/YO]4^)O[3_P 8_P!I
MK_@C#^SE\2[C]F/Q+<? ;XJ7<.@7?[.WQ9MOBOK7B_PSH7A[1[.3XF>*[/1;
M,:5X!\,W6D:):6NDV%[?2ZC=7]MJ<US';(T,2_IM?_\ !/']M/Q;_P %(_!O
M[5'@#X ?!#]CI/!_CKQQXC^*/QD^&GQXU_6K;]J7PY>VDL7AG0O&7P>T[2;:
MQTW4KZ\V77B/4[ZPC-U)=W>HW,UWJ5G9F=]%KUU_#6WS;WZ::A^G=>G]?IH?
MTT45\D_L6W?[8U[\&(Y_VY-)^%VC?&P^*O%*&R^$L]Q/X:'A%-6N%\*RS&;4
M=6C34Y=*$+W:P:C.I)4RQVTYDMX_K:D,**** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M'J4XQQ>$I-2=2<ZD).,Z=2E&<'[M/GG&$N3W4U]E]$/B_B#BSB?,:O\ 9E3
M99ALIJK,\13K2G@,=64Z<:$:5*I",H5Z-><)Q]^KR4YUH>TUDG];T445_(A_
MH8%%>;?%7XD>'/AAX/U?Q%K_ (BT3P\\-E='2Y=;N5A@N=06%S;0+%DRS;Y0
MJE8U;&?FP*^:_A=^VW\.?$OAKP^_C$Z[I'B*>SC_ +>O;?PMK$OA2WO"[!GM
M];@@ELWMC'LD,B.RQ[F5B"IKRL=GV199-4LQSK*L%B'.E!87%8_#4<5^^C4G
M2J/#SJ*JJ,E2J6JN*IWC;FNT9U:^%HTI5:V,P=)QK4J+H5,32AB>:M3JU(36
M'E)5'1Y:,U*JH\D9<L9-.<;_ &[165HNN:/XCTVUUC0=2L]7TN]C$EK?6$Z7
M%O,A[K)&2 1_$K8=3PR@\5JUZ<)PJ0A4ISC4ISC&<)PDI0G"23C*$HMQE&2:
M<9)M---.Q::DE*+4HM)IIIII[--:-/HT%%%%4,**** "BBB@ HHHH **** "
MBBB@ HHHH **** "BN1\>>._"OPS\(Z]XZ\;:M!H?A?PUI\^IZQJESGRK6TM
MU+R.0H+,<#"J!DD@<5^>,7_!7K]BF75X=*'C/Q1&LLBP_P!I2^#M6CTR-V;:
M&ENR/+2$?>:<DHJ\D]<?19+PAQ3Q'1KXC(>'LWSBAA9<F(K9=@,3BZ5&?*I\
MDYT:<HQGR-2Y+\W*T[6:/E.(>.^"N$J^%PW%'%G#W#V)QRYL'0SG-\#EU;$Q
MY_9\U&GBJ]*=2'/[G/%./-=7NF?IY17'^!/'_@[XG>%],\9^ O$.F^*/#.L0
MB:PU?2KA+FUF7 +(60Y26,D+)$X5T/48()["O"K4:V&JU,/B*52A7HSE2K4:
MT)4ZM*I!N,Z=2G-1G"<9)J49)2BTTTF?34*]'%4:6)PU:EB,/7IPK4*]"I"K
M1K4JD5.G5I58.4*E.<6I0G"3C*+33:8445\D?&G]N;]F3X!ZR_AOXB?$K3;3
MQ'$JM<Z#I4;ZQJMFK?=-W:VA9H"W97;>,'*C!KLRO)\USO%+!9/EN.S3%N+F
ML-@,+6Q5;DC;FFZ=&$Y*"NDY-**;2O=H\_.,\R7A[!2S'/LVRW)<!"482QN:
M8W#X#"J<[\L'7Q52E3YY6?+'FYFDVE9,^MZ*^7O@?^V5^SM^T3JUQX?^%?Q!
ML-=\06UBVIRZ%-%+9:J+%&59;A;68;F2%G59L'*%E!'(KZAJ<RRK,\FQ4L#F
MV7XS+,;",9SPN.PU7"XB,)IN$W2K0A/EDD^65K.SLW8O*<YRC/L%3S+),SP&
M;Y?5E.%/&Y;BZ&-PLYTWRSC&OAZE2DY0>DXJ5XO223"BBBN ](**** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HK,UK6M(\.:3J&NZ]J5EH^C:3:37VI:GJ-Q':V5
MC9VZ&2>YN;B5ECBBC12S,S 8&!DX%?G)XH_X*N_LI>';R<6FH>,O$N@6%RL6
MJ^+M \+W5WX=L;8S+"^I+=-(DMUIT+,'FN8H BQ@R+N09KKPN QF-YOJF&K5
M^2RDZ<'*,6]DY?"I/I&]WT3/8RGA_/,]E.&395C\RE3<8U/J>&J5E"<U)PIR
ME&+BJE11DZ=._//E?)&5F?I=17D_BKXP>%?#_P +!\6-/NH]>\-WND6.K:'<
M:=(LL6K0ZI"DVFF&56*B.=9%+-GY,,IPP./S(\1?MH_&+5M0EGTJZTO0;#>3
M;6-M9"=XX\Y59KF1PTS8QEMBXY ]:^AX?X,SKB.%:M@X4:.'H5)49U\54E3B
MZT4G*E&,85*DI14DY>ZHQNDY7T/RGC3Q(X<X$Q%'!9S+&3S"O!U8X'"8?VE>
MG2C.5)U*_M9T:=)>TA."C*?M)2A*T+)M?L?17Y!>'_\ @HCJO@F]T^S^*<OA
MR\LKV58HI!-%I&J,I8+NB221XKALG&Z5HUR",DC _2OX8_&/P'\6])CU3P?K
M-O>,8DDN-/D=$O[4.H8&2#=ED(^[+'N1ASG&*6?<%<1<.TH8G,,!4>"J-JGC
MZ"E5PDFFDTZG+%P:;2_>1BF]$V+A/Q-X.XSJSPF3YI3694DI5<JQG+ALP@FN
M9-47.4:JMK>C.I9)MI(]2HHHKY0^_"BBB@ K\]OVC?VMM:\'>)M3\!?#Z"TC
MO=(86NL:_>1_:#%?%%>:TL+?*H&M2PBEGD8E9TD01L!Q]W^)-;MO#7A[7?$5
MY_QZZ%I&HZO<#."T6G6DUVZ#_:=8BBCJ68 <FOYP?BK\1[71[7Q?\2O%<TCQ
MO>7>LZ@T0W37%YJE^!'!"I('F7-Y=QPQ@G:I<%B%4FOU/PNX6H<09EB:V+P:
MQU+#/#X?"X62<H5\=BJEJ<73VJ\D8M>SE>+E5@VG8_ _'GCS&\(9+@<)EF8O
M+,3F#Q>*QN.A*,*N%RO THNM*-5W=#VM2K%NM"TU3H55&4;MGJVO?%WXF^)K
MHWFL>./$EQ.6+#R=3N+&)3G(VPV+VT0V]%)0L!WSS7T%H/Q_\:^(?@#\3O!&
MIZI=7FLZ+IVB7=EK3R,=0D\+7WB+2=$UBRGFX>22)]2M(4G+&5[6\N!(2T7F
M-^2_P_\ VJO /C/4+K3=42;PA,B>;93:S<6_V2^7?M:);B)BD5R@*OY<A D7
M>8V/EM7WI\/C;S_"WXN^*[&1+ZRN=(\)>%;:\M7$]J9-;\7:=K4CB:(M&<6W
MA2>$DM\CS*AP[ 5^Z\2\)PRNE@Z&99+2P<L+F64U<)?#4H4X5)9AA8Q5&I2C
M[*49QFX580E).+E&4>:-E_*G!7'F,SC$YGB<IXEQ684\?D?$5',9?7L16JU*
M5/)L?5E*O3KS]M"K2G2C5H5:D8RC*,94Y\DFWY2[!%9ST568XZX4$G^5?GX_
M[:5[%XJF4^%[:7PE'>2P+Y5P_P#:TEFDC(EXI=5@\^1 )!;L50$[#*.37W!X
MQB\0S^%]=A\)O;)XCETVYCT=[PA;9;UXV6%I6((50QSN((!P2,9K\9?'?PY\
M6?#C4X-+\5Z>+*XNXFGM)8Y5N+:[B1PDCP3I@/Y;LJR @,I93C#*3^L>'^39
M)FSS"&:K#UZ\E3I8/"SKRAB%!1G/$UZ=.$X2E;FI*%2/,X\M31)-O\'\3L_X
MBR.&5U<D>)P^&A*M5S#&0PL*V&YG.C#!X>K5J0J1@I-5^>FU#GYZ24FW9?M-
M^R9\?/#_ ,2?C!X/L_ TNI6OB.PUW2+H65S T,DMI+J%O:2E77,<L3-.L,\>
M2-DOS_*U?TPU_/\ _P#!*C]G3PUX9O;3XI7@A9K#PSI^NZGKM^RPP+J.M6J3
MZ9IT+S%$ABL4FDNLY!>>T61OF*Y_9'5OVDO@7HE^FF:G\3?"MK?._E) ^HQ[
MVD!V[$'_ "T;/&(]^<C')K^5/&JAA,PXREEG"V!S#&T,HPJHXB<*%7$U56J3
M=24).E3<E2@DJE-5%S*-5N5FVE_?7T:*V,R;PXCG7&N:93EN(XAS"6)PE*IB
M:6"P[P]&G&A"I!8BLHRK59-TJSI/D<\.E&\5&3]OHKB=!^)'@+Q0H?0/%V@Z
MF#C:+?4;<.V>FV.5HY&)] I-<;\4_CQX%^#MQI<?C9]5LK/5K+4+NVU:WTV>
MZTM9+"-9/L5Q=Q QP7=VK?Z)'(1YQ4A3Q7X?7H5\-[7ZS1JX=T:56M55>G*D
MZ=*C!U*LY1J*+4:=.+G+32*;/ZBP52GF47/+ZM+'05*K7Y\)4AB(.C0IRK5:
MBE2E.+C3I0G4DTW:,6^A[117YD^&_P!J/]H3X[WU[J?P=\+>&/ _P^MKJ2UL
MO%'C>"XU.\U8Q-M9X--@>$8Z%O*E*Q[@K$NK*/<-%^-/Q1\"/ WQBTOP]KOA
MIY(XKWQGX*BN[5M&,K!!<ZKH5V7D&GHQ'G75M+)Y()>0!%+#X?+N.<IS2@LP
MPF#SIY+*[I9]5RRM1RJM33Y7B*<JDEC'@]&_KTL'#!*"=5XA4DYGF4,XPN)@
MJU*GBGA7\.,E0E'#SC>W/%R:JNEU5;V2I./O*=M3[&HJ"UNK:^MK>]LYX[FT
MNX8KBVN(6#Q3P3()(I8W&0R2(RLI'4$5/7V2:DE*+3BTFFFFFFKIIK1IK5-:
M-'K)IJZ=T]4ULUW"BBBF 4444 %%%% !1110 4444 %13_ZB;_KE)_Z U2TC
M*'5E/1E*GZ$$']#0!_,)_P &^GCSP/X3O_\ @J3:^*O&7A3PU=77_!1+XPSV
MUMX@\1:1HT]Q NL:PC300ZC>6TDT2N"ADC5D#@J3GBOD#_@J#^TA^TG\<O\
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M2^?4_22BBB@H**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M\7XO&":5HD8@U#5=/O-/GO7M.+;3XXK!K9U8P!A L:29,:MM&V-!CYM\:?L
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M1HX*F\''V6(Q-65&KCL;BI5,15J8C%RIRQ-6%&FXE%%%?D)^[A1110 4444
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M084DU+4I)54S,8X+>&WB>>YN;A\'9%!#$[MQEF"QJ"[J#_8+_P $\/V:M/\
M@]^RWIWA3Q1%'XAF\<:E>^*-5CU.W#6\MG=>5#IL$-K+N,-IY4$E_:*3Y@6_
M\TD2.Q/Y_?LH_P#!.O3M.^.>MZGK$&K2V'AS4;V76M1N\0Z>UI?3M-%I.A^3
M''#=1ZM;E#%>#>\>EN\H=6FCSXC_ ,%DOVM?VE=.^/'AG]EC]ES7_$GA/1O!
M'@/0O$/CZ;P4S6>H7FO>)FU"?1/#UQ<PH\Z6&E>&--L-4MK*U4R2_P!I3W$B
M_9[(LE^-OB#3XVKY?P?P[F%*AEU*G1SW-<=5?LH4'AH3J4'.LI<RC'VU.K!?
MNG&485)7C4A*'ZI] _Z+.;XWB3-<\X@_L[*,P^I9OE]'&9S6E3RW+\HHRP]/
M,\9BHRARI2K0AE\6U.-6MB_8<]-4ZLI?O?J_[)OP-U=I';PB-.,A)(TF]GL0
MI/78%+D?F:^;OB9_P3+^!GQ#OM%U2XN-5AG\/R7#V$-^R:E:(ET8&N!*)OGD
MP;:%T#?*'7)&#BOYHO@WK7[5FJ>!?&'B;Q[^U?\ '#P1\2=(GT23X<>'[35;
MG4;#Q)!?R.DEQ+?;+FT6(2!$#2O MG@W%TLL#A:_J9_X)X?$CXH?%?\ 9BT#
MQ+\6=7D\3Z[%XF\9>'=)\93VT5I>>,_"_A_69M*TOQ'?10*D#7EQ+!>V4UU
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MH(UD$5NT;R")))7=$5F<?'OPR^%OBWXIZT^D^%K=";002W^H3R-%:Z?'.[)
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M=2>,SK&8>MB8XO&XS%T,-"O4P^#E@Z+5&4HJ>*KJG*-653#0?['_  -_:M^
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MBI8G!T,+AL/4='+(4IX>M#&1K.:Y8N7[W]%[B.7B#X;2XJXWX3RZKXAX//\
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MC=3-H>M327ME-'GYU1Y6::W=AQYL3AU'W<5_%V>>$%;-<OSG#8FOE6;X;/\
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MT/3))-5U15=I(I;Y+-VC8VJNORP  , 8 X '0#TK[Y_X*U?L7?&[XE>&;?\
M:&^#.KWWC;XF?"WQ!!K.D>$#I]HVH6?@)+24:SI'A<Q1I->737ACOKVPE=_[
M4L8Y[:.-[HQ+)_/C_P -TZQH^B70\3_"#7K+Q!I=RVD:G+)+<Z;I=KK:1L6L
M[N"]L#<V5TI1GDT^:=;D*K !, U^MY%AX8W*L(LM5*:H*5+$T(54IT:\ZDJC
ME-5>2;515(QC4:=^3E3:@C^ZO"O X+/N!\EI<+/!UZF6QKX;.<OHXF,,5A,Q
MQ.+K8MXBO#&?5Z]6GB*6(HTJ>)<9QE]6="G4G3P\>7T_QA\28?V:OVOO@I\8
M?"EWJFC>)=4@OM-U$^'IH[9KMY;NQTNSDU>U93#J-E<)J4\=W;3J5N8K=5R&
MC!']OOAVSU/3]"TFRUG5#K6JVMA;PZAJS0);'4+I(P)KHVZ?+%YK9;8.G?G-
M?Q%?L,_LU?%+]N7XZZ5\<_'7@?QK?> / OC+P9>[M,L+:Q\*7VBV>N1R7N@6
M%]JSQ/>RPK^_N6TXW#(@N)+J5)C"DG]QU>%QS*C"IEF%4X5,7AJ%6&-E%PDX
MOFA.A1YE>25.%2:MI%W32;3M^7?22KY9#,.$\GHU\+BL[R?*\7AL^KT)T:TZ
M4I5Z-?+\OG5@Y5HO!4J^(7LY.,+58-1YHOEX7XH>-H?AK\-/B%\1;BU>^@\!
M^"?%7C&:RCW;[R/PUH=]K+6J[ 6!N!9&$%02N_/:OQ4_8B^!_P"T5^V]\'?A
M3^W)\:/VX/VE_!VN_&=H_BAX3^#'P4\<OX"^#?@GP+<:U=OX8\%:AX8TV-H/
M%DTFAVUK_;^H:P6NI[JYN()&<Q%F_='7-%TSQ)HFL>'=:M8[[1]>TO4-%U:Q
MF&8KS3-4M)K&_M91WCN+6>6%QW5S7Y!_!/\ X)__ +9/[*$FF_"G]FC]MG2]
M'_9,T7Q3>ZSX6^%?Q*^$7A[QMXR^'_AS5]:GUO5? GA+QM/&L\GAU;B[O$TE
M-66YETJ.X<6OE\D_#0:49*\8S;C:4E=<NMTM'9WLWIJEY'\RO==OUNK?=J?$
M_P"S[\,/VEOVJ_ G[>O[0&G?MY?M7_#;XI?!G]KO]HWP!\*M!TSXGWUY\$M'
M\-_"K0O"6O>%]#U?X6:@DGA^^TN:?5;NSU,R_*]G(',3/&2_IOB+XL_'7]J#
M_@F?\-?V_M8_;1\<_LC7'A?]G_QIXC\1>'?AQH_AJU\->,/C!X)\0>(_"]AJ
M>I7.HP2:IJ&F>+]>\-0V5CX,A:6PG.M0QVT!?;GT?0?^"7_[7OA*#]I/X4^
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M,_\ P4?_ &=OV4?V:/A1XBTG]H_X5_&3Q'K(^$%GIC?$#XM>$M+\?^+?!?Q
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MW-[I5M"D<ZZA93W^EJMDLXD:WG-W$Y=W18Y@"J?G[)X#LH-/EU'P9>V6O:;
MIEOK6RT]M,UO34X+3ZAHH:<&VW-\UYI]YJ-K$647,T#R(C?Z:>$_B5FF$\.<
MKRS&0Q,,<LMPF I8FI&=+#8/$T*7L<56PM5X>5*K#$5?>HQ=>*A6YHP]Y6E_
MGKXT^#>$QOB?CLY=3 8A2Q,\VS7!86K1Q&*Q_P!:A1KPP^+PT,7#$T'@VJD:
MK6%J.KA'3E4DJ23CY?X5\*:#X+T6T\/^&]/BTW2[-2(H(RS,SL=TDTTLA:6>
M>5R7EFE=Y)')9F)-=-^TYHFK_#_XT_#WXW1Z?-<>&_&MIX#^(NB7!4BWGO\
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M#'##;01>9-+Y,*JS;I9G+R2.ZK&I"#VE$>1T2-6=W9415!+,[$!54#DLQ(
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M@.$<9@\!G679EE&?498;-,HQ6!R['XO"X/+<HK8S&YCC<PQN85:M*A&M1RG
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MLKJ));*W_M58?,FD8F(M$(I/RWQ*XQRK+<!5XBXMS?+<-6HXO!5L'7S;%X;
MTGC:>(I0PM*E.HX0I0E=T9>SBE&G.>C;L_V+PCX2K5<TPO#N1Q_L?(<=0Q.3
MYQCISE2R[!X',Z4Z56MF.,K2]FY>VG3KP]O4E4JUZ=-Q4FM/SU^-WP>?XP:;
MH.FC7?[$CTG53?SM]B%X;B)[>6W>./\ ?0&*8"4E)&:2,<[H7)!7YUM?V2=:
M\-?$3PEJ/ASQ#--X<L[N"_U/4IY([75;&6R<2M# ENB+,MZ (8RJKY:LXE+
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M-;[)\ODNL?N;7F'*O/I?7L%%%%8#"BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@#!\1^%_#OB_3)M&\3:-I^MZ9./WEGJ-M%<Q;A]V1!(I,<J'YHY8RLB,
M RL" :^9M5_8I^".HW+7%K8Z_HR.Q<VVG:Y.\ ).6"#44OY$4GHJR!5'"@
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M>*13-IFII"@O=/NX@=\$UO-N"K(JF2$QS(#'(C'F_CW\2M ^&/PU\1ZOK%U
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M6OSH_6PHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MP^%IPE*O6Q-2G2P].GM*5:I5<:<(:VDYM1UL]SA/A3^S5\%?@GK?B'Q'\-?
M^G^'-:\40VEKJU_%->7<[65D9&MK"T:]GN/L-A$\KNMG:>3;AB,1@#%>ZU6L
MKVTU&TMK^PN8+VRO(([FTN[:5)[>YMYE#Q30S1EDDCD1@R.K%6!!!JS6N/QV
M/S'$SQ.98O%8W%N,*52OC:U7$8AQHP5*G3G4K2E4M2A"-.,6_<C%1225C'+\
MOR_+,+#"97@L'@,%&52K3PV!P]'#893Q%25>K4A2H0A34JU6I.K4FHWJ3G*<
MFY2;?FWQ6^$G@/XU>$;OP3\0]%&L:)=.)D,5S<Z?J.GW2H\:7NEZG920WNGW
MBQR21B>WE0M'(\;AD8J?*?A3^QI^S7\%K%[3X??"S0=*NKBR73[_ %VX$^H^
M(M4LQ.MQ);:CK-[++>7%O<2JIN[;>EM=(JQSPO&JJ/I^BK>:YF\HQ7#[S#&O
M(\<YO&Y.\36_LS%^T@X36)P7/]7KQG!\LXU:<HR7Q)V1S5<AR.MF^%S^MD^5
MUL]P5-T<'G%7 86IF>$I.2DX8;'3I/$T(N23:I5([=C\J_BS_P $C_V=OB9\
M1-.\8:=J?B3P!X874(=4U_X:^%S$OA76[Y95>\N;9;F5I=#FU5%\K49+))'=
M'?[*;0B/R_U%TK3++1=,L-(TV!;;3],L[>PLK=/NPVMK$D,$8[G;&BC)Y)&3
MR:OT5Z6<\6<2<187+,%GF<8W,\+D].I2RZEBZBJ?5HUN3VKY^55*U2HJ5.,J
MU>=6LXTX0Y^6*2\S(.".$N%<=G.9<.</Y;DV-X@K4*^<5\!05!XVIAHU(X=3
MA%^SI4Z/MJTJ="A"E1C4K5JJI^TJU)2****^>/J0KYQ_:6_:8\&?LQ>$=)\4
M>*])\0>);K7]9CT70?"_A6+3[CQ%K=RB"ZU!=+M]3U#3+6ZGL-.6:^-H+M;B
MX2%DMT=\X^CJ^.OVZ/@%IG[07P"U[P^UUIVB^+O#-_I/C#X?^+M2M+J\M_"G
MB?1M1M9A?W$=FDSC3KS3OMNF:I)/:WMI;65W)?S6DK6413V>'I\/4LZRVIQ9
M7>%X<AB8O.,4JDJ4,+@K2]IB:U2'[R&%P[Y:V+E1_?K#0J^Q3J\B/G.+Y\1T
M^&,\J<(T:>(XEIY=B*F38>JJ4OK&-A'GAAZ2K_[.\57BI4L']:_V7ZW.B\4U
MA_:,]Y^#OQ<\%?'7X;^%OBI\/K^74/"GBVREN]/DN;=[2]MY;2\N=.U'3[^T
MD_>6U]IVI6=W8W<)+*L]NYC>2(I(WIE?S8?!KXR>.OV4_@)\=-1^$?CKX;_$
M_P 9:[\1_A]<>)+S0]0G\2_#?X50:AX+NV\9^/;I- $-G=7_ (K\6Z??Z=IG
MASP_@O=1Z8;:RF5[/2KGZA_84_:B_:V^.?QRMXO%E_>>+/A'?^')]5U[51\)
M9O!W@W19!I$B6:^#O$FH:E;ZY=SKXF@.DWT.LV.H/>S1:A)I<8TR(:C;_IO$
M7A!C\!3XFSO+,QR^/#63U*]7"3S*MB,/F&(H+"X7&T\(J:P?LWBU#%K#T'B)
M8-YC+#SQ.&HQH5J-_P FX4\<\NS.KP?P]G&59E+B_/\ #T(8ZGD]#!XG*<+7
M^MX[+ZV/]L\RE5_L^57 /$XCZDLSCE"Q=# XW%2Q5*OR_I7^TQ\ K']I#X9S
M_#N]\4ZMX0(U?3=<M-6TNVM;Y#=Z89?+M-3TV[V1W^FW"3R+-"D]K<12B"[M
MKF*XMXVK\3/$'@K3_!?[2/P+_9>_:.F\4?$'2]"OX)M/^(FK>/#I5N%^+6OV
MR0>%K3P_K\_B?7?$_@/4K[X=0VUTK:_;:A9#6]=TV\<:?]EM&_HVKR#Q=\ ?
M@UX\^('A+XJ>,/AYX>U_XA>!1$/"GBF^@F;4=)%O<M>6H3RYX[>Z%G=O)<V0
MOH+H6<\LTMJ(7FE+_.\&<=5N'Z.*RS,*V8SR:> SEX&EE?U?#8_+\[S#!/!T
M,TPV/3P^.HRI4Y5:,H0QCPW)B*E6K@\6X1HR^IX_\.:7%-? YKED,NHYU3S#
M(X9G4S6-;%Y=FO#F6YG3S'%91BLOJ4\9@:CG6ITL11K+!0Q:JX>G2HX_ \RQ
M-+UFWM[>TMX+6U@AMK6VABM[:VMXDAM[>WA18X8((8U6.*&*-5CBBC54C151
M%"@ 3451CU339;^?2HK^SDU.VACN;C3TN(FO(+>5BL<TML',J1.RD*[(%)&
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MII----)IIW33U336C36J:W"BBBD,**** "BBB@ HHHH **** "BBB@#\W/\
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MR]34;.Y,\V_^O.OP]\8_\$B-;\2Z%^TQHMA\5O!^@P_'S]L/]EG]I_3;71?
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M#J8.O'#8?#8JE+#UOJ&"QD4ZN44,5F&&QF-PU/ZY1RA8.V*/NVBBOR:\&?\
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MKX:HJN'K5:%6/PU*-2=*HO2<)1DODS/$X7"XRE*AC,-0Q5"?QT<31IUZ4O\
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MBZM;FU,-Q;1Q^0DODED;] =9_P"":'[-6M?$%?B)<:-J7]K?:+.XDBFNOM2
MV*1Q6ZV[39BMQ%'%''$YMI98U1"'+C>>&_87^%[:AK.J_%+4H?\ 1=&$VB>'
MPZ\2:E<Q(=2O$)'2UM)5M49<@O=7"D@QXK]0:_E;Q XXSG!<58V619QC<!B:
MN%=#.:^"Q$J/UW$XFI*O6C74+1J3C"5&,Y-<RE%0;7LXI?WEX/\ AEP_F? .
M7+BOA[+,VPD,?];X<PV982GB/[-P.%I4L-AGA743G1IU*M*O5ITHR]DX3]JH
MMUYN5'3--L=&TZQTG3+:*ST[3;2"RLK6%0D5O:VT:Q0Q(HZ*D:*!W.,DDDFK
MU%%?C$I2E*4I2<I2;E*4FW*4F[N4F[MMMMMMW;U9_2L(0IPC3IQC"$(QA"$4
MHQA"*48QC%648Q22222222T"BBBD4%%%% 'A'QO_ &:_@Y^T-H;:%\4/"%EK
M<8:.2WOX]UIJ=K-"V^&2*\@VN_EMR(YQ+'@LNT!C7QIXF_X)]75@L</@#Q-I
M4FE6@06.EZQ9-:2VD<0 ABMY+99;<^4!\LK&)CUP"2:_4*BOJ<HXTXER2A3P
MF!S7$?4:4YU*> Q$OK.#ISJ**G*E0J\T:,IJ,5.5'V;DDN9NRM\)Q'X:<$\4
MXBICLVR+"O,JL(4JN:81/!YC5ITW)TX5L3A^26(C3<I.G'$JM&'-+D4>9W_*
M30/V#_'UU>QCQ#XBT'2M/60>>]JTU]=O'GYO(1$$0<CIYKJ,]37WEHWP+\(:
M#\+M4^%>ERZC8Z5K=A<6>K:M:2I#K%W+=H$N+P3E)%CF8 B-0K)$A*KW)]IH
MI9UQCGV?1ITL?BHJA2J1JPP^'I1HT75A\-2<5S2J2B]8^TE*,6WRI&O"/A[P
MOP1BGC\AP52GF#LEC\57GBL53C&49J%*53]W2BYPC*2ITXN;BE-R2L?/&F_L
MJ? C2UM&M? L,-U;6MK:RWMIK/B'39K_ .R0I"DVH1Z7JUE;7<SJ@+M+ P8G
M&W: H]J\/>&/#WA2P73/#>C:?HMB&+M;V%M' )9#UFN'4>;<SM_%/</+,_\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% 'RW^T=^SG8?&73HM4T
MI[;3_&6FP-%:W,RJ+;4[;DBQOF SP>(9FR(\X/R#!_-CPE^P7X]/CJ^U%/ ^
ME^%]1U +;:MXKE=$MY[9"/FC$+$7)(4';%$CO@;B<#'[ET5]UD7B)Q'P_EU7
M*\%7ISPTZ<J=/VZJ2E1A*2DZ:Y*L(U:*FE.-&O&I3C-)I65C\JXK\'.#.+\Y
MH9[F6%KTL;3JPJXAX2=*G#%SA!TXU*BG1JRI5W3;I3Q&&E1K3IMJ4FWS+XP^
M'W[%'PZ\,26E_P"*+J\\7ZC R2F"?%KI(F4AL?9H\O/&K %?-9"?X@1D'ZLU
MSPCX:\2Z$_AK7-%L-1T)XHX?[-GA7[/&D2[8O)5-IA:)>$:(JRC(S@D'HZ*^
M<S#/LXS3$4\7CLQQ->O0EST)^T=-8>5T^:A"ER0HNZC[U.,6[*[=D?:9/PGP
MYD&"K9?E.3X'"87$P]GBJ:HQJRQ<>5QMBZE;VE3$IQ<E:M.<;2DDDFT?/^G_
M ++OP-T^?[0G@6PN7#;U6\FNIXT/;:GG(,#L#D>H->RZ%X:\/^&;7[%X>T;3
M=&M>,Q:?:0VP?;PIE:-0\I X#2,Y Z&MNBN?%9IF6.CRXS,,;BH)IJ&(Q5:M
M!-;-0J3E%/3=*YV8#(LDRJ3EEF499E\W>\\'@<-AIM/1ISI4H2:MI9NU@HHH
MK@/5"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "N'\>?$OP!\+](.O?$+Q?H/@_2 Q1;W7=0@LDE< $QV\;MYUS( 0
M3';QRN!R5Q7<5_*-^TS\5K_XL?M+_'[XD_$;5_+\&?"#QIJ_PO\ AYI&I3D:
M+X5TKP3!!!XEU^&UD8VYU;7-<DO';4/+^UK:0Q6D3!!AO9R7*?[5KU83J.E1
MH4U4J."4JDY3FH4Z5-/3FFVWS--1C"3Y9.R?W_A[P/+CC-<5A)XJ>"P>7X2.
M+Q56E25;$574Q%+#8?"86FVHNO7J57+GFW&G2I59\E6:A1J?TC_"7]I7X%_'
M2_US2OA/\2_#7C75/#<<,^M:;I5TQO[&UN',=O>R6D\<,[6<\@,<=RB-$7&P
ML&(!]RK^(7]C?]J7QCX@_P""EWP*U#X,:=J-WHFJ:O:_#?Q);0129\1>"M8O
M"/$6I:E#&IV66EVY_M.RDN,K:2V:73%17]O5='$61_V'B<-24Y2AB<-&O&%1
MQ=:D^:4)0J<L8K5QYHOECI+E:O%M^EXK>'3\.<YRW 1Q-6O0S7**&:4:>*E2
M>.PLI5:N'K8?%1HQIQO[2BZE.:I4[PJ>S<?:4JC97D7Q5^.OPO\ @K>?#/3_
M (D>)K?P[=_&#XD^'/A)\/H9XII6U_Q]XLN#;:#H4'E(PCEO9QL664K$A(+,
M!73?$WQ1>>"/AO\ $'QIIUB=4U#PAX(\5^*+'3%#%M1O- T&_P!5M;$! 7)N
MY[1+<! 6)DPH)Q7\@NM>+/CM\=M'_P""-O[57Q:_;%/Q'O/VC?\ @H5\$/$6
MI? "VTGPW8>'OAA=)XZOX+#1/!)L[N76K+4/!=M;PZ;XD^WVVZYOO.:X566-
MI?#I4^?5NR3M;6[=G*RT:6B>KMVW9^6MVVW_ ."E;YW/[+998X(I)YG6*&&-
MY99'(5(XXU+N[L>%5%!9B>  2:X[X>_$?P)\6/"UEXW^&WBO1?&GA+4;C4;2
MQ\0:!>)?:9=7.DW]QI>I017$?RM)9:A:7-I.N,I-"Z]LG^96T_;4_;,U+XLM
M_P $W[WXD:TO[1OPV_:O^)?BCXE?$X:=9B_U7]BWPSX3O?BAX5U!A+;?9-OB
M>S^V^"UN&AQ,]A80;C)<,&\\_96^-/[77[0*_P#!,WX"?#[]HNZ_9[T7X_\
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MW4O$7QJ\27WQ$\7^$](U..[N[^/P]'X:T'P[X:T[6?&&E:5=-"]]J%Y'/)!
M(WB_2G_@C)\>_BO^TI^P?X'^*OQJ\=I\2O'VI>/OBWHU_P",HK>VM;?5[#PY
M\0-;T;29+2WM%6"*TCL+6%+=(P0L04;FQDYSI.$6W*+LTFE=_%>VMDG?E>FZ
MZ@FG\U?[K?YK_AK7_52BBBLAA1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M[&TN888[>6$1*$KI?^"9_P"P+_PP?\-_B9IFM:UX4UKQ_P#&CXDWWQ+\<+X
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M7_HY/PC_ ."7QM_\R] 6?9_U_P .OO/ORBO@/_AZ1^P+_P!')^$?_!+XV_\
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MK[S[\HKX#_X>D?L"_P#1R?A'_P $OC;_ .9>C_AZ1^P+_P!')^$?_!+XV_\
MF7H"S[/^O^'7WGWY17P'_P /2/V!?^CD_"/_ ()?&W_S+T?\/2/V!?\ HY/P
MC_X)?&W_ ,R] 6?9_P!?\.OO/ORBO@/_ (>D?L"_]')^$?\ P2^-O_F7H_X>
MD?L"_P#1R?A'_P $OC;_ .9>@+/L_P"O^'7WGWY17B/P2_:/^"7[1NEZUK7P
M3^(&E?$#3/#MY:Z?K5WI=IJ]HFGWEY%-/:P2IJ^G:=*S3103.IBCD3"'<P.
M?;J!!6##XJ\+W&MS^&K?Q)H,_B.VC,USX?AUC3Y=;MX@NXRSZ4EPU_%&%(8O
M) JA><XYIGBWQ/I'@GPKXF\9Z_<+::%X2\/ZSXFUJZ8@+;:5H6G7.J:A.2Q
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M^'I'[ O_ $<GX1_\$OC;_P"9>@+/L_Z_X=?>??E%? ?_  ](_8%_Z.3\(_\
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MZ^\^_**^ _\ AZ1^P+_T<GX1_P#!+XV_^9>C_AZ1^P+_ -')^$?_  2^-O\
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M6R1V\LQ!W)WTU!I\R3E=6BW)-K6_+;3F;LE?0AWZ;=7IIJM[M:6N>%?MJ?\
M!9Y? /P(MO$/[)?PTU+XL_$+QC^R';_M86>N1ZGI(\._"3P9J>JZ+HEC<>.+
M*\M+A-0U&/5]6.ER:3');,;R"3[RQLM>J>&O^"J/Q"'@;]G?P=<?LB?%#XB_
MM;?%_P"#]E\7]3^"?@CQ#X9VZ1\.[;3],CF^)NN>*)+9-*T+2_%>J7<@\-Z#
M]@ENC++%923Q@Q2O\0?\$Y?^"7FH^//V)OVSSXP?QA\,I/VTHO$O@;X!V/C_
M $L?\)C\'?V;=,\1ZOXD^&>D:EHDA6738]4\0:Q=Z[?^'R8Y4TVWTE)/+N%
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M?]$]\#_^$GH/_P KZ/\ A6/PV_Z)[X'_ /"3T'_Y7UW%%%WW?]?\,ON X?\
MX5C\-O\ HGO@?_PD]!_^5]'_  K'X;?]$]\#_P#A)Z#_ /*^NXHHN^[_ *_X
M9?<!P_\ PK'X;?\ 1/? _P#X2>@__*^C_A6/PV_Z)[X'_P#"3T'_ .5]=Q11
M=]W_ %_PR^X#A_\ A6/PV_Z)[X'_ /"3T'_Y7T?\*Q^&W_1/? __ (2>@_\
MROKN**+ON_Z_X9?<!P__  K'X;?]$]\#_P#A)Z#_ /*^C_A6/PV_Z)[X'_\
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M /*^C_A6/PV_Z)[X'_\ "3T'_P"5]=Q11=]W_7_#+[@.'_X5C\-O^B>^!_\
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MK'X;?]$]\#_^$GH/_P KZ[BBB[[O^O\ AE]P'#_\*Q^&W_1/? __ (2>@_\
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M$GH/_P KZ[BBB[[O^O\ AE]P'#_\*Q^&W_1/? __ (2>@_\ ROH_X5C\-O\
MHGO@?_PD]!_^5]=Q11=]W_7_  R^X#A_^%8_#;_HGO@?_P )/0?_ )7T?\*Q
M^&W_ $3WP/\ ^$GH/_ROKN**+ON_Z_X9?<!P_P#PK'X;?]$]\#_^$GH/_P K
MZ/\ A6/PV_Z)[X'_ /"3T'_Y7UW%%%WW?]?\,ON X?\ X5C\-O\ HGO@?_PD
M]!_^5]'_  K'X;?]$]\#_P#A)Z#_ /*^NXHHN^[_ *_X9?<!P_\ PK'X;?\
M1/? _P#X2>@__*^C_A6/PV_Z)[X'_P#"3T'_ .5]=Q11=]W_ %_PR^X#A_\
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M!?B33Y=+UC0H[GQ7JUU9V=U9RJICV6DL(C*;HG0!HG>,JQ_$&Z_9+_:QLO\
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M:OK&IZQ.MQ<0Q/+#=YEM8G.Q*Y>^E[6^;BE?[P3YMNC5V[_-;;^EUYG[._\
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M3^'OAC7;/0-6U&:*PGU;5M2%]=Z9K"I;:5IMM+<.OV!EF<+$9X-WF"K\<O\
M@IY\-_@__P $\O"?_!0S2/ FM_$7P5XR\.> -:T?P-HNNZ;INKG4/'4T-@=#
MGUR\M)[".?0=9:ZTG4;E;-XWN;*9HH@A&/QM_P""AVH?M ?MB_\ !7[PK\&/
MV:?A#\._C[9_L5_L[^*O$/C7PA\2_'EQX \#P>*_C+:2>%!?WVLPZ/K<D_B?
MPI!J^EWVD:=!:*TID\Z5FM8+DK^;4?Q/\6:%_P $,?VO?V,/B]:Q>&?B=^Q'
M^UEX(\&ZIX;FU5;Z#P[X)\6>.&\1Z%8V=[/';2WVFZ;J%OXAG.JF&**:WU&R
MF>.W:8(P)MJ_H[=M%?YWUZ]#^AKPY_P6QN/ _BKX4:3^VY^P_P#'G]C#P3\<
M+S1=-^&OQE\0>)?!'Q8^%%YJ'B**WN-$MO%'B3P/-!-X5;48+JWD@CN;"\O$
M\U3<V<$*R31^S_M-?\%9O"OPG^/$_P"RG^S=^SQ\7_VVOVD](T:U\1>,? ?P
M:DT+2O"_P\T:]"-:2^._B/K\SZ)H5[=++"T-I]DNHU::*"[N[2ZDCMV_(G_@
MIY^V%^SM^VA^Q?\ LT?\$_\ ]D?QUX9_:=_:;^*.N_L]_9/"_P ';J'QY;?#
MJQ\':?I<WB/Q)XL\2Z)]LT'PU+HP6:.6&YU)+NS:&YDU"&SMX_.)^P+\9_A;
M_P $IO\ @H-^W5\$/V]O&=A\*M<^.^I_#KQS\'/C_P#$2&[TWP-\0?"OAOPX
M-$O-.MO&T]L^F:>US<NEY*FIWEG:PW&F_9+J6+4'BMV=G\^W]>H72ZW5]]++
M1Z76G3\4?I5\9_\ @JK^U;\%_@AIGQRU[_@E)\=T\/Z=HGBK6_BM9:Q\:OA5
MH%Q\*[?PSJ262RW[FUU*;Q'8:O:R#4;"^T>R&80T9MV<9KW[_@GC^WU\:?VY
MM*'C;Q9^Q#X__9O^$NN>"].\8_#KXH>*/BIX&\=:/\0H]0OWM!I^F:1X>L=-
MUS3)8H(WO#<:G9Q1M&C1%$D*;^=_;N^/7P:_:/\ ^"5O[8'Q+^!'Q(\*?%;P
M!/\ "7QUHMOXO\&:G%K&@W&J:2;--1L[?4(1Y,\EJTT0D:)GC(D1D=E8&O#_
M -BC_AN?_AV5^P-_PQ@_[*BS_P#"E]._X3<?M,VGQ:N8C#Y]U_99\+'X7ZGI
M[I('\_[>-5$BE?*^SX.^D/YW^[^O^']#Z9_;"_X*E?"_]B_Q=K/AGQU^SC^V
MC\2='\*^']-\3^-OB;\$O@%+XV^%'@C1=3C69;OQ)XYU'Q3X:TZ'[% XFU.+
M3DU*6P3(G19%*#7^,G_!5#]E3X/_  +^ OQXANOB'\6=+_:B:RC_ &?/AY\&
M_!%QXO\ BQ\5YKJTCO;B#PQX.O;[04,FDPRQ#5FU+5-/BM9)%1))B:_+W_@L
M9\;?A+XS_9^^(OPB^(__  4_\&_LQ?M"_"OX1W,_Q>_9P^&VL1P>&/C=XFUC
M1(]:LO ;Z'JC6?Q4U70O%3B+08H_"_B=;K2K'4S-XC1!!<!?B:S^(\'PY\<_
M\$!_VOOCW\-M"_9D_9VT?X4>)?AGJ=M<1ZCI'PS^$7BR\M-0D\/Z]JMSXBN+
MZ]\(Z5XFTN[LKNQN_$VH&X=?MD\][)%:7,\;M_7YV[A??R:7I>V_WZ7MZ']!
MGPV_X*Q?LE?$C]FGXK_M/I<?%'P;X:^!?B-O!7Q@^&WC/X9Z[;_&SX?>.7U*
MST?3O!>O_#KPZ?$EV-?UG5=1TZPTU+&^O=.-Q>PB]U"R1+AX?6OV$OV[OA!_
MP4)^#M_\;?@MX=^)?ACPKIWC'7_ ]SIGQ5\/:+X8\4+K'AR<6]_(VE:)XG\5
M00VCN1Y'VJ_@O@,K<V-M("@_*G_@CC=Z;\8_VSO^"K_[3WPW:#6_V<_BM\?;
M'1/ASXOLH2WA7XA:MX8^U/KOBWPS</$D&L:;=R3PM_:ENLD;3$([B=&4<?\
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M ."94OQ>G_:7_;W\3?$S3OAYIGA#6?%^NZ!)\./@UX7^'OB;P7?>)OB]+?\
MAV77=.N;7Q%'K8MX[FQ\/Q?VA;26]\6=[6Z7?W7_ *^[4%+77:[2^]6V]?2V
MK[G]DG[3W[<'[/W[(FN? ?PY\9O$EUI>K_M&?&'P?\%?AY:Z;%I]T(_$GC.\
M-G9:[XEEO=4TV+0?!6EL#-KGB2=Y8+&$ 1P7,[)"WTO>>,O"&G:1IOB#4/%?
MANPT'639#2-;O-=TNUTC53J2+)IPTW4I[I+.^.H1LKV0M9I3=(RM!YBD$_Y_
M,WA[X5?$/_@EY_P0D^.G[5&GZ/XE\+^$/V^;#X$?&'XF^/\ [9<1:=^S%IWQ
MD^)MQJW@KQAJL\K7%OX*T[PWH9M1;3E!8Z3H]II\#1I;01'Z9_;A3PAXI_X*
M-1?"CQ%'^P7_ ,,A:1^Q!\,[#]A.V_;6^-WQ#^$/[+4?PPU_1-*-QXZ^!_C'
MP'H'B'PAJ'CTPF*STO5]6U6QNSX;LM(N=)N[NXBTAX2VWFOQ[?=^:!2[V2T>
M_1I;V3VO\^G6W]OFLZ[HGAVPDU7Q!K.E:%I<+1K-J6LZC::781-,ZQ0K)>7L
MT%NC2RND<8:0%W944%F /YY?L2_MW:O^UI\?/V[/@[?^ ](\*:=^R%\5?!?P
M\T/Q!IFMW6K3>.++Q9HWB'5&U:_MYK6"#3I;9M#188K.6YBFCN2Q<&,%_P"5
M_3O"7AOPG\4?^"3GP3_X*K_M _"?XV?L(:%\&?CLO@;XJ^$OBCXL\5_LM^./
M'^F^)/%MIX(LO%/Q-N]*\('6U\%Z0/#WA;1[K5[:VTO3X-.32EN)- &KO)^F
M?_!NC:_!RR^-O_!6JU_9ZG:Y^"$'Q^^$"?"ZX$^JW5K+X-&A_$TZ.^E76M%M
M2N=!-N0/#US,TD<^AC3Y;222S>WD9%)WTZ^;UV3V^;OJ?TXZUXJ\+^&Y=/A\
M1>)-!T&;5K@6>E1:UK&GZ7+J=VV,6NGQWUQ ]Y<'(Q!;"24Y&%YJ74/$?A[2
M=0TS2=5U[1M,U36Y7AT;3=0U2QL]0U>:, R0Z99W,\=Q?RH""\=I'*Z@@L *
M_CT^%D/[!'Q2_P""C?\ P4)_X?$^*/!UE\=?!OQ<\+Z7^SEX<_:$\<ZQX-\'
M:7\&8ENIO#O_  J6WFUC1_#M]<7T_P#85W<VMHUQJ$MS<33:9!(9M>9?A/\
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MKCX__LP_\$Y_@7\!/%6C_LE7>AZ#\<OB_P#M+>._%_ACPWJOCW6[:6ZD\ >
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M%\=Z^O@[P\NM>-='5/*72?%FJ#3A?>(M-$?[L6.KSWEL$RHBVDBOY-_VWO\
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M^&M$M([#1O#WAW2['1=#TBQBSY5EIFE:;!;6%A:1Y/EV]K!%"F3M09-?S4_
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M\7:MXM\<7NC::J6VL7NEC5FFS?WYL;FQL;*"SK^@WX+^/?VB_!G[/WB;Q_\
MMS:5\%O"GQ#\%IXJU_7U^ 6M>+=>^'[^"]#TN#4K._M+GQO8:9KL6K2^7J4-
MW9SPF!##:O%.1.ZQH$[I6]>MM4GY=&OZ1Z[XY^!GP3^)^L:/XA^)7P?^%WQ!
MU_PZROH&M^-_ /A3Q7J^ALD@E5M'U+7=)O[S36655D5K*:$B15<$,H(@\=_
M/X%_%+5-)USXF?!CX4?$36M!55T/5_'/P\\(^+-3T94<2(NE7^O:1?W6GJCJ
MKJ+26$!E5@,@$?D%^R1_P4*_;L_:GT"#]L:?X#?L]?";_@G-=)X_UW3]5\6^
M/_&.H_M*:S\/O W]M6;>-+#1-,TE? UN-3U71+JSCT35+BRNK>1)D2XN[5(-
M1N?CGX:?\'!OC7Q)XO\ @;\2O%OAK]DZ+]F;]H+XO'X7Z'\./!/QVG\1_MD_
M"[1+[6)]#\/_ !-^*?P^%HNBVFB:E<0&\F\/64,&K6EK/;F2Y^SSVM_=%O\
M@_AO^ 76GGMYZ7_4_>S6/$'[#5^GB/XBZ_K/[*EXD/D_ SQ9XYU>_P#A+<+%
MF46-O\(/$/B6\E<)F<BSA\!:C>C][BW32M^$KZ%TSP%X&T3P?#\/-&\&>%=)
M\ V^ES:'!X'TSP]I-AX0@T6Y65+C2(?#=K:1:-%I<ZSS+-8)9+:R++(KQ$.P
M/\ 'Q$_Y1X?MC?\ ::?PY_ZL!J_LD_X*7?MTP?L ?LWS_%ZP\$'XE^/?$GC#
MPS\-?AAX!.I'1K7Q#XX\87OV#21JNJ+;W4EEHUE(1<:C+!!+<-$%BB"&0S1
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MVSI);W7C>.YTB5/%=Q!)'')#-KHOY(G1&1E95(VK3X7_  NT7Q-;^/K#X>>
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M+4FT^.'7DU6WEN(IOJZBCGG_ #RTV]YZ:I]^Z3]4GT"R[+[A  H"@8   'H
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M[=/N_/YZ!9?CWMK;\[?A?NSYN^&O_!'_ ,,_ WXS_P#!+#Q=\(OB"MC\-/\
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M=UM^:_,--?[UKZ]N6WXM-=SYD?\ X(5^-3\-V\"+\?\ PMY[?\%'?"O[<O\
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MH*R^6V^FUE^'Z>1\5^/O^";.I^.?VA_^":/QEO/B%H$OA[]A'X??%GP'XO\
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MC:-W[KLKVOH];W3N[;6L'O7\N^FO];:6/5H_^"A>D^*_V@_&_P !/@A^S?\
MM!_M P?"3QUI?PW^-7Q?^'5E\,],^%'PJ\9WS0?VEH.KZQ\1/B1X(UKQ1J/A
M:&=9_%5E\/=!\776BA)8+F$7<;6X\C\+?\%A_@#XL^(O@G0K/X;_ !@M/@Q\
M3/C+J'P ^'/[45[;_#P?![QA\4K)M6BM]'L-*MOB!<?%RPT36KO1-2L/#WC7
M6OAIIG@S7+V 0:=KL[2Q[E^&_P"QW^V'^S-^TI\;_%?[.7Q4^ VL?LV_M,?'
MG4/V@?B/X*^+_ASQO'\3O 7BOQC>Q7GQ)L?A_K?A22XT'Q#I?B"Y^U:AHL?B
M*/1)=#N;I+:634;>V\RX^8?V3O\ @C;=_LG?%SPW8:7\'O\ @G!\5?@?X2^)
MFO\ CKPU\7_B%^S%I3_MKZ-I6J7^I:[HFB'X@1^&]0TW4_$GA/5[NRM],\?2
M>(K'4)M.L!(='M+J1!!25"SNU\,;:RNW9<U_LIIZ+I:^CW1[W3OKMIM:VBNF
MKM];]ME\9?\ !/K]N+XN:9J/_!/_ .(_Q[^-WQ+\3_#BU_X)C_MT?'_XW+J^
MMZSXC/B:X^#OQ0\!7D?B_6-+#SS^(?$7ASPG#K%GHTK1SWZP7$]G:'-TR/\
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M@S $@$D D4"MKW5DON=]>]_ZW/\ /DMO#/P^\2_\$[_@Q^P/\._V;_&^A_\
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MDTZQO?YA_".GR1_ +_@X>TOP7XEU_P"(G@'QA\&_V0_&/A/Q4/@9'^S]I7Q
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MIWPMUR\M9_$R:5:6]MJVO2ZG:V5W>:CJ9N-7U+4+>VN;ZYN;J..0?TP_%/\
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M[77[#'[3GP6\>ZWX&\9_"WQ7'JVD>*-?DM;RRTJ^O],\66.HSVXL]:\/ZA#
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M<;2I!/\ KUTM]Q^$/[)W_!:G]JOQ;\>?V:])UWQ_X#_:.T[]J!M3TCQ'\&_
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !7E_Q$^-?PC^$ENMS\3/B/X/\ !$3@%1XA
MURQT^9E(RK+;2R_:2C#E7$6UNQ-?%_\ P5!_;CM?V%_V;M5\=:7':WOQ(\5'
M4-"^'FGW0$D,5[:6#7FK>(;JWR&N+30;5H&$ (6?4K[3+>1DBF=A_F\_&O\
M:/\ C+^T!XYUGX@?%#Q_XE\3^(-8O+BZDN+_ %6[D%ND\K2BWM4$BQV]NA/R
M6\"10(?]7$@XK\]XGXX_LG&U,IRO#T<7F-"G2JXRKB9SCA<$J\?:4*4H4K5:
M^(JTK5G252C&G1G3J2JMU(0?[SX8^"=?C7+(\29WF%?)\@K8BOA<O6%P].OF
M&;5,))4\75H.O.%##8/#U6\.\54CB)5<5"M1IX=^PJSA_J@_#K]H?X&?%N9K
M?X:_%?P-XSN4.#::'X@L;J[8\\1VGFI<2XP2?+B? Y.!7LM?Y0'[/WQS\>>
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MRPHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BL[5=7TG0K&?5-;U33M&TVV7?<ZCJM[;:=8VZ?WI[N[
MEAMXE_VI)%'O6'X9\?\ @3QKYQ\&^-?"7BT6V?M!\,^)-'U[R,$*?._LJ]N_
M*PQ"G?MP2 >364JU&-2-&56E&K-7A2E4BJDUKK&#?-):/5)[/L;1P^(G2G7A
M0K2H4WRU*T:4Y4H2=K*=11<(O5:2DGJNZ.MHHHK4Q"BBB@ HHHH *\Q^(/QJ
M^$GPHC\WXD_$;P?X*S:RWJQ>(-<L;"ZDM8!NEGBLY9?M<L:CHT<+[CD)N(Q7
M!_M8?M :?^R_\ OB'\;=0TO^VU\%Z1]KM-(,XM8]0U">5+>SMIKDD""!I7WS
M2]5C1MO)%?YW/[:/Q]_:._:C^,VL_%&^U2:=O$\YN((["[S8Z%9E_P#1-(L/
M.9Q;:99P[%B$*GS2&F?+L37YKQSXA4.%<1A,JPL<)6S?%TGBG_:%:IA\#A,'
M%SBJM:K"+E4JUJE.4*.'IRC)J$YSG!*"J?O_ (,>!>8>*-#,\\QE?'X#AC*J
M\,#4Q&586CF&:8[-*BHU%@\+A*E:FJ5*C0K1K8G&UE*E3YZ5.$*LYS]G_H #
M_@HC^Q,VL:7H2?M(?#=]2UAXHK"%=3N/+DDG94A62Y-H+>#S68!3/+&JG)<H
M!FOLBTN[6_M;>]LKB&[L[N&.XMKJWD2:"X@E4/%-#+&622.1"&1U)5@00:_R
ME/B OQ9T?0-#DDU:>[,2L-1FTB%A,D^<Q&Y:-6>8!0,RA0"X)( XK][O^"0?
M_!6KXT_"2^\&_"_X^>*=5\7_  7GU-/"ROKB-=:YX.6\EA@TS4K6]GQ=_P!E
M6<CA+NTD9U6V9IXSB$(?E.'_ !>J5'3K\24\IIY?B<7#!TL;D\\0U@ZDJCI*
MIC:6+JSE/#2E:4JM)PG1@U)T:L).</U'CWZ*3R_#UH\!XOB#,,VR[+:V9XW*
M>(\/@Z5;,:%.A'$2AE%7+J:A]<IP<H+"8A36)J1E"GB*=:,:-3^X6BJ]I=07
MUI;7MK(LUK>6\-U;2K]V6"XC6:&1<\[7C=6'L:L5^Z)II----)IIW33U336C
M36S/XP::;3333:::LTUHTT]4T]&GL%%%%,1_*G_P<<Z;JVM^)/@'HMTTR>&]
M1\ _$"UL9#N\B/6[G5--BU.5.-IFCM/[$>0 [MBQ C!%?Q;>(/"FN^&M0GT_
M4]/N(GAD94F6)WMYT!.R6&95*.KKAASN (R!7^FO_P %./V+9/VS?@"VB>&3
M;0?%3X>WUSXJ^'5Q=%8X+^YEM5@UGPQ<SG_46_B"U@MA'-G;%J-AI\D@,2R
M_P )7Q \#_$#X6>)K#P/\6O#J^&_%5CJM[I.OZ3KND75I=K=HER;-=.AN(G1
MHY'MV)NE9[6>*,O!,P()_E/Q$6;\+<:9MF,\*\5E.?\ U;%X6I*4XWJX? 1I
M8BC3J1A."JT7A91=&:YG2J864;)R:_TV^CMC>%^/?"GA[ARCF,,NXFX,GF.!
MS#"I4IRGA,PSFIB\)C98>=:E4J8>O_:"7UFG>-/$T<;"K9NES?#_ ,)/ VJZ
MKXET_6[FSG@TO0YX]59Y(S')=W%FPGL[>UC?:TA>Y2(LX'EA58;BQP/Z<?\
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MRRO!QH8ENI"\:E3#Q]E@JTDW:KA9P;O&R****_43^=PHHHH **** "BOQ?\
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MM?\ P;OK+6M!^//B/4-+6:"0Z1XOU"/7O#VH[V!CCN+?4BWF^:N539.K88D
MD<?U(?\ !.W_ (*D>!_VR8E^'WC*RL? ?QRTZP:[?0H[C.B^,;.V0&ZU+PO+
M.PD^T6Z_O;[2)"]Q!'FYA,EL&,6'"7B]P[Q1C*66U:.)R;,<1+DPU'&RISP^
M*JZ?N*&+IVBZ[O:-*M3HNHVH4^><E%]7B?\ 1>\0/#;+*^?JKE_%&08."JX_
M'9*ZZQ.749:+$X[+Z\(UJ>%O?FQ.'J8FE22<Z\J4%S'ZST445^KG\VA1110
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MQ9&^611FOPZ_X-R=.O=/_9B^*:1327/AM/'7A^RT:Y <6UQ?6/A^9=;DM]X
MR[2Z>SE1AD:%@2A0UN_\'#^OZ_!^RQ\/O!NE33VNG>,OB--;ZN\;,L=TNF^&
M=8U"PLIL$*P%_!;WB G[]LI[5^O8?B[&4/#&/%-9.>.I8"I3C4K1=YUX8^>5
MT,77@TFW*2IXNO"T>:\XKE35OXMQOA=EN,^D+5\-,'-4LHK\24XN&&JQ?L,!
M5P%/.\7@,)5;G'GH495LOPU23G:<*<I<S3O_ #0?ML?\%O\ ]K;]I7QQKL'@
MOQEJ'PN^%T-]<V^@>$O"]U+9J^GQRLEO/JMY T5QJ%Z\:AGN&D10SL(HUCVB
MO#?V;/\ @I-^T_\ #OQCITNE_&+QMI6JRW2-:W9U_4;[3[R?<#]CU/3=1N+F
MUGMK@Y1UVKN#$,<&OS'O+2YL+JXLKN)X+FUE>&>*0%621"0P((!QW!Z,I##(
M(-=5\/\ 1;[7/%FC6MDCDQWD-Q/*H.VW@A<.\KL.%&!@9(R3@9-?C.:TH8NC
M7S'$XS$O'0I2Q$<W>*JK&4ZD8NI"M3Q$9Q<(J5G"G3Y:,8M0IPC%12_MGAW
M8#+)X3(,!D&4K**E:E@JG#\LLPM; XBE.<:,Z.)P]:C4>(K2C=5,3B'4Q,II
MU*M64^:3_P!(C_@F1_P4:LOVT/"FH^$?&]O8:'\:_!5C!<ZW:69$-AXHTEF$
M \0:5;L<PR)-A-0LXRRPLXDC"Q9K]7:_@S_X)*_$'6O#W[=/P+ET:/4+%?$?
MBRZ\$:K!,IB-SI.K6LT%X[1HS+);.JJ\3MTQNPI!%?WF5^P^$?%.8<3<-5/[
M6G*MF&4XV67U<3*SGBJ2HTJU"M5:TE64*CI59[U'3523<YR;_B_Z3GAODGAQ
MXB1H<-TUALBXBRJCGV!P$7)PRZ=7$XG"8O"4>=N:PJKX:5;#QD_W5.M["/N4
MHM_E/_P6:\/^./$/["OQ&B\(VUA<:3I5[HVO>/&NYS%-%X0TVZ_TXV<6UENG
M>:> 20G#%!N0Y&#_  \Z?(DT"RV[Q/9.J_8A%&T86%1L (=5/48'RC 'XU_I
M2_$OX<^$?B[X#\4?#3QYIG]L>#_&6ERZ-X@TSSI+?[983/'(\0GA998COBC8
M.C!@5&*_DI_;<_X(=?%GX>ZOKOQ&_9^F/CGX7^'[FZ\0:?X.M+VYB\;Z78&-
MC+IHLMCQ^)8K)-QC,<L5U(@ 6&>;[WY]XT\$YSF.9T>(LNP^)QV"CE]/#8V&
M'3Q-?!RPKQ-55(8.$%4>'J1E34JM.I4E"HZKJ04'%G[E]$7QAX1X:R/'<"<0
MX[!9-F.(SRKF658O&VP6#S%8ZGE^$EA:^9SJRI4\71E2J3HT<11HT:E)4HTZ
M_M5*+_",1K%#=:9I]VKWZ;;DC4#)="-)Y58^8#@M&R!UB4,=A*YX%>3Z?J_Q
M%C^+5KI5IX?F_LN_NH+"V73[5Y([@@D6E[')$"#>23>7$L?WCE(E4MMKZ(\5
M^#O&GA"\MK37_"^K^%=2G>.22V\4:%JFC7EQ8*75V@@O[>TG<B0!4?:\:D,,
M%N*_43_@EK_P3T\7?M6_$J;XA^(-;U;PI\+/AOXBT+6'U6/3U2ZUC6]-N[;4
M+?P_H4\\0A>-7MDFU.\83-;I,L4168YC_"^'L%C<TS)91@LNIYAC<SA4P\*%
M?FC5HU)*FZN)E.T(4HT(PE7O6E&,(1E[_/)<W]J\=\0Y)PQPW5XKS7.Y95E&
M2SI8M8G"RA5P^-C%U(87 4J<95JF(GC*M2&$<<-&3G*?-.G[&FW3_LE^!\OB
M&?X._"^7Q9:M9>)'\">&/[9M& 5K>^&D6JS1,HR%9" &'9L@\YKRG]LG]KKX
M7?L2_ GQ1\=/BK=2'2M%"6.B:#9/&NK>*_$EXDATS0=+20X\ZY:-Y+BX8&*S
MM8IKB0$(J/\ 4-M MK;6]LC,R6\$4"LYR[+#&L:LQ[L0H+'N<U_(=_P=+>*/
M$T]G^SMX&MIKD>%["SUSQA>VT;.()M3O[Z31DN)U4[)#:6^G1I&7!,7VMMO^
MM-?VYQ'F=7AOAM5:51SQ5.. RVA7JJ,G[>O4HX58BHFN24XQ<ZJBTX3JJ,)1
MY9,_QW\.^&J'B!X@87+,33]C@,76S3-\;A\,Y0?U+!4,3F57"4&KSA&HJ<<-
MSI\]&C*56+<J:O\ $/Q!_P"#F?\ ;:UKQM<ZI\/O#'PN\%^"5O7:Q\+7?AQ/
M$%V]@)#Y4=[K-_(;MKAHMOF26WD)O)*(HP*_H#_X)6?\%I/ O[>DY^%WQ%T/
M3_AK\=;.T:>VTZTNG?P[XRBMXC)</HK7+&>UU%(HY;E].D>19(8KB2!E6 H?
M\[JOJK]CWQWXE^%/QCT'XH^%]1DTG4_ ]]I&LZ=?+(\:?VU;:U87&EVSE"#(
MMVT$]M-$,B6VFGB<&*1Z_'?]<,ZR-O-9YAC<;2H3ISQ>#Q6(JXBEBJ$JD8U:
M5*G5E*&'KRC)O#SPZI*-94XRC.CS4I?V1CO!7@OBS!_ZO8#(LMR;,*V'K4\J
MS7+\/'"U\'C*="<\-5QE6G:6.PKJ0C'&K&NO-X>56I3J4JZA6C_JW5\D?&[]
MC?X5_M!_%'P+X\^*&G:7XH\,^$/#?BK1=1^&^K^&M$O]!\6:GK\VC-I7B35]
M3E@76XM3\*P:9>6NCK;7:PB'5[U77#8;Z+\!^)8?&?@GPCXNM@RP>)O#>BZ[
M"'QN$>J:?;WJ[L<9Q,,CL>*M^+O%6A^!O"OB3QIXGOX-*\.>$M!U;Q)KVI7,
MB106&CZ)83ZEJ-W+([*BI!:6TLA+, =N,Y-?T%4P>#SO#4:%?"TLPPV*>'K4
MJ%6DJU.M)RA4H?NI)JIS2<;0DI1FGR2C*,FG_G_A<PS/AW'5<3@L9B,JS#"+
M%8>>)PU:6'KX>\9T,0H5H.,Z4HQYTJL)1G3DE4ISC.,9+Y*T?]DOP'\%?'7P
MKU/]FWX'_ SP?H#>*=3'Q@U2^T"8>*H/"2^&M6DTB7P1=)(Z1:U_PE:Z.MR]
MSE5L#*T> LBO]K5_$A\*?^#@;]JW0OVE[OXB_%SP^-;_ &:/$^O/:WGP\TWP
M^+5_!_A"6Z:/3]3\+ZT84ENM7TFQ9;BX-Y.T.O,LHN&WM#)'_9)\(?C#\-?C
MS\/_  _\4/A-XNTCQKX)\36<5YIFLZ/=1SQ@R11RR65]"K>=I^IV@E5+W3KQ
M(;NUD(66(!E9ONN)?"C.O#.&$AC<LPN$P&9PIUZ,\KIP67T<0Z4%5P<E2H4(
M4<3#EYY1<7&LW.K1J5(J?)\%PYXR9+XN5,;B<#GV+SC,<HJU,'BY9K6KU,TK
M4E7J2I8R<L57KUJ^&J.;IT:BDG2A"%&M3I5$E+J=?\8>$O"L:R^*/%'AWPW$
MZEDDU_6],T>-U&065]1NK=64$$$@D#!R:LZ#XC\/>*M/35O#&O:+XCTJ21XH
M]3T'5+'6-/>6/'F1I>Z?/<6S21Y&]%E++D;@,BOY+O\ @OG^Q'\3C\8-$_:M
M\+^,_%C?"OQ[;Z'X-^(E@FJ:I-I?P^\5:;IT6C>&M3CL(IQ:V7AWQ3%;V6GW
M4PB2.UU_][.['5P8ORO_ &:/"O[>'P7\,_$3XM_L\_'^]\+^&?A-'I^N^*]+
MD\3ZA:VFK0.E]<FW'AVZ:\M-1B:TL)C/;2FW6]:06L'VB;>J_;+PSX:AX?9?
MQ[F'B-DF1X+'9GDF0.IGE.& R_#\2<09K@LARKA^KBWBJE58_,,ZS' Y;@%]
M6:Q=;%8=TX*%5-?E^:>-F+RGQ'Q?AW6X#SS&XS#Y7C\^I5LKK0Q5;%\/9=A<
M1CL7GE"A4P^&PTL'A<)A,34Q<%CO;X>=&=%PG6Y(3_T.JH:K8V6IZ;?Z?J-A
M;ZI87EI<6]WIMU%'/;WUO+$R2VLT,P:*2.="8V212A#888KY8_82^/NN?M/_
M +)?P5^.'BFRM=/\4^,_#M_%XHM;%0EF/$GA?Q'K7@_7+BUC7Y(H+[4M N;^
M&&,^7#'<K%'\B**^MJ_)LRR^OEN.Q^5XV$8XG 8K%8#%T[J<%7PM:IAZ\+M6
MG%5(3C=JTEK:S/W'+LPP^8X+ 9I@*KJ87'X7"YA@Z\>:#GA\51IXG#U5M*+E
M3G":VE&_1H_!37O^"-_[.O[3MCJ/Q"G\!?$?]DSQ%J/B?Q+:7W@&"^\/^(;"
M>#2M;N[+3_$%K83PW&G:?I_B.U@BUFRMK7;)!#=(LO[U2:7]F7_@B3\'?@[\
M;O%^M_$70K3XG_#K3++PYJWP^U?7=6,>IZQXJ9[G_A(8_%GA.PA@TA]/T^.&
MQ.ER,7:=GD,N?+%?O57/>+?"^D^-O#&O^$->2XDT7Q+I-]HNJ1VEU/8W3V.H
M0/;7*V]Y;/'<6LQBD;RYX762-L,C @&OSA>&O!D,13QRR'!3Q=.?MI7BZ>%Q
M5:,96]O@8WP$82J.-5QIX2,8U(0G&/N\K_:WX\>*U3+JV22XVSNGE-:E]5C3
M6)G7QN"PLIQ3AALTJ36;S]G04\/%5\QFIT*E2E.7OJ4=:PL;'3+*TT_3+6VL
M=/LK>*VLK.SBC@M;:VB0)##;PQ*L<<2( J(BA0!P*MUR?@3P5H7PX\&>&/ 7
MAB.[B\/>$-$T_P /Z-'?WUSJ=ZFG:9;I;6HN]0O'DNKVX$4:^;<W$CRROEW8
ML2:M6'BWPYJFOZQX7T_5K:ZU_P /Q6L^L:9%YAGL(KT$VKSDH(OWH4E521F'
M&X#(S]W2A-TX_NU%PIQ<X4[SA25HQ:4E&'N1DU&,G"">GNQ;L?DDX2J5*\Z7
MMJ].FYU)5I4VI^R=10C6KI2JJDYRG!2YJDTJDU#VDFTWT58OB3Q'H?A#0=7\
M4>)=3M-%T#0=/NM4U?5;^58+2PL+.)IKBXGD;A4CC4G RS-A$#,P!VJ_C@_X
M+/\ [9GQ3\3?M ^/_@#H'Q*O=&^$_A&+2M NO#VDS&UT_4/$[VHGOCK1C(.J
MO%/)%Y5O,S6Z %0AR:^,XZXQP_!63QS&IAIXS$XK$+!8'#1DHQGB9TJM6,Z\
MM9QP].-)RJNE"I4=XQC&\N:/ZAX.^%>8>+?%G^KV#QU'+,)@\%/-LWS"M&4W
MA\NH8C#T*L</!)0J8RM/$PIX>%:I1HN3<JE6,8M/]Q/''_!:3]@7P1)HT1^)
MVJ>)Y-8E:(1^%O#EU>/I^V0QDWRZA-I9&2-R+;?:2R?-QP#]:? ;]M;]F3]I
M:Y.F?!_XJZ#XEU^.S6_N/#$GVG3?$-M;D NSZ=?PP-,8<@3_ &.2Z6$D;V 9
M2?\ -J^*'@.]\2R^'-136A8OIKQ6EW.4E4MYTJM]HMTMU;9.9/E4$!%!&XA5
M-=!HG[3'CS]FGXD>&]7\':KJ5GXF\*MI^H:?XGTV[DL-40;49DE\HB&X25%,
M=S"Z>3<1$QR(=Q(_%<I\9.*,3B<%4>%RC,Z=?VDL;EF%PV)P6(PU&A.$*D\)
MBZ^+J4YU)1DIJ%>,TW)12BGS1_L'B7Z(? 6"RW-*>%SCB7)<;A%2AE6=9GB\
MOS++\?BL52E5HT<PR[!9=0Q.'HPE"=&57"SO%1E4?M91Y)_ZCE?,'[9GQYC_
M &:OV:?BK\7T,;:MX<\.S6_AJ&3!$_B;5W33-% 0X$@MKNY6_EC_ (X+24'B
ML+]AS]JOP=^V)^SGX ^,/A;4(9[_ %#1K"S\8:8)%-WH?BJWM8EU2QO(P=R,
M\VZX@D*JD\$J31#RV4U\5_\ !=$ZB/V&IOL'F>6WQ<\"#4O+S_R#OL/B<OYF
M./*^U"UW9XW;.^*_;>)<_P#9<$9OQ!E-7F?]B8C%8*M'XJ=2I1<:=1I-\M3#
MU)\TX/6%2G*$U>+1_&O G!KQ?BSPOP1Q)AY8=5.,,NRG.,+53CS4H8^G'$T&
MVE>GBJ494X5(Z3IU8U(-J46_\_K]HWXN>)?BK\1?$FJZ[J]WJL]SK-]?:C>7
M,\DTVIZQ=7$DU_?W$CL3*SS.RQ%B=L2J!TKQ;P[H5YXEUJPT6Q7-Q?3B/=@E
M88@"\T[X_ABB5G(XW$!0<L*3Q':W%EKVL6MT&%Q!J-W'*&SG<)GR3GUZ@]QT
MXKTOX%7=I:^/8%NF16N]-O;6U9SM'VIFMY5 )XW-%#*!TS]T<G!_G65LJR*I
M4P<?:2P^"E7@W[SJU73YY5YMM\\IR;JS;;YM==3_ $FI0_MGB;#X?'/ZO2Q&
M8TL'*G%*$,-AX550IX2C%6C2A2IQCAZ,(I1II1M'2Q]92^&-)OM)L/"VJ6DM
MQI^E1:9):S2R[!<7%FCH@5E;S&DB5<R@_>64=>2/5/A[\2O%GPJ^)/A'QEX'
MN-0T;Q-X/O;+Q1H?B"V(6WM-0TR\C,5G*0P:47*!DN;9U,-S9//#+N21E/E:
MO?W_ (BO#J&@21VGAY?/T'4TN03?S7=LZ74:PAL9"J(QY@4*6!Y.&'3:?=27
MME;74UI-8R3Q)(]I<%#- S $QR%"4+*>#M)&:_&JE2O2=*I[63E#EQ$'3Q"M
M0Q5=*JJU)TJTG&JU3IU*C2ING57LY13A%O\ HRGAL%BZ>*PL\-3]CB(U,%6I
MUL(VL;E^&OA:F%Q,*^'A"6'?MJU"E%RJ*MAI*M"<HU)J/^CK^SM\7M-^/?P.
M^%OQATM$AM_B#X+T/Q%-:(_F#3]1O+*(ZMIC/_%)IFIK=V,I_P">ENU>SU^9
M7_!'A-13_@GA\ QJ7F>83\2'MA+G>-/?XJ^-GT_K_P LS9M"T&./(,8'&*_3
M6O\ 07AK'5\SX<R#,L3KB<?DV68S$-)).MB<%0K56DM$G.<FE9:/9;'^%O'N
M387AWCGC+A_ OFP61\5<093@Y7<F\+EV:XO"8>\FVY/V5&%VV[O6[W"BBBO;
M/D@HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ KF/&/C#0? GA[4/$_B2\6QTG3H]\TI&Z21VR(
MX((P09)YF&V.,$%CW !-=/7C7Q^\#6WQ!^%7BG19Y'AEM;&76[*5&QLO-(BE
MNXMXR Z,BR*R$@,2.>*[LMI86OF&!H8VI.EA*V*H4L34II.<*,ZD8U)1OI=1
M;UL[;V=K/S,ZKX["Y1F>)RRE2KYCA\!BJV"HUVU1JXFE1G.E"HXM/EE.*32:
MOMS1O=?(FN_M]JE_)'X<\"I-IZ.52?5;]UN)T!P)!%;!%AWCD1LTA7."QQ7?
M^ _VX_ >OW,-AXOTB^\)3RLL:Z@L@U'3-S$#=-L1+BVC&?O;;@^PK\;?''BJ
M+P1X7U?Q//I][JD>DVQN'L;!-US, P! .UQ&B EY)64K&BEFX&:_)[XE?'3Q
MEX^\3G6[;4M1\/V%HX&C:7I]_/$MC&A!6222$PB>Z=ANDE*  G:B@;BW]<Y#
MX$Y%Q30JT\-A7EV&H1E3EF:Q5>I76(48RC!49UI*I-J2E)SIJE&-[-RY8/\
MSSXC^E/Q?P7BJ%?&X^GF^)Q,XU89++ 86EAY89SE&=1UZ="G*C3@XN$%"NZ\
MY\JMR<]2/]X>DZOI>NV%OJFC:A::GIUT@DM[RRGCN+>52,Y62-F&1GYE.&4\
M, >*T:_FJ_85_;.UO2-/T>-==N-2N=,CM;;QMX8O7^6^@#"%]7LXB?+6:1%,
ML<\&PK*/*F4*6%?TB:1J=KK6EZ?J]BXDM-2L[>]MG'.Z*XC65.>,X#8)QU%?
MSIQ]P%F7 >;3R_&R]M0E4JPP^)Y)4W/V?*VIPELY0G"I3G%N%6G)3C9\T(_V
M5X4>*V2^*N10S3+8?5L72HT*F-P3J1K*G[=2Y9TJL?B@JD*M&I"256A6IRI5
M$_=G/\-OVH?B-J'Q!_:A\8:%>7,AT;X9V<?A_P /Z87/D0W@*?VQJ/E$[&NI
M[HN@FV[T@*1!MJUYC74_M[?#;Q3\(OCY=_%C2K.:7PMX_:._6]$;O9IJYA2/
M5]'OY$XBEN)8C>VP8J7AD!B+/#(%^;(_C9HIM0\NEWZW>SF!'A:$OCH)R0P4
MGH3"2/0]:_PN\?>'.*Z_BGQ9BL?0Q&*Q%;-L3RJ<M:>%]K+ZBZ2JRC_L<\$Z
M$\-.'[N-)J+Y>6Q[^7\19?EU?-<!G&(6"QM+,<76YJ\9J.)P]:?/AJE.<5)2
MY:'LZ487NH0ARIK2/JNA?$34/A!\:/A1X[T:Y>WDEUR+1?$5O&[*FJ>&;N\L
M;:_M;F-2%F$<%W/-;&0,([N.WD49BQ7]$NM:W9:#H&J>(M0?R[#2-)O-8NVR
M 5M;&TDO)L$\;C'&P4=V( R3BOYJ?@!X!\6?M*?'CPA:1Z?,GAW1-4T[6O$%
MRL4C:?I'AS2[Y+N>&6X(V&[U:2!K"V&3)+<3-(L?D6LWE?T*_'#1=6UOX/\
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MLPQDI5/9X>24H*<>>E)Q="LZM2I.DG3DDU_1?X4B\CX7_%?493MAN/\ A"M
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MY0HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M"O?#7B_0].\0:'J$9CNM.U.VBNK>0=5<)(K;)8VPT<J;7C<!E8, :_&CXD?
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M S,S_/7W/^S!K_COQ1X%O-;\;:E<ZHMWJTBZ)=7BI]J>SB0)<,SJJ%X3<Y6
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M(9=F>-ITLQPU/%8'-*6(H8K,L/6^L83$4I.O0Q<L1A9550Q'L:C47^*.E?\
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M2AA*-=9?0H5,96E3C6G&$JE2/[G0>*/#-UJLVA6OB+0KG6[<$SZ-!J^GS:K
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M<5S#XUM=#U&.,MA?[5TNY8FPG7/[R%;FZVX)#GI7T)\/_P!D.#X0>&Y?C_\
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M?AJ[\+:3=F\\,Z_HRW-MJ>JM?!7OCK5E-YBI<1RJ=LZ7$AD7&0.B^1?M8?\
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M^%.A:E92^=9:QJ4%Y;66H^,]3MY0D]F-5L-/TRRE0$Z==N$E7]]  H"J %
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MVGPX\66EA>VZPR)"]B=9TNT*03&8N+M;B6":,)Y<@4%G_LS_ ."-/PJ_:/\
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MK*I3<98?V#5;\]/BEXFL=+\/WFE":.34M5A-M':JRL\=O)Q-/* 28T"9$98
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MG^%UA<7M]!;Z[%I\VI169>>'3I%AFDO)XHR\4?DPS!'F<I 90'*HK",?J?\
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MWBG4V6T\.ZM%:J1INN:5<WT</]F.ZPWD$4%S$MU&-R_V._!OX5>#_P!E_P
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M[-<HQ%.K'%8BC-REAL4ZBG"6+NXUHPQ,)_5HS2JPHMTN:<:%J?OU?!G[:/\
MP4;_ &<OV%(/#L7Q?G\:>(?$OBF.XN])\#?#+P_9^*?%YTFT(2ZUV^L;_6=!
MT_3=&AE98/MM_JEOYL[+%;QRL<5]"_M*?$;Q/\(O@%\7?B=X,\/KXI\5>!O
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MP!K7P!\6_L]^'+.:XT/XA_$WXU:)J.@:#HL0+VFJCP3X>O8++5_B1J,B>?\
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MJU(4&Y;?S??%/X=:W\-/%MSX=UR^MM5NI8TOX=1M7F87L-V[E)IEN%$T=R[
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MB_/XI'C#6=.C=A%?W-SI?B/PKH&B7%W&%D_LVW@\1I9LWE?VC?$;S^>FE_\
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MX-7M9!K'AK5#'K'@SQ.;.U,U],EG+&DWA[4Y(8IKBTN;1)&MY(PGVUE*P/\
MISX>^!?PL\0:-KWQFL?%<TOPVT&TNM7OO 8BD'BC3KZW@:X/AB_U!I3&;1I5
MV6FI1H\]]9E4'EW"S3+^7_PD^"?@[X7Z=:75AIYN/$]Q81)JFNWY\V^,DT:/
M<VUJF3!86JRYC$5JBR21HHN9[AAO/VQ\#9]6U7Q!JGP[L[IX['XD:'J7ANY@
M+,8/MLMK+)I-ZT?*[[.^6*3>%WF$RQ!E61J_.N/,+E3Q>.S'A*I7R7#QC"6/
MDFG3QM"E5<L;5A3FJLJ%18926$Q":Q-.W*Y0IRC3I?KOA7F.=/"95DG'U#"<
M3XF=2I#)HU.=5,KQN(HJ&64)U:3HQQ6&EC7!9A@I)X"JY^U4*E6G.MB/SM_;
M]U/Q7X]\/:%XHEN!!H'A[5!9IX<LOW&CZ%IUTC6VEPZ?:@B..&TD9;8D*9[F
M:ZDN[EY)WDD/YB^&[>PNO$&B6VJ7"VNG3ZK817UPYPD-J]S&L[N?X5$9;<QX
M498\"OW ^*7PMLO$EKJO@'QYI]];&RU%8[^TBF>SN[>\T^X#C;*%8%"Z A@K
MQS1,'0E65J^</$_[(OPWU2?09?#J7/AB/3KN)M6@CN+W4UUJQ5U:6)WU&\F>
MUNR5PEQ$?*",Z-;G,;Q?K7!7&.291D&&RC$.M0A%XGZO7PF'A/#TL-5A[:E-
MSC4E4J5)U)SY)QHS3O!SERWF?@GB+P'Q'G_%&*S^C[#$UIK!K&X7,,35IXNK
MB\/4^KUJ:ISHQI4J-.A"E[2G*O2E'EJQI0YN2F?;7PS\4VG@W4=/D$,>I>$[
MRR@TG6M)W^;9ZKX<GB2)XOEW*[1V^V>SG3+QRHDD3 G-?H%\%OV79-(^)^@?
M$;2]8TK7?AFENVO^&KLS%]5>2XC)LK*[L_+,7GV3.\5Q<+.T;&,D#S 4K\R;
M6U@LK6VLK:,16UI;PVMO$,D1P6\:Q11C.3A(T51DDX'-?KG^PQJ/B6[^&VL6
M>JQW!T/3];\OPY<3AMKQRPF2_A@9^7AAGV8"G9&6*@#=S_-OB+5QF7Y1C,RR
M[$QH_6(_4,=3K)-XK#XINE"K37-[N,H<[2G%N]&=534U3I\O]D>"]'+<YXCR
M_),YP,\4L#4>=91B*,I+ZAC,%R5JM"L^5J>78KDA*5*:BHXJE1<'"5>MS^ ?
M\%A+GQ!;?LO^'VTYKA?#3_&+X=Q>-A;[OGT5]5(@CNMGS&P:^\G[6&_<E0@E
MXP*_FN_;!^(7PKT;X?>)_AWXS\-^,M:^(_BA].U?X?:OI^L3V_@_2;&RD,$X
MU'2AJZ0G4(IF;;G0M0>]WK*NH:<8_)D_ML^*?PR\(_&/X?>*_AGXZTY=3\+^
M,-(N=(U2WR%E1)US#=VDN"8+VRG6*ZM)@"8YXD)#+N5OP8G_ ."+OC[QO\=?
MAQJ'Q6\<?#_6?@M\+=<75K76M*G\0+\2O'6D6=Q%=:7X8U[P[=:%'X?T9O.A
MA.L:M:^)M4COE25H-.A-T8H/Q'+)9/C<!@L)FN89ME:R?.L#Q!3J9+FV89-B
M<=5RS%X?,,/@L17RZM0J8[+L56PT<'FN48F4\'F> JRPV)HU:+GR?ZW>$W&'
M!F R*&7<4X_%Y3+A_-L9Q%0E@9^QQ&:R>%H_5L/1G]7Q'-B8XG#QHN,?8XB$
M:N&KX6O2>'KUJ7Z6_P#!,/X2>(_@M^Q!\"O!OBR6Y;7YO#">)+ZTNF9WTK_A
M)'.J0:7&7)/DVMM-%Y0 50),!17U=\4/A#X'^,.G^&M+\=6FLWEGX1\9:%X]
MT1-&\4^)_"DL7B7PXUPVE7%W<^%]7TBYU*QB-U-]HT?4);G2;T,JWEG.J*!Z
M%;06>FVEK96T<-I9VD$-I:6Z;8XH;>WC6&"")20 D42)&BCHH JUUZ5\WF%5
M9EB,77Q%.$UBZ]2M4ISA&5-\]1U.5Q:<6HMK1I[)GX7FN=8S-,]S+/Y3EA\;
MF68XW,ISP\I4G2K8VO5KS5*4&I0475E%6=^7=ZL_CB_X+D?LBP^"_P!H&3XV
M>![;1?%UO\08K3QMXQ\$:=KFD+XT\%7RW#:/J/C^^\-->)K,G@S4[U&'_"1+
M9MIL6KF;2I95N%A\W^?3Q5X.TSQ[;IHWB.\TZT\4V2375I-HYEDDM["69UMS
M+!=E))X9 H,\99 )@QAD0-EO]/O4/ '@/5O$#>+=5\$^$=3\5/X?N/";^)M0
M\-Z->>('\*W4TES=>&FUJYLI-2;P_<W$LMQ<:,;DZ=--+)+);,[LQ^(?&_\
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M1-4\.>(M$U"/S;'5M$UJRFT[5-.NX\@O;WEE<36\H#*VR0E65L$?Q7?M=_\
M!LO\;](\?:WKW[(?C#PKXW^&^KW]Q>:/X-\::S#X:\9^%X;B5I1I4VI7Z0^'
M]:L[)7%O:ZDE_97=RD>ZXTRV;!?^V^BOG\]X:R[/XTOK;KT*]!2C2Q>$G3IX
MB%.;3E3?MJ5>A4IN24E&M1J<DN9TW!SJ<WW7!/B)Q'P%7Q,\EJ86MA<9[.6+
MRW,:-3$8&O4I75*LXT:V&Q-&M",I0=3#8FA*I!J%5U(P@H_Q0?LE_P#!MO\
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MC?\ A8TT:9IJWIU)=/LEU%D\MK\6D O60C:4-T(_/*$<;3)C'&,5_,[_ ,$
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M@U2XTO0K2SU#5IK?P[)97-S/8VEC86%G%H6FV-C;6C"XAC:27S))G?\ 1/\
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MW@J;3Y!XD75%T<Z>)(G;[>\HB6/S5<P["S!FE,@C6/,CNJAB/U*_9E^#NK_
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M^)JYWBL)@<NIX-TL=B<17CAL+2HSI^QJ7KU'35.#YG&$FXRNXV]ZR/X6M1\
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M6L<>DKY0F$=U;^66EEE9I85AW[W'F'[+Z+_T@N,?%S \0<,\<YYC<TQ_#E'
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M2<J"WE 5]%7EY::?:W%]?7,%G9VD,EQ=75S*D%O;P1*7DEFFD94CC1069V8
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MG6LT]Q;:N+9A+;_:7NYY9H9DF57>:-V$R QR1D8(^DD0 *B+@ *B*H[# 55
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MUZ'1=)B+,^JZBMY!IWVJ.!6A@M45IRN]-_\ =0JJJA5 55 554 *J@8  '
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M,, Z\\#6GF6+GC<5@:_/5:K4*&&E##3>%IQ4:>'CC7"$E&J^7C>7 N;Y3A>
MN,Z^39?CN,I8ZE@L+5Q+^OX_%SY?J]3#1Q%2I06+R]>RI4*M"CAZ>(JWISC7
ME4<9?S,?\$G/V2/'_P"W3^V'X4\4_$G0;IOA)\$;VS\6^/);K3;BST:XN-*N
MQ<:-X-2.Y!22]U[58H8M0M0YG33(+ZY*C[,17]?7[;/[8<WP!M+#P1X%AL[S
MXC:]9?;1-=)YUIX;TEW>"&]EMD93/=W<L<D=C;DI'^YFED8B-8Y/LY?"&G>#
M_#OB2W^%WA;P?X8UG4EU#4[>WL-%L=#TG4/$MQ$YCU#6TT>TMVNI)[C8;R\D
M26ZD3<6=C7\XG[7LOC1/VC]?D^)@LF\1Q+X=.H#2O._L4VRV-LT T@3DR_8Q
M$<2[L WXO2!M()\_Z87C;Q-FG#53B;*I1RFM/$X/(,OHK$^WQF!HXJAB<7C<
M7AINE",L9B983V*K*$/84G3=/][0A-_+<-^'^#\'/#R659%CL,\5B\XHTL9C
MG3CA<3-XF$U"KA\)%U53P^$P]%48WJR<*E2I57OU';L=-\=_M#>*)X_%'B;X
MT>.+"^NB+J&STW4Y;2&-9,.GFV-JUMIR K@B$6SC;@2#.0?OS]FG]J;QG:>(
MM(\!?%S5XO$^FZQ/'IVA^-)[6"RU73M0F.RVL];2W"VUQ9W3;8(KZ%(7ADV_
M:4=7:5?AJ*2.:*.6%UDBE19(G0Y5XW4,C*1U4J01[5'<W!MA;R(6$YOK".U$
M9(E>[DO(%MHXMOS&1I2H4+SGD=*_Q]X&\=?$KA_C3+<UIY_FF84<3FF&IYAD
MN,Q5?%83,<-7Q$*=;#5:=>52;K.G*4:6)NZ]*K:<97NG^HT,KPV5X9UJ.(Q4
MJU*BZE3%5\9B*WUEQCS3E7A4JRHN-6UGRP7(G^[<6DS]L?VFOVE/A=^R?\(?
M%'QF^+6MQ:1X:\.6CM#;AE;4=<U1U(L=$T>UR'O-2OYML,$,8."Q=RJ*S#^/
M_P"./_!>K]M;]HW5YO#7[-^A:5\ O#"7\FW7["&W\4>*O[/,A2VFU#4M8L)-
M&T\M& ]Q:P:=>A9<I%=E1EOZ:OV[?^">/@'_ (*$?#3P/X0^)OC;QKX+U'P=
M(NL:9>^&IX9[$:Q=Z<MK=3:MH5RT-OJ;1%Y! 6NK=X26VM@D5^+WB+_@@;\=
M?AOI367P9^*_PT\=Z=:J5@L_%&E:AX+U^\568Q&:6QBU#29)@K%6DN=07KA6
MQU_Z*/!JIX-X:A#%<<8ND\\J5G.%#-\!BJN6X2C%VI0A[.G6P=6=5/GK5<7%
M^S=J<*<%&527X'X\_P#$?,506'\*L!"66_54JU3 9I@<'G->O57-4G*6-EAJ
MM"GAK1C0HX'$TZM9NI.K7:<:"]Y_X)B?\%4OB#XE\>>'_P!FO]KKQ58>)/%/
MC+?#\,_BN;&VT=]<UJ%2TGA/Q'!:0VVG#4;B(&32[NV@MEG*F%X=YWG^C*_N
MUL+&]OG5G2RM+F[=%^\ZV\+S,J_[3!"![D5_,5^S#_P1+^,\'QA^'WQ6_:6\
M:^$?"OA3X7Z_:^+M/\&>!M0N-6US6=8TQ_/MFU#7?+CL-.TQ2BF?[/--.RJ1
MY>UB5_IL34+?5-)DOM&GM-3BGM;AK*2*5)K2YD5'5$,BDHT;2KY;\X SFOE?
M&*' $N+%B/#^O1K9;B*,)YA2P5.=/+:&-YK.."G.$(J%:FG.I"DG1IS3<':4
MHP^Q\!WXIK@##4O%G"RH<187$UJ%"M6K8>OC\3E]N;#3S)X2K6H?6X^_34O:
M*K6IP4JL?:*4Y_P<>-/^"J__  4U^(7QU^(\G@;X\ZSX&\$:9X[\2Z/8:3IO
MAKP<^@:+I6F:Q>65M:Q-JGAZ^U&XN1;6R,X>]DD,S'D+G'OWP+_X*V_MA_!7
M]HCX3/\ &/XNZS\</AI\1?$6F>#/%7AG7]&\,Z;/IK:I?VE@FNZ!+H.DZ;+;
MSV4E[#(8)VN8[B!)8P#,%9OS@\2:5XZ^$/[2/QY^&7Q:\-S^!M>?Q[XJ\3PV
M&J0#3U%MJFN7][;S6[2LD4ME=6<\=Q;S1;DD#@JV, ^V?\$\O@G<_MI_\%"?
MAGX?B@>]^&_PAOX?'_BF[1=]G]D\,74=W9*TA C\W4=:6V%NCG,T,%Q&,[2*
M_L3-N%O#3">'>,S;$\/<//"_V ZLL7A\!@8XA0CA5.,L-C:-*-5U9/E]G7C4
M]I5J3@W-N21_".2<<^-N9>/&&X9P_$_$M+#X;B><9Y=BL9CYX&MAZF(:FL9@
M<14=%4*=%SE+"1I0HX:C0JRI4^:G[27^@1:7,5[:6UY 28;NWAN82P*L8IXU
MEC+*>0=CC(/(/!JQ3418T6-%5$151$4!555 554#@*H   X &!3J_P X':[M
MHKNR>K2Z79_JMZ_U^84444@"BBB@ HHHH **** "BBB@#\D_^"H?QIL_AYX=
M\/:5?WOV6TBLM0UE+;)\S4]:>-[71[2! /G;'VQF#91,+*Q58RP_EITGXG^.
M-'\4Q^+[?Q#J4NL+>&\F:ZN[F:VNRTC.]M=6QE$<EH^YD%N J1H0(1&50K_7
MI^WW^S59_&OPEI_B%]"3Q$?#4-Q'J>E;7-T^GR?.FH6)B*RBZT]MY C)8Q32
MG!VA3_+QH'[.VNW_ ,8+G0KGPSK47@/3?$ES'=W]T&MT;1H)G=(1=NJ&226,
M+#NC7>3N^Z_3^\_H]YKPI2X%Q5"HZ?US#4J\\WAB/J[C."JUI*C2C.2G*=95
M$^22M5YJ48R;IVC_ )5_2YR+CNKXI83%4U7678VMA*>05<+];BX3>'PL)8BK
M4I0E2A1PTZ,HN<7S8>4<1.<4JRE/[*^ GQIO?B]I^K-J.@-I%YHSVZ2W-O(\
MVG7GGJQQ#)(B-%.FW<\!\S:C*XD;) _<?]D'6_#OQ.^%?BKX.>.-+TSQ+I-G
M%/;76@ZW:P7^GZIX:U=3'<6=S9W"O%-;1S$H59.#*7!# ,/RCT#PYHOAK3X-
M'\.Z5::580@+%:6,"QJ6Z;FV@O-*W>21GD8]6-?>W[/>L^$?V=;+5/BG\8O$
M$/A&VUW3AI_AK1+A7DUS6(1*)I[VVTF(->RP@+Y<9\H!R2ZY"DU^6^-&;<,8
M3AW-\WQ.(PW#F78:OA\5ET\;C84%AL32J4XQ:Q%:I%0E-2JR:51JDIVC)\D6
M?J?T?_[?RKB;*8XW%1S*V"Q>'XCS"5*&&P:P-6G.?/7;4:4(TZT<-"DYJ$L1
M.$?<4JDHKYU_:U_X(B6OQ4\)?\*^_9L^.NM? WX5WFL2>(-4^#.J6;:_X$&M
MM.ETFH:-J2QR^)]+A%P@D.DO=WFGK)^\A6(#RS[;_P $I?\ @FU\4O\ @GG:
M_%32O&7QET7XC>'_ (@SZ5?V.A:)9:M!;Z7J^G;HI-5DFU6&W837%HS6[PP1
M%6R)'D+ "O;_  )_P40^$FM^-O$>G>)_$-OHGA2[N[&+P+J$NF7D4KVYA47T
MGB&7YUTT_:7Q";I;?$:$X;K2_M-_M1ZUH\]MX3^&UU##8ZII5OJ+^,+1TN%O
M;2^1MB:-,NZ( */WMP-S*6"JH;E?PC@WC3$\:8/,^!.$\\X5Q^"S/$QX@S]9
M93R.5>OC,:L'C:F=YOB\#1^NXO,L2EA77Q^*E7S#$N$*=6O/V?N_U;Q12\/N
M$<=3X_Q<UC<URG+\'EF GEF;8O,(T,'CL)[3"91A,%'&2P&"PL:5>;^JJE0P
MF%K.M)0A63;^L_CE>^&YOA-\0X]7DM[ZTL] NGN[:"6*:XAE^5;=O+5B\4BS
M%"&(5@ V#UK\%;F=+6VN+F0,8[:"6=PBEW*0QM(P11DLQ52%4<DX Y->J^ O
M'-WINOZC%K^I7EUHOC*TN-$\5/<7$L[3V]_\J7\YD9C)+97'EW =B6$:R*O4
M"N9\7^$M4\':Q-I6I1DH0)]/OD&ZTU.PE^>VOK24926&>(JWRL=I)1L$&OWC
M@[A]<*_6\LJXMXMXJI2QM&;BZ,:D(4HTL1"G3<JEJE*HE[22DVZ=2A)I6:7\
MP^)?&'_$0%EF?8;+E@(9?3Q&68NGSK$U:-2I7E7P=2O6C3I-T<11;5&,H1C#
M$4L73C*5XRE^'GQP\?O\1OB#JNMK!=6=C;A-,TZSO 4GAM;,LFZ2$DB&2:0O
M)(@P<D;@&R!Z_P#LV?$;XLGQ%H7A#2!<:[X1BF$-]:W5L)+?1[ AVDEAU$*K
MVWED@Q0S231D8BBB0$%?=OVB?@+KGQ%UKP]J/@G2=&MKA8[B#7+Z2:WT]I T
MBM!),JJ'NFC!?!5&D^8C))K]8?V&OV+Y8/#_ (7U#Q;ID-CX8T*WM9)$2U-M
M+XNU>'#RW+I(@E:Q:;+RRR@^=Q&B["U?T#Q9XA\*9)P+AZN(PV$J7P\L-1RN
MM6A7KX2I2ISI4YQM%5)5Y-)T7'V,Y*HZDY0IQFS^5> ?"7CKBGQ.Q6'P6+QU
M-?6Z>,Q.<X:A/#X7&T*]2C7JTZJYW3I8.DG*&(4_K%.,J,:-.%2K.G;],?V9
M-'U/0_@IX)L]662.ZDL)+U8I01)#;7LSW%M"ZMRACA=5VD#;BC]JCP7XA^(W
M[-/Q\\!>$E:7Q/XP^$'Q"\/:#;I]^\U35?"^IVEGIZ'LVH32K8J3@ W )( )
MKEOCM^V#^S[^S.EM8_$CQ8]IJ MDF7PYX9TB_P#$^O66FH-BWUUHVBPW-W9Z
M=&JG-S-&D:JI;[HS7L/PM^*_P\^-7@O2/B#\,/%6D^,/"6N0+/8:MI-S'<1'
M(!>"X129+6ZA)V3VTZI-$X*N@(K_ #WQ.)QSS)\1/"3I1K9F\?1E.E+ZLZOU
MCZS"GS-*,XII*UUSQ3:ZG^R^$X1S#*>$\KH5\#F2R7^SZ638?-:N%KTL-B_8
M82.'G['%2A[&564(N:C&<FK-J_*V?Y]?[-'@)-1^$_QC;QKXLT3X?:[\ (;R
M._\ #'B(O9ZMK=[;S7\DNFV\$RH\-TYMDL+1"K//J,\<;A$8$?V$?\$=_P!G
M"^_9X_8O\'2>(]/?3?'7QDU/4?C+XSM9D,=S:7OC%8)-&TZZC<>;%=:9X9MM
M%T^\AD)9+NVG.!NQ6O\ &G_@DK^R)\<OV@]%_:*\5>&]8L/$EMJ]CK_BOPOH
M>H16'@OX@ZSI<B36&H^*M%%LZ7-P98XVU,PO&NK+&@NU+F:2;[H^)?Q0\'?!
MSPP-6U^=+>*.(6NCZ/:!#>7\L,86&TLK?*X1%55:1ML4*8+LH!(_3^.?$?/N
M/(5\IPV>YMG&!S[-,JS/"<,XC)LLP5+A&6 R3"995R++<QP$5C<_PN/S2EC>
M(*V.S9^VPT\72PM)0HX>T?Y\\-?!SA7PFQF9<3XC+<HRG%X# 9GE]?B6EFN8
M8BIGV!QN;U<U6:YI@L<EA,FQN&H2PN44\)E<JM*K3P\ZG.WB(48?!?[?/P)\
M0_$QAXA3Q=X274-.L(++X<^"+N.+3]>U@@P7'B.&'4[B4"\OGG02:99QA(9(
MYF@(%UL\_P#+KP_XZ?P[#'X:\=V.HZ!K&E#[$6O[.XB\Y+?]TOFJT8>.6-5V
M2.<Q2$!T?+;1],_&'XMZ_P#&'Q;+XDUC%K;0)]ET;2H79H-,L%<ND2DX\R>1
MB9+B<@-)(> J*B+@I\1_%?V6&TO+K3=9BMQ&MO)XA\/:!XANX$BP$BCOM:TR
M^O1$J@(L33M&J *BJ ,?S+XV_0>I>+\<JSJAQ)A,@XCIX.CALRH5<OA/ U/9
M2J.E6AB<$H5YXV%*I[#$UL3#%1Q,*=*,94XT*;/"Q_CS@)\48O'87 5*& H8
M>EEN$Q&$P6%E_:>%PUW&OF&#=3+Y_6:E652I3QCQ4\5[*5.E6BU&43GO"^FZ
MC\2Y)K3PZ9M+\.1*I\3_ !!U.VFM/#WA?29<K<W2W,ZQ#4-5>$2+I6FVADFN
M[PQQ_**^GM!_:@U;P+XYT1?!Z72?"?PKH^C^"]'\'W!0>=X6T2UBL8;^0D#9
MKMUY3ZB\Y*EI9%MIV9%+UF?$'XD3_%#X'^&TCL].T2]^'OB@V/B/2-"LX-+T
MK4[7Q!8,-#\0C3K1(K>-[>;2;S3I]J%8KF\C8;1=1K7RG=W=K86L][>SQ6MI
M:Q//<7$[K'###&I9Y)'8A515!)).!7Z)]&/Z*'"G@EDN>4\54GQ%Q/GU2679
MQC<50A"G1PV'F_J^&R^C%SE3A6C4ABX5U-5IJM2=J<HJ,?EO$3Q7SC%9AE=3
M(L?/"X*C1P.;T,PH1EAI8J3A*4L/.A*I5]GAL)B5B,+C,/6J5HXK$X><JSE1
MI8>%/^AWP/X_\*_$30[/7_"NK6VH6=W&K-$DB"[M)=H,EM>6Q/FP3PD[9$=0
M0?:MKQ%I]CJV@:UIFIRR6^G:AI=_9WT\,\EK+#:7%M+%<2QW$+Q2P/'$S,LL
M<B.A 964C-?SO^$O&^I:;':>(/!GB6\LX+V*"[MM0T74IH8+R @20NSVTJQ7
M,)!R$E#H02"O)%?KEXH\4>,OBO\ L2?$'5_!LTL_Q'UKX,>.M+TE[0[+I_&E
MKH&JZ9:R1A,&.XN=1AANHU7&TSIMXQ7V?%_ 53AFKAL11Q<JF!Q./CA$ZU-T
M\1@JDKRA&N[\D^50J7J*--IT[2@G)'[GX2>)^'\2<93R3%X:CEF9QH86K6Q4
M:\:F78BA6Q%'"UL72O:I1ITI5Z56=.4JL53J7C5DHMO\?_!__!2+X!_L<>-?
M$5SX@\,?&OXA>#;BSTCX;^&?BCHW@_PQX<\'76B>%KF\$%U!I<?BR[U#5UO7
M(DTW5Y;"SBEM()I=$L8+/4I3<?N[^S[^T#\,?VG/A=H/Q>^$>NC7O!^O&X@C
MFD@EM+VPU&R94O\ 2M3LIU2>SO[-W3S8)44M')#.FZ&:-V_CQ\?W^@^-?V<+
M36(M"DU_2=+M/"VHZKX;@#0WL*>%M2TZ3Q!HK*$::TO+%+&]LYD\L21F,C9@
MBOW&_P""+GQE^&/Q5\'?M!V/P<\'7?P^^'_ASQOX.O;'PC>.))+75O$/A_4(
M-6U,$7-TD(U(>'K.(VL<KI&;#S]Y>Z=(_DL=PUD_"V!RK(N&N$,=EN3X+!9G
M5GF.6+*</PQD\L-F&60HY3B,"\;0S*CF6=ULYQN88)Y;E6(RYQRS-)8W$X2O
M4PE/$_W-XI^'63Y'P_\ VME&3\0/&X#&4,/G6=8K'U<=@*D9R6#IK%1K4)RH
M8V5;ZM'3%T*=JL(8;"5Z?MIX+E/VBM"D\/?&CQ]8R(46;6GU*%B"!+'J<,5\
M9$)ZKYTTJ$C(WHPSD&OF7QIX%\,?$#2&T3Q3IL>HV7F":([FBN;6=00)[6XC
MQ)!)M+*2IPR,R.&4D']=_P!J&U_9\\7:\NG>(/&4?AKXAV$"6IU&QLYK^V6/
MEX;/7?(5HX@F_<KEUFB1R0K XKXVD_9W\5WRM=>$=>\'>,]- )CO-'\0V*2.
M.V;.ZDBN48#[RL@*ME3R*_I#A7BJG'*<IQ.)GB\GQF'PN&C&OBJ=?"0J3I4X
MTXXC"XR4(49QK<O/#EJ*=I-.-DV_\=^/_#_%2XCXAPV74\!Q'EV*Q^-JSPN7
MXC"9C6H4\37E5G@L?EL)SQ-.>'=3V,^>A*F^5/GN[+\W?&/[)OPTU_3(+;P_
M!-X3U&UC5([^T>:\2Y"C'^GV]U,PE9C\QEB>)P<X!7"CZP^#/PZ?PO\  S5_
M!-A<3ZL? ]W8>)Y[UHMCS17CRZ;>%8@7$-O +@SD;C@("22>/8H/V=_BI);W
M5]/H=M8:78!VO]7OM4L+?2[*.,;I)+F]:;R8E1,L=[ X' KN?AK\;?V:_@WH
M7BC0->U#7/'VK>*K-]'\1:EX;T*]N= LK YS:Z??R0K%?JLG[U[JW+QLZ (2
M,BO,\3/'KA7A#)<'A^+..,JIJ>88;$8#!8[,\++%5JE.M#V\X.4Y8F5.&'G6
M5I2=.,JB22DTUXW G@_)9]7Q\LBI\,4<7E./P.)S'%X>IEU"I2GAI+#TZ.&D
MJ<*T_KD<+.I.A0<HPIN56HHJS^5Z_-+]I[XJ?$&T\=ZIX1L]3O\ 0?#]M:01
M0V]F?LYU2&XCS+=O<JHG>.0EH@D<B( C*P8DFOV<\.?"W0OBW/J%S\#/&VB>
M+K:W+W#Z!J\__".^*=-MLDG[9IVI"$RI$,K]HMR\;[=V0#7DGQU_X)V_&SXO
M^&;0Z+X7T=-<T^\BEL=7?4K20/9%REY;QSVSN9D91N5"63S$!&U@"/N_#3Q0
M\.,PQ.!SRCQ#P_FN38ZDZ=''+&X6K1PM2<H2C7<92:4Z<HNG437M*7-*2UC9
M_&>('A7XDYCD.*PV1Y/G4\12J*M"IE-&KBL-F=*DIQJ86ECL%*=%QJJ7M(VJ
M<LYTXTZJC&4G'\C_ -E+QGI'@_XE[]8U :9'JU@UA9WDCM'&NI&>)[.-I ?W
M;RR96&1B )=H#!F4'^@WQ]^S38_M^>#/A+\1])\4:7X1^-OP/FO/#LFKZKIC
MZEINOZ%?VZE]/U+[,PO+:.3*WUI<VR3-%-)(KHP:OSOB_P""4OQ-T:Z\-W$?
MA_QG<ZEI=_97>JR1:?#<Z=J!MYXYW2W*,'M4W($4EI-T>XMM;YA^[W[(/P8\
M5_"O0==O?%L(TZ]U^2U6WT?S!)+:6MH@5)+G:2J3R$L"G+*@4,<@BO-\=^)N
M$<ZP^%SSA_.\-BLVP[5.E&E*E4DUS1P\X*G[TI4<1A:E2=3F3BO94FW":Y3]
M;^AAA/%_PFXKG2KY/F&1X54L7[3%5<-/V"I8K"5'4CB%B*<L-4G&M4E@_9R@
M_:4\7B(Q4HQC57RM\*/^"6>D:?XY\,^.OCGX^A^(-OX.U2UU[P_\/M!TB32O
M"7_"06+B6PU77KR\GDU#7OL$X$]G8M:6-M'.B22F;&ROUQ55151%5$50JJH"
MJJJ,*JJ, *      !@<4M%?R7C,?B\?.$\55=3V:<:<5&,(4U)WDHP@E%.32
M<I6<I67,W96_T,S_ (GSSBC$4<3G>.GC)X>FZ.&A[.E0H8:E*7/.-##T(4J-
M/GG[U2:A[2K))U)S:311117&>"%%%% !1110 4444 %%%% &)XA\,^&_%NFM
MHWBOP_HGB?1WN+2\?2O$.DV&M::UW87$=Y8736.I6]S:M<65W#%=6DYB,MM<
M11SPLDJ*P^*_VVO^"B7[.7["?A:/5/BWXE-UXNU6TGG\*?#K056^\5^(9(P5
M1TLT;%AIWG;8IM3OF@LXBV#+NXK[OK_.9_X+(^&_C]I'[>OQCU#XZQ:C</K&
MM+-\.=3DAN!H-U\.0O\ Q3%GH,S@0&&SMS)#J$4+[EU8:A*X4R"OU'PDX&RO
MCGB:I@<UQGU;"83!O&U</1G"GC<Q5.K"$<-0G*,FJ</:2J5YQ4IPIMJFHN;J
M0_*O&+C_ #7P^X0_M7*<O>/Q=?'4\#0J5H5*N RR>(ISE+'8RG3E"3B_80HT
MX*5.-6O*C&<^5*,O3=!_X*+_ +9/Q4_:@^(?[57A+XO^+/ 5L^HN^B^ %U&Y
MUCP1!H5N'&D^%;KPO<W*:3<P"TB+:E?00Q7KWDLTL-S$9("G],'P<_:6N_\
M@HC^P;:?''4?#UAH7Q"^'?B[5-"\8:1I3R2V8U#0EMX=3U&Q$H^T0:?J%E>&
MYM[:8N8IHY8A)*(Q*_\ ,]<_$'1/B3X1^"7A'P+\'M(\/^+=%\'VF@S:+\/K
M!]5\0^-=5NXM-2*YN;+3K82S7-PT N9)+LRSQRW3IYR1(R'^DG_@D7^S/\7?
MV1?V5?CGJ_Q_\'7>B)\0?$EUX[TOX:M);SZ_IN@PZ7=QW46HVWF-!8ZGJC7"
MR&RFD$L#09FVY4G]PX[>5X+@3A/B3,N#,/X><=99G=3!87A;$9ID^89U6R+
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MX?:K<>#Y;[P3XPM;C0-2M=1NU@CU*)K4I<1R?9[VQF$@4Q3PW,38#X+%RHZ
MM^X_[*?[-3?".T/BGQ)%;P^*K_3ET^RTJU$8M?#VE.8I'M0(P(C=S&*%9!$
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MSQ+E+DC&K2@G6]A_#6,="V&EB;>TE0C[.]F[E%%%>&?<!1110 4444 %%%%
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M/BCQ%XVUFW;6=%\/2>7-XCN=3U/5;F2UCBDDALF$,@BN-19%M6:&:-S]P_\
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M7:W,TD5JNE:8EO;RI:QPQR-:LY5GE<UNZQ\0/!W[,/[:/P7\:_L<?$2W\?\
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MV#O!7B'P[\/[[5_$_B7QKJ4>K^-?'/B%;=-7UV\BC$<$2V]HJVUC86PSY-I
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M3P/\+_#$GQ5N-"NY;+5/%+ZJFF>&I+JWE,,\6DI%'-?ZA;K("J:D%BM)2&"
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M^5XWV:JTHU)4JU#$T')P5;"8O#5*V%Q=+GC*#J8>M4C"I&5.;C4C**XSQ_\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5"UO;O*EP\$+
M3Q@B.9HD:5 >H20J74')R%8 U-11=K9VZ?+L 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %>+?M
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M"S\'K>>1I/AFPF1C;:SXSO8&\ZUAF \ZSTB!H[^^MU:=I;*W>WGG_D7^._\
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M**]H^3"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
-HHH **** "BBB@#_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>24
<FILENAME>nt10014672x1_diagram10.jpg
<TEXT>
begin 644 nt10014672x1_diagram10.jpg
M_]C_X  02D9)1@ ! 0$ P #   #_[0 V4&AO=&]S:&]P(#,N,  X0DE- ^T*
M4F5S;VQU=&EO;@     0 ,     !  $ P     $  ?_B"^!)0T-?4%)/1DE,
M10 ! 0  "]!N;VYE @   &UN=')21T(@6%E:( ?4  < %0 3  L (6%C<W
M         $E%0R!S4D="     0            #VU@ !     -,M2% @(
M
M$&1E<V,   %$    =&)865H   &X    %&)44D,   ',   (#&1M9&0   G8
M    B&=865H   I@    %&=44D,   ',   (#&QU;6D   IT    %&UE87,
M  J(    )&)K<'0   JL    %')865H   K     %')44D,   ',   (#'1E
M8V@   K4    #'9U960   K@    AW=T<'0   MH    %&-P<G0   M\
M*&-H860   ND    +&1E<V,         &G-21T(@245#-C$Y-C8M,BTQ('=I
M=&A"4$,
M                                                    6%E:(
M     "2@   /A   ML]C=7)V        !      %  H #P 4 !D '@ C "@
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M;W5R(%-P86-E("T@<U)'0@
M
M      !865H@        8ID  +>%   8VEA96B            !0
M;65A<P         !                               "6%E:(
M  ,6   #,P   J1865H@        ;Z(  #CU   #D'-I9R      0U)4(&1E
M<V,         +5)E9F5R96YC92!6:65W:6YG($-O;F1I=&EO;B!I;B!)14,@
M-C$Y-C8M,BTQ
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MU=;7V-G:X>+CY.7FY^CIZO'R\_3U]O?X^?K_Q  ? 0 # 0$! 0$! 0$!
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MK-HA+X$_:3@B^+VCW\$94&S_ .$HU=H/B%IL;QKY8DTOQ5;.@.X[B!7]/?\
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M/J/\C\:7-'5W5EJW=:+NQ73=DTWVNKBL 1AL8SGG_/\ G/TK]PO^#<75]/\
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MVNG6?BCPQHQU 23>;8Z9?07<4CV]W:7L<$,UO?V5U"R3V=W!,!-;W$#QR12
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M?!WP-?>%=(TWX;2_&>'Q-;Z)X5U*6!_&7C"74['Q$L-UI4\O@>=[>/7;MX/
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M8_:LA\%67VAX?'AN9;'6+6'XQJ?"EU'&;70+3X<>(=*\<[YECBNKOZ#\1_\
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M3PE;P^ /"&DRZ%H&GW,E^+R%"\K[.S:W3TV3]/Z8S^JJBBBK **** "BBB@
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MX?FT?XBZ=XLU'POX/^U2W&L7UW8WD7C6P\,7.EW-CXC2*.\U&?Z;_P""IO\
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M0*HDGEV[Y7"J'D9FVC.!/5C"BBB@ HHHH **** "BBB@ HHHH _GB_X+ ?\
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M\(O_  !\>?\ S'U^HG_"L/AI_P!$\\#?^$EH'_ROH_X5A\-/^B>>!O\ PDM
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MT?\ #_+_ ((]_P#1]_PB_P# 'QY_\Q]?J)_PK#X:?]$\\#?^$EH'_P KZ/\
MA6'PT_Z)YX&_\)+0/_E?1[W]W[G_ )^O]/0T\_N_X/K_ $]/R[_X?Y?\$>_^
MC[_A%_X ^//_ )CZ/^'^7_!'O_H^_P"$7_@#X\_^8^OU$_X5A\-/^B>>!O\
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M[0O_ ,Z.C_B(T_X(N_\ 1\'AK_PTG[0O_P Z.OVUHHU[K[G_ )@?RP_M _\
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MOZDOR_K^OZ[!1113 **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MJ:)X&\/W_B+4=/T*#5=0TG3)=6O+:PDM[!-0U33[,W,D?VF\MX=\J_SYQ_\
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MX%%%% !1110 4444 %?ES^T%XD_:4\7^.OC/\'-.T#7X_@=XH^*'[-?POO\
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M:^'M3T>^BT*UNQIT>C_J3^W?XN_X*Q:K\,/@W8_M1_!/]ACP;\%)?VW_ -@
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M!6*,$(/\_I\%2",@C!^AZY]CT/KTK^V__@UP^*5[XJ_8&^(WPDU&Y>=OV?\
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M<VE4?+9*ST6JNJM:*L_.,8W7:ST327Y/_'/]MKXD?\$ZM%\-']K;P_JGQ\\
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MW\,>%-7UJ[\,ZCXFL]?L[+^SI+O3X/[7TP7?UG7Y#?M_?\G\_P#!&+_LY?\
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MBC2G^S>(/"FHI?;+*[N+;3-6MKBVN]/UG2-,U*UN+2/UVBE:VWW W??[^O\
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M--:;--=T]^TE*+[2C*+U32****9(4444 %%%% !1110 4444 %%%% !1110
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M^(GA:.5M)U/0O"+77A'X0^%M%NKS2](U(Z'H?@FV_P"$IN-/O[1FTWQ[X_\
MB"MI=WMA<6UU+^PM%?S1*A1E6IXF5*G+$4:=6C2K.$75ITJ\J,ZU.%1KFC"K
M*A1E4C%I3=*FY)N$;?TK3S/,:.78O)Z6/QE+*<PQF S#'9;3Q%6&!QF.RNCF
M&'RW&8G"QFJ-?$X"AFV9T<'7J0E4PU/,,9"E*$<354_RN_:T^%OQZ^+'[?\
M_P $WM?\%_ [Q/J'P9_9L^(OQ7^*'Q2^.L_C+X1V'@[3(?'GP'^)OPWTOPM8
M>$;[XB6_Q?U?Q!:Z_>Z"]]/IOPXN?#RV6OV<T&MS&RUE-,_5&BBM3A"BBB@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "D)"@LQ"JH)9B0
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M5L_??P]-%]W0****0!1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %?-?QT^$_C;QCXN^$7Q+^'=]X0;Q
M7\)+[QDUEX?^(-CJ-_X3U.V\;Z+9Z/>ZHG]E3P7NG>*-%CL%AT758B?+TK6/
M$NG. FJ-7TI11_FG]SN--IW5MFM4FK23B]'ILV>+_L]_"F?X*?"/PQ\.;O4K
M+5;[2[OQ9K.HW&E6)TO0[?4_&OC+Q#XXU/2?#6EL\C:7X5T*_P#$=QHGA736
M=FT_P[I^F6;'="0/:***;=VWW=P;;;;U;;;?F]6%%%%(04444 %%%% !1110
M 4444 %%%% 'B7[0WPLO_C+\+-2\#Z3?Z1I^JKXH^&WC/2SXBT^75O#&I:E\
M,?B5X1^)5CX?\5:7;RP3ZAX5\2W7A*+P_P")+2&599M%U.]6/<^U&PO@+\*?
M%O@+4?BIXS\>ZAX9E\8?%SQ=IOBC6=(\$6E_8^$M'.D^&],\.VPLXM2FGO+S
M5KZ.P,^L:O<,);Q4T^VQY6GPU]%44+3FM]I6?WQ;MVOR1OZ>MZYY<O)?W;M[
M=[=>VB_JP4444$A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !14<LL5O%+//+'#!#&\LTTKK'%%%&I>2661RJ1QQHI=W<A54%F( )K\ZOV
M'_\ @I9\%_VVO 'QU^(NE:7JOP<T3X$>);=_$*_%?4=+T"2X^#'B;X=Z'\6?
MA?\ M"7DUS):VGAOX:_$WX=ZQ/XHT.[UV>WEL-/T75YM3>&&U,I /T9HKR32
MOC]\"-=G\=6VB?&OX2:Q<_"_0++Q7\2[?2OB/X.U"?X=^%M2TJ?7=.\2^.HK
M369I/"6@7^AVMUK-EK.OKI^G76E6T^HP7,EG#),OP5X/_P""MO[,_P 9_!GP
M:\1_LZ^*_A;\2_%?Q8_:%TCX*7/PA\5_M(?L_P#PF^+'A;PV?B_KGPE\3_%"
M'P=XC\?:A?>,K:T?0O\ A+_ 7@3PK]M\9?%;P[KOA=O"]DEWK<<4 !^J%%?%
M'_!1']KFZ_83_9 ^*?[4MEX#M_B9<_#C4_A5IT7@JZ\1R>$X-7_X67\9/A]\
M*'FDU^+1/$4EE_8T?CA]=6-=(NOM[Z8NG%[-;LWMM[-HW[3G[-GB+P;XF^(W
MA_\ :%^!VN_#WP7XCM?!_C'QWHWQ9\!:GX-\)^+;_4=+T>Q\+>)O%%EK\^B:
M#XCO-7UO1=+M=$U2^M=3N-1U?2[&&U>YO[2*4 ]QHKAM;^)_PT\,ZEXCT?Q'
M\0_ WA_5_!W@9_B?XNTK6_%N@:5J7A;X:13ZM:R?$/Q'8W^H6]UH?@:.ZT#7
M;9_%NIQ6N@)/HNK0MJ DTV\6'BY_VE_V<;73_'>KW/[0'P2M])^%NGZ)JWQ-
MU.?XJ^!(=/\ ASI7B6R;4?#FI^.[V37EMO"&G^(-/5K_ $2]\02Z?;:K9*UU
M82SP R  ]MHKQOQM^T5^S[\-/!WACXA_$;XZ_!OP!\/_ !M!877@SQSXV^)W
M@GPKX.\76VJ:?'J^F7'ACQ-KNN6&BZ_!J.E30ZG83:5>W<=WI\L=[;M);.LI
MV?$_QH^#O@BRTK4O&?Q8^&GA'3M>\-Z]XRT/4/$_COPMH%EK/A#PM::;J'B?
MQ5I5UJNJVD&H^&_#EAK.CWNO:Y9R3:9I%IJVFW.H75O#?6KR@'I=%8/A?Q3X
M8\<>'-$\8>"_$>@^+_"7B;3+/6O#?BGPOJ^G^(/#GB#1M0A2YL-6T36])N+O
M3-5TR^MY$GL[^PNKBUN8726&5T8,?A;1/^"B?PNUK_@H)X@_X)_+X6\3V'B?
M1_!&MZMIWQ5OWM(? /BKXG^%/"_PP^(_C'X(>&^#>ZCXX\*_"3XP>!_B7K+Q
ML;&UT2^N[65DO[*6)@#]!Z*_-+XG?\%//A!\$/%_[9/@#XQ^$?%_@;QM^R=X
M \%?%CPWX:F-EJ6J?M-?#CXF/;^&?A[KGP(L[<QWGB/4-?\ C)<0? B[TE[4
M)H?Q.U'1-'O]1\O5XIH?4/V:OVSX/V@/CM^T?^SKJ_PF\3_"OXD_LO\ @C]E
M?Q5\1]/U[7O#_B"TCU;]I[X9ZW\1+?PC8WN@2207&H_#R7P]J7AKQ#J$3RZ7
MJM^D=]HMQ/92!@ ?;M%>%?M$?'[P[^SA\/CX\U[P9\5/B-=7NK0^'/"_@'X,
M_#W7/B-X]\7^)KG3-6UBVTC3M-TN.'1] M/[-T/5;[4O&/CS7?"'P^\-V=G+
M>>*/%NB6ICF?XLT[_@J1\/[_ /9;_8+_ &I/^%6^,8O#_P"WG^T%\!OV?/"/
MA;^U]%DUGP%K?QZU_P 0>']%\0>([OY++4M*T*YT"2?5+?3,7<T%RGV0/)&R
M, ?J117R;-^UIX9B_;IT_P#84_X1376\97W[)NK_ +6A\<?:M/'AF+PSI7Q@
MT3X/#PH++>=5DUVXU76#JYNO+CT^'3[81!Y;F<K#Y/\ LY_\%$O /[3/[3OQ
M._9O\'?"?XU>$(_AY\(/"7QETGXA?%GP3J'PQLOB5X3\7>,O$/@O3]:\%>!?
M%D6G_$2W\+SZCX<U Z3X@\8^'?"D_B&.VN-0T?1;CPW-H?B+70#]"J*_+WX:
M_P#!2#Q3XB_:2^"7P"^,?[$?[27[,NG?M0V/CZ7]G'Q]\6=3^#>HOXRU7X8^
M KOXE>,O#GC_ ,#_  X^)'C;Q#\'==@\):9JNI:/IOBYWO=4^Q&VEM]/O1=V
MME^H5 !1110 4444 %%%% !1110 4444 %%%% !115'4]0@TG3=0U6Z$C6VF
MV-WJ%PL*J\I@LX)+B41*S(K2&.-@BLZ*S8!90<@ O45\P_L=_M<?"+]N/]G_
M ,&_M(_!"YU2?X?^-I=;M;&#73X?_MW3-1\.ZQ>:%K&EZQ'X7\0>*=#BO[/4
M+&9'2PU[483&T4JSE9!7T]0 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !17R1^V/\ MH?"+]AWP'\/
MOB'\8K+QGJ.C_$WXV_#GX ^%;'P+I&EZUK%QX]^*%SJ-OX<%Q:ZOKOAZVAT>
M$:5?7&J7D=[-=6UM"7M["[?]V/K>@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** /SP_X*F:K\99OV,?B/\ "K]GGP]XAUSXU?M,:CX6_9<\":AH
MGA_Q'K.G>!/^%[ZY;>!?&7Q0\8ZEX:LKZY\%^$?AO\.M0\8^,+[QM?)#IFB:
MCI.E)/<Q37EL&_';]J_]F+]KC]FI?C7I6D^#_"WQ;^%_[5/_  23_:=_8<F\
M,?LC_ +XC>&M)\#^.?V;?V>_B/XO_9,U/QYH6L?$OXU>)]=U+Q!X5UKXI_!+
MPCJ^G7>FVTNJ:EX,\+7EK<WUWX?#?U,44 ?SS?LZ?LEVWPO^,_\ P1<O_#G[
M-I\!6MW_ ,$]/VD_"/[6=[I?PDE\.07?B_Q-\+?V1M0_X1W]HNZ@T&T2X\5>
M)/'2^/+R73?B9(^LZYXKA\53RQ7>KV^J-'\S_"+X=^+H?V./V7?V<(/V;_C9
MX8^,?[+7_!9CX,>)_BC:ZE^SO\1?#^A6/PV\1?\ !2_XJ?$_2O&W@OX@2^$(
M?!WCWX;Z+\,[O2-?U_Q9X'\0:WX7\*>'KO1K[6;[3](U31;J]_JQHH _GV_X
M*[_LN_M8^)O^"<W[9WAC4?C=\3_VPG^)?B#]G:+X?? ?PY^S]X!T_6/"]I:_
MM@?!?Q)JL'AQ/A'X6'COQG!H_A"TO8;YM;DU62VT/2;O7+Z420WEX/E/_@J+
M^PQXRO?$G[?7P^_9$_9EU#1/ OB+_@FW^Q%KFC^$?@E\*SX>\%>.OB#\!?\
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M\&4^*NA^(?#]QX>\*'4]7TC0-5^&4/BB"SM;W5=*T74?" FN=.TVXA_KPHH
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MX76.E^$9];\0^+O$OBB_M?WVHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M"OWOKP+]J/\ :7^%/['GP#^)'[2/QMU34M)^&OPPTJPU#7)=%TFYUW7=1O\
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MT_/0XG_B&/\ ^"*G_1H^J_\ B1/[37_SX*/^(8__ ((J?]&CZK_XD3^TU_\
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M5K\VBZC-XW_;+\,>,OV-?#?AVTU3XGW'ACX:7^O_  %M?%5K\.=9^'X\#?\
M"NKWQ;KVI^)/$'@7Q3K&K:P@!_0MXO\ %OAKP#X3\4>._&>M6'AOP?X*\.ZW
MXM\5^(M5F%MI>@>&O#FFW.L:[K6I7!!$%AI6EV=U?7DQ!$5O!(Y!"U\Y^/\
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MC?M]_L[E@%),?B]YD^90PQ)%8O&QP0& 8E6RK892 S_A^'_P21_Z/Z_9Z_\
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MXC)\%/\ YB:/^'=W_!/[_HQ?]CK_ ,1D^"G_ ,Q-&OE^/E_P?P\PU\OQ\O\
M@_AYGS?_ ,/P_P#@DC_T?U^SU_X55Q_\KZ/^'X?_  21_P"C^OV>O_"JN/\
MY7U](?\ #N[_ ()_?]&+_L=?^(R?!3_YB:/^'=W_  3^_P"C%_V.O_$9/@I_
M\Q-&OE^/E_P?P\PU\OQ\O^#^'F?-_P#P_#_X)(_]']?L]?\ A57'_P KZ/\
MA^'_ ,$D?^C^OV>O_"JN/_E?7TA_P[N_X)_?]&+_ +'7_B,GP4_^8FC_ (=W
M?\$_O^C%_P!CK_Q&3X*?_,31KY?CY?\ !_#S#7R_'R_X/X>9\W_\/P_^"2/_
M $?U^SU_X55Q_P#*^C_A^'_P21_Z/Z_9Z_\ "JN/_E?7TA_P[N_X)_?]&+_L
M=?\ B,GP4_\ F)H_X=W?\$_O^C%_V.O_ !&3X*?_ #$T:^7X^7_!_#S#7R_'
MR_X/X>9\M:[_ ,%T_P#@DUI.B:QJEG^W3\ M8O--TK4-0M-(M/%5T+K5;FSM
M)KB#3K8II4[BXOI8TMH=D$S>9*NV*0X0_@5J7_!Y]\&+/4=0L[/]ACXAZG:6
MM[=6UKJ4/QP\.PPZA;03R107T4,_PW6:**[B59XXIE$L:2!) '!%?U-?\.[O
M^"?W_1B_['7_ (C)\%/_ )B:][T?X,_!_P .Z1I7A_P_\*/AKH6@Z%IMCHVB
M:)H_@7POIFD:/I&F6L5EINE:5IMEI<%EI^FZ?900VEC8VD,-K:6L,5O;Q1Q1
MH@5I/JEZ*_Y^8:^7W-]O-=;_ ('Y:Z[_ ,&_O_!)CQ'KVO\ B75/V9/$IU?Q
M/K^M^)]:DT[]J']KW0[*XUOQ'JMWK>M7EOH^B?'O3M'TU+W5+Z[NS9Z986=C
M \S):VT,(2-7^'O^" '_  29\+^(_#?BO2?V8O$#ZSX2\2>'_%NA-K'[3?[6
M_B33(-?\+:Q9:_H5Y>:!XC^.^JZ!K$-CJ^G65X=.UG3-0TRZ:!8KVSN;=I(G
M\Q^#/_!4K]N#X\_"7X;_ !J\!_\ !/\ _9ZB\$_%;P5X<\?^$X_$O_!0+QGI
M7B%/#WBK2[;6-(76],L/V#-:L=/U46-W#]NL[35]3MK:Y\R*&_NXT6=^U;_@
MIE^U7X(\?_ K0?CE^Q/\&_!G@/XT_'OX5_ %_%_PX_;2\3?%#Q+X8U[XN>(H
MO"_A[6U\#Z[^QY\++#6]+LM5N('U>+_A-](N8; S7%H+RXBCLY_PO+?I@^ 6
M<\48;P[RSQQX7QW%6,S?_57#<+4,\Q,\;7SCZR\M_L6&$Y5!U_K,7A/J_P /
M/%T]D>U4X3SFEAY8^IDM>&&C26)EB94(*"I<JJ*LY[VY;3YM]F?M51117[L>
M,%%>:?$3XR_"GX1WGP[T_P")WQ!\*> [SXM_$+1OA/\ #2W\4:Q::0_C;XD^
M(K/4K[0/!/A\W<D:WWB'6H-)OUTK3T837]W'%86HEOKNSMI^A\*^./"7C?\
MX2/_ (1/7;'7?^$0\5ZQX'\2_86=O['\6Z!]G_MG0KS>B;;[3_M=M]H5-Z#S
MDVNV3@ ZJBBB@"-H87DBF>*)Y8-_DRM&K20^:H63RG(+1^8H"OL(WJ &R.*D
MK$\->)O#?C3P]HGB[P=X@T3Q9X4\2Z79:WX<\3^&M6L-=\/:_HNI6Z7>G:OH
MFM:7<76FZKI=_:RQ7-E?V-S/:75O(DT$LD;JQ\LT[]I#X(ZG\'?&?[0$7Q!T
MFS^#?P\NOB_9^-O'VMVNK>'='\-S? 3QIXQ^'OQ;?4H]?T[3=0CM?!_B_P
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MP[H&N>._AW\-;#5?['UW5[1?&7Q8\;Z#\-_A_INHOH6F:F=%L_$'CCQ/X?\
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M5K96<FHW-GID,]\]I9VEL]R\K06MO$4B1-7E?HDOOO?^O^'!J[OZ=-='??\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
-BB@ HHHH **** /_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>25
<FILENAME>nt10014672x1_diagram11.jpg
<TEXT>
begin 644 nt10014672x1_diagram11.jpg
M_]C_X  02D9)1@ ! 0$ P #   #_[0 V4&AO=&]S:&]P(#,N,  X0DE- ^T*
M4F5S;VQU=&EO;@     0 ,     !  $ P     $  ?_B"^!)0T-?4%)/1DE,
M10 ! 0  "]!N;VYE @   &UN=')21T(@6%E:( ?4  < %0 3  L (6%C<W
M         $E%0R!S4D="     0            #VU@ !     -,M2% @(
M
M$&1E<V,   %$    =&)865H   &X    %&)44D,   ',   (#&1M9&0   G8
M    B&=865H   I@    %&=44D,   ',   (#&QU;6D   IT    %&UE87,
M  J(    )&)K<'0   JL    %')865H   K     %')44D,   ',   (#'1E
M8V@   K4    #'9U960   K@    AW=T<'0   MH    %&-P<G0   M\
M*&-H860   ND    +&1E<V,         &G-21T(@245#-C$Y-C8M,BTQ('=I
M=&A"4$,
M                                                    6%E:(
M     "2@   /A   ML]C=7)V        !      %  H #P 4 !D '@ C "@
M+0 R #< .P!  $4 2@!/ %0 60!> &, : !M '( =P!\ ($ A@"+ )  E0":
M )\ I "I *X L@"W +P P0#& ,L T #5 -L X #E .L \ #V /L! 0$' 0T!
M$P$9 1\!)0$K 3(!. $^ 44!3 %2 5D!8 %G 6X!=0%\ 8,!BP&2 9H!H0&I
M ;$!N0'! <D!T0'9 >$!Z0'R ?H" P(, A0"'0(F B\". )! DL"5 )= F<"
M<0)Z H0"C@*8 J("K *V L$"RP+5 N "ZP+U P #"P,6 R$#+0,X T,#3P-:
M V8#<@-^ XH#E@.B ZX#N@/' ],#X /L _D$!@03!" $+00[!$@$501C!'$$
M?@2,!)H$J 2V!,0$TP3A!/ $_@4-!1P%*P4Z!4D%6 5G!7<%A@66!:8%M07%
M!=4%Y07V!@8&%@8G!C<&2 99!FH&>P:,!IT&KP; !M$&XP;U!P<'&0<K!ST'
M3P=A!W0'A@>9!ZP'OP?2!^4'^ @+"!\(,@A&"%H(;@B"")8(J@B^"-((YPC[
M"1 ))0DZ"4\)9 EY"8\)I FZ"<\)Y0G["A$*)PH]"E0*:@J!"I@*K@K%"MP*
M\PL+"R(+.0M1"VD+@ N8"[ +R OA"_D,$@PJ#$,,7 QU#(X,IPS #-D,\PT-
M#28-0 U:#70-C@VI#<,-W@WX#A,.+@Y)#F0.?PZ;#K8.T@[N#PD/)0]!#UX/
M>@^6#[,/SP_L$ D0)A!#$&$0?A";$+D0UQ#U$1,1,1%/$6T1C!&J$<D1Z!('
M$B8211)D$H02HQ+#$N,3 Q,C$T,38Q.#$Z03Q1/E% 84)Q1)%&H4BQ2M%,X4
M\!42%3055A5X%9L5O17@%@,6)A9)%FP6CQ:R%M86^A<=%T$791>)%ZX7TA?W
M&!L80!AE&(H8KQC5&/H9(!E%&6L9D1FW&=T:!!HJ&E$:=QJ>&L4:[!L4&SL;
M8QN*&[(;VAP"'"H<4AQ['*,<S!SU'1X=1QUP'9D=PQWL'A8>0!YJ'I0>OA[I
M'Q,?/A]I'Y0?OQ_J(!4@02!L()@@Q"#P(1PA2"%U(:$ASB'[(B<B52*"(J\B
MW2,*(S@C9B.4(\(C\"0?)$TD?"2K)-HE"24X)6@EER7')?<F)R97)H<FMR;H
M)Q@G22=Z)ZLGW"@-*#\H<2BB*-0I!BDX*6LIG2G0*@(J-2IH*ILJSRL"*S8K
M:2N=*]$L!2PY+&XLHBS7+0PM02UV+:LMX2X6+DPN@BZW+NXO)"]:+Y$OQR_^
M,#4P;#"D,-LQ$C%*,8(QNC'R,BHR8S*;,M0S#3-&,W\SN#/Q-"LT932>--@U
M$S5--8<UPC7]-C<V<C:N-NDW)#=@-YPWUS@4.% XC#C(.04Y0CE_.;PY^3HV
M.G0ZLCKO.RT[:SNJ.^@\)SQE/*0\XSTB/6$]H3W@/B ^8#Z@/N _(3]A/Z(_
MXD C0&1 ID#G02E!:D&L0>Y",$)R0K5"]T,Z0WU#P$0#1$=$BD3.11)%546:
M1=Y&(D9G1JM&\$<U1WM'P$@%2$M(D4C721U)8TFI2?!*-TI]2L1+#$M32YI+
MXDPJ3'),NDT"34I-DTW<3B5.;DZW3P!/24^33]U0)U!Q4+M1!E%049M1YE(Q
M4GQ2QU,34U]3JE/V5$)4CU3;52A5=57"5@]67%:I5O=71%>25^!8+UA]6,M9
M&EEI6;A:!UI66J9:]5M%6Y5;Y5PU7(9<UETG77A=R5X:7FQ>O5\/7V%?LV %
M8%=@JF#\84]AHF'U8DEBG&+P8T-CEV/K9$!DE&3I93UEDF7G9CUFDF;H9SUG
MDV?I:#]HEFCL:4-IFFGQ:DAJGVKW:T]KIVO_;%=LKVT(;6!MN6X2;FMNQ&\>
M;WAOT7 K<(9PX'$Z<95Q\')+<J9S 7-=<[AT%'1P=,QU*'6%=>%V/G:;=OAW
M5G>S>!%X;GC,>2IYB7GG>D9ZI7L$>V-[PGPA?(%\X7U!?:%^ 7YB?L)_(W^$
M?^6 1X"H@0J!:X'-@C""DH+T@U>#NH0=A("$XX5'A:N&#H9RAM>'.X>?B 2(
M:8C.B3.)F8G^BF2*RHLPBY:+_(QCC,J-,8V8C?^.9H[.CS:/GI &D&Z0UI$_
MD:B2$9)ZDN.339.VE""4BI3TE5^5R98TEI^7"I=UE^"83)BXF229D)G\FFB:
MU9M"FZ^<')R)G/>=9)W2GD">KI\=GXN?^J!IH-BA1Z&VHB:BEJ,&HW:CYJ16
MI,>E.*6IIAJFBZ;]IVZGX*A2J,2I-ZFIJARJCZL"JW6KZ:Q<K-"M1*VXKBVN
MH:\6KXNP +!UL.JQ8+'6LDNRPK,XLZZT);2<M1.UBK8!MGFV\+=HM^"X6;C1
MN4JYPKH[NK6[+KNGO"&\F[T5O8^^"KZ$OO^_>K_UP'# [,%GP>/"7\+;PUC#
MU,11Q,[%2\7(QD;&P\=!Q[_(/<B\R3K)N<HXRK?+-LNVS#7,M<TUS;7.-LZV
MSS?/N- YT+K1/-&^TC_2P=-$T\;42=3+U4[5T=95UMC77-?@V&38Z-ELV?':
M=MK[VX#<!=R*W1#=EMX<WJ+?*=^OX#;@O>%$X<SB4^+;XV/CZ^1SY/SEA.8-
MYI;G'^>IZ#+HO.E&Z=#J6^KEZW#K^^R&[1'MG.XH[K3O0._,\%CPY?%R\?_R
MC/,9\Z?T-/3"]5#UWO9M]OOWBO@9^*CY./G'^E?ZY_MW_ ?\F/TI_;K^2_[<
M_VW__V1E<V,         +DE%0R V,3DV-BTR+3$@1&5F875L="!21T(@0V]L
M;W5R(%-P86-E("T@<U)'0@
M
M      !865H@        8ID  +>%   8VEA96B            !0
M;65A<P         !                               "6%E:(
M  ,6   #,P   J1865H@        ;Z(  #CU   #D'-I9R      0U)4(&1E
M<V,         +5)E9F5R96YC92!6:65W:6YG($-O;F1I=&EO;B!I;B!)14,@
M-C$Y-C8M,BTQ
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MU=;7V-G:X>+CY.7FY^CIZO'R\_3U]O?X^?K_Q  ? 0 # 0$! 0$! 0$!
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M.Z;JFKV]SI'Q6\7?;7TN;4+RW?Y&T3_@EK^W_P"+K#XCGXT^(OACK/C;7?\
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MOA98Z'%HG@ZUOM/\1VECKGA#XG?#7X*^+-)\-V"^%]!OK'1-4MY+^S:#3X6
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M#HU[KOAM9YKWPQ+?1:3<7,.C:Y'9Z[#;O!/>V-JL\:'OX&\3Z&=>SR+B.5#
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M&E/'UG3]I[=XBC5AST:JC4=&I1Q-.*A0K3<ZK<*3]9C_ ."3?[:;W203:_\
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M^B>/_P!L72[[QQX4N_">MRZ1HGQ'TL>'-!L9_$VE&T\36L>B:+"U\D>G6 B
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M[[QQ\1OB-_P2$_99UWPEX,\<?%C]DWQ3_P %4/V&?&_@W]I+PT]GX.U_P_\
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M&/\ A?\ \.O^T#_\]FCWO[OWO_+U_I:GO?W?O?\ EZ_TM?I[_A[O_P $M/\
MI(9^QS_XD)\,O_FCH_X>[_\ !+3_ *2&?L<_^)"?#+_YHZ^8?^(<_P#X(O\
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M?_@EI_TD,_8Y_P#$A/AE_P#-'1_P]W_X):?])#/V.?\ Q(3X9?\ S1U\P_\
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MKVLMK[OR_P"#_2U+RO:RVON_+_@_TM?VP_X>D_\ !,G_ *2+_L)?^)=?L_\
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M_P#+U_I:GO?W?O?^7K_2U^Q?^'I/_!,G_I(O^PE_XEU^S_\ _/!H_P"'I/\
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M'1=-O-5^(/PWO_B5X\\<>(?A9X_\(^/?!^A_##X5^+O!NHZ)XA\/7?B_XD^
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M$?%.AW3SI:ZSX<\2:9=:-KFE7+VTL%RD&HZ9>W5I,]O/#.L<S&*6.0*X\_\
MA;\$O#7PJU#Q+KUGKWCGQKXM\767AK1M<\:?$?Q3=^+/%%SX9\%#6_\ A#/"
ML=]/';6]OH7AF3Q+XEO+**&S2]U#6/$?B#Q#X@OM9\0ZWJFJW7L=% !1110
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MP);>)O'AG^(7BI]?A^P>A_%?X_:7\.M=T[X?>&/!7C?XP_&'7=,@UG1OA?\
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MKX?>&-;\8>*M9N59HM.T'P]I\^IZG=&-/GEDCM+:7R8(P9;B8QP1*\LB*?\
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MY;'*)4YY5# X6&73I3<Z<L'"A".'<9/WFO9**?-[]T^=*5T%%%%>4>F%%%%
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M@WX-^)/&7C2]\5_#7P@VA^)?''PTU;6_AS\,H_%>M>)AXMM/#WPJN%UOY/\
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M_P#8^KF[O-%GL_#G["6K64EYK.F:K<^/_#6GZ1?IJ"NKV_K^M5^>P7_K[O\
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MP:E;217.GS3:1J5Y''?6\L<]H[+<12))&K#\_P#X[_&W]G;X6?'>V^*7A_\
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MZKI?PENO#IOM?TWH?V+/B+X ^%UMK'[,7Q U#Q%\,/C]XF^.7[67QPL/A?\
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M#7@KP1/\3_B5\2/B2OPY^'OA_P (?#;2/&OC_P 7:SX;\'Z(VLW$)YK]H/\
MX*:>!_!GB&\^%_P)TC_A9GQ$/B3Q#X"'BK4=(\97OP]MO'7A:[N=+\8>#_AO
MX4\":#XC^,G[6GQ/^'MY;7MQXU^%_P"S3X+\5:+X(?0M;TOX\_%_]GN&!O$$
M"?LS?%7QO\(OBI\4K']K/X?ZQ\%==_;#^+_@+XA_"GQ?K(\*1^ _$?C&P_9H
M_9^^ FJ?"7Q+=>#_ !_\3_#WPG^-6M^(_@EJOC7PG\+]5^(7C+1/$WA;QAH7
MA_X:_%;XJ^,_#'Q#TOPL:7_KRZ^>GK\AZ?UW_JQ^I-<?\0_ /A/XJ^ O&OPQ
M\>:3'KW@CXB>$_$/@CQ?HDLUS;1ZMX9\4Z3=Z)KFG&YLYK>\M3=Z;?7,"W5G
M<07=LSB>UGAGCCD7L*^3OCI^UC\,_A@_QM^&VF?$#P/I?[0?PQ_9DU7]I6P\
M&^/[3QW;^'8O!%W>^-/"7A+QIKU]X1\*>(M7U;P5#\0/!M[H_C>W^'VG>+/&
MOA?3GL;RZ\,(_B3PDFN,#\<?'G[=_P"U(?C9^SW^S!#^T9\ /V6=$_9=^(OE
M?MQ?M=_M->(_ACH_AS]I.P^'NOZQX7\.?"KX*^%->UKP]8^(_%7QX\#:?;_%
M#XR7/A"_T&P^!/B36+KX=:;\0;7Q_P##GQ-X6OOVB^!'PY_9TM-'^#OB'X&>
M(=!\8:!\&?@;#^S[\-=<\*^/+;QOH]K\*P_@:.'3I]3TW4M2LM9O6D^%GAE%
MUNZGGOG?3;Y1.6NKP-Z+\#?A+I/P-^%'@SX7:3J=]XA;PWI]S-X@\7ZO#9P:
M_P"/_'7B+4[[Q1\1?B9XI73X;>QD\7_$SQ[K7B3Q_P"+[BT@@MKOQ-XCU6ZA
MABCF6-?FC]I?X<?#/P!\2_V7?VE[/PGX0\+>(_!'[37@KP?XR\8Z%X2T:Q\:
M^+_#?[1WA;Q?^RMX<\#:IXGL-/AUF]\,W7QC^,/P:\7:II.H:@^E37G@#0-2
MEMY=1T+1F@E)K?7;Y;=7VM?;5]A*Z\]5]VB_X/FS[OHHHJAA1110 4444 %%
M%% !1UHHH _*'_@HK_P2!_9B_P""AMG'XG\26U[\)_C]H^G26/ACX]_#^SL(
MO$_D)%BRT;QYI,ZQ:?\ $?PK;2JC1:1KDL6HZ=%Y\7A[7-#-W<O+_)_\;/\
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MWOQ>\7?MZ_$+2/CM-X \?_M7>)_V-_B3\%O%^D^ +/4==_9G^+G[%VD67_"
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M ."6G_20S]CG_P 2$^&7_P T='_#W?\ X):?])#/V.?_ !(3X9?_ #1UY?\
M\.*O^"1/_1A/P)_\%6M__+RC_AQ5_P $B?\ HPGX$_\ @JUO_P"7E'O?W?O?
M^7K_ $M37R_'R_X/X>9ZA_P]W_X):?\ 20S]CG_Q(3X9?_-'1_P]W_X):?\
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M^S(_#T.FHU\^K-:+:XF*$>B_\.*O^"1/_1A/P)_\%6M__+RC_AQ5_P $B?\
MHPGX$_\ @JUO_P"7E'O?W?O?^7K_ $M3WO+\?+_@_AYG&?\ !OUXE^-'C?\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 5S'_"$>"_^$T_X61_PB'A?_A8?_"+_ /"$?\)[
M_8&E?\)I_P (7_:O]O?\(A_PE/V3^W/^$7_MS_B<_P!@?;O[*_M7_B8_9/MG
M[ZNGHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MAWUGQ79:UK^M^)-+TCPCHWB&^%_#8^4^)_\ @IW^SS;^#/V??%?PB\._&?\
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M?\.OO"Z[K^O^'7WGZ*45^=?_  ]W_P""6G_20S]CG_Q(3X9?_-'1_P /=_\
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M_FCHNNZ_K_AU]X77=?U_PZ^\_12BOSK_ .'N_P#P2T_Z2&?L<_\ B0GPR_\
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MT4HK^3__ (*/_P#!1?PO\?\ _@HA_P $2?A#_P $_OVW[?QIHOB3]KC4;_\
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MZ,)^!/\ X*M;_P#EY1_PXJ_X)$_]&$_ G_P5:W_\O*_62BBR[+[D%EV7]?\
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M%]R-1E;_ (33XD^%-3O8_M:VDJ@']TE<?X_^(/@3X4^#?$'Q$^)WC+PO\/?
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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<B@ HHHH **** "BBB@ HHHH **** "BBB@#_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>26
<FILENAME>nt10014672x1_diagram12.jpg
<TEXT>
begin 644 nt10014672x1_diagram12.jpg
M_]C_X  02D9)1@ ! 0$ P #   #_[0 V4&AO=&]S:&]P(#,N,  X0DE- ^T*
M4F5S;VQU=&EO;@     0 ,     !  $ P     $  ?_B"^!)0T-?4%)/1DE,
M10 ! 0  "]!N;VYE @   &UN=')21T(@6%E:( ?4  < %0 3  L (6%C<W
M         $E%0R!S4D="     0            #VU@ !     -,M2% @(
M
M$&1E<V,   %$    =&)865H   &X    %&)44D,   ',   (#&1M9&0   G8
M    B&=865H   I@    %&=44D,   ',   (#&QU;6D   IT    %&UE87,
M  J(    )&)K<'0   JL    %')865H   K     %')44D,   ',   (#'1E
M8V@   K4    #'9U960   K@    AW=T<'0   MH    %&-P<G0   M\
M*&-H860   ND    +&1E<V,         &G-21T(@245#-C$Y-C8M,BTQ('=I
M=&A"4$,
M                                                    6%E:(
M     "2@   /A   ML]C=7)V        !      %  H #P 4 !D '@ C "@
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M;W5R(%-P86-E("T@<U)'0@
M
M      !865H@        8ID  +>%   8VEA96B            !0
M;65A<P         !                               "6%E:(
M  ,6   #,P   J1865H@        ;Z(  #CU   #D'-I9R      0U)4(&1E
M<V,         +5)E9F5R96YC92!6:65W:6YG($-O;F1I=&EO;B!I;B!)14,@
M-C$Y-C8M,BTQ
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MU=;7V-G:X>+CY.7FY^CIZO'R\_3U]O?X^?K_Q  ? 0 # 0$! 0$! 0$!
M     0(#! 4&!P@)"@O_Q "U$0 " 0($! ,$!P4$!  ! G<  0(#$00%(3$&
M$D%1!V%Q$R(R@0@40I&AL<$)(S-2\!5B<M$*%B0TX27Q%Q@9&B8G*"DJ-38W
M.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U=G=X>7J"@X2%AH>(B8J2
MDY25EI>8F9JBHZ2EIJ>HJ:JRL[2UMK>XN;K"P\3%QL?(R<K2T]35UM?8V=KB
MX^3EYN?HZ>KR\_3U]O?X^?K_V@ , P$  A$#$0 _ /[^**** "BBB@ HHHH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MM<26\/[/?D23P*PBE>#S'\EY$9H][["NXY3_ %7YH3_5?FC]@J***8PHHHH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *^,O@E\5_V>O%W[7O[;
M_P +OAQ\+[CPK\>_A!_PS5_PTC\2I/"?A32(/BO_ ,)_\,=6\0_![[-XHTC6
MK[Q1XO\ ^$%\&6U]H$W_  E^CZ'_ ,(^]P-.T#^T]/EEND^S:_'W]C*SNX?^
M"LG_  6CNYK6XBM;W_AW/]CN9()8[>[^S_LU^*8[C[-,RB.?R)"(YO*9_*<A
M'VL0*3Z>;_1O]!=O77[F?L%1113&%%%% !7\KO[9O_!U!\ OV,_VI/C9^RYX
MF_95^,'C37O@IXTNO!>J>*="\9^"]/TC6[JUL[.[:]L++4(6O;>W9;Q46.X8
MR!D8G@BOZHJ_@E_9"\%^#O'O_!VI^V1X>\<^$_#7C30)+CX_74FA^+-"TOQ'
MH\EU:^"_";6UR^F:Q:WED\]NS%H)F@,D3$F-E))J9-IQ2TN_\O\ ,F3:M;JT
MCZ<_XC._V9?^C+OCM_X7_P /_P#XQ1_Q&=_LR_\ 1EWQV_\ "_\ A_\ _&*_
MK'_X9:_9C_Z-S^!'_AH?A_\ _,]1_P ,M?LQ_P#1N?P(_P##0_#_ /\ F>I6
MG_,ON7^7K_3T+2_F7W?\'^KORM_)Q_Q&=_LR_P#1EWQV_P#"_P#A_P#_ !BC
M_B,[_9E_Z,N^.W_A?_#_ /\ C%?UC_\ #+7[,?\ T;G\"/\ PT/P_P#_ )GJ
M/^&6OV8_^C<_@1_X:'X?_P#S/46G_,ON7^7K_3T+2_F7W?\ !_J[\K?R<?\
M$9W^S+_T9=\=O_"_^'__ ,8H_P"(SO\ 9E_Z,N^.W_A?_#__ .,5_6/_ ,,M
M?LQ_]&Y_ C_PT/P__P#F>H_X9:_9C_Z-S^!'_AH?A_\ _,]1:?\ ,ON7^7K_
M $]"TOYE]W_!_J[\K?R<?\1G?[,O_1EWQV_\+_X?_P#QBC_B,[_9E_Z,N^.W
M_A?_  __ /C%?UC_ /#+7[,?_1N?P(_\-#\/_P#YGJ/^&6OV8_\ HW/X$?\
MAH?A_P#_ #/46G_,ON7^7K_3T+2_F7W?\'^KORM_)Q_Q&=_LR_\ 1EWQV_\
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M_P#&*/\ B,[_ &9?^C+OCM_X7_P__P#C%?UC_P##+7[,?_1N?P(_\-#\/_\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M^&/_ !&/5?\ Y^M?!/\ P4R_X-E/$O\ P3A_8W^)G[7>H_MC:%\6[3X<:GX
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "OQ]_:1O+N+_
M (+0?\$Q;*.ZN8[.Z_9E_P""@DMS:)/*EM<26\/[/?D23P*PBE>#S'\EY$9H
M][["NXY_8*OB'XI_#O\ 9QUK]N_]DOXD^-?B7K.A_M,^"/A/^TMHGP+^%UMJ
MNE6^B>/? WBY/AF/C!KVJ:3<>&+_ %?4;KP8ND>#CIUQIWBK0+>Q_MJY^W6&
MM>? +)/]5^:$]?O7X-,^WJ***8PHHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HJK?WMMIMC>:C
M>.8K2PM+B]NI CR&.VM87GG<1QJTCE(HV8(BL[8VJI8@5^!'_$3]_P $7O\
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MC'PS>2);ZKI.HVB!XIK/5-,N-1T34M+U.]^B* "BBB@ HHHH *_G^_X.?O\
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M[/VQ?K^T+_ZA7A*HEO#U_5$R^S_B7ZG]VM%%%64%%%% !1110 4444 %%%%
M!1110 4444 %%%% !7^?Y_P= _\ *9S_ ()P_P#9,/@)_P"M5_$:O] .O\_S
M_@Z!_P"4SG_!.'_LF'P$_P#6J_B-4S^%_+\T)[?./YH_T Z***H84444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M "_JRL^5>?W^G^7]65OQ!_X<^?\ !TM_TE)'_B;?[3/_ ,[&C_ASY_P=+?\
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M_24D?^)M_M,__.QK^@[_ (+,_P#!1)_V1OV//VA-6_9W^/GPP\'?M4?#;3_
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M_5E;^6__ (-*_P!K3]I_]JCPE^W/=?M*?M ?%[X\7/@GQ%^SW;^$)_BQX_\
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MPZ')XBU"_;3(]6DTC2WU!+0Q+=MI]FTP<V\6W^I#]J7_ )-C_:,_[(1\7O\
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MK4=,U"\CL1#DG%]]-/FB>9-/H[/1^G]>?D?O%_P;G?\ *%_]A_\ [%?XK_\
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M\/:A\+]5UG1?$F@Z]X6L7^*OC/2?"7BF#Q'IL^K>)Y;#1CX9U*"5=%\)^$/
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M !Z\51>&_%NC^.;#1]9\.V5WX1\0V>G6&G#3Y[F]U"6/7;?2^$?[$'[=>B_
MSQ+\!OC;^W5X)^)VD^%?@KXB^!_P%\8V7[/VNZ1K36_B/PE!X%3XH_M#Z4OQ
MKAE^+'C7PGX-DU;P_P"$] L?%'A_P[<:EK%_X^\>77CKQ?'X?N/#(!YO\(O^
M"B7[;WB[]E[X-_M0>/\ ]E3X#^#_ (8?'/PC\ ?$>E?$Z3]HI-%\&?!KPO\
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M9O?$?A__ (1_Q'>VNG?\53I&B?VMYOVO1/[2L4DND_2>OS0_9>^.OQ7\??\
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M "B)\8?]EW^"/_IZU.H<4HOOIK\T3RI)]79ZOT_KS\SZ?_X-SO\ E"_^P_\
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M)>MX_NM.U'2+;XD7%_9KIL&H6U[>&XDT^+YN^&W[#G[>^G6G_!(+3_&?A_\
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M)HWBFAE19(I8I%*212QN&22.1&*.C@JRDJP()%.1$C1(XT6..-52.-%"(B(
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MYH_XAH/^")/_ $95_P";'_M:_P#S^:_=JBBR[+[D%EV7W(_"7_B&@_X(D_\
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M?[-6N>%_BM\0?A7\5#X6LO'-GX__ &BOCWKGBC6/"/@'4=0U/X>_#1/'=O\
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M1SQ\_N_K^D_*YSQ[_@_\C_0#HK_/\_XC _VT/^C /AA_X/OBM_\ *ZC_ (C
M_P!M#_HP#X8?^#[XK?\ RNHYX^?W?U_2?E<YX]_P?^1_H!T5_G^?\1@?[:'_
M $8!\,/_  ??%;_Y74?\1@?[:'_1@'PP_P#!]\5O_E=1SQ\_N_K^D_*YSQ[_
M (/_ "/] .BO\_S_ (C _P!M#_HP#X8?^#[XK?\ RNH_XC _VT/^C /AA_X/
MOBM_\KJ.>/G]W]?TGY7.>/?\'_D?Z =%?Y_G_$8'^VA_T8!\,/\ P??%;_Y7
M4?\ $8'^VA_T8!\,/_!]\5O_ )74<\?/[OZ_I/RN<\>_X/\ R/\ 0#HK_/\
M/^(P/]M#_HP#X8?^#[XK?_*ZC_B,#_;0_P"C /AA_P"#[XK?_*ZCGCY_=_7]
M)^5SGCW_  ?^1_H!T5_G^?\ $8'^VA_T8!\,/_!]\5O_ )754OO^#Q+]L+3+
M9[S4OV#?A+I]I$4$EU?>)_BA:6T9D=8XP\\]C'$A>1E1 S L[*JY8@4<\?/[
MOZ_I/RN<\>_X/_(_T#J*_-[_ (),?MP>*O\ @HM^PI\)?VMO&G@?P_\ #GQ%
M\1=6^)6G7OA'POJ.HZKHNG)X&^)7BKP-:26M]JRK?2M?VGAZ&^N!,,1W%Q+'
M%^Z5*_2&K6J3[E;A1110 5\1? GX=_LX^&_VS?V\?'_PT^)>L^*/V@_B5_PR
M]_PTU\.KW5=*N](^%O\ PAWPJU?1?@Q_8FF6GAC2]4TC_A-_!,]_KNI?VOXD
M\5?;[FW2XT_^P[=6L)/MVOQU_8N_Y2V?\%K/^\</_K-'BJD^GK]VC$^GK]VC
M/V*HHHIC"BBB@ K^$K]A;_E;L_;%^O[0O_J%>$J_NUK^$K]A;_E;L_;%^O[0
MO_J%>$JB6\/7]43+[/\ B7ZG]VM%%%64%%%% !1110 4444 %%%% !1110 4
M444 %%%% !7^?Y_P= _\IG/^"</_ &3#X"?^M5_$:O\ 0#K_ #_/^#H'_E,Y
M_P $X?\ LF'P$_\ 6J_B-4S^%_+\T)[?./YH_P! .BBBJ&%%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 5_)S_P:)?\ )F'[8/\ V?=X_P#_ %5/PBK^L:OY.?\ @T2_Y,P_;!_[/N\?
M_P#JJ?A%2ZKT?YQ%U7H_SB?UC4444QA1110 4444 %?S7?\ !U[_ ,HB?&'_
M &7?X(_^GK4Z_I1K\_/^"F?_  3\\'_\%,OV6]5_9<\<_$'Q+\,M!U7QIX/\
M:2>*?">EZ7J^KQ77@^\N+NVLDLM89+)K>\:X9)Y&;S(U4&/))I25TTA/5-=T
MS\N/^"!/[:?['/PN_P""17[&W@/XF?M9_LS_  Z\<^'_  W\3H=>\&>.OCO\
M+?"/BO1);WXZ?%#4[.+5_#OB#Q5I^KZ;)=Z;>V>H6R7MG"T]C=VUW$'@GBD?
M]A?^'B/_  3^_P"CZ/V.O_$F_@I_\VU?S#?\08G[,O\ T>C\=O\ P@/A_P#_
M !^C_B#$_9E_Z/1^.W_A ?#_ /\ C]2G))+EV\UY?\'^EJES))66ENOI_P '
M^M_Z>?\ AXC_ ,$_O^CZ/V.O_$F_@I_\VU'_  \1_P""?W_1]'['7_B3?P4_
M^;:OYAO^(,3]F7_H]'X[?^$!\/\ _P"/T?\ $&)^S+_T>C\=O_" ^'__ ,?H
MO/\ E7WK_/U_I:EY=E]_I_P?ZW_IY_X>(_\ !/[_ */H_8Z_\2;^"G_S;5\V
M?M=_&C_@E9^VO^SQ\1?V:/C)^W1^RY#X#^)%GH\=[JO@_P#:O^!VA^,/#FK^
M&_$.D^+/"_B?PIK-QXHU.VT[7_#OB70]*U:PEN]-U'3YWM6LM3T_4-,NKRRN
M/P9_X@Q/V9?^CT?CM_X0'P__ /C]'_$&)^S+_P!'H_';_P (#X?_ /Q^B\_Y
M5]Z_S]?Z6I>79??Z?\'^M_T?^%?AK]BGP5^UAX(_;&\?_P#!=7PK\7_BSX)_
M9]U#]FU7UWX\?L'^&M(\1?#F[\67GBVWTGQ-:>%_"-D=7M[;5VTCQ)<WETS^
M*]5\;Z/#K>H>+)?#[Q>#;31\"^#_ /@G5\(=$@M?A'_P6<\*^&O$FG_M2_%/
M]KK3/$^O_M,_L.^)DC^)/QG\+>-?#/Q(\,ZGX:L_!/AKP_K?PN\5/XZU37+S
MPE>VG]HZ5KEOIVJ^$?$GAC4;&TO(/S/_ .(,3]F7_H]'X[?^$!\/_P#X_1_Q
M!B?LR_\ 1Z/QV_\ " ^'_P#\?HO/^5?>O\_7^EJ7EV7W^G_!_K?[V\6?L^_\
M$E+WPC\';GX7_P#!4;X+? /]H;X&_%OX]_'?P5^TU\)?VDOV3M!\:W?Q._:;
MU>\UCXSMXJ\(N)_ >N> /$RSV'ART\!QZ+I]OI/@?PYX<\'0:M+I%KJ4>K^F
MZSX8_P"":U_XY_9]^,.A_P#!8;PYX(^._P #]'^+6A^(OC3X9_:Y_8^O/&'Q
MZL/CC<:!??$5?C#IOC3PWXO\&7YDOO#.C#P9:^%O#'A?2OAUI.F:%H?@W3=*
MT_P5\/$\'?EY_P 08G[,O_1Z/QV_\(#X?_\ Q^C_ (@Q/V9?^CT?CM_X0'P_
M_P#C]%Y_RK[U_GZ_TM2\NR^_T_X/];_H;\'_ (7?\$WOV</!GP]\$_L_?\%C
MOAWX-T3X;Z+^T%X.TC0O&/[1W[&_Q3\':O\ #W]H[XEZ%\4?&'@CQ-X2\4Z:
M+/6+/0/$FC7-]X/UXW-OXLM+OQ!XAAU_7?$7AS5KSPS->^(OP=_X)':Q\*?V
M.O WP2_X*:?!K]F3Q_\ L$Z#J^@_LT?'#X4?M4_LQGQUHMOXI\-V?AOQ['X^
MT[7;C4/"GCVQ^):V8UGXA:?+HNBIXBUN[U28366GZQJ^FW_YR?\ $&)^S+_T
M>C\=O_" ^'__ ,?H_P"(,3]F7_H]'X[?^$!\/_\ X_1>?\J^]?Y^O]+4O+LO
MO]/^#_6_]#WP1_:V_P"">7P5\ 6'@U?^"BG[,_Q$UV2^U+Q!XT^)GQ _:E^
M5]X\^(_C/7+DW>M^+?%EWHWB/1=(%Y<-Y&FZ1I&B:/I/AOPEX6TO0/!?A/1]
M&\*>'-$TBQ];_P"'B/\ P3^_Z/H_8Z_\2;^"G_S;5_,-_P 08G[,O_1Z/QV_
M\(#X?_\ Q^C_ (@Q/V9?^CT?CM_X0'P__P#C]%Y_RK[U_GZ_TM2\NR^_T_X/
M];_T\_\ #Q'_ ()_?]'T?L=?^)-_!3_YMJ/^'B/_  3^_P"CZ/V.O_$F_@I_
M\VU?S#?\08G[,O\ T>C\=O\ P@/A_P#_ !^C_B#$_9E_Z/1^.W_A ?#_ /\
MC]%Y_P J^]?Y^O\ 2U+R[+[_ $_X/];_ -//_#Q'_@G]_P!'T?L=?^)-_!3_
M .;:O%/VE/\ @H!^P=K'[.GQ^TG2?VV?V1M4U75/@I\5-.TS3-._:1^#=]J&
MHZA?>!==MK*PL+*V\9RW-Y>7=S+%;VMK;Q23W$\B11(\CJI_GQ_X@Q/V9?\
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M5_@#B:TT&6SNY(XXO$_Q6MO"'C+PU;SQ:QX+TO5H[CS3_11_P;;_ /":1_\
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MW_9^^&&E_L]VEC\)_CC\%_'+7/@GP1J-K\3+W7_$7BG19K+XK>-_&THU)M2
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M2M*\ ^+-+\67'C&#Q)HFL>$[[P;XW\47-O+IZP1SPZG'J.FWUG?1QO;+E%F
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M)S^/]7^/7P[O?AC^R%_P3<_:2_8Y\$_!C0OA5X#_ &:/VC-,U+X3/^SSK?\
MPE_B+Q-XY\4_!K4O"/P(^-?A*TLOB2TO@M_&M]>^#I?$2_\ "'6&F:#8P6^I
M^*;[Q#]H? /]@#X)?#[]G+QC^SM\2OA5\*/&7PO^)'Q!U_XCZO\  2;0IO&G
MP"^&XU>/1;;1?A[\+_#7Q"BU%K7PUX1M?#NEZI_:\6E^&H]>^)-YXN^)NB>#
M_AT?%-OX.\.@'!?\$[/V>#^S1K_[4'P^\-_M2/\ '7X43?$#PEXB\!?"#2O#
M'B.V\!?LFWWB3PY=:_XE^%/@7QCXG^*OQ;U&\TGQ!:ZIX9\>0?#8:[I<'PWT
M77/#^IVNB1V?Q MM2U+^33_@Z!_Y3.?\$X?^R8? 3_UJOXC5_=;\%?@7\'?V
M<?AWHOPE^!'PV\(?"?X;>'FNY-(\'>"-&M-$T:VN;^X>[U&_D@M45[S4]2NI
M'NM2U2^DN=1U"Y=I[VZGE)>OX4O^#H'_ )3.?\$X?^R8? 3_ -:K^(U3/X7\
MOS0GM\X_FC_0#HHHJAA1110 45_-=_Q%>_\ !(G_ *'#X[_^&1UK_P"6='_$
M5[_P2)_Z'#X[_P#AD=:_^6=3S1[K^O\ A_S[,5UW7WH_I1HK^:[_ (BO?^"1
M/_0X?'?_ ,,CK7_RSH_XBO?^"1/_ $.'QW_\,CK7_P LZ.:/=?U_P_Y]F%UW
M7WH_I1HK^:[_ (BO?^"1/_0X?'?_ ,,CK7_RSH_XBO?^"1/_ $.'QW_\,CK7
M_P LZ.:/=?U_P_Y]F%UW7WH_I1HK^:[_ (BO?^"1/_0X?'?_ ,,CK7_RSH_X
MBO?^"1/_ $.'QW_\,CK7_P LZ.:/=?U_P_Y]F%UW7WH_I1HK^:[_ (BO?^"1
M/_0X?'?_ ,,CK7_RSH_XBO?^"1/_ $.'QW_\,CK7_P LZ.:/=?U_P_Y]F%UW
M7WH_I1HK^:[_ (BO?^"1/_0X?'?_ ,,CK7_RSH_XBO?^"1/_ $.'QW_\,CK7
M_P LZ.:/=?U_P_Y]F%UW7WH_I1HK^:[_ (BO?^"1/_0X?'?_ ,,CK7_RSH_X
MBO?^"1/_ $.'QW_\,CK7_P LZ.:/=?U_P_Y]F%UW7WH_I1HK^:[_ (BO?^"1
M/_0X?'?_ ,,CK7_RSH_XBO?^"1/_ $.'QW_\,CK7_P LZ.:/=?U_P_Y]F%UW
M7WH_I1HK^:[_ (BO?^"1/_0X?'?_ ,,CK7_RSH_XBO?^"1/_ $.'QW_\,CK7
M_P LZ.:/=?U_P_Y]F%UW7WH_I1HK\0OV0?\ @X._X)S_ +</[1/P\_9=^ _B
M3XLZA\5OB?\ \);_ ,(K:>)OA;JGAS0YO^$*\#>)OB'KGVW6;B^FAL_+\-^$
MM8EMM\;?:+M+>T7#SJP_;VFFGL.Z>SN%%%%, HHHH **** "OY.?^#1+_DS#
M]L'_ +/N\?\ _JJ?A%7]8U?R<_\ !HE_R9A^V#_V?=X__P#54_"*EU7H_P X
MBZKT?YQ/ZQJ***8PHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "OQT_:4_Y34_\ !+[_ +-B_P""A7_H
MG]GBOV+KXI^*'@+]FS5_VYOV4OB%XW^(&H:/^T]X-^%7[2&C_ CX=PZO:VVG
M>-/ OBE/AL/C'K-[HTFA7=WJ<_A1=*\&FTN;?7](CL/[6F,]GJGGQ_94_P!5
M^:$]?O7X-,^UJ***8PHHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M$G_H]7_S7#]K7_YPU'_$-!_P1)_Z,J_\V/\ VM?_ )_-'_$-!_P1)_Z,J_\
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M1110!_FJ?\&N/_!/+]C?]OOQ/^VC8?M=?!/3/C):?"_0?@/>> X=2\5>/O#
M\/W/B[4/BU#XBEA;P+XK\+O>G4HO#FBHZZFUZD L5-HL!EN#-_7S_P 0Y_\
MP1?_ .C'_"__ (=?]H'_ .>S7\ZW_!E?_P CG_P4/_[%C]F/_P!.OQUK^]NH
MBERK1=>GFR(I<JT77IYL_$W_ (AS_P#@B_\ ]&/^%_\ PZ_[0/\ \]FC_B'/
M_P""+_\ T8_X7_\ #K_M _\ SV:_;*BJLNR^Y%679?<C\3?^(<__ ((O_P#1
MC_A?_P .O^T#_P#/9H_XAS_^"+__ $8_X7_\.O\ M __ #V:_;*BBR[+[D%E
MV7W(_$W_ (AS_P#@B_\ ]&/^%_\ PZ_[0/\ \]FC_B'/_P""+_\ T8_X7_\
M#K_M _\ SV:_;*BBR[+[D%EV7W(_$W_B'/\ ^"+_ /T8_P"%_P#PZ_[0/_SV
M:/\ B'/_ ."+_P#T8_X7_P##K_M _P#SV:_;*BBR[+[D%EV7W(_$W_B'/_X(
MO_\ 1C_A?_PZ_P"T#_\ /9H_XAS_ /@B_P#]&/\ A?\ \.O^T#_\]FOVRHHL
MNR^Y!9=E]R/Q-_XAS_\ @B__ -&/^%__  Z_[0/_ ,]FC_B'/_X(O_\ 1C_A
M?_PZ_P"T#_\ /9K]LJ*++LON0679?<C\3?\ B'/_ ."+_P#T8_X7_P##K_M
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MO!/CGP1K&C:SI<]_#864=[;2S7>GW$EEI]\UF-3TK2KVRLH_(3]I7P?\6_\
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M\0?%7Q#K&G^#O!GAWPC#X=:\U*'Q+XFCM0FG1>&;YGPU_P""O/B7]H'X-_\
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M&OC(OB?PKX8TGQ*WC[2)Y-'\+_$#P)+:VT?C:QOM!U/P=!X;C@\=3XG[)/\
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M% !1110 4444 %%%% !1110 4444 %%%% !7YK_&_P" 'Q;\8?\ !3_]@_\
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M_".Y_:>TS]G+7_V7OCO9:]\$_$FD?!CXL^ =6^(1^)'AC6?#OAO0_BO>^+?
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M )QE?VR_\(3X,_Z%'PQ_X(-*_P#D2C_A"?!G_0H^&/\ P0:5_P#(E%I?S?\
MDJ"TOYO_ "5'\37_ !&H>"_^D>/BC_Q)O2?_ )QE'_$:AX+_ .D>/BC_ ,2;
MTG_YQE?VR_\ "$^#/^A1\,?^"#2O_D2C_A"?!G_0H^&/_!!I7_R)1:7\W_DJ
M"TOYO_)4?Q-?\1J'@O\ Z1X^*/\ Q)O2?_G&4?\ $:AX+_Z1X^*/_$F])_\
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M? _Q%X#U>R\&MX@DT#P7XG70/B%J(U#6/#-AI7B"ZDO8X=4U6^.E:8UGR/\
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MB37F^$OQBOH/%UEXATGX>:Z-2M;_ ,+6U[<?\)3!XGT_5O".F;W[17[6VD_
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M/@!^S)JL/[*LOC?X6_\ !0'2?VPO%'B+3_C;\7!X5O\ POIG[3VM?M%R>%]
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MM)]?\8>(=+\)>%-%AN+N6**35?$GBC6]'\.Z'8(YN=5UO5=/TRRBFO+R"&0
MV:*** "OY_O^#G[_ )0O?M/_ /8S_L]_^M!_#2OZ :_G^_X.?O\ E"]^T_\
M]C/^SW_ZT'\-*4MGZ/\ (4MGZ/\ (/\ @V!_Y0O?LP?]C/\ M"?^M!_$NOZ
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M8U%%%,84444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MP5_]+HK^L>BCE\Y?>_Z_X=^5CE\Y?>_Z_P"'?E;^3C_AD7_@[L_Z2D_L)?\
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M'1115#"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M-6M86,H<RV,X* !2TW2EJ[>[^HGNO1_FC^X6BOR;_P"'ZO\ P2)_Z/V^!/\
MX-=;_P#E'1_P_5_X)$_]'[? G_P:ZW_\HZ=UW7WH+KNOZ_X=?>?K)17Y-_\
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MY6D:)_8Z0FS?^TF<7*)]/77[G^MA/IZZ_<_UL?9M%%%,84444 %?PE?L+?\
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M=)\3V^E7-U:W<DFBZCJ>E:W86EX);2(+-=:3?1!"X,!)!7^=[_B$%_X):?\
M0^?MB_\ AV/AG_\ .0K^I^BDTGNOZ_K^M1-)[J_]?\ _E@_XA!?^"6G_ $/G
M[8O_ (=CX9__ #D*/^(07_@EI_T/G[8O_AV/AG_\Y"OZGZ*7+'LOZ_X;\^[%
MRQ[+^O\ AOS[L_E@_P"(07_@EI_T/G[8O_AV/AG_ /.0H_XA!?\ @EI_T/G[
M8O\ X=CX9_\ SD*_J?HHY8]E_7_#?GW8<L>R_K_AOS[L_E@_XA!?^"6G_0^?
MMB_^'8^&?_SD*/\ B$%_X):?]#Y^V+_X=CX9_P#SD*_J?HHY8]E_7_#?GW8<
ML>R_K_AOS[L_E@_XA!?^"6G_ $/G[8O_ (=CX9__ #D*/^(07_@EI_T/G[8O
M_AV/AG_\Y"OZGZ*.6/9?U_PWY]V'+'LOZ_X;\^[/Y8/^(07_ ():?]#Y^V+_
M .'8^&?_ ,Y"C_B$%_X):?\ 0^?MB_\ AV/AG_\ .0K^I^BCECV7]?\ #?GW
M8<L>R_K_ (;\^[/Y8/\ B$%_X):?]#Y^V+_X=CX9_P#SD*/^(07_ ():?]#Y
M^V+_ .'8^&?_ ,Y"OZGZ*.6/9?U_PWY]V'+'LOZ_X;\^[/Y8/^(07_@EI_T/
MG[8O_AV/AG_\Y"C_ (A!?^"6G_0^?MB_^'8^&?\ \Y"OZGZ*.6/9?U_PWY]V
M'+'LOZ_X;\^[/Y8/^(07_@EI_P!#Y^V+_P"'8^&?_P Y"C_B$%_X):?]#Y^V
M+_X=CX9__.0K^I^BCECV7]?\-^?=ARQ[+^O^&_/NS^6#_B$%_P""6G_0^?MB
M_P#AV/AG_P#.0H_XA!?^"6G_ $/G[8O_ (=CX9__ #D*_J?HHY8]E_7_  WY
M]V'+'LOZ_P"&_/NSY*_8=_8Q^$O_  3^_9K\#_LK_ _4/&NJ?#;X?WWB_4-#
MO?B%K&E:]XKEG\:^+M;\:ZN-1U/1=!\-:=/''J^O7L=BL&CVS0V*6\,K7$L;
MW$OUK115;%;!1110 5^.O[%W_*6S_@M9_P!XX?\ UFCQ57[%5\,_ 7PK^S)I
M/[:G[?7B?X6>._$.O_M(>+O^&6/^&J?!&H_:_P"P?A__ &#\)]8T_P"!W_"-
M^=X5TFU_XJOP))J&KZQ]C\3^+?\ 388_M']@R8T^5/IZ_HQ/IY/]&OU/N:BB
MBF,**** "OX2OV%O^5NS]L7Z_M"_^H5X2K^[6OX2OV%O^5NS]L7Z_M"_^H5X
M2J);P]?U1,OL_P")?J?W:T445904444 %%%% !1110 4444 %%%% !1110 4
M444 %?Y_G_!T#_RF<_X)P_\ 9,/@)_ZU7\1J_P! .O\ /\_X.@?^4SG_  3A
M_P"R8? 3_P!:K^(U3/X7\OS0GM\X_FC_ $ Z***H84444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7\>/
M_!J)\9/A#\.?V0?VN-(^(7Q5^&_@35;W]N+Q[J-GIGC/QSX8\+ZA=Z>_PP^%
M-LE_;66MZI8W,]FUS;7%NMU%$\#3V\\0<R12*O\ 8=7\W>I?\&J/_!)'5=1O
M]4N_"'QT-UJ5[=7]R8_C7K2(;B\GDN)BB#3"$0R2,54$[1@9XI.]TU;L[^=O
M\O\ AQ.]TU;9K5VWMY/L?N;_ ,-2_LQ_]'&? C_P[WP__P#FAH_X:E_9C_Z.
M,^!'_AWOA_\ _-#7X2_\0H7_  2)_P"A/^.__A[M:_\ E91_Q"A?\$B?^A/^
M._\ X>[6O_E92O+LOO\ 3_@_UN:]E][_ ,C]VO\ AJ7]F/\ Z.,^!'_AWOA_
M_P#-#1_PU+^S'_T<9\"/_#O?#_\ ^:&OPE_XA0O^"1/_ $)_QW_\/=K7_P K
M*/\ B%"_X)$_]"?\=_\ P]VM?_*RB\NR^_T_X/\ 6YKV7WO_ "/W:_X:E_9C
M_P"CC/@1_P"'>^'_ /\ -#7/^+/VJ/V;8O"WB62R_:/^!\=['X?UE[22U^+_
M (#2Z2Z33KEK=[9H?$0E6=90C0M$1(L@4H0P%?B+_P 0H7_!(G_H3_CO_P"'
MNUK_ .5E8GB7_@U0_P""2.E^'-?U.T\(?'476G:)JM_;&3XUZTZ"XM+&>XA+
MH=, =!)&I920&&1GFB\NR^_T_P"#_6YKV7WO_(_ 7_@GC_P=N_M)_!;^P_AY
M^WMX)_X:@^'-M]FL?^%M^#(=$\(_M :#81[(_M&J:=_Q*?A[\5?LEI#%;VUO
MJ"_#[Q+?7$MSJOB'Q]KEVWE2?IO_ ,%ZO^"CG[&7_!0;_@BWXR\5_LJ_'+PI
M\0[NQ^-/P,OO$_@&::3P[\5/!"2:[?02?\)A\-]>2P\5Z191WTITZW\0KIUS
MX4UB\BF_X1[7]8ME6X?^+O\ 8@_X)E?ML?\ !0_Q2/#_ .RW\#_$OC+0[348
M].\3?%'5XQX6^$'@J3=9M=#Q/\1M;%MX?CU&RLKV+5&\*:1/K'C?4=.66?0O
M#&K.GE']P?\ @HQ_P;K^$O\ @F)_P3)\2?M,_%3XVZE\7OVFIOB'\+/""Z3X
M*LO^$=^"O@?3_%>I[/$-KI:ZM9MXS\?ZM&^GRVNG>*]7;P7IK:=?SK+\/(-3
MAM-3@SO)Q?5=WZ]^NOJ9IR:>EU9Z[?\ #_GYG[K_ /!!'PY^V7;?\$FO"OAW
M4/V??@I^UC^R_P#&S3?'@^'WP_\ B'\>[_PIKNDZ3<MJ?@/QKX&\1^"/%/P?
M\<^ $^#OB?QYX=UW5]033?$IU[3;S7?&7B-?A[XMNO$$%O+]F_ ;_@EM^TS^
MRI\$O^"86C_"W7/@IX\^)7[%_P 9OVBOB7\0/!7BWQO\1_"7PHL=,_:D^'OQ
M>\):_P"&?A/XI'@OXB^,[W0?A%J'Q0AGT.S\4:+8:E\18],U35]3U;PGJ>M&
MS@]<_P"#<[_E"_\ L/\ _8K_ !7_ /6@?BU7Z&7/[;/[+%M>_M3:</C+X:O[
MS]B?P=9^//VI8=%M=>U\?!WPY?:%XV\312>()=#TC4(;_68=#^'7C&^U#PKX
M=DUGQ5I2Z2D&J:+9W6IZ1!?ZQV7HOR-([+T7Y'X@?$7_ ():_MW?$7X@:+\1
M/%^E?L<_$#XN_"S_ (*8?#C]KSP/^T_XM^(WQ5?XP?$3]G?X:?%&Y\4_#_\
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MX;\%0^);34/%'@3X>:O8RZV^BS7LNC3:%.FG+)%&FJWQ=_)^KZ* /R$^-?\
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M:ZM5NFMA*+<W, E*&:/=_:G_ ,-2_LQ_]'&? C_P[WP__P#FAK_.U_X-N/\
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M:;I&I6TAM+[[?<V&VW\]/FZI;KKYK];_ -;IW[+==7W7EU/Z=O\ AJ7]F/\
MZ.,^!'_AWOA__P#-#1_PU+^S'_T<9\"/_#O?#_\ ^:&OPE_XA0O^"1/_ $)_
MQW_\/=K7_P K*/\ B%"_X)$_]"?\=_\ P]VM?_*RG>79??Z?\'^MWKV7WO\
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MUG2/$D.C6NE^)K07NAZEJ\<>C2ZCH-A?P/$$O-<LM/MX;BXM;.YDAN[NV@E
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M]K+_ ,.[X,_^=-1>79??Z?\ !_K<O+LOO]/^#_6_[M?\-[_L+?\ 1Z/[)O\
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M_#L5[JZ2T?\ [;?^O^'?],=%%%44%%%% !1110 4444 %%%% !1110 4444
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M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K_ #_/^#H'_E,Y_P $X?\
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MC[4=)F^(?A&QT^TEAT[0]3O?"M_XBT+0M:TNAXK_ ."3_P /H_C_ .)OCK\
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M %%%% !1110!X1^U+_R;'^T9_P!D(^+W_JOO$-?QU?\ !E?_ ,B7_P %#O\
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M4444 %%%% !1110 4444 %%%% !1110 4444 %?Y_G_!T#_RF<_X)P_]DP^
MG_K5?Q&K_0#K_/\ /^#H'_E,Y_P3A_[)A\!/_6J_B-4S^%_+\T)[?./YH_T
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M^$)\&?\ 0H^&/_!!I7_R)1_PA/@S_H4?#'_@@TK_ .1*+2_F_P#)4%I?S?\
MDJ/X<O\ B-;_ .L:/_FY7_Y*E'_$:W_UC1_\W*__ "5*_N-_X0GP9_T*/AC_
M ,$&E?\ R)1_PA/@S_H4?#'_ ((-*_\ D2BTOYO_ "5!:7\W_DJ/X<O^(UO_
M *QH_P#FY7_Y*E'_ !&M_P#6-'_S<K_\E2O[C?\ A"?!G_0H^&/_  0:5_\
M(E'_  A/@S_H4?#'_@@TK_Y$HM+^;_R5!:7\W_DJ/X<O^(UO_K&C_P";E?\
MY*E'_$:W_P!8T?\ S<K_ /)4K^XW_A"?!G_0H^&/_!!I7_R)1_PA/@S_ *%'
MPQ_X(-*_^1*+2_F_\E06E_-_Y*C^'+_B-;_ZQH_^;E?_ )*E'_$:W_UC1_\
M-RO_ ,E2O[C?^$)\&?\ 0H^&/_!!I7_R)1_PA/@S_H4?#'_@@TK_ .1*+2_F
M_P#)4%I?S?\ DJ/X<O\ B-;_ .L:/_FY7_Y*E<)\4_\ @\E_X67\,?B-\./^
M'<G]B_\ "?\ @/Q?X)_MG_AKW^TO[)_X2KP_J&A?VG_9W_#+]A]O^P?;_M7V
M+[=9?:O*\C[7;^9YR?WD?\(3X,_Z%'PQ_P""#2O_ )$H_P"$)\&?]"CX8_\
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MC1_\W*__ "5*_N-_X0GP9_T*/AC_ ,$&E?\ R)1_PA/@S_H4?#'_ ((-*_\
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M_+^K*QRKS^_T_P OZLK?P2?\.3?^#H#_ *2J>)__ !8E^V=_\R%'_#DW_@Z
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M3-.CN[Z9++3[2VLK816T$42?N#7\_P!_P; _\H7OV8/^QG_:$_\ 6@_B77]
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M:O\ 0#K_ #_/^#H'_E,Y_P $X?\ LF'P$_\ 6J_B-4S^%_+\T)[?./YH_P!
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M_9XI/]5^:$_U7YH_8NBBBF,**** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH YCQM_R)GB[_L6-?\
M_35=U_.K_P &H7_*(GP?_P!EW^-W_IZTROZ*O&W_ ")GB[_L6-?_ /35=U_)
ME_P;-?MQ?L5? 7_@EQX5^'WQS_; _9<^#'CVW^-'Q@U6X\$?%C]H#X3_  Z\
M7P:9J>KZ=+INI3>&O%_BW1]9BL-0C1Y+&\>R6WNT1G@DD520GNO1_FA=5Z/\
MXG]>E%?"7_#TG_@F3_TD7_82_P#$NOV?_P#YX-'_  ])_P""9/\ TD7_ &$O
M_$NOV?\ _P">#1==U_7_  Z^\+KNOZ_X=?>?=M%?"7_#TG_@F3_TD7_82_\
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MSG_!.'_LF'P$_P#6J_B-4S^%_+\T)[?./YH_T Z***H84444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 5\=?$KP=^S'J7[:O[+_C3QWXI^P?M4>&/AA^
MT+IGP!\)_P!N7=K_ ,)#X!\0I\.Q\:=0_L&.UDL]6_L--/\ !1^UW-U;R:;]
MN)MXY_M,GE_8M?CI^TI_RFI_X)??]FQ?\%"O_1/[/%)_JOS0G^J_-?D?L711
M13&%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 5KRSMM0L[NPO(A-:7UM/9W4)9U$MM<Q/#/$6C
M9'421.R%D97 .58$ C\5O^(<_P#X(O\ _1C_ (7_ /#K_M __/9K]LJ*32>Z
M3]1-)[I/U/Q-_P"(<_\ X(O_ /1C_A?_ ,.O^T#_ //9H_XAS_\ @B__ -&/
M^%__  Z_[0/_ ,]FOVRHHLNR^Y!9=E]R/Q-_XAS_ /@B_P#]&/\ A?\ \.O^
MT#_\]FC_ (AS_P#@B_\ ]&/^%_\ PZ_[0/\ \]FOVRHHLNR^Y!9=E]R/Q-_X
MAS_^"+__ $8_X7_\.O\ M __ #V:/^(<_P#X(O\ _1C_ (7_ /#K_M __/9K
M]LJ*++LON0679?<C\3?^(<__ ((O_P#1C_A?_P .O^T#_P#/9K^ /0?^"+W[
M8'[9?[<?[5GPK_8O_9_U+2_@3\-_VJOCQ\,])^*7C2ZU3PO\#?A[X7\%_%KQ
M%X7TW1KCXC^(UU*^\5WOA;2(=+AO_#WA%/'GQ$^PA-0GT&]#37)_UKJ9'''$
MNR*-(DW.VR-%1=TCM)(VU0!N>1F=SC+.S,Q+$DIQ3MT]%N)Q3MT]%N?P7?'S
M_@V8_9Q_8"_X)@?M<_M&?&?XA^(/VB/VHO!'P0U/7/"]_IQO? WP=^&OB*:\
MT*V>[\+^%K.[?Q#XSU;2UN]5T^W\1>.=9;0]2M+BVU2#X;^&]:M8+B#]-?\
M@T%_Y1:>//\ L\7XL?\ JL_@A7Z=_P#!=7_E$3^WM_V0G5?_ $]Z'7YB?\&@
MO_*+3QY_V>+\6/\ U6?P0I))2LOY?U!))JRZ/\T?U/T445904444 %%%% 'X
MS?\ !8W3OC#X<TK]AG]H[X=_#7QI\</ /[)_[;GPY^-/QV^$'P^\'WWCOQAJ
M'PT@\+^,?"^H?$SPYX6TJ6'5==\0?"5/$%SKNA:=;R+9V^JZA:^(=7:'2_#]
MU=6_R;^V_JL'QM^#/PN_;#^"7[*OC_P7\%O@W_P5&_89_; ^)OB+_A2'C'P=
M\>OCO\//A/>0:3\5_C\/@DWA*R^*.N^'O#?A[6?!FC>'M0\0:##XPUWPYX)\
M:>+CI,'@+3?#FNZU_2710!_&S^U3K7BGXS:__P '"W_"!_LY_M9>,)/VK_@3
M_P $]]*_9[TK3?V1_P!H35]1\?7W@7X>^(+'4;Q]/LOAQ>R^";FPE\0:!XBM
M=(^(:^$?%L6EO)J!T&WN](U2VT_]%/VP/,_9V_:'_P""?_[5+? OX[>(/V/]
M&^ _QF^"7QHL?V>/A]\8?!GQ"_9U\1>*M%^",W@[XP^(O WPFL_"?Q3DT&ZT
M;X,Z'\)]<MM2LK>T\+>#=#LX;:SNKD^'M!U+^A*B@#X<_P""?WPF^"WPM^"?
MB"_^ /P-\7? #X;?%[XL>._C+IGA'XA:K\2KCX@>(;SQ<^EV-]\2/&'AKXK:
MKK/BKX=:A\0'T%/$6D_#^XNK.?0O"MUX>GU_P_X2\8ZCXF\*:+]QT44 %%%%
M !1110 5_/\ ?\'/W_*%[]I__L9_V>__ %H/X:5_0#7\_P!_P<_?\H7OVG_^
MQG_9[_\ 6@_AI2EL_1_D*6S]'^0?\&P/_*%[]F#_ +&?]H3_ -:#^)=?T U_
M/]_P; _\H7OV8/\ L9_VA/\ UH/XEU_0#1'9>B_(([+T7Y!1113&%?'7P6\'
M_LR:+^UM^VMXM^%GBG^UOVD/&O\ PSA_PU3X9_MR[O\ _A$_^$<^&FJZ9\#O
M^)+-;16N@_V]X$EU#4/]#N;K^U/+^UW'D2((S]BU^.O[%W_*6S_@M9_WCA_]
M9H\54GT]?NT8GT]?NT9^Q5%%%,84444 %?PE?L+?\K=G[8OU_:%_]0KPE7]V
MM?PE?L+?\K=G[8OU_:%_]0KPE42WAZ_JB9?9_P 2_4_NUHHHJR@HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH *_S_ #_@Z!_Y3.?\$X?^R8? 3_UJOXC5
M_H!U_G^?\'0/_*9S_@G#_P!DP^ G_K5?Q&J9_"_E^:$]OG'\T?Z =%%%4,**
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH *^,OB;\8_@1X:_;=_98^"G
MBWX3V_B']H#XH?"W]HKQ/\'_ (OOX1\':C<_#?PA\/$^'+?%#PY!XQU*X3QK
MX:3QXOB+PN)M-\+VT^EZ]_8*#Q"\0L-.W_9M?D[^T+X&\;:M_P %??\ @G!X
M^TOP=XIU+P+X0_9R_;NTCQ9XTT_P]JUYX2\,:KXGA^ P\-Z9XB\1V]I)H^BZ
MAXA.F:D-#LM2O+:YU8Z??"PBN/LEQY:?ZK\T)_JOSU/UBHHHIC"BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MHH **** "BBB@ HHHH **** "BBB@ K_ #_/^#H'_E,Y_P $X?\ LF'P$_\
M6J_B-7^@'7^?Y_P= _\ *9S_ ()P_P#9,/@)_P"M5_$:IG\+^7YH3V^<?S1_
MH!T4450PHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KX1^+7[5'C7P
M!_P4!_8^_9+TO0/"UYX%_:(^$'[4/Q#\5^(;^'5F\6:-JOP.C^%K^&[/P]/;
MZK;Z/%I^JGQSJ8UQ-2TC4;F06MC]@N;';<?:/NZOS?\ C9^SU\5_&7_!3;]A
M7]H_P]X>MKSX1?!/X&?MA>"OB-XC?6]$M;G1/$?Q:C^#J^!;*#0KJ_AUW5DU
M8^$M>\Z[TG3[RTTW[&G]I36OVFU\Y/R[K\U?\!/R[K\U?\#](****8PHHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M #/]"RBOX2O^&Z?^#NS_ *,Z/_B/7@K_ .:VC_ANG_@[L_Z,Z/\ XCUX*_\
MFMHYUVE]W_!\U]X<WE+[G_7_  S\K_W:T5_"5_PW3_P=V?\ 1G1_\1Z\%?\
MS6T?\-T_\'=G_1G1_P#$>O!7_P UM'.NTON_X/FOO#F\I?<_Z_X9^5_[M:*_
MA*_X;I_X.[/^C.C_ .(]>"O_ )K:/^&Z?^#NS_HSH_\ B/7@K_YK:.==I?=_
MP?-?>'-Y2^Y_U_PS\K_W:T5_"5_PW3_P=V?]&='_ ,1Z\%?_ #6T?\-T_P#!
MW9_T9T?_ !'KP5_\UM'.NTON_P"#YK[PYO*7W/\ K_AGY7_NUHK^$K_ANG_@
M[L_Z,Z/_ (CUX*_^:VC_ (;I_P"#NS_HSH_^(]>"O_FMHYUVE]W_  ?-?>'-
MY2^Y_P!?\,_*_P#=K17\)7_#=/\ P=V?]&='_P 1Z\%?_-;1_P -T_\ !W9_
MT9T?_$>O!7_S6T<Z[2^[_@^:^\.;RE]S_K_AGY7_ +M:*_A*_P"&Z?\ @[L_
MZ,Z/_B/7@K_YK:/^&Z?^#NS_ *,Z/_B/7@K_ .:VCG7:7W?\'S7WAS>4ON?]
M?\,_*_\ =K17\)7_  W3_P '=G_1G1_\1Z\%?_-;1_PW3_P=V?\ 1G1_\1Z\
M%?\ S6T<Z[2^[_@^:^\.;RE]S_K_ (9^5_[M:_S_ #_@Z!_Y3.?\$X?^R8?
M3_UJOXC5Z=_PW3_P=V?]&='_ ,1Z\%?_ #6U^?/QV_9>_P""^?\ P4!_;._9
M@_:%_:__ &+/B#_:OPG\1_"KPFNM^%_A]X<\':+I/@'P[\59O&]Y=:E96/B&
MZ6>6RN=>UN[N+WF0VBQQ",B%<J4KII)ZVZ>:_P"!]Z!N]E9[KIYIG^EW1116
MA04444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5^.G[2G_*:G_@E]_V;
M%_P4*_\ 1/[/%?L77Q3\4-"_9:N_VYOV4O$'C[Q+J%C^UCH_PJ_:0L_V>?#$
M,OB!=.U[X?:HGPV'QOO[V*STFX\.23Z,EKX'-HVM:QIMZGVV;^R;:_)N_LZ?
MZK\T)_JOS1]K4444QA1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %?CI^TI_P IJ?\ @E]_V;%_P4*_]$_L
M\5^Q=?&7Q-^,?P(\-?MN_LL?!3Q;\)[?Q#^T!\4/A;^T5XG^#_Q??PCX.U&Y
M^&_A#X>)\.6^*'AR#QCJ5PGC7PTGCQ?$7A<3:;X7MI]+U[^P4'B%XA8:=O3_
M %7YH3_5?FOS/LVBBBF,**** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ K\=?V+O\ E+9_P6L_[QP_^LT>*J_8JOC+X)?&/X$^-?VO?VW_
M (2> /A/;^$/C;\%/^&:O^&@?BE'X2\'://\8/\ A9'PQU;Q-\*?M/BK1;B3
MQ;XQ_P"%?^$K6]\.P_\ ":V]M_PCR7)T[PWYVF2RN$^GK]^C$^GK]^C/LVBB
MBF,**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M% !1110 4444 %%%% !1110!^9'_  5W^,7QG^!_[$?CKQA\$V.F>(=2\=_
M7P!JGBVS\77'A+Q!X7T#XJ?M#?";X7ZR_AJZM-$U2\35]>T?QEJ?AR#7-/OM
M%U;P:=37Q;HUW-JND6EN_P N?!#X_P#@7]D[XE?\%-+-O@A^UY<^)_V;/A!\
M*OVB_B;X*\9_M3VW[0/A_P#X0[7+/XLZVGA_]EZP^)WQ1@T'P=\.M(L/#7C#
MXCZC_P )+JG@OQSK.I>(]9\/Q>#8['PW\/\ PP_Z#?M\_LL>-/VS/V?+_P"
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MA[XO@\/^+M!U^STJ<6.E>/-,U>SBFL+RYT>*WG6^D>I^T'_P4W\ _LJ?%O\
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MXEU*\;3;ZZU< \N^-'_!9SP?\"?"OQJU?Q1^SK\0/&.K_"+X<> /BP)?@_\
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M3HUC?W&LZ#_8_B&^MK*'^W;'3O[420W>E_:[5'F7]'Z_+_\ 95^,/Q.\:?\
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M7^+VHZ1=2VEE:R^()]+\2V>E:YK"3:M;>']"BGCTNU\+\8_\$K/'WC3X#?\
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M=?O_ (4:Q8^'I-/^'WA+P]X^\*ZYX$\/W5Q9>(/&OQ$UJ33O$6A 'U/\9O\
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MM\1=!T?P_P"$?#7B3PIXJMO'^F^T>&/^"GOA'XCZA^P)XC^&/PH\0Z_\ O\
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M59+[49+*PAEU'4)AY]_>R3WDY::9V)0!Z-1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %?%7Q0_99_X3[]N;]E+]K+_A86GZ-_PSS\*OVD/A[_PKB;1?M6H^
M-O\ A=Z?#9/[:LM<_MNU_LJ#PG_P@^;NU_L+5O[2_M>$?:]-^S9N?M6OQT_:
M4_Y34_\ !+[_ +-B_P""A7_HG]GBD_U7YH3_ %7YH_8NBBBF,**** "BBB@
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M1'[17B5?A?I'_!PO^S_XLT2XU7XS?M,Q> ]1_9TTBZTZUA\7?'[2OVJ/V:?
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M<^%_QY^&>F?$;XX_%;PI\-/VDOV%;^WU2U^%7QKTCXWW?BL?#GX@?#V8R/\
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M6$^HW=OH?AS1XI+J^O&@MWVM*]II]JH:ZU._L+"&XO(?RY_X)T?MA_LFV?P
MT2Y\5>.O"OPU_:.\=_M,ZG\#_P!I7P)XE\:VGB;QA'^W?XY\:>+X?$7@'3WT
M[5O$42>#?%OB[2/%=Y\ K?1KB'P.GPOM](L_#@L(M-U"QL_T+_; \3>'/!_[
M*7[2/B+Q9KVC^&= T_X'_% 7VM:_J5GI&E6C7O@W6-/LDN+^_F@M8I+V_NK6
MPLXWE#W5[<V]I LEQ/%&X!G^'OVI_"'BK]D[X<_M=>'?!'Q2\1>%/BM\(_A?
M\6_ _P -O#'A.+Q-\7]<M_C!H'AS7/!/@VU\,:)JMYHX\5W+^*=*TS5[J?Q+
M!X)\,N-1U_Q+XQTCP9H^K>)[+"_9(_;'\#?M>Z7\6#X>^'_Q:^$7C?X%_%/5
M/@Y\6_A1\;?#WAWP_P"/_!?C/3='T?Q!"+A?!OB[QYX0UC0]<T/7M-U?P]KW
MAWQ=K&GZKI\ZW,<B*R;_ )T_86^.7P6^%O\ P26_8-^('Q+^-?P^^%7@.V_8
MX_9.\#7GQ*\3>-/"&@>'?#WC"]^$/@3P=%I<VO>)IIO#-IX@T[Q1YFF3:?K,
M<\-CJEG<V^L6/DV=]$GS;^PI\4=!_9/;_@H[XW^,O[6GP_\ BI^Q3X<_:@\%
M>(/ _P"U]XOD^'6FZSX@^+_QJT[PZGQP\._$OQW\+_#7A;X>>,+;P%X_\6?#
M'X;:#XIT32[;0?!4=MJ'PG\OPEHOPH7P=X, /OS]HC]MFP^!/Q$TWX4^%/V;
M/VHOVI/'C^$]+\<>+="_9E\&_#OQ.WPR\+^)M9UW0/ NJ?$&]^)'Q5^%FGZ8
MGC_5?!_CRW\*PZ1=:Y<2IX$\2W&L1:-;)I,NJ\G\<?\ @I%\$_@-XV^*_ACQ
M%X1^*GB;PU^SCHOPL\0_M4?%3P1I7@K6? ?[-&E?&.YG'@H_$BRN_'FF?$?7
M=0.B10^./$>E?";P!\2;[PE\/[[3O%OB*+3['5M&74OSA_X*(?"#]D/Q?\;?
M%OQX_9!^/FD^ /\ @LKX,\0_!WP[X!T[X5_&NXUGXA_$+4O$.D^%XO"'PK^*
MO[/MSXCUK1_$'P,U_P"&M[;>,_B!J=AX(TZQ\.?#[P]K7Q-\2^($\)>&_&HO
M?(_VBO$J_"_2/^#A?]G_ ,6:)<:K\9OVF8O >H_LZ:1=:=:P^+OC]I7[5'[-
M/@3]F3X5:%\+=%DCTN[\<V?PV^,>F:AX"N[[0CJO_"/Z\EQ)JRB[9I=2 /UW
M^-G_  4G^!?P.\9?%3P_J_AKXF>,_!_[/&A?"GQ/^T]\8/A[IW@K7OAS^SGH
M7QHGF;P)=^/[:[\=Z5\1_$-Q<>'TM_'NNZ=\)OA]\2+[PK\.]0TOQ?XB@TZQ
MU?1DU']!+>X@NH(;JUFBN;:YBCN+>XMY$F@G@F19(9H9HV:.6*6-E>.1&9'1
ME96*D&OY)I]%UG]E?]FS_@M/^Q;\4H[GQK^T3\3_ (-_L\>$?@I/=VL4OB_]
MIB;X[?L;?"K]D+X?P?"VPO+;1-1^(5GX(^./AK5_!]WJVD17\NBZ_)<7&M01
M7TDC:C^S/[6WP_\ %/P@_P""-WQV\#WWCCQC9?$/X"?\$[_&RV_Q"\!^/O&G
M@CQ0/B-\$/V>+^^TSQ38^,/!VK>&/$LD<WBWPI;:G?V<UU%IOB6P>YTCQ)I>
MH:+J6I:7<@'ZBUQGQ%^(7@WX2^ ?&?Q0^(FNVWACP'\/O#&M^,?%_B&[AO+J
M'1_#OA[3[C5-6OC9Z=;7FI7TD%G;2M!I^F6=[J5_/Y=GIUG=7L\%O)_']X0\
M5Z!\#/A=^S5XT_9W_:)_:8\;^!?&/_!&G]I'XW?\%&[?X7?M)>,_BQXM\('3
M?@=\)_#?P>^(GPST?Q5XB\7>"/@I\:O"_P 3M0\5>#O ]QH>C^%=/\$>#/A[
MK41TJQT+P#XA9?F_]HWXD> ?'/P/_P""M7@70O$_PX\7_#;7OV?_ /@G9^TS
M\*/ 'P:^(OCKX]_"G0=6\+_%S5O#WQ^^*7@;QGK>FZ<GB.[TF'2CI?QU^*.D
M>"/A_HUQ\1/*\/>,-'@^(MN7U, _N.NO%&O0?$71/!D/P_\ $MYX9U/P=XD\
M2W_Q1AO?"Z>$-!UO1=9\,:;I7@;4-.GU^+QE/X@\3V.N:MKNF7FG^&;OP[;:
M?X5U.'4]:L]0NM-L[KMJ_ .7QGX L_\ @KC\!+']FGXB:'J_AKQA_P $O_VA
M-:^%/@B+XM>(-2^"^J^*_P#A9WPC;X>ZOX%\&S^(M3\&Z%I/C'P_I!UN+Q+\
M.O#]I#X_\)6S^-8;KQ+IXM]7?\PO!GQW^%'Q<_9#U;XKV/[;'Q$\#_M7?#3]
MA7]J31OVP/@?X&UCXG_!3XJO\8O!/P=:;4/B9^UKXAU_X[KXE;4?A]^TQ;>$
M?"?P@^(7@G0O#DOBS6_BC#\(+#PN?ASK'B3P=X" /[,[FYM[.WGN[N>&UM+6
M&6YNKJYE2"WMK>!&EFGGFE98X888U:2661E2-%9W8*"1S'@'QUX5^*'@3P5\
M2_ FK+KW@CXB>$O#GCKP;KJ6E_8)K7A7Q;H]GK_A[5DL=5M;'5+)=1TC4+.\
M6TU*RL[^V$PAO+6WN$DA3^-G1K+X=OHO@[X>>!/BGXC^)5O^U!_P;>?%;Q9\
M2OAUK_QU\8?%S2O&WQR\%^$OA_=> ;G2O!/BGQEXET_P]XL\/74?C#2?#7AG
MP?I>BV>BZ;I.O:)HVA6-G::W;M] :]\0M L_V&_^"<6M?LX>)/@Y\1_ 'A/_
M ()_>/OB'\=/V:-9^+WBKX"V'Q<TKP1X _9KO?BY\7/@;\=/">H6/ASPE^UI
M^S!XPT.^L(;SQ3+-/X7C\5_%_2+._P#"WB[POXNMX #^F?P;\=?"WBKXM_$7
MX%7]CJWA+XJ?#K2-$\9S>&=>6Q(\6?"WQ9J_B#0_"7Q0\%ZEIUY>V6L^&=3U
MCPOKV@ZQ9226?B7P?XATUM/\3Z'IUEK/A+5O$OME?@YX@U&\7_@H?_P0QU7X
M6>&OB1X9M/%_[''[7^F?%?0_'FD06WQ'\/\ P%MO@K\ /$G@C0_C9%HXN+#1
M_$6@?&-/ NFZE;HT6BQ>.KG5+*VO?M#Z9:WO[QT %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ KX(^+O[4OQ!\ _P#!0K]C?]DW1]'\
M'7/PZ_:&^#O[4WQ"\::UJ>GZW-XUTO6O@A'\*W\*6OA?4;7Q#9Z%9:7J!\<:
MM_PD,.K>'-;N[L6^G?V;>Z3Y-R;O[WK\W_C9^SU\5_&7_!3;]A7]H_P]X>MK
MSX1?!/X&?MA>"OB-XC?6]$M;G1/$?Q:C^#J^!;*#0KJ_AUW5DU8^$M>\Z[TG
M3[RTTW[&G]I36OVFU\Y/]5^:N)^7=?FK_@?I!1113&%%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 5\$_L^?M2_$#XL?MR?\%#/V9_$6
MC^#K+P'^R9_PR9_PKG5M%T_6[;Q=K7_"^/A#K7C_ ,7_ /";7]]XAU'1M1_L
M[6=.@MO#?]A:#X;^QZ8\L.I_VQ=,E['][5^<'[,W[/7Q7^''_!0G_@IQ\>_%
MWAZWT[X7_M(?\,7?\*AUZ/6]$O[CQ)_PI_X(Z]X,\?\ VG1K&_N-9T'^Q_$-
M];64/]NV.G?VHDAN]+^UVJ/,J?3UU^Y_K86NGKKZ6?ZV/T?HHHIC"BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %?E_P#LJ_&'XG>-/^"E'_!5SX2^*?&>LZW\-_@K_P ,+_\ "JO"%[)"
MVD>!_P#A8_P%\1>)?'']B1I"DL7_  DNO6MOJFI>=+-ON8D:/RU!4_J!7XZ_
ML7?\I;/^"UG_ 'CA_P#6:/%5)[KU_1B>Z]?T9^Q5%%%,84444 %%%% !1110
K 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>27
<FILENAME>nt10014672x1_linechart1.jpg
<TEXT>
begin 644 nt10014672x1_linechart1.jpg
M_]C_X  02D9)1@ ! 0$ P #   #_[0 V4&AO=&]S:&]P(#,N,  X0DE- ^T*
M4F5S;VQU=&EO;@     0 ,     !  $ P     $  ?_B"^!)0T-?4%)/1DE,
M10 ! 0  "]!N;VYE @   &UN=')21T(@6%E:( ?4  < %0 3  L (6%C<W
M         $E%0R!S4D="     0            #VU@ !     -,M2% @(
M
M$&1E<V,   %$    =&)865H   &X    %&)44D,   ',   (#&1M9&0   G8
M    B&=865H   I@    %&=44D,   ',   (#&QU;6D   IT    %&UE87,
M  J(    )&)K<'0   JL    %')865H   K     %')44D,   ',   (#'1E
M8V@   K4    #'9U960   K@    AW=T<'0   MH    %&-P<G0   M\
M*&-H860   ND    +&1E<V,         &G-21T(@245#-C$Y-C8M,BTQ('=I
M=&A"4$,
M                                                    6%E:(
M     "2@   /A   ML]C=7)V        !      %  H #P 4 !D '@ C "@
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M;W5R(%-P86-E("T@<U)'0@
M
M      !865H@        8ID  +>%   8VEA96B            !0
M;65A<P         !                               "6%E:(
M  ,6   #,P   J1865H@        ;Z(  #CU   #D'-I9R      0U)4(&1E
M<V,         +5)E9F5R96YC92!6:65W:6YG($-O;F1I=&EO;B!I;B!)14,@
M-C$Y-C8M,BTQ
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MU=;7V-G:X>+CY.7FY^CIZO'R\_3U]O?X^?K_Q  ? 0 # 0$! 0$! 0$!
M     0(#! 4&!P@)"@O_Q "U$0 " 0($! ,$!P4$!  ! G<  0(#$00%(3$&
M$D%1!V%Q$R(R@0@40I&AL<$)(S-2\!5B<M$*%B0TX27Q%Q@9&B8G*"DJ-38W
M.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U=G=X>7J"@X2%AH>(B8J2
MDY25EI>8F9JBHZ2EIJ>HJ:JRL[2UMK>XN;K"P\3%QL?(R<K2T]35UM?8V=KB
MX^3EYN?HZ>KR\_3U]O?X^?K_V@ , P$  A$#$0 _ /[^**** "BBB@ HHHH
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MHU[K[G_F&G9_>O\ (^6_^&T?V;?^B@7W_AOOB9_\QU'_  VC^S;_ -% OO\
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MHU[K[G_F&G9_>O\ (^6_^&T?V;?^B@7W_AOOB9_\QU'_  VC^S;_ -% OO\
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MHU[K[G_F&G9_>O\ (^6_^&T?V;?^B@7W_AOOB9_\QU'_  VC^S;_ -% OO\
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MUI-LGB65"Z+N&3WO+[O_ +;^K/RN:=G]Z_R/5/\ AM']FW_HH%]_X;[XF?\
MS'4?\-H_LV_]% OO_#??$S_YCJX3_A ?^"D?_1U_[$'_ (KY^//_ -,UKQ#]
MH#X@_P#!0?\ 9I\$:9\4/$WQT_8V^)/AZ'Q[X \,:UX1T+]B[XV_#O6=0TSQ
M=XHT[0+R32_%^H?M_P#Q%L='OK6&]>XMI[OP;KEN9459;1T)HU\ON_\ MOZL
M_*[23:23NVENNOR/NGX7?M!_!WXSZKXHT+X:>-K/Q+K?@NVT.\\5:,--US1]
M5T.S\3'5!H%W>Z?KVEZ7=I;:L=%U864Z0O%,;"Y ?,9%>RU^=/P6_P"4F/[=
M7_9 ?V*?_2K]HJOT6IK5?-K[FT)Z/Y)_>KA1113$%%%% !1110 4444 %?F_
MXO\ ^4O'[//_ &C?_;(_]:<_83K](*_-_P 7_P#*7C]GG_M&_P#MD?\ K3G[
M"= UM+T_5' _\$^KCXDVO[(GC2;X4:;X1U7Q@/VI/VEQ;6?C:]U/3]!:S/QJ
M\7?:WEN=(BEO%G1=A@54*,2P<CBO5_\ @G3KG[16N? O0+GXVV/AL:>;KX@?
MV/JT6K>)=0\:WM]%\4_&%O/!XAAU^&-8;"T@C:VT5X79VTN#3LJJ' \<^#G[
M/'_!1']G/1/%W@+X5^+/V0=;\"ZI\5/BA\0M!N_&Z_%R#Q/%:_$3QIJWBT6.
MJQZ-H4VFBXL/[3^RL;2:6)O+W*[9R?6_L7_!53_H*?L+?]_/CA_\SM>I0S2-
M')\7E+R_"5)XK%X3$K'SA-XJ@L-2Q5-TJ;4U%J?UJZDU:"A44H5'.$J63H\U
M6%7VK7+"4>2_NOG<'=Z=.7IO?=6=_'_V[_B%%X&_;'_8.3XZ^(T\%?L3:E:?
M']_B%XHUO5I?#OPO/[0EIH'A)?@=HGQH\22S66AZ1X7OM$N?B1+X1M?$VHVW
MAWQ!XRAM]/U%+FYATRVG\-^*_P"U[X5_9O\ 'WAGX3_LP?$#X<>"_ /QSD\6
M?%OP%\5/B?K.KZ_\)OB-\3X/%OAW1/$OP6^%NKO;ZI;Z\M_X>LDN/"GAOX>Z
MI]LO]:U62Q\++=7$$M@OVE]B_P""JG_04_86_P"_GQP_^9VC[%_P54_Z"G["
MW_?SXX?_ #.UY-WYZVZ;?#IY=;_/MKNK:*Z?E=I/6]VK>:W[>6GYCZ)_P5'_
M &AH5O6E^*G[-_C34]?T_P#X*&Z3X:TN*]T3PGHFE:Y^R)^V)J?P:^'^L3^(
M'U#57CB^(7PT@35X8]8@.E-;7'AW7O-6TNM0OYN@'_!4_P"/.N_#_P :>(?#
MUGIOAWQCX(^ /A?XQ_"[P-X^\*Z3;:U^U7XUF^-_C3X?^.?@]X*?0-5U33-3
MU/0-.\,>$_#VE7?PZOM1O=5UWXF:#KRQ#1;S3B/T8^Q?\%5/^@I^PM_W\^.'
M_P SM'V+_@JI_P!!3]A;_OY\</\ YG:6OGM;;RCKOON_)WZ(>G]V_>]NW3EM
M_3\S\]=7_P""DWQS\,:'XO\ &/BWXM_!?1? 5_\ M>_$_P#9;M_B%<V.BZ1\
M._@9+X2T@ZGX/USXD>,KF36]-L9/%.H7<>AR77B<V6BQ3Z1=K]JMI[I'C\FT
MS]LSQ#^T1^U)^Q!!\6/B#\//"/Q(^&/[8D/P\OOA+HXN/#>I>)/"VO\ [)ME
MXJTKXZZ?I?B2[L?&$OP[^,'BGQ+J%U\/&U/21I(T)=$T?S7\5VFL(?UC^Q?\
M%5/^@I^PM_W\^.'_ ,SM'V+_ (*J?]!3]A;_ +^?'#_YG:>OGNGJO.+_ ,_3
M7L'N]%%:6O=WUMWCVT^_K<I?\$SO^29?M(?]GY?MF_\ J[/$%?HY7QW^Q#\
M_B+^SS\)_%OASXL:_P"#?$7C[Q[\</C-\:/$-UX!CUF/PI97?Q8\;ZCXN_LC
M2?[?MK359(=,6^%J9;JW1G921N7#'[$JB'O\DON204444""BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ J"Z_X]KC_KA-_P"BVJ>H+K_CVN/^
MN$W_ *+:@#\%-.^$OA+XZ?\ !%[P9\)O&]M)+X=^(/Q5\*^"=1NK0K#JVE67
MC+]OBT\)ZGJ.A7VTS:9J\6DZW?Q6M];,DT8GDC+&*65'^$_VD_VA_C!\7/\
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MCT#]H#X@:QX;\4>'=2C!ET[7= UBSM=1TZ[C!VRPF.59()98W^X-&^%'C]-
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MHJOT6K\Z?@M_RDQ_;J_[(#^Q3_Z5?M%5^BU"V^<OS8GO\H_D@HHHIB"BBB@
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MH5ZM7ZK[3!XG#?6,34H5O;RPDOJ-*$,)*.-Q7U;%8CGPU5XFM3IPP7US&*>
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MC1+K_2M'\1>&_$6DW^FZE83Y*O$D\$D]K/;SR_'?B_\ Y2\?L\_]HW_VR/\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M:2OS+1IE/X+?\I,?VZO^R _L4_\ I5^T57Z+5^=/P6_Y28_MU?\ 9 ?V*?\
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M3]J7_P">A1_P[N^$O_19_P!MK_Q.3]J7_P">A7WM10.[[O\ K_AE]Q\#1_\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M.G"52I-J*;4*<(RG.3]V$(RE)I)LT;2W:6J6KMJW9+U;T2ZLZ:BBBH&%%%%
M!1110 4444 %%%% !1110 4444 %%%% !17+V?C7PKJ'BW6? EGK=E<>+_#V
MEZ9K6M:!&TAOM.TK67GCTN]N%,8C$-Z]M.L)61F)B;*KBNHJYTZE-Q52$Z;E
M"%2*G&4'*G4BITYQ4DFX5(-3A)>[*+4HMIIB33V:>K6G=;KU74****@84444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M"IUYM>_X2(_'G5CXK!:PBL/['&M_V5YHT$"+[8NF>5L%_)+<[]SE:^P**?\
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M_P!CT_\ H<Y+M6?^\XG_ )<S4$O]TWK)\]'^:";ER-6%[5_\^:V\5\,>JO\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M(M1U3PY:/H.GO?0"WM]:,E[<7!TUTNB_3^NG^:';K_7]:/;L?HG7YO\ B_\
MY2\?L\_]HW_VR/\ UIS]A.NF_9>_;'3Q3^Q#X0_:I_:PU#X?_!3RI?'NF>._
M$O\ :\NF?#*X@\#_ !3\7_#;1_B#X9U77)?/'@KXG:=X;TSQWX.EN9Y_M&@^
M*-+>WN;RWDAN9OEGX:_M6?LW?M0_\%;O@[??L[_&SX=?&6T\(?\ !.?]K>U\
M47'P^\2V'B*+0;G5_P!IC]AZ;2X=3:QDD%K)?Q6-X]JLF#*MM,5SY;85UIJM
M=OF.SM+TM\[H_:"BBBF2%%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 (W((')P>,XSQZ\X^N.*^<_ GBKQCX-\.S>'-9^#7Q0GO](U;QU.+
MG3O%/A3Q[8ZI;/?:_P"*])ETSQ1K_B#PAJUXNMV\]GHVFV&H^']+CT'7+J+P
MY)<2^']+3Q1<?1M%<6)PDZ]:A7I8JKA:E"%:E>G2PU15*=>>'G.,O;T*LXVE
MAJ=O93IIWESJ;5-T_5P.94L)AL7A*^78;'T<55PM?]_7S"C*A6PE/&4J<Z:P
M>,PU*?-#&U>;ZQ2K2BXP]C*E&5>-;R)?BCKC?:R?@K\74^S2ZO''NM_AW_IJ
MZ7X9T#Q#!-:!?B*W[K6[S6[KPGI'VG[-(WB;PWKZ:C'IVA+H^NZQ#=_%;7K:
M#69H_@=\8[UM*T;Q!JMO;VEM\-O/UVXT,Z0+70]&^T_$JVB;6?$O]J3GP^NI
MRZ9IC#1=7_MG4]&*Z<-1]CHK-X3&N]LUQ"OM_LV!T]U+KAM=4Y:O>37PI16\
M<SRM2IM\.9?)124HO&YRE4:=VY..8IQ<EHU!P2M=).YY5=?$O6K:;48D^#OQ
M6O%L)M3BBFM;?P 8=473M:T[289M.-Q\0+>1H=6M[^77M,-['92'1=+U%K^.
MPU,66EWL,?Q/UQUE8_!?XMQF.&YE5)+?X>;I6M_&=SX32&+9\1'7SKK3[=/'
M=L)&CC/@R[MI)Y(/$QG\,0>MT4/"8SFD_P"U<0DXM*/U? VC)O2:?U:[:6EF
MW%]5WE9CEJA&+X?P#DJD9RG]<S=2G!+6DTLPY5&>[E&*J)_#-+1_GO#^UC\3
MI/VK)OA8W[._[0$?@P?#W1+D63Z+\%0;?4[SXB^(/#=S\2Y=13XM-J)\"MI-
MI:R"W2677U@L;J6/PA]N=8KC[>\$^*X/&_A?2?%-MI>IZ+!JT=Q)'IFL2Z+-
MJ5H+>\N;)ENI?#NL:_HSM(ULTT9L=7O4$4D8E>.<2P1:O]AZ,-;;Q+_9ED-?
M;2X]%?6/(C_M!M(ANIKZ+3FNL>:;..\N)[E("VQ9II)  SL3YM\!9K"?X2>#
MI=+EL9[![;4S;RZ;?^%]3LG US4PY@OO!8'ABX42AP[:4/+20/'<?Z8EQ7F9
M=1S+ YB\-C<TJYC3QD<UQM)5*5*'L*=+$Y;"A34H4XR7)#%5%[.,E25_<AI>
M/T?$>8Y!GF3X?&Y/PM@.'*N50X=RC%SP6)Q]5YAB:N!SJ>+Q=6&+QN(AS8BI
M@:51U/9^W;3]I5?,U+UZBBBOI#X(**** "BBB@ HHHH **** "BBB@ HHHH
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M".S\->%?"GP\L_%'C7^P-%\.Z-:V>GP17'BK69IYDGGCELK.2TTNQ^0O%_\
MREX_9Y_[1O\ [9'_ *TY^PG7Z05^;_B__E+Q^SS_ -HW_P!LC_UIS]A.@%]K
MT_5'Z04444""BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "O M)\"?&?PMIMYH'AOXD^$[S2+2XOAX9NO%W@>?4?$$%
MC<Z0[P1^(;O0-?\ #6DZI=6_BJ>:^,^F:)H<,GA];?1S;#4(Y=:G]]HKCQ6!
MHXN5*=2>)ISHJI&$\-BL1A9<E;D=2$GAZE/GC)TJ<K3YK2@G&SO?TL!FN)RZ
M&(I4:>"K4L2Z,JM/'9?@L?#GP_M/8U*:QE"M[&I&-:M!RI<CG"I*,^962\[^
M&VL>*-9TSQ!)XL-NU_IOC?Q?HED]KH&I^'89=&T?6)['2YEM=5N[R:^$]M$L
MHUBVE73]35UNK&)+=DSZ)7D'PAMAIFG>.89U-J]S\6OB;J"1W'AX^%WDBU#Q
M??RPW"6TOB?Q.VKPW)D5H?$JSZ1'XAW#4(_#7A_SQI<'K(N;=B )X220H E0
MDLS%54 -DEF5E ZE@0.0:SRN<Y9?A'6E)U727.ZE7VLVTVKRJ-MS>UY-MZZF
MV?4J5/.,QCAHP^KQQ,U2=&A]7H\ME;V=%1BJ<==(**MV)J*@%S;$@"X@);&T
M"6,ELE@,8;G)1P,=2K ?=. 75L<$7$!!VXQ+'SO5G3'S<[D5G7^\JLPR 2._
MFC_,OO1Y/++^67W/_(GHKA_#/Q%\)^+M7\8:'HFH^?J'@;68M!\0QRQ-!'!J
M,NFV^K*EM+)A+R$65U#*T\!:)264L"K8['[3;<_Z1!P,G]['P-@?)^;@;&5\
M]-A#="#65+$4*\/:4:U.K3YZD.>G.,H\]*I*E4CS)M<T*D)4Y+>,XN+U3-\3
M@\7@ZOL,5AJ^'K>SH5O95J4Z=3V6)HT\3AZG+))\E;#U:5:E*UITZD)Q;C)-
MST5";FV&<W$ P')S+&,",*9"?FX$8="Y/W0ZEL;AF565QE65AZJ01^8R*U33
MV:?HSG::U::3V;30M%%%,04444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% 'YT_
M!;_E)C^W5_V0']BG_P!*OVBJ_1:OSI^"W_*3']NK_L@/[%/_ *5?M%5^BU);
M?.7YL;W^4?R04444Q!1110 4444 ?G;^V;\6_B!H_P"T#^P+^S9X+\2:UX"T
MC]I[XN_&*#Q_X]\.R6]OKMAX8^"'[//Q!^+EGX4TF]N[:ZM[";Q?XIT;P_\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M95,+BJ=K0ISJ9>U]_D<7\2BI73U<)2U2V:4=5VE%]6E]84445X9J%%%?E/\
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MBD90RLI+ ,I4E6*L 1C*LI#*PSPRD$'D$$5PEBT5^;O@_5(/$'P"^*DOQ/\
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MD.UW9UV89F().S7@3BX3E!VO"4HNS35XMIV:T:NM&M'N;)W2?=7"BBN?\5:
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ME)/?6NC:7!'<>*+BRU,VCR6VCV%H\5SXB!N8]/M[-TN-45+9A(??*^,OVB?
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M555F+L%4,Y !<@ %B!@ L>2 ,#.!Q3J],^1"BBB@#RR'_A3X^)]RT'_"&_\
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M>(WN);>PA6%))2OB *&?!;:H"H"$4;5%=G_P]6\)_P#1D?\ P4H_\1"\2?\
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M&2/2K^#Q0T_A#7?$&GRVEGXET=QMD\.:TEJT1A>$5^BX_P""JWA, #_AB/\
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MT?PUX6T6#['I.G6\?-Q=:GJ5P\EYJ=RQ]U_X>K>$_P#HR/\ X*4?^(A>)/\
MYH*TP/UI8:'UUIXERK.5N72$JU1T(R=.$*?/&@Z4:G(N7G4K2FESO3 PQJPT
M?KSA+$.IB)-PY4E1EB*LL+"7*HQ]K#"NC"LXKE=6,W%RBU)_J=4%U+)!;7$\
M5O)=RPP32QVL+1K-<R1QLZ6\33/'$LDS*(T:61(PS NZKEA^7'_#U;PG_P!&
M1_\ !2C_ ,1"\2?_ #05!=?\%5/#<EM<):?L4?\ !26"Z>"5+:>3]C[Q'+'#
M.T;"&5XO^$A'F+'(5=H\C> 5R,YKK;T>^W1:_*ZM?7KIWV9UN$K/1[=&K_*[
MM?UT[GN-U^V1J/@&#XMCX[_"=OA]J'PZ/P[_ .$:L?!_CJV^(R?$.Z^+.JMX
M?\ ^$["]OO#7@&#1/B%J&OFUTS6/#UV+O0=#CO;?6)/&%WH(GU.#ZL^'/BRY
M\;^$-+\27B>%8;N^^T)<V_@SQ<_CC0;6YM;B2VN+2W\22:!X8:]N+2>*2WO%
M_L>V6"YCDB5IE42M_/'J/[;_ (9%[HO@3XM?"'_@H-J/Q#\8?$?P[\8?A''_
M ,,07.A>)-6^(/P7U_3_ !M>:C]CD\527/BW3-+TF/3-&U/38D6/1_#=Q(UN
MUM++%,GUI\)O^"@_@3X5Z'KVFVG[%W_!2N^N_%7C?Q7\0-=N/^&/?$-O;-K_
M (OU)M1U&.PM4\0E;:RA/E11*2TL[I)>7+O<W,S'Q<!+-G77UM3^K>RJ?Q?J
MD:T:DJ]25-5?JO-"4X4'2II4E3IN*=6;E4DX0\7 0SB.(MBY3J83ZNW"598.
M&(5>6)KR_??54J4G"@Z%*"I0IPM"52<JE2;4/V@HK\L?^'JWA/\ Z,C_ ."E
M'_B(7B3_ .:"C_AZMX3_ .C(_P#@I1_XB%XD_P#F@KVK^OW/^NOY]F>UR2[?
MBO\ ,_3_ %2>]M=-O[G3K6VO;^WL[F>RL[R\DTZUNKF*%WAM[B_ALM2ELX9I
M%6.2YCT^]>%6,BVLQ7RV^(W_ &U%;X=_"#QC!\/+1-;^)_[/7BC]HN]\/:IX
MXDTS2M!\,^#8/ 1UWP[I7BC_ (0ZZ'BCQ2USX_L3I5DVB:#;W>F:3K&IWUQI
M31V5G>^(W_\ P51\-SV-Y#:?L3?\%(XKJ:UGBMY)_P!C_P 320QS21,D;RHG
MB)'>-7(9U5E9E! ()S7Q#:?MJ_!7Q-\+_!W[(&L_LO\ _!0#7]2^#'PZ\%V?
MCRRM/V+[VX\?1?#WQ/\ V]X:\)W:+=^(;J\\&6/Q#MO 'C'1KC6+)(9M4;P_
MK=OILRK8W"Q^9F*S%IK+YN$OJ]1J\:+C[=5\*Z2O5C)Q<J3Q$92<9TX1O)P=
M10/*S&GFLI+^SZBIVP]1OFC0E"5=8G!RIQO43E!SPZQ=-S]^%-3]HZ4ZD::7
M]"_A+Q+IWC/PIX9\8:0)QI/BSP]HOB72Q<QB*Y&G:[IMMJED+B(,XBG%M=1>
M;&'8))N4,V,GH*_*/3/^"HG@71=-T_1]+_89_P""D=CIFDV-IING64'[('B-
M(+.PL+>.UL[6%/\ A(?EBM[>*.*-?X411VJ]_P /5O"?_1D?_!2C_P 1"\2?
M_-!7HPYE""FTY\L>=Q347*RYFD]4F]D]EOLSTX0J*$5.SFHQYW&RBY67,TKZ
M)N[2Z(_4ZO'/CQ\4[_X,_#N?Q_9>&;7Q8ECXH\!Z#J&E7/B"7PX\=AXU\;Z!
MX*?4[.\CT'Q MU=:5<>(;;4!IDUO917]O!<1#4[27RO,^%/^'JWA/_HR/_@I
M1_XB%XD_^:"O'_CM_P %"/#OQB^&^H^ +7]CO_@I'H+:CKO@O67U.7]C?Q+>
M^4/!OC/0?&D$"6X\2Q _;;SP];64SLQ\NUN+AXQYPB9<<7[?ZKB?JKDL3["J
M\.XJ#?ME!NDK54Z>L^5/G7+:][6;6.+AB?JN)^K76)]A5^KM>S;5;DE[)VJ7
MI_'R_&G#^96N?HAXU_:'N/#G[0/@;X%:7H_@=I?$FFIJVKZUXZ\?>)/ ^H20
M7#W2VVG?#32+'X6>,=!^(WB.*.RN+K5M"U#QMX$GTVS:VN$FO%N $^GJ_"&;
M_@IQ\./CKXBM-:M_V:/^"@?B_P $?#;XA1[M!\._L:ZC>W&@_%/X>W-YIVMZ
M1?\ B&'Q/-=V=WI.HSM#J.ED17MK/&;:X8(S*?I#_AZMX3_Z,C_X*4?^(A>)
M/_F@J,,\5[3%?6'S4W6OA?<A!JBXKW6H2GS)2ORU)R4YI^]2I\OO9X6EC(U<
M8\14E4ISQ"EA8RA1I^QH^RIP=**IWE./M(RJ^UK3E4E*K)<M.G&$%^IU%?EC
M_P /5O"?_1D?_!2C_P 1"\2?_-!1_P /5O"?_1D?_!2C_P 1"\2?_-!77?U^
MY_UU_/LSLY)=OQ7^9]U^,OBEJ'A+XM_!OX;?\(S::AI7Q:;QW;'Q+_PD$MI?
M>'M0\%^%Y_%"P_\ "._V#<P:M::I;0/;?:QXATV6QF^8V5TF-V+X3^/6G>,?
MCOX\^"NE^'KS[-X%\#^'O%LWC:2^B_L[6-0UCQ#K_A^_T'3--6V,S+H4VA@W
MFJR7BQ3W5R]I;VA2V:[E_+;XJ_\ !1[P1?\ C;X9?%[7/V3O^"BWACPS\$8?
MB!KNM'4OV0/$<%K<:=XG\(7?AW5;R]U5_%$,>EVNCZ9+/J"W)P%ECW3MY*D5
MQ7P@_;8^!GA_XA0_'SX;_LG_ /!3K6O#7C/X4Z#H?AVVA_9>\4ZUX<OM$U#7
M-6\<6?B73+YO$TJ7UIK,7B-;FR96D@\J0W<$C&Z=CY<GF?UI*'*\+]?4I.?L
MU-8+ZE07+!*G=Q6,E7G*4Y*O>$8Q;HR37F3AFGUE<G*\-]?4I\SHJ7U+ZC23
MA!<C;7UQU)MMJM>*BI>R=E^_=%?EC_P]6\)_]&1_\%*/_$0O$G_S04?\/5O"
M?_1D?_!2C_Q$+Q)_\T%>I?U^Y_UU_/LST^27;\5_F?J=7A<?Q;UZX^+OQ'^$
M]IX*L+BZ\&_#[PGX[T#5_P#A+FA3Q)_PE.H:]I(TO5;.?PU&GAD:=?:#<//?
MV]_XE\_3YH[F*S%T&T^OB7_AZMX3_P"C(_\ @I1_XB%XD_\ F@KYA\:?\%,/
M!'@;XE^,/C'J_P"S=_P4!\$K\0O"7@3X0>'QXD_8YUH64&OV>NZW>Z)&'O\
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M6<$J=/\ !;_@HG\-OAGX#MM"\/?L:_\ !2C6+'5];\3^.)=4C_9"U];2^O\
MQ]XAU'Q?J$^FQ0>(F@@TQKK6)!I\419?LHCD9GDD=VX8RQO]H5%)1^H_5U[.
MW)?VW-"[E=.JY24IQ:]VE"$(N\ISDH<,8YA_:%53C#ZA["/L7%QYE633E*HW
M[[E*\HJ$5&G3A3C/FJ3K2C1_:6BORQ_X>K>$_P#HR/\ X*4?^(A>)/\ YH*/
M^'JWA/\ Z,C_ ."E'_B(7B3_ .:"NZ_K]S_KK^?9G=R2[?BO\S]3J^=_B_\
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MY_UU_/LSOY)=OQ7^9W'P6_Y28_MU?]D!_8I_]*OVBJ_1:ORF_8E\;^)/C?\
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M6_"%W<QWESX<U+5-.@O+K29KF,*LKV<LK1;BJ.  LJ)*KJ._IB"BBB@#Y?\
M%_P!U3Q+^UI\&OVC8=>L+;2/AA\+/BE\/KWP[+!<-J.IW?C_ %#PQ>6FH6MP
MBFVCM[!="F2YCE82NT\1B# /CZ@K\C_CA_P4IU;X3?$KXR6D'A3PI+\.?V=O
MC;^S1\'/B3H^M3ZI:_$[Q-9_M&:SI7AE/B#X$$5_'IXTKP5KGB70&.A-X?\
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M%?('[;G[0/CG]F;X.Z+\4/ WA[PIXEFD^,OP*^'VOV'BNZU>WBB\._%CXO\
M@SX8ZE?Z0FD!'GUG3H_%GV^Q6\NH+)9+;,Z72G[.X"U:7<Z+]CSX"ZK^S/\
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M/A;\#?BS\2?!FFZ#J_B?P%\/_%7B_1],\3W&H6N@WUWX=T>[U5;;4IM*CDU
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M+AKB"* >?+* /+V*OU_110#=PHHHH \L^->@_%'Q1\+_ !?X>^#/C'0OA_\
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M?A?\//#OPB^&GP[^%'A"&:W\)_##P+X2^'GA>"YE,]Q#X=\%:!I_AO1(9YB
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M]JT%Q<Z5XD\,:E-;_P"CS:CX8\2:?JWA^^N+;-M<76FRSVQ:WDC8_C/^R?\
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MGZ'45^>/_##'Q1_Z2+_MR?\ @_\ @3_\XJC_ (88^*/_ $D7_;D_\'_P)_\
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M?W>9^AU%?GC_ ,,,?%'_ *2+_MR?^#_X$_\ SBJ/^&&/BC_TD7_;D_\ !_\
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M?_ G_P"<50%EW[='Y?YO[O,_0ZBOSQ_X88^*/_21?]N3_P '_P "?_G%4?\
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MH1I1*#NC /Q+_P ,K_MF?])*/B-_XCO\ _\ Y1T?\,K_ +9G_22CXC?^([_
M/_Y1UI2JRI5:=6-.,I4YPJ1C5IT:U*3A)22J4JO/2JP;5ITZD)0G&\91E%V<
MN*::YTKIJZYT]=-&HII]FG=;H]+7X5_MA#PFVF-^U9X;;Q8=>-ZOB?\ X4;X
M5%NF@_8(X1HG]B_;OLK3?;UDO?[1+^?LD%OMV("36?A7^V%=Z3X6M='_ &K/
M#>DZMINEWEMXIU.3X'>%;^/Q+JDNM:E=V>I064U\L6CQVFBW&FZ0UG;,\4\N
MGO?NPFNI%'FG_#*_[9G_ $DH^(W_ (CO\ __ )1T?\,K_MF?])*/B-_XCO\
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M[A7WW31F:0!F(KXK_P"&5_VS/^DE'Q&_\1W^ ?\ \HZ/^&5_VS/^DE'Q&_\
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M"6_B/1_%&IZ);ZQK_A]=0LO$-A)IGAE[RWUB?3K=MD\,ME)/]0_\,K_MF?\
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!V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>28
<FILENAME>nt10014672x1_linechart1x1.jpg
<TEXT>
begin 644 nt10014672x1_linechart1x1.jpg
M_]C_X  02D9)1@ ! 0$ P #   #_[0 V4&AO=&]S:&]P(#,N,  X0DE- ^T*
M4F5S;VQU=&EO;@     0 ,     !  $ P     $  ?_B"^!)0T-?4%)/1DE,
M10 ! 0  "]!N;VYE @   &UN=')21T(@6%E:( ?4  < %0 3  L (6%C<W
M         $E%0R!S4D="     0            #VU@ !     -,M2% @(
M
M$&1E<V,   %$    =&)865H   &X    %&)44D,   ',   (#&1M9&0   G8
M    B&=865H   I@    %&=44D,   ',   (#&QU;6D   IT    %&UE87,
M  J(    )&)K<'0   JL    %')865H   K     %')44D,   ',   (#'1E
M8V@   K4    #'9U960   K@    AW=T<'0   MH    %&-P<G0   M\
M*&-H860   ND    +&1E<V,         &G-21T(@245#-C$Y-C8M,BTQ('=I
M=&A"4$,
M                                                    6%E:(
M     "2@   /A   ML]C=7)V        !      %  H #P 4 !D '@ C "@
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M;W5R(%-P86-E("T@<U)'0@
M
M      !865H@        8ID  +>%   8VEA96B            !0
M;65A<P         !                               "6%E:(
M  ,6   #,P   J1865H@        ;Z(  #CU   #D'-I9R      0U)4(&1E
M<V,         +5)E9F5R96YC92!6:65W:6YG($-O;F1I=&EO;B!I;B!)14,@
M-C$Y-C8M,BTQ
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MU=;7V-G:X>+CY.7FY^CIZO'R\_3U]O?X^?K_Q  ? 0 # 0$! 0$! 0$!
M     0(#! 4&!P@)"@O_Q "U$0 " 0($! ,$!P4$!  ! G<  0(#$00%(3$&
M$D%1!V%Q$R(R@0@40I&AL<$)(S-2\!5B<M$*%B0TX27Q%Q@9&B8G*"DJ-38W
M.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U=G=X>7J"@X2%AH>(B8J2
MDY25EI>8F9JBHZ2EIJ>HJ:JRL[2UMK>XN;K"P\3%QL?(R<K2T]35UM?8V=KB
MX^3EYN?HZ>KR\_3U]O?X^?K_V@ , P$  A$#$0 _ /[^**** "BBB@ HHHH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 96N:[HOAG2-1\0>(]7TW0="TBUEOM5UG6+Z
MVTW2]-LX1NENKZ_O)(;6UMXQR\LTJ(O&6R17Q0?^"B'P#,S:E#I/QAN?AK'.
M;:?XVV_PF\5R?">VG&4*3:U]F77!BZ5K',?AN13<J2";?_2*J_M^M:W?A3X
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MU'XLZ/XEUK18O%_@Z[T'2M \3ZMXATK17OM/UR;6)FLK/2;6R33+OR'X9?\
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MCX%_"_P5\//@+IMU>? G0O%7P2U+5M!\*?$K3?V@=?N[W3?%'Q!\86>J7'Q
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MUB>TV.[I]EEU"TN)+?:\CNOE,FUW=A@L2?WO!?2#P.%XOQO$<N!,MY,5EU+
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M,PF/PU7'TZ%.GF%-U\%4J8=5Z.,C6I8FC%J5"O"=*<(2@XHHHHKQ#ZD****
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MV4I5G3=>I]5]'_Q%XT\0.&LZAX@\/?ZN\6\+YW')<TP[PN*RVIBHXG*\OSK
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M\6^.;]-6\03R6^EP+H'@K1=>UR2*:6*02W4>GM;6P :XEB5E)_"#]B/]L_\
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MNE)TY246UJD[-K78****R.@**** "BBB@ HHHH **** "BBB@ HHHH ****
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M'?A?_E8R^*?_ &B'\$?^M7W% '[B4444 %%%% !1110 4444 %%%% !1110
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M\6O_ )O*^ZJ*/^(A\?\ _1<\8?\ B39U_P#-H?\ $&/![_HU'AK_ .(+PO\
M_.L^%?\ AVG^Q/\ ]$6_\R-\6O\ YO*/^':?[$__ $1;_P R-\6O_F\K[JHH
M_P"(A\?_ /1<\8?^)-G7_P VA_Q!CP>_Z-1X:_\ B"\+_P#SK/Q7_:0_96^
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MIT.D6UTME87%['>ZE807/T;10!_'%\"/C7_P2P^(W[47[?/Q6_;[^#7Q"_:
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M%+Q;*U:VFEM8(I;V\>< _ILHHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MUP**** "BBB@ HHHH **** "BBB@ HHHH ***^?_ -JC]I?X9?L=_L]_%/\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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ME96*D&@"6OP[\+_\K&7Q3_[1#^"/_6K[BOW$K\._"_\ RL9?%/\ [1#^"/\
MUJ^XH _<2BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M=M\+?C18:'<Z1KUIK>BZ7X6\5S^&M5TQ?%6A2PV<VNWD-K=7UU9[P#[_ /\
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M-1U"?Q7;:U\&D^*B^+9M?TR;2+?3;'3YSXSTC^QI[/6=1GO-MY]IM;'R8_.
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M^)>H_;+?Q/XTNK#2? 4%[H%A>>)[S]1:_)W]F3]A;XK?L6?M>>-?$7[/FK>
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M(_$5_#IL7AC5=:NK*/5_$OBW0M'74+[4-0U'4;2#3]06SFB^YJ* /Q#\4?\
M!*O]H7PUK?[9WA']ES]MS1_@-^S;^WAX[\:?$[XO?#+6/V<;'XC>/OA[X[^*
M^A:=H/QJ\1?!+XGP?%;P3#X?O?B?I^GBSC7Q+X0\1VOP_5H-2\+6K:S:)?/^
ML?P%^"_@O]G+X)?"7X!?#F*]B\"_!GX=>#_AGX4.IR6D^KW6B>#-!L= LM0U
MNZL;/3K2^U[4XK$:CKNH06%FFHZO=7M\;>)K@H/6:* "OP[\+_\ *QE\4_\
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MC^R+XW^"'@[X6>*];U?_ (:QT[XF_$#XI_"[QA\3OAQ;-H!TGX0>#/'?PO\
MAO\ $C5/#?@WQ_%)XLT[XNWEG:Z!XGOM"AT3P]H>N)HNN^+[&\]*_9R\+?M\
M?#SX(?$'X<>)_A3^P)\*M0^'_P )+3PK^R#X2^!_C[X[>)?A7IOBC0_#.NZ;
MX7T+XLVGB;X3_#_6_#_PXTO4;7P7;32> TUWQ!/HC^(FC@AU"WTXW@!_*%X9
M^,7_  3<^$?A[_@DQ\=_V*OB+J6E?\%);+XV_LR^"_VO_#OA]_C)J/Q?^,NA
M?$[7XO#G[8?A/]H+3O$FG7F@:UXW\0?%?Q7>K9:YXTO]+NM0EEM+7X?ZQ?:+
MIO@JVT_^\ROQ3U3]D_\ ;L_;%^/_ .S)XO\ VWM"_93^$/[/W[,'Q0T']HP?
M#3]GGQ_\2_B9XX^-O[1GP]T>XTWX2Z]XP\3^+_AE\,;3PS\.OA]J6L:KXGT[
MP];S>([[4[N"'0-?AU.QFM-7TC]K* "BBB@ HHHH _E0_P""E_\ P3Z_9@_9
M=U7]ECQ)^QKI?Q/TW_@JK\;_ -K/X<:;\ OBO=_';XO?$#XK^,&M=<MM;^/?
MC3XM+XO\=ZZFK?!70OAJFKCXHW\/AQO#F@1:]I5CJ%I8^&O$&N6U[^BO_!5'
MP%^P;:ZSX ^+_P"VY^S9^TI^U=8P^ OB!X)\)> ?A;\/OC+\9_AMX&TVVM);
M_P 8>-=<\!> ]0LO!'@[QMJUCXCM+#1_B7XK:UUVS70-,O/"VKZ/>>$#JMA\
MU_ []D?_ (+,_#/]H7XP?M:_$?1?^"9_QV_:.^*T+>$]+\>>+_CO^U5I6D_!
MKX*6MY%J.B_ CX*>$=/_ &9[G3_!'@&SU.,ZUKMP+K4?%'CCQ Y\0>,]=UK5
MVENY?U$^/NN?\%(_#_Q.T.]_9G^'?['GQ-^#=Y\.-.M?$?A_XP?%'XM_"GXD
M:'\78]2\5-J>K:/XC\+?#'XF>&M;^',^D7/@Q;;2KO0=+\3#4-*\0*U[#;ZM
M93Z< ?&/_!O9JFMZO_P3)^%E[K'Q?TKXI6TOC'XAR^%/#]C\0K/XH:I\!/ -
MWKBW_@/]G[Q9XN@U#4+^7Q-X#\*7>E7]UHFN_8M5\*:?XCTSPP--L]+TC3(S
M^W%?F[_P3)_8T^(_['GPJ^-<OQK\5>!?$WQS_:@_:B^,'[6/QAM_A-!K=I\'
M_"/C3XKW&C6S^#?A=#XCLM*UZX\*:-H_AK2FCU7Q!I-GK]_J%W>QW[7-O9V$
MM?I%0 4444 %>*?M!_"KQ9\:_A9KWPU\'_&[XD_L]:AXFET^SU+XF_"%/"D?
MQ'T[PT;N/_A)-*\):QXP\/>*-.\*ZUKNCF[TNP\96&DR>(/"EU<0ZYH$]OJ=
ME;R#VNO)?CC<_':T^&FOS_LUZ-\)=?\ C$LVCCPOIGQQ\3>,?"/PTF@;6;!=
M??7]<\!>$O&_BFWFA\/'5)-'BT[P]=)<ZRMA!>S6MB]Q<1@'X=?\$0?@A\//
M$?[(?_!2;]F_QAIVJ>-OA3KG_!1_]O'X)>)]*\5^(]?U;6_%GP^U'3/!G@76
M;#Q)XO;48O%.I:MKOAV:Y@U?Q(=7B\07=Y=7&J?VDFI2?:A\C?M _P#!)3_@
MG/8_\%)?V"_V/?V5?V9]&^'OC'0]2O/VW_VHO&VD>./BIKFI>%_V=/@[JK:-
M\/\ P:;3QGXYUG1S9_'+XUOI_A+4]0T01>+_  YIWA]K^SDM[#4II9/TX_X)
M5_LG?M\_L@:[^T+X;_:,M_V0-0^%GQY_:!^.O[4]QJ_P4^(_QG\3?$#0_B;\
M9-;\)WB^#(=&\=?!OP#X<E\":5I^DZMG6GUR3Q UX=.C&FS037,UM[-^PU^Q
MU\6/A-^T)^W-^U[^TMJ7@36_CI^UE\7--M/"%KX$U75_$6B_#3]F#X4Z4/#O
MP5^'L.J:_P"&_#5U:^)9K*:]U7XAKHEBFAZ]JUMH6JR-+J4$R6H!^G5%%% !
M1110 5_-5_P5E_9_USP[^V7_ ,$O?V@O%/QZ^,?Q#F\7?\%5_P!EWP1X#^$F
MMZMHFC_!;X-^"DTOQ7K&HVOA+P-X8T72(M?\::_XATS[=K/Q+\=7OB7Q@VCC
M3_"NF7NEZ'8S6^H?TJU^&W_!1G]E+_@I=^U5\:OV>M8^#>E_L,:7\(_V3_VJ
MOA5^U'\*[OXF_%KX^Z/\1_&VK_#WPS>6EWX9^(.B^%O@+XJ\,Z%IM_K^O:X+
M>X\.>(=4NET>TTJ:61+V>\MX0#K_ /@JCX"_8-M=9\ ?%_\ ;<_9L_:4_:NL
M8? 7Q \$^$O /PM^'WQE^,_PV\#:;;6DM_XP\:ZYX"\!ZA9>"/!WC;5K'Q':
M6&C_ !+\5M:Z[9KH&F7GA;5]'O/"!U6PP?\ @WLU36]7_P""9/PLO=8^+^E?
M%*VE\8_$.7PIX?L?B%9_%#5/@)X!N]<6_P# ?[/WBSQ=!J&H7\OB;P'X4N]*
MO[K1-=^Q:KX4T_Q'IGA@:;9Z7I&F1GZC^(>O_P#!5O1-<^'>I?#+X7_L(^/O
M#NH?!OPY;_%?PEXG^,7QR\ :MX9_:"6X\3/XKO\ X?\ C:U^#OC*U\5_!QK6
MZ\(QZ):^(?!7AGQK+-I.N&[-BNKVCZ92_P""9/[&GQ'_ &//A5\:Y?C7XJ\"
M^)OCG^U!^U%\8/VL?C#;_":#6[3X/^$?&GQ7N-&MG\&_"Z'Q'9:5KUQX4T;1
M_#6E-'JOB#2;/7[_ %"[O8[]KFWL["6@#](J*** "BBB@ K^0[_@JUXU_99^
M"_\ P4?^*_B3_@J'\%O$W[7/[-WCC]D?0]>_9-\&^"?&4OB6\^ FN^![76K#
MXRZ7K7P2TGQ_X?UKP=-\7]:;2+W3?VC=0TW1]!T>\L="\.67B"9]-\5:EX+_
M *\:_%G6/V3?VYO@'^W-^VK^U+^R]H'[*/QQ\$_MP^&_@+:>(/"W[0_Q'^)G
MPM\6?"CQ5\%/AWJOPXM8K+4/!OP?^+5AXZ^&6K6=TFNZKHD]WX=U87-R-&TF
MTLH;*XUG5P#W'_@C=HOQ#T#_ ()F_LDV/Q2^,NE?'GQI/\.[O5KWX@:+X\T_
MXGZ='I>N>*O$&L^&? T?C_3+O4;+Q3=_"[PS?:1\-=6U&VU/5+5=8\*:A:6%
M_<:=;69'Z:U^<_\ P2R_8F\0_L$_LE:+\%?''B7PSXH^).O>/_B/\7/B9=?#
MZWU#2_A5I7C/XE>);G6;KPU\)?#>H6>F-X6^'WAS2H](TC2M(M=(T6TN+ZUU
M37DT;2IM:GL(/T8H **** "BBB@#\Y_^"N7PU^(7QA_X)J?ME_#7X4^$]=\=
M?$+Q;\%=?T_PQX/\,6DFH>(O$5[%<V%]-I>BZ; ?M.J:E<V5I=+::79I-?:G
M+ML;&VNKNXAMY?RF_P""37AS_@E[\#/V@?A?\//#7["/[0_["?[>WC#X)W6B
M>&W_ &H_A[\3_"UQ\=+/1_"^E^(_C7?_  :U75OB1\3/AW?OHI\/1:SXBC1_
M"?BJPT:^>QL].2V;Q-IEE_05^T'+^T%!\(_%-Q^RS9_"/4?CI;S^&+CP9IOQ
MTOO%VF?"_4[2#Q=H,WC/3/$.I^!K+4O$^F7FH^ T\3V7A?4K#3K^WT_Q=/H-
MWJUE=:-#J$$GYE^'OV4OVX/VD/V[OV6_VM/VS])_9F^$GP\_8O\ "?QAG^#W
MPM^ /Q#^(GQ7\7^,?BS\:_".D> ?%?B+XA^+_&WPM^&>EZ=X&TSP]9OJ7A70
M/#ED^L6VOVUO#KE[K5@YF4 _9NBBB@ HHHH **** /YF?^"W7Q \1?MA>%_V
ML_V'?A7KFH:=\)OV/?V0/BQ^V'^W-XQT8K&LOC/PO\*?%GQ"_9#_ &98=0,5
M\D>K>*?'/AO2OCGX_P!.N;"S2?X?^"M%M=*\0PZCJ&H:=7["?\$Q?^4;'_!/
M7_LQW]DW_P!4+X!KY*_:P_X(U?L^_%GX=?MIZO\ !Z;XO^!OCY^U)X,^,^L7
M,UM^U?\ M,^#_A'XI^-WCSP)K>A>'=:^)/P^\-_$&Z\%ZOX/&LW.E66N>'[S
MP3KNA#PC!+X>B\-7FB1QZ(_UI_P3D_8]T[]AG]C[X+?L_I<WEYXN\/\ @/P+
M<?%>];X@^/OB)X=O?B[!\/\ PCX=^(=[X O/B#>2W_ASX?W>O>'I[GPMX1T/
M2/"?AK2;*4W%AX3T6[O]0BD /N.BBB@ HHHH *\#_:E\ ^!/B=^SQ\7O!?Q/
M'Q*F^'.I>"M4OO'.G?![5?&.C_$G7O"OAT1^)=<\+>%;CX>S6_C>\O/%FGZ1
M/X:NM!\+S)K/B?3=5O?#EF3)JH4^^5XO^T+_ ,-"#X0^*W_97'PC?X[PS>&K
MGP1;?':3Q;!\*[^&U\6Z#<>+M+\47?@6"[\5:>VK>!XO$NFZ#J>EV=[_ &7X
MEN]&U"^LKS3K:\M90#^9+_@GSJG[,47_  6>T_P_^Q!X,\:?L+_"#3/V-_L/
MQB_9T^-.E^*/@EXO_:D^)27^JP^!]2\(_L^_$S6AXE\0:C\//!6B/XV\3?&+
M3]*N-<OWLO$1UQI7\3^(_$FO?UJU^,7AS]D_]MW]HO\ ;M_9-_:]_;&T?]F7
MX-^$OV+?!WQG3X;> /V>_B'\1?BGXS^(GQ,^.'@K3_A[XIU/QUXM\9_"[X86
M7A_X<Z7H,=SJOAKPSH0U755UI7L?$-[K6F7CSQ?L[0 4444 %%%% !7\T7_!
M;;P=_P $^_ 5C^T+\3_VDOV6_P!IS]H[XY^._P!FC4IOAUX\T7PE\:O&WP=^
M!D_AZRN](\ 1>'/B!IE_#\+?V<;S_A/O#]IXK\7Z]8K;>));35-8U'7?[4T'
MQ5/H.M?TNU^</QSU7_@JW8_$KXKZ1^S]\./V#/'OP8\1:5I5O\&-?^,'Q/\
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M1ILVL)?^';*.VU=[VVLI+NRB@NY@#URBBB@ HHHH *^(_P#@I1\<O$G[-?[
M?[7WQQ\%ZA<Z1XW^'OP"^(VJ^!M9M+>VNY]#\<WF@76C>#-<6VO,VLZZ+XFU
M+2M4ECN(YH6BM'$EO<KF"3[<KQG]HSX*Z!^TC\ /C7^S[XJOKO2_#OQM^%7C
MWX5ZSJNGH)+_ $BP\=^&-3\-3ZO8Q-+"DU[I2ZE_:%I#+*D,UQ;1Q3'RG<$
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M?#V?[7X=_P"$E^'W_$__ .$DV67_ !36J_8OW !^DG_#SK_@FQ_TD*_8=_\
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M_P P-?FW_P $X?\ @D=\!?!/_#>?_#57[ 7[+][_ ,)=_P %)/VHO&_[-_\
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M;\!?_F!H /\ AYU_P38_Z2%?L._^)9? 7_YOJ/\ AYU_P38_Z2%?L._^)9?
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M *2%?L._^)9? 7_YOJ/^'8O_  38_P"D>O[#O_B)OP%_^8&C_AV+_P $V/\
MI'K^P[_XB;\!?_F!H /^'G7_  38_P"DA7[#O_B67P%_^;ZC_AYU_P $V/\
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M ,WU'_#SK_@FQ_TD*_8=_P#$LO@+_P#-]1_P[%_X)L?](]?V'?\ Q$WX"_\
MS T?\.Q?^";'_2/7]AW_ ,1-^ O_ ,P- !_P\Z_X)L?])"OV'?\ Q++X"_\
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MWU'_  [%_P"";'_2/7]AW_Q$WX"__,#1_P .Q?\ @FQ_TCU_8=_\1-^ O_S
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M .;ZC_AYU_P38_Z2%?L._P#B67P%_P#F^H_X=B_\$V/^D>O[#O\ XB;\!?\
MY@:/^'8O_!-C_I'K^P[_ .(F_ 7_ .8&@ _X>=?\$V/^DA7[#O\ XEE\!?\
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M< _0O_AYU_P38_Z2%?L._P#B67P%_P#F^H_X>=?\$V/^DA7[#O\ XEE\!?\
MYOJ/^'8O_!-C_I'K^P[_ .(F_ 7_ .8&C_AV+_P38_Z1Z_L._P#B)OP%_P#F
M!H /^'G7_!-C_I(5^P[_ .)9? 7_ .;ZC_AYU_P38_Z2%?L._P#B67P%_P#F
M^H_X=B_\$V/^D>O[#O\ XB;\!?\ Y@:/^'8O_!-C_I'K^P[_ .(F_ 7_ .8&
M@ _X>=?\$V/^DA7[#O\ XEE\!?\ YOJ/^'G7_!-C_I(5^P[_ .)9? 7_ .;Z
MC_AV+_P38_Z1Z_L._P#B)OP%_P#F!H_X=B_\$V/^D>O[#O\ XB;\!?\ Y@:
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M )OJ/^'8O_!-C_I'K^P[_P"(F_ 7_P"8&C_AV+_P38_Z1Z_L._\ B)OP%_\
MF!H /^'G7_!-C_I(5^P[_P")9? 7_P";ZC_AYU_P38_Z2%?L._\ B67P%_\
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M?A?\//#7["/[0_["?[>WC#X)W6B>&W_:C^'OQ/\ "UQ\=+/1_"^E^(_C7?\
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MO5KFWN[W4!?3SRQS<S\:/V1/AM_P3[_X)[?L>?\ !3'X4ZKXN@_;1^'WCO\
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M;KPU\)?#>H6>F-X6^'WAS2H](TC2M(M=(T6TN+ZUU37DT;2IM:GL(/T8HHH
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MX)^_#G]J#X-_LR_#CX,?M3V'P%MO%'P<\(>!/A5X+O\ ]G_Q?\0O&&@:_P"
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MQ_J;10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%?@O\
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MM+7XEVOBJ^\%G3+"WTRXN?$L^K6/@KQ/?36GAF/6+O1['3#>:Y!IMM>6$MT
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MK]B\:>%X;N0"2Z3POXOLM<\/"YD5'N/[-\YT1G*+]04 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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##__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>29
<FILENAME>nt10014672x1_linechart2.jpg
<TEXT>
begin 644 nt10014672x1_linechart2.jpg
M_]C_X  02D9)1@ ! 0$ P #   #_[0 V4&AO=&]S:&]P(#,N,  X0DE- ^T*
M4F5S;VQU=&EO;@     0 ,     !  $ P     $  ?_B"^!)0T-?4%)/1DE,
M10 ! 0  "]!N;VYE @   &UN=')21T(@6%E:( ?4  < %0 3  L (6%C<W
M         $E%0R!S4D="     0            #VU@ !     -,M2% @(
M
M$&1E<V,   %$    =&)865H   &X    %&)44D,   ',   (#&1M9&0   G8
M    B&=865H   I@    %&=44D,   ',   (#&QU;6D   IT    %&UE87,
M  J(    )&)K<'0   JL    %')865H   K     %')44D,   ',   (#'1E
M8V@   K4    #'9U960   K@    AW=T<'0   MH    %&-P<G0   M\
M*&-H860   ND    +&1E<V,         &G-21T(@245#-C$Y-C8M,BTQ('=I
M=&A"4$,
M                                                    6%E:(
M     "2@   /A   ML]C=7)V        !      %  H #P 4 !D '@ C "@
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M;W5R(%-P86-E("T@<U)'0@
M
M      !865H@        8ID  +>%   8VEA96B            !0
M;65A<P         !                               "6%E:(
M  ,6   #,P   J1865H@        ;Z(  #CU   #D'-I9R      0U)4(&1E
M<V,         +5)E9F5R96YC92!6:65W:6YG($-O;F1I=&EO;B!I;B!)14,@
M-C$Y-C8M,BTQ
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MU=;7V-G:X>+CY.7FY^CIZO'R\_3U]O?X^?K_Q  ? 0 # 0$! 0$! 0$!
M     0(#! 4&!P@)"@O_Q "U$0 " 0($! ,$!P4$!  ! G<  0(#$00%(3$&
M$D%1!V%Q$R(R@0@40I&AL<$)(S-2\!5B<M$*%B0TX27Q%Q@9&B8G*"DJ-38W
M.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U=G=X>7J"@X2%AH>(B8J2
MDY25EI>8F9JBHZ2EIJ>HJ:JRL[2UMK>XN;K"P\3%QL?(R<K2T]35UM?8V=KB
MX^3EYN?HZ>KR\_3U]O?X^?K_V@ , P$  A$#$0 _ /[^**** "BBB@ HHHH
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M/^7E^?=GR#_PJ#]KG_H\?1__ !&KP9_\V='_  J#]KG_ */'T?\ \1J\&?\
MS9U]?4467G][_P PYG_=_P# 8_Y>7Y]V?(/_  J#]KG_ */'T?\ \1J\&?\
MS9T?\*@_:Y_Z/'T?_P 1J\&?_-G7U]119>?WO_,.9_W?_ 8_Y>7Y]V?(/_"H
M/VN?^CQ]'_\ $:O!G_S9T?\ "H/VN?\ H\?1_P#Q&KP9_P#-G7U]119>?WO_
M ##F?]W_ ,!C_EY?GW9\@_\ "H/VN?\ H\?1_P#Q&KP9_P#-G1_PJ#]KG_H\
M?1__ !&KP9_\V=?7U%%EY_>_\PYG_=_\!C_EY?GW9\@_\*@_:Y_Z/'T?_P 1
MJ\&?_-G1_P *@_:Y_P"CQ]'_ /$:O!G_ ,V=?7U%%EY_>_\ ,.9_W?\ P&/^
M7E^?=GR#_P *@_:Y_P"CQ]'_ /$:O!G_ ,V='_"H/VN?^CQ]'_\ $:O!G_S9
MU]?4467G][_S#F?]W_P&/^7E^?=GR#_PJ#]KG_H\?1__ !&KP9_\V='_  J#
M]KG_ */'T?\ \1J\&?\ S9U]?4467G][_P PYG_=_P# 8_Y>7Y]V?(/_  J#
M]KG_ */'T?\ \1J\&?\ S9T?\*@_:Y_Z/'T?_P 1J\&?_-G7U]119>?WO_,.
M9_W?_ 8_Y>7Y]V?(/_"H/VN?^CQ]'_\ $:O!G_S9T?\ "H/VN?\ H\?1_P#Q
M&KP9_P#-G7U]119>?WO_ ##F?]W_ ,!C_EY?GW9\@_\ "H/VN?\ H\?1_P#Q
M&KP9_P#-G1_PJ#]KG_H\?1__ !&KP9_\V=?7U%%EY_>_\PYG_=_\!C_EY?GW
M9\@_\*@_:Y_Z/'T?_P 1J\&?_-G1_P *@_:Y_P"CQ]'_ /$:O!G_ ,V=?7U%
M%EY_>_\ ,.9_W?\ P&/^7E^?=GR#_P *@_:Y_P"CQ]'_ /$:O!G_ ,V='_"H
M/VN?^CQ]'_\ $:O!G_S9U]?4467G][_S#F?]W_P&/^7E^?=GR#_PJ#]KG_H\
M?1__ !&KP9_\V='_  J#]KG_ */'T?\ \1J\&?\ S9U]?4467G][_P PYG_=
M_P# 8_Y>7Y]V?(/_  J#]KG_ */'T?\ \1J\&?\ S9T?\*@_:Y_Z/'T?_P 1
MJ\&?_-G7U]119>?WO_,.9_W?_ 8_Y>7Y]V?(/_"H/VN?^CQ]'_\ $:O!G_S9
MT?\ "H/VN?\ H\?1_P#Q&KP9_P#-G7U]119>?WO_ ##F?]W_ ,!C_EY?GW9\
M@_\ "H/VN?\ H\?1_P#Q&KP9_P#-G1_PJ#]KG_H\?1__ !&KP9_\V=?7U%%E
MY_>_\PYG_=_\!C_EY?GW9\@_\*@_:Y_Z/'T?_P 1J\&?_-G1_P *@_:Y_P"C
MQ]'_ /$:O!G_ ,V=?7U%%EY_>_\ ,.9_W?\ P&/^7E^?=GR#_P *@_:Y_P"C
MQ]'_ /$:O!G_ ,V='_"H/VN?^CQ]'_\ $:O!G_S9U]?4467G][_S#F?]W_P&
M/^7E^?=GR#_PJ#]KG_H\?1__ !&KP9_\V='_  J#]KG_ */'T?\ \1J\&?\
MS9U]?4467G][_P PYG_=_P# 8_Y>7Y]V?(/_  J#]KG_ */'T?\ \1J\&?\
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M/^7E^?=GR#_PJ#]KG_H\?1__ !&KP9_\V='_  J#]KG_ */'T?\ \1J\&?\
MS9U]?4467G][_P PYG_=_P# 8_Y>7Y]V?(/_  J#]KG_ */'T?\ \1J\&?\
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MD@HHHH$%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MA3(ZJ2J!CPI<@+D\#.3Q7Y(>,?\ E.-\%O\ M&W\5_\ UH#PG7ZY4_G\]/\
M*WX ]T[)Z1TUMLM-'>WSOYGX,^&O &H_'#X97'QQ\4?!;QG^T/\ %'Q??_$.
M^\9>.[3]I33_ (/WO[.GB'P[XNU_2+'X;^#-(UC7-/'@Z/P/I^G65U'/':O(
M;R2>]U:6ZN)Y7?Z&_9/_ &G?VR?%O[//PQURZ_92UGXM336VHZ4/B//\=?A7
MX;N/%VD:+X@UC1-/\47-CJC)/>7=UI^G6C7>IVR1V'B.Y,NO:0L>F:A:H/JS
MQS^P[^S-\1/%FM>,O$?P_NDU/Q5=)?>--/T#QCXU\*^&?'=XFW-WXU\*>&O$
M.E>'?$US.J)%?7&J:;/-J=NB6NIR7ELBPCZCTC2-+T#2M.T/0].LM(T;2+*V
MTW2M+TZVBL[#3M/LH4M[2RLK6!4AM[:V@C2*&&)%CCC1450 !7P'#_"V997C
M?K%;%TJ"AAZE'$8C!2PU3$9S6E[%+$8^-3)Z#C:5.IBY2Q&(S/,%B\14I4<R
MHY?&IAL7_1/'GBYPIQ'D+RW"\/3SFI7SFAF>7X+B.EG6#P'!. I4<=&>1</5
M,LXZQ%.MAK8O"Y;3CEN6<)Y-/+,FP.*QO#^,S>K0Q64?'X^.G[77VAHS^PKJ
MHMQ"KK<_\-'_  <):8NZM!Y/F;QL0+)YI;:V_:!E35=OCS^V"+.:9?V#=4:[
M0SB&R_X:5^#(\\1RND)^TE_+C^T1*LP#K^ZWB-SN5B/MFBOL*>#Q$'1<LUQ]
M94ZF G.-2GEB6(CA/:?6*-;V66TG&GFG/'Z^Z#H5:?LJ?]F5<NO5]I^/U.(L
MHG&LH\!\*474IXZ$)4\9QPY8>6+=/ZO6H^UXRJQE4RODDL"J\:U*HJU3^TZ6
M8M472^+9/CK^UTLT")^PKJLD,GF^?/\ \-'_  ;3[/L0&+]T92TWFME/D(\O
M&YL@TD?QU_:[9KD/^PIJL:Q2;;9O^&D/@V_VI/)C?S,+)F#]ZSP['W-^[\S[
MKJ*^TZ*SC@,4J4:;SO,Y3C0C1=>5+)E5G4CC98IXJ2CE$:"KSH-9;*,*,<*L
M%&-2&&AF+ECY:/B7)75E47A]PA&$J\JRH+&\?>RA3E@HX586+EQO*LZ$*\7F
M493K2Q3QLY4YXF67*& C\3I\>/VP#:6<S?L&ZJEU,+0W=G_PTI\&6^Q&8(;H
M?:!)Y=S]C+,/W0 N-F8\;A4P^.O[71N'C/["NJBW6&-TN?\ AH_X.'S)F>19
M(?)\S>GE(L;^825?S=J@%&K[2HJYX+$S551S;,*3J?6>24*65-X?V]:E5I>R
M]IEE2,OJ4*<\-AO;QK<]&O5EC/K>(C0KT8I\1Y/"5%RX"X3JJDL-SQJ8SCI1
MQ'L*-6E5=;V7&E.47C9U(8G$_5Y4%"M0I1P:PF'=:A6^4O&/Q@_::T2YBB\)
M_L>ZCXV@?0-#U&2ZC^.WPM\.K#KFH:/:7NL^'##JTGFN^@:K-=:(^JHIL-3>
MR.H61-G<1&OYOO\ @JC^TI\8O%GQ!^+?@3XV_!KQ9X2A\+?##X?V/PF^%\/Q
MITAO"WAO5_',WB+4/%?QP\2:3X4FMX?BA?Z)I.@7VG:!?/='PM\/;BS,NO0/
M=WGEW']=U?GO^V]^SE\'/C[XI_9YT3XG?!2S^(G_  D/CS5_ VH^-K"[\8^'
M_%O@'P?J'@OQ1K.HR6?BKP1JVC7UKH^JZCIMGI5_IVO7%YX=NO[3='L3?36\
MH^HX-S^AP3F]+.LSQN8XZA#$T*<:CP6 Q5?"K%YKDZ5.A0P=/**CA[##XK+X
M5HXRE7H4<WQF(Q=3,*5"C@UFU@.*$LHP_".0X.K_ &9F-65;!9MQ%@<15J99
MD><XKZY4Q&<9WG67JK[;ZOCJ^%CERI8N>5X; X"&7SQ5>M5_B\^&'AG5H?V>
M/C#\3M,\/>.Y?$?P\M?@=XST'X_:1^TMX<\/:Y\,?&GB?Q3XFT*\\%_88]2B
MF\2C7=-TJS%GX1L8$\>>"KRS/B;5[L:#J5M:G^M7_@G]^U7^VI\7O@9^SMJG
MQ%_9/U77]#\3:'I-CK_[0-Q\:?AKI9UC1+:\GTM?B%=?#NY">*KJ>\L+2'4+
MN"V19-;N'EU'342UO;=!T6D_\$5?^"<.C7ME-:_ >[GTFQU2TUM/">I?$WXI
M:IX/N=7LX5@AO]0\/:AXQN+'4IBB[9DOEN()XV>UFA>S=K8_J+I6E:9H6EZ=
MHFBZ?9Z3H^CV-IIFE:7IUM%9V&FZ=801VME8V5I B06UI:6T44%O;PHD4,,:
M1QJJJ /USQ%\3.&^*L)##X'))8^L\?4Q=/$YU1Q>$GEE"> H83ZM@_J&?UI5
M)SKTY8J<>:AET9*'-@,1B)5<3+\RR?)\9@9\U;$1IQ5"-)T\/.-2-::JRJ>T
MJ>TPT$N6,O9Q=I57&_[R,5&"_!?]J/4?BU\>OV_/'GP+\7_LV>)OCY\)OA'\
M*_ WB;X=?!JQ_:1\*?!/POXYE\7R7\GB#XL>)-*U+4M+U#Q\^BZI9?\ "):7
MIB7$MKX0FT^6_OK99M=LY9,K]DKXP_M9?!?XZ?M$_L]_"[]C[QCXO^'/@O2/
MAGXMT[X/:[^UI\,?%,GP"UGQA!XA&H>'-(^(VMW=_:S:!XFMM+LO$.G> 'OI
M]7\),]Q?2;-,UW3D7]@?CO\ LH_ K]I"7P[J'Q5\'3:CXC\'B[7PEXT\.>(_
M$W@?QSX;AOROV^TTGQ?X-U?0]>@TZ_V*;W2I+Z;3+IE62:S>5$D7IO@A^S[\
M(/V<O"<_@OX.>#+/PAHM]J5QK>L2B\U36=<\1:Y=X%UK?B;Q+K]]JGB'Q%JT
MRJL9OM8U.\GC@2*V@:*VABA3YV7&V2?ZM4\JEDM/$U(Y7@< LKQ*S:&5T\9A
M:]"IB,X5;#<2TH?6<7&C4J2>%RC XQUL76I5<PJ86$Z>,[5@,1];]M[9QC[>
MK6=:+H^VE"<)QCAW&6%;Y*?-%+GK5(<M.$E34VG#\B?V[_VGOVW/^%5>!_"&
MK?LF>+?@#X8^*/QK^'7PU\7^//#_ .U'\(_[>N/#GB.?4Y+OP=H_BS1I(T^&
MU_XUN;"S\.1^/]6=--TB._DL8WBU;5=+E3Q6/0_B1^RI\?OV3-:^%O['_B_]
MEJ7XE?&WPU\+/&6BI^UEX8^,GAWXT>$/$UEJ,?B$^)/AQ9:WJ^KZEKWA:RCE
M\6:=X\M%@3PY-9SRZK++9WIA;^A'XA_#KP-\6?!FO_#SXD^%M'\:>"?%%B^G
M:]X;UZT2\TW4;5V5PLD;8>*:&5([BUN[=X;NSN8HKJTGAN(HY5^=_@U^PI^S
M)\!_&D'Q$\ ^!-3E\;Z=IUUHWA_Q-XV\=>//B1JGA'1+V,P7>C^#I_'WB3Q$
M/"]E=6[&UN_[%6TN;VT"VMY<W%NJQBLJXXR/!Y+4P$\CHX.7+F:K9?@%G%7+
M\V>-PT:.'EC:N*XHM&6&FM?KN SB-*$(U,%'#5I285L!B*F(]HJ[FFZ#C4J.
MBJE!4I\TU3C'"._/_=JT6VVIN4;'IW[/WQNTK]H'P%J'C[1M$U#P_96'Q(^+
M?PX^PZG<6]S=2W?PE^)OBKX9ZAJ>^U B2WU>^\*W&IV<&7DM[6[AAF=Y4=C[
M=7P%_P $UO\ DW#Q#_V=#^V=_P"M7_&&OOVO@^(,)0R_/<XP.%BX8;"9EC<-
M0@Y2FXTJ.(J4Z<7.;<I-1BDY2;;W;;/0PE257"X>K-WG4HTIR:22<I03;LM%
MJ]D%%%%>.= 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7
M_%/X@Z7\)_AOXX^)FMV=]J&C^ _#&L>*M3L=,$#:C=V6BV4M]<062W,UO;FY
MDCA981-/%$7(#R(N2.^KYD_;1_Y-*_:._P"R.>/?_4?O:]/)<+1QV<Y3@L0G
M*AC,SP&%KQC)QDZ.(Q5*E449+6+<)R2DM4]5JCR<^Q=;+\CSG'X9QCB,%E.8
MXN@YQ4XJMAL'6K4G*+TE%3A%N+TDKI[GYV?\/ROV;_\ HF'QD_\  /P=_P#-
M51_P_*_9O_Z)A\9/_ /P=_\ -57\MM%?WG_Q+OX9_P#0!FG_ (=\5_F?YG?\
M36^+W_0?D?\ X8\-_P#)?U=^5OZDO^'Y7[-__1,/C)_X!^#O_FJH_P"'Y7[-
M_P#T3#XR?^ ?@[_YJJ_EMHH_XEW\,_\ H S3_P .^*_S#_B:WQ>_Z#\C_P##
M'AO_ )+^KORM_4E_P_*_9O\ ^B8?&3_P#\'?_-51_P /ROV;_P#HF'QD_P#
M/P=_\U5?RVT4?\2[^&?_ $ 9I_X=\5_F'_$UOB]_T'Y'_P"&/#?_ "7]7?E;
M^I+_ (?E?LW_ /1,/C)_X!^#O_FJH_X?E?LW_P#1,/C)_P" ?@[_ .:JOY;:
M*/\ B7?PS_Z ,T_\.^*_S#_B:WQ>_P"@_(__  QX;_Y+^KORM_4E_P /ROV;
M_P#HF'QD_P# /P=_\U5'_#\K]F__ *)A\9/_  #\'?\ S55_+;11_P 2[^&?
M_0!FG_AWQ7^8?\36^+W_ $'Y'_X8\-_\E_5WY6_J2_X?E?LW_P#1,/C)_P"
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M/BWX;L-3TO0O'>BIK>F:?K*VR:I:VTEQ/;B*]6SN+JU68-;L2(;B9-I7#DY
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M32='\=W8?6_&=[%?7=S!K/V:&ST@*EO&TDLKM&_X=ZS^R%\$OB!\:?BI9?M
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M$T\6L76R;%*L_K.9NCE^'IXI>PP+\"HHHK]*/Q(**** "BBB@ HHHH ****
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M/B+#)M)?4,]U<<7/;(<S:7+@91Q+N]+Q?LTW?$*6'56+^F:***]D^4"BBB@
MHHHH **** /S^_8[_P"2]_\ !0W_ +.;\/\ _JD_AO7Z U\9_LR?#KQKX*^,
M7[:WB'Q3X?N]'T7XD?'O1O%7@>_N9+5XO$7A^V^%/@;0I]3LUM[B:6."/5],
MO[$K=1V\QEMG81&,H[?9E>_Q+5IULU<Z52%6']FY%#GISC.//3R++J=2/-%M
M<U.I"5.<;WC.,HR2E%I<^%3C1M)-/VM=V::=G7JM.SZ---=TTUH%%%%> = 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %?,G[:/_ ":5^T=_V1SQ[_ZC][7TW7S)^VC_ ,FE?M'?]D<\>_\
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M6EYK.JZ7-K/A^+2;<7%UK6H2V5REMI^I7#:+9Q:6C/!/+?.T70>+/V1?@_\
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MR4*]:GR5)%%%%>:>>%%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %?,G[:/_)I7[1W_ &1SQ[_ZC][7TW7S)^VC_P F
ME?M'?]D<\>_^H_>U[?#/_)1\/_\ 8[RK_P!3\.>!Q7_R2W$O_8@SC_U78D_A
M:KZG_9F^.7A_X!6OQF\5)::R_P 4_$'PQU'P+\)=8TT01VWA35O%,Z6GB#Q1
M<WIN(KNTO]-T1)(]&:SCE9KRY9I6B2,%OEBNK\$>!_%OQ)\5:+X(\"Z!J'B?
MQ7XAO$L-'T32X?.N[VY<%B%#,D<444:O-<7,\D5M;01R3W$L<,;NO^I><8+
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M;0JT,+2JYA4IU<;5A"OB,3.G[>=&C;#T:E+!8>-.,,)A</!RC(K^W'_@G?\
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M\LXJ2NNCLUH%%%%<I84444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M*J$\NQD\90O7P669WGF58JN\3CU/"U9Q5;BZ***_03\B"BBB@ HHHH ****
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M/B+Q#8WEW]LLA,ML;VS$_P!IU_-5\>OA%\;)M._;]_8FM/@9\7_$GC?]L_\
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M0M3_ &NM-^#FE^(;#2=.DNOASX)U;P-<_$35SX6CDM)H?#TOB+7-FG+=6L<
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M% !7]N/_  3O_P"3)_V<_P#LGUM_Z<]2K^(ZO[<?^"=__)D_[.?_ &3ZV_\
M3GJ5?S-]*'_DD>'_ /LHU_ZK,>?V%]#7_DM^*O\ LE5_ZM\O/&_VD_\ E)I_
MP3$_[$#]OO\ ]03X'44?M)_\I-/^"8G_ &('[??_ *@GP.HK^'UO+U_1'^B[
MVCZ?JS],Z*P?%2Z8_A?Q(FM:S)X=T9M!UA=6\01:E'HLNA:8VGW O]9BUB4K
M%I,FF6IEO4U*1ECL6@%TY"Q$U_+5X)_;3_;#\#^.K+P7_P $TOC-\8_^"O/P
MJL_$%KI&IVGQG^ =WI/ACP;8&YQ>PQ_M\63?#'P9K=W!;[C;-JWA;QR;F(12
MZ?&+..2>4;M_7]/KT3!*_P#F]OO_ *^\_JSHKY&_9$_:EO\ ]IKP]\1;?Q?\
M'O&?P%^+?P5^(#?"SXO_  N\8:EH'B--"\8KX6\.>+X[GPIXS\+WEWH?C3P?
MJFB^*-,N]%\16\>F7%TIGCO='TZ>(Q-]<TQ!1110 4444 ?D;XQ_Y3C?!;_M
M&W\5_P#UH#PG7ZY5^1OC'_E.-\%O^T;?Q7_]: \)U^N5 WO\H_D@HHHH$%%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 <+_ ,*N^&9CU:$_#KP+Y6O2QS:Y%_PB/A_R]:FAN'O(
MIM63^S]NHRQ7;O=1R7@F=+AWG4B5BQCD^%/PNEM],M)?AMX!DM=%,YT>VD\'
M>'GM])-S<?;+DZ9"VG&.P-Q=_P"E3FU6(RW'[^3=+\U=]17(\!@7H\%A&G'E
M:>'H_#S^UY?@^'VB52VW/[]N;4])9SFZ::S7,DU/VB:QV*3514?JZFOWNDUA
M_P!QS?%[']U?D]TXG_A6GPY_M'4M7_X0#P3_ &MK*WZ:QJG_  BNA?VCJJ:J
M6.IKJ5[]@^TWRZD7<WZW4LHO"[&X$FXYJ_\ "I?A6--.C#X9_#X:0U\NIMI7
M_"&>'/[-.I+ UJNH&Q_LW[*;Y;5WMENS%YX@=H1((V*GT"BF\#@7>^#PKOS-
MWP]%W<[<[?N:\]ES?S65[V$LXS>-N7-,Q7+[/EMCL2N7V*:HVM5T]DFU3M_#
M3:C:Y^2&E?LN?MS>#O"MM;ZM\9OV1/&=UX6T6\M(/'GBG]FO6;KXAOHUA'=_
MV<C:WIOC/3H8;O1=',.E:2=/L[.WL[6RM(H856/!A_9A\#?MXI^SC\"4^$O[
M0'[-$OPO3X2?#]/A[+XJ^!7C_P#X267P<OA?3%\.RZ]]G^)L$ U>32Q;/?B*
M&.-;EI%1%4 5^KGB-@GA[7G,"W031M48VS[]ER%L9R8'\IEDVS >6WELKX8[
M&#8->(?LC7L.I?LM?L[:A;^%;7P+!>_!?X;W47@NQ745LO"D<_A/2I$\/6JZ
MO-<:JMOI"L+&)=1GFO0D"BYD>;>Q]&>?R7$E&O')^%Z=>ME69SJRI<.9;1=2
M57'97.I.5*CAH8.3<E&\YTO;PTC1E&E*K%^]">,Q/A]FU/$8_-\1AZ7%W"T8
M1KYC&MAZ;IY+Q>J4?W]2>9QG&,JOLHX:I'+U">(>+IRQ$L%*/@W_  A'_!3/
M_HOG[)7_ (8GXB__ #TJ]7\'^&_VR[7X?_$.Q\<_%+X#ZO\ $R^BTX?"_7_#
MOPQ\7:3X2\/S1M*=4;Q?H5[XVO\ 4=>CN%,(LUTW5-*-N5D,K3!E"_55%>K7
MS^O7@H2R_(Z:52E4YJ&29;1FW1J0JJ+G3P\9.G-P4*M-ODJTW.G-.$I)_$QP
M\(NZG7>C7O8BM):JS=I3:NMT[73U5G8_/[_A"/\ @IG_ -%\_9*_\,3\1?\
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M*[53#X=2^D****]4^2"BBB@ HHHH **** "OS\_X)[?\B_\ M6_]GS_M)?\
MIYT2OT#K\B/V2?C[X?\ @WX[^/7P7\=^ ?C?8>+/'_[;7Q=U7PUJ5C\%?B+J
MG@JZT;Q_XHT73_#>MS^-K'09?#=GHLTJO/>:I<7Z66GV2/>7<T=NC./JLDPN
M)QN1\2T,)1J8BLEE-=TJ4>:I[&CB,0ZM3E6KA333G)*T4U?<Y:\X4Z^&E.2A
M%^UBG)V7-)0Y8W?5V=EULS]=Z*^0_BG^VK\*OA!XUU3P'XF\(_'?5-8TF.SD
MN;WP5\!_B=XU\.RK?6L5W"+/Q%X<\/7^DWK)%*JW"V]U(UO.'@F"2HZCSO\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M "BBB@#\S/VD_P#E)I_P3$_[$#]OO_U!/@=11^TG_P I-/\ @F)_V('[??\
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MX,U>QT"?Q=XU/QDT-+GP??7\9;7K"W\+'PN;OQ*GA^3$<5W::C8)K()>"*U
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M""BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M0 4444 ?#W[7GPH^/'C#QU^RQ\5O@#H?PU\5>)_V?OB;X[\8ZEX7^)WC77O
M6BZWIGC3X-^._A;Y5KKWA[P5XZNXKRQF\9+J@B?1A',ED83/&9=Z87_">_\
M!37_ *-J_8]_\2H^*7_T,U??U%>_1SY0PF#PF)R?*,PC@*-3#X:MC(9BJ\*%
M7%XC'.DWA,QPM.45B,7B)QDZ7/:IRN;C&*7++#-U*E2&(KT75E&<XT_8N+E&
M$*:E:I1J--PIP32E;3;5W^&O#OC?_@HO<>(-"M_%/[//[*&E^&)]9TR'Q'J>
MB_M,?$K5]9T[09;V!-7OM)TJ[_9TTJUU/4[33VN+BPT^YU/3;>]NHXK::_LX
MY6N(^E^*'B[]NG3/'6NV/P>^!_[-GB_X<0'3O^$<\1>/?C_X^\%>+-1632+"
M;53JWAG1?@7XPTS3#:ZY)J=E9"V\1ZD+S3K:SOYC:3W4MC;?8%%9O.,-[>-;
M_5_)%&-&=)X9+-O83E*=.:KROFSK>V@J;IPY:T:?)5J<].4G"4'["?*X_6\3
M=R4N?_9^=))KE7^S\O*[IN\7*Z7O)73^ ?\ A/?^"FO_ $;5^Q[_ .)4?%+_
M .AFH_X3W_@IK_T;5^Q[_P")4?%+_P"AFK[^HK;^W<)_T3'#W_@.=>7_ %.O
M+\7W)^K5/^@W%_\ EK_\S>7Y]V?$W@WQI_P4(O/%GANT\>_ #]EG0O!-SK>F
MP>+-:\,_M(?$;Q#XBTKP])=Q)JVH:'H6H?L]Z#8ZQJMI9&:>QTV\UK2;:\N$
MCMYM1LXY&G2Y\0?&/[?.G^,_$-G\,/@/^S'XF\ V]\8_"^O>,?VB/B%X4\3Z
MGIODQ$7&L^'=*^ ?B?3M)NS.9D-K::_JD0C2.3[3N=HT^S:*R_MC#>W5;_5_
M(^54O9?5^7-O8.7/&?MG_P *WMO:I1=/2LJ?)*5Z;E:2KV$^7E^MXF_,GS_[
M/S62MR_[OR<M]7[O-?[5FT_@'_A/?^"FO_1M7['O_B5'Q2_^AFH_X3W_ (*:
M_P#1M7['O_B5'Q2_^AFK[^HK7^W<)_T3'#W_ (#G7E_U.O+\7W)^K5/^@W%_
M^6O_ ,S>7Y]V?'OPT\7_ +=NI>-=%LOBY\#?V:O"?P_FDN!K^O\ @7]H'Q_X
MR\46$2VLS6SZ7X<UCX$^$M.U)Y+Q8(9DN?$&GB*WDEG1Y7C6&3(\9^-/^"A%
MGXM\26G@'X ?LLZ[X)MM:U&'PGK7B?\ :0^(WA[Q%JOA^.ZD72M0UO0M/_9\
MUZQT?5+JS$4U[IMGK>K6UG</)!#J%VB+._VS16*S?#+$.O\ ZOY(X.C&E]6<
M<U^KJ49N?MU_PJ^V]M)/V<KUG2<$K4E*\G?L)\BC]:Q%^;FY_P#9^=JR7*_W
M')RZ7^#FO>\FG8^ ?^$]_P""FO\ T;5^Q[_XE1\4O_H9J/\ A/?^"FO_ $;5
M^Q[_ .)4?%+_ .AFK[^HK;^W<)_T3'#W_@.=>7_4Z\OQ?<CZM4_Z#<7_ .6O
M_P S>7Y]V?(_PD\:?MJ:GX^L='^.GP.^ O@SP!=Z-K5U-XK^&/QV\4>/M;L=
M9L6L!I>G3^&O$WPE^'YFM=4%S=EK^QO[L67V)A=11F>V\[ZXKX,^,UY=Q?\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M'SWXTMO%3_M%_ ^YT_P;8:IX3@\)_%E/$?C2;0UN]0\*W\MKX8&A:=9:Z7#:
M1%XB9;V.[ME1QJ0L(58I]G&[Z$KYE\>PV+_M1_L^3S>-O[*OXO!?QH6S\#?8
M]=E_X2Z*2T\(BZU/[;9P/H%K_P (T%BD\O69X;JY_M$C2UD:.Y"_35>/E;OB
ML^U;MG$%K6HU4O\ A&R=V4:24Z"UO[&O>LVW63]C6HI?5<11MEO!3Y8QYN%:
MLKQPN+P[E_QEO%4>:=7$MTL=+W>7ZU@%'"1C&.$DOKN$QDF4445[!\J%%%%
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MG_@N%\&8M*TW3],BE_X)O?%>26+3[.WLHY)!\?\ PDHDD2VCC5W"@+N8%MH
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M^$?PQ\4:[>");O6O$7@'PKK>K72P1K#"MQJ.IZ3=7DXAB18HA+,PCC543"J
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MB"BBB@ HHK\D?BQ_P4R\5?#WQK\:_$^C? BP\2_LG_LN_&CP1\ /V@?C#/\
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M/VD_^4FG_!,3_L0/V^__ %!/@=126\O7]$-[1]/U9^F=%%%,04444 %?B/\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MI3Q6-REO)$WY!?LQ_MH_M/>(/"'[(_P9\'?%'4-;\5_#K_@H3XD_9E^/>O\
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M_$"">Y!U6]F,EQ=R"YN!-+(TPGE$@D;*^/GPS_8[\1>"/#OCC]I+P1\$=8\
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M^'D.C)X4MS8:#::+:6DVKM>/=&YGU'7FU#5-T,%O!<) @CKX^^&]]X8\%_\
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MUW4?"=OHOBOQMX]M=$T[4]0MM(T32-2AMI84T2_U>:>]2TTR.U>:YNX?;_\
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MT5^37_#)?_!5G_I+QX8_\5U?!K_Y[%'_  R7_P %6?\ I+QX8_\ %=7P:_\
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M7_P59_Z2\>&/_%=7P:_^>Q7S-\0O"'_!6#P-^U-^S7^S@G_!4WPGJ5O^T!X
M_:,\;3^+F_8#^#MI-X6?X##X/F#3HM$'Q%N$UA/$X^*<HENGU73#I']BQE(-
M1^WL+3YKB7AV'$5/ TYXBI@WA,3[652G!SJ5*%2*A7H0<,315.55<MJE15X0
M<+NA/2WZ?X8>)>)\-<;G6+H9;0S=9KED<+3PN)J8>GAJ./PV(ABLOQV(AB,K
MS">(HX2HJCGAL+4RW$UE-QIYEAU=5/W^HK\FO^&2_P#@JS_TEX\,?^*ZO@U_
M\]BC_ADO_@JS_P!)>/#'_BNKX-?_ #V*^EN_Y9?^2_\ R7]6?E?\PLOYH_\
MDW_R/]6?E?\ 66BOR:_X9+_X*L_])>/#'_BNKX-?_/8H_P"&2_\ @JS_ -)>
M/#'_ (KJ^#7_ ,]BB[_EE_Y+_P#)?U9^5RR_FC_Y-_\ (_U9^5_UEHK\FO\
MADO_ (*L_P#27CPQ_P"*ZO@U_P#/8H_X9+_X*L_])>/#'_BNKX-?_/8HN_Y9
M?^2__)?U9^5RR_FC_P"3?_(_U9^5_DOX?:+\4O _[1MCX6D;Q#XM^)&J?\%
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M\8^)O$^F^&]+UVXU">_-M96>E:/:Z1)>ZS+!/:27MIIRW2S_ %;^QSX0\&>
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M^#7_ ,]BO5N_Y9?^2_\ R7]6?E?Y"R_FC_Y-_P#(_P!6?E?]9:*_)K_ADO\
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MJS\K_.67\T?_ ";_ .1_JS\K_K+17Y-?\,E_\%6?^DO'AC_Q75\&O_GL4?\
M#)?_  59_P"DO'AC_P 5U?!K_P">Q1=_RR_\E_\ DOZL_*Y9?S1_\F_^1_JS
M\K^E_MNRIX4^+W[&OQ=\6Z5JVI_![X:_$WQS-\0[G3?#NK^*+;PW=>(OAUK6
MC>$O$>L:7HUCJ=XMA:ZS(MJM\+*1+6ZNH!N62:(-TG_!-OPYX@\._LQVS:UH
M6J^%].\2?%7XU^,O!/AO6],NM%U+1O 'BOXG^)M9\*13:->PV]SI45]87/\
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MESJ,]QH5A?G^SH(Y9KY$:TCBE>98V^<?^&2_^"K/_27CPQ_XKJ^#7_SV*/\
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MM[/X1?$W0/!>D^&8;S3-/B\$W*:?H^FPVOVI+=OZG:2=_+_AD_U')6ZW_P"
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M85^,4/ASQ?IG@\M?_#$>(7U;QN?AG;>+O!LGQ5\%0>+_ (91?$0S6T/@N_\
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M"*P\2:UH*:MJWAK3IX_^)U:^&_$"V\PN;&."X /6Z*** "BBB@ HHHH \/\
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MS[5]ILEBB%M+&(TV_0=%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M&;I[=IM&L=8TS2M-L-2M;!X(;VSL+2WN$DB@C5>)\"?LV_L^_"Z_T?5/AO\
M!3X7> ]1\/-XK?0;WPCX'\.^'[G16\=7-E>>,SI<NEZ?;-8#Q3=:=I\^NBU,
M0U.6RM6NQ*8(]L\OI;3_ -MO]_*W\Q\VEM;ZZ][W6OIIWVZ'\KNG?#KQ1XYL
M(OV:?!GCWX3>,?!WP,_X*6?\%"O /PO_ &(OVH/BC\5_!_PU^.GPC^'UG8/H
M'@/3/B'X<MO$4\=U\"$UZ?Q)X"\+^,1J&BNMP\ODF+29;BW]:U+QQH\W_!)?
M6;CP%H'Q:\%?%7]D[_@I5\*/!_P_\$_%#XJ>'?C9/\//C-X?_:G^%L%S\/\
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M&?AWP=HGPDM[+0)M#\/:3KW@/P9'I&FL+JRO9->1[W6/&6HW%_J>OV.DW5M
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M>WPA_P""/ND#QA^T3IOQF^)OQWO?@[XL^+/PCDT3X?Z=\8D?PK^T-\*O@_\
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MI?[:T2YM/'OAW5;B759KG2-1U&[M(+R::XG5)*Q_B)^Q+^UC>?M4_$F7X*_
MWQMX+\2?$7X[_%;XAWWQB^(T7P!\<?!KPSH/Q ^'GB;PM9_'/X6_&W2[[PS^
MU+X ^+5O=ZI8"/X+7&G^+O">CWR300O+X8B@O*_J-HHM;J_Z;?KU#F:Z+:WX
M)=_)?.Y_,9_P3:_86^-WP3^+?PN\>_$KX+?M">'[?]GO]F+XD?#;XEZ=XO7]
MC71O"?Q0\7^)-+\,17'@3X9:5\$/"%GXQ^/GAS6;O0+_ ,0:7XP^-?C3PPFD
MZM=6D4[:GJ^M^)+E/Z2/ =U:WW@?P;>V/A'4OA_97GA3P[=6?@+6=.TG1]7\
M$6MQI%G-;^$=5TG0+[4]"TO4O#43IHU]IVBZEJ&DV5U92VVG7UW9Q0W$G5T4
M)6$W?^G^K84444Q!1110 4444 %?AO\ !Y/VT/V+?A;\9/V2_ 7['/BSXV>)
M=2^*OQ^\8_LX?'32/%GPKB^ FMZ/\;_B'XJ^)>E:A\>7\3^//#WCKP5>> M4
M\:7>F^+='L/"'B:X\7V.B&3PS<7ESJ:(G[D44K>;7IV^?HON _"?P/\ \$[/
MB+\4/VP/VR_'WQZ\9_M ?#33?&/P:_8H\)>&O&7[,_QX^)G[//@7XF^+/!?P
M<\8>&_BY<)X6^&GC'2AJ.E>&O$\MG#X?T[Q;:W2Z%I^L36.G/-;WE^9/M?\
MX):_#/XC?!?]@_X"?"+XL>$[GP7X[^&=AXY\%:KHEYIVD:9=2:?H/Q.\:V7A
MC7[F+02=+O+SQ9X431/%-]J\#-/K5]K%SJNI'^U+N] _0&BA)+\?Q=QMMJVG
M3\%;\5OYA1113$%%%% !1110 4444 %?D-^T-^Q9XH_:$_X*7>!_B=KFJ?'G
MP%\'/#_[$?B'P'-\1O@7\;?'7P0U.;XBW7QOL=>MO!FKZW\-_$_A[Q)JEC<>
M''N-8;3+P3Z*\MM;W#G[9;0A?UYHI-7^]/[AIVOY_/\ K8_$+XO?\$SO#)_:
M4_X)Z>"/@WHOQE^%_P"SG\$_AS^W!)X[\??!KXU_$/X<>/M+\<?%J]^!6MZ-
M=>*OBEH'BVP^)?B+5_B7K^D>,-2UVZO=8U-M;N;&X;5Y!##:(OO/_!._]FWQ
MM^RS\3_V\/A[JUGX^UCX;>)/V@?"GQ,^$?Q5^*&O2>.O'?Q)T?Q?\'O!*^*A
MXA^)FKWE_P",_&TW@WQAIFJ>&;.X\:7ESJFF6-O#96EQ-IXAV?J)11:W]>25
MO31!=VMW^_>][_)?\.%%%%,04444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
*4444 %%%% '_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>30
<FILENAME>nt10014672x1_linechart3.jpg
<TEXT>
begin 644 nt10014672x1_linechart3.jpg
M_]C_X  02D9)1@ ! 0$ P #   #_[0 V4&AO=&]S:&]P(#,N,  X0DE- ^T*
M4F5S;VQU=&EO;@     0 ,     !  $ P     $  ?_B"^!)0T-?4%)/1DE,
M10 ! 0  "]!N;VYE @   &UN=')21T(@6%E:( ?4  < %0 3  L (6%C<W
M         $E%0R!S4D="     0            #VU@ !     -,M2% @(
M
M$&1E<V,   %$    =&)865H   &X    %&)44D,   ',   (#&1M9&0   G8
M    B&=865H   I@    %&=44D,   ',   (#&QU;6D   IT    %&UE87,
M  J(    )&)K<'0   JL    %')865H   K     %')44D,   ',   (#'1E
M8V@   K4    #'9U960   K@    AW=T<'0   MH    %&-P<G0   M\
M*&-H860   ND    +&1E<V,         &G-21T(@245#-C$Y-C8M,BTQ('=I
M=&A"4$,
M                                                    6%E:(
M     "2@   /A   ML]C=7)V        !      %  H #P 4 !D '@ C "@
M+0 R #< .P!  $4 2@!/ %0 60!> &, : !M '( =P!\ ($ A@"+ )  E0":
M )\ I "I *X L@"W +P P0#& ,L T #5 -L X #E .L \ #V /L! 0$' 0T!
M$P$9 1\!)0$K 3(!. $^ 44!3 %2 5D!8 %G 6X!=0%\ 8,!BP&2 9H!H0&I
M ;$!N0'! <D!T0'9 >$!Z0'R ?H" P(, A0"'0(F B\". )! DL"5 )= F<"
M<0)Z H0"C@*8 J("K *V L$"RP+5 N "ZP+U P #"P,6 R$#+0,X T,#3P-:
M V8#<@-^ XH#E@.B ZX#N@/' ],#X /L _D$!@03!" $+00[!$@$501C!'$$
M?@2,!)H$J 2V!,0$TP3A!/ $_@4-!1P%*P4Z!4D%6 5G!7<%A@66!:8%M07%
M!=4%Y07V!@8&%@8G!C<&2 99!FH&>P:,!IT&KP; !M$&XP;U!P<'&0<K!ST'
M3P=A!W0'A@>9!ZP'OP?2!^4'^ @+"!\(,@A&"%H(;@B"")8(J@B^"-((YPC[
M"1 ))0DZ"4\)9 EY"8\)I FZ"<\)Y0G["A$*)PH]"E0*:@J!"I@*K@K%"MP*
M\PL+"R(+.0M1"VD+@ N8"[ +R OA"_D,$@PJ#$,,7 QU#(X,IPS #-D,\PT-
M#28-0 U:#70-C@VI#<,-W@WX#A,.+@Y)#F0.?PZ;#K8.T@[N#PD/)0]!#UX/
M>@^6#[,/SP_L$ D0)A!#$&$0?A";$+D0UQ#U$1,1,1%/$6T1C!&J$<D1Z!('
M$B8211)D$H02HQ+#$N,3 Q,C$T,38Q.#$Z03Q1/E% 84)Q1)%&H4BQ2M%,X4
M\!42%3055A5X%9L5O17@%@,6)A9)%FP6CQ:R%M86^A<=%T$791>)%ZX7TA?W
M&!L80!AE&(H8KQC5&/H9(!E%&6L9D1FW&=T:!!HJ&E$:=QJ>&L4:[!L4&SL;
M8QN*&[(;VAP"'"H<4AQ['*,<S!SU'1X=1QUP'9D=PQWL'A8>0!YJ'I0>OA[I
M'Q,?/A]I'Y0?OQ_J(!4@02!L()@@Q"#P(1PA2"%U(:$ASB'[(B<B52*"(J\B
MW2,*(S@C9B.4(\(C\"0?)$TD?"2K)-HE"24X)6@EER7')?<F)R97)H<FMR;H
M)Q@G22=Z)ZLGW"@-*#\H<2BB*-0I!BDX*6LIG2G0*@(J-2IH*ILJSRL"*S8K
M:2N=*]$L!2PY+&XLHBS7+0PM02UV+:LMX2X6+DPN@BZW+NXO)"]:+Y$OQR_^
M,#4P;#"D,-LQ$C%*,8(QNC'R,BHR8S*;,M0S#3-&,W\SN#/Q-"LT932>--@U
M$S5--8<UPC7]-C<V<C:N-NDW)#=@-YPWUS@4.% XC#C(.04Y0CE_.;PY^3HV
M.G0ZLCKO.RT[:SNJ.^@\)SQE/*0\XSTB/6$]H3W@/B ^8#Z@/N _(3]A/Z(_
MXD C0&1 ID#G02E!:D&L0>Y",$)R0K5"]T,Z0WU#P$0#1$=$BD3.11)%546:
M1=Y&(D9G1JM&\$<U1WM'P$@%2$M(D4C721U)8TFI2?!*-TI]2L1+#$M32YI+
MXDPJ3'),NDT"34I-DTW<3B5.;DZW3P!/24^33]U0)U!Q4+M1!E%049M1YE(Q
M4GQ2QU,34U]3JE/V5$)4CU3;52A5=57"5@]67%:I5O=71%>25^!8+UA]6,M9
M&EEI6;A:!UI66J9:]5M%6Y5;Y5PU7(9<UETG77A=R5X:7FQ>O5\/7V%?LV %
M8%=@JF#\84]AHF'U8DEBG&+P8T-CEV/K9$!DE&3I93UEDF7G9CUFDF;H9SUG
MDV?I:#]HEFCL:4-IFFGQ:DAJGVKW:T]KIVO_;%=LKVT(;6!MN6X2;FMNQ&\>
M;WAOT7 K<(9PX'$Z<95Q\')+<J9S 7-=<[AT%'1P=,QU*'6%=>%V/G:;=OAW
M5G>S>!%X;GC,>2IYB7GG>D9ZI7L$>V-[PGPA?(%\X7U!?:%^ 7YB?L)_(W^$
M?^6 1X"H@0J!:X'-@C""DH+T@U>#NH0=A("$XX5'A:N&#H9RAM>'.X>?B 2(
M:8C.B3.)F8G^BF2*RHLPBY:+_(QCC,J-,8V8C?^.9H[.CS:/GI &D&Z0UI$_
MD:B2$9)ZDN.339.VE""4BI3TE5^5R98TEI^7"I=UE^"83)BXF229D)G\FFB:
MU9M"FZ^<')R)G/>=9)W2GD">KI\=GXN?^J!IH-BA1Z&VHB:BEJ,&HW:CYJ16
MI,>E.*6IIAJFBZ;]IVZGX*A2J,2I-ZFIJARJCZL"JW6KZ:Q<K-"M1*VXKBVN
MH:\6KXNP +!UL.JQ8+'6LDNRPK,XLZZT);2<M1.UBK8!MGFV\+=HM^"X6;C1
MN4JYPKH[NK6[+KNGO"&\F[T5O8^^"KZ$OO^_>K_UP'# [,%GP>/"7\+;PUC#
MU,11Q,[%2\7(QD;&P\=!Q[_(/<B\R3K)N<HXRK?+-LNVS#7,M<TUS;7.-LZV
MSS?/N- YT+K1/-&^TC_2P=-$T\;42=3+U4[5T=95UMC77-?@V&38Z-ELV?':
M=MK[VX#<!=R*W1#=EMX<WJ+?*=^OX#;@O>%$X<SB4^+;XV/CZ^1SY/SEA.8-
MYI;G'^>IZ#+HO.E&Z=#J6^KEZW#K^^R&[1'MG.XH[K3O0._,\%CPY?%R\?_R
MC/,9\Z?T-/3"]5#UWO9M]OOWBO@9^*CY./G'^E?ZY_MW_ ?\F/TI_;K^2_[<
M_VW__V1E<V,         +DE%0R V,3DV-BTR+3$@1&5F875L="!21T(@0V]L
M;W5R(%-P86-E("T@<U)'0@
M
M      !865H@        8ID  +>%   8VEA96B            !0
M;65A<P         !                               "6%E:(
M  ,6   #,P   J1865H@        ;Z(  #CU   #D'-I9R      0U)4(&1E
M<V,         +5)E9F5R96YC92!6:65W:6YG($-O;F1I=&EO;B!I;B!)14,@
M-C$Y-C8M,BTQ
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MU=;7V-G:X>+CY.7FY^CIZO'R\_3U]O?X^?K_Q  ? 0 # 0$! 0$! 0$!
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MZ"HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH _G7_X.A?^47K_ /9SW[.7_J8SU_117\Z__!T+_P HO7_[
M.>_9R_\ 4QGK^BBEU?HOSD 4444P"BBB@ HHHH **** "BBB@ HHHH ****
M"OR'_P""O5K^R+H/[/GCCXD_&[X<^ OB9\;]&^'FM^%O@1X?UF5;OQH_B#Q9
M<_V1I6I:'H,.HVM_>:#X:UR]C\5>([F*V>.'3-%OD2<7;VT$OZ\5_,?_ ,%-
M?#7Q._:Y_P""@O@O]FKX8:):'4_ W@#2])AGU&[M;:RN+OQ!8R_$'Q%XHUO5
M4EO&TGPSH7A^\T>SALVL(=;N-5L]1%G;ZNVL>'K*?]&\+>&L/Q1Q92PF.S"O
ME.59?@,?G.<9K0G1I+ 9;EU)3K5\34K5J$*>$E4G1H8B:FYQIUFXPDSY3C#Q
M0S7P>RS"<;Y!AJ6:9_@\[R3!9+PY+,\WRG%\68[,,RH8=\-9;B<CPF,S&6.S
M/"/%1C1ITH4Y8:EB9U\10HTYU8^*_P#! ?1_V5M8F\3>'_B]\-/">D_M/> ?
MB)8^.?@_X^\9>;H_B+7M U_1+/2!X?\ !JWMQ:)?ZMX1U?1]0U"ZLXHKB[N+
M/QG:RVMM+%8W\L/];5?QS^/?V8?C[_P3-^.?P"^,WC6V\.>,O"^E>.]$UFVU
MCP7?37>@ZVVF722^)/ M[=>(].\/77ASQ-?^'?[0DT*_OH8](?S1J45SJ2:1
MK>GV']C ((!!!!&01R"#T(/<&O<\8>&<JR;,,ESGA[.ZO$7#_$F!Q.(P69N5
M*6&^MX#$K#YA@\*H5:E2FL-*IAYUZ5:%&=*MB)04++2\D\>N+/'W/.,.(..^
M'*' W%>59OAL%C. XYQG.;8GA_!8G+L-B<'BW+-L'AH4,NSRO]?QN71RVMB\
M#/DQ/LZM.4)48%5[RZBLK2ZO9]_DVEO/=3>6I=_*MXFEDV(.7?8AVJ.6. .3
M5BBOQT^I5KJZ;5U=)V;75)V=FUUL[=F?CC_P_1_87_O?'+_PS/B3_P".U^-W
M[?\ ^VE\7_\ @I;\6K7P#^PI<?%/3/AM^SG\&?'_ ,:?'$MO<ZW\//$6M7^@
MP177BC4KS2]-U4ZAJ4>AV$/A[PKX'TF2U76+OQ9XBUV&WMS9:C;W<?\ 87KD
M&KW6BZQ:^']1L]'UZYTO4(-$U?4=,?6M/TO5YK2:/3=1OM'BU#29-6L[&]:&
MYN=,CU337OX8GM4U"S:47,?\@GP)_8E_X+E?LG>+_BUXA^"?AWP7_P )'\5]
M=^V^/_'FI^*_@#XRU'QQ<:=JFN7T.KQW_P 1;ZZURRMM7OM=U/6;J.2RTB^U
M*>]@FUVS-Y9VT5I]UP]4R53Q6,HT\+@<=A806#AG&:1EAJLJ[E"K-VP5'6E2
M4TN5U'S3C>$4U-?U=X.8SPRCB<\XDRS!Y#PMQ5D.&PU+AO#>)/'U"MDF/KYK
M*MAL?BFEPOEC4LOP$*_LW1>-G[?%454H4(N&)7Z*_LY?\%Z/V:-9^"7PXF^-
M\/Q3M_C%9>&-.TGXECPO\-=0\0Z%>^+=*A%AJ6N:=?Z.T5C%;>)3!'XDCTR.
M&,Z.NK#2F\TV?GR_HU^RE_P4&_9\_;+\0^+/#/P:/Q .I^#-&LM=UG_A,O V
MJ>$K;[!?WQT^W^Q7&H.R7<_V@'S(8QNCCPY."*_-_P#X(O?L.?MD_LE^./VA
MO$O[0UCX<^'W@KXE6/A^33_AMH>H^#]?M]8\9VVKZI?IXKTR3P7K-]I'@S2_
M#.DWNJ:"- M[2)==3Q#I[ 6=KX0LH[O^@"O)SV.1X?%XNAEU&5:[A.CBZ&80
MJX6#JJ%6=.-&.#2E&ES2I14<3)*T6Y\RE!?GOBQ3\*\HXBXARG@W*ZV9*<Z&
M*R[B#*^,L/C\AP]3'4\/C<1A*.6T^'%&M1P+JU\!2IT<\JQ@H4IU,1[:G6PL
M"OY?_P#@[7_Y1A^!O^SO/A7_ .JV^-5?U 5^-_\ P7&_X)Y_&G_@IA^QUX;_
M &>_@1XG^%_A/QIH_P =O!7Q/N=3^+>M>*]!\+R:!X<\(_$+0+ZS@O?!W@KQ
M[JK:Q+>>+-.DM+>318K)[:&]>;4()8X(;GYL_$C^2#]J3]J[XG:7_P $?/VC
M/^"4'[74KZ5^UO\ \$^_V@O@WX2T2&]%T#X__9TM/$#6'@K7]"OKYH;K7=+\
M&1:GH>EZ-JXTC1;+4?A3XI^#FJ6,>JWE]KM]'_3M^WG_ ,%0/VD?@A^T#^RG
M_P $[?V!_@'X(^-W[8GQW^$FG?%-M1^,&MSZ/\(_ ?PZL]/\5Q?:]472O$_A
M+4=2U06OP\\::]JRW/B?P^-*TK2-%LM$L/&OB#QEIND:?X__ ,%VO^"$7B#_
M (*:^)?A9\<OV;/$?PI^&W[1'A>V?P)\1[[XHZAXM\/^$OB'\,H8K[4?#=Y>
M:GX+\(>.]0'C7P1K<LVFZ6\OA=?[=\,>([FTU;Q%;P^"_"VE3^X_MW?\$U?V
MO?%W[7O[+G_!1/\ 8-^+OP7\)_M-?L]_!^+X%>)OAO\ 'ZS\9CX._$SX=K'X
M[N[B*\UGP-8ZAXA:]ENO'FMZ:=(N=(TY+M9-!U^S\7>%-5\*6JZB ?$NK_\
M!>[]KSX7?!+_ (*&?"_]HS]FSX-?"#_@HS^P?\/_ (8?$L^%K;5/$OC?X$?$
MSP=X_P#BO\+_  ?J&OP:%H?C5?$&@VFB^%_C!\.]3T^W@^,.OS:[-XOL=3ED
MT;^RM5\-"KI7_!:?_@IU\,8O^"<_[17[5'[,G[*7A?\ 8P_;H\4_"_X?9^'&
MN_%#4OC/X>NO'WASP\1\3KG4;G7M>\)>'M#URXU#5/BAX%^&;:%XN\32>"-)
MU#X=^)/%-EXI2'QT(=>_X(7_ +<?Q[\ ?\%,_C;^T[\8?V:]8_;P_;T\#_"O
MX8>#K?P+=_$;1_@%\*_AWX&^)GPC\;ZOHFH:[?>!]4\:.;O1?@]X&\.Z'96/
MA/77TK_A$(;C5_$WBF\\47^K:-]F?M=?\$I/VA_CY^P3_P $KOV6O!WC/X+Z
M;\0/V'O%_P"R-K_Q8UCQ+XB\<6?@[Q#9_ /X,O\ #OQA%\/-0TOX=:SK>K7.
MI:VPNO#2>)/#WA**\TO,^J3:-=_Z#0!]\?M!?\%(_P!ECX6>.O''[+^C?M)?
M OP[^VL=/LO"?PQ^$7Q0O_$L5A<_&7XB>%M.U/X*Z#XRA\/6:ZB/#_BG5/%'
M@V;4!H^H0ZDVAZNS6<]O>,C1_P SO_!OG\?/^"D=C^S9_P %"/C3X8\ ?#_]
MJ_18OB5\1M>@T;Q3\4=6T;]HCQY^V VC? S2[+^W_B5\6?&FD?#NU_9]T'X7
MOJWB+Q+J&MZJWQ&EO=#33] FOGEL]+N?ZE?'G_!-_P#89^)WQ]C_ &I/'_[,
M_P -O%/[0<7B/P5XOC^*VJ6.H2>*5\2_#FRT#3? ^L">/48K7[9X:L?"WAZV
MTUOLNQ(M)M1(DA5B_P#.=X._X(8_\%'/ ?[*_P#P4._8(\,?%7]EO1_V:_VC
M_&WB'XR?!WQEIOBCXM1?%Z^\>V7Q#^%%_P""_!'Q-=_!*>'M)^&>O_"[P!JF
MA^/;'1K36];L?&^H:5?:?K_B;PG:ZMH^K@'K?[,'_!;G]LC_ (;L_9E_9._:
MLM?^"=/Q7T3]J6*^T:"\_80^,&L>.?%_[/7CZ*V%TGA;XR/>?$+XB^'I=6TN
M6 Z3K&@:7]DL[J:^O-9\->/-<'AC4/#EUO\ PY_X*G?\%;OVE?V^/VO?V6?V
M9O@!^QYJGPB_9#_:CB^'/Q+^+?Q A\?:3?>#?@K<_$KQ-X*M]:UBPF^.N@Q>
M*O'7_"/>%O$OC%Y_#EGIVG-:^#M9M(?#$U[J>D6;^0_ 3_@B7^W_ .&?VI/^
M"=OQ\\:>'_\ @FI\(_ 7[%VJ^'M)U_X9_LV0?%#P7K_CG1;6PTG2O&7Q<\5>
M([GX0:DOQ(^-GC$V]QJ=U:Z[J7A_0GBT70[(^(;'4-=\1:Q;?JW_ ,$Y?^"=
MGQB_9'_:_P#^"K/Q\^*GB'X5>)/ ?[=?QQ\,_$CX7:)X,U;Q3K'B'1/#6D>*
M_CYK>H:=\2M-\1^"/#6C:;J=S8?%30;>*T\.ZSXOL)I[76HI[Z*&"REU$ _(
M[0O^"Z'_  59^-OP*_:J_;\_9P_8M_9PU+]@WX):IXS\*^&8/B!XA\9Q?':*
M?P]X2BU _$C6ETSQYI>B^,/"7@O4-7\.>)?B7X=\/^&?#4[:-J<_@OP?XOU#
M4O#/BWQSIOM'Q\_X+X?&GX:?L3?\$Y_%'@WX<? 75OVT_P#@H1X8?7=._P"$
MW\27/P]_9I^#VGZ5XJT?0=7\5^,U\2_$&TUZT\/ZK_:KV&@OK/Q*T?2=,?2_
M$GB36_$]Q;>'8_#'B#^>)_%6I_!/]@?_ (*!?LH_ K_@IA^S-IW[&D_CGQ!X
M@N_@?\5_!/Q9\ ?\%"+GQOY6F#3O@;X7^%GBOP]X=TMM)\8>(?"?ACP;\9_$
M/A?QCXU\.>&+;1O$WB+R=,M]2\4:#K_[93_\$>OB_P#M@?\ !-K_ ((O_%KX
M30?L^O\ '[]E/X6>$O&UQ\+_ -J/PUK6L?!+XS?#/XAR^'?B?:_#_P")UCIO
MAG7=9OK.'^SM/L9?#-QI-OI>H6'C'QA:MK^C3FPUB@#YW_;#_P""T'[6W[0G
M[#O_  4*_9>O9_V<_ _[3?[-]C\*_$_Q*^-G[)_Q=\<^(OA1\3_V:?%OCWPK
MX6\5Z[^S[XM\.Z[?7VA^++/Q;X\^#/A?7]/\2>-==TWQ'X$\<_$71]3T;0-<
MT2ZT>/ZU^&__  4\_:)_X)D?\$+OV3?BC\:/A[\#/B!\6?B=IOPQ^$7[$/A'
MP)KWBG2/#T_P@O\ X%>&M;^'_C_]HN;Q3JL>H7'BCPS?:9XA/Q)TWP#>Z'H&
MK2:EX)T32]5\))JVI^*-+].\*_\ !$K]I'Q_^S3_ ,%#O!WQPTO_ ()X?!KX
MH?M3> M.\$_L\^!OV._V=OAW\*OAQ\'-*T;Q3X9^)EOH?COXQ^&_V?O!OQY\
M5:#KGCOP'X"M]8T.^U/QSHVFV^@7OB@6WBC6+_1].\,YGQ7_ .",O[;G[6/_
M  29^#_[%_[07BK]DKP=^T9^R'\0/ DG[+OBWX?R_$;7/AQX@^$O@+X:Z9\/
M8_#/QKU3Q1X1U'7+;Q#XE>\\1:UKVH>#_"-]X>OWT+P-!+X6MUCU@, +^S?_
M ,%_/BAX.^*WQ0^ O[?'AG]E/Q1XP\+?LH?$O]J_P+\1_P!A'XMP_$GX>>)[
M7X4_#OQ'\2_$_P $]:6?Q7X^TK2_B=%X>\$>. ^HCQU:Z2NKZ%8Z?9:1J6E>
M*/#OB6__ "H_X*)_M_\ _!5#]M;_ ()(?$KX]?&S]E?]G[P9^PC^T3XS\.:?
M\,=?^'OB/Q0GQG^&2>"?CUX7NO!OB;XA6WB#Q1K%CXN\'^*KSPEK_P .X]3T
M_P (^!K[5_$TFF^-8=-\,>$[SP_I'BW]E?V;/^"./QY\8?$GXW^)/VS?A=_P
M3'^ OPH^(W[-/CWX%>$?A1_P3[_9;^%7AOQ5X=\4_%/P-K/PQ\<_$R/XT>-O
M@)IGQ<\(73>$O$GBMM.T3PQ\2M6L]4G\0:?8:N;31_#^H:7XL^(_'O\ P10_
MX+2?$/\ 8'\-?\$R-0^//[!]E^S=\%O&5QXM^'7BZ'6?V@-/^)GQ4@;QOXA\
M2:'X2^)EZG@;7M"T7PAX<7QEK7B&TT[2_#&I7EEXA\.>!_#\5_K&F64_B>T
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M,WXB^"?V??VF_P#@GEX7L_AQ\+];^)L.K'PQ\3/AH S:AH?Q'UWPOH>NW_\
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M#WPNO_%7A);>T;POJFF#Q=\,I_#6MZ3I/Q5TW488M)MIM4E /T:^#W_!7O\
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M:*"8QK=VDRH98(92H!DBC?*#U&@ HHHH **** "BBB@ HHHH **** "BBB@
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MK&M>)/$#O9VD-K9ZWXY\#Z!:Z;<ZWX=CN;OQ4FJW6NZ?H^A:M,.<_P""6O\
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M6Y>=C(?KZB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH _EI_;;\
M3?M\?#G]OK]M+QQ^RU\+?V9?V>/ O@#X)?#KXQ_%3]L6_P#V9)?BO^T7XP^&
M.C_!RYU;5_%^G^)-4N7TGQW:^&]9^!5_^SROP@TBYM-;TC0_$UKX]L/"FHS)
M?>,O#W]"'[)'Q ^*OQ7_ &6_V=_B=\<_!MO\/?C'\0O@O\-_&?Q-\$VMGJ6E
MP>&?&OB3PGI6K>(-*71M9>76- :WU"[F$GAO5[B\U7PY*7T/4;Z_O-/GO)_G
MW_@JI^U7\4/V)?V _P!HG]IWX->"]/\ 'GQ(^&/A_P -S^'='UJTOM0T'3V\
M2^._"W@[4O%OB#3]+N[+4[_1?!6D^(;[Q9?VEG<0K-%H^S4+K3M(_M#5+'\?
M+#X#_P#!U7XGL;+Q+9?MX?\ !/+0[/Q#:6VN6FB0^%H+^'1[;5H4OX-+AOK;
M]CSQ+;WL6GQ7"6D=W!XCU^&Y2$31:UJJ.M]. ?T4^ OV>O@3\*O&_CWXD_#'
MX/?#;X=>//BG'I"?$OQ5X'\&Z#X4UCQ\^A7.KW>D7?C"ZT*QL3XBU*QGUW5W
MBU751=:D5O98I+MXEB1/8JI:8E_'INGQZI+#<:G'96B:C/;C;!-?K!&MW+ /
M*AQ#)<"1XQY,6$91Y4?W!P7QEUCXE^'OA%\4==^#'A'3O'WQ@T?X>^,M2^%7
M@?6=4L]#T7Q=\1[/P]J$_@GPYK6M:AJ&E6>DZ-K'B5--L-6U*?4K-;'3I[FY
M6='B6@#TJBOX4?VO_B)_P7+_ ."<G[._P<_X*'_M*_\ !0>ZTW]H#XD_&F'X
M=^(OV!_$/@SX;>(?AW::+%)\0+C38-(E^&7B+Q+\,M?2_P#"V@V>K^(I?"OA
M[PIJFDZ?XITF*7XC+X]T+1H+W[C_ &G?V@?V^_\ @HM_P5>\8?\ !-O]EO\
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M;Y:<92T/V$K\4O\ @KY^V;??#7PC8?LD?"?Q$VA?%[XY>';Z^^('C6U"2?\
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M&-2T7P_XC\,ZCJD>E:OXAT[267Q!+9^$5T34O%T_A+6O$6F>')/S._X(>?\
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MTVG[Z_L'?\.]O^$M_;!_X88_L7_A*_\ AHKQ3_PUS_9/_"TO,_X:$_M/6_\
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M_L?X3> M,_X7Q_;G_"2?VW_PN;[%H$'_  M'^V/^$R\7_P!J?\)O_;G]H?\
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M_P!&NKNWFGTN]>VFFMVNK)X)V@EDB,AC=E.Y0!_$C_P76_X(N_\ !-+]A_\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M?#GB3]H4>,++5+>X2UMK'48]4_;!L-*DDOYG8Q1Z#J>OWD$<,ZW5E%=B"SG
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MR_\ 4QGK^BBOYU_^#H7_ )1>O_V<]^SE_P"IC/7]%%+J_1?G( HHHI@%%%%
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% 'PI_P4O_:YT+]A?]A_X^?M.^(_AO\
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MBBB@#^=?_@Z%_P"47K_]G/?LY?\ J8SU_117\Z__  ="_P#*+U_^SGOV<O\
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M#I'QX\:Z=X@T2QD;Q1<:U\.;"2+P_#X2\8V/B[3/Z._^"2_[!EM^SS_P2L^
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MUU>4I2GT>NL5I<HHHK^JSA"BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MX=T71_#^D0+:Z5H6EZ?HVF6RXVVVGZ7:0V5E N !MAMH(HQ@ 87@"OXEI_\
M&1>,V(JOW\!X:\'PPE-.ZA_K/Q]BH8K%-)+WL1EG#?#^ 492=H4.)JD81;J2
MDOP_X,.N]:HW?KR4E9+TE.;^</(U****_6CG"BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MHHK^$#_@M5_P6Q^"O[='[&5E\ _ W[)_[>OPAU_4?CS\%/$\?C+]H3X%>$_
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M6P_$E%<=9#B/$:E@,%43HT9U,VH4.'N'\\P^<8K UYQPE.>$JX&5%4%3H/\
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M^*;;4KC0O!>F?VET4 ?Q??'O]B'_ (*H_L;?M,_\%8_#O[%O[+.G?M/? O\
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M;>%/AQX3UV[TJ=T5;RTLO$&G&ZAWV\TK0221O^>W[0O["GQ>_;D_X.&?VZ/
M_P ,/VK_ (S?L87/AW]FCX+>,I_BC\(K7Q.FH^++&T\"?L_^'YO ]W=^'O'O
MPYDETR:\UB'6YHWUJ^A6]T&VWZ:TJ)<VOUI_Q#M_MB?])W_VXO\ S*/_ -%%
M0!_5*         !@ #@  <  < #I2U1TNTDT_3-.L)KJ6^EL;&TM);V?=YUY
M);6\<+W4VYY6\VX9#+)NDD;>YR[G+&]0 4444 %%%% !1110!_.O_P '0O\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M+_Q4DC&QO6E 6Z)LD^@O^"7?@#]O&]7PQ^T)^TA^TO8_%OX-_%OX$66N>#/
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M:_\ L-_";_U:_@VOJ#]@'_DQ_P#9*_[-Z^$__J&:17R__P %K_\ E'-\:_\
ML-_";_U:_@VOJ#]@'_DQ_P#9*_[-Z^$__J&:17Y]0_Y.GF/_ &0F5_\ J^S,
M_>,;_P HS\/_ /9[.)?_ %B>'#Z[K\VO^"O7_*.;]IC_ + G@3_U:_@.OTEK
M\VO^"O7_ "CF_:8_[ G@3_U:_@.O>XQ_Y)'BG_LG,\_]5F*/B?"/_DZWAC_V
M<+@O_P!:3+3M?^"8?_)@?[+/_9+[#_TY:G7WA7P?_P $P_\ DP/]EG_LE]A_
MZ<M3K[PK7A7_ ))CAS_L0Y/_ .J_#G'XE_\ )Q_$#_LMN*__ %>X\****]X^
M)"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M37KU882G@G1PU.4(-3=/GE^LU%%%?TB?L84444 %%%% !1110 4444 %%%%
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M*OA%K.I'74\'7_@72+TVGB%_ =U:6\8UDI927;-]JO3921S>,?\ !"3]H;X
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M.?% ZO\ "+5?%+Z%X=UNW\#Z+H?P_P#&]OX;2ZBLK]1X<\!SO-J#>)+?0]'
M/Z%/@%_P6\_X)I_M,_M%G]ESX0?M#V>O_%*]U'4='\)M>^%/%NA>#?B#K&E&
M[^W:7X$\;:OH]IX>U^\:.RFGTD)>6\/B> QR^%)M<6050_:&_P""Z7_!+_\
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MS\$/"G[-/P)^#_[/?@34/$.K>"_@I\./"'PP\*ZGXMN]-O\ Q1J&@>"]$L]
MTN\\07NCZ3H.E76L7%G8Q2:A<:=HNE64MRTCVVGVL16%/8Z* /EO]LW]CWX+
M_MX?L[>//V9/CWIVKW?P_P#'D>ES2ZEX9OK32?&'A;7=!U2TUK0/%7@_6KW3
MM6MM*\0:/J-G$\,MUIFI:;J%C+?Z)K>F:KH.JZII=Y\3?L@?\$7/V9_V4_B'
M\0_B_P"(OB+^T#^UK\5OB+\)_P#A1%]XX_:T\?:9\4=2\/?!R2QBTF^\ >%D
MMO#/A];#1]6T2TL-!OVOWU2Y@T*S;1-#ET72-3UVQU7]?:* /P=_9Q_X-[/V
M//V</CC\&OC#IWQ9_:I^*7AW]FWQ;XJ\<_LY? ;XQ?$_P[XR^"/P7\4^,;U=
M9U75_!WA:/P'IFH6%Y:^)+?2O%&FW-KK-I=S^)-!T/Q!XGN/$VN:;#J5>5^+
M?^#9O]D;Q?\ &/XH?'RX_:W_ ."A^@_%/XQ^+?%?C/Q]XG\'?&CX.>$KO6-7
M\9^(9_%&N0%]"_9VLY(M(DU>836ND"5K&SCMK.&")4M(-G]&U% 'X2?MI_\
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MAW4M;T[PEI<MEIFM7D6H^([RQAT>RDM-&U:Y2YO8F@TR_E"6LO?U^77_  6
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MSF>1XG+,D> \1*F)QU-4,'@,+B8JKC<MKO"VQ6,Y,-5I0JRE54ZA[37\VO\
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MHNNZ=J.E7L<=W9S1K_&G^P3/96FO?\'>MOXQGTO^UF_X:+?5FOEM%BGMDO\
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MEN P=*AA,#@J5?%8FM##8:C2I1JUZLU#FJ2;_HHHK^=?_A2__!SO_P!'A_\
M!,/_ ,-?\4?_ )UE?(?[>/QA_P"#C?\ X)^_LH_%7]KKXI_M/?\ !/3Q?X#^
M$G_"#_V[X=\ ?"CQM=>+M1_X3WXD>#_AEIG]DP>(O OA[1G^R:SXST^^O_MF
ML6>W3+:]>W^T72P6L^-_)_=Z?Y_@^QSG]<E%?SD:3\*/^#G+5]+TW5H/VP/^
M"8\<&IZ?9ZC#'-\+_B>)8XKVWCN8TE"?"YT$BI*%<([*&!VLPP3?_P"%+_\
M!SO_ -'A_P#!,/\ \-?\4?\ YUE%[]']WI_G^#[ ?T445_.O_P *7_X.=_\
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MJ;W:-NCNU)NGZ/\ :ET+]MOX7_MI?\$X];_;_P#C=\%/'-A9_'[PAK/A'7O
M0L_#^B>#?#^B?%?X37?CK4/%VH77PP^%=G:67D_V->K?7;:I;65IIVH3S7&F
MQ*YNO:SSCC.:?".&Q>$RS.LJS'$1R"#SO&Y;EL\LHRQ^-R^AB<1*F\;43IUJ
M=>JJ,70BN:I3_@_'#Y#@OP7X0Q/BKC\IS7B+@_B?(,#4XXK1X.R;B#B&CQ%B
MJ>291GF-R[ 0K1R;#RAB,+6P>&>,FL;-\E#$6^M/]W5^T9_^#A#X9VT4D]S^
MRQ\9K>")=TLT^L^'XHHUSC=))):JB+D@99@,GK7[-?LM?M :/^U+\!/A[\>]
M \/ZEX5TCXA6>M7EGH&L75K>:EIRZ+XFUKPS*EU<V0%K*TT^BRW49B "PSQH
MWSJU?$?_  4;_:6_9R\6_L._M*^&_"GQ_P#@GXG\1:Q\-[VSTC0/#WQ5\":U
MK6J7;:AISK:Z=I6FZ]<WU]<,J.RP6T$LI56(4A21^67[#WPD_P""SWB/]E'X
M0ZW^RY^TW^S?X%^!U]I_B1O 7A'QS::>?$VD647C7Q/!K*ZM/-^RI\1YGFN?
M$L.KWMLK>+-7 L;JW FM=HL+=8#B'B7*N+5DN*S.MQ[A:_#U3,HT\CRS(,NK
M83$QS*AA%.M.MFN&H.C&GSJ5\9S\^(IVH.,74B\[X#\.N)_"U\7Y;P[@_!#,
ML)Q[A^'JE;C3B/CG/\)FF7RX=Q>9RI86EA.&,QQD,55Q+I2I\N4NDJ6!Q%\=
M&4U0G_537Y.?\%1?V\?C'^Q.O[/]I\&_ O@3QWK/QEU_QGH$VG^-+3Q%=NMY
MH0\&1Z);Z,N@>(O#Y6XU"[\3S03B[>Y1REJ(O(Q*9/CK6/V7_P#@X1UBWN;6
MX_;-_9BCBNW629]-\8>(/#]RC+.EP!:W>A?L865W9H70*T=G/;QM"7MF1K:1
MXF_GZ^/?QX_:WT7]O[Q'^S3^V]\5[;XA:O\ L7>/?@)K-[XFT/Q=XB\:^$(;
M/XO^%O"'Q;OKWP[;ZCX!\#ZP9+/PW_95IK#-X:6_NM0L&L[..\MK:UN+G;CK
MBOB+"<,9CB,+P]GO#SC++X_VWB<;PTU@55S3!T:LG1PF<YA7:J4JDJ*:H347
M5<IJ,(.:X_!7PQ\/\T\2.'L!F7'O!7'D:L<]G_J=EV3>(T99U/#<-YMB\/2C
MC,TX1R'!0=#$488MQGC:4JBPRIT75K5(T7^_7BK_ (*%_P#!8OP1X8\1^-/%
MG[!?@#0O"WA#0=8\4>)=;OO#WCA++1_#^@:?<:KK.JWC)\5G=;73].M+F[N&
M1'98H7*JQ !_6+_@GW^TGXO_ &M_V5?A_P#'?QWHGAOP]XF\6ZAXVL[_ $GP
ME%JD&A6\?AGQKKWAJS:TBUC4]7U!7GL]*@GN?.OYE:YDE:(11%(D^&/VI_\
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MF%U34_CA\4=0^+'B6**5(S'=Z9%\*U;3K;4(PSNEEXA\-2P"4?9[M(@IE?\
M.K_@IM^R5^V_#^R_?>._C7^U_P",OVC;ZW\5^#;./X)_#OX/:;X-\&0W=[>3
MHVK3V_@^X6?Q*NA*;@V=WJ/A:TN5>2"ZGGC>(1MZ?_PI?_@YW_Z/#_X)A_\
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M*TBL+.TL8"YALK6WM(3(0TABMHDAC+L%4,Y1 6(506R0H'%6:\U^,OQ5\+?
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M)0W]GXTC^*^@>(-"EU>X\7MXBM)]!?0UUYKF.RC\.:LNH-;+$UU9B4R1Q?\
M!4'_ (*"> /^":_[(WCS]HGQ;'9ZUXMP/!WP8\!7$CJWQ"^+>N65])X8T&?R
M;BUGB\/Z='97WB?QG?07$-S9>$="UE]-^U:W)I6G7WYM>#O^"ZMQX3_X(L>%
M/^"GW[0?P_\ !P^*/CWQ=XU^&7@#X0_#R;7=!\,>,_B98_$3QYX4\(Z%:7_B
M+4O%>J:1I\7A?P1J_C?Q??W-_>S1Z-X>\0-HMI/J,FE:1.?U]P']&5%?S[_L
M'?\ !7?]I/XA_MBZ%^P=_P %$_V4=&_91_: ^+_PHD^.O[.R^$/%,?BO0?'/
M@,VOBC7O["UZ"WUOQ1)HGB>T\+^$/%=X]Y-J]M'-J'@CQ9I>L:!X4U9-)TJ^
M_H(H ***_/+_ (*@_P#!03P!_P $U_V1O'G[1/BV.SUKQ;@>#O@QX"N)'5OB
M%\6]<LKZ3PQH,_DW%K/%X?TZ.ROO$_C.^@N(;FR\(Z%K+Z;]JUN32M.O@"7]
MK;]@BP_:J_::_8(_:0N_B?>>";G]ACXF?$#XCV/A&W\)0Z_!\2I/'FC^%=)D
MTB[UJ3Q%I$GA5-,'AA)TO8=,U]KLWC1M:VX@#R_H17XQ?L8?\%./'GQT_P""
M/?B;_@I7\6_!'@72/&7@_P"%G[3GQ)U/P-X)?7M(\'Z@?@1JWQ%M=%T>REU_
M5_$VM6DOB.W\&6%K=2R:A?/_ &CJ$KV<"H8;5?A[]BK_ (*P_P#!8O\ ;'M?
M@+\5?"W_  2]^&S_ ++OQ=\<Z+IFJ?&?3/C3H]M)HWP_MOB%+X'^(/C"P\+^
M(/&.G>)KF3PJNE>)+JVLYM \W57TI'T^WOK6[M)+@_4#^GZBBB@ KX)_;Y_8
M:L?VZ-'_ &6-(OOB3=_#5?V8_P!M#X'_ +8=K/:>%8?%1\97GP7M?&5M#X!G
MCFU_P^-"MO$(\7.\OB2-]5ETPV"JFB7WV@F'X\_X*\_\%1?C3^P%XY_8S^#G
M[.?P$\+?M#?&;]L/QQXR\%>%/!WB3Q1=^&1'J6@7_P -]"T"RM+F"2ULX;CQ
M-X@^(]G9QZAK6HZ=I%A#IMY/=W$<"3W%KG?"_P#X*2_MK?!_]GC]KC]IO_@J
M5^Q7H?[(_P .?V>O OA3Q1X C\&_$KPW\0-6^+?B+Q!JFL>'AX'LUTGQ3XB@
MT;6-2\4S^ /"^@W.K-INFRZIXSADO+M+*SNY[5-)Z,#]RJ*_E^_9(_X+M_M/
M>)/CO^R'X._;M_8T\/?LX_!'_@HM&H_8P^*W@WQN?%D^MZA?2^%]-\-:;XRT
MEM3U+47MO%6M^+/#-A8ZM-HW@B]L4\;^#M0F\-77AZZOO$-O_4#3 ***_)+_
M (++_P#!2;Q+_P $O_V7_!GQN\$?#?P_\5_&GCSXX>$_@]H/@_Q%J^IZ38M_
M;WA7QSXKOM6+Z/#-J%R]I!X,&GPP1".,W>K6IDEX2&8 ]W_X*9?L-6/_  4=
M_8W^)G[(NI?$F[^$EI\1]3\ :C)X[L?"L/C2YT@^!/'_ (;\=1PIX=GU_P ,
M17HU.3PZNF.[:S:FT2[:[5;AH1;R_>U?CI^PI^U7_P %6?BY\8M:\.?MR?\
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M>!O%G@J35H[47KZ6GBK0-0T)]12R:>U6[>R6_-RMJUS;BX,0B,\(?S%^9_\
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MS8Z3KVDO<:AJ<47]O:3J=_I=OJNI)H=]I4EW+*0#\NO^#8O]H;X]_&#]G_\
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MVUK9>'O%E[J>KWWB_1=?O=3O+B7]@$1(T2.-%CCC54CC10B(B *J(J@*JJH
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M$"TMQ=WM[<76I:KJ=[+<ZGK.K7E]J^K7E[J=]=W<WHM !1110 4444 %%%%
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M6/B6]U'6-6L]%\3>++&+1[.3P5XUT^YEEU*&]MM0\):W%<6$4,-M/=?(,/\
MP<4?\$_%_9E\,_M0:KIO[0V@>'OB+\3?%OPH^#OPVU+X46=U\6OC5XC\ P>
M9_&]]\.-"T+Q=K/ABZ\->&&^(VA6&H:]XD\8^&;2?6X-3\/:9_:&OP6VF7@!
M^[]%?FI^P'_P5;_95_X*,:A\2?"GP7/Q+\#?%7X/FT;XD_!7XX>"T^'_ ,4O
M"UK>7]YI(OKG1[76/$6C:A;6.L6,^D:XNC:_J5UX:U*73;7Q';:4^MZ)_:/Z
M5T %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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44 %%%% !1110 4444 %%%% '_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>31
<FILENAME>nt10014672x1_linechart4.jpg
<TEXT>
begin 644 nt10014672x1_linechart4.jpg
M_]C_X  02D9)1@ ! 0$ P #   #_[0 V4&AO=&]S:&]P(#,N,  X0DE- ^T*
M4F5S;VQU=&EO;@     0 ,     !  $ P     $  ?_B"^!)0T-?4%)/1DE,
M10 ! 0  "]!N;VYE @   &UN=')21T(@6%E:( ?4  < %0 3  L (6%C<W
M         $E%0R!S4D="     0            #VU@ !     -,M2% @(
M
M$&1E<V,   %$    =&)865H   &X    %&)44D,   ',   (#&1M9&0   G8
M    B&=865H   I@    %&=44D,   ',   (#&QU;6D   IT    %&UE87,
M  J(    )&)K<'0   JL    %')865H   K     %')44D,   ',   (#'1E
M8V@   K4    #'9U960   K@    AW=T<'0   MH    %&-P<G0   M\
M*&-H860   ND    +&1E<V,         &G-21T(@245#-C$Y-C8M,BTQ('=I
M=&A"4$,
M                                                    6%E:(
M     "2@   /A   ML]C=7)V        !      %  H #P 4 !D '@ C "@
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M;W5R(%-P86-E("T@<U)'0@
M
M      !865H@        8ID  +>%   8VEA96B            !0
M;65A<P         !                               "6%E:(
M  ,6   #,P   J1865H@        ;Z(  #CU   #D'-I9R      0U)4(&1E
M<V,         +5)E9F5R96YC92!6:65W:6YG($-O;F1I=&EO;B!I;B!)14,@
M-C$Y-C8M,BTQ
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MU=;7V-G:X>+CY.7FY^CIZO'R\_3U]O?X^?K_Q  ? 0 # 0$! 0$! 0$!
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M"\2^&AI>H^$KNT\8:5J.C?T<U_'C^W;XT\)?M.?\'%'_  1TA^ _B#1?$_\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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ME_;:C<>&/#X\2:Q>Z=HNG--96<<UY9:>FOZC;6D%OJ^LZC&I#?IU110!_/\
M?\$U?^4T/_!P=_V,_P#P3=_]9\^*-?T U_/]_P $U?\ E-#_ ,'!W_8S_P#!
M-W_UGSXHU_0#4P^%?/\ -@%%%%4 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !117RI^UO^T+X[_9P\">'O%W@#
MX#>+?V@M4UKQ;!X<N_"O@^[UBTO]'L)='U?4V\07,FB^#/&]PUG%<:;;Z<R2
MZ;:P^=J,+&]60)!/Z&4Y5CL[S'"95EM.G6QV-J>QPU*KB<+@Z<ZG+*=IXK&U
ML/A:*Y8R?/7KTX727-=I/R<\SO+>',IQV>9O6K4,MRZC[?%UL/@L=F-:G2YX
MT^:G@LMPV+QV(ES3BN3#8:M4LW+EY8R:^JF945G=@JJ"S,Q"JJJ,EF)P   2
M22  ,FOF_2_VPOV6=;\;+\.M)^/_ ,*M0\8R7J:9;Z1;>,-(D6]U21X8H]*T
M[4OM TG4M5DGG2UCTRPO[F^>\$MFEN;J":*/\&OVYO\ @HA^T1\5_@A+\-M5
M_9A^)O[+V@^+O$FF6'B+QKXEU3Q5+;^(]%AM=1O+CP1!+J7PN\%-;C5;B"UU
M+438:E<W=[I&C7^DRZ?=:;J-^H^VOB__ ,$GOV1/#/[,/C";0+?5-#\<>"/A
M_K/B^#XT7WBK5[BZO]1\-Z)<ZW-?Z_I,^J'P<GA[4Q9F.]MM-TBP^PZ>YGTZ
M]@O$>\F_8:/A;DW#F!R>KXE9KFN48_BC,L7EF183AFGD_$%'"1P;P4*V9YOC
M<-F-;#U,/&MF%"']GY?4J8YP3J)N4G2I_P _5_&[B'B[,\_H>#N29)GV5\$Y
M1@<YXGQW&57B#A7$8YY@LQJX?)<@R[&93A\71Q<L-E>)J?VKFU*EEBJ.--I0
MC&M6_9RBOYOOV2_^"F_[2OA;X%^$?!__  R-\4OVDH_!XO/#EK\4] U?Q<BZ
MAI]E.9=,T;5'TSX5^-+6YU3P]IUQ:Z4UV=8%U<6%OI\E[;?;#/=W?[=?LP?&
MGQ=\?/A5:?$+QO\ !_Q'\#M=N=;UG2I/ ?BJXU.ZU:WMM+FCBMM3>75_"_@^
M\,&I*[20*VBI&JH1'<7 RP^2XS\,.*N!Y8RKFU' 3R[#9E/+J..PV;Y/B)XJ
M7-5]A6_LRAF%;-<-"O2HNJXXK!TI4.:-.OR5'%2^]\.O&G@CQ+AEU'(J^:4\
MWQF3T\WQ&68W(.(,+3P4>3#_ %K#O.<3E6'R/&U,+7Q$:"G@<PKQQ/+*MAO:
M4E*4?H>BBOY:O^"@&HZK_P $_O\ @NY^P7^VO97^H:7\$?VX=#G_ &1OV@T2
MZN4T&/Q@LNA>$O#7B3Q+?7\G]BZ%91PZI\&O$$0C:WN+C2_@OXIN1N3[:]?G
M9^M']2M%?RR6NLWW[?W_  <?Z](VJ7EY^S9_P2:^#&+QK:]N+SP'J?Q_\00!
MI5UC9+'::5XKT;Q9XJU4[9\G[=^S.^01;3;M*?\ X.49-0'C_P#:$\#?\$^/
MCMXY_P"":OPN^)NC_"OQI^VE8>+M'TO6;;5M8.FV4&NZ;\%M7\-VPN])?7]4
MTS3(+6Z^(]A<6]EXB\)W'BBZ\)>*?$6F^!9P#^HFBOXO9_VMOBGX _X.)_VR
M/B1^RA\!_%_[<.N?%7]@WX1?\*>^&G@;XB^&?A_X.U?1_%7A#]D'X@I\1_$/
MQ \:S/X?\(^"H_!FC:C<6.KP:/K&HZYXEUSPKX8MK"W_ .$EFUC2_JCXV?\
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MWQC\:KV_73ETZ[MY0+SP1I7Q-%Q,Q_L^:PO-/^T17UC'=6;_ *V_MF?L_?\
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M@ HHHH **** "BBB@ KX!\)_\$X_@AX._P""A?Q._P""E6F>*?BK/\=/BO\
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MQOC]_P!A?A)_ZTF=G]"M%%%?H)^$!1110 4444 %%%% !1110 4444 %%%%
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M%^Q'[7VJ_P#!;BT^,M[#^PEX:_X)J:I\ 1X?T%M/N_VH9_VC8_BL?%#02_\
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MX;#8[Q)P-/&X>A2Q-2%&ABX2P;E#%4J:C3Q$)-N-6,TW=,_H5HK^>K_A*O\
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M)K\%/_ _X+?_ #?4?\)5_P '"O\ T37X*?\ @?\ !;_YOJ/^(@P_Z(SQ!_\
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M'PSXC\&ZY:ZAXD\6Z1H(\1>&?&GAR/P]X8\26WAEH]4\8=;_ ,%'_P#@L_\
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M)7A+Q+IOQ.T/]KGXJZCXF^(GCZV^,6F7>MI;^*1X7\4>/[^1/"%KX6\2Z]X
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M_A#>C6O&7CGPS\1_&$^L:!X5MX-9TJTU3Q7<:Q_:?7X=_!__ ((R_P#"J/\
MA\U_QDA_;_\ P]S_ .%I?\T?_LK_ (9]_P"%E?\ #2'_ %5+4?\ A:_]B_\
M#07_ %37^T?^$1_Y</[?_P")* ?B/XN_X*O?\%9?"/[&O[!'_!6#Q%^T)\&I
M/@5\=_V@-#_9^\:_L@^$/@-X<TX:U;>%/$'Q2\/^*?&>K?$_Q))XE\71ZW\0
MY?@9XVNYK'PIJOA+2/!O]N^&H]#M;U%U>.+[_P#C_P#M8?\ !43]K?\ X*X?
M'3]@']@OX]?"O]E#X>?L=_"70OB!XW\;^,_AEX:^)EU\6O$WBOPC\-_$&G:#
MK=EXL\+>)M0TS3/[=\?VGA>T'A&+P^NDZ!IOB[QE?ZQXGUJ7P5X9B];\??\
M!!#_ (3G_@EG^R9_P32_X:N_LO\ X9=_:$U#X\?\+J_X47]M_P"$Y^W^)/V@
M/$'_  BO_"N/^%Q6G_",^5_PO3[)_;G_  GGB#S/^$6^T?V.G]M^3I'Y9?\
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MA;X>_#SPKXCT/PWI/AW2['P;J?Q1T2]N/$&O^);OQGXITQO#%O!\-]*\GO\
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MY\-/)I=YIG[$44 ?SS?L)?\ !%+XQ?!7]L#P'^VQ^VS^V;??MB?%CX%?"(?
MO]GNU;P ?"=IX'\%:=I&L>%-#U?6=8FU^_NO$&L6WA/Q-XLMVLKS3)[M_$/B
MS6_%>M^+/%/B&6/5!_0S110!_/\ ?\$U?^4T/_!P=_V,_P#P3=_]9\^*-?T
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M?TR4445^1GUX4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M[W3+:_M+J&'^,/XNZ5^UCXP_;'_X+NZ/_P $=?!%Q\6?@U\2-!\4> OV]O\
MA;6E_#FWUC3?B5X@U_XNZ7\3-._9QGU3Q?I>N>*H;UO^%QR>&Y3I5TMS97&L
M6@T#4]9@^$.N:UYE^W5XO^"NI?\ !L=_P3R\/_LV:KXNU#P%X=_;#_X1GXFG
MQO%HUEXQL/C,/!G[2OC/QQHNO6OAK4+[2H]&O?$7B?4/$?@:TEN+R];X?2>
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MJ6^&#1M5N)4*S0>=J,-O;:DC:;\Y_%[]D[]L&/X?>(99/CSXA^*UC#:B?4_
M<?B#Q>;G7M/MV$T\-G87UU/9ZS=0&-+J+1YMDE]Y!2Q6YU(6=E=>,^*?B?\
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MX)I>!/VH=1_9=\0_$CQI!?Z#XYD^&'BGXVP>!KF?]GOPG\1HKBZT^3PCK_Q
M74%U&&:'5K&\TRY\16?AB^\%64EG?:E?>)[;0-/O]7MNZ_;O_P""X/[#'_!/
M?XKZ7\#?B[JOQ,\>?%F;0[;Q3XJ\$_!/P5:>-]1^&GA:^MS?V.O?$*[U/Q#X
M8TC1H[O2(Y]?71;'4=6\56OAR.U\0W^@6FC:WX=OM8_CM^#6G^$;G_@U3_:_
MO]4BT:;Q';_\%"_#5]I=Q>RV[:JGC M^S-ITKVAFD^TMK?\ P@VH:XKP(&N1
MH%UJ5R8Q:R7$U?NE^TQ^TY\!?V!?@G\%O'7P6^$7A_XC_P#!;[]OS]CW]F_X
M.:9X=\,KK7C/QKKO]O?#GP-X4C\=>-] :_UKPE!X9T37/"VGZ;X6TUK"WOOB
M=K_A?1=#0:GX1\+^+-:\+ '])O[-_P"TG\$_VN/@YX0^/G[/7CO3_B+\*_'$
M-[)H'B2QM-3TR1I]+U"YTK5M,U31M<LM,US0]8TK4[.YLM0TK6-.LKZWEBWM
M 8)8)9?<J_GR_8P_X) _&GX&_P#!'VS_ &&M/_:;\=?LM_M(?$;Q=#\8?B/\
M;_@=KFO7FN?#WQEJ?B_PQK=]X0\'ZEX>\6> ]0>S3P%X0T#X=^)KC2/%%MI6
MJZBWB75K.34])U*."Y_=7P[H.O\ A+X;:%X8&OWOC'Q3X9\#Z9H(\4:XTC:C
MXIU_1M!@T_\ M_5WO;V\E:]US4;;^T=0:[U&ZD,]U,9[V=M\[@'X_>,O^#A'
M_@FEX$_:AU']EWQ#\2/&D%_H/CF3X8>*?C;!X&N9_P!GOPG\1HKBZT^3PCK_
M ,0%U!=1AFAU:QO-,N?$5GX8OO!5E)9WVI7WB>VT#3[_ %>V_;FO\V[X-:?X
M1N?^#5/]K^_U2+1IO$=O_P %"_#5]I=Q>RV[:JGC M^S-ITKVAFD^TMK?_"#
M:AKBO @:Y&@76I7)C%K)<35_?S^R?JFJI^QQ^S5K7Q+N[&TUQ/V9_@WJGC^^
MO[NU73;;55^%OAR[\57=[?23R6*V,-X+^:YNY+E[46ZO,\[0@R$ _,R[_P"#
MBG_@EW9_M-K^S*WQ:\47$Q\51^ V^.EEX,GOOV=T\;2W2:<GA_\ X6!:ZA+J
M<MM_:LBZ>_C.W\*S?#J)=^M2^,8_#,<FN+^Y=?Q;?\%N_@UX#O/V7O!OQ)_9
M1UK]DVX_X(O?!OXO_#;QA^T_\%_V)_$WPR\*_$WQM\?M<^(%]\.O$^K>&M=\
M%?#OQ-\-;:70O"/C'X>Z3%HUSXIBOTU*[FOM<\))9^&O#6K6O]@OP@^)'A;X
MQ_";X7_%[P.+U?!7Q4^'?@GXD>#UU.R;3=2'A;QQX:TSQ/X?&H:<[.]A>C2=
M4M!=V3NS6L_F0,S&,D@'HE%?YQ'P)^)_[??Q _X(H_M+_P#!1O4_^"FO[<=G
MX^_9&_:I\+>#OAMX)B^-NOZGX=\2?\)7K7[,VA^*;CXFZSKG]H^-_'&FI:_%
MK3IO"_A/7?%FH>!-!?1-?BB\(.?&_B.YO/TIA^+O[9W[//[6/_!!C]I36_VZ
M/VD/C7%_P5>L?".L?'_X'_$'Q+9V?P#\+?\ "P/#/P(DN-(^&7PJ\+VFD>#/
M#6C:#:?M .=!5-$DUFVUSP=9Z_-K<\VM7UI;@']IU?)_[;G[9'PI_8'_ &;?
M'7[4/QFT[QCK?@7P'>>$=.N_#WP\T[0]8\=:_J7C7QAH?@S2-.\,:3XC\1^$
MM'U"\COM=BU*^ANO$&G^3HFGZI>1&XFM4M9_Y;/A]KG[<7_!1#]KW_@KM\:1
M_P %+OC)^QWH?_!.'XD>-/ 'P1^%/@36VTCX2Z7H_P //%OQ;.GZ]\>OAS+J
MT'A3Q!X9FT3X5WZ^,-3\2:3X@U7Q'KFJZG=3:K:^&?AUH_@[4OEC]DGXO?%S
M]O#]FC_@B]^R-\9OB7X]^.?BOXV_\%*?C#\??BEXD^+7CWQ-\1/$NI_!C]C3
M2[;Q;JG@SQ!K'BS5-8UBX\/>(='\3Z];Z-:75TUE'J'A\1VD:R1%: /Z_/V3
M/^"A?P3_ &Q_C#^UG\#?AIX=^)WA[QY^QAXW\/?#WXQV_P 0-!\.:3II\2^(
M]3^(6CVUOX4OM \7^*#K-O97_P ,_$<6H7%W!I2QAM.>U6[6YE-M]W5_F;?'
M/]M7]H?]EW]MC_@LO\,/@MXD\>_!/P-^T9^WWX2TGX_?M;_#?2?%FI>,/V=_
MAOX+^-OQNM9)_#-SX7OM DTKQ'XQE\>W,MA-_P )9X?U?6+#PCK'A70+B*\\
M03:QH?\ 0I_P5J\?_';X76'_  1^_P""<?[*'[97Q>^'W@+]M7Q[-X-\<?MC
MZI\6/%/Q$^-?CG0;'Q#\%H]%\2:=\<K[Q6?%6LW?BV\^*.J>)I])\,>*?#>D
M^(OM/@SP!X?U'P]\-KR7P\0#^K6BOY'?V39_VIOV<?\ @X!\.?L/>._^"@/[
M0G[67P;\&_LF>*/$FD:#\3_B/KNHW6EKK5MJ?BK0M*^,&@VFK'P]XV^*.A+J
MQU*T^(7B#39_$^H>#]6\'HDNG:59:1I.F_UQ4 %%%% !1110 4444 ?S8_\
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MB1(XT5% 'YG?M"_\G^?LR?\ 8OZ3_P"I!XUK].J_,7]H7_D_S]F3_L7])_\
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MT*7X:_&Z\ET7Q3X3U>\T'Q#I,MWIOPSO-.NI--U:PN[-[FPO+NRG:$RVMS/
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ME4E3G;FB[.SNMDU9^C79K9I.Z"BBBOJS,**** "BBB@ HHHH **** "BBB@
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M-7_E-#_P<'?]C/\ \$W?_6?/BC7] -3#X5\_S8!1115 %%%% !1110 4444
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MA2Q6'K9/BG-86AE^"P]/D=+2%1MR=1.'\N__  3(_P""4'P/_;:_9XUGXO\
MQ&^('Q6\+Z]IWQ0\2>!X=.\$WOA"WTA]-T;0/"6K6]U)'KOA+7+TWTL_B"ZC
MF9;Q;<Q0VX2!'$CR?TW_ +(G[*O@G]C;X-V7P4^'^O\ BKQ+X=L?$&N^(H]4
M\8S:1<:T]WK\\5Q=0O)HFDZ+8_9X6B5;<+8K*%)\R20X(]O\$_#[P#\-=(D\
M/_#GP1X0\ :#-?3:G-HG@GPUHOA72)=2N8K>WN-0DTW0K*PLGOIX+2UAFNVA
M-Q+%;6\;R,D,:KU]>]P;P!DG"6%P-2E@L)+/*.!^IXS-J$:T)XOG<959<DZD
MHQC4E3IMKENG%6>]_B?%WQTXQ\4\RSFABLWS2EP9B\Z_M;*.%\94PM:CE?LH
M5*>%IJM1P]*=2="%:M&,N?E:J.Z>EBOY(?\ @YH^..L_%/QA^QA_P3"^'/AC
MXJ?$O6?C+X]M/V@?CO\ #OX#>&[WQ;\8]5^#'@&?5K+2=*\&^&4EM]+\27NI
MV^F?%7QM#I>IW%O9Z?J_PG\/:MJEYINE[[ROZWJ^5M/_ &)OV8]-_:RUS]N2
M#X9_:/VI?$'@:'X;7GQ0U7QG\0=<^P>"X;/1]/71?#/@G6O%=_\ #OP=OM-$
MM8;C4?"7A+1-6NOMGB"2YOY9?%7B=]7^\/Q _D[_ .">G[1$/[)/_!<SQQH3
M?LK_ +0?[#O[+'_!3OP_I^@?#_X5?M&?#E?A*VG?'?P%HFF7^DZIHEL=3UW3
MM;L-:\;ZAXW\+:+8:)J2-9Z[\=-$TV>QL[2SLS/]:_\ !$W6='T?_@K9_P %
M_&U;5=-TM9_VE]+$!U&^M;(3&/XN_M&F01&YEB$AC#H7";BH==V-PS_0%^TW
M^PM^RS^V+K_P7\5_M$?#*?QQXH_9X\677CGX+>)-,\??$SX>:_\ #_Q7>7OA
MO4KC6='UCX9>,O!VHRSOJ/@_PQ?K#J-S?6D5[H>GW45ND\ D/QG\6O\ @@A_
MP2:^.?Q/^('QE^*?[*/_  E'Q)^*7B_7_'GCOQ)_PO3]I31/[=\5^*-2N-7U
MW5?['\._&+2-!TS[=J-U<7'V'1]+T_3;;S/)L[.W@1(E /Y#?VE/"_B_]J;X
MT?\ !R7\=/V3K67Q)^SUIOPX^'FG>)=6\%7,FK^%?&7B+P+^TI^SOXY\;^+-
M%UF"[M['5[%?"OP3^/GQ(N]6TN'6-.?PQ>79LKU](\0V%WJ?]0/[/7_!0_\
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M)U32=9TW3M9T76]%U+3M9T36-/L=5TF_L]0L[>YC^2_V,?\ @E-^P=_P3_\
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MGKEC/X<;0O$.HW%_J&NZ3J-[JNJW%[UW[5?_  1Y_P""=?[;OQ6D^-W[4?P
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MP/%?^":O_*:'_@X._P"QG_X)N_\ K/GQ1K^@&OY=O^"$W[2'AO\ :Z_X*/\
M_!<C]HKPCX$^*7PS\._$K6_^"?-[IO@?XT^&+#P9\3M!30OA+\;?"D\7BKPS
MIFN^);'2Y[R[T&?4M.CM]<OQ<:/>:=>.\,EP]M#_ %$U,/A7S_-@%%%%4 44
M44 %%%% !1110 4444 %?P*?MNQR'_@IQ^V),(W,2^-=8C:4(WEK(Z>%F2-G
MQM#NL;LJ$[F5'(!"DC^X/]HGXW>%_P!G#X(_$KXW>,'B_L7X>^&+S65LI;H6
M3:YK<KQ:=X7\+VUVT,ZV]_XK\37ND>&].E>&2..^U2W>5?+#D?S]?L _L(?#
MO]N70/B[^TS^T+XH\4ZIK_BSXN>++6;1O!UUIOAJWE\1W]EI_BGQ-XDUF==*
MO9))KR^\66BZ'H^F#2]/T>VTUEN%U2TOK6QTK]W\$W@.',1FOB-GV*K87(>&
M:V78)PPV%EC,9F.9YE4J2P^#PU-5*5.G&G2H3K8BO6J0A"+IQBI2G[OYSXJ<
M:9U@^">*_!SAGAF.><1>/O!W$'">"S''9I')LFX;ROA_'<.YSGN=8NN\'C:N
M8XB@J^5X+"Y3AJ=.I4GF2Q=7$4J6&5+$_P!(_@S5-,UOPEX:U71M1L-7TN]T
M339K+4M,O+>_L+N+[)$GFVMY:R2V]Q'N5EWQ2.NY6&<@BN6^-W'P7^+N?^B8
M>/O_ %%-6K^=+PI\?Y_^"2_[5?QI^ _]H>+?B_\  >:PT+5=&\,S:UI]OK6A
M:WKFBZ)XCTK5C&\2Z+8:Q#I^IWV@^)7TZQTA?%=K%H&NW-K;"PTW3K7WBX_X
M*+:S^WEXX\(_LR?";0+OX-Z5X_DO+;Q5XE\4^(-/FN]4L;>WDN)]"C-BMMY5
MC=6L,L;Z7:3OJ'BN]FM-!,MGI\U]!J?YIXV>%W&7#' '%O%G"^09IQYPQB.%
M)YKDV-RM9?@,5C<+G> 7U98K!YEF%"6 GA)8N+Q[G*IR4*4ZE"%>O*GA)?%<
M!_2"X(SO,,#PAQ)C:'"GB)0S[$<)YCPE5>,S)0SS+\=/+I0P.:X3 _4<7A,7
M5I*6&KSG1MS.%2RA[6?Z,_\ !.G_ )-KTO\ [&_Q9_Z5P5]UU^,]GXI\6?\
M!//XLQ_#U]73XG?"/QW'%KMIH$%W:0^+=)EN)8]-;4UTB-IY=/U@2VXM5'E)
MHOC*SM4^RS6>IV-S#HO[)PRK/#%.BRJDT4<J+/#+;S*LB!U6:WG2.>"4!@)(
M9HTEB<%)$5U*C^5/H[\28:OP3A?#K&X;$95QIX4X+*^$^,,DQ2A4EA,30P\Z
M>!Q^%QF'E4P6.R[-L/AI8K"5L-7FXQYHU8Q7L:E;^AL9!^U=9-2IUW*=.2ZK
M3F33U3BW9W7IUM+1117[^<@4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 ?GG_ ,%5OVC_ (5_LF?L%?'KX\?&7X*^
M&/VC/ W@VR\$0S?!+QG::#>^%_B!XA\1?$GP?X;\'V&M0^)M"\3Z-'I^C^*]
M5T?Q1<WMQX?U>YTV'0GU+3+&?5;2R0_R<_M(_MI?M"> OCO\./!_[&__  36
M_83^%?QU_8__ &)O"_[<7[>FC/\ LV_ RTU'P9?P^!]!\??$31]!\1F^76O#
MO@WPMX+\9^!M8TBW\#>+!\5KC4?&$FC3:A--HUS:S_V.?MV?LB>#/V\/V3?C
M/^RAX]UF^\-:#\6_#UA80>*=,M1?WWA7Q+X<\0Z/XR\&>)X-.-YIRZJF@^+O
M#NB:G>:,^HZ?%K=C;76CSWMK!?2S)^"W@[_@W'\>>!?V:?VK_ 2?MT^,?''[
M3W[7NK?"GP3X]_:2UCPQJOAJ32/V;?!_B#2(_&OPI30QXO\ &?B7Q-!XV\(6
M]S;:YI5WXYT3P]KZ>'/AUX,ECT/POH.N77B0 _H/_8]_:*TC]KC]EKX!_M,:
M)I#^';/XU_"WPEX^F\.2737[>&M7UK2X)=?\-#47M;$ZFGA[7EU+1H]4%E:+
MJ4=BM\EM EPL2?2%>5? OX.>#?V>/@O\*/@/\.XKZ'P)\&_AWX/^&?A%=5N4
MO=6?P_X*T&Q\/:9<:M>QP6T=[JUU:V$=UJEZEM;K=W\UQ<+!$)/+7U6@ HHH
MH _CW^(O[)?_  5"_P"":?\ P41_;R^/G[ _[*EA^U?\&O\ @H'I>O:GH][-
MX\\$:1J'PH^,?Q!U34O&%UJOBC1];N=+O?["\$?$3Q!XWO++2IK*#P1KG@77
M/#MAJWCO3-=T^]2TPO$7_!OS^T%'_P $%=*_9!TV\TO5/VQ-)_:&B_;6E^'\
M/BC0D\+7?Q"O?"UQ\+K_ .#5GXVU*:+P_:26?PCOEN3J<>HV_A74/BOI?V<>
M(T\)WK>)A_9+10!_)5^RS^RI_P %)?VZ?^"K/[,W[??[?G[,%C^RQX._8V^
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M:>>YTVS^2?B+_P '*OBG7/V9]4T_X)_L+_MP#]IS5?AKI%MX.\;>(/@;HO\
MPJ8?$B\T[3H[CQ5<0Z=K?BK4-1\(K>R7NKV.CVGA]KC7+(6ND1WN@-??VYIG
M[>?\%>?VA?"_[*__  3I_:4^.?B[X-> _P!H#3?!NA>#(+#X3_%+PU:>+_AM
MXD\5>*/B9X+\)>";SQSX?OH)K34?#?A7QCKNA^+[^V:6PO+@:#';Z/JNEZY-
MIE]!^#/AKXN_\'97B[PUX:\3>"?V:/V7O /@[6_#F@:AX5\&V2? ?P]:^'?#
MUQI%FVCZ;%X?\3_&;4/$&@B*P\@MHFK7(O=)=FT^6UL3;BQM@#^F[]BOQ/\
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M8^"?'5YH5@;MO#_B#1]:U'Q6LL>FZ/#?Z9[)_P %&OVG/V5=*_X-YOA!:_\
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M<11L0"-VW ^7O^":O_*:'_@X._[&?_@F[_ZSY\4:_H!K^8C_ ((>_M)?!_\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M\)O\(YO@[!XZOQ9^'[>\MO@M)9W-QJ":B/"EQ\7-+;38/%L_@J>+Q8W]F5%
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M]EHE@\CII^GHY'+W=TTU[/-,WSO_ ,%._P#D@GA'_LKV@?\ J&>/Z_0K2?\
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MXI7EUX4U37M3\>S1:+'-;9M?$=]/96Z:QK5X^K^T1_P2G_;O\?\ _!O;\)?
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M /Y_O^":O_*:'_@X._[&?_@F[_ZSY\4:_H!K^?[_ ()J_P#*:'_@X._[&?\
MX)N_^L^?%&OZ :F'PKY_FP"BBBJ **** "BBB@ HHHH **** "BBB@ K\./^
M"D?_ "??_P $U_\ LK/A#_U<?PXK]B_BC\1?#GPB^'/C?XG^+99H_#?@/PSK
M'BC5Q:B%[VXM=(LI;O[#I\=Q-;PSZGJ,D<=AIMO+<0I<W]S;P&6/S-P_G*\0
MZ3^WO_P44\2>#?VQOAS\._!'@SPO\%]<&L? ?0;[7-/^W:WJGA7Q5;ZK<KIU
MSK%ND?B[4+/Q%X?M;34M1\00>$?"EW<V,VF:7 MQ!J\*_M?@MD]6.=8CBS'X
MW*\FX<RW!YQDF(S;.<?1P&%EFV?Y#F67Y=@,.ZC<Z]=SQ*Q.(5.#AAL%2JXB
MM**4(U/YV^D/Q'A_]6Z7 F69;G?$/%V>8OA[B+!Y%P]E6(S7&T\BX4XOR'.<
MWS3%JBE3PN%C2P,L%A'5J*IC,RKT,+AZ<[U9T?Z<:*_/C]@7]M;4/VKO#OC?
MPU\0_",7P\^./PBU6WT3XA>$TCO[&"X$SW=D-8L]&UD#6-"N+;6=,U?1=>\-
MWLVI7/A^^M+0W6I,=7M[6V_0>ORWB#(,TX7SC&Y'G.'6&S# SA&M3C4IUJ4X
M5J4,1AZ]"M2E*G6P^)P]6E7H582:G2J1>CO%?M'"G%.2<:Y!EW$W#V*>,RG,
MZ=2>'JSI5</6A4H5JF%Q6&Q.'K1A6P^*PF*HUL-B:-2*E3K4IQ3E&TF5^:O[
M"W_)9OVT_P#LIVF?^I5\6:^QOCC\<?!?P%\%W/B[Q=<^9/)YMMX>\/6TL:ZM
MXEU98]Z6%@C[O+@CW))J.HR(UMIMLPEE$D\EK:W/YA_LM_&&_P#@=\4?$VM_
M''PE?^ _#_[4]Q8^-_#GBV\#0Z!ITRZSXEOK87!E,CP:+>/XK99[V[N([O1;
M9M#U34[--#UD:Q;?R-XL<;\+Y1XS^"5#,,VH4/\ 5C,^*,?Q-7Y*U3!\-X/B
MKA/'\,\.XC/\92ISPN44<WSK'X;!X2ICZM"%JBQ%65/#-5G]=0I5)8?$N,6^
M>,(P6EYN%2,YJ*WERQ3;LGVWT/V@HK(TGQ#H&OK,^A:YH^M);^5]H?2=3LM2
M6#SPYA\YK.>81><(Y#%O*^8$<ID*V->OZ;HUJ.(IQK8>M2KT9W<*M&I"K3FE
M)Q;C4@Y1E:2<79NTDT]4SB::W5O4****U **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#^&3_@LO_P %</#W
M[7G[4WB7_@ESX5_:1TS]CG]D7P-XOU_P)^U[^TSK?AKQQXFUCQYKO@N]ET[Q
MG\-/"_A/P3I-YXDU+PGHVO6=YX8?2]^D:=\2/$5E<OJ_B'3?AQ:+=>)8?^"P
MWAS]DWX@_P#! ;]G2V_X)N>*;_XP?LQ_L;?M4>"?!/BKQI%H6MZ-=Z?)??#[
MQ_I7BKQCXVC\1>%? ]Q<:_XG^)OQ;\#W6O:II'ARTT:_\4?$DFPMK6$26ME_
M6EK7_!.#_@GAXDUG5O$7B+]@O]C#7_$&OZG?ZUKNNZU^RY\#]5UG6M9U6ZEO
MM3U;5M3OO T][J.IZE>SSWE_?WD\UU>74TMQ<2R32.[>M>%?V7?V9_ OPN\3
M? _P1^SO\#/!GP6\:2:K-XQ^$/A/X2^ ?#GPP\5S:[96>FZW-XD\ Z-H%EX5
MUR;5].T[3[#5)=3TJZDO[.PLK:Z:6&U@2, _DM^-WQ]^%/\ P4X_X.!_^"4F
ML?LJ>,]*^)7P\^$GP0\/_&_QWXS\#S7,EQX,N+'4/B'\4=2\%>/=0M&C?2+K
M3+2Q\ >&M=\.:BD$FE>(_'UQX/UN*/5[V^TFW_>?]K[_ ((D?\$X/V[/C+>_
M'[]IKX(ZWX[^*6H>']!\+W>OV'Q;^+7@ZWDT7PU!+;:/:C1?!_C30]%1[:&>
M16N$L%N+@L&N)9& (^O?V??V)/V0OV4;_P 0ZO\ LW?LW?!SX+:UXK6:+Q%K
MOP_\":%H.OZM8S7@U Z/=:[;6@U<^'X+U4N;+PZEZFA:?)'&;'3[<1H%^HZ&
MK[@?S$?\$/?V;?@_^R%_P4P_X+H_LY_ 3PU<^$/A'\,]=_X)ZV7@[PY>:]KW
MB>YTRVU[X0?&GQ9J:2Z[XGU'5M=U SZ[KVJ7:OJ&HW+PI<+;0LEM##%'_3O7
M\_W_  35_P"4T/\ P<'?]C/_ ,$W?_6?/BC7] -3#X5\_P V 44450!1110
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M3=_]9\^*-?T U_/]_P $U?\ E-#_ ,'!W_8S_P#!-W_UGSXHU_0#4P^%?/\
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M-TJ\9?[;;3XS->I"19>(H]80Z#JJ[].O)K9[;[3YMQ;"3]L*_GOZ(V;Y=C_
M[A?+L+BZ53,<AQ/$&"SG 7<,9EF*Q7$F<9GAJ.-PTU&K0EB,OQN%Q=!SBHU:
M-:,H2;C-1ZL?%K$S;7NR4'&7225.$6T]G9IIA1117],'&%%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M_P!_P35_Y30_\'!W_8S_ /!-W_UGSXHU_0#4P^%?/\V 44450!1110 4444
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MZ***=EY_>_\ ,#^=?_AT)_P5"_Z6!/VGO_$>O!W_ ,]>OSTU#]FG_@JA8_\
M!4[0_P#@G /^"W?[2<FFZQ^PY-^V&WQ;/PC\*)?6]Y%\:]8^$?\ P@(\%_\
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MN:K%INE>';*X\-KX;\1^$WL]0ENI=4?6+9X;2#[ I6WWWTU>UEY][@?SK_\
M#H3_ (*A?]+ G[3W_B/7@[_YZ]'_  Z$_P""H7_2P)^T]_XCUX._^>O7]%%%
M.R\_O?\ F!_.O_PZ$_X*A?\ 2P)^T]_XCUX._P#GKU^;_P#P50_9Z_X*H_\
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M]>OZ***++S^]_P"8'\Z__#H3_@J%_P!+ G[3W_B/7@[_ .>O1_PZ$_X*A?\
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M$:7X1^%-+NOAT?V>OA6WQ(MX;7PNGCB_A\4#Q7(O]D3/-KV@G1T/VU%U)O\
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M=TRSLO#FO7,]Y80QQ:/J3,+.;_/J_:6_8E_X)Z_LI?\ !-WPE_P44_X)Q_\
M!07X\>+/C9X:^.]OX1^&WC0^*C\+]7U>[N/$UUHWB?POI/PTMO"7A'XC>!-8
MT+0-,3QJ-0U>\M#KV@PRZA?6=SH_B;PW:6(!_HI^![SQ5J'@OPA?^.M)L]!\
M;7WA?0+SQCH>GSQ7-AHWBJYTFTF\0Z38W,-[J<-Q9Z=JSWEG;3Q:CJ$4L,*2
M1WMVK">3J*\%_95\<^/_ (G_ ++_ .S?\2OBOHW_  CGQ2^(?P%^#_CGXE>'
MOL,NE_V#X_\ %OP]\.Z_XRT;^S)OWVG?V7XBU#4;'[#+^]M/(^SR?/&:]ZH
M*_*C_@JK_P %7/@;_P $R/@YJ&K^)K^U\6?M#^-/#&NW'P ^!]M::M?:CXZU
M^S:+3X=7\0RZ5$(O#W@#0=0NXK_Q+J^HZCI=S?Z=8:EI?A<ZEXA\BRK]5Z^
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M2VU"^CCGALKW1_$GQ!\+Z!=6MG<I>0:CX)EL[F1"FIV*_P!=- !7X"_MY?\
M!1'_ (*;^&?VM]3_ &3O^";W[".G?%VZ^&OPLNOBC\4/B_\ M$:1XH\'_"WQ
M3$L/A74'\-?!CQ->^.OA'X4\3WVB6GBG1-&U*ZL_&/B/4;[Q=K]YIT?AC2M)
M^'OB36M2_?JOQ,_;Z^,'[)'[<OBKXP?\$BW_ &T?&?[,?Q_TCPK:_$SXGWOA
MS1M;\'RP^"M#\-:#XZ'A5/''BZ+PMX/\3Z?J^@>,/#?C?Q/H?A7Q%JSWW@30
M?%EGJ5SI,6GZY<:6 ?//A;_@N[J/Q'_X(I?&;_@IQX4^$7A_PU\6_@KXCTOX
M3>(/ACXIO]:U;X?7_P 6KSQE\+?#*7NA:C82:#XBU?P;J6C_ !4T+Q3%8)<V
MNI:-<#5/"]WK>I#0;CQ-?K^P_P#MK?\ !?#]H/X@?LZ>*OC3_P $^_V:O G[
M(OQ@M_"7C'Q)\7/"WQ$\-GQ5I'PK\9>'(_$FB^*-+\(WO[3_ (A\5V^H7=C?
M:3*=&U'P%=ZU8BZDMM1T.VNX)XH/PC_9,^.O[*'QW_X(A_%?]DS]MKXHS?LB
M_LZ? W]K7P+\,/!7[0G[.7P<\;>);+]H7Q#>^'_%OQ2TG3O'FAV?AWX@:EK7
MC#4[SP;K'C/Q!XDO;3P)IPL5^%^GROIMS92V6N>LI\#? '_!*3_@KW_P2\\"
M_P#!-7]I#XJ?&'P9^US<^!++]H#X>:Q\2;'XA:1XE^&/B77=-\'W/Q%U^U\#
MZ3X<\/:IHLOP[U/Q-\2/#(U33K\>$]6^'\GB;3);#1?L-I  ?W=T444 ?._[
M6'[4'PH_8R_9Z^*'[2WQKU:72OA]\+?#TFLZE'9I%-K&O:G<W$&F>'/"7AVT
MFFMX;SQ)XM\07NF^'="MY[BULSJ6HP2:A>6.GQ7=[;_D[_P2!_X*[>-/VY?V
M+OVJOVR/VI/#GPS^$WA+]G;XE_$F*ZC^&>E^,'L]#^#_ ,/_ (4^%?BGJ.J>
M(FU_Q)XJU#Q'XFTG3-7UA;_4-$M=!LM4BL;<V/ABPG=XY/S@_P""Q?QD^,GQ
M)_X*>? WX3?&?]BS]LKX\?\ !._]D*Z\)?&+4/!_[.WP&\1?%'1?VD?CQJ/A
M6'Q%H%SXIU/4(-(\#7?@3P5_;MIX0U3P\U]KERT-G\1-$NE9/'C#PI^;G_!&
MOXW^,_%O_!,K_@L'^R3X9^ _QBNQXZ^"_P"VE\;]/^-&G>'=4N?A]#K\'P&\
M'>%8/@/<7=C82K)\4O$%J[:A:>'8M0>\NM+N"%T^>)R[ 'Z/Z?\ \'%G[;.D
MZ#\.OVZ/B3^P]\/_  M_P2C^*?QYE^!_AOQI9^+;[4/VB;9K:'Q-9WWBAG'B
MXZ)K*6-]X3\2Z@]A;_"W2_#]Q?\ A?6/AY'XYCU6YTWQ7)_81;W$%U!!=6TL
M=Q;7,,=Q;SPNLD4T$R+)%+%(I*O')&RNCJ2K*P8$@U_G*_&WXQ?#+4O^#4[]
MBWX6:?JWA_Q+\1;?]LGQGX&F\-VFJVTWB7PEXGM/B;^TG\5;J[.B0/+?O+_P
M@?C'PG!.'@CBAL_B1H4SR!]2TZ.Z_P! O]G7PCX@^'_[/OP*\!^++J6^\5>"
M?@W\,?"/B6]N(X(9[SQ!X;\$Z'HVLW4T5K%#;12W&HV5S+)';PQ0([LL,4<8
M5  >R5%<7$%K!-=74T5M;6T4EQ<7%Q(D,$$$*-)----(RQQ111JSR2.RHB*S
M,P4$U+7\\'_!QI\8OVK_  Y^ROX#_9V_9=^$?QP\<6?[4OB3Q%X-^/7CWX%?
M#7Q7\4?%O@'X'Z#:Z%_PF'ARPT'PU:QP6^K?%"#Q*-(M[C7->T73]2\.:)XO
M\,[U;7VUK0 #*_8*_P""Y&I_\% ?^"K/QP_9*^$/ACX?3_LA_#GX1>-?%7@'
MXH/I?B=?BE\0_$O@3Q5\._"M_P")XM0?Q8?"ME\.]?O/%.NW/AC2W\%IXCN=
M%M=!UC4M6TZ[O[[P_9<)^U7_ ,%7_P#@J!+_ ,%+?V@/V O^"<O[)/P _:*N
MOV??A[X \<^*[KXA>))?"^N16?BCPE\/?$&L7LVO>(OC5\)_!C0Z=JGQ+\/Z
M':Z)8/>ZZ\D=[=,D\-GJ7]F_AY_P3J_:0\%_L^_\%S;=?@)^PQ^U;X0^'7B#
M]G?X,_LKZ-\#_%_PV;PU\:?A/H>I6_[.WA?6_CU\9_#FE6NIQV?AZYU30KSX
MA^-O%]Q]E&NR^,(_$NH75K=:Q+G[A^/_ /P3Z_X)"?MM?M3_ /!4SXN:O_P4
M$^-LW[0WPJA\:^+/BCX0U.)?A-H7P-\:^ )]>\/2);S>-OA=I%Y\7O"7P[UW
MP!IOAB"/P?=ZA::5HITB >(]5U?Q'X9U^( _J)_82\=_MG_$;X Z=XE_;U^"
MG@3X ?M!R^*/$MGJ/P[^'/B+2?%'AJV\*VES"GAG5HM5T7XA_$^Q>\U2V:>6
M[@7Q5-+"Z*LEE9DA&^R*_GU_X-G/C_\ '[]H7_@F3I.M_M ZYXI\7ZEX!^-?
MQ&^&/PX\=^-+[5M9\2>,_AAH>E>#=<TN_O\ Q%K=Q=W_ (AB\.^*_$WC'P!I
MU\]S*EEI?@ZRT%6!T9E7^@J@#PG]J/XR?\,[?LS_ +0WQ^%G9:C)\$?@A\5?
MBS!IFHRS0V.JW7P\\#:[XLM-*NI+8K<B+4[G28K!A:G[4_V@); SM&#_ #:_
ML@_\%-O^#@_]KSPA\&_CA\/O^"=/[*>M_LW?%+7[7'Q'L_B#I'AO4AX,TWQM
M=^$/&>N6'A;QE^U7IOBZ"XTB71M?-A%?>$WDU(V,-YIUEJ=A>64EW^W_ /P5
M.?X"O^P!^TOI?[3WQD\7_L__  '\4>"].\%?$;XM^!?"^M^,_$GA32/&WBWP
M[X3MH[;PYX>\*>-=4U*Q\2:MK&G^$]:C@\/7"KHVNW[S7NCQ*VL6/\4O[4_[
M.W[/G_!+WP/_ ,$TOVT?^"3'[7GQG^+OQG^-WCGP_8:;X9O_ !E"[_&_P@C6
M6NIH^H?#7PMH/AC6M \.W7BRXM?AEXQ^%/BM]1::7Q'%X>U"Q_X2/2-<O;L
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M\1-<U;Q[K/B;4-$TKX@:3%X>A/B""5='^QQ^&?$\-]]%>&O!_P"Q_P#\%3O
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M:\->']/M])T+P_H.CZ=#;Z?I.C:-I=I:Z=I>FV-O!9V-C;06MM#%#$B+O44
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MOAFUTW1_%UAXA36M<M8](\.:%'/9^-KGQ3I^I7>E66IZM9W^IQ"[KT;]B?\
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MAW5+.RUW01J5_JMQ96^N:?J%SH<NM:W/X<N]'NM8U">X^L_V</V:_@C^R/\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M,>'/#7B_Q.VK:]X@&LZ%J&D:?XRNO!$5YX>UJV\4K=CPYIOB34]!^I/V0?\
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<0 4444 %%%% !1110 4444 %%%% !1110!__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>32
<FILENAME>nt10014672x1_linechart5.jpg
<TEXT>
begin 644 nt10014672x1_linechart5.jpg
M_]C_X  02D9)1@ ! 0$ P #   #_[0 V4&AO=&]S:&]P(#,N,  X0DE- ^T*
M4F5S;VQU=&EO;@     0 ,     !  $ P     $  ?_B"^!)0T-?4%)/1DE,
M10 ! 0  "]!N;VYE @   &UN=')21T(@6%E:( ?4  < %0 3  L (6%C<W
M         $E%0R!S4D="     0            #VU@ !     -,M2% @(
M
M$&1E<V,   %$    =&)865H   &X    %&)44D,   ',   (#&1M9&0   G8
M    B&=865H   I@    %&=44D,   ',   (#&QU;6D   IT    %&UE87,
M  J(    )&)K<'0   JL    %')865H   K     %')44D,   ',   (#'1E
M8V@   K4    #'9U960   K@    AW=T<'0   MH    %&-P<G0   M\
M*&-H860   ND    +&1E<V,         &G-21T(@245#-C$Y-C8M,BTQ('=I
M=&A"4$,
M                                                    6%E:(
M     "2@   /A   ML]C=7)V        !      %  H #P 4 !D '@ C "@
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M;W5R(%-P86-E("T@<U)'0@
M
M      !865H@        8ID  +>%   8VEA96B            !0
M;65A<P         !                               "6%E:(
M  ,6   #,P   J1865H@        ;Z(  #CU   #D'-I9R      0U)4(&1E
M<V,         +5)E9F5R96YC92!6:65W:6YG($-O;F1I=&EO;B!I;B!)14,@
M-C$Y-C8M,BTQ
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MU=;7V-G:X>+CY.7FY^CIZO'R\_3U]O?X^?K_Q  ? 0 # 0$! 0$! 0$!
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M*/XA:G.]GJ5W+'H4T:27^G_UYU_*S_P0(\0?L7Q_&KXE^"OV:_\ @E_^T/\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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ML7U2&(3S::EW;M?Q0D1D3268D-PD1$L1$C1A")(R#AUS>K^030_C+X'^"?\
MP<O_ /!1;X_>/KG4]-^'?PM_X)IK\5O%EP-)O8M;MO"GA'X4_LM^*=66'0-0
MCL-2&MG3;&:*VT.\AL]0?4FCTZ:*"Z9D7U/PA_P<<_%+3[/X1_M+?M ?\$^_
M&7P;_P"";?[0'Q7U#X2_"_\ :E3XFZ#XF\4V>H6.I>+;.+Q%XL^&MK8V]W'I
MDD'AVZO=4L[2Z@CM;+PMXYN/!.M?$Z[TN'2J /ZJ**** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M;/();J%7^I: "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M>EV.M_"KP1XFANM7B_M/6/#V@>$Y;OQID?\ #L7]N+_B&K_X8!_X4C_QEO\
M\)S_ &Q_PJ;_ (65\(?^0;_PUS_PL_[3_P )Y_PG_P#PK/\ Y$;_ (GGD_\
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M,W_9,_\ @HC_ .J8\+T ?N)1110 4444 %%%% !1110 4444 %%%% !1110
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M]FA_LU_^J9\%U]>4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M-#_9K_\ 5,^"Z^O* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#\
MZ?C7^WYXK^#WQ/\ %?PWT[]@S]NCXO6?AB?3H(/B-\)OA!IGB3X>^)1?Z-IV
MKO/X;UN?Q3I\M_#82:@^DWSO9PF'5;"^MP&6$.WX$_LV_"KX*_\ !13_ (+2
M_MBM^TK^SMXZTGPO>_ J+QY9?!WXS1Z_\/\ Q[X/\4^'C^S=X+T^_P#$6G^#
M_$UE=VEU<:-JFL75A:/J]W97.D:[9WLL'V@P&W_L,K^;;X^_\$[/^"H&D_\
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M\S0;2#2=2\6^)1ITEIJK&_OH[ZU%AZQ^U3_P2*_;VUS_ (*G_&_]LGX&Z?\
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MQ?\ \%(/A'X-_P""C7PM_P"":&H>"_B/<_&'XL?"74?C!H?C>SM/#+?#73]
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MM5?M"_$#Q7\#?$>MZ]K6AZQJ&IPZEXWT2*PTRUB\3#7KG5]'L9]-^(OB75]
MU_5-.L9K+X?_ &R](_;J\4_\$V/VC=%_:_U/]NS3_A=^RI^U#X#M?V/]>_:;
MT/6? .O?&GX:?&KQ3XTTG7M*^/5IK5GJDOQ%\7_"JW^'G@W7_"<2^+-8NOAS
MKOQ%\:Z*NNZIX9/A73]+ /\ 29TO4(=6TS3M5MEE2WU.QM-0@2=469(;VWCN
M8EF6-Y$654D42*DDB!P0KN,,;U?Q;_\ !67Q]\<OV*/!'_!+W_@FK\%?VBOV
MYM5^'/Q_\1^(-?\ C#\9-)U^'XF?MB?$W2-4^(_@F\T?X6_"SQ[90^";_5/$
M^B7/BK6M*\/^#],DT3[?9WOPT\-ZM?:GI+W]EJ>G^Q!^T!_P4(_8N'_!3;18
M?!'[?'B7]BOX-?L6_&']H3]DWQG_ ,%#/A5J\'Q+\#?&3X7^ ?"FHZ3X#\3Z
M_P"<=)?PS>I?>(KJ[\+Z;K2Z5=>&_ FF>)O#GASP?<:SXLM)P#^H+]N7]L#P
M%^P3^RU\4?VL?B?X<\7^+? WPI_X0G^W/#_@.#1KGQ7J'_"=?$7PC\-M,_LJ
M#Q#K.@:._P!DUCQCI][??;-7M-NFVUX]OY]TL%M-[3\&/BAHOQO^#WPH^-'A
MNPU32_#OQ>^&O@7XH:#IFMI:1ZUIVB^/_"^E>*]+L-7CL+J^L8]4M+'5H+?4
M$LKZ\M$NXY5M[JXA"3/_ )^?QC_9T^-GQ&_X(%^-_P#@IO\ %#_@H)^TU\0?
MB-^T7XCTU?BW\#?&WCVT\3_ GQMX>MOVP-*\&^'O#6@^$=0L&NO#GC;PIXC\
M%Z/\28]7T#4-/L=&TW1=8\":/X?T_P /_;9]1_N:_P""?7_)A/[$7_9H?[-?
M_JF?!= 'Q]_P4P_X+2_LM?\ !+;QG\'_  #\;_#GQ.\<>)_B[I&N^)8=+^%5
MAX2U6]\&^%=%U73-%M_$?BNT\3>+O"]Q'I_B#4+G6;?P\-)CU.:^E\)>(XI$
MMGM;=;K[$_:V_;-^%O[(G[(WCS]L[Q+:ZW\1_A/X&\-^#O%H3X82Z!K.J>*M
M \=>)?"_AKP_J?A6YU36M'\/ZC97;^+-,U6.[DUJWMKC21)<6DL[M!%-_ _^
MUW^UC^R%^W%_P43_ ."G/Q/_ &H=5\8ZS\.;+X#^-OV3_P!AF]\(>"?$?Q&T
M7P]X_P#!&J6-IX#^+,.I^&H&&G^$F\7^'O%'Q#N+&1+B\U"P^+MY;V<3?9G9
M?MKX:?MHR_M0?\&L'[7'PD\6ZH;GXK_L<6/PF^!GB*QO)$&KO\-H_CA\+=0^
M"VLW-DD47V'3K;PQ#J/PSTY9LW=S<_"S5+JYS)+YD@!^N_A[_@YN_9-_L_X>
M>-?BO^RC^WO\"_@C\3M;TO0O#7[1'Q"^!>C-\&7EU5KF2/41XFT'QUJMUKVF
M6UA8:KJ=Q'X%TOQAKTMGI=])IV@WYMYA'^OO[27[?_[)_P"RE^S+I?[7?Q=^
M*^D6GP.\5:7X=U#X=^)/#D5QXGN?BG<>,_#MSXJ\$:-\.=/TI)9?$>J>+]!M
M+C5='97MM,ATJ"ZUS6=2TG0=/U'5+/\ &'X;#X:?\0KDY^+2Z&WA%?\ @G;\
M2&M1KYLUMO\ A._[,\5#X5?V:]^KVR>*#\43X.7P8Q1I1XN.B?9E:X\H'^>'
MXBW&LV?[!'_!LE=_M-B0_LSVO[1OQRN/BT/%$5S/H1^&,'[6/@"701XT@U97
MT>;2C\$5\6?\(A%*CVTG@C^U$VM:&4$ _ID^ W_!RO\ L3?%OXU> ?@S\1_A
M/^U!^R])\8[[0K;X->//CW\.=%T;P1XUM_%&I6GA_P -7=]?^&O%GB6^\/V6
MO>);B?2;+Q(MAK'P^L8;*XU+Q%XXT*VAN1;?T1U^;/\ P4F^)7_!,WX<>!_@
M^/\ @IA!\(+_ ,"ZY\45L_A)I'Q8^'NJ?$VRD^(4/AC6HI]1M/#&A^&O%=W;
MZ;8:#?7=GJ^OZKI<?A32KK5="M]7O[74]1\/B7](XV5HXV165&1616C>)E4J
M"JM%(J/&P& 8W170_*RJ00 #,U[7M#\+:)JWB7Q/K6D^'/#F@:=>:QKNOZ]J
M-GI&B:+I&G6\EWJ&J:MJNH36]AING6-K%+<WE]>3PVUK;QR33RI&C,/SG_X)
M[_\ !5']G/\ X*6Z_P#M):;^SGI?Q /A_P#9O\9>'O"=_P"-_%^D:1H^@?$:
MV\4W'C.+0O%?@*UM=<U'7U\.ZE;^";W4K9?%NC^%]=6PU+2C>Z+9WKWUC8_0
M/[9'[&?P3_;O^$%O\"/VA+/Q+J_PO/CKP?XZUOP[X:\0W'A=_%$_@R_DU&Q\
M/:WJ^GPG68?#NH7#@:JF@W^B:VZQ1'3]<TZ5/-/X!?\ !NKX'\)?#+]K[_@N
MU\-O .A6/A;P+\/?VWD\#^"_#.EH\>F>'/"7A/XG_M0Z#X<T+3DD>61+'2-'
ML+/3[1)))'6WMXP[NP+$ _JJHK^:7_@Z>^-/Q@^!'_!/[X+>-/@G\4_B'\(_
M%MQ^VA\.=%N_$GPV\9>(/!.M7VB2_!3]H759]#U#4?#FH:=<ZAHESJ>CZ3?W
M>CWLD^F7=WIMA/<VLLEI R?G1\=_@G^V=^SY_P %?/V6/V!_!'_!43]N75M!
M_;S^!(\0?M(^/O%?Q8M-3\0:9>1:_P#%'7_B1<? *SD\+2^'/@K=SZ)\(X-)
M^%NJ>&_#@\4_#R+5+_1;+Q2_A?4KK2(@#^W&BOX-OA]^W?\ MD_L4?LY?\'
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MWXJ?'+QY\?/^"OWA#XT_M)>//VFV^%7[4>@>$?"_COQ5XGO]6\.ZA;6GC/\
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M_9,_^"B/_JF/"] '[B4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M?1?C#\"=)TG3;.-8;33]-T[4;VSL;&UA7"Q6UI:PQ001J-J11JHX% '[$_\
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M1:O\/8]6NO'%_>>,-!\%:9YZO)>W5U_*+<_L$:I^TJG[&_[/OP._88_X+'^
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MP=^'R^*;SP:NMVGC+3K/Q3=+##\1KCPM#KVNROJ'B27PC=:R;=+6ZM=1U?\
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MN@#X:Z#X5T36M*\5:XNNWVK:[?C3[?0]+TCP9K^HZ[JUY<VMCH]G:?:;R:.
MM(GEG[.?_!=C_@F7^U-\?7_9O^%/[0$;?$._U1=$\$7/C'PMXA\#>$OBAK3S
MQVD>C?#WQ-XFLM/L=7UJ]O98[+1-%U :1JWBFY=(_"=EK@=&;^<GXP_\%,_&
M?QP_X)"?\%;?V?O'_P"SK\.?V5/VR?V9-8^#GPG^/\?P*L]!\(^#_&^@^)_V
MH= ^$OB]X-*T2[N;^$Z+'#XB^&_BW3H_$/C#P_J=IXNLM7TG66T;Q-?:'I?C
M7_!4#X??"_X)_P#!$O\ X(=?&/X6>$=$\&_'K1-0^#_BSPMXN\)VSZ'XXN;C
MQ3\)[SXJ^.M1AUK1U@U.XO;SXH6/@[Q"M\\\M_INLO;S:3);-<7 D /]!>OP
M[_;(_P"4W_\ P1F_[)G_ ,%$?_5,>%Z^[/VROVI/C)^S-9_#^Y^$7[%_QL_;
M"F\8W7B6#7K/X-:GX6TZ;P#'H<6AR:=<^(#XGNK99HO$;:K>Q::+,NR/HM]Y
M^T-%G\.T_:D^,G[3/_!;+_@E/<_%W]B_XV?L>S>#OAY^W9!H-G\9=3\+:C-X
M^CUSX)V<FHW/A\^&+JY6&+PXVE646IB\*,[ZW8^1N"RX /ZG**** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@#\ _C%)_PTM_P<*_LI?#..XM;[PA_P
M3U_8Y^+7[2&NQ"+[1#!\5/V@]3M?A)I_AW4\AHH-3L_"DW@?Q]H7F8F1+::Y
MM\;6:O-?VL?^#9#]C?\ :]_:-^+O[2_CSXY?M,^'/&'QD\6W'C#Q!H?A'6/A
M9!X:TW4+FUM+1[;1X=9^%^L:I'9JEI&RK>ZG>S!V?,Q& /2O^"-DG_"_?VH?
M^"O/[>\]Q:ZC8?&7]L:']F_X:ZC#%NM[SX5_LC>%8?!WAKQ%HMVP(?3/&&E^
M)-$DO/(;R9M3\..SYE@)'[^4 ?B!_P $T_\ @@_^S+_P2^^.OBSX^_!CXK_'
M;QWXH\7_  EUWX/W^D?$_4OA_>:!;:!K_C#P'XTNM2M(O"G@+PMJ*ZQ#J/P_
MTJUMY)M0FLA97FH+)9R3M;3V_P"W]%% !1110 4444 %%%?@5?\ _!QS^P/I
MU]>Z?<>$_P!I,SV%W<V<QC^'O@=HS-:S/!(8V;XI*S(71BC%5)7!*@\#VLGX
M<SWB!XA9+E>+S)X14GB5A:?M/8JO[3V//JK>T]E4Y>_)+L>-F_$.29"L.\YS
M/"Y<L4ZJP[Q53D]LZ/L_:\FCO[/VM/F[<\>Y^^M%?!7[#7_!1?X#?\%!+'XD
MZA\#M)^)&EP?"R[\*V?B0?$/P_H>@R3S>+X=?GTHZ4NB^*/$RW21IX<OQ>-<
M-9F%GMA$LXDD,7WJ2 "20 !DD\  =23V KBS'+L=E.,K9?F6%JX/&X=P5?#5
MX\M6DZM*%:GSQN[<]*I":U^&29VY?F&"S7!T<?EV)I8S!8A3='$T9<U*HJ=2
M=&?+*RORU:<X/^]%H_DS_P""EW[37@[]CK_@N/\ LW?M'>/]#\3>)/"/PZ_9
MH']K:+X/ATNX\1WO_"7:-^T;X$L/[.AUK5-&TQ_L^I^)[*[N_M.I6VVQ@NFA
M\ZX6*WE\S_X*,?\ !<W]FO\ ;%_8U^,?[./@#X5_''PWXN^(O_"O?[)UKQAI
MO@*W\.67_"(_%3P/X[O_ .T9M%\=ZSJ:?:-,\,7MI:?9M-N=U_/:K-Y-NTMQ
M%^HW[.@'_!23]OOQ7^V/JB#5?V4/V+=1USX._LDVUPD4^B_$+XPSK;-\2?C?
M9Q/<74%Y8Z:BV,7A;4DMXH+N(^ M5L9+#Q'X1UVV'SO_ ,&V?_),/VP_^R]:
M1_ZCU[7[W"OD&791@<YS3(\1CN(_#C*^#J56E2SBI@Z,,5C,UQV,PF$JQC@Z
MT57P*E2KXV$J=2U>O4R^7++"RJS_  N=#/<PS7'91EF=4,%P]XAYGQ=5IU:N
M44\76GAL)EF"PF*Q5)RQ=&3H8UQJ4,'.-2G>A1IX^*:Q4:4/V'_X)P_\F!?L
M9?\ 9M'P:_\ 4$T6OM.BBOP+'XKZ]CL;C?9^R^N8O$XKV7-S^S^L5IU?9\_+
M#GY.?EYN2/-:_+&]E^ZX#"_4L#@\%S^U^J83#X7VG+R>T^KT84N?DYI\G/R<
MW+SRY;VYI6NRBBBN0ZPHKS#XL>+?&/@WP[9:IX(\(7'C759]:MK"XTJW@OKA
M[?3Y;'4KB74"FGQR3!(KFUM+8LRB(&[4,=[(#\NZ;^U#\7=8U/4]%TKX/+J.
MKZ,[QZMIMG'KMQ>Z;)',UNZ7MM%"TMLR3JT3"55(D!7J,4TF]5Z;HES46D[W
M>UHM_DM?D?>-%4M-N+BZT[3[J\MS:7=S96MQ=6C!@UK<301R3V[!P'!AE9HR
M' 8%<, <U=I%'R%^VG_R2W0/^Q_TK_U'?%5?65A_QXV7_7I;?^B4KY-_;3_Y
M);H'_8_Z5_ZCOBJOK*P_X\;+_KTMO_1*4^B]7^42%\<_2'_MQ;HHKROXH?%[
MPQ\)X-!G\21:G,NOZE]A@.GV;SI:V\/E-?ZA=2G9$([**:)Q:1O)?W9?%I;2
MI'<2P)*^B*;25V[)=6>%_LZ_\EA_:2_['2Y_]2CQA7V17YQ_#3XQ>"_AYXW^
M/_BS4[Q]1L]=\9"3P]:Z3Y5Q>:Y#=>(_%5R+JQ666&$V<-E/'=SW<TT4"1R0
M1!VN;JU@F_0W2M3M-9TS3]7L&E>QU.SMK^S>>WN+29[:[A2>!Y+:ZBAN8&:-
MU8QS11R+G#*#523T]%^"5R*;3C9--IR=O63L7Z***DT"BBB@ HHHH **** "
MBBB@ HHHH **** "BBN8\6^,O#?@;3(]8\4:D-,L)[ZUTRV=;2^U"XN]1O2_
MV6RL[#3+6]O[RYF$4KK#;6TKB.*65@L<;NLRE&$7.<HPA%7E*348Q7=R;22\
MVS:AAZ^*K4\/A:%;$XBM-4Z-"A3G6K59RVA3I4XRG.;Z1C%M]$=/17 ^'/B=
MX+\5:Y=>&=(U*^'B"STX:O<:/J_AWQ+X;OUTQIX[87L=OXCT?2I)X//ECC+P
M"7:SKN !!KOJ4*E.I'FISA4C=KFA*,XW6C5XMJZ>ZW74O%8/&8&JJ&-PN)P=
M9PA55'%4*N'JNG47-3J*G6A";A4C[T)VY9+6+:"BBBK.8**_ 3XL?\%V?!'P
M)_X*Z6?_  3.^+'PGL?#'@;6+[X<^&-,_:-D\?S/':>-/BI\//#GBWP;I^O^
M!6\'K;Z=HFH^)_$5CX(GUS_A+VM]+DO;3Q%JBVFDP:C]D^FO'O\ P4OU/P5_
MP5S^"?\ P3 3X/6.HZ7\7?@3JWQEF^,S^.+BUO\ 09M,T7XN:N/#\?@4>%9[
M?48IC\,(H#J3>++)T&LR2"Q<V*I=@'ZPT5D:EK^@Z-<Z59:OK>D:5>:]>/I^
MAVFI:E9V-SK-_';RW<ECI4%U-%+J-Y':PS7+VUFDTRV\4LS((XV86KK4]-L9
M;2"^U"RLY[^86]C#=7<%O+>SEHT$%I'-(CW,Q>6)!'"'<M)&NW+J" 7:*R=.
MU[0M7NM6L=)UK2=4OM O%T[7;/3M1L[VZT74'@CNDL-6M[::6;3;Q[6:&Y6U
MO$AG:"6.8(8W5CY)^TG^T-\-/V4?@9\2_P!H;XOW^H:?\//A7X8O_%/B)M'L
M#JNN7EM9)F+3=#TL36_]H:OJ,[1VEC;27%K;^=*)KV[LK&*YNX #W&BO ?V7
M_P!H/PQ^U'^SO\'_ -HOPO8S:!X>^+_PY\*?$BRT'5-0T^]U;PUI_B[0K/Q#
M9Z3X@GT^22QAUBPL+^W74X897@@N/,6*>>%4N)/6?#7C/P?XSBU*?P?XK\->
M+(-&U2XT35YO#6NZ7KL6E:U:+&]WI&I2:7=726.J6J31/<:?=-%=PK+&TD*A
MU) .EHK$@\3>&[J>UM;7Q!HES<WTUS;V5O!JUA-/>3V4,=Q>06L,=PTEQ-:0
M2Q3W,<2N\$,L<DJHCJQ8/%/AAGU>)?$>@M)H$T%MKT8U?3R^B7%SL^S0:N@N
M-VFS7'F1^1%>"%Y=Z>6K;ER ;U%8>L^)_#7AW1I?$7B#Q#H>A>'X+<W<^NZS
MJUAIFC0VH@>Y-S+JE[<064=N+9'N#,\XC\A'EW>6I8>1_M%?M(?"O]E[X"_$
M;]I#XI:O<Q?#/X8^%;_Q;KEWX>MDUS5-1L[)/W6G^'K&&XACU35=2N#':6$!
MN[>U\Z3S;V\L[*&YNX #WBBO /V8OVA?"W[4'[.OPA_:.\-6<OAWPW\7/AOX
M5^)=IH>K:CIUWJGAC3?%FA6?B*UTKQ%<V$KV%OJVGZ??0#5(XI7M[><2K'//
M J7$GLF@^)O#?BFUEOO#'B#1/$=C!=7=C->:#JUAJ]K#?6%U/8WUG+<:?<7$
M,=U97MK<V=W;NXFM[JWGMYD2:*1% -NBOSY_X*0?MWZ3^P=^QU\?/VG_  [X
M>\-_&+Q-\"O^%:_VE\+!XZMO#5Y/_P +"^+7@/X9#^U]2L=+\3ZAH'V"+QH^
MLP?:- G^W2:>EB/(6Z-W!]2?L[_%27XZ_L__  ,^-T^B1^&I_C'\'?AE\5)O
M#D5^VJQ>'Y?B%X*T3Q=)HD6J/9Z>^I1Z4^KFP2_>PL6O%@%PUG;&0PH >Q45
M^,?_  66_P""O.B?\$G?AQ\&M>L_A7;?&SXC_&CQEXBTK0/A]=>,;GP+!;^"
MO!&@IJ7C;QG+KMKX5\7N[:)JNN>"-(BTI],MUO(_$5W?K?Q+H\T%Q]-_#7]O
M?PE\8/\ @FL?^"B7P]\/V^LZ0?V8?'7QY?P"VMSQ1VGB_P"&W@WQ%JGC?X6W
M?B5M%23SO#GCKPIX@\!7WB*'07AEGTR;5[+3KBVD@BE /T!HK^3?X6_\'"G[
M>?Q/_9WU;]L3PM_P1VU_QY^RYX5O-:@\8?$/X>_M/Z3K6JZ-:>&;F"V\5:FG
M@R+X3WGC6?3_  K'/_:>N:@?"Z:+I^D6UYJNIZQI>BV=_J]E^PG_  ]__8Q_
MX=X?\/,?^$F\3_\ #/\ ]G^R?\(__8VF?\+9_P"$Y_X2?_A#?^%6_P#"'?V]
M]A_X3[_A(?W7V3_A(/["_L/_ (K3^W_^$)_XJ*@#]1**_E$OO^#C3]I_X;^'
M?!/[2/[0/_!(CX]?#;]A;XC'29_#OQRTCQQ+XB\16/AS6)87T#QE>Z1JOP]\
M*^%GM?&]IK'AU_!6D^(O$_@/2M?:[N9O#'CCQ9"J*/ZD/ ?CCPG\3O _@WXD
M^ M<LO$_@;X@^%?#_C;P;XDTUVDT[Q!X5\5:3::[X?UJP=TC=K/5-)OK2^MF
M=$<PSIO16RH .KHKE?''CKP3\,O"/B'X@?$?Q=X9\ ^!?"6F7&M>*?&7C+7-
M,\->%_#FD6H!N=3UO7M9N;/2]+L8 5\RZO;J&%2RJ7W,H/XO_P#!/_\ X+;_
M  V_X**_MW?M&?LL?!'X<._P<^"OPZU/QOX._: O?%%PM[\53H7B[P-X+U.Y
ML?AY-X9M7\.^&=0U7Q5J5YX8U.]\37FK:GH&F:7J>IZ'H5]K5SHNB '[E456
MO+VSTZVDO-0N[6QLX=GG75Y<16MM%YDBQ1^9/.Z1)OE=(TW,-TCJBY9@#!#J
MVEW-TMC;ZEI]Q>O8Q:HEI#>6TMT^F3OY<&HK;QR-*UC-)\D5V$-O(_RI(6XH
M T**IV>H6&HK</I]]9WRVMU/8W36=S#=+;7MLP6YL[@P.XANK=B%GMY"LT3$
M"1%)%9H\4^&&?5XE\1Z"TF@306VO1C5]/+Z)<7.S[-!JZ"XW:;-<>9'Y$5X(
M7EWIY:MN7(!O45^;G[?G[<NO_LH^(?V(_AY\,O"GACXB?$C]LK]K/X>? 72-
M(UW4-3AM-#^&^MPW,WQ$^*UHNB;KC4X? ,5YX7N;FV\R*S>RUE[F:X184#^;
M_P#!)?\ X*>S?\%+_@A\9?C)XC^%.C_ N'X3?';7/@T=-3Q^_C&RU6'2?#'@
M_7X?$%QJ]_X8\()ILMY/XJ&GKIOV6Z16M8Y%OI'N?)B /UKHK%OO$OAS3-,A
MUK4M?T33]'N);>&#5K[5;&TTR>:[D$-K%#?SSQVLDMS,1%;QI*S32$)&&8XJ
MY%JFF3WLVFP:C8S:C;1)-<6$5W;R7MO#(L3QS36J2&>**1)H6222-4998F4D
M2(2 7J**^7_V3_VS?V:_VXO 7B?XG_LN?$C_ (6?X&\&_$+6OA5XDUS_ (0_
MQ[X*_L[Q[X>T;PYXAUC0?[,^(?A;PEK%Y]CT?Q;X?O/[4L-/NM&N/[0^SVNH
MSW5I>P6P!]044UW2-'DD=8XXU9Y)'8(B(@+,[LQ"JJJ"68D  $D@"N<\->,_
M!_C.+4I_!_BOPUXL@T;5+C1-7F\-:[I>NQ:5K5HL;W>D:E)I=U=)8ZI:I-$]
MQI]TT5W"LL;20J'4D Z6BN<NO&/A&QL!JM[XJ\.6>EMJ5KHPU*ZUS3+>P.L7
MTL,%EI0O)KI+<ZE>3W%O#:V(D^U7$L\,<43O*BM\>?MI_M_?!C]AZX^ &B_$
MJWU[6_%W[2WQP\"? OX9^'/#\5HH&M^,_$&F:+=>)_%&JW]Q;V>@>$O#-MJ/
M]HZE>E;S4+QHULM*TV\D-U+9 'W-17P5\2_VH_C_ .%/VW?V?/V=? _[+MS\
M0_V>/BSX&U'Q1X__ &I[/Q_96&E_"[6+:U^(%Q8^'F\&C1;R7Q&-0;PMX:2/
M4+?7+*-1XNB<1.+!OM'TG^T1\5)?@5^S_P#'/XW0:)'XEG^#GP=^)OQ4A\.2
MW[:5%X@E^'O@K6_%T>B2ZHEGJ#Z;'JKZ0+![]+"^:S6<W"V=R8Q"X![%17\E
M?P\_X.*OVW?''[-VL?MF:9_P1Z\1>,_V5O#5]K%CXK^*/P__ &HM+U6;PQ#X
M8GC'BW6M2\)Q?!W4_%R:'X7L_/O-:UB]T#2_#FG6L9O]4\1:=IL,]VGTQ^V)
M_P '!OACX0?L]?L&?M%_LL_L_7G[1GAC]N_6OB7X;\'>'_&OCE?@[XF\*^)?
MASXD\*^"KSPSJ]O%X;\=:9+K1\::[J?AV^=-5CT."71EU'3=:U?1]0MM0H _
MH\HK^=SP-_P7&^,'PK_:4^$7[./_  4R_P"">_C_ /82'[0&H6'A[X/_ !@3
MXK:!\9?A?K/B_5M=T[0+'0/$FO:%X9T'P]X?M+:[OX!X@U;3_%GB+4O"8U7P
MY?\ BSPMH7A;6%\4P?2/_!63_@L[^SW_ ,$N_A^(+IM ^,W[2VN76B)X0_9P
MTCQK9:'XACT34;@2W_C?XA:C:Z=XCOO 7@^UT>"_?0[V]\/7E]XO\0?V?HVB
M6+:=_P )#XA\- '[)45X[^SO\5)?CK^S_P# SXW3Z)'X:G^,?P=^&7Q4F\.1
M7[:K%X?E^(7@K1/%TFB1:H]GI[ZE'I3ZN;!+]["Q:\6 7#6=L9#"A0![%7\;
M7[7W[3?[>W_!2/\ :L_:@^"/[)__  2C_8@_:N^%'[$_Q8U_X$ZSX[_:Y\*>
M$O$7BV+QCH.KW^F:O-X;\0>-?C'\(XM%TS6M4T#5-1LM"\)P:K*NA-IFH>(=
M2#:M9VQ_LEK^)G3?V9O^"G_[77_!5O\ X*D^+?V7?VJO!/\ P3XUOX<?%CPS
MX%\1>!=*36M/U?XO^ +"PU:Q^#OQC\2>!-)TJ^TWQ0?%?@FS@\01_$?7DN;U
M]2\0W>B:1)%;V4\<(!^MG_!(#0?^"I/PU\?>+/A=^UC_ ,$__P!B?]BO]F"W
M^'.L>(/"K_LGZ5X"\/7>M_&5?$W@G3]+LM=TGP5\>?B:;RWOO!DWC"]OM8U#
MPU!<RWFD:7%<>(HW:*QU#]^J_%[_ ()R?L<?\%1OV>/C3XL\9?MN_P#!033_
M -K'X6ZK\+]7\,^'/A]::'?:7)H?C^[\5^#=5TWQDT]SH6EQR)8^'='\3Z(8
MA<.Y;7U<0LJ,\?[0T %%%% 'XB_\$1_^":7QN_X)U_#;]I6;]ICQ?\*_'OQV
M_:,^/=Y\3O$7BOX3ZSXN\1Z1>^&8M!LFTBWUC6_&_@GP'KTVNIXQUWXBZE<6
M?]DWFGV]KJUI=P:K<7FHZC;6?D7[</[%'_!6[PU^W+<?MT_\$YOVI/#GBK0]
M?\$VGA+Q/^R)^TKX[^($OPDT.2/1/#_AZ_/PZ\*1W%UX+MM(UZX\/:;XZU1(
M-1^'VNZ5XUBU?4;/5M?M?$E[I=O_ $+T4 ?S,_L?_P#!!3Q7X?\ V5O^"A_A
MC]M7XK^#OB-^U1_P4HCUS4/B?X[\#:;JFH>$/AIXC7Q'XG\?^#M=T.>]M?!6
MI>*=2M_BKKEC\3?%=E'HWA+0KN_T71_"%E;W>E:,-?UCXZ^"_P#P0W_X*6?%
M3Q!^P]^SC^WM\2/V;M5_86_X)\^,=4\2>%;#X;:OXMUKQA\<-,O_ !#;^*K3
MPMK=IJ/A_0C+ID$=A:?#TZCJ\7@R]\->!KG58M)LO$NL7+:Q<?V5T4 %?AW^
MV1_RF_\ ^",W_9,_^"B/_JF/"]?N)7X=_MD?\IO_ /@C-_V3/_@HC_ZICPO0
M!^XE%%% !1110 4444 %%%% !1110 4444 %%%% !7RG^W1\?D_99_8V_:>_
M:&6[L[/4OA)\$/B+XP\,M?L%M;OQM8^&K^/P'I,A;@MK?C.?0M&A3K)/?QH
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MX#^)_P 2_P#A,/'M]_PD_A3P[IO@K2-&TK_A#=2\4WGP_P!%^QZ=\._!UO\
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MG\7$^&VBU^#Q+XC\>ZMXR\-:A9S>$/#5WILGA/Q%H2Z7?:3;ZAIR6MZT]Q*
M?S[?\%._AU\(?VD?^"WO_!,O_@G_ /'?5;/PY_P3T/[,,7B_P;\(/"WBH_#?
MX5>)?%AT[X_:9X0TO0M0\'7GAZUT0ZJ?A]\-_ 7ARRT2_MK^#0(8O#W@B?1K
MGQNDL^+_ ,$8_ _P/^&/_!?W_@HU\-?V;?'FJ?$;X'?#S]ES1/ OP\\0:MXU
MU#XB2:9I'A'5/V9/#]QX TWQCJM[J5]K'AGX4ZKI^H?"[P@9M0OEL/"G@[1M
M+@N[BWLHI7^NO^"K?_!.3XFZU+^QWX'^ '_!-_X'?M]_L@_ GX>CX=7WP?\
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ME=0WG@?5;:TAE<36NIH3$W]&O[:'_)G?[6/_ &;3\=O_ %5WBJOS1_X-Z/\
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M%](ET+Q$-0T?XE>)M/\ $FB7GB+55T_PI#X3O;2X_(__ (*J>*?^"9?[7_\
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MKQ3X_P#$>@Z1X<M_'WB.![K]G2V.LZ_;7'BW2+7XL^$-!O)-+\)0^$_#WAT
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M<PVNMZ78ZK;0W(C>(7$4%_!/%'.(I9(Q*BB01R.@;:[ [-%2:' ?\*H^%O\
MT37P!_X1OAW_ .5U=W##%;Q10011P001I###"BQQ0Q1J$CBBC0*D<<:*$1$4
M*B@*H  %244"LELD@HHHH&%<!\2_ASHGQ3\+R^$_$%UJMGITU[9WS3:-/:6]
MZ)K)V>)5DO;'48!&Q8^8#;%B,;70\GOZ*BI3A5A.G4BIPG%QG%[2B]&GY-'3
M@\9B<OQ6'QV"K3P^+PM6%?#UZ;2G1K4Y*4*D&TTI1DDU=/5'Y9>%OV=_!6M_
MM ^//A3=ZIXIC\.^%_#BZQI][;WNDIK4UR1X3REY<2:)-8R0?\3V\^6#3K>3
M]W;?O?DE\[]-/#FAVGACP]H/AJPDN)K'P]HVEZ'92WCQ27<MII-C!86TEU)#
M#;PO</#;HT[Q001-*6:.&-"$7Y$^'O\ R>=\8/\ L1T_E\.:^U*\C)\-0I1Q
M<Z=*,)?7<71YE>_LJ=>2IPWVBE9'Z1XFYWFV8U^'L+CL?7Q.'_U7X<S+V522
M</KV.RJC/%XJRBG[6O-N51WLVW9(^1/VC/@+X/\ $^F>-?BI?ZEXDA\0Z+X0
MO+JUL[.\TN/1I)-"TZXFM!<6\VCW%\Z2,H%R(]1B9UR(FA/-<A^RG\#_  G_
M &!X#^-']H>(O^$H_P"*H_T#[7IO]@?\?OB+PI_QZ_V3_:/_ "#OWW_(5_X_
M?WG^H_T:OISXU?\ )(?B9_V(_B;_ ---U7#_ +*?_) _ ?\ W-'_ *F?B*IE
M@\*\ZIR="',\'4Q3=G=XB&*H\M7?XU=V>VKT.FCQ/G\?"S%T5FN*5*/$F"R"
M,.:/*LFQ'#^:.MER]W_=ZCIPYH_%[JM)'T-1117N'Y*%%%% !1110 4R2-)4
M>*5$DBD1HY(Y%#I(C@JZ.C JR,I*LK A@2""#3Z* VV,;0?#GA[PM8#2O#&@
MZ+X<TP327 T[0=+L=(L!<3;1-.+/3X+>W\Z4(@DE\O>^Q=S':,;-%%*,8PBH
MQBHQBDHQBE&,4MDDK))=$E8NI4G5G*I5G.I4FW*=2I)SG.3WE*4FY2;ZMMMA
M1113(/F[]H3]CO\ 95_:PL=/L/VD_P!GKX0_&P:-;75GH.H?$/P+H'B'7_#E
MK?2PSWT'AGQ+>63>(O#4=[+;P27BZ%JFG_:VAC^T>9L7':_!KX ? O\ 9U\)
MR^!/@%\'/AA\%O!MS?-JMYX8^%O@7PUX$T74=7DM+6PFUG5-/\-:;IMOJFLW
M-E96=M=:OJ"7.I74-K;I<W4JQ(%]<HH ^'/#W_!,K_@G;X6N_B%=Z'^Q!^RS
M:#XJV=KIGQ!TZ7X'_#R_T'Q/I-EKFA>)[;1KWPYJ.@W?A^'1(_%/A?PWXI.B
MV.F6NER>*-!TCQ'+:/K6G6M]%[Y;?LW_ +/%EXT^''Q(L_@+\%[3XB?!WPA%
M\/OA'X]MOA=X'@\:?"SP%!I.J:#!X(^''BF+0DUSP/X0AT/7-:T:+PUX9OM+
MT:/2=8U33DLA9ZA=PS>ST4 >!?'_ /96_9L_:K\.V'A7]I'X%_"SXW:'I#:A
M+H-M\2/!>A>*+GPS<:K#;V^I7OA75-2LYM5\*ZC?P6MK#=:CX=OM,OIXK:!)
M+AEAC"[&@?LZ?L_^%?@_/^SYX:^"'PET+X$76E:GH=Y\&=+^'GA*R^%U_H^M
MRS7&MZ=J'@.#24\,7]KK=S<7-UK,5YIDXU:[N;BZU#[3<3RRO[+10!\Y?L_?
ML@?LM?LI6WB&U_9L_9]^$GP17Q;=+=^*;CX<>!]!\,:CXB>*[O;VS@UO5M/L
MXM3U/3]*GU*_&AZ7>7DVFZ#!=36FBVEA:-Y%=[XZ^"'P6^*'BCX=^-_B7\(?
MA?\ $3QI\(=8N?$/PF\7>.O 'A3Q;XH^%^OWESH][=ZY\.]?U_2=0U7P5K%U
M>>'?#]W<ZGX:N],O9[G0M'GEG:73+)X/4** /@[XK?L.>'_B[^WE^S#^VOXA
MUGPE9S?LK^ /B9H'A#PYIOPRTQ?B!XJ\7?$K2=:\+?VAXR^,-SK<^H7GPX\$
M^&/$?B*Z\%_#&Q\+6<>G>//$>L>-9O$\SR0Z0GW1>6=IJ-I=:?J%K;7UA?6T
M]G>V5Y!%<VEY:7,307-K=6TZO#<6UQ"[PSP3(\4L3M'(K(Q!LT4 ?*WP0_8:
M_8V_9J\7^(?B!^S]^R[\"?@WXW\4Q3VNL^*OAU\,O"?A77)--NA8FZT2PU'2
MM,M[C1?#EW+IEA=W7AO1'T[0;G4+:/49].DO]UPWH_AG]G?]G_P5KGQ0\3^#
M?@9\'?"7B7XWS7%Q\:/$/AGX9>"M!USXO3W<NK374_Q0U;2M$M+_ ,?S7,VO
M:Y+<2>*[C5GFEUG5I)&9M1O#-[%10!\C_!7]@?\ 8H_9P\?:U\4_@)^RM\"/
MA#\0]>MKFQOO%_@#X;>&/#6M6^G7J6Z7^DZ+<Z;I\'_"-Z-J'V6V?4='\.KI
M6F:A-#'/>VD\ZB2OISQ/X8\->-O#7B'P9XS\/:'XN\'^+M#U;PQXK\*>)])L
M-?\ #7B?PUK]A<:5KOA[Q#H6JV]WI>M:'K6EW=UINK:3J5K<V&HV%S<6=Y;S
M6\TD;;E% 'SOJ?[(7[)NM?"/P]\ -8_9>_9VU;X#^$M8G\0^%/@GJ?P4^&M_
M\(_#.OW-[KFHW.N>'OAO=>&9?!NBZQ<:AXF\27\^IZ;HUM>RWOB'7+J2=I]6
MOY+CK]7^ ?P*U_XE>#?C/KOP6^$NM_&'X=:._A[X??%?5_ASX/U+XE>!- DB
MU:"30_!OCJ\T:;Q1X8T>2#7M<A?3-$U6QLFBUG5HV@*:C>+-ZS10!_(G\9?^
M"1G_  5^\2:E^TSX.T;Q+_P2I^-.G_'J'X@>!O#W[87QN^!>G^$/VW?"7P@\
M;Z'K7@[6-%U+XC_";]GC2]_BOQ7X&UF\\.^)M<U1_B9J.+R[.B^(-%M9H8K'
M]\_V$_\ @G_\&OV+O@Q^SWX6L/!O@37/C?\ !W]GG1?@/KGQTL_"NE6GC'7M
M&GUZ;XA>.-#T[Q =/M]=M? >M_%75-=\8V'ARYN&6.YNX;O43=ZM]IOI_OFB
M@#QSPU^SM^S]X,UOXH^)O!_P+^#GA3Q)\<);B;XU>(/#7PQ\$Z%K?Q?FO)-6
MFNYOBCJNEZ):W_C^6ZEU[7);B3Q9<:L\\FM:L\I9M1O#-^7_ /P4._X)R?%[
MQ_\  #X8?"C_ ()LP_L?_L_:#X'^(6J^)O&_[-?Q5_9W^$>J?LE_&30?$":=
M=:BWBSP ?@C\2=-T_P 8Z1JFAVS:%K6A^%-,U">T\1>)O/\ $.F:B-(U2Q_:
M.B@#^;[]@'_@E-^UIX'_ ."@.B_MU_MBZ5^PS\,=.^%'[/FM? _]GO\ 9^_8
M3\)^)?!WPX^'_P#;_B+7M1U/4CX>\1^"]'L]'MY[;QM\2K^ZFTW7M=UC6];\
M<227-WI&EZ:='O?Z0:** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** .5\5>!/ _CI=!3QOX-\*>,D\+>(+;Q9X83Q
M5X>TCQ"OASQ596&I:79^)=!75[.\&D>(+33-8U?3K;6=/%OJ,%AJNI6D5REO
M?7,<OCWPE_:W_9M^.WQ)^+_P?^$7Q@\(>._B?\ _$-[X5^,/@C1KFZ_M_P
MZ]IVJWNA7ECK5G=VEJ=L&LZ;J&EF\LVNK%KZQN[:.Y>6WE5?HNOXS_CM^QC_
M ,%C_P!DW_@H-^V#^V;^QIXU_9 _9Y^%'[1_Q!GEU-/B'X^\!:!X6^)6EV^I
MWVK:'K7C?P_\0--O[#3/'EY?:GJVH:CJGAJ_T'4[V^U+6+R5WN=;UJ;4 #^S
M"BOQ*_X)DZI_P6>U_P"*FOZ]_P %"?$O[+OBC]G;4_A1JMQ\/]5^ E[X8U._
MOOB8_BSP;_8MTVH^'H1'=^'6\)+XV6:6.XEMFOSI^<N$(_;6@ HHHH ****
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MK6EW=KJ6DZMIMU<V&HV%S;WEG<36\T<C?AC_ ,0SW_!'+_HVCQ-_X?WX]_\
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M1)'&KVR64C+!&?,7"A?ZU*^0?VL?^:1_]C]!_P"VE?CF0<5Y]PS5Q-7(\='
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M13>+XK4C3H+IK.WFBL[8"$$1PP(YB"C:ZN[6UV"HFXM)7NK;I6^^Q]0^$O\
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M%CC3<[,[;451N=F8XRS$DFIJ**0S^/#_ (*N?M5_L\Z9_P %#]2_9>_X+/\
M[&'P[UW]B&\\$V>M_LI_M:?#WP/\4[+XS6MYJ0\-7FI+JWQ%\"_$Q?$<O@SP
MQK%UXU\/^// ?A#1X-6GU_2/!_BR]\$ZIX<U[2'N?C7_ (),_#GQ!XV\;_\
M!9'P9_P3XF_:.\3?\$O_ !?^QG\?/!/P5TSXN6NM3:?XI_:6\9?#_P (Z=H5
MCX:L8M,L+";Q?;I)X]TBV:SL)_&O_"M[CP!;?$2WO-?U#1;N/^[_ ,0>&_#O
MBW2;O0/%6@Z+XFT*_01WVB^(-+L=:TF]16#*EWINI07-G<HK ,%FA<!@"!D
MUIVMK;65M!9V5O!:6EK#';VUK:PQV]M;P1*$B@@@B5(H88D54CCC5410%50
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MU*56F-O<>)=>-]XDO]-M9_[-M+_4)8;"&&UAMXXP#_/)^,/[%'QN_:>_;?\
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MN]92_GGTO3/"/BS4M$NP+%]8LK/2['PUX=TZVN/%?BC5[Z/6=:OK?4K7]MZ
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M7=UX@OM-36_%&@0RZ-/=3VE[I_\ 0M0 5R'C_P"('@CX5>"?%/Q(^)/BO0?
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MUN&+0]>6YLO&MEXO707M=>NM(DU?PSKW[F_\$B_VA_B/^U7_ ,$W/V2?CO\
M%V0W?Q)\9_#22Q\7ZO(KI<>)M5\#^)_$'P_;QE?*T<*+J?C:W\*P>+=4%K##
MIXU'6KK^S8HK#[,B@'Z.4444 %%%% !113))(X8Y)II$BBB1Y)99'5(XXT4L
M\DCL0J(B@L[L0JJ"20 30!4U35-,T/3-1UK6M1L='T;1[&[U35M6U2[M]/TS
M2],T^WDN[_4=1O[N2&ULK&RM89;F[N[F6*WMK>*2::1(T9A_$1_P1_\ ^"MW
M[.'_  3^^ GQ&^%GQD\%?&WQ+X@\7_%Z_P#'^FWGPR\-^!-9T:#1KKP9X.\.
MQVU]<>*OB3X,O8M3%[X>O97AM]/N;46LMJZWK3/+!!^UGB_QKXM_X+ _$K7/
M@E\++O7?"O\ P3;^&GB-;#XZ_&;3'FTG5?VJO%_AZ^MKV/X1_"_4V5+JV^&]
MEJ$%K=^+/%6GJ)]4MH8OL]U8P7NA?VO\Y_\ !<KX.:[\)OV$M3TCPO;^ ?#/
MP1T;XE?#'PYX&\">%=$L-+N/#VEVIOAI5DBVWAFR:."V2SF\X_VW=2SR2"2=
MKF221Q^R<(X/*\NE#@KB+"U\9C>,\RR)8S!8;%_4JF04L)4Q#P,L955*M*IC
M\1+'SK5LL4:4L+0A16(KPQ%:>'H?D'%F+S/'J7&7#^)HX3!\(9=G;PF,Q&$^
MN4\\JXJGAUC5A*3JT8PP%!8&-*EF3E6CB:\ZSH4)T*5.O6^ /B[^U;^S9_P5
M:_X*Q_L07F@_#GQO<_"<:5HGPJ\;^#OC'HGAS2I]?GA\1?$+Q/.BVGA#QIXN
MMI]&DMM;TY5EEU6SNS=V]RC6BPI%-/\ <'_!:W_@F[\//#/[,/PGL_V)?V,X
MKGQW%\;K*/Q$_P !?@_J_BSQV?!DW@GQ]<W1\07WA;1]9\43>'!K[Z,IDU6X
MDT^"]&DVJ/&4L85_6W_@GAX$^(^G?L^?LW^)?%^K>$-4\(7_ .S-\(;GPUI^
MGZ;9QZWIMS>^!O!=WI,]W<)X8TV7S;;2!>6MRXU>]9KB8$FYR;E/N3XA-XT3
MP=KK?#Y=/?Q:MFQTE-2&86<,OGB#>RV_]H?9_-_LW[:?L!OOLXOO]%,M<F/\
M0JN5YYD4<CP>+P.6<)QK9?3RJOG&(Q.&S"5+%8Q^WQ7LZ.%CS-5[6E2JRBH1
M7M&DDNK \ T\TR3.Y9WB\+C<RXJG2Q]3-*.44,-B<!&KAL&O8895*V)ERIT$
M[QJTXN4Y/V:=[_S3R_\ !?G]JV#XFVWP4G_X)<?$F'XRWMFVHV?PDE\3?$B/
MXFW>GIIEQK37UMX"?X%+XJGLUT:TNM6:ZBTIX%TRVN+\N+6&25?</^#>OX/_
M !H^$OPJ_:<3XT?![XG?!S5?%GQ>T'7M&TCXG> _%?@2^U*Q?PY<"YN=*MO%
M>CZ/<ZG9VMS*+66[M87A28".0I(=E?"_B_XT:_;_ /!>KP+\3[KP]#:>*],^
M#NI:1>:)="Y@M8-?B^!GCGPM--+;R!;V*&&ZE^WRZ7*R7*%'TQKP,/MU?TE>
M$M+^/?Q:\.Z7;?$'53\._#!M5CU,Z+:'3?'7C&,/'AKK>TD?AJUN(5*S^3;V
M<UQ)YZOI,FFWD*P;\7YGE.3Y%A,ER3AW!Y52XPX?X>S[,:]/'YEBJE.K2QF,
MJTL-2AC,3B(^SI.G)*:Y)R5:7/?EARX\)9?FF;9YB\XSGB#&9K5X2SW/LCR^
MA4P.786G.C5PF#I5<15GA,/0E[2JJL6X/FC#V*Y;<TN;SW]KCQ3\)]9M8-'M
MW_M?XE:5,EO:WVAF*2+2K87*_;-+\07P#17*,&N7M=+@,]_I^HJ9)&T^&YN8
M[_PG]G3PW\+O%'C!=(^)#WINKI81X5T^:X-EH.KW?F3)+97UU"T5V;QY1&=,
MM4GM[2^F2XM)GGN)+:RN?NCQ1\$OA?X5\(^)M=T+PE86.JZ'\._%NGV%V&N)
MY LNCZA(U[<"XFE6ZU5=\T2:K.'OTMIFMA/]GC@CA\V_9H^'G@[Q=\,_"6N^
M(-#M-1U7PQXKUR\TF[E#*\;K/&\<-P$95O+2*Y*7D5K<B6&.[B654 >=9?R.
MZ4=&][7ZIVOIY>5^K/U1PDZB;Y'I>VMFE9.^FKUT]%?30^QM/T[3](LK?3=*
ML;33=/M(Q%:V-A;0VEI;1 DB."W@2.*) 23M1%&23C))KY-_:Q_YI'_V/T'_
M +:5]?5\@_M8_P#-(_\ L?H/_;2HCNO5?F:5/@^<?_2D?7U%%%(L\D^*OPJ_
MX6?#HD7_  EFO>%O[&DOY-^AR;&O?MRVB[;G][%D6_V3,7WL&:3IGGQ/3/V0
M-.TB0/IWQ+\86:F>.XEBM$@M4G>-@09E@G0.2!M+,&."17KGQD\7?%;PI#X?
M?X7^"K3QE+?2ZDNLI=07<XT^.W2Q-@R"TU+3BIN6FNPQ<R@^0-H3!+?,OA#]
MI7]H/QR;B7PS\+_#>LVEA>Q66ISV%GK3"SED^8QR&3Q"NUQ$&<?*PXYSTKSZ
M^:4,-6^KSCB'4>L5##U*D9^[&;<)1BU/D37/RWY=4[:GV64\ 9QGF5O.L+B,
MDA@H.U:6+SK!82KAFZ]3#TUBJ56K&6&=>I1FL.JR@Z\4I4^92U_06N$O/BC\
M,M/N[JPO_B+X$L;ZQN)[.]LKSQ=X?MKNSN[:5H;FUNK:;4$FM[BWF1XIX)42
M6*5&CD574@=W7Y[?M;_"'P%X6\)7/CW1-(FM?%'B#QW')JM^^IZG<QW#:U#K
MFJ:B5LKF[ELH//O8DE4001B(#RXMD9*EYCB,1A<//$4*=*HJ2E.JJLYQ?(E]
MCEB[ROTDXJW4SX+R7)^(<ZP^39KB\QP=3,*E+#8"I@,/AJ\?K,Y._P!;>(K4
MG3HJ"NI4H5IN6CA;4^X=#\<>"O%%S+9>&O&'A;Q%>00&ZGM-#\0:3JUS#;+)
M'$;B6"PN[B6. 2RQ1&9T$8DDC0MN=0>HKP_X/_!WX?\ @*RTWQ1X7T::PUK6
M_"^G0:E=2:IJEZD\5Y%8:A<*MO>WD]O#ONX(Y T,2,@78I"%E/N%=&&E7G2C
M+$1I0J2UY:,I3ARO6.LXQE>VZM9/9M:GCYU1RG#YC6H9+6Q^(P-*T%5S*AA\
M/BI5H7C6O3PU:O25-33]G+VG-*.LHQ>AY7\7O$GQ#\+^&K'4/AIX5M_%VNS:
MY;6=WIMS#<SQP:3)8:G//?!+6^L) \5Y;V%N&,S(%N6!B9BKI\DZ/^TO^T/X
M@UK6?#NC?"WPWJ.M^'I)(=;TVWLM::YTZ2*X:UD2Y5O$2JI2X1HCM9AO!'3F
MOT*KX?\ V?\ _DXK]H;_ +"VJ?\ J47=>9F$,1];P<:6,Q%&&*JRI2A3]GRP
M4*,ZG-'FA)\TG%7NVK;)/4^[X-Q&3?ZN\35L?PQDV:8G(<!1S"ABL9]=]MB)
M8K,L+@_85_8XJE#V-*G6E*G[.,)\R7--JZ?VEI<UW<:9IUQJ$ M;^>QM)KVV
M4$+;W<MO&]S H9G8"&9GC 9W("X+,>3>HHKV4K)*][)*[W?F_4_,)R4IRDHJ
M"E*4E"-^6*;;48W;=H[*[;LM6SXV_;@_Y)/X>_[*'I/_ *C?BVOKZP_X\;+_
M *]+;_T2E? GQ^\>^'?B%J3^'-9\6^&M*^'/ASQ#J=E)]D,6M^,;CQAX?T34
MI&U)_#]OKFDZC'X;N))]3\+Z9=(/(FUF..\G>33=1TZ[@]&\,?M.^'/#.C)H
M_P 1]:TS6/%-M:V%U9R?#\6_B:QU:RO[.*X%D)]'NKG3K+6M#N_MFC:E:W=W
M:I<)96NJVK26^HKL\*CCL-#,<=5G5A"E4AAZ<:DI14>:@JO-?WKJ,_:+V4FN
M6HXR46Y))_KN8\*9[B^">%,#A,!B,5C\%BLYQ^(P5##XF==8?.*F7J@X?N52
MJ5<,\(WF-"%65; PKX>I7A&E.4X?8%9VKZMIN@Z7J&M:Q=QV.EZ59W%_?WDV
M\QV]K;1M+-(5C5Y9"J*=D42232N5CBC>1E0_.K_M#>(-5$0\%_ CXK:[YQ(B
MN-<TM/"NF2 J'C=-3==7MQ%(N6WR^5M4Q9!:4*.1\8>(?CKKJ:-J7B_P!X?^
M'WP_T+Q!I&N:_+>ZE%XZF$5K,O\ 9U_K&E:%XC\/2WF@:!JSV?B'5H%GM);=
M-.M[Z:.[M=.O;"][:F8T>23H1K5I6T<</7]C%NWO5*SA&E&G&_--NHK13U/E
M<'P1F;Q-"&:U<MRRA.?OTZ^=91',JJB]:&#RR&+KYC6Q==_N<-"."FI5IP4E
M:YR_[/?B/3-)^+GQ8O\ 5AJ6DV'Q9\53:C\.K_5="US3+'Q59R:SXDU:&;3[
MR^TZ"V0SV&J:=-;Q7<MM-<->000QR7#B*OO&OS:M7\0W,&KVBZ]X6N_^$RT>
MYM_A#IUKX=U">ZL#<^.I[^QT[0;>V\?V\_P[O9-5N_#'C:W;5?\ A)'T_0-/
MM0P6U\$7&C1_1<&D_M:VH#'Q3\&M48H$*:A8>([= 1@F8/INDV[F4D8VD"+#
ML0@(7'#EN)G1HNB\/7K14I5%*C"G)Q=>I.I*-1>V;UE)SI-).5&4'**:YI_6
M<=9#ALRS2.91SG*<NK5:%#!SHYEBL51A7AE>#PF"H5<'4_LR"E*%&G'#9C";
ME3I9EA\3&C7G&3H89O[6>HZ8/A%K/A^75=)M-:UJXT:32=.U#5=/TZYU"/3M
M>TNYOGM5O[FW$J6L \R9E;:@*J3N=%;5\'_%?X?>"_@GX%U;6/%.CRQ:1X1\
M-Z!/:Z3J%GJ]_/XATOP]I,5[H-E:Z?/.USJEO++ )X481VT4\-W=S063_:1X
M3XCN/B?!XGOEU_3/!]]\;(/$O@>/P+J.C>(=?LDCTF>UOC##X;T"Y\*2PW_A
M*XMSXY7QW<:KXFTUB([XW44*V/AMKK=^#OANTUSXB^%O$:^"_"\L^C>!KIO&
M>L7'B.^U[6;#Q;?:U--!J&JV5_X+T6.R^([ZY8^([?6K=+JY^QZ<S2+J%E%:
M:+:ZY"Q56>83J48J%2M3CA(QJTJK]G&G6E><N5)2JPE.=2K2YHPA2]F_:W<K
M=DLAP&%X-P^"S*M/$8++L;7XCK5\!F&6T_KM3&9704:%!UYRG0R_%QP^'P67
MXYT<1BL1F"QE/^SHQA1Y^V7PS\1OCTXN_'JZE\-_A6\B26?@&SF-MXM\501G
M=%-XNO0@DTRPG;YFTB-4EV@HT$=Q!9ZU)])Z%H.B^&-*L]#\/Z99Z1I&GQ^5
M:6%C"L%O"I8N[;5&9)9I&>:XGE+SW$[R3SR22R.[:]%>S0PT*+E4;E5KS5JE
M>I9U)*]^562C3IIZQI4U&"WLY7D_RW-<]Q.9TZ6#A2HY?E.%FYX/*,$I0P="
M3CR.O4<Y3K8W&SCI5QV,J5L545X*I"BH4H?%?P]_Y/.^,'_8CI_+X<U]J5\5
M_#W_ )/.^,'_ &(Z?R^'-?:E<N5_PL7_ -C''?\ I^1]#X@?[]P]_P!D3PE_
MZJ*!YC\:O^20_$S_ +$?Q-_Z:;JN'_93_P"2!^ _^YH_]3/Q%7<?&K_DD/Q,
M_P"Q'\3?^FFZKA_V4_\ D@?@/_N:/_4S\142_P"1S3_[%E;_ -2J 4O^388W
M_LO,L_\ 6>S8^AJ***],^#"BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MKIFDZ9:@[(84RTDTTTC2W5]?74L]]J-]/<ZAJ%S=7UU<7$O\HO\ P5'\$?\
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M?M(_M(^)O^"@WP'L_P!B/Q-\'M1^ EEXJ\$? 'XD_M+:3XTF_9\_:TUG4?\
MA8?A_0;^"*?P%X0CU#X9:C<^&]!NO%H\*>)/&;?\(MXS@>&YD!M7U$ _B;_8
M2_:&U+]JO4O K?M%_P#!Q!^V?^S!\=?B7\2-=5/A VJ_M+7_ ,*=#MQKR/X>
MTO5_BC=?&'P?\-?#,'BY3<G2M,B*^&M#T^73M'O-2M=0D33!_HA_'SXP:!^S
MU\"OC3\??%>FZQK'A?X'?"7XC?&#Q)I'AZ.REU_5= ^&G@_6?&FL:;H<6I7F
MG:=)K%]IVBW-KID=_J%C9/>RP+=7EK 9)T_AN_; \9_M3?\ !2K]E+]G#_@F
M9I7_  21\9?LX?MB^$?VBK_Q1XZU7PK^SA?_  8_9.^#_@/[=\1+!?$OPW\1
M3:_J9T#1/%MAK6CWGCC6=<NIO!WB34M UJ_\+S>)M8UOP:ND?V _MQ?#?Q/=
M?\$S_P!K_P"$/@^T\7?$WQG<?L+?M ?#?PM8V.FWWB7QY\0?$\OP!\6^&-$M
M+/2-'MKG4O$'B[Q9JK6L-OINEV=Q?:KK-^EK96TL\\43 'Y2:1_P<[?L67GA
M?X4_$[6_V?OVV?"?P(^(GBRT\ ^(_P!H?6?@?:2?!;X8^.[Z_P!70>#_ !!X
MRTWQ;?0^*/$>D^'=%N_'/B#0_AS;^+]:M_"8:70M-\1ZY8ZMH6G?4_[+O_!<
M/]F3]I_]JSPQ^R/#\(OVIO@?XY^*O@W5OB%^SWXC^/\ \'Y?AYX3_: \$:3I
MNKZ['XH^'Q?6]2\0QZ#XE\,^'/$_BKP9KOB'0M(T#7]%\.:G92:MIOB]].\*
M7_\ .Y\?OV._VK-4_P"#8#]B'X!Z%^RS^T)J/Q[\-_M4^+/$_C/X+:3\$/B/
M>?%[0-&G^*7[7ES:^(?$_P .;/PQ)XSTO3)M&U_PI<6^K:KHT%K)IFM>'I8[
M@VNHZ:TWZB?M(_L[?&F]_P""_?\ P27^*WA'X%_%"[^!WPK_ &4;[PCXS^)/
MAOX8^*[CX4_#?4X?"O[2MC8^&/$_C'3-$?PAX/OHO[:\/V=KHNJZCIUPG]K:
M/;PVP^WV22@'UU\9/^"]'[+?PI_:J^(/[,/A_P"$/[4'QWC^!=Q#:?M+_&/X
M!?"6Z^)GPU_9XD35%TKQ#??$,Z-J!\2KH7@"<7(^(&KZ3H=\NCW5AJ.AZ+;>
M)/$UA>:)!\V_M,_\%E?AU^TY_P $/?VS_P!L7]GKPW\2_AS<75QKO[)_A#2O
M'<FA:'X];Q]\21X!\%7&O>%9/!7B;Q'&EWH7A_XL3^)]%GM-5AU>&[\+WMQ'
M;P?9H)I?AO\ 9[UW]M/_ ()C?MR?\%<]'\(?\$]?C[^UU;?MM?'36O'?[/GQ
M9^%>A0>)_@]#X@G^('Q=UC0=!^/7Q.7S/"G@G0=-A^+LT?CV7Q-K.DZMX3UC
MPWK-MJ^BV^D^(SXAT;\^/^"5GPG^*'[2/[%?_!-[]EC1?AAXS\1_"7QW_P %
MA?B+^T9\<O&=OX4\0WWP^T?X7_LR?"'X0:K=>&?''B.VT^7P_I6G_$F?7?$.
MA^'DUB^MX]7\3^%FTVP$^H6K0* ?<W[//[3.L?\ !-[_ (*U_'CX<_M4?M(?
M$J3]GW]D7_@E?\%YO%_AG6_B+XK\0>$=9^*^C_"C]DC3=<UKPGX&UKQ"V@ZE
M\2OB5\0M;U\:,UO;P:IKGB3QE<Q->Q_VI>3']XKC_@L?\!?"/_!/F#_@H[\;
M/A;\:_@+\'?%&H6VF_"+P1\1]*\'+\7?C3+K%M/<>$;CP)X3\/>,=:LH;'QM
M'8:UJ'ABY\3ZUH!O?"N@ZGX^GBM? DNC^(]6_GW_ &^O^"/?Q7_X*/?\%M_V
MTK;Q!X-^,OPU^%=W^RSX;\4?!;]H&7X>>)K3X(>)/CEX5^#WP;\+^$O!^K?$
M6]\,W?AG5M(_MR_UP>)M(\-:HWB>./PYJL=HJSZ;?0#:_;7\'?M__P#!1'_@
MB3\%_!/Q1_9E^,F@?MH?L<_M1^"-,^(WPR^(/P\\1>#[[]I#P_X!^'?Q'\%V
M/Q"^$VE>(K:QLOC%JWB+1O$NF:CKUG\/;K5YM2U?0_B+=^&=$30M4\-PW !^
MLGP[_P"#AC]GGQC\6/V6_@1XM_98_;1^"WQ>_:I^(>A^!?"?A+XP_";3/ L>
MCZ1XNO\ P9IW@?XI/JVN^*+*W\4?#+QE=^*[^WT;6/"$6L:U'-X-\22:GX>L
M+"Z\)W_B;]NOBS\8?A3\!O NK?$_XU?$7P9\*?AUH,VFV^M>./'_ (BTOPKX
M6TJ?6=2M=&TF+4-;UFYM-/M9-2U:^L].LDFG1KF]NH+>(-+*BG^*[]LC]KSX
M\?MJ_P#!4[_@AOXG\??L-_'O]C_PCX3_ &DM.LO"MA^T'X8E\*_$SQUXR;QS
M\ M>^-#V7A2ZMK+Q&GPS^'=M;>$H_#'B_5='TVS\2)J7B75(X-.N;#7-&T/^
MSSXY? ;X/?M+?#37?@[\>/A_H'Q/^&/B6?1[G7O!?B:&>?1M4GT#5[+7]&EN
M8K>>VF9]/UC3;'4+<K,N+BVC+!E!4@'X3?L-?\%[/A%\</VG_P!OWX7_ +2?
MQY_8Y^%/P=^"'Q@\->#OV0/'-AXT7PA>?'3P-JOB;XN:7J7B&?7_ !A\2M?\
M/^/[BVTKPM\.[R+4O >D^'-,BD\4O/-92P:MI,5E_0;XW\:^%?AMX,\6_$/Q
MSK=GX:\%>!/#6N>,/%WB'4#(+'0O#7AK3+G6-<U>\\F.:8VVG:99W-W,L$,L
MS)$RQ122%4;^</\ 8K_X-W/@3\(_VE/VY?B'^TY\$_V:/BC\%_BE\6?#GBK]
MC+P3X?O?'>KZO\$O >F>)/BIJ6IZ!K^GZUX:\)Z;H5]<Z3K_ ,-K2&VT+7O&
MUH\WAB\CDU*&.UM9]3_=O]KK6_CGX;_9;_:%\0?LR:/:Z_\ M":+\'?B%J?P
M:T>[MX;U;_XB67AG49_#$-MIMU:WEEJ^IC4T@DT?1-0@_LS6]62RTG4IK6PO
M+BYA /Q-\+_\'*O[-&I^(OA?X@\<_LH_ML?!O]EGXS>(G\&?#C]K[XF_""+3
MOA%XA\5KJ=_IWE65QHFL:]#K&A1?V3JK7M[X2U;Q1XCT^?3KV"\\(11:?JUU
MIWTC^T1_P7'_ &>?V=OVP_BA^PW?_ C]JOXL_'[P#X,\,>)O"_A/X%_"_3_B
M=J?Q@UGQ5H7@SQ9;^#/AYHNC>)EU[^U]'\&^*]3\9>(]3\4Z9X<\.Z;X=\#>
M+'@U:^U?_A'='\0?QD?'7X??MN?MC?LR?"?Q5J_P,_X+(_M/_M;> ?C5<:]^
MTC<_&#PQ\0/$_P"SY\,TTK5_&&E:/X#_ &=OA)IGAY=6B\1:YI][X=UGQY*?
M#L,GP]FTZ?2HDAT?Q#)(G]0_P6^!'QGMO^#FW]JO]H75?@K\5+#X%^(?V.O#
M.A^$OC5K'PS\8:?\+=6\4KX*_9IL)]"T/X@ZCH<'A>Y\2Q#2?$=A=:/9ZJVK
MP-I>NV5Q:QO8:A%$ ,^+/_!P+X4^)O\ P3*_:3_:G_9%^$WQLL/CM\'_ !#9
M?"3Q;X"\3?#;3_%.J_L[^+_%>B^(K_1/BU\3["PUBZT1/A)I\OAG6-+3Q+J+
MXMO%T5CH_B3PK$LLEC<?'7[0?_!0F]^,7_!"_P#9V^-?[1_B#_@I)^S!XETG
MXN? SX>^)OC3\+-!TGX<_%7]H'Q==_ SQ)XIU'XG?#_4=5\=^ =*\5_L]^/K
MR^U.]M->T[4K2VO=:T.P@L- 2UL=UIYY\#?V-_VK;KX ?\'.?A2Y_9U^-6AZ
M_P#'GXI>*_$OP*T[Q-\,?&WAN?XUZ3I/Q&_:%\6//\(UUK0[+_A8[:CI%QIC
M:)'X/_MAM9NM<T"ST_SY];TU+GRO]JVX^/'[;'_!O#^RY\"?A+^QC^V*/BW^
MR]\9?V>/A!XP\$WO[/WC_4-:\5Q_#+X(?$GPUKOQ%^'^F^'](U?5]>\ 6VJS
M6>BZSJMUIFF7/AOQ1*^@:Q90^;I%_K !_<]X9E2?PWX?GBFN[B.;0])ECN+\
MAKZ=)+"W=)KQE>56NY5(>X*R2 S,Y#N/F/\ "I\)=#\7_M@_\%6_^"K_ ,,_
MC=_P5+_:V_8]\ ? ;XO?%O6?A/>^"?VL=4^%_A31)K?XM>)=&MM,33?%WB"/
M18?#/A?2[6WNXM&\-S^'6LK*W,<=_8VX22']T_CC_P $1IOVB_VJ++]KVY_;
M>_:@^%5QJ-S\$?$,_P $/".H/9_#[2YOA7X#^'_A2714L9-9M'BM?$K^"FU+
MQ!"]DCG4=9U3='(26?\ *K]CO_@DGX,_:?\ ^"NG_!6#Q+^WG^QG\3M>^">J
M?%SXC^+O@3XS^(WAGXT_##P%XKO==^,_B&5M8\!>--&N_!>E>-H-1\.2V][
MVG:OK-E)ILL6H6R"*1;A@#YB^$_[?'[9/BC_ ()1_P#!:SX::S^UIX[^/FB_
ML4^-?@?X2_9L_;4T/7O$GA[XD^-M!\7?M(ZGH.KZI;_$J#79_&FM6'B'P]X7
MTCQ%HLVI^)?$'B#0] \8W?AV_P#%.K>&[CPW;6WM/PY_8L_;9T__ ()/?#[_
M (*F_L\_\%2?VZ;7]H;P?\$K_P#:@\5?"SXH_&77_B3\%?%_AWX=V^O>(_%W
M@RT\(ZM,T-TTFC^'WU73=-\<VOQ%\/\ B*ZT\^%=5\/K'KL>NZ)^Q7_!3?\
M8&^'/P0_X(L?M=?LL_L%_LVZE81^)T\$^(]%^$OP=\->,?B#XU\9^*[KXS_"
MB]U[6391-XJ\=^,]<B\/>'H1<WEW/JUYI_AGP]:6B/;:)H=M!:?CKX9_:_\
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M +*/Q_B^*_Q \,^"[[XAZWX?3X9?&3P4UCX.TS7/#WAN^UC^T_B)\//".C7
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MXSUCPI96M_9RV'A3PJUQH>E^#] TW1X]?L+!UT-_MVI_:_JW]FGX;_\ !?\
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M]U LSJ(FGB#>8O\ 4=\!?VBO@'HOP0^$'@;]FZV\0_%WPKX7^&?A/PQX-B\
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MV^O5,:QW<QC>W=4D67<2X"$8/C7X[_"KP"98-=\6Z?+J<9EC.BZ,6UO5Q/$
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M? WA+XH:T\\=I'HWP]\3>)K+3['5]:O;V6.RT31=0&D:MXIN72/PG9:X'1F
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M,:=8Z;>>'=(NK&TL%ABMQ96UI<6<D$-KY$$,/D1HL1BBCC*E44#KJ*^4X/\
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M$SH8;"<'YEX=8#,YX7!^TKX6FJ52C@JV9T<%]:K990A7JJ7)BJ5-IUDJO%X
M\/\ @=PUGF?9=PEP_B,NXJXNR.KE61Y]XH8_*?$7!9/FV'Y\PPE*OF^;X.GB
MZ. S?$T:6#Q\X9=SUJD<$VN>A3<>W^#&G?$;XN_\% _ W[&G[6G[1]W\9_ O
MPJO_ !W\._[;TWQ=XJ@L;?Q3;>#O+?P[X-\2WVBZ5K$FO1>-- T;PIJ$WB2W
M6UU271=7L]/N;VYNM)N+[]4/VM_V5?V?OV)?@^?V@HOBW\:"_P /_'_PMU;P
ME\-/''Q,;7? OCK4-"^(7ASQ)'\.%\,KX=-]JHO=%T'4[C38C>,FD2Z7%X@U
M2?\ LO1K^2OQA^"W_!.SQS\2]4\.:'IFL>/;_P"-FL^'&\=^-]'TK4],\._\
M(/>7-S-?PZ7XBU;7UDG/B#2K2]T"7Q1)JEQI%]I'C75]2\$3:?\ VOH[:A?>
M[?M8_LE_\%+_ (7?LSZ[IWQ2^*FO?%GX%?VEH=QXD\-^+=1T7QUJG@)-%U!/
M^$;US3]2O;WQ9KGANT@N?+T^ZU'P=J>G0C3K^6PUI$TB_O[2O;\*?I#<68+)
M<VX<X8I\?9O4R[.L[IX26*P&;9YP9ALPI2IUJF4ULYJSA@:.'HR<*>.I0S"G
MC)8NKBVX0JU4Y<WB[X4_1[\3O%7"9CFV;\ Y+A<#1R?ACB7'93P]CN%<\S:&
M4<V%S7B#+<PRCA[,>':^.JU)5WEE7'3P^#6!PN6T8.K2I02])_X><_LO_P#"
M_?\ AI/^S]<^R_\ "??\)#_PSS_PB>M_\(P(OL'_  C7_"[_ .T/^$B_X1'_
M (:H_L__ $W[6/"__"(?\(V/^$7_ .$R_P"$HQX]/VU^R9XL_;'^.W@'Q+\<
MOV1OCM\#9OAMXP^,/QBU^X^"'Q6\'ZK;-\-=?\5>/]5\9W?A;4/$OASP]=Z_
M?:D^E>(=*\03&*_MM*\[Q'*EB\]H+:_?\7])_:Q^!5E_P31USX,W7PC^$DO[
M5T/C7_A5.F^+9?A5X/F\:M\*M8-QX@N/'DGB:?PZ]Q+X@TZTAU/X7I=6UZGB
M#3VN?#WB)+AM1\R^7Z:_83_:R_;C_9>_9NTOPA\*OV$]5^)?PYNO$'B3Q;;_
M !,T_P (?$$V_B&YU*Z2RU*]U+6_#>G7VC:S)ILVDC0H]425/LMAI-CHLY:3
M2][??<.^/7%^)QV%HYQ@>'^(<G_L'!0Q4<+P;C\UEDSH/$+ 9-B(5L3F,:-?
M!7Q?M<=[..9R4U&6/J4G448\2/HA^%^3Y'CL5PWF7%7 W%#XUS2GE57B'Q8X
M:X>PW%& EA\)6SCC#!57A.'JF*R[,KY53P^7T*]?*J51NH\IP\E3JR]E_:7_
M ."A6K>!_C'XH^%?[;VC6NJ>/O@G#X9U7P1\./@5X1T[QO\ L]>)_%.NVI\2
M7<_QN\-_%CQYI.H>(1+X5N?"UOX1N=,^UW/@E]=U7Q-I45GXFM$M9?,[#_@K
M-^SZWQBT+XV^%OA]\3_@WXJT_P 9^"M"?X??#'P3\,K;P+XP^$+7L-A\1(OB
MKX@M?%OA_6OB)XWU#2+Z\U'P!#>>&;+0O 6I^'?#=EI<IN=1U_Q/-\<?'W]N
MSXE^,_VMOA7^USJ'P2\._"OXE_"&[T?2?%^D:3J=Y-!XXTG2-1N;6XT;Q78Z
MK9B\L[V_\/:KK7@?5[Z02WDF@WNG6*+;'1[5J]+_ &E?V\/AS\9?^"A/P[^/
MUI\.]5^)O[-G[/VH>'(O!7@BP=/!-UK]WIMN=>N?%5W:W=IJ-M)?_P#"P9+?
M47TVXLXHO$WA;PEX?T'5GTZ*ZGNH/+QOC9QTLUQ='!U,IR[#5<RP^#RGA>/!
MF-I4J_"F9_[1C<1'#U,1+'O!NA@<74S6O#!XC%*JZT\%B:%+'RBOI\B^BKX,
MU^%<GS+'X+/.(:U+A;'YIQ-XBX?Q=R3$0PGB-D?L<'E651QF&P7]@/,<5B\Z
MRJ'#="MG."P4\+4HTLRP6+Q&41E/^A&'_@J_^R_87+V?Q!T?XW?"&\C#>;9_
M$GX3:U87414F+;)!X=N/$LB,;J.YLAE<"ZM+E&*HBR/^<7BC]FC]G#Q%<:+\
M6_CO\+/&OPF^'?QP\)>'_$O[,FG?LR01^((O%.I^+;5]8\/?"[QM;:QX2\2Z
MJ/V@O$^GWVE:CX>ADN-.^&?B"WEU2PMY+6_\-ZK+<?1\_P#P6[_9)^('@?QS
MH$6K?$_X >-]1\(:_I_A#Q'\4_A6_B?P[8>*=0TJ\M=#U*XT[X?7_P 0;K5-
M+TS4Y+2\U*SOM)M1>V<4UM&DC. ?Q5_8K_9Z^(G_  4 \'>*=,\6_MW>./AZ
M?V:;+2]8T3P7X]O/%?C+P]X2^'\6E+;VWBWP;<:C\3]$LO#&E^&_[";2=8@T
MO2+2S\.6-OX;=]0$6I6MM:?J^&\>.%^%\TPF X(X?SV>89W&LLPIX#C' QKT
M*.7T:M>$,-#,<%ECR[%RG.4IRS.ECW6P"Q5'!2H5)UIO^<5]#[C[C;AW.<_\
M5.,.&LFR'A2I@5EF)SCPXSS%83'UL\Q='"3K5ZV08W/*><Y=2]E2I*.2XC+X
MX7-JF KYI"K2IX6"_I/_ &!?AVOP-3QI\&?$GPK\$?#?XEVO@[X:?$36[_P7
MJUSK,OBGPCXNU'XB:/X5M_&UU]EMM(_X6#X1U'PIXGTGQ3/X92/PGJ=Q=0ZE
MX8@MM+N$M+7]&J_C1_8$N/AE^T7\;_C%JO[77[:/C*TL?!GA>RT;X._%+XE_
M&?6O 'Q.U*"W\7:A-9WGA?Q-X^\3>(=#T&PM])NKV^UOP'>WNL7ZW_BNWO="
MEEBTCQ'?2?LC::3KO@5I9/@%_P %@/!6MZ=^[DMO"GQ\\7_"/XR_;YR,PVL_
MCJZ\2'6M+L)RJ1B/1="CF5"6A8X\MZPG%_!_B!@(<89CQ9@.#<TS1R>-RSB>
M&-6 I8G"R6"Y\%G&"K9W5G@L6J"KX18K"X6GA85%A82>$HT<14^:XRX!XR\!
M\^Q?AW'ANMQUD>01H/ \1<+XK+<+CJ^&S'#T\U=',LCSNCPQ1HYGETL<\+F'
MU/&XZMBJM/ZY74<PQ&)P=#]@M9\2^'/#BV[>(?$&B:$MV95M6UG5;#2UN6A"
M&9;<WT\ F,0EC,HC+&,2(6QO7/PI^QGXT\':5HWQ"AU3Q9X9TV:X\66_V>*_
MU[2[.2?9;31/Y*7%U&TNV3]VVP-M?Y#AN*_!;_@I?^TW^UKJ_BWX(?"WQ[\5
M_P!E;_A%KVXN[N+Q]\"]1O/%/@*_N=3US1].NE^*S>((?%E[9V'AJWL;+5K_
M $&P\/'3M1TO5+Z2XT_Q,8+6TT_Q;]L/X6_MP_L6Q?"OQ;\3OB;^SUIVO>)M
M6O--\":5\#? ?P_\/>)=3M-!M;2XU&ZU6W\,_!#P%9:WX7TZ74-%LYK'6[[5
M(9;_ %C31;:5<H+FXM/RK-^/.%L%CLVJ4L1FF=TN&*M6C4S?AK!Y1F_#=?ZY
M0HPH5(9M4XBP%65.KB54PO-' ?NZM&:C'$34J4?Z:\.O"KB?BC@WAM8/&\%Y
M7@_%RC0QE# \3\3YWD_%N%_U4SC,O[3H83(\OX%X@RS$XC 82$,7BZ5?B*@X
M^T]EB7E].G]8G_:Q7Y<_M<_'^UU#1M4\#^(?#,G@W3- ^($]M;>+]>UB.STG
M6)-$;6]+B6U%]IUA;AM1CD-] D>H7#+"A"^<N91Y-X?_ ."PNCW_ (9T(7/[
M,WQHOO'$.CZ2WC.SL;;0=/\ "EGKC:?'_;:>'M:NM7O;K4-,35Q<1:0UY96=
MS=Z:JW<PBD22*OQLM/VW/VS_ -I+XW_%GXF?!S]G:[^)VOVNII9_V;-\+=)^
M,VI?"CP/)J.LV_A+P?80ZSX+UU?!T)T^VO+?6IM%M]%3Q9XDM]6U[6(;J[E\
MB#U^,.(LBX=R[*Z^9XG'9M#/85'E^3\#UN&>(L[S"E3CAYXB=6%7/<+A<JPN
M%I8BG4K5\57^MSE)4\'@,9R8F6&_+_!NEG?&&;<18WP\R/(>)\9P17RUYKFW
M$W$&)X0R'ARKCL1CJ& QL,3C:>$I\0RQN(P-?#4,+A*DL*E:KB<;A95,)3Q?
M]27[/OQPN?B6MIX=/@?4] L=(\(V-Y:^(+B^DO-/U=+4Z;I\8M#_ &59PD74
M=P;R)X[NX!BC8*'4^8/J"OY3/V#_ /@I'XS^!/[0/Q(^%G[27P^\1> /!^J:
M;>7WB'P3X3\#"PB^&/Q"TV323'JL?PVT33]#L_!6E:WI5S>6GBVS\/:$IU#Q
M!+X<U6XTR*\;6K^]_<S0?^"E'[%/B":&W@^-MEI,\YVA?%/@_P"(7A.!'X^6
M34?$?A/3-+! ()9;YHP,DO\ *V/9X1QD.+\ICF?#U#/,?AHXBI@ZU#'951PN
M;Y=C:%"C7Q&6YE@LKQ>:82GBL+3KTY2J87'8O#U:4X58U^9SITOG_$]T^ .*
M*>1\<8?A?@+.\;E>#SJEDM'C3 Y[@L7E^/KXFAA,WR[-:]>E4Q&%S.IA:U2E
M1J4Z5:A).G[-T_95:OTQ\6=&^)NM^'+*T^%/B32O"_B*/6[:XO=0U@9MIM%2
MQU**XLT']BZ[^_DOIM.G7_0X_P!W;R_Z2G^JF^1]"_9[_:<\,^(-?\4Z'\1O
M 5AKWBB66?7M02>_F?4)9KE[R5WAN? <UM#NN7>4BV@@4$[0 @"CY^_;U_X*
MT^ OV9?"G@>7X%1^ /C_ .)?'UQX@MAJ6A?$+0]2\,>!TT:UL#')XFM_#=SJ
MNK_VIJ=QJMN^CZ3>QZ);ZC9Z?K,\>J&33Y+<_$GB[_@K+_P4>^#VF1>.OC-^
MQ%+X1^'UKJVEVVJ:EXF\)_$/P7I\JWDR11Z5;>(M5MI[2SU'4@LR64TMKJ!C
ME/FBQN8H7A;X?BKB_(\DSROEF8X/B:MC<MCAYYC/+L-+ZMD_UFE&K3EB_:XG
M#5*,Y82HL3*5&E5YJ#:3E43I'[+X;\)^)V<<)99F7!V2<$YIP_Q76QN'RS%Y
MEF/!?UGB"6!Q_P!5Q6%I0S/-:&+Q]/"9C15*.'E2J1IUU!PC[T)/^E;3([V'
M3=/AU*:.YU&*QM([^XB_U4]ZD$:W4T?[N']W+.)'3]S%\K#]W']T7:\/_9J^
M,X_:(^ WPK^-H\):OX&/Q)\(Z?XE?PKK<D5Q>:5)<^9%*MO>PI$NIZ+>20/J
M'AS6&M=/FUGP]=Z7JMQI>E3WDFG6OL][<BRL[N\,%S<BTMI[DVUE"US>7 @B
M>4P6ENGSW%S*$\N"%/FEE9(UY85^AX;$4<5AL/BL/4]IA\10I8BC5:DO:4:M
M.-2G4:FHS7-"496E%25[22=T?AN8X'&9?F6/RW'48T,?@L=BL#C,/"5*<:.,
MPV(G0Q%&,Z,ZE"4:=:$X1E2J3I244Z<Y0:D[-%?SR>'_ /@NE\0_B-J_BJW^
M#'_!/?XI?%?1/#6J/;/J7AKQ[KVI:G;Z;=W5^GA^[\3:-X8^"'BNW\,:CK-I
MI]Q<?V5)K6I10W%M?VEIJ>II8R7;_3W[%G_!534_VJOVB-;_ &<?&_[,7BSX
M#>+]'\(:UXE?^U_%6L>*KZTOM$GT8SZ/XGT*Z^&/@F[\(QW&G:L;NUU?5YQ:
MRWB6&D+%]NUK31-\K@^/N$\PQ.%PF$S2=2MCL0L+A'++<VI4:^(;E%4J>*K8
M&GAG)RC))NLHMJR=S]0SCP'\5<ARW-,US7AFCAL)DN!>9YJH<1\*XK&X' J%
M.I+$8C+,'G>(S*,(PK4IRBL(YQC-2E%+4_7VBBOS>_X*!_\ !1/1_P!@\?"F
MTN?A'XD^*VM?%:Z\2Q:7::7K<?AC3;&#PQ_8<5TC:M+H7B!M0U>[N_$6FQ6>
MCV>GM)Y'GW-U=6Q-C!?_ $69YI@,FP-?,LRQ"PN"P_L_;5W3JU5#VM6%&FO9
MT85*LG.K4A!*$).\KNR3:_/N&N&<\XPSO!<.\-X"69YSF'M_J>"C7PV&=7ZK
MAJV,Q#=?&5L/AJ4:6&P]:K*5:M3CRP:3<G&+_2&BOY_/%'_!;#XP_#_2=1\2
M_$7_ ()P?&WP1X6MKRUMX?$'BCQ!XH\.:3!]K6&"WM]1U37?@O8Z=%>75^94
MM46Y7SEDA@1&F1GF_:SX%?%C3OCK\&_AE\9-(T;5O#VF_$OP5H'C&TT/7()8
M-2TN/6["&\-G,98+87D,3R,++5;>%;'6;'[-JVG-)87MM(_G93Q1D>>8FMA,
MLQLZ^)H48XBK0JX/'X.I&A.?LXU5'&X;#\\'-J-X<UGH['T'%7AEQMP5E^#S
M;B3)Z6"RW'XRI@,+C,-F^1YM0J8RE16(GAW/)\RQ_LJBHOVB594^:-W%NS/5
MZ*_#_P")7_!>7]E?X?\ C?QCX(M/AU\:_%LWA#Q#JGAQM=TO1_"6FZ)J]UH]
M[)87MU8)KGBVPUR&R-S!.ML=1T6SNY41'EM+?S,)ZA^R]_P6/_9T_:F^-/A'
MX&>%_ OQ;\(^*O&T6M#0M1\7:;X270);[0]"U#Q%<:?<76B>+=7O;>6YT[2K
M_P"Q3/I_D2W4<-M(\+W$9')1XXX2KXRG@*.>X*IBZN)CA*5&,JC=3$3J*E"E
M"?L_9R<ZC4(M3<9-JTFG<];%^"7BO@<HQ&?8S@?.L/E.$RZIFV)QE6&'C&AE
M]'#O%UL35I>W]O"-+#QE5JPE252G&,N>$7&27ZX445\9_MI?MP?"G]AOP3X4
M\:?$_1_&?B,>,_$LOAK0=#\$:987NIS2VNFSZGJ.HW5UK6IZ)HMI8V$4=M"\
M<VJ#4KJXO[?[!I]W;6^IW-A]!CL=@\LPE?'8_$4\+A,-%3KUZKM3IQ<HP3DT
MF[RG*,8I)N4I**3;2/@<DR/-N),UP61Y%@,1F>;9C5='!8'"Q4J^(J1ISJS4
M%)QBE"E3J59SE*,(4X3G.2C%M?9E%?@6O_!PG^RZ;B57^#7Q\6T6&!H)ELOA
MXUQ).SW N8Y;4^.TCAAAC6U:"=+N=[AYKA)+>U6VCDN_V#_9O_:!\"?M1?!C
MP5\<?AP-5B\*^-;6^DM['7;2.QUK2=0TC5+W1-:TC5+:"XN[9;O3-6TZ\M'F
ML[N[LKM(X[NRNKBTGAE?RLIXJX>SW$5,+E.:X7'8BG1=>=&DZBJ1HQG"$JG+
M4A"\8SJ4XR:ORN<4[7/J>*O"WQ!X(P%#-.*^%<SR3+\3BXX&CB\7&@Z,\7.E
M5KPP_-0K5>6I.C0K5(*?+SQI5.5OD=O<:*_'?]H3_@M9^S+^SU\8_'7P7UGP
M-\8/&&N?#W5ET'7M;\*:/X430'UJ*TMY]3T^Q?Q%XNT/5)SI%W/)I=W<R:9!
M:SWUG<OITM[IYM;^YP/@[_P7,_9;^+_Q1\ ?"RW\ _&;PCJ'Q#\4:1X/TO7_
M !'I'@^30;'6_$%TFFZ+'J3:)XQU;4XK6^U>XL].-W#IL\=HUVMW>""SAN)X
MN27'/"4,9+ 2SW K%QQ+P<J+E4TQ*J^Q=-S]G[/2K[KGS\BU;ERIL]:GX(^*
M];*(9]3X&SN>4U,NCFU/%JGA_?R^6&6,CB(T/;_66I89JJJ?L?;-/E5/G]T_
M:>BBBOJS\K"BBB@ HHHH **^#?B[_P %!OAC\&OB+XE^&FO?"C]HGQ#JWA>:
MP@O-9\%?#&'7O#%ZVH:38:Q$VE:L_B.Q:\CB@U"*WN&-K%Y5Y%<P ,(@[>"7
M/Q\UW]MG7?&FE_#QO&/PP^%'P6^'^B>-?'W@#XJR:M\%-8^,6I>)-<\0PMHF
ML>-/"WB)/$O@[X=Z3X4\&Z\O_"1:9JRZ6_BG6K63QCHGB#PWH<^C:C]G@N!,
M_K8>EF6/PE7*\DGAZ&+GFV(C"=&.'Q4J,,(Z=.-52J5<75Q&'H8>,Y4:2J5X
M2Q-?#8>-6O2_/LP\2^&,/BJV4Y9C:6<\0PQ6)P5/(\+.=/$2Q6#C7J8U5:M2
MDX4J.!H87%8C%SIQQ%=T</4A@\+C,5*AA:WZVT5^)?A?XGZ/\._!U]^V+^S9
MINH^ /V9_!OB3P1X*\7_  *&K:KXT\0_%F3QQXQ\$>&/%/B&#P,OCK5O"WPJ
M\7>$8_$.DW7P];1L:[\2[=;G5->N3X)\0>$[O4O>O^'JGP:_Z(?^UE_X9FW_
M /FMKLQ7ASQ"YR>3X/%9M1I59X3%I4*6&Q>79A1IT:U?+LPPZQ>)HT\52HXG
M#5I+#8S%THQKQI5:M+&4<5A</P8/Q8X54(QS['X+(\16H4L=@6\37QF!S7*\
M14Q%'#9KE>*E@<'B*N"K5\)B\/%XS 8&O.>&E7HT:V7U\%C<7^G5%0VTZW5O
M;W*+(B7$,4ZI*NR5%FC615D3)V2*& =<G:P(R<9J:O@6FFT]&G9KLT?IZ::3
M3NFDT^Z>J9X'\?/VJ/V:_P!EC0]-\1_M(?';X4_!#2-<?48O#]Q\2_''A_PG
M/XDN-)MXKK4[3PQI^K7UOJ/B2]L;>>WDN;'0K34+N(7-J&A#7,"R=A\)OC1\
M'_CUX1MO'_P/^*GP[^,'@:[GFM+?Q?\ #'QGX=\=>&Y+RV(6ZL?[9\,ZCJ>G
MI?V;GR[RQDG6[LY08;F&*560?R1_\%D/V-?VB_!'_!2^W_X*"^(?V%=:_P""
MKW[)NM_"'PUX#M_V?;36/%9U'X&^)=%T^WL9X=*\*^!K+QAXEN?#]Q?Z3JWC
M\^(;SX=>+_ R7_Q"\8V'B;3='U>R\+Z_+B?\$A?C5^P/\./#?_!3K]HG]A,?
M'3]GC]I/PS^S%\6OBE\1?^"?'QTO;#Q)\)_ 6I?!72M2UWPUXK\&:A8:#H7B
M_P 6^&/!OC74;WP3=6_B3Q7HOC#PY'XVUW0]3\-:1:ZAX:UB=#/[0Z*_F&_X
M?%?M5_\ $/\ ?\//_P"P/@S_ ,-%_P#"8_V!_8W_  B/BC_A5GV+_AJ#_A3F
M_P#X1K_A.O\ A(/M'_"*?Z1YG_"7;/[:_P!,\K[+_H-<%^TY_P %=?\ @I/I
MOQ^_X)J?LX?LD_#C]F[QG\2?VY_V%?A9\>=2T[XC:-XFTO3=-^*?CWPIX[UO
MQ#?Z7KD?Q$TNVT;P/X3M/#!\2QZ'?VVN:O>VFE7>D1:C?7FH6RJ ?TP_&+X[
M?!/]GGPDOCWX]_%[X9_!;P3)J4.BP>+/BKXY\,^ ?#]WK=S:7U_::'9:MXIU
M/2[*^UR\LM,U&ZLM&LYI]3O8;&[>UM9A;R[=;0OBQ\+/%'PXA^,7AGXE^ /$
M7PBN?#][XMM_BGH7C+P[J_PXN/"NFQ7-QJ/B:'QQI^I7'AF7P_806=W->ZS'
MJC:=:Q6MS)/<QI!*R_SW_MN?\$_/$/QC^"GP?_;[_P""@/P*\<?MR_M??LX?
M"&P\(W_[ /[,_B?6]"_9J^(/B/QM\3;O3)-1\/>&X?"WC[XFCQ/X<T/QKH_B
M/X@>)=/\3WF@^)$^%]G+<>'+?PEI=OID/\J=[XNU#P#_ ,$-?&GP,T/XHOX;
M\0?&'_@K)H&A?'O]FC13XSTK6?V>?!P^&_C.XT?X4>/-'^(WAVQ\00ZMKGCO
MX0:;XL22UUGQ3H[+\/M$L-0UN3QMIOQ T73 #_2;^#G[0GP$_:)T34O$OP ^
M-GPE^-_AW1M1_LC6-=^$?Q%\(_$;2-)U7R_.73=3U'PAJ^L6EA?/ 5N8K6ZE
MBGEMG2YB1X)$D:7XR?'SX(_L[^&M,\8_'GXM_#KX.>%-:\1V'A#1_$7Q+\8:
M%X,T?5O%>JVM_?:;X;TR_P!?OK&WO]<OK'2M4OK;2[5Y;V:STW4+I(3;V=Q)
M'_+!X4^!OPI_X)W_ /!S/^R7\ _V1O":?"/X0_M+?L,>(&^*/@/0[RZNM U>
MZ\/>'_VCM3L[V2'5WU*XBN)M3_9U^'NL7E[!<PZC>>(%U?4KF]E;Q!K<.H_+
M/_!RS^R7^TOI*^#OVQ?C[^T_+\0? =U^VGX-^"O[+_[./A[P_;:;X.^#_P *
M/&?@3QUXVUGQ!KNL1V6B2ZY\1]=UGX8:5::C-+I&I7-OI216USXTU^TATC3M
M  /[H***\)_:;\-?'?QC\!/BAX6_9C^('A[X5?'K7O#,VF_#+XC^*],MM:T#
MP9X@N;JU0Z_?Z3>>'_%5IJ7V#3_MLEK977A_4K>XO?L\<\443-<0@&WHOQ\^
M"/B/XO\ B[]G[P_\6_AUK?QR\ :#8^*/'/PBTGQAH6H?$;P?X=U.+19].UKQ
M-X0M;Z77-#TZ^M_$GAVYM;K4K*VBGMM=T>XC9H=2LWF];K^-3_@C5^SAX@_9
M,_X. /\ @HM\"O%_Q@\3?'[QGX;_ &4_#/B?QM\9?&%E_9OB+XA^-_BK<_LO
M?%OQEXAU"P.IZU):+/XF\<ZK#903ZOJ=S'I\%JMU?W5SYLS_ -3/[9?Q;\4?
M ']D#]JSX[^"(-'NO&GP4_9M^.?Q;\(VWB&TN;_0+CQ1\./AAXH\8Z!!KEC9
M7NFWEYH\VJZ-:1ZG:6FHZ?<W%DT\,%[:RND\8!])45_%+=?\%X/^"MG@7]B+
M]F[_ (*7>/\ X&_L5W_[*GCKXP'X->(_!VE7/Q9TOXS_ !/U.Q\1?$F'Q%XJ
M\,/+J^I>$?AGX82T^&^M^"-!NKVZ\>ZSIOC+3G\1ZMX7\3>&]333-)^^_@)_
MP53_ ."AG@[_ (*6_LX?L;_MY_"3]E_PQX)_;0^!^M?'#X81_!+4/B4GC/X%
M:6GAOX@^+?#WA[XHZUXY<:=XH\1V-K\,M;\*>/=,TKP]I&FPZ[K-AXKT'Q3;
MZ5I-]X.O@#^E^O+OC3\;/A1^SK\,O$_QE^-_CK0?AI\+O!B:5)XI\;>)KB2U
MT31%US7-,\,Z1]LFBBGD5M1U_6=*TFT2.)WEO;^WB5<N*_E3^'?_  63_P""
MM?[3GP0_;*_X*$_LQ_ 3]E'_ (8;_9Y/Q>T#0O 'Q/U'QU9?'Z6#P#\,3XQ_
MX63;7^CZBWA7Q''X$@U[PKX[^(GANZ?P]8Z_H5MKOPY\#:@?$4,_C73:G[2'
M[5?Q'_X*;_\ !./_ ((X?"7XKV^AV7Q!_P""F/[:?ARP^-GASX;Z9J&D>'+[
MX"_ 7XN>,4^)KZ5I.IZQXAU:UAT2TT_X<>)[J2?5+V%+O3+NYEFM()88X0#^
MICX5_M+_ +/OQQ\2>._!OP@^,OPY^(_C#X6W-C9?$SPEX1\5:3K'B?X>WVI3
M:C;6.G^-O#]K</J_A;49[K1]6M5L-<L[&\2ZTR_MI($GM)XX_<*_SU_ ?_!2
M[7/^">/_  42_P""UV@_!_P?H?CW]JC]J']M?P_\)OV<?"_C*1-,^'%OKR_&
MWXVV6N^*?'^O7>N^$]*TW0="'BC0=/M;:\\4Z$MUK&OZ;=WM[:>&=*\2ZGIO
M]!__  41_P""BW[<7[#_ ,+/V"OV<-!T'X&_%W_@I#^W+XX3X>6NNZ?H.O\
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MA^(+O2_#FA)IFH:IINJ>)KG2M/\ #/@RVU?76DU;3],TG^J^@ HHHH ****
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M-_P73_Z09>&?_%CG[,W_ ,=H_P"&YO\ @NG_ -(,O#/_ (L<_9F_^.U^]5%
M'X*_\-S?\%T_^D&7AG_Q8Y^S-_\ ':/^&YO^"Z?_ $@R\,_^+'/V9O\ X[7[
MU44 ?@K_ ,-S?\%T_P#I!EX9_P#%CG[,W_QVC_AN;_@NG_T@R\,_^+'/V9O_
M ([7[U44 ?@K_P -S?\ !=/_ *09>&?_ !8Y^S-_\=H_X;F_X+I_](,O#/\
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M]Y*%N/#7AS5-(74;;5K:ZU?3]1TLV$G8G]DK_@X"N<+=?L)W5NJY*FT_:?\
MV)-S,>"'\KQ78':!R-SR#/11UK^Z/P]X>T+PGH6C>%_"^CZ;X>\-^'=,L=%T
M'0M&LK?3M)T?2--MH[/3]-TVPM8XK:SLK*UABM[:V@C2*&*-$10J@5L5YT_
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MZ#9:-8:8(K2PT2_U"[\<^)-2\57<VE_TBT4 ?Q1Z?_P11_X+2>(O^">WB/\
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MEM>:'XWU3P)+H/B#PSHGB#24UZ\U6QN8;*6QM/#OB/Q':7<&N07NEP6U_-J
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M)9I76-&8?YL__!6GXX>(?^"I/@']H;_@HQKWQ'MO"G[/'P,^*'A3]FW]A#X
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MJWB(7&H(+;2KQO"FF7VB:5I-AK/BV*]C\=>,M9UC4+35)K&V@_HHHH ****
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M[C5]!\2_U"T %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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#!__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>33
<FILENAME>nt10014672x1_linechart6.jpg
<TEXT>
begin 644 nt10014672x1_linechart6.jpg
M_]C_X  02D9)1@ ! 0$ P #   #_[0 V4&AO=&]S:&]P(#,N,  X0DE- ^T*
M4F5S;VQU=&EO;@     0 ,     !  $ P     $  ?_B"^!)0T-?4%)/1DE,
M10 ! 0  "]!N;VYE @   &UN=')21T(@6%E:( ?4  < %0 3  L (6%C<W
M         $E%0R!S4D="     0            #VU@ !     -,M2% @(
M
M$&1E<V,   %$    =&)865H   &X    %&)44D,   ',   (#&1M9&0   G8
M    B&=865H   I@    %&=44D,   ',   (#&QU;6D   IT    %&UE87,
M  J(    )&)K<'0   JL    %')865H   K     %')44D,   ',   (#'1E
M8V@   K4    #'9U960   K@    AW=T<'0   MH    %&-P<G0   M\
M*&-H860   ND    +&1E<V,         &G-21T(@245#-C$Y-C8M,BTQ('=I
M=&A"4$,
M                                                    6%E:(
M     "2@   /A   ML]C=7)V        !      %  H #P 4 !D '@ C "@
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M;W5R(%-P86-E("T@<U)'0@
M
M      !865H@        8ID  +>%   8VEA96B            !0
M;65A<P         !                               "6%E:(
M  ,6   #,P   J1865H@        ;Z(  #CU   #D'-I9R      0U)4(&1E
M<V,         +5)E9F5R96YC92!6:65W:6YG($-O;F1I=&EO;B!I;B!)14,@
M-C$Y-C8M,BTQ
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MU=;7V-G:X>+CY.7FY^CIZO'R\_3U]O?X^?K_Q  ? 0 # 0$! 0$! 0$!
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M\2:Y>NEKINEV:%C^_OKR6STNRO[^UH?"W]K;X&?%C]ES0/VR-)\71^&/V?\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M444 %%%% !1110 4444 %%%% !1110 445^"O_$3#_P1R_Z.7\3?^&"^/?\
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MSH&MVE]I6J6GGPPS?9[ZTGA\V*.39O12/P_\$?\ !%/X2Z%_P5'^,7[6&O\
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MK'A/Q%X3T7PWH.M^%_%N@:9J%YI=S:>'=&4I9-/;6]UI-WI6JZ@ ?(_[._\
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M^'O#'AW3X-*T31K$W4UQ<_9--TZVM[2V$T\L@AB0-(Q&: .SHKX7_P""A/\
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MU32/$<6E,%^QSPS:!IWP_P!'FBM+BXE;3;ZV>>**W%O--];_ /!5^RT;2?\
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M.NE>#/#VR*1+I[;4-?NK,ZO+9B2XT[08=6U?RVAT^8K_ "*>'?@9^S_\3/\
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M!=ZQ;Z#X"O\ 7-+2'Q+H&F^)-+-OJ4%U%%.SZ9JMH\RJ@,,QDA.2A)/V9_\
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M:T\%_9_MO[1Y/K3I5+_7/9>S4US?5FGRK]>****_-S]#"BBB@ HHHH ****
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M=&_X0F[\5W'P[T_RK/P-X6A_M'2_"5EJS_V7YDE\\M[J+W?R;XX_X)P?#/\
M9T_83_:J_9[_ .">7P+^$ND>(/C''K?CP_"WXZZE\0?B[\*/BEX[N[?PY::]
MX<\80_$7XAWVI:;:>//"GAA/!NGW6G^)]!T?PIK-YIWBQ$MIM/NII@#^+K_@
MH%^R+^P5^SA_P3'_ ."8/Q*_9P^(M])^T%^TMK'[/?Q ^-?A73OB]K_BC1/B
MO/9?"[Q?>>,?B5XB^'%UK^I^'_"VM_"#XE^*M4^&7A<Z9I.B7'ANV\:>-?"M
M^-0UL>(+L_O1\8)/^&E?V]?^"\_QY:XM=1\)_L3_ /!+7Q-^Q/X$N(XO.M9O
M$/Q&^%/CWXQ_$:>VN"#'%KO@_P 6:1XM\(ZL(B)X[36(K>7]W*JU^8VF_P#!
M&+]JKXYZE^S9\'$_X(R?"/\ 8-T[3OV@OAO\0/VL?VGO#_[65G\9$USP?X<E
MU^RUC0_ACX.\9_'/XE^._ W@^YT3Q#J.HWW@CP7XU\9?\)-XOTCP5/JNM:-:
M:':7MI_9WX#_ &&_V9?AQX._:B\!>&?A]<1>&/VS?'?Q6^(W[1UK?>+O&6H7
M_P 0O$_QJT=]!^(LIUVYUY]>\-Z?J^E2W-M8:7X4U+1+'PZUW=W/AV'2[J>2
M<@'^?-_P3#M+[QC\5/\ @DAX=_X*6^%/$=S_ ,$Y[C6/CEX(_8DLKNYL!\#O
M%GQ__P"%U^)_$=]JOQCT /K1\06&I_%WQ==> +^#5[3P]::K'IG@FR\0"_\
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M[FOZY:_ +_@@C^P!\<OV-/!/[7OQ-_:-^$/@W]GGXF?M6?M#W_CS3O@)\/\
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M_GP_:S_Y6(?^"4/_ &;1^US_ .H#\0*_H/K^?#]K/_E8A_X)0_\ 9M'[7/\
MZ@/Q H _H/HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "O\ ,N_X
M*F^,=>^/?_!8+Q-^T:4NG^'6G?\ !0GP+^Q]\/)Y[C[1;PZI^R;!\*?#GQ.L
M]-(9HUTZ]\2>*M.\6P")C&[^*99ESYN3_HW_ +0_Q@T?]GOX!?&WX]>((#=:
M)\%OA+\1/BMJMFKB.2_L?A_X1U?Q5<:? S%<W-_'I1L[9 =\EQ/'&@+LH/\
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M_P!0'X@4 ?T'T444 %%%% !1110 4444 %%%% !1110 4444 %%%% 'X4_\
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MH^,&N(!!#)$T<(" *!&J@* HX&*_HW55151%5$10J(H"JJJ %55  55
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M//PM\;?![X@PZA<>"_B!HLN@>(H-*OGTS4)=/FFAG=;2_B1Y+64R01XE5&(
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MH=I<ZS!XG\9^%[H-K%_8:TNG#3[>^C9-#U)IY(3&BO\ G7^S9IM__P %2_\
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ME[&"4OU+HHHK^>3]_"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MAZ#I^L^,_ 5CJEQ!X:\1ZG8S_M%^'9K2^U;3$M[NXMY="TB2*25D;3[4@Q*
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M #2?'WXL_"VW_P"#AK]D;XB3?$GP&G@#P[^S1XO_ +>\;'Q=H!\)Z*8/A?\
MM4^<NJ>(5U Z38O']LM T=S=QN&N[9=NZXA#^O?\'+W_ "8E\)_^SM? G_JG
M?CS5S1/^#<7]@?4=%TC4)_%G[28GOM+L+R81_$+P.L8EN;2*>01JWPL8J@=V
MV@LQ"X!8GFOT_A+"\-Y%D:X@SW-<PP[XGR[BCANCA<'EL,4J4)8>AA*^*=5X
MFF^>G'&4YPI.GRS=TYQ2N_S7BO$\19YG?]@9'E> KKAK,.&>(JV)QF8SPKJS
MC7KXJAA526&J+DJ2PE2$ZJJ<T$TU!MV/2?\ @GP4_;O_ &J?C'_P4S\7S6]U
MX+\*S:K^S]^Q9X+NKFUDU#P=\--*FOK3Q?\ %35M%$/VO0O$OQ)N[C4K:P-_
M)#K%I9:CXUT.Y2^T"#PK>C]RJ_G!_P"#=GPUI_@SPK^W)X/TE[J32O"G[2P\
M-:9)>R1S7CZ?H6FZII=D]W-%%;Q2W36UK&UQ)'!#&\I=DBC4A%_H^KYGQ#I1
MPO%6.RZC-RP.5T,OP.64^3D6'RZ&!P];#T>7FE>HO;SJ8BK?FQ&*J5\3-1G6
ME%?1^']66*X7P.85H)8[,ZV.QV95.;G=?,)XVO1Q%;FY8VIOV,*>'I)<N'PM
M.AAHRE"C&3_"S_@L-^WW^R5X5_9X_:K_ &/M>^+'V#]HO5OAG9Z9I_P[_P"$
M$^)=U]HOO$UKH/B;1(/^$MLO!MQX%B^VZ)=V][YL_B:.&V\S[-=R6]VCVZ\E
M_P $1/VZ/V6-4_9@_9@_8SL?BEY_[2>G:!\2OMGPW_X0GXBQ>3]D\8_$'Q_<
M?\5A-X1C\!2>7X2D35OW7BE]^?L";M3!LA^LWQ'_ &+OV1_C#XNU+Q_\5?V:
MO@C\1?'&L16$.J^+?&?PV\*>(O$.HQ:78V^F:;'>ZMJFF7-[<)8Z=:6MC:K+
M,P@M;>&",+'&J@^''[%W[(_P>\7:;X_^%7[-7P1^'7CC1XK^'2O%O@SX;>%/
M#OB'3HM4L;C3-2CLM6TO3+:]MTOM.N[JQNUBF43VMQ-!(&CD93W+/N$%P7+A
MOZEQ)]=EBH9T\3];RSZK_;D,KG@$E#ZI[7^R>>HZCH7^N<J26+3O?C>1\6/C
M&/$7USAWZG'"SR=8;ZIF7UK^Q)YE#'-N?UKV7]J\E-05>WU3F;;PK5K?35%%
M%?G9^@!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M_P $3;_X+_&/_@J#_P %&?VE_P!@CX>:A\-/^"?.O_#7X7?#ZSBL_"5Y\//
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M:U/3]'T[6/&6AR>+] N],TJV2^NKWQ9X0T[Q)X2BT\36TA_M:>9RT=K+$_\
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MNP^$R7-<!EF9X/C_ #3,*V'RS-,NP>.I?4.$,ASK%U<UG#$4JCJ1JYR\+@<
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M?_AS^QSJ/[-W[-]E\?O'?@H>*? WP]NH=*>ZUCPKIFA^*-6DU&Y\30_M$?\
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M@WQ;XQU[[?\ V/X?TJXO)+_4/[+TR]UG4/(26SBC/V72].OKV7=(N(;:0C+
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M4. ]GJNHV+/+\8OBSI^)61SK,^I3:%X>URU18]6\)^(I]&U"./4?#&%^7O\
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MU*=6G4BITZE.I!N,X3BU*$XMQE%IIM-,****S+"BBB@ HHHH **** "BBB@
MHHHH **Q/$NA6WBCPYX@\,WLL\%GXBT35="NY[4QK<PVVKV$^GSRV[2QRQ">
M.*X=X3+%)&) I>-URI_GX_:A_P""1WP(^!W[/_Q4^+7AOXA_%O5-=\">%Y]<
MTS3]<OO!TNDW=S%=6L"Q7\=AX/L+QH"L[$BWO+>3<%Q(!D'[#A'(>'^(,5#
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M_H/K^?#]K/\ Y6(?^"4/_9M'[7/_ *@/Q H _H/HHHH **** "BBB@ HHHH
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M6-I#-=7=W<RQV]M;Q2332)&C,/XG?V/?V#/&7[2W[:/[9O[+NN?MD?M(>&=
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MR_\ 5E>,Z^]J^"?^"8/_ "8G\ /^P3XR_P#5E>,Z^]JWXY_Y+;C#_LJ>(/\
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M_MV?M>?L]_$O]K7]A[Q+X&^(EAXC\)?!7XHZ3XD^(GBO3[#5Y-%T73O^%E^
M-0NWAD;3TN]6-AIGA+4M2G?2+6^@GM);-K"6\DG\M/VB^$?[8W[-GQX\42>"
M_A'\3K/QOXEATVZUBXTW3/#WB^ 6FEV;PQ7%]>7NI>'K+3[.W6:YM[='NKN$
M37-Q!;0^9/-'&WV'&?#G$%'@GP[G5R+.*<,MR//I9E.>6XR,,OC6XCQ^(I/'
M3='EPGM*%6G6C]8=-NG.,_A:9\)X?\6<+8CQ#\5J=#B7(:M3-^).&HY33IYO
ME\JF:2H<)97A*RRZ"Q#ECO9XJE5P\_JJJI5J<Z;]Z+1]-4445^/'[T%%?/\
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M?Q(^)WB?2O"GP8_9<T?X@:EXA\6:EJ?BS1=7U_P5;?%'Q/J_@/PRGPVU+4=
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M;V_LK>.O^"B'['GBGQSX?MOB[^SMX?\ AD8?VL[:S\6_'KPW=?L^^*]9\/\
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MV&P&(P[IY;EN8YGCXXYXNM"M3J3I8.E1P*P]*K&I7JN%:5*/+,_HZ_9-TO\
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M5^*_Q8_Y39_LR?\ 9#]?_P#4$_:$K]J*_2/$/_=?#G_LV^3?^KCB _)?"O\
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MOBJU\,^//#!N6\-^--!MM<LKZ'2O%7A][RZDT37[)(-4TJ6>66QNH)&+5W5
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M6_O+46=Q,TWA_4],FN ]NH017#RQ(1O1%?FOP5_:,_8M_9V^'_\ P4%_9=^
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MNURU<-"OC,%AL0W%\Z<L91I1I*=>=6-*G)GZD>/_  [\ ?C9KUAXZ_X+6_\
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M;J/$ZZX_AKQ"GAB2&'Q*^AZLOAZ6X$)@BUQK"X&DR3BX26 PI?FW:43QR0E
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M^A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?DO_ ,%A/V ?
MB;_P43^!_P  /A;\+O$_P\\+:E\*?VO/A5^T#XDG^)-SX@M]'U;P=X&\(?$W
MP[K&A:;_ ,([X<\3W%QKU_<>-]/>SMK^SM-+EM;>_P#M6HP.L$5Q^CG_  I;
MX.?]$F^&?_A!^%O_ )55Z97\TGQK_P"#@#XR6O[2?QZ^ ?[%7_!+7]H;]M_1
M_P!F_P >ZQ\+?B7\3O GB#Q3I6CV7CWPY?W6C:]I46F>$/@A\5XK6RM];TS6
M+'2[S6-=TV^UR#39M2M-(BLL24 ?T8>'O G@?PC-<7/A3P;X4\,7%Y$D%W/X
M>\.Z1HLUU#&_F)#<2Z;9VSSQ(_SI'*S(K_, #S75U^1W_!.'_@H/^UK^V9XV
M^)'AG]HS_@FA\:OV%-%\%^%M)UWPYXL^*6M>,=4L/'>J7^K-I]WX=TJ/Q-\%
M/A9!%>:;:*-2F>UU#59FA8*]G"G[X_KC0 4444 %%%% !1110 5_*)_P6F_:
MJ\/_ +"7_!5#]@S]LGQ1H!\8:+\&OV>OC5IMSX,BUI?#EUXAE^):>+_!%N+3
M6VTO7?LL^F2:A_:/V9-$U"74$@:V3[+EKF/^KNOX:?\ @ZA?P'9?MO?\$\=6
M^,=GJFJ? BPT_09?C/I6D-=-J6H> 8?B[+/XGM-,BM+RRN1J5UX/C\5VMF]G
M<V=R]S/ BWD$JV[IZ>43PE+&JKC<O>:4*>%QU3ZBYXBE3K588+$2H3K5<)7P
M^)AA\-54,77=&K&4Z5"5-N,)RE'S<VABZF#]G@L>LLK5,3@:;QO)0JSHTIXR
M@JT*-+%4,1AZE?$TG+"456I2C"I7C42E.$82]$TW_@\)\+'Q3>W6M?L.^*M/
M^'6IV>FVGA:_/Q?MEU&+5K&ZU0>(]0U.]7X;3V>H:?=17.BV]II^E6GVS1)=
M+OIKJXU8ZU#;Z+^77A[P%IG_  <)?\%F?&^AV,U]^SE\#/%7@S0/C/\ $G1_
M"^LZ5XD\22>%_ W@/X7^%-<?POJ[^'--T+4?%7C?Q+J.CW5IJFM>'KG3] ;6
MM5\17FF>)+RP>PUC^NW_ (*A?%K_ ()^7?\ P2%^/9U[QE\ M4^ /BC]G'Q#
MHO[.ND>&=2\)7?AO6?'L7@C4I?V?]*^#>BZ#+]G.OZ/XLTW0;WPI;>'K:&'P
MU#HUQJ.H?V9H&BZQ<6?\=O\ P2>_X)<_\%/-3^%'PZ_X*=_\$[_'?PIT/XE^
M%/%GCKPKIGP]\9>(AI_B7QSHEH;31-8TTZ7XH\+7/PWN]!\0Z=J-[9W5EXI\
M8>&YS900:[HE_IFLV^B7[^AA\SJ?V9F]#!X3#Y?5KTL/'%XS"XG'4)5\L5:E
M3GE,Z$\35PM:-?$K!8MU)0IXJ:P>(52MB/;U(2\^OE=+^TLJKXO%8C'TZ%7$
MSPF$Q6'P5=4,RG3J5(9I#$1P]+%471H2Q>%5.,ZF%@\7A_9T<.L/2E'VW_@N
M1_P0_P#A3_P2P^"7PV_:;_9,^+GQ:N?#'B/XC6_P>^(_A'XJZ[X9\0ZNNH^)
MO#'B#7_"OB#PIJ/AGP1X.M$TZWB\(>(;37K#6K?4K^+4=3T34-"O+2&WO88O
MKKX*?LD_'W]DS_@G[\8?%WPU_P""8?@[0H/B]^RYXJU/XP_MF?&+]I'X=_$G
MXZZ_\.?'G@:?6]:U_P *Z#8W&BZM\.M)CT2];4)OAKI6A6%_J+6V@6WC!?$W
MB;1;C4I^M_:)_P""<'_!P-_P6 OO ND_MVC]FK]F'X2?"34VU_1OA1IOC>$^
M'O%GBFY2_L9?%TNE?"?7/CW-J_B2'1YY="M=1\6^,-*MO#>@ZGJ<?A/2K2^\
M0>*FU3^MOQ%^SYIOQ _90OOV7?&VKWMEI7B;X%1?!7Q1KGA22VCOK>UNO!,7
MA#5M2\/2ZKIL]JDR+YUQIKZAI,D0/E&XL<;H:[N'<ZHY3' 5L?0P&:X:CF^'
MGA\)CZ^:U9Y33I2A6QN/P>#P688/#0GBN>E'FQ%+$^VJ85)4XJ#=3DS_ "C$
M9H\?0R_$8_*J]?*<1#$XG 4LKI4\VJ5(5*."P6-Q6,P&+Q$X85*O[M"IAO94
ML9)>TG[2U/\ .?\ X(Q?"WX9?$;_ ()9_LF2?$+X=>!/'DFD+\=DTJ3QGX1\
M/^*'TQ+W]HSXJM>)I[:WI]\UDMVUK;&Y6V,0G-O 90YACV_FOXD_9=^'_P"U
M=_P< ?MA?"'XB:Y\0O#W@.W^!OP_\0:MI'PS\7W/@63Q78Z1\'_V8M/B\&^)
M;W3+>2[N_!5W_::7M]HUC+ITLU_I.CW$=["MEY<NK)_P:[^&S(YB_;1UQ(B[
M&-)/@-82R)&6.Q7D7XN1+(ZK@,ZQ1*[ L(T!VC]"O^"<'_!&+P=_P3X^,'B7
MXU0_'?Q+\6?$^L^!M0\ :=ITG@?2_ V@Z;H^M:MHNLZO=7MNOB#Q?J&JZD]U
MX=TJ/3IH-3TBULK<Z@ES9ZE)=6TMA^AU\XX/R?'<;\2Y'QK7QN;\1X/.*> R
M^EP]FF J8/$YKFV%S*$XYC7E*E*6%]@Z2J.E0<F_;0=.48TY?G]'*.+<WP7!
M?#F=<&T<'E7#V,RBICL?5S_+<=3Q>'RO*L3ETXRR^A&-6*Q7MU4Y%5KJ%O93
M4XR=1>[_ /#G;_@G=8^&[;P_X6_9[TOP3=Z?',ND^,?#/B?QC_PG6FSS.91>
M?\)1KNO:Y?:Q/!(=]LGB7^V[.WVHL=JJ11JG\YG_  6D_82^$G[,OC7X9_$G
MQU^T;\8?B!=?%73->\/>$=!\<!O$/BW3M"^%L/A&VN+1?&<>DWVGZE:V0\;6
M)M;.^L?"L-C9*;?34U!XWCC_ +:J^8OVFOV3OA9^UEIO@#PY\7; :KX3\$>,
M4\87&C6]M;0WOB(Q:==6(\.7/B#:=6TCPUJ$MQ#=Z]::'+8W^JS:9I)CU.PD
MT^&:O"X&\3L\R//L!6SW.\US#(X3Q4\=AL7/^U:LHU</4E;"O'*O5HU*F*C0
MG-8>OA%7:<:U>E"=2K'MX_\ "G(<]R/,7P_D.6Y;Q+4I82E@<=E\O[$5Z6)H
MQ_VR>!5.AB*5'"RKQ@\7A<<Z$7S4,-5J1ITI?YK_ ,&_#GP8\4^*=)T+XL^-
M/%/@72-6\3Z3I<WB70]&'B!-%T*]NHX+_6)]%ALY;S5;NQC=IH--M;BS-XZK
M ;BV60W$7^DS^QG)\(M+_9Q^$OP\^"_QBM_C;X-^%7@+PI\/=-\72ZCX?N?$
M TWPYHEG8:)I_B73- T_1UT#4=/T:&QLH=(U32+'6K:PM[0:N;[4OM6HW?&^
M)O\ @GY^RSJGCSX9?$WPK\(_A]\.?&?PNUC3[G3+KP9X&\+:5HFN^'8HY;#5
M/"?BCPQ;:9!HFK6-[HUU=6FFZHUK%K?A^]6PO+"_:SM)]*ON6^*/_!.3X$^+
M=;?Q]\)9O$O[,?Q;@CG.F_$'X%:G-X.19Y;:: 1ZKX3TZ6UT"[TZXDF\[5X=
M&B\.:KK04P7FM^5)(&^EXYX_X4\0\-E."Q.)SCA]86-:LJGU#!YCA*..E.=/
M_;J=*5',)T)X=4W#%X'%5W!SJ0GDTYTH5JOR_!G /&_AWC<YS' X/)^)EBIT
M:+PU3.,9EV+KY?&C0G?*:M6E4RRCB88I5E5P.9X*@JKC3JTL_I4ZU3#T4_X*
ME_!_XC?'S]@?]HKX3?";P[_PE?Q \6:!X4_X1_0/[7T+0OM_]A?$;P=XEU7_
M (FOB74]&T2U^RZ+H^I7O^FZE;>?]F^S6WG7<T$$O\?'P _X+M?MF_LW_!KX
M>? SP#X9^ EYX-^&?A^'PUX>N?$O@CQAJ.O3:?!//<(^J7MA\1=*L[FZ,EQ(
M&DM].M(RH4"($$G^ISQ1\8OV\?V/M,N[SX[^"/#/[7WP.L_M46I?$_X9V!\*
M_$W0=#'FM)JGCGP9!92Z))8VVDV]Q+=_8=-;2;7(;7_B LDT9E_';]H'XN_\
M$V?$_P 0OV9]7^"'[(WPR\,^!O"WQ!;Q%\=-%UCX!_##2M0\0^%FN=&T[_A'
MC;V,6MV>KQ?V%=>+;DVHO_LB:JVB7T;?VA86=U8^_P"&_#E:>7XC(L=P]EG&
M_#^)Q^)SC+LZRG%4\7@,-CJ.558UJ&/A5E2Q^ KXFGA<+AL%A\;EN#Q"KXF?
MM%.G4ING\YXE\>Y9A,;0SREG^;<!\287!8/*,QX>SO!U,#FF(P&*S>@J6)RZ
M=)5LMS/"X.>,Q6+Q^*RW-<?AOJ^$7LY1J4IJIVW_  07O?CK^TA^V/\ M9_M
MX^/_  IH=GX6^)GA37/ ?B'Q'X:NM-T[08?BK-XA^%/BQ_#6E^%+_P 1ZKXQ
MMK8>%K>/4UU.XM[O1@Q:T.LF_(LQ['_P7J_9H^!NM^)_@Y^T=\0?A;^U-\9/
M%NJ:"OP2A\+_ +/WCGPAX2TS0O#GA74/%?CNSU_6(=;^ 7QDU.YO[[4_&FJ:
M=)*MWI=B;>WL$BMQ<17$EU^G/[#/QZ_8V\73^(?AK^QS\%-3^''AM+J7Q5XO
MF\*?!_3_  #\/[76I[*UL+>YU_4M&D33%\1:O8Z9;6>FP3))J6H6NF.84:ST
MZXEM_P!(J_/L_P"*<TR/Q!6<5\BQ>2?4\'AL%1R*I6K99BX95#!+#X:A7K49
M5:M"3C&%12I*"G3A32@H3;?ZAPUD&3<1^'O]F8'B#!9]2QF-Q.+JY_0I4<SP
M4\TEC7B,56P]*M"E1Q$8RE.DU4<^2I.I>;G"T?\ -#^%OP0\#OXH\4VOQ6_9
M1_;=UKP_K'B>UA^&\?@/Q-I'@O4_#'ANYU'4(S;^/-2\2?LS>/++QAK$5E/H
MZMJN@Z9X%L#<6>J3G1UAU"UM],_T;?@I\)_#GP'^$'PR^"OA"]UK4?"WPI\#
M>&? 'AZ_\27-C>>(+W1O"NDVNC:?<ZU=:9INCZ=<:G-:VD<E[-8Z5IUK).SM
M!96\96)=[PCX_P#"'CNX\96OA/6K?6I? 'C&_P# 'BLVT<XBTOQ?I6EZ-J^I
MZ*9I8HXKJXT^TU[3DO)+1YX+>]>XT^25;VSNX(>QKS?$#CO'<7RP5#%997RA
M8)RK5,+5Q^+Q<:LZV'P\</65'$TJ2PSC04I<U**^L+$NK4<I<LGZO /!. X5
MAC,3A,SP^<+&I4:6+HX'"89TX4,17>)I.OA:M7ZRGB.6#C4DWAY8;V4.5<T4
M445F:CK6D:1)I<.JZG8:;+K>IQZ+H\=]=P6K:IJ\UK=WT.F6 F=/M5_-:6%[
M<16D.^>2*UG=$81MC\YC&4WRPC*4K-VBG)V2;;LKNR2;?9)MZ(_1)3A!<TY1
MA&\5S2DHJ\I*,5=M*\I-1BMW)I+5HTZ_+C]I?]HS_@H)\/\ XQ^)O"OP'_9=
M\/\ Q+^&&GVV@2:#XQO](\17=UJ=Q>Z!IM[K,4D^G^-M&M7&GZS<7U@@CT^$
MJELJNTKAI7_4>OSF_;X_:2_:1_9;\-Q_$?X;:)\ ]>^'OD65A>6_Q"US5M*\
M;VWB"6YG:X;2M'_X2CPS8^+M.DLEMUATSP_>3>)[>=[B\?2[K3+2XN(OL> J
M3Q/$-# PR;(<]Q&849X/"8'B'$5\+@7B:E6C.%2G6P^(PTEBN6G.E1C.HX3C
M5J14)5'31\!XFUEA.%<3F-3/^)N&\+E=>GC\;F7"F$PV-S)82E2KTZE*I0Q.
M%QD7@G*K"M7G"CSTY4:4Y3A2C59\"^#_ /@I;_P4-\?^,_&7P[\&_LM_#;Q#
MXV^'MQ<6GC7PWI^B^-7U+PY<VM_)I=Q#J,;_ !$CC1XM0ADM'$<D@$J$9(YK
M]*_@9>_'+]J;]G_XL>#OVO?A8/@UJ'BZ?Q%\/AH_A:*\TB^O/ VM^%M-@GUN
MRDUW5/%@BU WNIZO:07+A[5&LHMUBY21I?YQ/V8?VP_VC/"O[3?Q*^(?P=^'
MGAGX@?%+]H[5_$D^H^ WT7Q-JFEMJ.N^)9_'%VWAZPTOQ)I^K6\&B;+](9M2
MU>]@L-!%W/J4[^0]]'^W6E?%#_@K!XUT&^T'Q'^R3^SIHPUG[;8W=[XQ\8PW
M'AB?0;VR^Q7&F:KX4T?XF^(]9N_/=[K[7))<I;W=A+]C_LL?\?=Q^W^(O!U/
M)ZV&PN69/X?<*MT\IS##YM5XAAEV>4<315*IC7A,+F.:*-?#4L;"M3I3IT*D
MYTX12FZBDS^<_"?CZIGV'Q>-SC/O%+C6U7/,KQ624>%:F:<.5\'7E5I9<L=C
M,IR>4\-BZV75*%6O"KBJ=.G5JS<H*ER1?QK^W-_P3)_9G_9J_9E^('Q<\&^)
M/B:_C+0;KP=8^&;+Q5XJ\-WFDZE>:[XU\/Z1J-JUC9^$=*O+V>+P[=ZUJ$,5
MM?1/$;%KN026]M-&_K?P!_X)&_LJ_%/X%_!OXE:SXD^+IUOQ]\+O 7B_75T;
MQAX6CTJ#7O$/A?2]4URUL(9/!-[-;VUGJMS>6L=K/=W-Q:"'[-<3R3Q2,?Q[
M_;?_ &>OB5^SW\2M+TWXHZK\.SXB\<:)-XSM?"'PSU[XC^(]"\'^')=5N],T
MZU_M'XDPRZPEO<:I9ZS!8V?]NZ^]LMA*TUXB7%JLGOG_  3\_8:U;]IW2=6^
M)G@_XZ:'\/\ QC\+/&NG6\GA/Q#\+-/^(UK!#<:=:ZQX:\275AK^MQ>'=1T_
M5;I-7M;;3M3T*]A%QH-S-(LB20&ON\=A<XP?AWA<YK^,68T*3S&IF#XE638O
M%0K8?&4,/@,+E-2E@<7BJU/"TLPH3G''0]O2E5Q4N2E*,J4JGYIEV-R#'^*^
M-X?PW@'E6(K1RBCE:X/>?X'!U*&+P.)Q.9XW.Z5;,L%@L/5QM;+,33IRRVI]
M6KQHX./M*L)1K1I?TD_M!?LA_ 3]J&X\+77QJ\(7GBB;P7#K%OX=:U\3^)O#
MPLHM>?39-35U\/:MIBW9N'TFP*M=B9H?)(A,8EEW_AAX]_8Y_9>T;_@J#\'/
MV:-(\+O#\(_$7P\OM1\9>&&\:>*9;H^*V\%_%#7]-BDUZ?6WUZPN)Y-(\'W<
M%A;:E!'<1R6\:PO'J$J3_<?QB_X)^?M>?'K2M,T?XK?MU:9XBLM$N;B\TN6S
M_9X\&^%-2L)+N*.*]CAUOP?K/A_65LKU(+8WVGMJ!T^\>TLYKJVEEL[5X?Y<
M->LK'3O$>J6>FZO=:SHMKJ]_:Z3XB:P:QGUC1[/4+BTM-:33GO;K[*UY;0"Y
M^Q#4KE;:0M:&^E,33'YOP=R#%8W!9S@LL\4\3CJ>%R/,LMAE63X?B..5Y%B<
M[6*C@,VPU7-(Y/"6*H588G&4J&'P5"K]852<<3#E=6?UWCWQ/@\OS'(<PSGP
M5P>75,;Q'E&;U,[S[%\)SSKB7!\.RP4\SR/&4,FEGTX8+$T*F$R^MB<5F.)H
M+".C">#J<ZHT_P"V/X"?L2_LX?LS>*-6\8_!OP1>^&?$&N:#+X9U*\N?%OBW
MQ D^C3:AI^J26JVNOZUJ5K"S7NEV4OVB&%+@"(QB41R2*WU<S*BL[L%5069F
M(5551DLQ.   "220 !DU^('P$_X)<>/?AMI,?C'X+?MU:]H%IX\T32=3MO$G
MA3X+Z5876M>'-1MK?5=+4ZAJ'Q!U+4GTVYCEMK^.S6XM[8R&.:2U,Z*Z_2%K
M_P $^_B5.[#Q#_P4#_;+O8-NZ-- ^(USX8G6YR/WCW"3ZKYEML,@%H(D =HW
M\W]T%;\4XARWA_'9G7Q..\5)9]52IT7C<QR#BI9G)48J#I5J6-H5?9*C+FIT
MX?7:GNP;E&DVH/\ H?A7-^*,NR;"X3+O!6/#-"4JE=9?E/$_!3R:G]8DZBKX
M>MEV)I.L\1&U6K/^SJ+YI)1E65ZBPOV__P!JS]G#6/V1?CCX9\*_''X3>-?%
M/B#PK;:+H_AKP=\1/"/B77+^ZU/Q%HVGL;?3]&U>]N)%L(IY=1OE5-\.GV=W
M<E?+A8CY<_9B_P""C'P _9B_84^"?AO5=1G\;?%FSTWQK;0?"_PU+''J%I=2
M_$;QG+I\OBW7[N/^QO"&FWD,UA>&2\DN]9_LW4+?4M/T'4[7>X^,_P#@I!^Q
MAX0^!_B7PZOPY\5?'#XQ?$K7?#?B[XJ_&7Q!\1-:TWQ6VA>#=.O+#3-.\6ZW
MJUCX6T>ZMFUS6VUBP^WZYK5^]W?:?!I\*M?W]G'/Z[_P1F^$_P --6^(WC'5
M?BC\-EU#XB6GA/PS\2O@?KGBC2KZYTIO"ECXDU?PWXK\4^%H;P'0+G4-'\6P
M>'=/M?$$<%UJFD:G!J-GIEYIUU::K&_[+3X4X#P/A%+-)8C/<_R:CGM/BB6!
MIRP^6YAC<1##U,BA@IJ<%6P^67G4QM7%0I0QDL!3GBJ,8QY4?S_5XV\3<R\=
MX9/'"\-\,\08CAJKP9',JD,5F^5Y=A:F*I<2U,PIRA4>'Q6<)0HY=1P=2M4P
M$,RJT\%7G*HY2?Z#0_LR?M-_M?F'Q)^V5XYB^'WPJN&&HZ)^RK\']>EL=/U&
MW6=;C3;?XL?$+3VOI=:>1+>V:\MM'GUBW!E74]!N?"-^)M,7\B_B=^P!X6^&
M?[6_[,_[-_B7Q7J&J7/QH\,Q:W\0]=\.06NE:=HWB#7]=\:V'V/P)87-I*;;
M0?#T6C:='I_]LI=7.JS0W5[<P:=:WT&B:7_6;7X?_M?_ /*67]B'_L4_#_\
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M_P (=X^\._9M%AO[#3)+W[7XL\+:%8S;;[4[&#[/;W,MV?/\U8##'-)'N?\
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MFWNV%%%%> ?4!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ K^-+_@H)^WO\%M(_:&_;MM?V;_ /@F!X6^/7@6
M/4OA[^R9_P %'?VL_&FM^)?"WPU\0ZMK7CK0_ -IX!'A[PM<Z6FK>,?#/BW6
M;#08_'=AK&G^/TUW3K2\6T7P]X=T#Q)/_7IX_P#B?\-?A/HUMXB^*?Q#\#?#
M7P_>ZG#HMGKOC_Q;H'@W1KO6;FUO;ZWTFVU/Q%J&FV4^ISV6G:A>0V$4[W4M
MK87MPD30VL[Q_P 3'[?'[,'[07AK7?VR/ O[!?[9O[ OQ6_9(_;G^/\ X<_:
MC\>?"?X@?M&?!KPI\1?AM\:=*^(GA?XIZU>>'];UWQCH>D7/A[6O%WA'2(VE
MB\174T_AB*'0I?#=AJ.FQ^)M3 /UL_X(S^%?V'_V</VM_P#@H'^Q=\$/V4/&
M/[-7Q^^#WBY;C4_$?Q"\7^*?'VJ_'3]GJT\27UA\//B!X1U7Q=%#>^&?"TS:
MKI6I7'A[3(Y],U>'Q'X8U\^(?$=R6@\._P!&E?SQ_P#!'[X"?%36OVEOVEOV
M]?VO?VI/V:?CE^V!\;O 7A'X='X9_LQ>/_"WC3P=\$?@YH-_I]W!I%\WA[4+
MQ!<ZIJ^AZ!!;1VQU*QL!HUU?77B[Q3K7B?4&TO\ H<H **** "BBB@#\2_\
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M8O1+&(?JV@#^?#_ARC^U1_TG&_X*6_\ APKS_P":>C_ARC^U1_TG&_X*6_\
MAPKS_P":>OZ#Z* /Y\/^'*/[5'_2<;_@I;_X<*\_^:>C_ARC^U1_TG&_X*6_
M^'"O/_FGK^@^B@#^?#_ARC^U1_TG&_X*6_\ APKS_P":>C_ARC^U1_TG&_X*
M6_\ APKS_P":>OZ#Z* /X\O^"HW["W[9O[ 7["GQS_:V\(?\%E/^"B/Q \1?
M";_A6?\ 9WA'Q)\4-;TS1=6_X3OXP_#[X:7?VV^TOQ*U]!]@L?&5SJ=MY /F
MW=E!#+B&20U]TZ#_ ,$8OVJ]7T/1M6D_X+A?\%*X9-4TK3M1DA3XAWK)$][9
MPW+QHS>)]S*C2E5+<D $\U^PG[9O[)/PP_;I_9K^)'[*_P 9;[Q?IOPV^*7_
M  A__"27O@/5=-T3Q7!_PA'CWPM\1M'_ +*U/5]$\1:=:^9KWA'2X;[[1HUY
MYVFR7EO#]GGEBNH/I/3+"#2M-T_2[8R-;:;96EA;F5@\I@LX([>(RLJHK2&.
M-2[*B MDA5!P #^?W_ARC^U1_P!)QO\ @I;_ .'"O/\ YIZ/^'*/[5'_ $G&
M_P""EO\ X<*\_P#FGK^@^B@#^?#_ (<H_M4?])QO^"EO_APKS_YIZ/\ ARC^
MU1_TG&_X*6_^'"O/_FGK^@^B@#^?#_ARC^U1_P!)QO\ @I;_ .'"O/\ YIZ/
M^'*/[5'_ $G&_P""EO\ X<*\_P#FGK^@^B@#^?#_ (<H_M4?])QO^"EO_APK
MS_YIZ_-?QQ^QO^VGX4_X*I_!;_@GS;_\%C/^"AEWX.^*/[*WBO\ :#O_ (A3
M?%/74\3:7K/A[Q7XM\/0^'K/2T\2_P!ES:9<0^'(+F6ZF8722W,J(-B)7]F]
M?(OB/]BOX1^*/VU?A[^WEJ.H^-T^-/PT^"FM_ ;P]IEKK.E1> )O!6OZWKFO
MWMUJFAR:!-K%SKZ7OB"^6WOK?Q':6<=NEO&^FRO&\DH!^57_  Y1_:H_Z3C?
M\%+?_#A7G_S3T?\ #E']JC_I.-_P4M_\.%>?_-/7]!]% '\^'_#E']JC_I.-
M_P %+?\ PX5Y_P#-/1_PY1_:H_Z3C?\ !2W_ ,.%>?\ S3U_0?10!_/A_P .
M4?VJ/^DXW_!2W_PX5Y_\T]'_  Y1_:H_Z3C?\%+?_#A7G_S3U_0?10!_/A_P
MY1_:H_Z3C?\ !2W_ ,.%>?\ S3T?\.4?VJ/^DXW_  4M_P##A7G_ ,T]?T'T
M4 ?QD?\ !+[]C?\ ;3_;Y^$'QK^)/B__ (+&?\%#/ %]\+/VJ?C#^SY8:9X;
M^*>NZG::KHWPT@\*RV/B&\EU/Q*LT.IZF?$,PN[6$&UA%O%Y).YZ_2C_ (<H
M_M4?])QO^"EO_APKS_YIZ_57]C7]BOX1_L-> _B'\._@WJ/C?4M"^)OQK\>_
M'GQ#+X[UG2M;U*'QK\1H]%BUZUTNXTC0/#T%MH$*Z#9?V;8W%K=WEN6N#/J5
MUYB"/ZZH _GP_P"'*/[5'_2<;_@I;_X<*\_^:>C_ (<H_M4?])QO^"EO_APK
MS_YIZ_H/HH _GP_X<H_M4?\ 2<;_ (*6_P#APKS_ .:>C_ARC^U1_P!)QO\
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MP1R:MH=G'>K-I%R9K)KB&)H)72>/ZMH _GP_X<H_M4?])QO^"EO_ (<*\_\
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M6_$#]A__ (*T?"#]L7]D/3_VSO'/[/\ XV_8)N_%?CCXOZ5>V!\"^#==\4^
MX/&6A-:>--)\8:38ZU\5OAKX,\1>&[XZJW@>^M],MM:U;P7XBM;W6I;KPHMS
M_.[^U9\<OBG^V#_P;1?LW^++WX5:!X*T7]E?]N[P[\'-7A^&/@]?#?@G5/ G
MACX(>,])\.?%J^TFPFGL-"FU#Q9\3]/\$>)]0A6UL->^)&JWVH0VUA/K45B
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MM;Z^\(S?%/QGK;PKY.P7 T'XO>");H)=W!5+BU5HH %DN@#^NBBBB@ HHHH
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M3O-T[4_$%]97%Q!+^HM%% !1110 4444 %?*WQ6_8F_9B^-WQ^^"?[47Q/\
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M3ZBWB9_$LGB=V\7OXV?7&\9MXS8^,3K_ /PD_P#Q-J^J** /RZ_8J_X(V_\
M!/W]@'XBZ]\7/V<O@Y=Z1\2]:LM5T:U\8^,/&GBOQYJWA;PWK$T,M[X=\(CQ
M+JE[9Z'9RI!':3ZK#:R>*;[3O-T[4_$%]97%Q!+^HM%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M*L%K:?M(>([FYG<D)#;P>$["6:5R 2%CC1G8@$X!X-3?\%Y/^"L7[%W[3_[
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M:?$;0O#WQ$\>Z%\/O!,A\)Z)IDDU_>Z;H]_X>DN;#4+/Q==Z]I=]<0:VUS.
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH \<^,?[.W[/W[1.F:-HO[0/P+^#GQTT?PY?7&J>'M)^,
M?PQ\$_$W3-"U.ZMQ:76HZ-8>-=$UNUTN^N;4"VN+NQB@N)K<"&21HQMKA/AC
M^Q)^QC\$O%%MXW^#'[(W[,/PC\:62S)9^+_AC\ _A5X!\46B7%M<64Z6VO\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
F%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>34
<FILENAME>nt10014672x1_linechart7.jpg
<TEXT>
begin 644 nt10014672x1_linechart7.jpg
M_]C_X  02D9)1@ ! 0$ P #   #_[0 V4&AO=&]S:&]P(#,N,  X0DE- ^T*
M4F5S;VQU=&EO;@     0 ,     !  $ P     $  ?_B"^!)0T-?4%)/1DE,
M10 ! 0  "]!N;VYE @   &UN=')21T(@6%E:( ?4  < %0 3  L (6%C<W
M         $E%0R!S4D="     0            #VU@ !     -,M2% @(
M
M$&1E<V,   %$    =&)865H   &X    %&)44D,   ',   (#&1M9&0   G8
M    B&=865H   I@    %&=44D,   ',   (#&QU;6D   IT    %&UE87,
M  J(    )&)K<'0   JL    %')865H   K     %')44D,   ',   (#'1E
M8V@   K4    #'9U960   K@    AW=T<'0   MH    %&-P<G0   M\
M*&-H860   ND    +&1E<V,         &G-21T(@245#-C$Y-C8M,BTQ('=I
M=&A"4$,
M                                                    6%E:(
M     "2@   /A   ML]C=7)V        !      %  H #P 4 !D '@ C "@
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M;W5R(%-P86-E("T@<U)'0@
M
M      !865H@        8ID  +>%   8VEA96B            !0
M;65A<P         !                               "6%E:(
M  ,6   #,P   J1865H@        ;Z(  #CU   #D'-I9R      0U)4(&1E
M<V,         +5)E9F5R96YC92!6:65W:6YG($-O;F1I=&EO;B!I;B!)14,@
M-C$Y-C8M,BTQ
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MU=;7V-G:X>+CY.7FY^CIZO'R\_3U]O?X^?K_Q  ? 0 # 0$! 0$! 0$!
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MVPKW4?V0;C]I#1?V-O\ A7G@?4)O%7P@_9T\$?&OP[X?UB&UNQX\U#4]0O/
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M3B*[\6Z5\'OA'?\ A'Q-H6G^!]9\$O/XBDU+3[/4I=,_M<_X*+?\$:OV,_\
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MZ_DR^'WQ.^&W[:__  <Z_#WXR?LR^/M*^*_PJ_9X_8+DC\>_$'P%J.GZ_P"
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M:.L^(K_^V?$=Q:R:IJ/VS7M8N?M5S)YVI7C[IW_LNJ8;/U_1 %%%%6 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %?G[XS_X
M*@_L7?#_ ,8>*_ ?BGXGZII_B?P3XEUWPCXCL(_A[\0;V.RU[PWJEUHVKVB7
MEEX:GL[M+;4+*XA6YM)YK:=4$L$LD3H[?H%7\T7_  6-_9>^"WP?T_PG\6O
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M9&JLMGA%C%4G**QOUA492H^S;****^:/L@HHHH **** "BBB@ HHHH ****
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M10 4444 %%%% !1110 5^$?_  7:_P"23? ?_LHGB3_U&HZ_=ROPC_X+M?\
M))O@/_V43Q)_ZC4=?K?@3_R=G@S_ +#<;_ZJ,P/P;Z3O_)B?$/\ [%V6_P#J
M_P I/UK_ &8O^3:_V>O^R'?";_U M KW&O#OV8O^3:_V>O\ LAWPF_\ 4"T"
MO<:_.<]_Y'F<_P#8US'_ -2ZQ^N<+_\ ),\._P#8BRC_ -5^'"BBBO*/="BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M9#@*CE+%9GB,)FN68S%K#T:<9S]EA</#VF(Q%10PU!U*%.K5C5Q%"%3^D?\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MFWN[KS/LMK/KWB;4-,TJ&YN?*E\B"2[66;RY/+5MC8VK+Q=X4U'PM;^.=/\
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M;FL?LQ?LU^(?^%,_V_\ L]? [7/^&<?[+_X9Y_MCX3> M3_X4/\ V'_PC?\
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M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?(G[?%_\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M;V$[ZIJDDNIZE)(][J$TUY/-*_N= !117\U7QA_X.4?@UX$^)GCT_"_]DO\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH _/?_ (*P>&/
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MZ_K&K^3G_@A-_P I?O\ @X;_ .SGM&_]7#^TO7]8U1#9^OZ( HHHJP"BBB@
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M%% !1110!\\?M:?M(^"OV/\ ]FKXU?M-?$*&>\\*?!CP#K?C2\TFTN(;2_\
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M/"USX>\8:O\ :- G\'PV-_=,BZJFH:=+?Z?>_P!2=)/=-6M;SW_X9@%%%%,
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /PW_X*S_LY?\$2?&=O
M/\2_^"EUU\&?A_\ $'_A&%M-%\=_\+!UOP+\>=2T;3O,LK&3PYX9^'NJIXV^
M*8T(WCK8:7=>#/'EAIZ'YM*^S08C_CA\+?M#_$SX#_M V/PQ_P"#>/\ :-_X
M*3_''PE92WCZI\*_'OPHTCXB?#F:"YGA-SXKT;P3%:WFBR:/>-&(KO7_ !Q\
M /AMKF@6GG3OXD7;+.?[D_CU_P $9/V"OVIOVKM1_:__ &D/AMKOQF^(=WX<
M\&>&K'PCXM\6ZE;_  JT:W\#Q30Z9>1>#O#*^'Y/$$]\D[+K.G^.-7\6>'KU
M55$T2WC+H_Z+?#7X5?##X,^$[#P'\(/AQX#^%7@?2VD;3?!OPX\(^'_ _A73
MWF(:9[+P_P"&=/TS2;5YF :5X;1&E8;G+'F@#B?V8M9^-7B/]G3X&Z_^TAX=
MT[PE\?\ 6?A5X%U/XS^&-)6RCTS0/B7>^'-/N/&6DV,>G:MKUA';6.NR7MO'
M%9ZSJ=O&J;(KV=%#GW.BB@ K_/2_X+\_MM_$W]N_Q+H7B;X.:C;R_P#!.[]F
M+]K7P;^SKX;\76.HW,VE_M!?M4:AX1\4^+/&_COP^;:W.E:UX6^%GA32'\(Z
M!?F[EC2Q\;Q>*?#]]J^F_$6[MO#?]]GQ:^'EE\7?A5\3?A1J>M:[X<TWXG_#
M[QG\/-0\0^%[N&P\3:#9>-?#FI>&[O6O#M]<6]W!9Z[I<&I27VD7<]K<PV^H
M06\TEO,B-&W\:?\ P4+_ .#;/XU>"/V;O@M\*_V"_C1^V)^TQHOAOXXV>K7_
M , OBQ^T'\*= ^#_ ,+?"^I:-XROO$/Q1\">#_$DGPN\'Z7XX'B/4H+1[S0G
MN];NHO$^NW#Z;<BZOKN( ^M_^"KEIXB_;H_X+._L2_\ !*7QS\3_ (D^!/V3
MO$?[/_B_X[?%/0/A1XEF\&^(O&_C6/2/CGJ.E6NLZE+:ZOI.JZ7I$/PG\)1:
M1!J.B78TN#Q%XU>R>'4]0LKW3OQ2\9?\%#?VM_@3_P $ROVO/V%-$_:!\=ZW
MXP^#'_!2O1?V*_#GQEU;6-=;XCZ3^SEK6A_&J63PUHOC2"_@U6P@/B/X"/IE
MK&)I;K2_ WB_7O"%@]KH46@VFD?OM^V-_P $_P#]K[]FO]M#_@G+^WW^QA\/
M/&'[>/B']E3]GW4?V5OC+X ^)GQC\"^!_BC\0O"-AX7\?:!X6^*&M?$CQG#:
M0>(/&.NR_%?Q5<>,=6M;&_U&#5_#WA&6+P_>Z%J7B.XTGX O?^"$?[:_Q8_X
M)>_M-:Q\1O#OAWPY_P %$OC9^W'!^W1I7PGT_P 1?#9=(FO=#@\8^&XOAQJ/
MC>#4]3\':=?ZU8?%?XH^-]&MW\83>%;35/\ A!M U>^T OXIOX@#Z0_8?\#:
MK_P2M_X+E67_  38^&/QF^+OQ#_9;_:3_94D^+VD>"OBUXG;Q=<>&OBQH]AX
MEU/4O%UE/::?HVE:7K>L0_"?QC_:EWI>DZ?;:OIOB73M-UB'4;GPYX=NM-^U
MOV\/^#D/]AW_ ()Z?M.>._V4?C1\*_VK?$_Q$^'MAX.U'6M9^%_@?X0ZUX+N
MH/&_@[0_&VDKI>H^*_CGX*UR:6WTK7[.WU%;OPY9)%J$5S%;/=VR17<WFO[$
M?[,/[>G[1G_!63Q%_P %.OVZOV:])_9,T;X<_LSZ/\#/@C\*H?B3\._BGK.H
M>(=0@>U\4ZZ^M^$+K4;FVT:WFUOXF:DDFK6/AW68[?QIX9\.6-]X@T[0=>OM
M2_I0I._1V^5P/XT?^#9KXZ>$OVG?^"@7_!;;]HOP%IWB/2/!/QP^*GPU^*?A
M/2_%]IIEAXIT_P /^-_B+^T5X@TJS\16.C:OK^DVFLV]G?0Q:A;Z;KFK645T
MLB6VH7<069_[+J_DY_X(3?\ *7[_ (.&_P#LY[1O_5P_M+U_6-4PV?K^B **
M**L HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **_)']N3_@IUJ?['?QCTWX56?P;L/'T5_X$T7QF=;N?'-QX
M;DB?5]7\0Z6=/&GQ>%-;5U@&AK,+G[8ID-R8S @B#R<)^R3_ ,%;=7_:<_:#
M^'_P/NO@7IW@V#QO_P )7O\ $D'Q#N=<ETW_ (1KP3XD\7KLTJ3P;I277VQ]
M 6P;-_;^0MTUR/-,(AD_3*/@_P"(6(X9EQA1R.$^'HY3B,[>._M7)XR6687#
MU,37Q'U26/6,O"A2J3]C]7]O+EY8TY2<8O\ &\3X_>%&$XSCX?XCB:I#BR>>
M83AN.6?V'Q!.+SG&XJC@\-A/KT,KEEZ53$8BE3^L/%+#0YG.=:,(N2_:FBBB
MOS,_9 HHK,UG6]&\.:7>ZYXAU?3-!T73('NM1UC6;^TTO2]/MHQF2XO=0OI8
M+2T@0<O-/-'&H^\PJHQE.480C*<YR480BG*4I2:48QBDW*4FTDDFVVDE<BI4
MA2A.I5G"G3IQE.I4J24(0A%.4ISG)J,8QBFY2DTDDVVDC3K^9_\ X+ _ME_!
MKXRZ1X<^ /PQU*Z\7:M\/_B&?$WBOQAIZP_\(=;WNG:+XA\.2>'-'U!I/.UZ
M^AGU5[B^U*Q@_L*%(88;'4]4GFNTT[]$OVE_^"I?[*O@7PGXU\(>!?B/??$7
MXBZGX>U_0O#[?"O29?$NF:3XAU31KRUT+5Y?%4FH:!X8U"PM-4FM99SX:\2:
MGJ<81O(MO.V5^4W_  2!\6_LL^$O%?QFB_:&O_A?X?\ %ESIGA+_ (0+6/BV
M^A:?I$.EVL_B*/QGI^F:MXK$6A:;JLUS/X9>>TFNH-4U*VB(L(Y8-/U()_3/
MA-P/F'"> S;Q3XCX7XEQ&(X6>7U^&\@HX:M@,3FU7'5I8/$9A*%;#3Q,\'@*
M5>G74J=%TY4_:UY>TITE&7\:^.OB5E7'>:9#X(<(\:\&X3"<;+-<-QAQ3B,;
MALSP>1T,MH0Q^$RJ%3#XNG@Z>89I7PU7#<E;$1JQK*AA:;HUJTIP]?\ AO\
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MC3-8DT72W\0-8:/^V=?R3_\ !-3X=^ OA+_P<G?\%/\ X;_"[P9X8^'GP_\
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M?M8^)(6MS%<:=%XILOCKX,TS2$D<"272E'@B]\0:,N3"MIXD,D "3G/ZB_\
M!%+5[GXN_P#!37]MWQO_ ,%(? FNV_\ P5U\&:1I7BKX7>"/B'=VX\&?"_X%
M^(O#MG=R>%/@)H,DVMV'@^_T"U\7^']-O-6G\1:UJTWP[\:6,OARZEFU'XR:
MQXB /[%?.A\[[/YL7VCRO.\CS%\[R=^SS?*SO\K?\GF;=N_Y<YXJ2O\ -B^
MWP<_9K_:,_X);_\ !1C_ (*>_M8?M,_%B[_X*"V'C7XE>!X/$%I\6K[PQXGL
M[WQI\.=)\&>#/A=JG@M ]YXF\%_&N/QEXA\!>)M-EM7\.I\+M*U'P-X7MO"^
MD>"O&#7/]?\ _P &]'_*'+]BG_L6?BG_ .K[^*M '[/4444 %%%% !1110 4
M444 %%%% !1110 4444 ?B;_ ,'%'_*'W]J;_L:/V4?_ %LO]GNOVRK\3?\
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MPW_V<]HW_JX?VEZ_K&K^3G_@A-_RE^_X.&_^SGM&_P#5P_M+U_6-40V?K^B
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M+]E7XA_M3?#?]M?Q3\+6F_:A^$V@KX7\#?%C1?'/Q(\):E8>'Q'XBMVTC5]
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M .SGM&_]7#^TO7]8U?R<_P#!";_E+]_P<-_]G/:-_P"KA_:7K^L:HAL_7]$
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M?P6_:.@U;7]2\)^"K6]N=)^&0TZ'4=5NK#0X+JX>+XE2W(LH[F=996CMI)Q
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M?#/[06M1^-5U?P5?Z)=WL&JV_P //AE.DUAJ*6%S:^''L[:)=(UO5K>^R?\
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MX::AJGC^2V\$>&+Y/!6C>%-8\'^-_"_B/Q.^K^'_ !7XA@U72M+\4^']&\-
M'[K>,OVM/V5?AUKWBWPK\0?VF?V?? GBCP#<>&;3QWX;\9?&;X<^&->\%77C
M72I]=\&VWBW1];\26.H>'+CQ;HEM<ZSX9AUBWLY->TJWGU'2EN[2*29?H*O\
MX/\ X*(R?\+T_P""?/\ P4#_ ."@ES<76H0_M9_\%FO"?@SX:ZQ<1;(-:_9^
M_9J^$OQL\$_![4[!R,F(6/B36] NBA*-<>&U4Y,0"_T@_LZ?\%H/C!^U;XJ_
M;?\ VH_A9X0^#&D?\$M_V&/ _P 0]7U;Q-K^G^*=2_:K_:#\3> O 6M^-(T\
M Z,_Q$\*:#\*_#'B2QLK35-'OOB-\/-3O)H)-.\.6L=_XCU;Q8OPK /Z.Z*_
MC3\1?\%N_P#@M#H/["_BK_@I9/\ L?\ [&FG_LI^-=;;2?@VNI:]\1+GX@>
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M:]X,M?@_X<_LZYN=/U2^U+5_#6LZ]INKQ(EU-\/+.3Q7<>'K74$F\,Q?/_\
MP;B #]E?]L @ %O^"EW[5I8@ $G[%\,UR?4[0!D\X '0"OP$_92^&'Q!OO\
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MK(U"R\,^+-0O9-)T[P[>W=>=^'_^"^W['>I_\$[O&/\ P4!UW1_'?A.#X?\
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M53!JEW9V'PYT_0= UW]QP      , #@ #H .P%-1$C1(XT6..-52.-%"(B(
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MW" QS2H0OR2.N&/!^&O^"?'[!O@SQ_9_%7PA^Q=^RKX7^).G:FNMZ9XX\/?
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MCFJLGB3P[%KEOX8EU[18_$MY9W&H6GAZ35+%-<NK"T,(NKZWTEIQ?SV=L;B
M7%S%;M#"9X1(ZF1-P!X=^RY\#(/@1\"/@-\/]<L/"5[\2/AG^S]\&_@SXO\
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M]HW_ *N']I>OZQJB&S]?T0!1115@%%%% !1110 4444 %%%% !1110 4444
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MB \6_P#!2'_@M%\5?VQOVFO@%^RG\3O$?CD_"[XH_&>/1_!/ACX*?L\:O?\
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MTBVU'2O .B^(]8TW4O&&I6%QX@T&"]L?#UMJ-U:S:WI$4\4;ZE9K-XS9?\%
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MHT)87-@OA34]8\62F4/Y=_H_B3XI^'QOW+)IL84QC[FCX3YYA*5/%\89ED?
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M_LG0I)[:\US3/!'@G4[6TUN]\1^+&M(H9_$]WIE[96_D6;:AJ<EEH^C:(_\
M4^5YSPYA<OR1Y=Q=P/4\%<OX2KY=Q-P_BZ&'H9WFF<PH8J%6M4RVOAEF4LQQ
M^)6"Q-.,Z].MB/W[6&JUJN'Q-7^(<[X>XNQN:<1K.. _$NC](W->/,+FW!G%
M>"Q.,Q7#>2\/3Q6!J4</2SC"XUY/'*<KPCS+!U*E/"U\/A+852QM##4<5A*/
MV!I_B'_@L#^U/IUGJWANV^%_[*7P^U[3A?Z7J%U]C&O:MH>II'+:.S75O\1_
M&=AJ:VCB:UO+?2/ GF[Q*KP*\3+U'A__ ((]^'O%VKV_BO\ :G_:/^,7Q^\3
M1- P5]4GT;3Q;I(99])NM0\0WWC7Q)=:<[,R(VDZKX8DC1F:&.W8@)^Q]A8V
M>EV-EIFG6T-EI^G6EM8V%G;1K%;VEG:0I;VMM!$H"QPP01I%%&H"HB*H  %6
MZ_EFMXM<0815:'"6!R'@?!S<X17#63X7"YE4HMVIK$YWBUC<XJ5E!)3J4\=2
M4FY)14.6$?[<PW@/PICO88GCS,^*/$K,::IU9/C+B#'8W)Z.)44ZKP7#>!>7
M</T</*IK3HU,LK.,5%RG*KSU)_-GPC_8]_9C^!9M9_AA\%? WA_5;)S):^);
MK2SXC\7P.0NXP^,/%$NL^)H48HKF&'58X X#+$I Q])T45^=9AFF99OB98S-
M<PQV9XN?QXK,,77QN(EJW[U;$U*E1ZMO66[/US*<ER?(<)#+\CRG+<FP%/\
MAX+*L#A<NPD+)1]S#82E1HQT26D%HDMD%%%%<)Z84444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MN[AI+B:61@#^8_\ 8/MX+7_@Y\_X*N6MK#%;6UM^S)X$M[>WMXTA@@@AT?\
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M']I:/PI^QOXK\6WYUS26TJX\4_%N3Q#%X,\0Q65OI][;:WX.M?A7XS\2Z?I
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M].\(^+/%_P 5_#>H^#/!_A8GQ,VC^'-<U\VD5[8:JGA6Q\+1^"]%T?4+RXH
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M_P#NH']L?9_^H7YO_+*OD_P+^SW_ ,%!/VEO^"\'QF^'WB']KE?V+?VR[/\
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MSX9ZOJ-H\Z3VNC2:[K#K]GF\B62-M,T6[CGMUE*JMS \EO)N1HY75T9OX?\
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MQ+PQC,OP4<!1K8S&T<>\52Q->KB,-6HRQRJT8T8X*K#D=HT\53G*<_:*-/\
M;RBOP?U#_@O+\%(X VE?!;X@7MSYB@PZAXE\)Z9 (B&WN+BVFU:0R*P0+$;5
M58,S&9"@5\&7_@O?\.$BE=/@!XB9TC=D$OQ(T*&(NJDJ)9AX=E,49( >012%
M%RPC<C:?CH^!OBO-77!N.6MO>Q>5P?W3Q\6EYM6\S[R7TD_ ^+L_$'*WI?W<
M'G,^VSAELDWJM%KKL?:WC7_@KY_P3N^'WQ,\7_!SQ3^T(]K\2? ?B;6_!WBS
MPQI?PC^.GB6;2?$GAR^GTW7=,;4/#/PRUC1[UM+OK6YMKRYT[4+NRCD@E_TD
MK&S#!\0?\%H/^":_A18G\1?M$WVE0S[1#<77P._:)%K([J7$2W<?PE>V\\*"
M7M_-\] /GC6OYJ?V>_A)X7_;,_;DU^.2\@\!6?[4/QT^+?Q7\1:E97EIK.H:
M7I&O:GXO^);^%])U>XM+6WU'4+;28#X9T>]?3DL9-9F.L2:,4FN+%_JO_@J!
M_P $]/A9^RCIOP\O_ OBK7/$GA'XEC7_  [JOA'Q]<Z3J&O0WVB6MC<3ZMIM
M_H^E:'#>:-=6^HP0WD+Z9#=:)J8M)H=0NXM7@MM(_:(>!OAA@\[X<X,SOB#B
M_"<9\0Y/#-*.!H2RVK@*4HT<3.M1GBH9+6IP;J8''*G:O4BHX=J523G0E6_G
M^O\ 28\6<=D?%GB#PSPAP;F/AIPCQ \CQN:XFIF6'SC$J6(P=.EB\+@:N<X>
MI[.-/,\NE.%3"QJ2>*@^2ER8J&%_K#^'_COPI\4O ?@GXF^!-5&N^!_B+X1\
M-^._!NN"RU'31K/A3Q=HUEX@\.ZJ-.U>TT_5K :CI&H6=X++5+"RU&U\[R+V
MTMKF.6%.NK^(32O^"ZGQ=^"WP@^'7P \!:SX%\/:=\$_ /@OX2Z1JFB_#S5-
M=\87.G?#3PWI_A"TFU>_\8:EJ/@Z\U.]@T:)M0N-.T:SLFN69K.&VAYKY5^(
M7_!:S]J'QY('U'XT?&S&QHWA\-ZUH_PKMY(I'+RK):_#C^RK:8-]P>= _P"Z
M+0_+"3&WR=+Z,W%53%5_K6>\.9;@8XBM&C[3%XS,LP>'C.7L9SH8#+_JSJ.'
M+[1?6:;4^:T$DD?HL_I7<.5,)AWE7!/'.<XVIAJ%2<Y9=EV0Y4ZTX1=54\7G
M.;4L4J2DVZ4U@JL)PY7[1W;/]!C4-2T[2+.?4=5O[+3-/M8WFNK[4+J"RL[:
M&-&DDEGN;F2*"&.-%9W>1U545F8@ D?,WC/]M[]D3P!#-+XD_:+^$RR6TGDW
M%AH7B_3/%^KP2;6?9+HGA&77-8C(53G?8@ M&IPTL8?^#"V_;]^!FKW*:W\5
MO@=^T%\6?$\D_G:AJ5]^U?X<T"VOV:)%F-Q_:?[-WCK7I#-*F\LOB*&546*-
MII3&7?Z.\&?\%8OV&O!,EG=6O_!*+3/$%_:"#=>>,_VPO%WBR.[D@VD2WFBZ
MQ\%[CPU(97!>>*/1(K:7<T;0>0%B7T5]'W!9>KXROQ?Q%)_\N\AP/"634;JU
MU]:S[BJI7Y&](U/[-YU=<U#H<'_$PG%^;:9?DW /"4/^?O%&><7\08AIOW6L
M%PQP=2P_M()KGH_VO[-O2.*V9_4;XV_X++?L6^%B%T'5?B/\224#!_!O@.[T
MZ)7+LH20_$*^\"RC: )':.&4"-QL\R4-$/R,_8%\!_#+]O/]KWXL>*/VHKN7
MQ5K&O:+K?Q$TSP<==UC1[7Q'JL^N:=;/90:EIVH6>J-HG@O0[B"VTCPW8:C;
ML-)@L]@;1="O;1_&?!/_  <??![X:DM\.O\ @E_\-_ ;E#&TG@WXT>&?#,KH
M761A)+HW[,UE))ND19'+LQ>11(Q+C=7P_P#\$G/V?_BI^VOJ/CWX=^!O&GA_
MP9XE^"_ASP]XGT37-?GUZT%WIFI:U/I:V0U/0[?4;^PO='98FTV:WL722T"V
MKM;-;K/-]_PIPKE/"'#?'?-@<]\+IX[+,NP6&XWS3B'*^(\SA"IBJOM/9T>'
M*.&65THUGA(8F5*M">(5>G4IUJ$L&JL?RGQ!S3C'C7B3PXQE?&<+>,E')L\S
M#,<9X:9+PSFG"N35TL%2C&53$\58W'O.J_L5B9X2EB</.&&=.M"=#%4\=*A+
M] O^"B7PW^&W[%G[5=K%^SAXYUWX96EEX#T_Q5K+>&_%7B$ZS\*+W6H=>TG6
M["U\1P:I/XI@@U/PE''KD^G76IRZE_9GB"6 .^DZA80#]K/A/_P1X_9F\(W@
M\1?%K4_&W[0'C&YD%WJFH>,M9N]$\/7>J^?Y\FI1Z%H%Y%JUP\[<75MXE\5^
M)[6Y!?SHW#D5_)5_P5?^"'Q-_8P\;>$?@EXT\6>'_%FO?$SX?1_$?7O$/AZ?
M6[B*.QNO%_B3P]#HZWNM6NG7UW/<OX8>^U.\FLXQ+'>_V>J/''-<W/ZH_P#$
M5(/^C$Q_XD^/_H>:?'4/$+-.%.!\/X9\1YCQ'%93B\)Q%Q5A<9@<DS'.UAYX
M2&7U9X[,<5A<U=%5'F?+&EC*OM')U<54K5*D*]4\*\@\.LNXL\0<V\7."LGX
M6GB<_P +F'"? F,PN,S_ "CAFGB*6)EF,89;EV&Q.2+%5H1RKGE6R^DZ$*-.
ME@Z6%I1GA:/]77@KX?\ @3X;:*GASX>>"_"O@70(Y#,NB^$/#^E>'-+\]@ ]
MPUCI%I:6[W$@ \VX>-II3\TCLQ)KKZ_D6_XBI!_T8F/_ !)\?_0\T?\ $5&/
M^C$Q_P")/C_Z'FOYTK>"_BKB*M2OB.':E>M5DYU:U;/<@JU:DWO.I4GF\ISD
M^LI-M]6?USA_&'PLPE"EAL+GU'#8:A!4Z.'P^19Y1H4:<=(PI4J>41ITX16B
MC"*BNB/VD^(/_!:'_@FE\+/'OC?X8^//VD_["\<?#GQ?XE\!^,]$_P"%._'W
M4_[&\5^$-9O?#_B+2O[2T;X6:CI&H_V=J^GWEI]NTK4+[3;OR?M%C>7-K)%,
M_(?\/W?^"4__ $=/_P"8/_:._P#G05_*G_P3O^&_P9_X*7?\%3_BC=_'GX=7
M4OP_^.&L_M$?'2X\ 6GC3Q!:3>']5\2^([_QKIFDCQ=X9;PEJFJKH,NN/8M>
MI:Z5!JP@^TS:5:B06L7T+_P7F_X)]?LJ_L/Z#^S)??LV_#[4/ ]S\2-7^+-K
MXO>^\;>-?%PU*#PM9_#V;1$C3Q=KVM)8&UDU_5"[6"V[7/VA1<&40PB/] 7A
M9X;X;BC)>"<QQ7'-/B/-<LI8Z;H8GA^65T*GU3%8FO2E7> E73A+!8B$%"C7
MBW[->UDI.:^#_P"(H>(N)X8SGC3+\+P34X>RO,JN"C&OA\^CF=:'UO"8:A5C
M06/C0:FL=AYR<ZU"22J_NHN,82_MT\$^,_#/Q&\&>$?B%X*U6+7?!OCSPQH'
MC/PEK<,%W:PZSX9\4:5::YH.JQ6U_;VE];Q:CI5]:7<<%[:VUW$LPCN;>&97
MC7IZ_C ^ W_!RG_PI'X&_!CX+_\ #%W_  D__"HOA/\ #KX8?\))_P -&?V+
M_P )#_P@/A#1_"G]N?V/_P *)U;^R?[6_LG[?_9G]JZG]@^T?9?[0O/*^TR>
MK_\ $5%_U8E_YL]_^3S7P6*\#_$B&*Q,,)PY*KA8UZT<-5GG/#ZG4P\:DE1J
M33S.FU*=-1E).$&FVG".R^[POC7X=SPV'GBN(8TL5*A1EB:4,GS^4*=>5.+K
M4X26633C"HY1BU.::2:E+=_UT45_(Y#_ ,'4,+2H+C]A:6* MB22']IE+B5%
M]4AD^ %LDC9Q\K3Q#ONXP=7_ (BF_#O_ $9/K7_B0%C_ /.=KF?@GXGQWX8E
M\LWR"7_I.:LZ%XS^&CVXEC\\HSV/YY6OZ]&?U>:SK&F>'M(U77]:O8=-T;0]
M-OM8U;4;EBMO8:9IEK+>W][<, Q6&UM8)9Y6"DA(V(!/%?E1_P /T/\ @E;_
M -'5VG_AGOV@/_G4U^-'Q&_X.</#_CSX>^._ R?L:ZQIC^,_!OBCPHFI/\>+
M*[73W\1:)?:.M\UH/A';&Z6T-X+AK<7$!F$9C$T1;>OPA_P1,_X)J?L^_P#!
M0_\ X:9_X7MK'Q.TG_A4'_"F?^$6_P"%<^(]!T#[1_PL#_A:_P#;G]L_VWX3
M\4?:_*_X0G2/[.^R_8?(\R^\[[3YT7V?ZC*?"'#Y-D&?<0>*%'/LCPN5U,M6
M$CDV,R7%5<13QF)6#JRG"$,R3=/$5\)%)SH-0G4E:K:T?F<V\6L1G&>Y%D/A
ME5R/.\5F=/,7BI9Q@\YPM.A4P>'^MTHPJ3GEME/#T<7)VA7O.$(WIM^]_5#X
M9_X+6_\ !,3QAXD\/^$O#_[46GWFO>*=;TKP[HEI/\+/CCID%UJ^MW]OIFFV
MTVI:K\,K+2]/BGO;J&*2^U*]M+"T1C/>75O;QR2I^IU?YVG_  4__92^#O\
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M)/VNO_""^#7_ ,_RC_B%7B)_T26;?^"Z7_RWS_/LP_XBCX??]%7E7_@RK_\
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MPK^RQM2HZ"Y*-&BH*5%4Y.$XN<9N2<FE9?6>'O%6<\3X?/XY[@L!@<PR+/\
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MQM0O],\,^7X*\!S^,_&6N_V/<^+=5D?^P]!N_P"S-/O]3U;4OL^E65Y>6O\
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MIFCB(PZ=";LI%'(X6- 2#]>44 ?Q%_\ !2;XJ?LZ?%__ (*A?MC?"^U^!/[
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M>2"%HX-!_8;_ &*/"O\ PB'_  C'['O[+7AS_A7WCV7XJ^ ?[!_9^^$VC_\
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M4FE-XNM?#+W%_?3OH,&KQZ6TU[=RFU+W,S/XG/\ L!_L,7?B+XC>++S]C?\
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M'QMK?_!+#X__ +>/[-WP _9.\.>#--\/:)XC^)OP&^&OCO4P=:^)FK:_X?\
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M2M+G^S;FVN;/1-7\,7<FEVGBBXUW20#\W?\ @COX?T/]DC_@LY_P5C_X)_\
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M$265J)/!]_86T_\ 0%^U9^R/_P %A_#/[7OQ9^/W[ '[5OPK\1?"+XZ_"A?
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M8:;:J]WJ%X8+*UCDN)XT8 ]'HK\'/V=_^#@;]EKXV_#CXI_'_P >?!G]I?\
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M?B/2+/6+6TU&*":X@BOK:"\2&[CAGGB2X218YI$ =@#JJ*** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M*_*S_@M]_P HFOVZ_P#LAVJ_^GG1*_5.OE;]M_\ 9E_X;*_9-^.O[+O_  FW
M_"N/^%U>!KKP9_PG/_"-_P#"8?\ "-?:;VRO/[2_X1G^W_"_]L[/L?E_8_\
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M^+?@_P"+_&_A33?B0OC+Q3XH\5^#?'.K>-/'TEO%I%C+XT_X37P;9>)I+O\
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MC?M&?%C]I_\ 9W\9?L[Z)I7A[1=8\%_ #X2:=XN\$:CX"N_'<?P4T'Q7X7\
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M2T3P_/XDTF\A\7:KXOT[P]X>\*ZYXTG\)Z+#H\X!_/-X7_;F_:L_;/\ A_\
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M?"VGV%N+:YOK"P_HN_9!_P""'EA^SS\.?VY-1^*W[3GBK]HC]K;]O3X4>/\
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M_9KV]O/[2_X1G^W_ !1_8V_[9Y?V/_A(-5V^7O\ M3;]J_5- !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% %'5-+TS6],U'1=:TZQU?1]7L;O2]6TG5+2WO],U33+^WDM+_3M1L+N.
M6UO;&]M99;:[M+F*6WN;>62&:-XW93B>$? W@GX?Z;+HO@/P=X6\$Z//>2:A
M/I/A'P]I/AO39K^:*&":^EL-&M+*UDO)8+:WADN7B,SQ00QLY2) I10!U-%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
<% !1110 4444 %%%% !1110 4444 %%%% '_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>35
<FILENAME>nt10014672x1_linechart8.jpg
<TEXT>
begin 644 nt10014672x1_linechart8.jpg
M_]C_X  02D9)1@ ! 0$ P #   #_[0 V4&AO=&]S:&]P(#,N,  X0DE- ^T*
M4F5S;VQU=&EO;@     0 ,     !  $ P     $  ?_B"^!)0T-?4%)/1DE,
M10 ! 0  "]!N;VYE @   &UN=')21T(@6%E:( ?4  < %0 3  L (6%C<W
M         $E%0R!S4D="     0            #VU@ !     -,M2% @(
M
M$&1E<V,   %$    =&)865H   &X    %&)44D,   ',   (#&1M9&0   G8
M    B&=865H   I@    %&=44D,   ',   (#&QU;6D   IT    %&UE87,
M  J(    )&)K<'0   JL    %')865H   K     %')44D,   ',   (#'1E
M8V@   K4    #'9U960   K@    AW=T<'0   MH    %&-P<G0   M\
M*&-H860   ND    +&1E<V,         &G-21T(@245#-C$Y-C8M,BTQ('=I
M=&A"4$,
M                                                    6%E:(
M     "2@   /A   ML]C=7)V        !      %  H #P 4 !D '@ C "@
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M;W5R(%-P86-E("T@<U)'0@
M
M      !865H@        8ID  +>%   8VEA96B            !0
M;65A<P         !                               "6%E:(
M  ,6   #,P   J1865H@        ;Z(  #CU   #D'-I9R      0U)4(&1E
M<V,         +5)E9F5R96YC92!6:65W:6YG($-O;F1I=&EO;B!I;B!)14,@
M-C$Y-C8M,BTQ
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MU=;7V-G:X>+CY.7FY^CIZO'R\_3U]O?X^?K_Q  ? 0 # 0$! 0$! 0$!
M     0(#! 4&!P@)"@O_Q "U$0 " 0($! ,$!P4$!  ! G<  0(#$00%(3$&
M$D%1!V%Q$R(R@0@40I&AL<$)(S-2\!5B<M$*%B0TX27Q%Q@9&B8G*"DJ-38W
M.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U=G=X>7J"@X2%AH>(B8J2
MDY25EI>8F9JBHZ2EIJ>HJ:JRL[2UMK>XN;K"P\3%QL?(R<K2T]35UM?8V=KB
MX^3EYN?HZ>KR\_3U]O?X^?K_V@ , P$  A$#$0 _ /[^**** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M@^+KS7_"'B7PKJ,#:?H/B+7K&..349(I5U.2**UFNWMP #OOV$O^"[W["/\
MP4 ^+K? ;X:77Q9^%_Q=U#3&UOP-X)^.W@C2_!U]\4=&M])U'Q!J.H> -0\,
M^*_&^AWYTWP_I_\ PD$NF:UJF@ZWJ&AW']JZ%IFK66FZ]-I&=^W/_P %]/V
M_P!@/XTM^S_\4M1^*WQ"^)^D6UG>?$'1O@MX*TCQ7:?"BWU6RTW4=$'C_5?$
M?BWP9I\%YK-CJUA=6VD^&9_$VL64-U9OK6GZ4NH::;S\L_V5;KQ/_P %I/\
M@L/\-O\ @HK\/OAC?_#3]@O]@;PUK'PN^$_COQ!I#:'KWQ[\9Z:GC-M$CTF*
M$:=J-A8:=K'CM?%MQH9?5=)\)>&O#^EZ#KMKIWB7XAZI86GS-^PGI6E^*O$O
M_!W;JWCK2M,O?$*6W[0^E7$^IQ1R7FF:7>7_ .WC<ZWI5G=7$DMW8Z9#?>'/
M#;O%!<B.VET'0Y%D633K*2, _J*^//\ P5'_ &)_V>?V0_"O[</C+XOVFM?
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M6W:>5(=I /WCHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M7]!]?SX?LF?\K$/_  5>_P"S:/V1O_4!^'] ']!]%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M[(G_  3N_P"%#_\ "9_\-5>&=&\1?\+@_P"%H?\ "._\('_:_B;Q]X<^Q_\
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M6?$.K^)-.U33]3TK6+BV\,0ZY:WNA0:GI.J@']M7[07Q5_X43\!/C?\ &_\
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MP9\,/$_@7_@M;\./V0/V'/$\VO\ @;QYJG[/?AKQC\3OVC?BO\4=(O8)]?\
M"-A)\.[1_&W@7P5H7A#6O#,^JZE:HEFQ\403^*=*U30]5\/--S'P%_X-F_\
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MK>YU?Q'J'AWP]X2\/O-I^@Z1X>\+:7%I'AK2((M"\.Z4MW%>:J=1U6_^VZ*
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MM=3F\*+JFCR:YIOBA_#%_=:,-"N_WRHH _F-_8L_X)@_\%&_&W_!1#X+?\%
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M_A;5)[.\L!XAAU'2]:M-- /TAHK^86R_X.OOV +OP^OC&7]G;]OO3_ QU9]
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M'[!OA;QOX2^$'B/XD^(]-\>Z_I_B/6)_B1K'AC6+ZVOM-TYM,@BTV3PQX/\
M!\$-J\#%YDNK:\F:;#)/&G[NOMJO/KQHPJSCAZLJ]%-<E6=/V,IJR;;I\\^6
MTKJW.[I7ZV/C,WH99ALQQ5#)\PKYKEM.4%A<?B<"\MKXF#I0E.53!/$8IX=P
MJNI34?K%3FC!5+KGY8E<7\1/B-X%^$G@GQ%\1_B7XJT7P3X&\)Z>VI^(?$WB
M"]CL=,TVU$D=O$'E<EY[N]NY[?3],T^U2?4-5U.ZM-,TVUNM0N[:VEXSX_\
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M=K_PC^CF/2XHM'L=.L7M+73=.$<-C;VT*0PV\<<<,,2QHH'X!?\ !!K]J?\
M9Z^"_P"S]\1/AY\4_BQX5\$>-O%W[0$U[X:\.:U<746HZQ:ZIX)\ :'I\]FD
M-K-&R7>K6ES81%Y$)GA<$!0&/IPXIP-/+<VJ1Q.4X2IDD\MP="56OAI8K+89
MD\3"%*KB*T_:TJV(C3<J/-[/GDY^RAR)0C_0>1<0\78[@'B+..'^")827#M+
M),J\.L?#AW%9OG6!R/,Y9W@\]JY9GU?#U<7C*V&A2A6Q6+P4J>&P6(Q%6*H4
M,+.CAJ?]0MI:6EA:VUA86UO96-E;PVEG9VD,=M:VEI;1K#;VUM;PJD,%O!"B
M10PQ(D<4:*B*JJ /.OC!\9/AK\ _ &L?%'XN>*(/!O@/0)M+M]7\07.GZOJ<
M-G-K6J6FC:8C66A:?JFIRFZU._M+53!92K&TPDF,<*R2+Z;7F7Q@^#?PU^/G
M@#6/A=\7/"\'C+P'K\VEW&K^'[G4-7TR&\FT75+36=,=KW0M0TO4XC:ZG86E
MTH@O8ED:$1S"2%I(V^5QGUOZKB?J'U?Z]["K]4^N>U^J_6>27L?K/L?WWL/:
M<OM?9?O.3FY/>L?R]E3RMYKE[SYYB\F>.PSS=Y4\.\U>7.O!XYY>\9_LKQSP
M_M/JSQ7[CV_)[;W.8^+O^'N/_!.W_HY31?\ PA?BM_\ ,)7VO\(_BY\.OCM\
M/?#_ ,5?A/XE@\7^ /%7]K?V!XBM['5=,AU'^P];U+PYJNRRUNPTS5(/LFM:
M/J5BWVJQ@\Q[9IH/-MY(9I/Y;_\ AC?]FK_A]/\ \,N_\*OL?^%#_P#"+_VA
M_P *^_M_Q=]C^V?\,]_\)GYW]L_\)!_PDV?^$F_XFFS^VO+\S_1]GV/_ $>O
MZD/A'\(_AU\"?A[X?^%7PG\-0>$/ 'A7^UO[ \.V]]JNIPZ=_;FMZEXCU79>
MZW?ZGJD_VO6M8U*^;[5?3^6]RT,'E6\<,,?Q/!V=<4YSBLW_ +9IY!3P64YA
MC\EG_9D<QCBJF9X&IA'*I'ZU4J4I8"5*M5M)^SQ#J*G>G&*E?]E\7>#O#'@_
M+.$O]4,1QYB,YXIR#(>,:7^LD^'YY90X:SS#9DZ>'J?V9A\/BH9Y3Q>&PW/"
M/M\!'#RK\N(JU'3MZ/1117WQ^$A1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% 'YN_'SQO\ \%3-(^+/BS3OV<?@Q^RSXL^#-O\ V%_PAOB#
MXC^*O%6F^,]0\[PUHT_B'^V;+3?%FF64/V7Q5+KEEIWDV,'F:5;6,LGFRR23
M2?@S^W#KG[1OQ/\ VV?V,OA]_P %2]%\%_"#X#W&LV\MG!\(;K4+_P"&^K6>
MI:_!:^)KO6?$6K>)[BZM;^\O[?PGX8\<:B^L6LW@'P-?V_B?2]*$U_)+KO\
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M^)\VE^"=<\)MXQ\1Z;K>E>#]%TK1_#FF7%[-Y<VF:581QZ=8PV\5NG[*0_\
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MXN6O]L?\+$_X3W2O^$9^S?\ "T]_]G_\(+X@\[^PMOVZ+^U-VG'P+_X)F?\
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M\-/J*>'/#=YX@U2P:#1O' FN=.@19-2+BUN?] >OE;]F']B;]F+]C7_A:?\
MPS;\,_\ A7'_  NKQS/\2/B;_P 5G\0?&'_"2^-+K[3Y^L_\5YXK\4?V-O\
MMES_ ,2[P_\ V5I*^9\EBNR/: >R_%_7+WPQ\)OB?XDTWQKX*^&VH^'_ (>>
M--:T_P"(GQ)\K_A7?@*_TOPWJ5[9^,_'OG:GHD)\&>%[F"+6_% EUG28SHEC
M?!]3L%)NHO\ -]^//_!0;]J+X*Z;I?[37P,_X*_?ME?M9?&K1/CO<0?$J3P[
M\-_BWX<_X)XZ99ZH?$-_X=\)Z=IWQ+O_  OX0N=<U73M#CO$\ P?!.Q\(WUA
M<>)(_"EVEEX.L/$_BW_10_:?^ GAW]J7]G7XV_LY>+-6U?0/#OQL^&?B_P"&
MVJ:]H,SQ:OHD/BK1KK2TUBQ59H([N;3)YXKXZ;=R'3M52!],U.*?3KNZ@D_F
M.D_X-NOVL_'_ .R)X=_88^+O_!42V_X9K^#?CC5_&OP%\!^$/V6O#]Q;Z?K^
MK>(==UJY\3^/=5NOB%X?\9:U^X\<?$6'3/! \9:AI6A:IXIM]5A\1:C9Z%8Z
M$P!F?\%</CO^VUK'_!7K_@G=^R[^S3^UE\1?V:]&_:7_ &>_"NE>*/\ A&-6
MUF\\$:5?_$'QA\8_#7BOQZ?AU_:<&B^(_&6@^$HGN?!D^I2VUW:^(]$\+W$>
MOZ--IMMK%A\WZ=IG[<7A']MW_@JA_P $H-5_X*._M+?$;X8:-^PSJ?QL\)?%
MCXI:Y?\ CGXF^'=<TBT^ ?Q5NH-(U:\UZRUGP_;:YH'B_P >?"C6](\/>)].
M\*:MX6\1+J6H^'+F\T_3;"P_=OXJ_P#!(;7OC!^W-^P)^W%XJ_:=@_X2C]BO
MX1_#SX<^)/!]K\%I1;?&?7O!ESXOO]8\8V^OS_%V:?X=0>)=0\77%Q#X>FTK
MX@2Z-':K#)X@UAYC/'VT'_!*#2I_^"F?[2G_  4*UWXV7.I:)^TE^S1<_LVZ
MS\#K+X>C2KSP]I6H>$?ACX0U'Q):?%1O'.H+?W,UI\.YKB#36^'5B+:77$4Z
MC.-+WZB ?RE_L!Z!^T7^SO\ \&]_[;7[9GPS_:[^,GA:+4Y=*\'?#7X4>%M7
MU[PSI/P;\4:/^T?\+-/\3_$;P5XBTWQ7FS\0>.M$U>[T/7?[/\/:1<2:=+-;
MW&IWT,SQ5^W/PU_X+??"?]@'_@F?_P $R_B/^VI!^TI\<?'W[4_P>\;:M#XR
M\#V7@_X@>)=0U3X9ZMX8B\1ZAX\UGXD_%'P'?2WE_'X_T"/2;BUFUR6Y2QU)
M;YM/%M9B]Y[X$?\ !OC^T5\,/V./VL_V!_%/_!0^U\1_LW_'.QTY?AGHD/[/
MCS3?#?Q;#\2_A9\0=7^(ES87'Q8L;B>?6['X=3^%;GP);^)KC0[2XUF3QGI>
MLZ?J-QX@T?Q!^[/[&/[)>C?LF_LF_ 3]EW5_$&F?%O\ X49X&A\&6_CG4?!E
MKX=_M[R[VZO)=2A\,W.L^+?[!^T>?%')9IX@U3/V=':Z?Y50 _C<_P""JO[<
MFG_M+?ML?\$./VY_V8?@S\1/B.GB5I?&_P *O@9XMN/#_@?XB^/=?\!?M.R>
M&K3P-=WV@7_Q(T#P]J/BGQ'X4N+'3=0M+GQ+%;6E_97D]H\_G:?%]IP?LL_\
M%)_^"I'_  58_8V_;0_:+_8ATK]@/X%?LG:EX3\9O/K_ ,0?!_C;XD>-+[X;
M>.(?&VF>%]1U'1+7PQXY\1WGB/Q18V=AIEMK7@WPYX.\(^"E\17\5_J.J:O#
M8^+/V+_;,_X)/6G[6?[<'["_[8]A\;K;X76G[%?B70/$,/PKM/A1%XEM_B&-
M$^(NF_$!K*+Q7#\0O"L7@L7CV#::TZ>$_% A>X;4#!,4-I)^P- '\AW_  2^
M_P"5EK_@KO\ ]DT\9?\ JS?@'3D\,>%O@]_P=F^"-#_9ZTNT\,:/\5_V7?$N
MM_M.Z#X-TZ+1=!77=3^%7Q!\1O=:YIFFZ;!IRMK^N>#O@EXNU6Z7RO[5\8:O
M%K=_?W&MZA=PW/TO\3_^""W[1M[^W!^TA^V]^S1_P5'\6_LJ>,/VC=5U"77-
M&\'_ +-=KXGO],\-:C/X?OIO"MSXIN_CUH4>MV9U3PWIFHM=+X;TAWFMH5\A
M1&3)]C?\$VO^"0'A[]A#XO?&_P#:@^)W[1/Q#_:__:S^/=E%H/C#XX_$;18/
M#4UCX5^VZ=JVI:+H6@CQ!XOU""37]5T;0&U6ZU+Q9JEI:Z/X2\(:!X9TOPY8
M:7J(UL _GI_X*F?\$W_@5^PW^W5_P29^(_@'6_B7\0/C#^TW_P %$E\9_&GX
MJ?%3QC>>)?$'B6[M?C)^SYJVB:'I]A%'8Z)HWAWPU<^*-=BT94T^[\236=Y%
M:^(?$VOKI^FM9_W45^5G_!1+_@F9_P -\?&+]A#XL_\ "[/^%4?\,3?''_A<
MW]@?\*W_ .$Z_P"%F?\ %4_"[Q+_ ,(W_:O_  GO@[_A#/\ DFWV+^V/[-\5
M_P#(:^T_V7_Q+O(O_P!4Z "BBB@ HHHH **** "OX*/V!OV_O^"C7P4/[4'A
MG_@EO_P3F\0?M _L(:G^U+\6/$WPDO/&_AOQ-+KO@^_UF^L1K?ANV\:>%;WP
MIH^KZ0B6=EJ5GX;N]+UWQ!X+M=2LM U;QAK3VJ7=U_>J64,$+*'9694)&YE0
MJ'8+G)52Z!B!A2Z@D%AG^,3X5_L]_P#!R[^R?XV_:!TO]EKX7?LXZ#\%/BE\
M=OB1\7="^'VJ^(O@I?>%O#VI>--:\Z]U;PE8W_C&'7_"]MXBM;*PU*^\++JI
M\.:;J4][)H^A:.US/$0#]Q?^"7W[7'_!17]IW5OC+:?MV?L21?LB:?X-T[P-
M<?#6]BA\21?\)W>ZY<^*HO%5J?[?U?4U;_A'H-+T&4?91"1_;!\XR QA/UXK
M\AO^"7^L_P#!8#5-6^,H_P""I/A3X.^&='M]-\#M\&7^%MSX)GEN]1>Y\4_\
M)T-;_P"$1\2Z^Z106J>%38F_6U0M+=_9VF(F$?Z\*RLH92&5@&5E(*LI&001
MP01R".".10 M5+^_L=*L;W5-4O;33=,TVTN;_4=1O[F&SL;"QLX7N+N]O;NX
M>.WM;2UMXY)[FYGDCA@AC>65U1686Z_ '_@YC\#>,?'?_!*3XI6_A;XJ>#_A
MIIWACQYX!\;^.M*\9^*].\(VGQ;\'^%I=7U ?"O0[O5&CMM8\77WBL>%?&?A
M;PO%-%?^)=8\$VVDZ6+C4KFUL[D _9KX2_M%_L^?'T:ZWP)^.WP;^-2^%I;:
M#Q,WPE^)_@GXCCPY/>RWUO9PZZ?!VN:R-(ENY]+U.&VCU#[.\\NG7T<0=[2X
M6-OQ4_:-_9Z^!5[X;TWXW?'CX,_!S4?&3W<7A#3_ (J?%#P1\/;WQ7)IXB-_
M'X;M?%VN:1/KCV0N(#=II<=TUL)HO.">8F[^%C_@D%J7[,7Q@_X+<_LT>-?V
M&_A;JW[!_P +? 7[*.I-\5O@S\5/BYJU]XU_:&\7:Q\,/&B:E'\/M*\3ZYXA
MOOB#I-U_PD'@+QK]GA:QM=2\(_"N]^,TNB>&_$DJ(FKH7[.?PL_X*;_'C_@Y
M4_:$_:LM?$'Q#\??LA:/\2] _9@O[GQ+XAT.S^%EEX('[45K\.Y[71/#>LZ7
MINI'PKIOP'\%6ATC5!?:#JSWWBN\U:QO=2\0WNH, ?WM^)_%'AGP3X=UKQ?X
MS\1:%X1\)^&]-N]9\1>*/$^KZ?H'AW0-'L(6N+[5=:UK5;BTTW2M-LH$>>[O
MKZY@M;:%&EFE1%+#D_A7\9?A!\=/##>-O@C\5OAM\8_!BZC-I#>+OA7XY\+_
M !"\,+JUO:V5]<:8VO\ A+5-7TH:C!9:EIUY-9&[%S%:W]E</$L-U \G^=^W
MQZ\=?M=_L._\&^/[#OQ/\:^-=3^$WQA_;*\=?!3XYV9U66UOO&O@[P7^T1\'
M?A]\*]+378;R75'L? 'PV^+^N:!HMI.+>TL[G3_#]ZEI/=^'-)OH?UV_X)V^
M O 7[!/_  <@_M@?L3_L\6&M>"?V;/B!^SCX;\0:1\*XO$'B'Q#H.B^,+#X?
M?!OXE6NLW%[XJU[5M9O9M,GUGXE6NC7M[>:C=:;8^-+C0[>--.1)K8 _L3K^
M?#]DS_E8A_X*O?\ 9M'[(W_J _#^OHO]M'_@N7^P5^P1\<+_ /9[_:$\0?$[
M3OB-IWASP]XJN;;PK\-]1\3Z2-)\3V\USI3IJMK>01/.\4$AG@$8:%@%8G-?
MFW_P2._:U^#W[</_  6E_P""EW[2?P'O=?U#X8^./V=/V;;'0;KQ-H<_AS69
M+CPCH_A7PCK(N=(N99IK94UC1;Y+=FD83VZQSKA9   ?U44444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110!_%]_P43M/A6W_!SC^QHG[<.G>&
M-4_9DUOX&:#I'PZMOBMI^F:I\)[C6KW0?C-IWA*RUNTU"";1)HO^%]WEJUPG
MB&*:*UU:]\.WFO>3X9-C-'^B/_!S_:_LVP_\$N/'=U\7M/\ !S?%>'Q;X TO
M]EVYU"T@/C.R^(%UXV\,7'BVV\$7$2K>VEC+\+M.\6R^+H3(FB3Z-9PK>QRZ
MO'X=2OGG_@MU\-_!O_!47]O+]B+_ ()4^ -$L[SQ[\/;_7_VBOVFOCAIBR7&
MN_L[?L_ZKI>FV.K^$;&XA@U;3;'7OB?:PZ!?QV7B723:1>*W^ QED71_%>H7
M%O\ CQ_P09_X)'_LT_ML?'_]KB__ &H-6^(?Q.\-?L3?%_PGX,\#_#N?7X-.
M\%^/H]0UKXH6$LWQ'MULKK6[W2HQ\/=(N1X>\.:YX<L;V66>UUJ75=(:32Y@
M#^QC_@CQ;?$VT_X)<_L)V_Q<=7\8Q_LX?#SR0(3;RP^!WTL2?"NUO(FEFD74
MK/X7-X.M-4,S)</J,-U)<P6T[26\7Z2U'%%%;Q10011PP0QI%##$BQQ111J$
MCBBC0*D<<:*$1$ 55 50  *DH *_GQ_X*V?\G_?\$?O^SBM)_P#5T_ "OZ#J
M_G-_X*T>,O"$O[?O_!*+RO%7AN3_ (0[]HC37\7>7KFF/_PBR0_&/X$7,K^(
M]MT?[#6*WM+J>1M3^RA(;:XE8A(9&7V^'TWF4;)O_9<?LK[X+$)?>VEZZ'ZK
MX,TYSXZP[A"<U'(>,.9QBY<O-PGG4(WLG;FG*,8WWDU%:M(_HRKY?_:P_:Y^
M$'['?PVD^(/Q4U6=[S4IY=)\">!-$B^W^-/B-XJ,)DM/#?A72(]TLTTTK01W
MNJ7(ATG2%N;>34;N%[FTAN?+OVN_V_OA/^R]X0\,-HD;?&SXQ?%4I8_ SX+?
M#F]&M^(_B=JMUJ":1:36]WHMKK:Z9X<&J2&TEUHVEY)>W-O=Z;H-AK.JV\UE
M'XE^R;^PQX]U+XEQ_MI?MY:MIOQ-_:PUB&*7P;X+@%O>?#3]F704N;N[TCP?
M\/["*ZO]+NM?T=+MFN/$4,U]'IVJRWUSI>JZ]K=QJOCSQ-S8?"4X4UC,?ST\
M-=JE0BU'$8V<79PI*2_=T8O2MB9)Q@[PIJI5]V/AY-PU@\)@8<2\8/$8/(_:
M5:>6971:H9QQ3B\/+DJX;+E4C)X/+,-57L\TSRM2G0PTN;"8.GB\P;H4N#^
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M^"=/QA\1_';7/AD=:\+:3H/B;6/BM\2?#OQE\0:=IVOZOJNAZ5XCU'X5>+/
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M_#*.Z\:Z3?\ ABVN;V]U_4K%?"VDW>KZKX'\/>(_BCX T36[R36ORQ_X(/\
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M?@C_ ,&]O_)JOQ@_[."U3_U7/P[KZQ_:O_X*T?LP_L@?%>X^#7C[1OBOXO\
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MK571K8FI".#QJPT,+*]3%3K8:HZ6'I5Y1I3G!1/SB_X;D_9K_P"'R'_#7/\
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MU/LW_"+_ &W^V/[2T[SOMWV;^RXOLWGW'ZIT44 %%%% !1110 4444 %%%%
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M$=[X0\+6NK>);37M?U#1[@E8M?M4^+?B^RU+0K/1M'\*W%N ?TN?\$^/V,/
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M[)ME??\ !03]KOQ1^WYXOLKJ3]GGX&7?B#X1_L2>'M6M]2@M-;U"VG^P^/\
MX\#3KZ*QB>XU6YCFL-'GGT^62VN9(-&O1!XB^%MG?2=C_P %&_B/XQ^.OCKX
M=_\ !,_X#ZU<:?X[^/=M_P )'^T5XRTK[1.?A)^S3ITX/B5]1DM=D-KJ?C[8
M=&M+"_NHH-4TZ2+POJ<$4'Q$T6^'ZB_"_P"&O@SX.?#SP9\+/AYHUOX?\$^
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 5_*%X[_P"#D_1/!OC?QEX/;_@E=^TO
MKI\*^*O$7AIM:LK:T-EK!T/5[S2SJEIGX>S$VNH&U-W!F67,4R9D?[Q_5?\
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M  56_P"3[O\ @DK_ -G!:5_ZN/X#U^]U?@C_ ,%5O^3[O^"2O_9P6E?^KC^
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M[^#W_9BO#W\LV"BBBOO3\*"BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MZGK^BZ==!%D-M?:I8VEP$?)1S#<3QR!' )5BN&P<$U^ '[']]8ZE_P '#/\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M7HRE3G"I%5(1<H3C-)QDFRBBBMSB"BBB@ HHHH **** "BBB@ HHHH ****
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M>:9J5E."8;RPO[>2UO+68*5)BN+>62&0!@2CD @\U\2?\.R_V"?^C7?AC_X
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M53'U9TL!EN&P%/ZU/!/$TDYX>I&K3I1QN,A*$Y8V6&RNA.%'ZY_:'\+^I_\
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M;65A:_BA_P %Y-%^&OAF;]GSX]Z%XT\&Z-^TA\._%6FV&F>#;YM.U3Q!XN\
MI?7WB;2=5OO#<\5\]UH7@SQ=I=R(#J]E;^'-0A\6>(M.O+NZO6L--N/J>?\
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MF.VTWX>W/@BV\266G^%]>\4>,/ _BSXA65CX?U6QT'1=;UVR\4W.HV_Y:?\
M!'_2?!'PS_X+)_$7X?\ _!,GX[_'OXJ?\$]_AG\#M=O?VQ=8^-/B%+[1O$WQ
M(M-,\6Z;IFN>$M#;P[X);5=1C^(MOX8GT;Q3'X+CUV2!?BS#HU^_@/6K/[8
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M#;3XE?$SP;XIMFU);&UL;.#5VTWP-K]]H.FQ:5H=KXLU/Q7J^A:/'_;FK2@
M_JMHK^5W_@[.^+B>$/V(/V?OA59^+;KPIJWQ;_:G\.WFH36%SJ45Y-X"\!>!
M/&TWB:Z-KI9%U?V>E>(_%'@.]N+9?.9IQ9K#:S7+PR6_@?\ P;W^%_\ @E5'
M^UQ\2->_9'_:&_;?U3]H'0?A1XU\(ZC\$?VQ-/\  >AG4_ LOBWP1/K_ (U\
M,P^!M%N=,NM0T?5])T2R.E7WBRS\3V5CJ6H75YX1%I;W-[8 ']CU%?'/_!0#
M]KFT_80_9!^,_P"UE?\ @2Y^)EI\']-\+ZC-X&M/$47A.XU\>)?'?A;P0L,7
MB";1O$,6FFSD\3+J3.VCWOGI9M:A8C.)XOP@D_X.>M(\+6?[/_Q;^+W_  3T
M_:%^%7['_P >VMM'T;]I35_%6FZAN\5Z9X>TBX^(-OX0^'J>#;$^._"'@[Q9
M?ZCHMAXLM_&>B7_C+P]H>H^(]#\*C6K34?!6G ']4M%?@[^R9_P6^;X[_MR:
M1^PM\>OV)?CU^QC\1?B;X.UKXA? "?XS7:'5_B9X.TW1];\46%[X@\*-X7T%
M_ VH:MX9\*^,+@6]AKGCC1[#Q%X3UWP9=>(!XALWMJ^?C_P<>6/B[Q=\8?%W
MP'_X)\?M._'C]B;X%:SXE\/?$3]L_P %"\G\*:5>>&=)&H7OB%?!NF^!M=@/
M@.TCFL?$FNZS<>.K;Q3X6^&.I:=X^U_P-9/>6_AR0 _IA=TC1Y)'6..-6>21
MV"(B("S.[,0JJJ@EF)  !)( J"SO;/4;:.\T^[M;ZSFW^3=6=Q%=6TOER-%)
MY<\#O$^R5'C?:QVR(R-AE('\T_QW_P""O6G_ +3?_! ;]K;]M[1?AI>?!J_\
M9>&_B#^S?X;\&77C>'Q;JMMKWQ"UW1_@M'K^G>(;;P]X4\V\TZU\=WGBJ&UA
MTI);.'0IY3/,L;.OY3K\/? __!/W_@J=_P $$?"'Q3U71/A9X;^!7_!-O4/$
MWQCUOQ)J$&FZ'X5\5ZEX/_:X\>?%[4M2OKADCA@'CW7O%%R!\TLLDR00I+/)
M'&X!_=S17X3? 7_@N#X;^+?[//[3_P"W/XW_ &8_B!\%_P!@3X IJ\'@?X^>
M*O%MC>^//VB=:M_%MCX.T/1OAE\&O^$7TJUA.M:]J%AX9GUK5_B9%X;TSQUJ
M^F>#DUC4;K3_ !S>^"/B#Q9_P<U>.OAG\"[?]H3XN?\ !*G]I3X8?#3X@W'A
MN3]G3QQXI\8WEE\._C3I>N"2_9G\=77P>M+#P?K=[X62;QKX(TV.R\4Z1\0/
M"NF:]JVB^)8K?3[1]4 /ZN**X#P!X^M/&_PM\$_%&>S;0K#Q=X \-^/IK"6X
M-^VCVFO^';+Q#)9R745M UZVGPW;0O<16D)N3"9$MHRXB'\M/[3O_!R3\#=&
M_;G_ &./#7[./[2_P]\0?L6^(/[2_P"&M?%]]\)/B')JOA?9J-RFG_V;-KGA
M#3/%47F6"VSM_P (WH6L\L2^U]R@ _K5HKP_]G3]I'X)_M:?"3PY\=?V>?'5
MK\2/A1XMN==M/#WB^RTGQ#H=OJ5QX:US4/#6N1)IOBK2-"UN V&MZ5J%@[76
MF0),]N9K9IK9XIG_ "V_;F_X*[_%#]F[]I-/V3?V7_\ @GC^T-^V]\8-&\#R
M_$;QZ/"D^M?#?P/X>\)_V=I&HQ7'ASQ</AK\1QXZO;9==T6RUM=.TK3](TW6
MM<T3PO::WJWB^\N/#MB ?MS17X+_  Y_X+P?"_XI?\$MOCK_ ,%)?"WP(\90
MW_[.7BC2_ ?Q.^ 6O>++/2KZV\;7_B/X<Z1+8Z'\1H_#5]::KH<>E_$K2-8M
MM8N/!VFZA-/9W^DWWA_2YDCNG^.-8_X.<[[PO\-/@]^TQXL_X)I?M"Z%^QK\
M4?$.A^!9/VBY_B!X?CMV^(3:-/?^-?#/P[\)ZEX,TNS^(UKX6U/0?'NB:5X@
MNO&7@K3?%EUX'UA81I%];:KINC ']5]%?QR_\%@O^"G'[8_PB_X*M?L=_!KX
M1_!OX\^+_@IX&U/PC\2="^$/@'4M4T*R_;EUS5-!TSQ-:KHC:=X%N]9UBP^'
M^J:C_84WANZ;QMH5MXL\-+KKZ)IWB"SA-E[C_P $7/&7P \9_P#!5O\ X*L:
MQX$^$/Q\^%_QNU36M:UKXU1_%+XN^!_&_@X:_JGQ>U>[UK1?!O@C0?@3\-?%
M/@E]+\1SWD+6_BCQOXWN8+.%=/N&:\CDOG /ZJ:*_*S_ (+??\HFOVZ_^R':
MK_Z>=$K^&C1/V8O^"7W@G_@D;\+?VU/#/[:.H_"/_@ISX4M=8\3Z!\-_AA\=
M?".K_$*Z^)6E_%[7M*\$6FH?";2KE?B9\-EM?"6CZ3K]GXWTO5O"B^'X[A/%
M%P=>^T:3H]Z ?Z=5%?Y\?_!7GXK_ !Q_:7_X(U?\$9OBE^U$US=?%SXF?$;Q
ME-XNU6;3AHE]XHT!AJ^A^!_&=U:16UI!'J/CCX;VGA;Q=>7EE:6]A?WFMRZE
MIT*6-U;J/K#_ (*/_P#!+?\ X<>^ =&_X*6?\$Q/CM\9/AQJ'PL\<>#/#OQ5
M^#_COQ+:^,O /BSP/XYUG2/#LD-T$M-$O=9T+5/%5OX5LO%'@_Q0OB9-0.HV
MOB3P]K'A'5/!NCF0 _MLHK^;C_@J?\>/^"BG[2_["'A37?V%_ G@OX=_L_\
MQU_87U;]I[]H[]H7Q?XRCM/$OP^^'>J_#&+XE3_!_P"'$&F3S:C>>,?&?@V+
M6= F\0Z1X:\0VZ0ZI!%)JOP^-U:>+(_7?^#9[_E#E^S1_P!C-\?O_5]_$>@#
M]ZJ**_@:_P"#B3XJ_ GQU_P6 ^%'PM_:&^('Q\T/]GWX,?LF63?$W2OV94TS
M5OBW'XWUVX^*GCZPMO#.E>*I8/!-I=W>F:C\,=4\1ZAXB>VLK?P59:C.VIQ7
MG]FI; ']\M%?A)_P;[^'OV'M$_8^\;WG["GQS^-OQJ\!>)OC'J'B#QY!^T,F
MCV?Q2^&_Q!E\#^"M.N?!.K:;HF@:%I<-C'H6FZ+JMG?:1-XCT/4;K4-1_LSQ
M+?FUN[:PV_\ @HA_P6BL?V!/VN_@U^R/%^RG\3?VA_%?QP^$UQX[\%R?"KQ)
M:OXKU+QIJ>J_$'PKX%^'6F> 9?"]_<:M_P )+XQ\'Z1INJ^(K;7TF\.Z)X@O
MM>M_#GB"?P^NBZT ?N!17\P/@S_@XV\=^,M2^-OP-T[_ ():?M/:Q^W5\&-<
MU"/4OV3_  -XF@\>Q_\ "%^'D)\7>-_$WQ+T?X>Q7OA>T\-73:;I)T^T^&GB
M;_A(]:\7> ]/\(W^O#Q'=7&B_=?[./\ P6T_9>^.7_!-_P")O_!2;Q'HOB_X
M9_#KX(:IK?A3XN^ )OL'B?Q;H?C[3IO"D.B>#/#%ZCZ!I/BJ]\<R^/O =IX/
MU&YD\.:9<:EXJM;'7+C0C8:K-9 '[)U3NM0L+%[6.]OK.SDO9TM;*.ZN8;=[
MNZD(5+:U65T:XG=F4)#$'D8L %)(K^5/Q9_P<U>.OAG\"[?]H3XN?\$J?VE/
MAA\-/B#<>&Y/V=/''BGQC>67P[^-.EZX)+]F?QU=?!ZTL/!^MWOA9)O&O@C3
M8[+Q3I'Q \*Z9KVK:+XEBM]/M'U3TW]H_P 5I^W5_P %J/\ @D+\*HM 8>"O
MV>?V;_%7_!17XA:5%J8OET#6/'UA8V?PMM=3DCBMH[C4/!GQ$\&_#J>WN7M+
M9Y;/Q>UQ'!#'>!* /Z:Z*_@E_P"",/\ P4]^%/\ P3A_8 _: GU7PCK_ ,</
MCW\8_P#@H;XF\%_ K]FGX?7T2?$;XGZUJ'P^^#UA<7-I!#I^O:G8:%9375MI
MJZC9^'-<NM2\3:GH/AK2],N[W53)9_TE?MF_\%:[C]@[]G/]G7QM\=_V8?%]
M[^UO^U)K*^%OA/\ L5_"GQS:_$GQ3>^+1=Z,MYX=O_B)IO@^RM;V^T.'Q3X.
MT/68?!?@KQE=7'Q"\6:-X3\(V?BW2)9O&,0!^R%%?SE?"W_@OQXH\2_M:?LM
M?L5_&K_@GI\;OV9OCI^T#K;Z7XI\/_%;QA+IT7@'2[Y[U_"WC+PC/>_#/2/^
M%L^#_$<.FZI8_P!JVJ^#IM+\3Z!XD\/75D[:5%?WW]&M !1110 4444 %%%%
M !1110!^3O[>_P#P3W\?_M<?M@?\$ROVC_"?COP?X5\._L,?%SQ]\1?&_A_Q
M%;ZU-K7C33O%VJ?!N_M+#PK+IMG<6-O>VD?PTU)+AM7FM8&?4;'RG95G*?K%
M17\JGC[_ (.B_!3_ !0^(_@O]FK]@?\ :-_:?\%?#OQ5JGA*;XG>$-1:PTO7
M+S2;R>Q?5-/TC0O WCR:RT357MI+W0)M9U#3]5O])EM;R[T?3)Y9+*  _JKH
MK\B/^"7_ /P5(\7?\%&-6^,NF>)_V,_C%^RBGPGT[P/?V=Y\5+O4[J'QNWC&
MY\4V\]MHHU#P'X,"2Z /#<4M_P"5)J!9-6M=Z6P53/\ KO0 4444 %%%% !1
M110!E:[KNB^%]$UCQ-XEU?3= \.^'M+U#7->UW6;VWTW2-%T;2K26_U/5=4U
M&[DAM+#3M/LH)[N]O+F6*WMK:&2::1(T9A_+I\"OVP/V8_AE_P %N?\ @IK^
MT1XS^-7@C3_@GXY_9_\ V6?#_@CXCZ?J$OB3P]XTUO1/"?@/2-<TKPC+X8M]
M8N?$U]H6H0W$.N6^B6U])HR6EY<:F+6VL[J:'ZM_X+Y_&KXC^#/@A\)?@EX<
M:Z\'?#K]H+QQ/H'Q5^+L\%_-X?T'1/#LNC:A9^#=4?1+#5=9MX=?ENY_%&J1
M:?:#5=8\/>!]6T;2;/7K2\\0Z?!^&7_!Q/\ LJ_LM?L,?L<?LP:!^SE\/KY?
MB!\</&,.A>)_C_)X[\?:S:^)/!G@_P "17.MF:UN/%EY\.],U#XGZSKVA^(#
M+H.D6.GQ:+I&OV.C6=MI%XPA]>.!PE++:>,Q=7$QJXMXF."AAZ5.K33PZC#G
MQ,IU*7*G5E9TX2]IR+FTYD?J67<*\)99PCE'%7&>,XCE+B+%YM3R++>&:66R
M57#Y+*C0Q,LSS',)2IY=4KXVJZ%.-+"XZOAZ$8XN6#KPJ1IO^EA_^"ZW_!)2
M/5?[%?\ ;;^&*:D'>)H&TCXA!$GC<1O;27/_  AOV6.[$I\K[(\ZW)E#1K$7
M5E'VIX*_;&_9;\?_  N?XU^'?CM\.(OA5#K5]X<N?''B?Q!;^!=%L]>TV*UN
M+S2+^3QQ_P ([/87\=K?V%XEM>0023V-]97MN);2[MYI/PGTW_@U4_X)J?\
M#-*_"Z[7XGW?QVNO#J$_M3Q>/_$+^)+;Q;+&EV=0T_X9PZE:?"&X\%IJ.;6#
MP[=^$)?$,OA9OL,GCD>(V7Q<G\87[%?PR^+'[0UAXB^&Z?M"?"OX(>'/ASKH
MT27XC^/?#/Q!\6ZEK-KJL,ME!X;TJY\,^#?'MG9:)H4>E3:C8ZM_8.GZ]IIU
MB%$U*]TZ+3]/TWYZDZU&HJV88I3P5/#S]M1R[*,37QU;$N5.-+V"68U/9T;.
MHZD?JV)FERRYU",V>'D6&X(S.KB,'F*XCRK$5*L:F78JGFG#N)P;HP4W5P68
M/-:7#F'PU2I'EE3S6.82A3E3E1CD^*JUZ7)_>)_P4"_X+K?L@? /]G_XWGX&
M?&BP\>?'ZU^'/CNQ^%<GA?PY<ZSX2TKXDOX<OXO!FL:AXB\2V^D>"O$6DV'B
M"2QO);'0=3\2SZBML;)=,NOM,<4WY<_\&['_  2T_86_:3_8VN?VQ_VC? 7A
MC]JOX[_%WXA_%;0?&C?%NY;QWIOP\?2O$SVDFD3^'-0U&^T^7QYXFM4L/B+J
M/C3Q+92>-!:>,=._LBZT_3KF6\UOYI_9O_X(B?L.ZM=:=XJ^,/\ P4E^"/BK
MQ'%"D%Q'XWME\6I)I5Q!*PM+67XUZM\.-(LIDB\PP'4?A_JEUHUR8XU9;N5&
M?P;P#^Q+^WK\ /VB_CG\/_\ @AS^U_\ %#7_ (,PZ3JWB'Q=!JP_L#PX]W;:
M2UAJ5SINDOIWC?P3XNU*>6SDT?X<>,QX>\->/]2B2#3_  [%?PZ</$>HE#,/
MKU6I&EDF:Y9AJ48NGB,TKY?.>,E)ZN-'"8B=;#J*Y6H8FA2GK)._*G+3C'+.
M%,NIY?'AK.L%F$G*O#'86EC<SS/&4IKV;IU\3CZW"_#V4.,USQAA<JK9K3PZ
MM*6/Q$JDYQ]RTSX1^+/^"67_  <,P_LX_P#!+>QTCQ?9?M$? O5'\1? SQOX
MDCU'PE\.QXG\,>,/B++X8U_6[W7+?6+32OAW+\//"_Q8\/RZMJMMXXF\%ZVG
M@VTU#5T\3)=:_P#T[?#'_@FU_P )EXPTWXV_M\_$>X_:S^,5F#/HGA'5('LO
M@!\-&G:TEFTWP?\ #P0V6G:[ KVJPW-UKVE6>D:W&(KS4_"#:U NK/\ B+_P
M0O\ AC^S/^S=XE^.G[9/[;'[2]WXU_X*!>,=0U'PGXP\2?&'6-8SX8\&ZG/I
MS7*>!KSQ%=7GB#XA^)O$5UH%K:>+?$]_8:=K_A/2M)L? ^D^%O#GAR34M>^(
M7[RZ[_P5F_8KL76T\+>-O&/Q-UF26*"#0/ 'PS\;W6J74LS&-$M3XDT?PSIU
MR6F,,"B'4',DUU D>\F7RN/&Y'@LSQ='$YA"KC*>&A!4<OKU'++8UX5)U%BZ
MF"LJ6(Q2YHQA4Q2K1HJG"5"%*ISSGPY-QOG7#N58K+<AJ83*,1CJE;ZWGV"P
MT*/$E3!5J-*E+*:6<W>+P&6MPJ5*U'+G@ZN,EB*U+'U\5AHX>A0_2.***"*.
M""..&&&-(H88D6.***-0D<<<: )''&@"HB@*J@*H  %>??%CXK^ O@CX \1?
M$WXEZ_:^&_"'ABS-UJ.H7&7EFD=A%9Z;IMHF9]1U;4[EH[/3--M4DN;R[ECA
MB3DE?@6;_@H;\4?%)M!\&_\ @G_^U=XPCOD1[34/B!X=@^$VAW"2PR21RQ:_
M+;>,-)-N[H%$[7*QB-UD8B1XH)?RP_;[\8?M3^,_B/\ !KQG^VQ\$/%_PJ_9
M*MO&FD0K\-_ 7C?PQXO#>6D,_B*YUSQ-X<U)K>?QYJFD2:G#X>&OVWA1X]$@
MU73/"T6GWJ>*=<N?8C'9:)6VNMNR7H?(N>[U;;U;3W?5OYW[L_7#]B;_ (*/
M?#/]K_5_%O@^33T^'7Q!TK6=6NO"GA#5M3BN;OQ?X#B;S=/UG3[@)#;R^(K"
MV$@\4>'K-[LV"1KJEA<WVFO>/IOZ/5_,+_P4*U;]DWQAX@_9OD_8A::]_:3D
M7P/'X,?X#P&RL;?P=;V03P/9>((]/6VU#3/B9HEU:Z3%X>M(X[3Q9H6C07EO
MXW2TMK3PI%!^DNDZW_P6'T3P]X;COO!O[&WC"^33M/BU:6]OO'%EXIEG2TB-
MS<:])IOB30/!T>JRR[TO6\+V;Z,MYYC:=:"P\DEN*T:TOT?3I]W449/5/6UM
M5MK_ )?H^Q^JM?(UW^W#^SI9?M(VG[+5QXVMU^)-W:^4+K-O_P (I!XM>94M
M?AW<Z]]I$47CF\@)FM]):'[.UUY.@F^'B:ZM=$E_.']I?]J;_@JG\)/A!XYU
M_P 8_L^_"OP7H8C71F^*?PYU<^*;WP;#?2RV9\1IHK>./$5U;QS!HDTW6]7T
M6#3]&NY;=M4MC<W-K;CY-TO]C3]C[5?^"=%_^T1?_')7^+LSOXHOOBE/?:JZ
MZ=\35M&F;X$7/@MYFU&>>>[G$$^J?8W\6W^HS0?$6SNI?!#6VA2I1[O=V5M=
M?/T[;C<NRZ7=]-.WKY[']1-%?@O_ ,$\O^"J7AW5_!Z?##]K7X@:+X<\3^&X
M-+L?!?Q,\22:TLWCS2I&O+9K?Q?J4>CW.B66M>'EL[>*[\6:SK>G?\)';WMH
M]Y%=:Y9:WJVH?M]X/\=^"/B'I*Z_X \9>%?'&A.YB36O!_B'2/$VDO(HRT:Z
MEHMY>V;. 02@F+ ')%)IK<::>S^74ZJBOAC]M+]O#X7_ +&VC^'$UZ,^+_'W
MB?5=);3_ (>Z1>PPZTGA :K##XE\5ZA(ZR1:796FG1ZA;^'Q?"+_ (2+Q$D6
MGVG^@V6OZEHWU+\+/BK\/_C5X'T3XC_##Q-8>+?!WB&!I=.U:P,J8DB<Q75C
M?6=S'!?:9J=C.K6]_IFH6]M?6<Z-%<01L "6=K] NKVZGH5%%%(8445Y%\*_
MCU\(/C;<>-[7X5^/-#\:7'PZ\37/A'QA#I,LIDTG6;9I4R%N(H#?:3>26UY'
MI7B#3Q=:#K+V%^-)U*]%E<F, ]=HHHH ***^2OCA^VU^SU^SU\2/AW\+?B7X
MTMM)\3_$&^2%_+\J;3_!6E7,-PNF^(_'=WYJKX=T/5-5CM]*M+RY4A?/GU>[
M6VT+2]4U.T /K6BFHZ2HDD;K)'(JO'(C!T=' 9'1E)5E92&5E)# @@D&G4 %
M%%% !1161HNOZ%XDM)[_ ,/:SI6NV5MJ6JZ-<7FCZA::E:P:OH6HW.D:UI<T
M]G+-%%J&D:K9W>FZE9NRW%C?6T]K<QQSQ.B@&O1110 45XW;_M!?!J[^,]S^
MSW:>/]#N?C#9>'9?%%[X*@EFDOK/3(OL<AAN;M8?[,CUIK*^@U9?#OVTZ^-#
MW:[)IJ:1MO6]DH ***"0 22  ,DG@ #J2>P% !7X@?\ !2CX(?M*^#-/^-_[
M67@?]LSXM>!O ^CVO@6YTOX*>%?$?C[P]I.G%H_!7P_O(M/U#2/B!8Z19MJ6
ML2W?B>X-OX8C\^[OKB&59;J:6^D_4OQO^T]^SC\-GNH/'?QU^$WA>^LXIYIM
M)U3Q]X9AUTI;;Q,(- 74GUJ[E1XWB\BUL)IWG @2-IF5#^!7B?X[>,O^"MW[
M2.F_L\^'O'4'P4_9PTL2^)AX>U2[L;;QG\0K7PU/#+=W:Z?&\T>O^,;B"XFU
M+1_"PNY_#WA32--O?$EXFK:AHCR7M13O?9+>_;1_\$F35K=7M;OTO]Z/J'_@
MG%\"?VF?'6E? []J_P 9_MI?%SQCX*U8>+K_ %;X,>)_$?C_ ,0Z5J<=I<>+
MO \-IJ.H:K\0KS2;T6VI6L&OQ&Y\,R+#<6T,*1K<0I=K^Y%?S5>$OC)X^_X)
M5_M277[,MKXCU+]HCX!^*+BUUK1OA]X;>SUKXH^#YO%\S-I5I9Z1 +:.P\?E
MXX)KSPM%-9:#XWTS4M/\3VEGX>U#Q!&NG_I%:_\ !2'4;Y7>R_85_;QO$1@K
MM:_ J>X5&(R%=HM8<*Q'(!()'/2G)-OI9[6TTO9=NZ%%I:;-;^NB\^NA^F=%
M?F==_P#!1;Q2EM,]A^P%^WG<WBH3;P7?P,U&RMI9,C"S7<-UJ$L"$9S(EE<,
M" /+.<CF?^'D'Q:_Z1R_MF_^&X\2_P#S*U-GV_K3_-%77Y='UM_FC[P_:$^!
MGA+]I/X0>+O@KXYU'Q%I7A;QI_8']J7_ (3N],L?$%O_ ,([XGT7Q99?8+K6
M-(UW3HO-U'0K2&Z^T:5=;[*2YCA\B=XKF'^9:[_83_9[_P"'D.B_L=Z9X]^(
M%Y\-[GP]=S:QK:>)/!TWCFQ\5VOP^UKQ@^AKJD7@Q?#T4L=Q96"36,OAJ6\2
MUGFMVE2[*RP_H+^T[_P4X_:%\*_!CQ!J?A7]CKXY?!75=4$&BVGQ0^+/AG4;
M+P]X-?56:V74H[*YT&&WN?$#$_9] MM:GM-.CU.:WN[NWU:*W_L74?E'PO\
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MW/D01^?=W,]S+NFFD=MRBBI*/YL?^#BSX=:;\0? O[,\7Q)_X)__ !1_:_\
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MFNOL_B+5HD\=:YK%WJ7AB3Q%H7AO0OAGX7TCQ%J6FZ[KFAV][_8%10!^2O\
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M:QZGXB\"RV5B)KVT,:_J#_P6(_X)R^+/V^_^"UO[ _A;QG\)OCIJ_P"RA?\
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ME_M9HH _DC_X+1:1\;?@A_P4!_X)#?ML^'_V;?C?\=OA7\!]-FT?XAZ?\&/
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MZRU_3+K2KJ^\-^*O#]WI^O>&=?M(+N2XT?Q!HE_9:OHVHQVVHZ;=VU[;0S(
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M /P5_P"&&?\ @NG_ -)S?#/_ (KC_9F_^-4?\,,_\%T_^DYOAG_Q7'^S-_\
M&J_>JB@#\%?^&&?^"Z?_ $G-\,_^*X_V9O\ XU1_PPS_ ,%T_P#I.;X9_P#%
M<?[,W_QJOWJHH _!7_AAG_@NG_TG-\,_^*X_V9O_ (U1_P ,,_\ !=/_ *3F
M^&?_ !7'^S-_\:K]ZJ* /P5_X89_X+I_])S?#/\ XKC_ &9O_C5?GAX4U?\
MX+B>*/\ @IQ\2_\ @FVG_!7W1;+4OAS^R[8?M,2?%UOV$OV8)['5K:^\7_#_
M ,*#P>G@H>&(I[*>)_'D=\=<;Q1=1NNF/;_V4INUFM_Z^:_-GPC^P%?^%_\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MT#X;6.A7OCZ7PSMC'BKQ3JE^=?N-5UV)-0OY-+28:,1#ID++*3_3K0 4444
M%%%% !1110!XY^T'\>?AE^R_\$_B7^T%\9-?3PS\,_A/X4U'Q=XKU4HLUS]C
MLE2.UTS2K-I(3J7B#7]3GLM!\.:/%(MSK.O:EINE6N;F\B4_@O\ LI_\'&/@
M[X\_M'?!3X.?&+]B_P".W[+'PR_:PU:_T3]D7X]_$2^EU/PW\:-0?7;#0/#$
M4VE'P7X=TW2HO$6I7]KH<U]X*\8_%'3-"\4ZOX8TW4+YM%UUO$VG>[_\'*$>
MHR?\$9_VM#8N%MX]0_9]DU9/D)ETX?M*_"%410R,V5U-M-F;RRCB.)RS^4)$
M?\$/^"A=V^K_ +/'_!IS;> K_3#XSGT#X#V/A2ZA-I(;7Q'I_AS]B32+L&22
M&>!/L'BZ.SM]5CGCDC^WVQ6[AF:%U !_>'1110 4444 %%%% !1110 5^('_
M  5I_P""Y/[/W_!+K3O#7ABUT+1OVB_VA?$6LPQ7/P%\.?$W3_!VK^#/"0T\
M7]UXP^(6O6OA?Q_/X.BNOM.EP>%M%U3PTNI>+C>W-YI872]'U2_MOV_K^,__
M (.?OV'OV6_@E^QOXJ_:;^'WPET'3_V@OCU^VA\.=2^)OQ<U*6_UWQGJT&H?
M#WXN3W&@:/J&L7=Y'X0\+2MI6CF[\.>$;?0]*U>XT;2=1UVVU75;&"_4 _H"
M_P""B7_!3SX0?\$Z?@+X&^*WC[PKXG^(OQ#^,.J67A3X(_ GP)-;3>-/B3XV
MO]*AU'^S;6>>&26P\-Z1+>:79^(?$UMHVLW-A<:UH=EI_A[6-:UO2=&O?&_^
M"9W_  5_T#]OGXE?&/\ 9R^)W[.7Q,_8Y_:T^"&FVGBGQA\ ?BC=7NJZG)X%
MO#X?M?\ A)+#5=3\(^ =:@N=.U/Q+H<6JZ/KG@O1C_9/B7PAKVAW^NV>M7R:
M'^4__!=.Y.F_M\_\&Y&K:W=6MKX3L?VGM%N;B>\:%+2R-G\9_P!C"YUZZO9)
M% CM1IHT]Y&GD,(BMIF54"S,^O\ !I=3NO\ @[A_:Q;PU/;):6'[)7AUO'Z1
MK;B2XTQO@G^S3%:03,\+R27*:W>>"Y]T,D=PMK!'&TQMHY;9P#^M.BBB@ HH
MHH **** "BBB@#^;W]J3_@X:L?A;\=/VA/@Q^RO^PC^T!^VC8?L@7.NV?[5/
MQ1\&WUWX0\"?"F?PM/>6?BF:*XTWP#\2;^_TSPQJ6C^)])UG5O%5KX!L7O/!
MWBO4=#EUOPIH\OB:3Z"^+W_!>S]CSP!^PI\(/VV_ ^D?$#XJ2?M%>(M6^'WP
M+_9_TRRTO2OC%XK^*.A7=WI>O>#?$.EP7^OP>'+?POJ\-C9>)_$&DCQ?;Q)K
M_A>;PS9^*Y/%/ANVU;XV_P""J'[8GA?P'\2_B-_P3$_X):?L_?#CQ/\ \%#O
MVV=.N/#G[17B_P"&?@CPSX5_X5UX3\5Z/K=QJ?B[XN>,?#NGZ5-K'Q$C\->-
M_$GB6QUGQ;J=Q;_#72/$FI>/-;NTO=7TO2]>_-#]M7]BS2?^"<'Q8_X-C_V;
M[[Q-IGB&P^'O[66L^(?B/XV:"WLM+UOXC>)OVE?V2?&/Q.UL-+96-Q_PC-@=
M1L=!\-3:Q&+]?!WAS2(]2'VZ"]DD /Z)O^"9W_!7_0/V^?B5\8_V<OB=^SE\
M3/V.?VM/@AIMIXI\8? 'XHW5[JNIR>!;P^'[7_A)+#5=3\(^ =:@N=.U/Q+H
M<6JZ/KG@O1C_ &3XE\(:]H=_KMGK5\FA_LE7\EGP:74[K_@[A_:Q;PU/;):6
M'[)7AUO'Z1K;B2XTQO@G^S3%:03,\+R27*:W>>"Y]T,D=PMK!'&TQMHY;9_Z
MTZ "BBB@ HHHH **** "OYS/VM/^#A7PW\%/C+\=OAA^S9^Q?\<_VT/"O[(\
MLEK^UW\8OAW=ZCX;^'_P-OK+4M9TO6[*]OXO 'C5-1;0+SP]K]MJ6H:[<>#-
M#>7PWXJN=-U;4-'\,ZOJ]O\ T9U_.U_P6"TO7/VU_P!F']K7X<_L#?MH?L^>
M"M2_9_\  7Q"U7]OGP;X4N?">N^+/&VA^'M*\37VA?!?X@_$'03=WGPP8R>"
MOC)9Z_9:O?6EQ+J-M=>&?%$6G^'[WQ,Z@'T/^T#_ ,%QOV3?@U^PQ\"?VV_"
MFD^.OBW;_M42R:%^SA\$= L[#3?BGX^\>VES?Z/X@\(ZM8K<ZU!H*>!/%>GR
M^$?'VN:,OC&UTK7IM/L/#EMXNNM:T"WU:Y_P3._X*_Z!^WS\2OC'^SE\3OV<
MOB9^QS^UI\$--M/%/C#X _%&ZO=5U.3P+>'P_:_\))8:KJ?A'P#K4%SIVI^)
M=#BU71]<\%Z,?[)\2^$->T._UVSUJ^30_P"4/Q#\?OA!\9M/_P"#73Q-\+?A
MA+\!_A+\*?VP?%?PLU3P'K6OW?BJPT;Q/X%_:7_9#U+QYXL/C;5= \.'Q19^
M.K;6-,\>ZSJBZ=%8:=K^M>(O#@:6XT"_GF_7OX-+J=U_P=P_M8MX:GMDM+#]
MDKPZWC](UMQ)<:8WP3_9IBM()F>%Y)+E-;O/!<^Z&2.X6U@CC:8VT<MLX!_6
MG1110 4444 %%%% !1110!^</_!4+_@I3\)O^"7_ .S9>_'3XA:6OCGQ=K.L
M6?A7X2_!VS\0Q>&M=^*/BR>2*:_L[;66T?Q"= T#PWHOVK7O$_BB?0M2L]+M
M8+/3H[:\U[7= TK4^<\9_P#!5'X*?!S_ ()J?"__ (*2_'C0M4\">$?B=\*O
MA;X\TGX5^'-7L/&/B_4?%_Q7T&QUG0OAAX0U'4K?P79^*=:B%S>23ZI<6/AZ
MUAT+1M9\2ZA:Z;INFW@@_AG_ ."C'_!0K]GO_@H]XN_;N^-_QX^(6L:'XH^&
M7AC2/@5_P3*_9GG\,^.+^UTO3'^+?A2^^)WQP\8ZWHVFS_#W0?'7B?P/HFLI
M/8:QK=_-+-KO]B&>X7X;?#K5K_Z._P""B?[4?PW_ &F?^#<C]@'2?A3?ZW=P
M?LT_M$_L^_LY?%R'6=$DTA+;XL^"OV/?B1=WD6C23M*^K:+;V6K7"6^KP/#;
M7,EP4,)98V4 _I;_ ."?7_!='3/VO?VE=._9(^/_ .R#\7_V(OCAX_\ A^OQ
M2^!>@?$W4=2UW3_B_P""(]+UKQ%/J&FW.L?#_P"&NK:5/<^%=%OO$>@SPZ%K
MGAO7+30_%]FGB:TU30+2QUS]\*_D>_;YNWUO_@YM_P""1L_P^O\ 3);VX_9R
MT_5C>61M'BN? <VJ?M47^HF&8PS1265_X1A\2IIHCY!G>2R>WFECG']<- !1
M110 4444 %%%% !7X4?\%-/^"U5__P $_?VG/A+^RAX _8Y^)/[7/Q6^*_PH
ME^+6G^'OAGXLNM.\1P:.NO>-='CL],\):-\.?B%K_B&6.U^'WBK6]1N;6VM(
M=.TO39KEUFA@O)K7]UZ_EP_;:_X)K:W^W#_P5J\4?$[X-?\ !5_X??LX?'3X
M;_LX:;X-T_X5?!J.QUO]J_X.>&H-,C2[U#5+'0?BKX5\4^&?#OB6^^*S:U?>
M)XW\+ZS)X;\:Z7X7M(GT[7H]?F /L;P+_P %LM!T+]A;XR?MP_ME_LG?&W]C
M+3/A?\3[?X6^&?@YX]AU*[^)WQ?UO5?#_AW5_#Q^'VG^-/!WPF%\^KW>L:M:
M/N@?3-,T_P (^)==OM8CLM)U%++F/^"?7_!='3/VO?VE=._9(^/_ .R#\7_V
M(OCAX_\ A^OQ2^!>@?$W4=2UW3_B_P""(]+UKQ%/J&FW.L?#_P"&NK:5/<^%
M=%OO$>@SPZ%KGAO7+30_%]FGB:TU30+2QUS^.W]M#]M']JO]HG_@F=\6OV;O
MVG/B7<?'75OV)?\ @II\*O &D?'.]FLK^_\ '>D>)?@U^V%X:TS3[G7;6T2Z
M\5IH-_\ "/Q-KUIXLUG4=6U_5-.\?Z=;ZMJ5[%8Z7(O]$/[?-V^M_P#!S;_P
M2-G^'U_IDM[<?LY:?JQO+(VCQ7/@.;5/VJ+_ %$PS&&:*2RO_",/B5--$?(,
M[R63V\TL<X /ZX:*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ^,/VO/
M^">?[''[>?\ PKW_ (:T^"FF?&'_ (55_P )9_P@']H^*O'WAG_A'?\ A.?^
M$:_X2KR?^$&\5^&/MW]K_P#"'^&_,_M3[=]F_LQ/L7V;[1=_:/B__B'G_P""
M./\ T93X:_\ #J_'W_YZU?L_10!\3?LC?\$YOV+_ -A"]\=:C^R;\#],^$%Y
M\2[7P]9>.)].\6?$'Q,=>M?"LNL3Z!%*GCCQ;XGCLQITNOZNZ-IJ6;SF\873
M3K% (OMFBB@ HHHH **** "BBB@#R_XV?!OX>_M#?"+XD_ SXL:#%XF^&_Q8
M\&Z_X$\9Z))+);R7>A>(M/FT^[>QOH"MUI>K68F6^T;6;&2'4=&U:VLM5TZX
MM[ZSMYX_Q$_9,_X-T_V5_P!EKX]?"7XW7_QS_:8^/=G^SCJ6H:I^S;\+?C+X
MN\,ZQ\/?A'>ZE>W>NR:A8:1I7A32XIM2L?%]_>>-=,;P_%X0TB+Q8\/B#4-$
MU/6;>/4*_H+HH **** "BBB@ HHHH **** "O@__ (*(_P#!//X+?\%,/@3I
M/[/?QW\3_%#PGX+T?XC^'_B?;:G\)-:\*:#XHDU_PYHGBC0+&SGO?&/@KQ[I
M3:/+9^+-1DN[>/18KU[F&R>'4((HYX;G[PHH _/3_@H%_P $T/V>/^"CWP!\
M,_ /XX3^,]$M/ 7B#1_%GP[^(?@'4M(TGX@^#/$.CZ3=:']HL=1U70M:TF\T
MO6M)O)[+Q'H=_H\VG:D%LM0MX]/US1M!U;2O+/\ @G7_ ,$CO@K_ ,$]/&/Q
M7^,6G?%#XR_M%?M$_&^QT_2OB/\ '7X]>(;'Q-XSOM'L+N*_DT;1[J'3X=2L
M]/UC4+/2=0UY];UGQ)JFJWFAZ&9M36UTFQM8/U>HH **** "BBB@ HHHH **
M** /YLOBS_P:Z_L*_&3XT?%;X]>*/V@/VX;#X@?&3XA^./B9XQN?#?Q-^">D
MV/\ PD/Q \3:AXLUZWTR)OV=KJ\M=(75-2F6PL9[^[>WM(K:&2XG:$2M]$>*
M?^" G[&7C#]A;PS^P;KWC7]H'6_!G@+XK:S\:/AY\7M=\8^"K[XW^#O&^NPW
M%KJ<=EXCLOAUI7AF]\+7]A=3:?J'AN_\(36]W +.^^TQ:_H^@ZUI/[BT4 ?E
M#_P3K_X)'?!7_@GIXQ^*_P 8M.^*'QE_:*_:)^-]CI^E?$?XZ_'KQ#8^)O&=
M]H]A=Q7\FC:/=0Z?#J5GI^L:A9Z3J&O/K>L^)-4U6\T/0S-J:VNDV-K!^KU%
M% !1110 4444 %%%% !7X$?M:?\ !O1^R_\ M-_'/XL?'7PK\=/VFOV9=2_:
M,FA7]I3P+\!?&?AWPY\.?C)9.HN-;?6_#5WX6NU_MCQ3K4</B/Q+/K5QXF\.
M:MX@:_UZX\)G7=6U#59_WWHH _(OX]_\$3_V)?CQ^P]\(OV"Y]#\8?#OX7?
M/4K3Q#\(/&'@'6-*L_B9X3\6*-9?Q!XCGU[6="UG3=<N?'UYXAUS4O']EJ6B
MOI^O:KJ"ZO:V^E:QI/A[4='UO^"=?_!([X*_\$]/&/Q7^,6G?%#XR_M%?M$_
M&^QT_2OB/\=?CUXAL?$WC.^T>PNXK^31M'NH=/AU*ST_6-0L])U#7GUO6?$F
MJ:K>:'H9FU-;72;&U@_5ZB@ HHHH **** "BBB@ HHHH ^1_VO\ ]BKX+?MI
M?LZ?$W]F;XE6^K^$_!7Q5LM"L=>\1_#*'PIH/CO3H_#_ (LT'QC:2:#K&O\
MA7Q5I-G/<:EX>M+6]>]T#45ETZXO8(TAGEBNH/)O'_\ P3"_9A^)W[ &B?\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 5E:YKVA^&-)O]?\ $NLZ5X>T+2X#=:GK6N:C9Z3I.G6R
MLJM<7^I7\UO9V< 9E4S7$T<89E!;) .K7Y6?\%OO^437[=?_ &0[5?\ T\Z)
M0!^@7AGXX?!7QKJB:)X-^+_PN\6ZU)&9H](\,_$#PGKVJ/$)8H3*FGZ5JUW=
MM&)IX(BZPE1+-%&3OD0'U&OX>?\ @EY_P;__ +"'_!03_@DM^SW\;/&UK\2O
MAK^T9\2'^,=UJWQD\!>-M3NGFN?!OQT^+_@#PS9:C\/O%;Z[X"GT"'0_#_AZ
M/5K/1-&\-:]J3:0DEOXHTRYOM1NKKW__ ((E_P#!4KXF_ [X$?\ !1SX,_M]
M_$#Q3\3XO^"9NLV8TCQ4DMYX]^+?B+03XM\:?##6/AMIJW=^=3\5PZ3X_P#"
M7AK2/ FIZQ?-;Z8WQ!ATGQ)XGT3PII.B/8 ']@]%?R8S?\'.7Q)\ V_PS^,'
M[0O_  2L^/\ \&OV-_C%XDT[2_ '[15UXZO-4DUK0-4L[S6M)\0Z+X;U7X1>
M%?#'B>\UOPQ!_P )+I_A_3/B+;1W&F6&LS:#KWBB"Q>Y7]._@+_P5O@^*'_!
M4/XY?\$R/B/\"K7X1>*?AYX1U'QU\)OB>OQ9?QC8?'/PY]@\)>,/#G]G>$;C
MX9>#I_"^LZY\+?%J^/+K3(O$GBN'1&\.>*] FU"[N-(6^N@#]DZ*_G?\0?\
M!P?\,_"O[0'_  4-\#:W^S[XAD_9V_X)VZ'<Q?$/]HC0_B"NJZOXU^*3>._"
MGPDT'X1^&_A3<> -,T^P\0>*_BOJ_BKPWH6JZE\5#I,F@^ ]:\8WKV>GF:TL
M/ O!O_!Q7^T1;/\  WXC?'3_ ()&?M!?#7]EW]HG5M&MOAU\;O!/CO5OBW>W
M6BZO87.J6VLZ?X-TSX+>'SXFGO="L=0\6Z=H4&N:'J^I>%]-U+4?#UMXDAM#
M/( ?U.T4BL'574Y5E#*<$9##(.#@C(/0@'UI: "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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1%% !1110 4444 %%%% '_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>36
<FILENAME>nt10014672x1_linechart9.jpg
<TEXT>
begin 644 nt10014672x1_linechart9.jpg
M_]C_X  02D9)1@ ! 0$ P #   #_[0 V4&AO=&]S:&]P(#,N,  X0DE- ^T*
M4F5S;VQU=&EO;@     0 ,     !  $ P     $  ?_B"^!)0T-?4%)/1DE,
M10 ! 0  "]!N;VYE @   &UN=')21T(@6%E:( ?4  < %0 3  L (6%C<W
M         $E%0R!S4D="     0            #VU@ !     -,M2% @(
M
M$&1E<V,   %$    =&)865H   &X    %&)44D,   ',   (#&1M9&0   G8
M    B&=865H   I@    %&=44D,   ',   (#&QU;6D   IT    %&UE87,
M  J(    )&)K<'0   JL    %')865H   K     %')44D,   ',   (#'1E
M8V@   K4    #'9U960   K@    AW=T<'0   MH    %&-P<G0   M\
M*&-H860   ND    +&1E<V,         &G-21T(@245#-C$Y-C8M,BTQ('=I
M=&A"4$,
M                                                    6%E:(
M     "2@   /A   ML]C=7)V        !      %  H #P 4 !D '@ C "@
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M;W5R(%-P86-E("T@<U)'0@
M
M      !865H@        8ID  +>%   8VEA96B            !0
M;65A<P         !                               "6%E:(
M  ,6   #,P   J1865H@        ;Z(  #CU   #D'-I9R      0U)4(&1E
M<V,         +5)E9F5R96YC92!6:65W:6YG($-O;F1I=&EO;B!I;B!)14,@
M-C$Y-C8M,BTQ
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MU=;7V-G:X>+CY.7FY^CIZO'R\_3U]O?X^?K_Q  ? 0 # 0$! 0$! 0$!
M     0(#! 4&!P@)"@O_Q "U$0 " 0($! ,$!P4$!  ! G<  0(#$00%(3$&
M$D%1!V%Q$R(R@0@40I&AL<$)(S-2\!5B<M$*%B0TX27Q%Q@9&B8G*"DJ-38W
M.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U=G=X>7J"@X2%AH>(B8J2
MDY25EI>8F9JBHZ2EIJ>HJ:JRL[2UMK>XN;K"P\3%QL?(R<K2T]35UM?8V=KB
MX^3EYN?HZ>KR\_3U]O?X^?K_V@ , P$  A$#$0 _ /[^**H:KJ$6DZ7J6JSI
M))!IEA>:A-'"%,KQ65O)<R)$'9$,C)$50.Z*6(W,HR1_*%_Q%_\ [!/_ $;G
M^UY_X(O@S_\ /BH _K,HK^3/_B+_ /V"?^C<_P!KS_P1?!G_ .?%7]7NE:A%
MJVEZ;JL"21P:G86>H0QS!1*D5[;QW,:2A&=!(J2A7".ZA@=K,,$@%^BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "OFW]I']K#X,?LI
M:'X<UWXOZ[?:<GBS5+K2M TS1M-EUG6M0>PM1=:E>1:= \<@TW35ELH;Z]9A
M%;W.I:; V9+R('Y!_P"%^?\ !5#_ *,1^'?_ (?/X>__ #PJ_.^.]\6?M$?\
M%.OASX5_;]\):;\-7T/0;"#P1\'KJ73?$?@'6M2&FOK?A7P[-K46K:CX>UNP
M\7:W<W^H:C>+<ZU!XBUS3;3X87MJ79;#3OUSAGPVI8C&8W%9]FN3XO)\FRC,
MLZS#!\+\29'G.=XNC@*'-'#X3#9=BL=4I<]:=+VN*K4%AJ--252I"4Z<C\+X
MP\7:V%P&78+AG)<_P.?\09[E'#^5X_C/A'B3A_AW XC,L2H3Q6/QF:X/+:5?
MV>'A6]C@L-B'BZ]9P=*E5A3J1?ZH?"O_ (*B_LD_%_X@^%OAIX8\3^)[+Q)X
MRU--%T%_$?A6ZT72KG5[B.0V&FR:E+<2107>J7*1Z=ID<BC[7J5S:6:$2W$8
M/Z(5_/W_ ,%?_@A^SA\)?A;\*_&/PZ\,^#/@Y\68/'D\'A/3?AEX4\/>#IO%
M>C1V45YXAU#5(O#<&B3*WA"]M_#MWI?B+%[/I%]JB:5%;)_PD1O]/^A_ /[1
M/_!5/4_ W@W4G_8K\%>)&U#PMH%[_P )#JOQ2\$>$]4UT76EVLZZQJ?A>_\
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ML"ZI\&;#X(_\$]OC%^W)!\4+#QW>>([[X5ZOXUTN+X;2^$;CPG#I=IK8\(_
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MK&G?T2T4 ?RLK_P;">"A^P?X2_95E_:SUEOC1\)OVC?&O[1'P7_:6T3X0?\
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MAZ62RP<LMHQ='"K 5:=7"PC"34H4ITI3@^2?,I)2;4KIZW"BBBO-/1"BBB@
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M^'VEW4K^'X-4\6WOA/7)-%CUG3+2]\4Q?T9^#?\ @GQ^S':?LA? 3]C7XO\
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M;3KFYL-3TR_MKBRO[*XGM;J"6"62-O'-._95_9?TCX0ZK^SYI/[-_P !=+^
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M2R^'O%%A\,?AYI<&H^'-9B\.^,O!VI:[I-W:6^HR>-_#6G?M)^T+_P %1?\
M@II^P=^W#\</"'[0?[%/C[]IO]CC7-$OF_96\:_LI_!WQ/<WU[X@U>^74/AW
MH/COQ>VK^*]-CUYEN[OX=_$33KJVTK7#JFC6/COP+X*O=#OX-+\0_BI\//\
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MK7'@V'09_$*2IX(\.^('TT6<7B71V1]26U2Z-RPM3,;>X$?\HW@*_P#VQ/\
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M/CI(T+2VT$;M$SQQNT98H7C1B,HI'])M !1110 4444 %%%% !1110 4444
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MQ-XP\.RV=]>:5X>O="L=0U(SWGA_2/'H,:PZD8#Z]_P4Y\<^+?VB_B1\(?\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M6<$-M;01I##$D:*H_A9T_P#X*0_\%>?V3?V1OCK^T#XX_:!^'/QR\6?L>?\
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M3Q4L<\(JSJXZIA<)@ZV,JUJU2JZU:A@:-#"QJ*,XTKTZ4>:%*#E>5VRBBBO
M/HPHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH CEEBMXI9YY8X8(8WEFFE=8XHHHU+R2RR.52..-%+
MN[D*J@LQ !-?SO?\%4?A)_P3:_X*DZ5\%-+\6?\ !5+X%_!)/@MJ'CW4+&?X
M=_M#? :]D\1MX\MO"-O<1:L-2\>6XC32QX2A>S,.XLU_<[\!4S_0SJ%C;ZG8
M7VFW89K74+.YL;E48HYM[N%[>8(XY1C'(P5ARIP1TK^/[]O;_@C#_P $$O\
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MG.2E.G0C"C%QC)4TH12Y8)O5MLHHHK@.X**** "BBB@ HHHH **** "BBB@
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M]M]2LK/4;-S+:7]K;WMK(4>,R6]U"D\#F.15D0O%(K%'577.&4$$4 6J***
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MS!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M]E^9_9G]M_8H?[5_L[SOWWV'[?\ :/LGF_O/L_E[_FS0!KT444 <!\3?BO\
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MA#;W.D76H2:H/#EY:6BV)$BO/+;6\_S'_P $U/\ @KG\/O\ @HCXD^)O@T^
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M0C&*****\0^A"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K\-O\ @NE^V_\
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MQ:=9:'\2O$'COPOJ'A34;.U\8ZSH,6@^(_#%K+I\LEK?^;^$?^"(O[4VH_\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M_O\ PX?T+_HYG5O_  T]G_\ /"K] ?V%OV#[']B;_A:7V+XFW?Q%_P"%F?\
M"$>;]J\)P^%_['_X0S_A+MGE^5XAU[[=_:'_  E;[MWV3[-]A7'G_:#Y/Z T
M5Y&>>*?'O$F5XK)<ZS^>-RS&^P^LX5Y=E-!5?J^(HXNC^]PN HUX<F(P]*I[
ME6/,X<LN:$I1E[W#G@KX9<)9S@^(.'N&(9=G&7_6/J>,6:YYB71^MX2O@<1:
MCC,SQ&&G[3"XFM2_>49\OM'.'+449HHHHK\^/U(**** "BBB@ HHHH ****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M6*&VG,T"I#*98420RPHD4A;?&JH0  :5%%% 'XH?\%CO^"1?C#_@K/HGP/\
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M+J^OZM<.+70_"WAZSDDB6^\0>(M4EMM+TRW>6&VCFG-YJ-U8Z7:WM];?RL>
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M)]'\G4DBM-1UB[DU#3;5G.IV<5I?:E<VTDXM9'O(1% ;V>6SCM+8N\XAD?\
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MSN':6>TB^P6_EVL\C)&TDT";8I':.-G=&8HA.T?P5_MW? ']O3X.>(/VP_\
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M;.+E[?3(3',MZN\-*+U5[*][[NR6W](ESG%\KY>:5N5I.U[I._XO;_(^I_\
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M5;KP]]ADUBXENP#^R#3_ -J']FC5M8\ >'=*_:(^!>I^(/BOIT>L?"W0M/\
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M7_!>7]O_ .)'_!.G]@36_BW\&)+73OC)\1_B7X0^"/PR\4:AI6G:]8>"=?\
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M"A\<?_#TZS_\K:/^(6/_ ()-_P#0H?''_P /3K/_ ,K: /Z-:*_G*_XA8_\
M@DW_ -"A\<?_  ].L_\ RMH_XA8_^"3?_0H?''_P].L__*V@#^C6BOX+/^"F
MW_!$']A']EC]K?\ X)/?!WX3:!\2[/P5^U]^TWJ'PK^,L&N?$;4=:U&]\)6_
MB3X.Z9%#X?OYK..30;X6OC77 U[ DKEY+9]N;=0?V>_XA8_^"3?_ $*'QQ_\
M/3K/_P K: /Z-:*_G*_XA8_^"3?_ $*'QQ_\/3K/_P K:/\ B%C_ ."3?_0H
M?''_ ,/3K/\ \K: /Z-:SM7TC3=>TO4-%UBTBO\ 2]5M)[&_LYMXCN+6YC:*
M6,M&R2QL58E)8GCFB<++%(DB*X_G;_XA8_\ @DW_ -"A\<?_  ].L_\ RMH_
MXA8_^"3?_0H?''_P].L__*V@#]8;_P#8J\*2WSOI?C3Q%IVE32,TVG3VEE?S
M%.&BBCO5>R3;#)N*-<65RY38K,9%::3Z0^&OPO\ "WPJT-]#\,07#"ZN/M>I
M:GJ$J7&IZG<A?+CDNIHXH(5BMXL16MK;006T"F241&ZN;NXN/P._XA8_^"3?
M_0H?''_P].L__*VC_B%C_P""3?\ T*'QQ_\ #TZS_P#*VFY-Z-_UY]_F2H1B
M[I),_=CXW?#1?BIX"U#P]"\<.L6LT>L>'KB9F6&/5[..:..&X92"+>^M;BZL
M)7(=;<W*7GE2O;)&WRUH_P 2OVI/".A0>"Y?A;?ZM?Z9;)I.G>()O#VKZDT,
M%M$886N;_3+F31-2EMXO*2VOFG6*;R0UY_:$K3._YF?\0L?_  2;_P"A0^./
M_AZ=9_\ E;1_Q"Q_\$F_^A0^./\ X>G6?_E;33MHTGK?7Y?Y?UL)PN^9-Q=K
M.UM5?K?YGZ\? _X O;6_B'Q=\8]#TCQ!XL\6WDETVG:Y9Z=K1TN*:::ZN[R<
M-'/8Q:OJMW.9IA:AVL;:&WB2>&6XO;6+UC4OV>O@QJK%[GX?Z-$3D$:=)J&C
MK\RJAPFD7MBB\(""J@JQ9UP[NS?QB?M>_P#!";]@/X-?\%,_^"7?[+7@GP]\
M4(/A/^U=_P -/_\ "W;/4?B5J6H:Y>?\*J^'&G>)O"/]@ZU)9)-HGDZI<RO?
M^1'+]MA*POM49K]:_P#B%C_X)-_]"A\<?_#TZS_\K:5WWMZ:6\D-0BE:R:\T
MFWK?4_2O]H_]GCPIX/\ !T/B[X?:-=6*Z7J")X@M1J.HZE&NE7@,45\HU*ZN
MYT%E>_9H)!%(?W-XT\PV6[R+]$Z-^TO\)+[PK!X@OO$UGI5TEG U_P"'Y8[E
M]7M;XP[I;&ULDM_-OT256BBO+17LV4QO+-"&(7\7=&_X-?/^"67AS6-*\0^'
MM%_:#T+7M"U*QUC1-;T?X[>(],U?1]7TRYBO=.U32]1LK*&\T_4=/O(8;NRO
M;2:*YM;F*.>"1)45A^E.G?\ !/;X?:9I<&DP?&/X^3V]M;+:0W&HZY\--5U3
MRD3RU>?5]2^%5UJ=[<X^9KV^N[F\D?\ >23N_-.Z:]Z^FUK=>]R7&46W#ELT
MKIW2NMFK>NJ_5Z<I\%?AU??&/Q?\2OB$FN^+/ VA:CKNIR65SX7U :3?WEWK
M.J2ZQ-ILETD<T<MOIEJ]JU[$!AKFZLI$D/EN*^C)?V=M5CV_V9\<_C'9;L^?
MYOBBYG\W&/+V_9Y+#9LS)G?YN[>-NS:V_P#);X@_\&T__!-7XL>,-;^('Q*7
M]H_QQXU\1W7VS6_$OB3X]>(M4U6_F5$AA62YN;!S':VEO'%:6%E (K+3[*"W
ML;&WM[2"&%.,_P"(6/\ X)-_]"A\<?\ P].L_P#RMH<GTT2V6]MOU2'&FDDG
MJ]V]5K>_0_1;]H?X->)_"'AG2/%=SX]\9?$33M*U=(-1MO%-]=ZBFD17_EK#
M>P>?<W<=O;W-U!#I]XY"EYKG3TPX)"_7EI\??A+<^&(_$[>-=!MHCIYOI=&F
MU*T3Q'"\:'S; :"TJZG+>I*K01QPVSI<$+-;R2VKI.WXG>$_^#8__@F!X$\3
M:#XS\&:=^T+X8\6>&-4L];\/>(=$^.OB#3]6T?5M/F2XL[^PO+>P2:WN+>9%
M='1AG!5@R,RG],X_V#_A]'9K:?\ "S_C&\BQ^6+Z2]^&3WF>=LC9^%WV5Y%&
M%W/:L&P&D5W+,Q=-)2OIM;JM-/Z_X=<LHMN%K.UU*^C6B:>[TW3?IN>;_ [P
M-XY^)&L_$3Q[X1\87WPLTS5-?N1"UAI::LE^]]>W>K2Z5&&U#3!'#HD5S9JT
MP#K*;M%C53'*%9^T?X0^(GAN#P/JGQ"\;W'Q%\.C6;RWE6'0K+P^FFRNMC</
M:EK&;_2+C6+*VO1;O(R&V&GS&-U\YS7Q9\1_^#:O_@FO\7O&WB'XC_$Y/VC/
M&_CGQ5>G4->\2^(/CKKM]J5_.(H[>!#(^G".VLK&TAM[#2]-LX[?3M*TVUM-
M-TVUM+"TM[:+9^#?_!N1_P $Y?V?_B/X;^+7PAA^/G@WQ_X3GNIM$UVT^,%U
M?>0+^QN=,U"VNM.U;0[_ $K4K&_TZ\NK*\L=1LKJTN()W62$D*ROF]Z]M/1-
MVVWWO\Q>S]QJ[YM[W=F[WUC>UOEY[G[=6'BKP:?"</B6PUC18O!]MIT<L>H0
MSVT&E65A#"BI P4K%:&WCV6YL62.6"0"U,"2@15\!? .+XI7>L_$O7/@Q!X6
ML?"]]KJ1"T\91:C':>0;O5;S2(-.&G+*5N]+TZY6*_B-UMCBO[/<L^Z*2+X9
M\9Z[:^&/^"O7PF_X)S6MA<7/PZ^(G[(=_P#M*7OC^YOXAXVT_6+#QK\2O"G_
M  C%M!%IT>@RZ=-#X$MKPW\FGBY274)XA R0QLW9?&W_ (-U/^"=O[1?Q'U[
MXL?&-?C_ .,_'/B)K=;[5;OXR7]I!!:64*V]AI>E:7IVC6FEZ/I-A;J([33M
M-M+:UC+2SM&]S<7$\I=)::W[K1+S[O\ I6ZEI2DG)**C?9W;;5M';1?UKNOJ
MO]I2Z^,1M?!FG_%8>&(/#\NJWUS;W'@D:G)#)<QQ6<,YU"+4IMC7EG93W#Z4
M!%#O6ZU%?.E4,(?T"T_PKX&_X1&W\/Z=HGA^7P7<6$<L-A%:V<^BW=E/$LZ7
MK95X+HW"%;IK^1I)IW87;3O*WFG\:_V>O^#?/]@#]E?XBV_Q6^!9^.O@[QK!
MI&J:#+=2?%N^UC2=5T75XX_MFD>(-"U'2I=.UO2GNK:QU%+.\B86^JZ;IFJV
M<EKJ6G65W;_;"_LL_%*"W;PG:_&>[C\!.CQM8J^O0@PS.SW%L?#<>HG2VMY&
M=Y'B.JB&:9C))"KL6!=-)7M;R>OGIUW^?:X6E&4FH\ZDEK=75M+._3^GL>>_
M ?7?B-X>UKXF6'P=\)V_COPLNNP^5_:>NVFF0V5K'=ZQ#H]Y;R:A?Z<EQ<:G
MIT2_;&AC>5EL[1IQ$!"K?2'_  G7[3W_ $0_P_\ ^%MH'_R_K\X_VB_^" '[
M!7[6/CR#XE_'I_CAXQ\7VV@Z=X<LYK3XJ7?A_1-*TC3C/.EAH>@:9I266EV<
MM_=WVHS(IGN)[R]N)[JZN97\RO!/^(6/_@DW_P!"A\<?_#TZS_\ *VDVF[V3
M];W^=FE]PXP:BDY-/5V5K*[O973_ *OW/T"_:$\3?$WQ!<^ -#^*WA>#X?:!
M<:Q=7 ;3-8LM;COE633+2]OY8[+4+R(7&AV=Y*;6.5X6<:E. 2K$K]T2?!_X
M7_\ "-'PL_@KP\FAI"RB,V,0NHF\LQM>C57!U-=0"9SJ9O#>GDM<$9S^3?[.
M7_!!/]AS]D7Q3KGCG]G>Z^,_@OQ3K_ARY\-:D=8^)-UXM\-:G8RSPWEJNL^&
MM3T^.WOCI^H6T%Y9W-M=:=J=MBYMK74K>UO[^&Y^P!\!?VD'TI?!,OQ7TM?!
M0!M6V:IK37?]E$?9C9;/[&COI+?[(2@T636!I/E?Z,)1&!3O=)7Y;/;7:ZU]
M4^GST%9QD[Q]HI)6;M=6LFG=)6>_YWW//OV>M>^,.GQ^-/#OPETOP[XE\/V>
MMPW+WOBFXE@M;&2Y6\M[:YMEM]4TN:=]6L],B^T)!'.('@MI)%@24F6;XT3?
M$8>-?A)J_P <[#PI;^&HM>C\RR\-KJ-WIL6EP:QHTOB*/4XKJXOC)/=Z>D3K
M%#<2_:+9&C"AXGC3YO\ VB?^" ?[!_[6?C:P^)/[0,GQI\9^,[#PYIOA>UN=
M,^)EUX7T+3M*TZ2YNOL>B>'M-TUK;3;6?4K_ %'4I5DN+Z\DN;V4W-_<[8RE
M/]GS_@WO_P""?O[+7Q'L_BM\#G^/7@OQG:Z=?Z+/=I\7+C5M/U;0M4\DZCHF
MMZ+K.A7^DZOIES);6ET+>]M)3::C9:?JVGR6FJZ=87ML<RYKVNN_5[*_X:;?
MB)4WR)<SOO9N\4[II::]+;^>NB/VCUW4O"\'A;4=3UVXTF7PB=)DGOY[K[/=
M:/<Z1/!@J5(EM[RVNX9%BAA191>>;'#"DK2HK?GA^SGH7QKU/0_$UW\+_%.B
M^&/#IUQ(IHO$%FMZEUJ"6B.[68?2-66*6"REL4O65XC+OM0WF^4"OP_\*?'&
MF?$?_@JC^TE_P3;O=&UC3O#_ .SU\%/"'QIB^*-OXDM[C4?%4/BRT^%-TOAC
M_A#YO#JV.@SZ<?B;*A\0+KFL)>?V0K#0K3[>RVG4_&+_ (-Q?^"<7Q]^(_B?
MXM?%N#X^>,/'_B^ZM[K7=>N_C#>69N#9V5MIEA;6UAIFB66F:=8:=IMG:6%A
MI^GV=K9VEI;0PP0HJ\ETD[.[=MUIIY,JTI23DN51OHI:MNW5=-/F?J%_PB?[
M67_14? '_@DA_P#F1KYU^*FG>/\ 0?BA\)KSXYZ]HGB70?[6LG2YL+)(M$@T
MVUUNPDUR"\M#IFFPRL(9+2;4-UO-Y]B88G,BQB(?GW_Q"Q_\$F_^A0^./_AZ
M=9_^5M>]_LY_\&_W[ O[*'Q ;XF_ I_CKX-\5SZ/>>'=0F?XK2:WINL:#?SV
MEW=:1J^CZWH-_IM]9R7>GV-Y&9+<7-I>6=M=V5Q;7,*2JE*S6B^22?\ 7^;^
M1*%UHW=6:NVTVK;I[[?>[G['>+M2\)V_@[6=3\5R:;<>$!I,EQJ370@NK"\T
M^6-6BCB1BT5V]X7BCL(HB\EU<RV\=J&FDB!^!OV;O"_QHU;PAJ]WX!\?V7@S
MP^WB"6*2UU#0=/U?[=J*6%B+N\M6O]-O&B1(#9V[F&5(Y)(2I&^%B/1+7]B?
M1Q>[=2^(FN76AJ[M'IMGI%I97T:G?LVZC<WVIV7F)N.Z0:(%<EL1H&('YU_%
M3_@VV_X)M_&WXA>*OBK\4[?]H#QCX_\ &NIMJWB3Q%J/QFU"*>^NO)AM8(X;
M2QT:TT_3M/L+&VM=.TK2=,M+/2](TRTL],TRSM+&UM[>-W232=[^6B^3_K[@
MM*4DY+ELFM):N]NL;62M_P ,?:?Q;T+QI\./B/\ "OQM\3O%$GQ$T*SU>RW:
MBFAP:6NG)I>IPW]S9&QLI/L\ER893J-BTLBO?O:S6[JT%FU?9GC3XI?#G2?!
M&LZ[?>(/#VM:5-I%RD.G6VI6-^VOF]MI(X-*M[:"69[@ZCO\AQY9BA@::XNV
MAM8)Y8_Q_P#@9_P;N_\ !/;]FOXBZ7\5O@G)^T!X&\<Z3:W]A!JUI\7[C4K>
MZTW5+<VVH:7JVC:UH.I:)K6F72>7*UCJVG7EO%>VUEJ5O'#J6GV-W;_H?<_L
M2?#*>UDMXO%OQ)LIGB,:WUMJ7A![J)BNWSHTO/!-W9&4'YP);.6'=P8BGRTK
MII7OIV2UV]+!RRBY<J34K?$WHTK:WNVOGY=#RW]G7X7?$GQ#X%NM;\/?%'5_
MAWI-]KUZMMIUKH*ZE%JQM;:RMI]82>35M.PC3QR:9M6.0>;ILN7XVCWO_A2W
MQC_Z.2\0?^$A#_\ -/7Y&>,/^#9/_@F'\0?%.O\ C?QOI_[0OBGQ=XIU2[UO
MQ#XBUOXZ:_?ZKJ^JW\K375[>W4VGM)+++(QP,A(T"11(D2(B\W_Q"Q_\$F_^
MA0^./_AZ=9_^5M#E=MZ?<O\ @@J:22UNE_-):^B:[?@C]$/B-X<\1?"KXO\
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M3\-Z?<W36;:5<VTFCM,MK#)&DK)?7\/[X,MU:1K;.KP0;*_*W_B%C_X)-_\
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M83?:!\(=-L_"GP\T3P0GBR\O/$NJ:G>^,)M4EM[JT?0?#W[H44 %?FM\"_\
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M?!W2?'/AGP'=);^!]4\*>'_B'H5C_P )5J=?VQT4 ?Y]?_!,K]E?X5?M)_\
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M];7FN_#;X6W%OI?CG[/%8>"/$'AF#QMX?U_6K_3],74[5+RTOKD _I!HHHH
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MG4+?4H;R@#]@:*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MS?MM^*6\5_M)?!!_AV_B&.6Y7Q%K/C*+1?#QT'Q3X0TW7/"5IXD\0:U'X?\
M#U\/"\OA[P[J5QH%[J_BK3WG@N?Z-OV5OV;/AO\ L??L[?"']F;X26UY!X ^
M#G@W3_"6BW&IFS?6=;N(WFO]?\5^()-.L].TZ;Q+XQ\1WVK^*_$MQI^G:?8W
M&O:SJ,]G865M)%:Q 'T!1110 4444 %%%% !7\['_!>;_@GW^RWXY_9F_;$_
M;T\<> I?&'[17@/]D^#X=_#W7-?U:\NO#?@/3-#\4ZGJ,&M>'?"<1@TEO%D\
MGC35HCXAUF+5[O3(X[*3P\-%NX[BZNOZ)Z^5OVW_ -F7_ALK]DWXZ_LN_P#"
M;?\ "N/^%U>!KKP9_P )S_PC?_"8?\(U]IO;*\_M+_A&?[?\+_VSL^Q^7]C_
M .$@TK=YF_[4NS:P!_)!'_;/_$&-:?V/_P!1#^U?+^U?:O[&_P"'H.I_;OLG
MV7_ME_:'VG_1?[&_M/SOX:\5_P""I5IX0LO^#87_ ().0^%[;[) _P 6_@M=
MM%=PV,%\^M7_ ,#_ -IN^\?W-NEJJ;K"]\:W-_>"8 S7,,^G7&I,]_*SM_5C
M^R]_P3"\"? __@E]9?\ !,#XG>/;GXS^ 9_ 'QK^'?BGX@V'A&T^'NJZMI?Q
ME^(/Q#\=R:MH?AN_USXBVGAOQ#X/D\>11^'M2FU?7EBUOP_8>(A;P.ZZ;;?C
M5\(?^#9KXB6'C;X$?#_]I#]O?Q%\=/V&?V6OB1J'Q&^#W[,__"NFT=-8?6_$
M,OBS7/#'BB>^\5:OH6A:-KFN".+Q5/ING^([S7]$U/Q78>'?^%>W?B*34[0
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MK7_@EIIU_P")]"^%FD^'+!="^(H^P:OX]T_XF6/C _$>X^*<AU2*6Q?4]?\
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M%5NK32;;3YH3'J,-LR^X?LT_VW_Q%O?M]?\ "+?V=_8O_#*GAC_A-MOVO/\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M &B:CK<EG::?-K>IZ=X6TO2[;4M:GL=/L;2XU>^CN-1N+:SM89KF1((E4HH
M]<HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#__
!V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>37
<FILENAME>nt10014672x1_linechart10.jpg
<TEXT>
begin 644 nt10014672x1_linechart10.jpg
M_]C_X  02D9)1@ ! 0$ P #   #_[0 V4&AO=&]S:&]P(#,N,  X0DE- ^T*
M4F5S;VQU=&EO;@     0 ,     !  $ P     $  ?_B"^!)0T-?4%)/1DE,
M10 ! 0  "]!N;VYE @   &UN=')21T(@6%E:( ?4  < %0 3  L (6%C<W
M         $E%0R!S4D="     0            #VU@ !     -,M2% @(
M
M$&1E<V,   %$    =&)865H   &X    %&)44D,   ',   (#&1M9&0   G8
M    B&=865H   I@    %&=44D,   ',   (#&QU;6D   IT    %&UE87,
M  J(    )&)K<'0   JL    %')865H   K     %')44D,   ',   (#'1E
M8V@   K4    #'9U960   K@    AW=T<'0   MH    %&-P<G0   M\
M*&-H860   ND    +&1E<V,         &G-21T(@245#-C$Y-C8M,BTQ('=I
M=&A"4$,
M                                                    6%E:(
M     "2@   /A   ML]C=7)V        !      %  H #P 4 !D '@ C "@
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M;W5R(%-P86-E("T@<U)'0@
M
M      !865H@        8ID  +>%   8VEA96B            !0
M;65A<P         !                               "6%E:(
M  ,6   #,P   J1865H@        ;Z(  #CU   #D'-I9R      0U)4(&1E
M<V,         +5)E9F5R96YC92!6:65W:6YG($-O;F1I=&EO;B!I;B!)14,@
M-C$Y-C8M,BTQ
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MU=;7V-G:X>+CY.7FY^CIZO'R\_3U]O?X^?K_Q  ? 0 # 0$! 0$! 0$!
M     0(#! 4&!P@)"@O_Q "U$0 " 0($! ,$!P4$!  ! G<  0(#$00%(3$&
M$D%1!V%Q$R(R@0@40I&AL<$)(S-2\!5B<M$*%B0TX27Q%Q@9&B8G*"DJ-38W
M.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U=G=X>7J"@X2%AH>(B8J2
MDY25EI>8F9JBHZ2EIJ>HJ:JRL[2UMK>XN;K"P\3%QL?(R<K2T]35UM?8V=KB
MX^3EYN?HZ>KR\_3U]O?X^?K_V@ , P$  A$#$0 _ /[^**** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M97GC+7+"TAU#Q!<6L^H7TL$NI3W#Q27=PZ$-*Y(!_$5^Q;^TM\$_V$OV7O\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M>,]6_LOPW\>=1^!/PTE?3?#MCK?B76)GL[KP+H5W<QV-U<+,MSJ-\PM8KB\
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MZ_X?\^S#VD/YD?7M%?(7_#:?PM_Z 'C_ /\ !5X=_P#FJH_X;3^%O_0 \?\
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ML-C:>-Q_/@81P<,HC@Z.,P'UFEB,3BXQQ.(JSPL<*\+6YZLN=?2]?C5\0_\
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MN/PP_P#!$/\ X]1_PP)^QE_T;C\,/_!$/_CU?7M%'^M'$W_119[_ .'?,/\
MYH#_ %-X0_Z)7AO_ ,,>5_\ S*?(7_# G[&7_1N/PP_\$0_^/4?\,"?L9?\
M1N/PP_\ !$/_ (]7U[11_K1Q-_T46>_^'?,/_F@/]3>$/^B5X;_\,>5__,I\
MA?\ # G[&7_1N/PP_P#!$/\ X]1_PP)^QE_T;C\,/_!$/_CU?7M%'^M'$W_1
M19[_ .'?,/\ YH#_ %-X0_Z)7AO_ ,,>5_\ S*?(7_# G[&7_1N/PP_\$0_^
M/4?\,"?L9?\ 1N/PP_\ !$/_ (]7U[11_K1Q-_T46>_^'?,/_F@/]3>$/^B5
MX;_\,>5__,I\A?\ # G[&7_1N/PP_P#!$/\ X]1_PP)^QE_T;C\,/_!$/_CU
M?7M%'^M'$W_119[_ .'?,/\ YH#_ %-X0_Z)7AO_ ,,>5_\ S*?(7_# G[&7
M_1N/PP_\$0_^/4?\,"?L9?\ 1N/PP_\ !$/_ (]7U[11_K1Q-_T46>_^'?,/
M_F@/]3>$/^B5X;_\,>5__,I\A?\ # G[&7_1N/PP_P#!$/\ X]7\[G_!(WPO
MX<\1_MR:GI&OZ'I>M:7;_!7XL306&IV4%[:136_C/X80P2I#<)(BR10RR1HX
M&Y4D=0<,<_UP5_)Y_P $=/\ D_76?^R(?%[_ -3CX65^P\ YKF>9>'OC%_:.
M98_'^QR3)71^NXS$8KV3J5<V]HZ7MZE3V?/R0Y^2W-R1YK\JM^$>)62Y/E/B
MMX"O*LIRS+'B,^XG5?\ L_ 87!>W5+!Y/[-5OJU*G[14_:5.3GYN3GGRVYI7
M_IY_X4W\)_\ HG'@O_PG=+_^1J/^%-_"?_HG'@O_ ,)W2_\ Y&KTJBOP*[[O
M^O\ AE]Q_35EV7W(\U_X4W\)_P#HG'@O_P )W2__ )&H_P"%-_"?_HG'@O\
M\)W2_P#Y&KTJBB[[O^O^&7W!9=E]R/-?^%-_"?\ Z)QX+_\ "=TO_P"1J/\
MA3?PG_Z)QX+_ /"=TO\ ^1J]*HHN^[_K_AE]P679?<CS7_A3?PG_ .B<>"__
M  G=+_\ D:C_ (4W\)_^B<>"_P#PG=+_ /D:O2J*+ON_Z_X9?<%EV7W(\U_X
M4W\)_P#HG'@O_P )W2__ )&H_P"%-_"?_HG'@O\ \)W2_P#Y&KTJBB[[O^O^
M&7W!9=E]R/-?^%-_"?\ Z)QX+_\ "=TO_P"1J/\ A3?PG_Z)QX+_ /"=TO\
M^1J]*HHN^[_K_AE]P679?<CS7_A3?PG_ .B<>"__  G=+_\ D:C_ (4W\)_^
MB<>"_P#PG=+_ /D:O2J*+ON_Z_X9?<%EV7W(\U_X4W\)_P#HG'@O_P )W2__
M )&H_P"%-_"?_HG'@O\ \)W2_P#Y&KTJBB[[O^O^&7W!9=E]R/-?^%-_"?\
MZ)QX+_\ "=TO_P"1J/\ A3?PG_Z)QX+_ /"=TO\ ^1J]*HHN^[_K_AE]P679
M?<CS7_A3?PG_ .B<>"__  G=+_\ D:C_ (4W\)_^B<>"_P#PG=+_ /D:O2J*
M+ON_Z_X9?<%EV7W(\U_X4W\)_P#HG'@O_P )W2__ )&H_P"%-_"?_HG'@O\
M\)W2_P#Y&KTJBB[[O^O^&7W!9=E]R/-?^%-_"?\ Z)QX+_\ "=TO_P"1J/\
MA3?PG_Z)QX+_ /"=TO\ ^1J]*HHN^[_K_AE]P679?<CS7_A3?PG_ .B<>"__
M  G=+_\ D:C_ (4W\)_^B<>"_P#PG=+_ /D:O2J*+ON_Z_X9?<%EV7W(\U_X
M4W\)_P#HG'@O_P )W2__ )&H_P"%-_"?_HG'@O\ \)W2_P#Y&KTJBB[[O^O^
M&7W!9=E]R/-?^%-_"?\ Z)QX+_\ "=TO_P"1J/\ A3?PG_Z)QX+_ /"=TO\
M^1J]*HHN^[_K_AE]P679?<CS7_A3?PG_ .B<>"__  G=+_\ D:C_ (4W\)_^
MB<>"_P#PG=+_ /D:O2J*+ON_Z_X9?<%EV7W(\U_X4W\)_P#HG'@O_P )W2__
M )&H_P"%-_"?_HG'@O\ \)W2_P#Y&KTJBB[[O^O^&7W!9=E]R/-?^%-_"?\
MZ)QX+_\ "=TO_P"1J/\ A3?PG_Z)QX+_ /"=TO\ ^1J]*HHN^[_K_AE]P679
M?<CS7_A3?PG_ .B<>"__  G=+_\ D:C_ (4W\)_^B<>"_P#PG=+_ /D:O2J*
M+ON_Z_X9?<%EV7W(\U_X4W\)_P#HG'@O_P )W2__ )&H_P"%-_"?_HG'@O\
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MSX(M_AWXS\80IIFHVGQ+T7PSX:CN%U^Y^$_@31?%U]IWA;Q+K5GHUOKO]O\
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MBGPLUEXD?XA^-=4>V^P>*=(T>_N8HM/U[3;DW5M;RVS&9H5F,T4J)W/[7?\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KY*_:D_87_98
M_;2_X07_ (:8^%O_  LK_A6O_"3_ /"%?\5M\1?!W]B_\)C_ ,(]_P ))_R(
M'B[PK_:/]H_\(KH/_(6^W_8_L'^@?9?M5[]H^M:*ZL'C<9EV)IXS+\7BL#C*
M//['%8/$5<+B:7M*<J53V=>A.%6'/2G.G/EDN:G.4)7C)I\V,P6#S##U,'C\
M)AL=A*W)[7"XRA2Q.'J^SJ1JT_:4*T)TI\E6$*D.:+Y:D(SC:44U_!+_ ,%K
M_P!CKX+_ +'7[3_P>\+_ ++7PFU#P;X2U'X/:+XYUC2K;7/B'XYM[WQ7'\0O
M&NG/=S:EXQ\0^*=3M?,TS1=*MGL;34+6T5(1.ELEQ/-/+<_:I_X+7_M@?M;?
M 'XB?L\>.O@)\*O#WA3XDV>BV6KZSX3\*_$^#Q#91Z'XGT3Q5;/ILNL>,]7T
MU'EO="MK>?[5IURIM99UC6.8QRQ_WG45^NX3Q9PCP604\^X47$>9\/7J8/.<
M?GN)^M_677IXCZR^? UY^TYZ&'_BUJW\&&MM#\FQ?A7BUC,^J9'Q2^'LMS^U
M/%Y1@,CP_P!5^KJA4H?5URXVC'V?)6K_ ,*E1_C3TOJ?R0?\$5_^"8G[&O[5
M/[(WB'XE?M+_  )N_&?Q"LOC;XQ\)V>K7GC[XP>"9H_#&E^%? 6HZ;9#2/!W
MCGPMI4B0W^LZM*M])IKWLQN&BFNI8K>".'^H7X%_ OX5_LU?"OPM\%/@IX6_
MX0OX9>"_[;_X1GPS_;?B/Q'_ &;_ ,)'XCU?Q9K/_$Y\6:OKWB"\^V>(->U7
M4/\ B8:K=?9_M7V6U\BR@MK:'UJBOA.*N,,WXJQ^,Q&*QF8PR[$8UXW#9-6S
M/%8S X"?)*G!8>E4=.A&5.%2K"%2GAZ34*DXI)2DG]SPOPEE/"^!P=#"X3+Y
M9AA\&L'B<WHY;AL'C<=#GC.;KU::G7E&I.G3G.%3$54YTX2;;C%HK\#?^"KO
M[-'QY^-7_!0W_@B9\4OA5\+_ !/XX^'W[/?[0?Q5\4?&KQ7HD%O+I7PY\/ZU
MK_[.-SI6J^(I)KF&6&UOH/"GB*6%K>*X8II%V65=J[OWRHKY,^I/XE_VS_\
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M'\#_ +6GB7]MKPMXE^/+?'#Q!X]^+7Q/^PZY\4A?_#6+Q?\ &"V\81>(H_\
MA$4\-Q2+H%M)XTU1M)TQ=29M/2*R FN#;8D_GA^ ?[/_ /P6$^$W_!'_ /:&
M_8 ^#W[,'QX^!GQV^&_Q=N/']U\3]$\6Z'X>D^,OPZ\1^*+*V\8^ ?@EXFTW
M4K.XFUV"WLK37;[4M#\1(OB7PC9ZGH.C37]]KG]C7']U-% '\/\ ^Q)_P3_^
M.'@+_@J=_P $]_VMO!'_  3<_:"_9;^!&CZ9\6/#GQ>USXO?&6^^.OQ=UKQY
MJOP?\=>#)?BG\6%U74A>> M!U36?'>A>&_#>GV^BZ&FHV/AK7_%4GA_2[2[@
MC;]6/^"17['/Q>^%UY_P6)TG]H7X;^)/A-X<_:8_:W^,6M>"_$>NP:?92>*O
MA7XKE^(-M!XMT:\6XG5]+AL/$3W]E)>F*.!KMI6B02S$_P!%%(0&!5@&5@0R
MD @@C!!!X((X(/!% '^?$OBG]M3X%_\ !$3]L3]A33O@A\)/B?\ LZ?"K7?%
MMQ)_P4 ^'/[0_P -/'/P2UCX<:[\5O"WC+^P/!^D>#[KQ)J'BGXC>+?$>LV5
MGHNE3:II.J>&=$\9V=SXLT;1-0T**'5?HOXI_P#!/#XK^,O W_!&[]O'2/V3
M_'?[;?P3\-?\$S?V=?@;\>?V>/A;\5O&'P<^+^FQ67PYO]?\'^._"6M>"O%'
MA'Q?J5LUW\0H9[C1M#N[V&Y_X1EK+6[.UTWQ"NMZ7^V/B#_@W _X)@Z_XUUW
MQ&G@CXO>'O!'BCQ:GC;Q)\!?"GQI\8^'_@5J^O)<O=F23P98S)J%A9K*[1V>
MGZ/XATVTT>S$>G:#%I>G0P6L?[E^'] T3PGH.B>%O#.E6&A>'/#6D:;H'A_0
M]+MHK+3-&T31K*'3M*TK3K.!4AM+#3K"VM[.SMH46*"WACBC540  '\BWPF_
MX)I_&WQ9_P $W_\ @J=<>$/^"??AO]CWXJ?M4^%M-T'X&_!^?XX_&WXH?'#Q
M_P""/AUXEO/%^AQ?&75OC7\;/B-X5TKQE>P2IH7AQ=)L/A[?7^KIJ]QKVD:=
MHM_X=$7BGQP_8E_;)_:\_P""?/\ P3!\8:E^PE\4[3Q__P $NO$&C_!OXB_L
MH>.?B!<_"SQ]^TO\%[#X;_ >Q\;>/_AMXL\-ZIX;\0>$7U76/AM=^'=#L=.U
M,>,;:&6_US0CK,]M9Z3J?]M=% '\?/[*?_!,#7OVDKG]N37+;_@F\W_!/#P3
M\3/V3/B-^SM\!_&_QU^/_P"TO\6/VD]9\:?$/P]96-V_BW0?'OQR\:^#;/X7
MZ3K-I<:C>23?#;2=:,-QHMIX7U?5I4\17MO\@?'GX4?\%<OB]_P2$\$_\$PI
M?^"9_P 1M&\2?LV^*O!^C>,/BS'XQ\(ZIH?Q'\*>"O$NJR^"[3X4>';.[>Y\
M0ZK,-5TZ\\4>)=.UK4?"UAH_A74+D7BZAXJL-'TO^\6B@#Q3^UO$_P -/V<Q
MKFF^"]9\8^,_ /P575-/^'>D(I\0^*?$_A;P,+JT\%Z8A)C&L:WJUC'H=F&;
MRUO+J,NP0%A_)?\ L+?\&[7C[]H'X >.?C3^W%^T1^V5^SG^T%^U'X]^*7BO
MXX?!OX8>.O#'A+P[K.G:WXJ\0VT'_"R_#MWX<\3Q>)-2\3B^U[Q!-:ZAJ=U8
M+X?\46FGFSMYFU'S_P"SNB@#^-3PO^R%_P % (_^#?']M?\ X)R>.OV?_B)K
M'QD^$'QET/P;^SU:6MI9SI\8_A"/VF?AE\2_[>\%7,NHXOK#2[RQ^(VK)'<S
M0&S\*?V L*X9+>+I_$7QG_X+3_M%?L,Z'_P39^'G_!)7Q'\ IO$G[/\ X._9
MA\6_M'_%CX^>'Y_"UC\/[#P5I'PZ\<>(I/#,O@GPB^D2^(_#-IJ:/9V7B#QE
MJFEVNJ7$.E:/XEU&"V$_]@E% '\PW[37_!(C]HC]GSX7_P#!,7XV?\$^CX5^
M)?[4G_!,/PF?!U[X#\77UKX5T;]HGPAXHM)+CXDVFFZGJ6H:78:'J.J>(-9\
M<S6>DZEKNC)-X=\?:VD7B%=>T71[;5M3PIX]_P""WO\ P4"_:L_9GO/$?[/?
MBW_@EC^RS\"?&">,?CM<CXQZ+XU\6?'A8)+%[OP';Z?'HNCG6=#UJTL+G2-*
ML[OP9/X>\-)KFK>)M1\5:WK&G>&M);^F6B@#\Z?V6_VR/BU\;OVR/V[/V7_B
M/\#(/A=H?[*-_P#":Y^'OC9/$%UJ]W\5_!WQ8E^)(T3Q/?:8^GV]IX>2YMOA
M\]UIUHE[=SW<%U-,\<4,<,DWUO\ M":%J_BCX!_'#PSX?L)]5U[Q%\(/B7H6
MB:7:A6NM2U?5_!FM:?IMA;*S*K3WE[<0V\(9E4R2*"P'(U? GP=^%_PRU[XD
M>*? 7@C0O#/B7XP>+O\ A._B?X@T^V8ZUXW\5+IMIH]OJNOZI<23WMY]@TNQ
MMK#2[(S+IVDVJR1:;:6BW%P)?2J /QK_ ."!GP$^,7[,_P#P2_\ @9\'OCS\
M/M?^%_Q.\.>)?C)=ZYX,\3PP0:SIMMK_ ,7?&>N:/-<Q6T]S"J:AI&H6=_;E
M9F)@N(RP5B5'DW_!0?\ 9I^/'Q0_X*Z_\$B/CE\/_AAXF\5?"3X&W_QHE^+?
MCS2X+9]"\!Q^(--TV'1GUV66YBGB&HR0R);^1!/DH=VVOWMHH _G>_99_99_
M:%\&?\%4?^"T7QG\4?"CQ5HOPM^/_P ./A[I7P9\;7L%JNB_$/4=+\!Q:;J%
MIX?E2Z>:::TO@;647$-N!*" 2.:_#'P]^Q;^U7^RQ^PG_P $E_B[J_@?PEX3
M_:T_8O\ VU_CG\0=!_9+^,GQ.^'_ ,*?'7QQ\%?$3QY\--9U?3OAT/%>OVL/
MB7Q!'_PA'A:Q_LKP^VIZ]!I_C ZEI^EZCJ%K9:5?_P!]]?&G[;G[ W[,O_!0
MGX7Z;\*/VF?!-WXFT;P[K\?BKP=K^@ZWJ/A;QGX)\21VTMD^K>&?$>ER)/:M
M=64TEKJ&G7T6H:+J*"VEOM,N+FPTZ>T /Y=]'^-/[77CG_@O)XB^.'CO]F>Z
M^$7QPL_^"5OQ;\4_"']FS3/%>C_$WX@:3:Z+H_C4?#G0/'NKZ':Z9X?3QYXZ
M\<1S:G#H4+I#H6C>*_"F@ZM>KJ]OJ C]B_:3_P""<'[2VF_\&W'P,_8]^'GP
M;\7^,_VD?[>^&_Q-^('PXTN&SN?&-KXI\:?$?Q%\3_',&L^=J'D2ZCX6D\4#
M1M3D-](T?]F+$N1&$7]R/V)/^"3_ .R'^P3XW\;_ !6^#ND_$+Q7\8_B%HD?
MA;Q/\8/C+\0M:^)7Q"N?"<=UIU\/"]IJNHBTL-.TB2\T?2+B[%EI<-_?MI6E
MQ:A?75OIMA#;_I30!_*G^SC_ ,$[/BS_ ,$^?C?^T'^R+X&\-^/[K_@F/^WG
M^QWJT/BWXEZQJUGK5O\ LH?M VGP?U7P5XY\0>/]2U"]L#9:7XLL(]5U#5M8
MMM/MM+:35_!6GR2V.C^ KV2'\;?BYX\_;:^'/_! +XR_L1^(?V?OAAJ_[//P
M"\<:#I^I_MN>!?V@OAQ\1?A?\4/!VJ_M:>%/&OA3PQ\)-+\$RZW<>)?&MW\0
MO%FFWU_>MJNG1>'_ (::'J/_  E6FZ3XKNXM*E_T-;RSM-1M+K3]0M;:^L+Z
MVGL[VRO((KFTO+2YB:"YM;JVG5X;BVN(7>&>"9'BEB=HY%9&(/X2+_P;>_\
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MQ*M?";N=<N-!\,Z)\$_&<%W>:-;*MSX@TW0_$'B%M 5BNH72!"Y_HB_X(/\
M[27P?_:B^%G[0/Q ^ W_  3W\#?L#?#32_B5H7@^VTSP3;Z2$^*'B?1-&OW\
M2ZCK5UHG@'X?Z>=3\'F\T[1Y-,&GZC=:4=0=;G42;I+>'\NK+]@'_@JG\ _V
M!_V3-2T_X.?#CQK^U1_P26_;2\5Z[^S[X.\!ZM;7Z_M!?LI^+M)M=7\<7ZWM
MGXAMKB]O?%?B3Q%<:-_81LO!?C*Y\&^%KZ.^\.3^+FM)=:_2?_@A7\'OVT-&
MU/\ ;U_:H_;%^$B?L[:K^V?\?="^*7A'X!B*739?"%QH^F>(['Q;XIN?#MQ<
MW>H:+<>,)=6T"PGEUYK7Q'KUQX1FU[4;"WM-0TR:Z /Z Z*** /S?_X*M?\
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MHPM=#10!_*S_ ,'>O_*-CX(_]GQ?#7_U0O[2]?U35_*S_P '>O\ RC8^"/\
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MZ&\QU*X=[1#Y80 _'K]HN]O_ -AC]M?_ (.!O@W^QE8+\,OA;?\ _!._P?\
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M-OX'M+A+75;@1ZZNUEE_%[_@H=_P3OTW]AC_ ()4>"?@O\3OB#^TQ^TEX"^
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MG@OP*=*TS2O!UA877CO0IFTI9M5U'Q)XGUSQAXF35];@74+G3O[GZ "BBB@
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MP;JWPA^.GB34-$:Q\:>-?$FEQ17.M^$O#U^UU;V,5^CZ:D,5W';SW4,_]U-
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MK3=:GF.#^L4W7J8FO54ZGU?V+GR4Z:C5=17E'E9ZU1117Y4?J(4444 %%%%
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MJ<E.,*<.>I.4N2G"$(WM",8I)%%%%>*>R%%%% !1110 4444 %%%% !1110
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MWPM_8*\2_MJ>!(A\0/["_::^)OB+XG>.O''Q+W_%+QM)J9UOQ5J/CHWFJ_\
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M;:XN]8L9+>6YW1PS ']$%%?S??M1?\'#6G?!;XZ?M"?#OX(_L/?&K]JCX/\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M@"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M#0/&/[;OC+P?-\1/!6K_ !&^&7AS5M8U:7QIX0U35=*\,_$M-<L+B"RO]/\
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ME1A.I-I.T8MV/PK_ ."\'_(=_9F_[!/Q8_\ 2SX>U_0QH'_("T7_ +!.G?\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M#_$^B>)H-/GG1I((+V;1;Z]CM9IHT>2*.=HWD1&9%95)'\U?_$))_P $QO\
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M^'VG6_Q,\,>)_#FD>-/A_K_CO5_%EW\4_%/_ !(_$FGWFEZUI>E?$G5[S4-
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MRN_CUX(\-7/B'PU:7L&H3:#J/A#XB7U[I;O<7UQ&;6YN]*TZXD41AC):1$,
M"#\=?LJ?\%#O^"QWPM_9V^$OP^^ W[%FL?$#X/\ A3PG;Z5\/_&<'[*OQ_\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MQ#T/1]?T'1/%]EIFI1SV#ZWH^F>)]<BTJ[N;:<Z?/??;[18=0MK2ZM_YPO\
M@W&_Y+3_ ,%G_P#L_CQ)_P"I7\7* .'^,W_!='_@H%XR\<_MF_$?]@S]D'X+
M?%3]BK]@#Q-J?A[XY?$CXF>(O$,/CSQU;>%+K4D\8^(?ATFD^-O"UEI6E6.G
M:)K7B".,>%/']WI_A"UL/$FKQPW>L6WAJ'^C']CC]J'P/^VE^S#\%_VHOAU:
MW>F^%?C'X-MO$MOHNH317.H>'-7M[N\T3Q3X6OKN!(X+R\\+>*M*UKP]=7L$
M44%Y-ICW4,4<4R(O\>O_  2;\7^%_A+_ ,$C_P#@OM\.OB;K.G:/X_\ A]K7
M[4VF^-]'UB[M(M82_P#%?P,U?X9^&K.XBOYXKJ>ZU_XA:%K/AK3(KD+]LUU_
ML4+/>7#QU^F'_!)K]FKX]_&K_@W7^#/P0^%7Q[\7?LH_%GXE/XU\2^ /C7X8
MBUR?Q-\/M 3]KC7_ !X\VEVVB^)/".J+;^._".D:KI+#3_$.GQ2:1XTEO)_M
M<,US97(!Q7_!WK_RC8^"/_9\7PU_]4+^TO7]4U?YV/\ P79_X)R_MR?LA?LC
M?#KXE?M,_P#!4'XO?MK^ ];_ &C?"/@?2?A7X_L?'5KHV@>+M2^&?Q>U^P^(
M%M)XG^+/CRP.IZ5HWAG7O#D*0Z1;7AM?%=ZT>I0PK<6MY_HG4 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %?E[_P
M4[_;,\,_LY_"VY^%D6AQ>+_'?QP\(>-O#2Z0-:CTH>%?!^KZ!J?AVZ\9ZALL
MM3N9W.JZA#::%I;VUE;ZVUEKS+J]JVBR0W'ZA5_+C_P5%\&>)?@Y^W+X*^/'
MQ"TG_A:?PJ\6WW@OQ'H/A[7G']CW&E_#Z31;;Q9\+)UCC6WM[;?'_:L:M926
M5U:^+(Y=1BUJ\&NFY_4O![(,JXAXUPN&S9^UIX+!8S-,)ED:KP]7.<?@81J8
M;+Z-=5*2I2UGC)2E5A&5/"3A)J$IRC^+^/?$^=\*^'F,Q>1Q]A5S#,,!DV.S
MB5".*H9!EF95)4<7FE?#.G6=:#]S 04:-24:V.IU(1=2,(R\W_X)9?MF>'/V
M9_B+J/P\\9:'!_PB7QP\4>"]*U;QW/K::?'X%ETN#Q'I^E7UWI\UB]M>Z3=:
MKXBLTUJ^N-5TM-#TN*[U/%[Y!MG_ *UJ_DM_;Q_:D^&7[>7C+X&^#OV>OA!X
MET[Q?;ZG?^&X]3\3Z/X>T/Q1XAU'Q=J&D66@^%;&#PUXGUW2Y]&AO8I;Y[S6
M[DS65Y>R'3QI=I)K$NK?0\/_  21_;GCABC7]IOP; L<4:+!%\1?B^(H55 H
MBC"^%$41Q@;$VH@V@851P/UGQ&X2X=XEQ&4\5\29M0\,>(,\PV(>9Y)F_M<Y
MJXAY?5A@<+C(2PU6C["^#I4(R7L*-.I'V5J2KT\34K?AWA-QUQ7PAAL[X)X2
MR/$^,?"W#F+PJR?B/(_8Y!1PD<THSS'&X"I#&4,1]9Y<?6Q,XOZSB*M*?MFZ
MTL-5PM*A_2717\W/_#I3]NG_ *.@\(_^'&^,'_S+4?\ #I3]NG_HZ#PC_P"'
M&^,'_P RU?FW_$/.!/\ H[V0_P#AES#_ .:3]=_XBKXE?]&'XF_\2'*__F,_
MI&KX=_X*1?M,>._V/?V+OC-^T9\,])\):YXW^'?_  KO^Q-+\=6&LZGX5NO^
M$N^*_@7P+J7]J6.@:]X8U>?R-(\3W]Q8_9-<L?+U&&SFG^TVT<UG<?DW_P .
ME/VZ?^CH/"/_ (<;XP?_ #+5\L_MJ_L'?M-?LQ?LS?$OXX_&7XU:!\1OAOX(
M_P"$-_X2/P;IGB[X@:]?:S_PDOQ \*^$-'\C2?%6B:=H-W_9^O:_I>JR_;[R
M'R(;&2YM?,O(;>)_5R+PZX#GG>3PEXH9%FL9YKE\998LGQT'F2EBZ*> 4Y8G
ME@\8G]74GI%U+O1'F9WXK^)<,FS><?!;B7*Y1RS'R69O/\LFLN<<+5:QS@L(
MG-81KZPXIIR]G9--GY5?M5?'[]OS_@I[K7PI^.&O?LJZWK&F_#[3-3T+P?KO
MP"^!OQIU#P5K<47B,WNI?;-4O-9\?P:E=V.L6,NGW']EZM9+;-#<6D\(NHV=
M/WF_X)E?\%AOVN_VO/VRQ^S+\>OA9\%? %C8>&?B'>>([/PMX(^)WA7QYH?B
MCP.L<,VAZE;^,OB=XEATRXL]1%S9:SIE_H":A;W$#VS-:3Q2"OQ8^#/QL^#]
MS\/=&FG_ &W-!_9_E:;50WPKU3PY^U%+>^']NJWBK<2R?"7X0^,? A&MJ!K4
M?]D>(+R81WZC4TM=2%W:PO\ V6/"$_[8O[4VN_ _X(^(_#E[XVNC\0-?M/BW
MXF;Q+X<\-^--*\.WDDU_XGAOV\,WGQ$B/BZ&5-8L8/$GA/3-:D6\"^(;/2]1
M%Q;Q_N6?\%<*9AD>999CJN597E^18#,H91CYY+G%*GD<,14YZ^*IUL3.CAL8
MHRIPK2^JU91FX*<)*FTS\2R+Q'X[P.=9=F6"X<SW,L?G>.RV>:X&'$.1U*F=
M3H04*.&J4L-2J8G".49SI1^M4E*"FX3C[12/[_Z*_ER_X<N?MH?]%7^!7_AP
M?BM_\Z:OD#]K+]C/X\_L;VG@:\^*/CGP9KD7Q N/$-MHJ^ ?%7C+5I+:3PU'
MHTM^=4'B'PGX56!)5URT%H;1[YI&CN1,MN$B,WX?E7A%PCGF/P^5Y3XL91CL
MPQ3J+#X2AD6(=6JZ5&>(JJ"EF<5[E&G4J.[7NP?71?LF=^.O'/#>5XK.L\\$
M<^RW*L$J+Q>-Q'$>#5&@J]>CA:+FX93*7[S$5Z5*-HOWIQO97:_M,HK^-_1_
M^"&__!2GQ;I&E>*]&_;/\$Z=H_B;3;'Q#I6GS_%GX]P3V.FZU;1:E8V<T-KX
M.EM89;6UN8H)(K:62WC="D,CQA6.C_PX6_X*=_\ 1[G@3_P[W[07_P Q5?-U
M. ^#Z52=.7B?DRE3G*$D\IQMU*$N62:^L/5-/J]M]=/T6CQUQ;7HTJT/#3.'
M"M2IU8M9K@FG&I%3BT_JZNK-:V7HC^P^BOX\/^'"W_!3O_H]SP)_X=[]H+_Y
MBJ\ _P"";6E?'[X'_P#!:OX8_LT?%?XR^*/'UW\/?$GQL\,^)TM_'7C37?!F
MMWFG_LZ_$[58)[:S\226DMW;07!M+FW.H:5!+%=V\<R1))%')6B\.,EQ67YU
MC,GX[RW.*V2Y/CLXKX/#99BJ=2=# T)591]I4Q'+#VDE&DI\L^5S4G!JZ$_$
M3.,+C\FP>;\#YCE-+.<VP.44,7B,RPU2$*^-K1I)\E/#N4_9Q<JKC>',H-<R
M;3/[CJ***_)C]4"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MLS?]A;XL?^D?P]K^@*OY_?\ @O!_R OV9O\ L+?%C_TC^'M?9^"'_)T>%?\
MKYFW_JBS0_,OI'?\F8XU_P"O>1?^M/DI^WWPA_Y)-\+_ /LG?@G_ -1K3*]$
MKSOX0_\ ))OA?_V3OP3_ .HUIE>B5^:8_P#W[&_]A>)_]/3/U_*O^17EO_8!
M@_\ U'IA7\:/P5_Y6;-9_P"RM?'W_P!9?^(]?V75_&C\%?\ E9LUG_LK7Q]_
M]9?^(]?I7AE_N?B-_P!F\X@_]-1/SWQ)_P!\\//^R_R'_P!.R/[+J***_*C]
M1"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MIOAJQ\4Z[#J]MKG@[7=%T'6(')_?[_@E!_P2W\/^$O\ @COX*_8R_;=^%_\
M;L/QGU74/BW\:?A#K.JZ]H<VEZEJWC[1?'?@;P[K%_X7U?1=>TO6_#EGX.^'
M]_KVGVFIVDMEXCLM1T6^$]O#=0S@'Y3_ /!T/^W#^QS^TM^P)\(? ?[/?[3_
M ,"OC7XTTK]L#P#XNU/PK\,/B;X2\:Z]I_A>P^"_[0&C7OB"\TS0-4OKNWTB
MUU;7]$TZ>_EB6WCO-5L+=I!+<Q*W](G_  ]F_P""8?\ T?\ _LA_^']^&W_S
M0U_*]_P<D?\ !+#]@;]A_P#8<^%7Q8_99_9YTCX2_$'Q!^U=X'^'>L>(]/\
M&OQ.\1RWO@W5_A#\<_$NHZ(]AXS\;>)-*CCN=;\(^';XW<%A%J$;::L,-W';
M7%W#<?T%_P#$/1_P1R_Z,I\,_P#AT_CW_P#/5H ^EO\ A[-_P3#_ .C_ /\
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M_P!&4^&?_#I_'O\ ^>K1_P 0]'_!'+_HRGPS_P"'3^/?_P ]6@#Z6_X>S?\
M!,/_ */_ /V0_P#P_OPV_P#FAH_X>S?\$P_^C_\ ]D/_ ,/[\-O_ )H:^:?^
M(>C_ ((Y?]&4^&?_  Z?Q[_^>K1_Q#T?\$<O^C*?#/\ X=/X]_\ SU: /I;_
M (>S?\$P_P#H_P#_ &0__#^_#;_YH:/^'LW_  3#_P"C_P#]D/\ \/[\-O\
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M )ZM 'TM_P /9O\ @F'_ -'_ /[(?_A_?AM_\T-'_#V;_@F'_P!'_P#[(?\
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M\,_^'3^/?_SU:/\ B'H_X(Y?]&4^&?\ PZ?Q[_\ GJT ?2W_  ]F_P""8?\
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M^'3^/?\ \]6@#Z6_X>S?\$P_^C__ -D/_P /[\-O_FAH_P"'LW_!,/\ Z/\
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MW0=)\.2ZC=23S7&FZ/KOPX\2WVBP37-Q)I&GZY%H=J\.BZ9H]G:@']*]%%%
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MZ%J]U'_4K110 4444 %%%% !1110!_*G^WS_ ,%./V@_@M\6?VT_V1?VY_\
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M/#GB/_A#M1\/:@(/[,_^"77[,_B7]CW_ ()^?LJ_LY^-8X;?QO\ #OX76/\
MPG-C;7,=[;Z7XW\7:IJGCOQCHT-[ \EO>Q:+XE\3ZII27EL[VMVMF+BV8P21
MU][T4 %%%% !1110 4444 ?GC_P5@_99\5_MI_\ !._]J7]FSP'';7/CSQ_X
M"L-0\#:?=W<&GV^L>-?AWXO\-?$_PGH,FH74D-G8?V_X@\&:=HJWU]/!8V;W
MZW-]-#:132+_ !;?%%/''[>7[*?_  3?_P""5OP(_P"">OQX^!W[9G[,/Q%\
M(Z3\9_BOXG^$,'@OPC\/=.\.>&]=\,^-/&ESXX46^O65EX]U^^TSXP>.+CQ-
MI_AQ%\3^';;3]'E\7ZM>:/<W'^BO10!_(;^T[XG^('_!([_@N'\:/^"AGC3]
MG[XW_&K]E3]L7]G/3/ $_B/X'>$;?QGJ?@_XE:)HWPET]]#U>&[O](L-,U"^
MUKX.6.H1V^L:QI4.I:+XXN;_ ,/RZU=>%]5T>T^MO^#<W]FOXU_#WX7_ +8'
M[6?Q\^'7B'X1^,OVZ?VD-7^+>A?#WQ;I]WH_B;3/ -E>^)M9T75M6T:_M-/O
MM*76?$'Q \7+I4%[IUC<7VAZ?IFNPVXTW6-.9OZ/** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** /P*_;1_X.+OV*_P!AC]J'XF?LE_%3X2?M
M8^+?B3\*E\&MXAU7X7> OA/KW@^\7QO\/O"?Q(TIM&OO$?QO\(Z]<+:Z'XQT
MNTU(WWAO3A#JT-]!;&[LX[>^NO3?V#_^"^/[ /\ P4#^*-O\$/AKJ_Q/^%?Q
MAU6*_E\+?#SX\>$=$\(:OXS.E6]Q>ZG:>%]5\*>+_'?A2]U>RT^UFU%M NO$
M-CKUU8Q7-SI^FWD=AJ)M/RS^!?\ RMY_MF_]FU^%O_69OV4:Y[_@Z/\ "GAK
MX._$?_@F[^V!\-M&TSPW^T1X;_:$FTNW\5:!:6^G>)_%6G^%;KP=XT\,0ZQ>
MV4:ZAK"^%M?TUH=':=;HV,?BG4K4'R[](7 /[%:*_E^_X*Y>-OC3I/[5\%E\
M7?\ @L;\,/\ @FM^Q[HOPOM]4\$^"/@KXD\1ZQ^UOXU\:NNGK?Z[XT^&_A[1
MM*\5W/AB^U.XUNVTB_T#Q/K^AQ:1X8TVTA\/1>(/$.M:AIWYK_L8_MT?\%%O
MVL_^"5/_  4ZB\!?M9_$3QK\9?V%O%W@CXF_!#X^:=IEMH_Q#^(GPC@'C?5?
M&WAOQ%!J.E2ZOJ]IJ7@+P-XB\5>'[+Q#;W_C*'7=1T[1;W4KJ+3K&SM@#^ZF
MBOX[OVP/^"QOQQ\7?\$8_P#@GYXQ_9L^(&K:-^VO^VEXV\%?!%M:\,'3D\8+
MXV^$VIIX7^,NIZ7;3VMS!8WOB[XB67@W3HK3[$ = ^)<30,L,T#R>!_\%-OV
MWOVH_P!GC]NSX)?L3_M/?MR?M/\ [)O[+'@3]FSX62:E^TE\!/!HUCXC?'KX
MG2>"=-'C/XJ>(=;T\Z7XEN='OOB'%KV@:IIWAA=3LM".@K%;^"6GUJYU*V /
M[C:*_!;_ ((9_%OXS?$KP9\=++QE_P %%/@G_P %$_A#H7B^S?X*^-]!E\5:
M;^TCX)\-7EWK<=M8_M >$?%W@_PKKV@3>)]+M-.U;1;/69O$5UIVKVGB?3M.
M\6>(='CM$T?]Z: "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH _C^_:I_8K_ ."Q_P )?^"U?[2O_!1?]@K]G7X._$_P[\1O
M!/P_\!>$]3^+GQ#\"6NA:CHT'P(^"W@WQ=/)X3;XN_#CQ=8ZC8>*? %_86,]
M]<6]O+#!)=QVMY:7=I<5V_@W_@FM_P %6?\ @H]^V'^SE^T7_P %>IO@;\*_
M@I^RGKK>,? O[._P;U&UU?\ X2GQ4NKZ/K@M[B'2_$'CS3[31=?U7PQX9?QI
MJ^N_$'6=3NM!T.W\,:#H&GC6=1UK3?ZRJ* /Y#?C?^P+_P %'O@)_P %@_VA
MOVV/@G^QA\!?^"@/@#]H[0K&R\!:[\;/'7P^T2+X!:P^G>#[&VO+NQ\<:Q::
M]I%SX(3PG/H]O=>#M(U5M<\ 7L&FZ7K>DZY=WVD1?57_  0N_P"">?[8G[%7
MQ&_X*+:?^V7X"\$7VC_M*>.?!GC'0?'O@WQ-X2\0>!?B)<PZA\6V\>V\7A&/
M4F\5^'M'U(>.].N=*T[Q/X9TP2:?)J%C>1P2V\,%Q_217SK^U?\ LS>!OVPO
M@'X[_9W^(^O^/O"OA'Q^/#AU'Q'\+O$J>#_'ND3>%_%>A^,--N?#OB.33M6B
MTV=]2T"TM;TRZ==QW6EW%]8O&%N2Z '\-7_!(W]AVY\1_P#!;_QY\!(/%Q^(
M?[+'_!+[XT_M"_%WX?Q+=?VMX;TKQ7JOBG1O!WP_TVUNY$F%MXI7Q!H/A+Q+
MJ\,4SVYUSX2:V]M.[K+<W/\ 03_P4=^&/_!467]I67Q/X)_9B_9P_P""H7[
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-** "BBB@ HHHH __V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>38
<FILENAME>nt10014672x1_linechart11.jpg
<TEXT>
begin 644 nt10014672x1_linechart11.jpg
M_]C_X  02D9)1@ ! 0$ P #   #_[0 V4&AO=&]S:&]P(#,N,  X0DE- ^T*
M4F5S;VQU=&EO;@     0 ,     !  $ P     $  ?_B"^!)0T-?4%)/1DE,
M10 ! 0  "]!N;VYE @   &UN=')21T(@6%E:( ?4  < %0 3  L (6%C<W
M         $E%0R!S4D="     0            #VU@ !     -,M2% @(
M
M$&1E<V,   %$    =&)865H   &X    %&)44D,   ',   (#&1M9&0   G8
M    B&=865H   I@    %&=44D,   ',   (#&QU;6D   IT    %&UE87,
M  J(    )&)K<'0   JL    %')865H   K     %')44D,   ',   (#'1E
M8V@   K4    #'9U960   K@    AW=T<'0   MH    %&-P<G0   M\
M*&-H860   ND    +&1E<V,         &G-21T(@245#-C$Y-C8M,BTQ('=I
M=&A"4$,
M                                                    6%E:(
M     "2@   /A   ML]C=7)V        !      %  H #P 4 !D '@ C "@
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M;W5R(%-P86-E("T@<U)'0@
M
M      !865H@        8ID  +>%   8VEA96B            !0
M;65A<P         !                               "6%E:(
M  ,6   #,P   J1865H@        ;Z(  #CU   #D'-I9R      0U)4(&1E
M<V,         +5)E9F5R96YC92!6:65W:6YG($-O;F1I=&EO;B!I;B!)14,@
M-C$Y-C8M,BTQ
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MU=;7V-G:X>+CY.7FY^CIZO'R\_3U]O?X^?K_Q  ? 0 # 0$! 0$! 0$!
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M:.TD<K[9;:9HZ_TE:_SA_P!COP-_P0*C_:(^%7C?XM_MN?MP_M1?M#ZQ\7O
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MC=7$DR6UU:VTT2JZ%C_1U7^>E_P4<_X+5?L]?\%3_C'_ ,$W_ WP7^%_QE\
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M:!_9]I;Q10Z#X=\,#X[?$S0?#6EV*PZ=IFG:YIVC06XAMK/R/TQ_:+_X+T?
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M=<M?CC'\#O+^UV_C^_UI+KP&?BD\QLY_#]@_A6WA2XCO))0#Z+HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MXA\%ZS;ZG%9W@19)-+UNPS'JOAW6[='1KO0M?L=,UBS#K]JL82R@@'ME%%%
M!1110 4444 %%%% 'X*_L,_\IT_^"YO_ &+/_!./_P!9FBK].+;Q%^R-_P -
MR:GX1MK+P2/V[!^RUI_B74[]/!^IK\0F_97?XJ7.E65L_CTZ(-%?PH?BK"[R
M^%(O$3:P-3BL=6N]&%@FGWH_,?\ 89_Y3I_\%S?^Q9_X)Q_^LS15^OL/Q4UZ
M3]HR_P#@FWP4^)4/AFV^#-A\3H_VAWLM"_X5#?:U<>-+SPN?@_#J2ZP?$;?$
M*TLXF\8-8'1#ID?AZ1[FXOK6>?3H]2 /;:*** "BBB@ HHHH **** "BBB@
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M1R:^3OV??^"</[&'[*7QJ\<_'S]F[X(>'O@KXZ^)7A'_ (0KQK8> +S6-#\
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M ,%D="T/PO\ \%MO^"$?AOPSHVE>'?#N@^.OAEI&AZ#H6G6FD:+HVDZ?\?\
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M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7X4^-/\
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M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %?R7?\ !>+X!_\
M#3O_  4#_8>^!W[5/[2GB']EW_@GIXX^$WCP?\)\FJZ?H?@;4?VF-#U3Q%JD
MWA3Q+KOB2>'P#X>\2:YX,7P8O@O6/',=W$8K7Q1I?ANUDU#4;\C^M&OY O\
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M68GR714&ZOR:_;Q_9>_;*T_]E_XB:[XO_;'UCX\>$O#*Z+XC\3?#9/@CX3\
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M^*_!7A_7-<UBPU_XOR^.M>\-W^L>(CIT4>C@']U5%%% !1110 4444 %%%%
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M$,<?B$Z<[C689=**@C48Y+3SE/\ ;K7\9_PD_P""O7_!N1XJ^*WPQ\+^ /\
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M5XUSBG6APO02=I3R>A3G0QO%E:-I*$LOJ83)7-6GGJG&5"7P7^T/\+/VNO\
M@I;X,-]#\*_#O[/OPE\%G4_%WPJT?XG"?_A<_P 2O$8TK4[+3X[Z"-XK+P/X
M>UR"2"*2VU1;**UNYK#4UO?%VG1V][IOA>E?\%%/^"@G@&32_P!D[4_@-8ZO
M^T19:-#X:T+4M0T;7M6\9ZE#9Z2TT'B>?1;/4KK0_%5W;Z+87VKW'B>VNSX:
MNELYM:U*"YLK34EN?Z2J_"GQI_RG,^$?_9/=2_\ 5$?$ZOT?@KBG+^(<+GF2
MYIPCP]B,BX4X:X@XKX>RV<,;*6!QF64(5YT:N-EBWBL;1S*;C/,OK,I*O5A&
M4(4J484(_DOB'P7FG"V,X<XAR;COBK"\2\;<7\+<$<59O3J9="&98#.<34PU
M/$4,NA@5@\NKY1!3AE'U.$)8>E4G&K4KUIU,1/ZW_P"";_['_B;]F'X=^*O%
M'Q2O%O?C9\:-2T_Q)X_A2\CU*/P];V/]IW.D^')=1ADFM=1UN&ZUW6=1\3:G
MI\KZ?<ZI?C3[*XU*RT>SU?4/T>95=61U#*P*LK ,K*PP58'((()!!!!!P:6B
MOQ?/\]S#B7.,=GF:5(3QV/JJI5]E#V=&E"G3A1H8>A3O)TZ&&P]*EAZ$'*4H
MTJ4%*<Y7D_Z$X7X:RKA#(,MX;R:E4IY=E=!T:/MI^UQ%:I4JU,1B<5B:O+%5
M<5C,56K8K$U%"$9UZU1PIP@XPC_-5^UY^S1\5/\ @FS+JWQ__94^..N>#/AO
M\0/%]CX6O_A^Y:XO]&O=3L-=U;2K)H]0MM5\.>,=#TA;'6X=&U+7K&T\1^'[
M:\MK-+C6KF?4M:G^R_V"OV%=6LO$WA7]M3]H+XF7OQ@^+OCGPEI?B[PG#=RZ
ME?6?A:+QAX>MI++5M2U?5I$O-;U^R\,7Z:+IVG)I]AX?\*QRW46EQ:G):Z)J
M6EWO^"V'_)HGAS_LN'@W_P!1/X@5^AG[,G_)MO[/?_9#_A/_ .H%H%?LN><9
M\05_"W*,SGB<.LWX@S'-N',ZSFG@,%3S?,\ER[#87ZO@<7F,*$<54@XSY*\_
M:*KB(14:TYJ=7VGX!PWX?<+X;QHS[)Z>$Q3R+A?*<CXMX>X?JYEF%;(LGXAS
M7%XWZUF6!RFIB98.C54J2J8:FJ3HX6K)SP].FX4/9?/O_!0;]G;X.?%[]GOX
ML^//'O@NQU;QM\*/@[\3O%7@+Q7!<WVEZYHFI^'_  CK/B"P@>\TRZM3JNC_
M -I64<TNAZRNH:26EN)XK2*[E-R/C+_@CK^SE\&;CX*Z5^T+J'@G3]6^+I\7
M>,-$L/%FK2W>HR:'IVGRVEK - TRYG?2-(OC"\Z2:S:6":VT-U=6@U%;*XDM
MF_3G]KK_ )-0_:>_[-Y^-/\ ZK;Q+7QK_P $<O\ DRS1?^RB>/O_ $NLZ\3+
M,YS>EX-<08>GFF84Z%/BW*L!3HPQF(C3IX'%Y=CZV*P4(*HHPPF)K156OAXI
M4:U2\ZD)2;;^CS?A_(:WC_PQBZN2Y54Q53@;/,SJ8BIE^%G6J9E@<VRK#X+,
M*E25)RJ8["4)RHX;%S;KT*34*52,8Q2_5"BBBOQT_>PHHHH *AN;:WO+>>TN
MX(;JTNH9;:YMKF))[>YMYT:*:">&56CFAFC9HY8I%9)$9D=2I(,U%--IIIM-
M.Z:T::V:?1H32:::333335TT]&FGHTUNC\N?'_\ P2 _8X\=>*=0\46FD>.O
MA^-3FDNKKPYX \36&F>%DNYYY)[B;3]*UK0/$#:1#*\I6/2](NK'1;"%([?2
M]-L8(UC'W3\$_@1\*?V=_!-O\/\ X0^$;'PEX<BN9;^[2&2YO=3UG5;A42YU
M?7M8U":YU/6-2FCBB@6XOKJ46MG!:Z;8)::;9V=G!Z[17T6:<8<4YW@:&69O
MQ!FV8X##.$J6$Q>-KUJ*E3CRTYSC.;]M4IQNJ=2M[2<$Y<LES2O\GDW ?!?#
MN98G.,BX7R/*<SQ<9QK8W Y=AL/B'"K+GJTZ<Z<%["E5DE*K2H*E3J.,.>,N
M2-BBBBOG#ZT*^8/VM?V,OV:?VZ?AA9?!K]JKX8VWQ6^&^F^+M*\>:=X?G\3^
M-?"$MAXNT33M:TC3-;L]=\ >)/"GB.VN;?2_$6N:>T4.KI:W-IJ=U!=03QN%
M'T_10!YC\)?@S\,/@7\)? _P+^%/@_3O"7PG^'/A'3O O@_P;!+?:I9:;X7T
MNS%C;Z?=7FNW>J:MK<\\(>35=5U[4-3U?7+V>[U'6K^_U"\N[J;\B=0_X-R_
M^"1.H_%B;XL2?LPM:R7&LOXBN/ASIWQ(^(^G_"237)-6_MAKF/P):^)H["RT
MA;AI+6+P3IT]G\/K?2)&T6W\)Q:2L5G'^XE% 'QU\8/V OV1OCS\:?@'^T+\
M5/A!;>(OBY^R_=:1>? GQ/9^,OB'X5M/ $V@Z[9^)-'6U\)^#_%V@>#-:MK#
M6=/L[J"S\3>'M:L_*@6Q>!K M:M5^)G_  3U_8_^,7[2?A_]KSXC?"+_ (2+
M]H?PM\-/$?P?T'XA?\)]\3](^P_#GQ;X7\?^"_$/AW_A$]"\:Z9X'NO[0\-?
M%'QUIO\ :]YX:N-=M/[<^V6.IVVH:9H]UI_V?10!\(_"_P#X)E_L,?!W]E_X
MA_L8>!/V?M MOV8_BMJ^L:_X^^%'B7Q-X_\ B!I6O:YKEIX>M+O6!K7Q!\6>
M*/%6E:I:'PEX9U'0+_1=>TZZ\+Z]H>F^)/#,ND^(+6/4Q\P?LS?\$%?^"8_[
M)?QST3]HCX1? W6$^)'@_5)]9^'TWC'XE>/O&N@_#[4Y["]TW[?X>T'Q!KUW
M8WU_:VU_.^E:CXN7Q/J.B:BEIK6BW>GZU866H6_[&T4 ?G)X5_X)(_\ !.[P
M9\/_ -I+X6:)^S5H4O@#]KK5=/U[]H+PWX@\:_%'QA:>.=>T?4=?UC1==LKC
MQ=XYUR_\"ZWH6L>)M8UC0=7^'=WX3U'1-6FM-3TJYL[[2=)N+'R?]DS_ ((:
M?\$V?V+/C#9?'KX)_!#44^*6@S:O)X+\1^./B!XV\=IX"BUJS>PNXO"6D>(=
M:NM&M+J.RFN[6SU_4;#5/%-G!?W\5OKR)=S!OUSHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "OY$?^"YG
M[0GPS_8O_P""IG[#W[5.N_LMZK^U!KFC?L[>.O!'C?P=JFDZ;JGA&;P#J'BW
MQ,/"FL>%[R_T+Q)#X<^)O@CQ)K/BC48IK[0]0LO$6@^(#I:7WANYM$U*?^J_
MXL:9\1-;^%GQ*T;X0^)M'\%_%C5_ 'C+3/AAXQ\0Z4NNZ!X3^(E_X=U*U\%>
M)M<T1XITUC1]!\2RZ9JFIZ4\$RZA96L]HT4@F*-_-'XU_P""VG_!1[]@R]NO
M!G_!1_\ X)?>)O$UMI$C00?M(?LH:YK.H_!SQ=96_P"ZAU6RM]7T;Q7H^F7>
MI1A+^73=;^('A?7+3SS'>>#-%(%K" >-?"G_ (.(/V1?'OQ1^&W@72O^"5?Q
M$\,ZIXT\?>#O">F^([CP9\,H8/#]_P"(_$6G:/9ZW/+;>%H[B*+2;B\COY)(
M)(YD2W+12(X5A_8!7\G6A?\ !T3=_'*X_P"$:_8Y_P""87[6/[0GCVY*VMKH
ML=U;6EA:7<Q*+/J=U\/_  M\4KBWL+4/%<W4UW;Z;;K )3<7VGP(;Q?V(_X)
M]^)O^"H_Q/U7QQ\6/^"@/@GX'? #P5X@T/2;'X0_LU_#*>;Q/XZ\*W(OIKS4
M?%7Q3\=-JOB'3[C5KS37M-/L]$T+6DMH0;F75= T'4[?[/* ?I[7YL?M$_\
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M4</7Q<<7AZ=.CA93> JX>6)ESJ/-&2Y7^W-%%%?BQ_0@4444 %%%% !1110
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M['.C:S'X(EUCQ-XR\506$'BKQWXF:S;5;VWL%WQZ1H]G96\%IH'AX7SS7_\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MMO$IURVTR_TAY-"MM*6.,M^\$44<,<<,,:10Q(D4442+''%'&H5(XT4!41%
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M\-WE[XXB\#^$+:1FFU75/#&M6>F_:AI\A7]B_P#@IM^TM^WC9_M"_P#!-/\
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MB^)]S_P6Y_;"^&?[-'[-WB76-#^ /PK\%>+_ !MK?CO7O#^H65I+KYMO(O\
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M\._#_5[:X!^TZ1XVU?0-2M[?%Y-:I9D3GV[XO_MC_LN? .?X/6_QB^.?P^\
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M3#J?B^U\*^-O%=_9VLCV^+O[\_9F_9>\?_![_@NQ\&?&&BS?\$TOV2/B#8_
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M)H7V36/!OB:P.J>&?&5QJ]K<W.CZ'X0\2Z>#=>'/%'B"_P!*T'7HN=)U"\)
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M$^_X6?\ :?\ A//^$_\ ^%F?\CS_ ,3SR?\ A,_(_P"89Y7]C_\ $OK[UHH
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MO_8V^&O@_69O@;\0X/B1;_$#2?$GBO7-2\1^-(_BSIT^B>.'UOQ?976EZ_\
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M'1M<DAE\)Q:%-J9U1=8\2^'%MD=/$%B+0V[79E9;@2+"(T,OP5_Q$+?L+_\
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MT\ _"*Z\&:IX4^(K>'-)^$7AS5['1-:\5:7!J=]I-['J\&GZ#87FL#\Q+/\
M;B_X*$?#7Q'_ ,%A_P#@DO\ MK_%KPM^TIXO^'__  3W_:C^)?PM^.NC^&E\
M.^)95/[.>E^+].T,VWAC1='M6M-7^&_C6XUU8-;L)]8\._$'2[G0XO%/B;2=
M2TZ:/]L/^"GG_!'W5/VWOC?\$/VP?V?_ -I;Q+^R?^V#^SWH<7ASP3\2-.\.
M)XO\/ZUX=TW5O$/B+0]&U;2TUC0[S2+FPUKQ7XD236(9M=TW4=!\0:UH.O\
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M%% !1110 4444 %%%% !7\O_ /P6+\._&']O7_@HC^R7_P $BM"^.FL_L\_
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M,=MK%II>J'PMX>\.Z3_;VLZ;I7]O:WJ^E07.B:A_5]0 4444 %%%% !1110
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MXCO9=8U&UU&^ L/"EK/%?7T=]-I$=I?7^GNL?B35];EA^UMX-^TS_P %7_\
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MJ/BW2+/PYKLZI\;;QVATC6)K/4)0MI=,4MV"VTYQ$W]_U?PI?M'?\%B_&O\
MP51^-7[%7P]_8)_8K^,_P_\ VF/AC^U%\/OB/I'QP\06]A/K'A+P;;1:MX?\
M8^%]5O/"5C.UK\*O%&F:XMU\4/\ A*?$%IX0N?#N@O:ZMH^HF2WNM/\ [K:
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M#6[S_A5OAZ[UGQ)X2\#>$-1\3)<^'/.\.W8DMQHVK7$MGH_B**Z\.Z4^%J_
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MF48O"8_&/"XN.-I^VKU\SQ<*CEB(\\ZE2C.K[U3DJ0=2;91117SY^,!1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?,?[;'Q3\6_
M O\ 8T_:W^-O@&:QMO'7P=_9C^/7Q3\%7&IV4>I:;!XM^'WPK\5^+?#DVH:=
M*R1:A8Q:QI%F]W92.L=U;K) [*LA(^-O^"6'_!0#3/VF_P!@7]G;XZ?M'?&7
MX-:9\:O'^A^,+WQU8Q^)/!_@I+>\TGXE>-/#NEJOA>?6(Y=)W:!H^DR&)T!N
M"YO!D7 )_1#X[?"#PU^T'\$/C)\ _&=]KFF>#_C?\*OB'\(/%>I>&+FPLO$N
MG^&OB5X1U?P9KM]X>O-5TS6M+M-<M-+UJZN-)N=2T;5K""_CMY;S3+^W22UE
M_FN_XA"O^";'_1;OVXO_  Y7P%_^AHH _I+M?C]\";ZZMK*R^-?PDO+V\GAM
M;2TM?B/X.N+JZNKB18;>VMK>'67EGGGE=(H88D:261E1%9F /K=?S&?#G_@U
M#_X)W?#'XA> _B5H'QF_;1N]=^'GC/POXYT6TU?XB? ZXTFZU;PGK=CK^G6^
MJ067[.FGWD^G3WFGPQ7L-I?V5S);-*D%W;2LDR?TYT %%%% !1110!S;>#?"
M#^)T\;/X5\-MXSCTXZ/'XN;0],;Q.FDM(LS:6FOFU.JKIS2HDIL5NQ;&15<Q
M;E!&CK.BZ-XCTJ_T+Q#I.F:]H>JVTMEJFC:S86NJ:5J5G,-LUI?Z=?13VEY;
M2K\LL%Q#)%(.&0BM.B@#/TG2-*T'3;'1M#TS3]%T?3+:.STW2=)LK;3M-T^T
MA7;#:V-C9Q0VMI;1* L<$$4<2*,*H'%?)?[1'[?O[(G[*'C'0OA_^T#\9+#X
M>>,/$WA^#Q3H6AW/A3Q[X@N-1T&YU34M&@OX9O"?A77K1!+J>D:C:+;37$=Y
MOMBYMQ%)#))]B5_,E_P5=^#^G?&7_@I9^S-X+N+J#2[_ ,9?";X5^ +'7YK7
M[:_AVW\8?&GXH:7J>IVMH98DN+I+>5#%%YMN\PB:S^UV\%Y</7W7AWPQEO%O
M$:RO-\5BL%EU/+LQS'%XK!NFJ]&C@,/+$3G%5:&)4DE%W@J4IRVBT]3\[\4.
M,,PX'X4J9UE."PV8YG4S+*\KP&!Q3G&CB<5FF+AA*-*52%;#^R3G43=6550A
M%2;4G:+YG]ES]MC]F;X4_P#!5C_@K%^U!\0?B+=>&O@3^T5X?_8JM_@[X^NO
M 7Q*N;?Q=+\)?@5%X1^(7F:'I_@^\\4>&X_#OB+.G23>+=$T*'46!N='DU"S
M!N*_9;X#_&;X&_M&?$'QE^V?\'?VP?%?C#X%>&OAV?@-XC^%FH2)X0^!'A;Q
MOH.NZ?\ $74OBI=6?C7PGX;\3VWC[_A'?%6B^&Y]>?5AX;E\.7?V*6.\O;.V
M_L?YT^/_ /P28_94MO@#XO'PX\/ZOX,^('@KP?KGB+1?'-UXJ\0ZO<:WJ.A:
M3=ZE]C\7V&HWEWHDNFZQ);"&]FT71=,N=++K<Z4D<,4NG7G\IGP5_9D^*GQE
M^+NN?#O]E+X2_#KQ7\0I/ =SXT\6VT?Q:^$W@/X@VO@^/Q FFQZJWAWQIK<'
MBNY^'^G>*M1TJUEN])T2^\.KJ^L1Z;9SZ3J0EN(OT7+_  _\,.),CQ^=Y'Q1
MQ!D]#*<?AL)F$^*/[$I>Y74I4GA8TY8+"3J8V-.I'#1K9E1E2G3G[:G*T(U/
MS2MXC^+7#W%&5<*\3\*\)8_&Y_EV*QV4XGAJOQ'4P-'ZJX1Q7]IN.#S?-H0R
MZ56B\2\#DN-^L*M35"5./M*E+^J']J+_ (+2?L]_!P7_ (=^$,#_ !E\9*\M
MC::M#/+I/P\AU/?/;".TU,0S:]XTGM[A8)X[+PII+Z5K5K*JV'BN%V\Q/R#_
M &D[S_@J[^UG\&/BW\<_B+X7U[X8? SX9^!?&'Q)?3/B'%/\+/#-QIWA72+C
MQ%';>$OA&L<WC'Q5J)MP+CPCXI\>V.J:=(H:&Y\3Q0M(M?4_P)_X)M?\%1OA
MK/I^M_#G6/\ @G]^ROXAE@A34/'_ (7\&>,?CG\:8=^GR17L2^(_CAX<^*$%
MA;ZA)/&FIZ-X6\7Z+X<\^TWZ=IEO9J(KS:_;)_X)T_M>:;^S'^TC\6OCY_P5
M*_:#^+=GX,^!WQ*\3W?PN\'>'!\'OAWXJ;0O"^IZK;:!XIT'0/'.J^'=:\.W
MUQ"\&LV;^%K634+"5;1);7[/%+71E.-X4X<S++\-PQCN&L#7GC,+3_M;&_VC
MQ/Q/BG+$4Z<J>'K87*89%DCK)N,9X'$4ZD5-QJ8FM&/,_KLPPW]I9/FE;BCA
M[BGCC%3RW&-83,9X7@GP^RB4\+5DJ]'A;!\0RXAXEQ& E:=/$<59KFF6XF5.
M%5<+8"M^Z7A'_!-#X$_\% _'/[-'@_\ :"_9A^./@CX>Z)\5'\3VGB/PIK.J
M:BD*ZSX,\7:SX0FU4Z!J7@;QCX;:XOD\/Q7,.K6K6^KP6URVDNS6<.^?Q+XE
M^!_VDOV8_P#@J_\ L(>%/B[\5E\7?$/XP?%'X2>/_&?BOPMXB\37MYJ.D^(?
MB9??#RX\*:EKFJ6FA7M[I$VB:-=:?J.D1Z?%HK:+<PZ%%#+I-JMN_L__  2P
M_P""PW[%_P"R7^Q)\+/@3\8-<^(5EX_\):K\1;O6+?0? 5_KFEI#XE^(GB?Q
M+I9M]3@NHHIV?2]5M'F54'DS-)"V60D_(7[<W[3_ ,*_^"E?_!3#]BFY_9=^
M)?Q ^'RW,?PN^$=O\33X=OO#OBWP%XUU#XO>)=0L_$_A^Q.JZ?=75QH,/B/2
M]3LY8-5TYI;J%[=+NV=#,OW4,TXTQ?%7%^$S;(\)E_#V*P?$V$J\1KARE0Q6
M-RVC1Q$,N6,S2E1=?&X>-&-&<8+FG7C3BO?;:?XI#A+P_P NX=X/Q^49SF&8
MY[@,=P[C\'PO5XHQ.*RW+<TQ%;#SS"IE^35Z_P!6P.)]M.M'G=HX:=6<E[/E
MC*']Q]?EA\3O^"T'_!._X/?$7QO\*O'_ ,:-:T?QQ\.O%.M^#/%NE0_"GXJZ
MI%IWB'P[J$^F:M91ZEI?@Z[TZ^2WO;::);JQNKBUG"B2":2-E8^-?\,X?\%L
M/A%=6?\ PK#]O3]G_P#:/T"QMMAT3]H[X,+\/;F?RMHC1M5^'&B>+/$^IW$L
M:!6N=1\<6NZ1F:2169IQ^1'_  2Y^"^C?M#_ /!5?]N[1/VT?@Y\&_'_ (XL
M='^+/B/QKX/NO#=IXP^'6@?% ?&[P?8>(+SP7;>*9->GBL+>?4-7L='O+F]N
M]172;IH9[R9I9F?\1R'@SAVI@\_S7-<\I9UE^3Y;3QL*?#.+GAL=*4\53H6Q
M&'SK*:-6E#EGO[%14[+VCND_WW/.,.(:>,R'*\KR6KD^89OF,\'.IQ)A(8G
MQC'"U*]Z&(R;-:U*I/FA9KVSDX7?LU9V_:/_ (?T?\$P?^B\Z]_X9KXQ_P#S
M#5^G_P 'OBWX#^/'PR\&?&#X8:O-KW@#Q_HT6O\ A;6)],U/1IM0TN:6:".X
MDTO6;2QU2R9I()5\F]M()AMR8P&!/X@?\%C/V*/V0?A'_P $X?VB_B%\+OV9
MO@=\/?'7A_\ X5%_87B_P?\ #/PGX?\ $>D?VM\=OAAHFI_V=J^F:7;7UI]O
MT?4M0TN[\B9/M%C>W5K)NAFD1O:/^"3'[8O[*0_8>_9E^%EW^T9\&=(^)?A3
MX?V?AS7O 'B+XB>&/#7C"RUF#4=1>2SC\.^(-1TW5KX!)HF%SIUK=VC^8FR=
MBPSRYKPYD&,X3I<2\)X/B64H9_5R?&4,QJ87'*G2I9=2QKQ-LOP-'V4'*O1I
MJ=2;C=23C>46=.5\19]A.*ZG#G%.,X<2GD-/-\)6R^GBL$ZE6KF-3!+#WQ^-
MK>UDHT*M1PIP4K.#4K1DG^T%%1Q2Q3Q1SP21S0S1I+#-$ZR12Q2*'CDCD0E)
M(Y$(9'4E64AE)!!KX@_;S_;S^&/_  3Z^&/A/XJ?%3PGX\\7Z)XO\>6WP_L+
M#X?VOA^ZU2VU2Z\/^(/$:7EXGB/7_#MHNGK:>';N%FANYKG[3-;@6YB,DD?P
M6 R_&9IC,/E^7X>>*QN*G[/#X>GR\]6?*Y<L>9QC?EBWJUL?=8['X/+,'7S#
M'XB&&P>&A[2OB*EW"G!M1YI<JD[7DEHGN?<=%?SA?\1,W['7_1#_ -I?_P $
M_P +?_GGU]K_ +!__!8#X"?\% ?B]XC^#?PL^'/Q>\(>(/#7PWU?XFWFI>/[
M#P9:Z-/HVC>)_!_A6XL;:3P[XQ\0WK:G+>^,]/N(4ELHK4VMM>L]TDRP13_2
MX_P_XRRS!XC,,?D&-PN#PM-U<1B*CH<E*FFDY2Y:TI63:6B;U/G<#Q[P?F6+
MH8# Y]@\3C,545+#T*:K\]6HTVHQYJ48WLF]6EIN?K-1117QQ]<%%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M7-YXUAMH1?/&NM^PS_RG3_X+F_\ 8L_\$X__ %F:*OV A\3?')OVB+[P?/\
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MAKQ"B?&CX3N[Z'JR(B?$7P>SN[6%P%55&L$LS$@*H!))  S7\@?_  1'M_\
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MP;;ZC<7.K? 72?#EUXHC\#Z[IDFK0Z))KVKRZ:E_YSVJ7NJK8>4UY<^9C_\
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M*K"O2I5J4N:G6IPJTY6<>:%2*G"5I)25XM.TDFMFDPHK\^_V\_\ @I%\#O\
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M-[&+:R/B+6[W]KGPMIOAJ&=2QNM2U+Q1XM\/VT!=59KCQ+IEGG8J, #]-O\
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MC> ?_G?T ?T'T5_/A_PR9_P<0_\ 25[]FC_Q$;P#_P#._KX8_P"$S_X+[?\
M#Q3_ (=V?\/)/@3_ ,)I_P ,M?\ #4G_  L;_AECX7_\(O\ V!_PL#_A /\
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M>U^5*]KNU]KL_K$K\M_VY_\ @DC^SA_P4!^)7A7XI?&3QK\;?#7B#PAX'M_
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MB*_GY_X9,_X.(?\ I*]^S1_XB-X!_P#G?T?\,F?\'$/_ $E>_9H_\1&\ _\
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M"WU2V_:$\.)/!'+&\-PD;Z=\,=*ND,T+O$Q2\13&[HZ2*Q6OC_X0_P#!+?\
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MXM6.@:?XCUCX>:CH>D^,K*'PYXN\/^-+%M$U#Q)X<\6Z);2RZIX;L;>Z:_\
M#VI(]A+=Q0I!<20W4'P[\=?^"*O[+/[07[!?[/W_  3N\9^/OC_IGP4_9O\
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MT/AKQAX>\!Z3IEC>W?B[P;X'U*/7(+GPOJ#WUM!I-S81036;6^IW4DD\=O\
MKQ7YA_M[_P#!7G]B_P#X)N>+/A_X'_:9\3^--.\3_$GP[JOBOP]I7@OP3J'B
M^:+0=*U*/2'U#56M)[:.PCOM0-U;:<K-(]RVFZ@2L:P*9.M_8"_X*@?LJ?\
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M;_4=1O[F&SL;"QLX7N+N]O;NX>.WM;2UMXY)[FYGDCA@AC>65U168 'YL?\
M!7W]C+XH?M__ + _Q>_99^#>O> O#7Q!\?ZQ\,=0T;6/B9JGB'1O!MM#X*^)
MOA/QIJJZGJ'A;PMXSUN&6XTO0;RWT];7P]>I+?R6T5R]I;O+=0_HUX>T^;2=
M T/2KEHGN-,T?3-/G>!G:%YK*R@MI6A:1(W:)GC8QL\<;E""R(<J/S__ &!_
M^"HW[+W_  4DU#X^6W[,\OC_ %#2OV>_%&@>&?$GBCQAX9L/#>@>+$\43^+X
M_#_B'P,4U[4M8O?#^IVW@S4=1BD\1Z/X7U:&RO-,^UZ1;W4MU:V?R#'_ ,''
MG_!*.3]H1_V?3\=-6C*>(#X6'QLD\)7B_L_R:Z)Y[-HT^(8NFF_L,:A"MF/'
M#Z"G@!XKB#68O%3^&_-UJ( _=:BD!! ((((!!!R"#R""."".01UI: "BBOA_
M]OK_ (*$_LY?\$W?@M:_'#]H_5O$,>AZQXJTKP5X5\*>"-*LM?\ '?C+Q%J2
MSW<UIX=T74-6T*PDM]%T:SU'7M<U'5-9TO3K'3[$VZW4^LZCHNDZH ?,_P '
M/V _C%\/?^"R7[6W_!0W6O$OPTNO@M\>OV<O ?P@\'^&-+UGQ3-\4--\2^%[
M+X+6VH7WB31;OP;9>$[/0YI/ASKAL[G2_&VL7\B76E&?3+=I[M;']>*^#OCG
M_P %'?V9_P!G#]CCP%^W-\7-6\6>'/@E\2?#WPI\0^%XH?#3:OXVND^,6BV'
MB'PGI,GAS2KZ[A&L1:1?27NLP6^IW%I8PZ=J3Q7MVD$;3?*G[(/_  7G_P""
M??[</Q\\(?LV? ?Q%\4M0^)WCBS\3WV@VOB;X9ZGX<T:2W\(^&-6\7:R;G5[
MF]FAMF31]%OGMU:-C/<+' N&D! !^SE%%% !7RU^W!\$/%?[2W['7[4'[/?@
M34/#VD^-/C7\"?B=\,/"NI^+;O4K#POI^O\ C3PCJF@:7>>(+W1])U[5;71[
M>\OHI-0N-.T75;V*V61[;3[J4+"]7]L_]M+X$?L$? _4?V@_VBM;UC1/A[I_
MB+P]X45O#VAW/B/7-1U[Q/=/;Z9I^F:1:/')<R"*"]U"Z8RQ)!I]A>7!9FB6
M-_A+]D'_ (+S_P#!/O\ ;A^/GA#]FSX#^(OBEJ'Q.\<6?B>^T&U\3?#/4_#F
MC26_A'PQJWB[63<ZO<WLT-LR:/HM\]NK1L9[A8X%PT@( /O?]A_X(>*_V:?V
M.OV7_P!GOQWJ'A[5O&GP4^!/PQ^&'BK4_"5WJ5_X7U#7_!?A'2] U2\\/WNL
M:3H.JW6CW%Y8RR:?<:CHNE7LMLT;W.GVLI:%/J6OQ)_:'_X.$?\ @F1^S+^T
M7J?[,_Q#^*WBO4?&/A7Q _A/XC>*? _@34_%_P //AEXGM;Z/3]7\/\ BW7]
M-G_M"ZU7PY<--%XFM/!NB>+)- O;+4M$U3[-XATZ\TB']E?"/BWPOX_\*>&?
M'7@CQ!I'BSP9XT\/Z-XK\)>*= O[?5-"\2>&?$.G6^KZ%KVBZG:22VNH:5J^
MEW=KJ&GWUM+)!=6EQ#/"[1R*Q .AHHHH **** "BBB@ HHHH **** "BBB@
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M[6<\L2/-:M-'B.9K>1FB,L8"2%"Z?*15FBB@#P;]IG]F?X,?M@_!/QG^SO\
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M\1_#NQ\7:A\2-1\26NK_ !:N=.\(W>L>#C92^+M#T/7]3DN/#.C3ZI']>_\
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MP)K,_ASQOX33Q9H-_H1\3>#?$%K_ *3H7BK0?M_]J^'M8MP9M,U>TL[V(%X
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M]L7XB_M!^#OA3XT\,_$37/B+X._9.LOA[\4OCEJ>K?##]G7XKZ+\6_A_X\\
M^/K#Q%9^$-'U76]<^%OC?PUX9.HZI<?$S4+&YL-5O].\3VFI"/5M2_.V#_@W
M]_X*RO\ " ?\$SKG]HO]G:#_ ()Z+^T4OQX?XIQ3>+;CXGMIK@Z,=!B\"MI,
M!>\CLU'CD_#F76+?P:?'\GVM?BD\0,R@']6W_!-SQ-XB\:?\$\_V%?%OBZZO
M]0\3^)?V/_V;M;U[5-4O6U+4M:U34O@]X/NKO7K^^D9Y;F\UV65M8N))W>X\
MV]9;AWG61C]IUR'P^\">%_A;X!\$?#+P/IJZ-X+^'7A#PUX$\(:.LTUPNE>%
M_".BV7A_0--6XN9);B=;'2=/M+437$LDTHBWRR/(S,>OH Q?$GB/0/!_AW7O
M%WBO6=-\.^%_"VBZIXC\2>(-9O(-/T?0M T2QGU/6-9U74+EX[:QTW3-.M;F
M]OKRXDC@MK6"6:5UC1F'^<I_P5%^+5__ ,%6OA3^V+_P4D\6_$RT\(? #]F[
MQ!X)^ 7_  3V_9\O/$FEV'C'QI;Z[\7/ &D_%?XXZ[X+N[N'688=>\.3SW6H
M-;:'+-<ZA>:5X6G\126OP.G/B#_16^(/@/PI\5/ 7C?X8>/-*_MWP-\1_"'B
M7P'XST/[=J6E_P!L^%/%^C7OA[Q%I7]IZ->:=K&G?VCH^HWEG]NTK4+'4K3S
MOM%C>6UU'%.G\V7[<G_!L9^P_P"//V:O'/AC]@_X$> O@K^T[?WWA"3P)\1?
MB9\=_P!I_5?!NBV%GXNT6\\90:G8ZCXK^+5I++JW@Z#7-*T\R>!=6,=_>6TD
M<VF2*NI6H!\U_P#!0?X ?M%?\%*?^"-/_!,+X)_L$^&/"?[1MMX-TS]G?4?C
M=>>#_B[\)K#3/A]XC^'O[-6E>#8O"'C"YUOQ]H-Q'JUGJ/Q(N[CQ'X<L$O=8
M\.#28KW7++2V&G23^J?L@?MN?M,_LR_\%3_A_P#\$^/^"AO[(_[%'@#QS\;_
M  K<>)/@#\</V2_!6F^#]&TFTOM)\?R6<$5YJTEYKVK>'/%-WX/UWX:V5I=P
M^$?%VDZY86Z:CI_B31_$$.J+ZA\8/^"&7QK\"?L2?LE?"W_@G3\?%_9/_:)_
M9Y\2:)\7_B9IFG_%?XUW'P+^/WQRU/PS\(X?B#XK\376H2>(M4:*Q\9_"/1O
M$7PZTW4_ $_@ZRM;O6M)/@GPO%XEU"ZL=7]D#_@F#^WO\7O^"B?A#_@IG_P5
M9\<_!"?Q_P#!'X>6_@'X!_!CX#C4+[P]I=W!9^,-(_X2#Q1-J=A]ATVRTR3Q
M=XE\;Z/8Z;K?BG5M8\9^*X=2NM1\&Z5X-T[PGJ@!_2O1110!_.U_P<>?L?\
M[8_[<W[,OP"^!/[)'P@?XJ&V_:"LOB/\2)#XX^'_ (*L] T_P]X-\2>$?#8U
M-_&OC'PI=ZGIVH7OQ U*\NH] BU5]/CT(W]^MD8K&67Y?_9-_;A_:@_9=_X*
MA^"O^"?_ /P4#_8]_8J\&_$/XT>#+_Q5^SQ\8_V2?!^E>"-(M([K0_B%/ING
M0:EK3WFM:AX>\8W_ (-UOX7V$-_!X2\5Z+KMG;?VIIWB31=>BU,?J!_P5X_8
M2_:U_;'\'_ _Q7^Q7^U)JW[.GQQ_9\\>3^-=&T74?%OC/PU\*OBE'/J?A'6[
M*T^(,/A&VUI+[4_!VN>"M+UCP8^O>$/%>BA[[Q!H]]865MKT^J67Q;^R!_P3
M!_;W^+W_  43\(?\%,_^"K/CGX(3^/\ X(_#RW\ _ /X,? <:A?>'M+NX+/Q
MAI'_  D'BB;4[#[#IMEIDGB[Q+XWT>QTW6_%.K:QXS\5PZE=:CX-TKP;IWA/
M5 #\3?\ @E;\.O!'Q=_X('?\%K_BM\2O#>G>-/B3XOUOXM^(_$OC;Q!&^I>(
M]8UOX6_!KPQ\7_ 6IWFIW3RW$E[X<^)7B/7O%]I=!UN)-7U:\GNI9Q(%7^E3
M_@W1\3>(O%?_  1P_8ZO_$MU?W]WIUA\8_#.G:AJ-ZU]-<>'?"G[0/Q5\.>'
M+6%I&>6VL-!T73++PQIMD[;;6PT2VBMUCM!;QK^-7Q._X(3_ /!4'X4:G^VQ
M^R[^Q'\6?V<M)_8/_;P^(5EXKUY/'6O>-='\9_"+PMI'B:Y\36G@R&RM_#WB
M"\B::QU ?#_5M4T"7Q<_C[PCX?TIM=_X1">ZGMK?^JW]B_\ 9?\ "?[%O[*W
MP+_9;\%7S:QHGP8\ :5X5F\0O92Z8_BOQ(S3ZOXT\92:5+J6L'1Y?&?C+4]>
M\4RZ-'JE_;Z1)J[:;:W4UM:PN0#Z=HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBOD_P#;H_:8N?V-_P!D7X]?M06?@^#X@77P6\"7?C.#P9<ZY)X:
M@\0O;7MC:#3Y==BTK6Y-,1Q>&0W*:3?%?+"^0=VY0#ZPHK^/7P9_P<H?MW>/
M?A)+^T)X._X(M_%7QK\!K&RU[6=1^*WA/XC_ !#U;P''HGA"[O;3Q=?GQA8?
MLZZCHMM:^'I]+U.WUB_D>:VTB6PNVOE5;2=5_>/_ ()C_P#!4+]G_P#X*C_!
M2^^)_P '8=7\)^,O!,VAZ+\9/A%XHDM[CQ)\-?%&M:?<7=G&FIV:QV7BCP=K
MLFG:T?!GC*UM]./B"STB^&I:%X;UZPUCP[I0!^D]%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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$H __V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>39
<FILENAME>nt10014672x1_linechart12.jpg
<TEXT>
begin 644 nt10014672x1_linechart12.jpg
M_]C_X  02D9)1@ ! 0$ P #   #_[0 V4&AO=&]S:&]P(#,N,  X0DE- ^T*
M4F5S;VQU=&EO;@     0 ,     !  $ P     $  ?_B"^!)0T-?4%)/1DE,
M10 ! 0  "]!N;VYE @   &UN=')21T(@6%E:( ?4  < %0 3  L (6%C<W
M         $E%0R!S4D="     0            #VU@ !     -,M2% @(
M
M$&1E<V,   %$    =&)865H   &X    %&)44D,   ',   (#&1M9&0   G8
M    B&=865H   I@    %&=44D,   ',   (#&QU;6D   IT    %&UE87,
M  J(    )&)K<'0   JL    %')865H   K     %')44D,   ',   (#'1E
M8V@   K4    #'9U960   K@    AW=T<'0   MH    %&-P<G0   M\
M*&-H860   ND    +&1E<V,         &G-21T(@245#-C$Y-C8M,BTQ('=I
M=&A"4$,
M                                                    6%E:(
M     "2@   /A   ML]C=7)V        !      %  H #P 4 !D '@ C "@
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M;W5R(%-P86-E("T@<U)'0@
M
M      !865H@        8ID  +>%   8VEA96B            !0
M;65A<P         !                               "6%E:(
M  ,6   #,P   J1865H@        ;Z(  #CU   #D'-I9R      0U)4(&1E
M<V,         +5)E9F5R96YC92!6:65W:6YG($-O;F1I=&EO;B!I;B!)14,@
M-C$Y-C8M,BTQ
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MU=;7V-G:X>+CY.7FY^CIZO'R\_3U]O?X^?K_Q  ? 0 # 0$! 0$! 0$!
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M[ZP;0?#=H6B5M2\17FA^'M8_G^_;,_9B_9__ &2?^"UW_!#OX0_LW?"?P?\
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M0_%.B>(+FUT>X\8MXM\.)#XDM=+G\*ZTNH^']0,V@ZWJD-G]DOY+6^MO4O\
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M^&__ ,TM?G5_PXX_94_Z*9^T=_X5/PL_^<Y1_P ../V5/^BF?M'?^%3\+/\
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M?"7_ ,./X._^7-?BS_Q#<_L!?]#;^TM_X</P+_\ .KH_XAN?V O^AM_:6_\
M#A^!?_G5T?V7X<?]%;Q!_P"(S2_^>OK_ $M3^T_$/_HE<A_\22K_ /.L_:;_
M (7[\"?^BU?"7_PX_@[_ .7-'_"_?@3_ -%J^$O_ (<?P=_\N:_%G_B&Y_8"
M_P"AM_:6_P##A^!?_G5T?\0W/[ 7_0V_M+?^'#\"_P#SJZ/[+\./^BMX@_\
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M4N"HEW B@#JJ_GP_X*U?\I,_^""?_9R_Q_\ _41^%=?T'U_/A_P5J_Y29_\
M!!/_ +.7^/\ _P"HC\*Z /VX^-[_ !RC^&6OO^S=;?">[^,@N_#/_"+6_P ;
M[WQ?IWPRDL3XLT,>,O[?O/ =AJGBJ&[3P,?$K^&?[.L9X9/%BZ'%JOE:.]_-
M'ZO7SM^U=8>!=3^ _C*R^)7[1/B;]E'P9+J/@1]5^/'@_P")WA;X.>(?!L]O
M\1/"=SHVGV7Q$\:6.I>&M#A\=:[#IGP\U*UU"RF?Q'I?BN]\+Z>8M3UJSFC^
MB: "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH ^"?^"GW_)B?Q__ .P3X-_]65X,KK/^">O_ "97^SI_V3VT_P#3AJ-<G_P4
M^_Y,3^/_ /V"?!O_ *LKP976?\$]?^3*_P!G3_LGMI_Z<-1K],E_R9RC_P!G
M,Q7_ *RV$/R"'_)_*_\ V:#"?^MIC3[*HHHK\S/U\**** "BBB@ HHHH ***
M* "BBB@ HHHH *_"G_@X6_Y,7\*_]G%> ?\ U"OB=7[K5^%/_!PM_P F+^%?
M^SBO /\ ZA7Q.KULB_Y'&7?]A5/\S](\'_\ DYW!/_8^PG_MY^W7AC_D6O#W
M_8#TG_T@MZW*P_#'_(M>'O\ L!Z3_P"D%O6Y7E2W?J_S/SNM_%J_]?)_^E,*
M***1F%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %?QT_\ !8?P[H/[
M2W_!<[]@/]CG]MGQAJO@_P#8!\2?"/4O&6D:(GCRZ\">"/&WQ2DTSXT -X@\
M4/)HUKI'BW6O%_ASP'\.%M['4;W7K7P]JVCV7AO4/#NJ?$J>[B_L6K^9+_@O
MOK&H:=\3?V38OCY_P3=T3]O/]@L_\)+<_$_Q+\//!_QCOOVG_@KXM,LFGZNO
M@SXB_#/QQX.T[P+X:\8V=_\ #K5++0_$,T>B_$?4O GB'0-:U#2[VT\):_X>
M /RE_P""3W[9UW^Q1\8_^"VO[,7[//Q0NOBU^RQ^RI^SW^UA^TW^RS_PF.N/
MXST#2-;_ &??%;:'I<?A;4=)U1?#VH^%_B'J'CG2CX@U30UM+'QY)H&A^+--
M_LE]5U/[7\#S_L>2:3_P1:\-?\%J-#^+/QRD_;TN/VJ;[Q;K?QRC^)WB"/Q'
MIWAR?XH:U\%O+N-1GU(ZM>ZU<>)[73_$DWBR&\?Q+<7FO7&DWL\_AZ.2&']@
M_P#@D=_P2N\>_&I?^"H_[0OC[]G;5OV#?AS^V?\ L_\ Q/\ V/\ ]EWX*>(O
M!TFE:Q\/_A-\1--_LZY\8ZWX5U^UTKQ=<7OAD>$?AE=6OB'58](E^*/B1?&/
MC.:.9+O2-5E_,.WT+_@H-XF_X)T>%/\ @@X_["7[1NE_'[3/VM)M=N/B#J?@
M35['X,:;\%I_%>H^*4UV]\>VEN-(NM)7XK:MJNH2^.9YK_X>-X+LK74])\2:
MCJ%Q96.G ']Q7PV_;G^#6A?L6_LG?M2_M3_&'X3? VS_ &A/@K\$O&DFN^//
M%&C_  ]\)W_CGXF?"C2?B)?:!H$OB;5(T$IBEUB\L=)-]=WL.FV$S/),+:6:
MOQ4_;T_:[_9:_:@_X*=?\$.+7]G+]H7X._'*Y\&?M(_&FX\6P?"OX@^&?'$O
MAN#7?"GP[CT676T\/:C?MIL>JR:3J:6#W8B%TVGW@A+FWEV_O+H/[%/[/%Q^
MS3\ OV7_ (R?";X5?M$?#_\ 9]^'?PT\#>$['XS_  N\$>/=&%[\,_ -E\/=
M,\66?AGQ9I.O:-HNN7.BV]W#]HTZ%9[2UU.^T^"Y-K/*LGX7?\%!?V7/V9?V
M<_\ @IS_ ,$,[G]GO]G3X$_ BX\6_M)?&R#Q5/\ !KX1?#_X83>)H=%\*?#F
M31X?$$O@CP]H;ZS%I+ZGJ3Z;'J+7*6#ZA?-:B(W=P9 #^@?]I_7_  GX8^"/
MBW6_''P#\8_M.^&;/4? Z7_P3\ ?#GPY\6/%?BR>]\?^%K#2M0TWP'XMU'2=
M UB'P3K%U8>/M5NK[4('\/Z/X7U#Q)8B;4-(M()??J\P^,EE\8M1^'6N6?P"
M\0_#SPK\5I;KPXWAO7?BKX9U_P 8>!+*SA\4:+/XK36?#OA?Q)X1US4)[WP=
M'X@L-#:S\0Z>EEX@NM*U"\-U8VES97/I] !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 ?!/_!3[_DQ/X_\ _8)\&_\ JRO!
ME=9_P3U_Y,K_ &=/^R>VG_IPU&N3_P""GW_)B?Q__P"P3X-_]65X,KK/^">O
M_)E?[.G_ &3VT_\ 3AJ-?IDO^3.4?^SF8K_UEL(?D$/^3^5_^S083_UM,:?9
M5%%%?F9^OA1110 4444 %%%% !1110 4444 %%%% !7X4_\ !PM_R8OX5_[.
M*\ _^H5\3J_=:OPB_P""N^B>,?VQ?&/PB_X)W?!*#3[[XB2Z9XI_:B^(&KW\
MLB:5X.\,^!O"?BSPO\/=(UB=%>"U'Q%\8^()M!%S(PN-!O6\,:C<VTFF:N9E
M];([1S7"59-1IX>H\16J2=HTZ-&+G4G)]$DK+K*3C%7E))_I/A%RTO$/AO,*
MTX4,#D^*J9SFF+K24,/@LMRVA5Q&+Q5>H](0A"*A!?%5K5*5"E&=:K3A+]P?
M#'_(M>'O^P'I/_I!;UN5^(7P-_X+>?L;P?"'X>6'Q\\<>(?AS\:]&\+Z;X?^
M*7@R7X7?$2]_L;QSX=C.A^(O(ET/PWJFGQ66HZCI\^JZ?8K?37FFV-];Z=J:
MP:G:WEO%ZK_P_ _X)M_]%OUS_P -'\6__F+J:F2YM&<X_P!G8R7+.4>:&'JS
MA*SMS0G&#C*+WC)-IK5.QS8SPO\ $6CB\517!/$]=4L37IJOA<DS+$X6MR59
M1]KA\31PTZ.(H5+<]&O2E*G5IN-2$G%IGZT45^2__#\#_@FW_P!%OUS_ ,-'
M\6__ )BZ/^'X'_!-O_HM^N?^&C^+?_S%U/\ 8^;?]"W'_P#A)7_^0\_S[,Y_
M^(9^(O\ T0G%_P#XCN;?_,GG^?9GZT45^2__  _ _P"";?\ T6_7/_#1_%O_
M .8NC_A^!_P3;_Z+?KG_ (:/XM__ #%T?V/FW_0MQ_\ X25__D//\^S#_B&?
MB+_T0G%__B.YM_\ ,GG^?9GZT45^2_\ P_ _X)M_]%OUS_PT?Q;_ /F+H_X?
M@?\ !-O_ *+?KG_AH_BW_P#,71_8^;?]"W'_ /A)7_\ D//\^S#_ (AGXB_]
M$)Q?_P"([FW_ ,R>?Y]F?K117RG^R]^VM^SG^V1:^,[W]GSQK>^,K?X?W&A6
MOBI[WPGXL\+'3YO$D>K2Z.L:>*=&TAKT7*:)J19K(7"V_D*+@QF:$/\ 5E<-
M6C5H5)4J]*I1JPMSTZL)4YQYHJ2YH22DKQ:DKK5--:,^4S'+<QRC&ULNS7 X
MO+<PPS@L1@L?AZN$Q=!U:4*U-5L/7A"K3=2C4IU8<\5S4YPFKQDFRBBBLSB"
MBBB@ HHHH **** "BBB@ HHKDO'WCCPU\,? GC7XD^,[Z33/!_P]\)>(_''B
MO4HK.[U"73_#7A/1[S7M=OH[#3X+F_OI+32["ZN$L[*VN+NY:,0VT$LSI&SC
M%RDHQ3E*348Q2NVV[))+5MO1);LTI4JE>K3HT:<ZM:M4A2I4J<7.I4J5)*%.
MG3A%.4YSDU&,8IN4FDDVSK:*_)?_ (?@?\$V_P#HM^N?^&C^+?\ \Q=?'7[2
M7[<GQ5_;[\4:%\+?^"6WQ(\86*_!SP'XV_:(^*WC_3M#\5>#;KQ#JOA*SDL/
MAU\&--M-<LM'NM;G\8ZU/+!>Z!JEC-X>UV34]&O9)+JV\*>(+6+U:.29A.HE
M7P];!44I2J8K%T:M&A2BE>\YRAO)VA&*O*4Y));V_0\M\*N-,5BX4\WR3,^%
MLLC"K5QN?<1Y9F.6Y1E]*G3E-3Q6)JX9).M4]GAZ%*FIU:M>M3IP@[MK^BVB
MOQG^'O\ P74_8*USP)X/U?X@_$36O WCO4O#6C7GC/P='\-_B7KD'AGQ3-I\
M#Z]HMIK.E^%;VPU6QT_5#=6]CJ-O<,+RS2"XDC@EDD@C^H?V>O\ @II^QM^U
M+\1[;X3_  3^)FI^*?'5YI&JZY;Z3=> /'WAV%]-T6*.;49SJ7B+PWIFFJT,
M<B,L+70FESB)'((&-7*<SH1J3JX#%PA24G4J2P]7V<8Q^*3J<O)RK?FORVU3
ML>5F/AWQYE-+&8G,.#^(\+A,!&M/%XVKD^/6"HTJ#?M:\L8J#PSP\4G-8A57
M1E#WXS<-3[WJ.66*WBEGGECA@AC>6::5UCBBBC4O)++(Y5(XXT4N[N0JJ"S$
M $U)7R'_ ,%!?^3"?VW?^S0_VE/_ %3/C2O//C3ZQL[^QU"V6]L+VTOK-]^R
M[L[F&YMG\IF23;/"[Q-Y;JR/ASL965L$$!MAJ>FZK ;G2]0LM2MED:(W%A=P
M7D E0*S1&6WDDC$BJZ,R%MP#J2 &&?\ /]_X-R?VW?'_ .RC-H_[)/[0<5YH
MG[.G[?/AKX@^/?V1_&^KW=HOANS^-GA#5_$WPM\6>#K/49'2&UN/B/JG@V/P
M^_AR>].JV?C.Q^'#Z;H"Q?%@:M??4G_!#[_@H!\'O^";/_!"_P"*7[1?Q@LM
M>\01S?MM?$;P#\-_ ?ABVEDUOXD?%+7OA!\,M8\-^"[743;W&G>';:ZT[PWK
MNL:QXCU<&TTG0]%U.:RL]<UUM'\.:R ?VUT5_.3\%/\ @N3\=-(_:@^ ?[/W
M_!0[_@GC\0OV%M&_;!N[?3/V9_'>K^.X_'5K>^)[^^T'1=,\&?$.QN?"G@^[
MT/4Y];UO3M-U>4V^G^)_!^I>*?!-MXM^'>D:#K<OB^TY;5?^"Z?[4WC;]H']
MO/\ 9?\ V7?^";.N_'_XF_L;>._%^C+KFE_&O1- \$W7P]\!:SX[T'Q-XX\9
M3>(/#6D7EKXOO=2T'PK%X!^#_A"7Q)XA\?1ZIXQDL-<T^3P3';^(@#^E^BOR
MY_X)P?\ !4OX/_M\?L>:!^U;KMKH_P"SU&WC[7OA+XR\-^/O&^BQZ)I'Q(\/
M:=8ZY-I7AWQGJ\/AFV\2V6J>&]5T[7M-D.F:=?I%)J-E/8M)H]U<R?BM_P %
M(_V^/VY+3_@L-^PU\-OV5?AG:_';X2Z59>._%GP8^%W@K]I_X:^&?A_^U]XK
M'PG\00>,]8\7ZW'>2Z/X(O/@Q>WOB&QT?2OB+=7<%_>>&5UCPW9VMWKMO<R
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M/V:?C-X*_9K\2_#?X4_LF>'?V5/CA\7OVIOB9J][J$?Q5\7V/PV\-ZWXHD^
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M4L?F>/Q56N\/1I0JUJN)G.K[.,YN53FG+Y9_X89_8F_Z,\_99_\ $??A+_\
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MAK]J7X ?MV_\%HOC+\7/A=_PB7PV_:S^*DWB3]G[Q)_PFWPZU[_A/]%;QO\
M'/5UO?['\,^+M9U[PKG3O&/ARX^S^-=+\-W8_M'R3 )[._BM?Z&:* /Y2_\
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MQX_"[_@C+^VW\!M#^('[)_B#_@DU\)_VL_'.L_&&YU+X6?MI_$7]J3QAX1^
MFF?".UU#PO:ZA'XS^$/PT^+WP^UC4+2[M+#4]>TB&_UKPO\ $FSNO$FH0P>'
MO%@\+V&G2_L3^W[^QO\ MC_L[?M7?\$D?VE/V*?V3M+_ &G?"'[#_P (-9^"
M.O?"WP!XTM?AGI%E<:AX7;P+IMIIA^)GC/QUXR\,>#;[2?$&K3Z#KNJZO\3O
M^$-CT.*+Q[X@O]]MJ&M?U,T4 ?P/>-/^"0_[7/P,_:*_;*:#_@E'H7[<?@S]
MJ;QAJ/C;]F7Q?J?[4TOPQ\-?L[:YXZG\7>++SPY\5/#_ ()^*/A2\\;:=X6/
MB:P\*^+UU_7O"^@:UJ'@2WF\%_$%;/Q<\DWZ(_M>_P#!)K]J/X<?LZ_\$F_C
M#^R7\#OA%KG[0W_!.?XI7WQ9\>?LM?"/7_$WAKX:>(W^(GCKPA\7_&^B?#SQ
M'\<OBG\0/$=Q;^%?&'@YM N9=0\97NK^+[;Q3KGBKPWIVCM9:'X&@_K0HH _
ME0^!7[/_ /P5%_:4_P""VW[,W_!2O]IG]CC3OV;?@5X8^ 'C3X;67AJ+XW?#
M/X@>)/A5H<G@CXUZ3H6@>/+>#5/#7B_7?%GB?QYXWOO%(D\-?#UM)T'PUXT\
M-Z1J]S!K.A>)Q8_K/_P66\$?M<?%G_@GU\:_@C^Q3\,[[XF?&;XY6VF?"B]M
M+/QK\.? J^&_AEXGGD?XHZW>ZG\3?%7A#1+RSU?P;8ZG\/CIVGZG-KGVGQO;
M:G:V4EGIFH7%K^I%% '\IG_$+)\ O^&2/^%5_P##2?[5'_"WO^%1;?['_P"%
MO:;_ ,,W_P#"^_\ A'?[3_MO_A6/_"OOM/\ PKO_ (6E_P 3O^R/[5_X2#^Q
M_P#F.?VU_P 3.O@#XU_\$XO^"R?Q>_8A_P""4_PZ\1?L>77B3XU?\$^?BU\6
M=*U30]0_:)_9FMQXC^#FE7OP2\1? ^\3Q /BPVA6%K;Z/H.K?"6WTNSNM6UO
M2K+X<6VNZI81VVN:6;S^[*B@#^2K]HK]DK_@KW_P6.^,/[/7PQ_;G_95^$G[
M$W[#WPA^+=K\7O'.BZ-\;/ /Q?\ B+X_73+"+2'\.0:YX$\4^*C/K.H:)J?B
M;0-"NE\->!M!T>U\2:[K>OR>(;_2?#6E7/N/[=W["W[=WP%_X*F>%/\ @K3_
M ,$Y_AAX7_:&U/QE\/+/X9?M,_LZZ]\1O#_PZUKQE::?X2/@]=:T_7/%MYH6
MB#PZ?#/A7X9RV=MIVKWOB;2O'_@G1M4_X1KQ5X=U75]/T_\ IDHH _G9_8?^
M&7_!8[]H'_@HEX@_;0_;C/B+]C?]FCPAX%N_"'PU_8H\)_''3?'OA+QQ=75C
MK6F:+?\ C'0? _B75O"VI7GAVYU[6O%FO^/_ !-8^'/&&M^);/P=HVB>'(O
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MG_V1?V-?^"*>K>);K]GKX3?MQ_L=_M&_M$>//"_[-?Q\_:'^"W@2#XTV>O\
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M/_B)6)G[3V<N3D?#6%I*?/;EY75C*DI7M[1.%^9-'XU#$4/^)@*]'V]'VO\
MQ"/"T_9>TA[3VBXOQ==PY.;FYU1E&LXVYE2E&I;D:9]RT445^7G[*%%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!_.M_P0@_
MY*1_P4?_ .RW^%/_ $_?&BOZ*:_G6_X(0?\ )2/^"C__ &6_PI_Z?OC17]%-
M>WQ%_P CC%?X,'_ZA88_5?&S_DY?$'_8-PY_ZRV2!1117B'Y4%%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?"_
M_!13]K[QA^Q#^S3K'QM^'OP#\6?M,^/#XM\(^!O"'P>\%76J6NO^)=?\9:BV
MFV3VYT3PMXSUBXAT\J]W<66F>';Z\O(X_(B:VWFYB_EB^(O_  2R_P""K/\
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M,3R:+'K[Z]IH_M73+(CU>@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M\.WWBR_M/AMJ]Q=>)O#>B^'?$_AG2K[Q!);W/BRU\1VFG:?8VWTY10 4444
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M6^I6O[;T4 %%%% !1110 4444 %%%% !1110!^5G_!931/V(?$'[$'B?3?\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M:AJ46K^%(H+V:VMM0N)M&U^_U6#1VNK:?6Y-*71[%Y=0OK2VG_ K]G?X;_\
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ME-J_B#6?$GB7Q-_:_A]GT2X.M^+-9UW4&ATIC86#7!T^VQ%:J!]<T %%%?S
M_P#!QS^V?^T9^S[KO_!/WX"?LT?M'6O[+?B;]I+XN>-+3QI\8-6\2Z5X2\(>
M#O"V@W'PW\(6.K_$?Q'J&F:G)H?@'3K[XFWWB?7]3MX76TT_PE>W+VMY-;6L
M0 /Z?J*_F'_X)C:Q^VU\#O!/[3O[<'[57_!3CX+_ /!13]D_X5_LX_%371H_
MP ^)]U\29/#_ ([^&MKH?Q-UA[F2\\#>$=(TCQ!;^ =$UNP&FZEJ\6I6[>)-
M+EN=-CL;T7L?Y"O_ ,%&_P#@M5H/[)F@?\%N]2_:7^'-Y\&/$_[05[\+[7]B
M^;P/ GPNE^'T6KZSX=6[MHX7/B"VMH?&NCZKX9BN&\4K\24LK*TU^Z\=ZE:R
MRZ20#^_*OY\/^"M7_*3/_@@G_P!G+_'_ /\ 41^%=?N%\%?BEH?QR^#?PE^-
M?AFTOK#PW\8?AEX#^*7AZQU3[-_:=EH?Q!\*Z5XMTFTU'[%/=6?VZWL-7MX;
MO[)<W%M]H23R)YHMDC?A[_P5J_Y29_\ !!/_ +.7^/\ _P"HC\*Z /V&_:NO
M_ NF? ?QE>_$K]G;Q-^U=X,BU'P(FJ_ ?P?\,?"WQC\0^,I[CXB>$[;1M0LO
MAWXTOM-\-:Y#X%UV;3/B'J5UJ%["_AS2_"E[XHT\2ZGHMG#)]$UY1\;T^.4G
MPRU]/V;KGX3VGQD-WX9_X1:X^-]EXOU'X91V(\6:&?&7]OV?@._TOQ5-=OX&
M'B5/#/\ 9U]!#'XL;0Y=5\W1TOX9/5Z "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "OQ7_9\_
MY3-_M@?]D/@_E^SG7Z/?M/\ [0^D?LU?#6+QI=>'=6\;>)O$/B;0_ /PY\ :
M%O76?'7C_P 3R31Z'X<L9DMKS[+YT=K>WEQ<FUN)!;64L-E:WVI3V-A=?D_I
MWPU_;Q_9Y^-7Q+_X*%^+?A/\'_&-UXX\$W%C\4?@QX,\;:U'XM\'^![.S\*:
MA?7>F7-W87F@W6MZ!:?#[2#J+:1K_C1-1>74QI>CO'<P3:7^L>'^65O[)XKJ
MU\1E^!CQ-P[C>&\@689AA,#/-<X_M+)\7+#X6.)JTW[*G"C[.IC*OL\'#$5:
M6'E7564HQ_#_ !2S>@\\X'H87"YIF4^$.+,NXNXGEE65X[,89)D*RG/<%'%8
MR6$H55[:K4Q'MJ6 H^VQ]3"4:^*CAO8QC.?[U45YS\(OBCX6^-?PR\$?%;P7
M/+-X:\=^'['7M.2Y\D7MB;E"E[I&I);37%O%JNB:C%=Z1JT,%Q<0P:E8W4,4
M\R(LC>C5^6XC#U\)B*^%Q-*=#$X:M5P^(HU%RU*->C.5.K2G%ZQG3J1E"2>T
MDT?M&%Q6'QV%PV-P=:GB<)C,/1Q6%Q%*2G2KX?$4XU:%:G):2IU:4XSA):.,
MDUN%%%%8G0%%%% !1110 4444 %%%% !1110 445B^)/$>A>#_#NO^+?%&JV
M>A^&O"VBZIXC\1:WJ,HM]/T?0M$L9]3U?5;Z=OEAL]/T^UN+NZE;B."%W/"T
MTFVDDVVTDDKMMZ))+5MO9%0A.I.-.G&4YSE&$(0BY3G.348QC&*;E*3:48I-
MMM)*[/Y\/^"$'_)2/^"C_P#V6_PI_P"G[XT5_137\Q__  0;^)%C;_&?]K'P
MUXDTK6/"6L_M$V_A[]HCX1V.OV,UDWBWX<Z1XZ^*/AO7]5TRXE5+>]CT[6==
ML+*%K1IA?FSUVXM2]MH]W*G].%>YQ)&4<XQ-TU>&%L^CY<)0A*SV?+.$H.VT
MHRB]4T?K/CC0JT/$O/?:P<54PN02IRT<*BI</95A:KIS3<9JEBL/B,-4<6U"
MO0JTI-3IR2****\(_) HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MK:WNK6:"/ZIH *_FF_X*\_$C_@D-H_[?7['G@#_@I9^SI\2/%7B?7/!L=YX
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M'#_P9> O_F$H_P"'''[-O_14_CA_X,O 7_S"5^U%%9_\1>\2?^BNS/[L+_\
M,_E^?=FW_$"/"+_HA<G_ / L;_\ -?E^?=GXK_\ !#C_ )-M^*?_ &7#4O\
MU O E?M17XK_ /!#C_DVWXI_]EPU+_U O E?M11XO?\ )RN+O^QE'_U$PP_
MG_DT? O_ &)W_P"IF*"BBBOS<_6@HHHH **** "BBB@ K\.O^"WW[1=CX"^$
M_P )/V:+_P 5:A\-="_:D\=0:+\4/BJN@^(-7L/!7P6\(ZKX=N?'CVT'A^VG
MU36-8U";6=$$V@:/!J-SJ7AJTU_1]1M((=?T^:;]Q:IWFG:?J*HFH6-G?)&Q
M:-+RU@NEC8C!9%G1PK$<$J 2."<5UX#$4\)BZ&)J4G7C1DYJFIJ#YU%^SFI2
MIU8ITZG+42E"46X)25FSZ3A#.\'PYQ'E6>8[+IYK1RRO+%0P=/%4L'-XNG1J
M?4<1"O6P>845/ XQT,;"%7!UZ56>'C2JP=.<C^0#_@J=\<_^"9'[07P+^!-M
M^SQ\5H]4\<?LXMX:\">'O!&D_#WXL>#=3\4_ UH=-T75/!^G^*_%_P *H= L
M]8\,)IVFZ[X;OO$EW)I^GVX\6B#3]4U76X;&[^V_"'_!OE^QUXV\)^%_&>C_
M !B_:<M])\7>'=$\3Z7!K+^ -&U>'3M?TVVU6RBU71]0^&<-_I6I1VUW$E]I
MM]##>6-TLMK<Q1S1.@_H4_X1CPU_T+VA_P#@IL/_ )'K<KUI<08BCAJ&&R^I
MC,+&E.M.4ZV)I8F=15I1GR/EPE!)0J*I-.SDW4DFVN51_1<1XRYUEN195D7!
M>,XGR&CEV+S/$UL3F>?9?GF(Q<,RJ4<1]7;I<.Y3"$,/BUB\33FXU*LIXZO&
MI.4%1C1_GQ_XAR_V2_\ HL_[17_@U^&G_P [>C_B'+_9+_Z+/^T5_P"#7X:?
M_.WK^@ZBL/\ 6'.O^AA7^ZG_ /(>7Y]V>/\ \1J\4_\ HM,U_P# <'_\RG\Q
MO[1?_!!+]F'X._L^?';XN:!\6OCSJ6N_"SX-_$_XCZ)IVL:E\/I-(O\ 5_!'
M@G7/$VFV6J)9> +*\?3KJ\TR&"^2TO+2Y:VDE6"Y@E*2I^A7_!#_ /Y1M_!#
M_L.?%S_U;?C2OL+]N;_DR;]L/_LUG]H/_P!5+XNKX]_X(?\ _*-OX(?]ASXN
M?^K;\:5UU\?B\?D%:>+KSKRIYIAHP<^6\8O"XEM+E2W>NO4^DSGB[B3B[P>S
M+$\29OB<WKX/Q#R.AAJF)5)2HTI\/Y[4G"/LJ=-6E/WG=-WZGZT4445\T?A0
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?A[
M_P '"O[.'QF_:6_X)P>*_#_P.\(:C\2O%'PW^*/PV^,NM_"O2(KV[U7XF^"?
M MWJ8\3>%=/TO3F2_P!<N8;;5H?$RZ)IY;5=33PZ]MH<%WKCZ;9W'\NGB#_@
MM1^SEXQ_:3_:]\2>"?V+/B9JL_[2_P"P=\._V+_AO^RS-X*\&7>B>'_BMX<U
M'Q!;W6B:GH.AWLMQ<^!]#NM4LSX;M?#O@U?%&IWFG1V?_"+^%;DQW=K_ &"?
M\%AOVZ_&G_!/C]BKQ)\:/A9X7TSQ?\8O%GC?P;\&_A!I6NQ37.@P^/\ X@SW
MZV.KZQ9P3VDNH6VC:1I&M:E::9]KM(=3U:VT[3[NY@L[FXD7QW]H[3?^"F7@
M?_@E[H'Q3^&Z?!^P_P""E_@#P%X+\:?&OQ7)H_P]N[3Q+:>!U;Q!\5]!T:8^
M$G\):GJ'BG0M(&E#2;5= TA?M=]%X=U_3;JUTB]< ]^_X([_ +/OQ+_9;_X)
MH?LC_ [XQ6-UI/Q+\)?#W4M2\6:#?N)-0\,7WCKQMXI^(5OX2U+$DJ1:EX2T
M_P 5V?AO4+:.62&TO-+GMH6:*%#7Z6U\4?\ !.7]K*;]N;]B/]G;]JJ]T*S\
M,ZS\6O!$M[XHT+33<G2=-\9^&-?UKP/XV@T47DUQ>+H3>+?#.M2Z&EY<W5W'
MI,EFEU=7,ZR3R?:] !117Y9_\%:_^"AT'_!/K]FZ'5O ^D'QY^U+\===3X._
MLF?"2PMFUC6O&OQ;\0_9].LM9_X1RU2?4]:\.^"9]5TS4=6LK*U8:YKE_P"$
M_ HO-,U#QKIE]$ ?J917\.__  ;I?'SXE_ KX#_\%P/V@/C3?ZY\0_B/\!+'
M3_BWX\M?%7BJXU>_\2^./AUX1_:8\8>+;*]\1F?55FO?$GB+0[JWO=7LVO?M
MEU<_;(?MA:/?\,RZE_P4(T#_ ()U>'?^"^UO^WY\?[_]H[7OVC;WP[?>!S>B
M^^$5O\*?^$TUOX;KI>J^ A"/!%GIA^(6F3R1>$&\.+\-XM#U72].T_P]9:\M
MO?. ?Z-U?SX?\%:O^4F?_!!/_LY?X_\ _J(_"NOT^\._MU?L_P"C_LI?LW_M
M5?M!_%+X7?L\>$?VB?AE\*/&^AW/Q'\?:+X;\.IKWQ/^&]A\1H/".D^(?$4N
MC0:Q>VFF3:A);A(8+J\L=,N+XVD*)*L?X;_MZ?M=_LM?M0?\%.O^"'%K^SE^
MT+\'?CE<^#/VD?C3<>+8/A7\0?#/CB7PW!KOA3X=QZ++K:>'M1OVTV/59-)U
M-+![L1"Z;3[P0ES;R[0#^DKXR:%\5_$OPZUS1O@C\0?#7PM^)EU=>')/#_CG
MQ?X#D^)GA[1[6R\4:+?^);>_\%1>)_!LFKOKGA2VUSP_8RIXDTUM(U'5;36_
M],_LW[!=>GU\S_M@-^SXO[/7C=OVIO&LWP[^!:ZG\/3XP\86_P 0?&'PLETJ
M_'Q+\'?\(/&OCSP%K7A[Q5H:ZI\0/^$6T>1=-UBSCU:/4'T34S/I.I7]M-],
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 ?BO_P0X_Y-M^*?_9<-2_\
M4"\"5^U%?BO_ ,$./^3;?BG_ -EPU+_U O E?M17Z1XO?\G*XN_[&4?_ %$P
MQ^2^!/\ R:/@7_L3O_U,Q04445^;GZT%%%% !1110 4444 %%%% !1110 44
M44 ?+/[<W_)DW[8?_9K/[0?_ *J7Q=7Q[_P0_P#^4;?P0_[#GQ<_]6WXTK["
M_;F_Y,F_;#_[-9_:#_\ 52^+J^/?^"'_ /RC;^"'_8<^+G_JV_&E>U3_ .2>
MQ/\ V-L+_P"HN)/U+"?\F8SO_LY&0?\ K.9Z?K11117BGY:%%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% 'X__ /!<KPM^Q[XY
M_8 \:>"_VU/C!>? +X=^)_''@?3? ?QATWPMXB\;:AX#^,R75]?^!=:B\*>%
MK#4=8UW3XXK+6X?$UA;Q6SS>$9M?$.J:-=BVU:R_&/3O^"<'_!Q+^T#\-M(^
M$/BG_@JS\(]9_9%^)/@O3;6;Q[IB^(S\2O%?PC\5Z/ (?MHN?@#X-^*&K:MK
M_A;4A_;&A>*?BMIZZA%<7>G:YXDG:23SOW&_X+-_LC?'#]N']A#Q[^SM^SW:
M_#*Z^(GBWQ7X'O(C\58-)/A^UT/1]8^V:W=Z;J>I^&O%$_A_Q)#:@#1]=T2S
MLM<M&>>*SU6TBN;E9OP5^$?[-O\ P=,?";PUH_P3^'O[<W[+MSI_PW\/Z+H>
MG>&/$/B'X-?$'Q9X;\.Z?!!I&AVNI:GXP_9\\0^,Y;:.&&WL;.YU[4;J:4I'
M"MQ(P5: /ZMOV2?V9_ /[''[-OP>_9C^&,FHW/@KX.^#[3PMI>HZP\+ZOKEV
M;BYU37_$FK&VCAM4U3Q+XBU'5M?U"*SAALH+S4IH;."&VCBB7Z*KYM_8_P!)
M_:4T/]FGX1:3^V%XF\/>,OVE['PR\7Q>\3^%+?1K7P[K'B8ZKJ+I=:5;^'O#
MWA318K8:4^FP[=/\/:5#YL4A-N9"\LGTE0 5_,?^WI_P3$_X*J_&C_@J#HG[
M>_[,_P 8?V,O^$:^$/@G0/"/[-WA#]I+4?BAJDGPNFF\*):^.-?A\$>&O@QX
MF\(MXCU'QCJ_B[5M(\1W>NZ[JD%M>Z)<[[&]\.>&X?#_ /3A10!_GG?\$1/V
M<OVT?VDIO^"RGP:\/?$CX1:;\/\ XD_#KXR?![X^>'K^&^M[KQ5^T9\1_"GQ
MU\-?!GQ;X.U!? MWJ%AX"\*^-7\6ZAXCB/B'PM<S:1J&F++X>UYT:UT_Y@A_
M;%;Q+_P1=\)?\$7]#\ _$L?MSO\ MGW/P]N/@K%X,\06.L77A8_$?4/BE'<:
MS->V1LUUI?B=J<7@I_"9FL-<T^YT%];U2SM-(M%O-3_TT*YP>#O"*^)W\;KX
M6\.#QG)IJZ,_BX:'I@\3OI".9$TI]?%K_:K::DC-(MB;LVJNQ81!B30!\H_#
MG]B7X*O^R)^S#^RU^T9\)/@S^T+HO[//P?\ @]X"M-.^)_PX\,?$OP@GBGX8
M?#+2OAW)XJ\/Z-\0=&UJ*QNY[2VU."RU(VT6K)I>I7-K+,%NKF-_Q+_X*"_L
MN?LR_LY_\%.?^"&=S^SW^SI\"?@1<>+?VDOC9!XJG^#7PB^'_P ,)O$T.B^%
M/AS)H\/B"7P1X>T-]9BTE]3U)]-CU%KE+!]0OFM1$;NX,G]0M?SX?\%:O^4F
M?_!!/_LY?X__ /J(_"N@#]L?COXI^(O@OX6^(?$GPH^"LO[0WCS3[WPK'HWP
MCA\;>$/AW+XFM]0\8:!IFNWR>+_'CQ^%=,;PAX=O-6\:^1J4B2ZQ_P ([_8F
MEL-7U&PKUZO*/C?X3^*OC?X9:_X9^"?Q<M/@7\2[^[\,S:!\4+[X=:1\5[7P
M]:Z7XLT/5O$MG+X#U[5]!TO6?^$I\*V.M^$4N)]5M9-"DUY/$5F+B]TFWM9_
M5Z "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** /Q7_X(<?\FV_%/_LN&I?^
MH%X$K]J*_%?_ ((<?\FV_%/_ ++AJ7_J!>!*_:BOTCQ>_P"3E<7?]C*/_J)A
MC\E\"?\ DT? O_8G?_J9B@HHHK\W/UH**** "BBB@ HHHH **** "BBB@ HH
MHH _.7_@JC\:8/A5^QU\1_!VF:3+XJ^(_P"TG9W/[,OPI\%60EDU/Q-XO^,N
MFW_A*=;&&W628RZ1X?OM9U>U+H+6[UBUTC19IH9=9MF;\UOV&_VWOA1_P32\
M"^//V%/VV?$$W@#XA? CXC:W_P (EK'ASPAXO\7^'?''@/X@+%X\TS7+"^\-
MZ1JMRDKWVMZA?@:I8Z0RZ/J^AV0@?5;#7(++WC]L7PA^VC<?\%"_A3\=?#'[
M'\_[4'P1_9\^'MV?@MX=TOXT^ /AWIUO\4O&<2)XI\?>)4\7:3J^H#7-'6WC
MTW2]%MM)DLXGT#P7XOT_Q#::E!J.DOX3\4OA/^US^UM^VG^RM\</B7_P3 \*
M^ M#\#ZH/ /QF?XI_%_X/?'3P-XP^$>NW[0RSZQX1N-$TL6^L?#NVUSQ;XA\
M,ZC8Z7KNHW&LWFFQ/:21:7:0-]=@J&%67PPN*GAYX6O2J8_$5:>8X&EB*>+A
M%_5J$:=6K*HK48RIU$\.W[7%--J-)27])<+95P['@S!\/9]B<GQ.0YOE^,XQ
MSC,,%QKPGEV<X#B3"T:G]@Y1A\#C\PKXV"CE="M@,9">2U:CS'B"<92C2R^-
M6/VS_P /P/\ @FW_ -%OUS_PT?Q;_P#F+H_X?@?\$V_^BWZY_P"&C^+?_P Q
M=?87_##/[$W_ $9Y^RS_ .(^_"7_ .9&C_AAG]B;_HSS]EG_ ,1]^$O_ ,R-
M>7S\/_\ 0/F__A5A/_F;^KORM^??6_!G_H2^)'_A_P"&_+_J0^O];?'O_#\#
M_@FW_P!%OUS_ ,-'\6__ )BZ/^'X'_!-O_HM^N?^&C^+?_S%U]A?\,,_L3?]
M&>?LL_\ B/OPE_\ F1H_X89_8F_Z,\_99_\ $??A+_\ ,C1S\/\ _0/F_P#X
M583_ .9OZN_*Q];\&?\ H2^)'_A_X;\O^I#Z_P!;?'O_  _ _P"";?\ T6_7
M/_#1_%O_ .8NONG]F[]I[X,?M:> +OXG? KQ/=>+?!ECXEU'PC<ZG=^'O$'A
MJ6/7M*L=*U*^LQI_B73-*U!TBL]:TZ4726S6LAG:..9I(9E3P_XR_L3_ +&F
ME_"#XJZGIG[)'[,>G:EIWPV\<WVGZA8_ 7X5VE]8WUIX8U2XM+RSN[?PI'/:
MW5K/''/;W$$B30S(DD;JZJP^&/\ @WI_Y,7\5?\ 9Q7C[_U"OAC5UL+E=7+<
M3C,%#'4ZF'KX>BXXFM0J1DJZJ-M*E1IM->S_ )K:[/IV9ED/ .8<#9WQ1PMA
M^+,%C,ESC),MJ4<]S+*L;AZU/-H8V<IPA@<KP=2,Z?U-I-U;7G?E:T7[K444
M5X1^1!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!^&_\ P<.?M$_%
M_P#9O_X)M^+=<^#'B_5?AMX@^)/Q2^&OP;\1?%'0Y+ZVUCX;>!/'%YJ;^*?$
MVGWVFJVHZ;/<VND1>&#J.FM%JMG%XBDET>XMM7%C<1?SY>$?V#_V5_V9O%G_
M  5;_9T\%?M>ZVGPD\4?\$Q_@G\:&_:BUKQCX(U>ZU[Q_'\37^)5O?\ AS4=
M$BLM)O\ 0_&'B3P5I.DZ?X?TO4=5\57FFZW<:=I7B>^\0W-CJJ_MC_P5=_X+
M0?\ !*7X.:A\1OV#/VM?"'Q(_:4C\1Z19^'_ (T_#KX4^$-!\0:3X-34H[+7
M--M=?\2^(_B!\.$T[Q=I.=)\1:=)X(U;4/$OA/5(M.OEN=&UZSA6'X+_ &,_
M^#>+_@BS^V9X1\(_M8? +XU?M1?%'X&>(=3NW'PTUGQWX.T2WT?7-*N8O[:^
M'?C=K'X7Z3\1=%FT=I%M[O3H_$MIK<]C<Z=J^F^*]1TN_L-6U$ _=S_@C%\:
M?BI^T)_P3 _8^^+7QKU/4]=^)?B/X<ZGI_B#Q#K<DL^M>);?P=XY\6>"/#OB
MC6+N=1/J&J^)?"_AS1==U'5)S)/JMYJ$VHS33RW3S2?IY7*>!/ O@_X8>"O"
M?PX^'OAS2O"'@7P)X=T?PEX/\+:':I9Z/X>\-Z!80:9H^CZ;:IQ#:6%A;06\
M*DLY6,-([N6<]70 5\^_M&_M6_LX?LB>"K?XA_M+_&;P'\&/"%_?MI.E:IXV
MUJ'3YM=U9+:6]?2?#FDQ"XUKQ)JL=G#->2:;H6G:C>QVD4MR\"P1NX^@J_'/
M_@IQ^P!^S1\:?$WA3]O'X_?#KXY_M0:K^QK\,O%UY\/?V-_!T>C^+OAG\9-8
MNSJ=]%I&I_"Y?AYXG\5>)_$_B77;OPW#+'IVO6>AWZ>$O"L7B?1-5\/:9K%C
MJ8!^E?P-_:#^!W[3'@.S^)W[/WQ7\"?&'P#>W$ME'XH\ >(]-\1Z;;ZE!'#+
M<Z1J9L)Y9]'UNSCN('OM$U:&RU:R$T7VNSA,B9\CM?V_?V*+W]H*3]E2T_:B
M^"MQ^T1%?S:._P )XO'6C-XI_P"$AMWECN/":1"X^QR^,[9H)OM'@R.\?Q5
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M>Z@]7H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH _%?\ X(<?\FV_%/\
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M45XA^4A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M+_\ @K5_RDS_ .""?_9R_P ?_P#U$?A77]!]?SX?\%:O^4F?_!!/_LY?X_\
M_J(_"N@#]NOC9X2\6>.?AKKWA?P/\8=?^ GB?4;SPS)IWQ5\,:+X+\0ZYX<B
MTWQ7H>JZE9V6D?$+1O$/A"Z'BK2K&^\'W3:KH]X]K9:_<7FF"'5[>PN(?5:^
M9_VP+3X+WW[/7C>U_:$^$GB3XZ?".74_A[_PD_PN\)?#;Q)\7=?\17<?Q+\'
M2>%+FS^'OA&SU#Q#K\/AKQDGA_Q7J+V-G<)HVF:'>:]?(-/TN[9?IB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M\2?_ *'FC_AY9^U?_P!(M_VAO_ GXD__ $/-?.?\0KXV_P"@'*/_ !+>$/\
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M_P"'EG[5_P#TBW_:&_\  GXD_P#T/-'_ !"OC;_H!RC_ ,2WA#_Y^^:^\/\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MTL1#AG.<TPE+#85PS/-<HQF.G6PF#Q-6O4Q&$PU6D4445\F>V%%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %?S)_\ !<[_ ()._P#!
M0[_@I[\7?@R/@A\6OV:?"?[-OP:\.0ZIIWPY^+_C/XH:;>>(?C!J>KZD_B3Q
MAXA\.^$?@MXU\/ZIIT?A>'PYX8\/0ZEK=_<:?:#Q:UK#IL7BK5(+G^FRB@#\
M'/V'/V./^"L-A'\2O@9_P4T^.?[(GQA_8F\8_LN>,?@%HGP6_9R\+1^"+[19
M_$*^$O!^FV%JNC?LZ?!:/1O!&G?"5/'OA2"PTKQ&Z:=-J>ABQT)EM(K[2OQM
MTS_@@+_P52F^$^D?\$S/$/Q\_9W_ .'<VF_M)O\ 'Z\^*FD3^*(OC)J&ARYT
MI_"<'A*XT5K6'45LQ<>,8/!]S/+X7L_'>I2WDOQ,UC3[&QL8/[=:* .9\%>#
M?#/PZ\&^$OA]X*TBV\/^#? GAG0?!OA+0;,RFTT3PSX8TJTT30=(M3/)+,;;
M3=*L;2S@,TLDIBA4R2.^6/X+?\%:O^4F?_!!/_LY?X__ /J(_"NOZ#Z_GP_X
M*U?\I,_^""?_ &<O\?\ _P!1'X5T ?L-^U=JGPYT;X#^,M1^+/P"\3?M/> 8
M-1\")K?P2\'_  >L_CWXA\6SW/Q$\)VFA:A9?"J_@N;7Q)#X)\13Z3X^U*Z>
M"1_"^E^%[WQ? %N-!B9?HFO*/C>GQRD^&6OI^S=<_">T^,AN_#/_  BUQ\;[
M+Q?J/PRCL1XLT,^,O[?L_ =_I?BJ:[?P,/$J>&?[.OH(8_%C:'+JOFZ.E_#)
MZO0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %?G)_P4D_X*<?LX?\$T
MO@KK7Q#^+OBG1M2^)>I:'J<OP>^!ECJ]O'X_^*_B2**6'3[>QTV%+R_T7P9;
M:D(4\6>/[ZP;0?#=H6B5M2\17FA^'M8_1NOSY_;A_8\_9F^+OAWQ[^TA\4O@
M[X1^(7QC^#W[.7QCT#X7>*_&%M<Z_!X%MKSPUK6ORZCX?\-:C<S^%;7Q-#JU
MO;7FF^+GT27Q1HCP!=$U?3DFN5G /%/^"27_  46\6_MS_L!R_MD_M#Z7\-?
MA5/HWBCXJVOBR3P>-<TCP+X?\(?#79=7?B&^F\5^(/$=_:1VFE)=W^KW4^JF
MUBAMWE2*!$8'\A[7_@YU^(OVF#]IK4_^">WQ(L_^"8]]\6[CX)VG[0T7B6QG
M^*">*(;.754U2?P@"/"CW#Z8J&7PK%X@&D1W\=[I5I\3]1UJT;26XS_@E!#K
M$_\ P:[_ +9T.@*7U67X1?\ !0-+>-$FDGEC;X9^(1=PVB0(\SWTUE]HBL%B
M4N;UX I4_,/SRU[Q=X$F_P"#1/P5HT]Q:WWB"U_:AN_"-E%%?"SFT?QVW[1'
MBWQX]O<0.\/]JW4OPRN+N[6QB6[,=CJD&I%%&FR26P!_H'>&?$OA_P 9^&_#
M_C#PGK&G>(O"WBO1-*\2^&O$&D745]I.N^']=L+?5-&UC3+V!GAO-.U/3KJV
MO;*ZA9HKBVGBEC8HX)_ O_@K5_RDS_X()_\ 9R_Q_P#_ %$?A77O7@_X2_MY
M>,O^"6__  3P\'?L>?M"^"_V9/C;X;_9R_9<_P"%D^*?B7\,-,^(]KJN@Z;^
MSOHVEZ]X67P_XCT#5!I>L-XMETC49+YM/M+V"/2[JRD:'[1+ WXY?'_X1?\
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MUC6+-]-L_"UQJFE&;6;+3K:;W6@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M4M_\2ML__G:4 ?T'T5_/A_Q#B_LK_P#1WW_!2W_Q*VS_ /G:4?\ $.+^RO\
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M%UHGC'PC-J,VG:0=8;PEXPTK7?#8UR'3+&SUQ=+75["WCLKVW%?3U !1110
M4444 %%%% !1110 5X+\;_V9_@Y^T5J?P4UCXM>&;GQ%?_L]?&;PK\?_ (43
M6VOZ_H:^'OBGX+M]2M?#NOW$6AZEI\6MV]E#JU\KZ+K::AHMV95:[L)FBC*_
MB5_P6^_X+>Z3^P/X9\3_ +.7[-UKJOB_]N#6O"-OXE@<^"K_ %KP;\"? 5]
M;ZX^*'BF;5-/.@^)M3&D0WTGACP_9KK6C:=>0OKOQ!^QZ/86>@>+?I/X*?\
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? 4444 %%%% !1110 4444 %%%% !1110 4444 ?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>40
<FILENAME>nt10014672x1_linechart13.jpg
<TEXT>
begin 644 nt10014672x1_linechart13.jpg
M_]C_X  02D9)1@ ! 0$ P #   #_[0 V4&AO=&]S:&]P(#,N,  X0DE- ^T*
M4F5S;VQU=&EO;@     0 ,     !  $ P     $  ?_B"^!)0T-?4%)/1DE,
M10 ! 0  "]!N;VYE @   &UN=')21T(@6%E:( ?4  < %0 3  L (6%C<W
M         $E%0R!S4D="     0            #VU@ !     -,M2% @(
M
M$&1E<V,   %$    =&)865H   &X    %&)44D,   ',   (#&1M9&0   G8
M    B&=865H   I@    %&=44D,   ',   (#&QU;6D   IT    %&UE87,
M  J(    )&)K<'0   JL    %')865H   K     %')44D,   ',   (#'1E
M8V@   K4    #'9U960   K@    AW=T<'0   MH    %&-P<G0   M\
M*&-H860   ND    +&1E<V,         &G-21T(@245#-C$Y-C8M,BTQ('=I
M=&A"4$,
M                                                    6%E:(
M     "2@   /A   ML]C=7)V        !      %  H #P 4 !D '@ C "@
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M;W5R(%-P86-E("T@<U)'0@
M
M      !865H@        8ID  +>%   8VEA96B            !0
M;65A<P         !                               "6%E:(
M  ,6   #,P   J1865H@        ;Z(  #CU   #D'-I9R      0U)4(&1E
M<V,         +5)E9F5R96YC92!6:65W:6YG($-O;F1I=&EO;B!I;B!)14,@
M-C$Y-C8M,BTQ
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MU=;7V-G:X>+CY.7FY^CIZO'R\_3U]O?X^?K_Q  ? 0 # 0$! 0$! 0$!
M     0(#! 4&!P@)"@O_Q "U$0 " 0($! ,$!P4$!  ! G<  0(#$00%(3$&
M$D%1!V%Q$R(R@0@40I&AL<$)(S-2\!5B<M$*%B0TX27Q%Q@9&B8G*"DJ-38W
M.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U=G=X>7J"@X2%AH>(B8J2
MDY25EI>8F9JBHZ2EIJ>HJ:JRL[2UMK>XN;K"P\3%QL?(R<K2T]35UM?8V=KB
MX^3EYN?HZ>KR\_3U]O?X^?K_V@ , P$  A$#$0 _ /[^**** "OQH_X+%_&'
M]K']GKX1)\=/@W^UM\(OV1/@U\,O WQ UGQKJ_B'X8Z-\:/C-\;/C/-!IA^!
M_P "OA?X!\9Z=;>#DM/&FH6>NZ?K>MQ>)8_$]JU];WEMI,.BZ1J^N6'[+U^8
MW[>G_!+/X7?\%!?B#\"OB1\1OV@?VJOA%K?[.5WJ.M_"FU_9]\>?#OP58:#X
MTU*_T^_D^(:R^*?A-X\UI?'-E_9&D6VC:Y9ZQ9#08=-BFT:VL;^YU"]O0#XV
M_;@_:=_X*8>$O^"97[#WQ"^%?@SXO^!/VR/C9XS_ &<]%_:.A^ O[,-O^TC\
M0OA/X9\2_#3Q1XJ^+NNV/P.\8Z4GARSUJRUO2-%TZX\)^+]2\.6FBZYJ\G@T
M^--,:)O%%OY;\0?^"BOQ_P# /_!&+PO\>_@G^TU%^T_^TSX^^-^C_LX6OQ\^
M*7[.WA3X >(? 'C[QU\9;_P;J-EXT_9MTFXU'PEH'CGX2:6P\+6>DZG=7N@:
MOJ-KI'CG5X?$FAWDFE:W^KGQ)_8(T_XC_ OX!_"&;]J/]K70?&G[.'C;P[\0
M_ /[2MA\1O"6I_M Z[XH\-VFNVD'_"T->\2?#S6O!7Q'\.ZW'KF/%GA37? G
M]@^)$TG1H;^S,=D5E\^NO^"3?[,-U^PM=_L%_P!H_$Z#P5J'BF'XG:C\9H_$
M^ER?M#ZC\<4\>6WQ+N/CQ??$2[\.W-I<_%*_\76J37>M2>'S9#0F/A2UTVV\
M-Q6VFP 'P%\./^"D'[6'PB_89_X*SZQ\:=?\(?'']I+_ ()J?%KXJ?#'P=\4
M+WP-I7P_T7XKZ"-%T+4/A1XY\>^"/ >H'PQ9ZM%=:Y=W^O\ ACP?=^'XYM!L
M='T"\?2]?DU/Q%=>H_\ !);]K#]L?QI\=/CY^RA^VC\3]"^./B[P7^S_ /LE
M?M-^ /BCI?PX\&?#75!I/[0OPYBU[Q]\/];TCX=M!X3N],\!>,98-"\':M+H
M^C^)=;M+76M;U7[98:CH]KHWV;\+?^"8_P  OA[^S%^TQ^R_XEU_XC_&/0_V
MQ?%WQ<^(?[1WQ&^)NI^%9_B1\0/'_P :=.M--\5^*H;SPGX/\*^%?#5YI,>G
M:9<>";30/"ME8>%+W3+*_L[>6^2:YGT_V'_^"=7PR_8<U?XL>,/#_P 4?C1\
M;_B5\9M*^$'ACQE\2_CKKGA#7/%7_"%? /P2?AW\)?!VEGP7X(\"Z5:Z7X:\
M*'R+Z^N=.O=>\3:J\NM>(-6O[UHC" ?GK^UQ_P %2/\ @J7^SSX4_:-\8Z3_
M ,$;+F/X8_!S2/BAJ^C_ ![\6?MG?"C4_#'_  B7@N#69=*^*GB#X4>&_#%M
MXNU#0)-/L+;Q1J/@31O&-EXAN].>70[/Q%9:C(FH0_L5^R-\8=;_ &AOV4?V
M8OC]XETO2]#\1_'+]GKX+?&'7]%T/[7_ &)H^M_$SX;^&O&FJZ7H_P!ON+N^
M_LO3[[6Y[33_ +;=7-W]DAA^TW$TV^1OGS_@K-_RC#_;_P#^S0_C[_ZK;Q#7
M3?\ !,7_ )1L?\$]?^S'?V3?_5"^ : /N*BBB@ HHHH **** "BBB@ HHHH
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M9X_#XJCQRJE/@*67+)J-"=1\7U\/BH\.3;K0X@]A4ADT<7.G4Y?D?PC\>O\
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MJ=;"4YU8_P!+'CC_ (*$?LU?"K]J#Q)^RW\8/'7AWX.^(/#WPD^''Q9A\?\
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M 1OM7F(S107#PQ_;F2>S]M_;&5>Q]E[?VO\ :&$]G[#ZU]1]MS^VY?9?7?\
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MU*&;_4Y5()_05%?+'PA_;8_9=^.MM\8;[X9_%K2]6TWX 7GV'XPZMKFA^+?
MNC^!9@=>$DNJ:QX^\/\ AC3+BQ@'AC79+K4],N[[3;6&P>:YNXHIK9YOJ565
MU5T971U#(ZD,K*P!5E8$AE8$$$$@@@@XKIPV,PF-I1KX/%8?%T9J3A6PU>E7
MI24:E2C)QJ4I3A)1JTJM*33=JE.I!VE"27AYYPYQ#PQCJV5\2Y%G/#V9X>5*
M-?+L\RO'93CJ$J^#PF8T(UL)CZ&'Q%.5;+\?@<=24Z<74P>-PF*A>AB:,YNH
MHHKH/&"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MU<0[5V8&K0 4444 %%%% 'Y[_P#!6;_E&'^W_P#]FA_'W_U6WB&NF_X)B_\
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M:"1LZWP5^).H?%[X9>&/B%JOPY\>_";4?$$6H&\\ ?$S19/#_C/0+C3-6O\
M2)4U/2IML\-O?/8'4M'GGAMIK_1KS3]0>TMOM0A3LO%WBOP[X#\*>)_''C#5
M[+P_X2\&>'M:\5^*=>U*40:=HGAWP[IMSJ^MZO?SMQ#9:;IEG=7MU*>(X(9'
M/ K)9=@(\J6!P:4%2C!+#4$HQH3=2A&-H64:-1N=)+2G-N4+-W-Y\8\7U'6E
M4XJXDG+$U,?6Q$IYYF<G7K9KAX83-*M9RQ3=6IF6$IPPN/J3YI8S#PA1Q#J4
MXJ*\WTS]G#X Z+K'Q+\0Z1\&?AIINN_&:RUC3OBUK%EX-T*VU+XDV'B"2ZEU
MVS\;7D5DL_B2VU>2^O)-1AU5[F.\>ZG:=7,KDXVH_LG?LQZM\,M"^"VJ? 'X
M1:A\(O"^O3>*/#GPTO/ /ANX\$:'XCN/[9\_7=*\-2Z>VE6.JS?\)%KWF7UO
M:QW#_P!L:END/VR??^6'_!(K_@J%\;/VW/&?Q?\ AY^T_P#"SP_\%/&NK^#/
M"7[6/[*_AS3;74+'4?'G[%?Q4U_7_#7@SQ/J<=YK.N)JNL>&-6T/2X->\36S
MZ)8:XGCCP_)I_AZQ6"ZKSS]LW_@H[^W-^S[^W9H/_!/SX<^!_@%XG\<_M>:_
M\)=<_8P^+?B5]0L_#?PR^&S7^LV_[1*_M"^##XVTG6/&'B+P?#X2UB\^&T?@
MJ_\ #$/BS3=6M%MY-<\6:5<>#[L>7X!QE%X'!N,HU82B\-1<90K5%5K0DN2S
MC5JQC4JQ>E2HE.:<DF*/&/%T*M*O#BGB.-:CB,%BJ-:.>9G&K2Q6682>7Y;B
M:518I3IXC+\!5J8'!5HM5,)A*D\-0E3HSE!_N!J?P-^#6M?$CPM\8=7^%O@/
M4OBMX'T9?#O@[XC7WA?2+GQGX7T%%UE$T?0O$4MJVJ:7IJIXBUY5L[2YB@"Z
MQJ0"8O)]^-I/[-7[/F@V_P 5;31/@K\,=)MOCI]I_P"%S6^G^"]!M(?BG]L?
M7)+O_A/8X;%%\4_:9/$WB%Y_[8%WYC:WJC/DWMQYGR)_P4"_:T^*?[*_BC_@
MGUH'P]M?"&J0?M.?MW?!C]F7XE7/BO1]1OYX/ /CS2O%-UKVH^%AIFMZ1%I/
MB<3Z):MI]]?1ZQIUJCSI+I-SN1H_NWXC?%+X9?!_PU+XS^+?Q%\"?"WP?!>6
MFGS>+/B-XN\/^"/#4-_?NT=C8RZ[XFU#3-+CO+UT9+2V>Z$URZLL*.5(%/ X
M)R<W@\*YN=2HY/#TG)U*U+V%:;ER7<ZM%*C4DWS3I+V<FX:&,>*.)H488:/$
M6>QP]/#8+!PH1S?,%1AA,NQ[S3+\+"DL0H1PV S.4LQP5!15+"X]O&4(T\0W
M4//+_P#94_9HU7X=>%/A%J7P%^$M_P#"WP)K-SXB\%_#V[\!^')_!WA77KRZ
MU>^NM8T#P])I[:9I6I7%YK^MW4UY9VT4\D^K:A*SE[N8OU4_P-^#5S\5+/XY
M7'PM\!S?&73].;2+'XI2^%](?QY::6^G76D/I]OXH:T.KQ6;:7>WFGM;I=B(
MV=U/;E?*E=3\6?\ !2[]K[XU?LR?L1^./VDOV1_A=X9_: U[3_!>I^.]/\3W
MOBG0A\*?!7PVTKP9JWCO4_C#K]S!XCTB]\=^&X]!TJ*'PSX>\#:E/JGBS6M=
MT(6UQ!HIO]0@WOVE_P!MBZ_9@_X)L>*_VY/$?AJS\3^(?"G[/?@SXDIX4LA>
MV&C:SX^\=:7X9T_P]I$CQM?ZAIGANX\:^*M,@U&Y62[NM-T(W5SYLTMOYC"P
M.!CR\N#PJY'AW"V'HKD>$BXX5QM#W7AHR<<.U9T8MJGRIM%3XKXIJJNJG$N?
MU%BH9O3Q*GG.8S6(AQ!4IUL^A74L2U6AG=:E2JYO&IS+,JE.G4QJK2A%KZ'L
MOV3OV8]-\/?$3PEI_P  ?A%9>%_BY>Z?J/Q1\/VO@'PW#H_Q!O\ 2=2FUG3+
MSQAI\>GK;>(+G3]6N;C4K.;4X[A[>]FEN8F65V8V-7_99_9MU_0OASX8USX$
M_"C5O#GP@DDF^%>AZAX%\.W>E?#N6:>RNI9/!MC-8/;^'GDN=.L)W;3([8M+
M9VTA):&,K^>_["_[:7[5G[2&K?MS_LR_&3PW\#?!/[77[)^D?!R[TKQA\/M.
M\9WGP+U9_P!I_P""=[\5?@[=:GX9UGQ7KGBJ3_A#[JW;3O'MIIOC:9=;MH%E
MT6YTI[E2LO[ 7QK_ ."@WQ3_ &F_VI? /[1WC;]E/XB_ W]F_P#LCX37?CKX
M!?#GQ[X+O-:_::U33/!_CSQ%X.TRZ\5?$WQS#>Z)\*/ 'B"PT[X@&XTW2[I?
M'GC#3M T^9KCP?XH@$_V=E_+R?4,'R<GLN7ZK0Y?9JL\2J?+R6Y%B&Z_);E]
MLW5MS^\;_P"NG&+K+$/BSB;ZPL5+'*O_ &]FGMEC999')98Q5?K7.L5+)XQR
MF6(4O:O+(QP#G]52I+]+=.^"7P?TGXI:[\;]+^&7@;3_ (Q>*-*AT+Q'\3[/
MPSI-OXZUS1K>TT:P@TO5?$\5JNKWUA#9>'=!M([6XNI(4M]'TV)4"6< 3C=*
M_9._9CT+X:^)O@UHWP!^$6E_";QIJMGKOB[X;V'@'PW:^"O$NLZ?<:/=V.J:
MWX<AT]-*U*_L[KP_H5Q;75W;2S0S:1ITB.K6D!3;\._'SX/_ !)TGXBS?!WX
MM_"WXI:M\-;:]@\6V/@'QYX6\<2^$=;CMM5>RTOQ;:^&-8U"XT&\N+G1M1A2
MQU3[#=3-IVH1Q+OM+CROXQ4_X.;OVQO^&0_ OB"X\ ? :']K>_\ VD$LO&GA
M^+P/XRG\#:-^R=JOPY^$^N>#_B#/H*?$QM6T[7?&/C;XQ^']&TC5I/$5QIGV
M33I+:?1H[^_1XF\!@9<W-@\(^9XAROAZ+YGC$EBW*\-7BDDL1>_MTDJO-9&%
M/BOBFDJ2I<2Y_35!9-&@J><YC!48\.2G+AZ-)1Q*]FLAE.<LF4++*Y3F\#[!
MR;?]G&J?LX? '7)OA/<:Q\&?AIJD_P !X](A^"LM_P"#="NI/A5%X?;17T./
MP \UD[>%4TE_#>@-IRZ.;06C:-IAA"&R@V7(/@#\$+7Q[XS^*=M\)?A[!\2?
MB+X=N?"/CWQW%X3T5/%?C+PO>0:1;7?A[Q+KJV8U'6-'N;?0-$@FT^^GFMI(
MM)T]'C*VD(3\@O\ @J__ ,%/?C'_ ,$__P!J'_@G_P""_#&C?#BY^ 'QN\8:
MLW[4?BCQEHVLWNM^ _A=IWQ4^!7PZOO%_AG5=.\4:+9Z0^D)\6IKB=M0T?Q#
M'<7HTQ3;0VR71>'_ ((O_P#!4#XU?\%(_'?[=G_"RO#'@CPQ\/O@M\1_AT?@
M##X:\/ZUHOB.^^$WQ5'Q,\1>#=1\<7FI^)M>L]<U;4/!&A>#-2AU/1[+0;&Y
M-_>7D5CY%Y;16K^HX*_-]3PO-SPJ<WU>E?VE.DZ%.I?DOSTZ+=&$_BC2;IQ:
MAH3_ *T\3>S='_6//?9/#8K!.E_:^8>S>#QN/6:8S".'UCE>&Q>9QCF.*H6]
MEB,?%8RK">(2J'ZLP?LD?LO6WPTO/@S;_L^_!^'X2ZAXB7Q=??#:+X?^&D\$
MW?BA(K6!/$-QX;73AI4NL+#96<2Z@]L;D1VL""3;$@'37/[/GP+O-=^&WB>[
M^$/PZN?$?P<TJST+X3ZY/X1T235?AQHVG01VMAI?@N^>S-QX<L+.VBC@MK72
MY+:&&)$2-%50*_&ZX_X*V_$FT_X*N-^S5/X#\))^P6/BIIO[$8_:$$5_)JC_
M +>VJ_#.3XMVO@%-;CUE].:S55A^$5UX4'AC^T+7QO=6VK3^(4T]I+.+MO\
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M1\2?VN?V;?VIO!OPL\._'O\ 9(U#]GW4O$FN_!-?$MM\-/$_A']IKX4-\6/
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MPTO[.R_EY/J.#Y.3V?)]6H<OL_;?6/9\O);D^L?O^6W+[;][;G]XT_URXO\
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M&I=,M]--I:FRC@-O%LMZ?\#/@EI/BOQCX\TKX._"S3/'/Q$TV]T;X@>,]/\
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M5N/#VA?;'TC4!]D\2ZMHU];_ &?-U;0"6 R]G-^R_P#LT7'P_M?A-/\ L[_
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M9TES_P!J<BC]8O#ZI]6L[\6%Q'@HHY?]=RGQ2G-1X#_M5X7B#A*G&I*BJ_\
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M ()Z_P#9CO[)O_JA? - 'W%1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110!^)'_  7$\3^&KK]FGP1X6M?$.AW/
MB;3_ -H#PE>W_AV#5K";7;&S/PT^*!%W>:1'<-J%M:D:A8'[1-;I%B^LSO\
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M(M.A\(IH</A7;:QZ6NLJ-='TC^U?_P $_O"W[5?Q3^"?QK;]H;]IO]GOXH?
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M_P 4^*;F#XGV&EVM_KRZM:QW<>K>%O%UP@TN#SM1O0T:V^3X(_8@^,7A2_\
MV[[S4_VR_B7XGB_:[L_']M\+;2_TWQ2D?[*LGC&;XCRZ3<> #<?%;45OW\)+
MXXT:/3AX=B^&[2+X,TS[-)I@DM5TK3^T,V]JX?V!7]FJ]:FJW]HY=9T:>"^L
M4L1R>VYU&OB_^$^--KVE.I_M%2,</[YQK@[P\_LZGBGXOY4L=/*\KQD\L_U-
MXS]I2S'&<4?V/F&3O%?V9]5E5RCA[_C+ZN,A4>"QF$_X1\'5JYS_ +,>=?\
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MQCRG&?5H>(,L%R<%\:T/[2GPQ]5_U)IT_;Y7#ZL_$SVV(_LZ6*]G'A?ZG/\
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M7S.-;&5J>%5+T^BBBOH3\;"BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH *_(K]M7QY^Q7X=_;F_8?\-?'GX(^//'_P"T'XD\
M2^'H?@!\0_#OB+5]+\-?#W59?B%IEIIEWXDTJR^(GABQU6&U\3/::I*E]X5\
M4J]I"\+031L;-_UUKX;_ &@O%_[=6B?M&_LZZ%^SS\+/ ?C#]F_7-7TN+]HW
MQGXBU'P_:^)?!ND2>*;.VU6X\-VNI?$?POJEU-;^%6O+^)=,\)^*W:[C1$@F
MF*V4GA<10=3+HQ5)UO\ ;\MER+)XYX_=QU"7-]1E*"BH6YGC+WP*7UM)NC9_
MK7@MBXX/C.O6ECJ>7)\)<:TOK%3Q(J^%<6ZW"^:4E0_UII4,1.M+$N2HQX;]
MFH\5RFN'YU*<<P<X_<E%%%>Z?DH4444 %%%% 'YA_P#!9GQ]^T/\+_\ @F;^
MU=X\_9;U+Q-H7Q>\.^"M"N[;Q-X)MS=>,_"/@*;QUX5M/B_XO\*HJ":VUKPO
M\)KCQKKEOK%G>:7JOAN*QG\3:)JMAK>CZ=,/Y*_VA_C]\4_'?P8^,?[:GPH_
M;[_;;E\(? GQU^R+^QE_P2,-AXL\::+J'[8/Q7^%FE^#K#]H;XA?%KX=WGA.
M%?B'>^-5U76_&,?B+QG;:)K/C&Z;4O!7B>7Q!-X<?P+J/^@A7.W_ (0\)ZK-
MX;N-3\+^'=1N/!NH?VOX0GO]%TV\F\*:J-.O-'&I^&Y;BVD?0]0&DZCJ&E_;
M=+:UN?[.OKRQ\W[-<S1. ;-D;PV=H=06W6_-M ;Y;0R-:K>&)#<K;-+B5K<3
M;Q"9!YAC"E_FS5FBB@ HHHH **** /SW_P""LW_*,/\ ;_\ ^S0_C[_ZK;Q#
M73?\$Q?^4;'_  3U_P"S'?V3?_5"^ :YG_@K-_RC#_;_ /\ LT/X^_\ JMO$
M-=-_P3%_Y1L?\$]?^S'?V3?_ %0O@&@#[BHHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KA_B7\1O!_PB\!>*_B7X^U
MBWT'PAX,T>YUK6]2N&4;+> *D-K:Q%E:\U/4KN2WTW2--@W7>J:K=V>G6<<M
MU=0QOW%?E!XCF/\ P4(_:0G^'UFSWG['/[+_ (IAN/B'>QP2-HWQW^.>FY:R
M\#Q7<A2WU7P7X&$C7.NI MS9:C*Y,\-Y8>(_"&NV'T_"^14<WQ6(Q695:F#X
M>R6@LQS_ !]-1=2E@U4C3I8/"<_[N>:9KB)0P&64973Q%7ZQ64<)AL55I?&<
M:\38C(,#A,'E&'HYAQ7Q#BGE/"V5U925*OF$J4JM?,<?[-^UIY)D>$C4S3.<
M1"THX2A]6H.6.QF"HUOQ[_;B^"&N>*?@Y-_P4%\?:6_@3Q=^T?\ '/P_9>#/
MA;ID5E#I>@?"34/AYXHO?#>O>)W%F+J^\=>)K;P7I&LWMU:W%K93Q:C=ZM>6
M9U'7&L- _HM_8T_9<^%7[+?PDT_0?AK8ZC)=^,K?2?%7B_Q/X@N+6_\ $GB+
M5;G3(7MH[V\M++3[:+2M&AGFM=#TBSL[:RL(YKRZ:.?5=3U?4M0^&O\ @N4
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M=75S/>WVE1ZL^GWT$>I:;I6E^)?$/AVQ^Q[^R=#^SSH6N^,/'OB!_B9^T?\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MZNT445]$?C 4444 %%%% 'E7QPN/C3:_";QW<?LZ6'PXU3XWQ:'*_P -M/\
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M_P""LW_*,/\ ;_\ ^S0_C[_ZK;Q#73?\$Q?^4;'_  3U_P"S'?V3?_5"^ :
M/N*BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HKRG
MXX_"'0/CU\*/&OPA\4:IXAT30?'&F1:;J&J^%=132]>LTM]0L]3@DL;R6WNX
M-K75C!'>6MS:W%IJ%B]SI]W#+;74J'^9#5?^"=_PHL/^"BGAK]CV+QE\0W\
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MW"=+/UA<PEEV$<L?B_[9EF-"/U2%*C/+I-.K5Q$?:2I_I71117X@?TB%%%%
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MC6Q\&_'KXA>*O&GBJ72O&M_IWBCPYX5^(?Q*\'?%SXH_ /X<>,+>!?$G@/\
M9P^*7C[PE=^(/'/P:T+4H/"^H7_C;QS?6$6F:AJ]G>:7^CZ(D:)'&BQQQJJ1
MQHH1$1 %5$50%554 *H      %>V?EI\U_LK_ ?QU^SE\/=7^&_C/]I/XP?M
M0:?;^+[S4_A_XS^/+>%]5^*GA;P+<>'_  U96_@+Q3XZ\-:)X>E^)MQI_B;3
MO%'B.V\<>)M+B\436GBF'P[?SWEIX<T^[F^EJ** "BBB@ HHHH _/?\ X*S?
M\HP_V_\ _LT/X^_^JV\0UTW_  3%_P"4;'_!/7_LQW]DW_U0O@&N9_X*S?\
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MPZ_[.-\(_P#JL_B]7['^'O\ D :'_P!@?3/_ $B@HZ+U?Y1 V****0!1110
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MB 6DVTDFVW9):MM[)+JV#:2;;LEJV]DN[+%%?D3_ ,/W_P#@E+_T=1_Y@_\
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MNSJ "!5R@ HHHH **** /SW_ ."LW_*,/]O_ /[-#^/O_JMO$-=-_P $Q?\
ME&Q_P3U_[,=_9-_]4+X!KF?^"LW_ "C#_;__ .S0_C[_ .JV\0UTW_!,7_E&
MQ_P3U_[,=_9-_P#5"^ : /N*BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@#S'XS?%_P1\!/ACXN^+GQ&OKO3_!W@NP@O=5FL+&?4K^
M>6_U"ST?2=-L+*W&9K_5]:U'3M)LC/);6,5S>Q3:C>V%A'<WD'\MWQ$_;!^+
MFN?M.ZE_P4/^'OP \8Z7\/=$\.:U\-_"7B+Q#I>L7WA&UU&]\(>(/ FAZUKW
MBBRT<^'&U.TU;6(=5OO"]M?36[7$"^&/[;,UU'J[?TB_ME?!]OCS^R_\9OA9
M%J]GH5YXA\)-?:9JNI7J:;I5KK/A/4M/\8Z*-9U&0^7I^B3ZMX?LK;6KZ0.E
MII4UY<-'*(S&W\W'PM_;Z^,WB/\ 91LOV"OA]\"AXX\9>*O#7B;X>>'O%.A7
M>H7^J7WA#7+C6;W6(K?P'I.@!+S4]+T6?6(9/% \1PZ?8V=@^NZU87#66I7-
MQ_4'@/D^$JY%GV<X3),%Q%F=7-:/#/$V&S3.5D^ RC@#-L#[?,\TYZDZ5'$5
M*U3"XFE6CSU,11HX53H46IU>;^*_I/\ $&.H\3\+\/9AQ)F/"62T,CK\9\&X
MW)>'GQ!F>?>*>0YFL/DV2^SI4ZV(PE/#T\;@ZV'GR4L)B,3CO9XJO%TZ'+^Y
M_P#P3%\#> -)_9B\/?%/PSXBG\>^-_CQ>:C\0_C!\1=4L;ZSU[Q!\19=5U2T
M\1:'?MJB"_EM?!.NC6M MIPQTW6+^/6/%VF+Y/BAY9OJ#]HW]H#P'^S'\(O%
M/Q>^(5XL>EZ#;B#2='BF2/5?%OB>\21="\)Z%$RR//JFL7,94NL4L.F:=#J&
MN:CY&D:5J%U;^<_L9_!FY_96_91^'7PX\<:Q80:GX/T#6_$GCC4I[NT@T?0]
M1U[5=5\8^(;5M1,WV,Z7X9;4Y].DU9IUMKJ#39-4)AAG$<7QO\)["_\ ^"BG
M[15K^TCXIL;Z/]D;]GOQ!J&E_LW^&-2LY;&V^+7Q%TZ[2'6?B[J]E=QQW5[H
MNCWUE%'H5O=10PPWEI8:6T5MJ.F^/],U/\)XWQU+,^,>)\=0S">:82MGF9?4
ML?-13Q.7T\75I9?*G"G&G3IT5@J="&'I4J=*C1P\*=.C2I4H1IQ_IWPURRMD
MWA]P7EN*RNGDF.PW#.3?VEE=-SE]3S:M@*-?-J=6I4G5K5L3+,JN*J8NO7K5
M\1B,3.M7Q%>O6J3JS]E_88^ 'CBTO/%O[7O[1MO++^TM\?X4O)]&N[9K:#X/
M?#)W@G\,?#31;&=Y;O39Q86VF77B"*\D34+8VNE:+J, UK2M=U/7/T;HHKY9
MN[N?;G\UO_!1%O\ @HW^T[)XC^#5[^R>(OA'X*^,DWB/P)XB\$:/K>N>(]=M
MM"MO%'A'0-2O=<?Q3<:7J&DZSI/B6YUB<VO@[1)[1GLQ<O9I97R3_J+^PU\7
M_P!M7XD2^+]'_:K^ 'ASX1Z1X:TG0E\'Z[HUOK.B3ZU=2--:W.F3:+K'B?Q?
M)?F"UMA>7&K6^H:5#:.]M:?V==M>^?9_H;13;NK67K]WXNW]=0****D HHHH
M **** "O+_B+\;_@O\'VTI/BW\7OA?\ "U]=6\?1$^(OC_PIX(;64T\VXOWT
MI?$VK:8=16Q-W:B\:T$PMC<VXF*&:/=ZA7XK_P#!6G_@F5^SA^U+X(^*7[5G
MQ%N_B/IOQ5^"'[,GQ#7PL_A'Q+I6F>'=5@^'NB>./B%X9MO$NDZGX;UN6]BM
MM?U/45N'TV^TBYNM/O'M99]T-I-;^[PW@LHS'.,)@L[QV,R[ XF7L?K.!PD,
M976(J-0P\/95*U&,:<ZLHJI4O-PCM!WYH^'Q%C<VR_*,5C,EP6$S#&X>/M?J
M^-Q<\'0="G>>(G[6%&M*4X4HR<*=H*<G\:MRR_33P1^U#^S1\3==LO"_PW_:
M(^!?Q!\3:E'/-IWAWP1\6_ 'BS7;^&UA>XNI;+2-!\07^H74=M!&\\\D%O(L
M,*/)(512P]TK^1;_ ((3_P#!+_\ 9I^,'PA^#O[<?C:Y^(]Y\7?AY\:O$&I^
M']%L_$VE67P^.I_#O6+.X\)W]]HL?AMM<N)M.U$6^JLD?B:"VNKVRMDN8)+$
MW-G<?UTUZO'.19+PWGV)R7)\RQV9O+ZE;"YA/&X*GA/8XVA6J4ITZ$J=>JL1
M2<8QDJCA2LW9*6O+YG!&>9SQ'D>&SC.,NP.7+'TZ.*R^&"QE3%^UP5>C3J0J
M5XU*%)T*O-*4?9J=6Z5WRV3D5\B?\%!/^3"_VW/^S1/VD_\ U37C2OKNORG_
M ."G7[9_[+/PW_9P_:Z_9Z\=?&WP5X9^-7BW]E7XSZ1X;^'.IW5Y'XBUC4O'
M7PI\6Z7X1L[.&.SD@:;7M0N8+2P#7"!Y95#E!DCS.%\%C,=Q!E%/!83$XRI3
MS' UZE/"T*N(G"A3QE#VE:<*4)RC2IW7/4DE"%US-71Z7$N,PF"R+-:F-Q6&
MPE.I@,;0IU,57I8>$ZU3"5O9T83JRA&56I9\E.+<Y6?*G9G!?\$!_P#E%M\
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M>&_$^@W^AVT-K8Z+XPT?Q!I?A^=3J/ARTTG4Y)+Q_FOXL_\ !*7]A/XY>/\
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M1-%FU;Q!-<ZAK:V=A^Q=>0^(_@-\*/%OQF^&?[07B'PK_:'Q>^#OAGQ_X/\
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MR^-GPT\#6>OW'A?P2_QT^'NI?##7_B%X7TO1M"O-+^)/A3PKXAO)/%Z?#_Q
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MI1Y\C\*N.LRXHJ0E=8CB_,,OP4<7A9R3:G#A[!1P^2TXJ\88VGFM6&F*;?\
M&'%D)\48S@+Q4QD9^SXE\<?#')^"J=6/*\)P#E>;9A+ 8R$&E*%3BS,9XGB.
MK)^]4RZKD="HE+!)'[H?M7^./$_[8/QKM_V _@KK>H:;X)TD6>O_ +8OQ/T
MQ!/"_A&.6.>U^%6E:K*LMJWB7Q'*L=OJ=I!!>D74MMIE]%<Z3HWQ#TRT_4;P
M5X,\,?#KPCX;\">"M'M?#_A+PCHNG^'_  ]HUF96@T[2=+MH[6SMUEGDFN;B
M18HU:>[NYY[R\G:6ZO+B>YFEF?Y'_P""??P<^&'PI_9S\*ZM\._%]A\4=1^*
MD2_$3Q_\7[>XN[Z[^(WC+6=\FK7US=ZFD>L0V^C7C7>C6VCZO#::MIEQ;:@V
MO6-OXHO-?>;[?K^8GVZ+RMKU;_K:Q_:(4444@"BBB@ HHHH **** "BBB@ K
MYD_;7_Y,T_:V_P"S9/CU_P"JK\5U]-U\R?MK_P#)FG[6W_9LGQZ_]57XKKTL
MF_Y'&5?]C+ _^I5(\[./^13FG_8NQO\ ZC53\Q_^#=?_ )1L>&/^RN_%?_T[
M6-?NG7X6?\&Z_P#RC8\,?]E=^*__ *=K&OW/FFAMH9;BXEB@MX(I)IYYI%BA
MAAB4O+++*Y5(XHT5GDD=E5%4LQ !-?2>)&O'_%]O^B@S+_U)F?.^'>G G"5]
M/^$#+?\ U&@25_'G^W/X)_9W^)?_  <'_#CP3^U1)X./P&U7X1V:?$#_ (3K
MQB_@/PK&^G_ CXF:UX636/%<&N^&Y='8^+[3PT]@O]M6)O[^2PT\BY2^^RW'
MZ@_&S_@I#\8?VG_B+KO[*?\ P2=T#2/B9XWTJ0Z;\5_VP=?A6X_9[^!EM=22
M6BW.@:O+9ZCI/CWQ.6BO+G29X+/7-&O5T]YO#/A_XB6HU630?CW]J3_@@S^S
MYX,_9>_:,_:.^*GQR_:+^-'[2O@;X"_%_P"+OB/XB:_XOT&#1O&_Q(\&?#_Q
M%XKL[_4M#U/POXA\0IH4NH:5964FFW'C6^U Z5 +==9CE*S1_;^'^#H<'YA6
MK\39KB,AS#B7),9D.58# 4JE;B#!/.E0IX?.<33IU*/]D1HR]G5P4<35IXVO
M)QKTJ$*$%7E\5QYC*_%V!HT.&LKP^>X#AS.L)GF:8_'5:='(,8LF=6K7R?#5
M)TZW]K2K1<Z6,EAZ53!4(J5"I7G7E*A#\U?VW_V;OV2-)_X*<?L1?![_ ()\
M^/O"GPP\+?$@_"K3=2^)'P$^)M[\3;[P-\1_$'Q@\2:#_P )3IFOCQUKUUI7
MB[1-%CT'4-.LK?7]*DM6AT_48D@EG%S+_2A\&/\ @BO^PU\,?$DGQ"^(7A+Q
M9^U5\5[N[FO]4^)/[4_BNY^+.I:I>74 BN'U#PO>6^G^ =5"ONFLKK7_  IK
M6M63^6Z:Q)/&)S^3O_!%#_@E!^S/\4_@/^S'^W;XDUOXMP?&?P[\2]?\96&F
MZ5XI\.6O@)]6^%GQ7UW3O#<=SH=QX,O-8DLI[?P[8'5H4\112W4KW+6\]FLD
M:1?UDUT>)O&F.P-?!<*9'Q+GU>7#^&QV1Y]F&(E/"8[,L;A\PKQJ>VQL*L\7
MBL/RKD4)XAT9**;I7DS#PVX.P6-HXSBG.^&\CH1S[$8'.LBP&'C#%8'+L%B,
MOH2I^QP4Z4,)AL1=\[J0PZK0<FE4LDC/TG2=*T'3+'1=#TS3]%T?2[6&QTS2
M=)LK;3M,TZRMT$=O9V-A9Q0VMI:P1JL<-O;Q1Q1( J(J@"M"BBOPMMR;E)MR
M;;;;;;;=VVWJVWJV]6S]N244HQ244DDDDDDE9)):)):)+1(*_F1_X)[?\I\O
M^"FW_8@^*/\ U/O@Q7]-U?S(_P#!/;_E/E_P4V_[$'Q1_P"I]\&*_1N!?^1)
MXD_]D8__ %=Y0?GG&_\ R.O#G_LL%_ZI<U/Z;J***_.#]$"BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH *_-/]JO2_CE=_M<_LE7GP^_:^^%?P3^'-GKVBM\1/@5XP\?V_AOQI\<
MK1?&MA)=:9X,\,2Z1>R^)KC4=+$WAV"&*^L3+?W4=H&5G$@_2ROQ^_;;U/\
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M2DJ;J<JY_9J3<E#FOR*3<E&UVW<****S+"BBB@ HHHH **** "BBB@ HHHH
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M,,:JW(\!C:DWE. Q?L<7G<)Y71Q4'^EE%%%>V?EH5^47Q>_X*U?!SX>_M/\
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MW$YA@*.*]O0R['XG 83$X[ 4\/B\10IUJTT%?@GXT_X+=^,Y?'/C[0_V=O\
M@ES^WY^T_P##OP#\0?'WPO?XT_#KX=1GX?\ BWQ9\,O&.M^!_%\G@N]L(O$8
MU;P_::[H5W;VFI7LVEZE+(DT%_H>EW-N\+?O97\%5KX"T[P_\6_VL4^/=O\
M\''_ (&^(>M?MA_M,>)+F?\ X)\> CX!_9>\<:)J_P 5O$+^&O'_ (-\-0>#
MHQ!JGBC0H;"]\0:@KW]MK-WY>K6FKZG%=^>/5/@#^\JPN7O+&RO);::REN[2
MVN9+.Y&VXM'GA25[:X7 VS0,YBE&!B1&&!5NLO1 HT72 AU%D&EV 1M7_P"0
ML5%I%M.J9 /]HD8-[P/])\W@=*U* "BBB@ HHHH _/?_ (*S?\HP_P!O_P#[
M-#^/O_JMO$-=-_P3%_Y1L?\ !/7_ +,=_9-_]4+X!KF?^"LW_*,/]O\ _P"S
M0_C[_P"JV\0UTW_!,7_E&Q_P3U_[,=_9-_\ 5"^ : /N*BBB@ HHHH ****
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ML[L6'AGPC9ZYXBO%MIY+;2Y(XI'7]@S_ (8XE?A_P%AUP]GCKX7,>+WBJ/\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MFV"CA\TQF.KY7EN(Q6+QE>MB,OP5>=3#4BOY^?VS_P!O#_@K]^R+X?\ B_\
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M4;)N4ZDVHQBDWNW:*;7/_P#!NO\ \HV/#'_97?BO_P"G:QK]TZ_D,_X(2_\
M!4;]G7X1_"[X/_L(^+_#WQ=7XM?$'XR>(;/P_P")M(\):'K'PX%_\0=8LHO#
MEGJ&HV?BY_%]H9+C9!J-]_PA,FDZ0KF_U'4;?2K>\O[;^O.OI?%?*<RRSCKB
M&MC\'7PM+,\US#'Y?4JQM#%X.IBJBA7HR3:E!M-=)+2Z5U?YSPMS7+LRX(X?
MHX'&4,55RS*\!@<?3I2O/"8NGA:;G0K1:3C-)I]4];-V=BBBBOS@_0PHHHH
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M.3XIRRFGJX9YFV&FXRSB:VJ9;EM53I93%IPQ6-C5S./-2H9;5E_-E_P<]_\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *^#_ -HG3/V\;O\
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M3V'O*OFBSJJG[2>D\UCIC7;_ )>KI:'V3^9?&182/B=QBL!/ 3PBS1>PGE?
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M]4+X!KF?^"LW_*,/]O\ _P"S0_C[_P"JV\0UTW_!,7_E&Q_P3U_[,=_9-_\
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M?49[/3=1OOLFEZ9=SQV&GWU]*D=I9W$T?PL/^"W'_!,$D ?M-C)('/P8_:#
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M'H.*I9%AXT&L3F$G-TZD:L52DJ>O]]GPW^)7P_\ C#X'\._$KX6>,O#GQ \
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M,?F&)K8S&XJI*MB,3B)RJ5:M26\ISDV]$E&,5:,(J,(I1BDOOL%@<'EN$P^
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MINBZ3;VMA:OJ.LZEJ.KZA)%"LE]JE_>ZA=/+=W4\T@!WU%%% !1110 4444
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MQ=X2UE[66QGOM UJ**=4CO+.9H-0TK4K34M"U(Q65Q?Z7<W>F:9<6?R];_\
M!(K]E+P]^R5\2/V0_ ,7C3P7X5^+FN^!]>^(7Q$M]9M-8^*'B*Z\#^+-$\1V
M!GUC5--ET*!/L6DW6A6%A:^'8?#VDQ:UJNJ6^@RZI?7\][^4Y]P=FN9Y_F&-
MGA\#F.48F>$S">%KX_$4:^,_LK*JM# \/SINC+#4<%6S6I/,*N(YI13J\TX2
MJ4TI?Z">$7TE/#[@;PAX/X8PN<\5<%^(V38?B'A"AGV5<)Y/FF4\,Q\0/$#
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M (QT2'6;3P<NFV>BZ;KFIZ1%-=VL#^(KZ^\4^%[32[/5%O/#TX6XO-8L;O\
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M2?VA?V&_C-^QYH_@KQ#\<H_ VJ_#KXF>)=%TKQ+?_#QM+U?Q)X<N;>=M=O\
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M2\NM.C\3_#[Q7H/C/P\^H6107MBFM>'+_4M-:\M#)&+JV6Y,]N9$$J)O7/Y
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MZLSRIXJ=0M]7[S_\$Q?^4;'_  3U_P"S'?V3?_5"^ :YG_@K-_RC#_;_ /\
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M)VJJY/RJ!@#RO%3C[(N-YY#3X=R/$<-Y;DM#'TJ>3Q>64LIH2QU;#XBI7R_
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M;),J3"TU'4=,UJRM;J*)BXN;G3KBW)7Y[=%)*_U?_'3]IO\ 9\_9F\/CQ/\
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MX)B_\HV/^">O_9CO[)O_ *H7P#0!]Q4444 %%?!O[0'_  4L_8Z_9N\1^)O
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M.G\WOC[Q[^UA_P %>?BC-X1^$WA^Y\"?LS>#];*)=^(&EM?"6E2VX=H/$WQ
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MF*KX^A+"R^JT,-.E3H^UHU8SC*K7IR=1RIM23BHJ.UW8_;?#7B3PUR#ASBW
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MBV\.S6>CKJDNJ6"1Q^([C1YH#<*;N.W5)2AH/[:O[,/B;Q/\=O!NA_%6PO\
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M)\RG' YC/#8J2I/Z$HKY,^'O[=7[)/Q2^$GB[X\>#?CAX4N?@[X#\2Z?X/\
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M4O;%_P!FY=S*?U#!<ZFZJE]5H<RJ.@L,ZBE[._.\-&.'<[\WL$J5_9I1,O\
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M^K?V_FWU?ZI_:?\ ;7U;V/UOV?U?^V?^%;V/+[/^T_\ ;^7ZU^]/-[C]AO\
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M#BX25?"99*6 P]2GA).D_'M1_9_^#.K?&?0?VA]2^'GA^\^-GA?P]-X4\/\
MQ'FAG/B+2O#MQ!K5M-I-K,+@6ZVDEOXBUN)E:W9]FI7 #C<I7@]!_8P_9:\,
M>&?BUX.T#X)>"]+\,?'::&?XO:+:VUXMGX^FM[K4+V&37E:]9Y6CNM6U&=?(
M> ;[N8D$$ ?3M%7++LOE*4Y8#!RG*=>I*<L+0<I5,525#%3E)P;<\30C&C7D
MWS5J25.HY021STN-.,</1I8:AQ9Q-1P]'#93@Z-"EGV:4Z-+"9#F%3-LBPM*
ME#%1A3PV2YI5JYEE-",52R[,*E3&8.-'$SE4?ROJ/[$7[)^K^%/A1X&U+X%^
M![SPE\#=0U35?A)H,UK>FQ\!ZCK>L6^OZM=Z$HO0\4M]K-I;ZA.9Y)P;B%&
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MWGAGP_=VLD5VL!FTBT6XM[B#SH9?-?V"/BM\5?&-O\5_A?XN_9&UC]DWX5_
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MT;5;&>-L/'(K@,/Y'OBM^P5\??#/[7'B7]@#X<ZEXITS]E7XJ_'7P9\1M/\
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ME^WC_P"&,\)__/5H_P"'UGP5_P"C4OV\?_#&>$__ )ZM>]_K]P?_ -#S"_\
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M/G/$_B$_M;>!OC%XS_X6U_PQ1\!-('P__P"%3^!_&WC/^S3X"_MO4QXL.O\
M_"&C31>GQEX;.D_VD;L6NHBU-K=_V"U\[^./V4O@-\1OVA_@C^U7XO\  L6I
M_'C]G71_B!H/PC\=)K/B#3Y_#>D_$[0;KPSXPL[K2-.U2UT+Q%%>:+?ZG:6
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MCQ&?%OECPEY>O#1AIX(\2ZF+H);?>W_#N+_@L;_TGV\3?^*[/@)_\\ZOUN^
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M+V+0]*E\5?%WQ)XBNM+TT3_9;.;Q%K^NZU-!%'+JNKZE?-/>3<_+_P $CO\
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M[?'B_P#X*6_L/:+^RSJW_#9?P2^)_P#PTK^V?\$/V0_L_P#PS#\;/!9\%?\
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M72?!_AH?$#XDWNJZYIT/@K1IM @&JV4>C%[>OL37/^"2?_!/3Q)KMUXGUO\
M9UL;[Q!>P_M16UUJY^(WQ?@OIK?]L[1_$V@?M(PM/:_$&!A%\0=)\9>*;6T1
M=J^ CKNHW'PW'A"ZG:<?0H_8^_9T^W_LMZB_P[\^?]BW1[S0_P!FB"Z\6^.K
MO3/AO97O@&S^%YG?1KGQ-+I'C76+'P-8P:+HOB'XA6/BS7_#[O>:MH6IZ=K6
MH:AJ-R ?('_!'/\ ;-UO]L_]CJRUGXA>._"OQ(^.7P)^)'C_ /9P^.GCGP1>
MZ!J7@[QWXY^&&K_9]+^)7A'5?#!3P[KGAKXF> ]0\(^-K/7O#EM:^&=0U'6-
M7A\/1G3;*%C^:'['7[2O[9/QQ_:6\=GQCXY_X*?^)O!7A/\ X*$_&GX465]\
M(?@Y^PO<?L9:=\,?AO\ 'O4/#VC^%/'_ (Q\5:-8_M 6OAS3/#-E'HWQ)U7P
M]%/XIMM':XN_#6IS:R(KM?Z$/AY^S5\$_A1\7?CG\=?A[X)3PQ\4/VE+OP+J
M'QLU^SU_Q5/8>-M2^&V@W7AGPAJC^$[_ %R[\'>']4L=%O;FUU'4_"OA_0[_
M ,22R"^\37&L:A'%=)\GZ+_P20_8*\-_%6[^-7AWX5_$+0?B#?\ Q:U#XY7U
MWHO[4'[5NE^&KWXHZMXN;QWJOB6[^'MC\;H/AY<Q:EXI=]1U#P_-X5?PS>1,
MVF7.C2:2QL2 ?I)7\Z'_  7O_P""IOCW]CGP&G[/'[+WQ+\"?#']J;Q-\+]1
M^/\ K/CGQYJO@W3#X%^"7A;Q&^@6MG\.]&\?1W6E_$GXQ?&'QMI]UX'\&>"-
M!T#QCJMCX9T?XB>+]5TOP_9Z+IWB>R_9KP]^SEI^B_M:_%#]JZY\0_;=8\>_
M [X4? W2/"]O8ZQ90>'=&^'GB_XF>,]:UG4+VX\5ZGH^O:CXKU'QWI%K;&P\
M)^%Y?#^G^$UAFO-?DUJ>:RO_ +0?[)W[.'[57@_Q+X%_:!^#_@WXDZ%XM\.#
MPCK5QJEE-IOBD^'%O9-132M)\=^'[C2/''AR"*^GN+J%_#OB+2IX9KJ[>*5#
M=W/F@'I'PJ\<:!\3/AE\/OB'X5\2:1XQ\.>-_!GAKQ3HGBS0+ZSU/1/$>FZY
MI%IJ-KK6E:AI[/8WMAJ,5PMU;7-F[6TL4BO"?+*U_/SX;_X+N?'7XB^)O ?@
M[X8?\$Z_^$EUKXT>,?VMOA=\$;K4?VL_"&@Z/XO^)/['5XVO_$VQU^:^^%*W
MGA#PO-\)(KOQ?HVO7UI<7]_XXM!\.K?0I-'N1\2;?^BWP_H&B>%-"T?PQX:T
MJQT/P]X?TRQT;1-&TRWCM-/TO2M-MH[2PL+*VB"QP6UI;11PPQ( $1 *^-/
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M+O@;^T/^T[XXUWXV+XZO_"FG_"W]GGP9J?B6]\'>$]"^&VHZ9XCO_B'X\O\
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M'6AZ%\*=:@U;4/BCXMU.QN/#&F:H^K7/AG2=<_L:Q-GKMMXAN-6\-:?[=?\
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M^KZ1=66K:5/>Z-JE[;0ZEI=Y::C8R2+=65U;W,44J?E)^S?_ ,$6_@1^RO\
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M?%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%?R\W?P.^-O[<'
M_!77_@K=\(H?V^OVZOV<- _9V\*?L;7GP,\/_ 7]H7Q=X7^&/A/Q#\5_V;-&
MU+7[_6OA3/<W/AC7-)E\1:3'K]]HVDMX6EU34=2UV\N-434M3&HVWW'_ ,$P
M/V_/C-^T=_P2 \+?ME_$SPHGQ)^.7@_X=?&5O$.G'4O"'PBTCXO^*?@SK'B[
M2=+U./Q3X@.C?#[P5;>-+/P_I:^*_%$D.G>#O#/B*7Q//;:7:Z9I4>E1@'[1
MT5^%_P#P33_X+*R_MS_M-_$K]DWQO\)OA=X,^(_@GX+P_'S3O%/P#_:1\*_M
M.?"ZY\+GQ5X6\*:YX%USQMX6\.Z!H]M\0_!VI^-_#5IJ#^&;[Q9X:UUAK-[9
M:CI=I::6-;Y7P7_P6N\2>,?%'PR^ </[..C0?MA>)?\ @HUXY_86^('P,A^*
M=]>6O@SP-\+-(E\4_$G]IO1]>3X?Q:KXE\ ^&_"-UHVN06%QX;T1-6@?69;3
M6_LVE)/> '[]45_._P#M ?\ !<[Q+\'?^"A_CO\ 8CT?]GKX77=C\+M=^&>B
M:YJ'Q>_:G\%_L[_$'XCZ;\1]&\(>(;KQE\'8_BMX;T7X+:S;^$M*\177V#P/
MXB^,VB^+OB1=165OH/\ 8=U)=6EO_1!0 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% 'X[_'S_@C)\*/CI\?/VE/VAM-_:[_
M &\OV?\ Q3^UGIWPUT?XV^'?V<?C%\.?AQX3\3Z/\*OA]IGPU\+Z03=?!?Q'
MXP&E2>'].N'UG3KOQ?>V>JWFM:U'/ -*NH=+M?JF7_@GM^S>G[!EY_P3ETG1
M=?\ #G[.EW\(+_X.K'X?U:VL/&EM8:FL]W?^-8M<;3)]-G\?7OBFZN?'>HZI
MJ&@WNC:QXNNKNZUGP_J&EWMYI-P44 >'?L@?\$GOA5^R'\?-/_:5TWX]_M(_
M&3XG:3^S-IW[(VD)\6]9^$;>#M#^"6@Z_P"#?$'AC0-"\,_#OX/?#]],O- N
M? ^EB'4$U25M6N=3\2ZSXAAU?7M<GU2/Y._8Z_8*^+7BO_@K=^U+_P %0/VC
M_P!FK2_V:Y[KP3H_PH^!G@*?XH> _C'J?C'Q =&TOP3XP_:-.J>!;R;3_ -[
MK'PW\':%X+T[PW<6]MK=WI_B[Q8VN6\=U;B^U<HH ]]_:H_X(Q? O]K[XE>,
MO%GQ9^.?[2E]\-/B3\0?AS\2/'O[.TGB;X<^(/A+=Z[\-K;3;2TM? M_XQ^&
M/B/XK?![2/&$%A<)\0[#X5?$KPFOB=-4O8U?3HXM.2Q_8)$2-$CC18XXU5(X
MT4(B(@"JB*H"JJJ %4      "BB@!U%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
I110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>41
<FILENAME>nt10014672x1_linechart14.jpg
<TEXT>
begin 644 nt10014672x1_linechart14.jpg
M_]C_X  02D9)1@ ! 0$ P #   #_[0 V4&AO=&]S:&]P(#,N,  X0DE- ^T*
M4F5S;VQU=&EO;@     0 ,     !  $ P     $  ?_B"^!)0T-?4%)/1DE,
M10 ! 0  "]!N;VYE @   &UN=')21T(@6%E:( ?4  < %0 3  L (6%C<W
M         $E%0R!S4D="     0            #VU@ !     -,M2% @(
M
M$&1E<V,   %$    =&)865H   &X    %&)44D,   ',   (#&1M9&0   G8
M    B&=865H   I@    %&=44D,   ',   (#&QU;6D   IT    %&UE87,
M  J(    )&)K<'0   JL    %')865H   K     %')44D,   ',   (#'1E
M8V@   K4    #'9U960   K@    AW=T<'0   MH    %&-P<G0   M\
M*&-H860   ND    +&1E<V,         &G-21T(@245#-C$Y-C8M,BTQ('=I
M=&A"4$,
M                                                    6%E:(
M     "2@   /A   ML]C=7)V        !      %  H #P 4 !D '@ C "@
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M;W5R(%-P86-E("T@<U)'0@
M
M      !865H@        8ID  +>%   8VEA96B            !0
M;65A<P         !                               "6%E:(
M  ,6   #,P   J1865H@        ;Z(  #CU   #D'-I9R      0U)4(&1E
M<V,         +5)E9F5R96YC92!6:65W:6YG($-O;F1I=&EO;B!I;B!)14,@
M-C$Y-C8M,BTQ
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MU=;7V-G:X>+CY.7FY^CIZO'R\_3U]O?X^?K_Q  ? 0 # 0$! 0$! 0$!
M     0(#! 4&!P@)"@O_Q "U$0 " 0($! ,$!P4$!  ! G<  0(#$00%(3$&
M$D%1!V%Q$R(R@0@40I&AL<$)(S-2\!5B<M$*%B0TX27Q%Q@9&B8G*"DJ-38W
M.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U=G=X>7J"@X2%AH>(B8J2
MDY25EI>8F9JBHZ2EIJ>HJ:JRL[2UMK>XN;K"P\3%QL?(R<K2T]35UM?8V=KB
MX^3EYN?HZ>KR\_3U]O?X^?K_V@ , P$  A$#$0 _ /[^**** "O*OCA\;/AG
M^SC\)/'WQS^,GB3_ (1#X7_#'P]=>*?&OB3^R=:UUM(T6S:..:Y31_#FG:OK
MNI2F6:&**TTO3;R[FDD18X6Y(]5KGO%?A'PIX[\/ZEX2\<>&/#WC+PKK,44&
ML>&?%>BZ;XB\/ZM#!<0WD,.I:-J]M>:;?10W=O;W44=U;2I'<00SH!+$C* ?
MSN_\$L?^"U?Q1_X*2_\ !1;]IOX(6GPTT+X=?LO> ?@J_P 3_@G#KWAS7M-^
M->MZ:/%/POT/0/%?CG4;OQ!-H*Z=X\T+QC>^-=)T/2/#-O'I.D:SX>L(O$/B
M-=/GU_7?*O\ @K[_ ,'"\O[(OQ/TG]G#]C+PQH7Q'^+_ (,^*>B^#_VC_&_Q
M*\#^.9_AA\+I-5LKN;2/AKI+VU_X+_X2'XB>)XX;O7HM9M-;NO#.CZ'X:U.R
MLX/$VJWVIR>"M;]D!$C_ .#I3_@JK'&BQQQ_L@_!)$C10B(B?#;]BE51%4!5
M55 "J      !7/?\'4'@[PCX2_8/^ EQX5\*^'/#,_BS_@I/\(_%?BJ?P_H>
MF:--XF\4:A\%/VA(+_Q)X@DTZUMGUG7[Z"TM8;S6-1:YU&YBMK>.:Y=(8PH!
M^D'_  5M_P""E'Q _81TO]FCX3_L]?"G0/C)^UK^VC\5_P#A4?[/_A/QO?ZE
MI?P\L;^RU#PEI.L^)/%]QI=SI5WJ-M:ZYX^\#:%;:$GB7P@DL?B.]\1W/B>T
ML/"UY8:GQ?\ P3%_X*7_ !\_:*_:$_:>_80_;?\ @_X ^#O[9O[*]GH?B;7U
M^$FH^(-1^&7Q%\!>()-.>#Q-X<M-=NO$%[X>2PL/%/P]U&%=1\8:K-XGTWQQ
M8ZE9:;H;Z9JVEV?P=_P<*7-O\'OVT?\ @B-^USXZ-YI/P'^#/[66H:/\5_'3
M6SSZ-X';4_&GP0\::5/J/D-+>2R:AX5\!_$775M[2SFG?3_ ^J&%9[@P6[\S
M_P $X=>\(?M8_P#!Q+_P5E_:@^"^OMX^_9YM_P!F_P $? >?XH>#=4FA\.:C
MXONM&_9O\'E/#7BO2;ZTN[J+4-0_9]^)T_A3Q5X8GGT_4],T7_A(]$UL6=WH
MUY?@']8MY>6FG6EUJ&H75M8V%C;3WE[>WD\5M:6=I;1-/<W5U<SLD-O;6\*/
M-//,Z111(TDC*BDCE?A[\1OA]\6_!NA_$7X5^.O!_P 2O 'B>"XNO#GC?P%X
MET;Q?X1UZWM+VYTV[FT?Q'X?O-0TC4H[34K*\TZZ:SO)A;7]G=6<_EW-O-$G
M\DG[6W_!K7^P-\*_V=_VFOC_ *5\</VUO$?CWX<?!?XS_&'37\8_$SX,ZSI^
MN^+_  ?X'\2>-+-O%+P?L^Z?K>JV>J:SIT9UQH=:LM5OH9[HQZI;7<HNT_2'
M_@V<0+_P1S_9L8%R9/%/Q]=MTCN 1\>/B''B-79EB3;&I,<01"Y>4J99)'8
M_>VBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MGY?]1OK_ %N?V-]#W_HKO&O_ ,(.'/\ YR_U9^5_J'_A\1_P3?\ ^CEM-_\
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MU\;?\$[O^3#OV/?^S</A!_ZA&C5]DUYF/_W[&_\ 87B?_3TSXCC'_DKN*?\
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M8K^SU.UN8KVVO8H[J&=)T60?.O\ P;/?\H<OV:/^QF^/W_J^_B/0!^]5%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %?S$_\%?_ /D_O]GS
M_LEOPG_]71\3*_IVK^2S_@L+\3O"?C?]L7PG>_#/QIHFN7O@'X6^$_"6K:OH
M]]#=6'A[QSI'C_X@:[+IL^I!9-/>[T>#6M(GU P2W,%A<R2V%XT=]97UI;_N
MGT?<+B<1QKF,L/AZ]=4^$N(X3=&C4JJ$Z^!=*A&;A&2C*M5:ITHNSJ5&H03D
MTC^9OI5XW!X3PYRF.+Q>%PLJG'O!]2G'$8BE1=2&&S.-?$S@JDXN<,/1C*M7
ME&ZI4DZE1Q@FSZW_ ." W_( _:A_[#'PC_\ 2+XB5_0Y7\M7PT\:>+_^"0GB
M3PSXFLM?^'7[2_[//[3OAC1M3FUWP+KUC8:I)XA\#VES!JK>%I3?:F6M?#VJ
M^*+FV:^NK.?2_$6G3V=M=2>&/$$-Q9V/U/\ \/[/A'_T0/XC?^%-X9_^-5^(
MUJ-6G5J4ZE.=.I3G*G4IU(NG4IU(-PG3J0FE*$X23C.$DI1DFFDTT?TK1K4L
M12I8C#U:=>A7IPK4:U&<:M*M2JQ4Z=6E4@Y0J4ZD)1G"<).,XM2BVFF?O=17
MQ/\ L4?MK^%_VUO"_C?Q1X7\$:_X)M_!.OZ=H%U:Z_J.G:A-?3:CIS:BEQ;O
MIRJD<<:+Y;+)EBQR.*^V*R::=F:!1112 **** "BBB@#\J?^"W7_ "BW_:Q_
M[%_X=_\ JY?AS7@7_!NO_P HV/#'_97?BO\ ^G:QKY__ ."W7_!2O]E__A0G
M[6/[!G]J^,O^&@OL?PZTC^SO^$0O/^$6^VGQ-\./B7M_X2;[1]E\O_A%_P![
MYGDX^V_Z'C?\U?/'_!#+_@IO^RS\$_@!\'_V./'6K>-+?XU_$/X]7WASPW8Z
M;X.O-1\.RZG\5O%^BZ%X16[U^.X2WM(9M0OH%OYGB86,1:5PP4BOWO!\,<13
M\$L90ADN92K8CC/#YY0I1PE5SK9/+(,.XYE3BHWG@FD[5U>GIN?A>+XFX>AX
MS8.O+.<NC1H<'XC):U1XJDH4LW6?5KY;4ES6CC%UH/\ >>1_6U1117X(?N@4
M444 %%%% !1110 5_/W_ ,'('_)CWPK_ .SK/ __ *J+XYU_0)7\WW_!<+7_
M !1^U)\1?V;/^":_P,T;3_%?Q<\3>)[CX[>(_/OX[&V\+67A_P '^.-%\-6N
MH:B\C65E'>Z%J'COQ%K4-ZL=[:66E^%I+2*X'B*V23Z#A>+>>8&KI&EAIU,5
MB*DFHTZ.'H4ISJU:DY-1C""W;:5VENTC]?\  :C*7BKPKCI.%+ Y)B,7GN;X
MRO4A1PN791E>!Q.)QV/QE>HXTZ&'H4H^]4J2C%SG3IIN<XI_KQ_P3N_Y,._8
M]_[-P^$'_J$:-7V37\CO[)W_  7K\+?LU_L\?"W]G[XL_L^>/=;\;_!CPZOP
MWU#4]"UG1-#M9[#PG=W6D:#;W6BZS;IJ.FZQI>A6VG:1KD-PTC3ZO87EZ/LX
MNOL=M]$?\1+'P/\ ^C:/BM_X5OA#_P"-5V8WA3/ZF,Q=2GETZE.>)KSIU(5<
M/RSA*K.4)QO53Y91:DKI.SU2=T?3\4_1_P#%[&<3<18S!<&XK&8/%Y[FV)PF
M+H9AD[HXK"XC'XBKA\11<\PA/V=:E.%2'/"$U&24X0E>*_I:HK^:7_B)8^!_
M_1M'Q6_\*WPA_P#&J/\ B)8^!_\ T;1\5O\ PK?"'_QJN;_5+B+_ *%E7_P;
MAO\ Y<>%_P 2[^,__1"X_P#\+\E_^>9_2U17\TO_ !$L? __ *-H^*W_ (5O
MA#_XU1_Q$L? _P#Z-H^*W_A6^$/_ (U1_JEQ%_T+*O\ X-PW_P N#_B7?QG_
M .B%Q_\ X7Y+_P#/,_I:HK^:7_B)8^!__1M'Q6_\*WPA_P#&J/\ B)8^!_\
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MTJE*%:AB:7\*O3E>+E#65N2K&I2DKMJ4&]FCX_Q$X$Q/A]GZR>IF.$SK XK
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M'_"3Z-;)%YDRO( ?N;17S3^Q]\<?B'^TA^SI\._C1\5?V?\ QS^RWX^\9_\
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MR)_T:O\ LX?^&/\ AE_\R]'_  QS^R)_T:O^SA_X8_X9?_,O7T?17']<Q?\
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MH7*W<']I:7:F73M43.FW7\ /AW]B/X-_%GQW^SMJ_P"T1_P4O\=VFE_M??\
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MM7V&V\6>"/%FEZ!XS\+G5%L+Z71IM=T"PMM<M[*ZN]'FOK6"290#/_X*"_\
M)A/[;O\ V:'^TI_ZIGQI7YH_\&SW_*'+]FC_ +&;X_?^K[^(]?I=_P %!?\
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M_'_Q?C\4?!?QGX4^)W@3Q5K'A_QA8I\-/&=N?#UWX)T[4_!9\96GBWQQXO\
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MX33X;IX>C\%:U+X:L_&UMX,G.B1^%= 1=/G\.R:5?IIZKJEC>BXNQ. ?PD?
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M1?C/J/Q%.G_#"\/PJ&J:UXA_L2[BM1:>*]&\%:;_ &JKP?VM]D"WS=Y\>_\
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MI<WQ(^+-QX,M?!FE>&= L9?[0N?!/@O38M0U&9-%OM633#<F"/P[H$&A^$/
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MR<5%+\:O^' __!+;_H@6O_\ AZ/C/_\ -W1_PX'_ ."6W_1 M?\ _#T?&?\
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M\/0IQI4:%&E&C"E2I4H*,*=.G"*A"$$HQBE&*2204445^-GZ\%%%% !1110
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M6 HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MQ"NK@7VH:S%9:-82:-I]G?0Z3XFO'UNW_L*6WN/VUK^%7XB:W^T9_P %'/\
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M\ _AY\4OC3\!]:_9E^)WBRSUJX\5? SQ#XGA\9ZSX!N-.\3ZWHVGVE[XFM]
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M2;2O&5FL<?V6.W=_W#H *_SN/A!^SW\5/&?[6/\ P<-^(-,_;R^.O[#OCO\
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M,/B3X<N?#5GI'ASX$^!]:^'_ ((BUCQ59^)]=\1^&/A-92>$?"5KXWBODO\
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M_P"K[^(] '[U4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MB;X=\+^?_96BZCJ&O?"?1K2QGFM+[4/#VB^)/&%@NM-I.J20VX!_:717PO\
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M+K]I9_#NRT#P5XFTK5M8CL_A;X@CN;?Q+K7A*R2YO-'2+4)HKB]FT_PG0/\
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MVZNMO/J=OX3T?28;^:!9)%ADNDE>)7<(RAF!* *G[0?P4\(_M)? KXP?L_\
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M4-/NRDRPM#)_'5\"_P!O;_@AKHW_  0S_P"&)_BGXB^,$_Q$UGP)K'C?X@_
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M]=TR^T!'%MJ7]CK=:!INK2:O>1Z/?:O=#7O#5KX>N])O'N;F3Y)\/Z/\>_\
M@CGXK\ P^(_&WA?XH_LF?%WQW#8>.[BS\+3Z9K?A;Q'<6&EPZEXAMK-'OM:A
MUBT\/:5+=Z/96NMZ]HOB'3M"UBSO-&T;69M+U&/[>_;6_9S_ &@K?XZ?"O\
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M_P#S.'[1_P#\]^C_ (<0?\$I?^C5_P#S.'[1_P#\]^OS#G\#?^?7BG]_"O\
M\L_J[\K?I?)XV_\ /WPP^[BC_P"5_P!7?E; _P"'_'_!+;_HONO_ /AE_C/_
M /,)1_P_X_X);?\ 1?=?_P##+_&?_P"82M__ (<0?\$I?^C5_P#S.'[1_P#\
M]^C_ (<0?\$I?^C5_P#S.'[1_P#\]^CG\#?^?7BG]_"O_P L_J[\K')XV_\
M/WPP^[BC_P"5_P!7?E; _P"'_'_!+;_HONO_ /AE_C/_ /,)1_P_X_X);?\
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M/[(^Q?\ "3_VIYG_  C>I_:?L/V+9;_:?M=O^6WPY_X+_P#@7Q]_P2:^,_\
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MX*T+P[J&HZ]X;?PSK9&D>(YO$%C!+H]GH.I$6>LWE[!ITY"7)(_B8^&/[?\
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MI7YH_P#!L]_RAR_9H_[&;X_?^K[^(] '[U4444 %%%% !1110 4444 %%%%
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M_#:UGT=M_P"E_F']0]%%%9@%%%% !1110 4444 %%%% !1110 4444 %%%%
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M?$^O17EW*+U;FZO_ ++82&,6FGG4KZ&"]U!H=DDQGN8@\1N/L<326]K#(_J
M         &  .  !P !P .E+2<F^WW>G^0!7\*OQ$UO]HS_@HY_P5I_;T_:"
M^"O[!.I_\% /V?/@1\)_B'_P3G\'62?M&?";]FW1_ Y\5^'/$7@+QWXU\*>.
M_B+;:MIWCC4]7&M_'/4-'M_#FFWMUH6A?$[PGKNK:AIC?\(S%JO]U5>7_";X
M(?!;X!^'+WP=\"OA#\+_ (+>$=2UR\\3ZCX6^$W@#PI\.?#FH>)=0M+"PO\
MQ#>Z'X/TG1M,NM<OK'2M+LKS5I[62_N;33;"VFN'AL[=(Y _EL_X(A?\%$]/
M_9 _X)Z?MB?L_P#[<DEYX$^(/_!*'Q5XMTOQ5X1U&]T:[\2WW@7Q3K^MGPIX
M$\.WS:]<:7XQ\2M\8HO%?PX\,7&E:DWA)]-\1?"JPTS66T?4[&];\B_^"8VM
MZW_P3F_;4^ ?_!3+]JK]F'P;\'?V0?\ @I7>?&/PO\'?%VE->KH?[) ^)?CH
M:YX/OHK?5[>.W\*>$=2\-6<-AH%]J<]E>:U\ M9\1>-O#.IW6F^'_$GAC5?[
ML_B#^PY^Q3\6O%OB3Q]\5?V/OV6_B9X[\8C31XN\:_$']G[X3>,_%OBH:-9:
M?INCCQ)XC\1^$M2UC7!I6G:3I5AIHU.\NA8V6F:?:VOE06=M''Z?\0/@3\$/
MBSX M/A1\5/@W\*OB7\+;#^Q_L/PU^('P\\(^,O %E_PCL2P^'_LG@WQ'I&I
M>';;^PH56+1_)TY/[,B58[+R%   /Y3O^"4W[6W[+W[,/_!3G_@OE)^T7^T%
M\'_@?'X]_:Z\+/X)D^*7Q \,^"4\6)X;^)'[5;:^_AYM?U&Q75ET9?$.A'4F
MLC,+,:QIIG*"\@W_ *S?M>_M>_\ !0;XA>'/@[\0_P#@BKX'_8Z_;3^%VOO\
M1-,^+?CGQC\0M(U?0= \1>'KOPK!X9TKPKJ^B?'WX46-U-.EYXG'B"!?^$@E
MM)K'35D;2S*$OOLB]_X)J?\ !.74KJ6^U']@']B?4+V<J9[R]_95^!5U=3%$
M6)#+<3^ Y)9"D:)&I=SM1%0850!](_"OX._"/X%^$H? /P2^%GPX^#O@6WOK
MW5+?P7\*_ _AGX>^$H-3U)UDU'48?#GA+2](T>*^OY$22]NTLUN+IT5YY)&4
M$ '\K?\ P<&_ G0M/_X)*7O[3OQ:^!/PG\!?MR_&35OV0#^T_P",?"&D6>HZ
MM;>/[#PAX=T7Q=\/_#7C&[UCQ=JUO\.O#6L^'H])T30=*\6ZEH5W%I%IK5Q=
MZWJUS=:[?=__ ,%A-7T_X-?\%"O^""7[2WQ-U]/#WP&\*?$7Q/X&\6^*M9^P
MZ?X-^'7B#Q#%\+CI^O\ BCQ%?_9++1-/UBRNI=1O[_5-26RTK0?A[K>M;+:+
M3[Z6?^F7XJ?!WX1_'3PE-X!^-OPL^''QB\"W%]9:I<>"_BIX'\,_$+PE/J>F
MNTFG:C-X<\6Z7J^CRWUA([R65V]FUQ:N[/!)&S$G/^+/P'^"/QZ\$K\-OC=\
M(?AG\7OA]%=6=_!X*^)7@?PUXV\+VFH:=;SVNG:E9:'XBTW4=.L=2TVVN;F#
M3M1M+>&]L(YYDM)X1(V0#^;C_@@EK6D>*OVO/^"\'[6OA_Q!97W[./Q%_:Z5
M/!7Q&M9[>3P=XJ@\#^*OC_XU\1>)-.U9 T4NF:?X0^(7@[Q!!>0S"*YT;Q;9
MWMS&I-OM]N_X(-:7XD_:*\'_ +7G_!6/X@6=OJGQP_;F^,OC?3_AY'J,UG?1
M^ _@!\&K^Y\&_#7X7Z5<@07>E:?8Z_IFHZ-KJ"ZM/^$AT[P;X*U74Q+?V*:C
M-^Y_@/\ 9Y^ GPM^&%]\$OAM\$_A/X"^#FJV6MZ?J_PK\(?#WPGX>^'FLV7B
M:T>P\36^M>#M+TFU\/ZNGB6RDDM?$1U*PNFUV&65-5:[$LF[J?AO\,?AK\&_
M!>C?#?X0?#SP-\*OAWX<_M'_ (1[P%\-_">@>!O!>@_VQJU]KVK?V-X6\,:?
MI>AZ7_:FN:IJ>LZC]AL8/MNK:C?:C<^;>7=Q-( ?R$_\%"_BY_P6Q\??\$VO
MV_='_P""D7[+G[+7P2^!UM\"? VI^%?%?P0\0#5O%>H?%>']J?\ 9TM=#\/:
MA;#]HKXN[/#UWX0O/'6I7<__  C=CMU+2=)C_MRV\S[!J7Y#?!_X'>-)/VQ?
MV5?^"7]GX>O;_P" G[97Q4_X)E_\%"M2T^_NY(;'6?!V@?LI:WXY_:5@@M5_
M=3Z?XFU#6?'T$A8,L=W\+-'4@M&JI_HY_$/X;_#OXN^#=;^'7Q7\!>"_B?\
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M/_5,^-*_-'_@V>_Y0Y?LT?\ 8S?'[_U??Q'KY_\ VRO^#AK_ ()-_$S]E?\
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M]JNOZ[;>-]:UCP+X6L6\,6C?T7T4 ?DY^W9^PO\ L2^'?V)?VR/$WA_]CO\
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M.<)01_;)17X@?\/W_P!F;_HD_P =?_!;X _^;VC_ (?O_LS?]$G^.O\ X+?
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "OY ?B!_P2/_X+
M>^(?^"C7CS_@HQHOQM_X)ZZW\29M0\3Z1\$-(^+OB;XV_$/1O@5\-KF_N;?P
M3X;\$:+/^S=9Z+H^L^%/"L]SI3:WI]K&]_K/B#QCXLN(Y?$_B;4-8D_K^HH
M_G4_;5_X)F?\% _VQ/V8OV'?B;XK^,G[/>F?\%4/V(/C1XC^+OASQ]X8_P"$
MOL/V<_$EMJ?Q#3Q!9^';*VN/ ]IK-K?IH'@7X*WLE[K'@2?3;K7?"GB?PW=V
MXT;Q7)XFLO4/^"67_!.K]J7X._M/_M<?\%$/V^O&'POU_P#:Q_:RMO#WAJU\
M(?!B[UZX\#?"SX::4FBRMX3DNM6L["+4KVW@\)_#[PKHT,9\22Z'X?\ A_;W
M5SX\\6:MXLUJXM/W;HH ^0_^"@O_ "83^V[_ -FA_M*?^J9\:5^:/_!L]_RA
MR_9H_P"QF^/W_J^_B/7Z7?\ !07_ ),)_;=_[-#_ &E/_5,^-*_-'_@V>_Y0
MY?LT?]C-\?O_ %??Q'H _>JBBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M?9GZKU_,Y_P7*_Y+Y^S/_P!BAJ7_ *FEK7Z&?\/E?V)_^@Y\1?\ P@+_ /\
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M;VUG']G>)]8L)@]EK%Q!+G?L*:1!\)O^#F?_ (*P_"?X2>'M-\*_#75/V5_
M7Q&NO VA/+X;\$W7Q(N?#G[)7B.#4[VPTRWN-+L[_4=>^*/Q+U ZB-'O+RP?
MQ)XCET^#9>ZA;7(!^_7_  4%_P"3"?VW?^S0_P!I3_U3/C2OS1_X-GO^4.7[
M-'_8S?'[_P!7W\1Z_.']K_\ ;3_X.*_$G[/_ .U%H7C_ /X):_ ?X=? S7_@
M[\;-)\;:^/B1X?\ %/BCP+\)]4\%>)K/Q)K UC2OVCH[+Q'KWACP?/>WHU+3
M?!,=KJ^HV/VJS\++#<1Z2/T=_P"#9W=_PYS_ &:L@ #Q/\?=A#$EE_X7U\12
M2P*KM.XL-H+@J%;<"Q10#]ZZ*** "BBB@ HHHH **** "BBB@ HHHH ****
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M& S'!0S"GAH>WBYRJSJ? O\ PZ\_8/\ ^C?='_\ "Q^)7_S9T?\ #KS]@_\
MZ-]T?_PL?B5_\V=??5%>'_Q$+C[_ *+CC#_Q)<Z_^;?)?<?2_P#$)_"S_HVG
MA_\ ^(;P[_\ .WR7W'YG?$K_ ()Q_L6>"O 'C#Q;X8_9'_X6/XA\.^']3U;1
MO OA_P =>.[/6/%.H6=L\UMI%C<ZCXXCMXI+F10'9$O+TPK(NF:9JVI&TTN[
M_#K]DG]C?X'_ +5G@[]HCXD_$KXT^%/@%K7@]M<ETWX9Z,K:?:?"&PL[FQN8
M_%GB^#QSJ#:OJG@BQ,DWAA+;^VIK\RAY-9\8Q>("EH?Z]J_+']J;_@E3\'/V
MDOC%X<^+5KK5_P##>;4]4C/QLTCPS:1QP_$[1[?%['<0,LL4&A^*[O4+2QMM
M4UIK:^M[^V8:O/8OKNGK<:BUXA\>[?Z\<7KS_P!9<Z=K=+?7=M.GE>Z#_B$_
MA9_T;3P__P#$-X=_^=ODON/YK/!7BC4=,\/PZ1I/[('PC^.=CH][JNEP_%67
MPI^TS=2>,([34[I(M2,GA7XH^!-)$7D&*&T0^$- U-;**V.MV"ZP;Z23S7XF
M:[JEWXJT/4I_@9X8^!E[8V=H]KX5\,Z1\3=,L-::#4;F>+6KFU^)GC3QGKL]
MQ/+_ ,2UWTW4[/3GAL8HXK1+Q;FXF_O'\'^$/#/@#PMX?\$^#-%LO#OA3PKI
M-EH?A_1-.C:.STS2].@2WM+6$.SRR;(T!DGGDEN;F4R7%S--<2R2O_--_P %
ML/\ D[/X&_\ 9)O#G_JRO&=?MG@!Q?Q5G/B+A<%FW$W$.:8.>49U4GA,QSO,
ML=A93IX-RISEA\3B:E&4X22<).#<7K&SU/YR^E3P%P+P_P"$F,S+(>"^$\DS
M&GQ!P[2AC\HX<R?+<;"G6S"$*M.&*P>#HUXPJP]VI!5%&<?=DFM!W_#W?_@H
MI_T;1\./_#-?'+_YY=>V_LB_\%5/VI?C9^U7\,_@#\5/AK\)/"&F>+;_ %NU
M\01Z9X.^(F@>+].CL?!&N^*;!K9/$?Q$U:WLWN9-/L')O=&N5FT^Y9H51IH;
MA/Z#J_FSUS_E/Y!_V&/#W_K(VF5_,J::?NVLF]_3^O\ AV?V:?TF4445 !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %?E__P %8/\
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MR_VA<^"?!>FQ:AJ,R:+?:LFF&Y,$?AW0(-#\(> O#WASP3X7T[PN$U#]BJ*
M/D/_ (*"_P#)A/[;O_9H?[2G_JF?&E?FC_P;/?\ *'+]FC_L9OC]_P"K[^(]
M?I=_P4%_Y,)_;=_[-#_:4_\ 5,^-*_-'_@V>_P"4.7[-'_8S?'[_ -7W\1Z
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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ME_#SP+-J=QIGAK2+S6K^#3H;O_@G_96LM]+:V4L=I%<WEI;R7#1I-<P1EI4
M/ZT**_B%_8$\=_\ !S;_ ,%&/V>=-_:5^"7_  47_9D\+>!=4\5>)_"%OI/Q
M4^%7PFT3Q:FI^$[J"TU&>:P\)?L2>.-'6QFDG1K*5->DN)$#&>VMF 5OM3_A
MDW_@[)_Z2=?L._\ A ^#/_I>M ']4U%?RL_\,F_\'9/_ $DZ_8=_\('P9_\
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M4<$UR ?W+45_*S_PR;_P=D_]).OV'?\ P@?!G_TO6C_ADW_@[)_Z2=?L._\
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M^EZT ?U345_*S_PR;_P=D_\ 23K]AW_P@?!G_P!+UH_X9-_X.R?^DG7[#O\
MX0/@S_Z7K0!_5-17\+?[(/QJ_P"#EK]M3XW_ +:'P#^%G_!1#]G+0/&'["_Q
M5A^$'Q:U+Q_\)?@]I7AKQ%XEF\7?%7P8M]\.KSP[^Q=XJU35]#&J?"'Q+<-<
M^)=&\(WXL+[0Y1IAN+F_M=,^_O\ ADW_ (.R?^DG7[#O_A ^#/\ Z7K0!_5-
M7\D__!67XY?#+XQ_M2>#]7^%_B2#QOHGPQ\"Z+X7\5:]H$<EYH<>MV7C7Q)K
M%W:Z9JJ@66K06]KJ=E$=2L9I=+EO)'M;>]FDAF$?5W/['7_!U/KEM<Z+XO\
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M^EZT ?U345_*S_PR;_P=D_\ 23K]AW_P@?!G_P!+UH_X9-_X.R?^DG7[#O\
MX0/@S_Z7K0!_5-17\K/_  R;_P '9/\ TDZ_8=_\('P9_P#2]:^#_AQ\6O\
M@Y@^)_[?/[0/_!.G0/\ @HG^S;9_&S]F_P"''A?XG^./%&L?"?X0V_PLU70/
M%NB?"_7M-L_"FMV7[%6H>+;[6(+/XL^'([VWU?P1H5E'<V6MI!J%S%;6,VI
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M8>)9]1M+6*3Q"^J?&;5M)G@TMK_35T_P[IVHQZ@USJMSI^G?KO7\Z7_!1?\
MX+ ?M'?#;3O^":&C?\$Z_A9\)?BA\3/^"BW@C4OBMX7\)_M#6VJV4GA[X?77
M@CX=^-/",NKC0_BO\-M+\*WU_8^-=7GUG5M<\47N@Z=#X.UR(2?N?M9^[?\
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M=3_KE7\_W[?G_!5?]H7]EO\ X)N_L)?M&?![P/\ "3Q]^U-^V7J7[,_A?1_
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M_"BP>+H?".@_$K5/#UR+C1[EH/Z*J\S^+?P7^$/Q]\%7_P -_CA\,/ /Q>\
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M+1/%GQ!N]2\/>-?"^I1V][H%K86O@B_\-FQMO$_PCM-=GL]#UF.1LS_@VBU
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MAH_B;ZI^+WQ?\0_!O_@MU_P1J_;;_;@@L_@%H?QU_P""=>@>&_B1XG\80_\
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M5\.?".C^&!KVIV]K'8PZMXDO-.M8M0\2ZS'9116@UC7KO4=3-M'' UT8D50
M>ZT444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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4H **** "BBB@ HHHH **** /_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>42
<FILENAME>nt10014672x1_linechart15.jpg
<TEXT>
begin 644 nt10014672x1_linechart15.jpg
M_]C_X  02D9)1@ ! 0$ P #   #_[0 V4&AO=&]S:&]P(#,N,  X0DE- ^T*
M4F5S;VQU=&EO;@     0 ,     !  $ P     $  ?_B"^!)0T-?4%)/1DE,
M10 ! 0  "]!N;VYE @   &UN=')21T(@6%E:( ?4  < %0 3  L (6%C<W
M         $E%0R!S4D="     0            #VU@ !     -,M2% @(
M
M$&1E<V,   %$    =&)865H   &X    %&)44D,   ',   (#&1M9&0   G8
M    B&=865H   I@    %&=44D,   ',   (#&QU;6D   IT    %&UE87,
M  J(    )&)K<'0   JL    %')865H   K     %')44D,   ',   (#'1E
M8V@   K4    #'9U960   K@    AW=T<'0   MH    %&-P<G0   M\
M*&-H860   ND    +&1E<V,         &G-21T(@245#-C$Y-C8M,BTQ('=I
M=&A"4$,
M                                                    6%E:(
M     "2@   /A   ML]C=7)V        !      %  H #P 4 !D '@ C "@
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M;W5R(%-P86-E("T@<U)'0@
M
M      !865H@        8ID  +>%   8VEA96B            !0
M;65A<P         !                               "6%E:(
M  ,6   #,P   J1865H@        ;Z(  #CU   #D'-I9R      0U)4(&1E
M<V,         +5)E9F5R96YC92!6:65W:6YG($-O;F1I=&EO;B!I;B!)14,@
M-C$Y-C8M,BTQ
M                                                          !8
M65H@        ]M8  0    #3+71E>'0     0V]P>7)I9VAT($AE=VQE='0@
M4&%C:V%R9"P@,C P- !S9C,R       !#$0   7?___S)@  !Y0  /V/___[
MH?___:(   /;  # =?_; $,  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! ?_; $,! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! ?_  !$( DH"=@,!(@ "$0$#$0'_Q  ?   !!0$!
M 0$! 0           0(#! 4&!P@)"@O_Q "U$  " 0,# @0#!04$!    7T!
M @, !!$%$B$Q008346$'(G$4,H&1H0@C0K'!%5+1\"0S8G*""0H6%Q@9&B4F
M)R@I*C0U-C<X.3I#1$5&1TA)2E-455976%E:8V1E9F=H:6IS='5V=WAY>H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:X>+CY.7FY^CIZO'R\_3U]O?X^?K_Q  ? 0 # 0$! 0$! 0$!
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MKX5^+/Q'^,G[/NIMI\"F2XUG68-#^*WP0\-Z!#;1@O,UQ^T/<VL:JS.NT;B
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M91B]4[.,DV4445Y![X4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MX5UB&:TUP^"MMU=/9>--#WP#A7:X0*&MY&?^F2OQ ^$?_*<K]J+_ +(5X?\
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M&ES<K;7NL?#.;PS\1[OX=->6)M)7\+ZU\%=<:SNC(UMX]UBU?;#X-^V/>?\
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MS:/V1O\ U ?A_0!_0?1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MG+J?#&7+^SJF3X7"8K'8#%XI9=B<SR^,<?*.)Q^+G4Q56EA:5"K4I8?^MO\
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MX.4)QOS0DD4445S'A!1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M\%>&]4GU'06B+,VS2/%MI9R,239*KR*_X(?M?_L$:/\ M$?\%>W_ &)O@_\
M$&3]F#X=+^SWX:\<VB^$_#-]XET.'4M"\.S2WEQ=>%+?QGX,74]9UM)5BO\
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M &;1^R-_Z@/P_H _H/HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"OY8_B7XA_;4^*VN?MN_M4_ [P%H^K?LZ_%70/B-\._$7Q!U&\\!+-)\"OA?
MX?UCPMJ5QX7L/%'B2P\56MO>^&+"76]6;PWH]V=0\11/'9"\U/3S"O[N?MZ?
M&"X^"7[*7Q<\5Z3-,GBS6-!_X0'P-%93&+59?&'C^9/"NDW&C*@:2?4]#34K
MKQ-#;Q*TLD6B3[%)7%>?^*_A!:_ /_@F3\3?A#;QVR3^"/V/_BUIVM/9LSVM
MYXJN_A?XIU7QCJ=NS_-Y.J^*]0UG4XP?NK=A1P!7ZQP7GLN ^',?Q3#*\IS7
M'\09K1X<RW"YWAJV*P/]GY/]4SS.\2Z%#$X2I.K2S&IPNL+/VJIQG'$74YTU
M&/X5XB<,4_%#C#*N"*N=9]DF5<*Y+B.+<XQO#>,P^"S)9KG\L9PWPW@UB<3@
ML=1IT:V4TN-)8RDZ+K2ISPG*X4ZKE/\ )#]@#Q/_ ,%0+#X1_"J#]G[X?^ O
M$?[.W_"2ZW%87_B[4?AY8VKVUUXRU2/Q?<:JS^+M-^(D-KINLS:M-OT_1Y[[
MR[5#IEAJT)AM;O\ IOK\S?\ @D'_ ,F#_"'_ +#'Q._]6;XLK],J^8XTXRQ'
M&N9?VIB\CX=R?&2J8NMBZN08#$8)YCB,76]O5Q68/$8W&SQ&(]IS.-7FC+]Y
M/FYFTU]KX>>'N%\.,I>28#B7B[B#+Z=+!8? 4>*LTPN9+*,)E^'^JX?!94L+
MEV74\)A%24%*@H3C>G3Y.2,>5E?E+_P6-T3^U_V/M6E?XQP?#&'2_$^DW[>%
M;^YEM]/^,TT,=S+:_#WRM.M+G6[[5UFC'B/0K.)9] %]HOVWQ/;6=A9P^*?"
M_P!I_M)_M,_#G]E_P+%XP\=2:AJ>JZUJ$.@>!/ /ANW74O&WQ#\4W;Q16GA_
MPMHX=);N8RSP&]NVVVMA%+")'DO+K3[*\^5?@!^S3\2?C#\1-#_:[_;3ACNO
MB)8+<W?P/^ +%+CP1^SYHE_-#<V5]>6,D8CUGXHRQPVUQ>ZK?(\^DWD5K<W"
M_P!M:5H%MX,^/6EGTZ>=NW^?3UT/T _%76OVCOAC\4/V-/AY^PKX%_9+N#^T
MTOC3_A%%\.II5_;?\(UXTTJ2VBUOXG6E]<7=OXJ?QOXFV7FF:QHFNW%O8>'H
M[37/^$JO9/">@Z5I.L?T2_L0? [XD?L[_LY^!_A?\5/B%>?$'Q5HUN\K--(E
MUIO@S3[B*W^Q> /#FHR0IJ.I^'_#"1O;6%WJ<LK@RRVNEQ:;H%MI&DV'P'\-
M=/L5_P""X'Q_E6RM1(G[/NDZ@D@MXMZ7TOA?X+6<MZC;,I=2VDTUM)<*1*\$
MTL3.4E=6_;*G)]%MN^NK\_) ?(G_  4$_P"3"_VW/^S1/VD__5->-*_)W_@B
M-^U[^R;\*/\ @F_\$? WQ2_:@_9W^&OC;2=;^+<NJ^#_ !_\:_AKX-\4Z;%J
M7Q:\9ZEITNH>'_$7B;3M6LX[_3KJUO[)[FTC6ZLKF"Z@,D$T<C?HQ_P4V_:$
M\ _ C]D[X@Z/XM\'2_%CQ-\?],U/]G7X7_ VPEUZ/5_C/XX^+>D7_A*W\%6Y
M\*WVF>)[;2YM/U*]NM?U'0=4TC6+?3H6LM U2V\4ZEX?AN?Y.?\ @I#_ ,$O
MOA?^P;^R5^Q*^HZ4FK?M%_$3XC7^E?'CQK:^(/$DVDZA)?:5!K3>"M!T9]:E
M\/6NB^$)+L:%9^(M.TJPUOQ$;&76KVXMUU"+3+']O\/\ERKB'A>'"V=8G,<M
MEQ%Q?2Q62U\'0PU9XJ63Y)F"QTY1KUJ;CA,,L1"E5KJ$N;%5J%&BJKAC'AOQ
M3CW.<TR#B:7$V2X;+\QCP_PI5PN<T<77Q%&.%CF^=9<\#!2H4:BEB\2Z$ZM*
MA*<>7"T:U:LZ:GA%B?U0_80\>>!_B;_P<*?M[>.?AOXR\*?$'P3K_P"R_P";
MH7C#P1XBTCQ9X6UJ*SN_V1--NY=)\0:#>7^DZC':ZC9WEA<O9W<RP7MK<VLI
M6>"6-/Z>Z^%?V8O^":?[$_[&WCW5_B=^S=\%O^%<>.-=\(7_ (#U77/^%C?%
MKQ?]J\*:IK.@>(;[2O[-\>>//%&D0>?J_A?0KO[=;:?#J47V'[/#>1VMS>07
M'W57Y_QOG>59[FF K9-',(X#+L@R7):4LSHX:AC*O]DX*&#=:I2PF)Q=&/M5
M34THUGJVN6-D?=\%9)FF199CJ.<2P$L=F&>YSG-6.6UL17PE-9KBY8I4J=3%
M8;"UI>S<W!\U%:)/F=V%87BC_D6?$7_8"U?_ --]Q6[6%XH_Y%GQ%_V M7_]
M-]Q7R$/CC_BC^:/M:'\>C_U]I_\ I<3\&/\ @V__ .3'OBI_V=9XX_\ 51?
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MI/A^7XK6_C7XF7WP!\#:QXN\+:+';0W-IX$\>VFC>-?$9N=7N?$&N>&/$_\
MPC]WK5SJNCR:]?>7_"W]L;_@H]^P5\2O^"3?[1_[57[;NK?M3? S_@K"VBZY
M\5/A!XD\#>'?#>D_ ZU^)&D_"RZ\+:OX*UJR%Y]@@\+:;\8= \3ZCHO@C0O
M/AJ67POK_AV30+Y=6T_6[, _MCK^?#]DS_E8A_X*O?\ 9M'[(W_J _#^OW(\
M7?&/X1?#_48M'\>?%3X<>"=7GM4OH-+\7>./#'AO49K*222*.\BL=9U2RN9+
M626&:-+A(C"\D4B*Y9& _!C]B;Q7X6\:_P#!P1_P54\1>#?$N@>+?#]]^S5^
MR<EEKOAG6-.U[1[M[/P3X#M+M;74]*N;NRN&M;J*6VN%BG<P7$4D,H61&4 '
M]%U%%% !1110 4444 %%%% !1110 4444 %%%% !1102 "20 !DD\  =23V
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MO^&'[$7[)VL?\%\?VC/V:-3^!?@>]^ _A3X#Z'XE\._#":TO#X9TG7;GX9_
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M'%]#&8/BS.,3[.645H8+-,;5RZ6)Q266*4:-?&J=1*3Y'"BJM##J%"K6A/\
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MXILK0:?IUU=17EX;J\1[2V%M#(9[E6@BW2J4'\CK2R[M-^G1?K]Q_>Y\^?\
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M[8W[;W[-'[!?PEO_ (R_M-_$K2O ?AJ/[1:^'=&'_$R\;>/]=AB22/PO\/\
MPC;.=6\4:Y,98//6UB33-%M93K'B74]$T"VO=5M?@W_@B;_P4Y^(W_!4/]GS
MXV_'3XH> O 7PP3P#\?_ !%\./"^B^#)M=DMX?!5CX)\%>,--N?$^I^(=6U
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M7?'+Q/\ &_0/CZO@7P;K_P#;DWPXLO&EK-XN\3/KOP\7X%W'A_3_ !;X4O-
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M>$M'GB\,:=]EUIH+RRA-U>6YG-LEI_5+7\^'[)G_ "L0_P#!5[_LVC]D;_U
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M+XYQF%=TX5Z6'A@,'A,!E-.AEU']_J_ ']F'_E/;^W/_ -F\P?R_97K]_J_
M']F'_E/;^W/_ -F\P?R_97KZ/C7_ '[@/_LML'_ZJ,Z/SWP=_P"1+XX?]F:S
M?_UK.#C]_J***^\/Q **** "BBB@ HHHH **** "BBB@ K\+/^"['Q>_8/\
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MZ.69/E\)2IX3"4Y3G4FW*IB<7B)UL;C\1B\=B,1B:I7X _\ !NY_R:A\9/\
MLX;5?_5;?#FOW^K\ ?\ @W<_Y-0^,G_9PVJ_^JV^'-?+YY_R7W ?_8OXS_\
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MP2__ .#E]HHC/_P5S^&$<YC0S1Q>-OB?-%'*5!D2*9_V?;=Y8U?*I*\$+2*
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M_K^@^OY\/V3/^5B'_@J]_P!FT?LC?^H#\/Z /Z#Z*** "BBB@ HHHH ****
M,[6-7TKP_I.J:]KFHV6D:)HFG7NKZQJVHW,5GI^EZ5IMM+>ZAJ-_=SLD%K96
M5I#-<W5S,Z100122R,J*2/Y7?V_)O%_[5W@"^_;#USQO;>"?A^OCN'X7?LC?
M!;6;34)?%/Q4\&P7[6'B_P =Z-IEI%-+:ZWK^N"RU&47.GQK_96D?V'J&J :
M9X.F\1?;W_!5#]KK2IO$_AW]CGPL/$7B!-8U#P_J/QNT;P)EO%_BFWO;BTO?
M!GP)\,3P0WUS9Z_\0+M].NM=OX-.O9]'T6ZT>6WT[Q.EUJ_A:\^(?VOO 3?!
M#3_@%\:_VQ_VO]#_ &1/CEXK;6M.^"OPW\+_  W^*'C/P#\'OAK\,=/\+VUG
MX+^'EW\(_#_CB[\*^(?"+^(O#LM_J,M_&FH_VNT=AK&KWNF:MJ5Y^K9)1S?A
M/+L#+(J683X^XMPWM\LAE5+$5<VR/AA1EB'B<)#"QEBJ.9\00H3JQJTHJMA>
M'*%2LI.AG2G2_%,\EDOB#G>84.(99=+PPX&QCPN;K.)8:&2\4<:7A06#QKQC
M6$Q62\)RQ$*5:C6<L/C.+<32P\HK$<.3IUOE*71/A9\<?"_PX^!/[//[*?BW
M2_VP-9U>[T7XFS7WBCQC+X>\./X6G,=Y<^%])\1>,)XM).L"&2X\97/Q!MX;
M#P)%::EIEHMY-<V>NZ9_5!^RS\);+]BG]D[PUX'^)WQ*TBYTOX8Z#XF\6>-_
M&FKSZ?H'@SPK;ZAJ&J>,O%*V>HWD&G/;^$M NK_4YUUGQ#(+ZZ3[5J=RNE6L
M]MHNE?R1>&_CC^SQX3\?^*?B5X<_X*ZV'ASQSXL@F@U_QWHGP;_;1LO%_B:+
M4;NUU'58=?U*W^$=M>7$5QJ.GZ?>2B74;[[;<VL-S<+%-!'G]*/@5X"^//\
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M%0I*;C2]M4C)4,-26T:=&A"2IT::OR4J--07113;7X37S3'<:\0X.?$N?X?
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MX@?ZSXJG+'X+$8J5',*N)R[A:3R^E'"TJF'Q6(IRQ-+"XFE4^LU9?=S^!O\
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MJ4X4Z,I3BG_6!36+!6*!6<*2BLQ16;!VAG"N54G +!'*C)"L1@^$?L]?M.?
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MZ%:>'+KX;#6+WQ'>:G]T?MX_\$ZOVF?V??VL_P#@FS^WU_P3S^#$'[2_BO\
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M/H<WASPSXLUR[M+;Q%;_  C\!>$]7MM+BN[$:;J?CSQ;<>(A-=^&?#^G@']
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MT>7(!?-Q-XHM]1CV-'?0#_B4MONM.NT^6!4N7^./VV_%?[7'_!1#X$ZI\(]
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MZ;HFJ:)+/?A_"L4 FO-4BL[:WGG)M[JYDMA'_/?_ ,1 O[<.2?\ A%_V>L$
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M,JM=6H5Z..QG/1P5.EB,+5JPKY?@Z./IU)>RG+'SC2Y)?M?@54\/\+QFO#C
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MS4;#2KSQGX/EN/#L%]K,T-GILIOK+5M/O7DTR?48;2&X\J[D@O(IK6/\F/\
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MXXZ-\)O"OB'Q7J\<^M>%9?#9\27^D>&HM0U""T\2>%I+6./5;?3K:Q\/>,_
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M>%?B5K/A[3+2&*:XO]<UGPWX7UG3_#NG6RB?4?$,^E62$B=E;^4!?CC\-/\
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M/TRYT]2MIJ]S\./#&N>(HP9#(2WB;7]/U3Q#,V\@[I]3D8!(U!V11JOY?_\
M$,]_P1R_Z-H\3?\ A_?CW_\ /'H_XAGO^".7_1M'B;_P_OQ[_P#GCU[^4\'<
M,9+A\/0P.1Y7">'HTJ/UN6 PDL;6]E&,55Q&*='VU6K-QYYSE-MS;:MHE\)Q
M3XN>)/&&.Q^,SKC3B:M1Q^,Q.+_LNGGF:4\GP?UFI.?U; Y9'%K!X7"T8S]E
M2I4J45&E%1;D[M_O':VMK9016MG;06EK"NV&VM88[>")<EML4,2I'&NXDX10
M,DG&2:Q_%?A?P_XX\+^)/!?BS2[77/"WB[0=7\,>)-%O59[/5]!U[3[C2M7T
MR[561FMK_3[JXM9@KJQCE;:RG!'X:?\ $,]_P1R_Z-H\3?\ A_?CW_\ /'H_
MXAGO^".7_1M'B;_P_OQ[_P#GCU])*$)0E3E",J<HN$J<HIPE!KE<)1:<7%Q;
M3BU9K1JQ^>4ZU:E6AB*56I3KTJD:U.M3G*%6G6A)3A5A4BU.-2,TIQG%J49)
M2335S]0/V4OV,O@1^QCX7\3^%/@=X?U'2[7QCKL&O^(]3U[59-=U[4[FRL(]
M/TVSGU:XBBG.E:5$+N73=.Q]GL[O5=7NH@)=1N6?ZJK\%?\ B&>_X(Y?]&T>
M)O\ P_OQ[_\ GCT?\0SW_!'+_HVCQ-_X?WX]_P#SQZY\%@<'EN%HX' 8:A@\
M'AXN%##8>G&E1I1<I3:A3@E&*<Y2D[+64G)W;;._.,YS;B',\7G.>YCC,WS;
M'U(U<;F.88BIBL9BJD*<*,)5J]64JE1PI4Z=*'-)\M.$(1M&*2_>JBOXL/V,
M/^"(?_!-WXP?\%(O^"MW[//C[X(ZYK'PH_96US]C:R^"/AZ'XM_%K2[CPK;_
M !=^$OCGQ3X]2[US3/&EIK?B,ZOK>BZ==POXBU#5'TQ(6MM,-I;2RQ/^LO\
MQ#/?\$<O^C:/$W_A_?CW_P#/'KJ/,/WJHK\%?^(9[_@CE_T;1XF_\/[\>_\
MYX]'_$,]_P $<O\ HVCQ-_X?WX]__/'H _>JBOP5_P"(9[_@CE_T;1XF_P##
M^_'O_P">/1_Q#/?\$<O^C:/$W_A_?CW_ //'H _>JBOP5_XAGO\ @CE_T;1X
MF_\ #^_'O_YX]'_$,]_P1R_Z-H\3?^']^/?_ ,\>@#]ZJ*_!7_B&>_X(Y?\
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M/?\ !'+_ *-H\3?^']^/?_SQZ /WJHK\%?\ B&>_X(Y?]&T>)O\ P_OQ[_\
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MXOY[F+0;'38]2U34]2U74EN[^[>>OY&?^#C?_@L/\;O"?C.7]E;]A;XB^//
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M\^CZ=-<>$_%NGWEQXU\;>'?&^CZO\2+O4/!&@ZAX(TJ'P];6WZ;?MX?M9?\
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M5I8VUM<7;,YE9KF:&)))V:1FD8RLY+L7)+$F@#1HHHH **** "BBB@ HHHH
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M]Z:QLKBXM+RXL[6>[L#,;&ZFMX9;BS-PBQW!M)W1I;<SQJJ3&%D\U%57W
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M-7T32K**75=:TNQN_P!JJ "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M^"?_ .Q7X\_9I_X+90>.OA/\>-$U[QKX<\4GX7? ']CG]F+Q!X9\0:SJ=O\
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M)%XOAT"X\#7%EI]_KEKXGN/#MK)JX_;'6M<T7PWHFK>)?$.KZ9H7AW0-+O\
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MX:\5V3Z6]EXKU-KFV73$N)+A+1TNXDBDCF^XJ /\XCX:?LB?'[X3?LI^/_\
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M:;_6?10!_G<?'/\ X)T_MM:Q_P $L/VF?BA:?LA_'#PGXU_;&_X*A^&OV@?
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MHGPDT./PG+XIOK;33>_%4:KI6IVOASQ+H5SXO!^QI_P4+_X)S?\ !9W]F?\
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M+;Z=_#^MVMYHND:GJ$\KZ)JD,ULQTV[6'^GRB@#_ #H?@M^Q[^VC^SK^SO\
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MU2I2]K2ISG/V3I_O*TY;I2?X6?\ !)C_ ()^? 7_ (=^? '_ (:=_8C^$/\
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M!?[17PS\6R^*-+\.Z5>P7\NA?#KPAXLU?6FT;7WN6UV\\!V@\36>N^)K+0-
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MV)OV)/\ @HA^T%^VY_P3F^*_[;7[,4O[+?P;_P""8/[(FB?"WPPEU\5/AO\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M</\ P0 _::_;:^+'[1?QM^(/[2G[3?A?X0ZQ\*].^*7Q&\5^/9?V>O 7Q/\
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M_@FA^R;^W%\,?%/_  52_P""C7QN^"&G> _VP_VM-8\67O[//[,?B'QUX/\
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MC7Q&FH>)M;^%[V2W%S?V44OT)\$?U%^'/V@_@GXO^!R?M*^%OB7X4\0? 9_
MVL?$E?BEI&HK?>%/^$'\/6-_J6O>(&O;='D2VT6UTO4CJL#PK>Z?<:?>65W:
MQ7MM-;I\@>!O^"P?_!+SXC:_;>&/"W[=7[.#ZU>M''8VVO\ Q$TKP9!>W$TT
M=O;V5EJ'C-M TV[U&ZGECAM--M[N2_NY7"6UM*W%?S6?\$@?VD[2Q_X)J?\
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M7_"8?V__ ,(S_:7VRRL]G]L_\(OX@^Q^7YF[^RKK?LVKN_FM_P"#IO\ 9?\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
6**** "BBB@ HHHH **** "BBB@#_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>43
<FILENAME>nt10014672x1_linechart16.jpg
<TEXT>
begin 644 nt10014672x1_linechart16.jpg
M_]C_X  02D9)1@ ! 0$ P #   #_[0 V4&AO=&]S:&]P(#,N,  X0DE- ^T*
M4F5S;VQU=&EO;@     0 ,     !  $ P     $  ?_B"^!)0T-?4%)/1DE,
M10 ! 0  "]!N;VYE @   &UN=')21T(@6%E:( ?4  < %0 3  L (6%C<W
M         $E%0R!S4D="     0            #VU@ !     -,M2% @(
M
M$&1E<V,   %$    =&)865H   &X    %&)44D,   ',   (#&1M9&0   G8
M    B&=865H   I@    %&=44D,   ',   (#&QU;6D   IT    %&UE87,
M  J(    )&)K<'0   JL    %')865H   K     %')44D,   ',   (#'1E
M8V@   K4    #'9U960   K@    AW=T<'0   MH    %&-P<G0   M\
M*&-H860   ND    +&1E<V,         &G-21T(@245#-C$Y-C8M,BTQ('=I
M=&A"4$,
M                                                    6%E:(
M     "2@   /A   ML]C=7)V        !      %  H #P 4 !D '@ C "@
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M;W5R(%-P86-E("T@<U)'0@
M
M      !865H@        8ID  +>%   8VEA96B            !0
M;65A<P         !                               "6%E:(
M  ,6   #,P   J1865H@        ;Z(  #CU   #D'-I9R      0U)4(&1E
M<V,         +5)E9F5R96YC92!6:65W:6YG($-O;F1I=&EO;B!I;B!)14,@
M-C$Y-C8M,BTQ
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MU=;7V-G:X>+CY.7FY^CIZO'R\_3U]O?X^?K_Q  ? 0 # 0$! 0$! 0$!
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MW^),FIZMXPL]6\4Z+<Z1'X*B\*/XSA:*]\%^)2;JYT*&S-MIDEVLYMY;>24
M_2RBOS,_8S_X*_?L#?M_?$_7_@[^RU\7]7\??$#PSX!U7XFZSH^H_#'XF^"H
M+7P9HOB'PMX6U'5!JOC3PGH.E3R0:UXR\/6HL(+R2_E2\>YBMGMK2ZEAY#X:
M?\%P?^"8?Q>_:4MOV4_A_P#M/>'M<^*>J^(8O!WA>Z'A[Q=9?#SQIXTEO+C3
MX_"?@[XEW^AVW@O7]6N[Z&&RT.:TU@Z1XNOM0TW3_!NJ>(;Z]BMJ /UBHHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH \1_:8^(EK\(?V</V@?B
MS?>%M/\ '%E\+_@C\5OB)>>"M6FCMM+\86O@KP)KWB6X\+:E<36&JPP:?X@A
MTQ])O)I=,U&.*WNY'>PO%4V\G\[WB[_@J9^S-\/?^"1W[/7_  5(\2?\$WO@
MEJK_ !U^+6O_  KD^"VA_P#" 6:^&I=(\;_&_P )0ZVGCR_^#MR=5CG@^#GV
MZ6P;PEI[1R^(/LZ7;IIOG7O[O_MZZ??ZO^PS^V?I6E6-YJ>J:G^R?^T7I^FZ
M;I]M->W^H7][\(/&-M9V-C9VR2W%W>7=Q+';VUM;QR33S2)%$CR.JG_.%^)O
M[4G[0'Q"_P""0/[._P#P2WC_ &%/V@-*U3X%?&+6_BI/\:7T#QK>:?XEBU?Q
MI\<_%HT2+P&OPTMKC2I($^,<-B;]_%NH+(WA^6X%F@U)(;$ _L9_X*0_M2^%
MOV%_C=_P2Z\+_![]D[]E34+?]LS]H+1_ /B[6O%7PHT[_A)? >G?\)=\%=/L
MM:\ :GX7F\-)8>)+!/B+J-W;:AJ=MJD$5_INEW$5I&(YXY_Z$:_SY_VE?^"A
M'QL_X*>?M9_\$DM(/[ _QX^ &G?LR_M8?#+4-:\0>((?%OC'3=;L/%'Q*^"%
MK<WT\G_"K/!D'ARST.#P)/>WES=W5_"\%\6D>U2R>2?_ $&* /CC]NS]DN__
M &V_@!J?[/4?QS^)_P  /#OB[Q)X>E^(/BKX07SZ5XV\3?#NSEN5\7?#BTU4
MWL%GIVG^-].N#I6JW&K:=XFT9[$RVVJ>%M<L[B6T/\[O_!M1\+O"/P/_ &S_
M /@NU\%?A_:W=CX"^$'[3_P[^%W@BQO[Z?4[ZS\(_#_XK?MG^$_#=K>ZE=,U
MUJ-W;Z-I-E#<WURS3W<R/<3,9)&)_KIK\K/V O\ @F9_PPU^TI_P45_:&_X7
M9_PM'_AOOXXP?&;_ (1#_A6__"$_\*G\CQ[\<?&__"-_V_\ \)[XN_X3O=_P
MN;^R_P"V/[$\&[?^$;^V_P!EG^V/LFE@'Y8_\%T/AM^SUXA\<?LL?\$]O@'^
MSI^SQX9_:D_X*/\ QPM;;XA_&S0O@'\,=1^)OPR^"5CXFL=2^*_Q036;31K'
MQ1%XI\1W=WJ.I2^)9+R>34/"_A+XJ1SWUCJ\UEJ]IZC_ ,%D/^"6OQL^-?[(
M'[#/[$W_  3U^"_PLC^#WP(^-_ASQ5KOAWQGXMM/"WA;PKH?@[PEK_AGP_JG
MB=[O4K?Q%XQT[7)_'?C+5_B7J.C)K_Q%\1:G=7>N%-3US6+^ZG_0KXA_\$TK
M3XC?\%7/@7_P4^UCXQS12? 3X!ZO\%?"_P $8OA_ \5W?:Q;_&"QN/%]U\1F
M\7J\42V/QEU]%T!/ SW!N;.TE/B,6S&R3/\ ^"I'_!,#3?\ @HUX=^!VK^&?
MC=XG_9I^/_[-?Q(A^)/P6^-WA?1+CQ9+X<OS=:-J=]I^H>$4\5^#K;4C)K?A
M;PEK^B:U_;%OJWA?6O#MO<:9))8ZCKNEZL ?SG6G[2OQ-_9@;_@JE_P3P_:>
M_9H_8N^&/[6>C?\ !.G]H_QO\+OVG/V+/@SHGPIL_''@K4_@U_PF^L>"KBYT
MKP7X/UN]L+72)6UZQUE-/\,VNF^(/AM?6.K:9K.IV6CZ^WP1^TCX1\)Z#_P:
MR_\ !-;XDZ3I^G^'_B'%^V_\0;^R\6:98"W\1WVIW'CG]L_3YT_MJU"7=K*-
M+\#>%K@73S 8\&:);H5EM[7;_5+^QY_P19NOAC\;?VF?VFOVYOVF]4_;T^.7
M[4'P<UC]G[Q=JWB#X;6'PL\+:1\(O%.GV6A^,_#%CH&A^*M=@$GB3P]HVBZ%
M#<^'4\&VGA_1!K.EZ=IDSZW?:C+\7^!/^#:KQ%IVL_!SX.?%K]O'Q;\8_P#@
MGC\"/CMXF^./@3]CW6/A-8Z+<3W.N7%_>P^&M?\ B38^.)Y[NVN)KU[/Q-?P
M>'H+;4K'4_&L_A30_ FK>.M4U"T /TV_;,_;O_;I_9Q\:?#[PQ^SU_P2W^(_
M[:WA7Q-\+/#_ (Q\0_$_PC\:]%^&>F^'O&>H:CK-EJO@2;PU<?#3Q[J37FF6
M.G:5K<FI75SIMO/%XAALK2UEDTZ[F/S'_P $^?\ @J_^V+^U?_P4H^*/['?[
M1_['6C_L;^'_  1^R/<?'*S^'GB/Q-JOC_XN1^)[/XF?#3PK9ZI?^-X;3P?X
M9F\(>(]"^(-W-;Z%#\/8-4L;W1;2X_X2.XAN+JU?^@^OYROA-_RM&?M._P#:
M*S0/_5P_L]4 ?T:T444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !117P'^VCH?_!0#5]0\%-^QGXU\">&-#CL]07QG!KNF
M^%9O$,NJB=38RQ7GC;0O$VCRZ-+:2;%MM/L-/U.UOK:66XN[ZUO8H;'V,ARB
M.>9IA\LGFV3Y(L0JK_M+/L55P65T/94IU>7$8FCAL5.FZO)[.E^YDIU90@VG
M),^?XHSZ?#.2XK.89%Q!Q)+"RH+^R.%\#0S'.L2J]>G0YL+@\1B\#3JQH^T]
MK7_VB+A0A4J)24&C[\HK^8/X!_M"_P#!7+]I+Q-\2?"GPQ^-?AJ\U?X3W]GI
M_B^/6?!_P.TBWBN;W4-;TV!;&>7X:.+Y&NO#^HJ[Q[-J+$__ "U&/Z1/AG!\
M0+;X>>"K?XK7V@ZG\2HO#.CIXYOO"]M-:>'KGQ0+*'^V'TB&X(E^Q"]\U(IC
M%:+<A3<QV&G1RI8V_P!5QUX=XW@"K1PN9<0\*YICZDX*KEV19CC<7CL%3JX:
MEBZ%?&T,5EN!]C0Q-"M2G0FI3=13BU'E]X^(\,O%O+O%2AB,;DW"?'&2Y71I
MU)4,WXFRG+L!EF8U:&,K8#%87+L3@<XS/ZQB<)B</6IXFFX4U1=.493YURG<
M4445^>GZN%%%% !1110 4444 %%%% '#_$WXA^&/A%\-OB#\5_&UU/9>#/AA
MX'\6?$/Q;>VML]Y<VGACP5H-_P")->NK>TC(DNI[?2M,NY8K:,AYY$6)"&85
M_,/\)?\ @X _:*U_]AK]NC_@HG\8?V6_"WPP^ _@S6?AKX)_X)_Z)>W'B*VU
M#XZ^.?%7BGXA>#/&.G^(_&&H:PMMX\M/A_JFE^%M4\3WW@+PGX0TVVL]&^('
MA_3K_4M=T2_FT7^E7X_?"32OC_\  CXU_ C7=0N-)T/XU_"3XC_"36=5M((K
MF[TW2OB1X.UGP=J.H6UM.5@N+BSM-9FN88)B(I9(UCD(1B:_A1\/?\$O/^"U
M7[2GPU_9$_X)-?M ? KPI\'OV*_V5_C/X@\:>*OCUI/B+PI=CQ+X<\0^*O'&
MM2^*_P"U8/'/B"?QIKNA^'_&OCSP]\+O#?A#P=X=N(Y_%^C)\5[72EMKKQ+H
MX!]\_LG_ /!:'_@J;\*_CM^Q?:_\%,?@!\-[3]F7_@I)K'ANT_9X^(7P[L]#
M\/\ B/PC=?$6?P!;>#;YK'3O'OB*:+P1I:^./#U[XC\-_$G2--^(!TCQ3)XE
MT?Q7JX\*77A'5/[$*_D\_:T^ _[:W_!1?_@JY^S1^SA<?LM2? W_ ()[_P#!
M-[XO^$/B4WQ<U?2M>D\$?&G2M#M? 'BBTTCPOJNKZ5X?\.:ZVI:3HVF?#32?
M!?@>U\0#P%+J?C+5/%OB/5+>UM=,TS^L.@ HHHH **** "BBB@ K^<KX3?\
M*T9^T[_VBLT#_P!7#^SU7]&M?SE?";_E:,_:=_[16:!_ZN']GJ@#^C6BBB@
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M=_[16:!_ZN']GJOZ-:_G*^$W_*T9^T[_ -HK- _]7#^SU0!_1K1110 4444
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MZ-JFL21P7"I%K-GI'@;Q&A5XM0O+XEF;\Z?V5/@I^T#_ ,%1O%_A7X]?M/\
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MUE@$@ DD  9)/  '4D]@*_G/_P"%I_#+_A]U_P )M_PL3P/_ ,(9_8O]@?\
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MU9]2MK34'U22TM;1Y=-O9$^WJ**^.SO,L/F^:8K,<+E.7Y'0Q,J;AE>5K$K
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MP%XPUC2M5\:^&=*O]!\06G@V&^T;PQLF\9RR#QCXDU?6=7%Z+.PA^&?#7_!
M;_@HYXS^'_[.O_!/7]H?X]?LWZU_P3*_9U_:3\7?&?3=0\!W'CFR_:$\5^&=
M7OO&.I6^AS:=J/@Z/PWI.J:H?&_C"WCMTUV:W\%:A\0_%>I_V[X_M-"\,:7)
M_9O10 U$2-$CC18XXU5(XT4(B(@"JB*H"JJJ %4      "OYS/A-_P K1G[3
MO_:*S0/_ %</[/5?T:U_.5\)O^5HS]IW_M%9H'_JX?V>J /Z-:*** "BBB@
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M'7AK4_"^H:WX0UN:SU&'1O%&E6FJ37^@:K+I]]%IVK06EW)9W20F!_YO]=^
M?_!Q_P#L/ZH^A_LM?M$?!K_@I'\$-/N /"&B_M4)IVC_ !MLK*>WN&EL?&WB
MC6O%/@'5O$?]G7$T<,&O2?'O5[S5Y+."]&@^&K*>XT)/ZA*_.[_@HE_P5!_9
M6_X)C_#WPUXX_:.USQ'=:MX[OM2T[X>?#/X?:58>(/B-XXFT6"VGUR[T?2M4
MUC0-(L]%T);_ $U-8U[7=<TG2;.YU32[%;J;4=1L;.X /QVT>^_X.OOV@+JY
MM=3TG]AS]ANTEB6+^U+D>$O&LMH(KQ&EN])M-.U[]K(7.H7%M(Z0V^KK'ISP
MP;96L+IQ<O\ L7^P%^Q1\5/V2]/^*?BCX^?MB_&;]LWXX?&W4_#NI^.O'/Q*
M,.B>"O#-OX6G\5W.B^&?A#\.8+[6H/AUX9AD\9:NU_I&G:Y)HEY<1V=UH^@^
M&+='TT_+'[.'_!>O]BOX_P"N?LC>$M4@\??"'Q=^VNGQ$_X4MI'CNR\.W%JM
M]X+^+NO?!SP[X<\9ZCX>\0ZF?#?BCXH^)?#NJ1> K6.RU+0-0O["\T"X\36^
MMMI5IJ_[;4 %%%% !1110 4444 %?SE?";_E:,_:=_[16:!_ZN']GJOZ-:_G
M*^$W_*T9^T[_ -HK- _]7#^SU0!_1K1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 45\+_ +<GQN_:G^"GAKP)
M??LN_ VW^,VJZ_K.KV?BM[G0/%/BU/#%G96=G/I6?#G@_5=$U:4:U)-J"_VO
M)J*V&F/I:6L]M//JUHT/Y)>&_P#@JI_P4;\8^,O$?P[\*?LT?#/Q'X\\'_;?
M^$J\'Z+\*OC%J/B/P[_9M_#I6H?VSI%K\49+W3_L6I7$%A<_:88_)NYHX)-L
MCJI_3^%_"7BCB[)O[=RK$\.PP*5:558[/\!A,3AJ=#$2PLJV,PTYNIA*4JT>
M6E/$JE[2,J=2"<*M.4_Q;C7QXX)X#XA_U9SS!\6SS*3P\*$LMX6S3'8/&5L3
MA88V%#+\93IQHX^M##S4JT,&ZWL9QJTIM5:-6$/Z5:*\>_9_\7_$OQ[\&_ /
MC#XP^!(OAI\2=?T9KWQ3X(BDG=-$NOMUY#9CRKN2:]L'U#3(K'59='OYIM0T
M26^?1[^::\L9Y&^8_P!M3]J'Q7\.&\+_ +/G[/EE%XI_:K^-D<NG^ ])1+>Z
MM_ 6@R_:(=3^)?B..??:6EII-O;:C<:(=5C?2FNM,O\ 5M4M[[1]!U+3KWY'
M+N&,SS3B"?#F$^JSQE'$XNABL4L51GE>$H9?*I]?S+$9C2E4PT<JP=&C5Q5;
M'0G.B\-#VE)U.:"E][F_&>2Y+PK3XNQWUZGE^(P> Q."P3P.(IYUCL3FL:*R
MO)\+E%>-+&2SO,,1B*&"H994IT\0L94]C6C2Y*DH>1_M8_%?QQ^TO\3KC]@O
M]FW5VL9+RU!_:F^,%E!/=:9\+/ MSL^U^"[*Y@EMX;[Q9XDMC)IVH:;%=)N6
MY'AJ2>!I?%=YX5]%_:T^%/@CX(?\$X?C'\+/AUI*:-X1\'_"BYTW3+7*/<W#
MG5+*XO\ 5-2N$CB%[K&L:A/=:IJ]\T:->:C=W-P43S B^Y_LE_LO^%?V6/A?
M!X0TN[G\2^-O$-T?$WQ5^(NIO-<ZY\0/'5\&EU35[RZNGENDTVVFFFM="TZ2
M5VM++==7TU_KVHZWJ^I\E_P4/_Y,G_:._P"R=WG_ *<-.K[W!9[@)<5\$<*\
M-2J+A?)^+LCK+$U*?L<1Q'G$LRPE'%<0XZG\4%4BGA\HP=1O^S<L4*;2Q>(Q
M]6M^79CPSFD.!O$KCCC&%)\:\0<!<38=X.E56(PG"/#\<GQ^(P7">65E:%1T
M9N.+S[,*27]KYTZE6,G@,)EE'#^=_P#!*#_DP+X"?]U2_P#5T_$:OT2K\[?^
M"4'_ "8%\!/^ZI?^KI^(U?HE7ROB1_R<3CW_ ++3BG_U>8X^X\'_ /DTOA=_
MV;K@G_UFLL"OP+_YSP?]R?\ ^^V5^JG[7?@W]I#QW\(9M _9;^(.A?#;XDR^
M(M(GN]=U[=#'=>%8XK]-6TK3]3CT77Y=&U*:[ETN\CU"'37E:TL+RPCFMFOA
M.GXD?\.V_P#@IM_PMX_'/_A=GPU_X6X+,6O_  L3_A._$']M&W.BGPR;42_\
M*ZQQH(&G'-H$^R$*)#)G'Z)X18+(</EO&./S?C3AC)*O$/!_$G"&%R[,L3BJ
M6.H8G,EE\J&/Q$(X25+ZC>E-.5&K6K.SM3NI*/Y+X^9CQ1C,W\/\KR'PZXSX
MDH\)^(/!_'^.S;*,)@:V6XC!Y-/,UBLKPE2>.A6>9VK4VHXFCA\/'F5ZW*XR
ME_2O17S'^R1X/_:0\#?"*#0?VI/B%H'Q)^)46OZG+;:[X?CW0VGA5K?3X=(T
MG4-2.B>'I-;U2&Y@U*]N-4GTN*=H;^VLII[R2R:[F^G*_%LTP5/+LQQF I8_
M!9I3PF(J4(9CETZL\#C(P=E7PLZ]&A5E1GO&4Z,&]TG&TG_1>2YC5S?*<NS.
MOE>8Y+6QV$HXFIE.;0H4LRR^=6*D\-C:>&KXJA#$4]IQIUZB3T;4KQ11117
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M>-(M&\<>"M5T!+?^R;#Q3!XDN[230_",_AJ1M:^!?#W_  7Q_P""AW@?X=_
M+_@H]^T+\"_V==._X)E?M*_'W6/@=H/@_P  W7C2^_:&\ :;H6L>/=-N?%\N
MM:G>0^'/$FJV\?@#QI,T$EC::=XPN/!%UIEGHWPY75[766^?M0TB[_X*#?\
M!5+_ (+T_%W]DR&#XS?"V_\ ^"8?Q&^"7@WX@?#RV.O>'/'_ ,5]6^"/P/\
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MU#6M0G\977AEM"U,-XMU@:Q%IFJZM]I#WFD:#X>LWB7^S59_R$_X)Q_LP_\
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MMO#S36-S&]A*8="M$T"]N_$_CK\XOV3?V$_A/\6/VX_CS^SWX[UOQIJ?P\^
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M8D,DLTTLGPH5(XHT5GDD=E1$4LQ !- 'RKK'[=W[17_!3C]O'_@G1=_LV?\
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M-3I2RO!S7UK'5,SQU/#RP0      !@ <  = !V K\"_V"/\ E*I^WA_W5O\
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M-0Q&&KPA6H5HSI5(QG"211117.=84444 %%%% !1110 4444 %%%% !1110
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M],T17UK49O$6M6-EI$5CI"/JEW)>+;V"M=R1 _QH?&W_ (+"?\$E_P#@K?\
M#O1_V9_^"J/P7^._[$_Q(\!^++W4]"^(WA^'_A,)?A;XHCMH](U6PTOQI8^
M]1\>:$?%2C[#XJ\&^,/@7J?@Q#IVB:EKFIOJ_AO0]:T4 I_'#]BOP'_P0?\
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M?&G@OP9XOENKOPGX8^$GC62PTC26\=Z#HKZI+JDD4VI3^0ZV\["W7V#XR_\
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M%[X@\5:]HWAG0=.B:?4-;\0:I8Z-I%A @+/->ZEJ,]M9VL2J"6DGFC10"20
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MO1ING3!9/V4O$L$,DL@MWU/XHV^FS36Z-CS1 WPYN$\T*T9D@2>6.-GV_:'
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M^C'AF]T6]"1B?0Y+/QIK%Q5E=NU]%ZOK^']: ?V$>&?"GA?P5HUKX<\&^&]
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MWB;5-.O[Z31=,^&U_/8CPVWBBVAUQOM?_@LW\"_@A\)_V'OBG\1_AA^Q_P#
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M8CO?%"637C1_V[=O&\]P ?VI45_.5_PZ*_X*R?\ 2P5\<?\ Q%31O_HB:/\
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M?\%P_CG\6U^$J_#Q3\/4^ ^D_#U_$ \?_%;P-\,"5\81_&+QE)HS:3_PFO\
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M-\<?!O\ POCX'?";XS?\(@?V;-&\1'PK_P +0\!:!XW_ .$;/B _'30SKO\
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M0? ^N>$K;5[JR@E@FO+;39M72]GM89X9;B*%HHY8W<./\[_XE_\ !MK_ ,%
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M-T+6/'NFW/B^76M3O(?#GB35;>/P!XTF:"2QM-.\87'@BZTRST;X<KJ]KK+
M']E%%-1TD1)(W62.15>.1&#HZ. RNC*2K*RD%6!(((()!IU !1110 5^?W[$
M/[ _A_\ 8L\<_MK^/=+^(NK>/]4_;-_:N^(?[3FK6U]X?M/#UGX$B\<W]UJ]
MOX$L%@U35Y=>.BZGJ^O._BB>32CJEC=:7:?\(]I\^F7-[JN-_P %:/VPO&G[
M!?\ P3^^/W[4OPWT[PSJ_P 0OAW:^ ++P9I?C&QOM3\-W>M^.?BCX*\ JVJZ
M?INKZ#?7EMI]CXFO=5>"VU>QD86&1(X!AE_,[_@F;^U]_P %R/VF/C?\(-<_
M:1^"O['>E_L>Z_IFM:G\5/&'PE\5^%+_ .)7@W^U?A3XA\2_#O2]0\,V7[0W
MC;Q)X8\0WOC67P7IWB#PYKG@EM<TFPOM2AU2PTF2WN+RQ /Z2Z*** "BBO*O
MCA\;/AG^SC\)/'WQS^,GB3_A$/A?\,?#UUXI\:^)/[)UK76TC1;-HXYKE-'\
M.:=J^NZE*99H8HK32]-O+N:21%CA;D@ Z?X@>#[+XA^ O&_@#4[JZL=-\<^$
M?$G@_4+VQ\G[;9V7B;1KW1;NZL_M$<T'VJW@O9);?SXI8?.1/,C=-RGY4_X)
MT?L:VG_!/O\ 8T^#'[(=C\0;GXJ0?"*#QTK>/KOPS%X.E\0W/COXF^-/B9>S
M#PS#KOB9-(@L;WQG<:7:VYU[5)&M;&&>:Z:65U7\:O\ @EU_P6D^,'_!1K_@
MJE^T1\$]/\*S?#_]D3PU^S#>?%_X+>$?&G@FWT#XNW+V_B?]GO1]"\:^+=7B
MU/44DT[QSHWQ&\0>+M"TNP>;2D\-Z_X8>VO]4^R_VKJ/FO[1_P#P60_X*$_$
M/X[?\% [7_@GG\+?V=;G]GG_ ()366K7_P"TIK7QXB\97OCCXI7OA ^/;+QY
M9>";;POK-AIFF:3I=S\-OB%<:!;_ &FSO]3TWP4OB6Y\2I_;T'@>$ _JXHKX
M_P#V!OVOO"O[>G[(7P0_:Q\(:#?>%=-^+7AJ^N]2\*:A<QWMSX7\6^%_$.L^
M"?'/AY-0CC@_M33M)\9>&M=L]%UF2STZ;6]%BT[6)M+TR2^:PM_L"@ HHKY;
M_;'_ &QO@7^PA\!O%/[1G[0^O:OH?P]\,2V>G*GA_P /ZEXF\0>(/$FK^='X
M>\*Z%I>G1&(ZOX@O8?L%C=ZS>Z-X<LII%N=>U[1M,CN+^$ XO_@HK^QK9?\
M!0/]C;XR_LB:A\0+KX6VOQ<A\"*?'MEX;A\7S^'Y_ GQ.\%_$RSD'AN?6_#D
M>JPW]YX,@TJY@_MS37CMKZ:XBN/-A1'^K_ WA'3?A_X)\'> ]%EO)]'\$^%O
M#WA'29]0DBFOYM-\-Z3::-82WTT$-M!+>26ME$]S)#;P1/,7:.&)"$7\"?\
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M\]^+GC;5?AI\*_B5\1="\#>)OB=KG@3P'XN\8:+\-O!=LUYXP^(&K>&]!O\
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M^&'@WPUI]MI7@BR>%-<NQ)J>K^(--TVPNI[Z]M;$_J[_ ,$V_&O_  4#\>_
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MYU[XL_##P;X:T^VTKP19/"FN78DU/5_$&FZ;874]]>VMB=7XM?\ !5/]O?\
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M0%0RRQQAB"\B+EA^'W[2/A#_ ((.:O\ L8?MS?%GX+:C^T3\(/V_O ?QO9O
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MMKK0]8\4O>JEY_PF6L>&9=%U/QDEVBW,7BF[U>.=1(C"ON*D          P
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M  3_ -"L/B9X]\16D_A'P%X9^,/B'X._M$^'_$F@Z[-K%OIUOX*OM.UKXO\
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M-B_X1[0_+ME_LFP^S@'^<M\&OCW\,_V?_P#@@!_P4M_8%^+.OZ;X-_;%U?\
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M?3O@;\%-'^%$OP'T?X0?"[2?@=/H&I^%)O@UIG@#PII_PJD\+ZV;IM9\./\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MT:POKI[2*>\2%K2WGFC_ $+K^,/_ (.3O^">'[)G[+'[+7PO_;*_9/\ A/X
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M%% '\NW_  0<_P"";/[5W[*'CC_@IGI?[;W[._P\\$^"/VM[OX8W.B:7\/\
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MM\<;#6)/C!8P0^,EOM>L(O .D:AX!O?"6J7&D^)= TSQ596OC0=W_P &]_\
MP3L_:J_8IU7]LKX@?'3X>7'[,GPQ^._CW0]2^"?[(<?Q;TKXRP_#K0]+O?$]
M^-<UGQ7IFI^(X+K5++P]K?AKP'IVLS:W:^+/%%KX<U*^\=Z):M9>%/*_I9HH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HIKND:/)(ZQQ
MQJSR2.P1$1 69W9B%554$LQ(  )) %.H_K^OO0?U_7W,**** "BBB@ HHHH
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ME\?OVO?V6_AU_P $[_C?X6_:?^'^@:;XN^'?[=?@77_$H^$/Q;TK1;'P[/\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH _+_\ X*$_\$[=#_:N
MTN'XC_#:>P\$?M&>%8;9]$\3>9+IEAXSL]-99++0_%%[8QO<VVHZ?Y:GPSXH
MBCEO-+D2/3KSS=+-O)I7K'[#/[#/P_\ V,?A_P#8;'[)XF^*WB:TMF^(GQ$:
MV*37\RE9QX=\.B=1<:9X0TRX -M;$1W6L74:ZOJZB<65EIGW113N[6OI_7Y?
MUT ****0'P[_ ,%(OV,O^'@_[%WQF_9"_P"%D?\ "H_^%N?\*[_XN%_PA_\
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M!:>+_"OB;7?#OAY?$=I<:WXKU75]=N-'UQM;U35-(O+6UT&_\,:1J$7[V44
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M#4].\/RZ)<Z3XGO-%UJ6UTZ?]&Z "BBB@ HHHH **** "BBB@ HHHH ****
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MF2:OIFCWFE>&/!VCQS:L^D6*WOB+4M&U/Q<+%;O1;7Q#;:%J>IZ7> 'XZ_\
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MEWKFF6FK/H-G<>(-'T"V.JHMQ*H_?3_@GO\ \$\_@M_P38^$?CKX,? SQ/\
M%#Q7X7^(/QC\3_&_6;_XL:UX4UW7[;Q7XK\,^"O"FHZ?IEUX/\%>!-.A\/0Z
M=X$TB:RM+O2KW4H[VYU*2?5KF":UMK/VO]JW]F+X5?MF?L]?%#]F7XV6&I:A
M\-/BQH4&B^(!HE[#IVNZ=/IVK:=XA\/^(- O[JSU&TL]?\,^)='T?Q#HEQ>Z
M=J-C'J>F6IOM.O[/S[28 _B@^$WC3QGKG_!;S_@E+XU\!?L+ZY^P[XNN/V1]
M:\&^(_ASK/ASP[X)OOB5J'@[X)?'O3/&WQ(T_P (^'X]5\0:WX,MM,)T#X<^
M+O'^FQ:[\0--\#:3#+=6=KHUO/I/PMH'@[X:2?\ !M1XW^-L5OI>H?'2+_@I
MK8:U=_$:ZM(X/B!HOC.+PMX8L[?3]/\ %S!-=O8SX/U ^(Q:QWTUI#?>(-6U
M);==2BN+M/[4_P!AW_@C-^SW^Q#\94_:!M/B[^TE^TC\6M#^$^G? GX:>*/V
MG?B!H7Q$;X-_"+26B73_  9\*[;3_!_AP>%+*WL(CHD'V:5[;3- NM5T7P_9
M:)I_B#Q)!K/A2_\ !N[^Q@GQXF^*"?$/]HE?@W<?M$P?M23_ +%2^./#@_9%
MF^+UM!/%;ZM)\+!X-VOI\*W-QI\5FVI&Y3PK-)X'6_'A!SHY /RC_P"#E']B
M&?4?V6O$W_!0'XP_%OXO^*/B5+JO[/?@KX;_  !U+Q1<?\*0_9V;Q/X9\):1
M\7)/"'AE@1?>+/&OB/PE<7^LZ[!%X;TVXAOA!?>%[[5-+TK6[3^R7P5_R)OA
M+_L6=!_]-5I7RC^WW^PE\(_^"C'[/.I?LU?&WQ%\1_"W@75/%7ACQ?<:M\*]
M7\,Z)XM34_"=U/=Z=!#?^+?"'CC1UL9I)W6]B?09+B1 H@N;9@6;Y_\ VV/V
M.?B=\=OVE?\ @E_XS^&?B+XE>&?"/[+7QN\2^-/BWK6A_$C1?#G@F]^&>E^&
M?#6NV/A?QQX"$=MXC^(_B/QKX]^'_@7PYX;NM&F70/"/AS4/B7<>)-+N7US0
M;G3 #[1_:H^"?B7]HSX">/\ X+>$OC3\1/V>=;\=P^'K%/C!\)=0N=(^(_A'
M3=.\6Z#KFOKX1U>SU#3+C2-5\0Z!I>I^%4U5+IUTV'7)KV2RU.*!],N_YNO^
M" GP!\!?LL?\%'_^"S'[._PP;79/ ?PBUO\ 9M\&^'+GQ1J@UKQ)J%IIT'Q6
M:;5=?U1+:QM[S6=6O9KK4]2DLK#3M.%Y=S1Z;ING6"6UE!_617P[^SO^P'\'
M/V9_VF/VN?VJO GB7XEZM\0OVSM<\'Z_\4-&\6ZSX6O_  9H-YX*77UTJ+P#
MIVC>#=!US2[:X'B.^_M!/$/B+Q3+*8K3[--:;)O/ /S<_P"#CC]J?]H?]D7]
MCO\ 9^^)/[-'Q,U?X6^/-<_;:^%/@?5-7TORW@USPIJ7PN^..O7WA;7H'1GN
M_#NIZSX:T&YU2TMY+6YG33XTBNH22U?G7KVE?\%9/#W_  5;3_@F-9?\%9/B
M#<:%\=OV;)_VB/%WQLU'X(?#>[USPG=K>>)8=4TWX1>!5$"?#2"ZUKP<NB:7
MH^@^.TTK0_"VM:AJD#W/B."R$7]%/_!0C_@GG\%O^"D_PC\"_!CXY^)_BAX4
M\+_#[XQ^&/C?HU_\)]:\*:%K]SXK\*>&?&OA33M/U.Z\8>"O'>G3>'IM.\=Z
MO->VEII5EJ4E[;:;)!JUM!#=6UY>U;]@/X.:S^WYX8_X*,W7B7XEQ_&[PG\#
MKCX Z=X6@UGPLOPKF\'7.I>(=4?4KW1)/!LOBZ3Q,+CQ+?(EY!XXMM+$,5HI
MT9GCFDG /Y)YO^"R_P#P4+\-?\$K[_PCJ/Q?T9OVH5_X*2:[^P-'^UCJ'A?3
M83HOPUTCP3IGB[4/%FM7M[I[>%K/QV=3OYO#VF^*M0T*+4&^'L.IZY':+X]\
M/S>-&^Y_A]XU_;Z_8^_X+A_L!_\ !/WXQ?\ !03Q[^U9\%/'GP1^+7Q8UJ;Q
M;X5T+P5KVKVA^#?[0T6GZ#\0DL-2U^X\3VWASQM\'H_&/A7Q+J>L/K8_M.XT
MG4[O4(-%M9W]@_;P_P""17@;X$?\$Z_CW\&_V;_V=?C#^W)'\9_VO8OVI/'G
M@/6_BKX$\'_&/P)KFM^'KW2]8\:?L]^+-*^%0T^QU7P]<:=H>BP>'=1\#^/]
M9UCP;XJ\=:7*-16]C:R_-3]AW_@FY\</CY_P4;\!_'7P?\(/^"BG[-7P<^&'
M[*?QJ^'7Q _: _X*/ZB=?_:3\6?%WXK?!WXQ_ [P^? ]KK-OH-IJNC?#G1OB
M9X=;P1'H_A?3_"T/AWX97$_B+^S-8\4Z7:Z@ ?$O[<>?&?\ P2-\9_\ !0+5
M].EDO/VYO^"[/B3XY^%KN>82ZL_P4\$?#S]IWP1\-_"-Q.[2 0^$M4T+Q_IN
MDIYDD4-C=PJA*#<WZW_L'_\ !3S]IOXY_"?_ (*V?\%*/BU\5_$\?BO]E3PM
MX\M/@[_P3CM[74;;P)\$[:+P;=:MX!\:?%2PL=+\.>+/&HN]5T?4?">IZM?W
M.CPV;^%?BSXMU/1=.NYO!D7@C]D/BE_P1A_9C^,W[!O[+?\ P3]\9>+_ (LZ
M'\+?V6/$WP_\>>&?$WPTU+P7X7\7>*_'7@GPKXW\/7^M>)O^$D\%>.]$6R\8
MZC\1?%GBKQ!IVF:79W?]N7ELUGK$%K!<07N_\7O^"8?PC@_:!_:>_;H^%6E>
M+=>^.WQS_9@^(/P9^(G[-^J>)/!NG_LP_M.S7O@&\T+0=%^+_A_5_!ESXAL[
MCQ%=Z;X1TG5_$'A_Q]X6MHK?24O+RW==5\7GQ& ?RG?M#_M*?\%7_@I_P2?^
M!O\ P4O/_!4?QQXNU3]LGXL6OASQ#\*+/P7X*TJP^&UY?3_$C5M'N/A;XOT<
MK'HEUI=C\(M1T3QGX$TGPMH?A>)_$FK6ZZ:FJ>%HM5U#_0+K_-M\3_\ !+OX
M^?'[X??"G]D'X4?L$_\ !4#X*_%6+X^17&M7_P"U)\3H_B'^P=^S5\+M6N/$
M_P#PFNN?!/Q78>#OAEX9U;5?$TM]X=\1^-+B:QU[Q!=6_A!]&\*ZIXFUOQ"@
MU'_22H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
?"BBB@ HHHH **** "BBB@ HHHH **** "BBB@#__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>44
<FILENAME>nt10014672x1_piechart1.jpg
<TEXT>
begin 644 nt10014672x1_piechart1.jpg
M_]C_X  02D9)1@ ! 0$ P #   #_[0 V4&AO=&]S:&]P(#,N,  X0DE- ^T*
M4F5S;VQU=&EO;@     0 ,     !  $ P     $  ?_B"^!)0T-?4%)/1DE,
M10 ! 0  "]!N;VYE @   &UN=')21T(@6%E:( ?4  < %0 3  L (6%C<W
M         $E%0R!S4D="     0            #VU@ !     -,M2% @(
M
M$&1E<V,   %$    =&)865H   &X    %&)44D,   ',   (#&1M9&0   G8
M    B&=865H   I@    %&=44D,   ',   (#&QU;6D   IT    %&UE87,
M  J(    )&)K<'0   JL    %')865H   K     %')44D,   ',   (#'1E
M8V@   K4    #'9U960   K@    AW=T<'0   MH    %&-P<G0   M\
M*&-H860   ND    +&1E<V,         &G-21T(@245#-C$Y-C8M,BTQ('=I
M=&A"4$,
M                                                    6%E:(
M     "2@   /A   ML]C=7)V        !      %  H #P 4 !D '@ C "@
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M;W5R(%-P86-E("T@<U)'0@
M
M      !865H@        8ID  +>%   8VEA96B            !0
M;65A<P         !                               "6%E:(
M  ,6   #,P   J1865H@        ;Z(  #CU   #D'-I9R      0U)4(&1E
M<V,         +5)E9F5R96YC92!6:65W:6YG($-O;F1I=&EO;B!I;B!)14,@
M-C$Y-C8M,BTQ
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MU=;7V-G:X>+CY.7FY^CIZO'R\_3U]O?X^?K_Q  ? 0 # 0$! 0$! 0$!
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M+[;_ .-T?\(;X3_Z%S1O_!?;?_&ZZ6B@#FO^$-\)_P#0N:-_X+[;_P"-T?\
M"&^$_P#H7-&_\%]M_P#&ZZ6B@#FO^$-\)_\ 0N:-_P""^V_^-T?\(;X3_P"A
M<T;_ ,%]M_\ &ZZ6B@#FO^$-\)_]"YHW_@OMO_C='_"&^$_^A<T;_P %]M_\
M;KI:* .:_P"$-\)_]"YHW_@OMO\ XW1_PAOA/_H7-&_\%]M_\;KI:* .:_X0
MWPG_ -"YHW_@OMO_ (W1_P (;X3_ .A<T;_P7VW_ ,;KI:* .:_X0WPG_P!"
MYHW_ (+[;_XW1_PAOA/_ *%S1O\ P7VW_P ;KI:* .:_X0WPG_T+FC?^"^V_
M^-T?\(;X3_Z%S1O_  7VW_QNNEHH YK_ (0WPG_T+FC?^"^V_P#C='_"&^$_
M^A<T;_P7VW_QNNEHH YK_A#?"?\ T+FC?^"^V_\ C='_  AOA/\ Z%S1O_!?
M;?\ QNNEHH YK_A#?"?_ $+FC?\ @OMO_C='_"&^$_\ H7-&_P#!?;?_ !NN
MEHH YK_A#?"?_0N:-_X+[;_XW1_PAOA/_H7-&_\ !?;?_&ZZ6B@#FO\ A#?"
M?_0N:-_X+[;_ .-T?\(;X3_Z%S1O_!?;?_&ZZ6B@#FO^$-\)_P#0N:-_X+[;
M_P"-T?\ "&^$_P#H7-&_\%]M_P#&ZZ6B@#FO^$-\)_\ 0N:-_P""^V_^-T?\
M(;X3_P"A<T;_ ,%]M_\ &ZZ6B@#FO^$-\)_]"YHW_@OMO_C='_"&^$_^A<T;
M_P %]M_\;KI:* .:_P"$-\)_]"YHW_@OMO\ XW1_PAOA/_H7-&_\%]M_\;KI
M:* .:_X0WPG_ -"YHW_@OMO_ (W1_P (;X3_ .A<T;_P7VW_ ,;KI:* .:_X
M0WPG_P!"YHW_ (+[;_XW1_PAOA/_ *%S1O\ P7VW_P ;KI:* .:_X0WPG_T+
MFC?^"^V_^-T?\(;X3_Z%S1O_  7VW_QNNEHH YK_ (0WPG_T+FC?^"^V_P#C
M='_"&^$_^A<T;_P7VW_QNNEHH YK_A#?"?\ T+FC?^"^V_\ C='_  AOA/\
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M_AN-"%O=>,_#NE:AK6OZ1\3)-5TR?2K:\N?$6CZ9;P^*K[6?[%M]"7]G_P"
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M^*O[,FC:7X!O_B#^TCX#_9K^*FB^$DMK#3?C+\-/B;HVKW.H>)_B1;V*0_\
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M2M;\5W4DTLGB;Q2K:QJ7VGQ=JSW?B+4H+M;74-3N[2RTV"S /V[) (!(!;.
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MG3S>O>;'YGD^8GG;/-\K>OF>7NV^9LSNV;OEWXV[N,YXK\;_  %\(OA)=_\
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M^T%%\0/%7QZ\7_M@ZUKNL#XDQW?AGQ'XVT7Q?X1\;W-OX?M+2R^$VF>';?\
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MX*EUOX@^&V@;P[X[U>3PWICZEXRT%K5FMFT7Q/>--K>EM;LT!L;Z PL8]IH
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M2EM]*TO2S?:A=W]QJ/B36/$&K,-0'Q$W@K]@^?P#\//A7>?MI_MUR_#OX/\
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M7QDU;X7^)-&OK+Q+>:A^S=^U)-XQ\0^(]4U?_A)]2^(NKZ\OP*CBNOB!?>-
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MT/X0WVC)??$367\;_%/[/973W%MIWCW3;+6XX?$%IJL*?MU/;P743P7,$-Q
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M%% !7Q!XC_Y&'7O^PSJG_I=/7V_7Q!XC_P"1AU[_ +#.J?\ I=/0!]=>#?\
MD4_#G_8&T_\ ])HZZ6N:\&_\BGX<_P"P-I__ *31UTM !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !7Q!XC_Y&'7O^PSJG_I=/7V_7Q!X
MC_Y&'7O^PSJG_I=/0!]=>#?^13\.?]@;3_\ TFCKI:YKP;_R*?AS_L#:?_Z3
M1UTM !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7Q!XC_
M .1AU[_L,ZI_Z73U]OU\0>(_^1AU[_L,ZI_Z73T ?77@W_D4_#G_ &!M/_\
M2:.NEKFO!O\ R*?AS_L#:?\ ^DT==+0 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 5\0>(_^1AU[_L,ZI_Z73U]OU\0>(_^1AU[_L,Z
MI_Z73T ?77@W_D4_#G_8&T__ -)HZZ6N:\&_\BGX<_[ VG_^DT==+0 4444
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M%\-[4W?C3XO> -%C!0>2_B33;R^_><HPT[3I[O4#&PY$@MO+_P!JOS]^*?\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !7Q!XC_ .1AU[_L,ZI_Z73U]OU\0>(_^1AU[_L,ZI_Z73T ?77@W_D4
M_#G_ &!M/_\ 2:.NEKFO!O\ R*?AS_L#:?\ ^DT==+0 4444 %%%% !1110
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MBB@#:T?Q)XA\/3K<Z#KNL:+<*483:5J5[I\F8W#IE[2:)B%<!E!) /.*^C?
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M"C'@-G!/ .:Z2OXM?#?CWQIX0NX;[PSXHUO1;JWXADL=0GC5 #D 1%VA(!Y
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MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *^(/$?\
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MQ!V 'W$W,>RDU^/_ .T=_P %K?V=/A-<ZIX>^&%GJ?Q>\4:?=3V1N=-5-/\
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M?QJG^+]$?G&;?\C+%_\ 7W_VV(4445B><%%%% !1110 4444 %%%% !1110
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MESHX6I/!_7HXB/U^G*O@H5*]7!T88)RJWK?VC1M2E+"XB+\B''&8QDZ6(RW
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M5Y*?M8PE)QC4]G!S24G"-^5?77@W_D4_#G_8&T__ -)HZZ6N:\&_\BGX<_[
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M59RG.3?64Y-R;\VPHHHK4S"BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M3DVVV?AV89ECLTQ$L5C\14Q-:7VIO2$>D*<%:-."Z1@DOGJ%%%%>L<(4444
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M[_L)/_Z":]VKPGX _P#(JWW_ &$G_P#037NU>+B/XU3_ !?HC\XS;_D98O\
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MC7I8B>)IS]MB)<M6<L%.W+*LX.E3GEV"J4:#BZ-"IAJ=2C"$W-R****^</H
MHHHH **** "OB#Q'_P C#KW_ &&=4_\ 2Z>OM^OB#Q'_ ,C#KW_89U3_ -+I
MZ /KKP;_ ,BGX<_[ VG_ /I-'72US7@W_D4_#G_8&T__ -)HZZ6@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBCIUH BGGAMH9KFYEBM[>WB
MDGGGFD6*&&&)#)+++*Y5(XHT5GDD=@J*I9B ":_DN_X*H?\ !2[6/C!K.O\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M^1AU[_L,ZI_Z73T ?77@W_D4_#G_ &!M/_\ 2:.NEKFO!O\ R*?AS_L#:?\
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MAV%?(^*;S @[B_A6.+![ #^WY,Y[G(Q5";_@G-J"E?(^)$<@(.XR>'UC(.>
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M2I5\/B*,TI0J4JD91DFNETVFFRBBBO1/."BBB@ HHHH **** "BBB@ HHHH
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MJ?\ I=/0!]=>#?\ D4_#G_8&T_\ ])HZZ6N:\&_\BGX<_P"P-I__ *31UTM
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M7OB:?^%2?M ^/[9#XA^)WC#4/"]UX'L_"=O;R^'_ !-IFN^(9M#FT72I+_\
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M% !1110 4444 %%%% !1110 4444 %%%(2 ,D@ =S0 M%8UUK^E6A*RW<18
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M9#B\?)74<5F5:&"H-Z6E&A1]O7G'5WYYX>5U:UG=>K7?C'2H,B$RW+ <&)"
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MFLGSY4U"AG%&E3FZ61Y_R).KA:D^6.%Q[C/$Y=/X'/#2K4)E%698D*>? V^
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M'K'C?Q=;7::.U_'XAL] T:'1+=?$^G6&HG4FLK>'3(O.]>_96\?^,?V:;_\
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M6^'+RUTGPCX4\1>)[K[+I=Q)+>SW(T+3-02PBB29"CWSVPN#O2V\YXY%2O\
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M% !1110 5#<3I;02SR,%2)&=B>P49J:O(OC!XMB\-^&[I1,$FEB<G! (7:<
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M;1N&FG2_8_J?PORG^S_JT7&U1X>IB*O1KG4(1Z/935[VWW/Z9U(8!AT(R/\
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M]1PB7\OL,(J,9KSJ^TDUHY-:"DD]23]3FDHHK^A4DM$K+LCX8**** "BBB@
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M7A6Q4L5B%+WX3I74(J26))))/))Y//-)117\Z[[G]&;;!1110 4444 %%%%
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M2^4@LJWN0?F*HMUT! /RJ)R><'_6G.,/G=ET D'(.".01U!]:_:/ SQVXY\
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MHK]^/P(**** "BBB@ HHHH **** "BBB@ HHHH ***:[K&K.[!54$DDX  H
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M@ KX@\1_\C#KW_89U3_TNGK[?KX@\1_\C#KW_89U3_TNGH ^NO!O_(I^'/\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MX7,*$&I?4\?&/-# 9QAH22Q&$G/EJI/$8256@VX14445_2I_-04444 %%%%
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MNO!O_(I^'/\ L#:?_P"DT==+7->#?^13\.?]@;3_ /TFCKI: "BBB@ HHHH
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MN281XC/_  XKU\SK0I0<L1BN&,7",<XI0Y4Y2^HSI8;,TG?DHX?%\BYJCO\
MN'@;Q73R3B.KDN,J^SP7$$(8>DYRM3IYE3;^JN5W:*KQE4PS:UE4G13=HH_(
MV_3R[V[3TN)<=^"Y(_0U3;H?I_+FMG7XO)UB_C P!-D>^Y$8GMG))/UK&;H?
MH?Y5_8' ^9RSK@WA#.9V4\VX9R#,II6:4\=E>$Q4TK:64JK6FA^59SAEA,WS
M7"*]L-F6.PZO=.U'$U::WUVCZE1QR#VZ?SJJ_P!X_A_*K;]!]?Z&JK]1]/ZF
MOJYKW?1W_3]3R(;OT_5&<_WV_P!YOYFKNE:UJ.B70N;"XDA97#%58[6(.<XZ
M;NV<9JI* )&QZ@_B0"?U-56&&/US^?-4MEZ(G9^:?Y&WH'QXOK+Q'J*:G<R"
M1M1N2_G2%E=6E;8-QSD+$%55R2H&W&, ?5VA^,/"GCFU2"]-ND\B "3Y5R>,
MDG)SVX[<\9Z?E5XM0Q>(-44?*?M*OQQ_K(8Y!T_W@?UJWX=\=ZUX=GC,-S(T
M*,IVDG( QP"#T'/&#[$5_C'QCD-7#\3<24J,I3J4<]S>E5HUI2E)U*>/Q$:C
MC4E>7,VF[2ZM]=3_ &=X7QF$S7ACAK$5H_5JM7(<GJX?&X-*G*FJN78:I34H
M1TE3C%I)1LTK)*R1^CGBWX37$"/?:2!/"07S$58;3D\A3C@8!XSCFO$+S3KR
MQD:.X@D0J3R5;&!W/''0]?2NK^&'[1<3QQ6FH3)*A*K)%.P.!_$I!/J!C&,
M@D$#CZ6BC\ ^/[=6@DM[:ZD7D*RX+/D\=R,GC'/;H:^'GA6I.*O2JIVE1J+E
MU>UD]/1Q=GV>A]-'-,;ET4LQHO'8310S+!KG:CHKXBDFW%KJVD_,^,**]\\5
M_!?4M.WW.F@W%M@N'C&]=N"1G;G.<$Y##TZUXI?:5?:>[)=0/'M."2I XZ_E
MT/:N:<)TW:I%Q?G>W_@5K??9L]O"8W"8ZFJN$KTZ\;:J#]^+[3@_>BUL[HSJ
M***DZ0HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ J]
M;W",@MKDGRN?*E +/;LQ!) _BB+#+IU&69"&)S1HK[/@#Q XM\+^*LKXTX)S
MC$Y+G^4UE4P^*H2;IUZ3E%U\#CJ#?L\9E^+A'V6+P==2HUZ3<91NDU\=Q[P#
MPIXF<+9IP;QIE&'SK(,WHNEB<+7BN>E42?L<9@ZZ7M,)C\)-^UPF+H.-:A52
ME"6Z=R2,QL 2&5@&1QG:Z'HRY .#],@Y!P00(ZE@N@(S;3Y:!CE2!N>!\_ZR
M,$C(Z[X\@."<%3S1+"T1&2K(PRDB'*..F5/!'N& 93D,JL"!_P!%GT6_I5\)
M?2+X;C3<\+D?B)E&%I/B7A1U9)SM&$)YSDCK>_B\GQ%;F7)&=;$Y;.4,/C6U
M/#XC$_\ /!]*+Z*O%GT=^(I5X0Q6>>'>;8FJN'.*8THOV3<I3ADV=JE>.%S:
MA2Y;590HX;,HQG7P23AB,/AHJ***_K$_D\**** "BBL;4=>TW3$9[BX3*C)4
M,./8GL1W&#0-)MV2NS9K%U77M.TF)I+B=-P!(0,.P]<GGVZUX7XQ^-5AIL4Z
M0SQ($4G(< X7/?//&21U;L0.:^(?B/\ M&JJ3K]M[O@+)R.XQSG/IC [8.:\
MS'9M@\#"4JM:"Y5?5I=N[6]].IZN RC%XV<8TZ,Y7:2LFU^&_P"7YGUK\1OC
MG:Z?%/%#=)$JJP 5@HP<C.X$DD8]>W45^=?Q._:%FFDN(K:Z:1R7"JDA;).3
MR >!SCD#G@X-?.?C7XKZOXBFE6&=TB8G+[FRW)PP&>"1R?K^ \BEEDF=I)79
MW8Y9F.22>_H/PK\HS[CBOB7.A@?=A=Q]H[I6T^%*S;OU>F[/U')."Z-",*V/
M2E.R:I);/3=ZVVV5W;KU.BU_Q5JOB"=Y;NXD*,Q*Q[C@ ]0<=<_7'XUS-%%?
MGM6K4K3=2K.52<G=RDVW^/3R/O:5*G1A&G2A&$(JRC%))+Y!11169H%%%% !
M7[+?\$2OV6&^/7[5VF?$/7M.6Z\"? L6_C+4#<(WV>[\3QR ^&+$*W^CWBQW
MZ1W-_92"4/9G=)$8SFOQMBBDGECAB1I)976.-%!9G=V"JJ@9)))   SFO[W_
M /@DK^RG)^RW^R3X0L_$&FBQ^(GQ*2/Q_P"-Q(@6YMI]9A6?1M(F5E$L$VD:
M,]G8W<#MQ>0S.4C8E1\]Q+F'U++:D(2M6Q=Z%.SLU&2_>S77W87BFMI3BSZ'
MAO ?7,PC4G&]'"+VTVU[KJ)I4H/S<KSMVIORO^I5C"9IU ''3WSD=/?'!QSS
M[U] >"M.PJ.5(Z'W.1R1TR/0>O&,X \>\.V!FF0E2<L"..>0,X![=L_WAGIQ
M7T[X6TX10QDCY@H['KCICOU/&.N<XS7Y+-].^_X?*_XKYGZ=U_R^6[O\_/\
M/N[*/9&/H%Y SQ^&0.F!GUSVJY3(T"*!C' )YSSCG\NG^<T^LAA1110 4444
M %%%% !1110 5\0>(_\ D8=>_P"PSJG_ *73U]OU\0>(_P#D8=>_[#.J?^ET
M] 'UUX-_Y%/PY_V!M/\ _2:.NEKFO!O_ "*?AS_L#:?_ .DT==+0 4444 %%
M%% !1110 4444 %%%% !1110 4444 '7K7):_IXGBD&,@ YS^8].S8/&,G@'
MG/6U6NHA)&?ER0#DCKMP<]""1G'TZ^M 'R-XLT@QR2,$YW$$'/<@@@GV].N<
MY& :\BUG2;76--U#1]1B$MIJ%K/9W,; $-%.C1L1G^)<[E/564'J*^MO%VC;
MT=P@(^8@@'@XSG'/!_\ K>E?.6L63V\[$C@$D\'.#[X[<X]LGW+JT:&*H5L-
MB*<*]#$4JE"O1J14Z=6C5A[.K2J0E>,J=2$I0E%KEE%M--7O5.I.E.%2G.4*
ME*<9TYQ;4XS@U*,XM6:E&2336S2=[G\\/QS\$W_P^^)6O^&[]21#*+BQG\LQ
MI=Z=,SFUGC7D;=@$9 )*E1NQN&?(Z_:K]K#X#GXK^$7UW08H5\9>%+2ZOM/0
M0H)=:LX8C-<Z.TRJ9&EGCC/V!681_;%@5W2-G-?BQ)'+#(\,\4D$T3M'-#*C
M1RQ2(2KQR(P#*Z,"&! ((KP\ER/!<-9/EF0Y;&<,NRC!4,OP%.I)SE2P>%IJ
MEAJ+F]9*E1C"E%R]YQ@KMO5]^,QU;,L7B<=B6I8C%UIXBO**45*M5DY5)\JT
M7/-RDTM+O2VRI/\ =/M_^K^M5'Z@^W^?YU<<<,!V/\C523M^/]*]F7PM^GYH
MX(?$O.YGR_ZQOP_]!%57^\?P_D*N3_?'^Z/YFJC]?P_QIQV7HOR"2M)^M_OU
M/G_QW%Y?B*];G]ZEK+S_ ->\<7'MF/\ /-<._4?3^IKT;XC1A-<C/_/73K:0
M]>OGW*=_9!TXKSE^H/M_G^=?Y1^)N&6"\1N-*"23_P!9<VK66UL5C*N(T[:5
M5ILNES_6[PKQ?USPWX'KMMR?#.3TFY:M_5\)2PKN[[KV-OQ[D(N)K:02P2/$
MX(PR$@].G'TKTKPM\6/$'A^6+-Q*\4>W!1B&XZ9!.#V[\8]!BO+YA_,'],?S
MJ"OAZV#P^+ARUZ<9V;M+:<=%K&2U7Y>1]]0Q-?#RDZ5245=-Q>L))K9Q=TUH
M[Z'Z8_#3]J5&$5KJTT=Q$P"LL[9;J >&ZXR0?3'4X)KZ>A?X<_$NT+03VUG?
M2KG!V !NS$ CC/(Z@C.1BOPP6:6WD62&1XW'(9&*D8QW!!Y[_P"%>D^&/BQX
MA\-RQ[;J=E4K\RN0=HX((R!C'4X)QQ]/%Q&2XBDG]7:Q=%Z^PJV56*NE[L[6
MDM'H]=?D92I8'$U5B*<JN3X]6MB\"VJ4Y:?QJ%^5JZUM96WZM_IQXG^ 6H6R
MO<Z.Z7,')4Q<\=1\HZDC&>N"".2:\*U;PIK>C2-'=V4JA21NV,.F>#D#GCG!
M/L3QF/X=_M=:C9&&&]NS<)T:.Y8D9R-P^<G)!R3C(ZD9KZ]T#XP_#;X@01V^
MN06<%Q,H_>*(U.3@'D88=>",>@SW\&K@:<9<MZF$JO\ Y=5HM0;TV;NM;[IK
MMYKNIYGG^ C?$X:AGF#6^+R^2CBXQ76>'=G)VNW9-?)7?Q&05)# J1U!!!'U
M!YI*^X]=^!/AOQ'"][X6U&UEWEG6-9%+9)+*H.23@_*>2>G4\U\^>(_@QXMT
M*20FPFEA4MAT1G&%SW7)QP1T[9YR,\53#8BE\=-N/2</>BUWTV\M[_@>K@.(
M\GS%\E+%QHUUI+"XM?5J\9:7BXU.5-I]G?R/'Z*T+O2M0L6*7-K-$0<9*''Z
M=/Q_I6>01P1@^AK"ZVZ]MG\T]3W+:7Z/9K5/T:T84444P"BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M38@7 !ZD#_/I@''Z]:\*3N]-M/RZ]STEWUU[]-NG]=22BBBD,**** "BBB@
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MXY..,#KT]L?Y[@?D[^VK\!5\-W,_Q;\+64G]C7]T/^$NL[6#,.DSS9QK6(D
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MU"?Q/Y?DCQOXEQ 7NGS8^_9O'GO^ZF=P/<#S,].YKRN3M^/]*]C^)B9ATF0
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MG@\GD<D<'CH0#61K7[.^AZS&UUX8U*WE##<D8E1C\PRN I&,@$GZ8SWK\/\
M2?B%XCTF1'BNY&"$8^=U8 '/4$@GZCVR*^@?!G[5'BG07BW:E<H$V (\C%3M
M(/\ >P.C8&.Y]17DXK),3&_ML%3Q$=O:X:5I):+F]FU>^[TN^]R,-3EAK/)<
M_P 9E[OI@\ROB\(V^5J*D_?BKZ7U[]+O['\1?!#Q=H3M_H4\T8+898V8$#G(
MP,D!>2>P&3[>87OA_5[!F2YL9XV4X(*,#G!/0CVKTSPA^VX)8X8-9CMKR,@9
M9BK'.!GAOX2"<_,-IR02.*]TTOX\_![Q>J1ZI96D$TH 9AY7WF*@XXX#%@#W
M'T.:\.>6TKVC6G0EI:GB(2C;173<DMO)Z+S/;IYYQ#A4OKN34<QIJW^TY1B8
M-R6GO?5YNZNKNRUO?6UCXG9&0X=2I]&!!_6FU]WS>!OA%XN DT?5;>&24'8A
M:($L?4*PY' (/.3GK@UP.N?LY7(WRZ+>074?)78R\\^@W=<Y&"2>V,&N:>78
MJ"O&,:T?YJ4D[KO9[+_MY_B=U#BW)JDU3Q,\1EM5Z.GC\/4HV>S7M+<CL^NG
MWIGR=17JVK?![QAI9D+V$KHF>0A/&>,D=./8]ZX>[\,ZW9%A<6$Z;20?D;J/
MJ!7)*$X:3ISA_BA)?C:WXGOT,3AL3%2P^)P]=/9TJU.=[JZT4K]>WZ7P:*E>
M":,D/$ZD9R"I&,=<\5%4)I[-/YF]FMT_N"BBBF(**** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHR!U.* "BF&1%ZL!WY-5
MI+^UB&6E4=1U'4#..N?QQBFDWLAV?9V[]/O+E%<Q=^)[&WW8D4[?5@H_,\@]
M>?Q':N,U3XBV=ON GC7;Z.OL!G'8_A^O&]/"UZK4:=.<V^D(N3U_PIV^;1E4
MK4**;JUJ<$E=ZW?3IIM?O:_6VIZNTB("68 #.>1VZU1GU2S@4EYDX[9&>N/\
M^OMW^9]:^+]K#N_TD=#@;L=N!P3@9[9YQCBO'-?^.D$8<"\4$9'^L .>0>2>
M2"">0<>YZ?08#A'.,<XJGA:B3>\HO;3HKW^]'AXSBG)L$FYXB$G'6SFDNCL[
M:K3[E>_8^T-1\;Z?:J^)$&W(SN&.?4Y_A[XR._(Z>5Z]\6[6V$F+E0HXX8 <
M<8!X'<'/KGKQGX \4_'X;I$BNF?.0-K[N>1UR >>#TR>3@8KP37OBSK6ILPA
MD>)3Q]\GC!]#COV.?6OTS)/!_'XKDGB[P@[-W]R-K*Z;=F]>S;ZOH?F^=^+V
M78/GIX:4925[*G:4GMII^=UVV/T!\3_'2&%7S>(O7I(#Z =6)&<$9'IGD'%?
M*7Q)_:!9K>%;>[>23?+$%60L1&?F7!W'@.SD\<,3SQ@?,5YK6I7S%KBZE;.>
M-QQR<D=?7^0KB?$#$K;@L3EF/)R>!C/KWK^S/HO\(K@?Q1R3,<JQ#HXJI@<W
MP>)=*ZC6PM;+,0YTJKTYX^VIT:J35E.E"5[H_C+Z4'&+XU\+<[RS,L-&IA(8
MW*,7AO:-2G2Q5',L,H5:=[\DO93K4KIW=.K.+5GIT&O_ !*U[6G8?:7CC8MT
M8[B&&.3TR!Q]WOD8(KSZ:XGN&+S2R2,>I=B?T)Q]?7O4-%?Z3U\5B,3)SKU9
MU)-W]Z3:7HMD?YJT,+A\-%0H4H4TE;W8I/YO<****P-PHHHH **** "BBB@
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M+58(E '  P2!R>Y]\>ISS[BM&@  8  'H.!14#"BBB@ HHHH **** "BBB@
MHHHH *^(/$?_ ",.O?\ 89U3_P!+IZ^WZ^(/$?\ R,.O?]AG5/\ TNGH ^NO
M!O\ R*?AS_L#:?\ ^DT==+7->#?^13\.?]@;3_\ TFCKI: "O)?C%\<OAC\
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MBHJ.36O#\8/^E1]_XP<\XXY[>G3-4I/$F@)DBX#>P*YQZ\'D=>WTS5*C7?\
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MG2+[=':+-=W=_IZW<>F31?TN009V0PQ@(@5%2-0JHBX5550 JJJC"@   <#
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M/;WEE=Q"6WN(7RKQR1N,,I_/T(-?C_\ M-?L/ZOX+?4/'OP.L=0U_0KJ\O\
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M[Q@W=*FFW)/WM7RK]%R?AZCEZC7Q'+7QEKWM>E1?:DFM9+2]1J][\JBMZ]O
M7*11IM50%547"JJ@ *H VJ ,  8 '08&*]#\.^&I9W4NI"M@].3SSDGGIDXQ
MSC&  36KX<\)R2E&:,@ @Y*]L\_7G!//;GOGW?0O#\=LD9V -@#) '&,G/\
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M -BZ-9Z-;V=K<'2H5GEO([K>;"7]+Z* /R:F_8^^)OQEDOO%?BZ#PCX9\/\
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ME]874ECI9U7]*J** "BBB@ HHHH **** "H98(Y@0X[>@/T)!';\#[],344
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M2.@R,D9!VC.<@9/IQ[5ZS2,JL,, 1Z&FFUJ@/E+6O!$D1=DBR.3C!]L8'?G
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M_P ZBD[?C_2I6ZGZG^=12=OQ_I753Z_+]3SY_$_E^2*S]1]/ZFJDG^L'X_\
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M9I*+H99B*5*=OW^+C]5I*.BYKUN64UY4XSDTG9'R^8\:<-99&?MLSH5JL/\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M/;RY<C@>B=>O'M47_":: 3G[7C)[QR=_^ _SK.. QT7=X3$)6>OLI^7D#S#
MMJV,PST2_C0WLM_>T^9TK]1]/ZFJE8Q\6Z$S8^VKP #\CX&<^JBHQXET4_\
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M?ES^S#^R;^T_\/;_ /X)P6OC#X):SH5O^S;XN_:GN?BKJG_"<?"'4+33]/\
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MK[5I&KV[>%-*T2[\21S:3JD<FEJ^GW@A_&K]G+]DS]JGX9>(?V(=8\4_ /Q
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MRIF''V$Q&*]KA\/AXX?V.%X;X9Q[Q<X5Z*I<3T:<</6G/".M^RGPW^(GP_\
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MP-I__I-'72T %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !7Q!XC_ .1AU[_L,ZI_Z73U
M]OU\0>(_^1AU[_L,ZI_Z73T ?77@W_D4_#G_ &!M/_\ 2:.NEKFO!O\ R*?A
MS_L#:?\ ^DT==+0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %>-
M:#^SE^SUX5\5P>//#'P(^#7ASQQ;7E]J-MXST'X7^"-'\5V^H:G%<P:E?0>(
MM/T.WU>*\U""]O(;ZYCO%FNXKNYCG>1)Y0_LM%<U?!X3%3H5,3A<-B)X:HJN
M&G7H4JL\/53C)5*$JD9.E43A!J=-QE>,7>\5;KPV/QV#AB*6#QN+PM/%TW1Q
M=/#8FM0ABJ+4HNEB(4IQC7IN,YITZJE&TY*UI._FWA;X-_"3P/XDUOQCX,^&
M/@'PIXK\2W.H7NO^(_#GA'0=&UO5[S5YX+K6+J_U+3["WN[BXUB[M;6\U>:2
M4R:K>6\%W?M<7,4<J^7>'/V2_@G8:;XUT[Q3\.OASXQM_''Q<OOC3>Z7>_#[
MP];^&=#\;3Z'H?AFVU7PKH5S%JK:)J7]C^'K2ZU?5UU&YU+6/$VK>*];-Q96
MOB!M&LOIJBN6IDN4552C4RW RA0EB)TJ3PU+V,9XN/+B9NBHJE*=:.E24X2E
M*[UNW?MI<0Y[1=>5+-\QA4Q,,+3K5EBZ_P!8G3P4^?"4UB'-UX0P\]:4(5(Q
MC9:622Y#4/A]X$U7PI;>!-1\&^%[SP591Z1%8>$I]"TQO#FGIX?N[2_T :?H
MWV8:?8'0K^PL+[17M+>%])O;&SN]/:WN+6"2/"U3X+_"#6_!VB?#S6/A?X U
M+P'X9C\GPYX-O?".A7'AG083I=_H;PZ/HDEBVG:;%-HFJZKHMQ%9V\*7.D:I
MJ>F3K)8ZA=P3>F45TU,#@:O-[7!X6IS4(X67M,/1GS8:,E..'ES0=Z$9I3C2
M?[M22DHIJYR4\RS&CR^QQ^-I<N)EC(^SQ5>'+BYP=.>*CRU%;$RIMTY5U:K*
M#<7)Q=B&VMK:RMK>SL[>"TM+2"*VM;6VBC@MK:V@C6*"WMX(E2*&"&)%CBBC
M58XXU5$4* !-1172DDDDDDE9):));)+HD<;;;;;;;;;;=VV]6VWJVWNPHHHI
MB"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "OB#Q'_ ,C#KW_89U3_
M -+IZ^WZ^(/$?_(PZ]_V&=4_]+IZ /KKP;_R*?AS_L#:?_Z31UTM<UX-_P"1
M3\.?]@;3_P#TFCKI: "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M=_\ )-'_  E?A;_H9= _\'&G?_)- &_16!_PE?A;_H9= _\ !QIW_P DT?\
M"5^%O^AET#_P<:=_\DT ;]%8'_"5^%O^AET#_P '&G?_ "31_P )7X6_Z&70
M/_!QIW_R30!OT5@?\)7X6_Z&70/_  <:=_\ )-'_  E?A;_H9= _\'&G?_)-
M &_16!_PE?A;_H9= _\ !QIW_P DT?\ "5^%O^AET#_P<:=_\DT ;]%8'_"5
M^%O^AET#_P '&G?_ "31_P )7X6_Z&70/_!QIW_R30!OT5@?\)7X6_Z&70/_
M  <:=_\ )-'_  E?A;_H9= _\'&G?_)- &_16!_PE?A;_H9= _\ !QIW_P D
MT?\ "5^%O^AET#_P<:=_\DT ;]%8'_"5^%O^AET#_P '&G?_ "31_P )7X6_
MZ&70/_!QIW_R30!OT5@?\)7X6_Z&70/_  <:=_\ )-'_  E?A;_H9= _\'&G
M?_)- &_16!_PE?A;_H9= _\ !QIW_P DT?\ "5^%O^AET#_P<:=_\DT ;]%8
M'_"5^%O^AET#_P '&G?_ "31_P )7X6_Z&70/_!QIW_R30!OT5@?\)7X6_Z&
M70/_  <:=_\ )-'_  E?A;_H9= _\'&G?_)- &_16!_PE?A;_H9= _\ !QIW
M_P DT?\ "5^%O^AET#_P<:=_\DT ;]%8'_"5^%O^AET#_P '&G?_ "31_P )
M7X6_Z&70/_!QIW_R30!OT5@?\)7X6_Z&70/_  <:=_\ )-'_  E?A;_H9= _
M\'&G?_)- &_16!_PE?A;_H9= _\ !QIW_P DT?\ "5^%O^AET#_P<:=_\DT
M;]%8'_"5^%O^AET#_P '&G?_ "31_P )7X6_Z&70/_!QIW_R30!OT5@?\)7X
M6_Z&70/_  <:=_\ )-'_  E?A;_H9= _\'&G?_)- &_16!_PE?A;_H9= _\
M!QIW_P DT?\ "5^%O^AET#_P<:=_\DT ;]%8'_"5^%O^AET#_P '&G?_ "31
M_P )7X6_Z&70/_!QIW_R30!OT5@?\)7X6_Z&70/_  <:=_\ )-'_  E?A;_H
M9= _\'&G?_)- &_16!_PE?A;_H9= _\ !QIW_P DT?\ "5^%O^AET#_P<:=_
M\DT ;]%8'_"5^%O^AET#_P '&G?_ "31_P )7X6_Z&70/_!QIW_R30!OT5@?
M\)7X6_Z&70/_  <:=_\ )-'_  E?A;_H9= _\'&G?_)- &_16!_PE?A;_H9=
M _\ !QIW_P DT?\ "5^%O^AET#_P<:=_\DT ;]%8'_"5^%O^AET#_P '&G?_
M "31_P )7X6_Z&70/_!QIW_R30!OT5@?\)7X6_Z&70/_  <:=_\ )-'_  E?
MA;_H9= _\'&G?_)- &_16!_PE?A;_H9= _\ !QIW_P DT?\ "5^%O^AET#_P
M<:=_\DT ;]%8'_"5^%O^AET#_P '&G?_ "31_P )7X6_Z&70/_!QIW_R30!O
MT5@?\)7X6_Z&70/_  <:=_\ )-'_  E?A;_H9= _\'&G?_)- &_16!_PE?A;
M_H9= _\ !QIW_P DT?\ "5^%O^AET#_P<:=_\DT ;]%8'_"5^%O^AET#_P '
M&G?_ "31_P )7X6_Z&70/_!QIW_R30!OT5@?\)7X6_Z&70/_  <:=_\ )-'_
M  E?A;_H9= _\'&G?_)- &_16!_PE?A;_H9= _\ !QIW_P DT?\ "5^%O^AE
MT#_P<:=_\DT ;]%8'_"5^%O^AET#_P '&G?_ "31_P )7X6_Z&70/_!QIW_R
M30!OT5@?\)7X6_Z&70/_  <:=_\ )-'_  E?A;_H9= _\'&G?_)- &_16!_P
ME?A;_H9= _\ !QIW_P DT?\ "5^%O^AET#_P<:=_\DT ;]%8'_"5^%O^AET#
M_P '&G?_ "31_P )7X6_Z&70/_!QIW_R30!OT5@?\)7X6_Z&70/_  <:=_\
M)-'_  E?A;_H9= _\'&G?_)- &_16!_PE?A;_H9= _\ !QIW_P DT?\ "5^%
MO^AET#_P<:=_\DT ;]%8'_"5^%O^AET#_P '&G?_ "31_P )7X6_Z&70/_!Q
MIW_R30!OT5@?\)7X6_Z&70/_  <:=_\ )-'_  E?A;_H9= _\'&G?_)- &_1
M6!_PE?A;_H9= _\ !QIW_P DT?\ "5^%O^AET#_P<:=_\DT ;]%8'_"5^%O^
MAET#_P '&G?_ "31_P )7X6_Z&70/_!QIW_R30!OT5@?\)7X6_Z&70/_  <:
M=_\ )-'_  E?A;_H9= _\'&G?_)- &_16!_PE?A;_H9= _\ !QIW_P DT?\
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M^)H^SV__ #PA_P"_2?\ Q-%% !]GM_\ GA#_ -^D_P#B:/L]O_SPA_[])_\
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M^D_^)H^SV_\ SPA_[])_\3110 ?9[?\ YX0_]^D_^)H^SV__ #PA_P"_2?\
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M^)H^SV__ #PA_P"_2?\ Q-%% !]GM_\ GA#_ -^D_P#B:/L]O_SPA_[])_\
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M^D_^)H^SV_\ SPA_[])_\3110 ?9[?\ YX0_]^D_^)H^SV__ #PA_P"_2?\
MQ-%% !]GM_\ GA#_ -^D_P#B:/L]O_SPA_[])_\ $T44 'V>W_YX0_\ ?I/_
M (FC[/;_ //"'_OTG_Q-%% !]GM_^>$/_?I/_B:/L]O_ ,\(?^_2?_$T44 ?
"_]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
